export const guidelines = [
    {
        "page_number": 1,
        "content": "THE REPUBLIC OF UGANDA\nMINISTRY OF HEALTH\nUganda \nClinical \nGuidelines \n2023\nNational Guidelines for Management \nof Common Health Conditions",
        "formatted_content": "<h3>THE REPUBLIC OF UGANDA</h3>\n<h3>MINISTRY OF HEALTH</h3>\n<p>Uganda</p>\n<p>Clinical</p>\n<p>Guidelines</p>\n<p>2023</p>\n<p>National Guidelines for Management</p>\n<p>of Common Health Conditions</p>"
    },
    {
        "page_number": 2,
        "content": "Foreword\nThe overall goal of Uganda\u2019s health system is to provide accessible, \nequitable and quality services to the population, in order to promote a \nhealthy and productive life, which is a necessary factor for achieving \nsocio-economic growth and national development.\nCurrently, the health system is faced with multiple challenges that include \na high burden of infectious diseases that remain major causes of morbid\u00ad\nity and mortality, such as HIV, malaria, tuberculosis, lower respiratory \ntract infections, malnutrition and meningitis. In addition, new threats \nkeep emerging, for example, epidemics of hepatitis B, yellow fever, \nhaemorrhagic fevers, COVID-19 and nodding disease. The increase of \nnon-communicable conditions including diabetes, hypertension, heart \ndiseases, cancer and mental disorders complicates the scenario.\nThe push towards universal health coverage, including universal access \nto AntiRetroviral Therapy (ART) and particular attention to neonatal, \nchild, adolescent and maternal health, is also placing more demands on \na system with limited resources.\nTo respond appropriately, the health system has to ensure high standards \nof quality and efficiency in service delivery. The Uganda Clinical Guide\u00ad\nlines manual helps to achieve these standards by presenting updated, \npractical, and useful information on the diagnosis and management of \ncommon health conditions in Uganda. It also provides a rational basis for \nan efficient procurement and supply system that ensures the availability \nof safe, efficacious, quality medicines and health supplies.\nThe guidelines are based on principles of scientific evidence, cost effec\u00ad\ntiveness and prioritization of conditions to maximize the health benefit \nwith limited resources.\nThe regular update of clinical guidelines and essential medicines lists \nis one of the key interventions in the Health Sector Development Plan \n2015-2020, to promote the appropriate use of health products and \ntechnologies.",
        "formatted_content": "<p>Foreword</p>\n<p>The overall goal of Uganda\u2019s health system is to provide accessible,</p>\n<p>equitable and quality services to the population, in order to promote a</p>\n<p>healthy and productive life, which is a necessary factor for achieving</p>\n<p>socio-economic growth and national development.</p>\n<p>Currently, the health system is faced with multiple challenges that include</p>\n<p>a high burden of infectious diseases that remain major causes of morbid\u00ad</p>\n<p>ity and mortality, such as HIV, malaria, tuberculosis, lower respiratory</p>\n<p>tract infections, malnutrition and meningitis. In addition, new threats</p>\n<p>keep emerging, for example, epidemics of hepatitis B, yellow fever,</p>\n<p>haemorrhagic fevers, COVID-19 and nodding disease. The increase of</p>\n<p>non-communicable conditions including diabetes, hypertension, heart</p>\n<p>diseases, cancer and mental disorders complicates the scenario.</p>\n<p>The push towards universal health coverage, including universal access</p>\n<p>to AntiRetroviral Therapy (ART) and particular attention to neonatal,</p>\n<p>child, adolescent and maternal health, is also placing more demands on</p>\n<p>a system with limited resources.</p>\n<p>To respond appropriately, the health system has to ensure high standards</p>\n<p>of quality and efficiency in service delivery. The Uganda Clinical Guide\u00ad</p>\n<p>lines manual helps to achieve these standards by presenting updated,</p>\n<p>practical, and useful information on the diagnosis and management of</p>\n<p>common health conditions in Uganda. It also provides a rational basis for</p>\n<p>an efficient procurement and supply system that ensures the availability</p>\n<p>of safe, efficacious, quality medicines and health supplies.</p>\n<p>The guidelines are based on principles of scientific evidence, cost effec\u00ad</p>\n<p>tiveness and prioritization of conditions to maximize the health benefit</p>\n<p>with limited resources.</p>\n<p>The regular update of clinical guidelines and essential medicines lists</p>\n<p>is one of the key interventions in the Health Sector Development Plan</p>\n<p>2015-2020, to promote the appropriate use of health products and</p>\n<p>technologies.</p>"
    },
    {
        "page_number": 3,
        "content": "I wish to thank all the members of the Ministry of Health Update Task \nForce, government parastatals, medical consultants, district health work\u00ad\ners, the private sector, the Uganda Reproductive Maternal Child and \nAdolescent Health Improvement Project (URMCHIP) and development \npartners for their immense input in developing the 2023 UCG edition. \nFinally, I thank the consultancy firm, Zenith Solutions Limited, that \ncoordinated the overall inputs that led to the successful development \nof this book.\nDr. Aceng Jane Ruth Ocero\nHon.  Minister of Health \nIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>I wish to thank all the members of the Ministry of Health Update Task</p>\n<p>Force, government parastatals, medical consultants, district health work\u00ad</p>\n<p>ers, the private sector, the Uganda Reproductive Maternal Child and</p>\n<p>Adolescent Health Improvement Project (URMCHIP) and development</p>\n<p>partners for their immense input in developing the 2023 UCG edition.</p>\n<p>Finally, I thank the consultancy firm, Zenith Solutions Limited, that</p>\n<p>coordinated the overall inputs that led to the successful development</p>\n<p>of this book.</p>\n<p>Dr. Aceng Jane Ruth Ocero</p>\n<p>Hon.  Minister of Health</p>\n<h3>III</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 4,
        "content": "Contents\nForeword.......................................................................................II\nPreface........................................................................................XXI\nAcknowledgements....................................................................... XXIII\nUCG Taskforce ........................................................................... XXIII\nContributors to the clinical chapters................................................XXIV\nAdministrative Support................................................................. XXXII\nDesign/ Layout .......................................................................... XXXII\nAbbreviations.............................................................................. XXXIII\nIntroduction to Uganda Clinical Guidelines 2023............................... XLIV\n1 EMERGENCIES AND TRAUMA.....................................................1\n1.1 Common Emergencies................................................................1\n1.1.1  Anaphylactic Shock.........................................................................................1\n1.1.2 Hypovolaemic Shock........................................................................................3\n1.1.2.1 Hypvovolaemic  Shock In Children.................................................................6\n1.1.3 Dehydration ....................................................................................................8\n1.1.3.1 Dehydration in Children under 5 years...........................................................8\n1.1.3.2 Dehydration in Older Children and Adults......................................................13\n1.1.4 Fluids and Electrolytes Imbalances  ..................................................................15\n1.1.4.1 IV Fluid management in children ..................................................................19\n1.1.5 Febrile Convulsions..........................................................................................22\n1.1.6 Hypoglycaemia................................................................................................24\n1.2 Trauma and Injuries..................................................................26\n1.2.1 Bites and Stings..............................................................................................26\n1.2.1.1  Snakebites.........................................................................................28\n1.2.1.2 Insect Bites & Stings...........................................................................33\n1.2.1.3  Animal and Human Bites...................................................................34\n1.2.1.4  Rabies Post Exposure Prophylaxis ......................................................36\n1.2.1.5 Rabies Vaccine Schedules....................................................................42\n1.2.2 Fractures ........................................................................................................43\n1.2.3 Burns..............................................................................................................45\n1.2.4 Wounds...........................................................................................................52\n1.2.5 Head Injuries...................................................................................................55\n1.2.5.1 Traumatic Spinal Injury.......................................................................59\n1.2.6 Sexual Assault/Rape ......................................................................................60\nIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Contents</p>\n<p>Foreword.......................................................................................II</p>\n<p>Preface........................................................................................XXI</p>\n<p>Acknowledgements....................................................................... XXIII</p>\n<p>UCG Taskforce ........................................................................... XXIII</p>\n<p>Contributors to the clinical chapters................................................XXIV</p>\n<p>Administrative Support................................................................. XXXII</p>\n<p>Design/ Layout .......................................................................... XXXII</p>\n<p>Abbreviations.............................................................................. XXXIII</p>\n<p>Introduction to Uganda Clinical Guidelines 2023............................... XLIV</p>\n<h3>1 EMERGENCIES AND TRAUMA.....................................................1</h3>\n<li>.1 Common Emergencies................................................................1</li>\n<li>.1.1  Anaphylactic Shock.........................................................................................1</li>\n<li>.1.2 Hypovolaemic Shock........................................................................................3</li>\n<li>.1.2.1 Hypvovolaemic  Shock In Children.................................................................6</li>\n<li>.1.3 Dehydration ....................................................................................................8</li>\n<li>.1.3.1 Dehydration in Children under 5 years...........................................................8</li>\n<li>.1.3.2 Dehydration in Older Children and Adults......................................................13</li>\n<li>.1.4 Fluids and Electrolytes Imbalances  ..................................................................15</li>\n<li>.1.4.1 IV Fluid management in children ..................................................................19</li>\n<li>.1.5 Febrile Convulsions..........................................................................................22</li>\n<li>.1.6 Hypoglycaemia................................................................................................24</li>\n<li>.2 Trauma and Injuries..................................................................26</li>\n<li>.2.1 Bites and Stings..............................................................................................26</li>\n<li>.2.1.1  Snakebites.........................................................................................28</li>\n<li>.2.1.2 Insect Bites & Stings...........................................................................33</li>\n<li>.2.1.3  Animal and Human Bites...................................................................34</li>\n<li>.2.1.4  Rabies Post Exposure Prophylaxis ......................................................36</li>\n<li>.2.1.5 Rabies Vaccine Schedules....................................................................42</li>\n<li>.2.2 Fractures ........................................................................................................43</li>\n<li>.2.3 Burns..............................................................................................................45</li>\n<li>.2.4 Wounds...........................................................................................................52</li>\n<li>.2.5 Head Injuries...................................................................................................55</li>\n<li>.2.5.1 Traumatic Spinal Injury.......................................................................59</li>\n<li>.2.6 Sexual Assault/Rape ......................................................................................60</li>\n<p>IV</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 5,
        "content": "1.3 Poisoning................................................................................65\n1.3.1 General Management of Poisoning...................................................................65\n1.3.1.2 Removal and Elimination of Ingested Poison ........................................68\n1.3.2 Acute Organophosphate Poisoning...................................................................70\n1.3.3 Paraffin and Other Petroleum Products Poisoning..............................................72 \n1.3.4 Acetylsalicylic Acid (Aspirin) Poisoning..............................................................74\n1.3.5 Paracetamol Poisoning.....................................................................................75\n1.3.6 Iron Poisoning.................................................................................................76\n1.3.7 Carbon Monoxide Poisoning............................................................................77\n1.3.8 Barbiturate Poisoning.......................................................................................78 \n1.3.9 Opioid Poisoning.............................................................................................79 \n1.3.10 Warfarin Poisoning........................................................................................80\n1.3.11 Methyl Alcohol (Methanol) Poisoning..............................................................81\n1.3.12 Alcohol (Ethanol) Poisoning ...........................................................................82\n1.3.12.1 Acute Alcohol Poisoning....................................................................82\n1.3.12.2 Chronic Alcohol Poisoning.................................................................84\n1.3.13 Food Poisoning.............................................................................................85\n1.4 Hypoxeamia Management and Oxygen Therapy Guidelines.............87\n2 INFECTIOUS DISEASES..............................................................95\n2.1 Bacterial Infections...................................................................95\n2.1.1 Anthrax..........................................................................................................95\n2.1.2 Brucellosis.......................................................................................................97\n2.1.3 Diphtheria......................................................................................................100\n2.1.4 Leprosy/Hansens disease ..............................................................................101\n2.1.5 Meningitis......................................................................................................107\n2.1.5.1 Neonatal Meningitis............................................................................111\n2.1.5.2 Cryptococcal Meningitis........................................................................                             \n2.1.5.3 TB Meningitis....................................................................................113\n2.1.6 Plague............................................................................................................113\n2.1.7 Septicaemia...................................................................................................115\n2.1.7.1 Neonatal Septicaemia.........................................................................117\n2.1.7.2  Septic Shock Management, In Adults.................................................118\n2.1.8 Tetanus..........................................................................................................119\n2.1.8.1 Neonatal Tetanus...............................................................................123\n2.1.9 Typhoid Fever (Enteric Fever) .........................................................................124\n2.1.10 Typhus Fever................................................................................................126\nV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<li>.3 Poisoning................................................................................65</li>\n<li>.3.1 General Management of Poisoning...................................................................65</li>\n<li>.3.1.2 Removal and Elimination of Ingested Poison ........................................68</li>\n<li>.3.2 Acute Organophosphate Poisoning...................................................................70</li>\n<li>.3.3 Paraffin and Other Petroleum Products Poisoning..............................................72</li>\n<li>.3.4 Acetylsalicylic Acid (Aspirin) Poisoning..............................................................74</li>\n<li>.3.5 Paracetamol Poisoning.....................................................................................75</li>\n<li>.3.6 Iron Poisoning.................................................................................................76</li>\n<li>.3.7 Carbon Monoxide Poisoning............................................................................77</li>\n<li>.3.8 Barbiturate Poisoning.......................................................................................78</li>\n<li>.3.9 Opioid Poisoning.............................................................................................79</li>\n<li>.3.10 Warfarin Poisoning........................................................................................80</li>\n<li>.3.11 Methyl Alcohol (Methanol) Poisoning..............................................................81</li>\n<li>.3.12 Alcohol (Ethanol) Poisoning ...........................................................................82</li>\n<li>.3.12.1 Acute Alcohol Poisoning....................................................................82</li>\n<li>.3.12.2 Chronic Alcohol Poisoning.................................................................84</li>\n<li>.3.13 Food Poisoning.............................................................................................85</li>\n<li>.4 Hypoxeamia Management and Oxygen Therapy Guidelines.............87</li>\n<h3>2 INFECTIOUS DISEASES..............................................................95</h3>\n<p>2.1 Bacterial Infections...................................................................95</p>\n<p>2.1.1 Anthrax..........................................................................................................95</p>\n<p>2.1.2 Brucellosis.......................................................................................................97</p>\n<p>2.1.3 Diphtheria......................................................................................................100</p>\n<p>2.1.4 Leprosy/Hansens disease ..............................................................................101</p>\n<p>2.1.5 Meningitis......................................................................................................107</p>\n<p>2.1.5.1 Neonatal Meningitis............................................................................111</p>\n<p>2.1.5.2 Cryptococcal Meningitis........................................................................</p>\n<p>2.1.5.3 TB Meningitis....................................................................................113</p>\n<p>2.1.6 Plague............................................................................................................113</p>\n<p>2.1.7 Septicaemia...................................................................................................115</p>\n<p>2.1.7.1 Neonatal Septicaemia.........................................................................117</p>\n<p>2.1.7.2  Septic Shock Management, In Adults.................................................118</p>\n<p>2.1.8 Tetanus..........................................................................................................119</p>\n<p>2.1.8.1 Neonatal Tetanus...............................................................................123</p>\n<p>2.1.9 Typhoid Fever (Enteric Fever) .........................................................................124</p>\n<p>2.1.10 Typhus Fever................................................................................................126</p>\n<p>V</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 6,
        "content": "2.2 Fungal Infections.....................................................................128\n2.2.1 Candidiasis.....................................................................................................128\n2.3 Viral Infections........................................................................130\n2.3.1 Avian Influenza  .............................................................................................130\n2.3.2 Chicken pox...................................................................................................133\n2.3.3 Measles..........................................................................................................134\n2.3.4 Poliomyelitis...................................................................................................136\n2.3.5 Rabies............................................................................................................138\n2.3.6 Viral Haemorrhagic Fevers..............................................................................140\n2.3.6.1 Ebola and Marburg.............................................................................140\n2.3.6.2 Yellow Fever......................................................................................143\n2.3.7 COVID-19 Disease.........................................................................................144\n2.4 Helminthes Parasites................................................................150\n2.4.1 Intestinal Worms ...........................................................................................150\n2.4.1.1 Taeniasis (Tapeworm).........................................................................153\n2.4.2 Echinococcosis (Hydatid  Disease)...................................................................154\n2.4.3 Dracunculiasis (Guinea Worm).........................................................................156\n2.4.4 Lymphatic Filariasis........................................................................................157\n2.4.5 Onchocerciasis (River Blindness)......................................................................159\n2.4.6 Schistosomiasis (Bilharziasis)...........................................................................161\n2.5 Protozoal Parasites..................................................................162\n2.5.1 Leishmaniasis.................................................................................................162\n2.5.2 Malaria...........................................................................................................164\n2.5.2.1 Uncomplicated Malaria.......................................................................165\n2.5.2.2 Complicated/Severe Malaria...............................................................166\n2.5.3.3 Management of Complications of Severe Malaria.................................175\n2.5.3.4 Malaria Prophylaxis............................................................................179\n2.5.3.5 Malaria Prevention and Control...........................................................180\n2.5.4 Human African Trypanosomiasis (Sleeping Sickness)  .....................................181\n3 HIV/AIDS AND SEXUALLY TRANSMITTED INFECTIONS.............186\n3.1 HIV Infection And Acquired Immunodeficiency Syndrome (AIDS)  ..186\n3.1.1 Clinical Features of HIV .................................................................................187\n3.1.2 Diagnosis and Investigations of HIV.................................................................190\n3.1.3 Measures before ARV Treatment.....................................................................197\n3.1.4 General Principles of Antiretroviral Treatment (ART)........................................200\nVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>2.2 Fungal Infections.....................................................................128</p>\n<p>2.2.1 Candidiasis.....................................................................................................128</p>\n<p>2.3 Viral Infections........................................................................130</p>\n<p>2.3.1 Avian Influenza  .............................................................................................130</p>\n<p>2.3.2 Chicken pox...................................................................................................133</p>\n<p>2.3.3 Measles..........................................................................................................134</p>\n<p>2.3.4 Poliomyelitis...................................................................................................136</p>\n<p>2.3.5 Rabies............................................................................................................138</p>\n<p>2.3.6 Viral Haemorrhagic Fevers..............................................................................140</p>\n<p>2.3.6.1 Ebola and Marburg.............................................................................140</p>\n<p>2.3.6.2 Yellow Fever......................................................................................143</p>\n<p>2.3.7 COVID-19 Disease.........................................................................................144</p>\n<p>2.4 Helminthes Parasites................................................................150</p>\n<p>2.4.1 Intestinal Worms ...........................................................................................150</p>\n<p>2.4.1.1 Taeniasis (Tapeworm).........................................................................153</p>\n<p>2.4.2 Echinococcosis (Hydatid  Disease)...................................................................154</p>\n<p>2.4.3 Dracunculiasis (Guinea Worm).........................................................................156</p>\n<p>2.4.4 Lymphatic Filariasis........................................................................................157</p>\n<p>2.4.5 Onchocerciasis (River Blindness)......................................................................159</p>\n<p>2.4.6 Schistosomiasis (Bilharziasis)...........................................................................161</p>\n<p>2.5 Protozoal Parasites..................................................................162</p>\n<p>2.5.1 Leishmaniasis.................................................................................................162</p>\n<p>2.5.2 Malaria...........................................................................................................164</p>\n<p>2.5.2.1 Uncomplicated Malaria.......................................................................165</p>\n<p>2.5.2.2 Complicated/Severe Malaria...............................................................166</p>\n<p>2.5.3.3 Management of Complications of Severe Malaria.................................175</p>\n<p>2.5.3.4 Malaria Prophylaxis............................................................................179</p>\n<p>2.5.3.5 Malaria Prevention and Control...........................................................180</p>\n<p>2.5.4 Human African Trypanosomiasis (Sleeping Sickness)  .....................................181</p>\n<h3>3 HIV/AIDS AND SEXUALLY TRANSMITTED INFECTIONS.............186</h3>\n<p>3.1 HIV Infection And Acquired Immunodeficiency Syndrome (AIDS)  ..186</p>\n<p>3.1.1 Clinical Features of HIV .................................................................................187</p>\n<p>3.1.2 Diagnosis and Investigations of HIV.................................................................190</p>\n<p>3.1.3 Measures before ARV Treatment.....................................................................197</p>\n<p>3.1.4 General Principles of Antiretroviral Treatment (ART)........................................200</p>\n<p>VI</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 7,
        "content": "3.1.5 Recommended First Line Regimens.................................................................206\n3.1.6 Monitoring of ART.........................................................................................211\n3.1.7 ARV Toxicity..................................................................................................218\n3.1.8 Recommended Second Line Regimens ...........................................................222\n3.1.9 Mother-to-Child Transmission of HIV...............................................................229\n3.1.9.1 Management of HIV Positive Pregnant Mother....................................231\nKey Interventions for eMTCT...................................................................................231\n3.1.9.2 HIV-exposed infant care services........................................................239\n3.1.9.3 Care of HIV Exposed Infant................................................................248\n3.1.10  Opportunistic Infections In HIV....................................................................252\n3.1.10.1 Tuberculosis and HIV Co-Infection....................................................252\n3.1.10.2 Cryptococcal Meningitis...................................................................255\n3.1.10.3 Hepatitis B and HIV Co-Infection.....................................................261\n3.1.10.4 Pneumocystis Pneumonia.................................................................263\n3.1.10.5 Other Diseases.................................................................................264\n3.1.11 Prevention of HIV........................................................................................264\n3.1.11.1 Post-Exposure Prophylaxis................................................................265\n3.1.11.2 Pre-Exposure Prophylaxis (PrEP).......................................................269\n3.1.12.......................................................................................................................\n3.2 Sexually Transmitted Infections (STI)..........................................276\n3.2.1 Urethral Discharge Syndrome (Male) ...............................................................276\n3.2.2 Abnormal Vaginal Discharge Syndrome...........................................................279\n3.2.3 Pelvic Inflammatory Disease (PID)....................................................................283\n3.2.4 Genital Ulcer Disease (GUD) Syndrome..................................................283\n3.2.5 Inguinal Swelling (Bubo).........................................................................286\n3.2.6 Genital Warts........................................................................................288\n3.2.7 Syphilis.................................................................................................290\n3.2.8 Other Genital Infections..................................................................................292\n3.2.8.1 Balanitis......................................................................................................292\n3.2.8.2 Painful Scrotal Swelling................................................................................293\n3.2.9 Congenital STI Syndromes..............................................................................294\n3.2.9.1 Neonatal Conjunctivitis (Ophthalmia Neonatorum)........................................294\n3.2.9.2 Congenital Syphilis......................................................................................295\n4 CARDIOVASCULAR DISEASES...................................................298\n4.1.1 Deep Vein Thrombosis/Pulmonary Embolism (DVT/P)....................................298\n4.1.2 Infective Endocarditis......................................................................................301\n4.1.3 Heart Failure..................................................................................................304\n4.1.4 Pulmonary Oedema........................................................................................308\nVII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>3.1.5 Recommended First Line Regimens.................................................................206</p>\n<p>3.1.6 Monitoring of ART.........................................................................................211</p>\n<p>3.1.7 ARV Toxicity..................................................................................................218</p>\n<p>3.1.8 Recommended Second Line Regimens ...........................................................222</p>\n<p>3.1.9 Mother-to-Child Transmission of HIV...............................................................229</p>\n<p>3.1.9.1 Management of HIV Positive Pregnant Mother....................................231</p>\n<p>Key Interventions for eMTCT...................................................................................231</p>\n<p>3.1.9.2 HIV-exposed infant care services........................................................239</p>\n<p>3.1.9.3 Care of HIV Exposed Infant................................................................248</p>\n<p>3.1.10  Opportunistic Infections In HIV....................................................................252</p>\n<p>3.1.10.1 Tuberculosis and HIV Co-Infection....................................................252</p>\n<p>3.1.10.2 Cryptococcal Meningitis...................................................................255</p>\n<p>3.1.10.3 Hepatitis B and HIV Co-Infection.....................................................261</p>\n<p>3.1.10.4 Pneumocystis Pneumonia.................................................................263</p>\n<p>3.1.10.5 Other Diseases.................................................................................264</p>\n<p>3.1.11 Prevention of HIV........................................................................................264</p>\n<p>3.1.11.1 Post-Exposure Prophylaxis................................................................265</p>\n<p>3.1.11.2 Pre-Exposure Prophylaxis (PrEP).......................................................269</p>\n<p>3.1.12.......................................................................................................................</p>\n<p>3.2 Sexually Transmitted Infections (STI)..........................................276</p>\n<p>3.2.1 Urethral Discharge Syndrome (Male) ...............................................................276</p>\n<p>3.2.2 Abnormal Vaginal Discharge Syndrome...........................................................279</p>\n<p>3.2.3 Pelvic Inflammatory Disease (PID)....................................................................283</p>\n<p>3.2.4 Genital Ulcer Disease (GUD) Syndrome..................................................283</p>\n<p>3.2.5 Inguinal Swelling (Bubo).........................................................................286</p>\n<p>3.2.6 Genital Warts........................................................................................288</p>\n<p>3.2.7 Syphilis.................................................................................................290</p>\n<p>3.2.8 Other Genital Infections..................................................................................292</p>\n<p>3.2.8.1 Balanitis......................................................................................................292</p>\n<p>3.2.8.2 Painful Scrotal Swelling................................................................................293</p>\n<p>3.2.9 Congenital STI Syndromes..............................................................................294</p>\n<p>3.2.9.1 Neonatal Conjunctivitis (Ophthalmia Neonatorum)........................................294</p>\n<p>3.2.9.2 Congenital Syphilis......................................................................................295</p>\n<h3>4 CARDIOVASCULAR DISEASES...................................................298</h3>\n<p>4.1.1 Deep Vein Thrombosis/Pulmonary Embolism (DVT/P)....................................298</p>\n<p>4.1.2 Infective Endocarditis......................................................................................301</p>\n<p>4.1.3 Heart Failure..................................................................................................304</p>\n<p>4.1.4 Pulmonary Oedema........................................................................................308</p>\n<h3>VII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 8,
        "content": "4.1.5 Atrial Fibrillation.............................................................................................309\n4.1.6 Hypertension.................................................................................................311\n4.1.6.1 Hypertensive Emergencies and urgency  ............................................316\n4.1.7 Ischaemic Heart Disease (Coronary Heart Disease)...........................................317\n4.1.8 Pericarditis.....................................................................................................320\n4.1.9 Rheumatic Fever.............................................................................................322\n4.1.10 Rheumatic Heart Disease..............................................................................325\n4.1.11 Stroke..........................................................................................................326\n5 RESPIRATORY DISEASES..........................................................329\n5.1 Non-Infectious Respiratory Diseases...........................................329\n5.1.1 Asthma .........................................................................................................329\n5.1.1.1 Acute Asthma....................................................................................331\n5.1.1.2 Chronic Asthma.................................................................................337\n5.1.2 Chronic Obstructive Pulmonary Disease (COPD)..............................................340\n5.2 Infectious Respiratory Diseases..................................................344\n5.2.1 Bronchiolitis...................................................................................................344\n5.2.2 Acute Bronchitis.............................................................................................346\n5.2.3 Coryza (Common Cold)..................................................................................347\n5.2.4 Acute Epiglottitis............................................................................................349\n5.2.5 Influenza (\u201d Flu\u201d).............................................................................................350\n5.2.6  Laryngitis......................................................................................................352\n5.2.7 Acute Laryngotracheobronchitis (Croup)   .......................................................353\n5.2.8 Pertussis (Whooping Cough)............................................................................355\n5.2.9 Pneumonia.....................................................................................................357\n5.2.9.1 Pneumonia in an Infant (up to 2 months) ............................................358\n5.2.9.2 Pneumonia in a Child of 2 months-5 years..........................................360\n5.2.9.3 Pneumonia in Children > 5 years and adults........................................363\n5.2.9.4 Pneumonia by Specific Organisms......................................................364\n5.2.9.5 Pneumocystis jirovecii Pneumonia ......................................................365\n5.2.9.6 Lung Abscess.....................................................................................366\n5.3 Tuberculosis (Tb).....................................................................367\n5.3.1 Definition, Clinical Features and Diagnosis of TB.............................................367\n5.3.1.1 Tuberculosis in Children and adolescents......................................................373\n5.3.1.2 Drug-Resistant TB.......................................................................................374\n5.3.1.3 Post-TB patient management ......................................................................375\n5.3.2 Management of TB.........................................................................................376\n5.3.2.1 Anti-TB Drugs Side Effects..........................................................................382\nVIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>4.1.5 Atrial Fibrillation.............................................................................................309</p>\n<p>4.1.6 Hypertension.................................................................................................311</p>\n<p>4.1.6.1 Hypertensive Emergencies and urgency  ............................................316</p>\n<p>4.1.7 Ischaemic Heart Disease (Coronary Heart Disease)...........................................317</p>\n<p>4.1.8 Pericarditis.....................................................................................................320</p>\n<p>4.1.9 Rheumatic Fever.............................................................................................322</p>\n<p>4.1.10 Rheumatic Heart Disease..............................................................................325</p>\n<p>4.1.11 Stroke..........................................................................................................326</p>\n<h3>5 RESPIRATORY DISEASES..........................................................329</h3>\n<p>5.1 Non-Infectious Respiratory Diseases...........................................329</p>\n<p>5.1.1 Asthma .........................................................................................................329</p>\n<p>5.1.1.1 Acute Asthma....................................................................................331</p>\n<p>5.1.1.2 Chronic Asthma.................................................................................337</p>\n<p>5.1.2 Chronic Obstructive Pulmonary Disease (COPD)..............................................340</p>\n<p>5.2 Infectious Respiratory Diseases..................................................344</p>\n<p>5.2.1 Bronchiolitis...................................................................................................344</p>\n<p>5.2.2 Acute Bronchitis.............................................................................................346</p>\n<p>5.2.3 Coryza (Common Cold)..................................................................................347</p>\n<p>5.2.4 Acute Epiglottitis............................................................................................349</p>\n<p>5.2.5 Influenza (\u201d Flu\u201d).............................................................................................350</p>\n<p>5.2.6  Laryngitis......................................................................................................352</p>\n<p>5.2.7 Acute Laryngotracheobronchitis (Croup)   .......................................................353</p>\n<p>5.2.8 Pertussis (Whooping Cough)............................................................................355</p>\n<p>5.2.9 Pneumonia.....................................................................................................357</p>\n<p>5.2.9.1 Pneumonia in an Infant (up to 2 months) ............................................358</p>\n<p>5.2.9.2 Pneumonia in a Child of 2 months-5 years..........................................360</p>\n<p>5.2.9.3 Pneumonia in Children > 5 years and adults........................................363</p>\n<p>5.2.9.4 Pneumonia by Specific Organisms......................................................364</p>\n<p>5.2.9.5 Pneumocystis jirovecii Pneumonia ......................................................365</p>\n<p>5.2.9.6 Lung Abscess.....................................................................................366</p>\n<p>5.3 Tuberculosis (Tb).....................................................................367</p>\n<p>5.3.1 Definition, Clinical Features and Diagnosis of TB.............................................367</p>\n<p>5.3.1.1 Tuberculosis in Children and adolescents......................................................373</p>\n<p>5.3.1.2 Drug-Resistant TB.......................................................................................374</p>\n<p>5.3.1.3 Post-TB patient management ......................................................................375</p>\n<p>5.3.2 Management of TB.........................................................................................376</p>\n<p>5.3.2.1 Anti-TB Drugs Side Effects..........................................................................382</p>\n<h3>VIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 9,
        "content": "5.3.2.2 Prevention and Infection Control of TB.........................................................385\n5.3.2.3 Tuberculosis Preventive Treatment................................................................386\n5.3.2.5 TB Preventive Treatment Dosing Chart........................................................388\n6 GASTROINTESTINAL AND HEPATIC DISEASES..........................394\n6.1 Gastrointestinal Emergencies.....................................................394\n6.1.1 Appendicitis (Acute)........................................................................................394\n6.1.2  Acute Pancreatitis..........................................................................................395\n6.1.3 Upper Gastrointestinal Bleeding .....................................................................400\n6.1.4 Peritonitis.......................................................................................................401\n6.1.5 Diarrhoea.......................................................................................................403\n6.2 Gastrointestinal  Infections........................................................405\n6.2.1 Amoebiasis.....................................................................................................405\n6.2.2 Bacillary Dysentery (Shigellosis).......................................................................407\n6.2.4 Giardiasis.......................................................................................................409\n6.3 Gastrointestinal Disorders.........................................................410\n6.3.1 Dysphagia......................................................................................................410\n6.3.2  Dyspepsia.....................................................................................................412\n6.3.3 Gastroesophageal Reflux Disease (GERD/GORD)............................................413\n6.3.4 Gastritis.........................................................................................................415\n6.3.5 Peptic Ulcer Disease (PUD).............................................................................417\n6.3.6 Chronic Pancreatitis........................................................................................419\n6.4 Anorectal Disorders...........................................................................................421\n6.4.1 Constipation..................................................................................................421\n6.4.2 Haemorrhoids (Piles) and Anal Fissures...........................................................423\n6.5 Hepatic and Biliary Diseases......................................................425\n6.5.1 Viral Hepatitis................................................................................................425\n6.5.1.1 Acute Hepatitis..................................................................................425\n6.5.1.2 Chronic Hepatitis...............................................................................427\n6.5.2 Chronic Hepatitis B Infection..........................................................................428\n6.5.2.1 Inactive Hepatitis B Carriers...............................................................430\n6.5.2.2 Pregnant Mother HbsAg Positive.........................................................430\n6.5.3 Chronic Hepatitis C Infection.................................................................431\n6.5.4 Liver Cirrhosis................................................................................................431\n6.5.4.1 Ascites...............................................................................................434\n6.5.4.2 Spontaneous Bacterial Peritonitis (SBP) ..............................................436\n6.5.4.3 Hepatic Encephalopathy (HE) ............................................................437\nIX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>5.3.2.2 Prevention and Infection Control of TB.........................................................385</p>\n<p>5.3.2.3 Tuberculosis Preventive Treatment................................................................386</p>\n<p>5.3.2.5 TB Preventive Treatment Dosing Chart........................................................388</p>\n<h3>6 GASTROINTESTINAL AND HEPATIC DISEASES..........................394</h3>\n<p>6.1 Gastrointestinal Emergencies.....................................................394</p>\n<p>6.1.1 Appendicitis (Acute)........................................................................................394</p>\n<p>6.1.2  Acute Pancreatitis..........................................................................................395</p>\n<p>6.1.3 Upper Gastrointestinal Bleeding .....................................................................400</p>\n<p>6.1.4 Peritonitis.......................................................................................................401</p>\n<p>6.1.5 Diarrhoea.......................................................................................................403</p>\n<p>6.2 Gastrointestinal  Infections........................................................405</p>\n<p>6.2.1 Amoebiasis.....................................................................................................405</p>\n<p>6.2.2 Bacillary Dysentery (Shigellosis).......................................................................407</p>\n<p>6.2.4 Giardiasis.......................................................................................................409</p>\n<p>6.3 Gastrointestinal Disorders.........................................................410</p>\n<p>6.3.1 Dysphagia......................................................................................................410</p>\n<p>6.3.2  Dyspepsia.....................................................................................................412</p>\n<p>6.3.3 Gastroesophageal Reflux Disease (GERD/GORD)............................................413</p>\n<p>6.3.4 Gastritis.........................................................................................................415</p>\n<p>6.3.5 Peptic Ulcer Disease (PUD).............................................................................417</p>\n<p>6.3.6 Chronic Pancreatitis........................................................................................419</p>\n<p>6.4 Anorectal Disorders...........................................................................................421</p>\n<p>6.4.1 Constipation..................................................................................................421</p>\n<p>6.4.2 Haemorrhoids (Piles) and Anal Fissures...........................................................423</p>\n<p>6.5 Hepatic and Biliary Diseases......................................................425</p>\n<p>6.5.1 Viral Hepatitis................................................................................................425</p>\n<p>6.5.1.1 Acute Hepatitis..................................................................................425</p>\n<p>6.5.1.2 Chronic Hepatitis...............................................................................427</p>\n<p>6.5.2 Chronic Hepatitis B Infection..........................................................................428</p>\n<p>6.5.2.1 Inactive Hepatitis B Carriers...............................................................430</p>\n<p>6.5.2.2 Pregnant Mother HbsAg Positive.........................................................430</p>\n<p>6.5.3 Chronic Hepatitis C Infection.................................................................431</p>\n<p>6.5.4 Liver Cirrhosis................................................................................................431</p>\n<p>6.5.4.1 Ascites...............................................................................................434</p>\n<p>6.5.4.2 Spontaneous Bacterial Peritonitis (SBP) ..............................................436</p>\n<p>6.5.4.3 Hepatic Encephalopathy (HE) ............................................................437</p>\n<p>IX</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 10,
        "content": "6.5.4.2 Oesophageal Varices..........................................................................439\n6.5.4.3 Hepatorenal Syndrome.......................................................................440\n6.5.4.4 Hepatocellular Carcinoma...................................................................440\n6.5.5 Hepatic Schistosomiasis..................................................................................441\n6.5.6 Drug-Induced Liver Injury................................................................................442\n6.5.7 Jaundice (Hyperbilirubinemia)..........................................................................443\n6.5.8 Gallstones/Biliary Colic..................................................................................444\n6.5.9 Acute Cholecystitis/Cholangitis.......................................................................445\n7 RENAL AND URINARY DISEASES..............................................448\n7.1 Renal Diseases........................................................................448\n7.1.1 Acute Renal Failure.........................................................................................448\n7.1.2 Chronic Kidney Disease (CKD)........................................................................450\n7.1.3 Use of Drugs in Renal Failure..........................................................................453\n7.1.4 Glomerulonephritis.........................................................................................454\n7.1.5 Nephrotic Syndrome.......................................................................................457\n7.2 Urological Diseases..................................................................458\n7.2.1 Acute Cystitis.................................................................................................458\n7.2.2 Acute Pyelonephritis.......................................................................................460\n7.2.3 Prostatitis.......................................................................................................463\n7.2.4 Renal Colic.....................................................................................................464\n7.2.5 Benign Prostatic Hyperplasia..........................................................................465\n7.2.6 Bladder Outlet Obstruction..............................................................................466\n7.2.7 Urine Incontinence.........................................................................................467\n8 ENDOCRINE AND METABOLIC DISEASES..................................468\n8.1.1 Addison\u2019s Disease...........................................................................................468\n8.1.2 Cushing\u2019s Syndrome.......................................................................................470\n8.1.3 Diabetes Mellitus............................................................................................471\n8.1.4 Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemic State........................478\n8.1.5 Goitre............................................................................................................481\n8.1.6 Hyperthyroidism.............................................................................................482\n8.1.7 Hypothyroidism..............................................................................................484\n8.1.8. Central precocious puberty............................................................................486\nX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>6.5.4.2 Oesophageal Varices..........................................................................439</p>\n<p>6.5.4.3 Hepatorenal Syndrome.......................................................................440</p>\n<p>6.5.4.4 Hepatocellular Carcinoma...................................................................440</p>\n<p>6.5.5 Hepatic Schistosomiasis..................................................................................441</p>\n<p>6.5.6 Drug-Induced Liver Injury................................................................................442</p>\n<p>6.5.7 Jaundice (Hyperbilirubinemia)..........................................................................443</p>\n<p>6.5.8 Gallstones/Biliary Colic..................................................................................444</p>\n<p>6.5.9 Acute Cholecystitis/Cholangitis.......................................................................445</p>\n<h3>7 RENAL AND URINARY DISEASES..............................................448</h3>\n<p>7.1 Renal Diseases........................................................................448</p>\n<p>7.1.1 Acute Renal Failure.........................................................................................448</p>\n<p>7.1.2 Chronic Kidney Disease (CKD)........................................................................450</p>\n<p>7.1.3 Use of Drugs in Renal Failure..........................................................................453</p>\n<p>7.1.4 Glomerulonephritis.........................................................................................454</p>\n<p>7.1.5 Nephrotic Syndrome.......................................................................................457</p>\n<p>7.2 Urological Diseases..................................................................458</p>\n<p>7.2.1 Acute Cystitis.................................................................................................458</p>\n<p>7.2.2 Acute Pyelonephritis.......................................................................................460</p>\n<p>7.2.3 Prostatitis.......................................................................................................463</p>\n<p>7.2.4 Renal Colic.....................................................................................................464</p>\n<p>7.2.5 Benign Prostatic Hyperplasia..........................................................................465</p>\n<p>7.2.6 Bladder Outlet Obstruction..............................................................................466</p>\n<p>7.2.7 Urine Incontinence.........................................................................................467</p>\n<h3>8 ENDOCRINE AND METABOLIC DISEASES..................................468</h3>\n<p>8.1.1 Addison\u2019s Disease...........................................................................................468</p>\n<p>8.1.2 Cushing\u2019s Syndrome.......................................................................................470</p>\n<p>8.1.3 Diabetes Mellitus............................................................................................471</p>\n<p>8.1.4 Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemic State........................478</p>\n<p>8.1.5 Goitre............................................................................................................481</p>\n<p>8.1.6 Hyperthyroidism.............................................................................................482</p>\n<p>8.1.7 Hypothyroidism..............................................................................................484</p>\n<p>8.1.8. Central precocious puberty............................................................................486</p>\n<p>X</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 11,
        "content": "9 MENTAL, NEUROLOGICAL AND SUBSTANCE USE DISORDERS..488\n9.1 Neurological Disorders..............................................................488\n9.1.1 Epilepsy.........................................................................................................488\n9.1.2 Nodding Disease............................................................................................496\n9.1.3 Headache.......................................................................................................497\n9.1.3.1 Migraine............................................................................................498\n9.1.4 Dementia.......................................................................................................499\n9.1.5 Parkinsonism..................................................................................................502\n9.1.6 Delirium (Acute Confusional State)...................................................................504\n9.2 Psychiatric And Substance Use Disorders....................................506\n9.2.1 Anxiety..........................................................................................................506\n9.2.2 Depression.....................................................................................................508\n9.2.2.1 Postnatal Depression..........................................................................512\n9.2.2.2 Suicidal Behaviour/Self Harm ............................................................511\n9.2.3 Bipolar Disorder (Mania).................................................................................515\n9.2.4 Psychosis.......................................................................................................520\n9.2.4.1 Postnatal Psychosis.............................................................................522\n9.2 Psychiatric And Substance Use Disorders....................................524\n9.2.1 Anxiety..........................................................................................................524\n9.2.2 Depression.....................................................................................................526\n9.2.2.1 Postnatal Depression...................................................................................530\n9.2.2.2 Suicidal Behaviour/Self Harm......................................................................531\n9.2.3 Bipolar Disorder (Mania).................................................................................533\n9.2.4 Psychosis.......................................................................................................538\n9.1.1.1 Postnatal Psychosis......................................................................................541\n9.1.1 Alcohol Use Disorders....................................................................................543\n9.1.2 Substance Abuse............................................................................................547\n9.1.3 Childhood Behavioural Disorders....................................................................550\n9.1.4 Childhood Developmental Disorders................................................................552\n10 MUSCULOSKELETAL AND JOINT DISEASES............................554\n10.1 Infections..............................................................................554\n10.1.1 Pyogenic Arthritis (Septic Arthritis)................................................................554\n10.1.2 Osteomyelitis................................................................................................556\n10.1.3 Pyomyositis..................................................................................................559\nXI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>9 MENTAL, NEUROLOGICAL AND SUBSTANCE USE DISORDERS..488</h3>\n<p>9.1 Neurological Disorders..............................................................488</p>\n<p>9.1.1 Epilepsy.........................................................................................................488</p>\n<p>9.1.2 Nodding Disease............................................................................................496</p>\n<p>9.1.3 Headache.......................................................................................................497</p>\n<p>9.1.3.1 Migraine............................................................................................498</p>\n<p>9.1.4 Dementia.......................................................................................................499</p>\n<p>9.1.5 Parkinsonism..................................................................................................502</p>\n<p>9.1.6 Delirium (Acute Confusional State)...................................................................504</p>\n<p>9.2 Psychiatric And Substance Use Disorders....................................506</p>\n<p>9.2.1 Anxiety..........................................................................................................506</p>\n<p>9.2.2 Depression.....................................................................................................508</p>\n<p>9.2.2.1 Postnatal Depression..........................................................................512</p>\n<p>9.2.2.2 Suicidal Behaviour/Self Harm ............................................................511</p>\n<p>9.2.3 Bipolar Disorder (Mania).................................................................................515</p>\n<p>9.2.4 Psychosis.......................................................................................................520</p>\n<p>9.2.4.1 Postnatal Psychosis.............................................................................522</p>\n<p>9.2 Psychiatric And Substance Use Disorders....................................524</p>\n<p>9.2.1 Anxiety..........................................................................................................524</p>\n<p>9.2.2 Depression.....................................................................................................526</p>\n<p>9.2.2.1 Postnatal Depression...................................................................................530</p>\n<p>9.2.2.2 Suicidal Behaviour/Self Harm......................................................................531</p>\n<p>9.2.3 Bipolar Disorder (Mania).................................................................................533</p>\n<p>9.2.4 Psychosis.......................................................................................................538</p>\n<p>9.1.1.1 Postnatal Psychosis......................................................................................541</p>\n<p>9.1.1 Alcohol Use Disorders....................................................................................543</p>\n<p>9.1.2 Substance Abuse............................................................................................547</p>\n<p>9.1.3 Childhood Behavioural Disorders....................................................................550</p>\n<p>9.1.4 Childhood Developmental Disorders................................................................552</p>\n<h3>10 MUSCULOSKELETAL AND JOINT DISEASES............................554</h3>\n<p>10.1 Infections..............................................................................554</p>\n<p>10.1.1 Pyogenic Arthritis (Septic Arthritis)................................................................554</p>\n<p>10.1.2 Osteomyelitis................................................................................................556</p>\n<p>10.1.3 Pyomyositis..................................................................................................559</p>\n<p>XI</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 12,
        "content": "10.1.4 Tuberculosis of the Spine (Pott\u2019s Disease).......................................................560\n10.2 Inflammatory/Degenerative Disorders.......................................562\n10.2.1 Rheumatoid Arthritis....................................................................................562\n10.2.2 Gout Arhthritis.............................................................................................564\n10.2.3 Osteoarthritis...............................................................................................566\n11 BLOOD DISEASES AND BLOOD TRANSFUSION GUIDELINES....568\n11.1 Blood Disorders.....................................................................568\n11.1.1 Anaemia ............................................................................................568\n11.1.1.1 Iron Deficiency Anaemia...................................................................571\n11.1.1.2  Megaloblastic Anaemia....................................................................573\n11.1.1.3  Normocytic Anaemia......................................................................575\n11.1.2  Bleeding Disorders.............................................................................577\n11.1.3 Sickle Cell Disease..............................................................................579\n11.2 Blood and Blood Products.......................................................588\n11.2.1 General Principles of Good Clinical Practice in Transfusion Medicine.....589\n11.2.2 Blood and Blood Products: Characteristics and Indications ...................590\n11.2.2.1 Whole Blood ..................................................................................590\n11.2.2.2 Red Cell Concentrates (packed red cells) ...........................................591\n11.2.2.3 Clinical Indications for Blood Transfusion .........................................592\n11.2.3 Adverse Reactions following Transfusion .......................................................595\n11.2.3.1 Acute Transfusion Reactions ............................................................598\n12 ONCOLOGY...........................................................................602\n12.1 Introduction..........................................................................602\n12.1.1 Special Groups at Increased Risk of Cancer...................................................602\n12.1.2 Early Signs and Symptoms............................................................................603\n12.1.2.1 Urgent Signs and Symptoms.............................................................605\n12.2 Prevention of Cancer.............................................................605\n12.2.1 Primary Prevention ......................................................................................605\n12.2.1.1 Control of Risk Factors.....................................................................606\n12.2.2 Secondary Prevention.........................................................................609\n12.3 Common Cancers..................................................................612\n12.3.1 Common Cancers in Children.......................................................................612\nXII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>10.1.4 Tuberculosis of the Spine (Pott\u2019s Disease).......................................................560</p>\n<p>10.2 Inflammatory/Degenerative Disorders.......................................562</p>\n<p>10.2.1 Rheumatoid Arthritis....................................................................................562</p>\n<p>10.2.2 Gout Arhthritis.............................................................................................564</p>\n<p>10.2.3 Osteoarthritis...............................................................................................566</p>\n<h3>11 BLOOD DISEASES AND BLOOD TRANSFUSION GUIDELINES....568</h3>\n<p>11.1 Blood Disorders.....................................................................568</p>\n<p>11.1.1 Anaemia ............................................................................................568</p>\n<p>11.1.1.1 Iron Deficiency Anaemia...................................................................571</p>\n<p>11.1.1.2  Megaloblastic Anaemia....................................................................573</p>\n<p>11.1.1.3  Normocytic Anaemia......................................................................575</p>\n<p>11.1.2  Bleeding Disorders.............................................................................577</p>\n<p>11.1.3 Sickle Cell Disease..............................................................................579</p>\n<p>11.2 Blood and Blood Products.......................................................588</p>\n<p>11.2.1 General Principles of Good Clinical Practice in Transfusion Medicine.....589</p>\n<p>11.2.2 Blood and Blood Products: Characteristics and Indications ...................590</p>\n<p>11.2.2.1 Whole Blood ..................................................................................590</p>\n<p>11.2.2.2 Red Cell Concentrates (packed red cells) ...........................................591</p>\n<p>11.2.2.3 Clinical Indications for Blood Transfusion .........................................592</p>\n<p>11.2.3 Adverse Reactions following Transfusion .......................................................595</p>\n<p>11.2.3.1 Acute Transfusion Reactions ............................................................598</p>\n<h3>12 ONCOLOGY...........................................................................602</h3>\n<p>12.1 Introduction..........................................................................602</p>\n<p>12.1.1 Special Groups at Increased Risk of Cancer...................................................602</p>\n<p>12.1.2 Early Signs and Symptoms............................................................................603</p>\n<p>12.1.2.1 Urgent Signs and Symptoms.............................................................605</p>\n<p>12.2 Prevention of Cancer.............................................................605</p>\n<p>12.2.1 Primary Prevention ......................................................................................605</p>\n<p>12.2.1.1 Control of Risk Factors.....................................................................606</p>\n<p>12.2.2 Secondary Prevention.........................................................................609</p>\n<p>12.3 Common Cancers..................................................................612</p>\n<p>12.3.1 Common Cancers in Children.......................................................................612</p>\n<h3>XII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 13,
        "content": "1.1.1 Common Cancers in Adults............................................................................614\n13 PALLIATIVE CARE..................................................................621\n13.1 Pain................................................................................................................622\n13.1.1 Clinical Features and Investigations................................................................623\n13.1.2 Nociceptive Pain Management.............................................................623\n13.1.2.1 Pain  Management  In   Adults..........................................................625\n13.1.2.3 Pain Management In Children...........................................................627\n13.1.3  Neuropathic Pain.........................................................................................631\n13.1.4 Back or Bone Pain.......................................................................................632\n13.2 Other Conditions In Palliative Care...........................................633\n13.2.1 Breathlessness..............................................................................................633\n13.2.2 Nausea and Vomiting....................................................................................634\n13.2.3 Pressure Ulcer (Decubitus Ulcers)...................................................................634\n13.2.4 Fungating Wounds........................................................................................635\n13.2.5 Anorexia and Cachexia........................................................................636\n13.2.6 Hiccup................................................................................................637 \n13.2.7 Dry or Painful Mouth..........................................................................638\n13.2.8 Other Symptoms.................................................................................639\n13.2.9 End of Life Care..................................................................................639\n14 GYNECOLOGICAL CONDITIONS..............................................643\n14.1.1 Dysmenorrhoea............................................................................................643\n14.1.2  Pelvic Inflammatory Disease (PID).................................................................644\n14.1.3  Abnormal Uterine Bleeding..........................................................................647\n14.1.4 Menopause...................................................................................................649\n15 FAMILY PLANNING (FP)...........................................................651\n15.1  Key steps to be followed in provision of FP services...................651\n15.1.1 Provide Information about FP........................................................................652\n15.1.2 Counsel High-Risk Clients.............................................................................653\n15.1.3  Pre-Conception Care with Clients Who Desire to Conceive...........................654\n15.1.4  Discuss with PLW HIV Special Consideration for HIV Transmission...............654\n15.1.5  Educate and Counsel Clients to Make Informed Choice of FP Method............654\n15.1.6  Obtain and Record Client History.......................................................655\n15.1.7  Perform a Physical Assessment...........................................................657\n15.1.8  Perform a Pelvic Examination.............................................................658\n15.1.9  Manage Client for Chosen FP Method.................................................658\nXIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<li>.1.1 Common Cancers in Adults............................................................................614</li>\n<h3>13 PALLIATIVE CARE..................................................................621</h3>\n<p>13.1 Pain................................................................................................................622</p>\n<p>13.1.1 Clinical Features and Investigations................................................................623</p>\n<p>13.1.2 Nociceptive Pain Management.............................................................623</p>\n<p>13.1.2.1 Pain  Management  In   Adults..........................................................625</p>\n<p>13.1.2.3 Pain Management In Children...........................................................627</p>\n<p>13.1.3  Neuropathic Pain.........................................................................................631</p>\n<p>13.1.4 Back or Bone Pain.......................................................................................632</p>\n<p>13.2 Other Conditions In Palliative Care...........................................633</p>\n<p>13.2.1 Breathlessness..............................................................................................633</p>\n<p>13.2.2 Nausea and Vomiting....................................................................................634</p>\n<p>13.2.3 Pressure Ulcer (Decubitus Ulcers)...................................................................634</p>\n<p>13.2.4 Fungating Wounds........................................................................................635</p>\n<p>13.2.5 Anorexia and Cachexia........................................................................636</p>\n<p>13.2.6 Hiccup................................................................................................637</p>\n<p>13.2.7 Dry or Painful Mouth..........................................................................638</p>\n<p>13.2.8 Other Symptoms.................................................................................639</p>\n<p>13.2.9 End of Life Care..................................................................................639</p>\n<h3>14 GYNECOLOGICAL CONDITIONS..............................................643</h3>\n<p>14.1.1 Dysmenorrhoea............................................................................................643</p>\n<p>14.1.2  Pelvic Inflammatory Disease (PID).................................................................644</p>\n<p>14.1.3  Abnormal Uterine Bleeding..........................................................................647</p>\n<p>14.1.4 Menopause...................................................................................................649</p>\n<h3>15 FAMILY PLANNING (FP)...........................................................651</h3>\n<p>15.1  Key steps to be followed in provision of FP services...................651</p>\n<p>15.1.1 Provide Information about FP........................................................................652</p>\n<p>15.1.2 Counsel High-Risk Clients.............................................................................653</p>\n<p>15.1.3  Pre-Conception Care with Clients Who Desire to Conceive...........................654</p>\n<p>15.1.4  Discuss with PLW HIV Special Consideration for HIV Transmission...............654</p>\n<p>15.1.5  Educate and Counsel Clients to Make Informed Choice of FP Method............654</p>\n<p>15.1.6  Obtain and Record Client History.......................................................655</p>\n<p>15.1.7  Perform a Physical Assessment...........................................................657</p>\n<p>15.1.8  Perform a Pelvic Examination.............................................................658</p>\n<p>15.1.9  Manage Client for Chosen FP Method.................................................658</p>\n<h3>XIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 14,
        "content": "15.1.10  Summary of Medical Eligibility for Contraceptives..............................659\n15.2  Overview Of Key Contraceptive Methods.................................664\n15.2.1 Condom (Male).............................................................................................664\n15.2.2 Condom (Female).........................................................................................666\n15.2.3 Combined Oral Contraceptive Pill (COC) .............................................667\n15.2.4 Progestogen-Only Pill (POP)................................................................671\n15.2.5 Injectable Progestogen-Only Contraceptive...........................................674\n15.2.6 Progestogen-Only Sub-Dermal Implant.................................................679\n15.2.7 Emergency Contraception (Pill and IUD)..............................................683\n15.2.8 Intrauterine Device (IUD)...............................................................................685\n15.2.9 Natural FP: Cervical Mucus Method (CMM) and Moon Beads.........................688\n15.2.10 Natural FP: Lactational Amenorrhoea Method (LAM)...................................689\n15.2.11 Surgical Contraception for Men: Vasectomy.................................................690\n15.2.12  Surgical Contraception for Women: Tubal Ligation......................................691\n16 OBSTETRIC CONDITIONS........................................................693\n16.1  Antenatal Care (ANC)............................................................693\n16.1.1 Goal-Oriented Antenatal Care Protocol..........................................................693\n16.1.2  Management of Common Complaints during Pregnancy...............................698\n16.1.3 High Risk Pregnancy (HRP)...........................................................................700\n16.2  Management Of Selected Conditions in Pregnancy....................701\n16.2.1  Anaemia in Pregnancy.................................................................................701\n16.2.2  Pregnancy and HIV Infection.......................................................................704\n16.2.2.1 Care for HIV Positive Women (eMTCT) ............................................705\n16.2.2.2 Counselling for HIV Positive Mothers................................................706\n16.2.3 Chronic Hypertension in Pregnancy..............................................................708\n16.2.4   Malaria in Pregnancy .................................................................................709\n16.2.5  Diabetes in Pregnancy.................................................................................711                              \n16.2.6  Urinary Tract Infections in Pregnancy...........................................................713\n16.3 Antenatal Complications..................................................................................714\n16.3.1 Hyperemesis Gravidarum....................................................................714\n16.3.2  Vaginal Bleeding in Early Pregnancy/ Abortion...................................715\n16.3.3 Ectopic Pregnancy...............................................................................719\n16.3.4  Premature Rupture of Membranes (PROM & PPROM).........................721\n16.3.5  Chorioamnionitis................................................................................725\n16.3.6 Antepartum Haemorrhage (APH) \u2013 Abruptio Placentae and Placenta Praevia..726\n16.3.7 Pre-Eclampsia...............................................................................................729\nXIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>15.1.10  Summary of Medical Eligibility for Contraceptives..............................659</p>\n<p>15.2  Overview Of Key Contraceptive Methods.................................664</p>\n<p>15.2.1 Condom (Male).............................................................................................664</p>\n<p>15.2.2 Condom (Female).........................................................................................666</p>\n<p>15.2.3 Combined Oral Contraceptive Pill (COC) .............................................667</p>\n<p>15.2.4 Progestogen-Only Pill (POP)................................................................671</p>\n<p>15.2.5 Injectable Progestogen-Only Contraceptive...........................................674</p>\n<p>15.2.6 Progestogen-Only Sub-Dermal Implant.................................................679</p>\n<p>15.2.7 Emergency Contraception (Pill and IUD)..............................................683</p>\n<p>15.2.8 Intrauterine Device (IUD)...............................................................................685</p>\n<p>15.2.9 Natural FP: Cervical Mucus Method (CMM) and Moon Beads.........................688</p>\n<p>15.2.10 Natural FP: Lactational Amenorrhoea Method (LAM)...................................689</p>\n<p>15.2.11 Surgical Contraception for Men: Vasectomy.................................................690</p>\n<p>15.2.12  Surgical Contraception for Women: Tubal Ligation......................................691</p>\n<h3>16 OBSTETRIC CONDITIONS........................................................693</h3>\n<p>16.1  Antenatal Care (ANC)............................................................693</p>\n<p>16.1.1 Goal-Oriented Antenatal Care Protocol..........................................................693</p>\n<p>16.1.2  Management of Common Complaints during Pregnancy...............................698</p>\n<p>16.1.3 High Risk Pregnancy (HRP)...........................................................................700</p>\n<p>16.2  Management Of Selected Conditions in Pregnancy....................701</p>\n<p>16.2.1  Anaemia in Pregnancy.................................................................................701</p>\n<p>16.2.2  Pregnancy and HIV Infection.......................................................................704</p>\n<p>16.2.2.1 Care for HIV Positive Women (eMTCT) ............................................705</p>\n<p>16.2.2.2 Counselling for HIV Positive Mothers................................................706</p>\n<p>16.2.3 Chronic Hypertension in Pregnancy..............................................................708</p>\n<p>16.2.4   Malaria in Pregnancy .................................................................................709</p>\n<p>16.2.5  Diabetes in Pregnancy.................................................................................711</p>\n<p>16.2.6  Urinary Tract Infections in Pregnancy...........................................................713</p>\n<p>16.3 Antenatal Complications..................................................................................714</p>\n<p>16.3.1 Hyperemesis Gravidarum....................................................................714</p>\n<p>16.3.2  Vaginal Bleeding in Early Pregnancy/ Abortion...................................715</p>\n<p>16.3.3 Ectopic Pregnancy...............................................................................719</p>\n<p>16.3.4  Premature Rupture of Membranes (PROM & PPROM).........................721</p>\n<p>16.3.5  Chorioamnionitis................................................................................725</p>\n<p>16.3.6 Antepartum Haemorrhage (APH) \u2013 Abruptio Placentae and Placenta Praevia..726</p>\n<p>16.3.7 Pre-Eclampsia...............................................................................................729</p>\n<h3>XIV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 15,
        "content": "16.3.8 Eclampsia ....................................................................................................733\n16.4 Labour, Delivery and Acute Complications................................737\n16.4.1 Normal Labour and Delivery................................................................737\n16.4.2 Induction of Labour.............................................................................740\n16.4.3 Obstructed Labour........................................................................................742\n16.4.4 Ruptured Uterus...........................................................................................743\n16.4.5 Retained Placenta.........................................................................................745\n16.4.6 Postpartum Haemorrhage (PPH)...................................................................746\n16.4.7 Puerperal Fever/Sepsis ................................................................................750\n16.4.8  Care of Mother and Baby Immediately After Delivery....................................752\n16.4.8.1 Care of Mother Immediately After Delivery..................................................753\n16.4.8.2  Care of Baby Immediately After Delivery....................................................754\n16.5  Essential Care of the Newborn................................................756\n16.5.1 Newborn Resuscitation.................................................................................756\n16.5.2  General Care of Newborn After Delivery.......................................................759\n16.5.3    Extra Care of Small Babies or Twins in the First Days of Life.......................761\n16.5.4  Newborn Hygiene at Home.........................................................................763\n16.6 Postpartum Conditions...........................................................764\n16.6.1 Postpartum Care..........................................................................................764\n16.6.1.1 Postpartum Counselling....................................................................764\n16.5.1.2 Postpartum Examination of the Mother Up to 6 Weeks......................767\n16.6.2 Postnatal Depression....................................................................................781\n16.6.3 Mastitis/Breast Abscess................................................................................782\n16.6.4 Obstetric Fistula............................................................................................784\n16.7 Intrauterine Fetal Demise (IUFD) Or Fetal Death In Utero (FDIU)..788\n17 CHILDHOOD ILLNESS.............................................................796\n17.1  Sick Newborn.......................................................................796\n17.1.1 Newborn Examination/Danger Signs............................................................796\n17.1.2 Assess for Special Treatment Needs, Local Infection, and Jaundice.................801\n17.2 Sick Young Infant Age Up To 2 Months....................................806\n17.2.1 Check for Very Severe Disease and Local Bacterial Infection...........................807\n17.2.2 Check for Jaundice.......................................................................................810\n17.2.3 Check for Diarrhoea/Dehydration.................................................................811\nXV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>16.3.8 Eclampsia ....................................................................................................733</p>\n<p>16.4 Labour, Delivery and Acute Complications................................737</p>\n<p>16.4.1 Normal Labour and Delivery................................................................737</p>\n<p>16.4.2 Induction of Labour.............................................................................740</p>\n<p>16.4.3 Obstructed Labour........................................................................................742</p>\n<p>16.4.4 Ruptured Uterus...........................................................................................743</p>\n<p>16.4.5 Retained Placenta.........................................................................................745</p>\n<p>16.4.6 Postpartum Haemorrhage (PPH)...................................................................746</p>\n<p>16.4.7 Puerperal Fever/Sepsis ................................................................................750</p>\n<p>16.4.8  Care of Mother and Baby Immediately After Delivery....................................752</p>\n<p>16.4.8.1 Care of Mother Immediately After Delivery..................................................753</p>\n<p>16.4.8.2  Care of Baby Immediately After Delivery....................................................754</p>\n<p>16.5  Essential Care of the Newborn................................................756</p>\n<p>16.5.1 Newborn Resuscitation.................................................................................756</p>\n<p>16.5.2  General Care of Newborn After Delivery.......................................................759</p>\n<p>16.5.3    Extra Care of Small Babies or Twins in the First Days of Life.......................761</p>\n<p>16.5.4  Newborn Hygiene at Home.........................................................................763</p>\n<p>16.6 Postpartum Conditions...........................................................764</p>\n<p>16.6.1 Postpartum Care..........................................................................................764</p>\n<p>16.6.1.1 Postpartum Counselling....................................................................764</p>\n<p>16.5.1.2 Postpartum Examination of the Mother Up to 6 Weeks......................767</p>\n<p>16.6.2 Postnatal Depression....................................................................................781</p>\n<p>16.6.3 Mastitis/Breast Abscess................................................................................782</p>\n<p>16.6.4 Obstetric Fistula............................................................................................784</p>\n<p>16.7 Intrauterine Fetal Demise (IUFD) Or Fetal Death In Utero (FDIU)..788</p>\n<h3>17 CHILDHOOD ILLNESS.............................................................796</h3>\n<p>17.1  Sick Newborn.......................................................................796</p>\n<p>17.1.1 Newborn Examination/Danger Signs............................................................796</p>\n<p>17.1.2 Assess for Special Treatment Needs, Local Infection, and Jaundice.................801</p>\n<p>17.2 Sick Young Infant Age Up To 2 Months....................................806</p>\n<p>17.2.1 Check for Very Severe Disease and Local Bacterial Infection...........................807</p>\n<p>17.2.2 Check for Jaundice.......................................................................................810</p>\n<p>17.2.3 Check for Diarrhoea/Dehydration.................................................................811</p>\n<p>XV</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 16,
        "content": "17.2.4 Check for HIV Infection................................................................................815\n17.2.5  Check for Feeding Problem or Low Weight-for-Age.......................................817\n17.2.5.1 All Young Infants Except HIV-exposed Infants Not Breastfed..............817\n17.2.5.2  HIV-exposed Non Breastfeeding Infants...........................................820\n17.2.6  Check Young Infant\u2019s Immunization Status....................................................823\n17.2.7  Assess Other Problems................................................................................823\n17.2.8  Assess Mother\u2019s Health Needs.....................................................................823\n17.2.9 Summary of IMNCI Medicines Used for Young Infants...................................823\n117.2.10  Counsel the Mother.................................................................................824\n17.3  Sick Child Age 2 Months to 5 Years........................................825\n17.3.21   Check for General Danger Signs................................................................826\n17.3.2  Check for Cough or Difficult Breathing.........................................................827\n17.3.3  Child Has Diarrhoea....................................................................................830\n17.3.4  Check for Fever...........................................................................................834\n17.3.5   Check for Ear Problem................................................................................841\n17.3.6  Check for Malnutrition and Feeding Problems...............................................842\n17.3.7  Check for Anaemia......................................................................................846\n17.3.8  Check Immunization, Vitamin A, Deworming................................................850\n17.3.9  Assess Other Problems................................................................................850\n17.3.10  Summary of Medicines Used......................................................................850\n17.3.10.1  Medicines Used Only in Health Centers.........................................851\n17.3.10.2   Medicines for Home Use..............................................................852\n17.3.10.3  Treatment of Local Infections at Home...........................................856\n17.3.11  Counsel the Mother...................................................................................858\n17.3.12.1  Feeding Recommendation during Illness.........................................858\n17.3.12.2  Assessing Appetite and Feeding.....................................................858\n17.3.12.3   Feeding Recommendations...........................................................860\n17.3.12.4   Counselling for Feeding Problems.................................................863\n17.3.12.5  Mother\u2019s Health............................................................................865\n17.4  Integrated Community Case Management.................................866\n17.5  Child Growth Weight Standards Charts....................................868\n18 IMMUNIZATION......................................................................875\n18.1  Routine Childhood Vaccination...............................................875\n18.1.1   National Immunization Schedule..................................................................875\n18.1.2  Hepatitis B Vaccination...............................................................................881\n18.1.3  Yellow Fever Vaccination.............................................................................882\n18.1.4  Tetanus Prevention......................................................................................882\nXVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>17.2.4 Check for HIV Infection................................................................................815</p>\n<p>17.2.5  Check for Feeding Problem or Low Weight-for-Age.......................................817</p>\n<p>17.2.5.1 All Young Infants Except HIV-exposed Infants Not Breastfed..............817</p>\n<p>17.2.5.2  HIV-exposed Non Breastfeeding Infants...........................................820</p>\n<p>17.2.6  Check Young Infant\u2019s Immunization Status....................................................823</p>\n<p>17.2.7  Assess Other Problems................................................................................823</p>\n<p>17.2.8  Assess Mother\u2019s Health Needs.....................................................................823</p>\n<p>17.2.9 Summary of IMNCI Medicines Used for Young Infants...................................823</p>\n<p>117.2.10  Counsel the Mother.................................................................................824</p>\n<p>17.3  Sick Child Age 2 Months to 5 Years........................................825</p>\n<p>17.3.21   Check for General Danger Signs................................................................826</p>\n<p>17.3.2  Check for Cough or Difficult Breathing.........................................................827</p>\n<p>17.3.3  Child Has Diarrhoea....................................................................................830</p>\n<p>17.3.4  Check for Fever...........................................................................................834</p>\n<p>17.3.5   Check for Ear Problem................................................................................841</p>\n<p>17.3.6  Check for Malnutrition and Feeding Problems...............................................842</p>\n<p>17.3.7  Check for Anaemia......................................................................................846</p>\n<p>17.3.8  Check Immunization, Vitamin A, Deworming................................................850</p>\n<p>17.3.9  Assess Other Problems................................................................................850</p>\n<p>17.3.10  Summary of Medicines Used......................................................................850</p>\n<p>17.3.10.1  Medicines Used Only in Health Centers.........................................851</p>\n<p>17.3.10.2   Medicines for Home Use..............................................................852</p>\n<p>17.3.10.3  Treatment of Local Infections at Home...........................................856</p>\n<p>17.3.11  Counsel the Mother...................................................................................858</p>\n<p>17.3.12.1  Feeding Recommendation during Illness.........................................858</p>\n<p>17.3.12.2  Assessing Appetite and Feeding.....................................................858</p>\n<p>17.3.12.3   Feeding Recommendations...........................................................860</p>\n<p>17.3.12.4   Counselling for Feeding Problems.................................................863</p>\n<p>17.3.12.5  Mother\u2019s Health............................................................................865</p>\n<p>17.4  Integrated Community Case Management.................................866</p>\n<p>17.5  Child Growth Weight Standards Charts....................................868</p>\n<h3>18 IMMUNIZATION......................................................................875</h3>\n<p>18.1  Routine Childhood Vaccination...............................................875</p>\n<p>18.1.1   National Immunization Schedule..................................................................875</p>\n<p>18.1.2  Hepatitis B Vaccination...............................................................................881</p>\n<p>18.1.3  Yellow Fever Vaccination.............................................................................882</p>\n<p>18.1.4  Tetanus Prevention......................................................................................882</p>\n<h3>XVI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 17,
        "content": "18.2.3.1  Prophylaxis Against Neonatal Tetanus..............................................883\n18.2.4  Vaccination against COVID-19.....................................................................885\n19 NUTRITION............................................................................887\n19.1  Nutrition Guidelines In Special Populations...............................887\n19.1.1  Infant and Young Child Feeding (IYCF).........................................................887\n19.1.2  Nutrition in HIV/AIDS.................................................................................888\n19.1.3  Nutrition in Diabetes....................................................................................889\n19.2  Malnutrition.........................................................................890\n19.2.1  Introduction on Malnutrition.........................................................................890\n19.2.1.1 Classification of Malnutrition......................................................................892\n19.2.1.2 Assessing Malnutrition in Children 6 months to 5 years...............................893\n19.2.2   Management of Acute Malnutrition in Children............................................897\n19.2.2.1 Management of Moderate Acute Malnutrition....................................897\n19.2.2.2 Management of Uncomplicated Severe Acute Malnutrition.................898\n19.2.2.3 Management of Complicated Severe Acute Malnutrition.....................899\n19.2.2.4 Treatment of Associated Conditions..................................................914\n19.2.2.5 Discharge from Nutritional Programme.............................................916\n19.2.3  SAM in Infants Less than 6 Months.............................................................918\n19.2.4   Obesity and Overweight..............................................................................919\n20 EYE CONDITIONS...................................................................923\n20.1  Infections And Inflammatory Eye Conditions.............................923\n20.1.1 Notes on Use of Eye Preparations.................................................................923\n20.1.2 Conjunctivitis (\u201cRed Eye\u201d).............................................................................923\n20.1.3 Stye (Hordeolum).........................................................................................925\n20.1.4 Trachoma....................................................................................................926\n20.1.5 Keratitis.......................................................................................................927\n20.1.6 Uveitis.........................................................................................................928\n20.1.7 Orbital Cellulitis............................................................................................930\n20.1.8 Postoperative Endophthalmitis.......................................................................931\n20.1.9 Xerophthalmia..............................................................................................932\n20.2  Decreased or Reduced Vision Conditions.........................................................933\n20.2.1 Cataract..............................................................................................933\n20.2.1.1 Paediatric Cataract...........................................................................934\n20.2.2 Glaucoma...........................................................................................935\n20.2.3 Diabetic Retinopathy...........................................................................936\nXVII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>18.2.3.1  Prophylaxis Against Neonatal Tetanus..............................................883</p>\n<p>18.2.4  Vaccination against COVID-19.....................................................................885</p>\n<h3>19 NUTRITION............................................................................887</h3>\n<p>19.1  Nutrition Guidelines In Special Populations...............................887</p>\n<p>19.1.1  Infant and Young Child Feeding (IYCF).........................................................887</p>\n<p>19.1.2  Nutrition in HIV/AIDS.................................................................................888</p>\n<p>19.1.3  Nutrition in Diabetes....................................................................................889</p>\n<p>19.2  Malnutrition.........................................................................890</p>\n<p>19.2.1  Introduction on Malnutrition.........................................................................890</p>\n<p>19.2.1.1 Classification of Malnutrition......................................................................892</p>\n<p>19.2.1.2 Assessing Malnutrition in Children 6 months to 5 years...............................893</p>\n<p>19.2.2   Management of Acute Malnutrition in Children............................................897</p>\n<p>19.2.2.1 Management of Moderate Acute Malnutrition....................................897</p>\n<p>19.2.2.2 Management of Uncomplicated Severe Acute Malnutrition.................898</p>\n<p>19.2.2.3 Management of Complicated Severe Acute Malnutrition.....................899</p>\n<p>19.2.2.4 Treatment of Associated Conditions..................................................914</p>\n<p>19.2.2.5 Discharge from Nutritional Programme.............................................916</p>\n<p>19.2.3  SAM in Infants Less than 6 Months.............................................................918</p>\n<p>19.2.4   Obesity and Overweight..............................................................................919</p>\n<h3>20 EYE CONDITIONS...................................................................923</h3>\n<p>20.1  Infections And Inflammatory Eye Conditions.............................923</p>\n<p>20.1.1 Notes on Use of Eye Preparations.................................................................923</p>\n<p>20.1.2 Conjunctivitis (\u201cRed Eye\u201d).............................................................................923</p>\n<p>20.1.3 Stye (Hordeolum).........................................................................................925</p>\n<p>20.1.4 Trachoma....................................................................................................926</p>\n<p>20.1.5 Keratitis.......................................................................................................927</p>\n<p>20.1.6 Uveitis.........................................................................................................928</p>\n<p>20.1.7 Orbital Cellulitis............................................................................................930</p>\n<p>20.1.8 Postoperative Endophthalmitis.......................................................................931</p>\n<p>20.1.9 Xerophthalmia..............................................................................................932</p>\n<p>20.2  Decreased or Reduced Vision Conditions.........................................................933</p>\n<p>20.2.1 Cataract..............................................................................................933</p>\n<p>20.2.1.1 Paediatric Cataract...........................................................................934</p>\n<p>20.2.2 Glaucoma...........................................................................................935</p>\n<p>20.2.3 Diabetic Retinopathy...........................................................................936</p>\n<h3>XVII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 18,
        "content": "20.2.4  Refractive Errors................................................................................937\n20.2.5 Low Vision.........................................................................................939\n20.2.5.1 Vision Loss......................................................................................939\n20.3 Trauma and Injuries to the Eye................................................941\n20.3.1 Foreign Body in the Eye................................................................................941\n20.3.2 Ocular and Adnexa Injuries...........................................................................942\n20.3.2.1 Blunt Injuries....................................................................................942\n20.3.2.2 Penetrating Eye Injuries....................................................................943\n20.3.2.3 Chemical Injuries to the Eye..............................................................944\n20.4  Ocular Tumours.............................................................................................945\n20.4.1 Retinoblastoma...................................................................................945\n20.4.2 Squamous Cell Carcinoma of Conjunctiva......................................................946\n21 EAR,NOSE &THROAT CONDITIONS.........................................947\n21.1.1 Foreign Body in the Ear................................................................................947\n21.1.2 Wax in the Ear ............................................................................................948\n21.1.3 Otitis External..............................................................................................949\n21.1.4 Otitis Media (Suppurative).............................................................................951\n21.1.5 Glue Ear (Otitis Media with Effusion).............................................................953\n21.1.6 Mastoiditis ...................................................................................................954\n21.2 Nasal Conditions ...................................................................955 \n21.2.1 Foreign Body in the Nose .............................................................................955\n21.2.2 Epistaxis (Nose Bleeding)..............................................................................957\n21.2.3 Nasal Allergy................................................................................................958\n21.2.4 Sinusitis (Acute)............................................................................................960\n21.2.6 Atrophic Rhinitis..........................................................................................962\n21.2.6 Adenoid Disease...........................................................................................963 \n21.3 Throat Conditions .................................................................965 \n21.3.1 Foreign Body (FB) in the Airway....................................................................965\n21.3.2 Foreign Body in the Food Passage.................................................................967\n21.3.3 Pharyngitis (Sore Throat)..............................................................................969\n21.3.4 Pharyngo-Tonsillitis......................................................................................970\n21.3.5 Peritonsillar Abscess (Quinsy)........................................................................971\n22. SKIN DISEASES......................................................................974\n22.1 Bacterial Skin Infections ........................................................974 \n22.1.1 Impetigo......................................................................................................974\nXVIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>20.2.4  Refractive Errors................................................................................937</p>\n<p>20.2.5 Low Vision.........................................................................................939</p>\n<p>20.2.5.1 Vision Loss......................................................................................939</p>\n<p>20.3 Trauma and Injuries to the Eye................................................941</p>\n<p>20.3.1 Foreign Body in the Eye................................................................................941</p>\n<p>20.3.2 Ocular and Adnexa Injuries...........................................................................942</p>\n<p>20.3.2.1 Blunt Injuries....................................................................................942</p>\n<p>20.3.2.2 Penetrating Eye Injuries....................................................................943</p>\n<p>20.3.2.3 Chemical Injuries to the Eye..............................................................944</p>\n<p>20.4  Ocular Tumours.............................................................................................945</p>\n<p>20.4.1 Retinoblastoma...................................................................................945</p>\n<p>20.4.2 Squamous Cell Carcinoma of Conjunctiva......................................................946</p>\n<h3>21 EAR,NOSE &THROAT CONDITIONS.........................................947</h3>\n<p>21.1.1 Foreign Body in the Ear................................................................................947</p>\n<p>21.1.2 Wax in the Ear ............................................................................................948</p>\n<p>21.1.3 Otitis External..............................................................................................949</p>\n<p>21.1.4 Otitis Media (Suppurative).............................................................................951</p>\n<p>21.1.5 Glue Ear (Otitis Media with Effusion).............................................................953</p>\n<p>21.1.6 Mastoiditis ...................................................................................................954</p>\n<p>21.2 Nasal Conditions ...................................................................955</p>\n<p>21.2.1 Foreign Body in the Nose .............................................................................955</p>\n<p>21.2.2 Epistaxis (Nose Bleeding)..............................................................................957</p>\n<p>21.2.3 Nasal Allergy................................................................................................958</p>\n<p>21.2.4 Sinusitis (Acute)............................................................................................960</p>\n<p>21.2.6 Atrophic Rhinitis..........................................................................................962</p>\n<p>21.2.6 Adenoid Disease...........................................................................................963</p>\n<p>21.3 Throat Conditions .................................................................965</p>\n<p>21.3.1 Foreign Body (FB) in the Airway....................................................................965</p>\n<p>21.3.2 Foreign Body in the Food Passage.................................................................967</p>\n<p>21.3.3 Pharyngitis (Sore Throat)..............................................................................969</p>\n<p>21.3.4 Pharyngo-Tonsillitis......................................................................................970</p>\n<p>21.3.5 Peritonsillar Abscess (Quinsy)........................................................................971</p>\n<h3>22. SKIN DISEASES......................................................................974</h3>\n<p>22.1 Bacterial Skin Infections ........................................................974</p>\n<p>22.1.1 Impetigo......................................................................................................974</p>\n<h3>XVIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 19,
        "content": "22.1.2 Boils (Furuncle)/Carbuncle............................................................................976\n22.1.3 Cellulitis and Erysipelas.................................................................................977\n22.2 Viral Skin Infections ..............................................................979 \n22.2.1 Herpes Simplex ...........................................................................................979\n22.2.2 Herpes Zoster (Shingles)...............................................................................981\n22.3 Fungal Skin Infections ...........................................................982 \n22.3.1 Tineas..........................................................................................................982\n22.4 Parasitic Skin Infections .........................................................987 \n22.4.1 Scabies........................................................................................................987\n22.4.2 Pediculosis/Lice............................................................................................989\n22.4.3 Tungiasis (Jiggers).........................................................................................991\n22.5 Inflamatory & Allergic Skin Infections ......................................994 \n22.5.1 Acne............................................................................................................994\n22.5.2 Urticaria/Papular Urticari.............................................................................996\n22.5.3 Eczema (Dermatitis) .....................................................................................997\n22.5.4 Psoriasis.......................................................................................................999\n22.6 Skin Ulcers and Chronic Wounds ...........................................1001 \n22.6.1 Leg Ulcers...................................................................................................1001\n22.7 Drug Induced Skin Reactions .................................................1002 \n22.7.1 Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)..........1002\n22.8 Congenital Disorder .............................................................1004\n23 ORAL AND DENTAL CONDITIONS..........................................1005\n23.1.1. Halitosis/Bad Breath..................................................................................1005\n23.1.2 Dentin Hypersensitivity................................................................................1006\n23.1.3 Malocclusion...............................................................................................1006\n23.1.4 Fluorosis (Mottling)......................................................................................1007\n23.2 Oro-Dental Infections ...........................................................1009 \n23.2.1. Prevention of Dental Caries & Other Conditions Due to Poor Oral  lannin....1009\n23.2.2 Dental Caries..............................................................................................1010\n23.2.3 Pulpitis........................................................................................................1012\n23.2.4 Acute Periapical Abscess or Dental Abscess..................................................1013\n23.2.5. Gingivitis....................................................................................................1016\nXIX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>22.1.2 Boils (Furuncle)/Carbuncle............................................................................976</p>\n<p>22.1.3 Cellulitis and Erysipelas.................................................................................977</p>\n<p>22.2 Viral Skin Infections ..............................................................979</p>\n<p>22.2.1 Herpes Simplex ...........................................................................................979</p>\n<p>22.2.2 Herpes Zoster (Shingles)...............................................................................981</p>\n<p>22.3 Fungal Skin Infections ...........................................................982</p>\n<p>22.3.1 Tineas..........................................................................................................982</p>\n<p>22.4 Parasitic Skin Infections .........................................................987</p>\n<p>22.4.1 Scabies........................................................................................................987</p>\n<p>22.4.2 Pediculosis/Lice............................................................................................989</p>\n<p>22.4.3 Tungiasis (Jiggers).........................................................................................991</p>\n<p>22.5 Inflamatory & Allergic Skin Infections ......................................994</p>\n<p>22.5.1 Acne............................................................................................................994</p>\n<p>22.5.2 Urticaria/Papular Urticari.............................................................................996</p>\n<p>22.5.3 Eczema (Dermatitis) .....................................................................................997</p>\n<p>22.5.4 Psoriasis.......................................................................................................999</p>\n<p>22.6 Skin Ulcers and Chronic Wounds ...........................................1001</p>\n<p>22.6.1 Leg Ulcers...................................................................................................1001</p>\n<p>22.7 Drug Induced Skin Reactions .................................................1002</p>\n<p>22.7.1 Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)..........1002</p>\n<p>22.8 Congenital Disorder .............................................................1004</p>\n<h3>23 ORAL AND DENTAL CONDITIONS..........................................1005</h3>\n<p>23.1.1. Halitosis/Bad Breath..................................................................................1005</p>\n<p>23.1.2 Dentin Hypersensitivity................................................................................1006</p>\n<p>23.1.3 Malocclusion...............................................................................................1006</p>\n<p>23.1.4 Fluorosis (Mottling)......................................................................................1007</p>\n<p>23.2 Oro-Dental Infections ...........................................................1009</p>\n<p>23.2.1. Prevention of Dental Caries & Other Conditions Due to Poor Oral  lannin....1009</p>\n<p>23.2.2 Dental Caries..............................................................................................1010</p>\n<p>23.2.3 Pulpitis........................................................................................................1012</p>\n<p>23.2.4 Acute Periapical Abscess or Dental Abscess..................................................1013</p>\n<p>23.2.5. Gingivitis....................................................................................................1016</p>\n<h3>XIX</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 20,
        "content": "23.2.5.1 Chronic Gingivitis.....................................................................................1017\n23.2.6. Acute Necrotizing Ulcerative Gingivitis (ANUG)/Periodontitis/Stomatitis ......1018\n23.2.7 Periodontitis................................................................................................1020\n23.2.8 Periodontal Abscess.....................................................................................1021\n23.2.9 Stomatitis....................................................................................................1022\n23.2.10 Aphthous Ulceration..................................................................................1025\n23.2.11 Pericoronitis..............................................................................................1027\n23.2.12 Osteomyelitis of the Jaw............................................................................1028\n23.3 HIV/AIDS Associated Conditions ...........................................1030 \n23.3.1 Oral Candidiasis..........................................................................................1030\n23.3.2 Herpes Infections........................................................................................1030\n23.3.3 Kaposi\u2019s Sarcoma........................................................................................1031\n23.3.4 Hairy Leukoplakia.......................................................................................1032\n23.4 Oral Trauma .......................................................................1032 \n23.4.1 Traumatic lesions I.......................................................................................1032\n23.4.2 Traumatic lesions II......................................................................................1033\n23.4.3 Traumatic lesions III.....................................................................................1035\n23.5 Oral Tumours ......................................................................1036 \n23.5.1 Burkitt\u2019s Lymphoma....................................................................................1036\n24. SURGERY, RADIOLOGY AND ANAESTHESIA.........................1036\n24.1 Surgery ..............................................................................1039 \n24.1.1 Intestinal Obstruction...................................................................................1039\n24.1.2 Internal Haemorrhage..................................................................................1041\n24.1.3 Management of Medical Conditions in Surgical Patient..................................1042\n24.1.4 Newborn with Surgical Emergencies.............................................................1045\n24.1.5 Surgical Antibiotic Prophylaxis.....................................................................1046\n24.2 Diagnostic Imaging ...............................................................1047 \n24.2.1 Diagnostic Imaging: A Clinical Perspective....................................................1047\n24.3 Anaesthesia ........................................................................1055 \n24.3.1 General Considerations................................................................................1055\n24.3.1.1 General Anaesthesia.................................................................................1057\n24.3.3 Selection of Type of Anaesthesia for the Patient...........................................1060\nXX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>23.2.5.1 Chronic Gingivitis.....................................................................................1017</p>\n<p>23.2.6. Acute Necrotizing Ulcerative Gingivitis (ANUG)/Periodontitis/Stomatitis ......1018</p>\n<p>23.2.7 Periodontitis................................................................................................1020</p>\n<p>23.2.8 Periodontal Abscess.....................................................................................1021</p>\n<p>23.2.9 Stomatitis....................................................................................................1022</p>\n<p>23.2.10 Aphthous Ulceration..................................................................................1025</p>\n<p>23.2.11 Pericoronitis..............................................................................................1027</p>\n<p>23.2.12 Osteomyelitis of the Jaw............................................................................1028</p>\n<p>23.3 HIV/AIDS Associated Conditions ...........................................1030</p>\n<p>23.3.1 Oral Candidiasis..........................................................................................1030</p>\n<p>23.3.2 Herpes Infections........................................................................................1030</p>\n<p>23.3.3 Kaposi\u2019s Sarcoma........................................................................................1031</p>\n<p>23.3.4 Hairy Leukoplakia.......................................................................................1032</p>\n<p>23.4 Oral Trauma .......................................................................1032</p>\n<p>23.4.1 Traumatic lesions I.......................................................................................1032</p>\n<p>23.4.2 Traumatic lesions II......................................................................................1033</p>\n<p>23.4.3 Traumatic lesions III.....................................................................................1035</p>\n<p>23.5 Oral Tumours ......................................................................1036</p>\n<p>23.5.1 Burkitt\u2019s Lymphoma....................................................................................1036</p>\n<h3>24. SURGERY, RADIOLOGY AND ANAESTHESIA.........................1036</h3>\n<p>24.1 Surgery ..............................................................................1039</p>\n<p>24.1.1 Intestinal Obstruction...................................................................................1039</p>\n<p>24.1.2 Internal Haemorrhage..................................................................................1041</p>\n<p>24.1.3 Management of Medical Conditions in Surgical Patient..................................1042</p>\n<p>24.1.4 Newborn with Surgical Emergencies.............................................................1045</p>\n<p>24.1.5 Surgical Antibiotic Prophylaxis.....................................................................1046</p>\n<p>24.2 Diagnostic Imaging ...............................................................1047</p>\n<p>24.2.1 Diagnostic Imaging: A Clinical Perspective....................................................1047</p>\n<p>24.3 Anaesthesia ........................................................................1055</p>\n<p>24.3.1 General Considerations................................................................................1055</p>\n<p>24.3.1.1 General Anaesthesia.................................................................................1057</p>\n<p>24.3.3 Selection of Type of Anaesthesia for the Patient...........................................1060</p>\n<p>XX</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 21,
        "content": "Preface\nThe Uganda Clinical Guidelines (UCG) evolved from the National Standard \nTreatment Guidelines 1993, which were the first of the type published in \nUganda. Before then, individual guidelines existed to manage a limited \nnumber of specific conditions.\nThe purpose of national standard treatment guidelines is to provide \nevidence-based, practical and implementable guidance to prescribers \nto provide the most cost-effective and affordable treatment of priority \nhealth conditions in a country.\nTogether with the Practical Guidelines  for  Dispensing at Lower/\nHigher Health Facility Level, which provide information about medicine \ncharacteristics, administration, and side effects, the UCG is designed as \na practical tool to support daily clinical practice by providing a reliable \nreference for health workers on appropriate management of Uganda\u2019s \ncommon health conditions. It also gives health managers a reference \ntool to assess and measure service quality.\nThe guidelines are also the basis for the formulation of the essential \nmedicines and health supplies list of Uganda (EMHSLU), which is used \nto guide supply and procurement. This allows for more efficient use of \nlimited resources to improve rational prescribing.\nThe treatments described in the UCG are the nationally recognised \nstandard treatments, and in many cases, they are derived from those \nrecommended in the Ministry of Health Vertical Programmes, World \nHealth Organisation, and other international guidelines.\nThe guidelines have been reviewed and updated through a  three-month \nprocess involving extensive consultations with public health programs \nstaff, medical experts and health workers of all cadres and various health \ndevelopment partners.\nXXI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Preface</p>\n<p>The Uganda Clinical Guidelines (UCG) evolved from the National Standard</p>\n<p>Treatment Guidelines 1993, which were the first of the type published in</p>\n<p>Uganda. Before then, individual guidelines existed to manage a limited</p>\n<p>number of specific conditions.</p>\n<p>The purpose of national standard treatment guidelines is to provide</p>\n<p>evidence-based, practical and implementable guidance to prescribers</p>\n<p>to provide the most cost-effective and affordable treatment of priority</p>\n<p>health conditions in a country.</p>\n<p>Together with the Practical Guidelines  for  Dispensing at Lower/</p>\n<p>Higher Health Facility Level, which provide information about medicine</p>\n<p>characteristics, administration, and side effects, the UCG is designed as</p>\n<p>a practical tool to support daily clinical practice by providing a reliable</p>\n<p>reference for health workers on appropriate management of Uganda\u2019s</p>\n<p>common health conditions. It also gives health managers a reference</p>\n<p>tool to assess and measure service quality.</p>\n<p>The guidelines are also the basis for the formulation of the essential</p>\n<p>medicines and health supplies list of Uganda (EMHSLU), which is used</p>\n<p>to guide supply and procurement. This allows for more efficient use of</p>\n<p>limited resources to improve rational prescribing.</p>\n<p>The treatments described in the UCG are the nationally recognised</p>\n<p>standard treatments, and in many cases, they are derived from those</p>\n<p>recommended in the Ministry of Health Vertical Programmes, World</p>\n<p>Health Organisation, and other international guidelines.</p>\n<p>The guidelines have been reviewed and updated through a  three-month</p>\n<p>process involving extensive consultations with public health programs</p>\n<p>staff, medical experts and health workers of all cadres and various health</p>\n<p>development partners.</p>\n<h3>XXI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 22,
        "content": "As medicine is an ever-evolving field, this manual is to be used for guid\u00ad\nance, but cannot replace clinical judgement in individual cases.\nThe Ministry of Health and all those involved in updating the UCG \nsincerely hope that the manual will make a significant contribution to \nongoing improvements in national therapeutic services and medicines \nutilisation.\nDr. Henry G. Mwebesa\nDIRECTOR GENERAL HEALTH SERVICES \nMinistry of Health\nXXII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>As medicine is an ever-evolving field, this manual is to be used for guid\u00ad</p>\n<p>ance, but cannot replace clinical judgement in individual cases.</p>\n<p>The Ministry of Health and all those involved in updating the UCG</p>\n<p>sincerely hope that the manual will make a significant contribution to</p>\n<p>ongoing improvements in national therapeutic services and medicines</p>\n<p>utilisation.</p>\n<p>Dr. Henry G. Mwebesa</p>\n<h3>DIRECTOR GENERAL HEALTH SERVICES</h3>\n<p>Ministry of Health</p>\n<h3>XXII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 23,
        "content": "Acknowledgements\nThe UCG 2023 was produced by the Ministry of Health with financial \nassistance from the World Bank-funded Uganda Reproductive Maternal \nand Child Health Services Improvement Project (URMCHIP).\nWe extend sincere gratitude to all health workers from the health fa\u00ad\ncilities, academia, Ministry of Health Programmes and Departments, \nthe Uganda National Health Laboratory Services, Regional and District \nHealth Offices, World Health Organisation Country Office, Private-not-\nfor- profit, private for profit organisations and development partners, \nwho have cooperated extensively to make sure the UCG 2023 update is \nproduced in line with national and international guidelines and policies.\nUCG Taskforce \nDr. Olaro Charles (DHS- Clinical Services), Dr. Jackson Amone (CHS- \nClinical Services,  MOH), Mrs. Okuna Neville Oteba (CHS- Pharmacy), \nMr. Morries Seru (ACH - Pharmacy, MOH), Ms. Martha G. Ajulong \n(ACH \u2013 Pharmacy, MOH), Dr. Nakwagala Fredrick (Senior Consultant \nPhysician), Dr. Fualal Jane Odubu (Senior Consultant Surgeon), Dr. \nByanyima Rosemary (Senior Consultant Radiologist), Dr. Lakor Francis \n(Senior Consultant Maxillo-facial Surgery), Dr. Kajumbula Henry (Senior \nLecturer- Clinical Microbiology), Dr. Namagembe Imelda (Senior Con\u00ad\nsultant OBS/GYN), Dr. Orem Jackson (Senior Consultant Oncology), \nDr. Munube Deogratius (Senior Lecturer Paediatricts), Dr. Wasomoka \nAlex (ACHS \u2013 HLLHFs), Dr. Bahatungire R Rony (PMO \u2013 Clinical Ser\u00ad\nvices), Dr. Namwanje Lydia (SMO - Clinical Services), Dr. Katwesigye \nElizabeth (Physician, internal Medicine), Ms. Harriet Akello - (Senior \nPharmacist\u00a0MoH\u00a0DPNM)\nXXIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Acknowledgements</p>\n<p>The UCG 2023 was produced by the Ministry of Health with financial</p>\n<p>assistance from the World Bank-funded Uganda Reproductive Maternal</p>\n<p>and Child Health Services Improvement Project (URMCHIP).</p>\n<p>We extend sincere gratitude to all health workers from the health fa\u00ad</p>\n<p>cilities, academia, Ministry of Health Programmes and Departments,</p>\n<p>the Uganda National Health Laboratory Services, Regional and District</p>\n<p>Health Offices, World Health Organisation Country Office, Private-not-</p>\n<p>for- profit, private for profit organisations and development partners,</p>\n<p>who have cooperated extensively to make sure the UCG 2023 update is</p>\n<p>produced in line with national and international guidelines and policies.</p>\n<p>UCG Taskforce</p>\n<p>Dr. Olaro Charles (DHS- Clinical Services), Dr. Jackson Amone (CHS-</p>\n<p>Clinical Services,  MOH), Mrs. Okuna Neville Oteba (CHS- Pharmacy),</p>\n<p>Mr. Morries Seru (ACH - Pharmacy, MOH), Ms. Martha G. Ajulong</p>\n<p>(ACH \u2013 Pharmacy, MOH), Dr. Nakwagala Fredrick (Senior Consultant</p>\n<p>Physician), Dr. Fualal Jane Odubu (Senior Consultant Surgeon), Dr.</p>\n<p>Byanyima Rosemary (Senior Consultant Radiologist), Dr. Lakor Francis</p>\n<p>(Senior Consultant Maxillo-facial Surgery), Dr. Kajumbula Henry (Senior</p>\n<p>Lecturer- Clinical Microbiology), Dr. Namagembe Imelda (Senior Con\u00ad</p>\n<p>sultant OBS/GYN), Dr. Orem Jackson (Senior Consultant Oncology),</p>\n<p>Dr. Munube Deogratius (Senior Lecturer Paediatricts), Dr. Wasomoka</p>\n<p>Alex (ACHS \u2013 HLLHFs), Dr. Bahatungire R Rony (PMO \u2013 Clinical Ser\u00ad</p>\n<p>vices), Dr. Namwanje Lydia (SMO - Clinical Services), Dr. Katwesigye</p>\n<p>Elizabeth (Physician, internal Medicine), Ms. Harriet Akello - (Senior</p>\n<p>Pharmacist\u00a0MoH\u00a0DPNM)</p>\n<h3>XXIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 24,
        "content": "Contributors to the clinical chapters\nDr. Jacqueline Mabweijano, Consultant Surgeon Mulago NRH \nDr. Charles Kabugo, Director / Consultant Kiruddu Hospital \nDr. Denis Rubahika (MCP-MOH)\nDr. Florence Christine Najjuka (Microbiology) \nDr. Charles Mondo (Cardiovascular)\nDr. J B Waniaye \u2013 Emergency and Trauma\nDr. John.O. Omagino (Cardiovascular)\nDr. William Worodria, Senior Consultant, Mulago NRH  \nDr. Kalani SMO-MOH,  \nDr. Francis Lakor, Consultant, maxilla facial surgery Mulago NRH\nDr. Dhabangi consultant haematology \u2013 Blood transfusion Mulago NRH \nDr. Christine Sekaggya-Wiltshire, Physician-Hematologist, Mulago NRH\nDr. Henry Ddungu, Physician-Hematologist, UCI\nMr. Lule Albert, PNO- Mulago NRH\nDr. Patrick Musinguzi, Consultant, Mulago NRH\nDr. Abubaker Bugembe, Consultant, Mulago NRH \nDr. Jackson Orem, Director, Uganda Cancer Institute \nMr. Rodney Tabaruka, Pharmacist Kabale RRH\nMr. Emmanuel Ongom, Medical Clinical Officer, Gulu RRH\nMs. Martha Ajulong, (ACHS, Pharmacy)\nMs. Harriet Akello, Senior Pharmacist MOH\nMr. Gad Twikirize, Senior Pharmacist, Butabika NRH\nDr. Fualal Jane Odubu, Sen.Cons. -Mulago NRH,\nDr. Kajumbula Henry- S/Lecturer, MAK CHS,\nDr. Munube Deogratias, Consultant Paed-MNRH,\nMs. Atim Mary Gorret - Sen. Pharm-KNRH\t\nDr. Namagembe Imelda, Sen. Cons.- MNRH\t\nDr. Amone Jackson CHS(CS)-MOH\t\nDr. Wasomoka Alex ACHS - HLLHF -MOH\t\nDr. Namubiru Saudah Kizito, Clinical Microbiologist, MOH/NHLDS \nDr. Bahatungire Rony, PMO/CS -MOH\t\nXXIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Contributors to the clinical chapters</p>\n<p>Dr. Jacqueline Mabweijano, Consultant Surgeon Mulago NRH</p>\n<p>Dr. Charles Kabugo, Director / Consultant Kiruddu Hospital</p>\n<p>Dr. Denis Rubahika (MCP-MOH)</p>\n<p>Dr. Florence Christine Najjuka (Microbiology)</p>\n<p>Dr. Charles Mondo (Cardiovascular)</p>\n<p>Dr. J B Waniaye \u2013 Emergency and Trauma</p>\n<p>Dr. John.O. Omagino (Cardiovascular)</p>\n<p>Dr. William Worodria, Senior Consultant, Mulago NRH</p>\n<p>Dr. Kalani SMO-MOH,</p>\n<p>Dr. Francis Lakor, Consultant, maxilla facial surgery Mulago NRH</p>\n<p>Dr. Dhabangi consultant haematology \u2013 Blood transfusion Mulago NRH</p>\n<p>Dr. Christine Sekaggya-Wiltshire, Physician-Hematologist, Mulago NRH</p>\n<p>Dr. Henry Ddungu, Physician-Hematologist, UCI</p>\n<p>Mr. Lule Albert, PNO- Mulago NRH</p>\n<p>Dr. Patrick Musinguzi, Consultant, Mulago NRH</p>\n<p>Dr. Abubaker Bugembe, Consultant, Mulago NRH</p>\n<p>Dr. Jackson Orem, Director, Uganda Cancer Institute</p>\n<p>Mr. Rodney Tabaruka, Pharmacist Kabale RRH</p>\n<p>Mr. Emmanuel Ongom, Medical Clinical Officer, Gulu RRH</p>\n<p>Ms. Martha Ajulong, (ACHS, Pharmacy)</p>\n<p>Ms. Harriet Akello, Senior Pharmacist MOH</p>\n<p>Mr. Gad Twikirize, Senior Pharmacist, Butabika NRH</p>\n<p>Dr. Fualal Jane Odubu, Sen.Cons. -Mulago NRH,</p>\n<p>Dr. Kajumbula Henry- S/Lecturer, MAK CHS,</p>\n<p>Dr. Munube Deogratias, Consultant Paed-MNRH,</p>\n<p>Ms. Atim Mary Gorret - Sen. Pharm-KNRH</p>\n<p>Dr. Namagembe Imelda, Sen. Cons.- MNRH</p>\n<p>Dr. Amone Jackson CHS(CS)-MOH</p>\n<p>Dr. Wasomoka Alex ACHS - HLLHF -MOH</p>\n<p>Dr. Namubiru Saudah Kizito, Clinical Microbiologist, MOH/NHLDS</p>\n<p>Dr. Bahatungire Rony, PMO/CS -MOH</p>\n<h3>XXIV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 25,
        "content": "Mrs. Okuna Neville Oteba, CHS \u2013 PNM-MOH\nMs. Amuge Beatrice, CHS N&M-MOH\t\nMr. Komakech Alfred, Pharmacist-UCI\t\nDr. Katwesigye Elizabeth, SMO-MOH \nDr. Namwanje Lydia, SMO-MOH\nDr. Nakwagala Fred, Sen. Cons.-MNRH\t\nDr. Olaro Charles, DHS(CS)-MOH\t\nMr. Seru Morris, ACHS- Pharm-MOH\t\nMr. Opio Patrices Otuke, ASS. DHO/DMMS\nMr. Muwonge Raymond, Intern Pharm, Kiruddu NRH\nMr. Gidudu Ivan, Dispenser Soroti-RRH\t\nSr. Limio Christine, Mbale RRH-PNO\nMr. Sande Alex, Sen. Pharm Mbale RRH\t\nDr. Senjokyo Wilson, M.O Arua RRH\nMr. Manzi Mbabazize Gerald, Pharmacist-Mbarara RRH\nMr. Katugira Lauben, Pharmacist Mbarara RRH\nMr. Obua Thomas O, Sen. Pharm-MOH\t\nMr. Kabonero Timothy, Pharmacist\tMasaka RRH\nMr. Tabaruka Rodney, Sen. Pharm-Kabale RRH\t\nSr. Oyella M. Josephine, Pharmacist-Lacor Hospital\nMr. Aguma\u00a0Daniel, Pharmacist-Lira RRH\t\nDr. Kiwanuka Ivan, SMO-MOH \t\nMs. Twemanye Vivian, Project Pharmacist-IDI/Global Health\nMr. Lule Falisy, Pharmacist-Kiruddu NRH\nMs. Marion A Murungi - USAID/ MTaPS\nMr. Owona Joseph, PCO- Soroti RRH\nMs. Irene Bagaya Nurse -IDI \nMr. Muwaza Eriabu, Sen. Pharm- Azan-Fort Portal\nMr. Gideon Kisuule, P/Pharmacist -Butabika NRH\t\nMr. Bewayo Victor, Pharmacist-Arua RRH\nMs. Nyombi Vicky R. Babirye, Sen. Pharm Mulago-NRH\nMs. Kahwa Oliva, O.A-MOH\nMs. Nanyonga Stella, Sen. Pharm-Mulago Women Hospital\nXXV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Mrs. Okuna Neville Oteba, CHS \u2013 PNM-MOH</p>\n<p>Ms. Amuge Beatrice, CHS N&M-MOH</p>\n<p>Mr. Komakech Alfred, Pharmacist-UCI</p>\n<p>Dr. Katwesigye Elizabeth, SMO-MOH</p>\n<p>Dr. Namwanje Lydia, SMO-MOH</p>\n<p>Dr. Nakwagala Fred, Sen. Cons.-MNRH</p>\n<p>Dr. Olaro Charles, DHS(CS)-MOH</p>\n<p>Mr. Seru Morris, ACHS- Pharm-MOH</p>\n<p>Mr. Opio Patrices Otuke, ASS. DHO/DMMS</p>\n<p>Mr. Muwonge Raymond, Intern Pharm, Kiruddu NRH</p>\n<p>Mr. Gidudu Ivan, Dispenser Soroti-RRH</p>\n<p>Sr. Limio Christine, Mbale RRH-PNO</p>\n<p>Mr. Sande Alex, Sen. Pharm Mbale RRH</p>\n<p>Dr. Senjokyo Wilson, M.O Arua RRH</p>\n<p>Mr. Manzi Mbabazize Gerald, Pharmacist-Mbarara RRH</p>\n<p>Mr. Katugira Lauben, Pharmacist Mbarara RRH</p>\n<p>Mr. Obua Thomas O, Sen. Pharm-MOH</p>\n<p>Mr. Kabonero Timothy, Pharmacist\tMasaka RRH</p>\n<p>Mr. Tabaruka Rodney, Sen. Pharm-Kabale RRH</p>\n<p>Sr. Oyella M. Josephine, Pharmacist-Lacor Hospital</p>\n<p>Mr. Aguma\u00a0Daniel, Pharmacist-Lira RRH</p>\n<p>Dr. Kiwanuka Ivan, SMO-MOH</p>\n<p>Ms. Twemanye Vivian, Project Pharmacist-IDI/Global Health</p>\n<p>Mr. Lule Falisy, Pharmacist-Kiruddu NRH</p>\n<p>Ms. Marion A Murungi - USAID/ MTaPS</p>\n<p>Mr. Owona Joseph, PCO- Soroti RRH</p>\n<p>Ms. Irene Bagaya Nurse -IDI</p>\n<p>Mr. Muwaza Eriabu, Sen. Pharm- Azan-Fort Portal</p>\n<p>Mr. Gideon Kisuule, P/Pharmacist -Butabika NRH</p>\n<p>Mr. Bewayo Victor, Pharmacist-Arua RRH</p>\n<p>Ms. Nyombi Vicky R. Babirye, Sen. Pharm Mulago-NRH</p>\n<p>Ms. Kahwa Oliva, O.A-MOH</p>\n<p>Ms. Nanyonga Stella, Sen. Pharm-Mulago Women Hospital</p>\n<h3>XXV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 26,
        "content": "Mr. Emmanuel Watongola, LSCO-MOH/OPPU\t\nMr. Julius Mubiru, Regional Coordinator MSH\t\nMs. Gladys Karungi, Dispenser-Jinja RRH\t\nMs. Sandra Achiro, Dispenser-Lira RRH\t\nMs. Prossy Atimango, C.O Gulu RRH\t\nMs. Kabonesa Winnie, Dispenser- Mbarara RRH\t\nMs. Namirembe Maliyamu, C.O Masaka RRH\t\nMr. Julius Mayengo, SBO-NDA\t\nDr. Florence Oyella Otim, Paed-Gulu RRH\t\nMs. Nambatya Winnie, Pharmacist-MUK \u2013 CHS\nMs. Pamela Achii, PSM Specialist-MOH\t\nMr. Mugerwa Ibrahim, PO AMR/GHSA -MOH - NHLDS\nMr. Nankoola Dennis, Sen. Pharm -Gulu RRH\t\nMs. Akello Zainab, Pharmacist-Gulu RRH \nDr. Okot Christopher, Gen. Surgeon- Gulu RRH\t\nMr. Henry Kizito, SCA-NTLP\t\nMs. Tino Harriet O, Pharmacist-Lira RRH\nMr. Olum William, Sen. Pharm-JRRH\t\nDr. Helen Byomire Ndagije, DPS-NDA\nDr. Denis Kibira, Coordinator-META\t\nMr. Emmanuel Higenyi, DTS-JMS\t  \nMs. Musoke Joanne, META\t\nMs. Namulira John B, SPN-MAK\t\nMr Joseph Mwoga, NPO /EDM-WHO\t\nDr. Otiti Richard, UWEC\t\nDr. Victor Musiime, UWEC\t\nDr. James Ntulume, Snakes Uganda\t\nDr. Alfred Mubangizi ACHS -VB & MTD-MOH\t\nDr. Mukajayaka Ritah, Intern Pharmacist\nDr. Nabiryo Mary. Citycare Medical Centre- Jinja\t\nDr. Nakireka Susan Tumwesigye, Mengo Hospital /UNDA\nMr. Edson I. Munanura, Secretary PSU\t\nDr. Joanita Bamwanga Nanteza, Physician-Jinja RRH\t\nXXVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Mr. Emmanuel Watongola, LSCO-MOH/OPPU</p>\n<p>Mr. Julius Mubiru, Regional Coordinator MSH</p>\n<p>Ms. Gladys Karungi, Dispenser-Jinja RRH</p>\n<p>Ms. Sandra Achiro, Dispenser-Lira RRH</p>\n<p>Ms. Prossy Atimango, C.O Gulu RRH</p>\n<p>Ms. Kabonesa Winnie, Dispenser- Mbarara RRH</p>\n<p>Ms. Namirembe Maliyamu, C.O Masaka RRH</p>\n<p>Mr. Julius Mayengo, SBO-NDA</p>\n<p>Dr. Florence Oyella Otim, Paed-Gulu RRH</p>\n<p>Ms. Nambatya Winnie, Pharmacist-MUK \u2013 CHS</p>\n<p>Ms. Pamela Achii, PSM Specialist-MOH</p>\n<p>Mr. Mugerwa Ibrahim, PO AMR/GHSA -MOH - NHLDS</p>\n<p>Mr. Nankoola Dennis, Sen. Pharm -Gulu RRH</p>\n<p>Ms. Akello Zainab, Pharmacist-Gulu RRH</p>\n<p>Dr. Okot Christopher, Gen. Surgeon- Gulu RRH</p>\n<p>Mr. Henry Kizito, SCA-NTLP</p>\n<p>Ms. Tino Harriet O, Pharmacist-Lira RRH</p>\n<p>Mr. Olum William, Sen. Pharm-JRRH</p>\n<p>Dr. Helen Byomire Ndagije, DPS-NDA</p>\n<p>Dr. Denis Kibira, Coordinator-META</p>\n<p>Mr. Emmanuel Higenyi, DTS-JMS</p>\n<p>Ms. Musoke Joanne, META</p>\n<p>Ms. Namulira John B, SPN-MAK</p>\n<p>Mr Joseph Mwoga, NPO /EDM-WHO</p>\n<p>Dr. Otiti Richard, UWEC</p>\n<p>Dr. Victor Musiime, UWEC</p>\n<p>Dr. James Ntulume, Snakes Uganda</p>\n<p>Dr. Alfred Mubangizi ACHS -VB & MTD-MOH</p>\n<p>Dr. Mukajayaka Ritah, Intern Pharmacist</p>\n<p>Dr. Nabiryo Mary. Citycare Medical Centre- Jinja</p>\n<p>Dr. Nakireka Susan Tumwesigye, Mengo Hospital /UNDA</p>\n<p>Mr. Edson I. Munanura, Secretary PSU</p>\n<p>Dr. Joanita Bamwanga Nanteza, Physician-Jinja RRH</p>\n<h3>XXVI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 27,
        "content": "Mr. Ambrose Jakira, SPQS-MOH/DPNM\t\nMr. Rodgers Katusigye, Pharmacist-MJAP\t\nMr. Caroline Birungi, Psychiatrist -MJAP/CHS\t\nDr. Martin Muddu, Physician- MJAP\t\nDr. Musimbaggo Douglas, Coordinator -MJAP\nDr. Mugabe Frank, PMO-MOH/MCD\t\nDr. Patricia Alupo, Physician-MLI\t\nDr. Cewa Ssenyange, SDA-NDA\t\nDr. Wabwona George William, Physician-Mubende RRH\nDr. Katagira Winceslaus, Physician-Lung Institute\t\nDr. Ann Akiteng, D/Director-UINCD \nDr. Lumu William, Physician Diabetologist -MENGO\t\nDr. John B. Kiggundu, Coordinator-IDRC\t\nDr. Ocakacon James, SMO-MOH\t\nDr. Omale William, Sen. Pharm- Arua RRH\t\nMr. Daniel Chans Mwandah, Clinical Pharmacist MRRH/MUST\t\nDr. Kwizera Christopher, Proj. Manager-Uganda NCD Alliance\t\nDr. Isaac Kimera, Coordinator-MJAP\t\nDr. Oyoo Charles A, CHS \u2013 NCD-MOH\t\nDr. Gracious Ahumuza, ACHS \u2013 PSCL-MOH\t\nDr. Nantaba Deborah, MCO/Selfcare Trainer-MDLG\t\nMs. Jacqueline Twemanye, Comms Officer-CEHURD\nDr. Kimbowa Richard, MDRH\t\nDr. Kukundakwe Annah, SPO-CEHURD\t\nMs. Awilli Grace, Volunteer-CEHURD\t\nDr. Nsingo Simon Peter, M.O-Mukono C.O.U Hospital\nDr. Isaac Ssinabulya, Cons. Cardiologist-UHI/UINCD\t\nMs. Kironde Stella M, PHO- Komamboga HCIII\nMr. Pascal Aliganyira, SCO-SAMASHA \nDr. Christopher Arineitwe, NFPP Advisor- USAID FPA\nMs. Aruho Carol, Proj. Officer-HEPS UG \nMs. Precious Mutoni, Advocacy & Partnership-PSI Uganda\nMs. Joyce Zalwango, Ag. Programs Manager-PCAU\t\nXXVII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Mr. Ambrose Jakira, SPQS-MOH/DPNM</p>\n<p>Mr. Rodgers Katusigye, Pharmacist-MJAP</p>\n<p>Mr. Caroline Birungi, Psychiatrist -MJAP/CHS</p>\n<p>Dr. Martin Muddu, Physician- MJAP</p>\n<p>Dr. Musimbaggo Douglas, Coordinator -MJAP</p>\n<p>Dr. Mugabe Frank, PMO-MOH/MCD</p>\n<p>Dr. Patricia Alupo, Physician-MLI</p>\n<p>Dr. Cewa Ssenyange, SDA-NDA</p>\n<p>Dr. Wabwona George William, Physician-Mubende RRH</p>\n<p>Dr. Katagira Winceslaus, Physician-Lung Institute</p>\n<p>Dr. Ann Akiteng, D/Director-UINCD</p>\n<p>Dr. Lumu William, Physician Diabetologist -MENGO</p>\n<p>Dr. John B. Kiggundu, Coordinator-IDRC</p>\n<p>Dr. Ocakacon James, SMO-MOH</p>\n<p>Dr. Omale William, Sen. Pharm- Arua RRH</p>\n<p>Mr. Daniel Chans Mwandah, Clinical Pharmacist MRRH/MUST</p>\n<p>Dr. Kwizera Christopher, Proj. Manager-Uganda NCD Alliance</p>\n<p>Dr. Isaac Kimera, Coordinator-MJAP</p>\n<p>Dr. Oyoo Charles A, CHS \u2013 NCD-MOH</p>\n<p>Dr. Gracious Ahumuza, ACHS \u2013 PSCL-MOH</p>\n<p>Dr. Nantaba Deborah, MCO/Selfcare Trainer-MDLG</p>\n<p>Ms. Jacqueline Twemanye, Comms Officer-CEHURD</p>\n<p>Dr. Kimbowa Richard, MDRH</p>\n<p>Dr. Kukundakwe Annah, SPO-CEHURD</p>\n<p>Ms. Awilli Grace, Volunteer-CEHURD</p>\n<p>Dr. Nsingo Simon Peter, M.O-Mukono C.O.U Hospital</p>\n<p>Dr. Isaac Ssinabulya, Cons. Cardiologist-UHI/UINCD</p>\n<p>Ms. Kironde Stella M, PHO- Komamboga HCIII</p>\n<p>Mr. Pascal Aliganyira, SCO-SAMASHA</p>\n<p>Dr. Christopher Arineitwe, NFPP Advisor- USAID FPA</p>\n<p>Ms. Aruho Carol, Proj. Officer-HEPS UG</p>\n<p>Ms. Precious Mutoni, Advocacy & Partnership-PSI Uganda</p>\n<p>Ms. Joyce Zalwango, Ag. Programs Manager-PCAU</p>\n<h3>XXVII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 28,
        "content": "Dr. Karima Amin Kamru K, Head-MPU -Hospice Africa Uganda\t\nMr. Ogwang Christopher, SPO-CEHURD\t\nDr. Niwagaba Peter, Technical Advisor, SCM-USAID RHITES EC \nMr. Lubogo Patrick, Clinical Pharmacist\nMr. Tadele Mekuriya Yedesa Clinical Pharmacist - Mbarara RRH\t\nMr Aboda Alex Komakech Clinical Pharmacist - Kitgum District Hospital\nDr. Isiiko John, Oncology Pharmacist - Mbarara RRH, \nMr. Aguma Bush Herbert, Makerere University, School of Pharmacy, \nMs. Farida Khaukha. Pharmacist-NDA \nMr. Dennis Rogers Buwembo-Consultant R4D. \nMr. Patrick Mpiima, Registrar-Allied Health Professionals \nMr. Eric Jemera Nabuguzi, Principal Advisor, RMNCH\nMr. Lawrence Were, - RCHSC/TA-CHAI\nDr. Hafsa Lukwata, Mental Health/MOH\nDr. Benjamin Mwesige, Pharmacist, UCI \nDr. Martin Ssendyona, Quality Assurance/MOH \nDr. Fatunmbi Bayo Segun, WHO, \nDr. Patrick Tusiime, NDC/MOH, \nDr. S. Nanyonga, Jinja, \nDr. J. Ddamulira, MUSPH, Makerere. \nDr. Suuna Micheal, \nDr. D Musingo, \nDr. Turyahabwe Stavia, ACHS-NTLP/MOH\nDr. Henry Luzze, PMO -NTLP/MOH\nDr. Winters Mutamba, Consultant -MLI\nDr. Aldo Burua, TB case finding Advisor - NTLP/ LPHS\nMs. Hawa Nakato, Supply Chain Advisor -NTLP/MOH\nMr. Abdunoor Nyombi, Lab \u2013 NTRL - NTLP/MOH\nDr. Jeff Amanya, Epidemiologist - NTLP/MOH\nDr. Joshua Muhumuza, PPM Advisor - NTLP/ LPHS \nDr. Simon Muchuro, TB Prevention Advisor -NTLP/ LPHS\nMr. Muzamir Bamuloba, CSS Advisor - NTLP/MOH\nDr. Mary Mudiope, Project Director - LPHS TB Activity\nDr. Prossy Namuwenge, SPO TB/HIV - ACP/MOH\nMr. Ebony Quinto, M&E - NTLP/MOH\nXXVIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Dr. Karima Amin Kamru K, Head-MPU -Hospice Africa Uganda</p>\n<p>Mr. Ogwang Christopher, SPO-CEHURD</p>\n<p>Dr. Niwagaba Peter, Technical Advisor, SCM-USAID RHITES EC</p>\n<p>Mr. Lubogo Patrick, Clinical Pharmacist</p>\n<p>Mr. Tadele Mekuriya Yedesa Clinical Pharmacist - Mbarara RRH</p>\n<p>Mr Aboda Alex Komakech Clinical Pharmacist - Kitgum District Hospital</p>\n<p>Dr. Isiiko John, Oncology Pharmacist - Mbarara RRH,</p>\n<p>Mr. Aguma Bush Herbert, Makerere University, School of Pharmacy,</p>\n<p>Ms. Farida Khaukha. Pharmacist-NDA</p>\n<p>Mr. Dennis Rogers Buwembo-Consultant R4D.</p>\n<p>Mr. Patrick Mpiima, Registrar-Allied Health Professionals</p>\n<p>Mr. Eric Jemera Nabuguzi, Principal Advisor, RMNCH</p>\n<p>Mr. Lawrence Were, - RCHSC/TA-CHAI</p>\n<p>Dr. Hafsa Lukwata, Mental Health/MOH</p>\n<p>Dr. Benjamin Mwesige, Pharmacist, UCI</p>\n<p>Dr. Martin Ssendyona, Quality Assurance/MOH</p>\n<p>Dr. Fatunmbi Bayo Segun, WHO,</p>\n<p>Dr. Patrick Tusiime, NDC/MOH,</p>\n<p>Dr. S. Nanyonga, Jinja,</p>\n<p>Dr. J. Ddamulira, MUSPH, Makerere.</p>\n<p>Dr. Suuna Micheal,</p>\n<p>Dr. D Musingo,</p>\n<p>Dr. Turyahabwe Stavia, ACHS-NTLP/MOH</p>\n<p>Dr. Henry Luzze, PMO -NTLP/MOH</p>\n<p>Dr. Winters Mutamba, Consultant -MLI</p>\n<p>Dr. Aldo Burua, TB case finding Advisor - NTLP/ LPHS</p>\n<p>Ms. Hawa Nakato, Supply Chain Advisor -NTLP/MOH</p>\n<p>Mr. Abdunoor Nyombi, Lab \u2013 NTRL - NTLP/MOH</p>\n<p>Dr. Jeff Amanya, Epidemiologist - NTLP/MOH</p>\n<p>Dr. Joshua Muhumuza, PPM Advisor - NTLP/ LPHS</p>\n<p>Dr. Simon Muchuro, TB Prevention Advisor -NTLP/ LPHS</p>\n<p>Mr. Muzamir Bamuloba, CSS Advisor - NTLP/MOH</p>\n<p>Dr. Mary Mudiope, Project Director - LPHS TB Activity</p>\n<p>Dr. Prossy Namuwenge, SPO TB/HIV - ACP/MOH</p>\n<p>Mr. Ebony Quinto, M&E - NTLP/MOH</p>\n<h3>XXVIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 29,
        "content": "Dr. Raymond Byaruhanga, STA-Global Fund - NTLP/MOH\nMs. Shamimu Masika, Adm Assistant - LPHS TB Activity\nMr. Busingye Evas, IT Officer - NTLP/MOH\nDr. Ajuna Patrick\t, TB DSD Advisor - NTLP/MOH\nMr. Kamara Vincent, Data Manager - NTLP/MOH\nMr. Didas Tugumisirize, Laboratory Technologist - NTLP/MOH\nMr. Ignatius Senteza, STA\tLPHS- TB Activity\nMr. Moses Arineitwe, TA-M&E - NTLP/MOH\nDr. Gemagaine Godfrey, Cons. Pathologist-Naguru Hospital\nDr. Susan N. Nabadda, CHS-NHLDS- UNHLS/CPHL- MoH\nDr. Sam Kalungi\nDr. Achola Caroline\nDr. Kubengi Henry\nMr. Kenneth Mwehonge - HEPS-Uganda, ED.\nMr. Serunkuuma Richard-Positive Men\u2019s Union, ED\nMs. Jackline Mutimba - HEPS-Uganda, Senior M&E Officer \nMs. Bridget Jjuuko - ACTS101, ED \nMs. May Ndagire - Preventive Care International, Programs Officer \nMr. Peter Eceru \u2013 CEHURD- Program Coordinator\nMr. Okoth Charles - AWAC, CMO\nMr. Ssebibubbu Stuart - HEPS-Uganda, Pharmacist\t\nMr. Bukenya Denis Joseph - HURIC\nMs. Joan Esther Kilande - HEPS-Uganda, Health Policy Advocacy Manager\nMs. Mable Kukunda Musinguzi \u2013 UNHCO, Head of Advocacy and net\u00ad\nworking\t\nMr. Talibita Moses \u2013 UNHCO -Legal Officer\nMs. Kangabe Claire - Transparency International Uganda\nMs. Ninsiima Dorothy - Action Group for Health, Human Rights & HIV/\nAIDS Executive Associate\nMs. Nanteza Ruth - Uganda Young Positives (UYP),\t Peer Leader\nMr. Principle Edimon - Vision Group, Journalist\nMr. Gilbert Musinguzi - Uganda Debt Network (UDN)-Quality Assurance \nManager\nMs. Nabirah Namawanda - Lady Mermaid Empowerment Center, Com\u00ad\nmunication & Advocacy Officer\nXXIX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Dr. Raymond Byaruhanga, STA-Global Fund - NTLP/MOH</p>\n<p>Ms. Shamimu Masika, Adm Assistant - LPHS TB Activity</p>\n<p>Mr. Busingye Evas, IT Officer - NTLP/MOH</p>\n<p>Dr. Ajuna Patrick\t, TB DSD Advisor - NTLP/MOH</p>\n<p>Mr. Kamara Vincent, Data Manager - NTLP/MOH</p>\n<p>Mr. Didas Tugumisirize, Laboratory Technologist - NTLP/MOH</p>\n<p>Mr. Ignatius Senteza, STA\tLPHS- TB Activity</p>\n<p>Mr. Moses Arineitwe, TA-M&E - NTLP/MOH</p>\n<p>Dr. Gemagaine Godfrey, Cons. Pathologist-Naguru Hospital</p>\n<p>Dr. Susan N. Nabadda, CHS-NHLDS- UNHLS/CPHL- MoH</p>\n<p>Dr. Sam Kalungi</p>\n<p>Dr. Achola Caroline</p>\n<p>Dr. Kubengi Henry</p>\n<p>Mr. Kenneth Mwehonge - HEPS-Uganda, ED.</p>\n<p>Mr. Serunkuuma Richard-Positive Men\u2019s Union, ED</p>\n<p>Ms. Jackline Mutimba - HEPS-Uganda, Senior M&E Officer</p>\n<p>Ms. Bridget Jjuuko - ACTS101, ED</p>\n<p>Ms. May Ndagire - Preventive Care International, Programs Officer</p>\n<p>Mr. Peter Eceru \u2013 CEHURD- Program Coordinator</p>\n<p>Mr. Okoth Charles - AWAC, CMO</p>\n<p>Mr. Ssebibubbu Stuart - HEPS-Uganda, Pharmacist</p>\n<p>Mr. Bukenya Denis Joseph - HURIC</p>\n<p>Ms. Joan Esther Kilande - HEPS-Uganda, Health Policy Advocacy Manager</p>\n<p>Ms. Mable Kukunda Musinguzi \u2013 UNHCO, Head of Advocacy and net\u00ad</p>\n<p>working</p>\n<p>Mr. Talibita Moses \u2013 UNHCO -Legal Officer</p>\n<p>Ms. Kangabe Claire - Transparency International Uganda</p>\n<p>Ms. Ninsiima Dorothy - Action Group for Health, Human Rights & HIV/</p>\n<p>AIDS Executive Associate</p>\n<p>Ms. Nanteza Ruth - Uganda Young Positives (UYP),\t Peer Leader</p>\n<p>Mr. Principle Edimon - Vision Group, Journalist</p>\n<p>Mr. Gilbert Musinguzi - Uganda Debt Network (UDN)-Quality Assurance</p>\n<p>Manager</p>\n<p>Ms. Nabirah Namawanda - Lady Mermaid Empowerment Center, Com\u00ad</p>\n<p>munication & Advocacy Officer</p>\n<h3>XXIX</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 30,
        "content": "Mr. Jude Opolot - Oxygen Task Force Logistician, MoH\nMs. Doreen Nyakato - Oxygen Task Force Coordinator, MoH\nDr. Samalie Namukose (Assistant Commissioner, Nutrition Division, \nMinistry of Health)\nDr. Alex Mokori (Nutrition Specialist, UNICEF)\nMs. Jeniffer Luande (Nutrition Supply Chain Consultant, UNICEF)\nMr. Tim Mateba (Senior Nutritionist, Nutrition Division, Ministry of Health)\nDr. Hanifa Bachu (Technical Director Nutrition, USAID MCHN Activity)\nDr, Elizabeth Kiboneka (Nutrition Consultant)\nMr. George Kemugisha (Nutritionist, Mulago National Referral Hospital)\nMs. Amanda Murungi (Nutritionist, Mulago National Referral Hospital)\nMs. Agnes Kiro (Programme Officer, Nutrition Division, Ministry of Health)\nDr. Anne Mary Nanyonjo - Pharmacist Mubende RRH\nMr. Absolom Zisanhi - Senior Associate, CHAI\nDr. Margaret Abigaba - Senior Pharmacist, Hoima RRH\nMr. Michael Lukunyanga - Distribution manager, NMS\nDr. Emily Tumwakire - Senior Medical Officer, MoH\nMs. Dorcas Kemigisha - Senior Coordinator, CHAI\nEng. Owen Muhimbise - Biomedical Engineer, MoH\nBlasio Kunihiira - M&E coordinator, CHAI\nEng. Saad Waigonda - Senior Biomedical Engineer, MoH\nEng. Tadeo Byabagambi - ACHS-Biomedical/Electromechanical Engi\u00ad\nneering, MoH\nDr. Yewande Kamuntu, Program Manager, CHAI\nDr. Santa Engol, Senior Coordinator, CHAI\nDr. Aanyu Hellen, Consultant Pediatrician, Mulago NRRH\nMr. Jovan Baryamujura, Oxygen Task Force Administrator\nMs. Nakade Shamim \u2013 National Activity Manager SSCS Activity\nMr. Daniel Mawerere \u2013 Senior Technical Advisor MoH DPNM\nMr. Kasule Timothy \u2013 RHSC Analysts UNFPA\nMr. Joel Miti - Senior Technical Advisor NMCD MoH\nMs. Magona Sandra RMNCAH & Nutrition Senior Technical Officer \nMoH DPNM\nMs. Sarah Taratwebirwe, Condoms Logistics Management Officer MoH \nDPNM\nXXX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Mr. Jude Opolot - Oxygen Task Force Logistician, MoH</p>\n<p>Ms. Doreen Nyakato - Oxygen Task Force Coordinator, MoH</p>\n<p>Dr. Samalie Namukose (Assistant Commissioner, Nutrition Division,</p>\n<p>Ministry of Health)</p>\n<p>Dr. Alex Mokori (Nutrition Specialist, UNICEF)</p>\n<p>Ms. Jeniffer Luande (Nutrition Supply Chain Consultant, UNICEF)</p>\n<p>Mr. Tim Mateba (Senior Nutritionist, Nutrition Division, Ministry of Health)</p>\n<p>Dr. Hanifa Bachu (Technical Director Nutrition, USAID MCHN Activity)</p>\n<p>Dr, Elizabeth Kiboneka (Nutrition Consultant)</p>\n<p>Mr. George Kemugisha (Nutritionist, Mulago National Referral Hospital)</p>\n<p>Ms. Amanda Murungi (Nutritionist, Mulago National Referral Hospital)</p>\n<p>Ms. Agnes Kiro (Programme Officer, Nutrition Division, Ministry of Health)</p>\n<p>Dr. Anne Mary Nanyonjo - Pharmacist Mubende RRH</p>\n<p>Mr. Absolom Zisanhi - Senior Associate, CHAI</p>\n<p>Dr. Margaret Abigaba - Senior Pharmacist, Hoima RRH</p>\n<p>Mr. Michael Lukunyanga - Distribution manager, NMS</p>\n<p>Dr. Emily Tumwakire - Senior Medical Officer, MoH</p>\n<p>Ms. Dorcas Kemigisha - Senior Coordinator, CHAI</p>\n<p>Eng. Owen Muhimbise - Biomedical Engineer, MoH</p>\n<p>Blasio Kunihiira - M&E coordinator, CHAI</p>\n<p>Eng. Saad Waigonda - Senior Biomedical Engineer, MoH</p>\n<p>Eng. Tadeo Byabagambi - ACHS-Biomedical/Electromechanical Engi\u00ad</p>\n<p>neering, MoH</p>\n<p>Dr. Yewande Kamuntu, Program Manager, CHAI</p>\n<p>Dr. Santa Engol, Senior Coordinator, CHAI</p>\n<p>Dr. Aanyu Hellen, Consultant Pediatrician, Mulago NRRH</p>\n<p>Mr. Jovan Baryamujura, Oxygen Task Force Administrator</p>\n<p>Ms. Nakade Shamim \u2013 National Activity Manager SSCS Activity</p>\n<p>Mr. Daniel Mawerere \u2013 Senior Technical Advisor MoH DPNM</p>\n<p>Mr. Kasule Timothy \u2013 RHSC Analysts UNFPA</p>\n<p>Mr. Joel Miti - Senior Technical Advisor NMCD MoH</p>\n<p>Ms. Magona Sandra RMNCAH & Nutrition Senior Technical Officer</p>\n<p>MoH DPNM</p>\n<p>Ms. Sarah Taratwebirwe, Condoms Logistics Management Officer MoH</p>\n<h3>DPNM</h3>\n<h3>XXX</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 31,
        "content": "Mr. Tabu Fred \u2013 Senior Technical Officer MoH DPNM\nMr. Ian Nyamitoro, HP Quantification Specialist MoH DPNM\nMr. Deogratius Kamulegeya - Administrator, IMT Logistics Pillar, MoH\nMr. Ambrose Jakira, HP Quantification Specialist MoH DPNM\nMr. Isaac Namoma, GHSA Senior Technical Officer USAID/SSCS Activity\nMs. Judith Kyokushaba, Laboratory Advisor MoH DPNM\nMr. Henry Oundo, Technical Advisor MoH DPNM\nMs. Linacy Nampa, Technical Advisor MoH DPNM\nMr. Emiku Joseph, HIV/TB Technical Officer MoH DPNM\nMr. Denis Okidi Ladwar, Director Supply Chain USAID/SSCS Activity\nMr. Bamwine Jeremiah - Support on AIDS and Life Through Telephone \nHelpline (SALT), IT Officer\nMr. Raymond Ruyoka - YADNET UG, ED\nDr. Lutakome Jamadah Aldine - Hepatitis Aid Organisation, Programs \nDirector\nMs. Beatrice Ajonye- PC-International Community of Women Living \nwith HIV Eastern Africa (ICWEA)\nMr. Moses Supachager \u2013 JABASA, ED\nMr. Georgina Mugwera - Ministry of Trade\nMr. Grace Kiwanuka - Uganda Health Care Federation-ED\nMr. Ssebagereka Anthony - HEPS-Uganda-\tResearch\t\nMs. Nakalute Mastulah - GHC Mbarara \nMs. Aliyenka Lydia \u2013 BCCO\nMs. Baguma Anne Peace - SALT Helpline, ED\nMr. Kirunda Anthony - Sub-National Activity Manager USAID/SSCS \nActivity\nMr. Charles Twesige - HEPS-Uganda, M&E Officer\nMs. Barbara Amumphaire - HEPS-Uganda, Program Officer\nMr. Cliff Abenaitwe - HEPS-Uganda, Communication Officer\nDr. George Mukone Mudanga, MD- IFOTRODE\nDr. Sam Ononge (PhD), Sen. Lecturer- Ob&Gyn Muk-CHS\nMr. Joshua Musasizi, Knowledge Exchange Specialist USAID/SSCS \nActivity\nXXXI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Mr. Tabu Fred \u2013 Senior Technical Officer MoH DPNM</p>\n<p>Mr. Ian Nyamitoro, HP Quantification Specialist MoH DPNM</p>\n<p>Mr. Deogratius Kamulegeya - Administrator, IMT Logistics Pillar, MoH</p>\n<p>Mr. Ambrose Jakira, HP Quantification Specialist MoH DPNM</p>\n<p>Mr. Isaac Namoma, GHSA Senior Technical Officer USAID/SSCS Activity</p>\n<p>Ms. Judith Kyokushaba, Laboratory Advisor MoH DPNM</p>\n<p>Mr. Henry Oundo, Technical Advisor MoH DPNM</p>\n<p>Ms. Linacy Nampa, Technical Advisor MoH DPNM</p>\n<p>Mr. Emiku Joseph, HIV/TB Technical Officer MoH DPNM</p>\n<p>Mr. Denis Okidi Ladwar, Director Supply Chain USAID/SSCS Activity</p>\n<p>Mr. Bamwine Jeremiah - Support on AIDS and Life Through Telephone</p>\n<p>Helpline (SALT), IT Officer</p>\n<p>Mr. Raymond Ruyoka - YADNET UG, ED</p>\n<p>Dr. Lutakome Jamadah Aldine - Hepatitis Aid Organisation, Programs</p>\n<p>Director</p>\n<p>Ms. Beatrice Ajonye- PC-International Community of Women Living</p>\n<p>with HIV Eastern Africa (ICWEA)</p>\n<p>Mr. Moses Supachager \u2013 JABASA, ED</p>\n<p>Mr. Georgina Mugwera - Ministry of Trade</p>\n<p>Mr. Grace Kiwanuka - Uganda Health Care Federation-ED</p>\n<p>Mr. Ssebagereka Anthony - HEPS-Uganda-\tResearch</p>\n<p>Ms. Nakalute Mastulah - GHC Mbarara</p>\n<p>Ms. Aliyenka Lydia \u2013 BCCO</p>\n<p>Ms. Baguma Anne Peace - SALT Helpline, ED</p>\n<p>Mr. Kirunda Anthony - Sub-National Activity Manager USAID/SSCS</p>\n<p>Activity</p>\n<p>Mr. Charles Twesige - HEPS-Uganda, M&E Officer</p>\n<p>Ms. Barbara Amumphaire - HEPS-Uganda, Program Officer</p>\n<p>Mr. Cliff Abenaitwe - HEPS-Uganda, Communication Officer</p>\n<p>Dr. George Mukone Mudanga, MD- IFOTRODE</p>\n<p>Dr. Sam Ononge (PhD), Sen. Lecturer- Ob&Gyn Muk-CHS</p>\n<p>Mr. Joshua Musasizi, Knowledge Exchange Specialist USAID/SSCS</p>\n<p>Activity</p>\n<h3>XXXI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 32,
        "content": "Administrative Support\nMs. Noeline Namulindwa -MOH, Ms. Annet Namutebi- MOH, Mr. Dissan \nSsentumbwe, Coordinator -MOH, Ms. Namwano Babra, MOH PA/DHS/\nCS, Ms. Nalugonda Barbara, Admin. Pharmacy-MOH/DPNM, Ms. Irene \nNabatanzi, Admin. Zenith, Mr. Migadde Charles Kunobwa, RA-Zenith.\nWe thank the Zenith Solutions Consultancy team comprised of;- Mr. \nGordon Sematiko, Dr. Fred Sebisubi,  Dr. Henry W Kakande, Dr. \nAndrew Kiboneka, Dr. Watya S, Dr. Edward Ssemafumu and Dr. Clare \nLubulwa who have led and coordinated the entire process of reviewing \nand updating the UCG 2023 to completion.\nDesign/ Layout \nFinally, we thank the MoH taskforce secretariat and USAID/SSCS \nActivity for editing and formatting this edition. \nDr. Morries Seru\nAg. Commissioner Health Services, Pharmaceuticals and Natural \nMedicines, Ministry of Health\nXXXII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Administrative Support</p>\n<p>Ms. Noeline Namulindwa -MOH, Ms. Annet Namutebi- MOH, Mr. Dissan</p>\n<p>Ssentumbwe, Coordinator -MOH, Ms. Namwano Babra, MOH PA/DHS/</p>\n<p>CS, Ms. Nalugonda Barbara, Admin. Pharmacy-MOH/DPNM, Ms. Irene</p>\n<p>Nabatanzi, Admin. Zenith, Mr. Migadde Charles Kunobwa, RA-Zenith.</p>\n<p>We thank the Zenith Solutions Consultancy team comprised of;- Mr.</p>\n<p>Gordon Sematiko, Dr. Fred Sebisubi,  Dr. Henry W Kakande, Dr.</p>\n<p>Andrew Kiboneka, Dr. Watya S, Dr. Edward Ssemafumu and Dr. Clare</p>\n<p>Lubulwa who have led and coordinated the entire process of reviewing</p>\n<p>and updating the UCG 2023 to completion.</p>\n<p>Design/ Layout</p>\n<p>Finally, we thank the MoH taskforce secretariat and USAID/SSCS</p>\n<p>Activity for editing and formatting this edition.</p>\n<p>Dr. Morries Seru</p>\n<p>Ag. Commissioner Health Services, Pharmaceuticals and Natural</p>\n<p>Medicines, Ministry of Health</p>\n<h3>XXXII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 33,
        "content": "Abbreviations\n3TC\nLamivudine\nABC\nAbacavir\nAb\nAntibody\nACE\nAngiotensin Converting Enzyme \nACP\nAids Control Program\nACT\nArtemisinin-Based Combination Therapy \nACTH\nAdrenocorticotropic Hormone\nADHD\nAttention Deficit Hyperactivity Disorder \nADR\nAdverse Drug  Reaction\nAFASS\nAcceptable, Feasible, Affordable, Sustainable And Safe\n(A)AFB\n(Alcohol) Acid-Fast  Bacillus\nAIDS\nAcquired Immunodeficiency Syndrome \nALP\nAlkaline Phosphatase\nALT\nAlanine Aminotransferase \nAMI\nAcute Myocardial Infarction \nANC\nAntenatal Care\nAPH\nAntepartum Haemorrhage\nAPPE\nAppropriate Personal Protective Equipment \nAPRI\nAspartate Aminotransferase (Ast) To Platelets Ratio Index\naPTT\nActivated Partial Thromboplastin Time \nAQ\nAmodiaquine\nARB\nAldosterone  Recepto  Blocker \nART\nAntiretroviral Therapy\nARV\nAntiretroviral\nAS\nArtesunate\nASA\nAcetylsalicylic Acid \nASOT\nAnti-Streptolysin O Titre\nAST\nAspartate Aminotransferase \nXXXIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Abbreviations</p>\n<h3>3TC</h3>\n<p>Lamivudine</p>\n<h3>ABC</h3>\n<p>Abacavir</p>\n<p>Ab</p>\n<p>Antibody</p>\n<h3>ACE</h3>\n<p>Angiotensin Converting Enzyme</p>\n<h3>ACP</h3>\n<p>Aids Control Program</p>\n<h3>ACT</h3>\n<p>Artemisinin-Based Combination Therapy</p>\n<h3>ACTH</h3>\n<p>Adrenocorticotropic Hormone</p>\n<h3>ADHD</h3>\n<p>Attention Deficit Hyperactivity Disorder</p>\n<h3>ADR</h3>\n<p>Adverse Drug  Reaction</p>\n<h3>AFASS</h3>\n<p>Acceptable, Feasible, Affordable, Sustainable And Safe</p>\n<h3>(A)AFB</h3>\n<p>(Alcohol) Acid-Fast  Bacillus</p>\n<h3>AIDS</h3>\n<p>Acquired Immunodeficiency Syndrome</p>\n<h3>ALP</h3>\n<p>Alkaline Phosphatase</p>\n<h3>ALT</h3>\n<p>Alanine Aminotransferase</p>\n<h3>AMI</h3>\n<p>Acute Myocardial Infarction</p>\n<h3>ANC</h3>\n<p>Antenatal Care</p>\n<h3>APH</h3>\n<p>Antepartum Haemorrhage</p>\n<h3>APPE</h3>\n<p>Appropriate Personal Protective Equipment</p>\n<h3>APRI</h3>\n<p>Aspartate Aminotransferase (Ast) To Platelets Ratio Index</p>\n<p>aPTT</p>\n<p>Activated Partial Thromboplastin Time</p>\n<p>AQ</p>\n<p>Amodiaquine</p>\n<h3>ARB</h3>\n<p>Aldosterone  Recepto  Blocker</p>\n<h3>ART</h3>\n<p>Antiretroviral Therapy</p>\n<h3>ARV</h3>\n<p>Antiretroviral</p>\n<p>AS</p>\n<p>Artesunate</p>\n<h3>ASA</h3>\n<p>Acetylsalicylic Acid</p>\n<h3>ASOT</h3>\n<p>Anti-Streptolysin O Titre</p>\n<h3>AST</h3>\n<p>Aspartate Aminotransferase</p>\n<h3>XXXIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 34,
        "content": "ATV\nAtazanavir\nAZT\nZidovudine\nBCG\nBacillus Calmette-Gu\u00e9rin \nBMI\nBody Mass  Index\nBNP\nBrain Natriuretic Peptide \nBP\nBlood Pressure\nBPH\nBenign Prostatic Hyperplasia\nbpm\nBeats Per Minute\nBSE\nBreast Self-Examination\nBUN\nBlood Urea Nitrogen\nC&S\nCulture And Sensitivity\nCa2+\nCalcium\nCBC\nComplete Blood Count\nCCB\nCalcium Channel Blocker \nCD4\nCluster Of Differentiation 4\nCIN\nCervical  Intraepithelial  Neoplasia \nCK\nCreatin Kinase\nCKD\nChronic Kidney Disease\nCLL\nChronic Lymphocytic Leukaemia \nCM\nCryptococcal Meningitis\nCML\nChronic Myeloid Leukaemia \nCMM\nCervical Mucus Method \nCMV\nCytomegalovirus\nCNS\nCentral Nervous System\nCOC\nCombined Oral Contraceptive\nCOPD\nChronic Obstructive Pulmonary Disease \nCPD\nCephalopelvic Disproportion\nCPK\nCreatine Phosphokinase\nXXXIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>ATV</h3>\n<p>Atazanavir</p>\n<h3>AZT</h3>\n<p>Zidovudine</p>\n<h3>BCG</h3>\n<p>Bacillus Calmette-Gu\u00e9rin</p>\n<h3>BMI</h3>\n<p>Body Mass  Index</p>\n<h3>BNP</h3>\n<p>Brain Natriuretic Peptide</p>\n<p>BP</p>\n<p>Blood Pressure</p>\n<h3>BPH</h3>\n<p>Benign Prostatic Hyperplasia</p>\n<p>bpm</p>\n<p>Beats Per Minute</p>\n<h3>BSE</h3>\n<p>Breast Self-Examination</p>\n<h3>BUN</h3>\n<p>Blood Urea Nitrogen</p>\n<h3>C&S</h3>\n<p>Culture And Sensitivity</p>\n<p>Ca2+</p>\n<p>Calcium</p>\n<h3>CBC</h3>\n<p>Complete Blood Count</p>\n<h3>CCB</h3>\n<p>Calcium Channel Blocker</p>\n<h3>CD4</h3>\n<p>Cluster Of Differentiation 4</p>\n<h3>CIN</h3>\n<p>Cervical  Intraepithelial  Neoplasia</p>\n<p>CK</p>\n<p>Creatin Kinase</p>\n<h3>CKD</h3>\n<p>Chronic Kidney Disease</p>\n<h3>CLL</h3>\n<p>Chronic Lymphocytic Leukaemia</p>\n<p>CM</p>\n<p>Cryptococcal Meningitis</p>\n<h3>CML</h3>\n<p>Chronic Myeloid Leukaemia</p>\n<h3>CMM</h3>\n<p>Cervical Mucus Method</p>\n<h3>CMV</h3>\n<p>Cytomegalovirus</p>\n<h3>CNS</h3>\n<p>Central Nervous System</p>\n<h3>COC</h3>\n<p>Combined Oral Contraceptive</p>\n<h3>COPD</h3>\n<p>Chronic Obstructive Pulmonary Disease</p>\n<h3>CPD</h3>\n<p>Cephalopelvic Disproportion</p>\n<h3>CPK</h3>\n<p>Creatine Phosphokinase</p>\n<h3>XXXIV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 35,
        "content": "CrAg\nCryptococcal Antigen\nCRP\nC-Reactive   Protein\nCSF\nCerebrospinal Fluid\nCT\nComputed Tomography\nCuIUD\nCopper Bearing Intra-Uterine Device \nCVD\nCardiovascular Disease\nCXR\nChest X-Ray\nDBP\nDiastolic Blood Pressure\nDBS\nDried Blood Spots\nDHA\nDihydroartemisinin\nDIC\nDisseminated Intravascular Coagulation \nDKA\nDiabetic Ketoacidosis\nDMPA\nDepot Medroxyprogesterone Acetate \nDNA\nDeoxyribonucleic Acid\nDOT\nDirectly Observed  Therapy\nDOTS\nDirectly Observed Treatment, Short-Course \nDPT\nDiphtheria, Pertussis, And Tetanus\nDRE\nDigital Rectal  Exam\nDRV\nDarunavir\nDST\nDrug Susceptibility Testing \nDT\nDispersible Tablet\nDTG\nDolutegravir\nDVT\nDeep Vein Thrombosis\nEBV\nEpstein-Barr Virus\nEC\nEnteric Coated\nECG\nElectrocardiogram\nECP\nEmergency Contraceptive Pill \nEDD\nEstimated Delivery Date\nEFV\nEfavirenz\nXXXV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>CrAg</p>\n<p>Cryptococcal Antigen</p>\n<h3>CRP</h3>\n<p>C-Reactive   Protein</p>\n<h3>CSF</h3>\n<p>Cerebrospinal Fluid</p>\n<p>CT</p>\n<p>Computed Tomography</p>\n<p>CuIUD</p>\n<p>Copper Bearing Intra-Uterine Device</p>\n<h3>CVD</h3>\n<p>Cardiovascular Disease</p>\n<h3>CXR</h3>\n<p>Chest X-Ray</p>\n<h3>DBP</h3>\n<p>Diastolic Blood Pressure</p>\n<h3>DBS</h3>\n<p>Dried Blood Spots</p>\n<h3>DHA</h3>\n<p>Dihydroartemisinin</p>\n<h3>DIC</h3>\n<p>Disseminated Intravascular Coagulation</p>\n<h3>DKA</h3>\n<p>Diabetic Ketoacidosis</p>\n<h3>DMPA</h3>\n<p>Depot Medroxyprogesterone Acetate</p>\n<h3>DNA</h3>\n<p>Deoxyribonucleic Acid</p>\n<h3>DOT</h3>\n<p>Directly Observed  Therapy</p>\n<h3>DOTS</h3>\n<p>Directly Observed Treatment, Short-Course</p>\n<h3>DPT</h3>\n<p>Diphtheria, Pertussis, And Tetanus</p>\n<h3>DRE</h3>\n<p>Digital Rectal  Exam</p>\n<h3>DRV</h3>\n<p>Darunavir</p>\n<h3>DST</h3>\n<p>Drug Susceptibility Testing</p>\n<p>DT</p>\n<p>Dispersible Tablet</p>\n<h3>DTG</h3>\n<p>Dolutegravir</p>\n<h3>DVT</h3>\n<p>Deep Vein Thrombosis</p>\n<h3>EBV</h3>\n<p>Epstein-Barr Virus</p>\n<p>EC</p>\n<p>Enteric Coated</p>\n<h3>ECG</h3>\n<p>Electrocardiogram</p>\n<h3>ECP</h3>\n<p>Emergency Contraceptive Pill</p>\n<h3>EDD</h3>\n<p>Estimated Delivery Date</p>\n<h3>EFV</h3>\n<p>Efavirenz</p>\n<h3>XXXV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 36,
        "content": "ELISA\nEnzyme-Linked Immunosorbent  Assay\neMTCT\nElimination Of Mother-To-Child Transmission\nENT\nEar, Nose, And Throat\nESR\nErythrocyte  Sedimentation  Rate \nETV\nEtravirine F-75/F-100  Therapeutic Milk Formula 75 Or \n100 Kcals/100 Ml\nFB\nForeign Body\nFBC\nFull Blood Count\nFDC\nFixed Dose Combination \nFEV\nForced Expiratory Volume\nFNAC\nFine Needle Aspiration Cytology\nFP\nFamily Planning\nFSH\nFollicle Stimulating Hormone\nG6PD\nGlucose 6 Phosphate Dehydrogenase \nGBV\nGender-Based Violence\nGDM\nGestational Diabetes Mellitus \nGERD\nGastroesophageal Reflux Disease \nGFR\nGlomerular Filtration Rate\nGGT\nGamma-Glutamyl Transferase \nGIT\nGastrointestinal Tract\nH\nHospital\nHAART\nHighly Active Antiretroviral Therapy \nHb\nHaemoglobin\nHB\nHepatitis B\nHbA1c\nGlycated Haemoglobin, Haemoglobin A1c \nHBeAg\nHepatitis B Envelope Antigen\nHbF\nFoetal Haemoglobin F\nHbS\nAbnormal Haemoglobin \nHBsAg\nHepatitis B Surface Antigen \nXXXVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>ELISA</h3>\n<p>Enzyme-Linked Immunosorbent  Assay</p>\n<p>eMTCT</p>\n<p>Elimination Of Mother-To-Child Transmission</p>\n<h3>ENT</h3>\n<p>Ear, Nose, And Throat</p>\n<h3>ESR</h3>\n<p>Erythrocyte  Sedimentation  Rate</p>\n<h3>ETV</h3>\n<p>Etravirine F-75/F-100  Therapeutic Milk Formula 75 Or</p>\n<p>100 Kcals/100 Ml</p>\n<p>FB</p>\n<p>Foreign Body</p>\n<h3>FBC</h3>\n<p>Full Blood Count</p>\n<h3>FDC</h3>\n<p>Fixed Dose Combination</p>\n<h3>FEV</h3>\n<p>Forced Expiratory Volume</p>\n<h3>FNAC</h3>\n<p>Fine Needle Aspiration Cytology</p>\n<p>FP</p>\n<p>Family Planning</p>\n<h3>FSH</h3>\n<p>Follicle Stimulating Hormone</p>\n<h3>G6PD</h3>\n<p>Glucose 6 Phosphate Dehydrogenase</p>\n<h3>GBV</h3>\n<p>Gender-Based Violence</p>\n<h3>GDM</h3>\n<p>Gestational Diabetes Mellitus</p>\n<h3>GERD</h3>\n<p>Gastroesophageal Reflux Disease</p>\n<h3>GFR</h3>\n<p>Glomerular Filtration Rate</p>\n<h3>GGT</h3>\n<p>Gamma-Glutamyl Transferase</p>\n<h3>GIT</h3>\n<p>Gastrointestinal Tract</p>\n<p>H</p>\n<p>Hospital</p>\n<h3>HAART</h3>\n<p>Highly Active Antiretroviral Therapy</p>\n<p>Hb</p>\n<p>Haemoglobin</p>\n<p>HB</p>\n<p>Hepatitis B</p>\n<p>HbA1c</p>\n<p>Glycated Haemoglobin, Haemoglobin A1c</p>\n<p>HBeAg</p>\n<p>Hepatitis B Envelope Antigen</p>\n<p>HbF</p>\n<p>Foetal Haemoglobin F</p>\n<p>HbS</p>\n<p>Abnormal Haemoglobin</p>\n<p>HBsAg</p>\n<p>Hepatitis B Surface Antigen</p>\n<h3>XXXVI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 37,
        "content": "HBV\nHepatitis B Virus\nHC\nHealth Centre \nHct/Ht\nHaematocrit\nHCW\nHealth Care Worker\nHDU\nHigh Dependency  Unit\nHE\nHepatic Encephalopathy\nHepB\nHepatitis B\nHHS\nHyperosmolar Hyperglycaemic State \nHib\nHaemophilus Influenzae Type B\nHIV\nHuman Immunodeficiency Virus \nHPV\nHuman Papilloma Virus\nHR\nHeart Rate\nHRP\nHigh-Risk Pregnancy\nHRS\nHepatorenal Syndrome\nHSV\nHerpes Simplex Virus\nHVS\nHigh Vaginal  Swab\nICCM\nIntegrated Community Case Management \nICU\nIntensive Care  Unit\nIg\nImmunoglobulin\nIM\nIntramuscular\nIMNCI\nIntegrated Management Of  Neonatal And Childhood Illness\nIMPAC\nIntegrated  Management Of   Pregnancy And Childbirth\nINH\nIsoniazid\nINR\nInternational Normalised Ratio \nIOP\nIntraocular Pressure\nIPT\nIntermittent Preventive Treatment \nIPT\nIsoniazid Preventive Therapy\nIPTp\nIntermittent Preventive Treatment Of Malaria In \nPregnancy\nXXXVII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>HBV</h3>\n<p>Hepatitis B Virus</p>\n<p>HC</p>\n<p>Health Centre</p>\n<p>Hct/Ht</p>\n<p>Haematocrit</p>\n<h3>HCW</h3>\n<p>Health Care Worker</p>\n<h3>HDU</h3>\n<p>High Dependency  Unit</p>\n<p>HE</p>\n<p>Hepatic Encephalopathy</p>\n<p>HepB</p>\n<p>Hepatitis B</p>\n<h3>HHS</h3>\n<p>Hyperosmolar Hyperglycaemic State</p>\n<p>Hib</p>\n<p>Haemophilus Influenzae Type B</p>\n<h3>HIV</h3>\n<p>Human Immunodeficiency Virus</p>\n<h3>HPV</h3>\n<p>Human Papilloma Virus</p>\n<p>HR</p>\n<p>Heart Rate</p>\n<h3>HRP</h3>\n<p>High-Risk Pregnancy</p>\n<h3>HRS</h3>\n<p>Hepatorenal Syndrome</p>\n<h3>HSV</h3>\n<p>Herpes Simplex Virus</p>\n<h3>HVS</h3>\n<p>High Vaginal  Swab</p>\n<h3>ICCM</h3>\n<p>Integrated Community Case Management</p>\n<h3>ICU</h3>\n<p>Intensive Care  Unit</p>\n<p>Ig</p>\n<p>Immunoglobulin</p>\n<p>IM</p>\n<p>Intramuscular</p>\n<h3>IMNCI</h3>\n<p>Integrated Management Of  Neonatal And Childhood Illness</p>\n<h3>IMPAC</h3>\n<p>Integrated  Management Of   Pregnancy And Childbirth</p>\n<h3>INH</h3>\n<p>Isoniazid</p>\n<h3>INR</h3>\n<p>International Normalised Ratio</p>\n<h3>IOP</h3>\n<p>Intraocular Pressure</p>\n<h3>IPT</h3>\n<p>Intermittent Preventive Treatment</p>\n<h3>IPT</h3>\n<p>Isoniazid Preventive Therapy</p>\n<p>IPTp</p>\n<p>Intermittent Preventive Treatment Of Malaria In</p>\n<p>Pregnancy</p>\n<h3>XXXVII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 38,
        "content": "IPV\nInjectable Polio Vaccine\nIRIS\nImmune Reconstitution Inflammatory Syndrome \nITN\nInsecticide -Treated Nets\nIU\nInternational Units\nIUD\nIntrauterine Device\nIUGR\nIntrauterine Growth Restriction Iv\nIYCF\nInfant And Young Child Feeding\nIVU\nIntravenous Urogram\nJMS\nJoint Medical Store\nJVP\nJugular Vein Pressure\nKOH\nPotassium Hydroxide \nLAM\nLactational Amenorrhoea \nLBW\nLow Birth Weight\nLDH\nLactate Dehydrogenase\nLFT\nLiver Function Test\nLGV\nLymphogranuloma Venerium \nLH\nLuteinizing Hormone\nLLINs\nLong-Lasting Insecticide Treated  Nets \nLMP\nLast Menstrual Period\nLMWH\nLow Molecular Weight Heparin \nLNG\nLevonorgestrel\nLOC\nLevel Of  Care\nLP\nLumbar Puncture\nLPV\nLopinavir\nLTBI\nLatent Tuberculosis Infection \nMax\nMaximum Dose\nMB\nMultibacillary\nmcg\nMicrogram\nMCH\nMaternal And Child Health\nXXXVIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>IPV</h3>\n<p>Injectable Polio Vaccine</p>\n<h3>IRIS</h3>\n<p>Immune Reconstitution Inflammatory Syndrome</p>\n<h3>ITN</h3>\n<p>Insecticide -Treated Nets</p>\n<p>IU</p>\n<p>International Units</p>\n<h3>IUD</h3>\n<p>Intrauterine Device</p>\n<h3>IUGR</h3>\n<p>Intrauterine Growth Restriction Iv</p>\n<h3>IYCF</h3>\n<p>Infant And Young Child Feeding</p>\n<h3>IVU</h3>\n<p>Intravenous Urogram</p>\n<h3>JMS</h3>\n<p>Joint Medical Store</p>\n<h3>JVP</h3>\n<p>Jugular Vein Pressure</p>\n<h3>KOH</h3>\n<p>Potassium Hydroxide</p>\n<h3>LAM</h3>\n<p>Lactational Amenorrhoea</p>\n<h3>LBW</h3>\n<p>Low Birth Weight</p>\n<h3>LDH</h3>\n<p>Lactate Dehydrogenase</p>\n<h3>LFT</h3>\n<p>Liver Function Test</p>\n<h3>LGV</h3>\n<p>Lymphogranuloma Venerium</p>\n<p>LH</p>\n<p>Luteinizing Hormone</p>\n<p>LLINs</p>\n<p>Long-Lasting Insecticide Treated  Nets</p>\n<h3>LMP</h3>\n<p>Last Menstrual Period</p>\n<h3>LMWH</h3>\n<p>Low Molecular Weight Heparin</p>\n<h3>LNG</h3>\n<p>Levonorgestrel</p>\n<h3>LOC</h3>\n<p>Level Of  Care</p>\n<p>LP</p>\n<p>Lumbar Puncture</p>\n<h3>LPV</h3>\n<p>Lopinavir</p>\n<h3>LTBI</h3>\n<p>Latent Tuberculosis Infection</p>\n<p>Max</p>\n<p>Maximum Dose</p>\n<p>MB</p>\n<p>Multibacillary</p>\n<p>mcg</p>\n<p>Microgram</p>\n<h3>MCH</h3>\n<p>Maternal And Child Health</p>\n<h3>XXXVIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 39,
        "content": "MCH\nMean Corpuscular (Cell) Haemoglobin \nMCV\nMean Corpuscular Volume\nMDR-TB\nMulti-Drug Resistant  Tuberculosis \nMDT\nMulti-Drug Therapy\nMDVP\nMulti-Dose Vial  Policy\nmhGAP\nMental  Health  Gap Action Program \nMOH\nMinistry Of Health\nMRI\nMagnetic Resonance Imaging\nMRSA\nMulti-Resistant Staphylococcus Aureus \nMTB\nMycobacterium Tuberculosis\nMU\nMega Unit\nMUAC\nMid-Upper Arm Circumference \nNaCl\nSodium Chloride\nNBTS\nNational Blood Transfusion Services \nNCD\nNoncommunicable Disease\nNDA\nNational Drug Authority \nNET-EN\nNorethisterone Enanthate \nNG\nNasogastric\nNGT\nNasogastric Tube\nNMS\nNational Medical  Store\nNMCP\nNational Malaria Control Program\nNNRTI\nNon-Nucleoside Reverse Transcriptase Inhibitors \nNPH\nNeutral  Protamine  Hagedorn  (Isophane Insulin) \nNPO\nNil Per Os (Nothing By Mouth)\nNR\nNational Referral (Hospital)\nNS\nNormal Saline\nNSAID\nNonsteroidal Anti-Inflammatory Drugs\nNTLP\nNational  Tuberculosis  And  Leprosy  Programme \nNTRL\nNational TB Reference Laboratory\nNtRTI\nNucleoside Reverse  Transcriptase  Inhibitors \nXXXIX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>MCH</h3>\n<p>Mean Corpuscular (Cell) Haemoglobin</p>\n<h3>MCV</h3>\n<p>Mean Corpuscular Volume</p>\n<h3>MDR-TB</h3>\n<p>Multi-Drug Resistant  Tuberculosis</p>\n<h3>MDT</h3>\n<p>Multi-Drug Therapy</p>\n<h3>MDVP</h3>\n<p>Multi-Dose Vial  Policy</p>\n<p>mhGAP</p>\n<p>Mental  Health  Gap Action Program</p>\n<h3>MOH</h3>\n<p>Ministry Of Health</p>\n<h3>MRI</h3>\n<p>Magnetic Resonance Imaging</p>\n<h3>MRSA</h3>\n<p>Multi-Resistant Staphylococcus Aureus</p>\n<h3>MTB</h3>\n<p>Mycobacterium Tuberculosis</p>\n<p>MU</p>\n<p>Mega Unit</p>\n<h3>MUAC</h3>\n<p>Mid-Upper Arm Circumference</p>\n<p>NaCl</p>\n<p>Sodium Chloride</p>\n<h3>NBTS</h3>\n<p>National Blood Transfusion Services</p>\n<h3>NCD</h3>\n<p>Noncommunicable Disease</p>\n<h3>NDA</h3>\n<p>National Drug Authority</p>\n<h3>NET-EN</h3>\n<p>Norethisterone Enanthate</p>\n<p>NG</p>\n<p>Nasogastric</p>\n<h3>NGT</h3>\n<p>Nasogastric Tube</p>\n<h3>NMS</h3>\n<p>National Medical  Store</p>\n<h3>NMCP</h3>\n<p>National Malaria Control Program</p>\n<h3>NNRTI</h3>\n<p>Non-Nucleoside Reverse Transcriptase Inhibitors</p>\n<h3>NPH</h3>\n<p>Neutral  Protamine  Hagedorn  (Isophane Insulin)</p>\n<h3>NPO</h3>\n<p>Nil Per Os (Nothing By Mouth)</p>\n<p>NR</p>\n<p>National Referral (Hospital)</p>\n<p>NS</p>\n<p>Normal Saline</p>\n<h3>NSAID</h3>\n<p>Nonsteroidal Anti-Inflammatory Drugs</p>\n<h3>NTLP</h3>\n<p>National  Tuberculosis  And  Leprosy  Programme</p>\n<h3>NTRL</h3>\n<p>National TB Reference Laboratory</p>\n<p>NtRTI</p>\n<p>Nucleoside Reverse  Transcriptase  Inhibitors</p>\n<h3>XXXIX</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 40,
        "content": "NVP\nNevirapine\nOI\nOpportunistic Infection\nOPD\nOutpatient Department\nOPV\nOral Polio Vaccine\nORS\nOral   Rehydration Solution\nOTC\nOver The Counter\nPAP\nPapanicolaou Smear/Test\nPB\nPaucibacillary\nPBC\nPrimary Biliary Cirrhosis\nPCP\nPneumocystis Jirovecii Pneumonia \nPCR\nPolymerase Chain Reaction\nPCV\nPneumococcal Conjugate Vaccine \nPE\nPulmonary Embolism\nPEFR\nPeak Expiratory Flow Rate \nPEM\nProtein Energy Malnutrition \nPEP\nPost-Exposure  Prophylaxis\nPGD\nPractical Guidelines For Dispensing At Lower/ Higher \nLevel Health Facilities\nPI\nProtease Inhibitor\nPID\nPelvic Inflammatory Disease\nPIH\nPregnancy Induced Hypertension\nPMTCT\nPrevention  of  Maternal-To-Child Transmission\nPNFP\nPrivate Not-For-Profit\nPOC\nProducts Of  Conception\nPOI\nProgestogen Only Injection \nPOIM\nProgestogen Only Implant \nPOP\nProgestogen Only Pill\nPPD\nPurified Protein Derivative \nPPE\nPersonal  Protective  Equipment \nPPH\nPostpartum Haemorrhage\nXL\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>NVP</h3>\n<p>Nevirapine</p>\n<p>OI</p>\n<p>Opportunistic Infection</p>\n<h3>OPD</h3>\n<p>Outpatient Department</p>\n<h3>OPV</h3>\n<p>Oral Polio Vaccine</p>\n<h3>ORS</h3>\n<p>Oral   Rehydration Solution</p>\n<h3>OTC</h3>\n<p>Over The Counter</p>\n<h3>PAP</h3>\n<p>Papanicolaou Smear/Test</p>\n<p>PB</p>\n<p>Paucibacillary</p>\n<h3>PBC</h3>\n<p>Primary Biliary Cirrhosis</p>\n<h3>PCP</h3>\n<p>Pneumocystis Jirovecii Pneumonia</p>\n<h3>PCR</h3>\n<p>Polymerase Chain Reaction</p>\n<h3>PCV</h3>\n<p>Pneumococcal Conjugate Vaccine</p>\n<p>PE</p>\n<p>Pulmonary Embolism</p>\n<h3>PEFR</h3>\n<p>Peak Expiratory Flow Rate</p>\n<h3>PEM</h3>\n<p>Protein Energy Malnutrition</p>\n<h3>PEP</h3>\n<p>Post-Exposure  Prophylaxis</p>\n<h3>PGD</h3>\n<p>Practical Guidelines For Dispensing At Lower/ Higher</p>\n<p>Level Health Facilities</p>\n<p>PI</p>\n<p>Protease Inhibitor</p>\n<h3>PID</h3>\n<p>Pelvic Inflammatory Disease</p>\n<h3>PIH</h3>\n<p>Pregnancy Induced Hypertension</p>\n<h3>PMTCT</h3>\n<p>Prevention  of  Maternal-To-Child Transmission</p>\n<h3>PNFP</h3>\n<p>Private Not-For-Profit</p>\n<h3>POC</h3>\n<p>Products Of  Conception</p>\n<h3>POI</h3>\n<p>Progestogen Only Injection</p>\n<h3>POIM</h3>\n<p>Progestogen Only Implant</p>\n<h3>POP</h3>\n<p>Progestogen Only Pill</p>\n<h3>PPD</h3>\n<p>Purified Protein Derivative</p>\n<h3>PPE</h3>\n<p>Personal  Protective  Equipment</p>\n<h3>PPH</h3>\n<p>Postpartum Haemorrhage</p>\n<p>XL</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 41,
        "content": "PPQ\nPiperaquine\nPrEP\nPre-Exposure Prophylaxis Prn As Needed\nPROM\nPremature Rupture Of Membrane \nPSA\nProstate  Specific Antigen\nPT\nProthrombin Time\nPTT\nPartial  Thromboplastin  Time \nPUD\nPeptic Ulcer Disease\nPV\nPer Vagina\nQA\nQuality Assurance\nRAL\nRaltegravir\nRBC\nRed Blood  Cell\nRDT\nRapid Diagnostic Test Rhd\nRIA\nRadio Immune Assay\nRF\nRheumatoid  Factor\nRFT\nRenal  Function  Test\nRH\nRifampicin + Isoniazid\nRHZE\nRifampicin + Isoniazid + Pyrazinamide + Ethambutol\nRIF\nRifampicin\nRL\nRinger\u2019s Lactate\nRNA\nRibonucleic Acid\nRPR\nRapid Plasma Reagin [Assay] \nRR\nRegional Referral\nRR-TB\nRifampicin-Resistant Tuberculosis \nRTV\nRitonavir\nRUTF\nReady-To-Use  Therapeutic  Food \nSAM\nSevere Acute   Malnutrition\nSARS\nSevere  Acute Respiratory Syndrome \nSBP\nSystolic Blood Pressure\nSC\nSubcutaneous\nXLI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>PPQ</h3>\n<p>Piperaquine</p>\n<p>PrEP</p>\n<p>Pre-Exposure Prophylaxis Prn As Needed</p>\n<h3>PROM</h3>\n<p>Premature Rupture Of Membrane</p>\n<h3>PSA</h3>\n<p>Prostate  Specific Antigen</p>\n<p>PT</p>\n<p>Prothrombin Time</p>\n<h3>PTT</h3>\n<p>Partial  Thromboplastin  Time</p>\n<h3>PUD</h3>\n<p>Peptic Ulcer Disease</p>\n<p>PV</p>\n<p>Per Vagina</p>\n<p>QA</p>\n<p>Quality Assurance</p>\n<h3>RAL</h3>\n<p>Raltegravir</p>\n<h3>RBC</h3>\n<p>Red Blood  Cell</p>\n<h3>RDT</h3>\n<p>Rapid Diagnostic Test Rhd</p>\n<h3>RIA</h3>\n<p>Radio Immune Assay</p>\n<p>RF</p>\n<p>Rheumatoid  Factor</p>\n<h3>RFT</h3>\n<p>Renal  Function  Test</p>\n<p>RH</p>\n<p>Rifampicin + Isoniazid</p>\n<h3>RHZE</h3>\n<p>Rifampicin + Isoniazid + Pyrazinamide + Ethambutol</p>\n<h3>RIF</h3>\n<p>Rifampicin</p>\n<p>RL</p>\n<p>Ringer\u2019s Lactate</p>\n<h3>RNA</h3>\n<p>Ribonucleic Acid</p>\n<h3>RPR</h3>\n<p>Rapid Plasma Reagin [Assay]</p>\n<p>RR</p>\n<p>Regional Referral</p>\n<h3>RR-TB</h3>\n<p>Rifampicin-Resistant Tuberculosis</p>\n<h3>RTV</h3>\n<p>Ritonavir</p>\n<h3>RUTF</h3>\n<p>Ready-To-Use  Therapeutic  Food</p>\n<h3>SAM</h3>\n<p>Severe Acute   Malnutrition</p>\n<h3>SARS</h3>\n<p>Severe  Acute Respiratory Syndrome</p>\n<h3>SBP</h3>\n<p>Systolic Blood Pressure</p>\n<p>SC</p>\n<p>Subcutaneous</p>\n<h3>XLI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 42,
        "content": "SCA\nSickle Cell  Anaemia\nSCC\nSquamous Cell Carcinoma\nSCD\nSickle Cell Disease \nsdNVP\nSingle Dose Nevirapine \nSFH\nSymphysis-Fundal Height\nSJS\nStevens-Johnson Syndrome\nSP\nSulphadoxine + Pyrimethamine\nSpO2\nArterial  Oxygen Saturation\nSSRI\nSelective Serotonin Reuptake Inhibitor \nSTI\nSexually Transmitted  Infections\nT3 or T4\nThyroxine 3 Or 4\nTB\nTuberculosis\nTDF\nTenofovir Disoproxil Fumarate \nTEN\nToxic Epidermal Necrolysis\nTIG\nTetanus Immunoglobulin Human \nTSH\nThyroid Stimulating Hormone \nTST\nTuberculin Skin Test\nTT\nTetanus Toxoid\nU/S or US Ultrasound Sonography\nUBTS\nUganda Blood Transfusion Service\nUCI\nUganda Cancer Institute\nUCMB\nUganda Catholic Medical Bureau \nUE\nUrea Electrolytes\nUHI\nUganda Heart Institute \nUHSC\nUganda Health Supply Chain \nULN\nUpper Limit Of Normal\nUNEPI\nUganda National  Expanded  Program  On Immunisation\nUNHLS\nUganda National Health Laboratory Services\nXLII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>SCA</h3>\n<p>Sickle Cell  Anaemia</p>\n<h3>SCC</h3>\n<p>Squamous Cell Carcinoma</p>\n<h3>SCD</h3>\n<p>Sickle Cell Disease</p>\n<p>sdNVP</p>\n<p>Single Dose Nevirapine</p>\n<h3>SFH</h3>\n<p>Symphysis-Fundal Height</p>\n<h3>SJS</h3>\n<p>Stevens-Johnson Syndrome</p>\n<p>SP</p>\n<p>Sulphadoxine + Pyrimethamine</p>\n<p>SpO2</p>\n<p>Arterial  Oxygen Saturation</p>\n<h3>SSRI</h3>\n<p>Selective Serotonin Reuptake Inhibitor</p>\n<h3>STI</h3>\n<p>Sexually Transmitted  Infections</p>\n<p>T3 or T4</p>\n<p>Thyroxine 3 Or 4</p>\n<p>TB</p>\n<p>Tuberculosis</p>\n<h3>TDF</h3>\n<p>Tenofovir Disoproxil Fumarate</p>\n<h3>TEN</h3>\n<p>Toxic Epidermal Necrolysis</p>\n<h3>TIG</h3>\n<p>Tetanus Immunoglobulin Human</p>\n<h3>TSH</h3>\n<p>Thyroid Stimulating Hormone</p>\n<h3>TST</h3>\n<p>Tuberculin Skin Test</p>\n<p>TT</p>\n<p>Tetanus Toxoid</p>\n<p>U/S or US Ultrasound Sonography</p>\n<h3>UBTS</h3>\n<p>Uganda Blood Transfusion Service</p>\n<h3>UCI</h3>\n<p>Uganda Cancer Institute</p>\n<h3>UCMB</h3>\n<p>Uganda Catholic Medical Bureau</p>\n<p>UE</p>\n<p>Urea Electrolytes</p>\n<h3>UHI</h3>\n<p>Uganda Heart Institute</p>\n<h3>UHSC</h3>\n<p>Uganda Health Supply Chain</p>\n<h3>ULN</h3>\n<p>Upper Limit Of Normal</p>\n<h3>UNEPI</h3>\n<p>Uganda National  Expanded  Program  On Immunisation</p>\n<h3>UNHLS</h3>\n<p>Uganda National Health Laboratory Services</p>\n<h3>XLII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 43,
        "content": "USAID\nUnited States Agency For International Development\nUTI\nUrinary Tract Infection\nUV\nUltraviolet\nUVF\nUreterovaginal Fistula\nUVRI\nUganda Virus Research Institute\nVCT\nVoluntary Counselling And Testing \n[HIV] \nVDRL\nVenereal Disease Research Laboratory  [Test] \nVEN\nVital Essential Necessary\nVHT\nVillage Health Team\nVIA\nVisual Inspection With Acetic Acid \nVILI\nVisual Inspection With Lugol\u2019s Iodine \nVL\nViral Load\nVSC\nVoluntary Surgical Contraception \nVTE\nVenous Thromboembolism\nVVF\nVulvovaginal Fistula\nVVM\nVaccine Vial  Monitor\nVZV\nVaricella Zoster Virus\nWB\nWhole Blood\nWBC\nWhite Blood Cell\nWFA\nWeight For Age\nWFH/L\nWeight For Height/ Length \nWHO\nWorld  Health Organisation \nWOA\nWeeks of Amenorrhea\nXDR-TB\nExtensively Drug Resistant Tuberculosis \nZN\nZiehl - Neelsen [Stain]\nZn\nZinc\nXLIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>USAID</h3>\n<p>United States Agency For International Development</p>\n<h3>UTI</h3>\n<p>Urinary Tract Infection</p>\n<p>UV</p>\n<p>Ultraviolet</p>\n<h3>UVF</h3>\n<p>Ureterovaginal Fistula</p>\n<h3>UVRI</h3>\n<p>Uganda Virus Research Institute</p>\n<h3>VCT</h3>\n<p>Voluntary Counselling And Testing</p>\n<h3>[HIV]</h3>\n<h3>VDRL</h3>\n<p>Venereal Disease Research Laboratory  [Test]</p>\n<h3>VEN</h3>\n<p>Vital Essential Necessary</p>\n<h3>VHT</h3>\n<p>Village Health Team</p>\n<h3>VIA</h3>\n<p>Visual Inspection With Acetic Acid</p>\n<h3>VILI</h3>\n<p>Visual Inspection With Lugol\u2019s Iodine</p>\n<p>VL</p>\n<p>Viral Load</p>\n<h3>VSC</h3>\n<p>Voluntary Surgical Contraception</p>\n<h3>VTE</h3>\n<p>Venous Thromboembolism</p>\n<h3>VVF</h3>\n<p>Vulvovaginal Fistula</p>\n<h3>VVM</h3>\n<p>Vaccine Vial  Monitor</p>\n<h3>VZV</h3>\n<p>Varicella Zoster Virus</p>\n<p>WB</p>\n<p>Whole Blood</p>\n<h3>WBC</h3>\n<p>White Blood Cell</p>\n<h3>WFA</h3>\n<p>Weight For Age</p>\n<h3>WFH/L</h3>\n<p>Weight For Height/ Length</p>\n<h3>WHO</h3>\n<p>World  Health Organisation</p>\n<h3>WOA</h3>\n<p>Weeks of Amenorrhea</p>\n<h3>XDR-TB</h3>\n<p>Extensively Drug Resistant Tuberculosis</p>\n<p>ZN</p>\n<p>Ziehl - Neelsen [Stain]</p>\n<p>Zn</p>\n<p>Zinc</p>\n<h3>XLIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 44,
        "content": "Introduction to Uganda Clinical Guidelines \n2023\nThis fully updated publication replaces the UCG 2023 and is being cir\u00ad\nculated to all public and private sector prescribers, pharmacists, Training \nInstitutions and regulatory authorities in the country.\nFor effective use of the UCG, it is recommended that carefully designed \ndissemination sessions be organized countrywide to ensure that users \nappreciate the new features, changes, structural arrangement and content \nto  improve it\u2019s usability .\nThe following sections will present the structure and main features of \nthe guideline to highlight the changes in this latest edition and help the \nuser become familiar with the book and use it effectively.\nWhat is the aim of the UCG?\nThe UCG aims to provide summarized easy-to-use, practical, complete and \nuseful information on how to quickly and correctly diagnose and manage \ncommon conditions you are likely to encounter. This will ensure that patients \nreceive the best possible clinical services and obtain prompt and effective relief \nfrom or cure of their complaint, thereby making the most appropriate use of \nscarce diagnostic and clinical resources, including medicines. It should, \nhowever, be emphasised that the UCG does not replace or substitute \navailable textbooks on the subject.\nWhy is the UCG necessary?\nMedicine is an ever-evolving and expanding field in terms of needs and \nknowledge. The UCG helps the country to prioritize and effectively \nuse limited resources by guiding the procurement system to ensure the \navailability of the most needed medicines and supplies.\nXLIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Introduction to Uganda Clinical Guidelines</p>\n<p>2023</p>\n<p>This fully updated publication replaces the UCG 2023 and is being cir\u00ad</p>\n<p>culated to all public and private sector prescribers, pharmacists, Training</p>\n<p>Institutions and regulatory authorities in the country.</p>\n<p>For effective use of the UCG, it is recommended that carefully designed</p>\n<p>dissemination sessions be organized countrywide to ensure that users</p>\n<p>appreciate the new features, changes, structural arrangement and content</p>\n<p>to  improve it\u2019s usability .</p>\n<p>The following sections will present the structure and main features of</p>\n<p>the guideline to highlight the changes in this latest edition and help the</p>\n<p>user become familiar with the book and use it effectively.</p>\n<p>What is the aim of the UCG?</p>\n<p>The UCG aims to provide summarized easy-to-use, practical, complete and</p>\n<p>useful information on how to quickly and correctly diagnose and manage</p>\n<p>common conditions you are likely to encounter. This will ensure that patients</p>\n<p>receive the best possible clinical services and obtain prompt and effective relief</p>\n<p>from or cure of their complaint, thereby making the most appropriate use of</p>\n<p>scarce diagnostic and clinical resources, including medicines. It should,</p>\n<p>however, be emphasised that the UCG does not replace or substitute</p>\n<p>available textbooks on the subject.</p>\n<p>Why is the UCG necessary?</p>\n<p>Medicine is an ever-evolving and expanding field in terms of needs and</p>\n<p>knowledge. The UCG helps the country to prioritize and effectively</p>\n<p>use limited resources by guiding the procurement system to ensure the</p>\n<p>availability of the most needed medicines and supplies.</p>\n<h3>XLIV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 45,
        "content": "In the context  of new knowledge and changing priorities, as a tool, \nthe UCG assists health workers in their daily practice by providing \ninformation in an easy-to-follow and practical format.\nHow do I use the UCG?\nFirst of all, familiarize yourself with it. Check the table of contents \nand see how the chapters are arranged and organized.\nNew Feature\nThe order of chapters has been maintained as in the previous ver\u00ad\nsions. However, new chapters have been introduced, namely, self-care, \nmanagement of hypoxia and COVID-19. The Palliative Care section \nhas been expounded with more clarity. For the first time a purely \nherbal preparation with selenium has been included for management \nof stress. The snake bite section has been enriched with photographs \nof the common virulent snakes found in Uganda, to ease identification \nand thus more accurate intervention and management.\nMost chapters are organised by disease monographs, arranged either in \nalphabetical order or another logical order (e.g., according to occur\u00ad\nrence of disease progression). However, some chapters are organised \naccording to syndrome or symptoms (e.g., child health, palliative care, \noncology, sexually transmitted infections, emergencies and trauma), while \nTB and HIV are presented as individual sub-chapters.\nXLV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>In the context  of new knowledge and changing priorities, as a tool,</p>\n<p>the UCG assists health workers in their daily practice by providing</p>\n<p>information in an easy-to-follow and practical format.</p>\n<p>How do I use the UCG?</p>\n<p>First of all, familiarize yourself with it. Check the table of contents</p>\n<p>and see how the chapters are arranged and organized.</p>\n<p>New Feature</p>\n<p>The order of chapters has been maintained as in the previous ver\u00ad</p>\n<p>sions. However, new chapters have been introduced, namely, self-care,</p>\n<p>management of hypoxia and COVID-19. The Palliative Care section</p>\n<p>has been expounded with more clarity. For the first time a purely</p>\n<p>herbal preparation with selenium has been included for management</p>\n<p>of stress. The snake bite section has been enriched with photographs</p>\n<p>of the common virulent snakes found in Uganda, to ease identification</p>\n<p>and thus more accurate intervention and management.</p>\n<p>Most chapters are organised by disease monographs, arranged either in</p>\n<p>alphabetical order or another logical order (e.g., according to occur\u00ad</p>\n<p>rence of disease progression). However, some chapters are organised</p>\n<p>according to syndrome or symptoms (e.g., child health, palliative care,</p>\n<p>oncology, sexually transmitted infections, emergencies and trauma), while</p>\n<p>TB and HIV are presented as individual sub-chapters.</p>\n<h3>XLV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 46,
        "content": "New Feature\nThe chapters Covid -19, Self-care and Hypoxia management have \nbeen added with focus on primary care (prevention and early recog\u00ad\nnition of symptoms).\nDisease monographs are organized in the order of: definition, cause/\nrisk factors, clinical features and complications, differential diagnosis, \ninvestigations, management, and prevention.\nNew Feature\nPalliative care ladder has been introduced to make it easier for pain \nassessment. Treatments are presented in logical order from non-phar\u00ad\nmacological to\npharmacological, from the lower to the higher level of care. Where \npossible, alternatives and second-line options have been presented, \nas well as referral criteria.\nMedicines are presented by their generic name, in bold. Unless otherwise \nspecified, dosages are for adults and via oral route. Children\u2019s dosages \nare added whenever indicated, as well as duration and other instructions.\nThe level of care (LOC) is an important feature; it provides information \nabout the level at which the condition can be appropriately managed. \nOften, treatment can be initiated at lower level, but the patient needs to \nbe referred for further management, or for second-line treatment, or for \ncomplications. For antibiotics, it is recommended that treatment can be \ninitiated in some cases awaiting laboratory results. HC1-4 refers to health \ncentres of different levels (with HC1 being the community level), H to general \nhospital, RR to regional referral hospital, and NR to national referral hospital.\nAfter familiarizing yourself with it, try using it! Practice finding \nconditions and looking them up to see how they are managed, using either \nthe table of contents at the beginning or the index at the end.\nXLVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>New Feature</p>\n<p>The chapters Covid -19, Self-care and Hypoxia management have</p>\n<p>been added with focus on primary care (prevention and early recog\u00ad</p>\n<p>nition of symptoms).</p>\n<p>Disease monographs are organized in the order of: definition, cause/</p>\n<p>risk factors, clinical features and complications, differential diagnosis,</p>\n<p>investigations, management, and prevention.</p>\n<p>New Feature</p>\n<p>Palliative care ladder has been introduced to make it easier for pain</p>\n<p>assessment. Treatments are presented in logical order from non-phar\u00ad</p>\n<p>macological to</p>\n<p>pharmacological, from the lower to the higher level of care. Where</p>\n<p>possible, alternatives and second-line options have been presented,</p>\n<p>as well as referral criteria.</p>\n<p>Medicines are presented by their generic name, in bold. Unless otherwise</p>\n<p>specified, dosages are for adults and via oral route. Children\u2019s dosages</p>\n<p>are added whenever indicated, as well as duration and other instructions.</p>\n<p>The level of care (LOC) is an important feature; it provides information</p>\n<p>about the level at which the condition can be appropriately managed.</p>\n<p>Often, treatment can be initiated at lower level, but the patient needs to</p>\n<p>be referred for further management, or for second-line treatment, or for</p>\n<p>complications. For antibiotics, it is recommended that treatment can be</p>\n<p>initiated in some cases awaiting laboratory results. HC1-4 refers to health</p>\n<p>centres of different levels (with HC1 being the community level), H to general</p>\n<p>hospital, RR to regional referral hospital, and NR to national referral hospital.</p>\n<p>After familiarizing yourself with it, try using it! Practice finding</p>\n<p>conditions and looking them up to see how they are managed, using either</p>\n<p>the table of contents at the beginning or the index at the end.</p>\n<h3>XLVI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 47,
        "content": "Read all the introductory sections. They will give you useful advice \nfor your daily practice. There is always  something new to learn or to \nbe reminded of.\nUse it in your daily practice. The UCG is designed as a simple reference \nmanual to keep at your work station, where you   can consult it any time. \nUsing it in front of patients and colleagues will show that you care deeply \nabout the quality of your work, and it will provide good examples to \nother health workers.\nThe UCG cannot replace health workers\u2019 knowledge and skills; like your \nthermometer and stethoscope, it is a tool to help improve clinical practice \nby providing a quick and easily available summary of the recommended \nmanagement of common health conditions.\nWhat is the difference between the UCG and a textbook?\nThe UCG gives a summary of recommendations for managing priority \nconditions in Uganda. It does not provide extensive or in-depth information \nabout all diseases and all treatments available in the world.\nConditions have been selected based on their prevalence in the country \nand their impact on the population\u2019s health status. Treatments have been \nselected based on the following criteria:\nXLVII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Read all the introductory sections. They will give you useful advice</p>\n<p>for your daily practice. There is always  something new to learn or to</p>\n<p>be reminded of.</p>\n<p>Use it in your daily practice. The UCG is designed as a simple reference</p>\n<p>manual to keep at your work station, where you   can consult it any time.</p>\n<p>Using it in front of patients and colleagues will show that you care deeply</p>\n<p>about the quality of your work, and it will provide good examples to</p>\n<p>other health workers.</p>\n<p>The UCG cannot replace health workers\u2019 knowledge and skills; like your</p>\n<p>thermometer and stethoscope, it is a tool to help improve clinical practice</p>\n<p>by providing a quick and easily available summary of the recommended</p>\n<p>management of common health conditions.</p>\n<p>What is the difference between the UCG and a textbook?</p>\n<p>The UCG gives a summary of recommendations for managing priority</p>\n<p>conditions in Uganda. It does not provide extensive or in-depth information</p>\n<p>about all diseases and all treatments available in the world.</p>\n<p>Conditions have been selected based on their prevalence in the country</p>\n<p>and their impact on the population\u2019s health status. Treatments have been</p>\n<p>selected based on the following criteria:</p>\n<h3>XLVII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 48,
        "content": "Scientific evidence: recommendations are evidence-based, from inter\u00ad\nnational literature and local experts. For example, the situation analysis on \nantimicrobial resistance in Uganda conducted by the National Academy of \nSciences was used to guide the choice of antibiotic treatments.\nCost-effectiveness: treatments have been selected based on their effec\u00ad\ntiveness, but also their affordability, to get the best \u201cvalue for money\u201d, \nmeaning the maximum benefit with the limited resources available. \nFor example, a liver transplant  is a very effective way to treat terminal \ncirrhosis, but it is definitely not affordable\u2014money is better invested in \ntreating patients with chronic hepatitis B!\nWhat has changed compared to the previous edition?\n \n~\nThere are more chapters as explained before.\n \n~\nThe management sections have been re-edited to be more \nuser-friendly, using the suggestions collected during a user \nsurvey.\n \n~\nInformation on new diseases has been added, following \nnew epidemics and public health priorities (e.g., viral hae\u00ad\nmorrhagic fevers, Covid-19, yellow fever, nodding disease, \nsickle cell disease, newborn illnesses).\n \n~\nMore attention has been paid to non-communicable chron\u00ad\nic diseases; for example, stroke and chronic obstructive pul\u00ad\nmonary disease (COPD), and sections on diabetes, hyper\u00ad\ntension, asthma and mental conditions including diseases \nof elderly and dementia have been expanded.\n \n~\nRecommendations have been aligned with the most recent \nnational and international guidelines related to ART, TB, \nmalaria, IMNCI, IMPAC, mhGAP (see the list of references \nin Appendix 4).\n \n~\nMedications have been added or deleted and level of care \nhas changed according to recent evidence and national pol\u00ad\nicies.\nXLVIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Scientific evidence: recommendations are evidence-based, from inter\u00ad</p>\n<p>national literature and local experts. For example, the situation analysis on</p>\n<p>antimicrobial resistance in Uganda conducted by the National Academy of</p>\n<p>Sciences was used to guide the choice of antibiotic treatments.</p>\n<p>Cost-effectiveness: treatments have been selected based on their effec\u00ad</p>\n<p>tiveness, but also their affordability, to get the best \u201cvalue for money\u201d,</p>\n<p>meaning the maximum benefit with the limited resources available.</p>\n<p>For example, a liver transplant  is a very effective way to treat terminal</p>\n<p>cirrhosis, but it is definitely not affordable\u2014money is better invested in</p>\n<p>treating patients with chronic hepatitis B!</p>\n<p>What has changed compared to the previous edition?</p>\n<p>~</p>\n<p>There are more chapters as explained before.</p>\n<p>~</p>\n<p>The management sections have been re-edited to be more</p>\n<p>user-friendly, using the suggestions collected during a user</p>\n<p>survey.</p>\n<p>~</p>\n<p>Information on new diseases has been added, following</p>\n<p>new epidemics and public health priorities (e.g., viral hae\u00ad</p>\n<p>morrhagic fevers, Covid-19, yellow fever, nodding disease,</p>\n<p>sickle cell disease, newborn illnesses).</p>\n<p>~</p>\n<p>More attention has been paid to non-communicable chron\u00ad</p>\n<p>ic diseases; for example, stroke and chronic obstructive pul\u00ad</p>\n<p>monary disease (COPD), and sections on diabetes, hyper\u00ad</p>\n<p>tension, asthma and mental conditions including diseases</p>\n<p>of elderly and dementia have been expanded.</p>\n<p>~</p>\n<p>Recommendations have been aligned with the most recent</p>\n<p>national and international guidelines related to ART, TB,</p>\n<p>malaria, IMNCI, IMPAC, mhGAP (see the list of references</p>\n<p>in Appendix 4).</p>\n<p>~</p>\n<p>Medications have been added or deleted and level of care</p>\n<p>has changed according to recent evidence and national pol\u00ad</p>\n<p>icies.</p>\n<h3>XLVIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 49,
        "content": "~\nSkin management of Albinos using a sunscreen protection \nproduct has been included under the dermatological sec\u00ad\ntion.\n \n~\nThe essential medicines list has been removed from this \nedition to make the book pocket friendly.\nWhat about the Essential Medicines and Health Supply List (EMHSLU)?\nThe essential medicines list has been removed from this edition to make \nthe book pocket friendly. Always refer to the separate EMHSLU. \nTo implement the recommendations in the UCG, the medicines listed in \nthe EMHSLU have to be procured and distributed in adequate quantity. \nThis is why the procurement and supply system plays a fundamental role \nin the provision of quality healthcare.\nThe EMHSLU has all the medicines recommended in the UCG, with \nspecification of the level of care (LOC) at which they can start being used, \nbut it also has additional \u201cspecialty\u201d medicines, which are items used at \nreferral level (regional or national) or in the context of specialized services. \nThey may not be included in the UCG, which focus more on primary care, \nbut are still part of the list because they need to be procured to ensure the \nprovision of a wider range of services at secondary and tertiary levels. In \nthe context of limited resources, it is very important to learn to prioritize \nmedicines for procurement: this is reflected by the vital, essential, necessary \n(VEN) classification in the EMHSLU, introduced in 2012.\nXLIX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Skin management of Albinos using a sunscreen protection</p>\n<p>product has been included under the dermatological sec\u00ad</p>\n<p>tion.</p>\n<p>~</p>\n<p>The essential medicines list has been removed from this</p>\n<p>edition to make the book pocket friendly.</p>\n<p>What about the Essential Medicines and Health Supply List (EMHSLU)?</p>\n<p>The essential medicines list has been removed from this edition to make</p>\n<p>the book pocket friendly. Always refer to the separate EMHSLU.</p>\n<p>To implement the recommendations in the UCG, the medicines listed in</p>\n<p>the EMHSLU have to be procured and distributed in adequate quantity.</p>\n<p>This is why the procurement and supply system plays a fundamental role</p>\n<p>in the provision of quality healthcare.</p>\n<p>The EMHSLU has all the medicines recommended in the UCG, with</p>\n<p>specification of the level of care (LOC) at which they can start being used,</p>\n<p>but it also has additional \u201cspecialty\u201d medicines, which are items used at</p>\n<p>referral level (regional or national) or in the context of specialized services.</p>\n<p>They may not be included in the UCG, which focus more on primary care,</p>\n<p>but are still part of the list because they need to be procured to ensure the</p>\n<p>provision of a wider range of services at secondary and tertiary levels. In</p>\n<p>the context of limited resources, it is very important to learn to prioritize</p>\n<p>medicines for procurement: this is reflected by the vital, essential, necessary</p>\n<p>(VEN) classification in the EMHSLU, introduced in 2012.</p>\n<h3>XLIX</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 50,
        "content": "Medicines are classified into three categories according to health impact:\nV: vital medicines are potentially life-saving, and lack of availability \nwould cause serious harm and side effects. These must ALWAYS be \navailable\u2014for example insulin, metformin, most antibiotics, first-line \nantimalarials, some anti-epileptics, and parenteral diuretics.\nE: essential medicines are important; they are used to treat common \nillnesses that are maybe less severe but still significant. They are not \nabsolutely needed for the provision of basic health care (e.g., anti-helmin\u00ad\nthics, pain killers).\nN: necessary (or sometimes called non-essential) medicines are used \nfor minor or self-limiting illnesses, or may have a limited efficacy, or \na higher cost compared to the benefit.\nEvery effort has to be made to ensure health facilities do not suffer stock-outs \nof VITAL MEDICINES.\nAWaRe classification\nThe WHO AWaRe classification was used to describe overall antibiotic \nuse as assessed by the variation between use of Access, Watch, and \nReserve antibiotics. \nWhy is a laboratory test menu in the appendix?\nLaboratory is an important tool in supporting the diagnosis and man\u00ad\nagement of various conditions. Tests are listed according to the level at \nwhich they can be performed, in order to inform health workers about the \navailable diagnostics at each level for the suspected condition and guide \non managemeent or referral decisions.\nL\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Medicines are classified into three categories according to health impact:</p>\n<p>V: vital medicines are potentially life-saving, and lack of availability</p>\n<p>would cause serious harm and side effects. These must ALWAYS be</p>\n<p>available\u2014for example insulin, metformin, most antibiotics, first-line</p>\n<p>antimalarials, some anti-epileptics, and parenteral diuretics.</p>\n<p>E: essential medicines are important; they are used to treat common</p>\n<p>illnesses that are maybe less severe but still significant. They are not</p>\n<p>absolutely needed for the provision of basic health care (e.g., anti-helmin\u00ad</p>\n<p>thics, pain killers).</p>\n<p>N: necessary (or sometimes called non-essential) medicines are used</p>\n<p>for minor or self-limiting illnesses, or may have a limited efficacy, or</p>\n<p>a higher cost compared to the benefit.</p>\n<p>Every effort has to be made to ensure health facilities do not suffer stock-outs</p>\n<p>of VITAL MEDICINES.</p>\n<p>AWaRe classification</p>\n<p>The WHO AWaRe classification was used to describe overall antibiotic</p>\n<p>use as assessed by the variation between use of Access, Watch, and</p>\n<p>Reserve antibiotics.</p>\n<p>Why is a laboratory test menu in the appendix?</p>\n<p>Laboratory is an important tool in supporting the diagnosis and man\u00ad</p>\n<p>agement of various conditions. Tests are listed according to the level at</p>\n<p>which they can be performed, in order to inform health workers about the</p>\n<p>available diagnostics at each level for the suspected condition and guide</p>\n<p>on managemeent or referral decisions.</p>\n<p>L</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 51,
        "content": "Primary Health Care\nDefinition\n\t\nPrimary healthcare is essential healthcare based on \npractical, scientifically sound and socially acceptable methods and \ntechnologies. Primary healthcare should be universally accessible \nto individuals and families in the community through their full \nparticipation and at a cost that the community and country can \nafford in the spirit of self-reliance and self-determination.\n\t\nPrimary healthcare forms an integral part of both the country\u2019s \nhealth system, of which it is the main focus, and of the community\u2019s \noverall social and economic development.\n\t\nPrimary healthcare brings healthcare as close as possible to \nwhere people live and work and is the community\u2019s first level of \ncontact with the national health system.\n\t\n\u201cPrimary health care is the key to the attainment of the goal of \nHealth for All.\u201d\n\t\n\u2014Declaration of Alma-Ata International Conference on Primary Health Care, \nAlma-Ata, USSR, 6\u201312 September 1978\nLI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Primary Health Care</p>\n<p>Definition</p>\n<p>Primary healthcare is essential healthcare based on</p>\n<p>practical, scientifically sound and socially acceptable methods and</p>\n<p>technologies. Primary healthcare should be universally accessible</p>\n<p>to individuals and families in the community through their full</p>\n<p>participation and at a cost that the community and country can</p>\n<p>afford in the spirit of self-reliance and self-determination.</p>\n<p>Primary healthcare forms an integral part of both the country\u2019s</p>\n<p>health system, of which it is the main focus, and of the community\u2019s</p>\n<p>overall social and economic development.</p>\n<p>Primary healthcare brings healthcare as close as possible to</p>\n<p>where people live and work and is the community\u2019s first level of</p>\n<p>contact with the national health system.</p>\n<p>\u201cPrimary health care is the key to the attainment of the goal of</p>\n<p>Health for All.\u201d</p>\n<p>\u2014Declaration of Alma-Ata International Conference on Primary Health Care,</p>\n<p>Alma-Ata, USSR, 6\u201312 September 1978</p>\n<p>LI</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 52,
        "content": "How to diagnose and treat in primary care\nThe principles of healthcare are the same wherever it takes place.\n\u201cListen to the patient; he is telling you the diagnosis\u201d\n\u2014Sir William Osler, MD, 1849\u20131919.\nCommunication skills in the consultation room\nGood communication skills are essential for making a correct diagnosis and \nfor explaining or counselling on the illness, its treatment, and prevention of \nfuture illness.\nAt the beginning of the consultation, use open questions, which allow \nthe patient to express him or herself freely, listen without interrupting, and \ngive him or her the chance to share their interpretations, fears and worries.\nThe Golden Minute\nThe golden 60 seconds at the start of the consultation \nis eliciting ideas, concerns and expectations without \ninterrupting.\nMove to more specific questions later, to ask for further details and \nclarifications.\nLII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>How to diagnose and treat in primary care</p>\n<p>The principles of healthcare are the same wherever it takes place.</p>\n<p>\u201cListen to the patient; he is telling you the diagnosis\u201d</p>\n<p>\u2014Sir William Osler, MD, 1849\u20131919.</p>\n<p>Communication skills in the consultation room</p>\n<p>Good communication skills are essential for making a correct diagnosis and</p>\n<p>for explaining or counselling on the illness, its treatment, and prevention of</p>\n<p>future illness.</p>\n<p>At the beginning of the consultation, use open questions, which allow</p>\n<p>the patient to express him or herself freely, listen without interrupting, and</p>\n<p>give him or her the chance to share their interpretations, fears and worries.</p>\n<p>The Golden Minute</p>\n<p>The golden 60 seconds at the start of the consultation</p>\n<p>is eliciting ideas, concerns and expectations without</p>\n<p>interrupting.</p>\n<p>Move to more specific questions later, to ask for further details and</p>\n<p>clarifications.</p>\n<h3>LII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 53,
        "content": "Greet\n\u2022\t Greet and welcome the patient. Ensure adequate space and privacy!\n\t\nLook\n\u2022\t Observe the patient as he/she walks into your room for degree \nor state of illness. Look for danger signs and act immediately \nif necessary\n\t\nListen\n\u2022\t Ask about the main complaint or complaints, establish duration, \nand explore each symptom asking relevant questions\n\u2022\t Briefly ask about previous medical history, other past or present \nillnesses and current or recent medications\n\t\nExamine\n\u2022\t Perform a complete medical examination, focused on but not \nlimited to the complaints\n\t\nSuspect diagnosis\n\u2022\t Write your findings, and think about possible diagnosis and \ndifferentials\n\t\nTest\n\u2022\t Request tests to confirm or exclude possible diagnosis\n\t\nTreat\n\u2022\t Conclude on a diagnosis and decide on the treatment, if needed\n\u2022\t Explain diagnosis, treatment, and follow-up to the patient\n\u2022\t Give counselling and advice as appropriate\nThe Seven Steps in a Primary Care Consultation\n01\n02\n03\n04\n05\n06\n07\nLIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Greet</p>\n<li>Greet and welcome the patient. Ensure adequate space and privacy!</li>\n<p>Look</p>\n<li>Observe the patient as he/she walks into your room for degree</li>\n<p>or state of illness. Look for danger signs and act immediately</p>\n<p>if necessary</p>\n<p>Listen</p>\n<li>Ask about the main complaint or complaints, establish duration,</li>\n<p>and explore each symptom asking relevant questions</p>\n<li>Briefly ask about previous medical history, other past or present</li>\n<p>illnesses and current or recent medications</p>\n<p>Examine</p>\n<li>Perform a complete medical examination, focused on but not</li>\n<p>limited to the complaints</p>\n<p>Suspect diagnosis</p>\n<li>Write your findings, and think about possible diagnosis and</li>\n<p>differentials</p>\n<p>Test</p>\n<li>Request tests to confirm or exclude possible diagnosis</li>\n<p>Treat</p>\n<li>Conclude on a diagnosis and decide on the treatment, if needed</li>\n<li>Explain diagnosis, treatment, and follow-up to the patient</li>\n<li>Give counselling and advice as appropriate</li>\n<p>The Seven Steps in a Primary Care Consultation</p>\n<p>01</p>\n<p>02</p>\n<p>03</p>\n<p>04</p>\n<p>05</p>\n<p>06</p>\n<p>07</p>\n<h3>LIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 54,
        "content": "NEW FEATURE\nIntroduced a section on self-care interventions for sexual and repro\u00ad\nductive health (SRH), in the categories of self-awareness, self-testing \nand self-management, across the various health areas of Antenatal \nCare, Family Planning, HIV and STIs and post abortion care. \nWHO defines self-care as the ability of individuals, families and \ncommunities to promote health, prevent disease, maintain health, \nand cope with illness and disability with or without the support of a \nhealthcare provider.\nThe Ministry of Health developed the National Guideline on Self-Care \nInterventions for SRH. For details refer to the current guidelines\nChronic Care\n \n~\nHealth workers are faced with an increasing number of \nchronic diseases and conditions that require additional at\u00ad\ntention, such as hypertension, chronic heart problems, dia\u00ad\nbetes, cancers, mental conditions, HIV/AIDS, and TB.\n \n~\nCommunication is even more important to:\n \n~\nFind out the duration of the symptoms, previous diagnosis, \nprevious or current treatments and impact on daily life\n \n~\nExplain the nature and management of the condition to the \npatient and counsel on lifestyle and adjustment\n \n~\nChronic diseases require long-term (sometimes lifelong) fol\u00ad\nlow-up and treatment:\n \n~\nCounsel and advise the patient on the importance of fol\u00ad\nlow- up and treatment adherence\n \n~\nSet up a system for scheduling appointments (on the model \nof HIV care!)\n \n~\nAt each monitoring visit, determine whether the patient\u2019s \nLIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>NEW FEATURE</h3>\n<p>Introduced a section on self-care interventions for sexual and repro\u00ad</p>\n<p>ductive health (SRH), in the categories of self-awareness, self-testing</p>\n<p>and self-management, across the various health areas of Antenatal</p>\n<p>Care, Family Planning, HIV and STIs and post abortion care.</p>\n<p>WHO defines self-care as the ability of individuals, families and</p>\n<p>communities to promote health, prevent disease, maintain health,</p>\n<p>and cope with illness and disability with or without the support of a</p>\n<p>healthcare provider.</p>\n<p>The Ministry of Health developed the National Guideline on Self-Care</p>\n<p>Interventions for SRH. For details refer to the current guidelines</p>\n<p>Chronic Care</p>\n<p>~</p>\n<p>Health workers are faced with an increasing number of</p>\n<p>chronic diseases and conditions that require additional at\u00ad</p>\n<p>tention, such as hypertension, chronic heart problems, dia\u00ad</p>\n<p>betes, cancers, mental conditions, HIV/AIDS, and TB.</p>\n<p>~</p>\n<p>Communication is even more important to:</p>\n<p>~</p>\n<p>Find out the duration of the symptoms, previous diagnosis,</p>\n<p>previous or current treatments and impact on daily life</p>\n<p>~</p>\n<p>Explain the nature and management of the condition to the</p>\n<p>patient and counsel on lifestyle and adjustment</p>\n<p>~</p>\n<p>Chronic diseases require long-term (sometimes lifelong) fol\u00ad</p>\n<p>low-up and treatment:</p>\n<p>~</p>\n<p>Counsel and advise the patient on the importance of fol\u00ad</p>\n<p>low- up and treatment adherence</p>\n<p>~</p>\n<p>Set up a system for scheduling appointments (on the model</p>\n<p>of HIV care!)</p>\n<p>~</p>\n<p>At each monitoring visit, determine whether the patient\u2019s</p>\n<h3>LIV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 55,
        "content": "condition is improving, stable, or deteriorating and assess \nwhether patients are taking prescribed treatments properly \n(the right medicines, in the right doses, at the right time). \nTry to be consistent in prescribing and change the regimen \nonly if it is not working or has side effects. If a treatment is \nworking and well tolerated, maintain it!\n \n~\nCounsel and motivate the patient to follow lifestyle recom\u00ad\nmendations, including selfcare.\n \n~\nAssess the need for further support (e.g., pain manage\u00ad\nment, counselling, etc.)\n \n~\nA chronic care system requires collaboration among and \nintegration of all levels of healthcare\n \n~\nHigher levels of care may be responsible for initial diagno\u00ad\nsis and prescription of treatment and periodic reviews and \nre-assessment in case of problems or complications\n \n~\nLower levels of care (including the community) may be re\u00ad\nsponsible for routine follow-up, counselling and education, \nmedication refills and prompt and early referral in case of \nproblems.\nAppropriate Medicines Use\nAccording to WHO, \u201cRational [appropriate] use of medicines requires \nthat patients receive medications appropriate to their clinical needs, in \ndoses that meet their own individual requirements, for an adequate period \nof time, and at the lowest cost to them and their community\u201d.\nInappropriate medicine use can not only harm the patient, but by wasting \nresources, may limit the possibility of other people accessing healthcare! \nBoth health workers and patients have an important role to play in ensuring \nappropriate use by:\n \n~\nPrescribing (and taking) medicines ONLY when they are \nneeded\n \n~\nAvoiding giving unnecessary multiple medications to satisfy \npatients\u2019 demands or for financial gain\nLV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>condition is improving, stable, or deteriorating and assess</p>\n<p>whether patients are taking prescribed treatments properly</p>\n<p>(the right medicines, in the right doses, at the right time).</p>\n<p>Try to be consistent in prescribing and change the regimen</p>\n<p>only if it is not working or has side effects. If a treatment is</p>\n<p>working and well tolerated, maintain it!</p>\n<p>~</p>\n<p>Counsel and motivate the patient to follow lifestyle recom\u00ad</p>\n<p>mendations, including selfcare.</p>\n<p>~</p>\n<p>Assess the need for further support (e.g., pain manage\u00ad</p>\n<p>ment, counselling, etc.)</p>\n<p>~</p>\n<p>A chronic care system requires collaboration among and</p>\n<p>integration of all levels of healthcare</p>\n<p>~</p>\n<p>Higher levels of care may be responsible for initial diagno\u00ad</p>\n<p>sis and prescription of treatment and periodic reviews and</p>\n<p>re-assessment in case of problems or complications</p>\n<p>~</p>\n<p>Lower levels of care (including the community) may be re\u00ad</p>\n<p>sponsible for routine follow-up, counselling and education,</p>\n<p>medication refills and prompt and early referral in case of</p>\n<p>problems.</p>\n<p>Appropriate Medicines Use</p>\n<p>According to WHO, \u201cRational [appropriate] use of medicines requires</p>\n<p>that patients receive medications appropriate to their clinical needs, in</p>\n<p>doses that meet their own individual requirements, for an adequate period</p>\n<p>of time, and at the lowest cost to them and their community\u201d.</p>\n<p>Inappropriate medicine use can not only harm the patient, but by wasting</p>\n<p>resources, may limit the possibility of other people accessing healthcare!</p>\n<p>Both health workers and patients have an important role to play in ensuring</p>\n<p>appropriate use by:</p>\n<p>~</p>\n<p>Prescribing (and taking) medicines ONLY when they are</p>\n<p>needed</p>\n<p>~</p>\n<p>Avoiding giving unnecessary multiple medications to satisfy</p>\n<p>patients\u2019 demands or for financial gain</p>\n<p>LV</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 56,
        "content": "~\nAvoiding expensive alternative or second-line medications \nwhen an effective and inexpensive first-line is available\n \n~\nAvoiding injections when oral treatment is perfectly ade\u00ad\nquate\n \n~\nEnsuring that the correct dose and duration of treatment \nis prescribed, especially for antibiotics, to avoid resistance\n \n~\nProviding adequate information and counselling to the pa\u00ad\ntient to ensure adherence with instructions.\nAntimicrobial Resistance (AMR)\nAccording to the WHO definition\n\u201cAntimicrobial resistance occurs when microorganisms such as bacteria, \nviruses, fungi and parasites change in ways that render the medications \nused to cure the infections they cause ineffective. Antimicrobial resistance \nis facilitated by the inappropriate use of medicines, for example, when \ntaking substandard doses or not finishing a prescribed course of treatment. \nLow-quality medicines, wrong prescriptions and poor infection prevention \nand control also encourage the development and spread of drug resistance\u201d.\nThe problem of AMR is a serious threat for the modern world:\n \n~\nThe resistance of malaria parasites has caused several \nchanges in antimalarial regimens in the last 15 years\n \n~\nMDR-TB (multi-drug resistant tuberculosis) is spreading and \nrequires long and complex treatments\n \n~\nHIV resistance is a serious concern, especially after long- \nterm treatment\n \n~\nAMR is spreading and, in some cases, commonly used an\u00ad\ntimicrobials are not as effective as before\n \n~\nAntimicrobial resistance amomg bacteria other than TB \nand fungi (moulds and yeasts) that affect the immune-com\u00ad\npromised is evolving, spreading and responsible for death \nfrom sepsis in general  and high dependency units.\nLVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Avoiding expensive alternative or second-line medications</p>\n<p>when an effective and inexpensive first-line is available</p>\n<p>~</p>\n<p>Avoiding injections when oral treatment is perfectly ade\u00ad</p>\n<p>quate</p>\n<p>~</p>\n<p>Ensuring that the correct dose and duration of treatment</p>\n<p>is prescribed, especially for antibiotics, to avoid resistance</p>\n<p>~</p>\n<p>Providing adequate information and counselling to the pa\u00ad</p>\n<p>tient to ensure adherence with instructions.</p>\n<p>Antimicrobial Resistance (AMR)</p>\n<p>According to the WHO definition</p>\n<p>\u201cAntimicrobial resistance occurs when microorganisms such as bacteria,</p>\n<p>viruses, fungi and parasites change in ways that render the medications</p>\n<p>used to cure the infections they cause ineffective. Antimicrobial resistance</p>\n<p>is facilitated by the inappropriate use of medicines, for example, when</p>\n<p>taking substandard doses or not finishing a prescribed course of treatment.</p>\n<p>Low-quality medicines, wrong prescriptions and poor infection prevention</p>\n<p>and control also encourage the development and spread of drug resistance\u201d.</p>\n<p>The problem of AMR is a serious threat for the modern world:</p>\n<p>~</p>\n<p>The resistance of malaria parasites has caused several</p>\n<p>changes in antimalarial regimens in the last 15 years</p>\n<p>~</p>\n<p>MDR-TB (multi-drug resistant tuberculosis) is spreading and</p>\n<p>requires long and complex treatments</p>\n<p>~</p>\n<p>HIV resistance is a serious concern, especially after long-</p>\n<p>term treatment</p>\n<p>~</p>\n<p>AMR is spreading and, in some cases, commonly used an\u00ad</p>\n<p>timicrobials are not as effective as before</p>\n<p>~</p>\n<p>Antimicrobial resistance amomg bacteria other than TB</p>\n<p>and fungi (moulds and yeasts) that affect the immune-com\u00ad</p>\n<p>promised is evolving, spreading and responsible for death</p>\n<p>from sepsis in general  and high dependency units.</p>\n<h3>LVI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 57,
        "content": "Inappropriae use of antibiotics (in human medicine but also in animal agri\u00ad\nculture), poor quality products and ineffective infection control measures \nare all contributing factors. We are seriously at risk of finding ourselves \nin a situation with no affordable antimicrobial available to cure common \nand dangerous infections.\nIt is URGENT that both health workers and patients become aware of the \nproblem and start acting by:\n \n~\nUsing antimicrobials only when it is really necessary and \naccording to recommendations (e.g. not for simple viral in\u00ad\nfections!)\n \n~\nAvoiding self-prescription of antibiotics\n \n~\nAvoiding using last generation and broad spectrum antibi\u00ad\notics as first-line treatment\n \n~\nPrescribing correct dosages for the correct duration and \nensuring adherence to the prescription\n \n~\nPractising strict measures of infection control in health fa\u00ad\ncilities\n \n~\nImproving hygiene and sanitation in the community, there\u00ad\nby reducing the circulation of germs.\nAWaRE\n \n~\nWHO has further introduced the AWaRE classification to \nguide prescribers during prescribing of antibiotics. The ma\u00ad\njor focus of AWaRe approach is to reduce on the increasing \nantimicrobial resistance.\n \n~\nThe principal of AWaRe prescribing is based on Access, \nWatch, Reserve.\n \n~\nPrescribers are encouraged to adhere to the above.\nLVII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Inappropriae use of antibiotics (in human medicine but also in animal agri\u00ad</p>\n<p>culture), poor quality products and ineffective infection control measures</p>\n<p>are all contributing factors. We are seriously at risk of finding ourselves</p>\n<p>in a situation with no affordable antimicrobial available to cure common</p>\n<p>and dangerous infections.</p>\n<p>It is URGENT that both health workers and patients become aware of the</p>\n<p>problem and start acting by:</p>\n<p>~</p>\n<p>Using antimicrobials only when it is really necessary and</p>\n<p>according to recommendations (e.g. not for simple viral in\u00ad</p>\n<p>fections!)</p>\n<p>~</p>\n<p>Avoiding self-prescription of antibiotics</p>\n<p>~</p>\n<p>Avoiding using last generation and broad spectrum antibi\u00ad</p>\n<p>otics as first-line treatment</p>\n<p>~</p>\n<p>Prescribing correct dosages for the correct duration and</p>\n<p>ensuring adherence to the prescription</p>\n<p>~</p>\n<p>Practising strict measures of infection control in health fa\u00ad</p>\n<p>cilities</p>\n<p>~</p>\n<p>Improving hygiene and sanitation in the community, there\u00ad</p>\n<p>by reducing the circulation of germs.</p>\n<p>AWaRE</p>\n<p>~</p>\n<p>WHO has further introduced the AWaRE classification to</p>\n<p>guide prescribers during prescribing of antibiotics. The ma\u00ad</p>\n<p>jor focus of AWaRe approach is to reduce on the increasing</p>\n<p>antimicrobial resistance.</p>\n<p>~</p>\n<p>The principal of AWaRe prescribing is based on Access,</p>\n<p>Watch, Reserve.</p>\n<p>~</p>\n<p>Prescribers are encouraged to adhere to the above.</p>\n<h3>LVII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 58,
        "content": "Prescribing Guidelines\nThe current PGD (Practical Guidelines for Dispensing at Lower/ Higher \nLevel Health Facilities), provide comprehensive information about how \nto prescribe and dispense the medicines listed in the EMHSLU and UCG \n2023. Carefully consider the following key questions before writing \nany prescription:\nQUESTION\nCOMMENTS\nDoes the diag\u00ad\nnosed condition \nrequire drug treat\u00ad\nment?\n \n~\nNot all patients or conditions need a \nprescription for medicines (condition \nis self-limiting): non-medicine treat\u00ad\nments or simple advice may be more \nsuitable in certain situations\nIs the prescribed \ntreatment likely \nto have optimum \ntherapeutic effect \nand to benefit the \npatient?\n \n~\nGood therapeutics depends on:\n \n~\nAccurate diagnosis of the condition\n \n~\nKnowledge of the relevant vavailable \nmedicines\n \n~\nAsk patient about previous drug histo\u00ad\nry (eg. drug reaction /allergy)\n \n~\nSelection of the most appropriate med\u00ad\nicine, dose, route, and duration\n \n~\nIn all cases, carefully consider the ex\u00ad\npected benefit of a prescribed medica\u00ad\ntion against its potential risks\nIs the selected dos\u00ad\nage-form the most \nappropriate?\n \n~\nFor systemic medications, ALWAYS  \nUSE THE ORAL ROUTE if possible, \nas it is the cheapest and least hazard\u00ad\nous route\n \n~\nAlways resist patient demands for you \nto prescribe injections or other ex\u00ad\npensive dose forms when they are not \nclearly indicated or appropriate\nLVIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Prescribing Guidelines</p>\n<p>The current PGD (Practical Guidelines for Dispensing at Lower/ Higher</p>\n<p>Level Health Facilities), provide comprehensive information about how</p>\n<p>to prescribe and dispense the medicines listed in the EMHSLU and UCG</p>\n<p>2023. Carefully consider the following key questions before writing</p>\n<p>any prescription:</p>\n<h3>QUESTION</h3>\n<h3>COMMENTS</h3>\n<p>Does the diag\u00ad</p>\n<p>nosed condition</p>\n<p>require drug treat\u00ad</p>\n<p>ment?</p>\n<p>~</p>\n<p>Not all patients or conditions need a</p>\n<p>prescription for medicines (condition</p>\n<p>is self-limiting): non-medicine treat\u00ad</p>\n<p>ments or simple advice may be more</p>\n<p>suitable in certain situations</p>\n<p>Is the prescribed</p>\n<p>treatment likely</p>\n<p>to have optimum</p>\n<p>therapeutic effect</p>\n<p>and to benefit the</p>\n<p>patient?</p>\n<p>~</p>\n<p>Good therapeutics depends on:</p>\n<p>~</p>\n<p>Accurate diagnosis of the condition</p>\n<p>~</p>\n<p>Knowledge of the relevant vavailable</p>\n<p>medicines</p>\n<p>~</p>\n<p>Ask patient about previous drug histo\u00ad</p>\n<p>ry (eg. drug reaction /allergy)</p>\n<p>~</p>\n<p>Selection of the most appropriate med\u00ad</p>\n<p>icine, dose, route, and duration</p>\n<p>~</p>\n<p>In all cases, carefully consider the ex\u00ad</p>\n<p>pected benefit of a prescribed medica\u00ad</p>\n<p>tion against its potential risks</p>\n<p>Is the selected dos\u00ad</p>\n<p>age-form the most</p>\n<p>appropriate?</p>\n<p>~</p>\n<p>For systemic medications, ALWAYS</p>\n<p>USE THE ORAL ROUTE if possible,</p>\n<p>as it is the cheapest and least hazard\u00ad</p>\n<p>ous route</p>\n<p>~</p>\n<p>Always resist patient demands for you</p>\n<p>to prescribe injections or other ex\u00ad</p>\n<p>pensive dose forms when they are not</p>\n<p>clearly indicated or appropriate</p>\n<h3>LVIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 59,
        "content": "QUESTION\nCOMMENTS\n \n~\nLIMIT INJECTIONS to situations \nwhere they are absolutely necessary \n(they carry risks and are more expen\u00ad\nsive)\n \n~\nAlways explain to the patient the rea\u00ad\nsons for choosing a certain route\nCan I justify using \na combination of \nmedicines?\n \n~\nDo not prescribe a combination of \nmedicines unless they have a proven \nand significant therapeutic advantage \nover corresponding single ingredient \npreparations\n \n~\nDo not practise multiple medicine \nprescribing (polypharmacy), especially \nwhen the diagnosis is uncertain. It is \na tremendous waste of resources and \nputs the patient at increased risk with\u00ad\nout clear benefit\nDo I really need \nto prescribe more \nthan one medi\u00ad\ncine?\nHave I taken into \naccount all rele\u00ad\nvant patient cri\u00ad\nteria?\nConsider the following:\n \n~\nAge, gender, weight\u2014especially of \nchildren and elderly\n \n~\nLikelihood of side effects (including al\u00ad\nlergies)\n \n~\nPresence of renal or hepatic disease \n(many medicines may have to be used \nin reduced doses or avoided complete\u00ad\nly)\n \n~\nAny other medicines the patient may \nbe taking (risk of unwanted medicine \ninteractions or adverse effects)\nLIX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>QUESTION</h3>\n<h3>COMMENTS</h3>\n<p>~</p>\n<p>LIMIT INJECTIONS to situations</p>\n<p>where they are absolutely necessary</p>\n<p>(they carry risks and are more expen\u00ad</p>\n<p>sive)</p>\n<p>~</p>\n<p>Always explain to the patient the rea\u00ad</p>\n<p>sons for choosing a certain route</p>\n<p>Can I justify using</p>\n<p>a combination of</p>\n<p>medicines?</p>\n<p>~</p>\n<p>Do not prescribe a combination of</p>\n<p>medicines unless they have a proven</p>\n<p>and significant therapeutic advantage</p>\n<p>over corresponding single ingredient</p>\n<p>preparations</p>\n<p>~</p>\n<p>Do not practise multiple medicine</p>\n<p>prescribing (polypharmacy), especially</p>\n<p>when the diagnosis is uncertain. It is</p>\n<p>a tremendous waste of resources and</p>\n<p>puts the patient at increased risk with\u00ad</p>\n<p>out clear benefit</p>\n<p>Do I really need</p>\n<p>to prescribe more</p>\n<p>than one medi\u00ad</p>\n<p>cine?</p>\n<p>Have I taken into</p>\n<p>account all rele\u00ad</p>\n<p>vant patient cri\u00ad</p>\n<p>teria?</p>\n<p>Consider the following:</p>\n<p>~</p>\n<p>Age, gender, weight\u2014especially of</p>\n<p>children and elderly</p>\n<p>~</p>\n<p>Likelihood of side effects (including al\u00ad</p>\n<p>lergies)</p>\n<p>~</p>\n<p>Presence of renal or hepatic disease</p>\n<p>(many medicines may have to be used</p>\n<p>in reduced doses or avoided complete\u00ad</p>\n<p>ly)</p>\n<p>~</p>\n<p>Any other medicines the patient may</p>\n<p>be taking (risk of unwanted medicine</p>\n<p>interactions or adverse effects)</p>\n<h3>LIX</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 60,
        "content": "QUESTION\nCOMMENTS\n \n~\nPregnancy and breastfeeding: only use \nmedicines in pregnancy if the expect\u00ad\ned benefit to the mother is greater than \nany risk to the foetus/ baby and avoid \nall medicines if possible during the \nfirst trimester (the first three months \nof pregnancy)\n \n~\nLikely degree of adherence to treat\u00ad\nment (simpler, shorter dosage regimes \nincrease the chance of\n \n~\nthe patient correctly following pre\u00ad\nscribed therapy)\nPrescribing placebos\nAvoid placebos whenever possible. Instead, spend some time reassuring \nand educating the patient. Use home remedies when possible (e.g., honey \nfor cough in adults and children above 1 year).\nPrescription writing\nA wrong prescription is very risky for you and your patient.\nUnclear, incomplete, or inaccurate prescriptions are very dangerous for \nthe patient. To avoid problems, follow the guidance below in writing \nyour prescriptions:\nPRESCRIPTION WRITING RULES\n \n~\nWrite all prescriptions legibly in ink\n \n~\nPoor writing may lead to errors in interpretation by \nthe dispenser, which may have harmful and possibly \nlife-threatening consequences for the patient\nLX\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>QUESTION</h3>\n<h3>COMMENTS</h3>\n<p>~</p>\n<p>Pregnancy and breastfeeding: only use</p>\n<p>medicines in pregnancy if the expect\u00ad</p>\n<p>ed benefit to the mother is greater than</p>\n<p>any risk to the foetus/ baby and avoid</p>\n<p>all medicines if possible during the</p>\n<p>first trimester (the first three months</p>\n<p>of pregnancy)</p>\n<p>~</p>\n<p>Likely degree of adherence to treat\u00ad</p>\n<p>ment (simpler, shorter dosage regimes</p>\n<p>increase the chance of</p>\n<p>~</p>\n<p>the patient correctly following pre\u00ad</p>\n<p>scribed therapy)</p>\n<p>Prescribing placebos</p>\n<p>Avoid placebos whenever possible. Instead, spend some time reassuring</p>\n<p>and educating the patient. Use home remedies when possible (e.g., honey</p>\n<p>for cough in adults and children above 1 year).</p>\n<p>Prescription writing</p>\n<p>A wrong prescription is very risky for you and your patient.</p>\n<p>Unclear, incomplete, or inaccurate prescriptions are very dangerous for</p>\n<p>the patient. To avoid problems, follow the guidance below in writing</p>\n<p>your prescriptions:</p>\n<h3>PRESCRIPTION WRITING RULES</h3>\n<p>~</p>\n<p>Write all prescriptions legibly in ink</p>\n<p>~</p>\n<p>Poor writing may lead to errors in interpretation by</p>\n<p>the dispenser, which may have harmful and possibly</p>\n<p>life-threatening consequences for the patient</p>\n<p>LX</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 61,
        "content": "PRESCRIPTION WRITING RULES\n \n~\nWrite the full name, age, gender and address of the patient, \nthen sign and date the prescription form\n \n~\nAll prescriptions should clearly indicate the name and address \nof the prescriber and of the facility\n \n~\nA PRESCRIPTION IS A LEGAL DOCUMENT\n \n~\nWrite the name of the medicine or preparation using its full \ngeneric name.\n \n~\nUnofficial abbreviations, trade names, and obsolete names \nshould not be used.\n \n~\nState the strength of the medicine prescribed where rel\u00ad\nevant:\n \n~\nQuantities of one gram or more should be written as 1g, \n2.5g, 10g, and so on\n \n~\nQuantities <1g but >1mg should be expressed in milli\u00ad\ngrams rather than grams, for example, 500mg and not \n0.5g\n \n~\nQuantities <1mg should be expressed in micrograms and \nnot in mg, for example, 100 micrograms rather than 0.1 \nmg or 100 mcg\n \n~\nIf decimal figures are used, always write a zero in front \nof the decimal point where there is no other figure, for \nexample 0.5 ml and not .5 ml\n \n~\nAlways state dose regimen in full:\n \n- Dose size, Dose frequency, Duration of treatment\n \n~\nThe quantity to be dispensed is calculated from the reg\u00ad\nimen.\n \n~\nFor example, doxycycline 100 mg every 12 hours for 7 \ndays = to be dispensed: 14 tablets of 100 mg.\n \n~\nFor in-patients, clearly state the route of administration \nand specify time of administration, if relevant\nLXI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>PRESCRIPTION WRITING RULES</h3>\n<p>~</p>\n<p>Write the full name, age, gender and address of the patient,</p>\n<p>then sign and date the prescription form</p>\n<p>~</p>\n<p>All prescriptions should clearly indicate the name and address</p>\n<p>of the prescriber and of the facility</p>\n<p>~</p>\n<h3>A PRESCRIPTION IS A LEGAL DOCUMENT</h3>\n<p>~</p>\n<p>Write the name of the medicine or preparation using its full</p>\n<p>generic name.</p>\n<p>~</p>\n<p>Unofficial abbreviations, trade names, and obsolete names</p>\n<p>should not be used.</p>\n<p>~</p>\n<p>State the strength of the medicine prescribed where rel\u00ad</p>\n<p>evant:</p>\n<p>~</p>\n<p>Quantities of one gram or more should be written as 1g,</p>\n<p>2.5g, 10g, and so on</p>\n<p>~</p>\n<p>Quantities <1g but >1mg should be expressed in milli\u00ad</p>\n<p>grams rather than grams, for example, 500mg and not</p>\n<p>0.5g</p>\n<p>~</p>\n<p>Quantities <1mg should be expressed in micrograms and</p>\n<p>not in mg, for example, 100 micrograms rather than 0.1</p>\n<p>mg or 100 mcg</p>\n<p>~</p>\n<p>If decimal figures are used, always write a zero in front</p>\n<p>of the decimal point where there is no other figure, for</p>\n<p>example 0.5 ml and not .5 ml</p>\n<p>~</p>\n<p>Always state dose regimen in full:</p>\n<p>- Dose size, Dose frequency, Duration of treatment</p>\n<p>~</p>\n<p>The quantity to be dispensed is calculated from the reg\u00ad</p>\n<p>imen.</p>\n<p>~</p>\n<p>For example, doxycycline 100 mg every 12 hours for 7</p>\n<p>days = to be dispensed: 14 tablets of 100 mg.</p>\n<p>~</p>\n<p>For in-patients, clearly state the route of administration</p>\n<p>and specify time of administration, if relevant</p>\n<h3>LXI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 62,
        "content": "PRESCRIPTION WRITING RULES\n \n~\nAvoid use of instructions like \u201cprn\u201d or \u201cto be used/taken \nas required\u201d. Indicate a suitable dose frequency instead\n \n~\nIn the few cases where \u201cas required\u201d is appropriate, al\u00ad\nways state the actual quantity of the medicine to be sup\u00ad\nplied, when to take it and maximum amount\n \n~\nWhere relevant, always remember to include on the prescrip\u00ad\ntion any special instructions necessary for the correct use of \na medicine or preparation, for example \u201cbefore food\u201d or \u201cap\u00ad\nply sparingly\u201d.\nControlled medicine prescriptions\nThese medicines are covered by the provisions of the National Drug \nPolicy and Authority Act 1993, which should be consulted for details of the \nappropriate legal requirements as stipulated. Medicines covered by the Act \nand appear  in  the  UCG  2023  or EMHSLU 2023  include:\n \n~\nMorphine injection\n \n~\nMorphine oral solution\n \n~\nPapaveretum + hyoscine injection\n \n~\nPethidine injection\n \n~\nCodeine \n \n~\nTramadol\n \n~\nDiazepam injection\nThese are all medicines of potential abuse that may result in depend\u00ad\nence. All procedures involving them should be carefully recorded in the \nappropriate record books. They may only be prescribed by authorised \nprescribers who must observe the following legal requirements:\n \n~\nPrescriptions must be in the prescriber\u2019s own handwriting, \nwith a signature, date and the prescriber\u2019s address\nLXII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>PRESCRIPTION WRITING RULES</h3>\n<p>~</p>\n<p>Avoid use of instructions like \u201cprn\u201d or \u201cto be used/taken</p>\n<p>as required\u201d. Indicate a suitable dose frequency instead</p>\n<p>~</p>\n<p>In the few cases where \u201cas required\u201d is appropriate, al\u00ad</p>\n<p>ways state the actual quantity of the medicine to be sup\u00ad</p>\n<p>plied, when to take it and maximum amount</p>\n<p>~</p>\n<p>Where relevant, always remember to include on the prescrip\u00ad</p>\n<p>tion any special instructions necessary for the correct use of</p>\n<p>a medicine or preparation, for example \u201cbefore food\u201d or \u201cap\u00ad</p>\n<p>ply sparingly\u201d.</p>\n<p>Controlled medicine prescriptions</p>\n<p>These medicines are covered by the provisions of the National Drug</p>\n<p>Policy and Authority Act 1993, which should be consulted for details of the</p>\n<p>appropriate legal requirements as stipulated. Medicines covered by the Act</p>\n<p>and appear  in  the  UCG  2023  or EMHSLU 2023  include:</p>\n<p>~</p>\n<p>Morphine injection</p>\n<p>~</p>\n<p>Morphine oral solution</p>\n<p>~</p>\n<p>Papaveretum + hyoscine injection</p>\n<p>~</p>\n<p>Pethidine injection</p>\n<p>~</p>\n<p>Codeine</p>\n<p>~</p>\n<p>Tramadol</p>\n<p>~</p>\n<p>Diazepam injection</p>\n<p>These are all medicines of potential abuse that may result in depend\u00ad</p>\n<p>ence. All procedures involving them should be carefully recorded in the</p>\n<p>appropriate record books. They may only be prescribed by authorised</p>\n<p>prescribers who must observe the following legal requirements:</p>\n<p>~</p>\n<p>Prescriptions must be in the prescriber\u2019s own handwriting,</p>\n<p>with a signature, date and the prescriber\u2019s address</p>\n<h3>LXII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 63,
        "content": "~\nPrescriptions must state the name and address of the pa\u00ad\ntient\n \n~\nPrescriptions must state the total amount of the product to \nbe supplied in words and figures\n \n~\nIt is an offence for a prescriber to issue and for a pharmacy \nto dispense prescriptions for controlled medicines unless \nthey are in full compliance with the requirements of the \nlaw.\n Notes\n \n\u0083 Specialised palliative care nurses and clinical officers are autho\u00ad\nrised to prescribe oral morphine and other medicines used in pal\u00ad\nliative care.\n \n\u0083 Morphine rarely causes psychological dependence when pre\u00ad\nscribed for severe pain.\n \n\u0083 In certain exceptional circumstances, senior nurses in charge of \ndepartments, wards or theatres and midwives may also obtain \nand administer certain specified controlled medicines. Consult \nthe relevant sections of the Act for details of the appropriate \nlegal requirements in each case.\n \n\u0083 Hospital in-patient prescriptions written on treatment cards or \ncase sheets and signed/dated by the person administering the \nmedicine are considered as compliant under the Act.\nPrescribing in children and the elderly\nIn these guidelines, paediatric medicine doses are usually given according \nto body weight and not age,  and are therefore expressed as mg/kg.\nThe main reason for this is that children of the same age may vary \nsignificantly in weight. Thus, it is safer and more accurate to prescribe \nmedicines according to body weight. Moreover, this should encourage \nthe good practice of weighing children whenever possible.\nLXIII\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Prescriptions must state the name and address of the pa\u00ad</p>\n<p>tient</p>\n<p>~</p>\n<p>Prescriptions must state the total amount of the product to</p>\n<p>be supplied in words and figures</p>\n<p>~</p>\n<p>It is an offence for a prescriber to issue and for a pharmacy</p>\n<p>to dispense prescriptions for controlled medicines unless</p>\n<p>they are in full compliance with the requirements of the</p>\n<p>law.</p>\n<p>Notes</p>\n<p>\u0083 Specialised palliative care nurses and clinical officers are autho\u00ad</p>\n<p>rised to prescribe oral morphine and other medicines used in pal\u00ad</p>\n<p>liative care.</p>\n<p>\u0083 Morphine rarely causes psychological dependence when pre\u00ad</p>\n<p>scribed for severe pain.</p>\n<p>\u0083 In certain exceptional circumstances, senior nurses in charge of</p>\n<p>departments, wards or theatres and midwives may also obtain</p>\n<p>and administer certain specified controlled medicines. Consult</p>\n<p>the relevant sections of the Act for details of the appropriate</p>\n<p>legal requirements in each case.</p>\n<p>\u0083 Hospital in-patient prescriptions written on treatment cards or</p>\n<p>case sheets and signed/dated by the person administering the</p>\n<p>medicine are considered as compliant under the Act.</p>\n<p>Prescribing in children and the elderly</p>\n<p>In these guidelines, paediatric medicine doses are usually given according</p>\n<p>to body weight and not age,  and are therefore expressed as mg/kg.</p>\n<p>The main reason for this is that children of the same age may vary</p>\n<p>significantly in weight. Thus, it is safer and more accurate to prescribe</p>\n<p>medicines according to body weight. Moreover, this should encourage</p>\n<p>the good practice of weighing children whenever possible.</p>\n<h3>LXIII</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 64,
        "content": "However, as a guide to prescribing by weight when a weighing scale is not \navailable, the weight-for-age charts at the end of Chapter 17 can be used as \nan estimate for children from 1-24 months and 2-15 years, respectively. \nAlways use lean/ideal body weight for children who are overweight/obese \nto avoid giving them overdoses.\nNote: Paediatric doses calculated using mg/kg should not exceed \nthe normal adult dose.\nIn the case of some medicines that have a wide therapeutic range and a \ngood safety profile, dosages are given for age ranges for easy reference.\nPrescriptions in the elderly also need additional attention because the \nelderly are more prone to side effects; they are more likely to take several \nmedications (polypharmacy) with possible interactions, and they often have \nco-morbidities that can affect their response to medicines. Reduced doses \nand careful monitoring are always advised, and specific warnings have \nbeen added for some medicines.\nMedicine interactions\nBefore prescribing any medicine, take care to avoid problems of interactions \nwith other medicines by obtaining details of any other medication that the \npatient is taking, whether the medication is:\n \n~\nAlso prescribed at the same time\n \n~\nPreviously prescribed by another prescriber for the same or an\u00ad\nother condition and currently being taken by the patient\n \n~\nPurchased or otherwise obtained by the patient for the pur\u00ad\nposes of self-medication at home.\nLXIV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>However, as a guide to prescribing by weight when a weighing scale is not</p>\n<p>available, the weight-for-age charts at the end of Chapter 17 can be used as</p>\n<p>an estimate for children from 1-24 months and 2-15 years, respectively.</p>\n<p>Always use lean/ideal body weight for children who are overweight/obese</p>\n<p>to avoid giving them overdoses.</p>\n<p>Note: Paediatric doses calculated using mg/kg should not exceed</p>\n<p>the normal adult dose.</p>\n<p>In the case of some medicines that have a wide therapeutic range and a</p>\n<p>good safety profile, dosages are given for age ranges for easy reference.</p>\n<p>Prescriptions in the elderly also need additional attention because the</p>\n<p>elderly are more prone to side effects; they are more likely to take several</p>\n<p>medications (polypharmacy) with possible interactions, and they often have</p>\n<p>co-morbidities that can affect their response to medicines. Reduced doses</p>\n<p>and careful monitoring are always advised, and specific warnings have</p>\n<p>been added for some medicines.</p>\n<p>Medicine interactions</p>\n<p>Before prescribing any medicine, take care to avoid problems of interactions</p>\n<p>with other medicines by obtaining details of any other medication that the</p>\n<p>patient is taking, whether the medication is:</p>\n<p>~</p>\n<p>Also prescribed at the same time</p>\n<p>~</p>\n<p>Previously prescribed by another prescriber for the same or an\u00ad</p>\n<p>other condition and currently being taken by the patient</p>\n<p>~</p>\n<p>Purchased or otherwise obtained by the patient for the pur\u00ad</p>\n<p>poses of self-medication at home.</p>\n<h3>LXIV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 65,
        "content": "Note on interactions with alcohol. If a prescribed medicine inter\u00ad\nacts with alcohol (for example, metronidazole, diazepam, anti-diabetic \nmedicines, and tricyclic antidepressants), caution the patient to avoid taking \nalcoholic drinks during the course of treatment and for 48 hours afterwards.\nPatient counselling\nThis vital part of patient management is  often neglected with potentially se\u00ad\nrious consequences. Although counselling the patient may take time, \nif done systematically, it should only take a few minutes and could \nmake the difference between treatment success and failure.\nInclude the following key components when counselling the patient:\n \n~\nExplain the diagnosis and the likely cause of the disease or \ncondition and discuss the proposed approach to treatment\n \n~\nDescribe the prescribed medicine therapy in detail includ\u00ad\ning:\n \n\u0083 Medicine name\n \n\u0083 Function of the medicine\n \n\u0083 Dose regimen (size, frequency, duration)\n \n\u0083 Any additional instructions on correct use or storage of the med\u00ad\nicine\nLXV\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Note on interactions with alcohol. If a prescribed medicine inter\u00ad</p>\n<p>acts with alcohol (for example, metronidazole, diazepam, anti-diabetic</p>\n<p>medicines, and tricyclic antidepressants), caution the patient to avoid taking</p>\n<p>alcoholic drinks during the course of treatment and for 48 hours afterwards.</p>\n<p>Patient counselling</p>\n<p>This vital part of patient management is  often neglected with potentially se\u00ad</p>\n<p>rious consequences. Although counselling the patient may take time,</p>\n<p>if done systematically, it should only take a few minutes and could</p>\n<p>make the difference between treatment success and failure.</p>\n<p>Include the following key components when counselling the patient:</p>\n<p>~</p>\n<p>Explain the diagnosis and the likely cause of the disease or</p>\n<p>condition and discuss the proposed approach to treatment</p>\n<p>~</p>\n<p>Describe the prescribed medicine therapy in detail includ\u00ad</p>\n<p>ing:</p>\n<p>\u0083 Medicine name</p>\n<p>\u0083 Function of the medicine</p>\n<p>\u0083 Dose regimen (size, frequency, duration)</p>\n<p>\u0083 Any additional instructions on correct use or storage of the med\u00ad</p>\n<p>icine</p>\n<h3>LXV</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 66,
        "content": "\u0083 Any likely side effects and what to do if they occur\n \n\u0083 Advise on important medicine interactions (including with alcohol)\n \n~\nGive advice on how to contribute to the success of the treat\u00ad\nment (for example, rest, diet, fluids and other lifestyle chang\u00ad\nes) and how to avoid the same problem in future\n \n~\nEnsure the patient or caretaker fully understands the informa\u00ad\ntion and advice provided\u2014ask him or her to repeat key points\n \n~\nFor health conditions that require self-care, proper advice \nshould be given to the patient on self-awareness, self-testing \nand self-management.\n \n\u0083 Ensure the patient is satisfied with the proposed treatment and has \nan opportunity to raise any problems or queries with you.\nLXVI\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>\u0083 Any likely side effects and what to do if they occur</p>\n<p>\u0083 Advise on important medicine interactions (including with alcohol)</p>\n<p>~</p>\n<p>Give advice on how to contribute to the success of the treat\u00ad</p>\n<p>ment (for example, rest, diet, fluids and other lifestyle chang\u00ad</p>\n<p>es) and how to avoid the same problem in future</p>\n<p>~</p>\n<p>Ensure the patient or caretaker fully understands the informa\u00ad</p>\n<p>tion and advice provided\u2014ask him or her to repeat key points</p>\n<p>~</p>\n<p>For health conditions that require self-care, proper advice</p>\n<p>should be given to the patient on self-awareness, self-testing</p>\n<p>and self-management.</p>\n<p>\u0083 Ensure the patient is satisfied with the proposed treatment and has</p>\n<p>an opportunity to raise any problems or queries with you.</p>\n<h3>LXVI</h3>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 67,
        "content": "1.1 COMMON EMERGENCIES\n1.1.1  Anaphylactic Shock              ICD10 CODE: T78.2 \nSevere allergic reaction that occurs rapidly (seconds or minutes) after \nadministration, or exposure, and may be life threatening. It generally affects \nthe whole body.\nCauses\n \n~\nAllergy to pollens, some medicines (e.g., penicillins, vac\u00ad\ncines, acetylsalicylic acid), or certain foods (e.g. eggs, fish, \ncow\u2019s milk, nuts, some food additives)\n \n~\nReaction to insect bites, e.g., wasps and bees\nClinical features\n \n~\nBody itching, hives (urticarial rash), swelling of lips, eyes, \ntongue\n \n~\nDifficulty in breathing (stridor, wheezing)\n \n~\nHypotension and sudden collapse, excessive sweating, thin \npulse\n \n~\nAbdominal cramps, vomiting and diarrhoea.\nDifferential diagnosis\n \n~\nOther causes of shock, e.g., haemorrhagic (due to bleed\u00ad\ning), hypovolemic (severe dehydration), septic\n \n~\nAsthma, foreign body in airways.\nEmergencies and  Trauma\n1\n1\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>1.1 COMMON EMERGENCIES</h3>\n<li>.1.1  Anaphylactic Shock              ICD10 CODE: T78.2</li>\n<p>Severe allergic reaction that occurs rapidly (seconds or minutes) after</p>\n<p>administration, or exposure, and may be life threatening. It generally affects</p>\n<p>the whole body.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Allergy to pollens, some medicines (e.g., penicillins, vac\u00ad</p>\n<p>cines, acetylsalicylic acid), or certain foods (e.g. eggs, fish,</p>\n<p>cow\u2019s milk, nuts, some food additives)</p>\n<p>~</p>\n<p>Reaction to insect bites, e.g., wasps and bees</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Body itching, hives (urticarial rash), swelling of lips, eyes,</p>\n<p>tongue</p>\n<p>~</p>\n<p>Difficulty in breathing (stridor, wheezing)</p>\n<p>~</p>\n<p>Hypotension and sudden collapse, excessive sweating, thin</p>\n<p>pulse</p>\n<p>~</p>\n<p>Abdominal cramps, vomiting and diarrhoea.</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of shock, e.g., haemorrhagic (due to bleed\u00ad</p>\n<p>ing), hypovolemic (severe dehydration), septic</p>\n<p>~</p>\n<p>Asthma, foreign body in airways.</p>\n<p>Emergencies and  Trauma</p>\n<p>1</p>\n<p>1</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 68,
        "content": "Management\nTREATMENT\nLOC\nGeneral measures\nDetermine and remove the cause\nSecure the airways\nRestore BP: lay the patient flat and raise feet\nKeep patient warm\nHC2\nSodium chloride 0.9% infusion 20 ml/kg by IV infusion \nover 60 minutes\n\u2013 Start rapidly then adjust rate according to BP\nAdminister oxygen\nHC3\nHC4\nAdrenaline (epinephrine) injection 1 in 1000 (1 mg/ml) 0.5 \nmg (0.5 ml) IM immediately, into anterolateral thigh\n\u2013 Repeat every 5-10 minutes according to BP, pulse\nrate, and respiratory function until better\nChild <6 years: 150 micrograms (0.15 ml)\nChild 6-12 years: 300 micrograms (0.3 ml)\nIn severely affected patients\nHydrocortisone 200 mg IM or slow IV stat\nChild <1 year: 25 mg\nChild 1-5 years: 50 mg\nChild 6-12 years: 100 mg\nIf urticaria/itching\nGive an antihistamine as useful adjunctive treatment\ne.g., chlorpheniramine 4 mg every six hours\nChild 1-2 years: 1mg every 12 hours\nChild 2-5 years: 1 mg every 6 hours\nChild 5-12 years: 2 mg every 6 hours\n-Or Cetrizine 5mg once daily for adults Child 6 and above \nyears: 5mg daily\n    Child 1-6 years: 2.5mg once daily.\nHC2\nHC3\nHC2V \n2\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>Determine and remove the cause</p>\n<p>Secure the airways</p>\n<p>Restore BP: lay the patient flat and raise feet</p>\n<p>Keep patient warm</p>\n<h3>HC2</h3>\n<p>Sodium chloride 0.9% infusion 20 ml/kg by IV infusion</p>\n<p>over 60 minutes</p>\n<p>\u2013 Start rapidly then adjust rate according to BP</p>\n<p>Administer oxygen</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Adrenaline (epinephrine) injection 1 in 1000 (1 mg/ml) 0.5</p>\n<p>mg (0.5 ml) IM immediately, into anterolateral thigh</p>\n<p>\u2013 Repeat every 5-10 minutes according to BP, pulse</p>\n<p>rate, and respiratory function until better</p>\n<p>Child <6 years: 150 micrograms (0.15 ml)</p>\n<p>Child 6-12 years: 300 micrograms (0.3 ml)</p>\n<p>In severely affected patients</p>\n<p>Hydrocortisone 200 mg IM or slow IV stat</p>\n<p>Child <1 year: 25 mg</p>\n<p>Child 1-5 years: 50 mg</p>\n<p>Child 6-12 years: 100 mg</p>\n<p>If urticaria/itching</p>\n<p>Give an antihistamine as useful adjunctive treatment</p>\n<p>e.g., chlorpheniramine 4 mg every six hours</p>\n<p>Child 1-2 years: 1mg every 12 hours</p>\n<p>Child 2-5 years: 1 mg every 6 hours</p>\n<p>Child 5-12 years: 2 mg every 6 hours</p>\n<p>-Or Cetrizine 5mg once daily for adults Child 6 and above</p>\n<p>years: 5mg daily</p>\n<p>Child 1-6 years: 2.5mg once daily.</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC2V</h3>\n<p>2</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 69,
        "content": "TREATMENT\nLOC\nor promethazine 25-50 mg by deep IM or very slow IV (or oral)\nChild 1-5 years: 5 mg by deep IM\nChild 5-10 years: 6.25-12.5 mg by deep IM\nRepeat dose every 8 hours for 24-48 hours to prevent relapse\nRepeat adrenaline and hydrocortisone every\n2-6 hours prn depending on the patient\u2019s progress\nHC4\nNotes\n \n\u0083 Adrenaline: IM is the route of choice: absorption is rapid and \nmore reliable than SC\n \n\u0083 Monitor the patient for several hours (reaction may recur after \nseveral hours)\n \n\u0083 If drug reaction, compile adverse drug reaction reporting form \n(see appendix 2)\nPrevention\n \n~\nAlways ask about allergies before giving patients new med\u00ad\nicine\n \n~\nKeep emergency drugs at hand at health facilities and in \nsituatiuons where risk of anaphlaxis is high, e.g. visiting \nbee hives or places that usually harbour snakes\n \n~\nCounsel allergic patients to wear alert bracelet or tag.\n1.1.2 Hypovolaemic Shock      ICD10 CODE: R57.1\t\nCondition caused by severe acute loss of intravascular fluids leading to inad\u00ad\nequate circulating volume and inadequate perfusion.\nCauses\n \n~\nLoss of blood due to internal or external haemorrhage (e.g., \npost partum haemorrhage, splenic rupture etc.)\n3\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>or promethazine 25-50 mg by deep IM or very slow IV (or oral)</p>\n<p>Child 1-5 years: 5 mg by deep IM</p>\n<p>Child 5-10 years: 6.25-12.5 mg by deep IM</p>\n<p>Repeat dose every 8 hours for 24-48 hours to prevent relapse</p>\n<p>Repeat adrenaline and hydrocortisone every</p>\n<p>2-6 hours prn depending on the patient\u2019s progress</p>\n<h3>HC4</h3>\n<p>Notes</p>\n<p>\u0083 Adrenaline: IM is the route of choice: absorption is rapid and</p>\n<p>more reliable than SC</p>\n<p>\u0083 Monitor the patient for several hours (reaction may recur after</p>\n<p>several hours)</p>\n<p>\u0083 If drug reaction, compile adverse drug reaction reporting form</p>\n<p>(see appendix 2)</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Always ask about allergies before giving patients new med\u00ad</p>\n<p>icine</p>\n<p>~</p>\n<p>Keep emergency drugs at hand at health facilities and in</p>\n<p>situatiuons where risk of anaphlaxis is high, e.g. visiting</p>\n<p>bee hives or places that usually harbour snakes</p>\n<p>~</p>\n<p>Counsel allergic patients to wear alert bracelet or tag.</p>\n<li>.1.2 Hypovolaemic Shock      ICD10 CODE: R57.1</li>\n<p>Condition caused by severe acute loss of intravascular fluids leading to inad\u00ad</p>\n<p>equate circulating volume and inadequate perfusion.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Loss of blood due to internal or external haemorrhage (e.g.,</p>\n<p>post partum haemorrhage, splenic rupture etc.)</p>\n<p>3</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 70,
        "content": "~\nAcute loss of fluids, e.g. in gastroenteritis, or extensive \nburns\nClinical features\n \n~\nHigh heart rate, fast breathing rate\n \n~\nThin or absent pulse, cold extremities, slow capillary refill\n \n~\nLow blood pressure\n \n~\nMental agitation, confusion\nClassification of hypovolaemia in adults\nIndicator\nClass 1 \nMild\nClass 2 \nProGressing\nClass 3 \nSevere\nClass 4 End \nStage\nBlood loss \n(Litres)\n<0.75\n0.75 \u2013 1.5\n1.5 \u20132\n>2\n% of total blood \nvolume loss\n<15\n15- 30\n30 \u2013 40\n>40\nPulse rate\nNormal\n>100\n>120\n>140\nPulse pressure\nNormal\n\u00e2\n\u00e2\u00e2\n\uf0e2\uf0e2/A\nSystolic BP\nNormal\nN\n\u00e2\n\u00e2\u00e2\nCapillary refill\nNormal\n\u00e1\n\u00e1\u00e1\nAbsent\nRespiratory rate\nNormal\n20 \u2013 30\n30 \u2013 40\n>45 or \ngasping\nMental state\nAlert\nAnxious\nConfused\nConfused/ \nunconscious\nUrine output \n(ml/h)\n>30\n20 - 30\n5 \u2013 20\n<5\nDifferential diagnosis\n \n~\nOther types of shock\n4\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Acute loss of fluids, e.g. in gastroenteritis, or extensive</p>\n<p>burns</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>High heart rate, fast breathing rate</p>\n<p>~</p>\n<p>Thin or absent pulse, cold extremities, slow capillary refill</p>\n<p>~</p>\n<p>Low blood pressure</p>\n<p>~</p>\n<p>Mental agitation, confusion</p>\n<p>Classification of hypovolaemia in adults</p>\n<p>Indicator</p>\n<p>Class 1</p>\n<p>Mild</p>\n<p>Class 2</p>\n<p>ProGressing</p>\n<p>Class 3</p>\n<p>Severe</p>\n<p>Class 4 End</p>\n<p>Stage</p>\n<p>Blood loss</p>\n<p>(Litres)</p>\n<p><0.75</p>\n<p>0.75 \u2013 1.5</p>\n<li>.5 \u20132</li>\n<p>>2</p>\n<p>% of total blood</p>\n<p>volume loss</p>\n<p><15</p>\n<p>15- 30</p>\n<p>30 \u2013 40</p>\n<p>>40</p>\n<p>Pulse rate</p>\n<p>Normal</p>\n<p>>100</p>\n<p>>120</p>\n<p>>140</p>\n<p>Pulse pressure</p>\n<p>Normal</p>\n<p>\u00e2</p>\n<p>\u00e2\u00e2</p>\n<h3>\uf0e2\uf0e2/A</h3>\n<p>Systolic BP</p>\n<p>Normal</p>\n<p>N</p>\n<p>\u00e2</p>\n<p>\u00e2\u00e2</p>\n<p>Capillary refill</p>\n<p>Normal</p>\n<p>\u00e1</p>\n<p>\u00e1\u00e1</p>\n<p>Absent</p>\n<p>Respiratory rate</p>\n<p>Normal</p>\n<p>20 \u2013 30</p>\n<p>30 \u2013 40</p>\n<p>>45 or</p>\n<p>gasping</p>\n<p>Mental state</p>\n<p>Alert</p>\n<p>Anxious</p>\n<p>Confused</p>\n<p>Confused/</p>\n<p>unconscious</p>\n<p>Urine output</p>\n<p>(ml/h)</p>\n<p>>30</p>\n<p>20 - 30</p>\n<p>5 \u2013 20</p>\n<p><5</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other types of shock</p>\n<p>4</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 71,
        "content": "Management in adults\nTREATMENT\nLOC\n\t\n\u0089\nControl obvious bleeding with pressure\n\t\n\u0089\nKeep patient lying down with raised legs.\nHC3\nIf established hypovolaemia class 2 and above\n \n\u0083 Set 2 large bore IV lines\n \n\u0083 IV fluids Normal Saline 0.9% (or Ringer\u2019s lactate) 20-\n30 ml/kg over 60 minutes according to response\n \n- If possible, warm the fluid\n \n- Start rapidly, monitor BP\n \n- Assess response to fluid resuscitation: BP, HR, RR, \ncapillary refill, consciousness and urinary output\n\t\n\u0089\nIf internal or external haemorrhage, consider blood \ntransfusion\nIf rapid improvement and stable (blood loss <20% and \nnot progressing)\n\t\n\u0089\nSlow IV fluids to maintenance levels\n\t\n\u0089\nNo immediate transfusion but do cross-matching\n\t\n\u0089\nRegular reassessment\n\t\n\u0089\nDetailed examination and definitive treatment according \nto the cause\nIf transient improvement (blood loss 20-40% or ongo\u00ad\ning bleeding)\n\t\n\u0089\nRapid administration of fluids\n\t\n\u0089\nInitiate blood transfusion (see section 11.2)\n\t\n\u0089\nRegular reassessment\n\t\n\u0089\nDetailed examination and early surgery\nIf no improvement\n\t\n\u0089\nVigorous fluid administration \n\t\n\u0089\nUrgent blood transfusion\n\t\n\u0089\nImmediate surgery\nHC4\n5\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management in adults</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Control obvious bleeding with pressure</p>\n<p>\u0089</p>\n<p>Keep patient lying down with raised legs.</p>\n<h3>HC3</h3>\n<p>If established hypovolaemia class 2 and above</p>\n<p>\u0083 Set 2 large bore IV lines</p>\n<p>\u0083 IV fluids Normal Saline 0.9% (or Ringer\u2019s lactate) 20-</p>\n<p>30 ml/kg over 60 minutes according to response</p>\n<p>- If possible, warm the fluid</p>\n<p>- Start rapidly, monitor BP</p>\n<p>- Assess response to fluid resuscitation: BP, HR, RR,</p>\n<p>capillary refill, consciousness and urinary output</p>\n<p>\u0089</p>\n<p>If internal or external haemorrhage, consider blood</p>\n<p>transfusion</p>\n<p>If rapid improvement and stable (blood loss <20% and</p>\n<p>not progressing)</p>\n<p>\u0089</p>\n<p>Slow IV fluids to maintenance levels</p>\n<p>\u0089</p>\n<p>No immediate transfusion but do cross-matching</p>\n<p>\u0089</p>\n<p>Regular reassessment</p>\n<p>\u0089</p>\n<p>Detailed examination and definitive treatment according</p>\n<p>to the cause</p>\n<p>If transient improvement (blood loss 20-40% or ongo\u00ad</p>\n<p>ing bleeding)</p>\n<p>\u0089</p>\n<p>Rapid administration of fluids</p>\n<p>\u0089</p>\n<p>Initiate blood transfusion (see section 11.2)</p>\n<p>\u0089</p>\n<p>Regular reassessment</p>\n<p>\u0089</p>\n<p>Detailed examination and early surgery</p>\n<p>If no improvement</p>\n<p>\u0089</p>\n<p>Vigorous fluid administration</p>\n<p>\u0089</p>\n<p>Urgent blood transfusion</p>\n<p>\u0089</p>\n<p>Immediate surgery</p>\n<h3>HC4</h3>\n<p>5</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 72,
        "content": "- Tachycardia is often the first response to hypovolaemia but may \nalso be caused by fear or pain\nClassification of hypovolaemia in children\nIndicator\nClass 1 Mild\nClass 2 \nProgres- \nSing\nClass 3 \nSevere\nClass 4 End \nStage\n% of total blood volume loss \n<15\n15-25\n25-40\n>40\nPulse rate\nNormal\n>150\n>150\n>150\nPulse \npressure\nNormal\nN\n\u00e2\nAbsent\nSystolic BP\nNormal\nN\n\u00e2\nAbsent\nCapillary \nrefill\nNormal\n\u00e1\n\uf0e1\uf0e1\nAbsent\nRespiratory \nrate\nNormal\nN/\u00e1\n\uf0e1\uf0e1\n\uf0e1\uf0e1\nSlow sighing\nMental state\nNormal\nIrritable\nLethargic Comatose\nUrine \noutput (ml/\nkg/ hour)\n<1\n<1\n<1\n<1\nTREATMENT\nLOC\nCaution\nDo not use glucose solution or plain water as replacement \nfluids\n1.1.2.1 Hypvovolaemic  Shock In Children\nPrinciples of management are similar to the ones in adults BUT:\n \n- Recognising this may be more difficult than in adults\n \n- Vital signs may change little, even when up to 25% of blood \nvolume is lost (class 1 and 2 hypovolaemia)\n6\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>- Tachycardia is often the first response to hypovolaemia but may</p>\n<p>also be caused by fear or pain</p>\n<p>Classification of hypovolaemia in children</p>\n<p>Indicator</p>\n<p>Class 1 Mild</p>\n<p>Class 2</p>\n<p>Progres-</p>\n<p>Sing</p>\n<p>Class 3</p>\n<p>Severe</p>\n<p>Class 4 End</p>\n<p>Stage</p>\n<p>% of total blood volume loss</p>\n<p><15</p>\n<p>15-25</p>\n<p>25-40</p>\n<p>>40</p>\n<p>Pulse rate</p>\n<p>Normal</p>\n<p>>150</p>\n<p>>150</p>\n<p>>150</p>\n<p>Pulse</p>\n<p>pressure</p>\n<p>Normal</p>\n<p>N</p>\n<p>\u00e2</p>\n<p>Absent</p>\n<p>Systolic BP</p>\n<p>Normal</p>\n<p>N</p>\n<p>\u00e2</p>\n<p>Absent</p>\n<p>Capillary</p>\n<p>refill</p>\n<p>Normal</p>\n<p>\u00e1</p>\n<p>\uf0e1\uf0e1</p>\n<p>Absent</p>\n<p>Respiratory</p>\n<p>rate</p>\n<p>Normal</p>\n<p>N/\u00e1</p>\n<p>\uf0e1\uf0e1</p>\n<p>\uf0e1\uf0e1</p>\n<p>Slow sighing</p>\n<p>Mental state</p>\n<p>Normal</p>\n<p>Irritable</p>\n<p>Lethargic Comatose</p>\n<p>Urine</p>\n<p>output (ml/</p>\n<p>kg/ hour)</p>\n<p><1</p>\n<p><1</p>\n<p><1</p>\n<p><1</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Caution</p>\n<p>Do not use glucose solution or plain water as replacement</p>\n<p>fluids</p>\n<li>.1.2.1 Hypvovolaemic  Shock In Children</li>\n<p>Principles of management are similar to the ones in adults BUT:</p>\n<p>- Recognising this may be more difficult than in adults</p>\n<p>- Vital signs may change little, even when up to 25% of blood</p>\n<p>volume is lost (class 1 and 2 hypovolaemia)</p>\n<p>6</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 73,
        "content": "Normal ranges for vital signs in children\nAge (Years)\nPulse \n(Rate/Min)\nSystolic Bp \n(Mmhg)\nRespiration \n(Rate/Min)\nBlood Vol \n(Ml/Kg)\n<1\n120\u2013160\n70\u201390\n30\u201340\n85\u201390\n1\u20135\n100\u2013120\n80\u201390\n25\u201330\n80\n6\u201312\n80\u2013100\n90\u2013110\n20\u201325\n80\n>12\n60\u2013100\n100\u2013120\n15\u201320\n70\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nInitial fluid challenge should represent 25% of blood \nvolume as signs of hypovolaemia may only show after \nthis amount is lost\n\t\n\u0089\nIf there are signs of class 2 hypovolaemia or greater, \ngive 20-30 ml/kg of Normal Saline 0.9% (or Ringer\u2019s \nlactate) over 60 minutes\n \n- Start rapidly\n \n- Monitor BP\n \n- Reduce rate depending on BP response\n\t\n\u0089\nDepending on response, repeat up to 3 times if nec\u00ad\nessary i.e. up to max 60 ml/kg\n\t\n\u0089\nIf no response:\n\t\n\u0089\nGive further IV fluids and blood transfusion\n\t\n\u0089\nInitially transfuse 20 ml/kg of whole blood or 10 ml/\nkg of packed cells (only in severe anaemia)\nHC3\nHC4\n7\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Normal ranges for vital signs in children</p>\n<p>Age (Years)</p>\n<p>Pulse</p>\n<p>(Rate/Min)</p>\n<p>Systolic Bp</p>\n<p>(Mmhg)</p>\n<p>Respiration</p>\n<p>(Rate/Min)</p>\n<p>Blood Vol</p>\n<p>(Ml/Kg)</p>\n<p><1</p>\n<p>120\u2013160</p>\n<p>70\u201390</p>\n<p>30\u201340</p>\n<p>85\u201390</p>\n<p>1\u20135</p>\n<p>100\u2013120</p>\n<p>80\u201390</p>\n<p>25\u201330</p>\n<p>80</p>\n<p>6\u201312</p>\n<p>80\u2013100</p>\n<p>90\u2013110</p>\n<p>20\u201325</p>\n<p>80</p>\n<p>>12</p>\n<p>60\u2013100</p>\n<p>100\u2013120</p>\n<p>15\u201320</p>\n<p>70</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Initial fluid challenge should represent 25% of blood</p>\n<p>volume as signs of hypovolaemia may only show after</p>\n<p>this amount is lost</p>\n<p>\u0089</p>\n<p>If there are signs of class 2 hypovolaemia or greater,</p>\n<p>give 20-30 ml/kg of Normal Saline 0.9% (or Ringer\u2019s</p>\n<p>lactate) over 60 minutes</p>\n<p>- Start rapidly</p>\n<p>- Monitor BP</p>\n<p>- Reduce rate depending on BP response</p>\n<p>\u0089</p>\n<p>Depending on response, repeat up to 3 times if nec\u00ad</p>\n<p>essary i.e. up to max 60 ml/kg</p>\n<p>\u0089</p>\n<p>If no response:</p>\n<p>\u0089</p>\n<p>Give further IV fluids and blood transfusion</p>\n<p>\u0089</p>\n<p>Initially transfuse 20 ml/kg of whole blood or 10 ml/</p>\n<p>kg of packed cells (only in severe anaemia)</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>7</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 74,
        "content": "1.1.3 Dehydration                                           ICD10CODE: E86.0\nA condition brought about by the loss of significant quantities of fluids \nand salts from the body.\nCauses\n \n~\nVomiting and/or diarrhoea\n \n~\nDecreased fluid intake\n \n~\nExcessive loss of fluids, e.g. due to polyuria in diabetes, \nexcessive sweating as in high fever, burns\nClinical features\n \n~\nApathy, sunken eyes/fontanel, loss of skin turgor (especially \nin children)\n \n~\nHypotension, tachycardia, deep (acidotic) breathing, dry mu\u00ad\ncosae, poor or no urine output.\n1.1.3.1 Dehydration in Children under 5 years\nAssess degree of dehydration following the table below:\nClinical features of dehydration in children\nSigns\nDegree of Dehydration\nNone\nSome\nSevere\nGeneral \ncondition\nWell, alert\nRestless, irritable\nLethargic, drowsy or \nunconscious\nEyes\nNot sunken\nSunken\nSunken\nFontanel\nNot sunken\nSunken\nSunken\nAbility to \ndrink\nDrinks \nnormally\nDrinks eagerly, \nthirsty\nDrinks poorly or not \nable to drink\nSkin pinch\nGoes back \nimmediately\nGoes back slowly;\n<2 seconds\nGoes back very slowly;\n>2 seconds\nTreatment\nPlan A\nPlan B\nPlan C\n8\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.1.3 Dehydration                                           ICD10CODE: E86.0</li>\n<p>A condition brought about by the loss of significant quantities of fluids</p>\n<p>and salts from the body.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Vomiting and/or diarrhoea</p>\n<p>~</p>\n<p>Decreased fluid intake</p>\n<p>~</p>\n<p>Excessive loss of fluids, e.g. due to polyuria in diabetes,</p>\n<p>excessive sweating as in high fever, burns</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Apathy, sunken eyes/fontanel, loss of skin turgor (especially</p>\n<p>in children)</p>\n<p>~</p>\n<p>Hypotension, tachycardia, deep (acidotic) breathing, dry mu\u00ad</p>\n<p>cosae, poor or no urine output.</p>\n<li>.1.3.1 Dehydration in Children under 5 years</li>\n<p>Assess degree of dehydration following the table below:</p>\n<p>Clinical features of dehydration in children</p>\n<p>Signs</p>\n<p>Degree of Dehydration</p>\n<p>None</p>\n<p>Some</p>\n<p>Severe</p>\n<p>General</p>\n<p>condition</p>\n<p>Well, alert</p>\n<p>Restless, irritable</p>\n<p>Lethargic, drowsy or</p>\n<p>unconscious</p>\n<p>Eyes</p>\n<p>Not sunken</p>\n<p>Sunken</p>\n<p>Sunken</p>\n<p>Fontanel</p>\n<p>Not sunken</p>\n<p>Sunken</p>\n<p>Sunken</p>\n<p>Ability to</p>\n<p>drink</p>\n<p>Drinks</p>\n<p>normally</p>\n<p>Drinks eagerly,</p>\n<p>thirsty</p>\n<p>Drinks poorly or not</p>\n<p>able to drink</p>\n<p>Skin pinch</p>\n<p>Goes back</p>\n<p>immediately</p>\n<p>Goes back slowly;</p>\n<p><2 seconds</p>\n<p>Goes back very slowly;</p>\n<p>>2 seconds</p>\n<p>Treatment</p>\n<p>Plan A</p>\n<p>Plan B</p>\n<p>Plan C</p>\n<p>8</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 75,
        "content": "Management\nPlan A (No dehydration and for prevention)\nTREATMENT\nLOC\n\t\n\u0089\nCounsel the mother on the 4 rules of home treatment: \nextra fluids (ORS), continue feeding, zinc supplemen\u00ad\ntation, when to return\n\t\n\u0089\nGive extra fluids: as much as the child will take\n \n- If child exclusively breastfed, give ORS or safe \nclean water in addition to breast milk\n \n- If child not exclusively breastfed, give one or more\nof: ORS, soup, rice-water, yoghurt, clean water\n \n- In addition to the usual fluid intake, give ORS after \neach loose stool or episode of vomiting Child <2 \nyears: 50-100 ml\nChild 2-5 years: 100-200 ml\n \n- Give the mother 2 packets to use at home\n \n- Giving ORS is especially important if the child \nhas been treated with Plan B or Plan C during \ncurrent visit\n \n- Give frequent small sips from a cup\n\t\n\u0089\nAdvice the mother to continue or increase breastfeeding. \nIf child vomits, wait 10 minutes, then give more slowly\n \n- In a child with high fever or respiratory distress, \ngive plenty of fluids to counter the increased fluid \nlosses in these conditions\n \n- Continue giving extra fluid as well as ORS until\n \n- the diarrhoea or other cause of dehydration stops\n\t\n\u0089\nIf diarrhoea, give Zinc supplementation Child <6 months: \n10 mg once a day for 10 days Child >6 months: 20 mg \nonce a day for 10 days\nHC2\n9\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<p>Plan A (No dehydration and for prevention)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Counsel the mother on the 4 rules of home treatment:</p>\n<p>extra fluids (ORS), continue feeding, zinc supplemen\u00ad</p>\n<p>tation, when to return</p>\n<p>\u0089</p>\n<p>Give extra fluids: as much as the child will take</p>\n<p>- If child exclusively breastfed, give ORS or safe</p>\n<p>clean water in addition to breast milk</p>\n<p>- If child not exclusively breastfed, give one or more</p>\n<p>of: ORS, soup, rice-water, yoghurt, clean water</p>\n<p>- In addition to the usual fluid intake, give ORS after</p>\n<p>each loose stool or episode of vomiting Child <2</p>\n<p>years: 50-100 ml</p>\n<p>Child 2-5 years: 100-200 ml</p>\n<p>- Give the mother 2 packets to use at home</p>\n<p>- Giving ORS is especially important if the child</p>\n<p>has been treated with Plan B or Plan C during</p>\n<p>current visit</p>\n<p>- Give frequent small sips from a cup</p>\n<p>\u0089</p>\n<p>Advice the mother to continue or increase breastfeeding.</p>\n<p>If child vomits, wait 10 minutes, then give more slowly</p>\n<p>- In a child with high fever or respiratory distress,</p>\n<p>give plenty of fluids to counter the increased fluid</p>\n<p>losses in these conditions</p>\n<p>- Continue giving extra fluid as well as ORS until</p>\n<p>- the diarrhoea or other cause of dehydration stops</p>\n<p>\u0089</p>\n<p>If diarrhoea, give Zinc supplementation Child <6 months:</p>\n<p>10 mg once a day for 10 days Child >6 months: 20 mg</p>\n<p>once a day for 10 days</p>\n<h3>HC2</h3>\n<p>9</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 76,
        "content": "Plan B (Some dehydration)\nTREATMENT\nLOC\n\t\n\u0089\nGive ORS in the following approximate amounts during \nthe first 4 hours\nAge (Months)\n<4\n4\u201312\n13\u201324\n25\u201360\nWeight (Kg)\n<6\n6\u20139.9\n10\u201311.9\n12\u201319\nOrs (Ml)\n200\u2013400\n400\u2013700\n700\u2013900\n900\u20131400\n \n- Only use child\u2019s age if weight is not known\n \n- You can also calculate the approximate amount \nof ORS to give a child in the first 4 hours as \nweight (kg) x 75 ml\n\t\n\u0089\nShow the mother how to give the ORS\n \n- Give frequent small sips from a cup\n \n- If the child wants more than is shown in the table, \ngive more as required\n \n- If the child vomits, wait 10 minutes, then continue\n \n- more slowly\n\t\n\u0089\nFor infants <6 months who are not breastfed, also give \n100-200 ml of clean water during the first 4 hours\n\t\n\u0089\nReassess patient frequently (every 30-60 minutes) for \nclassification of dehydration and selection of Treat\u00ad\nment Plan\nAfter 4 hours\n\t\n\u0089\nReassess the patient\n\t\n\u0089\nReclassify the degree of dehydration\n\t\n\u0089\nSelect the appropriate Treatment Plan A, B or C\n\t\n\u0089\nBegin feeding the child in the clinic\nHC2\n10\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Plan B (Some dehydration)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give ORS in the following approximate amounts during</p>\n<p>the first 4 hours</p>\n<p>Age (Months)</p>\n<p><4</p>\n<p>4\u201312</p>\n<p>13\u201324</p>\n<p>25\u201360</p>\n<p>Weight (Kg)</p>\n<p><6</p>\n<p>6\u20139.9</p>\n<p>10\u201311.9</p>\n<p>12\u201319</p>\n<p>Ors (Ml)</p>\n<p>200\u2013400</p>\n<p>400\u2013700</p>\n<p>700\u2013900</p>\n<p>900\u20131400</p>\n<p>- Only use child\u2019s age if weight is not known</p>\n<p>- You can also calculate the approximate amount</p>\n<p>of ORS to give a child in the first 4 hours as</p>\n<p>weight (kg) x 75 ml</p>\n<p>\u0089</p>\n<p>Show the mother how to give the ORS</p>\n<p>- Give frequent small sips from a cup</p>\n<p>- If the child wants more than is shown in the table,</p>\n<p>give more as required</p>\n<p>- If the child vomits, wait 10 minutes, then continue</p>\n<p>- more slowly</p>\n<p>\u0089</p>\n<p>For infants <6 months who are not breastfed, also give</p>\n<p>100-200 ml of clean water during the first 4 hours</p>\n<p>\u0089</p>\n<p>Reassess patient frequently (every 30-60 minutes) for</p>\n<p>classification of dehydration and selection of Treat\u00ad</p>\n<p>ment Plan</p>\n<p>After 4 hours</p>\n<p>\u0089</p>\n<p>Reassess the patient</p>\n<p>\u0089</p>\n<p>Reclassify the degree of dehydration</p>\n<p>\u0089</p>\n<p>Select the appropriate Treatment Plan A, B or C</p>\n<p>\u0089</p>\n<p>Begin feeding the child in the clinic</p>\n<h3>HC2</h3>\n<p>10</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 77,
        "content": "TREATMENT\nLOC\nIf mother must leave before completing the child\u2019s treatment\n\t\n\u0089\nShow her how to prepare ORS at home and how much \nORS to give to finish the 4-hour treatment\n \n- Give her enough packets to complete this and 2 \nmore to complete Plan A at home\n\t\n\u0089\nCounsel mother on the 4 rules of home treatment: extra \nfluids, continue feeding, zinc, when to return\nPlan C (Severe dehydration)\nTREATMENT\nLOC\nIf you are unable to give IV fluids and this therapy is not \navailable nearby (within 30 minutes) but a nasogastric \ntube (NGT) is available or the child can drink\n\t\n\u0089\nStart rehydration with ORS by NGT or by mouth: Give \n20 ml/kg/hour for 6 hours (total = 120 ml/ kg)\n\t\n\u0089\nReassess the child every 1-2 hours\n \n- If there is repeated vomiting or increasing \nabdominal distension, give more slowly\n \n- If hydration status is not improving within 3hours, \nrefer the child urgently for IV therapy\n\t\n\u0089\nAfter 6 hours, reassess the child\n\t\n\u0089\nClassify the degree of dehydration\n\t\n\u0089\nSelect appropriate Plan A, B, or C to continue treatment\nHC2\n11\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If mother must leave before completing the child\u2019s treatment</p>\n<p>\u0089</p>\n<p>Show her how to prepare ORS at home and how much</p>\n<p>ORS to give to finish the 4-hour treatment</p>\n<p>- Give her enough packets to complete this and 2</p>\n<p>more to complete Plan A at home</p>\n<p>\u0089</p>\n<p>Counsel mother on the 4 rules of home treatment: extra</p>\n<p>fluids, continue feeding, zinc, when to return</p>\n<p>Plan C (Severe dehydration)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If you are unable to give IV fluids and this therapy is not</p>\n<p>available nearby (within 30 minutes) but a nasogastric</p>\n<p>tube (NGT) is available or the child can drink</p>\n<p>\u0089</p>\n<p>Start rehydration with ORS by NGT or by mouth: Give</p>\n<p>20 ml/kg/hour for 6 hours (total = 120 ml/ kg)</p>\n<p>\u0089</p>\n<p>Reassess the child every 1-2 hours</p>\n<p>- If there is repeated vomiting or increasing</p>\n<p>abdominal distension, give more slowly</p>\n<p>- If hydration status is not improving within 3hours,</p>\n<p>refer the child urgently for IV therapy</p>\n<p>\u0089</p>\n<p>After 6 hours, reassess the child</p>\n<p>\u0089</p>\n<p>Classify the degree of dehydration</p>\n<p>\u0089</p>\n<p>Select appropriate Plan A, B, or C to continue treatment</p>\n<h3>HC2</h3>\n<p>11</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 78,
        "content": "TREATMENT\nLOC\nIf you are unable to give IV fluids but IV treatment is \navailable nearby (i.e. within 30 minutes)\n\t\n\u0089\nRefer urgently for IV treatment\nIf the child can drink:\n\t\n\u0089\nProvide mother with ORS and show her how to give \nfrequent sips during the trip to the referral facility\nHC2\nIf you are able to give IV fluids\n\t\n\u0089\nSet up an IV line immediately\n \n- If child can drink, give ORS while the drip is set \nup\n\t\n\u0089\nGive 100 ml/kg of Ringer\u2019s Lactate\n \n- Or half-strength Darrow\u2019s solution in glucose \n2.5% or sodium chloride 0.9%\n \n- Divide the IV fluid as follows:\n\t\n\u0089\nReassess patient frequently (every 30-60 minutes) to \nre-classify dehydration and treatment plan\nIf the patient is not improving\n\t\n\u0089\nGive the IV fluids more rapidly\nHC3\nAs soon as patient can drink, usually after 3-4 hours in \ninfants or 1-2 hours in children\n\t\n\u0089\nAlso give ORS 5 ml/kg/hour\n\t\n\u0089\nContinue to reassess patient frequently; classify degree \nof dehydration; and select appropriate Plan A, B, or C \nto continue treatment.\nNote \nIf possible, observe child for at least 6 hours after rehydration to ensure \nthat the mother can correctly use ORS to maintain hydration.\n12\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If you are unable to give IV fluids but IV treatment is</p>\n<p>available nearby (i.e. within 30 minutes)</p>\n<p>\u0089</p>\n<p>Refer urgently for IV treatment</p>\n<p>If the child can drink:</p>\n<p>\u0089</p>\n<p>Provide mother with ORS and show her how to give</p>\n<p>frequent sips during the trip to the referral facility</p>\n<h3>HC2</h3>\n<p>If you are able to give IV fluids</p>\n<p>\u0089</p>\n<p>Set up an IV line immediately</p>\n<p>- If child can drink, give ORS while the drip is set</p>\n<p>up</p>\n<p>\u0089</p>\n<p>Give 100 ml/kg of Ringer\u2019s Lactate</p>\n<p>- Or half-strength Darrow\u2019s solution in glucose</p>\n<p>2.5% or sodium chloride 0.9%</p>\n<p>- Divide the IV fluid as follows:</p>\n<p>\u0089</p>\n<p>Reassess patient frequently (every 30-60 minutes) to</p>\n<p>re-classify dehydration and treatment plan</p>\n<p>If the patient is not improving</p>\n<p>\u0089</p>\n<p>Give the IV fluids more rapidly</p>\n<h3>HC3</h3>\n<p>As soon as patient can drink, usually after 3-4 hours in</p>\n<p>infants or 1-2 hours in children</p>\n<p>\u0089</p>\n<p>Also give ORS 5 ml/kg/hour</p>\n<p>\u0089</p>\n<p>Continue to reassess patient frequently; classify degree</p>\n<p>of dehydration; and select appropriate Plan A, B, or C</p>\n<p>to continue treatment.</p>\n<p>Note</p>\n<p>If possible, observe child for at least 6 hours after rehydration to ensure</p>\n<p>that the mother can correctly use ORS to maintain hydration.</p>\n<p>12</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 79,
        "content": "1.1.3.2 Dehydration in Older Children and Adults\nAssess degree of dehydration following the table below.\nCLINICAL FEATURE\nDEGREE OF DEHYDRATION\nMILD\nMODERATE\nSEVERE\nGeneral appearance\nThirsty, alert\nThirsty, alert Generally con\u00ad\nscious, anxious, \nclammy, cold \nextremities, cya\u00ad\nnosis, wrinkly skin \nof fingers, muscle \ncramps, dizzy if \nstanding\nPulse\nNormal\nRapid\nRapid, thready, \nsometimes absent\nRespiration\nNormal\nDeep, may \nbe rapid\nDeep and rapid\nSystolic BP\nNormal\nNormal\nLow, may be \nimmeasurable\nSkin pinch\nRturns \nrapidly\nRturns \nslowly\nReturns very slow\u00ad\nly (>2 seconds)\nEyes\nNormal\nSunken\nVery sunken\nTears\nPresent\nAbsent\nAbsent\nMucous \nmembranes\nMoist\nDry\nVery dry\nUrine output\nNormal\nReduced, \ndark urine\nAnuria, empt y \nbladder\nNote\nAt least 2 of these signs must be present\n13\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.1.3.2 Dehydration in Older Children and Adults</li>\n<p>Assess degree of dehydration following the table below.</p>\n<h3>CLINICAL FEATURE</h3>\n<h3>DEGREE OF DEHYDRATION</h3>\n<h3>MILD</h3>\n<h3>MODERATE</h3>\n<h3>SEVERE</h3>\n<p>General appearance</p>\n<p>Thirsty, alert</p>\n<p>Thirsty, alert Generally con\u00ad</p>\n<p>scious, anxious,</p>\n<p>clammy, cold</p>\n<p>extremities, cya\u00ad</p>\n<p>nosis, wrinkly skin</p>\n<p>of fingers, muscle</p>\n<p>cramps, dizzy if</p>\n<p>standing</p>\n<p>Pulse</p>\n<p>Normal</p>\n<p>Rapid</p>\n<p>Rapid, thready,</p>\n<p>sometimes absent</p>\n<p>Respiration</p>\n<p>Normal</p>\n<p>Deep, may</p>\n<p>be rapid</p>\n<p>Deep and rapid</p>\n<p>Systolic BP</p>\n<p>Normal</p>\n<p>Normal</p>\n<p>Low, may be</p>\n<p>immeasurable</p>\n<p>Skin pinch</p>\n<p>Rturns</p>\n<p>rapidly</p>\n<p>Rturns</p>\n<p>slowly</p>\n<p>Returns very slow\u00ad</p>\n<p>ly (>2 seconds)</p>\n<p>Eyes</p>\n<p>Normal</p>\n<p>Sunken</p>\n<p>Very sunken</p>\n<p>Tears</p>\n<p>Present</p>\n<p>Absent</p>\n<p>Absent</p>\n<p>Mucous</p>\n<p>membranes</p>\n<p>Moist</p>\n<p>Dry</p>\n<p>Very dry</p>\n<p>Urine output</p>\n<p>Normal</p>\n<p>Reduced,</p>\n<p>dark urine</p>\n<p>Anuria, empt y</p>\n<p>bladder</p>\n<p>Note</p>\n<p>At least 2 of these signs must be present</p>\n<p>13</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 80,
        "content": "Management\nTREATMENT\nLOC\nMild dehydration\n\t\n\u0089\nGive oral ORS 25 ml/kg in the first 4 hours\n \n- Increase or maintain until clinical improvement\nModerate dehydration\n\t\n\u0089\nGive oral ORS 50 mg/kg in the first 4 hours\nSevere dehydration\n\t\n\u0089\nRinger\u2019s lactate (or Normal Saline 0.9%) IV, 50 ml/kg \nin the first 4 hours\n \n- Give IV fluids rapidly until radial pulse can be felt,\n \n- then adjust rate\n \n- Re-evaluate vitals after 4 hours\nVolumes that are given over the first 24 hours in adults are \nshown in the table below\nHC2\nHC3\nTime period\nVolume of iv fluid\nFirst hour\n1 L\nNext 3 hours\n2 L\nNext 20 hours\n3 L\n\t\n\u0089\nAfter 4 hours, evaluate rehydration in terms of clinical signs (NOT \nin terms of volumes of fluid given)\n\t\n\u0089\nAs soon as signs of dehydration have disappeared (but not before), \nstart fluid maintenance therapy, alternating ORS and water (to avoid \nhypernatraemia) as much as the patient wants\nContinue for as long as the cause of the original dehydration persists.\n14\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild dehydration</p>\n<p>\u0089</p>\n<p>Give oral ORS 25 ml/kg in the first 4 hours</p>\n<p>- Increase or maintain until clinical improvement</p>\n<p>Moderate dehydration</p>\n<p>\u0089</p>\n<p>Give oral ORS 50 mg/kg in the first 4 hours</p>\n<p>Severe dehydration</p>\n<p>\u0089</p>\n<p>Ringer\u2019s lactate (or Normal Saline 0.9%) IV, 50 ml/kg</p>\n<p>in the first 4 hours</p>\n<p>- Give IV fluids rapidly until radial pulse can be felt,</p>\n<p>- then adjust rate</p>\n<p>- Re-evaluate vitals after 4 hours</p>\n<p>Volumes that are given over the first 24 hours in adults are</p>\n<p>shown in the table below</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Time period</p>\n<p>Volume of iv fluid</p>\n<p>First hour</p>\n<h3>1 L</h3>\n<p>Next 3 hours</p>\n<h3>2 L</h3>\n<p>Next 20 hours</p>\n<h3>3 L</h3>\n<p>\u0089</p>\n<p>After 4 hours, evaluate rehydration in terms of clinical signs (NOT</p>\n<p>in terms of volumes of fluid given)</p>\n<p>\u0089</p>\n<p>As soon as signs of dehydration have disappeared (but not before),</p>\n<p>start fluid maintenance therapy, alternating ORS and water (to avoid</p>\n<p>hypernatraemia) as much as the patient wants</p>\n<p>Continue for as long as the cause of the original dehydration persists.</p>\n<p>14</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 81,
        "content": "Notes\n \n\u0083 Volumes shown are guidelines only. If necessary, volumes can \nbe increased or initial high rate of administration maintained \nuntil clinical improvement occurs\n \n\u0083 In addition to ORS, other fluids such as soup, fruit juice and safe \nclean water may be given\n \n- Initially, adults can take up to 750 ml ORS/hour.\n \n\u0083 If sodium lactate compound IV infusion (Ringer\u2019s Lactate) is \nnot available, use half-strength Darrow\u2019s solution in glucose \n2.5% or sodium chloride infusion 0.9%. However, both of \nthese are less effective\n \n\u0083 Continued nutrition is important, and food should be \ncontinued during treatment for dehydration.\nCaution\n \n\u0083 Avoid artificially sweetened juices.\nPrevention (for all age groups)\n \n~\nEncourage prompt use of ORS at home if the personis \nvomiting and/or having diarrhoea.\n1.1.4 Fluids and Electrolytes Imbalances     ICD10 CODE: E87.8\nA condition where losses of bodily fluids from whatever cause has \nled to significant disturbance in the normal fluid and electrolyte \nlevels needed to maintain physiological functions.\nCauses\nDisorders may occur in the fluid volume, concentration (sodium com\u00ad\nposition), and distribution of fluid and other electrolytes and ph. The \nmain cause is problems in intake, loss and/or distribution and balance \nbetween water and electrolytes, as shown in the table below:\n15\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Notes</p>\n<p>\u0083 Volumes shown are guidelines only. If necessary, volumes can</p>\n<p>be increased or initial high rate of administration maintained</p>\n<p>until clinical improvement occurs</p>\n<p>\u0083 In addition to ORS, other fluids such as soup, fruit juice and safe</p>\n<p>clean water may be given</p>\n<p>- Initially, adults can take up to 750 ml ORS/hour.</p>\n<p>\u0083 If sodium lactate compound IV infusion (Ringer\u2019s Lactate) is</p>\n<p>not available, use half-strength Darrow\u2019s solution in glucose</p>\n<p>2.5% or sodium chloride infusion 0.9%. However, both of</p>\n<p>these are less effective</p>\n<p>\u0083 Continued nutrition is important, and food should be</p>\n<p>continued during treatment for dehydration.</p>\n<p>Caution</p>\n<p>\u0083 Avoid artificially sweetened juices.</p>\n<p>Prevention (for all age groups)</p>\n<p>~</p>\n<p>Encourage prompt use of ORS at home if the personis</p>\n<p>vomiting and/or having diarrhoea.</p>\n<li>.1.4 Fluids and Electrolytes Imbalances     ICD10 CODE: E87.8</li>\n<p>A condition where losses of bodily fluids from whatever cause has</p>\n<p>led to significant disturbance in the normal fluid and electrolyte</p>\n<p>levels needed to maintain physiological functions.</p>\n<p>Causes</p>\n<p>Disorders may occur in the fluid volume, concentration (sodium com\u00ad</p>\n<p>position), and distribution of fluid and other electrolytes and ph. The</p>\n<p>main cause is problems in intake, loss and/or distribution and balance</p>\n<p>between water and electrolytes, as shown in the table below:</p>\n<p>15</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 82,
        "content": "MECHANISM\nEXAMPLES\nGastrointestinal \nloss\n \n~\nExcessive vomiting and diarrhoea\n \n~\nNasogastric drainage\n \n~\nFistula drainage\nHaemorrhage\n \n~\nInternal or external\nFluid sequestration\n \n~\nParalytic ileus, intestinal obstruc\u00ad\ntion\n \n~\nPeritonitis\nLoss through skin/\nwounds\n \n~\nSweating\n \n~\nExtensive burns\nUrinary loss\n \n~\nDecompensated diabetes\nFluid retention \nand electrolytes or \nwater imbalances\n \n~\nRenal, hepatic and heart failure \n(see specific section for manage\u00ad\nment)\nReduced intake\n \n~\nPost operative patients\nExcessive intake\n \n~\nWater intoxication, IV fluids over\u00ad\nload\nClinical features\n \n~\nDehydration in mild/moderate fluid (water and electrolytes) \ndeficiency\n \n~\nHypovolaemic shock in severe fluid deficiency\n \n~\nOedema (including pulmonary oedema) in fluid excess\n \n~\nSpecific effects due to electrolytes imbalances\nManagement\nIV fluids and electrolytes therapy has three main objectives:\n16\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>MECHANISM</h3>\n<h3>EXAMPLES</h3>\n<p>Gastrointestinal</p>\n<p>loss</p>\n<p>~</p>\n<p>Excessive vomiting and diarrhoea</p>\n<p>~</p>\n<p>Nasogastric drainage</p>\n<p>~</p>\n<p>Fistula drainage</p>\n<p>Haemorrhage</p>\n<p>~</p>\n<p>Internal or external</p>\n<p>Fluid sequestration</p>\n<p>~</p>\n<p>Paralytic ileus, intestinal obstruc\u00ad</p>\n<p>tion</p>\n<p>~</p>\n<p>Peritonitis</p>\n<p>Loss through skin/</p>\n<p>wounds</p>\n<p>~</p>\n<p>Sweating</p>\n<p>~</p>\n<p>Extensive burns</p>\n<p>Urinary loss</p>\n<p>~</p>\n<p>Decompensated diabetes</p>\n<p>Fluid retention</p>\n<p>and electrolytes or</p>\n<p>water imbalances</p>\n<p>~</p>\n<p>Renal, hepatic and heart failure</p>\n<p>(see specific section for manage\u00ad</p>\n<p>ment)</p>\n<p>Reduced intake</p>\n<p>~</p>\n<p>Post operative patients</p>\n<p>Excessive intake</p>\n<p>~</p>\n<p>Water intoxication, IV fluids over\u00ad</p>\n<p>load</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Dehydration in mild/moderate fluid (water and electrolytes)</p>\n<p>deficiency</p>\n<p>~</p>\n<p>Hypovolaemic shock in severe fluid deficiency</p>\n<p>~</p>\n<p>Oedema (including pulmonary oedema) in fluid excess</p>\n<p>~</p>\n<p>Specific effects due to electrolytes imbalances</p>\n<p>Management</p>\n<p>IV fluids and electrolytes therapy has three main objectives:</p>\n<p>16</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 83,
        "content": "~\nReplace lost body fluids and continuing losses\n \n~\nCorrect eventual imbalances\n \n~\nMaintain daily fluid requirements.\nAlways use an IV drip for patients who are seriously ill (except patients \nwith congestive heart failure; for these, use only an indwelling needle) \nand may need IV drugs or surgery. If the fluid is not needed urgently, run \nit slowly to keep the IV line open.\nMaintenance fluid therapy\nTREATMENT\nLOC\n Administer daily fluid and electrolyte requirements to any \npatient not able to feed\n\t\n\u0089\nThe basic 24-hour maintenance requirement for an \nadult is 2.5-3 litres\n \n- One third of these daily fluids should be (isotonic)\n \n- sodium chloride 0.9% infusion (or Ringer\u2019s \nLactate), the other two thirds Glucose 5% infusion\n\t\n\u0089\nAs well as the daily requirements, replace fluid lost due \nto the particular condition according to the assessed \ndegree of dehydration.\nHC3\nNotes\n \n\u0083 Closely monitor all IV drips to ensure that the rate is adjusted as \nrequired\n \n\u0083 Check the drip site daily for any signs of infection; change \ndrip site every 2-3 days or when the drip goes into tissues \n(extravasation).\n17\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Replace lost body fluids and continuing losses</p>\n<p>~</p>\n<p>Correct eventual imbalances</p>\n<p>~</p>\n<p>Maintain daily fluid requirements.</p>\n<p>Always use an IV drip for patients who are seriously ill (except patients</p>\n<p>with congestive heart failure; for these, use only an indwelling needle)</p>\n<p>and may need IV drugs or surgery. If the fluid is not needed urgently, run</p>\n<p>it slowly to keep the IV line open.</p>\n<p>Maintenance fluid therapy</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Administer daily fluid and electrolyte requirements to any</p>\n<p>patient not able to feed</p>\n<p>\u0089</p>\n<p>The basic 24-hour maintenance requirement for an</p>\n<p>adult is 2.5-3 litres</p>\n<p>- One third of these daily fluids should be (isotonic)</p>\n<p>- sodium chloride 0.9% infusion (or Ringer\u2019s</p>\n<p>Lactate), the other two thirds Glucose 5% infusion</p>\n<p>\u0089</p>\n<p>As well as the daily requirements, replace fluid lost due</p>\n<p>to the particular condition according to the assessed</p>\n<p>degree of dehydration.</p>\n<h3>HC3</h3>\n<p>Notes</p>\n<p>\u0083 Closely monitor all IV drips to ensure that the rate is adjusted as</p>\n<p>required</p>\n<p>\u0083 Check the drip site daily for any signs of infection; change</p>\n<p>drip site every 2-3 days or when the drip goes into tissues</p>\n<p>(extravasation).</p>\n<p>17</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 84,
        "content": "TREATMENT\nLOC\nDehydration\n\t\n\u0089\nsee section 1.1.3\nHC3\nDiarrhoea and vomiting with severe dehydration, paralytic ileus, \nintestinal obstruction\n\t\n\u0089\nReplace fluid losses with isotonic (sodium) solutions containing \npotassium e.g. compound sodium lactate infusion (Ringer\u2019s \nLactate solution)\n\t\n\u0089\nOr half-strength Darrow\u2019s solution in 2.5% glucose infusion\nHaemorrhage\nIf there is blood loss and the patient is not in shock\n\t\n\u0089\nUse sodium chloride 0.9% infusion for blood volume replacement \ngiving 0.5-1 L in the 1st hour and not more than 2-3 L in 4 hours\nIf there is blood loss >1 litre\n\t\n\u0089\nGive 1-2 units of blood to replace volume and concentration\nShock\n\t\n\u0089\nGive Ringer\u2019s Lactate or sodium chloride 0.9% infusion 20 ml/\nkg IV over 60 minutes for initial volume resuscitation\n \n- Start rapidly, closely monitor BP\n \n- Reduce the rate according to BP response\n\t\n\u0089\nIn patients with severe shock and significant haemorrhage, give \na blood transfusion\nNotes\n \n\u0083 Closely monitor all IV drips to ensure that the rate is adjusted as \nrequired\n \n\u0083 Check the drip site daily for any signs of infection; change drip site \nevery 2-3 days or when the drip goes into tissues (extravasation).\nReplecment therapy in specific conditions\n18\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Dehydration</p>\n<p>\u0089</p>\n<p>see section 1.1.3</p>\n<h3>HC3</h3>\n<p>Diarrhoea and vomiting with severe dehydration, paralytic ileus,</p>\n<p>intestinal obstruction</p>\n<p>\u0089</p>\n<p>Replace fluid losses with isotonic (sodium) solutions containing</p>\n<p>potassium e.g. compound sodium lactate infusion (Ringer\u2019s</p>\n<p>Lactate solution)</p>\n<p>\u0089</p>\n<p>Or half-strength Darrow\u2019s solution in 2.5% glucose infusion</p>\n<p>Haemorrhage</p>\n<p>If there is blood loss and the patient is not in shock</p>\n<p>\u0089</p>\n<p>Use sodium chloride 0.9% infusion for blood volume replacement</p>\n<p>giving 0.5-1 L in the 1st hour and not more than 2-3 L in 4 hours</p>\n<p>If there is blood loss >1 litre</p>\n<p>\u0089</p>\n<p>Give 1-2 units of blood to replace volume and concentration</p>\n<p>Shock</p>\n<p>\u0089</p>\n<p>Give Ringer\u2019s Lactate or sodium chloride 0.9% infusion 20 ml/</p>\n<p>kg IV over 60 minutes for initial volume resuscitation</p>\n<p>- Start rapidly, closely monitor BP</p>\n<p>- Reduce the rate according to BP response</p>\n<p>\u0089</p>\n<p>In patients with severe shock and significant haemorrhage, give</p>\n<p>a blood transfusion</p>\n<p>Notes</p>\n<p>\u0083 Closely monitor all IV drips to ensure that the rate is adjusted as</p>\n<p>required</p>\n<p>\u0083 Check the drip site daily for any signs of infection; change drip site</p>\n<p>every 2-3 days or when the drip goes into tissues (extravasation).</p>\n<p>Replecment therapy in specific conditions</p>\n<p>18</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 85,
        "content": "1.1.4.1 IV Fluid management in children          ICD10 CODE: E87.8\nTREATMENT\nLOC\n\t\n\u0089\nTotal daily maintenance fluid requirement is 100 ml/kg \nfor the first 10 kg plus\n \n- 50 ml/kg for the next 10 kg plus 25 ml/kg for each \nsubsequent kg\n\t\n\u0089\nGive more than above if child is dehydrated or in fluid loss \nor fever (10% more for each 1\u00b0C of fever)\nHC4\nFluid management in neonates\nTREATMENT\nLOC\n\t\n\u0089\nEncourage mother to breastfeed or if child unable, give \nexpressed breast milk via NGT\n\t\n\u0089\nWithhold oral feeding in case of bowel obstruction, necrotiz\u00ad\ning enterocolitis, or if feeding is not tolerated (abdominal \ndistension, vomiting everything)\n\t\n\u0089\nWithhold oral feeding in acute phase of severe sickness, in \ninfants who are lethargic, unconscious or having frequent \nconvulsions\nHC4\nTotal amount of fluids (oral and/or IV)\nDay 1: 60 ml/kg/day of Dextrose 10%\nDay 2: 90 ml/kg/day of Dextrose 10%\nDay 3: 120 ml/kg/day of half normal saline and dextrose 5%\nDay 4 onwards: 150 ml/kg/day\n\t\n\u0089\nIf only IV fluids are given, do not exceed 100 ml/ kg/\nday unless child is dehydrated, under a radiant heater or \nphototherapy\n\t\n\u0089\nIf facial swelling develops, reduce rate of infusion\n\t\n\u0089\nWhen oral feeding is well established, raise the total amount \nto 180 ml/kg/day.\n19\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.1.4.1 IV Fluid management in children          ICD10 CODE: E87.8</li>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Total daily maintenance fluid requirement is 100 ml/kg</p>\n<p>for the first 10 kg plus</p>\n<p>- 50 ml/kg for the next 10 kg plus 25 ml/kg for each</p>\n<p>subsequent kg</p>\n<p>\u0089</p>\n<p>Give more than above if child is dehydrated or in fluid loss</p>\n<p>or fever (10% more for each 1\u00b0C of fever)</p>\n<h3>HC4</h3>\n<p>Fluid management in neonates</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Encourage mother to breastfeed or if child unable, give</p>\n<p>expressed breast milk via NGT</p>\n<p>\u0089</p>\n<p>Withhold oral feeding in case of bowel obstruction, necrotiz\u00ad</p>\n<p>ing enterocolitis, or if feeding is not tolerated (abdominal</p>\n<p>distension, vomiting everything)</p>\n<p>\u0089</p>\n<p>Withhold oral feeding in acute phase of severe sickness, in</p>\n<p>infants who are lethargic, unconscious or having frequent</p>\n<p>convulsions</p>\n<h3>HC4</h3>\n<p>Total amount of fluids (oral and/or IV)</p>\n<p>Day 1: 60 ml/kg/day of Dextrose 10%</p>\n<p>Day 2: 90 ml/kg/day of Dextrose 10%</p>\n<p>Day 3: 120 ml/kg/day of half normal saline and dextrose 5%</p>\n<p>Day 4 onwards: 150 ml/kg/day</p>\n<p>\u0089</p>\n<p>If only IV fluids are given, do not exceed 100 ml/ kg/</p>\n<p>day unless child is dehydrated, under a radiant heater or</p>\n<p>phototherapy</p>\n<p>\u0089</p>\n<p>If facial swelling develops, reduce rate of infusion</p>\n<p>\u0089</p>\n<p>When oral feeding is well established, raise the total amount</p>\n<p>to 180 ml/kg/day.</p>\n<p>19</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 86,
        "content": "Shock in non-malnourished child\nTREATMENT\nLOC\n\t\n\u0089\nUse Ringer\u2019s lactate or normal saline\n\t\n\u0089\nInfuse 20 ml/kg as rapidly as possible\nHC3\nIf no improvement\n\t\n\u0089\nRepeat 10-20 ml/kg of IV fluids\n\t\n\u0089\nIf bleeding, give blood at 20 ml/kg\nIf still no improvement\n\t\n\u0089\nGive another 20 ml/kg of IV fluids\nIf no improvement further still\n\t\n\u0089\nSuspect septic shock\n\t\n\u0089\nRepeat 20 ml/kg IV fluids and consider adrenaline or \ndopamine\nIf improvement noted at any stage (reducing heart rate, \nincrease in blood pressure and pulse volume, capillary \nrefill <2 seconds)\n\t\n\u0089\nGive 70 ml/kg of Ringer\u2019s lactate (or Normal saline if \nRinger\u2019s not available) over 5 hours (if infant <12 months) \nor 2.5 hours (if child >12 months)\nHC4\nNote\n \n\u0083 In children with suspected malaria or anaemia with shock, IV fluids \nshould be administered cautiously and blood should be used in severe \nanaemia\nShock in malnourished child\nTREATMENT\nLOC\n\t\n\u0089\nIn malnourished children, give 15 ml/kg over 1 hour, \nuse one of the following:\n \n- Ringer\u2019s lactate with 5% glucose\n \n- Half strength darrow\u2019s solution with 5% glucose\n \n- 0.45% Sodium chloride plus 5% glucose\nHC3\n20\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Shock in non-malnourished child</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Use Ringer\u2019s lactate or normal saline</p>\n<p>\u0089</p>\n<p>Infuse 20 ml/kg as rapidly as possible</p>\n<h3>HC3</h3>\n<p>If no improvement</p>\n<p>\u0089</p>\n<p>Repeat 10-20 ml/kg of IV fluids</p>\n<p>\u0089</p>\n<p>If bleeding, give blood at 20 ml/kg</p>\n<p>If still no improvement</p>\n<p>\u0089</p>\n<p>Give another 20 ml/kg of IV fluids</p>\n<p>If no improvement further still</p>\n<p>\u0089</p>\n<p>Suspect septic shock</p>\n<p>\u0089</p>\n<p>Repeat 20 ml/kg IV fluids and consider adrenaline or</p>\n<p>dopamine</p>\n<p>If improvement noted at any stage (reducing heart rate,</p>\n<p>increase in blood pressure and pulse volume, capillary</p>\n<p>refill <2 seconds)</p>\n<p>\u0089</p>\n<p>Give 70 ml/kg of Ringer\u2019s lactate (or Normal saline if</p>\n<p>Ringer\u2019s not available) over 5 hours (if infant <12 months)</p>\n<p>or 2.5 hours (if child >12 months)</p>\n<h3>HC4</h3>\n<p>Note</p>\n<p>\u0083 In children with suspected malaria or anaemia with shock, IV fluids</p>\n<p>should be administered cautiously and blood should be used in severe</p>\n<p>anaemia</p>\n<p>Shock in malnourished child</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>In malnourished children, give 15 ml/kg over 1 hour,</p>\n<p>use one of the following:</p>\n<p>- Ringer\u2019s lactate with 5% glucose</p>\n<p>- Half strength darrow\u2019s solution with 5% glucose</p>\n<p>- 0.45% Sodium chloride plus 5% glucose</p>\n<h3>HC3</h3>\n<p>20</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 87,
        "content": "Shock in malnourished child\nTREATMENT\nLOC\n\t\n\u0089\nRepeat once\nIf signs of improvement\n\t\n\u0089\nSwitch to oral or NGT ReSoMal at 10 ml/kg/hour for \nup to 10 hours\nIf no improvement\n\t\n\u0089\nGive maintenance IV fluids 4 ml/kg/hour f Transfuse \n10 ml/kg slowly (over 3 hours) f Start refeeding\n\t\n\u0089\nStart IV antibiotics.\nHC3\nCommonly used IV fluids and indication\nNAME\nCOMPOSITION\nINDICATIONS\nSodium Chloride \n0.9% (normal saline)\nNa 154 mmol/L\nCl 154 mmol/L\nShock, dehydration in \nadults (and children) \nMaintenance fluid in \nadults\nDextrose (Glucose) \n5%\nGlucose 25 g in \n500 ml\nMaintenance fluid in \nadults\nDextrose (Glucose) \n10%1 (to be pre\u00ad\npared)\nGlucose 50 g in \n500 ml\nHypoglycaemia in chil\u00ad\ndren and adults Mainte\u00ad\nnance fluids in newborns \nday 1 and 2\nDextrose 50%\nGlucose 50 g in \n100 ml\nHypoglycaemia in adults\nRinger\u2019s lactate (So\u00ad\ndium lactate com\u00ad\npound, Harmann\u2019s \nsolution)\nNa 130 mmol/L\nK 5.4 mmol/L\nCa 1.8 mmol/L\nShock, dehydration in \nchildren (and adults)\nMaintenance fluid in \nadults\n\u00bd strenghth Dar\u00ad\nrow\u2019s solution in 5% \nglucose\nNa 61 mmol/L\nK 17 mmol/L \nGlucose 25 g in \n500 ml\nShock and dehydration \nin malnourished children\n21\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Shock in malnourished child</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Repeat once</p>\n<p>If signs of improvement</p>\n<p>\u0089</p>\n<p>Switch to oral or NGT ReSoMal at 10 ml/kg/hour for</p>\n<p>up to 10 hours</p>\n<p>If no improvement</p>\n<p>\u0089</p>\n<p>Give maintenance IV fluids 4 ml/kg/hour f Transfuse</p>\n<p>10 ml/kg slowly (over 3 hours) f Start refeeding</p>\n<p>\u0089</p>\n<p>Start IV antibiotics.</p>\n<h3>HC3</h3>\n<p>Commonly used IV fluids and indication</p>\n<h3>NAME</h3>\n<h3>COMPOSITION</h3>\n<h3>INDICATIONS</h3>\n<p>Sodium Chloride</p>\n<p>0.9% (normal saline)</p>\n<p>Na 154 mmol/L</p>\n<p>Cl 154 mmol/L</p>\n<p>Shock, dehydration in</p>\n<p>adults (and children)</p>\n<p>Maintenance fluid in</p>\n<p>adults</p>\n<p>Dextrose (Glucose)</p>\n<p>5%</p>\n<p>Glucose 25 g in</p>\n<p>500 ml</p>\n<p>Maintenance fluid in</p>\n<p>adults</p>\n<p>Dextrose (Glucose)</p>\n<p>10%1 (to be pre\u00ad</p>\n<p>pared)</p>\n<p>Glucose 50 g in</p>\n<p>500 ml</p>\n<p>Hypoglycaemia in chil\u00ad</p>\n<p>dren and adults Mainte\u00ad</p>\n<p>nance fluids in newborns</p>\n<p>day 1 and 2</p>\n<p>Dextrose 50%</p>\n<p>Glucose 50 g in</p>\n<p>100 ml</p>\n<p>Hypoglycaemia in adults</p>\n<p>Ringer\u2019s lactate (So\u00ad</p>\n<p>dium lactate com\u00ad</p>\n<p>pound, Harmann\u2019s</p>\n<p>solution)</p>\n<p>Na 130 mmol/L</p>\n<p>K 5.4 mmol/L</p>\n<p>Ca 1.8 mmol/L</p>\n<p>Shock, dehydration in</p>\n<p>children (and adults)</p>\n<p>Maintenance fluid in</p>\n<p>adults</p>\n<p>\u00bd strenghth Dar\u00ad</p>\n<p>row\u2019s solution in 5%</p>\n<p>glucose</p>\n<p>Na 61 mmol/L</p>\n<p>K 17 mmol/L</p>\n<p>Glucose 25 g in</p>\n<p>500 ml</p>\n<p>Shock and dehydration</p>\n<p>in malnourished children</p>\n<p>21</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 88,
        "content": "NAME\nCOMPOSITION\nINDICATIONS\nHalf normal saline \n(Nacl 0.45%) dex\u00ad\ntrose\n5%2\n(to be prepared)\nNa 77 mmol/L\nCl 77 mmol/L \nGlucose 25 g in \n500 ml\nMaintenance fluid in \nchildren\nShock and dehydration \nin malnourished children\nNormal saline or \nRinger\u2019s lactate with \n5% dextrose3\n(to be prepared)\nNa 154/130 K \n0/5.4\nGlucose 25 g in \n500 ml\nMaintenance fluid in \nchildren\nNote\n1 Prepare from Dextrose 5% and 50%:\n \n\u0083 Remove 50 ml from Dextrose 5% 500 ml bottle and discard\n \n\u0083 Replace with 50 ml of Dextrose 50%. Shake\n \n\u0083 Follow normal aseptic techniques\n \n\u0083 Use immediately, DO NOT STORE\n2 Prepare from Normal saline 500 ml bottle and dextrose 5% and 50%\n \n\u0083 Replace 250 ml of Normal saline with 225 ml of\n \n\u0083 Dextrose 5% and 25 ml of Dextrose 50%\n3 Prepare by replacing 50 ml of normal saline or Ringer\u2019s 500 ml \nbottle with 50 ml of Dextrose 50%\n1.1.5 Febrile Convulsions\t                                             ICD10 CODE: R56\nA generalized tonic-clonic seizure associated with a rapid rise in temper\u00ad\nature due to an extracranial illness. It is a diagnosis of exclusion: specific \nconditions (cerebral malaria, meningitis, epilepsy) should be excluded. It \ncommonly affects children from age 3 months to 6 years.\nCauses\n \n~\nMalaria\n \n~\nRespiratory tract infections\n \n~\nUrinary tract infections\n22\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>NAME</h3>\n<h3>COMPOSITION</h3>\n<h3>INDICATIONS</h3>\n<p>Half normal saline</p>\n<p>(Nacl 0.45%) dex\u00ad</p>\n<p>trose</p>\n<p>5%2</p>\n<p>(to be prepared)</p>\n<p>Na 77 mmol/L</p>\n<p>Cl 77 mmol/L</p>\n<p>Glucose 25 g in</p>\n<p>500 ml</p>\n<p>Maintenance fluid in</p>\n<p>children</p>\n<p>Shock and dehydration</p>\n<p>in malnourished children</p>\n<p>Normal saline or</p>\n<p>Ringer\u2019s lactate with</p>\n<p>5% dextrose3</p>\n<p>(to be prepared)</p>\n<p>Na 154/130 K</p>\n<p>0/5.4</p>\n<p>Glucose 25 g in</p>\n<p>500 ml</p>\n<p>Maintenance fluid in</p>\n<p>children</p>\n<p>Note</p>\n<p>1 Prepare from Dextrose 5% and 50%:</p>\n<p>\u0083 Remove 50 ml from Dextrose 5% 500 ml bottle and discard</p>\n<p>\u0083 Replace with 50 ml of Dextrose 50%. Shake</p>\n<p>\u0083 Follow normal aseptic techniques</p>\n<p>\u0083 Use immediately, DO NOT STORE</p>\n<p>2 Prepare from Normal saline 500 ml bottle and dextrose 5% and 50%</p>\n<p>\u0083 Replace 250 ml of Normal saline with 225 ml of</p>\n<p>\u0083 Dextrose 5% and 25 ml of Dextrose 50%</p>\n<p>3 Prepare by replacing 50 ml of normal saline or Ringer\u2019s 500 ml</p>\n<p>bottle with 50 ml of Dextrose 50%</p>\n<li>.1.5 Febrile Convulsions\t                                             ICD10 CODE: R56</li>\n<p>A generalized tonic-clonic seizure associated with a rapid rise in temper\u00ad</p>\n<p>ature due to an extracranial illness. It is a diagnosis of exclusion: specific</p>\n<p>conditions (cerebral malaria, meningitis, epilepsy) should be excluded. It</p>\n<p>commonly affects children from age 3 months to 6 years.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Malaria</p>\n<p>~</p>\n<p>Respiratory tract infections</p>\n<p>~</p>\n<p>Urinary tract infections</p>\n<p>22</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 89,
        "content": "~\nOther febrile conditions\nClinical features\n \n~\nElevated temperature (>38\u00b0C)\n \n~\nConvulsions usually brief and self-limiting (usually <5 min\u00ad\nutes, always <15 minutes) but may recur if temperature re\u00ad\nmains high\n \n~\nNo neurological abnormality in the period between con\u00ad\nvulsions\n \n~\nGenerally benign and with good prognosis\nDifferential diagnosis\n \n~\nEpilepsy, brain lesions, meningitis, encephalitis\n \n~\nTrauma (head injury)\n \n~\nHypoglycaemia\n \n~\nIf intracranial pathology cannot be clinically excluded (es\u00ad\npecially in children <2 years) consider lumbar puncture or \ntreat children empirically for meningitis\nInvestigations\n \n\u0081\nBlood: Slide/RDT for malaria parasites\n \n\u0081\nRandom blood glucose\n \n\u0081\nFull blood count\n \n\u0081\nLP and CSF examination\n\u00be\t Urinalysis, culture and sensitivity\n\u00be\t Chest X-ray\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nUse tepid sponging to help lower temperature\n\t\n\u0089\nGive an antipyretic: paracetamol 15 mg/kg every 6 hours \nuntil fever subsides\nHC2\n23\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Other febrile conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Elevated temperature (>38\u00b0C)</p>\n<p>~</p>\n<p>Convulsions usually brief and self-limiting (usually <5 min\u00ad</p>\n<p>utes, always <15 minutes) but may recur if temperature re\u00ad</p>\n<p>mains high</p>\n<p>~</p>\n<p>No neurological abnormality in the period between con\u00ad</p>\n<p>vulsions</p>\n<p>~</p>\n<p>Generally benign and with good prognosis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Epilepsy, brain lesions, meningitis, encephalitis</p>\n<p>~</p>\n<p>Trauma (head injury)</p>\n<p>~</p>\n<p>Hypoglycaemia</p>\n<p>~</p>\n<p>If intracranial pathology cannot be clinically excluded (es\u00ad</p>\n<p>pecially in children <2 years) consider lumbar puncture or</p>\n<p>treat children empirically for meningitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Slide/RDT for malaria parasites</p>\n<p>\u0081</p>\n<p>Random blood glucose</p>\n<p>\u0081</p>\n<p>Full blood count</p>\n<p>\u0081</p>\n<p>LP and CSF examination</p>\n<p>\u00be\t Urinalysis, culture and sensitivity</p>\n<p>\u00be\t Chest X-ray</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Use tepid sponging to help lower temperature</p>\n<p>\u0089</p>\n<p>Give an antipyretic: paracetamol 15 mg/kg every 6 hours</p>\n<p>until fever subsides</p>\n<h3>HC2</h3>\n<p>23</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 90,
        "content": "TREATMENT\nLOC\nIf convulsing\n\t\n\u0089\nGive diazepam 500 micrograms/kg rectally (using suppos\u00ad\nitories/rectal tube or diluted parenteral solution)\nMaximum dose is 10 mg\nRepeat prn after 10 minutes\nIf unconscious\n\t\n\u0089\nPosition the patient on the side (recovery position) and \nensure airways, breathing and circulation (ABC)\nIf persistent convulsions\n\t\n\u0089\nsee section 9.1.1\nHC2\nHC4\nPrevention\nEducate caregivers on how to control fever (tepid sponging and parac\u00ad\netamol)\n1.1.6 Hypoglycaemia\t\n           ICD10 CODE: E16.2\nA clinical condition due to reduced levels of blood sugar (glucose). Symp\u00ad\ntoms generally occur with a blood glucose <3.0 mmol/L (55 mg/dl).\nCause\n \n~\nOverdose of insulin or anti-diabetic medicines\n \n~\nExcessive alcohol intakeSepsis, critical illnesses\n \n~\nHepatic disease\n \n~\nPrematurity\n \n~\nStarvation\n \n~\nOperations to reduce the size of the stomach (gastrectomy)\n \n~\nTumours of the pancreas (insulinomas)\n \n~\nCertain drugs e.g. quinine\n \n~\nHormone deficiencies (cortisol, growth hormone)\nClinical features\n \n~\nEarly symptoms: hunger, dizziness, tremors, sweating, ner\u00ad\nvousness and confusion\n24\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If convulsing</p>\n<p>\u0089</p>\n<p>Give diazepam 500 micrograms/kg rectally (using suppos\u00ad</p>\n<p>itories/rectal tube or diluted parenteral solution)</p>\n<p>Maximum dose is 10 mg</p>\n<p>Repeat prn after 10 minutes</p>\n<p>If unconscious</p>\n<p>\u0089</p>\n<p>Position the patient on the side (recovery position) and</p>\n<p>ensure airways, breathing and circulation (ABC)</p>\n<p>If persistent convulsions</p>\n<p>\u0089</p>\n<p>see section 9.1.1</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>Educate caregivers on how to control fever (tepid sponging and parac\u00ad</p>\n<p>etamol)</p>\n<li>.1.6 Hypoglycaemia</li>\n<h3>ICD10 CODE: E16.2</h3>\n<p>A clinical condition due to reduced levels of blood sugar (glucose). Symp\u00ad</p>\n<p>toms generally occur with a blood glucose <3.0 mmol/L (55 mg/dl).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Overdose of insulin or anti-diabetic medicines</p>\n<p>~</p>\n<p>Excessive alcohol intakeSepsis, critical illnesses</p>\n<p>~</p>\n<p>Hepatic disease</p>\n<p>~</p>\n<p>Prematurity</p>\n<p>~</p>\n<p>Starvation</p>\n<p>~</p>\n<p>Operations to reduce the size of the stomach (gastrectomy)</p>\n<p>~</p>\n<p>Tumours of the pancreas (insulinomas)</p>\n<p>~</p>\n<p>Certain drugs e.g. quinine</p>\n<p>~</p>\n<p>Hormone deficiencies (cortisol, growth hormone)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Early symptoms: hunger, dizziness, tremors, sweating, ner\u00ad</p>\n<p>vousness and confusion</p>\n<p>24</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 91,
        "content": "~\nProfuse sweating, palpitations, weakness\n \n~\nConvulsions\n \n~\nLoss of consciousness\nDifferential diagnosis\n \n~\nOther causes of loss of consciousness (poisoning, head in\u00ad\njury etc.)\nInvestigations\n \n\u0081\nBlood sugar (generally <3.0 mmol/L)\n \n\u0081\nSpecific investigations: to exclude other causes of hypoglycaemia\nManagement\nTREATMENT\nLOC\nIf patient is able to swallow\n\t\n\u0089\nOral glucose or sugar 10-20 g in 100-200 ml water (2-4 \nteaspoons) is usually taken initially and repeated after 15 \nminutes if necessary\nIf patient is unconscious\n\t\n\u0089\nAdults: glucose 50% 20-50 ml IV slowly (3 ml/ minute) \nor diluted with normal saline, followed by 10 % glucose \nsolution by drip at 5-10 mg /kg/\nminute until patient regains consciousness, then encourage \noral snacks\nChild: Dextrose 10% IV 2-5 ml/kg\n\t\n\u0089\nIf patient does not regain consciousness after 30 minutes, \nconsider other causes of coma\n\t\n\u0089\nMonitor blood sugar for several hours (at least 12 if hy\u00ad\npoglycaemia caused by oral antidiabetics) and investigate \nthe cause \u2013 manage accordingly.\nHC2\nHC3\n25\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Profuse sweating, palpitations, weakness</p>\n<p>~</p>\n<p>Convulsions</p>\n<p>~</p>\n<p>Loss of consciousness</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of loss of consciousness (poisoning, head in\u00ad</p>\n<p>jury etc.)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood sugar (generally <3.0 mmol/L)</p>\n<p>\u0081</p>\n<p>Specific investigations: to exclude other causes of hypoglycaemia</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If patient is able to swallow</p>\n<p>\u0089</p>\n<p>Oral glucose or sugar 10-20 g in 100-200 ml water (2-4</p>\n<p>teaspoons) is usually taken initially and repeated after 15</p>\n<p>minutes if necessary</p>\n<p>If patient is unconscious</p>\n<p>\u0089</p>\n<p>Adults: glucose 50% 20-50 ml IV slowly (3 ml/ minute)</p>\n<p>or diluted with normal saline, followed by 10 % glucose</p>\n<p>solution by drip at 5-10 mg /kg/</p>\n<p>minute until patient regains consciousness, then encourage</p>\n<p>oral snacks</p>\n<p>Child: Dextrose 10% IV 2-5 ml/kg</p>\n<p>\u0089</p>\n<p>If patient does not regain consciousness after 30 minutes,</p>\n<p>consider other causes of coma</p>\n<p>\u0089</p>\n<p>Monitor blood sugar for several hours (at least 12 if hy\u00ad</p>\n<p>poglycaemia caused by oral antidiabetics) and investigate</p>\n<p>the cause \u2013 manage accordingly.</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>25</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 92,
        "content": "Note\n \n\u0083 After dextrose 50%, flush the IV line to avoid sclerosis of the vein \n(dextrose is very irritant)\n \n\u0083 Preparation of Dextrose 10% from Dextrose 5% and Dextrose \n50%:\n \n- Remove 50 ml from Dextrose 5% bottle and discard\n \n- Replace with 50 ml of Dextrose 50%. Shake\n \n- Follow normal aseptic techniques\n \n- Use immediately, DO NOT STORE.\nPrevention\n \n~\nEducate patients at risk of hypoglycaemia on recognition \nof early symptoms e.g. diabetics, patients who have had a \ngastrectomy\n \n~\nAdvise patients at risk to have regular meals and to always \nhave glucose or sugar with them for emergency treatment \nof hypoglycaemia\n \n~\nAdvise diabetic patients to carry an identification tag\n1.2 TRAUMA AND INJURIES\n1.2.1 Bites and Stings\nWounds caused by teeth, fangs or stings.\nCauses\n \n~\nAnimals (e.g. dogs, snakes), humans or insects\nClinical features\n \n~\nDepend on the cause\n26\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Note</p>\n<p>\u0083 After dextrose 50%, flush the IV line to avoid sclerosis of the vein</p>\n<p>(dextrose is very irritant)</p>\n<p>\u0083 Preparation of Dextrose 10% from Dextrose 5% and Dextrose</p>\n<p>50%:</p>\n<p>- Remove 50 ml from Dextrose 5% bottle and discard</p>\n<p>- Replace with 50 ml of Dextrose 50%. Shake</p>\n<p>- Follow normal aseptic techniques</p>\n<p>- Use immediately, DO NOT STORE.</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Educate patients at risk of hypoglycaemia on recognition</p>\n<p>of early symptoms e.g. diabetics, patients who have had a</p>\n<p>gastrectomy</p>\n<p>~</p>\n<p>Advise patients at risk to have regular meals and to always</p>\n<p>have glucose or sugar with them for emergency treatment</p>\n<p>of hypoglycaemia</p>\n<p>~</p>\n<p>Advise diabetic patients to carry an identification tag</p>\n<h3>1.2 TRAUMA AND INJURIES</h3>\n<li>.2.1 Bites and Stings</li>\n<p>Wounds caused by teeth, fangs or stings.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Animals (e.g. dogs, snakes), humans or insects</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Depend on the cause</p>\n<p>26</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 93,
        "content": "General management\nTREATMENT\nLOC\nFirst aid\n\t\n\u0089\nImmediately clean the wound thoroughly with plenty of \nclean water and soap to remove any dirt or foreign bodies\n\t\n\u0089\nStop excessive bleeding by applying pressure where \nnecessary\n\t\n\u0089\nRinse the wound and allow to dry\n\t\n\u0089\nApply an antiseptic: Chlorhexidine solution 0.05% or \nPovidone iodine solution 10%\nHC2\nSupportive therapy\n\t\n\u0089\nTreat anaphylactic shock (see section 1.1.1)\n\t\n\u0089\nTreat swelling if significant as necessary, using ice packs \nor cold compresses\n\t\n\u0089\nGive analgesics prn\n\t\n\u0089\nReassure and immobilise the patient\nHC3\nAntibiotics\n\t\n\u0089\nGive only for infected or high-risk wounds including:\n \n- Moderate to severe wounds with extensive tissue\n \n- damage\n \n- Very contaminated wounds\n \n- Deep puncture wounds (especially by cats)\n \n- Wounds on hands, feet, genitalia or face\n \n- Wounds with underlying structures involved\n \n- Wounds in immunocompromised patients\n\t\n\u0089\nSee next sections on wound management, human and \nanimal bites for more details\nTetanus prophylaxis\n\t\n\u0089\nGive TT immunisation (tetanus toxoid, TT 0.5 ml) if not \npreviously immunised within the last 10 years\n27\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>General management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First aid</p>\n<p>\u0089</p>\n<p>Immediately clean the wound thoroughly with plenty of</p>\n<p>clean water and soap to remove any dirt or foreign bodies</p>\n<p>\u0089</p>\n<p>Stop excessive bleeding by applying pressure where</p>\n<p>necessary</p>\n<p>\u0089</p>\n<p>Rinse the wound and allow to dry</p>\n<p>\u0089</p>\n<p>Apply an antiseptic: Chlorhexidine solution 0.05% or</p>\n<p>Povidone iodine solution 10%</p>\n<h3>HC2</h3>\n<p>Supportive therapy</p>\n<p>\u0089</p>\n<p>Treat anaphylactic shock (see section 1.1.1)</p>\n<p>\u0089</p>\n<p>Treat swelling if significant as necessary, using ice packs</p>\n<p>or cold compresses</p>\n<p>\u0089</p>\n<p>Give analgesics prn</p>\n<p>\u0089</p>\n<p>Reassure and immobilise the patient</p>\n<h3>HC3</h3>\n<p>Antibiotics</p>\n<p>\u0089</p>\n<p>Give only for infected or high-risk wounds including:</p>\n<p>- Moderate to severe wounds with extensive tissue</p>\n<p>- damage</p>\n<p>- Very contaminated wounds</p>\n<p>- Deep puncture wounds (especially by cats)</p>\n<p>- Wounds on hands, feet, genitalia or face</p>\n<p>- Wounds with underlying structures involved</p>\n<p>- Wounds in immunocompromised patients</p>\n<p>\u0089</p>\n<p>See next sections on wound management, human and</p>\n<p>animal bites for more details</p>\n<p>Tetanus prophylaxis</p>\n<p>\u0089</p>\n<p>Give TT immunisation (tetanus toxoid, TT 0.5 ml) if not</p>\n<p>previously immunised within the last 10 years</p>\n<p>27</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 94,
        "content": "TREATMENT\nLOC\nCaution\n\t\n\u0089\nDo not suture bite wounds\n1.2.1.1  Snakebites\nSnakebites can cause both local and systemic effects. Non-venomous \nsnakes cause local effects (swelling, redness, laceration) and venomous \nsnakes cause both local and systemic effects due to envenomation.  Over \n70% of snakes in Uganda are non-venomous and most bites are from \nnon-venomous snakes. Of the venomous snakes, more than 50% of \nbites are \u201cdry\u201d i.e. no envenomation occurs. In the event that venom is \ninjected, the effect of the venom depends on the type of venom, quantity, \nlocation of the bite and size and general condition of the victim.\nCause\n \n~\nCommon venomous snakes in Uganda: Puff adder, Gaboon   \nviper, black mambas, Brown Forest cobra, Egyptian cobra \nand Boomslang  (see below images of some of the common \nsnakes in Uganda)\nClinical    features\nLocal symptoms and signs\nGeneralized (systemic) symptoms \nand signs\n \n\u0083 Fang marks\n \n\u0083 Malaise\n \n\u0083 Swelling\n \n\u0083 Local bleeding\n \n\u0083 Pain \n \n\u0083 Blistering\n \n\u0083 Redness \n \n\u0083 Skin discoloration \n(necrosis)\n \n\u0083 Vomiting\n \n\u0083 Difficulty in breathing\n \n\u0083 Abdominal pain \n \n\u0083 Weakness\n \n\u0083 Loss of consciousness \n \n\u0083 Confusion \n \n\u0083 Shock\nIf cytotoxic venom (Puff adder, Gaboon viper)\n \n~\nExtensive local swelling, pain, lymphadenopathy \u2013 starting \n10-30 minutes after the bite.\n28\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Caution</p>\n<p>\u0089</p>\n<p>Do not suture bite wounds</p>\n<li>.2.1.1  Snakebites</li>\n<p>Snakebites can cause both local and systemic effects. Non-venomous</p>\n<p>snakes cause local effects (swelling, redness, laceration) and venomous</p>\n<p>snakes cause both local and systemic effects due to envenomation.  Over</p>\n<p>70% of snakes in Uganda are non-venomous and most bites are from</p>\n<p>non-venomous snakes. Of the venomous snakes, more than 50% of</p>\n<p>bites are \u201cdry\u201d i.e. no envenomation occurs. In the event that venom is</p>\n<p>injected, the effect of the venom depends on the type of venom, quantity,</p>\n<p>location of the bite and size and general condition of the victim.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Common venomous snakes in Uganda: Puff adder, Gaboon</p>\n<p>viper, black mambas, Brown Forest cobra, Egyptian cobra</p>\n<p>and Boomslang  (see below images of some of the common</p>\n<p>snakes in Uganda)</p>\n<p>Clinical    features</p>\n<p>Local symptoms and signs</p>\n<p>Generalized (systemic) symptoms</p>\n<p>and signs</p>\n<p>\u0083 Fang marks</p>\n<p>\u0083 Malaise</p>\n<p>\u0083 Swelling</p>\n<p>\u0083 Local bleeding</p>\n<p>\u0083 Pain</p>\n<p>\u0083 Blistering</p>\n<p>\u0083 Redness</p>\n<p>\u0083 Skin discoloration</p>\n<p>(necrosis)</p>\n<p>\u0083 Vomiting</p>\n<p>\u0083 Difficulty in breathing</p>\n<p>\u0083 Abdominal pain</p>\n<p>\u0083 Weakness</p>\n<p>\u0083 Loss of consciousness</p>\n<p>\u0083 Confusion</p>\n<p>\u0083 Shock</p>\n<p>If cytotoxic venom (Puff adder, Gaboon viper)</p>\n<p>~</p>\n<p>Extensive local swelling, pain, lymphadenopathy \u2013 starting</p>\n<p>10-30 minutes after the bite.</p>\n<p>28</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 95,
        "content": "If neurotoxic venom (Jameson\u2019s mamba, Egyptian Cobra, Forest \nCobra, Black mamba)\n \n~\nWeakness, paralysis, difficulty in breathing, drooping eye\u00ad\nlids, difficulty in swallowing, double vision, slurred speech \n\u2013 starting 15-30 minutes after the bite\n \n~\nExcessive sweating and salivation\nIf hemotoxic venom (Boomslang, Vine/Twig snake)\n \n~\nExcessive swelling and oozing from the site\n \n~\nSkin discoloration\n \n~\nExcessive bleeding, bloody blisters\n \n~\nHaematuria, haematemesis \u2013 even after some days\n \n~\nShock\nIf combined venom toxicity \n \n~\nLate appearance of signs and symptoms \nInvestigations\n \n~\n Whole blood clotting test at arrival and every   4-6 hours \nafter the first day: \n \n\u0081\nPut 2-5 ml of blood   in a  dry tube and observe after 30 minutes\n \n\u0081\nIf   incomplete   or no clotting, it indicates coagulation ab\u00ad\nnormalities\n \n~\nOther useful tests depending on severity, level of care and \navailability:\n \n\u0081\nOxygen Saturation/PR/BP/RR\n \n\u0081\nHaemoglobin/PCV/Platelet count/PT/APTT/D-Dimer\n \n\u0081\nBiochemistry for Serum Creatinine/Urea/Potassium\n \n\u0081\nUrine Tests for Proteinuria/Haemoglobinuria/ Myoglobinuria\n \n\u0081\nImaging ECG/X-Ray/Ultrasound\n29\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>If neurotoxic venom (Jameson\u2019s mamba, Egyptian Cobra, Forest</p>\n<p>Cobra, Black mamba)</p>\n<p>~</p>\n<p>Weakness, paralysis, difficulty in breathing, drooping eye\u00ad</p>\n<p>lids, difficulty in swallowing, double vision, slurred speech</p>\n<p>\u2013 starting 15-30 minutes after the bite</p>\n<p>~</p>\n<p>Excessive sweating and salivation</p>\n<p>If hemotoxic venom (Boomslang, Vine/Twig snake)</p>\n<p>~</p>\n<p>Excessive swelling and oozing from the site</p>\n<p>~</p>\n<p>Skin discoloration</p>\n<p>~</p>\n<p>Excessive bleeding, bloody blisters</p>\n<p>~</p>\n<p>Haematuria, haematemesis \u2013 even after some days</p>\n<p>~</p>\n<p>Shock</p>\n<p>If combined venom toxicity</p>\n<p>~</p>\n<p>Late appearance of signs and symptoms</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Whole blood clotting test at arrival and every   4-6 hours</p>\n<p>after the first day:</p>\n<p>\u0081</p>\n<p>Put 2-5 ml of blood   in a  dry tube and observe after 30 minutes</p>\n<p>\u0081</p>\n<p>If   incomplete   or no clotting, it indicates coagulation ab\u00ad</p>\n<p>normalities</p>\n<p>~</p>\n<p>Other useful tests depending on severity, level of care and</p>\n<p>availability:</p>\n<p>\u0081</p>\n<p>Oxygen Saturation/PR/BP/RR</p>\n<p>\u0081</p>\n<p>Haemoglobin/PCV/Platelet count/PT/APTT/D-Dimer</p>\n<p>\u0081</p>\n<p>Biochemistry for Serum Creatinine/Urea/Potassium</p>\n<p>\u0081</p>\n<p>Urine Tests for Proteinuria/Haemoglobinuria/ Myoglobinuria</p>\n<p>\u0081</p>\n<p>Imaging ECG/X-Ray/Ultrasound</p>\n<p>29</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 96,
        "content": "Management\nWhat to do \nWhat not to do\n \n\u0083 Reassure the patient to \nstay calm\n \n\u0083 Lay the patient on the \nside to avoid movement \nof affected areas\n \n\u0083 Remove all tight items \naround the affected area\n \n\u0083 Leave the wound/bite \narea alone\n \n\u0083 Immobilize the patient\n \n\u0083 Do not panic\n \n\u0083 Do not lay the patient on \ntheir back as it may block \nairways\n \n\u0083 Do not apply a tourniquet\n \n\u0083 Do not squeeze or incise the \nwound\n \n\u0083 Do not attempt to suck the \nvenom out\n \n\u0083 Do not try to kill or attack \nthe snake \n \n\u0083 DON\u2019T use traditional \nmethods/herbs\nVenom in eyes\n \n~\nIrrigate eyes with plenty of water\n \n~\nCover with eye pads\nTREATMENT\nLOC\n \n~\nAssess  skin for  fang  penetration\nIf signs of fang penetration\n \n~\nImmobilise limb with a splint\n \n~\nAnalgesic e.g. paracetamol (avoid NSAIDS like \naspirin, diclofenac, ibuprofen)\nIf no signs and symptoms for 6-8 hours: most likely bite \nwithout envenomation\n \n~\nObservation for 12-24 hours recommended\n \n~\nTetanus toxoid (TT) IM 0.5 ml if not previously \nimmunised in the last 10 years\nIf local necrosis develops\n \n~\nRemove blisters, clean and dress daily, debride \nafter lesions stabilise (minimum 15 days)\nHC2\n30\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<p>What to do</p>\n<p>What not to do</p>\n<p>\u0083 Reassure the patient to</p>\n<p>stay calm</p>\n<p>\u0083 Lay the patient on the</p>\n<p>side to avoid movement</p>\n<p>of affected areas</p>\n<p>\u0083 Remove all tight items</p>\n<p>around the affected area</p>\n<p>\u0083 Leave the wound/bite</p>\n<p>area alone</p>\n<p>\u0083 Immobilize the patient</p>\n<p>\u0083 Do not panic</p>\n<p>\u0083 Do not lay the patient on</p>\n<p>their back as it may block</p>\n<p>airways</p>\n<p>\u0083 Do not apply a tourniquet</p>\n<p>\u0083 Do not squeeze or incise the</p>\n<p>wound</p>\n<p>\u0083 Do not attempt to suck the</p>\n<p>venom out</p>\n<p>\u0083 Do not try to kill or attack</p>\n<p>the snake</p>\n<p>\u0083 DON\u2019T use traditional</p>\n<p>methods/herbs</p>\n<p>Venom in eyes</p>\n<p>~</p>\n<p>Irrigate eyes with plenty of water</p>\n<p>~</p>\n<p>Cover with eye pads</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>~</p>\n<p>Assess  skin for  fang  penetration</p>\n<p>If signs of fang penetration</p>\n<p>~</p>\n<p>Immobilise limb with a splint</p>\n<p>~</p>\n<p>Analgesic e.g. paracetamol (avoid NSAIDS like</p>\n<p>aspirin, diclofenac, ibuprofen)</p>\n<p>If no signs and symptoms for 6-8 hours: most likely bite</p>\n<p>without envenomation</p>\n<p>~</p>\n<p>Observation for 12-24 hours recommended</p>\n<p>~</p>\n<p>Tetanus toxoid (TT) IM 0.5 ml if not previously</p>\n<p>immunised in the last 10 years</p>\n<p>If local necrosis develops</p>\n<p>~</p>\n<p>Remove blisters, clean and dress daily, debride</p>\n<p>after lesions stabilise (minimum 15 days)</p>\n<h3>HC2</h3>\n<p>30</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 97,
        "content": "TREATMENT\nLOC\nCriteria for referral for administration of antivenom\n \n~\nSigns of systemic envenoming (paralysis, respiratory dif\u00ad\nficulty, bleeding)\n \n~\nSpreading local damage:\n \n- Swelling of hand or foot (site of most bites) within 1 hour of \nbite\n \n- Swelling of elbow or knee within 3 hours of bite\n \n- Swelling of groin or chest at any time\n \n- Significant swelling of head or neck\n\t\n\u0089\nAntivenom sera polyvalent (Africa)\n \n- Check package insert for IV dosage details. Ensure the \nsolution is clear and check that patient has no history of allergy\nAntibiotics\n\t\n\u0089\nIndicated only if wound is infected\nImages of some common snakes in Uganda\nPuff Adder (Bitis arietans)                         Black Mamba (Dendroaspispolylepis)\nEgyptian cobra (Najahaje)\t                         Black-necked spitting cobra (Najanigricollis)\n31\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Criteria for referral for administration of antivenom</p>\n<p>~</p>\n<p>Signs of systemic envenoming (paralysis, respiratory dif\u00ad</p>\n<p>ficulty, bleeding)</p>\n<p>~</p>\n<p>Spreading local damage:</p>\n<p>- Swelling of hand or foot (site of most bites) within 1 hour of</p>\n<p>bite</p>\n<p>- Swelling of elbow or knee within 3 hours of bite</p>\n<p>- Swelling of groin or chest at any time</p>\n<p>- Significant swelling of head or neck</p>\n<p>\u0089</p>\n<p>Antivenom sera polyvalent (Africa)</p>\n<p>- Check package insert for IV dosage details. Ensure the</p>\n<p>solution is clear and check that patient has no history of allergy</p>\n<p>Antibiotics</p>\n<p>\u0089</p>\n<p>Indicated only if wound is infected</p>\n<p>Images of some common snakes in Uganda</p>\n<p>Puff Adder (Bitis arietans)                         Black Mamba (Dendroaspispolylepis)</p>\n<p>Egyptian cobra (Najahaje)\t                         Black-necked spitting cobra (Najanigricollis)</p>\n<p>31</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 98,
        "content": "Jameson\u2019s mamba (Dendroaspisjamesoni)  Boomslang (Dispholidus typus)\nVine, bird, twig or tree snakes (Thelotornisspp.)  Rhino-horned Viper (Bitis nasicornis)\nEgyptian Cobra (Naja haje)                                  Eastern Forest Cobra (Naja subfulva)\n\n \nRock Python (Python sebae)                                 Gaboon Adder (Bitis gabonica) \n32\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Jameson\u2019s mamba (Dendroaspisjamesoni)  Boomslang (Dispholidus typus)</p>\n<p>Vine, bird, twig or tree snakes (Thelotornisspp.)  Rhino-horned Viper (Bitis nasicornis)</p>\n<p>Egyptian Cobra (Naja haje)                                  Eastern Forest Cobra (Naja subfulva)</p>\n<p>Rock Python (Python sebae)                                 Gaboon Adder (Bitis gabonica)</p>\n<p>32</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 99,
        "content": "Battersby\u2019s green snake (Philothamnus battersbyi)  Olive House Snake (Lycodonomorphis inornatus)\n                    \n1.2.1.2 Insect Bites & Stings                 ICD10 CODE: T63.4\nCauses\n \n~\nBees, wasps, hornets and ants: venom is usually mild and \ncauses only local reaction but may cause anaphylactic \nshock in previously sensitized persons\n \n~\nSpiders and scorpions: Most are non-venomous or only \nmildly venomous\nOther stinging insectsClinical features\n \n~\nSwelling, discolouration, burning sensation, pain at the site \nof the sting\n \n~\nThere may be signs of anaphylactic shock.\nDifferential diagnosis\n \n~\nAllergic reaction\nMANAGEMENT\nLOC\n\t\n\u0089\nIf the sting remains implanted in the skin, carefully remove \nwith a needle or knife blade\n\t\n\u0089\nApply cold water/ice\nIf severe local reaction\nHC2\n33\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Battersby\u2019s green snake (Philothamnus battersbyi)  Olive House Snake (Lycodonomorphis inornatus)</p>\n<li>.2.1.2 Insect Bites & Stings                 ICD10 CODE: T63.4</li>\n<p>Causes</p>\n<p>~</p>\n<p>Bees, wasps, hornets and ants: venom is usually mild and</p>\n<p>causes only local reaction but may cause anaphylactic</p>\n<p>shock in previously sensitized persons</p>\n<p>~</p>\n<p>Spiders and scorpions: Most are non-venomous or only</p>\n<p>mildly venomous</p>\n<p>Other stinging insectsClinical features</p>\n<p>~</p>\n<p>Swelling, discolouration, burning sensation, pain at the site</p>\n<p>of the sting</p>\n<p>~</p>\n<p>There may be signs of anaphylactic shock.</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Allergic reaction</p>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If the sting remains implanted in the skin, carefully remove</p>\n<p>with a needle or knife blade</p>\n<p>\u0089</p>\n<p>Apply cold water/ice</p>\n<p>If severe local reaction</p>\n<h3>HC2</h3>\n<p>33</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 100,
        "content": "MANAGEMENT\nLOC\n\t\n\u0089\nGive chlorpheniramine 4 mg every 6 hours (max: 24 \nmg daily) until swelling subsides Child 1-2 years: 1 mg \nevery 12 hours\nChild 2-5 years: 1 mg every 6 hours (max: 6 mg daily)\nChild 6-12 years: 2 mg every 6 hours (max: 12 mg daily)\n\t\n\u0089\nApply calamine lotion prn every 6 hours\nIf very painful scorpion sting\n\t\n\u0089\nInfiltrate 2 ml of lignocaine 2% around the area of the bite\nIf signs of systemic envenomation\n\t\n\u0089\nRefer\nHC2\nPrevention\n \n~\nClear overgrown vegetation/bushes around the home\n \n~\nPrevent children from playing in the bush\n \n~\nCover exposed skin while moving in the bush\n \n~\nUse pest control methods to clear insect colonies.\n1.2.1.3  Animal and Human Bites             ICD10 CODE: W50.3, W54.0\nClinical features\n \n~\nTeeth marks or scratches, lacerations\n \n~\nPuncture wounds (especially cats)\n \n~\nComplications: bleeding, lesions of deep structures, wound \ninfection (by mixed flora, anaerobs), tissue necrosis, trans\u00ad\nmission of diseases (tetanus, rabies, others)\nMANAGEMENT\nLOC\nFirst aid\n\t\n\u0089\nImmediately clean the wound thoroughly with plenty of \nclean water and soap to remove any dirt or foreign bodies\nHC2\n34\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give chlorpheniramine 4 mg every 6 hours (max: 24</p>\n<p>mg daily) until swelling subsides Child 1-2 years: 1 mg</p>\n<p>every 12 hours</p>\n<p>Child 2-5 years: 1 mg every 6 hours (max: 6 mg daily)</p>\n<p>Child 6-12 years: 2 mg every 6 hours (max: 12 mg daily)</p>\n<p>\u0089</p>\n<p>Apply calamine lotion prn every 6 hours</p>\n<p>If very painful scorpion sting</p>\n<p>\u0089</p>\n<p>Infiltrate 2 ml of lignocaine 2% around the area of the bite</p>\n<p>If signs of systemic envenomation</p>\n<p>\u0089</p>\n<p>Refer</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Clear overgrown vegetation/bushes around the home</p>\n<p>~</p>\n<p>Prevent children from playing in the bush</p>\n<p>~</p>\n<p>Cover exposed skin while moving in the bush</p>\n<p>~</p>\n<p>Use pest control methods to clear insect colonies.</p>\n<li>.2.1.3  Animal and Human Bites             ICD10 CODE: W50.3, W54.0</li>\n<p>Clinical features</p>\n<p>~</p>\n<p>Teeth marks or scratches, lacerations</p>\n<p>~</p>\n<p>Puncture wounds (especially cats)</p>\n<p>~</p>\n<p>Complications: bleeding, lesions of deep structures, wound</p>\n<p>infection (by mixed flora, anaerobs), tissue necrosis, trans\u00ad</p>\n<p>mission of diseases (tetanus, rabies, others)</p>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>First aid</p>\n<p>\u0089</p>\n<p>Immediately clean the wound thoroughly with plenty of</p>\n<p>clean water and soap to remove any dirt or foreign bodies</p>\n<h3>HC2</h3>\n<p>34</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 101,
        "content": "MANAGEMENT\nLOC\n\t\n\u0089\nStop excessive bleeding where necessary by applying \npressure\n\t\n\u0089\nRinse the wound and allow to dry\n\t\n\u0089\nApply an antiseptic: Chlorhexidine solution 0.05% or \npovidone iodine solution 10%\n\t\n\u0089\nSoak punture wounds in antiseptic for 15 minutes\n\t\n\u0089\nThorough cleaning, exploration and debridement (under \nlocal anesthesia if possible)\nAs a general rule\nDO NOT SUTURE BITE WOUNDS\n\t\n\u0089\nRefer wounds on hands and face, deep wounds, wounds \nwith tissue defects to hospital for surgical management\nTetanus prophylaxis\n\t\n\u0089\nGive TT immunisation (tetanus toxoid, TT 0.5 ml) if not \npreviously immunised within the last 10 years\nHC2\nHC4\nProphylactic antibiotics\n\t\n\u0089\nIndicated in the following situations:\n \n- Deep puncture wounds (especially Cats)\n \n- Human bites\n \n- Severe (deep, extensive) wounds\n \n- Wounds on face, genitalia, hands\n \n- Wounds in immunicompromised hosts\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours for 5-7 days\nChild: 15 mg/kg per dose\n\t\n\u0089\nPlus Metronidazole 400 mg every 12 hours\nChild: 10-12.5 mg/kg per dose\nHC2\nNote\n \n\u0083 Do not use routine antibiotics for small uncomplicated dog \nbites/wounds\n35\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stop excessive bleeding where necessary by applying</p>\n<p>pressure</p>\n<p>\u0089</p>\n<p>Rinse the wound and allow to dry</p>\n<p>\u0089</p>\n<p>Apply an antiseptic: Chlorhexidine solution 0.05% or</p>\n<p>povidone iodine solution 10%</p>\n<p>\u0089</p>\n<p>Soak punture wounds in antiseptic for 15 minutes</p>\n<p>\u0089</p>\n<p>Thorough cleaning, exploration and debridement (under</p>\n<p>local anesthesia if possible)</p>\n<p>As a general rule</p>\n<h3>DO NOT SUTURE BITE WOUNDS</h3>\n<p>\u0089</p>\n<p>Refer wounds on hands and face, deep wounds, wounds</p>\n<p>with tissue defects to hospital for surgical management</p>\n<p>Tetanus prophylaxis</p>\n<p>\u0089</p>\n<p>Give TT immunisation (tetanus toxoid, TT 0.5 ml) if not</p>\n<p>previously immunised within the last 10 years</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Prophylactic antibiotics</p>\n<p>\u0089</p>\n<p>Indicated in the following situations:</p>\n<p>- Deep puncture wounds (especially Cats)</p>\n<p>- Human bites</p>\n<p>- Severe (deep, extensive) wounds</p>\n<p>- Wounds on face, genitalia, hands</p>\n<p>- Wounds in immunicompromised hosts</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours for 5-7 days</p>\n<p>Child: 15 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Plus Metronidazole 400 mg every 12 hours</p>\n<p>Child: 10-12.5 mg/kg per dose</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>\u0083 Do not use routine antibiotics for small uncomplicated dog</p>\n<p>bites/wounds</p>\n<p>35</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 102,
        "content": "1.2.1.4  Rabies Post Exposure Prophylaxis           ICD10 CODE: \nZ20.3, Z23\nPost exposure prophylaxis effectively prevents the development of rabies \nafter the contact with saliva of infected animals, through bites, scratches, \nlicks on broken skin or mucous membranes. For further details refer to \nRabies Post-Exposure Treatment Guidelines, Veterinary Public Health \nUnit, Community Health Dept, Ministry of Health, September 2001\nGeneral management\nDealing with the animal\nTREATMENT\nLOC\nIf the animal can be identified and caught \n\t\n\u0089\nIf domestic, confirm rabies vaccination \n\t\n\u0089\nIf no information on rabies vaccination or\nHC2\nIf the animal can be identified and caught \n\t\n\u0089\nIf domestic, confirm rabies vaccination \n\t\n\u0089\nIf no information on rabies vaccination or\nwild: quarantine for 10 days (only dogs, cats or endangered \nspecies) or kill humanely andsend the head to the veterinary \nDepartment for analysis\n \n\u0083 If no signs of rabies infection shown within 10\n \n\u0083 days: release the animal, stop immunisation\n \n\u0083 If it shows signs of rabies infection: kill the animal, \nremove its head, and send to the Veterinary \nDepartment for verification of the infection\nIf animal cannot be identified\n\t\n\u0089\nPresume animal infected and patient at risk\nHC2\nNotes\n \n\u0083 Consumption of properly cooked rabid meat is not harmful\n \n\u0083 Animals at risk: dogs, cats, bats, other wild carnivores\n \n\u0083 Non-mammals cannot harbour rabies\n36\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.2.1.4  Rabies Post Exposure Prophylaxis           ICD10 CODE:</li>\n<h3>Z20.3, Z23</h3>\n<p>Post exposure prophylaxis effectively prevents the development of rabies</p>\n<p>after the contact with saliva of infected animals, through bites, scratches,</p>\n<p>licks on broken skin or mucous membranes. For further details refer to</p>\n<p>Rabies Post-Exposure Treatment Guidelines, Veterinary Public Health</p>\n<p>Unit, Community Health Dept, Ministry of Health, September 2001</p>\n<p>General management</p>\n<p>Dealing with the animal</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If the animal can be identified and caught</p>\n<p>\u0089</p>\n<p>If domestic, confirm rabies vaccination</p>\n<p>\u0089</p>\n<p>If no information on rabies vaccination or</p>\n<h3>HC2</h3>\n<p>If the animal can be identified and caught</p>\n<p>\u0089</p>\n<p>If domestic, confirm rabies vaccination</p>\n<p>\u0089</p>\n<p>If no information on rabies vaccination or</p>\n<p>wild: quarantine for 10 days (only dogs, cats or endangered</p>\n<p>species) or kill humanely andsend the head to the veterinary</p>\n<p>Department for analysis</p>\n<p>\u0083 If no signs of rabies infection shown within 10</p>\n<p>\u0083 days: release the animal, stop immunisation</p>\n<p>\u0083 If it shows signs of rabies infection: kill the animal,</p>\n<p>remove its head, and send to the Veterinary</p>\n<p>Department for verification of the infection</p>\n<p>If animal cannot be identified</p>\n<p>\u0089</p>\n<p>Presume animal infected and patient at risk</p>\n<h3>HC2</h3>\n<p>Notes</p>\n<p>\u0083 Consumption of properly cooked rabid meat is not harmful</p>\n<p>\u0083 Animals at risk: dogs, cats, bats, other wild carnivores</p>\n<p>\u0083 Non-mammals cannot harbour rabies</p>\n<p>36</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 103,
        "content": "Dealing with the patient\n \n~\nThe combination of local wound treatment plus passive \nimmunisation with rabies immunoglobulin (RIG) plus vac\u00ad\ncination with rabies vaccine (RV) is recommended for all \nsuspected exposures to rabies\n \n~\nif the RI is not available, the patient should still be vaccinat\u00ad\ned with the Rabies Vaccine alone\n \n~\nSince prolonged rabies incubation periods are possible, \npersons who present for evaluation and treatment even \nmonths after having been bitten should be treated in the \nsame way as if the contact occurred recently\n \n~\nAdministration of Rabies IG and vaccine depends on the \ntype of exposure and the animal\u2019s condition\nTREATMENT\nLOC\n\t\n\u0089\nLOCAL WOUND TREATMENT: Prompt and thorough \nlocal treatment is an effective method to reduce risk of \ninfection\n\t\n\u0089\nFor mucous mebranes contact, rinse throroughly with \nwater or normal saline\n \n~\nif the wound is deep Tetanus Toxoid (TT) should \nbe given as well to prevent tetanus\nHC2\n\t\n\u0089\nLocal cleansing is indicated even if the patient presents late\n\t\n\u0089\nDO NOT SUTURE THE WOUND\nIf Veterinary Department confirms rabies infection or if \nanimal cannot be identified/tested\n\t\n\u0089\nGive rabies vaccine+/- rabies immunoglobulin human \nas per the recommendations in the next table.\nH\n37\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Dealing with the patient</p>\n<p>~</p>\n<p>The combination of local wound treatment plus passive</p>\n<p>immunisation with rabies immunoglobulin (RIG) plus vac\u00ad</p>\n<p>cination with rabies vaccine (RV) is recommended for all</p>\n<p>suspected exposures to rabies</p>\n<p>~</p>\n<p>if the RI is not available, the patient should still be vaccinat\u00ad</p>\n<p>ed with the Rabies Vaccine alone</p>\n<p>~</p>\n<p>Since prolonged rabies incubation periods are possible,</p>\n<p>persons who present for evaluation and treatment even</p>\n<p>months after having been bitten should be treated in the</p>\n<p>same way as if the contact occurred recently</p>\n<p>~</p>\n<p>Administration of Rabies IG and vaccine depends on the</p>\n<p>type of exposure and the animal\u2019s condition</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>LOCAL WOUND TREATMENT: Prompt and thorough</p>\n<p>local treatment is an effective method to reduce risk of</p>\n<p>infection</p>\n<p>\u0089</p>\n<p>For mucous mebranes contact, rinse throroughly with</p>\n<p>water or normal saline</p>\n<p>~</p>\n<p>if the wound is deep Tetanus Toxoid (TT) should</p>\n<p>be given as well to prevent tetanus</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Local cleansing is indicated even if the patient presents late</p>\n<p>\u0089</p>\n<h3>DO NOT SUTURE THE WOUND</h3>\n<p>If Veterinary Department confirms rabies infection or if</p>\n<p>animal cannot be identified/tested</p>\n<p>\u0089</p>\n<p>Give rabies vaccine+/- rabies immunoglobulin human</p>\n<p>as per the recommendations in the next table.</p>\n<p>H</p>\n<p>37</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 104,
        "content": "Recommendations for Rabies Vaccination/Serum\n \nCondition Of Animal\nNature Of \nExposure\nAt Time Of \nExposure\n10 Days \nLater\nRecommended \nAction\nSaliva in contact \nwith skin but no \nskin lesion\nHealthy\nHealthy\nDo not vaccinate\nRabid\nVaccinate\nSuspect/ \nUnknown\nHealthy\nDo not vaccinate\nRabid\nVaccinate\nUnknown\nVaccinate\nSaliva in \ncontact with \nskin that has \nlesions, minor \nbites on trunk \nor proximal \nlimbs\nHealthy\nHealthy\nDo not vaccinate\nRabid\nVaccinate\nSuspect/ \nunknown\nHealthy\nVaccinate; but \nstop course if \nanimal healthy \nafter 10 days\nRabid\nVaccinate\nUnknown\nVaccinate\nSaliva in contact \nwith mucosae, \nserious bites \n(face, head, fin\u00ad\ngers or multiple \nbites)\nDomestic or \nwild rabid ani\u00ad\nmal or suspect\nSuspect\nVaccinate and give \nantirabies immu\u00ad\nnoglobulin\nDomestic or \nwild rabid ani\u00ad\nmal or Suspect\nVaccinate but \nstop course if \nanimal healthy \nafter 10 days\nPrevention\n \n~\nVaccinate all domestic animals against rabies e.g. dogs, \ncats and others\n38\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Recommendations for Rabies Vaccination/Serum</p>\n<p>Condition Of Animal</p>\n<p>Nature Of</p>\n<p>Exposure</p>\n<p>At Time Of</p>\n<p>Exposure</p>\n<p>10 Days</p>\n<p>Later</p>\n<p>Recommended</p>\n<p>Action</p>\n<p>Saliva in contact</p>\n<p>with skin but no</p>\n<p>skin lesion</p>\n<p>Healthy</p>\n<p>Healthy</p>\n<p>Do not vaccinate</p>\n<p>Rabid</p>\n<p>Vaccinate</p>\n<p>Suspect/</p>\n<p>Unknown</p>\n<p>Healthy</p>\n<p>Do not vaccinate</p>\n<p>Rabid</p>\n<p>Vaccinate</p>\n<p>Unknown</p>\n<p>Vaccinate</p>\n<p>Saliva in</p>\n<p>contact with</p>\n<p>skin that has</p>\n<p>lesions, minor</p>\n<p>bites on trunk</p>\n<p>or proximal</p>\n<p>limbs</p>\n<p>Healthy</p>\n<p>Healthy</p>\n<p>Do not vaccinate</p>\n<p>Rabid</p>\n<p>Vaccinate</p>\n<p>Suspect/</p>\n<p>unknown</p>\n<p>Healthy</p>\n<p>Vaccinate; but</p>\n<p>stop course if</p>\n<p>animal healthy</p>\n<p>after 10 days</p>\n<p>Rabid</p>\n<p>Vaccinate</p>\n<p>Unknown</p>\n<p>Vaccinate</p>\n<p>Saliva in contact</p>\n<p>with mucosae,</p>\n<p>serious bites</p>\n<p>(face, head, fin\u00ad</p>\n<p>gers or multiple</p>\n<p>bites)</p>\n<p>Domestic or</p>\n<p>wild rabid ani\u00ad</p>\n<p>mal or suspect</p>\n<p>Suspect</p>\n<p>Vaccinate and give</p>\n<p>antirabies immu\u00ad</p>\n<p>noglobulin</p>\n<p>Domestic or</p>\n<p>wild rabid ani\u00ad</p>\n<p>mal or Suspect</p>\n<p>Vaccinate but</p>\n<p>stop course if</p>\n<p>animal healthy</p>\n<p>after 10 days</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Vaccinate all domestic animals against rabies e.g. dogs,</p>\n<p>cats and others</p>\n<p>38</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 105,
        "content": "Administration of Rabies Vaccine (RV)\nThe following schedules use Purified VERO Cell Culture Rabies Vaccine \n(PVRV), which contains one intramuscular immunising dose (at least 2.5 \nIU) in 0.5 ml of reconstituted vaccine.\nRV and RIG are both very expensive and should only be used \nwhen there is an absolute indication\nPost-Exposure Vaccination in Non-Previously Vaccinated Patients\nGive RV to all patients unvaccinated against rabies together with local \nwound treatment. In severe cases, also give rabies immunoglobulin\nThe 2-1-1 intramuscular regimen\nThis induces an early antibody response and may be particularly ef\u00ad\nfective when post-exposure treatment does not include administration \nof rabies immunoglobulins \n\t\n\u0089\nDay 0: One dose (0.5 ml) in right arm + one dose in left arm \n\t\n\u0089\nDay 7: One dose\n\t\n\u0089\nDay 21: One dose\nNotes on IM doses\n \n\u0083 Doses are given into the deltoid muscle of the arm. In young \nchildren, the anterolateral thigh may also be used\n \n\u0083 Never use the gluteal area (buttock) as fat deposits may interfere \nwith vaccine uptake making it less effective.\nAlternative: 2-site intradermal (ID) regimen \n\t\n\u0089\nThis uses PVRV intradermal (ID) doses of 0.1 ml (i.e. one fifth \nof the 0.5 ml IM dose of PVRV) \n\t\n\u0089\nDay 0: one dose of 0.1 ml in each arm (deltoid) \n\t\n\u0089\nDay 3: one dose of 0.1 ml in each arm\n39\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Administration of Rabies Vaccine (RV)</p>\n<p>The following schedules use Purified VERO Cell Culture Rabies Vaccine</p>\n<p>(PVRV), which contains one intramuscular immunising dose (at least 2.5</p>\n<p>IU) in 0.5 ml of reconstituted vaccine.</p>\n<p>RV and RIG are both very expensive and should only be used</p>\n<p>when there is an absolute indication</p>\n<p>Post-Exposure Vaccination in Non-Previously Vaccinated Patients</p>\n<p>Give RV to all patients unvaccinated against rabies together with local</p>\n<p>wound treatment. In severe cases, also give rabies immunoglobulin</p>\n<p>The 2-1-1 intramuscular regimen</p>\n<p>This induces an early antibody response and may be particularly ef\u00ad</p>\n<p>fective when post-exposure treatment does not include administration</p>\n<p>of rabies immunoglobulins</p>\n<p>\u0089</p>\n<p>Day 0: One dose (0.5 ml) in right arm + one dose in left arm</p>\n<p>\u0089</p>\n<p>Day 7: One dose</p>\n<p>\u0089</p>\n<p>Day 21: One dose</p>\n<p>Notes on IM doses</p>\n<p>\u0083 Doses are given into the deltoid muscle of the arm. In young</p>\n<p>children, the anterolateral thigh may also be used</p>\n<p>\u0083 Never use the gluteal area (buttock) as fat deposits may interfere</p>\n<p>with vaccine uptake making it less effective.</p>\n<p>Alternative: 2-site intradermal (ID) regimen</p>\n<p>\u0089</p>\n<p>This uses PVRV intradermal (ID) doses of 0.1 ml (i.e. one fifth</p>\n<p>of the 0.5 ml IM dose of PVRV)</p>\n<p>\u0089</p>\n<p>Day 0: one dose of 0.1 ml in each arm (deltoid)</p>\n<p>\u0089</p>\n<p>Day 3: one dose of 0.1 ml in each arm</p>\n<p>39</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 106,
        "content": "\u0089\nDay 3: one dose of 0.1 ml in each arm\n\t\n\u0089\nDay 7: one dose of 0.1 ml in each arm\n\t\n\u0089\nDay 28: one dose of 0.1 ml in each arm\nNotes on ID regime\n \n\u0083 Much cheaper as it requires less vaccine\n \n\u0083 Requires special staff training in ID technique using 1 ml syringes \nand short needles\n \n\u0083 Compliance with the Day 28 is vital but may be difficult to \nachieve\n \n\u0083 Patients must be followed up for at least 6-18 months to confirm \nthe outcome of treatment\n \n\u0083 If on malaria chemoprophylaxis, do NOT use.\nPost-exposure immunisation in previously vaccinated patients\nIn persons known to have previously received full pre- or post-exposure \nrabies vaccination within the last 3 years\nIntramuscular regimen \n\t\n\u0089\nDay 0: One booster dose IM \n\t\n\u0089\nDay 3: One booster dose IM\nIntradermal regimen\n\t\n\u0089\nDay 0: One booster dose ID\n\t\n\u0089\nDay 3: One booster dose ID\nNote\n \n\u0083 If incompletely vaccinated or immunosuppressed: give full post \nexposure regimen.\nPassive immunisation with rabies immunoglobulin (RIG) Give in all high-risk ra\u00ad\nbies cases irrespective of the time between exposure and start of treatment \nBUT within 7 days of first vaccine.DO NOT USE in patient previously immunised.\n40\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>\u0089</p>\n<p>Day 3: one dose of 0.1 ml in each arm</p>\n<p>\u0089</p>\n<p>Day 7: one dose of 0.1 ml in each arm</p>\n<p>\u0089</p>\n<p>Day 28: one dose of 0.1 ml in each arm</p>\n<p>Notes on ID regime</p>\n<p>\u0083 Much cheaper as it requires less vaccine</p>\n<p>\u0083 Requires special staff training in ID technique using 1 ml syringes</p>\n<p>and short needles</p>\n<p>\u0083 Compliance with the Day 28 is vital but may be difficult to</p>\n<p>achieve</p>\n<p>\u0083 Patients must be followed up for at least 6-18 months to confirm</p>\n<p>the outcome of treatment</p>\n<p>\u0083 If on malaria chemoprophylaxis, do NOT use.</p>\n<p>Post-exposure immunisation in previously vaccinated patients</p>\n<p>In persons known to have previously received full pre- or post-exposure</p>\n<p>rabies vaccination within the last 3 years</p>\n<p>Intramuscular regimen</p>\n<p>\u0089</p>\n<p>Day 0: One booster dose IM</p>\n<p>\u0089</p>\n<p>Day 3: One booster dose IM</p>\n<p>Intradermal regimen</p>\n<p>\u0089</p>\n<p>Day 0: One booster dose ID</p>\n<p>\u0089</p>\n<p>Day 3: One booster dose ID</p>\n<p>Note</p>\n<p>\u0083 If incompletely vaccinated or immunosuppressed: give full post</p>\n<p>exposure regimen.</p>\n<p>Passive immunisation with rabies immunoglobulin (RIG) Give in all high-risk ra\u00ad</p>\n<p>bies cases irrespective of the time between exposure and start of treatment</p>\n<p>BUT within 7 days of first vaccine.DO NOT USE in patient previously immunised.</p>\n<p>40</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 107,
        "content": "Human rabies immunoglobulin (HRIG)\n\t\n\u0089\nHRIG 20 IU/kg (do not exceed)\n \n- Infiltrate as much as possible of this dose around the wound/s \n(if multiple wounds and insufficient quantity, dilute it 2 to 3 \nfold with normal saline)\n \n- Give the remainder IM into gluteal muscle\n \n- Follow this with a complete course of rabies vaccine\n \n- The first dose of vaccine should be given at the same time \nas the immunoglobulin, but at a site as far away as possible \nfrom the site where the vaccine was injected. If the bite is at \nor near the upper arm, do not infiltrate the wound with the \nimmunoglobulin unless the vaccine won\u2019t be injected in the \ndeltoid muscle of that arm. If the wound near the deltoid is \ninfiltrated with the immunoglobulin, use the deltoid muscle of \nthe opposite arm for the vaccine\u201d.\nNotes\n \n\u0083 If RIG not available at first visit, its administration can be delayed \nup to 7 days after the first dose of vaccine.\nPre-exposure immunisation\nOffer rabies vaccine to persons at high risk of exposure such as:\n\t\n\u0089\nLaboratory staff working with rabies virus\n\t\n\u0089\nVeterinarians\n\t\n\u0089\nAnimal handlers\n\t\n\u0089\nZoologists/wildlife officers\n\t\n\u0089\nAny other persons considered to be at high risk\n\t\n\u0089\nDay 0: One dose IM or ID \n\t\n\u0089\nDay 7: One dose IM or ID \n\t\n\u0089\n Day 28: One dose IM or ID\n41\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Human rabies immunoglobulin (HRIG)</p>\n<p>\u0089</p>\n<p>HRIG 20 IU/kg (do not exceed)</p>\n<p>- Infiltrate as much as possible of this dose around the wound/s</p>\n<p>(if multiple wounds and insufficient quantity, dilute it 2 to 3</p>\n<p>fold with normal saline)</p>\n<p>- Give the remainder IM into gluteal muscle</p>\n<p>- Follow this with a complete course of rabies vaccine</p>\n<p>- The first dose of vaccine should be given at the same time</p>\n<p>as the immunoglobulin, but at a site as far away as possible</p>\n<p>from the site where the vaccine was injected. If the bite is at</p>\n<p>or near the upper arm, do not infiltrate the wound with the</p>\n<p>immunoglobulin unless the vaccine won\u2019t be injected in the</p>\n<p>deltoid muscle of that arm. If the wound near the deltoid is</p>\n<p>infiltrated with the immunoglobulin, use the deltoid muscle of</p>\n<p>the opposite arm for the vaccine\u201d.</p>\n<p>Notes</p>\n<p>\u0083 If RIG not available at first visit, its administration can be delayed</p>\n<p>up to 7 days after the first dose of vaccine.</p>\n<p>Pre-exposure immunisation</p>\n<p>Offer rabies vaccine to persons at high risk of exposure such as:</p>\n<p>\u0089</p>\n<p>Laboratory staff working with rabies virus</p>\n<p>\u0089</p>\n<p>Veterinarians</p>\n<p>\u0089</p>\n<p>Animal handlers</p>\n<p>\u0089</p>\n<p>Zoologists/wildlife officers</p>\n<p>\u0089</p>\n<p>Any other persons considered to be at high risk</p>\n<p>\u0089</p>\n<p>Day 0: One dose IM or ID</p>\n<p>\u0089</p>\n<p>Day 7: One dose IM or ID</p>\n<p>\u0089</p>\n<p>Day 28: One dose IM or ID</p>\n<p>41</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 108,
        "content": "1.2.1.5 Rabies Vaccine Schedules\nDAY\nVaccine \nDose\nNo. of Doses\n Comments \nIntramuscular Regimen\n0\n0.5ml\n2 (one in each \ndeltoid) \nInto the deltoid muscle\nNEVER IN THE GLUTEAL MUS\u00ad\nCLE (buttocks)\nChildren with less muscle mass: \nAnterolateral aspect of the thigh\nNote: Day 14 is skipped\nThe 2:1:1 regimen uses 4doses in \n3weeks\nIt has fewer patient appointments \nand it is easy to comply with\nIf the patient is on anti-malarial \nprophylaxis with Chloroquine, it \nshould be withheld and an alterna\u00ad\ntive malaria prophylaxis should be \nstarted if needed.  \n7\n0.5ml\n1\n21\n0.5ml\n1\n2-site Intradermal (ID) Regimen\n0\n0.1ml\n2 (one in each \ndeltoid)\nIt is cheaper since it uses less drug\nIt requires special staff training in ID \ntechnique using 1ml syringes with \nshorter needles\nNote: Days 14 and 21 are skipped \n3\n0.1ml\n2 (one in each \ndeltoid)\n7\n0.1ml\n2 (one in each \ndeltoid)\n28\n0.1ml\n2 (one in each \ndeltoid)\nRabies Immunoglobulin\n42\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.2.1.5 Rabies Vaccine Schedules</li>\n<h3>DAY</h3>\n<p>Vaccine</p>\n<p>Dose</p>\n<p>No. of Doses</p>\n<p>Comments</p>\n<p>Intramuscular Regimen</p>\n<p>0</p>\n<p>0.5ml</p>\n<p>2 (one in each</p>\n<p>deltoid)</p>\n<p>Into the deltoid muscle</p>\n<h3>NEVER IN THE GLUTEAL MUS\u00ad</h3>\n<p>CLE (buttocks)</p>\n<p>Children with less muscle mass:</p>\n<p>Anterolateral aspect of the thigh</p>\n<p>Note: Day 14 is skipped</p>\n<p>The 2:1:1 regimen uses 4doses in</p>\n<p>3weeks</p>\n<p>It has fewer patient appointments</p>\n<p>and it is easy to comply with</p>\n<p>If the patient is on anti-malarial</p>\n<p>prophylaxis with Chloroquine, it</p>\n<p>should be withheld and an alterna\u00ad</p>\n<p>tive malaria prophylaxis should be</p>\n<p>started if needed.</p>\n<p>7</p>\n<p>0.5ml</p>\n<p>1</p>\n<p>21</p>\n<p>0.5ml</p>\n<p>1</p>\n<p>2-site Intradermal (ID) Regimen</p>\n<p>0</p>\n<p>0.1ml</p>\n<p>2 (one in each</p>\n<p>deltoid)</p>\n<p>It is cheaper since it uses less drug</p>\n<p>It requires special staff training in ID</p>\n<p>technique using 1ml syringes with</p>\n<p>shorter needles</p>\n<p>Note: Days 14 and 21 are skipped</p>\n<p>3</p>\n<p>0.1ml</p>\n<p>2 (one in each</p>\n<p>deltoid)</p>\n<p>7</p>\n<p>0.1ml</p>\n<p>2 (one in each</p>\n<p>deltoid)</p>\n<p>28</p>\n<p>0.1ml</p>\n<p>2 (one in each</p>\n<p>deltoid)</p>\n<p>Rabies Immunoglobulin</p>\n<p>42</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 109,
        "content": "DAY\nVaccine \nDose\nNo. of Doses\n Comments \nDAYS Immu\u00ad\nnoglob\u00ad\nulin \ndose\nNumber of \ndoses \nComments \n0\n20IU/\nkg\nInfiltrate in the \narea around \nand in t he \nwound at the \nsame depth as \nthe wound\nThe Immunoglobulin should be ad\u00ad\nministered as far as possible from the \nvaccine to avoid antibody-antigen \nreaction \n1.2.2 Fractures                      ICD10 CODE: S00-T88 \nA fracture is a complete or incomplete break in a bone.  \nCauses\n \n~\nTrauma e.g. road traffic accident, assault, falls, sports\n \n~\nBone weakening by disease, e.g., cancer, TB, osteomyeli\u00ad\ntis, osteoporosis\nClinical features\n \n~\nPain, tenderness, swelling, deformity\n \n~\nInability to use/move the affected part\n \n~\nMay be open (with a wound) or closed\nDifferential diagnosis\n \n~\nSprain, dislocations\n \n~\nInfection (bone, joints and muscles)\n \n~\nBone cancer\n43\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>DAY</h3>\n<p>Vaccine</p>\n<p>Dose</p>\n<p>No. of Doses</p>\n<p>Comments</p>\n<p>DAYS Immu\u00ad</p>\n<p>noglob\u00ad</p>\n<p>ulin</p>\n<p>dose</p>\n<p>Number of</p>\n<p>doses</p>\n<p>Comments</p>\n<p>0</p>\n<h3>20IU/</h3>\n<p>kg</p>\n<p>Infiltrate in the</p>\n<p>area around</p>\n<p>and in t he</p>\n<p>wound at the</p>\n<p>same depth as</p>\n<p>the wound</p>\n<p>The Immunoglobulin should be ad\u00ad</p>\n<p>ministered as far as possible from the</p>\n<p>vaccine to avoid antibody-antigen</p>\n<p>reaction</p>\n<li>.2.2 Fractures                      ICD10 CODE: S00-T88</li>\n<p>A fracture is a complete or incomplete break in a bone.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Trauma e.g. road traffic accident, assault, falls, sports</p>\n<p>~</p>\n<p>Bone weakening by disease, e.g., cancer, TB, osteomyeli\u00ad</p>\n<p>tis, osteoporosis</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pain, tenderness, swelling, deformity</p>\n<p>~</p>\n<p>Inability to use/move the affected part</p>\n<p>~</p>\n<p>May be open (with a wound) or closed</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Sprain, dislocations</p>\n<p>~</p>\n<p>Infection (bone, joints and muscles)</p>\n<p>~</p>\n<p>Bone cancer</p>\n<p>43</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 110,
        "content": "Investigations\n \n\u0081\nX-ray: 2 views (AP and lateral) including the joints above and below\nManagement\nSuspected fractures should be referred to HC4 or Hospital after initial care.\nTREATMENT\nLOC\nIf polytrauma\n\t\n\u0089\nAssess and manage airways\n\t\n\u0089\nAssess and treat shock (see section 1.1.2)\nClosed fractures\n\t\n\u0089\nAssess nerve and blood supply distal to the injury: if \nno sensation/pulse, refer as an emergency\n\t\n\u0089\nImmobilise the affected part with a splint\n\t\n\u0089\nApply ice or cold compresses\n\t\n\u0089\nElevate any involved limb\nHC2\n\t\n\u0089\nGive Tetanus Toxoid if not fully vaccinated \n\t\n\u0089\nStart antibiotic\n \n-  Amoxicillin 500 mg every 8 hours\n \n- Child: 25 mg/kg every 8 hours (or 40 mg/kg \nevery 12 hours)\nIf severe soft tissue damage\n\t\n\u0089\nAdd gentamicin 2.5 mg/kg every 8 hours\n\t\n\u0089\nRefer URGENTLY to hospital for further management\nHC3\nNote\n \n\u0083 Treat sprains, strains and dislocations as above\nNote\n \n\u0083 Treat sprains, strains and dislocations as above\nCaution\n \n\u0083 Do not give pethidine and morphine for rib fractures and head \ninjuries as they cause respiratory depression\n44\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>X-ray: 2 views (AP and lateral) including the joints above and below</p>\n<p>Management</p>\n<p>Suspected fractures should be referred to HC4 or Hospital after initial care.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If polytrauma</p>\n<p>\u0089</p>\n<p>Assess and manage airways</p>\n<p>\u0089</p>\n<p>Assess and treat shock (see section 1.1.2)</p>\n<p>Closed fractures</p>\n<p>\u0089</p>\n<p>Assess nerve and blood supply distal to the injury: if</p>\n<p>no sensation/pulse, refer as an emergency</p>\n<p>\u0089</p>\n<p>Immobilise the affected part with a splint</p>\n<p>\u0089</p>\n<p>Apply ice or cold compresses</p>\n<p>\u0089</p>\n<p>Elevate any involved limb</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Give Tetanus Toxoid if not fully vaccinated</p>\n<p>\u0089</p>\n<p>Start antibiotic</p>\n<p>-  Amoxicillin 500 mg every 8 hours</p>\n<p>- Child: 25 mg/kg every 8 hours (or 40 mg/kg</p>\n<p>every 12 hours)</p>\n<p>If severe soft tissue damage</p>\n<p>\u0089</p>\n<p>Add gentamicin 2.5 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to hospital for further management</p>\n<h3>HC3</h3>\n<p>Note</p>\n<p>\u0083 Treat sprains, strains and dislocations as above</p>\n<p>Note</p>\n<p>\u0083 Treat sprains, strains and dislocations as above</p>\n<p>Caution</p>\n<p>\u0083 Do not give pethidine and morphine for rib fractures and head</p>\n<p>injuries as they cause respiratory depression</p>\n<p>44</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 111,
        "content": "1.2.3 Burns                       ICD10 CODE: T20-T25\nTissue injury caused by thermal, chemical, electrical, or radiation energy.\nCauses\n \n~\nThermal, e.g., hot fluids, flame, steam, hot solids, sun\n \n~\nChemical, e.g., acids, alkalis, and other caustic chemicals\n \n~\nElectrical, e.g., domestic (low voltage) transmission lines \n(high voltage), lightening\n \n~\nRadiation, e.g., exposure to excess radiotherapy or radio\u00ad\nactive materials\nClinical features\n \n~\nPain, swelling\n \n~\nSkin changes (hyperaemia, blisters, singed hairs)\n \n~\nSkin loss (eschar formation, charring)\n \n~\nReduced ability to use the affected part\n \n~\nSystemic effects in severe/extensive burns include shock, \nlow urine output, generalised swelling, respiratory insuffi\u00ad\nciency, deteriorated mental state\n \n~\nBreathing difficulty, hoarse voice and cough in smoke inha\u00ad\nlation injury \u2013 medical emergency\nCriteria for classification of the severity of burns\nThe following criteria are used to classify burns:\nCRITERIA\nLEVEL\nDepth of the burn (a \nfactor of temperature, \nof agent, and of du\u00ad\nration of contact with \nthe skin)\n1st Degree burns\nSuperficial epidermal injury with no\nblisters. Main sign is redness of the skin,\ntenderness, or hyper sensitivity with\nintact two-point discrimination. Healing in 7 days\n45\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.2.3 Burns                       ICD10 CODE: T20-T25</li>\n<p>Tissue injury caused by thermal, chemical, electrical, or radiation energy.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Thermal, e.g., hot fluids, flame, steam, hot solids, sun</p>\n<p>~</p>\n<p>Chemical, e.g., acids, alkalis, and other caustic chemicals</p>\n<p>~</p>\n<p>Electrical, e.g., domestic (low voltage) transmission lines</p>\n<p>(high voltage), lightening</p>\n<p>~</p>\n<p>Radiation, e.g., exposure to excess radiotherapy or radio\u00ad</p>\n<p>active materials</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pain, swelling</p>\n<p>~</p>\n<p>Skin changes (hyperaemia, blisters, singed hairs)</p>\n<p>~</p>\n<p>Skin loss (eschar formation, charring)</p>\n<p>~</p>\n<p>Reduced ability to use the affected part</p>\n<p>~</p>\n<p>Systemic effects in severe/extensive burns include shock,</p>\n<p>low urine output, generalised swelling, respiratory insuffi\u00ad</p>\n<p>ciency, deteriorated mental state</p>\n<p>~</p>\n<p>Breathing difficulty, hoarse voice and cough in smoke inha\u00ad</p>\n<p>lation injury \u2013 medical emergency</p>\n<p>Criteria for classification of the severity of burns</p>\n<p>The following criteria are used to classify burns:</p>\n<h3>CRITERIA</h3>\n<h3>LEVEL</h3>\n<p>Depth of the burn (a</p>\n<p>factor of temperature,</p>\n<p>of agent, and of du\u00ad</p>\n<p>ration of contact with</p>\n<p>the skin)</p>\n<p>1st Degree burns</p>\n<p>Superficial epidermal injury with no</p>\n<p>blisters. Main sign is redness of the skin,</p>\n<p>tenderness, or hyper sensitivity with</p>\n<p>intact two-point discrimination. Healing in 7 days</p>\n<p>45</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 112,
        "content": "CRITERIA\nLEVEL\n2nd Degree burns or Partial thickness burns\nIt is a dermal injury that is sub-classified as \nsuperficial and deep 2nd degree burns. In su\u00ad\nperficial 2nd degree burns, blisters result, the \npink moist wound is painful. A thin eschar is \nformed. Heals in 10-14 days.\nIn deep 2nd degree burns, blisters are lacking, \nthe wound is pale, moderately painful, a thick \nescar is formed. Heals in\n>1 month, requiring surgical debridement\n3rd Degree burns\nFull thickness skin destruction, leather- like \nrigid eschar. Painless on palpation or pinprick. \nRequires skin graft.\n4th Degree burns\nFull thickness skin and fascia, muscles, or bone \ndestruction. Lifeless body part\nPercentage of total \nbody surface area \n(TBSA)\nSmall areas are estimated using the open palm \nof the patient to represent 1% TBSA. Large \nareas estimated using the \u201crules of nines\u201d or \na Lund-Browder chart. Count all areas except \nthe ones with erythema only\nThe body parts \ninjured\nFace, neck, hands, feet, perineum and major \njoints burns are considered severe\nAge/general con\u00ad\ndition\nIn general, children and the elderly fare worse \nthan young adults and need more care. A person \nwho is sick or debilitated at the time of the burn \nwill be more affected than one who is healthy\n46\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>CRITERIA</h3>\n<h3>LEVEL</h3>\n<p>2nd Degree burns or Partial thickness burns</p>\n<p>It is a dermal injury that is sub-classified as</p>\n<p>superficial and deep 2nd degree burns. In su\u00ad</p>\n<p>perficial 2nd degree burns, blisters result, the</p>\n<p>pink moist wound is painful. A thin eschar is</p>\n<p>formed. Heals in 10-14 days.</p>\n<p>In deep 2nd degree burns, blisters are lacking,</p>\n<p>the wound is pale, moderately painful, a thick</p>\n<p>escar is formed. Heals in</p>\n<p>>1 month, requiring surgical debridement</p>\n<p>3rd Degree burns</p>\n<p>Full thickness skin destruction, leather- like</p>\n<p>rigid eschar. Painless on palpation or pinprick.</p>\n<p>Requires skin graft.</p>\n<p>4th Degree burns</p>\n<p>Full thickness skin and fascia, muscles, or bone</p>\n<p>destruction. Lifeless body part</p>\n<p>Percentage of total</p>\n<p>body surface area</p>\n<h3>(TBSA)</h3>\n<p>Small areas are estimated using the open palm</p>\n<p>of the patient to represent 1% TBSA. Large</p>\n<p>areas estimated using the \u201crules of nines\u201d or</p>\n<p>a Lund-Browder chart. Count all areas except</p>\n<p>the ones with erythema only</p>\n<p>The body parts</p>\n<p>injured</p>\n<p>Face, neck, hands, feet, perineum and major</p>\n<p>joints burns are considered severe</p>\n<p>Age/general con\u00ad</p>\n<p>dition</p>\n<p>In general, children and the elderly fare worse</p>\n<p>than young adults and need more care. A person</p>\n<p>who is sick or debilitated at the time of the burn</p>\n<p>will be more affected than one who is healthy</p>\n<p>46</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 113,
        "content": "Categorisation of severity of burns\nUsing the above criteria, a burn patient may be categorised as follows:\nSEVERITY\nCRITERIA\nMinor/mild \nburn\n \n- Adult with <15% TBSA affected or\n \n- Child/elderly with <10% TBSA affected or\n \n- Full thickness burn with <2% TBSA \naffected and no serious threat to function\nMinor/mild \nburn\n \n- Adult with <15% TBSA affected or\n \n- Child/elderly with <10% TBSA affected or\n \n- Full thickness burn with <2% TBSA \naffected and no serious threat to function\nModerate \n(intermediate) \nburn\nAdult with partial thickness burn 15- 25% TBSA or\nChild/elderly with partial thickness\nburn 10-20% TBSA\nAll above with no serious threat to function and no \ncosmetic impairment of eyes, ears, hands, feet or \nperineum\nMajor (severe) \nburn\nAdult with\n \n- Partial thickness burn >25% TBSA or\n \n- Full thickness burn >10% TBSA\nChild/elderly with\n \n- Partial thickness burn >20% TBSA or full \nthickness burn of >5% TBSA affected\nIrrespective of age\n \n- Any burns of the face and eyes, neck, ears, \nhand, feet, perineum and major joints with \ncosmetic or functional impairment risks, \ncircumferential burns\n \n- Chemical, high voltage, inhalation burns\n \n- Any burn with associated major trauma\n47\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Categorisation of severity of burns</p>\n<p>Using the above criteria, a burn patient may be categorised as follows:</p>\n<h3>SEVERITY</h3>\n<h3>CRITERIA</h3>\n<p>Minor/mild</p>\n<p>burn</p>\n<p>- Adult with <15% TBSA affected or</p>\n<p>- Child/elderly with <10% TBSA affected or</p>\n<p>- Full thickness burn with <2% TBSA</p>\n<p>affected and no serious threat to function</p>\n<p>Minor/mild</p>\n<p>burn</p>\n<p>- Adult with <15% TBSA affected or</p>\n<p>- Child/elderly with <10% TBSA affected or</p>\n<p>- Full thickness burn with <2% TBSA</p>\n<p>affected and no serious threat to function</p>\n<p>Moderate</p>\n<p>(intermediate)</p>\n<p>burn</p>\n<p>Adult with partial thickness burn 15- 25% TBSA or</p>\n<p>Child/elderly with partial thickness</p>\n<p>burn 10-20% TBSA</p>\n<p>All above with no serious threat to function and no</p>\n<p>cosmetic impairment of eyes, ears, hands, feet or</p>\n<p>perineum</p>\n<p>Major (severe)</p>\n<p>burn</p>\n<p>Adult with</p>\n<p>- Partial thickness burn >25% TBSA or</p>\n<p>- Full thickness burn >10% TBSA</p>\n<p>Child/elderly with</p>\n<p>- Partial thickness burn >20% TBSA or full</p>\n<p>thickness burn of >5% TBSA affected</p>\n<p>Irrespective of age</p>\n<p>- Any burns of the face and eyes, neck, ears,</p>\n<p>hand, feet, perineum and major joints with</p>\n<p>cosmetic or functional impairment risks,</p>\n<p>circumferential burns</p>\n<p>- Chemical, high voltage, inhalation burns</p>\n<p>- Any burn with associated major trauma</p>\n<p>47</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 114,
        "content": "Chart for Estimating Percentage of Total Body Surface Area (TBSA) Burnt\nLUND AND BROWDER CHARTS\t\n             Ignore simple erythema\nSuperficial Deep\nRegion\n%\nHead\nNeck\nRegion\n%\nAnt. Trunk\nPost. Trunk\nRight Arm\nLeft Arm\nButtocks\nGenitalia\nRight Leg\nLeft Leg\nTotal Burn\nRelative percentage of body surface area affected by growth\nArea\nAge 0\n1\n5\n10\n15\nAdult\nA = \u00bd of head\n9\u00bd\n8\u00bd\n6\u00bd\n5\u00bd\n4\u00bd\n3\u00bd\nB = \u00bd of one thigh\n2\u00be\n3\u00bc\n4\n4\u00bd\n4\u00bd\n4\u00be\nC = \u00bd of one lower leg\n2\u00bd\n2\u00bd\n2\u00be\n3\n3\u00bc\n3\u00bd\nManagement\nTREATMENT\nLOC\nMild/moderate burns \u2013 First aid\n\t\n\u0089\nStop the burning process and move the patient to safety\n\t\n\u0089\nRoll on the ground if clothing is on fire\nHC1\n48\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Chart for Estimating Percentage of Total Body Surface Area (TBSA) Burnt</p>\n<h3>LUND AND BROWDER CHARTS</h3>\n<p>Ignore simple erythema</p>\n<p>Superficial Deep</p>\n<p>Region</p>\n<p>%</p>\n<p>Head</p>\n<p>Neck</p>\n<p>Region</p>\n<p>%</p>\n<p>Ant. Trunk</p>\n<p>Post. Trunk</p>\n<p>Right Arm</p>\n<p>Left Arm</p>\n<p>Buttocks</p>\n<p>Genitalia</p>\n<p>Right Leg</p>\n<p>Left Leg</p>\n<p>Total Burn</p>\n<p>Relative percentage of body surface area affected by growth</p>\n<p>Area</p>\n<p>Age 0</p>\n<p>1</p>\n<p>5</p>\n<p>10</p>\n<p>15</p>\n<p>Adult</p>\n<p>A = \u00bd of head</p>\n<p>9\u00bd</p>\n<p>8\u00bd</p>\n<p>6\u00bd</p>\n<p>5\u00bd</p>\n<p>4\u00bd</p>\n<p>3\u00bd</p>\n<p>B = \u00bd of one thigh</p>\n<p>2\u00be</p>\n<p>3\u00bc</p>\n<p>4</p>\n<p>4\u00bd</p>\n<p>4\u00bd</p>\n<p>4\u00be</p>\n<p>C = \u00bd of one lower leg</p>\n<p>2\u00bd</p>\n<p>2\u00bd</p>\n<p>2\u00be</p>\n<p>3</p>\n<p>3\u00bc</p>\n<p>3\u00bd</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild/moderate burns \u2013 First aid</p>\n<p>\u0089</p>\n<p>Stop the burning process and move the patient to safety</p>\n<p>\u0089</p>\n<p>Roll on the ground if clothing is on fire</p>\n<h3>HC1</h3>\n<p>48</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 115,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nSwitch off electricity\n\t\n\u0089\nCool the burn by pouring or showering or soaking the \naffected area with cold water for 30 minutes, especially \nin the first hour after the burn (this may reduce the depth \nof injury if started immediately)\n\t\n\u0089\nRemove soaked clothes, wash off chemicals, remove any \nconstrictive clothing/rings\n\t\n\u0089\nClean the wound with clean water\n\t\n\u0089\nCover the wound with a clean dry cloth and keep the \npatient with warm\nHC1\nAt health facility\n\t\n\u0089\nGive oral or IV analgesics as required\n\t\n\u0089\nIf TBSA <10% and patient able to drink, give oral fluids \notherwise consider IV\n\t\n\u0089\nGive TT if not fully immunised\n\t\n\u0089\nLeave small blisters alone, drain large blisters and dress \nif closed dressing method is being used the urine output. \nThe normal urine output is: Children (<30 kg) 1-2 ml/kg/\nhour and adults 0.5 ml/kg/hour (30-50 ml /hour)\nHC2\n\t\n\u0089\nDress with silver sulphadiazine cream 1%, add saline \nmoistened gauze or paraffin gauze and dry gauze on top \nto prevent seepage\n\t\n\u0089\nSmall superficial 2nd degree burns can be dressed directly \nwith paraffin gauze dressing\n\t\n\u0089\nChange after 1-3 days then prn\n\t\n\u0089\nPatient may be exposed in a bed cradle if there are ex\u00ad\ntensive burns\n\t\n\u0089\nSaline bath should be done before wound dressing\nHC3\n49\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Switch off electricity</p>\n<p>\u0089</p>\n<p>Cool the burn by pouring or showering or soaking the</p>\n<p>affected area with cold water for 30 minutes, especially</p>\n<p>in the first hour after the burn (this may reduce the depth</p>\n<p>of injury if started immediately)</p>\n<p>\u0089</p>\n<p>Remove soaked clothes, wash off chemicals, remove any</p>\n<p>constrictive clothing/rings</p>\n<p>\u0089</p>\n<p>Clean the wound with clean water</p>\n<p>\u0089</p>\n<p>Cover the wound with a clean dry cloth and keep the</p>\n<p>patient with warm</p>\n<h3>HC1</h3>\n<p>At health facility</p>\n<p>\u0089</p>\n<p>Give oral or IV analgesics as required</p>\n<p>\u0089</p>\n<p>If TBSA <10% and patient able to drink, give oral fluids</p>\n<p>otherwise consider IV</p>\n<p>\u0089</p>\n<p>Give TT if not fully immunised</p>\n<p>\u0089</p>\n<p>Leave small blisters alone, drain large blisters and dress</p>\n<p>if closed dressing method is being used the urine output.</p>\n<p>The normal urine output is: Children (<30 kg) 1-2 ml/kg/</p>\n<p>hour and adults 0.5 ml/kg/hour (30-50 ml /hour)</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Dress with silver sulphadiazine cream 1%, add saline</p>\n<p>moistened gauze or paraffin gauze and dry gauze on top</p>\n<p>to prevent seepage</p>\n<p>\u0089</p>\n<p>Small superficial 2nd degree burns can be dressed directly</p>\n<p>with paraffin gauze dressing</p>\n<p>\u0089</p>\n<p>Change after 1-3 days then prn</p>\n<p>\u0089</p>\n<p>Patient may be exposed in a bed cradle if there are ex\u00ad</p>\n<p>tensive burns</p>\n<p>\u0089</p>\n<p>Saline bath should be done before wound dressing</p>\n<h3>HC3</h3>\n<p>49</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 116,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nIf wound infected dress more frequenly with silver sulphad\u00ad\niazine cream until infection is controlled.\nSevere burns\n\t\n\u0089\nFirst aid and wound management as above PLUS\n\t\n\u0089\nGive IV fluid replacement in a total volume per 24 hours \naccording to the calculation in the box below (use crystal\u00ad\nloids, i.e., Ringer\u2019s lactate, or normal saline)\n\t\n\u0089\nIf patient in shock, run the IV fluids fast until BP improves \n(see section 1.1.2)\n\t\n\u0089\nManage pain as necessary\n\t\n\u0089\nRefer for admission\n\t\n\u0089\nMonitor vital signs and urine output\n\t\n\u0089\nUse antibiotics if there are systemic signs of infection: \nbenzylpenicillin 3 MU every 6 hours\n+/- gentamicin 5-7 mg/kg IV or IM once a day\n\t\n\u0089\nBlood transfusion may be necessary\n\t\n\u0089\nIf signs/symptoms of inhalation injury, give oxygen and \nrefer for advanced life support (refer to regional level)\nSurgery\n\t\n\u0089\nEscharotomy and fasciotomy for circumferential finger, \nhand, limb or torso burns\n\t\n\u0089\nEscharectomy to excise dead skin\n\t\n\u0089\nSkin grafting to cover clean deep burn wounds\nEye injury\n\t\n\u0089\nIrrigate with abundant sterile saline\n\t\n\u0089\nPlace eye pad over eye ointment and refer\nHC3\nHC4\nH\n50\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If wound infected dress more frequenly with silver sulphad\u00ad</p>\n<p>iazine cream until infection is controlled.</p>\n<p>Severe burns</p>\n<p>\u0089</p>\n<p>First aid and wound management as above PLUS</p>\n<p>\u0089</p>\n<p>Give IV fluid replacement in a total volume per 24 hours</p>\n<p>according to the calculation in the box below (use crystal\u00ad</p>\n<p>loids, i.e., Ringer\u2019s lactate, or normal saline)</p>\n<p>\u0089</p>\n<p>If patient in shock, run the IV fluids fast until BP improves</p>\n<p>(see section 1.1.2)</p>\n<p>\u0089</p>\n<p>Manage pain as necessary</p>\n<p>\u0089</p>\n<p>Refer for admission</p>\n<p>\u0089</p>\n<p>Monitor vital signs and urine output</p>\n<p>\u0089</p>\n<p>Use antibiotics if there are systemic signs of infection:</p>\n<p>benzylpenicillin 3 MU every 6 hours</p>\n<p>+/- gentamicin 5-7 mg/kg IV or IM once a day</p>\n<p>\u0089</p>\n<p>Blood transfusion may be necessary</p>\n<p>\u0089</p>\n<p>If signs/symptoms of inhalation injury, give oxygen and</p>\n<p>refer for advanced life support (refer to regional level)</p>\n<p>Surgery</p>\n<p>\u0089</p>\n<p>Escharotomy and fasciotomy for circumferential finger,</p>\n<p>hand, limb or torso burns</p>\n<p>\u0089</p>\n<p>Escharectomy to excise dead skin</p>\n<p>\u0089</p>\n<p>Skin grafting to cover clean deep burn wounds</p>\n<p>Eye injury</p>\n<p>\u0089</p>\n<p>Irrigate with abundant sterile saline</p>\n<p>\u0089</p>\n<p>Place eye pad over eye ointment and refer</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>50</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 117,
        "content": "TREATMENT\nLOC\nAdditional care\n\t\n\u0089\nNutritional support\n\t\n\u0089\nPhysiotherapy of affected limb\n\t\n\u0089\nCounselling and psychosocial support\n\t\n\u0089\nHealth education on prevention (e.g. epilepsy control)\nCaution\n\t\n\u0089\nSilver sulphadiazine contraindicated in pregnancy, breast\u00ad\nfeeding and premature babies\nFluid replacement in burns\n \n~\nThe objective is to maintain normal physiology as shown by \nurine output, vital signs and mental status\n \n~\nFluid is lost from the circulation into the tissues surrounding \nthe burns and some is lost through the wounds, especially \nin 18-30 hours after the burns\n \n~\nLow intravascular volume results in tissue circulatory in\u00ad\nsufficiency (shock) with results such as kidney failure and \ndeepening of the burns\n \n~\nThe fluid requirements are often very high and so should be \ngiven as necessary to ensure adequate urine output\nTREATMENT\nLOC\n\t\n\u0089\nGive oral fluids (ORS or others) and/or IV fluids e.g. normal \nsaline or Ringer\u2019s Lactate depending on the degree of loss \nof intravascular fluid\nV The total volume of IV solution required in the first 24 hours \nof the burns is:\n4 ml x weight (kg) x % TBSA burned plus the normal daily \nfluid requirement\n\t\n\u0089\nGive 50% of fluid replacement in the first 8 hours and 50% \nin the next 16 hours. The fluid input is balanced against\nHC2 \nHC3\n51\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Additional care</p>\n<p>\u0089</p>\n<p>Nutritional support</p>\n<p>\u0089</p>\n<p>Physiotherapy of affected limb</p>\n<p>\u0089</p>\n<p>Counselling and psychosocial support</p>\n<p>\u0089</p>\n<p>Health education on prevention (e.g. epilepsy control)</p>\n<p>Caution</p>\n<p>\u0089</p>\n<p>Silver sulphadiazine contraindicated in pregnancy, breast\u00ad</p>\n<p>feeding and premature babies</p>\n<p>Fluid replacement in burns</p>\n<p>~</p>\n<p>The objective is to maintain normal physiology as shown by</p>\n<p>urine output, vital signs and mental status</p>\n<p>~</p>\n<p>Fluid is lost from the circulation into the tissues surrounding</p>\n<p>the burns and some is lost through the wounds, especially</p>\n<p>in 18-30 hours after the burns</p>\n<p>~</p>\n<p>Low intravascular volume results in tissue circulatory in\u00ad</p>\n<p>sufficiency (shock) with results such as kidney failure and</p>\n<p>deepening of the burns</p>\n<p>~</p>\n<p>The fluid requirements are often very high and so should be</p>\n<p>given as necessary to ensure adequate urine output</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give oral fluids (ORS or others) and/or IV fluids e.g. normal</p>\n<p>saline or Ringer\u2019s Lactate depending on the degree of loss</p>\n<p>of intravascular fluid</p>\n<p>V The total volume of IV solution required in the first 24 hours</p>\n<p>of the burns is:</p>\n<p>4 ml x weight (kg) x % TBSA burned plus the normal daily</p>\n<p>fluid requirement</p>\n<p>\u0089</p>\n<p>Give 50% of fluid replacement in the first 8 hours and 50%</p>\n<p>in the next 16 hours. The fluid input is balanced against</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>51</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 118,
        "content": "Prevention\n \n~\nPublic awareness of burn risks and first aid water use in \ncooling burnt skin\n \n~\nConstruction of raised cooking fire places as safety mea\u00ad\nsure\n \n~\nEnsure safe handling of hot water and food, keep well out \nof the reach of children\n \n~\nParticular care of high risk persons near fires e.g. children, \nepileptic patients, alcohol or drug abusers\n \n~\nEncourage people to use closed flames e.g. hurricane \nlamps. Avoid candles.\n \n~\nBeware of possible cases of child abuse\n1.2.4 Wounds                     ICD10 CODE: S00-T88\nAny break in the continuity of the skin or mucosa or disruption in the \nintegrity of tissue due to injury.\nCauses\n \n~\nSharp objects, e.g. knife, causing cuts, punctures\n \n~\nBlunt objects causing bruises, abrasions, lacerations\n \n~\nInfections, e.g. abscess\n \n~\nBites, e.g. insect, animal, human\n \n~\nMissile and blast injury, e.g. gunshot, mines, exlosives, \nlandmines\n \n~\nCrush injury, e.g. RTA, building collapse\nClinical features\n \n~\nRaw area of broken skin or mucous membrane\n \n~\nPain, swelling, bleeding, discharge\n52\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Public awareness of burn risks and first aid water use in</p>\n<p>cooling burnt skin</p>\n<p>~</p>\n<p>Construction of raised cooking fire places as safety mea\u00ad</p>\n<p>sure</p>\n<p>~</p>\n<p>Ensure safe handling of hot water and food, keep well out</p>\n<p>of the reach of children</p>\n<p>~</p>\n<p>Particular care of high risk persons near fires e.g. children,</p>\n<p>epileptic patients, alcohol or drug abusers</p>\n<p>~</p>\n<p>Encourage people to use closed flames e.g. hurricane</p>\n<p>lamps. Avoid candles.</p>\n<p>~</p>\n<p>Beware of possible cases of child abuse</p>\n<li>.2.4 Wounds                     ICD10 CODE: S00-T88</li>\n<p>Any break in the continuity of the skin or mucosa or disruption in the</p>\n<p>integrity of tissue due to injury.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Sharp objects, e.g. knife, causing cuts, punctures</p>\n<p>~</p>\n<p>Blunt objects causing bruises, abrasions, lacerations</p>\n<p>~</p>\n<p>Infections, e.g. abscess</p>\n<p>~</p>\n<p>Bites, e.g. insect, animal, human</p>\n<p>~</p>\n<p>Missile and blast injury, e.g. gunshot, mines, exlosives,</p>\n<p>landmines</p>\n<p>~</p>\n<p>Crush injury, e.g. RTA, building collapse</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Raw area of broken skin or mucous membrane</p>\n<p>~</p>\n<p>Pain, swelling, bleeding, discharge</p>\n<p>52</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 119,
        "content": "~\nReduced use of affected part\n \n~\nCuts: sharp edges\n \n~\nLacerations: Irregular edges\n \n~\nAbrasions: loss of surface skin\n \n~\nBruises: subcutaneous bleeding e.g. black eye\nManagement\nTREATMENT\nLOC\nMinor cuts and bruises\n\t\n\u0089\nFirst aid, tetanus prophylaxis, dressing and pain man\u00ad\nagement\n\t\n\u0089\nAntibiotics are not usually required but if the wound is \ngrossly contaminated, give\n \n- Cloxacillin or amoxicillin 500 mg every 6 hours\n \n- as empiric treatment\nChild: 125-250 mg every 6 hours\nHC2\nDeep and/or extensive\n\t\n\u0089\nIdentify the cause of the wound or injury if possible\n\t\n\u0089\nWash affected part and wound with plenty of water or \nsaline solution\n \n- (you can also clean with chlorhexidine 0.05%\n \n- or hydrogen peroxide 6% diluted with equal \namount of saline to 3% if wound is contaminated)\n\t\n\u0089\nExplore the wound under local anesthesia to ascertain the \nextent of the damage and remove foreign bodies\n\t\n\u0089\nSurgical toilet: carry out debridement to freshen the wound\n\t\n\u0089\nTetanus prophylaxis, pain management, immobilization\nHC4\n53\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Reduced use of affected part</p>\n<p>~</p>\n<p>Cuts: sharp edges</p>\n<p>~</p>\n<p>Lacerations: Irregular edges</p>\n<p>~</p>\n<p>Abrasions: loss of surface skin</p>\n<p>~</p>\n<p>Bruises: subcutaneous bleeding e.g. black eye</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Minor cuts and bruises</p>\n<p>\u0089</p>\n<p>First aid, tetanus prophylaxis, dressing and pain man\u00ad</p>\n<p>agement</p>\n<p>\u0089</p>\n<p>Antibiotics are not usually required but if the wound is</p>\n<p>grossly contaminated, give</p>\n<p>- Cloxacillin or amoxicillin 500 mg every 6 hours</p>\n<p>- as empiric treatment</p>\n<p>Child: 125-250 mg every 6 hours</p>\n<h3>HC2</h3>\n<p>Deep and/or extensive</p>\n<p>\u0089</p>\n<p>Identify the cause of the wound or injury if possible</p>\n<p>\u0089</p>\n<p>Wash affected part and wound with plenty of water or</p>\n<p>saline solution</p>\n<p>- (you can also clean with chlorhexidine 0.05%</p>\n<p>- or hydrogen peroxide 6% diluted with equal</p>\n<p>amount of saline to 3% if wound is contaminated)</p>\n<p>\u0089</p>\n<p>Explore the wound under local anesthesia to ascertain the</p>\n<p>extent of the damage and remove foreign bodies</p>\n<p>\u0089</p>\n<p>Surgical toilet: carry out debridement to freshen the wound</p>\n<p>\u0089</p>\n<p>Tetanus prophylaxis, pain management, immobilization</p>\n<h3>HC4</h3>\n<p>53</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 120,
        "content": "TREATMENT\nLOC\nIf wound is clean and fresh (<8 hours)\n\t\n\u0089\nCarry out primary closure by suturing under local anaes\u00ad\nthetic\n \n- Use lignocaine hydrochloride 2% (dilute to 1% with \nequal volume of water for injection)\nHC3\nIf wound is >8 hours old or dirty\n\t\n\u0089\nClean thoroughly and dress  daily  f Check the state of \nthe wound for 2-3 days f Carry out delayed primary \nclosure if clean\n \n- Use this for wounds up to 2-4 days old\nIf wound >4 days old or deep pucture wound, contaminated \nwounds, bite/gunshot wounds, abscess cavity\n\t\n\u0089\nLet it heal by secondary closure (granulation tissue)\n\t\n\u0089\nDress daily if contaminated/dirty, every other day if clean\n\t\n\u0089\nPack cavities (e.g. abscesses) with saline-soaked gauzes\nIn case of extensive/deep wound\n\t\n\u0089\nConsider closure with skin graft/flap\nNote\n \n~\nUse SOP for collection of wound discharge, or \ndeep tissue, submit to lab\n \n~\nStart on treatment, change treatment when re\u00ad\nsults return\n \n~\nIf MDR, gramnegative or MRSA or VRE impleme \nthe respective transmission-based precautions.\n \n~\nWhere can, use chlorine release for environmen\u00ad\ntal decontamination or alternate fumigation (not \nformaldehyde)\n54\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If wound is clean and fresh (<8 hours)</p>\n<p>\u0089</p>\n<p>Carry out primary closure by suturing under local anaes\u00ad</p>\n<p>thetic</p>\n<p>- Use lignocaine hydrochloride 2% (dilute to 1% with</p>\n<p>equal volume of water for injection)</p>\n<h3>HC3</h3>\n<p>If wound is >8 hours old or dirty</p>\n<p>\u0089</p>\n<p>Clean thoroughly and dress  daily  f Check the state of</p>\n<p>the wound for 2-3 days f Carry out delayed primary</p>\n<p>closure if clean</p>\n<p>- Use this for wounds up to 2-4 days old</p>\n<p>If wound >4 days old or deep pucture wound, contaminated</p>\n<p>wounds, bite/gunshot wounds, abscess cavity</p>\n<p>\u0089</p>\n<p>Let it heal by secondary closure (granulation tissue)</p>\n<p>\u0089</p>\n<p>Dress daily if contaminated/dirty, every other day if clean</p>\n<p>\u0089</p>\n<p>Pack cavities (e.g. abscesses) with saline-soaked gauzes</p>\n<p>In case of extensive/deep wound</p>\n<p>\u0089</p>\n<p>Consider closure with skin graft/flap</p>\n<p>Note</p>\n<p>~</p>\n<p>Use SOP for collection of wound discharge, or</p>\n<p>deep tissue, submit to lab</p>\n<p>~</p>\n<p>Start on treatment, change treatment when re\u00ad</p>\n<p>sults return</p>\n<p>~</p>\n<p>If MDR, gramnegative or MRSA or VRE impleme</p>\n<p>the respective transmission-based precautions.</p>\n<p>~</p>\n<p>Where can, use chlorine release for environmen\u00ad</p>\n<p>tal decontamination or alternate fumigation (not</p>\n<p>formaldehyde)</p>\n<p>54</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 121,
        "content": "1.2.5 Head Injuries                      ICD10 CODE: S00-S09\nTrauma to the head resulting in brain injuries due to:\n \n- Direct damage to the brain (contusion, concussion, \npenetrating injury, diffuse axonal damage)\n \n- Haemorrhage from rupture of blood vessels around and in\n \n- the brain\n \n- Severe swelling of the cerebral tissue (cerebral oedema)\nCauses\n \n~\nRoad traffic accident\n \n~\nAssault, fall or a blow to the head\nClinical features\n \n~\nMay be closed (without a cut) or open (with a cut)\n \n~\nSwelling on the head (scalp hematoma)\n \n~\nFracture of the skull, e.g., depressed area of the skull, open \nfracture (brain matter may be exposed)\n \n~\nRacoon eyes (haematoma around the eyes), bleeding and/ \nor leaking of CSF through nose, ears \u2013 signs of possible \nskull base fracture\nSevere head injury\n \n~\nAltered level of consciousness, agitation, coma (see GCS \nbelow)\n \n~\nSeizures, focal neurological deficits, pupil abnormalities\nMinor head injury (concussion)\n \n~\nTransient and short lived loss of mental function, e.g., loss \nof consciousness (<5 minutes), transient amnesia, head\u00ad\nache, disorientation, dizziness, drowsiness, vomiting\n \n- symptoms should improve by 4 hours after the trauma\n55\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.2.5 Head Injuries                      ICD10 CODE: S00-S09</li>\n<p>Trauma to the head resulting in brain injuries due to:</p>\n<p>- Direct damage to the brain (contusion, concussion,</p>\n<p>penetrating injury, diffuse axonal damage)</p>\n<p>- Haemorrhage from rupture of blood vessels around and in</p>\n<p>- the brain</p>\n<p>- Severe swelling of the cerebral tissue (cerebral oedema)</p>\n<p>Causes</p>\n<p>~</p>\n<p>Road traffic accident</p>\n<p>~</p>\n<p>Assault, fall or a blow to the head</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>May be closed (without a cut) or open (with a cut)</p>\n<p>~</p>\n<p>Swelling on the head (scalp hematoma)</p>\n<p>~</p>\n<p>Fracture of the skull, e.g., depressed area of the skull, open</p>\n<p>fracture (brain matter may be exposed)</p>\n<p>~</p>\n<p>Racoon eyes (haematoma around the eyes), bleeding and/</p>\n<p>or leaking of CSF through nose, ears \u2013 signs of possible</p>\n<p>skull base fracture</p>\n<p>Severe head injury</p>\n<p>~</p>\n<p>Altered level of consciousness, agitation, coma (see GCS</p>\n<p>below)</p>\n<p>~</p>\n<p>Seizures, focal neurological deficits, pupil abnormalities</p>\n<p>Minor head injury (concussion)</p>\n<p>~</p>\n<p>Transient and short lived loss of mental function, e.g., loss</p>\n<p>of consciousness (<5 minutes), transient amnesia, head\u00ad</p>\n<p>ache, disorientation, dizziness, drowsiness, vomiting</p>\n<p>- symptoms should improve by 4 hours after the trauma</p>\n<p>55</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 122,
        "content": "Severity classification of head injuries\nHead injuries are classified based on Glasgow Coma Scale (GCS) score as:\n \n- Severe (GCS 3-8)\n \n- Moderate ( GCS 9-13)\n \n- Mild (GCS > 13)\nGlasgow Coma Scale (GCS)\nEye Opening Verbal Response\nMotor Response\n1 = No response\n1 = No response\n1 = No response\n2 = Open in \nresponse to \npain\n2 =\nIncomprehensible sounds \n(grunting in children)\n2= Extension to painful \nstimuli\n(decerebrate)\n3 = Open in \nresponse to \nvoice\n3 = Inappropriate words \n(cries and screams/\ncries inappropriately in \nchildren)\n3 = Abnormal flexion to \npainful stimuli (decorti\u00ad\ncate)\n4 = Open \nspontane\u00ad\nously\n4 = Disoriented able \nto converse (use words \ninappropriately / cries in \nchildren)\n4 = Flexion/ withdrawal \nfrom painful stimuli\nNA\n5 = Oriented able to con\u00ad\nverse (use words appropri\u00ad\nately/\ncries appropriately in \nchildren)\n5 = Localize pain\nNA\n6 = Obeys command\n(NA in children\n<1 yr)\nFor infants and children use AVPU\nA\nAlert\nGCS >13\nV\nResponds to voice\nGCS 13\n56\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Severity classification of head injuries</p>\n<p>Head injuries are classified based on Glasgow Coma Scale (GCS) score as:</p>\n<p>- Severe (GCS 3-8)</p>\n<p>- Moderate ( GCS 9-13)</p>\n<p>- Mild (GCS > 13)</p>\n<p>Glasgow Coma Scale (GCS)</p>\n<p>Eye Opening Verbal Response</p>\n<p>Motor Response</p>\n<p>1 = No response</p>\n<p>1 = No response</p>\n<p>1 = No response</p>\n<p>2 = Open in</p>\n<p>response to</p>\n<p>pain</p>\n<p>2 =</p>\n<p>Incomprehensible sounds</p>\n<p>(grunting in children)</p>\n<p>2= Extension to painful</p>\n<p>stimuli</p>\n<p>(decerebrate)</p>\n<p>3 = Open in</p>\n<p>response to</p>\n<p>voice</p>\n<p>3 = Inappropriate words</p>\n<p>(cries and screams/</p>\n<p>cries inappropriately in</p>\n<p>children)</p>\n<p>3 = Abnormal flexion to</p>\n<p>painful stimuli (decorti\u00ad</p>\n<p>cate)</p>\n<p>4 = Open</p>\n<p>spontane\u00ad</p>\n<p>ously</p>\n<p>4 = Disoriented able</p>\n<p>to converse (use words</p>\n<p>inappropriately / cries in</p>\n<p>children)</p>\n<p>4 = Flexion/ withdrawal</p>\n<p>from painful stimuli</p>\n<p>NA</p>\n<p>5 = Oriented able to con\u00ad</p>\n<p>verse (use words appropri\u00ad</p>\n<p>ately/</p>\n<p>cries appropriately in</p>\n<p>children)</p>\n<p>5 = Localize pain</p>\n<p>NA</p>\n<p>6 = Obeys command</p>\n<p>(NA in children</p>\n<p><1 yr)</p>\n<p>For infants and children use AVPU</p>\n<p>A</p>\n<p>Alert</p>\n<h3>GCS >13</h3>\n<p>V</p>\n<p>Responds to voice</p>\n<h3>GCS 13</h3>\n<p>56</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 123,
        "content": "P\nResponds to pain\nGCS 8\nU\nUnresponsive\nGCS <8\nNote\nMild injuries can still be associated with significant brain damage and \ncan be divided into low and high risk according to the following criteria:\nLow Risk Mild Head Injury\nHigh Risk Mild Head Injury\n \n~\nGCS 15 at 2 hours\n \n~\nNo focal neurologi\u00ad\ncal deficits\n \n~\nNo signs/symptoms \nof skull fracture\n \n~\nNo recurrent vom\u00ad\niting\n \n~\nNo risk factors (age \n>65 years, bleeding \ndisorders, danger\u00ad\nous mechanism)\n \n~\nBrief LOC (<5 \nminutes) and post \ntraumatic amnesia \n(<30 minutes)\n \n~\nGCS <15 at 2 hours\n \n~\nDeterioration of GCS\n \n~\nFocal neurological \ndeficits\n \n~\nClinical suspicion of \nskull fracture\n \n~\nRecurrent vomiting\n \n~\nKnown bleeding disor\u00ad\nder\n \n~\nAge >65 years\n \n~\nPost traumatic seizure\n \n~\nLOC >5 minutes\n \n~\nPersistent amnesia\n \n~\nPersistent abnormal \nbehaviour\n \n~\nPersistent severe hea\n \n~\nache\nInvestigations\n\u00be\t\nSkull X ray useful only to detect fracture\n\u00be\t\nCT scan is the gold standard for detection of head injury\nDifferential diagnosis\n \n~\nAlcoholic coma - may occur together with a head injury\n \n~\nHypoglycaemia\n57\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>P</p>\n<p>Responds to pain</p>\n<h3>GCS 8</h3>\n<p>U</p>\n<p>Unresponsive</p>\n<h3>GCS <8</h3>\n<p>Note</p>\n<p>Mild injuries can still be associated with significant brain damage and</p>\n<p>can be divided into low and high risk according to the following criteria:</p>\n<p>Low Risk Mild Head Injury</p>\n<p>High Risk Mild Head Injury</p>\n<p>~</p>\n<p>GCS 15 at 2 hours</p>\n<p>~</p>\n<p>No focal neurologi\u00ad</p>\n<p>cal deficits</p>\n<p>~</p>\n<p>No signs/symptoms</p>\n<p>of skull fracture</p>\n<p>~</p>\n<p>No recurrent vom\u00ad</p>\n<p>iting</p>\n<p>~</p>\n<p>No risk factors (age</p>\n<p>>65 years, bleeding</p>\n<p>disorders, danger\u00ad</p>\n<p>ous mechanism)</p>\n<p>~</p>\n<p>Brief LOC (<5</p>\n<p>minutes) and post</p>\n<p>traumatic amnesia</p>\n<p>(<30 minutes)</p>\n<p>~</p>\n<p>GCS <15 at 2 hours</p>\n<p>~</p>\n<p>Deterioration of GCS</p>\n<p>~</p>\n<p>Focal neurological</p>\n<p>deficits</p>\n<p>~</p>\n<p>Clinical suspicion of</p>\n<p>skull fracture</p>\n<p>~</p>\n<p>Recurrent vomiting</p>\n<p>~</p>\n<p>Known bleeding disor\u00ad</p>\n<p>der</p>\n<p>~</p>\n<p>Age >65 years</p>\n<p>~</p>\n<p>Post traumatic seizure</p>\n<p>~</p>\n<p>LOC >5 minutes</p>\n<p>~</p>\n<p>Persistent amnesia</p>\n<p>~</p>\n<p>Persistent abnormal</p>\n<p>behaviour</p>\n<p>~</p>\n<p>Persistent severe hea</p>\n<p>~</p>\n<p>ache</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Skull X ray useful only to detect fracture</p>\n<p>\u00be</p>\n<p>CT scan is the gold standard for detection of head injury</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Alcoholic coma - may occur together with a head injury</p>\n<p>~</p>\n<p>Hypoglycaemia</p>\n<p>57</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 124,
        "content": "~\nMeningitis\n \n~\nPoisoning\n \n~\nOther cause of coma\nManagement (general principles)\nManagement depends on:\n \n~\nGCS and clinical features at first assessment\n \n~\nRisk factors (mechanism of trauma, age, baseline condi\u00ad\ntions)\n \n~\nGCS and clinical features at follow up\nTREATMENT\nLOC\n\t\n\u0089\nAssess mechanism of injury to assess risks of severe injury \n(which may not be apparent at the beginning)\n\t\n\u0089\nAssess medical history to assess risk of complication \n(e.g., elderly, anticoagulant treatment etc.)\n\t\n\u0089\nAssess level of consciousness using GCS or AVPU\n\t\n\u0089\nPerform general (including ears) and neurological exami\u00ad\nnation (pupils, motor and sensory examination, reflexes)\n \n- Assess other possible trauma especially if road \ntraffic accident, e.g., abdominal or chest trauma\n\t\n\u0089\nDO NOT SEDATE. Do NOT give opioids\n\t\n\u0089\nDo NOT give NSAIDs (risk of bleeding)\nHC3\nLow Risk Mild Head Injury\nHigh Risk Mild Head Injury\n \n~\nNo persistent head\u00ad\nache\n \n~\nNo large haemato\u00ad\nma/ laceration\n \n~\nIsolated head injury\n \n~\nNo risk of wrong \ninformation\n \n~\nLarge scalp haema\u00ad\ntoma\n \n~\nPolytrauma\n \n~\nDangerous mechanism \n(fall from height, car \ncrash etc.)\n \n~\nUnclear information\n58\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Meningitis</p>\n<p>~</p>\n<p>Poisoning</p>\n<p>~</p>\n<p>Other cause of coma</p>\n<p>Management (general principles)</p>\n<p>Management depends on:</p>\n<p>~</p>\n<p>GCS and clinical features at first assessment</p>\n<p>~</p>\n<p>Risk factors (mechanism of trauma, age, baseline condi\u00ad</p>\n<p>tions)</p>\n<p>~</p>\n<p>GCS and clinical features at follow up</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Assess mechanism of injury to assess risks of severe injury</p>\n<p>(which may not be apparent at the beginning)</p>\n<p>\u0089</p>\n<p>Assess medical history to assess risk of complication</p>\n<p>(e.g., elderly, anticoagulant treatment etc.)</p>\n<p>\u0089</p>\n<p>Assess level of consciousness using GCS or AVPU</p>\n<p>\u0089</p>\n<p>Perform general (including ears) and neurological exami\u00ad</p>\n<p>nation (pupils, motor and sensory examination, reflexes)</p>\n<p>- Assess other possible trauma especially if road</p>\n<p>traffic accident, e.g., abdominal or chest trauma</p>\n<p>\u0089</p>\n<p>DO NOT SEDATE. Do NOT give opioids</p>\n<p>\u0089</p>\n<p>Do NOT give NSAIDs (risk of bleeding)</p>\n<h3>HC3</h3>\n<p>Low Risk Mild Head Injury</p>\n<p>High Risk Mild Head Injury</p>\n<p>~</p>\n<p>No persistent head\u00ad</p>\n<p>ache</p>\n<p>~</p>\n<p>No large haemato\u00ad</p>\n<p>ma/ laceration</p>\n<p>~</p>\n<p>Isolated head injury</p>\n<p>~</p>\n<p>No risk of wrong</p>\n<p>information</p>\n<p>~</p>\n<p>Large scalp haema\u00ad</p>\n<p>toma</p>\n<p>~</p>\n<p>Polytrauma</p>\n<p>~</p>\n<p>Dangerous mechanism</p>\n<p>(fall from height, car</p>\n<p>crash etc.)</p>\n<p>~</p>\n<p>Unclear information</p>\n<p>58</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 125,
        "content": "TREATMENT\nLOC\n\t\n\u0089\n>90 mmHg\n\t\n\u0089\nMonitor GCS, pupils and neurological signs\nH\n\t\n\u0089\nEarly CT if available, otherwise observe and refer imme\u00ad\ndiately if not improving in the following hours\nManagement of severe traumatic head injury\nTREATMENT\nLOC\n\t\n\u0089\nEarly CT if available, otherwise observe and refer im\u00ad\nmediately if not improving in the following hours Refer \nimmediately for specialist management f Supportive care \nas per moderate head injury f If open head injury, give \nfirst dose of antibiotic prereferral\n \n- Ceftriaxone 2 g IV\nChild: 100 mg/kg\nNR\nPrevention\n \n~\nCareful (defensive) driving to avoid accidents\n \n~\nUse of safety belts by motorists\n \n~\nWearing of helmets by cyclists, motor-cyclists and people \nworking in hazardous environments\n \n~\nAvoid dangerous activities (e.g., climbing trees)\n1.2.5.1 Traumatic Spinal Injury\nEarly recognition of spinal injury.\nImmobilizations with a rigid cervical collar or thoracolumbar corset to \nprevent further nerve damage.\nDecompression:\nNon operative Skull traction, Skin traction of lower limbs\nOperative e.g., discectomy, anterior or posterior spinal decompression \nsurgery\n59\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>>90 mmHg</p>\n<p>\u0089</p>\n<p>Monitor GCS, pupils and neurological signs</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Early CT if available, otherwise observe and refer imme\u00ad</p>\n<p>diately if not improving in the following hours</p>\n<p>Management of severe traumatic head injury</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Early CT if available, otherwise observe and refer im\u00ad</p>\n<p>mediately if not improving in the following hours Refer</p>\n<p>immediately for specialist management f Supportive care</p>\n<p>as per moderate head injury f If open head injury, give</p>\n<p>first dose of antibiotic prereferral</p>\n<p>- Ceftriaxone 2 g IV</p>\n<p>Child: 100 mg/kg</p>\n<p>NR</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Careful (defensive) driving to avoid accidents</p>\n<p>~</p>\n<p>Use of safety belts by motorists</p>\n<p>~</p>\n<p>Wearing of helmets by cyclists, motor-cyclists and people</p>\n<p>working in hazardous environments</p>\n<p>~</p>\n<p>Avoid dangerous activities (e.g., climbing trees)</p>\n<li>.2.5.1 Traumatic Spinal Injury</li>\n<p>Early recognition of spinal injury.</p>\n<p>Immobilizations with a rigid cervical collar or thoracolumbar corset to</p>\n<p>prevent further nerve damage.</p>\n<p>Decompression:</p>\n<p>Non operative Skull traction, Skin traction of lower limbs</p>\n<p>Operative e.g., discectomy, anterior or posterior spinal decompression</p>\n<p>surgery</p>\n<p>59</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 126,
        "content": "1.2.6 Sexual Assault/Rape               ICD10 CODE Z04.4\nRape is typically defined as oral, anal or vaginal penetration that involves \nthreats or force against an unwilling person.\nSuch penetration, whether wanted or not, is considered statutory rape \nif victims are younger than the age of consent (18 years).\nSexual assault or any other sexual contact that results from coercion is \nrape, including seduction of a child through offers of affection or bribes; \nit also includes being touched, grabbed, kissed or shown genitals.\nClinical features\nRape may result in the following:\nManagement of mild traumatic head injury\nTREATMENT\nLOC\n\t\n\u0089\nFirst aid if necessary\n\t\n\u0089\nMild analgesia if necessary e.g. paracetamol\n\t\n\u0089\nObserve for at least 4-6 hours, monitor GCS and neuro\u00ad\nlogical symptoms\nIf low risk (see above)\n\t\n\u0089\nDischarge on paracetamol\n\t\n\u0089\nAdvise home observation and return to the facility in case \nof any change\nIf high risk\n\t\n\u0089\nMonitor for 24 hours\n\t\n\u0089\nRefer immediately if GCS worsens or other clinical signs \nappear/persist\n\t\n\u0089\nIf patient is fine at the end of observation period, send \nhome with instructions to come back in case of any problem \n(severe headache, seizures, alteration of consciousness, \nlethargy, change in behaviour etc.)\nHC3\n60\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.2.6 Sexual Assault/Rape               ICD10 CODE Z04.4</li>\n<p>Rape is typically defined as oral, anal or vaginal penetration that involves</p>\n<p>threats or force against an unwilling person.</p>\n<p>Such penetration, whether wanted or not, is considered statutory rape</p>\n<p>if victims are younger than the age of consent (18 years).</p>\n<p>Sexual assault or any other sexual contact that results from coercion is</p>\n<p>rape, including seduction of a child through offers of affection or bribes;</p>\n<p>it also includes being touched, grabbed, kissed or shown genitals.</p>\n<p>Clinical features</p>\n<p>Rape may result in the following:</p>\n<p>Management of mild traumatic head injury</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>First aid if necessary</p>\n<p>\u0089</p>\n<p>Mild analgesia if necessary e.g. paracetamol</p>\n<p>\u0089</p>\n<p>Observe for at least 4-6 hours, monitor GCS and neuro\u00ad</p>\n<p>logical symptoms</p>\n<p>If low risk (see above)</p>\n<p>\u0089</p>\n<p>Discharge on paracetamol</p>\n<p>\u0089</p>\n<p>Advise home observation and return to the facility in case</p>\n<p>of any change</p>\n<p>If high risk</p>\n<p>\u0089</p>\n<p>Monitor for 24 hours</p>\n<p>\u0089</p>\n<p>Refer immediately if GCS worsens or other clinical signs</p>\n<p>appear/persist</p>\n<p>\u0089</p>\n<p>If patient is fine at the end of observation period, send</p>\n<p>home with instructions to come back in case of any problem</p>\n<p>(severe headache, seizures, alteration of consciousness,</p>\n<p>lethargy, change in behaviour etc.)</p>\n<h3>HC3</h3>\n<p>60</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 127,
        "content": "~\nExtragenital injury\n \n~\nGenital injury (usually minor, but some vaginal lacerations \ncan be severe)\n \n~\nPsychologic symptoms: often the most prominent\n \n- Short term: fear, nightmares, sleep problems, anger, \nembarrassment\n \n- Long term: Post traumatic Stress Disorder, an anxiety\n \n- disorder; symptoms include re-experiencing (e.g., flashbacks, \nintrusive upsetting thoughts or images), avoidance (e.g., \nof trauma-related situations, thoughts, and feelings) and \nhyperarousal (e.g., sleep difficulties, irritability, concentration \nproblems).\n \n- Symptoms last for >1 month and significantly impair social \nand occupational functioning.\n \n- Shame, guilt or a combination of both\n \n- Sexually transmitted infections (STIs, e.g., hepatitis, syphilis, \ngonorrhea, chlamydial infection, trichomoniasis, HIV \ninfection)\n \n~\nPregnancy (may occur)\nNote\n \n\u0083 Headaches and dizziness following mild traumatic brain injury \nmay persist for weeks/months\nManagement of moderate traumatic head injury\nTREATMENT\nLOC\n\t\n\u0089\nRefer to hospital for appropriate management\n\t\n\u0089\nCareful positioning (head 300 up)\n\t\n\u0089\nUse fluids with caution\n\t\n\u0089\nKeep oxygen saturation >90% and systolic BP\nH\n61\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Extragenital injury</p>\n<p>~</p>\n<p>Genital injury (usually minor, but some vaginal lacerations</p>\n<p>can be severe)</p>\n<p>~</p>\n<p>Psychologic symptoms: often the most prominent</p>\n<p>- Short term: fear, nightmares, sleep problems, anger,</p>\n<p>embarrassment</p>\n<p>- Long term: Post traumatic Stress Disorder, an anxiety</p>\n<p>- disorder; symptoms include re-experiencing (e.g., flashbacks,</p>\n<p>intrusive upsetting thoughts or images), avoidance (e.g.,</p>\n<p>of trauma-related situations, thoughts, and feelings) and</p>\n<p>hyperarousal (e.g., sleep difficulties, irritability, concentration</p>\n<p>problems).</p>\n<p>- Symptoms last for >1 month and significantly impair social</p>\n<p>and occupational functioning.</p>\n<p>- Shame, guilt or a combination of both</p>\n<p>- Sexually transmitted infections (STIs, e.g., hepatitis, syphilis,</p>\n<p>gonorrhea, chlamydial infection, trichomoniasis, HIV</p>\n<p>infection)</p>\n<p>~</p>\n<p>Pregnancy (may occur)</p>\n<p>Note</p>\n<p>\u0083 Headaches and dizziness following mild traumatic brain injury</p>\n<p>may persist for weeks/months</p>\n<p>Management of moderate traumatic head injury</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to hospital for appropriate management</p>\n<p>\u0089</p>\n<p>Careful positioning (head 300 up)</p>\n<p>\u0089</p>\n<p>Use fluids with caution</p>\n<p>\u0089</p>\n<p>Keep oxygen saturation >90% and systolic BP</p>\n<p>H</p>\n<p>61</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 128,
        "content": "Investigations\n \n\u0081\nPregnancy test\n \n\u0081\nHIV, hepatitis B and RPR tests\nManagement\nWhenever possible, assessment of a rape case should be done by a specially \ntrained provider. Victims are traumatized so should be approached with \nempathy and respect. Explain and ask consent for every step undertaken.\nThe goals are:\n \n~\nMedical assessment and treatment of injuries\n \n~\nAssessment, treatment and prevention of pregnancy and \nSTIs\nCollection of forensic evidence\n \n~\nPsychologic evaluation and support\nTREATMENT\nLOC\n\t\n\u0089\nAdvise not to throw out or change clothing, wash, shower, \ndouche, brush their teeth or use mouthwash; doing so \nmay destroy evidence\nHC2\n\t\n\u0089\nInitial assessment (history and examination) \u2013 use standard \nforms if available\n \n- Type of injuries sustained (particularly to the\n \n- mouth, breasts, vagina and rectum)\n \n- Any bleeding from or abrasions on the patient or \nassailant (to help assess the risk of transmission of \nHIV and hepatitis)\n \n- Description of the attack (e.g., the orifices which\n \n- were penetrated, whether ejaculation occurred, or \nwhether a condom was used)\nHC4\n62\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Pregnancy test</p>\n<p>\u0081</p>\n<p>HIV, hepatitis B and RPR tests</p>\n<p>Management</p>\n<p>Whenever possible, assessment of a rape case should be done by a specially</p>\n<p>trained provider. Victims are traumatized so should be approached with</p>\n<p>empathy and respect. Explain and ask consent for every step undertaken.</p>\n<p>The goals are:</p>\n<p>~</p>\n<p>Medical assessment and treatment of injuries</p>\n<p>~</p>\n<p>Assessment, treatment and prevention of pregnancy and</p>\n<p>STIs</p>\n<p>Collection of forensic evidence</p>\n<p>~</p>\n<p>Psychologic evaluation and support</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Advise not to throw out or change clothing, wash, shower,</p>\n<p>douche, brush their teeth or use mouthwash; doing so</p>\n<p>may destroy evidence</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Initial assessment (history and examination) \u2013 use standard</p>\n<p>forms if available</p>\n<p>- Type of injuries sustained (particularly to the</p>\n<p>- mouth, breasts, vagina and rectum)</p>\n<p>- Any bleeding from or abrasions on the patient or</p>\n<p>assailant (to help assess the risk of transmission of</p>\n<p>HIV and hepatitis)</p>\n<p>- Description of the attack (e.g., the orifices which</p>\n<p>- were penetrated, whether ejaculation occurred, or</p>\n<p>whether a condom was used)</p>\n<h3>HC4</h3>\n<p>62</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 129,
        "content": "TREATMENT\nLOC\n \n- Assailant\u2019s use of aggression, threats, weapons\n \n- and violent behavior\n \n- Description of the assailant\n \n- Use of contraceptives (to assess risk of pregnancy), \nprevious coitus (to assess validity of sperm testing)\n \n- Clearly describe size, extent, nature of any injury.\n \n- If possible take photos of the lesions (with patient\u2019s \nconsent)\nHC4\n\t\n\u0089\nTest for HIV, RPR, hepatitis B and pregnancy, to assess \nbaseline status of the patient\n \n- If possible test for flunitrazepam and gamma \nhydroxybutyrate (\u201drape drugs\u201d)\nHC4\n\t\n\u0089\nCollect forensic evidence (with standard kits if available)\n \n- Condition of clothing (e.g., damaged, stained,\n \n- adhering foreign material)\n \n- Small samples of clothing including an unstained \nsample, given to the police or laboratory\n \n- Hair samples, including loose hairs adhering to\n \n- the patient or clothing, semen-encrusted pubic \nhair, and clipped scalp and pubic hairs of the \npatient (at least 10 of each for comparison)\n \n- Semen taken from the cervix, vagina, rectum, \nmouth and thighs\n \n- Blood taken from the patient\n \n- Dried samples of the assailant\u2019s blood taken from \nthe patient\u2019s body and clothing\n \n- Urine, saliva\n \n- Smears of buccal mucosa\n \n- Fingernail clippings and scrapings\n \n- Other specimen as indicated by the history or \nphysical examination\n63\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Assailant\u2019s use of aggression, threats, weapons</p>\n<p>- and violent behavior</p>\n<p>- Description of the assailant</p>\n<p>- Use of contraceptives (to assess risk of pregnancy),</p>\n<p>previous coitus (to assess validity of sperm testing)</p>\n<p>- Clearly describe size, extent, nature of any injury.</p>\n<p>- If possible take photos of the lesions (with patient\u2019s</p>\n<p>consent)</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Test for HIV, RPR, hepatitis B and pregnancy, to assess</p>\n<p>baseline status of the patient</p>\n<p>- If possible test for flunitrazepam and gamma</p>\n<p>hydroxybutyrate (\u201drape drugs\u201d)</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Collect forensic evidence (with standard kits if available)</p>\n<p>- Condition of clothing (e.g., damaged, stained,</p>\n<p>- adhering foreign material)</p>\n<p>- Small samples of clothing including an unstained</p>\n<p>sample, given to the police or laboratory</p>\n<p>- Hair samples, including loose hairs adhering to</p>\n<p>- the patient or clothing, semen-encrusted pubic</p>\n<p>hair, and clipped scalp and pubic hairs of the</p>\n<p>patient (at least 10 of each for comparison)</p>\n<p>- Semen taken from the cervix, vagina, rectum,</p>\n<p>mouth and thighs</p>\n<p>- Blood taken from the patient</p>\n<p>- Dried samples of the assailant\u2019s blood taken from</p>\n<p>the patient\u2019s body and clothing</p>\n<p>- Urine, saliva</p>\n<p>- Smears of buccal mucosa</p>\n<p>- Fingernail clippings and scrapings</p>\n<p>- Other specimen as indicated by the history or</p>\n<p>physical examination</p>\n<p>63</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 130,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nProphylaxis for STD including:\n \n- Ceftriaxone 1g IM or cefixime 400 mg orally stat\n \n- Azithromycin 1 g stat or doxycycline 100 mg\n \n- twice a day for 1 week\n \n- Metronidazole 2 g stat\n \n- HIV Post Exposure Prophylaxis if within 72 hours:\nAdults : TDF+3TC+ATV/r for 28 days\nChildren: ABC+3TC+LPV/r\n\t\n\u0089\nHepatitis B vaccine if not already immunised\n\t\n\u0089\nEmergency contraception if within 72 hours (but may \nbe useful up to 5 days after)\n \n- Levonorgestrel 1.5 mg (double the dose if patient \nis HIV positive on ARVs)\nHC4\n\t\n\u0089\nCounselling: use common sense measures (e.g., reas\u00ad\nsurance, general support, non-judgmental attitude) to \nrelieve strong emotions of guilt or anxiety\n\t\n\u0089\nProvide links and referral to:\n \n- Long-term psycho-social support\n \n- Legal counseling\n \n- Police investigations, restraining orders\n \n- Child protection services\n \n- Economic empowerment, emergency shelters\n \n- Long-term case management\nNotes\n \n\u0083 Because the full psychologic effects cannot always be \nascertained at the first examination, follow-up visits \nshould be scheduled at 2 weeks intervals\n \n\u0083 Reporting: Health facilities should use HMIS 105 to \nreport Gender-Based Violence (GBV)\n64\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Prophylaxis for STD including:</p>\n<p>- Ceftriaxone 1g IM or cefixime 400 mg orally stat</p>\n<p>- Azithromycin 1 g stat or doxycycline 100 mg</p>\n<p>- twice a day for 1 week</p>\n<p>- Metronidazole 2 g stat</p>\n<p>- HIV Post Exposure Prophylaxis if within 72 hours:</p>\n<p>Adults : TDF+3TC+ATV/r for 28 days</p>\n<p>Children: ABC+3TC+LPV/r</p>\n<p>\u0089</p>\n<p>Hepatitis B vaccine if not already immunised</p>\n<p>\u0089</p>\n<p>Emergency contraception if within 72 hours (but may</p>\n<p>be useful up to 5 days after)</p>\n<p>- Levonorgestrel 1.5 mg (double the dose if patient</p>\n<p>is HIV positive on ARVs)</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Counselling: use common sense measures (e.g., reas\u00ad</p>\n<p>surance, general support, non-judgmental attitude) to</p>\n<p>relieve strong emotions of guilt or anxiety</p>\n<p>\u0089</p>\n<p>Provide links and referral to:</p>\n<p>- Long-term psycho-social support</p>\n<p>- Legal counseling</p>\n<p>- Police investigations, restraining orders</p>\n<p>- Child protection services</p>\n<p>- Economic empowerment, emergency shelters</p>\n<p>- Long-term case management</p>\n<p>Notes</p>\n<p>\u0083 Because the full psychologic effects cannot always be</p>\n<p>ascertained at the first examination, follow-up visits</p>\n<p>should be scheduled at 2 weeks intervals</p>\n<p>\u0083 Reporting: Health facilities should use HMIS 105 to</p>\n<p>report Gender-Based Violence (GBV)</p>\n<p>64</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 131,
        "content": "TREATMENT\nLOC\nHarm classification for police reporting\n \n~\nHarm: any body hurt, disease or disorders, \nwhether permanent or temporary\n \n~\nGrievous harm: any harm which amounts to a \nmain or dangerous harm, or seriously or per\u00ad\nmanently injures health, or causes permanent \ndisfigurement or any permanent injeury to any \ninternal or external organ, membrane or sense\n \n~\nDangerous harm: means harm endangering life\n \n~\n\u201dMain\u201d means the destruction or permanent dis\u00ad\nabling of any external membrane or sense\n1.3 POISONING\n1.3.1 General Management of Poisoning   ICD10 CODE: T36-T50\nBodily entry of toxic substances in amounts that cause dysfunction of \nbody systems.\nCauses\n \n~\nMicroorganisms (food poisoning)\n \n~\nFluids and gases (organic), e.g., agricultural chemicals, pet\u00ad\nrol, paraffin, carbon monoxide\n \n~\nMetal poisoning (inorganic), e.g., lead, mercury, copper\n \n~\nAlcohol, drugs of abuse, medicines (in excessive amounts)\nAcute poisoning can occur by ingestion, inhalation, injection or cutane\u00ad\nous/mucosal absorption.\nExposure can be intentional (e.g., suicide or homicide attempt), uninten\u00ad\ntional (e.g., medication error) or environmental/ occupational.\n65\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Harm classification for police reporting</p>\n<p>~</p>\n<p>Harm: any body hurt, disease or disorders,</p>\n<p>whether permanent or temporary</p>\n<p>~</p>\n<p>Grievous harm: any harm which amounts to a</p>\n<p>main or dangerous harm, or seriously or per\u00ad</p>\n<p>manently injures health, or causes permanent</p>\n<p>disfigurement or any permanent injeury to any</p>\n<p>internal or external organ, membrane or sense</p>\n<p>~</p>\n<p>Dangerous harm: means harm endangering life</p>\n<p>~</p>\n<p>\u201dMain\u201d means the destruction or permanent dis\u00ad</p>\n<p>abling of any external membrane or sense</p>\n<h3>1.3 POISONING</h3>\n<li>.3.1 General Management of Poisoning   ICD10 CODE: T36-T50</li>\n<p>Bodily entry of toxic substances in amounts that cause dysfunction of</p>\n<p>body systems.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Microorganisms (food poisoning)</p>\n<p>~</p>\n<p>Fluids and gases (organic), e.g., agricultural chemicals, pet\u00ad</p>\n<p>rol, paraffin, carbon monoxide</p>\n<p>~</p>\n<p>Metal poisoning (inorganic), e.g., lead, mercury, copper</p>\n<p>~</p>\n<p>Alcohol, drugs of abuse, medicines (in excessive amounts)</p>\n<p>Acute poisoning can occur by ingestion, inhalation, injection or cutane\u00ad</p>\n<p>ous/mucosal absorption.</p>\n<p>Exposure can be intentional (e.g., suicide or homicide attempt), uninten\u00ad</p>\n<p>tional (e.g., medication error) or environmental/ occupational.</p>\n<p>65</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 132,
        "content": "Principles of general management\n\t\n\u0089\nIf possible, refer patients showing signs of poisoning to hospital \nfor admission. Send a note of what is known about the poison and \nwhat treatment has been given\n\t\n\u0089\nAlso refer/admit  patients who have taken slow-acting poisons even \nif they appear well. These include: acetylsalicylic acid, iron, par\u00ad\nacetamol, tricyclic antidepressants (e.g., amitriptyline, imipramine), \nparaquat, modified-release products\n\t\n\u0089\nOptimal management of the poisoned patient depends upon the \nspecific poison(s) involved, the presenting and predicted severity of \nillness and time that has elapsed between exposure and presentation\n\t\n\u0089\nTreatment includes supportive care, decontamination, antidotal \ntherapy and enhanced elimination techniques\n\t\n\u0089\nIt may not always be possible to identify the poison and the amount \ntaken. Anyway,\n\t\n\u0089\nOnly a few poisons have specific antidotes\n\t\n\u0089\nFew patients need active removal of the poison\n\t\n\u0089\nMost patients must be treated symptomatically\nHowever, knowledge of the poison will help you anticipate the likely \neffects on the patient.\nSupportive Treatment in Poisoning\nTREATMENT\nLOC\n\t\n\u0089\nEnsure safety of the patient and minimize/stop exposure \ne.g., wash off/clean skin with water and soap\n\t\n\u0089\nMonitor and stabilize all vitals (blood pressure, heart rate, \nrespiratory rate, oxygen saturation AND temperature)\nHC2\n66\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Principles of general management</p>\n<p>\u0089</p>\n<p>If possible, refer patients showing signs of poisoning to hospital</p>\n<p>for admission. Send a note of what is known about the poison and</p>\n<p>what treatment has been given</p>\n<p>\u0089</p>\n<p>Also refer/admit  patients who have taken slow-acting poisons even</p>\n<p>if they appear well. These include: acetylsalicylic acid, iron, par\u00ad</p>\n<p>acetamol, tricyclic antidepressants (e.g., amitriptyline, imipramine),</p>\n<p>paraquat, modified-release products</p>\n<p>\u0089</p>\n<p>Optimal management of the poisoned patient depends upon the</p>\n<p>specific poison(s) involved, the presenting and predicted severity of</p>\n<p>illness and time that has elapsed between exposure and presentation</p>\n<p>\u0089</p>\n<p>Treatment includes supportive care, decontamination, antidotal</p>\n<p>therapy and enhanced elimination techniques</p>\n<p>\u0089</p>\n<p>It may not always be possible to identify the poison and the amount</p>\n<p>taken. Anyway,</p>\n<p>\u0089</p>\n<p>Only a few poisons have specific antidotes</p>\n<p>\u0089</p>\n<p>Few patients need active removal of the poison</p>\n<p>\u0089</p>\n<p>Most patients must be treated symptomatically</p>\n<p>However, knowledge of the poison will help you anticipate the likely</p>\n<p>effects on the patient.</p>\n<p>Supportive Treatment in Poisoning</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure safety of the patient and minimize/stop exposure</p>\n<p>e.g., wash off/clean skin with water and soap</p>\n<p>\u0089</p>\n<p>Monitor and stabilize all vitals (blood pressure, heart rate,</p>\n<p>respiratory rate, oxygen saturation AND temperature)</p>\n<h3>HC2</h3>\n<p>66</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 133,
        "content": "TREATMENT\nLOC\nAirway and breathing (often impaired in unconscious \npatient)\n\t\n\u0089\nEnsure the airway is cleared and maintained\n\t\n\u0089\nInsert an airway cannula if necessary\n\t\n\u0089\nPosition patient semiprone to minimise risk of inhalation \nof vomit\n\t\n\u0089\nAssist ventilation if necessary\n\t\n\u0089\nAdminister oxygen if necessary\nHC2\nHC4\nBlood pressure\n \n- Hypotension is common in severe poisoning with \nCNS depressants. A systolic BP <70 mmHg may \ncause irreversible brain or renal damage\n\t\n\u0089\n Carry the patient\u2019s head down on the stretcher and \nnurse in this position in the ambulance\nHC2\n\t\n\u0089\nSet up an IV normal saline line\n \n- Fluid depletion without hypotension is common \nafter prolonged coma and after aspirin poisoning \ndue to vomiting, sweating and hyperpnoea\n\t\n\u0089\nHypertension is less common but may be associated \nwith sympathomimetic poisoning e.g. amphetamines, \ncocaine, pseudoephedrine\nHC3\nHeart\n \n- Cardiac conduction defects and arrhythmias may \noccur in acute poisoning especially with tricyclic \nantidepressants, but the defects usually respond \nto correction of any hypoxia or acidosis\nHC4\n67\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Airway and breathing (often impaired in unconscious</p>\n<p>patient)</p>\n<p>\u0089</p>\n<p>Ensure the airway is cleared and maintained</p>\n<p>\u0089</p>\n<p>Insert an airway cannula if necessary</p>\n<p>\u0089</p>\n<p>Position patient semiprone to minimise risk of inhalation</p>\n<p>of vomit</p>\n<p>\u0089</p>\n<p>Assist ventilation if necessary</p>\n<p>\u0089</p>\n<p>Administer oxygen if necessary</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Blood pressure</p>\n<p>- Hypotension is common in severe poisoning with</p>\n<p>CNS depressants. A systolic BP <70 mmHg may</p>\n<p>cause irreversible brain or renal damage</p>\n<p>\u0089</p>\n<p>Carry the patient\u2019s head down on the stretcher and</p>\n<p>nurse in this position in the ambulance</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Set up an IV normal saline line</p>\n<p>- Fluid depletion without hypotension is common</p>\n<p>after prolonged coma and after aspirin poisoning</p>\n<p>due to vomiting, sweating and hyperpnoea</p>\n<p>\u0089</p>\n<p>Hypertension is less common but may be associated</p>\n<p>with sympathomimetic poisoning e.g. amphetamines,</p>\n<p>cocaine, pseudoephedrine</p>\n<h3>HC3</h3>\n<p>Heart</p>\n<p>- Cardiac conduction defects and arrhythmias may</p>\n<p>occur in acute poisoning especially with tricyclic</p>\n<p>antidepressants, but the defects usually respond</p>\n<p>to correction of any hypoxia or acidosis</p>\n<h3>HC4</h3>\n<p>67</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 134,
        "content": "TREATMENT\nLOC\nBody temperature\n \n- Hypothermia may develop in patients with \nprolonged unconciousness especially after \noverdose of barbiturates or phenothiazines e.g., \nchlorpromazine, trifluoperazine\n \n- Hypothermia may be missed unless temperature \nis monitored\n \n- Treat by covering the patient with a blanket\n \n- f Hyperthermia may occur with anticholinergics \nand sympathomimetics\n \n- Treat by tepid sponging and antipyretics if\n \n- appropriate\nHC2\nConvulsions\n\t\n\u0089\nDiazepam 10 mg rectally repeated if necessary Child: \n0.5 mg/kg per dose (1.5-2.5 mg if <1 month, 5 mg if \n1 month-2 years, 5-10 mg if 2-12 years) Or diazepam \n5- 10 mg slow IV repeated if necessary max 30 mg\nChild: 200 micrograms (0.2 mg)/kg max 10 mg\nHC2\nHC3\nOther considerations\n\t\n\u0089\nCounsel patient and families concerning poisoning\n\t\n\u0089\nA psychiatric evaluation is necessary if poisoning was \nintentional\n\t\n\u0089\nIf environmental or ccupational exposure, follow up \nto assess if other people have been affected and take \nappropriate measures\nHC4\n1.3.1.2 Removal and Elimination of Ingested Poison \nRemoval and elimination of poison (decontamination) has to be imple\u00ad\nmented AFTER stabilization of vital signs.\n68\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Body temperature</p>\n<p>- Hypothermia may develop in patients with</p>\n<p>prolonged unconciousness especially after</p>\n<p>overdose of barbiturates or phenothiazines e.g.,</p>\n<p>chlorpromazine, trifluoperazine</p>\n<p>- Hypothermia may be missed unless temperature</p>\n<p>is monitored</p>\n<p>- Treat by covering the patient with a blanket</p>\n<p>- f Hyperthermia may occur with anticholinergics</p>\n<p>and sympathomimetics</p>\n<p>- Treat by tepid sponging and antipyretics if</p>\n<p>- appropriate</p>\n<h3>HC2</h3>\n<p>Convulsions</p>\n<p>\u0089</p>\n<p>Diazepam 10 mg rectally repeated if necessary Child:</p>\n<p>0.5 mg/kg per dose (1.5-2.5 mg if <1 month, 5 mg if</p>\n<p>1 month-2 years, 5-10 mg if 2-12 years) Or diazepam</p>\n<p>5- 10 mg slow IV repeated if necessary max 30 mg</p>\n<p>Child: 200 micrograms (0.2 mg)/kg max 10 mg</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Other considerations</p>\n<p>\u0089</p>\n<p>Counsel patient and families concerning poisoning</p>\n<p>\u0089</p>\n<p>A psychiatric evaluation is necessary if poisoning was</p>\n<p>intentional</p>\n<p>\u0089</p>\n<p>If environmental or ccupational exposure, follow up</p>\n<p>to assess if other people have been affected and take</p>\n<p>appropriate measures</p>\n<h3>HC4</h3>\n<li>.3.1.2 Removal and Elimination of Ingested Poison</li>\n<p>Removal and elimination of poison (decontamination) has to be imple\u00ad</p>\n<p>mented AFTER stabilization of vital signs.</p>\n<p>68</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 135,
        "content": "Removal from the stomach\n \n~\nBalance the dangers of attempting to empty the stomach \nagainst the likely toxicity of any swallowed poison as deter\u00ad\nmined by the type of poison and amount swallowed against \nthe risk of inhalation\n \n~\nDo not induce vomiting\n \n~\nGastric lavage\n\t\n\u0089\nOnly useful if done within 2 hours of poisoning (except with salicylates \nor anticholinergics when it may be of use within 4 to 6 hours)\n\t\n\u0089\nSeldom practicable or necessary before the patient reaches hospital\n\t\n\u0089\nContraindications: drowsy or comatose patients and if poisoning with \ncorrosive or petroleum products\nPrevention of absorption and active elimination\n \n~\nOral activated charcoal can bind many poisons in the stom\u00ad\nach and reduce their absorption\n \n~\nIt is more effective the sooner it is given but may still work \nup to 2 hours after poisoning (longer with modified-release \nproducts and anticholinergics)\n \n~\nContraindications\n \n- Depressed mental status\n \n- Late presentation\n \n- Ingestion of corrosives and petroleum products\n \n- Toxins poorly absorbed by charcoal (e.g. metals like iron, \nlithium, alcohol)\n \n- Intestinal obstruction\n \n~\nIt is generally safe and especially useful for poisons toxic in small \namounts, e.g. antidepressants\n69\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Removal from the stomach</p>\n<p>~</p>\n<p>Balance the dangers of attempting to empty the stomach</p>\n<p>against the likely toxicity of any swallowed poison as deter\u00ad</p>\n<p>mined by the type of poison and amount swallowed against</p>\n<p>the risk of inhalation</p>\n<p>~</p>\n<p>Do not induce vomiting</p>\n<p>~</p>\n<p>Gastric lavage</p>\n<p>\u0089</p>\n<p>Only useful if done within 2 hours of poisoning (except with salicylates</p>\n<p>or anticholinergics when it may be of use within 4 to 6 hours)</p>\n<p>\u0089</p>\n<p>Seldom practicable or necessary before the patient reaches hospital</p>\n<p>\u0089</p>\n<p>Contraindications: drowsy or comatose patients and if poisoning with</p>\n<p>corrosive or petroleum products</p>\n<p>Prevention of absorption and active elimination</p>\n<p>~</p>\n<p>Oral activated charcoal can bind many poisons in the stom\u00ad</p>\n<p>ach and reduce their absorption</p>\n<p>~</p>\n<p>It is more effective the sooner it is given but may still work</p>\n<p>up to 2 hours after poisoning (longer with modified-release</p>\n<p>products and anticholinergics)</p>\n<p>~</p>\n<p>Contraindications</p>\n<p>- Depressed mental status</p>\n<p>- Late presentation</p>\n<p>- Ingestion of corrosives and petroleum products</p>\n<p>- Toxins poorly absorbed by charcoal (e.g. metals like iron,</p>\n<p>lithium, alcohol)</p>\n<p>- Intestinal obstruction</p>\n<p>~</p>\n<p>It is generally safe and especially useful for poisons toxic in small</p>\n<p>amounts, e.g. antidepressants</p>\n<p>69</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 136,
        "content": "TREATMENT\nLOC\nPrevention of absorption\n\t\n\u0089\nDose: activated charcoal powder 50 g\nChild: 0.5-1 g/kg\n \n- Grind tablets into a fine powder before mixing \nwith 100-200 ml of water (50 g = 200 tablets of \n250 mg)\n \n- If patient unable to swallow the charcoal/water\n \n- mixture (slurry), give by gastric lavage tube\nActive elimination\n\t\n\u0089\nRepeated doses of activated charcoal may be beneficial \nin some cases, e.g., acetylsalicylic acid, carbamaze\u00ad\npine, phenobarbital, phenytoin, quinine, theophylline\n \n- Give activated charcoal 50 g repeated every \n4 hours\nHC2\n\t\n\u0089\nTreat any vomiting as this may reduce the effectiveness \nof the charcoal\nIn case of intolerance\n\t\n\u0089\nReduce dose and increase frequency, e.g., 25 g every \n2 hours, or 12.5 g every hour\n1.3.2 Acute Organophosphate Poisoning           ICD10 CODE: T60.0\nOrganophosphates are ingredients of some pesticides and insecticides \nintended for agricultural and household use. Poisoning occurs by ingestion, \ninhalation or absorption through the skin.\nCauses\n \n~\nMay be accidental, e.g., contamination of food\n \n~\nIntended poisoning, i.e., suicidal or homicidal\n70\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Prevention of absorption</p>\n<p>\u0089</p>\n<p>Dose: activated charcoal powder 50 g</p>\n<p>Child: 0.5-1 g/kg</p>\n<p>- Grind tablets into a fine powder before mixing</p>\n<p>with 100-200 ml of water (50 g = 200 tablets of</p>\n<p>250 mg)</p>\n<p>- If patient unable to swallow the charcoal/water</p>\n<p>- mixture (slurry), give by gastric lavage tube</p>\n<p>Active elimination</p>\n<p>\u0089</p>\n<p>Repeated doses of activated charcoal may be beneficial</p>\n<p>in some cases, e.g., acetylsalicylic acid, carbamaze\u00ad</p>\n<p>pine, phenobarbital, phenytoin, quinine, theophylline</p>\n<p>- Give activated charcoal 50 g repeated every</p>\n<p>4 hours</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Treat any vomiting as this may reduce the effectiveness</p>\n<p>of the charcoal</p>\n<p>In case of intolerance</p>\n<p>\u0089</p>\n<p>Reduce dose and increase frequency, e.g., 25 g every</p>\n<p>2 hours, or 12.5 g every hour</p>\n<li>.3.2 Acute Organophosphate Poisoning           ICD10 CODE: T60.0</li>\n<p>Organophosphates are ingredients of some pesticides and insecticides</p>\n<p>intended for agricultural and household use. Poisoning occurs by ingestion,</p>\n<p>inhalation or absorption through the skin.</p>\n<p>Causes</p>\n<p>~</p>\n<p>May be accidental, e.g., contamination of food</p>\n<p>~</p>\n<p>Intended poisoning, i.e., suicidal or homicidal</p>\n<p>70</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 137,
        "content": "~\nOccupational hazard, e.g., agricultural workers\nClinical features\n \n~\nPatient may smell of the chemicals\n \n~\nConstricted pupils\n \n~\nCold sweat, anxiety, restlessness\n \n~\nAbdominal pain, diarrhoea and vomiting\n \n~\nTwitching, convulsions\n \n~\nBradycardia\n \n~\nExcessive salivation, difficulty in breathing, abundant respi\u00ad\nratory secretions\n \n~\nHeadache, hypotension, urine incontinence\n \n~\nComa\nDifferential diagnosis\n \n~\nOther causes of poisoning\n \n~\nOther causes of convulsions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRemove contaminated clothing (use gloves) \n\t\n\u0089\nWash contaminated skin with lots of water \n\t\n\u0089\nEstablish and maintain the airway\n\t\n\u0089\nAssisted respiration with air or oxygen may be required \nduring the first 24 hours after poisoning\n\t\n\u0089\nGive IV fluids, e.g., normal saline prn for dehydration, \nhypovolaemia, and shock\n\t\n\u0089\nPrevent and treat convulsions with diazepam 10 mg IV\nChild: 0.2 mg/kg IV or 0.5 mg/kg rectal\n\t\n\u0089\nSalbutamol 5 mg (2.5 mg for children <5 years) nebuli\u00ad\nsation if bronchospasm:\nHC4\n71\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Occupational hazard, e.g., agricultural workers</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Patient may smell of the chemicals</p>\n<p>~</p>\n<p>Constricted pupils</p>\n<p>~</p>\n<p>Cold sweat, anxiety, restlessness</p>\n<p>~</p>\n<p>Abdominal pain, diarrhoea and vomiting</p>\n<p>~</p>\n<p>Twitching, convulsions</p>\n<p>~</p>\n<p>Bradycardia</p>\n<p>~</p>\n<p>Excessive salivation, difficulty in breathing, abundant respi\u00ad</p>\n<p>ratory secretions</p>\n<p>~</p>\n<p>Headache, hypotension, urine incontinence</p>\n<p>~</p>\n<p>Coma</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of poisoning</p>\n<p>~</p>\n<p>Other causes of convulsions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Remove contaminated clothing (use gloves)</p>\n<p>\u0089</p>\n<p>Wash contaminated skin with lots of water</p>\n<p>\u0089</p>\n<p>Establish and maintain the airway</p>\n<p>\u0089</p>\n<p>Assisted respiration with air or oxygen may be required</p>\n<p>during the first 24 hours after poisoning</p>\n<p>\u0089</p>\n<p>Give IV fluids, e.g., normal saline prn for dehydration,</p>\n<p>hypovolaemia, and shock</p>\n<p>\u0089</p>\n<p>Prevent and treat convulsions with diazepam 10 mg IV</p>\n<p>Child: 0.2 mg/kg IV or 0.5 mg/kg rectal</p>\n<p>\u0089</p>\n<p>Salbutamol 5 mg (2.5 mg for children <5 years) nebuli\u00ad</p>\n<p>sation if bronchospasm:</p>\n<h3>HC4</h3>\n<p>71</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 138,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nPerform gastric lavage if the poison was ingested (up to \n6 hours after ingestion) but consider risk of aspiration\n\t\n\u0089\nGive standard dose of activated charcoal if patient presents \nwithin 2 (up to 4) hours\n\t\n\u0089\nMonitor patient for a few days (worsening can occur a \nfew days after ingestion)\nIn moderate to severe poisoning (only if not responding to \nadequate doses of atropine) \n\t\n\u0089\nAdd pralidoxime mesylate 30 mg/kg IV over 30 minutes\nChild: 25-50 mg/kg IV\n \n- Continue with infusion 8 mg/kg/hour\n \n- Child: 10-20 mg/kg/hour\nNote\n \n\u0083 Pralidoxime: Only effective if given within 24 hours of \npoisoning\nPrevention\n \n~\nLabel agricultural and domestic pesticides properly \u2013 do \nnot use unlabelled bottles for pesticides\n \n~\nStore such products away from children\n \n~\nWear protective clothing when using the products\n1.3.3 Paraffin and Other Petroleum Products Poisoning\t ICD10 \nCODE: T53.7\nIncludes paraffin, petrol, paint thinners, organic solvents, and turpentine.\nClinical features\n \n~\nPatient may smell of paraffin/other petroleum product\n \n~\nBurning sensation in mouth and throat\n \n~\nPatient looks pale (transient cyanosis)\n72\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Perform gastric lavage if the poison was ingested (up to</p>\n<p>6 hours after ingestion) but consider risk of aspiration</p>\n<p>\u0089</p>\n<p>Give standard dose of activated charcoal if patient presents</p>\n<p>within 2 (up to 4) hours</p>\n<p>\u0089</p>\n<p>Monitor patient for a few days (worsening can occur a</p>\n<p>few days after ingestion)</p>\n<p>In moderate to severe poisoning (only if not responding to</p>\n<p>adequate doses of atropine)</p>\n<p>\u0089</p>\n<p>Add pralidoxime mesylate 30 mg/kg IV over 30 minutes</p>\n<p>Child: 25-50 mg/kg IV</p>\n<p>- Continue with infusion 8 mg/kg/hour</p>\n<p>- Child: 10-20 mg/kg/hour</p>\n<p>Note</p>\n<p>\u0083 Pralidoxime: Only effective if given within 24 hours of</p>\n<p>poisoning</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Label agricultural and domestic pesticides properly \u2013 do</p>\n<p>not use unlabelled bottles for pesticides</p>\n<p>~</p>\n<p>Store such products away from children</p>\n<p>~</p>\n<p>Wear protective clothing when using the products</p>\n<li>.3.3 Paraffin and Other Petroleum Products Poisoning\t ICD10</li>\n<h3>CODE: T53.7</h3>\n<p>Includes paraffin, petrol, paint thinners, organic solvents, and turpentine.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Patient may smell of paraffin/other petroleum product</p>\n<p>~</p>\n<p>Burning sensation in mouth and throat</p>\n<p>~</p>\n<p>Patient looks pale (transient cyanosis)</p>\n<p>72</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 139,
        "content": "~\nVomiting, diarrhoea, bloody stools\n \n~\nCough, dyspnoea, wheezing, tachypnoea, nasal flaring (due \nto chemical pneumonitis)\n \n~\nLethargy, convulsions, difficulty in breathing\nThe main risk is damage to lung tissue due to aspiration. AVOID \ngastric lavage or use of emetics as this may lead to inhalation of \ngastric content and pneumonitis\nDifferential diagnosis\n \n~\nOther causes of poisoning\n \n~\nAcute infections\nManagement\nTREATMENT\nLOC\nTreatment is supportive and symptomatic  \n\t\n\u0089\nRemove clothes and wash skin if contaminated \n\t\n\u0089\nAvoid gastric lavage or use of an emetic \n\t\n\u0089\nCharcoal is NOT useful\n\t\n\u0089\nGive oxygen if patient has hypoxia\nHC4\nPrevention\n\t\n\u0089\nAtropine 2-4 mg IM or IV (according to the severity of \nthe poisoning)\nChild: 0.05 mg/kg per dose\n \n- Double dose every 3-5 minutes until signs of \natropinisation occur (stopping of bronchial \nsecretions and broncoconstrictions)\n \n- Continuous infusion of atropine 0.05 mg/kg/\n \n- hour may be necessary\n \n- hour may be necessary\n \n- Reduce dose of atropine slowly over 24 hours but \nmonitor for patient\u2019s status\n73\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Vomiting, diarrhoea, bloody stools</p>\n<p>~</p>\n<p>Cough, dyspnoea, wheezing, tachypnoea, nasal flaring (due</p>\n<p>to chemical pneumonitis)</p>\n<p>~</p>\n<p>Lethargy, convulsions, difficulty in breathing</p>\n<p>The main risk is damage to lung tissue due to aspiration. AVOID</p>\n<p>gastric lavage or use of emetics as this may lead to inhalation of</p>\n<p>gastric content and pneumonitis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of poisoning</p>\n<p>~</p>\n<p>Acute infections</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment is supportive and symptomatic</p>\n<p>\u0089</p>\n<p>Remove clothes and wash skin if contaminated</p>\n<p>\u0089</p>\n<p>Avoid gastric lavage or use of an emetic</p>\n<p>\u0089</p>\n<p>Charcoal is NOT useful</p>\n<p>\u0089</p>\n<p>Give oxygen if patient has hypoxia</p>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>\u0089</p>\n<p>Atropine 2-4 mg IM or IV (according to the severity of</p>\n<p>the poisoning)</p>\n<p>Child: 0.05 mg/kg per dose</p>\n<p>- Double dose every 3-5 minutes until signs of</p>\n<p>atropinisation occur (stopping of bronchial</p>\n<p>secretions and broncoconstrictions)</p>\n<p>- Continuous infusion of atropine 0.05 mg/kg/</p>\n<p>- hour may be necessary</p>\n<p>- hour may be necessary</p>\n<p>- Reduce dose of atropine slowly over 24 hours but</p>\n<p>monitor for patient\u2019s status</p>\n<p>73</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 140,
        "content": "~\nStore paraffin and other petroleum products safely (e.g. in \na locked cupboard, out of reach of children)\n \n~\nDo not store paraffin and other petroleum products in com\u00ad\nmon beverage bottles.\n1.3.4 Acetylsalicylic Acid (Aspirin) Poisoning\nICD10 CODE: T39.0\nOverdose of ASA, due to consumption of >10 g of ASA in adults and \n3 g in children.\nClinical features\n \n~\nMild to moderate toxicity (after 1-2 hours): hyperventila\u00ad\ntion, tinnitus, deafness, nausea, vomiting, dizziness, vaso\u00ad\ndilation\n \n~\nSevere toxicity: hyperpyrexia, convulsions, altered mental \nstatus, non cardiac pulmonary oedema, coma\n \n~\nComplex acid-base disturbances (acidosis)\nManagement\nTREATMENT\nLOC\nStabilise vital signs\n\t\n\u0089\nOxygen and IV fluids as necessary\n\t\n\u0089\nGastric lavage: worthwhile up to 4 hours after poisoning \nas stomach emptying is delayed\n\t\n\u0089\nActivated charcoal 50 g repeated as needed every 4 hours \nor 25 g repeated prn every 2 hours\n \n- It delays absorption of any remaining salicylate\n\t\n\u0089\nTreat/prevent hypoglycaemia with Dextrose 50%\n50-100 ml (Dextrose 10% 2-5 ml/kg in children)\nH\n74\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Store paraffin and other petroleum products safely (e.g. in</p>\n<p>a locked cupboard, out of reach of children)</p>\n<p>~</p>\n<p>Do not store paraffin and other petroleum products in com\u00ad</p>\n<p>mon beverage bottles.</p>\n<li>.3.4 Acetylsalicylic Acid (Aspirin) Poisoning</li>\n<h3>ICD10 CODE: T39.0</h3>\n<p>Overdose of ASA, due to consumption of >10 g of ASA in adults and</p>\n<p>3 g in children.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Mild to moderate toxicity (after 1-2 hours): hyperventila\u00ad</p>\n<p>tion, tinnitus, deafness, nausea, vomiting, dizziness, vaso\u00ad</p>\n<p>dilation</p>\n<p>~</p>\n<p>Severe toxicity: hyperpyrexia, convulsions, altered mental</p>\n<p>status, non cardiac pulmonary oedema, coma</p>\n<p>~</p>\n<p>Complex acid-base disturbances (acidosis)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Stabilise vital signs</p>\n<p>\u0089</p>\n<p>Oxygen and IV fluids as necessary</p>\n<p>\u0089</p>\n<p>Gastric lavage: worthwhile up to 4 hours after poisoning</p>\n<p>as stomach emptying is delayed</p>\n<p>\u0089</p>\n<p>Activated charcoal 50 g repeated as needed every 4 hours</p>\n<p>or 25 g repeated prn every 2 hours</p>\n<p>- It delays absorption of any remaining salicylate</p>\n<p>\u0089</p>\n<p>Treat/prevent hypoglycaemia with Dextrose 50%</p>\n<p>50-100 ml (Dextrose 10% 2-5 ml/kg in children)</p>\n<p>H</p>\n<p>74</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 141,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nTepid sponging for hyperpyrexia\n\t\n\u0089\nTreat convulsions with IV diazepam 10 mg prn\nRefer to higher level of care if coma, pulmonary oedema, \nrenal insufficiency, clinical deterioration in spite of above \nmeasures\n\t\n\u0089\nTreat acidosis and enhance renal excretion in symptomatic \npatients with Sodium bicarbonate\n \n- Bolus 1-2 mEq/kg (max 100 mEq) in 3-5 minutes\n \n- Followed by an infusion of 50-75 mEq in 500 ml \nof Dextrose 5 %; run at 250 ml/hour in adults \n(run at 1.5-2 times maintenance in children)\n \n- Mantain urine pH 7.5-8\nRR\n1.3.5 Paracetamol Poisoning                 ICD10 CODE: T39.1\nAccidental or intentional assumption of excessive amount of paracetamol. \nToxic dose: >150 mg/kg or >7.5 g (200 mg/kg for children <6 years)\nClinical features\n \n~\nFirst 24 hours: asymptomatic or aspecific symptoms such \nas nausea and vomiting, malaise, anorexia, abdominal pain\n \n~\nIn patients with mild poisoning, symptoms will resolve \nand patient will recover. In patients with severe poisoning, \nsymptoms will progress to the next phase\n \n~\nIn 24-72 hours: progressive signs of hepatic toxicity (e.g. \nright upper quadrant abdominal pain, enlarged tender liver, \nincreased transaminases)\n \n~\nAfter 72 hours: signs and symptoms peak at 72-96 hours \nand this may be followed by full recovery in 5-7 days or progres\u00ad\nsion into irreversible hepatic failure (less frequently renal failure) \nand death\n75\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Tepid sponging for hyperpyrexia</p>\n<p>\u0089</p>\n<p>Treat convulsions with IV diazepam 10 mg prn</p>\n<p>Refer to higher level of care if coma, pulmonary oedema,</p>\n<p>renal insufficiency, clinical deterioration in spite of above</p>\n<p>measures</p>\n<p>\u0089</p>\n<p>Treat acidosis and enhance renal excretion in symptomatic</p>\n<p>patients with Sodium bicarbonate</p>\n<p>- Bolus 1-2 mEq/kg (max 100 mEq) in 3-5 minutes</p>\n<p>- Followed by an infusion of 50-75 mEq in 500 ml</p>\n<p>of Dextrose 5 %; run at 250 ml/hour in adults</p>\n<p>(run at 1.5-2 times maintenance in children)</p>\n<p>- Mantain urine pH 7.5-8</p>\n<p>RR</p>\n<li>.3.5 Paracetamol Poisoning                 ICD10 CODE: T39.1</li>\n<p>Accidental or intentional assumption of excessive amount of paracetamol.</p>\n<p>Toxic dose: >150 mg/kg or >7.5 g (200 mg/kg for children <6 years)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>First 24 hours: asymptomatic or aspecific symptoms such</p>\n<p>as nausea and vomiting, malaise, anorexia, abdominal pain</p>\n<p>~</p>\n<p>In patients with mild poisoning, symptoms will resolve</p>\n<p>and patient will recover. In patients with severe poisoning,</p>\n<p>symptoms will progress to the next phase</p>\n<p>~</p>\n<p>In 24-72 hours: progressive signs of hepatic toxicity (e.g.</p>\n<p>right upper quadrant abdominal pain, enlarged tender liver,</p>\n<p>increased transaminases)</p>\n<p>~</p>\n<p>After 72 hours: signs and symptoms peak at 72-96 hours</p>\n<p>and this may be followed by full recovery in 5-7 days or progres\u00ad</p>\n<p>sion into irreversible hepatic failure (less frequently renal failure)</p>\n<p>and death</p>\n<p>75</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 142,
        "content": "Investigations\n \n\u0081\nMonitor liver function, renal funtion, INR\n \n\u0081\nRule out pregnancy (it crosses the placental barrier)\nManagement\nTreatment\nLOC\n\t\n\u0089\nGive repeated doses of activated charcoal (25-50 g \nevery 4 hours)\n\t\n\u0089\nIf ingestion was <2 hours, empty the stomach to remove \nany remaining medicine using gastric lavage\n\t\n\u0089\nGive acetylcysteine IV preferrably within8 hours from \ningestion; if patient presents later, give it anyway\n \n- 150 mg/kg (max 15 g) in 200 ml of Dextrose 5% in\n \n- 60 minutes followed by\n \n- 50 mg/kg (max 5 g) in Dextrose 5% 500 ml in 4 hours \nfollowed by\n \n- 100 mg/kg (max 10 g) in Dextrose 5% 1000 ml in\n \n- 16 hours\n\t\n\u0089\nSupportive treatment\nHC2\nH\nNote\n \n\u0083 Acetylcysteine may cause histamine release, mimicking an \nallergic reaction. If patient is stable, slow the infusion. If \nbronchospasm, stop the infusion\n1.3.6 Iron Poisoning\t\nICD10 CODE: T45.4\nCommon in children, due to the candy-like aspect of iron tablets. Ingestion \nof a quantity <40 mg/kg of elemental iron is unlikely to cause problems. \nDoses >60 mg/kg can cause serious toxicity.\nNote: the common tablet of 200 mg of an iron salt contains 60-65 mg \nof elemental iron.\n76\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Monitor liver function, renal funtion, INR</p>\n<p>\u0081</p>\n<p>Rule out pregnancy (it crosses the placental barrier)</p>\n<p>Management</p>\n<p>Treatment</p>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give repeated doses of activated charcoal (25-50 g</p>\n<p>every 4 hours)</p>\n<p>\u0089</p>\n<p>If ingestion was <2 hours, empty the stomach to remove</p>\n<p>any remaining medicine using gastric lavage</p>\n<p>\u0089</p>\n<p>Give acetylcysteine IV preferrably within8 hours from</p>\n<p>ingestion; if patient presents later, give it anyway</p>\n<p>- 150 mg/kg (max 15 g) in 200 ml of Dextrose 5% in</p>\n<p>- 60 minutes followed by</p>\n<p>- 50 mg/kg (max 5 g) in Dextrose 5% 500 ml in 4 hours</p>\n<p>followed by</p>\n<p>- 100 mg/kg (max 10 g) in Dextrose 5% 1000 ml in</p>\n<p>- 16 hours</p>\n<p>\u0089</p>\n<p>Supportive treatment</p>\n<h3>HC2</h3>\n<p>H</p>\n<p>Note</p>\n<p>\u0083 Acetylcysteine may cause histamine release, mimicking an</p>\n<p>allergic reaction. If patient is stable, slow the infusion. If</p>\n<p>bronchospasm, stop the infusion</p>\n<li>.3.6 Iron Poisoning</li>\n<h3>ICD10 CODE: T45.4</h3>\n<p>Common in children, due to the candy-like aspect of iron tablets. Ingestion</p>\n<p>of a quantity <40 mg/kg of elemental iron is unlikely to cause problems.</p>\n<p>Doses >60 mg/kg can cause serious toxicity.</p>\n<p>Note: the common tablet of 200 mg of an iron salt contains 60-65 mg</p>\n<p>of elemental iron.</p>\n<p>76</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 143,
        "content": "Clinical features\n \n~\nClinical symptoms vary according to the time from ingestion\nTIME\nSYMPTOMS\nPhase 1\n(30 minutes\nto 6 hours)\nInitial symptoms (by corrosive action of iron in GIT): \nnausea, vomiting (may be blood stained), abdominal \npain, shock, metabolic acidosis\nPhase 2\n(6\u201312 hours)\nSymptoms improve or disappear\nPhase 3\n(12-48 hours)\nSevere shock, vascular collapse, metabolic \nacidosis, hypoglycaemia, convulsions, coma\nPhase 4\n(2-4 days)\nLiver and renal failure, pulmonary oedema\nPhase 5\n(>4 days)\nGastrointestinal scarring and obstruction \nin survivors\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIV fluids to manage shock and hypovolaemia\nIndication for use of antidote:\n \n- Severe symptoms\n \n- Metabolic acidosis\n\t\n\u0089\nDesferroxamine continuous infusion 15 mg/kg/ hour in \nnormal saline or glucose 5%\n \n- Do not use for more than 24 hours\n \n- Increase IV fluids if BP drops\n \n- Continue until metabolic acidosis clears or clinical \ncondition improves\n \n- Contraindication: renal failure/anuria\nNR\n1.3.7 Carbon Monoxide Poisoning     ICD10 CODE: T58\nUsually due to inhalation in confined spaces of smoke, car exhaust or \nfumes caused by incomplete combustion of fuel gases e.g. use of charcoal \nstoves in unventilated rooms.\n77\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Clinical symptoms vary according to the time from ingestion</p>\n<h3>TIME</h3>\n<h3>SYMPTOMS</h3>\n<p>Phase 1</p>\n<p>(30 minutes</p>\n<p>to 6 hours)</p>\n<p>Initial symptoms (by corrosive action of iron in GIT):</p>\n<p>nausea, vomiting (may be blood stained), abdominal</p>\n<p>pain, shock, metabolic acidosis</p>\n<p>Phase 2</p>\n<p>(6\u201312 hours)</p>\n<p>Symptoms improve or disappear</p>\n<p>Phase 3</p>\n<p>(12-48 hours)</p>\n<p>Severe shock, vascular collapse, metabolic</p>\n<p>acidosis, hypoglycaemia, convulsions, coma</p>\n<p>Phase 4</p>\n<p>(2-4 days)</p>\n<p>Liver and renal failure, pulmonary oedema</p>\n<p>Phase 5</p>\n<p>(>4 days)</p>\n<p>Gastrointestinal scarring and obstruction</p>\n<p>in survivors</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>IV fluids to manage shock and hypovolaemia</p>\n<p>Indication for use of antidote:</p>\n<p>- Severe symptoms</p>\n<p>- Metabolic acidosis</p>\n<p>\u0089</p>\n<p>Desferroxamine continuous infusion 15 mg/kg/ hour in</p>\n<p>normal saline or glucose 5%</p>\n<p>- Do not use for more than 24 hours</p>\n<p>- Increase IV fluids if BP drops</p>\n<p>- Continue until metabolic acidosis clears or clinical</p>\n<p>condition improves</p>\n<p>- Contraindication: renal failure/anuria</p>\n<p>NR</p>\n<li>.3.7 Carbon Monoxide Poisoning     ICD10 CODE: T58</li>\n<p>Usually due to inhalation in confined spaces of smoke, car exhaust or</p>\n<p>fumes caused by incomplete combustion of fuel gases e.g. use of charcoal</p>\n<p>stoves in unventilated rooms.</p>\n<p>77</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 144,
        "content": "Cause\n \n~\nCarbon monoxide, a colourless and odourless non- irritat\u00ad\ning gas\nClinical features\n \n~\nDue to hypoxia\n \n~\nHeadache, nausea, vomiting, dizziness, confusion, weak\u00ad\nness\n \n~\nCollapse, seizures, coma, death\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nMove person to fresh air\n\t\n\u0089\nClear the airway\n\t\n\u0089\nGive oxygen 100% (use non-rebreather masks) as soon \nas possible\n\t\n\u0089\nIV fluids for hypotension\n\t\n\u0089\nDiazepam for seizures\nHC4\n1.3.8 Barbiturate Poisoning\t\nICD10 CODE: T42.3\nBarbiturates are used in the treatment of epilepsy and convulsions (e.g. \nphenobarbital).\nClinical features\n \n~\nConfusion, irritability, combativeness\n \n~\nDrowsiness, lethargy\n \n~\nHypotension, bradycardia or tachycardia, until shock\n \n~\nRespiratory depression, until coma\n78\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Cause</p>\n<p>~</p>\n<p>Carbon monoxide, a colourless and odourless non- irritat\u00ad</p>\n<p>ing gas</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Due to hypoxia</p>\n<p>~</p>\n<p>Headache, nausea, vomiting, dizziness, confusion, weak\u00ad</p>\n<p>ness</p>\n<p>~</p>\n<p>Collapse, seizures, coma, death</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Move person to fresh air</p>\n<p>\u0089</p>\n<p>Clear the airway</p>\n<p>\u0089</p>\n<p>Give oxygen 100% (use non-rebreather masks) as soon</p>\n<p>as possible</p>\n<p>\u0089</p>\n<p>IV fluids for hypotension</p>\n<p>\u0089</p>\n<p>Diazepam for seizures</p>\n<h3>HC4</h3>\n<li>.3.8 Barbiturate Poisoning</li>\n<h3>ICD10 CODE: T42.3</h3>\n<p>Barbiturates are used in the treatment of epilepsy and convulsions (e.g.</p>\n<p>phenobarbital).</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Confusion, irritability, combativeness</p>\n<p>~</p>\n<p>Drowsiness, lethargy</p>\n<p>~</p>\n<p>Hypotension, bradycardia or tachycardia, until shock</p>\n<p>~</p>\n<p>Respiratory depression, until coma</p>\n<p>78</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 145,
        "content": "Management\nTREATMENT\nLOC\nSupportive care\n\t\n\u0089\nOxygen therapy\n\t\n\u0089\nIV fluids for hypotension\n\t\n\u0089\nCharcoal may be useful but only if given within 1 hour \nfrom ingestion and if the patient is not drowsy (risk of \ninhalation)\n\t\n\u0089\nRefer for ventilatory support if necessary\n\t\n\u0089\nAlkalinisation to increase renal excretion\n \n- Sodium bicarbonate 1 mEq/kg bolus followed by \ninfusion (specialist only)\nH\nRR\n1.3.9 Opioid Poisoning\t ICD10 CODE: T40\nVoluntary or accidental overdose of opioid drugs like codeine, \nmorphine, heroin used for therapeutic or recreational purposes.\nClinical features\n \n~\nRespiratory depression\n \n~\nHypotension, hypothermia\n \n~\nPinpoint pupils\n \n~\nDecreased mental status until coma\nTREATMENT\nLOC\n\t\n\u0089\nGastric lavage if ingestion within 1 hour from arrival or \npills visible in the stomach at X-ray\n\t\n\u0089\nNB: charcoal is NOT EFFECTIVE\n\t\n\u0089\nPatients who are asymptomatic after 6 hours from inges\u00ad\ntion most likely do not need specific treatment. Monitor \nfor at least 12 hours\n\t\n\u0089\nIV fluids to manage shock and hypovolaemia\nH\n79\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Supportive care</p>\n<p>\u0089</p>\n<p>Oxygen therapy</p>\n<p>\u0089</p>\n<p>IV fluids for hypotension</p>\n<p>\u0089</p>\n<p>Charcoal may be useful but only if given within 1 hour</p>\n<p>from ingestion and if the patient is not drowsy (risk of</p>\n<p>inhalation)</p>\n<p>\u0089</p>\n<p>Refer for ventilatory support if necessary</p>\n<p>\u0089</p>\n<p>Alkalinisation to increase renal excretion</p>\n<p>- Sodium bicarbonate 1 mEq/kg bolus followed by</p>\n<p>infusion (specialist only)</p>\n<p>H</p>\n<p>RR</p>\n<li>.3.9 Opioid Poisoning\t ICD10 CODE: T40</li>\n<p>Voluntary or accidental overdose of opioid drugs like codeine,</p>\n<p>morphine, heroin used for therapeutic or recreational purposes.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Respiratory depression</p>\n<p>~</p>\n<p>Hypotension, hypothermia</p>\n<p>~</p>\n<p>Pinpoint pupils</p>\n<p>~</p>\n<p>Decreased mental status until coma</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Gastric lavage if ingestion within 1 hour from arrival or</p>\n<p>pills visible in the stomach at X-ray</p>\n<p>\u0089</p>\n<p>NB: charcoal is NOT EFFECTIVE</p>\n<p>\u0089</p>\n<p>Patients who are asymptomatic after 6 hours from inges\u00ad</p>\n<p>tion most likely do not need specific treatment. Monitor</p>\n<p>for at least 12 hours</p>\n<p>\u0089</p>\n<p>IV fluids to manage shock and hypovolaemia</p>\n<p>H</p>\n<p>79</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 146,
        "content": "Management\nTREATMENT\nLOC\nAntidote:\n\t\n\u0089\nNaloxone 0.4-2 mg IV or IM, repeat every 2-3 minutes \nif not improving until max 10 mg Child: 0.01 mg/kg, \nincrease to 0.1 mg/kg if necessary\n\t\n\u0089\nAim at restoring ventilation not consciousness f Repeated \ndoses or infusion may be necessary f Manage complica\u00ad\ntions accordingly\nH\nNote\n \n\u0083 Naloxone doses used in acute poisoning may not be suitable for \ntreating opioid-induced respiratory depression and sedation in \npalliative care and in chronic opioid use\n1.3.10 Warfarin Poisoning\t\nICD10 CODE: T45.5\nOverdose may result from accidental ingestion of rat poison (containing \na warfarin-like substance) or overdose of warfarin used for therapeutic \npurposes. Warfarin inhibits the production of coagulation factors in the liver.\nClinical features\n \n~\nBleeding (can be life threatening) internal or from mucosae\n \n~\nUsually evident 24 hours after ingestion\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nEmpty the stomach\n\t\n\u0089\nGive activated charcoal 50 g if presenting early\nChild:25g (50g if severe)      \n\t\n\u0089\nPhytomenadione (vitamin K1) 5 mg IV slowly\nHC2\nHC4 \nRR\n80\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Antidote:</p>\n<p>\u0089</p>\n<p>Naloxone 0.4-2 mg IV or IM, repeat every 2-3 minutes</p>\n<p>if not improving until max 10 mg Child: 0.01 mg/kg,</p>\n<p>increase to 0.1 mg/kg if necessary</p>\n<p>\u0089</p>\n<p>Aim at restoring ventilation not consciousness f Repeated</p>\n<p>doses or infusion may be necessary f Manage complica\u00ad</p>\n<p>tions accordingly</p>\n<p>H</p>\n<p>Note</p>\n<p>\u0083 Naloxone doses used in acute poisoning may not be suitable for</p>\n<p>treating opioid-induced respiratory depression and sedation in</p>\n<p>palliative care and in chronic opioid use</p>\n<li>.3.10 Warfarin Poisoning</li>\n<h3>ICD10 CODE: T45.5</h3>\n<p>Overdose may result from accidental ingestion of rat poison (containing</p>\n<p>a warfarin-like substance) or overdose of warfarin used for therapeutic</p>\n<p>purposes. Warfarin inhibits the production of coagulation factors in the liver.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Bleeding (can be life threatening) internal or from mucosae</p>\n<p>~</p>\n<p>Usually evident 24 hours after ingestion</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Empty the stomach</p>\n<p>\u0089</p>\n<p>Give activated charcoal 50 g if presenting early</p>\n<p>Child:25g (50g if severe)</p>\n<p>\u0089</p>\n<p>Phytomenadione (vitamin K1) 5 mg IV slowly</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>RR</p>\n<p>80</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 147,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nSupportive treatment (IV fluids, bloodtransfusion, fresh \nfrozen plasma if active bleeding)\nHC2\nNote\n \n\u0083 Intoxication with rat poison may require prolonged treatment \nwith vitamin K\n1.3.11 Methyl Alcohol (Methanol) Poisoning\nICD10 CODE: T51.1\nMethanol is used as an industrial solvent and is an ingredient of methylated \nspirits. It is often ingested for self-harm or as a substitute for alcohol. It \ncan form in home-distilled crude alcohol due to incomplete conversion \nto ethanol. A dose >1 g/kg is potentially lethal: it is transformed into \ntoxic metabolites and causes profound acidosis.\nClinical features\n \n~\nInitial inebriation (as in alcohol assumption)\n \n~\nLatent asymptomatic period of 12-24 hours\n \n~\nHeadache, dizziness, nausea, vomiting, visual disturbances, \nCNS depression and respiratory failure\n \n~\nToxic metabolites may cause severe acidosis and retinal/ \noptic nerve damage\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nGastric aspiration and lavage\n \n- Only use if done within 2 hours of ingestion (it has \na very rapid absorption)\n\t\n\u0089\nCharcoal is NOT USEFUL\nH\n81\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Supportive treatment (IV fluids, bloodtransfusion, fresh</p>\n<p>frozen plasma if active bleeding)</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>\u0083 Intoxication with rat poison may require prolonged treatment</p>\n<p>with vitamin K</p>\n<li>.3.11 Methyl Alcohol (Methanol) Poisoning</li>\n<h3>ICD10 CODE: T51.1</h3>\n<p>Methanol is used as an industrial solvent and is an ingredient of methylated</p>\n<p>spirits. It is often ingested for self-harm or as a substitute for alcohol. It</p>\n<p>can form in home-distilled crude alcohol due to incomplete conversion</p>\n<p>to ethanol. A dose >1 g/kg is potentially lethal: it is transformed into</p>\n<p>toxic metabolites and causes profound acidosis.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Initial inebriation (as in alcohol assumption)</p>\n<p>~</p>\n<p>Latent asymptomatic period of 12-24 hours</p>\n<p>~</p>\n<p>Headache, dizziness, nausea, vomiting, visual disturbances,</p>\n<p>CNS depression and respiratory failure</p>\n<p>~</p>\n<p>Toxic metabolites may cause severe acidosis and retinal/</p>\n<p>optic nerve damage</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Gastric aspiration and lavage</p>\n<p>- Only use if done within 2 hours of ingestion (it has</p>\n<p>a very rapid absorption)</p>\n<p>\u0089</p>\n<p>Charcoal is NOT USEFUL</p>\n<p>H</p>\n<p>81</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 148,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nGive 1.5-2 ml/kg of oral alcohol 40% (e.g. waragi, \nwhisky, brandy) in 180 ml of water as loading dose, \noral or via NGT\n \n- Maintenance dose: 0.3 ml/kg/hour\n\t\n\u0089\nSodium bicarbonate 50-100 ml IV over 30-45 minutes\n\t\n\u0089\nCheck for and correct hypoglycaemia\nH\n1.3.12 Alcohol (Ethanol) Poisoning      ICD10 CODE: T51\nAlcohol poisoning may be acute or chronic.\n1.3.12.1 Acute Alcohol Poisoning\nSymptoms of alcoholic poisoning following ingestion of a large amount \nof alcohol over a short period.\nCause\n \n~\nDeliberate consumption of excessive alcohol in a short pe\u00ad\nriod of time\n \n~\nAccidental ingestion (may occur in children)\nClinical features\n \n~\nSmell of alcohol in the breath\n \n~\nSlurred speech, uninhibited behaviour,\n \n~\nAltered cognition and perception\n \n~\nNausea and vomiting\n \n~\nExcessive sweating, dilated pupils\n \n~\nHypoglycaemia and hypothermia\n \n~\nIn later stages, stupor and coma develop\n82\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give 1.5-2 ml/kg of oral alcohol 40% (e.g. waragi,</p>\n<p>whisky, brandy) in 180 ml of water as loading dose,</p>\n<p>oral or via NGT</p>\n<p>- Maintenance dose: 0.3 ml/kg/hour</p>\n<p>\u0089</p>\n<p>Sodium bicarbonate 50-100 ml IV over 30-45 minutes</p>\n<p>\u0089</p>\n<p>Check for and correct hypoglycaemia</p>\n<p>H</p>\n<li>.3.12 Alcohol (Ethanol) Poisoning      ICD10 CODE: T51</li>\n<p>Alcohol poisoning may be acute or chronic.</p>\n<li>.3.12.1 Acute Alcohol Poisoning</li>\n<p>Symptoms of alcoholic poisoning following ingestion of a large amount</p>\n<p>of alcohol over a short period.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Deliberate consumption of excessive alcohol in a short pe\u00ad</p>\n<p>riod of time</p>\n<p>~</p>\n<p>Accidental ingestion (may occur in children)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Smell of alcohol in the breath</p>\n<p>~</p>\n<p>Slurred speech, uninhibited behaviour,</p>\n<p>~</p>\n<p>Altered cognition and perception</p>\n<p>~</p>\n<p>Nausea and vomiting</p>\n<p>~</p>\n<p>Excessive sweating, dilated pupils</p>\n<p>~</p>\n<p>Hypoglycaemia and hypothermia</p>\n<p>~</p>\n<p>In later stages, stupor and coma develop</p>\n<p>82</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 149,
        "content": "As coma deepens the following appear:\n \n~\nThready pulse and falling BP\n \n~\nFall in body temperature\n \n~\nNoisy breathing\nDifferential diagnosis\nOther causes of coma:\n \n~\nMalaria and other intracranial infections\n \n~\nDiabetes mellitus\n \n~\nHead injury\n \n~\nStroke (cerebrovascular accidents)\nLow blood sugar (hypoglycaemia) due to other causes\n \n~\nPoisoning by other medicines e.g., narcotics\n \n~\nMental illness\nInvestigations\n \n~\nBlood: alcohol content, glucose level\n \n~\nUrine: for glucose and protein\n \n~\nLumbar puncture\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nManage airways (ventilation may be needed) \n\t\n\u0089\nCorrect hypothermia and hypovolaemia if present f Check \nand correct hypoglycaemia with Dextrose 50% 20-50 ml IV\n \n- Give it via NGT or rectal if IV not available\n \n- Maintain infusion of Dextrose 5-10% until patient \nwakes up and can eat\n\t\n\u0089\nThiamine IV 100 mg in 1 L of Dextrose 5%\nH\nH\n83\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>As coma deepens the following appear:</p>\n<p>~</p>\n<p>Thready pulse and falling BP</p>\n<p>~</p>\n<p>Fall in body temperature</p>\n<p>~</p>\n<p>Noisy breathing</p>\n<p>Differential diagnosis</p>\n<p>Other causes of coma:</p>\n<p>~</p>\n<p>Malaria and other intracranial infections</p>\n<p>~</p>\n<p>Diabetes mellitus</p>\n<p>~</p>\n<p>Head injury</p>\n<p>~</p>\n<p>Stroke (cerebrovascular accidents)</p>\n<p>Low blood sugar (hypoglycaemia) due to other causes</p>\n<p>~</p>\n<p>Poisoning by other medicines e.g., narcotics</p>\n<p>~</p>\n<p>Mental illness</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Blood: alcohol content, glucose level</p>\n<p>~</p>\n<p>Urine: for glucose and protein</p>\n<p>~</p>\n<p>Lumbar puncture</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Manage airways (ventilation may be needed)</p>\n<p>\u0089</p>\n<p>Correct hypothermia and hypovolaemia if present f Check</p>\n<p>and correct hypoglycaemia with Dextrose 50% 20-50 ml IV</p>\n<p>- Give it via NGT or rectal if IV not available</p>\n<p>- Maintain infusion of Dextrose 5-10% until patient</p>\n<p>wakes up and can eat</p>\n<p>\u0089</p>\n<p>Thiamine IV 100 mg in 1 L of Dextrose 5%</p>\n<p>H</p>\n<p>H</p>\n<p>83</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 150,
        "content": "1.3.12.2 Chronic Alcohol Poisoning\nCause\n \n~\nHeavy habitual drinking combined with poor nutrition\nClinical features\nFeatures of malnutrition\n \n~\nWeight loss, dry scaly skin\n \n~\nBrittle discolored hair, pale mucous membranes\nCerebral damage\n \n~\nMemory loss, hallucinations, tremors\nLiver disease\n \n~\nPoor appetite\n \n~\nFluid in the abdomen (ascites) as a result of cirrhosis\nWithdrawal\n \n~\nMild: 12-48 hours after the last drink, with anxiety, agita\u00ad\ntion, insomnia, tremors, palpitation, sweating. If not pro\u00ad\ngressing it may resolve over 24-48 hours\n \n~\nSevere: seizures, hallucinations (from 12 to 48 hours after \nthe last drink)\n \n~\nVery severe: delirium tremens characterized by hallucina\u00ad\ntions, disorientation, tachycardia, hypertension, hyperther\u00ad\nmia, agitation, and diaphoresis In the absence of complica\u00ad\ntions, symptoms of delirium tremens typically persist for up \nto seven days\nWernicke encephalopathy\n \n~\nDue to thiamine deficiency. Common in chronic alcohol \nabuse\n \n~\nCharacterized by acute mental confusion, ataxia (unstable \ngait) and nystagmus/ophthalmoplegia (abnormal eye move\u00ad\nments)\n84\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<li>.3.12.2 Chronic Alcohol Poisoning</li>\n<p>Cause</p>\n<p>~</p>\n<p>Heavy habitual drinking combined with poor nutrition</p>\n<p>Clinical features</p>\n<p>Features of malnutrition</p>\n<p>~</p>\n<p>Weight loss, dry scaly skin</p>\n<p>~</p>\n<p>Brittle discolored hair, pale mucous membranes</p>\n<p>Cerebral damage</p>\n<p>~</p>\n<p>Memory loss, hallucinations, tremors</p>\n<p>Liver disease</p>\n<p>~</p>\n<p>Poor appetite</p>\n<p>~</p>\n<p>Fluid in the abdomen (ascites) as a result of cirrhosis</p>\n<p>Withdrawal</p>\n<p>~</p>\n<p>Mild: 12-48 hours after the last drink, with anxiety, agita\u00ad</p>\n<p>tion, insomnia, tremors, palpitation, sweating. If not pro\u00ad</p>\n<p>gressing it may resolve over 24-48 hours</p>\n<p>~</p>\n<p>Severe: seizures, hallucinations (from 12 to 48 hours after</p>\n<p>the last drink)</p>\n<p>~</p>\n<p>Very severe: delirium tremens characterized by hallucina\u00ad</p>\n<p>tions, disorientation, tachycardia, hypertension, hyperther\u00ad</p>\n<p>mia, agitation, and diaphoresis In the absence of complica\u00ad</p>\n<p>tions, symptoms of delirium tremens typically persist for up</p>\n<p>to seven days</p>\n<p>Wernicke encephalopathy</p>\n<p>~</p>\n<p>Due to thiamine deficiency. Common in chronic alcohol</p>\n<p>abuse</p>\n<p>~</p>\n<p>Characterized by acute mental confusion, ataxia (unstable</p>\n<p>gait) and nystagmus/ophthalmoplegia (abnormal eye move\u00ad</p>\n<p>ments)</p>\n<p>84</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 151,
        "content": "Management\nTREATMENT\nLOC\nWithdrawal syndrome\n\t\n\u0089\nSupportive care (IV fluids, nutrition)\n\t\n\u0089\nCheck and correct hypoglycaemia with Dextrose 50% \n20-50 ml IV\n \n- Give it via NGT or rectal if IV not available\n \n- Maintain infusion of Dextrose until patient wakes up \nand can eat\n\t\n\u0089\nDiazepam 5-10 mg every 10 minutes until appropriate \nsedation is achieved\n \n- Very high doses may be required\n \n- Monitor respiration\nHC3\n\t\n\u0089\nIf not responsing, consider phenobarbital 100- 200 mg \nslow IV but it has a risk of respiratory depression and \nhypotension\n\t\n\u0089\nThiamine IV 100 mg in 1 L of Dextrose 5%\n\t\n\u0089\nIf delirium or hallucinations persist in spite of treatment, \nconsider haloperidol 2.5-5 mg up to 3 times a day\nIf Wernicke encephalopathy\n\t\n\u0089\nThiamine 100 mg IV or IM every 8 hours for 3-5 days\nHC4\nNote\n \n\u0083 See section 9.1.1 for general management of alcohol use \ndisorders\n1.3.13 Food Poisoning\t\nICD10 CODE: A05\nIllness caused by consumption of food or water contaminated by certain \npathogenic microorganisms. It usually affects large numbers of people \nafter ingestion of communal food in homes, hospitals, hotels and parties.\n85\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Withdrawal syndrome</p>\n<p>\u0089</p>\n<p>Supportive care (IV fluids, nutrition)</p>\n<p>\u0089</p>\n<p>Check and correct hypoglycaemia with Dextrose 50%</p>\n<p>20-50 ml IV</p>\n<p>- Give it via NGT or rectal if IV not available</p>\n<p>- Maintain infusion of Dextrose until patient wakes up</p>\n<p>and can eat</p>\n<p>\u0089</p>\n<p>Diazepam 5-10 mg every 10 minutes until appropriate</p>\n<p>sedation is achieved</p>\n<p>- Very high doses may be required</p>\n<p>- Monitor respiration</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>If not responsing, consider phenobarbital 100- 200 mg</p>\n<p>slow IV but it has a risk of respiratory depression and</p>\n<p>hypotension</p>\n<p>\u0089</p>\n<p>Thiamine IV 100 mg in 1 L of Dextrose 5%</p>\n<p>\u0089</p>\n<p>If delirium or hallucinations persist in spite of treatment,</p>\n<p>consider haloperidol 2.5-5 mg up to 3 times a day</p>\n<p>If Wernicke encephalopathy</p>\n<p>\u0089</p>\n<p>Thiamine 100 mg IV or IM every 8 hours for 3-5 days</p>\n<h3>HC4</h3>\n<p>Note</p>\n<p>\u0083 See section 9.1.1 for general management of alcohol use</p>\n<p>disorders</p>\n<li>.3.13 Food Poisoning</li>\n<h3>ICD10 CODE: A05</h3>\n<p>Illness caused by consumption of food or water contaminated by certain</p>\n<p>pathogenic microorganisms. It usually affects large numbers of people</p>\n<p>after ingestion of communal food in homes, hospitals, hotels and parties.</p>\n<p>85</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 152,
        "content": "Causes\n \n~\nCan be infective or toxic\n \n~\nInfective: by bacteria e.g. Salmonella typhimurium, Campy\u00ad\nlobacter jejuni, Bacillus cereus\n \n~\nToxic: by toxins from Staphylococcus aureus and Clostrid\u00ad\nium botulinum\nClinical features\n \n~\nNausea, vomiting\n \n~\nIntermittent abdominal pain (colic) with associated diar\u00ad\nrhoea\n \n~\nFever (especially if poisoning is the infective type)\n \n~\nOften self-limiting\nBotulism\n \n~\nParalysis of skeletal, ocular, pharyngeal and respiratory \nmuscles\nDifferential diagnosis\n \n~\nCholera, dysentery\n \n~\nOther causes of stomach and intestinal infections\nInvestigations\n \n\u0081\nGood history and examination is important for diagnosis\n \n\u0081\nStool microscopy, C&S\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nEstablish the cause and treat accordingly\n\t\n\u0089\nGive oral (ORS) or IV fluids (Normal saline) for rehydra\u00ad\ntion as required\n\t\n\u0089\nFor pain, give paracetamol 1 g every 4-6 hours\nChild: 10 mg/kg per dose\nIf diarrhoea severe and persisting or bloody, high fever\n\t\n\u0089\nGive an antibiotic for 3-7 days, depending on response:\n \n- Ciprofloxacin 500 mg every 12 hours\n \n- Child: 10 mg/kg per dose\n \n- Or erythromycin 500 mg every 6 hours\nChild: 10 mg/kg per dose\nHC2\nHC2\n86\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Causes</p>\n<p>~</p>\n<p>Can be infective or toxic</p>\n<p>~</p>\n<p>Infective: by bacteria e.g. Salmonella typhimurium, Campy\u00ad</p>\n<p>lobacter jejuni, Bacillus cereus</p>\n<p>~</p>\n<p>Toxic: by toxins from Staphylococcus aureus and Clostrid\u00ad</p>\n<p>ium botulinum</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Nausea, vomiting</p>\n<p>~</p>\n<p>Intermittent abdominal pain (colic) with associated diar\u00ad</p>\n<p>rhoea</p>\n<p>~</p>\n<p>Fever (especially if poisoning is the infective type)</p>\n<p>~</p>\n<p>Often self-limiting</p>\n<p>Botulism</p>\n<p>~</p>\n<p>Paralysis of skeletal, ocular, pharyngeal and respiratory</p>\n<p>muscles</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cholera, dysentery</p>\n<p>~</p>\n<p>Other causes of stomach and intestinal infections</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Good history and examination is important for diagnosis</p>\n<p>\u0081</p>\n<p>Stool microscopy, C&S</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Establish the cause and treat accordingly</p>\n<p>\u0089</p>\n<p>Give oral (ORS) or IV fluids (Normal saline) for rehydra\u00ad</p>\n<p>tion as required</p>\n<p>\u0089</p>\n<p>For pain, give paracetamol 1 g every 4-6 hours</p>\n<p>Child: 10 mg/kg per dose</p>\n<p>If diarrhoea severe and persisting or bloody, high fever</p>\n<p>\u0089</p>\n<p>Give an antibiotic for 3-7 days, depending on response:</p>\n<p>- Ciprofloxacin 500 mg every 12 hours</p>\n<p>- Child: 10 mg/kg per dose</p>\n<p>- Or erythromycin 500 mg every 6 hours</p>\n<p>Child: 10 mg/kg per dose</p>\n<h3>HC2</h3>\n<h3>HC2</h3>\n<p>86</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 153,
        "content": "Prevention\n \n~\nHeat cooked foods thoroughly before eating and avoid  eat\u00ad\ning cold left-over cooked foods\n \n~\nEnsure adequate personal and domestic hygiene\n1.4 HYPOXEAMIA MANAGEMENT AND OXYGEN THERA\u00ad\nPY GUIDELINES\nHypoxaemia is the low concentration of Oxygen in blood or oxygen \nsaturation (SpO2) less than 90% in peripheral arterial blood detected \non pulse oximeter reading. Hypoxaemia is a life-threatening condition \ncorrelated with disease severity and an emergency stat. Left untreated \nand for prolonged periods of time, it results into low tissue oxygen \nconcentration (Hypoxia), and this leads to death. \n Causes \n \n~\nSurgical causes.\n \n- Head Injury, Chest trauma\n \n~\nMedical Causes\n \n- Severe Asthma, Pneumonia, Sepsis, Shock, Malaria, \nCovid-19, Heart Failure, Cardiac arrest, Upper airway \nobstruction, Severe anaemia, Pertussis, Carbon Monoxide \npoisoning.\n \n~\nObstetric, gynaecological, and perioperative causes.\n \n- Obstructed labour, Ruptured uterus, Pre-eclampsia and \neclampsia, Post caesarean section, \n \n~\nNeonatal causes\n \n- Transient tachypnoea of the new-born, Hypoxic Ischaemic \nencephalopathy (Birth asphyxia), Respiratory distress \nSyndrome, Neonatal Septicaemia.\n87\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Heat cooked foods thoroughly before eating and avoid  eat\u00ad</p>\n<p>ing cold left-over cooked foods</p>\n<p>~</p>\n<p>Ensure adequate personal and domestic hygiene</p>\n<h3>1.4 HYPOXEAMIA MANAGEMENT AND OXYGEN THERA\u00ad</h3>\n<h3>PY GUIDELINES</h3>\n<p>Hypoxaemia is the low concentration of Oxygen in blood or oxygen</p>\n<p>saturation (SpO2) less than 90% in peripheral arterial blood detected</p>\n<p>on pulse oximeter reading. Hypoxaemia is a life-threatening condition</p>\n<p>correlated with disease severity and an emergency stat. Left untreated</p>\n<p>and for prolonged periods of time, it results into low tissue oxygen</p>\n<p>concentration (Hypoxia), and this leads to death.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Surgical causes.</p>\n<p>- Head Injury, Chest trauma</p>\n<p>~</p>\n<p>Medical Causes</p>\n<p>- Severe Asthma, Pneumonia, Sepsis, Shock, Malaria,</p>\n<p>Covid-19, Heart Failure, Cardiac arrest, Upper airway</p>\n<p>obstruction, Severe anaemia, Pertussis, Carbon Monoxide</p>\n<p>poisoning.</p>\n<p>~</p>\n<p>Obstetric, gynaecological, and perioperative causes.</p>\n<p>- Obstructed labour, Ruptured uterus, Pre-eclampsia and</p>\n<p>eclampsia, Post caesarean section,</p>\n<p>~</p>\n<p>Neonatal causes</p>\n<p>- Transient tachypnoea of the new-born, Hypoxic Ischaemic</p>\n<p>encephalopathy (Birth asphyxia), Respiratory distress</p>\n<p>Syndrome, Neonatal Septicaemia.</p>\n<p>87</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 154,
        "content": "Diagnosis\n \n\u0081\nDo a clinical assessment (history taking for symptoms and physical \nexamination for signs)\n \n\u0081\nPulse oximetry and blood gas analysis. The findings on clinical \nassessment (symptoms and signs) [It is non-invasive but associated \nwith missed opportunities for diagnosis].\nSymptoms\n \n\u0083 Fast/very slow breathing, Difficulty in breathing, \n \n\u0083 Inability to talk, complete sentences\n \n\u0083 Extreme weakness\n \n\u0083 Inability to feed\n \n\u0083 Confusion, sleepy, agitated\n \n\u0083 Convulsions\nClinical Features\nFast breathing rate for age (Tachypnoea)\nRate\nAge\nImplication\n > 60 bpm\n0 \u2013 2months\nTachypnoea\n > 50 bpm\n2-12 months\n Tachypnoea\n > 40bpm\n12- 59 months\n Tachypnoea\n> 40bpm\n5-12years\n Tachypnoea\n > 20bpm\nAdults\nTachypnoea\nNote: bpm = Breaths per minute\n \n\u0081\nNasal flaring\n \n\u0081\nHead nodding\n \n\u0081\nChest in drawing (Intercostal, subcostal recession)  \n \n\u0081\nCyanosis (peripheral or central)\n \n\u0081\nProstration\n \n\u0081\nGlasgow coma scale< 10/15\n \n\u0081\nUse of any accessory muscles of respiration \n88\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Diagnosis</p>\n<p>\u0081</p>\n<p>Do a clinical assessment (history taking for symptoms and physical</p>\n<p>examination for signs)</p>\n<p>\u0081</p>\n<p>Pulse oximetry and blood gas analysis. The findings on clinical</p>\n<p>assessment (symptoms and signs) [It is non-invasive but associated</p>\n<p>with missed opportunities for diagnosis].</p>\n<p>Symptoms</p>\n<p>\u0083 Fast/very slow breathing, Difficulty in breathing,</p>\n<p>\u0083 Inability to talk, complete sentences</p>\n<p>\u0083 Extreme weakness</p>\n<p>\u0083 Inability to feed</p>\n<p>\u0083 Confusion, sleepy, agitated</p>\n<p>\u0083 Convulsions</p>\n<p>Clinical Features</p>\n<p>Fast breathing rate for age (Tachypnoea)</p>\n<p>Rate</p>\n<p>Age</p>\n<p>Implication</p>\n<p>> 60 bpm</p>\n<p>0 \u2013 2months</p>\n<p>Tachypnoea</p>\n<p>> 50 bpm</p>\n<p>2-12 months</p>\n<p>Tachypnoea</p>\n<p>> 40bpm</p>\n<p>12- 59 months</p>\n<p>Tachypnoea</p>\n<p>> 40bpm</p>\n<p>5-12years</p>\n<p>Tachypnoea</p>\n<p>> 20bpm</p>\n<p>Adults</p>\n<p>Tachypnoea</p>\n<p>Note: bpm = Breaths per minute</p>\n<p>\u0081</p>\n<p>Nasal flaring</p>\n<p>\u0081</p>\n<p>Head nodding</p>\n<p>\u0081</p>\n<p>Chest in drawing (Intercostal, subcostal recession)</p>\n<p>\u0081</p>\n<p>Cyanosis (peripheral or central)</p>\n<p>\u0081</p>\n<p>Prostration</p>\n<p>\u0081</p>\n<p>Glasgow coma scale< 10/15</p>\n<p>\u0081</p>\n<p>Use of any accessory muscles of respiration</p>\n<p>88</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 155,
        "content": "Management\n \n~\nPulse oximetry use. Always refer to the manufacturer\u2019s in\u00ad\nsert or the steps outlined below for guidance on how to use \nthe pulse oximetera.\n \n~\nThe steps involved in conducting pulse-oximetry\n\t\n\u0089\nTurn on the Pulse oximeter.\n\t\n\u0089\nAttach the Oximeter probe to the finger or toe.\n\t\n\u0089\nWait until there is a consistent pulse -wave signal before you take \nthe reading, this may take 20-30 seconds.\n\t\n\u0089\nRecord the reading and act accordingly.\n \n~\nInterpreting pulse-oximetry results \n\t\n\u0089\nSpO2 > 90% without danger signs = Normal\n\t\n\u0089\nSpO2 < 90% =Low oxygen concentration in blood (Hypoxaemia)\n\t\n\u0089\nSpO2 <92- 95% in Pregnancy = Low oxygen concentration in \nblood (Hypoxaemia)\n\t\n\u0089\nSpO2 < 94 % with danger signs = Low oxygen concentration in \nblood (Hypoxaemia\nBlood gas analysis-direct measurement of the partial pressure of oxygen \n(Pao2) and Carbon dioxide (PC02) 2, the PH and electrolytes concen\u00ad\ntration in blood. It is the most accurate, but it is highly skill dependant, \nexpensive and invasive.\nTreatment\nOxygen therapy\nThe treatment of hypoxaemia includes the use of Medical Oxygen (Oxygen \ntherapy) and specifically treating the underlying cause. \nIndications \n \n~\nAll patients with documented Hypoxaemia-arterial Carbon\u00ad\ndioxide tension (Paco2) of < 60 mmHg or peripheral arteri\u00ad\nal oxygen saturation (SpO2) OF < 90%.\n89\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Management</p>\n<p>~</p>\n<p>Pulse oximetry use. Always refer to the manufacturer\u2019s in\u00ad</p>\n<p>sert or the steps outlined below for guidance on how to use</p>\n<p>the pulse oximetera.</p>\n<p>~</p>\n<p>The steps involved in conducting pulse-oximetry</p>\n<p>\u0089</p>\n<p>Turn on the Pulse oximeter.</p>\n<p>\u0089</p>\n<p>Attach the Oximeter probe to the finger or toe.</p>\n<p>\u0089</p>\n<p>Wait until there is a consistent pulse -wave signal before you take</p>\n<p>the reading, this may take 20-30 seconds.</p>\n<p>\u0089</p>\n<p>Record the reading and act accordingly.</p>\n<p>~</p>\n<p>Interpreting pulse-oximetry results</p>\n<p>\u0089</p>\n<p>SpO2 > 90% without danger signs = Normal</p>\n<p>\u0089</p>\n<p>SpO2 < 90% =Low oxygen concentration in blood (Hypoxaemia)</p>\n<p>\u0089</p>\n<p>SpO2 <92- 95% in Pregnancy = Low oxygen concentration in</p>\n<p>blood (Hypoxaemia)</p>\n<p>\u0089</p>\n<p>SpO2 < 94 % with danger signs = Low oxygen concentration in</p>\n<p>blood (Hypoxaemia</p>\n<p>Blood gas analysis-direct measurement of the partial pressure of oxygen</p>\n<p>(Pao2) and Carbon dioxide (PC02) 2, the PH and electrolytes concen\u00ad</p>\n<p>tration in blood. It is the most accurate, but it is highly skill dependant,</p>\n<p>expensive and invasive.</p>\n<p>Treatment</p>\n<p>Oxygen therapy</p>\n<p>The treatment of hypoxaemia includes the use of Medical Oxygen (Oxygen</p>\n<p>therapy) and specifically treating the underlying cause.</p>\n<p>Indications</p>\n<p>~</p>\n<p>All patients with documented Hypoxaemia-arterial Carbon\u00ad</p>\n<p>dioxide tension (Paco2) of < 60 mmHg or peripheral arteri\u00ad</p>\n<p>al oxygen saturation (SpO2) OF < 90%.</p>\n<p>89</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 156,
        "content": "~\nPatients with the following danger/emergency signs irre\u00ad\nspective of the documented SpO2, PaCO2. \n \n~\nAbsent or obstructed breathing, Features of severe respi\u00ad\nratory distress, Central cyanosis, Convulsions, Signs of \nshock, Coma\n \n~\nAll acute conditions in which Coma is suspected like:\n \n~\nAcute Asthma, Severe Trauma, Acute myocardial Infarc\u00ad\ntion, Carbon monoxide poisoning\n \n~\nPost anaesthesia recovery.\n \n~\nIncreased metabolic demand\n \n~\nSevere burns, Poisoning, Multiple injuries, Severe infec\u00ad\ntions\n Medical Oxygen dosing and appropriate use of delivery device. \n \n~\nThe dosing of oxygen is dependent on the age of the pa\u00ad\ntient and severity of disease while the choice of appropriate \ndelivery devices depends on the amount or dose of oxygen \nto be delivered to a patient.\nTitrate oxygen based on oxygen saturation and delivery device.\nDe\u00ad\nlivery \ndevice\nNeo\u00ad\nnates\nInfants \n(1month \n-1yr)\nPre-\nschool \nage\n(1-3 \nyrs.)\nSchool \nage \n(4 yrs. \nabove)\nAdults\nComments\nNasal \nCanu\u00ad\nlae\n0.5\u2013\n1.0 \nL/\nmin \n1\u20132 L/\nmin\n1\u20134 L/\nmin\n1\u20136 \nL/min \nFace \nMask\nNA\nNA\n6-10L/\nmin\n6-10L \n/min\nAt 5-7L/\nmin to \navoid CO2 \nrebreathing\n90\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Patients with the following danger/emergency signs irre\u00ad</p>\n<p>spective of the documented SpO2, PaCO2.</p>\n<p>~</p>\n<p>Absent or obstructed breathing, Features of severe respi\u00ad</p>\n<p>ratory distress, Central cyanosis, Convulsions, Signs of</p>\n<p>shock, Coma</p>\n<p>~</p>\n<p>All acute conditions in which Coma is suspected like:</p>\n<p>~</p>\n<p>Acute Asthma, Severe Trauma, Acute myocardial Infarc\u00ad</p>\n<p>tion, Carbon monoxide poisoning</p>\n<p>~</p>\n<p>Post anaesthesia recovery.</p>\n<p>~</p>\n<p>Increased metabolic demand</p>\n<p>~</p>\n<p>Severe burns, Poisoning, Multiple injuries, Severe infec\u00ad</p>\n<p>tions</p>\n<p>Medical Oxygen dosing and appropriate use of delivery device.</p>\n<p>~</p>\n<p>The dosing of oxygen is dependent on the age of the pa\u00ad</p>\n<p>tient and severity of disease while the choice of appropriate</p>\n<p>delivery devices depends on the amount or dose of oxygen</p>\n<p>to be delivered to a patient.</p>\n<p>Titrate oxygen based on oxygen saturation and delivery device.</p>\n<p>De\u00ad</p>\n<p>livery</p>\n<p>device</p>\n<p>Neo\u00ad</p>\n<p>nates</p>\n<p>Infants</p>\n<p>(1month</p>\n<p>-1yr)</p>\n<p>Pre-</p>\n<p>school</p>\n<p>age</p>\n<p>(1-3</p>\n<p>yrs.)</p>\n<p>School</p>\n<p>age</p>\n<p>(4 yrs.</p>\n<p>above)</p>\n<p>Adults</p>\n<p>Comments</p>\n<p>Nasal</p>\n<p>Canu\u00ad</p>\n<p>lae</p>\n<p>0.5\u2013</p>\n<li>.0</li>\n<p>L/</p>\n<p>min</p>\n<h3>1\u20132 L/</h3>\n<p>min</p>\n<h3>1\u20134 L/</h3>\n<p>min</p>\n<p>1\u20136</p>\n<p>L/min</p>\n<p>Face</p>\n<p>Mask</p>\n<p>NA</p>\n<p>NA</p>\n<h3>6-10L/</h3>\n<p>min</p>\n<h3>6-10L</h3>\n<p>/min</p>\n<p>At 5-7L/</p>\n<p>min to</p>\n<p>avoid CO2</p>\n<p>rebreathing</p>\n<p>90</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 157,
        "content": "De\u00ad\nlivery \ndevice\nNeo\u00ad\nnates\nInfants \n(1month \n-1yr)\nPre-\nschool \nage\n(1-3 \nyrs.)\nSchool \nage \n(4 yrs. \nabove)\nAdults\nComments\nFace \nmask \nwith \nreser\u00ad\nvoir \nNA\nNA\nNA\nNA\n10-\n15L /\nmin\nReser\u00ad\nvoir must \nbe filled \ncorrectly \nbefore \nadministra\u00ad\ntion\nCPAP\nWhen \nnasal \ncan\u00ad\nulae \nfailed \nto \nraise \nSpO2 \nabove \n90%\nWhen \nnasal \ncanulae \nfailed \nto raise \nSpO2 \nabove \n90%\nWhen \nnasal \ncan\u00ad\nulae \nfailed \nto raise \nSpO2 \nabove \n90%\nWhen \nnasal \ncan\u00ad\nulae \nfailed \nto raise \nSpO2 \nabove \n90%\nNA\n-Bubble \nCPAP with \nmodified \nnasal \nprongs can \nbe run with \nan oxygen \nconcen\u00ad\ntrator/ \ncylinder\n-CPAP de\u00ad\ncreases ate\u00ad\nlectasis and \nrespiratory \nfatigue and \nimproves \noxygena\u00ad\ntion\nHigh \nFlow \nNasal \nCanula\nNA\nNA\nNA\nNA\nIllness/disease \ncategorization\nFiO2\nO2 flow rate\nDelivery devices\nRange\nAver\u00ad\nage\nName\n1\nMild\n25-40% 1-5l/min\n3L/\nmin\nNasal Cannula\n2\nModerate\n40-60% 6-10l/\nmin\n8L/\nmin\nFace Mask\n3\nSevere\n60-90% 10-15l/\nmin\n13L/\nmin\nFace mask with \nreservoir bag \n91\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>De\u00ad</p>\n<p>livery</p>\n<p>device</p>\n<p>Neo\u00ad</p>\n<p>nates</p>\n<p>Infants</p>\n<p>(1month</p>\n<p>-1yr)</p>\n<p>Pre-</p>\n<p>school</p>\n<p>age</p>\n<p>(1-3</p>\n<p>yrs.)</p>\n<p>School</p>\n<p>age</p>\n<p>(4 yrs.</p>\n<p>above)</p>\n<p>Adults</p>\n<p>Comments</p>\n<p>Face</p>\n<p>mask</p>\n<p>with</p>\n<p>reser\u00ad</p>\n<p>voir</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>10-</p>\n<h3>15L /</h3>\n<p>min</p>\n<p>Reser\u00ad</p>\n<p>voir must</p>\n<p>be filled</p>\n<p>correctly</p>\n<p>before</p>\n<p>administra\u00ad</p>\n<p>tion</p>\n<h3>CPAP</h3>\n<p>When</p>\n<p>nasal</p>\n<p>can\u00ad</p>\n<p>ulae</p>\n<p>failed</p>\n<p>to</p>\n<p>raise</p>\n<p>SpO2</p>\n<p>above</p>\n<p>90%</p>\n<p>When</p>\n<p>nasal</p>\n<p>canulae</p>\n<p>failed</p>\n<p>to raise</p>\n<p>SpO2</p>\n<p>above</p>\n<p>90%</p>\n<p>When</p>\n<p>nasal</p>\n<p>can\u00ad</p>\n<p>ulae</p>\n<p>failed</p>\n<p>to raise</p>\n<p>SpO2</p>\n<p>above</p>\n<p>90%</p>\n<p>When</p>\n<p>nasal</p>\n<p>can\u00ad</p>\n<p>ulae</p>\n<p>failed</p>\n<p>to raise</p>\n<p>SpO2</p>\n<p>above</p>\n<p>90%</p>\n<p>NA</p>\n<p>-Bubble</p>\n<p>CPAP with</p>\n<p>modified</p>\n<p>nasal</p>\n<p>prongs can</p>\n<p>be run with</p>\n<p>an oxygen</p>\n<p>concen\u00ad</p>\n<p>trator/</p>\n<p>cylinder</p>\n<p>-CPAP de\u00ad</p>\n<p>creases ate\u00ad</p>\n<p>lectasis and</p>\n<p>respiratory</p>\n<p>fatigue and</p>\n<p>improves</p>\n<p>oxygena\u00ad</p>\n<p>tion</p>\n<p>High</p>\n<p>Flow</p>\n<p>Nasal</p>\n<p>Canula</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>Illness/disease</p>\n<p>categorization</p>\n<p>FiO2</p>\n<p>O2 flow rate</p>\n<p>Delivery devices</p>\n<p>Range</p>\n<p>Aver\u00ad</p>\n<p>age</p>\n<p>Name</p>\n<p>1</p>\n<p>Mild</p>\n<p>25-40% 1-5l/min</p>\n<h3>3L/</h3>\n<p>min</p>\n<p>Nasal Cannula</p>\n<p>2</p>\n<p>Moderate</p>\n<p>40-60% 6-10l/</p>\n<p>min</p>\n<h3>8L/</h3>\n<p>min</p>\n<p>Face Mask</p>\n<p>3</p>\n<p>Severe</p>\n<p>60-90% 10-15l/</p>\n<p>min</p>\n<h3>13L/</h3>\n<p>min</p>\n<p>Face mask with</p>\n<p>reservoir bag</p>\n<p>91</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 158,
        "content": "Illness/disease \ncategorization\nFiO2\nO2 flow rate\nDelivery devices\n4\nCritical\n100%\n20-60l/\nmin\n40l/\nmin\nHigh flow nasal \ncannula\n5\n?/\n?\n16-20l/\nmin\n18l/\nmin\nMechanical venti\u00ad\nlation\nNB: Mild \u2013Moderate illness start with 5l/min by nasal cannula\n\t\n\u0089\nFor older children and adults with severe disease, give 10-15l/min \nvia face mask with a reservoir bag.\n\t\n\u0089\nOlder children and severe disease with mild \u2013moderate disease give \n6-10l/min via a simple face mask\n\t\n\u0089\nChildren below 5years of age that require >5l/min of oxygen, the \npreferred delivery device is CPAP.\n \n~\nTitration and weaning patients off Oxygen \n \n\u0081\nHow to Escalate or increase oxygen in non-Responsive Adult \npatients with consistent Spo2 below 90%.\nStart oxygen therapy at a rate of 1-5litres/min\nUse Nasal prongs\nAssess response\nWorsening respiratory distress with \nSpO2<90%\nUse a simple face mask, give 5-10litres/minute\nAssess response\nWorsening respiratory distress with \nSpO2<90%\nWorsening respiratory distress with \nSpO2<90%\nContinue to try to find a higher level of care and consider one of the following if \navailable and adequate O2 supply: \nHFNO: 30-60 LPM (may also adjust FiO2)| CPAP: 10-15 cmH20\n BIPAP: PS (\u0394P) 5-15/PEEP (EPAP) 5-15\nUse a mask with a reservoir bag, ensure the bag is well inflated.\nGive 10-15litres/minute. Assess for response.\n92\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Illness/disease</p>\n<p>categorization</p>\n<p>FiO2</p>\n<p>O2 flow rate</p>\n<p>Delivery devices</p>\n<p>4</p>\n<p>Critical</p>\n<p>100%</p>\n<p>20-60l/</p>\n<p>min</p>\n<p>40l/</p>\n<p>min</p>\n<p>High flow nasal</p>\n<p>cannula</p>\n<p>5</p>\n<p>?/</p>\n<p>?</p>\n<p>16-20l/</p>\n<p>min</p>\n<p>18l/</p>\n<p>min</p>\n<p>Mechanical venti\u00ad</p>\n<p>lation</p>\n<p>NB: Mild \u2013Moderate illness start with 5l/min by nasal cannula</p>\n<p>\u0089</p>\n<p>For older children and adults with severe disease, give 10-15l/min</p>\n<p>via face mask with a reservoir bag.</p>\n<p>\u0089</p>\n<p>Older children and severe disease with mild \u2013moderate disease give</p>\n<p>6-10l/min via a simple face mask</p>\n<p>\u0089</p>\n<p>Children below 5years of age that require >5l/min of oxygen, the</p>\n<p>preferred delivery device is CPAP.</p>\n<p>~</p>\n<p>Titration and weaning patients off Oxygen</p>\n<p>\u0081</p>\n<p>How to Escalate or increase oxygen in non-Responsive Adult</p>\n<p>patients with consistent Spo2 below 90%.</p>\n<p>Start oxygen therapy at a rate of 1-5litres/min</p>\n<p>Use Nasal prongs</p>\n<p>Assess response</p>\n<p>Worsening respiratory distress with</p>\n<p>SpO2<90%</p>\n<p>Use a simple face mask, give 5-10litres/minute</p>\n<p>Assess response</p>\n<p>Worsening respiratory distress with</p>\n<p>SpO2<90%</p>\n<p>Worsening respiratory distress with</p>\n<p>SpO2<90%</p>\n<p>Continue to try to find a higher level of care and consider one of the following if</p>\n<p>available and adequate O2 supply:</p>\n<p>HFNO: 30-60 LPM (may also adjust FiO2)| CPAP: 10-15 cmH20</p>\n<h3>BIPAP: PS (\u0394P) 5-15/PEEP (EPAP) 5-15</h3>\n<p>Use a mask with a reservoir bag, ensure the bag is well inflated.</p>\n<p>Give 10-15litres/minute. Assess for response.</p>\n<p>92</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 159,
        "content": "~\nWeaning patient off oxygen\n\t\n\u0089\nThe oxygen flowrate/ dose should be decreased if patient stabilizes \nor improves with SpO2 above 90%.\n\t\n\u0089\nDecrease oxygen flow by 1-2Litre/min once patient is stable with \nOxygen saturation above 92%. \n\t\n\u0089\nObserve the patient for 2-3 minutes, reassess after 15 mins to en\u00ad\nsure Sp02 is still above 90% (by recording clinical exam and SpO2)\n\t\n\u0089\nIf a patient does not tolerate less oxygen, then maintain the flow \nrate that the patient has been on prior to reducing until the patient \nis stable (Sp02 >92%)\n\t\n\u0089\nIf a patient is in increased respiratory distress or Sp02 less than \n90%, then increased the oxygen flow rate to the previous rate until \nthe patient is stable.\n\t\n\u0089\nIf a patient remains stable after 15 mins of reassessment and Sp02 \n>92%, continue to titrate oxygen down as tolerated.\nRecheck clinical status and Sp02 on the patient after 1 hour for \ndelayed hypoxemia or respiratory distress.\n93\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>~</p>\n<p>Weaning patient off oxygen</p>\n<p>\u0089</p>\n<p>The oxygen flowrate/ dose should be decreased if patient stabilizes</p>\n<p>or improves with SpO2 above 90%.</p>\n<p>\u0089</p>\n<p>Decrease oxygen flow by 1-2Litre/min once patient is stable with</p>\n<p>Oxygen saturation above 92%.</p>\n<p>\u0089</p>\n<p>Observe the patient for 2-3 minutes, reassess after 15 mins to en\u00ad</p>\n<p>sure Sp02 is still above 90% (by recording clinical exam and SpO2)</p>\n<p>\u0089</p>\n<p>If a patient does not tolerate less oxygen, then maintain the flow</p>\n<p>rate that the patient has been on prior to reducing until the patient</p>\n<p>is stable (Sp02 >92%)</p>\n<p>\u0089</p>\n<p>If a patient is in increased respiratory distress or Sp02 less than</p>\n<p>90%, then increased the oxygen flow rate to the previous rate until</p>\n<p>the patient is stable.</p>\n<p>\u0089</p>\n<p>If a patient remains stable after 15 mins of reassessment and Sp02</p>\n<p>>92%, continue to titrate oxygen down as tolerated.</p>\n<p>Recheck clinical status and Sp02 on the patient after 1 hour for</p>\n<p>delayed hypoxemia or respiratory distress.</p>\n<p>93</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 160,
        "content": "Basic use  and Maintenance  of Oxygen sources \n94\nUganda Clinical Guidelines 2023\nCHAPTER 1: Emergencies and Trauma",
        "formatted_content": "<p>Basic use  and Maintenance  of Oxygen sources</p>\n<p>94</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 1: Emergencies and Trauma</p>"
    },
    {
        "page_number": 161,
        "content": "2.1 BACTERIAL INFECTIONS\n2.1.1 Anthrax                     ICD10 CODE: A22.10-A22.9\nAnthrax is an acute zoonotic infectious disease caused by the bacterium \nBacillus anthracis. It most commonly occurs in wild and domestic animals, \nsuch as cattle, sheep, goats, camels, antelopes, and other herbivores. \nB. anthracis spores can live in the soil for many years.\nIt occurs in humans when they are exposed to infected animals or tis\u00ad\nsue from infected animals. The incubation period is usually 1-3 days. \nAnthrax is a notifiable disease.\nCause\n \n~\nExposure to B. anthracis spores by handling products \nfrom infected animals or by inhaling anthrax spores from \ncontaminated animal products\n \n~\nAnthrax can also be spread by eating undercooked meat \nfrom infected animals\nClinical features\nSymptoms vary depending on how the disease was contracted, and \nusually occur within 7 days\nInfectious Diseases\n2\n95\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>2.1 BACTERIAL INFECTIONS</h3>\n<p>2.1.1 Anthrax                     ICD10 CODE: A22.10-A22.9</p>\n<p>Anthrax is an acute zoonotic infectious disease caused by the bacterium</p>\n<p>Bacillus anthracis. It most commonly occurs in wild and domestic animals,</p>\n<p>such as cattle, sheep, goats, camels, antelopes, and other herbivores.</p>\n<p>B. anthracis spores can live in the soil for many years.</p>\n<p>It occurs in humans when they are exposed to infected animals or tis\u00ad</p>\n<p>sue from infected animals. The incubation period is usually 1-3 days.</p>\n<p>Anthrax is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Exposure to B. anthracis spores by handling products</p>\n<p>from infected animals or by inhaling anthrax spores from</p>\n<p>contaminated animal products</p>\n<p>~</p>\n<p>Anthrax can also be spread by eating undercooked meat</p>\n<p>from infected animals</p>\n<p>Clinical features</p>\n<p>Symptoms vary depending on how the disease was contracted, and</p>\n<p>usually occur within 7 days</p>\n<p>Infectious Diseases</p>\n<p>2</p>\n<p>95</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 162,
        "content": "TYPE\nFEATURES\nCutaneous\n \n~\n95% of anthrax infections occur through \nskin cut or abrasion\n \n~\nStarts as raised itchy bump that resembles \nan insect bite\n \n~\nWithin 1-2 days, it develops into a vesicle \nand then a painless ulcer, usually 1-3 cm \nin diameter, with a characteristic black\n \n~\nnecrotic (dying) area in the centre (eschar)\n \n~\nLymph glands in adjacent area may swell\n \n~\nAbout 20% of untreated cutaneous an\u00ad\nthrax results in death\nInhalation\n \n~\nInitial symptoms resemble a cold\n \n~\nAfter several days, symptoms may prog\u00ad\nress to severe breathing problems and \nshock\n \n~\nInhalation anthrax is usually fatal\nGastro- in\u00ad\ntestinal\n \n~\nAcute inflammation of the intestinal tract\n \n~\nInitial signs of nausea, loss of appetite, \nvomiting and fever\n \n~\nThen abdominal pain, vomiting blood, \nand severe diarrhoea\n \n~\nIntestinal anthrax results in death in 25% \nto 60% of the cases\nInvestigations\n\u00be\t\nIsolation of Bacillus anthracis from blood, skin lesions, \nor respiratory secretions- Smear-many bacilli\n\u00be\t\nOr measure specific antibodies in the blood of persons \nwith suspected infection\n96\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TYPE</h3>\n<h3>FEATURES</h3>\n<p>Cutaneous</p>\n<p>~</p>\n<p>95% of anthrax infections occur through</p>\n<p>skin cut or abrasion</p>\n<p>~</p>\n<p>Starts as raised itchy bump that resembles</p>\n<p>an insect bite</p>\n<p>~</p>\n<p>Within 1-2 days, it develops into a vesicle</p>\n<p>and then a painless ulcer, usually 1-3 cm</p>\n<p>in diameter, with a characteristic black</p>\n<p>~</p>\n<p>necrotic (dying) area in the centre (eschar)</p>\n<p>~</p>\n<p>Lymph glands in adjacent area may swell</p>\n<p>~</p>\n<p>About 20% of untreated cutaneous an\u00ad</p>\n<p>thrax results in death</p>\n<p>Inhalation</p>\n<p>~</p>\n<p>Initial symptoms resemble a cold</p>\n<p>~</p>\n<p>After several days, symptoms may prog\u00ad</p>\n<p>ress to severe breathing problems and</p>\n<p>shock</p>\n<p>~</p>\n<p>Inhalation anthrax is usually fatal</p>\n<p>Gastro- in\u00ad</p>\n<p>testinal</p>\n<p>~</p>\n<p>Acute inflammation of the intestinal tract</p>\n<p>~</p>\n<p>Initial signs of nausea, loss of appetite,</p>\n<p>vomiting and fever</p>\n<p>~</p>\n<p>Then abdominal pain, vomiting blood,</p>\n<p>and severe diarrhoea</p>\n<p>~</p>\n<p>Intestinal anthrax results in death in 25%</p>\n<p>to 60% of the cases</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Isolation of Bacillus anthracis from blood, skin lesions,</p>\n<p>or respiratory secretions- Smear-many bacilli</p>\n<p>\u00be</p>\n<p>Or measure specific antibodies in the blood of persons</p>\n<p>with suspected infection</p>\n<p>96</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 163,
        "content": "Management\nTREATMENT\nLOC\nCutaneous anthrax\n\t\n\u0089\nTreat for 7\u201310 days\n\t\n\u0089\nFirst line is ciprofloxacin 500 mg every 12 hours \n\t\n\u0089\nAlternatives: doxycycline 100 mg every 12 hours \n\t\n\u0089\nOr amoxicillin 1 g every 8 hours\nHC2\nPrevention\nThe following public measures are key for quick prevention and control of \nanthrax infection:\n \n~\nHealth education and information\n \n~\nProper disposal by burying of carcasses, hides and skins; \n(no burning as it can spread spores)\n \n~\nNo skinning of dead animals; this allows spore formation, \nwhich can stay in soil for decades\n \n~\nNo eating of meat from dead animals\n \n~\nRestrict movement of animals and animal by-products from \ninfected to non-infected areas\n \n~\nMass vaccination of animals in endemic areas\n \n~\nVaccination using human anthrax vaccine for:\n \n- Persons who work directly with the organism in the laboratory\n \n- Persons who handle potentially infected animal products\n \n- in high-incidence areas\n2.1.2 Brucellosis             ICD11CODE: A23.9\n(Undulant fever, malta fever, abortus fever)\nA zoonotic bacterial infection of acute onset. Common as an occupational \n97\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Cutaneous anthrax</p>\n<p>\u0089</p>\n<p>Treat for 7\u201310 days</p>\n<p>\u0089</p>\n<p>First line is ciprofloxacin 500 mg every 12 hours</p>\n<p>\u0089</p>\n<p>Alternatives: doxycycline 100 mg every 12 hours</p>\n<p>\u0089</p>\n<p>Or amoxicillin 1 g every 8 hours</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>The following public measures are key for quick prevention and control of</p>\n<p>anthrax infection:</p>\n<p>~</p>\n<p>Health education and information</p>\n<p>~</p>\n<p>Proper disposal by burying of carcasses, hides and skins;</p>\n<p>(no burning as it can spread spores)</p>\n<p>~</p>\n<p>No skinning of dead animals; this allows spore formation,</p>\n<p>which can stay in soil for decades</p>\n<p>~</p>\n<p>No eating of meat from dead animals</p>\n<p>~</p>\n<p>Restrict movement of animals and animal by-products from</p>\n<p>infected to non-infected areas</p>\n<p>~</p>\n<p>Mass vaccination of animals in endemic areas</p>\n<p>~</p>\n<p>Vaccination using human anthrax vaccine for:</p>\n<p>- Persons who work directly with the organism in the laboratory</p>\n<p>- Persons who handle potentially infected animal products</p>\n<p>- in high-incidence areas</p>\n<p>2.1.2 Brucellosis             ICD11CODE: A23.9</p>\n<p>(Undulant fever, malta fever, abortus fever)</p>\n<p>A zoonotic bacterial infection of acute onset. Common as an occupational</p>\n<p>97</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 164,
        "content": "disease among people working with infected livestock or associated fresh \nanimal products, for example butchers, farmers, abattoir workers, and \nvendors of contaminated roasted meat (muchomo). Incubation is 2-4 \nweeks on average, but it can be from 1 to 8 weeks.\nCauses\n \n~\nBrucella abortus (cattle)\n \n~\nBrucella canis (dog)\n \n~\nBrucella melitensis (goats and sheep)\n \n~\nBrucella suis (pigs)\nClinical features\n \n~\nIntermittent (fluctuating) fever\n \n~\nAches and pains\n \n~\nOrchitis (inflammation of the testes)\n \n~\nVertebrae osteomyelitis (uncommon but characteristic)\nDifferential diagnosis\n \n~\nTyphoid fever, malaria, tuberculosis\n \n~\nTrypanosomiasis (sleeping sickness)\n \n~\nOther causes of prolonged fever\nInvestigations\n\u00be\t\nBlood: complement fixation test or agglutination \ntest (where possible)\nThe interpretation of serological tests can be difficult, particularly in \nendemic areas where a high proportion of the population has antibodies \nagainst brucellosis. Positive serological test results can persist long after \nrecovery in treated individuals so results have to be interpreted on the basis \nof the clinical picture.\n98\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>disease among people working with infected livestock or associated fresh</p>\n<p>animal products, for example butchers, farmers, abattoir workers, and</p>\n<p>vendors of contaminated roasted meat (muchomo). Incubation is 2-4</p>\n<p>weeks on average, but it can be from 1 to 8 weeks.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Brucella abortus (cattle)</p>\n<p>~</p>\n<p>Brucella canis (dog)</p>\n<p>~</p>\n<p>Brucella melitensis (goats and sheep)</p>\n<p>~</p>\n<p>Brucella suis (pigs)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Intermittent (fluctuating) fever</p>\n<p>~</p>\n<p>Aches and pains</p>\n<p>~</p>\n<p>Orchitis (inflammation of the testes)</p>\n<p>~</p>\n<p>Vertebrae osteomyelitis (uncommon but characteristic)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Typhoid fever, malaria, tuberculosis</p>\n<p>~</p>\n<p>Trypanosomiasis (sleeping sickness)</p>\n<p>~</p>\n<p>Other causes of prolonged fever</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Blood: complement fixation test or agglutination</p>\n<p>test (where possible)</p>\n<p>The interpretation of serological tests can be difficult, particularly in</p>\n<p>endemic areas where a high proportion of the population has antibodies</p>\n<p>against brucellosis. Positive serological test results can persist long after</p>\n<p>recovery in treated individuals so results have to be interpreted on the basis</p>\n<p>of the clinical picture.</p>\n<p>98</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 165,
        "content": "Isolation of the infectious agent from blood, bone marrow, or other \ntissues by culture\nManagement\nTREATMENT\nLOC\nAdult and child > 8 years:\n\t\n\u0089\nDoxycycline 100 mg every 12 hours for 6 weeks\nChild > 8 years: 2 mg/kg per dose\nHC4\n\t\n\u0089\nPlus gentamicin 5-7 mg/kg IV daily for 2 weeks \nChild < 8 years: 7.5 mg/kg daily in 1-3 divided doses\n \n- Or ciprofloxacin 500 mg twice daily for 2 weeks\nChild < 12 years: do not use\nChildren below 8 years\n\t\n\u0089\nCotrimoxazole 24 mg/kg every 12 hours for 6 weeks\n\t\n\u0089\nPlus gentamicin 5-7 mg/kg IV in single or divided doses \nfor 2 weeks\nCaution\n \n\u0083 Treatment duration must be adhered to at all times\n \n\u0083 Ciprofloxacin is contraindicated in children <12 \nyears\n \n\u0083 Doxycyline, gentamicin: Contraindicated in \npregnancy\nPrevention\n \n~\n Provide public health education on\n \n- Drinking only pasteurised or boiled milk\n \n- Careful handling of pigs, goats, dogs, and cattle if a person \nhas wounds or cuts\n \n- Provide veterinary services for domestic animals\n99\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Isolation of the infectious agent from blood, bone marrow, or other</p>\n<p>tissues by culture</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Adult and child > 8 years:</p>\n<p>\u0089</p>\n<p>Doxycycline 100 mg every 12 hours for 6 weeks</p>\n<p>Child > 8 years: 2 mg/kg per dose</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Plus gentamicin 5-7 mg/kg IV daily for 2 weeks</p>\n<p>Child < 8 years: 7.5 mg/kg daily in 1-3 divided doses</p>\n<p>- Or ciprofloxacin 500 mg twice daily for 2 weeks</p>\n<p>Child < 12 years: do not use</p>\n<p>Children below 8 years</p>\n<p>\u0089</p>\n<p>Cotrimoxazole 24 mg/kg every 12 hours for 6 weeks</p>\n<p>\u0089</p>\n<p>Plus gentamicin 5-7 mg/kg IV in single or divided doses</p>\n<p>for 2 weeks</p>\n<p>Caution</p>\n<p>\u0083 Treatment duration must be adhered to at all times</p>\n<p>\u0083 Ciprofloxacin is contraindicated in children <12</p>\n<p>years</p>\n<p>\u0083 Doxycyline, gentamicin: Contraindicated in</p>\n<p>pregnancy</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Provide public health education on</p>\n<p>- Drinking only pasteurised or boiled milk</p>\n<p>- Careful handling of pigs, goats, dogs, and cattle if a person</p>\n<p>has wounds or cuts</p>\n<p>- Provide veterinary services for domestic animals</p>\n<p>99</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 166,
        "content": "2.1.3 Diphtheria                ICD10 CODE: A36.9\nAn acute bacterial infection caused by Corynebacterium diphtheriae, \nwhich is spread through droplet infection and mainly occurs in the \nnasopharynx. The bacteria produce a toxin which is responsible for the \nsystemic effects. Incubation period is 2-7 days.\nCause\n \n~\nToxin of Corynebacterium diphtheriae\nClinical features\n \n~\nPseudomembranous tonsillitis (grey, tough and very stickly \nmembranes) with dysphagia, cervical adenitis, at times pro\u00ad\ngressing to massive swelling of the neck\n \n~\nAirway obstruction and possible suffocation when infection \nextends to the nasal passages, larynx, trachea and bronchi\n \n~\nLow grade fever\n \n~\nEffects of the toxin: cardiac dysfunction (myocarditis with \nheart failure), neuropathies 1-3 months after the onset af\u00ad\nfecting swallowing, vision, breathing and ambulation\n \n~\nRenal failure\nInvestigation\n\u00be\t\nCulture from throat swab\n2\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer urgently to hospital\n\t\n\u0089\nIsolate (contact and droplet precautions) until 3 throat \nswabs (nose, throat, or skin) are negative\n\t\n\u0089\nGive procaine benzylpenicillin 1.2 MIU daily IM until \npatients can switch to oral\nH\n100\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>2.1.3 Diphtheria                ICD10 CODE: A36.9</p>\n<p>An acute bacterial infection caused by Corynebacterium diphtheriae,</p>\n<p>which is spread through droplet infection and mainly occurs in the</p>\n<p>nasopharynx. The bacteria produce a toxin which is responsible for the</p>\n<p>systemic effects. Incubation period is 2-7 days.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Toxin of Corynebacterium diphtheriae</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pseudomembranous tonsillitis (grey, tough and very stickly</p>\n<p>membranes) with dysphagia, cervical adenitis, at times pro\u00ad</p>\n<p>gressing to massive swelling of the neck</p>\n<p>~</p>\n<p>Airway obstruction and possible suffocation when infection</p>\n<p>extends to the nasal passages, larynx, trachea and bronchi</p>\n<p>~</p>\n<p>Low grade fever</p>\n<p>~</p>\n<p>Effects of the toxin: cardiac dysfunction (myocarditis with</p>\n<p>heart failure), neuropathies 1-3 months after the onset af\u00ad</p>\n<p>fecting swallowing, vision, breathing and ambulation</p>\n<p>~</p>\n<p>Renal failure</p>\n<p>Investigation</p>\n<p>\u00be</p>\n<p>Culture from throat swab</p>\n<p>2</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer urgently to hospital</p>\n<p>\u0089</p>\n<p>Isolate (contact and droplet precautions) until 3 throat</p>\n<p>swabs (nose, throat, or skin) are negative</p>\n<p>\u0089</p>\n<p>Give procaine benzylpenicillin 1.2 MIU daily IM until</p>\n<p>patients can switch to oral</p>\n<p>H</p>\n<p>100</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 167,
        "content": "Management\nTREATMENT\nLOC\nChild: procaine benzylpenicillin 50,000 IU/kg per \nday IM once daily until patient can swallow\nWhen patient is able to swallow\n\t\n\u0089\nGive Penicillin V 250 mg every 6 hours per day to \ncomplete 14 days.\nChild 1-6 years: 125 mg 6 hourly\nChild< 1 years: 12.5 mg/kg every 6 hours\nIn case of penicillin allergy\n\t\n\u0089\nErythromycin 500 mg every 6 hours for 14 days\nChild: 50 mg/kg every 6 hours\nH\nPrevention\n \n~\nIsolation of patient and proper management of close con\u00ad\ntacts\n \n- Monitor close contacts for 7 days and give prophylactic\n \n- antibiotics: single dose benzathine penicillin IM (child\n \n- <10 years: 600,000 IU, child >10 yrs and adults: 1.2 MIU)\n \n- Verify immunisation status, complete if needed, give a booster \nif the last dose was more than a year before\n \n~\nImmunise all children during routine childhood immunisa\u00ad\ntion\n2.1.4 Leprosy/Hansens disease         ICD10 CODE: A30.0\nA chronic infectious disease caused by Mycobacterium leprae/Hansens \nbacillus - an acid-fast bacillus. It mainly affects the skin, peripheral nerves \nand mucous membranes. It is transmitted from one person to another \nvia the respiratory tract (possibly, very rarely, through broken skin). It is \nclassified into paucibacillary (PB) or Multibacillary (MB) Leprosy.\n101\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Child: procaine benzylpenicillin 50,000 IU/kg per</p>\n<p>day IM once daily until patient can swallow</p>\n<p>When patient is able to swallow</p>\n<p>\u0089</p>\n<p>Give Penicillin V 250 mg every 6 hours per day to</p>\n<p>complete 14 days.</p>\n<p>Child 1-6 years: 125 mg 6 hourly</p>\n<p>Child< 1 years: 12.5 mg/kg every 6 hours</p>\n<p>In case of penicillin allergy</p>\n<p>\u0089</p>\n<p>Erythromycin 500 mg every 6 hours for 14 days</p>\n<p>Child: 50 mg/kg every 6 hours</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Isolation of patient and proper management of close con\u00ad</p>\n<p>tacts</p>\n<p>- Monitor close contacts for 7 days and give prophylactic</p>\n<p>- antibiotics: single dose benzathine penicillin IM (child</p>\n<p>- <10 years: 600,000 IU, child >10 yrs and adults: 1.2 MIU)</p>\n<p>- Verify immunisation status, complete if needed, give a booster</p>\n<p>if the last dose was more than a year before</p>\n<p>~</p>\n<p>Immunise all children during routine childhood immunisa\u00ad</p>\n<p>tion</p>\n<p>2.1.4 Leprosy/Hansens disease         ICD10 CODE: A30.0</p>\n<p>A chronic infectious disease caused by Mycobacterium leprae/Hansens</p>\n<p>bacillus - an acid-fast bacillus. It mainly affects the skin, peripheral nerves</p>\n<p>and mucous membranes. It is transmitted from one person to another</p>\n<p>via the respiratory tract (possibly, very rarely, through broken skin). It is</p>\n<p>classified into paucibacillary (PB) or Multibacillary (MB) Leprosy.</p>\n<p>101</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 168,
        "content": "Clinical features\n \n~\nPale or reddish patches on the skin (The most common \nsign of leprosy)\n \n~\nLoss or decrease in feeling in the skin patch\n \n~\nNumbness or tingling of the hands or feet.\n \n~\nWeakness of the hands, feet or eyelids\n \n~\nPainful or tender nerves\n \n~\nSwelling or lamps in the face or earlobes\n \n~\nPainless wounds or burns on the hands or feet\nCase definition\nA case of leprosy is a person with clinical signs of leprosy who \nrequires chemotherapy.\nDiagnosis of leprosy\nDiagnosis of Leprosy must be based on careful clinical examination of \nthe patient and when necessary, backed by bacteriological examination\nLeprosy is diagnosed by finding at least one of the three cardinal signs:\n \n- Hypopigmented patches with definite loss of sensation in \nthem\n \n- Thickened or enlarged peripheral nerves, with loss of \nsensation and/or weakness of the muscles supplied by those \nnerves\n \n- The presence of acid-fast bacilli in a slit skin smear\nClassification of leprosy\nPaucibacillary (PB) leprosy - 1-5 patches\nMultibacillary (MB) Leprosy - More than 5 patches\n102\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Pale or reddish patches on the skin (The most common</p>\n<p>sign of leprosy)</p>\n<p>~</p>\n<p>Loss or decrease in feeling in the skin patch</p>\n<p>~</p>\n<p>Numbness or tingling of the hands or feet.</p>\n<p>~</p>\n<p>Weakness of the hands, feet or eyelids</p>\n<p>~</p>\n<p>Painful or tender nerves</p>\n<p>~</p>\n<p>Swelling or lamps in the face or earlobes</p>\n<p>~</p>\n<p>Painless wounds or burns on the hands or feet</p>\n<p>Case definition</p>\n<p>A case of leprosy is a person with clinical signs of leprosy who</p>\n<p>requires chemotherapy.</p>\n<p>Diagnosis of leprosy</p>\n<p>Diagnosis of Leprosy must be based on careful clinical examination of</p>\n<p>the patient and when necessary, backed by bacteriological examination</p>\n<p>Leprosy is diagnosed by finding at least one of the three cardinal signs:</p>\n<p>- Hypopigmented patches with definite loss of sensation in</p>\n<p>them</p>\n<p>- Thickened or enlarged peripheral nerves, with loss of</p>\n<p>sensation and/or weakness of the muscles supplied by those</p>\n<p>nerves</p>\n<p>- The presence of acid-fast bacilli in a slit skin smear</p>\n<p>Classification of leprosy</p>\n<p>Paucibacillary (PB) leprosy - 1-5 patches</p>\n<p>Multibacillary (MB) Leprosy - More than 5 patches</p>\n<p>102</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 169,
        "content": "Differential diagnosis\n \n~\nHypopigmentation e.g. birthmark, early vitiligo\n \n~\nFungal infections of the skin\n \n~\nMolluscum contagiosum\n \n~\nOther nodular conditions, e.g. Kaposi\u2019s sarcoma, neurofibro\u00ad\nmatosis, secondary syphilis\n \n~\nOther causes of peripheral nerve damage, e.g. diabetes \nmellitus\n \n~\nPsoriasis, molluscum contagiosum\nInvestigations\n\u00be\t\nIn most cases, a definite diagnosis of leprosy can be \nmade using clinical signs alone\n\u00be\t\nAt referral centre: stain slit skin smears for Acid \nFast Bacilli (AFB)\n\u00be\t\nSkin biopsies NOT recommended as a routine procedure\nManagement\nMulti-drug therapy (MDT) for leprosy is presented in the form of various \nmonthly dose blister packs. The same three drugs are used  for both PB \nleprosy and MB leprosy, with special packs for children \nSummary of Treatment of leprosy\nPB Leprosy\nMB Leprosy\nRifampicin \nRifampicin \nDapsone \nDapsone \nClofazimine \nClofazimine \nAll for 6 months\nAll for 12 months\n103\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Hypopigmentation e.g. birthmark, early vitiligo</p>\n<p>~</p>\n<p>Fungal infections of the skin</p>\n<p>~</p>\n<p>Molluscum contagiosum</p>\n<p>~</p>\n<p>Other nodular conditions, e.g. Kaposi\u2019s sarcoma, neurofibro\u00ad</p>\n<p>matosis, secondary syphilis</p>\n<p>~</p>\n<p>Other causes of peripheral nerve damage, e.g. diabetes</p>\n<p>mellitus</p>\n<p>~</p>\n<p>Psoriasis, molluscum contagiosum</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>In most cases, a definite diagnosis of leprosy can be</p>\n<p>made using clinical signs alone</p>\n<p>\u00be</p>\n<p>At referral centre: stain slit skin smears for Acid</p>\n<p>Fast Bacilli (AFB)</p>\n<p>\u00be</p>\n<p>Skin biopsies NOT recommended as a routine procedure</p>\n<p>Management</p>\n<p>Multi-drug therapy (MDT) for leprosy is presented in the form of various</p>\n<p>monthly dose blister packs. The same three drugs are used  for both PB</p>\n<p>leprosy and MB leprosy, with special packs for children</p>\n<p>Summary of Treatment of leprosy</p>\n<p>PB Leprosy</p>\n<p>MB Leprosy</p>\n<p>Rifampicin</p>\n<p>Rifampicin</p>\n<p>Dapsone</p>\n<p>Dapsone</p>\n<p>Clofazimine</p>\n<p>Clofazimine</p>\n<p>All for 6 months</p>\n<p>All for 12 months</p>\n<p>103</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 170,
        "content": "Recommended treatment (drugs and their doses)\nDrug\nDosage and frequency Duration\u00a0\nPB\nMB\nAdult\u00a0\nRifampicin\n600 mg once a month 6 \nmonths\n12 \nmonths\nClofazimine\n300 mg once a month \nand 50 mg daily\nDapsone\n100 mg daily\nChildren\n( 1 0 \u2013 1 4 \nyears)\nRifampicin\n450 mg once a month 6 \nmonths\n12 \nmonths\u00a0\nClofazimine\n150 mg once a month, \n50 mg daily\nDapsone\n50 mg daily\nChildren \n<10\nyears old \nor\n<40 kg\nRifampicin\n10 mg/kg once \nmonth\n6 \nmonths\n12 \nmonths\nClofazimine\n6 mg/kg once a \nmonth and 1 mg/kg \ndaily\nDapsone\n2 mg/kg daily\nSteroids for treatment of severe leprae reactions\n\t\n\u0089\nPrednisolone 40 mg once daily in morning\n \n- Treat for 12 weeks in PB and 24 weeks in MB\n \n- Reduce dose gradually by 10\u20135 mg once every 2 \nweeks (PB) or 3 weeks (MB)\nRR\nNote\n \n\u0083 In patients co-infected with HIV and  on cotrimoxazole , do \nnot use dapsone. \n \n\u0083 Health worker should directly observe that the medicines \ntaken once a month are actually swallowed\n \n\u0083 Treatment durations longer than 12 months and steroids for \nleprae reactions should only be prescribed by specialists at \nreferral centres\n \n\u0083 Lepra reactions: sudden inflammation (pain, redness, swelling, \nnew lesions, loss of nerve function) in skin lesions or nerves of \na person with leprosy. They can occur before, during or after \nMDT completion.\n104\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Recommended treatment (drugs and their doses)</p>\n<p>Drug</p>\n<p>Dosage and frequency Duration</p>\n<p>PB</p>\n<p>MB</p>\n<p>Adult</p>\n<p>Rifampicin</p>\n<p>600 mg once a month 6</p>\n<p>months</p>\n<p>12</p>\n<p>months</p>\n<p>Clofazimine</p>\n<p>300 mg once a month</p>\n<p>and 50 mg daily</p>\n<p>Dapsone</p>\n<p>100 mg daily</p>\n<p>Children</p>\n<p>( 1 0 \u2013 1 4</p>\n<p>years)</p>\n<p>Rifampicin</p>\n<p>450 mg once a month 6</p>\n<p>months</p>\n<p>12</p>\n<p>months</p>\n<p>Clofazimine</p>\n<p>150 mg once a month,</p>\n<p>50 mg daily</p>\n<p>Dapsone</p>\n<p>50 mg daily</p>\n<p>Children</p>\n<p><10</p>\n<p>years old</p>\n<p>or</p>\n<p><40 kg</p>\n<p>Rifampicin</p>\n<p>10 mg/kg once</p>\n<p>month</p>\n<p>6</p>\n<p>months</p>\n<p>12</p>\n<p>months</p>\n<p>Clofazimine</p>\n<p>6 mg/kg once a</p>\n<p>month and 1 mg/kg</p>\n<p>daily</p>\n<p>Dapsone</p>\n<p>2 mg/kg daily</p>\n<p>Steroids for treatment of severe leprae reactions</p>\n<p>\u0089</p>\n<p>Prednisolone 40 mg once daily in morning</p>\n<p>- Treat for 12 weeks in PB and 24 weeks in MB</p>\n<p>- Reduce dose gradually by 10\u20135 mg once every 2</p>\n<p>weeks (PB) or 3 weeks (MB)</p>\n<p>RR</p>\n<p>Note</p>\n<p>\u0083 In patients co-infected with HIV and  on cotrimoxazole , do</p>\n<p>not use dapsone.</p>\n<p>\u0083 Health worker should directly observe that the medicines</p>\n<p>taken once a month are actually swallowed</p>\n<p>\u0083 Treatment durations longer than 12 months and steroids for</p>\n<p>leprae reactions should only be prescribed by specialists at</p>\n<p>referral centres</p>\n<p>\u0083 Lepra reactions: sudden inflammation (pain, redness, swelling,</p>\n<p>new lesions, loss of nerve function) in skin lesions or nerves of</p>\n<p>a person with leprosy. They can occur before, during or after</p>\n<p>MDT completion.</p>\n<p>104</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 171,
        "content": "\u0083 Severe leprae reaction (Type 2) are also known as Erythema \nNodosum Leprosum (ENL or Type 2 reactions)\n \n\u0083 All patients should undergo rehabilitation and physiotherapy \nCounsel patient on: need to complete treatment, presence of \nresidual signs after completion of treatment\n \n\u0083 Presence of residual signs or post-treatment reactions is NOT \nan indication to re-start the treatment\n \n\u0083 Refer to the National Tuberculosis and Leprosy Programme \n(NTLP) manual 2016 for more details\nPrevention\n \n~\nEarly diagnosis of cases and effective treatment\n \n~\nScreening of contacts of known patients\n \n~\nAdministration of Single dose rifampicine in contacts of \nleprosy patients to prevent contacts of  leprosy patients \nfrom developing leprosy disease\n \n~\nRifampicine dose used in contacts of leprosy patiients\nAge/weight\nRifampicin  single dose\n15 years and above\n600mg\n10-14years\n450mg\nChildren 6-9years (weight \u226520kg)\n300mg\nChildren 20kg (\u22652years)\n10-15mg/kg\n \n~\nBCG vaccination may be help\nDisability due to Leprosy\nLeprosy commonly causes physical disabilities which generate social \nstigma.  Disability refers to an impairment (primary or secondary) that \nmakes it difficult or impossible for the affected person to carry out certain \nactivities, e.g. affecting manual dexterity, personal care, mobility and \ncommunication behavior\nDefinitions of disability:\nIn the hands and feet:\nGrade 0 = No anesthesia, no visible deformity or damage\nGrade 1 = Anaesthesia, but no visible deformity or damage\n105\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>\u0083 Severe leprae reaction (Type 2) are also known as Erythema</p>\n<p>Nodosum Leprosum (ENL or Type 2 reactions)</p>\n<p>\u0083 All patients should undergo rehabilitation and physiotherapy</p>\n<p>Counsel patient on: need to complete treatment, presence of</p>\n<p>residual signs after completion of treatment</p>\n<p>\u0083 Presence of residual signs or post-treatment reactions is NOT</p>\n<p>an indication to re-start the treatment</p>\n<p>\u0083 Refer to the National Tuberculosis and Leprosy Programme</p>\n<p>(NTLP) manual 2016 for more details</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Early diagnosis of cases and effective treatment</p>\n<p>~</p>\n<p>Screening of contacts of known patients</p>\n<p>~</p>\n<p>Administration of Single dose rifampicine in contacts of</p>\n<p>leprosy patients to prevent contacts of  leprosy patients</p>\n<p>from developing leprosy disease</p>\n<p>~</p>\n<p>Rifampicine dose used in contacts of leprosy patiients</p>\n<p>Age/weight</p>\n<p>Rifampicin  single dose</p>\n<p>15 years and above</p>\n<p>600mg</p>\n<p>10-14years</p>\n<p>450mg</p>\n<p>Children 6-9years (weight \u226520kg)</p>\n<p>300mg</p>\n<p>Children 20kg (\u22652years)</p>\n<p>10-15mg/kg</p>\n<p>~</p>\n<p>BCG vaccination may be help</p>\n<p>Disability due to Leprosy</p>\n<p>Leprosy commonly causes physical disabilities which generate social</p>\n<p>stigma.  Disability refers to an impairment (primary or secondary) that</p>\n<p>makes it difficult or impossible for the affected person to carry out certain</p>\n<p>activities, e.g. affecting manual dexterity, personal care, mobility and</p>\n<p>communication behavior</p>\n<p>Definitions of disability:</p>\n<p>In the hands and feet:</p>\n<p>Grade 0 = No anesthesia, no visible deformity or damage</p>\n<p>Grade 1 = Anaesthesia, but no visible deformity or damage</p>\n<p>105</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 172,
        "content": "Grade 2 = Visible deformity or damage present\nIn the eyes\nGrade 0 = no eye problem due to leprosy, no evidence of visual loss \nGrade 1 = eye problem due to presence of leprosy, but vision not severy \naffected as a result (6/60 or better, can count fingers at six meters)\nGrade 2 = severe visual impairment (vision worse than 6/60; inability to \ncount fingers at six meters), lagophthalmos, iridocyclitis, corneal opacities\nManagement of Disability in the hand and feet\nResting of the affected limb in the acute phase can be aided by splinting, \nespecially at night\n \n~\nSoaking and oiling for about 30 minutes every day of dry \nskin helps to prevent cracking and preserves the integrity \nof the epidermis.\n \n~\nUse of a clean dry cloth to cover the wounds and walking \nas little as possible and walk slowly, taking frequent rest. \nPassive exercise and stretching to avoid contractures and \nstrengthen muscle weakness\n \n~\nUse of a rough stone to smoothen the skin on the feet or \npalms,\n \n~\nProtective foot wear (MCR Sandals) al, the time. For insen\u00ad\nsitive feet and protective appliances like gloves for insensi\u00ad\ntive hands\nEye complications due to Leprosy\nThese include\n1. Lagophthalmos: whole spectrum\n2.Corneal hypoesthesia: with/without corneal ulcers\n3. Acute iritis and scleriti \n4.Chronic iritis and iris atrophy\n106\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Grade 2 = Visible deformity or damage present</p>\n<p>In the eyes</p>\n<p>Grade 0 = no eye problem due to leprosy, no evidence of visual loss</p>\n<p>Grade 1 = eye problem due to presence of leprosy, but vision not severy</p>\n<p>affected as a result (6/60 or better, can count fingers at six meters)</p>\n<p>Grade 2 = severe visual impairment (vision worse than 6/60; inability to</p>\n<p>count fingers at six meters), lagophthalmos, iridocyclitis, corneal opacities</p>\n<p>Management of Disability in the hand and feet</p>\n<p>Resting of the affected limb in the acute phase can be aided by splinting,</p>\n<p>especially at night</p>\n<p>~</p>\n<p>Soaking and oiling for about 30 minutes every day of dry</p>\n<p>skin helps to prevent cracking and preserves the integrity</p>\n<p>of the epidermis.</p>\n<p>~</p>\n<p>Use of a clean dry cloth to cover the wounds and walking</p>\n<p>as little as possible and walk slowly, taking frequent rest.</p>\n<p>Passive exercise and stretching to avoid contractures and</p>\n<p>strengthen muscle weakness</p>\n<p>~</p>\n<p>Use of a rough stone to smoothen the skin on the feet or</p>\n<p>palms,</p>\n<p>~</p>\n<p>Protective foot wear (MCR Sandals) al, the time. For insen\u00ad</p>\n<p>sitive feet and protective appliances like gloves for insensi\u00ad</p>\n<p>tive hands</p>\n<p>Eye complications due to Leprosy</p>\n<p>These include</p>\n<li>. Lagophthalmos: whole spectrum</li>\n<p>2.Corneal hypoesthesia: with/without corneal ulcers</p>\n<p>3. Acute iritis and scleriti</p>\n<p>4.Chronic iritis and iris atrophy</p>\n<p>106</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 173,
        "content": "Treatment & Management of eye complications\nMedical therapy for eye complications due to Leprosy- use of the topi\u00ad\ncal antibiotics and topical steroids. It is strongly recommended that an \nophthalmologist and a trained leprologist, if available, be included in the \ntreatment of Hansen disease with ocular manifestations.\n2.1.5 Meningitis\nICD10 CODES: A39.0 (MENINGOCOCCAL), G00, G01, G02\nMeningitis is acute inflammation of the meninges (the membranes cov\u00ad\nering the brain). Bacterial meningitis is a notifiable disease.\nCausative organisms\nMost commonly bacterial: Streptococcus pneumoniae, Haemophilus \ninfluenzae type b (mainly in young children), Neisseria meningitidis, \nEnteric bacilli\n \n~\nViral (HSV, enteroviruses, HIV, VZV etc)\n \n~\nCryptococcus neoformans (in the immune-suppressed)\n \n~\nMycobacterium tuberculosis\nClinical features\n \n~\nRapid onset of fever\n \n~\nSevere headache and neck stiffness or pain\n \n~\nPhotophobiaHaemorrhagic rash (N.meningitidis infection)\n \n~\nConvulsions, altered mental state, confusion, coma\n \n~\nIn mycobacterial and cryptococcal meningitis, the clinical \npresentation can be sub-acute , over a period of several \ndays or 1-2 weeks\n107\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Treatment & Management of eye complications</p>\n<p>Medical therapy for eye complications due to Leprosy- use of the topi\u00ad</p>\n<p>cal antibiotics and topical steroids. It is strongly recommended that an</p>\n<p>ophthalmologist and a trained leprologist, if available, be included in the</p>\n<p>treatment of Hansen disease with ocular manifestations.</p>\n<p>2.1.5 Meningitis</p>\n<h3>ICD10 CODES: A39.0 (MENINGOCOCCAL), G00, G01, G02</h3>\n<p>Meningitis is acute inflammation of the meninges (the membranes cov\u00ad</p>\n<p>ering the brain). Bacterial meningitis is a notifiable disease.</p>\n<p>Causative organisms</p>\n<p>Most commonly bacterial: Streptococcus pneumoniae, Haemophilus</p>\n<p>influenzae type b (mainly in young children), Neisseria meningitidis,</p>\n<p>Enteric bacilli</p>\n<p>~</p>\n<p>Viral (HSV, enteroviruses, HIV, VZV etc)</p>\n<p>~</p>\n<p>Cryptococcus neoformans (in the immune-suppressed)</p>\n<p>~</p>\n<p>Mycobacterium tuberculosis</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Rapid onset of fever</p>\n<p>~</p>\n<p>Severe headache and neck stiffness or pain</p>\n<p>~</p>\n<p>PhotophobiaHaemorrhagic rash (N.meningitidis infection)</p>\n<p>~</p>\n<p>Convulsions, altered mental state, confusion, coma</p>\n<p>~</p>\n<p>In mycobacterial and cryptococcal meningitis, the clinical</p>\n<p>presentation can be sub-acute , over a period of several</p>\n<p>days or 1-2 weeks</p>\n<p>107</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 174,
        "content": "Differential diagnosis\n \n~\nBrain abscess\n \n~\nSpace-occupying lesions in the brain\n \n~\nDrug reactions or intoxications\nInvestigations\n \n\u0081\nCSF: usually cloudy if bacterial, clear if viral. Analyse for white \ncell count and type, protein, sugar, Indian-ink staining (for Cryp\u00ad\ntococcus), gram stain, culture and sensitivity\n \n\u0081\nBlood: For serological studies and full blood count\n \n\u0081\nBlood: for culture and sensitivity\n \n\u0081\nChest X-ray and ultrasound to look for possible primary site\nManagement\nBecause of the potential severity of the disease, refer all patients to hospital \nafter pre-referral dose of antibiotic. Carry out lumbar puncture promptly \nand initiate empirical antibiotic regimen\nTreatment depends on whether the causative organisms are already iden\u00ad\ntified or not.\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nIV fluids\n\t\n\u0089\nControl of temperature\n\t\n\u0089\nNutrition support (NGT if necessary)\nCausative organisms not yet identified\n\t\n\u0089\nStart initial appropriate empirical broad spectrum therapy\n \n- Ceftriaxone 2 g IV or IM every 12 hours for 10-\n14 days\nHC4\n108\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Brain abscess</p>\n<p>~</p>\n<p>Space-occupying lesions in the brain</p>\n<p>~</p>\n<p>Drug reactions or intoxications</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>CSF: usually cloudy if bacterial, clear if viral. Analyse for white</p>\n<p>cell count and type, protein, sugar, Indian-ink staining (for Cryp\u00ad</p>\n<p>tococcus), gram stain, culture and sensitivity</p>\n<p>\u0081</p>\n<p>Blood: For serological studies and full blood count</p>\n<p>\u0081</p>\n<p>Blood: for culture and sensitivity</p>\n<p>\u0081</p>\n<p>Chest X-ray and ultrasound to look for possible primary site</p>\n<p>Management</p>\n<p>Because of the potential severity of the disease, refer all patients to hospital</p>\n<p>after pre-referral dose of antibiotic. Carry out lumbar puncture promptly</p>\n<p>and initiate empirical antibiotic regimen</p>\n<p>Treatment depends on whether the causative organisms are already iden\u00ad</p>\n<p>tified or not.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>IV fluids</p>\n<p>\u0089</p>\n<p>Control of temperature</p>\n<p>\u0089</p>\n<p>Nutrition support (NGT if necessary)</p>\n<p>Causative organisms not yet identified</p>\n<p>\u0089</p>\n<p>Start initial appropriate empirical broad spectrum therapy</p>\n<p>- Ceftriaxone 2 g IV or IM every 12 hours for 10-</p>\n<p>14 days</p>\n<h3>HC4</h3>\n<p>108</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 175,
        "content": "TREATMENT\nLOC\n \n- Child: 100 mg/kg daily dose given as above\n \n- Change to cheaper effective antibiotic if and \nwhen C&S results become available\nIf ceftriaxone not available/not improving\n\t\n\u0089\nUse chloramphenicol 1 g IV every 6 hours for up to 14 \ndays (use IM if IV not possible)\nChild: 25 mg/kg per dose\nOnce clinical improvement occurs\n \n- Change to 500-750 mg orally every 6 hours to \ncomplete the course;\nChild: 25 mg/kg per dose\nCausative organisms identified\nStreptococcus pneumoniae (10-14 day course; up to \n21 days in severe case)\n\t\n\u0089\nBenzylpenicillin 3-4 MU IV or IM every 4 hours\nChild: 100,000 IU/kg per dose\n\t\n\u0089\nOr ceftriaxone 2 g IV or IM every 12 hours\nChild: 100 mg/kg daily dose\nH\nHaemophilus influenzae (10 day course)\n\t\n\u0089\nCeftriaxone 2 g IV or IM every 12 hours\nChild: 100 mg/kg per dose\n\t\n\u0089\nOnly if the isolate is reported to be susceptible to the \nparticular drug\n\t\n\u0089\nChange to chloramphenicol 1 g IV every 6 hours\nChild: 25 mg/kg per dose\n\t\n\u0089\nOr ampicillin 2-3 g IV every 4-6 hours\nChild: 50 mg/kg per dose\nH\n109\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Child: 100 mg/kg daily dose given as above</p>\n<p>- Change to cheaper effective antibiotic if and</p>\n<p>when C&S results become available</p>\n<p>If ceftriaxone not available/not improving</p>\n<p>\u0089</p>\n<p>Use chloramphenicol 1 g IV every 6 hours for up to 14</p>\n<p>days (use IM if IV not possible)</p>\n<p>Child: 25 mg/kg per dose</p>\n<p>Once clinical improvement occurs</p>\n<p>- Change to 500-750 mg orally every 6 hours to</p>\n<p>complete the course;</p>\n<p>Child: 25 mg/kg per dose</p>\n<p>Causative organisms identified</p>\n<p>Streptococcus pneumoniae (10-14 day course; up to</p>\n<p>21 days in severe case)</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 3-4 MU IV or IM every 4 hours</p>\n<p>Child: 100,000 IU/kg per dose</p>\n<p>\u0089</p>\n<p>Or ceftriaxone 2 g IV or IM every 12 hours</p>\n<p>Child: 100 mg/kg daily dose</p>\n<p>H</p>\n<p>Haemophilus influenzae (10 day course)</p>\n<p>\u0089</p>\n<p>Ceftriaxone 2 g IV or IM every 12 hours</p>\n<p>Child: 100 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Only if the isolate is reported to be susceptible to the</p>\n<p>particular drug</p>\n<p>\u0089</p>\n<p>Change to chloramphenicol 1 g IV every 6 hours</p>\n<p>Child: 25 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or ampicillin 2-3 g IV every 4-6 hours</p>\n<p>Child: 50 mg/kg per dose</p>\n<p>H</p>\n<p>109</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 176,
        "content": "TREATMENT\nLOC\nNeisseria meningitidis (up to 14 day course)\n\t\n\u0089\nBenzylpenicillin IV 5-6 MU every 6 hours\nChild: 100,000-150,000 IU/kg every 6 hours\n\t\n\u0089\nOr Ceftriaxone 2 g IV or IM every 12 hours\nChild: 100 mg/kg daily dose\n\t\n\u0089\nOr Chloramphenicol 1 g IV every 6 hours (IM if IV not \npossible)\nChild: 25 mg/kg IV per dose\nOnce clinical improvement occurs\n \n- Change to chloramphenical 500-750 mg orally \nevery 6 hours to complete the course\nChild: 25 mg/kg per dose\nNote: Consider prophylaxis of close contacts (especially \nchildren < 5 years):\n\t\n\u0089\nAdults and children >12 years: Ciprofloxacin 500 mg \nsingle dose\nChild <12 yrs: 10 mg/kg single dose\n\t\n\u0089\nAlternative (e.g. in pregnancy): ceftriaxone 250 mg IM \nsingle dose\nChild < 12 yrs: 150 mg IM single dose\nH\nListeria monocytogenes (at least 3 weeks course)\n\t\n\u0089\nCommon cause of meningitis in neonates and immu\u00ad\nnosuppressed adults\n Benzylpenicillin 3 MU IV or IM every 4 hours\n\t\n\u0089\nOr ampicillin 3 g IV every 6 hours\nNotes\n \n\u0083 Both medicines are equally effective\n \n\u0083 Therapy may need to be prolonged for up to 6 weeks \nin some patients\nH\n110\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Neisseria meningitidis (up to 14 day course)</p>\n<p>\u0089</p>\n<p>Benzylpenicillin IV 5-6 MU every 6 hours</p>\n<p>Child: 100,000-150,000 IU/kg every 6 hours</p>\n<p>\u0089</p>\n<p>Or Ceftriaxone 2 g IV or IM every 12 hours</p>\n<p>Child: 100 mg/kg daily dose</p>\n<p>\u0089</p>\n<p>Or Chloramphenicol 1 g IV every 6 hours (IM if IV not</p>\n<p>possible)</p>\n<p>Child: 25 mg/kg IV per dose</p>\n<p>Once clinical improvement occurs</p>\n<p>- Change to chloramphenical 500-750 mg orally</p>\n<p>every 6 hours to complete the course</p>\n<p>Child: 25 mg/kg per dose</p>\n<p>Note: Consider prophylaxis of close contacts (especially</p>\n<p>children < 5 years):</p>\n<p>\u0089</p>\n<p>Adults and children >12 years: Ciprofloxacin 500 mg</p>\n<p>single dose</p>\n<p>Child <12 yrs: 10 mg/kg single dose</p>\n<p>\u0089</p>\n<p>Alternative (e.g. in pregnancy): ceftriaxone 250 mg IM</p>\n<p>single dose</p>\n<p>Child < 12 yrs: 150 mg IM single dose</p>\n<p>H</p>\n<p>Listeria monocytogenes (at least 3 weeks course)</p>\n<p>\u0089</p>\n<p>Common cause of meningitis in neonates and immu\u00ad</p>\n<p>nosuppressed adults</p>\n<p>Benzylpenicillin 3 MU IV or IM every 4 hours</p>\n<p>\u0089</p>\n<p>Or ampicillin 3 g IV every 6 hours</p>\n<p>Notes</p>\n<p>\u0083 Both medicines are equally effective</p>\n<p>\u0083 Therapy may need to be prolonged for up to 6 weeks</p>\n<p>in some patients</p>\n<p>H</p>\n<p>110</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 177,
        "content": "Prevention\n \n~\nAvoid overcrowding\n \n~\nImprove sanitation and nutrition\n \n~\nPrompt treatment of primary infection (e.g. in respiratory \ntract)\n \n~\nImmunisation as per national schedules\n \n~\nMass immunisation if N. Meningitis epidemic\n2.1.5.1 Neonatal Meningitis\nBacterial infection of the meninges in the first month of life.\n \n~\nOrganisms causing neonatal meningitis are similar to those \ncausing neonatal septicaemia and pneumonia, i.e. S.pneu\u00ad\nmoniae, group A & B streptococci, and enteric Gram-neg\u00ad\native bacilli.\nMeningitis due to group B streptococci: These organisms often col\u00ad\nonise the vagina and rectum of pregnant women, can be transmitted to \nbabies during labour, and cause infection. Meningitis and septicaemia \nduring the 1st week after birth may be particularly severe.\n \n~\nClinical presentation is aspecific with temperature distur\u00ad\nbances, lethargy, irritability, vomiting, feeding problems, \nconvulsions, apnoea, bulging fontanel\nManagement\nTREATMENT\nLOC\nRefer to hospital after initial dose of antibiotics Supportive \ncare\n\t\n\u0089\nKeep baby warm\n\t\n\u0089\nFor high temperature control environment (undress), avoid \nparacetamol\nH\n111\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Avoid overcrowding</p>\n<p>~</p>\n<p>Improve sanitation and nutrition</p>\n<p>~</p>\n<p>Prompt treatment of primary infection (e.g. in respiratory</p>\n<p>tract)</p>\n<p>~</p>\n<p>Immunisation as per national schedules</p>\n<p>~</p>\n<p>Mass immunisation if N. Meningitis epidemic</p>\n<p>2.1.5.1 Neonatal Meningitis</p>\n<p>Bacterial infection of the meninges in the first month of life.</p>\n<p>~</p>\n<p>Organisms causing neonatal meningitis are similar to those</p>\n<p>causing neonatal septicaemia and pneumonia, i.e. S.pneu\u00ad</p>\n<p>moniae, group A & B streptococci, and enteric Gram-neg\u00ad</p>\n<p>ative bacilli.</p>\n<p>Meningitis due to group B streptococci: These organisms often col\u00ad</p>\n<p>onise the vagina and rectum of pregnant women, can be transmitted to</p>\n<p>babies during labour, and cause infection. Meningitis and septicaemia</p>\n<p>during the 1st week after birth may be particularly severe.</p>\n<p>~</p>\n<p>Clinical presentation is aspecific with temperature distur\u00ad</p>\n<p>bances, lethargy, irritability, vomiting, feeding problems,</p>\n<p>convulsions, apnoea, bulging fontanel</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Refer to hospital after initial dose of antibiotics Supportive</p>\n<p>care</p>\n<p>\u0089</p>\n<p>Keep baby warm</p>\n<p>\u0089</p>\n<p>For high temperature control environment (undress), avoid</p>\n<p>paracetamol</p>\n<p>H</p>\n<p>111</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 178,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nPrevent hypoglycaemia (breastfeeding if tolerated/possible, \nNGT or IV glucose)\n\t\n\u0089\nEnsure hydration/nutrition\n\t\n\u0089\nGive oxygen if needed (SpO2 <92%)\nEmpirical regimen (for 21 days)\n\t\n\u0089\nAmpicillin IV\nNeonate < 7 days: 50-100 mg/kg every 12 hours\nNeonate > 7 days: 50-100 mg/kg every 8 hours\n\t\n\u0089\nPlus Gentamicin 2.5 mg/kg IV every 12 hours Need for \nblood culture\nIf group B streptococci\n\t\n\u0089\nBenzylpenicillin 100,000-150,000 IU/kg IV every 4-6 hours\n\t\n\u0089\nNeonates <7 days: 50,000-100,000 IU/kg IV every 8 hours\n\t\n\u0089\nPlus gentamicin 2.5 mg/kg IV every 12 hours\n\t\n\u0089\nContinue treatment for a total of 3 weeks\nH\n2.1.5.2 Cryptococcal Meningitis\t                     ICD10 CODE: B45.1 \nFungal meningitis caused by Crypotococcus neoformans and usually \noccurs in severely immunosuppressed patients (e.g. advanced HIV, \nusually CD4 < 100).\n \n~\nIt commonly presents with headache, fever, malaise devel\u00ad\noping over 1 or 2 weeks, progressing into confusion, pho\u00ad\ntophobia, stiff neck\n \n\u0081\nDiagnosis is through identification of the microorganism in the \nCSF with Indian Ink stain, antigen in CSF or culture\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer to hospital\nH\n112\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Prevent hypoglycaemia (breastfeeding if tolerated/possible,</p>\n<p>NGT or IV glucose)</p>\n<p>\u0089</p>\n<p>Ensure hydration/nutrition</p>\n<p>\u0089</p>\n<p>Give oxygen if needed (SpO2 <92%)</p>\n<p>Empirical regimen (for 21 days)</p>\n<p>\u0089</p>\n<p>Ampicillin IV</p>\n<p>Neonate < 7 days: 50-100 mg/kg every 12 hours</p>\n<p>Neonate > 7 days: 50-100 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Plus Gentamicin 2.5 mg/kg IV every 12 hours Need for</p>\n<p>blood culture</p>\n<p>If group B streptococci</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 100,000-150,000 IU/kg IV every 4-6 hours</p>\n<p>\u0089</p>\n<p>Neonates <7 days: 50,000-100,000 IU/kg IV every 8 hours</p>\n<p>\u0089</p>\n<p>Plus gentamicin 2.5 mg/kg IV every 12 hours</p>\n<p>\u0089</p>\n<p>Continue treatment for a total of 3 weeks</p>\n<p>H</p>\n<p>2.1.5.2 Cryptococcal Meningitis\t                     ICD10 CODE: B45.1</p>\n<p>Fungal meningitis caused by Crypotococcus neoformans and usually</p>\n<p>occurs in severely immunosuppressed patients (e.g. advanced HIV,</p>\n<p>usually CD4 < 100).</p>\n<p>~</p>\n<p>It commonly presents with headache, fever, malaise devel\u00ad</p>\n<p>oping over 1 or 2 weeks, progressing into confusion, pho\u00ad</p>\n<p>tophobia, stiff neck</p>\n<p>\u0081</p>\n<p>Diagnosis is through identification of the microorganism in the</p>\n<p>CSF with Indian Ink stain, antigen in CSF or culture</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to hospital</p>\n<p>H</p>\n<p>112</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 179,
        "content": "2.1.5.3 TB Meningitis\t\n                                              ICD10 CODE: A17.0\n Meningitis caused by M. tuberculosis. Onset may be gradual with fatigue, \nfever, vomiting, weight loss,  irritability, headache, progressing to confusion, \nfocal  neurological deficits, meningeal irritation, till coma.\n \n\u0081\nFor diagnosis: check CSF (raised protein, lymphocytosis), look \nfor possible primary TB site\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer to hospital\n\t\n\u0089\nTreat as per pulmonary TB but continuation phase is \n10 months instead of 4 (2RHZE/10RH)\n\t\n\u0089\nSee section 5.3 for more details\nH\n2.1.6 Plague                  ICD10 CODE: A20.9\nSevere acute bacterial infection with high fatality rate transmitted by \ninfected rodent fleas. It is a notifiable disease.\nCause\n \n~\nYersinia pestis (a coccobacillus) transmitted from ground \nrodents to man by bites from infected fleas\n \n~\nIt may also be spread from person to person by droplet \ninfection and may occur in epidemics\nClinical features\nTYPE\nFEATURES\nBubonic (A20.0)\n \n~\nInvolves lymph nodes (usually \nfemoral and inguinal)\n \n~\nRapidly \nrising \ntemperature \nwith rigors\n \n~\nHeadache\n113\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>2.1.5.3 TB Meningitis</p>\n<h3>ICD10 CODE: A17.0</h3>\n<p>Meningitis caused by M. tuberculosis. Onset may be gradual with fatigue,</p>\n<p>fever, vomiting, weight loss,  irritability, headache, progressing to confusion,</p>\n<p>focal  neurological deficits, meningeal irritation, till coma.</p>\n<p>\u0081</p>\n<p>For diagnosis: check CSF (raised protein, lymphocytosis), look</p>\n<p>for possible primary TB site</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to hospital</p>\n<p>\u0089</p>\n<p>Treat as per pulmonary TB but continuation phase is</p>\n<p>10 months instead of 4 (2RHZE/10RH)</p>\n<p>\u0089</p>\n<p>See section 5.3 for more details</p>\n<p>H</p>\n<p>2.1.6 Plague                  ICD10 CODE: A20.9</p>\n<p>Severe acute bacterial infection with high fatality rate transmitted by</p>\n<p>infected rodent fleas. It is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Yersinia pestis (a coccobacillus) transmitted from ground</p>\n<p>rodents to man by bites from infected fleas</p>\n<p>~</p>\n<p>It may also be spread from person to person by droplet</p>\n<p>infection and may occur in epidemics</p>\n<p>Clinical features</p>\n<h3>TYPE</h3>\n<h3>FEATURES</h3>\n<p>Bubonic (A20.0)</p>\n<p>~</p>\n<p>Involves lymph nodes (usually</p>\n<p>femoral and inguinal)</p>\n<p>~</p>\n<p>Rapidly</p>\n<p>rising</p>\n<p>temperature</p>\n<p>with rigors</p>\n<p>~</p>\n<p>Headache</p>\n<p>113</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 180,
        "content": "TYPE\nFEATURES\nPneumonic (A20.2)\n \n~\nVery infectious and highly fa\u00ad\ntal: PATIENT MUST BE ISO\u00ad\nLATED\n \n- Death occurs within 2 days if \nnot treated early\n \n~\nInfection is localised in the \nlungs with fever, general mal\u00ad\naise, headache, and frothy \nblood stained sputum\n \n~\nMay be complicated by respira\u00ad\ntory and cardiac distress\nDifferential diagnosis\n \n~\nMalaria, typhoid\n \n~\nLymphogranuloma venereum\n \n~\nPneumonia\nInvestigations\n \n\u0081\nBubo aspirate: for microscopy, C&S\n \n\u0081\nBlood and sputum: check for presence of the bacilli\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nDoxycycline 100 mg every 12 hours for 14 days\nChild > 8 years: 2 mg/kg per dose\nAlternatives:\n\t\n\u0089\nChloramphenicol 500 mg orally or IV every 6 hours \nfor 10 days\nChild: 25 mg/kg per dose\n\t\n\u0089\nOr gentamicin 1.7 mg/kg (adult and child) IV or IM \nevery 8 hours for 7-10 days\nHC2\nHC4\n114\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TYPE</h3>\n<h3>FEATURES</h3>\n<p>Pneumonic (A20.2)</p>\n<p>~</p>\n<p>Very infectious and highly fa\u00ad</p>\n<p>tal: PATIENT MUST BE ISO\u00ad</p>\n<h3>LATED</h3>\n<p>- Death occurs within 2 days if</p>\n<p>not treated early</p>\n<p>~</p>\n<p>Infection is localised in the</p>\n<p>lungs with fever, general mal\u00ad</p>\n<p>aise, headache, and frothy</p>\n<p>blood stained sputum</p>\n<p>~</p>\n<p>May be complicated by respira\u00ad</p>\n<p>tory and cardiac distress</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Malaria, typhoid</p>\n<p>~</p>\n<p>Lymphogranuloma venereum</p>\n<p>~</p>\n<p>Pneumonia</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Bubo aspirate: for microscopy, C&S</p>\n<p>\u0081</p>\n<p>Blood and sputum: check for presence of the bacilli</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Doxycycline 100 mg every 12 hours for 14 days</p>\n<p>Child > 8 years: 2 mg/kg per dose</p>\n<p>Alternatives:</p>\n<p>\u0089</p>\n<p>Chloramphenicol 500 mg orally or IV every 6 hours</p>\n<p>for 10 days</p>\n<p>Child: 25 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or gentamicin 1.7 mg/kg (adult and child) IV or IM</p>\n<p>every 8 hours for 7-10 days</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>114</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 181,
        "content": "Note\n \n\u0083 For use in pregnancy, consider gentamicin\nPrevention\n \n~\nHealth education\n \n~\nImproved housing\n \n~\nDestruction of rats (rodents) and fleas\n \n~\nEarly detection and treatment to reduce further spread\n2.1.7 Septicaemia\t\nICD10 CODE: A41.9\nBlood infection due to various bacteria which may be associated with \ninfection in specific sites (e.g., lungs, urinary tract, gastrointestinal tract) \nor there may be no specific focus. It is life threatening because it can \nprogress into multi-organ dysfunction and septic shock.\nCause\n \n~\nOrganisms commonly involved are Staphylococcus aureus, \nKlebsiella, Pseudomonas, Staphylococcus epidermidis, fun\u00ad\ngal (Candida spp), Coliforms and Salmonella spp, Pneumo\u00ad\ncocci, Proteus spp\nRisk factors\n \n~\nExtremes of age (children, elderly)\n \n~\nDiabetes, cancer, immunosuppression\n \n~\nHospital admission\n \n~\nCommunity acquired pneumonia\nClinical features\n \n~\nFever, prostration (extreme tiredness)\n \n~\nHypotension, anaemia\n115\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Note</p>\n<p>\u0083 For use in pregnancy, consider gentamicin</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Health education</p>\n<p>~</p>\n<p>Improved housing</p>\n<p>~</p>\n<p>Destruction of rats (rodents) and fleas</p>\n<p>~</p>\n<p>Early detection and treatment to reduce further spread</p>\n<p>2.1.7 Septicaemia</p>\n<h3>ICD10 CODE: A41.9</h3>\n<p>Blood infection due to various bacteria which may be associated with</p>\n<p>infection in specific sites (e.g., lungs, urinary tract, gastrointestinal tract)</p>\n<p>or there may be no specific focus. It is life threatening because it can</p>\n<p>progress into multi-organ dysfunction and septic shock.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Organisms commonly involved are Staphylococcus aureus,</p>\n<p>Klebsiella, Pseudomonas, Staphylococcus epidermidis, fun\u00ad</p>\n<p>gal (Candida spp), Coliforms and Salmonella spp, Pneumo\u00ad</p>\n<p>cocci, Proteus spp</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Extremes of age (children, elderly)</p>\n<p>~</p>\n<p>Diabetes, cancer, immunosuppression</p>\n<p>~</p>\n<p>Hospital admission</p>\n<p>~</p>\n<p>Community acquired pneumonia</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Fever, prostration (extreme tiredness)</p>\n<p>~</p>\n<p>Hypotension, anaemia</p>\n<p>115</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 182,
        "content": "~\nToxic shock is a complication\n \n~\nSigns and symptoms of the primary site of infection (e.g. \n,pneumonia)\nDifferential diagnosis\n \n~\nSevere cerebral malaria\n \n~\nMeningitis\n \n~\nTyphoid fever (enteric fever)\n \n~\nInfective endocarditis\nInvestigations\n\u00be\t\nLook for possible primary source of infection \n \n~\n (If identified use SOP for respective sample collection coey \nto the  lab)\n\u00be\t\nBlood: WBC count, culture and sensitivity \n \n~\n(Use the aseptic technique and collect sample(s) for culture \nand sensitivity, to RRH (if service present) before initiation \nof treatment)\nManagement\nSepticaemia is a life-threating condition,  refer to hospital after pre-referral \ndose of antibiotics.\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nIV fluids\n\t\n\u0089\nControl of temperature\n\t\n\u0089\nNutrition support (NGT if necessary)\n\t\n\u0089\nMonitoring of vitals and urinary output\nIf known focus of infection, treat immediately with IV \nantibiotics as per guidelines. If unknown focus, give:\nH\n116\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Toxic shock is a complication</p>\n<p>~</p>\n<p>Signs and symptoms of the primary site of infection (e.g.</p>\n<p>,pneumonia)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Severe cerebral malaria</p>\n<p>~</p>\n<p>Meningitis</p>\n<p>~</p>\n<p>Typhoid fever (enteric fever)</p>\n<p>~</p>\n<p>Infective endocarditis</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Look for possible primary source of infection</p>\n<p>~</p>\n<p>(If identified use SOP for respective sample collection coey</p>\n<p>to the  lab)</p>\n<p>\u00be</p>\n<p>Blood: WBC count, culture and sensitivity</p>\n<p>~</p>\n<p>(Use the aseptic technique and collect sample(s) for culture</p>\n<p>and sensitivity, to RRH (if service present) before initiation</p>\n<p>of treatment)</p>\n<p>Management</p>\n<p>Septicaemia is a life-threating condition,  refer to hospital after pre-referral</p>\n<p>dose of antibiotics.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>IV fluids</p>\n<p>\u0089</p>\n<p>Control of temperature</p>\n<p>\u0089</p>\n<p>Nutrition support (NGT if necessary)</p>\n<p>\u0089</p>\n<p>Monitoring of vitals and urinary output</p>\n<p>If known focus of infection, treat immediately with IV</p>\n<p>antibiotics as per guidelines. If unknown focus, give:</p>\n<p>H</p>\n<p>116</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 183,
        "content": "TREATMENT\nLOC\nUse aseptic technique to tale blood sample before initi\u00ad\nating treatment\nAdult\n\t\n\u0089\nGentamicin 7 mg/kg IV every 24 hours or 1.5-2 mg/\nkg IV or IM every 8 hours\n\t\n\u0089\nPlus either cloxacillin 2 g IV every 4-6 hours f Or \nchloramphenicol 750 mg IV every 6 hours\nChild\n\t\n\u0089\nGentamicin 3.5-4 mg/kg IV every 8 hours (neonate: \nevery 8-12 hours)\n\t\n\u0089\nPlus either: Ceftriaxone 50 mg/kg every 8 hours (< \n7 days old: every 12 hours)\n\t\n\u0089\nOr cloxacillin 50 mg/kg IV every 4-6 hours\n\t\n\u0089\nOr benzylpenicillin 50,000 IU/kg IV every 4-6 hours\nH\nPrevention\n \n~\nProtect groups at risk, for example immunosuppressed and \npost-surgical patients\n \n~\nFollow strictly aseptic surgical procedures\n2.1.7.1 Neonatal Septicaemia\nOrganisms causing neonatal septicemia are similar to the ones causing \nneonatal pneumonia and meningitis. Refer to hospital after pre-referral \ndose of antibiotics.\nManagement\nTREATMENT\nLOC\nSupportive care\n\t\n\u0089\nKeep baby warm\nH\n117\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Use aseptic technique to tale blood sample before initi\u00ad</p>\n<p>ating treatment</p>\n<p>Adult</p>\n<p>\u0089</p>\n<p>Gentamicin 7 mg/kg IV every 24 hours or 1.5-2 mg/</p>\n<p>kg IV or IM every 8 hours</p>\n<p>\u0089</p>\n<p>Plus either cloxacillin 2 g IV every 4-6 hours f Or</p>\n<p>chloramphenicol 750 mg IV every 6 hours</p>\n<p>Child</p>\n<p>\u0089</p>\n<p>Gentamicin 3.5-4 mg/kg IV every 8 hours (neonate:</p>\n<p>every 8-12 hours)</p>\n<p>\u0089</p>\n<p>Plus either: Ceftriaxone 50 mg/kg every 8 hours (<</p>\n<p>7 days old: every 12 hours)</p>\n<p>\u0089</p>\n<p>Or cloxacillin 50 mg/kg IV every 4-6 hours</p>\n<p>\u0089</p>\n<p>Or benzylpenicillin 50,000 IU/kg IV every 4-6 hours</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Protect groups at risk, for example immunosuppressed and</p>\n<p>post-surgical patients</p>\n<p>~</p>\n<p>Follow strictly aseptic surgical procedures</p>\n<p>2.1.7.1 Neonatal Septicaemia</p>\n<p>Organisms causing neonatal septicemia are similar to the ones causing</p>\n<p>neonatal pneumonia and meningitis. Refer to hospital after pre-referral</p>\n<p>dose of antibiotics.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Supportive care</p>\n<p>\u0089</p>\n<p>Keep baby warm</p>\n<p>H</p>\n<p>117</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 184,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nFor high temperature, control environment i.e. \n(undress), avoid paracetamol\n\t\n\u0089\nPrevent hypoglycaemia (breastfeeding if tolerated/\npossible, NGT or IV glucose)\n\t\n\u0089\nEnsure hydration/nutrition\n\t\n\u0089\nGive oxygen if needed (SpO2 < 90%)\nFirst line treatment\n\t\n\u0089\nGive ampicillin 50 mg/kg IV every 6 hours plus\ngentamicin 5 mg/kg every 24 hours for 10 days\nIf risk of staphylococcus infection (infected umbilicus \nor multiple skin pustules,\n\t\n\u0089\nGive cloxacillin 50 mg/Kg IV/IM every 6 hours and \ngentamicin 5-7 mg/Kg every 24 hours\n \n- Clean infected umbilicus and pustules and \napply gentian violet\nIf no improvement after 48-72 hours change from \nampicillin to:\n\t\n\u0089\nCeftriaxone 100 mg/kg daily\nH\n2.1.7.2  Septic Shock Management, In Adults\n1. At Emergency Unit\n \n\u0083 Early recognition and resuscitation with iv crystalloids Or Blood\n \n\u0083 Empirical Broad spectrum antibiotics Treatment: \n \n\u0083 Early and adequate broad-spectrum antibiotics\n \n\u0083 Intravenous access. Administer 30ml/kg of crystalloids. A large \nbore cannula, in an adult (gauge 16) is preferred.  \n \n\u0083 Urinary catheterization: UOP in an adult is 0.5ml/kg/hr or \nmore, an equivalent of 30-50mls/hr.\n \n\u0083 Transfer for management to ICU if not responding to \nresuscitation\n118\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>For high temperature, control environment i.e.</p>\n<p>(undress), avoid paracetamol</p>\n<p>\u0089</p>\n<p>Prevent hypoglycaemia (breastfeeding if tolerated/</p>\n<p>possible, NGT or IV glucose)</p>\n<p>\u0089</p>\n<p>Ensure hydration/nutrition</p>\n<p>\u0089</p>\n<p>Give oxygen if needed (SpO2 < 90%)</p>\n<p>First line treatment</p>\n<p>\u0089</p>\n<p>Give ampicillin 50 mg/kg IV every 6 hours plus</p>\n<p>gentamicin 5 mg/kg every 24 hours for 10 days</p>\n<p>If risk of staphylococcus infection (infected umbilicus</p>\n<p>or multiple skin pustules,</p>\n<p>\u0089</p>\n<p>Give cloxacillin 50 mg/Kg IV/IM every 6 hours and</p>\n<p>gentamicin 5-7 mg/Kg every 24 hours</p>\n<p>- Clean infected umbilicus and pustules and</p>\n<p>apply gentian violet</p>\n<p>If no improvement after 48-72 hours change from</p>\n<p>ampicillin to:</p>\n<p>\u0089</p>\n<p>Ceftriaxone 100 mg/kg daily</p>\n<p>H</p>\n<p>2.1.7.2  Septic Shock Management, In Adults</p>\n<li>. At Emergency Unit</li>\n<p>\u0083 Early recognition and resuscitation with iv crystalloids Or Blood</p>\n<p>\u0083 Empirical Broad spectrum antibiotics Treatment:</p>\n<p>\u0083 Early and adequate broad-spectrum antibiotics</p>\n<p>\u0083 Intravenous access. Administer 30ml/kg of crystalloids. A large</p>\n<p>bore cannula, in an adult (gauge 16) is preferred.</p>\n<p>\u0083 Urinary catheterization: UOP in an adult is 0.5ml/kg/hr or</p>\n<p>more, an equivalent of 30-50mls/hr.</p>\n<p>\u0083 Transfer for management to ICU if not responding to</p>\n<p>resuscitation</p>\n<p>118</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 185,
        "content": "2. At ICU, Intubation and Mechanical Ventilation. \n \n\u0083 The recommended tidal volume is kept at 6ml/Kg, with plateau \npressure kept at or below 30ml of water.\n \n\u0083 Iv vasopressor Norepinephrine; 5-20\u00b5g/min.\n \n\u0083 Second line is synthetic human angiotensin ii, \n \n\u0083 or vasopressin CVP; \u22648mmHg\n \n\u0083 Ionotropic therapy and Augumented oxygen therapy\n \n\u0083 Dobutamine up to 20\u00b5g/kg/ml\n \n\u0083 Corticosteroids Therapy:\n \n\u0083 Iv hydrocortisne200mg/Kg/day in 4 divided dosages,\n \n\u0083 Maintenance infusion of methyl prednisolone 1mg/kg/day for 7 \ndays, then tapper down for at least another 7 days.\n \n\u0083 Glycemic control Maintain glycemic level below 180mg/dl \nthrough insulin therapy\n \n\u0083 Deep Venous Thrombosis prophylaxis \n \n\u0083 UFH 2 or 3 times a day and LMWH\nDisseminated Intravenous Coagulation Management\n \n\u0083 Platelets and plasma transfusion\n \n\u0083 Anticoagulant\n \n\u0083 Fresh Frozen Plasma (FFP)\n \n\u0083 Antifibrinolytic e.g. tranexamic acid 1g 8hly\n \n2.1.8 Tetanus\t\nICD10 CODE: A35\nBacterial disease characterised by intermittent spasms (twitching) of \nvoluntary muscles. Incubation period is from few days to few weeks \n(average7-10 days).\nCause\n \n~\nExotoxin of Clostridium tetani\n \n~\nCommon sources of infection: tetanus spores enter the \nbody through deep penetrating skin wounds, the umbilical \ncord of the newborn, ear infection, or wounds produced \nduring delivery and septic abortions\n119\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>2. At ICU, Intubation and Mechanical Ventilation.</p>\n<p>\u0083 The recommended tidal volume is kept at 6ml/Kg, with plateau</p>\n<p>pressure kept at or below 30ml of water.</p>\n<p>\u0083 Iv vasopressor Norepinephrine; 5-20\u00b5g/min.</p>\n<p>\u0083 Second line is synthetic human angiotensin ii,</p>\n<p>\u0083 or vasopressin CVP; \u22648mmHg</p>\n<p>\u0083 Ionotropic therapy and Augumented oxygen therapy</p>\n<p>\u0083 Dobutamine up to 20\u00b5g/kg/ml</p>\n<p>\u0083 Corticosteroids Therapy:</p>\n<p>\u0083 Iv hydrocortisne200mg/Kg/day in 4 divided dosages,</p>\n<p>\u0083 Maintenance infusion of methyl prednisolone 1mg/kg/day for 7</p>\n<p>days, then tapper down for at least another 7 days.</p>\n<p>\u0083 Glycemic control Maintain glycemic level below 180mg/dl</p>\n<p>through insulin therapy</p>\n<p>\u0083 Deep Venous Thrombosis prophylaxis</p>\n<p>\u0083 UFH 2 or 3 times a day and LMWH</p>\n<p>Disseminated Intravenous Coagulation Management</p>\n<p>\u0083 Platelets and plasma transfusion</p>\n<p>\u0083 Anticoagulant</p>\n<p>\u0083 Fresh Frozen Plasma (FFP)</p>\n<p>\u0083 Antifibrinolytic e.g. tranexamic acid 1g 8hly</p>\n<p>2.1.8 Tetanus</p>\n<h3>ICD10 CODE: A35</h3>\n<p>Bacterial disease characterised by intermittent spasms (twitching) of</p>\n<p>voluntary muscles. Incubation period is from few days to few weeks</p>\n<p>(average7-10 days).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Exotoxin of Clostridium tetani</p>\n<p>~</p>\n<p>Common sources of infection: tetanus spores enter the</p>\n<p>body through deep penetrating skin wounds, the umbilical</p>\n<p>cord of the newborn, ear infection, or wounds produced</p>\n<p>during delivery and septic abortions</p>\n<p>119</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 186,
        "content": "Clinical features\n \n~\nStiff jaw, difficulty in opening mouth (trismus)\n \n~\nGeneralised spasms induced by sounds and/or strong light, \ncharacterised by grimace (risus sardonicus)\n \n~\nArching of back (opisthotonus) with the patient remaining \nclearly conscious\n \n~\nFever\n \n~\nGlottal spasms and difficulty in breathing\n \n~\nAbsence of a visible wound does not exclude tetanus\nDifferential diagnosis\n \n~\nMeningoencephalitis, meningitis\n \n~\nPhenothiazine side-effects\n \n~\nFebrile convulsions\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nIf at HC2 or 3, refer to hospital\n\t\n\u0089\nNurse patient intensively in a quiet isolated area\n\t\n\u0089\nMaintain close observation and attention to airway, \ntemperature, and spasms\n\t\n\u0089\nInsert nasogastric tube (NGT) for nutrition, hydration, \nand medicine administration\nH\n120\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Stiff jaw, difficulty in opening mouth (trismus)</p>\n<p>~</p>\n<p>Generalised spasms induced by sounds and/or strong light,</p>\n<p>characterised by grimace (risus sardonicus)</p>\n<p>~</p>\n<p>Arching of back (opisthotonus) with the patient remaining</p>\n<p>clearly conscious</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Glottal spasms and difficulty in breathing</p>\n<p>~</p>\n<p>Absence of a visible wound does not exclude tetanus</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Meningoencephalitis, meningitis</p>\n<p>~</p>\n<p>Phenothiazine side-effects</p>\n<p>~</p>\n<p>Febrile convulsions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>If at HC2 or 3, refer to hospital</p>\n<p>\u0089</p>\n<p>Nurse patient intensively in a quiet isolated area</p>\n<p>\u0089</p>\n<p>Maintain close observation and attention to airway,</p>\n<p>temperature, and spasms</p>\n<p>\u0089</p>\n<p>Insert nasogastric tube (NGT) for nutrition, hydration,</p>\n<p>and medicine administration</p>\n<p>H</p>\n<p>120</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 187,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nOxygen therapy if needed\n\t\n\u0089\nPrevent aspiration of fluid into the lungs\n\t\n\u0089\nAvoid IM injections as much as possible; use alternative \nroutes (e.g. NGT, rectal) where possible\n\t\n\u0089\nMaintain adequate nutrition as spasms result in hugh \nmetabolic demands\n\t\n\u0089\nTreat respiratory failure in ICU with ventilation\nNeutralise toxin\n\t\n\u0089\nGive tetanus immunoglobulin human (TIG)\n \n- 150 IU/kg (adults and children). Give the dose \nin at least 2 different sites IM, different from the \ntetanus toxoid site\n\t\n\u0089\nIn addition, administer full course of age- appropriate TT \nvaccine (TT or DPT) \u2013 starting immediately\n\t\n\u0089\nSee section 18.1.4\nH\nTreatment to eliminate source of toxin\n\t\n\u0089\nClean wounds and remove necrotic tissue.\nFirst line antibiotics\n\t\n\u0089\nMetronidazole 500 mg every 8 hours IV or by mouth \nfor 7 days\nChild: 7.5 mg/kg every 8 hours\nSecond line antibiotics\n\t\n\u0089\nBenzylpenicillin 2.5 MU every 6 hours for 10 days\nChild: 50,000-100,000 IU/kg per dose\nH\nControl muscle spasms First line\n\t\n\u0089\nDiazepam 10 mg (IV or rectal) every 1 to 4 hours\nChild: 0.2 mg/kg IV or 0.5 mg/kg rectal (maximum of \n10 mg) every 1 to 4 hours\nH\n121\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Oxygen therapy if needed</p>\n<p>\u0089</p>\n<p>Prevent aspiration of fluid into the lungs</p>\n<p>\u0089</p>\n<p>Avoid IM injections as much as possible; use alternative</p>\n<p>routes (e.g. NGT, rectal) where possible</p>\n<p>\u0089</p>\n<p>Maintain adequate nutrition as spasms result in hugh</p>\n<p>metabolic demands</p>\n<p>\u0089</p>\n<p>Treat respiratory failure in ICU with ventilation</p>\n<p>Neutralise toxin</p>\n<p>\u0089</p>\n<p>Give tetanus immunoglobulin human (TIG)</p>\n<p>- 150 IU/kg (adults and children). Give the dose</p>\n<p>in at least 2 different sites IM, different from the</p>\n<p>tetanus toxoid site</p>\n<p>\u0089</p>\n<p>In addition, administer full course of age- appropriate TT</p>\n<p>vaccine (TT or DPT) \u2013 starting immediately</p>\n<p>\u0089</p>\n<p>See section 18.1.4</p>\n<p>H</p>\n<p>Treatment to eliminate source of toxin</p>\n<p>\u0089</p>\n<p>Clean wounds and remove necrotic tissue.</p>\n<p>First line antibiotics</p>\n<p>\u0089</p>\n<p>Metronidazole 500 mg every 8 hours IV or by mouth</p>\n<p>for 7 days</p>\n<p>Child: 7.5 mg/kg every 8 hours</p>\n<p>Second line antibiotics</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 2.5 MU every 6 hours for 10 days</p>\n<p>Child: 50,000-100,000 IU/kg per dose</p>\n<p>H</p>\n<p>Control muscle spasms First line</p>\n<p>\u0089</p>\n<p>Diazepam 10 mg (IV or rectal) every 1 to 4 hours</p>\n<p>Child: 0.2 mg/kg IV or 0.5 mg/kg rectal (maximum of</p>\n<p>10 mg) every 1 to 4 hours</p>\n<p>H</p>\n<p>121</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 188,
        "content": "TREATMENT\nLOC\nOther agents\n\t\n\u0089\nMagnesium sulphate (alone or with diazepam): 5 g (or \n75 mg/kg) IV loading dose then 2 g/hour till spasm \ncontrol is achieved\n \n- Monitor knee-jerk reflex, stop infusion if absent\n\t\n\u0089\nOr chlorpromazine (alone or alternate with diazepam) \n50-100 mg IM every 4-8 hours \nChild: 4-12 mg IM every 4-8 hours or\n\t\n\u0089\n12.5 mg-25 mg by NGT every 4-6 hours\n \n- Continue for as long as spasms/rigidity lasts\nControl pain\n\t\n\u0089\nMorphine 2.5-10 mg IV every 4-6 hours (monitor for \nrespiratory depression)\nChild: 0.1 mg/kg per dose\n\t\n\u0089\nParacetamol 1 g every 8 hours\nChild: 10 mg/kg every 6 hours\nPrevention\n \n~\nImmunise all children against tetanus during routine child\u00ad\nhood immunisation\n \n~\nProper wound care and immunisation (see chapter 18):\n \n- Full course if patient not immunised or not fully immunised\n \n- Booster if fully immunised but last dose >10 years ago\n \n- Fully immunised who had a booster <10 years ago do not \nneed any specific treatment\n \n~\nProphylaxis in patients at risk as a result of contaminat\u00ad\ned wounds: give Tetanus immunoglobulin human (TIG) IM \nChild < 5 years: 75 IU\nChild 5-10 years: 125 IU\nChild > 10 years and adults: 250 IU\nDouble the dose if heavy contamination or wound obtained > 24 \nhours.\n122\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Other agents</p>\n<p>\u0089</p>\n<p>Magnesium sulphate (alone or with diazepam): 5 g (or</p>\n<p>75 mg/kg) IV loading dose then 2 g/hour till spasm</p>\n<p>control is achieved</p>\n<p>- Monitor knee-jerk reflex, stop infusion if absent</p>\n<p>\u0089</p>\n<p>Or chlorpromazine (alone or alternate with diazepam)</p>\n<p>50-100 mg IM every 4-8 hours</p>\n<p>Child: 4-12 mg IM every 4-8 hours or</p>\n<p>\u0089</p>\n<p>12.5 mg-25 mg by NGT every 4-6 hours</p>\n<p>- Continue for as long as spasms/rigidity lasts</p>\n<p>Control pain</p>\n<p>\u0089</p>\n<p>Morphine 2.5-10 mg IV every 4-6 hours (monitor for</p>\n<p>respiratory depression)</p>\n<p>Child: 0.1 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>Child: 10 mg/kg every 6 hours</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Immunise all children against tetanus during routine child\u00ad</p>\n<p>hood immunisation</p>\n<p>~</p>\n<p>Proper wound care and immunisation (see chapter 18):</p>\n<p>- Full course if patient not immunised or not fully immunised</p>\n<p>- Booster if fully immunised but last dose >10 years ago</p>\n<p>- Fully immunised who had a booster <10 years ago do not</p>\n<p>need any specific treatment</p>\n<p>~</p>\n<p>Prophylaxis in patients at risk as a result of contaminat\u00ad</p>\n<p>ed wounds: give Tetanus immunoglobulin human (TIG) IM</p>\n<p>Child < 5 years: 75 IU</p>\n<p>Child 5-10 years: 125 IU</p>\n<p>Child > 10 years and adults: 250 IU</p>\n<p>Double the dose if heavy contamination or wound obtained > 24</p>\n<p>hours.</p>\n<p>122</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 189,
        "content": "2.1.8.1 Neonatal Tetanus\t                                                  ICD10 CODE: A33\nNeonatal tetanus is a notifiable disease\n \n~\nCaused by infection of the umbilicus through cutting of the \ncord with unsterile instruments or from putting cow dung \nor other unsuitable materials on the stump\n \n~\nUsually presents 3-14 days after birth with irritability and \ndifficulty in feeding due to masseter ( jaw muscle) spasm, \nrigidity, generalised muscle spasms. The neonate behaves \nnormally for the first few days before the symptoms appear.\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer to hospital immediately\nGeneral measures\n\t\n\u0089\nNurse in quite, dark and cool environment\n\t\n\u0089\nSuction the mouth and turn the infant 30 min after \nsedative. A mucous extractor or other suction should be \navailable for use prn\n\t\n\u0089\nEnsure hydration/feeding\n \n- Start with IV fluids (half saline and dextrose 5%)\n \n- Put NGT and start feeding with expressed breast milk \n24 hours after admission\u2013 in small frequent feeds\n \n- Monitor and maintain body temperature\n \n- Monitor cardiorespiratory function closely. Refer for \nICU management if possible\nH\nRR\nNeutralise toxin\n\t\n\u0089\nGive tetanus immunoglobulin human (TIG)\n \n- 500 IU IM. Give the dose in at least 2 different sites \nIM, different from the tetanus toxoid site\n\t\n\u0089\nIn addition give 1st dose of DPT\nH\n123\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>2.1.8.1 Neonatal Tetanus\t                                                  ICD10 CODE: A33</p>\n<p>Neonatal tetanus is a notifiable disease</p>\n<p>~</p>\n<p>Caused by infection of the umbilicus through cutting of the</p>\n<p>cord with unsterile instruments or from putting cow dung</p>\n<p>or other unsuitable materials on the stump</p>\n<p>~</p>\n<p>Usually presents 3-14 days after birth with irritability and</p>\n<p>difficulty in feeding due to masseter ( jaw muscle) spasm,</p>\n<p>rigidity, generalised muscle spasms. The neonate behaves</p>\n<p>normally for the first few days before the symptoms appear.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to hospital immediately</p>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Nurse in quite, dark and cool environment</p>\n<p>\u0089</p>\n<p>Suction the mouth and turn the infant 30 min after</p>\n<p>sedative. A mucous extractor or other suction should be</p>\n<p>available for use prn</p>\n<p>\u0089</p>\n<p>Ensure hydration/feeding</p>\n<p>- Start with IV fluids (half saline and dextrose 5%)</p>\n<p>- Put NGT and start feeding with expressed breast milk</p>\n<p>24 hours after admission\u2013 in small frequent feeds</p>\n<p>- Monitor and maintain body temperature</p>\n<p>- Monitor cardiorespiratory function closely. Refer for</p>\n<p>ICU management if possible</p>\n<p>H</p>\n<p>RR</p>\n<p>Neutralise toxin</p>\n<p>\u0089</p>\n<p>Give tetanus immunoglobulin human (TIG)</p>\n<p>- 500 IU IM. Give the dose in at least 2 different sites</p>\n<p>IM, different from the tetanus toxoid site</p>\n<p>\u0089</p>\n<p>In addition give 1st dose of DPT</p>\n<p>H</p>\n<p>123</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 190,
        "content": "TREATMENT\nLOC\nTreatment to eliminate source of toxin\n\t\n\u0089\nClean and debride the infected umbilicus\nFirst line antibiotics\n\t\n\u0089\nMetronidazole loading dose 15 mg/kg over 60 min then\n \n- Infant <4 weeks : 7.5 mg/kg every 12 hours for 14\n \n- days\nH\n \n- Infant >4 weeks: 7.5 mg/kg every 8 hours for 14 \ndays\nSecond line antibiotics\n\t\n\u0089\nBenzylpenicillin 100,000 IU/kg every 12 hours for 10-\n14 days\nH\nControl muscle spasm\n\t\n\u0089\nDiazepam 0.2 mg/kg IV or 0.5 mg/kg rectal every 1 to \n4 hours\nOther medicines\n\t\n\u0089\nChlorpromazine oral 1 mg/kg 8 hourly via NGT\nPrevention\n \n~\nImmunise all pregnant women during routine ANC visits\n \n~\nProper cord care\n2.1.9 Typhoid Fever (Enteric Fever)      \nICD10 CODE: A01.00\nBacterial infection characterised by fever and abdominal symptoms. It is \nspread through contaminated food and water.\nCauses\n \n~\nSalmonella typhi and S. paratyphi A & B\nClinical features\n \n~\nGradual onset of chills and malaise, headache, anorexia, \nepistaxis, backache, and constipation\n124\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment to eliminate source of toxin</p>\n<p>\u0089</p>\n<p>Clean and debride the infected umbilicus</p>\n<p>First line antibiotics</p>\n<p>\u0089</p>\n<p>Metronidazole loading dose 15 mg/kg over 60 min then</p>\n<p>- Infant <4 weeks : 7.5 mg/kg every 12 hours for 14</p>\n<p>- days</p>\n<p>H</p>\n<p>- Infant >4 weeks: 7.5 mg/kg every 8 hours for 14</p>\n<p>days</p>\n<p>Second line antibiotics</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 100,000 IU/kg every 12 hours for 10-</p>\n<p>14 days</p>\n<p>H</p>\n<p>Control muscle spasm</p>\n<p>\u0089</p>\n<p>Diazepam 0.2 mg/kg IV or 0.5 mg/kg rectal every 1 to</p>\n<p>4 hours</p>\n<p>Other medicines</p>\n<p>\u0089</p>\n<p>Chlorpromazine oral 1 mg/kg 8 hourly via NGT</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Immunise all pregnant women during routine ANC visits</p>\n<p>~</p>\n<p>Proper cord care</p>\n<p>2.1.9 Typhoid Fever (Enteric Fever)</p>\n<h3>ICD10 CODE: A01.00</h3>\n<p>Bacterial infection characterised by fever and abdominal symptoms. It is</p>\n<p>spread through contaminated food and water.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Salmonella typhi and S. paratyphi A & B</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Gradual onset of chills and malaise, headache, anorexia,</p>\n<p>epistaxis, backache, and constipation</p>\n<p>124</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 191,
        "content": "~\nUsually occurring 10-15 days after infection\n \n~\nAbdominal pain and tenderness are prominent features\n \n~\nHigh fever > 38\u00b0C\n \n~\nDelirium and stupor in advanced stages\n \n~\nTender splenomegaly, relative bradycardia, cough\n \n~\nComplications may include perforation of the gut with peri\u00ad\ntonitis, gastrointestinal hemorrhage\nDifferential diagnosis\n \n~\nSevere malaria, other severe febrile illnesses\nInvestigations\n\u00be\t\nBlood culture (most reliable)\n\u00be\t\nStool culture\n\u00be\t\nRapid antibody test (e.g. Tubex, Typhidot) \u2013 not \nvery sensitive or specific, possibly useful in epidemics\nWidal\u2019s agglutination reaction is neither sensitive nor specific for typhoid \ndiagnosis: a single positive screening does not indicate presence of infection\nManagement\nTREATMENT\nLOC\n \n~\nDo culture and sensitivity to confirm right treat\u00ad\nment\n\t\n\u0089\nCiprofloxacin 500 mg every 12 hours for 10\u201314 days\nChild: 10-15 mg/kg per dose\nOther antibiotics\nHC3\n125\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Usually occurring 10-15 days after infection</p>\n<p>~</p>\n<p>Abdominal pain and tenderness are prominent features</p>\n<p>~</p>\n<p>High fever > 38\u00b0C</p>\n<p>~</p>\n<p>Delirium and stupor in advanced stages</p>\n<p>~</p>\n<p>Tender splenomegaly, relative bradycardia, cough</p>\n<p>~</p>\n<p>Complications may include perforation of the gut with peri\u00ad</p>\n<p>tonitis, gastrointestinal hemorrhage</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Severe malaria, other severe febrile illnesses</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Blood culture (most reliable)</p>\n<p>\u00be</p>\n<p>Stool culture</p>\n<p>\u00be</p>\n<p>Rapid antibody test (e.g. Tubex, Typhidot) \u2013 not</p>\n<p>very sensitive or specific, possibly useful in epidemics</p>\n<p>Widal\u2019s agglutination reaction is neither sensitive nor specific for typhoid</p>\n<p>diagnosis: a single positive screening does not indicate presence of infection</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>~</p>\n<p>Do culture and sensitivity to confirm right treat\u00ad</p>\n<p>ment</p>\n<p>\u0089</p>\n<p>Ciprofloxacin 500 mg every 12 hours for 10\u201314 days</p>\n<p>Child: 10-15 mg/kg per dose</p>\n<p>Other antibiotics</p>\n<h3>HC3</h3>\n<p>125</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 192,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nChloramphenicol 500 mg 6 hourly for 10 days\nChild: 25 mg/kg IV, IM or oral for 10-14 days\nIn severe, resistant forms or pregnancy\n\t\n\u0089\nCeftriaxone 1 g IV every 12 hours for 10-14 days\nChild: 50 mg/kg per dose\nAlternative in pregnancy\n\t\n\u0089\nAmoxicillin 1 g every 8 hours for 10 days\nChild: 10-15 mg/kg per dose\nHC3\nHC4\nPrevention\n \n~\nEarly detection, isolation, treatment, and reporting\n \n~\nProper faecal disposal\n \n~\nUse of safe clean water for drinking\n \n~\nPersonal hygiene especially hand washing\n \n~\nGood food hygiene\n2.1.10 Typhus Fever\t\nICD10 CODE: A75.9\nFebrile infection caused by Rickettsia species\nCauses\n \n~\nEpidemic louse-borne typhus fever: caused by Rickettsia \nprowazeki; the common type in Uganda, which is trans\u00ad\nmitted to man (the reservoir) by lice\n \n~\nMurine (endemic) typhus fever: caused by Rickettsia typhi \n(mooseri) and transmitted by rat fleas. Rats and mice are \nthe reservoir\n \n~\nScrub typhus fever (mite-borne typhus): caused by R. tsut\u00ad\nsugamushi and transmitted by rodent mites\n126\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Chloramphenicol 500 mg 6 hourly for 10 days</p>\n<p>Child: 25 mg/kg IV, IM or oral for 10-14 days</p>\n<p>In severe, resistant forms or pregnancy</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV every 12 hours for 10-14 days</p>\n<p>Child: 50 mg/kg per dose</p>\n<p>Alternative in pregnancy</p>\n<p>\u0089</p>\n<p>Amoxicillin 1 g every 8 hours for 10 days</p>\n<p>Child: 10-15 mg/kg per dose</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Early detection, isolation, treatment, and reporting</p>\n<p>~</p>\n<p>Proper faecal disposal</p>\n<p>~</p>\n<p>Use of safe clean water for drinking</p>\n<p>~</p>\n<p>Personal hygiene especially hand washing</p>\n<p>~</p>\n<p>Good food hygiene</p>\n<p>2.1.10 Typhus Fever</p>\n<h3>ICD10 CODE: A75.9</h3>\n<p>Febrile infection caused by Rickettsia species</p>\n<p>Causes</p>\n<p>~</p>\n<p>Epidemic louse-borne typhus fever: caused by Rickettsia</p>\n<p>prowazeki; the common type in Uganda, which is trans\u00ad</p>\n<p>mitted to man (the reservoir) by lice</p>\n<p>~</p>\n<p>Murine (endemic) typhus fever: caused by Rickettsia typhi</p>\n<p>(mooseri) and transmitted by rat fleas. Rats and mice are</p>\n<p>the reservoir</p>\n<p>~</p>\n<p>Scrub typhus fever (mite-borne typhus): caused by R. tsut\u00ad</p>\n<p>sugamushi and transmitted by rodent mites</p>\n<p>126</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 193,
        "content": "Clinical features\n \n~\nHeadaches, fever, chills, severe weakness, muscle pains\n \n~\nMacular rash that appears on the 5th day on the rest of the \nbody except the face, palms, and soles\n \n~\nJaundice, confusion, drowsiness\n \n~\nMurine typhus has a similar picture but is less severe\nDifferential diagnosis\n \n~\nAny cause of fever such as malaria, HIV, UTI, or typhoid\nInvestigations\n\u00be\t\nBlood: For Weil-Felix reaction\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nDoxycycline 100 mg every 12 hours for 5-7 days\nChild > 8 years: 2 mg/kg per dose\n\t\n\u0089\nOr chloramphenicol 500 mg orally or IV every 6 hours \nfor 5 days\nChild: 15 mg/kg per dose\nHC2 \nHC4\nNote\n \n\u0083 One single dose of doxycycline 200 mg may cure epidemic \ntyphus but there is risk of relapse\nPrevention\n \n~\nPersonal hygiene\n \n~\nDestruction of lice and rodents\n127\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Headaches, fever, chills, severe weakness, muscle pains</p>\n<p>~</p>\n<p>Macular rash that appears on the 5th day on the rest of the</p>\n<p>body except the face, palms, and soles</p>\n<p>~</p>\n<p>Jaundice, confusion, drowsiness</p>\n<p>~</p>\n<p>Murine typhus has a similar picture but is less severe</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Any cause of fever such as malaria, HIV, UTI, or typhoid</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Blood: For Weil-Felix reaction</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Doxycycline 100 mg every 12 hours for 5-7 days</p>\n<p>Child > 8 years: 2 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or chloramphenicol 500 mg orally or IV every 6 hours</p>\n<p>for 5 days</p>\n<p>Child: 15 mg/kg per dose</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Note</p>\n<p>\u0083 One single dose of doxycycline 200 mg may cure epidemic</p>\n<p>typhus but there is risk of relapse</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Personal hygiene</p>\n<p>~</p>\n<p>Destruction of lice and rodents</p>\n<p>127</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 194,
        "content": "2.2 FUNGAL INFECTIONS\n2.2.1 Candidiasis                      ICD10 CODE: B37\nFungal infection usually confined to the mucous membranes and external \nlayers of skin. Severe forms are usually associated with immunosup\u00ad\npressive conditions, such as HIV/AIDS, diabetes, pregnancy, cancer, \nprolonged antibiotic use, and steroids.\nCauses\n \n~\nCandida albicans, transmitted by direct contact\nClinical features\nIt may present as:\n \n~\nOral thrush\n \n~\nIntertrigo (between skin folds)\n \n~\nVulvo vaginitis and abnormal vaginal discharge (vaginal \ncandida is not a sexually transmitted disease)\n \n~\nChronic paronychia (inflammation involving the proximal \nand lateral fingernail folds)\n \n~\nGastrointestinal candidiasis may present with pain on \nswallowing, vomiting, diarrhoea, epigastric and retroster\u00ad\nnal pain\nInvestigations\n \n\u0081\nDiagnosis is mainly clinical\n \n\u0081\nIn case of vaginitis, sample collection \u2013a high vaginal swab \n(protected by a speculum), pH, KOH , wet preparation and\n \n~\n Gram stain, C&S\n \n\u0081\nSmear examination with potassium hydroxide (KOH)\nInvestigations\n \n\u0081\nDiagnosis is mainly clinical\n \n\u0081\nIn case of vaginitis, sample collection \u2013a high vaginal swab \n(protected by a speculum), pH, KOH , wet preparation and\n \n~\n Gram stain, C&S\n \n~\nSmear examination with potassium hydroxide (KOH)\n128\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>2.2 FUNGAL INFECTIONS</h3>\n<p>2.2.1 Candidiasis                      ICD10 CODE: B37</p>\n<p>Fungal infection usually confined to the mucous membranes and external</p>\n<p>layers of skin. Severe forms are usually associated with immunosup\u00ad</p>\n<p>pressive conditions, such as HIV/AIDS, diabetes, pregnancy, cancer,</p>\n<p>prolonged antibiotic use, and steroids.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Candida albicans, transmitted by direct contact</p>\n<p>Clinical features</p>\n<p>It may present as:</p>\n<p>~</p>\n<p>Oral thrush</p>\n<p>~</p>\n<p>Intertrigo (between skin folds)</p>\n<p>~</p>\n<p>Vulvo vaginitis and abnormal vaginal discharge (vaginal</p>\n<p>candida is not a sexually transmitted disease)</p>\n<p>~</p>\n<p>Chronic paronychia (inflammation involving the proximal</p>\n<p>and lateral fingernail folds)</p>\n<p>~</p>\n<p>Gastrointestinal candidiasis may present with pain on</p>\n<p>swallowing, vomiting, diarrhoea, epigastric and retroster\u00ad</p>\n<p>nal pain</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is mainly clinical</p>\n<p>\u0081</p>\n<p>In case of vaginitis, sample collection \u2013a high vaginal swab</p>\n<p>(protected by a speculum), pH, KOH , wet preparation and</p>\n<p>~</p>\n<p>Gram stain, C&S</p>\n<p>\u0081</p>\n<p>Smear examination with potassium hydroxide (KOH)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is mainly clinical</p>\n<p>\u0081</p>\n<p>In case of vaginitis, sample collection \u2013a high vaginal swab</p>\n<p>(protected by a speculum), pH, KOH , wet preparation and</p>\n<p>~</p>\n<p>Gram stain, C&S</p>\n<p>~</p>\n<p>Smear examination with potassium hydroxide (KOH)</p>\n<p>128</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 195,
        "content": "Investigations\n \n\u0081\nDiagnosis is mainly clinical\n \n\u0081\nIn case of vaginitis, sample collection \u2013a high vaginal swab (pro\u00ad\ntected by a speculum), pH, KOH , wet preparation and\n \n~\n Gram stain, C&S\n \n\u0081\nSmear examination with potassium hydroxide (KOH)\nManagement\nTREATMENT\nLOC\nOral candidiasis\n\t\n\u0089\nNystatin tablets 500,000-1,000,000 IU every 6 hours \nfor 10 days (chewed then swallowed)  \nChild < 5 years: Nystatin oral suspension 100,000 IU \nevery 6 hours for 10 days\nChild 5-12 years: 200,000 IU per dose every 6 hours \nfor 10 days\nHC3 \nHC2\nOropharyngeal candidiasis\n\t\n\u0089\nFluconazole  150-200 mg daily for 14 days\nChild: loading dose 6 mg/kg, then 3 mg/kg daily\nHC3\nVaginal\n\t\n\u0089\nInsert clotrimazole pessary 100 mg high into the \nvagina with an applicator each night for 6 days or \ntwice a day for 3 days\n\t\n\u0089\nOr insert one nystatin pessary 100,000 IU each \nnight for 10 days\n\t\n\u0089\nFor recurrent vaginal candidiasis, give fluconazole \n150-200 mg once daily for 5 days\nFluconazole is associated with spontaneous abortions and \ncongenital anomalies and should be avoided in pregnancy\nHC2\n129\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is mainly clinical</p>\n<p>\u0081</p>\n<p>In case of vaginitis, sample collection \u2013a high vaginal swab (pro\u00ad</p>\n<p>tected by a speculum), pH, KOH , wet preparation and</p>\n<p>~</p>\n<p>Gram stain, C&S</p>\n<p>\u0081</p>\n<p>Smear examination with potassium hydroxide (KOH)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Oral candidiasis</p>\n<p>\u0089</p>\n<p>Nystatin tablets 500,000-1,000,000 IU every 6 hours</p>\n<p>for 10 days (chewed then swallowed)</p>\n<p>Child < 5 years: Nystatin oral suspension 100,000 IU</p>\n<p>every 6 hours for 10 days</p>\n<p>Child 5-12 years: 200,000 IU per dose every 6 hours</p>\n<p>for 10 days</p>\n<h3>HC3</h3>\n<h3>HC2</h3>\n<p>Oropharyngeal candidiasis</p>\n<p>\u0089</p>\n<p>Fluconazole  150-200 mg daily for 14 days</p>\n<p>Child: loading dose 6 mg/kg, then 3 mg/kg daily</p>\n<h3>HC3</h3>\n<p>Vaginal</p>\n<p>\u0089</p>\n<p>Insert clotrimazole pessary 100 mg high into the</p>\n<p>vagina with an applicator each night for 6 days or</p>\n<p>twice a day for 3 days</p>\n<p>\u0089</p>\n<p>Or insert one nystatin pessary 100,000 IU each</p>\n<p>night for 10 days</p>\n<p>\u0089</p>\n<p>For recurrent vaginal candidiasis, give fluconazole</p>\n<p>150-200 mg once daily for 5 days</p>\n<p>Fluconazole is associated with spontaneous abortions and</p>\n<p>congenital anomalies and should be avoided in pregnancy</p>\n<h3>HC2</h3>\n<p>129</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 196,
        "content": "TREATMENT\nLOC\nChronic paronychia\n\t\n\u0089\nKeep hand dry and wear gloves for wet work\n\t\n\u0089\nHydrocortisone cream twice daily\nIf not responding\n\t\n\u0089\nBetametasone cream twice daily\n\t\n\u0089\nFluconazole 150-200 mg once a day for 5-7 days\nHC3\nHC4\nIntertrigo\n\t\n\u0089\nClotrimazole cream twice a day for 2-4 weeks\n\t\n\u0089\nIn severe forms use fluconazole 150-200 mg once \na day for 14-21 days\nHC3\nPrevention\n \n~\nEarly detection and treatment\n \n~\nImprove personal hygiene\n \n~\nAvoid unnecessary antibiotics\n2.3 VIRAL INFECTIONS\n2.3.1 Avian Influenza                         ICD10 CODE: J09.X2\nInfluenza caused by avian (bird) influenza Type A viruses (mainly H5N1 \nstrain). It is endemic in the poultry population in Eurasia and can oc\u00ad\ncasionally be transmitted to humans through direct contact with sick \nbirds (inhalation of infectious droplets). Disease can be mild or severe \nand has limited potential to spread from person to person but there is \nrisk of mutations giving rise to a very infectious virus which could cause \nwidespread epidemics. Avian flu is a notifiable disease.\nCause\n \n~\nAvian (bird) influenza Type A viruses\nClinical features\n \n~\nConjuctivitis\n130\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Chronic paronychia</p>\n<p>\u0089</p>\n<p>Keep hand dry and wear gloves for wet work</p>\n<p>\u0089</p>\n<p>Hydrocortisone cream twice daily</p>\n<p>If not responding</p>\n<p>\u0089</p>\n<p>Betametasone cream twice daily</p>\n<p>\u0089</p>\n<p>Fluconazole 150-200 mg once a day for 5-7 days</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Intertrigo</p>\n<p>\u0089</p>\n<p>Clotrimazole cream twice a day for 2-4 weeks</p>\n<p>\u0089</p>\n<p>In severe forms use fluconazole 150-200 mg once</p>\n<p>a day for 14-21 days</p>\n<h3>HC3</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Early detection and treatment</p>\n<p>~</p>\n<p>Improve personal hygiene</p>\n<p>~</p>\n<p>Avoid unnecessary antibiotics</p>\n<h3>2.3 VIRAL INFECTIONS</h3>\n<p>2.3.1 Avian Influenza                         ICD10 CODE: J09.X2</p>\n<p>Influenza caused by avian (bird) influenza Type A viruses (mainly H5N1</p>\n<p>strain). It is endemic in the poultry population in Eurasia and can oc\u00ad</p>\n<p>casionally be transmitted to humans through direct contact with sick</p>\n<p>birds (inhalation of infectious droplets). Disease can be mild or severe</p>\n<p>and has limited potential to spread from person to person but there is</p>\n<p>risk of mutations giving rise to a very infectious virus which could cause</p>\n<p>widespread epidemics. Avian flu is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Avian (bird) influenza Type A viruses</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Conjuctivitis</p>\n<p>130</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 197,
        "content": "~\nFlu symptoms: fever, cough, sore throat, muscle aches\n \n~\nGastrointestinal (diarrhoea) and neurological symptoms\n \n~\nIn some cases, severe acute respiratory syndrome (SARS)\nInvestigations\n \n\u0081\nBlood and respiratory specimens, nose swab: lab test for influenza \nand rule out bacterial infection\n \n- Testing must be in a special laboratory\nManagement\nTREATMENT\nLOC\nIf patient requires hospitalisation\n\t\n\u0089\nHospitalise patient under appropriate infection control \nprecautions\n\t\n\u0089\nAdminister oxygen as required. Avoid nebulisers and high \nair flow oxygen masks\nRR\n\t\n\u0089\nGive paracetamol or ibuprofen for fever prn\n\t\n\u0089\nGive oseltamivir phosphate in patients \u2265 1 year who have \nbeen symptomatic for no more than two days. Treat for 5 \ndays as below:\nAdults and children \u2265 13 years: 75 mg twice daily\nChild > 1 year and < 15 kg: 30 mg twice daily\nChild 15\u2013 23 kg: 45 mg twice daily\nChild 23\u201340 kg body weight:60 mg twice daily\nChild > 40 kg body weight: 75 mg twice daily If a case does \nnot require hospitalisation f Educate the patient and his/her \nfamily on:\nPersonal hygiene and infection control measures\nHand-washing, use of a paper or surgical mask by the ill person\nRestriction of social contacts\nSeek prompt medical care if the condition worsens\nProphylactic use of oseltamivir\nRR\n131\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Flu symptoms: fever, cough, sore throat, muscle aches</p>\n<p>~</p>\n<p>Gastrointestinal (diarrhoea) and neurological symptoms</p>\n<p>~</p>\n<p>In some cases, severe acute respiratory syndrome (SARS)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood and respiratory specimens, nose swab: lab test for influenza</p>\n<p>and rule out bacterial infection</p>\n<p>- Testing must be in a special laboratory</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If patient requires hospitalisation</p>\n<p>\u0089</p>\n<p>Hospitalise patient under appropriate infection control</p>\n<p>precautions</p>\n<p>\u0089</p>\n<p>Administer oxygen as required. Avoid nebulisers and high</p>\n<p>air flow oxygen masks</p>\n<p>RR</p>\n<p>\u0089</p>\n<p>Give paracetamol or ibuprofen for fever prn</p>\n<p>\u0089</p>\n<p>Give oseltamivir phosphate in patients \u2265 1 year who have</p>\n<p>been symptomatic for no more than two days. Treat for 5</p>\n<p>days as below:</p>\n<p>Adults and children \u2265 13 years: 75 mg twice daily</p>\n<p>Child > 1 year and < 15 kg: 30 mg twice daily</p>\n<p>Child 15\u2013 23 kg: 45 mg twice daily</p>\n<p>Child 23\u201340 kg body weight:60 mg twice daily</p>\n<p>Child > 40 kg body weight: 75 mg twice daily If a case does</p>\n<p>not require hospitalisation f Educate the patient and his/her</p>\n<p>family on:</p>\n<p>Personal hygiene and infection control measures</p>\n<p>Hand-washing, use of a paper or surgical mask by the ill person</p>\n<p>Restriction of social contacts</p>\n<p>Seek prompt medical care if the condition worsens</p>\n<p>Prophylactic use of oseltamivir</p>\n<p>RR</p>\n<p>131</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 198,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nIndicated in persons 13 years and above who have come \ninto contact with affected birds/patients  \n\t\n\u0089\nClose contact: 75 mg once daily for at least 7 days\n\t\n\u0089\nCommunity contacts: 75 mg once daily up to 6 weeks\n\t\n\u0089\nProtection lasts only during the period of chemoprophylaxis\nRR\nDischarge policy\n \n~\nInfection control precautions for adult patients should re\u00ad\nmain in place for 7 days after resolution of fever and for 21 \ndays in children younger than 12 years\n \n~\nChildren should not attend school during this period\nControl and Prevention of Nosocomial Spread of Influenza A (H5N1)\nHealth workers should observe the following to prevent the spread of \navian influenza in the health care facilities:\n \n~\nObserve droplet and contact precautions. In addition, get \nnegative pressure room if available\n \n~\nIsolate the patient to a single room\n \n~\nPlace beds more than 1 metre apart and preferably separat\u00ad\ned by a physical barrier (e.g., curtain, partition)\n \n~\nAppropriate personal protective equipment (APPE) in all \nthose entering patients\u2019 rooms. APPE includes high effi\u00ad\nciency mask, gown, face shield or goggles, and gloves\n \n~\nLimit the number of health care workers (HCWs) and other \nhospital employees who have direct contact with the pa\u00ad\ntient(s). These HCWs should:\n \n~\nBe properly trained in infection control precautions\n \n~\nMonitor their own temperature twice daily and report any \nfebrile event to hospital authorities\n \n~\nA HCW who has a fever (>380C) and who has had direct \npatient contact should be treated immediately\n132\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Indicated in persons 13 years and above who have come</p>\n<p>into contact with affected birds/patients</p>\n<p>\u0089</p>\n<p>Close contact: 75 mg once daily for at least 7 days</p>\n<p>\u0089</p>\n<p>Community contacts: 75 mg once daily up to 6 weeks</p>\n<p>\u0089</p>\n<p>Protection lasts only during the period of chemoprophylaxis</p>\n<p>RR</p>\n<p>Discharge policy</p>\n<p>~</p>\n<p>Infection control precautions for adult patients should re\u00ad</p>\n<p>main in place for 7 days after resolution of fever and for 21</p>\n<p>days in children younger than 12 years</p>\n<p>~</p>\n<p>Children should not attend school during this period</p>\n<p>Control and Prevention of Nosocomial Spread of Influenza A (H5N1)</p>\n<p>Health workers should observe the following to prevent the spread of</p>\n<p>avian influenza in the health care facilities:</p>\n<p>~</p>\n<p>Observe droplet and contact precautions. In addition, get</p>\n<p>negative pressure room if available</p>\n<p>~</p>\n<p>Isolate the patient to a single room</p>\n<p>~</p>\n<p>Place beds more than 1 metre apart and preferably separat\u00ad</p>\n<p>ed by a physical barrier (e.g., curtain, partition)</p>\n<p>~</p>\n<p>Appropriate personal protective equipment (APPE) in all</p>\n<p>those entering patients\u2019 rooms. APPE includes high effi\u00ad</p>\n<p>ciency mask, gown, face shield or goggles, and gloves</p>\n<p>~</p>\n<p>Limit the number of health care workers (HCWs) and other</p>\n<p>hospital employees who have direct contact with the pa\u00ad</p>\n<p>tient(s). These HCWs should:</p>\n<p>~</p>\n<p>Be properly trained in infection control precautions</p>\n<p>~</p>\n<p>Monitor their own temperature twice daily and report any</p>\n<p>febrile event to hospital authorities</p>\n<p>~</p>\n<p>A HCW who has a fever (>380C) and who has had direct</p>\n<p>patient contact should be treated immediately</p>\n<p>132</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 199,
        "content": "~\nRestrict the number of visitors, provide them with APPE, \nand instruct them in its use\n2.3.2 Chicken pox                ICD10 CODE: B01\nA highly contagious viral infection. Patients are contagious from 2 days \nbefore onset of the rash until all lesions have crusted. An attack of \nchicken pox usually confers lifelong immunity. Disease is more severe \nand complicated in adults.\nCauses\n \n~\nVaricella Zoster virus (VZV) by droplet infection\nClinical features\n \n~\nIncubation period is 14 days, but shorter in immuno- com\u00ad\npromised host\n \n~\nMild fevers occur 10-20 days after exposure\n \n~\nProdromal symptoms consisting of low fever, headache, \nand malaise occurring 2 to 3 days before the eruption\n \n~\nEruptive phase: they appear as macules, papules, vesicles, \npustules and crusts. The most characteristic lesion is a vesi\u00ad\ncle looking like a drop of water on the skin. Vesicles rupture \neasily and may become infected\n \n~\nThe rash begins on the trunk and spreads to the face and \nextremities\n \n~\nLesions of different stages (crops) exist together at the same \ntime in any given body area\n \n~\nComplications may include septicaemia, pneumonia, ful\u00ad\nminating haemorrhagic varicella, and meningoencephalitis\nDifferential diagnosis\n \n~\nDrug-induced eruption\n \n~\nScabies\n \n~\nInsect bites\n \n~\nErythema multiforme, impetigo\n \n~\nOther viral infections with fever and skin rash\n133\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Restrict the number of visitors, provide them with APPE,</p>\n<p>and instruct them in its use</p>\n<p>2.3.2 Chicken pox                ICD10 CODE: B01</p>\n<p>A highly contagious viral infection. Patients are contagious from 2 days</p>\n<p>before onset of the rash until all lesions have crusted. An attack of</p>\n<p>chicken pox usually confers lifelong immunity. Disease is more severe</p>\n<p>and complicated in adults.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Varicella Zoster virus (VZV) by droplet infection</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Incubation period is 14 days, but shorter in immuno- com\u00ad</p>\n<p>promised host</p>\n<p>~</p>\n<p>Mild fevers occur 10-20 days after exposure</p>\n<p>~</p>\n<p>Prodromal symptoms consisting of low fever, headache,</p>\n<p>and malaise occurring 2 to 3 days before the eruption</p>\n<p>~</p>\n<p>Eruptive phase: they appear as macules, papules, vesicles,</p>\n<p>pustules and crusts. The most characteristic lesion is a vesi\u00ad</p>\n<p>cle looking like a drop of water on the skin. Vesicles rupture</p>\n<p>easily and may become infected</p>\n<p>~</p>\n<p>The rash begins on the trunk and spreads to the face and</p>\n<p>extremities</p>\n<p>~</p>\n<p>Lesions of different stages (crops) exist together at the same</p>\n<p>time in any given body area</p>\n<p>~</p>\n<p>Complications may include septicaemia, pneumonia, ful\u00ad</p>\n<p>minating haemorrhagic varicella, and meningoencephalitis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Drug-induced eruption</p>\n<p>~</p>\n<p>Scabies</p>\n<p>~</p>\n<p>Insect bites</p>\n<p>~</p>\n<p>Erythema multiforme, impetigo</p>\n<p>~</p>\n<p>Other viral infections with fever and skin rash</p>\n<p>133</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 200,
        "content": "Investigations\n\u00be\t\nVirus isolation possible but not necessary\n\u00be\t\nDiagnosis is practically clinical\nManagement\nTREATMENT\nLOC\nSymptomatic and supportive treatment\n\t\n\u0089\n Apply calamine lotion every 12 hours f Cool, wet \ncompresses to provide relief\nChlorpheniramine: Adult 4 mg every 12 hours Child <5 \nyears: 1-2 mg every 12 hours for 3 days\nPain relief: paracetamol 10 mg/kg every 6 hours\nIn adults and children >12 years consider antivirals:  Oral \naciclovir 800 mg every 6 hours for 7 days  Keep child at \nhome/remove from school till healed to avoid spread\nHC2\nHC4\nPrevention\n \n~\nIsolation of infected patient\n \n~\nAvoid contact between infected persons and immuno- sup\u00ad\npressed persons\n2.3.3 Measles\t\nICD10 CODE: B05\nAn acute, highly communicable viral infection characterized by a general\u00ad\nised skin rash, fever, and inflammation of mucous membranes. Measles \nis a notifiable disease.\nCause\n \n~\nMeasles virus spreads by droplet infection and direct \ncontact\n134\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u00be</p>\n<p>Virus isolation possible but not necessary</p>\n<p>\u00be</p>\n<p>Diagnosis is practically clinical</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Symptomatic and supportive treatment</p>\n<p>\u0089</p>\n<p>Apply calamine lotion every 12 hours f Cool, wet</p>\n<p>compresses to provide relief</p>\n<p>Chlorpheniramine: Adult 4 mg every 12 hours Child <5</p>\n<p>years: 1-2 mg every 12 hours for 3 days</p>\n<p>Pain relief: paracetamol 10 mg/kg every 6 hours</p>\n<p>In adults and children >12 years consider antivirals:  Oral</p>\n<p>aciclovir 800 mg every 6 hours for 7 days  Keep child at</p>\n<p>home/remove from school till healed to avoid spread</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Isolation of infected patient</p>\n<p>~</p>\n<p>Avoid contact between infected persons and immuno- sup\u00ad</p>\n<p>pressed persons</p>\n<p>2.3.3 Measles</p>\n<h3>ICD10 CODE: B05</h3>\n<p>An acute, highly communicable viral infection characterized by a general\u00ad</p>\n<p>ised skin rash, fever, and inflammation of mucous membranes. Measles</p>\n<p>is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Measles virus spreads by droplet infection and direct</p>\n<p>contact</p>\n<p>134</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 201,
        "content": "Clinical features\n \n~\nCatarrhal stage: high fever, Koplik\u2019s spots (diagnostic) run\u00ad\nny nose, barking cough, conjunctivitis\n \n~\nMisery, anorexia, vomiting, diarrhoea\n \n~\nLater: generalised maculopapular skin rash followed by des\u00ad\nquamation after few days\nComplications\n \n~\nSecondary bacterial respiratory tract infection, e.g. bron\u00ad\nchopneumonia, otitis media\n \n~\nSevere acute malnutrition especially following diarrhoea\n \n~\nCancrum oris (from mouth sepsis)\n \n~\nCorneal ulceration and panophthalmitis \u2013 can lead to blind\u00ad\nness\n \n~\nDemyelinating encephalitis\n \n~\nThrombocytopaenic purpura\nDifferential diagnosis\n \n~\nGerman measles (Rubella)\n \n~\nOther viral diseases causing skin rash\nInvestigations\n \n\u0081\nClinical diagnosis is sufficient though virus isolation is possible\nManagement (symptomatic)\nTREATMENT\nLOC\n\t\n\u0089\nIsolate patients (at home or health centre)\n\t\n\u0089\nParacetamol prn for fever\n Apply tetracycline eye ointment 1% every 12 hours \nfor 5 days\n\t\n\u0089\nIncrease fluid and nutritional intake (high risk of mal\u00ad\nnutrition and dehydration\nHC2\n135\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Catarrhal stage: high fever, Koplik\u2019s spots (diagnostic) run\u00ad</p>\n<p>ny nose, barking cough, conjunctivitis</p>\n<p>~</p>\n<p>Misery, anorexia, vomiting, diarrhoea</p>\n<p>~</p>\n<p>Later: generalised maculopapular skin rash followed by des\u00ad</p>\n<p>quamation after few days</p>\n<p>Complications</p>\n<p>~</p>\n<p>Secondary bacterial respiratory tract infection, e.g. bron\u00ad</p>\n<p>chopneumonia, otitis media</p>\n<p>~</p>\n<p>Severe acute malnutrition especially following diarrhoea</p>\n<p>~</p>\n<p>Cancrum oris (from mouth sepsis)</p>\n<p>~</p>\n<p>Corneal ulceration and panophthalmitis \u2013 can lead to blind\u00ad</p>\n<p>ness</p>\n<p>~</p>\n<p>Demyelinating encephalitis</p>\n<p>~</p>\n<p>Thrombocytopaenic purpura</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>German measles (Rubella)</p>\n<p>~</p>\n<p>Other viral diseases causing skin rash</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Clinical diagnosis is sufficient though virus isolation is possible</p>\n<p>Management (symptomatic)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Isolate patients (at home or health centre)</p>\n<p>\u0089</p>\n<p>Paracetamol prn for fever</p>\n<p>Apply tetracycline eye ointment 1% every 12 hours</p>\n<p>for 5 days</p>\n<p>\u0089</p>\n<p>Increase fluid and nutritional intake (high risk of mal\u00ad</p>\n<p>nutrition and dehydration</p>\n<h3>HC2</h3>\n<p>135</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 202,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nGive 3 doses of vitamin A: first dose at diagnosis, 2nd \ndose the next day and 3rd dose on day 14 Child <6 \nmonths: 50,000 IU\nChild 6-12 months: 100,000 IU\nChild >12 months: 200,000 IU\n\t\n\u0089\nMonitor for and treat secondary bacterial infections \nwith appropriate antibiotics immediately\n\t\n\u0089\nRefer to hospital in case of complications\nPrevention\n \n~\nMeasles vaccination (see chapter 18)\n \n~\nAvoid contact between infected and uninfected persons\n \n~\nEducate the public against the common local myths e.g. \nstopping to feed meat and fish to measles patients\n2.3.4 Poliomyelitis             ICD10 CODE: A80.3\nAn acute viral infection characterised by acute onset of flaccid paralysis \nof skeletal muscles. It is transmitted from person to person through the \nfaecal-oral route. Poliomyelitis is a notifiable disease.\nCause\n \n~\nPolio virus (enterovirus) types I, II, and III\nClinical features\n \n~\nMajority of cases are asymptomatic, only 1% result in flac\u00ad\ncid paralysis\n \n~\nNon-paralytic form: minor illness of fever, malaise, head\u00ad\nache, and vomiting, muscle pains, spontaneous recovery \nin 10 days\n \n~\nParalytic form: after the aspecific symptoms, rapid onset \n(from morning to evening) of asymmetric flaccid paralysis, \n136\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give 3 doses of vitamin A: first dose at diagnosis, 2nd</p>\n<p>dose the next day and 3rd dose on day 14 Child <6</p>\n<p>months: 50,000 IU</p>\n<p>Child 6-12 months: 100,000 IU</p>\n<p>Child >12 months: 200,000 IU</p>\n<p>\u0089</p>\n<p>Monitor for and treat secondary bacterial infections</p>\n<p>with appropriate antibiotics immediately</p>\n<p>\u0089</p>\n<p>Refer to hospital in case of complications</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Measles vaccination (see chapter 18)</p>\n<p>~</p>\n<p>Avoid contact between infected and uninfected persons</p>\n<p>~</p>\n<p>Educate the public against the common local myths e.g.</p>\n<p>stopping to feed meat and fish to measles patients</p>\n<p>2.3.4 Poliomyelitis             ICD10 CODE: A80.3</p>\n<p>An acute viral infection characterised by acute onset of flaccid paralysis</p>\n<p>of skeletal muscles. It is transmitted from person to person through the</p>\n<p>faecal-oral route. Poliomyelitis is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Polio virus (enterovirus) types I, II, and III</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Majority of cases are asymptomatic, only 1% result in flac\u00ad</p>\n<p>cid paralysis</p>\n<p>~</p>\n<p>Non-paralytic form: minor illness of fever, malaise, head\u00ad</p>\n<p>ache, and vomiting, muscle pains, spontaneous recovery</p>\n<p>in 10 days</p>\n<p>~</p>\n<p>Paralytic form: after the aspecific symptoms, rapid onset</p>\n<p>(from morning to evening) of asymmetric flaccid paralysis,</p>\n<p>136</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 203,
        "content": "predominantly of the lower limbs, with ascending progres\u00ad\nsion\n \n~\nParalysis of respiratory muscles is life threatening (bulbar \npolio)\n \n~\nAseptic meningitis may occur as a complication\nDifferential diagnosis\n \n~\nGuillain-Barr\u00e9 syndrome\n \n~\nTraumatic neuritis\n \n~\nTransverse myelitis\n \n~\nPesticides and food poisoning\nConsider all cass of Acute Flaccid Paralysis as possible Poliomyelitis: alert \nthe district focal person for epidemic control, and send 2 stool samples \n(refrigerated).\nInvestigations\n \n\u0081\nIsolation of the virus from stool samples\n \n\u0081\nViral culture\n \n\u0081\nEnsure that Giardia intestinalis, Entamoeba histolytica, Cryp\u00ad\ntosporidium, Cyclospora, sarcocystis, Toxoplasma gondii are \nincluded in the investigations\nManagement\nTREATMENT\nLOC\nAcute stage\nPoliomyelitis in this stage without paralysis is difficult to \ndiagnose\nParalytic form\n\t\n\u0089\nIf paralysis is recent, rest the patient completely Note: \nDo not give IM injections as they make the paralysis \nworse\nH\n137\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>predominantly of the lower limbs, with ascending progres\u00ad</p>\n<p>sion</p>\n<p>~</p>\n<p>Paralysis of respiratory muscles is life threatening (bulbar</p>\n<p>polio)</p>\n<p>~</p>\n<p>Aseptic meningitis may occur as a complication</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Guillain-Barr\u00e9 syndrome</p>\n<p>~</p>\n<p>Traumatic neuritis</p>\n<p>~</p>\n<p>Transverse myelitis</p>\n<p>~</p>\n<p>Pesticides and food poisoning</p>\n<p>Consider all cass of Acute Flaccid Paralysis as possible Poliomyelitis: alert</p>\n<p>the district focal person for epidemic control, and send 2 stool samples</p>\n<p>(refrigerated).</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Isolation of the virus from stool samples</p>\n<p>\u0081</p>\n<p>Viral culture</p>\n<p>\u0081</p>\n<p>Ensure that Giardia intestinalis, Entamoeba histolytica, Cryp\u00ad</p>\n<p>tosporidium, Cyclospora, sarcocystis, Toxoplasma gondii are</p>\n<p>included in the investigations</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute stage</p>\n<p>Poliomyelitis in this stage without paralysis is difficult to</p>\n<p>diagnose</p>\n<p>Paralytic form</p>\n<p>\u0089</p>\n<p>If paralysis is recent, rest the patient completely Note:</p>\n<p>Do not give IM injections as they make the paralysis</p>\n<p>worse</p>\n<p>H</p>\n<p>137</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 204,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nRefer the patient to a hospital for supportive care\n\t\n\u0089\nAfter recovery (if partially/not immunised), complete \nrecommended immunisation schedule\nChronic stage\n\t\n\u0089\nEncourage active use of the limb to restore muscle \nfunction/physiotherapy\n\t\n\u0089\nIn event of severe contractures, refer for corrective \nsurgery\nH\nPrevention\n \n~\nIsolate patient for nursing and treatment, applying contact \nand droplets precautions\n \n~\nImmunise all children below 5 years from the area of the \nsuspected case\n \n~\nIf case is confirmed, organize mass immunisation campaign\n \n~\nProper disposal of children\u2019s faeces\n \n~\nImmunisation (see chapter 18)\n \n~\nProper hygiene and sanitation\n2.3.5 Rabies\t\nICD10 CODE: A82\nRabies is a viral infection of wild and domestic animals, transmitted to \nhumans by saliva of infected animals through bites, scratches or licks \non broken skin or mucuos membranes. Once symptoms develop, rabies \npresents as a fatal encephalitis: there is no cure and treatment is palliative.\nBefore symptomatic disease has developed, rabies can effectively be \nprevented by post-exposure prophylaxis.\nCause\n \n~\nRabies virus. Incubation is average 20-90 days but can be \n138\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer the patient to a hospital for supportive care</p>\n<p>\u0089</p>\n<p>After recovery (if partially/not immunised), complete</p>\n<p>recommended immunisation schedule</p>\n<p>Chronic stage</p>\n<p>\u0089</p>\n<p>Encourage active use of the limb to restore muscle</p>\n<p>function/physiotherapy</p>\n<p>\u0089</p>\n<p>In event of severe contractures, refer for corrective</p>\n<p>surgery</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Isolate patient for nursing and treatment, applying contact</p>\n<p>and droplets precautions</p>\n<p>~</p>\n<p>Immunise all children below 5 years from the area of the</p>\n<p>suspected case</p>\n<p>~</p>\n<p>If case is confirmed, organize mass immunisation campaign</p>\n<p>~</p>\n<p>Proper disposal of children\u2019s faeces</p>\n<p>~</p>\n<p>Immunisation (see chapter 18)</p>\n<p>~</p>\n<p>Proper hygiene and sanitation</p>\n<p>2.3.5 Rabies</p>\n<h3>ICD10 CODE: A82</h3>\n<p>Rabies is a viral infection of wild and domestic animals, transmitted to</p>\n<p>humans by saliva of infected animals through bites, scratches or licks</p>\n<p>on broken skin or mucuos membranes. Once symptoms develop, rabies</p>\n<p>presents as a fatal encephalitis: there is no cure and treatment is palliative.</p>\n<p>Before symptomatic disease has developed, rabies can effectively be</p>\n<p>prevented by post-exposure prophylaxis.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Rabies virus. Incubation is average 20-90 days but can be</p>\n<p>138</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 205,
        "content": "shorter in severe exposure (multiple bites, bites on face/ \nneck) of even longer (> a year) in a few cases\nClinical features\n \n~\nItching or paraesthesiae (abnormal sensation) around site \nof exposure, malaise, fever\n \n~\nNeurologic phase\n \n~\nFurious form: psychomotor agitation or hydrophobia (throat \nspasm and panic, triggered by attempt to drink or sight/\nsound/touch of water) and aerophobia (similar response to \na draft of air)\n \n~\nParalytic form (rarer): progressive ascending paralysis\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nThere is no cure. In case of suspected exposure, take \nall the appropriate steps to prevent the infection (see \nsection1.2.1.3 on animal bites) \n\t\n\u0089\nStart as soon as the exposure happens or as soon as \nthe patient comes for medical attention, regardless of \nwhatever time has passed from the exposure\nH\n\t\n\u0089\nAdmit case\n\t\n\u0089\nPalliative and supportive care\n\t\n\u0089\nObserve strict hygienic precautions\nAvoid contact with patient\u2019s body fluids or secretions\nPPE (personal protective equipment)\nCaution: the patient may bite\n\t\n\u0089\nCounsel caregivers on rabies and consequences\nH\n139\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>shorter in severe exposure (multiple bites, bites on face/</p>\n<p>neck) of even longer (> a year) in a few cases</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Itching or paraesthesiae (abnormal sensation) around site</p>\n<p>of exposure, malaise, fever</p>\n<p>~</p>\n<p>Neurologic phase</p>\n<p>~</p>\n<p>Furious form: psychomotor agitation or hydrophobia (throat</p>\n<p>spasm and panic, triggered by attempt to drink or sight/</p>\n<p>sound/touch of water) and aerophobia (similar response to</p>\n<p>a draft of air)</p>\n<p>~</p>\n<p>Paralytic form (rarer): progressive ascending paralysis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>There is no cure. In case of suspected exposure, take</p>\n<p>all the appropriate steps to prevent the infection (see</p>\n<p>section1.2.1.3 on animal bites)</p>\n<p>\u0089</p>\n<p>Start as soon as the exposure happens or as soon as</p>\n<p>the patient comes for medical attention, regardless of</p>\n<p>whatever time has passed from the exposure</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Admit case</p>\n<p>\u0089</p>\n<p>Palliative and supportive care</p>\n<p>\u0089</p>\n<p>Observe strict hygienic precautions</p>\n<p>Avoid contact with patient\u2019s body fluids or secretions</p>\n<p>PPE (personal protective equipment)</p>\n<p>Caution: the patient may bite</p>\n<p>\u0089</p>\n<p>Counsel caregivers on rabies and consequences</p>\n<p>H</p>\n<p>139</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 206,
        "content": "2.3.6 VIRAL HAEMORRHAGIC FEVERS\n2.3.6.1 Ebola  and  Marburg\t\n         ICD11 CODE: A99 \nEbola and Marburg are severe zoonotic multisystem febrile diseases \ncaused by RNA viruses. They are notifiable diseases.\nCause\n \n~\nEbola and Marburg viruses. Transmission to humans hap\u00ad\npens through contact with meat or body fluids of an in\u00ad\nfected animal. The disease can then be transmitted from \nhuman to human through body fluids (including semen for \nmonths after recovery) and it is highly contagious.\nRisk factors\n \n~\nCommunities around game parks\n \n~\nCommunities in endemic area\n \n~\nCultural practices like burial rituals\n \n~\nPoor infection control practices\n \n~\nHistory of exposure to infected people in the last 2 to 21 \ndays i.e sexual partner, breastfeeding mothers\n \n~\nRecent contact with infected animals e.g. monkeys, bats, \ninfected game meat\n \n~\nClinical features\n \n~\nEarly signs (non specific): sudden fever, weakness, headache, \nmuscle pains, loss of appetite, conjunctivitis\n \n~\nLate signs:\n \n~\nDiarrhoea (watery or bloody), vomiting\n \n~\nMucosal and gastrointestinal bleeding: chest pain, respiratory \ndistress, circulatory shock\n \n~\nCNS dysfunction, confusion, seizures\n140\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>2.3.6 VIRAL HAEMORRHAGIC FEVERS</h3>\n<p>2.3.6.1 Ebola  and  Marburg</p>\n<h3>ICD11 CODE: A99</h3>\n<p>Ebola and Marburg are severe zoonotic multisystem febrile diseases</p>\n<p>caused by RNA viruses. They are notifiable diseases.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Ebola and Marburg viruses. Transmission to humans hap\u00ad</p>\n<p>pens through contact with meat or body fluids of an in\u00ad</p>\n<p>fected animal. The disease can then be transmitted from</p>\n<p>human to human through body fluids (including semen for</p>\n<p>months after recovery) and it is highly contagious.</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Communities around game parks</p>\n<p>~</p>\n<p>Communities in endemic area</p>\n<p>~</p>\n<p>Cultural practices like burial rituals</p>\n<p>~</p>\n<p>Poor infection control practices</p>\n<p>~</p>\n<p>History of exposure to infected people in the last 2 to 21</p>\n<p>days i.e sexual partner, breastfeeding mothers</p>\n<p>~</p>\n<p>Recent contact with infected animals e.g. monkeys, bats,</p>\n<p>infected game meat</p>\n<p>~</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Early signs (non specific): sudden fever, weakness, headache,</p>\n<p>muscle pains, loss of appetite, conjunctivitis</p>\n<p>~</p>\n<p>Late signs:</p>\n<p>~</p>\n<p>Diarrhoea (watery or bloody), vomiting</p>\n<p>~</p>\n<p>Mucosal and gastrointestinal bleeding: chest pain, respiratory</p>\n<p>distress, circulatory shock</p>\n<p>~</p>\n<p>CNS dysfunction, confusion, seizures</p>\n<p>140</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 207,
        "content": "~\nMiscarriage in pregnancy\n \n~\nElevated AST and ALT, kidney injury, electrolyte abnormalities\nNote: Haemorrhage is seen in less than a third of Ebola patients\nDifferential diagnosis\n \n~\nMalaria, rickettsiosis, meningitis\n \n~\nShigellosis, typhoid\n \n~\nAnthrax, sepsis, viral hepatitis, dengue, leptospirosis\nInvestigations\n \n~\nSend blood sample to a   referral laboratory for specific test\u00ad\ning (taking off blood samples from patients suspected of viral \nhemorrhagic fever should be done by a trained healthcare \nworker in appropriate PPE.\n \n~\nNotify district surveillance focal person\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer all patients to regional referral hospital for man\u00ad\nagement in an appropriate setting\n\t\n\u0089\nNotify the district health team\nRR\nSafety of health workers: maximum level of infection control \nprocedures\nHealth workers should maintain a high level of suspicion for Ebola \nvirus disease. While standard precautions should be followed for all \npatients at all times, implementation of transmission-based precau\u00ad\ntions for cases suspected or confirmed to have Ebola or Marburg virus \ndiseases is essential. This includes: screening for rapid identification \nand isolation of cases,\n141\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Miscarriage in pregnancy</p>\n<p>~</p>\n<p>Elevated AST and ALT, kidney injury, electrolyte abnormalities</p>\n<p>Note: Haemorrhage is seen in less than a third of Ebola patients</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Malaria, rickettsiosis, meningitis</p>\n<p>~</p>\n<p>Shigellosis, typhoid</p>\n<p>~</p>\n<p>Anthrax, sepsis, viral hepatitis, dengue, leptospirosis</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Send blood sample to a   referral laboratory for specific test\u00ad</p>\n<p>ing (taking off blood samples from patients suspected of viral</p>\n<p>hemorrhagic fever should be done by a trained healthcare</p>\n<p>worker in appropriate PPE.</p>\n<p>~</p>\n<p>Notify district surveillance focal person</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer all patients to regional referral hospital for man\u00ad</p>\n<p>agement in an appropriate setting</p>\n<p>\u0089</p>\n<p>Notify the district health team</p>\n<p>RR</p>\n<p>Safety of health workers: maximum level of infection control</p>\n<p>procedures</p>\n<p>Health workers should maintain a high level of suspicion for Ebola</p>\n<p>virus disease. While standard precautions should be followed for all</p>\n<p>patients at all times, implementation of transmission-based precau\u00ad</p>\n<p>tions for cases suspected or confirmed to have Ebola or Marburg virus</p>\n<p>diseases is essential. This includes: screening for rapid identification</p>\n<p>and isolation of cases,</p>\n<p>141</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 208,
        "content": "\u0083\nHand hygiene according to the WHO 5 moments safe injection \npractices use of personal protective equipment (e.g. eye protec\u00ad\ntion, mask (medical or respirator), gloves, gown or coverall, head \ncovering, apron and gum (rubber) boots. \n\t\u0083\nHandling and disposing of all waste related to the care of an Ebola \npatients as infectious\n\t\u0083\nSafe handling and disinfection of linens (or disposal if not possible) \nand thorough cleaning and disinfection of the environment and \nmedical equipment. \n\t\u0083\nDisinfectants (e.g. chlorine mixture of 0.5% for surfaces) used \nmust be prepared and used ensuring adequate concentration and \ncontact time on surfaces.\n\t\u0083\nHandling of the deceased is particularly high risk and should be \nkept to a minimum. Strict adherence to IPC measures including \nhand hygiene, use of personal protective equipment (e.g. eye \nprotection, mask (medical or respirator), gloves, gown or coverall, \nhead covering, apron and gum (rubber) boots is required.  \nPatient care\nRefer to the MoH recent guidelines for management of viral hemor\u00ad\nrrhagic fevers\n\t\u0083\nOptimised   Supportive treatment of signs and symptoms\n\t\u0083\nReplace and monitor fluids and electrolytes for patients with \ndiarrhoea or vomiting\nTriage and contact tracing\n\t\u0083\nTriage patient (those who had contact with a patient or not)\n\t\u0083\nContact identification, contact listing and contact follow up\nDead Body handling\n\t\u0083\nAvoid washing or touching the dead f There should be no gathering \nat funerals. The dead should be buried promptly by a designated \nburial team\nPrevention\n \n~\nHealth education of the population (e.g. avoid eating wild ani\u00ad\nmals)\n142\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>\u0083</p>\n<p>Hand hygiene according to the WHO 5 moments safe injection</p>\n<p>practices use of personal protective equipment (e.g. eye protec\u00ad</p>\n<p>tion, mask (medical or respirator), gloves, gown or coverall, head</p>\n<p>covering, apron and gum (rubber) boots.</p>\n<p>\u0083</p>\n<p>Handling and disposing of all waste related to the care of an Ebola</p>\n<p>patients as infectious</p>\n<p>\u0083</p>\n<p>Safe handling and disinfection of linens (or disposal if not possible)</p>\n<p>and thorough cleaning and disinfection of the environment and</p>\n<p>medical equipment.</p>\n<p>\u0083</p>\n<p>Disinfectants (e.g. chlorine mixture of 0.5% for surfaces) used</p>\n<p>must be prepared and used ensuring adequate concentration and</p>\n<p>contact time on surfaces.</p>\n<p>\u0083</p>\n<p>Handling of the deceased is particularly high risk and should be</p>\n<p>kept to a minimum. Strict adherence to IPC measures including</p>\n<p>hand hygiene, use of personal protective equipment (e.g. eye</p>\n<p>protection, mask (medical or respirator), gloves, gown or coverall,</p>\n<p>head covering, apron and gum (rubber) boots is required.</p>\n<p>Patient care</p>\n<p>Refer to the MoH recent guidelines for management of viral hemor\u00ad</p>\n<p>rrhagic fevers</p>\n<p>\u0083</p>\n<p>Optimised   Supportive treatment of signs and symptoms</p>\n<p>\u0083</p>\n<p>Replace and monitor fluids and electrolytes for patients with</p>\n<p>diarrhoea or vomiting</p>\n<p>Triage and contact tracing</p>\n<p>\u0083</p>\n<p>Triage patient (those who had contact with a patient or not)</p>\n<p>\u0083</p>\n<p>Contact identification, contact listing and contact follow up</p>\n<p>Dead Body handling</p>\n<p>\u0083</p>\n<p>Avoid washing or touching the dead f There should be no gathering</p>\n<p>at funerals. The dead should be buried promptly by a designated</p>\n<p>burial team</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Health education of the population (e.g. avoid eating wild ani\u00ad</p>\n<p>mals)</p>\n<p>142</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 209,
        "content": "~\nEffective outbreak communication and having haemorrhagic \nviral fever protocols in place\n \n~\nAppropriate safety gear for patients/health workers in suspect \ncases\n \n~\nModification of burial practices\n \n~\nUse of condoms\n2.3.6.2 Yellow Fever                                 \nAn acute viral haemorrhagic fever transmitted through the bite of infected \nfemale Aedes aegypti mosquito. Incubation period is 3 to 6 days. It is \na notifiable disease.\ncause\n \n~\nYellow fever RNA virus\nRisk factors\n \n~\nResidents in endemic area\n \n~\nHunters and settlers around game parks\nClinical features\nFirst stage:\n \n~\nFever, chills, headache, backache, muscle pain, prostration, \nnausea, vomiting, fatigue. Usually resolves within 3-4 days.\nSecond stage:\n \n~\nAbout 15% of cases enter into a second or toxic stage af\u00ad\nter 1-2 day of remission: high fever, prostration, signs and \nsymptoms of hepatic failure, renal failure and bleeding ( \njaundice, nose bleeding, gingival bleeding, vomiting blood, \nblood in stool)\n \n~\nAbout half of these patients die within 7-10 days\nDifferential diagnosis\n \n~\nHepatitis E, liver failure\n \n~\nMalaria, Ebola\n143\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Effective outbreak communication and having haemorrhagic</p>\n<p>viral fever protocols in place</p>\n<p>~</p>\n<p>Appropriate safety gear for patients/health workers in suspect</p>\n<p>cases</p>\n<p>~</p>\n<p>Modification of burial practices</p>\n<p>~</p>\n<p>Use of condoms</p>\n<p>2.3.6.2 Yellow Fever</p>\n<p>An acute viral haemorrhagic fever transmitted through the bite of infected</p>\n<p>female Aedes aegypti mosquito. Incubation period is 3 to 6 days. It is</p>\n<p>a notifiable disease.</p>\n<p>cause</p>\n<p>~</p>\n<p>Yellow fever RNA virus</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Residents in endemic area</p>\n<p>~</p>\n<p>Hunters and settlers around game parks</p>\n<p>Clinical features</p>\n<p>First stage:</p>\n<p>~</p>\n<p>Fever, chills, headache, backache, muscle pain, prostration,</p>\n<p>nausea, vomiting, fatigue. Usually resolves within 3-4 days.</p>\n<p>Second stage:</p>\n<p>~</p>\n<p>About 15% of cases enter into a second or toxic stage af\u00ad</p>\n<p>ter 1-2 day of remission: high fever, prostration, signs and</p>\n<p>symptoms of hepatic failure, renal failure and bleeding (</p>\n<p>jaundice, nose bleeding, gingival bleeding, vomiting blood,</p>\n<p>blood in stool)</p>\n<p>~</p>\n<p>About half of these patients die within 7-10 days</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Hepatitis E, liver failure</p>\n<p>~</p>\n<p>Malaria, Ebola</p>\n<p>143</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 210,
        "content": "investigations\n \n~\nPCR in early phases\n \n~\nELISA in the late stageIt is a notifiable disease.\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer all cases to regional referral hospital\n\t\n\u0089\nNotify the district health team\n\t\n\u0089\nThere is no specific antiviral drug treatment\n\t\n\u0089\nSupportive treatment is recommended:\n \n- Rehydration\n \n- Management of liver and kidney failure\n \n- Antipyretics for fever\n \n- Blood transfusion\n\t\n\u0089\nTreat associated bacterial infections with antibiotics\nRR\nNote\n \n\u0083 Individuals who have recovered from a yellow fever infection \ndevelop life-long immunity\nPrevention\n \n~\nVaccination (see chapter 18)\n \n~\nElimination of mosquito breeding sites\n \n~\nEpidemic preparedness i.e prompt detection and treatment\n2.3.7 COVID-19 Disease\nCoronavirus disease (COVID-19) results from infection with the Severe \nAcute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is a novel \nvirus in humans, knowledge of which and its pathogenesis still evolving. \nAdditionally, the population-level immunity is uncertain. Complications \nof the severe infection can result in death.\n144\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>investigations</p>\n<p>~</p>\n<p>PCR in early phases</p>\n<p>~</p>\n<p>ELISA in the late stageIt is a notifiable disease.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer all cases to regional referral hospital</p>\n<p>\u0089</p>\n<p>Notify the district health team</p>\n<p>\u0089</p>\n<p>There is no specific antiviral drug treatment</p>\n<p>\u0089</p>\n<p>Supportive treatment is recommended:</p>\n<p>- Rehydration</p>\n<p>- Management of liver and kidney failure</p>\n<p>- Antipyretics for fever</p>\n<p>- Blood transfusion</p>\n<p>\u0089</p>\n<p>Treat associated bacterial infections with antibiotics</p>\n<p>RR</p>\n<p>Note</p>\n<p>\u0083 Individuals who have recovered from a yellow fever infection</p>\n<p>develop life-long immunity</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Vaccination (see chapter 18)</p>\n<p>~</p>\n<p>Elimination of mosquito breeding sites</p>\n<p>~</p>\n<p>Epidemic preparedness i.e prompt detection and treatment</p>\n<p>2.3.7 COVID-19 Disease</p>\n<p>Coronavirus disease (COVID-19) results from infection with the Severe</p>\n<p>Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is a novel</p>\n<p>virus in humans, knowledge of which and its pathogenesis still evolving.</p>\n<p>Additionally, the population-level immunity is uncertain. Complications</p>\n<p>of the severe infection can result in death.</p>\n<p>144</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 211,
        "content": "Clinical features \nEarly symptoms are non-specific and may include: \n \n\u0081\nfever, cough, myalgia, fatigue, shortness of breath, sore throat,  \nheadache, flu-like symptoms, diarrhea, nausea, respiratory \ndistress, features of renal failure, pericarditis, and Disseminated \nIntravascular Coagulation (DIC).\nIt is important to know that many individuals with COVID-19 are asymp\u00ad\ntomatic. It is therefore paramount that all health workers observe strict \ninfection prevention and control (IPC) measures at all times.\nClassification of COVID 19 disease\nDisease Stage\nHallmark\nFeatures\nMild Disease\nNo Respira\u00ad\ntory Distress\nNormal Vital Signs\nModerate\nDisease\nNon-Severe\nPneumonia\nCrackles in chest but Normal \nSPO2,\n mild respiratory distress (Resp \nRate <30)\nSevere\nDisease\nOxygen\nDe saturation\nSevere Respiratory distress \n(Resp Rate >30) & SPO2 <90%,\nCritical\nOrgan Dys\u00ad\nfunction\n\u2022    CNS: Altered Mental State\n\u2022    CVS: Hypotension & Shock\n\u2022    Kidney: Decreased Urine \nOutput, Raised Creatinine\n\u2022    Liver: Elevated liver enzymes\n\u2022    Coagulation: Raised PT & \nINR, Thrombocytopenia\n\u2022 Endocrine: Hypoglycemia\nGroups at High Risk of Developing Severe Disease or Complications\n \n\u0083 Age > 65 year\n \n\u0083  Obesity\n \n\u0083 Lung diseases (e.g. asthma, TB, COPD)\n \n\u0083 Hypertension\n145\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>Early symptoms are non-specific and may include:</p>\n<p>\u0081</p>\n<p>fever, cough, myalgia, fatigue, shortness of breath, sore throat,</p>\n<p>headache, flu-like symptoms, diarrhea, nausea, respiratory</p>\n<p>distress, features of renal failure, pericarditis, and Disseminated</p>\n<p>Intravascular Coagulation (DIC).</p>\n<p>It is important to know that many individuals with COVID-19 are asymp\u00ad</p>\n<p>tomatic. It is therefore paramount that all health workers observe strict</p>\n<p>infection prevention and control (IPC) measures at all times.</p>\n<p>Classification of COVID 19 disease</p>\n<p>Disease Stage</p>\n<p>Hallmark</p>\n<p>Features</p>\n<p>Mild Disease</p>\n<p>No Respira\u00ad</p>\n<p>tory Distress</p>\n<p>Normal Vital Signs</p>\n<p>Moderate</p>\n<p>Disease</p>\n<p>Non-Severe</p>\n<p>Pneumonia</p>\n<p>Crackles in chest but Normal</p>\n<h3>SPO2,</h3>\n<p>mild respiratory distress (Resp</p>\n<p>Rate <30)</p>\n<p>Severe</p>\n<p>Disease</p>\n<p>Oxygen</p>\n<p>De saturation</p>\n<p>Severe Respiratory distress</p>\n<p>(Resp Rate >30) & SPO2 <90%,</p>\n<p>Critical</p>\n<p>Organ Dys\u00ad</p>\n<p>function</p>\n<li>CNS: Altered Mental State</li>\n<li>CVS: Hypotension & Shock</li>\n<li>Kidney: Decreased Urine</li>\n<p>Output, Raised Creatinine</p>\n<li>Liver: Elevated liver enzymes</li>\n<li>Coagulation: Raised PT &</li>\n<p>INR, Thrombocytopenia</p>\n<li>Endocrine: Hypoglycemia</li>\n<p>Groups at High Risk of Developing Severe Disease or Complications</p>\n<p>\u0083 Age > 65 year</p>\n<p>\u0083  Obesity</p>\n<p>\u0083 Lung diseases (e.g. asthma, TB, COPD)</p>\n<p>\u0083 Hypertension</p>\n<p>145</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 212,
        "content": "Patient enters health facility grounds\nLow risk for \nCOVID-19: \nDirect to facil\u00ad\nity for further \nmanagement \nStabilize\n(Oxygen if availa\u00ad\nble) in a designat\u00ad\ned isolation area\nNo\nNo\nYes\nYes\nNo \nto \nAll\nYes to at least 1\nProvide a medical mask to the \npatient and direct to designated \ntriage area\nADMIT FOR ISOLATION\nAdmit for isolation to hos\u00ad\npital, another designated \nfacility (if available), or \nhome (case-by-case basis: \nmust have ability for close \nfollow up)\nADMIT FOR ISOLATION\nPrioritize for admission to \nisolation ward with critical \ncare capability\nDanger signs\nHigh risk for development of \nserious illness or complications\nCollect samples for:\n\u2022 COVID-19\n\u2022 Malaria RDT (if fever)\nDanger signs\n+ Rapid breathing:\n    >30 per min (adult/child>5y)\n    >40 per min (child 1-5y)\n    >50 per min (child<1y)\n+ Difficult breathing and/or \nchest indrawing\n+ Persistent high fever for 3 or \nmore days\n+ Disorientation, seizures or \nconvulsions\n+ Lethargy (excessive weakness, \ntiredness)\n+ Sunken eyes or other signs of \nsevere dehydration\n+ Inability to drink or eat\nWash or sanitize hands\nTake temperature (if infrared or \naxillary thermometer available)\nSUSPECT CASE\n1. Is the temperature T>37.5OC?\n2. Have had a fever?\n3. Do you have symptoms such as cough, \nshortness of breath, muscle aches, weakness, \nsore throat, or headache?\n146\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Patient enters health facility grounds</p>\n<p>Low risk for</p>\n<h3>COVID-19:</h3>\n<p>Direct to facil\u00ad</p>\n<p>ity for further</p>\n<p>management</p>\n<p>Stabilize</p>\n<p>(Oxygen if availa\u00ad</p>\n<p>ble) in a designat\u00ad</p>\n<p>ed isolation area</p>\n<p>No</p>\n<p>No</p>\n<p>Yes</p>\n<p>Yes</p>\n<p>No</p>\n<p>to</p>\n<p>All</p>\n<p>Yes to at least 1</p>\n<p>Provide a medical mask to the</p>\n<p>patient and direct to designated</p>\n<p>triage area</p>\n<h3>ADMIT FOR ISOLATION</h3>\n<p>Admit for isolation to hos\u00ad</p>\n<p>pital, another designated</p>\n<p>facility (if available), or</p>\n<p>home (case-by-case basis:</p>\n<p>must have ability for close</p>\n<p>follow up)</p>\n<h3>ADMIT FOR ISOLATION</h3>\n<p>Prioritize for admission to</p>\n<p>isolation ward with critical</p>\n<p>care capability</p>\n<p>Danger signs</p>\n<p>High risk for development of</p>\n<p>serious illness or complications</p>\n<p>Collect samples for:</p>\n<h3>\u2022 COVID-19</h3>\n<li>Malaria RDT (if fever)</li>\n<p>Danger signs</p>\n<p>+ Rapid breathing:</p>\n<p>>30 per min (adult/child>5y)</p>\n<p>>40 per min (child 1-5y)</p>\n<p>>50 per min (child<1y)</p>\n<p>+ Difficult breathing and/or</p>\n<p>chest indrawing</p>\n<p>+ Persistent high fever for 3 or</p>\n<p>more days</p>\n<p>+ Disorientation, seizures or</p>\n<p>convulsions</p>\n<p>+ Lethargy (excessive weakness,</p>\n<p>tiredness)</p>\n<p>+ Sunken eyes or other signs of</p>\n<p>severe dehydration</p>\n<p>+ Inability to drink or eat</p>\n<p>Wash or sanitize hands</p>\n<p>Take temperature (if infrared or</p>\n<p>axillary thermometer available)</p>\n<h3>SUSPECT CASE</h3>\n<li>. Is the temperature T>37.5OC?</li>\n<p>2. Have had a fever?</p>\n<p>3. Do you have symptoms such as cough,</p>\n<p>shortness of breath, muscle aches, weakness,</p>\n<p>sore throat, or headache?</p>\n<p>146</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 213,
        "content": "\u0083 Heart conditions such as history of heart attack or stroke\n \n\u0083 Diabetes\n \n\u0083 Cancer patients whether or not on chemotherapy\n \n\u0083 Advanced liver disease\n \n\u0083 Person living with HIV\n \n\u0083 Kidney disease\n \n\u0083 Severe Acute Malnutrition\n \n\u0083 Sickle cell disease\n \n\u0083 COVID 19 unvaccinated\n \n\u0083 Pregnancy and recent pregnancy\n \n\u0083 Hypertension\nDifferential diagnoses\n \n\u0081\nMalaria and other febrile illnesses.\n \n\u0081\ncommon respiratory, infectious, cardiovascular, oncological, \nand gastrointestinal diseases.\nInvestigations\n147\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>\u0083 Heart conditions such as history of heart attack or stroke</p>\n<p>\u0083 Diabetes</p>\n<p>\u0083 Cancer patients whether or not on chemotherapy</p>\n<p>\u0083 Advanced liver disease</p>\n<p>\u0083 Person living with HIV</p>\n<p>\u0083 Kidney disease</p>\n<p>\u0083 Severe Acute Malnutrition</p>\n<p>\u0083 Sickle cell disease</p>\n<p>\u0083 COVID 19 unvaccinated</p>\n<p>\u0083 Pregnancy and recent pregnancy</p>\n<p>\u0083 Hypertension</p>\n<p>Differential diagnoses</p>\n<p>\u0081</p>\n<p>Malaria and other febrile illnesses.</p>\n<p>\u0081</p>\n<p>common respiratory, infectious, cardiovascular, oncological,</p>\n<p>and gastrointestinal diseases.</p>\n<p>Investigations</p>\n<p>147</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 214,
        "content": "Management\n \n\u0081\nPerform SARS-CoV-2 Rapid Diagnostic Test (RDT)\n \n\u0081\nCarry out nasopharyngeal swabs for RT-RNA test\nCOVID-19 screening and triage process at health facilities\n \n~\nCOVID-19 triage aims to flag suspected patients at first \npoint of contact within the healthcare system in order to\n \n~\nprotect other patients and staff from potential exposure. \n \n~\nidentify and rapidly address severe symptoms, rule out oth\u00ad\ner conditions with features similar to COVID-19, ascertain \nif suspect case definition is met \n \n~\nAll suspected patients should be directed to a designated \narea away from other patients and handled as per standard \ncovid protection guidelines\n \n~\nRefer to the Comprehensive COVID-19 Case Management \nGuidelines for details.\nTREATMENT\nLOC\nSafety of health workers and caregivers: maximum \nlevel of infection control procedures\nHC2\nStrict isolation of suspect cases\nUse of adequate protective gear\nMinimize invasive intervention\nSafe handling of linen\nAppropriate use of chlorine mixtures\nProper disposal of health care waste\nEducate the patient and care givers on appropriate infection \ncontrol measures\nNo Hospitalization (mild to moderate diseases)\nHC2\n148\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Management</p>\n<p>\u0081</p>\n<p>Perform SARS-CoV-2 Rapid Diagnostic Test (RDT)</p>\n<p>\u0081</p>\n<p>Carry out nasopharyngeal swabs for RT-RNA test</p>\n<p>COVID-19 screening and triage process at health facilities</p>\n<p>~</p>\n<p>COVID-19 triage aims to flag suspected patients at first</p>\n<p>point of contact within the healthcare system in order to</p>\n<p>~</p>\n<p>protect other patients and staff from potential exposure.</p>\n<p>~</p>\n<p>identify and rapidly address severe symptoms, rule out oth\u00ad</p>\n<p>er conditions with features similar to COVID-19, ascertain</p>\n<p>if suspect case definition is met</p>\n<p>~</p>\n<p>All suspected patients should be directed to a designated</p>\n<p>area away from other patients and handled as per standard</p>\n<p>covid protection guidelines</p>\n<p>~</p>\n<p>Refer to the Comprehensive COVID-19 Case Management</p>\n<p>Guidelines for details.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Safety of health workers and caregivers: maximum</p>\n<p>level of infection control procedures</p>\n<h3>HC2</h3>\n<p>Strict isolation of suspect cases</p>\n<p>Use of adequate protective gear</p>\n<p>Minimize invasive intervention</p>\n<p>Safe handling of linen</p>\n<p>Appropriate use of chlorine mixtures</p>\n<p>Proper disposal of health care waste</p>\n<p>Educate the patient and care givers on appropriate infection</p>\n<p>control measures</p>\n<p>No Hospitalization (mild to moderate diseases)</p>\n<h3>HC2</h3>\n<p>148</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 215,
        "content": "TREATMENT\nLOC\nAll patients with no risk of developing severe COVID-19 \ndiseases.\n\t\n\u0089\nsymptom management, supportive care, and monitoring \n(at home, or in the community).\u00a0\n\t\n\u0089\nControl fevers with paracetamol, multivitamins and \nadvise on balanced diet\nAdults and Children >40kg at increased risk of de\u00ad\nveloping severe COVID-19 diseases. Refer to current \nCovid-19 treatment guidelines.\n\t\n\u0089\nnimatrelvir/ritonavir 300/100mg orally (PO) twice \ndaily for 5 days (must be initiated within 5 days of \nsymptom onset)\n\t\n\u0089\nOR remdesivir IV infusion Once daily for 3 days with a \nloading dose 200mg on Day 1 and 100mg on subse\u00ad\nquent days. (initiated within 7 days of symptom onset)\n\t\n\u0089\nOR molnupiravir 800mg orally (PO) twice daily for 5 \ndays\u00a0ONLY\u00a0when ritonavir-boosted nirmatrelvir or \nremdesivir cannot be used; treatment should be initiated \nas soon as possible and within 5 days of symptom \nonset (contraindicated in pregnant or breastfeeding \nwomen and children)\nIf the patient requires hospitalization (Severe to Critical \ndisease)\nRR\n \n~\nOxygen therapy\u00a0\u00a0\n \n~\nAnd Corticosteroids\u00a0\u00a0\n \n~\nAnd Venous thromboembolism prophylaxis\u00a0\u00a0\n \n~\nAnd Interleukin-6 receptor blocker (tocilizumab \nor sarilumab)\u00a0\u00a0\nor JAK Inhibitor (baricitinib)\u00a0\nFor details refer to the Comprehensive COVID-19 case \nManagement Guidelines\n149\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>All patients with no risk of developing severe COVID-19</p>\n<p>diseases.</p>\n<p>\u0089</p>\n<p>symptom management, supportive care, and monitoring</p>\n<p>(at home, or in the community).</p>\n<p>\u0089</p>\n<p>Control fevers with paracetamol, multivitamins and</p>\n<p>advise on balanced diet</p>\n<p>Adults and Children >40kg at increased risk of de\u00ad</p>\n<p>veloping severe COVID-19 diseases. Refer to current</p>\n<p>Covid-19 treatment guidelines.</p>\n<p>\u0089</p>\n<p>nimatrelvir/ritonavir 300/100mg orally (PO) twice</p>\n<p>daily for 5 days (must be initiated within 5 days of</p>\n<p>symptom onset)</p>\n<p>\u0089</p>\n<p>OR remdesivir IV infusion Once daily for 3 days with a</p>\n<p>loading dose 200mg on Day 1 and 100mg on subse\u00ad</p>\n<p>quent days. (initiated within 7 days of symptom onset)</p>\n<p>\u0089</p>\n<p>OR molnupiravir 800mg orally (PO) twice daily for 5</p>\n<p>days\u00a0ONLY\u00a0when ritonavir-boosted nirmatrelvir or</p>\n<p>remdesivir cannot be used; treatment should be initiated</p>\n<p>as soon as possible and within 5 days of symptom</p>\n<p>onset (contraindicated in pregnant or breastfeeding</p>\n<p>women and children)</p>\n<p>If the patient requires hospitalization (Severe to Critical</p>\n<p>disease)</p>\n<p>RR</p>\n<p>~</p>\n<p>Oxygen therapy</p>\n<p>~</p>\n<p>And Corticosteroids</p>\n<p>~</p>\n<p>And Venous thromboembolism prophylaxis</p>\n<p>~</p>\n<p>And Interleukin-6 receptor blocker (tocilizumab</p>\n<p>or sarilumab)</p>\n<p>or JAK Inhibitor (baricitinib)</p>\n<p>For details refer to the Comprehensive COVID-19 case</p>\n<p>Management Guidelines</p>\n<p>149</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 216,
        "content": "Prevention\n \n~\nVaccination (Refer to chapter 18: Immunization)\n \n~\nEpidemic preparedness i.e. prompt detection and treatment\n \n~\nInfection Prevention and control measures including Mask \nwearing, social distancing, regular handwashing, avoid \nshaking hands etc.\n2.4 HELMINTHES PARASITES\n2.4.1 Intestinal Worms                              ICD10 CODE: B83.9\nIntestinal worms enter the human body through ingestion of the worm eggs \nin food or water via dirty hands or through injured skin when walking barefoot. \nExamples include:\nTYPE OF INFESTA\u00ad\nTION\nFEATURES\nAscariasis: Ascaris lum\u00ad\nbricoides (round worm). \nInfests small intestines\n \n\u0083 Oro-faecal transmission\n \n\u0083 Usually few or no symptoms\n \n\u0083 Persistent dry irritating cough\n \n\u0083 Patient may pass out live worms \nthrough the anus, nose, or mouth\n \n\u0083 Pneumonitis- Loeffler\u2019s syndrome\n \n\u0083 Heavy infestations may cause \nnutritional deficiencies\n \n\u0083 Worms may also cause obstruction \nto bowel, bile duct, pancreatic duct, \nor appendix\nEnterobiasis: (thread\u00ad\nworm) Enterobias ver\u00ad\nmicularis\n \n\u0083 Transmitted by faecal-oral route\n \n\u0083 Mainly affects children\n \n\u0083 Intense itching at the anal orifice\n150\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Vaccination (Refer to chapter 18: Immunization)</p>\n<p>~</p>\n<p>Epidemic preparedness i.e. prompt detection and treatment</p>\n<p>~</p>\n<p>Infection Prevention and control measures including Mask</p>\n<p>wearing, social distancing, regular handwashing, avoid</p>\n<p>shaking hands etc.</p>\n<h3>2.4 HELMINTHES PARASITES</h3>\n<p>2.4.1 Intestinal Worms                              ICD10 CODE: B83.9</p>\n<p>Intestinal worms enter the human body through ingestion of the worm eggs</p>\n<p>in food or water via dirty hands or through injured skin when walking barefoot.</p>\n<p>Examples include:</p>\n<h3>TYPE OF INFESTA\u00ad</h3>\n<h3>TION</h3>\n<h3>FEATURES</h3>\n<p>Ascariasis: Ascaris lum\u00ad</p>\n<p>bricoides (round worm).</p>\n<p>Infests small intestines</p>\n<p>\u0083 Oro-faecal transmission</p>\n<p>\u0083 Usually few or no symptoms</p>\n<p>\u0083 Persistent dry irritating cough</p>\n<p>\u0083 Patient may pass out live worms</p>\n<p>through the anus, nose, or mouth</p>\n<p>\u0083 Pneumonitis- Loeffler\u2019s syndrome</p>\n<p>\u0083 Heavy infestations may cause</p>\n<p>nutritional deficiencies</p>\n<p>\u0083 Worms may also cause obstruction</p>\n<p>to bowel, bile duct, pancreatic duct,</p>\n<p>or appendix</p>\n<p>Enterobiasis: (thread\u00ad</p>\n<p>worm) Enterobias ver\u00ad</p>\n<p>micularis</p>\n<p>\u0083 Transmitted by faecal-oral route</p>\n<p>\u0083 Mainly affects children</p>\n<p>\u0083 Intense itching at the anal orifice</p>\n<p>150</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 217,
        "content": "TYPE OF INFESTA\u00ad\nTION\nFEATURES\nHook worm Caused by \nNecator americanus and \nAncylostoma duodenale\n \n\u0083 Chronic parasitic infestation of the \nintestines\n \n\u0083 Transmitted by penetration of the \nskin by larvae from the soil\n \n\u0083 Dermatitis (ground itch)\n \n\u0083 Cough and inflammation of the \ntrachea (tracheitis) common during \nlarvae migration phase\n \n\u0083 Iron-deficiency anaemia\n \n\u0083 Reduced blood proteins in heavy \ninfestations\n \n\u0083 Reduced blood proteins in heavy \ninfestations\nStrongyloidiasis \nStrongyloides stercoralis\n \n\u0083 Skin symptoms: Itchy eruption at \nthe site of larval penetration\n \n\u0083 Intestinal symptoms e.g. abdominal \npain, diarrhoea, and weight loss\n \n\u0083 Lung symptoms due to larvae in \nthe lungs, e.g. cough and wheezing\n \n\u0083 Specific organ involvement, e.g. \nmeningoencephalitis\n \n\u0083 Hyperinfection syndrome: \nOccurs when immunity against \nauto-infection fails, e.g. in \nimmunosuppressed cases\nWhip worm\nInfests human caecum \nand upper colon\n \n\u0083 May be symptomless\n \n\u0083 Heavy infestation may cause \nbloody, mucoid stools, and \ndiarrhoea\n \n\u0083 Complications include anaemia \nand prolapse of the rectum\n151\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TYPE OF INFESTA\u00ad</h3>\n<h3>TION</h3>\n<h3>FEATURES</h3>\n<p>Hook worm Caused by</p>\n<p>Necator americanus and</p>\n<p>Ancylostoma duodenale</p>\n<p>\u0083 Chronic parasitic infestation of the</p>\n<p>intestines</p>\n<p>\u0083 Transmitted by penetration of the</p>\n<p>skin by larvae from the soil</p>\n<p>\u0083 Dermatitis (ground itch)</p>\n<p>\u0083 Cough and inflammation of the</p>\n<p>trachea (tracheitis) common during</p>\n<p>larvae migration phase</p>\n<p>\u0083 Iron-deficiency anaemia</p>\n<p>\u0083 Reduced blood proteins in heavy</p>\n<p>infestations</p>\n<p>\u0083 Reduced blood proteins in heavy</p>\n<p>infestations</p>\n<p>Strongyloidiasis</p>\n<p>Strongyloides stercoralis</p>\n<p>\u0083 Skin symptoms: Itchy eruption at</p>\n<p>the site of larval penetration</p>\n<p>\u0083 Intestinal symptoms e.g. abdominal</p>\n<p>pain, diarrhoea, and weight loss</p>\n<p>\u0083 Lung symptoms due to larvae in</p>\n<p>the lungs, e.g. cough and wheezing</p>\n<p>\u0083 Specific organ involvement, e.g.</p>\n<p>meningoencephalitis</p>\n<p>\u0083 Hyperinfection syndrome:</p>\n<p>Occurs when immunity against</p>\n<p>auto-infection fails, e.g. in</p>\n<p>immunosuppressed cases</p>\n<p>Whip worm</p>\n<p>Infests human caecum</p>\n<p>and upper colon</p>\n<p>\u0083 May be symptomless</p>\n<p>\u0083 Heavy infestation may cause</p>\n<p>bloody, mucoid stools, and</p>\n<p>diarrhoea</p>\n<p>\u0083 Complications include anaemia</p>\n<p>and prolapse of the rectum</p>\n<p>151</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 218,
        "content": "Differential diagnosis\n \n\u0081\nOther causes of cough, diarrhea\n \n\u0081\nOther causes of intestinal obstruction and nutritional deficiency\n \n\u0081\nLoeffler\u2019s Syndrome\n \n\u0081\nOther causes of iron-deficiency anaemia\nInvestigations\n \n\u0081\nStool examination for ova, live worms or segments\n \n\u0081\nFull blood count\nManagement\nTREATMENT\nLOC\nRoundworm, threadworm, hookworm, whipworm\n\t\n\u0089\nAlbendazole 400 mg single dose\nChild <2 years: 200 mg\n\t\n\u0089\nMebendazole 500 mg single dose\nChild <2 years: 250 mg\nStrongyloides\n\t\n\u0089\nAlbendazole 400 mg every 12 hours for 3 days\n\t\n\u0089\nOr Ivermectin 150 micrograms/kg single dose\nHC1\nHC3\nPrevention\n \n~\nProper faecal disposal\n \n~\nPersonal and food hygiene\n \n~\nRegular deworming of children every 3-6 months\n \n~\nAvoid walking barefoot\n152\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Other causes of cough, diarrhea</p>\n<p>\u0081</p>\n<p>Other causes of intestinal obstruction and nutritional deficiency</p>\n<p>\u0081</p>\n<p>Loeffler\u2019s Syndrome</p>\n<p>\u0081</p>\n<p>Other causes of iron-deficiency anaemia</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Stool examination for ova, live worms or segments</p>\n<p>\u0081</p>\n<p>Full blood count</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Roundworm, threadworm, hookworm, whipworm</p>\n<p>\u0089</p>\n<p>Albendazole 400 mg single dose</p>\n<p>Child <2 years: 200 mg</p>\n<p>\u0089</p>\n<p>Mebendazole 500 mg single dose</p>\n<p>Child <2 years: 250 mg</p>\n<p>Strongyloides</p>\n<p>\u0089</p>\n<p>Albendazole 400 mg every 12 hours for 3 days</p>\n<p>\u0089</p>\n<p>Or Ivermectin 150 micrograms/kg single dose</p>\n<h3>HC1</h3>\n<h3>HC3</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Proper faecal disposal</p>\n<p>~</p>\n<p>Personal and food hygiene</p>\n<p>~</p>\n<p>Regular deworming of children every 3-6 months</p>\n<p>~</p>\n<p>Avoid walking barefoot</p>\n<p>152</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 219,
        "content": "2.4.1.1 Taeniasis (Tapeworm)\t\n                         ICD10 CODE: B68 \nAn infestation caused by Taenia (Taenia saginata (from undercooked \nbeef ), Taenia solium (from undercooked pork), Diphyllobothrium latum \n(from undercooked fish).\nCause\n \n~\nAdult Tapeworms: intestinal infestation, by ingestion of \nundercooked meat containing cysticerci (larval form of the \nworm)\n \n~\nLarvae forms (cysticercosis): by ingestion of food/water \ncontaminated by eggs of T.solium. The eggs hatch in the \nintestine, the embryos invade the intestinal walls and dis\u00ad\nseminate in the brain, muscles or other organs\nClinical features\nT. saginata, T.solium (adult tapeworm)\n \n\u0083 Usually asymptomatic, but live segments may be passed\n \n\u0083 Epigastric pain, diarrhoea, sometimes weight loss\nCysticercosis\n \n\u0083 Muscular: muscle pains, weakness, fever, subcutaneous nodules\n \n\u0083 Neurocysticercosis: headache, convulsions, coma, meningo-\nencephalitis, epilepsy\n \n\u0083 Ocular: exophthalmia, strabismus, iritis\nD. latum\n \n\u0083 Usually asymptomatic, but mild symptoms may occur\n \n\u0083 Megaloblastic anaemia may occur as a rare complication\nDifferential diagnosis\n \n\u0083 Other intestinal worm infestations\n153\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>2.4.1.1 Taeniasis (Tapeworm)</p>\n<h3>ICD10 CODE: B68</h3>\n<p>An infestation caused by Taenia (Taenia saginata (from undercooked</p>\n<p>beef ), Taenia solium (from undercooked pork), Diphyllobothrium latum</p>\n<p>(from undercooked fish).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Adult Tapeworms: intestinal infestation, by ingestion of</p>\n<p>undercooked meat containing cysticerci (larval form of the</p>\n<p>worm)</p>\n<p>~</p>\n<p>Larvae forms (cysticercosis): by ingestion of food/water</p>\n<p>contaminated by eggs of T.solium. The eggs hatch in the</p>\n<p>intestine, the embryos invade the intestinal walls and dis\u00ad</p>\n<p>seminate in the brain, muscles or other organs</p>\n<p>Clinical features</p>\n<p>T. saginata, T.solium (adult tapeworm)</p>\n<p>\u0083 Usually asymptomatic, but live segments may be passed</p>\n<p>\u0083 Epigastric pain, diarrhoea, sometimes weight loss</p>\n<p>Cysticercosis</p>\n<p>\u0083 Muscular: muscle pains, weakness, fever, subcutaneous nodules</p>\n<p>\u0083 Neurocysticercosis: headache, convulsions, coma, meningo-</p>\n<p>encephalitis, epilepsy</p>\n<p>\u0083 Ocular: exophthalmia, strabismus, iritis</p>\n<p>D. latum</p>\n<p>\u0083 Usually asymptomatic, but mild symptoms may occur</p>\n<p>\u0083 Megaloblastic anaemia may occur as a rare complication</p>\n<p>Differential diagnosis</p>\n<p>\u0083 Other intestinal worm infestations</p>\n<p>153</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 220,
        "content": "Investigations\n \n\u0081\nLaboratory: eggs, worm segments in stool or collected from \nperianal skin (scotch tape method)\n \n\u0081\nCysticercosis: hypereosinophilia in blood and CSF\nManagement\nTREATMENT\nLOC\nTapeworm\n\t\n\u0089\nPraziquantel 5-10 mg/kg single dose Alternative\n\t\n\u0089\nNiclosamide\nAdult and child > 6 years: 2 g single dose\nChild < 2 years: 500 mg\nChild 2-6 years: 1 g\n \n- Give Bisacodyl 2 hours after the dose\nHC3 \nHC4\nCysticercosis\n\t\n\u0089\nRefer to specialised facilties\n\t\n\u0089\nAntiparasitic treatment without diagnosis of location \nby CT or MRI scan can worsen symptoms, and even \nthreaten the life of the patient.\n\t\n\u0089\nNeurosurgical treatment required\nRR\nPrevention\n \n\u0083 Cook all fish and meat thorougly\n \n\u0083 Proper hygiene: handwashing, nail cutting, proper disposal of \nfaeces\n2.4.2 Echinococcosis (Hydatid  Disease)    ICD 10 CODE: B67\nTissue infestation by larvae of Echinococcus granulosus. It is transmitted \nthrough direct contact with dogs or by ingesting water and food con\u00ad\ntaminated by dog faeces.\n154\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Laboratory: eggs, worm segments in stool or collected from</p>\n<p>perianal skin (scotch tape method)</p>\n<p>\u0081</p>\n<p>Cysticercosis: hypereosinophilia in blood and CSF</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Tapeworm</p>\n<p>\u0089</p>\n<p>Praziquantel 5-10 mg/kg single dose Alternative</p>\n<p>\u0089</p>\n<p>Niclosamide</p>\n<p>Adult and child > 6 years: 2 g single dose</p>\n<p>Child < 2 years: 500 mg</p>\n<p>Child 2-6 years: 1 g</p>\n<p>- Give Bisacodyl 2 hours after the dose</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Cysticercosis</p>\n<p>\u0089</p>\n<p>Refer to specialised facilties</p>\n<p>\u0089</p>\n<p>Antiparasitic treatment without diagnosis of location</p>\n<p>by CT or MRI scan can worsen symptoms, and even</p>\n<p>threaten the life of the patient.</p>\n<p>\u0089</p>\n<p>Neurosurgical treatment required</p>\n<p>RR</p>\n<p>Prevention</p>\n<p>\u0083 Cook all fish and meat thorougly</p>\n<p>\u0083 Proper hygiene: handwashing, nail cutting, proper disposal of</p>\n<p>faeces</p>\n<p>2.4.2 Echinococcosis (Hydatid  Disease)    ICD 10 CODE: B67</p>\n<p>Tissue infestation by larvae of Echinococcus granulosus. It is transmitted</p>\n<p>through direct contact with dogs or by ingesting water and food con\u00ad</p>\n<p>taminated by dog faeces.</p>\n<p>154</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 221,
        "content": "Clinical features\n \n~\nCough, chest pain\n \n~\nLiver cysts may be asymptomatic but may also give abdom\u00ad\ninal pain, palpable mass and jaundice (if the bile duct is \nobstructed)\n \n~\nRupture of cysts may cause fever, urticaria, or anaphylactic \nreaction\n \n~\nPulmonary cysts can be seen on chest X-ray and may rup\u00ad\nture to cause cough, chest pain and haemoptysis\nDifferential diagnosis\n \n~\nAmoebiasis, hepatoma\n \n~\nOther causes of liver mass and obstructive jaundice\n \n~\nTuberculosis (TB)\nInvestigations\n \n\u0081\nSkin test\n \n\u0081\nUltrasound\n \n\u0081\nChest X-ray: for pulmonary cysts\n \n\u0081\nSerological tests\n \n\u0081\nNeedle aspiration under Ultrasound Sonography (US) or CT-\nscan guidance\nManagement\nTREATMENT\nLOC\nRefer for specialist management\n\t\n\u0089\nSurgical excision\n\t\n\u0089\nPrior to surgery or in cases not amenable to surgery\n\t\n\u0089\nAlbendazole\n \n- Child >2 years and adults: 7.5 mg/kg every 12 \nhours for 3-6 months\nRR\n155\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Cough, chest pain</p>\n<p>~</p>\n<p>Liver cysts may be asymptomatic but may also give abdom\u00ad</p>\n<p>inal pain, palpable mass and jaundice (if the bile duct is</p>\n<p>obstructed)</p>\n<p>~</p>\n<p>Rupture of cysts may cause fever, urticaria, or anaphylactic</p>\n<p>reaction</p>\n<p>~</p>\n<p>Pulmonary cysts can be seen on chest X-ray and may rup\u00ad</p>\n<p>ture to cause cough, chest pain and haemoptysis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Amoebiasis, hepatoma</p>\n<p>~</p>\n<p>Other causes of liver mass and obstructive jaundice</p>\n<p>~</p>\n<p>Tuberculosis (TB)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Skin test</p>\n<p>\u0081</p>\n<p>Ultrasound</p>\n<p>\u0081</p>\n<p>Chest X-ray: for pulmonary cysts</p>\n<p>\u0081</p>\n<p>Serological tests</p>\n<p>\u0081</p>\n<p>Needle aspiration under Ultrasound Sonography (US) or CT-</p>\n<p>scan guidance</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Refer for specialist management</p>\n<p>\u0089</p>\n<p>Surgical excision</p>\n<p>\u0089</p>\n<p>Prior to surgery or in cases not amenable to surgery</p>\n<p>\u0089</p>\n<p>Albendazole</p>\n<p>- Child >2 years and adults: 7.5 mg/kg every 12</p>\n<p>hours for 3-6 months</p>\n<p>RR</p>\n<p>155</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 222,
        "content": "Prevention\n \n~\nFood hygiene\n \n~\nHealth education\n \n~\nProper disposal of faeces\n2.4.3 Dracunculiasis (Guinea Worm)          ICD10 CODE: B72\nAn infestation of the subcutaneous and deeper tissue with the guinea \nworm. It is a notifiable disease.\nCause\n \n~\nDracunculus medinensis, transmitted to man by drinking \nwater containing cyclops (waterflea or small crustacean) in\u00ad\nfected with larvae of the guinea worm\nClinical features\n \n~\nAdult worm may be felt beneath the skin\n \n~\nLocal redness, tenderness, and blister (usually on the foot) \nat the point where the worm comes out of the skin to dis\u00ad\ncharge larvae into the water\n \n~\nThere may be fever, nausea, vomiting, diarrhoea, dys\u00ad\npnoea, generalised urticaria, and eosinophilia before ves\u00ad\nicle formation\n \n~\nComplications may include cellulitis, septicaemia, and \naseptic or pyogenic arthritis; tetanus may also occur\nDifferential diagnosis\n \n~\nCellulitis from any other causes\n \n~\nMyositis\nInvestigations\n\u00be\t\nRecognition of the adult worm under the skin\n156\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Food hygiene</p>\n<p>~</p>\n<p>Health education</p>\n<p>~</p>\n<p>Proper disposal of faeces</p>\n<p>2.4.3 Dracunculiasis (Guinea Worm)          ICD10 CODE: B72</p>\n<p>An infestation of the subcutaneous and deeper tissue with the guinea</p>\n<p>worm. It is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Dracunculus medinensis, transmitted to man by drinking</p>\n<p>water containing cyclops (waterflea or small crustacean) in\u00ad</p>\n<p>fected with larvae of the guinea worm</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Adult worm may be felt beneath the skin</p>\n<p>~</p>\n<p>Local redness, tenderness, and blister (usually on the foot)</p>\n<p>at the point where the worm comes out of the skin to dis\u00ad</p>\n<p>charge larvae into the water</p>\n<p>~</p>\n<p>There may be fever, nausea, vomiting, diarrhoea, dys\u00ad</p>\n<p>pnoea, generalised urticaria, and eosinophilia before ves\u00ad</p>\n<p>icle formation</p>\n<p>~</p>\n<p>Complications may include cellulitis, septicaemia, and</p>\n<p>aseptic or pyogenic arthritis; tetanus may also occur</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cellulitis from any other causes</p>\n<p>~</p>\n<p>Myositis</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Recognition of the adult worm under the skin</p>\n<p>156</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 223,
        "content": "\u00be\t\nX-ray may show calcified worms\nManagement\nTREATMENT\nLOC\nThere is no known drug treatment for guinea worm\nAll patients:\n\t\n\u0089\nTo facilitate removal of the worm, slowly and carefully \nroll it onto a small stick over a period of days\n\t\n\u0089\nDress the wound occlusively to prevent the worm passing \nova into the water\n\t\n\u0089\nGive analgesics for as long as necessary\nIf there is ulceration and secondary infection give:\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours for 5 days\nChild: 250 mg every 8 hours for 5 days\n\t\n\u0089\nOr cloxacillin 500 mg every 6 hours for 5 days\nHC2\nPrevention\n \n\u0083 Filter or boil drinking water\n \n\u0083 Infected persons should avoid all contact with sources of drinking \nwater\n2.4.4 Lymphatic Filariasis\t\n       ICD10 CODE: B74.9\nLymphatic filariasis is a disease caused by tissue dwelling nematode, \ntransmitted by the Aedes aegypti mosquito bite\nCauses\n \n~\nWuchereria bancrofti\nClinical features\nAcute\n \n~\nAdenolymphangitis- inflammation of lymph nodes and lym\u00ad\nphatic vessels (lower limbs, external genitalia, testis, epidid\u00ad\nymis or breast)\n157\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>\u00be</p>\n<p>X-ray may show calcified worms</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>There is no known drug treatment for guinea worm</p>\n<p>All patients:</p>\n<p>\u0089</p>\n<p>To facilitate removal of the worm, slowly and carefully</p>\n<p>roll it onto a small stick over a period of days</p>\n<p>\u0089</p>\n<p>Dress the wound occlusively to prevent the worm passing</p>\n<p>ova into the water</p>\n<p>\u0089</p>\n<p>Give analgesics for as long as necessary</p>\n<p>If there is ulceration and secondary infection give:</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours for 5 days</p>\n<p>Child: 250 mg every 8 hours for 5 days</p>\n<p>\u0089</p>\n<p>Or cloxacillin 500 mg every 6 hours for 5 days</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>\u0083 Filter or boil drinking water</p>\n<p>\u0083 Infected persons should avoid all contact with sources of drinking</p>\n<p>water</p>\n<p>2.4.4 Lymphatic Filariasis</p>\n<h3>ICD10 CODE: B74.9</h3>\n<p>Lymphatic filariasis is a disease caused by tissue dwelling nematode,</p>\n<p>transmitted by the Aedes aegypti mosquito bite</p>\n<p>Causes</p>\n<p>~</p>\n<p>Wuchereria bancrofti</p>\n<p>Clinical features</p>\n<p>Acute</p>\n<p>~</p>\n<p>Adenolymphangitis- inflammation of lymph nodes and lym\u00ad</p>\n<p>phatic vessels (lower limbs, external genitalia, testis, epidid\u00ad</p>\n<p>ymis or breast)</p>\n<p>157</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 224,
        "content": "~\nWith or without general signs like fever, nausea, vomiting\n \n~\nAttacks resolve spontaneously in one week and recur regu\u00ad\nlarly in patients with chronic disease\nChronic\n \n~\nLymphoedema (chronic hard swelling) of limbs or external \ngenitalia, hydrocele, chronic epididymo orchitis, initially re\u00ad\nversible but progressively chronic and severe (elephantiasis)\nDifferential diagnosis\n \n\u0083 DVT\n \n\u0083 Cellulitis\nInvestigations\n \n\u0081\nBlood slide for Microfilaria (collect specimen between 9 pm \nand 3 am)\nManagement\nTREATMENT\nLOC\nCase treatment\n\t\n\u0089\nSupportive treatment during an attack (bed rest, limb \nelevation, analgesics, cooling, hydration)\nHC2\n\t\n\u0089\nDoxycycline 100 mg twice a day for 4-6 weeks (do not \nadminister antiparasitic treatment during an acute attack)\nChronic case\n\t\n\u0089\nSupportive treatment: bandage during the day, elevation of \naffected limb at rest, analgesics and surgery (hydrocelectomy)\nLarge scale treatment/preventive chemotherapy Give annually \nto all population at risk, for 4-6 years \n\t\n\u0089\nIvermectin 150-200 mcg/kg plus albendazole 400 mg \nsingle dose\n158\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>With or without general signs like fever, nausea, vomiting</p>\n<p>~</p>\n<p>Attacks resolve spontaneously in one week and recur regu\u00ad</p>\n<p>larly in patients with chronic disease</p>\n<p>Chronic</p>\n<p>~</p>\n<p>Lymphoedema (chronic hard swelling) of limbs or external</p>\n<p>genitalia, hydrocele, chronic epididymo orchitis, initially re\u00ad</p>\n<p>versible but progressively chronic and severe (elephantiasis)</p>\n<p>Differential diagnosis</p>\n<h3>\u0083 DVT</h3>\n<p>\u0083 Cellulitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood slide for Microfilaria (collect specimen between 9 pm</p>\n<p>and 3 am)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Case treatment</p>\n<p>\u0089</p>\n<p>Supportive treatment during an attack (bed rest, limb</p>\n<p>elevation, analgesics, cooling, hydration)</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Doxycycline 100 mg twice a day for 4-6 weeks (do not</p>\n<p>administer antiparasitic treatment during an acute attack)</p>\n<p>Chronic case</p>\n<p>\u0089</p>\n<p>Supportive treatment: bandage during the day, elevation of</p>\n<p>affected limb at rest, analgesics and surgery (hydrocelectomy)</p>\n<p>Large scale treatment/preventive chemotherapy Give annually</p>\n<p>to all population at risk, for 4-6 years</p>\n<p>\u0089</p>\n<p>Ivermectin 150-200 mcg/kg plus albendazole 400 mg</p>\n<p>single dose</p>\n<p>158</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 225,
        "content": "TREATMENT\nLOC\nNot effective against adult worms\nIvermectin is not recommended in children < 5 years, pregnancy, \nor breast-feeding mothers\nNo food or alcohol to be taken within 2 hours of a dose\nPrevention\n \n\u0083 Use of treated mosquito nets\n \n\u0083 Patient Education\n2.4.5 Onchocerciasis (River Blindness)    ICD10 CODE: B73.0\nChronic filarial disease present in areas around rivers\nCause\n \n~\nOnchocerca volvulus, transmitted by a bite from a female \nblack fly (Simulium damnosum, S. naevi and S. oodi, etc), \nwhich breeds in rapidly flowing and well-aerated water\nClinical features\nSkin\n \n~\nOnchocercoma: painless smooth subcutaneous nodules \ncontaining adult worms, adherent to underlying tissues,u\u00ad\nsually on body prominences like iliac crests, pelvic girdle, \nribs, skull\n \n~\nAcute papular onchodermatitis: Intense pruritic rash, oede\u00ad\nma (due to microfilariae)\n \n~\nLate chronic skin lesions: dry thickened peeling skin (lizard \nskin), atrophy, patchy depigmentation Eye\n \n~\nInflammation of the eye (of the cornea, uvea, retina) lead\u00ad\ning to visual disturbances and blindness\nDifferential diagnosis\n \n~\nOther causes of skin depigmentation (e.g. yaws, burns, vit\u00ad\niligo)\n \n~\nOther causes of fibrous nodules in the skin (e.g. neurofi\u00ad\nbromatosis)\n159\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Not effective against adult worms</p>\n<p>Ivermectin is not recommended in children < 5 years, pregnancy,</p>\n<p>or breast-feeding mothers</p>\n<p>No food or alcohol to be taken within 2 hours of a dose</p>\n<p>Prevention</p>\n<p>\u0083 Use of treated mosquito nets</p>\n<p>\u0083 Patient Education</p>\n<p>2.4.5 Onchocerciasis (River Blindness)    ICD10 CODE: B73.0</p>\n<p>Chronic filarial disease present in areas around rivers</p>\n<p>Cause</p>\n<p>~</p>\n<p>Onchocerca volvulus, transmitted by a bite from a female</p>\n<p>black fly (Simulium damnosum, S. naevi and S. oodi, etc),</p>\n<p>which breeds in rapidly flowing and well-aerated water</p>\n<p>Clinical features</p>\n<p>Skin</p>\n<p>~</p>\n<p>Onchocercoma: painless smooth subcutaneous nodules</p>\n<p>containing adult worms, adherent to underlying tissues,u\u00ad</p>\n<p>sually on body prominences like iliac crests, pelvic girdle,</p>\n<p>ribs, skull</p>\n<p>~</p>\n<p>Acute papular onchodermatitis: Intense pruritic rash, oede\u00ad</p>\n<p>ma (due to microfilariae)</p>\n<p>~</p>\n<p>Late chronic skin lesions: dry thickened peeling skin (lizard</p>\n<p>skin), atrophy, patchy depigmentation Eye</p>\n<p>~</p>\n<p>Inflammation of the eye (of the cornea, uvea, retina) lead\u00ad</p>\n<p>ing to visual disturbances and blindness</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of skin depigmentation (e.g. yaws, burns, vit\u00ad</p>\n<p>iligo)</p>\n<p>~</p>\n<p>Other causes of fibrous nodules in the skin (e.g. neurofi\u00ad</p>\n<p>bromatosis)</p>\n<p>159</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 226,
        "content": "Management\nTREATMENT\nLOC\nCase treatment (adult worms)\n\t\n\u0089\nDoxycycline 100 mg twice a day for 6 weeks followed by\n\t\n\u0089\nIvermectin 150 micrograms/kg single dose\nMass treatment\n\t\n\u0089\nIvermectin 150 micrograms/kg once yearly for 10-14 \nyears (see also dose table below)\n \n\u0083 Not recommended in children <5 years, pregnancy, \nor breast-feeding mothers\n \n\u0083 No food or alcohol should be taken within 2 hours of \na dose Ivermectin dose based on height\nHC3\nInvestigations\n \n\u0081\nSkin snip after sunshine to show microfilariae in fresh preparations\n \n\u0081\nHigh eosinophils at the blood slide/CBC\n \n\u0081\nExcision of nodules for adult worms\n \n\u0081\nSlit-lamp eye examination for microfilariae in the anterior \nchamber of eye\nHEIGHT (CM)\nDOSE\n>158\n12 mg\n141\u2013158\n9 mg\n120\u2013140\n6 mg\n90\u2013119\n3 mg\n< 90\nDo not use\n160\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Case treatment (adult worms)</p>\n<p>\u0089</p>\n<p>Doxycycline 100 mg twice a day for 6 weeks followed by</p>\n<p>\u0089</p>\n<p>Ivermectin 150 micrograms/kg single dose</p>\n<p>Mass treatment</p>\n<p>\u0089</p>\n<p>Ivermectin 150 micrograms/kg once yearly for 10-14</p>\n<p>years (see also dose table below)</p>\n<p>\u0083 Not recommended in children <5 years, pregnancy,</p>\n<p>or breast-feeding mothers</p>\n<p>\u0083 No food or alcohol should be taken within 2 hours of</p>\n<p>a dose Ivermectin dose based on height</p>\n<h3>HC3</h3>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Skin snip after sunshine to show microfilariae in fresh preparations</p>\n<p>\u0081</p>\n<p>High eosinophils at the blood slide/CBC</p>\n<p>\u0081</p>\n<p>Excision of nodules for adult worms</p>\n<p>\u0081</p>\n<p>Slit-lamp eye examination for microfilariae in the anterior</p>\n<p>chamber of eye</p>\n<h3>HEIGHT (CM)</h3>\n<h3>DOSE</h3>\n<p>>158</p>\n<p>12 mg</p>\n<p>141\u2013158</p>\n<p>9 mg</p>\n<p>120\u2013140</p>\n<p>6 mg</p>\n<p>90\u2013119</p>\n<p>3 mg</p>\n<p>< 90</p>\n<p>Do not use</p>\n<p>160</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 227,
        "content": "Prevention\n \n\u0083 Vector control\n \n\u0083 Mass chemoprophylaxis\n2.4.6 Schistosomiasis (Bilharziasis)       ICD10 CODE: B65.1\nDisease of the large intestine and the urinary tract due to infestation by \na Schistosoma blood fluke.\nCauses\n \n~\nThe larvae form (cercariae) of Schistosoma penetrate the \nskin from contaminated water and they migrate to different \nparts of the body, usually the urinary tract (Schistosoma \nhaematobium) and the gut (S. mansoni)\nClinical features\nS. haematobium (urinary tract)\n \n~\nPainless blood stained urine at the end of urination - termi\u00ad\nnal haematuria\n \n~\nFrequent and painful micturition\n \n~\nIn females: low abdominal pain and abnormal vaginal dis\u00ad\ncharge\n \n~\nLate complications: fibrosis of bladder and ureters with in\u00ad\ncreased UTI risks, hydronephrosis, infertility\nS. mansoni (gastrointestinal tract)\n \n~\nAbdominal pain, frequent stool with blood-stained mucus, \nhepatomegaly\n \n~\nChronic cases: hepatic fibrosis with cirrhosis and portal hy\u00ad\npertension, haematemesis/melena are frequent\nDifferential diagnosis\n \n~\nCancer of the bladder (S. haematobium)\n \n~\nDysentery (S. mansoni)\n161\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>\u0083 Vector control</p>\n<p>\u0083 Mass chemoprophylaxis</p>\n<p>2.4.6 Schistosomiasis (Bilharziasis)       ICD10 CODE: B65.1</p>\n<p>Disease of the large intestine and the urinary tract due to infestation by</p>\n<p>a Schistosoma blood fluke.</p>\n<p>Causes</p>\n<p>~</p>\n<p>The larvae form (cercariae) of Schistosoma penetrate the</p>\n<p>skin from contaminated water and they migrate to different</p>\n<p>parts of the body, usually the urinary tract (Schistosoma</p>\n<p>haematobium) and the gut (S. mansoni)</p>\n<p>Clinical features</p>\n<p>S. haematobium (urinary tract)</p>\n<p>~</p>\n<p>Painless blood stained urine at the end of urination - termi\u00ad</p>\n<p>nal haematuria</p>\n<p>~</p>\n<p>Frequent and painful micturition</p>\n<p>~</p>\n<p>In females: low abdominal pain and abnormal vaginal dis\u00ad</p>\n<p>charge</p>\n<p>~</p>\n<p>Late complications: fibrosis of bladder and ureters with in\u00ad</p>\n<p>creased UTI risks, hydronephrosis, infertility</p>\n<p>S. mansoni (gastrointestinal tract)</p>\n<p>~</p>\n<p>Abdominal pain, frequent stool with blood-stained mucus,</p>\n<p>hepatomegaly</p>\n<p>~</p>\n<p>Chronic cases: hepatic fibrosis with cirrhosis and portal hy\u00ad</p>\n<p>pertension, haematemesis/melena are frequent</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cancer of the bladder (S. haematobium)</p>\n<p>~</p>\n<p>Dysentery (S. mansoni)</p>\n<p>161</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 228,
        "content": "Investigations\n \n\u0081\nHistory of staying in an endemic area (exposure to water bodies)\n \n\u0081\nUrine examination (for S. haematobium ova)\n \n\u0081\nStool examination (for S. mansoni ova)\n \n\u0081\nRectal snip (for S. mansoni)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nPraziquantel 40 mg/kg single dose\n\t\n\u0089\nRefer patient if they develop obstruction or bleeding\nHC4\nPrevention\n \n~\nAvoid urinating or defecating in or near water\n \n~\nAvoid washing or stepping in contaminated water\n \n~\nEffective treatment of cases\n \n~\nClear bushes around landing sites\n2.5 PROTOZOAL PARASITES\n2.5.1 Leishmaniasis                               ICD10 CODE: B55\nA chronic systemic infectious disease transmitted by the bite of a sand fly.\nCause\n \n~\nFlagellated protozoa Leishmania species\nClinical features\nVisceral Leishmaniasis (Kala-azar)\n \n~\nChronic disease characterized by fever, hepatosplenomeg\u00ad\naly, lymphadenopathy, anaemia, leucopenia, progressive \nemaciation and weakness\n \n~\nFever of gradual onset, irregular, with 2 daily peaks and \nalternating periods of apyrexia\n162\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>History of staying in an endemic area (exposure to water bodies)</p>\n<p>\u0081</p>\n<p>Urine examination (for S. haematobium ova)</p>\n<p>\u0081</p>\n<p>Stool examination (for S. mansoni ova)</p>\n<p>\u0081</p>\n<p>Rectal snip (for S. mansoni)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Praziquantel 40 mg/kg single dose</p>\n<p>\u0089</p>\n<p>Refer patient if they develop obstruction or bleeding</p>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid urinating or defecating in or near water</p>\n<p>~</p>\n<p>Avoid washing or stepping in contaminated water</p>\n<p>~</p>\n<p>Effective treatment of cases</p>\n<p>~</p>\n<p>Clear bushes around landing sites</p>\n<h3>2.5 PROTOZOAL PARASITES</h3>\n<p>2.5.1 Leishmaniasis                               ICD10 CODE: B55</p>\n<p>A chronic systemic infectious disease transmitted by the bite of a sand fly.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Flagellated protozoa Leishmania species</p>\n<p>Clinical features</p>\n<p>Visceral Leishmaniasis (Kala-azar)</p>\n<p>~</p>\n<p>Chronic disease characterized by fever, hepatosplenomeg\u00ad</p>\n<p>aly, lymphadenopathy, anaemia, leucopenia, progressive</p>\n<p>emaciation and weakness</p>\n<p>~</p>\n<p>Fever of gradual onset, irregular, with 2 daily peaks and</p>\n<p>alternating periods of apyrexia</p>\n<p>162</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 229,
        "content": "~\nThe disease progresses over several months and is fatalif \nnot treated\n \n~\nAfter recovery from Kala-azar, skin (cutaneous) leishmani\u00ad\nasis may develop\nCutaneous and Mucosal Leishmaniasis (Oriental sore)\n \n~\nStarts as papule, enlarges to become an indolent ulcer\n \n~\nSecondary bacterial infection is common\nDifferential diagnosis\n \n~\nOther causes of chronic fever, e.g. brucellosis\n \n~\n(For dermal leishmaniasis) Other causes of cutaneous le\u00ad\nsions, e.g. leprosy\nInvestigations\n\u00be\t\nStained smears from bone marrow, spleen, liver, lymph \nnodes, or blood to demonstrate Leishman Donovan bodies\n\u00be\t\nCulture of the above materials to isolate the parasites\n\u00be\t\nSerological tests, e.g. indirect fluorescent antibodies\n\u00be\t\nLeishmanin skin test (negative in Kala-azar)\nManagement\nRefer all cases to regional referral hospital\nTREATMENT\nLOC\nCutaneous Leishmaniasis (all patients)\n\t\n\u0089\nFrequently heals spontaneously but if severe or persistent, \ntreat as for Visceral Leishmaniasis below\nVisceral Leishmaniasis (Kala-azar): All patients\n\t\n\u0089\nCombination: Sodium stibogluconate 20 mg /kg per \nday IM or IV for 17 days\n\t\n\u0089\nPlus paromomycin 15 mg/kg [11 mg base] per day IM \nfor 17 days\nRR\n163\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>The disease progresses over several months and is fatalif</p>\n<p>not treated</p>\n<p>~</p>\n<p>After recovery from Kala-azar, skin (cutaneous) leishmani\u00ad</p>\n<p>asis may develop</p>\n<p>Cutaneous and Mucosal Leishmaniasis (Oriental sore)</p>\n<p>~</p>\n<p>Starts as papule, enlarges to become an indolent ulcer</p>\n<p>~</p>\n<p>Secondary bacterial infection is common</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of chronic fever, e.g. brucellosis</p>\n<p>~</p>\n<p>(For dermal leishmaniasis) Other causes of cutaneous le\u00ad</p>\n<p>sions, e.g. leprosy</p>\n<p>Investigations</p>\n<p>\u00be</p>\n<p>Stained smears from bone marrow, spleen, liver, lymph</p>\n<p>nodes, or blood to demonstrate Leishman Donovan bodies</p>\n<p>\u00be</p>\n<p>Culture of the above materials to isolate the parasites</p>\n<p>\u00be</p>\n<p>Serological tests, e.g. indirect fluorescent antibodies</p>\n<p>\u00be</p>\n<p>Leishmanin skin test (negative in Kala-azar)</p>\n<p>Management</p>\n<p>Refer all cases to regional referral hospital</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Cutaneous Leishmaniasis (all patients)</p>\n<p>\u0089</p>\n<p>Frequently heals spontaneously but if severe or persistent,</p>\n<p>treat as for Visceral Leishmaniasis below</p>\n<p>Visceral Leishmaniasis (Kala-azar): All patients</p>\n<p>\u0089</p>\n<p>Combination: Sodium stibogluconate 20 mg /kg per</p>\n<p>day IM or IV for 17 days</p>\n<p>\u0089</p>\n<p>Plus paromomycin 15 mg/kg [11 mg base] per day IM</p>\n<p>for 17 days</p>\n<p>RR</p>\n<p>163</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 230,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nPlus paromomycin 15 mg/kg [11 mg base] per day IM \nfor 17 days\nAlternative first line treatment is:\n\t\n\u0089\nSodium Stibogluconate 20 mg/kg per day for 30 days \n(in case paromomycin is contraindicated)\nIn relapse or pregnancy\n\t\n\u0089\nLiposomal amphotericin B (e.g. AmBisome) 3 mg/kg \nper day for 10 days\nIn HIV+ patients\n\t\n\u0089\nLiposomal amphotericin B 5 mg/kg per day for 8 days\nRR\nPost Kala-Azar Dermal Leishmaniasis (PKDL)\n\t\n\u0089\nRare in Uganda\n\t\n\u0089\nSodium Stibogluconate injection 20 mg/kg/day until \nclinical cure. Several weeks or even months of treatment \nare necessary\nRR\nNote\nContinue treatment until no parasites detected in 2 consec\u00ad\nutive splenic aspirates taken 14 days apart\nPatients who relapse after a 1st course of treatment with \nSodium stibogluconate should immediately be re- treated \nwith Ambisome 3 mg/kg/day for 10 days\nPrevention\n \n~\nCase detection and prompt treatment\n \n~\nResidual insecticide spraying\n \n~\nElimination of breeding places\n2.5.2 Malaria\t\nICD10 CODE: B50\nMalaria is an acute febrile illness caused by infection with Plasmodium \nparasites and is transmitted from person to person by an infected female \nanopheles mosquito.\n164\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Plus paromomycin 15 mg/kg [11 mg base] per day IM</p>\n<p>for 17 days</p>\n<p>Alternative first line treatment is:</p>\n<p>\u0089</p>\n<p>Sodium Stibogluconate 20 mg/kg per day for 30 days</p>\n<p>(in case paromomycin is contraindicated)</p>\n<p>In relapse or pregnancy</p>\n<p>\u0089</p>\n<p>Liposomal amphotericin B (e.g. AmBisome) 3 mg/kg</p>\n<p>per day for 10 days</p>\n<p>In HIV+ patients</p>\n<p>\u0089</p>\n<p>Liposomal amphotericin B 5 mg/kg per day for 8 days</p>\n<p>RR</p>\n<p>Post Kala-Azar Dermal Leishmaniasis (PKDL)</p>\n<p>\u0089</p>\n<p>Rare in Uganda</p>\n<p>\u0089</p>\n<p>Sodium Stibogluconate injection 20 mg/kg/day until</p>\n<p>clinical cure. Several weeks or even months of treatment</p>\n<p>are necessary</p>\n<p>RR</p>\n<p>Note</p>\n<p>Continue treatment until no parasites detected in 2 consec\u00ad</p>\n<p>utive splenic aspirates taken 14 days apart</p>\n<p>Patients who relapse after a 1st course of treatment with</p>\n<p>Sodium stibogluconate should immediately be re- treated</p>\n<p>with Ambisome 3 mg/kg/day for 10 days</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Case detection and prompt treatment</p>\n<p>~</p>\n<p>Residual insecticide spraying</p>\n<p>~</p>\n<p>Elimination of breeding places</p>\n<p>2.5.2 Malaria</p>\n<h3>ICD10 CODE: B50</h3>\n<p>Malaria is an acute febrile illness caused by infection with Plasmodium</p>\n<p>parasites and is transmitted from person to person by an infected female</p>\n<p>anopheles mosquito.</p>\n<p>164</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 231,
        "content": "Cause\n \n\u0083 There are five Plasmodium species of malaria parasites which \ninfect humans namely: P. falciparum, P. vivax, P. ovale, P. malariae \nand P. knowlesi.\n \n\u0083 P. falciparum is the most virulent and also the most common \nmalaria parasite in Uganda.\nClinical Features of Malaria\n \n\u0083 It may be asymptomatic, mild illness (uncomplicated malaria) or \nsevere illness (severe malaria)\n \n\u0083 Intermittent fever is the most characteristic symptom of malaria. \nThree classical stages can be distinguished in a typical attack of \nmalaria:\n \n\u0083 The cold stage: the patient feels cold and shivers\n \n\u0083 The hot stage: the patient feels hot\n \n\u0083 The sweating stage: associated with sweating and relief of \nsymptoms.\n \n\u0083 A complete physical examination has to be performed in any patient \npresenting with fever or history of fever.\n \n\u0083 When people are frequently exposed to malaria, they develop \npartial immunity. In such people, the classical stages of a malaria \nattack above may not be observed.\n \n\u0083 Also, in people who have had partial treatment with antimalarial \nmedicines, these classical stages may not be pronounced. \n2.5.2.1 Uncomplicated Malaria                     ICD 10 CODE: B50.9\nCommon symptoms/signs of uncomplicated malaria\n \n~\nFever: above 37.5\u00b0C (taken from the axilla ) or history of \nfever.\n \n~\nLoss of appetite, mild vomiting, diarrhoea\n \n~\nWeakness, headache, joint and muscle pain\n \n~\nMild anaemia (mild pallor of palms and mucous mem\u00ad\nbranes); occurs commonly in children.\n \n~\nMild dehydration\n165\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Cause</p>\n<p>\u0083 There are five Plasmodium species of malaria parasites which</p>\n<p>infect humans namely: P. falciparum, P. vivax, P. ovale, P. malariae</p>\n<p>and P. knowlesi.</p>\n<p>\u0083 P. falciparum is the most virulent and also the most common</p>\n<p>malaria parasite in Uganda.</p>\n<p>Clinical Features of Malaria</p>\n<p>\u0083 It may be asymptomatic, mild illness (uncomplicated malaria) or</p>\n<p>severe illness (severe malaria)</p>\n<p>\u0083 Intermittent fever is the most characteristic symptom of malaria.</p>\n<p>Three classical stages can be distinguished in a typical attack of</p>\n<p>malaria:</p>\n<p>\u0083 The cold stage: the patient feels cold and shivers</p>\n<p>\u0083 The hot stage: the patient feels hot</p>\n<p>\u0083 The sweating stage: associated with sweating and relief of</p>\n<p>symptoms.</p>\n<p>\u0083 A complete physical examination has to be performed in any patient</p>\n<p>presenting with fever or history of fever.</p>\n<p>\u0083 When people are frequently exposed to malaria, they develop</p>\n<p>partial immunity. In such people, the classical stages of a malaria</p>\n<p>attack above may not be observed.</p>\n<p>\u0083 Also, in people who have had partial treatment with antimalarial</p>\n<p>medicines, these classical stages may not be pronounced.</p>\n<p>2.5.2.1 Uncomplicated Malaria                     ICD 10 CODE: B50.9</p>\n<p>Common symptoms/signs of uncomplicated malaria</p>\n<p>~</p>\n<p>Fever: above 37.5\u00b0C (taken from the axilla ) or history of</p>\n<p>fever.</p>\n<p>~</p>\n<p>Loss of appetite, mild vomiting, diarrhoea</p>\n<p>~</p>\n<p>Weakness, headache, joint and muscle pain</p>\n<p>~</p>\n<p>Mild anaemia (mild pallor of palms and mucous mem\u00ad</p>\n<p>branes); occurs commonly in children.</p>\n<p>~</p>\n<p>Mild dehydration</p>\n<p>165</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 232,
        "content": "~\nEnlarged spleen (in acute malaria it may be minimally en\u00ad\nlarged, soft and mildly tender)\n2.5.2.2 Complicated/Severe Malaria    ICD10 CODE: B50.0, B50.8 \nIt is an immediate threat to life and is therefore a medical emergency. \nMalaria is regarded as severe if there are asexual forms of P. falciparum in \nblood plus one or more of the following complications in the table below.\nClassical definition of severe malaria\nCOMPLICATION\nCRITERION FOR DIAGNOSIS\nDefining manifestations\nCerebral malaria\nDeep coma (unable to localise a painful \nstimulus), Normal CSF, parasitaemia\nSevere anaemia\nHb <5g/dl with parasitaemia\n(<7 g/dl in pregnancy)\nRespiratory distress\nTachypnoea, nasal flaring and intercostal \nrecession in a patient with parasitaemia\nHypoglycaemia\nBlood glucose <40 mg/dl\n(2.2 mmol/L) with parasitaemia\nCirculatory collapse\nClinical shock (systolic pressure <50 \nmmHg for children and <80mmHg for \nadults, with cold peripheries, clammy \nskin) with parasitaemia\nRenal failure\nUrine output < 12 ml/kg in 24 hours \nand plasma creatinine > 3.0 mg/dl, with \nparasitaemia\nSpontaneous bleeding\nParasitaemia with unexplained sponta\u00ad\nneous bleeding (haematemesis, melaena, \nor prolonged bleeding from nose, gum or \nvenipuncture site\nRepeated convulsions\n2 or more convulsions in 24 hours, with \nparasitaemia\n166\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Enlarged spleen (in acute malaria it may be minimally en\u00ad</p>\n<p>larged, soft and mildly tender)</p>\n<p>2.5.2.2 Complicated/Severe Malaria    ICD10 CODE: B50.0, B50.8</p>\n<p>It is an immediate threat to life and is therefore a medical emergency.</p>\n<p>Malaria is regarded as severe if there are asexual forms of P. falciparum in</p>\n<p>blood plus one or more of the following complications in the table below.</p>\n<p>Classical definition of severe malaria</p>\n<h3>COMPLICATION</h3>\n<h3>CRITERION FOR DIAGNOSIS</h3>\n<p>Defining manifestations</p>\n<p>Cerebral malaria</p>\n<p>Deep coma (unable to localise a painful</p>\n<p>stimulus), Normal CSF, parasitaemia</p>\n<p>Severe anaemia</p>\n<p>Hb <5g/dl with parasitaemia</p>\n<p>(<7 g/dl in pregnancy)</p>\n<p>Respiratory distress</p>\n<p>Tachypnoea, nasal flaring and intercostal</p>\n<p>recession in a patient with parasitaemia</p>\n<p>Hypoglycaemia</p>\n<p>Blood glucose <40 mg/dl</p>\n<p>(2.2 mmol/L) with parasitaemia</p>\n<p>Circulatory collapse</p>\n<p>Clinical shock (systolic pressure <50</p>\n<p>mmHg for children and <80mmHg for</p>\n<p>adults, with cold peripheries, clammy</p>\n<p>skin) with parasitaemia</p>\n<p>Renal failure</p>\n<p>Urine output < 12 ml/kg in 24 hours</p>\n<p>and plasma creatinine > 3.0 mg/dl, with</p>\n<p>parasitaemia</p>\n<p>Spontaneous bleeding</p>\n<p>Parasitaemia with unexplained sponta\u00ad</p>\n<p>neous bleeding (haematemesis, melaena,</p>\n<p>or prolonged bleeding from nose, gum or</p>\n<p>venipuncture site</p>\n<p>Repeated convulsions</p>\n<p>2 or more convulsions in 24 hours, with</p>\n<p>parasitaemia</p>\n<p>166</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 233,
        "content": "COMPLICATION\nCRITERION FOR DIAGNOSIS\nAcidosis\nDeep (acidotic) breathing and plasma bi\u00ad\ncarbonate <15 mmol/L, with parasitaemia\nHaemoglobinuria\nParasitaemia, haemoglobin in urine (dark \ncoloured urine but no RBC\u2019s)\nPulmonary Oedema\nDeep breathing, fast breathing, laboured \nbreathing (nasal flaring, intercostal re\u00ad\ncession and chest in- drawing), Cheyne \nstokes breathing\nSupporting manifestations (some other signs in addition to above \ncomplications)\nImpaired conscious\u00ad\nness\nParasitaemia with depressed level of \nconsciousness but can localize a painful \nstimulus, or change of behavior, confu\u00ad\nsion, drowsiness\nJaundice\nParasitaemia with unexplained jaundice\nProstration\nUnable to sit, in a child normally able to \ndo so or unable to drink in one too young \nto sit\nSevere vomiting\nVomiting everything, not able to drink or \nbreastfeed\nSevere dehydration\nSunken eyes, coated tongue, lethargy, \ninability to drink\nHyperpyrexia\nTemperature >39.50 C, with\nparasitaemia\nHyper- parasitaemia\nParasite count > 250,000 /\u00b5l, > 10%\nThreatening abortion\nUterine contractions and vaginal bleeding\nDifferential diagnosis\n \n~\nRespiratory tract infection\n \n~\nUrinary tract infection\n167\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>COMPLICATION</h3>\n<h3>CRITERION FOR DIAGNOSIS</h3>\n<p>Acidosis</p>\n<p>Deep (acidotic) breathing and plasma bi\u00ad</p>\n<p>carbonate <15 mmol/L, with parasitaemia</p>\n<p>Haemoglobinuria</p>\n<p>Parasitaemia, haemoglobin in urine (dark</p>\n<p>coloured urine but no RBC\u2019s)</p>\n<p>Pulmonary Oedema</p>\n<p>Deep breathing, fast breathing, laboured</p>\n<p>breathing (nasal flaring, intercostal re\u00ad</p>\n<p>cession and chest in- drawing), Cheyne</p>\n<p>stokes breathing</p>\n<p>Supporting manifestations (some other signs in addition to above</p>\n<p>complications)</p>\n<p>Impaired conscious\u00ad</p>\n<p>ness</p>\n<p>Parasitaemia with depressed level of</p>\n<p>consciousness but can localize a painful</p>\n<p>stimulus, or change of behavior, confu\u00ad</p>\n<p>sion, drowsiness</p>\n<p>Jaundice</p>\n<p>Parasitaemia with unexplained jaundice</p>\n<p>Prostration</p>\n<p>Unable to sit, in a child normally able to</p>\n<p>do so or unable to drink in one too young</p>\n<p>to sit</p>\n<p>Severe vomiting</p>\n<p>Vomiting everything, not able to drink or</p>\n<p>breastfeed</p>\n<p>Severe dehydration</p>\n<p>Sunken eyes, coated tongue, lethargy,</p>\n<p>inability to drink</p>\n<p>Hyperpyrexia</p>\n<p>Temperature >39.50 C, with</p>\n<p>parasitaemia</p>\n<p>Hyper- parasitaemia</p>\n<p>Parasite count > 250,000 /\u00b5l, > 10%</p>\n<p>Threatening abortion</p>\n<p>Uterine contractions and vaginal bleeding</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Respiratory tract infection</p>\n<p>~</p>\n<p>Urinary tract infection</p>\n<p>167</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 234,
        "content": "~\nMeningitis, otitis media, tonsillitis\n \n~\nAbscess, skin sepsis\n \n~\nMeasles or other infections with rashes (before rash comes)\nInvestigations for Malaria\nNote: All suspected malaria patients MUST be tested by blood slide \nor RDT before they are treated. NOT all fevers are malaria.\n \n\u0081\nRDT or thick blood slide for diagnosis of malaria\n \n\u0081\nRandom blood sugar and Hb level if clinically indicated\n \n\u0081\nLumbar puncture: in case of convulsion/coma and negative \nmalaria test\n\u00be\t\nThin film for parasite identification\nNote on RDTs\n \n\u0083 RDTs (Rapid Diagnostic tests) detect malaria antigen (not whole \nparasites like the blood slide) and remain positive for 2 to 3 \nweeks after effective treatment\n \n\u0083 RDT do not become negative if the patient has already taken \nantimalarials\n \n\u0083 RDTs are reliable, quick and easily accessible tools for malaria \ndiagnosis.\nA blood slide for microscopy is specifically recommended over \nRDT in the following situations:\n\u00be\tPatients who have completed antimalarial treatment and \nsymptoms persist\n\u00be\tPatients who completed treatment but comes back within \n3 weeks\n\u00be\tRDT negative patients without any other evident cause of fe\u00ad\nver\n168\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Meningitis, otitis media, tonsillitis</p>\n<p>~</p>\n<p>Abscess, skin sepsis</p>\n<p>~</p>\n<p>Measles or other infections with rashes (before rash comes)</p>\n<p>Investigations for Malaria</p>\n<p>Note: All suspected malaria patients MUST be tested by blood slide</p>\n<p>or RDT before they are treated. NOT all fevers are malaria.</p>\n<p>\u0081</p>\n<p>RDT or thick blood slide for diagnosis of malaria</p>\n<p>\u0081</p>\n<p>Random blood sugar and Hb level if clinically indicated</p>\n<p>\u0081</p>\n<p>Lumbar puncture: in case of convulsion/coma and negative</p>\n<p>malaria test</p>\n<p>\u00be</p>\n<p>Thin film for parasite identification</p>\n<p>Note on RDTs</p>\n<p>\u0083 RDTs (Rapid Diagnostic tests) detect malaria antigen (not whole</p>\n<p>parasites like the blood slide) and remain positive for 2 to 3</p>\n<p>weeks after effective treatment</p>\n<p>\u0083 RDT do not become negative if the patient has already taken</p>\n<p>antimalarials</p>\n<p>\u0083 RDTs are reliable, quick and easily accessible tools for malaria</p>\n<p>diagnosis.</p>\n<p>A blood slide for microscopy is specifically recommended over</p>\n<p>RDT in the following situations:</p>\n<p>\u00be\tPatients who have completed antimalarial treatment and</p>\n<p>symptoms persist</p>\n<p>\u00be\tPatients who completed treatment but comes back within</p>\n<p>3 weeks</p>\n<p>\u00be\tRDT negative patients without any other evident cause of fe\u00ad</p>\n<p>ver</p>\n<p>168</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 235,
        "content": "Management of Malaria\nNATIONAL MALARIA TREATMENT POLICY\nUncomplicated Malaria\nAll patients: including children\n<4 months of age and pregnant \nwomen\nin 2nd and 3rd trimesters\nFirst line medicine\nArtemether/Lumefantrine\nFirst line alternative\nArtesunate/Amodiaquine\nSecond line medicine\n Dihydroartemisin/ Piperaquine\n If not available: quinine tablets\nPregnant women 1st trimester\n ACT currently used\nSevere Malaria\nAll age groups or patient categories First line IV Artesunate\nFirst line alternative\n IV Quinine\n Or Artemether injection\nPre-referral treatment\n Rectal artesunate for children 6 \nyears and below only. IM Artesu\u00ad\nnate, IM artemether or  quinine \nwhere  the parental medicine is \navailable\nIntermittent preventive treatment in pregnancy\n Sulfadoxine/Pyrimethamine (SP) for IPT. Start  at 13 weeks and give \nmonthly till delivery\nTreatment of uncomplicated malaria\nThe following tables contain dosages for medicines used in treatment of \nuncomplicated malaria.\n169\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Management of Malaria</p>\n<h3>NATIONAL MALARIA TREATMENT POLICY</h3>\n<p>Uncomplicated Malaria</p>\n<p>All patients: including children</p>\n<p><4 months of age and pregnant</p>\n<p>women</p>\n<p>in 2nd and 3rd trimesters</p>\n<p>First line medicine</p>\n<p>Artemether/Lumefantrine</p>\n<p>First line alternative</p>\n<p>Artesunate/Amodiaquine</p>\n<p>Second line medicine</p>\n<p>Dihydroartemisin/ Piperaquine</p>\n<p>If not available: quinine tablets</p>\n<p>Pregnant women 1st trimester</p>\n<p>ACT currently used</p>\n<p>Severe Malaria</p>\n<p>All age groups or patient categories First line IV Artesunate</p>\n<p>First line alternative</p>\n<p>IV Quinine</p>\n<p>Or Artemether injection</p>\n<p>Pre-referral treatment</p>\n<p>Rectal artesunate for children 6</p>\n<p>years and below only. IM Artesu\u00ad</p>\n<p>nate, IM artemether or  quinine</p>\n<p>where  the parental medicine is</p>\n<p>available</p>\n<p>Intermittent preventive treatment in pregnancy</p>\n<p>Sulfadoxine/Pyrimethamine (SP) for IPT. Start  at 13 weeks and give</p>\n<p>monthly till delivery</p>\n<p>Treatment of uncomplicated malaria</p>\n<p>The following tables contain dosages for medicines used in treatment of</p>\n<p>uncomplicated malaria.</p>\n<p>169</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 236,
        "content": "Dosage of artemether/lumefantrine 20/120 mg\nWEIGHT \n(KG)\nDAY 1\nDAY 2\nDAY 3\n<14\n1 tablet at 0 hours \nthen 1 tablet at 8 \nhours\n1 tab twice \ndaily\n1 tab twice \ndaily\n15\u201324\n2 tablets at 0 hours, \nthen, 2 tablets at 8 \nhours\n2 tab twice \ndaily\n2 tab twice \ndaily\n25\u201334\n3 tablets at 0 hours \nthen  3 tablets at \n8hours\n3 tab twice \ndaily\n3 tab twice \ndaily\n>35\n4 tablets at 0 hours \nthen  4 tablets at 8 \nhours\n4 tab twice \ndaily\n4 tab twice \ndaily\nNote: Give day 2 and day 3 doses every 12 hours\nDosage of artesunate (AS) tablets 50 mg once a day\nAGE\nDAY 1\nDAY 2\nDAY 3\n0\u201311\nmonths\n25 mg (\u00bd tab)\n25 mg (\u00bd tab)\n25 mg (\u00bd tab)\n1\u20136 years\n50 mg\n(1 tab)\n50 mg\n(1 tab)\n50 mg\n(1 tab)\n7\u201313 years\n100 mg\n(2 tabs)\n100 mg\n(2 tabs)\n100 mg\n(2 tabs)\n>13 years\n200 mg\n(4 tabs)\n200 mg\n(4 tabs)\n200 mg\n(4 tabs)\nNote: Do not use artesunate alone, give with amodiaquine tabs\n170\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Dosage of artemether/lumefantrine 20/120 mg</p>\n<h3>WEIGHT</h3>\n<h3>(KG)</h3>\n<h3>DAY 1</h3>\n<h3>DAY 2</h3>\n<h3>DAY 3</h3>\n<p><14</p>\n<p>1 tablet at 0 hours</p>\n<p>then 1 tablet at 8</p>\n<p>hours</p>\n<p>1 tab twice</p>\n<p>daily</p>\n<p>1 tab twice</p>\n<p>daily</p>\n<p>15\u201324</p>\n<p>2 tablets at 0 hours,</p>\n<p>then, 2 tablets at 8</p>\n<p>hours</p>\n<p>2 tab twice</p>\n<p>daily</p>\n<p>2 tab twice</p>\n<p>daily</p>\n<p>25\u201334</p>\n<p>3 tablets at 0 hours</p>\n<p>then  3 tablets at</p>\n<p>8hours</p>\n<p>3 tab twice</p>\n<p>daily</p>\n<p>3 tab twice</p>\n<p>daily</p>\n<p>>35</p>\n<p>4 tablets at 0 hours</p>\n<p>then  4 tablets at 8</p>\n<p>hours</p>\n<p>4 tab twice</p>\n<p>daily</p>\n<p>4 tab twice</p>\n<p>daily</p>\n<p>Note: Give day 2 and day 3 doses every 12 hours</p>\n<p>Dosage of artesunate (AS) tablets 50 mg once a day</p>\n<h3>AGE</h3>\n<h3>DAY 1</h3>\n<h3>DAY 2</h3>\n<h3>DAY 3</h3>\n<p>0\u201311</p>\n<p>months</p>\n<p>25 mg (\u00bd tab)</p>\n<p>25 mg (\u00bd tab)</p>\n<p>25 mg (\u00bd tab)</p>\n<p>1\u20136 years</p>\n<p>50 mg</p>\n<p>(1 tab)</p>\n<p>50 mg</p>\n<p>(1 tab)</p>\n<p>50 mg</p>\n<p>(1 tab)</p>\n<p>7\u201313 years</p>\n<p>100 mg</p>\n<p>(2 tabs)</p>\n<p>100 mg</p>\n<p>(2 tabs)</p>\n<p>100 mg</p>\n<p>(2 tabs)</p>\n<p>>13 years</p>\n<p>200 mg</p>\n<p>(4 tabs)</p>\n<p>200 mg</p>\n<p>(4 tabs)</p>\n<p>200 mg</p>\n<p>(4 tabs)</p>\n<p>Note: Do not use artesunate alone, give with amodiaquine tabs</p>\n<p>170</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 237,
        "content": "Dosage of amodiaquine (AQ) 153 mg tablets\nAGE\nDAY 1\nDAY 2\nDAY 3\n0\u201311\nmonths\n76 mg (1/2 tab)\n76 mg (1/2 tab)\n76 mg (1/2 tab)\n1\u20136 years\n153 mg (1 tab)\n153 mg (1 tab)\n153 mg (1tab)\n7\u201313 years\n306 mg (2 tabs)\n306 mg (2 tabs)\n306 mg (2 tabs)\n>13 years\n612 mg (4 tabs)\n612 mg (4 tabs)\n612 mg (4 tabs)\nNote: Do not use amodiaquine alone, use with artesunate tabs\nDosage of dihydroartemisinin (DHA)/Piperaquine tablets (PPQ) (40/320 \nmg) tablets\nWEIGHT (KG)\nAGE\nDAY 1\nDAY 2\nDAY 3\n<5\u20139.9\n<6 month\u2013 1 year\n0.5\n0.5\n0.5\n10\u201320\n2\u20137 years\n1\n1\n1\n20-40\n8-13 years\n2\n2\n2\n40-60\n3\n3\n3\n60-80\n4\n4\n4\n>80\n5\n5\n5\nDosage for Pyronaridine Tetraphosphate / Artesunate\nPYRONARIDINE TETRAPHOSPHATE/ ARTESUNATE (PYRAMAX)\n1 Sachet\nPyronaridine/Artesunate \n(60mg/20mg) Sacket \ngranules for Oral \nSuspension\nPyronaridine/Artesunate \n(180mg/60mg) Film \nCoated Tablet\nBody Weight\nProduct Description\nDay 1 Dose\nDay 2 Dose\nDay 3 Dose\n5kg to < 8kg\n8kg to < 15kg\n15kg to < 20kg\n20kg to < 24kg\n24kg to < 45kg\n45kg to < 65kg\n> = 65kg\n1 Tablet\n2 Tablet\n3 Tablet\n4 Tablet\n2 Sachet\n3 Sachet\n1 Sachet\n1 Tablet\n2 Tablet\n3 Tablet\n4 Tablet\n2 Sachet\n3 Sachet\n1 Sachet\n1 Tablet\n2 Tablet\n3 Tablet\n4 Tablet\n2 Sachet\n3 Sachet\n171\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Dosage of amodiaquine (AQ) 153 mg tablets</p>\n<h3>AGE</h3>\n<h3>DAY 1</h3>\n<h3>DAY 2</h3>\n<h3>DAY 3</h3>\n<p>0\u201311</p>\n<p>months</p>\n<p>76 mg (1/2 tab)</p>\n<p>76 mg (1/2 tab)</p>\n<p>76 mg (1/2 tab)</p>\n<p>1\u20136 years</p>\n<p>153 mg (1 tab)</p>\n<p>153 mg (1 tab)</p>\n<p>153 mg (1tab)</p>\n<p>7\u201313 years</p>\n<p>306 mg (2 tabs)</p>\n<p>306 mg (2 tabs)</p>\n<p>306 mg (2 tabs)</p>\n<p>>13 years</p>\n<p>612 mg (4 tabs)</p>\n<p>612 mg (4 tabs)</p>\n<p>612 mg (4 tabs)</p>\n<p>Note: Do not use amodiaquine alone, use with artesunate tabs</p>\n<p>Dosage of dihydroartemisinin (DHA)/Piperaquine tablets (PPQ) (40/320</p>\n<p>mg) tablets</p>\n<h3>WEIGHT (KG)</h3>\n<h3>AGE</h3>\n<h3>DAY 1</h3>\n<h3>DAY 2</h3>\n<h3>DAY 3</h3>\n<p><5\u20139.9</p>\n<p><6 month\u2013 1 year</p>\n<p>0.5</p>\n<p>0.5</p>\n<p>0.5</p>\n<p>10\u201320</p>\n<p>2\u20137 years</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>20-40</p>\n<p>8-13 years</p>\n<p>2</p>\n<p>2</p>\n<p>2</p>\n<p>40-60</p>\n<p>3</p>\n<p>3</p>\n<p>3</p>\n<p>60-80</p>\n<p>4</p>\n<p>4</p>\n<p>4</p>\n<p>>80</p>\n<p>5</p>\n<p>5</p>\n<p>5</p>\n<p>Dosage for Pyronaridine Tetraphosphate / Artesunate</p>\n<h3>PYRONARIDINE TETRAPHOSPHATE/ ARTESUNATE (PYRAMAX)</h3>\n<p>1 Sachet</p>\n<p>Pyronaridine/Artesunate</p>\n<p>(60mg/20mg) Sacket</p>\n<p>granules for Oral</p>\n<p>Suspension</p>\n<p>Pyronaridine/Artesunate</p>\n<p>(180mg/60mg) Film</p>\n<p>Coated Tablet</p>\n<p>Body Weight</p>\n<p>Product Description</p>\n<p>Day 1 Dose</p>\n<p>Day 2 Dose</p>\n<p>Day 3 Dose</p>\n<p>5kg to < 8kg</p>\n<p>8kg to < 15kg</p>\n<p>15kg to < 20kg</p>\n<p>20kg to < 24kg</p>\n<p>24kg to < 45kg</p>\n<p>45kg to < 65kg</p>\n<p>> = 65kg</p>\n<p>1 Tablet</p>\n<p>2 Tablet</p>\n<p>3 Tablet</p>\n<p>4 Tablet</p>\n<p>2 Sachet</p>\n<p>3 Sachet</p>\n<p>1 Sachet</p>\n<p>1 Tablet</p>\n<p>2 Tablet</p>\n<p>3 Tablet</p>\n<p>4 Tablet</p>\n<p>2 Sachet</p>\n<p>3 Sachet</p>\n<p>1 Sachet</p>\n<p>1 Tablet</p>\n<p>2 Tablet</p>\n<p>3 Tablet</p>\n<p>4 Tablet</p>\n<p>2 Sachet</p>\n<p>3 Sachet</p>\n<p>171</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 238,
        "content": "Dosage of quinine tablets (1 quinine tab = 300 mg salt)\nWEIGHT \n(KG)\nAGE\nDOSE (TO BE GIVEN EVERY 8 \nHOURS FOR 7 DAYS)\n<5\u201310\n3 months\u20131 year\n75 mg (\u00bc tab)\n10\u201318\n1\u20135 years\n150 mg (\u00bd tab)\n18\u201324\n5\u20137 years\n225 mg (\u00be tab)\n24\u201330\n7\u201310 years\n300 mg (1 tab)\n30\u201340\n10\u201313 years\n375 mg (1\u00bc tab)\n40\u201350\n13\u201315 years\n450 mg (1\u00bd tab)\n> 50\n> 15 years\n600 (2 tabs)\nManagement of severe malaria\nGeneral principles\n Manage complications as recommended in the section below\n Manage fluids very carefully. Adults with severe malaria are very vuner\u00ad\nable to fluid overload, while children are more likely to be dehydrated\nMonitor vitals signs carefully, including urine output.\nIntravenous artesunate is the medicine of choice\n \n- At a health unit without admission and IV drug administration \nfacilities, give a pre-referral dose of rectal artesunate* only \nrecommended for children of 6 years and below( see dosing \ntables below) as soon as possible and refer for further \nmanagement\n \n- At a health unit with admission and IV drug administration \nfacilities, treat with IV artesunate as in the table below\n \n- If IV route is not possible, use IM route.\n \n- If Iv artesunate is  not available, use IM artemether (into the \nthigh, never in the buttock) or IV quinine\n172\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Dosage of quinine tablets (1 quinine tab = 300 mg salt)</p>\n<h3>WEIGHT</h3>\n<h3>(KG)</h3>\n<h3>AGE</h3>\n<h3>DOSE (TO BE GIVEN EVERY 8</h3>\n<h3>HOURS FOR 7 DAYS)</h3>\n<p><5\u201310</p>\n<p>3 months\u20131 year</p>\n<p>75 mg (\u00bc tab)</p>\n<p>10\u201318</p>\n<p>1\u20135 years</p>\n<p>150 mg (\u00bd tab)</p>\n<p>18\u201324</p>\n<p>5\u20137 years</p>\n<p>225 mg (\u00be tab)</p>\n<p>24\u201330</p>\n<p>7\u201310 years</p>\n<p>300 mg (1 tab)</p>\n<p>30\u201340</p>\n<p>10\u201313 years</p>\n<p>375 mg (1\u00bc tab)</p>\n<p>40\u201350</p>\n<p>13\u201315 years</p>\n<p>450 mg (1\u00bd tab)</p>\n<p>> 50</p>\n<p>> 15 years</p>\n<p>600 (2 tabs)</p>\n<p>Management of severe malaria</p>\n<p>General principles</p>\n<p>Manage complications as recommended in the section below</p>\n<p>Manage fluids very carefully. Adults with severe malaria are very vuner\u00ad</p>\n<p>able to fluid overload, while children are more likely to be dehydrated</p>\n<p>Monitor vitals signs carefully, including urine output.</p>\n<p>Intravenous artesunate is the medicine of choice</p>\n<p>- At a health unit without admission and IV drug administration</p>\n<p>facilities, give a pre-referral dose of rectal artesunate* only</p>\n<p>recommended for children of 6 years and below( see dosing</p>\n<p>tables below) as soon as possible and refer for further</p>\n<p>management</p>\n<p>- At a health unit with admission and IV drug administration</p>\n<p>facilities, treat with IV artesunate as in the table below</p>\n<p>- If IV route is not possible, use IM route.</p>\n<p>- If Iv artesunate is  not available, use IM artemether (into the</p>\n<p>thigh, never in the buttock) or IV quinine</p>\n<p>172</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 239,
        "content": "Dosage of rectal artesunate\nWEIGHT (KG)\nAGE\nARTESUNATE \nDOSE (MG)\nREGIMEN  (SINGLE \nDOSE)\n5kg to<14 4 months to \n<3years\n100mg\n1 supp (100 mg)\n14-19\n3 years to \nless than 6 \nyears\n100 mg\n2 supp of 100mg\nNote\n \n\u0083 In the event that an artesunate suppository is expelled from \nthe rectum within 30 minutes of insertion, insert a repeat \ndose.\n \n\u0083 Hold the buttocks (especially in young children) together for \n10 minutes to ensure retention of rectal dose\nDosage of intravenous artesunate for severe malaria\nArtesunate IV\nDOSE\nTIME\nQUANTITY\nFirst dose: on admis\u00ad\nsion Loading dose\nAt 0 hours\nChild less than 20 kg: 3 mg/kg\nAdults and child >20kg: 2.4 mg/kg\nSecond dose\nAt 12 hours\nThird dose\nAt 24 hours\nThen once a day until patient is able to tolerate oral medication, then \ngive a full course of oral ACT.* currently all severe malaria cases to \nbe discharged on DP. Then reviewed every month for 3 months and \ngiven monthly DP for post severe malaria chemoprevention.\nPreparation of IV or IM artesunate\n \n~\nIV artesunate is usually dispensed in powder vial of 30mg, \n60mg,120mg, pre-packed with sodium bicarbonate solu\u00ad\ntion 1 ml\n173\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Dosage of rectal artesunate</p>\n<h3>WEIGHT (KG)</h3>\n<h3>AGE</h3>\n<h3>ARTESUNATE</h3>\n<h3>DOSE (MG)</h3>\n<h3>REGIMEN  (SINGLE</h3>\n<h3>DOSE)</h3>\n<p>5kg to<14 4 months to</p>\n<p><3years</p>\n<p>100mg</p>\n<p>1 supp (100 mg)</p>\n<p>14-19</p>\n<p>3 years to</p>\n<p>less than 6</p>\n<p>years</p>\n<p>100 mg</p>\n<p>2 supp of 100mg</p>\n<p>Note</p>\n<p>\u0083 In the event that an artesunate suppository is expelled from</p>\n<p>the rectum within 30 minutes of insertion, insert a repeat</p>\n<p>dose.</p>\n<p>\u0083 Hold the buttocks (especially in young children) together for</p>\n<p>10 minutes to ensure retention of rectal dose</p>\n<p>Dosage of intravenous artesunate for severe malaria</p>\n<p>Artesunate IV</p>\n<h3>DOSE</h3>\n<h3>TIME</h3>\n<h3>QUANTITY</h3>\n<p>First dose: on admis\u00ad</p>\n<p>sion Loading dose</p>\n<p>At 0 hours</p>\n<p>Child less than 20 kg: 3 mg/kg</p>\n<p>Adults and child >20kg: 2.4 mg/kg</p>\n<p>Second dose</p>\n<p>At 12 hours</p>\n<p>Third dose</p>\n<p>At 24 hours</p>\n<p>Then once a day until patient is able to tolerate oral medication, then</p>\n<p>give a full course of oral ACT.* currently all severe malaria cases to</p>\n<p>be discharged on DP. Then reviewed every month for 3 months and</p>\n<p>given monthly DP for post severe malaria chemoprevention.</p>\n<p>Preparation of IV or IM artesunate</p>\n<p>~</p>\n<p>IV artesunate is usually dispensed in powder vial of 30mg,</p>\n<p>60mg,120mg, pre-packed with sodium bicarbonate solu\u00ad</p>\n<p>tion 1 ml</p>\n<p>173</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 240,
        "content": "Preparation of IV or IM artesunate\n \n~\nIV artesunate is usually dispensed in powder vial of 30mg, \n60mg,120mg, pre-packed with sodium bicarbonate solu\u00ad\ntion 1 ml\n \n~\nCalculate the dose in mg according to the weight and the \nnumber  of vials needed\n \n~\nReconstitute each vial separately, and use within 1 hour\n \n~\nReconstitution: inject all the content of the bicarbonate am\u00ad\npoule (1 ml) in the artesunate vial. Shake gently till solution \nbecome clear (discard if not clear after 2 minutes)\nIV use\n \n~\nDilution: dilute solution by adding 5 ml of sodium chloride \n0.9% (normal saline) or Dextrose 5%, obtaining a concen\u00ad\ntration of 10 mg/ml\n \n~\nCalculate the required volume and withdraw\n \n~\nGive by IV injection slowly over 5 minutes\nIM use\n \n~\nDilution: dilute solution by adding 2 ml of sodium chloride \n0.9%, obtaining a concentration of 20 mg/ml\n \n~\nInject into the upper outer anterior thigh, NEVER in the \nbuttock\nDo not use water for injection for dilution\nDosage of IM artemether\nArtemether\nDOSE\nTIME\nQUANTITY\nFirst dose: on admission \nLoading dose\nAt 0 hours\n3.2 mg/kg\nSecond dose\nAt 24 hours\n1.6 mg/kg\nThird dose\nAt 48 hours\n1.6 mg/kg\nThen once a day until patient is able to tolerate oral medication, then \ngive a full course of oral ACT. If after 48hours (day 3) the patient is \nstill un stable and parasites density is still almost the same as at day \n0, switch to IV quinine for 3 to 4 doses then discharge on ACT (DP).\n174\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Preparation of IV or IM artesunate</p>\n<p>~</p>\n<p>IV artesunate is usually dispensed in powder vial of 30mg,</p>\n<p>60mg,120mg, pre-packed with sodium bicarbonate solu\u00ad</p>\n<p>tion 1 ml</p>\n<p>~</p>\n<p>Calculate the dose in mg according to the weight and the</p>\n<p>number  of vials needed</p>\n<p>~</p>\n<p>Reconstitute each vial separately, and use within 1 hour</p>\n<p>~</p>\n<p>Reconstitution: inject all the content of the bicarbonate am\u00ad</p>\n<p>poule (1 ml) in the artesunate vial. Shake gently till solution</p>\n<p>become clear (discard if not clear after 2 minutes)</p>\n<p>IV use</p>\n<p>~</p>\n<p>Dilution: dilute solution by adding 5 ml of sodium chloride</p>\n<p>0.9% (normal saline) or Dextrose 5%, obtaining a concen\u00ad</p>\n<p>tration of 10 mg/ml</p>\n<p>~</p>\n<p>Calculate the required volume and withdraw</p>\n<p>~</p>\n<p>Give by IV injection slowly over 5 minutes</p>\n<p>IM use</p>\n<p>~</p>\n<p>Dilution: dilute solution by adding 2 ml of sodium chloride</p>\n<p>0.9%, obtaining a concentration of 20 mg/ml</p>\n<p>~</p>\n<p>Inject into the upper outer anterior thigh, NEVER in the</p>\n<p>buttock</p>\n<p>Do not use water for injection for dilution</p>\n<p>Dosage of IM artemether</p>\n<p>Artemether</p>\n<h3>DOSE</h3>\n<h3>TIME</h3>\n<h3>QUANTITY</h3>\n<p>First dose: on admission</p>\n<p>Loading dose</p>\n<p>At 0 hours</p>\n<p>3.2 mg/kg</p>\n<p>Second dose</p>\n<p>At 24 hours</p>\n<li>.6 mg/kg</li>\n<p>Third dose</p>\n<p>At 48 hours</p>\n<li>.6 mg/kg</li>\n<p>Then once a day until patient is able to tolerate oral medication, then</p>\n<p>give a full course of oral ACT. If after 48hours (day 3) the patient is</p>\n<p>still un stable and parasites density is still almost the same as at day</p>\n<p>0, switch to IV quinine for 3 to 4 doses then discharge on ACT (DP).</p>\n<p>174</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 241,
        "content": "Dosage of quinine IV\nDose\n\t\n\u0089\n10 mg/kg in dextrose 5% every 8 hours till patient is able \nto tolerate oral medication \n\t\n\u0089\nThen complete with a full dose of ACT (3 days) or quinine \ntablets to complete 7 days\n2.5.3.3 Management of Complications of Severe Malaria\nDosage of IM artemether\nCOMPLICATION\nTREATMENT\nHyperpyrexia\nGive paracetamol 1 g every 6 hours Child: 10 mg/\nkg + tepid sponging + fanning\nConvulsions\nGive diazepam 0.2 mg/kg (max 10 mg) slow IV or \n(in adults) IM or 0.5 mg/kg rectally\nIf convulsions still persist:\nGive phenobarbital 200 mg IM/IV\nChild: 10-15 mg/kg loading dose then\n2.5 mg/kg once or twice daily if still necessary or\n  phenytoin 15 mg/kg loading dose\nHypoglycaemia\nAdult: dextrose 25% 2 ml/kg by slow IV bolus over \n3-5 min (to prepare, take dextrose 50% 1 ml/kg and \ndilute with an equal volume of water for injections)\n Child: dextrose 10% 5 ml/kg by slow IV bolus over \n5-7 min (to prepare, take 1 ml/kg of dextrose 50% \nand dilute with 4 ml/kg water for injection)\nDO NOT GIVE UNDILUTED  50% dextrose\n Monitor blood glucose frequently\n Ensure patient is feeding\nAcidosis\nCorrect fluid & electrolyte balance\n If there is severe acidosis without sodium depletion:\n175\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Dosage of quinine IV</p>\n<p>Dose</p>\n<p>\u0089</p>\n<p>10 mg/kg in dextrose 5% every 8 hours till patient is able</p>\n<p>to tolerate oral medication</p>\n<p>\u0089</p>\n<p>Then complete with a full dose of ACT (3 days) or quinine</p>\n<p>tablets to complete 7 days</p>\n<p>2.5.3.3 Management of Complications of Severe Malaria</p>\n<p>Dosage of IM artemether</p>\n<h3>COMPLICATION</h3>\n<h3>TREATMENT</h3>\n<p>Hyperpyrexia</p>\n<p>Give paracetamol 1 g every 6 hours Child: 10 mg/</p>\n<p>kg + tepid sponging + fanning</p>\n<p>Convulsions</p>\n<p>Give diazepam 0.2 mg/kg (max 10 mg) slow IV or</p>\n<p>(in adults) IM or 0.5 mg/kg rectally</p>\n<p>If convulsions still persist:</p>\n<p>Give phenobarbital 200 mg IM/IV</p>\n<p>Child: 10-15 mg/kg loading dose then</p>\n<p>2.5 mg/kg once or twice daily if still necessary or</p>\n<p>phenytoin 15 mg/kg loading dose</p>\n<p>Hypoglycaemia</p>\n<p>Adult: dextrose 25% 2 ml/kg by slow IV bolus over</p>\n<p>3-5 min (to prepare, take dextrose 50% 1 ml/kg and</p>\n<p>dilute with an equal volume of water for injections)</p>\n<p>Child: dextrose 10% 5 ml/kg by slow IV bolus over</p>\n<p>5-7 min (to prepare, take 1 ml/kg of dextrose 50%</p>\n<p>and dilute with 4 ml/kg water for injection)</p>\n<p>DO NOT GIVE UNDILUTED  50% dextrose</p>\n<p>Monitor blood glucose frequently</p>\n<p>Ensure patient is feeding</p>\n<p>Acidosis</p>\n<p>Correct fluid & electrolyte balance</p>\n<p>If there is severe acidosis without sodium depletion:</p>\n<p>175</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 242,
        "content": "Dosage of IM artemether\nCOMPLICATION\nTREATMENT\n \n- Give sodium bicarbonate 8.4% infusion \n50 ml IV\n \n- Monitor plasma pH\nSevere anaemia\n\t\n\u0089\nDo blood grouping and cross- matching\n\t\n\u0089\nTransfuse patient with packed cells 10-15 ml/\nkg or whole blood 20 ml/ kg especially if the \nanaemia is also causing heart failure\n\t\n\u0089\nRepeat Hb before discharge and preferably 28 \ndays after discharge\nPulmonary \nOedema\nRegulate the IV infusion (do not overload with IV \nfluids)\n\t\n\u0089\nProp up the patient\n\t\n\u0089\nGive oxygen\n\t\n\u0089\nGive furosemide 1-2 mg/kg\nAcute Renal \nFailure\n\t\n\u0089\nUrine output: <17 ml/hour for adult or <0.3 \nml/kg/hour for a child\n\t\n\u0089\nCheck to ensure that the cause of oliguria is \nnot dehydration or shock\n\t\n\u0089\nIf due to acute renal failure: Give a chal\u00ad\nlenge dose of furosemide 40 mg IM or \nslow IV (child: 1 mg/kg)\nIf this fails:\n\t\n\u0089\nRefer for peritoneal dialysis or haemodialysis\nShock\n\t\n\u0089\nIf systolic BP <80 mmHg (adult) or\n<50 mmHg (child) or if peripheral pulse absent \nand capillary refill is slow (>2 seconds)\n \n- Raise the foot of the bed\n \n- Give sodium chloride 0.9% by fast IV \ninfusion bolus 20 ml/kg in 15 min\n \n- Review fluid balance and urinary outputs\n \n- Look for evidence of haemorrhage or \nsepticaemia and treat accordingly\n176\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Dosage of IM artemether</p>\n<h3>COMPLICATION</h3>\n<h3>TREATMENT</h3>\n<p>- Give sodium bicarbonate 8.4% infusion</p>\n<p>50 ml IV</p>\n<p>- Monitor plasma pH</p>\n<p>Severe anaemia</p>\n<p>\u0089</p>\n<p>Do blood grouping and cross- matching</p>\n<p>\u0089</p>\n<p>Transfuse patient with packed cells 10-15 ml/</p>\n<p>kg or whole blood 20 ml/ kg especially if the</p>\n<p>anaemia is also causing heart failure</p>\n<p>\u0089</p>\n<p>Repeat Hb before discharge and preferably 28</p>\n<p>days after discharge</p>\n<p>Pulmonary</p>\n<p>Oedema</p>\n<p>Regulate the IV infusion (do not overload with IV</p>\n<p>fluids)</p>\n<p>\u0089</p>\n<p>Prop up the patient</p>\n<p>\u0089</p>\n<p>Give oxygen</p>\n<p>\u0089</p>\n<p>Give furosemide 1-2 mg/kg</p>\n<p>Acute Renal</p>\n<p>Failure</p>\n<p>\u0089</p>\n<p>Urine output: <17 ml/hour for adult or <0.3</p>\n<p>ml/kg/hour for a child</p>\n<p>\u0089</p>\n<p>Check to ensure that the cause of oliguria is</p>\n<p>not dehydration or shock</p>\n<p>\u0089</p>\n<p>If due to acute renal failure: Give a chal\u00ad</p>\n<p>lenge dose of furosemide 40 mg IM or</p>\n<p>slow IV (child: 1 mg/kg)</p>\n<p>If this fails:</p>\n<p>\u0089</p>\n<p>Refer for peritoneal dialysis or haemodialysis</p>\n<p>Shock</p>\n<p>\u0089</p>\n<p>If systolic BP <80 mmHg (adult) or</p>\n<p><50 mmHg (child) or if peripheral pulse absent</p>\n<p>and capillary refill is slow (>2 seconds)</p>\n<p>- Raise the foot of the bed</p>\n<p>- Give sodium chloride 0.9% by fast IV</p>\n<p>infusion bolus 20 ml/kg in 15 min</p>\n<p>- Review fluid balance and urinary outputs</p>\n<p>- Look for evidence of haemorrhage or</p>\n<p>septicaemia and treat accordingly</p>\n<p>176</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 243,
        "content": "COMPLICATION\nTREATMENT\nHaemoglo- bi\u00ad\nnuria (intravas\u00ad\ncular haemol\u00ad\nysis)\n\t\n\u0089\nRehydrate the patient\n\t\n\u0089\nAssess for anaemia and transfuse if necessary\nDehydration\n\t\n\u0089\nRehydrate using ORS or IV RL or NS (see \nrehydration, section 1.1.3)\n\t\n\u0089\nOver-enthusiasitc IV infusion may harm the \npatient and lead to fluid overlaod and pulmo\u00ad\nnary oedema\nBleeding\n\t\n\u0089\nTransfuse patient with whole fresh blood to \nprovide lacking clotting factors\nComa\n\t\n\u0089\nCheck and treat for hypoglycaemia: if not re\u00ad\nsponding within 20 min, consider another cause\n\t\n\u0089\nf Provide intensive nursing care with:\n \n- IV drip (for rehydration and IV \nmedication)\n \n- NGT (for feeding and oral\n \n- medication)\n \n- Urethral catheter (to monitor urine \noutput)\n \n- Turning of patient frequently to avoid \nbed sores\nCriteria for referral to regional/tertiary hospital\n \n~\nPersistent renal failure needing dialysis\n \n~\nAny complication that cannot be managed locally\nManagement of RDT/Blood Smear Negative Ptients\nPatients who have a negative malaria test (most likely, if RDT is used) \ndo not have malaria so other causes of fever have to be investigated for \nappropriate treatment.\n177\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>COMPLICATION</h3>\n<h3>TREATMENT</h3>\n<p>Haemoglo- bi\u00ad</p>\n<p>nuria (intravas\u00ad</p>\n<p>cular haemol\u00ad</p>\n<p>ysis)</p>\n<p>\u0089</p>\n<p>Rehydrate the patient</p>\n<p>\u0089</p>\n<p>Assess for anaemia and transfuse if necessary</p>\n<p>Dehydration</p>\n<p>\u0089</p>\n<p>Rehydrate using ORS or IV RL or NS (see</p>\n<p>rehydration, section 1.1.3)</p>\n<p>\u0089</p>\n<p>Over-enthusiasitc IV infusion may harm the</p>\n<p>patient and lead to fluid overlaod and pulmo\u00ad</p>\n<p>nary oedema</p>\n<p>Bleeding</p>\n<p>\u0089</p>\n<p>Transfuse patient with whole fresh blood to</p>\n<p>provide lacking clotting factors</p>\n<p>Coma</p>\n<p>\u0089</p>\n<p>Check and treat for hypoglycaemia: if not re\u00ad</p>\n<p>sponding within 20 min, consider another cause</p>\n<p>\u0089</p>\n<p>f Provide intensive nursing care with:</p>\n<p>- IV drip (for rehydration and IV</p>\n<p>medication)</p>\n<p>- NGT (for feeding and oral</p>\n<p>- medication)</p>\n<p>- Urethral catheter (to monitor urine</p>\n<p>output)</p>\n<p>- Turning of patient frequently to avoid</p>\n<p>bed sores</p>\n<p>Criteria for referral to regional/tertiary hospital</p>\n<p>~</p>\n<p>Persistent renal failure needing dialysis</p>\n<p>~</p>\n<p>Any complication that cannot be managed locally</p>\n<p>Management of RDT/Blood Smear Negative Ptients</p>\n<p>Patients who have a negative malaria test (most likely, if RDT is used)</p>\n<p>do not have malaria so other causes of fever have to be investigated for</p>\n<p>appropriate treatment.</p>\n<p>177</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 244,
        "content": "~\nRe-assess patient history, clinical signs and laboratory re\u00ad\nsults. Consider other frequent causes of fever such as:\n\t\n\u0089\nIf running nose, sore throat and cough: viral upper respiratory \ninfection\n\t\n\u0089\nIf swollen tonsils with exudate on it: tonsilitis\n\t\n\u0089\nIf ear pain and discharge: otitis\n\t\n\u0089\nIf cough, rapid breathing and difficulty in breathing: pneumonia\n\t\n\u0089\nIf urinary symptoms: urinary tract infection\n\t\n\u0089\nIf vomiting, diarrhoea and abdominal pain: gastro-enteritis\n\t\n\u0089\nIf skin rash: measles or other viral rash\n \n~\nIf malaria is still suspected, investigate according to the  \nflowchart below\n\t\n\u0089\nIf signs/symptoms of severe malaria, RDT and blood slide negative \nbut no other diagnosis is found, consider treating for malaria any\u00ad\nway but repeat RDTs after 24 hours to confirm.Also add a broad \nspectrum antibiotic\n\t\n\u0089\nIf RDT and blood slide negative, no signs of other illness and no \nsigns of severe sickness (patient has no danger signs) treat symp\u00ad\ntomatically with antipyretics, advise patient to return immediately \nif condition worsens or in 2 days if fever persists.\nPossible reasons for false negative tests (test is negative but patient has \nmalaria):\n \n~\nLow peripheral parasitaemia\n \n~\nTechnical error in performing the test or test reagents that \nare out of date\n \n~\nSequestration of parasites in the internal organs\n \n~\nHaving already taken antimalarial drugs, inadequate or \nincomplete dose: this affects only microscopy, while RDT \nremains positive even if the patient has already taken an \nantimalarial using prophylactic treatment for malaria\n178\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>~</p>\n<p>Re-assess patient history, clinical signs and laboratory re\u00ad</p>\n<p>sults. Consider other frequent causes of fever such as:</p>\n<p>\u0089</p>\n<p>If running nose, sore throat and cough: viral upper respiratory</p>\n<p>infection</p>\n<p>\u0089</p>\n<p>If swollen tonsils with exudate on it: tonsilitis</p>\n<p>\u0089</p>\n<p>If ear pain and discharge: otitis</p>\n<p>\u0089</p>\n<p>If cough, rapid breathing and difficulty in breathing: pneumonia</p>\n<p>\u0089</p>\n<p>If urinary symptoms: urinary tract infection</p>\n<p>\u0089</p>\n<p>If vomiting, diarrhoea and abdominal pain: gastro-enteritis</p>\n<p>\u0089</p>\n<p>If skin rash: measles or other viral rash</p>\n<p>~</p>\n<p>If malaria is still suspected, investigate according to the</p>\n<p>flowchart below</p>\n<p>\u0089</p>\n<p>If signs/symptoms of severe malaria, RDT and blood slide negative</p>\n<p>but no other diagnosis is found, consider treating for malaria any\u00ad</p>\n<p>way but repeat RDTs after 24 hours to confirm.Also add a broad</p>\n<p>spectrum antibiotic</p>\n<p>\u0089</p>\n<p>If RDT and blood slide negative, no signs of other illness and no</p>\n<p>signs of severe sickness (patient has no danger signs) treat symp\u00ad</p>\n<p>tomatically with antipyretics, advise patient to return immediately</p>\n<p>if condition worsens or in 2 days if fever persists.</p>\n<p>Possible reasons for false negative tests (test is negative but patient has</p>\n<p>malaria):</p>\n<p>~</p>\n<p>Low peripheral parasitaemia</p>\n<p>~</p>\n<p>Technical error in performing the test or test reagents that</p>\n<p>are out of date</p>\n<p>~</p>\n<p>Sequestration of parasites in the internal organs</p>\n<p>~</p>\n<p>Having already taken antimalarial drugs, inadequate or</p>\n<p>incomplete dose: this affects only microscopy, while RDT</p>\n<p>remains positive even if the patient has already taken an</p>\n<p>antimalarial using prophylactic treatment for malaria</p>\n<p>178</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 245,
        "content": "Patient with negative \nblood smear or RDT\nIs there evidence of \nnon-malarial illness? \nTreat non-malarial \nillness\nAre there signs and \nsymptoms suggestive \nof severe malaria?\nTreat for severe disease \nwith artesunate and broad-\nspectrum antibiotics. Repeat \ntesting (RDT) in 12-24 hours\nWithhold treatment for malaria, give \nsymptomatic treatment and ask the \npatient to come back immediately \nif the illness becomes worse or if it \npersists for more than two days.\nY s\nY s\nN\nN\n2.5.3.4 Malaria Prophylaxis\nNot recommended for all those living in a highly endemic area like \nUganda. However, it is recommended for certain high-risk groups but \nis not 100% effective\n179\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Patient with negative</p>\n<p>blood smear or RDT</p>\n<p>Is there evidence of</p>\n<p>non-malarial illness?</p>\n<p>Treat non-malarial</p>\n<p>illness</p>\n<p>Are there signs and</p>\n<p>symptoms suggestive</p>\n<p>of severe malaria?</p>\n<p>Treat for severe disease</p>\n<p>with artesunate and broad-</p>\n<p>spectrum antibiotics. Repeat</p>\n<p>testing (RDT) in 12-24 hours</p>\n<p>Withhold treatment for malaria, give</p>\n<p>symptomatic treatment and ask the</p>\n<p>patient to come back immediately</p>\n<p>if the illness becomes worse or if it</p>\n<p>persists for more than two days.</p>\n<p>Y s</p>\n<p>Y s</p>\n<p>N</p>\n<p>N</p>\n<p>2.5.3.4 Malaria Prophylaxis</p>\n<p>Not recommended for all those living in a highly endemic area like</p>\n<p>Uganda. However, it is recommended for certain high-risk groups but</p>\n<p>is not 100% effective</p>\n<p>179</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 246,
        "content": "PATIENT GROUP\nPROPHYLAXIS\nPregnancy\nIn endemic areas, \npregnant wom\u00ad\nen carry malaria \nparasites in their \nblood or placenta, \nwhich is harmful to \nthe health of both \nmother and foetus\n \n~\nGive intermittent preventive treatment \n(IPT) to ensure the well-being of moth\u00ad\ner and foetus\n\t\n\u0089\nSP single dose (3 tabs) given at 13 weeks and \ncontinued monthly until delivery\n\t\n\u0089\nEnsure doses are taken under supervision \nby the health provider as directly observed \ntherapy (DOT)\n\t\n\u0089\nRecord doses on the patient\u2019s card and treatment \nregister and summarise further in the delivery \nbook and monthly returns\n\t\n\u0089\nDo not give SP in HIV patients on cotrimoxazole\nSicke cell disease\n \n~\nSulphadoxine- pyrimethamine (SP) - \nsee section 11.1.3\nChloroquine is the alteranative:\nAdult: 300 mg base weekly\nChild: 5 mg (base)/kg weeklyf \nPeople living with \nHIV\n \n~\nCotrimoxazole daily as per national \nguidelines\nNon-immune visi\u00ad\ntors/tourists\n \n~\nMefloquine\nAdult: 250 mg once weekly\nChild: 5 mg/kg once weekly\n2.5.3.5 Malaria Prevention and Control\nGive effective treatment and prophylaxis\n \n~\nEliminate parasites from the human population by early diag\u00ad\nnosis and effective treatment\n \n~\nProtect vulnerable groups with chemoprophylaxis\n \n~\nGive IPT to all pregnant women\n180\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>PATIENT GROUP</h3>\n<h3>PROPHYLAXIS</h3>\n<p>Pregnancy</p>\n<p>In endemic areas,</p>\n<p>pregnant wom\u00ad</p>\n<p>en carry malaria</p>\n<p>parasites in their</p>\n<p>blood or placenta,</p>\n<p>which is harmful to</p>\n<p>the health of both</p>\n<p>mother and foetus</p>\n<p>~</p>\n<p>Give intermittent preventive treatment</p>\n<p>(IPT) to ensure the well-being of moth\u00ad</p>\n<p>er and foetus</p>\n<p>\u0089</p>\n<p>SP single dose (3 tabs) given at 13 weeks and</p>\n<p>continued monthly until delivery</p>\n<p>\u0089</p>\n<p>Ensure doses are taken under supervision</p>\n<p>by the health provider as directly observed</p>\n<p>therapy (DOT)</p>\n<p>\u0089</p>\n<p>Record doses on the patient\u2019s card and treatment</p>\n<p>register and summarise further in the delivery</p>\n<p>book and monthly returns</p>\n<p>\u0089</p>\n<p>Do not give SP in HIV patients on cotrimoxazole</p>\n<p>Sicke cell disease</p>\n<p>~</p>\n<p>Sulphadoxine- pyrimethamine (SP) -</p>\n<p>see section 11.1.3</p>\n<p>Chloroquine is the alteranative:</p>\n<p>Adult: 300 mg base weekly</p>\n<p>Child: 5 mg (base)/kg weeklyf</p>\n<p>People living with</p>\n<h3>HIV</h3>\n<p>~</p>\n<p>Cotrimoxazole daily as per national</p>\n<p>guidelines</p>\n<p>Non-immune visi\u00ad</p>\n<p>tors/tourists</p>\n<p>~</p>\n<p>Mefloquine</p>\n<p>Adult: 250 mg once weekly</p>\n<p>Child: 5 mg/kg once weekly</p>\n<p>2.5.3.5 Malaria Prevention and Control</p>\n<p>Give effective treatment and prophylaxis</p>\n<p>~</p>\n<p>Eliminate parasites from the human population by early diag\u00ad</p>\n<p>nosis and effective treatment</p>\n<p>~</p>\n<p>Protect vulnerable groups with chemoprophylaxis</p>\n<p>~</p>\n<p>Give IPT to all pregnant women</p>\n<p>180</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 247,
        "content": "Reduce human-mosquito contact\n \n~\nUse insecticide-treated materials (e.g. bed nets)\n \n~\nDestroy adult mosquitoes by indoor residual spraying of \ndwellings with insecticide or use of knock-down sprays\n \n~\nScreen houses\n \n~\nCarefully select house sites avoiding mosquito-infested areas\n \n~\nWear clothes which cover the arms and legs and use repel\u00ad\nlent mosquito coils and creams/sprays on the skin when sit\u00ad\nting outdoors at night\nControl mosquito breeding sites\n \n~\nEliminate collections of stagnant water where mosquitoes \nbreed, e.g. in empty cans/ containers, potholes, old car \ntyres, plastic bags, and footprints by disposal, draining, or \ncovering with soil or sand\n \n~\nDestroy mosquito larvae by dosing stagnant water bodies \nwith larvicides or with biological methods (e.g. larvae- eating \nfish)\nGive public health education on the above measures include the need \nfor self testing (self-care) using RDT before any medication.\n2.5.4 Human African Trypanosomiasis (Sleeping Sickness)                                                \nICD10 CODE: B56\nA disease caused by trypanosomes (a protozoa) and transmitted to \nhumans by several species of tsetse fly\nCause\n \n~\nTrypanosoma rhodesiense (mostly in the Central and East\u00ad\nern regions of Uganda)\n \n~\nTrypanosoma gambiense (mostly in West Nile region)\n \n~\nClinical features\n \n~\nMay be history of tsetse fly bite and swelling at site of bite \nafter 7-14 days (more often in T. rhodesiense, rarely in T. \nGambiense)\n181\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Reduce human-mosquito contact</p>\n<p>~</p>\n<p>Use insecticide-treated materials (e.g. bed nets)</p>\n<p>~</p>\n<p>Destroy adult mosquitoes by indoor residual spraying of</p>\n<p>dwellings with insecticide or use of knock-down sprays</p>\n<p>~</p>\n<p>Screen houses</p>\n<p>~</p>\n<p>Carefully select house sites avoiding mosquito-infested areas</p>\n<p>~</p>\n<p>Wear clothes which cover the arms and legs and use repel\u00ad</p>\n<p>lent mosquito coils and creams/sprays on the skin when sit\u00ad</p>\n<p>ting outdoors at night</p>\n<p>Control mosquito breeding sites</p>\n<p>~</p>\n<p>Eliminate collections of stagnant water where mosquitoes</p>\n<p>breed, e.g. in empty cans/ containers, potholes, old car</p>\n<p>tyres, plastic bags, and footprints by disposal, draining, or</p>\n<p>covering with soil or sand</p>\n<p>~</p>\n<p>Destroy mosquito larvae by dosing stagnant water bodies</p>\n<p>with larvicides or with biological methods (e.g. larvae- eating</p>\n<p>fish)</p>\n<p>Give public health education on the above measures include the need</p>\n<p>for self testing (self-care) using RDT before any medication.</p>\n<p>2.5.4 Human African Trypanosomiasis (Sleeping Sickness)</p>\n<h3>ICD10 CODE: B56</h3>\n<p>A disease caused by trypanosomes (a protozoa) and transmitted to</p>\n<p>humans by several species of tsetse fly</p>\n<p>Cause</p>\n<p>~</p>\n<p>Trypanosoma rhodesiense (mostly in the Central and East\u00ad</p>\n<p>ern regions of Uganda)</p>\n<p>~</p>\n<p>Trypanosoma gambiense (mostly in West Nile region)</p>\n<p>~</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>May be history of tsetse fly bite and swelling at site of bite</p>\n<p>after 7-14 days (more often in T. rhodesiense, rarely in T.</p>\n<p>Gambiense)</p>\n<p>181</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 248,
        "content": "T. Rhodesiense\n \n~\nIncubation is 2-3 weeks\n \n~\nEarly stage (haemolymphatic stage): headache not respond\u00ad\ning to common analgesics, fever, generalised lymphadenop\u00ad\nathy, joint pains\n \n~\nLate stage (meningoencephalitis stage): after some weeks, \nneurological and psychiatric symptoms like apathy, day \nsleepiness, paralysis, seizures\n \n~\nIf not treated: cachexia, lethargy, coma and death within 3-6 \nmonths\nT. gambiense\n \n~\nSimilar to the rhodesiense but less acute and with slower \nprogression\n \n~\nIncubation can last several years\nDifferential diagnosis\n \n~\nMalaria, meningitis\n \n~\nTB, HIV/AIDS\nInvestigations\n \n\u0081\nBlood: Slides for trypanosomes\n \n\u0081\nCSF: For trypanosomes, lymphocyte count\n \n\u0081\nAspirate from chancre/lymph node: for trypanosomes\nManagement\nThis is based on the findings of the CSF analysis, determining the stage \nof disease. To determine the medicine of choice, the disease is divided \ninto two stages: early and late stage\n182\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>T. Rhodesiense</p>\n<p>~</p>\n<p>Incubation is 2-3 weeks</p>\n<p>~</p>\n<p>Early stage (haemolymphatic stage): headache not respond\u00ad</p>\n<p>ing to common analgesics, fever, generalised lymphadenop\u00ad</p>\n<p>athy, joint pains</p>\n<p>~</p>\n<p>Late stage (meningoencephalitis stage): after some weeks,</p>\n<p>neurological and psychiatric symptoms like apathy, day</p>\n<p>sleepiness, paralysis, seizures</p>\n<p>~</p>\n<p>If not treated: cachexia, lethargy, coma and death within 3-6</p>\n<p>months</p>\n<p>T. gambiense</p>\n<p>~</p>\n<p>Similar to the rhodesiense but less acute and with slower</p>\n<p>progression</p>\n<p>~</p>\n<p>Incubation can last several years</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Malaria, meningitis</p>\n<p>~</p>\n<h3>TB, HIV/AIDS</h3>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Slides for trypanosomes</p>\n<p>\u0081</p>\n<p>CSF: For trypanosomes, lymphocyte count</p>\n<p>\u0081</p>\n<p>Aspirate from chancre/lymph node: for trypanosomes</p>\n<p>Management</p>\n<p>This is based on the findings of the CSF analysis, determining the stage</p>\n<p>of disease. To determine the medicine of choice, the disease is divided</p>\n<p>into two stages: early and late stage</p>\n<p>182</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 249,
        "content": "STAGE\nFEATURES\nEarly (first) stage\n \n~\nCSF is normal\n \n~\nLymphocytes <5 cells/mm3\n \n~\nTotal \nprotein \n<37 \nmg/dl \n(by \ndye-binding protein assay) or < 25 \nmg/dl (by Double Standard & Cen\u00ad\ntrifuge Metod)\n \n~\nAbsence of trypanosomes (by Dou\u00ad\nble Standard and Centrifuge Method)\nLate (second) stage\n \n~\nLymphocytes > 5 cell/ mm3 And/\nor\n \n~\nPresence of trypanosomes\nTREATMENT\nLOC\nEarly (first) stage\nT. rhodesiense sleeping sickness \nFor both children and adults \n\t\n\u0089\nSuramin IV\n \n- A test dose of 5 mg/kg of body weight should first \nbe administered to test for anaphylactic reaction\n \n- Followed by five injections of 20 mg/kg every 5 \ndays interval\nDay 0: 5 mg/kg body weight\nDay 3: 20 mg/kg body weight\nDay 8: 20 mg/kg body weight\nDay 13: 20 mg/kg body weight\nDay 18: 20 mg/kg body weight\nDay 23: 20 mg/kg body weight \nIf anaphylaxis: do not administer\nRR\nPatient with suspected or diagnosed sleeping sickness should be managed \nat referral facilities.\n183\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<h3>STAGE</h3>\n<h3>FEATURES</h3>\n<p>Early (first) stage</p>\n<p>~</p>\n<p>CSF is normal</p>\n<p>~</p>\n<p>Lymphocytes <5 cells/mm3</p>\n<p>~</p>\n<p>Total</p>\n<p>protein</p>\n<p><37</p>\n<p>mg/dl</p>\n<p>(by</p>\n<p>dye-binding protein assay) or < 25</p>\n<p>mg/dl (by Double Standard & Cen\u00ad</p>\n<p>trifuge Metod)</p>\n<p>~</p>\n<p>Absence of trypanosomes (by Dou\u00ad</p>\n<p>ble Standard and Centrifuge Method)</p>\n<p>Late (second) stage</p>\n<p>~</p>\n<p>Lymphocytes > 5 cell/ mm3 And/</p>\n<p>or</p>\n<p>~</p>\n<p>Presence of trypanosomes</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Early (first) stage</p>\n<p>T. rhodesiense sleeping sickness</p>\n<p>For both children and adults</p>\n<p>\u0089</p>\n<p>Suramin IV</p>\n<p>- A test dose of 5 mg/kg of body weight should first</p>\n<p>be administered to test for anaphylactic reaction</p>\n<p>- Followed by five injections of 20 mg/kg every 5</p>\n<p>days interval</p>\n<p>Day 0: 5 mg/kg body weight</p>\n<p>Day 3: 20 mg/kg body weight</p>\n<p>Day 8: 20 mg/kg body weight</p>\n<p>Day 13: 20 mg/kg body weight</p>\n<p>Day 18: 20 mg/kg body weight</p>\n<p>Day 23: 20 mg/kg body weight</p>\n<p>If anaphylaxis: do not administer</p>\n<p>RR</p>\n<p>Patient with suspected or diagnosed sleeping sickness should be managed</p>\n<p>at referral facilities.</p>\n<p>183</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 250,
        "content": "Adults >15 years\n \n- Nifurtimox/Elfornithine combination therapy (NECT)\n \n- Nifurtimox: 5 mg/kg every 8 hours orally for 10\n \n- days (15 mg/kg/day)\n \n- Plus Eflornithine 200 mg/kg 12 hourly for 7 days (400 \nmg/kg/day). Dilute Eflornithine dose of 200 mg/kg into \n250 ml of distilled water and administer the infusion over \nat least 2 hours (50 drops/minute)\n \n- Infusions are given slowly to prevent convulsions\nTREATMENT\nLOC\nT. gambiense sleeping sickness\nFor both children and adults\n\t\n\u0089\nPentamidine IM 4 mg/kg daily for 7 days\n \n- Give food 1 hour before to prevent hypoglycaemia\n \n- The patient should be in a supine position \nduring administration and 1 hour after to prevent \nhypotension\nLate (second) stage\nT. rhodesiense sleeping sickness\n \n- For both children and adults\n\t\n\u0089\nIV Melarsoprol 2.2 mg/kg body weight daily for 10 days\n \n- T.gambiense sleeping sickness Children \u2264 12 years \nand <35 kg\n \n- f Eflornithine IV 150 mg/kg 6 hourly for 14 days \n(total dose of 600 mg/kg/day. Dilute 150 mg/\nkg dose of eflornithine into the 100 ml of distilled \nwater. Administer the infusion over at least 2 hours\n \n- Children >12 years up to 15 years\n\t\n\u0089\nEflornithine IV 100 mg/kg 6 hourly for 14 days (total dose \nof 400 mg/kg per day). Dilute the eflornithine dose of \n100 mg/kg into the 100 ml of distilled water. Administer \nthe infusion over at least 2 hours (rate 20 drops/minute)\nRR\n184\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Adults >15 years</p>\n<p>- Nifurtimox/Elfornithine combination therapy (NECT)</p>\n<p>- Nifurtimox: 5 mg/kg every 8 hours orally for 10</p>\n<p>- days (15 mg/kg/day)</p>\n<p>- Plus Eflornithine 200 mg/kg 12 hourly for 7 days (400</p>\n<p>mg/kg/day). Dilute Eflornithine dose of 200 mg/kg into</p>\n<p>250 ml of distilled water and administer the infusion over</p>\n<p>at least 2 hours (50 drops/minute)</p>\n<p>- Infusions are given slowly to prevent convulsions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>T. gambiense sleeping sickness</p>\n<p>For both children and adults</p>\n<p>\u0089</p>\n<p>Pentamidine IM 4 mg/kg daily for 7 days</p>\n<p>- Give food 1 hour before to prevent hypoglycaemia</p>\n<p>- The patient should be in a supine position</p>\n<p>during administration and 1 hour after to prevent</p>\n<p>hypotension</p>\n<p>Late (second) stage</p>\n<p>T. rhodesiense sleeping sickness</p>\n<p>- For both children and adults</p>\n<p>\u0089</p>\n<p>IV Melarsoprol 2.2 mg/kg body weight daily for 10 days</p>\n<p>- T.gambiense sleeping sickness Children \u2264 12 years</p>\n<p>and <35 kg</p>\n<p>- f Eflornithine IV 150 mg/kg 6 hourly for 14 days</p>\n<p>(total dose of 600 mg/kg/day. Dilute 150 mg/</p>\n<p>kg dose of eflornithine into the 100 ml of distilled</p>\n<p>water. Administer the infusion over at least 2 hours</p>\n<p>- Children >12 years up to 15 years</p>\n<p>\u0089</p>\n<p>Eflornithine IV 100 mg/kg 6 hourly for 14 days (total dose</p>\n<p>of 400 mg/kg per day). Dilute the eflornithine dose of</p>\n<p>100 mg/kg into the 100 ml of distilled water. Administer</p>\n<p>the infusion over at least 2 hours (rate 20 drops/minute)</p>\n<p>RR</p>\n<p>184</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 251,
        "content": "Prevention\n \n~\nTrapping of tsetse flies\n \n~\nClearing of bushes around homes and paths\n \n~\nEarly detection and treatment of cases\nRelapses\n\t\n\u0089\nIV melarsoprol 2.2 mg/kg once daily for 10 days\nNote\n \n~\nCorticosteroids: Should be given to patients with late try\u00ad\npanosomiasis on melarsoprol who may have\n \n~\nhypoadrenalism - the steroids may also reduce any drug \nreactions\n \n~\nDo not give hydrocortisone after day 24, even though the \nmelarsoprol treatment is not yet complete\n \n~\nIf prednisolone is used instead of hydrocortisone, the an\u00ad\nti-inflammatory action is similar but the correction of the \nhypoadrenalism will be much less marked\n \n~\nSuramin: Do not use this medicine for early or late stage\nT. gambiense treatment in onchocerciasis-endemic areas as it may \ncause blindness in any onchocerciasis-infected patients by killing the \nfilariae in the eye\n185\nUganda Clinical Guidelines 2023\nCHAPTER 2: Infectious Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Trapping of tsetse flies</p>\n<p>~</p>\n<p>Clearing of bushes around homes and paths</p>\n<p>~</p>\n<p>Early detection and treatment of cases</p>\n<p>Relapses</p>\n<p>\u0089</p>\n<p>IV melarsoprol 2.2 mg/kg once daily for 10 days</p>\n<p>Note</p>\n<p>~</p>\n<p>Corticosteroids: Should be given to patients with late try\u00ad</p>\n<p>panosomiasis on melarsoprol who may have</p>\n<p>~</p>\n<p>hypoadrenalism - the steroids may also reduce any drug</p>\n<p>reactions</p>\n<p>~</p>\n<p>Do not give hydrocortisone after day 24, even though the</p>\n<p>melarsoprol treatment is not yet complete</p>\n<p>~</p>\n<p>If prednisolone is used instead of hydrocortisone, the an\u00ad</p>\n<p>ti-inflammatory action is similar but the correction of the</p>\n<p>hypoadrenalism will be much less marked</p>\n<p>~</p>\n<p>Suramin: Do not use this medicine for early or late stage</p>\n<p>T. gambiense treatment in onchocerciasis-endemic areas as it may</p>\n<p>cause blindness in any onchocerciasis-infected patients by killing the</p>\n<p>filariae in the eye</p>\n<p>185</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 2: Infectious Diseases</p>"
    },
    {
        "page_number": 252,
        "content": "Always refer to the latest Ministry of Health PMTCT, ART, and STI \nGuidelines for the management of HIV and Sexually Transmitted Infec\u00ad\ntions. This section has been adapted from the  \u201ccurrent Consolidated \nguidelines for prevention and treatment of HIV in Uganda\u201d.\n3.1 \t HIV INFECTION AND ACQUIRED IMMUNODEFI\u00ad\nCIENCY SYNDROME (AIDS)        ICD 10 CODE: B20\nAcquired Immunodeficiency Syndrome (AIDS) is a condition of reduced \nimmunity as a result of infection with the Human Immunodeficiency \nVirus (HIV). HIV should be confirmed with an HIV test.\nTest and Treat policy\nUganda has adopted the \u201cTest and Treat Policy\u201d, which involves pro\u00ad\nviding lif long antiretroviral therapy (ART) to ALL people living with \nHIV irrespective of CD4 count or clinical staging.\nHIV/AIDS and Sexually Transmitted \nInfections\n3\nCauses\n \n~\nHuman Immunodeficiency Virus\nModes of transmission\n \n~\nSexual intercourse with an HIV-infected person\n \n~\nTransfusion with HIV-infected blood\n \n~\nMother-To-Child Transmission during pregnancy, delivery, \nor through breastfeeding\n186\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Always refer to the latest Ministry of Health PMTCT, ART, and STI</p>\n<p>Guidelines for the management of HIV and Sexually Transmitted Infec\u00ad</p>\n<p>tions. This section has been adapted from the  \u201ccurrent Consolidated</p>\n<p>guidelines for prevention and treatment of HIV in Uganda\u201d.</p>\n<h3>3.1 \t HIV INFECTION AND ACQUIRED IMMUNODEFI\u00ad</h3>\n<h3>CIENCY SYNDROME (AIDS)        ICD 10 CODE: B20</h3>\n<p>Acquired Immunodeficiency Syndrome (AIDS) is a condition of reduced</p>\n<p>immunity as a result of infection with the Human Immunodeficiency</p>\n<p>Virus (HIV). HIV should be confirmed with an HIV test.</p>\n<p>Test and Treat policy</p>\n<p>Uganda has adopted the \u201cTest and Treat Policy\u201d, which involves pro\u00ad</p>\n<p>viding lif long antiretroviral therapy (ART) to ALL people living with</p>\n<p>HIV irrespective of CD4 count or clinical staging.</p>\n<p>HIV/AIDS and Sexually Transmitted</p>\n<p>Infections</p>\n<p>3</p>\n<p>Causes</p>\n<p>~</p>\n<p>Human Immunodeficiency Virus</p>\n<p>Modes of transmission</p>\n<p>~</p>\n<p>Sexual intercourse with an HIV-infected person</p>\n<p>~</p>\n<p>Transfusion with HIV-infected blood</p>\n<p>~</p>\n<p>Mother-To-Child Transmission during pregnancy, delivery,</p>\n<p>or through breastfeeding</p>\n<p>186</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 253,
        "content": "~\nHIV-contaminated sharp instruments, e.g., dental and surgi\u00ad\ncal equipment, needles, scalpels, razors, hair shaving equip\u00ad\nment, nail cutters, and other sharp objects\n \n~\nExposure to HIV-infected materials through an open wound \nor cut\nEpidemiological risk factors for HIV\n \n~\nPresent or past high-risk behaviour (multiple sexual part\u00ad\nners)\n \n~\nLoss of a spouse or partner from HIV disease\n \n~\nHaving sexually transmitted infections, especially Herpes \nsimplex virus type 2\n \n~\nBeing an uncircumcised man\n \n~\nBeing in an HIV-discordant sexual relationship or marriage\n \n~\nHistory of blood transfusion between 1975 and 1986\n3.1.1 Clinical Features of HIV \nThe WHO Clinical Staging of HIV for adults and children in the tables \nbelow shows the typical clinical features of HIV infection. The staging is \nbased on demonstration of one or more opportunistic infections or key \nfindings and correlates with disease progression and prognosis. Clinical \nstaging should be performed at HIV diagnosis, on entry into HIV care, \nat ART initiation and at every visit hereafter to help guide patient care \nand monitor disease progress.\n187\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>~</p>\n<p>HIV-contaminated sharp instruments, e.g., dental and surgi\u00ad</p>\n<p>cal equipment, needles, scalpels, razors, hair shaving equip\u00ad</p>\n<p>ment, nail cutters, and other sharp objects</p>\n<p>~</p>\n<p>Exposure to HIV-infected materials through an open wound</p>\n<p>or cut</p>\n<p>Epidemiological risk factors for HIV</p>\n<p>~</p>\n<p>Present or past high-risk behaviour (multiple sexual part\u00ad</p>\n<p>ners)</p>\n<p>~</p>\n<p>Loss of a spouse or partner from HIV disease</p>\n<p>~</p>\n<p>Having sexually transmitted infections, especially Herpes</p>\n<p>simplex virus type 2</p>\n<p>~</p>\n<p>Being an uncircumcised man</p>\n<p>~</p>\n<p>Being in an HIV-discordant sexual relationship or marriage</p>\n<p>~</p>\n<p>History of blood transfusion between 1975 and 1986</p>\n<p>3.1.1 Clinical Features of HIV</p>\n<p>The WHO Clinical Staging of HIV for adults and children in the tables</p>\n<p>below shows the typical clinical features of HIV infection. The staging is</p>\n<p>based on demonstration of one or more opportunistic infections or key</p>\n<p>findings and correlates with disease progression and prognosis. Clinical</p>\n<p>staging should be performed at HIV diagnosis, on entry into HIV care,</p>\n<p>at ART initiation and at every visit hereafter to help guide patient care</p>\n<p>and monitor disease progress.</p>\n<p>187</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 254,
        "content": "Clinical Stage I: Asymptomatic\n1. Asymptomatic\n2.\t Persistent generalised lymphadenopathy\nPerformance Scale 1: asymptomatic, normal activity\nClinical Stage II: Mild\n1.\t Moderate unexplained weight loss (< 10% of presumed or measured \nbody weight)\n2.\t Minor mucocutaneous manifestations (seborrheic dermatitis, popular \npruritic eruptions,  fungal nail infections, recurrent oral ulcerations, \nangular cheilitis)\n3.\t Herpes zoster\n4.\t Recurrent upper respiratory tract infections (e.g., bacterial sinusitis, \ntonsillitis, otitis media, pharyngitis)\nAnd/or performance scale 2: symptomatic but normal activity\nClinical Stage III: Advanced\n1.\t Unexplained severe weight loss (more than 10% of presumed or \nmeasured body weight)\n2.\t Unexplained chronic diarrhoea for longer than one month\n3.\t Unexplained persistent fever (intermittent or constant for longer \nthan one month)\n4.\t Persistent oral candidiasis\n5.\t Oral hairy leukoplakia\n6.\t Pulmonary tuberculosis\n7.\t Severe bacterial infections (such as pneumonia, pyomyositis, em\u00ad\npyema, bone or joint infection, bacteraemia, meningitis)\nWHO Staging for HIV Infection and Disease in Adults and Adolescents\n188\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Clinical Stage I: Asymptomatic</p>\n<li>. Asymptomatic</li>\n<p>2.\t Persistent generalised lymphadenopathy</p>\n<p>Performance Scale 1: asymptomatic, normal activity</p>\n<p>Clinical Stage II: Mild</p>\n<li>.\t Moderate unexplained weight loss (< 10% of presumed or measured</li>\n<p>body weight)</p>\n<p>2.\t Minor mucocutaneous manifestations (seborrheic dermatitis, popular</p>\n<p>pruritic eruptions,  fungal nail infections, recurrent oral ulcerations,</p>\n<p>angular cheilitis)</p>\n<p>3.\t Herpes zoster</p>\n<p>4.\t Recurrent upper respiratory tract infections (e.g., bacterial sinusitis,</p>\n<p>tonsillitis, otitis media, pharyngitis)</p>\n<p>And/or performance scale 2: symptomatic but normal activity</p>\n<p>Clinical Stage III: Advanced</p>\n<li>.\t Unexplained severe weight loss (more than 10% of presumed or</li>\n<p>measured body weight)</p>\n<p>2.\t Unexplained chronic diarrhoea for longer than one month</p>\n<p>3.\t Unexplained persistent fever (intermittent or constant for longer</p>\n<p>than one month)</p>\n<p>4.\t Persistent oral candidiasis</p>\n<p>5.\t Oral hairy leukoplakia</p>\n<p>6.\t Pulmonary tuberculosis</p>\n<p>7.\t Severe bacterial infections (such as pneumonia, pyomyositis, em\u00ad</p>\n<p>pyema, bone or joint infection, bacteraemia, meningitis)</p>\n<p>WHO Staging for HIV Infection and Disease in Adults and Adolescents</p>\n<p>188</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 255,
        "content": "8.\t Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis\n9.\t Unexplained anaemia (below 8 g/dl), neutropenia (below 0.5\u00d7109per \nlitre), or chronic thrombocytopenia (below 50\u00d7 109 per litre)\nAnd/or performance scale 3: Bed ridden for less than 50% of the day \nduring the last month\nClinical Stage IV: Severe\n1.\t HIV wasting syndrome\n2.\t Pneumocystis jirovecii pneumonia (PCP)\n3.\t Recurrent severe bacterial pneumonia (> 2 episodes within 1 year)\n4.\t Toxoplasmosis of the brain\n5.\t Cryptosporidiosis with diarrhoea for longer than 1 month\n6.\t Chronic isosporiasis\n7.\t Extrapulmonary cryptococcosis including meningitis\n8.\t Cytomegalovirus infection (retinitis or infection of other organs \nother than liver, spleen or lymph nodes)\n9.\t Chronic oro-labial, genital or ano-rectal herpes simplex virus (HSV) \ninfection for >1 month\n10. Progressive multifocal leukoencephalopathy (PML)\n11. Any disseminated endemic mycosis such as histoplasmosis, coc\u00ad\ncidioidomycosis\n12. Candidiasis of the oesophagus, trachea, bronchi, or lungs\n13. Disseminated non-tuberculous mycobacterial infection\n14. Recurrent septicaemia (including non-typhoid salmonella)\n15. Extrapulmonary tuberculosis\n16. Lymphoma (cerebral or B-cell non-Hodgkin)\n17. Invasive cancer of the cervix\n189\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>8.\t Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis</p>\n<p>9.\t Unexplained anaemia (below 8 g/dl), neutropenia (below 0.5\u00d7109per</p>\n<p>litre), or chronic thrombocytopenia (below 50\u00d7 109 per litre)</p>\n<p>And/or performance scale 3: Bed ridden for less than 50% of the day</p>\n<p>during the last month</p>\n<p>Clinical Stage IV: Severe</p>\n<li>.\t HIV wasting syndrome</li>\n<p>2.\t Pneumocystis jirovecii pneumonia (PCP)</p>\n<p>3.\t Recurrent severe bacterial pneumonia (> 2 episodes within 1 year)</p>\n<p>4.\t Toxoplasmosis of the brain</p>\n<p>5.\t Cryptosporidiosis with diarrhoea for longer than 1 month</p>\n<p>6.\t Chronic isosporiasis</p>\n<p>7.\t Extrapulmonary cryptococcosis including meningitis</p>\n<p>8.\t Cytomegalovirus infection (retinitis or infection of other organs</p>\n<p>other than liver, spleen or lymph nodes)</p>\n<p>9.\t Chronic oro-labial, genital or ano-rectal herpes simplex virus (HSV)</p>\n<p>infection for >1 month</p>\n<p>10. Progressive multifocal leukoencephalopathy (PML)</p>\n<p>11. Any disseminated endemic mycosis such as histoplasmosis, coc\u00ad</p>\n<p>cidioidomycosis</p>\n<p>12. Candidiasis of the oesophagus, trachea, bronchi, or lungs</p>\n<p>13. Disseminated non-tuberculous mycobacterial infection</p>\n<p>14. Recurrent septicaemia (including non-typhoid salmonella)</p>\n<p>15. Extrapulmonary tuberculosis</p>\n<p>16. Lymphoma (cerebral or B-cell non-Hodgkin)</p>\n<p>17. Invasive cancer of the cervix</p>\n<p>189</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 256,
        "content": "18. Kaposi sarcoma\n19. HIV encephalopathy\n20. Atypical disseminated leishmaniasis\n21. Symptomatic HIV-associated nephropathy or symptomatic HIV \nassociated cardiomyopathy and/or performance scale 4: Bed-ridden \nfor more than 50% of the day during the last month\nDifferential diagnosis\n \n~\nTB\n \n~\nUntreated diabetes mellitus\n \n~\nMalnutrition\n \n~\nCancer\n \n~\nOther chronic diseases\n3.1.2\t\nDiagnosis and Investigations of HIV\nHIV testing is the point of entry into comprehensive care HIV services. \nThe aim of HIV testing services (HTS) is to promptly identify HIV status \nto ensure early linkage to prevention, treatment, and support services. \nEarly diagnosis is fundamental for early treatment, good prognosis and \nreduction in transmission. HTS should be availed to all persons at risk \nof HIV infection using cost-effective and high-impact approaches. HTS \nshould be differentiated to subpopulations and geographical locations \nbecause less than 20% of PLHIV aged 15 years and above do not know \ntheir status. Uganda is currently implementing targeted HIV testing to \noptimize HIV case identification and linkage to care. People at high risk \nof HIV acquisition include: being in a sexual relationship with multiple \nconcurrent partners; belonging to a key, vulnerable or priority popu\u00ad\nlation (e.g., children, adolescent girls and young women, pregnant or \nbreastfeeding women); being a sexual contact to an index client; being \na biological child to an HIV positive client; not knowing your partner\u2019s \nHIV status; or being in a serodiscordant relationship.\n190\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>18. Kaposi sarcoma</p>\n<p>19. HIV encephalopathy</p>\n<p>20. Atypical disseminated leishmaniasis</p>\n<p>21. Symptomatic HIV-associated nephropathy or symptomatic HIV</p>\n<p>associated cardiomyopathy and/or performance scale 4: Bed-ridden</p>\n<p>for more than 50% of the day during the last month</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>TB</p>\n<p>~</p>\n<p>Untreated diabetes mellitus</p>\n<p>~</p>\n<p>Malnutrition</p>\n<p>~</p>\n<p>Cancer</p>\n<p>~</p>\n<p>Other chronic diseases</p>\n<p>3.1.2</p>\n<p>Diagnosis and Investigations of HIV</p>\n<p>HIV testing is the point of entry into comprehensive care HIV services.</p>\n<p>The aim of HIV testing services (HTS) is to promptly identify HIV status</p>\n<p>to ensure early linkage to prevention, treatment, and support services.</p>\n<p>Early diagnosis is fundamental for early treatment, good prognosis and</p>\n<p>reduction in transmission. HTS should be availed to all persons at risk</p>\n<p>of HIV infection using cost-effective and high-impact approaches. HTS</p>\n<p>should be differentiated to subpopulations and geographical locations</p>\n<p>because less than 20% of PLHIV aged 15 years and above do not know</p>\n<p>their status. Uganda is currently implementing targeted HIV testing to</p>\n<p>optimize HIV case identification and linkage to care. People at high risk</p>\n<p>of HIV acquisition include: being in a sexual relationship with multiple</p>\n<p>concurrent partners; belonging to a key, vulnerable or priority popu\u00ad</p>\n<p>lation (e.g., children, adolescent girls and young women, pregnant or</p>\n<p>breastfeeding women); being a sexual contact to an index client; being</p>\n<p>a biological child to an HIV positive client; not knowing your partner\u2019s</p>\n<p>HIV status; or being in a serodiscordant relationship.</p>\n<p>190</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 257,
        "content": "The following approaches are utilized in targeted HIV testing.\n1. Screening for HIV testing eligibility for children, adolescents and adults \n2. Index client testing (ICT), including Assisted Partner notification (APN) \nand testing for biological children/ Know Your Child Status (KYCS). \n3. Social Network Strategy (SNS) \n4. HIV Self-Testing (HIVST) \nPre and post counselling and consent are needed except in the following \nsituations:\n\t\n\u0089\nDiagnostic testing: test carried out on very sick,\nunconscious, symptomatic or mentall ill by attending health care team \nfor the purpose of better patient management\n\t\n\u0089\nRoutine testing: for individuals likely to pose a risk of HIV infection \nto others e.g. pregnant and breastfeeding mothers, sexual offenders \nand survivors, blood or body tissue or organ donors. Individuals \ntested using this appraoch must be given an opportunity to know \ntheir status\n \nIf a patient is positive, he/she must be IMMEDIATELY connected to \nHIV care services.\nIn adults and children >18 months, testing is based on serological (an\u00ad\ntibody) testing.\nDue to the window period between infection and production of detect\u00ad\nable levels of antibodies, patients who are negative should be re-tested \nafter three months if they had a possible exposure in the 3 months \nbefore the test.\n191\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>The following approaches are utilized in targeted HIV testing.</p>\n<li>. Screening for HIV testing eligibility for children, adolescents and adults</li>\n<p>2. Index client testing (ICT), including Assisted Partner notification (APN)</p>\n<p>and testing for biological children/ Know Your Child Status (KYCS).</p>\n<p>3. Social Network Strategy (SNS)</p>\n<p>4. HIV Self-Testing (HIVST)</p>\n<p>Pre and post counselling and consent are needed except in the following</p>\n<p>situations:</p>\n<p>\u0089</p>\n<p>Diagnostic testing: test carried out on very sick,</p>\n<p>unconscious, symptomatic or mentall ill by attending health care team</p>\n<p>for the purpose of better patient management</p>\n<p>\u0089</p>\n<p>Routine testing: for individuals likely to pose a risk of HIV infection</p>\n<p>to others e.g. pregnant and breastfeeding mothers, sexual offenders</p>\n<p>and survivors, blood or body tissue or organ donors. Individuals</p>\n<p>tested using this appraoch must be given an opportunity to know</p>\n<p>their status</p>\n<p>If a patient is positive, he/she must be IMMEDIATELY connected to</p>\n<p>HIV care services.</p>\n<p>In adults and children >18 months, testing is based on serological (an\u00ad</p>\n<p>tibody) testing.</p>\n<p>Due to the window period between infection and production of detect\u00ad</p>\n<p>able levels of antibodies, patients who are negative should be re-tested</p>\n<p>after three months if they had a possible exposure in the 3 months</p>\n<p>before the test.</p>\n<p>191</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 258,
        "content": "Screening Test\nDETERMINE\nReport HIV \nNegative\nReport HIV \nNegative\nTie-Breaker Test\nSD BIOLINE\nConfirmatory \nTest: STAT-PAK\nReport as \nInconclusive\nRe-Test after \n14 days\nReport HIV \nPositive\nSerial HIV Testing Algorithm for testing persons above 18 months of \nage in Uganda.\n192\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Screening Test</p>\n<h3>DETERMINE</h3>\n<p>Report HIV</p>\n<p>Negative</p>\n<p>Report HIV</p>\n<p>Negative</p>\n<p>Tie-Breaker Test</p>\n<h3>SD BIOLINE</h3>\n<p>Confirmatory</p>\n<p>Test: STAT-PAK</p>\n<p>Report as</p>\n<p>Inconclusive</p>\n<p>Re-Test after</p>\n<p>14 days</p>\n<p>Report HIV</p>\n<p>Positive</p>\n<p>Serial HIV Testing Algorithm for testing persons above 18 months of</p>\n<p>age in Uganda.</p>\n<p>192</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 259,
        "content": "Serological testing is available from HC2 level.\nIn children below 18 months, testing is virological, that is based on direct \ndetection of viral DNA (DNA-PCR).\nVirological testing (DNA-PCR and viral load) is done on DBS (dried \nblood spots) samples which can be collected from HC2 and are sent to \na central national laboratory through the hub system.\nHIV Testing Algorithm using the HIV-Syphilis Duo Kit in MCH Settings\nNo, Only HIV\nNo, Only syphilis\nDoes client need both syphilis and HIV \ntest (new, or previously negative)\nClient already know \nHIV postitive+ve \n(TRRK)\nTest for syphilis only \nusing the single \nsyphilis rapid test \nand manage as \nappropriate\nRe-test immediately \nwith the National \nAlgorithm\nReport HIV positive \nNotify the partner\nReactive\nNon-Reactive\nConfirmatory \ntest Statpak\nReactive for HIV*\nNon-Reactive for \nHIV and Syphilis\nClient tested positive \nfor syphilis and on \ntreatment within 1 year\nTest for HIV using the \nNational Algorithm\nReactive as Neg\u00ad\native for HIV and \nSyphilis Encourage \npartner testing\nReactive for syphilis \nUse appropriate \ntreatment for \nsyphilis \nNotify the partner\nScreening Test \nHIV/Syphilis Duo Test\n193\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Serological testing is available from HC2 level.</p>\n<p>In children below 18 months, testing is virological, that is based on direct</p>\n<p>detection of viral DNA (DNA-PCR).</p>\n<p>Virological testing (DNA-PCR and viral load) is done on DBS (dried</p>\n<p>blood spots) samples which can be collected from HC2 and are sent to</p>\n<p>a central national laboratory through the hub system.</p>\n<p>HIV Testing Algorithm using the HIV-Syphilis Duo Kit in MCH Settings</p>\n<p>No, Only HIV</p>\n<p>No, Only syphilis</p>\n<p>Does client need both syphilis and HIV</p>\n<p>test (new, or previously negative)</p>\n<p>Client already know</p>\n<p>HIV postitive+ve</p>\n<h3>(TRRK)</h3>\n<p>Test for syphilis only</p>\n<p>using the single</p>\n<p>syphilis rapid test</p>\n<p>and manage as</p>\n<p>appropriate</p>\n<p>Re-test immediately</p>\n<p>with the National</p>\n<p>Algorithm</p>\n<p>Report HIV positive</p>\n<p>Notify the partner</p>\n<p>Reactive</p>\n<p>Non-Reactive</p>\n<p>Confirmatory</p>\n<p>test Statpak</p>\n<p>Reactive for HIV*</p>\n<p>Non-Reactive for</p>\n<p>HIV and Syphilis</p>\n<p>Client tested positive</p>\n<p>for syphilis and on</p>\n<p>treatment within 1 year</p>\n<p>Test for HIV using the</p>\n<p>National Algorithm</p>\n<p>Reactive as Neg\u00ad</p>\n<p>ative for HIV and</p>\n<p>Syphilis Encourage</p>\n<p>partner testing</p>\n<p>Reactive for syphilis</p>\n<p>Use appropriate</p>\n<p>treatment for</p>\n<p>syphilis</p>\n<p>Notify the partner</p>\n<p>Screening Test</p>\n<p>HIV/Syphilis Duo Test</p>\n<p>193</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 260,
        "content": "HIV testing in children less than 18 months\nThe recommended test for children <18 months is virological (DNA-PCR) \ntesting, since antibody tests will detect antibodies passed to the child \nfrom the mother (so the test can give a false positive).\nIf the mother is HIV negative:\nf The child is classified as HIV negative\nIf the mother is positive:\n \n\u0081\nDo DNA PCR at 6 weeks of age or at an earlier opportunity \nthereafter\n\t\n\u0089\nStart cotrimoxazole prophylaxis and Niverapine syrup till \nHIV status is confirmed for the child\n \n\u0081\nIf PCR is positive, enroll child for ART\n \n\u0081\nIf PCR is negative and child never breasted the  child is negative.\n\t\n\u0089\nStop cotrimoxazole and Niverapine.\n\t\n\u0089\nFollow up every 3 months and do HIV rapid test (serolog\u00ad\nical) at 18 months.\n \n\u0081\nIf PCR is negative BUT child is breastfeeding/has breasfed \nin the last 6 weeks, re-check PCR 6 weeks after cessation of \nbreastfeeding.\nIf mother\u2019s status is unknown:\n \n\u0081\nTest the mother and continue management according to the \nresult\nIf mother unavailable:\n \n\u0081\nPerform rapid antibody testing on the child. The result will give \nindication on the mother\u2019s status:\n \n- If the test is negative: child negative\n \n- If the test is positive, follow algorithm for managing a child \nfrom a HIV positive mother.\n194\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>HIV testing in children less than 18 months</p>\n<p>The recommended test for children <18 months is virological (DNA-PCR)</p>\n<p>testing, since antibody tests will detect antibodies passed to the child</p>\n<p>from the mother (so the test can give a false positive).</p>\n<p>If the mother is HIV negative:</p>\n<p>f The child is classified as HIV negative</p>\n<p>If the mother is positive:</p>\n<p>\u0081</p>\n<p>Do DNA PCR at 6 weeks of age or at an earlier opportunity</p>\n<p>thereafter</p>\n<p>\u0089</p>\n<p>Start cotrimoxazole prophylaxis and Niverapine syrup till</p>\n<p>HIV status is confirmed for the child</p>\n<p>\u0081</p>\n<p>If PCR is positive, enroll child for ART</p>\n<p>\u0081</p>\n<p>If PCR is negative and child never breasted the  child is negative.</p>\n<p>\u0089</p>\n<p>Stop cotrimoxazole and Niverapine.</p>\n<p>\u0089</p>\n<p>Follow up every 3 months and do HIV rapid test (serolog\u00ad</p>\n<p>ical) at 18 months.</p>\n<p>\u0081</p>\n<p>If PCR is negative BUT child is breastfeeding/has breasfed</p>\n<p>in the last 6 weeks, re-check PCR 6 weeks after cessation of</p>\n<p>breastfeeding.</p>\n<p>If mother\u2019s status is unknown:</p>\n<p>\u0081</p>\n<p>Test the mother and continue management according to the</p>\n<p>result</p>\n<p>If mother unavailable:</p>\n<p>\u0081</p>\n<p>Perform rapid antibody testing on the child. The result will give</p>\n<p>indication on the mother\u2019s status:</p>\n<p>- If the test is negative: child negative</p>\n<p>- If the test is positive, follow algorithm for managing a child</p>\n<p>from a HIV positive mother.</p>\n<p>194</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 261,
        "content": "TEST\nDESCRIPTION\nLOC\nCD4\nIt measures the level of CD4 T lym\u00ad\nphocytes, a subtype white blood cell. It \nreflects the level of compromise of the \nimmune system. It is used for initial as\u00ad\nsessment pre ART and for monitoring \nof ART effect.\nHC2\nViral Load\nIt measures the quantity of virus in the \nblood. It is used to monitor the effect \nof ARVs. It is currently done by DBS \n(Dried Blood Spot)\nHC2\nGenot ype \nTesting\nHIV genotypic resistance test is a quali\u00ad\ntative test that detects mutations associ\u00ad\nated with ARV drug resistance. The test \nevaluates if the HIV strain infecting the \nindividual has developed resistance to \none or more ARV drugs. This is useful \nin identifying a combination of ARVs to \nwhich the HIV strain is susceptible\n195\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TEST</h3>\n<h3>DESCRIPTION</h3>\n<h3>LOC</h3>\n<h3>CD4</h3>\n<p>It measures the level of CD4 T lym\u00ad</p>\n<p>phocytes, a subtype white blood cell. It</p>\n<p>reflects the level of compromise of the</p>\n<p>immune system. It is used for initial as\u00ad</p>\n<p>sessment pre ART and for monitoring</p>\n<p>of ART effect.</p>\n<h3>HC2</h3>\n<p>Viral Load</p>\n<p>It measures the quantity of virus in the</p>\n<p>blood. It is used to monitor the effect</p>\n<p>of ARVs. It is currently done by DBS</p>\n<p>(Dried Blood Spot)</p>\n<h3>HC2</h3>\n<p>Genot ype</p>\n<p>Testing</p>\n<p>HIV genotypic resistance test is a quali\u00ad</p>\n<p>tative test that detects mutations associ\u00ad</p>\n<p>ated with ARV drug resistance. The test</p>\n<p>evaluates if the HIV strain infecting the</p>\n<p>individual has developed resistance to</p>\n<p>one or more ARV drugs. This is useful</p>\n<p>in identifying a combination of ARVs to</p>\n<p>which the HIV strain is susceptible</p>\n<p>195</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 262,
        "content": "HIV-Exposed Infants Testing Algorithm\nWhat is the mother\u2019s HIV status?\nNegative\nHIV Negative Infant\nHIV Negative\nHIV Negative Infant\nManage as \nHIV Negative\nInitiate infants on ART immediately send \nconfirmatory PCR as you initiate ART \nDo not wait until results are back\nFINAL OUTCOME: HIV \nRapid testing at 18 moths\n3rd DNA PCR 6 week after cessation \nof breastfeeding Advise mother to \nbreastfeed up to 1 year\nIs the child breastfeeding or had \nbreastfed within 6wks of 2nd PCR? \nManage as HIV Negative\n2nd DNA PCR at 9 months\nHas child breastfed within \n6wks of 1st PCR?\n1st DNA PCR at 4-6 weeks \n(or if identified after, earliest \nopportunity up to 18 months)\nStart cotrimoxazole\nPositive\nHIV-EXPOSED INFANT\nUnknown\nPos\nPos\nPos\nNeg\nNeg\nNeg\nHIV POSITIVE\nHIV POSITIVE\nHIV POSITIVE\nHIV \nNegative\nNeg\nNo\nNo\nYes\nYes\nPos\nHIV Rapid Test on mother or infant \nto determine infant\u2019s exposure status*\n\u2022\t If an infant with a Negative previous PCR is symptpmatic while still breastfeeding, take off a PCR sample at that point in time. If negative, \nanother PCR sample must be taken according to the algorithm either 9 konths or 6bweeks after breastfeeding\n\u2022\t If monther\u2019 status cannot be ascertained, may use rapid test in bables to determine HIV exposure status, should perform DNA PCR for \nbaby who is symptomatic, mainourished or has TB as routine\n\u2022\t If breastfeeding is stopped before 9 months then a final DNA PCR can be done at any point 6 weeks after cessation of breastfeeding.\n\u2022\t For infants whose mothers are filling on any regimen: take off 2 DBS at the time of confirming the positive test \u2013 one for confirmation \nand one for HIVDR tseting\n196\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>HIV-Exposed Infants Testing Algorithm</p>\n<p>What is the mother\u2019s HIV status?</p>\n<p>Negative</p>\n<p>HIV Negative Infant</p>\n<p>HIV Negative</p>\n<p>HIV Negative Infant</p>\n<p>Manage as</p>\n<p>HIV Negative</p>\n<p>Initiate infants on ART immediately send</p>\n<p>confirmatory PCR as you initiate ART</p>\n<p>Do not wait until results are back</p>\n<h3>FINAL OUTCOME: HIV</h3>\n<p>Rapid testing at 18 moths</p>\n<p>3rd DNA PCR 6 week after cessation</p>\n<p>of breastfeeding Advise mother to</p>\n<p>breastfeed up to 1 year</p>\n<p>Is the child breastfeeding or had</p>\n<p>breastfed within 6wks of 2nd PCR?</p>\n<p>Manage as HIV Negative</p>\n<p>2nd DNA PCR at 9 months</p>\n<p>Has child breastfed within</p>\n<p>6wks of 1st PCR?</p>\n<p>1st DNA PCR at 4-6 weeks</p>\n<p>(or if identified after, earliest</p>\n<p>opportunity up to 18 months)</p>\n<p>Start cotrimoxazole</p>\n<p>Positive</p>\n<h3>HIV-EXPOSED INFANT</h3>\n<p>Unknown</p>\n<p>Pos</p>\n<p>Pos</p>\n<p>Pos</p>\n<p>Neg</p>\n<p>Neg</p>\n<p>Neg</p>\n<h3>HIV POSITIVE</h3>\n<h3>HIV POSITIVE</h3>\n<h3>HIV POSITIVE</h3>\n<h3>HIV</h3>\n<p>Negative</p>\n<p>Neg</p>\n<p>No</p>\n<p>No</p>\n<p>Yes</p>\n<p>Yes</p>\n<p>Pos</p>\n<p>HIV Rapid Test on mother or infant</p>\n<p>to determine infant\u2019s exposure status*</p>\n<li>If an infant with a Negative previous PCR is symptpmatic while still breastfeeding, take off a PCR sample at that point in time. If negative,</li>\n<p>another PCR sample must be taken according to the algorithm either 9 konths or 6bweeks after breastfeeding</p>\n<li>If monther\u2019 status cannot be ascertained, may use rapid test in bables to determine HIV exposure status, should perform DNA PCR for</li>\n<p>baby who is symptomatic, mainourished or has TB as routine</p>\n<li>If breastfeeding is stopped before 9 months then a final DNA PCR can be done at any point 6 weeks after cessation of breastfeeding.</li>\n<li>For infants whose mothers are filling on any regimen: take off 2 DBS at the time of confirming the positive test \u2013 one for confirmation</li>\n<p>and one for HIVDR tseting</p>\n<p>196</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 263,
        "content": "3.1.3\t\nMeasures before ARV Treatment\nEven without the use of specific ARV treatment, there are many ways \nin which good HIV management can help patients:\nTREATMENT\nLOC\nProphylaxis against opportunistic infections\nThe following groups have been prioritized for cotrimox\u00ad\nazole preventive therapy: \n\u2022 All PLHIV newly initiating on ART.\n\u2022 Those having a current WHO stage 3 or 4 event or other \nsymptoms of advanced disease.\n\u2022\t Pregnant and breast-feeding women.\nNote: Additional intermittent preventive treatment for malaria \nusing Sulfadoxine-Pyrimethamine (SP) is not required for \npregnant women on CPT.\n\u2022\t Children and adolescents aged 0-15 years.\nPatients suspected to have treatment failure\n\t\n\u0089\nCotrimoxazole 960 mg once daily for adults and children \n>30 kg\nChild <5 kg: 120 mg once daily Child 5-14.9 kg: 240 mg \nonce daily Child 15-29.9 kg: 480 mg once daily\n\t\n\u0089\nContraindications: known allergies, severe anaemia and \nneutropenia\nGuidance for when to stop CPT in stable PLHIV\n\u2022\t Patient should be older than 15 years of age.\n\u2022\t Patient should not be pregnant.\nHC2\n197\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.3</p>\n<p>Measures before ARV Treatment</p>\n<p>Even without the use of specific ARV treatment, there are many ways</p>\n<p>in which good HIV management can help patients:</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Prophylaxis against opportunistic infections</p>\n<p>The following groups have been prioritized for cotrimox\u00ad</p>\n<p>azole preventive therapy:</p>\n<li>All PLHIV newly initiating on ART.</li>\n<li>Those having a current WHO stage 3 or 4 event or other</li>\n<p>symptoms of advanced disease.</p>\n<li>Pregnant and breast-feeding women.</li>\n<p>Note: Additional intermittent preventive treatment for malaria</p>\n<p>using Sulfadoxine-Pyrimethamine (SP) is not required for</p>\n<p>pregnant women on CPT.</p>\n<li>Children and adolescents aged 0-15 years.</li>\n<p>Patients suspected to have treatment failure</p>\n<p>\u0089</p>\n<p>Cotrimoxazole 960 mg once daily for adults and children</p>\n<p>>30 kg</p>\n<p>Child <5 kg: 120 mg once daily Child 5-14.9 kg: 240 mg</p>\n<p>once daily Child 15-29.9 kg: 480 mg once daily</p>\n<p>\u0089</p>\n<p>Contraindications: known allergies, severe anaemia and</p>\n<p>neutropenia</p>\n<p>Guidance for when to stop CPT in stable PLHIV</p>\n<li>Patient should be older than 15 years of age.</li>\n<li>Patient should not be pregnant.</li>\n<h3>HC2</h3>\n<p>197</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 264,
        "content": "TREATMENT\nLOC\n\u2022\t Patient should have been on ART for at least one year.\n\u2022\t Patient\u2019s last VL should be suppressed.\n\u2022\t Patient should not have a current WHO stage 3 or 4 event \nor other symptoms of advanced HIV disease at the time \nof stopping CPT. \nWhen to re-start CPT in PLHIV\nCPT can be restarted in the following scenarios:\n\u2022\t New pregnancy \n\u2022\t Suspected treatment failure\n\u2022\t New Treatment WHO stage 3 or 4 condition\n Alternative: dapsone\nAdults and child >12 years: dapsone 100 mg daily\nChildren below 12 years: dapsone 2 mg/kg daily\nHC2\nTPT (TB Preventive treatment)\n\t\n\u0089\nsuch as;   isoniazid + rifapentine(3HP)  weekly for 3 \nmonths in all adults, adolescents and children >12 \nmonths living with HIV and in whom TB disease has \nbeen excluded (other medications for TPT refer to the \ncurrent HIV/TB guidelines)\n\t\n\u0089\nIf child <12 months, give only if history of contact with \nTB case and no active disease (one-month daily rifap\u00ad\nentine and isoniazid (1HP).)\n\u2013 Dose:  (see section 5.3.2.1 )\nHC3\nPrompt and appropriate medical care\n By treating opportunistic infections as  they occur\nBy treating symptoms, such as pain, diarrhoea, and skin \nproblems, as they develop\n Going for treatment promptly if unwell\nHC3\n198\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<li>Patient should have been on ART for at least one year.</li>\n<li>Patient\u2019s last VL should be suppressed.</li>\n<li>Patient should not have a current WHO stage 3 or 4 event</li>\n<p>or other symptoms of advanced HIV disease at the time</p>\n<p>of stopping CPT.</p>\n<p>When to re-start CPT in PLHIV</p>\n<p>CPT can be restarted in the following scenarios:</p>\n<li>New pregnancy</li>\n<li>Suspected treatment failure</li>\n<li>New Treatment WHO stage 3 or 4 condition</li>\n<p>Alternative: dapsone</p>\n<p>Adults and child >12 years: dapsone 100 mg daily</p>\n<p>Children below 12 years: dapsone 2 mg/kg daily</p>\n<h3>HC2</h3>\n<p>TPT (TB Preventive treatment)</p>\n<p>\u0089</p>\n<p>such as;   isoniazid + rifapentine(3HP)  weekly for 3</p>\n<p>months in all adults, adolescents and children >12</p>\n<p>months living with HIV and in whom TB disease has</p>\n<p>been excluded (other medications for TPT refer to the</p>\n<p>current HIV/TB guidelines)</p>\n<p>\u0089</p>\n<p>If child <12 months, give only if history of contact with</p>\n<p>TB case and no active disease (one-month daily rifap\u00ad</p>\n<p>entine and isoniazid (1HP).)</p>\n<p>\u2013 Dose:  (see section 5.3.2.1 )</p>\n<h3>HC3</h3>\n<p>Prompt and appropriate medical care</p>\n<p>By treating opportunistic infections as  they occur</p>\n<p>By treating symptoms, such as pain, diarrhoea, and skin</p>\n<p>problems, as they develop</p>\n<p>Going for treatment promptly if unwell</p>\n<h3>HC3</h3>\n<p>198</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 265,
        "content": "Positive health, dignity, and prevention intervention\nIntervention\nDescription\nPreventing HIV trans\u00ad\nmission\nPLHIV should be encouraged to \nadopt safer sexual practices includ\u00ad\ning abstinence, correct and con\u00ad\nsistent condom use. Condom use \nprevents HIV transmission, reduces \nrisk of other STIs, and prevents \nunintended pregnancies.\nDisclosure and partner \ntesting\nPLHIV should actively explore ways \nof disclosing their HIV status to \nsexual partners, family members \nand significant others. Offer provid\u00ad\ner- and/or counselor-mediated or \nsupported disclosure as options for \nthose who do not feel comfortable \ndisclosing on their own.\nFamily planning\nEncourage PLHIV to discuss their \nreproductive choices and support \nthem to adopt those which do not \ncompromise their health. For women \nwho choose to conceive, link them \nto eMTCT services.\nAlcohol and other risk \nreduction \nEducate on risks of alcohol abuse \nleading to poor treatment adherence \nresulting in disease progression, \nand the likelihood of engaging in \nrisky sexual behaviours, placing \nthemselves at increased risk for \nacquiring STIs and placing their \nnegative partners at risk for \ninfection.\n199\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Positive health, dignity, and prevention intervention</p>\n<p>Intervention</p>\n<p>Description</p>\n<p>Preventing HIV trans\u00ad</p>\n<p>mission</p>\n<p>PLHIV should be encouraged to</p>\n<p>adopt safer sexual practices includ\u00ad</p>\n<p>ing abstinence, correct and con\u00ad</p>\n<p>sistent condom use. Condom use</p>\n<p>prevents HIV transmission, reduces</p>\n<p>risk of other STIs, and prevents</p>\n<p>unintended pregnancies.</p>\n<p>Disclosure and partner</p>\n<p>testing</p>\n<p>PLHIV should actively explore ways</p>\n<p>of disclosing their HIV status to</p>\n<p>sexual partners, family members</p>\n<p>and significant others. Offer provid\u00ad</p>\n<p>er- and/or counselor-mediated or</p>\n<p>supported disclosure as options for</p>\n<p>those who do not feel comfortable</p>\n<p>disclosing on their own.</p>\n<p>Family planning</p>\n<p>Encourage PLHIV to discuss their</p>\n<p>reproductive choices and support</p>\n<p>them to adopt those which do not</p>\n<p>compromise their health. For women</p>\n<p>who choose to conceive, link them</p>\n<p>to eMTCT services.</p>\n<p>Alcohol and other risk</p>\n<p>reduction</p>\n<p>Educate on risks of alcohol abuse</p>\n<p>leading to poor treatment adherence</p>\n<p>resulting in disease progression,</p>\n<p>and the likelihood of engaging in</p>\n<p>risky sexual behaviours, placing</p>\n<p>themselves at increased risk for</p>\n<p>acquiring STIs and placing their</p>\n<p>negative partners at risk for</p>\n<p>infection.</p>\n<p>199</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 266,
        "content": "3.1.4 General Principles of Antiretroviral Treatment (ART)\nAssessment of patient\u2019s history\n \n~\nLevel of understanding of HIV/AIDS\n \n~\nLength of time since the diagnosis of HIV infection\n \n~\nDemographics and lifestyle: whether employed and nature  \nof work\n \n~\nHistory of previous ART \n \n~\nPregnancy risks: contraception options and choices, current \nor planned pregnancy, access to contraceptive services\n \n~\nSexual risks and disclosure: willingness to practice safer sex, \ndisclosure of HIV serostatus, use of condoms, HIV counsel\u00ad\nling, and testing of sex partners and children\n \n~\nSymptoms of chronic pain and depression\n \n~\nHistory of opportunistic infections and other significant ill\u00ad\nnesses e.g. TB and STIs, hospitalisations, and surgeries\n \n~\nCurrent medications (including anti-TB drugs, traditional \ntherapies, etc.)\nPhysical exam\n \n~\nWeight\n \n~\nNutritional status\n \n~\nFunctional capacity and level of disability\n \n~\nVital signs, skin, eyes, oropharynx (presence of thrush), \nlymph nodes, lungs, heart, abdomen, genital tract (STIs), ex\u00ad\ntremities, nervous system\nBaseline laboratory tests to assess immunosuppression and disease \naggressiveness\n \n~\nConfirming HIV serostatus\n \n~\nCD4 testing\n200\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.4 General Principles of Antiretroviral Treatment (ART)</p>\n<p>Assessment of patient\u2019s history</p>\n<p>~</p>\n<p>Level of understanding of HIV/AIDS</p>\n<p>~</p>\n<p>Length of time since the diagnosis of HIV infection</p>\n<p>~</p>\n<p>Demographics and lifestyle: whether employed and nature</p>\n<p>of work</p>\n<p>~</p>\n<p>History of previous ART</p>\n<p>~</p>\n<p>Pregnancy risks: contraception options and choices, current</p>\n<p>or planned pregnancy, access to contraceptive services</p>\n<p>~</p>\n<p>Sexual risks and disclosure: willingness to practice safer sex,</p>\n<p>disclosure of HIV serostatus, use of condoms, HIV counsel\u00ad</p>\n<p>ling, and testing of sex partners and children</p>\n<p>~</p>\n<p>Symptoms of chronic pain and depression</p>\n<p>~</p>\n<p>History of opportunistic infections and other significant ill\u00ad</p>\n<p>nesses e.g. TB and STIs, hospitalisations, and surgeries</p>\n<p>~</p>\n<p>Current medications (including anti-TB drugs, traditional</p>\n<p>therapies, etc.)</p>\n<p>Physical exam</p>\n<p>~</p>\n<p>Weight</p>\n<p>~</p>\n<p>Nutritional status</p>\n<p>~</p>\n<p>Functional capacity and level of disability</p>\n<p>~</p>\n<p>Vital signs, skin, eyes, oropharynx (presence of thrush),</p>\n<p>lymph nodes, lungs, heart, abdomen, genital tract (STIs), ex\u00ad</p>\n<p>tremities, nervous system</p>\n<p>Baseline laboratory tests to assess immunosuppression and disease</p>\n<p>aggressiveness</p>\n<p>~</p>\n<p>Confirming HIV serostatus</p>\n<p>~</p>\n<p>CD4 testing</p>\n<p>200</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 267,
        "content": "~\nPregnancy test\n \n~\nFull blood count particularly for patients starting on a \nAZT-containing regimen\nBaseline Labs to assess general health and diagnose any pre-existing HIV \ncomplications\n \n~\nSputum smear for AFB for patients who have coughed for \n> 2-3 weeks and a chest X-ray for patients who have unpro\u00ad\nductive cough or whose AFB smears are negative\n \n~\nUrine analysis for proteinuria, particularly for patients start\u00ad\ning on TDF-containing regimen\n \n~\nSyphilis  and  Hepatitis B screening\n \n~\nLiver and renal function tests if available\n \n~\nCryptococcal antigen and urine LAM screening for patients \nwhose CD4 count is < 200 cells/ml\n \n~\nSymptom-directed lab tests to diagnose pre-existing illnesses\nStaging of disease\n \n~\nUsing WHO clinical criteria (see tables above) Counselling \nand assessment of patient\u2019s readiness to start therapy\n \n~\nAssess for education, information or counselling support \nneeds\n \n~\nDevelop an adherence plan\nGoals of treatment with antiretroviral medicines are to:\n \n~\nInhibit viral replication as reflected in plasma HIV concen\u00ad\ntration to as low as possible and for as long as possible. \nThis promotes restoration of the immune system.\n \n~\nPreserve or enhance the immune function (CD4 resto\u00ad\nration), which prevents/delays the clinical progression of \nHIV disease\n \n~\nMinimise toxicities and side effects associated with the \nmedicines\n201\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>~</p>\n<p>Pregnancy test</p>\n<p>~</p>\n<p>Full blood count particularly for patients starting on a</p>\n<p>AZT-containing regimen</p>\n<p>Baseline Labs to assess general health and diagnose any pre-existing HIV</p>\n<p>complications</p>\n<p>~</p>\n<p>Sputum smear for AFB for patients who have coughed for</p>\n<p>> 2-3 weeks and a chest X-ray for patients who have unpro\u00ad</p>\n<p>ductive cough or whose AFB smears are negative</p>\n<p>~</p>\n<p>Urine analysis for proteinuria, particularly for patients start\u00ad</p>\n<p>ing on TDF-containing regimen</p>\n<p>~</p>\n<p>Syphilis  and  Hepatitis B screening</p>\n<p>~</p>\n<p>Liver and renal function tests if available</p>\n<p>~</p>\n<p>Cryptococcal antigen and urine LAM screening for patients</p>\n<p>whose CD4 count is < 200 cells/ml</p>\n<p>~</p>\n<p>Symptom-directed lab tests to diagnose pre-existing illnesses</p>\n<p>Staging of disease</p>\n<p>~</p>\n<p>Using WHO clinical criteria (see tables above) Counselling</p>\n<p>and assessment of patient\u2019s readiness to start therapy</p>\n<p>~</p>\n<p>Assess for education, information or counselling support</p>\n<p>needs</p>\n<p>~</p>\n<p>Develop an adherence plan</p>\n<p>Goals of treatment with antiretroviral medicines are to:</p>\n<p>~</p>\n<p>Inhibit viral replication as reflected in plasma HIV concen\u00ad</p>\n<p>tration to as low as possible and for as long as possible.</p>\n<p>This promotes restoration of the immune system.</p>\n<p>~</p>\n<p>Preserve or enhance the immune function (CD4 resto\u00ad</p>\n<p>ration), which prevents/delays the clinical progression of</p>\n<p>HIV disease</p>\n<p>~</p>\n<p>Minimise toxicities and side effects associated with the</p>\n<p>medicines</p>\n<p>201</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 268,
        "content": "~\nImprove quality of life and reduce HIV-related morbidity and \nmortality\n \n~\nPromote growth and neurological development in children\nTools to achieve the goals of therapy\n \n~\nMaximisation of adherence to ART: adequate support to pa\u00ad\ntient to adhere to treatment and/or access to community/\nfacility level adherence counselling\n \n~\n\u2013 Disclosure of HIV serostatus reinforces patient\u2019s adherence \nto ART\n \n~\nRational sequencing of medicines to preserve future treat\u00ad\nment options\n \n~\nUse of ARV medicine resistance testing when appropriate \nand available\n \n~\nUse of viral load estimates for monitoring\nPrinciples of ART\n \n~\nAntiretroviral therapy is part of comprehensive HIV care. \nThe guiding principles of good ART include:\n \n~\nEfficacy and durability of the chosen medicine regimens\n \n~\nFreedom from serious adverse effects; low toxicity\n \n~\nEase of administration including no food restrictions, better \npalatability, and lower pill burden\n \n~\nAffordability and availability of medicines and medicine com\u00ad\nbinations\n \n~\nOrganised sequencing \u2013 spares other available formulations \nfor use in second line while allowing for harmonisation of \nregimens across age and population\n \n~\nOngoing support of the patient to maintain adherence\n202\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>~</p>\n<p>Improve quality of life and reduce HIV-related morbidity and</p>\n<p>mortality</p>\n<p>~</p>\n<p>Promote growth and neurological development in children</p>\n<p>Tools to achieve the goals of therapy</p>\n<p>~</p>\n<p>Maximisation of adherence to ART: adequate support to pa\u00ad</p>\n<p>tient to adhere to treatment and/or access to community/</p>\n<p>facility level adherence counselling</p>\n<p>~</p>\n<p>\u2013 Disclosure of HIV serostatus reinforces patient\u2019s adherence</p>\n<p>to ART</p>\n<p>~</p>\n<p>Rational sequencing of medicines to preserve future treat\u00ad</p>\n<p>ment options</p>\n<p>~</p>\n<p>Use of ARV medicine resistance testing when appropriate</p>\n<p>and available</p>\n<p>~</p>\n<p>Use of viral load estimates for monitoring</p>\n<p>Principles of ART</p>\n<p>~</p>\n<p>Antiretroviral therapy is part of comprehensive HIV care.</p>\n<p>The guiding principles of good ART include:</p>\n<p>~</p>\n<p>Efficacy and durability of the chosen medicine regimens</p>\n<p>~</p>\n<p>Freedom from serious adverse effects; low toxicity</p>\n<p>~</p>\n<p>Ease of administration including no food restrictions, better</p>\n<p>palatability, and lower pill burden</p>\n<p>~</p>\n<p>Affordability and availability of medicines and medicine com\u00ad</p>\n<p>binations</p>\n<p>~</p>\n<p>Organised sequencing \u2013 spares other available formulations</p>\n<p>for use in second line while allowing for harmonisation of</p>\n<p>regimens across age and population</p>\n<p>~</p>\n<p>Ongoing support of the patient to maintain adherence</p>\n<p>202</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 269,
        "content": "Limitations of ART\n \n~\nAntiretroviral medicines are not a cure for HIV but greatly \nimprove quality of life when used appropriately\n \n~\nARVs are relatively expensive, require an adequate infra\u00ad\nstructure, and knowledgeable healthcare workers\n \n~\nMedicine interactions and resistance may decrease the po\u00ad\ntency of ARVs\n \n~\nPatients may develop adverse medicine reactions\n \n~\nPatients have to take at least 95% of their pills in order to \nrespond well (adherence is key to successful therapy)\n \n~\nThe medications have to be taken for life\n \n~\nSome patients may not respond (benefit) to treatment and \ncontinue to regress in spite of high adherence\n \n~\nChildren are dependent on adults for adherence to ART\nAvailable Medicines for ART\nAt present, antiretroviral medicines come in six classes, which attack \ndifferent sites and stages of the HIV life cycle, thereby interfering with \nits reproduction.\nCLASS\nEXAMPLES\nNucleoside reverse transcriptase inhib\u00ad\nitors (NtRTIs) incorporate themselves into \nthe DNA of the virus, thereby stopping the \nbuilding process\nTenofovir (TDF) Zidovu\u00ad\ndine (AZT) Lamivudine \n(3TC)\nAbacavir (ABC\nNon-nucleoside reverse transcriptase \ninhibitors (NNRTIs) stop HIV production \nby binding directly onto the reverse\ntranscriptase enzyme, and prevent the con\u00ad\nversion of RNA to DNA\nEfavirenz (EFV) Nevi\u00ad\nrapine (NVP) Etravirine \n(ETV)\n203\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Limitations of ART</p>\n<p>~</p>\n<p>Antiretroviral medicines are not a cure for HIV but greatly</p>\n<p>improve quality of life when used appropriately</p>\n<p>~</p>\n<p>ARVs are relatively expensive, require an adequate infra\u00ad</p>\n<p>structure, and knowledgeable healthcare workers</p>\n<p>~</p>\n<p>Medicine interactions and resistance may decrease the po\u00ad</p>\n<p>tency of ARVs</p>\n<p>~</p>\n<p>Patients may develop adverse medicine reactions</p>\n<p>~</p>\n<p>Patients have to take at least 95% of their pills in order to</p>\n<p>respond well (adherence is key to successful therapy)</p>\n<p>~</p>\n<p>The medications have to be taken for life</p>\n<p>~</p>\n<p>Some patients may not respond (benefit) to treatment and</p>\n<p>continue to regress in spite of high adherence</p>\n<p>~</p>\n<p>Children are dependent on adults for adherence to ART</p>\n<p>Available Medicines for ART</p>\n<p>At present, antiretroviral medicines come in six classes, which attack</p>\n<p>different sites and stages of the HIV life cycle, thereby interfering with</p>\n<p>its reproduction.</p>\n<h3>CLASS</h3>\n<h3>EXAMPLES</h3>\n<p>Nucleoside reverse transcriptase inhib\u00ad</p>\n<p>itors (NtRTIs) incorporate themselves into</p>\n<p>the DNA of the virus, thereby stopping the</p>\n<p>building process</p>\n<p>Tenofovir (TDF) Zidovu\u00ad</p>\n<p>dine (AZT) Lamivudine</p>\n<h3>(3TC)</h3>\n<p>Abacavir (ABC</p>\n<p>Non-nucleoside reverse transcriptase</p>\n<p>inhibitors (NNRTIs) stop HIV production</p>\n<p>by binding directly onto the reverse</p>\n<p>transcriptase enzyme, and prevent the con\u00ad</p>\n<p>version of RNA to DNA</p>\n<p>Efavirenz (EFV) Nevi\u00ad</p>\n<p>rapine (NVP) Etravirine</p>\n<h3>(ETV)</h3>\n<p>203</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 270,
        "content": "CLASS\nEXAMPLES\nIntegrase inhibitors interfere with the HIV \nDNA\u2019s ability to insert itself into the host DNA \nand copy itself.\nDolutegravir\n(DTG)\nRaltegravir (RAL)\nProtease inhibitors (PIs) prevent HIV from \nbeing successfully assembled and released \nfrom the infected CD4 cell. Boosted PIs  are \ncombinations of low-dose ritonavir (RTV) with \na PI for pharmacoenhancement\nAtaza nav ir (AT V) \nLopinavir (LPV) Darun\u00ad\navir (DRV)\nRitonavir (RTV, abbre\u00ad\nviated as \u201dr\u201d if boosting \nother PIs, e.g. ATV/r, \nLPV/r\nEntry inhibitors (HIV fusion inhibitors) \nprevent the HIV virus particle from infecting \nthe CD4 cell\nEnfuvirtide\n(T-20)\nCCR5 antagonists block the CCR5 co-re\u00ad\nceptor molecules that HIV uses to infect \nnew target T-cells. Some forms of HIV use \na different co-\nreceptor and thus, some patients may not \nbenefit from maraviroc\nMaraviroc\nIt is recommended to initiate ART at the earliest opportunity in all do \numented HIV-infected adults, adolescents and children regardless of \nCD4 count and WHO clinical staging (Test and Treat)\nInitiation of ART\nEvidence and programmatic experience have shown that early initiation \nof ART results in reduced mortality, morbidity and HIV transmission \noutcomes. However,\npriority should be given to patients with lower CD4 counts as well as \nthose who are symptomatic.\n204\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>CLASS</h3>\n<h3>EXAMPLES</h3>\n<p>Integrase inhibitors interfere with the HIV</p>\n<p>DNA\u2019s ability to insert itself into the host DNA</p>\n<p>and copy itself.</p>\n<p>Dolutegravir</p>\n<h3>(DTG)</h3>\n<p>Raltegravir (RAL)</p>\n<p>Protease inhibitors (PIs) prevent HIV from</p>\n<p>being successfully assembled and released</p>\n<p>from the infected CD4 cell. Boosted PIs  are</p>\n<p>combinations of low-dose ritonavir (RTV) with</p>\n<p>a PI for pharmacoenhancement</p>\n<p>Ataza nav ir (AT V)</p>\n<p>Lopinavir (LPV) Darun\u00ad</p>\n<p>avir (DRV)</p>\n<p>Ritonavir (RTV, abbre\u00ad</p>\n<p>viated as \u201dr\u201d if boosting</p>\n<p>other PIs, e.g. ATV/r,</p>\n<p>LPV/r</p>\n<p>Entry inhibitors (HIV fusion inhibitors)</p>\n<p>prevent the HIV virus particle from infecting</p>\n<p>the CD4 cell</p>\n<p>Enfuvirtide</p>\n<h3>(T-20)</h3>\n<p>CCR5 antagonists block the CCR5 co-re\u00ad</p>\n<p>ceptor molecules that HIV uses to infect</p>\n<p>new target T-cells. Some forms of HIV use</p>\n<p>a different co-</p>\n<p>receptor and thus, some patients may not</p>\n<p>benefit from maraviroc</p>\n<p>Maraviroc</p>\n<p>It is recommended to initiate ART at the earliest opportunity in all do</p>\n<p>umented HIV-infected adults, adolescents and children regardless of</p>\n<p>CD4 count and WHO clinical staging (Test and Treat)</p>\n<p>Initiation of ART</p>\n<p>Evidence and programmatic experience have shown that early initiation</p>\n<p>of ART results in reduced mortality, morbidity and HIV transmission</p>\n<p>outcomes. However,</p>\n<p>priority should be given to patients with lower CD4 counts as well as</p>\n<p>those who are symptomatic.</p>\n<p>204</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 271,
        "content": "A CD4 count is not necessary for initiation but should be used to identify \npatients with advanced HIV disease.\nART in children\nThe vast majority (about 90%) of infants and children with HIV acquire \nthe infection through mother-to-child transmission.\nHIV infection follows a more aggressive course among infants and children \nthan among adults; 30% die by age 1 year and 50% die by age 2 years \nwithout access to life-saving medicines, including ART and preventive \ninterventions, such as cotrimoxazole prophylaxis.\nEarly HIV diagnosis and ARV treatment is critical for infants. A significant \nnumber of lives can be saved by initiating ART for HIV-positive infants \nimmediately after diagnosis within the first 12 weeks of life.\nGeneral principles\n \n~\nARV doses need to be adjusted from time to time as the chil\u00ad\ndren grow quickly and thus, their weight changes.\n \n~\nBefore a child begins ART, the following assessments must \nbe made:\n\t\n\u0089\nReadiness of parents/caretakers or child (if older) to start\nART\n\t\n\u0089\nComplete pre-treatment baseline assessment (see previous sections)\nProcess of initiating ART\nHealth workers should do the following before initiating ART:\nAssess all clients for any evidence of opportunistic infections (OIs). If \nthe patient has TB or cryptococcal meningitis, ART should be deferred \nand initiated after starting treatment of these OIs.\nFor patients without TB or cryptococcal meningitis, offer ART on the \nsame day through an opt-out approach. In this approach, patients should \nbe prepared and assessed for readiness to start ART on the same day.\n205\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>A CD4 count is not necessary for initiation but should be used to identify</p>\n<p>patients with advanced HIV disease.</p>\n<p>ART in children</p>\n<p>The vast majority (about 90%) of infants and children with HIV acquire</p>\n<p>the infection through mother-to-child transmission.</p>\n<p>HIV infection follows a more aggressive course among infants and children</p>\n<p>than among adults; 30% die by age 1 year and 50% die by age 2 years</p>\n<p>without access to life-saving medicines, including ART and preventive</p>\n<p>interventions, such as cotrimoxazole prophylaxis.</p>\n<p>Early HIV diagnosis and ARV treatment is critical for infants. A significant</p>\n<p>number of lives can be saved by initiating ART for HIV-positive infants</p>\n<p>immediately after diagnosis within the first 12 weeks of life.</p>\n<p>General principles</p>\n<p>~</p>\n<p>ARV doses need to be adjusted from time to time as the chil\u00ad</p>\n<p>dren grow quickly and thus, their weight changes.</p>\n<p>~</p>\n<p>Before a child begins ART, the following assessments must</p>\n<p>be made:</p>\n<p>\u0089</p>\n<p>Readiness of parents/caretakers or child (if older) to start</p>\n<h3>ART</h3>\n<p>\u0089</p>\n<p>Complete pre-treatment baseline assessment (see previous sections)</p>\n<p>Process of initiating ART</p>\n<p>Health workers should do the following before initiating ART:</p>\n<p>Assess all clients for any evidence of opportunistic infections (OIs). If</p>\n<p>the patient has TB or cryptococcal meningitis, ART should be deferred</p>\n<p>and initiated after starting treatment of these OIs.</p>\n<p>For patients without TB or cryptococcal meningitis, offer ART on the</p>\n<p>same day through an opt-out approach. In this approach, patients should</p>\n<p>be prepared and assessed for readiness to start ART on the same day.</p>\n<p>205</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 272,
        "content": "If a client is ready, ART should be initiated on the same day. If a client is \nnot ready or opts out of same-day initiation, a timely ART preparation \nplan should be agreed upon with the aim of initiating ART within seven \ndays for children and pregnant women, and within one month for adults.\n3.1.5 Recommended First Line Regimens in Adults, Adolescents, \nPregnant Women and Children\nHIV management guidelines are constantly being updated according \nto evidence and public policy decisions. Always refer to the latest \nofficial guidelines.\nThe 2022 guidelines recommend DOLUTEGRAVIR (DTG)  an \nintegrase inhibitor as the anchor ARV in the preferred first and \nsecond-line treatment regimens for all HIV infected clients; children, \nadolescents, men, women (including pregnant women, breastfeeding \nwomen, adolescent girls and women of child bearing potential).\nART regimens in children are age and weight dependent. When chil\u00ad\ndren grow, doses and regimens have to be changed according to the \nguidelines below.\nRecommended first-line ARV regimens in adults, adolescents, \npregnant or breastfeeding women and children\nPatient Category Preferred \nregimens \nAlternative regimens\nAdults And Adolescents\nAdults (including \npregnant women \nand breast feed\u00ad\ning mothers and \nadolescents 30Kg\nTDF +3TC+ \nDTG\nIf DTG is contraindicated1 use: ;:\nTDF + 3TC + EFV400\nIf TDF is contraindicated use: TAF\u00ad\n+FTC+\nDTG\nIf TDF or TAF is contraindicated,\n206\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>If a client is ready, ART should be initiated on the same day. If a client is</p>\n<p>not ready or opts out of same-day initiation, a timely ART preparation</p>\n<p>plan should be agreed upon with the aim of initiating ART within seven</p>\n<p>days for children and pregnant women, and within one month for adults.</p>\n<p>3.1.5 Recommended First Line Regimens in Adults, Adolescents,</p>\n<p>Pregnant Women and Children</p>\n<p>HIV management guidelines are constantly being updated according</p>\n<p>to evidence and public policy decisions. Always refer to the latest</p>\n<p>official guidelines.</p>\n<p>The 2022 guidelines recommend DOLUTEGRAVIR (DTG)  an</p>\n<p>integrase inhibitor as the anchor ARV in the preferred first and</p>\n<p>second-line treatment regimens for all HIV infected clients; children,</p>\n<p>adolescents, men, women (including pregnant women, breastfeeding</p>\n<p>women, adolescent girls and women of child bearing potential).</p>\n<p>ART regimens in children are age and weight dependent. When chil\u00ad</p>\n<p>dren grow, doses and regimens have to be changed according to the</p>\n<p>guidelines below.</p>\n<p>Recommended first-line ARV regimens in adults, adolescents,</p>\n<p>pregnant or breastfeeding women and children</p>\n<p>Patient Category Preferred</p>\n<p>regimens</p>\n<p>Alternative regimens</p>\n<p>Adults And Adolescents</p>\n<p>Adults (including</p>\n<p>pregnant women</p>\n<p>and breast feed\u00ad</p>\n<p>ing mothers and</p>\n<p>adolescents 30Kg</p>\n<h3>TDF +3TC+</h3>\n<h3>DTG</h3>\n<p>If DTG is contraindicated1 use: ;:</p>\n<h3>TDF + 3TC + EFV400</h3>\n<p>If TDF is contraindicated use: TAF\u00ad</p>\n<h3>+FTC+</h3>\n<h3>DTG</h3>\n<p>If TDF or TAF is contraindicated,</p>\n<p>206</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 273,
        "content": "Patient Cate\u00ad\ngory \nPreferred \nregimens \nAlternative regimens\nAdults And Adolescents\nABC +\n3TC +DTG\nIf TDF or TAF and DTG are contraindicated:\nABC +3TC +EFV400\nIf EFV and DTG are contraindicated:\nTDF +3TC + ATV/r or + 3TC + ATV/r\nChIldren\nC h i l d r e n \n\u226520Kg-<30Kg\nA B C  + \n3 T C  + \nDTG\nIf DTG is contraindicated:\nABC + 3TC + LPV/r (tablets)\nIf ABC is contraindicated:\nTAF+FTC+ DTG (For Children >6 years and\n>25kgs)\nif ABC and TAF are contraindicated\nAZT + 3TC + DTG\nC\nh\ni\nl\n\u00ad\ndren<20Kg \nA B C  + \n3 T C  + \nDTG \nIf intolerant or appropriate DTG formulations\nare not available:\nABC +3TC + LPV/r Granules.\nIf intolerant to LPV/r:\nABC + 3TC + EFV (in children > 3 years and\n>10Kg)\nIf ABC is contraindicated:\nAZT + 3TC + DTG or LPV/r \n207\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Patient Cate\u00ad</p>\n<p>gory</p>\n<p>Preferred</p>\n<p>regimens</p>\n<p>Alternative regimens</p>\n<p>Adults And Adolescents</p>\n<h3>ABC +</h3>\n<h3>3TC +DTG</h3>\n<p>If TDF or TAF and DTG are contraindicated:</p>\n<h3>ABC +3TC +EFV400</h3>\n<p>If EFV and DTG are contraindicated:</p>\n<p>TDF +3TC + ATV/r or + 3TC + ATV/r</p>\n<p>ChIldren</p>\n<p>C h i l d r e n</p>\n<p>\u226520Kg-<30Kg</p>\n<h3>A B C  +</h3>\n<h3>3 T C  +</h3>\n<h3>DTG</h3>\n<p>If DTG is contraindicated:</p>\n<p>ABC + 3TC + LPV/r (tablets)</p>\n<p>If ABC is contraindicated:</p>\n<p>TAF+FTC+ DTG (For Children >6 years and</p>\n<p>>25kgs)</p>\n<p>if ABC and TAF are contraindicated</p>\n<h3>AZT + 3TC + DTG</h3>\n<p>C</p>\n<p>h</p>\n<p>i</p>\n<p>l</p>\n<p>\u00ad</p>\n<p>dren<20Kg</p>\n<h3>A B C  +</h3>\n<h3>3 T C  +</h3>\n<h3>DTG</h3>\n<p>If intolerant or appropriate DTG formulations</p>\n<p>are not available:</p>\n<p>ABC +3TC + LPV/r Granules.</p>\n<p>If intolerant to LPV/r:</p>\n<p>ABC + 3TC + EFV (in children > 3 years and</p>\n<p>>10Kg)</p>\n<p>If ABC is contraindicated:</p>\n<p>AZT + 3TC + DTG or LPV/r</p>\n<p>207</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 274,
        "content": "1. Contraindications for \nDTG (use DTG screening \ntool prior to DTG initi\u00ad\nation) including: known \ndiabetics, patients on \nanticonvulsants (carba\u00ad\nmazepine, phenytoin, \nphenobarbital) \n2. Contraindications for \nTDF and TAF: Renal dis\u00ad\nease and/or GFR \n<60ml/min, weight \n<30Kg \n3 TAF can be used in sub populations with \nbone density anomalies.\n4. Children will be assessed individually \nfor ability to correctly take the different \nformulations of LPV/r.     \nDrug Family \nARV Drug \nInteraction \nAction \nA n t i - T B \nmedicines\nNVP\nRifampicin decreases \nNVP concentrations \nin blood. \nCould cause liver tox\u00ad\nicity  \nDo not co-admin\u00ad\nister NVP and ri\u00ad\nfampicin \nSee Table 30 and \nTable 31 for \nTB/ARV co-man\u00ad\nagement \nDTG \nRifampicin lowers DTG \nlevels \nAdjust DTG dose \nto twice daily \nA T V / r , \nLPV/r, DRV \nand RTV\nRifampicin boosts me\u00ad\ntabolism of PIs\nIf given together \nwith LPV/r in\u00ad\ncrease the dose \nof RTV to \nachieve 1:1 ratio \nImportant drug interactions\n208\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<li>. Contraindications for</li>\n<p>DTG (use DTG screening</p>\n<p>tool prior to DTG initi\u00ad</p>\n<p>ation) including: known</p>\n<p>diabetics, patients on</p>\n<p>anticonvulsants (carba\u00ad</p>\n<p>mazepine, phenytoin,</p>\n<p>phenobarbital)</p>\n<p>2. Contraindications for</p>\n<p>TDF and TAF: Renal dis\u00ad</p>\n<p>ease and/or GFR</p>\n<p><60ml/min, weight</p>\n<p><30Kg</p>\n<p>3 TAF can be used in sub populations with</p>\n<p>bone density anomalies.</p>\n<p>4. Children will be assessed individually</p>\n<p>for ability to correctly take the different</p>\n<p>formulations of LPV/r.</p>\n<p>Drug Family</p>\n<p>ARV Drug</p>\n<p>Interaction</p>\n<p>Action</p>\n<p>A n t i - T B</p>\n<p>medicines</p>\n<h3>NVP</h3>\n<p>Rifampicin decreases</p>\n<p>NVP concentrations</p>\n<p>in blood.</p>\n<p>Could cause liver tox\u00ad</p>\n<p>icity</p>\n<p>Do not co-admin\u00ad</p>\n<p>ister NVP and ri\u00ad</p>\n<p>fampicin</p>\n<p>See Table 30 and</p>\n<p>Table 31 for</p>\n<p>TB/ARV co-man\u00ad</p>\n<p>agement</p>\n<h3>DTG</h3>\n<p>Rifampicin lowers DTG</p>\n<p>levels</p>\n<p>Adjust DTG dose</p>\n<p>to twice daily</p>\n<p>A T V / r ,</p>\n<p>LPV/r, DRV</p>\n<p>and RTV</p>\n<p>Rifampicin boosts me\u00ad</p>\n<p>tabolism of PIs</p>\n<p>If given together</p>\n<p>with LPV/r in\u00ad</p>\n<p>crease the dose</p>\n<p>of RTV to</p>\n<p>achieve 1:1 ratio</p>\n<p>Important drug interactions</p>\n<p>208</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 275,
        "content": "Drug Family \nARV Drug \nInteraction \nAction \nCombi ned \noral contra\u00ad\nceptive pills, \nhormonal im\u00ad\nplants (etono\u00ad\ngestrel)\nEFV or AT\u00ad\nV/r, LPV/r, \nD R V  a n d \nRTV\nRisk of contraceptive \nfailure due to increased \nmetabolism of contra\u00ad\nceptives\nUse additional \nbarrier method \nor \nUse Depo-Pro\u00ad\nvera or IUDs\nAnxiolytics, \ne.g.  mida\u00ad\nzolam, diaz\u00ad\nepam \nA T V / r , \nLPV/r, DRV \nand RTV\nRisk of respiratory de\u00ad\npression \n(midazolam) \nIncreased sedation (di\u00ad\nazepam)\nReduce dose of \nmidazolam or \ndiazepam\nSimvastatin, \nrosuvastatin, \natorvastatin\nA T V / r , \nLPV/r, DRV \nand RTV\nInhibition of CYP450 \n3A4 (reduced metabo\u00ad\nlism of statins)\nUse atorvasta\u00ad\ntin with lowered \ndose and mon\u00ad\nitor for side ef\u00ad\nfects like muscle \npains\nAnti-epi\u00ad\nleptics, e.g. \ncarbamaze\u00ad\npine, pheno\u00ad\nbarbital, and \nphenytoin.\nEFV, DTG, \nEtravirine\nCarbamazepine de\u00ad\ncreases DTG levels by \n30-70%\nUse valproic \nacid \nDrugs for \nacid reflux or \nulcers, e.g. \nomeprazole, \nesomepra\u00ad\nzole, lan\u00ad\nsoprazole, \npantoprazole \nATV/r\nReduced concentrations \nof Atazanavir\nUse alternatives \nlike ranitidine, \ncimetidine, etc.\nImportant drug interactions\n209\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Drug Family</p>\n<p>ARV Drug</p>\n<p>Interaction</p>\n<p>Action</p>\n<p>Combi ned</p>\n<p>oral contra\u00ad</p>\n<p>ceptive pills,</p>\n<p>hormonal im\u00ad</p>\n<p>plants (etono\u00ad</p>\n<p>gestrel)</p>\n<p>EFV or AT\u00ad</p>\n<p>V/r, LPV/r,</p>\n<p>D R V  a n d</p>\n<h3>RTV</h3>\n<p>Risk of contraceptive</p>\n<p>failure due to increased</p>\n<p>metabolism of contra\u00ad</p>\n<p>ceptives</p>\n<p>Use additional</p>\n<p>barrier method</p>\n<p>or</p>\n<p>Use Depo-Pro\u00ad</p>\n<p>vera or IUDs</p>\n<p>Anxiolytics,</p>\n<p>e.g.  mida\u00ad</p>\n<p>zolam, diaz\u00ad</p>\n<p>epam</p>\n<p>A T V / r ,</p>\n<p>LPV/r, DRV</p>\n<p>and RTV</p>\n<p>Risk of respiratory de\u00ad</p>\n<p>pression</p>\n<p>(midazolam)</p>\n<p>Increased sedation (di\u00ad</p>\n<p>azepam)</p>\n<p>Reduce dose of</p>\n<p>midazolam or</p>\n<p>diazepam</p>\n<p>Simvastatin,</p>\n<p>rosuvastatin,</p>\n<p>atorvastatin</p>\n<p>A T V / r ,</p>\n<p>LPV/r, DRV</p>\n<p>and RTV</p>\n<p>Inhibition of CYP450</p>\n<p>3A4 (reduced metabo\u00ad</p>\n<p>lism of statins)</p>\n<p>Use atorvasta\u00ad</p>\n<p>tin with lowered</p>\n<p>dose and mon\u00ad</p>\n<p>itor for side ef\u00ad</p>\n<p>fects like muscle</p>\n<p>pains</p>\n<p>Anti-epi\u00ad</p>\n<p>leptics, e.g.</p>\n<p>carbamaze\u00ad</p>\n<p>pine, pheno\u00ad</p>\n<p>barbital, and</p>\n<p>phenytoin.</p>\n<h3>EFV, DTG,</h3>\n<p>Etravirine</p>\n<p>Carbamazepine de\u00ad</p>\n<p>creases DTG levels by</p>\n<p>30-70%</p>\n<p>Use valproic</p>\n<p>acid</p>\n<p>Drugs for</p>\n<p>acid reflux or</p>\n<p>ulcers, e.g.</p>\n<p>omeprazole,</p>\n<p>esomepra\u00ad</p>\n<p>zole, lan\u00ad</p>\n<p>soprazole,</p>\n<p>pantoprazole</p>\n<p>ATV/r</p>\n<p>Reduced concentrations</p>\n<p>of Atazanavir</p>\n<p>Use alternatives</p>\n<p>like ranitidine,</p>\n<p>cimetidine, etc.</p>\n<p>Important drug interactions</p>\n<p>209</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 276,
        "content": "Drug Family \nARV Drug \nInteraction \nAction \nPolyvalent \ncation prod\u00ad\nucts contain\u00ad\ning Mg, Al, \nFe, Ca, Zn \n(e.g. \nvitamin \nsupplements \nand antac\u00ad\nids) \nDTG\nReduce DTG levels\nUse DTG 2 \nhours before \nor 6 hours \nafter the prod\u00ad\nuct to avoid \ninteraction\nAntimalarial \ndrugs: \nartemether/\nlumefantrine, \nhalofantrine\nATV\nBoth could prolong QT \ninterval\nWhen \ngiven with \nartemether/\nlumefantrine \nmonitor close\u00ad\nly for unde\u00ad\nsired effects \nHalofantrine: \ndo not give \ntogether (con\u00ad\ntraindicated) \nMetformin \nDTG\nDTG increases met\u00ad\nformin levels. May \nincrease risk of \nhypoglycaemia and \nmetabolic acidosis \nClose fol\u00ad\nlow-up \n(routine elec\u00ad\ntrolytes, BUN \nand \nCreatinine, \nRandom \nBlood Sugar \ntests) recom\u00ad\nmended\n210\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Drug Family</p>\n<p>ARV Drug</p>\n<p>Interaction</p>\n<p>Action</p>\n<p>Polyvalent</p>\n<p>cation prod\u00ad</p>\n<p>ucts contain\u00ad</p>\n<p>ing Mg, Al,</p>\n<p>Fe, Ca, Zn</p>\n<p>(e.g.</p>\n<p>vitamin</p>\n<p>supplements</p>\n<p>and antac\u00ad</p>\n<p>ids)</p>\n<h3>DTG</h3>\n<p>Reduce DTG levels</p>\n<p>Use DTG 2</p>\n<p>hours before</p>\n<p>or 6 hours</p>\n<p>after the prod\u00ad</p>\n<p>uct to avoid</p>\n<p>interaction</p>\n<p>Antimalarial</p>\n<p>drugs:</p>\n<p>artemether/</p>\n<p>lumefantrine,</p>\n<p>halofantrine</p>\n<h3>ATV</h3>\n<p>Both could prolong QT</p>\n<p>interval</p>\n<p>When</p>\n<p>given with</p>\n<p>artemether/</p>\n<p>lumefantrine</p>\n<p>monitor close\u00ad</p>\n<p>ly for unde\u00ad</p>\n<p>sired effects</p>\n<p>Halofantrine:</p>\n<p>do not give</p>\n<p>together (con\u00ad</p>\n<p>traindicated)</p>\n<p>Metformin</p>\n<h3>DTG</h3>\n<p>DTG increases met\u00ad</p>\n<p>formin levels. May</p>\n<p>increase risk of</p>\n<p>hypoglycaemia and</p>\n<p>metabolic acidosis</p>\n<p>Close fol\u00ad</p>\n<p>low-up</p>\n<p>(routine elec\u00ad</p>\n<p>trolytes, BUN</p>\n<p>and</p>\n<p>Creatinine,</p>\n<p>Random</p>\n<p>Blood Sugar</p>\n<p>tests) recom\u00ad</p>\n<p>mended</p>\n<p>210</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 277,
        "content": "3.1.6 Monitoring of ART\nThe purpose of monitoring patients on ART is to assess:\n \n~\nResponse to ART and early detection of treatment failure\n \n~\nSide effects and toxicity\n \n~\nAdherence\nThe schedule of monitoring visits follow a pre-set calendar for the 1st \none year after initiation of ART, i.e:\n\t\n\u0089\nAt 1, 2 and 3 months from start of ART\n\t\n\u0089\nAt 6, 9, 12 months\nAfter 12 months from initiation of ART, the Differentiated Model of \nCare Delivery is followed, in which schedule and modalities of periodic \nchecks are based on individual needs and characteristics of the patient.\nThe aim of this model is:\n\t\n\u0089\nA client centered approach, so that stable patients have spaced \nchecks and fast tracks drug pick ups\n\t\n\u0089\nMore efficient use of resources by avoiding overcrowding and long \nwaiting times\n\t\n\u0089\nMore focus on unstable/complex patients\n(Refer to MOH HIV/ART guidelines for more details).\nImportant drug interactions\nTYPE OF MONITORING\nCOMPONENTS\nClinical Monitoring\n \n- Screen for and manage \nopportunistic infections (OI) and \nSTI\n \n- Assess for pregnancy, and/or \nuse or\n \n- need of FP\n \n- Screen and manage co-\nmorbidities  including depression\n \n- Weight and nutritional \nassessement\n211\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.6 Monitoring of ART</p>\n<p>The purpose of monitoring patients on ART is to assess:</p>\n<p>~</p>\n<p>Response to ART and early detection of treatment failure</p>\n<p>~</p>\n<p>Side effects and toxicity</p>\n<p>~</p>\n<p>Adherence</p>\n<p>The schedule of monitoring visits follow a pre-set calendar for the 1st</p>\n<p>one year after initiation of ART, i.e:</p>\n<p>\u0089</p>\n<p>At 1, 2 and 3 months from start of ART</p>\n<p>\u0089</p>\n<p>At 6, 9, 12 months</p>\n<p>After 12 months from initiation of ART, the Differentiated Model of</p>\n<p>Care Delivery is followed, in which schedule and modalities of periodic</p>\n<p>checks are based on individual needs and characteristics of the patient.</p>\n<p>The aim of this model is:</p>\n<p>\u0089</p>\n<p>A client centered approach, so that stable patients have spaced</p>\n<p>checks and fast tracks drug pick ups</p>\n<p>\u0089</p>\n<p>More efficient use of resources by avoiding overcrowding and long</p>\n<p>waiting times</p>\n<p>\u0089</p>\n<p>More focus on unstable/complex patients</p>\n<p>(Refer to MOH HIV/ART guidelines for more details).</p>\n<p>Important drug interactions</p>\n<h3>TYPE OF MONITORING</h3>\n<h3>COMPONENTS</h3>\n<p>Clinical Monitoring</p>\n<p>- Screen for and manage</p>\n<p>opportunistic infections (OI) and</p>\n<h3>STI</h3>\n<p>- Assess for pregnancy, and/or</p>\n<p>use or</p>\n<p>- need of FP</p>\n<p>- Screen and manage co-</p>\n<p>morbidities  including depression</p>\n<p>- Weight and nutritional</p>\n<p>assessement</p>\n<p>211</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 278,
        "content": "TYPE OF MONITORING\nCOMPONENTS\n \n- Disclosure\nFor children and adolescents:\n \n- Growth and development, school \nattendance, behavioural issues, \nsexual awareness\nATV/r, LPV/r, DRV and RTV\nLaboratory Monitoring\n \n\u0081\nViral load\n \n\u0081\nIs preferred method to monitor re\u00ad\nsponse to ART and treatment failure:\n \n\u0081\nChildren and adolescents under 19 \nyears of age: first VL at 6 and 12 \nmonths from initiation, if suppressed \nevery 6 months thereafter.\n \n\u0081\nAdults: First VL at 6 months after \ninitiation. Second VL following sup\u00ad\npressed viral load at 12 months , \nthen every 12 months if suppressed.\n \n\u0081\nHIV positive pregnant and breast\u00ad\nfeeding women: If newly initiated on \nART at ANC, conduct a VL test at \n3 months on ART. If VL suppressed \nrepeat VL every 3 months throughout \npregnancy and until cessation of \nbreastfeeding.\n \n\u0081\nHIV-positive pregnant and breast\u00ad\nfeeding women already on ART at \nANC1 or MBCP: conduct a VL test \nat first ANC or MBCP visit. If VL is \nsupressed repeat VL every 3 months \nthroughout pregnancy until cessation \nof breastfeeding.\n212\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TYPE OF MONITORING</h3>\n<h3>COMPONENTS</h3>\n<p>- Disclosure</p>\n<p>For children and adolescents:</p>\n<p>- Growth and development, school</p>\n<p>attendance, behavioural issues,</p>\n<p>sexual awareness</p>\n<p>ATV/r, LPV/r, DRV and RTV</p>\n<p>Laboratory Monitoring</p>\n<p>\u0081</p>\n<p>Viral load</p>\n<p>\u0081</p>\n<p>Is preferred method to monitor re\u00ad</p>\n<p>sponse to ART and treatment failure:</p>\n<p>\u0081</p>\n<p>Children and adolescents under 19</p>\n<p>years of age: first VL at 6 and 12</p>\n<p>months from initiation, if suppressed</p>\n<p>every 6 months thereafter.</p>\n<p>\u0081</p>\n<p>Adults: First VL at 6 months after</p>\n<p>initiation. Second VL following sup\u00ad</p>\n<p>pressed viral load at 12 months ,</p>\n<p>then every 12 months if suppressed.</p>\n<p>\u0081</p>\n<p>HIV positive pregnant and breast\u00ad</p>\n<p>feeding women: If newly initiated on</p>\n<p>ART at ANC, conduct a VL test at</p>\n<p>3 months on ART. If VL suppressed</p>\n<p>repeat VL every 3 months throughout</p>\n<p>pregnancy and until cessation of</p>\n<p>breastfeeding.</p>\n<p>\u0081</p>\n<p>HIV-positive pregnant and breast\u00ad</p>\n<p>feeding women already on ART at</p>\n<p>ANC1 or MBCP: conduct a VL test</p>\n<p>at first ANC or MBCP visit. If VL is</p>\n<p>supressed repeat VL every 3 months</p>\n<p>throughout pregnancy until cessation</p>\n<p>of breastfeeding.</p>\n<p>212</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 279,
        "content": "TYPE OF MONITORING\nCOMPONENTS\n \n\u0081\nIf unsuppressed in the above, refer \nto the algorithm below.\n \n\u0081\nAfter every switch in treatment (after \nfailure): VL at 6 months after a switch \nto second- and third-line ART. \n \n\u0081\nThird line ART patients: VL every 6 \nmonths. If VL is un-suppressed, then \ngenotype testing is recommended. \n \n\u0081\nCD4 monitoring\n \n\u0081\nRecommended at baseline to screen \nfor risk of opportunistic infections\n \n\u0081\nIn patients who are suppressed butare \nin clinical stage 3-4\n \n\u0081\nIn patients on prophylaxis for cryp\u00ad\ntococcus to inform decison on when \nto stop fluconazole\nOther tests\n \n- According to clinical findings\n213\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TYPE OF MONITORING</h3>\n<h3>COMPONENTS</h3>\n<p>\u0081</p>\n<p>If unsuppressed in the above, refer</p>\n<p>to the algorithm below.</p>\n<p>\u0081</p>\n<p>After every switch in treatment (after</p>\n<p>failure): VL at 6 months after a switch</p>\n<p>to second- and third-line ART.</p>\n<p>\u0081</p>\n<p>Third line ART patients: VL every 6</p>\n<p>months. If VL is un-suppressed, then</p>\n<p>genotype testing is recommended.</p>\n<p>\u0081</p>\n<p>CD4 monitoring</p>\n<p>\u0081</p>\n<p>Recommended at baseline to screen</p>\n<p>for risk of opportunistic infections</p>\n<p>\u0081</p>\n<p>In patients who are suppressed butare</p>\n<p>in clinical stage 3-4</p>\n<p>\u0081</p>\n<p>In patients on prophylaxis for cryp\u00ad</p>\n<p>tococcus to inform decison on when</p>\n<p>to stop fluconazole</p>\n<p>Other tests</p>\n<p>- According to clinical findings</p>\n<p>213</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 280,
        "content": "(Refer to MOH HIV/ART guidelines for more details).\n(Refer to MOH HIV/ART guidelines for more details).\nTime\nBefore \nART\nDuring ART\nDSD from 6 months\nAfter 12 months on ART\nBase\u00ad\nline\n1 \nmonth\n2 \nmonths\n3 \nmonths\n6 \nmonths\n9 \nmonths\n12 \nmonths\n3 \nmonth\u00ad\nly\n6 \nmonth\u00ad\nly\n12 \nmonth\u00ad\nly\nClinical assessment\nComprehensive \nclinical assessment\nX\nX\nX\nx\nX\nX\nx\nX\nX\nx\nPrepare for ART\nX\nAssess readiness for \nART\nX\nProvide CTX\nX\nX\nX\nx\nX\nX\nx\nx**\nx**\nx**\nProvide FP if \nrequired\nX\nAssess for drug intol\u00ad\nerance, side effects/\ntoxicities\nX\nX\nx\nX\nX\nx\nX\nX\nx\nAdherence assess\u00ad\nment, monitoring, \nand support\nX\nX\nx\nX\nX\nx\nX\nX\nx\n214\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>(Refer to MOH HIV/ART guidelines for more details).</p>\n<p>(Refer to MOH HIV/ART guidelines for more details).</p>\n<p>Time</p>\n<p>Before</p>\n<h3>ART</h3>\n<p>During ART</p>\n<p>DSD from 6 months</p>\n<p>After 12 months on ART</p>\n<p>Base\u00ad</p>\n<p>line</p>\n<p>1</p>\n<p>month</p>\n<p>2</p>\n<p>months</p>\n<p>3</p>\n<p>months</p>\n<p>6</p>\n<p>months</p>\n<p>9</p>\n<p>months</p>\n<p>12</p>\n<p>months</p>\n<p>3</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>6</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>12</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>Clinical assessment</p>\n<p>Comprehensive</p>\n<p>clinical assessment</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>Prepare for ART</p>\n<p>X</p>\n<p>Assess readiness for</p>\n<h3>ART</h3>\n<p>X</p>\n<p>Provide CTX</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>x**</p>\n<p>x**</p>\n<p>x**</p>\n<p>Provide FP if</p>\n<p>required</p>\n<p>X</p>\n<p>Assess for drug intol\u00ad</p>\n<p>erance, side effects/</p>\n<p>toxicities</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>Adherence assess\u00ad</p>\n<p>ment, monitoring,</p>\n<p>and support</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>214</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 281,
        "content": "Time\nBefore \nART\nDuring ART\nDSD from 6 months\nAfter 12 months on ART\nBase\u00ad\nline\n1 \nmonth\n2 \nmonths\n3 \nmonths\n6 \nmonths\n9 \nmonths\n12 \nmonths\n3 \nmonth\u00ad\nly\n6 \nmonth\u00ad\nly\n12 \nmonth\u00ad\nly\nClinical assessment\nAssess for Immune re\u00ad\nconstitution inflammatory \nsyndrome (IRIS)\nX\nX\nx\nX\nAdherence asseessment, \nmonitoring, and support\nX\nX\nX\nX\nX\nX\nX\nX\nX\nART and CTX refill (in \nchildren adjust dose \nbased on weight)\nX\nX\nx\nX\nX\nx\nX\nX\nx\nFP refill\nX\nX\nx\nX\nX\nx\nX\nX\nx\nTB Screening\nX\nX\nX\nx\nFollow up review: If the patient is clinically well:\nGive ONE month refill \nand appointment\nX\nX\nx\n215\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Time</p>\n<p>Before</p>\n<h3>ART</h3>\n<p>During ART</p>\n<p>DSD from 6 months</p>\n<p>After 12 months on ART</p>\n<p>Base\u00ad</p>\n<p>line</p>\n<p>1</p>\n<p>month</p>\n<p>2</p>\n<p>months</p>\n<p>3</p>\n<p>months</p>\n<p>6</p>\n<p>months</p>\n<p>9</p>\n<p>months</p>\n<p>12</p>\n<p>months</p>\n<p>3</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>6</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>12</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>Clinical assessment</p>\n<p>Assess for Immune re\u00ad</p>\n<p>constitution inflammatory</p>\n<p>syndrome (IRIS)</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>Adherence asseessment,</p>\n<p>monitoring, and support</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>ART and CTX refill (in</p>\n<p>children adjust dose</p>\n<p>based on weight)</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>FP refill</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>TB Screening</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>Follow up review: If the patient is clinically well:</p>\n<p>Give ONE month refill</p>\n<p>and appointment</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>215</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 282,
        "content": "Time\nBefore \nART\nDuring ART\nDSD from 6 months\nAfter 12 months on ART\nBase\u00ad\nline\n1 \nmonth\n2 \nmonths\n3 \nmonths\n6 \nmonths\n9 \nmonths\n12 \nmonths\n3 \nmonth\u00ad\nly\n6 \nmonth\u00ad\nly\n12 \nmonth\u00ad\nly\nGive THREEmonths refill \nand appointment\nX\nX\nx\nX\nLaboratory tests\nViral Load\nx*\nx*\nx**\nx\nCD 4\nX\nHBsAg, \nX\nCrAg if CD4 <200,\nX\nTB LAM if CD4 <200,\nX\nFBS/RBS (especially adults at \nrisk on DTG)\nX\nx\nX\nX\nX\nX\nGive ONE month refill and \nappointment\nX\nX\nx\nLFTs \nX\nDo other lab tests if clinically \nindicated (Table 58)\nX\nX\nX\nx\nX\nX\nX\nX\nX\nx\nCervical cancer screening\nx\n216\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Time</p>\n<p>Before</p>\n<h3>ART</h3>\n<p>During ART</p>\n<p>DSD from 6 months</p>\n<p>After 12 months on ART</p>\n<p>Base\u00ad</p>\n<p>line</p>\n<p>1</p>\n<p>month</p>\n<p>2</p>\n<p>months</p>\n<p>3</p>\n<p>months</p>\n<p>6</p>\n<p>months</p>\n<p>9</p>\n<p>months</p>\n<p>12</p>\n<p>months</p>\n<p>3</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>6</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>12</p>\n<p>month\u00ad</p>\n<p>ly</p>\n<p>Give THREEmonths refill</p>\n<p>and appointment</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>Laboratory tests</p>\n<p>Viral Load</p>\n<p>x*</p>\n<p>x*</p>\n<p>x**</p>\n<p>x</p>\n<h3>CD 4</h3>\n<p>X</p>\n<p>HBsAg,</p>\n<p>X</p>\n<p>CrAg if CD4 <200,</p>\n<p>X</p>\n<p>TB LAM if CD4 <200,</p>\n<p>X</p>\n<p>FBS/RBS (especially adults at</p>\n<p>risk on DTG)</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>Give ONE month refill and</p>\n<p>appointment</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>LFTs</p>\n<p>X</p>\n<p>Do other lab tests if clinically</p>\n<p>indicated (Table 58)</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>X</p>\n<p>x</p>\n<p>Cervical cancer screening</p>\n<p>x</p>\n<p>216</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 283,
        "content": "x* If VL is not suppressed, call the patient back for intensive ad\u00ad\nherence counseling\nx** This is to be done in children, adolescents, pregnant and \nbreastfeeding women\nVL testing algorithm for children, adolescents and adults for health \nfacilities using plasma and DBS samples\nRoutine Viral load monitoring:\n6 months after ART initiation then 12 months after ART initiation and thereafter every one (1) year for \nadults: 6 months for children & adolescents 0-19 years; and 3 months for pregnant and lactating women\nSuppressed \nPlasma:  200 copies/mL \nDBS: Target Not Detected\nConduct HIV DR testing & \nswitch to appropriate regimen\nContinue PSS 8 counselling\n\u2022\tMaintain preferred ART regimen\n\u2022\tIntensive Adherence counselling & support\n\u2022\tDo VL after 6 months for all and after 3 months \nfor pregnant and breastfeeding women\n\u2022\tTransition PLHIVs on non-DTG to DTG based \nregimens\n 1,00 copies/mL\n 201 to 999 copies/mL\nRepeat VL using Plasma\nHigh level Viremia \nPlasma & DBS:  1,00\n   200 copies/mL\nRepeat VL using 2 \nplasma samples\nProvide IAC (3-6 months); 3.C-good \nIAC sessions scores > 95%\nConduct CD4 testing & manage \nappropriately\nMaintain preferred ARV drug regimen\nContinue routine viral load\nMaintain preferred ARV drug regimen\nContinue routine viral load\nProvide IAC (3-6 months); 3.C-good \nIAC sessions scores > 95% \nNON SUPPRESSED \n217\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>x* If VL is not suppressed, call the patient back for intensive ad\u00ad</p>\n<p>herence counseling</p>\n<p>x** This is to be done in children, adolescents, pregnant and</p>\n<p>breastfeeding women</p>\n<p>VL testing algorithm for children, adolescents and adults for health</p>\n<p>facilities using plasma and DBS samples</p>\n<p>Routine Viral load monitoring:</p>\n<p>6 months after ART initiation then 12 months after ART initiation and thereafter every one (1) year for</p>\n<p>adults: 6 months for children & adolescents 0-19 years; and 3 months for pregnant and lactating women</p>\n<p>Suppressed</p>\n<p>Plasma:  200 copies/mL</p>\n<p>DBS: Target Not Detected</p>\n<p>Conduct HIV DR testing &</p>\n<p>switch to appropriate regimen</p>\n<p>Continue PSS 8 counselling</p>\n<li>Maintain preferred ART regimen</li>\n<li>Intensive Adherence counselling & support</li>\n<li>Do VL after 6 months for all and after 3 months</li>\n<p>for pregnant and breastfeeding women</p>\n<li>Transition PLHIVs on non-DTG to DTG based</li>\n<p>regimens</p>\n<p>1,00 copies/mL</p>\n<p>201 to 999 copies/mL</p>\n<p>Repeat VL using Plasma</p>\n<p>High level Viremia</p>\n<p>Plasma & DBS:  1,00</p>\n<p>200 copies/mL</p>\n<p>Repeat VL using 2</p>\n<p>plasma samples</p>\n<p>Provide IAC (3-6 months); 3.C-good</p>\n<p>IAC sessions scores > 95%</p>\n<p>Conduct CD4 testing & manage</p>\n<p>appropriately</p>\n<p>Maintain preferred ARV drug regimen</p>\n<p>Continue routine viral load</p>\n<p>Maintain preferred ARV drug regimen</p>\n<p>Continue routine viral load</p>\n<p>Provide IAC (3-6 months); 3.C-good</p>\n<p>IAC sessions scores > 95%</p>\n<h3>NON SUPPRESSED</h3>\n<p>217</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 284,
        "content": "3.1.7 ARV Toxicity\nARV drugs can cause a wide range of toxicities, from mild to life threat\u00ad\nening. Active monitoring and management of toxicities and side effects \nis important not only to avoid negative medical outcome but also to \nensure that they do not negatively affect adherence.\nCATEGORY\nACTION\nSevere Life-\nThreatening\nReactions\n(e.g. SJS/TEN,\nsevere hepatitis\nImmediately discontinue all ARV drugs \n(possibly all drugs in general), manage the \nmedical event and substitute the offending \ndrug when the patient is stabilised\nSevere\nReactions\n(e.g. Hepatitis, anae\u00ad\nmia)\nStop the offending drug and substitute\nit without stopping the ART (if\nclinically possible)\nModerate Reactionsy \n(Gynaecomastia, lipo\u00ad\ndystrophy)\nSubstitute with a drug in the same ARV \nclass but with a different toxicity profile, or \nwith a drug in a different class\nDo not discontinue ART. Continuation \nof ART as long as feasible. If the patient \ndoes not improve on symptomatic thera\u00ad\npy, consider single- drug substitution\nMild Reactions (Head\u00ad\nache, minor rash, nau\u00ad\nsea)\nDo not discontinue or substitute ART.\nReassure the patient or caregiver that \nwhile the reaction may be bothersome, it \ndoes not require a change in therapy and \noften it subsides in few weeks.\nProvide support to mitigate the adverse \nreactions as well as counseling about the \nevents\n218\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.7 ARV Toxicity</p>\n<p>ARV drugs can cause a wide range of toxicities, from mild to life threat\u00ad</p>\n<p>ening. Active monitoring and management of toxicities and side effects</p>\n<p>is important not only to avoid negative medical outcome but also to</p>\n<p>ensure that they do not negatively affect adherence.</p>\n<h3>CATEGORY</h3>\n<h3>ACTION</h3>\n<p>Severe Life-</p>\n<p>Threatening</p>\n<p>Reactions</p>\n<p>(e.g. SJS/TEN,</p>\n<p>severe hepatitis</p>\n<p>Immediately discontinue all ARV drugs</p>\n<p>(possibly all drugs in general), manage the</p>\n<p>medical event and substitute the offending</p>\n<p>drug when the patient is stabilised</p>\n<p>Severe</p>\n<p>Reactions</p>\n<p>(e.g. Hepatitis, anae\u00ad</p>\n<p>mia)</p>\n<p>Stop the offending drug and substitute</p>\n<p>it without stopping the ART (if</p>\n<p>clinically possible)</p>\n<p>Moderate Reactionsy</p>\n<p>(Gynaecomastia, lipo\u00ad</p>\n<p>dystrophy)</p>\n<p>Substitute with a drug in the same ARV</p>\n<p>class but with a different toxicity profile, or</p>\n<p>with a drug in a different class</p>\n<p>Do not discontinue ART. Continuation</p>\n<p>of ART as long as feasible. If the patient</p>\n<p>does not improve on symptomatic thera\u00ad</p>\n<p>py, consider single- drug substitution</p>\n<p>Mild Reactions (Head\u00ad</p>\n<p>ache, minor rash, nau\u00ad</p>\n<p>sea)</p>\n<p>Do not discontinue or substitute ART.</p>\n<p>Reassure the patient or caregiver that</p>\n<p>while the reaction may be bothersome, it</p>\n<p>does not require a change in therapy and</p>\n<p>often it subsides in few weeks.</p>\n<p>Provide support to mitigate the adverse</p>\n<p>reactions as well as counseling about the</p>\n<p>events</p>\n<p>218</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 285,
        "content": "Major Adverse/\nToxicity Events \nPRESENTING SIGNS/SYMPTOMS SUGGESTED MANAGEMENT\nREGIMENS FOR ADULTS AND ADOLESCENTS  \n1. 2. 3. \n4. Hyperglycaemia \nInsomnia \nHepatotoxicity \nHypersensitivity \nreactions \n1. 2. 3. \n4. Excessive drinking/eating, \nexcessive urination \nDifficulty falling asleep \nNausea, vomiting, right upper \nquadrant abdominal pain, yellow \nurine or eyes \nSkin itching (localized or diffuse), \ndizziness, faintness, difficulty \nbreathing, nausea, vomiting, diar\u00ad\nrhoea, and abdominal cramping\nDo RBS to confirm hyperglycaemia \nthen substitute with EFV \nInsomnia: Ensure patient is taking \nDTG during the day if it persists then \nsubstitute with EFV \nIf EFV is contraindicated: Substitute \nwith ATV/r \nEFV 1. 2. 3. 4. \n5. Persistent \ncentral nervous \nsystem toxicity\n1. 2. 3. 4. \n5. Dizziness, insomnia, abnormal \ndreams, or mental symptoms (anx\u00ad\niety, depression, mental confusion, \nsuicidality)\nIn case on EFV 600mg  \n\u2022Lower the dose of EFV to 400mg. \nIn case on EFV 400mg \n\u2022 Reassure,\n219\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Major Adverse/</p>\n<p>Toxicity Events</p>\n<h3>PRESENTING SIGNS/SYMPTOMS SUGGESTED MANAGEMENT</h3>\n<h3>REGIMENS FOR ADULTS AND ADOLESCENTS</h3>\n<li>. 2. 3.</li>\n<p>4. Hyperglycaemia</p>\n<p>Insomnia</p>\n<p>Hepatotoxicity</p>\n<p>Hypersensitivity</p>\n<p>reactions</p>\n<li>. 2. 3.</li>\n<p>4. Excessive drinking/eating,</p>\n<p>excessive urination</p>\n<p>Difficulty falling asleep</p>\n<p>Nausea, vomiting, right upper</p>\n<p>quadrant abdominal pain, yellow</p>\n<p>urine or eyes</p>\n<p>Skin itching (localized or diffuse),</p>\n<p>dizziness, faintness, difficulty</p>\n<p>breathing, nausea, vomiting, diar\u00ad</p>\n<p>rhoea, and abdominal cramping</p>\n<p>Do RBS to confirm hyperglycaemia</p>\n<p>then substitute with EFV</p>\n<p>Insomnia: Ensure patient is taking</p>\n<p>DTG during the day if it persists then</p>\n<p>substitute with EFV</p>\n<p>If EFV is contraindicated: Substitute</p>\n<p>with ATV/r</p>\n<h3>EFV 1. 2. 3. 4.</h3>\n<p>5. Persistent</p>\n<p>central nervous</p>\n<p>system toxicity</p>\n<li>. 2. 3. 4.</li>\n<p>5. Dizziness, insomnia, abnormal</p>\n<p>dreams, or mental symptoms (anx\u00ad</p>\n<p>iety, depression, mental confusion,</p>\n<p>suicidality)</p>\n<p>In case on EFV 600mg</p>\n<li>Lower the dose of EFV to 400mg.</li>\n<p>In case on EFV 400mg</p>\n<li>Reassure,</li>\n<p>219</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 286,
        "content": "Major Adverse/\nToxicity Events \nPRESENTING SIGNS/SYMPTOMS SUGGESTED MANAGEMENT\nConvulsions \nHepatotoxicity \nSevere skin and \nhypersensitivity \nreactions \nGynecomastia \nNew-onset seizures \nNausea, vomiting, right upper quad\u00ad\nrant abdominal pain, yellow urine \nor eyes New-onset skin rash \nBreast enlargement in men \n If symptoms persist \n\u2022Substitute EFV with DTG \nIf DTG is contraindicated:  substitute \nwith ATV/r \nTDF 1. 2. 3. 4. \t\nChronic kidney \ndisease, acute \nkidney injury and \nFanconi \nsyndrome \nDecreased bone \nmineral density \nLactic acidosis or \nsevere \nHepatomegaly \nwith steatosis\n1. 2. 3. \n4. Lower back pain, change in \nurine volume \nBone aches, spontaneous frac\u00ad\ntures \nExhaustion or extreme fatigue, \nmuscle cramps or pain, headache. \nAbdominal pain or discomfort, \ndecrease in appetite.\nDo LFTs and RFTs. If deranged (ele\u00ad\nvated liver enzymes and/or GFR is < \n60mls/min) then substitute with ABC \nIf ABC is contraindicated:  substitute \nwith AZT\n220\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Major Adverse/</p>\n<p>Toxicity Events</p>\n<h3>PRESENTING SIGNS/SYMPTOMS SUGGESTED MANAGEMENT</h3>\n<p>Convulsions</p>\n<p>Hepatotoxicity</p>\n<p>Severe skin and</p>\n<p>hypersensitivity</p>\n<p>reactions</p>\n<p>Gynecomastia</p>\n<p>New-onset seizures</p>\n<p>Nausea, vomiting, right upper quad\u00ad</p>\n<p>rant abdominal pain, yellow urine</p>\n<p>or eyes New-onset skin rash</p>\n<p>Breast enlargement in men</p>\n<p>If symptoms persist</p>\n<li>Substitute EFV with DTG</li>\n<p>If DTG is contraindicated:  substitute</p>\n<p>with ATV/r</p>\n<h3>TDF 1. 2. 3. 4.</h3>\n<p>Chronic kidney</p>\n<p>disease, acute</p>\n<p>kidney injury and</p>\n<p>Fanconi</p>\n<p>syndrome</p>\n<p>Decreased bone</p>\n<p>mineral density</p>\n<p>Lactic acidosis or</p>\n<p>severe</p>\n<p>Hepatomegaly</p>\n<p>with steatosis</p>\n<li>. 2. 3.</li>\n<p>4. Lower back pain, change in</p>\n<p>urine volume</p>\n<p>Bone aches, spontaneous frac\u00ad</p>\n<p>tures</p>\n<p>Exhaustion or extreme fatigue,</p>\n<p>muscle cramps or pain, headache.</p>\n<p>Abdominal pain or discomfort,</p>\n<p>decrease in appetite.</p>\n<p>Do LFTs and RFTs. If deranged (ele\u00ad</p>\n<p>vated liver enzymes and/or GFR is <</p>\n<p>60mls/min) then substitute with ABC</p>\n<p>If ABC is contraindicated:  substitute</p>\n<p>with AZT</p>\n<p>220</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 287,
        "content": "Major Adverse/\nToxicity Events \nPRESENTING SIGNS/\nSYMPTOMS \nSUGGESTED MANAGEMENT\nABC 1. Hypersensitivity \nreaction\n1. Skin itching (localized or dif\u00ad\nfuse) dizziness, faintness, difficulty \nbreathing, nausea, vomiting, di\u00ad\narrhoea, and abdominal cramping\nSubstitute with TDF \nIf TDF is contraindicated: substitute \nwith AZT\nAZT\n1. 2. 3. \n4. Severe anae\u00ad\nmia, neutropenia \nLactic acidosis or \nsevere hepatomeg\u00ad\naly with steatosis \nLipoatrophy, \nlipodystrophy, \nmyopathy \nSevere vomiting \n1. 2. 3. \n4. Easy fatigability, breathlessness, \nrecurrent infections Exhaustion or \nextreme fatigue, muscle cramps or \npain, headache. \nAbdominal pain or discomfort de\u00ad\ncrease in appetite. \nPersistent vomiting resulting in se\u00ad\nvere dehydration\nDo Hb (if < 8mg/dl): Substitute with TDF\n \nIf TDF is contraindicated: substitute \nwith ABC\n221\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Major Adverse/</p>\n<p>Toxicity Events</p>\n<h3>PRESENTING SIGNS/</h3>\n<h3>SYMPTOMS</h3>\n<h3>SUGGESTED MANAGEMENT</h3>\n<p>ABC 1. Hypersensitivity</p>\n<p>reaction</p>\n<li>. Skin itching (localized or dif\u00ad</li>\n<p>fuse) dizziness, faintness, difficulty</p>\n<p>breathing, nausea, vomiting, di\u00ad</p>\n<p>arrhoea, and abdominal cramping</p>\n<p>Substitute with TDF</p>\n<p>If TDF is contraindicated: substitute</p>\n<p>with AZT</p>\n<h3>AZT</h3>\n<li>. 2. 3.</li>\n<p>4. Severe anae\u00ad</p>\n<p>mia, neutropenia</p>\n<p>Lactic acidosis or</p>\n<p>severe hepatomeg\u00ad</p>\n<p>aly with steatosis</p>\n<p>Lipoatrophy,</p>\n<p>lipodystrophy,</p>\n<p>myopathy</p>\n<p>Severe vomiting</p>\n<li>. 2. 3.</li>\n<p>4. Easy fatigability, breathlessness,</p>\n<p>recurrent infections Exhaustion or</p>\n<p>extreme fatigue, muscle cramps or</p>\n<p>pain, headache.</p>\n<p>Abdominal pain or discomfort de\u00ad</p>\n<p>crease in appetite.</p>\n<p>Persistent vomiting resulting in se\u00ad</p>\n<p>vere dehydration</p>\n<p>Do Hb (if < 8mg/dl): Substitute with TDF</p>\n<p>If TDF is contraindicated: substitute</p>\n<p>with ABC</p>\n<p>221</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 288,
        "content": "3.1.8 Recommended Second Line Regimens in Adults, Adoles\u00ad\ncents, Pregnant Women and Children\nPatients may need to be switched to second line regimens   in case of \ntreatment failure, and to third line if they fail on second line drugs. Third \nline regimens require resistancetesting to inform the choice of appropriate \ndrugs, and needs referral to specialised ART centres. \nFactors involved in treatment failure are poor adherence, inadequate \ndrug levels or prior existing drug resistance.\nBefore switching therapy, it is essential to assess and address adher\u00ad\nence issues, and provide intensive adherence counselling if necessary.\nDEFINITION\nCOMMENT\nVIROLOGICAL FAILURE\nTwo consecutive viral loads >1000 copies/ml, \ndone at three to six months apart, with intensive \nadherence support following the 1st VL test\nPatient should \nhave been on \nART for at least \nsix months\nCLINICAL FAILURE\nAdults and adolescents:\nNew or recurrent WHO clinical stage 3 or 4 (with \nexception of TB) in a patient who has been on ef\u00ad\nfective ART regimen for at least six months\nChildren:\nNew or recurrent WHO clinical stage 3 or stage 4 \nevent (with the exception of TB) in a patient who has \nbeen on effective ART regimen for at least six months\nThe condi\u00ad\ntion must be \ndifferentiated \nfrom Immune \nReconstitution \nInflammatory \nSyndrome \n(IRIS)\noccurring after \ninitiating ART\nCriteria for defining treatment failure are presented in the follow\u00ad\ning table:\n222\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.8 Recommended Second Line Regimens in Adults, Adoles\u00ad</p>\n<p>cents, Pregnant Women and Children</p>\n<p>Patients may need to be switched to second line regimens   in case of</p>\n<p>treatment failure, and to third line if they fail on second line drugs. Third</p>\n<p>line regimens require resistancetesting to inform the choice of appropriate</p>\n<p>drugs, and needs referral to specialised ART centres.</p>\n<p>Factors involved in treatment failure are poor adherence, inadequate</p>\n<p>drug levels or prior existing drug resistance.</p>\n<p>Before switching therapy, it is essential to assess and address adher\u00ad</p>\n<p>ence issues, and provide intensive adherence counselling if necessary.</p>\n<h3>DEFINITION</h3>\n<h3>COMMENT</h3>\n<h3>VIROLOGICAL FAILURE</h3>\n<p>Two consecutive viral loads >1000 copies/ml,</p>\n<p>done at three to six months apart, with intensive</p>\n<p>adherence support following the 1st VL test</p>\n<p>Patient should</p>\n<p>have been on</p>\n<p>ART for at least</p>\n<p>six months</p>\n<h3>CLINICAL FAILURE</h3>\n<p>Adults and adolescents:</p>\n<p>New or recurrent WHO clinical stage 3 or 4 (with</p>\n<p>exception of TB) in a patient who has been on ef\u00ad</p>\n<p>fective ART regimen for at least six months</p>\n<p>Children:</p>\n<p>New or recurrent WHO clinical stage 3 or stage 4</p>\n<p>event (with the exception of TB) in a patient who has</p>\n<p>been on effective ART regimen for at least six months</p>\n<p>The condi\u00ad</p>\n<p>tion must be</p>\n<p>differentiated</p>\n<p>from Immune</p>\n<p>Reconstitution</p>\n<p>Inflammatory</p>\n<p>Syndrome</p>\n<h3>(IRIS)</h3>\n<p>occurring after</p>\n<p>initiating ART</p>\n<p>Criteria for defining treatment failure are presented in the follow\u00ad</p>\n<p>ing table:</p>\n<p>222</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 289,
        "content": "Criteria for defining treatment failure are presented in the following table:\nPopulation\nFailing first line \nregimens\nRecommended second \nline regimen \nAlternative second \nline regimen\nThird line \nregimens1,2\nAdults and \nadolescents \u2265 \n30Kg, includ\u00ad\ning pregnant \nand breast\u00ad\nfeeding \nwomen\nTDF + 3TC+EFV  \nTDF+3TC+NVP\nTAF + FTC + EFV \nAZT+3TC+DTG \nAZT+3TC++DRV/r \norATV/r \nAll third line regimens \nto be guided by HIV \ndrug resistance test\u00ad\ning. \nIn case of suscepti\u00ad\nbility\nto all drugs, use\nthe table to guide the\npreferred or alterna\u00ad\ntive choices.\nTDF+3TC+DTG or \nTAF + FTC + DTG \nAZT+3TC+DRV/r\nAZT+3TC+ATV/r\nAZT+3TC+NVP \nAZT+3TC+EFV  \nABC/3TC/NVP \nABC+ 3TC+ EFV \nTDF+3TC+DTG or TAF \n+ FTC + DTG\nTDF+3TC+ATV/r or \nTAF + FTC +ATV/r\nAZT+3TC+DTG  \nABC+3TC+DTG\nTDF+3TC+DRV/r or TAF \n+ FTC + DRV/r\nTDF+3TC+ATV/r or \nTAF + FTC +ATV/r\nChildren  \u2265 \n20Kg  - \n<30Kg\nABC+3TC+EFV \nABC+3TC+NVP\nAZT+3TC+DTG\nAZT+3TC+LPV/r\nABC+3TC+LPV/r\nAZT+3TC+DTG\nAZT+3TC+DRV/r\nABC+3TC+DTG\nAZT+3TC+DRV/r\nAZT+3TC+LPV/r\n223\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Criteria for defining treatment failure are presented in the following table:</p>\n<p>Population</p>\n<p>Failing first line</p>\n<p>regimens</p>\n<p>Recommended second</p>\n<p>line regimen</p>\n<p>Alternative second</p>\n<p>line regimen</p>\n<p>Third line</p>\n<p>regimens1,2</p>\n<p>Adults and</p>\n<p>adolescents \u2265</p>\n<p>30Kg, includ\u00ad</p>\n<p>ing pregnant</p>\n<p>and breast\u00ad</p>\n<p>feeding</p>\n<p>women</p>\n<h3>TDF + 3TC+EFV</h3>\n<h3>TDF+3TC+NVP</h3>\n<h3>TAF + FTC + EFV</h3>\n<h3>AZT+3TC+DTG</h3>\n<p>AZT+3TC++DRV/r</p>\n<p>orATV/r</p>\n<p>All third line regimens</p>\n<p>to be guided by HIV</p>\n<p>drug resistance test\u00ad</p>\n<p>ing.</p>\n<p>In case of suscepti\u00ad</p>\n<p>bility</p>\n<p>to all drugs, use</p>\n<p>the table to guide the</p>\n<p>preferred or alterna\u00ad</p>\n<p>tive choices.</p>\n<p>TDF+3TC+DTG or</p>\n<h3>TAF + FTC + DTG</h3>\n<p>AZT+3TC+DRV/r</p>\n<p>AZT+3TC+ATV/r</p>\n<h3>AZT+3TC+NVP</h3>\n<h3>AZT+3TC+EFV</h3>\n<h3>ABC/3TC/NVP</h3>\n<h3>ABC+ 3TC+ EFV</h3>\n<p>TDF+3TC+DTG or TAF</p>\n<h3>+ FTC + DTG</h3>\n<p>TDF+3TC+ATV/r or</p>\n<p>TAF + FTC +ATV/r</p>\n<h3>AZT+3TC+DTG</h3>\n<h3>ABC+3TC+DTG</h3>\n<p>TDF+3TC+DRV/r or TAF</p>\n<p>+ FTC + DRV/r</p>\n<p>TDF+3TC+ATV/r or</p>\n<p>TAF + FTC +ATV/r</p>\n<p>Children  \u2265</p>\n<p>20Kg  -</p>\n<p><30Kg</p>\n<h3>ABC+3TC+EFV</h3>\n<h3>ABC+3TC+NVP</h3>\n<h3>AZT+3TC+DTG</h3>\n<p>AZT+3TC+LPV/r</p>\n<p>ABC+3TC+LPV/r</p>\n<h3>AZT+3TC+DTG</h3>\n<p>AZT+3TC+DRV/r</p>\n<h3>ABC+3TC+DTG</h3>\n<p>AZT+3TC+DRV/r</p>\n<p>AZT+3TC+LPV/r</p>\n<p>223</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 290,
        "content": "Population\nFailing first line \nregimens\nRecommended second \nline regimen \nAlternative second \nline regimen\nThird line \nregimens1,2\nAZT+3TC+EFV \nAZT+3TC+NVP \nABC+3TC+DTG or TAF \n+ FTC + DTG\nABC+3TC+LPVr or TAF \n+ FTC + LPV/r\nNOTE: For details \non the third-line \nART, \nPlease see the third-\nline ART \nimplementat ion \nguides.\nAZT+3TC+LPV/r \nABC+3TC+DTG or TAF \n+ FTC + DTG\nABC+3TC+DRV/r or \nTAF + FTC + DRV/r \nAZT+3TC+DTG \nABC+3TC+DRV/r or TAF \n+ FTC + DRV/r\nABC+3TC+LPV/r or \nTAF + FTC + LPV/r\nChildren \n<20Kg\nABC+3TC+EFV  \nABC+3TC+NVP \nAZT+3TC+DTG \nAZT+3TC+LPV/r \nAC+3TC+LPV/r AZT+3TC+DTG  \nAZT+3TC+DRV/r \nAZT+3TC+EFV \nAZT+3TC+NVP \nABC+3TC+DTG \nABC+3TC+LPV/r \nAT+3TC+LPV/r  ABC+3TC+DTG  \nABC+3TC+DRV/r \nAZT+3TC+DTG \nABC+3TC+DRV/r \nABC+3TC+LPV/r \n\u2022\t All PLHIV should receive resistance testing to inform the prescription of 2ndand 3rd-line medicines.\n\u2022\t Since all 3rd-line PLHIV will have prior PI Exposure, DRV/r will be taken twice a day.\n\u2022\t For recipients of care on  NNRTI-based First Line regimen whose VL is not suppressed, switch \nwithout a second VL but conduct IAC to improve adherence to new regimen.\n\u2022\t  For all PLHIV failing first-line ART, optimize the second-line ART using HIVDR test\n224\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Population</p>\n<p>Failing first line</p>\n<p>regimens</p>\n<p>Recommended second</p>\n<p>line regimen</p>\n<p>Alternative second</p>\n<p>line regimen</p>\n<p>Third line</p>\n<p>regimens1,2</p>\n<h3>AZT+3TC+EFV</h3>\n<h3>AZT+3TC+NVP</h3>\n<p>ABC+3TC+DTG or TAF</p>\n<h3>+ FTC + DTG</h3>\n<p>ABC+3TC+LPVr or TAF</p>\n<p>+ FTC + LPV/r</p>\n<p>NOTE: For details</p>\n<p>on the third-line</p>\n<h3>ART,</h3>\n<p>Please see the third-</p>\n<p>line ART</p>\n<p>implementat ion</p>\n<p>guides.</p>\n<p>AZT+3TC+LPV/r</p>\n<p>ABC+3TC+DTG or TAF</p>\n<h3>+ FTC + DTG</h3>\n<p>ABC+3TC+DRV/r or</p>\n<p>TAF + FTC + DRV/r</p>\n<h3>AZT+3TC+DTG</h3>\n<p>ABC+3TC+DRV/r or TAF</p>\n<p>+ FTC + DRV/r</p>\n<p>ABC+3TC+LPV/r or</p>\n<p>TAF + FTC + LPV/r</p>\n<p>Children</p>\n<p><20Kg</p>\n<h3>ABC+3TC+EFV</h3>\n<h3>ABC+3TC+NVP</h3>\n<h3>AZT+3TC+DTG</h3>\n<p>AZT+3TC+LPV/r</p>\n<p>AC+3TC+LPV/r AZT+3TC+DTG</p>\n<p>AZT+3TC+DRV/r</p>\n<h3>AZT+3TC+EFV</h3>\n<h3>AZT+3TC+NVP</h3>\n<h3>ABC+3TC+DTG</h3>\n<p>ABC+3TC+LPV/r</p>\n<p>AT+3TC+LPV/r  ABC+3TC+DTG</p>\n<p>ABC+3TC+DRV/r</p>\n<h3>AZT+3TC+DTG</h3>\n<p>ABC+3TC+DRV/r</p>\n<p>ABC+3TC+LPV/r</p>\n<li>All PLHIV should receive resistance testing to inform the prescription of 2ndand 3rd-line medicines.</li>\n<li>Since all 3rd-line PLHIV will have prior PI Exposure, DRV/r will be taken twice a day.</li>\n<li>For recipients of care on  NNRTI-based First Line regimen whose VL is not suppressed, switch</li>\n<p>without a second VL but conduct IAC to improve adherence to new regimen.</p>\n<li>For all PLHIV failing first-line ART, optimize the second-line ART using HIVDR test</li>\n<p>224</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 291,
        "content": "Dosing Tables for ARV  Medicines\nFormulations \nand strengths\n3.0\u2013\n5.9kg\n6.0\u2013\n9.9kg\n10.0\u2013\n13.9kg\n14.0\u2013\n19.9kg\n20.0\u2013\n24.9kg\n25.0\u2013\n34.9kg\nAdoles\u00ad\ncents and \nadults \n>35kg\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nFixed \nDose \nCombi\u00ad\nnation \nTablets/\nGranules\nABC/3TC \n120/60mg\n\u2212\n1\n\u2212\n1.5\n\u2212\n2\n\u2212\n2.5\n\u2212\n3\n-\n-\n-\n-\nABC/3TC \n600/300mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n\u2212\n1\n\u2212\n1\nAZT/3TC \n60/30mg\n1\n1\n1.5\n1.5\n2\n2\n2.5\n2.5\n3\n3\n-\n-\n-\n-\nAZT/3TC \n300/150mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n1\n1\n1\nTDF/3TC \n300/300mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n\u2212\n1\nTDF/3TC/EFV\n300/300/400mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n225\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Dosing Tables for ARV  Medicines</p>\n<p>Formulations</p>\n<p>and strengths</p>\n<p>3.0\u2013</p>\n<p>5.9kg</p>\n<p>6.0\u2013</p>\n<p>9.9kg</p>\n<p>10.0\u2013</p>\n<p>13.9kg</p>\n<p>14.0\u2013</p>\n<p>19.9kg</p>\n<p>20.0\u2013</p>\n<p>24.9kg</p>\n<p>25.0\u2013</p>\n<p>34.9kg</p>\n<p>Adoles\u00ad</p>\n<p>cents and</p>\n<p>adults</p>\n<p>>35kg</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>Fixed</p>\n<p>Dose</p>\n<p>Combi\u00ad</p>\n<p>nation</p>\n<p>Tablets/</p>\n<p>Granules</p>\n<h3>ABC/3TC</h3>\n<p>120/60mg</p>\n<p>\u2212</p>\n<p>1</p>\n<p>\u2212</p>\n<li>.5</li>\n<p>\u2212</p>\n<p>2</p>\n<p>\u2212</p>\n<p>2.5</p>\n<p>\u2212</p>\n<p>3</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<h3>ABC/3TC</h3>\n<p>600/300mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>\u2212</p>\n<p>1</p>\n<p>\u2212</p>\n<p>1</p>\n<h3>AZT/3TC</h3>\n<p>60/30mg</p>\n<p>1</p>\n<p>1</p>\n<li>.5</li>\n<li>.5</li>\n<p>2</p>\n<p>2</p>\n<p>2.5</p>\n<p>2.5</p>\n<p>3</p>\n<p>3</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<h3>AZT/3TC</h3>\n<p>300/150mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<h3>TDF/3TC</h3>\n<p>300/300mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>\u2212</p>\n<p>1</p>\n<h3>TDF/3TC/EFV</h3>\n<p>300/300/400mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>225</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 292,
        "content": "Formulations \nand strengths\n3.0\u2013\n5.9kg\n6.0\u2013\n9.9kg\n10.0\u2013\n13.9kg\n14.0\u2013\n19.9kg\n20.0\u2013\n24.9kg\n25.0\u2013\n34.9kg\nAdoles\u00ad\ncents and \nadults \n>35kg\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nAM\nPM\nTDF/3TC/DTG\n300/300/50mg\n\u00ac-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n-\nTAF/FTC/DTG\n25/200/50mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n-\n1\n-\nABC/3TC/DTG \n600/300/50mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n-\n1\n-\nABC/3TC/DTG\n60/30/5mg\n2\n-\n3\n-\n4\n-\n5\n-\n6\n-\n-\n-\n-\n--\nABC/3TC/LPV/r\n30/15/40/10mg\n2\n2\n3\n3\n4\n4\n5\n5\n6\n6\n-\n-\n-\n-\n226\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Formulations</p>\n<p>and strengths</p>\n<p>3.0\u2013</p>\n<p>5.9kg</p>\n<p>6.0\u2013</p>\n<p>9.9kg</p>\n<p>10.0\u2013</p>\n<p>13.9kg</p>\n<p>14.0\u2013</p>\n<p>19.9kg</p>\n<p>20.0\u2013</p>\n<p>24.9kg</p>\n<p>25.0\u2013</p>\n<p>34.9kg</p>\n<p>Adoles\u00ad</p>\n<p>cents and</p>\n<p>adults</p>\n<p>>35kg</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<p>AM</p>\n<p>PM</p>\n<h3>TDF/3TC/DTG</h3>\n<p>300/300/50mg</p>\n<p>\u00ac-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<h3>TAF/FTC/DTG</h3>\n<p>25/200/50mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<h3>ABC/3TC/DTG</h3>\n<p>600/300/50mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<h3>ABC/3TC/DTG</h3>\n<p>60/30/5mg</p>\n<p>2</p>\n<p>-</p>\n<p>3</p>\n<p>-</p>\n<p>4</p>\n<p>-</p>\n<p>5</p>\n<p>-</p>\n<p>6</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>--</p>\n<p>ABC/3TC/LPV/r</p>\n<p>30/15/40/10mg</p>\n<p>2</p>\n<p>2</p>\n<p>3</p>\n<p>3</p>\n<p>4</p>\n<p>4</p>\n<p>5</p>\n<p>5</p>\n<p>6</p>\n<p>6</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>226</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 293,
        "content": "Formulations \nand strengths\n3.0\u2013\n5.9kg\n6.0\u2013\n9.9kg\n10.0\u201313.9kg\n14.0\u201319.9kg\n20.0\u201324.9kg\n25.0\u201334.9kg\nAdolescents and \nadults >35kg\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nFixed \nDose \nCombi\u00ad\nnation \nTablets/\nGranules\nDTG 50mg\n-\n-\n-\n-\n-\n-\n-\n-\n1\n-\n1\n-\n1\n-\nDTG 10mg\n1\n-\n1.5\n-\n2\n-\n2.5\n-\n3\n-\n-\n-\n-\n-\nEFV 200mg\n-\n-\n-\n-\n\u2212\n1\n\u2212\n1.5\n\u2212\n1.5\n\u2212\n2\n-\n-\nLPV/r 40/10mg1\nOral Granules\n2\n2\n3\n3\n4\n4\n5\n5\n6\n6\n\u2212\n\u2212\n-\n-\nLPV/r \n100/25mg2\n-\n-\n-\n-\n2\n1\n2\n2\n2\n2\n-\n-\n-\n-\nLPV/r 200\n/50mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n2\n1\n2\n2\nDRV/r \n400/50mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n2\n-\nATV/r \n300/100mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n\u2212\n1\nRaltegravir 25mg \nChewable Tablet\n-\n-\n-\n-\n3\n3\n-\n-\n-\n-\n-\n-\n-\n-\n227\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Formulations</p>\n<p>and strengths</p>\n<p>3.0\u2013</p>\n<p>5.9kg</p>\n<p>6.0\u2013</p>\n<p>9.9kg</p>\n<p>10.0\u201313.9kg</p>\n<p>14.0\u201319.9kg</p>\n<p>20.0\u201324.9kg</p>\n<p>25.0\u201334.9kg</p>\n<p>Adolescents and</p>\n<p>adults >35kg</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>Fixed</p>\n<p>Dose</p>\n<p>Combi\u00ad</p>\n<p>nation</p>\n<p>Tablets/</p>\n<p>Granules</p>\n<p>DTG 50mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<p>1</p>\n<p>-</p>\n<p>DTG 10mg</p>\n<p>1</p>\n<p>-</p>\n<li>.5</li>\n<p>-</p>\n<p>2</p>\n<p>-</p>\n<p>2.5</p>\n<p>-</p>\n<p>3</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>EFV 200mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>\u2212</p>\n<p>1</p>\n<p>\u2212</p>\n<li>.5</li>\n<p>\u2212</p>\n<li>.5</li>\n<p>\u2212</p>\n<p>2</p>\n<p>-</p>\n<p>-</p>\n<p>LPV/r 40/10mg1</p>\n<p>Oral Granules</p>\n<p>2</p>\n<p>2</p>\n<p>3</p>\n<p>3</p>\n<p>4</p>\n<p>4</p>\n<p>5</p>\n<p>5</p>\n<p>6</p>\n<p>6</p>\n<p>\u2212</p>\n<p>\u2212</p>\n<p>-</p>\n<p>-</p>\n<p>LPV/r</p>\n<p>100/25mg2</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>2</p>\n<p>1</p>\n<p>2</p>\n<p>2</p>\n<p>2</p>\n<p>2</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>LPV/r 200</p>\n<p>/50mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>2</p>\n<p>1</p>\n<p>2</p>\n<p>2</p>\n<p>DRV/r</p>\n<p>400/50mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>2</p>\n<p>-</p>\n<p>ATV/r</p>\n<p>300/100mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>\u2212</p>\n<p>1</p>\n<p>Raltegravir 25mg</p>\n<p>Chewable Tablet</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>3</p>\n<p>3</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>227</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 294,
        "content": "Formula\u00ad\ntions and \nstrengths\n3.0\u2013\n5.9kg\n6.0\u2013\n9.9kg\n10.0\u201313.9kg\n14.0\u201319.9kg\n20.0\u201324.9kg\n25.0\u201334.9kg\nAdolescents and \nadults >35kg\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nA\nM\nP\nM\nFixed \nDose \nCombi\u00ad\nnation \nTablets/\nGranules\nRaltegravir \n100mg Chew\u00ad\nable Tablet\n-\n-\n-\n-\n-\n-\n1\n1\n1.5\n1.5\n-\n-\n-\n-\nRaltegravir \n400mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n1\n1\n1\nDRV 75mg \nTablets3\n-\n-\n-\n-\n3 \n+RTV \n0.5ml\n3 \n+RTV \n0.5ml\n5 \n+RTV \n50mg\n5 \n+RTV \n50mg\n5 \n+RTV \n50mg\n5 \n+RTV \n50mg\n-\n-\n-\n-\nDRV 150mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n4 \n+RTV \n100mg\n4 \n+RTV \n100mg\n4 \n+RTV \n100mg\n4 \n+RTV \n100mg\nDRV 600mg4\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1 \n+RTV \n100mg\n1 \n+RTV \n100mg\n1 \n+RTV \n100mg\n1 \n+RTV \n100mg\nRTV 25mg\n-\n-\n-\n-\n-\n-\n2\n2\n2\n2\n-\n-\n-\n-\nRTV 100mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n1\n1\n1\nETV 200mg\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n-\n1\n1\n228\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Formula\u00ad</p>\n<p>tions and</p>\n<p>strengths</p>\n<p>3.0\u2013</p>\n<p>5.9kg</p>\n<p>6.0\u2013</p>\n<p>9.9kg</p>\n<p>10.0\u201313.9kg</p>\n<p>14.0\u201319.9kg</p>\n<p>20.0\u201324.9kg</p>\n<p>25.0\u201334.9kg</p>\n<p>Adolescents and</p>\n<p>adults >35kg</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>A</p>\n<p>M</p>\n<p>P</p>\n<p>M</p>\n<p>Fixed</p>\n<p>Dose</p>\n<p>Combi\u00ad</p>\n<p>nation</p>\n<p>Tablets/</p>\n<p>Granules</p>\n<p>Raltegravir</p>\n<p>100mg Chew\u00ad</p>\n<p>able Tablet</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>1</p>\n<li>.5</li>\n<li>.5</li>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>Raltegravir</p>\n<p>400mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>DRV 75mg</p>\n<p>Tablets3</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>3</p>\n<h3>+RTV</h3>\n<p>0.5ml</p>\n<p>3</p>\n<h3>+RTV</h3>\n<p>0.5ml</p>\n<p>5</p>\n<h3>+RTV</h3>\n<p>50mg</p>\n<p>5</p>\n<h3>+RTV</h3>\n<p>50mg</p>\n<p>5</p>\n<h3>+RTV</h3>\n<p>50mg</p>\n<p>5</p>\n<h3>+RTV</h3>\n<p>50mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>DRV 150mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>4</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>4</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>4</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>4</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>DRV 600mg4</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>1</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>1</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>1</p>\n<h3>+RTV</h3>\n<p>100mg</p>\n<p>RTV 25mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>2</p>\n<p>2</p>\n<p>2</p>\n<p>2</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>RTV 100mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>ETV 200mg</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>-</p>\n<p>1</p>\n<p>1</p>\n<p>228</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 295,
        "content": "1.\tFor children\u226510kg that are able to swallow tablets, give LPV/r \n100/25mg tablet.\n2.\ttablets of LPV/r 100/25mg can be substituted with 1 tablet of \nLPV/r 200/50mg in order to reduce the pill burden. These tablets \nshould be administered fully intact/whole i.e. not cut or crushed.\n3.\tDRV must be administered with 0.5mL of RTV 80mg/mL oral \nsuspension in children <15kg, with 2 tab of RTV 25mg in children \n15 to 25kg and 3 tab of RTV 25mg in children above 25kg. DRV \nis always taken with food.\n4.\tDRV 600mg must be co-administered with RTV 100mg.\n3.1.9 Mother-to-Child Transmission of HIV\nApproximately one-third of the women who are infected with HIV can \npass it to their babies.\nCause\nTime of transmission\n \n~\nDuring pregnancy (15-20%)\n \n~\nDuring time of labour and delivery (60%-70%)\n \n~\nAfter delivery through breast feeding (15%-20%)\nPre-disposing factors\n \n~\nHigh maternal viral load\n \n~\nDepleted maternal immunity (e.g. very low CD4 count)\n \n~\nProlonged rupture of membranes\n \n~\nIntra-partum haemorrhage and invasive obstetrical proce\u00ad\ndures\n229\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<li>.\tFor children\u226510kg that are able to swallow tablets, give LPV/r</li>\n<p>100/25mg tablet.</p>\n<p>2.\ttablets of LPV/r 100/25mg can be substituted with 1 tablet of</p>\n<p>LPV/r 200/50mg in order to reduce the pill burden. These tablets</p>\n<p>should be administered fully intact/whole i.e. not cut or crushed.</p>\n<p>3.\tDRV must be administered with 0.5mL of RTV 80mg/mL oral</p>\n<p>suspension in children <15kg, with 2 tab of RTV 25mg in children</p>\n<p>15 to 25kg and 3 tab of RTV 25mg in children above 25kg. DRV</p>\n<p>is always taken with food.</p>\n<p>4.\tDRV 600mg must be co-administered with RTV 100mg.</p>\n<p>3.1.9 Mother-to-Child Transmission of HIV</p>\n<p>Approximately one-third of the women who are infected with HIV can</p>\n<p>pass it to their babies.</p>\n<p>Cause</p>\n<p>Time of transmission</p>\n<p>~</p>\n<p>During pregnancy (15-20%)</p>\n<p>~</p>\n<p>During time of labour and delivery (60%-70%)</p>\n<p>~</p>\n<p>After delivery through breast feeding (15%-20%)</p>\n<p>Pre-disposing factors</p>\n<p>~</p>\n<p>High maternal viral load</p>\n<p>~</p>\n<p>Depleted maternal immunity (e.g. very low CD4 count)</p>\n<p>~</p>\n<p>Prolonged rupture of membranes</p>\n<p>~</p>\n<p>Intra-partum haemorrhage and invasive obstetrical proce\u00ad</p>\n<p>dures</p>\n<p>229</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 296,
        "content": "~\nIf delivering twins, first twin is at higher risk of infection than \nsecond twin\n \n~\nPremature baby is at higher risk than term baby\n \n~\nMixed feeding carries a higher risk than exclusive breastfeed\u00ad\ning or use of replacement feeding\nInvestigations\n \n\u0081\nBlood: HIV serological test\n \n\u0081\nHIV DNA PCR testing of babies (see algorithm in section 3.1.2 \nabove)\n \n\u0081\nViral load testing every 6 months\nManagement\nAll HIV services for pregnant mothers are offered in the MCH clinic. \nAfter delivery, mother and baby will remain in the MCH postnatal clinic \ntill HIV status of the child is\nconfirmed, then they will be transferred to the general ART clinic.\nThe current policy aims at elimination of Mother-to-Child Transmission \n(eMTCT) through provision of a continuum of care with the following \nelements:\n \n- Primary HIV prevention for men, women and adolescents\n \n- Prevention of unintended pregnancies among women living \nwith HIV\n \n- Prevention of HIV transmission from women living with HIV \nto their infants\n \n- Provision of treatment, care and support to ALL women \ninfected with HIV, their children and their families\n230\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>~</p>\n<p>If delivering twins, first twin is at higher risk of infection than</p>\n<p>second twin</p>\n<p>~</p>\n<p>Premature baby is at higher risk than term baby</p>\n<p>~</p>\n<p>Mixed feeding carries a higher risk than exclusive breastfeed\u00ad</p>\n<p>ing or use of replacement feeding</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: HIV serological test</p>\n<p>\u0081</p>\n<p>HIV DNA PCR testing of babies (see algorithm in section 3.1.2</p>\n<p>above)</p>\n<p>\u0081</p>\n<p>Viral load testing every 6 months</p>\n<p>Management</p>\n<p>All HIV services for pregnant mothers are offered in the MCH clinic.</p>\n<p>After delivery, mother and baby will remain in the MCH postnatal clinic</p>\n<p>till HIV status of the child is</p>\n<p>confirmed, then they will be transferred to the general ART clinic.</p>\n<p>The current policy aims at elimination of Mother-to-Child Transmission</p>\n<p>(eMTCT) through provision of a continuum of care with the following</p>\n<p>elements:</p>\n<p>- Primary HIV prevention for men, women and adolescents</p>\n<p>- Prevention of unintended pregnancies among women living</p>\n<p>with HIV</p>\n<p>- Prevention of HIV transmission from women living with HIV</p>\n<p>to their infants</p>\n<p>- Provision of treatment, care and support to ALL women</p>\n<p>infected with HIV, their children and their families</p>\n<p>230</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 297,
        "content": "Service \nDescription\nProvide HTS and \nsyphilis testing in \nANC \n \n\u0083 \u2022 Offer routine HTS and testing for syphilis \nto pregnant women and their partner(s) \nwith same-day results using the SD-\nBioline duo HIV/syphilis test according to \nalgorithm If found positive treat for syphilis \nin order to reduce HIV transmission from \nmother to child using the following:\n \n\u0083 o Pregnant women/girls with early syphilis: \ngive Benzathine Penicillin G 2.4 million \nunits intramuscularly once. Early syphilis \nfor this guideline is: (primary, secondary \nand early latent syphilis of not more than \ntwo years\u2019 duration).\n \n\u0083 o In late syphilis or unknown stage of \nsyphilis: give Benzathine Penicillin G 2.4 \nmillion units intramuscularly once weekly \nfor three consecutive weeks. Late syphilis \nfor this guideline is defined as infection \nof more than two years\u2019 duration without \nevidence of treponemal infection.\n \n\u0083 o Note: Adequate maternal treatment for \nprevention of congenital syphilis is defined \nas at least one injection of 2.4 million units \nof intramuscular Benzathine Penicillin at \nleast 30 days prior to delivery.\n \n\u0083 o Alternative treatment with Procaine \nPenicillin or Erythromycin, Azithromycin \nand Ceftriaxone if allergic to penicillin.\n3.1.9.1 Management of HIV Positive Pregnant Mother\nKey Interventions for eMTCT\neMTCT Services for Pregnant Women\n231\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>Provide HTS and</p>\n<p>syphilis testing in</p>\n<h3>ANC</h3>\n<p>\u0083 \u2022 Offer routine HTS and testing for syphilis</p>\n<p>to pregnant women and their partner(s)</p>\n<p>with same-day results using the SD-</p>\n<p>Bioline duo HIV/syphilis test according to</p>\n<p>algorithm If found positive treat for syphilis</p>\n<p>in order to reduce HIV transmission from</p>\n<p>mother to child using the following:</p>\n<p>\u0083 o Pregnant women/girls with early syphilis:</p>\n<p>give Benzathine Penicillin G 2.4 million</p>\n<p>units intramuscularly once. Early syphilis</p>\n<p>for this guideline is: (primary, secondary</p>\n<p>and early latent syphilis of not more than</p>\n<p>two years\u2019 duration).</p>\n<p>\u0083 o In late syphilis or unknown stage of</p>\n<p>syphilis: give Benzathine Penicillin G 2.4</p>\n<p>million units intramuscularly once weekly</p>\n<p>for three consecutive weeks. Late syphilis</p>\n<p>for this guideline is defined as infection</p>\n<p>of more than two years\u2019 duration without</p>\n<p>evidence of treponemal infection.</p>\n<p>\u0083 o Note: Adequate maternal treatment for</p>\n<p>prevention of congenital syphilis is defined</p>\n<p>as at least one injection of 2.4 million units</p>\n<p>of intramuscular Benzathine Penicillin at</p>\n<p>least 30 days prior to delivery.</p>\n<p>\u0083 o Alternative treatment with Procaine</p>\n<p>Penicillin or Erythromycin, Azithromycin</p>\n<p>and Ceftriaxone if allergic to penicillin.</p>\n<p>3.1.9.1 Management of HIV Positive Pregnant Mother</p>\n<p>Key Interventions for eMTCT</p>\n<p>eMTCT Services for Pregnant Women</p>\n<p>231</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 298,
        "content": "Service \nDescription\n\u2022 Offer syphilis screening using syphilis \nrapid tests for mothers who are already on \nART. \no Offer HTS (including PITC, VCT and cou\u00ad\nple testing) and support mutual disclosure.\n\u2022 Link all HIV-positive seroconcordant cou\u00ad\nples as well as HIV-positive individuals in \nserodiscordant relationships to ART. \n\u2022 Offer PrEP to all pregnant and breast\u00ad\nfeeding mothers at substantial risk of HIV \nacquisition as well as negative partners in \nthe discordant couples.\n\u2022 For HIV-negative pregnant women, re-\ntest in the third trimester, during labor, \nor shortly after delivery, because of the \nhigh risk of acquiring HIV infection during \npregnancy.  \n\u2022 Re-test HIV-negative pregnant women \nin a discordant relationship every three \nmonths.\n\u2022 Re-test the following HIV negative preg\u00ad\nnant women within four weeks of the first \ntest:\no STI, HBV or TB-infected pregnant woen.\no Those with a specific incident of HIV-ex\u00ad\nposure within the past three months\n\u2022 Provide risk reduction counseling to \nHIV-negative women.\n\u2022 Test pregnant women/girls and their part\u00ad\nners for Hepatitis B during antenatal\n232\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<li>Offer syphilis screening using syphilis</li>\n<p>rapid tests for mothers who are already on</p>\n<h3>ART.</h3>\n<p>o Offer HTS (including PITC, VCT and cou\u00ad</p>\n<p>ple testing) and support mutual disclosure.</p>\n<li>Link all HIV-positive seroconcordant cou\u00ad</li>\n<p>ples as well as HIV-positive individuals in</p>\n<p>serodiscordant relationships to ART.</p>\n<li>Offer PrEP to all pregnant and breast\u00ad</li>\n<p>feeding mothers at substantial risk of HIV</p>\n<p>acquisition as well as negative partners in</p>\n<p>the discordant couples.</p>\n<li>For HIV-negative pregnant women, re-</li>\n<p>test in the third trimester, during labor,</p>\n<p>or shortly after delivery, because of the</p>\n<p>high risk of acquiring HIV infection during</p>\n<p>pregnancy.</p>\n<li>Re-test HIV-negative pregnant women</li>\n<p>in a discordant relationship every three</p>\n<p>months.</p>\n<li>Re-test the following HIV negative preg\u00ad</li>\n<p>nant women within four weeks of the first</p>\n<p>test:</p>\n<p>o STI, HBV or TB-infected pregnant woen.</p>\n<p>o Those with a specific incident of HIV-ex\u00ad</p>\n<p>posure within the past three months</p>\n<li>Provide risk reduction counseling to</li>\n<p>HIV-negative women.</p>\n<li>Test pregnant women/girls and their part\u00ad</li>\n<p>ners for Hepatitis B during antenatal</p>\n<p>232</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 299,
        "content": "Service \nDescription\no\tFor patients who are HBsAg positive, assess \nthe HBeAg and HBV viral load. Patients \nwho are HBeAG negative with a HBV VL of \n<200,000 IU/ml should be monitored with \nCBC, LFTs and VL at 6 and 12 months (see \nFigure 10).   \no\tFor patients who are HBsAg positive assess \nthe HBeAg and HBV viral load. Patients \nwho are HBeAg positive with HBV VL of \n>200,000 IU/ml should initiate prophylactic \ntreatment at 24 weeks gestation or at the \nearliest contact.  Discontinue medication 3 \nmonths after delivery. After starting treat\u00ad\nment, LFTs should be monitored at 4, 8, \n12 and 24 weeks and thereafter annually. \nMonitor HBV viral load at 6 and 12 months \nAntenatal care pack\u00ad\nage for all pregnant \nwomen (regardless \nof HIV status)\nGeneral care:\n\u2022 All pregnant women/girls should have \nat least eight ANC visits: encourage and \nsupport mothers to start ANC in the first \ntrimester\n\u2022 Routinely provide iron, folic acid, and multi\u00ad\nvitamin supplements\n\u2022 Deworm in the 2nd trimester using Meben\u00ad\ndazole\n\u2022 Provide nutrition assessment, counseling \nand support \n\u2022 Counsel and encourage women to deliver at \nthe health facility\n\u2022Screen for TB and take appropriate action\n\u2022Take weight and BP at every visit\n233\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>o\tFor patients who are HBsAg positive, assess</p>\n<p>the HBeAg and HBV viral load. Patients</p>\n<p>who are HBeAG negative with a HBV VL of</p>\n<p><200,000 IU/ml should be monitored with</p>\n<p>CBC, LFTs and VL at 6 and 12 months (see</p>\n<p>Figure 10).</p>\n<p>o\tFor patients who are HBsAg positive assess</p>\n<p>the HBeAg and HBV viral load. Patients</p>\n<p>who are HBeAg positive with HBV VL of</p>\n<p>>200,000 IU/ml should initiate prophylactic</p>\n<p>treatment at 24 weeks gestation or at the</p>\n<p>earliest contact.  Discontinue medication 3</p>\n<p>months after delivery. After starting treat\u00ad</p>\n<p>ment, LFTs should be monitored at 4, 8,</p>\n<p>12 and 24 weeks and thereafter annually.</p>\n<p>Monitor HBV viral load at 6 and 12 months</p>\n<p>Antenatal care pack\u00ad</p>\n<p>age for all pregnant</p>\n<p>women (regardless</p>\n<p>of HIV status)</p>\n<p>General care:</p>\n<li>All pregnant women/girls should have</li>\n<p>at least eight ANC visits: encourage and</p>\n<p>support mothers to start ANC in the first</p>\n<p>trimester</p>\n<li>Routinely provide iron, folic acid, and multi\u00ad</li>\n<p>vitamin supplements</p>\n<li>Deworm in the 2nd trimester using Meben\u00ad</li>\n<p>dazole</p>\n<li>Provide nutrition assessment, counseling</li>\n<p>and support</p>\n<li>Counsel and encourage women to deliver at</li>\n<p>the health facility</p>\n<li>Screen for TB and take appropriate action</li>\n<li>Take weight and BP at every visit</li>\n<p>233</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 300,
        "content": "Service \nDescription\nLaboratory services:\n\u2022Screen and treat for syphilis, HIV, hepatitis \nB, other STIs and anemia. Use syndromic \napproach to treating STIs\n\u2022Perform urinalysis to detect a urinary tract \ninfection (UTI), protein in the urine (pro\u00ad\nteinuria), or blood in the urine (hematuria) \nindicating kidney damage, or sugar in urine \nsuggesting diabetes\n\u2022Do a blood slide for malaria for all preg\u00ad\nnant women.\n\u2022Perform a blood group test in anticipation \nof blood transfusion and check for heredi\u00ad\ntary conditions if suspected (sickling test)\nLaboratory investi\u00ad\ngations specific to \nHIV-positive pregnant \nwomen\n\u2022For HIV-positive women, perform a \nbaseline CD4 count. The test result is not \nrequired for ART initiation.\n\u2022Do Hb test for women/girls beginning \nAZT-based ART at baseline and four weeks \nafter initiating ART.\n\u2022For HIV-positive pregnant women/girls \nalready on ART, do VL test at first ANC \nvisit, then follow the VL testing algorithm \nfor pregnant and breast feeding women.\n\u2022For newly diagnosed HIV-positive pregnant \nwomen/girls, do VL test 3 months after \ninitiating ART and then every 3 months \nuntil end of MTCT period\n234\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>Laboratory services:</p>\n<li>Screen and treat for syphilis, HIV, hepatitis</li>\n<p>B, other STIs and anemia. Use syndromic</p>\n<p>approach to treating STIs</p>\n<li>Perform urinalysis to detect a urinary tract</li>\n<p>infection (UTI), protein in the urine (pro\u00ad</p>\n<p>teinuria), or blood in the urine (hematuria)</p>\n<p>indicating kidney damage, or sugar in urine</p>\n<p>suggesting diabetes</p>\n<li>Do a blood slide for malaria for all preg\u00ad</li>\n<p>nant women.</p>\n<li>Perform a blood group test in anticipation</li>\n<p>of blood transfusion and check for heredi\u00ad</p>\n<p>tary conditions if suspected (sickling test)</p>\n<p>Laboratory investi\u00ad</p>\n<p>gations specific to</p>\n<p>HIV-positive pregnant</p>\n<p>women</p>\n<li>For HIV-positive women, perform a</li>\n<p>baseline CD4 count. The test result is not</p>\n<p>required for ART initiation.</p>\n<li>Do Hb test for women/girls beginning</li>\n<p>AZT-based ART at baseline and four weeks</p>\n<p>after initiating ART.</p>\n<li>For HIV-positive pregnant women/girls</li>\n<p>already on ART, do VL test at first ANC</p>\n<p>visit, then follow the VL testing algorithm</p>\n<p>for pregnant and breast feeding women.</p>\n<li>For newly diagnosed HIV-positive pregnant</li>\n<p>women/girls, do VL test 3 months after</p>\n<p>initiating ART and then every 3 months</p>\n<p>until end of MTCT period</p>\n<p>234</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 301,
        "content": "Service \nDescription\nComprehensive care \nfor pregnant women \nwith HIV\nAt each visit provide:\n\u2022Comprehensive clinical evaluation\n\u2022Pregnant women on CPT should not be \ngiven Sulphadoxine-Pyrimethamine (Fan\u00ad\nsidar) for intermittent preventive treatment \nfor malaria (IPTp)\n\u2022Screen for TB and take appropriate action\n\u2022INH for eligible women/girls\n\u2022Screening and management of opportunis\u00ad\ntic infections (OIs)\nAssess risk of unborn \nbaby among pregnant \nwomen with HIV at \nANC 1\n\u2022 Conduct a risk assessment of the unborn \nbaby at 1st ANC among all HIV positive \npregnant women and at every visit and flag \nthose at high-risk including: \no Newly initiated on ART in the 3rd trimes\u00ad\nter or breastfeeding period\no Most recent VL is non-suppressed\no Mothers testing HIV positive later in preg\u00ad\nnancy or during breastfeeding\n\u2022 Closely monitor all high-risk pregnancies\n235\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>Comprehensive care</p>\n<p>for pregnant women</p>\n<p>with HIV</p>\n<p>At each visit provide:</p>\n<li>Comprehensive clinical evaluation</li>\n<li>Pregnant women on CPT should not be</li>\n<p>given Sulphadoxine-Pyrimethamine (Fan\u00ad</p>\n<p>sidar) for intermittent preventive treatment</p>\n<p>for malaria (IPTp)</p>\n<li>Screen for TB and take appropriate action</li>\n<li>INH for eligible women/girls</li>\n<li>Screening and management of opportunis\u00ad</li>\n<p>tic infections (OIs)</p>\n<p>Assess risk of unborn</p>\n<p>baby among pregnant</p>\n<p>women with HIV at</p>\n<h3>ANC 1</h3>\n<li>Conduct a risk assessment of the unborn</li>\n<p>baby at 1st ANC among all HIV positive</p>\n<p>pregnant women and at every visit and flag</p>\n<p>those at high-risk including:</p>\n<p>o Newly initiated on ART in the 3rd trimes\u00ad</p>\n<p>ter or breastfeeding period</p>\n<p>o Most recent VL is non-suppressed</p>\n<p>o Mothers testing HIV positive later in preg\u00ad</p>\n<p>nancy or during breastfeeding</p>\n<li>Closely monitor all high-risk pregnancies</li>\n<p>235</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 302,
        "content": "Service \nDescription\nART \no All women/girls living with HIV identified \nduring pregnancy, labour and delivery or \nwhile breastfeeding should be started on \nlifelong ART \no ART should be initiated on the same day, \nand adherence counseling should be initi\u00ad\nated and sustained intensively for the first \nthree months then maintained for life.\no Initiate mother on once-daily FDC of TD\u00ad\nF+3TC+DTG with pharmacovigilance \no The mothers initiated on TDF + 3TC \n+EFV400 shall be transitioned to TDF + \n3TC + DTG at 6-9 months post-partum if \nVL within past 6 months is suppressed. \no If mother is already on ART >6 months \nwith TDF/3TC/EFV, do VL test.  If she \nis virally suppressed, maintain her on \nTDF/3TC/EFV400 until 6-9 months after \ndelivery and then substitute EFV with DTG \nif VL within the past 6 months is sup\u00ad\npressed.\no If she is already on a DTG-based 1st-line \nregimen and virally suppressed, maintain \non the same regimen.\no If she is already on ART and VL is not \nsuppressed, manage as treatment failure \nand switch to DTG-based 2nd line regimen \n(if no previous exposure to DTG).\n236\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<h3>ART</h3>\n<p>o All women/girls living with HIV identified</p>\n<p>during pregnancy, labour and delivery or</p>\n<p>while breastfeeding should be started on</p>\n<p>lifelong ART</p>\n<p>o ART should be initiated on the same day,</p>\n<p>and adherence counseling should be initi\u00ad</p>\n<p>ated and sustained intensively for the first</p>\n<p>three months then maintained for life.</p>\n<p>o Initiate mother on once-daily FDC of TD\u00ad</p>\n<p>F+3TC+DTG with pharmacovigilance</p>\n<p>o The mothers initiated on TDF + 3TC</p>\n<p>+EFV400 shall be transitioned to TDF +</p>\n<p>3TC + DTG at 6-9 months post-partum if</p>\n<p>VL within past 6 months is suppressed.</p>\n<p>o If mother is already on ART >6 months</p>\n<p>with TDF/3TC/EFV, do VL test.  If she</p>\n<p>is virally suppressed, maintain her on</p>\n<p>TDF/3TC/EFV400 until 6-9 months after</p>\n<p>delivery and then substitute EFV with DTG</p>\n<p>if VL within the past 6 months is sup\u00ad</p>\n<p>pressed.</p>\n<p>o If she is already on a DTG-based 1st-line</p>\n<p>regimen and virally suppressed, maintain</p>\n<p>on the same regimen.</p>\n<p>o If she is already on ART and VL is not</p>\n<p>suppressed, manage as treatment failure</p>\n<p>and switch to DTG-based 2nd line regimen</p>\n<p>(if no previous exposure to DTG).</p>\n<p>236</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 303,
        "content": "Service \nDescription\nART \no If she is on 2ndline ART with ATV/r or \nLPV/r and virally suppressed, maintain on \nthe same regimen until 6-9 months after \ndelivery and then substitute PI with DTG if \nVL within the past 6 months is suppressed \nand no previous exposure to DTG.\no All women should receive Pre-ART adher\u00ad\nence counseling before initiating ART and \nongoing adherence support after that\no ART should be initiated and maintained in \nmother-baby care point in MCH.\nWhat to do if mum refuses ART or if you \nknow adherence is poor:\nMaternal VL suppression is key for prevent\u00ad\ning breastfeeding transmission, so if VL \nsuppression is not certain infant prophy\u00ad\nlaxis may serve as a \u201cback up\u201d to prevent \nMTCT - similar to \u201cOption A\u201d. Clinical \nproviders should continue infant prophy\u00ad\nlaxis with NVP for these specific scenari\u00ad\nos. Continuation of prophylaxis should be \nseen as an interim measure while maternal \nadherence is improved\nRisk reduction coun\u00ad\nseling and support\n\u2022\tEncourage consistent and correct condom \nuse \n\u2022\tEncourage women to deliver at the health \nfacilities \n\u2022\tFor negative pregnant women, offer other \nprevention services like SMC to partner \nand mitigate or manage GBV\n \n237\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<h3>ART</h3>\n<p>o If she is on 2ndline ART with ATV/r or</p>\n<p>LPV/r and virally suppressed, maintain on</p>\n<p>the same regimen until 6-9 months after</p>\n<p>delivery and then substitute PI with DTG if</p>\n<p>VL within the past 6 months is suppressed</p>\n<p>and no previous exposure to DTG.</p>\n<p>o All women should receive Pre-ART adher\u00ad</p>\n<p>ence counseling before initiating ART and</p>\n<p>ongoing adherence support after that</p>\n<p>o ART should be initiated and maintained in</p>\n<p>mother-baby care point in MCH.</p>\n<p>What to do if mum refuses ART or if you</p>\n<p>know adherence is poor:</p>\n<p>Maternal VL suppression is key for prevent\u00ad</p>\n<p>ing breastfeeding transmission, so if VL</p>\n<p>suppression is not certain infant prophy\u00ad</p>\n<p>laxis may serve as a \u201cback up\u201d to prevent</p>\n<p>MTCT - similar to \u201cOption A\u201d. Clinical</p>\n<p>providers should continue infant prophy\u00ad</p>\n<p>laxis with NVP for these specific scenari\u00ad</p>\n<p>os. Continuation of prophylaxis should be</p>\n<p>seen as an interim measure while maternal</p>\n<p>adherence is improved</p>\n<p>Risk reduction coun\u00ad</p>\n<p>seling and support</p>\n<li>Encourage consistent and correct condom</li>\n<p>use</p>\n<li>Encourage women to deliver at the health</li>\n<p>facilities</p>\n<li>For negative pregnant women, offer other</li>\n<p>prevention services like SMC to partner</p>\n<p>and mitigate or manage GBV</p>\n<p>237</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 304,
        "content": "Service \nDescription\nVisit schedules \nfor HIV-infected \npregnant women\nHIV-positive pregnant \nwoman/ girl already on \nART and stable:\nStable pregnant and \nbreastfeeding mother\n\u2022 Viral suppression\n\u2022 Adherence above 95%\n\u2022 On ART for more \nthan one-year Stage \nT1 and no active OIs\n\u2022 Not due for vital lab \ntests in the next twom\u00ad\nonths,e.g., viral load\n\u2022 Has disclosed to sig\u00ad\nnificant other/ house\u00ad\nhold member/ family \nmember\nHIV-positive pregnant \nwoman/girl initiating \nART in ANC (new \nclients):\nUnstable pregnant \nand breastfeeding \nwomen/ adolescent \ngirl\n\u2022 Recently initiated \non ART (less than \none year on ART)\n\u2022 Poor viral suppres\u00ad\nsion: most recent \nVL \n\u2022 Adherence less \nthan 95%\n\u2022 Stage T3,4 and \nactive OIs \n\u2022 Comorbidities/ \nco-infection\n\u2022 CD4 less than 500\n\u2022 Due for vital lab \ntests in the next two \nmonths,e.g., viral \nload\n\u2022 Has not disclosed \nto    significant \nother/ household \nmember/ family \nmember\n238\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>Visit schedules</p>\n<p>for HIV-infected</p>\n<p>pregnant women</p>\n<p>HIV-positive pregnant</p>\n<p>woman/ girl already on</p>\n<p>ART and stable:</p>\n<p>Stable pregnant and</p>\n<p>breastfeeding mother</p>\n<li>Viral suppression</li>\n<li>Adherence above 95%</li>\n<li>On ART for more</li>\n<p>than one-year Stage</p>\n<p>T1 and no active OIs</p>\n<li>Not due for vital lab</li>\n<p>tests in the next twom\u00ad</p>\n<p>onths,e.g., viral load</p>\n<li>Has disclosed to sig\u00ad</li>\n<p>nificant other/ house\u00ad</p>\n<p>hold member/ family</p>\n<p>member</p>\n<p>HIV-positive pregnant</p>\n<p>woman/girl initiating</p>\n<p>ART in ANC (new</p>\n<p>clients):</p>\n<p>Unstable pregnant</p>\n<p>and breastfeeding</p>\n<p>women/ adolescent</p>\n<p>girl</p>\n<li>Recently initiated</li>\n<p>on ART (less than</p>\n<p>one year on ART)</p>\n<li>Poor viral suppres\u00ad</li>\n<p>sion: most recent</p>\n<p>VL</p>\n<li>Adherence less</li>\n<p>than 95%</p>\n<li>Stage T3,4 and</li>\n<p>active OIs</p>\n<li>Comorbidities/</li>\n<p>co-infection</p>\n<li>CD4 less than 500</li>\n<li>Due for vital lab</li>\n<p>tests in the next two</p>\n<p>months,e.g., viral</p>\n<p>load</p>\n<li>Has not disclosed</li>\n<p>to    significant</p>\n<p>other/ household</p>\n<p>member/ family</p>\n<p>member</p>\n<p>238</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 305,
        "content": "Service \nDescription\n\u2022 8 ANC visits\n\u2022 Synchronize ART \nrefills and adherence \nsupport with the ANC \nvisits\n\u2022 Two weeks after \ninitiating ART\n\u2022 After that, monthly \nuntil delivery\n\u2022 Follow routine \nMCH schedule after \ndelivery together \nwith the exposed \ninfant visit schedule\nService\nDescription\nIdentification of \nHIV-exposed in\u00ad\nfants\n\u2022 Identify all HIV-exposed infants; document the \nHIV status of the mother in the child card and \nmothers\u2019 passport. Infants whose HIV status \nis not documented or is unknown should be \noffered rapid HIV testing; including those whose \nmothers did not receive eMTCT services or have \nbecome newly infected after pregnancy. Rapid \ndiagnostic tests for HIV serology can be used \nto assess HIV exposure among infants younger \nthan four months of age. HIV-exposure status \namong infants and children 4\u201318 months of age \nshould therefore be ascertained by HIV serolog\u00ad\nical testing the mother. The mother should be \ntested every 3 months until end of breastfeeding. \nThe entry points for identification of HIV-ex\u00ad\nposed infants include YCC, OPD pediatric/\nNutrition/TB wards and outreaches.  Special at\u00ad\ntention should be paid during immunization both \nat static and outreach areas to ensure that all \nchildren have their exposure status ascertained. \n3.1.9.2 HIV-exposed infant care services\n239\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<li>8 ANC visits</li>\n<li>Synchronize ART</li>\n<p>refills and adherence</p>\n<p>support with the ANC</p>\n<p>visits</p>\n<li>Two weeks after</li>\n<p>initiating ART</p>\n<li>After that, monthly</li>\n<p>until delivery</p>\n<li>Follow routine</li>\n<p>MCH schedule after</p>\n<p>delivery together</p>\n<p>with the exposed</p>\n<p>infant visit schedule</p>\n<p>Service</p>\n<p>Description</p>\n<p>Identification of</p>\n<p>HIV-exposed in\u00ad</p>\n<p>fants</p>\n<li>Identify all HIV-exposed infants; document the</li>\n<p>HIV status of the mother in the child card and</p>\n<p>mothers\u2019 passport. Infants whose HIV status</p>\n<p>is not documented or is unknown should be</p>\n<p>offered rapid HIV testing; including those whose</p>\n<p>mothers did not receive eMTCT services or have</p>\n<p>become newly infected after pregnancy. Rapid</p>\n<p>diagnostic tests for HIV serology can be used</p>\n<p>to assess HIV exposure among infants younger</p>\n<p>than four months of age. HIV-exposure status</p>\n<p>among infants and children 4\u201318 months of age</p>\n<p>should therefore be ascertained by HIV serolog\u00ad</p>\n<p>ical testing the mother. The mother should be</p>\n<p>tested every 3 months until end of breastfeeding.</p>\n<p>The entry points for identification of HIV-ex\u00ad</p>\n<p>posed infants include YCC, OPD pediatric/</p>\n<p>Nutrition/TB wards and outreaches.  Special at\u00ad</p>\n<p>tention should be paid during immunization both</p>\n<p>at static and outreach areas to ensure that all</p>\n<p>children have their exposure status ascertained.</p>\n<p>3.1.9.2 HIV-exposed infant care services</p>\n<p>239</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 306,
        "content": "Service \nDescription\nHIV test\u00ad\ning for in\u00ad\nfants\n\u2022 8 ANC visits\nFollow the infant testing algorithm in  \nto test and interpret the test results:\n\u2022 Provide 1st PCR within 4-6 weeks \nor the earliest opportunity thereafter.\nProvide 1st \nPCR within \n4-6 weeks or \nthe earliest \nopportnity\nFollow the infant testing algorithm in  \nto test and interpret the test results:\n\u2022 Provide 1st PCR within 4-6 weeks \nor the earliest opportunity thereafter.\n\u2022 Provide 2nd PCR at 9months there\u00ad\nafter\n\u2022 Provide 3rdPCR 6 weeks after cessa\u00ad\ntion of breastfeeding\n\u2022 Do DBS for confirmatory DNA PCR \nfor all infants who test positive on the \nday they start ART\n\u2022 Do a DNA PCR test for all HEI who \ndevelop signs/symptoms suggestive \nof HIV during follow-up, irrespective \nof breastfeeding status.\n\u2022 Conduct rapid HIV test at 18 \nmonths for all infants who test nega\u00ad\ntive at 1st, 2nd and 3rdPCR\n\u2022***  Where available Point-of-care \nnucleic acid testing should be used \nto diagnose HIV among infants and \nchildren younger than 18 months of \nage\n\u2022 8 ANC visits\nProvide 1st \nPCR within \n4-6 weeks or \nthe earliest \nopportunity\n240\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>HIV test\u00ad</p>\n<p>ing for in\u00ad</p>\n<p>fants</p>\n<li>8 ANC visits</li>\n<p>Follow the infant testing algorithm in</p>\n<p>to test and interpret the test results:</p>\n<li>Provide 1st PCR within 4-6 weeks</li>\n<p>or the earliest opportunity thereafter.</p>\n<p>Provide 1st</p>\n<p>PCR within</p>\n<p>4-6 weeks or</p>\n<p>the earliest</p>\n<p>opportnity</p>\n<p>Follow the infant testing algorithm in</p>\n<p>to test and interpret the test results:</p>\n<li>Provide 1st PCR within 4-6 weeks</li>\n<p>or the earliest opportunity thereafter.</p>\n<li>Provide 2nd PCR at 9months there\u00ad</li>\n<p>after</p>\n<li>Provide 3rdPCR 6 weeks after cessa\u00ad</li>\n<p>tion of breastfeeding</p>\n<li>Do DBS for confirmatory DNA PCR</li>\n<p>for all infants who test positive on the</p>\n<p>day they start ART</p>\n<li>Do a DNA PCR test for all HEI who</li>\n<p>develop signs/symptoms suggestive</p>\n<p>of HIV during follow-up, irrespective</p>\n<p>of breastfeeding status.</p>\n<li>Conduct rapid HIV test at 18</li>\n<p>months for all infants who test nega\u00ad</p>\n<p>tive at 1st, 2nd and 3rdPCR</p>\n<li>***  Where available Point-of-care</li>\n<p>nucleic acid testing should be used</p>\n<p>to diagnose HIV among infants and</p>\n<p>children younger than 18 months of</p>\n<p>age</p>\n<li>8 ANC visits</li>\n<p>Provide 1st</p>\n<p>PCR within</p>\n<p>4-6 weeks or</p>\n<p>the earliest</p>\n<p>opportunity</p>\n<p>240</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 307,
        "content": "Service \nDescription\nHIV test\u00ad\ning for in\u00ad\nfants\nFollow the infant testing algorithm in  \nto test and interpret the test results:\n\u2022 Provide 1st PCR within 4-6 weeks \nor the earliest opportunity thereafter.\nProvide 1st \nPCR within 4-6 \nweeks or the \nearliest opport\u00ad\nnity\n\u2022 ART for mothers and ePNP causing \nlow viral particles difficult to detect, \nsometimes below cycle threshold. \nAn indeterminate range of viral copy \nequivalents should be used to improve \nthe accuracy of all nucleic acid\u2013based \nearly infant diagnosis assays\n\u2022 Indeterminate range: a range of \nviral copy equivalents that would be \ntoo low to be accurately diagnosed \nas HIV infected. The indeterminate \nrange suggested is currently estimat\u00ad\ned to be approximately equivalent to \na cycle threshold of 33 on the Roche \nCOBAS\u00ae Ampliprep/COBAS\u00ae \nTaqMan\u00ae HIV-1 Qualitative Test \nv2.0 assay\n\u2022Indeterminate range: a range of viral \ncopy equivalents that would be too \nlow to be accurately diagnosed as \nHIV infected. The indeterminate \nrange suggested is currently estimat\u00ad\ned to be approximately equivalent to \na cycle threshold of 33 on the Roche \nCOBAS\u00ae Ampliprep/COBAS\u00ae \nTaqMan\u00ae HIV-1 Qualitative Test \nv2.0 assay\nGuidance for \nindetermi\u00ad\nnate test:\nTake off whole \nblood and  test \nat CPHL and \ntransport with\u00ad\nin 2 days \nHold off ART \nuntil results of \nwhole blood.\nCommunicat\u00ad\ning results to \ncaregiver\nTesting inter\u00ad\nvals for infants \nwith repeated \ndiscordant \nresults 4 weeks, \n4 months, 8 \nmonths\n241\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Service</p>\n<p>Description</p>\n<p>HIV test\u00ad</p>\n<p>ing for in\u00ad</p>\n<p>fants</p>\n<p>Follow the infant testing algorithm in</p>\n<p>to test and interpret the test results:</p>\n<li>Provide 1st PCR within 4-6 weeks</li>\n<p>or the earliest opportunity thereafter.</p>\n<p>Provide 1st</p>\n<p>PCR within 4-6</p>\n<p>weeks or the</p>\n<p>earliest opport\u00ad</p>\n<p>nity</p>\n<li>ART for mothers and ePNP causing</li>\n<p>low viral particles difficult to detect,</p>\n<p>sometimes below cycle threshold.</p>\n<p>An indeterminate range of viral copy</p>\n<p>equivalents should be used to improve</p>\n<p>the accuracy of all nucleic acid\u2013based</p>\n<p>early infant diagnosis assays</p>\n<li>Indeterminate range: a range of</li>\n<p>viral copy equivalents that would be</p>\n<p>too low to be accurately diagnosed</p>\n<p>as HIV infected. The indeterminate</p>\n<p>range suggested is currently estimat\u00ad</p>\n<p>ed to be approximately equivalent to</p>\n<p>a cycle threshold of 33 on the Roche</p>\n<p>COBAS\u00ae Ampliprep/COBAS\u00ae</p>\n<p>TaqMan\u00ae HIV-1 Qualitative Test</p>\n<p>v2.0 assay</p>\n<li>Indeterminate range: a range of viral</li>\n<p>copy equivalents that would be too</p>\n<p>low to be accurately diagnosed as</p>\n<p>HIV infected. The indeterminate</p>\n<p>range suggested is currently estimat\u00ad</p>\n<p>ed to be approximately equivalent to</p>\n<p>a cycle threshold of 33 on the Roche</p>\n<p>COBAS\u00ae Ampliprep/COBAS\u00ae</p>\n<p>TaqMan\u00ae HIV-1 Qualitative Test</p>\n<p>v2.0 assay</p>\n<p>Guidance for</p>\n<p>indetermi\u00ad</p>\n<p>nate test:</p>\n<p>Take off whole</p>\n<p>blood and  test</p>\n<p>at CPHL and</p>\n<p>transport with\u00ad</p>\n<p>in 2 days</p>\n<p>Hold off ART</p>\n<p>until results of</p>\n<p>whole blood.</p>\n<p>Communicat\u00ad</p>\n<p>ing results to</p>\n<p>caregiver</p>\n<p>Testing inter\u00ad</p>\n<p>vals for infants</p>\n<p>with repeated</p>\n<p>discordant</p>\n<p>results 4 weeks,</p>\n<p>4 months, 8</p>\n<p>months</p>\n<p>241</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 308,
        "content": "SERVICE \nDESCRIPTION\nRoutine immuni\u00ad\nzation\n\u2022 HIV-infected children are more susceptible \nto diseases preventable by immunization than \ntheir HIV-uninfected counterparts.\n\u2022 HIV-infected infants and children can safely \nreceive most childhood vaccines if given at the \nright time. All HIV-infected and exposed chil\u00ad\ndren should be immunized as per EPI immuni\u00ad\nzation schedule.\n\u2022 Health workers should review child immuniza\u00ad\ntion status at every visit\n\u2022 Some special considerations/modifications for \nHIV-exposed children:\no BCG: When considering BCG vaccination at a \nlater age (re-vaccination for no scar or missed \nearlier vaccination), exclude symptomatic HIV \ninfection. Children with symptomatic HIV infec\u00ad\ntion should not receive BCG.\no Measles: Although the measles vaccine is a \nlive vaccine, it should be given at six and nine \nmonths even when the child has symptoms of \nHIV.  The measles illness from the vaccine is \nmilder than that from the wild measles virus, \nwhich is more severe and likely to cause death.\no Yellow Fever: Do not give yellow fever vaccine \nto symptomatic HIV-infected children; asympto\u00ad\nmatic children in endemic areas should receive \nthe vaccine at nine months of age\n242\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<p>Routine immuni\u00ad</p>\n<p>zation</p>\n<li>HIV-infected children are more susceptible</li>\n<p>to diseases preventable by immunization than</p>\n<p>their HIV-uninfected counterparts.</p>\n<li>HIV-infected infants and children can safely</li>\n<p>receive most childhood vaccines if given at the</p>\n<p>right time. All HIV-infected and exposed chil\u00ad</p>\n<p>dren should be immunized as per EPI immuni\u00ad</p>\n<p>zation schedule.</p>\n<li>Health workers should review child immuniza\u00ad</li>\n<p>tion status at every visit</p>\n<li>Some special considerations/modifications for</li>\n<p>HIV-exposed children:</p>\n<p>o BCG: When considering BCG vaccination at a</p>\n<p>later age (re-vaccination for no scar or missed</p>\n<p>earlier vaccination), exclude symptomatic HIV</p>\n<p>infection. Children with symptomatic HIV infec\u00ad</p>\n<p>tion should not receive BCG.</p>\n<p>o Measles: Although the measles vaccine is a</p>\n<p>live vaccine, it should be given at six and nine</p>\n<p>months even when the child has symptoms of</p>\n<p>HIV.  The measles illness from the vaccine is</p>\n<p>milder than that from the wild measles virus,</p>\n<p>which is more severe and likely to cause death.</p>\n<p>o Yellow Fever: Do not give yellow fever vaccine</p>\n<p>to symptomatic HIV-infected children; asympto\u00ad</p>\n<p>matic children in endemic areas should receive</p>\n<p>the vaccine at nine months of age</p>\n<p>242</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 309,
        "content": "SERVICE \nDESCRIPTION\nGrowth moni\u00ad\ntoring and nu\u00ad\ntritional assess\u00ad\nment\n \n\u0083 Growth and child nutrition should be \nmonitored using weight, length/height, \nand MUAC at all encounters with a child, \nand recorded on the growth monitoring \ncard\n \n\u0083 MUAC should only be measured starting \nat six months of age.\n \n\u0083 Failure to gain weight or height, slow \nweight or height gain, and loss of weight \nmay be an indication of HIV infection in \nan infant/young child. Failure to thrive \naffects as many as 50% of HIV-infected \ninfants and children. HIV-infected infants \nand children who are failing to thrive have \na significantly increased risk of mortality. \n \n\u0083 Counsel the mother/caregiver on the \nchild\u2019s growth trend and take appropriate \naction where necessary.\nDevelopment \nmonitoring\n \n\u0083 At each visit assess the infant\u2019s age-specific \ndevelopmental milestones. \n \n\u0083 Infants are at high risk for HIV \nencephalopathy and severe neurologic \ndisease\n \n\u0083 Early identification of developmental \ndelay can facilitate intervention and these \nchildren can improve with treatment.\n \n\u0083 \u2022 Some forms of development delay are:\n \n\u0083 The child may reach some developmental \nmilestones but not others.\n \n\u0083 The child may reach some milestones but \nlose them after some time.\n \n\u0083 The child may fail to reach any \ndevelopmental milestones at all.\n \n\u0083 Test children with developmental delay for \nHIV and, if infected, initiate on ART.\n \n\u0083 Measure the infant\u2019s head circumference.\n243\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<p>Growth moni\u00ad</p>\n<p>toring and nu\u00ad</p>\n<p>tritional assess\u00ad</p>\n<p>ment</p>\n<p>\u0083 Growth and child nutrition should be</p>\n<p>monitored using weight, length/height,</p>\n<p>and MUAC at all encounters with a child,</p>\n<p>and recorded on the growth monitoring</p>\n<p>card</p>\n<p>\u0083 MUAC should only be measured starting</p>\n<p>at six months of age.</p>\n<p>\u0083 Failure to gain weight or height, slow</p>\n<p>weight or height gain, and loss of weight</p>\n<p>may be an indication of HIV infection in</p>\n<p>an infant/young child. Failure to thrive</p>\n<p>affects as many as 50% of HIV-infected</p>\n<p>infants and children. HIV-infected infants</p>\n<p>and children who are failing to thrive have</p>\n<p>a significantly increased risk of mortality.</p>\n<p>\u0083 Counsel the mother/caregiver on the</p>\n<p>child\u2019s growth trend and take appropriate</p>\n<p>action where necessary.</p>\n<p>Development</p>\n<p>monitoring</p>\n<p>\u0083 At each visit assess the infant\u2019s age-specific</p>\n<p>developmental milestones.</p>\n<p>\u0083 Infants are at high risk for HIV</p>\n<p>encephalopathy and severe neurologic</p>\n<p>disease</p>\n<p>\u0083 Early identification of developmental</p>\n<p>delay can facilitate intervention and these</p>\n<p>children can improve with treatment.</p>\n<p>\u0083 \u2022 Some forms of development delay are:</p>\n<p>\u0083 The child may reach some developmental</p>\n<p>milestones but not others.</p>\n<p>\u0083 The child may reach some milestones but</p>\n<p>lose them after some time.</p>\n<p>\u0083 The child may fail to reach any</p>\n<p>developmental milestones at all.</p>\n<p>\u0083 Test children with developmental delay for</p>\n<p>HIV and, if infected, initiate on ART.</p>\n<p>\u0083 Measure the infant\u2019s head circumference.</p>\n<p>243</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 310,
        "content": "SERVICE \nDESCRIPTION\nEarly Childhood \nDevelopment\n \n\u0083 The first two years of life are the most \ncritical for brain development and \ninfluences during this period significantly \ncontribute to longer-term developmental \noutcomes.\n \n\u0083 ECD therefore comprises all the essential \ncare and support a young child needs to \nsurvive and thrive in life and spans the \nperiod from prenatal to eight years of \nage across multiple domains consisting \nof physical, cognitive, language and \ncommunication, social and emotional and \nspiritual development. Years 0-8 most \ncritical stage of life because the brain \nundergoes most dramatic growth\n \n\u0083 It is well established that infants and young \nchildren exposed or affected by HIV \nhave poorer health and developmental \noutcomes compared to their non-HIV \naffected peers. Prevention of mother-\nto-child transmission (PMTCT) services, \nwhich focus on mothers and infants \nthroughout the exposure period provide \nan ideal platform during a period of life \nthat affects both longer-term health and \ndevelopmental potential, moreover, the \nservices along the PMTCT cascade are \nwell aligned with intervention points for \nECD.\n \n\u0083 ECD services and messages will therefore \nbe well integrated into PMTCT/HEI \nservices to improve outcomes of HEI.\n244\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<p>Early Childhood</p>\n<p>Development</p>\n<p>\u0083 The first two years of life are the most</p>\n<p>critical for brain development and</p>\n<p>influences during this period significantly</p>\n<p>contribute to longer-term developmental</p>\n<p>outcomes.</p>\n<p>\u0083 ECD therefore comprises all the essential</p>\n<p>care and support a young child needs to</p>\n<p>survive and thrive in life and spans the</p>\n<p>period from prenatal to eight years of</p>\n<p>age across multiple domains consisting</p>\n<p>of physical, cognitive, language and</p>\n<p>communication, social and emotional and</p>\n<p>spiritual development. Years 0-8 most</p>\n<p>critical stage of life because the brain</p>\n<p>undergoes most dramatic growth</p>\n<p>\u0083 It is well established that infants and young</p>\n<p>children exposed or affected by HIV</p>\n<p>have poorer health and developmental</p>\n<p>outcomes compared to their non-HIV</p>\n<p>affected peers. Prevention of mother-</p>\n<p>to-child transmission (PMTCT) services,</p>\n<p>which focus on mothers and infants</p>\n<p>throughout the exposure period provide</p>\n<p>an ideal platform during a period of life</p>\n<p>that affects both longer-term health and</p>\n<p>developmental potential, moreover, the</p>\n<p>services along the PMTCT cascade are</p>\n<p>well aligned with intervention points for</p>\n<h3>ECD.</h3>\n<p>\u0083 ECD services and messages will therefore</p>\n<p>be well integrated into PMTCT/HEI</p>\n<p>services to improve outcomes of HEI.</p>\n<p>244</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 311,
        "content": "SERVICE \nDESCRIPTION\nARV prophy\u00ad\nlaxis\n\u2022 Provide NVP syrup to HEI from birth until six \nweeks of age.\n\u2022 For high-risk infants, give NVP syrup from \nbirth until 12 weeks of age.\n\u2022 High-riskinfants are breastfeeding infants \nwhose mothers:\no Have received ART for four weeks or less \nbefore delivery; or\no Have VL >1000 co.pies in four weeks before \ndelivery; or\no Diagnosed with HIV during 3rd trimester or \nbreastfeeding period (postnatal).\nWhat to do if baby presents after 6 \nweeks: \na. Do first PCR\nb. Give ART (First Line Paed regimen; give \nweight appropriate dose) for 6weeks \nc. If PCR results are negative, give NVP for 6 \nweeks (after completing the 6 weeks of ART)\nd. If PCR results are positive, continue with ART \nfirst line ART. \nIrrespective of timing, the mother should be \nstarted on ART as soon as possible for her own \nhealth and to decrease risk of transmission to \nbreastfeeding baby.\n245\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<p>ARV prophy\u00ad</p>\n<p>laxis</p>\n<li>Provide NVP syrup to HEI from birth until six</li>\n<p>weeks of age.</p>\n<li>For high-risk infants, give NVP syrup from</li>\n<p>birth until 12 weeks of age.</p>\n<li>High-riskinfants are breastfeeding infants</li>\n<p>whose mothers:</p>\n<p>o Have received ART for four weeks or less</p>\n<p>before delivery; or</p>\n<p>o Have VL >1000 co.pies in four weeks before</p>\n<p>delivery; or</p>\n<p>o Diagnosed with HIV during 3rd trimester or</p>\n<p>breastfeeding period (postnatal).</p>\n<p>What to do if baby presents after 6</p>\n<p>weeks:</p>\n<p>a. Do first PCR</p>\n<p>b. Give ART (First Line Paed regimen; give</p>\n<p>weight appropriate dose) for 6weeks</p>\n<p>c. If PCR results are negative, give NVP for 6</p>\n<p>weeks (after completing the 6 weeks of ART)</p>\n<p>d. If PCR results are positive, continue with ART</p>\n<p>first line ART.</p>\n<p>Irrespective of timing, the mother should be</p>\n<p>started on ART as soon as possible for her own</p>\n<p>health and to decrease risk of transmission to</p>\n<p>breastfeeding baby.</p>\n<p>245</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 312,
        "content": "SERVICE \nDESCRIPTION\nOpportunistic \ninfection proph\u00ad\nylaxis\nCotrimoxazole prophylaxis\nCotrimoxazole (CTX) prophylaxis significantly re\u00ad\nduces the incidence and severity of Pneumocystis \nJiroveci pneumonia. It also offers protection \nagainst common bacterial infections, Toxoplas\u00ad\nmosis and Malaria. \n\u2022 Provide CTX prophylaxis to all HIV-exposed \ninfants from six weeks of age until they are prov\u00ad\nen to be uninfected.\n\u2022 Infants who become HIV-infected should con\u00ad\ntinue to receive CTX prophylaxis for life.\n\u2022 If CTX is contraindicated, offer Dapsone at \ndose of 2mg/kg once daily (up to 100mg).\nTB Preventive Treatment (TPT)\n\u2022 Give INH for six months to HEI who are ex\u00ad\nposed to TB after excluding TB disease.\n\u2022 For newborn infants, if the mother has TB \ndisease and has been on anti-TB drugs for at \nleast two weeks before delivery, INH prophylaxis \nshould not be given.\nMalaria prevention:\n\u2022 All HEI and HIV-infected children should \nreceive insecticide treated nets and CTX.  Using \nboth reduces risk of malaria by 97%.\nActively look \nfor and treat \ninfections early    \nHEI are susceptible to common infections and \nOIs.\n\u2022 Counsel caregivers to seek care to receive \ntimely treatment.\n246\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<p>Opportunistic</p>\n<p>infection proph\u00ad</p>\n<p>ylaxis</p>\n<p>Cotrimoxazole prophylaxis</p>\n<p>Cotrimoxazole (CTX) prophylaxis significantly re\u00ad</p>\n<p>duces the incidence and severity of Pneumocystis</p>\n<p>Jiroveci pneumonia. It also offers protection</p>\n<p>against common bacterial infections, Toxoplas\u00ad</p>\n<p>mosis and Malaria.</p>\n<li>Provide CTX prophylaxis to all HIV-exposed</li>\n<p>infants from six weeks of age until they are prov\u00ad</p>\n<p>en to be uninfected.</p>\n<li>Infants who become HIV-infected should con\u00ad</li>\n<p>tinue to receive CTX prophylaxis for life.</p>\n<li>If CTX is contraindicated, offer Dapsone at</li>\n<p>dose of 2mg/kg once daily (up to 100mg).</p>\n<p>TB Preventive Treatment (TPT)</p>\n<li>Give INH for six months to HEI who are ex\u00ad</li>\n<p>posed to TB after excluding TB disease.</p>\n<li>For newborn infants, if the mother has TB</li>\n<p>disease and has been on anti-TB drugs for at</p>\n<p>least two weeks before delivery, INH prophylaxis</p>\n<p>should not be given.</p>\n<p>Malaria prevention:</p>\n<li>All HEI and HIV-infected children should</li>\n<p>receive insecticide treated nets and CTX.  Using</p>\n<p>both reduces risk of malaria by 97%.</p>\n<p>Actively look</p>\n<p>for and treat</p>\n<p>infections early</p>\n<p>HEI are susceptible to common infections and</p>\n<p>OIs.</p>\n<li>Counsel caregivers to seek care to receive</li>\n<p>timely treatment.</p>\n<p>246</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 313,
        "content": "SERVICE \nDESCRIPTION\n\u2022 At every visit, assess HEI for signs and symp\u00ad\ntoms of common childhood illnesses using the \nIntegrated Maternal, New-born and Childhood \nIllnesses Guidelines and provide treatment.\nCounseling and \nfeeding advice\nProvide infant feeding counseling and advice \naccording to guidance.\nEducate the \ncaregiver and \nfamily\n\u2022 HEI depend on their caregivers to receive care.\n\u2022 Provide information to the caregivers and family \nabout the care plan including what to expect and \nhow to provide care for the infant.\n\u2022 Caregivers should participate in making decisions \nand planning care for the child, including decisions \nabout therapy and where the child should receive \ncare.\n\u2022 Empower caregivers to be partners with the health \nfacility.\n\u2022 Provide key aspects of home-based care for the \nchild, including:  \no Dispensing prophylaxis and treatment\no Maintaining adherence\no Complying with the follow-up schedule\no Ensuring good personal and food hygiene to pre\u00ad\nvent common infections\no Seeking prompt treatment for any infections or \nother health-related problem\nThe most important thing for the child is to have a \nhealthy mother. Ensure the mother/infected caregiver \nis receiving their care. If the mother is sick, the infant \nwill not receive care.\n247\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<li>At every visit, assess HEI for signs and symp\u00ad</li>\n<p>toms of common childhood illnesses using the</p>\n<p>Integrated Maternal, New-born and Childhood</p>\n<p>Illnesses Guidelines and provide treatment.</p>\n<p>Counseling and</p>\n<p>feeding advice</p>\n<p>Provide infant feeding counseling and advice</p>\n<p>according to guidance.</p>\n<p>Educate the</p>\n<p>caregiver and</p>\n<p>family</p>\n<li>HEI depend on their caregivers to receive care.</li>\n<li>Provide information to the caregivers and family</li>\n<p>about the care plan including what to expect and</p>\n<p>how to provide care for the infant.</p>\n<li>Caregivers should participate in making decisions</li>\n<p>and planning care for the child, including decisions</p>\n<p>about therapy and where the child should receive</p>\n<p>care.</p>\n<li>Empower caregivers to be partners with the health</li>\n<p>facility.</p>\n<li>Provide key aspects of home-based care for the</li>\n<p>child, including:</p>\n<p>o Dispensing prophylaxis and treatment</p>\n<p>o Maintaining adherence</p>\n<p>o Complying with the follow-up schedule</p>\n<p>o Ensuring good personal and food hygiene to pre\u00ad</p>\n<p>vent common infections</p>\n<p>o Seeking prompt treatment for any infections or</p>\n<p>other health-related problem</p>\n<p>The most important thing for the child is to have a</p>\n<p>healthy mother. Ensure the mother/infected caregiver</p>\n<p>is receiving their care. If the mother is sick, the infant</p>\n<p>will not receive care.</p>\n<p>247</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 314,
        "content": "SERVICE \nDESCRIPTION\n\u2022 When members of the same family such as moth\u00ad\ner-baby pair are in care, their appointments should \nbe on the same day.\nReferrals and \nLinkage\n\u2022 Link the caregiver and HEI to appropriate \nservices like OVC care, psychosocial support \nincluding FSG and other community support \ngroups.\nART for infect\u00ad\ned infants\nInitiate ART in infants who become infected accord\u00ad\ning to guidance\n3.1.9.3\t Care of HIV Exposed Infant\nHIV-exposed infants should receive care at the mother-baby care point \ntogether with their mothers until they are 18 months of age. The goals \nof HIV-exposed infant care services are:\n \n~\nTo prevent the infant from being HIV infected\n \n~\nAmong those who get infected: to diagnose HIV infection \nearly and treat\n \n~\nOffer child survival interventions to prevent early death from \npreventable childhood illnesses\nThe HIV Exposed Infant and the mother should consistently visit the \nhealth facility at least nine times during that period.\nThe visits are synchronised with the child\u2019s immunisation schedule (i.e., \nat 6, 10 and 14 weeks, then at 5, 6, 9, 12, 15 and\n18 months).\n248\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SERVICE</h3>\n<h3>DESCRIPTION</h3>\n<li>When members of the same family such as moth\u00ad</li>\n<p>er-baby pair are in care, their appointments should</p>\n<p>be on the same day.</p>\n<p>Referrals and</p>\n<p>Linkage</p>\n<li>Link the caregiver and HEI to appropriate</li>\n<p>services like OVC care, psychosocial support</p>\n<p>including FSG and other community support</p>\n<p>groups.</p>\n<p>ART for infect\u00ad</p>\n<p>ed infants</p>\n<p>Initiate ART in infants who become infected accord\u00ad</p>\n<p>ing to guidance</p>\n<p>3.1.9.3\t Care of HIV Exposed Infant</p>\n<p>HIV-exposed infants should receive care at the mother-baby care point</p>\n<p>together with their mothers until they are 18 months of age. The goals</p>\n<p>of HIV-exposed infant care services are:</p>\n<p>~</p>\n<p>To prevent the infant from being HIV infected</p>\n<p>~</p>\n<p>Among those who get infected: to diagnose HIV infection</p>\n<p>early and treat</p>\n<p>~</p>\n<p>Offer child survival interventions to prevent early death from</p>\n<p>preventable childhood illnesses</p>\n<p>The HIV Exposed Infant and the mother should consistently visit the</p>\n<p>health facility at least nine times during that period.</p>\n<p>The visits are synchronised with the child\u2019s immunisation schedule (i.e.,</p>\n<p>at 6, 10 and 14 weeks, then at 5, 6, 9, 12, 15 and</p>\n<p>18 months).</p>\n<p>248</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 315,
        "content": "Management\nTREATMENT\nLOC\nNevirapine prophylaxis\n\t\n\u0089\nProvide NVP suspension from birth for 6 weeks\n\t\n\u0089\nGive NVP for 12 weeks for babies at high risk, \nthat is breastfeeding infants who mothers:\n \n- Have received ART for 4 weeks or less before\n \n- delivery; or\n \n- Have VL >1000 copies in 4 weeks before \ndelivery; or\n \n- Diagnosed with HIV during 3rd trimester or \nbreastfeeding period (Postnatal)\n\t\n\u0089\nDo PCR at 6 weeks (or at first encounter after \nthis age) and start cotrimoxazole prophylaxis\n \n- If PCR positive, start treatment with ARVs and\n \n- cotrimoxazole and repeat PCR (for confirmation)\n \n- If PCR negative and baby never breastfed, child \nis confirmed HIV negative. Stop cotrimoxazole,\n \n- continue clinical monitoring and do HIV serology \ntest at 18 months.\n \n- If PCR negative but baby has breastfed/is\nbreasfeeding, start/continue cotrimoxazole prophylaxis and \nrepeat PCR 6 weeks after stopping breastfeeding\n\t\n\u0089\nFollow up any exposed child and do PCR if they develop \nany clinical symptom suggestive of HIV at any time and \nindependently of previously negative results\n\t\n\u0089\nFor negative infants, do serology at 18 months before \nfinal discharge\nHC3\n249\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Nevirapine prophylaxis</p>\n<p>\u0089</p>\n<p>Provide NVP suspension from birth for 6 weeks</p>\n<p>\u0089</p>\n<p>Give NVP for 12 weeks for babies at high risk,</p>\n<p>that is breastfeeding infants who mothers:</p>\n<p>- Have received ART for 4 weeks or less before</p>\n<p>- delivery; or</p>\n<p>- Have VL >1000 copies in 4 weeks before</p>\n<p>delivery; or</p>\n<p>- Diagnosed with HIV during 3rd trimester or</p>\n<p>breastfeeding period (Postnatal)</p>\n<p>\u0089</p>\n<p>Do PCR at 6 weeks (or at first encounter after</p>\n<p>this age) and start cotrimoxazole prophylaxis</p>\n<p>- If PCR positive, start treatment with ARVs and</p>\n<p>- cotrimoxazole and repeat PCR (for confirmation)</p>\n<p>- If PCR negative and baby never breastfed, child</p>\n<p>is confirmed HIV negative. Stop cotrimoxazole,</p>\n<p>- continue clinical monitoring and do HIV serology</p>\n<p>test at 18 months.</p>\n<p>- If PCR negative but baby has breastfed/is</p>\n<p>breasfeeding, start/continue cotrimoxazole prophylaxis and</p>\n<p>repeat PCR 6 weeks after stopping breastfeeding</p>\n<p>\u0089</p>\n<p>Follow up any exposed child and do PCR if they develop</p>\n<p>any clinical symptom suggestive of HIV at any time and</p>\n<p>independently of previously negative results</p>\n<p>\u0089</p>\n<p>For negative infants, do serology at 18 months before</p>\n<p>final discharge</p>\n<h3>HC3</h3>\n<p>249</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 316,
        "content": "TREATMENT\nLOC\nDosages of nevirapine\n \n- Child 0-6 weeks, 2-2.5 Kg: 10 mg once daily (1 \nml of syrup 10 mg/ml)\n \n- Child 0-6 weeks, >2.5 kg: 15 mg once daily (1.5 \nml\n \n- of syrup 10 mg/ml)\n \n- Child 6 weeks \u2013 12 weeks: 20 mg once daily (2 \nml)\nHC3\nCotrimoxazole prophylaxis\n\t\n\u0089\nProvide cotrimoxazole prophylaxis to all HIV- exposed \ninfants from 6 weeks of age until they are proven to be \nuninfected. Dosages:\nChild <5 kg: 120 mg once daily\nChild 5-14.9 kg: 240 mg once daily\n\t\n\u0089\nInfants who become HIV infected should continue to \nreceive cotrimoxazole prophylaxis for life\n\t\n\u0089\nIf cotrimoxazole is contraindicated, offer dapsone at a \ndose of 2 mg/kg once daily ( up to 100 mg max)\nHC2\n TB preventive therapy (TPT)\n\t\n\u0089\nGive INH for six months to HIV-exposed infant who \nare exposed to TB (close contact with PTB case) after \nexcluding TB disease (see section 5.3.2.3)\n\t\n\u0089\nDose: Isoniazid 10 mg/kg + pyridoxine 25 mg daily\n\t\n\u0089\nFor newborn infants, if the mother has TB disease and \nhas been on anti-TB drugs for at least two weeks before \ndelivery, INH prophylaxis is not required.\nHC3\n250\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Dosages of nevirapine</p>\n<p>- Child 0-6 weeks, 2-2.5 Kg: 10 mg once daily (1</p>\n<p>ml of syrup 10 mg/ml)</p>\n<p>- Child 0-6 weeks, >2.5 kg: 15 mg once daily (1.5</p>\n<p>ml</p>\n<p>- of syrup 10 mg/ml)</p>\n<p>- Child 6 weeks \u2013 12 weeks: 20 mg once daily (2</p>\n<p>ml)</p>\n<h3>HC3</h3>\n<p>Cotrimoxazole prophylaxis</p>\n<p>\u0089</p>\n<p>Provide cotrimoxazole prophylaxis to all HIV- exposed</p>\n<p>infants from 6 weeks of age until they are proven to be</p>\n<p>uninfected. Dosages:</p>\n<p>Child <5 kg: 120 mg once daily</p>\n<p>Child 5-14.9 kg: 240 mg once daily</p>\n<p>\u0089</p>\n<p>Infants who become HIV infected should continue to</p>\n<p>receive cotrimoxazole prophylaxis for life</p>\n<p>\u0089</p>\n<p>If cotrimoxazole is contraindicated, offer dapsone at a</p>\n<p>dose of 2 mg/kg once daily ( up to 100 mg max)</p>\n<h3>HC2</h3>\n<p>TB preventive therapy (TPT)</p>\n<p>\u0089</p>\n<p>Give INH for six months to HIV-exposed infant who</p>\n<p>are exposed to TB (close contact with PTB case) after</p>\n<p>excluding TB disease (see section 5.3.2.3)</p>\n<p>\u0089</p>\n<p>Dose: Isoniazid 10 mg/kg + pyridoxine 25 mg daily</p>\n<p>\u0089</p>\n<p>For newborn infants, if the mother has TB disease and</p>\n<p>has been on anti-TB drugs for at least two weeks before</p>\n<p>delivery, INH prophylaxis is not required.</p>\n<h3>HC3</h3>\n<p>250</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 317,
        "content": "Immunisation\n\t\n\u0089\nImmunise HIV exposed children as per national immu\u00ad\nnisation schedule\n\t\n\u0089\nIn case of missed BCG at birth, do not give if child has \nsymptomatic HIV\n\t\n\u0089\nAvoid yellow fever vaccine in symptomatic HIV\n\t\n\u0089\nMeasles vaccine can be given even in symptomatic HIV\nCounselling on infant feeding choice\n \n- Explain the risks of HIV transmission by breastfeeding (15%) \nand other risks of not breastfeeding (malnutrition, diarrhoea)\n \n- Mixed feeding may also increase risk of HIV transmission\n \n- and diarrhoea\n \n- Tell her about options for feeding, advantages, and risks\n \n- Help her to assess choices, decide on the best option, and \nthen support her choice\n \n- Feeding options\n \n- Recommended \noption: \nExclusive \nbreastfeeding \nthen \ncomplementary feeding after child is six  months old\n \n- Exclusive breastfeeding stopping at 3-6 months old if\n \n- replacement feeding possible after this\n \n- If replacement feeding introduced early, mother must stop \nbreastfeeding\n \n- Replacement feeding with home-prepared formula or \ncommercial formula and then family foods (provided this is \nacceptable, feasible, safe, and sustainable/ affordable)\nIf mother chooses breastfeeding\n \n- The risk may be reduced by keeping the breasts healthy \n(mastitis and cracked nipples raise HIV infection risk)\n \n- Advise exclusive breastfeeding for 3-6 months\n251\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Immunisation</p>\n<p>\u0089</p>\n<p>Immunise HIV exposed children as per national immu\u00ad</p>\n<p>nisation schedule</p>\n<p>\u0089</p>\n<p>In case of missed BCG at birth, do not give if child has</p>\n<p>symptomatic HIV</p>\n<p>\u0089</p>\n<p>Avoid yellow fever vaccine in symptomatic HIV</p>\n<p>\u0089</p>\n<p>Measles vaccine can be given even in symptomatic HIV</p>\n<p>Counselling on infant feeding choice</p>\n<p>- Explain the risks of HIV transmission by breastfeeding (15%)</p>\n<p>and other risks of not breastfeeding (malnutrition, diarrhoea)</p>\n<p>- Mixed feeding may also increase risk of HIV transmission</p>\n<p>- and diarrhoea</p>\n<p>- Tell her about options for feeding, advantages, and risks</p>\n<p>- Help her to assess choices, decide on the best option, and</p>\n<p>then support her choice</p>\n<p>- Feeding options</p>\n<p>- Recommended</p>\n<p>option:</p>\n<p>Exclusive</p>\n<p>breastfeeding</p>\n<p>then</p>\n<p>complementary feeding after child is six  months old</p>\n<p>- Exclusive breastfeeding stopping at 3-6 months old if</p>\n<p>- replacement feeding possible after this</p>\n<p>- If replacement feeding introduced early, mother must stop</p>\n<p>breastfeeding</p>\n<p>- Replacement feeding with home-prepared formula or</p>\n<p>commercial formula and then family foods (provided this is</p>\n<p>acceptable, feasible, safe, and sustainable/ affordable)</p>\n<p>If mother chooses breastfeeding</p>\n<p>- The risk may be reduced by keeping the breasts healthy</p>\n<p>(mastitis and cracked nipples raise HIV infection risk)</p>\n<p>- Advise exclusive breastfeeding for 3-6 months</p>\n<p>251</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 318,
        "content": "If mother chooses replacement feeding\n\t\n\u0089\nCounsel and teach her on safe preparation, hygiene, amounts, \ntimes to feed the baby etc.\n\t\n\u0089\nFollow up within a week from birth and at any visit to\nhealth facility.\n3.1.10  OPPORTUNISTIC INFECTIONS IN HIV\n3.1.10.1\t Tuberculosis and HIV Co-Infection\nActive TB may be present when ART needs to be initiated or it may \ndevelop during treatment.\nTB and HIV care for co-infected patients should be provided in an \nintegrated manner under one roof by one care team (one-stop-shop).\nCo-management of TB and HIV is complicated by:\n \n~\nDrug interactions between rifampicin and both the NNRTI \nand PI classes\n \n~\nImmune reconstitution inflammatory syndrome (IRIS)\n \n~\nPill burden, overlapping toxicities and adherence issues.\nManagement\nART should be initiated in all TB/HIV co-infected people irrespective \nof their clinical stage or CD4 count. However, the timing of initiation \nof treatment may differ based on whether the patient is diagnosed with \nTB before or after initiating ART.\n252\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>If mother chooses replacement feeding</p>\n<p>\u0089</p>\n<p>Counsel and teach her on safe preparation, hygiene, amounts,</p>\n<p>times to feed the baby etc.</p>\n<p>\u0089</p>\n<p>Follow up within a week from birth and at any visit to</p>\n<p>health facility.</p>\n<h3>3.1.10  OPPORTUNISTIC INFECTIONS IN HIV</h3>\n<p>3.1.10.1\t Tuberculosis and HIV Co-Infection</p>\n<p>Active TB may be present when ART needs to be initiated or it may</p>\n<p>develop during treatment.</p>\n<p>TB and HIV care for co-infected patients should be provided in an</p>\n<p>integrated manner under one roof by one care team (one-stop-shop).</p>\n<p>Co-management of TB and HIV is complicated by:</p>\n<p>~</p>\n<p>Drug interactions between rifampicin and both the NNRTI</p>\n<p>and PI classes</p>\n<p>~</p>\n<p>Immune reconstitution inflammatory syndrome (IRIS)</p>\n<p>~</p>\n<p>Pill burden, overlapping toxicities and adherence issues.</p>\n<p>Management</p>\n<p>ART should be initiated in all TB/HIV co-infected people irrespective</p>\n<p>of their clinical stage or CD4 count. However, the timing of initiation</p>\n<p>of treatment may differ based on whether the patient is diagnosed with</p>\n<p>TB before or after initiating ART.</p>\n<p>252</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 319,
        "content": "SITUATION\nRECOMMENDATIONS\nTB patients diagnosed with \nHIV\nStart anti-TB medicines immediately, THEN \nstart ARVs 2 weeks later (see table below)\nPatient already on ART, di\u00ad\nagnosed with TB\nStart anti-TB medicines immediately, \nadjust regimen as per guidelines below\nADULT TB patients diag\u00ad\nnosed with TB \nStart anti-TB medicines immediately, \nstart ARVs before completing 2 weeks\nARV regimen in ART-naive patients on TB treatment\nAGE GROUP\nRECOMMENDED REGIMEN\nAdults, Pregnant and Breast\u00ad\nfeeding Women, and Ado\u00ad\nlescents\nTDF+3TC+EFV\nChildren aged 3 - < 12 years ABC+3TC+EFV\nChildren 0 - < 3 years\nABC+3TC+AZT\nARV regimen substitution for patients initiating TB treatment while on ART\nAge Group\nRegimen When Di\u00ad\nagnosed With Tb\nRecommended Action/ Sub\u00ad\nstitution\nAdults, \nPregnant and \nBreastfeeding \nWomen and \nAdolescents\nIf on EFV- based \nregimen\nContinue the same regimen but \ndouble the dose of DTG (give \nDTG twice daily)\nIf on NVP based \nregimen\nSubstitute NVP with EFV. If EFV \nis contraindicated, give DTG as \nabove. If DTG not available, \ngive a triple NRTI regimen (AB\u00ad\nC+3TC+AZT).\n253\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>SITUATION</h3>\n<h3>RECOMMENDATIONS</h3>\n<p>TB patients diagnosed with</p>\n<h3>HIV</h3>\n<p>Start anti-TB medicines immediately, THEN</p>\n<p>start ARVs 2 weeks later (see table below)</p>\n<p>Patient already on ART, di\u00ad</p>\n<p>agnosed with TB</p>\n<p>Start anti-TB medicines immediately,</p>\n<p>adjust regimen as per guidelines below</p>\n<p>ADULT TB patients diag\u00ad</p>\n<p>nosed with TB</p>\n<p>Start anti-TB medicines immediately,</p>\n<p>start ARVs before completing 2 weeks</p>\n<p>ARV regimen in ART-naive patients on TB treatment</p>\n<h3>AGE GROUP</h3>\n<h3>RECOMMENDED REGIMEN</h3>\n<p>Adults, Pregnant and Breast\u00ad</p>\n<p>feeding Women, and Ado\u00ad</p>\n<p>lescents</p>\n<h3>TDF+3TC+EFV</h3>\n<p>Children aged 3 - < 12 years ABC+3TC+EFV</p>\n<p>Children 0 - < 3 years</p>\n<h3>ABC+3TC+AZT</h3>\n<p>ARV regimen substitution for patients initiating TB treatment while on ART</p>\n<p>Age Group</p>\n<p>Regimen When Di\u00ad</p>\n<p>agnosed With Tb</p>\n<p>Recommended Action/ Sub\u00ad</p>\n<p>stitution</p>\n<p>Adults,</p>\n<p>Pregnant and</p>\n<p>Breastfeeding</p>\n<p>Women and</p>\n<p>Adolescents</p>\n<p>If on EFV- based</p>\n<p>regimen</p>\n<p>Continue the same regimen but</p>\n<p>double the dose of DTG (give</p>\n<p>DTG twice daily)</p>\n<p>If on NVP based</p>\n<p>regimen</p>\n<p>Substitute NVP with EFV. If EFV</p>\n<p>is contraindicated, give DTG as</p>\n<p>above. If DTG not available,</p>\n<p>give a triple NRTI regimen (AB\u00ad</p>\n<h3>C+3TC+AZT).</h3>\n<p>253</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 320,
        "content": "ARV regimen substitution for patients initiating TB treatment while on ART\nAge Group\nRegimen When Di\u00ad\nagnosed With Tb\nRecommended Action/ Sub\u00ad\nstitution\nAdults, Preg\u00ad\nn a n t  a n d \nBreastfeeding \nWomen and \nAdolescents\nIf on LPV/r based \nregimen\nContinue the same regimen but \ndouble the dose of DTG (give \nDTG twice daily)\nIf on ATV/r based \nregimen\nContinue the same regimen and \ngive Rifabutin for TB treatment\nChildren aged \n3 - <12 years\nIf on EFV- based \nregimen\nContinue the same regimen\nIf on NVP or based \nregimen\nSubstitute NVP with EFV.\nIf EFV is contraindicated, give \na triple NRTI regimen (AB\u00ad\nC+3TC+AZT)\nLPV/r\nContinue the same regimen and \ngive Rifabutin for TB treatment\nChildren 0 - <3 \nyears\nIf on LPV/r or \nNVP based regi\u00ad\nmen\nGive triple NRTI regimen AB\u00ad\nC+3TC+AZT\nSecond line ART for patients with TB\n \n~\nThere are significant drug interactions with PIs and rifam\u00ad\npicin.\n \n~\nIf rifabutin is available, it may be used in place of rifampicin \nwith ATV/r or LPV/r, but it is contraindicated in patients \nwith WBC counts below 1000/mm3.\n \n~\nMaintaining PI in second line regimens while switching from \n254\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>ARV regimen substitution for patients initiating TB treatment while on ART</p>\n<p>Age Group</p>\n<p>Regimen When Di\u00ad</p>\n<p>agnosed With Tb</p>\n<p>Recommended Action/ Sub\u00ad</p>\n<p>stitution</p>\n<p>Adults, Preg\u00ad</p>\n<p>n a n t  a n d</p>\n<p>Breastfeeding</p>\n<p>Women and</p>\n<p>Adolescents</p>\n<p>If on LPV/r based</p>\n<p>regimen</p>\n<p>Continue the same regimen but</p>\n<p>double the dose of DTG (give</p>\n<p>DTG twice daily)</p>\n<p>If on ATV/r based</p>\n<p>regimen</p>\n<p>Continue the same regimen and</p>\n<p>give Rifabutin for TB treatment</p>\n<p>Children aged</p>\n<p>3 - <12 years</p>\n<p>If on EFV- based</p>\n<p>regimen</p>\n<p>Continue the same regimen</p>\n<p>If on NVP or based</p>\n<p>regimen</p>\n<p>Substitute NVP with EFV.</p>\n<p>If EFV is contraindicated, give</p>\n<p>a triple NRTI regimen (AB\u00ad</p>\n<h3>C+3TC+AZT)</h3>\n<p>LPV/r</p>\n<p>Continue the same regimen and</p>\n<p>give Rifabutin for TB treatment</p>\n<p>Children 0 - <3</p>\n<p>years</p>\n<p>If on LPV/r or</p>\n<p>NVP based regi\u00ad</p>\n<p>men</p>\n<p>Give triple NRTI regimen AB\u00ad</p>\n<h3>C+3TC+AZT</h3>\n<p>Second line ART for patients with TB</p>\n<p>~</p>\n<p>There are significant drug interactions with PIs and rifam\u00ad</p>\n<p>picin.</p>\n<p>~</p>\n<p>If rifabutin is available, it may be used in place of rifampicin</p>\n<p>with ATV/r or LPV/r, but it is contraindicated in patients</p>\n<p>with WBC counts below 1000/mm3.</p>\n<p>~</p>\n<p>Maintaining PI in second line regimens while switching from</p>\n<p>254</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 321,
        "content": "Rifampicin to Rifabutin (if available) is ideal\nTB prevention\n \n~\nBCG immunisation: it protects children against severe \nforms of TB. It can be given at birth. If delayed, avoid in \nsymptomatic HIV\n \n~\nIPT (Isoniazid Preventive Treatment) (see section 5.3.2.3)\n3.1.10.2\tCryptococcal Meningitis\t            ICD10 CODE: B45 \nCrytococcal meningitis is an opportunistic  infection  caused by a fungus \nCryptococcus neoformans.\n \n~\nIn Uganda, cryptococcal meningitis (CM) associated mor\u00ad\ntality is up to 39%. Patients with a CD4 cell count of <100 \nare at the highest risk, so early screening and management \nis critical.\n \n~\nScreening In ART-Naive Patients\n \n~\nScreen routinely for Cryptococcal Meningitis with the cryp\u00ad\ntococcal antigen (CrAg) test (a bedside finger prick test):\n \n- All ART naive individuals with CD4 <100 cells/\u00b5L\n \n- Patients on ART with viral load (VL >1000 copies/ml) or \nclinical (stage 3 or 4 disease) failure\n \n~\nIf serum CrAg negative and no signs of meningitis: start \nART immediately (or switch regimen)\n \n~\nIf CrAg positive and/or signs or symptoms of meningitis \n(headache, presence of seizures, altered consciousness, \nphotophobia, neck stiffness, and a positive Kernigs\u2019 sign)\n \n- Perform lumbar puncture and test for CSF CrAg (culture if \npossible)\n \n~\nIf CSF CrAg positive, diagnose and treat for Cryptococcal \nMeningitis\n \n~\nIf CSF CrAg negative but blood CrAg positive, give pre \nemptive treatment for asymptomatic cryptococcal disease \nor non CNS cryptococcal disease\n255\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Rifampicin to Rifabutin (if available) is ideal</p>\n<p>TB prevention</p>\n<p>~</p>\n<p>BCG immunisation: it protects children against severe</p>\n<p>forms of TB. It can be given at birth. If delayed, avoid in</p>\n<p>symptomatic HIV</p>\n<p>~</p>\n<p>IPT (Isoniazid Preventive Treatment) (see section 5.3.2.3)</p>\n<p>3.1.10.2\tCryptococcal Meningitis\t            ICD10 CODE: B45</p>\n<p>Crytococcal meningitis is an opportunistic  infection  caused by a fungus</p>\n<p>Cryptococcus neoformans.</p>\n<p>~</p>\n<p>In Uganda, cryptococcal meningitis (CM) associated mor\u00ad</p>\n<p>tality is up to 39%. Patients with a CD4 cell count of <100</p>\n<p>are at the highest risk, so early screening and management</p>\n<p>is critical.</p>\n<p>~</p>\n<p>Screening In ART-Naive Patients</p>\n<p>~</p>\n<p>Screen routinely for Cryptococcal Meningitis with the cryp\u00ad</p>\n<p>tococcal antigen (CrAg) test (a bedside finger prick test):</p>\n<p>- All ART naive individuals with CD4 <100 cells/\u00b5L</p>\n<p>- Patients on ART with viral load (VL >1000 copies/ml) or</p>\n<p>clinical (stage 3 or 4 disease) failure</p>\n<p>~</p>\n<p>If serum CrAg negative and no signs of meningitis: start</p>\n<p>ART immediately (or switch regimen)</p>\n<p>~</p>\n<p>If CrAg positive and/or signs or symptoms of meningitis</p>\n<p>(headache, presence of seizures, altered consciousness,</p>\n<p>photophobia, neck stiffness, and a positive Kernigs\u2019 sign)</p>\n<p>- Perform lumbar puncture and test for CSF CrAg (culture if</p>\n<p>possible)</p>\n<p>~</p>\n<p>If CSF CrAg positive, diagnose and treat for Cryptococcal</p>\n<p>Meningitis</p>\n<p>~</p>\n<p>If CSF CrAg negative but blood CrAg positive, give pre</p>\n<p>emptive treatment for asymptomatic cryptococcal disease</p>\n<p>or non CNS cryptococcal disease</p>\n<p>255</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 322,
        "content": "ART naive patient with CD4 <100 \nor suspected treatment failure\nDo serum CRAG test\nYES\nNO\nYES\nNO\nNO\nYES\nNO\nthe serum CRAG \ntest positive\nCan you do a lumbar \npuncture (LP) at site?\nScreen for signs \nand symptoms of \nmeningitis\nStart Fluconazole \n1200 mg\nDo LP and CSF \nanalysis CRAG test\nIs CSF CRAG\npositive?\nRefer to facility \nwhere LP can \nbe done\nStart ART 4\u20136 weeks after \ninitiating treatment for \nCryptococcal Meningitis\nTreat as Cryptococcal Meningitis\nStart Fluconazole\n\u2022 400 mg BD for 2 weeks\n\u2022 Then 400 mg OD for 8 weeks\n\u2022 Then 200 mg OD for 14 weeks\nStart ART 2 weeks after starting \nFluconazole\nStart ART \nimmediately\nScreen for signs \nand symptoms of \nmeningitis\nDoes patient have \nsigns and symptoms \nof meningitis\n256\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>ART naive patient with CD4 <100</p>\n<p>or suspected treatment failure</p>\n<p>Do serum CRAG test</p>\n<h3>YES</h3>\n<p>NO</p>\n<h3>YES</h3>\n<p>NO</p>\n<p>NO</p>\n<h3>YES</h3>\n<p>NO</p>\n<p>the serum CRAG</p>\n<p>test positive</p>\n<p>Can you do a lumbar</p>\n<p>puncture (LP) at site?</p>\n<p>Screen for signs</p>\n<p>and symptoms of</p>\n<p>meningitis</p>\n<p>Start Fluconazole</p>\n<p>1200 mg</p>\n<p>Do LP and CSF</p>\n<p>analysis CRAG test</p>\n<p>Is CSF CRAG</p>\n<p>positive?</p>\n<p>Refer to facility</p>\n<p>where LP can</p>\n<p>be done</p>\n<p>Start ART 4\u20136 weeks after</p>\n<p>initiating treatment for</p>\n<p>Cryptococcal Meningitis</p>\n<p>Treat as Cryptococcal Meningitis</p>\n<p>Start Fluconazole</p>\n<li>400 mg BD for 2 weeks</li>\n<li>Then 400 mg OD for 8 weeks</li>\n<li>Then 200 mg OD for 14 weeks</li>\n<p>Start ART 2 weeks after starting</p>\n<p>Fluconazole</p>\n<p>Start ART</p>\n<p>immediately</p>\n<p>Screen for signs</p>\n<p>and symptoms of</p>\n<p>meningitis</p>\n<p>Does patient have</p>\n<p>signs and symptoms</p>\n<p>of meningitis</p>\n<p>256</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 323,
        "content": "ART timing with CCM \nArt Naive\nWait \nfor 4-6 \nweeks\nWait \nfor 4-6 \nweeks\nWait \nfor 4-6 \nweeks\nWait \nfor 4-6 \nweeks\nStart 1st line \nART regimen as \nper guidelines\nrestart 1st, 2nd \nor 3rd line ART \nregimen*\nrestart 1st, 2nd \nor 3rd line ART \nregimen*\nContinue 1st, \n2nd or 3rd line \nART regimen*\nrestart 1st, 2nd \nor 3rd line ART \nregimen*\nDo not \nstart ART at \nadmission\nART experienced reportedly \nnot adherent or uncertain \nof adherence\nART experienced reportedly \nadherent on ART > 6 months\nART experienced reportedly \nadherent on ART < 14 days-6 \nmonths very recent ART intro\u00ad\nduction or re-introduction\nART experienced reportedly \nadherent on ART < 14 days-6 \nmonths Recent ART introduction \nor re-introduction\nContinue ART at \nAdmission**\nStop ART at \nAdmission\nStop ART at \nAdmission\nStop ART at \nAdmission\nDecision on which ART regimen to restart should be made according \nto patient\u2019s history, ART guidelines, HIV viral and genotypic resistance \ntesting if possible. If it is considered likely that the patient has developed \nresistance to 1stline ARVs, then restart with 2ndline containing boosted \nPI or DTG is possible. ** Unless documented to have a suppressed viral \nload at time of admission or within the month prior to admission, in \nwhich case continue ART\n257\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>ART timing with CCM</p>\n<p>Art Naive</p>\n<p>Wait</p>\n<p>for 4-6</p>\n<p>weeks</p>\n<p>Wait</p>\n<p>for 4-6</p>\n<p>weeks</p>\n<p>Wait</p>\n<p>for 4-6</p>\n<p>weeks</p>\n<p>Wait</p>\n<p>for 4-6</p>\n<p>weeks</p>\n<p>Start 1st line</p>\n<p>ART regimen as</p>\n<p>per guidelines</p>\n<p>restart 1st, 2nd</p>\n<p>or 3rd line ART</p>\n<p>regimen*</p>\n<p>restart 1st, 2nd</p>\n<p>or 3rd line ART</p>\n<p>regimen*</p>\n<p>Continue 1st,</p>\n<p>2nd or 3rd line</p>\n<p>ART regimen*</p>\n<p>restart 1st, 2nd</p>\n<p>or 3rd line ART</p>\n<p>regimen*</p>\n<p>Do not</p>\n<p>start ART at</p>\n<p>admission</p>\n<p>ART experienced reportedly</p>\n<p>not adherent or uncertain</p>\n<p>of adherence</p>\n<p>ART experienced reportedly</p>\n<p>adherent on ART > 6 months</p>\n<p>ART experienced reportedly</p>\n<p>adherent on ART < 14 days-6</p>\n<p>months very recent ART intro\u00ad</p>\n<p>duction or re-introduction</p>\n<p>ART experienced reportedly</p>\n<p>adherent on ART < 14 days-6</p>\n<p>months Recent ART introduction</p>\n<p>or re-introduction</p>\n<p>Continue ART at</p>\n<p>Admission**</p>\n<p>Stop ART at</p>\n<p>Admission</p>\n<p>Stop ART at</p>\n<p>Admission</p>\n<p>Stop ART at</p>\n<p>Admission</p>\n<p>Decision on which ART regimen to restart should be made according</p>\n<p>to patient\u2019s history, ART guidelines, HIV viral and genotypic resistance</p>\n<p>testing if possible. If it is considered likely that the patient has developed</p>\n<p>resistance to 1stline ARVs, then restart with 2ndline containing boosted</p>\n<p>PI or DTG is possible. ** Unless documented to have a suppressed viral</p>\n<p>load at time of admission or within the month prior to admission, in</p>\n<p>which case continue ART</p>\n<p>257</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 324,
        "content": "Management of CCM\nPhase                                                Drug                                                                         Comments\nLOC\nNewly Diagnosed Patient\nInduction \nPhase \n(2 weeks)\nRecommended:\n\u2022 Amphotericin B \nliposomal single \nhigh dose (10mg/\nkg) + Flucytosine\n(100mg/kg/day in \nfour divided dos\u00ad\nes) + Fluconazole \n1200mg/ day for\n14 days OR\n\u2022 Amphotericin \nB deoxycholate \n(1mg/kg/day) \n+ Flucy tosine \n(100mg/kg/\nday in four divided \ndoses) for 1 week, \nfollowed by 1 week \nof fluconazole\n(1200 mg/day for \nadults, 12 mg/kg/\nday for children \nand adolescents). \nOR\nPreventing Amphotericin \ntoxicity:\nTo prevent nephrotoxicity \nand hypokalemia, for pa\u00ad\ntients on amphotericin \ndeoxycholate do the fol\u00ad\nlowing:\n\u2022Pre-hydration with 1L nor\u00ad\nmal saline before starting \nthe daily Amphotericin \nB dose.\n\u2022\tMonitor serum potassium \nand creatinine levels at \ninitiation and at least twice \nweekly to detect changes \nin renal function.\n\u2022\tRoutine administration \nof 40 mEq/day (mixed in \n500ml NS over 4 hours) \nof potassium chloride or 1 \ntablet of 600mg twice dai\u00ad\nly while on amphotericin B \ncan decrease the incidence \nof Amphotericin B-related \nhypokalemia.\nH\nRR\nH4\nH\nRR\n258\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management of CCM</p>\n<p>Phase                                                Drug                                                                         Comments</p>\n<h3>LOC</h3>\n<p>Newly Diagnosed Patient</p>\n<p>Induction</p>\n<p>Phase</p>\n<p>(2 weeks)</p>\n<p>Recommended:</p>\n<li>Amphotericin B</li>\n<p>liposomal single</p>\n<p>high dose (10mg/</p>\n<p>kg) + Flucytosine</p>\n<p>(100mg/kg/day in</p>\n<p>four divided dos\u00ad</p>\n<p>es) + Fluconazole</p>\n<p>1200mg/ day for</p>\n<p>14 days OR</p>\n<li>Amphotericin</li>\n<p>B deoxycholate</p>\n<p>(1mg/kg/day)</p>\n<p>+ Flucy tosine</p>\n<p>(100mg/kg/</p>\n<p>day in four divided</p>\n<p>doses) for 1 week,</p>\n<p>followed by 1 week</p>\n<p>of fluconazole</p>\n<p>(1200 mg/day for</p>\n<p>adults, 12 mg/kg/</p>\n<p>day for children</p>\n<p>and adolescents).</p>\n<p>OR</p>\n<p>Preventing Amphotericin</p>\n<p>toxicity:</p>\n<p>To prevent nephrotoxicity</p>\n<p>and hypokalemia, for pa\u00ad</p>\n<p>tients on amphotericin</p>\n<p>deoxycholate do the fol\u00ad</p>\n<p>lowing:</p>\n<li>Pre-hydration with 1L nor\u00ad</li>\n<p>mal saline before starting</p>\n<p>the daily Amphotericin</p>\n<p>B dose.</p>\n<li>Monitor serum potassium</li>\n<p>and creatinine levels at</p>\n<p>initiation and at least twice</p>\n<p>weekly to detect changes</p>\n<p>in renal function.</p>\n<li>Routine administration</li>\n<p>of 40 mEq/day (mixed in</p>\n<p>500ml NS over 4 hours)</p>\n<p>of potassium chloride or 1</p>\n<p>tablet of 600mg twice dai\u00ad</p>\n<p>ly while on amphotericin B</p>\n<p>can decrease the incidence</p>\n<p>of Amphotericin B-related</p>\n<p>hypokalemia.</p>\n<p>H</p>\n<p>RR</p>\n<p>H4</p>\n<p>H</p>\n<p>RR</p>\n<p>258</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 325,
        "content": "Management of CCM\nPhase                                                Drug                                                                         Comments\nLOC\nInduction \nPhase \n(2 weeks)\n\u2022 Fluconazole \n(1200 mg dai\u00ad\nly for adults, 12 \nmg/kg/day for \nchildren and\nadolescents) + \nFluc y tosi ne \n(100 mg/kg/\nday, divided \ninto four doses \nper day. OR\n\u2022 Amphotericin \nB deoxycholate \n(1mg/kg/day) + \nhigh-dose Flu\u00ad\nconazole\n1200mg/day.\n\u2022\tFor electrolyte supplemen\u00ad\ntation, two tablets daily of \nMagnesium Chloride 310 \nmg or slow Magnesium Chlo\u00ad\nride 535mg or Magnesium \ntrisilicate 250mg while on \namphotericin B \n\u2022\tConsider alternate day Am\u00ad\nphotericin B if creatinine is \n>3mg/dl.\n\u2022\tTo monitor for flucytosine \n(5FC) toxicity, CBC with dif\u00ad\nferential counts at least twice \nweekly is recommended\nH4\nH\nR\nConsol\u00ad\nidation \nphase               \n(8 weeks)\nF l u c o n a z o l e \n800mg/day \n(or 6-12mg/kg/\nday in children \nand adoles\u00ad\ncents)\nInitiate ART 4\u20136 weeks after \nstarting CM treatment and \nthere is clinical response to \nantifungal therapy.\nH4\n259\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management of CCM</p>\n<p>Phase                                                Drug                                                                         Comments</p>\n<h3>LOC</h3>\n<p>Induction</p>\n<p>Phase</p>\n<p>(2 weeks)</p>\n<li>Fluconazole</li>\n<p>(1200 mg dai\u00ad</p>\n<p>ly for adults, 12</p>\n<p>mg/kg/day for</p>\n<p>children and</p>\n<p>adolescents) +</p>\n<p>Fluc y tosi ne</p>\n<p>(100 mg/kg/</p>\n<p>day, divided</p>\n<p>into four doses</p>\n<p>per day. OR</p>\n<li>Amphotericin</li>\n<p>B deoxycholate</p>\n<p>(1mg/kg/day) +</p>\n<p>high-dose Flu\u00ad</p>\n<p>conazole</p>\n<p>1200mg/day.</p>\n<li>For electrolyte supplemen\u00ad</li>\n<p>tation, two tablets daily of</p>\n<p>Magnesium Chloride 310</p>\n<p>mg or slow Magnesium Chlo\u00ad</p>\n<p>ride 535mg or Magnesium</p>\n<p>trisilicate 250mg while on</p>\n<p>amphotericin B</p>\n<li>Consider alternate day Am\u00ad</li>\n<p>photericin B if creatinine is</p>\n<p>>3mg/dl.</p>\n<li>To monitor for flucytosine</li>\n<p>(5FC) toxicity, CBC with dif\u00ad</p>\n<p>ferential counts at least twice</p>\n<p>weekly is recommended</p>\n<p>H4</p>\n<p>H</p>\n<p>R</p>\n<p>Consol\u00ad</p>\n<p>idation</p>\n<p>phase</p>\n<p>(8 weeks)</p>\n<p>F l u c o n a z o l e</p>\n<p>800mg/day</p>\n<p>(or 6-12mg/kg/</p>\n<p>day in children</p>\n<p>and adoles\u00ad</p>\n<p>cents)</p>\n<p>Initiate ART 4\u20136 weeks after</p>\n<p>starting CM treatment and</p>\n<p>there is clinical response to</p>\n<p>antifungal therapy.</p>\n<p>H4</p>\n<p>259</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 326,
        "content": "Phase                                                Drug                                                                         Comments\nLOC\nMainte\u00ad\nnance\nPhase (18 \nmonths)\nF l u c o n a z o l e \n200mg/day \n(or 6 mg/kg/day \nup to 200mg \nin children and \nadolescents)\nCriteria to stop after a minimum \nof 18 months of maintenance \nphase:\nAdults: VL<1,000 copies/mm3 \n& CD4 \u2265 200 or CD4 \u2265200 (if \nviral load not available) after \n12 and 18 months\nChildren: If CD4>25% or viral \nsuppressed\nH4\nRelapse disease\nPresents with a recurrence of symptoms of Meningitis and \nhave a positive cerebrospinal fluid culture following a prior \nconfirmed diagnosis of Cryptococcal Meningitis.\nEvaluate for drug resistance: Send CSF to Central Public Health \nLaboratory (CPHL) for culture and sensitivity testing, if there \nare no drug resistance results, re-initiate the induction therapy \nfor two weeks and complete other phases of treatment.\nAdequate control of elevated CSF pressure\n\u2022\tControl of increased intracranial pressure improves survival \nby 25% in persons with Cryptococcal Meningitis.\n\u2022\tAll patients with a CSF Pressure >250mm H2O will need a \ntherapeutic LP the following day to reduce the CSF pressure \nto <200 mm.\n\u2022\tIn the absence of a manometer, one may use an IV giving \nset to create an improvised manometer measuring the height \nwith a meter stick.\nRemoving 20-30mL of CSF (even in the absence of a manometer) \nmay be adequate to decrease CSF pressure. Most patients \nwill need 2-3LPs during the induction phase.\n260\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Phase                                                Drug                                                                         Comments</p>\n<h3>LOC</h3>\n<p>Mainte\u00ad</p>\n<p>nance</p>\n<p>Phase (18</p>\n<p>months)</p>\n<p>F l u c o n a z o l e</p>\n<p>200mg/day</p>\n<p>(or 6 mg/kg/day</p>\n<p>up to 200mg</p>\n<p>in children and</p>\n<p>adolescents)</p>\n<p>Criteria to stop after a minimum</p>\n<p>of 18 months of maintenance</p>\n<p>phase:</p>\n<p>Adults: VL<1,000 copies/mm3</p>\n<p>& CD4 \u2265 200 or CD4 \u2265200 (if</p>\n<p>viral load not available) after</p>\n<p>12 and 18 months</p>\n<p>Children: If CD4>25% or viral</p>\n<p>suppressed</p>\n<p>H4</p>\n<p>Relapse disease</p>\n<p>Presents with a recurrence of symptoms of Meningitis and</p>\n<p>have a positive cerebrospinal fluid culture following a prior</p>\n<p>confirmed diagnosis of Cryptococcal Meningitis.</p>\n<p>Evaluate for drug resistance: Send CSF to Central Public Health</p>\n<p>Laboratory (CPHL) for culture and sensitivity testing, if there</p>\n<p>are no drug resistance results, re-initiate the induction therapy</p>\n<p>for two weeks and complete other phases of treatment.</p>\n<p>Adequate control of elevated CSF pressure</p>\n<li>Control of increased intracranial pressure improves survival</li>\n<p>by 25% in persons with Cryptococcal Meningitis.</p>\n<li>All patients with a CSF Pressure >250mm H2O will need a</li>\n<p>therapeutic LP the following day to reduce the CSF pressure</p>\n<p>to <200 mm.</p>\n<li>In the absence of a manometer, one may use an IV giving</li>\n<p>set to create an improvised manometer measuring the height</p>\n<p>with a meter stick.</p>\n<p>Removing 20-30mL of CSF (even in the absence of a manometer)</p>\n<p>may be adequate to decrease CSF pressure. Most patients</p>\n<p>will need 2-3LPs during the induction phase.</p>\n<p>260</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 327,
        "content": "3.1.10.3\tHepatitis B and HIV Co-Infection ICD10 CODE: B18\n \n~\nHepatitis B virus (HBV) is the leading cause of chronic liver \ndisease among HIV patients. In Uganda, the prevalence of \nHepatitis B among HIV patients is estimated to be at 17%. \n(see section 6.5.2 for more details on hepatitis B infection)\n \n~\nAll HIV-infected patients initiating and those failing ART \nshould be routinely screened for HBV infection using Hep \nB surface Antigen (HBsAg)\n \n~\nPeople living with HIV with a positive HBsAg should have \nother complementary tests at baseline and repeated every \n6 months and these include:\n\t\n\u0089\nA complete blood count\n\t\n\u0089\nLiver function tests: ALT, AST, albumin, bilirubin, PT-INR\n\t\n\u0089\nLiver ultrasound scan: to assess stage of liver fibrosis\n \n~\nRepeat tests every 6 months since patients with chronic \nHBV infection are at increased risk for hepatocellular car\u00ad\ncinoma\nManagement of HBV/HIV co-infection\nThe goal of HBV/HIV treatment is to prevent dual disease progression \nand to reduce HBV-related morbidity and mortality\nTREATMENT\nLOC\nPreferably ART regimen containing:\n\t\n\u0089\nTDF 300 mg + 3TC 300 mg PO once daily for life\n\t\n\u0089\nAfter 6 months of treatment, patients should be evaluated \nfor HBV treatment failure\nH\n261\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.10.3\tHepatitis B and HIV Co-Infection ICD10 CODE: B18</p>\n<p>~</p>\n<p>Hepatitis B virus (HBV) is the leading cause of chronic liver</p>\n<p>disease among HIV patients. In Uganda, the prevalence of</p>\n<p>Hepatitis B among HIV patients is estimated to be at 17%.</p>\n<p>(see section 6.5.2 for more details on hepatitis B infection)</p>\n<p>~</p>\n<p>All HIV-infected patients initiating and those failing ART</p>\n<p>should be routinely screened for HBV infection using Hep</p>\n<p>B surface Antigen (HBsAg)</p>\n<p>~</p>\n<p>People living with HIV with a positive HBsAg should have</p>\n<p>other complementary tests at baseline and repeated every</p>\n<p>6 months and these include:</p>\n<p>\u0089</p>\n<p>A complete blood count</p>\n<p>\u0089</p>\n<p>Liver function tests: ALT, AST, albumin, bilirubin, PT-INR</p>\n<p>\u0089</p>\n<p>Liver ultrasound scan: to assess stage of liver fibrosis</p>\n<p>~</p>\n<p>Repeat tests every 6 months since patients with chronic</p>\n<p>HBV infection are at increased risk for hepatocellular car\u00ad</p>\n<p>cinoma</p>\n<p>Management of HBV/HIV co-infection</p>\n<p>The goal of HBV/HIV treatment is to prevent dual disease progression</p>\n<p>and to reduce HBV-related morbidity and mortality</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Preferably ART regimen containing:</p>\n<p>\u0089</p>\n<p>TDF 300 mg + 3TC 300 mg PO once daily for life</p>\n<p>\u0089</p>\n<p>After 6 months of treatment, patients should be evaluated</p>\n<p>for HBV treatment failure</p>\n<p>H</p>\n<p>261</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 328,
        "content": "TREATMENT\nLOC\nIf jaundice, malaise and abdominal right upper quadrant pain \nare present or if liver function tests are abnormal\n\t\n\u0089\nDo HBV DNA (hepatitis viral load) if any of the above \nis present\nTreatment Failure\n\t\n\u0089\nPatients with HB VL >2000 IU/ml at 24 weeks of \ntherapy should be referred for further evaluation and \nmanagement\nPrevention of HBV infection\n \n~\nCounseling: emphasize sexual transmission as well as the \nrisks associated with sharing needles and syringes, tattoo\u00ad\ning or body-piercing\n \n~\nAdvise patients with chronic HBV disease to avoid alcohol \nconsumption\n \n~\nAll household members and sexual partners of people liv\u00ad\ning with HIV with HBV should be screened for HBsAG\n \n~\nHBV Vaccination is the most effective way to prevent HBV \ninfection and its consequences\n \n- All HIV-infected patients who test negative on HBsAg\n \n- should be vaccinated with HBV vaccine\n \n- All sexual partners and contacts should receive HBV \nvaccination regardless of whether they are HIV-infected or \nnot\n262\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If jaundice, malaise and abdominal right upper quadrant pain</p>\n<p>are present or if liver function tests are abnormal</p>\n<p>\u0089</p>\n<p>Do HBV DNA (hepatitis viral load) if any of the above</p>\n<p>is present</p>\n<p>Treatment Failure</p>\n<p>\u0089</p>\n<p>Patients with HB VL >2000 IU/ml at 24 weeks of</p>\n<p>therapy should be referred for further evaluation and</p>\n<p>management</p>\n<p>Prevention of HBV infection</p>\n<p>~</p>\n<p>Counseling: emphasize sexual transmission as well as the</p>\n<p>risks associated with sharing needles and syringes, tattoo\u00ad</p>\n<p>ing or body-piercing</p>\n<p>~</p>\n<p>Advise patients with chronic HBV disease to avoid alcohol</p>\n<p>consumption</p>\n<p>~</p>\n<p>All household members and sexual partners of people liv\u00ad</p>\n<p>ing with HIV with HBV should be screened for HBsAG</p>\n<p>~</p>\n<p>HBV Vaccination is the most effective way to prevent HBV</p>\n<p>infection and its consequences</p>\n<p>- All HIV-infected patients who test negative on HBsAg</p>\n<p>- should be vaccinated with HBV vaccine</p>\n<p>- All sexual partners and contacts should receive HBV</p>\n<p>vaccination regardless of whether they are HIV-infected or</p>\n<p>not</p>\n<p>262</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 329,
        "content": "3.1.10.4\tPneumocystis Pneumonia\t\nICD10 CODE: B59 \nInterstitial  pneumonitis  caused  by  the  parasite  Pneumocystis jirovecii \n(formerly carinii). It is common in severely immunosuppresed patients \n(e.g. in HIV).\n \n~\nClinical features\n \n~\nFever\n \n~\nDry cough\n \n~\nShortness of breath (significant hypoxemia)\n \n~\n \nInvestigations\n \n\u0081\nChest x-ray shows characteristic bilateral interstitial infiltrates\nManagement\nPre-emptive treatment for cryptococcal disease\nTREATMENT\nLOC\nPneumocystis Jirovecii pneumonia\n\t\n\u0089\nGive oxygen if SpO2 <94%\n\t\n\u0089\nCotrimoxazole 120 mg/kg/daily in 2-4 divided doses \nfor 21 days\n \n- For example cotrimoxazole 480 mg tablets:\n \n- If patient is < 60 kg: give 3 tablets If patient >60 \nkg: give 4 tablets\n\t\n\u0089\nPlus prednisolone 2 mg/kg daily in 3 divided doses for 5 \ndays, then reduce dose to complete 21 days of treatment\nOr (in patients who cannot tolerate or do not respond \nto cotrimoxazole)\n\t\n\u0089\nPentamidine 4 mg/kg by IV infusion daily for 21 days\n \n- Reduce dose in renal impairment\nHC4\nRR\nH\n263\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.10.4\tPneumocystis Pneumonia</p>\n<h3>ICD10 CODE: B59</h3>\n<p>Interstitial  pneumonitis  caused  by  the  parasite  Pneumocystis jirovecii</p>\n<p>(formerly carinii). It is common in severely immunosuppresed patients</p>\n<p>(e.g. in HIV).</p>\n<p>~</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Dry cough</p>\n<p>~</p>\n<p>Shortness of breath (significant hypoxemia)</p>\n<p>~</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Chest x-ray shows characteristic bilateral interstitial infiltrates</p>\n<p>Management</p>\n<p>Pre-emptive treatment for cryptococcal disease</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Pneumocystis Jirovecii pneumonia</p>\n<p>\u0089</p>\n<p>Give oxygen if SpO2 <94%</p>\n<p>\u0089</p>\n<p>Cotrimoxazole 120 mg/kg/daily in 2-4 divided doses</p>\n<p>for 21 days</p>\n<p>- For example cotrimoxazole 480 mg tablets:</p>\n<p>- If patient is < 60 kg: give 3 tablets If patient >60</p>\n<p>kg: give 4 tablets</p>\n<p>\u0089</p>\n<p>Plus prednisolone 2 mg/kg daily in 3 divided doses for 5</p>\n<p>days, then reduce dose to complete 21 days of treatment</p>\n<p>Or (in patients who cannot tolerate or do not respond</p>\n<p>to cotrimoxazole)</p>\n<p>\u0089</p>\n<p>Pentamidine 4 mg/kg by IV infusion daily for 21 days</p>\n<p>- Reduce dose in renal impairment</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>H</p>\n<p>263</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 330,
        "content": "TREATMENT\nLOC\n \n- Reduce dose in renal impairment\n \n- Avoid direct bolus injections whenever possible \nbut if unavoidable, never give rapidly\nAlternative regimen (21-day course) if above not avail\u00ad\nable/ tolerated\n \n- Clindamycin 600 mg every 8 hours\n \n- Plus dapsone 100 mg daily\nProphylaxis\nGive to all patients with history of PCP infection and consider \nalso for severely immunocompromised patients\n \n- Cotrimoxazole 960 mg daily or\n \n- Dapsone 100 mg daily\n \n- Continue until immunity recovers sufficiently\n3.1.10.5\tOther Diseases\nPeople living with HIV are at higher risk of acquiring any other infection and \ndiseases, including non-communicable diseases, due to HIV itself and drug \nside effects.\n \n- Treat any other infection (e.g. malaria, STI) as per guidelines \nfor the general population\n \n- Screen regularly for NCD (diabetes, hypertension and\n \n- depression)\n \n- Screen women at enrolment in HIV care and then annually \nfor cervical cancer using Visual Inspection with Acetic Acid \n(VIA) (see section 12.2.2)\n3.1.11 Prevention of HIV\nBehavioural change\n \n~\nAlways follow safe sex practices (e.g. use condoms; avoid \nmultiple sexual partners)\n \n~\nNever share used needles, syringes, razors, hair shavers, \nnail cutters, and other sharp objects\n264\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Reduce dose in renal impairment</p>\n<p>- Avoid direct bolus injections whenever possible</p>\n<p>but if unavoidable, never give rapidly</p>\n<p>Alternative regimen (21-day course) if above not avail\u00ad</p>\n<p>able/ tolerated</p>\n<p>- Clindamycin 600 mg every 8 hours</p>\n<p>- Plus dapsone 100 mg daily</p>\n<p>Prophylaxis</p>\n<p>Give to all patients with history of PCP infection and consider</p>\n<p>also for severely immunocompromised patients</p>\n<p>- Cotrimoxazole 960 mg daily or</p>\n<p>- Dapsone 100 mg daily</p>\n<p>- Continue until immunity recovers sufficiently</p>\n<p>3.1.10.5\tOther Diseases</p>\n<p>People living with HIV are at higher risk of acquiring any other infection and</p>\n<p>diseases, including non-communicable diseases, due to HIV itself and drug</p>\n<p>side effects.</p>\n<p>- Treat any other infection (e.g. malaria, STI) as per guidelines</p>\n<p>for the general population</p>\n<p>- Screen regularly for NCD (diabetes, hypertension and</p>\n<p>- depression)</p>\n<p>- Screen women at enrolment in HIV care and then annually</p>\n<p>for cervical cancer using Visual Inspection with Acetic Acid</p>\n<p>(VIA) (see section 12.2.2)</p>\n<p>3.1.11 Prevention of HIV</p>\n<p>Behavioural change</p>\n<p>~</p>\n<p>Always follow safe sex practices (e.g. use condoms; avoid</p>\n<p>multiple sexual partners)</p>\n<p>~</p>\n<p>Never share used needles, syringes, razors, hair shavers,</p>\n<p>nail cutters, and other sharp objects</p>\n<p>264</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 331,
        "content": "~\nAvoid tattooing, body-piercing, and scarification unless \ncarried out under strictly hygienic conditions in properly \ncontrolled premises\n \n~\nDelay start of sexual activity in adolescence\n \n~\nDiscourage cross generational and transactional sex\n \n~\nAvoid violence and abuse\nBiomedical prevention interventions\n \n~\nPMTCT\n \n~\nSafe Male Circumcision\n \n~\nART with viral suppression\n \n~\nPEP (Post Exposure Prophylaxis)\n \n~\nPrEP (Pre Exposure Prophylaxis)\n \n~\nBlood transfusion safety\n \n~\nSTI screening and treatment\n \n~\nSafe infusion and injection practices\n \n~\nAdherence to infection control procedures\n3.1.11.1 Post-Exposure Prophylaxis\t\nICD10 CODE: Z20.6 \nPost-exposure prophylaxis (PEP) is the short-term use of ARVs to reduce \nthe likelihood of acquiring HIV infection after potential occupational or \nnon-occupational exposure.\nTypes of Exposure\n \n~\nOccupational exposures: Occur in health care settings and \ninclude sharps and needlestick injuries or splashes of body \nfluids to the skin and mucous membranes\n \n~\nNon-occupational exposures: Include unprotected sex, ex\u00ad\nposure following assault like in rape & defilement, road \ntraffic accidents and injuries at construction sites where ex\u00ad\nposure to body fluids occur\n265\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>~</p>\n<p>Avoid tattooing, body-piercing, and scarification unless</p>\n<p>carried out under strictly hygienic conditions in properly</p>\n<p>controlled premises</p>\n<p>~</p>\n<p>Delay start of sexual activity in adolescence</p>\n<p>~</p>\n<p>Discourage cross generational and transactional sex</p>\n<p>~</p>\n<p>Avoid violence and abuse</p>\n<p>Biomedical prevention interventions</p>\n<p>~</p>\n<h3>PMTCT</h3>\n<p>~</p>\n<p>Safe Male Circumcision</p>\n<p>~</p>\n<p>ART with viral suppression</p>\n<p>~</p>\n<p>PEP (Post Exposure Prophylaxis)</p>\n<p>~</p>\n<p>PrEP (Pre Exposure Prophylaxis)</p>\n<p>~</p>\n<p>Blood transfusion safety</p>\n<p>~</p>\n<p>STI screening and treatment</p>\n<p>~</p>\n<p>Safe infusion and injection practices</p>\n<p>~</p>\n<p>Adherence to infection control procedures</p>\n<p>3.1.11.1 Post-Exposure Prophylaxis</p>\n<h3>ICD10 CODE: Z20.6</h3>\n<p>Post-exposure prophylaxis (PEP) is the short-term use of ARVs to reduce</p>\n<p>the likelihood of acquiring HIV infection after potential occupational or</p>\n<p>non-occupational exposure.</p>\n<p>Types of Exposure</p>\n<p>~</p>\n<p>Occupational exposures: Occur in health care settings and</p>\n<p>include sharps and needlestick injuries or splashes of body</p>\n<p>fluids to the skin and mucous membranes</p>\n<p>~</p>\n<p>Non-occupational exposures: Include unprotected sex, ex\u00ad</p>\n<p>posure following assault like in rape & defilement, road</p>\n<p>traffic accidents and injuries at construction sites where ex\u00ad</p>\n<p>posure to body fluids occur</p>\n<p>265</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 332,
        "content": "TREATMENT\nLOC\nStep 1: Rapid assessment and first aid\nConduct a rapid assessment of the client to assess exposure \nand risk and provide immediate care\nOccupation exposure:\nAfter a needle stick or sharp injury:\n\t\n\u0089\nDo not squeeze or rub the injury site\n\t\n\u0089\nWash the site immediately with soap or mild disinfectant \n(chlorhexidine gluconate solution) or, use antiseptic hand \nrub/ gel if no running water (do not use strong irritating \nantiseptics (like bleach or iodine)\nAfter a splash of blood or body fluids in contact with intact \nskin/broken:\n\t\n\u0089\nWash the area immediately or use antiseptic hand \nrub/ gel if no running water (don\u2019t use strong irritating \nantiseptics)\nAfter a splash of blood or body fluids contact with mucosae:\n\t\n\u0089\nWash abundantly with water\nHC2\nStep 2: Eligibility assessment\nProvide PEP when:\n \n- Exposure occurred within the past 72 hours; and\n \n- The exposed individual is not infected with HIV; \nand\n \n- The \u2018source\u2019 is HIV-infected or has unknown HIV \nstatus or high risk\nDo not provide PEP when:\n \n- The exposed individual is already HIV positive;\n \n- When the source is established to be HIV \nnegative;\nSteps in providing PEP\n266\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Step 1: Rapid assessment and first aid</p>\n<p>Conduct a rapid assessment of the client to assess exposure</p>\n<p>and risk and provide immediate care</p>\n<p>Occupation exposure:</p>\n<p>After a needle stick or sharp injury:</p>\n<p>\u0089</p>\n<p>Do not squeeze or rub the injury site</p>\n<p>\u0089</p>\n<p>Wash the site immediately with soap or mild disinfectant</p>\n<p>(chlorhexidine gluconate solution) or, use antiseptic hand</p>\n<p>rub/ gel if no running water (do not use strong irritating</p>\n<p>antiseptics (like bleach or iodine)</p>\n<p>After a splash of blood or body fluids in contact with intact</p>\n<p>skin/broken:</p>\n<p>\u0089</p>\n<p>Wash the area immediately or use antiseptic hand</p>\n<p>rub/ gel if no running water (don\u2019t use strong irritating</p>\n<p>antiseptics)</p>\n<p>After a splash of blood or body fluids contact with mucosae:</p>\n<p>\u0089</p>\n<p>Wash abundantly with water</p>\n<h3>HC2</h3>\n<p>Step 2: Eligibility assessment</p>\n<p>Provide PEP when:</p>\n<p>- Exposure occurred within the past 72 hours; and</p>\n<p>- The exposed individual is not infected with HIV;</p>\n<p>and</p>\n<p>- The \u2018source\u2019 is HIV-infected or has unknown HIV</p>\n<p>status or high risk</p>\n<p>Do not provide PEP when:</p>\n<p>- The exposed individual is already HIV positive;</p>\n<p>- When the source is established to be HIV</p>\n<p>negative;</p>\n<p>Steps in providing PEP</p>\n<p>266</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 333,
        "content": "TREATMENT\nLOC\n\u2013 Exposure to bodily fluids that do not pose a\nsignificant risk: e.g. to tears, non-blood-stained saliva, urine, \nand sweat, or small splashes on intact skin\n\u2013 Exposed people who decline an HIV test\nStep 3: Counseling and support\n\t\n\u0089\nCounsel on:\n \n- The risk of HIV from the exposure\n \n- Risks and benefits of PEP\n \n- Side effects of ARVs\n \n- Provide enhanced adherence counseling if PEP \nis prescribed\n \n- Link for further support for sexual assault cases \n(see below)\nStep 4: Prescription\n\t\n\u0089\nPEP should be started as early as possible, and not \nbeyond 72 hours from exposure\n\t\n\u0089\nRecommended regimens:\n \n- Adults : TDF+3TC+ATV/r\n \n- Children: ABC+3TC+LPV/r\n\t\n\u0089\nA complete course of PEP should run for 28 days\t\n\t\n\u0089\nDo not delay the first doses because of lack of baseline \nHIV Test\t\nStep 5: Follow up\n\t\n\u0089\nTo monitor adherence and manage side effects\n\t\n\u0089\nDiscontinue PEP after 28 days\n\t\n\u0089\nPerform follow-up HIV testing 6-week, 3 and 6 months \nafter exposure\n \n- If HIV infected, provide counseling and link to\n \n- HIV clinic for care and treatment\n \n- If HIV uninfected, provide HIV prevention \neducation/risk reduction.\n267\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u2013 Exposure to bodily fluids that do not pose a</p>\n<p>significant risk: e.g. to tears, non-blood-stained saliva, urine,</p>\n<p>and sweat, or small splashes on intact skin</p>\n<p>\u2013 Exposed people who decline an HIV test</p>\n<p>Step 3: Counseling and support</p>\n<p>\u0089</p>\n<p>Counsel on:</p>\n<p>- The risk of HIV from the exposure</p>\n<p>- Risks and benefits of PEP</p>\n<p>- Side effects of ARVs</p>\n<p>- Provide enhanced adherence counseling if PEP</p>\n<p>is prescribed</p>\n<p>- Link for further support for sexual assault cases</p>\n<p>(see below)</p>\n<p>Step 4: Prescription</p>\n<p>\u0089</p>\n<p>PEP should be started as early as possible, and not</p>\n<p>beyond 72 hours from exposure</p>\n<p>\u0089</p>\n<p>Recommended regimens:</p>\n<p>- Adults : TDF+3TC+ATV/r</p>\n<p>- Children: ABC+3TC+LPV/r</p>\n<p>\u0089</p>\n<p>A complete course of PEP should run for 28 days</p>\n<p>\u0089</p>\n<p>Do not delay the first doses because of lack of baseline</p>\n<p>HIV Test</p>\n<p>Step 5: Follow up</p>\n<p>\u0089</p>\n<p>To monitor adherence and manage side effects</p>\n<p>\u0089</p>\n<p>Discontinue PEP after 28 days</p>\n<p>\u0089</p>\n<p>Perform follow-up HIV testing 6-week, 3 and 6 months</p>\n<p>after exposure</p>\n<p>- If HIV infected, provide counseling and link to</p>\n<p>- HIV clinic for care and treatment</p>\n<p>- If HIV uninfected, provide HIV prevention</p>\n<p>education/risk reduction.</p>\n<p>267</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 334,
        "content": "Post-rape care (see also section 1.2.6)\nHealth facilities should provide the following clinical services as \npart of post-rape care:\n \n~\nInitial assessment of the client\n \n~\nRapid HIV testing and referral to care and treatmentif \nHIV-infected\n \n~\nPost-exposure prophylaxis (PEP) for HIV\n \n~\nSTI screening/testing and treatment\n \n~\nForensic interviews and examinations\n \n~\nEmergency contraception \u2013 if person reached within the \nfirst 72 hours\n \n~\nCounselling\nThe health facility should also identify, refer and link clients to \nnon-clinical services\n\t\n\u0089\nSome of the services include the following:\n\t\n\u0089\nLong-term psycho-social support\n\t\n\u0089\nLegal counseling\n\t\n\u0089\nPolice investigations, restraining orders\n\t\n\u0089\nChild protection services (e.g. emergency out of family care, \nreintegration into family care or permanent options when reinte\u00ad\ngration into family is impossible)\n\t\n\u0089\nEconomic empowerment\n\t\n\u0089\nEmergency shelters\n\t\n\u0089\nLong-term case management\nReporting: Health facilities should use HMIS 105 to report Gender \nBased Violence (GBV)\n268\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Post-rape care (see also section 1.2.6)</p>\n<p>Health facilities should provide the following clinical services as</p>\n<p>part of post-rape care:</p>\n<p>~</p>\n<p>Initial assessment of the client</p>\n<p>~</p>\n<p>Rapid HIV testing and referral to care and treatmentif</p>\n<p>HIV-infected</p>\n<p>~</p>\n<p>Post-exposure prophylaxis (PEP) for HIV</p>\n<p>~</p>\n<p>STI screening/testing and treatment</p>\n<p>~</p>\n<p>Forensic interviews and examinations</p>\n<p>~</p>\n<p>Emergency contraception \u2013 if person reached within the</p>\n<p>first 72 hours</p>\n<p>~</p>\n<p>Counselling</p>\n<p>The health facility should also identify, refer and link clients to</p>\n<p>non-clinical services</p>\n<p>\u0089</p>\n<p>Some of the services include the following:</p>\n<p>\u0089</p>\n<p>Long-term psycho-social support</p>\n<p>\u0089</p>\n<p>Legal counseling</p>\n<p>\u0089</p>\n<p>Police investigations, restraining orders</p>\n<p>\u0089</p>\n<p>Child protection services (e.g. emergency out of family care,</p>\n<p>reintegration into family care or permanent options when reinte\u00ad</p>\n<p>gration into family is impossible)</p>\n<p>\u0089</p>\n<p>Economic empowerment</p>\n<p>\u0089</p>\n<p>Emergency shelters</p>\n<p>\u0089</p>\n<p>Long-term case management</p>\n<p>Reporting: Health facilities should use HMIS 105 to report Gender</p>\n<p>Based Violence (GBV)</p>\n<p>268</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 335,
        "content": "3.1.11.2 Pre-Exposure Prophylaxis (PrEP)\nOral Pre-Exposure Prophylaxis (PrEP)\nDefinition: PrEP is the use of ARV drugs by HIV uninfected persons \nto prevent the acquisition of HIV before exposure to HIV. Table below \ndescribes processes involved in offering PrEP.\nProcess\nDescription\nScreening for risk \nof HIV\nPrEP provides an effective additional biomedical prevention \noption for HIV-negative people at substantial risk of acquiring \nHIV infection. These include people who:\na)\t Live in discordant sexual relationships \nb)\t Have had unprotected vaginal sexual intercourse with \nmore than one partner of unknown HIV status in the \npast six months \nc)\t\nHave had anal sexual intercourse in the past six months\nd)\t Have had sex in exchange for money, goods or a service \nin the last six months\ne)\t Use or abuse of drugs especially injectable drugs in the \nlast six months\nf)\t\nHave had more than one episode of a STI within the \nlast twelve months\ng)\t Are part of a discordant couple, especially if the \nHIV-positive partner is not on ART or has been on \nART for less than six months or not virally suppressed.\nh)\t Recurrent post-exposure prophylaxis (PEP) users. (Re\u00ad\ncurrent implies PEP use more than 3 times a years). \ni)\t\nAre members of key or priority populations who are \nunable or unwilling to achieve consistent use of condoms.\nThe process of providing pre-exposure prophylaxis (PrEP)\n269\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.1.11.2 Pre-Exposure Prophylaxis (PrEP)</p>\n<p>Oral Pre-Exposure Prophylaxis (PrEP)</p>\n<p>Definition: PrEP is the use of ARV drugs by HIV uninfected persons</p>\n<p>to prevent the acquisition of HIV before exposure to HIV. Table below</p>\n<p>describes processes involved in offering PrEP.</p>\n<p>Process</p>\n<p>Description</p>\n<p>Screening for risk</p>\n<p>of HIV</p>\n<p>PrEP provides an effective additional biomedical prevention</p>\n<p>option for HIV-negative people at substantial risk of acquiring</p>\n<p>HIV infection. These include people who:</p>\n<p>a)\t Live in discordant sexual relationships</p>\n<p>b)\t Have had unprotected vaginal sexual intercourse with</p>\n<p>more than one partner of unknown HIV status in the</p>\n<p>past six months</p>\n<p>c)</p>\n<p>Have had anal sexual intercourse in the past six months</p>\n<p>d)\t Have had sex in exchange for money, goods or a service</p>\n<p>in the last six months</p>\n<p>e)\t Use or abuse of drugs especially injectable drugs in the</p>\n<p>last six months</p>\n<p>f)</p>\n<p>Have had more than one episode of a STI within the</p>\n<p>last twelve months</p>\n<p>g)\t Are part of a discordant couple, especially if the</p>\n<p>HIV-positive partner is not on ART or has been on</p>\n<p>ART for less than six months or not virally suppressed.</p>\n<p>h)\t Recurrent post-exposure prophylaxis (PEP) users. (Re\u00ad</p>\n<p>current implies PEP use more than 3 times a years).</p>\n<p>i)</p>\n<p>Are members of key or priority populations who are</p>\n<p>unable or unwilling to achieve consistent use of condoms.</p>\n<p>The process of providing pre-exposure prophylaxis (PrEP)</p>\n<p>269</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 336,
        "content": "Process\nDescription\nNB: Eligibility is likely to be more prevalent in populations \nsuch as discordant couple, sex workers, fisher folk, \nlong-distance truck drivers, men who have sex with \nmen (MSM), uniformed forces, and adolescents and \nyoung women including pregnant and lactating AGYW \nat substantial risk.\nScreening for \nPrEP eligibility\nAfter meeting the substantial risk for HIV criteria:\n \n\u0083 Confirm HIV-negative status using the \nnational HTS algorithm\n \n\u0083 Rule out signs and symptoms of acute HIV \ninfection\n \n\u0083 Assess for hepatitis B infection: if negative, \npatient is eligible for PrEP; if positive, refer \npatient for Hepatitis B management. \nNote:\n \n\u0083 HEP B positive test is not a contraindication for \ninitiating PrEP, however precaution\nneeds to be taken when making a decision to stop PrEP to \navoid HEP B viral load flare.\n \n\u0083 Creatinine test and creatinine clearance \ncalculation using GFR formula is done. Do \nnot offer PrEP if Creatinine clearance is \nless than 1.2mg/dl. \nNote: Absence of this should not delay PrEP initiation in \npersons with no signs and symptoms of renal impairment. \nIf available, creatinine test can be done at initiation and \nrepeated every 6 months.\nI.\t\nAssess for contraindications to TDF/FTC or TDF/3TC.\n270\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Process</p>\n<p>Description</p>\n<p>NB: Eligibility is likely to be more prevalent in populations</p>\n<p>such as discordant couple, sex workers, fisher folk,</p>\n<p>long-distance truck drivers, men who have sex with</p>\n<p>men (MSM), uniformed forces, and adolescents and</p>\n<p>young women including pregnant and lactating AGYW</p>\n<p>at substantial risk.</p>\n<p>Screening for</p>\n<p>PrEP eligibility</p>\n<p>After meeting the substantial risk for HIV criteria:</p>\n<p>\u0083 Confirm HIV-negative status using the</p>\n<p>national HTS algorithm</p>\n<p>\u0083 Rule out signs and symptoms of acute HIV</p>\n<p>infection</p>\n<p>\u0083 Assess for hepatitis B infection: if negative,</p>\n<p>patient is eligible for PrEP; if positive, refer</p>\n<p>patient for Hepatitis B management.</p>\n<p>Note:</p>\n<p>\u0083 HEP B positive test is not a contraindication for</p>\n<p>initiating PrEP, however precaution</p>\n<p>needs to be taken when making a decision to stop PrEP to</p>\n<p>avoid HEP B viral load flare.</p>\n<p>\u0083 Creatinine test and creatinine clearance</p>\n<p>calculation using GFR formula is done. Do</p>\n<p>not offer PrEP if Creatinine clearance is</p>\n<p>less than 1.2mg/dl.</p>\n<p>Note: Absence of this should not delay PrEP initiation in</p>\n<p>persons with no signs and symptoms of renal impairment.</p>\n<p>If available, creatinine test can be done at initiation and</p>\n<p>repeated every 6 months.</p>\n<p>I.</p>\n<p>Assess for contraindications to TDF/FTC or TDF/3TC.</p>\n<p>270</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 337,
        "content": "Process\nDescription\nSteps to initiation \nof PrEP\nProvide risk-reduction and PrEP medication adherence \ncounseling:\nII.\t Provide condoms and education on their use\nIII.\t Initiate a medication adherence plan \nIV.\t Prescribe a once-daily pill of TDF (300mg) and FTC \n(200mg) or TDF (300mg)/ 3TC (300mg)\nV.\t Initially, provide a 1-month TDF/FTC or TDF/3TC \nprescription (1 tablet orally, daily) together with a \n1-month follow-up date\nVI.\t Counsel client on side effects of TDF/FTC or TDF/3TC\nFollow-up/ mon\u00ad\nitoring clients\nVII.\tAfter the initial visit, the patient should be given a two-\nmonth follow-up appointment and thereafter quarterly \nappointments\non PrEP\nVIII.\tPerform an HIV antibody test using the national HTS \nalgorithm and every three months. Note: Blood based \nHIVST is an alternative for PrEP refill in case of absence \nof the national HTS standard recommended in patients \non PrEP.\nIX.\t For women, perform a pregnancy test if there is history \nof amenorrhea.\nX.\t Review the patient\u2019s understanding of PrEP, any barriers \nto adherence, tolerance to the medication as well as any \nside effects.\nXI.\t Review the patient\u2019s risk exposure profile and perform \nrisk-reduction counseling.\nXII.\tEvaluate and support PrEP adherence at each clinic \nvisit.\nXIII.\tEvaluate the patient for any symptoms of STIs at every \nvisit and treat according to current STI treatment Guide\u00ad\nlines.\n271\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Process</p>\n<p>Description</p>\n<p>Steps to initiation</p>\n<p>of PrEP</p>\n<p>Provide risk-reduction and PrEP medication adherence</p>\n<p>counseling:</p>\n<p>II.\t Provide condoms and education on their use</p>\n<p>III.\t Initiate a medication adherence plan</p>\n<p>IV.\t Prescribe a once-daily pill of TDF (300mg) and FTC</p>\n<p>(200mg) or TDF (300mg)/ 3TC (300mg)</p>\n<p>V.\t Initially, provide a 1-month TDF/FTC or TDF/3TC</p>\n<p>prescription (1 tablet orally, daily) together with a</p>\n<p>1-month follow-up date</p>\n<p>VI.\t Counsel client on side effects of TDF/FTC or TDF/3TC</p>\n<p>Follow-up/ mon\u00ad</p>\n<p>itoring clients</p>\n<p>VII.\tAfter the initial visit, the patient should be given a two-</p>\n<p>month follow-up appointment and thereafter quarterly</p>\n<p>appointments</p>\n<p>on PrEP</p>\n<p>VIII.\tPerform an HIV antibody test using the national HTS</p>\n<p>algorithm and every three months. Note: Blood based</p>\n<p>HIVST is an alternative for PrEP refill in case of absence</p>\n<p>of the national HTS standard recommended in patients</p>\n<p>on PrEP.</p>\n<p>IX.\t For women, perform a pregnancy test if there is history</p>\n<p>of amenorrhea.</p>\n<p>X.\t Review the patient\u2019s understanding of PrEP, any barriers</p>\n<p>to adherence, tolerance to the medication as well as any</p>\n<p>side effects.</p>\n<p>XI.\t Review the patient\u2019s risk exposure profile and perform</p>\n<p>risk-reduction counseling.</p>\n<p>XII.\tEvaluate and support PrEP adherence at each clinic</p>\n<p>visit.</p>\n<p>XIII.\tEvaluate the patient for any symptoms of STIs at every</p>\n<p>visit and treat according to current STI treatment Guide\u00ad</p>\n<p>lines.</p>\n<p>271</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 338,
        "content": "Process\nDescription\nGuidance on dis\u00ad\ncontinuing PrEP\n\u2022\t\nAcquisition of HIV infection\n\u2022\t\nSuspected signs and symptoms of acute HIV infection \nfollowing a recent exposure within 4 weeks\n\u2022\t\nChanged life situations resulting in lowered risk of \nHIV acquisition (no longer at substantial risk of HIV \nacquisition)\n\u2022\t\nIntolerable toxicities and side effects of ARVs\n\u2022\t\nChronic non-adherence to the prescribed regimen despite \nefforts to improve daily pill-taking.\n\u2022\t\nPersonal choice\n\u2022\t\nHIV-negative in a sero-discordant relationship when the \npositive partner on ART for >6months has achieved \nsustained viral load suppression (condoms should still \nbe used consistently).  The HIV negative partner can be \nallowed to continue PrEP even if the positive partner \nis virally suppressed if they choose to. \nFor detailed guidance on the provision of PrEP, please refer to the \nTechnical Guidance on Pre-Exposure Prophylaxis for Persons at High \nRisk of HIV in Uganda, 2022.\nThe PrEP Ring\nThe PrEP ring is a long-acting HIV prevention method developed spe\u00ad\ncifically for clients who are unable or do not want to take oral PrEP or \nwhen oral PrEP is not available. The ring is made of a flexible silicone \nmaterial containing 25 mg of an ARV drug called dapivirine. It is inserted \ninto the vagina and should remain in place for one month. Dapivirine \nbelongs to a class of ARVs called non-nucleoside reverse transcriptase \ninhibitors (NNRTI) that reduce the ability of HIV to replicate itself inside \na healthy cell. The ring delivers the drug directly to the site of potential \ninfection over the course of one month, with low absorption elsewhere \nin the body, lowering the likelihood of systemic side effects.\n272\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Process</p>\n<p>Description</p>\n<p>Guidance on dis\u00ad</p>\n<p>continuing PrEP</p>\n<li></li>\n<p>Acquisition of HIV infection</p>\n<li></li>\n<p>Suspected signs and symptoms of acute HIV infection</p>\n<p>following a recent exposure within 4 weeks</p>\n<li></li>\n<p>Changed life situations resulting in lowered risk of</p>\n<p>HIV acquisition (no longer at substantial risk of HIV</p>\n<p>acquisition)</p>\n<li></li>\n<p>Intolerable toxicities and side effects of ARVs</p>\n<li></li>\n<p>Chronic non-adherence to the prescribed regimen despite</p>\n<p>efforts to improve daily pill-taking.</p>\n<li></li>\n<p>Personal choice</p>\n<li></li>\n<p>HIV-negative in a sero-discordant relationship when the</p>\n<p>positive partner on ART for >6months has achieved</p>\n<p>sustained viral load suppression (condoms should still</p>\n<p>be used consistently).  The HIV negative partner can be</p>\n<p>allowed to continue PrEP even if the positive partner</p>\n<p>is virally suppressed if they choose to.</p>\n<p>For detailed guidance on the provision of PrEP, please refer to the</p>\n<p>Technical Guidance on Pre-Exposure Prophylaxis for Persons at High</p>\n<p>Risk of HIV in Uganda, 2022.</p>\n<p>The PrEP Ring</p>\n<p>The PrEP ring is a long-acting HIV prevention method developed spe\u00ad</p>\n<p>cifically for clients who are unable or do not want to take oral PrEP or</p>\n<p>when oral PrEP is not available. The ring is made of a flexible silicone</p>\n<p>material containing 25 mg of an ARV drug called dapivirine. It is inserted</p>\n<p>into the vagina and should remain in place for one month. Dapivirine</p>\n<p>belongs to a class of ARVs called non-nucleoside reverse transcriptase</p>\n<p>inhibitors (NNRTI) that reduce the ability of HIV to replicate itself inside</p>\n<p>a healthy cell. The ring delivers the drug directly to the site of potential</p>\n<p>infection over the course of one month, with low absorption elsewhere</p>\n<p>in the body, lowering the likelihood of systemic side effects.</p>\n<p>272</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 339,
        "content": "Possible Side Effects of the PrEP Ring\nPossible side effects of the ring are typically mild and include urinary \ntract infections (UTIs \u2013 experienced by about 15% of users), vaginal dis\u00ad\ncharge (experienced by about 7% of users), vulvar itching (experienced \nby about 6% of users), and pelvic and lower abdominal pain (experienced \nby about 6% of users).\nContraindications for PrEP Ring Use\nThe ring should not be provided to people with:\n \n\u0083 An HIV-positive test result according to the national HIV testing \nalgorithm\n \n\u0083 Known exposure to HIV in the past 72 hours (because such \nclients may derive more benefit from post-exposure prophylaxis \n(PEP) if the potential for HIV exposure was high)\n \n\u0083 Signs of AHI (Box 1) AND potential exposure within the past \n14 days\n \n\u0083 Inability to commit to effectively using the ring and attend \nscheduled follow-up visits \n \n\u0083 Allergy or hypersensitivity to active substance or other \nsubstances listed in the product information sheet\nLong acting injectable cabotegravir (CAB-LA)\nThe long acting injectable cabotegravir:  Is a long acting injectable drug \ncontaining Cabotegravir, an integrase inhibitor, is effective in preventing \nHIV among people at high risk of acquiring HIV.\nIt is indicated in all HIV negative persons at high risk of HIV.\nBefore initiation, individuals must be screened for HIV using the national \nHTS algorithm and rule out signs of Acute HIV infection as for oral PrEP. \n \n- Administration: Its administrated in the buttock once every \n8 weeks  \n \n- Side effects: The injectable cabotegravir is safe and well-\ntolerated. \n \n- Efficacy/Effectiveness: The injectable cabotegravir was found \nto be over 95% effective\n273\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Possible Side Effects of the PrEP Ring</p>\n<p>Possible side effects of the ring are typically mild and include urinary</p>\n<p>tract infections (UTIs \u2013 experienced by about 15% of users), vaginal dis\u00ad</p>\n<p>charge (experienced by about 7% of users), vulvar itching (experienced</p>\n<p>by about 6% of users), and pelvic and lower abdominal pain (experienced</p>\n<p>by about 6% of users).</p>\n<p>Contraindications for PrEP Ring Use</p>\n<p>The ring should not be provided to people with:</p>\n<p>\u0083 An HIV-positive test result according to the national HIV testing</p>\n<p>algorithm</p>\n<p>\u0083 Known exposure to HIV in the past 72 hours (because such</p>\n<p>clients may derive more benefit from post-exposure prophylaxis</p>\n<p>(PEP) if the potential for HIV exposure was high)</p>\n<p>\u0083 Signs of AHI (Box 1) AND potential exposure within the past</p>\n<p>14 days</p>\n<p>\u0083 Inability to commit to effectively using the ring and attend</p>\n<p>scheduled follow-up visits</p>\n<p>\u0083 Allergy or hypersensitivity to active substance or other</p>\n<p>substances listed in the product information sheet</p>\n<p>Long acting injectable cabotegravir (CAB-LA)</p>\n<p>The long acting injectable cabotegravir:  Is a long acting injectable drug</p>\n<p>containing Cabotegravir, an integrase inhibitor, is effective in preventing</p>\n<p>HIV among people at high risk of acquiring HIV.</p>\n<p>It is indicated in all HIV negative persons at high risk of HIV.</p>\n<p>Before initiation, individuals must be screened for HIV using the national</p>\n<p>HTS algorithm and rule out signs of Acute HIV infection as for oral PrEP.</p>\n<p>- Administration: Its administrated in the buttock once every</p>\n<p>8 weeks</p>\n<p>- Side effects: The injectable cabotegravir is safe and well-</p>\n<p>tolerated.</p>\n<p>- Efficacy/Effectiveness: The injectable cabotegravir was found</p>\n<p>to be over 95% effective</p>\n<p>273</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 340,
        "content": "- Safety: No safety concerns have been associated \n \n- Acceptability and barriers: In a study setting it was highly \nacceptable \n \n- Contraindications: Hypersensitivity to active substance\nNote:\n \n\u0083 For detailed guidance on the provision of CAB-LA, please \nrefer to the Technical Guidance on Pre-Exposure Prophylaxis \nfor Persons at High Risk of HIV in Uganda, 2022.\n3.1.12\t\nPsychosocial Support for HIV-Positive Persons\nHIV-positive persons benefit greatly from the following support after the \nfirst impact of the test result is overcome:\n \n~\nProvide of emotional support\n \n~\nHelp the person understand the social, medical, and psy\u00ad\nchological implications for him/herself, the unborn child (in \nthe case of a pregnant woman), and any sexual partners\n \n~\nConnect the person with support services, including (re\u00ad\nligious) support groups, orphan care, income- generating \nactivities, home care and others\n \n~\nHelp the person find strategies to involve his/her partner \nand extended family in sharing responsibility\n \n~\nHelp the person identify someone from the community to \nsupport and care for him/her\n \n~\nDiscuss with HIV positive mothers how to provide for the \nother children in the family\n \n~\nHelp him/her identify a person from the extended family or \ncommunity who will provide support\n \n~\nAs appropriate, confirm and support information given in \nHIV counselling and testing on mother-to-child transmis\u00ad\nsion, possibility of ARV treatment, safer sex, infant feeding \nand FP advice\n274\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>- Safety: No safety concerns have been associated</p>\n<p>- Acceptability and barriers: In a study setting it was highly</p>\n<p>acceptable</p>\n<p>- Contraindications: Hypersensitivity to active substance</p>\n<p>Note:</p>\n<p>\u0083 For detailed guidance on the provision of CAB-LA, please</p>\n<p>refer to the Technical Guidance on Pre-Exposure Prophylaxis</p>\n<p>for Persons at High Risk of HIV in Uganda, 2022.</p>\n<p>3.1.12</p>\n<p>Psychosocial Support for HIV-Positive Persons</p>\n<p>HIV-positive persons benefit greatly from the following support after the</p>\n<p>first impact of the test result is overcome:</p>\n<p>~</p>\n<p>Provide of emotional support</p>\n<p>~</p>\n<p>Help the person understand the social, medical, and psy\u00ad</p>\n<p>chological implications for him/herself, the unborn child (in</p>\n<p>the case of a pregnant woman), and any sexual partners</p>\n<p>~</p>\n<p>Connect the person with support services, including (re\u00ad</p>\n<p>ligious) support groups, orphan care, income- generating</p>\n<p>activities, home care and others</p>\n<p>~</p>\n<p>Help the person find strategies to involve his/her partner</p>\n<p>and extended family in sharing responsibility</p>\n<p>~</p>\n<p>Help the person identify someone from the community to</p>\n<p>support and care for him/her</p>\n<p>~</p>\n<p>Discuss with HIV positive mothers how to provide for the</p>\n<p>other children in the family</p>\n<p>~</p>\n<p>Help him/her identify a person from the extended family or</p>\n<p>community who will provide support</p>\n<p>~</p>\n<p>As appropriate, confirm and support information given in</p>\n<p>HIV counselling and testing on mother-to-child transmis\u00ad</p>\n<p>sion, possibility of ARV treatment, safer sex, infant feeding</p>\n<p>and FP advice</p>\n<p>274</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 341,
        "content": "~\nHelp the person to understand and develop strategies to \napply new information within daily life.\nHIV-positive persons benefit greatly from the following support after the \nfirst impact of the test result is overcome:\n \n~\nProvide of emotional support\n \n~\nHelp the person understand the social, medical, and psy\u00ad\nchological implications for him/herself, the unborn child (in \nthe case of a pregnant woman), and any sexual partners\n \n~\nConnect the person with support services, including (re\u00ad\nligious) support groups, orphan care, income- generating \nactivities, home care and others\n \n~\nHelp the person find strategies to involve his/her partner \nand extended family in sharing responsibility\n \n~\nHelp the person identify someone from the community to \nsupport and care for him/her\n \n~\nDiscuss with HIV positive mothers how to provide for the \nother children in the family\n \n~\nHelp him/her identify a person from the extended family or \ncommunity who will provide support\n \n~\nAs appropriate, confirm and support information given in \nHIV counselling and testing on mother-to-child transmis\u00ad\nsion, possibility of ARV treatment, safer sex, infant feeding \nand FP advice\n \n~\nHelp the person to understand and develop strategies to \napply new information within daily life.\n275\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>~</p>\n<p>Help the person to understand and develop strategies to</p>\n<p>apply new information within daily life.</p>\n<p>HIV-positive persons benefit greatly from the following support after the</p>\n<p>first impact of the test result is overcome:</p>\n<p>~</p>\n<p>Provide of emotional support</p>\n<p>~</p>\n<p>Help the person understand the social, medical, and psy\u00ad</p>\n<p>chological implications for him/herself, the unborn child (in</p>\n<p>the case of a pregnant woman), and any sexual partners</p>\n<p>~</p>\n<p>Connect the person with support services, including (re\u00ad</p>\n<p>ligious) support groups, orphan care, income- generating</p>\n<p>activities, home care and others</p>\n<p>~</p>\n<p>Help the person find strategies to involve his/her partner</p>\n<p>and extended family in sharing responsibility</p>\n<p>~</p>\n<p>Help the person identify someone from the community to</p>\n<p>support and care for him/her</p>\n<p>~</p>\n<p>Discuss with HIV positive mothers how to provide for the</p>\n<p>other children in the family</p>\n<p>~</p>\n<p>Help him/her identify a person from the extended family or</p>\n<p>community who will provide support</p>\n<p>~</p>\n<p>As appropriate, confirm and support information given in</p>\n<p>HIV counselling and testing on mother-to-child transmis\u00ad</p>\n<p>sion, possibility of ARV treatment, safer sex, infant feeding</p>\n<p>and FP advice</p>\n<p>~</p>\n<p>Help the person to understand and develop strategies to</p>\n<p>apply new information within daily life.</p>\n<p>275</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 342,
        "content": "3.2 SEXUALLY TRANSMITTED INFECTIONS (STI)\nSTIs are a collection of disorders, several of which are better \nregarded as syndromes for more effective management using a \nsyndromic approach.\nPrevention of STIs\n \n~\nGeneral preventive measures include:\n \n~\nGive health education about STIs\n \n~\nProvide specific education on the need for early reporting \nand compliance with treatment\n \n~\nEnsure notification and treatment of sexual partners\n \n~\nCounsel patient on risk reduction e.g. practice of safe sex \nby using condoms, remaining faithful to one sexual partner, \npersonal hygiene\n \n~\nProvide condoms\n \n~\nIf necessary and possible, schedule return visits\n3.2.1\t\nUrethral Discharge Syndrome (Male) \nICD10 CODE: R36\nIt refers to urethral discharge in men with or without dysuria, \ncaused by a number of diseases usually spread by sexual inter\u00ad\ncourse, which produce similar manifestations in males and may \nbe difficult to distinguish clinically.\nCauses\n \n~\nCommon: Neisseria gonorrhoea (causing gonorrhoea),\n \n~\nChlamydia trachomatis and Ureaplasma urealyticum\n \n~\nUncommon: Trichomonas vaginalis\n276\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>3.2 SEXUALLY TRANSMITTED INFECTIONS (STI)</h3>\n<p>STIs are a collection of disorders, several of which are better</p>\n<p>regarded as syndromes for more effective management using a</p>\n<p>syndromic approach.</p>\n<p>Prevention of STIs</p>\n<p>~</p>\n<p>General preventive measures include:</p>\n<p>~</p>\n<p>Give health education about STIs</p>\n<p>~</p>\n<p>Provide specific education on the need for early reporting</p>\n<p>and compliance with treatment</p>\n<p>~</p>\n<p>Ensure notification and treatment of sexual partners</p>\n<p>~</p>\n<p>Counsel patient on risk reduction e.g. practice of safe sex</p>\n<p>by using condoms, remaining faithful to one sexual partner,</p>\n<p>personal hygiene</p>\n<p>~</p>\n<p>Provide condoms</p>\n<p>~</p>\n<p>If necessary and possible, schedule return visits</p>\n<p>3.2.1</p>\n<p>Urethral Discharge Syndrome (Male)</p>\n<h3>ICD10 CODE: R36</h3>\n<p>It refers to urethral discharge in men with or without dysuria,</p>\n<p>caused by a number of diseases usually spread by sexual inter\u00ad</p>\n<p>course, which produce similar manifestations in males and may</p>\n<p>be difficult to distinguish clinically.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Common: Neisseria gonorrhoea (causing gonorrhoea),</p>\n<p>~</p>\n<p>Chlamydia trachomatis and Ureaplasma urealyticum</p>\n<p>~</p>\n<p>Uncommon: Trichomonas vaginalis</p>\n<p>276</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 343,
        "content": "Clinical features\n \n~\nMucus or pus at the tip of the penis; staining underwear\n \n~\nBurning pain on passing urine (dysuria), frequent urition\n Investigations\n \n\u0081\nPus swab: Gram stain, culture and sensitivity\n \n\u0081\nBlood: Screen for syphilis and HIV\n \n\u0081\nExamine patient carefully to confirm discharge\nPatient complains of urethral discharge or dysuria\nTake history and examine. \nMilk urethra if necessary.\nRetract prepuce and \nexamine for ulcers.\nCefixime 400 mg stat plus Doxycycline \n100 mg 12 hourly for 7 days. Treat \npartner with similar drugs.\nIf partner is pregnant, instead of Doxycy\u00ad\ncline give Erythromycim 500 mg every 6 \nhours for 7 days.\nDischarge not \nconfirmed\nIf discharge persists, find \nout if partners were treated\nIf discharge persists\nIf discharge persists\nCeftriaxone \ninjection, 1g stat\nRefer for specialist\u2019s \nmanagement\nIf partners were not \ntreated: Re-start \ntreatment all over\nIf partners were treated, \nrepeat Doxycycline 100 \nmg 12 hourly for 7 days \nplus Metronidazole 2 g \nsingle dose\n\u2022Reassure\n\u2022Educate and counsel\n\u2022Promote and provide \t  \ncondoms\n\u2022Offer or refer for HCT\nDischarge \nconfirmed\n277\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Mucus or pus at the tip of the penis; staining underwear</p>\n<p>~</p>\n<p>Burning pain on passing urine (dysuria), frequent urition</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pus swab: Gram stain, culture and sensitivity</p>\n<p>\u0081</p>\n<p>Blood: Screen for syphilis and HIV</p>\n<p>\u0081</p>\n<p>Examine patient carefully to confirm discharge</p>\n<p>Patient complains of urethral discharge or dysuria</p>\n<p>Take history and examine.</p>\n<p>Milk urethra if necessary.</p>\n<p>Retract prepuce and</p>\n<p>examine for ulcers.</p>\n<p>Cefixime 400 mg stat plus Doxycycline</p>\n<p>100 mg 12 hourly for 7 days. Treat</p>\n<p>partner with similar drugs.</p>\n<p>If partner is pregnant, instead of Doxycy\u00ad</p>\n<p>cline give Erythromycim 500 mg every 6</p>\n<p>hours for 7 days.</p>\n<p>Discharge not</p>\n<p>confirmed</p>\n<p>If discharge persists, find</p>\n<p>out if partners were treated</p>\n<p>If discharge persists</p>\n<p>If discharge persists</p>\n<p>Ceftriaxone</p>\n<p>injection, 1g stat</p>\n<p>Refer for specialist\u2019s</p>\n<p>management</p>\n<p>If partners were not</p>\n<p>treated: Re-start</p>\n<p>treatment all over</p>\n<p>If partners were treated,</p>\n<p>repeat Doxycycline 100</p>\n<p>mg 12 hourly for 7 days</p>\n<p>plus Metronidazole 2 g</p>\n<p>single dose</p>\n<li>Reassure</li>\n<li>Educate and counsel</li>\n<li>Promote and provide</li>\n<p>condoms</p>\n<li>Offer or refer for HCT</li>\n<p>Discharge</p>\n<p>confirmed</p>\n<p>277</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 344,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nTake history and examine the client. Milk urethra if \ndischarge is not obvious\nRetract prepuce and examine for ulcers f Treat both patient \nand sexual partners f Advise abstinence or condom use\nMedicines\n\t\n\u0089\nCeftriaxone 250 mg IM or Cefixime 400 mg single \ndose plus\n\t\n\u0089\nDoxycycline 100 mg every 12 hours for 7 days\nIf partner is pregnant\n\t\n\u0089\nSubstitute doxycycline with erythromycin 500 mg every \n6 hours for 7 days\n\t\n\u0089\nor Azithromycin 1 g stat if available\nIf discharge or dysuria persists and partners were treated:\n\t\n\u0089\nExclude presence of ulcers under prepuce\n\t\n\u0089\nRepeat doxycycline 100 mg every 12 hours for 7 days\n\t\n\u0089\nAlso give metronidazole 2 g single dose\nIf discharge or dysuria persists and partners were not treated:\n\t\n\u0089\nStart the initial treatment all over again and treat partners\nIf dicharge persists still\n\t\n\u0089\nCeftriaxone 1 g IM\n\t\n\u0089\nRefer for specialist management if not better\nHC2\nHC3\n278\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Take history and examine the client. Milk urethra if</p>\n<p>discharge is not obvious</p>\n<p>Retract prepuce and examine for ulcers f Treat both patient</p>\n<p>and sexual partners f Advise abstinence or condom use</p>\n<p>Medicines</p>\n<p>\u0089</p>\n<p>Ceftriaxone 250 mg IM or Cefixime 400 mg single</p>\n<p>dose plus</p>\n<p>\u0089</p>\n<p>Doxycycline 100 mg every 12 hours for 7 days</p>\n<p>If partner is pregnant</p>\n<p>\u0089</p>\n<p>Substitute doxycycline with erythromycin 500 mg every</p>\n<p>6 hours for 7 days</p>\n<p>\u0089</p>\n<p>or Azithromycin 1 g stat if available</p>\n<p>If discharge or dysuria persists and partners were treated:</p>\n<p>\u0089</p>\n<p>Exclude presence of ulcers under prepuce</p>\n<p>\u0089</p>\n<p>Repeat doxycycline 100 mg every 12 hours for 7 days</p>\n<p>\u0089</p>\n<p>Also give metronidazole 2 g single dose</p>\n<p>If discharge or dysuria persists and partners were not treated:</p>\n<p>\u0089</p>\n<p>Start the initial treatment all over again and treat partners</p>\n<p>If dicharge persists still</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IM</p>\n<p>\u0089</p>\n<p>Refer for specialist management if not better</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>278</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 345,
        "content": "3.2.2\t\nAbnormal Vaginal Discharge Syndrome     \nICD10 CODE: N76\nOften the first evidence of genital infection al, though absence of abnor\u00ad\nmal vaginal discharge does not mean absence\nof infection. Normal discharge is small in quantity and white to colourless. \nNot all vaginal infections are sexually transmitted diseases.\nCauses\n \n~\nCan be a variety and often mixture of organisms\n \n~\nVaginitis: by Candida albicanis, Trichomonas vaginalis or \nbacterial vaginosis (by Gardnerella vaginalis, Mycoplasma \nhominis)\n \n~\nCervicitis: commonly due to gonorrhoea and chlamydia: \nusually asymptomatic and rarely a cause of abnormal vag\u00ad\ninal discharge.\n \n~\nClinical features\n \n~\nIncreased quantity of discharge, abnormal colour and odour\n \n~\nLower abdominal pain, itching and pain at sexual inter\u00ad\ncourse may be present\n \n~\nIn Candida albicans vaginitis: very itchy thick or lumpy \nwhite discharge, red inflamed vulva\n \n~\nTrichomonas vaginalis: itchy greenish-yellow frothy dis\u00ad\ncharge with offensive smell\n \n~\nBacterial vaginosis: thin discharge with a fishy smell from \nthe vagina\n279\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.2.2</p>\n<p>Abnormal Vaginal Discharge Syndrome</p>\n<h3>ICD10 CODE: N76</h3>\n<p>Often the first evidence of genital infection al, though absence of abnor\u00ad</p>\n<p>mal vaginal discharge does not mean absence</p>\n<p>of infection. Normal discharge is small in quantity and white to colourless.</p>\n<p>Not all vaginal infections are sexually transmitted diseases.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Can be a variety and often mixture of organisms</p>\n<p>~</p>\n<p>Vaginitis: by Candida albicanis, Trichomonas vaginalis or</p>\n<p>bacterial vaginosis (by Gardnerella vaginalis, Mycoplasma</p>\n<p>hominis)</p>\n<p>~</p>\n<p>Cervicitis: commonly due to gonorrhoea and chlamydia:</p>\n<p>usually asymptomatic and rarely a cause of abnormal vag\u00ad</p>\n<p>inal discharge.</p>\n<p>~</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Increased quantity of discharge, abnormal colour and odour</p>\n<p>~</p>\n<p>Lower abdominal pain, itching and pain at sexual inter\u00ad</p>\n<p>course may be present</p>\n<p>~</p>\n<p>In Candida albicans vaginitis: very itchy thick or lumpy</p>\n<p>white discharge, red inflamed vulva</p>\n<p>~</p>\n<p>Trichomonas vaginalis: itchy greenish-yellow frothy dis\u00ad</p>\n<p>charge with offensive smell</p>\n<p>~</p>\n<p>Bacterial vaginosis: thin discharge with a fishy smell from</p>\n<p>the vagina</p>\n<p>279</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 346,
        "content": "Candida vaginitis and bacterial vaginosis are NOT sexually transmitted \ndiseases, even though sexual activity is a risk factor.\n \n~\nGonorrhoea causes cervicitis and rarely vaginitis. Thereis a \npurulent thin mucoid slightly yellow pus discharge with no \nsmell and non-itchy\n \n~\nChlamydia causes cervicitis which may present with a non-\nitchy, thin, colourless discharge\nDifferential diagnosis\n \n~\nCancer of the cervix (blood-stained smelly discharge)\n \n~\nIntra-vaginal use of detergents, chemicals, physical agents \nand herbs, chronic tampon use, allergic vaginitis\nInvestigations\n \n\u0081\nSpeculum examination\n \n\u0081\nPus swab: microscopy, Gram stain, C&S\n \n\u0081\nPH, KOH\n \n\u0081\nBlood: syphilis tests (RPR/VDRL)\n \n\u0081\nHIV Testing\n280\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Candida vaginitis and bacterial vaginosis are NOT sexually transmitted</p>\n<p>diseases, even though sexual activity is a risk factor.</p>\n<p>~</p>\n<p>Gonorrhoea causes cervicitis and rarely vaginitis. Thereis a</p>\n<p>purulent thin mucoid slightly yellow pus discharge with no</p>\n<p>smell and non-itchy</p>\n<p>~</p>\n<p>Chlamydia causes cervicitis which may present with a non-</p>\n<p>itchy, thin, colourless discharge</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cancer of the cervix (blood-stained smelly discharge)</p>\n<p>~</p>\n<p>Intra-vaginal use of detergents, chemicals, physical agents</p>\n<p>and herbs, chronic tampon use, allergic vaginitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Speculum examination</p>\n<p>\u0081</p>\n<p>Pus swab: microscopy, Gram stain, C&S</p>\n<p>\u0081</p>\n<h3>PH, KOH</h3>\n<p>\u0081</p>\n<p>Blood: syphilis tests (RPR/VDRL)</p>\n<p>\u0081</p>\n<p>HIV Testing</p>\n<p>280</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 347,
        "content": "NO\nNO\nYES\nYES\nTake history and examine \nfor gen tal ulcers and \nabdominal tenderness. \nPerform speculum examin \ntion for cervical lesions.\nIf there are ulcers, \ntreat as genital \nulcers\nOn speculum examin \ntion, are signs of \ncancer of the cervix\nRefer to Gynaecolo\u00ad\ngist immediately\nCheck for erythema \nexcoriations or thrush\nFluconazole 150 mg-200mg plus \nMetronidazole tablets, 2 g single \ndose.\nIf pregnant replace Fluconazole \nwith Clotrimazole pessary 100 mg \nonce for 6 days and add Metroni\u00ad\ndazole only after 1st trimester\nCexfixime 400 mg stat plus \nDoxycycline 100 mg 12 hourly \nfor 7 days plus Metronidazole \n2 g single dose. Treat sexual \npartners. If pregnant replace \nDoxycycline with Erythromycin \n500 mg 6 hourly for 7 days\nIf discharge persists \nbeyond 7 days\nIf discharge persists beyond \n7 days and partners were \ntreated, refer for specialist\u2019s \nmanagement\nGive cefixime 400 mg stat plus \ndoxycycline 100 mg 12 hourly for 7 \ndays and if pregnant give Erythro\u00ad\nmycin 500 mg 6 hourly for 7 days \nand treat sexual partners.\nIf discharge persists beyond 7 \ndays and partners were treated, \nrefer for specialist\u2019s management\nIf there is abdominal \ntenderness, treat as \nlower abdominal\n281\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>NO</p>\n<p>NO</p>\n<h3>YES</h3>\n<h3>YES</h3>\n<p>Take history and examine</p>\n<p>for gen tal ulcers and</p>\n<p>abdominal tenderness.</p>\n<p>Perform speculum examin</p>\n<p>tion for cervical lesions.</p>\n<p>If there are ulcers,</p>\n<p>treat as genital</p>\n<p>ulcers</p>\n<p>On speculum examin</p>\n<p>tion, are signs of</p>\n<p>cancer of the cervix</p>\n<p>Refer to Gynaecolo\u00ad</p>\n<p>gist immediately</p>\n<p>Check for erythema</p>\n<p>excoriations or thrush</p>\n<p>Fluconazole 150 mg-200mg plus</p>\n<p>Metronidazole tablets, 2 g single</p>\n<p>dose.</p>\n<p>If pregnant replace Fluconazole</p>\n<p>with Clotrimazole pessary 100 mg</p>\n<p>once for 6 days and add Metroni\u00ad</p>\n<p>dazole only after 1st trimester</p>\n<p>Cexfixime 400 mg stat plus</p>\n<p>Doxycycline 100 mg 12 hourly</p>\n<p>for 7 days plus Metronidazole</p>\n<p>2 g single dose. Treat sexual</p>\n<p>partners. If pregnant replace</p>\n<p>Doxycycline with Erythromycin</p>\n<p>500 mg 6 hourly for 7 days</p>\n<p>If discharge persists</p>\n<p>beyond 7 days</p>\n<p>If discharge persists beyond</p>\n<p>7 days and partners were</p>\n<p>treated, refer for specialist\u2019s</p>\n<p>management</p>\n<p>Give cefixime 400 mg stat plus</p>\n<p>doxycycline 100 mg 12 hourly for 7</p>\n<p>days and if pregnant give Erythro\u00ad</p>\n<p>mycin 500 mg 6 hourly for 7 days</p>\n<p>and treat sexual partners.</p>\n<p>If discharge persists beyond 7</p>\n<p>days and partners were treated,</p>\n<p>refer for specialist\u2019s management</p>\n<p>If there is abdominal</p>\n<p>tenderness, treat as</p>\n<p>lower abdominal</p>\n<p>281</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 348,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nTake history and examine for genital ulcers, abdominal \ntenderness\n\t\n\u0089\nPerform speculum examination for cervical lesions\n\t\n\u0089\nAssess risk for sexually transmitted disease\nIf there is lower abdominal tenderness and sexually active:\n\t\n\u0089\nTreat as in PID (see section 14.1.2)\nIf no lower abdominal pain and discharge is thick and lumpy, vagina \nis itchy and erythema or excoriations are present: likely Candida\n\t\n\u0089\nGive clotrimazole pessaries 100 mg; insert high in \nvagina once daily before bedtime for 6 days or twice \ndaily for 3 days\n\t\n\u0089\nOr fluconazole 200 mg tablets single dose, orally\n\t\n\u0089\n\u00b1 Metronidazole 2 g stat dose\nHC2\nIf abundant/smelly discharge/vaginosis: possible trichomonas \nor vaginosis\n\t\n\u0089\nMetronidazole 2 g stat\nHC2\nIf purulent discharge, or high risk of STD, or previous treatment \nnon effective: treat for gonorrhea, and chlamydia, and trichomonas \n\t\n\u0089\nGive cefixime 400 mg stat or ceftriaxone 1g\nIV stat\n\t\n\u0089\nPlus doxycycline 100 mg 12 hourly for 7 days\n Plus metronidazole 2 g stat\nHC3\n282\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Take history and examine for genital ulcers, abdominal</p>\n<p>tenderness</p>\n<p>\u0089</p>\n<p>Perform speculum examination for cervical lesions</p>\n<p>\u0089</p>\n<p>Assess risk for sexually transmitted disease</p>\n<p>If there is lower abdominal tenderness and sexually active:</p>\n<p>\u0089</p>\n<p>Treat as in PID (see section 14.1.2)</p>\n<p>If no lower abdominal pain and discharge is thick and lumpy, vagina</p>\n<p>is itchy and erythema or excoriations are present: likely Candida</p>\n<p>\u0089</p>\n<p>Give clotrimazole pessaries 100 mg; insert high in</p>\n<p>vagina once daily before bedtime for 6 days or twice</p>\n<p>daily for 3 days</p>\n<p>\u0089</p>\n<p>Or fluconazole 200 mg tablets single dose, orally</p>\n<p>\u0089</p>\n<p>\u00b1 Metronidazole 2 g stat dose</p>\n<h3>HC2</h3>\n<p>If abundant/smelly discharge/vaginosis: possible trichomonas</p>\n<p>or vaginosis</p>\n<p>\u0089</p>\n<p>Metronidazole 2 g stat</p>\n<h3>HC2</h3>\n<p>If purulent discharge, or high risk of STD, or previous treatment</p>\n<p>non effective: treat for gonorrhea, and chlamydia, and trichomonas</p>\n<p>\u0089</p>\n<p>Give cefixime 400 mg stat or ceftriaxone 1g</p>\n<p>IV stat</p>\n<p>\u0089</p>\n<p>Plus doxycycline 100 mg 12 hourly for 7 days</p>\n<p>Plus metronidazole 2 g stat</p>\n<h3>HC3</h3>\n<p>282</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 349,
        "content": "TREATMENT\nLOC\nHowever if client is pregnant\n\t\n\u0089\nReplace doxycycline with erythromycin 500 mg 6 \nhourly for 7 days or\n \n- Azithromycin 1 g stat\n\t\n\u0089\nTreat the partner\nIf discharge or dysuria still persists and partners treated:\n\t\n\u0089\nRefer for further management\nHC3\n3.2.3 Pelvic Inflammatory Disease (PID)\nSee section 14.1.2\n3.2.4 Genital Ulcer Disease (GUD) Syndrome  ICD10 CODES: \nN76.5-6, N48.5\nGenital ulcer syndrome is one of the commonest syndromes that affect \nmen and women. Single or multiple ulcers can be present.\nCauses\nMultiple organisms can cause genital sores, commonly:\n \n~\nTreponema pallidum bacteria: syphilis\n \n~\nHerpes simplex virus: genital herpes\n \n~\nHaemophilus ducreyi: Chancroid\n \n~\nDonovania granulomatis: Granuloma inguinale\n \n~\nChlamydia strains: lymphogranuloma venerium (LGV)\nClinical features\nMixed infections are common\n \n~\nPrimary syphilis: the ulcer is at first painless and may be \nbetween or on the labia or on the penis\n \n~\nSecondary syphilis: multiple, painless ulcers on the penis \nor vulva\n \n~\nGenital Herpes: small, multiple, usually painful blisters, \n283\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>However if client is pregnant</p>\n<p>\u0089</p>\n<p>Replace doxycycline with erythromycin 500 mg 6</p>\n<p>hourly for 7 days or</p>\n<p>- Azithromycin 1 g stat</p>\n<p>\u0089</p>\n<p>Treat the partner</p>\n<p>If discharge or dysuria still persists and partners treated:</p>\n<p>\u0089</p>\n<p>Refer for further management</p>\n<h3>HC3</h3>\n<p>3.2.3 Pelvic Inflammatory Disease (PID)</p>\n<p>See section 14.1.2</p>\n<p>3.2.4 Genital Ulcer Disease (GUD) Syndrome  ICD10 CODES:</p>\n<h3>N76.5-6, N48.5</h3>\n<p>Genital ulcer syndrome is one of the commonest syndromes that affect</p>\n<p>men and women. Single or multiple ulcers can be present.</p>\n<p>Causes</p>\n<p>Multiple organisms can cause genital sores, commonly:</p>\n<p>~</p>\n<p>Treponema pallidum bacteria: syphilis</p>\n<p>~</p>\n<p>Herpes simplex virus: genital herpes</p>\n<p>~</p>\n<p>Haemophilus ducreyi: Chancroid</p>\n<p>~</p>\n<p>Donovania granulomatis: Granuloma inguinale</p>\n<p>~</p>\n<p>Chlamydia strains: lymphogranuloma venerium (LGV)</p>\n<p>Clinical features</p>\n<p>Mixed infections are common</p>\n<p>~</p>\n<p>Primary syphilis: the ulcer is at first painless and may be</p>\n<p>between or on the labia or on the penis</p>\n<p>~</p>\n<p>Secondary syphilis: multiple, painless ulcers on the penis</p>\n<p>or vulva</p>\n<p>~</p>\n<p>Genital Herpes: small, multiple, usually painful blisters,</p>\n<p>283</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 350,
        "content": "vesicles, or ulcers. Often recurrent\n \n~\nGranuloma inguinale: an irregular ulcer which increases in \nsize and may cover a large area\n \n~\nChancroid: multiple, large, irregular ulcers with enlarged \npainful suppurating lymph nodes\nDifferential diagnosis\n \n~\nCancer of the penis in elderly men\n \n~\nCancer of the vulva in women >50 years\nInvestigations\n \n\u0081\nSwab: for microscopy\n \n\u0081\nBlood: for VDRL/TPR\nPatient complains of ulcers or sores\nYES\nNO\nIf vesicle or blisters persist\nRepeat Acyclovir for 7 days\nIf ulcers still persist\nRefer for specialist\u2019s management\nIf ulcers persist for >10 days \nand partner was treated\nIf ulcers persist for >10 days \nand partner was treated\nTake history and examine. \nIs there presence of history \nof recurrent painful ulcers/\nvesicles?\nAcyclovir 400 mg 6hourly for 7 \ndays and perform RPR test, if \npositive, give Bezathine penicillin \n2.4 MU IM single does (half \ninto each buttock). If allergic to \npenicillin, give Erythromycin 500 \nmg every 6 hours for 14 days.  \nApply acyclovir cream\nCiprofloxacin 500 mg bd for 3 \ndays plus Bezathine penicillin \n2.4 MU IM single does (half \ninto each buttock). If allergic to \npenicillin, give Erythromycin 500 \nmg every 6 hours for 14 days. In \npregnancy avoid Ciprofloxacin.\n284\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>vesicles, or ulcers. Often recurrent</p>\n<p>~</p>\n<p>Granuloma inguinale: an irregular ulcer which increases in</p>\n<p>size and may cover a large area</p>\n<p>~</p>\n<p>Chancroid: multiple, large, irregular ulcers with enlarged</p>\n<p>painful suppurating lymph nodes</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cancer of the penis in elderly men</p>\n<p>~</p>\n<p>Cancer of the vulva in women >50 years</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Swab: for microscopy</p>\n<p>\u0081</p>\n<p>Blood: for VDRL/TPR</p>\n<p>Patient complains of ulcers or sores</p>\n<h3>YES</h3>\n<p>NO</p>\n<p>If vesicle or blisters persist</p>\n<p>Repeat Acyclovir for 7 days</p>\n<p>If ulcers still persist</p>\n<p>Refer for specialist\u2019s management</p>\n<p>If ulcers persist for >10 days</p>\n<p>and partner was treated</p>\n<p>If ulcers persist for >10 days</p>\n<p>and partner was treated</p>\n<p>Take history and examine.</p>\n<p>Is there presence of history</p>\n<p>of recurrent painful ulcers/</p>\n<p>vesicles?</p>\n<p>Acyclovir 400 mg 6hourly for 7</p>\n<p>days and perform RPR test, if</p>\n<p>positive, give Bezathine penicillin</p>\n<p>2.4 MU IM single does (half</p>\n<p>into each buttock). If allergic to</p>\n<p>penicillin, give Erythromycin 500</p>\n<p>mg every 6 hours for 14 days.</p>\n<p>Apply acyclovir cream</p>\n<p>Ciprofloxacin 500 mg bd for 3</p>\n<p>days plus Bezathine penicillin</p>\n<p>2.4 MU IM single does (half</p>\n<p>into each buttock). If allergic to</p>\n<p>penicillin, give Erythromycin 500</p>\n<p>mg every 6 hours for 14 days. In</p>\n<p>pregnancy avoid Ciprofloxacin.</p>\n<p>284</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 351,
        "content": "Management\nTREATMENT\nLOC\nMultiple painful blisters or vesicles: likely herpes\n\t\n\u0089\nAciclovir 400 mg every 6 hours for 7 days\n\t\n\u0089\nIf RPR positive add Benzathine penicillin 2.4 MU IM \nsingle dose (half in each buttock)\n\t\n\u0089\nIf lesions persist, repeat acyclovir for 7 days\nHC4\nHC3\nAll other cases\n\t\n\u0089\nCiprofloxacin 500 mg every 12 hours for 3 days plus \nBenzathine penicillin 2.4 MU IM single dose (half into \neach buttock)\n\t\n\u0089\nIn penicillin allergy, give Erythromycin 500 mg every \n6 hours for 14 days\nIf ulcer persists >10 days and partner was treated\n\t\n\u0089\nAdd Erythromicin 500 mg every 6 hours for 7 days\nIf ulcer still persists\n\t\n\u0089\nRefer for specialist management\nNote\n \n\u0083 Negative RPR does not exclude early syphilis\n \n\u0083 Genital ulcers may appear with enlarged and \nfluctuating inguinal lymph nodes (buboes). Do not \nincise buboes\n285\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Multiple painful blisters or vesicles: likely herpes</p>\n<p>\u0089</p>\n<p>Aciclovir 400 mg every 6 hours for 7 days</p>\n<p>\u0089</p>\n<p>If RPR positive add Benzathine penicillin 2.4 MU IM</p>\n<p>single dose (half in each buttock)</p>\n<p>\u0089</p>\n<p>If lesions persist, repeat acyclovir for 7 days</p>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>All other cases</p>\n<p>\u0089</p>\n<p>Ciprofloxacin 500 mg every 12 hours for 3 days plus</p>\n<p>Benzathine penicillin 2.4 MU IM single dose (half into</p>\n<p>each buttock)</p>\n<p>\u0089</p>\n<p>In penicillin allergy, give Erythromycin 500 mg every</p>\n<p>6 hours for 14 days</p>\n<p>If ulcer persists >10 days and partner was treated</p>\n<p>\u0089</p>\n<p>Add Erythromicin 500 mg every 6 hours for 7 days</p>\n<p>If ulcer still persists</p>\n<p>\u0089</p>\n<p>Refer for specialist management</p>\n<p>Note</p>\n<p>\u0083 Negative RPR does not exclude early syphilis</p>\n<p>\u0083 Genital ulcers may appear with enlarged and</p>\n<p>fluctuating inguinal lymph nodes (buboes). Do not</p>\n<p>incise buboes</p>\n<p>285</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 352,
        "content": "3.2.5 Inguinal Swelling (Bubo)\t\n           ICD 10 CODE: A57\nIt is an STI syndrome presenting as localised swellings or enlarged lymph \nglands in the groin and femoral area.\nCauses\n \n~\nChlamydia strains: lymphogranuloma venerium (LGV)\n \n~\nHeamophilus ducreyi: chancroid\n \n~\nTreponema pallidum: syphilis\nClinical features\n \n~\nExcessively swollen inguinal glands\n \n~\nPain, tenderness\n \n~\nSwellings may become fluctuant if pus forms\nDifferential diagnosis\n \n~\nOther causes of swollen inguinal lymph nodes, e.g. leg ul\u00ad\ncer\n \n~\nObstructed inguinal hernia\nInvestigations\n \n\u0081\nAs for Genital Ulcers\n \n\u0081\nC&S of pus\n286\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.2.5 Inguinal Swelling (Bubo)</p>\n<h3>ICD 10 CODE: A57</h3>\n<p>It is an STI syndrome presenting as localised swellings or enlarged lymph</p>\n<p>glands in the groin and femoral area.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Chlamydia strains: lymphogranuloma venerium (LGV)</p>\n<p>~</p>\n<p>Heamophilus ducreyi: chancroid</p>\n<p>~</p>\n<p>Treponema pallidum: syphilis</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Excessively swollen inguinal glands</p>\n<p>~</p>\n<p>Pain, tenderness</p>\n<p>~</p>\n<p>Swellings may become fluctuant if pus forms</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of swollen inguinal lymph nodes, e.g. leg ul\u00ad</p>\n<p>cer</p>\n<p>~</p>\n<p>Obstructed inguinal hernia</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>As for Genital Ulcers</p>\n<p>\u0081</p>\n<p>C&S of pus</p>\n<p>286</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 353,
        "content": "Patient complains of inguinal swelling\nIf genital ulcer is present\nTreat as genital ulcer\nIf no improvement\nRefer for specialist\u2019s management\nIf buboes persist, check to see if partner \nwas treated. If partner not treated\nContinue with Doxycycline 100 mg 12 \nhourly for 14 days or Erythromycin 500 \nmg every 6 hours for 14 days.\nInguinal/femoral buboes \npresent and no ulcer\nGive Doxycycline 100 mg 12 hourly for 14 days. \nTreat partner. If partner pregnant, instead of Dox\u00ad\nycycline give Erythromycin 500 mg every 6 hours \nfor 14 days. Do not incise bubo. Aspirate through \nnormal skin with a large bore needle gauge <20 \nevery 2 days until resolution.\nTake history and examine for genital \nulcers, rule out infection of the foot, leg \nor buttock and exclude inguinal hernia\n287\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Patient complains of inguinal swelling</p>\n<p>If genital ulcer is present</p>\n<p>Treat as genital ulcer</p>\n<p>If no improvement</p>\n<p>Refer for specialist\u2019s management</p>\n<p>If buboes persist, check to see if partner</p>\n<p>was treated. If partner not treated</p>\n<p>Continue with Doxycycline 100 mg 12</p>\n<p>hourly for 14 days or Erythromycin 500</p>\n<p>mg every 6 hours for 14 days.</p>\n<p>Inguinal/femoral buboes</p>\n<p>present and no ulcer</p>\n<p>Give Doxycycline 100 mg 12 hourly for 14 days.</p>\n<p>Treat partner. If partner pregnant, instead of Dox\u00ad</p>\n<p>ycycline give Erythromycin 500 mg every 6 hours</p>\n<p>for 14 days. Do not incise bubo. Aspirate through</p>\n<p>normal skin with a large bore needle gauge <20</p>\n<p>every 2 days until resolution.</p>\n<p>Take history and examine for genital</p>\n<p>ulcers, rule out infection of the foot, leg</p>\n<p>or buttock and exclude inguinal hernia</p>\n<p>287</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 354,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nExamine for genital ulcers, rule out infection of the foot, \nleg or buttock and exclude inguinal hernia\n\t\n\u0089\nIf genital ulcer is present, treat as per above protocol\n\t\n\u0089\nGive doxycycline 100 mg 12 hourly for 14 days\n\t\n\u0089\nTreat partner\nIf partner is pregnant\n\t\n\u0089\nGive erythromycin 500 mg every 6 hours for 14 days\nIf bubo persisting, and partner was not treated\n\t\n\u0089\nContinue treatment for 14 days\nIf not improving\n\t\n\u0089\nRefer for specialist management\nHC2\nHC3\nCaution\n \n\u0083 Do not incise bubo. Aspirate through normal skin with a large \nbore needle gauge <20 every 2 days until resolution\n \n\u0083 Alternative to doxycycline: azithromycin 1 g single dose\n3.2.6 Genital Warts                    ICD10 CODE: A63.0\nSuperficial mucocutaneous infection\nCauses\n \n~\nHuman papilloma virus (HPV): causes viral warts (condyl \nmata acuminata)\n \n~\nTreponema pallidum: causes syphilitic warts (condylomata \nlata)\n \n~\nMolluscum contagiosum virus\n288\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Examine for genital ulcers, rule out infection of the foot,</p>\n<p>leg or buttock and exclude inguinal hernia</p>\n<p>\u0089</p>\n<p>If genital ulcer is present, treat as per above protocol</p>\n<p>\u0089</p>\n<p>Give doxycycline 100 mg 12 hourly for 14 days</p>\n<p>\u0089</p>\n<p>Treat partner</p>\n<p>If partner is pregnant</p>\n<p>\u0089</p>\n<p>Give erythromycin 500 mg every 6 hours for 14 days</p>\n<p>If bubo persisting, and partner was not treated</p>\n<p>\u0089</p>\n<p>Continue treatment for 14 days</p>\n<p>If not improving</p>\n<p>\u0089</p>\n<p>Refer for specialist management</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Caution</p>\n<p>\u0083 Do not incise bubo. Aspirate through normal skin with a large</p>\n<p>bore needle gauge <20 every 2 days until resolution</p>\n<p>\u0083 Alternative to doxycycline: azithromycin 1 g single dose</p>\n<p>3.2.6 Genital Warts                    ICD10 CODE: A63.0</p>\n<p>Superficial mucocutaneous infection</p>\n<p>Causes</p>\n<p>~</p>\n<p>Human papilloma virus (HPV): causes viral warts (condyl</p>\n<p>mata acuminata)</p>\n<p>~</p>\n<p>Treponema pallidum: causes syphilitic warts (condylomata</p>\n<p>lata)</p>\n<p>~</p>\n<p>Molluscum contagiosum virus</p>\n<p>288</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 355,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nAdvise on personal hygiene\n\t\n\u0089\nTreat underlying infection\nHPV viral warts\n\t\n\u0089\nApply podophyllum resin paint 15% to the warts 1\u20133 \ntimes weekly until warts have resolved; may require \nmultiple weekly treatments\n \n- Protect normal skin with petroleum jelly before \napplication\n \n- Apply precisely on the lesion avoiding normal \nskin\n \n- Wash off with water 4 hours after each application\n \n\u0083 Do not use in pregnancy\nIf no improvement after 3 applications\n\t\n\u0089\nRefer for specialist management\nSyphilitic Warts\n\t\n\u0089\nGive: benzathine penicillin injection 2.4 MU single dose \n(half into each buttock)\nHC4\nHC3\nClinical features\n \n~\nPenis, foreskin, labia and vagina are the most common sites \nof the warts\n \n~\nWarts can be variable in number and size, either few or \nmultiple, small to very large\n \n~\nHPV warts: soft fleshy growth on genitals\n \n~\nSyphilitic warts: flat-topped and broad based growth\n \n~\nMolluscum contagiosum: light coloured, umbilicated \ngrowths on the face and genital areas\nDifferential diagnosis\n \n~\nRashes\n \n~\nEruptive skin lesions\n289\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Advise on personal hygiene</p>\n<p>\u0089</p>\n<p>Treat underlying infection</p>\n<p>HPV viral warts</p>\n<p>\u0089</p>\n<p>Apply podophyllum resin paint 15% to the warts 1\u20133</p>\n<p>times weekly until warts have resolved; may require</p>\n<p>multiple weekly treatments</p>\n<p>- Protect normal skin with petroleum jelly before</p>\n<p>application</p>\n<p>- Apply precisely on the lesion avoiding normal</p>\n<p>skin</p>\n<p>- Wash off with water 4 hours after each application</p>\n<p>\u0083 Do not use in pregnancy</p>\n<p>If no improvement after 3 applications</p>\n<p>\u0089</p>\n<p>Refer for specialist management</p>\n<p>Syphilitic Warts</p>\n<p>\u0089</p>\n<p>Give: benzathine penicillin injection 2.4 MU single dose</p>\n<p>(half into each buttock)</p>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>Clinical features</p>\n<p>~</p>\n<p>Penis, foreskin, labia and vagina are the most common sites</p>\n<p>of the warts</p>\n<p>~</p>\n<p>Warts can be variable in number and size, either few or</p>\n<p>multiple, small to very large</p>\n<p>~</p>\n<p>HPV warts: soft fleshy growth on genitals</p>\n<p>~</p>\n<p>Syphilitic warts: flat-topped and broad based growth</p>\n<p>~</p>\n<p>Molluscum contagiosum: light coloured, umbilicated</p>\n<p>growths on the face and genital areas</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Rashes</p>\n<p>~</p>\n<p>Eruptive skin lesions</p>\n<p>289</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 356,
        "content": "TREATMENT\nLOC\nMolluscum contagiosum\n\t\n\u0089\nUsually self limiting\n\t\n\u0089\nTreat underlying conditions that may be compromising \nthe person\u2019s immunity\n3.2.7 Syphilis\t\n                ICD10 CODE: A51-53\nComplex chronic bacterial infection affecting a variety of organs and \nwith multiple manifestations.\nCause\n \n~\nTreponema pallidum\n \n~\nTransmitted sexually and from mother to foetus, rarely \nthrough blood transfusion or non sexual contact\nClinical features\nThe disease has several stages\n \n~\nPrimary syphilis: 10-90 days following inoculation, char\u00ad\nacterized by a painless genital ulcer with clean base and \nindurated margins, regional lymphadenopathy. It can heal \nspontaneously but the disease will progress to secondary \nlesions\n \n~\nSecondary syphilis: few weeks to months (max 6 months) \nfrom primary lesions, characterised by:\n\t\n\u0089\nGeneralised maculopapular rash\n\t\n\u0089\nMucous membranes lesions (patches and ulcers)\n\t\n\u0089\nWeeping papules (condyloma alata) in moist skin areas\n\t\n\u0089\nGeneralized non tender lymphadenopathy\n290\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Molluscum contagiosum</p>\n<p>\u0089</p>\n<p>Usually self limiting</p>\n<p>\u0089</p>\n<p>Treat underlying conditions that may be compromising</p>\n<p>the person\u2019s immunity</p>\n<p>3.2.7 Syphilis</p>\n<h3>ICD10 CODE: A51-53</h3>\n<p>Complex chronic bacterial infection affecting a variety of organs and</p>\n<p>with multiple manifestations.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Treponema pallidum</p>\n<p>~</p>\n<p>Transmitted sexually and from mother to foetus, rarely</p>\n<p>through blood transfusion or non sexual contact</p>\n<p>Clinical features</p>\n<p>The disease has several stages</p>\n<p>~</p>\n<p>Primary syphilis: 10-90 days following inoculation, char\u00ad</p>\n<p>acterized by a painless genital ulcer with clean base and</p>\n<p>indurated margins, regional lymphadenopathy. It can heal</p>\n<p>spontaneously but the disease will progress to secondary</p>\n<p>lesions</p>\n<p>~</p>\n<p>Secondary syphilis: few weeks to months (max 6 months)</p>\n<p>from primary lesions, characterised by:</p>\n<p>\u0089</p>\n<p>Generalised maculopapular rash</p>\n<p>\u0089</p>\n<p>Mucous membranes lesions (patches and ulcers)</p>\n<p>\u0089</p>\n<p>Weeping papules (condyloma alata) in moist skin areas</p>\n<p>\u0089</p>\n<p>Generalized non tender lymphadenopathy</p>\n<p>290</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 357,
        "content": "\u0089\nFever, meningitis, hepatitis, osteitis, arthritis, iritis\n \n~\nEarly latent syphilis (<1 year in duration): clinically quies\u00ad\ncent but possible relapse of secondary syphilis\n \n~\nLate latent syphilis: clinically quiescent, not very infectious \n(but possible maternal foetal transmission)\n \n~\nLate (tertiary) syphilis: at any time after secondary syphilis \n(even many years):\n \n- nfiltrative tumour of skin, bones, liver\n \n- Aortitis, aneurysms, aortic regurgitation\n \n- Central nervous system disorders (neurosyphilis): meningo \nvascular \nsyphilis, \nhemiparesis, \nseizures, \nprogressive \ndegeneration with paraesthesias, shooting pains, dementia, \npsychosis\nInvestigations\n \n\u0081\nNon-treponemal antibody tests (VDRL and RPR)\n \n- Positive 4-6 weeks after infection\n \n- Used as screening test\n \n- Possibility of false positive\n \n- Remains positive 6-12 months after treatment\n \n\u0081\nTreponemal antibody tests (TPHA): very sensitive, used to confirm \na positive non-treponemal test. Remains positive for long even \nafter treatment so its positivity may not indicate active disease.\nManagement\nTREATMENT\nLOC\nPrimary, seconday and early latent syphilis\n\t\n\u0089\nBenzathine penicillin 2.4 million IU IM stat, half in \neach buttock\n\t\n\u0089\nor Doxycycline 100 mg every 12 hours for 14 days\nHC3\n291\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>\u0089</p>\n<p>Fever, meningitis, hepatitis, osteitis, arthritis, iritis</p>\n<p>~</p>\n<p>Early latent syphilis (<1 year in duration): clinically quies\u00ad</p>\n<p>cent but possible relapse of secondary syphilis</p>\n<p>~</p>\n<p>Late latent syphilis: clinically quiescent, not very infectious</p>\n<p>(but possible maternal foetal transmission)</p>\n<p>~</p>\n<p>Late (tertiary) syphilis: at any time after secondary syphilis</p>\n<p>(even many years):</p>\n<p>- nfiltrative tumour of skin, bones, liver</p>\n<p>- Aortitis, aneurysms, aortic regurgitation</p>\n<p>- Central nervous system disorders (neurosyphilis): meningo</p>\n<p>vascular</p>\n<p>syphilis,</p>\n<p>hemiparesis,</p>\n<p>seizures,</p>\n<p>progressive</p>\n<p>degeneration with paraesthesias, shooting pains, dementia,</p>\n<p>psychosis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Non-treponemal antibody tests (VDRL and RPR)</p>\n<p>- Positive 4-6 weeks after infection</p>\n<p>- Used as screening test</p>\n<p>- Possibility of false positive</p>\n<p>- Remains positive 6-12 months after treatment</p>\n<p>\u0081</p>\n<p>Treponemal antibody tests (TPHA): very sensitive, used to confirm</p>\n<p>a positive non-treponemal test. Remains positive for long even</p>\n<p>after treatment so its positivity may not indicate active disease.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Primary, seconday and early latent syphilis</p>\n<p>\u0089</p>\n<p>Benzathine penicillin 2.4 million IU IM stat, half in</p>\n<p>each buttock</p>\n<p>\u0089</p>\n<p>or Doxycycline 100 mg every 12 hours for 14 days</p>\n<h3>HC3</h3>\n<p>291</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 358,
        "content": "Management\nTREATMENT\nLOC\nLate latent or uncertain duration, or tertiary without \nneurosyphilis\n\t\n\u0089\nBenzathine penicillin 2.4 million IU IM weekly for 3 weeks\n\t\n\u0089\nOr Doxycycline 100 mg every 12 hours for 28 days\nHC3\nNeurosyphilis\n\t\n\u0089\nBenzylpenicillin 4 million IU IV every 4 hours or\n\t\n\u0089\nCeftriaxone 2 g IV or IM daily for 10-14 days\nHC2\nHC3\nFollowed by\n\t\n\u0089\nBenzathine penicillin 2.4 million IU IM weekly for 3 weeks\n\t\n\u0089\nTreat partner(s), abstain from sex during treatment and \n10 days after\nHC3\n3.2.8\t\n Other Genital Infections\n3.2.8.1\t Balanitis                        ICD10 CODE: N48.1\nInflammation of the glans penis\nCause\n \n~\nUsually caused by Candida, rarely by Trichomonas\nClinical features\n \n~\nDischarge, erythema, erosions\n \n~\nPrepuce is retractable\n292\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Late latent or uncertain duration, or tertiary without</p>\n<p>neurosyphilis</p>\n<p>\u0089</p>\n<p>Benzathine penicillin 2.4 million IU IM weekly for 3 weeks</p>\n<p>\u0089</p>\n<p>Or Doxycycline 100 mg every 12 hours for 28 days</p>\n<h3>HC3</h3>\n<p>Neurosyphilis</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 4 million IU IV every 4 hours or</p>\n<p>\u0089</p>\n<p>Ceftriaxone 2 g IV or IM daily for 10-14 days</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Followed by</p>\n<p>\u0089</p>\n<p>Benzathine penicillin 2.4 million IU IM weekly for 3 weeks</p>\n<p>\u0089</p>\n<p>Treat partner(s), abstain from sex during treatment and</p>\n<p>10 days after</p>\n<h3>HC3</h3>\n<p>3.2.8</p>\n<p>Other Genital Infections</p>\n<p>3.2.8.1\t Balanitis                        ICD10 CODE: N48.1</p>\n<p>Inflammation of the glans penis</p>\n<p>Cause</p>\n<p>~</p>\n<p>Usually caused by Candida, rarely by Trichomonas</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Discharge, erythema, erosions</p>\n<p>~</p>\n<p>Prepuce is retractable</p>\n<p>292</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 359,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nFluconazole 200 mg stat\n\t\n\u0089\nPlus metronidazole 400 mg every 12 hours for 7 days\n\t\n\u0089\nAdvise on hygiene and circumcision\nIf not better:\n\t\n\u0089\nTreat partner\nHC3\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat as per urethral discharge protocol above (section \n3.2.1)\nHC3\n3.2.8.2\t Painful Scrotal Swelling\t                 ICD10 CODE: N45\n \n~\nInflammation of epididymis and testis\nCauses\n\t\n\u0089\nUsually caused by N. gonorrhoea, Chlamydia\n\t\n\u0089\nClinical features\n\t\n\u0089\nAcute painful and tender unilateral swelling of epididymus and testis, \nwith or without urethral discharge\n Differential diagnosis\n \n~\nAcute testicular torsion\n \n~\nScrotal hernia, tumors\n293\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Fluconazole 200 mg stat</p>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg every 12 hours for 7 days</p>\n<p>\u0089</p>\n<p>Advise on hygiene and circumcision</p>\n<p>If not better:</p>\n<p>\u0089</p>\n<p>Treat partner</p>\n<h3>HC3</h3>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat as per urethral discharge protocol above (section</p>\n<p>3.2.1)</p>\n<h3>HC3</h3>\n<p>3.2.8.2\t Painful Scrotal Swelling\t                 ICD10 CODE: N45</p>\n<p>~</p>\n<p>Inflammation of epididymis and testis</p>\n<p>Causes</p>\n<p>\u0089</p>\n<p>Usually caused by N. gonorrhoea, Chlamydia</p>\n<p>\u0089</p>\n<p>Clinical features</p>\n<p>\u0089</p>\n<p>Acute painful and tender unilateral swelling of epididymus and testis,</p>\n<p>with or without urethral discharge</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Acute testicular torsion</p>\n<p>~</p>\n<p>Scrotal hernia, tumors</p>\n<p>293</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 360,
        "content": "3.2.9 Congenital STI Syndromes\nCongenital STIs in newborns occur as a result of infection of babies \nin utero or during delivery as a complication of untreated STIs among \nmothers. Syphilis, HIV, gonococcal, chlamydia and herpes simplex are \nthe most serious congenital STIs.\n3.2.9.1\t Neonatal Conjunctivitis (Ophthalmia Neonatorum)\t\nICD10 CODE: P39.1\nRefers to conjunctival infection of neonates by STI organisms in the \ninfected mother\u2019s birth canal. It is a very serious condition that can lead \nto corneal ulceration and ultimately to blindness. Blindness in children \nis associated with high infant morbidity and mortality.\nCauses\n \n~\nCommonly caused by Neisseria gonorrhoeae and\n \n~\nChlamydia trachomatis\n \n~\nOther non-STI causes of neonatal conjunctivitis predis\u00ad\nposed by difficult labour such as early rupture of mem\u00ad\nbranes, vacuum extraction or other assisted vaginal delivery\nClinical features\n \n~\nPurulent discharge from one or both eyes within 30 days \nfrom birth\n \n~\nInflamed and swollen eyelids\n \n~\nComplications of untreated conjuctivitis: corneal ulceration, \nperforation, scarring and blindness\nInvestigations\n \n\u0081\nPus swab: Gram stain, Culture & Sensitivity\n294\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>3.2.9 Congenital STI Syndromes</p>\n<p>Congenital STIs in newborns occur as a result of infection of babies</p>\n<p>in utero or during delivery as a complication of untreated STIs among</p>\n<p>mothers. Syphilis, HIV, gonococcal, chlamydia and herpes simplex are</p>\n<p>the most serious congenital STIs.</p>\n<p>3.2.9.1\t Neonatal Conjunctivitis (Ophthalmia Neonatorum)</p>\n<h3>ICD10 CODE: P39.1</h3>\n<p>Refers to conjunctival infection of neonates by STI organisms in the</p>\n<p>infected mother\u2019s birth canal. It is a very serious condition that can lead</p>\n<p>to corneal ulceration and ultimately to blindness. Blindness in children</p>\n<p>is associated with high infant morbidity and mortality.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Commonly caused by Neisseria gonorrhoeae and</p>\n<p>~</p>\n<p>Chlamydia trachomatis</p>\n<p>~</p>\n<p>Other non-STI causes of neonatal conjunctivitis predis\u00ad</p>\n<p>posed by difficult labour such as early rupture of mem\u00ad</p>\n<p>branes, vacuum extraction or other assisted vaginal delivery</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Purulent discharge from one or both eyes within 30 days</p>\n<p>from birth</p>\n<p>~</p>\n<p>Inflamed and swollen eyelids</p>\n<p>~</p>\n<p>Complications of untreated conjuctivitis: corneal ulceration,</p>\n<p>perforation, scarring and blindness</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pus swab: Gram stain, Culture & Sensitivity</p>\n<p>294</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 361,
        "content": "Management\nTREATMENT\nLOC\nTreatment should cover both gonorrhoea and chlamydia\n\t\n\u0089\nStart cleaning with normal saline and apply tetracycline \nointment every hour while referring for systemic treatment\n\t\n\u0089\nCeftriaxone 125 mg single dose IM plus azithromycin \nsyrup 20 mg/kg orally, once daily for 3 days\n\t\n\u0089\nIrrigate the eyes with saline or sterile water\n\t\n\u0089\nUse gloves and wash hands thoroughly after handling \nthe eyelids\n\t\n\u0089\nCover the eye with gauze while opening the eyelid as \npus may be under pressure\n\t\n\u0089\nTopical tetracycline eye ointment has NO added benefit \nin active disease\n\t\n\u0089\nTreat both parents for Gonorrhoea and Chlamydia and \nscreen for HIV and syphilis\nHC2\nHC3\nPrevention\n \n~\nScreen and treat all infected mothers in antenatal care\n \n~\nApply prophylactic tetracycline eye ointment 1% to both \neyes of ALL newborns at the time of delivery\n \n~\n3.2.9.2\t Congenital Syphilis\t\n            ICD10 CODE: A50 \nIt is a serious debilitating and disfiguring condition that can   be fatal. \nAbout one third of syphilis infected mothers have adverse pregnancy \noutcome, one third give birth to a healthy baby, while the remaining \nthird may result into congenital syphilis infection.\nCause\n \n~\nTreponema pallidum bacteria\n295\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment should cover both gonorrhoea and chlamydia</p>\n<p>\u0089</p>\n<p>Start cleaning with normal saline and apply tetracycline</p>\n<p>ointment every hour while referring for systemic treatment</p>\n<p>\u0089</p>\n<p>Ceftriaxone 125 mg single dose IM plus azithromycin</p>\n<p>syrup 20 mg/kg orally, once daily for 3 days</p>\n<p>\u0089</p>\n<p>Irrigate the eyes with saline or sterile water</p>\n<p>\u0089</p>\n<p>Use gloves and wash hands thoroughly after handling</p>\n<p>the eyelids</p>\n<p>\u0089</p>\n<p>Cover the eye with gauze while opening the eyelid as</p>\n<p>pus may be under pressure</p>\n<p>\u0089</p>\n<p>Topical tetracycline eye ointment has NO added benefit</p>\n<p>in active disease</p>\n<p>\u0089</p>\n<p>Treat both parents for Gonorrhoea and Chlamydia and</p>\n<p>screen for HIV and syphilis</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Screen and treat all infected mothers in antenatal care</p>\n<p>~</p>\n<p>Apply prophylactic tetracycline eye ointment 1% to both</p>\n<p>eyes of ALL newborns at the time of delivery</p>\n<p>~</p>\n<p>3.2.9.2\t Congenital Syphilis</p>\n<h3>ICD10 CODE: A50</h3>\n<p>It is a serious debilitating and disfiguring condition that can   be fatal.</p>\n<p>About one third of syphilis infected mothers have adverse pregnancy</p>\n<p>outcome, one third give birth to a healthy baby, while the remaining</p>\n<p>third may result into congenital syphilis infection.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Treponema pallidum bacteria</p>\n<p>295</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 362,
        "content": "Clinical features\n \n~\nMay be asymptomatic\n \n~\nEarly congenital syphilis: begins to show after 6-8 weeks \nof delivery\n \n- Snuffle, palmar/plantar bullae, hepatosplenomegaly, pallor, \njoint swelling with or without paralysis and cutaneous lesions. \nThese signs are non-specific.\n \n~\nLate congenital syphilis: begins to show at 2 years\n \n- Microcephaly, depressed nasal bridge, arched palate, \nperforated nasal septum, failure to thrive, mental sub \nnormality and musculoskeletal abnormalities\nInvestigations\nPreferably perform the tests on mother:\n \n\u0081\nVDRL/RPR\n \n\u0081\nTPHA\nManagement of congenital syphilis\nTREATMENT\nLOC\n\t\n\u0089\nAssume cerebrospinal involvement in all babies less \nthan 2 years\n\t\n\u0089\nAqueous benzylpenicillin 150,000 IU/kg body weight \nIV every 12 hours for a total of 10 days\n\t\n\u0089\nOR procaine penicillin, 50,000 IU/kg body weight, IM \nsingle dose daily for 10 days\n\t\n\u0089\nTreat both parents for syphilis with benzathine penicillin \n2.4 MU single dose (half on each buttock)\nHC3\nNote\n \n\u0083 Assume that infants whose mothers had untreated \nsyphilis or started treatment within 30 days of \ndelivery have congenital syphilis\n \n\u0083 If mother is diagnosed with syphilis during\n296\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>May be asymptomatic</p>\n<p>~</p>\n<p>Early congenital syphilis: begins to show after 6-8 weeks</p>\n<p>of delivery</p>\n<p>- Snuffle, palmar/plantar bullae, hepatosplenomegaly, pallor,</p>\n<p>joint swelling with or without paralysis and cutaneous lesions.</p>\n<p>These signs are non-specific.</p>\n<p>~</p>\n<p>Late congenital syphilis: begins to show at 2 years</p>\n<p>- Microcephaly, depressed nasal bridge, arched palate,</p>\n<p>perforated nasal septum, failure to thrive, mental sub</p>\n<p>normality and musculoskeletal abnormalities</p>\n<p>Investigations</p>\n<p>Preferably perform the tests on mother:</p>\n<p>\u0081</p>\n<h3>VDRL/RPR</h3>\n<p>\u0081</p>\n<h3>TPHA</h3>\n<p>Management of congenital syphilis</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Assume cerebrospinal involvement in all babies less</p>\n<p>than 2 years</p>\n<p>\u0089</p>\n<p>Aqueous benzylpenicillin 150,000 IU/kg body weight</p>\n<p>IV every 12 hours for a total of 10 days</p>\n<p>\u0089</p>\n<p>OR procaine penicillin, 50,000 IU/kg body weight, IM</p>\n<p>single dose daily for 10 days</p>\n<p>\u0089</p>\n<p>Treat both parents for syphilis with benzathine penicillin</p>\n<p>2.4 MU single dose (half on each buttock)</p>\n<h3>HC3</h3>\n<p>Note</p>\n<p>\u0083 Assume that infants whose mothers had untreated</p>\n<p>syphilis or started treatment within 30 days of</p>\n<p>delivery have congenital syphilis</p>\n<p>\u0083 If mother is diagnosed with syphilis during</p>\n<p>296</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 363,
        "content": "TREATMENT\nLOC\n \n\u0083 pregnancy, use benzathine penicilln as first line \nsince erythromycin does not cross the placental \nbarrier and therefore does not effectively prevent in \nutero acquisition of congenital syphilis\n \n\u0083 Do not use doxycycline in pregnancy\nPrevention\n \n~\nRoutine screening and treatment of syphilis infected moth\u00ad\ners in antenatal clinics\n297\nUganda Clinical Guidelines 2023\nCHAPTER 3: HIV/AIDS and Sexually Transmitted Infections",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0083 pregnancy, use benzathine penicilln as first line</p>\n<p>since erythromycin does not cross the placental</p>\n<p>barrier and therefore does not effectively prevent in</p>\n<p>utero acquisition of congenital syphilis</p>\n<p>\u0083 Do not use doxycycline in pregnancy</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Routine screening and treatment of syphilis infected moth\u00ad</p>\n<p>ers in antenatal clinics</p>\n<p>297</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 3: HIV/AIDS and Sexually Transmitted Infections</p>"
    },
    {
        "page_number": 364,
        "content": "4.1.1\t\nThrombosis/Pulmonary Embolism (DVT/PE)                                  \nICD10 CODE: I82.409\nClot formation within the deep venous system, usually of the calf, thigh, \nor pelvic veins. The clot can cause a local problem at site of formation \nor dislodge, leading to thromboembolism in various parts of the body, \nparticularly the lungs (pulmonary embolism).\nCauses\n \n~\nVenous stasis (slowing of blood flow)\n \n~\nIncreased coagulability states\n \n~\nEndothelial injury\nRisk factors\n \n~\nImmobilisation, prolonged bed rest, surgery, limb paralysis\n \n~\nHeart failure, myocardial infarction\n \n~\nBlunt trauma, venous injury including cannulation\n \n~\nOral contraceptive pills, pregnancy and postpartum\n \n~\nMalignancies and some forms of chemotherapy\n \n~\nLong distance airtravel\n \n~\nInherited thrombophilic states\n \n~\nFor PE: any other cause of dyspnoea and chest pain e.g. \nbronchopneumonia and myocardial infarction\nCardiovascular Diseases\n4\n298\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>4.1.1</p>\n<p>Thrombosis/Pulmonary Embolism (DVT/PE)</p>\n<h3>ICD10 CODE: I82.409</h3>\n<p>Clot formation within the deep venous system, usually of the calf, thigh,</p>\n<p>or pelvic veins. The clot can cause a local problem at site of formation</p>\n<p>or dislodge, leading to thromboembolism in various parts of the body,</p>\n<p>particularly the lungs (pulmonary embolism).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Venous stasis (slowing of blood flow)</p>\n<p>~</p>\n<p>Increased coagulability states</p>\n<p>~</p>\n<p>Endothelial injury</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Immobilisation, prolonged bed rest, surgery, limb paralysis</p>\n<p>~</p>\n<p>Heart failure, myocardial infarction</p>\n<p>~</p>\n<p>Blunt trauma, venous injury including cannulation</p>\n<p>~</p>\n<p>Oral contraceptive pills, pregnancy and postpartum</p>\n<p>~</p>\n<p>Malignancies and some forms of chemotherapy</p>\n<p>~</p>\n<p>Long distance airtravel</p>\n<p>~</p>\n<p>Inherited thrombophilic states</p>\n<p>~</p>\n<p>For PE: any other cause of dyspnoea and chest pain e.g.</p>\n<p>bronchopneumonia and myocardial infarction</p>\n<p>Cardiovascular Diseases</p>\n<p>4</p>\n<p>298</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 365,
        "content": "Clinical  features\n \n~\n50% of cases may be clinically silent\n \n~\nPain, swelling and warmth of the calf, thigh, and groin\n \n~\nDislodgement of the thrombus may lead to pulmonary em\u00ad\nbolism characterised by dyspnoea, tachycardia, chest pain, \nhypotension\n \n~\nHalf of the cases of PE are associated with silent DVT\nDifferential diagnosis\n \n\u0081\nCellulitis, myositis, phlebitis, contusion\n \n\u0081\nFor PE: any other cause of dyspnoea and chest pain\nInvestigations\nCompression ultrasound +/- doppler\n\t\u00bb In case of pulmonary embolism: chest CT angiogram\n\t\u00bb Other useful tests (not specific): blood D-dimer, ECG, Chest X ray, \necho cardiogram\nManagement\nTREATMENT\nLOC\n Enoxaparin (Low molecular weight heparin- LMWH) 1 mg/\nkg every 12 hours for at least 5 days\n \n- No monitoring is required\n Plus warfarin 5 mg single dose given in the evening, com\u00ad\nmencing on the same day as the heparin\n \n- Maintenance dose: 2.5-7.5 mg single dose daily,\n \n- adjusted according to the INR 2 -3\nIf enoxaparin not available\n \n- Unfractionated heparin given as: 5000 units IV \nbolus and then 1000 units hourly or 17500 units \nsubcutaneuosly 12 hourly for 5 days. Adjust dose \naccording to activated partial thromboplastin \ntime (APTT)\nH\nH\nH\n299\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Clinical  features</p>\n<p>~</p>\n<p>50% of cases may be clinically silent</p>\n<p>~</p>\n<p>Pain, swelling and warmth of the calf, thigh, and groin</p>\n<p>~</p>\n<p>Dislodgement of the thrombus may lead to pulmonary em\u00ad</p>\n<p>bolism characterised by dyspnoea, tachycardia, chest pain,</p>\n<p>hypotension</p>\n<p>~</p>\n<p>Half of the cases of PE are associated with silent DVT</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Cellulitis, myositis, phlebitis, contusion</p>\n<p>\u0081</p>\n<p>For PE: any other cause of dyspnoea and chest pain</p>\n<p>Investigations</p>\n<p>Compression ultrasound +/- doppler</p>\n<p>\u00bb In case of pulmonary embolism: chest CT angiogram</p>\n<p>\u00bb Other useful tests (not specific): blood D-dimer, ECG, Chest X ray,</p>\n<p>echo cardiogram</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Enoxaparin (Low molecular weight heparin- LMWH) 1 mg/</p>\n<p>kg every 12 hours for at least 5 days</p>\n<p>- No monitoring is required</p>\n<p>Plus warfarin 5 mg single dose given in the evening, com\u00ad</p>\n<p>mencing on the same day as the heparin</p>\n<p>- Maintenance dose: 2.5-7.5 mg single dose daily,</p>\n<p>- adjusted according to the INR 2 -3</p>\n<p>If enoxaparin not available</p>\n<p>- Unfractionated heparin given as: 5000 units IV</p>\n<p>bolus and then 1000 units hourly or 17500 units</p>\n<p>subcutaneuosly 12 hourly for 5 days. Adjust dose</p>\n<p>according to activated partial thromboplastin</p>\n<p>time (APTT)</p>\n<p>H</p>\n<p>H</p>\n<p>H</p>\n<p>299</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 366,
        "content": "Management\nTREATMENT\nLOC\n \n- Or 333 units/kg SC as an initial dose followed by \n250 units/kg SC every 12 hours\n \n- Plus warfarin as above\nAlternative to warfarin and heparin combination:\nRivaroxiban\n \n- No need to initiate with heparin\n \n- Dose: 15mg orally twice a day for 3 weeks then \n20mg daily for the duration of anticoagulation. \n \n- Patients must take the drug at the same time \nevery day to prevent re-thrombosis.\n \n- Not to be used in pregnant or breast feeding \nmothers\n \n- Associated with reduced bleeding risk compared \nto warfarin\nApixaban\n \n- Dose: 10mg twice a day for 7 days then 5mg \ntwice a day for the duration of the anticoagulation\n \n- Associated with a reduced bleeding risk than \nwarfarin\n \n- Not to be used in pregnant or breast-feeding \nmothers\nH\nNotes\n \n\u0083 Monitor for bleeding complications\n \n\u0083 When using Apixaban, patients should be asked to \nambulate as soon as possible\n \n\u0083 See section 1.3.10. for treatment of warfarin \noverdose and PGD 2015 monograph on protamine \nfor excessive heparin dose\n \n\u0083 Do not start therapy with warfarin alone because it \ninitially increases risk of thrombus progression\n300\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Or 333 units/kg SC as an initial dose followed by</p>\n<p>250 units/kg SC every 12 hours</p>\n<p>- Plus warfarin as above</p>\n<p>Alternative to warfarin and heparin combination:</p>\n<p>Rivaroxiban</p>\n<p>- No need to initiate with heparin</p>\n<p>- Dose: 15mg orally twice a day for 3 weeks then</p>\n<p>20mg daily for the duration of anticoagulation.</p>\n<p>- Patients must take the drug at the same time</p>\n<p>every day to prevent re-thrombosis.</p>\n<p>- Not to be used in pregnant or breast feeding</p>\n<p>mothers</p>\n<p>- Associated with reduced bleeding risk compared</p>\n<p>to warfarin</p>\n<p>Apixaban</p>\n<p>- Dose: 10mg twice a day for 7 days then 5mg</p>\n<p>twice a day for the duration of the anticoagulation</p>\n<p>- Associated with a reduced bleeding risk than</p>\n<p>warfarin</p>\n<p>- Not to be used in pregnant or breast-feeding</p>\n<p>mothers</p>\n<p>H</p>\n<p>Notes</p>\n<p>\u0083 Monitor for bleeding complications</p>\n<p>\u0083 When using Apixaban, patients should be asked to</p>\n<p>ambulate as soon as possible</p>\n<p>\u0083 See section 1.3.10. for treatment of warfarin</p>\n<p>overdose and PGD 2015 monograph on protamine</p>\n<p>for excessive heparin dose</p>\n<p>\u0083 Do not start therapy with warfarin alone because it</p>\n<p>initially increases risk of thrombus progression</p>\n<p>300</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 367,
        "content": "Prevention\n \n\u0083 Early mobilisation\n \n\u0083 Prophylaxis with enoxaparin 40 mg SC daily in any acutely ill \nmedical patient and in prolonged admission\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nLow molecular weight heparin- \n \n- (LMWH) e.g., Enoxaparin given as 1 mg/kg \n \n- every 12 hours or 1.5mg/kg once a day, for at \nleast 5 days \n\t\n\u0089\nPlus warfarin 5 mg single dose given in the evening, \ncommencing on the same day as the heparin. Overlap \ntreatment of warfarin and heparin. Heparin is stopped \nwhen the warfarin dose leads to an optimal INR of 2-3. \nH\nH\n4.1.2 Infective Endocarditis               ICD10 CODE: I33.0\nAn infection of the heart valves and lining of the heart chambers by \nmicroorganisms, usually bacterial, rarely fungal.\n\t\n\u0089\nMaintenance dose: single dose daily, that need a higher \nmaintenance dose than others especially when there are \ndrugs that may interact with warfarin. Typical dose may \nrange between 2.5 \u2013 10mg daily. adjusted according to \nthe INR 2 -3 \nH\n301\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>\u0083 Early mobilisation</p>\n<p>\u0083 Prophylaxis with enoxaparin 40 mg SC daily in any acutely ill</p>\n<p>medical patient and in prolonged admission</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Low molecular weight heparin-</p>\n<p>- (LMWH) e.g., Enoxaparin given as 1 mg/kg</p>\n<p>- every 12 hours or 1.5mg/kg once a day, for at</p>\n<p>least 5 days</p>\n<p>\u0089</p>\n<p>Plus warfarin 5 mg single dose given in the evening,</p>\n<p>commencing on the same day as the heparin. Overlap</p>\n<p>treatment of warfarin and heparin. Heparin is stopped</p>\n<p>when the warfarin dose leads to an optimal INR of 2-3.</p>\n<p>H</p>\n<p>H</p>\n<p>4.1.2 Infective Endocarditis               ICD10 CODE: I33.0</p>\n<p>An infection of the heart valves and lining of the heart chambers by</p>\n<p>microorganisms, usually bacterial, rarely fungal.</p>\n<p>\u0089</p>\n<p>Maintenance dose: single dose daily, that need a higher</p>\n<p>maintenance dose than others especially when there are</p>\n<p>drugs that may interact with warfarin. Typical dose may</p>\n<p>range between 2.5 \u2013 10mg daily. adjusted according to</p>\n<p>the INR 2 -3</p>\n<p>H</p>\n<p>301</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 368,
        "content": "Causes\nIt is classified into 3 types:\n \n\u0083 Sub-acute endocarditis: caused by low virulence organisms such \nas Streptococcus viridans\n \n\u0083 Acute endocarditis: caused by common pyogenic organisms \nsuch as Staphylococcus aureus\n \n\u0083 Post-operative endocarditis: following cardiac surgery and \nprosthetic heart valve placement. The most common organism \ninvolved is Staphylococcus aureus\nClinical features\n \n\u0083 Disease may present as acute or chronic depending on the \nmicroorganism involved and patient\u2019s condition\n \n\u0083 Fatigue, weight loss\n \n\u0083 Low grade fever and chills or acute severe septicaemia\n \n\u0083 Embolic phenomena affecting various body organs (e.g. brain)\n \n\u0083 Heart failure, prominent and changing heart murmurs\n \n\u0083 Splenomegaly, hepatomegaly\n \n\u0083 Anaemia\n \n\u0083 Splinter haemorrhages (nail bed and retina)\n \n\u0083 Finger clubbing\n \n\u0083 Diagnostic triad: persistent fever, emboli, changing murmur\nRisk factors\n \n\u0083 Rheumatic heart disease, congenital heart disease\n \n\u0083 Prosthetic valve\n \n\u0083 Invasive dental/diagnostic/surgical procedures (including cardiac \ncatheterization)\n \n\u0083 Immunosuppression\n \n\u0083 IV drug use/abuse\n302\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Causes</p>\n<p>It is classified into 3 types:</p>\n<p>\u0083 Sub-acute endocarditis: caused by low virulence organisms such</p>\n<p>as Streptococcus viridans</p>\n<p>\u0083 Acute endocarditis: caused by common pyogenic organisms</p>\n<p>such as Staphylococcus aureus</p>\n<p>\u0083 Post-operative endocarditis: following cardiac surgery and</p>\n<p>prosthetic heart valve placement. The most common organism</p>\n<p>involved is Staphylococcus aureus</p>\n<p>Clinical features</p>\n<p>\u0083 Disease may present as acute or chronic depending on the</p>\n<p>microorganism involved and patient\u2019s condition</p>\n<p>\u0083 Fatigue, weight loss</p>\n<p>\u0083 Low grade fever and chills or acute severe septicaemia</p>\n<p>\u0083 Embolic phenomena affecting various body organs (e.g. brain)</p>\n<p>\u0083 Heart failure, prominent and changing heart murmurs</p>\n<p>\u0083 Splenomegaly, hepatomegaly</p>\n<p>\u0083 Anaemia</p>\n<p>\u0083 Splinter haemorrhages (nail bed and retina)</p>\n<p>\u0083 Finger clubbing</p>\n<p>\u0083 Diagnostic triad: persistent fever, emboli, changing murmur</p>\n<p>Risk factors</p>\n<p>\u0083 Rheumatic heart disease, congenital heart disease</p>\n<p>\u0083 Prosthetic valve</p>\n<p>\u0083 Invasive dental/diagnostic/surgical procedures (including cardiac</p>\n<p>catheterization)</p>\n<p>\u0083 Immunosuppression</p>\n<p>\u0083 IV drug use/abuse</p>\n<p>302</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 369,
        "content": "Differential diagnosis\n \n\u0083 Cardiac failure with heart murmurs\n \n\u0083 Febrile conditions associated with anaemia\nNote: Any unexplained fever in a patient with a heart valve \nproblem should be regarded as endocarditis\nInvestigations\n \n\u0083 Blood cultures: These are usually positive and all efforts should \nbe made to identify the responsible pathogen and obtain \nsensitivity data\n \n\u0083 At least 3 sets of blood cultures (8 ml) each should be obtained \n(each from a separate venipucture) at least one hour apart\n \n\u0083 Blood: Complete blood count, ESR\n \n\u0083 Urinalysis for microscopic haematuria, proteinuria\n \n\u0083 Echocardiography\n \n\u0083 ECG\n303\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>\u0083 Cardiac failure with heart murmurs</p>\n<p>\u0083 Febrile conditions associated with anaemia</p>\n<p>Note: Any unexplained fever in a patient with a heart valve</p>\n<p>problem should be regarded as endocarditis</p>\n<p>Investigations</p>\n<p>\u0083 Blood cultures: These are usually positive and all efforts should</p>\n<p>be made to identify the responsible pathogen and obtain</p>\n<p>sensitivity data</p>\n<p>\u0083 At least 3 sets of blood cultures (8 ml) each should be obtained</p>\n<p>(each from a separate venipucture) at least one hour apart</p>\n<p>\u0083 Blood: Complete blood count, ESR</p>\n<p>\u0083 Urinalysis for microscopic haematuria, proteinuria</p>\n<p>\u0083 Echocardiography</p>\n<h3>\u0083 ECG</h3>\n<p>303</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 370,
        "content": "Management\nTREATMENT\nLOC\n Bed rest\n Treat complications e.g. heart failure Initial empirical \nantibiotic therapy\n Benzylpenicillin 5 MU IV every 6 hours for 4 weeks\nH\nChild: Benzylpenicillin 50,000 IU/kg every 6 hours for \n4 weeks\n  Plus gentamicin 1 mg/kg IV every 8 hours for 2 weeks\nIf staphylococcus suspected, (acute onset) add:\n Cloxacillin IV 3 g every 6 hours\nChild: 50 mg/kg every 6 hours for 4 weeks\nIf MRSA (Multi-Resistant Staphylococcus aureus)\n Vancomycin 500 mg IV every 6 hours\n Child: 10 mg/kg (infused over 1 hour) 6 hourly for 6 \nweeks\nOnce a pathogen has been identified\n Amend treatment to correspond with the sensitivity \nresults\nRR\nPrevention\n \n\u0083 Prophylaxis in case of dental procedures and tonsillectomy \nin patients at risk (valvular defects, congenital heart disease, \nprosthetic valve). Give amoxicillin 2 g (50 mg/kg for children) as \na single dose, 1 hour before the procedure.\n4.1.3 Heart Failure                           ICD10 CODE: I50\nClinical syndrome caused by inadequate cardiac output for the body\u2019s \nneeds, despite adequate venous return.\nFor management purposes, it can be classified into:\n \n- Congestive/acute heart failure\n304\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Bed rest</p>\n<p>Treat complications e.g. heart failure Initial empirical</p>\n<p>antibiotic therapy</p>\n<p>Benzylpenicillin 5 MU IV every 6 hours for 4 weeks</p>\n<p>H</p>\n<p>Child: Benzylpenicillin 50,000 IU/kg every 6 hours for</p>\n<p>4 weeks</p>\n<p>Plus gentamicin 1 mg/kg IV every 8 hours for 2 weeks</p>\n<p>If staphylococcus suspected, (acute onset) add:</p>\n<p>Cloxacillin IV 3 g every 6 hours</p>\n<p>Child: 50 mg/kg every 6 hours for 4 weeks</p>\n<p>If MRSA (Multi-Resistant Staphylococcus aureus)</p>\n<p>Vancomycin 500 mg IV every 6 hours</p>\n<p>Child: 10 mg/kg (infused over 1 hour) 6 hourly for 6</p>\n<p>weeks</p>\n<p>Once a pathogen has been identified</p>\n<p>Amend treatment to correspond with the sensitivity</p>\n<p>results</p>\n<p>RR</p>\n<p>Prevention</p>\n<p>\u0083 Prophylaxis in case of dental procedures and tonsillectomy</p>\n<p>in patients at risk (valvular defects, congenital heart disease,</p>\n<p>prosthetic valve). Give amoxicillin 2 g (50 mg/kg for children) as</p>\n<p>a single dose, 1 hour before the procedure.</p>\n<p>4.1.3 Heart Failure                           ICD10 CODE: I50</p>\n<p>Clinical syndrome caused by inadequate cardiac output for the body\u2019s</p>\n<p>needs, despite adequate venous return.</p>\n<p>For management purposes, it can be classified into:</p>\n<p>- Congestive/acute heart failure</p>\n<p>304</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 371,
        "content": "- Chronic heart failure\n \n- Acute pulmonary oedema (see section 4.1.4)\nCauses\n \n\u0083 Hypertension\n \n\u0083 Valvular heart disease, e.g. rheumatic heart disease\n \n\u0083 Myocardial infarction\n \n\u0083 Myocarditis\n \n\u0083 Prolonged rapid irregular heartbeat (arrhythmias)\n \n\u0083 Congenital heart disease\n \n\u0083 Severe anaemia, thyroid disease\nClinical features\nInfants and young children\n \n\u0083 Respiratory distress with rapid respiration, cyanosis, wheezing, \nsubcostal, intercostal, and sternal recession\n \n\u0083 Rapid pulse, gallop rhythm, excessive sweating\n \n\u0083 Tender hepatomegaly\n \n\u0083 Difficulty with feeding\n \n\u0083 Cardiomegaly\nOlder children and adults\n \n\u0083 Palpitations, shortness of breath, exercise intolerance\n \n\u0083 Fatigue, orthopnea, exertional dyspnoea, wheezing\n \n\u0083 Rapid pulse, gallop rhythm\n \n\u0083 Raised jugular venous pressure (JVP)\n \n\u0083 Dependent oedema, enlarged tender liver\n \n\u0083 Basal crepitations\nDifferential diagnosis\n \n\u0083 Severe anaemia, severe acute malnutrition\n \n\u0083 Nephrotic syndrome, cirrhosis\n \n\u0083 Severe pneumonia\n \n\u0083 Any severe sickness in infants\nInvestigations\n \n\u0083 Chest X-ray\n \n\u0083 Blood: Haemogram (for ESR, anaemia)\n \n\u0083 Urea and electrolytes\n \n\u0083 Echocardiogram, ECG\n305\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>- Chronic heart failure</p>\n<p>- Acute pulmonary oedema (see section 4.1.4)</p>\n<p>Causes</p>\n<p>\u0083 Hypertension</p>\n<p>\u0083 Valvular heart disease, e.g. rheumatic heart disease</p>\n<p>\u0083 Myocardial infarction</p>\n<p>\u0083 Myocarditis</p>\n<p>\u0083 Prolonged rapid irregular heartbeat (arrhythmias)</p>\n<p>\u0083 Congenital heart disease</p>\n<p>\u0083 Severe anaemia, thyroid disease</p>\n<p>Clinical features</p>\n<p>Infants and young children</p>\n<p>\u0083 Respiratory distress with rapid respiration, cyanosis, wheezing,</p>\n<p>subcostal, intercostal, and sternal recession</p>\n<p>\u0083 Rapid pulse, gallop rhythm, excessive sweating</p>\n<p>\u0083 Tender hepatomegaly</p>\n<p>\u0083 Difficulty with feeding</p>\n<p>\u0083 Cardiomegaly</p>\n<p>Older children and adults</p>\n<p>\u0083 Palpitations, shortness of breath, exercise intolerance</p>\n<p>\u0083 Fatigue, orthopnea, exertional dyspnoea, wheezing</p>\n<p>\u0083 Rapid pulse, gallop rhythm</p>\n<p>\u0083 Raised jugular venous pressure (JVP)</p>\n<p>\u0083 Dependent oedema, enlarged tender liver</p>\n<p>\u0083 Basal crepitations</p>\n<p>Differential diagnosis</p>\n<p>\u0083 Severe anaemia, severe acute malnutrition</p>\n<p>\u0083 Nephrotic syndrome, cirrhosis</p>\n<p>\u0083 Severe pneumonia</p>\n<p>\u0083 Any severe sickness in infants</p>\n<p>Investigations</p>\n<p>\u0083 Chest X-ray</p>\n<p>\u0083 Blood: Haemogram (for ESR, anaemia)</p>\n<p>\u0083 Urea and electrolytes</p>\n<p>\u0083 Echocardiogram, ECG</p>\n<p>305</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 372,
        "content": "Management\nTREATMENT\nLOC\n Bed rest with head of bed elevated\n Prop up patient in sitting position\n Reduce salt intake and limit fluid intake (1-1.5 L/ day)\n Furosemide 20-40 mg oral or IV daily for every 12 \nhours increasing as required to 80-160 mg according \nto response\nChild: 1 mg/kg oral or IV daily or every 12 hours \naccording to response (max: 8 mg/kg daily)\n ACE inhibitors: start with low dose Enalapril  2.5 \nmg once daily, increase gradually over 2 weeks to 10-\n20 mg (max 40 mg) if tolerated (or     Lisinopril 5mg \nincrease gradually over 2 weeks to 40mg)\n Child: Enalapril 0.1-1 mg/kg daily in 1-2 doses Or\n Captopril 6.25-12.5 mg 8 -12 hourly, increase over \n2-4 weeks to max 150 mg daily in divided doses\n Child: Captopril 0.1-0.3 mg/kg daily every 8-12 hours\nIf available and when patient stable add:\n Adults: Carvedilol 3.125 mg every 12 hours, increase \ngradually every 2 weeks to max 25 mg 12 hourly            \n(or Bisoprolol 1.25mg once daily increase gradually to \nmax 10mg)\n Child: Carvedilol 0.05 mg/kg every 12 hours, increase \ngradually to max 0.35 mg/kg every 12 hours\nHC4\nHC4\nHC4\nH\nH\n306\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Bed rest with head of bed elevated</p>\n<p>Prop up patient in sitting position</p>\n<p>Reduce salt intake and limit fluid intake (1-1.5 L/ day)</p>\n<p>Furosemide 20-40 mg oral or IV daily for every 12</p>\n<p>hours increasing as required to 80-160 mg according</p>\n<p>to response</p>\n<p>Child: 1 mg/kg oral or IV daily or every 12 hours</p>\n<p>according to response (max: 8 mg/kg daily)</p>\n<p>ACE inhibitors: start with low dose Enalapril  2.5</p>\n<p>mg once daily, increase gradually over 2 weeks to 10-</p>\n<p>20 mg (max 40 mg) if tolerated (or     Lisinopril 5mg</p>\n<p>increase gradually over 2 weeks to 40mg)</p>\n<p>Child: Enalapril 0.1-1 mg/kg daily in 1-2 doses Or</p>\n<p>Captopril 6.25-12.5 mg 8 -12 hourly, increase over</p>\n<p>2-4 weeks to max 150 mg daily in divided doses</p>\n<p>Child: Captopril 0.1-0.3 mg/kg daily every 8-12 hours</p>\n<p>If available and when patient stable add:</p>\n<p>Adults: Carvedilol 3.125 mg every 12 hours, increase</p>\n<p>gradually every 2 weeks to max 25 mg 12 hourly</p>\n<p>(or Bisoprolol 1.25mg once daily increase gradually to</p>\n<p>max 10mg)</p>\n<p>Child: Carvedilol 0.05 mg/kg every 12 hours, increase</p>\n<p>gradually to max 0.35 mg/kg every 12 hours</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>H</p>\n<p>306</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 373,
        "content": "TREATMENT\nLOC\nAdditional medicines (second/third line)\n Spironolactone 25-50 mg once a day\nChild: Initially 1.5-3 mg/kg daily in divided doses\n Digoxin 125-250 micrograms/daily\nChild maintenance dose: 15 micrograms/kg daily\nH\nHC4\nCaution\n Use ACE inhibitors and beta blockers with caution if systolic BP is \nless than 90 mmHg: monitor renal function\n Use digoxin with caution in elderly and renal disease\nPrevention\n \n\u0083 Management of risk factors\n \n\u0083 Early diagnosis and treatment of the cause (e.g. hypertension)\n \n\u0083 Treatment adherence\nChronic heart failure\nPatients with chronic heart failure need continuous treatment to control \nsymptoms and prevent disease progression and complications\nManagement\nTREATMENT\nLOC\n Periodic monitoring of body weight, blood pressure, \nheart rate, respiratory rate and oxygen saturation\n Salt and fluid restriction\n Limit alcohol intake\n Regular exercise within limits of symptoms\n Continued treatment with the medicines listed above, \nwith doses progressively increased to achieve control\nHC2\nHC4\n307\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Additional medicines (second/third line)</p>\n<p>Spironolactone 25-50 mg once a day</p>\n<p>Child: Initially 1.5-3 mg/kg daily in divided doses</p>\n<p>Digoxin 125-250 micrograms/daily</p>\n<p>Child maintenance dose: 15 micrograms/kg daily</p>\n<p>H</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>Use ACE inhibitors and beta blockers with caution if systolic BP is</p>\n<p>less than 90 mmHg: monitor renal function</p>\n<p>Use digoxin with caution in elderly and renal disease</p>\n<p>Prevention</p>\n<p>\u0083 Management of risk factors</p>\n<p>\u0083 Early diagnosis and treatment of the cause (e.g. hypertension)</p>\n<p>\u0083 Treatment adherence</p>\n<p>Chronic heart failure</p>\n<p>Patients with chronic heart failure need continuous treatment to control</p>\n<p>symptoms and prevent disease progression and complications</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Periodic monitoring of body weight, blood pressure,</p>\n<p>heart rate, respiratory rate and oxygen saturation</p>\n<p>Salt and fluid restriction</p>\n<p>Limit alcohol intake</p>\n<p>Regular exercise within limits of symptoms</p>\n<p>Continued treatment with the medicines listed above,</p>\n<p>with doses progressively increased to achieve control</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>307</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 374,
        "content": "Management\nTREATMENT\nLOC\nAcute\n Prop up patient in sitting position\n High concentration oxygen : start with 5 L/min, aim \nat SpO2 >95%\nHC4\n4.1.4 Pulmonary Oedema            ICD10 CODE: I50.21\nCongestion of the lung tissue with fluid, usually due to heart failure.\nCause\n \n\u0083 Cardiogenic\n \n\u0083 Severe fluid overload e.g. in renal failure or iatrogenic\n \n\u0083 Non-cardiogenic pulmonary oedema: severe pneumonia, altitude \nsickness, inhalation of toxic gases, acute respiratory distress \nsyndrome\nClinical features\n \n\u0083 Severe dyspnoea, rapid breathing, breathlessness\n \n\u0083 Tachycardia, wheezing\n \n\u0083 Cough with frothy blood stained sputum\nDifferential diagnosis\n \n\u0083 Pneumonia, pleural effusion\n \n\u0083 Foreign body\n \n\u0083 Trauma (pneumothorax, pulmonary contusion)\nInvestigations\n \n\u0083 Chest X-ray\n \n\u0083 ECG\n \n\u0083 Renal function, electrolytes\n \n\u0083 Echocardiography\n308\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute</p>\n<p>Prop up patient in sitting position</p>\n<p>High concentration oxygen : start with 5 L/min, aim</p>\n<p>at SpO2 >95%</p>\n<h3>HC4</h3>\n<p>4.1.4 Pulmonary Oedema            ICD10 CODE: I50.21</p>\n<p>Congestion of the lung tissue with fluid, usually due to heart failure.</p>\n<p>Cause</p>\n<p>\u0083 Cardiogenic</p>\n<p>\u0083 Severe fluid overload e.g. in renal failure or iatrogenic</p>\n<p>\u0083 Non-cardiogenic pulmonary oedema: severe pneumonia, altitude</p>\n<p>sickness, inhalation of toxic gases, acute respiratory distress</p>\n<p>syndrome</p>\n<p>Clinical features</p>\n<p>\u0083 Severe dyspnoea, rapid breathing, breathlessness</p>\n<p>\u0083 Tachycardia, wheezing</p>\n<p>\u0083 Cough with frothy blood stained sputum</p>\n<p>Differential diagnosis</p>\n<p>\u0083 Pneumonia, pleural effusion</p>\n<p>\u0083 Foreign body</p>\n<p>\u0083 Trauma (pneumothorax, pulmonary contusion)</p>\n<p>Investigations</p>\n<p>\u0083 Chest X-ray</p>\n<h3>\u0083 ECG</h3>\n<p>\u0083 Renal function, electrolytes</p>\n<p>\u0083 Echocardiography</p>\n<p>308</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 375,
        "content": "TREATMENT\nLOC\n Furosemide 40-80 mg IM or slow IV - Repeat prn up \nto 2 hourly according to response\nChild: 0.5-1.5 mg/kg every 8-12 hours (max: 6 mg/ \nkg) daily)\n Glyceryl trinitrate 500 microgram sublingually every \n4-6 hours\n Give morphine 5-15 mg IM or 2-4 mg slow IV\nChild: 0.1 mg/kg slow IV single dose\n Repeat these every 4-6 hours till there is improvement\nConsider also\n Digoxin loading dose IV 250 micrograms 3-4 times \nin the first 24 hours then maintenance dose of 125-\n250 micrograms daily\nChild: 10 mg/Kg per dose as above then\nmaintenance dose of 15 microgram/kg/day\nHC4\nH\nHC4\nH\nCaution\n Do not give loading dose if patient has had digoxin within the \npast 14 days but give maintenance dose\nPrevention\n \n\u0083 Early diagnosis and treatment of cardiac conditions\n \n\u0083 Compliance with treatment for chronic cardiac conditions\n \n\u0083 Avoid fluid overload\n4.1.5 Atrial Fibrillation\t\nICD10 CODE: I48\nCommon cardiac arrhythmia characterised by irregular pulse due to \nthe loss of the regular atrial electrical activity. Its onset can be acute or \nchronic, and it can be symptomatic or asymptomatic.\n309\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Furosemide 40-80 mg IM or slow IV - Repeat prn up</p>\n<p>to 2 hourly according to response</p>\n<p>Child: 0.5-1.5 mg/kg every 8-12 hours (max: 6 mg/</p>\n<p>kg) daily)</p>\n<p>Glyceryl trinitrate 500 microgram sublingually every</p>\n<p>4-6 hours</p>\n<p>Give morphine 5-15 mg IM or 2-4 mg slow IV</p>\n<p>Child: 0.1 mg/kg slow IV single dose</p>\n<p>Repeat these every 4-6 hours till there is improvement</p>\n<p>Consider also</p>\n<p>Digoxin loading dose IV 250 micrograms 3-4 times</p>\n<p>in the first 24 hours then maintenance dose of 125-</p>\n<p>250 micrograms daily</p>\n<p>Child: 10 mg/Kg per dose as above then</p>\n<p>maintenance dose of 15 microgram/kg/day</p>\n<h3>HC4</h3>\n<p>H</p>\n<h3>HC4</h3>\n<p>H</p>\n<p>Caution</p>\n<p>Do not give loading dose if patient has had digoxin within the</p>\n<p>past 14 days but give maintenance dose</p>\n<p>Prevention</p>\n<p>\u0083 Early diagnosis and treatment of cardiac conditions</p>\n<p>\u0083 Compliance with treatment for chronic cardiac conditions</p>\n<p>\u0083 Avoid fluid overload</p>\n<p>4.1.5 Atrial Fibrillation</p>\n<h3>ICD10 CODE: I48</h3>\n<p>Common cardiac arrhythmia characterised by irregular pulse due to</p>\n<p>the loss of the regular atrial electrical activity. Its onset can be acute or</p>\n<p>chronic, and it can be symptomatic or asymptomatic.</p>\n<p>309</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 376,
        "content": "Risk factors\n \n\u0083 Heart disease (heart failure, valvular heart diseases, ischaemic \nheart disease)\n \n\u0083 Thyroid disease (hyperthyroidism)\nClinical features\n \n\u0083 Irregular pulse (frequency and volume), heart rate can be either \nnormal or very high\n \n\u0083 Acute onset (often with high heart rate): palpitations, dizziness, \nfainting, chest pain, shortness of breath\n \n\u0083 Chronic (with normal or almost normal heart rate): often \nasymptomatic, discovered at routine checks\n \n\u0083 It can precipitate heart failure or pulmonary oedema\n \n\u0083 It can cause embolic stroke if clots form in the heart and are then \ndislodged to the brain circulation\nInvestigations\n \n\u0083 ECG\nObjectives\n \n\u0083 Control heart rate\n \n\u0083 Restore normal rhythm if possible (specialist only)\n \n\u0083 Prevent or treat complications\n \n\u0083 Treat underlying conditions\nManagement\nTREATMENT\nLOC\nIf acute onset, high heart rate or patient in congestive heart failure and/\nor pulmonary oedema:\n  Treat heart failure as per guidelines (section 4.1.3), \nuse digoxin and or Carvedilol (or Bisoprolol) to reduce \nheart rate\nIf acute onset and high heart rate but no signs of heart \nfailure:\n  Use atenolol 50 mg to control heart rate\nHC4\nHC4\n310\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Risk factors</p>\n<p>\u0083 Heart disease (heart failure, valvular heart diseases, ischaemic</p>\n<p>heart disease)</p>\n<p>\u0083 Thyroid disease (hyperthyroidism)</p>\n<p>Clinical features</p>\n<p>\u0083 Irregular pulse (frequency and volume), heart rate can be either</p>\n<p>normal or very high</p>\n<p>\u0083 Acute onset (often with high heart rate): palpitations, dizziness,</p>\n<p>fainting, chest pain, shortness of breath</p>\n<p>\u0083 Chronic (with normal or almost normal heart rate): often</p>\n<p>asymptomatic, discovered at routine checks</p>\n<p>\u0083 It can precipitate heart failure or pulmonary oedema</p>\n<p>\u0083 It can cause embolic stroke if clots form in the heart and are then</p>\n<p>dislodged to the brain circulation</p>\n<p>Investigations</p>\n<h3>\u0083 ECG</h3>\n<p>Objectives</p>\n<p>\u0083 Control heart rate</p>\n<p>\u0083 Restore normal rhythm if possible (specialist only)</p>\n<p>\u0083 Prevent or treat complications</p>\n<p>\u0083 Treat underlying conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If acute onset, high heart rate or patient in congestive heart failure and/</p>\n<p>or pulmonary oedema:</p>\n<p>Treat heart failure as per guidelines (section 4.1.3),</p>\n<p>use digoxin and or Carvedilol (or Bisoprolol) to reduce</p>\n<p>heart rate</p>\n<p>If acute onset and high heart rate but no signs of heart</p>\n<p>failure:</p>\n<p>Use atenolol 50 mg to control heart rate</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>310</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 377,
        "content": "Management\nTREATMENT\nLOC\nIf chronic but normal heart rate:\n Only treat underlying conditions\n Refer to regional level to assess indication for \nanticoagulation with aspirin or warfarin to prevent \nstroke\nH\n4.1.6 Hypertension      ICD10 code: I10\nPersistently high resting blood pressure (>140/90 mmHg for at least \ntwo measurements five minutes apart with patient seated) on at least 2 \nor 3 occasions 1 week apart.\nClassification of blood pressure (BP)\nCategory\nSbp Mmhg\nDbp Mmhg\nNormal\n<120\nand\n<80\nPre-hypertension\n120-139\nor\n80-89\nHypertension, stage 1 140-159\nor\n90-99\nHypertension, stage 2 >160\nor\n>100\nSBP=systolic blood pressure; DBP=diastolic blood pressure\nCauses\n \n\u0083 In the majority of cases, the cause is not known (essential \nhypertension)\n311\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If chronic but normal heart rate:</p>\n<p>Only treat underlying conditions</p>\n<p>Refer to regional level to assess indication for</p>\n<p>anticoagulation with aspirin or warfarin to prevent</p>\n<p>stroke</p>\n<p>H</p>\n<p>4.1.6 Hypertension      ICD10 code: I10</p>\n<p>Persistently high resting blood pressure (>140/90 mmHg for at least</p>\n<p>two measurements five minutes apart with patient seated) on at least 2</p>\n<p>or 3 occasions 1 week apart.</p>\n<p>Classification of blood pressure (BP)</p>\n<p>Category</p>\n<p>Sbp Mmhg</p>\n<p>Dbp Mmhg</p>\n<p>Normal</p>\n<p><120</p>\n<p>and</p>\n<p><80</p>\n<p>Pre-hypertension</p>\n<p>120-139</p>\n<p>or</p>\n<p>80-89</p>\n<p>Hypertension, stage 1 140-159</p>\n<p>or</p>\n<p>90-99</p>\n<p>Hypertension, stage 2 >160</p>\n<p>or</p>\n<p>>100</p>\n<p>SBP=systolic blood pressure; DBP=diastolic blood pressure</p>\n<p>Causes</p>\n<p>\u0083 In the majority of cases, the cause is not known (essential</p>\n<p>hypertension)</p>\n<p>311</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 378,
        "content": "Secondary hypertension is associated with:\n \n\u0083 Kidney diseases\n \n\u0083 Endocrine diseases\n \n\u0083 Eclampsia/pre-eclampsia\n \n\u0083 Medicines (steroids and decongestants containing caffeine and \npseudoephedrine)\nRisk factors\n \n\u0083 Family history, race\n \n\u0083 Obesity, physical inactivity\n \n\u0083 Excessive intake of salt and alcohol\n \n\u0083 Diabetes and dyslipidaemia\nClinical features\nThe majority of cases are symptomless and are only discovered on routine \nexamination or screening.\nGeneral symptoms include:\n \n\u0083 Headache\n \n\u0083 Palpitations, dizziness\nHypertension may present as a complication affecting:\n \n\u0083 Brain (stroke)\n \n\u0083 Heart (heart failure)\n \n\u0083 Kidney (renal failure)\n \n\u0083 Eyes (impairment of vision)\nDifferential diagnosis\n \n\u0083 Anxiety\nInvestigations\nTo identify complications and possible cases of secondary hypertension:\n\t\u00bb Urine analysis\n\t\u00bb Blood sugar\n\t\u00bb Plasma urea and electrolytes\n \n\u0083 Chest X-ray\n \n\u0083 ECG\n312\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Secondary hypertension is associated with:</p>\n<p>\u0083 Kidney diseases</p>\n<p>\u0083 Endocrine diseases</p>\n<p>\u0083 Eclampsia/pre-eclampsia</p>\n<p>\u0083 Medicines (steroids and decongestants containing caffeine and</p>\n<p>pseudoephedrine)</p>\n<p>Risk factors</p>\n<p>\u0083 Family history, race</p>\n<p>\u0083 Obesity, physical inactivity</p>\n<p>\u0083 Excessive intake of salt and alcohol</p>\n<p>\u0083 Diabetes and dyslipidaemia</p>\n<p>Clinical features</p>\n<p>The majority of cases are symptomless and are only discovered on routine</p>\n<p>examination or screening.</p>\n<p>General symptoms include:</p>\n<p>\u0083 Headache</p>\n<p>\u0083 Palpitations, dizziness</p>\n<p>Hypertension may present as a complication affecting:</p>\n<p>\u0083 Brain (stroke)</p>\n<p>\u0083 Heart (heart failure)</p>\n<p>\u0083 Kidney (renal failure)</p>\n<p>\u0083 Eyes (impairment of vision)</p>\n<p>Differential diagnosis</p>\n<p>\u0083 Anxiety</p>\n<p>Investigations</p>\n<p>To identify complications and possible cases of secondary hypertension:</p>\n<p>\u00bb Urine analysis</p>\n<p>\u00bb Blood sugar</p>\n<p>\u00bb Plasma urea and electrolytes</p>\n<p>\u0083 Chest X-ray</p>\n<h3>\u0083 ECG</h3>\n<p>312</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 379,
        "content": "Management of hypertension\nTarget: blood pressure below 140/90 mmHg\nTREATMENT\nLOC\nHypertension, stage 1\nStep 1: Lifestyle adjustments\n Do not add extra salt to cooked food, increase physical \nactivity/exercise, reduce body weight\n Stop smoking\n Decrease alcohol intake\nIf all the above fail (within 3 months), initiate medicine \ntherapy\nStep 2:\n Emphasize lifestyle changes with medicines\n Give amlodipine 5 mg once daily\n If not controlled after 1 month, treat as in stage 2\nHC3\nHypertension, stage 2\nStep3 \nGive Amlodipine 5 mg once daily Plus\n Angiotensin II receptor blocker (ARB) e.g. Losartan 50mg \n(or Valsartan 80mg or Telmisartan 40mg) once daily\n Note: Instead of ARBs, you can use angiotensin con\u00ad\nverting enzyme inhibitors (ACEI) like Lisinopril 20mg \nor Enalapril 5mg once daily.\nHC3\n313\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management of hypertension</p>\n<p>Target: blood pressure below 140/90 mmHg</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Hypertension, stage 1</p>\n<p>Step 1: Lifestyle adjustments</p>\n<p>Do not add extra salt to cooked food, increase physical</p>\n<p>activity/exercise, reduce body weight</p>\n<p>Stop smoking</p>\n<p>Decrease alcohol intake</p>\n<p>If all the above fail (within 3 months), initiate medicine</p>\n<p>therapy</p>\n<p>Step 2:</p>\n<p>Emphasize lifestyle changes with medicines</p>\n<p>Give amlodipine 5 mg once daily</p>\n<p>If not controlled after 1 month, treat as in stage 2</p>\n<h3>HC3</h3>\n<p>Hypertension, stage 2</p>\n<p>Step3</p>\n<p>Give Amlodipine 5 mg once daily Plus</p>\n<p>Angiotensin II receptor blocker (ARB) e.g. Losartan 50mg</p>\n<p>(or Valsartan 80mg or Telmisartan 40mg) once daily</p>\n<p>Note: Instead of ARBs, you can use angiotensin con\u00ad</p>\n<p>verting enzyme inhibitors (ACEI) like Lisinopril 20mg</p>\n<p>or Enalapril 5mg once daily.</p>\n<h3>HC3</h3>\n<p>313</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 380,
        "content": "TREATMENT\nLOC\nStep4\nIf  blood pressure \u2265 140/90 mmHg after 1 month\n Give Amlodipine 10 mg once daily \nPlus\n Losartan 50mg (or Valsartan 80mg or Telmisartan 40mg) \nonce daily\nHC3\nStep5\nIf  blood pressure \u2265 140/90 mmHg after 1 month\n Give Amlodipine 10 mg once daily  \nPlus\n Losartan 100mg (or Valsartan 160mg or Telmisartan \n80mg) once daily \nPlus \n Thiazide diuretic like Hydrochlorothiazide 12.5mg (or \nBendroflumethiazide 5mg) once in the morning\nHC3\nStep6  \nIf  blood pressure \u2265 140/90 mmHg after 1 month\n Give Amlodipine 10 mg once daily  \nPlus\n Losartan 100mg (or Valsartan 160mg or Telmisartan \n80mg) once daily \nPlus \n Thiazide diuretic like Hydrochlorothiazide 12.5mg (or \nBendroflumethiazide 5mg) once in the morning\nHC3\n314\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Step4</p>\n<p>If  blood pressure \u2265 140/90 mmHg after 1 month</p>\n<p>Give Amlodipine 10 mg once daily</p>\n<p>Plus</p>\n<p>Losartan 50mg (or Valsartan 80mg or Telmisartan 40mg)</p>\n<p>once daily</p>\n<h3>HC3</h3>\n<p>Step5</p>\n<p>If  blood pressure \u2265 140/90 mmHg after 1 month</p>\n<p>Give Amlodipine 10 mg once daily</p>\n<p>Plus</p>\n<p>Losartan 100mg (or Valsartan 160mg or Telmisartan</p>\n<p>80mg) once daily</p>\n<p>Plus</p>\n<p>Thiazide diuretic like Hydrochlorothiazide 12.5mg (or</p>\n<p>Bendroflumethiazide 5mg) once in the morning</p>\n<h3>HC3</h3>\n<p>Step6</p>\n<p>If  blood pressure \u2265 140/90 mmHg after 1 month</p>\n<p>Give Amlodipine 10 mg once daily</p>\n<p>Plus</p>\n<p>Losartan 100mg (or Valsartan 160mg or Telmisartan</p>\n<p>80mg) once daily</p>\n<p>Plus</p>\n<p>Thiazide diuretic like Hydrochlorothiazide 12.5mg (or</p>\n<p>Bendroflumethiazide 5mg) once in the morning</p>\n<h3>HC3</h3>\n<p>314</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 381,
        "content": "TREATMENT\nLOC\nStep7\nIf BP is \u2265 140/90mmHg, refer for further management to a higher \nlevel of care.\n  Provision for specific patients\n  Assess the cardiovascular disease (CVD) risk in all patients with \nhypertension.\n  Patients with diabetes, coronary heart disease, stroke or chronic \nkidney disease are considered having a high CVD risk.\n  The target BP is <130/80 mmHg in people with high CVD risk.\n  Start statin (atorvastatin 20-40 mg once daily or simvastatin 20-40 \nmg once daily) and aspirin 75mg in people with prior heart attack \nor ischemic stroke. Consider statin in people at high risk.\n  Start beta blocker (Atenolol 50mg or Bisoprolol 5mg or Nebivolol \n5mg once daily) in people with heart attack in past 3 years.\n  A combination of ACEI or ARB and a CCB or a diuretic is recom\u00ad\nmended as initial therapy in patients with chronic kidney disease.\n  For hypertension secondary to thyroid disease consider adding \nPropranolol 40mg twice daily\nCaution\n In pregnancy, do NOT use ACEI or ARBs and diuretics.\nMethyldopa and calcium channel blockers are safe to use\n Don\u2019t use both an ACEI  and ARB due to increased risk \nof side effects\nChoice of antihypertensive medicine\nChoice of medicine may depend on concomitant risk factors/ other con\u00ad\nditions: the table below indicates the suitable medicines for such patients.\n315\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Step7</p>\n<p>If BP is \u2265 140/90mmHg, refer for further management to a higher</p>\n<p>level of care.</p>\n<p>Provision for specific patients</p>\n<p>Assess the cardiovascular disease (CVD) risk in all patients with</p>\n<p>hypertension.</p>\n<p>Patients with diabetes, coronary heart disease, stroke or chronic</p>\n<p>kidney disease are considered having a high CVD risk.</p>\n<p>The target BP is <130/80 mmHg in people with high CVD risk.</p>\n<p>Start statin (atorvastatin 20-40 mg once daily or simvastatin 20-40</p>\n<p>mg once daily) and aspirin 75mg in people with prior heart attack</p>\n<p>or ischemic stroke. Consider statin in people at high risk.</p>\n<p>Start beta blocker (Atenolol 50mg or Bisoprolol 5mg or Nebivolol</p>\n<p>5mg once daily) in people with heart attack in past 3 years.</p>\n<p>A combination of ACEI or ARB and a CCB or a diuretic is recom\u00ad</p>\n<p>mended as initial therapy in patients with chronic kidney disease.</p>\n<p>For hypertension secondary to thyroid disease consider adding</p>\n<p>Propranolol 40mg twice daily</p>\n<p>Caution</p>\n<p>In pregnancy, do NOT use ACEI or ARBs and diuretics.</p>\n<p>Methyldopa and calcium channel blockers are safe to use</p>\n<p>Don\u2019t use both an ACEI  and ARB due to increased risk</p>\n<p>of side effects</p>\n<p>Choice of antihypertensive medicine</p>\n<p>Choice of medicine may depend on concomitant risk factors/ other con\u00ad</p>\n<p>ditions: the table below indicates the suitable medicines for such patients.</p>\n<p>315</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 382,
        "content": "Risk Factor\nHeart failure\nPost myocardial infarction\nAngina\nDiabetes\nMild/moderate kidney disease\nAdvanced chronic kidney disease\nStroke\nCarvedilol or Bisoprolol  only\nDiuretic\nBeta Blocker\nCcb\nAce Inhibitor\n/Arbs\nAldosteron \nAntagonist\nPrevention\n \n\u0083 Regular physical exercise\n \n\u0083 Reduce salt intake\n \n\u0083 Healthy diet, stop smoking\n \n\u0083 Periodic screening of blood pressure\n4.1.6.1\t Hypertensive Emergencies and urgency  \nICD10 CODE: I16.2\nHypertensive emergency\nBP >180/110 mmHg with symptoms and acute life threatening com\u00ad\nplications:\n \n\u0083 Hypertensive encephalopathy (severe headache, confusion, \nseizures, visual disturbances)\n \n\u0083 Acute angina or acute myocardial infarction (AMI)\n \n\u0083 Pulmonary oedema\n \n\u0083 Acute kidney failure\n \n\u0083 Acute aortic dissection\n \n\u0083 Eclampsia or pre-eclampsia (section 16.3.7 and 16.3.8)\n316\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Risk Factor</p>\n<p>Heart failure</p>\n<p>Post myocardial infarction</p>\n<p>Angina</p>\n<p>Diabetes</p>\n<p>Mild/moderate kidney disease</p>\n<p>Advanced chronic kidney disease</p>\n<p>Stroke</p>\n<p>Carvedilol or Bisoprolol  only</p>\n<p>Diuretic</p>\n<p>Beta Blocker</p>\n<p>Ccb</p>\n<p>Ace Inhibitor</p>\n<p>/Arbs</p>\n<p>Aldosteron</p>\n<p>Antagonist</p>\n<p>Prevention</p>\n<p>\u0083 Regular physical exercise</p>\n<p>\u0083 Reduce salt intake</p>\n<p>\u0083 Healthy diet, stop smoking</p>\n<p>\u0083 Periodic screening of blood pressure</p>\n<p>4.1.6.1\t Hypertensive Emergencies and urgency</p>\n<h3>ICD10 CODE: I16.2</h3>\n<p>Hypertensive emergency</p>\n<p>BP >180/110 mmHg with symptoms and acute life threatening com\u00ad</p>\n<p>plications:</p>\n<p>\u0083 Hypertensive encephalopathy (severe headache, confusion,</p>\n<p>seizures, visual disturbances)</p>\n<p>\u0083 Acute angina or acute myocardial infarction (AMI)</p>\n<p>\u0083 Pulmonary oedema</p>\n<p>\u0083 Acute kidney failure</p>\n<p>\u0083 Acute aortic dissection</p>\n<p>\u0083 Eclampsia or pre-eclampsia (section 16.3.7 and 16.3.8)</p>\n<p>316</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 383,
        "content": "Management\nTREATMENT\nLOC\n Admit and give parenteral medicines. Aim at lowering \nthe blood pressure over 24 hours (not too rapidly except if \nabsolutely necessary)\n Treatment depends also on the presenting complications\n \n- In acute ischaemic stroke, do not lower below \n220/120 mmHg\n \n- In acute aortic dissection, lower BP rapidly\n \n- In pulmonary oedema, AMI: treat the complication\n Give IV furosemide 40-80 mg\n If aggressive BP lowering is needed, use IV hydralazine 5-10 \nmg slowly over 20 minutes. Check blood pressure regularly, \nrepeat dose after 20-30 minutes if necessary\nHC4\nHypertensive urgency\nBP > 180/110 mmHg without evidence of target organ damage, such \nas pulmonary edema, cardiac ischemia, neurologic deficits, or acute \nrenal failure. \nManagement\nTREATMENT\nLOC\n Admit\n Treat with combination of oral antihypertensive therapy \n(ACEI/ARB inhibitor + calcium channel blocker \u00b1 diuretics)\n Aim at lowering blood pressure over the next 48- 72 hours\nHC4\n4.1.7\t\nIschaemic Heart Disease (Coronary Heart Disease)\t\n ICD10 CODE: I20, I21, I25\nA condition in which there is insufficient blood flow through the coro\u00ad\nnary arteries of the heart, thus leading to ischaemia and/or infarction.\n317\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Admit and give parenteral medicines. Aim at lowering</p>\n<p>the blood pressure over 24 hours (not too rapidly except if</p>\n<p>absolutely necessary)</p>\n<p>Treatment depends also on the presenting complications</p>\n<p>- In acute ischaemic stroke, do not lower below</p>\n<p>220/120 mmHg</p>\n<p>- In acute aortic dissection, lower BP rapidly</p>\n<p>- In pulmonary oedema, AMI: treat the complication</p>\n<p>Give IV furosemide 40-80 mg</p>\n<p>If aggressive BP lowering is needed, use IV hydralazine 5-10</p>\n<p>mg slowly over 20 minutes. Check blood pressure regularly,</p>\n<p>repeat dose after 20-30 minutes if necessary</p>\n<h3>HC4</h3>\n<p>Hypertensive urgency</p>\n<p>BP > 180/110 mmHg without evidence of target organ damage, such</p>\n<p>as pulmonary edema, cardiac ischemia, neurologic deficits, or acute</p>\n<p>renal failure.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Admit</p>\n<p>Treat with combination of oral antihypertensive therapy</p>\n<p>(ACEI/ARB inhibitor + calcium channel blocker \u00b1 diuretics)</p>\n<p>Aim at lowering blood pressure over the next 48- 72 hours</p>\n<h3>HC4</h3>\n<p>4.1.7</p>\n<p>Ischaemic Heart Disease (Coronary Heart Disease)</p>\n<h3>ICD10 CODE: I20, I21, I25</h3>\n<p>A condition in which there is insufficient blood flow through the coro\u00ad</p>\n<p>nary arteries of the heart, thus leading to ischaemia and/or infarction.</p>\n<p>317</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 384,
        "content": "Cause\n \n\u0083 Deposition of fatty material (cholesterol plaques) and platelet \naggregation inside the coronary arteries causing partial or total \nobstruction of blood flow\nRisk factors\n \n\u0083 Hypertension, diabetes mellitus\n \n\u0083 Smoking\n \n\u0083 Obesity, unhealthy diet, physical inactivity\n \n\u0083 Hyperlipidemia\n \n\u0083 Family history of heart disease\nClinical features\n \n\u0083 Acute coronary syndrome (including acute myocardial infarction): \nprolonged chest pain, which may be localised on the left or \ncentral part of the chest, ranging from mild to severe, at times \nradiating to the left arm, neck and back,\n \n\u0083 and associated with sweating, dyspnoea, vomiting, anxiety, low \nBP, tachycardia\n \n\u0083 Stable angina: tightness in the chest or a sense of oppression \nworsening on exertion, relieved by rest and lasting only a few \nminutes\n \n\u0083 Sudden cardiac death: usually due to fatal arrhythmias\nDifferential diagnosis\n \n\u0083 Indigestion, hiatus hernia, peptic ulcer\n \n\u0083 Pleurisy, pericarditis, pulmonary embolism\n \n\u0083 Dissecting aneurysm\nInvestigations\n \n\u0083 Cardiac enzymes (CPK, troponin)\n \n\u0083 ECG (at rest and stress ECG)\n \n\u0083 Echocardiogram\n318\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Cause</p>\n<p>\u0083 Deposition of fatty material (cholesterol plaques) and platelet</p>\n<p>aggregation inside the coronary arteries causing partial or total</p>\n<p>obstruction of blood flow</p>\n<p>Risk factors</p>\n<p>\u0083 Hypertension, diabetes mellitus</p>\n<p>\u0083 Smoking</p>\n<p>\u0083 Obesity, unhealthy diet, physical inactivity</p>\n<p>\u0083 Hyperlipidemia</p>\n<p>\u0083 Family history of heart disease</p>\n<p>Clinical features</p>\n<p>\u0083 Acute coronary syndrome (including acute myocardial infarction):</p>\n<p>prolonged chest pain, which may be localised on the left or</p>\n<p>central part of the chest, ranging from mild to severe, at times</p>\n<p>radiating to the left arm, neck and back,</p>\n<p>\u0083 and associated with sweating, dyspnoea, vomiting, anxiety, low</p>\n<p>BP, tachycardia</p>\n<p>\u0083 Stable angina: tightness in the chest or a sense of oppression</p>\n<p>worsening on exertion, relieved by rest and lasting only a few</p>\n<p>minutes</p>\n<p>\u0083 Sudden cardiac death: usually due to fatal arrhythmias</p>\n<p>Differential diagnosis</p>\n<p>\u0083 Indigestion, hiatus hernia, peptic ulcer</p>\n<p>\u0083 Pleurisy, pericarditis, pulmonary embolism</p>\n<p>\u0083 Dissecting aneurysm</p>\n<p>Investigations</p>\n<p>\u0083 Cardiac enzymes (CPK, troponin)</p>\n<p>\u0083 ECG (at rest and stress ECG)</p>\n<p>\u0083 Echocardiogram</p>\n<p>318</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 385,
        "content": "Management of acute coronary syndrome\nTREATMENT\nLOC\n Give acetylsalicylic acid 300 mg single dose (to be chewed)\nRefer immediately to hospital\n Glyceryl trinitrate 500 micrograms sublingually Repeat after \n5 min if no response\n Oxygen therapy if SpO2 < 94%\n Morphine 2.5-5 mg IV if persisting pain\n Simvastatin 40 mg or atorvastatin 40 mg\n Enoxaparin 1 mg/kg SC every 12 hours\n Treat complications accordingly (pulmonary oedema, \narrhythmias)\nHC2\nH\nConsider adding:\n Beta blockers if no contraindications (SBP <90 mmHg, HR \n<60 bpm) e.g. Atenolol 25-50 mg daily\n\u2013 Ensure close observation of the pulse rate and circulatory \nstatus\n ACE inhibitor e.g. Enalapril 2.5-10 mg/daily\n Refer for further management to higher level of care if unstable\nWhen patient is stable, continue with:\n Acetylsalicylic acid 75 mg once daily,\n Atorvastatin 40 mg daily\n Beta blocker (Atenolol or Carvedilol or Bisoprolol) and ACE \ninhibitor if tolerated\n Emphasize life changes (healthy diet, no smoking, regular \nexercise, control of other risk factors)\nH\n319\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management of acute coronary syndrome</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Give acetylsalicylic acid 300 mg single dose (to be chewed)</p>\n<p>Refer immediately to hospital</p>\n<p>Glyceryl trinitrate 500 micrograms sublingually Repeat after</p>\n<p>5 min if no response</p>\n<p>Oxygen therapy if SpO2 < 94%</p>\n<p>Morphine 2.5-5 mg IV if persisting pain</p>\n<p>Simvastatin 40 mg or atorvastatin 40 mg</p>\n<p>Enoxaparin 1 mg/kg SC every 12 hours</p>\n<p>Treat complications accordingly (pulmonary oedema,</p>\n<p>arrhythmias)</p>\n<h3>HC2</h3>\n<p>H</p>\n<p>Consider adding:</p>\n<p>Beta blockers if no contraindications (SBP <90 mmHg, HR</p>\n<p><60 bpm) e.g. Atenolol 25-50 mg daily</p>\n<p>\u2013 Ensure close observation of the pulse rate and circulatory</p>\n<p>status</p>\n<p>ACE inhibitor e.g. Enalapril 2.5-10 mg/daily</p>\n<p>Refer for further management to higher level of care if unstable</p>\n<p>When patient is stable, continue with:</p>\n<p>Acetylsalicylic acid 75 mg once daily,</p>\n<p>Atorvastatin 40 mg daily</p>\n<p>Beta blocker (Atenolol or Carvedilol or Bisoprolol) and ACE</p>\n<p>inhibitor if tolerated</p>\n<p>Emphasize life changes (healthy diet, no smoking, regular</p>\n<p>exercise, control of other risk factors)</p>\n<p>H</p>\n<p>319</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 386,
        "content": "Management of stable angina\nTREATMENT\nLOC\n Aggressive control of risk factors (hypertension, diabetes, \nsmoking, obesity)\n Acetylsalicylic acid 75-150 mg once a day\n Atorvastatin 40 mg once a day\n Beta blockers (e.g. Atenolol 25-100 mg) if not diabetic\n Refer to higher level if still uncontrolled\nHC2\nH\nPrevention\n \n\u0083 Low fat, low cholesterol diet\n \n\u0083 Stop smoking\n \n\u0083 Effective control of hypertension and diabetes mellitus\n \n\u0083 Consider treatment with acetylsalicylic acid and statin in patients \nwith multiple risk factors\n4.1.8 Pericarditis\t\n          ICD10 CODE: I30\nInflammation of the heart membrane (pericardium), which may be:\n\t\n\u0089\nAcute and self-limiting, sub-acute or chronic\n\t\n\u0089\nFibrinous, serous, haemorrhagic or purulent\nCauses\n \n\u0083 Idiopathic or viral (most common causes) e.g. CoxsackieA & \nB, influenza A & B, varicella\n \n\u0083 Bacterial e.g. mycobacterium, staphylococcus, meningococcus, \nstreptococcus, pneumococcus, gonococcus, mycoplasma\n \n\u0083 Fungal: Histoplasmosis\n \n\u0083 Severe kidney failure (less common)\n \n\u0083 Hypersensitivity such as acute rheumatic fever\n \n\u0083 Myocardial infarction\n \n\u0083 Radiation, trauma, neoplasms\n320\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management of stable angina</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Aggressive control of risk factors (hypertension, diabetes,</p>\n<p>smoking, obesity)</p>\n<p>Acetylsalicylic acid 75-150 mg once a day</p>\n<p>Atorvastatin 40 mg once a day</p>\n<p>Beta blockers (e.g. Atenolol 25-100 mg) if not diabetic</p>\n<p>Refer to higher level if still uncontrolled</p>\n<h3>HC2</h3>\n<p>H</p>\n<p>Prevention</p>\n<p>\u0083 Low fat, low cholesterol diet</p>\n<p>\u0083 Stop smoking</p>\n<p>\u0083 Effective control of hypertension and diabetes mellitus</p>\n<p>\u0083 Consider treatment with acetylsalicylic acid and statin in patients</p>\n<p>with multiple risk factors</p>\n<p>4.1.8 Pericarditis</p>\n<h3>ICD10 CODE: I30</h3>\n<p>Inflammation of the heart membrane (pericardium), which may be:</p>\n<p>\u0089</p>\n<p>Acute and self-limiting, sub-acute or chronic</p>\n<p>\u0089</p>\n<p>Fibrinous, serous, haemorrhagic or purulent</p>\n<p>Causes</p>\n<p>\u0083 Idiopathic or viral (most common causes) e.g. CoxsackieA &</p>\n<p>B, influenza A & B, varicella</p>\n<p>\u0083 Bacterial e.g. mycobacterium, staphylococcus, meningococcus,</p>\n<p>streptococcus, pneumococcus, gonococcus, mycoplasma</p>\n<p>\u0083 Fungal: Histoplasmosis</p>\n<p>\u0083 Severe kidney failure (less common)</p>\n<p>\u0083 Hypersensitivity such as acute rheumatic fever</p>\n<p>\u0083 Myocardial infarction</p>\n<p>\u0083 Radiation, trauma, neoplasms</p>\n<p>320</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 387,
        "content": "Clinical features\n \n~\nPericarditis without effusion: retrosternal pain radiating to \nshoulder, which worsens on deep breathing, movement, \nchange of position or exercise; pericardial rub is a diag\u00ad\nnostic sign\n \n~\nPericardial effusion: reduced cardiac impulses, muffled \nheart sounds, cardiomegaly\n \n~\nCardiac tamponade (compression) in case of massive ef\u00ad\nfusion or constrictive pericarditis: dyspnoea, restlessness, \nrising pulmonary and systemic venous pressure, rapid heart \nrate, pulsus paradoxus, low BP, and low output cardiac fail\u00ad\nure\nDifferential diagnosis\n \n~\nOther causes of chest pain\n \n~\nOther cause of heart failure\nInvestigations\n \n\u0081\nECG, chest X-ray\n \n\u0081\nEcho-cardiography\nTREATMENT\nLOC\nIf viral or idiopathic\n\t\n\u0089\nRest\n\t\n\u0089\nIbuprofen 600 mg every 8 hours\n\t\n\u0089\nIf there is fluid, perform tapping\nIf other causes, treat accordingly\nH\nManagement of stable angina\nPrevention\n \n~\nEarly detection and treatment of potential (treatable) causes\n321\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Pericarditis without effusion: retrosternal pain radiating to</p>\n<p>shoulder, which worsens on deep breathing, movement,</p>\n<p>change of position or exercise; pericardial rub is a diag\u00ad</p>\n<p>nostic sign</p>\n<p>~</p>\n<p>Pericardial effusion: reduced cardiac impulses, muffled</p>\n<p>heart sounds, cardiomegaly</p>\n<p>~</p>\n<p>Cardiac tamponade (compression) in case of massive ef\u00ad</p>\n<p>fusion or constrictive pericarditis: dyspnoea, restlessness,</p>\n<p>rising pulmonary and systemic venous pressure, rapid heart</p>\n<p>rate, pulsus paradoxus, low BP, and low output cardiac fail\u00ad</p>\n<p>ure</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of chest pain</p>\n<p>~</p>\n<p>Other cause of heart failure</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>ECG, chest X-ray</p>\n<p>\u0081</p>\n<p>Echo-cardiography</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If viral or idiopathic</p>\n<p>\u0089</p>\n<p>Rest</p>\n<p>\u0089</p>\n<p>Ibuprofen 600 mg every 8 hours</p>\n<p>\u0089</p>\n<p>If there is fluid, perform tapping</p>\n<p>If other causes, treat accordingly</p>\n<p>H</p>\n<p>Management of stable angina</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Early detection and treatment of potential (treatable) causes</p>\n<p>321</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 388,
        "content": "4.1.9\t\nRheumatic Fever\t\nICD10 CODE: I00, I01\nA systemic connective tissue disease which follows a streptococcal \nupper respiratory tract infection. It may involve the heart, joints, skin, \nsubcutaneous tissue, and CNS. The first attack usually occurs between \nages of 3\u201315 years.\nCauses\n \n~\nHypersensitivity reaction to group A streptococcal throat \ninfection\nClinical features\n \n~\nArthritis (migrating asymmetric polyarthritis)\n \n~\nAcute rheumatic carditis, signs of cardiac failure, murmurs \nand pericarditis\n \n~\nSubcutaneous nodules\n \n~\nChorea (involuntary movements of limbs)\n \n~\nSkin rash\n \n~\nOther minor signs/symptoms: fever, arthralgia, laboratory \nfindings\nDifferential diagnosis\n \n~\nAny form of arthralgia/arthritis including sickle cell disease, \nhaemophilia\n \n~\nPyrexia with cardiac failure\nInvestigations\n \n\u0081\nBlood: Haemogram (raised ESR)\n \n\u0081\nChest X-ray\n \n\u0081\nECG\n \n\u0081\nEchocardiography\n \n\u0081\nAntistreptolysin O titre (ASOT)\nDiagnostic criteria (revised Jones criteria)\n \n~\nEvidence of recent streptococcal infection\n322\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>4.1.9</p>\n<p>Rheumatic Fever</p>\n<h3>ICD10 CODE: I00, I01</h3>\n<p>A systemic connective tissue disease which follows a streptococcal</p>\n<p>upper respiratory tract infection. It may involve the heart, joints, skin,</p>\n<p>subcutaneous tissue, and CNS. The first attack usually occurs between</p>\n<p>ages of 3\u201315 years.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Hypersensitivity reaction to group A streptococcal throat</p>\n<p>infection</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Arthritis (migrating asymmetric polyarthritis)</p>\n<p>~</p>\n<p>Acute rheumatic carditis, signs of cardiac failure, murmurs</p>\n<p>and pericarditis</p>\n<p>~</p>\n<p>Subcutaneous nodules</p>\n<p>~</p>\n<p>Chorea (involuntary movements of limbs)</p>\n<p>~</p>\n<p>Skin rash</p>\n<p>~</p>\n<p>Other minor signs/symptoms: fever, arthralgia, laboratory</p>\n<p>findings</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Any form of arthralgia/arthritis including sickle cell disease,</p>\n<p>haemophilia</p>\n<p>~</p>\n<p>Pyrexia with cardiac failure</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Haemogram (raised ESR)</p>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<p>\u0081</p>\n<h3>ECG</h3>\n<p>\u0081</p>\n<p>Echocardiography</p>\n<p>\u0081</p>\n<p>Antistreptolysin O titre (ASOT)</p>\n<p>Diagnostic criteria (revised Jones criteria)</p>\n<p>~</p>\n<p>Evidence of recent streptococcal infection</p>\n<p>322</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 389,
        "content": "\u0089\nElevated ASO-titer or other streptococcal Ab titres or positive \nthroat swab for group A beta-hemolyticus streptococcus\nPLUS\n \n~\nTwo major manifestations or one major and two minor \nmanifestations\nMAJOR MANIFESTATIONS\nMINOR MANIFESTATIONS\n \n~\nPolyarthritis\n \n~\nCarditis\n \n~\nErythema \nmargina\u00ad\ntum\n \n~\nSubcutaneous \nnod\u00ad\nules\n \n~\nSydehnam\u2019s chorea\n \n~\nPolyarthralgia\n \n~\nFever\n \n~\nAcute phase reac\u00ad\ntants (increased ESR/\nCRP)\n \n~\nECG: prolonged PR \nin\nTREATMENT\nLOC\n\t\n\u0089\nBed rest\nTo eradicate any streptococci:\n\t\n\u0089\nPhenoxymethylpenicillin (Pen V) 250 mg every 6 hours \nfor 10 days\nChild: 125 mg per dose\n\t\n\u0089\nOr Benzathine benzylpenicillin dose 1.2 MU IM stat\nChild < 30 kg: 0.6 MU\nChild > 30 kg: 1.2 MU\nTo treat the inflammation\n\t\n\u0089\nAcetylsalicylic acid 4-8 g/day untill signs of inflammation \nsubside (usually 4-8 weeks)\nChild: 80-100 mg/kg/day in 3 doses\n\t\n\u0089\nPlus magnesium trisilicate compound 2-4 tablets every 8 hours\nHC4\nManagement of stable angina\n323\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>\u0089</p>\n<p>Elevated ASO-titer or other streptococcal Ab titres or positive</p>\n<p>throat swab for group A beta-hemolyticus streptococcus</p>\n<h3>PLUS</h3>\n<p>~</p>\n<p>Two major manifestations or one major and two minor</p>\n<p>manifestations</p>\n<h3>MAJOR MANIFESTATIONS</h3>\n<h3>MINOR MANIFESTATIONS</h3>\n<p>~</p>\n<p>Polyarthritis</p>\n<p>~</p>\n<p>Carditis</p>\n<p>~</p>\n<p>Erythema</p>\n<p>margina\u00ad</p>\n<p>tum</p>\n<p>~</p>\n<p>Subcutaneous</p>\n<p>nod\u00ad</p>\n<p>ules</p>\n<p>~</p>\n<p>Sydehnam\u2019s chorea</p>\n<p>~</p>\n<p>Polyarthralgia</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Acute phase reac\u00ad</p>\n<p>tants (increased ESR/</p>\n<h3>CRP)</h3>\n<p>~</p>\n<p>ECG: prolonged PR</p>\n<p>in</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Bed rest</p>\n<p>To eradicate any streptococci:</p>\n<p>\u0089</p>\n<p>Phenoxymethylpenicillin (Pen V) 250 mg every 6 hours</p>\n<p>for 10 days</p>\n<p>Child: 125 mg per dose</p>\n<p>\u0089</p>\n<p>Or Benzathine benzylpenicillin dose 1.2 MU IM stat</p>\n<p>Child < 30 kg: 0.6 MU</p>\n<p>Child > 30 kg: 1.2 MU</p>\n<p>To treat the inflammation</p>\n<p>\u0089</p>\n<p>Acetylsalicylic acid 4-8 g/day untill signs of inflammation</p>\n<p>subside (usually 4-8 weeks)</p>\n<p>Child: 80-100 mg/kg/day in 3 doses</p>\n<p>\u0089</p>\n<p>Plus magnesium trisilicate compound 2-4 tablets every 8 hours</p>\n<h3>HC4</h3>\n<p>Management of stable angina</p>\n<p>323</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 390,
        "content": "TREATMENT\nLOC\nTaken 30 minutes after the acetylsalicylic acid tablets\nIf allergic to aspirin\n\t\n\u0089\nLow dose steroid\nHC4\nIf carditis/heart failure symptoms\n\t\n\u0089\nTreat as per heart failure guidelines (section 4.1.3)\n\t\n\u0089\nConsider high dose steroids (specialist only)\nIf chorea:\n\t\n\u0089\nValproate 10-20 mg/kg/day\nH\nProphylaxis\nTo prevent further episodes\n\t\n\u0089\nPen V 500 mg 12 hourly\nChild: 125-250 mg 12 hourly\n\t\n\u0089\nOr Benzathine benzylpenicillin 1.2 MU IM every 4 weeks\nChild <30 kg: 0.6 MU\nIf allergic to penicillin: \n\t\n\u0089\nErythromycin 250 mg 12 hourly \n\t\n\u0089\nChild: 10 mg/kg twice a day\nDuration of prophylaxis depends on severity of disease:\n \n- Rheumatic fever without carditis: for 5 years or \nuntil age 18 or 21 years old\n \n- Carditis but no residual heart disease: for 10 years\n \n- or until age 25 years old\n \n- Carditis with residual heart disease: untill age 40- \n45 years or for life\nHC3\nManagement of stable angina\n324\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Taken 30 minutes after the acetylsalicylic acid tablets</p>\n<p>If allergic to aspirin</p>\n<p>\u0089</p>\n<p>Low dose steroid</p>\n<h3>HC4</h3>\n<p>If carditis/heart failure symptoms</p>\n<p>\u0089</p>\n<p>Treat as per heart failure guidelines (section 4.1.3)</p>\n<p>\u0089</p>\n<p>Consider high dose steroids (specialist only)</p>\n<p>If chorea:</p>\n<p>\u0089</p>\n<p>Valproate 10-20 mg/kg/day</p>\n<p>H</p>\n<p>Prophylaxis</p>\n<p>To prevent further episodes</p>\n<p>\u0089</p>\n<p>Pen V 500 mg 12 hourly</p>\n<p>Child: 125-250 mg 12 hourly</p>\n<p>\u0089</p>\n<p>Or Benzathine benzylpenicillin 1.2 MU IM every 4 weeks</p>\n<p>Child <30 kg: 0.6 MU</p>\n<p>If allergic to penicillin:</p>\n<p>\u0089</p>\n<p>Erythromycin 250 mg 12 hourly</p>\n<p>\u0089</p>\n<p>Child: 10 mg/kg twice a day</p>\n<p>Duration of prophylaxis depends on severity of disease:</p>\n<p>- Rheumatic fever without carditis: for 5 years or</p>\n<p>until age 18 or 21 years old</p>\n<p>- Carditis but no residual heart disease: for 10 years</p>\n<p>- or until age 25 years old</p>\n<p>- Carditis with residual heart disease: untill age 40-</p>\n<p>45 years or for life</p>\n<h3>HC3</h3>\n<p>Management of stable angina</p>\n<p>324</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 391,
        "content": "Prevention\n \n~\nEarly diagnosis and treatment of group A Streptococcus \nthroat infection\n \n~\nAvoid overcrowding, good housing\n \n~\nGood nutrition\n4.1.10\t\nRheumatic Heart Disease           ICD10 CODE: I05-I09\nDisease of the heart valves following an episode of rheumatic fever. The \nvalves commonly involved are:\n \n~\nMitral valve, leading to stenosis, incompetence, or both\n \n~\nAortic valve, leading to stenosis and incompetence or both\nClinical features\n \n~\nHeart failure\n \n~\nArrhythmias, palpitations\n \n~\nThromboembolic problems e.g. stroke\n \n~\nHeart murmurs depending on valves affected and nature of \neffect caused\n \n~\nThe patient may be asymptomatic and the valvular lesion \ndiscovered as an incidental finding\n \n~\nIncreased cardiac demand as in pregnancy and anaemia \nmay present as congestive cardiac failure\nDifferential diagnosis\n \n~\nOther causes of cardiac failure\nInvestigations\n \n\u0081\nChest X-ray\n \n\u0081\nECG where available\n \n\u0081\nEchocardiography\n325\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Early diagnosis and treatment of group A Streptococcus</p>\n<p>throat infection</p>\n<p>~</p>\n<p>Avoid overcrowding, good housing</p>\n<p>~</p>\n<p>Good nutrition</p>\n<p>4.1.10</p>\n<p>Rheumatic Heart Disease           ICD10 CODE: I05-I09</p>\n<p>Disease of the heart valves following an episode of rheumatic fever. The</p>\n<p>valves commonly involved are:</p>\n<p>~</p>\n<p>Mitral valve, leading to stenosis, incompetence, or both</p>\n<p>~</p>\n<p>Aortic valve, leading to stenosis and incompetence or both</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Heart failure</p>\n<p>~</p>\n<p>Arrhythmias, palpitations</p>\n<p>~</p>\n<p>Thromboembolic problems e.g. stroke</p>\n<p>~</p>\n<p>Heart murmurs depending on valves affected and nature of</p>\n<p>effect caused</p>\n<p>~</p>\n<p>The patient may be asymptomatic and the valvular lesion</p>\n<p>discovered as an incidental finding</p>\n<p>~</p>\n<p>Increased cardiac demand as in pregnancy and anaemia</p>\n<p>may present as congestive cardiac failure</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of cardiac failure</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<p>\u0081</p>\n<p>ECG where available</p>\n<p>\u0081</p>\n<p>Echocardiography</p>\n<p>325</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 392,
        "content": "Management of stable angina\nTREATMENT\nLOC\n\t\n\u0089\nTreat heart failure if present\n\t\n\u0089\nProphylaxis for life as in rheumatic fever above\n\t\n\u0089\nCardiac surgery if necessary (only at national referral \nhospital)\nHC4\nNR\n4.1.11 Stroke                              ICD10 CODE: I63\nA cerebral neurological dysfunction due to a problem in blood circulation: \na clot (ischaemic stroke) or bleeding (haemorrhagic stroke).\nCauses\n \n~\nClot (a thrombus in a brain vessel or an embolus from a clot \nsowhere else) \u2013 most common\n \n~\nHaemorrhage (from trauma or spontaneous)\nClinical features\n \n~\nFocal neurological deficits as one-sided weakness (face, \narm, leg. Note that eyes are not affected) \u2013 hemiparesis or \nhemiplegia\n \n~\nDifficulty in speaking/swallowing\n \n~\nSevere headache (especially in haemorrhage)\n \n~\nAlteration of consciousness\n \n~\nConvulsions\nInvestigations\n \n\u0081\nCT scan of the brain\nIn the absence of neuroimaging, the following clinical features may help \nto distinguish the stroke subtypes:\n326\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management of stable angina</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat heart failure if present</p>\n<p>\u0089</p>\n<p>Prophylaxis for life as in rheumatic fever above</p>\n<p>\u0089</p>\n<p>Cardiac surgery if necessary (only at national referral</p>\n<p>hospital)</p>\n<h3>HC4</h3>\n<p>NR</p>\n<p>4.1.11 Stroke                              ICD10 CODE: I63</p>\n<p>A cerebral neurological dysfunction due to a problem in blood circulation:</p>\n<p>a clot (ischaemic stroke) or bleeding (haemorrhagic stroke).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Clot (a thrombus in a brain vessel or an embolus from a clot</p>\n<p>sowhere else) \u2013 most common</p>\n<p>~</p>\n<p>Haemorrhage (from trauma or spontaneous)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Focal neurological deficits as one-sided weakness (face,</p>\n<p>arm, leg. Note that eyes are not affected) \u2013 hemiparesis or</p>\n<p>hemiplegia</p>\n<p>~</p>\n<p>Difficulty in speaking/swallowing</p>\n<p>~</p>\n<p>Severe headache (especially in haemorrhage)</p>\n<p>~</p>\n<p>Alteration of consciousness</p>\n<p>~</p>\n<p>Convulsions</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>CT scan of the brain</p>\n<p>In the absence of neuroimaging, the following clinical features may help</p>\n<p>to distinguish the stroke subtypes:</p>\n<p>326</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 393,
        "content": "Type\nClinical \nCourse\nRisk Factors\nOther Clues\nIntracerebral \nhaemorrhage\nGradual \nprogression \nover minutes/ \nhours\nHypertension, \ntrauma, bleeding \ndisorders, illicit \ndrugs\nPatients may \nhave reduced \nalertness and \nsevere head\u00ad\nache\nSubarachnoid \nhaemorrhage\nAbrupt onset \nof very severe \nheadache, fo\u00ad\ncal symptoms\nless common\nSmoking, hy\u00ad\npertension, illicit \ndrugs, but at times \nnone (due to rup\u00ad\nture of congenital \naneurysms)\nPatients may \nhave reduced \nalertness\nIt may hap\u00ad\npen in young \npeople\nIschaemic \n(thrombotic)\nGradual de\u00ad\nvelopment of \nfocal deficits \nover hours or \ndays\nAge, smoking, dia\u00ad\nbetes, dyslipidemia\nSymptoms can \nimprove and \nworsen\nin the follow\u00ad\ning days\nIschaemic \n(embolic)\nSudden onset \nof focal defi\u00ad\ncits\nAs above plus val\u00ad\nvular heart disease \nand arrhythmias\nOften improves \nslowly\nManagement of stable angina\nTREATMENT\nLOC\nGeneral care\n\t\n\u0089\nEnsure airways and respiration if unconscious\n\t\n\u0089\nDo not give anything by mouth before assessing the \nability to swallow, to avoid risk of inhalation\n\t\n\u0089\nIV or NGT for hydration and nutrition if unable to swallow\n\t\n\u0089\nControl blood sugar with insulin if diabetic\nH\n327\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Type</p>\n<p>Clinical</p>\n<p>Course</p>\n<p>Risk Factors</p>\n<p>Other Clues</p>\n<p>Intracerebral</p>\n<p>haemorrhage</p>\n<p>Gradual</p>\n<p>progression</p>\n<p>over minutes/</p>\n<p>hours</p>\n<p>Hypertension,</p>\n<p>trauma, bleeding</p>\n<p>disorders, illicit</p>\n<p>drugs</p>\n<p>Patients may</p>\n<p>have reduced</p>\n<p>alertness and</p>\n<p>severe head\u00ad</p>\n<p>ache</p>\n<p>Subarachnoid</p>\n<p>haemorrhage</p>\n<p>Abrupt onset</p>\n<p>of very severe</p>\n<p>headache, fo\u00ad</p>\n<p>cal symptoms</p>\n<p>less common</p>\n<p>Smoking, hy\u00ad</p>\n<p>pertension, illicit</p>\n<p>drugs, but at times</p>\n<p>none (due to rup\u00ad</p>\n<p>ture of congenital</p>\n<p>aneurysms)</p>\n<p>Patients may</p>\n<p>have reduced</p>\n<p>alertness</p>\n<p>It may hap\u00ad</p>\n<p>pen in young</p>\n<p>people</p>\n<p>Ischaemic</p>\n<p>(thrombotic)</p>\n<p>Gradual de\u00ad</p>\n<p>velopment of</p>\n<p>focal deficits</p>\n<p>over hours or</p>\n<p>days</p>\n<p>Age, smoking, dia\u00ad</p>\n<p>betes, dyslipidemia</p>\n<p>Symptoms can</p>\n<p>improve and</p>\n<p>worsen</p>\n<p>in the follow\u00ad</p>\n<p>ing days</p>\n<p>Ischaemic</p>\n<p>(embolic)</p>\n<p>Sudden onset</p>\n<p>of focal defi\u00ad</p>\n<p>cits</p>\n<p>As above plus val\u00ad</p>\n<p>vular heart disease</p>\n<p>and arrhythmias</p>\n<p>Often improves</p>\n<p>slowly</p>\n<p>Management of stable angina</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General care</p>\n<p>\u0089</p>\n<p>Ensure airways and respiration if unconscious</p>\n<p>\u0089</p>\n<p>Do not give anything by mouth before assessing the</p>\n<p>ability to swallow, to avoid risk of inhalation</p>\n<p>\u0089</p>\n<p>IV or NGT for hydration and nutrition if unable to swallow</p>\n<p>\u0089</p>\n<p>Control blood sugar with insulin if diabetic</p>\n<p>H</p>\n<p>327</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 394,
        "content": "Management of stable angina\nTREATMENT\nLOC\nIf ischaemic stroke\n\t\n\u0089\nAspirin 150-300 mg every 24 hours\n\t\n\u0089\nIn the acute phase, treat hypertension only if extreme \n(more than 220/120) or if there are other complications \n(pulmonary oedema, angina, etc), otherwise re-start \nantihypertensive 24 hours after the event and reduce \nblood pressure slowly\n\t\n\u0089\nConsider DVT prophylaxis with enoxaparin 40 mg \nSC daily\nIf stroke clinically haemorrhagic\n\t\n\u0089\nSupportive care as above\n\t\n\u0089\nRefer for CT scan and neurosurgical evaluation\nChronic care of ischaemic stroke \n\t\n\u0089\nEarly mobilization and physiotherapy f Aspirin 75-100 \nmg once daily for life f Atorvastatin 40 mg daily for life\n\t\n\u0089\nControl of risk factors\nH\n328\nUganda Clinical Guidelines 2023\nCHAPTER 4: Cardiovascular Diseases",
        "formatted_content": "<p>Management of stable angina</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If ischaemic stroke</p>\n<p>\u0089</p>\n<p>Aspirin 150-300 mg every 24 hours</p>\n<p>\u0089</p>\n<p>In the acute phase, treat hypertension only if extreme</p>\n<p>(more than 220/120) or if there are other complications</p>\n<p>(pulmonary oedema, angina, etc), otherwise re-start</p>\n<p>antihypertensive 24 hours after the event and reduce</p>\n<p>blood pressure slowly</p>\n<p>\u0089</p>\n<p>Consider DVT prophylaxis with enoxaparin 40 mg</p>\n<p>SC daily</p>\n<p>If stroke clinically haemorrhagic</p>\n<p>\u0089</p>\n<p>Supportive care as above</p>\n<p>\u0089</p>\n<p>Refer for CT scan and neurosurgical evaluation</p>\n<p>Chronic care of ischaemic stroke</p>\n<p>\u0089</p>\n<p>Early mobilization and physiotherapy f Aspirin 75-100</p>\n<p>mg once daily for life f Atorvastatin 40 mg daily for life</p>\n<p>\u0089</p>\n<p>Control of risk factors</p>\n<p>H</p>\n<p>328</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 4: Cardiovascular Diseases</p>"
    },
    {
        "page_number": 395,
        "content": "5.1 NON-INFECTIOUS RESPIRATORY DISEASES\n5.1.1\t\nAsthma                     ICD10 CODE: J45\nA chronic inflammatory disease of the airways which leads to muscle \nspasm, mucus plugging and oedema. It results in recurrent wheezing, \ncough, breathlessness and chest tightness.\nAcute attacks may be precipitated by upper respiratory tract infections \n(e.g., flu) and exposure to irritant substances (e.g. dust, exercise, and cold).\nCauses\n \n~\nNot known but associated with allergies, inherited and en\u00ad\nvironmental factors\nClinical features\n \n~\nNo fever (if fever present, refer to pneumonia)\n \n~\nDifficulty in breathing (usually recurrent attacks) with chest \ntightness, with or without use of accessory muscles. Pa\u00ad\ntients may not appear very distressed despite a severe at\u00ad\ntack\n \n~\nWheezing, rhonchi\n \n~\nCough \u2013 usually dry, may be intermittent, persistent, or \nacute, especially at night\nSevere forms: failure to complete sentences, darkening of lips, oral \nmucosa and extremities (cyanosis)\nRespiratory Diseases\n5\n329\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>5.1 NON-INFECTIOUS RESPIRATORY DISEASES</h3>\n<p>5.1.1</p>\n<p>Asthma                     ICD10 CODE: J45</p>\n<p>A chronic inflammatory disease of the airways which leads to muscle</p>\n<p>spasm, mucus plugging and oedema. It results in recurrent wheezing,</p>\n<p>cough, breathlessness and chest tightness.</p>\n<p>Acute attacks may be precipitated by upper respiratory tract infections</p>\n<p>(e.g., flu) and exposure to irritant substances (e.g. dust, exercise, and cold).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not known but associated with allergies, inherited and en\u00ad</p>\n<p>vironmental factors</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>No fever (if fever present, refer to pneumonia)</p>\n<p>~</p>\n<p>Difficulty in breathing (usually recurrent attacks) with chest</p>\n<p>tightness, with or without use of accessory muscles. Pa\u00ad</p>\n<p>tients may not appear very distressed despite a severe at\u00ad</p>\n<p>tack</p>\n<p>~</p>\n<p>Wheezing, rhonchi</p>\n<p>~</p>\n<p>Cough \u2013 usually dry, may be intermittent, persistent, or</p>\n<p>acute, especially at night</p>\n<p>Severe forms: failure to complete sentences, darkening of lips, oral</p>\n<p>mucosa and extremities (cyanosis)</p>\n<p>Respiratory Diseases</p>\n<p>5</p>\n<p>329</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 396,
        "content": "Differential diagnosis\n \n~\nHeart failure\n \n~\nOther causes of chronic cough\n \n~\nBronchiolitis\n \n~\nBronchiectasis\nInvestigations\n \n\u0081\nDiagnosis is mainly by clinical features\nSpecialised investigations\n \n\u0081\nPeak flow rate: the peak flow rate increases to about 200 ml \nfollowing administration of a bronchodilator\n \n\u0081\nSpirometry (an increase in Forced Expiratory Volume (FEV) of \n>12% after bronchodilation)\n \n\u0081\nSputum: for eosinophilia\nIf evidence of bacterial infection\n \n\u0081\nChest X-ray\n \n\u0081\nBlood: complete blood count\nGeneral principles of management\nThe four essential components of Asthma Management: Patient edu\u00ad\ncation, control of asthma triggers, monitoring for changes in symptoms \nor lung function, and pharmacologic therapy.\n \n \n~\nInhalation route is always preferred as it delivers the med\u00ad\nicines directly to the airways; the dose required is smaller, \nthe side-effects are reduced\n\t\n\u0089\nE.g., nebuliser solutions for acute severe asthma are given\n\t\n\u0089\nover 5-10 minutes, usually driven by oxygen in hospital\n330\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Heart failure</p>\n<p>~</p>\n<p>Other causes of chronic cough</p>\n<p>~</p>\n<p>Bronchiolitis</p>\n<p>~</p>\n<p>Bronchiectasis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is mainly by clinical features</p>\n<p>Specialised investigations</p>\n<p>\u0081</p>\n<p>Peak flow rate: the peak flow rate increases to about 200 ml</p>\n<p>following administration of a bronchodilator</p>\n<p>\u0081</p>\n<p>Spirometry (an increase in Forced Expiratory Volume (FEV) of</p>\n<p>>12% after bronchodilation)</p>\n<p>\u0081</p>\n<p>Sputum: for eosinophilia</p>\n<p>If evidence of bacterial infection</p>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<p>\u0081</p>\n<p>Blood: complete blood count</p>\n<p>General principles of management</p>\n<p>The four essential components of Asthma Management: Patient edu\u00ad</p>\n<p>cation, control of asthma triggers, monitoring for changes in symptoms</p>\n<p>or lung function, and pharmacologic therapy.</p>\n<p>~</p>\n<p>Inhalation route is always preferred as it delivers the med\u00ad</p>\n<p>icines directly to the airways; the dose required is smaller,</p>\n<p>the side-effects are reduced</p>\n<p>\u0089</p>\n<p>E.g., nebuliser solutions for acute severe asthma are given</p>\n<p>\u0089</p>\n<p>over 5-10 minutes, usually driven by oxygen in hospital</p>\n<p>330</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 397,
        "content": "\u0089\nIn children having acute attacks, use spacers to administer inhaler puffs\n \n~\nOral route may be used if inhalation is not possible but sys\u00ad\ntemic side-effects occur more frequently, onset of action is \nslower and dose required is higher\n \n~\nParenteral route is used only in very severe cases when \nnebulisation is not adequate.\n5.1.1.1\t\nAcute Asthma\nAsthma attack is a substantial worsening of asthma symptoms. The severity \nand duration of attacks are variable and unpredictable. Most attacks are \ntriggered by viral infections. Assess severity using the following table:\nNot all features may be present. If the patient says they feel very \nunwell, listen to them!\nAssessment of Severity\nChildren Below 12 Years\nAdults And Children\n>12 Yrs\nMild to moderate\n \n~\nAble to talk in setenc\u00ad\nes\n \n~\nPeak flow is  50% of \npredicted or best\n \n~\nPulse (beats/minute) \nChild > 5 years: \n \n125 bpm Child < 5 \nyears:  140 bpm\n \n~\nRespiratory rate\n \n~\nChild > 5 years:  30\n \n~\nChild < 5 years:  40\n \n~\nSpO2  92%\n \n~\nAble to talk\n \n~\nPulse < 110 bpm\n \n~\nRespiratory rate < 25\n \n~\nPeak flow >50% of \npredicted or best\n \n~\nSpO2  92%\n331\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>\u0089</p>\n<p>In children having acute attacks, use spacers to administer inhaler puffs</p>\n<p>~</p>\n<p>Oral route may be used if inhalation is not possible but sys\u00ad</p>\n<p>temic side-effects occur more frequently, onset of action is</p>\n<p>slower and dose required is higher</p>\n<p>~</p>\n<p>Parenteral route is used only in very severe cases when</p>\n<p>nebulisation is not adequate.</p>\n<p>5.1.1.1</p>\n<p>Acute Asthma</p>\n<p>Asthma attack is a substantial worsening of asthma symptoms. The severity</p>\n<p>and duration of attacks are variable and unpredictable. Most attacks are</p>\n<p>triggered by viral infections. Assess severity using the following table:</p>\n<p>Not all features may be present. If the patient says they feel very</p>\n<p>unwell, listen to them!</p>\n<p>Assessment of Severity</p>\n<p>Children Below 12 Years</p>\n<p>Adults And Children</p>\n<p>>12 Yrs</p>\n<p>Mild to moderate</p>\n<p>~</p>\n<p>Able to talk in setenc\u00ad</p>\n<p>es</p>\n<p>~</p>\n<p>Peak flow is  50% of</p>\n<p>predicted or best</p>\n<p>~</p>\n<p>Pulse (beats/minute)</p>\n<p>Child > 5 years:</p>\n<p>125 bpm Child < 5</p>\n<p>years:  140 bpm</p>\n<p>~</p>\n<p>Respiratory rate</p>\n<p>~</p>\n<p>Child > 5 years:  30</p>\n<p>~</p>\n<p>Child < 5 years:  40</p>\n<p>~</p>\n<p>SpO2  92%</p>\n<p>~</p>\n<p>Able to talk</p>\n<p>~</p>\n<p>Pulse < 110 bpm</p>\n<p>~</p>\n<p>Respiratory rate < 25</p>\n<p>~</p>\n<p>Peak flow >50% of</p>\n<p>predicted or best</p>\n<p>~</p>\n<p>SpO2  92%</p>\n<p>331</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 398,
        "content": "Children Below 12 Years\nAdults And Children\n>12 Yrs\nSevere\n \n~\nCannot complete \nsentences in one \nbreath or, too breath\u00ad\nless to talk or feed\n \n~\nPeak flow < 50% of \npredicted or best\n \n~\nPulse (beats/minute) \nChild > 5 years: > \n125 bpm Child <5 \nyears: > 140 bpm\n \n~\nRespiratory rate\n \n~\nChild > 5 years: > 30\n \n~\nChild < 5 years: >40\n \n~\nUse of accessory \nmuscles for breathing \n(young children)\n \n~\nSpO2 < 92%\n \n~\nCannot complete \nsentences in one \nbreath\n \n~\nPulse  110 bpm\n \n~\nRespiratory rate >25\n \n~\nPeak flow <50% of \npredicted or best\n \n~\nSpO2  92%\nLife threatening (Adults and Children)\n \n~\nSilent chest, feeble respiratory effort, cyanosis\n \n~\nHypotension, bradycardia or exhaustion, agitation\n \n~\nReduced level of consciousness\n \n~\nPeak flow < 33% of predicted or best\n \n~\nArterial oxygen saturation < 92%\nManagement of asthma attacks\nTREATMENT\nLOC\nMild to moderate\nHC3\n\t\n\u0089\nTreat as an out-patient\n\t\n\u0089\nReassure patient; place him in a \u00bd sitting position\n\t\n\u0089\nGive salbutamol\n \n- Inhaler 2-10 puffs via a large volume spacer\nHC3\nHC3\n332\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Children Below 12 Years</p>\n<p>Adults And Children</p>\n<p>>12 Yrs</p>\n<p>Severe</p>\n<p>~</p>\n<p>Cannot complete</p>\n<p>sentences in one</p>\n<p>breath or, too breath\u00ad</p>\n<p>less to talk or feed</p>\n<p>~</p>\n<p>Peak flow < 50% of</p>\n<p>predicted or best</p>\n<p>~</p>\n<p>Pulse (beats/minute)</p>\n<p>Child > 5 years: ></p>\n<p>125 bpm Child <5</p>\n<p>years: > 140 bpm</p>\n<p>~</p>\n<p>Respiratory rate</p>\n<p>~</p>\n<p>Child > 5 years: > 30</p>\n<p>~</p>\n<p>Child < 5 years: >40</p>\n<p>~</p>\n<p>Use of accessory</p>\n<p>muscles for breathing</p>\n<p>(young children)</p>\n<p>~</p>\n<p>SpO2 < 92%</p>\n<p>~</p>\n<p>Cannot complete</p>\n<p>sentences in one</p>\n<p>breath</p>\n<p>~</p>\n<p>Pulse  110 bpm</p>\n<p>~</p>\n<p>Respiratory rate >25</p>\n<p>~</p>\n<p>Peak flow <50% of</p>\n<p>predicted or best</p>\n<p>~</p>\n<p>SpO2  92%</p>\n<p>Life threatening (Adults and Children)</p>\n<p>~</p>\n<p>Silent chest, feeble respiratory effort, cyanosis</p>\n<p>~</p>\n<p>Hypotension, bradycardia or exhaustion, agitation</p>\n<p>~</p>\n<p>Reduced level of consciousness</p>\n<p>~</p>\n<p>Peak flow < 33% of predicted or best</p>\n<p>~</p>\n<p>Arterial oxygen saturation < 92%</p>\n<p>Management of asthma attacks</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild to moderate</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>Treat as an out-patient</p>\n<p>\u0089</p>\n<p>Reassure patient; place him in a \u00bd sitting position</p>\n<p>\u0089</p>\n<p>Give salbutamol</p>\n<p>- Inhaler 2-10 puffs via a large volume spacer</p>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<p>332</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 399,
        "content": "Management of asthma attacks\nTREATMENT\nLOC\nMild to moderate\nHC3\n \n- Or 5 mg (2.5 mg in children) nebulisation\n \n- Repeat every 20-30 min if necessary\n\t\n\u0089\nPrednisolone 50 mg (1 mg/kg for children)\nMonitor response for 30-60 min. If not improving or \nrelapse in 3-4 hours\n\t\n\u0089\nRefer to higher level\nIf improving, send home with\n\t\n\u0089\nPrednisolone 50 mg (1 mg/kg for children) once a day \nfor 5 days (3 days for children)\n\t\n\u0089\nInstitute or step up chronic treatment (see section 5.1.1.2)\n \n\u0083 Follow up after 1-2 weeks\n\t\n\u0089\nInstruct the patients on self-treatment and when to \ncome back\n\t\n\u0089\nReview in 48 hours\n \n\u0083 Do not give routine antibiotics unless there are clear \nsigns of bacterial infection\nHC3\nHC3\nHC3\nHC3\nSevere\nHC4\nPatients with severe asthma need to be referred to HC4 \nor hospital after initial treatment\n\t\n\u0089\nAdmit patient; place him in a \u00bd sitting position\n\t\n\u0089\nGive high flow oxygen continuously, at least 5 litres/\nminute, to maintain the SpO2  94% if available\n\t\n\u0089\nGive salbutamol\n \n- Inhaler 2-10 puffs via a large volume spacer\n \n- Or 5 mg (2.5 mg in children) nebulisation\n \n- Repeat every 20-30 min if necessary during the \n1st hour\nHC4\nHC4\n333\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Management of asthma attacks</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild to moderate</p>\n<h3>HC3</h3>\n<p>- Or 5 mg (2.5 mg in children) nebulisation</p>\n<p>- Repeat every 20-30 min if necessary</p>\n<p>\u0089</p>\n<p>Prednisolone 50 mg (1 mg/kg for children)</p>\n<p>Monitor response for 30-60 min. If not improving or</p>\n<p>relapse in 3-4 hours</p>\n<p>\u0089</p>\n<p>Refer to higher level</p>\n<p>If improving, send home with</p>\n<p>\u0089</p>\n<p>Prednisolone 50 mg (1 mg/kg for children) once a day</p>\n<p>for 5 days (3 days for children)</p>\n<p>\u0089</p>\n<p>Institute or step up chronic treatment (see section 5.1.1.2)</p>\n<p>\u0083 Follow up after 1-2 weeks</p>\n<p>\u0089</p>\n<p>Instruct the patients on self-treatment and when to</p>\n<p>come back</p>\n<p>\u0089</p>\n<p>Review in 48 hours</p>\n<p>\u0083 Do not give routine antibiotics unless there are clear</p>\n<p>signs of bacterial infection</p>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<p>Severe</p>\n<h3>HC4</h3>\n<p>Patients with severe asthma need to be referred to HC4</p>\n<p>or hospital after initial treatment</p>\n<p>\u0089</p>\n<p>Admit patient; place him in a \u00bd sitting position</p>\n<p>\u0089</p>\n<p>Give high flow oxygen continuously, at least 5 litres/</p>\n<p>minute, to maintain the SpO2  94% if available</p>\n<p>\u0089</p>\n<p>Give salbutamol</p>\n<p>- Inhaler 2-10 puffs via a large volume spacer</p>\n<p>- Or 5 mg (2.5 mg in children) nebulisation</p>\n<p>- Repeat every 20-30 min if necessary during the</p>\n<p>1st hour</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>333</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 400,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nPrednisolone 50 mg (1 mg/kg for children) or f Or hy\u00ad\ndrocortisone 100 mg (children 4 mg/kg max 100 mg) \nIV every 6 hours until patient can take oral prednisolone\n\t\n\u0089\nMonitor response after nebulisation\nIf response poor\n\t\n\u0089\nIpratropium bromide nebuliser 500 micrograms (250 \nmicrogram in children below 12) every 20- 30 min for \nthe first 2 hours then every 4-6 hours\n\t\n\u0089\nOr  aminophylline 250 mg slow IV bolus (child 5 mg/\nkg) if patient is not taking an oral theophylline\nAlternatively, if symptoms have improved, respiration and \npulse settling, and peak flow >50% \n\t\n\u0089\nStep up the usual treatment\n\t\n\u0089\nAnd continue with prednisolone to complete 5 days \nof treatment\n\t\n\u0089\nReview within 24 hours\n \n- Monitor symptoms and peak flow\n \n- Arrange self-management plan\nHC4\nHC4\nLife threatening\nHC4\n\t\n\u0089\nArrange for immediate hospital referral and admission\nFirst aid\n\t\n\u0089\nAdmit  patient; place  him  in   a \u00bd sitting position\n\t\n\u0089\nGive high flow oxygen continuously, at least 5 litres/\nminute, to maintain the SpO2  94% if available\n\t\n\u0089\nGive salbutamol\n \n- Inhaler 2-10 puffs via a large volume spacer\n \n- Or 5 mg (2.5 mg in children) nebulisation\n \n- Repeat every 20 min for 1 hour\nHC4\nHC4\n334\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Prednisolone 50 mg (1 mg/kg for children) or f Or hy\u00ad</p>\n<p>drocortisone 100 mg (children 4 mg/kg max 100 mg)</p>\n<p>IV every 6 hours until patient can take oral prednisolone</p>\n<p>\u0089</p>\n<p>Monitor response after nebulisation</p>\n<p>If response poor</p>\n<p>\u0089</p>\n<p>Ipratropium bromide nebuliser 500 micrograms (250</p>\n<p>microgram in children below 12) every 20- 30 min for</p>\n<p>the first 2 hours then every 4-6 hours</p>\n<p>\u0089</p>\n<p>Or  aminophylline 250 mg slow IV bolus (child 5 mg/</p>\n<p>kg) if patient is not taking an oral theophylline</p>\n<p>Alternatively, if symptoms have improved, respiration and</p>\n<p>pulse settling, and peak flow >50%</p>\n<p>\u0089</p>\n<p>Step up the usual treatment</p>\n<p>\u0089</p>\n<p>And continue with prednisolone to complete 5 days</p>\n<p>of treatment</p>\n<p>\u0089</p>\n<p>Review within 24 hours</p>\n<p>- Monitor symptoms and peak flow</p>\n<p>- Arrange self-management plan</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>Life threatening</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Arrange for immediate hospital referral and admission</p>\n<p>First aid</p>\n<p>\u0089</p>\n<p>Admit  patient; place  him  in   a \u00bd sitting position</p>\n<p>\u0089</p>\n<p>Give high flow oxygen continuously, at least 5 litres/</p>\n<p>minute, to maintain the SpO2  94% if available</p>\n<p>\u0089</p>\n<p>Give salbutamol</p>\n<p>- Inhaler 2-10 puffs via a large volume spacer</p>\n<p>- Or 5 mg (2.5 mg in children) nebulisation</p>\n<p>- Repeat every 20 min for 1 hour</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>334</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 401,
        "content": "Life threatening\nHC4\n\t\n\u0089\nHydrocortisone 100 mg (children 4 mg/kg max 100 \nmg) IV stat or prednisolone 50 mg (1 mg/kg for children)\n\t\n\u0089\nIpratropium bromide nebuliser 500 micrograms (250 \nmicrogram in children below 12) every 20- 30 minutes \nfor the first 2 hours then every 4-6 hours\n\t\n\u0089\nMonitor response for 15-30 minutes\nIf response is poor\n\t\n\u0089\nAminophylline 250 mg slow IV bolus (child 5 mg/kg) if \npatient is not taking an oral theophylline\nHC4\nHC4\nNote\n \n\u0083 The use of aminophylline and theophylline in the management \nof asthma exacerbations is discouraged because of their poor \nefficacy and poor safety profile\n335\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Life threatening</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Hydrocortisone 100 mg (children 4 mg/kg max 100</p>\n<p>mg) IV stat or prednisolone 50 mg (1 mg/kg for children)</p>\n<p>\u0089</p>\n<p>Ipratropium bromide nebuliser 500 micrograms (250</p>\n<p>microgram in children below 12) every 20- 30 minutes</p>\n<p>for the first 2 hours then every 4-6 hours</p>\n<p>\u0089</p>\n<p>Monitor response for 15-30 minutes</p>\n<p>If response is poor</p>\n<p>\u0089</p>\n<p>Aminophylline 250 mg slow IV bolus (child 5 mg/kg) if</p>\n<p>patient is not taking an oral theophylline</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>Note</p>\n<p>\u0083 The use of aminophylline and theophylline in the management</p>\n<p>of asthma exacerbations is discouraged because of their poor</p>\n<p>efficacy and poor safety profile</p>\n<p>335</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 402,
        "content": "PRIMARY CARE - Patient presents with \nacute or sub-acute asthma exacerbation\nASSESS the PATIENT - Is it asthma? Risk factor \nfor asthma related death? Severity of exacerbation\nMILD OR MODER\u00ad\nATE Talks in phrases, \nprefers sitting not \nlying, not agitated. \nRespiratory rate \nincreased Accessory \nmuscles not used\nSTART TREATMENT - \nHC3 Salbutamol: 5mg by \nnebulizer or inhaler+ spacer \n4 - 6 puffs (200\u00b5g) every 20 \nminutes for 1 hour Predni\u00ad\nsolone: adults 1 mg/kg max \n50mg, children 1-2 mg/kg\nASSESS FOR DISCHARGE \nSymptoms improved, not need\u00ad\ning salbutamol PEF improving, \nand> 60-80% of personal best \ninhaler or predicted Oxygen \nsaturation >94% room air\nFOLLOW UP Reliever: reduce to as needed Controller: continue \nhigher dose for short term (3 months), depending on back\u00ad\nground to exacerb tion Risk factor: check and correct modifiable \nrisk factors that may have contributed to exacerbation, including \ninhaler technique and adherence.\nARRANGE AT DISCHARGE \nReliever: continue as needed \nController: start or step up, check \ntechniques, adherence Predniso\u00ad\nlone: continue usually for 5 days\nCONTINUE TREATMENT with salbutamol as needed\nASSESS FOR RESPONSE AT 1 HOUR (or earlier)\nTRANSFER TO HIGH\u00ad\nER CARE FACILITY\u00ad\nWhile waiting: repeat \ninhaled Salbutamol \nAminophylline: 250mg \nslow IV bolus if not tak\u00ad\ning an oral theophylline\nWORSENING\nWORSENING\nIMPROVING\nSEVERE Talks in words, \nsits hunched forwards, \nagitated Respiratory \nrate >30/min Accessory \nmuscles in use Pulse \nrate >120 bpm\nLIFE THREAT\u00ad\nENING Cyanosis, \ndrowsy, confused \nor silent chest\nAdapted with modification GINA Pocket Guide for Health Professionals 2016\n336\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>PRIMARY CARE - Patient presents with</p>\n<p>acute or sub-acute asthma exacerbation</p>\n<p>ASSESS the PATIENT - Is it asthma? Risk factor</p>\n<p>for asthma related death? Severity of exacerbation</p>\n<h3>MILD OR MODER\u00ad</h3>\n<p>ATE Talks in phrases,</p>\n<p>prefers sitting not</p>\n<p>lying, not agitated.</p>\n<p>Respiratory rate</p>\n<p>increased Accessory</p>\n<p>muscles not used</p>\n<h3>START TREATMENT -</h3>\n<p>HC3 Salbutamol: 5mg by</p>\n<p>nebulizer or inhaler+ spacer</p>\n<p>4 - 6 puffs (200\u00b5g) every 20</p>\n<p>minutes for 1 hour Predni\u00ad</p>\n<p>solone: adults 1 mg/kg max</p>\n<p>50mg, children 1-2 mg/kg</p>\n<h3>ASSESS FOR DISCHARGE</h3>\n<p>Symptoms improved, not need\u00ad</p>\n<p>ing salbutamol PEF improving,</p>\n<p>and> 60-80% of personal best</p>\n<p>inhaler or predicted Oxygen</p>\n<p>saturation >94% room air</p>\n<p>FOLLOW UP Reliever: reduce to as needed Controller: continue</p>\n<p>higher dose for short term (3 months), depending on back\u00ad</p>\n<p>ground to exacerb tion Risk factor: check and correct modifiable</p>\n<p>risk factors that may have contributed to exacerbation, including</p>\n<p>inhaler technique and adherence.</p>\n<h3>ARRANGE AT DISCHARGE</h3>\n<p>Reliever: continue as needed</p>\n<p>Controller: start or step up, check</p>\n<p>techniques, adherence Predniso\u00ad</p>\n<p>lone: continue usually for 5 days</p>\n<p>CONTINUE TREATMENT with salbutamol as needed</p>\n<p>ASSESS FOR RESPONSE AT 1 HOUR (or earlier)</p>\n<h3>TRANSFER TO HIGH\u00ad</h3>\n<h3>ER CARE FACILITY\u00ad</h3>\n<p>While waiting: repeat</p>\n<p>inhaled Salbutamol</p>\n<p>Aminophylline: 250mg</p>\n<p>slow IV bolus if not tak\u00ad</p>\n<p>ing an oral theophylline</p>\n<h3>WORSENING</h3>\n<h3>WORSENING</h3>\n<h3>IMPROVING</h3>\n<p>SEVERE Talks in words,</p>\n<p>sits hunched forwards,</p>\n<p>agitated Respiratory</p>\n<p>rate >30/min Accessory</p>\n<p>muscles in use Pulse</p>\n<p>rate >120 bpm</p>\n<h3>LIFE THREAT\u00ad</h3>\n<p>ENING Cyanosis,</p>\n<p>drowsy, confused</p>\n<p>or silent chest</p>\n<p>Adapted with modification GINA Pocket Guide for Health Professionals 2016</p>\n<p>336</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 403,
        "content": "5.1.1.2\t Chronic Asthma\nGeneral principles of management\n \n~\nFollow a stepped approach\n\t\n\u0089\nBefore initiating a new drug, check that diagnosis is correct, compli\u00ad\nance and inhaler technique are correct and eliminate trigger factors \nfor acute exacerbations\n \n~\nStart at the step most appropriate to initial severity\n \n~\nRescue course\n\t\n\u0089\nGive a 3-5 days \u201crescue course\u201d of prednisolone at any step and \nat any time as required to control acute exacerbations of asthma \nat a dose of:\nChild < 1 year: 1-2 mg/kg daily; 1-5 years: up to 20 mg daily; 5-15 \nyears: Up to 40 mg daily; adult: 40-60 mg daily for up to 3-5 days.\n \n~\nStepping down\n\t\n\u0089\nReview treatment every 3-6 months\n\t\n\u0089\nIf control is achieved, stepwise reduction may be possible\n\t\n\u0089\nIf treatment started recently at Step 4 (or contained corticosteroid \ntablets, see below), reduction may take place after a short interval; \nin other patients 1-3 months or longer of stability may be needed \nbefore stepwise reduction can be done\nTREATMENT\nLOC\nSTEP 1: Intermittent asthma\n \n~\nIntermittent symptoms (< once/week)\n \n~\nNight time symptoms < twice/month\n \n~\nNormal physical activity\nOccasional relief bronchodilator\n\t\n\u0089\nInhaled short-acting beta2 agonist e.g. salbutamol inhaler \n1-2 puffs (100-200 micrograms)\nHC3\n337\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>5.1.1.2\t Chronic Asthma</p>\n<p>General principles of management</p>\n<p>~</p>\n<p>Follow a stepped approach</p>\n<p>\u0089</p>\n<p>Before initiating a new drug, check that diagnosis is correct, compli\u00ad</p>\n<p>ance and inhaler technique are correct and eliminate trigger factors</p>\n<p>for acute exacerbations</p>\n<p>~</p>\n<p>Start at the step most appropriate to initial severity</p>\n<p>~</p>\n<p>Rescue course</p>\n<p>\u0089</p>\n<p>Give a 3-5 days \u201crescue course\u201d of prednisolone at any step and</p>\n<p>at any time as required to control acute exacerbations of asthma</p>\n<p>at a dose of:</p>\n<p>Child < 1 year: 1-2 mg/kg daily; 1-5 years: up to 20 mg daily; 5-15</p>\n<p>years: Up to 40 mg daily; adult: 40-60 mg daily for up to 3-5 days.</p>\n<p>~</p>\n<p>Stepping down</p>\n<p>\u0089</p>\n<p>Review treatment every 3-6 months</p>\n<p>\u0089</p>\n<p>If control is achieved, stepwise reduction may be possible</p>\n<p>\u0089</p>\n<p>If treatment started recently at Step 4 (or contained corticosteroid</p>\n<p>tablets, see below), reduction may take place after a short interval;</p>\n<p>in other patients 1-3 months or longer of stability may be needed</p>\n<p>before stepwise reduction can be done</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>STEP 1: Intermittent asthma</p>\n<p>~</p>\n<p>Intermittent symptoms (< once/week)</p>\n<p>~</p>\n<p>Night time symptoms < twice/month</p>\n<p>~</p>\n<p>Normal physical activity</p>\n<p>Occasional relief bronchodilator</p>\n<p>\u0089</p>\n<p>Inhaled short-acting beta2 agonist e.g. salbutamol inhaler</p>\n<p>1-2 puffs (100-200 micrograms)</p>\n<h3>HC3</h3>\n<p>337</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 404,
        "content": "TREATMENT\nLOC\n\t\n\u0089\n1-2 puffs (100-200 micrograms)\n \n- Use with spacer for children\n\t\n\u0089\nMove to Step 2 if use  of  salbutamol  needed more \nthan twice a week or if there are night-time symptoms \nat least once a week\nHC3\nSTEP 2: Mild persistent asthma\n \n~\nSymptoms > once/week, but < once/day\n \n~\nNight time symptoms > twice/month\n \n~\nSymptoms may affect activity\nRegular inhaled preventer therapy \n\t\n\u0089\nSalbutamol inhaler 1-2 puffs prn \n\t\n\u0089\nPlus regular standard-dose inhaled\ncorticosteroid, e.g. beclomethasone 100-400 micrograms \nevery 12 hours (children: 100-200 micrograms every 12 hours)\n \n- Assess after 1 month and adjust the dose prn\n \n- Higher dose may be needed initially to gain \ncontrol\n \n- Doubling of the regular dose may be useful to \ncover exacerbations\nHC3\nHC4\nSTEP 3: Moderate persistent asthma\n \n~\nDaily symptoms\n \n~\nSymptoms affect activity\n \n~\nNight time symptoms > once/week\n \n~\nDaily use of salbutamol\nChildren below 5 years: refer to specialist\nRegular high-dose inhaled corticosteroids\nHC4\n338\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>1-2 puffs (100-200 micrograms)</p>\n<p>- Use with spacer for children</p>\n<p>\u0089</p>\n<p>Move to Step 2 if use  of  salbutamol  needed more</p>\n<p>than twice a week or if there are night-time symptoms</p>\n<p>at least once a week</p>\n<h3>HC3</h3>\n<p>STEP 2: Mild persistent asthma</p>\n<p>~</p>\n<p>Symptoms > once/week, but < once/day</p>\n<p>~</p>\n<p>Night time symptoms > twice/month</p>\n<p>~</p>\n<p>Symptoms may affect activity</p>\n<p>Regular inhaled preventer therapy</p>\n<p>\u0089</p>\n<p>Salbutamol inhaler 1-2 puffs prn</p>\n<p>\u0089</p>\n<p>Plus regular standard-dose inhaled</p>\n<p>corticosteroid, e.g. beclomethasone 100-400 micrograms</p>\n<p>every 12 hours (children: 100-200 micrograms every 12 hours)</p>\n<p>- Assess after 1 month and adjust the dose prn</p>\n<p>- Higher dose may be needed initially to gain</p>\n<p>control</p>\n<p>- Doubling of the regular dose may be useful to</p>\n<p>cover exacerbations</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>STEP 3: Moderate persistent asthma</p>\n<p>~</p>\n<p>Daily symptoms</p>\n<p>~</p>\n<p>Symptoms affect activity</p>\n<p>~</p>\n<p>Night time symptoms > once/week</p>\n<p>~</p>\n<p>Daily use of salbutamol</p>\n<p>Children below 5 years: refer to specialist</p>\n<p>Regular high-dose inhaled corticosteroids</p>\n<h3>HC4</h3>\n<p>338</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 405,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nSalbutamol inhaler 1-2 puffs prn up to 2-3 hourly Usu\u00ad\nally 4-12 hourly\n\t\n\u0089\nPLUS beclomethasone inhaler 400-1000 micrograms \nevery 12 hours (In child 5-12 years: 100-400 micro\u00ad\ngrams every 12 hours)\nIn adults, also consider 6-week trial with \n\t\n\u0089\nAminophylline 200 mg every 12 hours\nSTEP 4: Severe persistent asthma\n \n~\nDaily symptoms\n \n~\nFrequent night time symptoms\n \n~\nDaily use of salbutamol\nRefer to specialist clinic especially children <12 years\nRegular corticosteroid tablets\nplus\n\t\n\u0089\nRegular high-dose beclomethasone  (as in Step 3)\n\t\n\u0089\nPlus regular prednisolone 10-20 mg daily after breakfast\nRR\nNote\n \n\u0083 If inhaler not available, consider salbutamol tablets\n4 mg every 8 hours\nChild < 2 years: 100 micrograms/kg per dose\nChild 2-5 years: 1-2 mg per dose\nCaution\n \n\u0083 Do not give medicines such as morphine, propranolol, or \nother B-blockers to patients with asthma as they worsen \nrespiratory problems\n \n\u0083 Do not give sedatives to children with asthma, even if they \nare restless\n339\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Salbutamol inhaler 1-2 puffs prn up to 2-3 hourly Usu\u00ad</p>\n<p>ally 4-12 hourly</p>\n<p>\u0089</p>\n<p>PLUS beclomethasone inhaler 400-1000 micrograms</p>\n<p>every 12 hours (In child 5-12 years: 100-400 micro\u00ad</p>\n<p>grams every 12 hours)</p>\n<p>In adults, also consider 6-week trial with</p>\n<p>\u0089</p>\n<p>Aminophylline 200 mg every 12 hours</p>\n<p>STEP 4: Severe persistent asthma</p>\n<p>~</p>\n<p>Daily symptoms</p>\n<p>~</p>\n<p>Frequent night time symptoms</p>\n<p>~</p>\n<p>Daily use of salbutamol</p>\n<p>Refer to specialist clinic especially children <12 years</p>\n<p>Regular corticosteroid tablets</p>\n<p>plus</p>\n<p>\u0089</p>\n<p>Regular high-dose beclomethasone  (as in Step 3)</p>\n<p>\u0089</p>\n<p>Plus regular prednisolone 10-20 mg daily after breakfast</p>\n<p>RR</p>\n<p>Note</p>\n<p>\u0083 If inhaler not available, consider salbutamol tablets</p>\n<p>4 mg every 8 hours</p>\n<p>Child < 2 years: 100 micrograms/kg per dose</p>\n<p>Child 2-5 years: 1-2 mg per dose</p>\n<p>Caution</p>\n<p>\u0083 Do not give medicines such as morphine, propranolol, or</p>\n<p>other B-blockers to patients with asthma as they worsen</p>\n<p>respiratory problems</p>\n<p>\u0083 Do not give sedatives to children with asthma, even if they</p>\n<p>are restless</p>\n<p>339</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 406,
        "content": "Prevention\n \n~\nAvoid precipitating factors e.g.\n\t\n\u0089\nCigarette smoking\n\t\n\u0089\nAcetylsalicylic acid\n\t\n\u0089\nKnown allergens such as dust, pollens, animal skins\n\t\n\u0089\nExposure to cold air\n \n~\nExercise can precipitate asthma in children, advise them to \nkeep an inhaler handy during sports and play\n \n~\nEffectively treat respiratory infections\n5.1.2\t\nChronic Obstructive Pulmonary Disease (COPD)          \nICD10 CODE: J42-44\nChronic obstructive pulmonary disease (COPD) is a lung disease charac\u00ad\nterized by chronic obstruction of lung airflow that interferes with normal \nbreathing and is not fully reversible.\n \n- The more familiar terms \u2018chronic bronchitis\u2019 and \u2018emphysema\u2019 \nare no longer used, but are now included within the COPD \ndiagnosis.\n \n- Such a diagnosis should be considered in any patient who\n \n- has symptoms of cough, sputum production, or dyspnea \n(difficult or labored breathing), and/or a history of exposure \nto risk factors for the disease.\nA COPD exacerbation is an acute worsening of the patient\u2019s respiratory \nsymptoms needing a change in medications.\nCauses and predisposing factors\n \n~\nTobacco smoking is the commonest cause\n \n~\nIndoor air pollution: Biomass fuel smoke (firewood, char\u00ad\ncoal and cow dung) exposure in poorly ventilated kitchens\n \n~\nExposure to occupational dust and chemicals (cement, \npaint, saw dust, fumes) without adequate protection\n \n~\nIt may frequently follow TB disease (residual symptoms)\n340\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Avoid precipitating factors e.g.</p>\n<p>\u0089</p>\n<p>Cigarette smoking</p>\n<p>\u0089</p>\n<p>Acetylsalicylic acid</p>\n<p>\u0089</p>\n<p>Known allergens such as dust, pollens, animal skins</p>\n<p>\u0089</p>\n<p>Exposure to cold air</p>\n<p>~</p>\n<p>Exercise can precipitate asthma in children, advise them to</p>\n<p>keep an inhaler handy during sports and play</p>\n<p>~</p>\n<p>Effectively treat respiratory infections</p>\n<p>5.1.2</p>\n<p>Chronic Obstructive Pulmonary Disease (COPD)</p>\n<h3>ICD10 CODE: J42-44</h3>\n<p>Chronic obstructive pulmonary disease (COPD) is a lung disease charac\u00ad</p>\n<p>terized by chronic obstruction of lung airflow that interferes with normal</p>\n<p>breathing and is not fully reversible.</p>\n<p>- The more familiar terms \u2018chronic bronchitis\u2019 and \u2018emphysema\u2019</p>\n<p>are no longer used, but are now included within the COPD</p>\n<p>diagnosis.</p>\n<p>- Such a diagnosis should be considered in any patient who</p>\n<p>- has symptoms of cough, sputum production, or dyspnea</p>\n<p>(difficult or labored breathing), and/or a history of exposure</p>\n<p>to risk factors for the disease.</p>\n<p>A COPD exacerbation is an acute worsening of the patient\u2019s respiratory</p>\n<p>symptoms needing a change in medications.</p>\n<p>Causes and predisposing factors</p>\n<p>~</p>\n<p>Tobacco smoking is the commonest cause</p>\n<p>~</p>\n<p>Indoor air pollution: Biomass fuel smoke (firewood, char\u00ad</p>\n<p>coal and cow dung) exposure in poorly ventilated kitchens</p>\n<p>~</p>\n<p>Exposure to occupational dust and chemicals (cement,</p>\n<p>paint, saw dust, fumes) without adequate protection</p>\n<p>~</p>\n<p>It may frequently follow TB disease (residual symptoms)</p>\n<p>340</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 407,
        "content": "Clinical features\n \n~\nChronic cough in a current or previous smoker who is over \n40 years\n \n~\nBreathlessness: persistent, progressive and worse with ex\u00ad\nercise +/- tight chest and wheezing\n \n~\nChronic sputum (mucuos) production and \u2018bronchitis\u2019 for at \nleast 3 months in 2 successive years\n \n~\nOn examination, there may be a barrel chest (increased \nantero-posterior diameter)\n \n~\nRapid breathing, reduced chest expansion, with or without \nincreased use of accessory muscles of respiration, rhonchi, \ncyanosis\n \n~\nDecreased breath sounds, ankle swelling and other signs of \nright heart failure\nDifferential diagnosis\n \n~\nAsthma\n \n~\nCongestive heart  failure\n \n~\nPulmonary embolism\n \n~\nPulmonary TB\nInvestigation\n \n\u0081\nSpirometry: gold standard for diagnosis but if not available use \nall available tools (history of exposure to risk factors + clinical \nsymptoms + any available investigations).\n \n\u0081\nHistory of exposure to risk factors\n \n\u0081\nChest X-ray (Hyper-inflated lungs)\n \n\u0081\nPeak flometry\n \n\u0081\nEchocardiography \u2013 when one suspects right-sided heart failure \nsecondary to COPD\n341\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Chronic cough in a current or previous smoker who is over</p>\n<p>40 years</p>\n<p>~</p>\n<p>Breathlessness: persistent, progressive and worse with ex\u00ad</p>\n<p>ercise +/- tight chest and wheezing</p>\n<p>~</p>\n<p>Chronic sputum (mucuos) production and \u2018bronchitis\u2019 for at</p>\n<p>least 3 months in 2 successive years</p>\n<p>~</p>\n<p>On examination, there may be a barrel chest (increased</p>\n<p>antero-posterior diameter)</p>\n<p>~</p>\n<p>Rapid breathing, reduced chest expansion, with or without</p>\n<p>increased use of accessory muscles of respiration, rhonchi,</p>\n<p>cyanosis</p>\n<p>~</p>\n<p>Decreased breath sounds, ankle swelling and other signs of</p>\n<p>right heart failure</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Asthma</p>\n<p>~</p>\n<p>Congestive heart  failure</p>\n<p>~</p>\n<p>Pulmonary embolism</p>\n<p>~</p>\n<p>Pulmonary TB</p>\n<p>Investigation</p>\n<p>\u0081</p>\n<p>Spirometry: gold standard for diagnosis but if not available use</p>\n<p>all available tools (history of exposure to risk factors + clinical</p>\n<p>symptoms + any available investigations).</p>\n<p>\u0081</p>\n<p>History of exposure to risk factors</p>\n<p>\u0081</p>\n<p>Chest X-ray (Hyper-inflated lungs)</p>\n<p>\u0081</p>\n<p>Peak flometry</p>\n<p>\u0081</p>\n<p>Echocardiography \u2013 when one suspects right-sided heart failure</p>\n<p>secondary to COPD</p>\n<p>341</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 408,
        "content": "Management\n \n~\nTreatment aims at:\n\t\n\u0089\nRemoving risk factors and preventing further damage\n\t\n\u0089\nRelief of symptoms and prevention of the severity and frequency \nof COPD exacerbations\n\t\n\u0089\nImproving the patients exercise tolerance and maintaining\n \n~\ngood health\n \n~\nInhalers are the preferred formulation for the treatment of \nCOPD.\nTREATMENT\nLOC\n\t\n\u0089\nExplain to the patient that:\n \n- COPD is chronic lung damage and there is no \ncure\n \n- Treatment is to prevent exacerbations, further \ndamage, and infections\nNon-pharmacological management\n\t\n\u0089\nAdvise the patient that:\n \n- They must stop smoking \u2013 it is the only way to \nstop it from getting worse\n \n- Reduce exposure to charcoal and wood/dung\n \n- cooking smoke. Keep cooking areas well- \nventilated by opening windows and doors. Use \nalternative clean energy sources like Biogas, \nimproved cooking stoves etc.\n \n- Use masks for respiratory protection or stop \nworking in areas with occupational dust or \npollution\n \n- Physical exercise to train lung capacity\n \n- (pulmonary rehabilitation) under supervision\n \n- Get treatment quickly in case of increased \nbreathlessness, cough or sputum\n\t\n\u0089\nPhysiotherapy is beneficial to improve exercise tolerance\nHC2\n342\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Management</p>\n<p>~</p>\n<p>Treatment aims at:</p>\n<p>\u0089</p>\n<p>Removing risk factors and preventing further damage</p>\n<p>\u0089</p>\n<p>Relief of symptoms and prevention of the severity and frequency</p>\n<p>of COPD exacerbations</p>\n<p>\u0089</p>\n<p>Improving the patients exercise tolerance and maintaining</p>\n<p>~</p>\n<p>good health</p>\n<p>~</p>\n<p>Inhalers are the preferred formulation for the treatment of</p>\n<h3>COPD.</h3>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Explain to the patient that:</p>\n<p>- COPD is chronic lung damage and there is no</p>\n<p>cure</p>\n<p>- Treatment is to prevent exacerbations, further</p>\n<p>damage, and infections</p>\n<p>Non-pharmacological management</p>\n<p>\u0089</p>\n<p>Advise the patient that:</p>\n<p>- They must stop smoking \u2013 it is the only way to</p>\n<p>stop it from getting worse</p>\n<p>- Reduce exposure to charcoal and wood/dung</p>\n<p>- cooking smoke. Keep cooking areas well-</p>\n<p>ventilated by opening windows and doors. Use</p>\n<p>alternative clean energy sources like Biogas,</p>\n<p>improved cooking stoves etc.</p>\n<p>- Use masks for respiratory protection or stop</p>\n<p>working in areas with occupational dust or</p>\n<p>pollution</p>\n<p>- Physical exercise to train lung capacity</p>\n<p>- (pulmonary rehabilitation) under supervision</p>\n<p>- Get treatment quickly in case of increased</p>\n<p>breathlessness, cough or sputum</p>\n<p>\u0089</p>\n<p>Physiotherapy is beneficial to improve exercise tolerance</p>\n<h3>HC2</h3>\n<p>342</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 409,
        "content": "TREATMENT\nLOC\nStep 1: Mild\n\t\n\u0089\nInhaled salbutamol 2 puffs 2-4 times a day, may be used \nperiodically for short periods. The main purpose of this \ntreatment is to reduce or prevent symptoms.\nIf inhalers not available, consider:\n\t\n\u0089\nAminophylline 200 mg twice dail\nHC3\nHC4\nStep 2: Moderate\n\t\n\u0089\nInhaled salbutamol 2 puffs 2-4 times a day\n\t\n\u0089\nPlus inhaled steroid beclomethasone 100-400 micro\u00ad\ngrams 2-4 times a day\nHC4\nStep 3: Severe\n\t\n\u0089\nAs in step 2 plus ipratropium inhaler 2 puff 2-4 times \na day\nH\nNote\n \n\u0083 If available, long acting bronchodilators salmeterol \nand formeterol can be used in moderate and severe \nCOPD in combination with inhaled steroids\nRR\nCOPD exacerbations\n \n~\nIf more sputum, changed to more yellow/green \ncoloured, and/or breathlessness, temp >38\u00b0C \nand or rapid breathing (\u201cbronchitis\u201d), then\n\t\n\u0089\nTreat with antibiotic e.g. amoxicillin 500 mg every 8 \nhours for 7-10 days or doxycycline 100 mg every 12 \nhours for 7-10 days\n\t\n\u0089\nOral Prednisolone 40 mg once daily in the morning for \n5 days. Do NOT use oral steroids for extended periods \nin patients with COPD\n \n- Refer urgently to hospital if:\n \n- Rapid pulse (>100 beats per minute) or breathing \n(>30 breaths per minute)\n343\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Step 1: Mild</p>\n<p>\u0089</p>\n<p>Inhaled salbutamol 2 puffs 2-4 times a day, may be used</p>\n<p>periodically for short periods. The main purpose of this</p>\n<p>treatment is to reduce or prevent symptoms.</p>\n<p>If inhalers not available, consider:</p>\n<p>\u0089</p>\n<p>Aminophylline 200 mg twice dail</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Step 2: Moderate</p>\n<p>\u0089</p>\n<p>Inhaled salbutamol 2 puffs 2-4 times a day</p>\n<p>\u0089</p>\n<p>Plus inhaled steroid beclomethasone 100-400 micro\u00ad</p>\n<p>grams 2-4 times a day</p>\n<h3>HC4</h3>\n<p>Step 3: Severe</p>\n<p>\u0089</p>\n<p>As in step 2 plus ipratropium inhaler 2 puff 2-4 times</p>\n<p>a day</p>\n<p>H</p>\n<p>Note</p>\n<p>\u0083 If available, long acting bronchodilators salmeterol</p>\n<p>and formeterol can be used in moderate and severe</p>\n<p>COPD in combination with inhaled steroids</p>\n<p>RR</p>\n<p>COPD exacerbations</p>\n<p>~</p>\n<p>If more sputum, changed to more yellow/green</p>\n<p>coloured, and/or breathlessness, temp >38\u00b0C</p>\n<p>and or rapid breathing (\u201cbronchitis\u201d), then</p>\n<p>\u0089</p>\n<p>Treat with antibiotic e.g. amoxicillin 500 mg every 8</p>\n<p>hours for 7-10 days or doxycycline 100 mg every 12</p>\n<p>hours for 7-10 days</p>\n<p>\u0089</p>\n<p>Oral Prednisolone 40 mg once daily in the morning for</p>\n<p>5 days. Do NOT use oral steroids for extended periods</p>\n<p>in patients with COPD</p>\n<p>- Refer urgently to hospital if:</p>\n<p>- Rapid pulse (>100 beats per minute) or breathing</p>\n<p>(>30 breaths per minute)</p>\n<p>343</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 410,
        "content": "- Tongue or lips are \u201cblue\u201d (central cyanosis)\n \n- Confused\n \n- Failure to improve\n\t\n\u0089\nGive oxygen by nasal cannula (1-3 litres/min) if available, \ntarget SpO2 88-92%\nNote\n \n\u0083 Give oxygen with care (minimum flow required to reach the \ntarget SpO2) because COPD patients are at risk of hypercapnia \n(CO2 retention) which cause respiratory depression and coma\n5.2 INFECTIOUS RESPIRATORY DISEASES\n5.2.1 Bronchiolitis                       ICD10 CODE: J21\nAcute inflammatory obstructive disease of small airways (bronchioles) \ncommon in children less than 2 years.\nCauses\n \n~\nMainly viral (often respiratory syncitial virus, RSV)\n \n~\nMycoplasma\nClinical features\n \n~\nFirst 24-72 hours: rhinopharyngitis with dry cough\n \n~\nLater tachypnoea, difficulty in breathing, wheezing (poorly \nresponsive to bronchodilators)\n \n~\nCough (profuse, frothy, obstructive secretions)\n \n~\nMucoid nasal discharge\n \n~\nModerate or no fever\n \n~\nCriteria for severity: child < 3 months, worsening of general \ncondition, pallor, cyanosis, respiratory distress, anxiety, re\u00ad\nspiratory rate >60/minute, difficulty feeding, SpO2 < 92%\nDifferential diagnosis\n \n~\nAsthma\n344\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>- Tongue or lips are \u201cblue\u201d (central cyanosis)</p>\n<p>- Confused</p>\n<p>- Failure to improve</p>\n<p>\u0089</p>\n<p>Give oxygen by nasal cannula (1-3 litres/min) if available,</p>\n<p>target SpO2 88-92%</p>\n<p>Note</p>\n<p>\u0083 Give oxygen with care (minimum flow required to reach the</p>\n<p>target SpO2) because COPD patients are at risk of hypercapnia</p>\n<p>(CO2 retention) which cause respiratory depression and coma</p>\n<h3>5.2 INFECTIOUS RESPIRATORY DISEASES</h3>\n<p>5.2.1 Bronchiolitis                       ICD10 CODE: J21</p>\n<p>Acute inflammatory obstructive disease of small airways (bronchioles)</p>\n<p>common in children less than 2 years.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Mainly viral (often respiratory syncitial virus, RSV)</p>\n<p>~</p>\n<p>Mycoplasma</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>First 24-72 hours: rhinopharyngitis with dry cough</p>\n<p>~</p>\n<p>Later tachypnoea, difficulty in breathing, wheezing (poorly</p>\n<p>responsive to bronchodilators)</p>\n<p>~</p>\n<p>Cough (profuse, frothy, obstructive secretions)</p>\n<p>~</p>\n<p>Mucoid nasal discharge</p>\n<p>~</p>\n<p>Moderate or no fever</p>\n<p>~</p>\n<p>Criteria for severity: child < 3 months, worsening of general</p>\n<p>condition, pallor, cyanosis, respiratory distress, anxiety, re\u00ad</p>\n<p>spiratory rate >60/minute, difficulty feeding, SpO2 < 92%</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Asthma</p>\n<p>344</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 411,
        "content": "~\nPneumonia, whooping cough\n \n~\nForeign body inhalation\n \n~\nHeart failure\nInvestigations\n \n\u0081\nClinical diagnosis\n \n\u0081\nX-ray: Chest (to exclude pneumonia)\n \n\u0081\nBlood: Haemogram\nTREATMENT\nLOC\nMild-moderate bronchiolitis\nWheezing, 50-60 breaths/minute, no cyanosis, able to drink/feed\n\t\n\u0089\nTreat the symptoms (possibly as an out-patient)\n \n- Nasal irrigation with normal saline\n \n- Small, frequent feeds\n \n- Increased fluids and nutrition\n \n- Treat fever (paracetamol)\nSevere bronchiolitis\nWheezing, fast breathing > 60 breaths/min, cyanosis\n\t\n\u0089\nAdmit and give supportive treatment as above f Give \nhumidified nasal oxygen (1-2 litres/min) f Salbutamol \ninhaler 100 micrograms/puff: 2 puffs with spacer, every \n30 minutes or nebulisation salbutamol 2.5 mg in 4 ml \nnormal saline.\n \n- If symptoms improve, continue salbutamol every\n6 hours\n \n- If symptoms non-responsive, stop the salbutamol\n\t\n\u0089\nNebulise Adrenaline 1:1000, 1 ml diluted in 2-4 ml \nnormal saline every 2-4 hours\n\t\n\u0089\nGive as much oral fluids as the child will take:\ne.g. ORS. Use NGT or IV line if child cannot take orally\n \n- Give basic total fluid requirement of 150 ml/kg in \n24 hours plus extra to cover increased losses due \nto illness\n345\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>~</p>\n<p>Pneumonia, whooping cough</p>\n<p>~</p>\n<p>Foreign body inhalation</p>\n<p>~</p>\n<p>Heart failure</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Clinical diagnosis</p>\n<p>\u0081</p>\n<p>X-ray: Chest (to exclude pneumonia)</p>\n<p>\u0081</p>\n<p>Blood: Haemogram</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild-moderate bronchiolitis</p>\n<p>Wheezing, 50-60 breaths/minute, no cyanosis, able to drink/feed</p>\n<p>\u0089</p>\n<p>Treat the symptoms (possibly as an out-patient)</p>\n<p>- Nasal irrigation with normal saline</p>\n<p>- Small, frequent feeds</p>\n<p>- Increased fluids and nutrition</p>\n<p>- Treat fever (paracetamol)</p>\n<p>Severe bronchiolitis</p>\n<p>Wheezing, fast breathing > 60 breaths/min, cyanosis</p>\n<p>\u0089</p>\n<p>Admit and give supportive treatment as above f Give</p>\n<p>humidified nasal oxygen (1-2 litres/min) f Salbutamol</p>\n<p>inhaler 100 micrograms/puff: 2 puffs with spacer, every</p>\n<p>30 minutes or nebulisation salbutamol 2.5 mg in 4 ml</p>\n<p>normal saline.</p>\n<p>- If symptoms improve, continue salbutamol every</p>\n<p>6 hours</p>\n<p>- If symptoms non-responsive, stop the salbutamol</p>\n<p>\u0089</p>\n<p>Nebulise Adrenaline 1:1000, 1 ml diluted in 2-4 ml</p>\n<p>normal saline every 2-4 hours</p>\n<p>\u0089</p>\n<p>Give as much oral fluids as the child will take:</p>\n<p>e.g. ORS. Use NGT or IV line if child cannot take orally</p>\n<p>- Give basic total fluid requirement of 150 ml/kg in</p>\n<p>24 hours plus extra to cover increased losses due</p>\n<p>to illness</p>\n<p>345</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 412,
        "content": "TREATMENT\nLOC\nNote\n \n\u0083 Antibiotics   are  usually  not   needed  for  bronchiolitis since \nit is viral.\n \n\u0083 Steroids are not recommended\nPrevention\n \n\u0083 Avoid exposure to cold and viral infections\n \n\u0083 Proper handwashing after contact with patients\n5.2.2 Acute Bronchitis\t\n     ICD10 CODE: J20\nAcute inflammatory disease of the bronchi.\nCauses\n \n~\nMostly viral\n \n~\nIn older children, can be caused by Mycoplasma pneu\u00ad\nmonae\n \n~\nSecondary Bacterial infection: Streptococcus pneumoniae, \nHaemophilus influenzae\nPredisposing factors\n \n~\nExposure to cold, dust, smoke\n \n~\nCigarette smoking\nClinical features\n \n~\nOften starts with rhinopharyngitis, descend progressively \nto larynx, pharynx, tracheitis\n \n~\nIrritating, productive cough sometimes with scanty mu\u00ad\ncoid, blood streaked sputum\n \n~\nChest tightness, sometimes with wheezing\n \n~\nFever may be present\n \n~\nNo tachypnoea or dyspnoea\n \n~\nSecondary bacterial infection: fever > 38.5\u00b0C, dyspnoea, \npurulent expectorations\n346\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\u0083 Antibiotics   are  usually  not   needed  for  bronchiolitis since</p>\n<p>it is viral.</p>\n<p>\u0083 Steroids are not recommended</p>\n<p>Prevention</p>\n<p>\u0083 Avoid exposure to cold and viral infections</p>\n<p>\u0083 Proper handwashing after contact with patients</p>\n<p>5.2.2 Acute Bronchitis</p>\n<h3>ICD10 CODE: J20</h3>\n<p>Acute inflammatory disease of the bronchi.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Mostly viral</p>\n<p>~</p>\n<p>In older children, can be caused by Mycoplasma pneu\u00ad</p>\n<p>monae</p>\n<p>~</p>\n<p>Secondary Bacterial infection: Streptococcus pneumoniae,</p>\n<p>Haemophilus influenzae</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>Exposure to cold, dust, smoke</p>\n<p>~</p>\n<p>Cigarette smoking</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Often starts with rhinopharyngitis, descend progressively</p>\n<p>to larynx, pharynx, tracheitis</p>\n<p>~</p>\n<p>Irritating, productive cough sometimes with scanty mu\u00ad</p>\n<p>coid, blood streaked sputum</p>\n<p>~</p>\n<p>Chest tightness, sometimes with wheezing</p>\n<p>~</p>\n<p>Fever may be present</p>\n<p>~</p>\n<p>No tachypnoea or dyspnoea</p>\n<p>~</p>\n<p>Secondary bacterial infection: fever > 38.5\u00b0C, dyspnoea,</p>\n<p>purulent expectorations</p>\n<p>346</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 413,
        "content": "Differential diagnosis\n \n~\nBronchial asthma, emphysema\n \n~\nPneumonia, tuberculosis\nInvestigations\n \n\u0081\nDiagnosis based on clinical features\n \n\u0081\nChest X-ray\nTREATMENT\nLOC\n\t\n\u0089\nMost cases are viral and mild\n\t\n\u0089\nParacetamol 1 g every 4-6 hours (max: 4 g daily) \n\t\n\u0089\nChild: 10 mg/kg (max: 500 mg) per dose  f Plenty of \noral fluids\n\t\n\u0089\nChildren: nasal irrigation with normal saline to clear \nthe airway\n\t\n\u0089\nLocal   remedies for cough (honey, ginger, lemon)\nIf there is suspicion of bacterial infection, especially if patient is \nin general poor conditions (malnutrition, measles, rickets, severe \nanaemia, elderly, cardiac disease)\n\t\n\u0089\nGive Amoxicillin 500 mg every 8 hours\nChild: 40 mg/kg dispersible tablets every 12 hours\n\t\n\u0089\nOr Doxycycline 100 mg every 12 hours\nChild >8 years: 2 mg/kg per dose\nHC2\nPrevention\n \n~\nAvoid predisposing factors above.\n5.2.3 Coryza (Common Cold)\t\n       ICD10 CODE: J00\nAcute inflammation of the upper respiratory tract; rhinitis (nasal mucosa) \nand rhinopharyngitis (nasal and pharyngitis).\nCause\n \n~\nViruses - several types, often rhinoviruses\n347\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Bronchial asthma, emphysema</p>\n<p>~</p>\n<p>Pneumonia, tuberculosis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis based on clinical features</p>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Most cases are viral and mild</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 4-6 hours (max: 4 g daily)</p>\n<p>\u0089</p>\n<p>Child: 10 mg/kg (max: 500 mg) per dose  f Plenty of</p>\n<p>oral fluids</p>\n<p>\u0089</p>\n<p>Children: nasal irrigation with normal saline to clear</p>\n<p>the airway</p>\n<p>\u0089</p>\n<p>Local   remedies for cough (honey, ginger, lemon)</p>\n<p>If there is suspicion of bacterial infection, especially if patient is</p>\n<p>in general poor conditions (malnutrition, measles, rickets, severe</p>\n<p>anaemia, elderly, cardiac disease)</p>\n<p>\u0089</p>\n<p>Give Amoxicillin 500 mg every 8 hours</p>\n<p>Child: 40 mg/kg dispersible tablets every 12 hours</p>\n<p>\u0089</p>\n<p>Or Doxycycline 100 mg every 12 hours</p>\n<p>Child >8 years: 2 mg/kg per dose</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid predisposing factors above.</p>\n<p>5.2.3 Coryza (Common Cold)</p>\n<h3>ICD10 CODE: J00</h3>\n<p>Acute inflammation of the upper respiratory tract; rhinitis (nasal mucosa)</p>\n<p>and rhinopharyngitis (nasal and pharyngitis).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Viruses - several types, often rhinoviruses</p>\n<p>347</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 414,
        "content": "Clinical features\n \n~\nOnset usually sudden\n \n~\nTickling sensation in nose and sneezing\n \n~\nThroat dry and sore\n \n~\nProfuse nasal watery or purulent discharge, tearing\nComplications\n \n~\nSinusitis\n \n~\nLower respiratory tract infection (pneumonia)\n \n~\nEar ache, deafness, otitis media\n \n~\nHeadache\nDifferential diagnosis\n \n~\nNasal allergy\nManagemen\nCommon cold   is   a viral disease  and so does NOT require any anti\u00ad\nbiotics. Antibiotics do not promote recovery or prevent complications \nand cause patients unnecessary side effects\nTREATMENT\nLOC\nNo antibiotics, give only symptomatic treatment \n\t\n\u0089\nIncrease fluid intake, preferably warm drinks f Give \nparacetamol for 2-3 days\n\t\n\u0089\nHome remedies (steam, honey)\n\t\n\u0089\nXylometazoline 0.05 - 0.1% nasal drops 2-3 drops into \neach nostril 3 times daily (max: 5 days)\nFor breastfeeding children\n\t\n\u0089\nContinue breastfeeding\n\t\n\u0089\nClear the nose with normal saline to ease breathing \nor feeding\n\t\n\u0089\nKeep the child warm\nHC2\nHC4\n348\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Onset usually sudden</p>\n<p>~</p>\n<p>Tickling sensation in nose and sneezing</p>\n<p>~</p>\n<p>Throat dry and sore</p>\n<p>~</p>\n<p>Profuse nasal watery or purulent discharge, tearing</p>\n<p>Complications</p>\n<p>~</p>\n<p>Sinusitis</p>\n<p>~</p>\n<p>Lower respiratory tract infection (pneumonia)</p>\n<p>~</p>\n<p>Ear ache, deafness, otitis media</p>\n<p>~</p>\n<p>Headache</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Nasal allergy</p>\n<p>Managemen</p>\n<p>Common cold   is   a viral disease  and so does NOT require any anti\u00ad</p>\n<p>biotics. Antibiotics do not promote recovery or prevent complications</p>\n<p>and cause patients unnecessary side effects</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>No antibiotics, give only symptomatic treatment</p>\n<p>\u0089</p>\n<p>Increase fluid intake, preferably warm drinks f Give</p>\n<p>paracetamol for 2-3 days</p>\n<p>\u0089</p>\n<p>Home remedies (steam, honey)</p>\n<p>\u0089</p>\n<p>Xylometazoline 0.05 - 0.1% nasal drops 2-3 drops into</p>\n<p>each nostril 3 times daily (max: 5 days)</p>\n<p>For breastfeeding children</p>\n<p>\u0089</p>\n<p>Continue breastfeeding</p>\n<p>\u0089</p>\n<p>Clear the nose with normal saline to ease breathing</p>\n<p>or feeding</p>\n<p>\u0089</p>\n<p>Keep the child warm</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>348</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 415,
        "content": "TREATMENT\nLOC\nNote\n \n\u0083 Avoid cough syrups in children below 6 years\nPrevention\n \n~\nAvoid contact with infected persons\n \n~\nInclude adequate fresh fruits and vegetables in the diet\n5.2.4 Acute Epiglottitis\t ICD10 CODE: J05.1\nAn acute inflammation of the epiglottis, a rare but serious disease of \nyoung children. Airway obstruction is always severe, and intubation or \ntracheostomy is often needed. It is rare since routine childhood  mmu\u00ad\nnization with Hib vaccine was introduced.\nCause\n \n~\nBacterial infection, commonly Haemophilus influenzae\nClinical features\n \n~\nRapid onset of high fever\n \n~\nTypical: \u201ctripod or sniffing\u201d position, preferring to sit, lean\u00ad\ning forward with an open mouth, appears anxious\n \n~\nSore throat, difficulty swallowing, drooling, respiratory dis\u00ad\ntress\n \n~\nStridor and maybe cough\n \n~\nAppears critically ill (weak, grunting, crying, drowsy, does \nnot smile, anxious gaze, pallor, cyanosis)\n \n~\nAsphyxia leading to quick death\nDifferential diagnosis\n \n~\nLaryngeal cause of stridor e.g., laryngotracheobronchitis\nCaution\n \n\u0083 Avoid tongue depression examination as this may cause \ncomplete airway blockage and sudden death\n \n\u0083 Do not force child to lie down as it may precipitate airway \nobstruction\n349\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\u0083 Avoid cough syrups in children below 6 years</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid contact with infected persons</p>\n<p>~</p>\n<p>Include adequate fresh fruits and vegetables in the diet</p>\n<p>5.2.4 Acute Epiglottitis\t ICD10 CODE: J05.1</p>\n<p>An acute inflammation of the epiglottis, a rare but serious disease of</p>\n<p>young children. Airway obstruction is always severe, and intubation or</p>\n<p>tracheostomy is often needed. It is rare since routine childhood  mmu\u00ad</p>\n<p>nization with Hib vaccine was introduced.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Bacterial infection, commonly Haemophilus influenzae</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Rapid onset of high fever</p>\n<p>~</p>\n<p>Typical: \u201ctripod or sniffing\u201d position, preferring to sit, lean\u00ad</p>\n<p>ing forward with an open mouth, appears anxious</p>\n<p>~</p>\n<p>Sore throat, difficulty swallowing, drooling, respiratory dis\u00ad</p>\n<p>tress</p>\n<p>~</p>\n<p>Stridor and maybe cough</p>\n<p>~</p>\n<p>Appears critically ill (weak, grunting, crying, drowsy, does</p>\n<p>not smile, anxious gaze, pallor, cyanosis)</p>\n<p>~</p>\n<p>Asphyxia leading to quick death</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Laryngeal cause of stridor e.g., laryngotracheobronchitis</p>\n<p>Caution</p>\n<p>\u0083 Avoid tongue depression examination as this may cause</p>\n<p>complete airway blockage and sudden death</p>\n<p>\u0083 Do not force child to lie down as it may precipitate airway</p>\n<p>obstruction</p>\n<p>349</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 416,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nAdmit and treat as an emergency \u2013 intubation or tra\u00ad\ncheostomy may often be needed\n\t\n\u0089\nAvoid examination or procedures that agitate child as \nthis may worsen symptoms. Avoid IM medication\n\t\n\u0089\nInsert IV line and provide IV hydration\n\t\n\u0089\nCeftriaxone 50 mg/kg once daily for 7-10 days\nH\nPrevention\n \n~\nHib vaccine is part of the pentavalent DPT/HepB/Hib vac\u00ad\ncine used in routine immunisation of children\n5.2.5\t\nInfluenza (\u201d Flu\u201d)\t                  ICD10 CODE: J9-11\nA specific acute respiratory tract illness occurring in epidemics and occa\u00ad\nsionally pandemics. Influenza virus strains can be transmitted to humans \nfrom animals (pigs, birds) and can occasionally mutate and spread from \nperson to person (e.g., swine flu, or H1N1).\nCause\n \n~\nInfluenza viruses of several types and strains\n \n~\nSpread by droplet inhalation\nClinical features\n \n~\nSudden onset\n \n~\nHeadache, pain in back and limbs\n \n~\nAnorexia, sometimes nausea and vomiting\n \n~\nFever for 2-3 days with shivering\n \n~\nInflamed throat\n \n~\nHarsh unproductive cough\n350\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Admit and treat as an emergency \u2013 intubation or tra\u00ad</p>\n<p>cheostomy may often be needed</p>\n<p>\u0089</p>\n<p>Avoid examination or procedures that agitate child as</p>\n<p>this may worsen symptoms. Avoid IM medication</p>\n<p>\u0089</p>\n<p>Insert IV line and provide IV hydration</p>\n<p>\u0089</p>\n<p>Ceftriaxone 50 mg/kg once daily for 7-10 days</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Hib vaccine is part of the pentavalent DPT/HepB/Hib vac\u00ad</p>\n<p>cine used in routine immunisation of children</p>\n<p>5.2.5</p>\n<p>Influenza (\u201d Flu\u201d)\t                  ICD10 CODE: J9-11</p>\n<p>A specific acute respiratory tract illness occurring in epidemics and occa\u00ad</p>\n<p>sionally pandemics. Influenza virus strains can be transmitted to humans</p>\n<p>from animals (pigs, birds) and can occasionally mutate and spread from</p>\n<p>person to person (e.g., swine flu, or H1N1).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Influenza viruses of several types and strains</p>\n<p>~</p>\n<p>Spread by droplet inhalation</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Sudden onset</p>\n<p>~</p>\n<p>Headache, pain in back and limbs</p>\n<p>~</p>\n<p>Anorexia, sometimes nausea and vomiting</p>\n<p>~</p>\n<p>Fever for 2-3 days with shivering</p>\n<p>~</p>\n<p>Inflamed throat</p>\n<p>~</p>\n<p>Harsh unproductive cough</p>\n<p>350</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 417,
        "content": "Complications\n \n~\nSecondary bacterial infection: bronchopneumonia\n \n~\nToxic cardiomyopathy and sudden death\n Differential diagnosis\n \n~\nOther respiratory viral infections\nInvestigations\n \n\u0081\nIsolation of virus\n \n\u0081\nViral serology to identify virus\nTREATMENT\nLOC\nIf no complications, treat symptoms\n\t\n\u0089\nParacetamol 1 g every 4-6 hours  (max: 4 g/ day)\nChild: 10 mg/kg per dose\nFor nasal congestion\n\t\n\u0089\nUse steam inhalation prn\n\t\n\u0089\nOr xylometazoline nose drops 0.05 -0.1% 2-3 drops \ninto each nostril 3 times daily (max: 5 days)\nIn the breastfeeding child\n\t\n\u0089\nIf  blockage interferes with breastfeeding, clean/ clear \nnose with normal saline\n\t\n\u0089\nKeep child warm\n\t\n\u0089\nBreastfeed more frequently\nFor troublesome cough\n\t\n\u0089\nFrequent warm drinks, home remedies (honey, ginger)\nHC2\nHC4\nPrevention\n \n~\nAvoid contact with infected persons\n \n~\nInactivated Influenza vaccine yearly (for vulnerable popu\u00ad\nlations)\n351\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Complications</p>\n<p>~</p>\n<p>Secondary bacterial infection: bronchopneumonia</p>\n<p>~</p>\n<p>Toxic cardiomyopathy and sudden death</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other respiratory viral infections</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Isolation of virus</p>\n<p>\u0081</p>\n<p>Viral serology to identify virus</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If no complications, treat symptoms</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 4-6 hours  (max: 4 g/ day)</p>\n<p>Child: 10 mg/kg per dose</p>\n<p>For nasal congestion</p>\n<p>\u0089</p>\n<p>Use steam inhalation prn</p>\n<p>\u0089</p>\n<p>Or xylometazoline nose drops 0.05 -0.1% 2-3 drops</p>\n<p>into each nostril 3 times daily (max: 5 days)</p>\n<p>In the breastfeeding child</p>\n<p>\u0089</p>\n<p>If  blockage interferes with breastfeeding, clean/ clear</p>\n<p>nose with normal saline</p>\n<p>\u0089</p>\n<p>Keep child warm</p>\n<p>\u0089</p>\n<p>Breastfeed more frequently</p>\n<p>For troublesome cough</p>\n<p>\u0089</p>\n<p>Frequent warm drinks, home remedies (honey, ginger)</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid contact with infected persons</p>\n<p>~</p>\n<p>Inactivated Influenza vaccine yearly (for vulnerable popu\u00ad</p>\n<p>lations)</p>\n<p>351</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 418,
        "content": "5.2.6  Laryngitis\t                              ICD10 CODE: J04\nInflammation of the larynx which may involve surrounding structures, \ne.g., pharynx and trachea\nCause\n \n~\nViruses: Para-influenza group, influenza \u2212 by far the most \ncommon cause. Usually acute (up to 3 weeks)\n \n~\nExcessive use of the voice, allergic reactions, inhalation of \nirritating substances, e.g., cigarette smoke, gastroesopha\u00ad\ngeal reflux. Often chronic symptoms (>3 weeks)\nClinical features\n \n~\nOnset similar to any upper respiratory tract infection\n \n~\nFever usually mild\n \n~\nHoarseness\nDifferential diagnosis\n \n~\nDiphtheria, whooping cough\n \n~\nLaryngotracheobronchitis, epiglottitis\n \n~\nBacterial tracheitis\n \n~\nForeign body aspiration\n \n~\nAsthma\n \n~\nAirway compression by extrinsic mass (e.g., tumours, hae\u00ad\nmangioma, cysts)\nInvestigations\n \n\u0081\nBlood: Complete blood count\n \n\u0081\nX-ray: Chest\n \n\u0081\nLaryngeal swab for C&S\n352\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>5.2.6  Laryngitis\t                              ICD10 CODE: J04</p>\n<p>Inflammation of the larynx which may involve surrounding structures,</p>\n<p>e.g., pharynx and trachea</p>\n<p>Cause</p>\n<p>~</p>\n<p>Viruses: Para-influenza group, influenza \u2212 by far the most</p>\n<p>common cause. Usually acute (up to 3 weeks)</p>\n<p>~</p>\n<p>Excessive use of the voice, allergic reactions, inhalation of</p>\n<p>irritating substances, e.g., cigarette smoke, gastroesopha\u00ad</p>\n<p>geal reflux. Often chronic symptoms (>3 weeks)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Onset similar to any upper respiratory tract infection</p>\n<p>~</p>\n<p>Fever usually mild</p>\n<p>~</p>\n<p>Hoarseness</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Diphtheria, whooping cough</p>\n<p>~</p>\n<p>Laryngotracheobronchitis, epiglottitis</p>\n<p>~</p>\n<p>Bacterial tracheitis</p>\n<p>~</p>\n<p>Foreign body aspiration</p>\n<p>~</p>\n<p>Asthma</p>\n<p>~</p>\n<p>Airway compression by extrinsic mass (e.g., tumours, hae\u00ad</p>\n<p>mangioma, cysts)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Complete blood count</p>\n<p>\u0081</p>\n<p>X-ray: Chest</p>\n<p>\u0081</p>\n<p>Laryngeal swab for C&S</p>\n<p>352</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 419,
        "content": "TREATMENT\nLOC\nThe cause is usually viral for which there is no specific treat\u00ad\nment and no need for antibiotics f Give analgesics\n\t\n\u0089\nUse steam inhalations 2-3 times daily\n\t\n\u0089\nRest the voice\n\t\n\u0089\nFor chronic laryngitis: identify and treat the cause\nHC2\n5.2.7\t\nAcute Laryngotracheobronchitis (Croup)   \n ICD10 CODE: J05.0\nAn acute inflammation of larynx, trachea and bronchi primarily in chil\u00ad\ndren < 3 years, usually viral.\nCause\n \n~\nMeasles virus\n \n~\nInfluenza and Parainfluenza type 1 viruses\n \n~\nRarely - superinfection with bacteria e.g. H. influenzae\nNote: Secondary bacterial infection is rare, therefore antibiotics are \nrarely needed\nClinical features\nEarly phase (mild croup)\n \n~\nBarking cough, hoarse voice or cry\n \n~\nInspiratory stridor (abnormal high-pitched sound)\n \n~\nCommon cold\nLate phase (severe croup)\n \n~\nSevere dyspnoea and stridor at rest\n \n~\nCyanosis (blue colour of child - especially extremities and \nmouth)\n \n~\nAsphyxia (suffocation)\n353\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>The cause is usually viral for which there is no specific treat\u00ad</p>\n<p>ment and no need for antibiotics f Give analgesics</p>\n<p>\u0089</p>\n<p>Use steam inhalations 2-3 times daily</p>\n<p>\u0089</p>\n<p>Rest the voice</p>\n<p>\u0089</p>\n<p>For chronic laryngitis: identify and treat the cause</p>\n<h3>HC2</h3>\n<p>5.2.7</p>\n<p>Acute Laryngotracheobronchitis (Croup)</p>\n<h3>ICD10 CODE: J05.0</h3>\n<p>An acute inflammation of larynx, trachea and bronchi primarily in chil\u00ad</p>\n<p>dren < 3 years, usually viral.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Measles virus</p>\n<p>~</p>\n<p>Influenza and Parainfluenza type 1 viruses</p>\n<p>~</p>\n<p>Rarely - superinfection with bacteria e.g. H. influenzae</p>\n<p>Note: Secondary bacterial infection is rare, therefore antibiotics are</p>\n<p>rarely needed</p>\n<p>Clinical features</p>\n<p>Early phase (mild croup)</p>\n<p>~</p>\n<p>Barking cough, hoarse voice or cry</p>\n<p>~</p>\n<p>Inspiratory stridor (abnormal high-pitched sound)</p>\n<p>~</p>\n<p>Common cold</p>\n<p>Late phase (severe croup)</p>\n<p>~</p>\n<p>Severe dyspnoea and stridor at rest</p>\n<p>~</p>\n<p>Cyanosis (blue colour of child - especially extremities and</p>\n<p>mouth)</p>\n<p>~</p>\n<p>Asphyxia (suffocation)</p>\n<p>353</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 420,
        "content": "TREATMENT\nLOC\nMild croup\n\t\n\u0089\nIsolate patient, ensure plenty of rest\n\t\n\u0089\nKeep well hydrated with oral fluids\n \n- Use oral rehydration solution\n\t\n\u0089\nGive analgesics\n\t\n\u0089\nSingle dose steroid:\n \n- Prednisolone 1-2 mg/kg single dose\n \n- or Dexamethasone 0.15 mg/kg single dose\nIf condition is severe \n\t\n\u0089\nAdmit  the   patient f Ensure close supervision\n\t\n\u0089\nGive humidified oxygen 30-40%\n\t\n\u0089\nKeep well hydrated with IV fluids\n\t\n\u0089\nUse Darrow\u2019s solution \u00bd strength in glucose\n2.5%\n\t\n\u0089\nSteroids: hydrocortisone slow IV or IM\nChild <1 year: 25 mg\nChild 1-5 years: 50 mg\nChild 6-12 years: 100 mg\n \n- Or dexamethasone 300 micrograms/kg IM \n\t\n\u0089\nRepeat steroid dose after 6 hours if necessary \n\t\n\u0089\nIf not controlled, nebulise adrenaline 0.4 mg/kg (max \n5 mg) diluted with normal saline, repeat after 30 min \nif necessary\nHC2\nHC3\nHC4\nH\nCaution\n \n\u0083 Avoid throat examination. Gagging can cause acute \nobstruction\n354\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild croup</p>\n<p>\u0089</p>\n<p>Isolate patient, ensure plenty of rest</p>\n<p>\u0089</p>\n<p>Keep well hydrated with oral fluids</p>\n<p>- Use oral rehydration solution</p>\n<p>\u0089</p>\n<p>Give analgesics</p>\n<p>\u0089</p>\n<p>Single dose steroid:</p>\n<p>- Prednisolone 1-2 mg/kg single dose</p>\n<p>- or Dexamethasone 0.15 mg/kg single dose</p>\n<p>If condition is severe</p>\n<p>\u0089</p>\n<p>Admit  the   patient f Ensure close supervision</p>\n<p>\u0089</p>\n<p>Give humidified oxygen 30-40%</p>\n<p>\u0089</p>\n<p>Keep well hydrated with IV fluids</p>\n<p>\u0089</p>\n<p>Use Darrow\u2019s solution \u00bd strength in glucose</p>\n<p>2.5%</p>\n<p>\u0089</p>\n<p>Steroids: hydrocortisone slow IV or IM</p>\n<p>Child <1 year: 25 mg</p>\n<p>Child 1-5 years: 50 mg</p>\n<p>Child 6-12 years: 100 mg</p>\n<p>- Or dexamethasone 300 micrograms/kg IM</p>\n<p>\u0089</p>\n<p>Repeat steroid dose after 6 hours if necessary</p>\n<p>\u0089</p>\n<p>If not controlled, nebulise adrenaline 0.4 mg/kg (max</p>\n<p>5 mg) diluted with normal saline, repeat after 30 min</p>\n<p>if necessary</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>Caution</p>\n<p>\u0083 Avoid throat examination. Gagging can cause acute</p>\n<p>obstruction</p>\n<p>354</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 421,
        "content": "TREATMENT\nLOC\nIf severe respiratory distress develops\n\t\n\u0089\nCarry out nasotracheal intubation or tracheostomy if \nnecessary\n\t\n\u0089\nAdmit to ICU or HDU\nRR\nSuspect bacterial infection if child does not improve or ap\u00ad\npears critically ill\n\t\n\u0089\nTreat as epiglottitis (see section 5.2.4)\nNote\n \n\u0083 Avoid cough mixtures in children < 6 years\nPrevention\n \n~\nAvoid contact with infected persons\n \n~\nIsolate infected persons\n5.2.8\t\nPertussis (Whooping Cough)               ICD10 CODE: A37\nAn acute bacterial respiratory infection characterised by an inspiratory \nwhoop following paroxysmal cough. It is highly contagious with an \nincubation period of 7-10 days. It is a notifiable disease.\nCause\n \n~\nBordetella pertussis, spread by droplet infection\nClinical features\nStage 1: Coryzal (catarrhal: 1-2 weeks)\n \n~\nMost infectious stage\n \n~\nRunning nose, mild cough, slight fever\nStage 2: Paroxysmal (1-6 weeks)\n \n~\nMore severe and frequent repetitive cough ending in a \nwhoop, vomiting, conjuctival haemorrhage\n \n~\nFever may be present; patient becomes increasingly tired\n355\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If severe respiratory distress develops</p>\n<p>\u0089</p>\n<p>Carry out nasotracheal intubation or tracheostomy if</p>\n<p>necessary</p>\n<p>\u0089</p>\n<p>Admit to ICU or HDU</p>\n<p>RR</p>\n<p>Suspect bacterial infection if child does not improve or ap\u00ad</p>\n<p>pears critically ill</p>\n<p>\u0089</p>\n<p>Treat as epiglottitis (see section 5.2.4)</p>\n<p>Note</p>\n<p>\u0083 Avoid cough mixtures in children < 6 years</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid contact with infected persons</p>\n<p>~</p>\n<p>Isolate infected persons</p>\n<p>5.2.8</p>\n<p>Pertussis (Whooping Cough)               ICD10 CODE: A37</p>\n<p>An acute bacterial respiratory infection characterised by an inspiratory</p>\n<p>whoop following paroxysmal cough. It is highly contagious with an</p>\n<p>incubation period of 7-10 days. It is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Bordetella pertussis, spread by droplet infection</p>\n<p>Clinical features</p>\n<p>Stage 1: Coryzal (catarrhal: 1-2 weeks)</p>\n<p>~</p>\n<p>Most infectious stage</p>\n<p>~</p>\n<p>Running nose, mild cough, slight fever</p>\n<p>Stage 2: Paroxysmal (1-6 weeks)</p>\n<p>~</p>\n<p>More severe and frequent repetitive cough ending in a</p>\n<p>whoop, vomiting, conjuctival haemorrhage</p>\n<p>~</p>\n<p>Fever may be present; patient becomes increasingly tired</p>\n<p>355</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 422,
        "content": "~\nIn infants <6 months: paroxyms lead to apnoea, cyanosis \n(coughing bouts and whoops may be absent)\nStage 3: Convalescent\n \n~\nParoxysmal symptoms reduce over weeks or months\n \n~\nCough may persist\nComplications may include\n \n~\nRespiratory: pneumonia (new onset fever a symptom), atel\u00ad\nectasis, emphysema, bronchiectasis, otitis media\n \n~\nNervous system: convulsions, coma, intracranial haemor\u00ad\nrhage\n \n~\nOthers: malnutrition, dehydration, inguinal hernia, rectal \nprolapse\nDifferential diagnosis\n \n~\nChlamydial and bacterial respiratory tract infection\n \n~\nForeign body in the trachea\nInvestigations\n \n\u0081\nClinical diagnosis\n \n\u0081\nBlood: complete blood count\n \n\u0081\nChest X-ray\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nMaintain nutrition and fluids\n\t\n\u0089\nGive oxygen and perform suction if the child is cyanotic\n\t\n\u0089\nFor the unimmunised or partly immunised, give DPT (three \ndoses) as per routine immunisation schedule\n\t\n\u0089\nIsolate the patient (avoid contact with other infants) until \nafter 5 days of antibiotic treatment\n\t\n\u0089\nTreatment should be initiated within 3 weeks from onset \nof cough: Erythromycin 500 mg every 6 hours for 7 days\nChild: 10-15 mg/kg every 6 hours\nHC4\n356\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>~</p>\n<p>In infants <6 months: paroxyms lead to apnoea, cyanosis</p>\n<p>(coughing bouts and whoops may be absent)</p>\n<p>Stage 3: Convalescent</p>\n<p>~</p>\n<p>Paroxysmal symptoms reduce over weeks or months</p>\n<p>~</p>\n<p>Cough may persist</p>\n<p>Complications may include</p>\n<p>~</p>\n<p>Respiratory: pneumonia (new onset fever a symptom), atel\u00ad</p>\n<p>ectasis, emphysema, bronchiectasis, otitis media</p>\n<p>~</p>\n<p>Nervous system: convulsions, coma, intracranial haemor\u00ad</p>\n<p>rhage</p>\n<p>~</p>\n<p>Others: malnutrition, dehydration, inguinal hernia, rectal</p>\n<p>prolapse</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Chlamydial and bacterial respiratory tract infection</p>\n<p>~</p>\n<p>Foreign body in the trachea</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Clinical diagnosis</p>\n<p>\u0081</p>\n<p>Blood: complete blood count</p>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Maintain nutrition and fluids</p>\n<p>\u0089</p>\n<p>Give oxygen and perform suction if the child is cyanotic</p>\n<p>\u0089</p>\n<p>For the unimmunised or partly immunised, give DPT (three</p>\n<p>doses) as per routine immunisation schedule</p>\n<p>\u0089</p>\n<p>Isolate the patient (avoid contact with other infants) until</p>\n<p>after 5 days of antibiotic treatment</p>\n<p>\u0089</p>\n<p>Treatment should be initiated within 3 weeks from onset</p>\n<p>of cough: Erythromycin 500 mg every 6 hours for 7 days</p>\n<p>Child: 10-15 mg/kg every 6 hours</p>\n<h3>HC4</h3>\n<p>356</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 423,
        "content": "TREATMENT\nLOC\nNote\n \n\u0083 Cough mixtures, sedatives, mucolytics, and \nantihistamines are USELESS in pertussis and should \nNOT be given\nPrevention\n \n~\nEducate parents on the importance of following the routine \nchildhood immunisation schedule:\n \n~\nEnsure good nutrition\n \n~\nAvoid overcrowding\n \n~\nBooster doses of vaccine in exposed infants\n5.2.9 Pneumonia                 ICD10 CODE: J13-18\nAcute infection and inflammation of the lungs alveoli. There are two \nmajor types:\n \n~\nBronchopneumonia: involves both the lung parenchyma \nand the bronchi. Common in children and the elderly\n \n~\nLobar pneumonia: involves one or more lobes of the lung. \nCommon in young people\nCauses\nCausative agents can be viral, bacterial or parasitic. Pathogens vary \naccording  to  age, patient\u2019s  condition and whether infection was ac\u00ad\nquired in the community or hospital (Gram negative are more common \nin hospital).\n \n~\nNeonates: group B streptococcus, Klebsiella, E.coli, Chla\u00ad\nmydia and S. aureus\n \n~\nChildren <5 years: Pneumococcus, Haemophilus influen\u00ad\nzae, less frequently: S. aureus, M. catarrhalis, M. Pneumo\u00ad\nniae, viruses (RSV, influenza, measles)\n \n~\nAdults and children >5 years: most commonly S.pneumo\u00ad\n357\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\u0083 Cough mixtures, sedatives, mucolytics, and</p>\n<p>antihistamines are USELESS in pertussis and should</p>\n<p>NOT be given</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Educate parents on the importance of following the routine</p>\n<p>childhood immunisation schedule:</p>\n<p>~</p>\n<p>Ensure good nutrition</p>\n<p>~</p>\n<p>Avoid overcrowding</p>\n<p>~</p>\n<p>Booster doses of vaccine in exposed infants</p>\n<p>5.2.9 Pneumonia                 ICD10 CODE: J13-18</p>\n<p>Acute infection and inflammation of the lungs alveoli. There are two</p>\n<p>major types:</p>\n<p>~</p>\n<p>Bronchopneumonia: involves both the lung parenchyma</p>\n<p>and the bronchi. Common in children and the elderly</p>\n<p>~</p>\n<p>Lobar pneumonia: involves one or more lobes of the lung.</p>\n<p>Common in young people</p>\n<p>Causes</p>\n<p>Causative agents can be viral, bacterial or parasitic. Pathogens vary</p>\n<p>according  to  age, patient\u2019s  condition and whether infection was ac\u00ad</p>\n<p>quired in the community or hospital (Gram negative are more common</p>\n<p>in hospital).</p>\n<p>~</p>\n<p>Neonates: group B streptococcus, Klebsiella, E.coli, Chla\u00ad</p>\n<p>mydia and S. aureus</p>\n<p>~</p>\n<p>Children <5 years: Pneumococcus, Haemophilus influen\u00ad</p>\n<p>zae, less frequently: S. aureus, M. catarrhalis, M. Pneumo\u00ad</p>\n<p>niae, viruses (RSV, influenza, measles)</p>\n<p>~</p>\n<p>Adults and children >5 years: most commonly S.pneumo\u00ad</p>\n<p>357</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 424,
        "content": "niae, followed by atypical bacteria, e.g. Mycloplasma pneu\u00ad\nmoniae, viruses\n \n~\nImmunosuppressed: Pneumocystis (in HIV infected)\nPredisposing factors\n \n~\nMalnutrition\n \n~\nOld age\n \n~\nImmunosuppression (HIV, cancer, alcohol dependence)\n \n~\nMeasles, pertussis\n \n~\nPre-existing lung or heart diseases, diabetes\nInvestigations\nIf facilities are available\n\t\n\u0089\nDo a chest X-ray and look for complications, e.g.\n \n- Pneumothorax, pyothorax\n \n- Pneumonitis suggestive of pneumocystis jiroveci pneumonia \n(PCP)\n \n- Pneumatocoeles (cavities filled with air) suggestive of \nstaphylococcal pneumonia\n \n\u0081\nSputum: For Gram stain, Ziehl-Neelsen (ZN) stain, culture     for \nAFB\n \n\u0081\nBlood: Complete blood count\n5.2.9.1\t Pneumonia in an Infant (up to 2 months) \nIn infants, not all respiratory distress is due to infection. But as pneumonia \nmay be rapidly fatal in this age group,\nsuspected cases should be treated promptly and referred for parenteral \ntreatment with antimicrobials. Consider all children < 2 months with \npneumonia as SEVERE disease.\nClinical features\n \n~\nRapid breathing ( 60 breaths/minute)\n358\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>niae, followed by atypical bacteria, e.g. Mycloplasma pneu\u00ad</p>\n<p>moniae, viruses</p>\n<p>~</p>\n<p>Immunosuppressed: Pneumocystis (in HIV infected)</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>Malnutrition</p>\n<p>~</p>\n<p>Old age</p>\n<p>~</p>\n<p>Immunosuppression (HIV, cancer, alcohol dependence)</p>\n<p>~</p>\n<p>Measles, pertussis</p>\n<p>~</p>\n<p>Pre-existing lung or heart diseases, diabetes</p>\n<p>Investigations</p>\n<p>If facilities are available</p>\n<p>\u0089</p>\n<p>Do a chest X-ray and look for complications, e.g.</p>\n<p>- Pneumothorax, pyothorax</p>\n<p>- Pneumonitis suggestive of pneumocystis jiroveci pneumonia</p>\n<h3>(PCP)</h3>\n<p>- Pneumatocoeles (cavities filled with air) suggestive of</p>\n<p>staphylococcal pneumonia</p>\n<p>\u0081</p>\n<p>Sputum: For Gram stain, Ziehl-Neelsen (ZN) stain, culture     for</p>\n<h3>AFB</h3>\n<p>\u0081</p>\n<p>Blood: Complete blood count</p>\n<p>5.2.9.1\t Pneumonia in an Infant (up to 2 months)</p>\n<p>In infants, not all respiratory distress is due to infection. But as pneumonia</p>\n<p>may be rapidly fatal in this age group,</p>\n<p>suspected cases should be treated promptly and referred for parenteral</p>\n<p>treatment with antimicrobials. Consider all children < 2 months with</p>\n<p>pneumonia as SEVERE disease.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Rapid breathing ( 60 breaths/minute)</p>\n<p>358</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 425,
        "content": "~\nSevere chest in drawing, grunting respiration\n \n~\nInability to breastfeed\n \n~\nConvulsions\n \n~\nDrowsiness\n \n~\nStridor in a calm child, wheezing\n \n~\nFever may or may not be present\n \n~\nCyanosis and apnoeic attacks (SpO2 less than 90%)\nManagement\nInfants with suspected pneumonia should be referred to hospital after \npre-referral dose of antibiotics.\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nAdmit\n\t\n\u0089\nKeep baby warm\n\t\n\u0089\nPrevent hypoglycaemia by breastfeeding/giving expressed \nbreast milk/NGT\n\t\n\u0089\nIf child is lethargic, do not give oral feeds. Use IV fluids \nwith care (see section 1.1.4)\n\t\n\u0089\nGive oxygen to keep SpO2  >94% f Ampicillin 50 mg/\nkg IV every 6 hours f Plus gentamicin 7.5 mg/kg IV \nonce daily\n\t\n\u0089\nNeonates < 7 days old: 5 mg/kg IV once daily\n\t\n\u0089\nIn premature babies, the doses may need to be reduced \n(specialist only)\nIn severely ill infants\n\t\n\u0089\nCeftriaxone 100 mg/kg IV once daily\nAlternative (only use if above not available)\n\t\n\u0089\nChloramphenicol 25 mg/kg IV every 6 hours (contrain\u00ad\ndicated in premature babies and neonates < 7 days old)\nH\n359\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>~</p>\n<p>Severe chest in drawing, grunting respiration</p>\n<p>~</p>\n<p>Inability to breastfeed</p>\n<p>~</p>\n<p>Convulsions</p>\n<p>~</p>\n<p>Drowsiness</p>\n<p>~</p>\n<p>Stridor in a calm child, wheezing</p>\n<p>~</p>\n<p>Fever may or may not be present</p>\n<p>~</p>\n<p>Cyanosis and apnoeic attacks (SpO2 less than 90%)</p>\n<p>Management</p>\n<p>Infants with suspected pneumonia should be referred to hospital after</p>\n<p>pre-referral dose of antibiotics.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Admit</p>\n<p>\u0089</p>\n<p>Keep baby warm</p>\n<p>\u0089</p>\n<p>Prevent hypoglycaemia by breastfeeding/giving expressed</p>\n<p>breast milk/NGT</p>\n<p>\u0089</p>\n<p>If child is lethargic, do not give oral feeds. Use IV fluids</p>\n<p>with care (see section 1.1.4)</p>\n<p>\u0089</p>\n<p>Give oxygen to keep SpO2  >94% f Ampicillin 50 mg/</p>\n<p>kg IV every 6 hours f Plus gentamicin 7.5 mg/kg IV</p>\n<p>once daily</p>\n<p>\u0089</p>\n<p>Neonates < 7 days old: 5 mg/kg IV once daily</p>\n<p>\u0089</p>\n<p>In premature babies, the doses may need to be reduced</p>\n<p>(specialist only)</p>\n<p>In severely ill infants</p>\n<p>\u0089</p>\n<p>Ceftriaxone 100 mg/kg IV once daily</p>\n<p>Alternative (only use if above not available)</p>\n<p>\u0089</p>\n<p>Chloramphenicol 25 mg/kg IV every 6 hours (contrain\u00ad</p>\n<p>dicated in premature babies and neonates < 7 days old)</p>\n<p>H</p>\n<p>359</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 426,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nContinue treatment for at least 5 days, and for 3 days \nafter the child is well\n\t\n\u0089\nIf meningitis is suspected, continue for 21 days\n\t\n\u0089\nIf septicaemia is suspected, continue for 10 days\nH\n5.2.9.2\t Pneumonia in a Child of 2 months-5 years\nClinical features\n \n~\nFever -  may be high, low grade or absent (in severe illness)\nPneumonia\n \n~\nCough\n \n~\nFast breathing (2-12 months: 50 bpm, 1-5 years: 40 \nbpm)\n \n~\nMild chest wall in-drawing\nSevere pneumonia\n \n~\nAs above plus at least one of the following\n \n~\nCentral cyanosis (blue lips, oral mucosa, finger nails or ox\u00ad\nygen saturation < 90% using a pulse oximeter)\n \n~\nInability to feed, vomiting everything\n \n~\nConvulsions, lethargy, decreased level of consciousness\n \n~\nSevere respiratory distress (severe chest indrawing, grunt\u00ad\ning, nasal flaring)\n \n~\nExtrapulmonary features, e.g. confusion or disorientation, \nmay predominate and may be the only signs of pneumonia \nin malnourished or immunosuppressed children\n360\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Continue treatment for at least 5 days, and for 3 days</p>\n<p>after the child is well</p>\n<p>\u0089</p>\n<p>If meningitis is suspected, continue for 21 days</p>\n<p>\u0089</p>\n<p>If septicaemia is suspected, continue for 10 days</p>\n<p>H</p>\n<p>5.2.9.2\t Pneumonia in a Child of 2 months-5 years</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Fever -  may be high, low grade or absent (in severe illness)</p>\n<p>Pneumonia</p>\n<p>~</p>\n<p>Cough</p>\n<p>~</p>\n<p>Fast breathing (2-12 months: 50 bpm, 1-5 years: 40</p>\n<p>bpm)</p>\n<p>~</p>\n<p>Mild chest wall in-drawing</p>\n<p>Severe pneumonia</p>\n<p>~</p>\n<p>As above plus at least one of the following</p>\n<p>~</p>\n<p>Central cyanosis (blue lips, oral mucosa, finger nails or ox\u00ad</p>\n<p>ygen saturation < 90% using a pulse oximeter)</p>\n<p>~</p>\n<p>Inability to feed, vomiting everything</p>\n<p>~</p>\n<p>Convulsions, lethargy, decreased level of consciousness</p>\n<p>~</p>\n<p>Severe respiratory distress (severe chest indrawing, grunt\u00ad</p>\n<p>ing, nasal flaring)</p>\n<p>~</p>\n<p>Extrapulmonary features, e.g. confusion or disorientation,</p>\n<p>may predominate and may be the only signs of pneumonia</p>\n<p>in malnourished or immunosuppressed children</p>\n<p>360</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 427,
        "content": "Management of pneumonia\nTREATMENT\nLOC\nNon-severe pneumonia\n\t\n\u0089\nGive oral amoxicillin dispersible tabs (DT) 40 mg/kg \nevery 12 hours for 5 days O\n \n- 2-12 months 250 mg (1 tab) every 12 hours for \n5 days\n \n- 1-3 years 500 mg (2 tabs) every 12 hours for 5 \ndays\n \n- 3-5 years 750 mg (3 tabs) every 12 hours for 5 \ndays\nIf wheezing present\n\t\n\u0089\nSalbutamol inhaler 1-2 puffs every 4-6 hours until \nwheezing stops\n\t\n\u0089\nReassess child for progress after 3 days\nHC2\nHC3\nSevere pneumonia\n\t\n\u0089\nRefer to hospital after 1st dose of antibiotic\n\t\n\u0089\nAdmit\n\t\n\u0089\nGive Oxygen if SpO2 < 90% with nasal prongs and \nmonitor through pulse oximetry\n\t\n\u0089\nGive ampicillin 50 mg/kg IV every 6 hours or\n\t\n\u0089\nbenzyl penicillin 50,000 IU/kg IM or IV\n\t\n\u0089\nPlus gentamicin 7.5 mg/kg IM or IV once daily\n \n- Continue treatment for at least 5 days, up to 10 \ndays\n\t\n\u0089\nIf not better after 48 hours, use second line f Ceftriax\u00ad\none 80 mg/kg IM or IV once daily f If staphylococcus \nis suspected (empyema, pneumatocele at X ray) , give \ngentamicin 7.5 mg/ kg once daily plus cloxacillin 50 \nmg/kg IM or IV every 6 hours\nHC4\nHC4\n361\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Non-severe pneumonia</p>\n<p>\u0089</p>\n<p>Give oral amoxicillin dispersible tabs (DT) 40 mg/kg</p>\n<p>every 12 hours for 5 days O</p>\n<p>- 2-12 months 250 mg (1 tab) every 12 hours for</p>\n<p>5 days</p>\n<p>- 1-3 years 500 mg (2 tabs) every 12 hours for 5</p>\n<p>days</p>\n<p>- 3-5 years 750 mg (3 tabs) every 12 hours for 5</p>\n<p>days</p>\n<p>If wheezing present</p>\n<p>\u0089</p>\n<p>Salbutamol inhaler 1-2 puffs every 4-6 hours until</p>\n<p>wheezing stops</p>\n<p>\u0089</p>\n<p>Reassess child for progress after 3 days</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Severe pneumonia</p>\n<p>\u0089</p>\n<p>Refer to hospital after 1st dose of antibiotic</p>\n<p>\u0089</p>\n<p>Admit</p>\n<p>\u0089</p>\n<p>Give Oxygen if SpO2 < 90% with nasal prongs and</p>\n<p>monitor through pulse oximetry</p>\n<p>\u0089</p>\n<p>Give ampicillin 50 mg/kg IV every 6 hours or</p>\n<p>\u0089</p>\n<p>benzyl penicillin 50,000 IU/kg IM or IV</p>\n<p>\u0089</p>\n<p>Plus gentamicin 7.5 mg/kg IM or IV once daily</p>\n<p>- Continue treatment for at least 5 days, up to 10</p>\n<p>days</p>\n<p>\u0089</p>\n<p>If not better after 48 hours, use second line f Ceftriax\u00ad</p>\n<p>one 80 mg/kg IM or IV once daily f If staphylococcus</p>\n<p>is suspected (empyema, pneumatocele at X ray) , give</p>\n<p>gentamicin 7.5 mg/ kg once daily plus cloxacillin 50</p>\n<p>mg/kg IM or IV every 6 hours</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>361</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 428,
        "content": "TREATMENT\nLOC\nOnce the patient improves\n\t\n\u0089\nSwitch to oral amoxicillin 40 mg/kg every 12 hours for \n5 days to complete a total of at least 5 days of antibiotics\nAlternative (if above not available/not working)\n\t\n\u0089\nChloramphenicol 25 mg/kg IV every 6 hours\nOther treatments\n\t\n\u0089\nGive Paracetamol 10 mg/kg every 4-6 hours for fever\n\t\n\u0089\nIf wheezing, give salbutamol 1-2 puffs every 4-6 hours\n\t\n\u0089\nGentle suction of thick secretions from upper airway\n\t\n\u0089\nDaily maintenance fluids \u2013 careful to avoid overload \nespecially in small and malnourished children (see \nsection 1.1.4)\n\t\n\u0089\nIf convulsions, give diazepam 0.5 mg/kg rectally or \n0.2 mg/kg IV\nIf convulsions are continuous\n\t\n\u0089\nGive a long-acting anticonvulsant, e.g., phenobarbital \n10-15 mg/kg IM as a loading dose. Depending on \nresponse, repeat this dose after 12 hours or switch to \noral maintenance dose of 3-5 mg/kg every 8-12 hours\n \n- Monitor and record\n \n- Respiratory rate (every 2 hours)\n \n- Body temperature (every 6 hours)\n \n- Oxygen saturation (every 12 hours)\n \n- Improvement in appetite and playing\n \n- Use of accessory muscles of respiration\n \n- Ability to breastfeed, drink and eat\n362\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Once the patient improves</p>\n<p>\u0089</p>\n<p>Switch to oral amoxicillin 40 mg/kg every 12 hours for</p>\n<p>5 days to complete a total of at least 5 days of antibiotics</p>\n<p>Alternative (if above not available/not working)</p>\n<p>\u0089</p>\n<p>Chloramphenicol 25 mg/kg IV every 6 hours</p>\n<p>Other treatments</p>\n<p>\u0089</p>\n<p>Give Paracetamol 10 mg/kg every 4-6 hours for fever</p>\n<p>\u0089</p>\n<p>If wheezing, give salbutamol 1-2 puffs every 4-6 hours</p>\n<p>\u0089</p>\n<p>Gentle suction of thick secretions from upper airway</p>\n<p>\u0089</p>\n<p>Daily maintenance fluids \u2013 careful to avoid overload</p>\n<p>especially in small and malnourished children (see</p>\n<p>section 1.1.4)</p>\n<p>\u0089</p>\n<p>If convulsions, give diazepam 0.5 mg/kg rectally or</p>\n<p>0.2 mg/kg IV</p>\n<p>If convulsions are continuous</p>\n<p>\u0089</p>\n<p>Give a long-acting anticonvulsant, e.g., phenobarbital</p>\n<p>10-15 mg/kg IM as a loading dose. Depending on</p>\n<p>response, repeat this dose after 12 hours or switch to</p>\n<p>oral maintenance dose of 3-5 mg/kg every 8-12 hours</p>\n<p>- Monitor and record</p>\n<p>- Respiratory rate (every 2 hours)</p>\n<p>- Body temperature (every 6 hours)</p>\n<p>- Oxygen saturation (every 12 hours)</p>\n<p>- Improvement in appetite and playing</p>\n<p>- Use of accessory muscles of respiration</p>\n<p>- Ability to breastfeed, drink and eat</p>\n<p>362</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 429,
        "content": "5.2.9.3\t Pneumonia in Children > 5 years and adults\nClinical features\nModerate\n \n~\nFever, chest pain, cough (with or without sputum), rapid \nbreathing (> 30 bpm), no chest indrawing\nSevere\n \n~\nAs above plus\n \n~\nChest indrawing\n \n~\nPulse >120/minute\n \n~\nTemperature > 39.5 o C\n \n~\nLow BP < 90/60 mmHg\n \n~\nOxygen saturation less than 90%\nNote\n \n\u0083 Extrapulmonary features, e.g. confusion or disorientation, may \npredominate and may be the only signs of pneumonia in elderly \nor immunosuppressed patients\nTREATMENT\nLOC\nModerate pneumonia (ambulatory patients) \n\t\n\u0089\nAmoxicillin 500 mg-1 g every 8 hours for 5 days \n\t\n\u0089\nChildren: 40 mg/kg every 12 hours for 5 days.\n\t\n\u0089\nPreferably use dispersible tablets in younger children\nIf penicillin allergy or poor response after 48 hours \n(possible atypical pneumonia), give: \n\t\n\u0089\nDoxycycline 100 mg every 12 hours for 7-10 days\n\t\n\u0089\nChild > 8 years only: 2 mg/kg per dose\n\t\n\u0089\nOr Erythromycin 500 mg every 6 hours for 5 days\nManagement of pneumonia\n363\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>5.2.9.3\t Pneumonia in Children > 5 years and adults</p>\n<p>Clinical features</p>\n<p>Moderate</p>\n<p>~</p>\n<p>Fever, chest pain, cough (with or without sputum), rapid</p>\n<p>breathing (> 30 bpm), no chest indrawing</p>\n<p>Severe</p>\n<p>~</p>\n<p>As above plus</p>\n<p>~</p>\n<p>Chest indrawing</p>\n<p>~</p>\n<p>Pulse >120/minute</p>\n<p>~</p>\n<p>Temperature > 39.5 o C</p>\n<p>~</p>\n<p>Low BP < 90/60 mmHg</p>\n<p>~</p>\n<p>Oxygen saturation less than 90%</p>\n<p>Note</p>\n<p>\u0083 Extrapulmonary features, e.g. confusion or disorientation, may</p>\n<p>predominate and may be the only signs of pneumonia in elderly</p>\n<p>or immunosuppressed patients</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Moderate pneumonia (ambulatory patients)</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg-1 g every 8 hours for 5 days</p>\n<p>\u0089</p>\n<p>Children: 40 mg/kg every 12 hours for 5 days.</p>\n<p>\u0089</p>\n<p>Preferably use dispersible tablets in younger children</p>\n<p>If penicillin allergy or poor response after 48 hours</p>\n<p>(possible atypical pneumonia), give:</p>\n<p>\u0089</p>\n<p>Doxycycline 100 mg every 12 hours for 7-10 days</p>\n<p>\u0089</p>\n<p>Child > 8 years only: 2 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or Erythromycin 500 mg every 6 hours for 5 days</p>\n<p>Management of pneumonia</p>\n<p>363</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 430,
        "content": "TREATMENT\nLOC\n\u2013 14 days in cases of atypical pneumonia\nChild: 10-15 mg/kg per dose\nSevere pneumonia (hospitalised patients)\n\t\n\u0089\nGive oxygen and monitor SpO2 saturation with pulse \noximeter\n\t\n\u0089\nBenzylpenicillin 2 MU IV or IM daily every 4-6 hours\nChild: 50,000-100,000 IU/kg per dose\nIf not better in 48 hours:\n\t\n\u0089\nCeftriaxone 1 g IV or IM every 24 hours\nChild: 50 mg/kg per dose (max: 1 g)\nIf S. Aureus is suspected\n\t\n\u0089\nCloxacillin 500 mg IV every 6 hours\nIf other options are not available\n\t\n\u0089\nChloramphenicol 1 g IV every 6 hours for 7 days\nChild: 25 mg/kg per dose (max: 750 mg)\nHC3\nManagement of pneumonia\nTREATMENT\nLOC\nStapylococcus pneumonia\nThis form is especially common following a recent \ninfluenza infection. It can cause empyema and pneu\u00ad\nmatocele.\nAdults and children >5 years:\n\t\n\u0089\nCloxacillin 1-2 g IV or IM every 6 hours for 10-14 days\nChild >5 years: 50 mg/kg per dose (max: 2 g)\nChild 2 months-5 years\n5.2.9.4\t Pneumonia by Specific Organisms\n364\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u2013 14 days in cases of atypical pneumonia</p>\n<p>Child: 10-15 mg/kg per dose</p>\n<p>Severe pneumonia (hospitalised patients)</p>\n<p>\u0089</p>\n<p>Give oxygen and monitor SpO2 saturation with pulse</p>\n<p>oximeter</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 2 MU IV or IM daily every 4-6 hours</p>\n<p>Child: 50,000-100,000 IU/kg per dose</p>\n<p>If not better in 48 hours:</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV or IM every 24 hours</p>\n<p>Child: 50 mg/kg per dose (max: 1 g)</p>\n<p>If S. Aureus is suspected</p>\n<p>\u0089</p>\n<p>Cloxacillin 500 mg IV every 6 hours</p>\n<p>If other options are not available</p>\n<p>\u0089</p>\n<p>Chloramphenicol 1 g IV every 6 hours for 7 days</p>\n<p>Child: 25 mg/kg per dose (max: 750 mg)</p>\n<h3>HC3</h3>\n<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Stapylococcus pneumonia</p>\n<p>This form is especially common following a recent</p>\n<p>influenza infection. It can cause empyema and pneu\u00ad</p>\n<p>matocele.</p>\n<p>Adults and children >5 years:</p>\n<p>\u0089</p>\n<p>Cloxacillin 1-2 g IV or IM every 6 hours for 10-14 days</p>\n<p>Child >5 years: 50 mg/kg per dose (max: 2 g)</p>\n<p>Child 2 months-5 years</p>\n<p>5.2.9.4\t Pneumonia by Specific Organisms</p>\n<p>364</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 431,
        "content": "Management of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\nCloxacillin 25-50 mg/kg IV or IM every 6 hours\n\t\n\u0089\nPlus gentamicin 7.5 mg/kg IV in 1-3 divided doses daily\n \n- Continue both medicines for at least 21 days\nMycoplasma pneumoniae\n\t\n\u0089\nDoxycycline 100 mg every 12 hours for 7-10 days\n    Child >8 years: 2 mg/kg per dose\n\t\n\u0089\nContraindicated in pregnancy\n\t\n\u0089\nOr erythromycin 500 mg every 6 hours for 5 days\n    Child: 10-15 mg/kg per dose\nH\nKlebsiella pneumonia\n\t\n\u0089\nGentamicin 5-7 mg/kg IV daily in divided doses\n\t\n\u0089\nOr ciprofloxacin 500 mg every 12 hours\n    Child: chloramphenicol 25 mg/kg every 6 hours\n \n- Give a 5-day course\n \n- Amend therapy as guided by C&S results\nH\nPneumococcal pneumonia\n\t\n\u0089\n Benzylpenicillin 50,000 IU/kg IV or IM every 6 hours \nfor 2-3 days then switch to oral Amoxicillin 500 mg-1 \ng every 8 hours for 5 days Children: 40 mg/kg every \n12 hours for 5 days.\nPreferably use dispersible tablets in younger children\nH\n5.2.9.5\t Pneumocystis jirovecii Pneumonia \nRefer to section 3.1.10.2\n365\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Cloxacillin 25-50 mg/kg IV or IM every 6 hours</p>\n<p>\u0089</p>\n<p>Plus gentamicin 7.5 mg/kg IV in 1-3 divided doses daily</p>\n<p>- Continue both medicines for at least 21 days</p>\n<p>Mycoplasma pneumoniae</p>\n<p>\u0089</p>\n<p>Doxycycline 100 mg every 12 hours for 7-10 days</p>\n<p>Child >8 years: 2 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Contraindicated in pregnancy</p>\n<p>\u0089</p>\n<p>Or erythromycin 500 mg every 6 hours for 5 days</p>\n<p>Child: 10-15 mg/kg per dose</p>\n<p>H</p>\n<p>Klebsiella pneumonia</p>\n<p>\u0089</p>\n<p>Gentamicin 5-7 mg/kg IV daily in divided doses</p>\n<p>\u0089</p>\n<p>Or ciprofloxacin 500 mg every 12 hours</p>\n<p>Child: chloramphenicol 25 mg/kg every 6 hours</p>\n<p>- Give a 5-day course</p>\n<p>- Amend therapy as guided by C&S results</p>\n<p>H</p>\n<p>Pneumococcal pneumonia</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 50,000 IU/kg IV or IM every 6 hours</p>\n<p>for 2-3 days then switch to oral Amoxicillin 500 mg-1</p>\n<p>g every 8 hours for 5 days Children: 40 mg/kg every</p>\n<p>12 hours for 5 days.</p>\n<p>Preferably use dispersible tablets in younger children</p>\n<p>H</p>\n<p>5.2.9.5\t Pneumocystis jirovecii Pneumonia</p>\n<p>Refer to section 3.1.10.2</p>\n<p>365</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 432,
        "content": "5.2.9.6\t Lung Abscess\t\n              ICD10 CODE: J85.0-1\nLocalised inflammation and necrosis (destruction) of lung tissue leading \nto pus formation. It is most commonly\ncaused by aspiration of oral secretions by patients who have impaired \nconsciousness.\nCause\n \n~\nInfection of lungs with pus forming organisms: e.g.\n \n~\nKlebsiella pneumoniae, Staphylococcus aureus\nClinical features\n \n~\nOnset is acute or gradual\n \n~\nMalaise, loss of appetite, sweating with chills and fever\n \n~\nCough with purulent sputum, foul-smelling breath (halitosis)\n \n~\nChest pain indicates pleurisy\n \n~\nFinger clubbing\nComplications\n \n~\nPus in the pleural cavity (empyema)\n \n~\nCoughing out blood (haemoptysis)\n \n~\nSeptic emboli to various parts of the body, e.g. brain (caus\u00ad\ning brain abscess)\n \n~\nBronchiectasis (pus in the bronchi)\nDifferential diagnosis\n \n~\nBronchogenic carcinoma\n \n~\nBronchiectasis\n \n~\nPrimary empyema communicating with a bronchus\n \n~\nTB of the lungs\n \n~\nLiver abscess communicating into the lung\n366\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>5.2.9.6\t Lung Abscess</p>\n<h3>ICD10 CODE: J85.0-1</h3>\n<p>Localised inflammation and necrosis (destruction) of lung tissue leading</p>\n<p>to pus formation. It is most commonly</p>\n<p>caused by aspiration of oral secretions by patients who have impaired</p>\n<p>consciousness.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Infection of lungs with pus forming organisms: e.g.</p>\n<p>~</p>\n<p>Klebsiella pneumoniae, Staphylococcus aureus</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Onset is acute or gradual</p>\n<p>~</p>\n<p>Malaise, loss of appetite, sweating with chills and fever</p>\n<p>~</p>\n<p>Cough with purulent sputum, foul-smelling breath (halitosis)</p>\n<p>~</p>\n<p>Chest pain indicates pleurisy</p>\n<p>~</p>\n<p>Finger clubbing</p>\n<p>Complications</p>\n<p>~</p>\n<p>Pus in the pleural cavity (empyema)</p>\n<p>~</p>\n<p>Coughing out blood (haemoptysis)</p>\n<p>~</p>\n<p>Septic emboli to various parts of the body, e.g. brain (caus\u00ad</p>\n<p>ing brain abscess)</p>\n<p>~</p>\n<p>Bronchiectasis (pus in the bronchi)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Bronchogenic carcinoma</p>\n<p>~</p>\n<p>Bronchiectasis</p>\n<p>~</p>\n<p>Primary empyema communicating with a bronchus</p>\n<p>~</p>\n<p>TB of the lungs</p>\n<p>~</p>\n<p>Liver abscess communicating into the lung</p>\n<p>366</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 433,
        "content": "Investigations\n \n\u0081\nChest X-ray\n\t\n\u0089\nEarly stages: Signs of consolidation\n\t\n\u0089\nLater stages: A cavity with a fluid level\n \n\u0081\nSputum: For microscopy and culture and sensitivity\nManagement of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\nBenzylpenicillin 1-2 MU IV or IM every 4-6 hours\n\t\n\u0089\nChild: 50,000-100,000 IU/kg per dose (max: 2 MU)\n\t\n\u0089\nPlus metronidazole 500 mg IV every 8-12 hours\nChild: 12.5 mg/kg per dose\nOnce improvement occurs, change to oral medication and \ncontinue for 4-8 weeks f Metronidazole 400 mg every 12 hours\nChild: 10 mg/kg per dose\nPlus Amoxicillin 500 mg-1 g 8 hourly\nChild: 25-50 mg/kg per dose for 4-6 weeks\nPostural drainage/physiotherapy\nSurgical drainage may be necessary\nHC4\nPrevention\n \n~\nEarly detection and treatment of pneumonia\n5.3 TUBERCULOSIS (TB)                        ICD11 CODE: A15-A19\n5.3.1Definition, Clinical Features and Diagnosis of TB\nA chronic infection caused by Mycobacterium tuberculosis complex. It \ncommonly affects lungs but can affect any organ (lymph nodes, bones, \nmeninges, abdomen, kidney).\n367\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<p>\u0089</p>\n<p>Early stages: Signs of consolidation</p>\n<p>\u0089</p>\n<p>Later stages: A cavity with a fluid level</p>\n<p>\u0081</p>\n<p>Sputum: For microscopy and culture and sensitivity</p>\n<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Benzylpenicillin 1-2 MU IV or IM every 4-6 hours</p>\n<p>\u0089</p>\n<p>Child: 50,000-100,000 IU/kg per dose (max: 2 MU)</p>\n<p>\u0089</p>\n<p>Plus metronidazole 500 mg IV every 8-12 hours</p>\n<p>Child: 12.5 mg/kg per dose</p>\n<p>Once improvement occurs, change to oral medication and</p>\n<p>continue for 4-8 weeks f Metronidazole 400 mg every 12 hours</p>\n<p>Child: 10 mg/kg per dose</p>\n<p>Plus Amoxicillin 500 mg-1 g 8 hourly</p>\n<p>Child: 25-50 mg/kg per dose for 4-6 weeks</p>\n<p>Postural drainage/physiotherapy</p>\n<p>Surgical drainage may be necessary</p>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Early detection and treatment of pneumonia</p>\n<h3>5.3 TUBERCULOSIS (TB)                        ICD11 CODE: A15-A19</h3>\n<p>5.3.1Definition, Clinical Features and Diagnosis of TB</p>\n<p>A chronic infection caused by Mycobacterium tuberculosis complex. It</p>\n<p>commonly affects lungs but can affect any organ (lymph nodes, bones,</p>\n<p>meninges, abdomen, kidney).</p>\n<p>367</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 434,
        "content": "For more information on the management of TB see:\n \n\u0081\nManual of the National TB/Leprosy Programme (NTLP) in \nUganda 4th Edition, 2022\n \n\u0081\nNTLP desk guide\n \n\u0081\nLatent TB guidelines \n \n\u0081\nNational drug resistant TB guidelines\nCauses\n \n~\nMycobacterium tuberculosis complex (e.g. M. tuberculosis,\n \n~\nM. bovis, M. avium, M. africanum and M. Microti)\n \n~\nM. tuberculosis is the commonest cause of tuberculosis \n \n~\nTransmission by droplet inhalation (cough from a patient \nwith open pulmonary TB); can also be through drinking \nunpasteurised milk, especially M.bovis\nClinical features\nGeneral symptoms\n \n~\nFevers especially in the evening, \n \n~\nexcessive night sweats\n \n~\nWeight loss and loss of appetite\nPulmonary TB\n \n~\nChronic cough of >2 weeks (however, in HIV settings, \ncough of any duration)\n \n~\nChest pain, purulent sputum occasionally blood-stained, \nshortness of breath\nExtrapulmonary TB\n \n~\nLymphnode TB: Localized enlargement of lymph nodes de\u00ad\npending on the site affected (commonly neck)\n368\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>For more information on the management of TB see:</p>\n<p>\u0081</p>\n<p>Manual of the National TB/Leprosy Programme (NTLP) in</p>\n<p>Uganda 4th Edition, 2022</p>\n<p>\u0081</p>\n<p>NTLP desk guide</p>\n<p>\u0081</p>\n<p>Latent TB guidelines</p>\n<p>\u0081</p>\n<p>National drug resistant TB guidelines</p>\n<p>Causes</p>\n<p>~</p>\n<p>Mycobacterium tuberculosis complex (e.g. M. tuberculosis,</p>\n<p>~</p>\n<p>M. bovis, M. avium, M. africanum and M. Microti)</p>\n<p>~</p>\n<p>M. tuberculosis is the commonest cause of tuberculosis</p>\n<p>~</p>\n<p>Transmission by droplet inhalation (cough from a patient</p>\n<p>with open pulmonary TB); can also be through drinking</p>\n<p>unpasteurised milk, especially M.bovis</p>\n<p>Clinical features</p>\n<p>General symptoms</p>\n<p>~</p>\n<p>Fevers especially in the evening,</p>\n<p>~</p>\n<p>excessive night sweats</p>\n<p>~</p>\n<p>Weight loss and loss of appetite</p>\n<p>Pulmonary TB</p>\n<p>~</p>\n<p>Chronic cough of >2 weeks (however, in HIV settings,</p>\n<p>cough of any duration)</p>\n<p>~</p>\n<p>Chest pain, purulent sputum occasionally blood-stained,</p>\n<p>shortness of breath</p>\n<p>Extrapulmonary TB</p>\n<p>~</p>\n<p>Lymphnode TB: Localized enlargement of lymph nodes de\u00ad</p>\n<p>pending on the site affected (commonly neck)</p>\n<p>368</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 435,
        "content": "~\nPleural or pericardial effusion\n \n~\nAbdominal TB: ascites and abdominal pain\n \n~\nTB meningitis: subacute meningitis (headache, alteration of \nconsciousness)\n \n~\nBone or joint TB: swelling and deformity\nComplications\n \n~\nMassive haemoptysis - coughing up >250 mL blood per \nepisode\n \n~\nSpontaneous pneumothorax and pleural effusion\n \n~\nTB pericarditis, TB meningitis, TB peritonitis\n \n~\nBone TB: can be TB spine with gibbus, TB joints with \ndeformity)\n \n~\nRespiratory failure\nTB Case Definitions\nCASE DEFINITION\nDESCRIPTION\nPresumptive TB \npatient\nAny patient who presents with \nsymptoms and signs suggestive of \nTB or found to have chest X-ray \nsuggestive of active TB disease \nBacteriologically \nconfirmed TB patient\nPatient in whom biological \nspecimen is positive by smear \nmicroscopy, culture or molecular \nWHO Recommended Diagnostic \n(mWRD) test like GeneXpert  \nTruenat or TB LAMP. All such \ncases should be notified (regis\u00ad\ntered in the unit TB register)\nClinically diagnosed \nTB patient\nPatient who does not fulfil the \ncriteria for bacteriological confir\u00ad\nmation but has been diagnosed \nwith active TB by a clinician on \nthe basis of clinical signs and \nsymptoms supported by relevant  \ninvestigations\n369\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>~</p>\n<p>Pleural or pericardial effusion</p>\n<p>~</p>\n<p>Abdominal TB: ascites and abdominal pain</p>\n<p>~</p>\n<p>TB meningitis: subacute meningitis (headache, alteration of</p>\n<p>consciousness)</p>\n<p>~</p>\n<p>Bone or joint TB: swelling and deformity</p>\n<p>Complications</p>\n<p>~</p>\n<p>Massive haemoptysis - coughing up >250 mL blood per</p>\n<p>episode</p>\n<p>~</p>\n<p>Spontaneous pneumothorax and pleural effusion</p>\n<p>~</p>\n<p>TB pericarditis, TB meningitis, TB peritonitis</p>\n<p>~</p>\n<p>Bone TB: can be TB spine with gibbus, TB joints with</p>\n<p>deformity)</p>\n<p>~</p>\n<p>Respiratory failure</p>\n<p>TB Case Definitions</p>\n<h3>CASE DEFINITION</h3>\n<h3>DESCRIPTION</h3>\n<p>Presumptive TB</p>\n<p>patient</p>\n<p>Any patient who presents with</p>\n<p>symptoms and signs suggestive of</p>\n<p>TB or found to have chest X-ray</p>\n<p>suggestive of active TB disease</p>\n<p>Bacteriologically</p>\n<p>confirmed TB patient</p>\n<p>Patient in whom biological</p>\n<p>specimen is positive by smear</p>\n<p>microscopy, culture or molecular</p>\n<p>WHO Recommended Diagnostic</p>\n<p>(mWRD) test like GeneXpert</p>\n<p>Truenat or TB LAMP. All such</p>\n<p>cases should be notified (regis\u00ad</p>\n<p>tered in the unit TB register)</p>\n<p>Clinically diagnosed</p>\n<p>TB patient</p>\n<p>Patient who does not fulfil the</p>\n<p>criteria for bacteriological confir\u00ad</p>\n<p>mation but has been diagnosed</p>\n<p>with active TB by a clinician on</p>\n<p>the basis of clinical signs and</p>\n<p>symptoms supported by relevant</p>\n<p>investigations</p>\n<p>369</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 436,
        "content": "Classification of TB Disease \nCASE DEFINITION\nDESCRIPTION\nSite of the disease\nPulmonary TB: bacteriologically \nconfirmed or clinically diagnosed \ncase, affecting lung parenchyma or \ntracheobronchial tree. \nExtrapulmonary TB: Any other \ncase of TB. \nIsolated TB pleural effusion and \nmediastinal lymphadenopathy\nwithout lung tissue involvement is \nconsidered extrapulmonary TB \nIf the patient has pulmonary and \nextrapulmonary involvement, he/ \nshe will be classified as pulmonary \nTB\nHistory of treatment\nNew: no previous TB treatment (or \ntreatment less < 1 month)\nRelapse: patient who completed a \nprevious course of treatment, was \ndeclared cured or treatment\ncompleted, and is now diagnosed \nwith a recurrent episode of TB\nTreatment after failure: those who \nhave previously been treated for \nTB and whose treatment failed at \nthe end of their most recent course \nof treatment\nTreatment after loss to follow-up: \nPatient has been previously \ntreated for TB and were declared \nlost to follow-up at the end of their \nmost recent course of treatment.\n370\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Classification of TB Disease</p>\n<h3>CASE DEFINITION</h3>\n<h3>DESCRIPTION</h3>\n<p>Site of the disease</p>\n<p>Pulmonary TB: bacteriologically</p>\n<p>confirmed or clinically diagnosed</p>\n<p>case, affecting lung parenchyma or</p>\n<p>tracheobronchial tree.</p>\n<p>Extrapulmonary TB: Any other</p>\n<p>case of TB.</p>\n<p>Isolated TB pleural effusion and</p>\n<p>mediastinal lymphadenopathy</p>\n<p>without lung tissue involvement is</p>\n<p>considered extrapulmonary TB</p>\n<p>If the patient has pulmonary and</p>\n<p>extrapulmonary involvement, he/</p>\n<p>she will be classified as pulmonary</p>\n<p>TB</p>\n<p>History of treatment</p>\n<p>New: no previous TB treatment (or</p>\n<p>treatment less < 1 month)</p>\n<p>Relapse: patient who completed a</p>\n<p>previous course of treatment, was</p>\n<p>declared cured or treatment</p>\n<p>completed, and is now diagnosed</p>\n<p>with a recurrent episode of TB</p>\n<p>Treatment after failure: those who</p>\n<p>have previously been treated for</p>\n<p>TB and whose treatment failed at</p>\n<p>the end of their most recent course</p>\n<p>of treatment</p>\n<p>Treatment after loss to follow-up:</p>\n<p>Patient has been previously</p>\n<p>treated for TB and were declared</p>\n<p>lost to follow-up at the end of their</p>\n<p>most recent course of treatment.</p>\n<p>370</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 437,
        "content": "CASE DEFINITION\nDESCRIPTION\nTreatment history unknown: \nThose who have previously been \ntreated for TB but whose Outcome \nafter their most recent course of \ntreatment is unknown or undocu\u00ad\nmented\nDrug susceptibility \nstatus (based on \ndrug susceptibility \nTests)\nDrug Sensitive TB (DS-TB): These \nare sensitive to 1st line anti-TB \ndrugs\nDrug resistant TB (DR-TB): Resis\u00ad\ntant to any anti-TB drug. Can be \nclassified as follows.\nRifampicin resistant: any case of \nrifampicin resistance (isolated or in \ncombination with other resistance) \n(RR-TB)\nMonoresistant: resistant to only \none first line anti-TB drug\nPoly drug resistant: resistant to \nmore than one first line anti TB \nother than both rifampicin and \nisoniazid\nMulti drug resistant: resistant to ri\u00ad\nfampicin and isoniazid (MDR \u2013TB)\nExtensive drug resistance (XDR-\nTB): resistant to rifampicin, \nisoniazid (MDR TB) and any \nfluoroquinolone and at least one of \neither bedaquiline or Linezolid )\nHIV status\nPositive: patients who tested \nHIV-positive at time of diagnosis \nor already enrolled in HIV care\n371\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>CASE DEFINITION</h3>\n<h3>DESCRIPTION</h3>\n<p>Treatment history unknown:</p>\n<p>Those who have previously been</p>\n<p>treated for TB but whose Outcome</p>\n<p>after their most recent course of</p>\n<p>treatment is unknown or undocu\u00ad</p>\n<p>mented</p>\n<p>Drug susceptibility</p>\n<p>status (based on</p>\n<p>drug susceptibility</p>\n<p>Tests)</p>\n<p>Drug Sensitive TB (DS-TB): These</p>\n<p>are sensitive to 1st line anti-TB</p>\n<p>drugs</p>\n<p>Drug resistant TB (DR-TB): Resis\u00ad</p>\n<p>tant to any anti-TB drug. Can be</p>\n<p>classified as follows.</p>\n<p>Rifampicin resistant: any case of</p>\n<p>rifampicin resistance (isolated or in</p>\n<p>combination with other resistance)</p>\n<h3>(RR-TB)</h3>\n<p>Monoresistant: resistant to only</p>\n<p>one first line anti-TB drug</p>\n<p>Poly drug resistant: resistant to</p>\n<p>more than one first line anti TB</p>\n<p>other than both rifampicin and</p>\n<p>isoniazid</p>\n<p>Multi drug resistant: resistant to ri\u00ad</p>\n<p>fampicin and isoniazid (MDR \u2013TB)</p>\n<p>Extensive drug resistance (XDR-</p>\n<p>TB): resistant to rifampicin,</p>\n<p>isoniazid (MDR TB) and any</p>\n<p>fluoroquinolone and at least one of</p>\n<p>either bedaquiline or Linezolid )</p>\n<p>HIV status</p>\n<p>Positive: patients who tested</p>\n<p>HIV-positive at time of diagnosis</p>\n<p>or already enrolled in HIV care</p>\n<p>371</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 438,
        "content": "CASE DEFINITION\nDESCRIPTION\nHIV status\nNegative: patients who tested neg\u00ad\native at the moment of diagnosis\nUnknown:  If testing is then \nperformed at any moment during \ntreatment, patient should be re \nclassified\nDifferential diagnosis\n \n~\nHistoplasma pneumonia, trypanosomiasis, brucellosis\n \n~\nPneumonia\n \n~\nCOVID-19\n \n~\nHIV/AIDS\n \n~\nMalignancy\n \n~\nCOPD, asthma, bronchiectasis, emphysema etc.\n \n~\nPost TB lung disease\n \n~\nFungal infection of the lungs e.g. Aspergillosis\nScreening and diagnosis   of TB disease \nTB screening: is defined as the systematic identification of peo\u00ad\nple at risk for TB disease, in a predetermined target group, by \nassessing using tests, examinations or other procedures that can \nbe applied rapidly\nTB screening approaches: \n\u2022\tSymptom screening or CXR\n\u2022\tAll individuals seeking health care should be screened for TB at each \nvisit\nInvestigations for TB\n Obtain sputum sample or other relevant samples from presumptive \nTB patients for diagnosis \n\u2022\tXpert MTB/RIF is the recommended diagnostic test for TB diagnosis \n372\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<h3>CASE DEFINITION</h3>\n<h3>DESCRIPTION</h3>\n<p>HIV status</p>\n<p>Negative: patients who tested neg\u00ad</p>\n<p>ative at the moment of diagnosis</p>\n<p>Unknown:  If testing is then</p>\n<p>performed at any moment during</p>\n<p>treatment, patient should be re</p>\n<p>classified</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Histoplasma pneumonia, trypanosomiasis, brucellosis</p>\n<p>~</p>\n<p>Pneumonia</p>\n<p>~</p>\n<h3>COVID-19</h3>\n<p>~</p>\n<h3>HIV/AIDS</h3>\n<p>~</p>\n<p>Malignancy</p>\n<p>~</p>\n<p>COPD, asthma, bronchiectasis, emphysema etc.</p>\n<p>~</p>\n<p>Post TB lung disease</p>\n<p>~</p>\n<p>Fungal infection of the lungs e.g. Aspergillosis</p>\n<p>Screening and diagnosis   of TB disease</p>\n<p>TB screening: is defined as the systematic identification of peo\u00ad</p>\n<p>ple at risk for TB disease, in a predetermined target group, by</p>\n<p>assessing using tests, examinations or other procedures that can</p>\n<p>be applied rapidly</p>\n<p>TB screening approaches:</p>\n<li>Symptom screening or CXR</li>\n<li>All individuals seeking health care should be screened for TB at each</li>\n<p>visit</p>\n<p>Investigations for TB</p>\n<p>Obtain sputum sample or other relevant samples from presumptive</p>\n<p>TB patients for diagnosis</p>\n<li>Xpert MTB/RIF is the recommended diagnostic test for TB diagnosis</li>\n<p>372</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 439,
        "content": "\u2022\tWhere Xpert MTB/RIF test is not available, do \nSputum smear microscopy for AAFBs (ZN stain) but send the sample \nfor Xpert MTB/RIF test.\nGeneXpert MTB/Rif: automated DNA test on body samples (sputum, \nlymphonodes tissue, pleural fluid, CSF etc) which can diagnose pulmonary \nTB and determine susceptibility to Rifampicin. It is superior to microscopy.\nOther investigations\n \n\u0083 X- ray, abdominal ultrasound, biopsies etc. can be used \nfor sputum and GeneXpert negative patients or in case of \nextrapulmonary TB according to clinical judgement  \n \n\u0083 TST can be used as a supportive test to guide decision to treat \nfor TB in children\n \n\u0081\nputum culture and Drug susceptibility test: is a confirmatory \ntest for TB and also provides resistance pattern to TB medicines. \nDo this test for:\n\t\n\u0089\nPatients with Rifampicin resistance reported with GeneXpert\n\t\n\u0089\nAlso patients on first-line treatment who remain positive at 2 months \nand are reported Rifampicin sensitive on GeneXpert\n\t\n\u0089\nPatients suspected to be failing on first-line treatment\nNote: All presumed and diagnosed TB patients should be \noffered an HIV test\n5.3.1.1Tuberculosis in Children and adolescents\nTB may present at any age in children though the risk is highest below \nthe age of two years. When compared to adults, children are more prone \nto TB infection, TB disease, and severe forms of TB disease.\nRisk factors\n \n~\nContact with infectious (pulmonary) case of TB\n \n~\nAge < 5 years\n373\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<li>Where Xpert MTB/RIF test is not available, do</li>\n<p>Sputum smear microscopy for AAFBs (ZN stain) but send the sample</p>\n<p>for Xpert MTB/RIF test.</p>\n<p>GeneXpert MTB/Rif: automated DNA test on body samples (sputum,</p>\n<p>lymphonodes tissue, pleural fluid, CSF etc) which can diagnose pulmonary</p>\n<p>TB and determine susceptibility to Rifampicin. It is superior to microscopy.</p>\n<p>Other investigations</p>\n<p>\u0083 X- ray, abdominal ultrasound, biopsies etc. can be used</p>\n<p>for sputum and GeneXpert negative patients or in case of</p>\n<p>extrapulmonary TB according to clinical judgement</p>\n<p>\u0083 TST can be used as a supportive test to guide decision to treat</p>\n<p>for TB in children</p>\n<p>\u0081</p>\n<p>putum culture and Drug susceptibility test: is a confirmatory</p>\n<p>test for TB and also provides resistance pattern to TB medicines.</p>\n<p>Do this test for:</p>\n<p>\u0089</p>\n<p>Patients with Rifampicin resistance reported with GeneXpert</p>\n<p>\u0089</p>\n<p>Also patients on first-line treatment who remain positive at 2 months</p>\n<p>and are reported Rifampicin sensitive on GeneXpert</p>\n<p>\u0089</p>\n<p>Patients suspected to be failing on first-line treatment</p>\n<p>Note: All presumed and diagnosed TB patients should be</p>\n<p>offered an HIV test</p>\n<p>5.3.1.1Tuberculosis in Children and adolescents</p>\n<p>TB may present at any age in children though the risk is highest below</p>\n<p>the age of two years. When compared to adults, children are more prone</p>\n<p>to TB infection, TB disease, and severe forms of TB disease.</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Contact with infectious (pulmonary) case of TB</p>\n<p>~</p>\n<p>Age < 5 years</p>\n<p>373</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 440,
        "content": "~\nImmunosuppression (HIV, malnutrition, diabetes, etc).\n \n~\nAge < 1 year and lack of BCG vaccination are risk factors \nfor severe disease\nClinical features\n \n~\nSuspect TB in all children with\n \n- Fever > 2 weeks\n \n- Cough >2 weeks\n \n- Poor weight gain for one month\n \n- Close (home) contact of pulmonary TB case.\n \n- In young children, reduced playfulness, poor feeding, \ndecreased activity\n \n- Other signs include swollen lymph nodes in the neck, groin \nregion etc.\nInvestigations\n \n\u0081\nBacteriological confirmation of TB is more difficult in children. \nThe diagnosis of TB in children is dependent on conducting a \ndetailed clinical assessment combined with available tests\n \n\u0081\nWhenever possible, geneXpert should be performed\nManagement\nThe principles and objectives of TB treatment are similar to those of \nadults. In addition, effective treatment of TB in children promotes growth \nand development.\n \n5.3.1.2 Drug-Resistant TB\nDrug resistance is said to occur when TB organisms continue to grow \nin the presence of one or more anti-TB medicines.\n \n~\nAlthough several factors can contribute to the development \nof drug-resistant TB, inadequate anti-TB treatment is prob\u00ad\nably the most important. Inadequate anti-TB treatment \nleads to mutation in drug-susceptibility bacilli making them \ndrug resistant.\n374\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>~</p>\n<p>Immunosuppression (HIV, malnutrition, diabetes, etc).</p>\n<p>~</p>\n<p>Age < 1 year and lack of BCG vaccination are risk factors</p>\n<p>for severe disease</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Suspect TB in all children with</p>\n<p>- Fever > 2 weeks</p>\n<p>- Cough >2 weeks</p>\n<p>- Poor weight gain for one month</p>\n<p>- Close (home) contact of pulmonary TB case.</p>\n<p>- In young children, reduced playfulness, poor feeding,</p>\n<p>decreased activity</p>\n<p>- Other signs include swollen lymph nodes in the neck, groin</p>\n<p>region etc.</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Bacteriological confirmation of TB is more difficult in children.</p>\n<p>The diagnosis of TB in children is dependent on conducting a</p>\n<p>detailed clinical assessment combined with available tests</p>\n<p>\u0081</p>\n<p>Whenever possible, geneXpert should be performed</p>\n<p>Management</p>\n<p>The principles and objectives of TB treatment are similar to those of</p>\n<p>adults. In addition, effective treatment of TB in children promotes growth</p>\n<p>and development.</p>\n<p>5.3.1.2 Drug-Resistant TB</p>\n<p>Drug resistance is said to occur when TB organisms continue to grow</p>\n<p>in the presence of one or more anti-TB medicines.</p>\n<p>~</p>\n<p>Although several factors can contribute to the development</p>\n<p>of drug-resistant TB, inadequate anti-TB treatment is prob\u00ad</p>\n<p>ably the most important. Inadequate anti-TB treatment</p>\n<p>leads to mutation in drug-susceptibility bacilli making them</p>\n<p>drug resistant.</p>\n<p>374</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 441,
        "content": "Who is at risk for drug-resistant TB:\n \n\u0081\nContact with known drug-resistant tuberculosis\n \n\u0081\nRetreatments (relapses, treatment after failures, return after loss \nto follow-up)\n \n\u0081\nHistory of frequent interruption of drug treatment\n \n\u0081\nPatients who remain sputum smear-positive at month 2 or 3 of \nfirst-line anti-TB treatment\n \n~\nPatients presumed to have DR-TB should be screened \nusing rapid drug susceptibility testing (DST) of rifampicin \n(Xpert MTB/RIF, Truenat)\n\t\n\u0089\nAll patients who are drug-resistant TB suspects should therefore \nhave sputum/other specimens taken for culture and DST.\n \n~\nPatients with drug-resistant TB should be linked to desi na\u00ad\nted MDR TB treatment initiation centers in the respective \nregions\nDRUG RESISTANT TB IS A MAJOR PUBLIC HEALTH PROBLEM. INADE\u00ad\nQUATE TB TREATMENT IS THE MAJOR CONTRIBUTING FACTOR\n5.3.1.3 Post-TB patient management \nA post-TB patient is one who was successfully treated for TB but presents \nwith respiratory symptoms (chest pain, shortness of breath, cough).\n \n~\nRe-do standard TB diagnostic evaluation (sputum geneX\u00ad\npert and Chest X ray)\n \n~\nIf negative, evaluate for post-TB lung disease e.g., bronchi\u00ad\nectasias, COPD, pulmonary hypertension.\n \n~\nIn most cases these patients have residual lung damage \non Chest X-ray from previous TB, BUT they do not need \nretreatment if bacteriologically negative\n \n~\nCounsel the patient and give supportive treatment e.g., \nPulmonary rehabilitation, etc.\n375\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Who is at risk for drug-resistant TB:</p>\n<p>\u0081</p>\n<p>Contact with known drug-resistant tuberculosis</p>\n<p>\u0081</p>\n<p>Retreatments (relapses, treatment after failures, return after loss</p>\n<p>to follow-up)</p>\n<p>\u0081</p>\n<p>History of frequent interruption of drug treatment</p>\n<p>\u0081</p>\n<p>Patients who remain sputum smear-positive at month 2 or 3 of</p>\n<p>first-line anti-TB treatment</p>\n<p>~</p>\n<p>Patients presumed to have DR-TB should be screened</p>\n<p>using rapid drug susceptibility testing (DST) of rifampicin</p>\n<p>(Xpert MTB/RIF, Truenat)</p>\n<p>\u0089</p>\n<p>All patients who are drug-resistant TB suspects should therefore</p>\n<p>have sputum/other specimens taken for culture and DST.</p>\n<p>~</p>\n<p>Patients with drug-resistant TB should be linked to desi na\u00ad</p>\n<p>ted MDR TB treatment initiation centers in the respective</p>\n<p>regions</p>\n<h3>DRUG RESISTANT TB IS A MAJOR PUBLIC HEALTH PROBLEM. INADE\u00ad</h3>\n<h3>QUATE TB TREATMENT IS THE MAJOR CONTRIBUTING FACTOR</h3>\n<p>5.3.1.3 Post-TB patient management</p>\n<p>A post-TB patient is one who was successfully treated for TB but presents</p>\n<p>with respiratory symptoms (chest pain, shortness of breath, cough).</p>\n<p>~</p>\n<p>Re-do standard TB diagnostic evaluation (sputum geneX\u00ad</p>\n<p>pert and Chest X ray)</p>\n<p>~</p>\n<p>If negative, evaluate for post-TB lung disease e.g., bronchi\u00ad</p>\n<p>ectasias, COPD, pulmonary hypertension.</p>\n<p>~</p>\n<p>In most cases these patients have residual lung damage</p>\n<p>on Chest X-ray from previous TB, BUT they do not need</p>\n<p>retreatment if bacteriologically negative</p>\n<p>~</p>\n<p>Counsel the patient and give supportive treatment e.g.,</p>\n<p>Pulmonary rehabilitation, etc.</p>\n<p>375</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 442,
        "content": "5.3.2 Management of TB\nGeneral principles\n \n~\nThe country has adopted patient centered care. It is rec\u00ad\nommended that all TB medicines are taken under direct \nobservation by a treatment supporter (DOT). Digital Adher\u00ad\nence Technologies (DAT) have been introduced to support \ntreatment adherence.\n \n~\nAnti-TB drugs are given in fixed dose combination (FDC)   \nregimens according to the patient\u2019s TB classification\n\u2022\t Treatment is divided into two  phases: an initial (intensive) \nphase of 2 months and a continuation phase of 4 months \n(longer in severe forms of TB particularly TB meningitis and \nosteoarticular TB)TB treatment regimens are expressed in a \nstandard format, e.g. 2RHZE/4RH where:\n \n- Letters represent abbreviated drug names\n \n- Numbers show the duration in months\n \n- shows the division between treatment phases\n \n~\nOther shorter term (4-months) treatment regimen recently \nadopted  \n\u2022\t 2 HRE(Z)/2RH for children 2 months to 16 years\n\u2022\t 2 HPMZ/2HPM for adults  \n \n~\nAnti-TB drugs have side effects and they should be man\u00ad\naged appropriately (see section 5.3.2.1)\n \n~\nTB treatment monitoring should be done by clinical, spu\u00ad\ntum and where possible radiological\n \n~\nA conclusion of \u201ctreatment outcome\u201d status should be done \nfor every patient treated for TB.\n376\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>5.3.2 Management of TB</p>\n<p>General principles</p>\n<p>~</p>\n<p>The country has adopted patient centered care. It is rec\u00ad</p>\n<p>ommended that all TB medicines are taken under direct</p>\n<p>observation by a treatment supporter (DOT). Digital Adher\u00ad</p>\n<p>ence Technologies (DAT) have been introduced to support</p>\n<p>treatment adherence.</p>\n<p>~</p>\n<p>Anti-TB drugs are given in fixed dose combination (FDC)</p>\n<p>regimens according to the patient\u2019s TB classification</p>\n<li>Treatment is divided into two  phases: an initial (intensive)</li>\n<p>phase of 2 months and a continuation phase of 4 months</p>\n<p>(longer in severe forms of TB particularly TB meningitis and</p>\n<p>osteoarticular TB)TB treatment regimens are expressed in a</p>\n<p>standard format, e.g. 2RHZE/4RH where:</p>\n<p>- Letters represent abbreviated drug names</p>\n<p>- Numbers show the duration in months</p>\n<p>- shows the division between treatment phases</p>\n<p>~</p>\n<p>Other shorter term (4-months) treatment regimen recently</p>\n<p>adopted</p>\n<li>2 HRE(Z)/2RH for children 2 months to 16 years</li>\n<li>2 HPMZ/2HPM for adults</li>\n<p>~</p>\n<p>Anti-TB drugs have side effects and they should be man\u00ad</p>\n<p>aged appropriately (see section 5.3.2.1)</p>\n<p>~</p>\n<p>TB treatment monitoring should be done by clinical, spu\u00ad</p>\n<p>tum and where possible radiological</p>\n<p>~</p>\n<p>A conclusion of \u201ctreatment outcome\u201d status should be done</p>\n<p>for every patient treated for TB.</p>\n<p>376</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 443,
        "content": "Drug\nAdult Dose\nChildren \nDose\nContraindications\n(C) / Interactions (I)\nIsoniazid (H) \noral\n5 mg/kg \n(max 300 \nmg)\n10 mg/ \nkg (range \n7\u201315 mg/ \nkg)\nC: Liver disease, \nknown hypersensitivity \nI: carbamazepine, \nphenytoin\nRifampicin\n(R) oral\n10 mg/kg\n(max 600 \nmg)\n15 mg/ \nkg (range \n10\u201320 \nmg/kg)\nC: Liver disease, known \nhypersensitivity I: Oral \ncontraceptives, nevirap\u00ad\nine, warfarin, phenytoin, \nglibenclamide\nPyrazina- mide\n(Z) oral\n30-40\nmg/kg (max \n2500 mg)\n3 5  m g / \nkg (range \n30\u201340\nmg/kg)\nC: Liver disease, known\nHypersensitivity\nEtham- butol \n(E) oral\n15 mg/kg\n2 0  m g / \nkg (range \n15\u201325\nmg/kg)\nC: Pre existing optic neu\u00ad\nritis, established kidney \nfailure\nMoxifloxacin \n(M) oral\n10-15mg /\nKg\nResistance to a fluoro\u00ad\nquinolone\nNote\n \n\u0083 Rifampicin interacts with oestrogen-containing contraceptives \nand reduces the protective efficacy of the contraceptives. Use \nhigh dose contraceptive or use an additional barrier method.\nFirst line anti-TB medication\n377\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Drug</p>\n<p>Adult Dose</p>\n<p>Children</p>\n<p>Dose</p>\n<p>Contraindications</p>\n<p>(C) / Interactions (I)</p>\n<p>Isoniazid (H)</p>\n<p>oral</p>\n<p>5 mg/kg</p>\n<p>(max 300</p>\n<p>mg)</p>\n<p>10 mg/</p>\n<p>kg (range</p>\n<p>7\u201315 mg/</p>\n<p>kg)</p>\n<p>C: Liver disease,</p>\n<p>known hypersensitivity</p>\n<p>I: carbamazepine,</p>\n<p>phenytoin</p>\n<p>Rifampicin</p>\n<p>(R) oral</p>\n<p>10 mg/kg</p>\n<p>(max 600</p>\n<p>mg)</p>\n<p>15 mg/</p>\n<p>kg (range</p>\n<p>10\u201320</p>\n<p>mg/kg)</p>\n<p>C: Liver disease, known</p>\n<p>hypersensitivity I: Oral</p>\n<p>contraceptives, nevirap\u00ad</p>\n<p>ine, warfarin, phenytoin,</p>\n<p>glibenclamide</p>\n<p>Pyrazina- mide</p>\n<p>(Z) oral</p>\n<p>30-40</p>\n<p>mg/kg (max</p>\n<p>2500 mg)</p>\n<p>3 5  m g /</p>\n<p>kg (range</p>\n<p>30\u201340</p>\n<p>mg/kg)</p>\n<p>C: Liver disease, known</p>\n<p>Hypersensitivity</p>\n<p>Etham- butol</p>\n<p>(E) oral</p>\n<p>15 mg/kg</p>\n<p>2 0  m g /</p>\n<p>kg (range</p>\n<p>15\u201325</p>\n<p>mg/kg)</p>\n<p>C: Pre existing optic neu\u00ad</p>\n<p>ritis, established kidney</p>\n<p>failure</p>\n<p>Moxifloxacin</p>\n<p>(M) oral</p>\n<p>10-15mg /</p>\n<p>Kg</p>\n<p>Resistance to a fluoro\u00ad</p>\n<p>quinolone</p>\n<p>Note</p>\n<p>\u0083 Rifampicin interacts with oestrogen-containing contraceptives</p>\n<p>and reduces the protective efficacy of the contraceptives. Use</p>\n<p>high dose contraceptive or use an additional barrier method.</p>\n<p>First line anti-TB medication</p>\n<p>377</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 444,
        "content": "Important: The choice of regimen now depends on rifampicin \nsensitivity and not on the previous history of treatment:\n\t\n\u0089\nAll patients without rifampicin resistance (either new or re-treat\u00ad\nments) are treated with 1st line regimen.\n\t\n\u0089\nPatients with rifampicin resistance (either new or re- treatments) \nare treated with second line medication in a designated MDR-TB \ntreatment facility.\nSusceptible TB: 1st line treatment regimens\nFor patients without rifampicin resistance to  Gene Xpert MTB/Rif (both \nnew and re-treatment cases).\nNew cases not belonging to priority (risk) groups and in which diagnosis \nwas done by sputum examination will also be treated with this regimen.\nType Of TB Disease\nRegimen For \nSusceptible TB\nLOC\nIntensive \nPhase\nContinuation \nPhase\nAll forms of TB in adults \nand children of all ages but \nexcluding TB meningitis and \nBone TB)\n2RHZE\n4RH\nHC3\nTB meningitis Bone (Osteo\u00ad\narticular) TB\n2RHZE\n10RH\nH C 4 a n d \nabove\nAlternative 1st-line treat\u00ad\nment regimen\nAll forms of TB in children \n(2 months to 16 years) with \nnon-severe disease\n2 HRE(Z) \n2RH\nG e n e r a l \nHospital and \nabove\nAll forms of TB in adults \nabove 12 years, weight \n>40 Kgs, if HIV positive \nCD4>100 cells/L\n2 HPMZ\n2HPM\n378\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Important: The choice of regimen now depends on rifampicin</p>\n<p>sensitivity and not on the previous history of treatment:</p>\n<p>\u0089</p>\n<p>All patients without rifampicin resistance (either new or re-treat\u00ad</p>\n<p>ments) are treated with 1st line regimen.</p>\n<p>\u0089</p>\n<p>Patients with rifampicin resistance (either new or re- treatments)</p>\n<p>are treated with second line medication in a designated MDR-TB</p>\n<p>treatment facility.</p>\n<p>Susceptible TB: 1st line treatment regimens</p>\n<p>For patients without rifampicin resistance to  Gene Xpert MTB/Rif (both</p>\n<p>new and re-treatment cases).</p>\n<p>New cases not belonging to priority (risk) groups and in which diagnosis</p>\n<p>was done by sputum examination will also be treated with this regimen.</p>\n<p>Type Of TB Disease</p>\n<p>Regimen For</p>\n<p>Susceptible TB</p>\n<h3>LOC</h3>\n<p>Intensive</p>\n<p>Phase</p>\n<p>Continuation</p>\n<p>Phase</p>\n<p>All forms of TB in adults</p>\n<p>and children of all ages but</p>\n<p>excluding TB meningitis and</p>\n<p>Bone TB)</p>\n<h3>2RHZE</h3>\n<h3>4RH</h3>\n<h3>HC3</h3>\n<p>TB meningitis Bone (Osteo\u00ad</p>\n<p>articular) TB</p>\n<h3>2RHZE</h3>\n<h3>10RH</h3>\n<p>H C 4 a n d</p>\n<p>above</p>\n<p>Alternative 1st-line treat\u00ad</p>\n<p>ment regimen</p>\n<p>All forms of TB in children</p>\n<p>(2 months to 16 years) with</p>\n<p>non-severe disease</p>\n<h3>2 HRE(Z)</h3>\n<h3>2RH</h3>\n<p>G e n e r a l</p>\n<p>Hospital and</p>\n<p>above</p>\n<p>All forms of TB in adults</p>\n<p>above 12 years, weight</p>\n<p>>40 Kgs, if HIV positive</p>\n<p>CD4>100 cells/L</p>\n<h3>2 HPMZ</h3>\n<h3>2HPM</h3>\n<p>378</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 445,
        "content": "Drug -resistant TB\nPatients with drug-resistant TB should undergo culture and Drug Sen\u00ad\nsitivity testing, and be treated with second line regimens according to \nnational guidelines. \nNotify the relevant TB focal persons and organize referral to MDR-TB \ntreatment initiation center for appropriate management.\nType Of TB \nDisease\nRegimen For Drug \nResistant TB\nLOC\nINH mono-resist\u00ad\nance \n 6(H)REZ\u2013levoflox\u00ad\nacin)\nDTUS\nRR/MDR TB\nTreatment at des\u00ad\nignated MDR TB \ntreatment initiation \ncenters as per the \nnational guidelines\nHospital and above \nPre XDR, XDR\nTreatment at des\u00ad\nignated MDR TB \ntreatment initiation \ncenters as per the \nnational guidelines\nHospital and above in \nconsultation with national \npanel \nAdjunctive treatment\nTREATMENT\nLOC\n\t\n\u0089\nVitamin B6 (pyridoxine): 25 mg per day; given con\u00ad\ncomitantly with isoniazid for the duration of therapy, \nto prevent peripheral neuropathy\n\t\n\u0089\nPrednisolone in TB patients in whom complications of \nfibrosis are anticipated because of severe inflammation \nsuch as TB meningitis.\n \n- Prednisolone is given in a dose of 1-2 mg/kg \nbody weight (not more than 60 mg/day) as a \nsingle dose for 4 weeks, and then tapered off \nover 2 weeks\nHC3H\n379\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Drug -resistant TB</p>\n<p>Patients with drug-resistant TB should undergo culture and Drug Sen\u00ad</p>\n<p>sitivity testing, and be treated with second line regimens according to</p>\n<p>national guidelines.</p>\n<p>Notify the relevant TB focal persons and organize referral to MDR-TB</p>\n<p>treatment initiation center for appropriate management.</p>\n<p>Type Of TB</p>\n<p>Disease</p>\n<p>Regimen For Drug</p>\n<p>Resistant TB</p>\n<h3>LOC</h3>\n<p>INH mono-resist\u00ad</p>\n<p>ance</p>\n<p>6(H)REZ\u2013levoflox\u00ad</p>\n<p>acin)</p>\n<h3>DTUS</h3>\n<h3>RR/MDR TB</h3>\n<p>Treatment at des\u00ad</p>\n<p>ignated MDR TB</p>\n<p>treatment initiation</p>\n<p>centers as per the</p>\n<p>national guidelines</p>\n<p>Hospital and above</p>\n<p>Pre XDR, XDR</p>\n<p>Treatment at des\u00ad</p>\n<p>ignated MDR TB</p>\n<p>treatment initiation</p>\n<p>centers as per the</p>\n<p>national guidelines</p>\n<p>Hospital and above in</p>\n<p>consultation with national</p>\n<p>panel</p>\n<p>Adjunctive treatment</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Vitamin B6 (pyridoxine): 25 mg per day; given con\u00ad</p>\n<p>comitantly with isoniazid for the duration of therapy,</p>\n<p>to prevent peripheral neuropathy</p>\n<p>\u0089</p>\n<p>Prednisolone in TB patients in whom complications of</p>\n<p>fibrosis are anticipated because of severe inflammation</p>\n<p>such as TB meningitis.</p>\n<p>- Prednisolone is given in a dose of 1-2 mg/kg</p>\n<p>body weight (not more than 60 mg/day) as a</p>\n<p>single dose for 4 weeks, and then tapered off</p>\n<p>over 2 weeks</p>\n<h3>HC3H</h3>\n<p>379</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 446,
        "content": "Laboratory Monitoring (For Pulmonary Tb)\nAt the end of the initial 2 months:\n \n- Sputum smear-negative; start continuation phase\n \n- Sputum smear-positive; do GeneXpert to rule out rifampicin \nresistance, start continuation phase and Xpert MTB/XDR \nwhere accessible, to rule out resistance to other drugs\n \n- If Rifampicin-resistant, refer for MDR-TB treatment and\n \n- If Rifampicin-sensitive, continue with first-line\n \n- treatment, explore adherence issues but repeat smear at \nAt the beginning of 5 months:\n \n- Sputum smear-negative, continue with continuation \ntreatment\n \n- Sputum smear-positive, diagnose Treatment Failure\n \n- Take sputum for GeneXpert to rule out Rifampicin \nResistance and Xpert MTB/XDR where accessible, to rule \nout resistance to other drugs\n \n- If Rifampicin Resistant, refer for DR treatment\n \n- If INH resistant manage as INH mono-resistant TB as \nabove\n \n- If TB detected but not Rifampicin Resistant, restart first line \nregimen but explore adherence issues\nDuring the 6th month:\n \n- Sputum smear-negative, complete treatment and declare \ncured or treatment completed\n \n- Sputum smear-positive, diagnose treatment failure\n \n- Take sputum for GeneXpert to rule out rifampicin \nresistance and Xpert MTB/XDR where accessible, to rule \nout resistance to other drugs\n \n- If Rifampicin-resistant, refer for MDR-TB treatment\n \n- If Rifampicin-sensitive, restart first-line treatment, explore \nadherence issues\nMonitoring of susceptible TB\n380\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Laboratory Monitoring (For Pulmonary Tb)</p>\n<p>At the end of the initial 2 months:</p>\n<p>- Sputum smear-negative; start continuation phase</p>\n<p>- Sputum smear-positive; do GeneXpert to rule out rifampicin</p>\n<p>resistance, start continuation phase and Xpert MTB/XDR</p>\n<p>where accessible, to rule out resistance to other drugs</p>\n<p>- If Rifampicin-resistant, refer for MDR-TB treatment and</p>\n<p>- If Rifampicin-sensitive, continue with first-line</p>\n<p>- treatment, explore adherence issues but repeat smear at</p>\n<p>At the beginning of 5 months:</p>\n<p>- Sputum smear-negative, continue with continuation</p>\n<p>treatment</p>\n<p>- Sputum smear-positive, diagnose Treatment Failure</p>\n<p>- Take sputum for GeneXpert to rule out Rifampicin</p>\n<p>Resistance and Xpert MTB/XDR where accessible, to rule</p>\n<p>out resistance to other drugs</p>\n<p>- If Rifampicin Resistant, refer for DR treatment</p>\n<p>- If INH resistant manage as INH mono-resistant TB as</p>\n<p>above</p>\n<p>- If TB detected but not Rifampicin Resistant, restart first line</p>\n<p>regimen but explore adherence issues</p>\n<p>During the 6th month:</p>\n<p>- Sputum smear-negative, complete treatment and declare</p>\n<p>cured or treatment completed</p>\n<p>- Sputum smear-positive, diagnose treatment failure</p>\n<p>- Take sputum for GeneXpert to rule out rifampicin</p>\n<p>resistance and Xpert MTB/XDR where accessible, to rule</p>\n<p>out resistance to other drugs</p>\n<p>- If Rifampicin-resistant, refer for MDR-TB treatment</p>\n<p>- If Rifampicin-sensitive, restart first-line treatment, explore</p>\n<p>adherence issues</p>\n<p>Monitoring of susceptible TB</p>\n<p>380</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 447,
        "content": "Clinical Monitoring (For All Tb Cases)\n \n- Monitor wellbeing and weight gain\n \n- Assess and reinforce treatment adherence\n \n- Assess and manage side effects\nNote\n \n\u0083 Radiological monitoring\u2013 this method should not be used as \nthe sole monitoring tool.\nManagement of treatment interruptions\nRefer to NTLP  manual\nTreatment outcomes\nA conclusion should be made regarding treatment outcome of EVERY \nTB patient who has been started on anti-TB treatment.\nOUTCOME\nDESCRIPTION\nCure\nA pulmonary TB patient with bacteri\u00ad\nologically confirmed TB at the begin\u00ad\nning of treatment who was smear- or \nculture-negative in the last month of \ntreatment and on at least one previous \noccasion\nTreatment \ncompleted\nA TB patient who completed treatment \nwithout evidence of failure BUT with \nno record to show that sputum smear \nor culture results in the last month of \ntreatment and on at least one previous \noccasion were negative, either because \ntests were not done or because results \nare unavailable\nLost to fol\u00ad\nlow-up\nA TB patient who did not start treat\u00ad\nment, or completed more than one \nmonth of treatment and whose\ntreatment was interrupted for two or \nmore consecutive months\n381\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Clinical Monitoring (For All Tb Cases)</p>\n<p>- Monitor wellbeing and weight gain</p>\n<p>- Assess and reinforce treatment adherence</p>\n<p>- Assess and manage side effects</p>\n<p>Note</p>\n<p>\u0083 Radiological monitoring\u2013 this method should not be used as</p>\n<p>the sole monitoring tool.</p>\n<p>Management of treatment interruptions</p>\n<p>Refer to NTLP  manual</p>\n<p>Treatment outcomes</p>\n<p>A conclusion should be made regarding treatment outcome of EVERY</p>\n<p>TB patient who has been started on anti-TB treatment.</p>\n<h3>OUTCOME</h3>\n<h3>DESCRIPTION</h3>\n<p>Cure</p>\n<p>A pulmonary TB patient with bacteri\u00ad</p>\n<p>ologically confirmed TB at the begin\u00ad</p>\n<p>ning of treatment who was smear- or</p>\n<p>culture-negative in the last month of</p>\n<p>treatment and on at least one previous</p>\n<p>occasion</p>\n<p>Treatment</p>\n<p>completed</p>\n<p>A TB patient who completed treatment</p>\n<p>without evidence of failure BUT with</p>\n<p>no record to show that sputum smear</p>\n<p>or culture results in the last month of</p>\n<p>treatment and on at least one previous</p>\n<p>occasion were negative, either because</p>\n<p>tests were not done or because results</p>\n<p>are unavailable</p>\n<p>Lost to fol\u00ad</p>\n<p>low-up</p>\n<p>A TB patient who did not start treat\u00ad</p>\n<p>ment, or completed more than one</p>\n<p>month of treatment and whose</p>\n<p>treatment was interrupted for two or</p>\n<p>more consecutive months</p>\n<p>381</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 448,
        "content": "Common side effects\nDrug\nSide-Effects\nIsoniazid\nHepatitis, peripheral neuropathy\nRifampicin\nFlu-like syndrome, dermatitis, hepatitis, \nreddish-brown colouration of urine\nPyrazin\u00ad\namide\nJoint pains, hepatitis\nEthambutol\nImpaired visual acuity and colour vision\nMoxifloxacin\nTendonitis, arthralgia, GI disturbance, \nheamaturia \nTreatment \ncompleted\nA TB patient who completed treatment \nwithout evidence of failure BUT with \nno record to show that sputum smear \nor culture results in the last month of \ntreatment and on at least one previous \noccasion were negative, either because \ntests were not done or because results are \nunavailable\nOUTCOME\nDESCRIPTION\nDied\nA TB patient who dies for any reason \nbefore starting or during the course of \ntreatment\nTreatment \nfailure\nA TB patient whose sputum smear or \nculture is positive at month five or later \nduring treatment\nNot evaluated\nA patient for whom no treatment out\u00ad\ncome is assigned. This includes cases \n\u201ctransferred out\u201d to another treatment \nunit as well as cases for whom the \ntreatment outcome is unknown to the \nreporting unit\nTreatment \nsuccess\nThe sum of cured and treatment \ncompleted\n5.3.2.1\t Anti-TB Drugs Side Effects\n382\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Common side effects</p>\n<p>Drug</p>\n<p>Side-Effects</p>\n<p>Isoniazid</p>\n<p>Hepatitis, peripheral neuropathy</p>\n<p>Rifampicin</p>\n<p>Flu-like syndrome, dermatitis, hepatitis,</p>\n<p>reddish-brown colouration of urine</p>\n<p>Pyrazin\u00ad</p>\n<p>amide</p>\n<p>Joint pains, hepatitis</p>\n<p>Ethambutol</p>\n<p>Impaired visual acuity and colour vision</p>\n<p>Moxifloxacin</p>\n<p>Tendonitis, arthralgia, GI disturbance,</p>\n<p>heamaturia</p>\n<p>Treatment</p>\n<p>completed</p>\n<p>A TB patient who completed treatment</p>\n<p>without evidence of failure BUT with</p>\n<p>no record to show that sputum smear</p>\n<p>or culture results in the last month of</p>\n<p>treatment and on at least one previous</p>\n<p>occasion were negative, either because</p>\n<p>tests were not done or because results are</p>\n<p>unavailable</p>\n<h3>OUTCOME</h3>\n<h3>DESCRIPTION</h3>\n<p>Died</p>\n<p>A TB patient who dies for any reason</p>\n<p>before starting or during the course of</p>\n<p>treatment</p>\n<p>Treatment</p>\n<p>failure</p>\n<p>A TB patient whose sputum smear or</p>\n<p>culture is positive at month five or later</p>\n<p>during treatment</p>\n<p>Not evaluated</p>\n<p>A patient for whom no treatment out\u00ad</p>\n<p>come is assigned. This includes cases</p>\n<p>\u201ctransferred out\u201d to another treatment</p>\n<p>unit as well as cases for whom the</p>\n<p>treatment outcome is unknown to the</p>\n<p>reporting unit</p>\n<p>Treatment</p>\n<p>success</p>\n<p>The sum of cured and treatment</p>\n<p>completed</p>\n<p>5.3.2.1\t Anti-TB Drugs Side Effects</p>\n<p>382</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 449,
        "content": "Side-Effects\nDrug(S) Likely \nTo Cause\nManagement\nLow appe\u00ad\ntite, nausea, \nabdominal \npain\nPyrazinamide, Ri\u00ad\nfampicin\nGive drugs with small meal or \njust before going to bed\nJoint pains\nPyrazinamide\nGive an analgesic\ne.g. ibuprofen or Paracetamol\nBurning \nsensation in \nthe feet\nIsoniazid\nPyridoxine 25-100 mg daily\nOrange/red \nurine\nRifampicin\nReassure the patient that it \nis not harmful\nSkin rash \n(hyper\u00ad\nsensitivity \nreaction)\nAny anti-TB drug\nDepending on degree, see\nguidelines below\nDeafness \n(no wax on \nauroscopy) \nDizziness, \nvertigo, and \nnystagmus\nStreptomycin\nStop streptomycin. Use Eth\u00ad\nambutol\nJaundice \n(other caus\u00ad\nes excluded)\nPyrazinamide, Ri\u00ad\nfampicin and Iso\u00ad\nniazid\nStop anti-TB drugs see guide\u00ad\nlines below\nMental con\u00ad\nfusion\nIsoniazid, \nRifampicin and \nPyrazinamide\n1. If jaundiced, suspect \nliver failure, stop drugs (see \nbelow)\n2. If no jaundice, suspect \nIsoniazid, increase dose of \npyridoxine\nManagement of side effects\n383\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Side-Effects</p>\n<p>Drug(S) Likely</p>\n<p>To Cause</p>\n<p>Management</p>\n<p>Low appe\u00ad</p>\n<p>tite, nausea,</p>\n<p>abdominal</p>\n<p>pain</p>\n<p>Pyrazinamide, Ri\u00ad</p>\n<p>fampicin</p>\n<p>Give drugs with small meal or</p>\n<p>just before going to bed</p>\n<p>Joint pains</p>\n<p>Pyrazinamide</p>\n<p>Give an analgesic</p>\n<p>e.g. ibuprofen or Paracetamol</p>\n<p>Burning</p>\n<p>sensation in</p>\n<p>the feet</p>\n<p>Isoniazid</p>\n<p>Pyridoxine 25-100 mg daily</p>\n<p>Orange/red</p>\n<p>urine</p>\n<p>Rifampicin</p>\n<p>Reassure the patient that it</p>\n<p>is not harmful</p>\n<p>Skin rash</p>\n<p>(hyper\u00ad</p>\n<p>sensitivity</p>\n<p>reaction)</p>\n<p>Any anti-TB drug</p>\n<p>Depending on degree, see</p>\n<p>guidelines below</p>\n<p>Deafness</p>\n<p>(no wax on</p>\n<p>auroscopy)</p>\n<p>Dizziness,</p>\n<p>vertigo, and</p>\n<p>nystagmus</p>\n<p>Streptomycin</p>\n<p>Stop streptomycin. Use Eth\u00ad</p>\n<p>ambutol</p>\n<p>Jaundice</p>\n<p>(other caus\u00ad</p>\n<p>es excluded)</p>\n<p>Pyrazinamide, Ri\u00ad</p>\n<p>fampicin and Iso\u00ad</p>\n<p>niazid</p>\n<p>Stop anti-TB drugs see guide\u00ad</p>\n<p>lines below</p>\n<p>Mental con\u00ad</p>\n<p>fusion</p>\n<p>Isoniazid,</p>\n<p>Rifampicin and</p>\n<p>Pyrazinamide</p>\n<li>. If jaundiced, suspect</li>\n<p>liver failure, stop drugs (see</p>\n<p>below)</p>\n<p>2. If no jaundice, suspect</p>\n<p>Isoniazid, increase dose of</p>\n<p>pyridoxine</p>\n<p>Management of side effects</p>\n<p>383</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 450,
        "content": "Side-Effects\nDrug(S) Likely \nTo Cause\nManagement\nVisual              \nimpairment \n(other causes\nexcluded)\nEthambutol\nStop Ethambutol. Use \nstreptomycin\nHypersensitivity reaction\nMost anti-TB drugs can cause hypersensitisation between week 3 and \nweek 8 of treatment in order of frequency: ethambutol, pyrazinamide, \nrifampicin and isoniazid.\nIf mild (simple itchy rash), give antihistamine (e.g. chlorpheniramine) and \nmoisturizer and continue treatment.\nSevere reactions are characterised by\n \n- Fever, headache, vomiting\n \n- Macular dark erythematous rash which can progress to a \nSteven Johnson-Toxic Epidermal Necrolysis syndrome\nAdjunctive treatment\nTREATMENT\nLOC\n\t\n\u0089\nStop all drugs immediately\n\t\n\u0089\nManage supportively\n\t\n\u0089\nRefer for specialised management\nH\nRR\nDrug-induced hepatitis\nSevere hepatic damage, presenting with jaundice, vomiting, severe malaise. \nIn order of frequency, the implicated drugs are Isoniazid, Pyrazinamide, \nRifampicin and Ethambutol.\nAdjunctive treatment\nTREATMENT\nLOC\n\t\n\u0089\nStop all drugs immediately\n\t\n\u0089\nManage supportively\n\t\n\u0089\nWhen jaundice has resolved, re-introduce single drugs at \n3-7 days interval, starting from the least likely involved\nH\nRR\n384\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Side-Effects</p>\n<p>Drug(S) Likely</p>\n<p>To Cause</p>\n<p>Management</p>\n<p>Visual</p>\n<p>impairment</p>\n<p>(other causes</p>\n<p>excluded)</p>\n<p>Ethambutol</p>\n<p>Stop Ethambutol. Use</p>\n<p>streptomycin</p>\n<p>Hypersensitivity reaction</p>\n<p>Most anti-TB drugs can cause hypersensitisation between week 3 and</p>\n<p>week 8 of treatment in order of frequency: ethambutol, pyrazinamide,</p>\n<p>rifampicin and isoniazid.</p>\n<p>If mild (simple itchy rash), give antihistamine (e.g. chlorpheniramine) and</p>\n<p>moisturizer and continue treatment.</p>\n<p>Severe reactions are characterised by</p>\n<p>- Fever, headache, vomiting</p>\n<p>- Macular dark erythematous rash which can progress to a</p>\n<p>Steven Johnson-Toxic Epidermal Necrolysis syndrome</p>\n<p>Adjunctive treatment</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stop all drugs immediately</p>\n<p>\u0089</p>\n<p>Manage supportively</p>\n<p>\u0089</p>\n<p>Refer for specialised management</p>\n<p>H</p>\n<p>RR</p>\n<p>Drug-induced hepatitis</p>\n<p>Severe hepatic damage, presenting with jaundice, vomiting, severe malaise.</p>\n<p>In order of frequency, the implicated drugs are Isoniazid, Pyrazinamide,</p>\n<p>Rifampicin and Ethambutol.</p>\n<p>Adjunctive treatment</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stop all drugs immediately</p>\n<p>\u0089</p>\n<p>Manage supportively</p>\n<p>\u0089</p>\n<p>When jaundice has resolved, re-introduce single drugs at</p>\n<p>3-7 days interval, starting from the least likely involved</p>\n<p>H</p>\n<p>RR</p>\n<p>384</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 451,
        "content": "Adjunctive treatment\nTREATMENT\nLOC\n\t\n\u0089\nIf reaction very severe, do not try to restart pyrazina\u00ad\nmide. If RH tolerated, do not try pyrazinamide\n\t\n\u0089\nUse alternative regimen avoiding the causative drug\nH\nRR\n5.3.2.2\t Prevention and Infection Control of TB\nCase diagnosis and management\nA TB patient is more infectious before they start TB treatment. \n \n~\nProvide PPE to sputum-positive patients\n \n~\nEarly detection of cases and initiation of appropriate TB \ntreatment\n \n~\nTreatment under directly observed treatment (DOT) and fol\u00ad\nlow up to ensure adherence and cure \nContact tracing\n \n~\nTracing of contacts of TB patients\n \n~\nRoutine screening of health workers for latent & active TB\nHigh Priority Patients For Contact Tracing\n \n~\nBacteriologically confirmed PTB (Smear positive or Xpert \npositive or Culture positive) \n \n~\nCavitation of chest x-ray \n \n~\nAge < 5 years \n \n~\nMDR TB \u2022 PLHIV\nOther preventive measures\n \n~\nBCG vaccination at birth to prevent severe forms of TB\n \n~\nTB Preventive Treatment for categories at risk\nGeneral hygiene\n \n~\nAvoidance of overcrowding\n \n~\nAvoid drinking unboiled milk\n385\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Adjunctive treatment</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If reaction very severe, do not try to restart pyrazina\u00ad</p>\n<p>mide. If RH tolerated, do not try pyrazinamide</p>\n<p>\u0089</p>\n<p>Use alternative regimen avoiding the causative drug</p>\n<p>H</p>\n<p>RR</p>\n<p>5.3.2.2\t Prevention and Infection Control of TB</p>\n<p>Case diagnosis and management</p>\n<p>A TB patient is more infectious before they start TB treatment.</p>\n<p>~</p>\n<p>Provide PPE to sputum-positive patients</p>\n<p>~</p>\n<p>Early detection of cases and initiation of appropriate TB</p>\n<p>treatment</p>\n<p>~</p>\n<p>Treatment under directly observed treatment (DOT) and fol\u00ad</p>\n<p>low up to ensure adherence and cure</p>\n<p>Contact tracing</p>\n<p>~</p>\n<p>Tracing of contacts of TB patients</p>\n<p>~</p>\n<p>Routine screening of health workers for latent & active TB</p>\n<p>High Priority Patients For Contact Tracing</p>\n<p>~</p>\n<p>Bacteriologically confirmed PTB (Smear positive or Xpert</p>\n<p>positive or Culture positive)</p>\n<p>~</p>\n<p>Cavitation of chest x-ray</p>\n<p>~</p>\n<p>Age < 5 years</p>\n<p>~</p>\n<h3>MDR TB \u2022 PLHIV</h3>\n<p>Other preventive measures</p>\n<p>~</p>\n<p>BCG vaccination at birth to prevent severe forms of TB</p>\n<p>~</p>\n<p>TB Preventive Treatment for categories at risk</p>\n<p>General hygiene</p>\n<p>~</p>\n<p>Avoidance of overcrowding</p>\n<p>~</p>\n<p>Avoid drinking unboiled milk</p>\n<p>385</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 452,
        "content": "~\nCough hygiene (cover cough with pieces of cloth, washing \nhands with soap, proper disposal of sputum)\n \n~\nGood nutrition\n \n~\nPromote good ventilation in housing & transport \n\u2022\t\nOpen ventilators, windows & doors that allow air exchange \n5.3.2.3\t Tuberculosis Preventive Treatment\nTuberculosis preventive treatment is recommended to prevent the \ndevelopment of active TB disease in an individual who has latent TB \ninfection (LTBI).\nUganda  guidelines for programmatic management of Latent TB infection \nrecommend TB preventive treatment (TPT ) in the following categories \nof people: \n \n- Persons living with HIV\n \n- Child & adult contacts of pulmonary TB patients\nDo not use TPT in cases of active TB \nDo not use TPT in contacts of MDR-TB\nTREATMENT\nLOC\n\t\n\u0089\nExclude active TB\n \n- Assess for cough, fever, weight loss and nights \nsweats (Children: cough, fever, poor weight \ngain)\n \n- If any of the TB symptoms are present, do \nclinical\n \n- evaluation for TB\n \n- If none is present, TB is unlikely, then rule out \ncontra-indications for TPT medicines. If none, \nthen give\n\t\n\u0089\nGive TPT as per dosing chart below.\nHc3\nNote\n \n\u0083 HIV-positive children < 1 year should receive TPT only if they \nhave history of contact with TB case and active TB has been \nexcluded\n386\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>~</p>\n<p>Cough hygiene (cover cough with pieces of cloth, washing</p>\n<p>hands with soap, proper disposal of sputum)</p>\n<p>~</p>\n<p>Good nutrition</p>\n<p>~</p>\n<p>Promote good ventilation in housing & transport</p>\n<li></li>\n<p>Open ventilators, windows & doors that allow air exchange</p>\n<p>5.3.2.3\t Tuberculosis Preventive Treatment</p>\n<p>Tuberculosis preventive treatment is recommended to prevent the</p>\n<p>development of active TB disease in an individual who has latent TB</p>\n<p>infection (LTBI).</p>\n<p>Uganda  guidelines for programmatic management of Latent TB infection</p>\n<p>recommend TB preventive treatment (TPT ) in the following categories</p>\n<p>of people:</p>\n<p>- Persons living with HIV</p>\n<p>- Child & adult contacts of pulmonary TB patients</p>\n<p>Do not use TPT in cases of active TB</p>\n<p>Do not use TPT in contacts of MDR-TB</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Exclude active TB</p>\n<p>- Assess for cough, fever, weight loss and nights</p>\n<p>sweats (Children: cough, fever, poor weight</p>\n<p>gain)</p>\n<p>- If any of the TB symptoms are present, do</p>\n<p>clinical</p>\n<p>- evaluation for TB</p>\n<p>- If none is present, TB is unlikely, then rule out</p>\n<p>contra-indications for TPT medicines. If none,</p>\n<p>then give</p>\n<p>\u0089</p>\n<p>Give TPT as per dosing chart below.</p>\n<p>Hc3</p>\n<p>Note</p>\n<p>\u0083 HIV-positive children < 1 year should receive TPT only if they</p>\n<p>have history of contact with TB case and active TB has been</p>\n<p>excluded</p>\n<p>386</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 453,
        "content": "This is a blank page\n387\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>This is a blank page</p>\n<p>387</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 454,
        "content": "Medicine frequency \n& duration \nFormulation\nDose of TPT \nmedicine \n(mgs)\nDose/ \nweight\nRecom\n3HP (once weekly \nrifapentine plus isoni\u00ad\nazid for 3 months)\nFixed Doze \nCombination \n(FDC) Tablet\nRifapentine \n300mg/ Iso\u00ad\nniazid 300mg \n3\u20135.9\nSingle medicine \ntablet\nPyridoxine \n25mg/day\n6H (daily isoniazid \nfor 6 months)\nSingle medicine \ntablet\n3\u20135.9\nkgs\nIsoniazid 100 \nmg\n<10 years\n10mg/kg\n0.5\n> 10 years\n5mg/kg\nIsoniazid 300 \nmg\n> 10 years\n5mg/kg\nSingle medicine \ntablet\nPyridoxine 25 \nmg\n0.5\n3RH (daily Rifampic\u00ad\nin Isoniazid for 3 \nmonths)\nFixed Doze \nCombination \n(FDC) Tablet\n< 4kgs\n5.3.2.5\t TB Preventive Treatment Dosing Chart\n388\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Medicine frequency</p>\n<p>& duration</p>\n<p>Formulation</p>\n<p>Dose of TPT</p>\n<p>medicine</p>\n<p>(mgs)</p>\n<p>Dose/</p>\n<p>weight</p>\n<p>Recom</p>\n<p>3HP (once weekly</p>\n<p>rifapentine plus isoni\u00ad</p>\n<p>azid for 3 months)</p>\n<p>Fixed Doze</p>\n<p>Combination</p>\n<p>(FDC) Tablet</p>\n<p>Rifapentine</p>\n<p>300mg/ Iso\u00ad</p>\n<p>niazid 300mg</p>\n<p>3\u20135.9</p>\n<p>Single medicine</p>\n<p>tablet</p>\n<p>Pyridoxine</p>\n<p>25mg/day</p>\n<p>6H (daily isoniazid</p>\n<p>for 6 months)</p>\n<p>Single medicine</p>\n<p>tablet</p>\n<p>3\u20135.9</p>\n<p>kgs</p>\n<p>Isoniazid 100</p>\n<p>mg</p>\n<p><10 years</p>\n<p>10mg/kg</p>\n<p>0.5</p>\n<p>> 10 years</p>\n<p>5mg/kg</p>\n<p>Isoniazid 300</p>\n<p>mg</p>\n<p>> 10 years</p>\n<p>5mg/kg</p>\n<p>Single medicine</p>\n<p>tablet</p>\n<p>Pyridoxine 25</p>\n<p>mg</p>\n<p>0.5</p>\n<p>3RH (daily Rifampic\u00ad</p>\n<p>in Isoniazid for 3</p>\n<p>months)</p>\n<p>Fixed Doze</p>\n<p>Combination</p>\n<p>(FDC) Tablet</p>\n<p>< 4kgs</p>\n<p>5.3.2.5\t TB Preventive Treatment Dosing Chart</p>\n<p>388</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 455,
        "content": "mmended number of tablets per body weight in kilograms\n9kgs\n6\u20139.9Kgs\n10\u2013\n15kgs\n16\u2013\n23kgs\n24\u2013\n30kgs\n31-\n34kgs\n35-\n45kgs\n>45kgs\n1\n1.5\n2\n2.5\n3\n3\n1\n1\n1\n1\n1\n1\n6\u20139.9 \nKgs\n1 0 \u2013\n1 3 . 9 \nkgs\n1 4 \u2013\n19.9\nkgs\n2 0 \u2013\n24.9\nkgs\n2 5 -\n3 4 . 5 \nkgs\n3 5 -\n44.5\nkgs\n4 5 -\n49.9\nkgs\n>50 kgs\n1\n1.5\n2\n2.5\n1.5\n2\n2.5\n1\n0.5\n1\n1\n1\n1\n1\n1\n1\ns\n4-7 kgs\n8-11\n kgs\n12-15\nkgs\n16\u201324\nkgs\n25-\n32 \nkgs\n33-\n39\nkgs\n40-54\nkgs\n389\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>mmended number of tablets per body weight in kilograms</p>\n<p>9kgs</p>\n<p>6\u20139.9Kgs</p>\n<p>10\u2013</p>\n<p>15kgs</p>\n<p>16\u2013</p>\n<p>23kgs</p>\n<p>24\u2013</p>\n<p>30kgs</p>\n<p>31-</p>\n<p>34kgs</p>\n<p>35-</p>\n<p>45kgs</p>\n<p>>45kgs</p>\n<p>1</p>\n<li>.5</li>\n<p>2</p>\n<p>2.5</p>\n<p>3</p>\n<p>3</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>6\u20139.9</p>\n<p>Kgs</p>\n<p>1 0 \u2013</p>\n<p>1 3 . 9</p>\n<p>kgs</p>\n<p>1 4 \u2013</p>\n<p>19.9</p>\n<p>kgs</p>\n<p>2 0 \u2013</p>\n<p>24.9</p>\n<p>kgs</p>\n<p>2 5 -</p>\n<p>3 4 . 5</p>\n<p>kgs</p>\n<p>3 5 -</p>\n<p>44.5</p>\n<p>kgs</p>\n<p>4 5 -</p>\n<p>49.9</p>\n<p>kgs</p>\n<p>>50 kgs</p>\n<p>1</p>\n<li>.5</li>\n<p>2</p>\n<p>2.5</p>\n<li>.5</li>\n<p>2</p>\n<p>2.5</p>\n<p>1</p>\n<p>0.5</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>s</p>\n<p>4-7 kgs</p>\n<p>8-11</p>\n<p>kgs</p>\n<p>12-15</p>\n<p>kgs</p>\n<p>16\u201324</p>\n<p>kgs</p>\n<p>25-</p>\n<p>32</p>\n<p>kgs</p>\n<p>33-</p>\n<p>39</p>\n<p>kgs</p>\n<p>40-54</p>\n<p>kgs</p>\n<p>389</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 456,
        "content": "Single medicine \ntablet\nRH \n75mg/50mg\n< 10 years \nR-15mg/kg\nH-10mg/kg\n0.5\nRH \n150mg/75mg\n>10 years\nR-10mg/kg\nH-5 mg/kg\nSingle medicine \ntablet\nPyridoxine \n25mg/day\n0.5\n Medicine frequency \n& duration \nFormulation\nDose of TPT \nmedicine \n(mgs)\nDose/ \nweight\nRecom\n1HP (once daily \nrifapentine plus isoni\u00ad\nazid for 1 month - 28 \ndays) for adolescents \n>13 years & adults\nRegardless \nof weight \nband\n3\u20135.9\nSingle medicine \ntablets \nne Isoniazid \n(H) 300mg \ntablet\n4 Rifapentine \n(P) 150mg \ntablets / day\nPyridoxine \n25mg/day\n390\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Single medicine</p>\n<p>tablet</p>\n<p>RH</p>\n<p>75mg/50mg</p>\n<p>< 10 years</p>\n<p>R-15mg/kg</p>\n<p>H-10mg/kg</p>\n<p>0.5</p>\n<p>RH</p>\n<p>150mg/75mg</p>\n<p>>10 years</p>\n<p>R-10mg/kg</p>\n<p>H-5 mg/kg</p>\n<p>Single medicine</p>\n<p>tablet</p>\n<p>Pyridoxine</p>\n<p>25mg/day</p>\n<p>0.5</p>\n<p>Medicine frequency</p>\n<p>& duration</p>\n<p>Formulation</p>\n<p>Dose of TPT</p>\n<p>medicine</p>\n<p>(mgs)</p>\n<p>Dose/</p>\n<p>weight</p>\n<p>Recom</p>\n<p>1HP (once daily</p>\n<p>rifapentine plus isoni\u00ad</p>\n<p>azid for 1 month - 28</p>\n<p>days) for adolescents</p>\n<p>>13 years & adults</p>\n<p>Regardless</p>\n<p>of weight</p>\n<p>band</p>\n<p>3\u20135.9</p>\n<p>Single medicine</p>\n<p>tablets</p>\n<p>ne Isoniazid</p>\n<p>(H) 300mg</p>\n<p>tablet</p>\n<p>4 Rifapentine</p>\n<p>(P) 150mg</p>\n<p>tablets / day</p>\n<p>Pyridoxine</p>\n<p>25mg/day</p>\n<p>390</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 457,
        "content": "1\n2\n3\n4\n4\n2\n3\n1\n1\n1\n1\n1\n1\n1\nmmended number of tablets per body weight in kilograms\n9kgs\n6\u20139.9Kgs\n10\u2013\n15kgs\n16\u2013\n23kgs\n24\u2013\n30kgs\n31-\n34kgs\n35-\n45kgs\n>45kgs\n1\n1.5\n2\n2.5\n1\n1\n1\n1\n1\n1\n4\n4\n1\n1\n1\n1\n1\n1\n391\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>1</p>\n<p>2</p>\n<p>3</p>\n<p>4</p>\n<p>4</p>\n<p>2</p>\n<p>3</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>mmended number of tablets per body weight in kilograms</p>\n<p>9kgs</p>\n<p>6\u20139.9Kgs</p>\n<p>10\u2013</p>\n<p>15kgs</p>\n<p>16\u2013</p>\n<p>23kgs</p>\n<p>24\u2013</p>\n<p>30kgs</p>\n<p>31-</p>\n<p>34kgs</p>\n<p>35-</p>\n<p>45kgs</p>\n<p>>45kgs</p>\n<p>1</p>\n<li>.5</li>\n<p>2</p>\n<p>2.5</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>4</p>\n<p>4</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>1</p>\n<p>391</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 458,
        "content": "Preferred options for T\nTPT medicine option\nTarg\nIsoniazid monotherapy\nConta\nPLHIV\n3. Pre\na. hist\nb. CD\nc. WH\nIsoniazid/co-trimoxazole/pyridoxine (Q-TIB)\nPLHIV\nnew (<\nCD4 \nWHO\n3 months of Rifapentine/Isoniazid \nPLHIV\nConta\n1 month of Rifapentine/Isoniazid \nPrison\nHealth\n392\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>Preferred options for T</p>\n<p>TPT medicine option</p>\n<p>Targ</p>\n<p>Isoniazid monotherapy</p>\n<p>Conta</p>\n<h3>PLHIV</h3>\n<p>3. Pre</p>\n<p>a. hist</p>\n<p>b. CD</p>\n<p>c. WH</p>\n<p>Isoniazid/co-trimoxazole/pyridoxine (Q-TIB)</p>\n<h3>PLHIV</h3>\n<p>new (<</p>\n<h3>CD4</h3>\n<h3>WHO</h3>\n<p>3 months of Rifapentine/Isoniazid</p>\n<h3>PLHIV</h3>\n<p>Conta</p>\n<p>1 month of Rifapentine/Isoniazid</p>\n<p>Prison</p>\n<p>Health</p>\n<p>392</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 459,
        "content": "TB Preventive Treatment\net population (active TB ruled out)\nacts of PBC TB patients < 2 years of age\nV on protease inhibitors \negnant women living with HIV with;\ntory of contact with a TB patient \nD4 < 200 cells/ml\nHO stage 3 or 4\nV;\n<12 months) in care \n< 200 cells/ml\nO stage 3 or 4\nV > 2 years of age (not on protease inhibitors (PI)\nacts of PBC TB patients > 2 years\nners\nh workers\n393\nUganda Clinical Guidelines 2023\nCHAPTER 5: Respiratory Diseases",
        "formatted_content": "<p>TB Preventive Treatment</p>\n<p>et population (active TB ruled out)</p>\n<p>acts of PBC TB patients < 2 years of age</p>\n<p>V on protease inhibitors</p>\n<p>egnant women living with HIV with;</p>\n<p>tory of contact with a TB patient</p>\n<p>D4 < 200 cells/ml</p>\n<p>HO stage 3 or 4</p>\n<p>V;</p>\n<p><12 months) in care</p>\n<p>< 200 cells/ml</p>\n<p>O stage 3 or 4</p>\n<p>V > 2 years of age (not on protease inhibitors (PI)</p>\n<p>acts of PBC TB patients > 2 years</p>\n<p>ners</p>\n<p>h workers</p>\n<p>393</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 5: Respiratory Diseases</p>"
    },
    {
        "page_number": 460,
        "content": "6.1 GASTROINTESTINAL EMERGENCIES\n6.1.1 Appendicitis (Acute)\t\nICD10 CODE: K35-K37\nInflammation of the appendix.\nCauses\n \n~\nBlockage of the appendix duct with stool or particles, fol\u00ad\nlowed by infection by intestinal bacteria\nClinical features\n \n~\nConstipation (common)\n \n~\nPain situated around the umbilicus\n \n- Crampy, keeps on increasing in severity\n \n~\nAfter some hours, the pain is localised in the right iliac \nfossa and becomes continuous\n \n~\nThere may be nausea and vomiting\n \n~\nFever (low grade in initial stages)\n \n~\nTenderness and rigidity (guarding) in right iliac fossa\n \n~\nGeneralized abdominal pain and signs of peritonitis follows \nrupture when the contents are poured into the abdominal \ncavity\nDifferential diagnosis\n \n~\nSalpingitis (in females), ovarian cyst\n \n~\nEctopic pregnancy\nGastrointestinal and \nHepatic Diseases\n6\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n394\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>6.1 GASTROINTESTINAL EMERGENCIES</h3>\n<p>6.1.1 Appendicitis (Acute)</p>\n<h3>ICD10 CODE: K35-K37</h3>\n<p>Inflammation of the appendix.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Blockage of the appendix duct with stool or particles, fol\u00ad</p>\n<p>lowed by infection by intestinal bacteria</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Constipation (common)</p>\n<p>~</p>\n<p>Pain situated around the umbilicus</p>\n<p>- Crampy, keeps on increasing in severity</p>\n<p>~</p>\n<p>After some hours, the pain is localised in the right iliac</p>\n<p>fossa and becomes continuous</p>\n<p>~</p>\n<p>There may be nausea and vomiting</p>\n<p>~</p>\n<p>Fever (low grade in initial stages)</p>\n<p>~</p>\n<p>Tenderness and rigidity (guarding) in right iliac fossa</p>\n<p>~</p>\n<p>Generalized abdominal pain and signs of peritonitis follows</p>\n<p>rupture when the contents are poured into the abdominal</p>\n<p>cavity</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Salpingitis (in females), ovarian cyst</p>\n<p>~</p>\n<p>Ectopic pregnancy</p>\n<p>Gastrointestinal and</p>\n<p>Hepatic Diseases</p>\n<p>6</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>394</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 461,
        "content": "~\nPyelonephritis, ureteritis (inflammation of the ureter)\n \n~\nIntestinal obstruction\nInvestigations\n \n\u0081\nNo special investigations - good history and physical examination \nare essential for diagnosis\n \n\u0081\nComplete blood count: look for leucocytosis\n \n\u0081\nTransabdominal ultrasound\n \n\u0081\nAbdominal X ray (to assess for perforation and intestinal occlusion)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nEmergency surgery\n\t\n\u0089\nIf surgery is delayed, start antibiotic treatment while \nreferring\n \n- ceftriaxone 2 g IV once daily\n \n- Child: 80 mg/kg IV once daily\n \n- plus metronidazole 500 mg IV every 8 hours \nchild 10 mg/kg IV every 8 hours\n\t\n\u0089\nStart antibiotic prophylaxis before the surgery and \ncontinue for a duration depending on the findings (< \n24 hours for unperforated appendix, at least 5 days \nfor perforated appendix)\nH\n6.1.2  Acute Pancreatitis\t                        ICD10 CODE: K85\nAcute inflammation of the pancreas.\nCause\n \n~\nExcessive alcohol intake\n \n~\nGall stones, biliary tract disease (obstructive cancer or ana\u00ad\ntomical abnormalities)\n \n~\nInfections, e.g. mumps, HIV, hepatitis A, ascaris\n \n~\nDrugs, e.g. sulphonamides, furosemide, lamivudine, anal\u00ad\ngesics, organosphosphate poisoning\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n395\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Pyelonephritis, ureteritis (inflammation of the ureter)</p>\n<p>~</p>\n<p>Intestinal obstruction</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>No special investigations - good history and physical examination</p>\n<p>are essential for diagnosis</p>\n<p>\u0081</p>\n<p>Complete blood count: look for leucocytosis</p>\n<p>\u0081</p>\n<p>Transabdominal ultrasound</p>\n<p>\u0081</p>\n<p>Abdominal X ray (to assess for perforation and intestinal occlusion)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Emergency surgery</p>\n<p>\u0089</p>\n<p>If surgery is delayed, start antibiotic treatment while</p>\n<p>referring</p>\n<p>- ceftriaxone 2 g IV once daily</p>\n<p>- Child: 80 mg/kg IV once daily</p>\n<p>- plus metronidazole 500 mg IV every 8 hours</p>\n<p>child 10 mg/kg IV every 8 hours</p>\n<p>\u0089</p>\n<p>Start antibiotic prophylaxis before the surgery and</p>\n<p>continue for a duration depending on the findings (<</p>\n<p>24 hours for unperforated appendix, at least 5 days</p>\n<p>for perforated appendix)</p>\n<p>H</p>\n<p>6.1.2  Acute Pancreatitis\t                        ICD10 CODE: K85</p>\n<p>Acute inflammation of the pancreas.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Excessive alcohol intake</p>\n<p>~</p>\n<p>Gall stones, biliary tract disease (obstructive cancer or ana\u00ad</p>\n<p>tomical abnormalities)</p>\n<p>~</p>\n<p>Infections, e.g. mumps, HIV, hepatitis A, ascaris</p>\n<p>~</p>\n<p>Drugs, e.g. sulphonamides, furosemide, lamivudine, anal\u00ad</p>\n<p>gesics, organosphosphate poisoning</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>395</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 462,
        "content": "~\nPeptic/duodenal ulcers\nClinical features\n \n~\nAcute abdominal pain usually in the epigastrium radiating \nto the back\n \n~\n Pain worsened by eating or lying down and relieved by \nsitting up or leaning forward\n \n~\nNausea, vomiting, abdominal distension\n \n~\nFever, tachycardia, dehydration (may be severely ill with \nshock)\n \n~\nAbdomen is very tender but in the absence of peritonitis \nthere is no rigidity/rebound tenderness\nComplications\n \n~\nPseudocysts\n \n~\nNecrotizing pancreatitis with infection\n \n~\nPeritonitis\nDifferential diagnosis\n \n~\nPerforated peptic ulcer, peritonitis\n \n~\nAcute cholecystitis, inflammation of the biliary tract\n \n~\nSickle-cell anaemia crisis\nInvestigations\n \n\u0081\nBlood: Serum analysis, complete blood count, random blood sugar\n \n\u0081\nRaised pancreatic amylase and lipase > 3 times normal\n \n\u0081\nUltrasound: gallstones, pancreatic oedema, abdominal fluid\n \n\u0081\nLiver function tests: raised liver enzymes\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n396\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Peptic/duodenal ulcers</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Acute abdominal pain usually in the epigastrium radiating</p>\n<p>to the back</p>\n<p>~</p>\n<p>Pain worsened by eating or lying down and relieved by</p>\n<p>sitting up or leaning forward</p>\n<p>~</p>\n<p>Nausea, vomiting, abdominal distension</p>\n<p>~</p>\n<p>Fever, tachycardia, dehydration (may be severely ill with</p>\n<p>shock)</p>\n<p>~</p>\n<p>Abdomen is very tender but in the absence of peritonitis</p>\n<p>there is no rigidity/rebound tenderness</p>\n<p>Complications</p>\n<p>~</p>\n<p>Pseudocysts</p>\n<p>~</p>\n<p>Necrotizing pancreatitis with infection</p>\n<p>~</p>\n<p>Peritonitis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Perforated peptic ulcer, peritonitis</p>\n<p>~</p>\n<p>Acute cholecystitis, inflammation of the biliary tract</p>\n<p>~</p>\n<p>Sickle-cell anaemia crisis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Serum analysis, complete blood count, random blood sugar</p>\n<p>\u0081</p>\n<p>Raised pancreatic amylase and lipase > 3 times normal</p>\n<p>\u0081</p>\n<p>Ultrasound: gallstones, pancreatic oedema, abdominal fluid</p>\n<p>\u0081</p>\n<p>Liver function tests: raised liver enzymes</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>396</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 463,
        "content": "Management\nTREATMENT\nLOC\nMild acute pancreatitis\n(No organ failure, no local or systematic com\u00ad\nplications, no signs of peritonitis, normal serum \ncreatinine,  normal  haematocrit  [not  increased] \nEarly aggressive fluid resuscitation and acid-base \nbalance\n\t\n\u0089\nPrevent volume depletion (adequate fluids with\nRinger\u2019s Lactate). Give 5-10 ml/kg/hour or \n250-\n 500 ml of isotonic crystalloids in the first 12-24 \nhours or urine output of at least 0.5 ml/kg/\nhour\n\t\n\u0089\nGive IV fluids to correct metabolic and electrolyte \ndisturbances and to prevent hypovolaemia and \nhypotension\n\t\n\u0089\nMonitor electrolytes\n\t\n\u0089\nGoal is to decrease haematocrit and BUN in 48 \nhours, evaluate every 4-6 hours \nPain control\n\t\n\u0089\nOpioids, paracetamol, epidural anaesthesia [avoid \nNSAIDs)\n \n- Rectal/IV paracetamol 500 mg 6-8 hourly\n \n- or Pethidine 25-100 mg SC or IM or 25-50 \nmg slow IV. Repeat prn every 4-6 hours\n \n- IV morphine 1-3 mg every 4 hours\n \n- Be aware of complications e.g. constipation, \ndysphagia, respiratory depression, confusion \nEmesis\n\t\n\u0089\nAnti-emetics as appropriate\n \n- Metoclopramide 10 mg IV/IM every 8 hours\n\t\n\u0089\nPass a nasogastric tube for suction when persistent \nvomiting or ileus occurs\n  HC4\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n397\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild acute pancreatitis</p>\n<p>(No organ failure, no local or systematic com\u00ad</p>\n<p>plications, no signs of peritonitis, normal serum</p>\n<p>creatinine,  normal  haematocrit  [not  increased]</p>\n<p>Early aggressive fluid resuscitation and acid-base</p>\n<p>balance</p>\n<p>\u0089</p>\n<p>Prevent volume depletion (adequate fluids with</p>\n<p>Ringer\u2019s Lactate). Give 5-10 ml/kg/hour or</p>\n<p>250-</p>\n<p>500 ml of isotonic crystalloids in the first 12-24</p>\n<p>hours or urine output of at least 0.5 ml/kg/</p>\n<p>hour</p>\n<p>\u0089</p>\n<p>Give IV fluids to correct metabolic and electrolyte</p>\n<p>disturbances and to prevent hypovolaemia and</p>\n<p>hypotension</p>\n<p>\u0089</p>\n<p>Monitor electrolytes</p>\n<p>\u0089</p>\n<p>Goal is to decrease haematocrit and BUN in 48</p>\n<p>hours, evaluate every 4-6 hours</p>\n<p>Pain control</p>\n<p>\u0089</p>\n<p>Opioids, paracetamol, epidural anaesthesia [avoid</p>\n<p>NSAIDs)</p>\n<p>- Rectal/IV paracetamol 500 mg 6-8 hourly</p>\n<p>- or Pethidine 25-100 mg SC or IM or 25-50</p>\n<p>mg slow IV. Repeat prn every 4-6 hours</p>\n<p>- IV morphine 1-3 mg every 4 hours</p>\n<p>- Be aware of complications e.g. constipation,</p>\n<p>dysphagia, respiratory depression, confusion</p>\n<p>Emesis</p>\n<p>\u0089</p>\n<p>Anti-emetics as appropriate</p>\n<p>- Metoclopramide 10 mg IV/IM every 8 hours</p>\n<p>\u0089</p>\n<p>Pass a nasogastric tube for suction when persistent</p>\n<p>vomiting or ileus occurs</p>\n<h3>HC4</h3>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>397</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 464,
        "content": "TREATMENT\nLOC\nFeeding and nutrition\n\t\n\u0089\nNo feeding by mouth until signs and symptoms of \nacute inflammation subside (i.e. cessation of abdominal \ntenderness and pain, return of hunger and well-being)\n\t\n\u0089\nProvide energy with dextrose 50% 300-500 ml a \nday (add 50 ml to 500 ml Normal saline) to prevent \nmuscle wasting\n\t\n\u0089\nStart early oral re-feeding on demand, start within \n48-72 hours as soon as the patient is able and can \ntolerate feeds\n\t\n\u0089\nStart with clear liquids, then low fat semi-solid feeds \nthen a normal diet \u2013 according to tolerance\n\t\n\u0089\nMonitor daily for vital signs, fluid intake, urinary output, \nand GI symptoms\n\t\n\u0089\nIf oral feeding not possible, consider peripheral par\u00ad\nenteral and central parenteral nutrition\nGlycaemic control (hyperglycaemia is common) \n\t\n\u0089\nKeep serum blood sugar between 6-9 mmol/l f Avoid \nhypoglycemia\nAntibiotics\n\t\n\u0089\nAvoid inappropriate use of antibiotics and other med\u00ad\nications e.g. for prophylaxis\n\t\n\u0089\nIn case of specific infection, e.g. biliary sepsis, pulmo\u00ad\nnary infection, or UTI, treat vigorously with appropriate \nantibiotic therapy\nOther measures\n\t\n\u0089\nAddress the underlying cause as is appropriate\n\t\n\u0089\nStop alcohol or drugs\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n398\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Feeding and nutrition</p>\n<p>\u0089</p>\n<p>No feeding by mouth until signs and symptoms of</p>\n<p>acute inflammation subside (i.e. cessation of abdominal</p>\n<p>tenderness and pain, return of hunger and well-being)</p>\n<p>\u0089</p>\n<p>Provide energy with dextrose 50% 300-500 ml a</p>\n<p>day (add 50 ml to 500 ml Normal saline) to prevent</p>\n<p>muscle wasting</p>\n<p>\u0089</p>\n<p>Start early oral re-feeding on demand, start within</p>\n<p>48-72 hours as soon as the patient is able and can</p>\n<p>tolerate feeds</p>\n<p>\u0089</p>\n<p>Start with clear liquids, then low fat semi-solid feeds</p>\n<p>then a normal diet \u2013 according to tolerance</p>\n<p>\u0089</p>\n<p>Monitor daily for vital signs, fluid intake, urinary output,</p>\n<p>and GI symptoms</p>\n<p>\u0089</p>\n<p>If oral feeding not possible, consider peripheral par\u00ad</p>\n<p>enteral and central parenteral nutrition</p>\n<p>Glycaemic control (hyperglycaemia is common)</p>\n<p>\u0089</p>\n<p>Keep serum blood sugar between 6-9 mmol/l f Avoid</p>\n<p>hypoglycemia</p>\n<p>Antibiotics</p>\n<p>\u0089</p>\n<p>Avoid inappropriate use of antibiotics and other med\u00ad</p>\n<p>ications e.g. for prophylaxis</p>\n<p>\u0089</p>\n<p>In case of specific infection, e.g. biliary sepsis, pulmo\u00ad</p>\n<p>nary infection, or UTI, treat vigorously with appropriate</p>\n<p>antibiotic therapy</p>\n<p>Other measures</p>\n<p>\u0089</p>\n<p>Address the underlying cause as is appropriate</p>\n<p>\u0089</p>\n<p>Stop alcohol or drugs</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>398</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 465,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nMobilisation\n\t\n\u0089\nEvaluation for gall stones by ultrasound scans\n\t\n\u0089\nManage complications e.g. acute peri-pancreatic fluid \ncollections, acute necrosis, pseudocyst\nModerately acute pancreatitis\n\u2013\t Transient organ failure (< 48 hours)\n\u2013\t Local or systematic complications without \npersistent organ failure\tRR\nRR\nSevere acute pancreatitis\n\u2013\t Persistent organ failure (> 48 hours)\n\u2013\t Either single or multiple organ failure\nRR\nTreatment as above plus\n\t\n\u0089\nRefer or consult with specialist at higher level \n\t\n\u0089\nHDU/ICU (monitoring and nursing) f Volume resus\u00ad\ncitation\n\t\n\u0089\nPain management f Nutrition/ re-feeding f Glycaemic \ncontrol f Nasogastric tube\n\t\n\u0089\nOxygen / mechanical ventilation\n\t\n\u0089\nRenal replacement\n\t\n\u0089\nAddress the cause where possible\n\t\n\u0089\nManage complications as appropriate e.g. acute \nperi-pancreatic fluid collection, acute necrosis, pseu\u00ad\ndocyst.\nRR\nNote\n \n\u0083 Look out for diabetes mellitus as a consequence of damage \nto the pancreas\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n399\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Mobilisation</p>\n<p>\u0089</p>\n<p>Evaluation for gall stones by ultrasound scans</p>\n<p>\u0089</p>\n<p>Manage complications e.g. acute peri-pancreatic fluid</p>\n<p>collections, acute necrosis, pseudocyst</p>\n<p>Moderately acute pancreatitis</p>\n<p>\u2013\t Transient organ failure (< 48 hours)</p>\n<p>\u2013\t Local or systematic complications without</p>\n<p>persistent organ failure\tRR</p>\n<p>RR</p>\n<p>Severe acute pancreatitis</p>\n<p>\u2013\t Persistent organ failure (> 48 hours)</p>\n<p>\u2013\t Either single or multiple organ failure</p>\n<p>RR</p>\n<p>Treatment as above plus</p>\n<p>\u0089</p>\n<p>Refer or consult with specialist at higher level</p>\n<p>\u0089</p>\n<p>HDU/ICU (monitoring and nursing) f Volume resus\u00ad</p>\n<p>citation</p>\n<p>\u0089</p>\n<p>Pain management f Nutrition/ re-feeding f Glycaemic</p>\n<p>control f Nasogastric tube</p>\n<p>\u0089</p>\n<p>Oxygen / mechanical ventilation</p>\n<p>\u0089</p>\n<p>Renal replacement</p>\n<p>\u0089</p>\n<p>Address the cause where possible</p>\n<p>\u0089</p>\n<p>Manage complications as appropriate e.g. acute</p>\n<p>peri-pancreatic fluid collection, acute necrosis, pseu\u00ad</p>\n<p>docyst.</p>\n<p>RR</p>\n<p>Note</p>\n<p>\u0083 Look out for diabetes mellitus as a consequence of damage</p>\n<p>to the pancreas</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>399</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 466,
        "content": "Prevention\n \n~\nReduce alcohol intake - moderate consumption\n \n~\nLimit use of toxic drugs\n6.1.3 Upper Gastrointestinal Bleeding         ICD10 CODE: K92.2\nBleeding from the upper gastrointestinal tract (oesophagus, stomach \nand duodenum). It can be a medical emergency.\nCause\n \n~\nGastro-oesophageal varices\n \n~\nPeptic ulcer disease/severe gastritis/cancer\n \n~\nMallory Weiss tear (a tear in the oesophageal mucosa \ncaused by forceful retching)\n \nClinical features\n \n~\nVomiting of fresh blood (haematemesis)\n \n~\nCoffee brown emesis (degraded blood mixed with stomach \ncontent)\n \n~\nMelena: passing of soft dark red smelly stool\n \n~\nBlack stools (in case of minor bleeding)\nComplications\n \n~\nAcute hypovolaemia (if acute and abundant): syncope, hy\u00ad\npotension, tachycardia, sweating\n \n~\nChronic anaemia (if subacute/chronic loss)\nDiagnosis\n \n\u0081\nEndoscopy\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n400\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Reduce alcohol intake - moderate consumption</p>\n<p>~</p>\n<p>Limit use of toxic drugs</p>\n<p>6.1.3 Upper Gastrointestinal Bleeding         ICD10 CODE: K92.2</p>\n<p>Bleeding from the upper gastrointestinal tract (oesophagus, stomach</p>\n<p>and duodenum). It can be a medical emergency.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Gastro-oesophageal varices</p>\n<p>~</p>\n<p>Peptic ulcer disease/severe gastritis/cancer</p>\n<p>~</p>\n<p>Mallory Weiss tear (a tear in the oesophageal mucosa</p>\n<p>caused by forceful retching)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Vomiting of fresh blood (haematemesis)</p>\n<p>~</p>\n<p>Coffee brown emesis (degraded blood mixed with stomach</p>\n<p>content)</p>\n<p>~</p>\n<p>Melena: passing of soft dark red smelly stool</p>\n<p>~</p>\n<p>Black stools (in case of minor bleeding)</p>\n<p>Complications</p>\n<p>~</p>\n<p>Acute hypovolaemia (if acute and abundant): syncope, hy\u00ad</p>\n<p>potension, tachycardia, sweating</p>\n<p>~</p>\n<p>Chronic anaemia (if subacute/chronic loss)</p>\n<p>Diagnosis</p>\n<p>\u0081</p>\n<p>Endoscopy</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>400</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 467,
        "content": "6.1.4 Peritonitis\t                             ICD10 code K65\nIrritation (inflammation) of the peritoneum\nCauses\nInfection following:\n \n~\nPerforation of the gut and leakage of its contents, e.g. burst \nappendix, perforated peptic ulcer\n \n~\nPerforated bowel due to obstruction or injury\n \n~\nPerforation of gall bladder, containing infected bile\n \n~\nPerforation of the uterus\n \n~\nTuberculosis, abscess, typhoid ulcers\n \n~\nMalignancy\n \n~\nPost-operative peritonitis\nChemical causes\n \n~\nLeakage of urine, blood, bile or stomach or pancreas con\u00ad\ntent into the peritoneal cavity\nClinical features\n \n~\nSevere and continuous pain\n\t\n\u0089\nGeneralised if the whole peritoneum is affected\n \n~\nAbdominal swelling (distension)\n \n~\nFever, vomiting, tachycardia, hypoxia\n \n~\nHypovolemic shock, reduced urinary volume\n \n~\nTenderr rigid abdomen\n \n~\nRebound tenderness - pressure on the abdomen and sud\u00ad\nden release causes sharper pain\n \n~\nAbsent bowel sounds\ninvestigations\n \n~\nAbdominal X-ray and/or ultrasound\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n401\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>6.1.4 Peritonitis\t                             ICD10 code K65</p>\n<p>Irritation (inflammation) of the peritoneum</p>\n<p>Causes</p>\n<p>Infection following:</p>\n<p>~</p>\n<p>Perforation of the gut and leakage of its contents, e.g. burst</p>\n<p>appendix, perforated peptic ulcer</p>\n<p>~</p>\n<p>Perforated bowel due to obstruction or injury</p>\n<p>~</p>\n<p>Perforation of gall bladder, containing infected bile</p>\n<p>~</p>\n<p>Perforation of the uterus</p>\n<p>~</p>\n<p>Tuberculosis, abscess, typhoid ulcers</p>\n<p>~</p>\n<p>Malignancy</p>\n<p>~</p>\n<p>Post-operative peritonitis</p>\n<p>Chemical causes</p>\n<p>~</p>\n<p>Leakage of urine, blood, bile or stomach or pancreas con\u00ad</p>\n<p>tent into the peritoneal cavity</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Severe and continuous pain</p>\n<p>\u0089</p>\n<p>Generalised if the whole peritoneum is affected</p>\n<p>~</p>\n<p>Abdominal swelling (distension)</p>\n<p>~</p>\n<p>Fever, vomiting, tachycardia, hypoxia</p>\n<p>~</p>\n<p>Hypovolemic shock, reduced urinary volume</p>\n<p>~</p>\n<p>Tenderr rigid abdomen</p>\n<p>~</p>\n<p>Rebound tenderness - pressure on the abdomen and sud\u00ad</p>\n<p>den release causes sharper pain</p>\n<p>~</p>\n<p>Absent bowel sounds</p>\n<p>investigations</p>\n<p>~</p>\n<p>Abdominal X-ray and/or ultrasound</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>401</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 468,
        "content": "~\nBlood: Complete blood cell count, culture and sensitivity\n \n~\nRenal function and electrolytes\n \n~\nLiver function tests\nTREATMENT\nLOC\n\t\n\u0089\nRefer to hospital\n\t\n\u0089\nStart initial treatment before referral\n\t\n\u0089\nMonitor temperature\n\t\n\u0089\nMonitor BP, pulse, Sp02, urine output, mention\n\t\n\u0089\nPut up an IV drip with normal saline or ringer\u2019s \nlactate or any other crystalloid: 1 L every 1-2 hours \nuntil BP is normal, then 1 L every 4-6 hours when \nBP is normal\n\t\n\u0089\nNil by mouth. Pass a nasogastric tube and start suction\n\t\n\u0089\nAsk patient to lie on their side in a comfortable position\n\t\n\u0089\nGive oxygen if patient is hypoxic\n\t\n\u0089\nPain control (avoid NSAIDs)\n \n- Pethidine 50 mg IM or IV\n \n- Child: 0.5-2 mg/kg\n \n- Or Morphine 5-15 mg IV or IM or SC\nChild: 2.5-5 mg IM IV SC\n\t\n\u0089\nRefer patient to hospital for further management, \nincluding possible exploratory laparotomy\nIn suspected bacterial infection and fever: (minimum \n7-day course)\n\t\n\u0089\nCeftriaxone 1-2 g IV once daily\n\t\n\u0089\nChild: 50 mg/kg per dose\n\t\n\u0089\nPlus gentamicin 7 mg/kg IV daily in divided doses\nChild: 2.5 mg/kg every 8 hours\nH\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n402\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Blood: Complete blood cell count, culture and sensitivity</p>\n<p>~</p>\n<p>Renal function and electrolytes</p>\n<p>~</p>\n<p>Liver function tests</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to hospital</p>\n<p>\u0089</p>\n<p>Start initial treatment before referral</p>\n<p>\u0089</p>\n<p>Monitor temperature</p>\n<p>\u0089</p>\n<p>Monitor BP, pulse, Sp02, urine output, mention</p>\n<p>\u0089</p>\n<p>Put up an IV drip with normal saline or ringer\u2019s</p>\n<p>lactate or any other crystalloid: 1 L every 1-2 hours</p>\n<p>until BP is normal, then 1 L every 4-6 hours when</p>\n<p>BP is normal</p>\n<p>\u0089</p>\n<p>Nil by mouth. Pass a nasogastric tube and start suction</p>\n<p>\u0089</p>\n<p>Ask patient to lie on their side in a comfortable position</p>\n<p>\u0089</p>\n<p>Give oxygen if patient is hypoxic</p>\n<p>\u0089</p>\n<p>Pain control (avoid NSAIDs)</p>\n<p>- Pethidine 50 mg IM or IV</p>\n<p>- Child: 0.5-2 mg/kg</p>\n<p>- Or Morphine 5-15 mg IV or IM or SC</p>\n<p>Child: 2.5-5 mg IM IV SC</p>\n<p>\u0089</p>\n<p>Refer patient to hospital for further management,</p>\n<p>including possible exploratory laparotomy</p>\n<p>In suspected bacterial infection and fever: (minimum</p>\n<p>7-day course)</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1-2 g IV once daily</p>\n<p>\u0089</p>\n<p>Child: 50 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Plus gentamicin 7 mg/kg IV daily in divided doses</p>\n<p>Child: 2.5 mg/kg every 8 hours</p>\n<p>H</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>402</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 469,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nPlus metronidazole 500 mg by IV infusion every \n8 hours; change when possible to 400 mg orally \nevery 8 hours\nChild: 12.5 mg/kg IV per dose; change when \npossible to oral route\n\t\n\u0089\nIdentify and control the source of infection\n\t\n\u0089\nPrevent and control complications through: proper \nnutrition, early ambulation, rehabilitation\n6.1.5 Diarrhoea\t         ICD10 CODE: DEPENDING ON THE CAUSE\nOccurrence of 3 or more loose watery stools in 24 hrs. Acute diarrhoea: \n3 loose, watery stools within 24 hours Dysentery: bloody diarrhoea, \nvisible blood and mucus Persistent diarrhoea: episodes of diarrhoea \nlasting more than 14 days\nCauses\n \n~\nViruses: Rotavirus, Norovirus , adenovirus, measles, hepa\u00ad\ntitis A virus , hepatitis E virus, Ebola\n \n~\nBacteria: Vibrio cholera, E.coli , Salmonella, shigella, cam\u00ad\npylobacter\n \n~\nProtozoa: giardiasis, malaria, cryptosporia\n \n~\nHeliminthes e.g. strongyloidiasis, schistosomiasis\n \n~\nInfectious diseases, e.g. measles, malaria, and other fever- \ncausing conditions\n \n~\nMalnutrition e.g. kwashiorkor\n \n~\nDrugs e.g., prolonged use of purgatives and broad-spec\u00ad\ntrum antibiotics\n \n~\nUnhygienic feeding methods\n \n~\nMalabsorption syndrome\n \n~\nLactose intolerance\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n403\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Plus metronidazole 500 mg by IV infusion every</p>\n<p>8 hours; change when possible to 400 mg orally</p>\n<p>every 8 hours</p>\n<p>Child: 12.5 mg/kg IV per dose; change when</p>\n<p>possible to oral route</p>\n<p>\u0089</p>\n<p>Identify and control the source of infection</p>\n<p>\u0089</p>\n<p>Prevent and control complications through: proper</p>\n<p>nutrition, early ambulation, rehabilitation</p>\n<p>6.1.5 Diarrhoea\t         ICD10 CODE: DEPENDING ON THE CAUSE</p>\n<p>Occurrence of 3 or more loose watery stools in 24 hrs. Acute diarrhoea:</p>\n<p>3 loose, watery stools within 24 hours Dysentery: bloody diarrhoea,</p>\n<p>visible blood and mucus Persistent diarrhoea: episodes of diarrhoea</p>\n<p>lasting more than 14 days</p>\n<p>Causes</p>\n<p>~</p>\n<p>Viruses: Rotavirus, Norovirus , adenovirus, measles, hepa\u00ad</p>\n<p>titis A virus , hepatitis E virus, Ebola</p>\n<p>~</p>\n<p>Bacteria: Vibrio cholera, E.coli , Salmonella, shigella, cam\u00ad</p>\n<p>pylobacter</p>\n<p>~</p>\n<p>Protozoa: giardiasis, malaria, cryptosporia</p>\n<p>~</p>\n<p>Heliminthes e.g. strongyloidiasis, schistosomiasis</p>\n<p>~</p>\n<p>Infectious diseases, e.g. measles, malaria, and other fever-</p>\n<p>causing conditions</p>\n<p>~</p>\n<p>Malnutrition e.g. kwashiorkor</p>\n<p>~</p>\n<p>Drugs e.g., prolonged use of purgatives and broad-spec\u00ad</p>\n<p>trum antibiotics</p>\n<p>~</p>\n<p>Unhygienic feeding methods</p>\n<p>~</p>\n<p>Malabsorption syndrome</p>\n<p>~</p>\n<p>Lactose intolerance</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>403</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 470,
        "content": "~\nHIV associated-diarrhoea\n \n~\nIrritable bowel syndrome\n \n~\nMetabolic: diabetes, thyroid disease\n \n~\nTravellers\u2019 diarrhoea\n \n~\nInflammatory bowel disease (persistent diarrhoea usually \nbloody)\nClinical features\n \n~\nLoose watery stools\n \n~\nAbdominal cramps\n \n~\nDehydration - thirst, sunken eyes, loss of skin elasticity, low \nurine output\n \n~\nSigns of malnutrition if diarrhoea persists for > 14 days\n \n~\nBlood in stool (in dysentery)\nInvestigations\n \n\u0081\nStool: Microscopy, C&S\n \n\u0081\nOther investigations may be necessary according to history and \nphysical examination\nRed flags\n \n- Fever\n \n- Extremes of age\n \n- History of travel from a known endemic area\n \n- Dysentery\n \n- Shock, failure to feed, mental confusion\nTREATMENT\nLOC\n\t\n\u0089\nPrevent or correct dehydration with ORS or IV \nfluids according to treatment plans A, B or C (see \nsection 1.1.3)\n\t\n\u0089\nFind and treat the cause if indicated\n \n- Avoid inappropriate use of antibiotics e.g. \nmetronidazole, ciprofloxacin\nHC2\nHC4\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n404\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>HIV associated-diarrhoea</p>\n<p>~</p>\n<p>Irritable bowel syndrome</p>\n<p>~</p>\n<p>Metabolic: diabetes, thyroid disease</p>\n<p>~</p>\n<p>Travellers\u2019 diarrhoea</p>\n<p>~</p>\n<p>Inflammatory bowel disease (persistent diarrhoea usually</p>\n<p>bloody)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Loose watery stools</p>\n<p>~</p>\n<p>Abdominal cramps</p>\n<p>~</p>\n<p>Dehydration - thirst, sunken eyes, loss of skin elasticity, low</p>\n<p>urine output</p>\n<p>~</p>\n<p>Signs of malnutrition if diarrhoea persists for > 14 days</p>\n<p>~</p>\n<p>Blood in stool (in dysentery)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Stool: Microscopy, C&S</p>\n<p>\u0081</p>\n<p>Other investigations may be necessary according to history and</p>\n<p>physical examination</p>\n<p>Red flags</p>\n<p>- Fever</p>\n<p>- Extremes of age</p>\n<p>- History of travel from a known endemic area</p>\n<p>- Dysentery</p>\n<p>- Shock, failure to feed, mental confusion</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Prevent or correct dehydration with ORS or IV</p>\n<p>fluids according to treatment plans A, B or C (see</p>\n<p>section 1.1.3)</p>\n<p>\u0089</p>\n<p>Find and treat the cause if indicated</p>\n<p>- Avoid inappropriate use of antibiotics e.g.</p>\n<p>metronidazole, ciprofloxacin</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>404</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 471,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nRoutinely use zinc supplementation, at a dosage of \n20 milligrams per day for children older than six \nmonths for 10\u201314 days\n\t\n\u0089\nPrevent or treat undernutrition and micronutrient \ndeficiencies\nPersistent or chronic diarrhoea:\n\t\n\u0089\nAdults only: As above plus codeine phosphate\n30 mg every 8-12 hours as required\n\t\n\u0089\nChild: vitamin A\n \n- 6-11 months: 100,000 IU; 1-6 years: \n200,000 IU\nHC2\nHC4\nPrevention\n \n~\nVaccination: measles, rotavirus, polio, hepatitis A virus\n \n~\nNotify in case of suspected epidemics e.g. cholera, hepati\u00ad\ntis A or E virus infections, Ebola\n \n~\nEncourage handwashing, use of clean drinking water, and \nproper waste disposal\n6.2 GASTROINTESTINAL  INFECTIONS\n6.2.1 Amoebiasis\t\n                 ICD10 CODE: A06\nA common parasitic infection of the gastrointestinal system acquired \nthrough oral-faecal transmission.\nCauses\n \n~\nProtozoan Entamoeba histolytica\nClinical features\nIt may present as:\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n405\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Routinely use zinc supplementation, at a dosage of</p>\n<p>20 milligrams per day for children older than six</p>\n<p>months for 10\u201314 days</p>\n<p>\u0089</p>\n<p>Prevent or treat undernutrition and micronutrient</p>\n<p>deficiencies</p>\n<p>Persistent or chronic diarrhoea:</p>\n<p>\u0089</p>\n<p>Adults only: As above plus codeine phosphate</p>\n<p>30 mg every 8-12 hours as required</p>\n<p>\u0089</p>\n<p>Child: vitamin A</p>\n<p>- 6-11 months: 100,000 IU; 1-6 years:</p>\n<h3>200,000 IU</h3>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Vaccination: measles, rotavirus, polio, hepatitis A virus</p>\n<p>~</p>\n<p>Notify in case of suspected epidemics e.g. cholera, hepati\u00ad</p>\n<p>tis A or E virus infections, Ebola</p>\n<p>~</p>\n<p>Encourage handwashing, use of clean drinking water, and</p>\n<p>proper waste disposal</p>\n<h3>6.2 GASTROINTESTINAL  INFECTIONS</h3>\n<p>6.2.1 Amoebiasis</p>\n<h3>ICD10 CODE: A06</h3>\n<p>A common parasitic infection of the gastrointestinal system acquired</p>\n<p>through oral-faecal transmission.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Protozoan Entamoeba histolytica</p>\n<p>Clinical features</p>\n<p>It may present as:</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>405</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 472,
        "content": "Amoebic dysentery\n \n~\nPersistent mucoid/bloody diarrhoea\n \n~\nAbdominal pain, tenesmus\n \n~\nChronic carriers are symptomless\nAmoebic abscess (as a result of spread via the blood stream):\n \n~\nLiver abscess: swelling/pain in the right sub-costal area, \nfever, chills, sweating, weight loss\n \n~\nBrain: presenting as space-occupying lesion\n \n~\nLungs: cough and blood stained sputum\n \n~\nAmoeboma: swelling anywhere in the abdomen, especially \nascending colon\n \n~\nAnal ulceration: may occur by direct extension from the \nintestinal infection\nDifferential diagnosis\n \n~\nBacillary dysentery\n \n~\nAny other cause of bloody diarrhoea\n \n~\nCancer of the liver\n \n~\nOther causes of swelling in the liver\n \n~\nCarcinoma colon\nInvestigations\n \n\u0081\nStool: Microscopy for cysts and motile organisms\n \n\u0081\nUltrasound\nTREATMENT\nLOC\n\t\n\u0089\nCorrect any dehydration (section 1.1.3)\n\t\n\u0089\nMetronidazole 800 mg every 8 hours for 10 days\nChild: 10 mg/kg per dose\n\t\n\u0089\nOr tinidazole 2 g daily for 5 days\nChild: 50 mg/kg per dose\nHC2\nH\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n406\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Amoebic dysentery</p>\n<p>~</p>\n<p>Persistent mucoid/bloody diarrhoea</p>\n<p>~</p>\n<p>Abdominal pain, tenesmus</p>\n<p>~</p>\n<p>Chronic carriers are symptomless</p>\n<p>Amoebic abscess (as a result of spread via the blood stream):</p>\n<p>~</p>\n<p>Liver abscess: swelling/pain in the right sub-costal area,</p>\n<p>fever, chills, sweating, weight loss</p>\n<p>~</p>\n<p>Brain: presenting as space-occupying lesion</p>\n<p>~</p>\n<p>Lungs: cough and blood stained sputum</p>\n<p>~</p>\n<p>Amoeboma: swelling anywhere in the abdomen, especially</p>\n<p>ascending colon</p>\n<p>~</p>\n<p>Anal ulceration: may occur by direct extension from the</p>\n<p>intestinal infection</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Bacillary dysentery</p>\n<p>~</p>\n<p>Any other cause of bloody diarrhoea</p>\n<p>~</p>\n<p>Cancer of the liver</p>\n<p>~</p>\n<p>Other causes of swelling in the liver</p>\n<p>~</p>\n<p>Carcinoma colon</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Stool: Microscopy for cysts and motile organisms</p>\n<p>\u0081</p>\n<p>Ultrasound</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Correct any dehydration (section 1.1.3)</p>\n<p>\u0089</p>\n<p>Metronidazole 800 mg every 8 hours for 10 days</p>\n<p>Child: 10 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or tinidazole 2 g daily for 5 days</p>\n<p>Child: 50 mg/kg per dose</p>\n<h3>HC2</h3>\n<p>H</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>406</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 473,
        "content": "TREATMENT\nLOC\nCaution\n \n\u0083 Metronidazole/tinidazole: do not use in 1st trimester of \npregnancy; avoid alcohol during treatment and for 48 hours \nthereafter\n \n\u0083 Metronidazole: Take after food\nPrevention\n \n~\nEducate the public on personal and food hygiene (washing \nhands before eating), proper faecal disposal\n \n~\nEnsure proper management of carriers and patients\n \n~\nPromote use of clean drinking water\n6.2.2\t\nBacillary Dysentery (Shigellosis)      ICD10 CODE: A03.9\nAn acute bacterial disease involving the large and small intestine, char\u00ad\nacterised by bloody mucoid diarrhoea.\nBacillary dysentery is a notifiable disease.\nCause\n \n~\nShigella dysenteriae, Shigella flexneri, Shigella sonnei, all \nspread by faecal-oral route\nClinical features\n \n~\nMucoid bloody diarrhoea\n \n~\nFever\n \n~\nNausea, vomiting, abdominal cramps\n \n~\nTenesmus (sensation of desire to defecate without produc\u00ad\ntion of significant amounts of faeces)\n \n~\nToxaemia (sometimes)\n \n~\nS. flexneri infection may be complicated with Reiter\u2019s syn\u00ad\ndrome \u2013 urethritis, conjutivitis and arthritis\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n407\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Caution</p>\n<p>\u0083 Metronidazole/tinidazole: do not use in 1st trimester of</p>\n<p>pregnancy; avoid alcohol during treatment and for 48 hours</p>\n<p>thereafter</p>\n<p>\u0083 Metronidazole: Take after food</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Educate the public on personal and food hygiene (washing</p>\n<p>hands before eating), proper faecal disposal</p>\n<p>~</p>\n<p>Ensure proper management of carriers and patients</p>\n<p>~</p>\n<p>Promote use of clean drinking water</p>\n<p>6.2.2</p>\n<p>Bacillary Dysentery (Shigellosis)      ICD10 CODE: A03.9</p>\n<p>An acute bacterial disease involving the large and small intestine, char\u00ad</p>\n<p>acterised by bloody mucoid diarrhoea.</p>\n<p>Bacillary dysentery is a notifiable disease.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Shigella dysenteriae, Shigella flexneri, Shigella sonnei, all</p>\n<p>spread by faecal-oral route</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Mucoid bloody diarrhoea</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Nausea, vomiting, abdominal cramps</p>\n<p>~</p>\n<p>Tenesmus (sensation of desire to defecate without produc\u00ad</p>\n<p>tion of significant amounts of faeces)</p>\n<p>~</p>\n<p>Toxaemia (sometimes)</p>\n<p>~</p>\n<p>S. flexneri infection may be complicated with Reiter\u2019s syn\u00ad</p>\n<p>drome \u2013 urethritis, conjutivitis and arthritis</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>407</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 474,
        "content": "Differential diagnosis\n \n~\nAmoebic dysentery\n \n~\nOther causes of bloody diarrhoea\nInvestigations\n \n\u0081\nStool: For C&S, microscopy\n \n\u0081\nMobile vibrios under microscope\nManagement\nUp to 90% of patients with cholera only require prompt oral rehydration. \nOnly severely dehydrated patients need IV fluids and antimicrobials\nTREATMENT\nLOC\n\t\n\u0089\nStart rehydration with ORS at HC1/2 and refer for \nisolation\n\t\n\u0089\nGive oral (ORS) or IV fluids (Ringer\u2019s lactate) according \nto degree of dehydration (see section 1.1.3)\n\t\n\u0089\nGive glucose IV for hypoglycemia\n\t\n\u0089\nGive maintenance fluid; at least 4-5 litres/day\n\t\n\u0089\nDoxycycline 300 mg single dose (children 4 mg/ \nkg single dose)\nOr erythromycin 25-50 mg/kg every 6 hours for \n3 days in children under 12 years\n\t\n\u0089\nOr ciprofloxacin 1 g single dose or 20 mg/kg 12 \nhourly for 3 days\nHC2\nHC3\nCaution\n \n\u0083 Ciprofloxacin, \ndoxycycline: \nusually \ncontraindicated \nin \npregnancy and children < 8 years but single dose in cholera \nshould not provoke adverse effect\n \n\u0083 Alternative: erythromycin 500 mg every 6 hours for 5 days\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n408\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Amoebic dysentery</p>\n<p>~</p>\n<p>Other causes of bloody diarrhoea</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Stool: For C&S, microscopy</p>\n<p>\u0081</p>\n<p>Mobile vibrios under microscope</p>\n<p>Management</p>\n<p>Up to 90% of patients with cholera only require prompt oral rehydration.</p>\n<p>Only severely dehydrated patients need IV fluids and antimicrobials</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Start rehydration with ORS at HC1/2 and refer for</p>\n<p>isolation</p>\n<p>\u0089</p>\n<p>Give oral (ORS) or IV fluids (Ringer\u2019s lactate) according</p>\n<p>to degree of dehydration (see section 1.1.3)</p>\n<p>\u0089</p>\n<p>Give glucose IV for hypoglycemia</p>\n<p>\u0089</p>\n<p>Give maintenance fluid; at least 4-5 litres/day</p>\n<p>\u0089</p>\n<p>Doxycycline 300 mg single dose (children 4 mg/</p>\n<p>kg single dose)</p>\n<p>Or erythromycin 25-50 mg/kg every 6 hours for</p>\n<p>3 days in children under 12 years</p>\n<p>\u0089</p>\n<p>Or ciprofloxacin 1 g single dose or 20 mg/kg 12</p>\n<p>hourly for 3 days</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Caution</p>\n<p>\u0083 Ciprofloxacin,</p>\n<p>doxycycline:</p>\n<p>usually</p>\n<p>contraindicated</p>\n<p>in</p>\n<p>pregnancy and children < 8 years but single dose in cholera</p>\n<p>should not provoke adverse effect</p>\n<p>\u0083 Alternative: erythromycin 500 mg every 6 hours for 5 days</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>408</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 475,
        "content": "Prevention\nEducate the patient/public to:\n \n~\nRehydrate with plenty of fluids\n \n~\nContinue breastfeeding or weaning\n \n~\nPersonal and food hygiene, e.g. washing hands before pre\u00ad\nparing and eating food and after using the toilet\n \n~\nUsing and drinking clean safe water\n \n~\nProper human faeces disposal\n \n~\nPrompt isolation, treatment, and reporting of cases\n6.2.4\t\nGiardiasis                     ICD10 CODE: A07.1\nA protozoan infection of the upper small intestine transmitted by fae\u00ad\ncal-oral route.\nCause\n \n~\nGiardia lamblia (a flagellated protozoan)\nClinical features\n \n~\nOften asymptomatic\n \n~\nProlonged diarrhoea, steatorrhoea\n \n~\nAbdominal cramps, bloating\n \n~\nFatigue, weight  loss\n \n~\nMalabsorption of fats and fat-soluble vitamins\n \n~\nSevere giardiasis may cause reactive arthritis, damage to \nduodenal, and jejunal mucosa\nDifferential diagnosis\n \n~\nOther causes of prolonged diarrhoea\n \n~\nOther causes of malabsorption\nInvestigations\n \n\u0081\nStool: For cysts and trophozoites\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n409\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Prevention</p>\n<p>Educate the patient/public to:</p>\n<p>~</p>\n<p>Rehydrate with plenty of fluids</p>\n<p>~</p>\n<p>Continue breastfeeding or weaning</p>\n<p>~</p>\n<p>Personal and food hygiene, e.g. washing hands before pre\u00ad</p>\n<p>paring and eating food and after using the toilet</p>\n<p>~</p>\n<p>Using and drinking clean safe water</p>\n<p>~</p>\n<p>Proper human faeces disposal</p>\n<p>~</p>\n<p>Prompt isolation, treatment, and reporting of cases</p>\n<p>6.2.4</p>\n<p>Giardiasis                     ICD10 CODE: A07.1</p>\n<p>A protozoan infection of the upper small intestine transmitted by fae\u00ad</p>\n<p>cal-oral route.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Giardia lamblia (a flagellated protozoan)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Often asymptomatic</p>\n<p>~</p>\n<p>Prolonged diarrhoea, steatorrhoea</p>\n<p>~</p>\n<p>Abdominal cramps, bloating</p>\n<p>~</p>\n<p>Fatigue, weight  loss</p>\n<p>~</p>\n<p>Malabsorption of fats and fat-soluble vitamins</p>\n<p>~</p>\n<p>Severe giardiasis may cause reactive arthritis, damage to</p>\n<p>duodenal, and jejunal mucosa</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of prolonged diarrhoea</p>\n<p>~</p>\n<p>Other causes of malabsorption</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Stool: For cysts and trophozoites</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>409</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 476,
        "content": "TREATMENT\nLOC\nMetronidazole 2 g after food daily for 3 days\nChild: 30 mg/kg (max: 1.2 g) per dose\n\t\n\u0089\nOr tinidazole 2 g single dose\nChild: 50 mg/kg\nHC2\nH\nCaution\n \n\u0083 Metronidazole, tinidazole: Avoid in first trimester, avoid alcohol \nduring treatment and for 48 hours after\n \n\u0083 Metronidazole: Take after food\nPrevention\n \n~\nProvide health education on\n \n- Personal and food hygiene e.g. washing hands before \nhandling or eating food and after using toilets\n \n- Proper disposal of human faeces\n \n- Use of safe clean drinking water\n6.3 GASTROINTESTINAL DISORDERS\n6.3.1 Dysphagia\t                       ICD10 CODE: R13.1\nDysphagia is difficulty in swallowing. It may be oropharyngeal dysphagia \nor oesophageal dysphagia\nCauses\nOropharyngeal dysphagia\n \n~\nNeurological: stroke, parkinson\u2019s, dementia, multiple scle\u00ad\nrosis, Guillianbarre, myasthenia, cerebral palsy, tardive dys\u00ad\nkinesia, brain tumours, trauma\n \n~\nMyopathy: connective tissue diseases, sarcoidosis, derma\u00ad\ntomyositis\n \n~\nStructural: Zenker\u2019s diverticulum, webs, oropharyngeal tu\u00ad\nmours, osteophytes\n \n~\nInfections: syphilis botulism, rabies, mucositis\n \n~\nMetabolic: Cushing\u2019s, thyrotoxicosis, Wilson\u2019s disease\n \n~\nIatrogenic: chemotherapy, neuroleptics, post surgery, post \nradiation\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n410\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Metronidazole 2 g after food daily for 3 days</p>\n<p>Child: 30 mg/kg (max: 1.2 g) per dose</p>\n<p>\u0089</p>\n<p>Or tinidazole 2 g single dose</p>\n<p>Child: 50 mg/kg</p>\n<h3>HC2</h3>\n<p>H</p>\n<p>Caution</p>\n<p>\u0083 Metronidazole, tinidazole: Avoid in first trimester, avoid alcohol</p>\n<p>during treatment and for 48 hours after</p>\n<p>\u0083 Metronidazole: Take after food</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Provide health education on</p>\n<p>- Personal and food hygiene e.g. washing hands before</p>\n<p>handling or eating food and after using toilets</p>\n<p>- Proper disposal of human faeces</p>\n<p>- Use of safe clean drinking water</p>\n<h3>6.3 GASTROINTESTINAL DISORDERS</h3>\n<p>6.3.1 Dysphagia\t                       ICD10 CODE: R13.1</p>\n<p>Dysphagia is difficulty in swallowing. It may be oropharyngeal dysphagia</p>\n<p>or oesophageal dysphagia</p>\n<p>Causes</p>\n<p>Oropharyngeal dysphagia</p>\n<p>~</p>\n<p>Neurological: stroke, parkinson\u2019s, dementia, multiple scle\u00ad</p>\n<p>rosis, Guillianbarre, myasthenia, cerebral palsy, tardive dys\u00ad</p>\n<p>kinesia, brain tumours, trauma</p>\n<p>~</p>\n<p>Myopathy: connective tissue diseases, sarcoidosis, derma\u00ad</p>\n<p>tomyositis</p>\n<p>~</p>\n<p>Structural: Zenker\u2019s diverticulum, webs, oropharyngeal tu\u00ad</p>\n<p>mours, osteophytes</p>\n<p>~</p>\n<p>Infections: syphilis botulism, rabies, mucositis</p>\n<p>~</p>\n<p>Metabolic: Cushing\u2019s, thyrotoxicosis, Wilson\u2019s disease</p>\n<p>~</p>\n<p>Iatrogenic: chemotherapy, neuroleptics, post surgery, post</p>\n<p>radiation</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>410</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 477,
        "content": "Oesophageal dysphagia\n \n~\nTumours: cancer of the oesophagus\n \n~\nOesophagiitis: gastroesophageal reflux disease, candidiasis, \npill oesophagitis (e.g. doxycycline), caustic soda injury\n \n~\nExtrinsic compression: tumors, lymph nodes\n \n~\nMotility: achalasia, scleroderma, oesophageal spasms\nClinical presentation\n \n~\nDifficulty initiating a swallow, repetitive swallowing\n \n~\nNasal regurgitation\n \n~\nCoughing, nasal speech, drooling\n \n~\nDiminished cough reflex\n \n~\nChoking (aspiration may occur without concurrent choking \nor coughing)\n \n~\nDysarthria and diplopia (may accompany neurologic condi\u00ad\ntions that cause oropharyngeal dysphagia)\n \n~\nHalitosis in patients with a large, residue-containing Zenk\u00ad\ner\u2019s diverticulum or in patients with advanced achalasia or \nlong-term obstruction with luminal accumulation of decom\u00ad\nposing residue\n \n~\nRecurrent pneumonia\n \n~\nOther features due to causative problem\nInvestigations\n \n\u0081\nMedical history and physical examination\n \n\u0081\nTimed water swallow test (complemented by a food test)\n \n\u0081\nEndoscopy (mandatory)\n \n\u0081\nHIV serology, RBS, electrolytes\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n411\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Oesophageal dysphagia</p>\n<p>~</p>\n<p>Tumours: cancer of the oesophagus</p>\n<p>~</p>\n<p>Oesophagiitis: gastroesophageal reflux disease, candidiasis,</p>\n<p>pill oesophagitis (e.g. doxycycline), caustic soda injury</p>\n<p>~</p>\n<p>Extrinsic compression: tumors, lymph nodes</p>\n<p>~</p>\n<p>Motility: achalasia, scleroderma, oesophageal spasms</p>\n<p>Clinical presentation</p>\n<p>~</p>\n<p>Difficulty initiating a swallow, repetitive swallowing</p>\n<p>~</p>\n<p>Nasal regurgitation</p>\n<p>~</p>\n<p>Coughing, nasal speech, drooling</p>\n<p>~</p>\n<p>Diminished cough reflex</p>\n<p>~</p>\n<p>Choking (aspiration may occur without concurrent choking</p>\n<p>or coughing)</p>\n<p>~</p>\n<p>Dysarthria and diplopia (may accompany neurologic condi\u00ad</p>\n<p>tions that cause oropharyngeal dysphagia)</p>\n<p>~</p>\n<p>Halitosis in patients with a large, residue-containing Zenk\u00ad</p>\n<p>er\u2019s diverticulum or in patients with advanced achalasia or</p>\n<p>long-term obstruction with luminal accumulation of decom\u00ad</p>\n<p>posing residue</p>\n<p>~</p>\n<p>Recurrent pneumonia</p>\n<p>~</p>\n<p>Other features due to causative problem</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Medical history and physical examination</p>\n<p>\u0081</p>\n<p>Timed water swallow test (complemented by a food test)</p>\n<p>\u0081</p>\n<p>Endoscopy (mandatory)</p>\n<p>\u0081</p>\n<p>HIV serology, RBS, electrolytes</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>411</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 478,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nEnsure rehydration with IV fluids\n\t\n\u0089\nPrevent malnutrition through appropriate energy \nreplacement\n\t\n\u0089\nTreat cause if possible (e.g. fluconazole trial in case \nof suspected oral candidiasis among HIV patients)\n\t\n\u0089\nConsult and/or refer the patient\nHC3\n6.3.2  Dyspepsia\t\n        ICD10 CODE: K30\nUpper abdominal discomfort arising from the upper gastrointestinal tract \nusually lasting more than 2\u20134 weeks.\nCauses\n \n~\nPeptic ulcer disease\n \n~\nGastroesophageal reflux disease (GERD)\n \n~\nFunctional dyspepsia\n \n~\nGastric or oesophageal cancer\n \n~\nOesophagitis (drugs, candida, and others)\n \n~\nGastroparesis or gastric outlet obstruction\n \n~\nOther motility disorders\nClinical features\n \n~\nEpigastric pain or discomfort, heartburn\n \n~\nBloating , early satiety and/or fullness after meals\n \n~\nRepeated belching or regurgitation (often rumination)\n \n~\nNausea\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n412\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure rehydration with IV fluids</p>\n<p>\u0089</p>\n<p>Prevent malnutrition through appropriate energy</p>\n<p>replacement</p>\n<p>\u0089</p>\n<p>Treat cause if possible (e.g. fluconazole trial in case</p>\n<p>of suspected oral candidiasis among HIV patients)</p>\n<p>\u0089</p>\n<p>Consult and/or refer the patient</p>\n<h3>HC3</h3>\n<p>6.3.2  Dyspepsia</p>\n<h3>ICD10 CODE: K30</h3>\n<p>Upper abdominal discomfort arising from the upper gastrointestinal tract</p>\n<p>usually lasting more than 2\u20134 weeks.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Peptic ulcer disease</p>\n<p>~</p>\n<p>Gastroesophageal reflux disease (GERD)</p>\n<p>~</p>\n<p>Functional dyspepsia</p>\n<p>~</p>\n<p>Gastric or oesophageal cancer</p>\n<p>~</p>\n<p>Oesophagitis (drugs, candida, and others)</p>\n<p>~</p>\n<p>Gastroparesis or gastric outlet obstruction</p>\n<p>~</p>\n<p>Other motility disorders</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Epigastric pain or discomfort, heartburn</p>\n<p>~</p>\n<p>Bloating , early satiety and/or fullness after meals</p>\n<p>~</p>\n<p>Repeated belching or regurgitation (often rumination)</p>\n<p>~</p>\n<p>Nausea</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>412</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 479,
        "content": "Dyspepsia alarm features: requires endoscopy\u2013REFER\n \n~\nDysphagia\n \n~\nOdynophagia (among patients who are HIV negative)\n \n~\nWeight loss\n \n~\nAbdominal mass or cervical lymphadenopathy\n \n~\nEvidence of upper GI bleeding\n \n~\nIron deficiency anaemia\n \n~\nRecurrent vomiting\n \n~\nRecent dyspeptic symptoms or new dyspepsia in individ\u00ad\nuals over the age of 40 years\nOther indications for endoscopy\n \n~\nHistory of long term smoking and alcohol misuse\n \n~\nPersistent dyspepsia despite appropriate treatment (e.g \nProton-pump inhibitors in GERD)\n \n~\nHepatobiliary disease\n \n6.3.3\t\nGastroesophageal Reflux Disease (GERD/GORD)\t ICD10 \nCODE: K21\nDyspepsia with mainly heart burn caused by regurgitation of gastric \ncontents into the lower oesphagus (acid reflux).\nPredisposing factors\n \n~\nHiatus hernia\n \n~\nIncreased intra-abdominal pressure\n \n~\nGastric ulcer\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n413\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Dyspepsia alarm features: requires endoscopy\u2013REFER</p>\n<p>~</p>\n<p>Dysphagia</p>\n<p>~</p>\n<p>Odynophagia (among patients who are HIV negative)</p>\n<p>~</p>\n<p>Weight loss</p>\n<p>~</p>\n<p>Abdominal mass or cervical lymphadenopathy</p>\n<p>~</p>\n<p>Evidence of upper GI bleeding</p>\n<p>~</p>\n<p>Iron deficiency anaemia</p>\n<p>~</p>\n<p>Recurrent vomiting</p>\n<p>~</p>\n<p>Recent dyspeptic symptoms or new dyspepsia in individ\u00ad</p>\n<p>uals over the age of 40 years</p>\n<p>Other indications for endoscopy</p>\n<p>~</p>\n<p>History of long term smoking and alcohol misuse</p>\n<p>~</p>\n<p>Persistent dyspepsia despite appropriate treatment (e.g</p>\n<p>Proton-pump inhibitors in GERD)</p>\n<p>~</p>\n<p>Hepatobiliary disease</p>\n<p>6.3.3</p>\n<p>Gastroesophageal Reflux Disease (GERD/GORD)\t ICD10</p>\n<h3>CODE: K21</h3>\n<p>Dyspepsia with mainly heart burn caused by regurgitation of gastric</p>\n<p>contents into the lower oesphagus (acid reflux).</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>Hiatus hernia</p>\n<p>~</p>\n<p>Increased intra-abdominal pressure</p>\n<p>~</p>\n<p>Gastric ulcer</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>413</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 480,
        "content": "Clinical features\n \n~\nHeartburn: a burning sensation in the chest. Usually \nbrought about by bending or exertion or lying down\n \n~\nUnpleasant sour taste (due to stomach acid reflux)\n \n~\nOesophagitis with pain and difficulty when swallowing\n \n~\nHalitosis, bloating and belching\n \n~\nNausea, chronic pharyngitis\nComplications\n \n~\nDysphagia\n \n~\nReflux asthma\nDifferential diagnosis\n \n~\nPeptic ulcer, gastritis, pancreatitis\nInvestigations\n \n~\nGastroscopy\n \n~\nBarium meal and follow through\nManagement\nLifestyle modifications include the following:\n\t\n\u0089\nLosing weight (if overweight)\n\t\n\u0089\nAvoiding alcohol, chocolate, citrus juice, and tomato-based products \nalso suggest avoiding peppermint, coffee, and possibly the onion \nfamily, spicy foods, food with high fat content, carbonated beverages)\n\t\n\u0089\nAvoiding large meals\n\t\n\u0089\nWaiting 3 hours after a meal before lying down or eating within \n2-3 hours before bedtime should be avoided\n\t\n\u0089\nElevating the head of the bed by 8 inches\n\t\n\u0089\nAvoid tight fitting clothes\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n414\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Heartburn: a burning sensation in the chest. Usually</p>\n<p>brought about by bending or exertion or lying down</p>\n<p>~</p>\n<p>Unpleasant sour taste (due to stomach acid reflux)</p>\n<p>~</p>\n<p>Oesophagitis with pain and difficulty when swallowing</p>\n<p>~</p>\n<p>Halitosis, bloating and belching</p>\n<p>~</p>\n<p>Nausea, chronic pharyngitis</p>\n<p>Complications</p>\n<p>~</p>\n<p>Dysphagia</p>\n<p>~</p>\n<p>Reflux asthma</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Peptic ulcer, gastritis, pancreatitis</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Gastroscopy</p>\n<p>~</p>\n<p>Barium meal and follow through</p>\n<p>Management</p>\n<p>Lifestyle modifications include the following:</p>\n<p>\u0089</p>\n<p>Losing weight (if overweight)</p>\n<p>\u0089</p>\n<p>Avoiding alcohol, chocolate, citrus juice, and tomato-based products</p>\n<p>also suggest avoiding peppermint, coffee, and possibly the onion</p>\n<p>family, spicy foods, food with high fat content, carbonated beverages)</p>\n<p>\u0089</p>\n<p>Avoiding large meals</p>\n<p>\u0089</p>\n<p>Waiting 3 hours after a meal before lying down or eating within</p>\n<p>2-3 hours before bedtime should be avoided</p>\n<p>\u0089</p>\n<p>Elevating the head of the bed by 8 inches</p>\n<p>\u0089</p>\n<p>Avoid tight fitting clothes</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>414</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 481,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nModify diet: avoid precipitating causes  and increase \nmilk intake\n\t\n\u0089\nGive an antacid\nMagnesium trisilicate compound 1-2 tablets every \n8 hours\nHC2\nIf no response and no alarm signs\n\t\n\u0089\nOmeprazole 20 mg once daily for 8 weeks\nIf not responding to 4 weeks of omeprazole, refer \nfor further management\nHC3\n6.3.4 Gastritis\t           ICD10 CODE: K29\nAcute or chronic inflammation of the gastric mucosa.\nCauses\nAcute gastritis\n \n~\nNon-steroidal anti-inflammatory drugs (NSAIDS), e.g. ace\u00ad\ntylsalicylic acid, diclofenac, ibuprofen\n \n~\nAlcohol\n \n~\nRegurgitation of bile into the stomach\nChronic gastritis\n \n~\nAutoimmune gastric ulceration\n \n~\nBacterial infection (Helicobacter pylori)\nClinical features\n \n~\nMay be asymptomatic or have associated anorexia, nausea, \nepigastric pain, and heartburn\nDifferential diagnosis\n \n~\nPancreatitis, cholecystitis\n \n~\nPeptic and duodenal ulcers, cancer of the stomach\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n415\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Modify diet: avoid precipitating causes  and increase</p>\n<p>milk intake</p>\n<p>\u0089</p>\n<p>Give an antacid</p>\n<p>Magnesium trisilicate compound 1-2 tablets every</p>\n<p>8 hours</p>\n<h3>HC2</h3>\n<p>If no response and no alarm signs</p>\n<p>\u0089</p>\n<p>Omeprazole 20 mg once daily for 8 weeks</p>\n<p>If not responding to 4 weeks of omeprazole, refer</p>\n<p>for further management</p>\n<h3>HC3</h3>\n<p>6.3.4 Gastritis\t           ICD10 CODE: K29</p>\n<p>Acute or chronic inflammation of the gastric mucosa.</p>\n<p>Causes</p>\n<p>Acute gastritis</p>\n<p>~</p>\n<p>Non-steroidal anti-inflammatory drugs (NSAIDS), e.g. ace\u00ad</p>\n<p>tylsalicylic acid, diclofenac, ibuprofen</p>\n<p>~</p>\n<p>Alcohol</p>\n<p>~</p>\n<p>Regurgitation of bile into the stomach</p>\n<p>Chronic gastritis</p>\n<p>~</p>\n<p>Autoimmune gastric ulceration</p>\n<p>~</p>\n<p>Bacterial infection (Helicobacter pylori)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>May be asymptomatic or have associated anorexia, nausea,</p>\n<p>epigastric pain, and heartburn</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Pancreatitis, cholecystitis</p>\n<p>~</p>\n<p>Peptic and duodenal ulcers, cancer of the stomach</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>415</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 482,
        "content": "~\nEpigastric hernia\nInvestigations\n \n\u0081\nGastroscopy\n \n\u0081\nStool for occult blood\n \n\u0081\nBarium meal for chronic gastritis\n \n\u0081\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nModify diet: Avoid precipitating causes and increase \nmilk intake\n\t\n\u0089\nGive an antacid\nMagnesium trisilicate compound 2 tablets every 8 \nhours as required\nIf no response\n\t\n\u0089\nOmeprazole 20 mg in the evening for 4 weeks\nIf vomiting\n\t\n\u0089\nMetoclopramide 10 mg IM repeated when necessary \nup to 3 times daily\n\t\n\u0089\nOr chlorpromazine 25 mg deep IM or oral (if tolerated) \nrepeated prn every 4 hours\nHC2\nHC3\nHC4\nCaution\n \n\u0083 Acetylsalicylic acid and other NSAIDS are contraindicated in \npatients with gastritis\nPrevention\n \n~\nAvoid spices, tobacco, alcohol, and carbonated drinks\n \n~\nEncourage regular, small, and frequent meals\n \n~\nEncourage milk intake\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n416\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Epigastric hernia</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Gastroscopy</p>\n<p>\u0081</p>\n<p>Stool for occult blood</p>\n<p>\u0081</p>\n<p>Barium meal for chronic gastritis</p>\n<p>\u0081</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Modify diet: Avoid precipitating causes and increase</p>\n<p>milk intake</p>\n<p>\u0089</p>\n<p>Give an antacid</p>\n<p>Magnesium trisilicate compound 2 tablets every 8</p>\n<p>hours as required</p>\n<p>If no response</p>\n<p>\u0089</p>\n<p>Omeprazole 20 mg in the evening for 4 weeks</p>\n<p>If vomiting</p>\n<p>\u0089</p>\n<p>Metoclopramide 10 mg IM repeated when necessary</p>\n<p>up to 3 times daily</p>\n<p>\u0089</p>\n<p>Or chlorpromazine 25 mg deep IM or oral (if tolerated)</p>\n<p>repeated prn every 4 hours</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>\u0083 Acetylsalicylic acid and other NSAIDS are contraindicated in</p>\n<p>patients with gastritis</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid spices, tobacco, alcohol, and carbonated drinks</p>\n<p>~</p>\n<p>Encourage regular, small, and frequent meals</p>\n<p>~</p>\n<p>Encourage milk intake</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>416</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 483,
        "content": "6.3.5 Peptic Ulcer Disease (PUD)\t                   ICD10 CODE: K27\nUlceration of gastro-duodenal mucosa. It tends to be chronic and recur\u00ad\nrent if untreated.\nCauses\n \n~\nHelicobacter pylori infection\nHyperacidity due to\n \n~\nDrugs (NSAIDS e.g. acetylsalicylic acid, corticosteroids)\n \n~\nIrregular meals\n \n~\nStress\n \n~\nAlcohol and smoking\n \n~\nCaffeine-containing beverages\nClinical features\nGeneral\n \n~\nEpigastric pain typically worse at night and when hungry \n(duodenal ulcer) alleviated by food, milk, or antacid medi\u00ad\ncation\n \n~\nEpigastric pain, worse with food (gastric ulcer)\n \n~\nVomiting, nausea, regurgitation\n \n~\nDiscomfort on palpation of the upper abdomen\nBleeding ulcer\n \n~\nHaematemesis (coffee brown or red vomitus)\n \n~\nBlack stools (i.e. melena)\n \n~\nSudden weakness and dizziness\n \n~\nCold, clammy skin (when patient has lost a lot of blood)\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n417\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>6.3.5 Peptic Ulcer Disease (PUD)\t                   ICD10 CODE: K27</p>\n<p>Ulceration of gastro-duodenal mucosa. It tends to be chronic and recur\u00ad</p>\n<p>rent if untreated.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Helicobacter pylori infection</p>\n<p>Hyperacidity due to</p>\n<p>~</p>\n<p>Drugs (NSAIDS e.g. acetylsalicylic acid, corticosteroids)</p>\n<p>~</p>\n<p>Irregular meals</p>\n<p>~</p>\n<p>Stress</p>\n<p>~</p>\n<p>Alcohol and smoking</p>\n<p>~</p>\n<p>Caffeine-containing beverages</p>\n<p>Clinical features</p>\n<p>General</p>\n<p>~</p>\n<p>Epigastric pain typically worse at night and when hungry</p>\n<p>(duodenal ulcer) alleviated by food, milk, or antacid medi\u00ad</p>\n<p>cation</p>\n<p>~</p>\n<p>Epigastric pain, worse with food (gastric ulcer)</p>\n<p>~</p>\n<p>Vomiting, nausea, regurgitation</p>\n<p>~</p>\n<p>Discomfort on palpation of the upper abdomen</p>\n<p>Bleeding ulcer</p>\n<p>~</p>\n<p>Haematemesis (coffee brown or red vomitus)</p>\n<p>~</p>\n<p>Black stools (i.e. melena)</p>\n<p>~</p>\n<p>Sudden weakness and dizziness</p>\n<p>~</p>\n<p>Cold, clammy skin (when patient has lost a lot of blood)</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>417</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 484,
        "content": "Perforated ulcer\n \n~\nAcute abdominal pain, signs of peritonitis such as rigid ab\u00ad\ndomen\n \n~\nGround coffee-brown vomitus (due to blood)\n \n~\nFever\n \n~\nShock (weak pulse, clammy skin, low blood pressure)\nDifferential diagnosis\n \n~\nPancreatitis, hepatitis\n \n~\nDisease of aorta, myocardial infarction\n \n~\nLung disease (haemoptysis)\nInvestigations\n \n\u0081\nPositive stool antigen for H. pylori. Used for diagnosis and to \nconfirm eradication.\n \n- This test may give false negative if the patient has been taking \nantibiotics or omeprazole in the previous 2 weeks\nSERUM ANTIBODY TEST IS NOT USEFUL FOR DIAGNOSIS \nAND FOLLOW UP\n \n\u0081\nGastroscopy\n \n\u0081\nBiopsy of stomach wall\n \n\u0081\nBarium meal\nTREATMENT\nLOC\n\t\n\u0089\nModify diet: avoid precipitating causes and increase \nmilk intake\n\t\n\u0089\nGive an antacid\n \n- Magnesium trisilicate compound 2 tablets \nevery 8 hours as required\nHC3\nHC4\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n418\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Perforated ulcer</p>\n<p>~</p>\n<p>Acute abdominal pain, signs of peritonitis such as rigid ab\u00ad</p>\n<p>domen</p>\n<p>~</p>\n<p>Ground coffee-brown vomitus (due to blood)</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Shock (weak pulse, clammy skin, low blood pressure)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Pancreatitis, hepatitis</p>\n<p>~</p>\n<p>Disease of aorta, myocardial infarction</p>\n<p>~</p>\n<p>Lung disease (haemoptysis)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Positive stool antigen for H. pylori. Used for diagnosis and to</p>\n<p>confirm eradication.</p>\n<p>- This test may give false negative if the patient has been taking</p>\n<p>antibiotics or omeprazole in the previous 2 weeks</p>\n<h3>SERUM ANTIBODY TEST IS NOT USEFUL FOR DIAGNOSIS</h3>\n<h3>AND FOLLOW UP</h3>\n<p>\u0081</p>\n<p>Gastroscopy</p>\n<p>\u0081</p>\n<p>Biopsy of stomach wall</p>\n<p>\u0081</p>\n<p>Barium meal</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Modify diet: avoid precipitating causes and increase</p>\n<p>milk intake</p>\n<p>\u0089</p>\n<p>Give an antacid</p>\n<p>- Magnesium trisilicate compound 2 tablets</p>\n<p>every 8 hours as required</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>418</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 485,
        "content": "TREATMENT\nLOC\nTreatment for eradication of H. pylori (Triple \ntherapy)\nCombination 1 (First line)\n\t\n\u0089\nAmoxycillin 1 g every 12 hours PLUS metronidazole \n400 mg every 12 hours PLUS omeprazole 20 mg \nevery 12 hours for two weeks\n \n\u0081\nCheck eradication with a stool antigen test after \n4 weeks\nFor bleeding and perforated ulcer\n\t\n\u0089\nRefer patient to hospital immediately for\n \n- IV fluids and blood if necessary\n \n- IV ranitidine 50 mg in 20 ml slowly every 8 \nhours\nHC3\nH\nNote\n \n\u0083 Tinidazole 500 mg every 12 hours can be used instead of \nmetronidazole\n \n\u0083 Confirm eradication with stool antigen test a month after \ncompletion of treatment; test should be negative\n6.3.6\t\nChronic Pancreatitis      ICD10 CODE: K86.0-K86.1\nChronic pancreatitis is a disease of the pancreas in which recurrent \nepisodes of inflammation lead to replacement of the pancreatic paren\u00ad\nchyma with fibrotic connective tissue, formation of calculous and loss \nof duct architecture. This leads to progressive loss of pancreas function.\nCauses\n \n~\nToxic/metabolic: alcohol, tobacco, hypercalcemia, hyper\u00ad\nlipidemia, chronic renal failure\n \n~\nIdiopathic: tropical\n \n~\nGenetic, autoimmune\n \n~\nRecurrent and severe acute pancreatitis\n \n~\nObstructive cancer or anatomical abnormalities\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n419\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment for eradication of H. pylori (Triple</p>\n<p>therapy)</p>\n<p>Combination 1 (First line)</p>\n<p>\u0089</p>\n<p>Amoxycillin 1 g every 12 hours PLUS metronidazole</p>\n<p>400 mg every 12 hours PLUS omeprazole 20 mg</p>\n<p>every 12 hours for two weeks</p>\n<p>\u0081</p>\n<p>Check eradication with a stool antigen test after</p>\n<p>4 weeks</p>\n<p>For bleeding and perforated ulcer</p>\n<p>\u0089</p>\n<p>Refer patient to hospital immediately for</p>\n<p>- IV fluids and blood if necessary</p>\n<p>- IV ranitidine 50 mg in 20 ml slowly every 8</p>\n<p>hours</p>\n<h3>HC3</h3>\n<p>H</p>\n<p>Note</p>\n<p>\u0083 Tinidazole 500 mg every 12 hours can be used instead of</p>\n<p>metronidazole</p>\n<p>\u0083 Confirm eradication with stool antigen test a month after</p>\n<p>completion of treatment; test should be negative</p>\n<p>6.3.6</p>\n<p>Chronic Pancreatitis      ICD10 CODE: K86.0-K86.1</p>\n<p>Chronic pancreatitis is a disease of the pancreas in which recurrent</p>\n<p>episodes of inflammation lead to replacement of the pancreatic paren\u00ad</p>\n<p>chyma with fibrotic connective tissue, formation of calculous and loss</p>\n<p>of duct architecture. This leads to progressive loss of pancreas function.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Toxic/metabolic: alcohol, tobacco, hypercalcemia, hyper\u00ad</p>\n<p>lipidemia, chronic renal failure</p>\n<p>~</p>\n<p>Idiopathic: tropical</p>\n<p>~</p>\n<p>Genetic, autoimmune</p>\n<p>~</p>\n<p>Recurrent and severe acute pancreatitis</p>\n<p>~</p>\n<p>Obstructive cancer or anatomical abnormalities</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>419</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 486,
        "content": "Clinical features\n \n~\nChronic pain: main symptom in chronic pancreatitis\n \n~\nDiarrhoea\n \n~\nLoss of weight\n \n~\nDiabetes mellitus\nComplications of chronic pancreatitis\n \n~\nPseudocysts\n \n~\nStenosis of the pancreatic duct\n \n~\nDuodenal stenosis\n \n~\nVascular complications\n \n~\nCompression of the bile ducts\n \n~\nMalnutrition\n \n~\nIncreased risk of cancer of the pancreas\nInvestigations\n \n\u0081\nBlood: Serum analysis, complete blood count, random blood sugar\n \n\u0081\nRaised pancreatic amylase/lipase > 3 times normal\n \n\u0081\nUltrasound: gallstones, pancreatic oedema, abdominal fluid\n \n\u0081\nLiver function tests: raised liver enzymes\nTREATMENT\nLOC\n\t\n\u0089\nRefer for specialist management\n\t\n\u0089\nUse WHO Pain Analgesic ladder\n\u2013 Pethidine 50-100 mg IM or Tramadol 50-100 \nmg oral or IM as required\n\t\n\u0089\nAvoid alcohol and fatty foods\nRR\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n420\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Chronic pain: main symptom in chronic pancreatitis</p>\n<p>~</p>\n<p>Diarrhoea</p>\n<p>~</p>\n<p>Loss of weight</p>\n<p>~</p>\n<p>Diabetes mellitus</p>\n<p>Complications of chronic pancreatitis</p>\n<p>~</p>\n<p>Pseudocysts</p>\n<p>~</p>\n<p>Stenosis of the pancreatic duct</p>\n<p>~</p>\n<p>Duodenal stenosis</p>\n<p>~</p>\n<p>Vascular complications</p>\n<p>~</p>\n<p>Compression of the bile ducts</p>\n<p>~</p>\n<p>Malnutrition</p>\n<p>~</p>\n<p>Increased risk of cancer of the pancreas</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Serum analysis, complete blood count, random blood sugar</p>\n<p>\u0081</p>\n<p>Raised pancreatic amylase/lipase > 3 times normal</p>\n<p>\u0081</p>\n<p>Ultrasound: gallstones, pancreatic oedema, abdominal fluid</p>\n<p>\u0081</p>\n<p>Liver function tests: raised liver enzymes</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer for specialist management</p>\n<p>\u0089</p>\n<p>Use WHO Pain Analgesic ladder</p>\n<p>\u2013 Pethidine 50-100 mg IM or Tramadol 50-100</p>\n<p>mg oral or IM as required</p>\n<p>\u0089</p>\n<p>Avoid alcohol and fatty foods</p>\n<p>RR</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>420</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 487,
        "content": "6.4 ANORECTAL DISORDERS\n6.4.1 Constipation\t\n               ICD10 CODE: K59.0\nA condition characterised by hardened faeces and difficulty emptying \nthe bowels\nCauses\n \n~\nDietary: lack of roughage, inadequate fluid intake\n \n~\nIn infants: concentrated feeds\n \n~\nLack of exercise, bedridden patient especially in elderly\n \n~\nPregnancy\n \n~\nCertain drugs e.g. narcotic analgesics, antidepressants, di\u00ad\nuretics, antipsychotics, iron\n \n~\nColon or anorectal disorders: stricture, cancer, fissure, \nproctitis , congenital bowel abnormalities, irritable bowel \nsyndrome, volvulus, intussusception\n \n~\nMetabolic: hypercalcemia, diabetes, hypothyroidism\n \n~\nNeurological disorders: spinal cord lesions, stroke, Parkin\u00ad\nsonism\n Clinical features\n \n~\nAbdominal discomfort\n \n~\nSmall hard stools passed irregularly under strain\n \n~\nCan cause haemorrhoids and anal fissure\nAlarm features\n \n~\nSymptoms and signs of intestinal obstruction or acute ab\u00ad\ndomen\n \n~\nConfusion/disorientation\n \n~\nAbnormal vital signs\n \n~\nIron deficiency\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n421\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>6.4 ANORECTAL DISORDERS</h3>\n<p>6.4.1 Constipation</p>\n<h3>ICD10 CODE: K59.0</h3>\n<p>A condition characterised by hardened faeces and difficulty emptying</p>\n<p>the bowels</p>\n<p>Causes</p>\n<p>~</p>\n<p>Dietary: lack of roughage, inadequate fluid intake</p>\n<p>~</p>\n<p>In infants: concentrated feeds</p>\n<p>~</p>\n<p>Lack of exercise, bedridden patient especially in elderly</p>\n<p>~</p>\n<p>Pregnancy</p>\n<p>~</p>\n<p>Certain drugs e.g. narcotic analgesics, antidepressants, di\u00ad</p>\n<p>uretics, antipsychotics, iron</p>\n<p>~</p>\n<p>Colon or anorectal disorders: stricture, cancer, fissure,</p>\n<p>proctitis , congenital bowel abnormalities, irritable bowel</p>\n<p>syndrome, volvulus, intussusception</p>\n<p>~</p>\n<p>Metabolic: hypercalcemia, diabetes, hypothyroidism</p>\n<p>~</p>\n<p>Neurological disorders: spinal cord lesions, stroke, Parkin\u00ad</p>\n<p>sonism</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Abdominal discomfort</p>\n<p>~</p>\n<p>Small hard stools passed irregularly under strain</p>\n<p>~</p>\n<p>Can cause haemorrhoids and anal fissure</p>\n<p>Alarm features</p>\n<p>~</p>\n<p>Symptoms and signs of intestinal obstruction or acute ab\u00ad</p>\n<p>domen</p>\n<p>~</p>\n<p>Confusion/disorientation</p>\n<p>~</p>\n<p>Abnormal vital signs</p>\n<p>~</p>\n<p>Iron deficiency</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>421</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 488,
        "content": "~\nRectal bleeding or haematochesia or rectal mass\n \n~\nHaem postive stool\n \n~\nPatients > 45 years with no previous history of colon can\u00ad\ncer screening\n \n~\nHistory of colon cancer in immediate family relatives\n \n~\nWeight loss\nInvestigations\n \n\u0081\nPhysical examination\n \n- Abdominal mass and tenderness\n \n- Anorectal examination (faecal impaction, stricture, rectal \nprolapse, rectal mass)\n \n\u0081\nStool examination\nInvestigations for patients with alarm features\n \n\u0081\nAbdominal series (supine, upright, left lateral decubitus)\n \n\u0081\nTransabdominal ultrasound\n \n\u0081\nEndoscopy\n \n\u0081\nComplete blood count, renal function tests, serum calcium, \nthyroid function tests, blood sugar\n \n\u0081\nBarium enema +/- CT scan or X-ray\nManagement\nTREATMENT\nLOC\nNo alarm features or chronic constipation\n\t\n\u0089\nHigh dietary fibre\n\t\n\u0089\nAdequate fluid intake\n\t\n\u0089\nBisacodyl: Adult 10 mg at night. Take until stool is \npassed\nChild 5-12 years: 5 mg (suppository only)\n \n- Contraindicated in acute abdomen as it \naggravates the condition\n\t\n\u0089\nOral or rectal lactulose (osmotic agent). Provides \nfaster relief than bisacodyl\nHC2\nHC3\nHC4\nH\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n422\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Rectal bleeding or haematochesia or rectal mass</p>\n<p>~</p>\n<p>Haem postive stool</p>\n<p>~</p>\n<p>Patients > 45 years with no previous history of colon can\u00ad</p>\n<p>cer screening</p>\n<p>~</p>\n<p>History of colon cancer in immediate family relatives</p>\n<p>~</p>\n<p>Weight loss</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Physical examination</p>\n<p>- Abdominal mass and tenderness</p>\n<p>- Anorectal examination (faecal impaction, stricture, rectal</p>\n<p>prolapse, rectal mass)</p>\n<p>\u0081</p>\n<p>Stool examination</p>\n<p>Investigations for patients with alarm features</p>\n<p>\u0081</p>\n<p>Abdominal series (supine, upright, left lateral decubitus)</p>\n<p>\u0081</p>\n<p>Transabdominal ultrasound</p>\n<p>\u0081</p>\n<p>Endoscopy</p>\n<p>\u0081</p>\n<p>Complete blood count, renal function tests, serum calcium,</p>\n<p>thyroid function tests, blood sugar</p>\n<p>\u0081</p>\n<p>Barium enema +/- CT scan or X-ray</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>No alarm features or chronic constipation</p>\n<p>\u0089</p>\n<p>High dietary fibre</p>\n<p>\u0089</p>\n<p>Adequate fluid intake</p>\n<p>\u0089</p>\n<p>Bisacodyl: Adult 10 mg at night. Take until stool is</p>\n<p>passed</p>\n<p>Child 5-12 years: 5 mg (suppository only)</p>\n<p>- Contraindicated in acute abdomen as it</p>\n<p>aggravates the condition</p>\n<p>\u0089</p>\n<p>Oral or rectal lactulose (osmotic agent). Provides</p>\n<p>faster relief than bisacodyl</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>422</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 489,
        "content": "Management\nTREATMENT\nLOC\nIf alarm features or severe chronic constipation \nare present\n\t\n\u0089\nRefer to hospital for specialist management\nHC2\nHC3\nPrevention\n \n~\nDiet rich in roughage - plenty of vegetables and fruit\n \n~\nPlenty of oral fluids with meals\n \n~\nIncreased exercise\n6.4.2\t\nHaemorrhoids (Piles) and Anal Fissures\nICD10 CODE: K64/K60.0-K60.1-K60.2\nHaemorrhoids are swellings in the upper anal canal and lower rectum \ndue to engorgement of veins. May be internal or external. Anal fissure \nis a tear in the lining of the lower rectum.\nCauses\n \n~\nConstipation and straining in defecation\n \n~\nPortal hypertension from any cause\n \n~\nCompression of pelvic veins, e.g. abdominal tumours, \npregnancy\n \n~\nSedentary life style\nClinical features\nHaemorrhoids\n \n~\nPainless rectal bleeding\n \n~\nVisible swelling at the anus or prolapse of the swelling, es\u00ad\npecially at defecation\n \n~\nBlood is usually not mixed with stool but instead coats the \nsurface of the stool or toiletry\n \n~\nMucous discharge and irritation at anus\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n423\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If alarm features or severe chronic constipation</p>\n<p>are present</p>\n<p>\u0089</p>\n<p>Refer to hospital for specialist management</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Diet rich in roughage - plenty of vegetables and fruit</p>\n<p>~</p>\n<p>Plenty of oral fluids with meals</p>\n<p>~</p>\n<p>Increased exercise</p>\n<p>6.4.2</p>\n<p>Haemorrhoids (Piles) and Anal Fissures</p>\n<h3>ICD10 CODE: K64/K60.0-K60.1-K60.2</h3>\n<p>Haemorrhoids are swellings in the upper anal canal and lower rectum</p>\n<p>due to engorgement of veins. May be internal or external. Anal fissure</p>\n<p>is a tear in the lining of the lower rectum.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Constipation and straining in defecation</p>\n<p>~</p>\n<p>Portal hypertension from any cause</p>\n<p>~</p>\n<p>Compression of pelvic veins, e.g. abdominal tumours,</p>\n<p>pregnancy</p>\n<p>~</p>\n<p>Sedentary life style</p>\n<p>Clinical features</p>\n<p>Haemorrhoids</p>\n<p>~</p>\n<p>Painless rectal bleeding</p>\n<p>~</p>\n<p>Visible swelling at the anus or prolapse of the swelling, es\u00ad</p>\n<p>pecially at defecation</p>\n<p>~</p>\n<p>Blood is usually not mixed with stool but instead coats the</p>\n<p>surface of the stool or toiletry</p>\n<p>~</p>\n<p>Mucous discharge and irritation at anus</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>423</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 490,
        "content": "Anal fissure\n \n~\nPain in passing stool\n \n~\nBleeding at passing of stool\nDifferential diagnosis\n \n~\nSchistosomiasis, amoeboma\n \n~\nRectal polyps, prolapsed rectum\n \n~\nAnal tags (harmless growths that hang off the skin around \nthe outside of the anus)\n \n~\nTumour of rectum\n \n~\nAnal warts\nInvestigations\n \n\u0081\nVisual inspection and digital rectal examination\n \n\u0081\nProtoscopy, sigmoidoscopy, colonoscopy\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nEstablish the cause\n\t\n\u0089\nIncrease fibre and fluid diet intake\n\t\n\u0089\nCorrect any constipation\n\t\n\u0089\nSitz bath (sitting for 10-15 minutes in lukewarm water \nwith a spoon of salt) 2 or 3 times a day\n\t\n\u0089\nInsert a bismuth subgallate compound rectally every \n12 hours for 5 days (e.g. Anusol, Sediproct cream \nor suppositories)\nHC2\nHC4\nIf signs of infection:\n\t\n\u0089\nGive metronidazole 400 mg every 8 hours for 5 days\n\t\n\u0089\nGive analgesics as required for the pain\nIf there is no response:\n\t\n\u0089\nRefer to hospital for surgery\nHC2\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n424\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Anal fissure</p>\n<p>~</p>\n<p>Pain in passing stool</p>\n<p>~</p>\n<p>Bleeding at passing of stool</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Schistosomiasis, amoeboma</p>\n<p>~</p>\n<p>Rectal polyps, prolapsed rectum</p>\n<p>~</p>\n<p>Anal tags (harmless growths that hang off the skin around</p>\n<p>the outside of the anus)</p>\n<p>~</p>\n<p>Tumour of rectum</p>\n<p>~</p>\n<p>Anal warts</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Visual inspection and digital rectal examination</p>\n<p>\u0081</p>\n<p>Protoscopy, sigmoidoscopy, colonoscopy</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Establish the cause</p>\n<p>\u0089</p>\n<p>Increase fibre and fluid diet intake</p>\n<p>\u0089</p>\n<p>Correct any constipation</p>\n<p>\u0089</p>\n<p>Sitz bath (sitting for 10-15 minutes in lukewarm water</p>\n<p>with a spoon of salt) 2 or 3 times a day</p>\n<p>\u0089</p>\n<p>Insert a bismuth subgallate compound rectally every</p>\n<p>12 hours for 5 days (e.g. Anusol, Sediproct cream</p>\n<p>or suppositories)</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>If signs of infection:</p>\n<p>\u0089</p>\n<p>Give metronidazole 400 mg every 8 hours for 5 days</p>\n<p>\u0089</p>\n<p>Give analgesics as required for the pain</p>\n<p>If there is no response:</p>\n<p>\u0089</p>\n<p>Refer to hospital for surgery</p>\n<h3>HC2</h3>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>424</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 491,
        "content": "Prevention\n \n~\nMaintain high residue (fibre) diet\n \n~\nEnsure adequate fluid intake\n \n~\nRegular exercise\n \n~\nRefrain from straining and reading in the toilet\n6.5 HEPATIC AND BILIARY DISEASES\n6.5.1 Viral Hepatitis\nA condition characterised by inflammation of the liver due to hepatitis \nviruses. They may cause acute hepatitis, symptomatic or not. The hep\u00ad\natitis B, D, C virus can cause\nchronic hepatitis. The hepatitis B virus can also give chronic carrier status.\nCause\n \n~\nHepatitis A and E: orofaecal transmission\n \n~\nHepatitis B: sexual, mother to child, transmission by infect\u00ad\ned body fluids /blood\n \n~\nHepatitis C virus: contact with infectious blood (possibly \nsexual and vertical)\n \n~\nHepatitis D: contact with infectious blood, sexual (possibly \nvertical)\n \n6.5.1.1\t Acute Hepatitis\tICD10 CODES: B15, B16, B17, B19\nClinical features\n \n~\nAsymptomatic\n \n~\nClassic form: fever, fatigue, malaise, abdominal discomfort \n(right upper quadrant), nausea, diarrhoea, anorexia, fol\u00ad\nlowed by jaundice, dark urine and more or less clay co\u00ad\nloured stool\n \n~\nFulminant form: acute liver failure due to massive liver ne\u00ad\ncrosis, often fatal. It is more common in HepB patients \nwith secondary infection with D virus and pregnant women \nwho get hepatitis E in their third trimester\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n425\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Maintain high residue (fibre) diet</p>\n<p>~</p>\n<p>Ensure adequate fluid intake</p>\n<p>~</p>\n<p>Regular exercise</p>\n<p>~</p>\n<p>Refrain from straining and reading in the toilet</p>\n<h3>6.5 HEPATIC AND BILIARY DISEASES</h3>\n<p>6.5.1 Viral Hepatitis</p>\n<p>A condition characterised by inflammation of the liver due to hepatitis</p>\n<p>viruses. They may cause acute hepatitis, symptomatic or not. The hep\u00ad</p>\n<p>atitis B, D, C virus can cause</p>\n<p>chronic hepatitis. The hepatitis B virus can also give chronic carrier status.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Hepatitis A and E: orofaecal transmission</p>\n<p>~</p>\n<p>Hepatitis B: sexual, mother to child, transmission by infect\u00ad</p>\n<p>ed body fluids /blood</p>\n<p>~</p>\n<p>Hepatitis C virus: contact with infectious blood (possibly</p>\n<p>sexual and vertical)</p>\n<p>~</p>\n<p>Hepatitis D: contact with infectious blood, sexual (possibly</p>\n<p>vertical)</p>\n<p>6.5.1.1\t Acute Hepatitis\tICD10 CODES: B15, B16, B17, B19</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Asymptomatic</p>\n<p>~</p>\n<p>Classic form: fever, fatigue, malaise, abdominal discomfort</p>\n<p>(right upper quadrant), nausea, diarrhoea, anorexia, fol\u00ad</p>\n<p>lowed by jaundice, dark urine and more or less clay co\u00ad</p>\n<p>loured stool</p>\n<p>~</p>\n<p>Fulminant form: acute liver failure due to massive liver ne\u00ad</p>\n<p>crosis, often fatal. It is more common in HepB patients</p>\n<p>with secondary infection with D virus and pregnant women</p>\n<p>who get hepatitis E in their third trimester</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>425</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 492,
        "content": "Differential diagnosis\n \n~\nOther causes of hepatitis, e.g. drugs, herbs, tumours, and \nautoimmune diseases\n \n~\nGastroenteritis, relapsing fever\n \n~\nPancreatitis\n \n~\nMalaria, leptospirosis, yellow fever\n \n~\nHaemorhagic fevers, e.g. Marburg and Ebola\nInvestigations\n \n\u0081\nComplete blood count\n \n\u0081\nSlide or RDT for malaria parasites\n \n\u0081\nLiver function tests\n \n\u0081\nViral antigens and antibodies: Hepatitis B, Hepatitis C, and \nHIV serology\nManagement\nTREATMENT\nLOC\nClassic form\n\t\n\u0089\nSupportive management\n\t\n\u0089\nRest and hydration\n\t\n\u0089\nDiet: high in carbohydrates and vitamins and vegetable \nproteins. Avoid animal proteins e.g. \n\t\n\u0089\nAvoid any drug \u2013 they may aggravate symptoms Refer \nif patient has features of liver failure or decompen\u00ad\nsated liver disease\nHC4\nCaution\n \n\u0083 Avoid drugs generally but especially sedatives and hepatotoxic \ndrugs\n \n\u0083 Ensure effective infection control measures e.g. institute \nbarrier nursing, personal hygiene\n \n\u0083 Patient isolation is not necessary unless there is high suspicion \nof viral haemorrhagic fevers\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n426\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of hepatitis, e.g. drugs, herbs, tumours, and</p>\n<p>autoimmune diseases</p>\n<p>~</p>\n<p>Gastroenteritis, relapsing fever</p>\n<p>~</p>\n<p>Pancreatitis</p>\n<p>~</p>\n<p>Malaria, leptospirosis, yellow fever</p>\n<p>~</p>\n<p>Haemorhagic fevers, e.g. Marburg and Ebola</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Complete blood count</p>\n<p>\u0081</p>\n<p>Slide or RDT for malaria parasites</p>\n<p>\u0081</p>\n<p>Liver function tests</p>\n<p>\u0081</p>\n<p>Viral antigens and antibodies: Hepatitis B, Hepatitis C, and</p>\n<p>HIV serology</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Classic form</p>\n<p>\u0089</p>\n<p>Supportive management</p>\n<p>\u0089</p>\n<p>Rest and hydration</p>\n<p>\u0089</p>\n<p>Diet: high in carbohydrates and vitamins and vegetable</p>\n<p>proteins. Avoid animal proteins e.g.</p>\n<p>\u0089</p>\n<p>Avoid any drug \u2013 they may aggravate symptoms Refer</p>\n<p>if patient has features of liver failure or decompen\u00ad</p>\n<p>sated liver disease</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>\u0083 Avoid drugs generally but especially sedatives and hepatotoxic</p>\n<p>drugs</p>\n<p>\u0083 Ensure effective infection control measures e.g. institute</p>\n<p>barrier nursing, personal hygiene</p>\n<p>\u0083 Patient isolation is not necessary unless there is high suspicion</p>\n<p>of viral haemorrhagic fevers</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>426</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 493,
        "content": "Management\nTREATMENT\nLOC\nClassic form\n\t\n\u0089\nSupportive management\n\t\n\u0089\nRest and hydration\n\t\n\u0089\nDiet: high in carbohydrates and vitamins and vegetable \nproteins. Avoid animal proteins e.g. \n\t\n\u0089\nAvoid any drug \u2013 they may aggravate symptoms Refer \nif patient has features of liver failure or decompen\u00ad\nsated liver disease\nHC4\nCaution\n \n\u0083 Avoid drugs generally but especially sedatives and hepatotoxic \ndrugs\n \n\u0083 Ensure effective infection control measures e.g. institute \nbarrier nursing, personal hygiene\n \n\u0083 Patient isolation is not necessary unless there is high suspicion \nof viral haemorrhagic fevers\nPrevention\n \n~\nHygiene and sanitation\n \n~\nImmunization against hepatitis B (all children, health work\u00ad\ners, household contacts of people with chronic hepatitis B, \nsex workers and other populations at risk)\n \n~\nSafe transfusion practices\n \n~\nInfection control in health facilities\n \n~\nScreening of pregnant women\n \n~\nSafe sexual practices (condom use)\n6.5.1.2\t Chronic Hepatitis                             ICD10 CODE: B18 \nThe hepatitis viruses B, C and D can give chronic infection \nwith chronic low level inflammation of the liver and progressive \ndamage which may progress to liver cirrhosis.\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n427\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Classic form</p>\n<p>\u0089</p>\n<p>Supportive management</p>\n<p>\u0089</p>\n<p>Rest and hydration</p>\n<p>\u0089</p>\n<p>Diet: high in carbohydrates and vitamins and vegetable</p>\n<p>proteins. Avoid animal proteins e.g.</p>\n<p>\u0089</p>\n<p>Avoid any drug \u2013 they may aggravate symptoms Refer</p>\n<p>if patient has features of liver failure or decompen\u00ad</p>\n<p>sated liver disease</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>\u0083 Avoid drugs generally but especially sedatives and hepatotoxic</p>\n<p>drugs</p>\n<p>\u0083 Ensure effective infection control measures e.g. institute</p>\n<p>barrier nursing, personal hygiene</p>\n<p>\u0083 Patient isolation is not necessary unless there is high suspicion</p>\n<p>of viral haemorrhagic fevers</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Hygiene and sanitation</p>\n<p>~</p>\n<p>Immunization against hepatitis B (all children, health work\u00ad</p>\n<p>ers, household contacts of people with chronic hepatitis B,</p>\n<p>sex workers and other populations at risk)</p>\n<p>~</p>\n<p>Safe transfusion practices</p>\n<p>~</p>\n<p>Infection control in health facilities</p>\n<p>~</p>\n<p>Screening of pregnant women</p>\n<p>~</p>\n<p>Safe sexual practices (condom use)</p>\n<p>6.5.1.2\t Chronic Hepatitis                             ICD10 CODE: B18</p>\n<p>The hepatitis viruses B, C and D can give chronic infection</p>\n<p>with chronic low level inflammation of the liver and progressive</p>\n<p>damage which may progress to liver cirrhosis.</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>427</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 494,
        "content": "6.5.2\t\nChronic Hepatitis B Infection       \nICD10 CODES: 18.0, 18.1, 19.1\nClinical features\nCan be symptomatic or asymptomatic:\n \n~\nWeakness and malaise, low grade fever\n \n~\nNausea, loss of appetite and vomiting\n \n~\nPain or tenderness over the right upper abdomen\n \n~\n Jaundice, dark urine, severe pruritus\n \n~\nEnlarged liver\n \n~\nComplications: liver cirrhosis, hepatocarcinoma\nInvestigations\n \n\u0081\nHepatitis B surface antigen positive for >6 months\n \n\u0081\nHepatitis B core antibody: Negative IgM and Positive IgG to \nexclude acute hepatitis B infection\n \n\u0081\nLiver tests, repeated at 6 months\n \n\u0081\nHBeAg (can be positive or negative)\n \n\u0081\nHBV DNA if available\n \n\u0081\nHIV serology\n \n\u0081\nAPRI (AST to Platelets Ratio Index): a marker for fibrosis\nAPRI =\t (AST/ULN) \u00d7 100\nPlatelet count (109/L)\n(ULN: upper limit of normal, usually 40 IU/L)\n \n\u0081\nAlpha fetoprotein at 6 months\n \n\u0081\nAbdominal ultrasound at 4-6 months\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n428\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>6.5.2</p>\n<p>Chronic Hepatitis B Infection</p>\n<h3>ICD10 CODES: 18.0, 18.1, 19.1</h3>\n<p>Clinical features</p>\n<p>Can be symptomatic or asymptomatic:</p>\n<p>~</p>\n<p>Weakness and malaise, low grade fever</p>\n<p>~</p>\n<p>Nausea, loss of appetite and vomiting</p>\n<p>~</p>\n<p>Pain or tenderness over the right upper abdomen</p>\n<p>~</p>\n<p>Jaundice, dark urine, severe pruritus</p>\n<p>~</p>\n<p>Enlarged liver</p>\n<p>~</p>\n<p>Complications: liver cirrhosis, hepatocarcinoma</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Hepatitis B surface antigen positive for >6 months</p>\n<p>\u0081</p>\n<p>Hepatitis B core antibody: Negative IgM and Positive IgG to</p>\n<p>exclude acute hepatitis B infection</p>\n<p>\u0081</p>\n<p>Liver tests, repeated at 6 months</p>\n<p>\u0081</p>\n<p>HBeAg (can be positive or negative)</p>\n<p>\u0081</p>\n<p>HBV DNA if available</p>\n<p>\u0081</p>\n<p>HIV serology</p>\n<p>\u0081</p>\n<p>APRI (AST to Platelets Ratio Index): a marker for fibrosis</p>\n<h3>APRI =\t (AST/ULN) \u00d7 100</h3>\n<p>Platelet count (109/L)</p>\n<p>(ULN: upper limit of normal, usually 40 IU/L)</p>\n<p>\u0081</p>\n<p>Alpha fetoprotein at 6 months</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound at 4-6 months</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>428</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 495,
        "content": "TREATMENT\nLOC\nGeneral principles\n\t\n\u0089\nScreen for HIV: if positive, refer to HIV clinic for ART: \nconinfection is a risk factor for disease progression \nand some ARVs are active against Hepatitis B virus\n\t\n\u0089\nIf HIV negative: refer to a regional hospital for spe\u00ad\ncialist management\n\t\n\u0089\nAntiviral treatment is given to prevent complications \nand it is usually given for life\n\t\n\u0089\nPatients with chronic hepatitis B need periodic \nmonitoring and follow up for life\n\t\n\u0089\nPeriodic screening for hepatocarcinoma with alfa \nfetoprotein and abdominal ultrasound once a year\nRR\nTreat with antivirals if the patient has any one of these:\n \n- All persons with chronic HBV infections who \nhave cirrhosis (whether compensated or not) \nbased on clinical findings and/or APRI score \n>2, irrespective of liver enzyme levels, HbeAg \nstatus or hepatitis B viral load)\n \n- HIV co-infection (use a tenofovir based \ncombination)\n \n- Patients with no cirrhosis (APRI score <2) but\n \n- persistently elevated ALT on 3 occasion within \n6-12 months and viral load >20,000 IU/L (if \navailable) regardless of HbeAg status\n\t\n\u0089\nFirst line antivirals\nAdults and children >12 years or >35 kg: tenofovir\n300 mg once a day\nChild 2-11 years (>10 kg): Entecavir 0.02 mg/kg\nRR\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n429\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General principles</p>\n<p>\u0089</p>\n<p>Screen for HIV: if positive, refer to HIV clinic for ART:</p>\n<p>coninfection is a risk factor for disease progression</p>\n<p>and some ARVs are active against Hepatitis B virus</p>\n<p>\u0089</p>\n<p>If HIV negative: refer to a regional hospital for spe\u00ad</p>\n<p>cialist management</p>\n<p>\u0089</p>\n<p>Antiviral treatment is given to prevent complications</p>\n<p>and it is usually given for life</p>\n<p>\u0089</p>\n<p>Patients with chronic hepatitis B need periodic</p>\n<p>monitoring and follow up for life</p>\n<p>\u0089</p>\n<p>Periodic screening for hepatocarcinoma with alfa</p>\n<p>fetoprotein and abdominal ultrasound once a year</p>\n<p>RR</p>\n<p>Treat with antivirals if the patient has any one of these:</p>\n<p>- All persons with chronic HBV infections who</p>\n<p>have cirrhosis (whether compensated or not)</p>\n<p>based on clinical findings and/or APRI score</p>\n<p>>2, irrespective of liver enzyme levels, HbeAg</p>\n<p>status or hepatitis B viral load)</p>\n<p>- HIV co-infection (use a tenofovir based</p>\n<p>combination)</p>\n<p>- Patients with no cirrhosis (APRI score <2) but</p>\n<p>- persistently elevated ALT on 3 occasion within</p>\n<p>6-12 months and viral load >20,000 IU/L (if</p>\n<p>available) regardless of HbeAg status</p>\n<p>\u0089</p>\n<p>First line antivirals</p>\n<p>Adults and children >12 years or >35 kg: tenofovir</p>\n<p>300 mg once a day</p>\n<p>Child 2-11 years (>10 kg): Entecavir 0.02 mg/kg</p>\n<p>RR</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>429</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 496,
        "content": "TREATMENT\nLOC\nThe following patients should NOT be treated\n\t\n\u0089\nPatients without evidence of cirrhosis (APRI 2) and \nwith persistently normal ALT level and HBV viral \nload < 2000 IU/ml (if available)\nHealth education\n \n~\nMangement is lifelong because of the need to monitor hep\u00ad\natitis\n \n~\nBed rest\n \n~\nUrge patient to avoid alcohol as it worsens disease\n \n~\nImmunisation of household contacts\n \n~\nDo not share items that the patient puts in mouth (e.g.  \ntoothbrushes, cutlery) and razor blades\n 6.5.2.1\t Inactive Hepatitis B Carriers\t\nICD10 CODE: B18.1\nCarriers are patients with chronic but inactive infection:\n \n- HBsAg positive for more than 6 months plus\n \n- Persistently normal liver function (at least 3 times in 12 \nmonths) and\n \n- No evidence of viral replication (negative HBeAg and/or\n \n- HBV DNA < 2000 IU/ml)\nPatients classified as inactive carriers need to be monitored once a year \nwith CBC, renal and liver tests, HBsAg, abdominal ultrasound. If possible, \ndo HBV-DNA every 3 years.\nThey are not highly infectious but close contacts should be immunized \nand appropriate precautions should be followed.\n6.5.2.2\t Pregnant Mother HbsAg Positive        ICD10 CODE: B18.1\nIf a pregnant mother is found HBsAg positive:\n \n~\nIf also HIV positive,\n \n- Start ARVs.\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n430\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>The following patients should NOT be treated</p>\n<p>\u0089</p>\n<p>Patients without evidence of cirrhosis (APRI 2) and</p>\n<p>with persistently normal ALT level and HBV viral</p>\n<p>load < 2000 IU/ml (if available)</p>\n<p>Health education</p>\n<p>~</p>\n<p>Mangement is lifelong because of the need to monitor hep\u00ad</p>\n<p>atitis</p>\n<p>~</p>\n<p>Bed rest</p>\n<p>~</p>\n<p>Urge patient to avoid alcohol as it worsens disease</p>\n<p>~</p>\n<p>Immunisation of household contacts</p>\n<p>~</p>\n<p>Do not share items that the patient puts in mouth (e.g.</p>\n<p>toothbrushes, cutlery) and razor blades</p>\n<p>6.5.2.1\t Inactive Hepatitis B Carriers</p>\n<h3>ICD10 CODE: B18.1</h3>\n<p>Carriers are patients with chronic but inactive infection:</p>\n<p>- HBsAg positive for more than 6 months plus</p>\n<p>- Persistently normal liver function (at least 3 times in 12</p>\n<p>months) and</p>\n<p>- No evidence of viral replication (negative HBeAg and/or</p>\n<p>- HBV DNA < 2000 IU/ml)</p>\n<p>Patients classified as inactive carriers need to be monitored once a year</p>\n<p>with CBC, renal and liver tests, HBsAg, abdominal ultrasound. If possible,</p>\n<p>do HBV-DNA every 3 years.</p>\n<p>They are not highly infectious but close contacts should be immunized</p>\n<p>and appropriate precautions should be followed.</p>\n<p>6.5.2.2\t Pregnant Mother HbsAg Positive        ICD10 CODE: B18.1</p>\n<p>If a pregnant mother is found HBsAg positive:</p>\n<p>~</p>\n<p>If also HIV positive,</p>\n<p>- Start ARVs.</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>430</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 497,
        "content": "- Child should receive HepB vaccine at birth\n \n~\nIf she is HIV negative,\n \n- She should be referred for further testing (HBeAg, HBV \nDNA) to assess the risk of transmission to the baby and \neventual need of antiretrovirals\n \n- Child should be immunized at birth\n \n~\nBreastfeeding is safe\n6.5.3\t\nChronic Hepatitis C Infection        ICD10 CODE: B18.2\nClinical features\n \n~\nCan be symptomatic or asymptomatic\nInvestigation\n \n~\nAnti hepatitis C antibody positive at 0 and 6 months\n \n~\nAbdominal ultrasound\n \n~\nLiver function tests, INR\n \n~\nRenal function tests\n \n~\nBlood glucose\nTREATMENT\nLOC\n\t\n\u0089\nRefer to a regional hospital or higher for confirmatory \ninvestigations and management\nRR\n6.5.4\t\nLiver Cirrhosis\t\nCICD10 CODES: K74, K70.3\nCirrhosis is a chronic disease with necrosis of liver cells followed by \nfibrosis and nodule formation. Decompensated cirrhosis is defined by \nthe presence of complications such as ascites, variceal bleeding, enceph\u00ad\nalopathy, or jaundice which result from the portal hypertension and liver \ninsufficiency caused by cirrhosis.\nCauses\n \n~\nInfections e.g. viral hepatitis B and D, hepatitis C\n \n~\nIntoxication with alcohol, drugs, or toxins e.g. methotrex\u00ad\nate, isoniazid, methyldopa\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n431\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>- Child should receive HepB vaccine at birth</p>\n<p>~</p>\n<p>If she is HIV negative,</p>\n<p>- She should be referred for further testing (HBeAg, HBV</p>\n<p>DNA) to assess the risk of transmission to the baby and</p>\n<p>eventual need of antiretrovirals</p>\n<p>- Child should be immunized at birth</p>\n<p>~</p>\n<p>Breastfeeding is safe</p>\n<p>6.5.3</p>\n<p>Chronic Hepatitis C Infection        ICD10 CODE: B18.2</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Can be symptomatic or asymptomatic</p>\n<p>Investigation</p>\n<p>~</p>\n<p>Anti hepatitis C antibody positive at 0 and 6 months</p>\n<p>~</p>\n<p>Abdominal ultrasound</p>\n<p>~</p>\n<p>Liver function tests, INR</p>\n<p>~</p>\n<p>Renal function tests</p>\n<p>~</p>\n<p>Blood glucose</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to a regional hospital or higher for confirmatory</p>\n<p>investigations and management</p>\n<p>RR</p>\n<p>6.5.4</p>\n<p>Liver Cirrhosis</p>\n<h3>CICD10 CODES: K74, K70.3</h3>\n<p>Cirrhosis is a chronic disease with necrosis of liver cells followed by</p>\n<p>fibrosis and nodule formation. Decompensated cirrhosis is defined by</p>\n<p>the presence of complications such as ascites, variceal bleeding, enceph\u00ad</p>\n<p>alopathy, or jaundice which result from the portal hypertension and liver</p>\n<p>insufficiency caused by cirrhosis.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Infections e.g. viral hepatitis B and D, hepatitis C</p>\n<p>~</p>\n<p>Intoxication with alcohol, drugs, or toxins e.g. methotrex\u00ad</p>\n<p>ate, isoniazid, methyldopa</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>431</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 498,
        "content": "~\nInfiltrative disorders, e.g. non-alcoholic fatty liver disease, \nWilson\u2019s disease, haemochromatosis\n \n~\nIron overload (e.g. in over transfused SCD patients)\n \n~\nImmunological, chronic autoimmune hepatitis\n \n~\n Congestion with bile e.g. primary biliary cirrhosis (PBC)\n \n~\nCongestion with blood e.g. chronic cardiac failure, Budd \nChiari syndrome\n \n~\nIdiopathic\nClinical features\n \n~\nGeneral symptoms: Fatigue, weight loss, features of malnu\u00ad\ntrition, nausea, vomiting and loss of appetite\n \n~\nInitially enlarged liver which later decreases in size\n \n~\nDistension of blood vessels on the abdomen\n \n~\nEnlarged spleen\n \n~\nLoss of libido\n \n~\nCirrhosis is decompensated when the following are present:\n \n~\nJaundice\n \n~\nEncephalopathy\n \n~\nAscites (fluid in abdominal cavity) with or without leg oe\u00ad\ndema\n \n~\nVomiting of blood from ruptured blood vessels in oesoph\u00ad\nagus (varices)\nFirst line anti-TB medication\nStage\nClinical\nDeath At 1 Year\n0\nFibrosis\n1%\n1\nCompensated \ncirrhosis\nNo varices No ascites\n1%\n2\nNo ascites Varices present 3%\n3\nDecom\u00ad\npensated \ncirrhosis\nAscites\n\u00b1 varices\n20%\n4\nBleeding\n\u00b1 ascites\n57%\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n432\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Infiltrative disorders, e.g. non-alcoholic fatty liver disease,</p>\n<p>Wilson\u2019s disease, haemochromatosis</p>\n<p>~</p>\n<p>Iron overload (e.g. in over transfused SCD patients)</p>\n<p>~</p>\n<p>Immunological, chronic autoimmune hepatitis</p>\n<p>~</p>\n<p>Congestion with bile e.g. primary biliary cirrhosis (PBC)</p>\n<p>~</p>\n<p>Congestion with blood e.g. chronic cardiac failure, Budd</p>\n<p>Chiari syndrome</p>\n<p>~</p>\n<p>Idiopathic</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>General symptoms: Fatigue, weight loss, features of malnu\u00ad</p>\n<p>trition, nausea, vomiting and loss of appetite</p>\n<p>~</p>\n<p>Initially enlarged liver which later decreases in size</p>\n<p>~</p>\n<p>Distension of blood vessels on the abdomen</p>\n<p>~</p>\n<p>Enlarged spleen</p>\n<p>~</p>\n<p>Loss of libido</p>\n<p>~</p>\n<p>Cirrhosis is decompensated when the following are present:</p>\n<p>~</p>\n<p>Jaundice</p>\n<p>~</p>\n<p>Encephalopathy</p>\n<p>~</p>\n<p>Ascites (fluid in abdominal cavity) with or without leg oe\u00ad</p>\n<p>dema</p>\n<p>~</p>\n<p>Vomiting of blood from ruptured blood vessels in oesoph\u00ad</p>\n<p>agus (varices)</p>\n<p>First line anti-TB medication</p>\n<p>Stage</p>\n<p>Clinical</p>\n<p>Death At 1 Year</p>\n<p>0</p>\n<p>Fibrosis</p>\n<p>1%</p>\n<p>1</p>\n<p>Compensated</p>\n<p>cirrhosis</p>\n<p>No varices No ascites</p>\n<p>1%</p>\n<p>2</p>\n<p>No ascites Varices present 3%</p>\n<p>3</p>\n<p>Decom\u00ad</p>\n<p>pensated</p>\n<p>cirrhosis</p>\n<p>Ascites</p>\n<p>\u00b1 varices</p>\n<p>20%</p>\n<p>4</p>\n<p>Bleeding</p>\n<p>\u00b1 ascites</p>\n<p>57%</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>432</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 499,
        "content": "First line anti-TB medication\nStage\nClinical\nDeath At 1 Year\nSpontaneous bacterial \nperitonitis + sepsis\nRenal failure Hepatocel\u00ad\nlular carcinoma Jaundice \nHepatic encephalopathy\nDifferential diagnosis\n \n~\nDiffuse hepatic parenchymal disease\n \n~\nMetastatic or multifocal cancer in the liver\n \n~\nHepatic vein obstruction\n \n~\nAny cause of enlarged spleen\n \n~\nHeart failure, renal disease\nInvestigations\n \n\u0081\nBlood: Hb, film, WBC, platelets, prothrombin time (INR), serology \n(hepatitis B, C, and D), HIV serology\n \n\u0081\nStool and urine\n \n\u0081\nAbdominal ultrasound\n \n\u0081\nLiver: Liver function tests, alpha fetoprotein, and biopsy\n\t\n\u0089\nAPRI score >2 is diagnostic\n \n\u0081\nEndoscopy (for varices)\nManagement\nRefer to a regional hospital or higher for the attention of specialist\nTREATMENT\nLOC\nGeneral principles\n\t\n\u0089\nTreat cause and prevent progression\n \n- Stop alcohol\n \n- Appropriate nutrition\n \n- If chronic hepatitis B, start antiviral treatment\n \n- Specific treatment according to the cause\nRR\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n433\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>First line anti-TB medication</p>\n<p>Stage</p>\n<p>Clinical</p>\n<p>Death At 1 Year</p>\n<p>Spontaneous bacterial</p>\n<p>peritonitis + sepsis</p>\n<p>Renal failure Hepatocel\u00ad</p>\n<p>lular carcinoma Jaundice</p>\n<p>Hepatic encephalopathy</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Diffuse hepatic parenchymal disease</p>\n<p>~</p>\n<p>Metastatic or multifocal cancer in the liver</p>\n<p>~</p>\n<p>Hepatic vein obstruction</p>\n<p>~</p>\n<p>Any cause of enlarged spleen</p>\n<p>~</p>\n<p>Heart failure, renal disease</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Hb, film, WBC, platelets, prothrombin time (INR), serology</p>\n<p>(hepatitis B, C, and D), HIV serology</p>\n<p>\u0081</p>\n<p>Stool and urine</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound</p>\n<p>\u0081</p>\n<p>Liver: Liver function tests, alpha fetoprotein, and biopsy</p>\n<p>\u0089</p>\n<p>APRI score >2 is diagnostic</p>\n<p>\u0081</p>\n<p>Endoscopy (for varices)</p>\n<p>Management</p>\n<p>Refer to a regional hospital or higher for the attention of specialist</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General principles</p>\n<p>\u0089</p>\n<p>Treat cause and prevent progression</p>\n<p>- Stop alcohol</p>\n<p>- Appropriate nutrition</p>\n<p>- If chronic hepatitis B, start antiviral treatment</p>\n<p>- Specific treatment according to the cause</p>\n<p>RR</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>433</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 500,
        "content": "TREATMENT\nLOC\n \n- Avoid herbs and self medication\n \n- Use medicines only after prescription from a \nhealth worker\n\t\n\u0089\nManage and prevent complications (see below)\n \n- Ascites\n \n- Encephalopathy\n \n- Bleeding varices\nRR\nGeneral principles\n\t\n\u0089\nTreat cause and prevent progression\n \n- Stop alcohol\n \n- Appropriate nutrition\n \n- If chronic hepatitis B, start antiviral treatment\n \n- Specific treatment according to the cause\n \n- Avoid herbs and self medication\n \n- \u2013\t\nUse medicines only after prescription \nfrom a health worker\n\t\n\u0089\nManage and prevent complications (see below)\n \n- Ascites\n \n- Encephalopathy\n \n- Bleeding varices\nRR\n6.5.4.1 Ascites\t ICD10 CODES: 70.31, 70.11, 71.51\nPathological accumulation of fluid in the peritoneal cavity.\nClinical features\n \n~\nAscites not infected and not associated with hepatorenal \nsyndrome\nCLASSIFICATION\nFEATURES\nGrade 1 Ascites \n(mild)\nOnly detectable by ultrasound exam\u00ad\nination\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n434\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Avoid herbs and self medication</p>\n<p>- Use medicines only after prescription from a</p>\n<p>health worker</p>\n<p>\u0089</p>\n<p>Manage and prevent complications (see below)</p>\n<p>- Ascites</p>\n<p>- Encephalopathy</p>\n<p>- Bleeding varices</p>\n<p>RR</p>\n<p>General principles</p>\n<p>\u0089</p>\n<p>Treat cause and prevent progression</p>\n<p>- Stop alcohol</p>\n<p>- Appropriate nutrition</p>\n<p>- If chronic hepatitis B, start antiviral treatment</p>\n<p>- Specific treatment according to the cause</p>\n<p>- Avoid herbs and self medication</p>\n<p>- \u2013</p>\n<p>Use medicines only after prescription</p>\n<p>from a health worker</p>\n<p>\u0089</p>\n<p>Manage and prevent complications (see below)</p>\n<p>- Ascites</p>\n<p>- Encephalopathy</p>\n<p>- Bleeding varices</p>\n<p>RR</p>\n<p>6.5.4.1 Ascites\t ICD10 CODES: 70.31, 70.11, 71.51</p>\n<p>Pathological accumulation of fluid in the peritoneal cavity.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Ascites not infected and not associated with hepatorenal</p>\n<p>syndrome</p>\n<h3>CLASSIFICATION</h3>\n<h3>FEATURES</h3>\n<p>Grade 1 Ascites</p>\n<p>(mild)</p>\n<p>Only detectable by ultrasound exam\u00ad</p>\n<p>ination</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>434</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 501,
        "content": "CLASSIFICATION\nFEATURES\nGrade 2 Ascites \n(moderate)\nAscites causing moderate symmetrical \ndistension of the abdomen\nGrade 3 Ascites \n(severe)\nAscites causing marked abdominal dis\u00ad\ntension\nClinical diagnosis\n \n~\nFluid thrill (fluid wave)\n \n~\nShifting dullness\nInvestigations\n \n\u0081\nAbdominal ultrasound scan\n \n\u0081\nPeritoneal tap (paracentesis)\n \n\u0081\nAnalysis of fluid\nManagement\nThe main principles of management are: diet modification, daily mon\u00ad\nitoring, diuretics and drainage\nTREATMENT\nLOC\nDiet\n\t\n\u0089\nRestrict dietary salt to a no-add or low salt diet\n\t\n\u0089\nAvoid protein malnutrition (associated with higher \nmortality), so consume plant proteins liberally and \nanimal proteins occasionally (titrate to symptoms and \nsigns of hepatic encephalopathy)\n\t\n\u0089\nRestrict water if oedema and hyponatremia are present\n\t\n\u0089\nAbstain from alcohol, NSAIDS, herbs\nDaily monitoring\n\t\n\u0089\nDaily weight, BP, pulse, stool for melaena, enceph\u00ad\nalopathy\nH\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n435\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>CLASSIFICATION</h3>\n<h3>FEATURES</h3>\n<p>Grade 2 Ascites</p>\n<p>(moderate)</p>\n<p>Ascites causing moderate symmetrical</p>\n<p>distension of the abdomen</p>\n<p>Grade 3 Ascites</p>\n<p>(severe)</p>\n<p>Ascites causing marked abdominal dis\u00ad</p>\n<p>tension</p>\n<p>Clinical diagnosis</p>\n<p>~</p>\n<p>Fluid thrill (fluid wave)</p>\n<p>~</p>\n<p>Shifting dullness</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound scan</p>\n<p>\u0081</p>\n<p>Peritoneal tap (paracentesis)</p>\n<p>\u0081</p>\n<p>Analysis of fluid</p>\n<p>Management</p>\n<p>The main principles of management are: diet modification, daily mon\u00ad</p>\n<p>itoring, diuretics and drainage</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Diet</p>\n<p>\u0089</p>\n<p>Restrict dietary salt to a no-add or low salt diet</p>\n<p>\u0089</p>\n<p>Avoid protein malnutrition (associated with higher</p>\n<p>mortality), so consume plant proteins liberally and</p>\n<p>animal proteins occasionally (titrate to symptoms and</p>\n<p>signs of hepatic encephalopathy)</p>\n<p>\u0089</p>\n<p>Restrict water if oedema and hyponatremia are present</p>\n<p>\u0089</p>\n<p>Abstain from alcohol, NSAIDS, herbs</p>\n<p>Daily monitoring</p>\n<p>\u0089</p>\n<p>Daily weight, BP, pulse, stool for melaena, enceph\u00ad</p>\n<p>alopathy</p>\n<p>H</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>435</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 502,
        "content": "TREATMENT\nLOC\nDiuretics\n\t\n\u0089\nUse spironolactone 50-100 mg/day in the morning, \nto reach goal of weight loss: 300\u2013500 g/ day. If \nneeded, doses to be increased every 7 days up to \nmaximum of 400 mg/day of spironolactone\n\t\n\u0089\nFurosemide can be added at a starting dose of 20\u201340 \nmg/day and subsequently increased to 160 mg/day \nif needed. Best used if pedal oedema is present; \nmonitor for hypotension\n\t\n\u0089\nFor maintenance, it is best to titrate to the lowest \ndiuretic dose. Most patients do well with\nspironolactone 50 mg/day if they have no ascites\nDrainage\n\t\n\u0089\nIndicated for severe ascites (Grade 3). Paracentesis \nis always followed by spironolactone\nHow much should you tap?\n \n- Small volume (less than 5 L in 3\u20134 hours) \nor large volume (5\u201310 L) with infusion of a \nplasma expander (e.g. 8 g albumin per litre of \nascites removed)\n \n- Monitor for hypotension or reduced urine \noutput\n\t\n\u0089\nRefer if patient has or develops complicated ascites\n6.5.4.2\t Spontaneous Bacterial Peritonitis (SBP) \n ICD10 CODE: K65.2\nSBP is an acute bacterial infection of ascitic fluid. It is a common and \nsevere complication of advanced liver cirrhosis and it is associated with \na poor prognosis.\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n436\nUganda Clinical Guidelines 2023",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Diuretics</p>\n<p>\u0089</p>\n<p>Use spironolactone 50-100 mg/day in the morning,</p>\n<p>to reach goal of weight loss: 300\u2013500 g/ day. If</p>\n<p>needed, doses to be increased every 7 days up to</p>\n<p>maximum of 400 mg/day of spironolactone</p>\n<p>\u0089</p>\n<p>Furosemide can be added at a starting dose of 20\u201340</p>\n<p>mg/day and subsequently increased to 160 mg/day</p>\n<p>if needed. Best used if pedal oedema is present;</p>\n<p>monitor for hypotension</p>\n<p>\u0089</p>\n<p>For maintenance, it is best to titrate to the lowest</p>\n<p>diuretic dose. Most patients do well with</p>\n<p>spironolactone 50 mg/day if they have no ascites</p>\n<p>Drainage</p>\n<p>\u0089</p>\n<p>Indicated for severe ascites (Grade 3). Paracentesis</p>\n<p>is always followed by spironolactone</p>\n<p>How much should you tap?</p>\n<p>- Small volume (less than 5 L in 3\u20134 hours)</p>\n<p>or large volume (5\u201310 L) with infusion of a</p>\n<p>plasma expander (e.g. 8 g albumin per litre of</p>\n<p>ascites removed)</p>\n<p>- Monitor for hypotension or reduced urine</p>\n<p>output</p>\n<p>\u0089</p>\n<p>Refer if patient has or develops complicated ascites</p>\n<p>6.5.4.2\t Spontaneous Bacterial Peritonitis (SBP)</p>\n<h3>ICD10 CODE: K65.2</h3>\n<p>SBP is an acute bacterial infection of ascitic fluid. It is a common and</p>\n<p>severe complication of advanced liver cirrhosis and it is associated with</p>\n<p>a poor prognosis.</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>436</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 503,
        "content": "Clinical features\nPatients must be admitted to hospital and should be suspected of SBP \ninfection when:\n \n~\nAscites increases in severity\n \n~\nPresence of fever\n \n~\nAbdominal pain, abdominal tenderness\n \n~\nWorsening encephalopathy\n \n~\nComplications: renal failure, bleeding varices, death\nInvestigations\n \n\u0081\nDiagnosis is confirmed by an ascitic tap and cell counts. A neu\u00ad\ntrophil count of > 250/mm3 in ascitic fluid confirms the diagnosis\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat with IV antibiotics for 5\u201310 days\n\t\n\u0089\nIV ceftriaxone 1-2 g daily\n \n- If needed, add metronidazole 500 mg IV every \n8 hours\nH\n\t\n\u0089\nGive albumin infusion 1 g/kg to prevent hepato- \nrenal syndrome\n\t\n\u0089\nConsult or refer for specialist care as soon as possible\nRR\nCaution\n \n\u0083 Avoid gentamicin and NSAIDs\n6.5.4.3\t Hepatic Encephalopathy (HE) \nICD10 CODES: 70.41, 71.11, 72.11, 72.91\nHepatic encephalopathy is a syndrome of neuropsychiatric symptoms and \nsigns, including coma, observed in patients with cirrhosis. It is probably \ndue to the accumulation of toxins in the blood.\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n437\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Clinical features</p>\n<p>Patients must be admitted to hospital and should be suspected of SBP</p>\n<p>infection when:</p>\n<p>~</p>\n<p>Ascites increases in severity</p>\n<p>~</p>\n<p>Presence of fever</p>\n<p>~</p>\n<p>Abdominal pain, abdominal tenderness</p>\n<p>~</p>\n<p>Worsening encephalopathy</p>\n<p>~</p>\n<p>Complications: renal failure, bleeding varices, death</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is confirmed by an ascitic tap and cell counts. A neu\u00ad</p>\n<p>trophil count of > 250/mm3 in ascitic fluid confirms the diagnosis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat with IV antibiotics for 5\u201310 days</p>\n<p>\u0089</p>\n<p>IV ceftriaxone 1-2 g daily</p>\n<p>- If needed, add metronidazole 500 mg IV every</p>\n<p>8 hours</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Give albumin infusion 1 g/kg to prevent hepato-</p>\n<p>renal syndrome</p>\n<p>\u0089</p>\n<p>Consult or refer for specialist care as soon as possible</p>\n<p>RR</p>\n<p>Caution</p>\n<p>\u0083 Avoid gentamicin and NSAIDs</p>\n<p>6.5.4.3\t Hepatic Encephalopathy (HE)</p>\n<h3>ICD10 CODES: 70.41, 71.11, 72.11, 72.91</h3>\n<p>Hepatic encephalopathy is a syndrome of neuropsychiatric symptoms and</p>\n<p>signs, including coma, observed in patients with cirrhosis. It is probably</p>\n<p>due to the accumulation of toxins in the blood.</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>437</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 504,
        "content": "6.5.4.3\t Hepatic Encephalopathy (HE) \nICD10 CODES: 70.41, 71.11, 72.11, 72.91\nHepatic encephalopathy is a syndrome of neuropsychiatric symptoms and \nsigns, including coma, observed in patients with cirrhosis. It is probably \ndue to the accumulation of toxins in the blood.\nClinical features\n \n~\nGrade 0: Subclinical \u2013 personaity changes, construction \napraxia (inability or difficulty to build, assemble, or draw \nobjects)\n \n~\nGrade I: Confusion, flap tremor\n \n~\nGrade II: Drowsy\n \n~\nGrade III: Stuporous\n \n~\nGrade IV: Coma\n \n~\nEncephalopathy may be aggravated by surgery, parencen\u00ad\ntsis, excessive diuretics, sedatives, and opioid analgesics\n \n~\nIntracranial hypertension and sepsis are the main causes \nof death\nManagement\nManagement involves addressing the pathophysiological mechanisms \nrelated to brain, gut and liver\nManagement of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\ndentify and correct precipitating factors including renal \nimpairment, gastrointestinal bleeding, infections, and \nelectrolyte disturbances\n\t\n\u0089\nEmpty the gut\n \n- Give oral lactulose 15-30 mL every 8 hours until \nthe condition resolves (aim at 2-3 soft stools/\nday)\nH\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n438\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>6.5.4.3\t Hepatic Encephalopathy (HE)</p>\n<h3>ICD10 CODES: 70.41, 71.11, 72.11, 72.91</h3>\n<p>Hepatic encephalopathy is a syndrome of neuropsychiatric symptoms and</p>\n<p>signs, including coma, observed in patients with cirrhosis. It is probably</p>\n<p>due to the accumulation of toxins in the blood.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Grade 0: Subclinical \u2013 personaity changes, construction</p>\n<p>apraxia (inability or difficulty to build, assemble, or draw</p>\n<p>objects)</p>\n<p>~</p>\n<p>Grade I: Confusion, flap tremor</p>\n<p>~</p>\n<p>Grade II: Drowsy</p>\n<p>~</p>\n<p>Grade III: Stuporous</p>\n<p>~</p>\n<p>Grade IV: Coma</p>\n<p>~</p>\n<p>Encephalopathy may be aggravated by surgery, parencen\u00ad</p>\n<p>tsis, excessive diuretics, sedatives, and opioid analgesics</p>\n<p>~</p>\n<p>Intracranial hypertension and sepsis are the main causes</p>\n<p>of death</p>\n<p>Management</p>\n<p>Management involves addressing the pathophysiological mechanisms</p>\n<p>related to brain, gut and liver</p>\n<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>dentify and correct precipitating factors including renal</p>\n<p>impairment, gastrointestinal bleeding, infections, and</p>\n<p>electrolyte disturbances</p>\n<p>\u0089</p>\n<p>Empty the gut</p>\n<p>- Give oral lactulose 15-30 mL every 8 hours until</p>\n<p>the condition resolves (aim at 2-3 soft stools/</p>\n<p>day)</p>\n<p>H</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>438</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 505,
        "content": "Management of pneumonia\nTREATMENT\nLOC\n \n- Lactulose can be administered through a \nnasogastric tube (grade 1 and 2) or as an enema \nin patients with acute HE (grade 3 and 4)\n\t\n\u0089\nRefer to a specialist\nIf referral delays\n\t\n\u0089\nGive an antibiotic with a local action on the gut: oral \nmetronidazole 400\u2013800 mg every 8 hours for 5 days\n\t\n\u0089\nOr oral paromomycin 1000 mg every 6 hours for 5 days\nRR\nManagement of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\nScreen patients with liver cirrhosis with endoscopy to \nassess for presence of varices\n\t\n\u0089\nIn case of varices, consider the use of beta blockers to \nprevent bleeding\n \n- Propranolol 20 mg every 12 hours, titrate to \nkeep resting heart rate at 55-60 bpm\n \n- Avoid in refractery ascitis and SBP\nH\n\t\n\u0089\nEndoscopic ligation sclerotherapy\n\t\n\u0089\nIf acute bleeding, see section 6.1.3\nNR\n6.5.4.2\t Oesophageal Varices\t\nICD10 CODE: I85.1 \nExtremely dilated sub-mucosal veins in  the  lower  third  of the eso\u00ad\nphagus, due to portal hypertension caused by liver cirrhosis. They can \ncause severe upper gastrointestinal bleeding.\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n439\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Lactulose can be administered through a</p>\n<p>nasogastric tube (grade 1 and 2) or as an enema</p>\n<p>in patients with acute HE (grade 3 and 4)</p>\n<p>\u0089</p>\n<p>Refer to a specialist</p>\n<p>If referral delays</p>\n<p>\u0089</p>\n<p>Give an antibiotic with a local action on the gut: oral</p>\n<p>metronidazole 400\u2013800 mg every 8 hours for 5 days</p>\n<p>\u0089</p>\n<p>Or oral paromomycin 1000 mg every 6 hours for 5 days</p>\n<p>RR</p>\n<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Screen patients with liver cirrhosis with endoscopy to</p>\n<p>assess for presence of varices</p>\n<p>\u0089</p>\n<p>In case of varices, consider the use of beta blockers to</p>\n<p>prevent bleeding</p>\n<p>- Propranolol 20 mg every 12 hours, titrate to</p>\n<p>keep resting heart rate at 55-60 bpm</p>\n<p>- Avoid in refractery ascitis and SBP</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Endoscopic ligation sclerotherapy</p>\n<p>\u0089</p>\n<p>If acute bleeding, see section 6.1.3</p>\n<p>NR</p>\n<p>6.5.4.2\t Oesophageal Varices</p>\n<h3>ICD10 CODE: I85.1</h3>\n<p>Extremely dilated sub-mucosal veins in  the  lower  third  of the eso\u00ad</p>\n<p>phagus, due to portal hypertension caused by liver cirrhosis. They can</p>\n<p>cause severe upper gastrointestinal bleeding.</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>439</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 506,
        "content": "6.5.4.3\t Hepatorenal Syndrome\t       ICD10 CODE: K76.7 \nHepatorenal syndrome (HRS) is the development of renal failure in \npatients with advanced chronic liver disease. It\ncan be precipitated by infection (SBP) and large volume paracentesis \nwithout albumin replacement. It carries a very poor prognosis.\nIt is characterized by:\n\t\n\u0089\nReduced urinary output (< 500 ml in 24 hours in adults)\n\t\n\u0089\nAbnormal renal function test (progressively raising creatinine)\n\t\n\u0089\nNormal urine sediment\nManagement of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\nCorrect hypovolemia\n\t\n\u0089\nTreat precipitating factors\n\t\n\u0089\nRefer for specialised management\nH\n6.5.4.4\t Hepatocellular Carcinoma\t\nICD10 CODE: C22.0 \nLiver cancer usually in patients with risk factors such as Hepatitis B and \nC, aflatoxin, alcoholic liver disease and cirrhosis.\nClinical features\n \n~\nPresents with right upper quadrant pain, hepatomegaly \nwith or without splenomegaly\n \n~\nWeight loss\n \n~\nJaundice, ascites, and lymphadenopathy\nDifferential diagnosis\n \n~\nLiver metastasis\n \n~\nLiver abscess, hydatid cyst\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n440\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>6.5.4.3\t Hepatorenal Syndrome\t       ICD10 CODE: K76.7</p>\n<p>Hepatorenal syndrome (HRS) is the development of renal failure in</p>\n<p>patients with advanced chronic liver disease. It</p>\n<p>can be precipitated by infection (SBP) and large volume paracentesis</p>\n<p>without albumin replacement. It carries a very poor prognosis.</p>\n<p>It is characterized by:</p>\n<p>\u0089</p>\n<p>Reduced urinary output (< 500 ml in 24 hours in adults)</p>\n<p>\u0089</p>\n<p>Abnormal renal function test (progressively raising creatinine)</p>\n<p>\u0089</p>\n<p>Normal urine sediment</p>\n<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Correct hypovolemia</p>\n<p>\u0089</p>\n<p>Treat precipitating factors</p>\n<p>\u0089</p>\n<p>Refer for specialised management</p>\n<p>H</p>\n<p>6.5.4.4\t Hepatocellular Carcinoma</p>\n<h3>ICD10 CODE: C22.0</h3>\n<p>Liver cancer usually in patients with risk factors such as Hepatitis B and</p>\n<p>C, aflatoxin, alcoholic liver disease and cirrhosis.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Presents with right upper quadrant pain, hepatomegaly</p>\n<p>with or without splenomegaly</p>\n<p>~</p>\n<p>Weight loss</p>\n<p>~</p>\n<p>Jaundice, ascites, and lymphadenopathy</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Liver metastasis</p>\n<p>~</p>\n<p>Liver abscess, hydatid cyst</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>440</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 507,
        "content": "Investigations\n \n\u0081\nAbdominal ultrasound ( sonogram)\n \n\u0081\nAlpha fetoprotein\n \n\u0081\nLiver tests\n \n\u0081\nLiver biopsy\nManagement of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\nRefer to a regional hospital or higher\nRR\n6.5.5\t\nHepatic Schistosomiasis\t\nICD10 CODE: B65.1\nMost common cause of liver disease among communities where Schis\u00ad\ntosoma mansoni is endemic (see section 2)\nCause\n \n~\nInflammatory and fibrotic reaction to eggs laid by Schis\u00ad\ntosoma parasites and transported to the liver through the \nveins from the intestine\nClinical features\n \n~\nUpper gastrointestinal bleeding due to varices or portal hy\u00ad\npertensive gastropathy\n \n~\nSplenomegaly and ruptured spleen\n \n~\nThrombocytopenia\n \n~\nPortal vein thrombosis\n \n~\nBloody diarrhoea, anaemia and stunting\nInvestigations\n \n\u0081\nLiver ultrasound features: periportal fibrosis patterns and por\u00ad\ntal vein thickening as described by World Health Organization \nNiamey ultrasound protocol\n \n\u0081\nScreen for varices with endoscopy\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n441\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound ( sonogram)</p>\n<p>\u0081</p>\n<p>Alpha fetoprotein</p>\n<p>\u0081</p>\n<p>Liver tests</p>\n<p>\u0081</p>\n<p>Liver biopsy</p>\n<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to a regional hospital or higher</p>\n<p>RR</p>\n<p>6.5.5</p>\n<p>Hepatic Schistosomiasis</p>\n<h3>ICD10 CODE: B65.1</h3>\n<p>Most common cause of liver disease among communities where Schis\u00ad</p>\n<p>tosoma mansoni is endemic (see section 2)</p>\n<p>Cause</p>\n<p>~</p>\n<p>Inflammatory and fibrotic reaction to eggs laid by Schis\u00ad</p>\n<p>tosoma parasites and transported to the liver through the</p>\n<p>veins from the intestine</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Upper gastrointestinal bleeding due to varices or portal hy\u00ad</p>\n<p>pertensive gastropathy</p>\n<p>~</p>\n<p>Splenomegaly and ruptured spleen</p>\n<p>~</p>\n<p>Thrombocytopenia</p>\n<p>~</p>\n<p>Portal vein thrombosis</p>\n<p>~</p>\n<p>Bloody diarrhoea, anaemia and stunting</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Liver ultrasound features: periportal fibrosis patterns and por\u00ad</p>\n<p>tal vein thickening as described by World Health Organization</p>\n<p>Niamey ultrasound protocol</p>\n<p>\u0081</p>\n<p>Screen for varices with endoscopy</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>441</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 508,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nRefer to a specialist\n\t\n\u0089\nPraziquantel 40 mg/kg single dose if schistosoma eggs \nare detected\n\t\n\u0089\nCorrect anaemia as appropriate\n\t\n\u0089\nSurveillance for oesophageal varices with endoscopy\n\t\n\u0089\nPrimary and secondary prevention of bleeding oesoph\u00ad\nageal varices with propranolol (see section 6.5.4.4), \nendoscopic band ligation\n\t\n\u0089\nTreat acute upper gastrointestinal bleeding (see section \non 6.1.3)\nHC4\nHC4 \nRR\n6.5.6\t\nDrug-Induced Liver Injury\t\nICD10 CODE: K71\nDrugs are an important and common cause of liver injury. Many med\u00ad\nicines and herbs are known to cause liver damage. The drug-induced \nliver injury can range from asymptomatic elevation of liver enzymes to \nsevere hepatic failure. Health workers must be vigilant in identifying \ndrug-related liver injury because early detection can decrease the severity \nof hepatotoxicity if the drug is discontinued. Knowledge of the commonly \nimplicated agents is essential in diagnosis.\nCommon causes\n \n~\nPhenytoin, carbamazepine, anti-tuberculosis drugs, cotri\u00ad\nmoxazole, diclofenac, paracetamol, antiretroviral drugs, \nketoconazole\nClinical features\nIt is a diagnosis of exclusion:\n \n~\nAny patient with liver enzyme elevation that cannot be at\u00ad\ntributed to infections, autoimmune disease or malignancy\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n442\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to a specialist</p>\n<p>\u0089</p>\n<p>Praziquantel 40 mg/kg single dose if schistosoma eggs</p>\n<p>are detected</p>\n<p>\u0089</p>\n<p>Correct anaemia as appropriate</p>\n<p>\u0089</p>\n<p>Surveillance for oesophageal varices with endoscopy</p>\n<p>\u0089</p>\n<p>Primary and secondary prevention of bleeding oesoph\u00ad</p>\n<p>ageal varices with propranolol (see section 6.5.4.4),</p>\n<p>endoscopic band ligation</p>\n<p>\u0089</p>\n<p>Treat acute upper gastrointestinal bleeding (see section</p>\n<p>on 6.1.3)</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>RR</p>\n<p>6.5.6</p>\n<p>Drug-Induced Liver Injury</p>\n<h3>ICD10 CODE: K71</h3>\n<p>Drugs are an important and common cause of liver injury. Many med\u00ad</p>\n<p>icines and herbs are known to cause liver damage. The drug-induced</p>\n<p>liver injury can range from asymptomatic elevation of liver enzymes to</p>\n<p>severe hepatic failure. Health workers must be vigilant in identifying</p>\n<p>drug-related liver injury because early detection can decrease the severity</p>\n<p>of hepatotoxicity if the drug is discontinued. Knowledge of the commonly</p>\n<p>implicated agents is essential in diagnosis.</p>\n<p>Common causes</p>\n<p>~</p>\n<p>Phenytoin, carbamazepine, anti-tuberculosis drugs, cotri\u00ad</p>\n<p>moxazole, diclofenac, paracetamol, antiretroviral drugs,</p>\n<p>ketoconazole</p>\n<p>Clinical features</p>\n<p>It is a diagnosis of exclusion:</p>\n<p>~</p>\n<p>Any patient with liver enzyme elevation that cannot be at\u00ad</p>\n<p>tributed to infections, autoimmune disease or malignancy</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>442</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 509,
        "content": "Management of pneumonia\nTREATMENT\nLOC\n\t\n\u0089\nStop all drugs or herbs\n\t\n\u0089\nGive supportive care: rehydration\n\t\n\u0089\nSee section 1.3.5 for paracetamol poisoning\n\t\n\u0089\nDo not give the drug again (do not rechallenge!)\n\t\n\u0089\nRefer to a regional hospital or higher for attention of \na specialist\nH\n \n~\nPatient exposed to a drug or herbal medication known to \ncause liver cell injury\n \n~\nPatients may present with skin or mucosal drug reactions\n \n~\ne.g. Stevens-Johnson syndrome or toxic epidermal necrol\u00ad\nsis\n6.5.7\t\nJaundice (Hyperbilirubinemia)      ICD10 CODE: R17\nYellowish discoloration of sclera and skin due to raised levels of bilirubin \nin the body. Bilirubin is a by-product of red cell breakdown, processed \nin the liver and excreted mainly in bile. Jaundice may be benign or life \nthreatening.\nCauses\n \n~\nPre hepatic \u2013 haemolysis e.g sepsis, sickle cell disease, \npregnancy (HELLP syndrome), disseminated intravascular \ncoagulation (DIC), vascular\n \n~\nHepatic \u2013 hepatitis, drugs, tumors, alcohol, toxins, herbs, \nautoimmune disease, pregnancy, cholangitis\n \n~\nPost hepatic \u2013 gall stones, strictures, tumors, surgery, pan\u00ad\ncreatitis, biliary disease\nComplications\n \n~\nRenal failure , coagulopathy\n \n~\nSepsis\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n443\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management of pneumonia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stop all drugs or herbs</p>\n<p>\u0089</p>\n<p>Give supportive care: rehydration</p>\n<p>\u0089</p>\n<p>See section 1.3.5 for paracetamol poisoning</p>\n<p>\u0089</p>\n<p>Do not give the drug again (do not rechallenge!)</p>\n<p>\u0089</p>\n<p>Refer to a regional hospital or higher for attention of</p>\n<p>a specialist</p>\n<p>H</p>\n<p>~</p>\n<p>Patient exposed to a drug or herbal medication known to</p>\n<p>cause liver cell injury</p>\n<p>~</p>\n<p>Patients may present with skin or mucosal drug reactions</p>\n<p>~</p>\n<p>e.g. Stevens-Johnson syndrome or toxic epidermal necrol\u00ad</p>\n<p>sis</p>\n<p>6.5.7</p>\n<p>Jaundice (Hyperbilirubinemia)      ICD10 CODE: R17</p>\n<p>Yellowish discoloration of sclera and skin due to raised levels of bilirubin</p>\n<p>in the body. Bilirubin is a by-product of red cell breakdown, processed</p>\n<p>in the liver and excreted mainly in bile. Jaundice may be benign or life</p>\n<p>threatening.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Pre hepatic \u2013 haemolysis e.g sepsis, sickle cell disease,</p>\n<p>pregnancy (HELLP syndrome), disseminated intravascular</p>\n<p>coagulation (DIC), vascular</p>\n<p>~</p>\n<p>Hepatic \u2013 hepatitis, drugs, tumors, alcohol, toxins, herbs,</p>\n<p>autoimmune disease, pregnancy, cholangitis</p>\n<p>~</p>\n<p>Post hepatic \u2013 gall stones, strictures, tumors, surgery, pan\u00ad</p>\n<p>creatitis, biliary disease</p>\n<p>Complications</p>\n<p>~</p>\n<p>Renal failure , coagulopathy</p>\n<p>~</p>\n<p>Sepsis</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>443</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 510,
        "content": "~\nInvestigations\n \n~\nLiver function tests (AST, ALT, bilirubin), Coomb\u2019s tests, \nlow haptoglobin, LDH\n \n~\nHepatitis A, B, C\n \n~\nMalaria, sickle cell screen\n \n~\nUltrasound shows dilated bile ducts and gall bladder\n \n~\nCBC, INR, RFTS, LDH, Endoscopic retrograde cholan\u00ad\ngiopancreatogram (ERCP)\n \n~\nLiver biopsy\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer and/or consult as appropriate \n\t\n\u0089\nTreat  the  underlying   cause f Discontinue offfending \nfactors\n\t\n\u0089\nUse phototherapy with UV light for newborn babies \nOR expose the newborn to natural sun\nH\n6.5.8\t\nGallstones/Biliary Colic\t ICD10 CODES: K80 \nSmall hard masses formed in the gallbladder or biliary tree. \nRisk factors\n \n~\nAge, gender, family history\n \n~\nObesity, diabetes, use of oral contraceptives, dyslipidemia\nClinical features\n \n~\nAsymptomatic and often found by chance at an abdominal \nultrasound\n \n~\nBiliary colic: episodes of intense acute epigastric right hy\u00ad\npocondrial pain (due to acute temporary blockage of a bile \nduct) lasting few minutes to few hours, often triggere by a \nhigh-fat meal. It can occur sporadically. NO fever or jaun\u00ad\ndice are present.\n \n~\nCholecystitis or cholangitis due to blockage and infection \nof bile\n \n~\nPancreatitis due to blockage of the pancreatic duct\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n444\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>~</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Liver function tests (AST, ALT, bilirubin), Coomb\u2019s tests,</p>\n<p>low haptoglobin, LDH</p>\n<p>~</p>\n<p>Hepatitis A, B, C</p>\n<p>~</p>\n<p>Malaria, sickle cell screen</p>\n<p>~</p>\n<p>Ultrasound shows dilated bile ducts and gall bladder</p>\n<p>~</p>\n<p>CBC, INR, RFTS, LDH, Endoscopic retrograde cholan\u00ad</p>\n<p>giopancreatogram (ERCP)</p>\n<p>~</p>\n<p>Liver biopsy</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer and/or consult as appropriate</p>\n<p>\u0089</p>\n<p>Treat  the  underlying   cause f Discontinue offfending</p>\n<p>factors</p>\n<p>\u0089</p>\n<p>Use phototherapy with UV light for newborn babies</p>\n<p>OR expose the newborn to natural sun</p>\n<p>H</p>\n<p>6.5.8</p>\n<p>Gallstones/Biliary Colic\t ICD10 CODES: K80</p>\n<p>Small hard masses formed in the gallbladder or biliary tree.</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Age, gender, family history</p>\n<p>~</p>\n<p>Obesity, diabetes, use of oral contraceptives, dyslipidemia</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Asymptomatic and often found by chance at an abdominal</p>\n<p>ultrasound</p>\n<p>~</p>\n<p>Biliary colic: episodes of intense acute epigastric right hy\u00ad</p>\n<p>pocondrial pain (due to acute temporary blockage of a bile</p>\n<p>duct) lasting few minutes to few hours, often triggere by a</p>\n<p>high-fat meal. It can occur sporadically. NO fever or jaun\u00ad</p>\n<p>dice are present.</p>\n<p>~</p>\n<p>Cholecystitis or cholangitis due to blockage and infection</p>\n<p>of bile</p>\n<p>~</p>\n<p>Pancreatitis due to blockage of the pancreatic duct</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>444</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 511,
        "content": "Differential diagnosis\n \n~\nPeptic ulcer disease\nInvestigations\n \n\u0081\nAbdominal ultrasound\n \n\u0081\nLiver function tests\nManagement\nTREATMENT\nLOC\nAsymptomatic\n\t\n\u0089\nDoes not require any intervention \nBiliary colic\n\t\n\u0089\nDiclofenac 75 mg IM and/or f Pethidine 50-100 mg IM\n\t\n\u0089\n Low-fat diet, Weight management\n\t\n\u0089\nRefer for cholecystectomy after acute phase\nHC4\nRR\n6.5.9\t\nAcute Cholecystitis/Cholangitis    ICD10 CODES: K81\nInflammation of the gall bladder and/or of the biliary tract. It often \nrequires surgical management.\nCauses\n \n~\nObstruction of gall bladder duct by gall stones (calculi)\n \n~\nMay occur after major trauma, burns, or surgery\n \n~\nOccurs in HIV infected persons as acalculous cholecystitis\nClinical features\n \n~\nSudden onset of pain and tenderness in the right upper \nquadrant of the abdomen; worsens on deep breathing\n \n~\nNausea and vomiting\n \n~\nJaundice (in cholangitis)\n \n~\nFever (38-39\u00b0C) with chills\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n445\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Peptic ulcer disease</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound</p>\n<p>\u0081</p>\n<p>Liver function tests</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Asymptomatic</p>\n<p>\u0089</p>\n<p>Does not require any intervention</p>\n<p>Biliary colic</p>\n<p>\u0089</p>\n<p>Diclofenac 75 mg IM and/or f Pethidine 50-100 mg IM</p>\n<p>\u0089</p>\n<p>Low-fat diet, Weight management</p>\n<p>\u0089</p>\n<p>Refer for cholecystectomy after acute phase</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>6.5.9</p>\n<p>Acute Cholecystitis/Cholangitis    ICD10 CODES: K81</p>\n<p>Inflammation of the gall bladder and/or of the biliary tract. It often</p>\n<p>requires surgical management.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Obstruction of gall bladder duct by gall stones (calculi)</p>\n<p>~</p>\n<p>May occur after major trauma, burns, or surgery</p>\n<p>~</p>\n<p>Occurs in HIV infected persons as acalculous cholecystitis</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Sudden onset of pain and tenderness in the right upper</p>\n<p>quadrant of the abdomen; worsens on deep breathing</p>\n<p>~</p>\n<p>Nausea and vomiting</p>\n<p>~</p>\n<p>Jaundice (in cholangitis)</p>\n<p>~</p>\n<p>Fever (38-39\u00b0C) with chills</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>445</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 512,
        "content": "Severity of acute cholecystitis is classified into:\nTREATMENT\nGrade I (mild acute\ncholecystitis)\nAssociated with no organ dysfunction and limited \ndisease in the gallbladder, making cholecystectomy \na low-risk procedure\nGrade II (moderate \nacute cholecystitis)\nAssociated with no organ dysfunction, but with \nextensive disease in the gallbladder, resulting in \ndifficulty in safely performing a cholecystectomy\nUsually characterized by:\n \n- An elevated white blood cell count\n \n- A palpable, tender mass in the right \nupper abdominal quadrant\n \n- Disease duration of more than 72 \nhours\n \n- Imaging studies indicating significant \ninflammatory changes in the \ngallbladder.\nAcute cholecystitis with organ dysfunction (shock)\nDifferential diagnosis\n \n~\nAcute alcoholic hepatitis\n \n~\nIntestinal obstruction\nInvestigations\n \n\u0081\nX-ray, abdominal ultrasound: findings are wall thickening \u00b1 stone \npericholecystic fluid\n \n\u0081\nBlood: Haemogram, liver tests, pancreatitis. Findings are: fever, \nelevated white blood cells\n \n\u0081\nEnzymes and renal function tests\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n446\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Severity of acute cholecystitis is classified into:</p>\n<h3>TREATMENT</h3>\n<p>Grade I (mild acute</p>\n<p>cholecystitis)</p>\n<p>Associated with no organ dysfunction and limited</p>\n<p>disease in the gallbladder, making cholecystectomy</p>\n<p>a low-risk procedure</p>\n<p>Grade II (moderate</p>\n<p>acute cholecystitis)</p>\n<p>Associated with no organ dysfunction, but with</p>\n<p>extensive disease in the gallbladder, resulting in</p>\n<p>difficulty in safely performing a cholecystectomy</p>\n<p>Usually characterized by:</p>\n<p>- An elevated white blood cell count</p>\n<p>- A palpable, tender mass in the right</p>\n<p>upper abdominal quadrant</p>\n<p>- Disease duration of more than 72</p>\n<p>hours</p>\n<p>- Imaging studies indicating significant</p>\n<p>inflammatory changes in the</p>\n<p>gallbladder.</p>\n<p>Acute cholecystitis with organ dysfunction (shock)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Acute alcoholic hepatitis</p>\n<p>~</p>\n<p>Intestinal obstruction</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>X-ray, abdominal ultrasound: findings are wall thickening \u00b1 stone</p>\n<p>pericholecystic fluid</p>\n<p>\u0081</p>\n<p>Blood: Haemogram, liver tests, pancreatitis. Findings are: fever,</p>\n<p>elevated white blood cells</p>\n<p>\u0081</p>\n<p>Enzymes and renal function tests</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>446</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 513,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nNil by mouth (duration?)\n\t\n\u0089\nRelieve pain: Pethidine 50\u2013100 mg IM every 6 hours\n\t\n\u0089\nRehydrate with IV fluids and electrolytes e.g.\nRinger\u2019s lactate\n\t\n\u0089\nCeftriaxone 1-2 g daily\nIn cholecystitis:\n\t\n\u0089\nRefer to hospital within 2\u20133 days for surgery (chole\u00ad\ncystectomy)\n\t\n\u0089\nIn cholangitis, if not better refer for urgent surgical \nmanagement\nHC4\nRR\nCHAPTER 6: Gastrointestinal and Hepatic Diseases\n447\nUganda Clinical Guidelines 2023",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Nil by mouth (duration?)</p>\n<p>\u0089</p>\n<p>Relieve pain: Pethidine 50\u2013100 mg IM every 6 hours</p>\n<p>\u0089</p>\n<p>Rehydrate with IV fluids and electrolytes e.g.</p>\n<p>Ringer\u2019s lactate</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1-2 g daily</p>\n<p>In cholecystitis:</p>\n<p>\u0089</p>\n<p>Refer to hospital within 2\u20133 days for surgery (chole\u00ad</p>\n<p>cystectomy)</p>\n<p>\u0089</p>\n<p>In cholangitis, if not better refer for urgent surgical</p>\n<p>management</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>CHAPTER 6: Gastrointestinal and Hepatic Diseases</p>\n<p>447</p>\n<p>Uganda Clinical Guidelines 2023</p>"
    },
    {
        "page_number": 514,
        "content": "Renal and Urinary Diseases\n7\n7.1 RENAL DISEASES\n7.1.1\t\nAcute Renal Failure\t\nICD10 CODE: N17\nAcute impairment of renal function\nCauses\n \n~\nCompromised renal perfusion e.g. dehydration, heart fail\u00ad\nure, shock (acute)\n \n~\nObstructed urinary flow\n \n~\nDamage to renal tissue by infectious and inflammatory \ndieases (e.g. glomerulonephritis), intoxications, nephrotox\u00ad\nic drugs\nClinical features\n \n~\nOliguria (urine flow <1 ml/kg/hour)\n \n~\nGeneralised oedema\n \n~\nHypertension, heart failure, dyspnoea\n \n~\nNausea and vomiting, anorexia\n \n~\nLethargy, convulsions\nDifferential diagnosis\n \n~\nOther renal disorders\n \n~\nBiventricular heart failure\n448\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Renal and Urinary Diseases</p>\n<p>7</p>\n<h3>7.1 RENAL DISEASES</h3>\n<p>7.1.1</p>\n<p>Acute Renal Failure</p>\n<h3>ICD10 CODE: N17</h3>\n<p>Acute impairment of renal function</p>\n<p>Causes</p>\n<p>~</p>\n<p>Compromised renal perfusion e.g. dehydration, heart fail\u00ad</p>\n<p>ure, shock (acute)</p>\n<p>~</p>\n<p>Obstructed urinary flow</p>\n<p>~</p>\n<p>Damage to renal tissue by infectious and inflammatory</p>\n<p>dieases (e.g. glomerulonephritis), intoxications, nephrotox\u00ad</p>\n<p>ic drugs</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Oliguria (urine flow <1 ml/kg/hour)</p>\n<p>~</p>\n<p>Generalised oedema</p>\n<p>~</p>\n<p>Hypertension, heart failure, dyspnoea</p>\n<p>~</p>\n<p>Nausea and vomiting, anorexia</p>\n<p>~</p>\n<p>Lethargy, convulsions</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other renal disorders</p>\n<p>~</p>\n<p>Biventricular heart failure</p>\n<p>448</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 515,
        "content": "Investigation\n \n\u0081\nUrine analysis: for blood, proteins, leucocytes, casts\n \n\u0081\nUrea, creatinine and electrolytes\nManagement\n \n\u0081\nManagement of acute kidney condition can be started at \nhospital level but the patient should be referred at higher \nlevel for more appropriate management:\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat underlying conditions e.g. dehydration\n\t\n\u0089\nMonitor fluid input and output\n \n- Daily fluid requirements = 10 ml/kg + total of \nlosses through urine, vomitus and diarrhoea\n\t\n\u0089\nMonitor BP twice daily\n\t\n\u0089\nDaily weighing\n\t\n\u0089\nRestrict salt intake (<2 g or half teaspoonful daily)\n\t\n\u0089\nRestrict potassium intake e.g. oranges, bananas, veg\u00ad\netables, meat, fizzy drinks\n\t\n\u0089\nModerate protein intake\n\t\n\u0089\nEnsure  adequate calories in diet f Check urine and \nelectrolytes frequently f Treat any complications (e.g. \ninfections,\nhypertension, convulsions), adjusting drug dosages according \nto the clinical response where appropriate\n\t\n\u0089\nIf oliguria, furosemide IV according to response (high \ndoses may be necessary)\nIf no response to above general measures, worsening kidney \nfunction or anuria (urine output less than 100 ml/24 hours)\nHC4\nRR\n449\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Investigation</p>\n<p>\u0081</p>\n<p>Urine analysis: for blood, proteins, leucocytes, casts</p>\n<p>\u0081</p>\n<p>Urea, creatinine and electrolytes</p>\n<p>Management</p>\n<p>\u0081</p>\n<p>Management of acute kidney condition can be started at</p>\n<p>hospital level but the patient should be referred at higher</p>\n<p>level for more appropriate management:</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat underlying conditions e.g. dehydration</p>\n<p>\u0089</p>\n<p>Monitor fluid input and output</p>\n<p>- Daily fluid requirements = 10 ml/kg + total of</p>\n<p>losses through urine, vomitus and diarrhoea</p>\n<p>\u0089</p>\n<p>Monitor BP twice daily</p>\n<p>\u0089</p>\n<p>Daily weighing</p>\n<p>\u0089</p>\n<p>Restrict salt intake (<2 g or half teaspoonful daily)</p>\n<p>\u0089</p>\n<p>Restrict potassium intake e.g. oranges, bananas, veg\u00ad</p>\n<p>etables, meat, fizzy drinks</p>\n<p>\u0089</p>\n<p>Moderate protein intake</p>\n<p>\u0089</p>\n<p>Ensure  adequate calories in diet f Check urine and</p>\n<p>electrolytes frequently f Treat any complications (e.g.</p>\n<p>infections,</p>\n<p>hypertension, convulsions), adjusting drug dosages according</p>\n<p>to the clinical response where appropriate</p>\n<p>\u0089</p>\n<p>If oliguria, furosemide IV according to response (high</p>\n<p>doses may be necessary)</p>\n<p>If no response to above general measures, worsening kidney</p>\n<p>function or anuria (urine output less than 100 ml/24 hours)</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>449</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 516,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nRefer for specialist management including possible \ndialysis as soon as possible and before the patient\u2019s \ncondition becomes critical\nHC4\nCaution\n \n\u0083 Do not give any drugs which may make kidney \ndamage worse e.g. use gentamicin with caution\n7.1.2\t\nChronic Kidney Disease (CKD)      ICD10 CODE: N18\nChronic impairment of kidney function\nCauses/risk factors\n \n~\nDiabetes mellitus\n \n~\nHypertension/cardiovascular disease\n \n~\nAge >50 years\n \n~\nKidney stones\n \n~\nDrugs especially pain killers like diclofenac, ibuprofen and \nother NSAIDs\n \n~\nFamily history of kidney disease\n \n~\nHIV/AIDS\nClinical features\n \n~\nMost patients with CKD have no symptoms until the dis\u00ad\nease is advanced\n \n~\nMay present with features of predisposing risk factor\n \n~\nAnaemia, lethargy, easy fatigue, appetite loss, nausea, \nvomiting, skin itching, bone pains\n450\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer for specialist management including possible</p>\n<p>dialysis as soon as possible and before the patient\u2019s</p>\n<p>condition becomes critical</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>\u0083 Do not give any drugs which may make kidney</p>\n<p>damage worse e.g. use gentamicin with caution</p>\n<p>7.1.2</p>\n<p>Chronic Kidney Disease (CKD)      ICD10 CODE: N18</p>\n<p>Chronic impairment of kidney function</p>\n<p>Causes/risk factors</p>\n<p>~</p>\n<p>Diabetes mellitus</p>\n<p>~</p>\n<p>Hypertension/cardiovascular disease</p>\n<p>~</p>\n<p>Age >50 years</p>\n<p>~</p>\n<p>Kidney stones</p>\n<p>~</p>\n<p>Drugs especially pain killers like diclofenac, ibuprofen and</p>\n<p>other NSAIDs</p>\n<p>~</p>\n<p>Family history of kidney disease</p>\n<p>~</p>\n<h3>HIV/AIDS</h3>\n<p>Clinical features</p>\n<p>~</p>\n<p>Most patients with CKD have no symptoms until the dis\u00ad</p>\n<p>ease is advanced</p>\n<p>~</p>\n<p>May present with features of predisposing risk factor</p>\n<p>~</p>\n<p>Anaemia, lethargy, easy fatigue, appetite loss, nausea,</p>\n<p>vomiting, skin itching, bone pains</p>\n<p>450</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 517,
        "content": "~\nMay have body swelling\n \n~\nMay have loin pain\nDifferential diagnosis\n \n~\nOther causes of chronic anaemia\n \n~\nHeart failure\n \n~\nProtein-energy malnutrition\n \n~\nChronic liver disease\nInvestigations\n \n\u0081\nCreatinine/Urea/electrolytes\n \n\u0081\nUrine dip stick for protein and blood\n \n\u0081\nKidney ultrasound\nHow to screen for CKD in patient at risk\n \n\u0081\nUrine dipsticks (for protein and blood) and blood pressure \nmeasurement at least once a year in high risk patients\n \n\u0081\nIn diabetics, urine microalbumin where possible or a spot \nurine for protein: creatinine ratio at least once a year\n \n\u0081\nPatients with detected abnormalities should have a serum \ncreatinine test performed and GFR calculated as suggested \nabove\nRefer the following patients for specialist attention:\n \n~\nChildren\n \n~\nPersistent proteinuria or haematuria beyond 3 months\n \n~\nGFR <60 ml/min or creatinine >1.9 mg/dl\n \n~\nFamilial kidney disease, e.g. polycystic kidney disease\nManagement\nTreatment of end stage renal disease is complex and expensive, and \navailable only at national referral hospital\n451\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>~</p>\n<p>May have body swelling</p>\n<p>~</p>\n<p>May have loin pain</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of chronic anaemia</p>\n<p>~</p>\n<p>Heart failure</p>\n<p>~</p>\n<p>Protein-energy malnutrition</p>\n<p>~</p>\n<p>Chronic liver disease</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Creatinine/Urea/electrolytes</p>\n<p>\u0081</p>\n<p>Urine dip stick for protein and blood</p>\n<p>\u0081</p>\n<p>Kidney ultrasound</p>\n<p>How to screen for CKD in patient at risk</p>\n<p>\u0081</p>\n<p>Urine dipsticks (for protein and blood) and blood pressure</p>\n<p>measurement at least once a year in high risk patients</p>\n<p>\u0081</p>\n<p>In diabetics, urine microalbumin where possible or a spot</p>\n<p>urine for protein: creatinine ratio at least once a year</p>\n<p>\u0081</p>\n<p>Patients with detected abnormalities should have a serum</p>\n<p>creatinine test performed and GFR calculated as suggested</p>\n<p>above</p>\n<p>Refer the following patients for specialist attention:</p>\n<p>~</p>\n<p>Children</p>\n<p>~</p>\n<p>Persistent proteinuria or haematuria beyond 3 months</p>\n<p>~</p>\n<p>GFR <60 ml/min or creatinine >1.9 mg/dl</p>\n<p>~</p>\n<p>Familial kidney disease, e.g. polycystic kidney disease</p>\n<p>Management</p>\n<p>Treatment of end stage renal disease is complex and expensive, and</p>\n<p>available only at national referral hospital</p>\n<p>451</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 518,
        "content": "Goals\n \n~\nEstablish diagnosis and treat reversible diseases\n \n~\nIdentify co-morbid conditions and manage further compli\u00ad\ncations of CKD\n \n~\nSlow progression of CKD by optimizing treatment\n \n~\nPlan renal replacement therapy well before end stage kid\u00ad\nney disease is reached\nManagement\nTREATMENT\nLOC\nTreatment to preserve kidney function in patients with \nCKD\n\t\n\u0089\nLifestyle modifications: Weight loss, stop smok\u00ad\ning, exercise, healthy balanced diet, lipid control, salt \nrestriction\n\t\n\u0089\nBlood pressure control: Target 130/80 mmHg (lower \nin children). Use ACE inhibitors as first line antihyper\u00ad\ntensives for diabetics and patients with proteinuria, \nplus low salt diet\n\t\n\u0089\nIn diabetics: BP control is paramount\n\t\n\u0089\nOptimal blood sugar control (HbA1C <7%)\n\t\n\u0089\nProteinuria: Reduce using ACE inhibitors and/or \nARBs; target < 1 g/day\n\t\n\u0089\nAvoid nephrotoxic medicines, e.g. NSAIDs, \ncelecoxibs, aminoglycosides, contrast agents\nPrevention of complications\n\t\n\u0089\nAnaemia: due to multiple causes. Consider iron and \nfolic supplements. Target Hb 11-12 gr/dL \n\t\n\u0089\n Bone mineral disease: consider adding calcium\nTreatment of symptoms\nHC4\nRR\nHR\n452\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Goals</p>\n<p>~</p>\n<p>Establish diagnosis and treat reversible diseases</p>\n<p>~</p>\n<p>Identify co-morbid conditions and manage further compli\u00ad</p>\n<p>cations of CKD</p>\n<p>~</p>\n<p>Slow progression of CKD by optimizing treatment</p>\n<p>~</p>\n<p>Plan renal replacement therapy well before end stage kid\u00ad</p>\n<p>ney disease is reached</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment to preserve kidney function in patients with</p>\n<h3>CKD</h3>\n<p>\u0089</p>\n<p>Lifestyle modifications: Weight loss, stop smok\u00ad</p>\n<p>ing, exercise, healthy balanced diet, lipid control, salt</p>\n<p>restriction</p>\n<p>\u0089</p>\n<p>Blood pressure control: Target 130/80 mmHg (lower</p>\n<p>in children). Use ACE inhibitors as first line antihyper\u00ad</p>\n<p>tensives for diabetics and patients with proteinuria,</p>\n<p>plus low salt diet</p>\n<p>\u0089</p>\n<p>In diabetics: BP control is paramount</p>\n<p>\u0089</p>\n<p>Optimal blood sugar control (HbA1C <7%)</p>\n<p>\u0089</p>\n<p>Proteinuria: Reduce using ACE inhibitors and/or</p>\n<p>ARBs; target < 1 g/day</p>\n<p>\u0089</p>\n<p>Avoid nephrotoxic medicines, e.g. NSAIDs,</p>\n<p>celecoxibs, aminoglycosides, contrast agents</p>\n<p>Prevention of complications</p>\n<p>\u0089</p>\n<p>Anaemia: due to multiple causes. Consider iron and</p>\n<p>folic supplements. Target Hb 11-12 gr/dL</p>\n<p>\u0089</p>\n<p>Bone mineral disease: consider adding calcium</p>\n<p>Treatment of symptoms</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>HR</p>\n<p>452</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 519,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nIf fluid retention/oliguria, furosemide tablet according \nto response (high doses may be necessary)\n\t\n\u0089\nDialysis for end stage cases\nCaution\n \n\u0083 Start ACE inhibitors at low doses and monitor renal function\nPrevention\n \n~\nScreening of high risk patients\n \n~\nOptimal treatment of risk factors\n \n~\nTreatments to slow progression in initial phases\n \n~\nAvoidance of nephrotoxic drugs\n7.1.3\t\nUse of Drugs in Renal Failure\n \n~\nBe very careful when prescribing any medicine and check \navailable prescribing information (e.g. in Practical Guide\u00ad\nlines for Dispensing 2015) regarding use in renal failure/\nimpairment\n \n~\nMany medicines are excreted through the kidneys and acc \nmulate when urinary output is reduced\n \n~\nSome drugs are presented as sodium or potassium salts \nand contribute to accumulation of these electrolytes\n \n~\nWith life-threatening infections (e.g. meningitis), use normal \nor high doses of antibiotics initially, and then reduce doses \nonce the condition has responded\nDrugs which are usually safe fDoxycycline  \n\t\n\u0089\nErythromycin\n\t\n\u0089\nBenzylpenicillin (max 6 g daily in severe impairment)\n\t\n\u0089\nPhenytoin\n\t\n\u0089\nRifampicin\n453\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If fluid retention/oliguria, furosemide tablet according</p>\n<p>to response (high doses may be necessary)</p>\n<p>\u0089</p>\n<p>Dialysis for end stage cases</p>\n<p>Caution</p>\n<p>\u0083 Start ACE inhibitors at low doses and monitor renal function</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Screening of high risk patients</p>\n<p>~</p>\n<p>Optimal treatment of risk factors</p>\n<p>~</p>\n<p>Treatments to slow progression in initial phases</p>\n<p>~</p>\n<p>Avoidance of nephrotoxic drugs</p>\n<p>7.1.3</p>\n<p>Use of Drugs in Renal Failure</p>\n<p>~</p>\n<p>Be very careful when prescribing any medicine and check</p>\n<p>available prescribing information (e.g. in Practical Guide\u00ad</p>\n<p>lines for Dispensing 2015) regarding use in renal failure/</p>\n<p>impairment</p>\n<p>~</p>\n<p>Many medicines are excreted through the kidneys and acc</p>\n<p>mulate when urinary output is reduced</p>\n<p>~</p>\n<p>Some drugs are presented as sodium or potassium salts</p>\n<p>and contribute to accumulation of these electrolytes</p>\n<p>~</p>\n<p>With life-threatening infections (e.g. meningitis), use normal</p>\n<p>or high doses of antibiotics initially, and then reduce doses</p>\n<p>once the condition has responded</p>\n<p>Drugs which are usually safe fDoxycycline</p>\n<p>\u0089</p>\n<p>Erythromycin</p>\n<p>\u0089</p>\n<p>Benzylpenicillin (max 6 g daily in severe impairment)</p>\n<p>\u0089</p>\n<p>Phenytoin</p>\n<p>\u0089</p>\n<p>Rifampicin</p>\n<p>453</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 520,
        "content": "Drugs to use with care in reduced doses\nACE inhibitors (e.g. captopril)\n \n\u0083 Amoxicillin\n \n\u0083 Chloramphenicol (avoid in severe impairment)\n \n\u0083 Ciprofloxacin r Cotrimoxazole r Diazepam\n \n\u0083 Digoxin\n \n\u0083 Insulin\n \n\u0083 Isoniazid-containing medicines\n \n\u0083 Pethidine (increase dose interval, avoid in severe impairment)\n \n\u0083 Phenobarbital\n \n\u0083 Propranolol\nDrugs to avoid using\n \n\u0083 Acetylsalicylic acid (aspirin) and other NSAIDS e.g. ibuprofen, \nindomethacin\n \n\u0083 Codeine\n \n\u0083 Ethambutol\n \n\u0083 Gentamicin\n \n\u0083 Metformin\n \n\u0083 Nalidixic acid\n \n\u0083 Nitrofurantoin\n \n\u0083 Streptomycin\n \n\u0083 Tenofovir (TDF)\n7.1.4 Glomerulonephritis\t               ICD10 CODE: N00-N01\nAcute inflammation of the renal glomeruli (small blood vessels in the kidney)\nCause\n \n~\nImmune reactions often following an infection - usually 1-5 \nweeks after a streptococcal skin or throat infection\n454\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Drugs to use with care in reduced doses</p>\n<p>ACE inhibitors (e.g. captopril)</p>\n<p>\u0083 Amoxicillin</p>\n<p>\u0083 Chloramphenicol (avoid in severe impairment)</p>\n<p>\u0083 Ciprofloxacin r Cotrimoxazole r Diazepam</p>\n<p>\u0083 Digoxin</p>\n<p>\u0083 Insulin</p>\n<p>\u0083 Isoniazid-containing medicines</p>\n<p>\u0083 Pethidine (increase dose interval, avoid in severe impairment)</p>\n<p>\u0083 Phenobarbital</p>\n<p>\u0083 Propranolol</p>\n<p>Drugs to avoid using</p>\n<p>\u0083 Acetylsalicylic acid (aspirin) and other NSAIDS e.g. ibuprofen,</p>\n<p>indomethacin</p>\n<p>\u0083 Codeine</p>\n<p>\u0083 Ethambutol</p>\n<p>\u0083 Gentamicin</p>\n<p>\u0083 Metformin</p>\n<p>\u0083 Nalidixic acid</p>\n<p>\u0083 Nitrofurantoin</p>\n<p>\u0083 Streptomycin</p>\n<p>\u0083 Tenofovir (TDF)</p>\n<p>7.1.4 Glomerulonephritis\t               ICD10 CODE: N00-N01</p>\n<p>Acute inflammation of the renal glomeruli (small blood vessels in the kidney)</p>\n<p>Cause</p>\n<p>~</p>\n<p>Immune reactions often following an infection - usually 1-5</p>\n<p>weeks after a streptococcal skin or throat infection</p>\n<p>454</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 521,
        "content": "Clinical features\n \n~\nCommon in children >3 years and adolescents\n \n~\nHaematuria (red, or tea-coloured urine)\n \n~\nOedema: Puffiness of the face/around the eyes, less com\u00ad\nmonly generalised body swelling\n \n~\nDiscomfort in the kidney area (abdominal or back pain)\n \n~\nAnorexia\n \n~\nGeneral weakness (malaise)\n \n~\nHigh blood pressure for age, commonly presenting as \nheadaches, visual disturbances, vomiting, and occasionally \npulmonary oedema with dyspnoea\n \n~\nConvulsions (in hypertensive crisis)\n \n~\nOliguria (passing little urine) as renal failure sets in\n \n~\nEvidence of primary streptococcal infection:\n\t\n\u0089\nUsually as acute tonsillitis with cervical adenitis\n\t\n\u0089\nLess often as skin sepsis\nDifferential diagnosis\n \n~\nKidney infections e.g. TB, pyelonephritis\n \n~\nKidney tumours\n \n~\nHeart failure\n \n~\nMalnutrition\n \n~\nAllergic reactions\nInvestigations\n \n\u0081\nUrine: Protein, microscopy for RBCs and casts, WBCs\n \n\u0081\nBlood: Urea (uraemia) and creatinine levels, ASOT, electrolytes\n \n\u0081\nUltrasound: Kidneys\nManagement\nInflammatory kidney disease with oedema, hypertension and oliguria \nshould be referred to regional hospital for specialised management.\n455\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Common in children >3 years and adolescents</p>\n<p>~</p>\n<p>Haematuria (red, or tea-coloured urine)</p>\n<p>~</p>\n<p>Oedema: Puffiness of the face/around the eyes, less com\u00ad</p>\n<p>monly generalised body swelling</p>\n<p>~</p>\n<p>Discomfort in the kidney area (abdominal or back pain)</p>\n<p>~</p>\n<p>Anorexia</p>\n<p>~</p>\n<p>General weakness (malaise)</p>\n<p>~</p>\n<p>High blood pressure for age, commonly presenting as</p>\n<p>headaches, visual disturbances, vomiting, and occasionally</p>\n<p>pulmonary oedema with dyspnoea</p>\n<p>~</p>\n<p>Convulsions (in hypertensive crisis)</p>\n<p>~</p>\n<p>Oliguria (passing little urine) as renal failure sets in</p>\n<p>~</p>\n<p>Evidence of primary streptococcal infection:</p>\n<p>\u0089</p>\n<p>Usually as acute tonsillitis with cervical adenitis</p>\n<p>\u0089</p>\n<p>Less often as skin sepsis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Kidney infections e.g. TB, pyelonephritis</p>\n<p>~</p>\n<p>Kidney tumours</p>\n<p>~</p>\n<p>Heart failure</p>\n<p>~</p>\n<p>Malnutrition</p>\n<p>~</p>\n<p>Allergic reactions</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine: Protein, microscopy for RBCs and casts, WBCs</p>\n<p>\u0081</p>\n<p>Blood: Urea (uraemia) and creatinine levels, ASOT, electrolytes</p>\n<p>\u0081</p>\n<p>Ultrasound: Kidneys</p>\n<p>Management</p>\n<p>Inflammatory kidney disease with oedema, hypertension and oliguria</p>\n<p>should be referred to regional hospital for specialised management.</p>\n<p>455</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 522,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nMonitor urine output, BP, daily weight\n\t\n\u0089\nRestrict fluid input (in oliguria)\n\t\n\u0089\nRestrict salt and regulate protein in the diet (in oliguria)\n\t\n\u0089\nAvoid or use with caution any drugs excreted by the \nkidney (see section 7.1.3)\n\t\n\u0089\nTreat any continuing hypertension (see section 4.1.6)\nH\nIf post-streptococcal\n\t\n\u0089\nTreat primary streptococcal infection (10-day course): \nph noxymethylpenicillin 500 mg every 6 hours\nChild: 10-20 mg/kg per dose\n\t\n\u0089\nOr Amoxicillin 500 mg every 8 hours for 10 days\nChild: 20 mg/kg per dose\nIf allergic to penicillin\n\t\n\u0089\nErythromycin 500 mg every 6 hours for 10 days\nChild: 15 mg/kg per dose\nFor fluid overload (oedema)\n\t\n\u0089\nFurosemide 80 mg IV (slow bolus)\nChild:1 mg/kg every 8-12 hours\nFor fluid overload (oedema)\nH\n\t\n\u0089\nFurosemide 80 mg IV (slow bolus)\nChild:1 mg/kg every 8-12 hours\nFor high blood pressure\n\t\n\u0089\nNifedipine 20 mg every 12 hours\nChildren: refer to specialist\n456\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Monitor urine output, BP, daily weight</p>\n<p>\u0089</p>\n<p>Restrict fluid input (in oliguria)</p>\n<p>\u0089</p>\n<p>Restrict salt and regulate protein in the diet (in oliguria)</p>\n<p>\u0089</p>\n<p>Avoid or use with caution any drugs excreted by the</p>\n<p>kidney (see section 7.1.3)</p>\n<p>\u0089</p>\n<p>Treat any continuing hypertension (see section 4.1.6)</p>\n<p>H</p>\n<p>If post-streptococcal</p>\n<p>\u0089</p>\n<p>Treat primary streptococcal infection (10-day course):</p>\n<p>ph noxymethylpenicillin 500 mg every 6 hours</p>\n<p>Child: 10-20 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or Amoxicillin 500 mg every 8 hours for 10 days</p>\n<p>Child: 20 mg/kg per dose</p>\n<p>If allergic to penicillin</p>\n<p>\u0089</p>\n<p>Erythromycin 500 mg every 6 hours for 10 days</p>\n<p>Child: 15 mg/kg per dose</p>\n<p>For fluid overload (oedema)</p>\n<p>\u0089</p>\n<p>Furosemide 80 mg IV (slow bolus)</p>\n<p>Child:1 mg/kg every 8-12 hours</p>\n<p>For fluid overload (oedema)</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Furosemide 80 mg IV (slow bolus)</p>\n<p>Child:1 mg/kg every 8-12 hours</p>\n<p>For high blood pressure</p>\n<p>\u0089</p>\n<p>Nifedipine 20 mg every 12 hours</p>\n<p>Children: refer to specialist</p>\n<p>456</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 523,
        "content": "Prevention\n \n~\nTreat throat and skin infections promptly and effectively\n \n~\nAvoid overcrowding\n \n~\nAdequate ventilation in dwellings\n7.1.5\t\nNephrotic Syndrome\t\nICD10 CODE: N04\nDisorder characterised by loss of protein in the urine due to damage of \nthe kidney. It is common in children.\nCauses\n \n~\nIdiopathic/unknown (majority of cases)\n \n~\nCongenital (rare)\n \n~\nSecondary: Due to post-streptococcal acute glomerulone\u00ad\nphritis, malaria, allergy, UTI, hepatitis B, HIV\nClinical features\n \n~\nGeneralised oedema\n \n~\nSevere loss of protein in urine (proteinuria)\n \n~\nLow protein (albumin) levels in the blood serum (hypoalbu\u00ad\nminaemia)\n \n~\nHyperlipidaemia (high blood cholesterol)\nInvestigations\n \n\u0081\nAs for Acute glomerulonephritis plus\n \n\u0081\n24-hour urine protein quantification or Albumin creatinine ratio \n(ACR)\n \n\u0081\nSerum protein and cholesterol\nDifferential diagnosis\n \n~\nCardiac failure, liver disease\n \n~\nMalnutrition with oedema e.g. kwashiorkor\n \n~\nMalabsorption syndrome\n457\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Treat throat and skin infections promptly and effectively</p>\n<p>~</p>\n<p>Avoid overcrowding</p>\n<p>~</p>\n<p>Adequate ventilation in dwellings</p>\n<p>7.1.5</p>\n<p>Nephrotic Syndrome</p>\n<h3>ICD10 CODE: N04</h3>\n<p>Disorder characterised by loss of protein in the urine due to damage of</p>\n<p>the kidney. It is common in children.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Idiopathic/unknown (majority of cases)</p>\n<p>~</p>\n<p>Congenital (rare)</p>\n<p>~</p>\n<p>Secondary: Due to post-streptococcal acute glomerulone\u00ad</p>\n<p>phritis, malaria, allergy, UTI, hepatitis B, HIV</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Generalised oedema</p>\n<p>~</p>\n<p>Severe loss of protein in urine (proteinuria)</p>\n<p>~</p>\n<p>Low protein (albumin) levels in the blood serum (hypoalbu\u00ad</p>\n<p>minaemia)</p>\n<p>~</p>\n<p>Hyperlipidaemia (high blood cholesterol)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>As for Acute glomerulonephritis plus</p>\n<p>\u0081</p>\n<p>24-hour urine protein quantification or Albumin creatinine ratio</p>\n<h3>(ACR)</h3>\n<p>\u0081</p>\n<p>Serum protein and cholesterol</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cardiac failure, liver disease</p>\n<p>~</p>\n<p>Malnutrition with oedema e.g. kwashiorkor</p>\n<p>~</p>\n<p>Malabsorption syndrome</p>\n<p>457</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 524,
        "content": "~\nAllergic states causing generalised body swelling\n \n~\nChronic glomerulonephritis\nTREATMENT\nLOC\n\t\n\u0089\nRestrict salt intake (<2 g daily, i.e. less than a half \nteaspoon/day)\n\t\n\u0089\nRestrict water/fluid intake\n \n- Both salt and water/fluid intake should be \nmoderated until diuresis is induced and swelling \nis subsiding, which can take several weeks\n\t\n\u0089\nFurosemide 40-80 mg each morning to induce diuresis\nChild: 1-2 mg/kg per dose (but see notes below)\n\t\n\u0089\nPrednisolone 2 mg/kg daily (max: 60 mg)\n \n- Continue until no further proteinuria (around 6 \nweeks)\n \n- Gradually reduce the dose after the first 4 \nweeks,e.g. reduce by 0.5 mg/kg per day each \nweek\nWhen oedema has subsided and if still hypertensive\n\t\n\u0089\nGive appropriate treatment (see section 4.1.6)\nIf clinical signs of/suspected streptococcal infection:\n\t\n\u0089\nGive antibiotic as in Acute glomerulonephritis\nIf patient from area of endemic schistosomiasis\n\t\n\u0089\nPraziquantel 40 mg/kg single dose\nIf no improvement after 4 weeks or patient relapses\n\t\n\u0089\nRefer for further management\nH\nRR\nManagement\n7.2 UROLOGICAL DISEASES\n7.2.1 Acute Cystitis\t\n  ICD10 CODE: N30\nAn infection/inflammation involving the bladder, a part of the lower uri\u00ad\nnary tract. It is a common manifestation of uncomplicated UTI (Urinary \nTract Infection) in non- pregnant women.\n458\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>~</p>\n<p>Allergic states causing generalised body swelling</p>\n<p>~</p>\n<p>Chronic glomerulonephritis</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Restrict salt intake (<2 g daily, i.e. less than a half</p>\n<p>teaspoon/day)</p>\n<p>\u0089</p>\n<p>Restrict water/fluid intake</p>\n<p>- Both salt and water/fluid intake should be</p>\n<p>moderated until diuresis is induced and swelling</p>\n<p>is subsiding, which can take several weeks</p>\n<p>\u0089</p>\n<p>Furosemide 40-80 mg each morning to induce diuresis</p>\n<p>Child: 1-2 mg/kg per dose (but see notes below)</p>\n<p>\u0089</p>\n<p>Prednisolone 2 mg/kg daily (max: 60 mg)</p>\n<p>- Continue until no further proteinuria (around 6</p>\n<p>weeks)</p>\n<p>- Gradually reduce the dose after the first 4</p>\n<p>weeks,e.g. reduce by 0.5 mg/kg per day each</p>\n<p>week</p>\n<p>When oedema has subsided and if still hypertensive</p>\n<p>\u0089</p>\n<p>Give appropriate treatment (see section 4.1.6)</p>\n<p>If clinical signs of/suspected streptococcal infection:</p>\n<p>\u0089</p>\n<p>Give antibiotic as in Acute glomerulonephritis</p>\n<p>If patient from area of endemic schistosomiasis</p>\n<p>\u0089</p>\n<p>Praziquantel 40 mg/kg single dose</p>\n<p>If no improvement after 4 weeks or patient relapses</p>\n<p>\u0089</p>\n<p>Refer for further management</p>\n<p>H</p>\n<p>RR</p>\n<p>Management</p>\n<h3>7.2 UROLOGICAL DISEASES</h3>\n<p>7.2.1 Acute Cystitis</p>\n<h3>ICD10 CODE: N30</h3>\n<p>An infection/inflammation involving the bladder, a part of the lower uri\u00ad</p>\n<p>nary tract. It is a common manifestation of uncomplicated UTI (Urinary</p>\n<p>Tract Infection) in non- pregnant women.</p>\n<p>458</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 525,
        "content": "Uncomplicated cystitis is less common in men and needs to be differen\u00ad\ntiated from prostatitis and urethritis (sexually transmitted).\nCause\n \n~\nBacterial infection, usually gram negative (from intestinal \nflora) e.g. Escherichia coli\nClinical features\n \n~\nDysuria (pain and difficulty in passing urine)\n \n~\nUrgency of passing urine, frequent passing of small \namounts of urine\n \n~\nSuprapubic pain and tenderness\n \n~\nPyuria/haematuria (pus/blood in the urine makingit cloudy)\n \n~\nFoul smelling urine\n \n~\nThere may be retention of urine in severe infection\nInvestigations\n \n\u0081\nMidstream urine: urine analysis for protein, blood, leucocytes, \nnitrates, sediment\n \n\u0081\nCulture and sensitivity (if resistant/repeated infections)\nDiagnostic criteria\nSymptoms \u00b1 leucocytes and/ or nitrates at urine analysis\nDifferential diagnosis\n \n~\nWomen: vaginitis\n \n~\nMen: urethritis (in young sexually active patients), prostati\u00ad\ntis (fever, chills, malaise, perineal pain, confusion, in older \nmen)\nNote: Asymptomatic bacteriuria or pyuria (leucocytes in urine) does not need \ntreatment except in risk groups such as pregnant women, patients undergoing \nurological interventions and post kidney transplant patients\n459\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Uncomplicated cystitis is less common in men and needs to be differen\u00ad</p>\n<p>tiated from prostatitis and urethritis (sexually transmitted).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Bacterial infection, usually gram negative (from intestinal</p>\n<p>flora) e.g. Escherichia coli</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Dysuria (pain and difficulty in passing urine)</p>\n<p>~</p>\n<p>Urgency of passing urine, frequent passing of small</p>\n<p>amounts of urine</p>\n<p>~</p>\n<p>Suprapubic pain and tenderness</p>\n<p>~</p>\n<p>Pyuria/haematuria (pus/blood in the urine makingit cloudy)</p>\n<p>~</p>\n<p>Foul smelling urine</p>\n<p>~</p>\n<p>There may be retention of urine in severe infection</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Midstream urine: urine analysis for protein, blood, leucocytes,</p>\n<p>nitrates, sediment</p>\n<p>\u0081</p>\n<p>Culture and sensitivity (if resistant/repeated infections)</p>\n<p>Diagnostic criteria</p>\n<p>Symptoms \u00b1 leucocytes and/ or nitrates at urine analysis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Women: vaginitis</p>\n<p>~</p>\n<p>Men: urethritis (in young sexually active patients), prostati\u00ad</p>\n<p>tis (fever, chills, malaise, perineal pain, confusion, in older</p>\n<p>men)</p>\n<p>Note: Asymptomatic bacteriuria or pyuria (leucocytes in urine) does not need</p>\n<p>treatment except in risk groups such as pregnant women, patients undergoing</p>\n<p>urological interventions and post kidney transplant patients</p>\n<p>459</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 526,
        "content": "Management\nTREATMENT\nLOC\nUncomplicated UTI (cystitis) in non-pregnant women\n\t\n\u0089\nEnsure high fluid intake\nFirst line agents:\n\t\n\u0089\nNitrofurantoin 100 mg 6 hourly  for 5-7 days[advise \npatient to take after meals]\nChild: 3 mg/kg/day 6 hourly for 7 days\nSecond line agents\n\t\n\u0089\nCiprofloxacin 500 mg 12 hourly for 7 days (adults)\nChildren: amoxicillin 125-250 mg 8 hourly for 7 days\nIf poor response or recurrent infections\n\t\n\u0089\nRefer for investigation of culture and sensitivity and \nfurther management\nHC2\nNote\n \n\u0083 For urinary tract infection in pregnancy, see section 16.2.6\nPrevention\n \n~\nImproved personal/genital hygiene\n \n~\nPass urine after coitus\n \n~\nDrink plenty of fluids\n7.2.2\t\nAcute Pyelonephritis\t\nICD10 CODE: N10\nUpper urinary tract infection involving one or both kidneys (but not \nusually involving the glomeruli)\nCause\n \n~\nBacterial infection, e.g. Escherichia coli, usually due to as\u00ad\ncending infection (faecal-perineal-urethral progression of \nbacteria)\n460\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Uncomplicated UTI (cystitis) in non-pregnant women</p>\n<p>\u0089</p>\n<p>Ensure high fluid intake</p>\n<p>First line agents:</p>\n<p>\u0089</p>\n<p>Nitrofurantoin 100 mg 6 hourly  for 5-7 days[advise</p>\n<p>patient to take after meals]</p>\n<p>Child: 3 mg/kg/day 6 hourly for 7 days</p>\n<p>Second line agents</p>\n<p>\u0089</p>\n<p>Ciprofloxacin 500 mg 12 hourly for 7 days (adults)</p>\n<p>Children: amoxicillin 125-250 mg 8 hourly for 7 days</p>\n<p>If poor response or recurrent infections</p>\n<p>\u0089</p>\n<p>Refer for investigation of culture and sensitivity and</p>\n<p>further management</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>\u0083 For urinary tract infection in pregnancy, see section 16.2.6</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Improved personal/genital hygiene</p>\n<p>~</p>\n<p>Pass urine after coitus</p>\n<p>~</p>\n<p>Drink plenty of fluids</p>\n<p>7.2.2</p>\n<p>Acute Pyelonephritis</p>\n<h3>ICD10 CODE: N10</h3>\n<p>Upper urinary tract infection involving one or both kidneys (but not</p>\n<p>usually involving the glomeruli)</p>\n<p>Cause</p>\n<p>~</p>\n<p>Bacterial infection, e.g. Escherichia coli, usually due to as\u00ad</p>\n<p>cending infection (faecal-perineal-urethral progression of</p>\n<p>bacteria)</p>\n<p>460</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 527,
        "content": "Risk factors\n \n~\nBladder outlet obstruction\n \n~\nMalformations of urinary tract\n \n~\nPregnancy\n \n~\nHIV, old age, diabetes\nClinical features\n \n~\nLoin pain, tenderness in one or both kidney areas (renal \na gle)\n \n~\nFever, rigors (generalised body tremors)\n \n~\nVomiting\n \n~\nIf associated cystitis: dysuria, urgency, frequency\n \n~\nDiarrhoea and convulsions (common in children)\n \n~\nIn infants and elderly: may simply present as fever and poor \nfeeding/disorientation without other signs\nDifferential diagnosis\n \n~\nAppendicitis\n \n~\nInfection of the fallopian tubes (salpingitis)\n \n~\nInfection of the gall bladder (cholecystitis)\nInvestigations\n \n\u0081\nUrine: Microscopy for pus cells and organisms, C&S of mid-\nstream urine\n\t\n\u0089\nSpecimen should reach the lab within 2 hours of collection or be \nrefrigerated at 4\u00b0C for not >24 hours\n \n\u0081\nBlood: Full count, C&S, urea, electrolytes\n \n\u0081\nUltrasound kidneys/prostate\n461\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Risk factors</p>\n<p>~</p>\n<p>Bladder outlet obstruction</p>\n<p>~</p>\n<p>Malformations of urinary tract</p>\n<p>~</p>\n<p>Pregnancy</p>\n<p>~</p>\n<p>HIV, old age, diabetes</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Loin pain, tenderness in one or both kidney areas (renal</p>\n<p>a gle)</p>\n<p>~</p>\n<p>Fever, rigors (generalised body tremors)</p>\n<p>~</p>\n<p>Vomiting</p>\n<p>~</p>\n<p>If associated cystitis: dysuria, urgency, frequency</p>\n<p>~</p>\n<p>Diarrhoea and convulsions (common in children)</p>\n<p>~</p>\n<p>In infants and elderly: may simply present as fever and poor</p>\n<p>feeding/disorientation without other signs</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Appendicitis</p>\n<p>~</p>\n<p>Infection of the fallopian tubes (salpingitis)</p>\n<p>~</p>\n<p>Infection of the gall bladder (cholecystitis)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine: Microscopy for pus cells and organisms, C&S of mid-</p>\n<p>stream urine</p>\n<p>\u0089</p>\n<p>Specimen should reach the lab within 2 hours of collection or be</p>\n<p>refrigerated at 4\u00b0C for not >24 hours</p>\n<p>\u0081</p>\n<p>Blood: Full count, C&S, urea, electrolytes</p>\n<p>\u0081</p>\n<p>Ultrasound kidneys/prostate</p>\n<p>461</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 528,
        "content": "Management\nTREATMENT\nLOC\n\t\n\u0089\nEnsure adequate intake of fluid (oral or IV) to irrigate \nbladder and dilute bacterial concentrations\n\t\n\u0089\nGive paracetamol 1 g every 6-8 hours for pain and fever\nIf outpatient (only adults):\n\t\n\u0089\nCiprofloxacin 500 mg every 12 hours for 10-14 days \n(only adults)\nIn severe cases, all children or if no response to above in 48 \nhours:\n\t\n\u0089\nCeftriaxone 1 g IV once a day\nChild: 50-80 mg/kg IV once a day\nFollowing initial response to parenteral therapy\n\t\n\u0089\nConsider changing to:\n \n- Ciprofloxacin 750 mg every 12 hours to \ncomplete 10 days (adults only)\n \n- Or cefixime 200 mg every 12 hours to complete \n10 days of treatment\nChild: 16 mg/kg the first day then 8 mg/kg to complete 10 days\nAlternative regimen\nHC3\nHC3\nHC3\nHC3\n\t\n\u0089\nGentamicin 5-7 mg/kg IV in one or divided doses \nwith or without ampicillin 2 g IV every 6 hours Child \n: gentamicin 2.5 mg/kg every 8 hours (or 7.5 mg/kg \nonce daily on outpatient basis) with or without ampicillin \n25 mg/kg every 6 hours\n\t\n\u0089\nConsider referral if there is no response in 72 hours \nand for children with recurrent infections (to exclude \nurinary tract malformations)\nHC2\n462\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure adequate intake of fluid (oral or IV) to irrigate</p>\n<p>bladder and dilute bacterial concentrations</p>\n<p>\u0089</p>\n<p>Give paracetamol 1 g every 6-8 hours for pain and fever</p>\n<p>If outpatient (only adults):</p>\n<p>\u0089</p>\n<p>Ciprofloxacin 500 mg every 12 hours for 10-14 days</p>\n<p>(only adults)</p>\n<p>In severe cases, all children or if no response to above in 48</p>\n<p>hours:</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV once a day</p>\n<p>Child: 50-80 mg/kg IV once a day</p>\n<p>Following initial response to parenteral therapy</p>\n<p>\u0089</p>\n<p>Consider changing to:</p>\n<p>- Ciprofloxacin 750 mg every 12 hours to</p>\n<p>complete 10 days (adults only)</p>\n<p>- Or cefixime 200 mg every 12 hours to complete</p>\n<p>10 days of treatment</p>\n<p>Child: 16 mg/kg the first day then 8 mg/kg to complete 10 days</p>\n<p>Alternative regimen</p>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>Gentamicin 5-7 mg/kg IV in one or divided doses</p>\n<p>with or without ampicillin 2 g IV every 6 hours Child</p>\n<p>: gentamicin 2.5 mg/kg every 8 hours (or 7.5 mg/kg</p>\n<p>once daily on outpatient basis) with or without ampicillin</p>\n<p>25 mg/kg every 6 hours</p>\n<p>\u0089</p>\n<p>Consider referral if there is no response in 72 hours</p>\n<p>and for children with recurrent infections (to exclude</p>\n<p>urinary tract malformations)</p>\n<h3>HC2</h3>\n<p>462</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 529,
        "content": "Prevention\n\t\n\u0089\nEnsure perianal hygiene\n\t\n\u0089\nEnsure regular complete emptying of the bladder and/or double \nvoiding (additional attempt to empty bladder after initial urine flow \nceases)\n7.2.3\t\nProstatitis\t\nICD10 CODE: N41\nAcute inflammation/infection of the prostate, a gland present in the male \nand located below the bladder, around the proximal urethra.\nCause\n \n~\nBacterial infection as for UTI\nClinical features\n \n~\nFever, chills\n \n~\nRectal, perineal and low back pain\n \n~\nUrinary urgency, frequency and dysuria\n \n~\nMay cause acute urinary retention\n \n~\nAt rectal examination: tender enlarged prostate (avoid vig\u00ad\norous examination)\nInvestigations\n \n\u0081\nHaemogram\n \n\u0081\nUrine analysis and C&S\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIV fluids, antipyretics, bed rest\n\t\n\u0089\nStool softeners\n\t\n\u0089\nCiprofloxacin 500 mg 12 hourly for 4-6 weeks\nHC4\n463\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>\u0089</p>\n<p>Ensure perianal hygiene</p>\n<p>\u0089</p>\n<p>Ensure regular complete emptying of the bladder and/or double</p>\n<p>voiding (additional attempt to empty bladder after initial urine flow</p>\n<p>ceases)</p>\n<p>7.2.3</p>\n<p>Prostatitis</p>\n<h3>ICD10 CODE: N41</h3>\n<p>Acute inflammation/infection of the prostate, a gland present in the male</p>\n<p>and located below the bladder, around the proximal urethra.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Bacterial infection as for UTI</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Fever, chills</p>\n<p>~</p>\n<p>Rectal, perineal and low back pain</p>\n<p>~</p>\n<p>Urinary urgency, frequency and dysuria</p>\n<p>~</p>\n<p>May cause acute urinary retention</p>\n<p>~</p>\n<p>At rectal examination: tender enlarged prostate (avoid vig\u00ad</p>\n<p>orous examination)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Haemogram</p>\n<p>\u0081</p>\n<p>Urine analysis and C&S</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>IV fluids, antipyretics, bed rest</p>\n<p>\u0089</p>\n<p>Stool softeners</p>\n<p>\u0089</p>\n<p>Ciprofloxacin 500 mg 12 hourly for 4-6 weeks</p>\n<h3>HC4</h3>\n<p>463</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 530,
        "content": "7.2.4\t\nRenal Colic\t\nICD10 CODE: N23\nAcute severe pain in the loin (kidney area) as a result of obstruction of \nthe ureters by a stone.\nCauses\n \n~\nUrinary stones\n \n~\nRarely clot or tumor\nClinical features\n \n~\nAcute, severe, colicky loin pain often radiating to the iliac \nfossa, testes, or labia of the same side\n \n~\nAt times dysuria\n \n~\nNausea and vomiting\nDifferential diagnosis\n \n~\nLower UTI\n \n~\nAcute upper UTI\n \n~\nOther causes of acute abdominal pain\nInvestigations\n \n\u0081\nUrinalysis (for blood)\n \n\u0081\nPlain abdominal X-ray: for radio-opaque stones\n \n\u0081\nUltrasound\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nOral or IV fluids to mantain hydration\n\t\n\u0089\nAntiemetics if necessary e.g. metoclopramide 10 mg \nIM or IV\n\t\n\u0089\nDiclofenac 75 mg IM single dose and/or\n\t\n\u0089\nPethidine 50-100 mg IM single dose\nRefer if repeated episodes/unresolving episode.\nHC4\n464\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>7.2.4</p>\n<p>Renal Colic</p>\n<h3>ICD10 CODE: N23</h3>\n<p>Acute severe pain in the loin (kidney area) as a result of obstruction of</p>\n<p>the ureters by a stone.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Urinary stones</p>\n<p>~</p>\n<p>Rarely clot or tumor</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Acute, severe, colicky loin pain often radiating to the iliac</p>\n<p>fossa, testes, or labia of the same side</p>\n<p>~</p>\n<p>At times dysuria</p>\n<p>~</p>\n<p>Nausea and vomiting</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Lower UTI</p>\n<p>~</p>\n<p>Acute upper UTI</p>\n<p>~</p>\n<p>Other causes of acute abdominal pain</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urinalysis (for blood)</p>\n<p>\u0081</p>\n<p>Plain abdominal X-ray: for radio-opaque stones</p>\n<p>\u0081</p>\n<p>Ultrasound</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Oral or IV fluids to mantain hydration</p>\n<p>\u0089</p>\n<p>Antiemetics if necessary e.g. metoclopramide 10 mg</p>\n<p>IM or IV</p>\n<p>\u0089</p>\n<p>Diclofenac 75 mg IM single dose and/or</p>\n<p>\u0089</p>\n<p>Pethidine 50-100 mg IM single dose</p>\n<p>Refer if repeated episodes/unresolving episode.</p>\n<h3>HC4</h3>\n<p>464</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 531,
        "content": "Prevention\n \n~\nEnsure oral fluid intake of 3-4 L/day\n \n~\nReduce salt intake and animal protein\n7.2.5\t\nBenign Prostatic Hyperplasia     ICD10 CODE: N40\nEnlargement of the prostate causing urinary symptoms. Common in \nmen above 50 years.\nCause\n \n~\nBenign growth of prostate size, age related\nClinical features\n \n~\nObstructive symptoms: weak urine stream, straining at mi \nturition, hesitancy, intermittency, sensation of incomplete \nbladder emptying\n \n~\nIrritative symptoms: frequent micturition especially during \nthe night, urgency, urge incontinence\n \n~\nComplications: acute urinary retention, frequent infections \nwhich may precipitate symptoms\nInvestigations\n \n\u0081\nUrine analysis (blood, leucocytes)\n \n\u0081\nRenal function\n \n\u0081\nAbdominal ultrasound\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat with antibiotics if infection present (see prostatitis \nor acute cystitis in previous section 7.2.3)\n\t\n\u0089\nSurgical management if severe symptoms\nHC2\nRR\n465\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Ensure oral fluid intake of 3-4 L/day</p>\n<p>~</p>\n<p>Reduce salt intake and animal protein</p>\n<p>7.2.5</p>\n<p>Benign Prostatic Hyperplasia     ICD10 CODE: N40</p>\n<p>Enlargement of the prostate causing urinary symptoms. Common in</p>\n<p>men above 50 years.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Benign growth of prostate size, age related</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Obstructive symptoms: weak urine stream, straining at mi</p>\n<p>turition, hesitancy, intermittency, sensation of incomplete</p>\n<p>bladder emptying</p>\n<p>~</p>\n<p>Irritative symptoms: frequent micturition especially during</p>\n<p>the night, urgency, urge incontinence</p>\n<p>~</p>\n<p>Complications: acute urinary retention, frequent infections</p>\n<p>which may precipitate symptoms</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine analysis (blood, leucocytes)</p>\n<p>\u0081</p>\n<p>Renal function</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat with antibiotics if infection present (see prostatitis</p>\n<p>or acute cystitis in previous section 7.2.3)</p>\n<p>\u0089</p>\n<p>Surgical management if severe symptoms</p>\n<h3>HC2</h3>\n<p>RR</p>\n<p>465</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 532,
        "content": "7.2.6\t\nBladder Outlet Obstruction\nObstruction of urinary tract anywhere below the bladder, causing dis\u00ad\ntension and incomplete emptying of the bladder. It can be acute (Acute \nUrinary Retention) or chronic.\nCauses\n \n~\nBPH/ prostate cancer\n \n~\nBladder  tumors, stones\n \n~\nPelvic masses (rarely pregnancy)\n \n~\nRarely neurological causes\n \n~\nInfections can precipitate acute retention\n \n~\nChronic obstruction can cause hydronephrosis and chronic \nkidney damage\nClinical features\n \n~\nAcute: painful and tender pelvic mass, difficulty in passing \nurine\n \n~\nChronic: obstructive and irritative symptoms (see BPH), \npainless pelvic mass\nInvestigations\n \n\u0081\nUrine analysis, C&S\n \n\u0081\nAbdominal ultrasound\n \n\u0081\nRenal function tests\n \n\u0081\nOther specialised investigations (Cystourethrogram)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nUrethral catheter to relieve obstruction ( 18 F)\n\t\n\u0089\nSuprapubic catheter if urethral fails\n\t\n\u0089\nTreat infection if present\n\t\n\u0089\nRefer to specialist for assessment/care\nHC4\nRR\n466\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>7.2.6</p>\n<p>Bladder Outlet Obstruction</p>\n<p>Obstruction of urinary tract anywhere below the bladder, causing dis\u00ad</p>\n<p>tension and incomplete emptying of the bladder. It can be acute (Acute</p>\n<p>Urinary Retention) or chronic.</p>\n<p>Causes</p>\n<p>~</p>\n<p>BPH/ prostate cancer</p>\n<p>~</p>\n<p>Bladder  tumors, stones</p>\n<p>~</p>\n<p>Pelvic masses (rarely pregnancy)</p>\n<p>~</p>\n<p>Rarely neurological causes</p>\n<p>~</p>\n<p>Infections can precipitate acute retention</p>\n<p>~</p>\n<p>Chronic obstruction can cause hydronephrosis and chronic</p>\n<p>kidney damage</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Acute: painful and tender pelvic mass, difficulty in passing</p>\n<p>urine</p>\n<p>~</p>\n<p>Chronic: obstructive and irritative symptoms (see BPH),</p>\n<p>painless pelvic mass</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine analysis, C&S</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound</p>\n<p>\u0081</p>\n<p>Renal function tests</p>\n<p>\u0081</p>\n<p>Other specialised investigations (Cystourethrogram)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Urethral catheter to relieve obstruction ( 18 F)</p>\n<p>\u0089</p>\n<p>Suprapubic catheter if urethral fails</p>\n<p>\u0089</p>\n<p>Treat infection if present</p>\n<p>\u0089</p>\n<p>Refer to specialist for assessment/care</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>466</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 533,
        "content": "7.2.7\t\nUrine Incontinence\t\nICD10 CODE: N39.3-4\nInvoluntary urine leakage\nCauses and clinical features\n \n~\nPelvic floor muscles dysfunction (e.g. following pregnancy): \nstress incontinence (at strains like coughing, sneezing)\n \n~\nOveractive bladder: urge incontinence (sudden compelling \nneed to urinate, difficult to defer)\n \n~\nAnatomical problems: continuous incontinence (VVF, ec\u00ad\ntopic ureter)\n \n~\nChronic bladder outlet obstruction: overflow incontinence\nInvestigations\n \n\u0081\nCareful history and examination\n \n\u0081\nUrine analysis\n \n\u0081\nAbdominal ultrasound\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nStress incontinence: pelvic floor exercises\n\t\n\u0089\nOther: specific according to the cause\nHC2\nH\n467\nUganda Clinical Guidelines 2023\nCHAPTER 7: Renal and Urinary Diseases",
        "formatted_content": "<p>7.2.7</p>\n<p>Urine Incontinence</p>\n<h3>ICD10 CODE: N39.3-4</h3>\n<p>Involuntary urine leakage</p>\n<p>Causes and clinical features</p>\n<p>~</p>\n<p>Pelvic floor muscles dysfunction (e.g. following pregnancy):</p>\n<p>stress incontinence (at strains like coughing, sneezing)</p>\n<p>~</p>\n<p>Overactive bladder: urge incontinence (sudden compelling</p>\n<p>need to urinate, difficult to defer)</p>\n<p>~</p>\n<p>Anatomical problems: continuous incontinence (VVF, ec\u00ad</p>\n<p>topic ureter)</p>\n<p>~</p>\n<p>Chronic bladder outlet obstruction: overflow incontinence</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Careful history and examination</p>\n<p>\u0081</p>\n<p>Urine analysis</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stress incontinence: pelvic floor exercises</p>\n<p>\u0089</p>\n<p>Other: specific according to the cause</p>\n<h3>HC2</h3>\n<p>H</p>\n<p>467</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 7: Renal and Urinary Diseases</p>"
    },
    {
        "page_number": 534,
        "content": "8.1.1\t\nAddison\u2019s Disease\t\nICD10 CODE: E27.1-4\nA condition where the adrenal gland produces insufficient gluco\u00ad\ncorticoid hormones (adrenal insufficiency)\nCauses\n \n~\nMore common: abrupt cessation of steroid treatment after \nlong use\n \n~\nAutoimmune (self destruction of the gland)\n \n~\nTB of the adrenals, HIV/AIDS\n \n~\nSurgical adrenal removal, cancer affecting adrenal glands, \nbleeding into the adrenals, necrosis of the adrenals\nClinical features\nAcute\n \n\u0081\nWeakness and fatigability (getting tired easily)\n \n\u0081\nShock, very low BP\n \n\u0081\nHypoglycaemic attacks\n \n\u0081\nMental changes, e.g., irritability and restlessness until coma\n \n\u0081\nFever, hyponatremia (low Na), hyperkalemia (high K), acidosis\nChronic\n \n~\nAs above plus weight loss, hair loss\n \n~\nDarkening of the skin and mouth\n \n~\nMenstrual disturbance and infertility\n \n~\nSymptoms are worse in situations of stress (e.g., infections)\nEndocrine and Metabolic Diseases\n8\n468\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>8.1.1</p>\n<p>Addison\u2019s Disease</p>\n<h3>ICD10 CODE: E27.1-4</h3>\n<p>A condition where the adrenal gland produces insufficient gluco\u00ad</p>\n<p>corticoid hormones (adrenal insufficiency)</p>\n<p>Causes</p>\n<p>~</p>\n<p>More common: abrupt cessation of steroid treatment after</p>\n<p>long use</p>\n<p>~</p>\n<p>Autoimmune (self destruction of the gland)</p>\n<p>~</p>\n<p>TB of the adrenals, HIV/AIDS</p>\n<p>~</p>\n<p>Surgical adrenal removal, cancer affecting adrenal glands,</p>\n<p>bleeding into the adrenals, necrosis of the adrenals</p>\n<p>Clinical features</p>\n<p>Acute</p>\n<p>\u0081</p>\n<p>Weakness and fatigability (getting tired easily)</p>\n<p>\u0081</p>\n<p>Shock, very low BP</p>\n<p>\u0081</p>\n<p>Hypoglycaemic attacks</p>\n<p>\u0081</p>\n<p>Mental changes, e.g., irritability and restlessness until coma</p>\n<p>\u0081</p>\n<p>Fever, hyponatremia (low Na), hyperkalemia (high K), acidosis</p>\n<p>Chronic</p>\n<p>~</p>\n<p>As above plus weight loss, hair loss</p>\n<p>~</p>\n<p>Darkening of the skin and mouth</p>\n<p>~</p>\n<p>Menstrual disturbance and infertility</p>\n<p>~</p>\n<p>Symptoms are worse in situations of stress (e.g., infections)</p>\n<p>Endocrine and Metabolic Diseases</p>\n<p>8</p>\n<p>468</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 535,
        "content": "Differential diagnosis\n \n~\nHIV/AIDS, TB, cancer\n \n~\nDepression\n \n~\nDiabetes mellitus\n \n~\nHypothyroidism\nInvestigations\n \n\u0081\nDrug history\n \n\u0081\nRefer at higher level for hormone tests if no clear history of \nabrupt withdrawal of steroid treatment\nManagement\nTREATMENT\nLOC\nAcute crisis\n\t\n\u0089\nHydrocortisone 100 mg IV 6 hourly until stable, then \nswitch to oral\nChild 0-3 years: 25 mg\nChild 3-12 years: 50 mg\n\t\n\u0089\nIV fluids and dextrose to maintain normal volume and \nblood sugar\n\t\n\u0089\nTreat complications/concomitant illnesses (e.g. in\u00ad\nfections)\nH\nChronic case\nHydrocortisone tablets 10mg\n\t\n\u0089\nIf history of abrupt steroid cessation, restart prednisolone \ntreatment, and slowly decrease it by 2.5-5 mg per week\n\t\n\u0089\nReplacement treatment with prednisolone (5-7.5 mg/day)\nChild: 1-5 mg/day\n\t\n\u0089\nUse doses as in acute regimens in case of stress (e.g., \nsurgery, disease, labour)\nH\nPrevention\n \n~\nAvoid self medication with steroids (prednisolone, dexa\u00ad\nmethasone)\n \n~\nDecrease steroids gradually if used for treatment durations \nlonger than 2 weeks (see above)\n469\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>HIV/AIDS, TB, cancer</p>\n<p>~</p>\n<p>Depression</p>\n<p>~</p>\n<p>Diabetes mellitus</p>\n<p>~</p>\n<p>Hypothyroidism</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Drug history</p>\n<p>\u0081</p>\n<p>Refer at higher level for hormone tests if no clear history of</p>\n<p>abrupt withdrawal of steroid treatment</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute crisis</p>\n<p>\u0089</p>\n<p>Hydrocortisone 100 mg IV 6 hourly until stable, then</p>\n<p>switch to oral</p>\n<p>Child 0-3 years: 25 mg</p>\n<p>Child 3-12 years: 50 mg</p>\n<p>\u0089</p>\n<p>IV fluids and dextrose to maintain normal volume and</p>\n<p>blood sugar</p>\n<p>\u0089</p>\n<p>Treat complications/concomitant illnesses (e.g. in\u00ad</p>\n<p>fections)</p>\n<p>H</p>\n<p>Chronic case</p>\n<p>Hydrocortisone tablets 10mg</p>\n<p>\u0089</p>\n<p>If history of abrupt steroid cessation, restart prednisolone</p>\n<p>treatment, and slowly decrease it by 2.5-5 mg per week</p>\n<p>\u0089</p>\n<p>Replacement treatment with prednisolone (5-7.5 mg/day)</p>\n<p>Child: 1-5 mg/day</p>\n<p>\u0089</p>\n<p>Use doses as in acute regimens in case of stress (e.g.,</p>\n<p>surgery, disease, labour)</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid self medication with steroids (prednisolone, dexa\u00ad</p>\n<p>methasone)</p>\n<p>~</p>\n<p>Decrease steroids gradually if used for treatment durations</p>\n<p>longer than 2 weeks (see above)</p>\n<p>469</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 536,
        "content": "8.1.2\t\nCushing\u2019s Syndrome\t\nICD10 CODE: E24\nConstellation of signs and symptoms caused by chronic glucocorticoid \n(steroid) excess, from excessive secretion or, more commonly, from \nchronic glucocorticoid therapy.\nCauses\n \n~\nIatrogenic (steroid treatment)\n \n~\nCushing\u2019s Disease\n \n~\nAdrenal adenoma, adrenal carcinoma\nClinical Features\n \n~\nCentral (truncal) obesity, moon face, buffalo hump\n \n~\nThinning of the skin, striae\n \n~\nPoor wound healing, muscle weakness and atrophy\n \n~\nHirsutism and acne (females)\n \n~\nHypertension and hyperglycaemia\nDifferential diagnosis\n \n~\nOrdinary obesity\n \n~\nAlcoholism (alcohol-induced pseudo-Cushing\u2019s syndrome)\nInvestigations\n \n\u0081\nDrug history\n \n\u0081\nRefer to higher level for hormonal tests (dexamethasone sup\u00ad\npression test) if no history of steroid overuse\nManagement\nTREATMENT\nLOC\nIatrogenic\n\t\n\u0089\nSlowly decrease steroid dose by 2.5-5 mg every 1 to \n2 weeks\nH\n470\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>8.1.2</p>\n<p>Cushing\u2019s Syndrome</p>\n<h3>ICD10 CODE: E24</h3>\n<p>Constellation of signs and symptoms caused by chronic glucocorticoid</p>\n<p>(steroid) excess, from excessive secretion or, more commonly, from</p>\n<p>chronic glucocorticoid therapy.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Iatrogenic (steroid treatment)</p>\n<p>~</p>\n<p>Cushing\u2019s Disease</p>\n<p>~</p>\n<p>Adrenal adenoma, adrenal carcinoma</p>\n<p>Clinical Features</p>\n<p>~</p>\n<p>Central (truncal) obesity, moon face, buffalo hump</p>\n<p>~</p>\n<p>Thinning of the skin, striae</p>\n<p>~</p>\n<p>Poor wound healing, muscle weakness and atrophy</p>\n<p>~</p>\n<p>Hirsutism and acne (females)</p>\n<p>~</p>\n<p>Hypertension and hyperglycaemia</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Ordinary obesity</p>\n<p>~</p>\n<p>Alcoholism (alcohol-induced pseudo-Cushing\u2019s syndrome)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Drug history</p>\n<p>\u0081</p>\n<p>Refer to higher level for hormonal tests (dexamethasone sup\u00ad</p>\n<p>pression test) if no history of steroid overuse</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Iatrogenic</p>\n<p>\u0089</p>\n<p>Slowly decrease steroid dose by 2.5-5 mg every 1 to</p>\n<p>2 weeks</p>\n<p>H</p>\n<p>470</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 537,
        "content": "Management\nTREATMENT\nLOC\nNon-iatrogenic\n\t\n\u0089\nRefer non-iatrogenic Cushing\u2019s, or iatrogenic cases with \ncomplications to higher level of care\nRR\n8.1.3\t\nDiabetes Mellitus\t\nICD10 CODE: E08-E13\nMetabolic disease resulting from insulin insufficiency or ineffectiveness, \ndue to decreased insulin secretion, or peripheral resistance to the action \nof insulin, or a combination of the two.\nCauses\n Type 1: decreased insulin production due to autoimmune destruction \nof the pancreas. Usually starts at a young age\n Type 2: insulin resistance, usually combined with insufficient produc\u00ad\ntion of insulin as the disease progresses. Usually starts in adulthood\n Gestational Diabetes - any degree of glucose intolerance with onset or \nfirst recognition during pregnancy.\n Secondary diabetes: due to other identifiable causes, e.g.,\nCushing\u2019s syndrome, chronic pancreatitis, etc.\nRisk factors\n Type 1: genetic factors, environmental factors (e.g., some viral infections)\n Type 2\n Non-Modifiable risk factors: Age >40 years, Family history in first degree \nrelatives, Gestational DM, delivery of big baby >4kg\n Modifiable risk factors; Unhealthy diets, physical inactivity, tobacco use, \nharmful use of alcohol, hypertension, stress, obesity, high cholesterol \nlevels, impaired glucose tolerance\n471\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Non-iatrogenic</p>\n<p>\u0089</p>\n<p>Refer non-iatrogenic Cushing\u2019s, or iatrogenic cases with</p>\n<p>complications to higher level of care</p>\n<p>RR</p>\n<p>8.1.3</p>\n<p>Diabetes Mellitus</p>\n<h3>ICD10 CODE: E08-E13</h3>\n<p>Metabolic disease resulting from insulin insufficiency or ineffectiveness,</p>\n<p>due to decreased insulin secretion, or peripheral resistance to the action</p>\n<p>of insulin, or a combination of the two.</p>\n<p>Causes</p>\n<p>Type 1: decreased insulin production due to autoimmune destruction</p>\n<p>of the pancreas. Usually starts at a young age</p>\n<p>Type 2: insulin resistance, usually combined with insufficient produc\u00ad</p>\n<p>tion of insulin as the disease progresses. Usually starts in adulthood</p>\n<p>Gestational Diabetes - any degree of glucose intolerance with onset or</p>\n<p>first recognition during pregnancy.</p>\n<p>Secondary diabetes: due to other identifiable causes, e.g.,</p>\n<p>Cushing\u2019s syndrome, chronic pancreatitis, etc.</p>\n<p>Risk factors</p>\n<p>Type 1: genetic factors, environmental factors (e.g., some viral infections)</p>\n<p>Type 2</p>\n<p>Non-Modifiable risk factors: Age >40 years, Family history in first degree</p>\n<p>relatives, Gestational DM, delivery of big baby >4kg</p>\n<p>Modifiable risk factors; Unhealthy diets, physical inactivity, tobacco use,</p>\n<p>harmful use of alcohol, hypertension, stress, obesity, high cholesterol</p>\n<p>levels, impaired glucose tolerance</p>\n<p>471</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 538,
        "content": "Clinical features\nClassical symptoms\no Polyuria \u2013 frequent urination, night waking to urinate\no Polydipsia \u2013 frequent thirst, drink a lot of water \no Polyphagia \u2013 increased appetite, feeling hungry all the time, frequent, \neating \no Polyneuropathy-burning pains, pins and needles, numbness\nOther symptoms \no Weight loss despite high appetite\no Frequent skin infections like boils, itchy genitalia (candidiasis), slow \nhealing wounds\no Fatigue \u2013 feeling tired all the time, children not wanting to play\no Bed-wetting in children\no Poor vision\no May present with complications\n \n~\nType 2 diabetes often only presents with minor aspecific \nsymptoms, and it is diagnosed either by screening or when \nthe patient presents with complications\nComplications\nAcute complications of diabetes\n  Acute coma due to diabetic ketoacidosis, or hyperosmolar hypergly\u00ad\ncaemia (see section 8.1.4), or hypoglycaemia (see section 1.1.6)\nChronic complications\n1.Microvascular complications: affect the small blood vessels, such \nas those supplying blood to the eyes and kidneys. The microvascular \n472\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>Classical symptoms</p>\n<p>o Polyuria \u2013 frequent urination, night waking to urinate</p>\n<p>o Polydipsia \u2013 frequent thirst, drink a lot of water</p>\n<p>o Polyphagia \u2013 increased appetite, feeling hungry all the time, frequent,</p>\n<p>eating</p>\n<p>o Polyneuropathy-burning pains, pins and needles, numbness</p>\n<p>Other symptoms</p>\n<p>o Weight loss despite high appetite</p>\n<p>o Frequent skin infections like boils, itchy genitalia (candidiasis), slow</p>\n<p>healing wounds</p>\n<p>o Fatigue \u2013 feeling tired all the time, children not wanting to play</p>\n<p>o Bed-wetting in children</p>\n<p>o Poor vision</p>\n<p>o May present with complications</p>\n<p>~</p>\n<p>Type 2 diabetes often only presents with minor aspecific</p>\n<p>symptoms, and it is diagnosed either by screening or when</p>\n<p>the patient presents with complications</p>\n<p>Complications</p>\n<p>Acute complications of diabetes</p>\n<p>Acute coma due to diabetic ketoacidosis, or hyperosmolar hypergly\u00ad</p>\n<p>caemia (see section 8.1.4), or hypoglycaemia (see section 1.1.6)</p>\n<p>Chronic complications</p>\n<li>.Microvascular complications: affect the small blood vessels, such</li>\n<p>as those supplying blood to the eyes and kidneys. The microvascular</p>\n<p>472</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 539,
        "content": "complications of diabetes are retinopathy, nephropathy and neuropathy.\n2. Macrovasculary complications: affect the larger blood vessels, \nsuch as those supplying blood to the heart, brain and legs: stroke, heart \nattack, peripheral artery disease\n  Stroke, ischaemic heart disease, kidney failure\n  Blindness, impotence, peripheral neuropathy\n  Diabetic foot which may lead to amputations\nDifferential diagnosis\n \n~\nDiabetes insipidus, HIV/AIDS, TB\nInvestigations\n \n\u0081\nBlood glucose (fasting, random, and/or 2 hours after 75mg of \nglucose)\n \n\u0081\nUrine: for glucose, and ketones (in type 1)\nHbA1c \u2013 Glycated haemoglobin 1c\n Other baseline tests- RFTs, Lipid profile, ECG, urine protein or mi\u00ad\ncroalbuminuria\n1\nFasting blood sugar >7.0 mmol/L (126 mg/dl)\n2\nTwo-hour blood sugar after 75 mg of glucose >11.1 \nmmol/L (200 mg/dl)\n3\nHbA1c >6.5%\n4\nIn a patient with classical symptoms of hyperglycaemia: \nRandom Blood Sugar >11.1 mmol/L (200 mg/dl)\nDiagnostic criteria\nCaution\n \n\u0083 In the absence of unequivocal hyperglycaemia (very high levels \nof blood sugar), criteria 1-3 should be confirmed by repeated \ntesting. One single slightly elevated blood sugar in the absence \nof symptoms IS NOT DIAGNOSTIC for diabetes\n473\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>complications of diabetes are retinopathy, nephropathy and neuropathy.</p>\n<p>2. Macrovasculary complications: affect the larger blood vessels,</p>\n<p>such as those supplying blood to the heart, brain and legs: stroke, heart</p>\n<p>attack, peripheral artery disease</p>\n<p>Stroke, ischaemic heart disease, kidney failure</p>\n<p>Blindness, impotence, peripheral neuropathy</p>\n<p>Diabetic foot which may lead to amputations</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Diabetes insipidus, HIV/AIDS, TB</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood glucose (fasting, random, and/or 2 hours after 75mg of</p>\n<p>glucose)</p>\n<p>\u0081</p>\n<p>Urine: for glucose, and ketones (in type 1)</p>\n<p>HbA1c \u2013 Glycated haemoglobin 1c</p>\n<p>Other baseline tests- RFTs, Lipid profile, ECG, urine protein or mi\u00ad</p>\n<p>croalbuminuria</p>\n<p>1</p>\n<p>Fasting blood sugar >7.0 mmol/L (126 mg/dl)</p>\n<p>2</p>\n<p>Two-hour blood sugar after 75 mg of glucose >11.1</p>\n<p>mmol/L (200 mg/dl)</p>\n<p>3</p>\n<p>HbA1c >6.5%</p>\n<p>4</p>\n<p>In a patient with classical symptoms of hyperglycaemia:</p>\n<p>Random Blood Sugar >11.1 mmol/L (200 mg/dl)</p>\n<p>Diagnostic criteria</p>\n<p>Caution</p>\n<p>\u0083 In the absence of unequivocal hyperglycaemia (very high levels</p>\n<p>of blood sugar), criteria 1-3 should be confirmed by repeated</p>\n<p>testing. One single slightly elevated blood sugar in the absence</p>\n<p>of symptoms IS NOT DIAGNOSTIC for diabetes</p>\n<p>473</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 540,
        "content": "General Management\nGoals of treatment\n\t\n\u0089\nTreatment of hyperglycaemia\n\t\n\u0089\nTreatment of associated risk factors\n\t\n\u0089\nPrevention and treatment of acute and chronic complications\nTREATMENT\nLOC\nLifestyle   modifications f Diabetic diet (see section \n19.1.3) Weight loss if overweight \n\t\n\u0089\nRegular physical exercise \n\t\n\u0089\nModerate, or no alcohol intake \n\t\n\u0089\nSmoking cessation\nHC2\nManagement of risk factors\n\t\n\u0089\nAssess for other risk factors (hypertension, obesity, \nsmoking, etc.), and manage accordingly\n\t\n\u0089\nHypertension: target BP 120/80, first line medication \nare ACE inhibitors (renal protection effect), e.g., enalapril \n(see section 4.1.6)\n\t\n\u0089\nDyslipidaemia: consider statin treatment, e.g. atorvastatin \n20-40 mg once daily or simvastatin 20-40 mg once \ndaily in the evening, especially if:\n \n- Ischaemic heart disease or cerebrovascular \ndisease already present\n \n- Age >40 years\nHC2\n HC4 \nH\nCaution\n \n\u0083 Do not use beta blockers, e.g., atenolol in diabetes\n474\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>General Management</p>\n<p>Goals of treatment</p>\n<p>\u0089</p>\n<p>Treatment of hyperglycaemia</p>\n<p>\u0089</p>\n<p>Treatment of associated risk factors</p>\n<p>\u0089</p>\n<p>Prevention and treatment of acute and chronic complications</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Lifestyle   modifications f Diabetic diet (see section</p>\n<p>19.1.3) Weight loss if overweight</p>\n<p>\u0089</p>\n<p>Regular physical exercise</p>\n<p>\u0089</p>\n<p>Moderate, or no alcohol intake</p>\n<p>\u0089</p>\n<p>Smoking cessation</p>\n<h3>HC2</h3>\n<p>Management of risk factors</p>\n<p>\u0089</p>\n<p>Assess for other risk factors (hypertension, obesity,</p>\n<p>smoking, etc.), and manage accordingly</p>\n<p>\u0089</p>\n<p>Hypertension: target BP 120/80, first line medication</p>\n<p>are ACE inhibitors (renal protection effect), e.g., enalapril</p>\n<p>(see section 4.1.6)</p>\n<p>\u0089</p>\n<p>Dyslipidaemia: consider statin treatment, e.g. atorvastatin</p>\n<p>20-40 mg once daily or simvastatin 20-40 mg once</p>\n<p>daily in the evening, especially if:</p>\n<p>- Ischaemic heart disease or cerebrovascular</p>\n<p>disease already present</p>\n<p>- Age >40 years</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>Caution</p>\n<p>\u0083 Do not use beta blockers, e.g., atenolol in diabetes</p>\n<p>474</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 541,
        "content": "TREATMENT\nLOC\nManagement of complications\n\t\n\u0089\nAssess for complications (renal disease, eye problems, \ndiabetic foot, peripheral neuropathy, heart problem, \nstroke), and refer/ treat accordingly\nHC3\n\t\n\u0089\nAspirin 75-100 mg/daily in ischaemic heart disease, \nor stroke\n\t\n\u0089\nAmitriptyline 10-25 mg at night (max 100 mg in divided \ndoses) for peripheral neuropathy\n\t\n\u0089\nAtorvastatin 20-40 mg once a day in ischaemic heart \ndisease, or stroke\nHC3\nH\nTreatment targets\n \n- Fasting blood sugar <7 mmol/l\n \n- Postprandial sugar <10 mmol/l\n \n- HbA1c <7% (7.5 % for elderly)\nElderly people are at higher risk of hypoglycaemia. Monitor carefully, \nand do not aim at very strict control of blood sugar.\nManagement of Type 1 Diabetes\nInsulin SC: 0.6 -1.5 IU/kg/day HC4 Children <5 years: start with 0.5 \nIU/Kg/day, and refer to a paediatrician\nType of \nInsulin\nUsual\nProtocol\nAction\nOnset\nPeak\nDuration\nInsulin short \nacting, reg\u00ad\nular soluble \n(e.g. Actrap\u00ad\nid)\n3 times\ndai ly, 30 \nminutes be\u00ad\nfore meals\n30\nminutes\n2\u20135\nhours\n5\u20138\nhours\n475\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Management of complications</p>\n<p>\u0089</p>\n<p>Assess for complications (renal disease, eye problems,</p>\n<p>diabetic foot, peripheral neuropathy, heart problem,</p>\n<p>stroke), and refer/ treat accordingly</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>Aspirin 75-100 mg/daily in ischaemic heart disease,</p>\n<p>or stroke</p>\n<p>\u0089</p>\n<p>Amitriptyline 10-25 mg at night (max 100 mg in divided</p>\n<p>doses) for peripheral neuropathy</p>\n<p>\u0089</p>\n<p>Atorvastatin 20-40 mg once a day in ischaemic heart</p>\n<p>disease, or stroke</p>\n<h3>HC3</h3>\n<p>H</p>\n<p>Treatment targets</p>\n<p>- Fasting blood sugar <7 mmol/l</p>\n<p>- Postprandial sugar <10 mmol/l</p>\n<p>- HbA1c <7% (7.5 % for elderly)</p>\n<p>Elderly people are at higher risk of hypoglycaemia. Monitor carefully,</p>\n<p>and do not aim at very strict control of blood sugar.</p>\n<p>Management of Type 1 Diabetes</p>\n<p>Insulin SC: 0.6 -1.5 IU/kg/day HC4 Children <5 years: start with 0.5</p>\n<p>IU/Kg/day, and refer to a paediatrician</p>\n<p>Type of</p>\n<p>Insulin</p>\n<p>Usual</p>\n<p>Protocol</p>\n<p>Action</p>\n<p>Onset</p>\n<p>Peak</p>\n<p>Duration</p>\n<p>Insulin short</p>\n<p>acting, reg\u00ad</p>\n<p>ular soluble</p>\n<p>(e.g. Actrap\u00ad</p>\n<p>id)</p>\n<p>3 times</p>\n<p>dai ly, 30</p>\n<p>minutes be\u00ad</p>\n<p>fore meals</p>\n<p>30</p>\n<p>minutes</p>\n<p>2\u20135</p>\n<p>hours</p>\n<p>5\u20138</p>\n<p>hours</p>\n<p>475</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 542,
        "content": "Type of \nInsulin\nUsual\nProtocol\nAction\nOnset\nPeak\nDuration\nInsulin As\u00ad\npart\n3 times daily \n10-15 min\u00ad\nutes before \nmeals\n10-20mins\n45 mins\n3-5hours\nInsulin in\u00ad\ntermediate \nacting,\nNPH, (e.g.\nInsulatard)\nO n c e  o r \ntwice daily \n(evening \u00b1 \nmorning)\n1\u20133\nhours\n6\u201312\nhours\n16\u201324\nhours\nInsulin bi\u00ad\nphasic, mix\u00ad\nture of regu\u00ad\nlar and NPH \n(e.g.\nMixtard\n30/70)\nO n c e  o r \ntwice daily\n30\nminutes\n2\u201312\nhours\n16\u201324\nhours\nPreferably, a combination of intermediate and short acting insulin \nshould be used, in the following regimens e.g.,\n Pre-meals short acting insulin (e.g. actrapid) or Rapid acting insulin \nanalogue (e.g Aspart) and evening intermediate acting insulin (e.g. \nInsulatard) or long acting insulin analogues (e.g Glargine). The evening \ndose should be 40-50% of the daily dose (basal-bolus therapy)\nOR\n Twice daily premixed insulin Mixtard: usually 2/3 of total dose in the \nmorning and 1/3 in the evening, 30 minutes before meals or Biphasic \nInsulin Aspart 2/3 of total dose in the morning and 1/3 in the evening \n10-15 minutes before meals.\n476\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Type of</p>\n<p>Insulin</p>\n<p>Usual</p>\n<p>Protocol</p>\n<p>Action</p>\n<p>Onset</p>\n<p>Peak</p>\n<p>Duration</p>\n<p>Insulin As\u00ad</p>\n<p>part</p>\n<p>3 times daily</p>\n<p>10-15 min\u00ad</p>\n<p>utes before</p>\n<p>meals</p>\n<p>10-20mins</p>\n<p>45 mins</p>\n<p>3-5hours</p>\n<p>Insulin in\u00ad</p>\n<p>termediate</p>\n<p>acting,</p>\n<p>NPH, (e.g.</p>\n<p>Insulatard)</p>\n<p>O n c e  o r</p>\n<p>twice daily</p>\n<p>(evening \u00b1</p>\n<p>morning)</p>\n<p>1\u20133</p>\n<p>hours</p>\n<p>6\u201312</p>\n<p>hours</p>\n<p>16\u201324</p>\n<p>hours</p>\n<p>Insulin bi\u00ad</p>\n<p>phasic, mix\u00ad</p>\n<p>ture of regu\u00ad</p>\n<p>lar and NPH</p>\n<p>(e.g.</p>\n<p>Mixtard</p>\n<p>30/70)</p>\n<p>O n c e  o r</p>\n<p>twice daily</p>\n<p>30</p>\n<p>minutes</p>\n<p>2\u201312</p>\n<p>hours</p>\n<p>16\u201324</p>\n<p>hours</p>\n<p>Preferably, a combination of intermediate and short acting insulin</p>\n<p>should be used, in the following regimens e.g.,</p>\n<p>Pre-meals short acting insulin (e.g. actrapid) or Rapid acting insulin</p>\n<p>analogue (e.g Aspart) and evening intermediate acting insulin (e.g.</p>\n<p>Insulatard) or long acting insulin analogues (e.g Glargine). The evening</p>\n<p>dose should be 40-50% of the daily dose (basal-bolus therapy)</p>\n<p>OR</p>\n<p>Twice daily premixed insulin Mixtard: usually 2/3 of total dose in the</p>\n<p>morning and 1/3 in the evening, 30 minutes before meals or Biphasic</p>\n<p>Insulin Aspart 2/3 of total dose in the morning and 1/3 in the evening</p>\n<p>10-15 minutes before meals.</p>\n<p>476</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 543,
        "content": "Type of \nInsulin\nUsual\nProtocol\nAction\nOnset\nPeak\nDuration\nNote\n \n\u0083 Patients on insulin should measure their blood glucose level \nat least twice daily (before breakfast, and before dinner), and \ninsulin doses adjusted accordingly\n \n\u0083 More frequent pre- and post-meals measurements are required \nto adjust the doses especially with a basal-bolus therapy.\nCaution\n \n\u0083 Oral antidiabetic medicines are NOT used in type 1.\nMetformin can be used but only under specialist advice\nManagement of Type 2 Diabetes\nTREATMENT\nLOC\nFirst line\n\t\n\u0089\nLife style modifications\n \n- If sugar levels not very high, and patient is \nwilling, try lifestyle modifications for 3 months, \nand  reassess\nIf lifestyle modifications not enough, and/or sugar level initially \nvery high, start on:\n\t\n\u0089\nMetformin 1.5-2 g daily in divided doses at meals (start with \n500 mg once a day for one week,then increase by 500 mg \nevery week until target control is achieved)\nIf treatment targets not achieved with lifestyle modifications \nand metformin, add a second line drug.\nIf intolerance or contraindication to metformin, start directly \nwith second line\nHC2\nHC3\nSecond line\n\t\n\u0089\n0r Glimepiride 1-4 mg once daily before or with the \nfirst meal of the day\n \n- Start with lowest dose, and increase every 1-2 \nweeks according to response\nIf control not achieved, add basal insulin (third line)\nHC4\nH\n477\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Type of</p>\n<p>Insulin</p>\n<p>Usual</p>\n<p>Protocol</p>\n<p>Action</p>\n<p>Onset</p>\n<p>Peak</p>\n<p>Duration</p>\n<p>Note</p>\n<p>\u0083 Patients on insulin should measure their blood glucose level</p>\n<p>at least twice daily (before breakfast, and before dinner), and</p>\n<p>insulin doses adjusted accordingly</p>\n<p>\u0083 More frequent pre- and post-meals measurements are required</p>\n<p>to adjust the doses especially with a basal-bolus therapy.</p>\n<p>Caution</p>\n<p>\u0083 Oral antidiabetic medicines are NOT used in type 1.</p>\n<p>Metformin can be used but only under specialist advice</p>\n<p>Management of Type 2 Diabetes</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First line</p>\n<p>\u0089</p>\n<p>Life style modifications</p>\n<p>- If sugar levels not very high, and patient is</p>\n<p>willing, try lifestyle modifications for 3 months,</p>\n<p>and  reassess</p>\n<p>If lifestyle modifications not enough, and/or sugar level initially</p>\n<p>very high, start on:</p>\n<p>\u0089</p>\n<p>Metformin 1.5-2 g daily in divided doses at meals (start with</p>\n<p>500 mg once a day for one week,then increase by 500 mg</p>\n<p>every week until target control is achieved)</p>\n<p>If treatment targets not achieved with lifestyle modifications</p>\n<p>and metformin, add a second line drug.</p>\n<p>If intolerance or contraindication to metformin, start directly</p>\n<p>with second line</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Second line</p>\n<p>\u0089</p>\n<p>0r Glimepiride 1-4 mg once daily before or with the</p>\n<p>first meal of the day</p>\n<p>- Start with lowest dose, and increase every 1-2</p>\n<p>weeks according to response</p>\n<p>If control not achieved, add basal insulin (third line)</p>\n<h3>HC4</h3>\n<p>H</p>\n<p>477</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 544,
        "content": "Management of Type 2 Diabetes\nTREATMENT\nLOC\nThird line\n\t\n\u0089\nInsulin SC NPH (Insulatard)\n8 IU (or 0.3 IU/Kg) in the evening, increase by 2-4 IU every \n3-7 days until fasting blood glucose is in range\nHC4\nIf control still not achieved, consider a full insulin regimen. Stop \nglimepiride, but maintain metformin if possible\n\t\n\u0089\nBiphasic insulin (e.g. Mixtard 30/70) twice a day, 2/3 \ntotal dose in the morning before breakfast, and 1/3 in \nthe evening before supper\nE.g., Starting dose: 10 IU SC morning, 5 IU SC\nevening, increase by 4-5 IU/weekly. Adjust morning dose as \nper pre-supper blood glucose, and evening dose as per \npre-breakfast blood glucose OR\n\t\n\u0089\nBasal-bolus regimen: 0.4-0.6 IU/kg/day, half is given \nas basal insulin (e.g. Insulatard) in the evening, and half \ngiven as rapid insulin 30 minutes before meals\nAdjust basal dose according to fasting blood sugar, and pre-meals \ninsulin according to pre- and post- meals blood sugar levels\nHC4\nCaution\n \n\u0083 Metformin is contraindicated in advanced kidney disease\n \n\u0083 Do not use oral anti-diabetics in acute complications, and in \nacutely sick patients: use insulin for initial management\n8.1.4\t\nDiabetic Ketoacidosis (DKA) and Hyperosmolar Hyper\u00ad\nglycaemic State (HHS)    ICD10 CODE: E10.1 AND E11.0\nAcute metabolic complications of diabetes mellitus:\n \n- DKA is characterized by ketosis, acidosis, and hyperglycaemia. \nIt is more common in type 1 diabetes.\n \n- HHS is characterized by hyperglycaemia, severe\n \n- dehydration and hypovolemia, but no ketosis and acidosis. It \nis more common in type 2 diabetes.\n478\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Management of Type 2 Diabetes</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Third line</p>\n<p>\u0089</p>\n<p>Insulin SC NPH (Insulatard)</p>\n<p>8 IU (or 0.3 IU/Kg) in the evening, increase by 2-4 IU every</p>\n<p>3-7 days until fasting blood glucose is in range</p>\n<h3>HC4</h3>\n<p>If control still not achieved, consider a full insulin regimen. Stop</p>\n<p>glimepiride, but maintain metformin if possible</p>\n<p>\u0089</p>\n<p>Biphasic insulin (e.g. Mixtard 30/70) twice a day, 2/3</p>\n<p>total dose in the morning before breakfast, and 1/3 in</p>\n<p>the evening before supper</p>\n<p>E.g., Starting dose: 10 IU SC morning, 5 IU SC</p>\n<p>evening, increase by 4-5 IU/weekly. Adjust morning dose as</p>\n<p>per pre-supper blood glucose, and evening dose as per</p>\n<p>pre-breakfast blood glucose OR</p>\n<p>\u0089</p>\n<p>Basal-bolus regimen: 0.4-0.6 IU/kg/day, half is given</p>\n<p>as basal insulin (e.g. Insulatard) in the evening, and half</p>\n<p>given as rapid insulin 30 minutes before meals</p>\n<p>Adjust basal dose according to fasting blood sugar, and pre-meals</p>\n<p>insulin according to pre- and post- meals blood sugar levels</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>\u0083 Metformin is contraindicated in advanced kidney disease</p>\n<p>\u0083 Do not use oral anti-diabetics in acute complications, and in</p>\n<p>acutely sick patients: use insulin for initial management</p>\n<p>8.1.4</p>\n<p>Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyper\u00ad</p>\n<p>glycaemic State (HHS)    ICD10 CODE: E10.1 AND E11.0</p>\n<p>Acute metabolic complications of diabetes mellitus:</p>\n<p>- DKA is characterized by ketosis, acidosis, and hyperglycaemia.</p>\n<p>It is more common in type 1 diabetes.</p>\n<p>- HHS is characterized by hyperglycaemia, severe</p>\n<p>- dehydration and hypovolemia, but no ketosis and acidosis. It</p>\n<p>is more common in type 2 diabetes.</p>\n<p>478</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 545,
        "content": "Causes\n \n~\nNewly diagnosed diabetes\n \n~\nPoor control of diabetes mellitus\n \n\u0081\nTreatment interruptions\n \n\u0081\nInfections and trauma\nClinical features\nDKA\n \n\u0081\nAcute onset (24 hours or less)\n \n\u0081\nMay be preceded by the typical symptoms of excessive thirst, \nfluid intake, and passing of urine, weight loss, tiredness\n \n\u0081\nAbdominal pain, vomiting\n \n\u0081\nAlterated consciousness, coma\n \n\u0081\nDeep breathing (acidotic)\n \n\u0081\nSweet, acetone smell on the breath (from ketosis)\n \n\u0081\nCardiovascular collapse (hypotension)\nHHS\n \n\u0081\nSlower onset\n \n\u0081\nMore severe dehydration and fluid deficit\n \n\u0081\nNo ketosis and acidosis (no/few ketones in urine)\nDifferential diagnosis\n \n\u0081\nOther causes of ketoacidosis/hyperglycaemia\n \n\u0081\nOther causes of acute abdominal pain\n \n\u0081\nOther causes of coma\nInvestigations\n \n\u0081\nBlood sugar\n \n\u0081\nUrine analysis (for ketones, positive)\n \n\u0081\nFull blood count\n \n\u0081\nRenal function and electrolytes (Na,K)\n479\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Causes</p>\n<p>~</p>\n<p>Newly diagnosed diabetes</p>\n<p>~</p>\n<p>Poor control of diabetes mellitus</p>\n<p>\u0081</p>\n<p>Treatment interruptions</p>\n<p>\u0081</p>\n<p>Infections and trauma</p>\n<p>Clinical features</p>\n<h3>DKA</h3>\n<p>\u0081</p>\n<p>Acute onset (24 hours or less)</p>\n<p>\u0081</p>\n<p>May be preceded by the typical symptoms of excessive thirst,</p>\n<p>fluid intake, and passing of urine, weight loss, tiredness</p>\n<p>\u0081</p>\n<p>Abdominal pain, vomiting</p>\n<p>\u0081</p>\n<p>Alterated consciousness, coma</p>\n<p>\u0081</p>\n<p>Deep breathing (acidotic)</p>\n<p>\u0081</p>\n<p>Sweet, acetone smell on the breath (from ketosis)</p>\n<p>\u0081</p>\n<p>Cardiovascular collapse (hypotension)</p>\n<h3>HHS</h3>\n<p>\u0081</p>\n<p>Slower onset</p>\n<p>\u0081</p>\n<p>More severe dehydration and fluid deficit</p>\n<p>\u0081</p>\n<p>No ketosis and acidosis (no/few ketones in urine)</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Other causes of ketoacidosis/hyperglycaemia</p>\n<p>\u0081</p>\n<p>Other causes of acute abdominal pain</p>\n<p>\u0081</p>\n<p>Other causes of coma</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood sugar</p>\n<p>\u0081</p>\n<p>Urine analysis (for ketones, positive)</p>\n<p>\u0081</p>\n<p>Full blood count</p>\n<p>\u0081</p>\n<p>Renal function and electrolytes (Na,K)</p>\n<p>479</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 546,
        "content": "Management\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nMonitor BP, urine output, and blood sugar hourly\n\t\n\u0089\nUrinary catheter if unconscious\n\t\n\u0089\nTreat infections if present (they can be a precipitating factor)\n\t\n\u0089\nEnoxaparin 4000 IU SC until patient is able to move (to \nprevent thromboembolism)\nHC4\nH\n\t\n\u0089\nNormal saline (NaCl 0.9%)\n \n- 15-20 ml/kg in the first hour (500-1000 ml)\n \n- Children: 10-20 ml/kg\n \n- Continue with 5-15 ml/kg/hour according to \nvital signs, urinary output, and clinical condition\n\t\n\u0089\nIf blood sugar <14 mmol/L, switch to dextrose 5% if \nketones still present, and/or clinical condition not yet \nnormal (patient unable to eat)\nHC4\n\t\n\u0089\nSoluble insulin 4-6 IU IM every hour until condition stabilises\nChild >5 years: 0.1 IU/kg/hour\nChild <5 years: 0.05 IU/Kg/hour\n \n- Continue insulin until ketosis resolves, and \npatient is able to eat\n \n- Once clinical condition normalises (normal BP, \nconsciousness, urine output, and able to eat), \nstart Insulin SC regimen (see section 8.1.3) 1-2 \nhours before stopping the IM insulin\nHC4\nPotassium (KCl)\nIf potassium level not available\n\t\n\u0089\nAdd potassium chloride 1 ampoule in every 1 litre of \ninfusion as soon as the patient has started passing urine\nHC4\n480\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Monitor BP, urine output, and blood sugar hourly</p>\n<p>\u0089</p>\n<p>Urinary catheter if unconscious</p>\n<p>\u0089</p>\n<p>Treat infections if present (they can be a precipitating factor)</p>\n<p>\u0089</p>\n<p>Enoxaparin 4000 IU SC until patient is able to move (to</p>\n<p>prevent thromboembolism)</p>\n<h3>HC4</h3>\n<p>H</p>\n<p>\u0089</p>\n<p>Normal saline (NaCl 0.9%)</p>\n<p>- 15-20 ml/kg in the first hour (500-1000 ml)</p>\n<p>- Children: 10-20 ml/kg</p>\n<p>- Continue with 5-15 ml/kg/hour according to</p>\n<p>vital signs, urinary output, and clinical condition</p>\n<p>\u0089</p>\n<p>If blood sugar <14 mmol/L, switch to dextrose 5% if</p>\n<p>ketones still present, and/or clinical condition not yet</p>\n<p>normal (patient unable to eat)</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Soluble insulin 4-6 IU IM every hour until condition stabilises</p>\n<p>Child >5 years: 0.1 IU/kg/hour</p>\n<p>Child <5 years: 0.05 IU/Kg/hour</p>\n<p>- Continue insulin until ketosis resolves, and</p>\n<p>patient is able to eat</p>\n<p>- Once clinical condition normalises (normal BP,</p>\n<p>consciousness, urine output, and able to eat),</p>\n<p>start Insulin SC regimen (see section 8.1.3) 1-2</p>\n<p>hours before stopping the IM insulin</p>\n<h3>HC4</h3>\n<p>Potassium (KCl)</p>\n<p>If potassium level not available</p>\n<p>\u0089</p>\n<p>Add potassium chloride 1 ampoule in every 1 litre of</p>\n<p>infusion as soon as the patient has started passing urine</p>\n<h3>HC4</h3>\n<p>480</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 547,
        "content": "TREATMENT\nLOC\nIf potassium levels available:\n \n- K <3.5 mmol/L: add 40 mmol (2 ampoules) per \n1 litre of fluid\n \n- K 3.5-5.5 mmol/L: add 20 mmol (1 ampoule) \nper 1 litre of infusion\n \n- K >5.5 mmol/L: do not add any potassium\nPrevention\n \n~\nEarly detection\n \n~\nGood control of diabetes\n \n~\nPrompt treatment of infections\n \n~\nGeneral education\nHypoglycemia\nFor hypoglycaemia in patients on anti-DM drugs, manage as in section \n1.1.6, and\nAdd Glucagon 1mg (1 unit) IM/SC, repeat every 15minutes once or \ntwice according to response to treat severe hypoglycemia in diabetes \npatients treated with insulin who are unconscious or cannot take some \nform of sugar by mouth.\n8.1.5 Goitre\t\nICD10 CODE: E04\nVisible enlargement of thyroid gland. May be associated with abnormal \nthyroid function (hyper or hypothyroidism), or not.\nCauses\n \n~\nIodine deficiency\n \n~\nGrave\u2019s disease\n481\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If potassium levels available:</p>\n<p>- K <3.5 mmol/L: add 40 mmol (2 ampoules) per</p>\n<p>1 litre of fluid</p>\n<p>- K 3.5-5.5 mmol/L: add 20 mmol (1 ampoule)</p>\n<p>per 1 litre of infusion</p>\n<p>- K >5.5 mmol/L: do not add any potassium</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Early detection</p>\n<p>~</p>\n<p>Good control of diabetes</p>\n<p>~</p>\n<p>Prompt treatment of infections</p>\n<p>~</p>\n<p>General education</p>\n<p>Hypoglycemia</p>\n<p>For hypoglycaemia in patients on anti-DM drugs, manage as in section</p>\n<li>.1.6, and</li>\n<p>Add Glucagon 1mg (1 unit) IM/SC, repeat every 15minutes once or</p>\n<p>twice according to response to treat severe hypoglycemia in diabetes</p>\n<p>patients treated with insulin who are unconscious or cannot take some</p>\n<p>form of sugar by mouth.</p>\n<p>8.1.5 Goitre</p>\n<h3>ICD10 CODE: E04</h3>\n<p>Visible enlargement of thyroid gland. May be associated with abnormal</p>\n<p>thyroid function (hyper or hypothyroidism), or not.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Iodine deficiency</p>\n<p>~</p>\n<p>Grave\u2019s disease</p>\n<p>481</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 548,
        "content": "~\nThyroiditis\n \n~\nMultinodular\n \n~\nPhysiological (pregnancy, puberty)\nClinical features\n \n~\nVisible neck swelling\n \n~\n(Rarely) difficulty in swallowing\nInvestigations\n \n\u0081\nThyroid hormones\n \n\u0081\nNeck ultrasound\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer for thyroid hormones and specialist management\n\u2013\t If hypo or hyperthyroidism, (see sections 1.1.6) \n\u2013\t If causing obstruction, surgery is indicated\nRR\n8.1.6 Hyperthyroidism\t\nICD10 CODE: E05\nA condition resulting from an excess of thyroid hormones, usually due \nto excessive production.\nCauses\n \n~\nGrave\u2019s disease (autoimmune, common in females)\n \n~\nNeonatal thyrotoxicosis\n \n~\nTumours of thyroid gland (adenomas, multinodular toxic \ngo ter)\n \n~\nInflammation of the thyroid gland (thyroiditis)\n \n~\nIatrogenic causes (side effect of some medications)\nClinical features\n \n~\nWeight loss with increased appetite\n \n~\nSwelling in the neck (goitre)\n482\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>~</p>\n<p>Thyroiditis</p>\n<p>~</p>\n<p>Multinodular</p>\n<p>~</p>\n<p>Physiological (pregnancy, puberty)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Visible neck swelling</p>\n<p>~</p>\n<p>(Rarely) difficulty in swallowing</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Thyroid hormones</p>\n<p>\u0081</p>\n<p>Neck ultrasound</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer for thyroid hormones and specialist management</p>\n<p>\u2013\t If hypo or hyperthyroidism, (see sections 1.1.6)</p>\n<p>\u2013\t If causing obstruction, surgery is indicated</p>\n<p>RR</p>\n<p>8.1.6 Hyperthyroidism</p>\n<h3>ICD10 CODE: E05</h3>\n<p>A condition resulting from an excess of thyroid hormones, usually due</p>\n<p>to excessive production.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Grave\u2019s disease (autoimmune, common in females)</p>\n<p>~</p>\n<p>Neonatal thyrotoxicosis</p>\n<p>~</p>\n<p>Tumours of thyroid gland (adenomas, multinodular toxic</p>\n<p>go ter)</p>\n<p>~</p>\n<p>Inflammation of the thyroid gland (thyroiditis)</p>\n<p>~</p>\n<p>Iatrogenic causes (side effect of some medications)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Weight loss with increased appetite</p>\n<p>~</p>\n<p>Swelling in the neck (goitre)</p>\n<p>482</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 549,
        "content": "~\nPalpitations, tachycardia\n \n~\nIrritability, nervousness, inability to rest or sleep\n \n~\nIrregular, scanty menstrual periods\n \n~\nProfuse sweating, extreme discomfort in hot weather\n \n~\nHigh blood pressure\n \n~\nProtruding eyes (exophthalmos) in some forms\n \n~\nFrequent defecation\nDifferential diagnosis\n \n~\nAnxiety states\n \n~\nTumours of the adrenal gland (pheochromocytoma)\n \n~\nOther causes of weight loss\n \n~\nOther causes of protruding eyes\nInvestigations\n \n\u0081\nBlood levels of thyroid hormone (high T3, T4, low TSH)\n \n\u0081\nThyroid ultrasound scan\n \n\u0081\nBiopsy of thyroid gland for cytology/histology\nManagement\nThe aim is to restore the euthyroid state\n \n~\nUse pulse rate and thyroid hormones level to monitor pro \nress\nTREATMENT\nLOC\n\t\n\u0089\nCarbimazole 15-40 mg (max 60 mg) in 2-3 divided \ndoses for 1-2 months\nChild: 750 micrograms/kg/day in divided doses (max 30 mg)\n \n- Adjust dose according to thyroid hormone levels \n(under specialist management only)\nH\n483\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>~</p>\n<p>Palpitations, tachycardia</p>\n<p>~</p>\n<p>Irritability, nervousness, inability to rest or sleep</p>\n<p>~</p>\n<p>Irregular, scanty menstrual periods</p>\n<p>~</p>\n<p>Profuse sweating, extreme discomfort in hot weather</p>\n<p>~</p>\n<p>High blood pressure</p>\n<p>~</p>\n<p>Protruding eyes (exophthalmos) in some forms</p>\n<p>~</p>\n<p>Frequent defecation</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Anxiety states</p>\n<p>~</p>\n<p>Tumours of the adrenal gland (pheochromocytoma)</p>\n<p>~</p>\n<p>Other causes of weight loss</p>\n<p>~</p>\n<p>Other causes of protruding eyes</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood levels of thyroid hormone (high T3, T4, low TSH)</p>\n<p>\u0081</p>\n<p>Thyroid ultrasound scan</p>\n<p>\u0081</p>\n<p>Biopsy of thyroid gland for cytology/histology</p>\n<p>Management</p>\n<p>The aim is to restore the euthyroid state</p>\n<p>~</p>\n<p>Use pulse rate and thyroid hormones level to monitor pro</p>\n<p>ress</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Carbimazole 15-40 mg (max 60 mg) in 2-3 divided</p>\n<p>doses for 1-2 months</p>\n<p>Child: 750 micrograms/kg/day in divided doses (max 30 mg)</p>\n<p>- Adjust dose according to thyroid hormone levels</p>\n<p>(under specialist management only)</p>\n<p>H</p>\n<p>483</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 550,
        "content": "TREATMENT\nLOC\n \n- To control excessive sympathetic symptoms (e.g. \npalpitations), add:\n\t\n\u0089\nPropranolol 40-80 mg every 12 hours for at least 1 \nmonth\n \n- Child: 250-500 micrograms/kg 3-4 times daily\nH\nOnce patient is euthyroid\n\t\n\u0089\nStop propranolol, and progressively reduce carbima\u00ad\nzole to daily maintenance dose of 5-15 mg. Continue \ncarbimazole for at least 18 months\n\t\n\u0089\nSurgery may be required in certain cases, e.g., obstruc\u00ad\ntion, intolerance, or lack of response to drug treatment\n\t\n\u0089\nRadioactive iodine may also be used especially in\ntoxic multinodular goitre\nCaution\n \n\u0083 Patients treated with carbimazole should be advised to report \nany sore throat immediately because of the rare complication \nof agranulocytosis (low white cell count)\n8.1.7\t\nHypothyroidism\t     ICD10 CODE: E03\nA condition resulting from thyroid hormone deficiency. It is 5 times more \ncommon in females than in males.\nCauses\n \n~\nAutoimmune disease\n \n~\nPost-therapeutic, especially after radiotherapy, or surgical \ntreatment for hyperthyroidism\n \n~\nSecondary; due to enzyme defects (congenital)\n \n~\nIodine deficiency\n \n~\nIatrogenic (side effects of some medicines)\n484\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- To control excessive sympathetic symptoms (e.g.</p>\n<p>palpitations), add:</p>\n<p>\u0089</p>\n<p>Propranolol 40-80 mg every 12 hours for at least 1</p>\n<p>month</p>\n<p>- Child: 250-500 micrograms/kg 3-4 times daily</p>\n<p>H</p>\n<p>Once patient is euthyroid</p>\n<p>\u0089</p>\n<p>Stop propranolol, and progressively reduce carbima\u00ad</p>\n<p>zole to daily maintenance dose of 5-15 mg. Continue</p>\n<p>carbimazole for at least 18 months</p>\n<p>\u0089</p>\n<p>Surgery may be required in certain cases, e.g., obstruc\u00ad</p>\n<p>tion, intolerance, or lack of response to drug treatment</p>\n<p>\u0089</p>\n<p>Radioactive iodine may also be used especially in</p>\n<p>toxic multinodular goitre</p>\n<p>Caution</p>\n<p>\u0083 Patients treated with carbimazole should be advised to report</p>\n<p>any sore throat immediately because of the rare complication</p>\n<p>of agranulocytosis (low white cell count)</p>\n<p>8.1.7</p>\n<p>Hypothyroidism\t     ICD10 CODE: E03</p>\n<p>A condition resulting from thyroid hormone deficiency. It is 5 times more</p>\n<p>common in females than in males.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Autoimmune disease</p>\n<p>~</p>\n<p>Post-therapeutic, especially after radiotherapy, or surgical</p>\n<p>treatment for hyperthyroidism</p>\n<p>~</p>\n<p>Secondary; due to enzyme defects (congenital)</p>\n<p>~</p>\n<p>Iodine deficiency</p>\n<p>~</p>\n<p>Iatrogenic (side effects of some medicines)</p>\n<p>484</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 551,
        "content": "Clinical features\n \n~\nDull facial expression, puffiness, periorbital swelling\n \n~\nHoarse voice, slow speech\n \n~\nWeight gain, drooping eyelids\n \n~\nHair sparse, coarse, and dry: skin dry, scaly, and thick\n \n~\nForgetfullness, other signs of mental impairment\n \n~\nGradual personality change\n \n~\n Bradycardia, constipation (often), anaemia (often)\n \n~\nParaesthesia (numbness) of hands and feet\nDifferential diagnosis\n \n~\nMyasthenia gravis\n \n~\nDepression\nInvestigations\n \n\u0081\nBlood levels of thyroid hormone (low T3, T4, high TSH)\nTREATMENT\nLOC\n\t\n\u0089\nLevothyroxine\n \n- Initial dose 50-100 micrograms once daily before \nbreakfast\nElderly: start with 50 micrograms\n \n- Gradually increase by 25-50 micrograms every \n4 weeks to maintenance dose of 100-200 \nmicrograms daily, according to hormonal levels\n \n- Once stable, check hormone levels every 6-12 \nmonths\nChild: refer for specialist management\nH\nNote\n \n- In most cases, the treatment is for life\n485\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Dull facial expression, puffiness, periorbital swelling</p>\n<p>~</p>\n<p>Hoarse voice, slow speech</p>\n<p>~</p>\n<p>Weight gain, drooping eyelids</p>\n<p>~</p>\n<p>Hair sparse, coarse, and dry: skin dry, scaly, and thick</p>\n<p>~</p>\n<p>Forgetfullness, other signs of mental impairment</p>\n<p>~</p>\n<p>Gradual personality change</p>\n<p>~</p>\n<p>Bradycardia, constipation (often), anaemia (often)</p>\n<p>~</p>\n<p>Paraesthesia (numbness) of hands and feet</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Myasthenia gravis</p>\n<p>~</p>\n<p>Depression</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood levels of thyroid hormone (low T3, T4, high TSH)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Levothyroxine</p>\n<p>- Initial dose 50-100 micrograms once daily before</p>\n<p>breakfast</p>\n<p>Elderly: start with 50 micrograms</p>\n<p>- Gradually increase by 25-50 micrograms every</p>\n<p>4 weeks to maintenance dose of 100-200</p>\n<p>micrograms daily, according to hormonal levels</p>\n<p>- Once stable, check hormone levels every 6-12</p>\n<p>months</p>\n<p>Child: refer for specialist management</p>\n<p>H</p>\n<p>Note</p>\n<p>- In most cases, the treatment is for life</p>\n<p>485</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 552,
        "content": "Prevention\n \n- Educate patients on the use of iodised salt\n8.1.8. Central precocious puberty\t\nAlso referred to as gonadotropin dependent precocious puberty is an \nendocrine- related developmental disease characterized by the onset of \npubertal changes, with development of secondary sexual characteristics \nand accelerated growth and bone maturation, before the normal age of \npuberty (8 years in girls and 9 years in boys).\nCauses\n \n~\nPremature activation of the hypothalamic-pituitary-gonadal \n(HPG) axis. \n \n~\nIdiopathic \n \n~\nSecondary causes include brain tumors (glioma, astrocyto\u00ad\nma), CNS infections (meningitism, encephalitis), brain mal\u00ad\nformations (hydroceohalus, arachnoid cysts), trauma and \ninjuries.\nClinical features\n \n~\nAccelerated growth and bone maturation\n \n~\nPremature breast development\n \n~\nEarly menarche in girls, and testicular and penile enlarge\u00ad\nment with development of facial and sexual hair in boys\nGenetic counselling\n \n~\nMost cases are sporadic, familiar caese show autosomal \ndominant mode of transmission with incomplete, gender-de\u00ad\npendent penetrance\n486\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Prevention</p>\n<p>- Educate patients on the use of iodised salt</p>\n<p>8.1.8. Central precocious puberty</p>\n<p>Also referred to as gonadotropin dependent precocious puberty is an</p>\n<p>endocrine- related developmental disease characterized by the onset of</p>\n<p>pubertal changes, with development of secondary sexual characteristics</p>\n<p>and accelerated growth and bone maturation, before the normal age of</p>\n<p>puberty (8 years in girls and 9 years in boys).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Premature activation of the hypothalamic-pituitary-gonadal</p>\n<p>(HPG) axis.</p>\n<p>~</p>\n<p>Idiopathic</p>\n<p>~</p>\n<p>Secondary causes include brain tumors (glioma, astrocyto\u00ad</p>\n<p>ma), CNS infections (meningitism, encephalitis), brain mal\u00ad</p>\n<p>formations (hydroceohalus, arachnoid cysts), trauma and</p>\n<p>injuries.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Accelerated growth and bone maturation</p>\n<p>~</p>\n<p>Premature breast development</p>\n<p>~</p>\n<p>Early menarche in girls, and testicular and penile enlarge\u00ad</p>\n<p>ment with development of facial and sexual hair in boys</p>\n<p>Genetic counselling</p>\n<p>~</p>\n<p>Most cases are sporadic, familiar caese show autosomal</p>\n<p>dominant mode of transmission with incomplete, gender-de\u00ad</p>\n<p>pendent penetrance</p>\n<p>486</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 553,
        "content": "Differential diagnosis\n \n~\nGonadotropin-independent precocious puberty\n \n~\nMcCune-Albright syndrome\n \n~\nGonadal tumours\n \n~\nBenign premature the larche \nInvestigations\n \n\u0081\nPelvic ultrasound \n \n\u0081\nScreening of basal luteinizing hormone (LH) levels or measurement \nof gonadotropin levels after stimulation tests using gonadotropin \nreleasing hormone (GnRH)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreatment of progressive CPP using GnRH agonists \n(leuprolide acetate for depot suspension)\n\t\n\u0089\nILeuprolide acetate for depot suspension 7.5mg inj \nmonthly\nNH\nPrognosis\nThe disease has minimal consequences during adulthood, although the \nassociation of variation of pubertal timing with adult disease or behaviour \nmay be questioned.\n487\nUganda Clinical Guidelines 2023\nCHAPTER 8: Endocrine and Metabolic Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Gonadotropin-independent precocious puberty</p>\n<p>~</p>\n<p>McCune-Albright syndrome</p>\n<p>~</p>\n<p>Gonadal tumours</p>\n<p>~</p>\n<p>Benign premature the larche</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pelvic ultrasound</p>\n<p>\u0081</p>\n<p>Screening of basal luteinizing hormone (LH) levels or measurement</p>\n<p>of gonadotropin levels after stimulation tests using gonadotropin</p>\n<p>releasing hormone (GnRH)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treatment of progressive CPP using GnRH agonists</p>\n<p>(leuprolide acetate for depot suspension)</p>\n<p>\u0089</p>\n<p>ILeuprolide acetate for depot suspension 7.5mg inj</p>\n<p>monthly</p>\n<p>NH</p>\n<p>Prognosis</p>\n<p>The disease has minimal consequences during adulthood, although the</p>\n<p>association of variation of pubertal timing with adult disease or behaviour</p>\n<p>may be questioned.</p>\n<p>487</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 8: Endocrine and Metabolic Diseases</p>"
    },
    {
        "page_number": 554,
        "content": "Mental, Neurological and Substance \nUse Disorders\n9\n9.1 NEUROLOGICAL DISORDERS\n9.1.1\t\nEpilepsy           ICD10 CODE: G40\n \n~\nA chronic condition characterised by recurrent unprovoked \nseizures. Seizures are caused by abnormal discharges in the \nbrain and present in two different forms: convulsive and \nnon-convulsive forms.\n \n~\nConvulsive epilepsy has features such as sudden muscle \ncontraction, causing the person to fall and lie rigidly, fol\u00ad\nlowed by the muscles alternating between relaxation and \nrigidity with or without loss of bowel or bladder control\n \n~\nNon-convulsive epilepsy has features such as change in \nawareness, behaviour, emotions or senses (such as taste, \nsmell, vision or hearing) similar to mental health conditions, \nso may be confused with them\n \n~\nConsider a diagnosis of epilepsy if a person has had at least \n2 seizures in the last calendar year on two different days.\n \n~\nSeizures during an acute event (e.g. meningitis, acute trau\u00ad\nmatic brain injury) are not epilepsy.\nCauses\n \n~\nGenetic, congenital malformation, birth asphyxia, brain \ntumour\n \n~\nBrain infections, cysticercosis, trauma (acute or in the past)\n \n~\nMetabolic disorders\n \n~\nIn some cases, no specific causes can be identified.\n488\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Mental, Neurological and Substance</p>\n<p>Use Disorders</p>\n<p>9</p>\n<h3>9.1 NEUROLOGICAL DISORDERS</h3>\n<p>9.1.1</p>\n<p>Epilepsy           ICD10 CODE: G40</p>\n<p>~</p>\n<p>A chronic condition characterised by recurrent unprovoked</p>\n<p>seizures. Seizures are caused by abnormal discharges in the</p>\n<p>brain and present in two different forms: convulsive and</p>\n<p>non-convulsive forms.</p>\n<p>~</p>\n<p>Convulsive epilepsy has features such as sudden muscle</p>\n<p>contraction, causing the person to fall and lie rigidly, fol\u00ad</p>\n<p>lowed by the muscles alternating between relaxation and</p>\n<p>rigidity with or without loss of bowel or bladder control</p>\n<p>~</p>\n<p>Non-convulsive epilepsy has features such as change in</p>\n<p>awareness, behaviour, emotions or senses (such as taste,</p>\n<p>smell, vision or hearing) similar to mental health conditions,</p>\n<p>so may be confused with them</p>\n<p>~</p>\n<p>Consider a diagnosis of epilepsy if a person has had at least</p>\n<p>2 seizures in the last calendar year on two different days.</p>\n<p>~</p>\n<p>Seizures during an acute event (e.g. meningitis, acute trau\u00ad</p>\n<p>matic brain injury) are not epilepsy.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Genetic, congenital malformation, birth asphyxia, brain</p>\n<p>tumour</p>\n<p>~</p>\n<p>Brain infections, cysticercosis, trauma (acute or in the past)</p>\n<p>~</p>\n<p>Metabolic disorders</p>\n<p>~</p>\n<p>In some cases, no specific causes can be identified.</p>\n<p>488</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 555,
        "content": "Clinical features\n \n~\nDepending on the type of epilepsy:\nTYPE OF EPILEPSY DESCRIPTION\nGeneralized epilepsy Seizure involves whole brain, consciousness is \nlost at the onset\nTonic Clonic (grand-\nmal) or convulsive \nepilepsy\n May commence with a warning sensation in the \nform of sound, light or abdominal pain (aura)\n There may be a sharp cry followed by loss of \nconsciousness and falling\n Tonic contraction (rigidity) of muscles occurs \nfollowed by jerking movements (clonic phase)\n There may be incontinence of urine or faeces, \nfrothing, and tongue biting\n A period of deep sleep follows\nAbsence seizures \n(petit mal)\n Mainly a disorder of children\n The attack is characterized by a brief loss of \nconsciousness (5-10 seconds) in which posture \nis retained but other activities cease\n The child has a vacant stare\n Previous activities are resumed at the end of \nthe attack\n Several attacks may occur in a single day\nAtonic or tonic sei\u00ad\nzures (drop attacks)\n Sudden loss of muscular tone, of brief duration \n(15 seconds), with consciousness maintained or\n Sudden stiffening of muscle\nMyoclonus epilepsy\n  Abnormal jerking movements occurring usually \nin the limbs but may involve the whole body\n489\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Depending on the type of epilepsy:</p>\n<h3>TYPE OF EPILEPSY DESCRIPTION</h3>\n<p>Generalized epilepsy Seizure involves whole brain, consciousness is</p>\n<p>lost at the onset</p>\n<p>Tonic Clonic (grand-</p>\n<p>mal) or convulsive</p>\n<p>epilepsy</p>\n<p>May commence with a warning sensation in the</p>\n<p>form of sound, light or abdominal pain (aura)</p>\n<p>There may be a sharp cry followed by loss of</p>\n<p>consciousness and falling</p>\n<p>Tonic contraction (rigidity) of muscles occurs</p>\n<p>followed by jerking movements (clonic phase)</p>\n<p>There may be incontinence of urine or faeces,</p>\n<p>frothing, and tongue biting</p>\n<p>A period of deep sleep follows</p>\n<p>Absence seizures</p>\n<p>(petit mal)</p>\n<p>Mainly a disorder of children</p>\n<p>The attack is characterized by a brief loss of</p>\n<p>consciousness (5-10 seconds) in which posture</p>\n<p>is retained but other activities cease</p>\n<p>The child has a vacant stare</p>\n<p>Previous activities are resumed at the end of</p>\n<p>the attack</p>\n<p>Several attacks may occur in a single day</p>\n<p>Atonic or tonic sei\u00ad</p>\n<p>zures (drop attacks)</p>\n<p>Sudden loss of muscular tone, of brief duration</p>\n<p>(15 seconds), with consciousness maintained or</p>\n<p>Sudden stiffening of muscle</p>\n<p>Myoclonus epilepsy</p>\n<p>Abnormal jerking movements occurring usually</p>\n<p>in the limbs but may involve the whole body</p>\n<p>489</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 556,
        "content": "TYPE OF EPILEPSY DESCRIPTION\nFocal Epilepsy\nSeizure activity starts in one area of the brain\nSimple\n Patient remains alert but has abnormal sensory, \nmotor, psychic or autonomic manifestation e.g. \njerking of a limb, d\u00e9j\u00e0 vu, nausea, strange taste \nor smell, signs of autonomic nerve dysfunction\ni.e. sweating, flushing, and gastric sensation, \nmotor contraction or sensory change in a \nparticular point of the body)\nComplex\n  Altered awareness and behaviour e.g. confu\u00ad\nsion, repetitive movements\nStatus epilepticus\n  A convulsive state in which the convulsions \nlast >30 minutes or several epileptic convul\u00ad\nsions occur in succession without recovery \nof consciousness in between or convulsions \nnot responsive to 2 doses of diazepam. It is a \nmedical emergency.\nDifferential diagnosis\n \n\u0081\nSyncope (fainting), \n \n\u0081\nHypoglycaemia (low blood sugar)\n \n\u0081\nHypocalcaemia (low blood calcium levels)\n \n\u0081\nConversion disorder (previously known as hysteria) \n \n\u0081\nHyperventilation (fast breathing) and  Panic attacks\nInvestigations\n \n\u0081\nA complete medical and mental health assessment\n \n\u0081\nElectroencephalogram (EEG)\n \n- Useful in petit mal and focal seizures\n \n- To be done at specialist level (RR and NR)\n \n\u0081\nOther investigations are guided by suspected cause\n490\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TYPE OF EPILEPSY DESCRIPTION</h3>\n<p>Focal Epilepsy</p>\n<p>Seizure activity starts in one area of the brain</p>\n<p>Simple</p>\n<p>Patient remains alert but has abnormal sensory,</p>\n<p>motor, psychic or autonomic manifestation e.g.</p>\n<p>jerking of a limb, d\u00e9j\u00e0 vu, nausea, strange taste</p>\n<p>or smell, signs of autonomic nerve dysfunction</p>\n<p>i.e. sweating, flushing, and gastric sensation,</p>\n<p>motor contraction or sensory change in a</p>\n<p>particular point of the body)</p>\n<p>Complex</p>\n<p>Altered awareness and behaviour e.g. confu\u00ad</p>\n<p>sion, repetitive movements</p>\n<p>Status epilepticus</p>\n<p>A convulsive state in which the convulsions</p>\n<p>last >30 minutes or several epileptic convul\u00ad</p>\n<p>sions occur in succession without recovery</p>\n<p>of consciousness in between or convulsions</p>\n<p>not responsive to 2 doses of diazepam. It is a</p>\n<p>medical emergency.</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Syncope (fainting),</p>\n<p>\u0081</p>\n<p>Hypoglycaemia (low blood sugar)</p>\n<p>\u0081</p>\n<p>Hypocalcaemia (low blood calcium levels)</p>\n<p>\u0081</p>\n<p>Conversion disorder (previously known as hysteria)</p>\n<p>\u0081</p>\n<p>Hyperventilation (fast breathing) and  Panic attacks</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>A complete medical and mental health assessment</p>\n<p>\u0081</p>\n<p>Electroencephalogram (EEG)</p>\n<p>- Useful in petit mal and focal seizures</p>\n<p>- To be done at specialist level (RR and NR)</p>\n<p>\u0081</p>\n<p>Other investigations are guided by suspected cause</p>\n<p>490</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 557,
        "content": "Management\nGeneral principles\n \n~\nAll suspected cases of non-convulsive epilepsy should be \nconfirmed and treated by a specialist\n \n~\nConvulsive epilepsy can be diagnosed at hospital/HC3\n \n~\nlevel but drug refills should be available at lower levels\n \n~\nOne brief isolated seizure does not need further treatment \nbut review at 3 months and re-assessment. Treat patients \nwith repeated episodes as per definition\n \n~\nTreatment can effectively control epilepsy in most cases\n \n~\nTreatment should include psychological and social support\n \n~\nStart with a single anti-epileptic medicine \n \n~\nStart with low doses and increase gradually according to \nresponse\n \n~\nIf a patient has been seizure free for 2 years, consider grad\u00ad\nual stopping of medication\nCommonly used antiepileptics include:\n \n~\nGeneralized tonic-clonic seizures\n\u2022Children <2 years: phenobarbital or carbamazepine\n\u2022Children >2 years: carbamazepine or valproate\n \n~\nAbsence seizures: Valproate or ethosuximide\n \n~\nCaution: Avoid phenobarbital and phenytoin in children \nwith intellectual disability and/or behavioural problems\nManagement\nTREATMENT\nLOC\nFirst aid for acute seizure\n DO NOT RESTRAIN or put anything in the mouth\n Protect person from injury: make sure they are in a safe \nplace away from fire or other things that might injure them\nHC2\n491\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<p>General principles</p>\n<p>~</p>\n<p>All suspected cases of non-convulsive epilepsy should be</p>\n<p>confirmed and treated by a specialist</p>\n<p>~</p>\n<p>Convulsive epilepsy can be diagnosed at hospital/HC3</p>\n<p>~</p>\n<p>level but drug refills should be available at lower levels</p>\n<p>~</p>\n<p>One brief isolated seizure does not need further treatment</p>\n<p>but review at 3 months and re-assessment. Treat patients</p>\n<p>with repeated episodes as per definition</p>\n<p>~</p>\n<p>Treatment can effectively control epilepsy in most cases</p>\n<p>~</p>\n<p>Treatment should include psychological and social support</p>\n<p>~</p>\n<p>Start with a single anti-epileptic medicine</p>\n<p>~</p>\n<p>Start with low doses and increase gradually according to</p>\n<p>response</p>\n<p>~</p>\n<p>If a patient has been seizure free for 2 years, consider grad\u00ad</p>\n<p>ual stopping of medication</p>\n<p>Commonly used antiepileptics include:</p>\n<p>~</p>\n<p>Generalized tonic-clonic seizures</p>\n<li>Children <2 years: phenobarbital or carbamazepine</li>\n<li>Children >2 years: carbamazepine or valproate</li>\n<p>~</p>\n<p>Absence seizures: Valproate or ethosuximide</p>\n<p>~</p>\n<p>Caution: Avoid phenobarbital and phenytoin in children</p>\n<p>with intellectual disability and/or behavioural problems</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First aid for acute seizure</p>\n<p>DO NOT RESTRAIN or put anything in the mouth</p>\n<p>Protect person from injury: make sure they are in a safe</p>\n<p>place away from fire or other things that might injure them</p>\n<h3>HC2</h3>\n<p>491</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 558,
        "content": "Management\nTREATMENT\nLOC\n DO NOT leave patient alone. Seek help if possible\n After the crisis, check airway, breathing and circulation and, \nwhile unconscious, put the person in recovery position (on \ntheir side)\nHC2\n Most seizures resolve spontaneously.\nHC3\nStatus epilepticus\n Dextrose 50% 1 mL/kg adults and Dextrose 10%\n Give diazepam 10 mg IV or rectal 5 mL/kg children\n \n- Child: 0.05 mg/kg rectally, 0.02 mg/kg IV \nrepeat dose  after 5-10 min if seizures persist\nIf not responsive, consider\n Phenobarbital 10-15 mg/kg slowly IV. Dilute the solution \nwith 10 times its volume of water for\ninjections and give VERY SLOWLY (at a rate 0.1 mg/minute)\n \n- Monitor BP and respiration, be ready to \nadminister IV fluids if hypotension develops and \nventilate with Ambu bag in case of respiratory \ndepression\n Or phenytoin 15-18 mg/kg over 1 hour\n Phenytoin can cause severe tissue damage so use a good IV line\nIf not responsive\n Give another drug (if available) or add phenytoin\n10 mg/kg in 30 minutes\n \n- Monitor for respiratory depression\n492\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>DO NOT leave patient alone. Seek help if possible</p>\n<p>After the crisis, check airway, breathing and circulation and,</p>\n<p>while unconscious, put the person in recovery position (on</p>\n<p>their side)</p>\n<h3>HC2</h3>\n<p>Most seizures resolve spontaneously.</p>\n<h3>HC3</h3>\n<p>Status epilepticus</p>\n<p>Dextrose 50% 1 mL/kg adults and Dextrose 10%</p>\n<p>Give diazepam 10 mg IV or rectal 5 mL/kg children</p>\n<p>- Child: 0.05 mg/kg rectally, 0.02 mg/kg IV</p>\n<p>repeat dose  after 5-10 min if seizures persist</p>\n<p>If not responsive, consider</p>\n<p>Phenobarbital 10-15 mg/kg slowly IV. Dilute the solution</p>\n<p>with 10 times its volume of water for</p>\n<p>injections and give VERY SLOWLY (at a rate 0.1 mg/minute)</p>\n<p>- Monitor BP and respiration, be ready to</p>\n<p>administer IV fluids if hypotension develops and</p>\n<p>ventilate with Ambu bag in case of respiratory</p>\n<p>depression</p>\n<p>Or phenytoin 15-18 mg/kg over 1 hour</p>\n<p>Phenytoin can cause severe tissue damage so use a good IV line</p>\n<p>If not responsive</p>\n<p>Give another drug (if available) or add phenytoin</p>\n<p>10 mg/kg in 30 minutes</p>\n<p>- Monitor for respiratory depression</p>\n<p>492</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 559,
        "content": "Chronic epilepsy\nTREATMENT\nLOC\nGeneral principles\n Start with a single anti-epileptic medicine. The effective dose \nmust   be reached progressively and patient monitored for \ntolerance and side effects. Aim at the lowest dose able to \ncontrol (prevent) the seizures\n If treatment is ineffective (less than 50% reduction in crisis) \ntry another monotherapy (slowly reduce the current antie\u00ad\npileptic and introduce the new one)\n If high doses with side effects are required\nand seizures are anyway infrequent, less than complete control \ncan be the goal\n Follow up monthly until stable, then every 3 months\n Warn patient that treatment interruptions can trigger seizures \nor even status epilepticus\n If no seizure for 2 years and no known cause like head trauma \nor infection, consider possibility of stopping treatment (over \n2 months). Discuss with the patient\n If 2 monotherapy trials fail, refer to specialist\nHC3\nCarbamazepine\nEffective in all generalized tonic-clonic seizures, focal seizures\n \n- Given twice daily, steady state reached in 8 days\n \n- Adult: starting dose of 100-200 mg daily and \nincreased in 100 mg increments every 1-2 weeks \nto a maintenance dose of 400 to 1400 mg daily\n \n- Child: starting dose of 5 mg/kg/day and \nmaintenance dose of 10-20 mg/kg/day in \ndivided doses\n Side effects: skin rash, diplopia, blurred vision, ataxia (stag\u00ad\ngering gait), nausea\nHC4\n493\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Chronic epilepsy</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General principles</p>\n<p>Start with a single anti-epileptic medicine. The effective dose</p>\n<p>must   be reached progressively and patient monitored for</p>\n<p>tolerance and side effects. Aim at the lowest dose able to</p>\n<p>control (prevent) the seizures</p>\n<p>If treatment is ineffective (less than 50% reduction in crisis)</p>\n<p>try another monotherapy (slowly reduce the current antie\u00ad</p>\n<p>pileptic and introduce the new one)</p>\n<p>If high doses with side effects are required</p>\n<p>and seizures are anyway infrequent, less than complete control</p>\n<p>can be the goal</p>\n<p>Follow up monthly until stable, then every 3 months</p>\n<p>Warn patient that treatment interruptions can trigger seizures</p>\n<p>or even status epilepticus</p>\n<p>If no seizure for 2 years and no known cause like head trauma</p>\n<p>or infection, consider possibility of stopping treatment (over</p>\n<p>2 months). Discuss with the patient</p>\n<p>If 2 monotherapy trials fail, refer to specialist</p>\n<h3>HC3</h3>\n<p>Carbamazepine</p>\n<p>Effective in all generalized tonic-clonic seizures, focal seizures</p>\n<p>- Given twice daily, steady state reached in 8 days</p>\n<p>- Adult: starting dose of 100-200 mg daily and</p>\n<p>increased in 100 mg increments every 1-2 weeks</p>\n<p>to a maintenance dose of 400 to 1400 mg daily</p>\n<p>- Child: starting dose of 5 mg/kg/day and</p>\n<p>maintenance dose of 10-20 mg/kg/day in</p>\n<p>divided doses</p>\n<p>Side effects: skin rash, diplopia, blurred vision, ataxia (stag\u00ad</p>\n<p>gering gait), nausea</p>\n<h3>HC4</h3>\n<p>493</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 560,
        "content": "Chronic epilepsy\nTREATMENT\nLOC\nPhenobarbital\nEffective for tonic-clonic seizures and focal seizures but is \nsedative in adults and cause behavioural disturbances and \nhyperkinesia in children. It may be tried for atypical absences, \natonic and tonic seizures\n \n- Given once a day in the evening to reduce \ndrowsiness\n \n- Adult: starting dose of 1 mg/kg (60 mg) daily \nfor 2\n \n- weeks, if not controlled increase to 2 mg/kg \n(120 mg) for 2 months, if not controlled increase \nto 3 mg/kg (180 mg)\n \n- Child: starting dose of 2 mg/kg/day for 2 \nweeks,if\n \n- not controlled increase to 3 mg/kg for 2 months, \nif not controlled increase until maximum of 6 \nmg/ kg/day\n \n- It takes 2-3 weeks for the drug to achieve steady \nblood levels so assess effect only after this period\n Side effects: drowsiness, lethargy, hyperactivity\nand irritability in children, skin rash, confusion in elderly, \ndepression\nHC3\nPhenytoin\nEffective in all forms of epilepsy except absences.\n \n- Adult: starting dose of 150-200 mg daily as \nsingle dose or 2 divided doses and maintenance \ndose of 200-400 mg daily\n \n- Child: starting dose of 3-4 mg/kg and\n \n- maintenance dose of 3-8 mg/kg/day (max 300 \nmg daily)\n \n- Increase slowly by 25-30 mg every 2 weeks\n Side effects: drowsiness, ataxia, slurred speech, blurred \nvision, twitching, confusion, gum hyperplasia, blood ab\u00ad\nnormalities, rash, hepatitis\n494\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Chronic epilepsy</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Phenobarbital</p>\n<p>Effective for tonic-clonic seizures and focal seizures but is</p>\n<p>sedative in adults and cause behavioural disturbances and</p>\n<p>hyperkinesia in children. It may be tried for atypical absences,</p>\n<p>atonic and tonic seizures</p>\n<p>- Given once a day in the evening to reduce</p>\n<p>drowsiness</p>\n<p>- Adult: starting dose of 1 mg/kg (60 mg) daily</p>\n<p>for 2</p>\n<p>- weeks, if not controlled increase to 2 mg/kg</p>\n<p>(120 mg) for 2 months, if not controlled increase</p>\n<p>to 3 mg/kg (180 mg)</p>\n<p>- Child: starting dose of 2 mg/kg/day for 2</p>\n<p>weeks,if</p>\n<p>- not controlled increase to 3 mg/kg for 2 months,</p>\n<p>if not controlled increase until maximum of 6</p>\n<p>mg/ kg/day</p>\n<p>- It takes 2-3 weeks for the drug to achieve steady</p>\n<p>blood levels so assess effect only after this period</p>\n<p>Side effects: drowsiness, lethargy, hyperactivity</p>\n<p>and irritability in children, skin rash, confusion in elderly,</p>\n<p>depression</p>\n<h3>HC3</h3>\n<p>Phenytoin</p>\n<p>Effective in all forms of epilepsy except absences.</p>\n<p>- Adult: starting dose of 150-200 mg daily as</p>\n<p>single dose or 2 divided doses and maintenance</p>\n<p>dose of 200-400 mg daily</p>\n<p>- Child: starting dose of 3-4 mg/kg and</p>\n<p>- maintenance dose of 3-8 mg/kg/day (max 300</p>\n<p>mg daily)</p>\n<p>- Increase slowly by 25-30 mg every 2 weeks</p>\n<p>Side effects: drowsiness, ataxia, slurred speech, blurred</p>\n<p>vision, twitching, confusion, gum hyperplasia, blood ab\u00ad</p>\n<p>normalities, rash, hepatitis</p>\n<p>494</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 561,
        "content": "TREATMENT\nLOC\nEthosuximide\nEffective in absence seizures.\n \n- Child >6 years: initially 500 mg daily in 2 divided \ndoses, increase if necessary by 250 mg every \n5-7 days up to a usual daily dose of 1-1.5 g in 2 \ndivided doses\n \n- Child 1 month to 6 years: Initially 250 mg single\n \n- dose at night increased gradually every 5-7 days \nas required to usual dose of 20 to 40 mg/kg daily \nin 2 divided doses\n Side effects: gastrointestinal disorders, blood\ndisorders, gum hyperplasia, drowsiness\nRR\nNote\n \n\u0083 In children, look for presence of associated intellectual disability \nor behavioural problems. If present, consider carbamazepine \nor valproate. (avoid phenobarbital and phenytoin) and manage \nassociated intellectual disability or behavioural problem\n \n\u0083 All pregnant women with epilepsy should be referred to \nspecialist for appropriate management (most\nHealth education\n \n~\nHealth/psycho-education to patients, carers and commu\u00ad\nnity\n \n~\nAdvice on management of seizures and safety precautions\n \n~\nIn children, look for and manage presence of associated  \nintellectual disability or behavioural problems\nPrevention\n \n~\nGood antenatal care and delivery\n \n~\nAvoid causative factors\n495\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Ethosuximide</p>\n<p>Effective in absence seizures.</p>\n<p>- Child >6 years: initially 500 mg daily in 2 divided</p>\n<p>doses, increase if necessary by 250 mg every</p>\n<p>5-7 days up to a usual daily dose of 1-1.5 g in 2</p>\n<p>divided doses</p>\n<p>- Child 1 month to 6 years: Initially 250 mg single</p>\n<p>- dose at night increased gradually every 5-7 days</p>\n<p>as required to usual dose of 20 to 40 mg/kg daily</p>\n<p>in 2 divided doses</p>\n<p>Side effects: gastrointestinal disorders, blood</p>\n<p>disorders, gum hyperplasia, drowsiness</p>\n<p>RR</p>\n<p>Note</p>\n<p>\u0083 In children, look for presence of associated intellectual disability</p>\n<p>or behavioural problems. If present, consider carbamazepine</p>\n<p>or valproate. (avoid phenobarbital and phenytoin) and manage</p>\n<p>associated intellectual disability or behavioural problem</p>\n<p>\u0083 All pregnant women with epilepsy should be referred to</p>\n<p>specialist for appropriate management (most</p>\n<p>Health education</p>\n<p>~</p>\n<p>Health/psycho-education to patients, carers and commu\u00ad</p>\n<p>nity</p>\n<p>~</p>\n<p>Advice on management of seizures and safety precautions</p>\n<p>~</p>\n<p>In children, look for and manage presence of associated</p>\n<p>intellectual disability or behavioural problems</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Good antenatal care and delivery</p>\n<p>~</p>\n<p>Avoid causative factors</p>\n<p>495</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 562,
        "content": "9.1.2\t\nNodding Disease\t\nICD10 CODE: G40.4\nAn unexplained neurologic condition characterized by episodes of \nrepetitive dropping forward of the head, often accompanied by other \nseizure-like activity, such as  convulsions or staring spells.\nThe condition predominantly affects children aged 5\u201315 years and has \nbeen reported in South Sudan from the states of Western and Central \nEquatorial, northern Uganda and southern Tanzania.\nCause\nNot yet certain but consistent association with onchocerciasis has been \nfound\nOther associated factors: malnutrition, pyridoxine   deficiency\nClinical features\n \n~\nStarts at age 5-7 years in previously normal child\n \n~\nEarly symptoms: problems in concentration and thinking\n \n~\nThen \u201cnodding\u201d starts, which is a type of seizure (atonic \nseizures) often triggered by eating or cold temperatures\n \n~\nCognitive impairment appears\n \n~\nNeurological deterioration, delayed puberty and growth \nretardation progresses until the child becomes mentally \nand physically disabled\nInvestigations\n \n\u0081\nNo diagnostic investigations have been identified\nChronic epilepsy\nTREATMENT\nLOC\n Supportive\n Antiepileptic drugs as above (valproate and\nphenobarbital)\nHC4\n496\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>9.1.2</p>\n<p>Nodding Disease</p>\n<h3>ICD10 CODE: G40.4</h3>\n<p>An unexplained neurologic condition characterized by episodes of</p>\n<p>repetitive dropping forward of the head, often accompanied by other</p>\n<p>seizure-like activity, such as  convulsions or staring spells.</p>\n<p>The condition predominantly affects children aged 5\u201315 years and has</p>\n<p>been reported in South Sudan from the states of Western and Central</p>\n<p>Equatorial, northern Uganda and southern Tanzania.</p>\n<p>Cause</p>\n<p>Not yet certain but consistent association with onchocerciasis has been</p>\n<p>found</p>\n<p>Other associated factors: malnutrition, pyridoxine   deficiency</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Starts at age 5-7 years in previously normal child</p>\n<p>~</p>\n<p>Early symptoms: problems in concentration and thinking</p>\n<p>~</p>\n<p>Then \u201cnodding\u201d starts, which is a type of seizure (atonic</p>\n<p>seizures) often triggered by eating or cold temperatures</p>\n<p>~</p>\n<p>Cognitive impairment appears</p>\n<p>~</p>\n<p>Neurological deterioration, delayed puberty and growth</p>\n<p>retardation progresses until the child becomes mentally</p>\n<p>and physically disabled</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>No diagnostic investigations have been identified</p>\n<p>Chronic epilepsy</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Supportive</p>\n<p>Antiepileptic drugs as above (valproate and</p>\n<p>phenobarbital)</p>\n<h3>HC4</h3>\n<p>496</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 563,
        "content": "9.1.3\t\nHeadache\t\nICD10 CODE: R51 \nCommon complaint and cause of disability. Pain can be of varying \nintensity and affect different areas of the head.\nCauses\n \n~\nFacial and frontal headache: sinusitis, eye problems, oro\u00ad\npharyngeal disorders\n \n~\nTemporal headache: severe hypertension, stress, ear disor\u00ad\nders, subarachnoid haemorrhage\n \n~\nTop of the head: stress, tension\n \n~\nUnilateral (one sided): migraine\n \n~\nWhole head: malaria, meningitis, severe hypertension, de\u00ad\nhydration\n \n~\nBack of the head (occiput and neck): meningitis, malaria, \nrefractive eye problems, neck trauma or sprain, tension\nSign Or Symptom\nPossible Cause\nRecent trauma to the \nhead\nIntracranial bleeding\nHead injury\nHigh fever\nMalaria Meningitis\nOther infections\nAcute onset, severe\nIntracranial bleeding\nChronic worsening \nheadache\nTumours, hypertension\nAltered consciousness \nand/or focal neurolog\u00ad\nical symptoms and/or \nseizure\nTumour, intracranial bleeding, intracranial \ninfection\nDanger signs\n497\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>9.1.3</p>\n<p>Headache</p>\n<h3>ICD10 CODE: R51</h3>\n<p>Common complaint and cause of disability. Pain can be of varying</p>\n<p>intensity and affect different areas of the head.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Facial and frontal headache: sinusitis, eye problems, oro\u00ad</p>\n<p>pharyngeal disorders</p>\n<p>~</p>\n<p>Temporal headache: severe hypertension, stress, ear disor\u00ad</p>\n<p>ders, subarachnoid haemorrhage</p>\n<p>~</p>\n<p>Top of the head: stress, tension</p>\n<p>~</p>\n<p>Unilateral (one sided): migraine</p>\n<p>~</p>\n<p>Whole head: malaria, meningitis, severe hypertension, de\u00ad</p>\n<p>hydration</p>\n<p>~</p>\n<p>Back of the head (occiput and neck): meningitis, malaria,</p>\n<p>refractive eye problems, neck trauma or sprain, tension</p>\n<p>Sign Or Symptom</p>\n<p>Possible Cause</p>\n<p>Recent trauma to the</p>\n<p>head</p>\n<p>Intracranial bleeding</p>\n<p>Head injury</p>\n<p>High fever</p>\n<p>Malaria Meningitis</p>\n<p>Other infections</p>\n<p>Acute onset, severe</p>\n<p>Intracranial bleeding</p>\n<p>Chronic worsening</p>\n<p>headache</p>\n<p>Tumours, hypertension</p>\n<p>Altered consciousness</p>\n<p>and/or focal neurolog\u00ad</p>\n<p>ical symptoms and/or</p>\n<p>seizure</p>\n<p>Tumour, intracranial bleeding, intracranial</p>\n<p>infection</p>\n<p>Danger signs</p>\n<p>497</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 564,
        "content": "TREATMENT\nLOC\n Investigate and treat cause if found/possible\n If any danger signs, refer to hospital for further assessment\n Follow pain ladder for control of symptoms\nHC2\n9.1.3.1 Migraine\t               ICD10 CODE: G43 \nPeriodic severe headache, usually unilateral, which may occur with or \nwithout an aura (neurological warning signs) and associated with nausea \nand/or vomiting\nCauses\nThe cause is unknown but thought to be linked to:\n \n~\nFamilial factors\n \n~\nCraniovascular disorders, which can be precipitated by: \nstress, anxiety, menstruation, flashing lights, hunger, lack \nof sleep, oestrogens (in COC), perfumes, tyramine- con\u00ad\ntaining foods e.g. red wine, cheese, chocolate\n \n~\nClinical features\n \n~\nWarning signs (aura): visual or sensory sympotms (flashing \nlights) preceeding the start of the headache\n \n~\nMigraine with warning signs is called migraine with aura. \nThey are not always present\n \n~\nModerate to severe episodic unilateral headache throbbing \n(pulsating)\n \n~\nNausea and vomiting, sensitivity to light and sound\nDifferential diagnosis\n \n~\nAny cause of headache\n \n~\nConversion disorder (hysteria)\n498\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Investigate and treat cause if found/possible</p>\n<p>If any danger signs, refer to hospital for further assessment</p>\n<p>Follow pain ladder for control of symptoms</p>\n<h3>HC2</h3>\n<p>9.1.3.1 Migraine\t               ICD10 CODE: G43</p>\n<p>Periodic severe headache, usually unilateral, which may occur with or</p>\n<p>without an aura (neurological warning signs) and associated with nausea</p>\n<p>and/or vomiting</p>\n<p>Causes</p>\n<p>The cause is unknown but thought to be linked to:</p>\n<p>~</p>\n<p>Familial factors</p>\n<p>~</p>\n<p>Craniovascular disorders, which can be precipitated by:</p>\n<p>stress, anxiety, menstruation, flashing lights, hunger, lack</p>\n<p>of sleep, oestrogens (in COC), perfumes, tyramine- con\u00ad</p>\n<p>taining foods e.g. red wine, cheese, chocolate</p>\n<p>~</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Warning signs (aura): visual or sensory sympotms (flashing</p>\n<p>lights) preceeding the start of the headache</p>\n<p>~</p>\n<p>Migraine with warning signs is called migraine with aura.</p>\n<p>They are not always present</p>\n<p>~</p>\n<p>Moderate to severe episodic unilateral headache throbbing</p>\n<p>(pulsating)</p>\n<p>~</p>\n<p>Nausea and vomiting, sensitivity to light and sound</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Any cause of headache</p>\n<p>~</p>\n<p>Conversion disorder (hysteria)</p>\n<p>498</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 565,
        "content": "Investigations\n \n\u0081\nNo specific investigations needed except if another cause is \nsuspected\nTREATMENT\nLOC\nTreatment of acute episode\n Paracetamol 1 g every 6 hours\n Or Ibuprofen 400 mg every 6-8 hours\n Or Acetylsalicilic acid 300-900 mg every 4-6 hours (max \n4 g daily)\nHC2\nIf severe and/or not responding to the above treatment\n Diclofenac 75 mg IM\n \n- Plus metoclopramide 10 mg IM /IV for the \nnausea and vomiting\n Or ergotamine 2 mg sublingual, then 1-2 mg\nhourly to a max of 6 mg in 24 hours\n Or Sumatriptan 50 mg, repeat after 2 hours if necessary, \nmax 300 mg in 24 hours\nHC4\nRR\nProphylaxis: in case of >3 attacks/month and/or functional \nimpairment\n Amitriptyline 10-75 mg nocte or\n Propranolol 40-80 mg every 12 hours\nHC3\nHC4\nPrevention\n \n~\nAvoid precipitating factors\n9.1.4 Dementia\t ICD10 CODE: F01, F03\nA chronic slowly progressive organic mental disorder characterised by \nprogressive loss of memory and cognitive function, with difficulty in \ncarrying out everyday activities.\n499\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>No specific investigations needed except if another cause is</p>\n<p>suspected</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment of acute episode</p>\n<p>Paracetamol 1 g every 6 hours</p>\n<p>Or Ibuprofen 400 mg every 6-8 hours</p>\n<p>Or Acetylsalicilic acid 300-900 mg every 4-6 hours (max</p>\n<p>4 g daily)</p>\n<h3>HC2</h3>\n<p>If severe and/or not responding to the above treatment</p>\n<p>Diclofenac 75 mg IM</p>\n<p>- Plus metoclopramide 10 mg IM /IV for the</p>\n<p>nausea and vomiting</p>\n<p>Or ergotamine 2 mg sublingual, then 1-2 mg</p>\n<p>hourly to a max of 6 mg in 24 hours</p>\n<p>Or Sumatriptan 50 mg, repeat after 2 hours if necessary,</p>\n<p>max 300 mg in 24 hours</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>Prophylaxis: in case of >3 attacks/month and/or functional</p>\n<p>impairment</p>\n<p>Amitriptyline 10-75 mg nocte or</p>\n<p>Propranolol 40-80 mg every 12 hours</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid precipitating factors</p>\n<p>9.1.4 Dementia\t ICD10 CODE: F01, F03</p>\n<p>A chronic slowly progressive organic mental disorder characterised by</p>\n<p>progressive loss of memory and cognitive function, with difficulty in</p>\n<p>carrying out everyday activities.</p>\n<p>499</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 566,
        "content": "Causes\n \n~\nPrimary degeneration of the brain\n \n~\nVascular disorders\n \n~\nInfections e.g. syphilis, TB, HIV/AIDS, meningitis\n \n~\nMetabolic disorders e.g. hypothyroidism\n \n~\nDeficiencies of vitamin B12 and B1\n \n~\nBrain trauma (chronic subdural haematoma, hydrocepha\u00ad\nlus)\n \n~\nToxic agents e.g. carbon monoxide, alcohol\nClinical features\n \n~\nImpairment of short and long-term memory\n \n~\nImpaired judgment, poor abstract thinking\n \n~\nLanguage disturbances (aphasia)\n \n~\nPersonality changes: may become apathetic or withdrawn,  \nmay have associated anxiety or depression because of fail\u00ad\ning memory, may become aggressive\n \n~\nWandering and incontinence in later stages\nDifferential diagnosis \n \n\u0081\nNormal aging \n \n\u0081\nDelirium, chronic psychosis, depression\nInvestigations\n \n\u0081\nGuided by history and clinical picture to establish cause\n \n\u0081\nThorough physical, neurologic and mental state examination\n \n\u0081\nLaboratory: thyroid hormones, RPR and vitamin B12 levels, \nother tests as indicated\n500\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Causes</p>\n<p>~</p>\n<p>Primary degeneration of the brain</p>\n<p>~</p>\n<p>Vascular disorders</p>\n<p>~</p>\n<p>Infections e.g. syphilis, TB, HIV/AIDS, meningitis</p>\n<p>~</p>\n<p>Metabolic disorders e.g. hypothyroidism</p>\n<p>~</p>\n<p>Deficiencies of vitamin B12 and B1</p>\n<p>~</p>\n<p>Brain trauma (chronic subdural haematoma, hydrocepha\u00ad</p>\n<p>lus)</p>\n<p>~</p>\n<p>Toxic agents e.g. carbon monoxide, alcohol</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Impairment of short and long-term memory</p>\n<p>~</p>\n<p>Impaired judgment, poor abstract thinking</p>\n<p>~</p>\n<p>Language disturbances (aphasia)</p>\n<p>~</p>\n<p>Personality changes: may become apathetic or withdrawn,</p>\n<p>may have associated anxiety or depression because of fail\u00ad</p>\n<p>ing memory, may become aggressive</p>\n<p>~</p>\n<p>Wandering and incontinence in later stages</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Normal aging</p>\n<p>\u0081</p>\n<p>Delirium, chronic psychosis, depression</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Guided by history and clinical picture to establish cause</p>\n<p>\u0081</p>\n<p>Thorough physical, neurologic and mental state examination</p>\n<p>\u0081</p>\n<p>Laboratory: thyroid hormones, RPR and vitamin B12 levels,</p>\n<p>other tests as indicated</p>\n<p>500</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 567,
        "content": "TREATMENT\nLOC\n Where possible, identify and treat the cause\n Psychosocial interventions:\n \n- psychoeducation of family members about the \nillness and about following a regular routine \nprogramme\n \n- provision of regular orientation information\n \n- creation of an environment to support activities \nof daily living\n Assess for and treat other co-occurring health problems \ne.g. depression, HIV\nHC2\n Donepezil 5mg once daily initially, can increase to 10mg \nafter 4-6 weeks\n Alternatively; Memantine 10mg once daily initially, can \nincrease to 20mg after 4-6 weeks \nPreferably at bed time\nNote: These medicines only slow progression of symptoms \nbut not cure dementia.\nIf restless and agitated\n Haloperidol 0.5-1 mg every 8 hours with higher dose at \nnight if required\nAlternatively; Risperidone 0.5-1 mg once daily, preferably \nat night.\n \n- Adjust dose according to response and review \nregularly, monitor for and treat extrapyramidal \nside effects with Benzhexol 2 mg every 12 hours \nif necessary\nH\nHC4\nCaution\n Avoid Diazepam: it can lead to falls and is often not effective\n501\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Where possible, identify and treat the cause</p>\n<p>Psychosocial interventions:</p>\n<p>- psychoeducation of family members about the</p>\n<p>illness and about following a regular routine</p>\n<p>programme</p>\n<p>- provision of regular orientation information</p>\n<p>- creation of an environment to support activities</p>\n<p>of daily living</p>\n<p>Assess for and treat other co-occurring health problems</p>\n<p>e.g. depression, HIV</p>\n<h3>HC2</h3>\n<p>Donepezil 5mg once daily initially, can increase to 10mg</p>\n<p>after 4-6 weeks</p>\n<p>Alternatively; Memantine 10mg once daily initially, can</p>\n<p>increase to 20mg after 4-6 weeks</p>\n<p>Preferably at bed time</p>\n<p>Note: These medicines only slow progression of symptoms</p>\n<p>but not cure dementia.</p>\n<p>If restless and agitated</p>\n<p>Haloperidol 0.5-1 mg every 8 hours with higher dose at</p>\n<p>night if required</p>\n<p>Alternatively; Risperidone 0.5-1 mg once daily, preferably</p>\n<p>at night.</p>\n<p>- Adjust dose according to response and review</p>\n<p>regularly, monitor for and treat extrapyramidal</p>\n<p>side effects with Benzhexol 2 mg every 12 hours</p>\n<p>if necessary</p>\n<p>H</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>Avoid Diazepam: it can lead to falls and is often not effective</p>\n<p>501</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 568,
        "content": "Caution\n \n~\nAvoid Diazepam: it can lead to falls and is often not effec\u00ad\ntive\n \n~\nPrevention\n \n~\nAvoid and treat preventable causes\n9.1.5\t\nParkinsonism\t\nICD10 CODE: G20, G21\nA syndrome characterized by tremor, rigidity, bradykinesia (slow move\u00ad\nment) and postural disturbances, due to primary degeneration or damage \nto particular areas of the brain\n(basal ganglia).\nCauses\nPrimary Parkinsonism:\n \n~\nCause is unknown\nSecondary Parkinsonism:\n \n~\nInfections e.g. sleeping sickness, syphilis\n \n~\nPoisoning e.g. manganese, carbon monoxide\n \n~\nDrugs e.g. chlorpromazine, haloperidol\n \n~\nVascular disorders, intracranial tumour, trauma\nClinical features\n \n~\nNon intentional tremor\n \n~\nMuscle rigidity\n \n~\nSlowness of voluntary movement\n \n~\nWalking with short quick steps (shuffling gait)\n \n~\nVacant facial expression (mask face)\n502\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Caution</p>\n<p>~</p>\n<p>Avoid Diazepam: it can lead to falls and is often not effec\u00ad</p>\n<p>tive</p>\n<p>~</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid and treat preventable causes</p>\n<p>9.1.5</p>\n<p>Parkinsonism</p>\n<h3>ICD10 CODE: G20, G21</h3>\n<p>A syndrome characterized by tremor, rigidity, bradykinesia (slow move\u00ad</p>\n<p>ment) and postural disturbances, due to primary degeneration or damage</p>\n<p>to particular areas of the brain</p>\n<p>(basal ganglia).</p>\n<p>Causes</p>\n<p>Primary Parkinsonism:</p>\n<p>~</p>\n<p>Cause is unknown</p>\n<p>Secondary Parkinsonism:</p>\n<p>~</p>\n<p>Infections e.g. sleeping sickness, syphilis</p>\n<p>~</p>\n<p>Poisoning e.g. manganese, carbon monoxide</p>\n<p>~</p>\n<p>Drugs e.g. chlorpromazine, haloperidol</p>\n<p>~</p>\n<p>Vascular disorders, intracranial tumour, trauma</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Non intentional tremor</p>\n<p>~</p>\n<p>Muscle rigidity</p>\n<p>~</p>\n<p>Slowness of voluntary movement</p>\n<p>~</p>\n<p>Walking with short quick steps (shuffling gait)</p>\n<p>~</p>\n<p>Vacant facial expression (mask face)</p>\n<p>502</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 569,
        "content": "~\nExcessive salivation\n \n~\nUrinary incontinence (sometimes occurs)\n \n~\nVariable cognitive impairment\nDifferential diagnosis\n \n~\nEssential tremor (isolated intentional tremor, benign)\n \n~\nThyrotoxicosis\n \n~\nDementia, depression\nInvestigations\n \n\u0081\nGood history and clinical examination\nManagement\nTREATMENT\nLOC\n Levodopa-carbidopa 10/100 mg. The dose can increased \nto 25/100mg\n Start with 1 tablet every 8 hours (specialist only management)\nOnly for drug-induced parkinsonism\n Benzhexol 2-15 mg daily in 1-3 divided doses\n \n- Initially: 1 mg/day; increase by 2 mg increments \nat intervals of 3 to 5 days\n \n- Usual dose: 6 to 10 mg/day in 3 to 4 divided \ndoses; doses of 12 to 15 mg/day may be required\nRR\nHC2\nCaution\n Benzhexol side effects: dry mouth, constipation, \npalpitations, urinary retention, confusion and agitation \n(especially in the elderly)\n Do not give benzhexol routinely to patients on\nantipsychotic medicines in the absence of Parkinson- \nlike\n503\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Excessive salivation</p>\n<p>~</p>\n<p>Urinary incontinence (sometimes occurs)</p>\n<p>~</p>\n<p>Variable cognitive impairment</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Essential tremor (isolated intentional tremor, benign)</p>\n<p>~</p>\n<p>Thyrotoxicosis</p>\n<p>~</p>\n<p>Dementia, depression</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Good history and clinical examination</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Levodopa-carbidopa 10/100 mg. The dose can increased</p>\n<p>to 25/100mg</p>\n<p>Start with 1 tablet every 8 hours (specialist only management)</p>\n<p>Only for drug-induced parkinsonism</p>\n<p>Benzhexol 2-15 mg daily in 1-3 divided doses</p>\n<p>- Initially: 1 mg/day; increase by 2 mg increments</p>\n<p>at intervals of 3 to 5 days</p>\n<p>- Usual dose: 6 to 10 mg/day in 3 to 4 divided</p>\n<p>doses; doses of 12 to 15 mg/day may be required</p>\n<p>RR</p>\n<h3>HC2</h3>\n<p>Caution</p>\n<p>Benzhexol side effects: dry mouth, constipation,</p>\n<p>palpitations, urinary retention, confusion and agitation</p>\n<p>(especially in the elderly)</p>\n<p>Do not give benzhexol routinely to patients on</p>\n<p>antipsychotic medicines in the absence of Parkinson-</p>\n<p>like</p>\n<p>503</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 570,
        "content": "9.1.6\t\nDelirium (Acute Confusional State)\t\nICD10 CODE: \nF05\nA clinical syndrome usually with acute onset, which involves abnormalities \nin thought and perception and fluctuating level of consciousness. It is \ncaused by impaired brain function resulting from diffuse physiological \nchange.\nCauses\n \n~\nInfections e.g. malaria, trypanosomiasis, syphilis, meningi\u00ad\ntis, rabies, typhoid fever, HIV/AIDS\n \n~\nPneumonia and urinary tract infections in elderly\n \n~\nIntoxication with or withdrawal from alcohol or other sub\u00ad\nstances of dependence\n \n~\nSome medicines e.g. anticonvulsants and neuropsychiatric \nmedications\n \n~\nCerebral pathology e.g. head trauma, tumour\n \n~\nSevere anaemia, dehydration\n \n~\nElectrolyte imbalances, hyperglycemia\nClinical features\n \n~\nAcute onset of mental confusion with associated disorien\u00ad\ntation, developing within hours or a few days. Attention, \nconcentration and memory for recent events is impaired\n \n~\nReduced ability to think coherently: reasoning and problem \nsolving are difficult or impossible\n \n~\nIllusions and hallucinations are common\n \n~\nSymptoms tend to fluctuate: patients feel better in the day \nand worse at night\n \n~\nSome patients may present with reduced activity and/or \nmovement (hypoactive delirium)\n504\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>9.1.6</p>\n<p>Delirium (Acute Confusional State)</p>\n<h3>ICD10 CODE:</h3>\n<h3>F05</h3>\n<p>A clinical syndrome usually with acute onset, which involves abnormalities</p>\n<p>in thought and perception and fluctuating level of consciousness. It is</p>\n<p>caused by impaired brain function resulting from diffuse physiological</p>\n<p>change.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Infections e.g. malaria, trypanosomiasis, syphilis, meningi\u00ad</p>\n<p>tis, rabies, typhoid fever, HIV/AIDS</p>\n<p>~</p>\n<p>Pneumonia and urinary tract infections in elderly</p>\n<p>~</p>\n<p>Intoxication with or withdrawal from alcohol or other sub\u00ad</p>\n<p>stances of dependence</p>\n<p>~</p>\n<p>Some medicines e.g. anticonvulsants and neuropsychiatric</p>\n<p>medications</p>\n<p>~</p>\n<p>Cerebral pathology e.g. head trauma, tumour</p>\n<p>~</p>\n<p>Severe anaemia, dehydration</p>\n<p>~</p>\n<p>Electrolyte imbalances, hyperglycemia</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Acute onset of mental confusion with associated disorien\u00ad</p>\n<p>tation, developing within hours or a few days. Attention,</p>\n<p>concentration and memory for recent events is impaired</p>\n<p>~</p>\n<p>Reduced ability to think coherently: reasoning and problem</p>\n<p>solving are difficult or impossible</p>\n<p>~</p>\n<p>Illusions and hallucinations are common</p>\n<p>~</p>\n<p>Symptoms tend to fluctuate: patients feel better in the day</p>\n<p>and worse at night</p>\n<p>~</p>\n<p>Some patients may present with reduced activity and/or</p>\n<p>movement (hypoactive delirium)</p>\n<p>504</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 571,
        "content": "Differential diagnosis\nAcute psychosis\nInvestigations\n \n~\nGuided by history and physical examination: aim at identi\u00ad\nfying the cause\nNB: drug history is very important!\n \n~\nCBC, blood glucose, RDT, renal function and electrolytes\nManagement\nDue to the complexity of underlying conditions, patients with acute con\u00ad\nfusional state should be referred to hospital for appropriate management \nand investigation.\nManagement\nTREATMENT\nLOC\n Identify and treat the cause such as substance \nand alcohol use disorders, diabetes, head injury or \ninfections e.g. malaria, UTI, pneumonia in older \npeople\nSupportive treatment\n Ensure hydration, control of fever, safe and quiet \nenvironment, constant monitoring\n Withhold any unnecessary medicines, keep the \nuse of sedatives and antipsychotics to the minimum \nnecessary\nH\nIf patient is agitated and acutely disturbed\n Haloperidol 5 mg IM: repeat after 60 min if \nnecessary\n \n- Continue with haloperidol 1.25-5 mg every 8 \nto 12 hours\n Or chlorpromazine 25-50 mg every 8-12 hours \n(IM or oral)\n Trifluoperazine 5-10 mg every 12 hours\n505\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>Acute psychosis</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Guided by history and physical examination: aim at identi\u00ad</p>\n<p>fying the cause</p>\n<p>NB: drug history is very important!</p>\n<p>~</p>\n<p>CBC, blood glucose, RDT, renal function and electrolytes</p>\n<p>Management</p>\n<p>Due to the complexity of underlying conditions, patients with acute con\u00ad</p>\n<p>fusional state should be referred to hospital for appropriate management</p>\n<p>and investigation.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Identify and treat the cause such as substance</p>\n<p>and alcohol use disorders, diabetes, head injury or</p>\n<p>infections e.g. malaria, UTI, pneumonia in older</p>\n<p>people</p>\n<p>Supportive treatment</p>\n<p>Ensure hydration, control of fever, safe and quiet</p>\n<p>environment, constant monitoring</p>\n<p>Withhold any unnecessary medicines, keep the</p>\n<p>use of sedatives and antipsychotics to the minimum</p>\n<p>necessary</p>\n<p>H</p>\n<p>If patient is agitated and acutely disturbed</p>\n<p>Haloperidol 5 mg IM: repeat after 60 min if</p>\n<p>necessary</p>\n<p>- Continue with haloperidol 1.25-5 mg every 8</p>\n<p>to 12 hours</p>\n<p>Or chlorpromazine 25-50 mg every 8-12 hours</p>\n<p>(IM or oral)</p>\n<p>Trifluoperazine 5-10 mg every 12 hours</p>\n<p>505</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 572,
        "content": "Prevention\n \n~\nEarly diagnosis and treatment of underlying cause\n9.2 PSYCHIATRIC AND SUBSTANCE USE DISORDERS\n9.2.1\t\nAnxiety\t     ICD10 CODE: F40-F48\nAnxiety is a normal physiological response, which enables a person to \ntake steps to deal with a threat. When anxiety is prolonged or interferes \nwith normal functions of the\nindividual, it constitutes the clinical condition of an anxiety disorder.\nCauses\n \n~\nNot fully understood: possibly external traumatic events \nmay trigger anxiety in predisposed people\n \n~\nAssociation with other mental conditions e.g. depression, \nalcohol and substance abuse\nTypes and clinical features\n \n~\nGeneralized anxiety: Unrealistic and excessive worry about \nalmost everything\n \n~\nPanic attacks: Episodes of sudden onset of intense appre\u00ad\nhension or fear; anxiety symptoms usually peak within 10-\n15 minutes and resolve in a few minutes to one hour\n \n~\nPhobia: An excessive fear of a known stimulus (object or\n \n~\nsituation) e.g. animals, water, confined space) causing the \nperson to consciously avoid the object or situation\nEach of the above clinical types will have one or more of the \nfollowing manifestations:\n \n~\nSleep, mood and concentration problems\n506\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Early diagnosis and treatment of underlying cause</p>\n<h3>9.2 PSYCHIATRIC AND SUBSTANCE USE DISORDERS</h3>\n<p>9.2.1</p>\n<p>Anxiety\t     ICD10 CODE: F40-F48</p>\n<p>Anxiety is a normal physiological response, which enables a person to</p>\n<p>take steps to deal with a threat. When anxiety is prolonged or interferes</p>\n<p>with normal functions of the</p>\n<p>individual, it constitutes the clinical condition of an anxiety disorder.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not fully understood: possibly external traumatic events</p>\n<p>may trigger anxiety in predisposed people</p>\n<p>~</p>\n<p>Association with other mental conditions e.g. depression,</p>\n<p>alcohol and substance abuse</p>\n<p>Types and clinical features</p>\n<p>~</p>\n<p>Generalized anxiety: Unrealistic and excessive worry about</p>\n<p>almost everything</p>\n<p>~</p>\n<p>Panic attacks: Episodes of sudden onset of intense appre\u00ad</p>\n<p>hension or fear; anxiety symptoms usually peak within 10-</p>\n<p>15 minutes and resolve in a few minutes to one hour</p>\n<p>~</p>\n<p>Phobia: An excessive fear of a known stimulus (object or</p>\n<p>~</p>\n<p>situation) e.g. animals, water, confined space) causing the</p>\n<p>person to consciously avoid the object or situation</p>\n<p>Each of the above clinical types will have one or more of the</p>\n<p>following manifestations:</p>\n<p>~</p>\n<p>Sleep, mood and concentration problems</p>\n<p>506</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 573,
        "content": "~\nPalpitations, dizziness, shortness of breath\n \n~\nShakiness or tremors, excessive sweatiness\n \n~\nEasily frightened\n \n~\nOther symptoms: urinary frequency, hesitancy, or urgency, \ndiarrhoea\nDifferential diagnosis\n \n~\nConsider organic conditions e.g. hyperthyroidism, hypogly\u00ad\ncaemia, phaeochromocytoma\nManagement\nTREATMENT\nLOC\n Psychosocial interventions: counselling, \npsychotherapy (individual and group psychotherapy)\nFor an acute episode or intense prolonged anxiety\n Benzodiazepines e.g. diazepam 5 mg 1-2 times daily\n \n- Increase if necessary to 15-30 mg daily in \ndivided doses\nElderly: Alprazolam 0.25mg -0.5mg  twice daily \ninitially, Increase if necessary  to 3-6 mg daily in \ndivided doses.\nIf alprazolam is not available, Give half the above dose \nof diazepam\n \n- Duration of therapy 1-2 weeks, tapering off to \nzero within 6 weeks\nIf poor response: refer to specialist\n Fluoxetine 20 mg once a day for long term \nmanagement of the anxiety disorder\nOr Sertraline 50mg once daily\n \n- Continue antidepressant for 4 to 6 weeks then \nevaluate the response\nHC2\nHC4\n507\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Palpitations, dizziness, shortness of breath</p>\n<p>~</p>\n<p>Shakiness or tremors, excessive sweatiness</p>\n<p>~</p>\n<p>Easily frightened</p>\n<p>~</p>\n<p>Other symptoms: urinary frequency, hesitancy, or urgency,</p>\n<p>diarrhoea</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Consider organic conditions e.g. hyperthyroidism, hypogly\u00ad</p>\n<p>caemia, phaeochromocytoma</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Psychosocial interventions: counselling,</p>\n<p>psychotherapy (individual and group psychotherapy)</p>\n<p>For an acute episode or intense prolonged anxiety</p>\n<p>Benzodiazepines e.g. diazepam 5 mg 1-2 times daily</p>\n<p>- Increase if necessary to 15-30 mg daily in</p>\n<p>divided doses</p>\n<p>Elderly: Alprazolam 0.25mg -0.5mg  twice daily</p>\n<p>initially, Increase if necessary  to 3-6 mg daily in</p>\n<p>divided doses.</p>\n<p>If alprazolam is not available, Give half the above dose</p>\n<p>of diazepam</p>\n<p>- Duration of therapy 1-2 weeks, tapering off to</p>\n<p>zero within 6 weeks</p>\n<p>If poor response: refer to specialist</p>\n<p>Fluoxetine 20 mg once a day for long term</p>\n<p>management of the anxiety disorder</p>\n<p>Or Sertraline 50mg once daily</p>\n<p>- Continue antidepressant for 4 to 6 weeks then</p>\n<p>evaluate the response</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>507</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 574,
        "content": "Caution\n Diazepam is addictive and abrupt cessation can cause \nwithdrawal symptoms. Use for short periods and gradually \nreduce the dose. Avoid alcohol\nNotes\n \n\u0083 Diazepam is NOT appropriate for treating depression, phobic \nor obsessional states, or chronic psychoses (see relevant \nsections 9.2.2 for more information)\n \n\u0083 Antidepressants: May be useful in managing panic disorders \nand other anxiety disorders which require long term treatment\nPrevention\n \n~\nGood personality development\n \n~\nGood stress management\n9.2.2\t\nDepression\t\nICD10 CODE: F32, F33\nA common disorder characterised by low mood, loss of interest and \nenjoyment and reduced energy leading to diminished activity and in \nsevere forms, difficult day-to-day functioning.\nCauses\n \n~\nBiological, genetic, and environmental factors\nClinical features\nFor at least two weeks, the person had at least two of the symptoms below:\n \n~\nLow mood (most of the day, almost every day)\n \n~\nLoss of interest or pleasure in activities that are normally \npleasurable\n508\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Caution</p>\n<p>Diazepam is addictive and abrupt cessation can cause</p>\n<p>withdrawal symptoms. Use for short periods and gradually</p>\n<p>reduce the dose. Avoid alcohol</p>\n<p>Notes</p>\n<p>\u0083 Diazepam is NOT appropriate for treating depression, phobic</p>\n<p>or obsessional states, or chronic psychoses (see relevant</p>\n<p>sections 9.2.2 for more information)</p>\n<p>\u0083 Antidepressants: May be useful in managing panic disorders</p>\n<p>and other anxiety disorders which require long term treatment</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Good personality development</p>\n<p>~</p>\n<p>Good stress management</p>\n<p>9.2.2</p>\n<p>Depression</p>\n<h3>ICD10 CODE: F32, F33</h3>\n<p>A common disorder characterised by low mood, loss of interest and</p>\n<p>enjoyment and reduced energy leading to diminished activity and in</p>\n<p>severe forms, difficult day-to-day functioning.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Biological, genetic, and environmental factors</p>\n<p>Clinical features</p>\n<p>For at least two weeks, the person had at least two of the symptoms below:</p>\n<p>~</p>\n<p>Low mood (most of the day, almost every day)</p>\n<p>~</p>\n<p>Loss of interest or pleasure in activities that are normally</p>\n<p>pleasurable</p>\n<p>508</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 575,
        "content": "~\nAssociated lack of energy, body weakness or easily fatigued\n \n~\nDuring the 2 weeks, the person also has some of the symp\u00ad\ntoms below:\n \n~\nDifficulty in concentrating, reduced attention\n \n~\nReduced self-esteem and self confidence\n \n~\nPoor sleep, poor appetite, reduced libido\n \n~\nBleak and pessimistic view of the future\n \n~\nFeeling of guilt and unworthiness\n \n~\nMultiple body pains or other medically unexplained somat\u00ad\nic symptoms\n \n~\nIdeas or acts of self harm or suicide (occurs in up to 65% \nof patients)\n \n~\nChildren and adolescents usually present with irritability, \nschool phobia, truancy, poor academic performance, alco\u00ad\nhol and drug abuse\nDifferential diagnosis\n \n~\nThyroid dysfunction (hypothyroidism)\n \n~\nAdrenal dysfunction (Addison\u2019s disease)\n \n~\nParkinson\u2019s disease, stroke, dementia\n \n~\nAnxiety disorder\nInvestigations\n \n\u0081\nMedical, social and personal history\n \n\u0081\nCheck for bereavement or other major personal loss\n \n\u0081\nFind out if person has had an episode of mania in the past: if so \nconsider treatment for bipolar disorder and consult a specialist\n \n\u0081\nFind out if they have psychotic features e.g. hallucinations (refer \nto section 9.2.4 on Psychosis)\n \n\u0081\nAssess for co-occurring health conditions (e.g. HIV/AIDS), \nsubstance or alcohol abuse\n \n\u0081\nAssess risk of self-harm/suicide\n509\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Associated lack of energy, body weakness or easily fatigued</p>\n<p>~</p>\n<p>During the 2 weeks, the person also has some of the symp\u00ad</p>\n<p>toms below:</p>\n<p>~</p>\n<p>Difficulty in concentrating, reduced attention</p>\n<p>~</p>\n<p>Reduced self-esteem and self confidence</p>\n<p>~</p>\n<p>Poor sleep, poor appetite, reduced libido</p>\n<p>~</p>\n<p>Bleak and pessimistic view of the future</p>\n<p>~</p>\n<p>Feeling of guilt and unworthiness</p>\n<p>~</p>\n<p>Multiple body pains or other medically unexplained somat\u00ad</p>\n<p>ic symptoms</p>\n<p>~</p>\n<p>Ideas or acts of self harm or suicide (occurs in up to 65%</p>\n<p>of patients)</p>\n<p>~</p>\n<p>Children and adolescents usually present with irritability,</p>\n<p>school phobia, truancy, poor academic performance, alco\u00ad</p>\n<p>hol and drug abuse</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Thyroid dysfunction (hypothyroidism)</p>\n<p>~</p>\n<p>Adrenal dysfunction (Addison\u2019s disease)</p>\n<p>~</p>\n<p>Parkinson\u2019s disease, stroke, dementia</p>\n<p>~</p>\n<p>Anxiety disorder</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Medical, social and personal history</p>\n<p>\u0081</p>\n<p>Check for bereavement or other major personal loss</p>\n<p>\u0081</p>\n<p>Find out if person has had an episode of mania in the past: if so</p>\n<p>consider treatment for bipolar disorder and consult a specialist</p>\n<p>\u0081</p>\n<p>Find out if they have psychotic features e.g. hallucinations (refer</p>\n<p>to section 9.2.4 on Psychosis)</p>\n<p>\u0081</p>\n<p>Assess for co-occurring health conditions (e.g. HIV/AIDS),</p>\n<p>substance or alcohol abuse</p>\n<p>\u0081</p>\n<p>Assess risk of self-harm/suicide</p>\n<p>509</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 576,
        "content": "Management\nTREATMENT\nLOC\nFirst line\n Psychological therapy (Individual or group psychotherapy) \nis first line for mild cases:\n \n- Psychoeducation (counselling of patient and \nfamily)\n \n- Addressing current stressors (abuse, neglect\u2026)\n \n- Re activating social networks\n \n- Structured physical activities\n \n- Regular follow up\n Manage concurrent physical medical problems\n Address co-existing mental problems e.g. \nsubstance abuse\n If available, consider psychotherapy (cognitive \nbehavioural therapy, interpersonal psychotherapy, \nbehavioural activation etc)\nIf bereavement or another major personal loss\n \n-\n  Counselling and support\n \n-\n Do not consider drugs or psychotherapy as first \nline\n \n- If not responding to all above\n Consider antidepressant\n \n- DO NOT use in children <12 years\n \n- Adolescents: only under specialist supervision\n Fluoxetine 20 mg once daily in the morning\n \n- Start with 10 mg in elderly\n \n- If not better after 4-6 weeks, increase to 40 mg\n Or Amitriptyline 50 mg at bedtime\n \n- Increase by 25 mg every week aiming at 100-150 \nmg in divided doses or single bedtime dose by 4-6 \nweeks of treatment\nHC4\nRR\nH\n510\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First line</p>\n<p>Psychological therapy (Individual or group psychotherapy)</p>\n<p>is first line for mild cases:</p>\n<p>- Psychoeducation (counselling of patient and</p>\n<p>family)</p>\n<p>- Addressing current stressors (abuse, neglect\u2026)</p>\n<p>- Re activating social networks</p>\n<p>- Structured physical activities</p>\n<p>- Regular follow up</p>\n<p>Manage concurrent physical medical problems</p>\n<p>Address co-existing mental problems e.g.</p>\n<p>substance abuse</p>\n<p>If available, consider psychotherapy (cognitive</p>\n<p>behavioural therapy, interpersonal psychotherapy,</p>\n<p>behavioural activation etc)</p>\n<p>If bereavement or another major personal loss</p>\n<p>-</p>\n<p>Counselling and support</p>\n<p>-</p>\n<p>Do not consider drugs or psychotherapy as first</p>\n<p>line</p>\n<p>- If not responding to all above</p>\n<p>Consider antidepressant</p>\n<p>- DO NOT use in children <12 years</p>\n<p>- Adolescents: only under specialist supervision</p>\n<p>Fluoxetine 20 mg once daily in the morning</p>\n<p>- Start with 10 mg in elderly</p>\n<p>- If not better after 4-6 weeks, increase to 40 mg</p>\n<p>Or Amitriptyline 50 mg at bedtime</p>\n<p>- Increase by 25 mg every week aiming at 100-150</p>\n<p>mg in divided doses or single bedtime dose by 4-6</p>\n<p>weeks of treatment</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>H</p>\n<p>510</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 577,
        "content": "Management\nTREATMENT\nLOC\n \n- weeks of treatment\n \n- Useful in case of associated anxiety\n \n- Avoid in adolescents, elderly, heart diseases, \nsuicide risks\n \n- Or Venflaxine 37.5 mg given in the morning or \nevening\n \n- Increase dose to75mg per day divided 8-12 hourly \nHC4\nRR\nH\n \n- Maintenance dose is 75 to 225 mg once a day\n \n- Maximum dose is 375mg; Useful in the patients \nwith comorbid anxiety disorders.\n \n- Or Sertaline 50mg per day; preferred for patients \non other medicines due to its low potential for \ndrug interactions and for breast feeding mothers, \nmay increase dose by 25mg at weekly intervals\n \n- Do not exceed 200mg per day\n \n- Or Escitalopram10mg, may increase dose to 20mg \nper day.\n \n- Or Bupropion 150 mg/day PO for those than \ncannot tolerate SSRIs and with comorbid Nicotine \nuse disorder. Titrate to 150-450 mg/day based on \ntolerability and efficacy; may administer in divided \ndoses\nH\nRR\nRR\nIf patient responding to medication\n Continue for at least 9-12 months\n Consider stopping if patient has been without \ndepressive symptoms and able to carry out normal \nactivities for at least 9 months\n \n- Counsel the patient about withdrawal symptoms\n \n- (dizziness, tingling, anxiety, irritability, nausea, \nheadache, sleep problems)\n511\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- weeks of treatment</p>\n<p>- Useful in case of associated anxiety</p>\n<p>- Avoid in adolescents, elderly, heart diseases,</p>\n<p>suicide risks</p>\n<p>- Or Venflaxine 37.5 mg given in the morning or</p>\n<p>evening</p>\n<p>- Increase dose to75mg per day divided 8-12 hourly</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>H</p>\n<p>- Maintenance dose is 75 to 225 mg once a day</p>\n<p>- Maximum dose is 375mg; Useful in the patients</p>\n<p>with comorbid anxiety disorders.</p>\n<p>- Or Sertaline 50mg per day; preferred for patients</p>\n<p>on other medicines due to its low potential for</p>\n<p>drug interactions and for breast feeding mothers,</p>\n<p>may increase dose by 25mg at weekly intervals</p>\n<p>- Do not exceed 200mg per day</p>\n<p>- Or Escitalopram10mg, may increase dose to 20mg</p>\n<p>per day.</p>\n<p>- Or Bupropion 150 mg/day PO for those than</p>\n<p>cannot tolerate SSRIs and with comorbid Nicotine</p>\n<p>use disorder. Titrate to 150-450 mg/day based on</p>\n<p>tolerability and efficacy; may administer in divided</p>\n<p>doses</p>\n<p>H</p>\n<p>RR</p>\n<p>RR</p>\n<p>If patient responding to medication</p>\n<p>Continue for at least 9-12 months</p>\n<p>Consider stopping if patient has been without</p>\n<p>depressive symptoms and able to carry out normal</p>\n<p>activities for at least 9 months</p>\n<p>- Counsel the patient about withdrawal symptoms</p>\n<p>- (dizziness, tingling, anxiety, irritability, nausea,</p>\n<p>headache, sleep problems)</p>\n<p>511</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 578,
        "content": "Management\nTREATMENT\nLOC\n \n- Counsel the patient about possibility of relapse \nand when to come back\n \n- Reduce slowly over at least 4 weeks even slower \nif\n \n- withdrawal symptoms are significant\n \n- Monitor periodically for re-emergence of \nsymptoms\nIn case of pregnant woman, child, adolescent, \npatients not responding to treatment with \nantidepressant, psychotic features, history of mania\n Refer for specialist management\nCaution\n SSRI in bipolar depression can trigger a manic\nPrevention\n \n~\nStress management skills\n \n~\nPromotion of useful social support networks\n9.2.2.1\t Postnatal Depression\nRefer to section 16.6.2\n \n9.2.2.2\t Suicidal Behaviour/Self Harm ICD10 CODES: T14.91, Z91.5\nSuicidal behaviour is an emergency and requires immediate attention. \nIt is an attempted conscious act of self-destruction, which the individual \nconcerned views as the best solution. It is usually associated with feelings \nof hopelessness, helplessness and conflicts between survival and death.\nSelf-harm is a broader term referring to intentional poisoning or self-in\u00ad\nflicted harm, which may or may not have an intent of fatal outcome.\n512\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Counsel the patient about possibility of relapse</p>\n<p>and when to come back</p>\n<p>- Reduce slowly over at least 4 weeks even slower</p>\n<p>if</p>\n<p>- withdrawal symptoms are significant</p>\n<p>- Monitor periodically for re-emergence of</p>\n<p>symptoms</p>\n<p>In case of pregnant woman, child, adolescent,</p>\n<p>patients not responding to treatment with</p>\n<p>antidepressant, psychotic features, history of mania</p>\n<p>Refer for specialist management</p>\n<p>Caution</p>\n<p>SSRI in bipolar depression can trigger a manic</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Stress management skills</p>\n<p>~</p>\n<p>Promotion of useful social support networks</p>\n<p>9.2.2.1\t Postnatal Depression</p>\n<p>Refer to section 16.6.2</p>\n<p>9.2.2.2\t Suicidal Behaviour/Self Harm ICD10 CODES: T14.91, Z91.5</p>\n<p>Suicidal behaviour is an emergency and requires immediate attention.</p>\n<p>It is an attempted conscious act of self-destruction, which the individual</p>\n<p>concerned views as the best solution. It is usually associated with feelings</p>\n<p>of hopelessness, helplessness and conflicts between survival and death.</p>\n<p>Self-harm is a broader term referring to intentional poisoning or self-in\u00ad</p>\n<p>flicted harm, which may or may not have an intent of fatal outcome.</p>\n<p>512</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 579,
        "content": "Causes/risk factors\n \n~\nPhysical illness e.g. HIV/AIDS, head injury, malignancies, \nbody disfigurement, chronic pain\n \n~\nPsychiatric disorders e.g. depression, chronic psychosis, \ndementia, alcohol and substance use disorders, personali\u00ad\nty disorders, epilepsy\nRisk is high in the following cases:\n \n~\nPatient >45 years old\n \n~\nAlcohol and substance use\n \n~\nHistory of suicide attempts\n \n~\nFamily history of suicide\n \n~\nHistory of recent loss or disappointment\n \n~\nCurrent mental illness e.g. depression, psychosis\n \n~\nEvidence of violent behaviour or previous psychiatric admi \nsion\nRisk may be low if patient is\n \n~\n<45 years old\n \n~\nMarried or in stable interpersonal relationships\n \n~\nEmployed\n \n~\nIn good physical health\nClinical features\nPatients can present in one of the following situations:\n \n~\nA current suicide attempt or self harm\n \n~\nA situation of imminent risk of suicidal attempt or self \nharm:\n \n- Current thoughts or plans of suicide/self harm or history of \nthoughts or plans of suicide/self harm in the last 1 month, \n513\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Causes/risk factors</p>\n<p>~</p>\n<p>Physical illness e.g. HIV/AIDS, head injury, malignancies,</p>\n<p>body disfigurement, chronic pain</p>\n<p>~</p>\n<p>Psychiatric disorders e.g. depression, chronic psychosis,</p>\n<p>dementia, alcohol and substance use disorders, personali\u00ad</p>\n<p>ty disorders, epilepsy</p>\n<p>Risk is high in the following cases:</p>\n<p>~</p>\n<p>Patient >45 years old</p>\n<p>~</p>\n<p>Alcohol and substance use</p>\n<p>~</p>\n<p>History of suicide attempts</p>\n<p>~</p>\n<p>Family history of suicide</p>\n<p>~</p>\n<p>History of recent loss or disappointment</p>\n<p>~</p>\n<p>Current mental illness e.g. depression, psychosis</p>\n<p>~</p>\n<p>Evidence of violent behaviour or previous psychiatric admi</p>\n<p>sion</p>\n<p>Risk may be low if patient is</p>\n<p>~</p>\n<p><45 years old</p>\n<p>~</p>\n<p>Married or in stable interpersonal relationships</p>\n<p>~</p>\n<p>Employed</p>\n<p>~</p>\n<p>In good physical health</p>\n<p>Clinical features</p>\n<p>Patients can present in one of the following situations:</p>\n<p>~</p>\n<p>A current suicide attempt or self harm</p>\n<p>~</p>\n<p>A situation of imminent risk of suicidal attempt or self</p>\n<p>harm:</p>\n<p>- Current thoughts or plans of suicide/self harm or history of</p>\n<p>thoughts or plans of suicide/self harm in the last 1 month,</p>\n<p>513</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 580,
        "content": "or acts of self harm/suicide attempts in the last 1 years plus\n \n- Person is agitated, violent, emotionally distressed or \nuncommunicative and socially isolated, hopeless\n \n~\nA situation of no imminent risk but\n \n- Thoughts or plans of suicide/self harm in the last 1 month \nor acts of self/harm/suicide attempt in the last one year in \nperson not acutely distressed\nInvestigations\n \n\u0081\nComplete medical, social and family history\n \n\u0081\nAsk the patient about suicidal or self harm thoughts/plans/ acts \nand reasons for it\n \n\u0081\nAsking about self harm or suicide does not increase the risk of \nthose acts. On the contrary, it may help the patient to feel under\u00ad\nstood and considered. First try to establish a good relationship \nwith the patient before asking\n \n\u0081\nAlways assess risk of suicide and self-harm in patient\n \n\u0081\nWith any other mental illness (depression, mania, psychosis, \nalcohol and substance abuse, dementia, behavioural or devel\u00ad\nopment disorders)\n \n\u0081\nChronic pain, severe emotional distress\nManagement\nTREATMENT\nLOC\nIf acute suicidal behaviour/act of self harm or \nimminent risk\n Admit the patient and treat any medical \ncomplications (bleeding, poisoning etc.)\n Keep in a secure and supportive environment\n\u2013\t Do not leave patient alone\n\u2013\t Remove any means of self-harm\n Continuous monitoring\n Offer/activate psychosocial support\n Consult mental health specialist\n Treat any medical and mental condition present\nHC4\nIf no imminent risk\n Offer/activate psychosocial support\n Refer to mental health specialist for further \nassessment\n Establish regular follow up\n514\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>or acts of self harm/suicide attempts in the last 1 years plus</p>\n<p>- Person is agitated, violent, emotionally distressed or</p>\n<p>uncommunicative and socially isolated, hopeless</p>\n<p>~</p>\n<p>A situation of no imminent risk but</p>\n<p>- Thoughts or plans of suicide/self harm in the last 1 month</p>\n<p>or acts of self/harm/suicide attempt in the last one year in</p>\n<p>person not acutely distressed</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Complete medical, social and family history</p>\n<p>\u0081</p>\n<p>Ask the patient about suicidal or self harm thoughts/plans/ acts</p>\n<p>and reasons for it</p>\n<p>\u0081</p>\n<p>Asking about self harm or suicide does not increase the risk of</p>\n<p>those acts. On the contrary, it may help the patient to feel under\u00ad</p>\n<p>stood and considered. First try to establish a good relationship</p>\n<p>with the patient before asking</p>\n<p>\u0081</p>\n<p>Always assess risk of suicide and self-harm in patient</p>\n<p>\u0081</p>\n<p>With any other mental illness (depression, mania, psychosis,</p>\n<p>alcohol and substance abuse, dementia, behavioural or devel\u00ad</p>\n<p>opment disorders)</p>\n<p>\u0081</p>\n<p>Chronic pain, severe emotional distress</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If acute suicidal behaviour/act of self harm or</p>\n<p>imminent risk</p>\n<p>Admit the patient and treat any medical</p>\n<p>complications (bleeding, poisoning etc.)</p>\n<p>Keep in a secure and supportive environment</p>\n<p>\u2013\t Do not leave patient alone</p>\n<p>\u2013\t Remove any means of self-harm</p>\n<p>Continuous monitoring</p>\n<p>Offer/activate psychosocial support</p>\n<p>Consult mental health specialist</p>\n<p>Treat any medical and mental condition present</p>\n<h3>HC4</h3>\n<p>If no imminent risk</p>\n<p>Offer/activate psychosocial support</p>\n<p>Refer to mental health specialist for further</p>\n<p>assessment</p>\n<p>Establish regular follow up</p>\n<p>514</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 581,
        "content": "TREATMENT\nLOC\nNote\n \n\u0083 Suicide is less frequent in children and adolescents, but there \nis increased risk if there is disturbed family background (e.g. \ndeath of parents, divorce), use of alcohol and other drugs of \nabuse, physical illness, psychiatric disorder\n9.2.3\t\nBipolar Disorder (Mania)\t      ICD10 CODE: F30, F31\nA disorder of mood control characterized by episodes in which the \nperson\u2019s mood and activity level are significantly disturbed: in some \noccasions, there is an elevation of mood and increased energy and \nactivity (mania) and in other occasions, there is a lowering of mood and \ndecreased energy and activity (depression). Characteristically, recovery \nis complete in between the episodes.\nCauses\n \n~\nBiological, genetic, environmental factors\nClinical features\nPatient can present in an acute manic episode, in a depressive episode \nor in between the episodes.\nMania\n \n~\nElevated, expansive or irritable moods and increased activ\u00ad\nity or subjective experience of increased energy\n \n~\nIncreased  talkativeness \n \n~\nFlight of ideas \n \n~\nIncreased self-image, self-esteem or grandiosity, \n \n~\nDecreased need for sleep\n \n~\nDistractibility \n \n~\nImpulsive reckless behavior, extravagancy, partying and, \nincreased \n \n~\nIncreased sexual drive, sociability and goal directed behaviour\n515\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\u0083 Suicide is less frequent in children and adolescents, but there</p>\n<p>is increased risk if there is disturbed family background (e.g.</p>\n<p>death of parents, divorce), use of alcohol and other drugs of</p>\n<p>abuse, physical illness, psychiatric disorder</p>\n<p>9.2.3</p>\n<p>Bipolar Disorder (Mania)\t      ICD10 CODE: F30, F31</p>\n<p>A disorder of mood control characterized by episodes in which the</p>\n<p>person\u2019s mood and activity level are significantly disturbed: in some</p>\n<p>occasions, there is an elevation of mood and increased energy and</p>\n<p>activity (mania) and in other occasions, there is a lowering of mood and</p>\n<p>decreased energy and activity (depression). Characteristically, recovery</p>\n<p>is complete in between the episodes.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Biological, genetic, environmental factors</p>\n<p>Clinical features</p>\n<p>Patient can present in an acute manic episode, in a depressive episode</p>\n<p>or in between the episodes.</p>\n<p>Mania</p>\n<p>~</p>\n<p>Elevated, expansive or irritable moods and increased activ\u00ad</p>\n<p>ity or subjective experience of increased energy</p>\n<p>~</p>\n<p>Increased  talkativeness</p>\n<p>~</p>\n<p>Flight of ideas</p>\n<p>~</p>\n<p>Increased self-image, self-esteem or grandiosity,</p>\n<p>~</p>\n<p>Decreased need for sleep</p>\n<p>~</p>\n<p>Distractibility</p>\n<p>~</p>\n<p>Impulsive reckless behavior, extravagancy, partying and,</p>\n<p>increased</p>\n<p>~</p>\n<p>Increased sexual drive, sociability and goal directed behaviour</p>\n<p>515</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 582,
        "content": "~\nIncreased appetite but weight loss occurs due to over- ac\u00ad\ntivity\n \n~\nAuditory and visual hallucinations may be present\nDepression\n \n~\nAs for depression described above, but with a history of \nmanic episode\n \n~\nHigh index of suspicion for bipolar in early onset depres\u00ad\nsion with family history of bipolar illness\n \n~\nDifferential diagnosis\n \n~\nOrganic mental states e.g. drug or alcohol intoxication, de\u00ad\nlirium\n \n~\nChronic Psychosis\nInvestigations\n \n~\nGood medical, social and personal history\n \n~\nAssess for acute state of mania\n \n~\nIf depressive symptoms, investigate for previous manic ep\u00ad\nisodes\n \n~\nAssess for other medical or mental conditions (alcohol or \nsubstance abuse, dementia, suicide/self harm)\nManagement\nPatients with suspected bipolar disorder should be referred for specialist \nassessment\nManagement\nTREATMENT\nLOC\nManic episode\nMultiple symptoms as above for > 1 week and \nsevere enough to interfere with work/social \nactivities and/or requiring hospitalization\nHC3\nHC4\nH\n516\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Increased appetite but weight loss occurs due to over- ac\u00ad</p>\n<p>tivity</p>\n<p>~</p>\n<p>Auditory and visual hallucinations may be present</p>\n<p>Depression</p>\n<p>~</p>\n<p>As for depression described above, but with a history of</p>\n<p>manic episode</p>\n<p>~</p>\n<p>High index of suspicion for bipolar in early onset depres\u00ad</p>\n<p>sion with family history of bipolar illness</p>\n<p>~</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Organic mental states e.g. drug or alcohol intoxication, de\u00ad</p>\n<p>lirium</p>\n<p>~</p>\n<p>Chronic Psychosis</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Good medical, social and personal history</p>\n<p>~</p>\n<p>Assess for acute state of mania</p>\n<p>~</p>\n<p>If depressive symptoms, investigate for previous manic ep\u00ad</p>\n<p>isodes</p>\n<p>~</p>\n<p>Assess for other medical or mental conditions (alcohol or</p>\n<p>substance abuse, dementia, suicide/self harm)</p>\n<p>Management</p>\n<p>Patients with suspected bipolar disorder should be referred for specialist</p>\n<p>assessment</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Manic episode</p>\n<p>Multiple symptoms as above for > 1 week and</p>\n<p>severe enough to interfere with work/social</p>\n<p>activities and/or requiring hospitalization</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>516</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 583,
        "content": "Management\nTREATMENT\nLOC\n Aseess  risk to self and others \nDiscontinue antidepressant if any\n Provide counseling and education\n Chlorpromazine initially 100-200 mg every 8 \nhours, then adjust according to response\n \n- Daily doses of up to 300 mg may be given as \na single dose at night\n \n- Gradually reduce the dose when symptoms \nof mania resolve and maintain on doses as \nindicated in section 9.2.4 on Chronic psychosis\n Or haloperidol initially 5-10 mg every 12 hours\nthen adjust according to response\n \n- Up to 30-40 mg daily may be required in \nsevere or resistant cases\n Or trifluoperazine initially 5-10 mg every\n12hours then adjust according to response\n \n- Up to 40 mg or more daily may be required in \nsevere or resistant cases\n \n- Or Olanzapine 10-15 mg/day initially; may \nadjust to 20mg according to response\n \n- Or Risperidone 2-3mg initially, may increase \nto 6mg in over 3 weeks according to response. \nHC3\nHC4\nH\nIf under specialist supervision: initiate a mood stabilizer\n Carbamazepine initial dose 200 mg at night, increase \nslowly to 600-1000 mg/day in divided doses\n Or Valproate initial dose of 500 mg/day. Usual mainte\u00ad\nnance dose 1000-2000 mg\nOr Lithium 900-1800mg/day in in two divided doses (RR)\nH\nRR\nRR\n517\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Aseess  risk to self and others</p>\n<p>Discontinue antidepressant if any</p>\n<p>Provide counseling and education</p>\n<p>Chlorpromazine initially 100-200 mg every 8</p>\n<p>hours, then adjust according to response</p>\n<p>- Daily doses of up to 300 mg may be given as</p>\n<p>a single dose at night</p>\n<p>- Gradually reduce the dose when symptoms</p>\n<p>of mania resolve and maintain on doses as</p>\n<p>indicated in section 9.2.4 on Chronic psychosis</p>\n<p>Or haloperidol initially 5-10 mg every 12 hours</p>\n<p>then adjust according to response</p>\n<p>- Up to 30-40 mg daily may be required in</p>\n<p>severe or resistant cases</p>\n<p>Or trifluoperazine initially 5-10 mg every</p>\n<p>12hours then adjust according to response</p>\n<p>- Up to 40 mg or more daily may be required in</p>\n<p>severe or resistant cases</p>\n<p>- Or Olanzapine 10-15 mg/day initially; may</p>\n<p>adjust to 20mg according to response</p>\n<p>- Or Risperidone 2-3mg initially, may increase</p>\n<p>to 6mg in over 3 weeks according to response.</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>If under specialist supervision: initiate a mood stabilizer</p>\n<p>Carbamazepine initial dose 200 mg at night, increase</p>\n<p>slowly to 600-1000 mg/day in divided doses</p>\n<p>Or Valproate initial dose of 500 mg/day. Usual mainte\u00ad</p>\n<p>nance dose 1000-2000 mg</p>\n<p>Or Lithium 900-1800mg/day in in two divided doses (RR)</p>\n<p>H</p>\n<p>RR</p>\n<p>RR</p>\n<p>517</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 584,
        "content": "Management\nTREATMENT\nLOC\nNote\nSerum lithium should be monitored 12 hours after dose, \ntwice weekly until serum concentration and clinical con\u00ad\ndition stabilize, and every 3 months thereafter.\n Increase dose as tolerated to target serum lithium con\u00ad\ncentrations of 0.8-1.2 mEq/L.\nMonitor Wt, BP, PR, Lipid profile and LFTs. Do RFTS, \nTSH and Ca levels for those on Lithium\nIf agitation/restlessness, add a benzodiazepine for short \nperiod (until symptoms improve)\n Diazepam 5-10 mg every 12 hours\nZuclopenthixaol acetate 50-100 mg given 48-72 hours \nif available\nHC2\nNote\n \n\u0083 If extrapyramidal side-effects (muscle rigidity, \ndripping of saliva, tongue protrusion, tremors) \nare present while on antipsychotic drugs\n \n- Add an anticholinergic: Benzhexol initially 2 \nmg every 12 hours then reduce gradually to \nonce daily and eventually give 2 mg only when \nrequired\nDO NOT INITIATE LITHIUM AND VALPROATE AT \nLOWER CENTRE EXECEPT AS CONTINUATION\nREFER if poor response, poor adherence, pregnant, side \neffects, underlying physical or mental comorbidity\nBipolar depression\nDepressive symptoms but with history of manic episode/\ndiagnosis of bipolar disorder\n Counsel about bipolar disorder\n518\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>Serum lithium should be monitored 12 hours after dose,</p>\n<p>twice weekly until serum concentration and clinical con\u00ad</p>\n<p>dition stabilize, and every 3 months thereafter.</p>\n<p>Increase dose as tolerated to target serum lithium con\u00ad</p>\n<p>centrations of 0.8-1.2 mEq/L.</p>\n<p>Monitor Wt, BP, PR, Lipid profile and LFTs. Do RFTS,</p>\n<p>TSH and Ca levels for those on Lithium</p>\n<p>If agitation/restlessness, add a benzodiazepine for short</p>\n<p>period (until symptoms improve)</p>\n<p>Diazepam 5-10 mg every 12 hours</p>\n<p>Zuclopenthixaol acetate 50-100 mg given 48-72 hours</p>\n<p>if available</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>\u0083 If extrapyramidal side-effects (muscle rigidity,</p>\n<p>dripping of saliva, tongue protrusion, tremors)</p>\n<p>are present while on antipsychotic drugs</p>\n<p>- Add an anticholinergic: Benzhexol initially 2</p>\n<p>mg every 12 hours then reduce gradually to</p>\n<p>once daily and eventually give 2 mg only when</p>\n<p>required</p>\n<h3>DO NOT INITIATE LITHIUM AND VALPROATE AT</h3>\n<h3>LOWER CENTRE EXECEPT AS CONTINUATION</h3>\n<p>REFER if poor response, poor adherence, pregnant, side</p>\n<p>effects, underlying physical or mental comorbidity</p>\n<p>Bipolar depression</p>\n<p>Depressive symptoms but with history of manic episode/</p>\n<p>diagnosis of bipolar disorder</p>\n<p>Counsel about bipolar disorder</p>\n<p>518</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 585,
        "content": "TREATMENT\nLOC\nPsychological support for mild depression otherwise refer \nfor specialist care\n If on olanzapine, add fluoxetine or give quetiapine alone. \nIf not available\n Begin treatment with a mood stabilizer (carbamazepine \nor valproate, see above)\n Psychoeducation and psychotherapy if available\n If moderate/severe depression, consider treatment with \nantidepressant in addition to mood stabilizer BUT under \nspecialist supervision (there is risk of triggering a manic \nepisode)\nIn between episodes\nIndication for use of mood stabilizers to prevent both \nmanic and depressive episodes\n \n- 2 or more episodes (2 manic or 1 manic and \n1 depressive)\n \n- 1 severe manic episode involving significant \nrisk and consequences\n Valproate (or carbamazepine) as above or lithium at \nhigher levels.\nProvide psychoeducation and support\nCaution\n Avoid mood stabilizers in pregnant women. Use low dose haloperidol \nif necessary\n Use lower doses in elderly\n Refer adolescents for specialist management\nPrevention\n \n~\nInformation and support\n \n~\nSelf management techniques\n \n~\nAdherence to care\n \n~\nGood psychosocial support\n519\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Psychological support for mild depression otherwise refer</p>\n<p>for specialist care</p>\n<p>If on olanzapine, add fluoxetine or give quetiapine alone.</p>\n<p>If not available</p>\n<p>Begin treatment with a mood stabilizer (carbamazepine</p>\n<p>or valproate, see above)</p>\n<p>Psychoeducation and psychotherapy if available</p>\n<p>If moderate/severe depression, consider treatment with</p>\n<p>antidepressant in addition to mood stabilizer BUT under</p>\n<p>specialist supervision (there is risk of triggering a manic</p>\n<p>episode)</p>\n<p>In between episodes</p>\n<p>Indication for use of mood stabilizers to prevent both</p>\n<p>manic and depressive episodes</p>\n<p>- 2 or more episodes (2 manic or 1 manic and</p>\n<p>1 depressive)</p>\n<p>- 1 severe manic episode involving significant</p>\n<p>risk and consequences</p>\n<p>Valproate (or carbamazepine) as above or lithium at</p>\n<p>higher levels.</p>\n<p>Provide psychoeducation and support</p>\n<p>Caution</p>\n<p>Avoid mood stabilizers in pregnant women. Use low dose haloperidol</p>\n<p>if necessary</p>\n<p>Use lower doses in elderly</p>\n<p>Refer adolescents for specialist management</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Information and support</p>\n<p>~</p>\n<p>Self management techniques</p>\n<p>~</p>\n<p>Adherence to care</p>\n<p>~</p>\n<p>Good psychosocial support</p>\n<p>519</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 586,
        "content": "9.2.4 Psychosis\t ICD10 CODE: F20-F29\nA mental condition characterized by distortions of thinking and percep\u00ad\ntion, as well as inappropriate or narrowed range of emotions.\nCauses\n \n~\nNot known, but there are associated biological, genetic and \nenvironmental factors\nClinical features\nAny one or more of these may be diagnostic:\n \n~\nDelusions (abnormal, fixed, false beliefs) or excessive and \nunwarranted suspicions (may be multiple, fragmented or \nbizarre)\n \n~\nDisconnected ideas with vague or incoherent speech and \ninadequate in content\n \n~\nHallucinations: hearing voices or seeing things that are not \nwitnessed by others\n \n~\nSevere behaviour abnormalities: agitation or disorganised \nbehaviour, excitement, inactivity or overactivity\n \n~\nDisturbance of emotions such as marked apathy or discon\u00ad\nnection between reported emotions and observed effect\n \n~\nMood is usually inappropriate\n \n~\nDifficulty in forming and sustaining relationships\n \n~\nSocial withdrawal and neglect of usual responsibilities\nChronic psychosis or schizophrenia\n \n\u0081\nSymptoms of psychosis lasting for 3 or more months\n \n\u0081\nAccompanied by deterioration in social, general and occupational \nfunctioning\nDifferential diagnosis\n \n\u0081\nAlcohol and drug intoxication or withdrawal\n \n\u0081\nOrganic delirium, dementia, mood disorders\n520\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>9.2.4 Psychosis\t ICD10 CODE: F20-F29</p>\n<p>A mental condition characterized by distortions of thinking and percep\u00ad</p>\n<p>tion, as well as inappropriate or narrowed range of emotions.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not known, but there are associated biological, genetic and</p>\n<p>environmental factors</p>\n<p>Clinical features</p>\n<p>Any one or more of these may be diagnostic:</p>\n<p>~</p>\n<p>Delusions (abnormal, fixed, false beliefs) or excessive and</p>\n<p>unwarranted suspicions (may be multiple, fragmented or</p>\n<p>bizarre)</p>\n<p>~</p>\n<p>Disconnected ideas with vague or incoherent speech and</p>\n<p>inadequate in content</p>\n<p>~</p>\n<p>Hallucinations: hearing voices or seeing things that are not</p>\n<p>witnessed by others</p>\n<p>~</p>\n<p>Severe behaviour abnormalities: agitation or disorganised</p>\n<p>behaviour, excitement, inactivity or overactivity</p>\n<p>~</p>\n<p>Disturbance of emotions such as marked apathy or discon\u00ad</p>\n<p>nection between reported emotions and observed effect</p>\n<p>~</p>\n<p>Mood is usually inappropriate</p>\n<p>~</p>\n<p>Difficulty in forming and sustaining relationships</p>\n<p>~</p>\n<p>Social withdrawal and neglect of usual responsibilities</p>\n<p>Chronic psychosis or schizophrenia</p>\n<p>\u0081</p>\n<p>Symptoms of psychosis lasting for 3 or more months</p>\n<p>\u0081</p>\n<p>Accompanied by deterioration in social, general and occupational</p>\n<p>functioning</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Alcohol and drug intoxication or withdrawal</p>\n<p>\u0081</p>\n<p>Organic delirium, dementia, mood disorders</p>\n<p>520</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 587,
        "content": "Investigations\n \n\u0081\nGood social, personal and family history\n \n\u0081\nLaboratory investigations for infectious diseases e.g. HIV,\nManagement\nTREATMENT\nLOC\n \n- Acute psychosis\n Counselling/psychoeducation of patient and \ncarers\n \n- Antipsychotic drugs\n Chlorpromazine: starting dose 75-150 mg daily \nand maintenance dose of 75-300 mg daily. Up to \n1000 mg daily in divided does may be required for \nthose with severe disturbance\n Or Haloperidol: starting dose 5-10 mg daily\n \n- (Lower in elderly) and maintenance dose of \n5-20 mg daily in divided doses\n \n- Or Olanzapine 5-10 mg daily, maintenance \ndose is 10-20mg/day\n \n- Or Risperidone 2 mg initially, may increase to \n8 mg/day in divided.\n \n- Or Quetiapine 150-750mg/day twice daily\n \n- Or For treatment resistant schizophrenia, \nClozapine 25-50mg/day initially, if well \ntolerated titrate to 450mg per day in two \nweeks depending on response\nHC2\nHC4\nH\nH\nNR\nNR\n Administer orally or IM for those with agitation\n Only use one antipsychotic at a time\n Gradually adjust doses depending on response\n Monitor for side effects e.g. extrapyramidal side \neffects\n Use therapeutic dose for 4-6 weeks to assess \neffect\n Psychological interventions (family therapy or \nsocial skills therapy) if available\n Ensure follow up\nRR\n521\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Good social, personal and family history</p>\n<p>\u0081</p>\n<p>Laboratory investigations for infectious diseases e.g. HIV,</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Acute psychosis</p>\n<p>Counselling/psychoeducation of patient and</p>\n<p>carers</p>\n<p>- Antipsychotic drugs</p>\n<p>Chlorpromazine: starting dose 75-150 mg daily</p>\n<p>and maintenance dose of 75-300 mg daily. Up to</p>\n<p>1000 mg daily in divided does may be required for</p>\n<p>those with severe disturbance</p>\n<p>Or Haloperidol: starting dose 5-10 mg daily</p>\n<p>- (Lower in elderly) and maintenance dose of</p>\n<p>5-20 mg daily in divided doses</p>\n<p>- Or Olanzapine 5-10 mg daily, maintenance</p>\n<p>dose is 10-20mg/day</p>\n<p>- Or Risperidone 2 mg initially, may increase to</p>\n<p>8 mg/day in divided.</p>\n<p>- Or Quetiapine 150-750mg/day twice daily</p>\n<p>- Or For treatment resistant schizophrenia,</p>\n<p>Clozapine 25-50mg/day initially, if well</p>\n<p>tolerated titrate to 450mg per day in two</p>\n<p>weeks depending on response</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>H</p>\n<p>NR</p>\n<p>NR</p>\n<p>Administer orally or IM for those with agitation</p>\n<p>Only use one antipsychotic at a time</p>\n<p>Gradually adjust doses depending on response</p>\n<p>Monitor for side effects e.g. extrapyramidal side</p>\n<p>effects</p>\n<p>Use therapeutic dose for 4-6 weeks to assess</p>\n<p>effect</p>\n<p>Psychological interventions (family therapy or</p>\n<p>social skills therapy) if available</p>\n<p>Ensure follow up</p>\n<p>RR</p>\n<p>521</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 588,
        "content": "TREATMENT\nLOC\n For acute psychosis, continue treatment for at \nleast 12 months. Discuss discontinuation with \npatient, carergivers and specialist\nRR\nIf extrapyramidal side-effects\n Add an anticholinergic: Benzhexol initially 2 \nmg every 12 hours then reduce gradually to \nonce daily and eventually give 2 mg only when \nrequired\nIf no response\n Refer to specialist\nHC2\nChronic psychosis\nTreat as above, but if adherence is a problem or \nthe patient prefers, use:\n Fluphenazine decanoate 12.5-50 mg every 2-5 \nweeks deep IM into gluteal muscle\n Or Haloperidol injection (oily) 50-200 mg (300 \nmg) deep IM into gluteal muscle every 3-4 weeks\nOR Zuclopenthixol decanoate 200-500mg every \n4 weeks depending on response\nPsychosocial support for long term care\nHC4\nRR\n9.2.4.1\t Postnatal Psychosis\t\nICD10 CODE: F53 Postpartum\npsychosis is the most severe form of postpartum psychiatric illness.\nCauses\n \n~\nNot well known, but hormonal changes may have a role\nPredisposing factors\n \n~\nFirst child\n \n~\nPrevious episode of post-natal psychosis\n \n~\nPrevious major psychiatric history\n522\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>For acute psychosis, continue treatment for at</p>\n<p>least 12 months. Discuss discontinuation with</p>\n<p>patient, carergivers and specialist</p>\n<p>RR</p>\n<p>If extrapyramidal side-effects</p>\n<p>Add an anticholinergic: Benzhexol initially 2</p>\n<p>mg every 12 hours then reduce gradually to</p>\n<p>once daily and eventually give 2 mg only when</p>\n<p>required</p>\n<p>If no response</p>\n<p>Refer to specialist</p>\n<h3>HC2</h3>\n<p>Chronic psychosis</p>\n<p>Treat as above, but if adherence is a problem or</p>\n<p>the patient prefers, use:</p>\n<p>Fluphenazine decanoate 12.5-50 mg every 2-5</p>\n<p>weeks deep IM into gluteal muscle</p>\n<p>Or Haloperidol injection (oily) 50-200 mg (300</p>\n<p>mg) deep IM into gluteal muscle every 3-4 weeks</p>\n<p>OR Zuclopenthixol decanoate 200-500mg every</p>\n<p>4 weeks depending on response</p>\n<p>Psychosocial support for long term care</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>9.2.4.1\t Postnatal Psychosis</p>\n<p>ICD10 CODE: F53 Postpartum</p>\n<p>psychosis is the most severe form of postpartum psychiatric illness.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not well known, but hormonal changes may have a role</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>First child</p>\n<p>~</p>\n<p>Previous episode of post-natal psychosis</p>\n<p>~</p>\n<p>Previous major psychiatric history</p>\n<p>522</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 589,
        "content": "~\nFamily history of mental illness\n \n~\nInadequate psychosocial support during pregnancy\n \n~\nInfections in early puerperium\nClinical features\n \n~\nSymptoms develop within the first 2 postpartum weeks \n(sometimes as early as 48-72 hours after delivery)\n \n~\nThe condition resembles a rapidly evolving manic or \nmixed episode with symptoms such as restlessness and \ninsomnia, irritability, rapidly shifting depressed or elated \nmood and disorganized behavior\n \n~\nThe mother may have delusional beliefs that relate to the \ninfant (e.g. the baby is defective or dying, the infant is\n \n~\nSatan or God) or she may have auditory hallucinations \nthat instruct her to harm herself or her infant\n \n~\nThe risk for infanticide and suicide is high\nDifferential diagnosis\n \n~\nDepression with psychotic features\n \n~\nMania, chronic psychosis\nInvestigations\n Good history, physical and psychiatric assessment\nManagement\nTREATMENT\nLOC\n It is a psychiatric emergency: admit to hospital\n Treat any identifiable cause/precipitant e.g. \ninfection\n Haloperidol 10 mg or Chlorpromazine 200 mg \n[Intramuscular Injection or tablets} every 8 or \n12 hours. Monitor response to medication and \nadjust dosage accordingly\n If restless and agitated, add rectal or I.V\nH\n523\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Family history of mental illness</p>\n<p>~</p>\n<p>Inadequate psychosocial support during pregnancy</p>\n<p>~</p>\n<p>Infections in early puerperium</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Symptoms develop within the first 2 postpartum weeks</p>\n<p>(sometimes as early as 48-72 hours after delivery)</p>\n<p>~</p>\n<p>The condition resembles a rapidly evolving manic or</p>\n<p>mixed episode with symptoms such as restlessness and</p>\n<p>insomnia, irritability, rapidly shifting depressed or elated</p>\n<p>mood and disorganized behavior</p>\n<p>~</p>\n<p>The mother may have delusional beliefs that relate to the</p>\n<p>infant (e.g. the baby is defective or dying, the infant is</p>\n<p>~</p>\n<p>Satan or God) or she may have auditory hallucinations</p>\n<p>that instruct her to harm herself or her infant</p>\n<p>~</p>\n<p>The risk for infanticide and suicide is high</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Depression with psychotic features</p>\n<p>~</p>\n<p>Mania, chronic psychosis</p>\n<p>Investigations</p>\n<p>Good history, physical and psychiatric assessment</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>It is a psychiatric emergency: admit to hospital</p>\n<p>Treat any identifiable cause/precipitant e.g.</p>\n<p>infection</p>\n<p>Haloperidol 10 mg or Chlorpromazine 200 mg</p>\n<p>[Intramuscular Injection or tablets} every 8 or</p>\n<p>12 hours. Monitor response to medication and</p>\n<p>adjust dosage accordingly</p>\n<p>If restless and agitated, add rectal or I.V</p>\n<p>H</p>\n<p>523</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 590,
        "content": "TREATMENT\nLOC\n Diazepam 5-10 mg slow infusion; repeat after \n10 minutes if still agitated\n \n- Continue with diazepam tablet 5 mg every \n12 hours until calm\n Refer to specialist\nH\nPrevention\n \n~\nProper antenatal screening, good psychosocial support\n \n~\nEarly detection and treatment\n \n~\nAdherence to treatment for a current mental illness e.g de\u00ad\npression, bipolar, chronic psychosis\nNotes\n \n\u0083 Post-natal psychoses are no different from other similar \npsychoses, give concurrent psychosocial interventions and drug \ntherapy\n9.2 PSYCHIATRIC AND SUBSTANCE USE DISORDERS\n9.2.1\t\nAnxiety\t     ICD10 CODE: F40-F48\nAnxiety is a normal physiological response, which enables a person to \ntake steps to deal with a threat. When anxiety is prolonged or interferes \nwith normal functions of the\nindividual, it constitutes the clinical condition of an anxiety disorder.\nCauses\n \n~\nNot fully understood: possibly external traumatic events \nmay trigger anxiety in predisposed people\n \n~\nAssociation with other mental conditions e.g. depression, \nalcohol and substance abuse\n524\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Diazepam 5-10 mg slow infusion; repeat after</p>\n<p>10 minutes if still agitated</p>\n<p>- Continue with diazepam tablet 5 mg every</p>\n<p>12 hours until calm</p>\n<p>Refer to specialist</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Proper antenatal screening, good psychosocial support</p>\n<p>~</p>\n<p>Early detection and treatment</p>\n<p>~</p>\n<p>Adherence to treatment for a current mental illness e.g de\u00ad</p>\n<p>pression, bipolar, chronic psychosis</p>\n<p>Notes</p>\n<p>\u0083 Post-natal psychoses are no different from other similar</p>\n<p>psychoses, give concurrent psychosocial interventions and drug</p>\n<p>therapy</p>\n<h3>9.2 PSYCHIATRIC AND SUBSTANCE USE DISORDERS</h3>\n<p>9.2.1</p>\n<p>Anxiety\t     ICD10 CODE: F40-F48</p>\n<p>Anxiety is a normal physiological response, which enables a person to</p>\n<p>take steps to deal with a threat. When anxiety is prolonged or interferes</p>\n<p>with normal functions of the</p>\n<p>individual, it constitutes the clinical condition of an anxiety disorder.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not fully understood: possibly external traumatic events</p>\n<p>may trigger anxiety in predisposed people</p>\n<p>~</p>\n<p>Association with other mental conditions e.g. depression,</p>\n<p>alcohol and substance abuse</p>\n<p>524</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 591,
        "content": "Types and clinical features\n \n~\nGeneralized anxiety: Unrealistic and excessive worry \nabout almost everything\n \n~\nPanic attacks: Episodes of sudden onset of intense ap\u00ad\nprehension or fear; anxiety symptoms usually peak within \n10-15 minutes and resolve in a few minutes to one hour\n \n~\nPhobia: An excessive fear of a known stimulus (object or\n \n~\nsituation) e.g. animals, water, confined space) causing the \nperson to consciously avoid the object or situation\nEach of the above clinical types will have one or more of the \nfollowing manifestations:\n \n~\nSleep, mood and concentration problems\n \n~\nPalpitations, dizziness, shortness of breath\n \n~\nShakiness or tremors, excessive sweatiness\n \n~\nEasily frightened\n \n~\nOther symptoms: urinary frequency, hesitancy, or urgen\u00ad\ncy, diarrhoea\nDifferential diagnosis\n \n~\nConsider organic conditions e.g. hyperthyroidism, hypo\u00ad\nglycaemia, phaeochromocytoma\nManagement\nTREATMENT\nLOC\n Psychosocial interventions: counselling, \npsychotherapy (individual and group psychotherapy)\nFor an acute episode or intense prolonged anxiety\n Benzodiazepines e.g. diazepam 5 mg 1-2 times daily\n \n- Increase if necessary to 15-30 mg daily in \ndivided doses\nElderly: Alprazolam 0.25mg -0.5mg  twice daily \ninitially, Increase if necessary  to 3-6 mg daily in \ndivided doses.\nIf alprazolam is not available, Give half the above dose \nof diazepam\nHC2\nHC4\n525\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Types and clinical features</p>\n<p>~</p>\n<p>Generalized anxiety: Unrealistic and excessive worry</p>\n<p>about almost everything</p>\n<p>~</p>\n<p>Panic attacks: Episodes of sudden onset of intense ap\u00ad</p>\n<p>prehension or fear; anxiety symptoms usually peak within</p>\n<p>10-15 minutes and resolve in a few minutes to one hour</p>\n<p>~</p>\n<p>Phobia: An excessive fear of a known stimulus (object or</p>\n<p>~</p>\n<p>situation) e.g. animals, water, confined space) causing the</p>\n<p>person to consciously avoid the object or situation</p>\n<p>Each of the above clinical types will have one or more of the</p>\n<p>following manifestations:</p>\n<p>~</p>\n<p>Sleep, mood and concentration problems</p>\n<p>~</p>\n<p>Palpitations, dizziness, shortness of breath</p>\n<p>~</p>\n<p>Shakiness or tremors, excessive sweatiness</p>\n<p>~</p>\n<p>Easily frightened</p>\n<p>~</p>\n<p>Other symptoms: urinary frequency, hesitancy, or urgen\u00ad</p>\n<p>cy, diarrhoea</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Consider organic conditions e.g. hyperthyroidism, hypo\u00ad</p>\n<p>glycaemia, phaeochromocytoma</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Psychosocial interventions: counselling,</p>\n<p>psychotherapy (individual and group psychotherapy)</p>\n<p>For an acute episode or intense prolonged anxiety</p>\n<p>Benzodiazepines e.g. diazepam 5 mg 1-2 times daily</p>\n<p>- Increase if necessary to 15-30 mg daily in</p>\n<p>divided doses</p>\n<p>Elderly: Alprazolam 0.25mg -0.5mg  twice daily</p>\n<p>initially, Increase if necessary  to 3-6 mg daily in</p>\n<p>divided doses.</p>\n<p>If alprazolam is not available, Give half the above dose</p>\n<p>of diazepam</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>525</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 592,
        "content": "TREATMENT\nLOC\n \n- Duration of therapy 1-2 weeks, tapering off to \nzero within 6 weeks\nIf poor response: refer to specialist\n Fluoxetine 20 mg once a day for long term \nmanagement of the anxiety disorder\nOr Sertraline 50mg once daily\n \n- Continue antidepressant for 4 to 6 weeks then \nevaluate the response\nHC2\nHC4\nCaution\n Diazepam is addictive and abrupt cessation can cause \nwithdrawal symptoms. Use for short periods and gradually \nreduce the dose. Avoid alcohol\nNotes\n \n\u0083 Diazepam is NOT appropriate for treating depression, phobic \nor obsessional states, or chronic psychoses (see relevant \nsections for more information)\n \n\u0083 Antidepressants: May be useful in managing panic disorders \nand other anxiety disorders which require long term treatment\nPrevention\n \n~\nGood personality development\n \n~\nGood stress management\n9.2.2\t\nDepression\t\nICD10 CODE: F32, F33\nA common disorder characterised by low mood, loss of interest and \nenjoyment and reduced energy leading to diminished activity and in \nsevere forms, difficult day-to-day functioning.\n526\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Duration of therapy 1-2 weeks, tapering off to</p>\n<p>zero within 6 weeks</p>\n<p>If poor response: refer to specialist</p>\n<p>Fluoxetine 20 mg once a day for long term</p>\n<p>management of the anxiety disorder</p>\n<p>Or Sertraline 50mg once daily</p>\n<p>- Continue antidepressant for 4 to 6 weeks then</p>\n<p>evaluate the response</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>Diazepam is addictive and abrupt cessation can cause</p>\n<p>withdrawal symptoms. Use for short periods and gradually</p>\n<p>reduce the dose. Avoid alcohol</p>\n<p>Notes</p>\n<p>\u0083 Diazepam is NOT appropriate for treating depression, phobic</p>\n<p>or obsessional states, or chronic psychoses (see relevant</p>\n<p>sections for more information)</p>\n<p>\u0083 Antidepressants: May be useful in managing panic disorders</p>\n<p>and other anxiety disorders which require long term treatment</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Good personality development</p>\n<p>~</p>\n<p>Good stress management</p>\n<p>9.2.2</p>\n<p>Depression</p>\n<h3>ICD10 CODE: F32, F33</h3>\n<p>A common disorder characterised by low mood, loss of interest and</p>\n<p>enjoyment and reduced energy leading to diminished activity and in</p>\n<p>severe forms, difficult day-to-day functioning.</p>\n<p>526</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 593,
        "content": "Causes\n \n~\nBiological, genetic, and environmental factors\nClinical features\nFor at least two weeks, the person had at least two of the symptoms below:\n \n~\nLow mood (most of the day, almost every day)\n \n~\nLoss of interest or pleasure in activities that are normally \npleasurable\n \n~\nAssociated lack of energy, body weakness or easily fatigued\n \n~\nDuring the 2 weeks, the person also has some of the symp\u00ad\ntoms below:\n \n~\nDifficulty in concentrating, reduced attention\n \n~\nReduced self-esteem and self confidence\n \n~\nPoor sleep, poor appetite, reduced libido\n \n~\nBleak and pessimistic view of the future\n \n~\nFeeling of guilt and unworthiness\n \n~\nMultiple body pains or other medically unexplained somat\u00ad\nic symptoms\n \n~\nIdeas or acts of self harm or suicide (occurs in up to 65% \nof patients)\n \n~\nChildren and adolescents usually present with irritability, \nschool phobia, truancy, poor academic performance, alco\u00ad\nhol and drug abuse\nDifferential diagnosis\n \n~\nThyroid dysfunction (hypothyroidism)\n \n~\nAdrenal dysfunction (Addison\u2019s disease)\n \n~\nParkinson\u2019s disease, stroke, dementia\n \n~\nAnxiety disorder\n527\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Causes</p>\n<p>~</p>\n<p>Biological, genetic, and environmental factors</p>\n<p>Clinical features</p>\n<p>For at least two weeks, the person had at least two of the symptoms below:</p>\n<p>~</p>\n<p>Low mood (most of the day, almost every day)</p>\n<p>~</p>\n<p>Loss of interest or pleasure in activities that are normally</p>\n<p>pleasurable</p>\n<p>~</p>\n<p>Associated lack of energy, body weakness or easily fatigued</p>\n<p>~</p>\n<p>During the 2 weeks, the person also has some of the symp\u00ad</p>\n<p>toms below:</p>\n<p>~</p>\n<p>Difficulty in concentrating, reduced attention</p>\n<p>~</p>\n<p>Reduced self-esteem and self confidence</p>\n<p>~</p>\n<p>Poor sleep, poor appetite, reduced libido</p>\n<p>~</p>\n<p>Bleak and pessimistic view of the future</p>\n<p>~</p>\n<p>Feeling of guilt and unworthiness</p>\n<p>~</p>\n<p>Multiple body pains or other medically unexplained somat\u00ad</p>\n<p>ic symptoms</p>\n<p>~</p>\n<p>Ideas or acts of self harm or suicide (occurs in up to 65%</p>\n<p>of patients)</p>\n<p>~</p>\n<p>Children and adolescents usually present with irritability,</p>\n<p>school phobia, truancy, poor academic performance, alco\u00ad</p>\n<p>hol and drug abuse</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Thyroid dysfunction (hypothyroidism)</p>\n<p>~</p>\n<p>Adrenal dysfunction (Addison\u2019s disease)</p>\n<p>~</p>\n<p>Parkinson\u2019s disease, stroke, dementia</p>\n<p>~</p>\n<p>Anxiety disorder</p>\n<p>527</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 594,
        "content": "Investigations\n \n\u0081\nMedical, social and personal history\n \n\u0081\nCheck for bereavement or other major personal loss\n \n\u0081\nFind out if person has had an episode of mania in the past: if so \nconsider treatment for bipolar disorder and consult a specialist\n \n\u0081\nFind out if they have psychotic features e.g. hallucinations (refer \nto section 9..2.4 on Psychosis)\n \n\u0081\nAssess for co-occurring health conditions (e.g. HIV/AIDS), \nsubstance or alcohol abuse\n \n\u0081\nAssess risk of self-harm/suicide\nManagement\nTREATMENT\nLOC\nFirst line\n Psychological therapy (Individual or group psychotherapy) is first line \nfor mild cases:\n \n- Psychoeducation (counselling of patient and family)\n \n- Addressing current stressors (abuse, neglect\u2026)\n \n- Re activating social networks\n \n- Structured physical activities\n \n- Regular follow up\n Manage concurrent physical medical problems\n Address co-existing mental problems e.g. substance abuse\n If available, consider psychotherapy (cognitive behavioural \ntherapy, interpersonal psychotherapy, behavioural activation \netc)\nIf bereavement or another major personal loss\n \n-\n  Counselling and support\n \n-\n Do not consider drugs or psychotherapy as first line\n528\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Medical, social and personal history</p>\n<p>\u0081</p>\n<p>Check for bereavement or other major personal loss</p>\n<p>\u0081</p>\n<p>Find out if person has had an episode of mania in the past: if so</p>\n<p>consider treatment for bipolar disorder and consult a specialist</p>\n<p>\u0081</p>\n<p>Find out if they have psychotic features e.g. hallucinations (refer</p>\n<p>to section 9..2.4 on Psychosis)</p>\n<p>\u0081</p>\n<p>Assess for co-occurring health conditions (e.g. HIV/AIDS),</p>\n<p>substance or alcohol abuse</p>\n<p>\u0081</p>\n<p>Assess risk of self-harm/suicide</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First line</p>\n<p>Psychological therapy (Individual or group psychotherapy) is first line</p>\n<p>for mild cases:</p>\n<p>- Psychoeducation (counselling of patient and family)</p>\n<p>- Addressing current stressors (abuse, neglect\u2026)</p>\n<p>- Re activating social networks</p>\n<p>- Structured physical activities</p>\n<p>- Regular follow up</p>\n<p>Manage concurrent physical medical problems</p>\n<p>Address co-existing mental problems e.g. substance abuse</p>\n<p>If available, consider psychotherapy (cognitive behavioural</p>\n<p>therapy, interpersonal psychotherapy, behavioural activation</p>\n<p>etc)</p>\n<p>If bereavement or another major personal loss</p>\n<p>-</p>\n<p>Counselling and support</p>\n<p>-</p>\n<p>Do not consider drugs or psychotherapy as first line</p>\n<p>528</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 595,
        "content": "TREATMENT\nLOC\n \n- If not responding to all above\n Consider antidepressant\n \n- DO NOT use in children <12 years\n \n- Adolescents: only under specialist supervision\n Fluoxetine 20 mg once daily in the morning\n \n- Start with 10 mg in elderly\n \n- If not better after 4-6 weeks, increase to 40 mg\n Or Amitriptyline 50 mg at bedtime\n \n- Increase by 25 mg every week aiming at 100-150 \nmg in divided doses or single bedtime dose by 4-6 \nweeks of treatment\n \n- Useful in case of associated anxiety\n \n- Avoid in adolescents, elderly, heart diseases, \nsuicide risks\n \n- Or Venflaxine 37.5 mg given in the morning or \nevening\n \n- Increase dose to75mg per day divided 8-12 hourly \nHC4\nRR\nH\n \n- Maintenance dose is 75 to 225 mg once a day\n \n- Maximum dose is 375mg; Useful in the patients \nwith comorbid anxiety disorders.\n \n- Or Sertaline 50mg per day; preferred for patients \non other medicines due to its low potential for \ndrug interactions and for breast feeding mothers, \nmay increase dose by 25mg at weekly intervals\n \n- Do not exceed 200mg per day\n \n- Or Escitalopram10mg, may increase dose to 20mg \nper day.\n \n- Or Bupropion 150 mg/day PO for those than \ncannot tolerate SSRIs and with comorbid Nicotine \nuse disorder. Titrate to 150-450 mg/day based on \ntolerability and efficacy; may administer in divided \ndoses\nH\nRR\nRR\n529\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- If not responding to all above</p>\n<p>Consider antidepressant</p>\n<p>- DO NOT use in children <12 years</p>\n<p>- Adolescents: only under specialist supervision</p>\n<p>Fluoxetine 20 mg once daily in the morning</p>\n<p>- Start with 10 mg in elderly</p>\n<p>- If not better after 4-6 weeks, increase to 40 mg</p>\n<p>Or Amitriptyline 50 mg at bedtime</p>\n<p>- Increase by 25 mg every week aiming at 100-150</p>\n<p>mg in divided doses or single bedtime dose by 4-6</p>\n<p>weeks of treatment</p>\n<p>- Useful in case of associated anxiety</p>\n<p>- Avoid in adolescents, elderly, heart diseases,</p>\n<p>suicide risks</p>\n<p>- Or Venflaxine 37.5 mg given in the morning or</p>\n<p>evening</p>\n<p>- Increase dose to75mg per day divided 8-12 hourly</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>H</p>\n<p>- Maintenance dose is 75 to 225 mg once a day</p>\n<p>- Maximum dose is 375mg; Useful in the patients</p>\n<p>with comorbid anxiety disorders.</p>\n<p>- Or Sertaline 50mg per day; preferred for patients</p>\n<p>on other medicines due to its low potential for</p>\n<p>drug interactions and for breast feeding mothers,</p>\n<p>may increase dose by 25mg at weekly intervals</p>\n<p>- Do not exceed 200mg per day</p>\n<p>- Or Escitalopram10mg, may increase dose to 20mg</p>\n<p>per day.</p>\n<p>- Or Bupropion 150 mg/day PO for those than</p>\n<p>cannot tolerate SSRIs and with comorbid Nicotine</p>\n<p>use disorder. Titrate to 150-450 mg/day based on</p>\n<p>tolerability and efficacy; may administer in divided</p>\n<p>doses</p>\n<p>H</p>\n<p>RR</p>\n<p>RR</p>\n<p>529</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 596,
        "content": "Management\nTREATMENT\nLOC\nIf patient responding to medication\n Continue for at least 9-12 months\n Consider stopping if patient has been without \ndepressive symptoms and able to carry out normal \nactivities for at least 9 months\n \n- Counsel the patient about withdrawal symptoms\n \n- (dizziness, tingling, anxiety, irritability, nausea, \nheadache, sleep problems)\n \n- Counsel the patient about possibility of relapse \nand when to come back\n \n- Reduce slowly over at least 4 weeks even slower \nif\n \n- withdrawal symptoms are significant\n \n- Monitor periodically for re-emergence of \nsymptoms\nIn case of pregnant woman, child, adolescent, \npatients not responding to treatment with \nantidepressant, psychotic features, history of mania\n Refer for specialist management\nCaution\n SSRI in bipolar depression can trigger a manic\nPrevention\n \n~\nStress management skills\n \n~\nPromotion of useful social support networks\n9.2.2.1\t Postnatal Depression\nRefer to section 16.6.2\n530\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If patient responding to medication</p>\n<p>Continue for at least 9-12 months</p>\n<p>Consider stopping if patient has been without</p>\n<p>depressive symptoms and able to carry out normal</p>\n<p>activities for at least 9 months</p>\n<p>- Counsel the patient about withdrawal symptoms</p>\n<p>- (dizziness, tingling, anxiety, irritability, nausea,</p>\n<p>headache, sleep problems)</p>\n<p>- Counsel the patient about possibility of relapse</p>\n<p>and when to come back</p>\n<p>- Reduce slowly over at least 4 weeks even slower</p>\n<p>if</p>\n<p>- withdrawal symptoms are significant</p>\n<p>- Monitor periodically for re-emergence of</p>\n<p>symptoms</p>\n<p>In case of pregnant woman, child, adolescent,</p>\n<p>patients not responding to treatment with</p>\n<p>antidepressant, psychotic features, history of mania</p>\n<p>Refer for specialist management</p>\n<p>Caution</p>\n<p>SSRI in bipolar depression can trigger a manic</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Stress management skills</p>\n<p>~</p>\n<p>Promotion of useful social support networks</p>\n<p>9.2.2.1\t Postnatal Depression</p>\n<p>Refer to section 16.6.2</p>\n<p>530</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 597,
        "content": "9.2.2.2\t Suicidal Behaviour/Self Harm ICD10 CODES: T14.91, Z91.5\nSuicidal behaviour is an emergency and requires immediate attention. \nIt is an attempted conscious act of self-destruction, which the individual \nconcerned views as the best solution. It is usually associated with feelings \nof hopelessness, helplessness and conflicts between survival and death.\nSelf-harm is a broader term referring to intentional poisoning or self-in\u00ad\nflicted harm, which may or may not have an intent of fatal outcome.\nCauses/risk factors\n \n~\nPhysical illness e.g. HIV/AIDS, head injury, malignancies, \nbody disfigurement, chronic pain\n \n~\nPsychiatric disorders e.g. depression, chronic psychosis, \ndementia, alcohol and substance use disorders, personality \ndisorders, epilepsy\nRisk is high in the following cases:\n \n~\nPatient >45 years old\n \n~\nAlcohol and substance use\n \n~\nHistory of suicide attempts\n \n~\nFamily history of suicide\n \n~\nHistory of recent loss or disappointment\n \n~\nCurrent mental illness e.g. depression, psychosis\n \n~\nEvidence of violent behaviour or previous psychiatric admi \nsion\nRisk may be low if patient is\n \n~\n<45 years old\n \n~\nMarried or in stable interpersonal relationships\n \n~\nEmployed\n \n~\nIn good physical health\n531\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>9.2.2.2\t Suicidal Behaviour/Self Harm ICD10 CODES: T14.91, Z91.5</p>\n<p>Suicidal behaviour is an emergency and requires immediate attention.</p>\n<p>It is an attempted conscious act of self-destruction, which the individual</p>\n<p>concerned views as the best solution. It is usually associated with feelings</p>\n<p>of hopelessness, helplessness and conflicts between survival and death.</p>\n<p>Self-harm is a broader term referring to intentional poisoning or self-in\u00ad</p>\n<p>flicted harm, which may or may not have an intent of fatal outcome.</p>\n<p>Causes/risk factors</p>\n<p>~</p>\n<p>Physical illness e.g. HIV/AIDS, head injury, malignancies,</p>\n<p>body disfigurement, chronic pain</p>\n<p>~</p>\n<p>Psychiatric disorders e.g. depression, chronic psychosis,</p>\n<p>dementia, alcohol and substance use disorders, personality</p>\n<p>disorders, epilepsy</p>\n<p>Risk is high in the following cases:</p>\n<p>~</p>\n<p>Patient >45 years old</p>\n<p>~</p>\n<p>Alcohol and substance use</p>\n<p>~</p>\n<p>History of suicide attempts</p>\n<p>~</p>\n<p>Family history of suicide</p>\n<p>~</p>\n<p>History of recent loss or disappointment</p>\n<p>~</p>\n<p>Current mental illness e.g. depression, psychosis</p>\n<p>~</p>\n<p>Evidence of violent behaviour or previous psychiatric admi</p>\n<p>sion</p>\n<p>Risk may be low if patient is</p>\n<p>~</p>\n<p><45 years old</p>\n<p>~</p>\n<p>Married or in stable interpersonal relationships</p>\n<p>~</p>\n<p>Employed</p>\n<p>~</p>\n<p>In good physical health</p>\n<p>531</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 598,
        "content": "Clinical features\nPatients can present in one of the following situations:\n \n~\nA current suicide attempt or self harm\n \n~\nA situation of imminent risk of suicidal attempt or self harm:\n \n- Current thoughts or plans of suicide/self harm or history of \nthoughts or plans of suicide/self harm in the last 1 month, \nor acts of self harm/suicide attempts in the last 1 years plus\n \n- Person is agitated, violent, emotionally distressed or \nuncommunicative and socially isolated, hopeless\n \n~\nA situation of no imminent risk but\n \n- Thoughts or plans of suicide/self harm in the last 1 month \nor acts of self/harm/suicide attempt in the last one year in \nperson not acutely distressed\nInvestigations\n \n\u0081\nComplete medical, social and family history\n \n\u0081\nAsk the patient about suicidal or self harm thoughts/plans/ acts \nand reasons for it\n \n\u0081\nAsking about self harm or suicide does not increase the risk of \nthose acts. On the contrary, it may help the patient to feel under\u00ad\nstood and considered. First try to establish a good relationship \nwith the patient before asking\n \n\u0081\nAlways assess risk of suicide and self-harm in patient\n \n\u0081\nWith any other mental illness (depression, mania, psychosis, \nalcohol and substance abuse, dementia, behavioural or devel\u00ad\nopment disorders)\n \n\u0081\nChronic pain, severe emotional distress\n532\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Clinical features</p>\n<p>Patients can present in one of the following situations:</p>\n<p>~</p>\n<p>A current suicide attempt or self harm</p>\n<p>~</p>\n<p>A situation of imminent risk of suicidal attempt or self harm:</p>\n<p>- Current thoughts or plans of suicide/self harm or history of</p>\n<p>thoughts or plans of suicide/self harm in the last 1 month,</p>\n<p>or acts of self harm/suicide attempts in the last 1 years plus</p>\n<p>- Person is agitated, violent, emotionally distressed or</p>\n<p>uncommunicative and socially isolated, hopeless</p>\n<p>~</p>\n<p>A situation of no imminent risk but</p>\n<p>- Thoughts or plans of suicide/self harm in the last 1 month</p>\n<p>or acts of self/harm/suicide attempt in the last one year in</p>\n<p>person not acutely distressed</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Complete medical, social and family history</p>\n<p>\u0081</p>\n<p>Ask the patient about suicidal or self harm thoughts/plans/ acts</p>\n<p>and reasons for it</p>\n<p>\u0081</p>\n<p>Asking about self harm or suicide does not increase the risk of</p>\n<p>those acts. On the contrary, it may help the patient to feel under\u00ad</p>\n<p>stood and considered. First try to establish a good relationship</p>\n<p>with the patient before asking</p>\n<p>\u0081</p>\n<p>Always assess risk of suicide and self-harm in patient</p>\n<p>\u0081</p>\n<p>With any other mental illness (depression, mania, psychosis,</p>\n<p>alcohol and substance abuse, dementia, behavioural or devel\u00ad</p>\n<p>opment disorders)</p>\n<p>\u0081</p>\n<p>Chronic pain, severe emotional distress</p>\n<p>532</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 599,
        "content": "Management\nTREATMENT\nLOC\nIf acute suicidal behaviour/act of self harm or \nimminent risk\n Admit the patient and treat any medical \ncomplications (bleeding, poisoning etc.)\n Keep in a secure and supportive environment\n\u2013\t Do not leave patient alone\n\u2013\t Remove any means of self-harm\n Continuous monitoring\n Offer/activate psychosocial support\n Consult mental health specialist\n Treat any medical and mental condition present\nHC4\nIf no imminent risk\n Offer/activate psychosocial support\n Refer to mental health specialist for further \nassessment\n Establish regular follow up\nNote\n \n\u0083 Suicide is less frequent in children and adolescents, but there \nis increased risk if there is disturbed family background (e.g. \ndeath of parents, divorce), use of alcohol and other drugs of \nabuse, physical illness, psychiatric disorder\n9.2.3\t\nBipolar Disorder (Mania)\t      ICD10 CODE: F30, F31\nA disorder of mood control characterized by episodes in which the \nperson\u2019s mood and activity level are significantly disturbed: in some \noccasions, there is an elevation of mood and increased energy and \nactivity (mania) and in other occasions, there is a lowering of mood and \ndecreased energy and activity (depression). Characteristically, recovery \nis complete in between the episodes.\n533\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If acute suicidal behaviour/act of self harm or</p>\n<p>imminent risk</p>\n<p>Admit the patient and treat any medical</p>\n<p>complications (bleeding, poisoning etc.)</p>\n<p>Keep in a secure and supportive environment</p>\n<p>\u2013\t Do not leave patient alone</p>\n<p>\u2013\t Remove any means of self-harm</p>\n<p>Continuous monitoring</p>\n<p>Offer/activate psychosocial support</p>\n<p>Consult mental health specialist</p>\n<p>Treat any medical and mental condition present</p>\n<h3>HC4</h3>\n<p>If no imminent risk</p>\n<p>Offer/activate psychosocial support</p>\n<p>Refer to mental health specialist for further</p>\n<p>assessment</p>\n<p>Establish regular follow up</p>\n<p>Note</p>\n<p>\u0083 Suicide is less frequent in children and adolescents, but there</p>\n<p>is increased risk if there is disturbed family background (e.g.</p>\n<p>death of parents, divorce), use of alcohol and other drugs of</p>\n<p>abuse, physical illness, psychiatric disorder</p>\n<p>9.2.3</p>\n<p>Bipolar Disorder (Mania)\t      ICD10 CODE: F30, F31</p>\n<p>A disorder of mood control characterized by episodes in which the</p>\n<p>person\u2019s mood and activity level are significantly disturbed: in some</p>\n<p>occasions, there is an elevation of mood and increased energy and</p>\n<p>activity (mania) and in other occasions, there is a lowering of mood and</p>\n<p>decreased energy and activity (depression). Characteristically, recovery</p>\n<p>is complete in between the episodes.</p>\n<p>533</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 600,
        "content": "Causes\n \n~\nBiological, genetic, environmental factors\nClinical features\nPatient can present in an acute manic episode, in a depressive episode \nor in between the episodes.\nMania\n \n~\nElevated, expansive or irritable moods and increased activ\u00ad\nity or subjective experience of increased energy\n \n~\nIncreased  talkativeness \n \n~\nFlight of ideas \n \n~\nIncreased self-image, self-esteem or grandiosity, \n \n~\nDecreased need for sleep\n \n~\nDistractibility \n \n~\nImpulsive reckless behavior, extravagancy, partying and , \nincreased \n \n~\nIncreased sexual drive, sociability and goal directed be\u00ad\nhaviour\n \n~\nIncreased appetite but weight loss occurs due to over- ac\u00ad\ntivity\n \n~\nAuditory and visual hallucinations may be present\nDepression\n \n~\nAs for depression described above, but with a history of \nmanic episode\n \n~\nHigh index of suspicion for bipolar in early onset depres\u00ad\nsion with family history of bipolar illness\n \n~\nDifferential diagnosis\n \n~\nOrganic mental states e.g. drug or alcohol intoxication, de\u00ad\nlirium\n \n~\nChronic Psychosis\n534\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Causes</p>\n<p>~</p>\n<p>Biological, genetic, environmental factors</p>\n<p>Clinical features</p>\n<p>Patient can present in an acute manic episode, in a depressive episode</p>\n<p>or in between the episodes.</p>\n<p>Mania</p>\n<p>~</p>\n<p>Elevated, expansive or irritable moods and increased activ\u00ad</p>\n<p>ity or subjective experience of increased energy</p>\n<p>~</p>\n<p>Increased  talkativeness</p>\n<p>~</p>\n<p>Flight of ideas</p>\n<p>~</p>\n<p>Increased self-image, self-esteem or grandiosity,</p>\n<p>~</p>\n<p>Decreased need for sleep</p>\n<p>~</p>\n<p>Distractibility</p>\n<p>~</p>\n<p>Impulsive reckless behavior, extravagancy, partying and ,</p>\n<p>increased</p>\n<p>~</p>\n<p>Increased sexual drive, sociability and goal directed be\u00ad</p>\n<p>haviour</p>\n<p>~</p>\n<p>Increased appetite but weight loss occurs due to over- ac\u00ad</p>\n<p>tivity</p>\n<p>~</p>\n<p>Auditory and visual hallucinations may be present</p>\n<p>Depression</p>\n<p>~</p>\n<p>As for depression described above, but with a history of</p>\n<p>manic episode</p>\n<p>~</p>\n<p>High index of suspicion for bipolar in early onset depres\u00ad</p>\n<p>sion with family history of bipolar illness</p>\n<p>~</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Organic mental states e.g. drug or alcohol intoxication, de\u00ad</p>\n<p>lirium</p>\n<p>~</p>\n<p>Chronic Psychosis</p>\n<p>534</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 601,
        "content": "Investigations\n \n~\nGood medical, social and personal history\n \n~\nAssess for acute state of mania\n \n~\nIf depressive symptoms, investigate for previous manic ep\u00ad\nisodes\n \n~\nAssess for other medical or mental conditions (alcohol or \nsubstance abuse, dementia, suicide/self harm)\nManagement\nPatients with suspected bipolar disorder should be referred for specialist \nassessment\nManagement\nTREATMENT\nLOC\nManic episode\nMultiple symptoms as above for > 1 week and \nsevere enough to interfere with work/social \nactivities and/or requiring hospitalization\n Aseess  risk to self and others \nDiscontinue antidepressant if any\n Provide counseling and education\n Chlorpromazine initially 100-200 mg every 8 \nhours, then adjust according to response\n \n- Daily doses of up to 300 mg may be given as \na single dose at night\n \n- Gradually reduce the dose when symptoms \nof mania resolve and maintain on doses as \nindicated in section 9.2.4 on Chronic psychosis\n Or haloperidol initially 5-10 mg every 12 hours\nthen adjust according to response\n \n- Up to 30-40 mg daily may be required in \nsevere or resistant cases\n Or trifluoperazine initially 5-10 mg every\n12hours then adjust according to response\nHC3\nHC4\nH\n535\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Investigations</p>\n<p>~</p>\n<p>Good medical, social and personal history</p>\n<p>~</p>\n<p>Assess for acute state of mania</p>\n<p>~</p>\n<p>If depressive symptoms, investigate for previous manic ep\u00ad</p>\n<p>isodes</p>\n<p>~</p>\n<p>Assess for other medical or mental conditions (alcohol or</p>\n<p>substance abuse, dementia, suicide/self harm)</p>\n<p>Management</p>\n<p>Patients with suspected bipolar disorder should be referred for specialist</p>\n<p>assessment</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Manic episode</p>\n<p>Multiple symptoms as above for > 1 week and</p>\n<p>severe enough to interfere with work/social</p>\n<p>activities and/or requiring hospitalization</p>\n<p>Aseess  risk to self and others</p>\n<p>Discontinue antidepressant if any</p>\n<p>Provide counseling and education</p>\n<p>Chlorpromazine initially 100-200 mg every 8</p>\n<p>hours, then adjust according to response</p>\n<p>- Daily doses of up to 300 mg may be given as</p>\n<p>a single dose at night</p>\n<p>- Gradually reduce the dose when symptoms</p>\n<p>of mania resolve and maintain on doses as</p>\n<p>indicated in section 9.2.4 on Chronic psychosis</p>\n<p>Or haloperidol initially 5-10 mg every 12 hours</p>\n<p>then adjust according to response</p>\n<p>- Up to 30-40 mg daily may be required in</p>\n<p>severe or resistant cases</p>\n<p>Or trifluoperazine initially 5-10 mg every</p>\n<p>12hours then adjust according to response</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>535</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 602,
        "content": "TREATMENT\nLOC\n \n- Or Olanzapine 10-15 mg/day initially; may \nadjust to 20mg according to response\n \n- Or Risperidone 2-3mg initially, may increase \nto 6mg in over 3 weeks according to response. \nHC3\nIf under specialist supervision: initiate a mood stabilizer\n Carbamazepine initial dose 200 mg at night, increase \nslowly to 600-1000 mg/day in divided doses\n Or Valproate initial dose of 500 mg/day. Usual mainte\u00ad\nnance dose 1000-2000 mg\nOr Lithium 900-1800mg/day in in two divided doses (RR)\nH\nRR\nRR\nNote\nSerum lithium should be monitored 12 hours after dose, \ntwice weekly until serum concentration and clinical con\u00ad\ndition stabilize, and every 3 months thereafter.\n Increase dose as tolerated to target serum lithium con\u00ad\ncentrations of 0.8-1.2 mEq/L.\nMonitor Wt, BP, PR, Lipid profile and LFTs. Do RFTS, \nTSH and Ca levels for those on Lithium\nIf agitation/restlessness, add a benzodiazepine for short \nperiod (until symptoms improve)\n Diazepam 5-10 mg every 12 hours\nZuclopenthixaol acetate 50-100 mg given 48-72 hours \nif available\nHC2\n536\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Or Olanzapine 10-15 mg/day initially; may</p>\n<p>adjust to 20mg according to response</p>\n<p>- Or Risperidone 2-3mg initially, may increase</p>\n<p>to 6mg in over 3 weeks according to response.</p>\n<h3>HC3</h3>\n<p>If under specialist supervision: initiate a mood stabilizer</p>\n<p>Carbamazepine initial dose 200 mg at night, increase</p>\n<p>slowly to 600-1000 mg/day in divided doses</p>\n<p>Or Valproate initial dose of 500 mg/day. Usual mainte\u00ad</p>\n<p>nance dose 1000-2000 mg</p>\n<p>Or Lithium 900-1800mg/day in in two divided doses (RR)</p>\n<p>H</p>\n<p>RR</p>\n<p>RR</p>\n<p>Note</p>\n<p>Serum lithium should be monitored 12 hours after dose,</p>\n<p>twice weekly until serum concentration and clinical con\u00ad</p>\n<p>dition stabilize, and every 3 months thereafter.</p>\n<p>Increase dose as tolerated to target serum lithium con\u00ad</p>\n<p>centrations of 0.8-1.2 mEq/L.</p>\n<p>Monitor Wt, BP, PR, Lipid profile and LFTs. Do RFTS,</p>\n<p>TSH and Ca levels for those on Lithium</p>\n<p>If agitation/restlessness, add a benzodiazepine for short</p>\n<p>period (until symptoms improve)</p>\n<p>Diazepam 5-10 mg every 12 hours</p>\n<p>Zuclopenthixaol acetate 50-100 mg given 48-72 hours</p>\n<p>if available</p>\n<h3>HC2</h3>\n<p>536</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 603,
        "content": "TREATMENT\nLOC\nNote\n \n\u0083 If extrapyramidal side-effects (muscle rigidity, \ndripping of saliva, tongue protrusion, tremors) \nare present while on antipsychotic drugs\n \n- Add an anticholinergic: Benzhexol initially 2 \nmg every 12 hours then reduce gradually to \nonce daily and eventually give 2 mg only when \nrequired\nDO NOT INITIATE LITHIUM AND VALPROATE AT \nLOWER CENTRE EXECEPT AS CONTINUATION\nREFER if poor response, poor adherence, pregnant, side \neffects, underlying physical or mental comorbidity\nBipolar depression\nDepressive symptoms but with history of manic episode/\ndiagnosis of bipolar disorder\n Counsel about bipolar disorder\nPsychological support for mild depression otherwise refer \nfor specialist care\n If on olanzapine, add fluoxetine or give quetiapine alone. \nIf not available\n Begin treatment with a mood stabilizer (carbamazepine \nor valproate, see above)\n Psychoeducation and psychotherapy if available\n If moderate/severe depression, consider treatment with \nantidepressant in addition to mood stabilizer BUT under \nspecialist supervision (there is risk of triggering a manic \nepisode)\n537\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\u0083 If extrapyramidal side-effects (muscle rigidity,</p>\n<p>dripping of saliva, tongue protrusion, tremors)</p>\n<p>are present while on antipsychotic drugs</p>\n<p>- Add an anticholinergic: Benzhexol initially 2</p>\n<p>mg every 12 hours then reduce gradually to</p>\n<p>once daily and eventually give 2 mg only when</p>\n<p>required</p>\n<h3>DO NOT INITIATE LITHIUM AND VALPROATE AT</h3>\n<h3>LOWER CENTRE EXECEPT AS CONTINUATION</h3>\n<p>REFER if poor response, poor adherence, pregnant, side</p>\n<p>effects, underlying physical or mental comorbidity</p>\n<p>Bipolar depression</p>\n<p>Depressive symptoms but with history of manic episode/</p>\n<p>diagnosis of bipolar disorder</p>\n<p>Counsel about bipolar disorder</p>\n<p>Psychological support for mild depression otherwise refer</p>\n<p>for specialist care</p>\n<p>If on olanzapine, add fluoxetine or give quetiapine alone.</p>\n<p>If not available</p>\n<p>Begin treatment with a mood stabilizer (carbamazepine</p>\n<p>or valproate, see above)</p>\n<p>Psychoeducation and psychotherapy if available</p>\n<p>If moderate/severe depression, consider treatment with</p>\n<p>antidepressant in addition to mood stabilizer BUT under</p>\n<p>specialist supervision (there is risk of triggering a manic</p>\n<p>episode)</p>\n<p>537</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 604,
        "content": "TREATMENT\nLOC\nIn between episodes\nIndication for use of mood stabilizers to prevent both \nmanic and depressive episodes\n \n- 2 or more episodes (2 manic or 1 manic and \n1 depressive)\n \n- 1 severe manic episode involving significant \nrisk and consequences\n Valproate (or carbamazepine) as above or lithium at \nhigher levels.\nProvide psychoeducation and support\nCaution\n Avoid mood stabilizers in pregnant women. Use low dose haloperidol \nif necessary\n Use lower doses in elderly\n Refer adolescents for specialist management\nPrevention\n \n~\nInformation and support\n \n~\nSelf management techniques\n \n~\nAdherence to care\n \n~\nGood psychosocial support\n9.2.4\t\nPsychosis\t\nICD10 CODE: F20-F29\nA mental condition characterized by distortions of thinking and percep\u00ad\ntion, as well as inappropriate or narrowed range of emotions.\nCauses\n \n~\nNot known, but there are associated biological, genetic and \nenvironmental factors\n538\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>In between episodes</p>\n<p>Indication for use of mood stabilizers to prevent both</p>\n<p>manic and depressive episodes</p>\n<p>- 2 or more episodes (2 manic or 1 manic and</p>\n<p>1 depressive)</p>\n<p>- 1 severe manic episode involving significant</p>\n<p>risk and consequences</p>\n<p>Valproate (or carbamazepine) as above or lithium at</p>\n<p>higher levels.</p>\n<p>Provide psychoeducation and support</p>\n<p>Caution</p>\n<p>Avoid mood stabilizers in pregnant women. Use low dose haloperidol</p>\n<p>if necessary</p>\n<p>Use lower doses in elderly</p>\n<p>Refer adolescents for specialist management</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Information and support</p>\n<p>~</p>\n<p>Self management techniques</p>\n<p>~</p>\n<p>Adherence to care</p>\n<p>~</p>\n<p>Good psychosocial support</p>\n<p>9.2.4</p>\n<p>Psychosis</p>\n<h3>ICD10 CODE: F20-F29</h3>\n<p>A mental condition characterized by distortions of thinking and percep\u00ad</p>\n<p>tion, as well as inappropriate or narrowed range of emotions.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not known, but there are associated biological, genetic and</p>\n<p>environmental factors</p>\n<p>538</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 605,
        "content": "Clinical features\nAny one or more of these may be diagnostic:\n \n~\nDelusions (abnormal, fixed, false beliefs) or excessive and \nunwarranted suspicions (may be multiple, fragmented or \nbizarre)\n \n~\nDisconnected ideas with vague or incoherent speech and \ninadequate in content\n \n~\nHallucinations: hearing voices or seeing things that are not \nwitnessed by others\n \n~\nSevere behaviour abnormalities: agitation or disorganised \nbehaviour, excitement, inactivity or overactivity\n \n~\nDisturbance of emotions such as marked apathy or discon\u00ad\nnection between reported emotions and observed effect\n \n~\nMood is usually inappropriate\n \n~\nDifficulty in forming and sustaining relationships\n \n~\nSocial withdrawal and neglect of usual responsibilities\nChronic psychosis or schizophrenia\n \n~\nSymptoms of psychosis lasting for 3 or more months\n \n~\nAccompanied by deterioration in social, general and occu\u00ad\npational functioning\nDifferential diagnosis\n \n~\nAlcohol and drug intoxication or withdrawal\n \n~\nOrganic delirium, dementia, mood disorders\nInvestigations\n \n\u0081\nGood social, personal and family history\n \n\u0081\nLaboratory investigations for infectious diseases e.g. HIV,\n539\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Clinical features</p>\n<p>Any one or more of these may be diagnostic:</p>\n<p>~</p>\n<p>Delusions (abnormal, fixed, false beliefs) or excessive and</p>\n<p>unwarranted suspicions (may be multiple, fragmented or</p>\n<p>bizarre)</p>\n<p>~</p>\n<p>Disconnected ideas with vague or incoherent speech and</p>\n<p>inadequate in content</p>\n<p>~</p>\n<p>Hallucinations: hearing voices or seeing things that are not</p>\n<p>witnessed by others</p>\n<p>~</p>\n<p>Severe behaviour abnormalities: agitation or disorganised</p>\n<p>behaviour, excitement, inactivity or overactivity</p>\n<p>~</p>\n<p>Disturbance of emotions such as marked apathy or discon\u00ad</p>\n<p>nection between reported emotions and observed effect</p>\n<p>~</p>\n<p>Mood is usually inappropriate</p>\n<p>~</p>\n<p>Difficulty in forming and sustaining relationships</p>\n<p>~</p>\n<p>Social withdrawal and neglect of usual responsibilities</p>\n<p>Chronic psychosis or schizophrenia</p>\n<p>~</p>\n<p>Symptoms of psychosis lasting for 3 or more months</p>\n<p>~</p>\n<p>Accompanied by deterioration in social, general and occu\u00ad</p>\n<p>pational functioning</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Alcohol and drug intoxication or withdrawal</p>\n<p>~</p>\n<p>Organic delirium, dementia, mood disorders</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Good social, personal and family history</p>\n<p>\u0081</p>\n<p>Laboratory investigations for infectious diseases e.g. HIV,</p>\n<p>539</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 606,
        "content": "Management\nTREATMENT\nLOC\n \n- Acute psychosis\n Counselling/psychoeducation of patient and \ncarers\n \n- Antipsychotic drugs\n Chlorpromazine: starting dose 75-150 mg daily \nand maintenance dose of 75-300 mg daily. Up to \n1000 mg daily in divided does may be required for \nthose with severe disturbance\n Or Haloperidol: starting dose 5-10 mg daily\n \n- (Lower in elderly) and maintenance dose of \n5-20 mg daily in divided doses\n \n- Or Olanzapine 5-10 mg daily, maintenance \ndose is 10-20mg/day\n \n- Or Risperidone 2 mg initially, may increase to \n8 mg/day in divided.\n \n- Or Quetiapine 150-750mg/day twice daily\n \n- Or For treatment resistant schizophrenia, \nClozapine 25-50mg/day initially, if well \ntolerated titrate to 450mg per day in two \nweeks depending on response\nHC2\nHC4\nH\nH\nNR\nNR\n Administer orally or IM for those with agitation\n Only use one antipsychotic at a time\n Gradually adjust doses depending on response\n Monitor for side effects e.g. extrapyramidal side \neffects\n Use therapeutic dose for 4-6 weeks to assess \neffect\n Psychological interventions (family therapy or \nsocial skills therapy) if available\n Ensure follow up\n For acute psychosis, continue treatment for at \nleast 12 months. Discuss discontinuation with \npatient, carergivers and specialist\nRR\n540\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Acute psychosis</p>\n<p>Counselling/psychoeducation of patient and</p>\n<p>carers</p>\n<p>- Antipsychotic drugs</p>\n<p>Chlorpromazine: starting dose 75-150 mg daily</p>\n<p>and maintenance dose of 75-300 mg daily. Up to</p>\n<p>1000 mg daily in divided does may be required for</p>\n<p>those with severe disturbance</p>\n<p>Or Haloperidol: starting dose 5-10 mg daily</p>\n<p>- (Lower in elderly) and maintenance dose of</p>\n<p>5-20 mg daily in divided doses</p>\n<p>- Or Olanzapine 5-10 mg daily, maintenance</p>\n<p>dose is 10-20mg/day</p>\n<p>- Or Risperidone 2 mg initially, may increase to</p>\n<p>8 mg/day in divided.</p>\n<p>- Or Quetiapine 150-750mg/day twice daily</p>\n<p>- Or For treatment resistant schizophrenia,</p>\n<p>Clozapine 25-50mg/day initially, if well</p>\n<p>tolerated titrate to 450mg per day in two</p>\n<p>weeks depending on response</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>H</p>\n<p>NR</p>\n<p>NR</p>\n<p>Administer orally or IM for those with agitation</p>\n<p>Only use one antipsychotic at a time</p>\n<p>Gradually adjust doses depending on response</p>\n<p>Monitor for side effects e.g. extrapyramidal side</p>\n<p>effects</p>\n<p>Use therapeutic dose for 4-6 weeks to assess</p>\n<p>effect</p>\n<p>Psychological interventions (family therapy or</p>\n<p>social skills therapy) if available</p>\n<p>Ensure follow up</p>\n<p>For acute psychosis, continue treatment for at</p>\n<p>least 12 months. Discuss discontinuation with</p>\n<p>patient, carergivers and specialist</p>\n<p>RR</p>\n<p>540</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 607,
        "content": "TREATMENT\nLOC\nIf extrapyramidal side-effects\n Add an anticholinergic: Benzhexol initially 2 \nmg every 12 hours then reduce gradually to \nonce daily and eventually give 2 mg only when \nrequired\nIf no response\n Refer to specialist\nHC2\nChronic psychosis\nTreat as above, but if adherence is a problem or \nthe patient prefers, use:\n Fluphenazine decanoate 12.5-50 mg every 2-5 \nweeks deep IM into gluteal muscle\n Or Haloperidol injection (oily) 50-200 mg (300 \nmg) deep IM into gluteal muscle every 3-4 weeks\nOR Zuclopenthixol decanoate 200-500mg every \n4 weeks depending on response\nPsychosocial support for long term care\nHC4\nRR\n9.1.1.1\t\nPostnatal Psychosis\t\nICD10 CODE: F53 Postpartum\npsychosis is the most severe form of postpartum psychiatric illness.\nCauses\n \n~\nNot well known, but hormonal changes may have a role\nPredisposing factors\n \n~\nFirst child\n \n~\nPrevious episode of post-natal psychosis\n \n~\nPrevious major psychiatric history\n \n~\nFamily history of mental illness\n \n~\nInadequate psychosocial support during pregnancy\n \n~\nInfections in early puerperium\n541\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If extrapyramidal side-effects</p>\n<p>Add an anticholinergic: Benzhexol initially 2</p>\n<p>mg every 12 hours then reduce gradually to</p>\n<p>once daily and eventually give 2 mg only when</p>\n<p>required</p>\n<p>If no response</p>\n<p>Refer to specialist</p>\n<h3>HC2</h3>\n<p>Chronic psychosis</p>\n<p>Treat as above, but if adherence is a problem or</p>\n<p>the patient prefers, use:</p>\n<p>Fluphenazine decanoate 12.5-50 mg every 2-5</p>\n<p>weeks deep IM into gluteal muscle</p>\n<p>Or Haloperidol injection (oily) 50-200 mg (300</p>\n<p>mg) deep IM into gluteal muscle every 3-4 weeks</p>\n<p>OR Zuclopenthixol decanoate 200-500mg every</p>\n<p>4 weeks depending on response</p>\n<p>Psychosocial support for long term care</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>9.1.1.1</p>\n<p>Postnatal Psychosis</p>\n<p>ICD10 CODE: F53 Postpartum</p>\n<p>psychosis is the most severe form of postpartum psychiatric illness.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Not well known, but hormonal changes may have a role</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>First child</p>\n<p>~</p>\n<p>Previous episode of post-natal psychosis</p>\n<p>~</p>\n<p>Previous major psychiatric history</p>\n<p>~</p>\n<p>Family history of mental illness</p>\n<p>~</p>\n<p>Inadequate psychosocial support during pregnancy</p>\n<p>~</p>\n<p>Infections in early puerperium</p>\n<p>541</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 608,
        "content": "Clinical features\n \n~\nSymptoms develop within the first 2 postpartum weeks \n(sometimes as early as 48-72 hours after delivery)\n \n~\nThe condition resembles a rapidly evolving manic or mixed \nepisode with symptoms such as restlessness and insomnia, \nirritability, rapidly shifting depressed or elated mood and \ndisorganized behavior\n \n~\nThe mother may have delusional beliefs that relate to the \ninfant (e.g. the baby is defective or dying, the infant is\n \n~\nSatan or God) or she may have auditory hallucinations that \ninstruct her to harm herself or her infant\n \n~\nThe risk for infanticide and suicide is high\nDifferential diagnosis\n \n~\nDepression with psychotic features\n \n~\nMania, chronic psychosis\nInvestigations\n Good history, physical and psychiatric assessment\nManagement\nTREATMENT\nLOC\n It is a psychiatric emergency: admit to hospital\n Treat any identifiable cause/precipitant e.g. \ninfection\n Haloperidol 10 mg or Chlorpromazine 200 mg \n[Intramuscular Injection or tablets} every 8 or \n12 hours. Monitor response to medication and \nadjust dosage accordingly\n If restless and agitated, add rectal or I.V \nDiazepam 5-10 mg slow infusion; repeat after 10 \nminutes if still agitated\n \n- Continue with diazepam tablet 5 mg every \n12 hours until calm\n Refer to specialist\nH\n542\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Symptoms develop within the first 2 postpartum weeks</p>\n<p>(sometimes as early as 48-72 hours after delivery)</p>\n<p>~</p>\n<p>The condition resembles a rapidly evolving manic or mixed</p>\n<p>episode with symptoms such as restlessness and insomnia,</p>\n<p>irritability, rapidly shifting depressed or elated mood and</p>\n<p>disorganized behavior</p>\n<p>~</p>\n<p>The mother may have delusional beliefs that relate to the</p>\n<p>infant (e.g. the baby is defective or dying, the infant is</p>\n<p>~</p>\n<p>Satan or God) or she may have auditory hallucinations that</p>\n<p>instruct her to harm herself or her infant</p>\n<p>~</p>\n<p>The risk for infanticide and suicide is high</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Depression with psychotic features</p>\n<p>~</p>\n<p>Mania, chronic psychosis</p>\n<p>Investigations</p>\n<p>Good history, physical and psychiatric assessment</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>It is a psychiatric emergency: admit to hospital</p>\n<p>Treat any identifiable cause/precipitant e.g.</p>\n<p>infection</p>\n<p>Haloperidol 10 mg or Chlorpromazine 200 mg</p>\n<p>[Intramuscular Injection or tablets} every 8 or</p>\n<p>12 hours. Monitor response to medication and</p>\n<p>adjust dosage accordingly</p>\n<p>If restless and agitated, add rectal or I.V</p>\n<p>Diazepam 5-10 mg slow infusion; repeat after 10</p>\n<p>minutes if still agitated</p>\n<p>- Continue with diazepam tablet 5 mg every</p>\n<p>12 hours until calm</p>\n<p>Refer to specialist</p>\n<p>H</p>\n<p>542</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 609,
        "content": "Prevention\n \n~\nProper antenatal screening, good psychosocial support\n \n~\nEarly detection and treatment\n \n~\nAdherence to treatment for a current mental illness e.g de\u00ad\npression, bipolar, chronic psychosis\n9.1.1\t\nAlcohol Use Disorders\t\nICD10 CODE: F10\nConditions resulting from different patterns of alcohol consumption, \nincluding acute alcohol intoxication, harmful alcohol use, alcohol de\u00ad\npendence syndrome and alcohol withdrawal state.\nCauses\n \n~\nNo single cause; a combination of factors usually leads to \nalcohol use disorders\nRisk / Predisposing factors\n \n~\nGenetic\n \n~\nSocial and environmental factors including availability\n \n~\nStress, peer pressure\n \n~\nPersonality disorders\nClinical features\nAcute intoxication\n \n~\nTransient condition following intake of alcohol resulting in \ndisturbances of consciousness, cognition, perception, af\u00ad\nfect or behaviour\n543\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Proper antenatal screening, good psychosocial support</p>\n<p>~</p>\n<p>Early detection and treatment</p>\n<p>~</p>\n<p>Adherence to treatment for a current mental illness e.g de\u00ad</p>\n<p>pression, bipolar, chronic psychosis</p>\n<p>9.1.1</p>\n<p>Alcohol Use Disorders</p>\n<h3>ICD10 CODE: F10</h3>\n<p>Conditions resulting from different patterns of alcohol consumption,</p>\n<p>including acute alcohol intoxication, harmful alcohol use, alcohol de\u00ad</p>\n<p>pendence syndrome and alcohol withdrawal state.</p>\n<p>Causes</p>\n<p>~</p>\n<p>No single cause; a combination of factors usually leads to</p>\n<p>alcohol use disorders</p>\n<p>Risk / Predisposing factors</p>\n<p>~</p>\n<p>Genetic</p>\n<p>~</p>\n<p>Social and environmental factors including availability</p>\n<p>~</p>\n<p>Stress, peer pressure</p>\n<p>~</p>\n<p>Personality disorders</p>\n<p>Clinical features</p>\n<p>Acute intoxication</p>\n<p>~</p>\n<p>Transient condition following intake of alcohol resulting in</p>\n<p>disturbances of consciousness, cognition, perception, af\u00ad</p>\n<p>fect or behaviour</p>\n<p>543</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 610,
        "content": "Harmful alcohol use\n \n~\nPattern of alcohol consumption that is causing damage to \nthe health, physical (e.g. liver disease) or mental (e.g. de\u00ad\npressive disorder). \n \n~\nAnd causing problems to one\u2019s social, occupational and \nother important areas of life. Criteria:\n \n- More than five drinks in any given occasion in the last 12 \nmonths\n \n- More than two drinks a day \n \n- Drinking every day\n \n~\nThese patients consume more alcohol than \n \n~\nRecommended but they do not fulfil (yet) the criteria for \nalcohol dependence\nAlcohol consumption during pregnancy is extremely harmful for the \nbaby: it can cause foetal \nAlcohol dependence\n \n~\nA disorder characterised by the need to take large daily \namounts of alcohol for adequate functioning. The use of \nalcohol takes on a much higher priority for the individual \nthan other behaviours that once had greater value\n \n~\nComplications: malnutrition, thiamine deficiency (causing \nWernicke encephalopathy), liver disease, chronic pancreati\u00ad\ntis, peptic ulcer, cardiomyopathy, neuropathy, head trauma \netc.\n \n~\nAlcohol withdrawal\n \n~\nSymptoms occurring upon cessation of alcohol after its \nprolonged daily use (6 hours to 6 days after)\n \n~\nInclude \n \n~\nTremor in hands, sweating, vomiting, tachycardia, hyper\u00ad\ntension, agitation, anxiety, headache, seizure and confusion \nin severe cases\n544\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Harmful alcohol use</p>\n<p>~</p>\n<p>Pattern of alcohol consumption that is causing damage to</p>\n<p>the health, physical (e.g. liver disease) or mental (e.g. de\u00ad</p>\n<p>pressive disorder).</p>\n<p>~</p>\n<p>And causing problems to one\u2019s social, occupational and</p>\n<p>other important areas of life. Criteria:</p>\n<p>- More than five drinks in any given occasion in the last 12</p>\n<p>months</p>\n<p>- More than two drinks a day</p>\n<p>- Drinking every day</p>\n<p>~</p>\n<p>These patients consume more alcohol than</p>\n<p>~</p>\n<p>Recommended but they do not fulfil (yet) the criteria for</p>\n<p>alcohol dependence</p>\n<p>Alcohol consumption during pregnancy is extremely harmful for the</p>\n<p>baby: it can cause foetal</p>\n<p>Alcohol dependence</p>\n<p>~</p>\n<p>A disorder characterised by the need to take large daily</p>\n<p>amounts of alcohol for adequate functioning. The use of</p>\n<p>alcohol takes on a much higher priority for the individual</p>\n<p>than other behaviours that once had greater value</p>\n<p>~</p>\n<p>Complications: malnutrition, thiamine deficiency (causing</p>\n<p>Wernicke encephalopathy), liver disease, chronic pancreati\u00ad</p>\n<p>tis, peptic ulcer, cardiomyopathy, neuropathy, head trauma</p>\n<p>etc.</p>\n<p>~</p>\n<p>Alcohol withdrawal</p>\n<p>~</p>\n<p>Symptoms occurring upon cessation of alcohol after its</p>\n<p>prolonged daily use (6 hours to 6 days after)</p>\n<p>~</p>\n<p>Include</p>\n<p>~</p>\n<p>Tremor in hands, sweating, vomiting, tachycardia, hyper\u00ad</p>\n<p>tension, agitation, anxiety, headache, seizure and confusion</p>\n<p>in severe cases</p>\n<p>544</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 611,
        "content": "Alcohol dependence\n \n~\nA disorder characterised by the need to take large daily \namounts of alcohol for adequate functioning. The use of \nalcohol takes on a much higher priority for the individual \nthan other behaviours that once had greater value\n \n~\nComplications: malnutrition, thiamine deficiency (causing \nWernicke encephalopathy), liver disease, chronic pancreati\u00ad\ntis, peptic ulcer, cardiomyopathy, neuropathy, head trauma \netc.\n \n~\nAlcohol withdrawal\n \n~\nSymptoms occurring upon cessation of alcohol after its \nprolonged daily use (6 hours to 6 days after)\n \n~\nInclude \n \n~\nTremor in hands, sweating, vomiting, tachycardia, hyper\u00ad\ntension, agitation, anxiety, headache, seizure and confusion \nin severe cases\nDiagnostic criteria for alcohol dependence:\nIf 3 or more of the features below are present:\n \n~\nA strong desire to take alcohol\n \n~\nDifficulties controlling alcohol use in terms of onset, termi\u00ad\nnation or levels of use\n \n~\nA physiological withdrawal state when alcohol use has \nceased or been reduced (alcohol withdrawal syndrome)\n \n~\nEvidence of tolerance: increased doses of alcohol are re\u00ad\nquired to achieve effects originally produced by lower doses\n \n~\nProgressive neglect of alternative pleasures or interests be\u00ad\ncause of alcohol use\n \n~\nAlcohol use persists despite clear evidence of harmful con\u00ad\nsequences e.g. liver damage, depression, cognitive impair\u00ad\nment, loss of a job, friends, relationships\n545\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Alcohol dependence</p>\n<p>~</p>\n<p>A disorder characterised by the need to take large daily</p>\n<p>amounts of alcohol for adequate functioning. The use of</p>\n<p>alcohol takes on a much higher priority for the individual</p>\n<p>than other behaviours that once had greater value</p>\n<p>~</p>\n<p>Complications: malnutrition, thiamine deficiency (causing</p>\n<p>Wernicke encephalopathy), liver disease, chronic pancreati\u00ad</p>\n<p>tis, peptic ulcer, cardiomyopathy, neuropathy, head trauma</p>\n<p>etc.</p>\n<p>~</p>\n<p>Alcohol withdrawal</p>\n<p>~</p>\n<p>Symptoms occurring upon cessation of alcohol after its</p>\n<p>prolonged daily use (6 hours to 6 days after)</p>\n<p>~</p>\n<p>Include</p>\n<p>~</p>\n<p>Tremor in hands, sweating, vomiting, tachycardia, hyper\u00ad</p>\n<p>tension, agitation, anxiety, headache, seizure and confusion</p>\n<p>in severe cases</p>\n<p>Diagnostic criteria for alcohol dependence:</p>\n<p>If 3 or more of the features below are present:</p>\n<p>~</p>\n<p>A strong desire to take alcohol</p>\n<p>~</p>\n<p>Difficulties controlling alcohol use in terms of onset, termi\u00ad</p>\n<p>nation or levels of use</p>\n<p>~</p>\n<p>A physiological withdrawal state when alcohol use has</p>\n<p>ceased or been reduced (alcohol withdrawal syndrome)</p>\n<p>~</p>\n<p>Evidence of tolerance: increased doses of alcohol are re\u00ad</p>\n<p>quired to achieve effects originally produced by lower doses</p>\n<p>~</p>\n<p>Progressive neglect of alternative pleasures or interests be\u00ad</p>\n<p>cause of alcohol use</p>\n<p>~</p>\n<p>Alcohol use persists despite clear evidence of harmful con\u00ad</p>\n<p>sequences e.g. liver damage, depression, cognitive impair\u00ad</p>\n<p>ment, loss of a job, friends, relationships</p>\n<p>545</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 612,
        "content": "Differential diagnosis\n \n~\nAbuse of other psychoactive substances\n \n~\nDepression, chronic psychosis (often co-existing!)\nInvestigations\n  Blood: complete blood count, liver enzymes\n \n- Shows elevated MCV and GGT levels\n  Social investigations\nManagement\nTREATMENT\nLOC\nAcute intoxication, withdrawal and Wernicke\u2019s \nencephalopathy\nsee section 1.3.12\nHarmful alcohol consumption\n  Counselling and advice\n  Investigate and treat concurrent medical or \npsychiatric illness (dementia, depression anxiety, \npsychosis  seizures etc.)\n  Follow up and refer if not better\nHC3\nAlcohol dependence\n Counselling and education of the patient\n Assess and manage concurrent medical and \nmental conditions\n Advise thiamine 100 mg daily for at least two \nweeks\nIf patient willing to stop, facilitate alcohol cessation\n Determine appropriate setting, refer for \ndetoxification, treat withdrawal symptoms with \ndiazepam\nHC4\nRR\n546\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Abuse of other psychoactive substances</p>\n<p>~</p>\n<p>Depression, chronic psychosis (often co-existing!)</p>\n<p>Investigations</p>\n<p>Blood: complete blood count, liver enzymes</p>\n<p>- Shows elevated MCV and GGT levels</p>\n<p>Social investigations</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute intoxication, withdrawal and Wernicke\u2019s</p>\n<p>encephalopathy</p>\n<p>see section 1.3.12</p>\n<p>Harmful alcohol consumption</p>\n<p>Counselling and advice</p>\n<p>Investigate and treat concurrent medical or</p>\n<p>psychiatric illness (dementia, depression anxiety,</p>\n<p>psychosis  seizures etc.)</p>\n<p>Follow up and refer if not better</p>\n<h3>HC3</h3>\n<p>Alcohol dependence</p>\n<p>Counselling and education of the patient</p>\n<p>Assess and manage concurrent medical and</p>\n<p>mental conditions</p>\n<p>Advise thiamine 100 mg daily for at least two</p>\n<p>weeks</p>\n<p>If patient willing to stop, facilitate alcohol cessation</p>\n<p>Determine appropriate setting, refer for</p>\n<p>detoxification, treat withdrawal symptoms with</p>\n<p>diazepam</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>546</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 613,
        "content": "TREATMENT\nLOC\nDETOXIFIATION should only be undertaken \nwithin inpatient settings \n Consider referral to self -help groups (AA groups)\n Counsel the family, provide psychosocial \ninterventions if available\nHC4\nRR\nPrevention\n \n~\nHealth education on dangers of alcohol abuse\n \n~\nReduce accessibility to alcohol\n9.1.2\t\nSubstance Abuse\t\nICD10 CODE: F11-F19\nConditions resulting from different patterns of drug use including acute \nsedative overdose, acute stimulant intoxication, harmful or hazardous drug \nuse, cannabis dependence, opioid dependence, stimulant dependence, \nbenzodiazepine dependence and their corresponding withdrawal states.\n \n- Harmful or hazardous use: causing damage to health \n(physical, mental or social functioning)\n \n- Dependence: situation in which drug use takes on a much\nhigher priority for a given individual than other behaviours that once \nhad greater value.\nCauses\n \n~\nSocial factors: peer pressure, idleness/unemployment, so\u00ad\ncial pressures, poverty, cultural use, increased availability\n \n~\nPsychological factors: other psychiatric disorders e.g. anx\u00ad\niety, depression, stress, adolescent development changes\nCommonly abused drugs\n \n~\nTobacco (cigarettes, shisha, kuber, mirage, migagi)\n \n~\nCannabis (njaga, bhangi, marijuana)\n547\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>DETOXIFIATION should only be undertaken</p>\n<p>within inpatient settings</p>\n<p>Consider referral to self -help groups (AA groups)</p>\n<p>Counsel the family, provide psychosocial</p>\n<p>interventions if available</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Health education on dangers of alcohol abuse</p>\n<p>~</p>\n<p>Reduce accessibility to alcohol</p>\n<p>9.1.2</p>\n<p>Substance Abuse</p>\n<h3>ICD10 CODE: F11-F19</h3>\n<p>Conditions resulting from different patterns of drug use including acute</p>\n<p>sedative overdose, acute stimulant intoxication, harmful or hazardous drug</p>\n<p>use, cannabis dependence, opioid dependence, stimulant dependence,</p>\n<p>benzodiazepine dependence and their corresponding withdrawal states.</p>\n<p>- Harmful or hazardous use: causing damage to health</p>\n<p>(physical, mental or social functioning)</p>\n<p>- Dependence: situation in which drug use takes on a much</p>\n<p>higher priority for a given individual than other behaviours that once</p>\n<p>had greater value.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Social factors: peer pressure, idleness/unemployment, so\u00ad</p>\n<p>cial pressures, poverty, cultural use, increased availability</p>\n<p>~</p>\n<p>Psychological factors: other psychiatric disorders e.g. anx\u00ad</p>\n<p>iety, depression, stress, adolescent development changes</p>\n<p>Commonly abused drugs</p>\n<p>~</p>\n<p>Tobacco (cigarettes, shisha, kuber, mirage, migagi)</p>\n<p>~</p>\n<p>Cannabis (njaga, bhangi, marijuana)</p>\n<p>547</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 614,
        "content": "~\nKhat (mairungi)\n \n~\nHeroin (brown sugar)\n \n~\nCocaine\n \n~\nPetrol fumes and organic solvents (e.g. thinners)\n \n~\nOpioids: pethidine, morphine, Tramadol\n \n~\nAmphetamines (e.g. speed)\n \n~\nMandrax\u00ae (methaqualone)\n \n~\nBenzodiazepines\n \n~\nBarbiturates (phenabarbitone)\nClinical features\nPresenting features that may point to drug use disorders\n \n~\nChange in behaviour e.g. excessive irritability\n \n~\nChange in function e.g. decline in school/work perfor\u00ad\nmance\n \n~\nLoss of interest\n \n~\nEpisodes of intoxication e.g. slurred speech, staggering gait\n \n~\nInvolvement in illegal activities e.g. rape, theft\n \n~\nChange in appearance e.g. weight loss, red eyes, puffy \nface, untidy, scars from multiple needle pricks\n \n~\nFinancial difficulties e.g. stealing, unpaid debts\n \n~\nRelationship problems e.g. increased conflicts, communi\u00ad\ncation breakdown\n \n~\nFind out if person uses illegal or prescribed drugs in a way \nthat risks damage to their health\n \n~\nNeonatal Abstinence Syndrome -Symptoms (W ithdrawal, I \nrritability, T remors, Hyperactive, high pitched cry, hypo\u00ad\ntonia, D iarrhea, disorganized suck,  R espiratory distress, \nrhinorrhea, A pnoeic attacks, W eight loss,  A lkalosis (re\u00ad\nspiratory), L acrimation\n548\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Khat (mairungi)</p>\n<p>~</p>\n<p>Heroin (brown sugar)</p>\n<p>~</p>\n<p>Cocaine</p>\n<p>~</p>\n<p>Petrol fumes and organic solvents (e.g. thinners)</p>\n<p>~</p>\n<p>Opioids: pethidine, morphine, Tramadol</p>\n<p>~</p>\n<p>Amphetamines (e.g. speed)</p>\n<p>~</p>\n<p>Mandrax\u00ae (methaqualone)</p>\n<p>~</p>\n<p>Benzodiazepines</p>\n<p>~</p>\n<p>Barbiturates (phenabarbitone)</p>\n<p>Clinical features</p>\n<p>Presenting features that may point to drug use disorders</p>\n<p>~</p>\n<p>Change in behaviour e.g. excessive irritability</p>\n<p>~</p>\n<p>Change in function e.g. decline in school/work perfor\u00ad</p>\n<p>mance</p>\n<p>~</p>\n<p>Loss of interest</p>\n<p>~</p>\n<p>Episodes of intoxication e.g. slurred speech, staggering gait</p>\n<p>~</p>\n<p>Involvement in illegal activities e.g. rape, theft</p>\n<p>~</p>\n<p>Change in appearance e.g. weight loss, red eyes, puffy</p>\n<p>face, untidy, scars from multiple needle pricks</p>\n<p>~</p>\n<p>Financial difficulties e.g. stealing, unpaid debts</p>\n<p>~</p>\n<p>Relationship problems e.g. increased conflicts, communi\u00ad</p>\n<p>cation breakdown</p>\n<p>~</p>\n<p>Find out if person uses illegal or prescribed drugs in a way</p>\n<p>that risks damage to their health</p>\n<p>~</p>\n<p>Neonatal Abstinence Syndrome -Symptoms (W ithdrawal, I</p>\n<p>rritability, T remors, Hyperactive, high pitched cry, hypo\u00ad</p>\n<p>tonia, D iarrhea, disorganized suck,  R espiratory distress,</p>\n<p>rhinorrhea, A pnoeic attacks, W eight loss,  A lkalosis (re\u00ad</p>\n<p>spiratory), L acrimation</p>\n<p>548</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 615,
        "content": "Investigations\n \n\u0081\nAsk about use of illicit or non-prescribed drugs\nIf yes, assess for features of dependence (3 or more of the following):\n \n- A strong desire to take drugs\n \n- Difficulties controlling drug use in terms of onset, termination \nor levels of use\n \n- A physiological withdrawal state when drug use has\n \n- ceased or been reduced (as shown by classic withdrawal \nsymptoms)\n \n- Evidence of tolerance: increased doses of the drug are \nrequired to achieve effects originally produced by lower doses\n \n- Progressive neglect of alternative pleasures or interests \nbecause of drug use\n \n- Drug use persists despite clear evidence of harmful\n \n- consequences e.g. depression, loss of a job\n \n\u0081\nInvestigate concurrent physical or mental illnesses\nManagement\nTREATMENT\nLOC\n Assess for and manage co-existing medical \nconditions e.g. HIV\n Assess for harmful use (substance abuse but not \nmeeting criteria for dependence) or dependence\n Psychoeducation and counselling \nRefer to higher LOC for medical treatment of SUD\nTreat presenting symptoms (acute intoxication or \nwithdrawal)\n Refer to self help groups if possible\nHC2\nRR\n Refer to specialist for further management \n(detoxification and Medication Assisted Treatment; \nNaltrexone for; alcohol and opiods; Methadone \nand  Buprenophine for opiods use disorder at RRH \nand Acamprosate at NRH for alcohol.)\n549\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Ask about use of illicit or non-prescribed drugs</p>\n<p>If yes, assess for features of dependence (3 or more of the following):</p>\n<p>- A strong desire to take drugs</p>\n<p>- Difficulties controlling drug use in terms of onset, termination</p>\n<p>or levels of use</p>\n<p>- A physiological withdrawal state when drug use has</p>\n<p>- ceased or been reduced (as shown by classic withdrawal</p>\n<p>symptoms)</p>\n<p>- Evidence of tolerance: increased doses of the drug are</p>\n<p>required to achieve effects originally produced by lower doses</p>\n<p>- Progressive neglect of alternative pleasures or interests</p>\n<p>because of drug use</p>\n<p>- Drug use persists despite clear evidence of harmful</p>\n<p>- consequences e.g. depression, loss of a job</p>\n<p>\u0081</p>\n<p>Investigate concurrent physical or mental illnesses</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Assess for and manage co-existing medical</p>\n<p>conditions e.g. HIV</p>\n<p>Assess for harmful use (substance abuse but not</p>\n<p>meeting criteria for dependence) or dependence</p>\n<p>Psychoeducation and counselling</p>\n<p>Refer to higher LOC for medical treatment of SUD</p>\n<p>Treat presenting symptoms (acute intoxication or</p>\n<p>withdrawal)</p>\n<p>Refer to self help groups if possible</p>\n<h3>HC2</h3>\n<p>RR</p>\n<p>Refer to specialist for further management</p>\n<p>(detoxification and Medication Assisted Treatment;</p>\n<p>Naltrexone for; alcohol and opiods; Methadone</p>\n<p>and  Buprenophine for opiods use disorder at RRH</p>\n<p>and Acamprosate at NRH for alcohol.)</p>\n<p>549</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 616,
        "content": "Prevention\n \n~\nHealth education on dangers of drug use\n \n~\nEmployment/recreational opportunities\n \n~\nEncourage social and cultural values\n \n~\nAttempt to reduce availability of drugs of abuse in commu\u00ad\nnities\n9.1.3 Childhood Behavioural Disorders   ICD10 CODE: F90-F98\nA general term including more specific disorders such as attention deficit \nhyperactivity disorder (ADHD) and other behavioural disorders. Only \nchildren and adolescents with moderate to severe degree of psychological, \nsocial, educational or occupational impairment should be\ndiagnosed as having behavioural disorders. In some children the problem \npersists into adulthood.\nInvestigate if the child\u2019s behavior is a reaction to trauma and/or fear \n(child is bullied or harmed at home or outside home). In this case, it is \nNOT a behavioral disorder; The bullying, and or Abuse must STOP\u2019!\nCauses\n \n~\nGenetic\n \n~\nDepression\n \n~\nMedical conditions, alcohol or drug use\n \n~\nReaction to fear or trauma\nClinical features\n \n~\nAttention Deficit Hyperactivity Disorder (ADHD)\n \n~\nImpaired attention (breaking off from tasks and leaving ac\u00ad\ntivities unfinished) so severe as to affect normal functioning \nand learning\n550\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>Prevention</p>\n<p>~</p>\n<p>Health education on dangers of drug use</p>\n<p>~</p>\n<p>Employment/recreational opportunities</p>\n<p>~</p>\n<p>Encourage social and cultural values</p>\n<p>~</p>\n<p>Attempt to reduce availability of drugs of abuse in commu\u00ad</p>\n<p>nities</p>\n<p>9.1.3 Childhood Behavioural Disorders   ICD10 CODE: F90-F98</p>\n<p>A general term including more specific disorders such as attention deficit</p>\n<p>hyperactivity disorder (ADHD) and other behavioural disorders. Only</p>\n<p>children and adolescents with moderate to severe degree of psychological,</p>\n<p>social, educational or occupational impairment should be</p>\n<p>diagnosed as having behavioural disorders. In some children the problem</p>\n<p>persists into adulthood.</p>\n<p>Investigate if the child\u2019s behavior is a reaction to trauma and/or fear</p>\n<p>(child is bullied or harmed at home or outside home). In this case, it is</p>\n<p>NOT a behavioral disorder; The bullying, and or Abuse must STOP\u2019!</p>\n<p>Causes</p>\n<p>~</p>\n<p>Genetic</p>\n<p>~</p>\n<p>Depression</p>\n<p>~</p>\n<p>Medical conditions, alcohol or drug use</p>\n<p>~</p>\n<p>Reaction to fear or trauma</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Attention Deficit Hyperactivity Disorder (ADHD)</p>\n<p>~</p>\n<p>Impaired attention (breaking off from tasks and leaving ac\u00ad</p>\n<p>tivities unfinished) so severe as to affect normal functioning</p>\n<p>and learning</p>\n<p>550</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 617,
        "content": "~\nExcessive restlessness, overactivity especially in situations \nrequiring calm, talkativeness, fidgeting\n \n~\nOf early onset (<6 years) and lasting >6 months\n \n~\nOther behavioural disorders\n \n~\nUnusually frequent and severe tantrums, persistent severe \ndisobedience\n \n~\nRepetitive and persistent pattern of dissocial, aggressive or \ndefiant conduct (bullying, cruelty to animals, destructive\u00ad\nness, fire setting etc.), more severe than ordinary mischief, \nnot only in response to severe family or social stressors, \nand lasting >six months\nDifferential diagnosis\n \n\u0081\nDepression, psychosis\n \n\u0081\nEpilepsy, developmental disorders\n \n\u0081\nMedical conditions e.g. .hyperthyroidism\nManagement\nTREATMENT\nLOC\n Family psychoeducation and counselling\n Parent skill training\n Contact teachers, advise and plan for special \nneeds education\n Psychosocial interventions if available\nHC4\n Support to family\n Refer to specialist for further management\nFor ADHD not improving with above interventions\n Consider methylphenidate under specialist \nsupervision\nRR\n551\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>~</p>\n<p>Excessive restlessness, overactivity especially in situations</p>\n<p>requiring calm, talkativeness, fidgeting</p>\n<p>~</p>\n<p>Of early onset (<6 years) and lasting >6 months</p>\n<p>~</p>\n<p>Other behavioural disorders</p>\n<p>~</p>\n<p>Unusually frequent and severe tantrums, persistent severe</p>\n<p>disobedience</p>\n<p>~</p>\n<p>Repetitive and persistent pattern of dissocial, aggressive or</p>\n<p>defiant conduct (bullying, cruelty to animals, destructive\u00ad</p>\n<p>ness, fire setting etc.), more severe than ordinary mischief,</p>\n<p>not only in response to severe family or social stressors,</p>\n<p>and lasting >six months</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Depression, psychosis</p>\n<p>\u0081</p>\n<p>Epilepsy, developmental disorders</p>\n<p>\u0081</p>\n<p>Medical conditions e.g. .hyperthyroidism</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Family psychoeducation and counselling</p>\n<p>Parent skill training</p>\n<p>Contact teachers, advise and plan for special</p>\n<p>needs education</p>\n<p>Psychosocial interventions if available</p>\n<h3>HC4</h3>\n<p>Support to family</p>\n<p>Refer to specialist for further management</p>\n<p>For ADHD not improving with above interventions</p>\n<p>Consider methylphenidate under specialist</p>\n<p>supervision</p>\n<p>RR</p>\n<p>551</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 618,
        "content": "9.1.4\t\nChildhood Developmental Disorders ICD10 CODE: F80-F89\nA broad spectrum of disorders with childhood onset, characterized by \nimpairment or delay in functions related to central nervous system mat\u00ad\nuration, and with a steady course rather than remissions and relapses \nas in other mental illnesses. They include intellectual disability/mental \nretardation as well as pervasive developmental disorders such as autism.\nCauses\n \n~\nMay not be known\n \n~\nNutritional deficiencies e.g. iodine deficiencies\n \n~\nMedical conditions\n \n~\nAlcohol use during pregnancy\n \n~\nRisk factors: maternal depression, infections in pregnancy\nClinical features\n \n~\nDelay in development (using local developmental mile\u00ad\nstones or comparison with other children)\n \n~\nIntellectual disability\n \n~\nImpairment of skills across multiple development areas (i.e. \ncognitive, (thinking),  language, motor and skills)\n \n~\nLower intellingence and decreased ability to adapt to daily \ndemands of life\nPervasive developmental disorders including autism\n \n\u0081\nImpaired social behaviour, communication and language\n \n\u0081\nOddities in communication (lack of social use of language skills, \nlack of flexibility of language used)\n \n\u0081\nLoss of previously acquired skills\n \n\u0081\nNarrow range of interests and activities that are both unique to \nthe individual and carried out repetitively originating in infancy \nor early childhood\n552\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>9.1.4</p>\n<p>Childhood Developmental Disorders ICD10 CODE: F80-F89</p>\n<p>A broad spectrum of disorders with childhood onset, characterized by</p>\n<p>impairment or delay in functions related to central nervous system mat\u00ad</p>\n<p>uration, and with a steady course rather than remissions and relapses</p>\n<p>as in other mental illnesses. They include intellectual disability/mental</p>\n<p>retardation as well as pervasive developmental disorders such as autism.</p>\n<p>Causes</p>\n<p>~</p>\n<p>May not be known</p>\n<p>~</p>\n<p>Nutritional deficiencies e.g. iodine deficiencies</p>\n<p>~</p>\n<p>Medical conditions</p>\n<p>~</p>\n<p>Alcohol use during pregnancy</p>\n<p>~</p>\n<p>Risk factors: maternal depression, infections in pregnancy</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Delay in development (using local developmental mile\u00ad</p>\n<p>stones or comparison with other children)</p>\n<p>~</p>\n<p>Intellectual disability</p>\n<p>~</p>\n<p>Impairment of skills across multiple development areas (i.e.</p>\n<p>cognitive, (thinking),  language, motor and skills)</p>\n<p>~</p>\n<p>Lower intellingence and decreased ability to adapt to daily</p>\n<p>demands of life</p>\n<p>Pervasive developmental disorders including autism</p>\n<p>\u0081</p>\n<p>Impaired social behaviour, communication and language</p>\n<p>\u0081</p>\n<p>Oddities in communication (lack of social use of language skills,</p>\n<p>lack of flexibility of language used)</p>\n<p>\u0081</p>\n<p>Loss of previously acquired skills</p>\n<p>\u0081</p>\n<p>Narrow range of interests and activities that are both unique to</p>\n<p>the individual and carried out repetitively originating in infancy</p>\n<p>or early childhood</p>\n<p>552</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 619,
        "content": "\u0081\nSome degree of intellectual disability may be present\n \n\u0081\nSome children may be gifted in specific areas e,g Music, computer\nInvestigations\n \n\u0081\nLook for other priority mental, neurological or substance use \ndisorder (depression, epilepsy, behavioural disorder)\n \n\u0081\nConsider if delay in development could be due to non- stimulating \nenvironment or maternal depression\n \n\u0081\nAssess for nutritional and other medical conditions e.g. sensory \nimpairments (blindness, deafness etc.)\nManagement\nTREATMENT\nLOC\n Address medical issues including visual and \nhearing impairment, nutritional problems\n Family psychoeducation\n Parent skills training\n Contact teachers, advise and plan for special \nneeds education. if their needs are not met in \ninclusive schools\n Provide support to caregivers/family\n Link with community based rehabilitation services \nif available\n Protect and promote human rights of the child: \nTHESE CHILDREN ARE VERY VULNERABLE \nTO ABUSE\n Refer to specialist for more comprehensive \nassessment and management\nHC4\nRR\n553\nUganda Clinical Guidelines 2023\nCHAPTER 9: Mental, Neurological and Substance Use Disorders",
        "formatted_content": "<p>\u0081</p>\n<p>Some degree of intellectual disability may be present</p>\n<p>\u0081</p>\n<p>Some children may be gifted in specific areas e,g Music, computer</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Look for other priority mental, neurological or substance use</p>\n<p>disorder (depression, epilepsy, behavioural disorder)</p>\n<p>\u0081</p>\n<p>Consider if delay in development could be due to non- stimulating</p>\n<p>environment or maternal depression</p>\n<p>\u0081</p>\n<p>Assess for nutritional and other medical conditions e.g. sensory</p>\n<p>impairments (blindness, deafness etc.)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Address medical issues including visual and</p>\n<p>hearing impairment, nutritional problems</p>\n<p>Family psychoeducation</p>\n<p>Parent skills training</p>\n<p>Contact teachers, advise and plan for special</p>\n<p>needs education. if their needs are not met in</p>\n<p>inclusive schools</p>\n<p>Provide support to caregivers/family</p>\n<p>Link with community based rehabilitation services</p>\n<p>if available</p>\n<p>Protect and promote human rights of the child:</p>\n<h3>THESE CHILDREN ARE VERY VULNERABLE</h3>\n<h3>TO ABUSE</h3>\n<p>Refer to specialist for more comprehensive</p>\n<p>assessment and management</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>553</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 9: Mental, Neurological and Substance Use Disorders</p>"
    },
    {
        "page_number": 620,
        "content": "Musculoskeletal and\nJoint Diseases\n10\n10.1 INFECTIONS\n10.1.1 Pyogenic Arthritis (Septic Arthritis)   ICD10 CODE: M00\nAcute infection of a single joint (usually a large joint), commonly affecting \nchildren.\nCauses\n \n~\nUsually haematologenous spread from a primary focus \nfollowing bacteraemia (e.g. septic skin lesions, sinus infec\u00ad\ntions, throat infections, abrasions, wounds, pressure sores, \nand osteomyelitis)\n \n~\nCommonly involved in acute arthritis: Staphylococcus au\u00ad\nreus and Gram negative bacilli, e.g., Salmonella spp, Strep\u00ad\ntococcus spp, Gonococcus\n \n~\nIn chronic septic arthritis: Brucella, tuberculosis\nClinical features\n \n~\nSwollen and warm joint\n \n~\nSevere pain, reduced or abolished movement, temporary \nloss of limb function (pseudoparalysis)\n \n~\nLocalised heat and tenderness\n \n~\nSystemic symptoms: fever (neonates may not show fever \nbut refuse to feed), general malaise\n \n~\nComplications: irreversible joint damage if immediate treat\u00ad\nment is not established\n554\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Musculoskeletal and</p>\n<p>Joint Diseases</p>\n<p>10</p>\n<h3>10.1 INFECTIONS</h3>\n<p>10.1.1 Pyogenic Arthritis (Septic Arthritis)   ICD10 CODE: M00</p>\n<p>Acute infection of a single joint (usually a large joint), commonly affecting</p>\n<p>children.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Usually haematologenous spread from a primary focus</p>\n<p>following bacteraemia (e.g. septic skin lesions, sinus infec\u00ad</p>\n<p>tions, throat infections, abrasions, wounds, pressure sores,</p>\n<p>and osteomyelitis)</p>\n<p>~</p>\n<p>Commonly involved in acute arthritis: Staphylococcus au\u00ad</p>\n<p>reus and Gram negative bacilli, e.g., Salmonella spp, Strep\u00ad</p>\n<p>tococcus spp, Gonococcus</p>\n<p>~</p>\n<p>In chronic septic arthritis: Brucella, tuberculosis</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Swollen and warm joint</p>\n<p>~</p>\n<p>Severe pain, reduced or abolished movement, temporary</p>\n<p>loss of limb function (pseudoparalysis)</p>\n<p>~</p>\n<p>Localised heat and tenderness</p>\n<p>~</p>\n<p>Systemic symptoms: fever (neonates may not show fever</p>\n<p>but refuse to feed), general malaise</p>\n<p>~</p>\n<p>Complications: irreversible joint damage if immediate treat\u00ad</p>\n<p>ment is not established</p>\n<p>554</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 621,
        "content": "Differential diagnosis\n \n~\nInflammatory joint disease\n \n~\nIntra-articular haemorrhage, e.g., haemophilia and other \nbleeding disorders\n \n~\nTrauma\n \n~\nOsteomyelitis of neighbouring bone\nInvestigations\n \n\u0081\nBlood: Full blood count, C&S, ESR (usually elevated)\n \n\u0081\nJoint fluid: Aspirate for C&S; in case of failure to get pus by \naspiration, use arthrotomy (in theatre)\n \n\u0081\nJoint fluid: Gram stain\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nProvide pain relief, e.g., paracetamol, or ibuprofen\n\t\n\u0089\nImmobilise the involved limb, try splinting\n\t\n\u0089\nREFER URGENTLY to HC4, or hospital\nHC2\n\t\n\u0089\nAspirate articular fluid for gram stain, and C&S if \navailable (use local skin and subcutaneous anaesthesia \nif indicated)\n \n- Repeat daily until no further pus is obtained\n \n- Use diazepam 2.5 mg rectal for sedation in \nchildren\n\t\n\u0089\nOr open drainage in theatre\nHC4\nRR\n\t\n\u0089\nContinue pain relief, use paracetamol, ibuprofen\n \n- Or diclofenac 50 mg every 8 hours Child: 0.3-\n2 mg/kg rectally every 6-8 hours (max 150 \nmg)\n \n- Or indomethacin 25-50 mg every 8 hours \nChild:\n0.5-1 mg/kg every 12 hours\nHC4\nH\n555\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Inflammatory joint disease</p>\n<p>~</p>\n<p>Intra-articular haemorrhage, e.g., haemophilia and other</p>\n<p>bleeding disorders</p>\n<p>~</p>\n<p>Trauma</p>\n<p>~</p>\n<p>Osteomyelitis of neighbouring bone</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Full blood count, C&S, ESR (usually elevated)</p>\n<p>\u0081</p>\n<p>Joint fluid: Aspirate for C&S; in case of failure to get pus by</p>\n<p>aspiration, use arthrotomy (in theatre)</p>\n<p>\u0081</p>\n<p>Joint fluid: Gram stain</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Provide pain relief, e.g., paracetamol, or ibuprofen</p>\n<p>\u0089</p>\n<p>Immobilise the involved limb, try splinting</p>\n<p>\u0089</p>\n<p>REFER URGENTLY to HC4, or hospital</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Aspirate articular fluid for gram stain, and C&S if</p>\n<p>available (use local skin and subcutaneous anaesthesia</p>\n<p>if indicated)</p>\n<p>- Repeat daily until no further pus is obtained</p>\n<p>- Use diazepam 2.5 mg rectal for sedation in</p>\n<p>children</p>\n<p>\u0089</p>\n<p>Or open drainage in theatre</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>\u0089</p>\n<p>Continue pain relief, use paracetamol, ibuprofen</p>\n<p>- Or diclofenac 50 mg every 8 hours Child: 0.3-</p>\n<p>2 mg/kg rectally every 6-8 hours (max 150</p>\n<p>mg)</p>\n<p>- Or indomethacin 25-50 mg every 8 hours</p>\n<p>Child:</p>\n<p>0.5-1 mg/kg every 12 hours</p>\n<h3>HC4</h3>\n<p>H</p>\n<p>555</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 622,
        "content": "TREATMENT\nLOC\nAntibiotics: if possible, get guidance from gram \nstain, and culture and sensitivity results\nIf Gram positive at gram stain, or negative stain but \nimmunocompetent  adult  patient: \n\t\n\u0089\nCloxacillin 500-1 g IV every 6 hours Child: 50\nmg/kg IV every 6 hours\n \n- Give IV for 2 weeks, then if better, switch to \noral to complete 4 weeks\n\t\n\u0089\nAlternative/second line: Chloramphenicol 500 mg \nIV every 6 hours for at least 2 weeks Child: 12.5 mg \nevery 6 hours\nIf Gram negative at gram stain \n\t\n\u0089\nCeftriaxone 1 g IV for 2-4 weeks Alternatives\n\t\n\u0089\nCiprofloxacin 500 mg every 12 hours for 3 weeks\nIn adults with negative stain and underlying \nconditions (suspect gram negative, e.g. Salmonella \nin Sickle Cell Disease), and all children with \nnegative stain, or underlying  conditions \n\t\n\u0089\nCloxacillin + ceftriaxone\nIf suspicion of gonococcal (e.g. in sexually active \nadolescents)\n\t\n\u0089\nCeftriaxone 1 g IV daily for 1 week\nHC4\n10.1.2\t Osteomyelitis\t ICD10 CODE: M86\nInfection of bone by pus-forming bacteria, mainly affecting older children \nand adults.\nCauses\n \n~\nAny type of bacterium but most commonly S.aureus,\n \n~\nfollowing infection elsewhere in the body\n556\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Antibiotics: if possible, get guidance from gram</p>\n<p>stain, and culture and sensitivity results</p>\n<p>If Gram positive at gram stain, or negative stain but</p>\n<p>immunocompetent  adult  patient:</p>\n<p>\u0089</p>\n<p>Cloxacillin 500-1 g IV every 6 hours Child: 50</p>\n<p>mg/kg IV every 6 hours</p>\n<p>- Give IV for 2 weeks, then if better, switch to</p>\n<p>oral to complete 4 weeks</p>\n<p>\u0089</p>\n<p>Alternative/second line: Chloramphenicol 500 mg</p>\n<p>IV every 6 hours for at least 2 weeks Child: 12.5 mg</p>\n<p>every 6 hours</p>\n<p>If Gram negative at gram stain</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV for 2-4 weeks Alternatives</p>\n<p>\u0089</p>\n<p>Ciprofloxacin 500 mg every 12 hours for 3 weeks</p>\n<p>In adults with negative stain and underlying</p>\n<p>conditions (suspect gram negative, e.g. Salmonella</p>\n<p>in Sickle Cell Disease), and all children with</p>\n<p>negative stain, or underlying  conditions</p>\n<p>\u0089</p>\n<p>Cloxacillin + ceftriaxone</p>\n<p>If suspicion of gonococcal (e.g. in sexually active</p>\n<p>adolescents)</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV daily for 1 week</p>\n<h3>HC4</h3>\n<p>10.1.2\t Osteomyelitis\t ICD10 CODE: M86</p>\n<p>Infection of bone by pus-forming bacteria, mainly affecting older children</p>\n<p>and adults.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Any type of bacterium but most commonly S.aureus,</p>\n<p>~</p>\n<p>following infection elsewhere in the body</p>\n<p>556</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 623,
        "content": "~\nRisk factor: sickle cell disease (causative agent mostly S. \nAureus, Salmonella also common)\nClinical features\nAcute osteomyelitis\n \n~\nOnset is usually over several days\n \n~\nFever, usually high but may be absent, especially in neo\u00ad\nnates\n \n~\nPain (usually severe)\n \n~\nTenderness and increased \u201cheat\u201d at the site of infection, \nswelling of the surrounding tissues and joint\n \n~\nReduced or complete loss of use of the affected limb\n \n~\nThe patient is usually a child of four years or above with \nreduced immunity, but adults may also be affected\n \n~\nHistory of injury may be given, and may be misleading, \nespecially if there is no fever\nChronic osteomyelitis\n \n~\nMay present with pain, erythema, or swelling, sometimes \nin association with a draining sinus tract\n \n~\nDeep or extensive ulcers that fail to heal after several \nweeks of appropriate ulcer care (e.g. in diabetic foot), and \nnon-healing fractures, should raise suspicion of chronic os\u00ad\nteomyelitis\nDifferential diagnosis\n \n~\nInfection of joints\n \n~\nInjury (trauma) to a limb, fracture (children)\n \n~\nBone cancer (osteosarcoma, around the knee)\n \n~\n Pyomyositis (bacterial infection of muscle)\n \n~\nCellulitis\n \n~\nSickle-cell disease (thrombotic crisis)\n557\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>~</p>\n<p>Risk factor: sickle cell disease (causative agent mostly S.</p>\n<p>Aureus, Salmonella also common)</p>\n<p>Clinical features</p>\n<p>Acute osteomyelitis</p>\n<p>~</p>\n<p>Onset is usually over several days</p>\n<p>~</p>\n<p>Fever, usually high but may be absent, especially in neo\u00ad</p>\n<p>nates</p>\n<p>~</p>\n<p>Pain (usually severe)</p>\n<p>~</p>\n<p>Tenderness and increased \u201cheat\u201d at the site of infection,</p>\n<p>swelling of the surrounding tissues and joint</p>\n<p>~</p>\n<p>Reduced or complete loss of use of the affected limb</p>\n<p>~</p>\n<p>The patient is usually a child of four years or above with</p>\n<p>reduced immunity, but adults may also be affected</p>\n<p>~</p>\n<p>History of injury may be given, and may be misleading,</p>\n<p>especially if there is no fever</p>\n<p>Chronic osteomyelitis</p>\n<p>~</p>\n<p>May present with pain, erythema, or swelling, sometimes</p>\n<p>in association with a draining sinus tract</p>\n<p>~</p>\n<p>Deep or extensive ulcers that fail to heal after several</p>\n<p>weeks of appropriate ulcer care (e.g. in diabetic foot), and</p>\n<p>non-healing fractures, should raise suspicion of chronic os\u00ad</p>\n<p>teomyelitis</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Infection of joints</p>\n<p>~</p>\n<p>Injury (trauma) to a limb, fracture (children)</p>\n<p>~</p>\n<p>Bone cancer (osteosarcoma, around the knee)</p>\n<p>~</p>\n<p>Pyomyositis (bacterial infection of muscle)</p>\n<p>~</p>\n<p>Cellulitis</p>\n<p>~</p>\n<p>Sickle-cell disease (thrombotic crisis)</p>\n<p>557</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 624,
        "content": "Investigations\n \n\u0081\nX-ray shows\n\t\n\u0089\nNothing abnormal in first 1-2 weeks\n\t\n\u0089\nLoss of bone density (rarefaction) at about 2 weeks\n\t\n\u0089\nMay show a thin \u201cwhite\u201d line on the surface of the infected part of \nthe bone (periosteal reaction)\n\t\n\u0089\nLater, may show a piece of dead bone (sequestrum)\n \n\u0081\nBlood: CBC, ESR, C&S: Type of bacterium may be detected\n \n\u0081\nattempt ZN,gene expert, culture if lesion suspect\nCalcoflour stain for fungus\nManagement\nPatients with suspected osteomyelitis need to be referred to hospital for \nappropriate management.\nTREATMENT\nLOC\n\t\n\u0089\nImmobilize the limb, splint\n\t\n\u0089\nProvide pain and fever relief with paracetamol,\nor ibuprofen\n\t\n\u0089\nRefer URGENTLY to hospital\n\t\n\u0089\nAdmit and elevate affected limb\n\t\n\u0089\nCloxacillin 500 mg IV every 6 hours for 2 weeks.\nContinue orally for at least 4 weeks (but up to 3 \nmonths) Child: 50 mg/kg every 6 hours\n\t\n\u0089\nSee pyogenic arthritis for other antibiotic treatments \n(section 10.1.1)\n\t\n\u0089\nOsteomyelitis in SCD: see section 11.1.3\n\t\n\u0089\nSurgical intervention may be indicated in the following \ncases:\nHC3\nH\nRR\n558\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>X-ray shows</p>\n<p>\u0089</p>\n<p>Nothing abnormal in first 1-2 weeks</p>\n<p>\u0089</p>\n<p>Loss of bone density (rarefaction) at about 2 weeks</p>\n<p>\u0089</p>\n<p>May show a thin \u201cwhite\u201d line on the surface of the infected part of</p>\n<p>the bone (periosteal reaction)</p>\n<p>\u0089</p>\n<p>Later, may show a piece of dead bone (sequestrum)</p>\n<p>\u0081</p>\n<p>Blood: CBC, ESR, C&S: Type of bacterium may be detected</p>\n<p>\u0081</p>\n<p>attempt ZN,gene expert, culture if lesion suspect</p>\n<p>Calcoflour stain for fungus</p>\n<p>Management</p>\n<p>Patients with suspected osteomyelitis need to be referred to hospital for</p>\n<p>appropriate management.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Immobilize the limb, splint</p>\n<p>\u0089</p>\n<p>Provide pain and fever relief with paracetamol,</p>\n<p>or ibuprofen</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to hospital</p>\n<p>\u0089</p>\n<p>Admit and elevate affected limb</p>\n<p>\u0089</p>\n<p>Cloxacillin 500 mg IV every 6 hours for 2 weeks.</p>\n<p>Continue orally for at least 4 weeks (but up to 3</p>\n<p>months) Child: 50 mg/kg every 6 hours</p>\n<p>\u0089</p>\n<p>See pyogenic arthritis for other antibiotic treatments</p>\n<p>(section 10.1.1)</p>\n<p>\u0089</p>\n<p>Osteomyelitis in SCD: see section 11.1.3</p>\n<p>\u0089</p>\n<p>Surgical intervention may be indicated in the following</p>\n<p>cases:</p>\n<h3>HC3</h3>\n<p>H</p>\n<p>RR</p>\n<p>558</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 625,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nDrainage of subperiosteal and soft tissue abscesses, \nand intramedullary purulence\n \n- Debridement of contiguous foci of infection\n \n- (which also require antimicrobial therapy)\n \n- Excision of sequestra (i.e. devitalized bone)\n \n- Failure to improve after 48-72 hours of \nantimicrobial therapy\nHC3\nH\nRR\n \n- Chronic osteomyelitis\n\t\n\u0089\nSurgery and antibiotics\nRR\n10.1.3\t Pyomyositis\t\nICD10 CODE: M60.0\nInflammation of muscle, which may lead to pus formation and deep-seated \nmuscle abscess.\nCauses\n \n~\nBacterial infection (commonly Staphylococcus aureus)\nClinical features\n \n~\nMost commonly localised in one muscle; usually large stri\u00ad\nated muscle\n \n~\nFever, painful swelling of the involved muscle\n \n~\nAffected area is hot, swollen, and tender\n \n~\nFluctuation when pus forms\nDifferential diagnosis\n \n~\nCellulitis, boil\n \n~\nOsteomyelitis\n \n~\nPeritonitis (in pyomyositis of abdominal muscles)\n559\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Drainage of subperiosteal and soft tissue abscesses,</p>\n<p>and intramedullary purulence</p>\n<p>- Debridement of contiguous foci of infection</p>\n<p>- (which also require antimicrobial therapy)</p>\n<p>- Excision of sequestra (i.e. devitalized bone)</p>\n<p>- Failure to improve after 48-72 hours of</p>\n<p>antimicrobial therapy</p>\n<h3>HC3</h3>\n<p>H</p>\n<p>RR</p>\n<p>- Chronic osteomyelitis</p>\n<p>\u0089</p>\n<p>Surgery and antibiotics</p>\n<p>RR</p>\n<p>10.1.3\t Pyomyositis</p>\n<h3>ICD10 CODE: M60.0</h3>\n<p>Inflammation of muscle, which may lead to pus formation and deep-seated</p>\n<p>muscle abscess.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Bacterial infection (commonly Staphylococcus aureus)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Most commonly localised in one muscle; usually large stri\u00ad</p>\n<p>ated muscle</p>\n<p>~</p>\n<p>Fever, painful swelling of the involved muscle</p>\n<p>~</p>\n<p>Affected area is hot, swollen, and tender</p>\n<p>~</p>\n<p>Fluctuation when pus forms</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cellulitis, boil</p>\n<p>~</p>\n<p>Osteomyelitis</p>\n<p>~</p>\n<p>Peritonitis (in pyomyositis of abdominal muscles)</p>\n<p>559</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 626,
        "content": "Investigations\n \n\u0081\nBlood: Full blood count\n \n\u0081\nPus: culture and sensitivity\n \n\u0081\nConsider HIV infection\nTREATMENT\nLOC\n\t\n\u0089\nElevate and immobilise affected limb\n\t\n\u0089\nCloxacillin 500 mg IV or oral every 6 hours for 5-10 \ndays Child: 12.5-25 mg/kg per dose\n\t\n\u0089\nDuring the early stage, when the muscle is indurated, \nhot and swollen, antibiotic treatment may be sufficient \nto resolve the infection\nWhen abscess has formed,\n\t\n\u0089\nSurgical drainage is the only effective treatment\n \n- Leave the wound open, pack and clean daily\nHC3\nHC4\n10.1.4\t Tuberculosis of the Spine (Pott\u2019s Disease)  ICD10 CODE: \nA18.01\nTuberculous spondylitis (Pott\u2019s disease) is the most common form of \nskeletal TB; it usually affects the lower thoracic and upper lumbar region. \nInfection begins with inflammation\nof the intervertebral joints and can spread to involve the adjacent vertebral \nbody. Once two adjacent vertebrae are involved, infection can involve \nthe adjoining intervertebral disc space, leading to vertebral collapse. \nSubsequent kyphosis can lead to cord compression and paraplegia.\nCauses\n \n~\nA chronic infection caused by Mycobacteria\n560\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Full blood count</p>\n<p>\u0081</p>\n<p>Pus: culture and sensitivity</p>\n<p>\u0081</p>\n<p>Consider HIV infection</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Elevate and immobilise affected limb</p>\n<p>\u0089</p>\n<p>Cloxacillin 500 mg IV or oral every 6 hours for 5-10</p>\n<p>days Child: 12.5-25 mg/kg per dose</p>\n<p>\u0089</p>\n<p>During the early stage, when the muscle is indurated,</p>\n<p>hot and swollen, antibiotic treatment may be sufficient</p>\n<p>to resolve the infection</p>\n<p>When abscess has formed,</p>\n<p>\u0089</p>\n<p>Surgical drainage is the only effective treatment</p>\n<p>- Leave the wound open, pack and clean daily</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>10.1.4\t Tuberculosis of the Spine (Pott\u2019s Disease)  ICD10 CODE:</p>\n<h3>A18.01</h3>\n<p>Tuberculous spondylitis (Pott\u2019s disease) is the most common form of</p>\n<p>skeletal TB; it usually affects the lower thoracic and upper lumbar region.</p>\n<p>Infection begins with inflammation</p>\n<p>of the intervertebral joints and can spread to involve the adjacent vertebral</p>\n<p>body. Once two adjacent vertebrae are involved, infection can involve</p>\n<p>the adjoining intervertebral disc space, leading to vertebral collapse.</p>\n<p>Subsequent kyphosis can lead to cord compression and paraplegia.</p>\n<p>Causes</p>\n<p>~</p>\n<p>A chronic infection caused by Mycobacteria</p>\n<p>560</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 627,
        "content": "Clinical features\n \n~\nMost common in young adults\n \n~\nLocal pain, which increases in severity over weeks to \nmonths, sometimes in association with muscle spasm and \nrigidity\n \n~\nConstitutional symptoms such as fever and weight loss are \npresent in < 40% of cases\n \n~\nWith the progression and spreading of the disease, anteri\u00ad\nor collapse of affected vertebrae leads to visible deformity \n(angular kyphosis or gibbus), and risk of cord compression:\n \n~\nWeakness of legs (Pott\u2019s paraplegia)\n \n- Visceral dysfunction\n \n~\nDifferential diagnosis\n \n~\nStaphylococcal spondylitis\n \n~\nBrucellosis\n \n~\nMetastatic lesion\nInvestigations\n \n\u0081\nAdequate history and careful examination\n \n\u0081\nX-ray spine: disc space narrowing, paravertebral shadow, single/\nmultiple vertebral involvement, destruction lesions of 2 or more \nvertebrae without new bone formation, destruction of vertebral \nend-plates\n \n\u0081\nBlood: raised ESR, WBC (within normal limits)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRest the spine\n\t\n\u0089\nFit a spinal corset or plaster jacket for pain relief\n\t\n\u0089\nTB treatment as per guidelines (see section 5.3 for \nmore details)\n\t\n\u0089\nSurgical intervention is warranted for patients in the \nfollowing circumstances:\nHC4\nRR\n561\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Clinical features</p>\n<p>~</p>\n<p>Most common in young adults</p>\n<p>~</p>\n<p>Local pain, which increases in severity over weeks to</p>\n<p>months, sometimes in association with muscle spasm and</p>\n<p>rigidity</p>\n<p>~</p>\n<p>Constitutional symptoms such as fever and weight loss are</p>\n<p>present in < 40% of cases</p>\n<p>~</p>\n<p>With the progression and spreading of the disease, anteri\u00ad</p>\n<p>or collapse of affected vertebrae leads to visible deformity</p>\n<p>(angular kyphosis or gibbus), and risk of cord compression:</p>\n<p>~</p>\n<p>Weakness of legs (Pott\u2019s paraplegia)</p>\n<p>- Visceral dysfunction</p>\n<p>~</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Staphylococcal spondylitis</p>\n<p>~</p>\n<p>Brucellosis</p>\n<p>~</p>\n<p>Metastatic lesion</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Adequate history and careful examination</p>\n<p>\u0081</p>\n<p>X-ray spine: disc space narrowing, paravertebral shadow, single/</p>\n<p>multiple vertebral involvement, destruction lesions of 2 or more</p>\n<p>vertebrae without new bone formation, destruction of vertebral</p>\n<p>end-plates</p>\n<p>\u0081</p>\n<p>Blood: raised ESR, WBC (within normal limits)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Rest the spine</p>\n<p>\u0089</p>\n<p>Fit a spinal corset or plaster jacket for pain relief</p>\n<p>\u0089</p>\n<p>TB treatment as per guidelines (see section 5.3 for</p>\n<p>more details)</p>\n<p>\u0089</p>\n<p>Surgical intervention is warranted for patients in the</p>\n<p>following circumstances:</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>561</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 628,
        "content": "TREATMENT\nLOC\n \n- Patients with spinal disease and advanced\n \n- neurological deficits\n \n- Patients with spinal disease and worsening \nneurological deficits, progressing while on \nappropriate therapy\n \n- Patients with spinal disease and kyphosis >40\n \n- degrees at the time of presentation\n \n- Patients with chest wall cold abscess\nHC4\nRR\n10.2 INFLAMMATORY/DEGENERATIVE DISORDERS\n10.2.1\t Rheumatoid Arthritis\t\nICD10 CODE: M05\nMost common form of chronic inflammatory joint disease affecting mainly \nwomen. Attacks tend to be bilateral with symmetrical involvement that \ncause joint destruction.\nCauses\n \n~\nUnknown origin, probably autoimmune\nClinical features\n \n~\nStiffness and pain in the joints (usually >3, symmetrical, \nworse in the morning)\n \n~\nJoints are swollen, warm, inflamed, and sensitive to touch\n \n~\nFingers are most affected (metacarpophalangeal, or proxi\u00ad\nmal interpahalangeal), but all small and medium size joints \ncan be affected (rarely hips and spine)\n \n~\nExtra articular manifestations: mild fever, weakness, leth\u00ad\nargy, anorexia, weight loss, rheumatoid nodules (20%) at \nextensor surface like forearm below joint\n \n~\nIt is a CHRONIC disease with flare-up, remission, and ex\u00ad\nacerbations\n \n~\nIn advanced cases, joint deformities may occur\n562\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Patients with spinal disease and advanced</p>\n<p>- neurological deficits</p>\n<p>- Patients with spinal disease and worsening</p>\n<p>neurological deficits, progressing while on</p>\n<p>appropriate therapy</p>\n<p>- Patients with spinal disease and kyphosis >40</p>\n<p>- degrees at the time of presentation</p>\n<p>- Patients with chest wall cold abscess</p>\n<h3>HC4</h3>\n<p>RR</p>\n<h3>10.2 INFLAMMATORY/DEGENERATIVE DISORDERS</h3>\n<p>10.2.1\t Rheumatoid Arthritis</p>\n<h3>ICD10 CODE: M05</h3>\n<p>Most common form of chronic inflammatory joint disease affecting mainly</p>\n<p>women. Attacks tend to be bilateral with symmetrical involvement that</p>\n<p>cause joint destruction.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Unknown origin, probably autoimmune</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Stiffness and pain in the joints (usually >3, symmetrical,</p>\n<p>worse in the morning)</p>\n<p>~</p>\n<p>Joints are swollen, warm, inflamed, and sensitive to touch</p>\n<p>~</p>\n<p>Fingers are most affected (metacarpophalangeal, or proxi\u00ad</p>\n<p>mal interpahalangeal), but all small and medium size joints</p>\n<p>can be affected (rarely hips and spine)</p>\n<p>~</p>\n<p>Extra articular manifestations: mild fever, weakness, leth\u00ad</p>\n<p>argy, anorexia, weight loss, rheumatoid nodules (20%) at</p>\n<p>extensor surface like forearm below joint</p>\n<p>~</p>\n<p>It is a CHRONIC disease with flare-up, remission, and ex\u00ad</p>\n<p>acerbations</p>\n<p>~</p>\n<p>In advanced cases, joint deformities may occur</p>\n<p>562</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 629,
        "content": "Differential diagnosis\n \n~\nOsteoarthritis, gout arthritis (in males)\n \n~\nReactive arthritis\nInvestigations\n \n\u0081\nBlood: Full blood count, ESR, rheumatoid factor, antinuclear factor\n \n\u0081\nX-ray of affected joints\nManagement\nGoals of treatment\n \n~\nRelief of symptoms\n \n~\nPreservation of joint function\n \n~\nSuppression of active disease, and slowing progression of \ndisease (prevention of structure damage and deformity)\n \n~\nMaintenance of patient\u2019s normal lifestyle\nSymptomatic treatment can be started at lower level but appropriate \nmanagement requires referral for specialist care.\nTREATMENT\nLOC\n \n- For pain and inflammation in acute flare\n\t\n\u0089\nRest the affected joints\n\t\n\u0089\nAny NSAIDS e.g. ibuprofen 400 mg every 8hours\n\t\n\u0089\nOr diclofenac 50 mg every 8 hours\n\t\n\u0089\nOr indomethacin 50 mg every 8 hours\n \n- Long term treatment is not advised because \nof toxicity, and because NSAIDS do not \nmodify the progression of disease\n \n- Consider adding gastroprotection with \nomeprazole 20 mg once daily\n \n- For severe acute inflammation\n\t\n\u0089\nPrednisolone 5\u201310 mg once daily in the morning\nHC2\nHC3\nRR\n563\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Osteoarthritis, gout arthritis (in males)</p>\n<p>~</p>\n<p>Reactive arthritis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Full blood count, ESR, rheumatoid factor, antinuclear factor</p>\n<p>\u0081</p>\n<p>X-ray of affected joints</p>\n<p>Management</p>\n<p>Goals of treatment</p>\n<p>~</p>\n<p>Relief of symptoms</p>\n<p>~</p>\n<p>Preservation of joint function</p>\n<p>~</p>\n<p>Suppression of active disease, and slowing progression of</p>\n<p>disease (prevention of structure damage and deformity)</p>\n<p>~</p>\n<p>Maintenance of patient\u2019s normal lifestyle</p>\n<p>Symptomatic treatment can be started at lower level but appropriate</p>\n<p>management requires referral for specialist care.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- For pain and inflammation in acute flare</p>\n<p>\u0089</p>\n<p>Rest the affected joints</p>\n<p>\u0089</p>\n<p>Any NSAIDS e.g. ibuprofen 400 mg every 8hours</p>\n<p>\u0089</p>\n<p>Or diclofenac 50 mg every 8 hours</p>\n<p>\u0089</p>\n<p>Or indomethacin 50 mg every 8 hours</p>\n<p>- Long term treatment is not advised because</p>\n<p>of toxicity, and because NSAIDS do not</p>\n<p>modify the progression of disease</p>\n<p>- Consider adding gastroprotection with</p>\n<p>omeprazole 20 mg once daily</p>\n<p>- For severe acute inflammation</p>\n<p>\u0089</p>\n<p>Prednisolone 5\u201310 mg once daily in the morning</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>RR</p>\n<p>563</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 630,
        "content": "TREATMENT\nLOC\n \n- They slow disease progression, but should not \nbe used for long periods due to side effects\n \n- Used for treating acute symptoms, and while\n \n- waiting to start specific medicines\n \n- Refer to specialist for Disease Modifying Anti-\n \n- Rheumatic Drugs \n\t\n\u0089\nMethotrexate \n\t\n\u0089\nChloroquine\nHC2\nHC3\nRR\n \n- Counselling and health education\n\t\n\u0089\nWeight loss and appropriate exercise/ physiotherapy\n10.2.2\t Gout Arhthritis\t ICD10 CODE: M10\nAn inflammation disorder involving a joint(s) due to deposition of uric \nacid crystals; predominant in males.\nCauses\n \n~\nAltered urate metabolism with deposition of urate salts in \nthe joint and other tissues in advanced cases\nClinical features\nAcute gout\n \n~\nAffected joint is hot, red, and swollen\n \n~\nMostly attacks the big toe at the metatarsophalangeal joint \n(podagra), may occasionally start in other joints\n \n~\nSudden severe pain (often at night)\nChronic gout\n \n~\nRepetitive acute attacks are followed by progressive carti\u00ad\nlage and bone erosion\n \n~\nDeposition of tophi in soft tissue, e.g., ear cartilage, bur\u00ad\nsae, and tendon sheaths\n564\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- They slow disease progression, but should not</p>\n<p>be used for long periods due to side effects</p>\n<p>- Used for treating acute symptoms, and while</p>\n<p>- waiting to start specific medicines</p>\n<p>- Refer to specialist for Disease Modifying Anti-</p>\n<p>- Rheumatic Drugs</p>\n<p>\u0089</p>\n<p>Methotrexate</p>\n<p>\u0089</p>\n<p>Chloroquine</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>RR</p>\n<p>- Counselling and health education</p>\n<p>\u0089</p>\n<p>Weight loss and appropriate exercise/ physiotherapy</p>\n<p>10.2.2\t Gout Arhthritis\t ICD10 CODE: M10</p>\n<p>An inflammation disorder involving a joint(s) due to deposition of uric</p>\n<p>acid crystals; predominant in males.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Altered urate metabolism with deposition of urate salts in</p>\n<p>the joint and other tissues in advanced cases</p>\n<p>Clinical features</p>\n<p>Acute gout</p>\n<p>~</p>\n<p>Affected joint is hot, red, and swollen</p>\n<p>~</p>\n<p>Mostly attacks the big toe at the metatarsophalangeal joint</p>\n<p>(podagra), may occasionally start in other joints</p>\n<p>~</p>\n<p>Sudden severe pain (often at night)</p>\n<p>Chronic gout</p>\n<p>~</p>\n<p>Repetitive acute attacks are followed by progressive carti\u00ad</p>\n<p>lage and bone erosion</p>\n<p>~</p>\n<p>Deposition of tophi in soft tissue, e.g., ear cartilage, bur\u00ad</p>\n<p>sae, and tendon sheaths</p>\n<p>564</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 631,
        "content": "Differential diagnosis\n \n~\nJoint infection\n \n~\nRheumatoid arthritis\n \n~\nInjury\n \n~\nPseudo gout (osteoarthritis)\nInvestigations\n \n\u0081\nJoint aspiration uric acid crystals viewed by a polarising mi\u00ad\ncroscope\n \n\u0081\nX-ray: Of the joint(s)\n \n\u0081\nBlood: Serum uric acid (usually elevated)\nTREATMENT\nLOC\nAcute attack\n\t\n\u0089\nRest and immobilisation\n\t\n\u0089\nStart NSAIDS such as ibuprofen 400 mg every 8 hours\n\t\n\u0089\nor Indomethacin 50 mg every 8 hours\n\t\n\u0089\nOr Diclofenac 50 mg every 8 hours\n \n- Continue for the duration of the attack\n \n- If NSAIDS contraindicated\n\t\n\u0089\nPrednisolone 40 mg once daily for 5 days\n\t\n\u0089\nOr colchicine 0.5-1 mg initially followed by\n0.5 mg every 2-3 hours until relief of pain, or if \nvomiting and diarrhoea occurs (max dose 6 mg). \nDo NOT repeat the course within 3 days\nHC2\nHC4\nHC3\nH\nChronic gout\n\t\n\u0089\nWeight reduction\n\t\n\u0089\nControl diet: healthy diet, limit alcohol consumption, \ncoffee is beneficial\n\t\n\u0089\nAvoid medicines which may increase uric acid: thi\u00ad\nazide diuretics\nIf more than 2 attacks per year, and/or \ncomplications (renal stones, chronic tophaceous \ngout), give:\nH\n565\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<p>Differential diagnosis</p>\n<p>~</p>\n<p>Joint infection</p>\n<p>~</p>\n<p>Rheumatoid arthritis</p>\n<p>~</p>\n<p>Injury</p>\n<p>~</p>\n<p>Pseudo gout (osteoarthritis)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Joint aspiration uric acid crystals viewed by a polarising mi\u00ad</p>\n<p>croscope</p>\n<p>\u0081</p>\n<p>X-ray: Of the joint(s)</p>\n<p>\u0081</p>\n<p>Blood: Serum uric acid (usually elevated)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute attack</p>\n<p>\u0089</p>\n<p>Rest and immobilisation</p>\n<p>\u0089</p>\n<p>Start NSAIDS such as ibuprofen 400 mg every 8 hours</p>\n<p>\u0089</p>\n<p>or Indomethacin 50 mg every 8 hours</p>\n<p>\u0089</p>\n<p>Or Diclofenac 50 mg every 8 hours</p>\n<p>- Continue for the duration of the attack</p>\n<p>- If NSAIDS contraindicated</p>\n<p>\u0089</p>\n<p>Prednisolone 40 mg once daily for 5 days</p>\n<p>\u0089</p>\n<p>Or colchicine 0.5-1 mg initially followed by</p>\n<p>0.5 mg every 2-3 hours until relief of pain, or if</p>\n<p>vomiting and diarrhoea occurs (max dose 6 mg).</p>\n<p>Do NOT repeat the course within 3 days</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>H</p>\n<p>Chronic gout</p>\n<p>\u0089</p>\n<p>Weight reduction</p>\n<p>\u0089</p>\n<p>Control diet: healthy diet, limit alcohol consumption,</p>\n<p>coffee is beneficial</p>\n<p>\u0089</p>\n<p>Avoid medicines which may increase uric acid: thi\u00ad</p>\n<p>azide diuretics</p>\n<p>If more than 2 attacks per year, and/or</p>\n<p>complications (renal stones, chronic tophaceous</p>\n<p>gout), give:</p>\n<p>H</p>\n<p>565</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 632,
        "content": "TREATMENT\nLOC\n\t\n\u0089\nAllopurinol starting dose 100 mg , increase monthly \nby 100 mg. Average maintenance dose 300 mg, max \n900 mg. Titrate to keep uric acid level <0.35 mmol/L\nH\n\t\n\u0089\nDo not start during acute attack, but continue with \nit if already started\n\t\n\u0089\nGive prophylactic colchicine 0.5 mg every 12 hours \nfor the first 3 months to prevent acute attacks\nNote\n \n\u0083 DO NOT use allopurinol to treat asymptomatic \nhyperuricemia\n10.2.3\t Osteoarthritis\t ICD10 CODE: M15-M19\nA degenerative joint disease with damage to articular cartilage usually \ncaused by inorganic calcium deposit. It is the commonest form of joint \ndisease. The pathological changes in osteoarthritis are irreversible.\nCauses/risk factors\n \n~\nPrevious injury\n \n~\nOverweight\n \n~\nAge\nClinical features\n \n~\nMay involve any joint; most commonly the hip, spine, and \nknees, usually not symmetrical\n \n~\nRestriction of movement, pain on moving the joint but \ntends to be absent at rest, limp in case of lower limbs\n \n~\nDeformity, moderate tenderness\n \n~\nImprovement with rest, deterioration with physical activity, \nand cold and wet weather conditions\n \n~\nJoints are usually not swollen or warm but there may be \nsome accumulation of (clear) articular fluid\n566\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Allopurinol starting dose 100 mg , increase monthly</p>\n<p>by 100 mg. Average maintenance dose 300 mg, max</p>\n<p>900 mg. Titrate to keep uric acid level <0.35 mmol/L</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Do not start during acute attack, but continue with</p>\n<p>it if already started</p>\n<p>\u0089</p>\n<p>Give prophylactic colchicine 0.5 mg every 12 hours</p>\n<p>for the first 3 months to prevent acute attacks</p>\n<p>Note</p>\n<p>\u0083 DO NOT use allopurinol to treat asymptomatic</p>\n<p>hyperuricemia</p>\n<p>10.2.3\t Osteoarthritis\t ICD10 CODE: M15-M19</p>\n<p>A degenerative joint disease with damage to articular cartilage usually</p>\n<p>caused by inorganic calcium deposit. It is the commonest form of joint</p>\n<p>disease. The pathological changes in osteoarthritis are irreversible.</p>\n<p>Causes/risk factors</p>\n<p>~</p>\n<p>Previous injury</p>\n<p>~</p>\n<p>Overweight</p>\n<p>~</p>\n<p>Age</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>May involve any joint; most commonly the hip, spine, and</p>\n<p>knees, usually not symmetrical</p>\n<p>~</p>\n<p>Restriction of movement, pain on moving the joint but</p>\n<p>tends to be absent at rest, limp in case of lower limbs</p>\n<p>~</p>\n<p>Deformity, moderate tenderness</p>\n<p>~</p>\n<p>Improvement with rest, deterioration with physical activity,</p>\n<p>and cold and wet weather conditions</p>\n<p>~</p>\n<p>Joints are usually not swollen or warm but there may be</p>\n<p>some accumulation of (clear) articular fluid</p>\n<p>566</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 633,
        "content": "TREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nWeight reduction\n\t\n\u0089\nEncourage activity and regular  exercise \n\t\n\u0089\nUse of appropriate foot wear and walking aids \n\t\n\u0089\nParacetamol 1 g every 8 hours\nIn acute exacerbation, or severe pain\n\t\n\u0089\nNSAID (ibuprofen, or diclofenac)\n\u2013 Limit use to brief periods\n\t\n\u0089\nDiclofenac 1% gel if available\n\t\n\u0089\nIntra-articular steroids e.g. triamcinolone\n(specialist only), maximum 4 times/year\nHC2\nHC2\nHC4\nRR\nDifferential diagnosis\n \n~\nGout; gouty arthritis\n \n~\nRheumatoid arthri\nInvestigations\n \n\u0081\nNormal blood count and ESR\n \n\u0081\nX-ray: Of the joint(s)\nManagement\nGoals of treatment\n \n~\nPain relief\n \n~\nOptimisation of function\n \n~\nMinimise progression\n567\nUganda Clinical Guidelines 2023\nCHAPTER 10: Musculoskeletal andJoint Diseases",
        "formatted_content": "<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Weight reduction</p>\n<p>\u0089</p>\n<p>Encourage activity and regular  exercise</p>\n<p>\u0089</p>\n<p>Use of appropriate foot wear and walking aids</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>In acute exacerbation, or severe pain</p>\n<p>\u0089</p>\n<p>NSAID (ibuprofen, or diclofenac)</p>\n<p>\u2013 Limit use to brief periods</p>\n<p>\u0089</p>\n<p>Diclofenac 1% gel if available</p>\n<p>\u0089</p>\n<p>Intra-articular steroids e.g. triamcinolone</p>\n<p>(specialist only), maximum 4 times/year</p>\n<h3>HC2</h3>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>RR</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Gout; gouty arthritis</p>\n<p>~</p>\n<p>Rheumatoid arthri</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Normal blood count and ESR</p>\n<p>\u0081</p>\n<p>X-ray: Of the joint(s)</p>\n<p>Management</p>\n<p>Goals of treatment</p>\n<p>~</p>\n<p>Pain relief</p>\n<p>~</p>\n<p>Optimisation of function</p>\n<p>~</p>\n<p>Minimise progression</p>\n<p>567</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 10: Musculoskeletal andJoint Diseases</p>"
    },
    {
        "page_number": 634,
        "content": "568\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nBlood Diseases and Blood \nTransfusion Guidelines\n11\n11.1 BLOOD DISORDERS\n11.1.1  Anaemia                         ICD10 CODE: D50-D64\nConditions characterised by inadequate blood haemoglobin (Hb) levels. \nIt is quite common in tropical settings, and often caused by multiple \nfactors. Children and young women are particularly at risk.\nNormal haemoglobin levels by age\nCategory\nNormal \nValue\nMild Anaemia\nModerate \nAnaemia\nSevere \nAnaemia\nMen >15 years\n>13 g/dL\n11-12.9 g/dL\n8-10.9 g/dL\n<8 g/dL\nWomen\n>12 g/dL\n11-11.9 g/dL\n8-10.9 g/dL\n<8 g/dL\nPregnant women\n>11 g/dL\n10-10.9 g/dL\n7-9.9 g/dL\n<7 g/dL\nChild 12 - 14 years\n>12 g/dL\n11-11.9 g/dL\n8-10.9 g/dL\n< 8 g/dL\nChild 5 \u2013 11 years\n>11.5 g/dL\n11-11.5 g/dL\n8-10.9 g/dL\n<8 g/dL\nChild 6 months \u2013 5 \nyears\n>11 g/dL\n10-10.9 g/dL\n7-9.9 g/dL\n<7 g/dL\nFrom WHO/NMH/NHD/MNM/11.1\nReference range in newborns and infants\nAge\nNormal Range\nBirth\n>13.5 g/dL\n2 weeks\n>12.5 g/dL\n1-6 months\n> 9.5 g/dL\nAdapted from Medscape Sept 2016 \u201chaemoglobin concentration\u201d",
        "formatted_content": "<p>568</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Blood Diseases and Blood</p>\n<p>Transfusion Guidelines</p>\n<p>11</p>\n<h3>11.1 BLOOD DISORDERS</h3>\n<p>11.1.1  Anaemia                         ICD10 CODE: D50-D64</p>\n<p>Conditions characterised by inadequate blood haemoglobin (Hb) levels.</p>\n<p>It is quite common in tropical settings, and often caused by multiple</p>\n<p>factors. Children and young women are particularly at risk.</p>\n<p>Normal haemoglobin levels by age</p>\n<p>Category</p>\n<p>Normal</p>\n<p>Value</p>\n<p>Mild Anaemia</p>\n<p>Moderate</p>\n<p>Anaemia</p>\n<p>Severe</p>\n<p>Anaemia</p>\n<p>Men >15 years</p>\n<p>>13 g/dL</p>\n<p>11-12.9 g/dL</p>\n<p>8-10.9 g/dL</p>\n<p><8 g/dL</p>\n<p>Women</p>\n<p>>12 g/dL</p>\n<p>11-11.9 g/dL</p>\n<p>8-10.9 g/dL</p>\n<p><8 g/dL</p>\n<p>Pregnant women</p>\n<p>>11 g/dL</p>\n<p>10-10.9 g/dL</p>\n<p>7-9.9 g/dL</p>\n<p><7 g/dL</p>\n<p>Child 12 - 14 years</p>\n<p>>12 g/dL</p>\n<p>11-11.9 g/dL</p>\n<p>8-10.9 g/dL</p>\n<p>< 8 g/dL</p>\n<p>Child 5 \u2013 11 years</p>\n<p>>11.5 g/dL</p>\n<p>11-11.5 g/dL</p>\n<p>8-10.9 g/dL</p>\n<p><8 g/dL</p>\n<p>Child 6 months \u2013 5</p>\n<p>years</p>\n<p>>11 g/dL</p>\n<p>10-10.9 g/dL</p>\n<p>7-9.9 g/dL</p>\n<p><7 g/dL</p>\n<p>From WHO/NMH/NHD/MNM/11.1</p>\n<p>Reference range in newborns and infants</p>\n<p>Age</p>\n<p>Normal Range</p>\n<p>Birth</p>\n<p>>13.5 g/dL</p>\n<p>2 weeks</p>\n<p>>12.5 g/dL</p>\n<p>1-6 months</p>\n<p>> 9.5 g/dL</p>\n<p>Adapted from Medscape Sept 2016 \u201chaemoglobin concentration\u201d</p>"
    },
    {
        "page_number": 635,
        "content": "569\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nCauses\nDecreased production of red blood cells\n \n~\nNutritional iron, and/or folic acid/vitamin B12 deficiency\n \n~\nDepressed bone marrow function (leukaemia, aplasia)\n \n~\nInfections (HIV, TB, visceral leishmaniasis)\n \n~\nAplastic anaemia\nIncreased destruction of red blood cells (haemolysis)\n \n~\nMalaria\n \n~\nDrug side effects (dapsone, cotrimoxazole, AZT)\n \n~\nCongenital disorder, e.g. sickle cell anaemia, G6PD \n\ndeficiecy\nLoss of red blood cells\n \n~\nAcute and chronic blood loss (e.g. haemorrhage after trau\u00ad\nma, hookworm infestation, pregnancy, abortion, heavy \nmenstrual loss, schistosomiasis, massive or chronic GI \nbleeding)\nClinical features (Commonly)\n \n~\nPallor of conjuctivae, mucous membranes, palms, soles\n \n~\nFatigue, dizziness, palpitations, headache, anorexia, \nsometimes weight loss, low exercise tolerance\n \n~\nSigns of heart failure if severe: oedema in lower limbs, \ndyspnoea, tachycardia, heart murmurs\n \n~\nIf due to acute blood loss: postural hypotension, decreased \ncardiac out put, tachycardia, sweating, restlessness and \nthirst\n \n~\nLook for signs of specific pathology, e.g., splenomegaly, \nmalaria, nutrition deficiency, haemolysis jaundice, etc.",
        "formatted_content": "<p>569</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Causes</p>\n<p>Decreased production of red blood cells</p>\n<p>~</p>\n<p>Nutritional iron, and/or folic acid/vitamin B12 deficiency</p>\n<p>~</p>\n<p>Depressed bone marrow function (leukaemia, aplasia)</p>\n<p>~</p>\n<p>Infections (HIV, TB, visceral leishmaniasis)</p>\n<p>~</p>\n<p>Aplastic anaemia</p>\n<p>Increased destruction of red blood cells (haemolysis)</p>\n<p>~</p>\n<p>Malaria</p>\n<p>~</p>\n<p>Drug side effects (dapsone, cotrimoxazole, AZT)</p>\n<p>~</p>\n<p>Congenital disorder, e.g. sickle cell anaemia, G6PD</p>\n<p>deficiecy</p>\n<p>Loss of red blood cells</p>\n<p>~</p>\n<p>Acute and chronic blood loss (e.g. haemorrhage after trau\u00ad</p>\n<p>ma, hookworm infestation, pregnancy, abortion, heavy</p>\n<p>menstrual loss, schistosomiasis, massive or chronic GI</p>\n<p>bleeding)</p>\n<p>Clinical features (Commonly)</p>\n<p>~</p>\n<p>Pallor of conjuctivae, mucous membranes, palms, soles</p>\n<p>~</p>\n<p>Fatigue, dizziness, palpitations, headache, anorexia,</p>\n<p>sometimes weight loss, low exercise tolerance</p>\n<p>~</p>\n<p>Signs of heart failure if severe: oedema in lower limbs,</p>\n<p>dyspnoea, tachycardia, heart murmurs</p>\n<p>~</p>\n<p>If due to acute blood loss: postural hypotension, decreased</p>\n<p>cardiac out put, tachycardia, sweating, restlessness and</p>\n<p>thirst</p>\n<p>~</p>\n<p>Look for signs of specific pathology, e.g., splenomegaly,</p>\n<p>malaria, nutrition deficiency, haemolysis jaundice, etc.</p>"
    },
    {
        "page_number": 636,
        "content": "570\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nInvestigations\n \n~\nComplete blood count (CBC) with differentials, Mean   \nCorpuscular Volume (MCV), platelets, and a peripheral \nsmear, reticulocyte count\n \n~\nEvaluate Hb levels according to the patient\u2019s age\n \n~\nClassify anaemia according to MCV\n \n~\nMicrocytic (small RBCs): measure serum ferritin to \nevaluate for iron deficiency, HB electrophoresis for thalas\u00ad\nsemias, sideroblastic anaemia may be caused by drugs like \nisoniazid and chloramphenicol, evaluate for chronic blood \nloss especially gastrointestinal bleeding through stool anal\u00ad\nysis for parasites, and occult blood.\n \n~\nMacrocytic: Do vitamin B12 and fasting serum folate \nlevels to evaluate for vitamin B12 orfolate deficiency, do \nTSH to evaluate for thyroid disease, evaluate for chronic \nalcohol abuse and use of, drugs like zidovudine, metho\u00ad\ntrexate, hyroxyureaantifolate medications. \n \n~\nNormocytic: evaluate for acute blood loss loss, chronic \ndiseases, renal failure. , Investigate for the cause of hemo\u00ad\nlysis using peripheral film for schistocytes suggestive of \nmicroangiopathic hemolytic anaemia, HB.\n \n~\nDo bone marrow aspirate and biopsy if patient has bone \nmarrow failure for example aplastic anaemia or hemato\u00ad\nlogical malignancy for example leukemia, lymphomas and \nmyeloma is suspected.\nNote\n \n\u0083 Anaemia is not a final diagnosis: careful history, physical \nexamination and laboratory tests are essential to determine \nthe cause",
        "formatted_content": "<p>570</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Complete blood count (CBC) with differentials, Mean</p>\n<p>Corpuscular Volume (MCV), platelets, and a peripheral</p>\n<p>smear, reticulocyte count</p>\n<p>~</p>\n<p>Evaluate Hb levels according to the patient\u2019s age</p>\n<p>~</p>\n<p>Classify anaemia according to MCV</p>\n<p>~</p>\n<p>Microcytic (small RBCs): measure serum ferritin to</p>\n<p>evaluate for iron deficiency, HB electrophoresis for thalas\u00ad</p>\n<p>semias, sideroblastic anaemia may be caused by drugs like</p>\n<p>isoniazid and chloramphenicol, evaluate for chronic blood</p>\n<p>loss especially gastrointestinal bleeding through stool anal\u00ad</p>\n<p>ysis for parasites, and occult blood.</p>\n<p>~</p>\n<p>Macrocytic: Do vitamin B12 and fasting serum folate</p>\n<p>levels to evaluate for vitamin B12 orfolate deficiency, do</p>\n<p>TSH to evaluate for thyroid disease, evaluate for chronic</p>\n<p>alcohol abuse and use of, drugs like zidovudine, metho\u00ad</p>\n<p>trexate, hyroxyureaantifolate medications.</p>\n<p>~</p>\n<p>Normocytic: evaluate for acute blood loss loss, chronic</p>\n<p>diseases, renal failure. , Investigate for the cause of hemo\u00ad</p>\n<p>lysis using peripheral film for schistocytes suggestive of</p>\n<p>microangiopathic hemolytic anaemia, HB.</p>\n<p>~</p>\n<p>Do bone marrow aspirate and biopsy if patient has bone</p>\n<p>marrow failure for example aplastic anaemia or hemato\u00ad</p>\n<p>logical malignancy for example leukemia, lymphomas and</p>\n<p>myeloma is suspected.</p>\n<p>Note</p>\n<p>\u0083 Anaemia is not a final diagnosis: careful history, physical</p>\n<p>examination and laboratory tests are essential to determine</p>\n<p>the cause</p>"
    },
    {
        "page_number": 637,
        "content": "571\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nManagement\nGeneral principles\n\t\n\u0089\nDetermine and treat the cause for example Antithymocyte globulin \n(ATG) is used in aplastic anaemia and should be managed by a \nspecialist. \n\t\n\u0089\nConsider need for blood transfusion according to:\n \n\u0083 Level of haemoglobin\n \n\u0083 Clinical condition (haemodynamic status of patient, presence \nof heart failure, ongoing blood loss)\n11.1.1.1 Iron Deficiency Anaemia\t ICD10 CODE: D50\nAnaemia due to iron deficiency\nCause\n \n~\nPoor nutritional intake with iron-poor foods.\n \n~\nChronic blood loss, e.g., infestation with hook worms, \nprolonged/excessive menstrual bleeding, chronic gastroin\u00ad\ntestinal bleeding (e.g., chronic use of NSAIDS, large bowel \ntumors, esophageal varices)\nClinical features\n \n~\nIt usually develops slowly\n \n~\nAs per general anaemia symptoms plus:\n \n\u0083 Sore tongue, atrophy of lingual papillae\n \n\u0083 Erosions of the corners of the mouth\n \n\u0083 Brittle, fragile fingernails\nDifferential diagnosis\n \n~\nConditions that cause microcytic red cells\nInvestigations\n\t\n\u0089\nBlood: CBC, Hb, (haematocrit (Hct) rarely <28% unless iron de\u00ad\nficiency is present)",
        "formatted_content": "<p>571</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Management</p>\n<p>General principles</p>\n<p>\u0089</p>\n<p>Determine and treat the cause for example Antithymocyte globulin</p>\n<p>(ATG) is used in aplastic anaemia and should be managed by a</p>\n<p>specialist.</p>\n<p>\u0089</p>\n<p>Consider need for blood transfusion according to:</p>\n<p>\u0083 Level of haemoglobin</p>\n<p>\u0083 Clinical condition (haemodynamic status of patient, presence</p>\n<p>of heart failure, ongoing blood loss)</p>\n<p>11.1.1.1 Iron Deficiency Anaemia\t ICD10 CODE: D50</p>\n<p>Anaemia due to iron deficiency</p>\n<p>Cause</p>\n<p>~</p>\n<p>Poor nutritional intake with iron-poor foods.</p>\n<p>~</p>\n<p>Chronic blood loss, e.g., infestation with hook worms,</p>\n<p>prolonged/excessive menstrual bleeding, chronic gastroin\u00ad</p>\n<p>testinal bleeding (e.g., chronic use of NSAIDS, large bowel</p>\n<p>tumors, esophageal varices)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>It usually develops slowly</p>\n<p>~</p>\n<p>As per general anaemia symptoms plus:</p>\n<p>\u0083 Sore tongue, atrophy of lingual papillae</p>\n<p>\u0083 Erosions of the corners of the mouth</p>\n<p>\u0083 Brittle, fragile fingernails</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Conditions that cause microcytic red cells</p>\n<p>Investigations</p>\n<p>\u0089</p>\n<p>Blood: CBC, Hb, (haematocrit (Hct) rarely <28% unless iron de\u00ad</p>\n<p>ficiency is present)</p>"
    },
    {
        "page_number": 638,
        "content": "572\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n\t\n\u0089\nLow MCV and Mean Corpuscular Hb (MCH)- hypochromia.\n\nThis may not be obvious in patients who have already been transfused\n\t\n\u0089\nHypochromic microcytic (small size) red cells\n\t\n\u0089\nInvestigate the cause of iron deficiency\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIdentify, and treat cause of iron deficiency\n\t\n\u0089\nAdjust diet if poor diet is one of underlying causes \n\t\n\u0089\nAdult: Oral ferrous sulphate 200 mg (or ferrous\n\t\n\u0089\nsulphate/folic acid 200/0.4 mg) every 8 hours (equivalent \nto 180 mg elemental iron per day)\nHC2\nTREATMENT\nLOC\n\t\n\u0089\nChild: Oral ferrous sulphate 5 mg/kg (max 200 mg) \nevery 8 hours (equivalent to around 5 mg/kg elemental \niron per day)\n\u2022\t\nHb rises in 2-3 weeks and returns to normal after 2 months\n\u2022\t\nTreat for 6 months to 1 year to replenish stores\n\t\n\u0089\nGive an antihelminthic\n\u2022\t\nAlbendazole 400 mg single dose\nRefer to hospital in case of:\n\u2022\t\nSevere symptoms \u2013 for blood transfusion\n\u2022\t\nGastrointestinal bleeding\n\u2022\t\nMalabsorption\n\u2022\t\nIntolerance to oral therapy\n\u2022\t\nUnclear cause \u2013 not improving",
        "formatted_content": "<p>572</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0089</p>\n<p>Low MCV and Mean Corpuscular Hb (MCH)- hypochromia.</p>\n<p>This may not be obvious in patients who have already been transfused</p>\n<p>\u0089</p>\n<p>Hypochromic microcytic (small size) red cells</p>\n<p>\u0089</p>\n<p>Investigate the cause of iron deficiency</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Identify, and treat cause of iron deficiency</p>\n<p>\u0089</p>\n<p>Adjust diet if poor diet is one of underlying causes</p>\n<p>\u0089</p>\n<p>Adult: Oral ferrous sulphate 200 mg (or ferrous</p>\n<p>\u0089</p>\n<p>sulphate/folic acid 200/0.4 mg) every 8 hours (equivalent</p>\n<p>to 180 mg elemental iron per day)</p>\n<h3>HC2</h3>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Child: Oral ferrous sulphate 5 mg/kg (max 200 mg)</p>\n<p>every 8 hours (equivalent to around 5 mg/kg elemental</p>\n<p>iron per day)</p>\n<li></li>\n<p>Hb rises in 2-3 weeks and returns to normal after 2 months</p>\n<li></li>\n<p>Treat for 6 months to 1 year to replenish stores</p>\n<p>\u0089</p>\n<p>Give an antihelminthic</p>\n<li></li>\n<p>Albendazole 400 mg single dose</p>\n<p>Refer to hospital in case of:</p>\n<li></li>\n<p>Severe symptoms \u2013 for blood transfusion</p>\n<li></li>\n<p>Gastrointestinal bleeding</p>\n<li></li>\n<p>Malabsorption</p>\n<li></li>\n<p>Intolerance to oral therapy</p>\n<li></li>\n<p>Unclear cause \u2013 not improving</p>"
    },
    {
        "page_number": 639,
        "content": "573\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nNote\n \n\u0083 Side effects of oral iron: diarrhoea, abdominal discomfort, \nconstipation, black stools. Warn patient not to worry\n \n\u0083 Parenteral iron is rarely necessary, and can cause \nanaphylaxis.It should only be used by specialists\n11.1.1.2  Megaloblastic Anaemia    ICD10 CODE: D51-52\nAnaemia characterised  by large red blood cells.  Usually due to folate \nand/or vitamin B12 deficiency. Some medicines (hydroxyurea, zidovu\u00ad\ndine, stavudine can cause macrocytic anaemia without folate and/or \nvitamin B12 deficiency).\nCause\n \n~\nLow dietary intake of folate/increased need (e.g., children, \npregnancy)\n \n~\nLow dietary intake of vitamin B12 (in exclusively vegetari\u00ad\nan diets, without any animal proteins)\n \n~\nMalabsorption of folate and vitamin B12 (severe gastritis, \ngiardia infection, severe intestinal diseases)\n \n~\nMedicines e.g., metformin, zidovudine, hydroxyurea, \nstavudine, phenytoin\n \n~\nOther causes of macrocytosis: myelodysplasia, hypothy\u00ad\nroidism, chronic alcohol use, multiple myeloma\nClinical features\n \n~\nGeneral anaemia signs\n \n~\nVitamin B12 deficiency: neuropsychiatric abnormalities \ne.g.,  hyperpigmented palms and feet, smooth beefy \ntongue, peripheral neuropathy, impaired vibration and po\u00ad\nsition sense, abnormal gait, weakness, decreased muscle \nstrength, spastic motions, memory loss, disorientation, \ndepression, and acute confusional state",
        "formatted_content": "<p>573</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Note</p>\n<p>\u0083 Side effects of oral iron: diarrhoea, abdominal discomfort,</p>\n<p>constipation, black stools. Warn patient not to worry</p>\n<p>\u0083 Parenteral iron is rarely necessary, and can cause</p>\n<p>anaphylaxis.It should only be used by specialists</p>\n<p>11.1.1.2  Megaloblastic Anaemia    ICD10 CODE: D51-52</p>\n<p>Anaemia characterised  by large red blood cells.  Usually due to folate</p>\n<p>and/or vitamin B12 deficiency. Some medicines (hydroxyurea, zidovu\u00ad</p>\n<p>dine, stavudine can cause macrocytic anaemia without folate and/or</p>\n<p>vitamin B12 deficiency).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Low dietary intake of folate/increased need (e.g., children,</p>\n<p>pregnancy)</p>\n<p>~</p>\n<p>Low dietary intake of vitamin B12 (in exclusively vegetari\u00ad</p>\n<p>an diets, without any animal proteins)</p>\n<p>~</p>\n<p>Malabsorption of folate and vitamin B12 (severe gastritis,</p>\n<p>giardia infection, severe intestinal diseases)</p>\n<p>~</p>\n<p>Medicines e.g., metformin, zidovudine, hydroxyurea,</p>\n<p>stavudine, phenytoin</p>\n<p>~</p>\n<p>Other causes of macrocytosis: myelodysplasia, hypothy\u00ad</p>\n<p>roidism, chronic alcohol use, multiple myeloma</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>General anaemia signs</p>\n<p>~</p>\n<p>Vitamin B12 deficiency: neuropsychiatric abnormalities</p>\n<p>e.g.,  hyperpigmented palms and feet, smooth beefy</p>\n<p>tongue, peripheral neuropathy, impaired vibration and po\u00ad</p>\n<p>sition sense, abnormal gait, weakness, decreased muscle</p>\n<p>strength, spastic motions, memory loss, disorientation,</p>\n<p>depression, and acute confusional state</p>"
    },
    {
        "page_number": 640,
        "content": "574\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nInvestigations\n \n~\nBlood smear: macrocytosis\n \n~\nElevated MCH/MCV\n \n~\nPancytopenia in severe cases\n \n~\nFull blood count: oval macrocytes, hypersegmentation of \nneutrophils, thrombocytopenia\n \n~\nDecreased serum Vitamin B12 or fasting red cell folate\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nIdentify and treat underlying cause of anaemia\n\u2022\t\nOral B12 may be given at a dose of 1mg (1000\u00b5g) daily in \npatients who cannot tolerate parenteral therapy.\nHC2\nRR\n\u2022\t\nThere is also a Nasal formulation of vitamin B12 that can be \ngiven on alternate days.\n\t\n\u0089\nDietary modifications to ensure adequate intake of \nfolate and vitamin B12, e.g., eat plenty of green leafy \nvegetables, and/or food of animal origin\nFolic acid and vitamin B12 supplementation\n\t\n\u0089\nFolic acid: 5 mg daily until haemoglobin levels\nreturn to normal\n\t\n\u0089\nVitamin B12: 1 mg IM daily for 5 days; then weekly for \na further 3 doses\n\u2022\t\nFollow with 1 mg every second month for life in patients with \npernicious anaemia\nHC2\nRR",
        "formatted_content": "<p>574</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Blood smear: macrocytosis</p>\n<p>~</p>\n<p>Elevated MCH/MCV</p>\n<p>~</p>\n<p>Pancytopenia in severe cases</p>\n<p>~</p>\n<p>Full blood count: oval macrocytes, hypersegmentation of</p>\n<p>neutrophils, thrombocytopenia</p>\n<p>~</p>\n<p>Decreased serum Vitamin B12 or fasting red cell folate</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Identify and treat underlying cause of anaemia</p>\n<li></li>\n<p>Oral B12 may be given at a dose of 1mg (1000\u00b5g) daily in</p>\n<p>patients who cannot tolerate parenteral therapy.</p>\n<h3>HC2</h3>\n<p>RR</p>\n<li></li>\n<p>There is also a Nasal formulation of vitamin B12 that can be</p>\n<p>given on alternate days.</p>\n<p>\u0089</p>\n<p>Dietary modifications to ensure adequate intake of</p>\n<p>folate and vitamin B12, e.g., eat plenty of green leafy</p>\n<p>vegetables, and/or food of animal origin</p>\n<p>Folic acid and vitamin B12 supplementation</p>\n<p>\u0089</p>\n<p>Folic acid: 5 mg daily until haemoglobin levels</p>\n<p>return to normal</p>\n<p>\u0089</p>\n<p>Vitamin B12: 1 mg IM daily for 5 days; then weekly for</p>\n<p>a further 3 doses</p>\n<li></li>\n<p>Follow with 1 mg every second month for life in patients with</p>\n<p>pernicious anaemia</p>\n<h3>HC2</h3>\n<p>RR</p>"
    },
    {
        "page_number": 641,
        "content": "575\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nNote\n \n\u0083 If vitamin B12 deficiency is suspected: (low leucocytes \nand platelets, neuropsychiatric symptoms, vegan diet) DO \nNOT GIVE folic acid alone but refer for further testing and \ntreatment. Giving folic acid alone in\n \n\u0083 patients with B12 deficiency may precipitate permanent \nneurological deficit.\n \n\u0083 Anaemia normally corrects within 1-2 months. White cell \ncount and thrombocytopenia normalise within 7-10 days\n \n\u0083 DO NOT use ferrous-folate combination tablets to treat folic \ndeficiency because the quantity of folic acid is too low\n11.1.1.3  Normocytic Anaemia\nAnaemia characterised by normal-sized red blood cells\nCause\n \n~\nAcute blood loss\n \n~\nHaemolysis (destruction of red cells), e.g., auto-immune \ndisorder, hypersplenism, haemoglobin abnormalities (sick\u00ad\nle cell disease, thalassemia), drugs (sulphonamides, dap\u00ad\nsone, primaquine)\n \n~\nDecreased reticulocytosis (formation of new blood cells),\n \n~\ne.g. chronic kidney disease and chronic diseases ..\nClinical features\n \n~\nGeneral features of anaemia\nInvestigations\n \n\u0081\nEvidence of haemolysis\n \n\u0081\nFull blood count smear: spherocytes\n \n\u0081\nHIV serology",
        "formatted_content": "<p>575</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Note</p>\n<p>\u0083 If vitamin B12 deficiency is suspected: (low leucocytes</p>\n<p>and platelets, neuropsychiatric symptoms, vegan diet) DO</p>\n<p>NOT GIVE folic acid alone but refer for further testing and</p>\n<p>treatment. Giving folic acid alone in</p>\n<p>\u0083 patients with B12 deficiency may precipitate permanent</p>\n<p>neurological deficit.</p>\n<p>\u0083 Anaemia normally corrects within 1-2 months. White cell</p>\n<p>count and thrombocytopenia normalise within 7-10 days</p>\n<p>\u0083 DO NOT use ferrous-folate combination tablets to treat folic</p>\n<p>deficiency because the quantity of folic acid is too low</p>\n<p>11.1.1.3  Normocytic Anaemia</p>\n<p>Anaemia characterised by normal-sized red blood cells</p>\n<p>Cause</p>\n<p>~</p>\n<p>Acute blood loss</p>\n<p>~</p>\n<p>Haemolysis (destruction of red cells), e.g., auto-immune</p>\n<p>disorder, hypersplenism, haemoglobin abnormalities (sick\u00ad</p>\n<p>le cell disease, thalassemia), drugs (sulphonamides, dap\u00ad</p>\n<p>sone, primaquine)</p>\n<p>~</p>\n<p>Decreased reticulocytosis (formation of new blood cells),</p>\n<p>~</p>\n<p>e.g. chronic kidney disease and chronic diseases ..</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>General features of anaemia</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Evidence of haemolysis</p>\n<p>\u0081</p>\n<p>Full blood count smear: spherocytes</p>\n<p>\u0081</p>\n<p>HIV serology</p>"
    },
    {
        "page_number": 642,
        "content": "576\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nManagement\nTREATMENT\nLOC\nGenerally\n\t\n\u0089\nIdentify and treat cause of anaemia\nMedicine treatment\n\t\n\u0089\nDO NOT treat with iron, folic acid or vitamin B12 unless \nthere is clear documented deficiency\n\t\n\u0089\nTreat all patients with folic acid 5 mg daily in haemolytic \nanaemia\n\t\n\u0089\nRefer to hospital for further management\nHC4\nPrevention/Health Education for Anaemia\nEducate the public about:\n \n~\nThe life long effects of anaemia on health, and cognitive \ndevelopment\n \n~\nDietary measures: encourage exclusive breastfeeding for \nthe first 6 months. Encourage the use of iron-containing \nweaning locally available foods (red meat, beans, peas, \ndark leafy vegetables)\n \n~\nHygiene: avoid walking barefeet to avoid hook worm infes\u00ad\ntation, use of pit latrines for faecal disposal, and practice \ngood hand washing habits\n \n~\nMedical: encourage periodic screening for children and \npregnant mothers, and presumptive iron therapy for ei\u00ad\nther groups in cases of anaemia (see IMCI and pregnancy \nguidelines, chapters 16 and 17)\n \n~\nRoutine iron supplementation for all pregnant mothers\n \n~\nEarly treatment of malaria, helminthic infections, etc.",
        "formatted_content": "<p>576</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Generally</p>\n<p>\u0089</p>\n<p>Identify and treat cause of anaemia</p>\n<p>Medicine treatment</p>\n<p>\u0089</p>\n<p>DO NOT treat with iron, folic acid or vitamin B12 unless</p>\n<p>there is clear documented deficiency</p>\n<p>\u0089</p>\n<p>Treat all patients with folic acid 5 mg daily in haemolytic</p>\n<p>anaemia</p>\n<p>\u0089</p>\n<p>Refer to hospital for further management</p>\n<h3>HC4</h3>\n<p>Prevention/Health Education for Anaemia</p>\n<p>Educate the public about:</p>\n<p>~</p>\n<p>The life long effects of anaemia on health, and cognitive</p>\n<p>development</p>\n<p>~</p>\n<p>Dietary measures: encourage exclusive breastfeeding for</p>\n<p>the first 6 months. Encourage the use of iron-containing</p>\n<p>weaning locally available foods (red meat, beans, peas,</p>\n<p>dark leafy vegetables)</p>\n<p>~</p>\n<p>Hygiene: avoid walking barefeet to avoid hook worm infes\u00ad</p>\n<p>tation, use of pit latrines for faecal disposal, and practice</p>\n<p>good hand washing habits</p>\n<p>~</p>\n<p>Medical: encourage periodic screening for children and</p>\n<p>pregnant mothers, and presumptive iron therapy for ei\u00ad</p>\n<p>ther groups in cases of anaemia (see IMCI and pregnancy</p>\n<p>guidelines, chapters 16 and 17)</p>\n<p>~</p>\n<p>Routine iron supplementation for all pregnant mothers</p>\n<p>~</p>\n<p>Early treatment of malaria, helminthic infections, etc.</p>"
    },
    {
        "page_number": 643,
        "content": "577\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n11.1.2  Bleeding Disorders            ICD10 CODE: D65-D69\nA bleeding disorder is suspected if a patient has unexplained bruising \nand bleeding (i.e. no history of trauma). Prolonged bleeding or oozing \ncan also occur after injury or surgery (e.g., tooth extraction, small cut).\nCauses\n \n~\nBlood vessel defect\n\t\n\u0089\nAcquired: age, side effects of steroids, NSAIDS (e.g. easy bruising)\n\t\n\u0089\nGenetic e.g. hereditary telangiectasia\n \n~\nPlatelet defect\n\t\n\u0089\nDecreased platelet number/function e.g., blood cancer, viruses, \naplastic anaemia\n\t\n\u0089\nIncreased destruction e.g., in hypersplenism, autoimmune disease, \nimmune thrombocytopenic purpura (ITP) massive blood transfusion\n \n~\nCoagulation defect\n\t\n\u0089\nHereditary e.g., haemophilia A or B, von Willebrand disease\n\t\n\u0089\nAcquired e.g., warfarin or heparin, liver disease, alcoholism, ac\u00ad\nquired factor inhibitors for example in malignancies, autoimmune \ndiseases and pregnancy.  \n\t\n\u0089\nInfections: meningococcal sepsis, haemorrhagic fevers (causing \nwidespread endothelial damage and disseminated intravascular \ncoagulation)\nClinical features\n \n~\nPlatelet disorder: mucosal bleeding (gingivitis, nose bleeds), \nsuperficial ecchymoses, excessive bleeding after minor in\u00ad\njury, petechiae, heavy menstrual bleeding\n \n~\nCoagulation disorder: large, deep haematomas or hae\u00ad\nmathrosis",
        "formatted_content": "<p>577</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>11.1.2  Bleeding Disorders            ICD10 CODE: D65-D69</p>\n<p>A bleeding disorder is suspected if a patient has unexplained bruising</p>\n<p>and bleeding (i.e. no history of trauma). Prolonged bleeding or oozing</p>\n<p>can also occur after injury or surgery (e.g., tooth extraction, small cut).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Blood vessel defect</p>\n<p>\u0089</p>\n<p>Acquired: age, side effects of steroids, NSAIDS (e.g. easy bruising)</p>\n<p>\u0089</p>\n<p>Genetic e.g. hereditary telangiectasia</p>\n<p>~</p>\n<p>Platelet defect</p>\n<p>\u0089</p>\n<p>Decreased platelet number/function e.g., blood cancer, viruses,</p>\n<p>aplastic anaemia</p>\n<p>\u0089</p>\n<p>Increased destruction e.g., in hypersplenism, autoimmune disease,</p>\n<p>immune thrombocytopenic purpura (ITP) massive blood transfusion</p>\n<p>~</p>\n<p>Coagulation defect</p>\n<p>\u0089</p>\n<p>Hereditary e.g., haemophilia A or B, von Willebrand disease</p>\n<p>\u0089</p>\n<p>Acquired e.g., warfarin or heparin, liver disease, alcoholism, ac\u00ad</p>\n<p>quired factor inhibitors for example in malignancies, autoimmune</p>\n<p>diseases and pregnancy.</p>\n<p>\u0089</p>\n<p>Infections: meningococcal sepsis, haemorrhagic fevers (causing</p>\n<p>widespread endothelial damage and disseminated intravascular</p>\n<p>coagulation)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Platelet disorder: mucosal bleeding (gingivitis, nose bleeds),</p>\n<p>superficial ecchymoses, excessive bleeding after minor in\u00ad</p>\n<p>jury, petechiae, heavy menstrual bleeding</p>\n<p>~</p>\n<p>Coagulation disorder: large, deep haematomas or hae\u00ad</p>\n<p>mathrosis</p>"
    },
    {
        "page_number": 644,
        "content": "578\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nInvestigations\n\t\n\u0089\nComplete blood count, and platelet count (can be estimated using a \nperipheral smear if an auto-analyser is not available)\n\t\n\u0089\nA bone marrow aspirate and biopsy is indicated if a haematological \nmalignancy is suspected to be the cause of the bleeding\n \n\u0081\nBleeding time (time required for bleeding to stop). It is normal with \ncoagulation factor deficiencies (except Von Willebrand disease), and \nabnormal in thrombocytopenia and qualitative platelet defects\n \n\u0081\nCoagulation tests\n \n\u0083 Prothrombin time (PT): prolonged in factor VII, X, V, II \ndeficiencies, liver disease, warfarin treatment\n \n\u0083 International normalised ratio (INR) to monitor anticoagulation  \nwith warfarin (not useful for heparin and direct acting \nanticoagulants like rivaroxaban)\n \n\u0083 Partial thromboplastin time (aPTT): prolonged in factor VIII,  \n(hemophilia A) XII, XI, IX, (hemophilia B) X, V and I deficiencies\n \n\u0081\nIf acute, consider if haemorrhagic fevers are the cause\nManagement\nPatients with acute bleeding disorders should be referred to hospital for ap\u00ad\npropriate investigations and treatment.\nPatients with chronic bleeding disorders should be referred to a specialist.\nTREATMENT\nLOC\n\t\n\u0089\nIdentify and treat root cause of bleeding disorder\n\t\n\u0089\nGive phytomenadione (vitamin K) injection to: Newborn: 1 \nmg for full-term baby; 500 mcg for a pre-term baby IM or \nIV. Repeat every 8 hours if necessary\n\t\n\u0089\nIn patients on warfarin with acute bleeding, give vitamin K \n5 mg slow IV to reverse warfarin effect. If patient has severe \nor active bleeding, give fresh frozen plasma\n\t\n\u0089\nDiscontinue any medications that will interfere with coagu\u00ad\nlation or platelet function, e.g., cephalosporins, dipyridazole, \nthiazide, alcohol, chloropromazine, sulfonamides, rifampicin, \nmethyldopa, phenytoin, barbiturates, quinidine, isoniazid.\nHC2\nHC4",
        "formatted_content": "<p>578</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Investigations</p>\n<p>\u0089</p>\n<p>Complete blood count, and platelet count (can be estimated using a</p>\n<p>peripheral smear if an auto-analyser is not available)</p>\n<p>\u0089</p>\n<p>A bone marrow aspirate and biopsy is indicated if a haematological</p>\n<p>malignancy is suspected to be the cause of the bleeding</p>\n<p>\u0081</p>\n<p>Bleeding time (time required for bleeding to stop). It is normal with</p>\n<p>coagulation factor deficiencies (except Von Willebrand disease), and</p>\n<p>abnormal in thrombocytopenia and qualitative platelet defects</p>\n<p>\u0081</p>\n<p>Coagulation tests</p>\n<p>\u0083 Prothrombin time (PT): prolonged in factor VII, X, V, II</p>\n<p>deficiencies, liver disease, warfarin treatment</p>\n<p>\u0083 International normalised ratio (INR) to monitor anticoagulation</p>\n<p>with warfarin (not useful for heparin and direct acting</p>\n<p>anticoagulants like rivaroxaban)</p>\n<p>\u0083 Partial thromboplastin time (aPTT): prolonged in factor VIII,</p>\n<p>(hemophilia A) XII, XI, IX, (hemophilia B) X, V and I deficiencies</p>\n<p>\u0081</p>\n<p>If acute, consider if haemorrhagic fevers are the cause</p>\n<p>Management</p>\n<p>Patients with acute bleeding disorders should be referred to hospital for ap\u00ad</p>\n<p>propriate investigations and treatment.</p>\n<p>Patients with chronic bleeding disorders should be referred to a specialist.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Identify and treat root cause of bleeding disorder</p>\n<p>\u0089</p>\n<p>Give phytomenadione (vitamin K) injection to: Newborn: 1</p>\n<p>mg for full-term baby; 500 mcg for a pre-term baby IM or</p>\n<p>IV. Repeat every 8 hours if necessary</p>\n<p>\u0089</p>\n<p>In patients on warfarin with acute bleeding, give vitamin K</p>\n<p>5 mg slow IV to reverse warfarin effect. If patient has severe</p>\n<p>or active bleeding, give fresh frozen plasma</p>\n<p>\u0089</p>\n<p>Discontinue any medications that will interfere with coagu\u00ad</p>\n<p>lation or platelet function, e.g., cephalosporins, dipyridazole,</p>\n<p>thiazide, alcohol, chloropromazine, sulfonamides, rifampicin,</p>\n<p>methyldopa, phenytoin, barbiturates, quinidine, isoniazid.</p>\n<h3>HC2</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 645,
        "content": "579\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n\t\n\u0089\nIn patients with ITP, first line treatment is oral prednisolone \n(0.5-2mg/kg/day). Rituximab and Intravenous Immunoglob\u00ad\nulin (IVIG) are second line treatments for ITP, however these \nshould be given by a specialist. \n\t\n\u0089\nTransfuse with platelets if Patient is bleeding (therapeutic \ntransfusion) or prophylactically when platelet count is less \nthan 10,000/\u00b5L in patients at high risk of bleeding \u2013 e.g., \ncancer patients. \n\t\n\u0089\nTransfuse with fresh fozenfrozen plasma if bleeding is thought \nto be due to disorders related to clotting factors\nRefer to a higher level of care if the above options are not viable.\nH\nReferral criteria\n\t\n\u0089\nRefer patient to hospital if any of the following signs \nare present\n \n\u0083 If cause cannot be determined locally\n \n\u0083 Spontaneous bleeding\n \n\u0083 Bleeding into muscles or joints, GIT, or CNS\n \n\u0083 Bleeding patients who are on warafrin\n \n\u0083 Postpartum bleeding\n \n\u0083 Family history of bleeding\nRR\nHealth education\n \n~\nAdvise the patient with chronic bleeding disorder to:\n\t\n\u0089\nPrevent injury\n\t\n\u0089\nAvoid injections and unnecessary surgery\n\t\n\u0089\nVisit the clinic immediately if symptoms occur\n\t\n\u0089\nContinue all medication as prescribed\n \n~\nAll haemophiliacs should have prophylactic treatment be\u00ad\nfore traumatic procedures, e.g., tooth extractions, or sur\u00ad\ngery\n11.1.3 Sickle Cell Disease\t              ICD10: D57\nSickle cell disease (SCD) is a genetic haemoglobin disorder in which",
        "formatted_content": "<p>579</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0089</p>\n<p>In patients with ITP, first line treatment is oral prednisolone</p>\n<p>(0.5-2mg/kg/day). Rituximab and Intravenous Immunoglob\u00ad</p>\n<p>ulin (IVIG) are second line treatments for ITP, however these</p>\n<p>should be given by a specialist.</p>\n<p>\u0089</p>\n<p>Transfuse with platelets if Patient is bleeding (therapeutic</p>\n<p>transfusion) or prophylactically when platelet count is less</p>\n<p>than 10,000/\u00b5L in patients at high risk of bleeding \u2013 e.g.,</p>\n<p>cancer patients.</p>\n<p>\u0089</p>\n<p>Transfuse with fresh fozenfrozen plasma if bleeding is thought</p>\n<p>to be due to disorders related to clotting factors</p>\n<p>Refer to a higher level of care if the above options are not viable.</p>\n<p>H</p>\n<p>Referral criteria</p>\n<p>\u0089</p>\n<p>Refer patient to hospital if any of the following signs</p>\n<p>are present</p>\n<p>\u0083 If cause cannot be determined locally</p>\n<p>\u0083 Spontaneous bleeding</p>\n<p>\u0083 Bleeding into muscles or joints, GIT, or CNS</p>\n<p>\u0083 Bleeding patients who are on warafrin</p>\n<p>\u0083 Postpartum bleeding</p>\n<p>\u0083 Family history of bleeding</p>\n<p>RR</p>\n<p>Health education</p>\n<p>~</p>\n<p>Advise the patient with chronic bleeding disorder to:</p>\n<p>\u0089</p>\n<p>Prevent injury</p>\n<p>\u0089</p>\n<p>Avoid injections and unnecessary surgery</p>\n<p>\u0089</p>\n<p>Visit the clinic immediately if symptoms occur</p>\n<p>\u0089</p>\n<p>Continue all medication as prescribed</p>\n<p>~</p>\n<p>All haemophiliacs should have prophylactic treatment be\u00ad</p>\n<p>fore traumatic procedures, e.g., tooth extractions, or sur\u00ad</p>\n<p>gery</p>\n<p>11.1.3 Sickle Cell Disease\t              ICD10: D57</p>\n<p>Sickle cell disease (SCD) is a genetic haemoglobin disorder in which</p>"
    },
    {
        "page_number": 646,
        "content": "580\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nred blood cells which carry oxygen around the body change shape \nfrom a smooth doughnut shape into a crescent or half-moon shape. It \nis sometimes called Sickle Cell Anaemia (SCA).\nCause\n \n~\nIt is caused by a defect in beta chains where a given amino \nacid is replaced by another (Substitution of valine for glu\u00ad\ntamic acid) at position 6 of the chain. This change creates \nabnormal haemoglobin called HbS.\nClinical features\n \n~\nSymptoms usually appear from age of 3 to 6 months: \nanaemia, dactylitis (swelling of fingers), lobar pneumonia, \nrecurrent severe bacterial infections. This results from the \nreduction of the foetal haemoglobin F (HbF), and increase \nin HbS in the blood\n \n~\nChronic anaemia: Hb 6\u20139 g/dl with episodes of acute \nworsening, which can be due to\n \n\u0083 Aplastic crisis: sudden transient arrest of blood cells production \nin the bone marrow (low Hb and low reticulocyes), often due to \nParvoB19 virus infection)\n \n\u0083 Splenic sequestration: pooling of large amounts of red blood \ncells in the spleen with painful and rapidly enlarging spleen, \ndecreasing haemoglobin with high reticulocyte count\n \n~\nAcute vaso-occlusive phenomenon (occlusion of blood \nvessels) causing:\n \n\u0083 Painful crisis (acute, intense) at the back, chest, limbs, abdomen. \nIn children <2 years, pain and swelling of hands and feet.\n \n\u0083 Stroke: hemiplegia, altered consciousness, seizures.\n \n\u0083 Acute chest syndrome: fever, chest pain, difficulty in breathing, \nlow oxygen level, cough, wheezing\n \n\u0083 Acute abdomen or mesenteric crisis (\u201cintestinal crisis\u201d): \nabdominal pain and distension, reduced or absent bowel \nsounds, pallor, fever, Abdominal X-ray may show dilated bowel \nloops. Anaemia, high reticulocyte count, high CRP will be \npresent.\n \n\u0083 Renal infarction, bone infarction and necrosis, especially at the \nhead of femur, priapism",
        "formatted_content": "<p>580</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>red blood cells which carry oxygen around the body change shape</p>\n<p>from a smooth doughnut shape into a crescent or half-moon shape. It</p>\n<p>is sometimes called Sickle Cell Anaemia (SCA).</p>\n<p>Cause</p>\n<p>~</p>\n<p>It is caused by a defect in beta chains where a given amino</p>\n<p>acid is replaced by another (Substitution of valine for glu\u00ad</p>\n<p>tamic acid) at position 6 of the chain. This change creates</p>\n<p>abnormal haemoglobin called HbS.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Symptoms usually appear from age of 3 to 6 months:</p>\n<p>anaemia, dactylitis (swelling of fingers), lobar pneumonia,</p>\n<p>recurrent severe bacterial infections. This results from the</p>\n<p>reduction of the foetal haemoglobin F (HbF), and increase</p>\n<p>in HbS in the blood</p>\n<p>~</p>\n<p>Chronic anaemia: Hb 6\u20139 g/dl with episodes of acute</p>\n<p>worsening, which can be due to</p>\n<p>\u0083 Aplastic crisis: sudden transient arrest of blood cells production</p>\n<p>in the bone marrow (low Hb and low reticulocyes), often due to</p>\n<p>ParvoB19 virus infection)</p>\n<p>\u0083 Splenic sequestration: pooling of large amounts of red blood</p>\n<p>cells in the spleen with painful and rapidly enlarging spleen,</p>\n<p>decreasing haemoglobin with high reticulocyte count</p>\n<p>~</p>\n<p>Acute vaso-occlusive phenomenon (occlusion of blood</p>\n<p>vessels) causing:</p>\n<p>\u0083 Painful crisis (acute, intense) at the back, chest, limbs, abdomen.</p>\n<p>In children <2 years, pain and swelling of hands and feet.</p>\n<p>\u0083 Stroke: hemiplegia, altered consciousness, seizures.</p>\n<p>\u0083 Acute chest syndrome: fever, chest pain, difficulty in breathing,</p>\n<p>low oxygen level, cough, wheezing</p>\n<p>\u0083 Acute abdomen or mesenteric crisis (\u201cintestinal crisis\u201d):</p>\n<p>abdominal pain and distension, reduced or absent bowel</p>\n<p>sounds, pallor, fever, Abdominal X-ray may show dilated bowel</p>\n<p>loops. Anaemia, high reticulocyte count, high CRP will be</p>\n<p>present.</p>\n<p>\u0083 Renal infarction, bone infarction and necrosis, especially at the</p>\n<p>head of femur, priapism</p>"
    },
    {
        "page_number": 647,
        "content": "581\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n \n~\nChronic organ damage due to anaemia and vasocclusive \nphenomenon:\n \n\u0083 Hyposplenia (spleen undergoes autosplenectomy due to \nmultiple infarcts and is not functional anymore or has to be \nremoved because of splenic sequestration)\n \n\u0083 Pulmonary hypertension, asthma\n \n\u0083 Chronic renal and hepatic disease, gallbladder stones\n \n\u0083 Nephropathy and acute kidney injury due to hypovolemia and \nhypoperfuson\n \n\u0083 Trans-cranial doppler velocity of >200cm/sec predicts high risk \nof having a stroke. This is less predictive in adults\n \n\u0083 Osteoporosis, retinopathy\n \n\u0083 Chronic leg ulcers\n \n~\nInfections associated with asplenia and hyposplenism like \npneumococcal infections \n \n\u0083 Osteomyelitis, pneumonia, septicaemia\nInvestigations\n \n~\nFamily history of sickle cell disease\n \n~\nFull blood count & peripeharl film comment\n \n~\nScreening tests for sickling (not fully reliable)\n \n~\nHaemoglobin electrophoresis (confirms diagnosis)\n \n~\nChest radiography (for Acute Chest Syndrome)\n \n~\nAbdominal ultrasound\n \n~\nUrinalysis\n \n~\nLiver and renal function tests",
        "formatted_content": "<p>581</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>~</p>\n<p>Chronic organ damage due to anaemia and vasocclusive</p>\n<p>phenomenon:</p>\n<p>\u0083 Hyposplenia (spleen undergoes autosplenectomy due to</p>\n<p>multiple infarcts and is not functional anymore or has to be</p>\n<p>removed because of splenic sequestration)</p>\n<p>\u0083 Pulmonary hypertension, asthma</p>\n<p>\u0083 Chronic renal and hepatic disease, gallbladder stones</p>\n<p>\u0083 Nephropathy and acute kidney injury due to hypovolemia and</p>\n<p>hypoperfuson</p>\n<p>\u0083 Trans-cranial doppler velocity of >200cm/sec predicts high risk</p>\n<p>of having a stroke. This is less predictive in adults</p>\n<p>\u0083 Osteoporosis, retinopathy</p>\n<p>\u0083 Chronic leg ulcers</p>\n<p>~</p>\n<p>Infections associated with asplenia and hyposplenism like</p>\n<p>pneumococcal infections</p>\n<p>\u0083 Osteomyelitis, pneumonia, septicaemia</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Family history of sickle cell disease</p>\n<p>~</p>\n<p>Full blood count & peripeharl film comment</p>\n<p>~</p>\n<p>Screening tests for sickling (not fully reliable)</p>\n<p>~</p>\n<p>Haemoglobin electrophoresis (confirms diagnosis)</p>\n<p>~</p>\n<p>Chest radiography (for Acute Chest Syndrome)</p>\n<p>~</p>\n<p>Abdominal ultrasound</p>\n<p>~</p>\n<p>Urinalysis</p>\n<p>~</p>\n<p>Liver and renal function tests</p>"
    },
    {
        "page_number": 648,
        "content": "582\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nManagement\nChronic Management\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nRegular follow up and education of patients and families. \nFamily support\n\t\n\u0089\nAlways keep well-hydrated\n\t\n\u0089\nGive folic acid 5 mg daily for life\n\t\n\u0089\nPromptly assess, and treat any fever with antibiotics \nuntil source of fever is identified\n\t\n\u0089\nEnsure complete immunisation using the UNEPI pro\u00ad\ngramme, which includes the pneumococcal vaccine \nfor all infants\n \n\u0083 Plus, if available, immunisation against \nmeningococcus (to be given in regions within the \nmeningococal belt) and influenza\nHC2\n\t\n\u0089\nProphylactic penicillin V (up to 5 years of age) \n \n\u0083 Child 3 months-3 years: penicillin V 125 mg every \n12 hours\n \n\u0083 Child 3-5 years: penicillin V 250 mg every 12 hours\n\t\n\u0089\nMalaria prophylaxis with monthly sulphadoxine- pirimet\u00ad\namine (SP)\n \n\u0083 Child 2-5 years: \u00bd tab monthly\n \n\u0083 Child 5-10 years: 1 tab monthly\n \n\u0083 Child 10-15 years: 2 tabs monthly\n \n\u0083 Child >15 years: 3 tablets monthly\nFor those with sulphur allergy consider use of erythromycin \n250 mg every 12 hours\nHC2\nHC2",
        "formatted_content": "<p>582</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Management</p>\n<p>Chronic Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Regular follow up and education of patients and families.</p>\n<p>Family support</p>\n<p>\u0089</p>\n<p>Always keep well-hydrated</p>\n<p>\u0089</p>\n<p>Give folic acid 5 mg daily for life</p>\n<p>\u0089</p>\n<p>Promptly assess, and treat any fever with antibiotics</p>\n<p>until source of fever is identified</p>\n<p>\u0089</p>\n<p>Ensure complete immunisation using the UNEPI pro\u00ad</p>\n<p>gramme, which includes the pneumococcal vaccine</p>\n<p>for all infants</p>\n<p>\u0083 Plus, if available, immunisation against</p>\n<p>meningococcus (to be given in regions within the</p>\n<p>meningococal belt) and influenza</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Prophylactic penicillin V (up to 5 years of age)</p>\n<p>\u0083 Child 3 months-3 years: penicillin V 125 mg every</p>\n<p>12 hours</p>\n<p>\u0083 Child 3-5 years: penicillin V 250 mg every 12 hours</p>\n<p>\u0089</p>\n<p>Malaria prophylaxis with monthly sulphadoxine- pirimet\u00ad</p>\n<p>amine (SP)</p>\n<p>\u0083 Child 2-5 years: \u00bd tab monthly</p>\n<p>\u0083 Child 5-10 years: 1 tab monthly</p>\n<p>\u0083 Child 10-15 years: 2 tabs monthly</p>\n<p>\u0083 Child >15 years: 3 tablets monthly</p>\n<p>For those with sulphur allergy consider use of erythromycin</p>\n<p>250 mg every 12 hours</p>\n<h3>HC2</h3>\n<h3>HC2</h3>"
    },
    {
        "page_number": 649,
        "content": "583\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nRefer to a specialised treatment centre for specialised \nmanagement, especially if uncontrolled symptoms\n\t\n\u0089\nHydroxyurea starting dose 20 mg/kg\nIndications for hydroxyurea\nChildren of 9 months and above should be initiated on \nhydroxyurea\n \n~\nFrequent crises: >3 crises in a year\n \n~\nPain interfering with activities of daily living\n \n~\nPatients with abnormal Transcranial Doppler \n(TCD) Ultrasonography velocity >200 cm/s\n \n~\nRecurrent or severe acute Chest Syndrome\n \n~\nStroke\nRR\nNote: However, the decision to give a patient hydroxyurea should \nbe done by a senior health worker after full laboratory investigation \nof the patient including:\n\t\n\u0089\nComplete blood count\n\t\n\u0089\nRenal function tests\n\t\n\u0089\nLiver function tests\nManagement of acute complications\nTREATMENT\nLOC\nPainful crisis \u2013 home management (mild to moderate pain)\n\t\n\u0089\nOral hydration\n\t\n\u0089\nWarm compresses (not cold)\n\t\n\u0089\nParacetamol 1 g every 8 hours \n \n\u0083 Child: 10-15 mg/kg 6-8 hourly\nHC2",
        "formatted_content": "<p>583</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Refer to a specialised treatment centre for specialised</p>\n<p>management, especially if uncontrolled symptoms</p>\n<p>\u0089</p>\n<p>Hydroxyurea starting dose 20 mg/kg</p>\n<p>Indications for hydroxyurea</p>\n<p>Children of 9 months and above should be initiated on</p>\n<p>hydroxyurea</p>\n<p>~</p>\n<p>Frequent crises: >3 crises in a year</p>\n<p>~</p>\n<p>Pain interfering with activities of daily living</p>\n<p>~</p>\n<p>Patients with abnormal Transcranial Doppler</p>\n<p>(TCD) Ultrasonography velocity >200 cm/s</p>\n<p>~</p>\n<p>Recurrent or severe acute Chest Syndrome</p>\n<p>~</p>\n<p>Stroke</p>\n<p>RR</p>\n<p>Note: However, the decision to give a patient hydroxyurea should</p>\n<p>be done by a senior health worker after full laboratory investigation</p>\n<p>of the patient including:</p>\n<p>\u0089</p>\n<p>Complete blood count</p>\n<p>\u0089</p>\n<p>Renal function tests</p>\n<p>\u0089</p>\n<p>Liver function tests</p>\n<p>Management of acute complications</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Painful crisis \u2013 home management (mild to moderate pain)</p>\n<p>\u0089</p>\n<p>Oral hydration</p>\n<p>\u0089</p>\n<p>Warm compresses (not cold)</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>\u0083 Child: 10-15 mg/kg 6-8 hourly</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 650,
        "content": "584\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n\t\n\u0089\nAnd/or ibuprofen 400-600 mg every 6-8 hours \n \n\u0083 Child: 5-10 mg/kg 8 hourly\n\t\n\u0089\nAnd/or oral diclofenac 50 mg 8 hourly \n \n\u0083 Children only >9 years and >35 kg: 2 mg/kg in 3 \ndivided doses \nIf pain not controlled, add:\n\t\n\u0089\nCodeine 30-60 mg every 6 hours (only in patients \n>12 years)\n\t\n\u0089\nOr oral tramadol 50-100 mg every 6-8 hours (only in \npatients >12 years)\n\t\n\u0089\nOr Oral morphine at 0.2-0.4 mg/kg every 4 hours and \nre-assess pain level\n(see section 13.1.2) for thr WHO analgesic Ladder\nIf pain still not controlled, refer to hospital\nHC4\nRR\nPainful crisis \u2013 hospital management (severe pain)\n\t\n\u0089\nIV fluids for rehydration\n\t\n\u0089\nOxygen, keep oxygen saturation >95% \n\t\n\u0089\nAssess for malaria and other infections\n\t\n\u0089\nInjectable diclofenac\n \n\u0083 Child: 1 mg/kg IM 8 hourly\n \n\u0083 Adult: 50-75 mg IM 8 hourly\n\t\n\u0089\nMorphine oral (see section 13.1.2)\n \n\u0083 Child and Adult: 0.3-0.6 mg/kg per dose and re- \nassess\n\t\n\u0089\nOr Morphine IV\n \n\u0083 Child: 0.1-0.2 mg/kg per dose\n \n\u0083 Adult: 5-10 mg dose and re-assess\nHC4\nHC4\nHC3\nH\nNote\n \n\u0083 Use of laxative: bisacodyl 2.5 mg to 5 mg orally to prevent \nconstipation due to morphine",
        "formatted_content": "<p>584</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0089</p>\n<p>And/or ibuprofen 400-600 mg every 6-8 hours</p>\n<p>\u0083 Child: 5-10 mg/kg 8 hourly</p>\n<p>\u0089</p>\n<p>And/or oral diclofenac 50 mg 8 hourly</p>\n<p>\u0083 Children only >9 years and >35 kg: 2 mg/kg in 3</p>\n<p>divided doses</p>\n<p>If pain not controlled, add:</p>\n<p>\u0089</p>\n<p>Codeine 30-60 mg every 6 hours (only in patients</p>\n<p>>12 years)</p>\n<p>\u0089</p>\n<p>Or oral tramadol 50-100 mg every 6-8 hours (only in</p>\n<p>patients >12 years)</p>\n<p>\u0089</p>\n<p>Or Oral morphine at 0.2-0.4 mg/kg every 4 hours and</p>\n<p>re-assess pain level</p>\n<p>(see section 13.1.2) for thr WHO analgesic Ladder</p>\n<p>If pain still not controlled, refer to hospital</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>Painful crisis \u2013 hospital management (severe pain)</p>\n<p>\u0089</p>\n<p>IV fluids for rehydration</p>\n<p>\u0089</p>\n<p>Oxygen, keep oxygen saturation >95%</p>\n<p>\u0089</p>\n<p>Assess for malaria and other infections</p>\n<p>\u0089</p>\n<p>Injectable diclofenac</p>\n<p>\u0083 Child: 1 mg/kg IM 8 hourly</p>\n<p>\u0083 Adult: 50-75 mg IM 8 hourly</p>\n<p>\u0089</p>\n<p>Morphine oral (see section 13.1.2)</p>\n<p>\u0083 Child and Adult: 0.3-0.6 mg/kg per dose and re-</p>\n<p>assess</p>\n<p>\u0089</p>\n<p>Or Morphine IV</p>\n<p>\u0083 Child: 0.1-0.2 mg/kg per dose</p>\n<p>\u0083 Adult: 5-10 mg dose and re-assess</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>H</p>\n<p>Note</p>\n<p>\u0083 Use of laxative: bisacodyl 2.5 mg to 5 mg orally to prevent</p>\n<p>constipation due to morphine</p>"
    },
    {
        "page_number": 651,
        "content": "585\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nTREATMENT\nLOC\nAcute anaemia (acute splenic sequestration, aplastic crisis)\n\t\n\u0089\nTransfuse (see section 11.1.1)\n\t\n\u0089\nIV fluids if necessary\n\t\n\u0089\nInvestigate and treat malaria, and infections\n\t\n\u0089\nAvoid splenectomy in acute sequestration (high mortality)\nHC4\nAcute Chest syndrome\n\t\n\u0089\nRestricted IV fluids use, always use calculated required \namounts of IV fluids. NB: limit in cases of pulmonary \noedema\n\t\n\u0089\nOxygen therapy\n\t\n\u0089\nPain management as above\n\t\n\u0089\nSalbutamol inhaler (2-4 puffs prn) or nebulisation 5 mg \n(2.5 mg for children <5 years)\n\t\n\u0089\nCeftriaxone 1-2 g once daily for 7-10 days\nChild: 80-100 mg/kg once daily\n\t\n\u0089\nPlus erythromycin 500 mg every 6 hours for 7-10 days\nChild: 5-10 mg/kg every 6 hours\n\t\n\u0089\nTransfuse if no improvement, and/or Hb falls <9 g/dL. \nStart incentive spirometry (or blowing of a balloon) early \nin acute chest syndrome\nHC4\nStroke\n\t\n\u0089\nOxygen to mantain SpO2 >94%\n\t\n\u0089\nTranfuse if Hb <9 g/dl\n\t\n\u0089\nIV fluids\n\t\n\u0089\nRefer for neuroimaging and advanced management\nRR",
        "formatted_content": "<p>585</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute anaemia (acute splenic sequestration, aplastic crisis)</p>\n<p>\u0089</p>\n<p>Transfuse (see section 11.1.1)</p>\n<p>\u0089</p>\n<p>IV fluids if necessary</p>\n<p>\u0089</p>\n<p>Investigate and treat malaria, and infections</p>\n<p>\u0089</p>\n<p>Avoid splenectomy in acute sequestration (high mortality)</p>\n<h3>HC4</h3>\n<p>Acute Chest syndrome</p>\n<p>\u0089</p>\n<p>Restricted IV fluids use, always use calculated required</p>\n<p>amounts of IV fluids. NB: limit in cases of pulmonary</p>\n<p>oedema</p>\n<p>\u0089</p>\n<p>Oxygen therapy</p>\n<p>\u0089</p>\n<p>Pain management as above</p>\n<p>\u0089</p>\n<p>Salbutamol inhaler (2-4 puffs prn) or nebulisation 5 mg</p>\n<p>(2.5 mg for children <5 years)</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1-2 g once daily for 7-10 days</p>\n<p>Child: 80-100 mg/kg once daily</p>\n<p>\u0089</p>\n<p>Plus erythromycin 500 mg every 6 hours for 7-10 days</p>\n<p>Child: 5-10 mg/kg every 6 hours</p>\n<p>\u0089</p>\n<p>Transfuse if no improvement, and/or Hb falls <9 g/dL.</p>\n<p>Start incentive spirometry (or blowing of a balloon) early</p>\n<p>in acute chest syndrome</p>\n<h3>HC4</h3>\n<p>Stroke</p>\n<p>\u0089</p>\n<p>Oxygen to mantain SpO2 >94%</p>\n<p>\u0089</p>\n<p>Tranfuse if Hb <9 g/dl</p>\n<p>\u0089</p>\n<p>IV fluids</p>\n<p>\u0089</p>\n<p>Refer for neuroimaging and advanced management</p>\n<p>RR</p>"
    },
    {
        "page_number": 652,
        "content": "586\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nTREATMENT\nLOC\nAcute Abdomen/Mesenteric crisis\n\t\n\u0089\nIV fluids\n\t\n\u0089\nNil by mouth\n\t\n\u0089\nNGT tube on free drainage\n\t\n\u0089\nAntibiotics\n\t\n\u0089\nCeftriaxone 1-2 g once daily for 7-10 days\n\t\n\u0089\nChild: 80 mg/kg once daily\n\t\n\u0089\nPlus metronidazole 500 mg IV every eight hours \nfor 7-10 days\n\t\n\u0089\nChild: 10 mg/kg IV every 8 hours\n\t\n\u0089\nRed cell transfusion\n \n\u0081\nPlain abdominal X-ray to rule out obstruction or \nstool impaction\n\t\n\u0089\nSurgical review\nH\nInfections\n\t\n\u0089\nPrompt assessment and treatment of cause (osteo\u00ad\nmyelitis, pneumonia, chronic leg ulcers,cellulitis, etc.)\n\t\n\u0089\nTreat according to cause. If no localising focal symp\u00ad\ntoms, and no malaria, give:\n\t\n\u0089\nCeftriaxone 1-2 g once daily for 7-10 days\n\t\n\u0089\nChild: 80 mg/kg once daily\nIf osteomyelitis or septic arthritis\n\t\n\u0089\nOr Cloxacillin 500 mg 6 hourly IV or orally\n\t\n\u0089\nChild: 50 mg/kg 6 hourly for at least 21 days\n\t\n\u0089\nor Ciprofloxacin 500 mg 12 hourly for at least 21 days\n \n\u0083 In child: Ceftriaxone 50 mg/kg IV once a day for\nat least 21 days\nH",
        "formatted_content": "<p>586</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute Abdomen/Mesenteric crisis</p>\n<p>\u0089</p>\n<p>IV fluids</p>\n<p>\u0089</p>\n<p>Nil by mouth</p>\n<p>\u0089</p>\n<p>NGT tube on free drainage</p>\n<p>\u0089</p>\n<p>Antibiotics</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1-2 g once daily for 7-10 days</p>\n<p>\u0089</p>\n<p>Child: 80 mg/kg once daily</p>\n<p>\u0089</p>\n<p>Plus metronidazole 500 mg IV every eight hours</p>\n<p>for 7-10 days</p>\n<p>\u0089</p>\n<p>Child: 10 mg/kg IV every 8 hours</p>\n<p>\u0089</p>\n<p>Red cell transfusion</p>\n<p>\u0081</p>\n<p>Plain abdominal X-ray to rule out obstruction or</p>\n<p>stool impaction</p>\n<p>\u0089</p>\n<p>Surgical review</p>\n<p>H</p>\n<p>Infections</p>\n<p>\u0089</p>\n<p>Prompt assessment and treatment of cause (osteo\u00ad</p>\n<p>myelitis, pneumonia, chronic leg ulcers,cellulitis, etc.)</p>\n<p>\u0089</p>\n<p>Treat according to cause. If no localising focal symp\u00ad</p>\n<p>toms, and no malaria, give:</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1-2 g once daily for 7-10 days</p>\n<p>\u0089</p>\n<p>Child: 80 mg/kg once daily</p>\n<p>If osteomyelitis or septic arthritis</p>\n<p>\u0089</p>\n<p>Or Cloxacillin 500 mg 6 hourly IV or orally</p>\n<p>\u0089</p>\n<p>Child: 50 mg/kg 6 hourly for at least 21 days</p>\n<p>\u0089</p>\n<p>or Ciprofloxacin 500 mg 12 hourly for at least 21 days</p>\n<p>\u0083 In child: Ceftriaxone 50 mg/kg IV once a day for</p>\n<p>at least 21 days</p>\n<p>H</p>"
    },
    {
        "page_number": 653,
        "content": "587\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nTREATMENT\nLOC\nIndications for blood transfusion\n\t\n\u0089\nAcute exacerbation of baseline anaemia:\n(drop in HB of \u2265 2g/dl)\n \n\u0083 Hyperhaemolysis\n \n\u0083 Hepatic sequestration\n \n\u0083 Splenic sequestration\n \n\u0083 Aplastic crisis\n\t\n\u0089\nSevere vaso-occlusive events:\n \n\u0083 Stroke\n \n\u0083 Acute chest syndrome\n \n\u0083 Multi-organ failure\n\t\n\u0089\nPreparation for procedures:\n \n\u0083 Surgery\n \n\u0083 Radiography with ionic contrast\n \n\u0083 General anaesthesia\nHC4\nPrevention/health education\n \n~\nPatient, family and community education\n \n~\nTimely initiation of hydroxyurea\n \n~\nPeriodic comprehensive evaluations, and other disease- \nspecific health maintenance services\n \n~\nPeriodic evaluation for sickle cell complications for exam\u00ad\nple urinalysis and renal function for sickle cell nephropa\u00ad\nthy, cardiac echo for pulmonary hypertension, transcra\u00ad\nnial doppler in children for early detection of stroke risk. \nPatienst with these complications should be referred to a \nspecialist",
        "formatted_content": "<p>587</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Indications for blood transfusion</p>\n<p>\u0089</p>\n<p>Acute exacerbation of baseline anaemia:</p>\n<p>(drop in HB of \u2265 2g/dl)</p>\n<p>\u0083 Hyperhaemolysis</p>\n<p>\u0083 Hepatic sequestration</p>\n<p>\u0083 Splenic sequestration</p>\n<p>\u0083 Aplastic crisis</p>\n<p>\u0089</p>\n<p>Severe vaso-occlusive events:</p>\n<p>\u0083 Stroke</p>\n<p>\u0083 Acute chest syndrome</p>\n<p>\u0083 Multi-organ failure</p>\n<p>\u0089</p>\n<p>Preparation for procedures:</p>\n<p>\u0083 Surgery</p>\n<p>\u0083 Radiography with ionic contrast</p>\n<p>\u0083 General anaesthesia</p>\n<h3>HC4</h3>\n<p>Prevention/health education</p>\n<p>~</p>\n<p>Patient, family and community education</p>\n<p>~</p>\n<p>Timely initiation of hydroxyurea</p>\n<p>~</p>\n<p>Periodic comprehensive evaluations, and other disease-</p>\n<p>specific health maintenance services</p>\n<p>~</p>\n<p>Periodic evaluation for sickle cell complications for exam\u00ad</p>\n<p>ple urinalysis and renal function for sickle cell nephropa\u00ad</p>\n<p>thy, cardiac echo for pulmonary hypertension, transcra\u00ad</p>\n<p>nial doppler in children for early detection of stroke risk.</p>\n<p>Patienst with these complications should be referred to a</p>\n<p>specialist</p>"
    },
    {
        "page_number": 654,
        "content": "588\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n \n~\nTimely and appropriate treatment of painful crisis and \nacute illness \n \n~\nGenetic counseling (for couples planning to have children)\n \n~\nAntenatalscreening \n \n~\n Early recognition /screening of children with low Hb \n \n~\n Vaccination (pneumococcal vaccine, H-influenza vaccine, \nHepatitisBvaccine evaluation) \n \n~\nAntibiotic (oral penicillin twice a day\n \n~\nTimely and appropriate treatment of acute illness\n \n~\nGenetic counseling (for couples planning to have children)\n \n~\nAntenatal screening\n \n~\nEarly recognition/screening of children with low Hb\nVaccination (pneumococcal vaccine, H-influenza vaccine, Hepatitis B \nvaccine evaluation)\n \n~\nAntibiotic (oral penicillin twice a day in >5years), and an\u00ad\ntimalarial chemoprophylaxis\n11.2 Blood And Blood Products\nThe Uganda Blood Transfusion Service (UBTS) collects blood and \nproduces all blood products. Whole blood (WB): unseparated blood \ncollected inanapprovedcontainerandcontainingapreservative or anti\u00ad\ncoagulant solution \u201cBlood\u201dreferstoany blood component in which the \nmain constituentisredbloodcells,e.g.,wholeblood(WB), red cell concen\u00ad\ntrate,orred cell suspension \nUnless otherwise specified, others are referred to as blood components \nor products. Blood components are preparedfrom WB, and contain \nnegligible quantity of red cells,e.g., platelet concentrate, Fresh Frozen \nPlasma, Cryoprecipitate.(Referto the \u201dNational Blood Transfusion \nGuidelines for appropriate use of blood\u201d formoredetails) UBTS ensures \nthat all blood and blood products are producedinaway that ensures the \nhealth and safety of both patients and donors andminimisesthe risk",
        "formatted_content": "<p>588</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>~</p>\n<p>Timely and appropriate treatment of painful crisis and</p>\n<p>acute illness</p>\n<p>~</p>\n<p>Genetic counseling (for couples planning to have children)</p>\n<p>~</p>\n<p>Antenatalscreening</p>\n<p>~</p>\n<p>Early recognition /screening of children with low Hb</p>\n<p>~</p>\n<p>Vaccination (pneumococcal vaccine, H-influenza vaccine,</p>\n<p>HepatitisBvaccine evaluation)</p>\n<p>~</p>\n<p>Antibiotic (oral penicillin twice a day</p>\n<p>~</p>\n<p>Timely and appropriate treatment of acute illness</p>\n<p>~</p>\n<p>Genetic counseling (for couples planning to have children)</p>\n<p>~</p>\n<p>Antenatal screening</p>\n<p>~</p>\n<p>Early recognition/screening of children with low Hb</p>\n<p>Vaccination (pneumococcal vaccine, H-influenza vaccine, Hepatitis B</p>\n<p>vaccine evaluation)</p>\n<p>~</p>\n<p>Antibiotic (oral penicillin twice a day in >5years), and an\u00ad</p>\n<p>timalarial chemoprophylaxis</p>\n<p>11.2 Blood And Blood Products</p>\n<p>The Uganda Blood Transfusion Service (UBTS) collects blood and</p>\n<p>produces all blood products. Whole blood (WB): unseparated blood</p>\n<p>collected inanapprovedcontainerandcontainingapreservative or anti\u00ad</p>\n<p>coagulant solution \u201cBlood\u201dreferstoany blood component in which the</p>\n<p>main constituentisredbloodcells,e.g.,wholeblood(WB), red cell concen\u00ad</p>\n<p>trate,orred cell suspension</p>\n<p>Unless otherwise specified, others are referred to as blood components</p>\n<p>or products. Blood components are preparedfrom WB, and contain</p>\n<p>negligible quantity of red cells,e.g., platelet concentrate, Fresh Frozen</p>\n<p>Plasma, Cryoprecipitate.(Referto the \u201dNational Blood Transfusion</p>\n<p>Guidelines for appropriate use of blood\u201d formoredetails) UBTS ensures</p>\n<p>that all blood and blood products are producedinaway that ensures the</p>\n<p>health and safety of both patients and donors andminimisesthe risk</p>"
    },
    {
        "page_number": 655,
        "content": "589\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\noftransmitting infection through blood.\n11.2.1 General Principles of Good Clinical Practice in Transfusion \nMedicine\n \n~\nBlood is a scarce and expensive resource. Blood trans\u00ad\nfusion carries risks of adverse reactions and transfu\u00ad\nsion-transmitted infections\n \n~\nUse blood appropriately, that is, to treat conditions that \ncan lead to significant morbidity or mortality, which can\u00ad\nnot be prevented or effectively managed by other means\n \n~\nMinimise the need for transfusion by:\n \n\u0083 Early diagnosis, and treatment of anaemia, in particular iron \ndeficiency anaemia\n \n\u0083 Stop blood loss, through good surgical and anaesthetic \nmanagement\n \n\u0083 Appropriate and timely management of coagulation disorders\n \n\u0083 Use of simple alternatives to transfusion when appropriate, \ne.g., IV fluids as first line treatment of hypovolemic shock\nPrescribe transfusion according to patients individual needs, using \nclinical signs and symptoms, and expected outcome, but NOT only \naccording to Hb level \nDo not use blood transfusion to:\n \n\u0083 Expand blood volume, unless there has been blood loss of \n>30% of total volume\n \n\u0083 Enhance wound healing\n \n\u0083 \u201cTop up\u201d Hb prior to surgery\n \n\u0083 Improve general well-being of the patient in patients with \non-going fluid losses, e.g. surgical blood loss\n \n~\nBlood should not be transfused unless it has been:\n\t\n\u0089\nObtained from appropriately selected donors (voluntary non-re\u00ad\nmunerated donors)",
        "formatted_content": "<p>589</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>oftransmitting infection through blood.</p>\n<p>11.2.1 General Principles of Good Clinical Practice in Transfusion</p>\n<p>Medicine</p>\n<p>~</p>\n<p>Blood is a scarce and expensive resource. Blood trans\u00ad</p>\n<p>fusion carries risks of adverse reactions and transfu\u00ad</p>\n<p>sion-transmitted infections</p>\n<p>~</p>\n<p>Use blood appropriately, that is, to treat conditions that</p>\n<p>can lead to significant morbidity or mortality, which can\u00ad</p>\n<p>not be prevented or effectively managed by other means</p>\n<p>~</p>\n<p>Minimise the need for transfusion by:</p>\n<p>\u0083 Early diagnosis, and treatment of anaemia, in particular iron</p>\n<p>deficiency anaemia</p>\n<p>\u0083 Stop blood loss, through good surgical and anaesthetic</p>\n<p>management</p>\n<p>\u0083 Appropriate and timely management of coagulation disorders</p>\n<p>\u0083 Use of simple alternatives to transfusion when appropriate,</p>\n<p>e.g., IV fluids as first line treatment of hypovolemic shock</p>\n<p>Prescribe transfusion according to patients individual needs, using</p>\n<p>clinical signs and symptoms, and expected outcome, but NOT only</p>\n<p>according to Hb level</p>\n<p>Do not use blood transfusion to:</p>\n<p>\u0083 Expand blood volume, unless there has been blood loss of</p>\n<p>>30% of total volume</p>\n<p>\u0083 Enhance wound healing</p>\n<p>\u0083 \u201cTop up\u201d Hb prior to surgery</p>\n<p>\u0083 Improve general well-being of the patient in patients with</p>\n<p>on-going fluid losses, e.g. surgical blood loss</p>\n<p>~</p>\n<p>Blood should not be transfused unless it has been:</p>\n<p>\u0089</p>\n<p>Obtained from appropriately selected donors (voluntary non-re\u00ad</p>\n<p>munerated donors)</p>"
    },
    {
        "page_number": 656,
        "content": "590\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n\t\n\u0089\nScreened for transfusion-transmissible infections (TTIs), namely; \nHIV, hepatitis B, hepatitis C, and syphilis Tested for compatibility \n(pre-transfusion) between the donor\u2019s red cells and the antibodies \nin the patient\u2019s plasma in accordance with national guidelines\n \n~\nThe mandate to collect blood from donors, and screen it \nfor TTI is reserved for UBTS\n \n~\nGuidelines and procedures for requesting, administering, \nand recording blood transfusion should be clearly spelled \nout, and strictly followed to avoid catastrophic mistakes \n(see below for)\n \n~\nEnsure the transfused patient is closely monitored (during \nand after transfusion) and that there is immediate response \nif any adverse reactions occur\n11.2.2 Blood and Blood Products: Characteristics and Indica\u00ad\ntions \nThe following section will present only whole blood and red cells con\u00ad\ncentrate. Availability and use of other blood components is reserved for \nreferral hospitals and is beyond the scope of this guideline.\n11.2.2.1 Whole Blood \n \n~\nWhole blood provides red blood cells, plasma volume, sta\u00ad\nble coagulation factors (VII, XI), and others\n \n~\nMay not have enough functional platelets and labile coag\u00ad\nulation factors (V and VIII)\n \n~\nIt is also used as a raw material from which other blood \ncomponents are prepared\n \n~\n1 unit of whole blood is about 450 ml of donor blood; \nobtained from a single donation plus 63 mL of anticoag\u00ad\nulant/preservative solution. It is available from HC4 level\n \n~\nHct is approximately 35%\n \n~\nEach unit of blood will raise the HB by about 1g/dl",
        "formatted_content": "<p>590</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0089</p>\n<p>Screened for transfusion-transmissible infections (TTIs), namely;</p>\n<p>HIV, hepatitis B, hepatitis C, and syphilis Tested for compatibility</p>\n<p>(pre-transfusion) between the donor\u2019s red cells and the antibodies</p>\n<p>in the patient\u2019s plasma in accordance with national guidelines</p>\n<p>~</p>\n<p>The mandate to collect blood from donors, and screen it</p>\n<p>for TTI is reserved for UBTS</p>\n<p>~</p>\n<p>Guidelines and procedures for requesting, administering,</p>\n<p>and recording blood transfusion should be clearly spelled</p>\n<p>out, and strictly followed to avoid catastrophic mistakes</p>\n<p>(see below for)</p>\n<p>~</p>\n<p>Ensure the transfused patient is closely monitored (during</p>\n<p>and after transfusion) and that there is immediate response</p>\n<p>if any adverse reactions occur</p>\n<p>11.2.2 Blood and Blood Products: Characteristics and Indica\u00ad</p>\n<p>tions</p>\n<p>The following section will present only whole blood and red cells con\u00ad</p>\n<p>centrate. Availability and use of other blood components is reserved for</p>\n<p>referral hospitals and is beyond the scope of this guideline.</p>\n<p>11.2.2.1 Whole Blood</p>\n<p>~</p>\n<p>Whole blood provides red blood cells, plasma volume, sta\u00ad</p>\n<p>ble coagulation factors (VII, XI), and others</p>\n<p>~</p>\n<p>May not have enough functional platelets and labile coag\u00ad</p>\n<p>ulation factors (V and VIII)</p>\n<p>~</p>\n<p>It is also used as a raw material from which other blood</p>\n<p>components are prepared</p>\n<p>~</p>\n<p>1 unit of whole blood is about 450 ml of donor blood;</p>\n<p>obtained from a single donation plus 63 mL of anticoag\u00ad</p>\n<p>ulant/preservative solution. It is available from HC4 level</p>\n<p>~</p>\n<p>Hct is approximately 35%</p>\n<p>~</p>\n<p>Each unit of blood will raise the HB by about 1g/dl</p>"
    },
    {
        "page_number": 657,
        "content": "591\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nIndications\n \n~\nRed blood cell replacement in acute blood loss (haemor\u00ad\nrhage) with significant hypovolaemia such as in trauma, sur\u00ad\ngery, invasive procedures, GIT haemorrhage\n \n~\nPatients in need of red blood cell transfusion, where red \ncell concentrates or suspensions are not available (consider \nadding furosemide to avoid fluid overload)\n \n~\nOnly Specialist Use: exchange transfusion in neonates, us\u00ad\ning less than 5-day old blood units\n Dose\n \n\u0083 Adults: 1 unit at a time\n \n\u0083 Children: 20mL/kg\nCaution\n \n~\nTransfusion must be started within 30 minutes of removal \nfrom the refrigerator, and completed within 4 hours of \nstarting\n \n~\nStorage is 2-6\u00b0C in approved blood bank refrigerator with \ntemperature charts and alarm\n \n~\nWB is contraindicated in severe chronic anaemia and in\u00ad\ncipient cardiac failure (risk of volume overload)\n \n~\nBlood should not be warmed (improvised warming meth\u00ad\nod commonly used in health facilities is not necessary)\n \n~\nThe routine use of diuretics (furosemide, or lasix), pre-trans\u00ad\nfusion is not necessary in most patients. Pre-transfusion \ndiuretics are indicated in known cardiac and renal patients \n\u2013 to prevent circulatory overload.\n11.2.2.2 Red Cell Concentrates (packed red cells) \nRed cell concentrates contain red blood cells, suspended in a small \namount of plasma and additive solutions (which provides nutrients to \nthe red cells in storage). It is in a form of two, or three pediatric bags,",
        "formatted_content": "<p>591</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Indications</p>\n<p>~</p>\n<p>Red blood cell replacement in acute blood loss (haemor\u00ad</p>\n<p>rhage) with significant hypovolaemia such as in trauma, sur\u00ad</p>\n<p>gery, invasive procedures, GIT haemorrhage</p>\n<p>~</p>\n<p>Patients in need of red blood cell transfusion, where red</p>\n<p>cell concentrates or suspensions are not available (consider</p>\n<p>adding furosemide to avoid fluid overload)</p>\n<p>~</p>\n<p>Only Specialist Use: exchange transfusion in neonates, us\u00ad</p>\n<p>ing less than 5-day old blood units</p>\n<p>Dose</p>\n<p>\u0083 Adults: 1 unit at a time</p>\n<p>\u0083 Children: 20mL/kg</p>\n<p>Caution</p>\n<p>~</p>\n<p>Transfusion must be started within 30 minutes of removal</p>\n<p>from the refrigerator, and completed within 4 hours of</p>\n<p>starting</p>\n<p>~</p>\n<p>Storage is 2-6\u00b0C in approved blood bank refrigerator with</p>\n<p>temperature charts and alarm</p>\n<p>~</p>\n<p>WB is contraindicated in severe chronic anaemia and in\u00ad</p>\n<p>cipient cardiac failure (risk of volume overload)</p>\n<p>~</p>\n<p>Blood should not be warmed (improvised warming meth\u00ad</p>\n<p>od commonly used in health facilities is not necessary)</p>\n<p>~</p>\n<p>The routine use of diuretics (furosemide, or lasix), pre-trans\u00ad</p>\n<p>fusion is not necessary in most patients. Pre-transfusion</p>\n<p>diuretics are indicated in known cardiac and renal patients</p>\n<p>\u2013 to prevent circulatory overload.</p>\n<p>11.2.2.2 Red Cell Concentrates (packed red cells)</p>\n<p>Red cell concentrates contain red blood cells, suspended in a small</p>\n<p>amount of plasma and additive solutions (which provides nutrients to</p>\n<p>the red cells in storage). It is in a form of two, or three pediatric bags,</p>"
    },
    {
        "page_number": 658,
        "content": "592\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\neach containing 80-150 ml, obtained from a single donation. HCT is \napproximately 55%. It is available from HC4 level.\nIndications\n \n~\nRed blood cell replacement in anaemic patients\n \n~\nIn acute blood loss, together with crystalloid solution if \nWB is not available\nCaution\n \n~\nTransfusion must be started within 30 minutes of removal \nfrom the refrigerator, and completed within 4 hours of start\u00ad\ning\n \n~\nStorage is 2-6\u00b0C in approved blood bank refrigerator with \ntemperature charts and alarm\n11.2.2.3 Clinical Indications for Blood Transfusion \nThe indication for blood transfusion (with whole blood or red cell con\u00ad\ncentrates) depends on:\n\t\n\u0089\nThe degree of anaemia (estimated by Hb level)\n\t\n\u0089\nThe clinical conditions (high risk or presence of signs and symptoms \nof tissue hypoxia, or impaired tissue oxygenation resulting from \nanemia or blood loss)\nPresence of ongoing blood loss (e.g., internal or external haemorrhage) \nSevere acute anaemia in children and infants\nTransfuse, if;\n \n~\nHb \u2264 4 g/dL (or haematocrit \u2264 12%), whatever the clinical \ncondition of the patient\n \n~\nHb  4 \u2013 6 g/dL (or haematocrit 13-18%), in case of life \nthreatening complications, such as, clinical features of hy\u00ad\npoxia and cardiac decompensation, acidosis (usually caus\u00ad\nes respiratory distress , impaired consciousness/coma, hy\u00ad\nperparasitaemia (>20%) or cerebral malaria, septicaemia,",
        "formatted_content": "<p>592</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>each containing 80-150 ml, obtained from a single donation. HCT is</p>\n<p>approximately 55%. It is available from HC4 level.</p>\n<p>Indications</p>\n<p>~</p>\n<p>Red blood cell replacement in anaemic patients</p>\n<p>~</p>\n<p>In acute blood loss, together with crystalloid solution if</p>\n<p>WB is not available</p>\n<p>Caution</p>\n<p>~</p>\n<p>Transfusion must be started within 30 minutes of removal</p>\n<p>from the refrigerator, and completed within 4 hours of start\u00ad</p>\n<p>ing</p>\n<p>~</p>\n<p>Storage is 2-6\u00b0C in approved blood bank refrigerator with</p>\n<p>temperature charts and alarm</p>\n<p>11.2.2.3 Clinical Indications for Blood Transfusion</p>\n<p>The indication for blood transfusion (with whole blood or red cell con\u00ad</p>\n<p>centrates) depends on:</p>\n<p>\u0089</p>\n<p>The degree of anaemia (estimated by Hb level)</p>\n<p>\u0089</p>\n<p>The clinical conditions (high risk or presence of signs and symptoms</p>\n<p>of tissue hypoxia, or impaired tissue oxygenation resulting from</p>\n<p>anemia or blood loss)</p>\n<p>Presence of ongoing blood loss (e.g., internal or external haemorrhage)</p>\n<p>Severe acute anaemia in children and infants</p>\n<p>Transfuse, if;</p>\n<p>~</p>\n<p>Hb \u2264 4 g/dL (or haematocrit \u2264 12%), whatever the clinical</p>\n<p>condition of the patient</p>\n<p>~</p>\n<p>Hb  4 \u2013 6 g/dL (or haematocrit 13-18%), in case of life</p>\n<p>threatening complications, such as, clinical features of hy\u00ad</p>\n<p>poxia and cardiac decompensation, acidosis (usually caus\u00ad</p>\n<p>es respiratory distress , impaired consciousness/coma, hy\u00ad</p>\n<p>perparasitaemia (>20%) or cerebral malaria, septicaemia,</p>"
    },
    {
        "page_number": 659,
        "content": "593\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nmeningitis\nDose: Transfuse 10-15 mL/kg of packed red cells (or 20 mL/kg of \nwhole blood)\nNote: In children with chronic anaemia caused by iron deficiency, it \nmay be possible to correct with iron therapy alone.\nSevere anaemia in adults\n \n~\nConsider blood transfusion only in anaemia whose sever\u00ad\nity is likely to cause/ has already caused clinical signs of \nhypoxia, or impaired tissue oxygenation. These signs may \ninclude; tachycardia, shock, respiratory distress, weak\u00ad\nness, dizziness and or unconsciousness.\n\t\n\u0089\nSymptomatic anaemia (see above) in adults with <7 g/dL\n\t\n\u0089\nHaemoglobin <8g/dL if with cardiac disease or CNS symptoms\n \n~\nGive the minimum number of transfusions necessary to \nrelieve hypoxia: \n \n\u0083 Transfuse 1 unit at a  time, then re-assess\n \n\u0083 If symptoms persist give another unit\n \n\u0083 Transfuse in 2-4 hours \nSevere anaemia in pregnancy\n \n~\nGenerally, it is important to screen for iron deficiency \nanaemia early in pregnancy and treating with iron as nec\u00ad\nessary.\nPregnancy <36 weeks\n \n~\nHb  5 g/dL irrespective of clinical condition\n \n~\nHb 5-7 g/dL in case of established or incipient heart fail\u00ad\nure/impaired tissue oxygenation, pneumonia or other seri\u00ad\nous infection, malaria, pre- existing heart disease\nPregnancy >36 weeks\n \n~\nHb \u2264 6 g/dL\n\t\n\u0089\nHb 6-8 g/dL in case of, established or incipient heart failure/im\u00ad\npaired tissue oxygenation, pneumonia or other serious infection,",
        "formatted_content": "<p>593</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>meningitis</p>\n<p>Dose: Transfuse 10-15 mL/kg of packed red cells (or 20 mL/kg of</p>\n<p>whole blood)</p>\n<p>Note: In children with chronic anaemia caused by iron deficiency, it</p>\n<p>may be possible to correct with iron therapy alone.</p>\n<p>Severe anaemia in adults</p>\n<p>~</p>\n<p>Consider blood transfusion only in anaemia whose sever\u00ad</p>\n<p>ity is likely to cause/ has already caused clinical signs of</p>\n<p>hypoxia, or impaired tissue oxygenation. These signs may</p>\n<p>include; tachycardia, shock, respiratory distress, weak\u00ad</p>\n<p>ness, dizziness and or unconsciousness.</p>\n<p>\u0089</p>\n<p>Symptomatic anaemia (see above) in adults with <7 g/dL</p>\n<p>\u0089</p>\n<p>Haemoglobin <8g/dL if with cardiac disease or CNS symptoms</p>\n<p>~</p>\n<p>Give the minimum number of transfusions necessary to</p>\n<p>relieve hypoxia:</p>\n<p>\u0083 Transfuse 1 unit at a  time, then re-assess</p>\n<p>\u0083 If symptoms persist give another unit</p>\n<p>\u0083 Transfuse in 2-4 hours</p>\n<p>Severe anaemia in pregnancy</p>\n<p>~</p>\n<p>Generally, it is important to screen for iron deficiency</p>\n<p>anaemia early in pregnancy and treating with iron as nec\u00ad</p>\n<p>essary.</p>\n<p>Pregnancy <36 weeks</p>\n<p>~</p>\n<p>Hb  5 g/dL irrespective of clinical condition</p>\n<p>~</p>\n<p>Hb 5-7 g/dL in case of established or incipient heart fail\u00ad</p>\n<p>ure/impaired tissue oxygenation, pneumonia or other seri\u00ad</p>\n<p>ous infection, malaria, pre- existing heart disease</p>\n<p>Pregnancy >36 weeks</p>\n<p>~</p>\n<p>Hb \u2264 6 g/dL</p>\n<p>\u0089</p>\n<p>Hb 6-8 g/dL in case of, established or incipient heart failure/im\u00ad</p>\n<p>paired tissue oxygenation, pneumonia or other serious infection,</p>"
    },
    {
        "page_number": 660,
        "content": "594\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nmalaria, pre-existing heart disease\nElective caesarean section\nIf history of APH, PPH, previous caesarean section\n \n~\nHb is 8-10 g/dL\n\t\n\u0089\nEstablish/confirm blood group, and save freshly taken serum for \ncross-matching\n \n~\nHb <8 g/dL\n\t\n\u0089\nHave 2 units of blood cross-matched and made available\nPre-operative anaemia\nPre-operative anaemia should be investigated, and promptly managed \nbefore surgery;\n \n\u0083 Prompt management may include iron supplementation (oral, \non intravenous)\n \n\u0083 Where possible, surgery should be delayed or postponed, until \nanaemia is corrected, since pre-operative anemia is associated \nwith poor surgical outcomes (morbidity and mortality), as well \nas an increased need for blood transfusion.\n \n~\n\u2264 8 g/dL in case of:\n\t\n\u0089\nInadequate compensation for the anaemia (symptomatic anaemia)\n\t\n\u0089\nSignificant co-existing cardiorespiratory disease\n\t\n\u0089\nMajor surgery or significant blood loss expected\n\t\n\u0089\nPre-surgical correction has not been possible\nManagement of acute haemorrhage/hypovolemia\n \n~\nIV fluids (crystalloids: Normal saline) is the first line in \ntreatment of hypovolaemia during acute haemorrhage\n \n~\nWhole blood (or red blood cells if WB unavailable) are \nindicated when blood loss is >20- 30% of blood volume \n(>15-20 mL/kg)\n \n~\nThe need for blood must be determined by:\n\t\n\u0089\nAmount and speed of blood loss",
        "formatted_content": "<p>594</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>malaria, pre-existing heart disease</p>\n<p>Elective caesarean section</p>\n<p>If history of APH, PPH, previous caesarean section</p>\n<p>~</p>\n<p>Hb is 8-10 g/dL</p>\n<p>\u0089</p>\n<p>Establish/confirm blood group, and save freshly taken serum for</p>\n<p>cross-matching</p>\n<p>~</p>\n<p>Hb <8 g/dL</p>\n<p>\u0089</p>\n<p>Have 2 units of blood cross-matched and made available</p>\n<p>Pre-operative anaemia</p>\n<p>Pre-operative anaemia should be investigated, and promptly managed</p>\n<p>before surgery;</p>\n<p>\u0083 Prompt management may include iron supplementation (oral,</p>\n<p>on intravenous)</p>\n<p>\u0083 Where possible, surgery should be delayed or postponed, until</p>\n<p>anaemia is corrected, since pre-operative anemia is associated</p>\n<p>with poor surgical outcomes (morbidity and mortality), as well</p>\n<p>as an increased need for blood transfusion.</p>\n<p>~</p>\n<p>\u2264 8 g/dL in case of:</p>\n<p>\u0089</p>\n<p>Inadequate compensation for the anaemia (symptomatic anaemia)</p>\n<p>\u0089</p>\n<p>Significant co-existing cardiorespiratory disease</p>\n<p>\u0089</p>\n<p>Major surgery or significant blood loss expected</p>\n<p>\u0089</p>\n<p>Pre-surgical correction has not been possible</p>\n<p>Management of acute haemorrhage/hypovolemia</p>\n<p>~</p>\n<p>IV fluids (crystalloids: Normal saline) is the first line in</p>\n<p>treatment of hypovolaemia during acute haemorrhage</p>\n<p>~</p>\n<p>Whole blood (or red blood cells if WB unavailable) are</p>\n<p>indicated when blood loss is >20- 30% of blood volume</p>\n<p>(>15-20 mL/kg)</p>\n<p>~</p>\n<p>The need for blood must be determined by:</p>\n<p>\u0089</p>\n<p>Amount and speed of blood loss</p>"
    },
    {
        "page_number": 661,
        "content": "595\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n\t\n\u0089\nPatient\u2019s critical signs\n\t\n\u0089\nInitial response to IV fluid resuscitation\n \n~\nHb level is NOT a reliable indicator for blood need in acute \nhaemorrhage\nSickle cell anaemia\n \n~\nBlood transfusion is not necessary for asymptomatic sickle \ncell patient with steady Hb 6-8 g/dL nor for an uncompli\u00ad\ncated painful episode\n \n~\nIn addition to general indications, blood transfusion is in\u00ad\ndicated if:\n\t\n\u0089\nAcute severe anaemia (Hb <5 g/dL or 2 g/dL lower than usual \nlevel for the patient) in aplastic and acute sequestration crisis. Aim \nat Hb 7-8 g/dL\n\t\n\u0089\nHb <6 g/dL in uncomplicated pregnancy\n\t\n\u0089\nHb <8 g/dL if caesarean section\n\t\n\u0089\nHb <9 g/dL in case of acute chest syndrome (ACS), or stroke. For \nthese four patient categories (pregnancy, C/section, ACS, and \nstroke), the target Hb is 11g/dL, and not any higher.\n \n~\nUse packed cells if available (rather than WB)\u2013 whole \nblood is indicated \nNeonatal conditions\n \n~\nSevere anaemia (of any cause (prematurity, sepsis, etc.)\n \n~\nTransfusion in neonates should be managed at specialist \nlevel\n11.2.3 Adverse Reactions following Transfusion \nAny potentially adverse sign or symptom resulting from a blood transfusion.\nCommon Acute Transfusion reactions (ATR)include;",
        "formatted_content": "<p>595</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0089</p>\n<p>Patient\u2019s critical signs</p>\n<p>\u0089</p>\n<p>Initial response to IV fluid resuscitation</p>\n<p>~</p>\n<p>Hb level is NOT a reliable indicator for blood need in acute</p>\n<p>haemorrhage</p>\n<p>Sickle cell anaemia</p>\n<p>~</p>\n<p>Blood transfusion is not necessary for asymptomatic sickle</p>\n<p>cell patient with steady Hb 6-8 g/dL nor for an uncompli\u00ad</p>\n<p>cated painful episode</p>\n<p>~</p>\n<p>In addition to general indications, blood transfusion is in\u00ad</p>\n<p>dicated if:</p>\n<p>\u0089</p>\n<p>Acute severe anaemia (Hb <5 g/dL or 2 g/dL lower than usual</p>\n<p>level for the patient) in aplastic and acute sequestration crisis. Aim</p>\n<p>at Hb 7-8 g/dL</p>\n<p>\u0089</p>\n<p>Hb <6 g/dL in uncomplicated pregnancy</p>\n<p>\u0089</p>\n<p>Hb <8 g/dL if caesarean section</p>\n<p>\u0089</p>\n<p>Hb <9 g/dL in case of acute chest syndrome (ACS), or stroke. For</p>\n<p>these four patient categories (pregnancy, C/section, ACS, and</p>\n<p>stroke), the target Hb is 11g/dL, and not any higher.</p>\n<p>~</p>\n<p>Use packed cells if available (rather than WB)\u2013 whole</p>\n<p>blood is indicated</p>\n<p>Neonatal conditions</p>\n<p>~</p>\n<p>Severe anaemia (of any cause (prematurity, sepsis, etc.)</p>\n<p>~</p>\n<p>Transfusion in neonates should be managed at specialist</p>\n<p>level</p>\n<p>11.2.3 Adverse Reactions following Transfusion</p>\n<p>Any potentially adverse sign or symptom resulting from a blood transfusion.</p>\n<p>Common Acute Transfusion reactions (ATR)include;</p>"
    },
    {
        "page_number": 662,
        "content": "596\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n\t\n\u0089\nMinor allergic reaction (Urticaria)\n\t\n\u0089\nFebrile non-haemolytic transfusion reaction\n\t\n\u0089\nAcute haemolytic transfusion reaction (caused by ABO incompat\u00ad\nibility): is a severe, and life threatening reaction\n\t\n\u0089\nBacterial contamination\n\t\n\u0089\nTransfusion-associated circulatory overload (TACO)\n\t\n\u0089\nTransfusion-related acute lung injury (TRALI)\n\t\n\u0089\nSevere allergic (Anaphylactic) reaction; relatively rare\nDelayed Transfusion reactions\n \n~\nTransfusion-transmitted infections, e.g., HIV, Hepatitis B, \nand Hepatitis C\n \n~\nDelayed hemolytic transfusion reactions\nGeneral principles\n \n~\nAcute transfusion reactions (ATRs) may occur in 1-2% of \ntransfused patients. \n \n~\nRapid recognition and management of transfusion reac\u00ad\ntions may save the patient\u2019s life\nKey points\n \n~\nAccurate patient identification \u2013 at bed side, is critical \nduring;\n \n\u0083 Blood sample collection\n \n\u0083 Administration of blood \n \n~\nMonitoring transfusion is only way to identify ATRs\n \n~\nMonitoring transfusion is performed by taking vital \nsigns; before, 15 minutes into, whenever a reaction is \nsuspected, and at the end of transfusion",
        "formatted_content": "<p>596</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0089</p>\n<p>Minor allergic reaction (Urticaria)</p>\n<p>\u0089</p>\n<p>Febrile non-haemolytic transfusion reaction</p>\n<p>\u0089</p>\n<p>Acute haemolytic transfusion reaction (caused by ABO incompat\u00ad</p>\n<p>ibility): is a severe, and life threatening reaction</p>\n<p>\u0089</p>\n<p>Bacterial contamination</p>\n<p>\u0089</p>\n<p>Transfusion-associated circulatory overload (TACO)</p>\n<p>\u0089</p>\n<p>Transfusion-related acute lung injury (TRALI)</p>\n<p>\u0089</p>\n<p>Severe allergic (Anaphylactic) reaction; relatively rare</p>\n<p>Delayed Transfusion reactions</p>\n<p>~</p>\n<p>Transfusion-transmitted infections, e.g., HIV, Hepatitis B,</p>\n<p>and Hepatitis C</p>\n<p>~</p>\n<p>Delayed hemolytic transfusion reactions</p>\n<p>General principles</p>\n<p>~</p>\n<p>Acute transfusion reactions (ATRs) may occur in 1-2% of</p>\n<p>transfused patients.</p>\n<p>~</p>\n<p>Rapid recognition and management of transfusion reac\u00ad</p>\n<p>tions may save the patient\u2019s life</p>\n<p>Key points</p>\n<p>~</p>\n<p>Accurate patient identification \u2013 at bed side, is critical</p>\n<p>during;</p>\n<p>\u0083 Blood sample collection</p>\n<p>\u0083 Administration of blood</p>\n<p>~</p>\n<p>Monitoring transfusion is only way to identify ATRs</p>\n<p>~</p>\n<p>Monitoring transfusion is performed by taking vital</p>\n<p>signs; before, 15 minutes into, whenever a reaction is</p>\n<p>suspected, and at the end of transfusion</p>"
    },
    {
        "page_number": 663,
        "content": "597\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n \n~\nVital signs should always be taken (at a minimum) immedi\u00ad\nately prior to beginning the transfusion, 15 min after start \nand at end (see box with Key Points). In addition, a nurse \nor physician should observe the patient for the first 15 \nminutes after a new blood unit is started, and vital signs \nrecorded\n \n~\nErrors and failure to follow correct procedures are the \nmost common causes of life threatening acute haemolyt\u00ad\nic reactions. Such errors include; misidentification of pa\u00ad\ntients \u2013 resulting in administering the wrong blood unit to \nthe wrong patient, not repeating blood grouping of the \nblood units received at hospital, not cross-matching, and \nerrors in labeling blood samples for pre-transfusion group\u00ad\ning and cross-match. These errors must be avoided.\n \n~\nALWAYS store blood used for the compatibility testing for \n7 days at 2-8\u00b0C for possible investigation on transfusion \nreactions\n \n~\nIn a conscious patient with a severe acute haemolytic \ntransfusion reaction, signs/symptoms may appear within \nminutes of infusing only 5-10 mL of blood\n\t\n\u0089\nIn an unconscious or anaesthetised patient, hypotension, hypoxia \nand uncontrolled bleeding may be the only signs of a transfusion \nproblem. As such, taking vitals regularly is important.\nVital signs taken;\n \n\u0083 Temperature\n \n\u0083 BP\n \n\u0083 Respiratory rate\n \n\u0083 Pulse rate\n \n~\nAny unexpected change(s) in vitals = a possible ATR, \nuntil proved otherwise\nIf atransfusion reaction is suspected\n \n\u0081\nStop the transfusion, and remove the giving set. Prior to dis\u00ad\nconnecting, the unit must be closed to avoid reflux of patient \nblood into the donor blood",
        "formatted_content": "<p>597</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>~</p>\n<p>Vital signs should always be taken (at a minimum) immedi\u00ad</p>\n<p>ately prior to beginning the transfusion, 15 min after start</p>\n<p>and at end (see box with Key Points). In addition, a nurse</p>\n<p>or physician should observe the patient for the first 15</p>\n<p>minutes after a new blood unit is started, and vital signs</p>\n<p>recorded</p>\n<p>~</p>\n<p>Errors and failure to follow correct procedures are the</p>\n<p>most common causes of life threatening acute haemolyt\u00ad</p>\n<p>ic reactions. Such errors include; misidentification of pa\u00ad</p>\n<p>tients \u2013 resulting in administering the wrong blood unit to</p>\n<p>the wrong patient, not repeating blood grouping of the</p>\n<p>blood units received at hospital, not cross-matching, and</p>\n<p>errors in labeling blood samples for pre-transfusion group\u00ad</p>\n<p>ing and cross-match. These errors must be avoided.</p>\n<p>~</p>\n<p>ALWAYS store blood used for the compatibility testing for</p>\n<p>7 days at 2-8\u00b0C for possible investigation on transfusion</p>\n<p>reactions</p>\n<p>~</p>\n<p>In a conscious patient with a severe acute haemolytic</p>\n<p>transfusion reaction, signs/symptoms may appear within</p>\n<p>minutes of infusing only 5-10 mL of blood</p>\n<p>\u0089</p>\n<p>In an unconscious or anaesthetised patient, hypotension, hypoxia</p>\n<p>and uncontrolled bleeding may be the only signs of a transfusion</p>\n<p>problem. As such, taking vitals regularly is important.</p>\n<p>Vital signs taken;</p>\n<p>\u0083 Temperature</p>\n<h3>\u0083 BP</h3>\n<p>\u0083 Respiratory rate</p>\n<p>\u0083 Pulse rate</p>\n<p>~</p>\n<p>Any unexpected change(s) in vitals = a possible ATR,</p>\n<p>until proved otherwise</p>\n<p>If atransfusion reaction is suspected</p>\n<p>\u0081</p>\n<p>Stop the transfusion, and remove the giving set. Prior to dis\u00ad</p>\n<p>connecting, the unit must be closed to avoid reflux of patient</p>\n<p>blood into the donor blood</p>"
    },
    {
        "page_number": 664,
        "content": "598\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n \n\u0081\nCheck the blood pack labels and patient\u2019s identity. If there is a \ndiscrepancy, consult the blood bank\n \n\u0081\nEvaluate the patient; take vitals, and manage accordingly (See \ntable below)\n \n\u0081\nMaintain intravenous access\n \n\u0081\nObtain a post-transfusion blood sample. Return the implicated \nblood unit to the hospital blood bank. Re-grouping and testing \nare done on both patient and transfused samples\n \n\u0081\nImmediately report all suspected acute transfusion reactions to \nthe hospital blood bank laboratory that works with the clinician\n \n\u0081\nFor category two reactions, record the following in the patient\u2019s \nnotes: type of reaction, time reaction occurred from start of \ntransfusion, volume, type, and pack numbers of blood products \ntransfused\n \n\u0081\nThe type of reaction should be diagnosed, and a quick and \nclear investigation should be started in the hospital blood bank \nlaboratory\n11.2.3.1   Acute Transfusion Reactions \nOccurring within 24 hours of transfusion.",
        "formatted_content": "<p>598</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0081</p>\n<p>Check the blood pack labels and patient\u2019s identity. If there is a</p>\n<p>discrepancy, consult the blood bank</p>\n<p>\u0081</p>\n<p>Evaluate the patient; take vitals, and manage accordingly (See</p>\n<p>table below)</p>\n<p>\u0081</p>\n<p>Maintain intravenous access</p>\n<p>\u0081</p>\n<p>Obtain a post-transfusion blood sample. Return the implicated</p>\n<p>blood unit to the hospital blood bank. Re-grouping and testing</p>\n<p>are done on both patient and transfused samples</p>\n<p>\u0081</p>\n<p>Immediately report all suspected acute transfusion reactions to</p>\n<p>the hospital blood bank laboratory that works with the clinician</p>\n<p>\u0081</p>\n<p>For category two reactions, record the following in the patient\u2019s</p>\n<p>notes: type of reaction, time reaction occurred from start of</p>\n<p>transfusion, volume, type, and pack numbers of blood products</p>\n<p>transfused</p>\n<p>\u0081</p>\n<p>The type of reaction should be diagnosed, and a quick and</p>\n<p>clear investigation should be started in the hospital blood bank</p>\n<p>laboratory</p>\n<p>11.2.3.1   Acute Transfusion Reactions</p>\n<p>Occurring within 24 hours of transfusion.</p>"
    },
    {
        "page_number": 665,
        "content": "599\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nCATEGORY 1: MILD REACTIONs\nSIGNS AND SYMPTOMS\nPOSSIBLE CAUSES\nMANAGEMENT\n \n~\nLocalised \ncutaneous \nreactions, \ne.g. \nurticaria/\nhives, \nrash, \n \n~\nitching \n \n~\nWith no \nrespirato\u00ad\nry or oth\u00ad\ner signs/\nsymptoms\n \n~\nMild fever \n(<38.9\u00b0C),  \nwithout \nANY oth\u00ad\ner symp\u00ad\ntoms/\nsigns.\n \n~\nMinor \nallergic \nreac\u00ad\ntions, \ndue to \nhyper\u00ad\nsensitiv\u00ad\nity\n \n~\nFebrile \nnon-he\u00ad\nmolytic \ntransfu\u00ad\nsion re\u00ad\naction; \ndue to \ninflam\u00ad\nmatory \nre\u00ad\nsponse\n \n~\nTemporarily stop the transfusion\n \n~\nCheck vitals\n \n~\nGive antihistamine, e.g. prometh\u00ad\nazine 25-50 mg by deep IM or \nslow IV (Child 1-5 years: 5 mg by \ndeep IM Child 5-10 years: 6.25-\n12.5 mg by deep IM)\n \n~\nAlternatives: Oral cetirizine 10mg, \nloratidine 10mg (Child; half dose )\n \n~\nIf patient remains hemodynamical\u00ad\nly stable, then no cause for alarm\n \n~\nRestart transfusion slowly with \nclose monitoring\n \n~\nRe-assure patient.\n \n~\nTemporarily stop the transfusion\n \n~\nAdminister oral paracetamol; 15 \nmg/kg (adult: 1 g)\n \n~\nEvaluate the patient; take vitals\n \n~\nIf patient remains hemodynamical\u00ad\nly stable, then no cause for alarm\n \n~\nRestart transfusion slowly with \nclose monitoring\n \n~\nRe-assure patient.\nIf no clinical improvement within 30 minutes, or if condition worsens: treat as category 2, below",
        "formatted_content": "<p>599</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>CATEGORY 1: MILD REACTIONs</p>\n<h3>SIGNS AND SYMPTOMS</h3>\n<h3>POSSIBLE CAUSES</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Localised</p>\n<p>cutaneous</p>\n<p>reactions,</p>\n<p>e.g.</p>\n<p>urticaria/</p>\n<p>hives,</p>\n<p>rash,</p>\n<p>~</p>\n<p>itching</p>\n<p>~</p>\n<p>With no</p>\n<p>respirato\u00ad</p>\n<p>ry or oth\u00ad</p>\n<p>er signs/</p>\n<p>symptoms</p>\n<p>~</p>\n<p>Mild fever</p>\n<h3>(<38.9\u00b0C),</h3>\n<p>without</p>\n<p>ANY oth\u00ad</p>\n<p>er symp\u00ad</p>\n<p>toms/</p>\n<p>signs.</p>\n<p>~</p>\n<p>Minor</p>\n<p>allergic</p>\n<p>reac\u00ad</p>\n<p>tions,</p>\n<p>due to</p>\n<p>hyper\u00ad</p>\n<p>sensitiv\u00ad</p>\n<p>ity</p>\n<p>~</p>\n<p>Febrile</p>\n<p>non-he\u00ad</p>\n<p>molytic</p>\n<p>transfu\u00ad</p>\n<p>sion re\u00ad</p>\n<p>action;</p>\n<p>due to</p>\n<p>inflam\u00ad</p>\n<p>matory</p>\n<p>re\u00ad</p>\n<p>sponse</p>\n<p>~</p>\n<p>Temporarily stop the transfusion</p>\n<p>~</p>\n<p>Check vitals</p>\n<p>~</p>\n<p>Give antihistamine, e.g. prometh\u00ad</p>\n<p>azine 25-50 mg by deep IM or</p>\n<p>slow IV (Child 1-5 years: 5 mg by</p>\n<p>deep IM Child 5-10 years: 6.25-</p>\n<p>12.5 mg by deep IM)</p>\n<p>~</p>\n<p>Alternatives: Oral cetirizine 10mg,</p>\n<p>loratidine 10mg (Child; half dose )</p>\n<p>~</p>\n<p>If patient remains hemodynamical\u00ad</p>\n<p>ly stable, then no cause for alarm</p>\n<p>~</p>\n<p>Restart transfusion slowly with</p>\n<p>close monitoring</p>\n<p>~</p>\n<p>Re-assure patient.</p>\n<p>~</p>\n<p>Temporarily stop the transfusion</p>\n<p>~</p>\n<p>Administer oral paracetamol; 15</p>\n<p>mg/kg (adult: 1 g)</p>\n<p>~</p>\n<p>Evaluate the patient; take vitals</p>\n<p>~</p>\n<p>If patient remains hemodynamical\u00ad</p>\n<p>ly stable, then no cause for alarm</p>\n<p>~</p>\n<p>Restart transfusion slowly with</p>\n<p>close monitoring</p>\n<p>~</p>\n<p>Re-assure patient.</p>\n<p>If no clinical improvement within 30 minutes, or if condition worsens: treat as category 2, below</p>"
    },
    {
        "page_number": 666,
        "content": "600\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\nCategory 2: Severe And Life Threatening Reactions\nSigns And Symptoms\nPossible Causes\nManagement\n \n\u0083 Severe generalised \nrash\n \n\u0083 Airway edema \nand  obstruction \n(wheezing or \nstridor)\n \n\u0083 Hypoxia, and \nshock\n \n\u0083 Severe allergic\n \n\u0083 (anaphylaxis)      \nreaction\n \n\u0083 Stop the transfusion, and DO NOT \nre-start.\n \n\u0083 Evaluate the patient; take vitals\n \n\u0083 Notify the hospital blood bank.\n \n\u0083 Resuscitate patient, as appropriate.\n \n\u0083 Administer an anti-histamine, e.g., \npromethazine (i.v)  \n \n\u0083 Airway support, give oxygen \n \n\u0083 Give hydrocortisone 4 mg/\n \n\u0083 kg IV and\n \n\u0083 Salbutamol 2.5-5 mg nebulization\n \n\u0083 Stop the transfusion, and DO NOT \nre-start.\n \n\u0083 Evaluate the patient; take vitals\n \n\u0083 Fever (\u226539\u00b0C), \nrigors, chills\n \n\u0083 Nausea & \nvomiting, \ntachycardia, \n \n\u0083 Hypotension, \ndyspnea.\n \n\u0083 Any one of;\n \n\u0083 Acute hemolytic \ntransfusion \nreaction\n \n\u0083 Bacterial  \ncontamination\n \n\u0083 Notify the medical officer in charge \nand blood bank immediately \n \n\u0083 Resuscitate patient, as appropriate.\n \n\u0083 Maintain airway and give high flow \noxygen by mask\nCATEGORY 1: MILD REACTIONs\nSIGNS AND SYMPTOMS\nPOSSIBLE CAUSES\nMANAGEMENT",
        "formatted_content": "<p>600</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>Category 2: Severe And Life Threatening Reactions</p>\n<p>Signs And Symptoms</p>\n<p>Possible Causes</p>\n<p>Management</p>\n<p>\u0083 Severe generalised</p>\n<p>rash</p>\n<p>\u0083 Airway edema</p>\n<p>and  obstruction</p>\n<p>(wheezing or</p>\n<p>stridor)</p>\n<p>\u0083 Hypoxia, and</p>\n<p>shock</p>\n<p>\u0083 Severe allergic</p>\n<p>\u0083 (anaphylaxis)</p>\n<p>reaction</p>\n<p>\u0083 Stop the transfusion, and DO NOT</p>\n<p>re-start.</p>\n<p>\u0083 Evaluate the patient; take vitals</p>\n<p>\u0083 Notify the hospital blood bank.</p>\n<p>\u0083 Resuscitate patient, as appropriate.</p>\n<p>\u0083 Administer an anti-histamine, e.g.,</p>\n<p>promethazine (i.v)</p>\n<p>\u0083 Airway support, give oxygen</p>\n<p>\u0083 Give hydrocortisone 4 mg/</p>\n<p>\u0083 kg IV and</p>\n<p>\u0083 Salbutamol 2.5-5 mg nebulization</p>\n<p>\u0083 Stop the transfusion, and DO NOT</p>\n<p>re-start.</p>\n<p>\u0083 Evaluate the patient; take vitals</p>\n<p>\u0083 Fever (\u226539\u00b0C),</p>\n<p>rigors, chills</p>\n<p>\u0083 Nausea &</p>\n<p>vomiting,</p>\n<p>tachycardia,</p>\n<p>\u0083 Hypotension,</p>\n<p>dyspnea.</p>\n<p>\u0083 Any one of;</p>\n<p>\u0083 Acute hemolytic</p>\n<p>transfusion</p>\n<p>reaction</p>\n<p>\u0083 Bacterial</p>\n<p>contamination</p>\n<p>\u0083 Notify the medical officer in charge</p>\n<p>and blood bank immediately</p>\n<p>\u0083 Resuscitate patient, as appropriate.</p>\n<p>\u0083 Maintain airway and give high flow</p>\n<p>oxygen by mask</p>\n<p>CATEGORY 1: MILD REACTIONs</p>\n<h3>SIGNS AND SYMPTOMS</h3>\n<h3>POSSIBLE CAUSES</h3>\n<h3>MANAGEMENT</h3>"
    },
    {
        "page_number": 667,
        "content": "601\nUganda Clinical Guidelines 2023\nCHAPTER 11: Blood Diseases and Blood Transfusion Guidelines\n \n\u0083 Restlessness, \nanxiety\n \n\u0083 Hypotension (fall \nof >20% in systolic \nBP)\n \n\u0083 Hypertension\n \n\u0083 Tachycardia\n \n\u0083 Haemoglobinuria\n \n\u0083 Transfusion-\nassociated \ncirculatory \noverload (TACO)\n \n\u0083 Transfusion-\nrelated acute \nlung injury \n(TRALI) \n \n\u0083 I.V fluids; sodium chloride 0.9% \n20-30 mL/kg; bolus to maintain \nsystolic BP [withhold fluids ONLY if \nthere is hypertension instead]\n \n\u0083 Give a diuretic: Furosemide\n \n\u0083 1 mg/kg IV\n \n\u0083 For hypotension/shock; give \nadrenaline (epinephrine) injection; \n0.01 mg/kg slow IM\n \n\u0083 Unexplained \nbleeding (DIC)\n \n\u0083 Pain: in the chest, \nor near infusion \nsite, or in loin/\nback, headache\n \n\u0083 Respiratory \ndistress, shortness \nof breath, dyspoea\n \n\u0083 Send the blood bag with infusion \nset, a freshly collected urine, and \nnew blood samples (one clotted \nand one anti-coagulated) from the \nvein opposite infusion site, with \nappropriate request form to blood \nbank for laboratory investigations\n \n\u0083 Check fresh urine specimen for \nhaemoglobinuria\n \n\u0083 Start a 24\u2013hour urine collection and \nfluid balance chart, and record all \nintake and output\n \n\u0083 Maintain fluid balance\n \n\u0083 If signs/symptoms of sepsis, start \nbroad spectrum antibiotics\n \n\u0083 Refer for further management \nwhere necessary",
        "formatted_content": "<p>601</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 11: Blood Diseases and Blood Transfusion Guidelines</p>\n<p>\u0083 Restlessness,</p>\n<p>anxiety</p>\n<p>\u0083 Hypotension (fall</p>\n<p>of >20% in systolic</p>\n<h3>BP)</h3>\n<p>\u0083 Hypertension</p>\n<p>\u0083 Tachycardia</p>\n<p>\u0083 Haemoglobinuria</p>\n<p>\u0083 Transfusion-</p>\n<p>associated</p>\n<p>circulatory</p>\n<p>overload (TACO)</p>\n<p>\u0083 Transfusion-</p>\n<p>related acute</p>\n<p>lung injury</p>\n<h3>(TRALI)</h3>\n<p>\u0083 I.V fluids; sodium chloride 0.9%</p>\n<p>20-30 mL/kg; bolus to maintain</p>\n<p>systolic BP [withhold fluids ONLY if</p>\n<p>there is hypertension instead]</p>\n<p>\u0083 Give a diuretic: Furosemide</p>\n<p>\u0083 1 mg/kg IV</p>\n<p>\u0083 For hypotension/shock; give</p>\n<p>adrenaline (epinephrine) injection;</p>\n<p>0.01 mg/kg slow IM</p>\n<p>\u0083 Unexplained</p>\n<p>bleeding (DIC)</p>\n<p>\u0083 Pain: in the chest,</p>\n<p>or near infusion</p>\n<p>site, or in loin/</p>\n<p>back, headache</p>\n<p>\u0083 Respiratory</p>\n<p>distress, shortness</p>\n<p>of breath, dyspoea</p>\n<p>\u0083 Send the blood bag with infusion</p>\n<p>set, a freshly collected urine, and</p>\n<p>new blood samples (one clotted</p>\n<p>and one anti-coagulated) from the</p>\n<p>vein opposite infusion site, with</p>\n<p>appropriate request form to blood</p>\n<p>bank for laboratory investigations</p>\n<p>\u0083 Check fresh urine specimen for</p>\n<p>haemoglobinuria</p>\n<p>\u0083 Start a 24\u2013hour urine collection and</p>\n<p>fluid balance chart, and record all</p>\n<p>intake and output</p>\n<p>\u0083 Maintain fluid balance</p>\n<p>\u0083 If signs/symptoms of sepsis, start</p>\n<p>broad spectrum antibiotics</p>\n<p>\u0083 Refer for further management</p>\n<p>where necessary</p>"
    },
    {
        "page_number": 668,
        "content": "602\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nOncology\n12\n12.1 INTRODUCTION\nCancer is an unregulated growth of a previously normal set of body \ncells. Oncology is the study, diagnosis, and management of cancers or \ntumours. It is important to note that any organ or system as well as \nany individual can be\naffected by cancer. This section will outline major symptoms and signs \nof cancer, key population groups affected, ways to mitigate risk of cancer \nand provide an overview of common cancers in adults and children.\nCancer or malignant neoplasm is collective term for a group of more \nthan 100 diseases that result from abnormal / uncontrolled growth \nof body cells and is able to invade normal tissues and spread to other \nparts of the body. The uncontrolled growth causes a lump/ swelling \ncalled a tumours or neoplasm in many types of cancer or an abnormal \nnumber of abnormal cells in some types of cancer such as blood cancers \n(Leukaemia).  Tumours are broadly divided into benign tumors, meaning \nnon-cancerous / unable to metastasize (spread to other parts of the body) \nor malignant tumors (able to invade normal tissues / spread to other \nparts of the body). Cancers are classified by their type of cell, tissue, or \norgan of origin.  In Uganda, in 2020, it was estimated that there were \n34,008 new cancer cases, 22,992 cancer deaths, and 62,548 adults \nliving with cancer. The top five causes of cancer morbidity are cervix, \nKaposi sarcoma (KS), breast, prostate, and non-Hodgkin lymphoma. \nThe top five causes of cancer deaths are cancers of the cervix, KS, \nesophagus, liver, and non-Hodgkin lymphoma. In Uganda, children aged \n0 \u2013 14 years of age, constitute ten percent (10%) of cancer patients.\n12.1.1 Special Groups at Increased Risk of Cancer\n \n~\nHIV-positive patients\n \n~\nAlbinos\n \n~\nAge group >65 years",
        "formatted_content": "<p>602</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>Oncology</p>\n<p>12</p>\n<h3>12.1 INTRODUCTION</h3>\n<p>Cancer is an unregulated growth of a previously normal set of body</p>\n<p>cells. Oncology is the study, diagnosis, and management of cancers or</p>\n<p>tumours. It is important to note that any organ or system as well as</p>\n<p>any individual can be</p>\n<p>affected by cancer. This section will outline major symptoms and signs</p>\n<p>of cancer, key population groups affected, ways to mitigate risk of cancer</p>\n<p>and provide an overview of common cancers in adults and children.</p>\n<p>Cancer or malignant neoplasm is collective term for a group of more</p>\n<p>than 100 diseases that result from abnormal / uncontrolled growth</p>\n<p>of body cells and is able to invade normal tissues and spread to other</p>\n<p>parts of the body. The uncontrolled growth causes a lump/ swelling</p>\n<p>called a tumours or neoplasm in many types of cancer or an abnormal</p>\n<p>number of abnormal cells in some types of cancer such as blood cancers</p>\n<p>(Leukaemia).  Tumours are broadly divided into benign tumors, meaning</p>\n<p>non-cancerous / unable to metastasize (spread to other parts of the body)</p>\n<p>or malignant tumors (able to invade normal tissues / spread to other</p>\n<p>parts of the body). Cancers are classified by their type of cell, tissue, or</p>\n<p>organ of origin.  In Uganda, in 2020, it was estimated that there were</p>\n<p>34,008 new cancer cases, 22,992 cancer deaths, and 62,548 adults</p>\n<p>living with cancer. The top five causes of cancer morbidity are cervix,</p>\n<p>Kaposi sarcoma (KS), breast, prostate, and non-Hodgkin lymphoma.</p>\n<p>The top five causes of cancer deaths are cancers of the cervix, KS,</p>\n<p>esophagus, liver, and non-Hodgkin lymphoma. In Uganda, children aged</p>\n<p>0 \u2013 14 years of age, constitute ten percent (10%) of cancer patients.</p>\n<p>12.1.1 Special Groups at Increased Risk of Cancer</p>\n<p>~</p>\n<p>HIV-positive patients</p>\n<p>~</p>\n<p>Albinos</p>\n<p>~</p>\n<p>Age group >65 years</p>"
    },
    {
        "page_number": 669,
        "content": "603\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\n \n~\nWomen (breast and cervical)\n \n~\nSmokers\n \n~\nAlcoholics\n \n~\nConsistent occupational exposure to toxins and/or radio\u00ad\nactive material\nNote: Routine screening is recommended for these groups\n12.1.2 Early Signs and Symptoms\nCancer should be investigated in an individual with the following symp\u00ad\ntoms having occurred for >2 weeks:\n \n~\nSudden weight loss\n \n~\nPainless or painful swelling, lump, or thickening\n \n~\nSores that fail to heal\nHoarseness or cough\n \n~\nAbnormal bleeding or discharge\n \n~\nPersistent indigestion or difficulty in swallowing\n \n~\nChange in normal bowel or bladder habits\n \n~\nChronic ulcers\n \n~\nChronic pain\n \n~\nChange in a skin wart or mole\n12.1.2.1 Urgent Signs and Symptoms\nCommon Signs and Symptoms of Cancer\nHealth workers should inform clients / communities that don\u2019t wait \nfor signs and symptoms of cancer. In most types of cancer, signs and \nsymptoms manifest when the disease is advancing or in late stage. Each",
        "formatted_content": "<p>603</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>~</p>\n<p>Women (breast and cervical)</p>\n<p>~</p>\n<p>Smokers</p>\n<p>~</p>\n<p>Alcoholics</p>\n<p>~</p>\n<p>Consistent occupational exposure to toxins and/or radio\u00ad</p>\n<p>active material</p>\n<p>Note: Routine screening is recommended for these groups</p>\n<p>12.1.2 Early Signs and Symptoms</p>\n<p>Cancer should be investigated in an individual with the following symp\u00ad</p>\n<p>toms having occurred for >2 weeks:</p>\n<p>~</p>\n<p>Sudden weight loss</p>\n<p>~</p>\n<p>Painless or painful swelling, lump, or thickening</p>\n<p>~</p>\n<p>Sores that fail to heal</p>\n<p>Hoarseness or cough</p>\n<p>~</p>\n<p>Abnormal bleeding or discharge</p>\n<p>~</p>\n<p>Persistent indigestion or difficulty in swallowing</p>\n<p>~</p>\n<p>Change in normal bowel or bladder habits</p>\n<p>~</p>\n<p>Chronic ulcers</p>\n<p>~</p>\n<p>Chronic pain</p>\n<p>~</p>\n<p>Change in a skin wart or mole</p>\n<p>12.1.2.1 Urgent Signs and Symptoms</p>\n<p>Common Signs and Symptoms of Cancer</p>\n<p>Health workers should inform clients / communities that don\u2019t wait</p>\n<p>for signs and symptoms of cancer. In most types of cancer, signs and</p>\n<p>symptoms manifest when the disease is advancing or in late stage. Each</p>"
    },
    {
        "page_number": 670,
        "content": "604\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\ntype of cancer manifest with unique signs and symptoms. However, \nmany cancer patients report having experienced / noticed some symp\u00ad\ntoms or signs weeks/ months / years earlier before they felt very sick.\nCancer should be investigated in an individual with the following com\u00ad\nmon signs and symptoms of cancer, especially when having occurred \nfor >2 weeks:\n \n\u0083 Sudden unexplained weight loss\n \n\u0083 Painless or painful swelling, lump, or thickening\n \n\u0083 Sores that fail to heal.\n \n\u0083 Hoarseness or cough\n \n\u0083 Abnormal bleeding or discharge\n \n\u0083 Persistent indigestion or difficulty in swallowing\n \n\u0083 Change in normal bowel or bladder habits\n \n\u0083 Chronic ulcers\n \n\u0083 Chronic pain\n \n\u0083 Change in a skin wart or mole\nUrgent referral for a possible cancer malignancy might be necessary in \npatients with any of the following:\nBODY PART\nSIGNS AND SYMPTOMS\nHaematological Neutropenia, anaemia, infection, bleeding, hyper\u00ad\nviscosity, leukocytosis\n>50 x 106\nLung (excluding \nTB)\nCoughing blood, superior vena cava obstruction\nUpper GI Tract\nChronic GI bleeding and bowel habit changes, dys\u00ad\nphagia, persistent vomiting, unexplained pain and\nweight loss, abdominal mass without dyspepsia, \nobstructive jaundice\nLower GI Tract\nBleeding and bowel habit changes, palpable rectal \nmass, unexplained iron deficiency anaemia",
        "formatted_content": "<p>604</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>type of cancer manifest with unique signs and symptoms. However,</p>\n<p>many cancer patients report having experienced / noticed some symp\u00ad</p>\n<p>toms or signs weeks/ months / years earlier before they felt very sick.</p>\n<p>Cancer should be investigated in an individual with the following com\u00ad</p>\n<p>mon signs and symptoms of cancer, especially when having occurred</p>\n<p>for >2 weeks:</p>\n<p>\u0083 Sudden unexplained weight loss</p>\n<p>\u0083 Painless or painful swelling, lump, or thickening</p>\n<p>\u0083 Sores that fail to heal.</p>\n<p>\u0083 Hoarseness or cough</p>\n<p>\u0083 Abnormal bleeding or discharge</p>\n<p>\u0083 Persistent indigestion or difficulty in swallowing</p>\n<p>\u0083 Change in normal bowel or bladder habits</p>\n<p>\u0083 Chronic ulcers</p>\n<p>\u0083 Chronic pain</p>\n<p>\u0083 Change in a skin wart or mole</p>\n<p>Urgent referral for a possible cancer malignancy might be necessary in</p>\n<p>patients with any of the following:</p>\n<h3>BODY PART</h3>\n<h3>SIGNS AND SYMPTOMS</h3>\n<p>Haematological Neutropenia, anaemia, infection, bleeding, hyper\u00ad</p>\n<p>viscosity, leukocytosis</p>\n<p>>50 x 106</p>\n<p>Lung (excluding</p>\n<h3>TB)</h3>\n<p>Coughing blood, superior vena cava obstruction</p>\n<p>Upper GI Tract</p>\n<p>Chronic GI bleeding and bowel habit changes, dys\u00ad</p>\n<p>phagia, persistent vomiting, unexplained pain and</p>\n<p>weight loss, abdominal mass without dyspepsia,</p>\n<p>obstructive jaundice</p>\n<p>Lower GI Tract</p>\n<p>Bleeding and bowel habit changes, palpable rectal</p>\n<p>mass, unexplained iron deficiency anaemia</p>"
    },
    {
        "page_number": 671,
        "content": "605\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nBODY PART\nSIGNS AND SYMPTOMS\nBreast\nDiscrete hard lump with fixation, eczematous skin \nand nipple changes, unilateral nipple discharge, \nGynaecological\nPostmenopausal bleeding, persistent intramenstrual \nbleeding, vulval lump and bleeding\nUrological\nHard irregular prostate, urinary symptoms, macro\u00ad\nscopic haematuria, swelling or mass in testes, or \nany abdominal mass along urological tract\nCentral Nervous \nSystem\nProgressive neurological deficit, new onset seizures, \nheadaches, mental changes, unilateral deafness, and \nsigns of raised intracranial pressure (e.g., vomiting, \ndrowsiness, posture-related headache, tinnitus, and \nother CNS symptoms)\n12.2 Prevention of Cancer\nCancer prevention means activities or actions directed at avoiding, \nreducing, eliminating, or eradicating the risk of developing cancer or \nthe impact of cancer on individuals and populations to promote health.\nApproximately 40% of cancers are preventable through interventions \nsuch as prevention of oncogenic infections (HPV, HIV, HBV, etc), \nalcohol, tobacco, and, environmental controls, promotion of healthy \ndiets, and physical activity.\nPrevention offers the most cost-effective long-term strategy for \ncontrol of cancer.\nHealth workers are responsible for educating the public on:\n \n~\nPrimary Prevention \u2013 sustained action to prevent a cancer\u00ad\nous process from developing through risk factor reduction\n \n~\nSecondary Prevention \u2013 active discovery and control of \ncancerous or pre-cancerous lesions\n12.2.1 Primary Prevention \nPrevention of cancer includes activities or actions directed at avoiding, \nreducing, eliminating, or eradicating the risk of developing cancer prior \nto the onset of cancer.",
        "formatted_content": "<p>605</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>BODY PART</h3>\n<h3>SIGNS AND SYMPTOMS</h3>\n<p>Breast</p>\n<p>Discrete hard lump with fixation, eczematous skin</p>\n<p>and nipple changes, unilateral nipple discharge,</p>\n<p>Gynaecological</p>\n<p>Postmenopausal bleeding, persistent intramenstrual</p>\n<p>bleeding, vulval lump and bleeding</p>\n<p>Urological</p>\n<p>Hard irregular prostate, urinary symptoms, macro\u00ad</p>\n<p>scopic haematuria, swelling or mass in testes, or</p>\n<p>any abdominal mass along urological tract</p>\n<p>Central Nervous</p>\n<p>System</p>\n<p>Progressive neurological deficit, new onset seizures,</p>\n<p>headaches, mental changes, unilateral deafness, and</p>\n<p>signs of raised intracranial pressure (e.g., vomiting,</p>\n<p>drowsiness, posture-related headache, tinnitus, and</p>\n<p>other CNS symptoms)</p>\n<p>12.2 Prevention of Cancer</p>\n<p>Cancer prevention means activities or actions directed at avoiding,</p>\n<p>reducing, eliminating, or eradicating the risk of developing cancer or</p>\n<p>the impact of cancer on individuals and populations to promote health.</p>\n<p>Approximately 40% of cancers are preventable through interventions</p>\n<p>such as prevention of oncogenic infections (HPV, HIV, HBV, etc),</p>\n<p>alcohol, tobacco, and, environmental controls, promotion of healthy</p>\n<p>diets, and physical activity.</p>\n<p>Prevention offers the most cost-effective long-term strategy for</p>\n<p>control of cancer.</p>\n<p>Health workers are responsible for educating the public on:</p>\n<p>~</p>\n<p>Primary Prevention \u2013 sustained action to prevent a cancer\u00ad</p>\n<p>ous process from developing through risk factor reduction</p>\n<p>~</p>\n<p>Secondary Prevention \u2013 active discovery and control of</p>\n<p>cancerous or pre-cancerous lesions</p>\n<p>12.2.1 Primary Prevention</p>\n<p>Prevention of cancer includes activities or actions directed at avoiding,</p>\n<p>reducing, eliminating, or eradicating the risk of developing cancer prior</p>\n<p>to the onset of cancer.</p>"
    },
    {
        "page_number": 672,
        "content": "606\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nPrimary prevention gives control to the individual in maintaining a \nhealthy lifestyle and environment to avoid or reduce cancer risk.\n12.2.1.1 Control of Risk Factors\nSmoking/Tobacco Use\n \n\u0083 Tobacco use increases the risk of several types of cancer, \nespecially cancer of the lungs, oesophagus, larynx, mouth, \nthroat, kidney, bladder, pancreas, stomach, and cervix\n \n\u0083 Health workers must educate patients / clients / communities \non the dangers of tobacco consumption and smoking; patients \nshould be advised to avoid tobacco use. For patients /clients \nwho smoke or use tobacco in any other form, health workers \nmust encourage and support them to stop tobacco use.\n Unhealthy Diet \nConsumption of unhealthy (unbalanced diet, sweetened food and bever\u00ad\nages, charred, and unhygienic food) increases the risk of several types \nof cancer, especially cancer of the colon and rectum, mouth, pharynx, \nand larynx, corpus uteri, breast, kidney, liver, pancreas, esophagus, \nthyroid, prostate, multiple myeloma, and gallbladder. \n \n\u0083 Health workers must educate patients / clients / communities \nto:\n \n\u0083 balance their diet with various types of healthy foods,\n \n\u0083 eat plenty of healthy food such as whole grains, pulses, fruits, \nand vegetables, \n \n\u0083 limit food high in sugar or fat and avoid sugary drinks,\n \n\u0083 limit the amount of salt intake,\n \n\u0083 limit eating red meat and avoid eating processed meat,\n \n\u0083 avoid eating burnt or charred food.\nOverweight and Obesity \nBeing overweight or obese increases the risk of cancer, specifically \nthe oesophageal, colorectal, breast, endometrial, and kidney cancers.",
        "formatted_content": "<p>606</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>Primary prevention gives control to the individual in maintaining a</p>\n<p>healthy lifestyle and environment to avoid or reduce cancer risk.</p>\n<p>12.2.1.1 Control of Risk Factors</p>\n<p>Smoking/Tobacco Use</p>\n<p>\u0083 Tobacco use increases the risk of several types of cancer,</p>\n<p>especially cancer of the lungs, oesophagus, larynx, mouth,</p>\n<p>throat, kidney, bladder, pancreas, stomach, and cervix</p>\n<p>\u0083 Health workers must educate patients / clients / communities</p>\n<p>on the dangers of tobacco consumption and smoking; patients</p>\n<p>should be advised to avoid tobacco use. For patients /clients</p>\n<p>who smoke or use tobacco in any other form, health workers</p>\n<p>must encourage and support them to stop tobacco use.</p>\n<p>Unhealthy Diet</p>\n<p>Consumption of unhealthy (unbalanced diet, sweetened food and bever\u00ad</p>\n<p>ages, charred, and unhygienic food) increases the risk of several types</p>\n<p>of cancer, especially cancer of the colon and rectum, mouth, pharynx,</p>\n<p>and larynx, corpus uteri, breast, kidney, liver, pancreas, esophagus,</p>\n<p>thyroid, prostate, multiple myeloma, and gallbladder.</p>\n<p>\u0083 Health workers must educate patients / clients / communities</p>\n<p>to:</p>\n<p>\u0083 balance their diet with various types of healthy foods,</p>\n<p>\u0083 eat plenty of healthy food such as whole grains, pulses, fruits,</p>\n<p>and vegetables,</p>\n<p>\u0083 limit food high in sugar or fat and avoid sugary drinks,</p>\n<p>\u0083 limit the amount of salt intake,</p>\n<p>\u0083 limit eating red meat and avoid eating processed meat,</p>\n<p>\u0083 avoid eating burnt or charred food.</p>\n<p>Overweight and Obesity</p>\n<p>Being overweight or obese increases the risk of cancer, specifically</p>\n<p>the oesophageal, colorectal, breast, endometrial, and kidney cancers.</p>"
    },
    {
        "page_number": 673,
        "content": "607\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nHeath workers must advise patients to maintain a healthy lifestyle, \nespecially, regular physical activity and a healthy diet.\nAlso, inform them to maintain their body weight within the healthy range. \nPhysical inactivity\nSedentary lifestyle increases the risk of colon, endometrial, bladder, \nbreast, lung, esophageal adenocarcinoma, renal, and gastric cancers.\nHeath workers must advise patients / clients to be physically active in \neveryday life. Limit the time you spend sitting and engage in at least \n30 minutes of regularly physical activity per day or on most days of \nthe week.\nAlcohol Use\nExcess consumption of alcohol increases the risk of cancer of the oral \ncavity, oesophagus, larynx, liver, colorectal, and breast.\nHealth workers should educate patients / clients/ communities of the \ndangers of excessive and regular alcohol consumption.  The key messages \nshould include: Not drinking alcohol is better for cancer prevention. If \nyou drink alcohol of any type, limit your intake.\nEnvironmental Pollution\nRegular exposure to carcinogenic chemicals in the environment can occur \nthrough unsafe drinking water, air pollution, and food contaminated \nby aflatoxin or dioxin chemicals, occupational exposure to dangerous \ngases or dusts.\nEnvironmental carcinogens (aflatoxins, asbestos, vehicle emissions, \nlead, ultraviolet light, and ionizing radiation) will lead to increased risk \nof developing cancer, e.g. lung cancer\nHealth workers must educate patients on environmental dangers and \nprovide suggestions to limit exposure such as:\n \n\u0083 Limiting indoor air pollution due to smoke from use of charcoal",
        "formatted_content": "<p>607</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>Heath workers must advise patients to maintain a healthy lifestyle,</p>\n<p>especially, regular physical activity and a healthy diet.</p>\n<p>Also, inform them to maintain their body weight within the healthy range.</p>\n<p>Physical inactivity</p>\n<p>Sedentary lifestyle increases the risk of colon, endometrial, bladder,</p>\n<p>breast, lung, esophageal adenocarcinoma, renal, and gastric cancers.</p>\n<p>Heath workers must advise patients / clients to be physically active in</p>\n<p>everyday life. Limit the time you spend sitting and engage in at least</p>\n<p>30 minutes of regularly physical activity per day or on most days of</p>\n<p>the week.</p>\n<p>Alcohol Use</p>\n<p>Excess consumption of alcohol increases the risk of cancer of the oral</p>\n<p>cavity, oesophagus, larynx, liver, colorectal, and breast.</p>\n<p>Health workers should educate patients / clients/ communities of the</p>\n<p>dangers of excessive and regular alcohol consumption.  The key messages</p>\n<p>should include: Not drinking alcohol is better for cancer prevention. If</p>\n<p>you drink alcohol of any type, limit your intake.</p>\n<p>Environmental Pollution</p>\n<p>Regular exposure to carcinogenic chemicals in the environment can occur</p>\n<p>through unsafe drinking water, air pollution, and food contaminated</p>\n<p>by aflatoxin or dioxin chemicals, occupational exposure to dangerous</p>\n<p>gases or dusts.</p>\n<p>Environmental carcinogens (aflatoxins, asbestos, vehicle emissions,</p>\n<p>lead, ultraviolet light, and ionizing radiation) will lead to increased risk</p>\n<p>of developing cancer, e.g. lung cancer</p>\n<p>Health workers must educate patients on environmental dangers and</p>\n<p>provide suggestions to limit exposure such as:</p>\n<p>\u0083 Limiting indoor air pollution due to smoke from use of charcoal</p>"
    },
    {
        "page_number": 674,
        "content": "608\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nand firewood inside a poorly ventilated house\n \n\u0083 Avoiding fumes from cars\n \n\u0083 Avoiding exposure to garbage pollution (burning rubbish)\n \n\u0083 Employers should provide employees with a safe working \nenvironment with limited occupational hazards\nOncogenic Infections\nThe following infections are associated with causing certain types of \ncancer:\n \n\u0083 Viral Hepatitis B/C: cancer of the liver\n \n\u0083 Human Papilloma Virus (HPV): cervical, oral, anal, and cancer\n \n\u0083 Helicobacter Pylori: Gastric (stomach) cancer\n \n\u0083 HIV/AIDS: aggressive lymphoma subtypes, Kaposi\u2019s sarcoma, \nanorectal cancer, cervical cancer, etc.\n \n\u0083 Schistosomiasis: increases risk of bladder cancer\n \n\u0083 Liver Fluke: increases risk of cholangio-carcinoma\n \n\u0083 Preventative measures to control oncogenic infection risk \ninclude   vaccination, and prevention/treatment of infection \nand    infestation:\n \n\u0083 Engage in safe sexual behaviour to avoid sexually transmitted \ndiseases that can cause or increase the risk of certain types of \ncancer such as cervical, Kaposi sarcoma, lymphoma, and liver \ncancers.\n \n\u0083 HPV Vaccination: vaccinate all girls aged 10 years with 2 doses \nof HPV vaccine (for detail see section 18 on immunization)\n \n\u0083 Hepatitis B Vaccination: routinely offered in the national \nchildhood schedule and populations at risk, in order to prevent \ninfection with hepatitis B, the main risk factor for liver cancer \n(for detail see section 18 on immunization)\n \n\u0083 Treatment of HIV/AIDS, schistosomiasis, H. pylori, and \nhepatitis B&C and other infections is also a preventive measure.\nRadiation\n \n~\nUltraviolet (UV) radiation, and in particular solar radiation, \nis carcinogenic to humans, causing all major types of skin \ncancer, such as basal cell carcinoma, squamous cell carci\u00ad\nnoma and melanoma\n \n\u0083 People with albinism are at a much higher risk of skin cancer \nand health workers should encourage them to wear protective \nclothing and wide brimmed hats",
        "formatted_content": "<p>608</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>and firewood inside a poorly ventilated house</p>\n<p>\u0083 Avoiding fumes from cars</p>\n<p>\u0083 Avoiding exposure to garbage pollution (burning rubbish)</p>\n<p>\u0083 Employers should provide employees with a safe working</p>\n<p>environment with limited occupational hazards</p>\n<p>Oncogenic Infections</p>\n<p>The following infections are associated with causing certain types of</p>\n<p>cancer:</p>\n<p>\u0083 Viral Hepatitis B/C: cancer of the liver</p>\n<p>\u0083 Human Papilloma Virus (HPV): cervical, oral, anal, and cancer</p>\n<p>\u0083 Helicobacter Pylori: Gastric (stomach) cancer</p>\n<p>\u0083 HIV/AIDS: aggressive lymphoma subtypes, Kaposi\u2019s sarcoma,</p>\n<p>anorectal cancer, cervical cancer, etc.</p>\n<p>\u0083 Schistosomiasis: increases risk of bladder cancer</p>\n<p>\u0083 Liver Fluke: increases risk of cholangio-carcinoma</p>\n<p>\u0083 Preventative measures to control oncogenic infection risk</p>\n<p>include   vaccination, and prevention/treatment of infection</p>\n<p>and    infestation:</p>\n<p>\u0083 Engage in safe sexual behaviour to avoid sexually transmitted</p>\n<p>diseases that can cause or increase the risk of certain types of</p>\n<p>cancer such as cervical, Kaposi sarcoma, lymphoma, and liver</p>\n<p>cancers.</p>\n<p>\u0083 HPV Vaccination: vaccinate all girls aged 10 years with 2 doses</p>\n<p>of HPV vaccine (for detail see section 18 on immunization)</p>\n<p>\u0083 Hepatitis B Vaccination: routinely offered in the national</p>\n<p>childhood schedule and populations at risk, in order to prevent</p>\n<p>infection with hepatitis B, the main risk factor for liver cancer</p>\n<p>(for detail see section 18 on immunization)</p>\n<p>\u0083 Treatment of HIV/AIDS, schistosomiasis, H. pylori, and</p>\n<p>hepatitis B&C and other infections is also a preventive measure.</p>\n<p>Radiation</p>\n<p>~</p>\n<p>Ultraviolet (UV) radiation, and in particular solar radiation,</p>\n<p>is carcinogenic to humans, causing all major types of skin</p>\n<p>cancer, such as basal cell carcinoma, squamous cell carci\u00ad</p>\n<p>noma and melanoma</p>\n<p>\u0083 People with albinism are at a much higher risk of skin cancer</p>\n<p>and health workers should encourage them to wear protective</p>\n<p>clothing and wide brimmed hats</p>"
    },
    {
        "page_number": 675,
        "content": "609\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\n \n~\nIonizing radiation from radioactive isotopes (used in med\u00ad\nical diagnostics and treatment) is also associated with leu\u00ad\nkaemia and other solid tissue tumours. Proper disposal of \nhighly radioactive isotopes is mandatory to prevent haz\u00ad\nardous exposures\nPrevention of Infections\nThe following infections are associated with causing certain types of \ncancer:\n \n~\nViral Hepatitis B/C: cancer of the liver\n \n~\nHuman Papilloma Virus (HPV): cervical cancer\n \n~\nHelicobacter Pylori: stomach cancer\nHIV/AIDS: aggressive lymphoma subtypes, Kaposi\u2019s sarcoma, anorectal \ncancer, cervical cancer, etc\n \n~\nSchistosomiasis: increases risk of bladder cancer\n \n~\nLiver Fluke: increases risk of cholangio-carcinoma\n \n~\nPreventative measures to control infection risk include \nvaccination, and prevention/treatment of infection and \ninfestation:\n \n~\nHPV Vaccination: immunize all girls from age 10 with 2 \ndoses of HPV vaccine (see section 18.1)\n \n~\nHepatitis B Vaccination: routinely offered in the national \nchildhood schedule and populations at risk, in order to \nprevent infection with hepatitis B, the main risk factor for \nliver cancer (see section 18.2.2)\n \n~\nTreatment of HIV/AIDS, schistosomiasis, H. pylori, and \nhepatitis B&C and other infections is also a preventive \nmeasure\n12.2.2 Secondary Prevention\nSecondary prevention of cancer includes activities or actions directed \nat halting the progress of cancer at its incipient stage through screen\u00ad",
        "formatted_content": "<p>609</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>~</p>\n<p>Ionizing radiation from radioactive isotopes (used in med\u00ad</p>\n<p>ical diagnostics and treatment) is also associated with leu\u00ad</p>\n<p>kaemia and other solid tissue tumours. Proper disposal of</p>\n<p>highly radioactive isotopes is mandatory to prevent haz\u00ad</p>\n<p>ardous exposures</p>\n<p>Prevention of Infections</p>\n<p>The following infections are associated with causing certain types of</p>\n<p>cancer:</p>\n<p>~</p>\n<p>Viral Hepatitis B/C: cancer of the liver</p>\n<p>~</p>\n<p>Human Papilloma Virus (HPV): cervical cancer</p>\n<p>~</p>\n<p>Helicobacter Pylori: stomach cancer</p>\n<p>HIV/AIDS: aggressive lymphoma subtypes, Kaposi\u2019s sarcoma, anorectal</p>\n<p>cancer, cervical cancer, etc</p>\n<p>~</p>\n<p>Schistosomiasis: increases risk of bladder cancer</p>\n<p>~</p>\n<p>Liver Fluke: increases risk of cholangio-carcinoma</p>\n<p>~</p>\n<p>Preventative measures to control infection risk include</p>\n<p>vaccination, and prevention/treatment of infection and</p>\n<p>infestation:</p>\n<p>~</p>\n<p>HPV Vaccination: immunize all girls from age 10 with 2</p>\n<p>doses of HPV vaccine (see section 18.1)</p>\n<p>~</p>\n<p>Hepatitis B Vaccination: routinely offered in the national</p>\n<p>childhood schedule and populations at risk, in order to</p>\n<p>prevent infection with hepatitis B, the main risk factor for</p>\n<p>liver cancer (see section 18.2.2)</p>\n<p>~</p>\n<p>Treatment of HIV/AIDS, schistosomiasis, H. pylori, and</p>\n<p>hepatitis B&C and other infections is also a preventive</p>\n<p>measure</p>\n<p>12.2.2 Secondary Prevention</p>\n<p>Secondary prevention of cancer includes activities or actions directed</p>\n<p>at halting the progress of cancer at its incipient stage through screen\u00ad</p>"
    },
    {
        "page_number": 676,
        "content": "610\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\ning, early diagnosis, pre-cancer treatment or cancer management, and \nreferral to avoid or reduce complications associated with the cancer. \nSecondary prevention strategies relate to the discovery and control of \ncancerous or pre-cancerous lesions.\nEarly detection of cancer greatly increases the chances for successful \ntreatment and cure. It comprises of:\n \n~\nEarly diagnosis in symptomatic populations\n \n~\nScreening in asymptomatic high-risk populations\nScreening refers to the use of simple tests across a healthy population \nin order to identify individuals who have disease, but do not yet have \nsymptoms.\nBased on existing evidence, mass population screening is advocated for \nbreast and cervical cancer. Other cancers that are commonly screened \nfor include prostate and colorectal cancers\nScreening for Breast Cancer\nScreening / health checkup for breast cancer involves:\nBreast Self-Examination (BSE): a simple, quick examination done by the \nclient herself, aimed at early detection of lumps. Regular (monthly-not \nduring menstruation, at least seven days after ending the menstruation) \nand correct technique of breast examination is important and easy to \nteach and administer. Health workers should note that BSE is not a \nstandard screening test for breast cancer, but is beneficial for breast \nhealth awareness.\nClinical Breast Examination (CBE): performed by a trained and skilled \nhealth care provider from HC3\n \n\u0083 Take a detailed history and conduct a physical\n \n\u0083 examination\n \n\u0083 All breast quadrants must be examined in detail plus the \narmpits for lymph nodes\n \n\u0083 Inspect the skin for changes and swellings, for tethering of",
        "formatted_content": "<p>610</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>ing, early diagnosis, pre-cancer treatment or cancer management, and</p>\n<p>referral to avoid or reduce complications associated with the cancer.</p>\n<p>Secondary prevention strategies relate to the discovery and control of</p>\n<p>cancerous or pre-cancerous lesions.</p>\n<p>Early detection of cancer greatly increases the chances for successful</p>\n<p>treatment and cure. It comprises of:</p>\n<p>~</p>\n<p>Early diagnosis in symptomatic populations</p>\n<p>~</p>\n<p>Screening in asymptomatic high-risk populations</p>\n<p>Screening refers to the use of simple tests across a healthy population</p>\n<p>in order to identify individuals who have disease, but do not yet have</p>\n<p>symptoms.</p>\n<p>Based on existing evidence, mass population screening is advocated for</p>\n<p>breast and cervical cancer. Other cancers that are commonly screened</p>\n<p>for include prostate and colorectal cancers</p>\n<p>Screening for Breast Cancer</p>\n<p>Screening / health checkup for breast cancer involves:</p>\n<p>Breast Self-Examination (BSE): a simple, quick examination done by the</p>\n<p>client herself, aimed at early detection of lumps. Regular (monthly-not</p>\n<p>during menstruation, at least seven days after ending the menstruation)</p>\n<p>and correct technique of breast examination is important and easy to</p>\n<p>teach and administer. Health workers should note that BSE is not a</p>\n<p>standard screening test for breast cancer, but is beneficial for breast</p>\n<p>health awareness.</p>\n<p>Clinical Breast Examination (CBE): performed by a trained and skilled</p>\n<p>health care provider from HC3</p>\n<p>\u0083 Take a detailed history and conduct a physical</p>\n<p>\u0083 examination</p>\n<p>\u0083 All breast quadrants must be examined in detail plus the</p>\n<p>armpits for lymph nodes</p>\n<p>\u0083 Inspect the skin for changes and swellings, for tethering of</p>"
    },
    {
        "page_number": 677,
        "content": "611\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\n \n\u0083 the breast on the chest wall, palpate for lumps, check for \nnipple discharge\n \n\u0083 A suspicious lump or bloody nipple discharge MUST    \nBE REFERRED for evaluation by mammography or \nultrasonography as well as core needle biopsy\nMammography: a low-dose x-ray of the breast is the test of choice \nfor screening of early breast cancer but it is available only at national \nreferral hospital level.\nBreast Ultrasound: not used as a screening test, but is useful as an \nadditional tool in characterizing palpable tumors and taking of im\u00ad\nage-directed biopsies. It may be used as a screening tool in lactating \nwomen, small- breasted women and in males, and as diagnostic tests in \nsymptomatic patients.\nScreening for Cervical Cancer\nThis aims to detect pre-cancerous lesions that are then treated to prevent \nprogression to invasive cancer. The following methods are recommended:\nVisual Inspection with Acetic Acid (VIA): involves applying 3-5% freshly \nprepared acetic acid to the cervix and observing results after one minute.\n \n\u0083 The VIA results are generally categorized into 3 subsets: \nsuspicious for cancer, VIA negative and VIA positive\n \n\u0083 It uses readily available equipment, does not require a\n \n\u0083 laboratory and provides an immediate result.\n \n\u0083 Positive cases can be treated with cryotherapy by adequately \ntrained providers.\nConsider the following if using VIA as a screening method:\n \n\u0083 Women <25 years of age should be screened only if they are \nat high risk for disease: HIV positive, early sexual exposure, \nmultiple partners, previous abnormal screening results, cervical \nintraepithelial neoplasia (CIN)\n \n\u0083 VIA is not appropriate for women >50 years\n \n\u0083 Screening is advised every 3-5 years in case of normal results, \nbut after 1 years in case of abnormal results and treatment \n(cryotherapy) nd every year in HIV positive women.\n \n\u0083 Visual Inspection with Lugol\u2019s Iodine (VILI): it involves looking \nat the cervix with the naked eye or low magnification after",
        "formatted_content": "<p>611</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>\u0083 the breast on the chest wall, palpate for lumps, check for</p>\n<p>nipple discharge</p>\n<p>\u0083 A suspicious lump or bloody nipple discharge MUST</p>\n<p>BE REFERRED for evaluation by mammography or</p>\n<p>ultrasonography as well as core needle biopsy</p>\n<p>Mammography: a low-dose x-ray of the breast is the test of choice</p>\n<p>for screening of early breast cancer but it is available only at national</p>\n<p>referral hospital level.</p>\n<p>Breast Ultrasound: not used as a screening test, but is useful as an</p>\n<p>additional tool in characterizing palpable tumors and taking of im\u00ad</p>\n<p>age-directed biopsies. It may be used as a screening tool in lactating</p>\n<p>women, small- breasted women and in males, and as diagnostic tests in</p>\n<p>symptomatic patients.</p>\n<p>Screening for Cervical Cancer</p>\n<p>This aims to detect pre-cancerous lesions that are then treated to prevent</p>\n<p>progression to invasive cancer. The following methods are recommended:</p>\n<p>Visual Inspection with Acetic Acid (VIA): involves applying 3-5% freshly</p>\n<p>prepared acetic acid to the cervix and observing results after one minute.</p>\n<p>\u0083 The VIA results are generally categorized into 3 subsets:</p>\n<p>suspicious for cancer, VIA negative and VIA positive</p>\n<p>\u0083 It uses readily available equipment, does not require a</p>\n<p>\u0083 laboratory and provides an immediate result.</p>\n<p>\u0083 Positive cases can be treated with cryotherapy by adequately</p>\n<p>trained providers.</p>\n<p>Consider the following if using VIA as a screening method:</p>\n<p>\u0083 Women <25 years of age should be screened only if they are</p>\n<p>at high risk for disease: HIV positive, early sexual exposure,</p>\n<p>multiple partners, previous abnormal screening results, cervical</p>\n<p>intraepithelial neoplasia (CIN)</p>\n<p>\u0083 VIA is not appropriate for women >50 years</p>\n<p>\u0083 Screening is advised every 3-5 years in case of normal results,</p>\n<p>but after 1 years in case of abnormal results and treatment</p>\n<p>(cryotherapy) nd every year in HIV positive women.</p>\n<p>\u0083 Visual Inspection with Lugol\u2019s Iodine (VILI): it involves looking</p>\n<p>at the cervix with the naked eye or low magnification after</p>"
    },
    {
        "page_number": 678,
        "content": "612\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nswabbing with Lugol\u2019s iodine. VILI has a sensitivity and \nspecificity of about 92% and 85%, respectively. Test results \nare available immediately thereby decreasing loss to follow-up. \nRecommendations and timings of VIA outlined above also \napply to VILI.\n \n\u0083 Cytology Testing by Pap Smear: it is a microscopic examination \nof cells scraped from the opening of the cervix. The PAP \nsmear is best taken around mid-cycle. It should be postponed \nin case of cervicitis until after treatment; otherwise, the pus \ncells obscure clarity of the smear and affect interpretation. It \nrequires histocytology      services so it is available only at \nreferral facilities.\n \n\u0083 HPV DNA testing is currently being piloted as a standard \nscreening test in Uganda.\n12.3 Common Cancers\nThis section describes the signs and symptoms of common cancers in \nadults and children, and outline some of the investigations required. \nHealth workers should suspect cancer if they observe any of these clin\u00ad\nical features and refer patients to the cancer treatment centers (Uganda \nCancer Institte and regional referral hospitals).\n12.3.1 Common Cancers in Children\nClinical Features\nInvestigations\n \n~\nLeukaemia\n \n~\nAnaemia\n \n~\nBone pains\n \n~\nHaemorrhagic tendencies \n(epistaxis, gum bleeding)\n \n~\nRecurrent infections\n \n\u0081\nCBC, peripheral \nblood film\n \n\u0081\nUric acid, lactate de\u00ad\nhydrogenase\n \n\u0081\nAbdominal ultra\u00ad\nsound scan\nBurkitt\u2019s Lymphoma\n \n~\nRapidly growing tumour\n \n\u0081\nCBC\n \n\u0081\nPeripheral blood film",
        "formatted_content": "<p>612</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>swabbing with Lugol\u2019s iodine. VILI has a sensitivity and</p>\n<p>specificity of about 92% and 85%, respectively. Test results</p>\n<p>are available immediately thereby decreasing loss to follow-up.</p>\n<p>Recommendations and timings of VIA outlined above also</p>\n<p>apply to VILI.</p>\n<p>\u0083 Cytology Testing by Pap Smear: it is a microscopic examination</p>\n<p>of cells scraped from the opening of the cervix. The PAP</p>\n<p>smear is best taken around mid-cycle. It should be postponed</p>\n<p>in case of cervicitis until after treatment; otherwise, the pus</p>\n<p>cells obscure clarity of the smear and affect interpretation. It</p>\n<p>requires histocytology      services so it is available only at</p>\n<p>referral facilities.</p>\n<p>\u0083 HPV DNA testing is currently being piloted as a standard</p>\n<p>screening test in Uganda.</p>\n<p>12.3 Common Cancers</p>\n<p>This section describes the signs and symptoms of common cancers in</p>\n<p>adults and children, and outline some of the investigations required.</p>\n<p>Health workers should suspect cancer if they observe any of these clin\u00ad</p>\n<p>ical features and refer patients to the cancer treatment centers (Uganda</p>\n<p>Cancer Institte and regional referral hospitals).</p>\n<p>12.3.1 Common Cancers in Children</p>\n<p>Clinical Features</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Leukaemia</p>\n<p>~</p>\n<p>Anaemia</p>\n<p>~</p>\n<p>Bone pains</p>\n<p>~</p>\n<p>Haemorrhagic tendencies</p>\n<p>(epistaxis, gum bleeding)</p>\n<p>~</p>\n<p>Recurrent infections</p>\n<p>\u0081</p>\n<p>CBC, peripheral</p>\n<p>blood film</p>\n<p>\u0081</p>\n<p>Uric acid, lactate de\u00ad</p>\n<p>hydrogenase</p>\n<p>\u0081</p>\n<p>Abdominal ultra\u00ad</p>\n<p>sound scan</p>\n<p>Burkitt\u2019s Lymphoma</p>\n<p>~</p>\n<p>Rapidly growing tumour</p>\n<p>\u0081</p>\n<h3>CBC</h3>\n<p>\u0081</p>\n<p>Peripheral blood film</p>"
    },
    {
        "page_number": 679,
        "content": "613\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\n \n~\nUsually a jaw or abdomi\u00ad\nnal mass or tumour\n \n~\nMay also present as a \ncentral nervous system \ntumour\n \n\u0081\nBone marrow, X-Ray\n \n\u0081\nLumbar puncture\n \n\u0081\nLDH\nHodgkin\u2019s Disease\n \n~\nLymph node enlargement\n \n\u0081\nCBC\n \n\u0081\nChest X-ray\n \n\u0081\nLymph node biopsy\n \n~\nSplenomegaly, abdominal \nmasses\nNeuroblastoma\n \n~\nEmbryonal tumour\n \n~\nAbdominal mass in loin \nregion\n \n~\nMarkedly elevated blood \npressure\n \n~\nFast-growing often cross\u00ad\ning midline\n \n~\nChild is sick looking\n \n\u0081\nCBC\n \n\u0081\nIVU\n \n\u0081\nFNAC\n \n\u0081\nUltra sound\n \n\u0081\nCXR for metastasis\nRhabdosarcoma, rhabdomyosarcoma\n \n~\nTumour of muscle\n \n~\nCan occur anywhere \nbut more commonly in \npelvis, bladder, vagina\n \n~\nMay present with a \nfungating mass (sarcoma \nbotryoid)\n \n~\nMay ulcerate and bleed\n \n\u0081\nGood physical \nexamination\n \n\u0081\nFull Blood Count\n \n\u0081\nU/S\n \n\u0081\nCXR\n \n\u0081\nCT scan when avail\u00ad\nable\n \n\u0081\nBiopsy FNAC\nRetinoblastoma\n \n~\nAge usually <3 years, \ninherited through chro\u00ad\nmosome 13\n \n\u0081\nSkull X\u2212Ray\n \n\u0081\nUrine catechola\u00ad\nmines",
        "formatted_content": "<p>613</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<p>~</p>\n<p>Usually a jaw or abdomi\u00ad</p>\n<p>nal mass or tumour</p>\n<p>~</p>\n<p>May also present as a</p>\n<p>central nervous system</p>\n<p>tumour</p>\n<p>\u0081</p>\n<p>Bone marrow, X-Ray</p>\n<p>\u0081</p>\n<p>Lumbar puncture</p>\n<p>\u0081</p>\n<h3>LDH</h3>\n<p>Hodgkin\u2019s Disease</p>\n<p>~</p>\n<p>Lymph node enlargement</p>\n<p>\u0081</p>\n<h3>CBC</h3>\n<p>\u0081</p>\n<p>Chest X-ray</p>\n<p>\u0081</p>\n<p>Lymph node biopsy</p>\n<p>~</p>\n<p>Splenomegaly, abdominal</p>\n<p>masses</p>\n<p>Neuroblastoma</p>\n<p>~</p>\n<p>Embryonal tumour</p>\n<p>~</p>\n<p>Abdominal mass in loin</p>\n<p>region</p>\n<p>~</p>\n<p>Markedly elevated blood</p>\n<p>pressure</p>\n<p>~</p>\n<p>Fast-growing often cross\u00ad</p>\n<p>ing midline</p>\n<p>~</p>\n<p>Child is sick looking</p>\n<p>\u0081</p>\n<h3>CBC</h3>\n<p>\u0081</p>\n<h3>IVU</h3>\n<p>\u0081</p>\n<h3>FNAC</h3>\n<p>\u0081</p>\n<p>Ultra sound</p>\n<p>\u0081</p>\n<p>CXR for metastasis</p>\n<p>Rhabdosarcoma, rhabdomyosarcoma</p>\n<p>~</p>\n<p>Tumour of muscle</p>\n<p>~</p>\n<p>Can occur anywhere</p>\n<p>but more commonly in</p>\n<p>pelvis, bladder, vagina</p>\n<p>~</p>\n<p>May present with a</p>\n<p>fungating mass (sarcoma</p>\n<p>botryoid)</p>\n<p>~</p>\n<p>May ulcerate and bleed</p>\n<p>\u0081</p>\n<p>Good physical</p>\n<p>examination</p>\n<p>\u0081</p>\n<p>Full Blood Count</p>\n<p>\u0081</p>\n<h3>U/S</h3>\n<p>\u0081</p>\n<h3>CXR</h3>\n<p>\u0081</p>\n<p>CT scan when avail\u00ad</p>\n<p>able</p>\n<p>\u0081</p>\n<p>Biopsy FNAC</p>\n<p>Retinoblastoma</p>\n<p>~</p>\n<p>Age usually <3 years,</p>\n<p>inherited through chro\u00ad</p>\n<p>mosome 13</p>\n<p>\u0081</p>\n<p>Skull X\u2212Ray</p>\n<p>\u0081</p>\n<p>Urine catechola\u00ad</p>\n<p>mines</p>"
    },
    {
        "page_number": 680,
        "content": "614\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\n1.1.1 Common Cancers in Adults\nCLINICAL FEATURES\nINVESTIGATIONS\nCancer of the oesophagus\n \n~\nProgressive dysphagia\n \n~\nRegurgitation\n \n~\nWeight loss\n \n~\nIron deficiency anaemia\n \n\u0081\nFBC\n \n\u0081\nBarium Swallow\n \n\u0081\nEndoscopy; visual\u00ad\nise and biopsy \ntumour\n \n\u0081\nCXR\nGastric Cancer\n \n~\nAnorexia, weight loss, \nvomiting\n \n\u0081\nHaemogram\n \n\u0081\nOccult blood in \nstool\nCLINICAL FEATURES\nINVESTIGATIONS\n \n~\nMay be unilateral or \nbilateral\n \n~\nYellowish whitish reflex \nin eye\n \n\u0081\nFundoscopy\n \n\u0081\nCT scan head\nCNS Tumours\n \n~\nHeadache, worse in \nthe morning and eases \nduring the day\n \n~\nSeizures or convulsions\n \n~\nNausea or vomiting\n \n~\nWeakness or loss of feel\u00ad\ning in arms or legs\n \n~\nStumbling/lack of coordi\u00ad\nnation in walking\n \n~\nAbnormal eye move\u00ad\nments or changes/loss in \nvision\n \n~\nDrowsiness\n \n~\nChanges in personality, \nmemory, speech\n \n\u0081\nX-Ray skull\n \n\u0081\nCT scan",
        "formatted_content": "<p>614</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<li>.1.1 Common Cancers in Adults</li>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>Cancer of the oesophagus</p>\n<p>~</p>\n<p>Progressive dysphagia</p>\n<p>~</p>\n<p>Regurgitation</p>\n<p>~</p>\n<p>Weight loss</p>\n<p>~</p>\n<p>Iron deficiency anaemia</p>\n<p>\u0081</p>\n<h3>FBC</h3>\n<p>\u0081</p>\n<p>Barium Swallow</p>\n<p>\u0081</p>\n<p>Endoscopy; visual\u00ad</p>\n<p>ise and biopsy</p>\n<p>tumour</p>\n<p>\u0081</p>\n<h3>CXR</h3>\n<p>Gastric Cancer</p>\n<p>~</p>\n<p>Anorexia, weight loss,</p>\n<p>vomiting</p>\n<p>\u0081</p>\n<p>Haemogram</p>\n<p>\u0081</p>\n<p>Occult blood in</p>\n<p>stool</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>~</p>\n<p>May be unilateral or</p>\n<p>bilateral</p>\n<p>~</p>\n<p>Yellowish whitish reflex</p>\n<p>in eye</p>\n<p>\u0081</p>\n<p>Fundoscopy</p>\n<p>\u0081</p>\n<p>CT scan head</p>\n<p>CNS Tumours</p>\n<p>~</p>\n<p>Headache, worse in</p>\n<p>the morning and eases</p>\n<p>during the day</p>\n<p>~</p>\n<p>Seizures or convulsions</p>\n<p>~</p>\n<p>Nausea or vomiting</p>\n<p>~</p>\n<p>Weakness or loss of feel\u00ad</p>\n<p>ing in arms or legs</p>\n<p>~</p>\n<p>Stumbling/lack of coordi\u00ad</p>\n<p>nation in walking</p>\n<p>~</p>\n<p>Abnormal eye move\u00ad</p>\n<p>ments or changes/loss in</p>\n<p>vision</p>\n<p>~</p>\n<p>Drowsiness</p>\n<p>~</p>\n<p>Changes in personality,</p>\n<p>memory, speech</p>\n<p>\u0081</p>\n<p>X-Ray skull</p>\n<p>\u0081</p>\n<p>CT scan</p>"
    },
    {
        "page_number": 681,
        "content": "615\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nCLINICAL FEATURES\nINVESTIGATIONS\n \n~\nAnaemia\n \n~\nHaematemesis\n \n~\nPain, epigastric mass\n \n~\nMelaena stool\n \n\u0081\nBarium Meal\n \n\u0081\nEndoscopy; visualise \nand biopsy\nColorectal & Anal Cancer\n \n~\nChange in bowel habits; \nconstipation, diarrhoea\n \n~\nBlood in stool\n \n~\nAnaemia, weight loss\n \n~\nTenesmus\n \n~\nLower abdominal mass\n \n\u0081\nHaemogram\n \n\u0081\nIron-deficiency \nanaemia\n \n\u0081\nOccult blood in stool\n \n\u0081\nBarium Enema (dou\u00ad\nble contrast)\n \n\u0081\nSigmoidoscopy\n \n\u0081\nColoscopy; visualise \nand biopsy tumour\nNephroblastoma (Wilms\u2019 tumour)\n \n~\nAverage age 2 years: \nEmbryonal tumour\n \n~\nEarly childhood\n \n~\nPainless abdominal (loin) \nmass\n \n~\nFast growing\n \n\u0081\nCBC\n \n\u0081\nU/E in normal IV \nurography shows \ndisplaced calices\n \n\u0081\nFNAC\n \n\u0081\nCXR for metastasis\nOvarian Cancer\n \n~\nNo specific signs and \nsymptoms, usually over \n70% present as late \nstage\n \n~\nAbdominal discomfort \ne.g., pressure, poor ap\u00ad\npetite, nausea, vomiting, \nweight loss\n \n\u0081\nPelvic ultrasound\n \n\u0081\nLiver ultrasound",
        "formatted_content": "<p>615</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>~</p>\n<p>Anaemia</p>\n<p>~</p>\n<p>Haematemesis</p>\n<p>~</p>\n<p>Pain, epigastric mass</p>\n<p>~</p>\n<p>Melaena stool</p>\n<p>\u0081</p>\n<p>Barium Meal</p>\n<p>\u0081</p>\n<p>Endoscopy; visualise</p>\n<p>and biopsy</p>\n<p>Colorectal & Anal Cancer</p>\n<p>~</p>\n<p>Change in bowel habits;</p>\n<p>constipation, diarrhoea</p>\n<p>~</p>\n<p>Blood in stool</p>\n<p>~</p>\n<p>Anaemia, weight loss</p>\n<p>~</p>\n<p>Tenesmus</p>\n<p>~</p>\n<p>Lower abdominal mass</p>\n<p>\u0081</p>\n<p>Haemogram</p>\n<p>\u0081</p>\n<p>Iron-deficiency</p>\n<p>anaemia</p>\n<p>\u0081</p>\n<p>Occult blood in stool</p>\n<p>\u0081</p>\n<p>Barium Enema (dou\u00ad</p>\n<p>ble contrast)</p>\n<p>\u0081</p>\n<p>Sigmoidoscopy</p>\n<p>\u0081</p>\n<p>Coloscopy; visualise</p>\n<p>and biopsy tumour</p>\n<p>Nephroblastoma (Wilms\u2019 tumour)</p>\n<p>~</p>\n<p>Average age 2 years:</p>\n<p>Embryonal tumour</p>\n<p>~</p>\n<p>Early childhood</p>\n<p>~</p>\n<p>Painless abdominal (loin)</p>\n<p>mass</p>\n<p>~</p>\n<p>Fast growing</p>\n<p>\u0081</p>\n<h3>CBC</h3>\n<p>\u0081</p>\n<p>U/E in normal IV</p>\n<p>urography shows</p>\n<p>displaced calices</p>\n<p>\u0081</p>\n<h3>FNAC</h3>\n<p>\u0081</p>\n<p>CXR for metastasis</p>\n<p>Ovarian Cancer</p>\n<p>~</p>\n<p>No specific signs and</p>\n<p>symptoms, usually over</p>\n<p>70% present as late</p>\n<p>stage</p>\n<p>~</p>\n<p>Abdominal discomfort</p>\n<p>e.g., pressure, poor ap\u00ad</p>\n<p>petite, nausea, vomiting,</p>\n<p>weight loss</p>\n<p>\u0081</p>\n<p>Pelvic ultrasound</p>\n<p>\u0081</p>\n<p>Liver ultrasound</p>"
    },
    {
        "page_number": 682,
        "content": "616\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nCLINICAL FEATURES\nINVESTIGATIONS\n \n~\nUrinary frequency\n \n~\nPelvic pressure\n \n~\nMass/masses in abdo\u00ad\nmen; if mass >15 cm \nin 40-69 years, suspect \novarian cancer\n \n~\nAbdominal distension\n \n~\nIrregular vaginal bleeding\n \n~\nLow back pain, fatigue\n \n~\nDyspareunia\n \n~\nAscitic tap for \ncytology, chem\u00ad\nistry and micros\u00ad\ncopy\n \n~\nto rule out Tuber\u00ad\nculosis\n \n~\nCXR\nMelanoma\nSuspect where naevus shows:\n \n~\nA: Asymmetry\n \n~\nB: Border irregularity\n \n~\nC: Colour variegation\n \n~\nD: Diameter >6 mm\n \n~\nUlceration\n \n~\nRegional lymph nodes\n \n\u0081\nWide excision punch \nbiopsy\n \n\u0081\nCXR\n \n\u0081\nAbdominal U/S\nCervical Cancer\nEarly stage:\n \n~\nVaginal discharge, some\u00ad\ntimes foul smeling\n \n~\nIrregular vaginal bleeding\n \n~\nPost-coital bleeding in \nwomen of any age\n \n~\nPost-menopausal bleed\u00ad\ning (especially if not \nresponding to appropri\u00ad\nate treatment)\n \n\u0081\nBiopsy\n \n\u0081\nAbdominal ultra\u00ad\nsound/CT",
        "formatted_content": "<p>616</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>~</p>\n<p>Urinary frequency</p>\n<p>~</p>\n<p>Pelvic pressure</p>\n<p>~</p>\n<p>Mass/masses in abdo\u00ad</p>\n<p>men; if mass >15 cm</p>\n<p>in 40-69 years, suspect</p>\n<p>ovarian cancer</p>\n<p>~</p>\n<p>Abdominal distension</p>\n<p>~</p>\n<p>Irregular vaginal bleeding</p>\n<p>~</p>\n<p>Low back pain, fatigue</p>\n<p>~</p>\n<p>Dyspareunia</p>\n<p>~</p>\n<p>Ascitic tap for</p>\n<p>cytology, chem\u00ad</p>\n<p>istry and micros\u00ad</p>\n<p>copy</p>\n<p>~</p>\n<p>to rule out Tuber\u00ad</p>\n<p>culosis</p>\n<p>~</p>\n<h3>CXR</h3>\n<p>Melanoma</p>\n<p>Suspect where naevus shows:</p>\n<p>~</p>\n<p>A: Asymmetry</p>\n<p>~</p>\n<p>B: Border irregularity</p>\n<p>~</p>\n<p>C: Colour variegation</p>\n<p>~</p>\n<p>D: Diameter >6 mm</p>\n<p>~</p>\n<p>Ulceration</p>\n<p>~</p>\n<p>Regional lymph nodes</p>\n<p>\u0081</p>\n<p>Wide excision punch</p>\n<p>biopsy</p>\n<p>\u0081</p>\n<h3>CXR</h3>\n<p>\u0081</p>\n<p>Abdominal U/S</p>\n<p>Cervical Cancer</p>\n<p>Early stage:</p>\n<p>~</p>\n<p>Vaginal discharge, some\u00ad</p>\n<p>times foul smeling</p>\n<p>~</p>\n<p>Irregular vaginal bleeding</p>\n<p>~</p>\n<p>Post-coital bleeding in</p>\n<p>women of any age</p>\n<p>~</p>\n<p>Post-menopausal bleed\u00ad</p>\n<p>ing (especially if not</p>\n<p>responding to appropri\u00ad</p>\n<p>ate treatment)</p>\n<p>\u0081</p>\n<p>Biopsy</p>\n<p>\u0081</p>\n<p>Abdominal ultra\u00ad</p>\n<p>sound/CT</p>"
    },
    {
        "page_number": 683,
        "content": "617\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nCLINICAL FEATURES\nINVESTIGATIONS\nLate stage:\n \n~\nUrinary frequency and ur\u00ad\ngency\n \n~\nBackache, lower abdominal \npain\nVery late stage:\n \n~\nSevere back pain\n \n~\nWeight loss\n \n~\nOliguria (due to ureteric ob\u00ad\nstruction or renal failure)\n \n~\nUrinary/ \nfaecal \ninconti\u00ad\nnence\n \n~\nOedema of lower limbs\n \n~\nDyspnoea (due to anaemia, \nmetastasis or pleural effsion)\nBreast Cancer\n \n~\nA painless lump\n \n~\nNipple retraction\n \n~\nSkin changes such as dark\u00ad\nening and dimpling appear\u00ad\ning like orange skin\n \n~\nNipple discharge that may \nbe bloody\n \n~\nUlceration\n \n~\nUniform breast enlargement\n \n~\nPain is usually a late symp\u00ad\ntom\n \n~\nSymptoms and signs of me\u00ad\ntastasis\n \n\u0081\nMammography\n \n\u0081\nFNAC Biopsy\n \n\u0081\nExcisional biopsy \n(see section 12.2.2 \nabove)",
        "formatted_content": "<p>617</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>Late stage:</p>\n<p>~</p>\n<p>Urinary frequency and ur\u00ad</p>\n<p>gency</p>\n<p>~</p>\n<p>Backache, lower abdominal</p>\n<p>pain</p>\n<p>Very late stage:</p>\n<p>~</p>\n<p>Severe back pain</p>\n<p>~</p>\n<p>Weight loss</p>\n<p>~</p>\n<p>Oliguria (due to ureteric ob\u00ad</p>\n<p>struction or renal failure)</p>\n<p>~</p>\n<p>Urinary/</p>\n<p>faecal</p>\n<p>inconti\u00ad</p>\n<p>nence</p>\n<p>~</p>\n<p>Oedema of lower limbs</p>\n<p>~</p>\n<p>Dyspnoea (due to anaemia,</p>\n<p>metastasis or pleural effsion)</p>\n<p>Breast Cancer</p>\n<p>~</p>\n<p>A painless lump</p>\n<p>~</p>\n<p>Nipple retraction</p>\n<p>~</p>\n<p>Skin changes such as dark\u00ad</p>\n<p>ening and dimpling appear\u00ad</p>\n<p>ing like orange skin</p>\n<p>~</p>\n<p>Nipple discharge that may</p>\n<p>be bloody</p>\n<p>~</p>\n<p>Ulceration</p>\n<p>~</p>\n<p>Uniform breast enlargement</p>\n<p>~</p>\n<p>Pain is usually a late symp\u00ad</p>\n<p>tom</p>\n<p>~</p>\n<p>Symptoms and signs of me\u00ad</p>\n<p>tastasis</p>\n<p>\u0081</p>\n<p>Mammography</p>\n<p>\u0081</p>\n<p>FNAC Biopsy</p>\n<p>\u0081</p>\n<p>Excisional biopsy</p>\n<p>(see section 12.2.2</p>\n<p>above)</p>"
    },
    {
        "page_number": 684,
        "content": "618\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nCLINICAL FEATURES\nINVESTIGATIONS\nNon-Hodgkin\u2019s Lymphoma (NHL)\n \n~\nProgressive lymph node \nenlargement\n \n~\nUnexplained weight loss\n \n~\nDrenching night sweats\n \n~\nPersistent fever\n \n~\nPallor (anaemia)\n \n~\nLymphadenopathy (gen\u00ad\neralised)\n \n~\nSplenomegaly\n \n~\nHepatomegaly\n \n\u0081\nLymph node excision \nbiopsy\n \n\u0081\nFine needle aspira\u00ad\ntions (FNA)\n \n\u0081\nFull blood count\n \n\u0081\nBone marrow aspi\u00ad\nrate\n \n\u0081\nLFTs, RFTs\n \n\u0081\nLDH\n \n\u0081\nViral serology for HIV\nSquamous cell cancer of skin\n \n~\nNon\u2212healing ulcers\n \n~\nBleeding\n \n~\nPain\n \n~\nLymph nodes\n \n\u0081\nWide excision inci\u00ad\nsional biopsy\n \n\u0081\nX\u2212Rays of bones\n \n\u0081\nCXR\nKaposi\u2019s Sarcoma (KS)\n \n~\nIndolent KS: nodular skin \nlesions, fungating nod\u00ad\nules, bone involvement\n \n~\nLymphadenopathic KS: \nlymph nodes, visceral \ninvolvement, GIT symp\u00ad\ntoms\n \n~\nAIDS related KS: skin \nnodules, mucous mem\u00ad\nbranes, mouth palate and \nENT lesions, lymphade\u00ad\nnopathy, paraplegias, any \norgan can be impacted\n \n\u0081\nBiopsies\n \n\u0081\nFull blood count\n \n\u0081\nHIV screening\n \n\u0081\nCXR: pleural effu\u00ad\nsions\n \n\u0081\nAbdominal X-Ray",
        "formatted_content": "<p>618</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>Non-Hodgkin\u2019s Lymphoma (NHL)</p>\n<p>~</p>\n<p>Progressive lymph node</p>\n<p>enlargement</p>\n<p>~</p>\n<p>Unexplained weight loss</p>\n<p>~</p>\n<p>Drenching night sweats</p>\n<p>~</p>\n<p>Persistent fever</p>\n<p>~</p>\n<p>Pallor (anaemia)</p>\n<p>~</p>\n<p>Lymphadenopathy (gen\u00ad</p>\n<p>eralised)</p>\n<p>~</p>\n<p>Splenomegaly</p>\n<p>~</p>\n<p>Hepatomegaly</p>\n<p>\u0081</p>\n<p>Lymph node excision</p>\n<p>biopsy</p>\n<p>\u0081</p>\n<p>Fine needle aspira\u00ad</p>\n<p>tions (FNA)</p>\n<p>\u0081</p>\n<p>Full blood count</p>\n<p>\u0081</p>\n<p>Bone marrow aspi\u00ad</p>\n<p>rate</p>\n<p>\u0081</p>\n<p>LFTs, RFTs</p>\n<p>\u0081</p>\n<h3>LDH</h3>\n<p>\u0081</p>\n<p>Viral serology for HIV</p>\n<p>Squamous cell cancer of skin</p>\n<p>~</p>\n<p>Non\u2212healing ulcers</p>\n<p>~</p>\n<p>Bleeding</p>\n<p>~</p>\n<p>Pain</p>\n<p>~</p>\n<p>Lymph nodes</p>\n<p>\u0081</p>\n<p>Wide excision inci\u00ad</p>\n<p>sional biopsy</p>\n<p>\u0081</p>\n<p>X\u2212Rays of bones</p>\n<p>\u0081</p>\n<h3>CXR</h3>\n<p>Kaposi\u2019s Sarcoma (KS)</p>\n<p>~</p>\n<p>Indolent KS: nodular skin</p>\n<p>lesions, fungating nod\u00ad</p>\n<p>ules, bone involvement</p>\n<p>~</p>\n<p>Lymphadenopathic KS:</p>\n<p>lymph nodes, visceral</p>\n<p>involvement, GIT symp\u00ad</p>\n<p>toms</p>\n<p>~</p>\n<p>AIDS related KS: skin</p>\n<p>nodules, mucous mem\u00ad</p>\n<p>branes, mouth palate and</p>\n<p>ENT lesions, lymphade\u00ad</p>\n<p>nopathy, paraplegias, any</p>\n<p>organ can be impacted</p>\n<p>\u0081</p>\n<p>Biopsies</p>\n<p>\u0081</p>\n<p>Full blood count</p>\n<p>\u0081</p>\n<p>HIV screening</p>\n<p>\u0081</p>\n<p>CXR: pleural effu\u00ad</p>\n<p>sions</p>\n<p>\u0081</p>\n<p>Abdominal X-Ray</p>"
    },
    {
        "page_number": 685,
        "content": "619\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nCLINICAL FEATURES\nINVESTIGATIONS\nHead and Neck cancers\n \n~\nPainless mass\n \n~\nLocal ulceration with or \nwithout pain\n \n~\nReferred pain to teeth or \near\n \n~\nDysphagia, loosening of \nteeth\n \n~\nAlteration of speech: \ndifficulty pronouncing \nwords, change in \ncharacter, persistent \nhoarseness\n \n~\nUnilateral tonsillar \nenlargement in an adult\n \n~\nPersistent unilateral \n\u201csinusitis\u201d, nosebleed or \nobstruction\n \n~\nUnilateral hearing loss\n \n~\nCranial nerve palsies\n \n\u0081\nChest X-Rays and \nother relevant\n \n\u0081\nX-Rays\n \n\u0081\nCT scan\n \n\u0081\nBiopsy\nProstate Cancer\n \n~\nUrge to urinate often, \nespecially at night\n \n~\nDifficulty in starting or \nstopping urine flow, \ninability to urinate\n \n~\nWeak, decreased or \ninterrupted urine stream, \na sense of incomplete \nemptying of bladder\n \n\u0081\nDigital Rectal Exam \n(DRE)\n \n\u0081\nSerum PSA\n \n\u0081\nUltrasound guided \nbiopsy",
        "formatted_content": "<p>619</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>Head and Neck cancers</p>\n<p>~</p>\n<p>Painless mass</p>\n<p>~</p>\n<p>Local ulceration with or</p>\n<p>without pain</p>\n<p>~</p>\n<p>Referred pain to teeth or</p>\n<p>ear</p>\n<p>~</p>\n<p>Dysphagia, loosening of</p>\n<p>teeth</p>\n<p>~</p>\n<p>Alteration of speech:</p>\n<p>difficulty pronouncing</p>\n<p>words, change in</p>\n<p>character, persistent</p>\n<p>hoarseness</p>\n<p>~</p>\n<p>Unilateral tonsillar</p>\n<p>enlargement in an adult</p>\n<p>~</p>\n<p>Persistent unilateral</p>\n<p>\u201csinusitis\u201d, nosebleed or</p>\n<p>obstruction</p>\n<p>~</p>\n<p>Unilateral hearing loss</p>\n<p>~</p>\n<p>Cranial nerve palsies</p>\n<p>\u0081</p>\n<p>Chest X-Rays and</p>\n<p>other relevant</p>\n<p>\u0081</p>\n<p>X-Rays</p>\n<p>\u0081</p>\n<p>CT scan</p>\n<p>\u0081</p>\n<p>Biopsy</p>\n<p>Prostate Cancer</p>\n<p>~</p>\n<p>Urge to urinate often,</p>\n<p>especially at night</p>\n<p>~</p>\n<p>Difficulty in starting or</p>\n<p>stopping urine flow,</p>\n<p>inability to urinate</p>\n<p>~</p>\n<p>Weak, decreased or</p>\n<p>interrupted urine stream,</p>\n<p>a sense of incomplete</p>\n<p>emptying of bladder</p>\n<p>\u0081</p>\n<p>Digital Rectal Exam</p>\n<h3>(DRE)</h3>\n<p>\u0081</p>\n<p>Serum PSA</p>\n<p>\u0081</p>\n<p>Ultrasound guided</p>\n<p>biopsy</p>"
    },
    {
        "page_number": 686,
        "content": "620\nUganda Clinical Guidelines 2023\nCHAPTER 12: Oncology\nCLINICAL FEATURES\nINVESTIGATIONS\n \n~\nBurning or pain during \nurination\n \n~\nBlood in the urine or \nsemen\n \n~\nPainful ejaculation\nChronic Leukaemia\n \n~\nClassified into two: CLL \nand CML\n \n~\nRecurrent infections\n \n~\nBleeding or easy bruisabil\u00ad\nity\n \n~\nUnexplained weight loss\n \n~\nDrenching night sweats\n \n~\nPersistent fever\n \n~\nWaxing and waning lymph \nnode enlargement (CLL)\n \n~\nSwelling and discomfort in \nthe left flank due to massive \nsplenomegaly (CML)\nThe following clinical signs require full \nphysical examination:\n \n~\nPallor (anaemia)\n \n~\nSplenomegaly\n \n~\nHepatomegaly\n \n~\nBruising (purpura)\n \n~\nLymphadenopathy\n \n\u0081\nFBC\n \n\u0081\nPeripheral blood \nfilm\n \n\u0081\nBone Marrow As\u00ad\npirate\n \n\u0081\nBiopsy\n \n\u0081\nCLL: blood film\n \n\u0081\n>500 monoclonal \nlymphocytes\n \n\u0081\nCML: leukocytosis, \nbasophilia\n \n\u0081\nw ith immature \ngranulocytes\n \n\u0081\nCXR\n \n\u0081\nLDH\n \n\u0081\nViral serology for \nHIV, Hepatitis \nB&C\n \n\u0081\nAbdominal US scan\n \n\u0081\nCT scan\n \n\u0081\nEcho/ECG",
        "formatted_content": "<p>620</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 12: Oncology</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>INVESTIGATIONS</h3>\n<p>~</p>\n<p>Burning or pain during</p>\n<p>urination</p>\n<p>~</p>\n<p>Blood in the urine or</p>\n<p>semen</p>\n<p>~</p>\n<p>Painful ejaculation</p>\n<p>Chronic Leukaemia</p>\n<p>~</p>\n<p>Classified into two: CLL</p>\n<p>and CML</p>\n<p>~</p>\n<p>Recurrent infections</p>\n<p>~</p>\n<p>Bleeding or easy bruisabil\u00ad</p>\n<p>ity</p>\n<p>~</p>\n<p>Unexplained weight loss</p>\n<p>~</p>\n<p>Drenching night sweats</p>\n<p>~</p>\n<p>Persistent fever</p>\n<p>~</p>\n<p>Waxing and waning lymph</p>\n<p>node enlargement (CLL)</p>\n<p>~</p>\n<p>Swelling and discomfort in</p>\n<p>the left flank due to massive</p>\n<p>splenomegaly (CML)</p>\n<p>The following clinical signs require full</p>\n<p>physical examination:</p>\n<p>~</p>\n<p>Pallor (anaemia)</p>\n<p>~</p>\n<p>Splenomegaly</p>\n<p>~</p>\n<p>Hepatomegaly</p>\n<p>~</p>\n<p>Bruising (purpura)</p>\n<p>~</p>\n<p>Lymphadenopathy</p>\n<p>\u0081</p>\n<h3>FBC</h3>\n<p>\u0081</p>\n<p>Peripheral blood</p>\n<p>film</p>\n<p>\u0081</p>\n<p>Bone Marrow As\u00ad</p>\n<p>pirate</p>\n<p>\u0081</p>\n<p>Biopsy</p>\n<p>\u0081</p>\n<p>CLL: blood film</p>\n<p>\u0081</p>\n<p>>500 monoclonal</p>\n<p>lymphocytes</p>\n<p>\u0081</p>\n<p>CML: leukocytosis,</p>\n<p>basophilia</p>\n<p>\u0081</p>\n<p>w ith immature</p>\n<p>granulocytes</p>\n<p>\u0081</p>\n<h3>CXR</h3>\n<p>\u0081</p>\n<h3>LDH</h3>\n<p>\u0081</p>\n<p>Viral serology for</p>\n<p>HIV, Hepatitis</p>\n<h3>B&C</h3>\n<p>\u0081</p>\n<p>Abdominal US scan</p>\n<p>\u0081</p>\n<p>CT scan</p>\n<p>\u0081</p>\n<p>Echo/ECG</p>"
    },
    {
        "page_number": 687,
        "content": "621\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nPalliative  Care\n13\n13. PALLIATIVE CARE        ICD10 CODE: Z51.5\nPalliative care aims to improve the quality of life of patients (and their \nfamilies) who are faced with life-threatening illness, through the preven\u00ad\ntion and relief of suffering. This is achieved through early identification, \nongoing assessment, treatment of pain and other physical, psychosocial \nand spiritual problems.\n13.1 Pain\n\u201cPain is what the patient says hurts\u201d\nPain is an unpleasant sensory and emotional experience associated \nwith actual or potential tissue damage, or described in terms of such \ndamage. Pain is the most common symptom of a disease.\nThe nature, location and cause of pain will differ in each case. Pain \nrequires a holistic approach as it can be affected by spiritual, psycho\u00ad\nlogical, social, and cultural factors, which may need to be addressed \nafter physical pain is controlled.\nCauses of pain\nPain can be divided into two types of causative categories:\n \n~\nAcute Pain: Caused by a specific action with a definite \ntime period, e.g., postoperative, acute infection, or trauma\n \n~\nChronic pain: Ongoing pain with an indefinite time peri\u00ad\nod, for example\n \n\u0083 Constant and usually increasing: cancer\n \n\u0083 Recurrent sickle-cell crisis, arthritis, HIV/AIDS\n \n\u0083 Drug side-effect or toxicity (e.g., peripheral neuropathy due to \nisoniazid, chemotherapy)",
        "formatted_content": "<p>621</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Palliative  Care</p>\n<p>13</p>\n<h3>13. PALLIATIVE CARE        ICD10 CODE: Z51.5</h3>\n<p>Palliative care aims to improve the quality of life of patients (and their</p>\n<p>families) who are faced with life-threatening illness, through the preven\u00ad</p>\n<p>tion and relief of suffering. This is achieved through early identification,</p>\n<p>ongoing assessment, treatment of pain and other physical, psychosocial</p>\n<p>and spiritual problems.</p>\n<p>13.1 Pain</p>\n<p>\u201cPain is what the patient says hurts\u201d</p>\n<p>Pain is an unpleasant sensory and emotional experience associated</p>\n<p>with actual or potential tissue damage, or described in terms of such</p>\n<p>damage. Pain is the most common symptom of a disease.</p>\n<p>The nature, location and cause of pain will differ in each case. Pain</p>\n<p>requires a holistic approach as it can be affected by spiritual, psycho\u00ad</p>\n<p>logical, social, and cultural factors, which may need to be addressed</p>\n<p>after physical pain is controlled.</p>\n<p>Causes of pain</p>\n<p>Pain can be divided into two types of causative categories:</p>\n<p>~</p>\n<p>Acute Pain: Caused by a specific action with a definite</p>\n<p>time period, e.g., postoperative, acute infection, or trauma</p>\n<p>~</p>\n<p>Chronic pain: Ongoing pain with an indefinite time peri\u00ad</p>\n<p>od, for example</p>\n<p>\u0083 Constant and usually increasing: cancer</p>\n<p>\u0083 Recurrent sickle-cell crisis, arthritis, HIV/AIDS</p>\n<p>\u0083 Drug side-effect or toxicity (e.g., peripheral neuropathy due to</p>\n<p>isoniazid, chemotherapy)</p>"
    },
    {
        "page_number": 688,
        "content": "622\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nRisk factors and mitigators\nThese factors increase pain perception:\n \n~\nAnxiety and depression, social abandonment\n \n~\nInsomnia\n \n~\nLack of understanding of the problem\nThese factors decrease pain perception:\n \n~\nRelaxation, sleep\n \n~\nRelief of other symptoms\n \n~\nExplanation/understanding, venting feelings\n13.1.1 Clinical Features and Investigations\nTypes of Pain\nThere are 2 types of pain that health workers need to be aware of:\nTYPE OF PAIN\nFEATURES\nNociceptive Pain\nThe pain pathways are intact. \nThis kind of pain responds to the \nanalgesic ladder\n \n~\nSomatic Pain (from bones \nand muscles): described as \naching/ throbbing\n \n~\nVisceral Pain: described \nas colicky pain (for hollow \nviscera), pressure, cramp\u00ad\ning and ache for solid \nviscera\nNeuropathic Pain\nThere is damage to nerves or the \npathways. The pain responds \nonly partially\nto the analgesic ladder and needs \nadjuvants of amitriptyline or phe\u00ad\nnytoin\n \n~\nDescribed as burning, \nprickling, stinging, pins \nand needles, insects crawl\u00ad\ning under skin, numbness, \nhypersensitivity,\n \n~\nshooting, or electric shock",
        "formatted_content": "<p>622</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Risk factors and mitigators</p>\n<p>These factors increase pain perception:</p>\n<p>~</p>\n<p>Anxiety and depression, social abandonment</p>\n<p>~</p>\n<p>Insomnia</p>\n<p>~</p>\n<p>Lack of understanding of the problem</p>\n<p>These factors decrease pain perception:</p>\n<p>~</p>\n<p>Relaxation, sleep</p>\n<p>~</p>\n<p>Relief of other symptoms</p>\n<p>~</p>\n<p>Explanation/understanding, venting feelings</p>\n<p>13.1.1 Clinical Features and Investigations</p>\n<p>Types of Pain</p>\n<p>There are 2 types of pain that health workers need to be aware of:</p>\n<h3>TYPE OF PAIN</h3>\n<h3>FEATURES</h3>\n<p>Nociceptive Pain</p>\n<p>The pain pathways are intact.</p>\n<p>This kind of pain responds to the</p>\n<p>analgesic ladder</p>\n<p>~</p>\n<p>Somatic Pain (from bones</p>\n<p>and muscles): described as</p>\n<p>aching/ throbbing</p>\n<p>~</p>\n<p>Visceral Pain: described</p>\n<p>as colicky pain (for hollow</p>\n<p>viscera), pressure, cramp\u00ad</p>\n<p>ing and ache for solid</p>\n<p>viscera</p>\n<p>Neuropathic Pain</p>\n<p>There is damage to nerves or the</p>\n<p>pathways. The pain responds</p>\n<p>only partially</p>\n<p>to the analgesic ladder and needs</p>\n<p>adjuvants of amitriptyline or phe\u00ad</p>\n<p>nytoin</p>\n<p>~</p>\n<p>Described as burning,</p>\n<p>prickling, stinging, pins</p>\n<p>and needles, insects crawl\u00ad</p>\n<p>ing under skin, numbness,</p>\n<p>hypersensitivity,</p>\n<p>~</p>\n<p>shooting, or electric shock</p>"
    },
    {
        "page_number": 689,
        "content": "623\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nClinical Investigation\nIt is important for health workers to conduct a thorough investigation \nof a patient indicating they are in pain. The following points can be \nused to guide the investigation:\n \n~\nDuration of pain\n \n~\nSeverity: assess using the Numerical Rating Scale, where \nthe patient grades his/her pain on a scale of 0 = no pain \nto 5\n \n~\n= worst pain ever experienced\n \n~\nSite and radiation\n \n~\nNature (e.g., stabbing, throbbing, crushing, cramp-like)\n \n~\nPeriodicity (constant or intermittent)\n \n~\nRelieving or aggravating factors\n \n~\nAccompanying symptoms\n \n~\nAsk the patient for a detailed history for each pain expe\u00ad\nrienced, as there may be more than one type of pain and \narea experiencing pain\n \n~\nA targeted physical examination\n13.1.2 Nociceptive Pain Management\nThere are two goals of pain management:\n \n~\nDiagnose and treat the disease causing the pain\n \n~\nAchieve total pain relief with minimal side-effects and en\u00ad\nable the patient to live as normal a life as possible\n \n~\nPain can be treated through use of medicines and/or non- \ndrug treatment",
        "formatted_content": "<p>623</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Clinical Investigation</p>\n<p>It is important for health workers to conduct a thorough investigation</p>\n<p>of a patient indicating they are in pain. The following points can be</p>\n<p>used to guide the investigation:</p>\n<p>~</p>\n<p>Duration of pain</p>\n<p>~</p>\n<p>Severity: assess using the Numerical Rating Scale, where</p>\n<p>the patient grades his/her pain on a scale of 0 = no pain</p>\n<p>to 5</p>\n<p>~</p>\n<p>= worst pain ever experienced</p>\n<p>~</p>\n<p>Site and radiation</p>\n<p>~</p>\n<p>Nature (e.g., stabbing, throbbing, crushing, cramp-like)</p>\n<p>~</p>\n<p>Periodicity (constant or intermittent)</p>\n<p>~</p>\n<p>Relieving or aggravating factors</p>\n<p>~</p>\n<p>Accompanying symptoms</p>\n<p>~</p>\n<p>Ask the patient for a detailed history for each pain expe\u00ad</p>\n<p>rienced, as there may be more than one type of pain and</p>\n<p>area experiencing pain</p>\n<p>~</p>\n<p>A targeted physical examination</p>\n<p>13.1.2 Nociceptive Pain Management</p>\n<p>There are two goals of pain management:</p>\n<p>~</p>\n<p>Diagnose and treat the disease causing the pain</p>\n<p>~</p>\n<p>Achieve total pain relief with minimal side-effects and en\u00ad</p>\n<p>able the patient to live as normal a life as possible</p>\n<p>~</p>\n<p>Pain can be treated through use of medicines and/or non-</p>\n<p>drug treatment</p>"
    },
    {
        "page_number": 690,
        "content": "624\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nNon pharmacological treatment of pain\nTREATMENT\nLOC\n\t\n\u0089\nLifestyle adjustment\n\t\n\u0089\nPatient counselling\n\t\n\u0089\nMassage with aromatherapy oils: may be useful for \nneuropathic pain and muscular pain\n\t\n\u0089\nReflexology\nHC2\n\t\n\u0089\nApplication of heat or cold packs\n\t\n\u0089\nRelaxation\n\t\n\u0089\nDistraction (e.g., listening to radio or partaking in a \nnon-invasive hobby)\n\t\n\u0089\nNon-pharmacological treatment of underlying cause \n(e.g., surgery or radiotherapy of cancer)\n\t\n\u0089\nSocial and spiritual support\nMedicines-Based Treatment\nThe WHO Analgesic Ladder and the following tables describe the use \nof medicines to relieve pain based on the type and degree of pain.",
        "formatted_content": "<p>624</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Non pharmacological treatment of pain</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Lifestyle adjustment</p>\n<p>\u0089</p>\n<p>Patient counselling</p>\n<p>\u0089</p>\n<p>Massage with aromatherapy oils: may be useful for</p>\n<p>neuropathic pain and muscular pain</p>\n<p>\u0089</p>\n<p>Reflexology</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Application of heat or cold packs</p>\n<p>\u0089</p>\n<p>Relaxation</p>\n<p>\u0089</p>\n<p>Distraction (e.g., listening to radio or partaking in a</p>\n<p>non-invasive hobby)</p>\n<p>\u0089</p>\n<p>Non-pharmacological treatment of underlying cause</p>\n<p>(e.g., surgery or radiotherapy of cancer)</p>\n<p>\u0089</p>\n<p>Social and spiritual support</p>\n<p>Medicines-Based Treatment</p>\n<p>The WHO Analgesic Ladder and the following tables describe the use</p>\n<p>of medicines to relieve pain based on the type and degree of pain.</p>"
    },
    {
        "page_number": 691,
        "content": "625\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\n13.1.2.1 Pain  Management  In   Adults\nANALGESICS\nCOMMENTS\nSTEP 1: MILD PAIN (NON-OPIOID \u00b1 ADJUVANTS)\n\t\n\u0089\nParacetamol 1 g every 6 \nhours (500 mg in elderly)\n\t\n\u0089\nAnd/or\n\t\n\u0089\nIbuprofen 400 mg every \n6- 8 hours (max\n\t\n\u0089\n2,400 mg/daily) or\n\t\n\u0089\nDiclofenac 50 mg every \n8 hours\n \n\u0083 Continue with step 1 \nanalgesics when moving to \nstep 2 and 3\n \n\u0083 Prolonged use of high \ndoses of paracetamol may \ncause liver toxicity\n \n\u0083 Do not use NSAIDS in \nrenal impairment\n \n\u0083 Caution when using \nNSAIDS for more than 10 \ndays",
        "formatted_content": "<p>625</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>13.1.2.1 Pain  Management  In   Adults</p>\n<h3>ANALGESICS</h3>\n<h3>COMMENTS</h3>\n<h3>STEP 1: MILD PAIN (NON-OPIOID \u00b1 ADJUVANTS)</h3>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 6</p>\n<p>hours (500 mg in elderly)</p>\n<p>\u0089</p>\n<p>And/or</p>\n<p>\u0089</p>\n<p>Ibuprofen 400 mg every</p>\n<p>6- 8 hours (max</p>\n<p>\u0089</p>\n<p>2,400 mg/daily) or</p>\n<p>\u0089</p>\n<p>Diclofenac 50 mg every</p>\n<p>8 hours</p>\n<p>\u0083 Continue with step 1</p>\n<p>analgesics when moving to</p>\n<p>step 2 and 3</p>\n<p>\u0083 Prolonged use of high</p>\n<p>doses of paracetamol may</p>\n<p>cause liver toxicity</p>\n<p>\u0083 Do not use NSAIDS in</p>\n<p>renal impairment</p>\n<p>\u0083 Caution when using</p>\n<p>NSAIDS for more than 10</p>\n<p>days</p>"
    },
    {
        "page_number": 692,
        "content": "626\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nANALGESICS\nCOMMENTS\nSTEP 2: MODERATE PAIN\n(WEAK OPIOID \u00b1 NON-OPIOID \u00b1 ADJUVANT)\n\t\n\u0089\nMorphine 2.5-5 mg \nevery 4 hours during \nday, double dose at \nnight\n\t\n\u0089\nOr\n\t\n\u0089\nCodeine 30-60 mg \nevery 6 hours (max 240 \nmg)\n\t\n\u0089\nOr\n\t\n\u0089\nTramadol 50-100 mg \nevery 6 hours (max 400 \nmg)\n \n\u0083 Low dose morphine is \nconsidered step 2 analgesic \nand recomended first line if \navailable\n \n\u0083 Discontinue step 2 \nanalgesics when starting \nstep 3\n\t\n\u0089\nGive Bisacodyl 10-15 mg nocte \nto prevent constipation except \nif diarrhoea is present\n\t\n\u0089\nAdd liquid paraffin 10 ml once \na day if Bisacodyl is not enough\nSTEP 3: SEVERE PAIN\n(STRONG OPIOID \u00b1 NON-OPIOID \u00b1 ADJUVANT\n\t\n\u0089\nMorphine 7.5-10 mg \nevery  4 hours during day \nand double dose at night\n \n\u0083 If breakthrough \npain, give equivalent \nadditional dose\n \n\u0083 Increase dose by\n \n\u0083 30-50% as required \nto control patient\u2019s \npain\n \n\u0083 Give additional dose\n30 minutes before an ac\u00ad\ntivity causing pain (e.g. \nwound dressing)\n \n\u0083 Elderly and renal \nimpairment may require \ndose adjustment\n \n\u0083 Give Bisacodyl 10-15 \nmg nocte to prevent \nconstipation except if \ndiarrhoea is present\n \n\u0083 Add liquid paraffin 10 mL\nonce a day if Bisacodyl not \nenough\n\t\n\u0089\nIf modified release tablets are \navailable, use the same 24-hour \ndose but given in 1 or 2 doses \ndaily",
        "formatted_content": "<p>626</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>ANALGESICS</h3>\n<h3>COMMENTS</h3>\n<h3>STEP 2: MODERATE PAIN</h3>\n<h3>(WEAK OPIOID \u00b1 NON-OPIOID \u00b1 ADJUVANT)</h3>\n<p>\u0089</p>\n<p>Morphine 2.5-5 mg</p>\n<p>every 4 hours during</p>\n<p>day, double dose at</p>\n<p>night</p>\n<p>\u0089</p>\n<p>Or</p>\n<p>\u0089</p>\n<p>Codeine 30-60 mg</p>\n<p>every 6 hours (max 240</p>\n<p>mg)</p>\n<p>\u0089</p>\n<p>Or</p>\n<p>\u0089</p>\n<p>Tramadol 50-100 mg</p>\n<p>every 6 hours (max 400</p>\n<p>mg)</p>\n<p>\u0083 Low dose morphine is</p>\n<p>considered step 2 analgesic</p>\n<p>and recomended first line if</p>\n<p>available</p>\n<p>\u0083 Discontinue step 2</p>\n<p>analgesics when starting</p>\n<p>step 3</p>\n<p>\u0089</p>\n<p>Give Bisacodyl 10-15 mg nocte</p>\n<p>to prevent constipation except</p>\n<p>if diarrhoea is present</p>\n<p>\u0089</p>\n<p>Add liquid paraffin 10 ml once</p>\n<p>a day if Bisacodyl is not enough</p>\n<h3>STEP 3: SEVERE PAIN</h3>\n<h3>(STRONG OPIOID \u00b1 NON-OPIOID \u00b1 ADJUVANT</h3>\n<p>\u0089</p>\n<p>Morphine 7.5-10 mg</p>\n<p>every  4 hours during day</p>\n<p>and double dose at night</p>\n<p>\u0083 If breakthrough</p>\n<p>pain, give equivalent</p>\n<p>additional dose</p>\n<p>\u0083 Increase dose by</p>\n<p>\u0083 30-50% as required</p>\n<p>to control patient\u2019s</p>\n<p>pain</p>\n<p>\u0083 Give additional dose</p>\n<p>30 minutes before an ac\u00ad</p>\n<p>tivity causing pain (e.g.</p>\n<p>wound dressing)</p>\n<p>\u0083 Elderly and renal</p>\n<p>impairment may require</p>\n<p>dose adjustment</p>\n<p>\u0083 Give Bisacodyl 10-15</p>\n<p>mg nocte to prevent</p>\n<p>constipation except if</p>\n<p>diarrhoea is present</p>\n<p>\u0083 Add liquid paraffin 10 mL</p>\n<p>once a day if Bisacodyl not</p>\n<p>enough</p>\n<p>\u0089</p>\n<p>If modified release tablets are</p>\n<p>available, use the same 24-hour</p>\n<p>dose but given in 1 or 2 doses</p>\n<p>daily</p>"
    },
    {
        "page_number": 693,
        "content": "627\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nAdjuvants\n\t\n\u0089\nAmitriptyline 12.5\u201325 mg nocte for neuropathic pain (max \n50-75 mg if tolerated)\n\t\n\u0089\nClonazepam 0.5-1 mg nocte for neuropathic pain (second line)\n\t\n\u0089\nDexamethasone 4-8 mg once a day for swelling or oedema\n\t\n\u0089\nHyoscine 20 mg every 6 hours for smooth muscle spasm\n\t\n\u0089\nDiazepam 5-20 mg nocte for painful skeletal muscle spasms\nCaution\n \n\u0083 Do not use pethidine for chronic pain; accumulates with severe \nside-effects on the gut. Only use as one off-dose for acute severe \npain if morphine not available\n \n\u0083 Side effects of NSAIDS: gastritis, renal toxicity, bleeding, \nbronchospasm\nANALGESICS\nCOMMENTS\n\t\n\u0089\nAvoid amitriptyline in heart \ndisease\n\t\n\u0089\nSide effects of opioids: see sec\u00ad\ntions 13.1.2.3\n13.1.2.3 Pain Management In Children\nANALGESICS\nCOMMENTS\nSTEP 1: MILD PAIN (NON-OPIOID \u00b1 ADJUVANTS)\n\t\n\u0089\nParacetamol 10-15 mg/kg \nevery 6 hours And/or\n\t\n\u0089\nIbuprofen 5-10 mg/ kg every \n6-8 hours (use only in children \n>3 months)\nw\tContinue with step 1 anal\u00ad\ngesics when moving to step 2\nw\tProlonged use of high doses \nof paracetamol may cause \nliver toxicity",
        "formatted_content": "<p>627</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Adjuvants</p>\n<p>\u0089</p>\n<p>Amitriptyline 12.5\u201325 mg nocte for neuropathic pain (max</p>\n<p>50-75 mg if tolerated)</p>\n<p>\u0089</p>\n<p>Clonazepam 0.5-1 mg nocte for neuropathic pain (second line)</p>\n<p>\u0089</p>\n<p>Dexamethasone 4-8 mg once a day for swelling or oedema</p>\n<p>\u0089</p>\n<p>Hyoscine 20 mg every 6 hours for smooth muscle spasm</p>\n<p>\u0089</p>\n<p>Diazepam 5-20 mg nocte for painful skeletal muscle spasms</p>\n<p>Caution</p>\n<p>\u0083 Do not use pethidine for chronic pain; accumulates with severe</p>\n<p>side-effects on the gut. Only use as one off-dose for acute severe</p>\n<p>pain if morphine not available</p>\n<p>\u0083 Side effects of NSAIDS: gastritis, renal toxicity, bleeding,</p>\n<p>bronchospasm</p>\n<h3>ANALGESICS</h3>\n<h3>COMMENTS</h3>\n<p>\u0089</p>\n<p>Avoid amitriptyline in heart</p>\n<p>disease</p>\n<p>\u0089</p>\n<p>Side effects of opioids: see sec\u00ad</p>\n<p>tions 13.1.2.3</p>\n<p>13.1.2.3 Pain Management In Children</p>\n<h3>ANALGESICS</h3>\n<h3>COMMENTS</h3>\n<h3>STEP 1: MILD PAIN (NON-OPIOID \u00b1 ADJUVANTS)</h3>\n<p>\u0089</p>\n<p>Paracetamol 10-15 mg/kg</p>\n<p>every 6 hours And/or</p>\n<p>\u0089</p>\n<p>Ibuprofen 5-10 mg/ kg every</p>\n<p>6-8 hours (use only in children</p>\n<p>>3 months)</p>\n<p>w\tContinue with step 1 anal\u00ad</p>\n<p>gesics when moving to step 2</p>\n<p>w\tProlonged use of high doses</p>\n<p>of paracetamol may cause</p>\n<p>liver toxicity</p>"
    },
    {
        "page_number": 694,
        "content": "628\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nANALGESICS\nCOMMENTS\nSTEP 2: MODERATE AND SEVERE PAIN (OPIOID \u00b1 NON-OPIOID \u00b1 ADJUVANT)\n\t\n\u0089\nMorphine every 4 hours\n1-6 months: 0.01 mg/kg\n6-12 months: 0.2 mg/kg\n1-2 years: 0.2-0.4 mg/kg\n2-12 years: 0.2-0.5 mg/ kg (max \n10 mg)\nIncrease the dose\nslowly, until pain is controlled\nIncrease dose by max\n50% every 24 hours\nw\tCodeine and tramadol are \nnot used in children\nw\tGive Bisacodyl \n(suppository only) 5 \nmg nocte to prevent \nconstipation except if \ndiarrhoea is present\nAdjuvants\n\t\n\u0089\nAmitriptyline nocte for neu\u00ad\nropathic pain\n\t\n\u0089\nChild 2-12 years: 0.2-0.5 \nmg/kg (max 1 mg/kg or 25 \nmg)\n\t\n\u0089\nOr Carbamazepine 5-20 mg/\nkg in 2-3 divided doses, in\u00ad\ncrease gradually to avoid side \neffects (second line)\n\t\n\u0089\nPrednisolone 1-2 mg/kg per \nday\n\t\n\u0089\nHyoscine\n\t\n\u0089\n1 month-2 years: 0.5 mg/kg \nevery 8 hours\n\t\n\u0089\n2-5 years: 5 mg every 8 hours\n\t\n\u0089\n6-12 years: 10 mg every 8 \nhours\n\t\n\u0089\nDiazepam for associated \nanxiety\n\t\n\u0089\nChild 1-6 years: 1 mg/day \nin 2-3 divided doses\n\t\n\u0089\nChild 6-14 years: 2-10 mg/\nday in 2-3 divided doses",
        "formatted_content": "<p>628</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>ANALGESICS</h3>\n<h3>COMMENTS</h3>\n<h3>STEP 2: MODERATE AND SEVERE PAIN (OPIOID \u00b1 NON-OPIOID \u00b1 ADJUVANT)</h3>\n<p>\u0089</p>\n<p>Morphine every 4 hours</p>\n<p>1-6 months: 0.01 mg/kg</p>\n<p>6-12 months: 0.2 mg/kg</p>\n<p>1-2 years: 0.2-0.4 mg/kg</p>\n<p>2-12 years: 0.2-0.5 mg/ kg (max</p>\n<p>10 mg)</p>\n<p>Increase the dose</p>\n<p>slowly, until pain is controlled</p>\n<p>Increase dose by max</p>\n<p>50% every 24 hours</p>\n<p>w\tCodeine and tramadol are</p>\n<p>not used in children</p>\n<p>w\tGive Bisacodyl</p>\n<p>(suppository only) 5</p>\n<p>mg nocte to prevent</p>\n<p>constipation except if</p>\n<p>diarrhoea is present</p>\n<p>Adjuvants</p>\n<p>\u0089</p>\n<p>Amitriptyline nocte for neu\u00ad</p>\n<p>ropathic pain</p>\n<p>\u0089</p>\n<p>Child 2-12 years: 0.2-0.5</p>\n<p>mg/kg (max 1 mg/kg or 25</p>\n<p>mg)</p>\n<p>\u0089</p>\n<p>Or Carbamazepine 5-20 mg/</p>\n<p>kg in 2-3 divided doses, in\u00ad</p>\n<p>crease gradually to avoid side</p>\n<p>effects (second line)</p>\n<p>\u0089</p>\n<p>Prednisolone 1-2 mg/kg per</p>\n<p>day</p>\n<p>\u0089</p>\n<p>Hyoscine</p>\n<p>\u0089</p>\n<p>1 month-2 years: 0.5 mg/kg</p>\n<p>every 8 hours</p>\n<p>\u0089</p>\n<p>2-5 years: 5 mg every 8 hours</p>\n<p>\u0089</p>\n<p>6-12 years: 10 mg every 8</p>\n<p>hours</p>\n<p>\u0089</p>\n<p>Diazepam for associated</p>\n<p>anxiety</p>\n<p>\u0089</p>\n<p>Child 1-6 years: 1 mg/day</p>\n<p>in 2-3 divided doses</p>\n<p>\u0089</p>\n<p>Child 6-14 years: 2-10 mg/</p>\n<p>day in 2-3 divided doses</p>"
    },
    {
        "page_number": 695,
        "content": "629\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nGeneral principles in use of opioids\n \n~\nHealth professionals specially trained in palliative care \nshould supervise management of chronic pain in advanced \nor incurable conditions (e.g., cancer, AIDS)\n \n~\nMorphine is usually the drug of choice for severe pain. \nLiquid morphine is available, easy to dose, and is well ab\u00ad\nsorbed from the oral mucosae and can be dripped in the \nmouth of adults and children\n \n~\nIn continuous pain, analgesics should be given:\n\t\n\u0089\nBy the clock (i.e. according to a regular dose schedule)\n\t\n\u0089\nBy the patient (i.e. self-administered)\n\t\n\u0089\nBy the mouth (i.e. as oral dose forms)\n \n~\nPain is better controlled using regular oral doses which \ncontrol pain. If pain is not controlled, increase the 24-hour \ndose by 30-50%\n\t\n\u0089\nRepeated injections are not indicated\n \n~\nConsider extra doses when painful procedure is planned \nand for breakthrough pain. If using breakthrough doses \nregularly, then increase the regular dose!\n \n~\nSide effects are minor and well-manageable if careful dos\u00ad\ning and titration are done\nCautions on use of opioids\nOpioids need to be effectively managed and administered, considering \nthe associated cautions and side effects below. r Do not use opioids in \nsevere respiratory depression and\nhead injury\n \n\u0083 Use with care in the following conditions\n \n\u0083 Advanced liver disease (but can be used in hepatocellular \ncarcinoma when titrated as above)\n \n\u0083 Acute asthma\n \n\u0083 Acute abdominal pain (can use while awaiting diagnostic tests; \nnever leave the patient in pain)\n \n\u0083 Hypothyroidism",
        "formatted_content": "<p>629</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>General principles in use of opioids</p>\n<p>~</p>\n<p>Health professionals specially trained in palliative care</p>\n<p>should supervise management of chronic pain in advanced</p>\n<p>or incurable conditions (e.g., cancer, AIDS)</p>\n<p>~</p>\n<p>Morphine is usually the drug of choice for severe pain.</p>\n<p>Liquid morphine is available, easy to dose, and is well ab\u00ad</p>\n<p>sorbed from the oral mucosae and can be dripped in the</p>\n<p>mouth of adults and children</p>\n<p>~</p>\n<p>In continuous pain, analgesics should be given:</p>\n<p>\u0089</p>\n<p>By the clock (i.e. according to a regular dose schedule)</p>\n<p>\u0089</p>\n<p>By the patient (i.e. self-administered)</p>\n<p>\u0089</p>\n<p>By the mouth (i.e. as oral dose forms)</p>\n<p>~</p>\n<p>Pain is better controlled using regular oral doses which</p>\n<p>control pain. If pain is not controlled, increase the 24-hour</p>\n<p>dose by 30-50%</p>\n<p>\u0089</p>\n<p>Repeated injections are not indicated</p>\n<p>~</p>\n<p>Consider extra doses when painful procedure is planned</p>\n<p>and for breakthrough pain. If using breakthrough doses</p>\n<p>regularly, then increase the regular dose!</p>\n<p>~</p>\n<p>Side effects are minor and well-manageable if careful dos\u00ad</p>\n<p>ing and titration are done</p>\n<p>Cautions on use of opioids</p>\n<p>Opioids need to be effectively managed and administered, considering</p>\n<p>the associated cautions and side effects below. r Do not use opioids in</p>\n<p>severe respiratory depression and</p>\n<p>head injury</p>\n<p>\u0083 Use with care in the following conditions</p>\n<p>\u0083 Advanced liver disease (but can be used in hepatocellular</p>\n<p>carcinoma when titrated as above)</p>\n<p>\u0083 Acute asthma</p>\n<p>\u0083 Acute abdominal pain (can use while awaiting diagnostic tests;</p>\n<p>never leave the patient in pain)</p>\n<p>\u0083 Hypothyroidism</p>"
    },
    {
        "page_number": 696,
        "content": "630\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\n \n\u0083 Renal failure (reduce starting dose and/or reduce dose \nfrequency)\n \n\u0083 Elderly or severely wasted patient (reduce starting dose\n \n\u0083 and/or reduce dose frequency)\n \n\u0083 Use with extreme care (i.e., start with small doses and use \nsmall incremental increases) in:\n \n\u0083 Recurrent or concurrent intake of alcohol or other CNS\n \n\u0083 depressants\nManagement of Side Effects of Opioids\nSIDE EFFECT\nMANAGE AS:\nRespiratory depression\n \n\u0083 Rarely occurs if small oral doses are used and gradually \ntitrated to response\n \n\u0083 Can occur when morphine used parenterally\n\t\n\u0089\nReverse respiratory depression using naloxone 0.4-2 mg slow \nIV every\n2-3 minutes according to response\nChild: 0.01 mg/kg slow IV; repeat 0.1 mg/kg if no response\nConstipation\n\t\n\u0089\nGive Bisacodyl 10-15 mg nocte to prevent \nconstipation except if diarrhoea is present \nChild: 5 mg rectally\n\t\n\u0089\nAdd liquid paraffin 10 ml once a day if bisacodyl \nis not enough\nNausea or \nVomiting\n\t\n\u0089\nUsually occurs in first 5 days and is self-limiting\n\t\n\u0089\nVomiting later on may be due to another cause\n\t\n\u0089\nGive anti-emetic (e.g.\n\t\n\u0089\nmetoclopramide 10 mg\n\t\n\u0089\nevery 8 hours for 3\u20135 days)\nChild 9-18 yrs: 5 mg 8 hourly\nChild 5-9 yrs: 2.5 mg 8 hourly\nChild 3-9 yrs: 2-2.5 mg 8 hourly\nChild 1-3 yrs: 1 mg 8 hourly\nChild <1 yr: 100 micrograms per kg every 12 hours",
        "formatted_content": "<p>630</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>\u0083 Renal failure (reduce starting dose and/or reduce dose</p>\n<p>frequency)</p>\n<p>\u0083 Elderly or severely wasted patient (reduce starting dose</p>\n<p>\u0083 and/or reduce dose frequency)</p>\n<p>\u0083 Use with extreme care (i.e., start with small doses and use</p>\n<p>small incremental increases) in:</p>\n<p>\u0083 Recurrent or concurrent intake of alcohol or other CNS</p>\n<p>\u0083 depressants</p>\n<p>Management of Side Effects of Opioids</p>\n<h3>SIDE EFFECT</h3>\n<h3>MANAGE AS:</h3>\n<p>Respiratory depression</p>\n<p>\u0083 Rarely occurs if small oral doses are used and gradually</p>\n<p>titrated to response</p>\n<p>\u0083 Can occur when morphine used parenterally</p>\n<p>\u0089</p>\n<p>Reverse respiratory depression using naloxone 0.4-2 mg slow</p>\n<p>IV every</p>\n<p>2-3 minutes according to response</p>\n<p>Child: 0.01 mg/kg slow IV; repeat 0.1 mg/kg if no response</p>\n<p>Constipation</p>\n<p>\u0089</p>\n<p>Give Bisacodyl 10-15 mg nocte to prevent</p>\n<p>constipation except if diarrhoea is present</p>\n<p>Child: 5 mg rectally</p>\n<p>\u0089</p>\n<p>Add liquid paraffin 10 ml once a day if bisacodyl</p>\n<p>is not enough</p>\n<p>Nausea or</p>\n<p>Vomiting</p>\n<p>\u0089</p>\n<p>Usually occurs in first 5 days and is self-limiting</p>\n<p>\u0089</p>\n<p>Vomiting later on may be due to another cause</p>\n<p>\u0089</p>\n<p>Give anti-emetic (e.g.</p>\n<p>\u0089</p>\n<p>metoclopramide 10 mg</p>\n<p>\u0089</p>\n<p>every 8 hours for 3\u20135 days)</p>\n<p>Child 9-18 yrs: 5 mg 8 hourly</p>\n<p>Child 5-9 yrs: 2.5 mg 8 hourly</p>\n<p>Child 3-9 yrs: 2-2.5 mg 8 hourly</p>\n<p>Child 1-3 yrs: 1 mg 8 hourly</p>\n<p>Child <1 yr: 100 micrograms per kg every 12 hours</p>"
    },
    {
        "page_number": 697,
        "content": "631\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nSIDE EFFECT\nMANAGE AS:\nConfusion or \nDrowsiness\n\t\n\u0089\nIf excessive continuous drowsiness, titrate \nthe opioid dose down slowly\nReferral criteria\n \n~\nIf pain does not respond to above measures, refer to pal\u00ad\nliative care specialist\n \n~\nRefer for radiotherapy at national referral hospital for se\u00ad\nvere bone pain not responding to above medications\n \n~\nRefer for surgery if the cause of pain is amenable to sur\u00ad\ngery\n13.1.3  Neuropathic Pain\nNeuropathic pain occurs as a result of damage to nerve tissue. There are \ntwo clinical kinds of neuropathic pain, both elements may be combined:\n \n~\nStabbing-type: pain in a nerve distribution with minimal \npain in between (e.g. trigeminal neuralgia) but can occur \nwith any nerve. Responds to Phenytoin\n \n~\nParaesthesia dysaesthesiae, or burning-type pain: (e.g. \npost-herpetic neuralgia). Responds well to small doses of \nAmitriptyline\nManagement\nTREATMENT\nLOC\nTrigeminal neuralgia or stabbing-type pain\nAcute phase\n\t\n\u0089\nCarbamazepine initially 100 mg every 12 hours\n \n\u0083 Increase gradually by 200 mg every 2-3 days \naccording to response, max 1200 mg\n \n\u0083 Causes white cell depression\nHC3\nBurning type pain (post-herpetic neuralgia, diabetic neuropathy)\n\t\n\u0089\nAmitriptyline 12.5-25 mg at night or every\n\t\n\u0089\n12 hours depending on response, max 50-75 mg\nHC3",
        "formatted_content": "<p>631</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>SIDE EFFECT</h3>\n<h3>MANAGE AS:</h3>\n<p>Confusion or</p>\n<p>Drowsiness</p>\n<p>\u0089</p>\n<p>If excessive continuous drowsiness, titrate</p>\n<p>the opioid dose down slowly</p>\n<p>Referral criteria</p>\n<p>~</p>\n<p>If pain does not respond to above measures, refer to pal\u00ad</p>\n<p>liative care specialist</p>\n<p>~</p>\n<p>Refer for radiotherapy at national referral hospital for se\u00ad</p>\n<p>vere bone pain not responding to above medications</p>\n<p>~</p>\n<p>Refer for surgery if the cause of pain is amenable to sur\u00ad</p>\n<p>gery</p>\n<p>13.1.3  Neuropathic Pain</p>\n<p>Neuropathic pain occurs as a result of damage to nerve tissue. There are</p>\n<p>two clinical kinds of neuropathic pain, both elements may be combined:</p>\n<p>~</p>\n<p>Stabbing-type: pain in a nerve distribution with minimal</p>\n<p>pain in between (e.g. trigeminal neuralgia) but can occur</p>\n<p>with any nerve. Responds to Phenytoin</p>\n<p>~</p>\n<p>Paraesthesia dysaesthesiae, or burning-type pain: (e.g.</p>\n<p>post-herpetic neuralgia). Responds well to small doses of</p>\n<p>Amitriptyline</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Trigeminal neuralgia or stabbing-type pain</p>\n<p>Acute phase</p>\n<p>\u0089</p>\n<p>Carbamazepine initially 100 mg every 12 hours</p>\n<p>\u0083 Increase gradually by 200 mg every 2-3 days</p>\n<p>according to response, max 1200 mg</p>\n<p>\u0083 Causes white cell depression</p>\n<h3>HC3</h3>\n<p>Burning type pain (post-herpetic neuralgia, diabetic neuropathy)</p>\n<p>\u0089</p>\n<p>Amitriptyline 12.5-25 mg at night or every</p>\n<p>\u0089</p>\n<p>12 hours depending on response, max 50-75 mg</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 698,
        "content": "632\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\n13.1.4 Back or Bone Pain\nIncludes pain in the lumbar region of the spine or bone pain anywhere \nwithin the body.\nCauses\nPotential causes of back or bone pain:\n \n~\nDisc degeneration (often has a neuropathic element be\u00ad\ncause of pressure on sciatic or other nerve)\n \n~\nOsteoporosis (if collapse of vertebrae or fracture)\nInfection (e.g. TB, brucellosis, PID, retroperitoneal)\n \n~\nMetastatic cancers, renal disease\n \n~\nStrain\n \n~\nCongenital abnormalities\n \n~\nSpondylolisthesis\nClinical Features\nEach situation will differ depending on the cause of the pain\n \n~\nIf an infection is present: throbbing and constant pain\n \n~\nIf sciatica, sciatic nerve roots will be involved\nInvestigations\n \n\u0081\nTry to establish the cause and type of pain\n \n\u0081\nX-ray: Spine and pelvis\nManagement of Back or Bone Pain\nTREATMENT\nLOC\nAnalgesics\n\t\n\u0089\nAnalgesics (see section 13.1.2 above)\n \n\u0083 Give a Step 1 drug for 7 days or as long as required \naccording to patient\n \n\u0083 NSAIDs are the Step 1 drug of choice in bone \npain\n \n\u0083 May have to add a Step 2 or 3 drug, especially in \nmetastatic disease\nHC4",
        "formatted_content": "<p>632</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>13.1.4 Back or Bone Pain</p>\n<p>Includes pain in the lumbar region of the spine or bone pain anywhere</p>\n<p>within the body.</p>\n<p>Causes</p>\n<p>Potential causes of back or bone pain:</p>\n<p>~</p>\n<p>Disc degeneration (often has a neuropathic element be\u00ad</p>\n<p>cause of pressure on sciatic or other nerve)</p>\n<p>~</p>\n<p>Osteoporosis (if collapse of vertebrae or fracture)</p>\n<p>Infection (e.g. TB, brucellosis, PID, retroperitoneal)</p>\n<p>~</p>\n<p>Metastatic cancers, renal disease</p>\n<p>~</p>\n<p>Strain</p>\n<p>~</p>\n<p>Congenital abnormalities</p>\n<p>~</p>\n<p>Spondylolisthesis</p>\n<p>Clinical Features</p>\n<p>Each situation will differ depending on the cause of the pain</p>\n<p>~</p>\n<p>If an infection is present: throbbing and constant pain</p>\n<p>~</p>\n<p>If sciatica, sciatic nerve roots will be involved</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Try to establish the cause and type of pain</p>\n<p>\u0081</p>\n<p>X-ray: Spine and pelvis</p>\n<p>Management of Back or Bone Pain</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Analgesics</p>\n<p>\u0089</p>\n<p>Analgesics (see section 13.1.2 above)</p>\n<p>\u0083 Give a Step 1 drug for 7 days or as long as required</p>\n<p>according to patient</p>\n<p>\u0083 NSAIDs are the Step 1 drug of choice in bone</p>\n<p>pain</p>\n<p>\u0083 May have to add a Step 2 or 3 drug, especially in</p>\n<p>metastatic disease</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 699,
        "content": "633\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\nFor acute back pain:\n\t\n\u0089\nRest the back on a firm but not hard surface\nFor neuropathic element:\n\t\n\u0089\nManage as for neuropathic pain above\nHC4\n13.2 OTHER CONDITIONS IN PALLIATIVE CARE\nIn palliative care, other conditions that are commonly encountered are \nsummarised in the table below.\n13.2.1 Breathlessness    ICD10 CODE: R06\nDue to palliative care conditions or anxiety\nManagement\nTREATMENT\nLOC\nNon-drug treatment\n\t\n\u0089\nReassure patient; explore patient\u2019s fears and anxieties; \nanxiety worsens condition\n\t\n\u0089\nBreathing exercises and relaxation techniques; teach \npatient how to slow down breathing by pursing their \nlips and breathe with diaphragm rather than chest\n\t\n\u0089\nPulmonary rehabilitation\n\t\n\u0089\nPosition patient in most comfortable position in bed\n\t\n\u0089\nEnsure good ventilation (e.g., open windows, use fans, \nloosen tight clothing)\n\t\n\u0089\nConserve energy (e.g., encourage exertion to breath\u00ad\nlessness)\n\t\n\u0089\nRefer if symptoms persist, in airway obstruction, or \nneed for pleurodesis\nMedicines\n\t\n\u0089\nOral morphine 2.5-5 mg every 4 hours. Oxygen \nif patient  is  hypoxic. Diazepam if patient is anxious\n \n\u0083 Diazepam 2.5-5 mg orally; once a day if \nbreathlessness is associated with panic attacks\nHC2\nHC4",
        "formatted_content": "<p>633</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>For acute back pain:</p>\n<p>\u0089</p>\n<p>Rest the back on a firm but not hard surface</p>\n<p>For neuropathic element:</p>\n<p>\u0089</p>\n<p>Manage as for neuropathic pain above</p>\n<h3>HC4</h3>\n<h3>13.2 OTHER CONDITIONS IN PALLIATIVE CARE</h3>\n<p>In palliative care, other conditions that are commonly encountered are</p>\n<p>summarised in the table below.</p>\n<p>13.2.1 Breathlessness    ICD10 CODE: R06</p>\n<p>Due to palliative care conditions or anxiety</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Non-drug treatment</p>\n<p>\u0089</p>\n<p>Reassure patient; explore patient\u2019s fears and anxieties;</p>\n<p>anxiety worsens condition</p>\n<p>\u0089</p>\n<p>Breathing exercises and relaxation techniques; teach</p>\n<p>patient how to slow down breathing by pursing their</p>\n<p>lips and breathe with diaphragm rather than chest</p>\n<p>\u0089</p>\n<p>Pulmonary rehabilitation</p>\n<p>\u0089</p>\n<p>Position patient in most comfortable position in bed</p>\n<p>\u0089</p>\n<p>Ensure good ventilation (e.g., open windows, use fans,</p>\n<p>loosen tight clothing)</p>\n<p>\u0089</p>\n<p>Conserve energy (e.g., encourage exertion to breath\u00ad</p>\n<p>lessness)</p>\n<p>\u0089</p>\n<p>Refer if symptoms persist, in airway obstruction, or</p>\n<p>need for pleurodesis</p>\n<p>Medicines</p>\n<p>\u0089</p>\n<p>Oral morphine 2.5-5 mg every 4 hours. Oxygen</p>\n<p>if patient  is  hypoxic. Diazepam if patient is anxious</p>\n<p>\u0083 Diazepam 2.5-5 mg orally; once a day if</p>\n<p>breathlessness is associated with panic attacks</p>\n<h3>HC2</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 700,
        "content": "634\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\n13.2.2 Nausea and Vomiting\t\nICD10 CODE: R11\nCan be due to disease or medicines\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat the cause\n\t\n\u0089\nVomiting typically relieves nausea\nIf due to gastric stasis or delayed bowel transit time\n\t\n\u0089\nGive metoclopramide 10\u201320 mg every 8 hours (30 \nminutes before meals; same dose SC or IV)\nIf due to metabolic disturbance (liver/renal failure, medicines \ne.g., chemotherapy)\n\t\n\u0089\nGive haloperidol 1.25 -2.5 mg nocte (PO or SC)\nIf due to raised intracranial pressure\n\t\n\u0089\nDexamethasone 8-16 mg od\n\t\n\u0089\nIf due to visceral stretch or compression f Promethaz\u00ad\nine 25 mg every 8 hours or f Hyoscine butylblomide \n20-40 mg 8 hourly\nHC4\nHC4 \nH\nHC3 \nHC4\n13.2.3 Pressure Ulcer (Decubitus Ulcers)     ICD10 CODE: L89\nUlcer of the skin and/or subcutaneous tissue caused by ischaemia \nsecondary to extrinsic pressure or shear\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nNon-drug treatment f Debridement of necrotic tissue \n\t\n\u0089\nClean with normal saline\n\t\n\u0089\nIf able, encourage patients to raise themselves off the \nseat and shift their weight every 15-20 minutes or to \ntake short walks\nHC3",
        "formatted_content": "<p>634</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>13.2.2 Nausea and Vomiting</p>\n<h3>ICD10 CODE: R11</h3>\n<p>Can be due to disease or medicines</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat the cause</p>\n<p>\u0089</p>\n<p>Vomiting typically relieves nausea</p>\n<p>If due to gastric stasis or delayed bowel transit time</p>\n<p>\u0089</p>\n<p>Give metoclopramide 10\u201320 mg every 8 hours (30</p>\n<p>minutes before meals; same dose SC or IV)</p>\n<p>If due to metabolic disturbance (liver/renal failure, medicines</p>\n<p>e.g., chemotherapy)</p>\n<p>\u0089</p>\n<p>Give haloperidol 1.25 -2.5 mg nocte (PO or SC)</p>\n<p>If due to raised intracranial pressure</p>\n<p>\u0089</p>\n<p>Dexamethasone 8-16 mg od</p>\n<p>\u0089</p>\n<p>If due to visceral stretch or compression f Promethaz\u00ad</p>\n<p>ine 25 mg every 8 hours or f Hyoscine butylblomide</p>\n<p>20-40 mg 8 hourly</p>\n<h3>HC4</h3>\n<h3>HC4</h3>\n<p>H</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>13.2.3 Pressure Ulcer (Decubitus Ulcers)     ICD10 CODE: L89</p>\n<p>Ulcer of the skin and/or subcutaneous tissue caused by ischaemia</p>\n<p>secondary to extrinsic pressure or shear</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Non-drug treatment f Debridement of necrotic tissue</p>\n<p>\u0089</p>\n<p>Clean with normal saline</p>\n<p>\u0089</p>\n<p>If able, encourage patients to raise themselves off the</p>\n<p>seat and shift their weight every 15-20 minutes or to</p>\n<p>take short walks</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 701,
        "content": "635\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\n\t\n\u0089\nRepositioning of those who cannot move themselves \nfrequently, determined by need and skin status\n\t\n\u0089\nInspect skin every time the patient\u2019s position is changed\n\t\n\u0089\nMaintain optimal hydration and hygiene of skin\n\t\n\u0089\nAvoid trauma, by not dragging patient\n\t\n\u0089\nGood nutrition for those with good prognosis to maintain \nnormal serum albumin\n\t\n\u0089\nEducate patient caretakers on risk factors for developing \npressure ulcers, how to inspect and care for skin, and \ninform health care professional\n\t\n\u0089\nMay need skin grafting and flaps; refer to hospital\nHC3\nMedicines\n\t\n\u0089\nGive antibiotics if there is evidence of surrounding cellulitis (see \nsection 22.1.3)\n\t\n\u0089\nControl pain\n\t\n\u0089\nControl odour with topical metronidazole\n\t\n\u0089\npowder or gel until there is no foul smell\n\t\n\u0089\nIf patient has sepsis, give parenteral antibiotics (see section 2.1.7 \nfor treatment of sepsis)\n13.2.4 Fungating Wounds\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat underlying cause\n\t\n\u0089\nClean the wound regularly every day with 0.9% saline \n(or dissolve 1 teaspoon of salt per pint of cooled boiled \nwater)\n\t\n\u0089\nApply clean dressings daily\n\t\n\u0089\nProtect the normal skin around the wound with barrier \ncreams (petroleum jelly)\n\t\n\u0089\nGive analgesia for pain\nHC2",
        "formatted_content": "<p>635</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Repositioning of those who cannot move themselves</p>\n<p>frequently, determined by need and skin status</p>\n<p>\u0089</p>\n<p>Inspect skin every time the patient\u2019s position is changed</p>\n<p>\u0089</p>\n<p>Maintain optimal hydration and hygiene of skin</p>\n<p>\u0089</p>\n<p>Avoid trauma, by not dragging patient</p>\n<p>\u0089</p>\n<p>Good nutrition for those with good prognosis to maintain</p>\n<p>normal serum albumin</p>\n<p>\u0089</p>\n<p>Educate patient caretakers on risk factors for developing</p>\n<p>pressure ulcers, how to inspect and care for skin, and</p>\n<p>inform health care professional</p>\n<p>\u0089</p>\n<p>May need skin grafting and flaps; refer to hospital</p>\n<h3>HC3</h3>\n<p>Medicines</p>\n<p>\u0089</p>\n<p>Give antibiotics if there is evidence of surrounding cellulitis (see</p>\n<p>section 22.1.3)</p>\n<p>\u0089</p>\n<p>Control pain</p>\n<p>\u0089</p>\n<p>Control odour with topical metronidazole</p>\n<p>\u0089</p>\n<p>powder or gel until there is no foul smell</p>\n<p>\u0089</p>\n<p>If patient has sepsis, give parenteral antibiotics (see section 2.1.7</p>\n<p>for treatment of sepsis)</p>\n<p>13.2.4 Fungating Wounds</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat underlying cause</p>\n<p>\u0089</p>\n<p>Clean the wound regularly every day with 0.9% saline</p>\n<p>(or dissolve 1 teaspoon of salt per pint of cooled boiled</p>\n<p>water)</p>\n<p>\u0089</p>\n<p>Apply clean dressings daily</p>\n<p>\u0089</p>\n<p>Protect the normal skin around the wound with barrier</p>\n<p>creams (petroleum jelly)</p>\n<p>\u0089</p>\n<p>Give analgesia for pain</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 702,
        "content": "636\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\n\t\n\u0089\nIf malodour/exudate: apply metronidazole powder daily \ndirectly to the wound when changing dressing\n\t\n\u0089\nIf cellulitis, give appropriate antibiotic\n13.2.5 Anorexia and Cachexia      ICD10 CODE: R63.0 AND R64\nAnorexia is loss of desire to eat. Cachexia is a complex metabolic syn\u00ad\ndrome, characterized by profound loss of lean body mass, in terminal \nillnesses.\nCauses\n \n~\nNausea and vomiting, constipation, gastrointestinal ob\u00ad\nstruction\n \n~\nSore mouth, mouth tumours, malodour\n \n~\nHypercalcaemia, hyponatraemia, uraemia, liver failure\n \n~\nMedications\n \n~\nDepression\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat underlying causes if possible.\n\t\n\u0089\nIn cancer patients, give corticosteroids for one week \nonly, under supervision of specialist\n \n\u0083 Prednisolone 15-40 mg once a day for 7 days\n \n\u0083 Or dexamethasone 2-6 mg in the morning for 7 \ndays\nNon-medicine treatment\n\t\n\u0089\nSmall amounts of food frequently\n\t\n\u0089\nGive energy-dense food, and limit fat intake\n\t\n\u0089\nAvoid extremes in taste and smell\n\t\n\u0089\nPleasant environment, nice presentation of food\nHC4",
        "formatted_content": "<p>636</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If malodour/exudate: apply metronidazole powder daily</p>\n<p>directly to the wound when changing dressing</p>\n<p>\u0089</p>\n<p>If cellulitis, give appropriate antibiotic</p>\n<p>13.2.5 Anorexia and Cachexia      ICD10 CODE: R63.0 AND R64</p>\n<p>Anorexia is loss of desire to eat. Cachexia is a complex metabolic syn\u00ad</p>\n<p>drome, characterized by profound loss of lean body mass, in terminal</p>\n<p>illnesses.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Nausea and vomiting, constipation, gastrointestinal ob\u00ad</p>\n<p>struction</p>\n<p>~</p>\n<p>Sore mouth, mouth tumours, malodour</p>\n<p>~</p>\n<p>Hypercalcaemia, hyponatraemia, uraemia, liver failure</p>\n<p>~</p>\n<p>Medications</p>\n<p>~</p>\n<p>Depression</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat underlying causes if possible.</p>\n<p>\u0089</p>\n<p>In cancer patients, give corticosteroids for one week</p>\n<p>only, under supervision of specialist</p>\n<p>\u0083 Prednisolone 15-40 mg once a day for 7 days</p>\n<p>\u0083 Or dexamethasone 2-6 mg in the morning for 7</p>\n<p>days</p>\n<p>Non-medicine treatment</p>\n<p>\u0089</p>\n<p>Small amounts of food frequently</p>\n<p>\u0089</p>\n<p>Give energy-dense food, and limit fat intake</p>\n<p>\u0089</p>\n<p>Avoid extremes in taste and smell</p>\n<p>\u0089</p>\n<p>Pleasant environment, nice presentation of food</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 703,
        "content": "637\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\n\t\n\u0089\nEating is a social habit and people eat better with others\n\t\n\u0089\nNutritional counselling\n\t\n\u0089\nIf prognosis <2 months, counsel patient and family to \nunderstand and adjust to reduced appetite as a normal \ndisease process\nCaution\n \n\u0083 In established cancer and cachexia, aggressive \nparenteral and enteral nutritional supplementation \nis of minimal value\n13.2.6 Hiccup\t\nICD10 CODE: R06.6\nRepeated involuntary spasmodic diaphragmatic and inspiratory inter\u00ad\ncostal muscle contractions. Hiccups up to 48 hours are acute, those \nlasting more than 48 hours are persistent and more than 2 months \nare intractable.\nCauses\n \n~\nGastric distension, GERD, gastritis, diaphragmatic irrita\u00ad\ntion by supraphrenic metastasis, phrenic nerve irritation\n \n~\nMetabolic: uraemia, hypokalaemia, hypocalcaemia, hyper\u00ad\nglycaemia, hypocapnia\n \n~\nInfection: oesophageal candidiasis\n \n~\nBrain tumour, stroke, stress\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nMost hiccups are short-lived and self-limiting\n\t\n\u0089\nTreat underlying cause\nHC2",
        "formatted_content": "<p>637</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Eating is a social habit and people eat better with others</p>\n<p>\u0089</p>\n<p>Nutritional counselling</p>\n<p>\u0089</p>\n<p>If prognosis <2 months, counsel patient and family to</p>\n<p>understand and adjust to reduced appetite as a normal</p>\n<p>disease process</p>\n<p>Caution</p>\n<p>\u0083 In established cancer and cachexia, aggressive</p>\n<p>parenteral and enteral nutritional supplementation</p>\n<p>is of minimal value</p>\n<p>13.2.6 Hiccup</p>\n<h3>ICD10 CODE: R06.6</h3>\n<p>Repeated involuntary spasmodic diaphragmatic and inspiratory inter\u00ad</p>\n<p>costal muscle contractions. Hiccups up to 48 hours are acute, those</p>\n<p>lasting more than 48 hours are persistent and more than 2 months</p>\n<p>are intractable.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Gastric distension, GERD, gastritis, diaphragmatic irrita\u00ad</p>\n<p>tion by supraphrenic metastasis, phrenic nerve irritation</p>\n<p>~</p>\n<p>Metabolic: uraemia, hypokalaemia, hypocalcaemia, hyper\u00ad</p>\n<p>glycaemia, hypocapnia</p>\n<p>~</p>\n<p>Infection: oesophageal candidiasis</p>\n<p>~</p>\n<p>Brain tumour, stroke, stress</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Most hiccups are short-lived and self-limiting</p>\n<p>\u0089</p>\n<p>Treat underlying cause</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 704,
        "content": "638\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nNon-medicine treatment\n\t\n\u0089\nDirect stimulation of the pharynx by swallowing dry \nbread or other dry food\n\t\n\u0089\nStimulation of vagus nerve by ingesting crushed ice or \nvalsalva manouvre\n\t\n\u0089\nRapidly ingest 2 heaped teaspoons of sugar\n\t\n\u0089\nIndirect stimulation of the pharynx\n\t\n\u0089\n\u2013 C3-5 dermatome stimulation by tapping or rubbing \nthe back of the neck\n\t\n\u0089\nRefer if hiccups persist or are intractable\n\t\n\u0089\nMedicines\n\t\n\u0089\nFor persistent or intractable hiccups use:\n\t\n\u0089\nMetoclopramide 10 mg 8 hourly (if the cause is gastric \ndistension)\n\t\n\u0089\nOr Haloperidol 2\u20135 mg once a day\n\t\n\u0089\nOr chlorpromazine 25 mg 6 hourly\nHC4\nHC3\n13.2.7 Dry or Painful Mouth\t\nICD10 CODE: R68.2\nDry mouth, painful mouth and mouth ulcers are caused by infec\u00ad\ntions, drugs, chemotherapy, trauma, dryness, radiotherapy, HIV \nand opportunistic infections.\nTREATMENT\nLOC\nNon-medicine treatment\n\t\n\u0089\nMouth wash with salted water (hourly), frequent sipping \nto keep mouth moist\n\t\n\u0089\nBrush teeth and tongue at least 3 times a day\n\t\n\u0089\nSuck fresh cold pineapple cubes once or twice daily\n\t\n\u0089\nAvoid sugary foods and drinks, eat soft food\n\t\n\u0089\nApply vaseline to cracked lips\n\t\n\u0089\nReview medications (dry mouth can be a side effect, \ne.g. of amitriptyline)\nHC2",
        "formatted_content": "<p>638</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Non-medicine treatment</p>\n<p>\u0089</p>\n<p>Direct stimulation of the pharynx by swallowing dry</p>\n<p>bread or other dry food</p>\n<p>\u0089</p>\n<p>Stimulation of vagus nerve by ingesting crushed ice or</p>\n<p>valsalva manouvre</p>\n<p>\u0089</p>\n<p>Rapidly ingest 2 heaped teaspoons of sugar</p>\n<p>\u0089</p>\n<p>Indirect stimulation of the pharynx</p>\n<p>\u0089</p>\n<p>\u2013 C3-5 dermatome stimulation by tapping or rubbing</p>\n<p>the back of the neck</p>\n<p>\u0089</p>\n<p>Refer if hiccups persist or are intractable</p>\n<p>\u0089</p>\n<p>Medicines</p>\n<p>\u0089</p>\n<p>For persistent or intractable hiccups use:</p>\n<p>\u0089</p>\n<p>Metoclopramide 10 mg 8 hourly (if the cause is gastric</p>\n<p>distension)</p>\n<p>\u0089</p>\n<p>Or Haloperidol 2\u20135 mg once a day</p>\n<p>\u0089</p>\n<p>Or chlorpromazine 25 mg 6 hourly</p>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>13.2.7 Dry or Painful Mouth</p>\n<h3>ICD10 CODE: R68.2</h3>\n<p>Dry mouth, painful mouth and mouth ulcers are caused by infec\u00ad</p>\n<p>tions, drugs, chemotherapy, trauma, dryness, radiotherapy, HIV</p>\n<p>and opportunistic infections.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Non-medicine treatment</p>\n<p>\u0089</p>\n<p>Mouth wash with salted water (hourly), frequent sipping</p>\n<p>to keep mouth moist</p>\n<p>\u0089</p>\n<p>Brush teeth and tongue at least 3 times a day</p>\n<p>\u0089</p>\n<p>Suck fresh cold pineapple cubes once or twice daily</p>\n<p>\u0089</p>\n<p>Avoid sugary foods and drinks, eat soft food</p>\n<p>\u0089</p>\n<p>Apply vaseline to cracked lips</p>\n<p>\u0089</p>\n<p>Review medications (dry mouth can be a side effect,</p>\n<p>e.g. of amitriptyline)</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 705,
        "content": "639\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\nTreat appropriate infection:\n\t\n\u0089\nCandidiasis with fluconazole 200 mg od for 7 days\n\t\n\u0089\nHerpes simplex with oral acyclovir 200 mg, 5 times a \nday for 5\u201310 days depending on severity\n\t\n\u0089\nAnaerobic gingivitis, halitosis, with metronidazole \nmouthwash (mix 50 mL of IV metronidazole with 450 \nmL of water, plus 50 mL of juice)\nSevere mucositis or aphtous ulcers\n\t\n\u0089\nConsider steroids dexamethasone 8 mg once daily for \n5 days\n\t\n\u0089\nAnalgesic gel (Bonjela, Oracure) on ulcers\nPainful mouth\n\t\n\u0089\nOral liquid morphine as above (before swallowing, hold \nliquid morphine in the mouth for at least 30 seconds)\nHC3\nHC4\nHC3\n13.2.8 Other Symptoms\nTREATMENT\nLOC\nAnxiety and muscle spasm\n\t\n\u0089\nDiazepam 5-10 mg once a day, titrated to three times \na day\nHC2\nExcessive bronchial secretions\n\t\n\u0089\nHyoscine 20 mg once a day titrated to 3 times a day \naccording to response\nHC4\nIntractable cough\n\t\n\u0089\nMorphine as above (see section 13.1.2)\nHC3\n13.2.9 End of Life Care\nCare in the last days of life.",
        "formatted_content": "<p>639</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treat appropriate infection:</p>\n<p>\u0089</p>\n<p>Candidiasis with fluconazole 200 mg od for 7 days</p>\n<p>\u0089</p>\n<p>Herpes simplex with oral acyclovir 200 mg, 5 times a</p>\n<p>day for 5\u201310 days depending on severity</p>\n<p>\u0089</p>\n<p>Anaerobic gingivitis, halitosis, with metronidazole</p>\n<p>mouthwash (mix 50 mL of IV metronidazole with 450</p>\n<p>mL of water, plus 50 mL of juice)</p>\n<p>Severe mucositis or aphtous ulcers</p>\n<p>\u0089</p>\n<p>Consider steroids dexamethasone 8 mg once daily for</p>\n<p>5 days</p>\n<p>\u0089</p>\n<p>Analgesic gel (Bonjela, Oracure) on ulcers</p>\n<p>Painful mouth</p>\n<p>\u0089</p>\n<p>Oral liquid morphine as above (before swallowing, hold</p>\n<p>liquid morphine in the mouth for at least 30 seconds)</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>13.2.8 Other Symptoms</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Anxiety and muscle spasm</p>\n<p>\u0089</p>\n<p>Diazepam 5-10 mg once a day, titrated to three times</p>\n<p>a day</p>\n<h3>HC2</h3>\n<p>Excessive bronchial secretions</p>\n<p>\u0089</p>\n<p>Hyoscine 20 mg once a day titrated to 3 times a day</p>\n<p>according to response</p>\n<h3>HC4</h3>\n<p>Intractable cough</p>\n<p>\u0089</p>\n<p>Morphine as above (see section 13.1.2)</p>\n<h3>HC3</h3>\n<p>13.2.9 End of Life Care</p>\n<p>Care in the last days of life.</p>"
    },
    {
        "page_number": 706,
        "content": "640\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nClinical  Features\nClinical signs at of end of life include (should be considered in those with \nterminal conditions who have been gradually deteriorating):\n \n~\nPatient becomes bed-bound and is increasingly drowsy or \nin a semi-conscious state\n \n~\nMinimal oral intake; patient not managing oral medication \nand only able to take sips of fluid\n \n~\nThe patient\u2019s condition is deteriorating rapidly (e.g. day by \nday or hour by hour)\n \n~\nBreathing becomes irregular +/- noisy (death rattle)\n \n~\nChanges in skin colour and/ or temperature\n \n~\nLimited attention span\nInvestigations\n \n\u0081\nExclude reversible problems (e.g. drug toxicity, infections, de\u00ad\nhydration, biochemical abnormalities)\n \n\u0081\nBefore ordering a test, always ask \u201dwill this test change my \nmanagement plan or the outcome for the patient?\u201d\n \n\u0081\nIt is important to weigh the benefit versus the burden in assessing \nan intervention, and/or management plan based on the clinical \nfeatures exhibited by the patient\nManagement\nTREATMENT\nLOC\nGeneral principles of medicine treatment\n\t\n\u0089\nFocus on giving medication that will improve the pa\u00ad\ntient\u2019s quality of life\n\t\n\u0089\nTreat symptoms of discomfort as in sections above\n\t\n\u0089\nIf the patient is unable to swallow choose an appropriate \nroute to give necessary medications (e.g., via NG tube, \nparenteral or rectally)\n\t\n\u0089\nSubcutaneous (SC) is recommended when the enteral \nroute is not possible. It is preferred over IV and IM \naccess due to its reduced trauma and pharmacokinetics\nHC2",
        "formatted_content": "<p>640</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<p>Clinical  Features</p>\n<p>Clinical signs at of end of life include (should be considered in those with</p>\n<p>terminal conditions who have been gradually deteriorating):</p>\n<p>~</p>\n<p>Patient becomes bed-bound and is increasingly drowsy or</p>\n<p>in a semi-conscious state</p>\n<p>~</p>\n<p>Minimal oral intake; patient not managing oral medication</p>\n<p>and only able to take sips of fluid</p>\n<p>~</p>\n<p>The patient\u2019s condition is deteriorating rapidly (e.g. day by</p>\n<p>day or hour by hour)</p>\n<p>~</p>\n<p>Breathing becomes irregular +/- noisy (death rattle)</p>\n<p>~</p>\n<p>Changes in skin colour and/ or temperature</p>\n<p>~</p>\n<p>Limited attention span</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Exclude reversible problems (e.g. drug toxicity, infections, de\u00ad</p>\n<p>hydration, biochemical abnormalities)</p>\n<p>\u0081</p>\n<p>Before ordering a test, always ask \u201dwill this test change my</p>\n<p>management plan or the outcome for the patient?\u201d</p>\n<p>\u0081</p>\n<p>It is important to weigh the benefit versus the burden in assessing</p>\n<p>an intervention, and/or management plan based on the clinical</p>\n<p>features exhibited by the patient</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General principles of medicine treatment</p>\n<p>\u0089</p>\n<p>Focus on giving medication that will improve the pa\u00ad</p>\n<p>tient\u2019s quality of life</p>\n<p>\u0089</p>\n<p>Treat symptoms of discomfort as in sections above</p>\n<p>\u0089</p>\n<p>If the patient is unable to swallow choose an appropriate</p>\n<p>route to give necessary medications (e.g., via NG tube,</p>\n<p>parenteral or rectally)</p>\n<p>\u0089</p>\n<p>Subcutaneous (SC) is recommended when the enteral</p>\n<p>route is not possible. It is preferred over IV and IM</p>\n<p>access due to its reduced trauma and pharmacokinetics</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 707,
        "content": "641\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\n\t\n\u0089\nIf repeated injections are anticipated or experienced, a \nbutterfly needle can be inserted and used as a route for \nregular SC injections\n\t\n\u0089\nConsider prescribing medications pre-emptively (antic\u00ad\nipatory) to combat developing symptoms\n\t\n\u0089\nMorphine concentrations can vary depending on the \npreparation used; remember that SC morphine has twice \nthe potency of oral morphine\nHydration and nutrition\n\t\n\u0089\nPatients should eat and drink as they wish, and take \nsips of water as long as they are able\n\t\n\u0089\nFamilies should be educated that it is normal for patients \nto lose their appetite, have a sense of thirst and stop \nfeeding towards the end of life.\n\t\n\u0089\nThey should not feed patients if they are no longer able \nto swallow as this may cause choking and distress\n\t\n\u0089\nIV fluids at this stage will not prolong life or prevent \nthirst. Over-hydration is discouraged as it may contrib\u00ad\nute to distressing respiratory secretions or generalised \noedema; good regular mouthcare is the best way to keep \nthe patient comfortable\n\t\n\u0089\nIV dextrose for calorie supplementation is unlikely to \nbe of benefit\n\t\n\u0089\nIf there is a reduced level of consciousness, patients \nshould not be fed due to the risk of aspiration.\n\t\n\u0089\nArtificial nutrition is generally discouraged at the end of life\nSupportive care\n\t\n\u0089\nKeep the patient clean and dry\n\t\n\u0089\nRegularly clean the mouth with a moist cloth wrapped \nround a spoon\n\t\n\u0089\nPrevent and manage pressure sores appropriately\n\t\n\u0089\nManage any associated pain",
        "formatted_content": "<p>641</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If repeated injections are anticipated or experienced, a</p>\n<p>butterfly needle can be inserted and used as a route for</p>\n<p>regular SC injections</p>\n<p>\u0089</p>\n<p>Consider prescribing medications pre-emptively (antic\u00ad</p>\n<p>ipatory) to combat developing symptoms</p>\n<p>\u0089</p>\n<p>Morphine concentrations can vary depending on the</p>\n<p>preparation used; remember that SC morphine has twice</p>\n<p>the potency of oral morphine</p>\n<p>Hydration and nutrition</p>\n<p>\u0089</p>\n<p>Patients should eat and drink as they wish, and take</p>\n<p>sips of water as long as they are able</p>\n<p>\u0089</p>\n<p>Families should be educated that it is normal for patients</p>\n<p>to lose their appetite, have a sense of thirst and stop</p>\n<p>feeding towards the end of life.</p>\n<p>\u0089</p>\n<p>They should not feed patients if they are no longer able</p>\n<p>to swallow as this may cause choking and distress</p>\n<p>\u0089</p>\n<p>IV fluids at this stage will not prolong life or prevent</p>\n<p>thirst. Over-hydration is discouraged as it may contrib\u00ad</p>\n<p>ute to distressing respiratory secretions or generalised</p>\n<p>oedema; good regular mouthcare is the best way to keep</p>\n<p>the patient comfortable</p>\n<p>\u0089</p>\n<p>IV dextrose for calorie supplementation is unlikely to</p>\n<p>be of benefit</p>\n<p>\u0089</p>\n<p>If there is a reduced level of consciousness, patients</p>\n<p>should not be fed due to the risk of aspiration.</p>\n<p>\u0089</p>\n<p>Artificial nutrition is generally discouraged at the end of life</p>\n<p>Supportive care</p>\n<p>\u0089</p>\n<p>Keep the patient clean and dry</p>\n<p>\u0089</p>\n<p>Regularly clean the mouth with a moist cloth wrapped</p>\n<p>round a spoon</p>\n<p>\u0089</p>\n<p>Prevent and manage pressure sores appropriately</p>\n<p>\u0089</p>\n<p>Manage any associated pain</p>"
    },
    {
        "page_number": 708,
        "content": "642\nUganda Clinical Guidelines 2023\nCHAPTER 13:  Palliative  Care\nTREATMENT\nLOC\n\t\n\u0089\nThe end of life is an emotional time for all involved and \nrequires health care professionals to be considerate and \ncompassionate. Take time to listen to the concerns of \nthe patient and their family; break bad news sensitively\n\t\n\u0089\nEncourage the family to be present, holding a hand \nor talking to the patient even if there is no visible re\u00ad\nsponse; the patient may be able to hear even if they \ncannot respond\n\t\n\u0089\nConsider spiritual support\n\t\n\u0089\nConsider the best place of death for the patient and their \nfamily; would discharging them to go home be best?",
        "formatted_content": "<p>642</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 13:  Palliative  Care</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>The end of life is an emotional time for all involved and</p>\n<p>requires health care professionals to be considerate and</p>\n<p>compassionate. Take time to listen to the concerns of</p>\n<p>the patient and their family; break bad news sensitively</p>\n<p>\u0089</p>\n<p>Encourage the family to be present, holding a hand</p>\n<p>or talking to the patient even if there is no visible re\u00ad</p>\n<p>sponse; the patient may be able to hear even if they</p>\n<p>cannot respond</p>\n<p>\u0089</p>\n<p>Consider spiritual support</p>\n<p>\u0089</p>\n<p>Consider the best place of death for the patient and their</p>\n<p>family; would discharging them to go home be best?</p>"
    },
    {
        "page_number": 709,
        "content": "643\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\n14.1.1  DYSMENORRHOEA\t\nICD10 CODE: N94.6\nAbdominal pain that occurs just before or during menstruation. Symptoms \nbegin about 12 hours before onset of menses and last for 1\u20133 days.\nPrimary dysmenorrhoea occurs more commonly among adolescents and \nyoung women. Symptoms usually begin 6\u201312 months after menarche \nand occur mainly with ovulatory cycles. Generally, severity of symptoms \ndecreases with age, sexual activity and child birth.\nSecondary dysmenorrhoea is usually due to a gynaecological condition \nsuch as infection or fibroids, and usually occurs in older women above \n30 years.\nCauses of primary dysmenorrheaoa\n \n~\nNot known\nCauses of secondary dysmenorrhoea\n \n~\nPelvic inflammatory disease\n \n~\nEndometriosis\n \n~\nUterine fibroids\nClinical features\n \n~\nLower abdominal cramping\n \n~\nBackache, headache\n \n~\nNausea, vomiting, diarrhoea, fainting, fever, fatigue, diz\u00ad\nziness\nGynecological Conditions\n14",
        "formatted_content": "<p>643</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<h3>14.1.1  DYSMENORRHOEA</h3>\n<h3>ICD10 CODE: N94.6</h3>\n<p>Abdominal pain that occurs just before or during menstruation. Symptoms</p>\n<p>begin about 12 hours before onset of menses and last for 1\u20133 days.</p>\n<p>Primary dysmenorrhoea occurs more commonly among adolescents and</p>\n<p>young women. Symptoms usually begin 6\u201312 months after menarche</p>\n<p>and occur mainly with ovulatory cycles. Generally, severity of symptoms</p>\n<p>decreases with age, sexual activity and child birth.</p>\n<p>Secondary dysmenorrhoea is usually due to a gynaecological condition</p>\n<p>such as infection or fibroids, and usually occurs in older women above</p>\n<p>30 years.</p>\n<p>Causes of primary dysmenorrheaoa</p>\n<p>~</p>\n<p>Not known</p>\n<p>Causes of secondary dysmenorrhoea</p>\n<p>~</p>\n<p>Pelvic inflammatory disease</p>\n<p>~</p>\n<p>Endometriosis</p>\n<p>~</p>\n<p>Uterine fibroids</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Lower abdominal cramping</p>\n<p>~</p>\n<p>Backache, headache</p>\n<p>~</p>\n<p>Nausea, vomiting, diarrhoea, fainting, fever, fatigue, diz\u00ad</p>\n<p>ziness</p>\n<p>Gynecological Conditions</p>\n<p>14</p>"
    },
    {
        "page_number": 710,
        "content": "644\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\nDifferential diagnosis\n \n~\nEndometriosis\n \n~\nOther causes of lower abdominal pain\nManagement\nTREATMENT\nLOC\nNon-pharmacological\n\t\n\u0089\nEncourage the patient to rest or sleep \n\t\n\u0089\nEncourage the patient to do some exercises \n\t\n\u0089\nAdvise the patient to apply a warm compress to the \nabdomen\n\t\n\u0089\nEncourage the patient to wear loose fitting clothes\n\t\n\u0089\nAdvise the patient to have a diet low in fats and supple\u00ad\nments such magnesium, vitamin B1, vitamin E and zinc\n\t\n\u0089\nPharmacological\n\t\n\u0089\nGive NSAIDs e.g. ibuprofen 200\u2013400 mg every 8 hours \nas required\n\t\n\u0089\nOther medications include paracetamol 1 g every 6 \nhours (in case of mild pain); or diclofenac 50 mg every \n8 hours for severe forms\n\t\n\u0089\nReview the patient after 5 days and if no response or \nif recurrent, refer for specialist management\n\t\n\u0089\nIn secondary dysmenorrhoea, treat cause e.g. PID\n\t\n\u0089\nwith antibiotics\nHC2\nH C 2 \nHC4\n14.1.2  Pelvic Inflammatory Disease (PID) ICD10 CODE: N70-N73\nInfection (usually ascending from the vagina) occurring in the uterus, ovary, \nor uterine tubes and leading to salpingitis, endometritis, pelvic peritonitis \nor formation of tubal ovarian abscess.\nRisk factors\n \n~\nPrevious pelvic inflammatory disease infections",
        "formatted_content": "<p>644</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Endometriosis</p>\n<p>~</p>\n<p>Other causes of lower abdominal pain</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Non-pharmacological</p>\n<p>\u0089</p>\n<p>Encourage the patient to rest or sleep</p>\n<p>\u0089</p>\n<p>Encourage the patient to do some exercises</p>\n<p>\u0089</p>\n<p>Advise the patient to apply a warm compress to the</p>\n<p>abdomen</p>\n<p>\u0089</p>\n<p>Encourage the patient to wear loose fitting clothes</p>\n<p>\u0089</p>\n<p>Advise the patient to have a diet low in fats and supple\u00ad</p>\n<p>ments such magnesium, vitamin B1, vitamin E and zinc</p>\n<p>\u0089</p>\n<p>Pharmacological</p>\n<p>\u0089</p>\n<p>Give NSAIDs e.g. ibuprofen 200\u2013400 mg every 8 hours</p>\n<p>as required</p>\n<p>\u0089</p>\n<p>Other medications include paracetamol 1 g every 6</p>\n<p>hours (in case of mild pain); or diclofenac 50 mg every</p>\n<p>8 hours for severe forms</p>\n<p>\u0089</p>\n<p>Review the patient after 5 days and if no response or</p>\n<p>if recurrent, refer for specialist management</p>\n<p>\u0089</p>\n<p>In secondary dysmenorrhoea, treat cause e.g. PID</p>\n<p>\u0089</p>\n<p>with antibiotics</p>\n<h3>HC2</h3>\n<h3>H C 2</h3>\n<h3>HC4</h3>\n<p>14.1.2  Pelvic Inflammatory Disease (PID) ICD10 CODE: N70-N73</p>\n<p>Infection (usually ascending from the vagina) occurring in the uterus, ovary,</p>\n<p>or uterine tubes and leading to salpingitis, endometritis, pelvic peritonitis</p>\n<p>or formation of tubal ovarian abscess.</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Previous pelvic inflammatory disease infections</p>"
    },
    {
        "page_number": 711,
        "content": "645\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\n \n~\nPresence of bacterial vaginosis\n \n~\nMultiple or new sexual partners\nHistory of STIs in the patient or her partner\n \n~\nHistory of abortion\n \n~\nYoung age of less than 25 years\n \n~\nPostpartum endometritis\nCauses\n \n~\nOften due to multiple pathogens: Neisseria gonorrhoea, \nChlamydia trachomatis, Mycoplasma, Gardnerella, Bacte\u00ad\nroids, Gram-negative bacilli, e.g. Escherichia coli\nClinical features\n \n~\nPain in lower abdomen (usually <2 weeks) PLUS\n \n~\nDysuria, fever\n \n~\nVaginal discharge: could be smelly and mixed with pus\n \n~\nPainful sexual intercourse (dysperunia)\n \n~\nCervical motion tenderness: vaginal examination will pro\u00ad\nduce tenderness when the cervix is moved\n \n~\nAbnormal uterine bleeding\nIf severe\n \n~\nSwellings may be felt if there is pus in the tubes or pelvic \nabscess\n \n~\nSigns of peritonitis (rebound tenderness)\nComplications of PID\n \n~\nInfertility\n \n~\nEctopic pregnancy\n \n~\nChronic pelvic pain",
        "formatted_content": "<p>645</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<p>~</p>\n<p>Presence of bacterial vaginosis</p>\n<p>~</p>\n<p>Multiple or new sexual partners</p>\n<p>History of STIs in the patient or her partner</p>\n<p>~</p>\n<p>History of abortion</p>\n<p>~</p>\n<p>Young age of less than 25 years</p>\n<p>~</p>\n<p>Postpartum endometritis</p>\n<p>Causes</p>\n<p>~</p>\n<p>Often due to multiple pathogens: Neisseria gonorrhoea,</p>\n<p>Chlamydia trachomatis, Mycoplasma, Gardnerella, Bacte\u00ad</p>\n<p>roids, Gram-negative bacilli, e.g. Escherichia coli</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pain in lower abdomen (usually <2 weeks) PLUS</p>\n<p>~</p>\n<p>Dysuria, fever</p>\n<p>~</p>\n<p>Vaginal discharge: could be smelly and mixed with pus</p>\n<p>~</p>\n<p>Painful sexual intercourse (dysperunia)</p>\n<p>~</p>\n<p>Cervical motion tenderness: vaginal examination will pro\u00ad</p>\n<p>duce tenderness when the cervix is moved</p>\n<p>~</p>\n<p>Abnormal uterine bleeding</p>\n<p>If severe</p>\n<p>~</p>\n<p>Swellings may be felt if there is pus in the tubes or pelvic</p>\n<p>abscess</p>\n<p>~</p>\n<p>Signs of peritonitis (rebound tenderness)</p>\n<p>Complications of PID</p>\n<p>~</p>\n<p>Infertility</p>\n<p>~</p>\n<p>Ectopic pregnancy</p>\n<p>~</p>\n<p>Chronic pelvic pain</p>"
    },
    {
        "page_number": 712,
        "content": "646\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\nDo Not Treat Chronic Pelvic Pain With Antibiotics\nDifferential diagnosis\n \n~\nEctopic pregnancy, threated abortion\n \n~\nOvulation pain\n \n~\nAcute appendicitis\n \n~\nComplicated or twisted ovarian cyst\n \n~\nCancer of the cervix\nInvestigations\n \n\u0081\nSpeculum examination\n \n\u0081\nPregnancy test\n \n\u0081\nPus swab: For C&S. Thespeculum protects the sampling item; \nsample  is from endocervix, aspirate from  endometrial cavity/\ncurretings  or an aspirate through the posterior pouch\n \n\u0081\nUltrasound (if available) for detection of tubo ovarian masses, \nfree fluid, peritonitis\nManagement\nTREATMENT\nLOC\nTreatment is based on a combination of medicines that cover \nthe multiple microorganisms involved.\nOutpatient treatment\n\t\n\u0089\nCeftriaxone 250 mg IM (or cefixime 400 mg stat if \nceftriaxone is not available)\n\t\n\u0089\nPlus doxycycline 100 mg orally every 12 hours for 14 days\n\t\n\u0089\nPlus metronidazole 400 mg twice daily orally for 14 days\n\t\n\u0089\nTreat sexual partners as for urethral discharge syndrome \nto avoid re-infection",
        "formatted_content": "<p>646</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<p>Do Not Treat Chronic Pelvic Pain With Antibiotics</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Ectopic pregnancy, threated abortion</p>\n<p>~</p>\n<p>Ovulation pain</p>\n<p>~</p>\n<p>Acute appendicitis</p>\n<p>~</p>\n<p>Complicated or twisted ovarian cyst</p>\n<p>~</p>\n<p>Cancer of the cervix</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Speculum examination</p>\n<p>\u0081</p>\n<p>Pregnancy test</p>\n<p>\u0081</p>\n<p>Pus swab: For C&S. Thespeculum protects the sampling item;</p>\n<p>sample  is from endocervix, aspirate from  endometrial cavity/</p>\n<p>curretings  or an aspirate through the posterior pouch</p>\n<p>\u0081</p>\n<p>Ultrasound (if available) for detection of tubo ovarian masses,</p>\n<p>free fluid, peritonitis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Treatment is based on a combination of medicines that cover</p>\n<p>the multiple microorganisms involved.</p>\n<p>Outpatient treatment</p>\n<p>\u0089</p>\n<p>Ceftriaxone 250 mg IM (or cefixime 400 mg stat if</p>\n<p>ceftriaxone is not available)</p>\n<p>\u0089</p>\n<p>Plus doxycycline 100 mg orally every 12 hours for 14 days</p>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg twice daily orally for 14 days</p>\n<p>\u0089</p>\n<p>Treat sexual partners as for urethral discharge syndrome</p>\n<p>to avoid re-infection</p>"
    },
    {
        "page_number": 713,
        "content": "647\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\nTREATMENT\nLOC\n\t\n\u0089\nIn pregnancy, use erythromycin 500 mg every 6 hours \nfor 14 days instead of doxycycline\n\t\n\u0089\nIf severe or not improving after 7 days\n\t\n\u0089\nRefer for ultrasound scan and parenteral treatment \n\t\n\u0089\nCeftriaxone 1 g IV daily plus metronidazole 500 mg IV \nevery 8 hours until clinical improvement,\n\t\n\u0089\nthen continue oral regimen as above\nHC3\nHC4\nNotes\n \n\u0083 All women with PID should be tested for HIV\n \n\u0083 Abstain from sex or use barrier methods during the \ncourse of treatment\n \n\u0083 Do not take alcohol when taking metronidazole\n \n\u0083 Avoid sex during menstrual period and for 6 weeks \nafter an abortion\n \n\u0083 In IUD users with PID, the IUD need not be removed. \nHowever, if there is no clinical improvement within 48\u201372 \nhours of initiating treatment, providers should consider \nremoving the IUD and help patient choose an alternative \ncontraceptive method (see chapter 15)\n14.1.3  Abnormal Uterine Bleeding   ICD10 CODE: N39.9\nAny vaginal bleeding which represents a variation from the normal \npattern of regular menstruation.\nCauses\n \n~\nHormonal abnormalities (ovulatory dysfunction)\n \n~\nAbortion, ectopic pregnancy\n \n~\nUterine diseases (fibroids, polyps etc)\n \n~\nCancers (cervical, uterine, rarely vaginal)\n \n~\nInfections (STIs)\n \n~\nOthers (coagulation disorders etc.)\n \n~\nIatrogenic (IUD, hormonal contraceptives)",
        "formatted_content": "<p>647</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>In pregnancy, use erythromycin 500 mg every 6 hours</p>\n<p>for 14 days instead of doxycycline</p>\n<p>\u0089</p>\n<p>If severe or not improving after 7 days</p>\n<p>\u0089</p>\n<p>Refer for ultrasound scan and parenteral treatment</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV daily plus metronidazole 500 mg IV</p>\n<p>every 8 hours until clinical improvement,</p>\n<p>\u0089</p>\n<p>then continue oral regimen as above</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Notes</p>\n<p>\u0083 All women with PID should be tested for HIV</p>\n<p>\u0083 Abstain from sex or use barrier methods during the</p>\n<p>course of treatment</p>\n<p>\u0083 Do not take alcohol when taking metronidazole</p>\n<p>\u0083 Avoid sex during menstrual period and for 6 weeks</p>\n<p>after an abortion</p>\n<p>\u0083 In IUD users with PID, the IUD need not be removed.</p>\n<p>However, if there is no clinical improvement within 48\u201372</p>\n<p>hours of initiating treatment, providers should consider</p>\n<p>removing the IUD and help patient choose an alternative</p>\n<p>contraceptive method (see chapter 15)</p>\n<p>14.1.3  Abnormal Uterine Bleeding   ICD10 CODE: N39.9</p>\n<p>Any vaginal bleeding which represents a variation from the normal</p>\n<p>pattern of regular menstruation.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Hormonal abnormalities (ovulatory dysfunction)</p>\n<p>~</p>\n<p>Abortion, ectopic pregnancy</p>\n<p>~</p>\n<p>Uterine diseases (fibroids, polyps etc)</p>\n<p>~</p>\n<p>Cancers (cervical, uterine, rarely vaginal)</p>\n<p>~</p>\n<p>Infections (STIs)</p>\n<p>~</p>\n<p>Others (coagulation disorders etc.)</p>\n<p>~</p>\n<p>Iatrogenic (IUD, hormonal contraceptives)</p>"
    },
    {
        "page_number": 714,
        "content": "648\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\nClinical features\n \n~\nAbnormal menstrual pattern\n \n~\nContinuous or subcontinuous bleeding\n \n~\nIt can be acute and heavy or light and subcontinuous\nInvestigations\n \n\u0081\nPregnancy test to exclude abortion and pregnancy\n \n\u0081\nHaemoglobin level\n \n\u0081\nVaginal examination (for cervical and vaginal abnormalities \ne.g., cervical cancer)\n \n\u0081\nAbdominal ultrasound\nManagement\nManagement is based on the possible cause.\nCAUSE/ISSUE\nTREATMENT\nLOC\nGeneral measures\nFerrous sulphate or Fefol 1\ntablet once or twice a day\nHC2\nPositive pregnancy \ntest\nSee section on abortion and ectop\u00ad\nic pregnancy (chapter 16)\nHC4\nBleeding in postmen\u00ad\nopausal woman\nRefer for specialist assessment\n(possible endometrial pathology)\nRR\nLesion (ulcer, growth) \nin vagina/on cervix\nRefer for specialist assessment\nRR\nSuspect fibroid (bulky \nhard uterus)\nUse analgesics, iron supplement, \nrefer for ultrasound scan\nH\nOther signs of infec\u00ad\ntion\nTreat as PID and review\nHC3\nWomen on family \nplanning\nSee sections on FP methods and \nside effects (chapter 15)\nHC2",
        "formatted_content": "<p>648</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Abnormal menstrual pattern</p>\n<p>~</p>\n<p>Continuous or subcontinuous bleeding</p>\n<p>~</p>\n<p>It can be acute and heavy or light and subcontinuous</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pregnancy test to exclude abortion and pregnancy</p>\n<p>\u0081</p>\n<p>Haemoglobin level</p>\n<p>\u0081</p>\n<p>Vaginal examination (for cervical and vaginal abnormalities</p>\n<p>e.g., cervical cancer)</p>\n<p>\u0081</p>\n<p>Abdominal ultrasound</p>\n<p>Management</p>\n<p>Management is based on the possible cause.</p>\n<h3>CAUSE/ISSUE</h3>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>Ferrous sulphate or Fefol 1</p>\n<p>tablet once or twice a day</p>\n<h3>HC2</h3>\n<p>Positive pregnancy</p>\n<p>test</p>\n<p>See section on abortion and ectop\u00ad</p>\n<p>ic pregnancy (chapter 16)</p>\n<h3>HC4</h3>\n<p>Bleeding in postmen\u00ad</p>\n<p>opausal woman</p>\n<p>Refer for specialist assessment</p>\n<p>(possible endometrial pathology)</p>\n<p>RR</p>\n<p>Lesion (ulcer, growth)</p>\n<p>in vagina/on cervix</p>\n<p>Refer for specialist assessment</p>\n<p>RR</p>\n<p>Suspect fibroid (bulky</p>\n<p>hard uterus)</p>\n<p>Use analgesics, iron supplement,</p>\n<p>refer for ultrasound scan</p>\n<p>H</p>\n<p>Other signs of infec\u00ad</p>\n<p>tion</p>\n<p>Treat as PID and review</p>\n<h3>HC3</h3>\n<p>Women on family</p>\n<p>planning</p>\n<p>See sections on FP methods and</p>\n<p>side effects (chapter 15)</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 715,
        "content": "649\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\n14.1.4 Menopause\t\n    ICD10 CODE: Z78.0\nMenopause is the cessation of menstruation in a female and usually \nspontaneously occurs at the age of 45-55 years. Peri- menopause is the \ntime around menopause and can last a few years until the menopause \nhas set in.\nMenopause can also be caused by surgical removal of ovaries.\nClinical features\n \n~\n\u201cHot flushes\u201d (sudden unanticipated, unpleasant wave of \nbody heat; can range from mild to intense)\n \n~\nNight sweats, palpitations, headaches, insomnia, tiredness\n \n~\nIrregular menstruation till cessation\n \n~\nVaginal atrophy and dryness, loss of libido, painful inter\u00ad\ncourse\n \n~\nBladder irritability, incontinence, UTIs\n \n~\nWeight gain (sometimes)\n \n~\nSkin changes: dryness, thinning, loss of head hair, in\u00ad\ncrease or loss of body hair)\n \n~\nMood swings, emotional changes (e.g. depression, irrita\u00ad\nbility, short temperedness, weepiness)\n \n~\nLack of concentration, failing memory\n \n~\nOsteoporosis, denture problem\n \n~\nInvestigations\n \n~\nExclude pregnancy\nManagement\nTREATMENT\nLOC\nNon-pharmacological\n\t\n\u0089\nExplain process of menopause to the patient and reas\u00ad\nsure her it is normal\n\t\n\u0089\nSuggest lifestyle adjustment\n \n\u0083 Follow a healthy diet\n \n\u0083 Sleep and exercise enough\n \n\u0083 Wear loose light clothing",
        "formatted_content": "<p>649</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<p>14.1.4 Menopause</p>\n<h3>ICD10 CODE: Z78.0</h3>\n<p>Menopause is the cessation of menstruation in a female and usually</p>\n<p>spontaneously occurs at the age of 45-55 years. Peri- menopause is the</p>\n<p>time around menopause and can last a few years until the menopause</p>\n<p>has set in.</p>\n<p>Menopause can also be caused by surgical removal of ovaries.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>\u201cHot flushes\u201d (sudden unanticipated, unpleasant wave of</p>\n<p>body heat; can range from mild to intense)</p>\n<p>~</p>\n<p>Night sweats, palpitations, headaches, insomnia, tiredness</p>\n<p>~</p>\n<p>Irregular menstruation till cessation</p>\n<p>~</p>\n<p>Vaginal atrophy and dryness, loss of libido, painful inter\u00ad</p>\n<p>course</p>\n<p>~</p>\n<p>Bladder irritability, incontinence, UTIs</p>\n<p>~</p>\n<p>Weight gain (sometimes)</p>\n<p>~</p>\n<p>Skin changes: dryness, thinning, loss of head hair, in\u00ad</p>\n<p>crease or loss of body hair)</p>\n<p>~</p>\n<p>Mood swings, emotional changes (e.g. depression, irrita\u00ad</p>\n<p>bility, short temperedness, weepiness)</p>\n<p>~</p>\n<p>Lack of concentration, failing memory</p>\n<p>~</p>\n<p>Osteoporosis, denture problem</p>\n<p>~</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Exclude pregnancy</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Non-pharmacological</p>\n<p>\u0089</p>\n<p>Explain process of menopause to the patient and reas\u00ad</p>\n<p>sure her it is normal</p>\n<p>\u0089</p>\n<p>Suggest lifestyle adjustment</p>\n<p>\u0083 Follow a healthy diet</p>\n<p>\u0083 Sleep and exercise enough</p>\n<p>\u0083 Wear loose light clothing</p>"
    },
    {
        "page_number": 716,
        "content": "650\nUganda Clinical Guidelines 2023\nCHAPTER 14:  Gynecological Conditions\nTREATMENT\nLOC\n \n\u0083 Avoid alcohol\n \n\u0083 Diet low in fats, high in fruit and vegetables\n \n\u0083 Food rich supplements such as magnesium, vitamin \nB1, vitamin E and zinc\n\t\n\u0089\nCalcium-rich food (or supplements) such as milk and \nsoya beans and vitamin D supplements\nHC2\n\t\n\u0089\nScreen for CVD (hypertension, heart disease) and urine \nincontinence\n\t\n\u0089\nFor severe symptoms (severe hot flushes, depression) \nconsider\n \n\u0083 Fluoxetine 20 mg daily\nNB: URGENTLY REFER ANY MENOPAUSAL WOM\u00ad\nAN WITH VAGINAL BLEEDING FOR FURTHER \nASSESSMENT\nHC4 \nRR",
        "formatted_content": "<p>650</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 14:  Gynecological Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0083 Avoid alcohol</p>\n<p>\u0083 Diet low in fats, high in fruit and vegetables</p>\n<p>\u0083 Food rich supplements such as magnesium, vitamin</p>\n<p>B1, vitamin E and zinc</p>\n<p>\u0089</p>\n<p>Calcium-rich food (or supplements) such as milk and</p>\n<p>soya beans and vitamin D supplements</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Screen for CVD (hypertension, heart disease) and urine</p>\n<p>incontinence</p>\n<p>\u0089</p>\n<p>For severe symptoms (severe hot flushes, depression)</p>\n<p>consider</p>\n<p>\u0083 Fluoxetine 20 mg daily</p>\n<h3>NB: URGENTLY REFER ANY MENOPAUSAL WOM\u00ad</h3>\n<h3>AN WITH VAGINAL BLEEDING FOR FURTHER</h3>\n<h3>ASSESSMENT</h3>\n<h3>HC4</h3>\n<p>RR</p>"
    },
    {
        "page_number": 717,
        "content": "651\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nFamily Planning (FP)\n15\nFor further detailed information on Family Planning (FP) and Maternal \nHealth, please refer to \u201cProcedure Manual for Family Planning and \nMaternal Health Service Delivery MOH, 2016\u201d.\nFamily planning is a basic human right for an individual and couples \nto exercise control over their fertility, make informed decision on the \nnumber of children they want to have, plan pregnancies, and the space \nbetween pregnancies.\nFP has health benefits for the mother and the children and economic \nbenefits for the family and the country at large.\n15.1  Key steps to be followed in provision of fp services            \nIcd10 code: z10.0\n1.\t Provide information about FP, including preconception care to \ndifferent groups\n2.\t Counsel clients at high risk of unwanted pregnancies to accept/\nuse FP services\n3.\t Counsel clients to make informed choice of FP methods, including \ndual methods\n4.\t Obtain and record client history\n5.\t Perform a physical assessment\n6.\t Perform a pelvic examination\n7.\t Screen for cervical cancer and HIV\n8.\t Manage client according to chosen FP method",
        "formatted_content": "<p>651</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Family Planning (FP)</p>\n<p>15</p>\n<p>For further detailed information on Family Planning (FP) and Maternal</p>\n<p>Health, please refer to \u201cProcedure Manual for Family Planning and</p>\n<p>Maternal Health Service Delivery MOH, 2016\u201d.</p>\n<p>Family planning is a basic human right for an individual and couples</p>\n<p>to exercise control over their fertility, make informed decision on the</p>\n<p>number of children they want to have, plan pregnancies, and the space</p>\n<p>between pregnancies.</p>\n<p>FP has health benefits for the mother and the children and economic</p>\n<p>benefits for the family and the country at large.</p>\n<p>15.1  Key steps to be followed in provision of fp services</p>\n<p>Icd10 code: z10.0</p>\n<li>.\t Provide information about FP, including preconception care to</li>\n<p>different groups</p>\n<p>2.\t Counsel clients at high risk of unwanted pregnancies to accept/</p>\n<p>use FP services</p>\n<p>3.\t Counsel clients to make informed choice of FP methods, including</p>\n<p>dual methods</p>\n<p>4.\t Obtain and record client history</p>\n<p>5.\t Perform a physical assessment</p>\n<p>6.\t Perform a pelvic examination</p>\n<p>7.\t Screen for cervical cancer and HIV</p>\n<p>8.\t Manage client according to chosen FP method</p>"
    },
    {
        "page_number": 718,
        "content": "652\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n15.1.1   Provide Information about FP including Pre-Conception\u00ad\nCare to Different Groups\nThe procedures used here are also used in the next step to recruit clients \nfor FP and maternal health services in young child, antenatal, labour \nand delivery wards, outpatients, outreach, and postpartum clinics and \nin providing education on specific chosen FP methods.\nThe objective is to:\n \n~\nCreate awareness\n \n~\nDisseminate correct information to influence people to \nchange beliefs, attitudes and practices\n \n~\nRecruit new clients and offer several FP methods\n15.1.2 Counsel High-Risk Clients\nRisk factors to look out for in clients include:\n \n~\nRecent delivery/abortion\n \n~\n>4 pregnancies\n \n~\n>35 years old or <20 years old\n \n~\nComplicating medical conditions (e.g., diabetes, heart \ndisease)\n \n~\nPeople living with HIV/AIDS\n \n~\nHaving children with birth interval <2 years\n \n~\nPoor obstetric history, which is likely to recur in future \npregnancies (e.g., postpartum haemorrhage, pre- ec\u00ad\nlampsia)\nIdentify eligible women (non-pregnant) while conducting clinics such as:\n \n~\nYoung child clinics and paediatric wards\n \n~\nMaternity and postnatal clinics and wards\n \n~\nOutpatient clinics",
        "formatted_content": "<p>652</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>15.1.1   Provide Information about FP including Pre-Conception\u00ad</p>\n<p>Care to Different Groups</p>\n<p>The procedures used here are also used in the next step to recruit clients</p>\n<p>for FP and maternal health services in young child, antenatal, labour</p>\n<p>and delivery wards, outpatients, outreach, and postpartum clinics and</p>\n<p>in providing education on specific chosen FP methods.</p>\n<p>The objective is to:</p>\n<p>~</p>\n<p>Create awareness</p>\n<p>~</p>\n<p>Disseminate correct information to influence people to</p>\n<p>change beliefs, attitudes and practices</p>\n<p>~</p>\n<p>Recruit new clients and offer several FP methods</p>\n<p>15.1.2 Counsel High-Risk Clients</p>\n<p>Risk factors to look out for in clients include:</p>\n<p>~</p>\n<p>Recent delivery/abortion</p>\n<p>~</p>\n<p>>4 pregnancies</p>\n<p>~</p>\n<p>>35 years old or <20 years old</p>\n<p>~</p>\n<p>Complicating medical conditions (e.g., diabetes, heart</p>\n<p>disease)</p>\n<p>~</p>\n<p>People living with HIV/AIDS</p>\n<p>~</p>\n<p>Having children with birth interval <2 years</p>\n<p>~</p>\n<p>Poor obstetric history, which is likely to recur in future</p>\n<p>pregnancies (e.g., postpartum haemorrhage, pre- ec\u00ad</p>\n<p>lampsia)</p>\n<p>Identify eligible women (non-pregnant) while conducting clinics such as:</p>\n<p>~</p>\n<p>Young child clinics and paediatric wards</p>\n<p>~</p>\n<p>Maternity and postnatal clinics and wards</p>\n<p>~</p>\n<p>Outpatient clinics</p>"
    },
    {
        "page_number": 719,
        "content": "653\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nYouths and Adolescent centers\n \n~\nHIV/AIDS care centers/ ART clinics\n \n~\nSexual Reproductive Health clinics (e.g. Cervical cancer, \nPost abortion care, Adolescent/Youth clinics)\n \n~\nMale clinics\n \n~\nGender based violence clinics/ corners\nYou can also identify the eligible women while:\n \n~\nConducting outreaches (Immunisation or Home visits)\nDiscuss with clients about reproductive choices and risk factors. Give \nspecial consideration to first time parents and adolescents in provision \nof appropriate information on sexuality, family planning and family \nplanning services: types, benefits, availability and procedures.\n15.1.3  Pre-Conception Care with Clients Who Desire to Con\u00ad\nceive\nPre-conception care discussion topics for clients who desire to conceive \ninclude:\n \n~\nPregnancy planning and appropriate contraception\n \n~\nFolic acid supplementation 3 months preceeding concep\u00ad\ntion\n \n~\nGood diet, risk assessment and management of pre exist\u00ad\ning conditions and risk factors\n \n~\nBenefits of preconception care (e.g., prevention of unin\u00ad\ntended pregnancies, good maternal and foetal outcomes)\n \n~\nScreening for hereditary diseases e.g., sickle cell disease\n \n~\nScreening for STI, including HIV and hepatitis",
        "formatted_content": "<p>653</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Youths and Adolescent centers</p>\n<p>~</p>\n<p>HIV/AIDS care centers/ ART clinics</p>\n<p>~</p>\n<p>Sexual Reproductive Health clinics (e.g. Cervical cancer,</p>\n<p>Post abortion care, Adolescent/Youth clinics)</p>\n<p>~</p>\n<p>Male clinics</p>\n<p>~</p>\n<p>Gender based violence clinics/ corners</p>\n<p>You can also identify the eligible women while:</p>\n<p>~</p>\n<p>Conducting outreaches (Immunisation or Home visits)</p>\n<p>Discuss with clients about reproductive choices and risk factors. Give</p>\n<p>special consideration to first time parents and adolescents in provision</p>\n<p>of appropriate information on sexuality, family planning and family</p>\n<p>planning services: types, benefits, availability and procedures.</p>\n<p>15.1.3  Pre-Conception Care with Clients Who Desire to Con\u00ad</p>\n<p>ceive</p>\n<p>Pre-conception care discussion topics for clients who desire to conceive</p>\n<p>include:</p>\n<p>~</p>\n<p>Pregnancy planning and appropriate contraception</p>\n<p>~</p>\n<p>Folic acid supplementation 3 months preceeding concep\u00ad</p>\n<p>tion</p>\n<p>~</p>\n<p>Good diet, risk assessment and management of pre exist\u00ad</p>\n<p>ing conditions and risk factors</p>\n<p>~</p>\n<p>Benefits of preconception care (e.g., prevention of unin\u00ad</p>\n<p>tended pregnancies, good maternal and foetal outcomes)</p>\n<p>~</p>\n<p>Screening for hereditary diseases e.g., sickle cell disease</p>\n<p>~</p>\n<p>Screening for STI, including HIV and hepatitis</p>"
    },
    {
        "page_number": 720,
        "content": "654\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n15.1.4  Discuss with PLW HIV Special Consideration for HIV \nTransmission\nKey areas for discussion include:\n \n~\nPrevention of HIV transmission to spouse and child\n \n~\nSafer sexual practices and safe conception\n \n~\nEducation/counseling about perinatal transmission risk\n \n~\nInitiation or modification of ART considering toxicity\n \n~\nEvaluation of opportunistic infections and offering umma\u00ad\nrizedn\n \n~\nSome ARV drugs may interact and reduce the effect of \nhormonal contraceptives. It is always ummarize to use \nadditional barrier methods (condoms), which also prevent \nSTIs.\n15.1.5  Educate and Counsel Clients to Make Informed Choice of \nFP Method\nThe primary objectives are:\n9.\t To dispel any rumours and misconceptions about FP\n10.\tTo help the client make a voluntary informed choice\nProcedure\n \n~\nPrepare the room/materials needed, ensuring privacy\n \n~\nAssess client\u2019s knowledge and experience of FP methods\n \n~\nExplain about different FP methods available\n\t\n\u0089\nType\n\t\n\u0089\nMechanism of action and method of use\n\t\n\u0089\nAdvantages and disadvantages\n\t\n\u0089\nIndications\n\t\n\u0089\nContraindications\n\t\n\u0089\nSide-effects",
        "formatted_content": "<p>654</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>15.1.4  Discuss with PLW HIV Special Consideration for HIV</p>\n<p>Transmission</p>\n<p>Key areas for discussion include:</p>\n<p>~</p>\n<p>Prevention of HIV transmission to spouse and child</p>\n<p>~</p>\n<p>Safer sexual practices and safe conception</p>\n<p>~</p>\n<p>Education/counseling about perinatal transmission risk</p>\n<p>~</p>\n<p>Initiation or modification of ART considering toxicity</p>\n<p>~</p>\n<p>Evaluation of opportunistic infections and offering umma\u00ad</p>\n<p>rizedn</p>\n<p>~</p>\n<p>Some ARV drugs may interact and reduce the effect of</p>\n<p>hormonal contraceptives. It is always ummarize to use</p>\n<p>additional barrier methods (condoms), which also prevent</p>\n<p>STIs.</p>\n<p>15.1.5  Educate and Counsel Clients to Make Informed Choice of</p>\n<p>FP Method</p>\n<p>The primary objectives are:</p>\n<p>9.\t To dispel any rumours and misconceptions about FP</p>\n<p>10.\tTo help the client make a voluntary informed choice</p>\n<p>Procedure</p>\n<p>~</p>\n<p>Prepare the room/materials needed, ensuring privacy</p>\n<p>~</p>\n<p>Assess client\u2019s knowledge and experience of FP methods</p>\n<p>~</p>\n<p>Explain about different FP methods available</p>\n<p>\u0089</p>\n<p>Type</p>\n<p>\u0089</p>\n<p>Mechanism of action and method of use</p>\n<p>\u0089</p>\n<p>Advantages and disadvantages</p>\n<p>\u0089</p>\n<p>Indications</p>\n<p>\u0089</p>\n<p>Contraindications</p>\n<p>\u0089</p>\n<p>Side-effects</p>"
    },
    {
        "page_number": 721,
        "content": "655\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n\t\n\u0089\nComplications/warning signs\n\t\n\u0089\nCheck understanding\n\t\n\u0089\nHelp client choose appropriate method using family\nplanning medical eligibility criteria wheel (see summary of wheel \nin section 15.1.10 below)\n \n~\nExplain next steps needed\n15.1.6  Obtain and Record Client History\nThe primary objectives are:\n \n~\nTo obtain client\u2019s personal and social data and information \non health status\n \n~\nTo identify abnormalities/problems requiring treatment or \nreferral\nFor FP clients, it is important to pay particular attention to information \noutlined in the table below:\nHISTORY\nINFORMATION NEEDED\nSocial History\n \n~\nSmoking? How many ummarized per \nday?\n \n~\nDrinking? How much alcohol per day?\nFamily Health \nHistory\n \n~\nDiabetes mellitus, high blood pressure, \nasthma, heart disease\nPersonal Med\u00ad\nical History\n \n~\nExcessive weight gain/loss (+/- 5 kg/ \nyear)\n \n~\nSevere headaches (relieved by analge\u00ad\nsics?)\n \n~\nGrowth on neck (enlarged thyroid)\n \n~\nCurrent or past diseases: asthma, car\u00ad\ndiac disease, high BP, diabetes mellitus, \nmental illness, epilepsy, thrombophle\u00ad\nbitis, varicose veins, unilateral pain in \nthighs or calves, chronic anaemia (e.g. \nsickle-cell anaemia), liver disease/jaun\u00ad\ndice in the last 6 months or during preg\u00ad\nnancy",
        "formatted_content": "<p>655</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>\u0089</p>\n<p>Complications/warning signs</p>\n<p>\u0089</p>\n<p>Check understanding</p>\n<p>\u0089</p>\n<p>Help client choose appropriate method using family</p>\n<p>planning medical eligibility criteria wheel (see summary of wheel</p>\n<p>in section 15.1.10 below)</p>\n<p>~</p>\n<p>Explain next steps needed</p>\n<p>15.1.6  Obtain and Record Client History</p>\n<p>The primary objectives are:</p>\n<p>~</p>\n<p>To obtain client\u2019s personal and social data and information</p>\n<p>on health status</p>\n<p>~</p>\n<p>To identify abnormalities/problems requiring treatment or</p>\n<p>referral</p>\n<p>For FP clients, it is important to pay particular attention to information</p>\n<p>outlined in the table below:</p>\n<h3>HISTORY</h3>\n<h3>INFORMATION NEEDED</h3>\n<p>Social History</p>\n<p>~</p>\n<p>Smoking? How many ummarized per</p>\n<p>day?</p>\n<p>~</p>\n<p>Drinking? How much alcohol per day?</p>\n<p>Family Health</p>\n<p>History</p>\n<p>~</p>\n<p>Diabetes mellitus, high blood pressure,</p>\n<p>asthma, heart disease</p>\n<p>Personal Med\u00ad</p>\n<p>ical History</p>\n<p>~</p>\n<p>Excessive weight gain/loss (+/- 5 kg/</p>\n<p>year)</p>\n<p>~</p>\n<p>Severe headaches (relieved by analge\u00ad</p>\n<p>sics?)</p>\n<p>~</p>\n<p>Growth on neck (enlarged thyroid)</p>\n<p>~</p>\n<p>Current or past diseases: asthma, car\u00ad</p>\n<p>diac disease, high BP, diabetes mellitus,</p>\n<p>mental illness, epilepsy, thrombophle\u00ad</p>\n<p>bitis, varicose veins, unilateral pain in</p>\n<p>thighs or calves, chronic anaemia (e.g.</p>\n<p>sickle-cell anaemia), liver disease/jaun\u00ad</p>\n<p>dice in the last 6 months or during preg\u00ad</p>\n<p>nancy</p>"
    },
    {
        "page_number": 722,
        "content": "656\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nHISTORY\nINFORMATION NEEDED\n \n~\nTB (on treatment?)\n \n~\nAllergies\n \n~\nAny medicines being taken and rea\u00ad\nson\nSurgical History\n \n~\nAny previous or planned operations\n \n~\nWhere and when operation was per\u00ad\nformed, or is to be performed\nReproductive \nHistory\n \n~\nTotal pregnancies\n \n~\nNumber and sex of live children\n \n~\nNumber of abortions/ miscarriages\n \n~\nNumber of children who died\n \n~\nAge of youngest child\n \n~\nType of delivery for her children\n \n~\nAny problems in previous pregnancy \nor deliveries\n \n~\nNumber of children desired\n \n~\nWhen does she wish to have next \nchild\n \n~\nWhether breastfeeding\nMenstrual \nHistory\n \n~\nAge at onset of menstruation\n \n~\nLength of cycles\n \n~\nPeriods regular or not?\n \n~\nNumber of days and amount of blood \nloss\n \n~\nBleeding after intercourse\n \n~\nDate and length of last normal period",
        "formatted_content": "<p>656</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>HISTORY</h3>\n<h3>INFORMATION NEEDED</h3>\n<p>~</p>\n<p>TB (on treatment?)</p>\n<p>~</p>\n<p>Allergies</p>\n<p>~</p>\n<p>Any medicines being taken and rea\u00ad</p>\n<p>son</p>\n<p>Surgical History</p>\n<p>~</p>\n<p>Any previous or planned operations</p>\n<p>~</p>\n<p>Where and when operation was per\u00ad</p>\n<p>formed, or is to be performed</p>\n<p>Reproductive</p>\n<p>History</p>\n<p>~</p>\n<p>Total pregnancies</p>\n<p>~</p>\n<p>Number and sex of live children</p>\n<p>~</p>\n<p>Number of abortions/ miscarriages</p>\n<p>~</p>\n<p>Number of children who died</p>\n<p>~</p>\n<p>Age of youngest child</p>\n<p>~</p>\n<p>Type of delivery for her children</p>\n<p>~</p>\n<p>Any problems in previous pregnancy</p>\n<p>or deliveries</p>\n<p>~</p>\n<p>Number of children desired</p>\n<p>~</p>\n<p>When does she wish to have next</p>\n<p>child</p>\n<p>~</p>\n<p>Whether breastfeeding</p>\n<p>Menstrual</p>\n<p>History</p>\n<p>~</p>\n<p>Age at onset of menstruation</p>\n<p>~</p>\n<p>Length of cycles</p>\n<p>~</p>\n<p>Periods regular or not?</p>\n<p>~</p>\n<p>Number of days and amount of blood</p>\n<p>loss</p>\n<p>~</p>\n<p>Bleeding after intercourse</p>\n<p>~</p>\n<p>Date and length of last normal period</p>"
    },
    {
        "page_number": 723,
        "content": "657\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nHISTORY\nINFORMATION NEEDED\nGynaecological \nHistory\n \n~\nVulval sores or warts\n \n~\nPID and STI? If yes, which one, wasit \ntreated and when?\n \n~\nLower abdominal pain\n \n~\nOffensive vaginal odour/discharge\n \n~\nPain during intercourse\n \n~\nPain on urination\n \n~\nBleeding between periods\nFamily Planning \nHistory\n \n~\nHow/where first learned about FP\n \n~\nWhether new to FP, or used FP before\n \n~\nIf used before, which method used\n \n~\nAge when started using FP\nLast FP method used:\n \n~\nDuration of using each FP method \nused\n \n~\nReasons for discontinuation of FP\n \n~\nCurrently preferred method\nInform Client\n \n~\nIf chosen method seems suitable or \ncontraindicated\n \n~\nExplain that physical assessment will \nconfirm suitability of this method\n \n~\nNext steps needed\n15.1.7  Perform a Physical Assessment\n \n~\nAssess general health status\n \n~\nExamine client from head to toe\n \n- Especially, look out for alopecia, acne, chloasma, hirsuitism,",
        "formatted_content": "<p>657</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>HISTORY</h3>\n<h3>INFORMATION NEEDED</h3>\n<p>Gynaecological</p>\n<p>History</p>\n<p>~</p>\n<p>Vulval sores or warts</p>\n<p>~</p>\n<p>PID and STI? If yes, which one, wasit</p>\n<p>treated and when?</p>\n<p>~</p>\n<p>Lower abdominal pain</p>\n<p>~</p>\n<p>Offensive vaginal odour/discharge</p>\n<p>~</p>\n<p>Pain during intercourse</p>\n<p>~</p>\n<p>Pain on urination</p>\n<p>~</p>\n<p>Bleeding between periods</p>\n<p>Family Planning</p>\n<p>History</p>\n<p>~</p>\n<p>How/where first learned about FP</p>\n<p>~</p>\n<p>Whether new to FP, or used FP before</p>\n<p>~</p>\n<p>If used before, which method used</p>\n<p>~</p>\n<p>Age when started using FP</p>\n<p>Last FP method used:</p>\n<p>~</p>\n<p>Duration of using each FP method</p>\n<p>used</p>\n<p>~</p>\n<p>Reasons for discontinuation of FP</p>\n<p>~</p>\n<p>Currently preferred method</p>\n<p>Inform Client</p>\n<p>~</p>\n<p>If chosen method seems suitable or</p>\n<p>contraindicated</p>\n<p>~</p>\n<p>Explain that physical assessment will</p>\n<p>confirm suitability of this method</p>\n<p>~</p>\n<p>Next steps needed</p>\n<p>15.1.7  Perform a Physical Assessment</p>\n<p>~</p>\n<p>Assess general health status</p>\n<p>~</p>\n<p>Examine client from head to toe</p>\n<p>- Especially, look out for alopecia, acne, chloasma, hirsuitism,</p>"
    },
    {
        "page_number": 724,
        "content": "658\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\njaundice, anaemia, enlarged glands, goitre\n \n- Pay particular attention to breasts (e.g. lumps) and\n \n- abdomen (enlarged organs, e.g., liver, uterus)\n15.1.8  Perform a Pelvic Examination\nThe following areas need to be investigated:\n \n~\nInspect external genitalia\n \n~\nPerform speculum examination\n \n~\nPerform cancer cervix screening (VIA, VILI, Pap smear)\n \n~\nPerform bimanual examination to determine size of uterus \nfor comparison later\n \n~\nShare findings with the client in simple language\n \n~\nExplain next steps needed\n \n~\nAdvise on when to have next examination (e.g., routine, \nannual, follow-up, if problems)\n15.1.9  Manage Client for Chosen FP Method\n \n~\nTake and record client\u2019s BP and weight\n \n~\nTake and record client\u2019s history\n \n~\nUse the table at in the following section 15.1.10 to quickly \nassess suitability of method considered\n \n~\nProvide suitable method, and ensure client understands \nfully how the method works, and how any medicine for \nhome use is to be taken\n \n~\nAdvise client on any potential problems with the chosen \nmethod and when to immediately return\n \n~\nDiscuss management of any serious side-effects and com\u00ad\nplications\n \n~\nArrange for client to return for routine follow-up, and for \nadditional FP supplies",
        "formatted_content": "<p>658</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>jaundice, anaemia, enlarged glands, goitre</p>\n<p>- Pay particular attention to breasts (e.g. lumps) and</p>\n<p>- abdomen (enlarged organs, e.g., liver, uterus)</p>\n<p>15.1.8  Perform a Pelvic Examination</p>\n<p>The following areas need to be investigated:</p>\n<p>~</p>\n<p>Inspect external genitalia</p>\n<p>~</p>\n<p>Perform speculum examination</p>\n<p>~</p>\n<p>Perform cancer cervix screening (VIA, VILI, Pap smear)</p>\n<p>~</p>\n<p>Perform bimanual examination to determine size of uterus</p>\n<p>for comparison later</p>\n<p>~</p>\n<p>Share findings with the client in simple language</p>\n<p>~</p>\n<p>Explain next steps needed</p>\n<p>~</p>\n<p>Advise on when to have next examination (e.g., routine,</p>\n<p>annual, follow-up, if problems)</p>\n<p>15.1.9  Manage Client for Chosen FP Method</p>\n<p>~</p>\n<p>Take and record client\u2019s BP and weight</p>\n<p>~</p>\n<p>Take and record client\u2019s history</p>\n<p>~</p>\n<p>Use the table at in the following section 15.1.10 to quickly</p>\n<p>assess suitability of method considered</p>\n<p>~</p>\n<p>Provide suitable method, and ensure client understands</p>\n<p>fully how the method works, and how any medicine for</p>\n<p>home use is to be taken</p>\n<p>~</p>\n<p>Advise client on any potential problems with the chosen</p>\n<p>method and when to immediately return</p>\n<p>~</p>\n<p>Discuss management of any serious side-effects and com\u00ad</p>\n<p>plications</p>\n<p>~</p>\n<p>Arrange for client to return for routine follow-up, and for</p>\n<p>additional FP supplies</p>"
    },
    {
        "page_number": 725,
        "content": "659\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n15.1.10  Summary of Medical Eligibility for Contraceptives\nThe tables below contain a ummarized version of the medical eligibility \ncriteria for initiating a patient on contraceptive methods, based on the \nMOH (2016) and WHO (2020) Medical Eligibility Criteria for Contracep\u00ad\ntive Use. It guides family planning providers in recommending safe and \neffective contraception methods for women with medical conditions or \nmedially-relevant characteristics. For more detailed information, consult \nthe above-named documents.\nThe tables below include recommendations on initiating use of common \ntypes of contraceptive methods:\n1.\t Combined oral contraceptive pills (COC)\n2.\t Progestogen only pills (POP)\n3.\t Progestogen only injectable (POI) e.g., DMPA- IM/SC\n4.\t Progestogen only implants (POIM)\n5.\t Copper-bearing IUD (CuIUD)\n6.\t LAM- Lactational amenorrhoea\n7.\t Hormonal IUD\n8.\t Condoms\n9.\t Fertility Awareness Method (FAM) and standard days methods\nInterpretation of eligibilty\nY- Use method\nN- Do not use method\nDrug Interactions\nDrug\nContraceptives\nCoc\nPop\nPoi\nPoim\nCuiud\nAbacavir\nY\nY\nY\nY\nY",
        "formatted_content": "<p>659</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>15.1.10  Summary of Medical Eligibility for Contraceptives</p>\n<p>The tables below contain a ummarized version of the medical eligibility</p>\n<p>criteria for initiating a patient on contraceptive methods, based on the</p>\n<p>MOH (2016) and WHO (2020) Medical Eligibility Criteria for Contracep\u00ad</p>\n<p>tive Use. It guides family planning providers in recommending safe and</p>\n<p>effective contraception methods for women with medical conditions or</p>\n<p>medially-relevant characteristics. For more detailed information, consult</p>\n<p>the above-named documents.</p>\n<p>The tables below include recommendations on initiating use of common</p>\n<p>types of contraceptive methods:</p>\n<li>.\t Combined oral contraceptive pills (COC)</li>\n<p>2.\t Progestogen only pills (POP)</p>\n<p>3.\t Progestogen only injectable (POI) e.g., DMPA- IM/SC</p>\n<p>4.\t Progestogen only implants (POIM)</p>\n<p>5.\t Copper-bearing IUD (CuIUD)</p>\n<p>6.\t LAM- Lactational amenorrhoea</p>\n<p>7.\t Hormonal IUD</p>\n<p>8.\t Condoms</p>\n<p>9.\t Fertility Awareness Method (FAM) and standard days methods</p>\n<p>Interpretation of eligibilty</p>\n<p>Y- Use method</p>\n<p>N- Do not use method</p>\n<p>Drug Interactions</p>\n<p>Drug</p>\n<p>Contraceptives</p>\n<p>Coc</p>\n<p>Pop</p>\n<p>Poi</p>\n<p>Poim</p>\n<p>Cuiud</p>\n<p>Abacavir</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>"
    },
    {
        "page_number": 726,
        "content": "660\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nDrug\nContraceptives\nCoc\nPop\nPoi\nPoim\nCuiud\nTenofovir\nY\nY\nY\nY\nY\nZidovudine\nY\nY\nY\nY\nY\nLamivudine\nY\nY\nY\nY\nY\nEfavirenz\nY\nY\nY\nY\nY\nNevirapine\nNevirapine\nY\nY\nY\nY\nY\nAtazanavir/r\nAtazanavir/r\nY\nY\nY\nY\nY\nLopinavir/r\nY\nY\nY\nY\nY\nDarunavir/r\nY\nY\nY\nY\nY\nRaltegravir\nY\nY\nY\nY\nY\nDolutegravir\nY\nY\nY\nY\nY\nPhenytoin\nN\nN\nY\nY\nY\nPhenobarbital\nN\nN\nY\nY\nY\nCarbamazepine\nN\nN\nY\nY\nY\nBroad spectrum an\u00ad\ntibiotic\nY\nY\nY\nY\nY\nRifampicin\nN\nN\nY\nY\nY\nRifabutin\nN\nN\nY\nY\nY\nMedical Conditions and Patient Characteristics\nCondition\nContraceptives\nCoc\nPop\nPoi\nPoim\nCuiud\nReproductive Tract Infections And Disorders\nUnexplained vaginal \nbleeding\nY\nY\nN\nN\nN\nSevere dysmenorrhoea Y\nY\nY\nY\nY\nTrophoblastic disease\nY\nY\nY\nY\nN",
        "formatted_content": "<p>660</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Drug</p>\n<p>Contraceptives</p>\n<p>Coc</p>\n<p>Pop</p>\n<p>Poi</p>\n<p>Poim</p>\n<p>Cuiud</p>\n<p>Tenofovir</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Zidovudine</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Lamivudine</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Efavirenz</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Nevirapine</p>\n<p>Nevirapine</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Atazanavir/r</p>\n<p>Atazanavir/r</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Lopinavir/r</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Darunavir/r</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Raltegravir</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Dolutegravir</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Phenytoin</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Phenobarbital</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Carbamazepine</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Broad spectrum an\u00ad</p>\n<p>tibiotic</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Rifampicin</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Rifabutin</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Medical Conditions and Patient Characteristics</p>\n<p>Condition</p>\n<p>Contraceptives</p>\n<p>Coc</p>\n<p>Pop</p>\n<p>Poi</p>\n<p>Poim</p>\n<p>Cuiud</p>\n<p>Reproductive Tract Infections And Disorders</p>\n<p>Unexplained vaginal</p>\n<p>bleeding</p>\n<p>Y</p>\n<p>Y</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>Severe dysmenorrhoea Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Trophoblastic disease</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>N</p>"
    },
    {
        "page_number": 727,
        "content": "661\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nCondition\nContraceptives\nCoc\nPop\nPoi\nPoim\nCuiud\nUterine fibroids\nY\nY\nY\nY\nY\nCervical neoplasia\nY\nY\nY\nY\nY\nCervical cancer\nY\nY\nY\nY\nN\nCurrent pelvic inflam\u00ad\nmatory disease\nY\nY\nY\nY\nY\nPost abortion sepsis\nY\nY\nY\nY\nN\nBreast cancer\nN\nN\nN\nN\nY\nLiver Diseases\nAcute hepatitis\nN\nY\nY\nY\nY\nLiver tumour\nN\nN\nN\nN\nY\nVenous Thromboembolism (Vte E.g Dvt, Pe)\nHistory of VTE\nN\nY\nY\nY\nY\nAcute VTE\nN\nN\nN\nN\nY\nMajor surgery with pro\u00ad\nlonged immobilisation\nN\nN\nY\nY\nY\nCardiovascular Disease\nIschaemic heart disease N\nY\nN\nY\nY\nStroke\nN\nY\nN\nY\nY\nMultiple risk factors\ne.g. dyslipidaemias\nY\nY\nY\nY\nY\nHypertension, Obesity And Diabetes\nBP 140-159/90-99 or\nadequately controlled\nN\nY\nY\nY\nY\nBP \u00b3160/99 mmHg\nN\nY\nN\nY\nY\nBMI \u00b330 kg/m2",
        "formatted_content": "<p>661</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Condition</p>\n<p>Contraceptives</p>\n<p>Coc</p>\n<p>Pop</p>\n<p>Poi</p>\n<p>Poim</p>\n<p>Cuiud</p>\n<p>Uterine fibroids</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Cervical neoplasia</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Cervical cancer</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>N</p>\n<p>Current pelvic inflam\u00ad</p>\n<p>matory disease</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Post abortion sepsis</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>N</p>\n<p>Breast cancer</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Liver Diseases</p>\n<p>Acute hepatitis</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Liver tumour</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Venous Thromboembolism (Vte E.g Dvt, Pe)</p>\n<p>History of VTE</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Acute VTE</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Major surgery with pro\u00ad</p>\n<p>longed immobilisation</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Cardiovascular Disease</p>\n<p>Ischaemic heart disease N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Stroke</p>\n<p>N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Multiple risk factors</p>\n<p>e.g. dyslipidaemias</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Hypertension, Obesity And Diabetes</p>\n<p>BP 140-159/90-99 or</p>\n<p>adequately controlled</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>BP \u00b3160/99 mmHg</p>\n<p>N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>BMI \u00b330 kg/m2</p>"
    },
    {
        "page_number": 728,
        "content": "662\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nCondition\nContraceptives\nCoc\nPop\nPoi\nPoim\nCuiud\nDiabetes (current)\nY\nY\nY\nY\nY\nDiabetes with neuro-, \nretinal or nephropathy\nN\nY\nN\nY\nY\nSmoker Age \u00b335\nN\nY\nY\nY\nY\nSmoker Age <35\nY\nY\nY\nY\nY\nHeadache\nNon-migraine head\u00ad\nache\nY\nY\nY\nY\nY\nMigraine with aura \n(neurological symptom)\nN\nN\nY\nY\nY\nHiv And Stis\nHIV Clinical Stage 3 \nor 4\nY\nY\nY\nY\nN\nGonorrhoea\nY\nY\nY\nY\nY\nChlamydia\nY\nY\nY\nY\nY\nOther STIs and vag\u00ad\ninalis\nY\nY\nY\nY\nY\nIncreased risk of STIs\nY\nY\nY\nY\nY\nPostpartum And Breastfeeding\n<48 hours\nN\nY\nN\nY\nY\n48 hours to <4 weeks N\nY\nN\nY\nN\n4 weeks to <6 weeks\nN\nY\nN\nY\nY\n6 weeks to <6 months\n(primary breastfeeding)\nN\nY\nY\nY\nY\n\u00b36 months\nY\nY\nY\nY\nY",
        "formatted_content": "<p>662</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Condition</p>\n<p>Contraceptives</p>\n<p>Coc</p>\n<p>Pop</p>\n<p>Poi</p>\n<p>Poim</p>\n<p>Cuiud</p>\n<p>Diabetes (current)</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Diabetes with neuro-,</p>\n<p>retinal or nephropathy</p>\n<p>N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Smoker Age \u00b335</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Smoker Age <35</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Headache</p>\n<p>Non-migraine head\u00ad</p>\n<p>ache</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Migraine with aura</p>\n<p>(neurological symptom)</p>\n<p>N</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Hiv And Stis</p>\n<p>HIV Clinical Stage 3</p>\n<p>or 4</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>N</p>\n<p>Gonorrhoea</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Chlamydia</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Other STIs and vag\u00ad</p>\n<p>inalis</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Increased risk of STIs</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Postpartum And Breastfeeding</p>\n<p><48 hours</p>\n<p>N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>48 hours to <4 weeks N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>N</p>\n<p>4 weeks to <6 weeks</p>\n<p>N</p>\n<p>Y</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>6 weeks to <6 months</p>\n<p>(primary breastfeeding)</p>\n<p>N</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>\u00b36 months</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>"
    },
    {
        "page_number": 729,
        "content": "663\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nCondition\nContraceptives\nCoc\nPop\nPoi\nPoim\nCuiud\nPeurperal sepsis\nY\nY\nY\nY\nN\nAge And Pregnancy History (Parity)\nAdolescents (menarche \nto age < 18 years)\nY\nY\nY\nY\nY\nNulliparity\nY\nY\nY\nY\nY\nParous\nY\nY\nY\nY\nY\nPregnancy\nNA\nNA\nNA\nNA\nNA\nNotes on continuation\n \n\u0083 If venous thromboembolism develops while on hormonal \ncontraceptives, discontinue  \n \n\u0083 Refer for further management\n \n\u0083 Recommend  another none hormonal family planning method\nConditions where all methods can be used\nCategory\nConditions\nRepro- duc\u00ad\ntive\nBenign breast disease or undiagnosed mass, benign \novarian tumours and cysts, dysmenorrhoea, endo\u00ad\nmetriosis, history of gestational diabetes, history of \nhigh blood pressure during pregnancy, history of \npelvic surgery including caeserean delivery, irregular, \nheavy prolonged menstrual bleeding (explained), past \nectopic pregnancy, past pelvic inflammatory disease, \npost-abortion (no sepsis), postpartum (all methods \nexcept COCs which are given  \u00b36 months)\nMedical\nDepression, epilepsy, HIV asymptomatic (WHO clinical \nstage 1 or 2), iron-deficiency anaemia, sickle-cell disease, \nthalassaemia, malaria, mild cirrhosis, schistosomiasis, \nsuperficial venous disorders including varicose veins,",
        "formatted_content": "<p>663</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Condition</p>\n<p>Contraceptives</p>\n<p>Coc</p>\n<p>Pop</p>\n<p>Poi</p>\n<p>Poim</p>\n<p>Cuiud</p>\n<p>Peurperal sepsis</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>N</p>\n<p>Age And Pregnancy History (Parity)</p>\n<p>Adolescents (menarche</p>\n<p>to age < 18 years)</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Nulliparity</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Parous</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Y</p>\n<p>Pregnancy</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>NA</p>\n<p>Notes on continuation</p>\n<p>\u0083 If venous thromboembolism develops while on hormonal</p>\n<p>contraceptives, discontinue</p>\n<p>\u0083 Refer for further management</p>\n<p>\u0083 Recommend  another none hormonal family planning method</p>\n<p>Conditions where all methods can be used</p>\n<p>Category</p>\n<p>Conditions</p>\n<p>Repro- duc\u00ad</p>\n<p>tive</p>\n<p>Benign breast disease or undiagnosed mass, benign</p>\n<p>ovarian tumours and cysts, dysmenorrhoea, endo\u00ad</p>\n<p>metriosis, history of gestational diabetes, history of</p>\n<p>high blood pressure during pregnancy, history of</p>\n<p>pelvic surgery including caeserean delivery, irregular,</p>\n<p>heavy prolonged menstrual bleeding (explained), past</p>\n<p>ectopic pregnancy, past pelvic inflammatory disease,</p>\n<p>post-abortion (no sepsis), postpartum (all methods</p>\n<p>except COCs which are given  \u00b36 months)</p>\n<p>Medical</p>\n<p>Depression, epilepsy, HIV asymptomatic (WHO clinical</p>\n<p>stage 1 or 2), iron-deficiency anaemia, sickle-cell disease,</p>\n<p>thalassaemia, malaria, mild cirrhosis, schistosomiasis,</p>\n<p>superficial venous disorders including varicose veins,</p>"
    },
    {
        "page_number": 730,
        "content": "664\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nCategory\nConditions\nthyroid disorders, tuberculosis (non-pelvic), uncompli\u00ad\ncated heart disease, viral hepatitis (carrier or chronic), \ncholecystitis, gall stones\nOthers\nAdolescents, breast cancer family history, venous \nthromboembolism (VTE) family history, high risk for \nHIV, surgery\nwithout prolonged immobilisation, taking antibiotics \n(except rifampicin or rifabutin)\nMethods all couples (except a few) can safely use\nEmergency contraceptive pill (for emergency use only) Bilateral Tubal \nLigation (BTL) and Vasectomy\nBarrier methods (condoms, diaphragm) Lactational amenorrhoea \nmethod (LAM)\nFertility awareness (FAM) and Standard days methods\n15.2  Overview Of Key Contraceptive Methods\nThe following sections contain an overview of mainstream contraceptive \nmethods and how to manage side effects\nof each (in case they occur). Side effects are one of most common reasons \nwhy women stop using contraception, and the health worker should \nbe able to counsel the patient and address her concerns appropriately.\n15.2.1 Condom (Male)\t\n    ICD10 CODE: Z30.018/Z30.49 \nFor example no-logo donation condoms, branded condoms. \nIndications\n \n~\nCouples needing an immediately effective method\n \n~\nWhere this is preferred FP method by client\n \n~\nCouples waiting to rule out suspected pregnancy\n \n~\nProtection against exposure to STIs including HIV/AIDS",
        "formatted_content": "<p>664</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Category</p>\n<p>Conditions</p>\n<p>thyroid disorders, tuberculosis (non-pelvic), uncompli\u00ad</p>\n<p>cated heart disease, viral hepatitis (carrier or chronic),</p>\n<p>cholecystitis, gall stones</p>\n<p>Others</p>\n<p>Adolescents, breast cancer family history, venous</p>\n<p>thromboembolism (VTE) family history, high risk for</p>\n<p>HIV, surgery</p>\n<p>without prolonged immobilisation, taking antibiotics</p>\n<p>(except rifampicin or rifabutin)</p>\n<p>Methods all couples (except a few) can safely use</p>\n<p>Emergency contraceptive pill (for emergency use only) Bilateral Tubal</p>\n<p>Ligation (BTL) and Vasectomy</p>\n<p>Barrier methods (condoms, diaphragm) Lactational amenorrhoea</p>\n<p>method (LAM)</p>\n<p>Fertility awareness (FAM) and Standard days methods</p>\n<p>15.2  Overview Of Key Contraceptive Methods</p>\n<p>The following sections contain an overview of mainstream contraceptive</p>\n<p>methods and how to manage side effects</p>\n<p>of each (in case they occur). Side effects are one of most common reasons</p>\n<p>why women stop using contraception, and the health worker should</p>\n<p>be able to counsel the patient and address her concerns appropriately.</p>\n<p>15.2.1 Condom (Male)</p>\n<h3>ICD10 CODE: Z30.018/Z30.49</h3>\n<p>For example no-logo donation condoms, branded condoms.</p>\n<p>Indications</p>\n<p>~</p>\n<p>Couples needing an immediately effective method</p>\n<p>~</p>\n<p>Where this is preferred FP method by client</p>\n<p>~</p>\n<p>Couples waiting to rule out suspected pregnancy</p>\n<p>~</p>\n<p>Protection against exposure to STIs including HIV/AIDS</p>"
    },
    {
        "page_number": 731,
        "content": "665\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nWhere back-up method is needed, e.g. when womanis \nstarting or has forgotten to take oral contraceptives\n \n~\nCouples where one or both partners have HIV/AIDS, \neven if using another FP method\nAdvantages\n \n~\nMale plays role in FP\n \n~\nProtects against unwanted pregnancy\n \n~\nAlso protects against STIs and HIV infection\nDisadvantages\n \n~\nSome men may have difficulty maintaining an erection \nwith condom on\n \n~\nMay cause insensitivity of the penis\n \n~\nOccasional hypersensitivity to latex or lubricants (may re\u00ad\nsult in a severe allergic reaction)\n \n~\nRequires correct use with every act of sex for greatest ef\u00ad\nfectiveness\nManagement\nINSTRUCTIONS\nLOC\n \n~\nEnsure client understands correct use, storage, \nand disposal of condom\n \n~\nSupply at least 100 condoms to each client for \nthree months, and if available, a water or sili\u00ad\ncone based lubricant\n \n~\nAdvise client to return for more before they are \nfinished\n \n~\nIn case of hypersensitivity to latex or lubricants, \navoid latex based condoms, and use the female \ncondom or another FP method\nHC2",
        "formatted_content": "<p>665</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Where back-up method is needed, e.g. when womanis</p>\n<p>starting or has forgotten to take oral contraceptives</p>\n<p>~</p>\n<p>Couples where one or both partners have HIV/AIDS,</p>\n<p>even if using another FP method</p>\n<p>Advantages</p>\n<p>~</p>\n<p>Male plays role in FP</p>\n<p>~</p>\n<p>Protects against unwanted pregnancy</p>\n<p>~</p>\n<p>Also protects against STIs and HIV infection</p>\n<p>Disadvantages</p>\n<p>~</p>\n<p>Some men may have difficulty maintaining an erection</p>\n<p>with condom on</p>\n<p>~</p>\n<p>May cause insensitivity of the penis</p>\n<p>~</p>\n<p>Occasional hypersensitivity to latex or lubricants (may re\u00ad</p>\n<p>sult in a severe allergic reaction)</p>\n<p>~</p>\n<p>Requires correct use with every act of sex for greatest ef\u00ad</p>\n<p>fectiveness</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>~</p>\n<p>Ensure client understands correct use, storage,</p>\n<p>and disposal of condom</p>\n<p>~</p>\n<p>Supply at least 100 condoms to each client for</p>\n<p>three months, and if available, a water or sili\u00ad</p>\n<p>cone based lubricant</p>\n<p>~</p>\n<p>Advise client to return for more before they are</p>\n<p>finished</p>\n<p>~</p>\n<p>In case of hypersensitivity to latex or lubricants,</p>\n<p>avoid latex based condoms, and use the female</p>\n<p>condom or another FP method</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 732,
        "content": "666\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n15.2.2 Condom (Female)\t                    ICD10 CODE: Z30.018/Z30.49\nFor example Femidom, Care and FC2.\nA soft plastic pre-lubricated sheath with an inner and outer ring which \nis inserted into the vagina before sexual intercourse.\nIndications\n \n~\nAs for condoms (male) above\n \n~\nFor women whose partners will not use male condom\n \n~\nWhere the man has allergy/sensitivity to latex condom\nAdvantages\n \n~\nWoman-controlled (but requires partner\u2019s cooperation)\n \n~\nCan be inserted hours before intercourse and so does not \ninterrupt sexual spontaneity\n \n~\nNot dependent on male erection and does not require im\u00ad\nmediate withdrawal after ejaculation\n \n~\nProtects against STI and HIV infection\n \n~\nNo special storage required\nDisadvantages and Side-Effects\n \n~\nRequires special training and practice to use correctly\n \n~\nRelatively new product with limited public awareness\n \n~\nIn some cases, hypersensitivity to polyurethane female \ncondoms occurs\n \n~\nRequires correct use with every act of sex for greatest ef\u00ad\nfectiveness\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nEnsure client understands correct use, storage, and \ndisposal",
        "formatted_content": "<p>666</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>15.2.2 Condom (Female)\t                    ICD10 CODE: Z30.018/Z30.49</p>\n<p>For example Femidom, Care and FC2.</p>\n<p>A soft plastic pre-lubricated sheath with an inner and outer ring which</p>\n<p>is inserted into the vagina before sexual intercourse.</p>\n<p>Indications</p>\n<p>~</p>\n<p>As for condoms (male) above</p>\n<p>~</p>\n<p>For women whose partners will not use male condom</p>\n<p>~</p>\n<p>Where the man has allergy/sensitivity to latex condom</p>\n<p>Advantages</p>\n<p>~</p>\n<p>Woman-controlled (but requires partner\u2019s cooperation)</p>\n<p>~</p>\n<p>Can be inserted hours before intercourse and so does not</p>\n<p>interrupt sexual spontaneity</p>\n<p>~</p>\n<p>Not dependent on male erection and does not require im\u00ad</p>\n<p>mediate withdrawal after ejaculation</p>\n<p>~</p>\n<p>Protects against STI and HIV infection</p>\n<p>~</p>\n<p>No special storage required</p>\n<p>Disadvantages and Side-Effects</p>\n<p>~</p>\n<p>Requires special training and practice to use correctly</p>\n<p>~</p>\n<p>Relatively new product with limited public awareness</p>\n<p>~</p>\n<p>In some cases, hypersensitivity to polyurethane female</p>\n<p>condoms occurs</p>\n<p>~</p>\n<p>Requires correct use with every act of sex for greatest ef\u00ad</p>\n<p>fectiveness</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure client understands correct use, storage, and</p>\n<p>disposal</p>"
    },
    {
        "page_number": 733,
        "content": "667\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nINSTRUCTIONS\nLOC\n\t\n\u0089\nSupply at least 40 female condoms to each client \nper month\n\t\n\u0089\nAdvise client to return for more before they are finished\n\t\n\u0089\nIn case of hypersensitivity, avoid use and change to \nanother FP method\nHC2\n15.2.3 Combined Oral Contraceptive Pill (COC)                             \nICD10 CODE: Z30.011/Z30.41\nContains an oestrogen plus a progestin, the types and quantities of \nwhich may vary in different preparations. \nIndications\n \n~\nWomen <35 years needing highly effective FP method\n \n~\nNon-breastfeeding clients, or breastfeeding clients after 6 \nmonths postpartum\n \n~\nClients with dysmenorrhoea\n \n~\nClients with heavy periods or ovulation pain\n \n~\nClients concerned by irregular menstrual cycles\nContraindications\n \n~\nDiastolic BP >100 mmHg\n \n~\nCardiac disease\n \n~\nThromboembolic disease (e.g. deep vein thrombosis)\n \n~\nActive liver disease\n \n~\nLess than 6months  after  childbirth\n \n~\nWhen major surgery is planned within 4 weeks\n \n~\nUnexplained abnormal vaginal bleeding\n \n~\nKnown/suspected cervical cancer\nUndiagnosed breast lumps or breast cancer\n \n~\nPregnancy (known or suspected)",
        "formatted_content": "<p>667</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Supply at least 40 female condoms to each client</p>\n<p>per month</p>\n<p>\u0089</p>\n<p>Advise client to return for more before they are finished</p>\n<p>\u0089</p>\n<p>In case of hypersensitivity, avoid use and change to</p>\n<p>another FP method</p>\n<h3>HC2</h3>\n<p>15.2.3 Combined Oral Contraceptive Pill (COC)</p>\n<h3>ICD10 CODE: Z30.011/Z30.41</h3>\n<p>Contains an oestrogen plus a progestin, the types and quantities of</p>\n<p>which may vary in different preparations.</p>\n<p>Indications</p>\n<p>~</p>\n<p>Women <35 years needing highly effective FP method</p>\n<p>~</p>\n<p>Non-breastfeeding clients, or breastfeeding clients after 6</p>\n<p>months postpartum</p>\n<p>~</p>\n<p>Clients with dysmenorrhoea</p>\n<p>~</p>\n<p>Clients with heavy periods or ovulation pain</p>\n<p>~</p>\n<p>Clients concerned by irregular menstrual cycles</p>\n<p>Contraindications</p>\n<p>~</p>\n<p>Diastolic BP >100 mmHg</p>\n<p>~</p>\n<p>Cardiac disease</p>\n<p>~</p>\n<p>Thromboembolic disease (e.g. deep vein thrombosis)</p>\n<p>~</p>\n<p>Active liver disease</p>\n<p>~</p>\n<p>Less than 6months  after  childbirth</p>\n<p>~</p>\n<p>When major surgery is planned within 4 weeks</p>\n<p>~</p>\n<p>Unexplained abnormal vaginal bleeding</p>\n<p>~</p>\n<p>Known/suspected cervical cancer</p>\n<p>Undiagnosed breast lumps or breast cancer</p>\n<p>~</p>\n<p>Pregnancy (known or suspected)</p>"
    },
    {
        "page_number": 734,
        "content": "668\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nRisk factors\nIf any 2 of the following, recommend progrestogen-only or non-hor\u00ad\nmonal FP method\n \n~\nSmoking (especially if >10 cigarettes/day)\n \n~\nAge >35 years\n \n~\nDiabetes\nAdvantages and other potential health benefits/uses\n \n~\nProtects against:\n\t\n\u0089\nRisk of unwanted pregnancy\n\t\n\u0089\nCancer of the ovary or lining of uterus\n\t\n\u0089\nSymptomatic pelvic inflammatory disease\n \n~\nReduces:\n\t\n\u0089\nMenstrual cramps and bleeding problems\n\t\n\u0089\nOvulation pain\n\t\n\u0089\nExcess hair on body/face, acne\n\t\n\u0089\nSymptoms of polycystic ovarian syndrome\nDisadvantages and common side effects\n \n~\nDOES NOT PROTECT AGAINST STIs\n \n~\nSpotting, nausea, and vomiting within first few months\n \n~\nChanges in bleeding patterns including: fewer days, irregu\u00ad\nlar, lighter, infrequent, or no monthly bleeding\n \n~\nMay cause headaches, dizziness, weight gain\n \n~\nEffectiveness dependent on regular daily dosage\n \n~\nMood changes\n \n~\nBreast tenderness\n \n~\nSuppresses lactation\n \n~\nMedicine interactions reduce effectiveness including:",
        "formatted_content": "<p>668</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Risk factors</p>\n<p>If any 2 of the following, recommend progrestogen-only or non-hor\u00ad</p>\n<p>monal FP method</p>\n<p>~</p>\n<p>Smoking (especially if >10 cigarettes/day)</p>\n<p>~</p>\n<p>Age >35 years</p>\n<p>~</p>\n<p>Diabetes</p>\n<p>Advantages and other potential health benefits/uses</p>\n<p>~</p>\n<p>Protects against:</p>\n<p>\u0089</p>\n<p>Risk of unwanted pregnancy</p>\n<p>\u0089</p>\n<p>Cancer of the ovary or lining of uterus</p>\n<p>\u0089</p>\n<p>Symptomatic pelvic inflammatory disease</p>\n<p>~</p>\n<p>Reduces:</p>\n<p>\u0089</p>\n<p>Menstrual cramps and bleeding problems</p>\n<p>\u0089</p>\n<p>Ovulation pain</p>\n<p>\u0089</p>\n<p>Excess hair on body/face, acne</p>\n<p>\u0089</p>\n<p>Symptoms of polycystic ovarian syndrome</p>\n<p>Disadvantages and common side effects</p>\n<p>~</p>\n<p>DOES NOT PROTECT AGAINST STIs</p>\n<p>~</p>\n<p>Spotting, nausea, and vomiting within first few months</p>\n<p>~</p>\n<p>Changes in bleeding patterns including: fewer days, irregu\u00ad</p>\n<p>lar, lighter, infrequent, or no monthly bleeding</p>\n<p>~</p>\n<p>May cause headaches, dizziness, weight gain</p>\n<p>~</p>\n<p>Effectiveness dependent on regular daily dosage</p>\n<p>~</p>\n<p>Mood changes</p>\n<p>~</p>\n<p>Breast tenderness</p>\n<p>~</p>\n<p>Suppresses lactation</p>\n<p>~</p>\n<p>Medicine interactions reduce effectiveness including:</p>"
    },
    {
        "page_number": 735,
        "content": "669\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n\t\n\u0089\nMedicines which increase hepatic enzyme activity, e.g., rifampicin \n(especially), carbamazepine, griseofulvin, nevirapine, phenytoin, \nphenobarbital\n \n- Short courses of some broad spectrum antibiotics, e.g., \nampicillin, amoxicillin, doxycycline\nAn additional FP method must be used during course of treatment \nwith these medicines and for at least 7 days after completion.\nComplications and warning signs\n \n~\nSevere headaches, blurred vision\n \n~\nDepression\n \n~\nAcute severe abdominal pain\n \n~\nChest pain plus dyspnoea (pulmonary embolism)\n \n~\nSwelling or pain in calf muscle (Deep vein thrombosis)\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nGive 3 cycles of COC and explain carefully:\n \n\u0083 How to take the tablets\n \n\u0083 Strict compliance is essential\nHC2\n \n\u0083 What to do if doses are missed or there are side- \neffects or warning signs\nIf starting COC within 5 days of period\n\t\n\u0089\nSupply and show how to use back-up FP method\n\t\n\u0089\nAsk client to return when <7 tablets remain in last cycle\nMANAGEMENT OF SIDE EFFECTS OF COCS\nNausea\n \n~\nAssess for pregnancy and malaria",
        "formatted_content": "<p>669</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>\u0089</p>\n<p>Medicines which increase hepatic enzyme activity, e.g., rifampicin</p>\n<p>(especially), carbamazepine, griseofulvin, nevirapine, phenytoin,</p>\n<p>phenobarbital</p>\n<p>- Short courses of some broad spectrum antibiotics, e.g.,</p>\n<p>ampicillin, amoxicillin, doxycycline</p>\n<p>An additional FP method must be used during course of treatment</p>\n<p>with these medicines and for at least 7 days after completion.</p>\n<p>Complications and warning signs</p>\n<p>~</p>\n<p>Severe headaches, blurred vision</p>\n<p>~</p>\n<p>Depression</p>\n<p>~</p>\n<p>Acute severe abdominal pain</p>\n<p>~</p>\n<p>Chest pain plus dyspnoea (pulmonary embolism)</p>\n<p>~</p>\n<p>Swelling or pain in calf muscle (Deep vein thrombosis)</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give 3 cycles of COC and explain carefully:</p>\n<p>\u0083 How to take the tablets</p>\n<p>\u0083 Strict compliance is essential</p>\n<h3>HC2</h3>\n<p>\u0083 What to do if doses are missed or there are side-</p>\n<p>effects or warning signs</p>\n<p>If starting COC within 5 days of period</p>\n<p>\u0089</p>\n<p>Supply and show how to use back-up FP method</p>\n<p>\u0089</p>\n<p>Ask client to return when <7 tablets remain in last cycle</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF COCS</h3>\n<p>Nausea</p>\n<p>~</p>\n<p>Assess for pregnancy and malaria</p>"
    },
    {
        "page_number": 736,
        "content": "670\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF COCS\n \n~\nSuggest taking COCs at bedtime or with food\n \n~\nTake pill at same time daily\nIf symptoms continue:\n\t\n\u0089\nConsider locally available remedies (e.g. eating roasted grains, \nroasted cassava, boiled greens)\nBreast Tenderness\n \n~\nAssess for pregnancy\n \n~\nRecommend that she wears a supportive bra\n \n~\nExamine for cancer symptoms, such as breast infection, \nlumps, or nipple discharge\nIf breastfeeding, examine for breast infection\n \n~\nIf there is infection, use warm compresses. Refer for ap\u00ad\npropriate evaluation\n \n~\nIf the examination shows a suspicious lump or discharge, \nrefer for appropriate evaluation\n \n~\nCounsel her on non-hormonal FP methods\n \n~\nTry hot or cold compresses\n\t\n\u0089\nSuggest ibuprofen, paracetamol, or other pain relievers\nMild Headaches\n \n~\nTake proper history (explore when headaches occur, \nwhether she can continue with her daily tasks, what \nmedicines relieve her headaches)\n \n~\nTake her blood pressure\nIf blood pressure is normal:\n\t\n\u0089\nGive pain relievers such as ibuprofen or paracetamol\n\t\n\u0089\nIf headaches get worse or occur more often, refer for appropriate \nevaluation",
        "formatted_content": "<p>670</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF COCS</h3>\n<p>~</p>\n<p>Suggest taking COCs at bedtime or with food</p>\n<p>~</p>\n<p>Take pill at same time daily</p>\n<p>If symptoms continue:</p>\n<p>\u0089</p>\n<p>Consider locally available remedies (e.g. eating roasted grains,</p>\n<p>roasted cassava, boiled greens)</p>\n<p>Breast Tenderness</p>\n<p>~</p>\n<p>Assess for pregnancy</p>\n<p>~</p>\n<p>Recommend that she wears a supportive bra</p>\n<p>~</p>\n<p>Examine for cancer symptoms, such as breast infection,</p>\n<p>lumps, or nipple discharge</p>\n<p>If breastfeeding, examine for breast infection</p>\n<p>~</p>\n<p>If there is infection, use warm compresses. Refer for ap\u00ad</p>\n<p>propriate evaluation</p>\n<p>~</p>\n<p>If the examination shows a suspicious lump or discharge,</p>\n<p>refer for appropriate evaluation</p>\n<p>~</p>\n<p>Counsel her on non-hormonal FP methods</p>\n<p>~</p>\n<p>Try hot or cold compresses</p>\n<p>\u0089</p>\n<p>Suggest ibuprofen, paracetamol, or other pain relievers</p>\n<p>Mild Headaches</p>\n<p>~</p>\n<p>Take proper history (explore when headaches occur,</p>\n<p>whether she can continue with her daily tasks, what</p>\n<p>medicines relieve her headaches)</p>\n<p>~</p>\n<p>Take her blood pressure</p>\n<p>If blood pressure is normal:</p>\n<p>\u0089</p>\n<p>Give pain relievers such as ibuprofen or paracetamol</p>\n<p>\u0089</p>\n<p>If headaches get worse or occur more often, refer for appropriate</p>\n<p>evaluation</p>"
    },
    {
        "page_number": 737,
        "content": "671\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF COCS\nPalpitations\n \n~\nRule out anaemia and check blood pressure and weight\n \n~\nReassure that this is common in COC users, and usually \ndisappears in a few months\n \n~\nEvaluate for other causes unrelated to the method, and \nrefer if necessary\nChest Pain\n \n~\nEvaluate for the cause and refer if necessary\n15.2.4 Progestogen-Only Pill (POP)                                                     \nICD10 CODE: Z30.011/Z30.41\nPills that contain very low doses of a progestin like the natural hormone \nprogesterone in a woman\u2019s body. Since these pills do not contain oes\u00ad\ntrogen, they are safe to use throughout breastfeeding, and by women \nwho cannot use methods with oestrogen.\nIndications\n \n~\nBreastfeeding and non-breastfeeding clients immediately \npostpartum\n \n~\nWomen who cannot take COC but prefer to use pills\n \n~\nWomen of all ages with desire to use contraceptive pills\nContraindications\n \n~\nBreast or genital malignancy (known or suspected)\n \n~\nPregnancy (known or suspected)\n \n~\nBreast cancer >5 years ago, and it has not recurred\n \n~\nSevere liver disease, infection, or tumor\n \n~\nTaking barbiturates, carbamazepine, oxcarbazepine, phe\u00ad\nnytoin, primidone, topiramate, rifampicin, rifabutin, or \nritonavir or ritonavir-boosted protease inhibitors. Use a \nbackup contraceptive method as these medications reduce \nthe effectiveness of POPs",
        "formatted_content": "<p>671</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF COCS</h3>\n<p>Palpitations</p>\n<p>~</p>\n<p>Rule out anaemia and check blood pressure and weight</p>\n<p>~</p>\n<p>Reassure that this is common in COC users, and usually</p>\n<p>disappears in a few months</p>\n<p>~</p>\n<p>Evaluate for other causes unrelated to the method, and</p>\n<p>refer if necessary</p>\n<p>Chest Pain</p>\n<p>~</p>\n<p>Evaluate for the cause and refer if necessary</p>\n<p>15.2.4 Progestogen-Only Pill (POP)</p>\n<h3>ICD10 CODE: Z30.011/Z30.41</h3>\n<p>Pills that contain very low doses of a progestin like the natural hormone</p>\n<p>progesterone in a woman\u2019s body. Since these pills do not contain oes\u00ad</p>\n<p>trogen, they are safe to use throughout breastfeeding, and by women</p>\n<p>who cannot use methods with oestrogen.</p>\n<p>Indications</p>\n<p>~</p>\n<p>Breastfeeding and non-breastfeeding clients immediately</p>\n<p>postpartum</p>\n<p>~</p>\n<p>Women who cannot take COC but prefer to use pills</p>\n<p>~</p>\n<p>Women of all ages with desire to use contraceptive pills</p>\n<p>Contraindications</p>\n<p>~</p>\n<p>Breast or genital malignancy (known or suspected)</p>\n<p>~</p>\n<p>Pregnancy (known or suspected)</p>\n<p>~</p>\n<p>Breast cancer >5 years ago, and it has not recurred</p>\n<p>~</p>\n<p>Severe liver disease, infection, or tumor</p>\n<p>~</p>\n<p>Taking barbiturates, carbamazepine, oxcarbazepine, phe\u00ad</p>\n<p>nytoin, primidone, topiramate, rifampicin, rifabutin, or</p>\n<p>ritonavir or ritonavir-boosted protease inhibitors. Use a</p>\n<p>backup contraceptive method as these medications reduce</p>\n<p>the effectiveness of POPs</p>"
    },
    {
        "page_number": 738,
        "content": "672\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nSystemic lupus erythematosus with positive (or unknown) \nantiphospholipid antibodies\n \n~\nUndiagnosed vaginal bleeding\n \n~\nCurrent or history of blood clot\n \n~\nHigh blood presure\nDisadvantages and common side effects\n \n~\nDOES NOT PROTECT AGAINST STIs\n \n~\nSpotting, amenorrhoea\n \n~\nUnpredictable irregular periods\n \n~\nNot as effective as COC\n \n~\nMedicine interactions: the effectiveness is educed by med\u00ad\nicines which increase hepatic enzyme activity\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nGive 3 cycles of POP: Explain carefully how to take the \ntablets, and what to do if doses are missed, or if there \nare side-effects\n\t\n\u0089\nSupply and show how to use back-up FP method for \nfirst 14 days of first packet, e.g. condoms or abstinence \nfrom sex\n\t\n\u0089\nAsk client to return 11 weeks after starting POP\n\t\n\u0089\nUse the last pill packet to show when this will be\nHC2\nMANAGEMENT OF SIDE EFFECTS OF POPS\nNo Monthly Periods\nAssess for pregnancy\n \n~\nIf not pregnant and/or breast-feeding, reassure that itis \nnormal. Some women using POPs stop having monthly \nperiods, but this is not harmful",
        "formatted_content": "<p>672</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Systemic lupus erythematosus with positive (or unknown)</p>\n<p>antiphospholipid antibodies</p>\n<p>~</p>\n<p>Undiagnosed vaginal bleeding</p>\n<p>~</p>\n<p>Current or history of blood clot</p>\n<p>~</p>\n<p>High blood presure</p>\n<p>Disadvantages and common side effects</p>\n<p>~</p>\n<p>DOES NOT PROTECT AGAINST STIs</p>\n<p>~</p>\n<p>Spotting, amenorrhoea</p>\n<p>~</p>\n<p>Unpredictable irregular periods</p>\n<p>~</p>\n<p>Not as effective as COC</p>\n<p>~</p>\n<p>Medicine interactions: the effectiveness is educed by med\u00ad</p>\n<p>icines which increase hepatic enzyme activity</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give 3 cycles of POP: Explain carefully how to take the</p>\n<p>tablets, and what to do if doses are missed, or if there</p>\n<p>are side-effects</p>\n<p>\u0089</p>\n<p>Supply and show how to use back-up FP method for</p>\n<p>first 14 days of first packet, e.g. condoms or abstinence</p>\n<p>from sex</p>\n<p>\u0089</p>\n<p>Ask client to return 11 weeks after starting POP</p>\n<p>\u0089</p>\n<p>Use the last pill packet to show when this will be</p>\n<h3>HC2</h3>\n<h3>MANAGEMENT OF SIDE EFFECTS OF POPS</h3>\n<p>No Monthly Periods</p>\n<p>Assess for pregnancy</p>\n<p>~</p>\n<p>If not pregnant and/or breast-feeding, reassure that itis</p>\n<p>normal. Some women using POPs stop having monthly</p>\n<p>periods, but this is not harmful</p>"
    },
    {
        "page_number": 739,
        "content": "673\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF POPS\n \n~\nIf pregnant, reassure that the POPs will not affect her \npregnancy, and refer her to ANC\nNausea/Dizziness\n \n~\nNausea: suggest taking POPs at bedtime or with food\n \n~\nIf symptoms continue, consider locally available reme\u00ad\ndies\nMigraine/Headaches\n \n~\nWithout Aura (e.g. hallucinations, hearing voices): able \nto continue using POPs voluntarily\n \n~\nWith Aura: stop POPs and choose a method without \nhormones\nIrregular Bleeding\n \n~\nAssess for pregnancy/abortion\n \n~\nReassure that many women using POPs get irregular \nbleeding whether breast-feeding or not. It is not harmful \nand should lessen or stop after several months of use\n \n~\nCounsel on how to reduce irregular bleeding, e.g. mak\u00ad\ning up for missed pills after vomiting or diarrhoea\nIf bleeding continues:\n \n~\nGive 400\u2013800 mg ibuprofen every 8 hours after meals \nfor 5 days when irregular bleeding starts\n \n~\nMefenamic acid 500mg three times a day for 5-7days\n \n~\nCheck for anaemia and treat accordingly\nIf irregular bleeding persists or starts after several months of normal \nor no monthly bleeding:\n \n~\nInvestigate other reasons (unrelated to POPs) and treat \naccordingly\n \n~\nChange to another pill formulation for at least 3 months\n \n~\nOr help client choose another method of family planning",
        "formatted_content": "<p>673</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF POPS</h3>\n<p>~</p>\n<p>If pregnant, reassure that the POPs will not affect her</p>\n<p>pregnancy, and refer her to ANC</p>\n<p>Nausea/Dizziness</p>\n<p>~</p>\n<p>Nausea: suggest taking POPs at bedtime or with food</p>\n<p>~</p>\n<p>If symptoms continue, consider locally available reme\u00ad</p>\n<p>dies</p>\n<p>Migraine/Headaches</p>\n<p>~</p>\n<p>Without Aura (e.g. hallucinations, hearing voices): able</p>\n<p>to continue using POPs voluntarily</p>\n<p>~</p>\n<p>With Aura: stop POPs and choose a method without</p>\n<p>hormones</p>\n<p>Irregular Bleeding</p>\n<p>~</p>\n<p>Assess for pregnancy/abortion</p>\n<p>~</p>\n<p>Reassure that many women using POPs get irregular</p>\n<p>bleeding whether breast-feeding or not. It is not harmful</p>\n<p>and should lessen or stop after several months of use</p>\n<p>~</p>\n<p>Counsel on how to reduce irregular bleeding, e.g. mak\u00ad</p>\n<p>ing up for missed pills after vomiting or diarrhoea</p>\n<p>If bleeding continues:</p>\n<p>~</p>\n<p>Give 400\u2013800 mg ibuprofen every 8 hours after meals</p>\n<p>for 5 days when irregular bleeding starts</p>\n<p>~</p>\n<p>Mefenamic acid 500mg three times a day for 5-7days</p>\n<p>~</p>\n<p>Check for anaemia and treat accordingly</p>\n<p>If irregular bleeding persists or starts after several months of normal</p>\n<p>or no monthly bleeding:</p>\n<p>~</p>\n<p>Investigate other reasons (unrelated to POPs) and treat</p>\n<p>accordingly</p>\n<p>~</p>\n<p>Change to another pill formulation for at least 3 months</p>\n<p>~</p>\n<p>Or help client choose another method of family planning</p>"
    },
    {
        "page_number": 740,
        "content": "674\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nHeavy or prolonged bleeding (twice as much as usual or longer than 8 \ndays)\n \n~\nAssess for pregnancy/abortion\n \n~\nReassure/comfort the patient\n\t\n\u0089\nGive 800 mg ibuprofen every 8 hours after meals for 5 days \nwhen irregular bleeding starts\n\t\n\u0089\nOr other non-steroidal anti-inflammatory drugs (NSAID)\n\t\n\u0089\nFerrous salt tablets (60 mg iron) to prevent anaemia\n\t\n\u0089\nEducate on nutrition\nIf heavy bleeding persists:\n \n~\nInvestigate other reasons (unrelated to POPs) and treat \naccordingly\n \n~\nChange to another pill formulation for at least 3 months\n \n~\nOr help client choose another method of family plan\u00ad\nning preferably COC if there is no contra-indication\n15.2.5 Injectable Progestogen-Only Contraceptive\t\n     \nICD10 CODE: Z30.013/Z30.42\nA slowly absorbed depot IM injection or subcutaneous injection, which \nprovides contraceptive protection. \nIndications\n \n~\nFertile women requiring contraception\n \n~\nBreastfeeding postpartum women\n \n~\nKnown/suspected HIV positive women who need an effec\u00ad\ntive FP method\n \n~\nWomen with sickle-cell disease\n \n~\nWomen who cannot use COC due to oestrogen content\n \n~\nWomen who do not want more children but do not (yet) \nwant voluntary surgical contraception",
        "formatted_content": "<p>674</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Heavy or prolonged bleeding (twice as much as usual or longer than 8</p>\n<p>days)</p>\n<p>~</p>\n<p>Assess for pregnancy/abortion</p>\n<p>~</p>\n<p>Reassure/comfort the patient</p>\n<p>\u0089</p>\n<p>Give 800 mg ibuprofen every 8 hours after meals for 5 days</p>\n<p>when irregular bleeding starts</p>\n<p>\u0089</p>\n<p>Or other non-steroidal anti-inflammatory drugs (NSAID)</p>\n<p>\u0089</p>\n<p>Ferrous salt tablets (60 mg iron) to prevent anaemia</p>\n<p>\u0089</p>\n<p>Educate on nutrition</p>\n<p>If heavy bleeding persists:</p>\n<p>~</p>\n<p>Investigate other reasons (unrelated to POPs) and treat</p>\n<p>accordingly</p>\n<p>~</p>\n<p>Change to another pill formulation for at least 3 months</p>\n<p>~</p>\n<p>Or help client choose another method of family plan\u00ad</p>\n<p>ning preferably COC if there is no contra-indication</p>\n<p>15.2.5 Injectable Progestogen-Only Contraceptive</p>\n<h3>ICD10 CODE: Z30.013/Z30.42</h3>\n<p>A slowly absorbed depot IM injection or subcutaneous injection, which</p>\n<p>provides contraceptive protection.</p>\n<p>Indications</p>\n<p>~</p>\n<p>Fertile women requiring contraception</p>\n<p>~</p>\n<p>Breastfeeding postpartum women</p>\n<p>~</p>\n<p>Known/suspected HIV positive women who need an effec\u00ad</p>\n<p>tive FP method</p>\n<p>~</p>\n<p>Women with sickle-cell disease</p>\n<p>~</p>\n<p>Women who cannot use COC due to oestrogen content</p>\n<p>~</p>\n<p>Women who do not want more children but do not (yet)</p>\n<p>want voluntary surgical contraception</p>"
    },
    {
        "page_number": 741,
        "content": "675\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nWomen awaiting surgical contraception\nContraindications\n \n~\nAs for POP above\nAdvantages and other health benefits/uses\n \n~\nDo not require daily action (e.g. taking pills)\n \n~\nDo not interfere with sex\n \n~\nPrivate method: no one else can tell that a woman is using \ncontraception\n \n~\nCause no monthly bleeding (for many women)\n \n~\nInjections can be stopped at anytime\n \n~\nReduces:\n\t\n\u0089\nCancer of the lining of the uterus (DMPA)\n\t\n\u0089\nReduces heavy flow in Uterine fibroids (DMPA)\n\t\n\u0089\nIron-deficiency anaemia (NET-EN)\nDisadvantages and common side-effects\n \n~\nDOES NOT PROTECT AGAINST STI\n \n~\nAmenorrhoea\n \n- Often after 1st injection and after 9\u201312 months of use\n \n~\nCan cause heavy prolonged vaginal bleeding during first \n1-2 months after injection\n \n~\nWeight gain\n \n~\nLoss of libido\n \n~\nMay delay return to fertility (Up to 12 months after stop\u00ad\nping injection)\nComplications and warning signs\n \n~\nHeadaches\n \n~\nHeavy vaginal bleeding",
        "formatted_content": "<p>675</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Women awaiting surgical contraception</p>\n<p>Contraindications</p>\n<p>~</p>\n<p>As for POP above</p>\n<p>Advantages and other health benefits/uses</p>\n<p>~</p>\n<p>Do not require daily action (e.g. taking pills)</p>\n<p>~</p>\n<p>Do not interfere with sex</p>\n<p>~</p>\n<p>Private method: no one else can tell that a woman is using</p>\n<p>contraception</p>\n<p>~</p>\n<p>Cause no monthly bleeding (for many women)</p>\n<p>~</p>\n<p>Injections can be stopped at anytime</p>\n<p>~</p>\n<p>Reduces:</p>\n<p>\u0089</p>\n<p>Cancer of the lining of the uterus (DMPA)</p>\n<p>\u0089</p>\n<p>Reduces heavy flow in Uterine fibroids (DMPA)</p>\n<p>\u0089</p>\n<p>Iron-deficiency anaemia (NET-EN)</p>\n<p>Disadvantages and common side-effects</p>\n<p>~</p>\n<h3>DOES NOT PROTECT AGAINST STI</h3>\n<p>~</p>\n<p>Amenorrhoea</p>\n<p>- Often after 1st injection and after 9\u201312 months of use</p>\n<p>~</p>\n<p>Can cause heavy prolonged vaginal bleeding during first</p>\n<p>1-2 months after injection</p>\n<p>~</p>\n<p>Weight gain</p>\n<p>~</p>\n<p>Loss of libido</p>\n<p>~</p>\n<p>May delay return to fertility (Up to 12 months after stop\u00ad</p>\n<p>ping injection)</p>\n<p>Complications and warning signs</p>\n<p>~</p>\n<p>Headaches</p>\n<p>~</p>\n<p>Heavy vaginal bleeding</p>"
    },
    {
        "page_number": 742,
        "content": "676\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nSevere abdominal pain\n \n~\nExcessive weight gain\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nMedroxyprogesterone acetate depot injection\n\t\n\u0089\nGive 150 mg deep IM into deltoid or buttock\nmuscle\n \n- Do not rub the area as this increases absorption \nand shortens depot effect\n\t\n\u0089\nMedroxyprogesterone acetate depot injection\n \n- Inject 104 mg in the fatty tissue (subcutaneous) at \nthe front of the thigh, the back of the upper arm, or \nthe abdomen\n \n- This can be administered at community level\nHC1\nIf given after day 1\u20137 of menstrual cycle\n\t\n\u0089\nAdvise client\n \n\u0083 To abstain from sex or use a back-up FP method, \ne.g., condoms, for the first 7 days after injection\n \n\u0083 To return for the next dose on a specific date\n \n\u0083 12 weeks after the injection (if client returns\n>2-4 weeks later than the date advised, client should be \ncertain that she is not pregnant . Rule out pregnancy before \ngiving the next dose)\n \n\u0083 On likely side-effects\n \n\u0083 To return promptly if there are any warning signs\nHC1\nMANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC\nNo Monthly Period\nAssess for pregnancy:\n \n~\nIf pregnant, reassure that the injectable POC will not \naffect her pregnancy and refer to ANC\n \n~\nIf not pregnant, reassure her that this contraceptive \nmay stop women having monthly periods, but it is not \nharmful. She can continue with the method or choose \nanother",
        "formatted_content": "<p>676</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Severe abdominal pain</p>\n<p>~</p>\n<p>Excessive weight gain</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Medroxyprogesterone acetate depot injection</p>\n<p>\u0089</p>\n<p>Give 150 mg deep IM into deltoid or buttock</p>\n<p>muscle</p>\n<p>- Do not rub the area as this increases absorption</p>\n<p>and shortens depot effect</p>\n<p>\u0089</p>\n<p>Medroxyprogesterone acetate depot injection</p>\n<p>- Inject 104 mg in the fatty tissue (subcutaneous) at</p>\n<p>the front of the thigh, the back of the upper arm, or</p>\n<p>the abdomen</p>\n<p>- This can be administered at community level</p>\n<h3>HC1</h3>\n<p>If given after day 1\u20137 of menstrual cycle</p>\n<p>\u0089</p>\n<p>Advise client</p>\n<p>\u0083 To abstain from sex or use a back-up FP method,</p>\n<p>e.g., condoms, for the first 7 days after injection</p>\n<p>\u0083 To return for the next dose on a specific date</p>\n<p>\u0083 12 weeks after the injection (if client returns</p>\n<p>>2-4 weeks later than the date advised, client should be</p>\n<p>certain that she is not pregnant . Rule out pregnancy before</p>\n<p>giving the next dose)</p>\n<p>\u0083 On likely side-effects</p>\n<p>\u0083 To return promptly if there are any warning signs</p>\n<h3>HC1</h3>\n<h3>MANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC</h3>\n<p>No Monthly Period</p>\n<p>Assess for pregnancy:</p>\n<p>~</p>\n<p>If pregnant, reassure that the injectable POC will not</p>\n<p>affect her pregnancy and refer to ANC</p>\n<p>~</p>\n<p>If not pregnant, reassure her that this contraceptive</p>\n<p>may stop women having monthly periods, but it is not</p>\n<p>harmful. She can continue with the method or choose</p>\n<p>another</p>"
    },
    {
        "page_number": 743,
        "content": "677\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC\nIrregular Bleeding\nAssess for pregnancy/abortion:\n \n~\nReassure that many women using injectable POC have \nirregular bleeding. It is not harmful in the first few \nmonths   and should lessen or stop after a few months\nIf irregular bleeding continues, immediately:\n\t\n\u0089\nGive 400\u2013800 mg ibuprofen 8 hourly when irregular bleeding starts\n\t\n\u0089\nOr 500 mg mefenamic acid eight hourly after meals for five days\nAvoid Tranexamic acid for treatment of bleeding as a result of using \ncontraceptives for fear of blood clots.\n \n~\nIf irregular bleeding continues or starts after several \nmonths of normal or no monthly bleeding:\n \n~\nInvestigate other reasons (unrelated to the contraceptive) \nand treat accordingly\n \n~\nHelp client choose another FP method if necessary\nHeavy Bleeding\nBlood clots, flow interfears with client daily routine, should not be \nmore than 7days, feel of thirst all the time.\nIf heavy bleeding is between 8\u201312 weeks of first injection:\n \n~\nAssess for pregnancy/ abortion\n \n~\nReassure (as for irregular bleeding)\n \n~\nRepeat progestogen-only injection and change return \ndate to 3 months after the latest injection\nHeavy bleeding after 2nd injection:\n \n~\nAssess for pregnancy/abortion\n \n~\nReassure/comfort\n\t\n\u0089\nGive 1 COC pill daily for 21 days (1 cycle)\nHeavy bleeding after 3rd or later injection:",
        "formatted_content": "<p>677</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC</h3>\n<p>Irregular Bleeding</p>\n<p>Assess for pregnancy/abortion:</p>\n<p>~</p>\n<p>Reassure that many women using injectable POC have</p>\n<p>irregular bleeding. It is not harmful in the first few</p>\n<p>months   and should lessen or stop after a few months</p>\n<p>If irregular bleeding continues, immediately:</p>\n<p>\u0089</p>\n<p>Give 400\u2013800 mg ibuprofen 8 hourly when irregular bleeding starts</p>\n<p>\u0089</p>\n<p>Or 500 mg mefenamic acid eight hourly after meals for five days</p>\n<p>Avoid Tranexamic acid for treatment of bleeding as a result of using</p>\n<p>contraceptives for fear of blood clots.</p>\n<p>~</p>\n<p>If irregular bleeding continues or starts after several</p>\n<p>months of normal or no monthly bleeding:</p>\n<p>~</p>\n<p>Investigate other reasons (unrelated to the contraceptive)</p>\n<p>and treat accordingly</p>\n<p>~</p>\n<p>Help client choose another FP method if necessary</p>\n<p>Heavy Bleeding</p>\n<p>Blood clots, flow interfears with client daily routine, should not be</p>\n<p>more than 7days, feel of thirst all the time.</p>\n<p>If heavy bleeding is between 8\u201312 weeks of first injection:</p>\n<p>~</p>\n<p>Assess for pregnancy/ abortion</p>\n<p>~</p>\n<p>Reassure (as for irregular bleeding)</p>\n<p>~</p>\n<p>Repeat progestogen-only injection and change return</p>\n<p>date to 3 months after the latest injection</p>\n<p>Heavy bleeding after 2nd injection:</p>\n<p>~</p>\n<p>Assess for pregnancy/abortion</p>\n<p>~</p>\n<p>Reassure/comfort</p>\n<p>\u0089</p>\n<p>Give 1 COC pill daily for 21 days (1 cycle)</p>\n<p>Heavy bleeding after 3rd or later injection:</p>"
    },
    {
        "page_number": 744,
        "content": "678\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC\n \n~\nAssess for pregnancy/abortion\n \n~\nReassure/comfort\n\t\n\u0089\nGive 1 COC pill daily for 21 days (1 cycle) when irregular \nbleeding starts\n\t\n\u0089\nOr 50 \u03bcg ethinyl estradiol daily for 21 days\n\t\n\u0089\nAnd ibuprofen 800 mg 8 hourly\n\t\n\u0089\nOr 500 mg mefenamic acid eight hourly after meals for 5 days\n\t\n\u0089\nFerrous salt tablets (60 mg iron) to prevent anaemia\nIf bleeding persists:\n \n~\nInvestigate other reasons (unrelated to injectable POC) \nand treat accordingly\n \n~\nHelp client choose another FP method if necessary\nDelayed Return to Fertility\n \n~\nA woman should not be worried if she has not become \npregnant even after stopping use for 12 months\n \n~\nReassure and counsel her about the fertile days; ovula\u00ad\ntion normally occurs 14 days before the next menstru\u00ad\nal period (if woman\u2019s cycle is 28 days and has regular \nmenstruation)\nWeight Gain\n \n~\nRule out weight gain due to pregnancy\n \n~\nInterview client on diet, exercises, and eating habits pro\u00ad\nmoting weight gain; counsel as needed. Explain to client \nthat all hormonal contraceptives may have a slight effect \non weight\n \n~\nIf weight gain is more than 2 kg, instruct her on diet and \nexercises\nLoss of Libido\n \n~\nTake proper history\n \n~\nFind out if she has stress, fatigue, anxiety, depression, \nand if she is on new medication. Explore if this is due to \ndry vagina and/or painful intercourse",
        "formatted_content": "<p>678</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC</h3>\n<p>~</p>\n<p>Assess for pregnancy/abortion</p>\n<p>~</p>\n<p>Reassure/comfort</p>\n<p>\u0089</p>\n<p>Give 1 COC pill daily for 21 days (1 cycle) when irregular</p>\n<p>bleeding starts</p>\n<p>\u0089</p>\n<p>Or 50 \u03bcg ethinyl estradiol daily for 21 days</p>\n<p>\u0089</p>\n<p>And ibuprofen 800 mg 8 hourly</p>\n<p>\u0089</p>\n<p>Or 500 mg mefenamic acid eight hourly after meals for 5 days</p>\n<p>\u0089</p>\n<p>Ferrous salt tablets (60 mg iron) to prevent anaemia</p>\n<p>If bleeding persists:</p>\n<p>~</p>\n<p>Investigate other reasons (unrelated to injectable POC)</p>\n<p>and treat accordingly</p>\n<p>~</p>\n<p>Help client choose another FP method if necessary</p>\n<p>Delayed Return to Fertility</p>\n<p>~</p>\n<p>A woman should not be worried if she has not become</p>\n<p>pregnant even after stopping use for 12 months</p>\n<p>~</p>\n<p>Reassure and counsel her about the fertile days; ovula\u00ad</p>\n<p>tion normally occurs 14 days before the next menstru\u00ad</p>\n<p>al period (if woman\u2019s cycle is 28 days and has regular</p>\n<p>menstruation)</p>\n<p>Weight Gain</p>\n<p>~</p>\n<p>Rule out weight gain due to pregnancy</p>\n<p>~</p>\n<p>Interview client on diet, exercises, and eating habits pro\u00ad</p>\n<p>moting weight gain; counsel as needed. Explain to client</p>\n<p>that all hormonal contraceptives may have a slight effect</p>\n<p>on weight</p>\n<p>~</p>\n<p>If weight gain is more than 2 kg, instruct her on diet and</p>\n<p>exercises</p>\n<p>Loss of Libido</p>\n<p>~</p>\n<p>Take proper history</p>\n<p>~</p>\n<p>Find out if she has stress, fatigue, anxiety, depression,</p>\n<p>and if she is on new medication. Explore if this is due to</p>\n<p>dry vagina and/or painful intercourse</p>"
    },
    {
        "page_number": 745,
        "content": "679\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC\n \n~\nExplore lifestyle and suggest changes where needed. \nAdvise on foreplay and if possible, involve spouse\n \n~\nHelp client choose another FP method if necessary\nHeadache\n \n~\nExplore possible social, financial, health, or physical \ncauses of headaches. Ask her to keep a record of the \ntiming and number of headaches for the next 2 weeks \nand ask her to come for follow-up\n \n~\nEvaluate cause of headache (Is blood pressure raised? \nDoes she have sinus infection [purulent nasal discharge \nand tenderness in the area of sinuses]?)\n\t\n\u0089\nGive pain relievers such as acetylsalicylic acid, ibuprofen, or \nparacetamol\n \n~\nRegardless of age, a woman who develops migraine \nheadaches with aura or whose migraine headaches be\u00ad\ncomes worse while using monthly injections should stop \nusing injectable. If migraine headaches are without aura, \nshe can continue using the method if she wishes\n15.2.6 Progestogen-Only Sub-Dermal Implant                          \nICD10 CODE: Z30.017/Z30.46\nFlexible progestogen-releasing plastic rods surgically inserted under the \nskin of the woman\u2019s upper arm which provide contraceptive protection \nfor 3\u20137 years depending on the type of implant (Implanon: 3 years; \nJadelle: 5 years; Femplant: 4 years, Norplant: 5 years: implanon NXT: \nLevoplan).\nIndications\n \n~\nWomen wanting long-term, highly-effective but not per\u00ad\nmanent contraception where alternative FP methods are \ninappropriate or undesirable",
        "formatted_content": "<p>679</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF INJECTABLE POC</h3>\n<p>~</p>\n<p>Explore lifestyle and suggest changes where needed.</p>\n<p>Advise on foreplay and if possible, involve spouse</p>\n<p>~</p>\n<p>Help client choose another FP method if necessary</p>\n<p>Headache</p>\n<p>~</p>\n<p>Explore possible social, financial, health, or physical</p>\n<p>causes of headaches. Ask her to keep a record of the</p>\n<p>timing and number of headaches for the next 2 weeks</p>\n<p>and ask her to come for follow-up</p>\n<p>~</p>\n<p>Evaluate cause of headache (Is blood pressure raised?</p>\n<p>Does she have sinus infection [purulent nasal discharge</p>\n<p>and tenderness in the area of sinuses]?)</p>\n<p>\u0089</p>\n<p>Give pain relievers such as acetylsalicylic acid, ibuprofen, or</p>\n<p>paracetamol</p>\n<p>~</p>\n<p>Regardless of age, a woman who develops migraine</p>\n<p>headaches with aura or whose migraine headaches be\u00ad</p>\n<p>comes worse while using monthly injections should stop</p>\n<p>using injectable. If migraine headaches are without aura,</p>\n<p>she can continue using the method if she wishes</p>\n<p>15.2.6 Progestogen-Only Sub-Dermal Implant</p>\n<h3>ICD10 CODE: Z30.017/Z30.46</h3>\n<p>Flexible progestogen-releasing plastic rods surgically inserted under the</p>\n<p>skin of the woman\u2019s upper arm which provide contraceptive protection</p>\n<p>for 3\u20137 years depending on the type of implant (Implanon: 3 years;</p>\n<p>Jadelle: 5 years; Femplant: 4 years, Norplant: 5 years: implanon NXT:</p>\n<p>Levoplan).</p>\n<p>Indications</p>\n<p>~</p>\n<p>Women wanting long-term, highly-effective but not per\u00ad</p>\n<p>manent contraception where alternative FP methods are</p>\n<p>inappropriate or undesirable</p>"
    },
    {
        "page_number": 746,
        "content": "680\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nContraindications\n \n~\nAs for Progesteron-Only Pills\nAdvantages and Health Benefits\n \n~\nHighly effective (only 1-3% failure rate)\n \n~\nNo delay in return to fertility after removal\n \n~\nLong-acting\n \n~\nLow user-responsibility (no need for daily action)\n \n~\nProtects against symptomatic pelvic inflammatory disease\nDisadvantages and Common Side Effects\n \n~\nDOES NOT PROTECT AGAINST STI\n \n~\nIrregular bleeding, spotting, or heavy bleeding in first few \nmonths; amenorrhoea\nPossibility of local infection at insertion site\n \n~\nMust be surgically inserted and removed by specially \ntrained service provider\n \n~\nMay not be as effective in women >70kg\n \n~\nWarning signs (require urgent return to clinic)\n\t\n\u0089\nHeavy vaginal bleeding\n\t\n\u0089\nSevere chest pain\n\t\n\u0089\nPus, bleeding, or pain at insertion site on arm\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nInsert the implant subdermally under the skin of the \nupper arm following recommended procedures\nHC2",
        "formatted_content": "<p>680</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Contraindications</p>\n<p>~</p>\n<p>As for Progesteron-Only Pills</p>\n<p>Advantages and Health Benefits</p>\n<p>~</p>\n<p>Highly effective (only 1-3% failure rate)</p>\n<p>~</p>\n<p>No delay in return to fertility after removal</p>\n<p>~</p>\n<p>Long-acting</p>\n<p>~</p>\n<p>Low user-responsibility (no need for daily action)</p>\n<p>~</p>\n<p>Protects against symptomatic pelvic inflammatory disease</p>\n<p>Disadvantages and Common Side Effects</p>\n<p>~</p>\n<h3>DOES NOT PROTECT AGAINST STI</h3>\n<p>~</p>\n<p>Irregular bleeding, spotting, or heavy bleeding in first few</p>\n<p>months; amenorrhoea</p>\n<p>Possibility of local infection at insertion site</p>\n<p>~</p>\n<p>Must be surgically inserted and removed by specially</p>\n<p>trained service provider</p>\n<p>~</p>\n<p>May not be as effective in women >70kg</p>\n<p>~</p>\n<p>Warning signs (require urgent return to clinic)</p>\n<p>\u0089</p>\n<p>Heavy vaginal bleeding</p>\n<p>\u0089</p>\n<p>Severe chest pain</p>\n<p>\u0089</p>\n<p>Pus, bleeding, or pain at insertion site on arm</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Insert the implant subdermally under the skin of the</p>\n<p>upper arm following recommended procedures</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 747,
        "content": "681\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nINSTRUCTIONS\nLOC\n\t\n\u0089\nCarefully explain warning signs and need to return if \nthey occur\n\t\n\u0089\nAdvise client to return\n \n\u0083 After two weeks: To examine implant site\n \n\u0083 After three months: For first routine follow-up\n \n\u0083 Annually until implant removed: routine follow- up\nHC2\nMANAGEMENT OF SIDE EFFECTS OF IMPLANTS\nNo Monthly Periods\nAssess for pregnancy:\n \n~\nIf pregnant, reassure that the implant will not affect her \npregnancy and refer her to ANC\n \n~\nIf not pregnant, reassure that implants may stop women \nfrom having monthly periods, but this is not harmful. \nShe can continue with the method\nIf irregular bleeding continues:\n\t\n\u0089\nGive 400\u2013800 mg ibuprofen  eight hourly when irregular bleed\u00ad\ning starts\n\t\n\u0089\nOr 500 mg mefenamic acid eight hourly after meals for 5 days\n\t\n\u0089\nCheck for anaemia and treat accordingly\nIf bleeding persists:\n\t\n\u0089\nGive 1 COC pill daily for 21 days (1 cycle)\n\t\n\u0089\nOr 50 \u00b5g ethinyl estradiol daily for 21 days\n\t\n\u0089\nInvestigate other reasons (unrelated to implants) and treat ac\u00ad\ncordingly\n\t\n\u0089\nHelp client choose another method of family planning\nHeavy or prolonged bleeding (twice as much as usual or longer than 8 \ndays)\n \n~\nAssess for pregnancy/abortion\n \n~\nReassure",
        "formatted_content": "<p>681</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Carefully explain warning signs and need to return if</p>\n<p>they occur</p>\n<p>\u0089</p>\n<p>Advise client to return</p>\n<p>\u0083 After two weeks: To examine implant site</p>\n<p>\u0083 After three months: For first routine follow-up</p>\n<p>\u0083 Annually until implant removed: routine follow- up</p>\n<h3>HC2</h3>\n<h3>MANAGEMENT OF SIDE EFFECTS OF IMPLANTS</h3>\n<p>No Monthly Periods</p>\n<p>Assess for pregnancy:</p>\n<p>~</p>\n<p>If pregnant, reassure that the implant will not affect her</p>\n<p>pregnancy and refer her to ANC</p>\n<p>~</p>\n<p>If not pregnant, reassure that implants may stop women</p>\n<p>from having monthly periods, but this is not harmful.</p>\n<p>She can continue with the method</p>\n<p>If irregular bleeding continues:</p>\n<p>\u0089</p>\n<p>Give 400\u2013800 mg ibuprofen  eight hourly when irregular bleed\u00ad</p>\n<p>ing starts</p>\n<p>\u0089</p>\n<p>Or 500 mg mefenamic acid eight hourly after meals for 5 days</p>\n<p>\u0089</p>\n<p>Check for anaemia and treat accordingly</p>\n<p>If bleeding persists:</p>\n<p>\u0089</p>\n<p>Give 1 COC pill daily for 21 days (1 cycle)</p>\n<p>\u0089</p>\n<p>Or 50 \u00b5g ethinyl estradiol daily for 21 days</p>\n<p>\u0089</p>\n<p>Investigate other reasons (unrelated to implants) and treat ac\u00ad</p>\n<p>cordingly</p>\n<p>\u0089</p>\n<p>Help client choose another method of family planning</p>\n<p>Heavy or prolonged bleeding (twice as much as usual or longer than 8</p>\n<p>days)</p>\n<p>~</p>\n<p>Assess for pregnancy/abortion</p>\n<p>~</p>\n<p>Reassure</p>"
    },
    {
        "page_number": 748,
        "content": "682\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF IMPLANTS\n\t\n\u0089\nGive ibuprofen 800 mg eight hourly when irregular bleeding starts\n\t\n\u0089\nOr 500 mg mefenamic acid eight hourly after meals for five days\n\t\n\u0089\nGive 1 COC pill daily for 21 days (one cycle)\n\t\n\u0089\nGive ferrous salt tablets (60 mg iron) to prevent anaemia\n\t\n\u0089\nEducate on nutrition\nIf bleeding persists:\n\t\n\u0089\nInvestigate other reasons (unrelated to implants) and treat ac\u00ad\ncordingly\n\t\n\u0089\nHelp client choose another method of family planning\nWeight Gain\n \n~\nManage the same as for Injectable POC\nLoss of Libido\n \n~\nManage the same as for Injectable POC\nInfection at the Insertion Site\n \n~\nDo not remove the implant\n \n~\nClean the infected area with soap and water or anti\u00ad\nseptic\n\t\n\u0089\nGive oral antibiotics for 7\u201310 days like Amoxycillin 500mg 8 hourly \nIf no improvement after the 10days refer\n \n~\nAsk the client to return after taking all antibiotics if the \ninfection does not clear. If infection has not cleared, re\u00ad\nmove the implant or refer for removal\n \n~\nExpulsion or partial expulsion often follows infection. \nAsk the client to return if she notices an implant coming \nout\nMigraine Headaches\n \n~\nIf she has migraine headaches without aura, she can \ncontinue to use implant if she wishes\n \n~\nIf she has migraine aura, remove the implant. Help her \nchoose a method without hormones",
        "formatted_content": "<p>682</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF IMPLANTS</h3>\n<p>\u0089</p>\n<p>Give ibuprofen 800 mg eight hourly when irregular bleeding starts</p>\n<p>\u0089</p>\n<p>Or 500 mg mefenamic acid eight hourly after meals for five days</p>\n<p>\u0089</p>\n<p>Give 1 COC pill daily for 21 days (one cycle)</p>\n<p>\u0089</p>\n<p>Give ferrous salt tablets (60 mg iron) to prevent anaemia</p>\n<p>\u0089</p>\n<p>Educate on nutrition</p>\n<p>If bleeding persists:</p>\n<p>\u0089</p>\n<p>Investigate other reasons (unrelated to implants) and treat ac\u00ad</p>\n<p>cordingly</p>\n<p>\u0089</p>\n<p>Help client choose another method of family planning</p>\n<p>Weight Gain</p>\n<p>~</p>\n<p>Manage the same as for Injectable POC</p>\n<p>Loss of Libido</p>\n<p>~</p>\n<p>Manage the same as for Injectable POC</p>\n<p>Infection at the Insertion Site</p>\n<p>~</p>\n<p>Do not remove the implant</p>\n<p>~</p>\n<p>Clean the infected area with soap and water or anti\u00ad</p>\n<p>septic</p>\n<p>\u0089</p>\n<p>Give oral antibiotics for 7\u201310 days like Amoxycillin 500mg 8 hourly</p>\n<p>If no improvement after the 10days refer</p>\n<p>~</p>\n<p>Ask the client to return after taking all antibiotics if the</p>\n<p>infection does not clear. If infection has not cleared, re\u00ad</p>\n<p>move the implant or refer for removal</p>\n<p>~</p>\n<p>Expulsion or partial expulsion often follows infection.</p>\n<p>Ask the client to return if she notices an implant coming</p>\n<p>out</p>\n<p>Migraine Headaches</p>\n<p>~</p>\n<p>If she has migraine headaches without aura, she can</p>\n<p>continue to use implant if she wishes</p>\n<p>~</p>\n<p>If she has migraine aura, remove the implant. Help her</p>\n<p>choose a method without hormones</p>"
    },
    {
        "page_number": 749,
        "content": "683\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n15.2.7 Emergency Contraception (Pill and IUD)                             \nICD10 CODE: Z30.012\nEmergency Contraception can be used to prevent unwanted pregnancy \nafter unprotected sex, rape, defilement or contraceptive method failure. \nMethods available include Emergency Contraceptive Pills and IUDs. \nCaution: Emergency contraceptive methods do not cause abortion.\nRegular Emergency Contraceptive Pill users should be counselled to use \nroutine contraceptive method.\nTYPE\nFEATURES\nE m e r g e n c y \nContraceptive \nPill (ECP)\n \n~\nThe ECP contains a special dose of \nprogestin (Levonorgestrel or LNG): \nmay come as one pill (1.5 mg) or two \npills (0.75 mg). \n \n~\nThe dose (1.5 mg) should be taken as \nsoon as possible within 72 hours, but \ncan be taken up to five days after un\u00ad\nprotected sex, or in case of contracep\u00ad\ntive method failure, e.g.,\n \n~\ncondom burst, failure to take regular FP \nmethods, or in cases of rape\n \n~\nECPs are NOT regular contraceptive \npills and should not be used as a fam\u00ad\nily planning method\nE m e r g e n c y \nContraceptive \nIUD\n \n~\nThis IUD should be inserted as soon as \npossible after penetrative sexual inter\u00ad\ncourse but within 5 days\n \n~\nIt is important to monitor side-effects \nthat may occur, as outlined below",
        "formatted_content": "<p>683</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>15.2.7 Emergency Contraception (Pill and IUD)</p>\n<h3>ICD10 CODE: Z30.012</h3>\n<p>Emergency Contraception can be used to prevent unwanted pregnancy</p>\n<p>after unprotected sex, rape, defilement or contraceptive method failure.</p>\n<p>Methods available include Emergency Contraceptive Pills and IUDs.</p>\n<p>Caution: Emergency contraceptive methods do not cause abortion.</p>\n<p>Regular Emergency Contraceptive Pill users should be counselled to use</p>\n<p>routine contraceptive method.</p>\n<h3>TYPE</h3>\n<h3>FEATURES</h3>\n<p>E m e r g e n c y</p>\n<p>Contraceptive</p>\n<p>Pill (ECP)</p>\n<p>~</p>\n<p>The ECP contains a special dose of</p>\n<p>progestin (Levonorgestrel or LNG):</p>\n<p>may come as one pill (1.5 mg) or two</p>\n<p>pills (0.75 mg).</p>\n<p>~</p>\n<p>The dose (1.5 mg) should be taken as</p>\n<p>soon as possible within 72 hours, but</p>\n<p>can be taken up to five days after un\u00ad</p>\n<p>protected sex, or in case of contracep\u00ad</p>\n<p>tive method failure, e.g.,</p>\n<p>~</p>\n<p>condom burst, failure to take regular FP</p>\n<p>methods, or in cases of rape</p>\n<p>~</p>\n<p>ECPs are NOT regular contraceptive</p>\n<p>pills and should not be used as a fam\u00ad</p>\n<p>ily planning method</p>\n<p>E m e r g e n c y</p>\n<p>Contraceptive</p>\n<h3>IUD</h3>\n<p>~</p>\n<p>This IUD should be inserted as soon as</p>\n<p>possible after penetrative sexual inter\u00ad</p>\n<p>course but within 5 days</p>\n<p>~</p>\n<p>It is important to monitor side-effects</p>\n<p>that may occur, as outlined below</p>"
    },
    {
        "page_number": 750,
        "content": "684\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nIndications\n \n~\nAll women and adolescents at risk of becoming pregnant \nafter unprotected sex\nAdvantages\n \n~\nPrevents unplanned pregnancy after penetrative sexual \nintercourse\n \n~\nSafe for all women and have no long-term side effects\n \n~\nDo not cause infertility\n \n~\nAble to have on hand in case of emergency\n \n~\nControlled by the woman\nDisadvantages and side effects\n \n~\nDOES NOT PROTECT AGAINST STI\n \n~\nPotential misuse as a regular contraceptive method\n \n~\nMinor, short-term side effects: nausea and vomiting, al\u00ad\ntered menstrual bleeding, headaches, abdominal pain \nbreast tenderness, dizziness and fatigue\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nShould be taken as soon as possible after unprotected \nsex where pregnancy is not desired\n\t\n\u0089\nCan prevent pregnancy if taken anytime within 5 days \nafter unprotected sex (decreasing efficacy over this 5 \nday window)\n\t\n\u0089\nSafe and suitable for all women at risk of an unplanned \npregnancy\n\t\n\u0089\nWomen on ARVs have to take double dose (levonorgestrel \n3 mg = e.g. Postinor 4 tablets)\nHC2",
        "formatted_content": "<p>684</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Indications</p>\n<p>~</p>\n<p>All women and adolescents at risk of becoming pregnant</p>\n<p>after unprotected sex</p>\n<p>Advantages</p>\n<p>~</p>\n<p>Prevents unplanned pregnancy after penetrative sexual</p>\n<p>intercourse</p>\n<p>~</p>\n<p>Safe for all women and have no long-term side effects</p>\n<p>~</p>\n<p>Do not cause infertility</p>\n<p>~</p>\n<p>Able to have on hand in case of emergency</p>\n<p>~</p>\n<p>Controlled by the woman</p>\n<p>Disadvantages and side effects</p>\n<p>~</p>\n<h3>DOES NOT PROTECT AGAINST STI</h3>\n<p>~</p>\n<p>Potential misuse as a regular contraceptive method</p>\n<p>~</p>\n<p>Minor, short-term side effects: nausea and vomiting, al\u00ad</p>\n<p>tered menstrual bleeding, headaches, abdominal pain</p>\n<p>breast tenderness, dizziness and fatigue</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Should be taken as soon as possible after unprotected</p>\n<p>sex where pregnancy is not desired</p>\n<p>\u0089</p>\n<p>Can prevent pregnancy if taken anytime within 5 days</p>\n<p>after unprotected sex (decreasing efficacy over this 5</p>\n<p>day window)</p>\n<p>\u0089</p>\n<p>Safe and suitable for all women at risk of an unplanned</p>\n<p>pregnancy</p>\n<p>\u0089</p>\n<p>Women on ARVs have to take double dose (levonorgestrel</p>\n<p>3 mg = e.g. Postinor 4 tablets)</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 751,
        "content": "685\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nINSTRUCTIONS\nLOC\nNote\n \n\u0083 Warn women against regular/frequent use of \nemergency contraceptive. Advise them to consider \nusing other long- term methods\n15.2.8 Intrauterine Device (IUD)                        ICD10 CODE: Z30.014\nEasily reversible long-term FP method effective for up to 10 years, \nwhich can be inserted as soon as 6 weeks postpartum:\n\t\n\u0089\nNon hormonal: Copper loaded\n\t\n\u0089\nHormonal : Levonorgestrel loaded\nIndications\n \n~\nWomen desiring long-term contraception\n \n~\nBreastfeeding mothers\n \n~\nWhen hormonal FP methods are contraindicated\n \n~\nTreatment of heavy periods- menorrhagia (for levonorge\u00ad\nstrel)\nContraindications\n \n~\nPregnancy (known or suspected)\n \n~\nPID or history of this in last 3 months\n \n~\nUndiagnosed abnormal uterine bleeding\n \n~\nWomen at risk of STIs \nReduced immunity, e.g., diabetes mellitus, terminal AIDS\n \n~\nKnown or suspected cancer of pelvic organs\n \n~\nSevere anaemia or heavy menstrual bleeding\nAdvantages\n \n~\nPrevents unplanned pregnancy after penetrative sexual \nintercourse",
        "formatted_content": "<p>685</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\u0083 Warn women against regular/frequent use of</p>\n<p>emergency contraceptive. Advise them to consider</p>\n<p>using other long- term methods</p>\n<p>15.2.8 Intrauterine Device (IUD)                        ICD10 CODE: Z30.014</p>\n<p>Easily reversible long-term FP method effective for up to 10 years,</p>\n<p>which can be inserted as soon as 6 weeks postpartum:</p>\n<p>\u0089</p>\n<p>Non hormonal: Copper loaded</p>\n<p>\u0089</p>\n<p>Hormonal : Levonorgestrel loaded</p>\n<p>Indications</p>\n<p>~</p>\n<p>Women desiring long-term contraception</p>\n<p>~</p>\n<p>Breastfeeding mothers</p>\n<p>~</p>\n<p>When hormonal FP methods are contraindicated</p>\n<p>~</p>\n<p>Treatment of heavy periods- menorrhagia (for levonorge\u00ad</p>\n<p>strel)</p>\n<p>Contraindications</p>\n<p>~</p>\n<p>Pregnancy (known or suspected)</p>\n<p>~</p>\n<p>PID or history of this in last 3 months</p>\n<p>~</p>\n<p>Undiagnosed abnormal uterine bleeding</p>\n<p>~</p>\n<p>Women at risk of STIs</p>\n<p>Reduced immunity, e.g., diabetes mellitus, terminal AIDS</p>\n<p>~</p>\n<p>Known or suspected cancer of pelvic organs</p>\n<p>~</p>\n<p>Severe anaemia or heavy menstrual bleeding</p>\n<p>Advantages</p>\n<p>~</p>\n<p>Prevents unplanned pregnancy after penetrative sexual</p>\n<p>intercourse</p>"
    },
    {
        "page_number": 752,
        "content": "686\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nCan be used as an emergency\n \n~\nSafe for all women including breast feeding mothers\n \n~\nDoes not affect libido (copper)\n \n~\nLong term \n \n~\n97-99% effective\n \n~\nReduces chances of getting STIs (Lenovorgestrel)\n \n~\nIt\u2019s recommended for women with NCDs like diabetes, \nhypertension\n \n~\nDoes not increase the risk of STIs\nDisadvantages and common side effects\n \n~\nMild cramps during first 3-5 days after insertion\n \n~\nLonger and heavier menstrual blood loss in first 3 months\n \n~\nVaginal discharge in first 3 months\n \n~\nSpotting or bleeding between periods\n \n~\nIncreased cramping pains during menstruation\n \n~\nThreads might prick the spose during sex (cut the treads \nshorter)\nComplications and warning signs\n \n~\nLower abdominal pain and PID\n \n~\nFoul-smelling vaginal discharge\n \n~\nMissed period\n \n~\nDisplaced IUD/missing strings\n \n~\nProlonged vaginal bleeding\n \n~\nPerforation",
        "formatted_content": "<p>686</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Can be used as an emergency</p>\n<p>~</p>\n<p>Safe for all women including breast feeding mothers</p>\n<p>~</p>\n<p>Does not affect libido (copper)</p>\n<p>~</p>\n<p>Long term</p>\n<p>~</p>\n<p>97-99% effective</p>\n<p>~</p>\n<p>Reduces chances of getting STIs (Lenovorgestrel)</p>\n<p>~</p>\n<p>It\u2019s recommended for women with NCDs like diabetes,</p>\n<p>hypertension</p>\n<p>~</p>\n<p>Does not increase the risk of STIs</p>\n<p>Disadvantages and common side effects</p>\n<p>~</p>\n<p>Mild cramps during first 3-5 days after insertion</p>\n<p>~</p>\n<p>Longer and heavier menstrual blood loss in first 3 months</p>\n<p>~</p>\n<p>Vaginal discharge in first 3 months</p>\n<p>~</p>\n<p>Spotting or bleeding between periods</p>\n<p>~</p>\n<p>Increased cramping pains during menstruation</p>\n<p>~</p>\n<p>Threads might prick the spose during sex (cut the treads</p>\n<p>shorter)</p>\n<p>Complications and warning signs</p>\n<p>~</p>\n<p>Lower abdominal pain and PID</p>\n<p>~</p>\n<p>Foul-smelling vaginal discharge</p>\n<p>~</p>\n<p>Missed period</p>\n<p>~</p>\n<p>Displaced IUD/missing strings</p>\n<p>~</p>\n<p>Prolonged vaginal bleeding</p>\n<p>~</p>\n<p>Perforation</p>"
    },
    {
        "page_number": 753,
        "content": "687\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nInsert the IUD closely following recommended proce\u00ad\ndures; explain each step to the client (ensure the thread \nis cut short not to cause discomfort)\n\t\n\u0089\nCarefully explain possible side-effects and what to do \nif they should arise\n\t\n\u0089\nAdvise client\n \n\u0083 To avoid vaginal douching\n \n\u0083 Not to have more than 1 sexual partner\n \n\u0083 To check each sanitary pad before disposal to ensure \nthe IUD has not been expelled, in which case to use \nan alternative FP method and return to the clinic\n \n\u0083 How to check that the IUD is still in place after each \nmenstruation\nHC3\n\u2022\t\nTo report to the clinic promptly if: Late period or pregnancy, \nabdominal pain during intercourse\n\u2022\t\nExposure to STI, feeling unwell with chills/fever,\n\u2022\t\nshorter/longer/missing strings, feeling hard part of IUD in \nvagina or at cervix\n\u2022\t\nTo use condoms if any risk of STIs including HIV\n\t\n\u0089\nRecommendation for a follow-up visit after 3-6 weeks \nto check-in on client\nMANAGEMENT OF SIDE EFFECTS OF IUD\nNo Monthly Period\nAssess for pregnancy:\n \n~\nIf pregnant, reassure that IUD will not affect her preg\u00ad\nnancy and refer her to ANC\n \n~\nIf not pregnant, investigate other reasons for amenor\u00ad\nrhea\n \n~\nIf no pregnancy reassure the client",
        "formatted_content": "<p>687</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Insert the IUD closely following recommended proce\u00ad</p>\n<p>dures; explain each step to the client (ensure the thread</p>\n<p>is cut short not to cause discomfort)</p>\n<p>\u0089</p>\n<p>Carefully explain possible side-effects and what to do</p>\n<p>if they should arise</p>\n<p>\u0089</p>\n<p>Advise client</p>\n<p>\u0083 To avoid vaginal douching</p>\n<p>\u0083 Not to have more than 1 sexual partner</p>\n<p>\u0083 To check each sanitary pad before disposal to ensure</p>\n<p>the IUD has not been expelled, in which case to use</p>\n<p>an alternative FP method and return to the clinic</p>\n<p>\u0083 How to check that the IUD is still in place after each</p>\n<p>menstruation</p>\n<h3>HC3</h3>\n<li></li>\n<p>To report to the clinic promptly if: Late period or pregnancy,</p>\n<p>abdominal pain during intercourse</p>\n<li></li>\n<p>Exposure to STI, feeling unwell with chills/fever,</p>\n<li></li>\n<p>shorter/longer/missing strings, feeling hard part of IUD in</p>\n<p>vagina or at cervix</p>\n<li></li>\n<p>To use condoms if any risk of STIs including HIV</p>\n<p>\u0089</p>\n<p>Recommendation for a follow-up visit after 3-6 weeks</p>\n<p>to check-in on client</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF IUD</h3>\n<p>No Monthly Period</p>\n<p>Assess for pregnancy:</p>\n<p>~</p>\n<p>If pregnant, reassure that IUD will not affect her preg\u00ad</p>\n<p>nancy and refer her to ANC</p>\n<p>~</p>\n<p>If not pregnant, investigate other reasons for amenor\u00ad</p>\n<p>rhea</p>\n<p>~</p>\n<p>If no pregnancy reassure the client</p>"
    },
    {
        "page_number": 754,
        "content": "688\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nMANAGEMENT OF SIDE EFFECTS OF IUD\nIrregular Bleeding\nAssess for pregnancy/abortion:\n \n~\nReassure that many women using IUD get irregular \nbleeding. It is not harmful and should lessen or stop after \nseveral months of use\nIf bleeding continues:\n\t\n\u0089\nGive 400-800 mg ibuprofen  eight hourly after meals for 5 days \nwhen irregular bleeding starts\n\t\n\u0089\nTranexamic acid 500mg 8hourly 5-7days\n\t\n\u0089\nCheck for anaemia and treat accordingly\nIf irregular bleeding persists:\n\t\n\u0089\nInvestigate other reasons (unrelated to IUD) and treat accordingly\n\t\n\u0089\nHelp client choose another FP method if necessary\nHeavy Bleeding\nAssess for pregnancy/abortion:\n\t\n\u0089\nGive ibuprofen 400-800 mg every eight hours after meals for \n5 days\n\t\n\u0089\nOr tranexamic acid 1500 mg every eight hours for 3 days, then \n1000 mg once daily for two days\n\t\n\u0089\nGive ferrous salt tablets (60 mg iron) to prevent anaemia\n\t\n\u0089\nEducate on nutrition\nIf bleeding persists:\n\t\n\u0089\nInvestigate other reasons (unrelated to IUD) and treat accordingly\n\t\n\u0089\nHelp client choose another FP method if necessary\n15.2.9    Natural FP: Cervical Mucus Method (CMM) and Moon \nBeads\t\nICD10 CODE: Z30.02\nCMM is a fertility awareness-based method of FP which relies on the \nchange in the nature of vaginal mucus during the menstrual cycle in order \nto detect the fertile time. During this time, the couple avoids pregnancy by \nchanging sexual behaviour as follows:",
        "formatted_content": "<p>688</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<h3>MANAGEMENT OF SIDE EFFECTS OF IUD</h3>\n<p>Irregular Bleeding</p>\n<p>Assess for pregnancy/abortion:</p>\n<p>~</p>\n<p>Reassure that many women using IUD get irregular</p>\n<p>bleeding. It is not harmful and should lessen or stop after</p>\n<p>several months of use</p>\n<p>If bleeding continues:</p>\n<p>\u0089</p>\n<p>Give 400-800 mg ibuprofen  eight hourly after meals for 5 days</p>\n<p>when irregular bleeding starts</p>\n<p>\u0089</p>\n<p>Tranexamic acid 500mg 8hourly 5-7days</p>\n<p>\u0089</p>\n<p>Check for anaemia and treat accordingly</p>\n<p>If irregular bleeding persists:</p>\n<p>\u0089</p>\n<p>Investigate other reasons (unrelated to IUD) and treat accordingly</p>\n<p>\u0089</p>\n<p>Help client choose another FP method if necessary</p>\n<p>Heavy Bleeding</p>\n<p>Assess for pregnancy/abortion:</p>\n<p>\u0089</p>\n<p>Give ibuprofen 400-800 mg every eight hours after meals for</p>\n<p>5 days</p>\n<p>\u0089</p>\n<p>Or tranexamic acid 1500 mg every eight hours for 3 days, then</p>\n<p>1000 mg once daily for two days</p>\n<p>\u0089</p>\n<p>Give ferrous salt tablets (60 mg iron) to prevent anaemia</p>\n<p>\u0089</p>\n<p>Educate on nutrition</p>\n<p>If bleeding persists:</p>\n<p>\u0089</p>\n<p>Investigate other reasons (unrelated to IUD) and treat accordingly</p>\n<p>\u0089</p>\n<p>Help client choose another FP method if necessary</p>\n<p>15.2.9    Natural FP: Cervical Mucus Method (CMM) and Moon</p>\n<p>Beads</p>\n<h3>ICD10 CODE: Z30.02</h3>\n<p>CMM is a fertility awareness-based method of FP which relies on the</p>\n<p>change in the nature of vaginal mucus during the menstrual cycle in order</p>\n<p>to detect the fertile time. During this time, the couple avoids pregnancy by</p>\n<p>changing sexual behaviour as follows:</p>"
    },
    {
        "page_number": 755,
        "content": "689\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\n \n~\nAbstaining from sexual intercourse: Avoiding vaginal sex \ncompletely (also called periodic abstinence)\n \n~\nUsing barriers methods, e.g., condoms, cervical caps\n \n~\nGuidance on correct use of the method is only available at \ncentres with specially trained service providers.\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nEnsure client understands how the method works\nHC1\n\t\n\u0089\nExplain how to distinguish the different types of mucus\n\t\n\u0089\nShow client how to complete the CMM chart, can be used \ntogether with the moon beads\n\t\n\u0089\nCarry out a practice/trial period of at least 3 cycles\n\t\n\u0089\nConfirm that the chart is correctly filled\n\t\n\u0089\nAdvise client to\n \n\u0083 Always use condoms as well as CMM if there is any risk of \nexposure to STIs/HIV\n \n\u0083 Return on a specific follow-up date after one\n \n\u0083 menstrual cycle\n15.2.10  Natural FP: Lactational Amenorrhoea Method (LAM)\t\nICD10 CODE: Z30.02\nLAM relies on the suppression of ovulation through exclusive breastfeed\u00ad\ning as a means of contraception. Guidance on correct use of the method \nis only available at centres with trained service providers. LAM requires 3 \nconditions which must ALL be met:\n\t\n\u0089\nThe mother\u2019s monthly bleeding has not returned\n\t\n\u0089\nThe baby is fully or nearly fully breastfed; and is fed often, day \nand night\n\t\n\u0089\nThe baby is less than 6 months old",
        "formatted_content": "<p>689</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>~</p>\n<p>Abstaining from sexual intercourse: Avoiding vaginal sex</p>\n<p>completely (also called periodic abstinence)</p>\n<p>~</p>\n<p>Using barriers methods, e.g., condoms, cervical caps</p>\n<p>~</p>\n<p>Guidance on correct use of the method is only available at</p>\n<p>centres with specially trained service providers.</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure client understands how the method works</p>\n<h3>HC1</h3>\n<p>\u0089</p>\n<p>Explain how to distinguish the different types of mucus</p>\n<p>\u0089</p>\n<p>Show client how to complete the CMM chart, can be used</p>\n<p>together with the moon beads</p>\n<p>\u0089</p>\n<p>Carry out a practice/trial period of at least 3 cycles</p>\n<p>\u0089</p>\n<p>Confirm that the chart is correctly filled</p>\n<p>\u0089</p>\n<p>Advise client to</p>\n<p>\u0083 Always use condoms as well as CMM if there is any risk of</p>\n<p>exposure to STIs/HIV</p>\n<p>\u0083 Return on a specific follow-up date after one</p>\n<p>\u0083 menstrual cycle</p>\n<p>15.2.10  Natural FP: Lactational Amenorrhoea Method (LAM)</p>\n<h3>ICD10 CODE: Z30.02</h3>\n<p>LAM relies on the suppression of ovulation through exclusive breastfeed\u00ad</p>\n<p>ing as a means of contraception. Guidance on correct use of the method</p>\n<p>is only available at centres with trained service providers. LAM requires 3</p>\n<p>conditions which must ALL be met:</p>\n<p>\u0089</p>\n<p>The mother\u2019s monthly bleeding has not returned</p>\n<p>\u0089</p>\n<p>The baby is fully or nearly fully breastfed; and is fed often, day</p>\n<p>and night</p>\n<p>\u0089</p>\n<p>The baby is less than 6 months old</p>"
    },
    {
        "page_number": 756,
        "content": "690\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nDisadvantages\n \n~\nDOES NOT PROTECT AGAINST STI\n \n~\nLow couple years of protection\nManagement\nINTRUCTIONS\nLOC\n\t\n\u0089\nEnsure client understands how the method works\n\t\n\u0089\nExplain to client that:\n\t\n\u0089\nEnsure client understands how the method works\n\t\n\u0089\nExplain to client that:\n \n\u0083 She must breastfeed her child on demand on both \nbreasts at least 10-12 times during day and night \n(including at least once nightly in the first months)\n \n\u0083 Daytime feedings should be no >4 hours apart, and \nnight-time feedings no >6 hours apart\n \n\u0083 She must not give the child any solid foods or\n \n\u0083 other liquids apart from breast milk\n\t\n\u0089\nAdvise the client that LAM will no longer be an effective \nFP method IF:\n \n\u0083 The baby does not feed regularly on demand\n \n\u0083 Menstruation resumes; she will then need to use \nanother FP method\n\t\n\u0089\nAdvise the client\n \n\u0083 To use condoms as well as LAM if there is any risk of \nexposure to STIs/HIV\n \n\u0083 To return after 3 months for a routine follow-up\n \n\u0083 or earlier if she has any problem\n \n\u0083 If she wants to change to another FP method\nHC1\n15.2.11   Surgical Contraception for Men: Vasectomy\t\n       \nICD10 CODE: Z30.2\nThis permanent FP method involves a minor operation carried out \nunder local anaesthetic to cut and tie the two sperm-carrying tubes (vas \ndeferens). It is only available at centres with specially trained service \nproviders. There is need to dispel the myths of impotence following \nvasectomy.",
        "formatted_content": "<p>690</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Disadvantages</p>\n<p>~</p>\n<h3>DOES NOT PROTECT AGAINST STI</h3>\n<p>~</p>\n<p>Low couple years of protection</p>\n<p>Management</p>\n<h3>INTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure client understands how the method works</p>\n<p>\u0089</p>\n<p>Explain to client that:</p>\n<p>\u0089</p>\n<p>Ensure client understands how the method works</p>\n<p>\u0089</p>\n<p>Explain to client that:</p>\n<p>\u0083 She must breastfeed her child on demand on both</p>\n<p>breasts at least 10-12 times during day and night</p>\n<p>(including at least once nightly in the first months)</p>\n<p>\u0083 Daytime feedings should be no >4 hours apart, and</p>\n<p>night-time feedings no >6 hours apart</p>\n<p>\u0083 She must not give the child any solid foods or</p>\n<p>\u0083 other liquids apart from breast milk</p>\n<p>\u0089</p>\n<p>Advise the client that LAM will no longer be an effective</p>\n<p>FP method IF:</p>\n<p>\u0083 The baby does not feed regularly on demand</p>\n<p>\u0083 Menstruation resumes; she will then need to use</p>\n<p>another FP method</p>\n<p>\u0089</p>\n<p>Advise the client</p>\n<p>\u0083 To use condoms as well as LAM if there is any risk of</p>\n<p>exposure to STIs/HIV</p>\n<p>\u0083 To return after 3 months for a routine follow-up</p>\n<p>\u0083 or earlier if she has any problem</p>\n<p>\u0083 If she wants to change to another FP method</p>\n<h3>HC1</h3>\n<p>15.2.11   Surgical Contraception for Men: Vasectomy</p>\n<h3>ICD10 CODE: Z30.2</h3>\n<p>This permanent FP method involves a minor operation carried out</p>\n<p>under local anaesthetic to cut and tie the two sperm-carrying tubes (vas</p>\n<p>deferens). It is only available at centres with specially trained service</p>\n<p>providers. There is need to dispel the myths of impotence following</p>\n<p>vasectomy.</p>"
    },
    {
        "page_number": 757,
        "content": "691\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nIndications\n \n~\nFully aware, counselled clients who have voluntarily signed \nthe consent form\n \n~\nMales of couples\n\t\n\u0089\nWho have definitely reached their desired family size and want \nno more children\n\t\n\u0089\nWhere the woman cannot risk another pregnancy due to\n\t\n\u0089\nage or health problems\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nEnsure client understands how the method works and \nthat it is permanent, not reversible, and highly effective\n\t\n\u0089\nExplain to client that:\n \n\u0083 Vasectomy is not castration and sexual ability/ \nactivity is not affected\n \n\u0083 The procedure is not immediately effective and that \nthe client will need to use a condom for at least 15 \nejaculations after the operation (or three months)\n\t\n\u0089\nAfter the operation, advise client:\n \n\u0083 On wound care\n \n\u0083 To return for routine follow-up after days days or \nearlier if there is fever, excessive swelling, pus, or \ntenderness at the site of operation\n \n\u0083 To continue using condoms or other\n \n\u0083 contraceptive devices for three-months following \nthe procedure\n \n\u0083 To use condoms if there is any risk of HIV/STIs\nHC4\n15.2.12  Surgical Contraception for Women: Tubal Ligation\t\nICD10 CODE: Z30.2\nThis permanent FP method involves a minor 15-minute operation \ncarried out under local anaesthetic to cut and tie the two egg-carrying",
        "formatted_content": "<p>691</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>Indications</p>\n<p>~</p>\n<p>Fully aware, counselled clients who have voluntarily signed</p>\n<p>the consent form</p>\n<p>~</p>\n<p>Males of couples</p>\n<p>\u0089</p>\n<p>Who have definitely reached their desired family size and want</p>\n<p>no more children</p>\n<p>\u0089</p>\n<p>Where the woman cannot risk another pregnancy due to</p>\n<p>\u0089</p>\n<p>age or health problems</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure client understands how the method works and</p>\n<p>that it is permanent, not reversible, and highly effective</p>\n<p>\u0089</p>\n<p>Explain to client that:</p>\n<p>\u0083 Vasectomy is not castration and sexual ability/</p>\n<p>activity is not affected</p>\n<p>\u0083 The procedure is not immediately effective and that</p>\n<p>the client will need to use a condom for at least 15</p>\n<p>ejaculations after the operation (or three months)</p>\n<p>\u0089</p>\n<p>After the operation, advise client:</p>\n<p>\u0083 On wound care</p>\n<p>\u0083 To return for routine follow-up after days days or</p>\n<p>earlier if there is fever, excessive swelling, pus, or</p>\n<p>tenderness at the site of operation</p>\n<p>\u0083 To continue using condoms or other</p>\n<p>\u0083 contraceptive devices for three-months following</p>\n<p>the procedure</p>\n<p>\u0083 To use condoms if there is any risk of HIV/STIs</p>\n<h3>HC4</h3>\n<p>15.2.12  Surgical Contraception for Women: Tubal Ligation</p>\n<h3>ICD10 CODE: Z30.2</h3>\n<p>This permanent FP method involves a minor 15-minute operation</p>\n<p>carried out under local anaesthetic to cut and tie the two egg-carrying</p>"
    },
    {
        "page_number": 758,
        "content": "692\nUganda Clinical Guidelines 2023\nCHAPTER 15: Family Planning (FP)\nfallopian tubes. It is only available at centres with specially trained \nservice providers.\nIndications\n \n~\nAs for vasectomy (above) but for females\nManagement\nINSTRUCTIONS\nLOC\n\t\n\u0089\nEnsure client understands how the method works and \nthat it is permanent, irreversible, and highly and im\u00ad\nmediately effective\n\t\n\u0089\nExplain to client that:\n \n\u0083 There may be some discomfort/pain over the small \nwound for a few days\n\t\n\u0089\nAdvise client:\n \n\u0083 On wound care\n \n\u0083 To use condoms if there is any risk of exposure to \nSTIs/HIV\n \n\u0083 To return after 7 days for routine follow-up or\n \n\u0083 earlier if there is fever, excessive swelling, pus, or \ntenderness at the site of operation\nHC4",
        "formatted_content": "<p>692</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 15: Family Planning (FP)</p>\n<p>fallopian tubes. It is only available at centres with specially trained</p>\n<p>service providers.</p>\n<p>Indications</p>\n<p>~</p>\n<p>As for vasectomy (above) but for females</p>\n<p>Management</p>\n<h3>INSTRUCTIONS</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ensure client understands how the method works and</p>\n<p>that it is permanent, irreversible, and highly and im\u00ad</p>\n<p>mediately effective</p>\n<p>\u0089</p>\n<p>Explain to client that:</p>\n<p>\u0083 There may be some discomfort/pain over the small</p>\n<p>wound for a few days</p>\n<p>\u0089</p>\n<p>Advise client:</p>\n<p>\u0083 On wound care</p>\n<p>\u0083 To use condoms if there is any risk of exposure to</p>\n<p>STIs/HIV</p>\n<p>\u0083 To return after 7 days for routine follow-up or</p>\n<p>\u0083 earlier if there is fever, excessive swelling, pus, or</p>\n<p>tenderness at the site of operation</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 759,
        "content": "693\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nObstetric Conditions\n16\n16.1  ANTENATAL CARE (ANC)     ICD10 CODE: Z36\nAntenatal care is a planned programme of medical care offered to \npregnant women by a skilled birth attendant, from the time of con\u00ad\nception to delivery, aimed at ensuring a safe and satisfying pregnancy \nand birth outcome.\nThe main objective of antenatal care is to give information on:\n \n~\nScreening, prevention, and treatment of complications\n \n~\nEmergency preparedness\n \n~\nBirth planning\n \n~\nSatisfying any unmet nutritional, social, emotional, and \nphysical needs of the pregnant woman\n \n~\nProvision of patient education, including successful care \nand nutrition of the newborn\n \n~\nIdentification of high-risk pregnancy\n \n~\nEncouragement of male partner involvement in antenatal \ncare\n16.1.1    Goal-Oriented Antenatal Care Protocol\nImportant:  Goals are different depending on the timing of the visit. \n4 visits are aimed for in an uncomplicated pregnancy.\nIf a woman books later than in first trimester, preceding goals should be \ncombined and attended to.  At all visits address any identified problems, \ncheck the BP and measure the Symphysio-Fundal Height (SFH). All \nwomen must receive Hb, HIV testing and Syphilis testing (RPR) routinely.",
        "formatted_content": "<p>693</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Obstetric Conditions</p>\n<p>16</p>\n<h3>16.1  ANTENATAL CARE (ANC)     ICD10 CODE: Z36</h3>\n<p>Antenatal care is a planned programme of medical care offered to</p>\n<p>pregnant women by a skilled birth attendant, from the time of con\u00ad</p>\n<p>ception to delivery, aimed at ensuring a safe and satisfying pregnancy</p>\n<p>and birth outcome.</p>\n<p>The main objective of antenatal care is to give information on:</p>\n<p>~</p>\n<p>Screening, prevention, and treatment of complications</p>\n<p>~</p>\n<p>Emergency preparedness</p>\n<p>~</p>\n<p>Birth planning</p>\n<p>~</p>\n<p>Satisfying any unmet nutritional, social, emotional, and</p>\n<p>physical needs of the pregnant woman</p>\n<p>~</p>\n<p>Provision of patient education, including successful care</p>\n<p>and nutrition of the newborn</p>\n<p>~</p>\n<p>Identification of high-risk pregnancy</p>\n<p>~</p>\n<p>Encouragement of male partner involvement in antenatal</p>\n<p>care</p>\n<p>16.1.1    Goal-Oriented Antenatal Care Protocol</p>\n<p>Important:  Goals are different depending on the timing of the visit.</p>\n<p>4 visits are aimed for in an uncomplicated pregnancy.</p>\n<p>If a woman books later than in first trimester, preceding goals should be</p>\n<p>combined and attended to.  At all visits address any identified problems,</p>\n<p>check the BP and measure the Symphysio-Fundal Height (SFH). All</p>\n<p>women must receive Hb, HIV testing and Syphilis testing (RPR) routinely.</p>"
    },
    {
        "page_number": 760,
        "content": "694\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nVisit\nTiming \nOf Visit\nGoals\nHistory \nTaking\nExamination\nLaboratory Investi\u00ad\ngations\nHealth Promotion\nActions\nBOOKING \nVISIT\nAny time \nbefore \n14 weeks \ngestation\n-\t\nPatient \nassessment\n-\t\nPlan for ANC\n-\t\nIdentify and \nmanage any \nillness\n-\t\nDevelop birth \nand emergen\u00ad\ncy plan\n-\t\nGive health \neducation\n-\t\nCheck foetal \ngrowth and \nmaternal \nwell-being\n-\t\nStart \npreventive \ninterventions\n-\t\nMedical \n-\t\nSurgical\n-\t\nObstetric\n-\t\nLMP\n-\t\nConfirm \nperiod of \ngestation\n-\t\nContra\u00ad\nceptive \nuse (type, \nduration)\n-\t\nSTI\n-\t\nFamily \nhistory\n-\t\nAccess for \nSGBV\n-\t\nGeneral exam \nincluding evidence \nof trauma and \nmood, \n-\t\n Vital observations \n(BP, Pulse rate, \nrespiratory rate)\n-\t\nSFH (symphys\u00ad\nio-fundal height)\n-\t\nAbdominal exam \nVulva exam (spec\u00ad\nulum if indicated\n-\t\nSyphilis test (RPR)\n-\t\nHIV test\n-\t\nUrinalysis (Urine strip \n& microscopy)\n-\t\nIf BP > 140/90, \ncheck urine for \nprotein\n-\t\nHb estimation\n-\t\nHBsAg testing\n-\t\nBlood grouping\n-\t\nIf Mother has fever \n(Temp above 37.5oC \ndo RDT/ BS\n-\t\nIf RDT/BS positive, \nfollow guidelines\n-\t\nCheck for hereditary \nconditions if sus\u00ad\npected sickling test \nG6PD)\n-\t\nEducate on ANC visits\n-\t\nAddress any observed \nor volunteered prob\u00ad\nlems and illnesses\n-\t\nInvolve husband in \nANC\n-\t\nDevelop emergency \nplan\n-\t\nTeach danger signs \nduring pregnancy\n-\t\nDiscuss STI/HIV/\nAIDS prevention \nand care\n-\t\nAfter HIV test, \nprovide counselling. \nIf HIV-positive, start \nART for eMTCT \nimmediately\n-\t\nDiscuss pregnancy \ndiscomforts, sexual \nrelations\n-\t\nGive TT1\n-\t\nGive iron/folic acid\n-\t\nHIV counselling, \ntesting and post-test \ncounselling\n-\t\nIf HIV+, begin ART \nas soon as identified \nas HIV positive\n-\t\nTreat any illness\n-\t\nCounsel woman\n-\t\nStart IPTp with \nSP after 13 weeks \ngestation\n-\t\nProvide ITN (LLINs)",
        "formatted_content": "<p>694</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Visit</p>\n<p>Timing</p>\n<p>Of Visit</p>\n<p>Goals</p>\n<p>History</p>\n<p>Taking</p>\n<p>Examination</p>\n<p>Laboratory Investi\u00ad</p>\n<p>gations</p>\n<p>Health Promotion</p>\n<p>Actions</p>\n<h3>BOOKING</h3>\n<h3>VISIT</h3>\n<p>Any time</p>\n<p>before</p>\n<p>14 weeks</p>\n<p>gestation</p>\n<p>-</p>\n<p>Patient</p>\n<p>assessment</p>\n<p>-</p>\n<p>Plan for ANC</p>\n<p>-</p>\n<p>Identify and</p>\n<p>manage any</p>\n<p>illness</p>\n<p>-</p>\n<p>Develop birth</p>\n<p>and emergen\u00ad</p>\n<p>cy plan</p>\n<p>-</p>\n<p>Give health</p>\n<p>education</p>\n<p>-</p>\n<p>Check foetal</p>\n<p>growth and</p>\n<p>maternal</p>\n<p>well-being</p>\n<p>-</p>\n<p>Start</p>\n<p>preventive</p>\n<p>interventions</p>\n<p>-</p>\n<p>Medical</p>\n<p>-</p>\n<p>Surgical</p>\n<p>-</p>\n<p>Obstetric</p>\n<p>-</p>\n<h3>LMP</h3>\n<p>-</p>\n<p>Confirm</p>\n<p>period of</p>\n<p>gestation</p>\n<p>-</p>\n<p>Contra\u00ad</p>\n<p>ceptive</p>\n<p>use (type,</p>\n<p>duration)</p>\n<p>-</p>\n<h3>STI</h3>\n<p>-</p>\n<p>Family</p>\n<p>history</p>\n<p>-</p>\n<p>Access for</p>\n<h3>SGBV</h3>\n<p>-</p>\n<p>General exam</p>\n<p>including evidence</p>\n<p>of trauma and</p>\n<p>mood,</p>\n<p>-</p>\n<p>Vital observations</p>\n<p>(BP, Pulse rate,</p>\n<p>respiratory rate)</p>\n<p>-</p>\n<p>SFH (symphys\u00ad</p>\n<p>io-fundal height)</p>\n<p>-</p>\n<p>Abdominal exam</p>\n<p>Vulva exam (spec\u00ad</p>\n<p>ulum if indicated</p>\n<p>-</p>\n<p>Syphilis test (RPR)</p>\n<p>-</p>\n<p>HIV test</p>\n<p>-</p>\n<p>Urinalysis (Urine strip</p>\n<p>& microscopy)</p>\n<p>-</p>\n<p>If BP > 140/90,</p>\n<p>check urine for</p>\n<p>protein</p>\n<p>-</p>\n<p>Hb estimation</p>\n<p>-</p>\n<p>HBsAg testing</p>\n<p>-</p>\n<p>Blood grouping</p>\n<p>-</p>\n<p>If Mother has fever</p>\n<p>(Temp above 37.5oC</p>\n<p>do RDT/ BS</p>\n<p>-</p>\n<p>If RDT/BS positive,</p>\n<p>follow guidelines</p>\n<p>-</p>\n<p>Check for hereditary</p>\n<p>conditions if sus\u00ad</p>\n<p>pected sickling test</p>\n<h3>G6PD)</h3>\n<p>-</p>\n<p>Educate on ANC visits</p>\n<p>-</p>\n<p>Address any observed</p>\n<p>or volunteered prob\u00ad</p>\n<p>lems and illnesses</p>\n<p>-</p>\n<p>Involve husband in</p>\n<h3>ANC</h3>\n<p>-</p>\n<p>Develop emergency</p>\n<p>plan</p>\n<p>-</p>\n<p>Teach danger signs</p>\n<p>during pregnancy</p>\n<p>-</p>\n<p>Discuss STI/HIV/</p>\n<p>AIDS prevention</p>\n<p>and care</p>\n<p>-</p>\n<p>After HIV test,</p>\n<p>provide counselling.</p>\n<p>If HIV-positive, start</p>\n<p>ART for eMTCT</p>\n<p>immediately</p>\n<p>-</p>\n<p>Discuss pregnancy</p>\n<p>discomforts, sexual</p>\n<p>relations</p>\n<p>-</p>\n<p>Give TT1</p>\n<p>-</p>\n<p>Give iron/folic acid</p>\n<p>-</p>\n<p>HIV counselling,</p>\n<p>testing and post-test</p>\n<p>counselling</p>\n<p>-</p>\n<p>If HIV+, begin ART</p>\n<p>as soon as identified</p>\n<p>as HIV positive</p>\n<p>-</p>\n<p>Treat any illness</p>\n<p>-</p>\n<p>Counsel woman</p>\n<p>-</p>\n<p>Start IPTp with</p>\n<p>SP after 13 weeks</p>\n<p>gestation</p>\n<p>-</p>\n<p>Provide ITN (LLINs)</p>"
    },
    {
        "page_number": 761,
        "content": "695\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nVisit\nTiming \nOf Visit\nGoals\nHistory \nTaking\nExamination\nLaboratory Investi\u00ad\ngations\nHealth Promotion\nActions\n-\t\nSocial: \nsmoking, \nalcohol/\ndrugs\n-\t\nSocial \nsupport\n-\t\nCounsel on ITN use\n-\t\nDiscuss the danger of \nSGBV in pregnancy\n-\t\nEmphasise on \nhygiene, nutrition \nand adherence to \ntreatment\n-\t\nAdvise on common \ndiscomforts of \npregnancy\nSECOND \nVISIT\n24-28 \nweeks\n-\t\nGive TT\n-\t\nExclude \nmultiple \npregnancy\n-\t\nCheck for \npregnan\u00ad\ncy-induced \nhypertension \n(PIH)\n-\t\nDetermine \nfoetal growth \nand move\u00ad\nment\n-\t\nExclude \nanaemia\n-\t\nScreen for \nGDM if the \nmother is at \nrisk.\n-\t\nAsk for \nany social \nproblems \nand \nillnesses\n-\t\nAsk date \nof first \nfoetal \nmove\u00ad\nments\n-\t\nAsk if \nthere is/\nwas any \nvaginal \nbleeding \nor dis\u00ad\ncharge\n-\t\nMeasure BP and \nweight\n-\t\nCheck for Oedema \nand Pallor\n-\t\nMeasure SFH\n-\t\nAbdominal exam: \nrule out multiple \npregnancy\n-\t\nCheck foetal \nheartbeat\n-\t\nAccess for SGBV\n-\t\nIf BP > 140/90, \ncheck urine for \nprotein\n-\t\nCheck Hb\n-\t\nDo OGGT\n-\t\nIf Mother has fever \n(Temp above 37.5oC \ndo RDT/ BS\n-\t\nIf RDT/BS positive, \nfollow guidelines\n-\t\nRepeat HIV test\n-\t\nViral load/CD4 for \nHIV positive mothers\n-\t\nFor Rhesus Negative \nmothers, do anti \nbody screening\n-\t\nAddress any observed \nor volunteered prob\u00ad\nlems and illnesses\n-\t\nUpdate birth and \nemergency plan\n-\t\nReview danger signs \nin pregnancy\n-\t\nIf HIV-positive, coun\u00ad\nsel on eMTCT\n-\t\nCounsel on ITN use\n-\t\nAdvise on common \ndiscomforts of \npregnancy\n-\t\nDiscuss the danger of \nSGBV in pregnancy\n-\t\nEmphasise on \nhygiene, nutrition \nand adherence to \ntreatment\n-\t\nGive TT2\n-\t\nRefill iron/folic acid\n-\t\nGive IPTp-SP if 1 \nmonth has passed \nsince previous dose\n-\t\nGive mebendazole\n-\t\nIf HIV+, on eMTCT \nand refill of ARVs\n-\t\nTreat any illnesses \nproblems\n-\t\nCounsel woman\n-\t\nHealth educate on \nLLINs use, care and \nmaintenance",
        "formatted_content": "<p>695</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Visit</p>\n<p>Timing</p>\n<p>Of Visit</p>\n<p>Goals</p>\n<p>History</p>\n<p>Taking</p>\n<p>Examination</p>\n<p>Laboratory Investi\u00ad</p>\n<p>gations</p>\n<p>Health Promotion</p>\n<p>Actions</p>\n<p>-</p>\n<p>Social:</p>\n<p>smoking,</p>\n<p>alcohol/</p>\n<p>drugs</p>\n<p>-</p>\n<p>Social</p>\n<p>support</p>\n<p>-</p>\n<p>Counsel on ITN use</p>\n<p>-</p>\n<p>Discuss the danger of</p>\n<p>SGBV in pregnancy</p>\n<p>-</p>\n<p>Emphasise on</p>\n<p>hygiene, nutrition</p>\n<p>and adherence to</p>\n<p>treatment</p>\n<p>-</p>\n<p>Advise on common</p>\n<p>discomforts of</p>\n<p>pregnancy</p>\n<h3>SECOND</h3>\n<h3>VISIT</h3>\n<p>24-28</p>\n<p>weeks</p>\n<p>-</p>\n<p>Give TT</p>\n<p>-</p>\n<p>Exclude</p>\n<p>multiple</p>\n<p>pregnancy</p>\n<p>-</p>\n<p>Check for</p>\n<p>pregnan\u00ad</p>\n<p>cy-induced</p>\n<p>hypertension</p>\n<h3>(PIH)</h3>\n<p>-</p>\n<p>Determine</p>\n<p>foetal growth</p>\n<p>and move\u00ad</p>\n<p>ment</p>\n<p>-</p>\n<p>Exclude</p>\n<p>anaemia</p>\n<p>-</p>\n<p>Screen for</p>\n<p>GDM if the</p>\n<p>mother is at</p>\n<p>risk.</p>\n<p>-</p>\n<p>Ask for</p>\n<p>any social</p>\n<p>problems</p>\n<p>and</p>\n<p>illnesses</p>\n<p>-</p>\n<p>Ask date</p>\n<p>of first</p>\n<p>foetal</p>\n<p>move\u00ad</p>\n<p>ments</p>\n<p>-</p>\n<p>Ask if</p>\n<p>there is/</p>\n<p>was any</p>\n<p>vaginal</p>\n<p>bleeding</p>\n<p>or dis\u00ad</p>\n<p>charge</p>\n<p>-</p>\n<p>Measure BP and</p>\n<p>weight</p>\n<p>-</p>\n<p>Check for Oedema</p>\n<p>and Pallor</p>\n<p>-</p>\n<p>Measure SFH</p>\n<p>-</p>\n<p>Abdominal exam:</p>\n<p>rule out multiple</p>\n<p>pregnancy</p>\n<p>-</p>\n<p>Check foetal</p>\n<p>heartbeat</p>\n<p>-</p>\n<p>Access for SGBV</p>\n<p>-</p>\n<p>If BP > 140/90,</p>\n<p>check urine for</p>\n<p>protein</p>\n<p>-</p>\n<p>Check Hb</p>\n<p>-</p>\n<p>Do OGGT</p>\n<p>-</p>\n<p>If Mother has fever</p>\n<p>(Temp above 37.5oC</p>\n<p>do RDT/ BS</p>\n<p>-</p>\n<p>If RDT/BS positive,</p>\n<p>follow guidelines</p>\n<p>-</p>\n<p>Repeat HIV test</p>\n<p>-</p>\n<p>Viral load/CD4 for</p>\n<p>HIV positive mothers</p>\n<p>-</p>\n<p>For Rhesus Negative</p>\n<p>mothers, do anti</p>\n<p>body screening</p>\n<p>-</p>\n<p>Address any observed</p>\n<p>or volunteered prob\u00ad</p>\n<p>lems and illnesses</p>\n<p>-</p>\n<p>Update birth and</p>\n<p>emergency plan</p>\n<p>-</p>\n<p>Review danger signs</p>\n<p>in pregnancy</p>\n<p>-</p>\n<p>If HIV-positive, coun\u00ad</p>\n<p>sel on eMTCT</p>\n<p>-</p>\n<p>Counsel on ITN use</p>\n<p>-</p>\n<p>Advise on common</p>\n<p>discomforts of</p>\n<p>pregnancy</p>\n<p>-</p>\n<p>Discuss the danger of</p>\n<p>SGBV in pregnancy</p>\n<p>-</p>\n<p>Emphasise on</p>\n<p>hygiene, nutrition</p>\n<p>and adherence to</p>\n<p>treatment</p>\n<p>-</p>\n<p>Give TT2</p>\n<p>-</p>\n<p>Refill iron/folic acid</p>\n<p>-</p>\n<p>Give IPTp-SP if 1</p>\n<p>month has passed</p>\n<p>since previous dose</p>\n<p>-</p>\n<p>Give mebendazole</p>\n<p>-</p>\n<p>If HIV+, on eMTCT</p>\n<p>and refill of ARVs</p>\n<p>-</p>\n<p>Treat any illnesses</p>\n<p>problems</p>\n<p>-</p>\n<p>Counsel woman</p>\n<p>-</p>\n<p>Health educate on</p>\n<p>LLINs use, care and</p>\n<p>maintenance</p>"
    },
    {
        "page_number": 762,
        "content": "696\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nVisit\nTiming \nOf Visit\nGoals\nHistory \nTaking\nExamination\nLaboratory Investi\u00ad\ngations\nHealth Promotion\nActions\nTHIRD \nVISIT\n30-32 \nweeks\n-\t\nDetermine \nfoetal growth\n-\t\nExclude \nanaemia\n-\t\nCheck for \nPIH\n-\t\nUpdate birth \nand emergen\u00ad\ncy plan\n-\t\nAsk for \nany social \nproblems \nand \nillnesses\n-\t\nAsk if \nthere is/\nwas  any \nvaginal \nbleeding \nand dis\u00ad\ncharge\n-\t\nMeasure BP \n-\t\nCheck for pallor\n-\t\nMeasure SFH\n-\t\nAbdominal exam\n-\t\nCheck foetal \nheartbeat\n-\t\nIf BP > 140/90, \ncheck urine for \nprotein\n-\t\nCheck Hb\n-\t\nIf Mother has fever \n(Temp above 37.5oC \ndo RDT/ BS\n-\t\nIf RDT/BS positive, \nfollow guidelines\n-\t\nAddress any observed \nor volunteered prob\u00ad\nlems and illnesses\n-\t\nTeach danger signs in \npregnancy/labour\n-\t\nDiscuss labour\n-\t\nDiscuss and update \nbirth and emergency \nplan\n-\t\nDiscuss family \nplanning\n-\t\nIf HIV-positive, coun\u00ad\nsel on eMTCT\n-\t\nCounsel ITN use\n-\t\nTeach about postpar\u00ad\ntum care\n-\t\nTeach care of the \nnewborn: early ex\u00ad\nclusive breast-feeding \nthermal care, cord \ncare, danger signs\n-\t\nDiscuss the danger of \nSGBV in pregnancy\n-\t\nEmphasise on \nhygiene, nutrition \nand adherence to \ntreatment\n-\t\nRefill iron/folic acid\n-\t\nGive IPTp-SP if 1 \nmonth has passed \nsince previous dose\n-\t\nTreat any problems\n-\t\nIf HIV+, eMTCT\n-\t\nCounsel to use dual \nprotection for FP/\nHIV\n-\t\nCounsel woman\n-\t\nHealth educate on \nLLINs use, care and \nmaintenance",
        "formatted_content": "<p>696</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Visit</p>\n<p>Timing</p>\n<p>Of Visit</p>\n<p>Goals</p>\n<p>History</p>\n<p>Taking</p>\n<p>Examination</p>\n<p>Laboratory Investi\u00ad</p>\n<p>gations</p>\n<p>Health Promotion</p>\n<p>Actions</p>\n<h3>THIRD</h3>\n<h3>VISIT</h3>\n<p>30-32</p>\n<p>weeks</p>\n<p>-</p>\n<p>Determine</p>\n<p>foetal growth</p>\n<p>-</p>\n<p>Exclude</p>\n<p>anaemia</p>\n<p>-</p>\n<p>Check for</p>\n<h3>PIH</h3>\n<p>-</p>\n<p>Update birth</p>\n<p>and emergen\u00ad</p>\n<p>cy plan</p>\n<p>-</p>\n<p>Ask for</p>\n<p>any social</p>\n<p>problems</p>\n<p>and</p>\n<p>illnesses</p>\n<p>-</p>\n<p>Ask if</p>\n<p>there is/</p>\n<p>was  any</p>\n<p>vaginal</p>\n<p>bleeding</p>\n<p>and dis\u00ad</p>\n<p>charge</p>\n<p>-</p>\n<p>Measure BP</p>\n<p>-</p>\n<p>Check for pallor</p>\n<p>-</p>\n<p>Measure SFH</p>\n<p>-</p>\n<p>Abdominal exam</p>\n<p>-</p>\n<p>Check foetal</p>\n<p>heartbeat</p>\n<p>-</p>\n<p>If BP > 140/90,</p>\n<p>check urine for</p>\n<p>protein</p>\n<p>-</p>\n<p>Check Hb</p>\n<p>-</p>\n<p>If Mother has fever</p>\n<p>(Temp above 37.5oC</p>\n<p>do RDT/ BS</p>\n<p>-</p>\n<p>If RDT/BS positive,</p>\n<p>follow guidelines</p>\n<p>-</p>\n<p>Address any observed</p>\n<p>or volunteered prob\u00ad</p>\n<p>lems and illnesses</p>\n<p>-</p>\n<p>Teach danger signs in</p>\n<p>pregnancy/labour</p>\n<p>-</p>\n<p>Discuss labour</p>\n<p>-</p>\n<p>Discuss and update</p>\n<p>birth and emergency</p>\n<p>plan</p>\n<p>-</p>\n<p>Discuss family</p>\n<p>planning</p>\n<p>-</p>\n<p>If HIV-positive, coun\u00ad</p>\n<p>sel on eMTCT</p>\n<p>-</p>\n<p>Counsel ITN use</p>\n<p>-</p>\n<p>Teach about postpar\u00ad</p>\n<p>tum care</p>\n<p>-</p>\n<p>Teach care of the</p>\n<p>newborn: early ex\u00ad</p>\n<p>clusive breast-feeding</p>\n<p>thermal care, cord</p>\n<p>care, danger signs</p>\n<p>-</p>\n<p>Discuss the danger of</p>\n<p>SGBV in pregnancy</p>\n<p>-</p>\n<p>Emphasise on</p>\n<p>hygiene, nutrition</p>\n<p>and adherence to</p>\n<p>treatment</p>\n<p>-</p>\n<p>Refill iron/folic acid</p>\n<p>-</p>\n<p>Give IPTp-SP if 1</p>\n<p>month has passed</p>\n<p>since previous dose</p>\n<p>-</p>\n<p>Treat any problems</p>\n<p>-</p>\n<p>If HIV+, eMTCT</p>\n<p>-</p>\n<p>Counsel to use dual</p>\n<p>protection for FP/</p>\n<h3>HIV</h3>\n<p>-</p>\n<p>Counsel woman</p>\n<p>-</p>\n<p>Health educate on</p>\n<p>LLINs use, care and</p>\n<p>maintenance</p>"
    },
    {
        "page_number": 763,
        "content": "697\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nVisit\nTiming \nOf Visit\nGoals\nHistory \nTaking\nExamination\nLaboratory Investi\u00ad\ngations\nHealth Promotion\nActions\nFOURTH \nVISIT\n>36 weeks\n-\t\nDetermine \nfoetal growth\n-\t\nExclude \nanaemia \n-\t\nCheck for \nPIH\n-\t\nCheck for \npreeclampsia\n-\t\nExclude \ncephalopelvic \ndisproportion, \nabnormal \npresenta\u00ad\ntion/lie\n-\t\nExplain \nsymptoms of \nlabour\n-\t\nUpdate birth \nand emergen\u00ad\ncy plan\n-\t\nAsk for \nproblems\n-\t\nAsk if any \nvaginal \nbleeding\n-\t\nMeasure BP\n-\t\nMeasure SFH\n-\t\nCount foetal heart \nrate\n-\t\nAbdominal exam\n-\t\nCheck lie\n-\t\nCheck presenta\u00ad\ntion\n-\t\nIf BP >140/90 check \nurine for protein\n-\t\nCheck Hb\n-\t\nIf Mother has fever \n(Temp above 37.5oC \ndo RDT/ BS\n-\t\nIf RDT/BS positive, \nfollow guidelines\n-\t\nAddress any observed \nor volunteered prob\u00ad\nlems and illnesses\n-\t\nDiscuss labour\n-\t\nupdate birth and \nemergency plan\n-\t\nTeach eMTCT in \nlabour, birth, post\u00ad\npartum\n-\t\nCounsel on ITN use\n-\t\nRe-discuss FP and \nHIV prevention\n-\t\nTeach about postpar\u00ad\ntum care\n-\t\nTeach care of \nnewborn: danger \nsigns in newborn, \nearly and exclusive \nbreastfeeding, thermal \ncare, cord care\n-\t\nDiscuss  the danger of \nSGBV in pregnancy\n-\t\nEmphasise on \nhygiene, nutrition \nand adherence to \ntreatment\n-\t\nRefill iron/folic acid\n-\t\nGive IPTp-SP if 1 \nmonth has passed \nsince previous dose\n-\t\nTreat any problems\n-\t\nIf HIV+, eMTCT\n-\t\nCounsel to use dual \nprotection for FP/\nHIV prevention\n-\t\nCounsel woman\n-\t\nHealth educate on \nLLINs use, care and \nmaintenance",
        "formatted_content": "<p>697</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Visit</p>\n<p>Timing</p>\n<p>Of Visit</p>\n<p>Goals</p>\n<p>History</p>\n<p>Taking</p>\n<p>Examination</p>\n<p>Laboratory Investi\u00ad</p>\n<p>gations</p>\n<p>Health Promotion</p>\n<p>Actions</p>\n<h3>FOURTH</h3>\n<h3>VISIT</h3>\n<p>>36 weeks</p>\n<p>-</p>\n<p>Determine</p>\n<p>foetal growth</p>\n<p>-</p>\n<p>Exclude</p>\n<p>anaemia</p>\n<p>-</p>\n<p>Check for</p>\n<h3>PIH</h3>\n<p>-</p>\n<p>Check for</p>\n<p>preeclampsia</p>\n<p>-</p>\n<p>Exclude</p>\n<p>cephalopelvic</p>\n<p>disproportion,</p>\n<p>abnormal</p>\n<p>presenta\u00ad</p>\n<p>tion/lie</p>\n<p>-</p>\n<p>Explain</p>\n<p>symptoms of</p>\n<p>labour</p>\n<p>-</p>\n<p>Update birth</p>\n<p>and emergen\u00ad</p>\n<p>cy plan</p>\n<p>-</p>\n<p>Ask for</p>\n<p>problems</p>\n<p>-</p>\n<p>Ask if any</p>\n<p>vaginal</p>\n<p>bleeding</p>\n<p>-</p>\n<p>Measure BP</p>\n<p>-</p>\n<p>Measure SFH</p>\n<p>-</p>\n<p>Count foetal heart</p>\n<p>rate</p>\n<p>-</p>\n<p>Abdominal exam</p>\n<p>-</p>\n<p>Check lie</p>\n<p>-</p>\n<p>Check presenta\u00ad</p>\n<p>tion</p>\n<p>-</p>\n<p>If BP >140/90 check</p>\n<p>urine for protein</p>\n<p>-</p>\n<p>Check Hb</p>\n<p>-</p>\n<p>If Mother has fever</p>\n<p>(Temp above 37.5oC</p>\n<p>do RDT/ BS</p>\n<p>-</p>\n<p>If RDT/BS positive,</p>\n<p>follow guidelines</p>\n<p>-</p>\n<p>Address any observed</p>\n<p>or volunteered prob\u00ad</p>\n<p>lems and illnesses</p>\n<p>-</p>\n<p>Discuss labour</p>\n<p>-</p>\n<p>update birth and</p>\n<p>emergency plan</p>\n<p>-</p>\n<p>Teach eMTCT in</p>\n<p>labour, birth, post\u00ad</p>\n<p>partum</p>\n<p>-</p>\n<p>Counsel on ITN use</p>\n<p>-</p>\n<p>Re-discuss FP and</p>\n<p>HIV prevention</p>\n<p>-</p>\n<p>Teach about postpar\u00ad</p>\n<p>tum care</p>\n<p>-</p>\n<p>Teach care of</p>\n<p>newborn: danger</p>\n<p>signs in newborn,</p>\n<p>early and exclusive</p>\n<p>breastfeeding, thermal</p>\n<p>care, cord care</p>\n<p>-</p>\n<p>Discuss  the danger of</p>\n<p>SGBV in pregnancy</p>\n<p>-</p>\n<p>Emphasise on</p>\n<p>hygiene, nutrition</p>\n<p>and adherence to</p>\n<p>treatment</p>\n<p>-</p>\n<p>Refill iron/folic acid</p>\n<p>-</p>\n<p>Give IPTp-SP if 1</p>\n<p>month has passed</p>\n<p>since previous dose</p>\n<p>-</p>\n<p>Treat any problems</p>\n<p>-</p>\n<p>If HIV+, eMTCT</p>\n<p>-</p>\n<p>Counsel to use dual</p>\n<p>protection for FP/</p>\n<p>HIV prevention</p>\n<p>-</p>\n<p>Counsel woman</p>\n<p>-</p>\n<p>Health educate on</p>\n<p>LLINs use, care and</p>\n<p>maintenance</p>"
    },
    {
        "page_number": 764,
        "content": "698\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.1.2  Management of Common Complaints during Pregnancy\nCOMPLAINT\nACTION\nREMARKS\nLow back \nache, and \nfrequency of \npassing urine\n \n~\nExclude urinary \ntract infection \nand local lesion. \nIf none, reassure\nAvoid unnecessary \nmedication\nMorning sick\u00ad\nness (nausea \n& vomiting)\n \n~\nReassure; usually \nlasts only up to 3 \nmonths\n \n~\nGive general \nadvice (frequent \nsmall dry meals, \navoid spicy \nand fatty food, \ntake ginger and \nlemon)\n \n~\nIf severe with de\u00ad\nhydration, admit \nfor observation \nand rehydration \n(using IV RL or \nNS)\n \n~\nVitamin B6 (Pyr\u00ad\nidoxine) 25 mg \n2-3 times daily\nAvoid anti- emetics \nin the first trimes\u00ad\nter.\nAnti-emetics may \nbe necessary ONLY \nin severe forms (see \nsection 16.3.1)\nSwelling of \nthe feet\n \n~\nCheck for \nanaemia, blood \npressure, urine \nprotein, and \nmanage appropri\u00ad\nately\nAdvise mother to \nelevate feet if find\u00ad\nings are normal\nIndigestion \n(flatulence & \nconstipation)\n \n~\nHigh \nroughage \ndiet, increase flu\u00ad\nids.\nAvoid strong laxa\u00ad\ntives & enemas\n \n~\nIf severe, treat as \nconstipation",
        "formatted_content": "<p>698</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.1.2  Management of Common Complaints during Pregnancy</p>\n<h3>COMPLAINT</h3>\n<h3>ACTION</h3>\n<h3>REMARKS</h3>\n<p>Low back</p>\n<p>ache, and</p>\n<p>frequency of</p>\n<p>passing urine</p>\n<p>~</p>\n<p>Exclude urinary</p>\n<p>tract infection</p>\n<p>and local lesion.</p>\n<p>If none, reassure</p>\n<p>Avoid unnecessary</p>\n<p>medication</p>\n<p>Morning sick\u00ad</p>\n<p>ness (nausea</p>\n<p>& vomiting)</p>\n<p>~</p>\n<p>Reassure; usually</p>\n<p>lasts only up to 3</p>\n<p>months</p>\n<p>~</p>\n<p>Give general</p>\n<p>advice (frequent</p>\n<p>small dry meals,</p>\n<p>avoid spicy</p>\n<p>and fatty food,</p>\n<p>take ginger and</p>\n<p>lemon)</p>\n<p>~</p>\n<p>If severe with de\u00ad</p>\n<p>hydration, admit</p>\n<p>for observation</p>\n<p>and rehydration</p>\n<p>(using IV RL or</p>\n<h3>NS)</h3>\n<p>~</p>\n<p>Vitamin B6 (Pyr\u00ad</p>\n<p>idoxine) 25 mg</p>\n<p>2-3 times daily</p>\n<p>Avoid anti- emetics</p>\n<p>in the first trimes\u00ad</p>\n<p>ter.</p>\n<p>Anti-emetics may</p>\n<p>be necessary ONLY</p>\n<p>in severe forms (see</p>\n<p>section 16.3.1)</p>\n<p>Swelling of</p>\n<p>the feet</p>\n<p>~</p>\n<p>Check for</p>\n<p>anaemia, blood</p>\n<p>pressure, urine</p>\n<p>protein, and</p>\n<p>manage appropri\u00ad</p>\n<p>ately</p>\n<p>Advise mother to</p>\n<p>elevate feet if find\u00ad</p>\n<p>ings are normal</p>\n<p>Indigestion</p>\n<p>(flatulence &</p>\n<p>constipation)</p>\n<p>~</p>\n<p>High</p>\n<p>roughage</p>\n<p>diet, increase flu\u00ad</p>\n<p>ids.</p>\n<p>Avoid strong laxa\u00ad</p>\n<p>tives & enemas</p>\n<p>~</p>\n<p>If severe, treat as</p>\n<p>constipation</p>"
    },
    {
        "page_number": 765,
        "content": "699\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCOMPLAINT\nACTION\nREMARKS\nExcessive \nsalivation \n(ptyalism)\n \n~\nReassure\n \n~\nAdvise mother to \nuse ginger\nAvoid anticholiner\u00ad\ngic drugs\nFood craving \n(pica)\n \n~\nEnsure balanced \ndiet\nDiscourage harmful \nmaterials, e.g. soil\nSoil craving is a \nsign of iron defi\u00ad\nciency anaemia, \ngive ferrous + folic \nacid\nGeneralised \npruritus\n \n~\nReassure.\n \n~\nIf severe, treat \nas skin allergy/ \nurticaria\nAvoid steroids\nVulval \npruritus with \nwhitish non- \nfoul smelling \ndischarge \nBurning \nsensation on \npassing urine\n \n~\nTreat as for \nabnormal vaginal \ndischarge (most \nlikely candida)\n \n~\nUse Clotrimazole \ncream or pessa\u00ad\nries\n \n~\nIn severe cases, \nuse fluconazole \n150 mg stat.\n \n~\nAvoid repeat dos\u00ad\nes or prolonged \nuse\nAvoid douching \nwith antiseptics\nCramps\n \n~\nGive calcium \nlactate\n \n~\n600 mg 8 hourly \nfor 5 days\nAvoid giving \nNSAIDS\nFatigue\n \n~\nReassure, bed rest\nAvoid drugs",
        "formatted_content": "<p>699</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>COMPLAINT</h3>\n<h3>ACTION</h3>\n<h3>REMARKS</h3>\n<p>Excessive</p>\n<p>salivation</p>\n<p>(ptyalism)</p>\n<p>~</p>\n<p>Reassure</p>\n<p>~</p>\n<p>Advise mother to</p>\n<p>use ginger</p>\n<p>Avoid anticholiner\u00ad</p>\n<p>gic drugs</p>\n<p>Food craving</p>\n<p>(pica)</p>\n<p>~</p>\n<p>Ensure balanced</p>\n<p>diet</p>\n<p>Discourage harmful</p>\n<p>materials, e.g. soil</p>\n<p>Soil craving is a</p>\n<p>sign of iron defi\u00ad</p>\n<p>ciency anaemia,</p>\n<p>give ferrous + folic</p>\n<p>acid</p>\n<p>Generalised</p>\n<p>pruritus</p>\n<p>~</p>\n<p>Reassure.</p>\n<p>~</p>\n<p>If severe, treat</p>\n<p>as skin allergy/</p>\n<p>urticaria</p>\n<p>Avoid steroids</p>\n<p>Vulval</p>\n<p>pruritus with</p>\n<p>whitish non-</p>\n<p>foul smelling</p>\n<p>discharge</p>\n<p>Burning</p>\n<p>sensation on</p>\n<p>passing urine</p>\n<p>~</p>\n<p>Treat as for</p>\n<p>abnormal vaginal</p>\n<p>discharge (most</p>\n<p>likely candida)</p>\n<p>~</p>\n<p>Use Clotrimazole</p>\n<p>cream or pessa\u00ad</p>\n<p>ries</p>\n<p>~</p>\n<p>In severe cases,</p>\n<p>use fluconazole</p>\n<p>150 mg stat.</p>\n<p>~</p>\n<p>Avoid repeat dos\u00ad</p>\n<p>es or prolonged</p>\n<p>use</p>\n<p>Avoid douching</p>\n<p>with antiseptics</p>\n<p>Cramps</p>\n<p>~</p>\n<p>Give calcium</p>\n<p>lactate</p>\n<p>~</p>\n<p>600 mg 8 hourly</p>\n<p>for 5 days</p>\n<p>Avoid giving</p>\n<h3>NSAIDS</h3>\n<p>Fatigue</p>\n<p>~</p>\n<p>Reassure, bed rest</p>\n<p>Avoid drugs</p>"
    },
    {
        "page_number": 766,
        "content": "700\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.1.3 High Risk Pregnancy (HRP)                             ICD10 CODE: O09\nThis is a pregnancy with a higher than average risk of an adverse out\u00ad\ncome for the mother or baby, e.g., abortion, intrauterine death, still \nbirth, prematurity, other morbidity or mortality.\nHigh risk criteria: if a woman has history of or current\n \n~\nExtremes of reproductive age: <18 and >35 years\n \n~\nPrimigravida: Especially if too young (<18 years), short \n(<150cm), or old (>35 years)\n \n~\nHigh parity: 5+ or short birth-to-pregnancy interval below \n2 years\n \n~\nMaternal Obesity (BMI >30)\n \n~\nHistory of:\n\t\n\u0089\nLarge infants: 4 kg and over\n\t\n\u0089\nPrematurity and Low birth weight (LBW) <2.5kg\n\t\n\u0089\nObstructed and difficult labours\n\t\n\u0089\nInstrumental delivery\n \n~\nPoor obstetric history, e.g., stillbirths, neonatal deaths, \nabortions, caesarean section\n \n~\nHistory of reproductive tract surgery, e.g., VVF repair, re\u00ad\npaired (ruptured uterus), surgery on the cervix, myomec\u00ad\ntomy\n \n~\nGenetic or familial diseases, such as sickle cell disease\n \n~\nMedical conditions: Diabetes, HIV, cardiac, renal, hyper\u00ad\ntension, rhesus, those with disabilities\n \n~\nObstetrical conditions, e.g. multiple pregnancy, malpresen\u00ad\ntations, APH, PPH, DVT, IUGR,(FGR) , IVF, PROM, post dates, \nCPD, Surrogate Mother",
        "formatted_content": "<p>700</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.1.3 High Risk Pregnancy (HRP)                             ICD10 CODE: O09</p>\n<p>This is a pregnancy with a higher than average risk of an adverse out\u00ad</p>\n<p>come for the mother or baby, e.g., abortion, intrauterine death, still</p>\n<p>birth, prematurity, other morbidity or mortality.</p>\n<p>High risk criteria: if a woman has history of or current</p>\n<p>~</p>\n<p>Extremes of reproductive age: <18 and >35 years</p>\n<p>~</p>\n<p>Primigravida: Especially if too young (<18 years), short</p>\n<p>(<150cm), or old (>35 years)</p>\n<p>~</p>\n<p>High parity: 5+ or short birth-to-pregnancy interval below</p>\n<p>2 years</p>\n<p>~</p>\n<p>Maternal Obesity (BMI >30)</p>\n<p>~</p>\n<p>History of:</p>\n<p>\u0089</p>\n<p>Large infants: 4 kg and over</p>\n<p>\u0089</p>\n<p>Prematurity and Low birth weight (LBW) <2.5kg</p>\n<p>\u0089</p>\n<p>Obstructed and difficult labours</p>\n<p>\u0089</p>\n<p>Instrumental delivery</p>\n<p>~</p>\n<p>Poor obstetric history, e.g., stillbirths, neonatal deaths,</p>\n<p>abortions, caesarean section</p>\n<p>~</p>\n<p>History of reproductive tract surgery, e.g., VVF repair, re\u00ad</p>\n<p>paired (ruptured uterus), surgery on the cervix, myomec\u00ad</p>\n<p>tomy</p>\n<p>~</p>\n<p>Genetic or familial diseases, such as sickle cell disease</p>\n<p>~</p>\n<p>Medical conditions: Diabetes, HIV, cardiac, renal, hyper\u00ad</p>\n<p>tension, rhesus, those with disabilities</p>\n<p>~</p>\n<p>Obstetrical conditions, e.g. multiple pregnancy, malpresen\u00ad</p>\n<p>tations, APH, PPH, DVT, IUGR,(FGR) , IVF, PROM, post dates,</p>\n<p>CPD, Surrogate Mother</p>"
    },
    {
        "page_number": 767,
        "content": "701\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement\nTREATMENT\nLOC\nPrinciples of management\n\t\n\u0089\nEarly identification of high risk pregnant women and \nreferral as appropriate\n\t\n\u0089\nPreconception care and folic acid supplementation\n\t\n\u0089\nProphylaxis and antenatal counselling will prevent \nsome HRPs\n\t\n\u0089\nEarly start of antenatal care\n\t\n\u0089\nClose medical supervision during pregnancy\n\t\n\u0089\nSpecial investigations to evaluate foetal development \nand maternal well-being\n\t\n\u0089\nBirth preparedness plan\n\t\n\u0089\nTimely intervention for therapy and delivery\n\t\n\u0089\nSkilled birth attendance\n\t\n\u0089\nEarly referral to higher level as appropriate\nHC3\nHC4\nNote: Skilled attendance at birth remains the most important com\u00ad\nponent of comprehensive emergency obstetric and new-born care.\n16.2  MANAGEMENT OF SELECTED CONDITIONS IN \nPREGNANCY\n16.2.1     Anaemia in Pregnancy\t\n\t\nICD10 CODE: 099.019\nAnaemia is the most frequent and major complication of pregnancy. \nIt may be defined as haemoglobin level below the normal (11 g/dL for \npregnant women). For second trimester the cut off is 10.5g/dL.",
        "formatted_content": "<p>701</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Principles of management</p>\n<p>\u0089</p>\n<p>Early identification of high risk pregnant women and</p>\n<p>referral as appropriate</p>\n<p>\u0089</p>\n<p>Preconception care and folic acid supplementation</p>\n<p>\u0089</p>\n<p>Prophylaxis and antenatal counselling will prevent</p>\n<p>some HRPs</p>\n<p>\u0089</p>\n<p>Early start of antenatal care</p>\n<p>\u0089</p>\n<p>Close medical supervision during pregnancy</p>\n<p>\u0089</p>\n<p>Special investigations to evaluate foetal development</p>\n<p>and maternal well-being</p>\n<p>\u0089</p>\n<p>Birth preparedness plan</p>\n<p>\u0089</p>\n<p>Timely intervention for therapy and delivery</p>\n<p>\u0089</p>\n<p>Skilled birth attendance</p>\n<p>\u0089</p>\n<p>Early referral to higher level as appropriate</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Note: Skilled attendance at birth remains the most important com\u00ad</p>\n<p>ponent of comprehensive emergency obstetric and new-born care.</p>\n<h3>16.2  MANAGEMENT OF SELECTED CONDITIONS IN</h3>\n<h3>PREGNANCY</h3>\n<p>16.2.1     Anaemia in Pregnancy</p>\n<h3>ICD10 CODE: 099.019</h3>\n<p>Anaemia is the most frequent and major complication of pregnancy.</p>\n<p>It may be defined as haemoglobin level below the normal (11 g/dL for</p>\n<p>pregnant women). For second trimester the cut off is 10.5g/dL.</p>"
    },
    {
        "page_number": 768,
        "content": "702\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCauses\n \n~\nNutritional causes; iron deficiency, folic acid deficiency\n \n~\nInfections and infestations; hookworm infestation, malar\u00ad\nia, UTI, HIV/AIDS\n \n~\nHaemorrhagic causes: bleeding in pregnancy, trauma\n \n~\nHaemoglopathies eg. Sickle cell anaemia, thalassemias\n \n~\nMalignancies \n \n~\nDue to medications from HIV /Cancer treatment\n \n~\nAny other causes\nClinical features\nMother may give history of\n \n~\nGradual onset of exhaustion or weakness\n \n~\nSwelling of the legs\n \n~\nDyspnoea, dizziness, and palpitations\nOn examination\n \n~\nPallor of the conjunctiva, tongue, palm, vagina, etc., of \nvarying degree, depending on the severity of anaemia\n \n~\nGlossitis and stomatitis\n \n~\nOedema of the legs\n \n~\nIn very severe cases: evidence of heart failure such as en\u00ad\ngorged neck veins, dyspnoea, hepatomegally, ascites, gal\u00ad\nlop rhythm, and oedema\nComplications\n \n~\nUntreated anaemia may increase the risk of premature \nlabour, poor intrauterine foetal growth, weak uterine con\u00ad\ntractions, foetal hypoxia, postpartum haemorrhage, poor \nlactation, post-partum sepsis\nInvestigations\n \n\u0081\nBlood\n\t\n\u0089\nHb (<11 g/dL is considered abnormal)\n\t\n\u0089\nPeripheral smear to determine the type of anaemia and presence \nof malaria parasites\n\t\n\u0089\nHB electrophoresis  \n \n\u0081\nStool: ova and cysts of hookworm infestation",
        "formatted_content": "<p>702</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Causes</p>\n<p>~</p>\n<p>Nutritional causes; iron deficiency, folic acid deficiency</p>\n<p>~</p>\n<p>Infections and infestations; hookworm infestation, malar\u00ad</p>\n<p>ia, UTI, HIV/AIDS</p>\n<p>~</p>\n<p>Haemorrhagic causes: bleeding in pregnancy, trauma</p>\n<p>~</p>\n<p>Haemoglopathies eg. Sickle cell anaemia, thalassemias</p>\n<p>~</p>\n<p>Malignancies</p>\n<p>~</p>\n<p>Due to medications from HIV /Cancer treatment</p>\n<p>~</p>\n<p>Any other causes</p>\n<p>Clinical features</p>\n<p>Mother may give history of</p>\n<p>~</p>\n<p>Gradual onset of exhaustion or weakness</p>\n<p>~</p>\n<p>Swelling of the legs</p>\n<p>~</p>\n<p>Dyspnoea, dizziness, and palpitations</p>\n<p>On examination</p>\n<p>~</p>\n<p>Pallor of the conjunctiva, tongue, palm, vagina, etc., of</p>\n<p>varying degree, depending on the severity of anaemia</p>\n<p>~</p>\n<p>Glossitis and stomatitis</p>\n<p>~</p>\n<p>Oedema of the legs</p>\n<p>~</p>\n<p>In very severe cases: evidence of heart failure such as en\u00ad</p>\n<p>gorged neck veins, dyspnoea, hepatomegally, ascites, gal\u00ad</p>\n<p>lop rhythm, and oedema</p>\n<p>Complications</p>\n<p>~</p>\n<p>Untreated anaemia may increase the risk of premature</p>\n<p>labour, poor intrauterine foetal growth, weak uterine con\u00ad</p>\n<p>tractions, foetal hypoxia, postpartum haemorrhage, poor</p>\n<p>lactation, post-partum sepsis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood</p>\n<p>\u0089</p>\n<p>Hb (<11 g/dL is considered abnormal)</p>\n<p>\u0089</p>\n<p>Peripheral smear to determine the type of anaemia and presence</p>\n<p>of malaria parasites</p>\n<p>\u0089</p>\n<p>HB electrophoresis</p>\n<p>\u0081</p>\n<p>Stool: ova and cysts of hookworm infestation</p>"
    },
    {
        "page_number": 769,
        "content": "703\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement\nTREATMENT\nLOC\nProphylaxis\n\t\n\u0089\nAll pregnant women should receive ferrous and folic \nacid daily from 12 weeks. Continue supplementation \nuntil 6months after delivery.\nHC2\nIf severe anaemia(Hb \u22647 g/dL) or patient has heart failure\n\t\n\u0089\nRefer patient to a well-equipped facility for further \nmanagement\nHC4\nIf Hb >7 g/dL\n\t\n\u0089\nGive combination of ferrous and folic acid\n\t\n\u0089\nonce daily(Fe-200mg+400mcg)\n\t\n\u0089\nReview the mother every 2 weeks (Hb should rise by \n0.7-1 g/dL per week)\nHC2\n\t\n\u0089\nEmphasise a realistic balanced diet rich in proteins, \niron, and vitamins, e.g. beans, peas, millet, sorghum, \npeanuts, red meat, liver, dark green vegetables, fortified \nfoods, Bananas.\n\t\n\u0089\nTreat malaria presumptively with SP and follow up\n\t\n\u0089\nDe-worm the patient with mebendazole 500 mg single \ndose in 2nd and 3rd trimesters\n\t\n\u0089\nTreat any other cause as found from investigations\n\t\n\u0089\nAdvise child spacing with an interval of at least 2 years\nIf not improving, refer to hospital\nHC2\nIf mother still anaemic at 36 weeks of gestation, or at time \nof delivery\n\t\n\u0089\nRefer to a well-equipped facility for further management \n(blood transfusion)\nHC4\nIf patient has sickle-cell disease\n\t\n\u0089\nRefer to higher level for ANC and delivery\nHC4",
        "formatted_content": "<p>703</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Prophylaxis</p>\n<p>\u0089</p>\n<p>All pregnant women should receive ferrous and folic</p>\n<p>acid daily from 12 weeks. Continue supplementation</p>\n<p>until 6months after delivery.</p>\n<h3>HC2</h3>\n<p>If severe anaemia(Hb \u22647 g/dL) or patient has heart failure</p>\n<p>\u0089</p>\n<p>Refer patient to a well-equipped facility for further</p>\n<p>management</p>\n<h3>HC4</h3>\n<p>If Hb >7 g/dL</p>\n<p>\u0089</p>\n<p>Give combination of ferrous and folic acid</p>\n<p>\u0089</p>\n<p>once daily(Fe-200mg+400mcg)</p>\n<p>\u0089</p>\n<p>Review the mother every 2 weeks (Hb should rise by</p>\n<p>0.7-1 g/dL per week)</p>\n<h3>HC2</h3>\n<p>\u0089</p>\n<p>Emphasise a realistic balanced diet rich in proteins,</p>\n<p>iron, and vitamins, e.g. beans, peas, millet, sorghum,</p>\n<p>peanuts, red meat, liver, dark green vegetables, fortified</p>\n<p>foods, Bananas.</p>\n<p>\u0089</p>\n<p>Treat malaria presumptively with SP and follow up</p>\n<p>\u0089</p>\n<p>De-worm the patient with mebendazole 500 mg single</p>\n<p>dose in 2nd and 3rd trimesters</p>\n<p>\u0089</p>\n<p>Treat any other cause as found from investigations</p>\n<p>\u0089</p>\n<p>Advise child spacing with an interval of at least 2 years</p>\n<p>If not improving, refer to hospital</p>\n<h3>HC2</h3>\n<p>If mother still anaemic at 36 weeks of gestation, or at time</p>\n<p>of delivery</p>\n<p>\u0089</p>\n<p>Refer to a well-equipped facility for further management</p>\n<p>(blood transfusion)</p>\n<h3>HC4</h3>\n<p>If patient has sickle-cell disease</p>\n<p>\u0089</p>\n<p>Refer to higher level for ANC and delivery</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 770,
        "content": "704\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nPrevention/Health Education / mother selfcare\n \n~\nExplain the possible causes of anaemia\n \n~\nAdvise on nutrition and diet: mother should increase con\u00ad\nsumption of foods rich in iron and vitamins\n \n~\nInstruct patient to use medication as prescribed, and the \ndangers of not complying\n \n~\nAdvise on side effects of iron medicines (e.g. darkened \nstools)\n \n~\nInstruct patient to come every 2 weeks for follow-up\n16.2.2  Pregnancy and HIV Infection\nAll HIV services for pregnant mothers are offered in the MCH clinic. \nAfter delivery, mother and baby will remain in the MCH postnatal clinic \nuntil HIV status of the child is\nconfirmed, then they will be transferred to the general ART clinic.\nAll pregnant mothers and partners should receive routine counselling \nand testing for HIV.\nIf mother tests negative:\n \n~\nCounsel on HIV prevention\n \n~\nRepeat test in third trimester/during labour and delivery\nIf mother tests positive or is already known positive but not yet on ART\n \n~\nEnroll on HIV care (eMTCT).\nIf mother is already positive and already on ART:\n \n~\nContinue on their existing regimen; may not be switched \nto\n \n~\nOption B+ regimens\n \n~\nPerform viral load at first contact",
        "formatted_content": "<p>704</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Prevention/Health Education / mother selfcare</p>\n<p>~</p>\n<p>Explain the possible causes of anaemia</p>\n<p>~</p>\n<p>Advise on nutrition and diet: mother should increase con\u00ad</p>\n<p>sumption of foods rich in iron and vitamins</p>\n<p>~</p>\n<p>Instruct patient to use medication as prescribed, and the</p>\n<p>dangers of not complying</p>\n<p>~</p>\n<p>Advise on side effects of iron medicines (e.g. darkened</p>\n<p>stools)</p>\n<p>~</p>\n<p>Instruct patient to come every 2 weeks for follow-up</p>\n<p>16.2.2  Pregnancy and HIV Infection</p>\n<p>All HIV services for pregnant mothers are offered in the MCH clinic.</p>\n<p>After delivery, mother and baby will remain in the MCH postnatal clinic</p>\n<p>until HIV status of the child is</p>\n<p>confirmed, then they will be transferred to the general ART clinic.</p>\n<p>All pregnant mothers and partners should receive routine counselling</p>\n<p>and testing for HIV.</p>\n<p>If mother tests negative:</p>\n<p>~</p>\n<p>Counsel on HIV prevention</p>\n<p>~</p>\n<p>Repeat test in third trimester/during labour and delivery</p>\n<p>If mother tests positive or is already known positive but not yet on ART</p>\n<p>~</p>\n<p>Enroll on HIV care (eMTCT).</p>\n<p>If mother is already positive and already on ART:</p>\n<p>~</p>\n<p>Continue on their existing regimen; may not be switched</p>\n<p>to</p>\n<p>~</p>\n<p>Option B+ regimens</p>\n<p>~</p>\n<p>Perform viral load at first contact</p>"
    },
    {
        "page_number": 771,
        "content": "705\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nFor more information on HIV, including clinical diagnosis, management, \nand psychosocial support, refer to specific HIV/AIDS guidelines (see \nchapter 3).\n16.2.2.1     Care for HIV Positive Women (eMTCT) \t \t\n    \nICD10 CODE: 098.719\nEnsure the following care is provided during pregnancy, labour, delivery, \nand postpartum period for all HIV+ women\n \n~\nFind out what she has told her partner (degree of disclo\u00ad\nsure), labour companion, and family support. Respect her \nchoice and desired confidentiality\nDuring labour: safe obstetric practices\n \n\u0083 Avoid episiotomy\n \n\u0083 Avoid artifical rupture of membranes\n \n\u0083 Avoid instrumental delivery (vacuum)\n \n\u0083 Avoid frequent vaginal examination\n \n\u0083 Do not milk umbilical cord before cutting\n \n\u0083 Actively manage third stage of labour\nBaby (see section 3.1.9.3)\n\t\n\u0089\nGive infants daily Nevirapine (NVP) for for 6 weeks \n(12 weeks for high risk infants)\n\t\n\u0089\nGive Cotrimoxazole beginning at 6 weeks, continue \nuntil final HIV status is confirmed negative\n \n\u0083 Offer DNA PCR test at 6 weeks, and again 6 \nweeks after cessation of breastfeeding\nHC3\nNotes\n \n\u0083 TDF and EFV are now considered safe in pregnancy\n \n\u0083 Those newly diagnosed during labour will receive\n \n\u0083 sdNVP tablet and begin HAART for life after delivery\nCaution\n \n\u0083 In case of low body weight, high creatinine, diabetes, \nhypertension, chronic renal disease, and concomitant \nnephrotoxic medications: perform renal investigation before \ngiving TDF",
        "formatted_content": "<p>705</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>For more information on HIV, including clinical diagnosis, management,</p>\n<p>and psychosocial support, refer to specific HIV/AIDS guidelines (see</p>\n<p>chapter 3).</p>\n<p>16.2.2.1     Care for HIV Positive Women (eMTCT)</p>\n<h3>ICD10 CODE: 098.719</h3>\n<p>Ensure the following care is provided during pregnancy, labour, delivery,</p>\n<p>and postpartum period for all HIV+ women</p>\n<p>~</p>\n<p>Find out what she has told her partner (degree of disclo\u00ad</p>\n<p>sure), labour companion, and family support. Respect her</p>\n<p>choice and desired confidentiality</p>\n<p>During labour: safe obstetric practices</p>\n<p>\u0083 Avoid episiotomy</p>\n<p>\u0083 Avoid artifical rupture of membranes</p>\n<p>\u0083 Avoid instrumental delivery (vacuum)</p>\n<p>\u0083 Avoid frequent vaginal examination</p>\n<p>\u0083 Do not milk umbilical cord before cutting</p>\n<p>\u0083 Actively manage third stage of labour</p>\n<p>Baby (see section 3.1.9.3)</p>\n<p>\u0089</p>\n<p>Give infants daily Nevirapine (NVP) for for 6 weeks</p>\n<p>(12 weeks for high risk infants)</p>\n<p>\u0089</p>\n<p>Give Cotrimoxazole beginning at 6 weeks, continue</p>\n<p>until final HIV status is confirmed negative</p>\n<p>\u0083 Offer DNA PCR test at 6 weeks, and again 6</p>\n<p>weeks after cessation of breastfeeding</p>\n<h3>HC3</h3>\n<p>Notes</p>\n<p>\u0083 TDF and EFV are now considered safe in pregnancy</p>\n<p>\u0083 Those newly diagnosed during labour will receive</p>\n<p>\u0083 sdNVP tablet and begin HAART for life after delivery</p>\n<p>Caution</p>\n<p>\u0083 In case of low body weight, high creatinine, diabetes,</p>\n<p>hypertension, chronic renal disease, and concomitant</p>\n<p>nephrotoxic medications: perform renal investigation before</p>\n<p>giving TDF</p>"
    },
    {
        "page_number": 772,
        "content": "706\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u0083 TDF is contraindicated in advanced chronic renal disease\nBenefits of Option B +\n \n~\nReduction of new HIV infection in children, by minimizing \nthe risk of HIV transmission from infected pregnant\n \n~\nand lactating women, to less than 5% in breastfeeding \npopulations, and to less than 2% in non-breastfeeding \npopulations\n \n~\nImproved health, and reduced maternal mortality and \nmorbidity of HIV-infected mothers through lifelong ART\n \n~\nReduction of the risk of HIV transmission to non-HIV- in\u00ad\nfected sexual partner in discordant relationship\n \n~\nReduction in the number of HIV/AIDS orphans\n \n~\nContribution to the achievement of the 90/90/90 goals \nby 2020\n \n~\nContributes to achievement of the Sustainable Develop\u00ad\nment Goals by 2030\n16.2.2.2  Counselling for HIV Positive Mothers\n \n~\nGive psychosocial support\n \n~\nEncourage mothers to enroll in Family Support Groups \n(FSG) for peer support\n \n~\nAdvise on the importance of good nutrition\n \n\u0083 Talk to family members to encourage the woman to eat enough \nand help her avoid hard physical work\n \n\u0083 Micronutrient supplementation during pregnancy and\n \n\u0083 breastfeeding; iron + folic acid and multivitamins\n \n~\nAdvise her that she is more liable to infections, and to seek \nmedical help as soon as possible\n \n~\nReview the birth plan\n \n\u0083 Advise her to continue attending ANC\n \n\u0083 Advise her to deliver in a health facility where appropriate care \ncan be provided for her and the baby\n \n\u0083 Advise her to go to the health facility as soon as labour\n \n\u0083 starts or membranes rupture",
        "formatted_content": "<p>706</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u0083 TDF is contraindicated in advanced chronic renal disease</p>\n<p>Benefits of Option B +</p>\n<p>~</p>\n<p>Reduction of new HIV infection in children, by minimizing</p>\n<p>the risk of HIV transmission from infected pregnant</p>\n<p>~</p>\n<p>and lactating women, to less than 5% in breastfeeding</p>\n<p>populations, and to less than 2% in non-breastfeeding</p>\n<p>populations</p>\n<p>~</p>\n<p>Improved health, and reduced maternal mortality and</p>\n<p>morbidity of HIV-infected mothers through lifelong ART</p>\n<p>~</p>\n<p>Reduction of the risk of HIV transmission to non-HIV- in\u00ad</p>\n<p>fected sexual partner in discordant relationship</p>\n<p>~</p>\n<p>Reduction in the number of HIV/AIDS orphans</p>\n<p>~</p>\n<p>Contribution to the achievement of the 90/90/90 goals</p>\n<p>by 2020</p>\n<p>~</p>\n<p>Contributes to achievement of the Sustainable Develop\u00ad</p>\n<p>ment Goals by 2030</p>\n<p>16.2.2.2  Counselling for HIV Positive Mothers</p>\n<p>~</p>\n<p>Give psychosocial support</p>\n<p>~</p>\n<p>Encourage mothers to enroll in Family Support Groups</p>\n<p>(FSG) for peer support</p>\n<p>~</p>\n<p>Advise on the importance of good nutrition</p>\n<p>\u0083 Talk to family members to encourage the woman to eat enough</p>\n<p>and help her avoid hard physical work</p>\n<p>\u0083 Micronutrient supplementation during pregnancy and</p>\n<p>\u0083 breastfeeding; iron + folic acid and multivitamins</p>\n<p>~</p>\n<p>Advise her that she is more liable to infections, and to seek</p>\n<p>medical help as soon as possible</p>\n<p>~</p>\n<p>Review the birth plan</p>\n<p>\u0083 Advise her to continue attending ANC</p>\n<p>\u0083 Advise her to deliver in a health facility where appropriate care</p>\n<p>can be provided for her and the baby</p>\n<p>\u0083 Advise her to go to the health facility as soon as labour</p>\n<p>\u0083 starts or membranes rupture</p>"
    },
    {
        "page_number": 773,
        "content": "707\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nDuring postpartum period\n \n~\nAdvise on the infectiousness of lochia and blood- stained \nsanitary pads, and how to dispose them off safely accord\u00ad\ning to local facilities\n \n~\nIf not breastfeeding exclusively, advise her to use a family \nplanning method immediately to prevent unwanted preg\u00ad\nnancy\n \n~\nLinkage of mother-baby pair and her family, for on-going \ncare beyond peurperium\n \n~\nBreast care: If not breastfeeding, advise that:\n\t\n\u0089\nThe breasts may be uncomfortable for a while\n\t\n\u0089\nShe should avoid expressing the breast to remove milk (the more \nyou remove the more it forms)\n\t\n\u0089\nShe should support her breasts with a firm, well-fitting\n\t\n\u0089\nbra or cloth, and give her paracetamol for painful breasts\n\t\n\u0089\nAdvise her to seek care if breasts become painful,\n\t\n\u0089\nswollen, red; if she feels ill; or has fever\nCounselling on infant feeding choice\n \n~\nBegin infant feeding counselling before birth when the \npregnant mother has been identified to be HIV positive.\n \n~\nThe decision on how she will feed the baby should be \nmade before delivery. The mother should then be support\u00ad\ned to implement the feeding option she has chosen\n \n~\nAll mothers are encouraged to breastfeed their babies ex\u00ad\nclusively for 6 months and then introduce complimentary \nfeeding until 1 year\n \n~\nThe mother has to continue her ARVs all through breast\u00ad\nfeeding\n \n~\nThe child should continue cotrimoxazole prophylaxis, un\u00ad\ntil status confirmed negative with a PCR at 6 weeks after \nstopping breastfeeding",
        "formatted_content": "<p>707</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>During postpartum period</p>\n<p>~</p>\n<p>Advise on the infectiousness of lochia and blood- stained</p>\n<p>sanitary pads, and how to dispose them off safely accord\u00ad</p>\n<p>ing to local facilities</p>\n<p>~</p>\n<p>If not breastfeeding exclusively, advise her to use a family</p>\n<p>planning method immediately to prevent unwanted preg\u00ad</p>\n<p>nancy</p>\n<p>~</p>\n<p>Linkage of mother-baby pair and her family, for on-going</p>\n<p>care beyond peurperium</p>\n<p>~</p>\n<p>Breast care: If not breastfeeding, advise that:</p>\n<p>\u0089</p>\n<p>The breasts may be uncomfortable for a while</p>\n<p>\u0089</p>\n<p>She should avoid expressing the breast to remove milk (the more</p>\n<p>you remove the more it forms)</p>\n<p>\u0089</p>\n<p>She should support her breasts with a firm, well-fitting</p>\n<p>\u0089</p>\n<p>bra or cloth, and give her paracetamol for painful breasts</p>\n<p>\u0089</p>\n<p>Advise her to seek care if breasts become painful,</p>\n<p>\u0089</p>\n<p>swollen, red; if she feels ill; or has fever</p>\n<p>Counselling on infant feeding choice</p>\n<p>~</p>\n<p>Begin infant feeding counselling before birth when the</p>\n<p>pregnant mother has been identified to be HIV positive.</p>\n<p>~</p>\n<p>The decision on how she will feed the baby should be</p>\n<p>made before delivery. The mother should then be support\u00ad</p>\n<p>ed to implement the feeding option she has chosen</p>\n<p>~</p>\n<p>All mothers are encouraged to breastfeed their babies ex\u00ad</p>\n<p>clusively for 6 months and then introduce complimentary</p>\n<p>feeding until 1 year</p>\n<p>~</p>\n<p>The mother has to continue her ARVs all through breast\u00ad</p>\n<p>feeding</p>\n<p>~</p>\n<p>The child should continue cotrimoxazole prophylaxis, un\u00ad</p>\n<p>til status confirmed negative with a PCR at 6 weeks after</p>\n<p>stopping breastfeeding</p>"
    },
    {
        "page_number": 774,
        "content": "708\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n~\nIf a mother chooses to feed the newborn on replacement \nfeeding from the beginning, the choice of replacement \nfeeds should fulfil the AFASS Criteria (Affordable, Feasi\u00ad\nble, Available, Sustainable and Safe).\n16.2.3    Chronic Hypertension in Pregnancy\t\n                          \nICD 10 CODE: O10, O13\nBlood pressure >140/90 present before the pregnancy or starting \nbefore 20 weeks.\nPregnant women with chronic hypertension should continue to follow \nthe lifestyle modifications for controlling hypertension such as:\n \n~\nNo alcohol\n \n~\nRegular moderate exercise, brisk walking for 30 minutes at \nleast 3 times a week\n \n~\nSmoking cessation.\nHealth worker should:\n \n~\nAsk mother about foetal movements at each visit\n \n~\nAim for BP <140/90 mmHg\n \n~\nConsider labour if BP is persistently \u00b3160/90 mmHg, \npregnancy \u00b337 weeks gestation, and if there is maternal or \nfoetal compromise, e.g. poor SFH growth\nManagement\nTREATMENT\nLOC\nSwitch chronic antihypertensive medication to or start\n\t\n\u0089\nMethyldopa 250 mg 8 hourly, increase as necessary, \nmax 500 mg 6 hourly\nAnd/or\n\t\n\u0089\nNifedipine 20-40 mg every 12 hours\nIf not controlled or any sign of pre eclampsia: refer to hospital\nHC3",
        "formatted_content": "<p>708</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>~</p>\n<p>If a mother chooses to feed the newborn on replacement</p>\n<p>feeding from the beginning, the choice of replacement</p>\n<p>feeds should fulfil the AFASS Criteria (Affordable, Feasi\u00ad</p>\n<p>ble, Available, Sustainable and Safe).</p>\n<p>16.2.3    Chronic Hypertension in Pregnancy</p>\n<h3>ICD 10 CODE: O10, O13</h3>\n<p>Blood pressure >140/90 present before the pregnancy or starting</p>\n<p>before 20 weeks.</p>\n<p>Pregnant women with chronic hypertension should continue to follow</p>\n<p>the lifestyle modifications for controlling hypertension such as:</p>\n<p>~</p>\n<p>No alcohol</p>\n<p>~</p>\n<p>Regular moderate exercise, brisk walking for 30 minutes at</p>\n<p>least 3 times a week</p>\n<p>~</p>\n<p>Smoking cessation.</p>\n<p>Health worker should:</p>\n<p>~</p>\n<p>Ask mother about foetal movements at each visit</p>\n<p>~</p>\n<p>Aim for BP <140/90 mmHg</p>\n<p>~</p>\n<p>Consider labour if BP is persistently \u00b3160/90 mmHg,</p>\n<p>pregnancy \u00b337 weeks gestation, and if there is maternal or</p>\n<p>foetal compromise, e.g. poor SFH growth</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Switch chronic antihypertensive medication to or start</p>\n<p>\u0089</p>\n<p>Methyldopa 250 mg 8 hourly, increase as necessary,</p>\n<p>max 500 mg 6 hourly</p>\n<p>And/or</p>\n<p>\u0089</p>\n<p>Nifedipine 20-40 mg every 12 hours</p>\n<p>If not controlled or any sign of pre eclampsia: refer to hospital</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 775,
        "content": "709\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nCaution\n \n\u0083 ACE inhibitors, ARBs are contraindicated in \npregnancy\n \n\u0083 Avoid beta blockers and diuretics\n16.2.4   Malaria in Pregnancy \t\n            ICD10 CODE: B54\nMalaria can contribute to pregnancy complications such as abortion, \npoor foetal mental development, premature labour, intrauterine growth \nretardation and foetal death, severe maternal anaemia due to haemol\u00ad\nysis, and death.\nComplications are more common in mothers of low gravidity (primi- and \nsecundigravidae), HIV positivity, adolescent age, sickle-cell disease, and \nthose from areas of low endemicity,e.g. in Kisoro and Kabale.\n. see section 2.5.2 for more information on features and diagnosis of \nmalaria\nManagement of Malaria in Pregnancy\nAPPROACH\nMANAGEMENT\nLOC\nProphylaxis All \npregnant mothers \nWexcept those \nwith HIV on \ncotrimoxazole \nprophylaxis\n\t\n\u0089\nIntermittent Preventive Treatment \n(IPTp) with Sulphadoxine/ pyrimeth\u00ad\namine (SP) once a month starting \nat 13 weeks until delivery\nHC2\nTreatment of \nUncomplicated \nmalaria in 1st \ntrimester\n\t\n\u0089\nQuinine oral 600 mg 8 hourly for 7 \ndays (if Quinine not available, ACT \nmay be used)\nHC2",
        "formatted_content": "<p>709</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Caution</p>\n<p>\u0083 ACE inhibitors, ARBs are contraindicated in</p>\n<p>pregnancy</p>\n<p>\u0083 Avoid beta blockers and diuretics</p>\n<p>16.2.4   Malaria in Pregnancy</p>\n<h3>ICD10 CODE: B54</h3>\n<p>Malaria can contribute to pregnancy complications such as abortion,</p>\n<p>poor foetal mental development, premature labour, intrauterine growth</p>\n<p>retardation and foetal death, severe maternal anaemia due to haemol\u00ad</p>\n<p>ysis, and death.</p>\n<p>Complications are more common in mothers of low gravidity (primi- and</p>\n<p>secundigravidae), HIV positivity, adolescent age, sickle-cell disease, and</p>\n<p>those from areas of low endemicity,e.g. in Kisoro and Kabale.</p>\n<p>. see section 2.5.2 for more information on features and diagnosis of</p>\n<p>malaria</p>\n<p>Management of Malaria in Pregnancy</p>\n<h3>APPROACH</h3>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>Prophylaxis All</p>\n<p>pregnant mothers</p>\n<p>Wexcept those</p>\n<p>with HIV on</p>\n<p>cotrimoxazole</p>\n<p>prophylaxis</p>\n<p>\u0089</p>\n<p>Intermittent Preventive Treatment</p>\n<p>(IPTp) with Sulphadoxine/ pyrimeth\u00ad</p>\n<p>amine (SP) once a month starting</p>\n<p>at 13 weeks until delivery</p>\n<h3>HC2</h3>\n<p>Treatment of</p>\n<p>Uncomplicated</p>\n<p>malaria in 1st</p>\n<p>trimester</p>\n<p>\u0089</p>\n<p>Quinine oral 600 mg 8 hourly for 7</p>\n<p>days (if Quinine not available, ACT</p>\n<p>may be used)</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 776,
        "content": "710\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nAPPROACH\nMANAGEMENT\nLOC\nTreatment of \nUncomplicated \nmalaria in\n2nd and 3rd \ntrimesters\nFirst line\n\t\n\u0089\nArtemether/Lumefantrine\n\t\n\u0089\n80/480 mg 12 hourly for 3 days\nFirst line alternative\n\t\n\u0089\nDihydroartemisinin/ Piperaquine \n3 tablets (1080 mg) once daily for \n3 days\nAnd if no response\n\t\n\u0089\nQuinine, oral 600 mg 8 hourly for \n7 days\nHC2\nHC4\nHC3\nSevere malaria \nAll trimesters and \nlactation\n\t\n\u0089\nIM/IV Artesunate 2.4 mg/kg at \n0, 12 and 24 hours, then once a \nday until mother can tolerate oral \nmedication. Complete treatment \nwith 3 days of oral ACT\nFirst line alternative\n\t\n\u0089\nIM artemether 3.2 mg/kg loading \ndose then 1.6 mg/ Kg once daily \nuntil mother can tolerate oral med\u00ad\nication. Complete treatment with 3 \ndays of oral ACT\nIf artesunate or arthemeter not availa\u00ad\nble, use\n\t\n\u0089\nQuinine 10 mg/Kg IV every 8 hours \nin Dextrose 5%\nHC3\nHC3\nCaution\n \n\u0083 Quinine is associated with an increased risk of hypoglycaemia \nin late pregnancy\nPrevention and control of malaria in pregnancy\n \n~\nUse insecticide-treated mosquito nets (ITN) before, during, \nand after pregnancy.",
        "formatted_content": "<p>710</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>APPROACH</h3>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>Treatment of</p>\n<p>Uncomplicated</p>\n<p>malaria in</p>\n<p>2nd and 3rd</p>\n<p>trimesters</p>\n<p>First line</p>\n<p>\u0089</p>\n<p>Artemether/Lumefantrine</p>\n<p>\u0089</p>\n<p>80/480 mg 12 hourly for 3 days</p>\n<p>First line alternative</p>\n<p>\u0089</p>\n<p>Dihydroartemisinin/ Piperaquine</p>\n<p>3 tablets (1080 mg) once daily for</p>\n<p>3 days</p>\n<p>And if no response</p>\n<p>\u0089</p>\n<p>Quinine, oral 600 mg 8 hourly for</p>\n<p>7 days</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>Severe malaria</p>\n<p>All trimesters and</p>\n<p>lactation</p>\n<p>\u0089</p>\n<p>IM/IV Artesunate 2.4 mg/kg at</p>\n<p>0, 12 and 24 hours, then once a</p>\n<p>day until mother can tolerate oral</p>\n<p>medication. Complete treatment</p>\n<p>with 3 days of oral ACT</p>\n<p>First line alternative</p>\n<p>\u0089</p>\n<p>IM artemether 3.2 mg/kg loading</p>\n<p>dose then 1.6 mg/ Kg once daily</p>\n<p>until mother can tolerate oral med\u00ad</p>\n<p>ication. Complete treatment with 3</p>\n<p>days of oral ACT</p>\n<p>If artesunate or arthemeter not availa\u00ad</p>\n<p>ble, use</p>\n<p>\u0089</p>\n<p>Quinine 10 mg/Kg IV every 8 hours</p>\n<p>in Dextrose 5%</p>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<p>Caution</p>\n<p>\u0083 Quinine is associated with an increased risk of hypoglycaemia</p>\n<p>in late pregnancy</p>\n<p>Prevention and control of malaria in pregnancy</p>\n<p>~</p>\n<p>Use insecticide-treated mosquito nets (ITN) before, during,</p>\n<p>and after pregnancy.</p>"
    },
    {
        "page_number": 777,
        "content": "711\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n~\nGive all pregnant women intermittent preventive treat\u00ad\nment (IPTp) with sulfadoxine pyrimethamine (SP) \u2013 Except \nin allergy to sulphonamide\n \n~\nPrompt diagnosis and effective treatment of malaria in \npregnancy\nEducation messages to mothers and the community\n \n~\nMalaria is transmitted by female anopheles mosquitoes\n \n~\nPregnant women and children are at particular risk of ma\u00ad\nlaria\n \n~\nIf untreated, malaria can cause severe anaemia and death \nin pregnant women\n \n~\nMalaria can lead to anaemia, miscarriage, stillbirth, men\u00ad\ntally-retarded children, or low birth weight children, who \nare more prone to infant/childhood mortality compared \nto normal weight children\n \n~\nIt is better and cheaper to prevent than to treat malaria\n \n~\nThe individual, family, and the community can control ma\u00ad\nlaria by taking appropriate actions\n \n~\nSleeping under an insecticide-treated mosquito netis the \nbest way to prevent malaria\n \n~\nIt is very important to complete the course of treatment in \norder to achieve a cure\n \n~\nSevere complicated malaria needs special management, \ntherefore refer\n16.2.5  Diabetes in Pregnancy\t\n                 ICD10 CODE: O24\nDiabetes can be pre-existent or presenting during pregnancy: the latter \nis called gestational diabetes (GDM).\nRisk factors (and indication for screening)\n \n~\nBMI >35 kg/m2\n \n~\nAge >40 years",
        "formatted_content": "<p>711</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>~</p>\n<p>Give all pregnant women intermittent preventive treat\u00ad</p>\n<p>ment (IPTp) with sulfadoxine pyrimethamine (SP) \u2013 Except</p>\n<p>in allergy to sulphonamide</p>\n<p>~</p>\n<p>Prompt diagnosis and effective treatment of malaria in</p>\n<p>pregnancy</p>\n<p>Education messages to mothers and the community</p>\n<p>~</p>\n<p>Malaria is transmitted by female anopheles mosquitoes</p>\n<p>~</p>\n<p>Pregnant women and children are at particular risk of ma\u00ad</p>\n<p>laria</p>\n<p>~</p>\n<p>If untreated, malaria can cause severe anaemia and death</p>\n<p>in pregnant women</p>\n<p>~</p>\n<p>Malaria can lead to anaemia, miscarriage, stillbirth, men\u00ad</p>\n<p>tally-retarded children, or low birth weight children, who</p>\n<p>are more prone to infant/childhood mortality compared</p>\n<p>to normal weight children</p>\n<p>~</p>\n<p>It is better and cheaper to prevent than to treat malaria</p>\n<p>~</p>\n<p>The individual, family, and the community can control ma\u00ad</p>\n<p>laria by taking appropriate actions</p>\n<p>~</p>\n<p>Sleeping under an insecticide-treated mosquito netis the</p>\n<p>best way to prevent malaria</p>\n<p>~</p>\n<p>It is very important to complete the course of treatment in</p>\n<p>order to achieve a cure</p>\n<p>~</p>\n<p>Severe complicated malaria needs special management,</p>\n<p>therefore refer</p>\n<p>16.2.5  Diabetes in Pregnancy</p>\n<h3>ICD10 CODE: O24</h3>\n<p>Diabetes can be pre-existent or presenting during pregnancy: the latter</p>\n<p>is called gestational diabetes (GDM).</p>\n<p>Risk factors (and indication for screening)</p>\n<p>~</p>\n<p>BMI >35 kg/m2</p>\n<p>~</p>\n<p>Age >40 years</p>"
    },
    {
        "page_number": 778,
        "content": "712\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n~\nGDM in previous pregnancy\n \n~\nFamily history (8 first degree relatives) of diabetes\n \n~\nPrevious unexplained third trimester death, macrosomic \nbaby (weight >4 kg)\n \n~\nPolyhydramnios\n \n~\nGlycosuria\n \n~\nFoetus large for gestational age\nDiagnostic criteria for gestational diabetes\n \n\u0081\nFasting blood sugar >5.6 mmol/L or\n \n\u0081\nPlasma glucose >7.8 mmol/L 2 hours after 75 g glucose tol\u00ad\nerance test\nTherapeutic targets\n \n~\nPre prandial blood glucose <5.3 mmol/L\n \n~\n1-hour postprandial glucose <7.8 mmol/L\n \n~\n2-hour postprandial glucose <6.4 mmol/L\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nStop smoking, moderate exercise, dietary advice (see \nsection 19.1.3)\nIf obese and mild diabetes consider\n\t\n\u0089\nMetformin 500 mg (start with one tablet a day, increase \nby 500 mg per week up to max 2 g per day in divided \ndoses)\nHC3\nIf not controlled:\n\t\n\u0089\nInsulin (see section 8.1.3)\nHC4\nNote\n \n\u0083 Mothers with diabetes should be advised to deliver in hospital",
        "formatted_content": "<p>712</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>~</p>\n<p>GDM in previous pregnancy</p>\n<p>~</p>\n<p>Family history (8 first degree relatives) of diabetes</p>\n<p>~</p>\n<p>Previous unexplained third trimester death, macrosomic</p>\n<p>baby (weight >4 kg)</p>\n<p>~</p>\n<p>Polyhydramnios</p>\n<p>~</p>\n<p>Glycosuria</p>\n<p>~</p>\n<p>Foetus large for gestational age</p>\n<p>Diagnostic criteria for gestational diabetes</p>\n<p>\u0081</p>\n<p>Fasting blood sugar >5.6 mmol/L or</p>\n<p>\u0081</p>\n<p>Plasma glucose >7.8 mmol/L 2 hours after 75 g glucose tol\u00ad</p>\n<p>erance test</p>\n<p>Therapeutic targets</p>\n<p>~</p>\n<p>Pre prandial blood glucose <5.3 mmol/L</p>\n<p>~</p>\n<p>1-hour postprandial glucose <7.8 mmol/L</p>\n<p>~</p>\n<p>2-hour postprandial glucose <6.4 mmol/L</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stop smoking, moderate exercise, dietary advice (see</p>\n<p>section 19.1.3)</p>\n<p>If obese and mild diabetes consider</p>\n<p>\u0089</p>\n<p>Metformin 500 mg (start with one tablet a day, increase</p>\n<p>by 500 mg per week up to max 2 g per day in divided</p>\n<p>doses)</p>\n<h3>HC3</h3>\n<p>If not controlled:</p>\n<p>\u0089</p>\n<p>Insulin (see section 8.1.3)</p>\n<h3>HC4</h3>\n<p>Note</p>\n<p>\u0083 Mothers with diabetes should be advised to deliver in hospital</p>"
    },
    {
        "page_number": 779,
        "content": "713\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.2.6      Urinary Tract Infections in Pregnancy                              \nICD10 CODE: O23\nUrinary tract infections are common in pregnancy, and maybe associated \nwith adverse consequences.\nClinical features\nUncomplicated cystitis\n \n\u008d\nLow abdominal pain\n \n\u008d\nFrequency and urgency of micturition\n \n\u008d\nDysuria (pain at micturition)\nPyelonephritis\n \n\u008d\nFever\n \n\u008d\nRenal angle tenderness\n \n\u008d\nVomiting, tachycardia\nInvestigations\n \n\u0081\nUrine dipstick (for nitrate and/or leucocytes, also protein and \nblood may be present)\n \n\u0081\nFull blood count (raised in pyelonephritis)\nManagement\nTREATMENT\nLOC\nFor cystitis\n\t\n\u0089\nEncourage increased oral fluid intake\n\t\n\u0089\nNitrofurantoin 100 mg twice a day for 5 days (avoid in \n1st trimester and at term)\n\t\n\u0089\nOr Amoxicillin 500 mg every 8 hours for 5 days\nHC2",
        "formatted_content": "<p>713</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.2.6      Urinary Tract Infections in Pregnancy</p>\n<h3>ICD10 CODE: O23</h3>\n<p>Urinary tract infections are common in pregnancy, and maybe associated</p>\n<p>with adverse consequences.</p>\n<p>Clinical features</p>\n<p>Uncomplicated cystitis</p>\n<p>\u008d</p>\n<p>Low abdominal pain</p>\n<p>\u008d</p>\n<p>Frequency and urgency of micturition</p>\n<p>\u008d</p>\n<p>Dysuria (pain at micturition)</p>\n<p>Pyelonephritis</p>\n<p>\u008d</p>\n<p>Fever</p>\n<p>\u008d</p>\n<p>Renal angle tenderness</p>\n<p>\u008d</p>\n<p>Vomiting, tachycardia</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine dipstick (for nitrate and/or leucocytes, also protein and</p>\n<p>blood may be present)</p>\n<p>\u0081</p>\n<p>Full blood count (raised in pyelonephritis)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>For cystitis</p>\n<p>\u0089</p>\n<p>Encourage increased oral fluid intake</p>\n<p>\u0089</p>\n<p>Nitrofurantoin 100 mg twice a day for 5 days (avoid in</p>\n<p>1st trimester and at term)</p>\n<p>\u0089</p>\n<p>Or Amoxicillin 500 mg every 8 hours for 5 days</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 780,
        "content": "714\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nFor pyelonephritis\n\t\n\u0089\nAdmit and hydrate\n\t\n\u0089\nCeftriaxone 1 g IV daily for 48 hours or until fever \nsubsides, then switch to\n\t\n\u0089\nCefixime 200 mg every 12 hours for 10 days\nHC4 \nH\nIf ceftriaxone not available\n\t\n\u0089\nAmpicillin 500 mg IV every 6 hours + gentamicin 5-7 \nmg/kg in 2-3 divided doses IM (max 80 mg/dose) for \n10-14 days\nHC3\n16.3  ANTENATAL  COMPLICATIONS\n16.3.1  Hyperemesis Gravidarum                              ICD10 CODE: O21\nExcessive vomiting during pregnancy, associated with ketosis, dehydra\u00ad\ntion and weight loss (>5% of pre-pregnancy weight).\nCause\nNot known but may be common in multiple and molar pregnancy\nClinical features\n \n\u008d\nMay occur from the 4th week of pregnancy and can continu \nbeyond the 12th week\n \n\u008d\nDefining symptoms are nausea and vomiting so severe that \noral intake is compromised\n \n\u008d\nPatient may develop complications of excessive vomiting, \nsuch as vomiting blood and dehydration\nDifferential diagnosis\n \n\u008d\nIntestinal obstruction\n \n\u008d\nOther causes of vomiting",
        "formatted_content": "<p>714</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>For pyelonephritis</p>\n<p>\u0089</p>\n<p>Admit and hydrate</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV daily for 48 hours or until fever</p>\n<p>subsides, then switch to</p>\n<p>\u0089</p>\n<p>Cefixime 200 mg every 12 hours for 10 days</p>\n<h3>HC4</h3>\n<p>H</p>\n<p>If ceftriaxone not available</p>\n<p>\u0089</p>\n<p>Ampicillin 500 mg IV every 6 hours + gentamicin 5-7</p>\n<p>mg/kg in 2-3 divided doses IM (max 80 mg/dose) for</p>\n<p>10-14 days</p>\n<h3>HC3</h3>\n<h3>16.3  ANTENATAL  COMPLICATIONS</h3>\n<p>16.3.1  Hyperemesis Gravidarum                              ICD10 CODE: O21</p>\n<p>Excessive vomiting during pregnancy, associated with ketosis, dehydra\u00ad</p>\n<p>tion and weight loss (>5% of pre-pregnancy weight).</p>\n<p>Cause</p>\n<p>Not known but may be common in multiple and molar pregnancy</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>May occur from the 4th week of pregnancy and can continu</p>\n<p>beyond the 12th week</p>\n<p>\u008d</p>\n<p>Defining symptoms are nausea and vomiting so severe that</p>\n<p>oral intake is compromised</p>\n<p>\u008d</p>\n<p>Patient may develop complications of excessive vomiting,</p>\n<p>such as vomiting blood and dehydration</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Intestinal obstruction</p>\n<p>\u008d</p>\n<p>Other causes of vomiting</p>"
    },
    {
        "page_number": 781,
        "content": "715\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nMolar pregnancy\nInvestigations\n \n\u0081\nBlood: complete count, RDT for malaria parasites\n \n\u0081\nUrinalysis: to exclude urinary tract infection\n \n\u0081\nUltrasound scan: to detect molar or multiple pregnancies\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIV fluids to correct dehydration (see section 1.1.3) \nand ketosis (give Ringer\u2019s lactate or Normal saline and \nGlucose 5%)\n\t\n\u0089\nPromethazine 25 mg IM or orally every 8 hours prn\n\t\n\u0089\nVitamin B6 (Pyridoxine) 1 tablet every 12 hours for 7 days\n\t\n\u0089\nOr Metoclopramide 10 mg IM or IV or orally every 6-8 \nhours prn and\nIf not responding to the above\n\t\n\u0089\nChlorpromazine 25 mg IM or orally every 6 hours prn \nand refer\nHC3\nHC4\nHC3\n16.3.2     Vaginal Bleeding in Early Pregnancy/ Abortion\t\n    \nICD10 CODE: O20\nThis is almost always abnormal, and patients may need to be admitted \nor referred. The most common causes of bleeding in the first six months \n(<26 weeks gestation) are abortion and ectopic pregnancy\nAbortion (miscarriage) occurs when the foetus is lost before 28 weeks \nof pregnancy.",
        "formatted_content": "<p>715</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>Molar pregnancy</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: complete count, RDT for malaria parasites</p>\n<p>\u0081</p>\n<p>Urinalysis: to exclude urinary tract infection</p>\n<p>\u0081</p>\n<p>Ultrasound scan: to detect molar or multiple pregnancies</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>IV fluids to correct dehydration (see section 1.1.3)</p>\n<p>and ketosis (give Ringer\u2019s lactate or Normal saline and</p>\n<p>Glucose 5%)</p>\n<p>\u0089</p>\n<p>Promethazine 25 mg IM or orally every 8 hours prn</p>\n<p>\u0089</p>\n<p>Vitamin B6 (Pyridoxine) 1 tablet every 12 hours for 7 days</p>\n<p>\u0089</p>\n<p>Or Metoclopramide 10 mg IM or IV or orally every 6-8</p>\n<p>hours prn and</p>\n<p>If not responding to the above</p>\n<p>\u0089</p>\n<p>Chlorpromazine 25 mg IM or orally every 6 hours prn</p>\n<p>and refer</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>16.3.2     Vaginal Bleeding in Early Pregnancy/ Abortion</p>\n<h3>ICD10 CODE: O20</h3>\n<p>This is almost always abnormal, and patients may need to be admitted</p>\n<p>or referred. The most common causes of bleeding in the first six months</p>\n<p>(<26 weeks gestation) are abortion and ectopic pregnancy</p>\n<p>Abortion (miscarriage) occurs when the foetus is lost before 28 weeks</p>\n<p>of pregnancy.</p>"
    },
    {
        "page_number": 782,
        "content": "716\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCause\n \n\u008d\nNot known in the majority of patients\n \n\u008d\nMay be intentional (induced abortion)\n \n\u008d\nMay be spontaneous (often as a result of fever)\n \n\u008d\nIf mother has more than 2 miscarriages, refer for assessment\nDifferential diagnosis\n \n\u008d\nPregnancy outside the uterus (ectopic pregnancy)\n \n\u008d\nOther causes of bleeding from the vagina, e.g. cancer\n \n\u008d\nOther causes of lower abdominal pain, e.g. PID\nInvestigations\n \n\u0081\nUrine: Pregnancy test\n \n\u0081\nUltrasound\n \n\u0081\nBlood: Complete count\nClinical features, terminology and management\n \n\u008d\nDepend on the stage of the abortion See table below.\nFEATURES\nMANAGEMENT\nLOC\nThreatened \nabortion\nLittle vaginal \nbleeding\nNo or moderate \nlower abdominal \npain\nUterus is of \nexpected size by \ndate\nCervix is closed\nPregnancy may \nstill continue\n\t\n\u0089\nMedical treatment is usually not \nnecessary (hormones and tocolyt\u00ad\nics will not prevent a miscarriage)\n\t\n\u0089\nObserve for 4-6 hours\n\t\n\u0089\nParacetamol 1 g every 6-8 hours \nprn for 5 days\n\t\n\u0089\nIf bleeding stops:\n\t\n\u0089\nAvoid strenuous activity and ab\u00ad\nstain from sex for at least 14 days\n\t\n\u0089\nFollow up in 2 days in ANC clinic\nIf bleeding persists, refer to HC3\nHC2",
        "formatted_content": "<p>716</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Cause</p>\n<p>\u008d</p>\n<p>Not known in the majority of patients</p>\n<p>\u008d</p>\n<p>May be intentional (induced abortion)</p>\n<p>\u008d</p>\n<p>May be spontaneous (often as a result of fever)</p>\n<p>\u008d</p>\n<p>If mother has more than 2 miscarriages, refer for assessment</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Pregnancy outside the uterus (ectopic pregnancy)</p>\n<p>\u008d</p>\n<p>Other causes of bleeding from the vagina, e.g. cancer</p>\n<p>\u008d</p>\n<p>Other causes of lower abdominal pain, e.g. PID</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine: Pregnancy test</p>\n<p>\u0081</p>\n<p>Ultrasound</p>\n<p>\u0081</p>\n<p>Blood: Complete count</p>\n<p>Clinical features, terminology and management</p>\n<p>\u008d</p>\n<p>Depend on the stage of the abortion See table below.</p>\n<h3>FEATURES</h3>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>Threatened</p>\n<p>abortion</p>\n<p>Little vaginal</p>\n<p>bleeding</p>\n<p>No or moderate</p>\n<p>lower abdominal</p>\n<p>pain</p>\n<p>Uterus is of</p>\n<p>expected size by</p>\n<p>date</p>\n<p>Cervix is closed</p>\n<p>Pregnancy may</p>\n<p>still continue</p>\n<p>\u0089</p>\n<p>Medical treatment is usually not</p>\n<p>necessary (hormones and tocolyt\u00ad</p>\n<p>ics will not prevent a miscarriage)</p>\n<p>\u0089</p>\n<p>Observe for 4-6 hours</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 6-8 hours</p>\n<p>prn for 5 days</p>\n<p>\u0089</p>\n<p>If bleeding stops:</p>\n<p>\u0089</p>\n<p>Avoid strenuous activity and ab\u00ad</p>\n<p>stain from sex for at least 14 days</p>\n<p>\u0089</p>\n<p>Follow up in 2 days in ANC clinic</p>\n<p>If bleeding persists, refer to HC3</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 783,
        "content": "717\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nFEATURES\nMANAGEMENT\nLOC\nInevitable abortion\nProcess irreversible\nProducts of \nconception not yet \nexpelled but painful \ncontractions (pain \nsimilar to labour \npains) and bleeding\nCervix proceeds to \nopen\n\t\n\u0089\nBed rest\n\t\n\u0089\nIf there are signs of infection, \ngive antibiotics\n\t\n\u0089\nObserve for continued bleeding\n\t\n\u0089\nIf patient in shock\n\t\n\u0089\nResuscitate with IV fluids (Nor\u00ad\nmal Saline)\n\t\n\u0089\nIf anaemic\n\t\n\u0089\nRefer to HC4 for replacement \nof blood lost\n\t\n\u0089\nEstablish IV access before re\u00ad\nferral\n\t\n\u0089\nGive stat dose of antibiotics \nbefore referral\nHC3\nHC4\nIncomplete \nabortion\nUterine contents \nnot completely \npassed out\nBleeding \nsometimes with \nclots from\nthe vagina (may be \nsevere) or\nSevere lower \nabdominal cramps\nCervix open\nProducts of \nconception (POC) \nmay be felt in the \ncervical canal\nIf evacuation of uterus is not imme\u00ad\ndiately possible \n\t\n\u0089\nGive oral misoprostol 600 mi\u00ad\ncrogram sublingual stat (repeat \nonce after 4 hours if necessary)\n\t\n\u0089\nIf at HC2, refer to HC3 after \nmisoprostol\n\t\n\u0089\nUse fingers to remove POC \nprotruding through the cervix \nEvacuate the uterus by Manual \nVacuum\n\t\n\u0089\nAspiration (if pregnancy\n\t\n\u0089\n<16 weeks) or Dilation and \nCurettage\n\t\n\u0089\nEnsure follow up\n\t\n\u0089\nGive stat dose of antibiotics \nbefore referral\n\t\n\u0089\nTreat anaemia\nHC2\nHC3\nHC4",
        "formatted_content": "<p>717</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>FEATURES</h3>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>Inevitable abortion</p>\n<p>Process irreversible</p>\n<p>Products of</p>\n<p>conception not yet</p>\n<p>expelled but painful</p>\n<p>contractions (pain</p>\n<p>similar to labour</p>\n<p>pains) and bleeding</p>\n<p>Cervix proceeds to</p>\n<p>open</p>\n<p>\u0089</p>\n<p>Bed rest</p>\n<p>\u0089</p>\n<p>If there are signs of infection,</p>\n<p>give antibiotics</p>\n<p>\u0089</p>\n<p>Observe for continued bleeding</p>\n<p>\u0089</p>\n<p>If patient in shock</p>\n<p>\u0089</p>\n<p>Resuscitate with IV fluids (Nor\u00ad</p>\n<p>mal Saline)</p>\n<p>\u0089</p>\n<p>If anaemic</p>\n<p>\u0089</p>\n<p>Refer to HC4 for replacement</p>\n<p>of blood lost</p>\n<p>\u0089</p>\n<p>Establish IV access before re\u00ad</p>\n<p>ferral</p>\n<p>\u0089</p>\n<p>Give stat dose of antibiotics</p>\n<p>before referral</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Incomplete</p>\n<p>abortion</p>\n<p>Uterine contents</p>\n<p>not completely</p>\n<p>passed out</p>\n<p>Bleeding</p>\n<p>sometimes with</p>\n<p>clots from</p>\n<p>the vagina (may be</p>\n<p>severe) or</p>\n<p>Severe lower</p>\n<p>abdominal cramps</p>\n<p>Cervix open</p>\n<p>Products of</p>\n<p>conception (POC)</p>\n<p>may be felt in the</p>\n<p>cervical canal</p>\n<p>If evacuation of uterus is not imme\u00ad</p>\n<p>diately possible</p>\n<p>\u0089</p>\n<p>Give oral misoprostol 600 mi\u00ad</p>\n<p>crogram sublingual stat (repeat</p>\n<p>once after 4 hours if necessary)</p>\n<p>\u0089</p>\n<p>If at HC2, refer to HC3 after</p>\n<p>misoprostol</p>\n<p>\u0089</p>\n<p>Use fingers to remove POC</p>\n<p>protruding through the cervix</p>\n<p>Evacuate the uterus by Manual</p>\n<p>Vacuum</p>\n<p>\u0089</p>\n<p>Aspiration (if pregnancy</p>\n<p>\u0089</p>\n<p><16 weeks) or Dilation and</p>\n<p>Curettage</p>\n<p>\u0089</p>\n<p>Ensure follow up</p>\n<p>\u0089</p>\n<p>Give stat dose of antibiotics</p>\n<p>before referral</p>\n<p>\u0089</p>\n<p>Treat anaemia</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 784,
        "content": "718\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nFEATURES\nMANAGEMENT\nLOC\nIf signs of infection (fever, foul \nsmelling blood)\n\t\n\u0089\nGive a stat dose of IV Ceftriax\u00ad\none 2 g and IV metronidazole \n500 mg\n\t\n\u0089\nAmoxicillin 500 mg orally \nevery 6 hours for 7 days\n\t\n\u0089\nPlus metronidazole 400 mg \norally every 8 hours for 7 days\nHC2\nHC3\nHC4\nComplete abortion\n\t\n\u0089\nExamine to make sure that all \nproducts have been passed\nAll uterine contents \nhave been passed out\nBleeding is decreasing\nCervix closed\nUterus empty and \nreduced in size\n\t\n\u0089\nFollow up for continuous \nbleeding (it should stop in a \nfew days)\nHC3\nSeptic abortion\nIncomplete abortion \nwith infection (may \nfollow induced \nabortion)\nFever\nOffensive vaginal \ndischarge\nLower abdominal \npain\nTenderness on \npalpating the \nabdomen\n\t\n\u0089\nGive 7-day course of antibiot\u00ad\nics as in incomplete abortion \n(above)\n\t\n\u0089\nEvacuate the uterus\nHC4",
        "formatted_content": "<p>718</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>FEATURES</h3>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>If signs of infection (fever, foul</p>\n<p>smelling blood)</p>\n<p>\u0089</p>\n<p>Give a stat dose of IV Ceftriax\u00ad</p>\n<p>one 2 g and IV metronidazole</p>\n<p>500 mg</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg orally</p>\n<p>every 6 hours for 7 days</p>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg</p>\n<p>orally every 8 hours for 7 days</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Complete abortion</p>\n<p>\u0089</p>\n<p>Examine to make sure that all</p>\n<p>products have been passed</p>\n<p>All uterine contents</p>\n<p>have been passed out</p>\n<p>Bleeding is decreasing</p>\n<p>Cervix closed</p>\n<p>Uterus empty and</p>\n<p>reduced in size</p>\n<p>\u0089</p>\n<p>Follow up for continuous</p>\n<p>bleeding (it should stop in a</p>\n<p>few days)</p>\n<h3>HC3</h3>\n<p>Septic abortion</p>\n<p>Incomplete abortion</p>\n<p>with infection (may</p>\n<p>follow induced</p>\n<p>abortion)</p>\n<p>Fever</p>\n<p>Offensive vaginal</p>\n<p>discharge</p>\n<p>Lower abdominal</p>\n<p>pain</p>\n<p>Tenderness on</p>\n<p>palpating the</p>\n<p>abdomen</p>\n<p>\u0089</p>\n<p>Give 7-day course of antibiot\u00ad</p>\n<p>ics as in incomplete abortion</p>\n<p>(above)</p>\n<p>\u0089</p>\n<p>Evacuate the uterus</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 785,
        "content": "719\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nFEATURES\nMANAGEMENT\nLOC\nPost-abortal Sepsis\nPatient has signs and symptoms \nof sepsis following an abortion, \nbut there are no products of \nconception in the uterus\n\t\n\u0089\nGive IV antibiotics cef\u00ad\ntriaxone 2 g + metroni\u00ad\ndazole 500\n\t\n\u0089\nmg IV 8 hourly for \n48 hours, until fever \nhas disappeared, then \nswitch to oral treatment \nas for septic abortion\nHC4\nMissed abortion\nFoetus died\nContents of the uterus not \nexpelled\nMay be dark blood drops \n(spotting) from the vagina\nUterus smaller than expected \nby dates/not growing\n\t\n\u0089\nRefer to hospital for \nevacuation\nH\nMolar abortion\nAbnormal placenta, no foetus, \nvaginal bleeding, and passing \nof red material like ripe coffee \nberries/ white (translucent) \ngrape like material; uterus much \nbigger than expected; mother \nfeels no foetal movements even \nafter five months\n\t\n\u0089\nResuscitate and refer \nthe patient\n\t\n\u0089\nDo not attempt to evac\u00ad\nuate the uterus unless \nyou have facilities for \nblood transfusion and \noxytocin\n\t\n\u0089\nRefer to hospital for \nfurther management\nH\n16.3.3    Ectopic Pregnancy\t\n                             ICD10 CODE: O00\nPregnancy outside the uterus, usually in the uterine tubes; could result \nin an emergency when the tube ruptures\nCause\n \n\u008d\nPartial blockage of the tube due to a previous infection\n \n\u008d\nCongenital malformation of the fallopian tubes\n \n\u008d\nExcessively long tubes",
        "formatted_content": "<p>719</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>FEATURES</h3>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>Post-abortal Sepsis</p>\n<p>Patient has signs and symptoms</p>\n<p>of sepsis following an abortion,</p>\n<p>but there are no products of</p>\n<p>conception in the uterus</p>\n<p>\u0089</p>\n<p>Give IV antibiotics cef\u00ad</p>\n<p>triaxone 2 g + metroni\u00ad</p>\n<p>dazole 500</p>\n<p>\u0089</p>\n<p>mg IV 8 hourly for</p>\n<p>48 hours, until fever</p>\n<p>has disappeared, then</p>\n<p>switch to oral treatment</p>\n<p>as for septic abortion</p>\n<h3>HC4</h3>\n<p>Missed abortion</p>\n<p>Foetus died</p>\n<p>Contents of the uterus not</p>\n<p>expelled</p>\n<p>May be dark blood drops</p>\n<p>(spotting) from the vagina</p>\n<p>Uterus smaller than expected</p>\n<p>by dates/not growing</p>\n<p>\u0089</p>\n<p>Refer to hospital for</p>\n<p>evacuation</p>\n<p>H</p>\n<p>Molar abortion</p>\n<p>Abnormal placenta, no foetus,</p>\n<p>vaginal bleeding, and passing</p>\n<p>of red material like ripe coffee</p>\n<p>berries/ white (translucent)</p>\n<p>grape like material; uterus much</p>\n<p>bigger than expected; mother</p>\n<p>feels no foetal movements even</p>\n<p>after five months</p>\n<p>\u0089</p>\n<p>Resuscitate and refer</p>\n<p>the patient</p>\n<p>\u0089</p>\n<p>Do not attempt to evac\u00ad</p>\n<p>uate the uterus unless</p>\n<p>you have facilities for</p>\n<p>blood transfusion and</p>\n<p>oxytocin</p>\n<p>\u0089</p>\n<p>Refer to hospital for</p>\n<p>further management</p>\n<p>H</p>\n<p>16.3.3    Ectopic Pregnancy</p>\n<h3>ICD10 CODE: O00</h3>\n<p>Pregnancy outside the uterus, usually in the uterine tubes; could result</p>\n<p>in an emergency when the tube ruptures</p>\n<p>Cause</p>\n<p>\u008d</p>\n<p>Partial blockage of the tube due to a previous infection</p>\n<p>\u008d</p>\n<p>Congenital malformation of the fallopian tubes</p>\n<p>\u008d</p>\n<p>Excessively long tubes</p>"
    },
    {
        "page_number": 786,
        "content": "720\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nRisk factors\n \n\u008d\nHistory of prior ectopic pregnancy\n \n\u008d\nPrior abdominal or tubal surgery\n \n\u008d\nHistory of PID, endometriosis, history of infertility\n \n\u008d\nCigarette smoking\n \n\u008d\nMultiple sexual partners\nClinical features\n \n\u008d\nThere may be a period of amenorrhoea as in normal \npregnancy\n \n\u008d\nLower abdominal pain, often acute and followed by slight \nbleeding from the vagina\n \n\u008d\nIf the tube ruptures, the patient may suddenly become \nanaemic and go into shock\n \n\u008d\nAbdomen may be very tender with rebound tenderness and \nguarding on palpation\n \n\u008d\nAbdomen may not be moving with normal breathing\n \n\u008d\nTenderness of moving cervix during vaginal examination\n \n\u008d\nThere may be features of free fluid in the abdomen\nDifferential diagnosis\n \n\u008d\nOther causes of acute abdominal pain and vaginal bleeding, \ne.g., twisted ovarian cyst\n \n\u008d\nAppendicitis, pelvic inflammatory disease\n \n\u008d\nIncomplete abortion\nInvestigations\n \n\u0081\nUsually diagnosed clinically\n \n- If the tube ruptures, there may be little time for investigations \nbut ultrasound could be useful (if the patient is not in shock)\n \n\u0081\nPregnancy test (to exclude other causes)\n \n\u0081\nComplete blood count, blood grouping and cross-matching",
        "formatted_content": "<p>720</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Risk factors</p>\n<p>\u008d</p>\n<p>History of prior ectopic pregnancy</p>\n<p>\u008d</p>\n<p>Prior abdominal or tubal surgery</p>\n<p>\u008d</p>\n<p>History of PID, endometriosis, history of infertility</p>\n<p>\u008d</p>\n<p>Cigarette smoking</p>\n<p>\u008d</p>\n<p>Multiple sexual partners</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>There may be a period of amenorrhoea as in normal</p>\n<p>pregnancy</p>\n<p>\u008d</p>\n<p>Lower abdominal pain, often acute and followed by slight</p>\n<p>bleeding from the vagina</p>\n<p>\u008d</p>\n<p>If the tube ruptures, the patient may suddenly become</p>\n<p>anaemic and go into shock</p>\n<p>\u008d</p>\n<p>Abdomen may be very tender with rebound tenderness and</p>\n<p>guarding on palpation</p>\n<p>\u008d</p>\n<p>Abdomen may not be moving with normal breathing</p>\n<p>\u008d</p>\n<p>Tenderness of moving cervix during vaginal examination</p>\n<p>\u008d</p>\n<p>There may be features of free fluid in the abdomen</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Other causes of acute abdominal pain and vaginal bleeding,</p>\n<p>e.g., twisted ovarian cyst</p>\n<p>\u008d</p>\n<p>Appendicitis, pelvic inflammatory disease</p>\n<p>\u008d</p>\n<p>Incomplete abortion</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Usually diagnosed clinically</p>\n<p>- If the tube ruptures, there may be little time for investigations</p>\n<p>but ultrasound could be useful (if the patient is not in shock)</p>\n<p>\u0081</p>\n<p>Pregnancy test (to exclude other causes)</p>\n<p>\u0081</p>\n<p>Complete blood count, blood grouping and cross-matching</p>"
    },
    {
        "page_number": 787,
        "content": "721\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nSet up IV drip with normal saline and run very slowly \njust to maintain IV access\n\t\n\u0089\nRefer to hospital for surgery\nHC3\nH\nNote\n \n\u0081\nDO NOT RUN A LOT OF FLUIDS BEFORE SURGERY, as \nthis raises blood pressure, which may worsen the patient\u2019s \nbleeding, and worsen state of shock.\n16.3.4  Premature Rupture of Membranes (PROM & PPROM)\t\nICD10 CODE: O42\nPROM is a rupture of membranes before the start of labour. It can \noccur either:\n \n- When foetus is mature/term at or after 37 weeks (PROM)\n \n- Or when foetus is immature/preterm between 24-37 \nweeks of gestation. This is referred to as Pre-term PROM \n(PPROM).\nIn all cases of PPROM, prematurity and its attendant problems are \nthe principal concerns for the foetus, while infection morbidity and its \ncomplications are the primary concerns for the mother.\nRisk factors associated with PPROM\nLow socioeconomic status, tobacco use\n \n\u008d\nLow body mass index\n \n\u008d\nPrior history of PV bleeding during pregnancy\n \n\u008d\nHistory of preterm labour\n \n\u008d\nUrinary tract infection, chorioamnionitis\n \n\u008d\nCervical cerclage, amniocentesis\nClinical features associated with PROM\n \n\u008d\nLeakage of fluid or vaginal discharge",
        "formatted_content": "<p>721</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Set up IV drip with normal saline and run very slowly</p>\n<p>just to maintain IV access</p>\n<p>\u0089</p>\n<p>Refer to hospital for surgery</p>\n<h3>HC3</h3>\n<p>H</p>\n<p>Note</p>\n<p>\u0081</p>\n<p>DO NOT RUN A LOT OF FLUIDS BEFORE SURGERY, as</p>\n<p>this raises blood pressure, which may worsen the patient\u2019s</p>\n<p>bleeding, and worsen state of shock.</p>\n<p>16.3.4  Premature Rupture of Membranes (PROM & PPROM)</p>\n<h3>ICD10 CODE: O42</h3>\n<p>PROM is a rupture of membranes before the start of labour. It can</p>\n<p>occur either:</p>\n<p>- When foetus is mature/term at or after 37 weeks (PROM)</p>\n<p>- Or when foetus is immature/preterm between 24-37</p>\n<p>weeks of gestation. This is referred to as Pre-term PROM</p>\n<h3>(PPROM).</h3>\n<p>In all cases of PPROM, prematurity and its attendant problems are</p>\n<p>the principal concerns for the foetus, while infection morbidity and its</p>\n<p>complications are the primary concerns for the mother.</p>\n<p>Risk factors associated with PPROM</p>\n<p>Low socioeconomic status, tobacco use</p>\n<p>\u008d</p>\n<p>Low body mass index</p>\n<p>\u008d</p>\n<p>Prior history of PV bleeding during pregnancy</p>\n<p>\u008d</p>\n<p>History of preterm labour</p>\n<p>\u008d</p>\n<p>Urinary tract infection, chorioamnionitis</p>\n<p>\u008d</p>\n<p>Cervical cerclage, amniocentesis</p>\n<p>Clinical features associated with PROM</p>\n<p>\u008d</p>\n<p>Leakage of fluid or vaginal discharge</p>"
    },
    {
        "page_number": 788,
        "content": "722\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nMay be with or without vaginal bleeding\n \n\u008d\nPelvic pressure but no contractions\n \n\u008d\nIf ROM has been prolonged, the patient may present with fever, \nabdominal pain, and a foul smelling vaginal discharge\nInvestigation\n \n\u0081\nThe typical odour of amniotic fluid is diagnostic\n\t\n\u0089\nPlace a vaginal pad over the vulva; examine visually and by smell \nafter 1 hour\n\t\n\u0089\nUse a high-level disinfected or sterile speculum for vagina\n\t\n\u0089\nexamination: fluid may be seen coming from the cervix or forming \na pool in the posterior fornix\n\t\n\u0089\nAsk patient to cough: this may cause a gush of fluid\n\t\n\u0089\nIf membrane rupture is not recent or leakage is gradual, confirming \nthe diagnosis may be difficult\n\t\n\u0089\nAbdominal US scan may show absence of or very low\n\t\n\u0089\namounts of amniotic fluid\n\t\n\u0089\nIf available, do Nitrazine test and Ferning test\nCaution\n \n\u0083 Do NOT do digital vaginal examination \u2013 it does not help \ndiagnosis and may cause infection\nManagement of PROM (>37 weeks)\n \n\u008d\nOver 90% of patients with PROM go into spontaneous \nlabour within 24 hours\n \n\u008d\nExpectant management carries a risk of infection\n \n\u008d\nInduction of labour decreases the risk of infection without \nincreasing the C/S delivery rate\n \n\u008d\nExpectant management also carries a risk of neonatal issues, \ne.g., infection, abruptio placenta, foetal distress, foetal re\u00ad\nstriction deformities, and death",
        "formatted_content": "<p>722</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>May be with or without vaginal bleeding</p>\n<p>\u008d</p>\n<p>Pelvic pressure but no contractions</p>\n<p>\u008d</p>\n<p>If ROM has been prolonged, the patient may present with fever,</p>\n<p>abdominal pain, and a foul smelling vaginal discharge</p>\n<p>Investigation</p>\n<p>\u0081</p>\n<p>The typical odour of amniotic fluid is diagnostic</p>\n<p>\u0089</p>\n<p>Place a vaginal pad over the vulva; examine visually and by smell</p>\n<p>after 1 hour</p>\n<p>\u0089</p>\n<p>Use a high-level disinfected or sterile speculum for vagina</p>\n<p>\u0089</p>\n<p>examination: fluid may be seen coming from the cervix or forming</p>\n<p>a pool in the posterior fornix</p>\n<p>\u0089</p>\n<p>Ask patient to cough: this may cause a gush of fluid</p>\n<p>\u0089</p>\n<p>If membrane rupture is not recent or leakage is gradual, confirming</p>\n<p>the diagnosis may be difficult</p>\n<p>\u0089</p>\n<p>Abdominal US scan may show absence of or very low</p>\n<p>\u0089</p>\n<p>amounts of amniotic fluid</p>\n<p>\u0089</p>\n<p>If available, do Nitrazine test and Ferning test</p>\n<p>Caution</p>\n<p>\u0083 Do NOT do digital vaginal examination \u2013 it does not help</p>\n<p>diagnosis and may cause infection</p>\n<p>Management of PROM (>37 weeks)</p>\n<p>\u008d</p>\n<p>Over 90% of patients with PROM go into spontaneous</p>\n<p>labour within 24 hours</p>\n<p>\u008d</p>\n<p>Expectant management carries a risk of infection</p>\n<p>\u008d</p>\n<p>Induction of labour decreases the risk of infection without</p>\n<p>increasing the C/S delivery rate</p>\n<p>\u008d</p>\n<p>Expectant management also carries a risk of neonatal issues,</p>\n<p>e.g., infection, abruptio placenta, foetal distress, foetal re\u00ad</p>\n<p>striction deformities, and death</p>"
    },
    {
        "page_number": 789,
        "content": "723\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nMANAGEMENT\nLOC\n\t\n\u0089\nRefer all patients to hospital and keep in hospital until \ndelivery\nIf the membranes have been ruptured for >18 hours \nand no signs of infection\nHC4\n\t\n\u0089\nGive prophylactic antibiotics until delivery to help reduce \nneonatal group B streptococcus infection: Ampicillin 2 \ng IV every 6 hours or benzylpenicillin 2 MU IV every \n6 hours\n\t\n\u0089\nAssess the cervix\n\t\n\u0089\nRefer to HC4 or above (with facilities for emergency \nobstetric management) for induction with oxytocin (see \nsection 16.4.2)\nHC4\nManagement of PPROM (<37 weeks)\n \n\u008d\nThe primary determinant of neonatal morbidity and mortality \nis gestational age at delivery, hence stressing the need for \nconservative management whenever possible for Pre-PROM\n \n\u008d\nAll patients with Pre-PROM should receive antenatal steroids \nfor foetal lung maturity\n \n\u008d\nAll patients with PPROM should receive prophylactic antibi\u00ad\notics since there is a high risk of infection\n \n\u008d\nAdministration of tocolytics for 48 hours may allow adminis\u00ad\ntration of steroids to accelerate lung maturity\n \n\u008d\nIn general, prognosis is good after 34 weeks of gestation\n \n\u008d\nAll patients with PPROM should be cared for in a facility \nwhere a Neonatal Intensive Care Unit (NICU) is available",
        "formatted_content": "<p>723</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer all patients to hospital and keep in hospital until</p>\n<p>delivery</p>\n<p>If the membranes have been ruptured for >18 hours</p>\n<p>and no signs of infection</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Give prophylactic antibiotics until delivery to help reduce</p>\n<p>neonatal group B streptococcus infection: Ampicillin 2</p>\n<p>g IV every 6 hours or benzylpenicillin 2 MU IV every</p>\n<p>6 hours</p>\n<p>\u0089</p>\n<p>Assess the cervix</p>\n<p>\u0089</p>\n<p>Refer to HC4 or above (with facilities for emergency</p>\n<p>obstetric management) for induction with oxytocin (see</p>\n<p>section 16.4.2)</p>\n<h3>HC4</h3>\n<p>Management of PPROM (<37 weeks)</p>\n<p>\u008d</p>\n<p>The primary determinant of neonatal morbidity and mortality</p>\n<p>is gestational age at delivery, hence stressing the need for</p>\n<p>conservative management whenever possible for Pre-PROM</p>\n<p>\u008d</p>\n<p>All patients with Pre-PROM should receive antenatal steroids</p>\n<p>for foetal lung maturity</p>\n<p>\u008d</p>\n<p>All patients with PPROM should receive prophylactic antibi\u00ad</p>\n<p>otics since there is a high risk of infection</p>\n<p>\u008d</p>\n<p>Administration of tocolytics for 48 hours may allow adminis\u00ad</p>\n<p>tration of steroids to accelerate lung maturity</p>\n<p>\u008d</p>\n<p>In general, prognosis is good after 34 weeks of gestation</p>\n<p>\u008d</p>\n<p>All patients with PPROM should be cared for in a facility</p>\n<p>where a Neonatal Intensive Care Unit (NICU) is available</p>"
    },
    {
        "page_number": 790,
        "content": "724\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n\t\n\u0089\nRefer all patients to hospital, and keep in hospital \nuntil delivery\nIf no signs of infection and pregnancy 24-34 weeks (if \ngestational age is accurate)\n\t\n\u0089\nGive dexamethasone 6 mg IM every 12 hours for a \ntotal of 4 doses (or betamethasone 12 mg IM, 2 doses \n24 hours apart)\nH\n\t\n\u0089\nRoutine antibiotics: Erythromycin 250 mg every 8 \nhours plus amoxicillin 500 mg every 8 hours\n \n-\nStop them after delivery if no signs of \ninfection\n\t\n\u0089\nDeliver at 34 weeks\nIf palpable contractions and blood- stained mucus\n\t\n\u0089\nSuspect preterm labour\n\t\n\u0089\nHydrate with IV fluids before administering nifedipine\n\t\n\u0089\nConsider administration of tocolytics\n \n-\nTocolytics: Nifedipine 10 mg sublingual tablet \nplaced under the tongue every 15 minutes \nif necessary, up to a maximum of 40 mg in \nthe first hour. Then 60-160 mg daily in 3-4 \ndivided doses, adjusted to uterine activity, for \nmax 48 hours\nH\nIf vaginal bleeding with abdominal pain (intermittent or constant)\n\t\n\u0089\nSuspect and treat as abruptio placentae (see section \n16.3.6)\nIf signs of infection (fever, foul-smelling vaginal discharge)\n\t\n\u0089\nGive antibiotics as for Amnionitis (section 16.3.5)\n\t\n\u0089\nDeliver immediately\nCaution\n \n\u0083 Do not use steroids in presence of infection",
        "formatted_content": "<p>724</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer all patients to hospital, and keep in hospital</p>\n<p>until delivery</p>\n<p>If no signs of infection and pregnancy 24-34 weeks (if</p>\n<p>gestational age is accurate)</p>\n<p>\u0089</p>\n<p>Give dexamethasone 6 mg IM every 12 hours for a</p>\n<p>total of 4 doses (or betamethasone 12 mg IM, 2 doses</p>\n<p>24 hours apart)</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Routine antibiotics: Erythromycin 250 mg every 8</p>\n<p>hours plus amoxicillin 500 mg every 8 hours</p>\n<p>-</p>\n<p>Stop them after delivery if no signs of</p>\n<p>infection</p>\n<p>\u0089</p>\n<p>Deliver at 34 weeks</p>\n<p>If palpable contractions and blood- stained mucus</p>\n<p>\u0089</p>\n<p>Suspect preterm labour</p>\n<p>\u0089</p>\n<p>Hydrate with IV fluids before administering nifedipine</p>\n<p>\u0089</p>\n<p>Consider administration of tocolytics</p>\n<p>-</p>\n<p>Tocolytics: Nifedipine 10 mg sublingual tablet</p>\n<p>placed under the tongue every 15 minutes</p>\n<p>if necessary, up to a maximum of 40 mg in</p>\n<p>the first hour. Then 60-160 mg daily in 3-4</p>\n<p>divided doses, adjusted to uterine activity, for</p>\n<p>max 48 hours</p>\n<p>H</p>\n<p>If vaginal bleeding with abdominal pain (intermittent or constant)</p>\n<p>\u0089</p>\n<p>Suspect and treat as abruptio placentae (see section</p>\n<p>16.3.6)</p>\n<p>If signs of infection (fever, foul-smelling vaginal discharge)</p>\n<p>\u0089</p>\n<p>Give antibiotics as for Amnionitis (section 16.3.5)</p>\n<p>\u0089</p>\n<p>Deliver immediately</p>\n<p>Caution</p>\n<p>\u0083 Do not use steroids in presence of infection</p>"
    },
    {
        "page_number": 791,
        "content": "725\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.3.5  Chorioamnionitis\t\t\n       ICD10 CODE: O41.1\nInfection of the chorionic and amniotic membranes/fluid before delivery.\nRisk factors\n \n\u008d\nProlonged rupture of membranes\n \n\u008d\nProlonged labour\n \n\u008d\nUntreated STI\nClinical features\n \n\u008d\nHistory of vaginal draining of liquor\n \n\u008d\nFever >37.8\u00b0C\n \n\u008d\nMaternal tachycardia\n \n\u008d\nFoetal tachycardia\n \n\u008d\nUterine tenderness\n \n\u008d\nFoul-smelling or purulent vaginal discharge\n \n\u008d\nAcute complications: postpartum haemorrhage, puerperal \nsepsis, renal failure\n \n\u008d\nChronic complications: infertility due to salpingitis, and/ or \nuterine sinechie\nInvestigations\n \n\u0081\nRDT or BS to rule out Malaria\n \n\u0081\nUrinalysis to rule out UTI\n \n\u0081\nSwab (vaginal discharge) for gram stain\nManagement\nCare for mother and neonate includes early delivery and antibiotic \nadministration. The risk of neonatal sepsis is increased.",
        "formatted_content": "<p>725</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.3.5  Chorioamnionitis</p>\n<h3>ICD10 CODE: O41.1</h3>\n<p>Infection of the chorionic and amniotic membranes/fluid before delivery.</p>\n<p>Risk factors</p>\n<p>\u008d</p>\n<p>Prolonged rupture of membranes</p>\n<p>\u008d</p>\n<p>Prolonged labour</p>\n<p>\u008d</p>\n<p>Untreated STI</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>History of vaginal draining of liquor</p>\n<p>\u008d</p>\n<p>Fever >37.8\u00b0C</p>\n<p>\u008d</p>\n<p>Maternal tachycardia</p>\n<p>\u008d</p>\n<p>Foetal tachycardia</p>\n<p>\u008d</p>\n<p>Uterine tenderness</p>\n<p>\u008d</p>\n<p>Foul-smelling or purulent vaginal discharge</p>\n<p>\u008d</p>\n<p>Acute complications: postpartum haemorrhage, puerperal</p>\n<p>sepsis, renal failure</p>\n<p>\u008d</p>\n<p>Chronic complications: infertility due to salpingitis, and/ or</p>\n<p>uterine sinechie</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>RDT or BS to rule out Malaria</p>\n<p>\u0081</p>\n<p>Urinalysis to rule out UTI</p>\n<p>\u0081</p>\n<p>Swab (vaginal discharge) for gram stain</p>\n<p>Management</p>\n<p>Care for mother and neonate includes early delivery and antibiotic</p>\n<p>administration. The risk of neonatal sepsis is increased.</p>"
    },
    {
        "page_number": 792,
        "content": "726\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n\t\n\u0089\nStart antibiotics and refer to hospital\n \n-\nAmpicillin 2 g IV every 6 hours\n \n-\nPlus gentamicin 5 mg/kg IV every 24 hours\nFor penicillin allergic patients, give\n\t\n\u0089\nClindamycin 300-600 mg IV 12 hourly\nIf patient delivers vaginally\n\t\n\u0089\nContinue parenteral antibiotics until woman is afebrile \nfor 48 hours and no foul-smelling discharge\nH\n\t\n\u0089\nIf the mother comes back with complications, refer \nfor further care\nIf the woman has a Caesarean section\n\t\n\u0089\nContinue the above antibiotics, and add metronidazole \n500 mg IV every 8 hours\n \n-\nContinue until 48 hours after fever has gone\nH\nNewborn\n\t\n\u0089\nExamine the neonate for suspected sepsis before \ndischarge\n\t\n\u0089\nIf newborn sepsis is suspected manage as in section \n2.1.7.1\n\t\n\u0089\nAdvise the mother on how to recognize danger signs \n(see section 17.1.1)\nH\n16.3.6       Antepartum Haemorrhage (APH) \u2013 Abruptio Placentae \nand Placenta Praevia                       ICD10 CODE: O44-O46\nVaginal bleeding occurring after 28 weeks of pregnancy, and up to \nsecond stage of labour.",
        "formatted_content": "<p>726</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Start antibiotics and refer to hospital</p>\n<p>-</p>\n<p>Ampicillin 2 g IV every 6 hours</p>\n<p>-</p>\n<p>Plus gentamicin 5 mg/kg IV every 24 hours</p>\n<p>For penicillin allergic patients, give</p>\n<p>\u0089</p>\n<p>Clindamycin 300-600 mg IV 12 hourly</p>\n<p>If patient delivers vaginally</p>\n<p>\u0089</p>\n<p>Continue parenteral antibiotics until woman is afebrile</p>\n<p>for 48 hours and no foul-smelling discharge</p>\n<p>H</p>\n<p>\u0089</p>\n<p>If the mother comes back with complications, refer</p>\n<p>for further care</p>\n<p>If the woman has a Caesarean section</p>\n<p>\u0089</p>\n<p>Continue the above antibiotics, and add metronidazole</p>\n<p>500 mg IV every 8 hours</p>\n<p>-</p>\n<p>Continue until 48 hours after fever has gone</p>\n<p>H</p>\n<p>Newborn</p>\n<p>\u0089</p>\n<p>Examine the neonate for suspected sepsis before</p>\n<p>discharge</p>\n<p>\u0089</p>\n<p>If newborn sepsis is suspected manage as in section</p>\n<p>2.1.7.1</p>\n<p>\u0089</p>\n<p>Advise the mother on how to recognize danger signs</p>\n<p>(see section 17.1.1)</p>\n<p>H</p>\n<p>16.3.6       Antepartum Haemorrhage (APH) \u2013 Abruptio Placentae</p>\n<p>and Placenta Praevia                       ICD10 CODE: O44-O46</p>\n<p>Vaginal bleeding occurring after 28 weeks of pregnancy, and up to</p>\n<p>second stage of labour.</p>"
    },
    {
        "page_number": 793,
        "content": "727\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCauses\n \n\u008d\nLocal causes from genital tract\n \n\u008d\nPlacenta praevia: All or part of the placenta is found in the \nlower segment of the uterus\n \n\u008d\nAbruptio placentae: Premature separation of a normally \nplaced placenta\nComparison of Clinical features\nSIGN/SYMPTOM\nPLACENTA PRAEVIA\nABRUPTIO PLACENTAE\nAbdominal pain\nPainless\nSevere pain\nFoetal movements\nFoetal movements usu\u00ad\nally present\nLoss of foetal move\u00ad\nments common\nAmount of vaginal \nbleeding\nSignificant bleeding from \nthe vagina\nSignificant bleeding \nmay be absent; only \nserous fluid in some \ncases (bleeding is \nbehind the placenta)\nMaternal general \ncondition\nShock and anaemia if \nbleeding is heavy\nShock and anaemia, \neven when no frank \nbleeding\nUterine consistency Uterus soft and not \ntender\nUterus hard and \ntender\nPosition of foetal \npresenting part\nHigh presenting part \n(head) or malpresenta\u00ad\ntion (the part in the \nlower uterus not head)\nFoetal parts difficult \nto feel because of \nhard uterus\nFoetal heart sounds Foetal heart sounds \nusually heard\nFoetal heart sounds \noften absent",
        "formatted_content": "<p>727</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Local causes from genital tract</p>\n<p>\u008d</p>\n<p>Placenta praevia: All or part of the placenta is found in the</p>\n<p>lower segment of the uterus</p>\n<p>\u008d</p>\n<p>Abruptio placentae: Premature separation of a normally</p>\n<p>placed placenta</p>\n<p>Comparison of Clinical features</p>\n<h3>SIGN/SYMPTOM</h3>\n<h3>PLACENTA PRAEVIA</h3>\n<h3>ABRUPTIO PLACENTAE</h3>\n<p>Abdominal pain</p>\n<p>Painless</p>\n<p>Severe pain</p>\n<p>Foetal movements</p>\n<p>Foetal movements usu\u00ad</p>\n<p>ally present</p>\n<p>Loss of foetal move\u00ad</p>\n<p>ments common</p>\n<p>Amount of vaginal</p>\n<p>bleeding</p>\n<p>Significant bleeding from</p>\n<p>the vagina</p>\n<p>Significant bleeding</p>\n<p>may be absent; only</p>\n<p>serous fluid in some</p>\n<p>cases (bleeding is</p>\n<p>behind the placenta)</p>\n<p>Maternal general</p>\n<p>condition</p>\n<p>Shock and anaemia if</p>\n<p>bleeding is heavy</p>\n<p>Shock and anaemia,</p>\n<p>even when no frank</p>\n<p>bleeding</p>\n<p>Uterine consistency Uterus soft and not</p>\n<p>tender</p>\n<p>Uterus hard and</p>\n<p>tender</p>\n<p>Position of foetal</p>\n<p>presenting part</p>\n<p>High presenting part</p>\n<p>(head) or malpresenta\u00ad</p>\n<p>tion (the part in the</p>\n<p>lower uterus not head)</p>\n<p>Foetal parts difficult</p>\n<p>to feel because of</p>\n<p>hard uterus</p>\n<p>Foetal heart sounds Foetal heart sounds</p>\n<p>usually heard</p>\n<p>Foetal heart sounds</p>\n<p>often absent</p>"
    },
    {
        "page_number": 794,
        "content": "728\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nAny bleeding in late pregnancy needs immediate referral \nto hospital\n\t\n\u0089\nGive IV normal saline infusion\n\t\n\u0089\nAdmit, inspect the vulva to ascertain colour and amount \nof bleeding but DO NOT perform a digital vaginal ex\u00ad\namination if you suspect placenta praevia\n\t\n\u0089\nCorrect anaemia and coagulation defects (transfuse \nblood and fresh frozen plasma)\n\t\n\u0089\nIn case of confirmed Abruptio Placentae where the baby \nis dead, and facilities for theatre and blood transfusion \nare available, with no contraindication to vaginal delivery:\n \n-\nRupture membranes and start oxytocin 10 IU \nin 500 mL of Normal saline to induce labour\nH\nDifferential diagnosis\n \n\u008d\nRuptured uterus especially in a patient with previous caesar\u00ad\nean section or grand multipara\n \n\u008d\nLocal causes, e.g. cervical cancer\nInvestigations\n \n\u0081\nUltrasound: To find the site of the placenta and viability of the \nbaby, this may not be conclusive for AP (take note of clinical \nsigns and symptoms)\n \n\u0081\nBlood:\n\t\n\u0089\nGrouping, cross-matching\n\t\n\u0089\nHaemoglobin, fibrinogen levels\n\t\n\u0089\nClotting time and bleeding time",
        "formatted_content": "<p>728</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Any bleeding in late pregnancy needs immediate referral</p>\n<p>to hospital</p>\n<p>\u0089</p>\n<p>Give IV normal saline infusion</p>\n<p>\u0089</p>\n<p>Admit, inspect the vulva to ascertain colour and amount</p>\n<p>of bleeding but DO NOT perform a digital vaginal ex\u00ad</p>\n<p>amination if you suspect placenta praevia</p>\n<p>\u0089</p>\n<p>Correct anaemia and coagulation defects (transfuse</p>\n<p>blood and fresh frozen plasma)</p>\n<p>\u0089</p>\n<p>In case of confirmed Abruptio Placentae where the baby</p>\n<p>is dead, and facilities for theatre and blood transfusion</p>\n<p>are available, with no contraindication to vaginal delivery:</p>\n<p>-</p>\n<p>Rupture membranes and start oxytocin 10 IU</p>\n<p>in 500 mL of Normal saline to induce labour</p>\n<p>H</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Ruptured uterus especially in a patient with previous caesar\u00ad</p>\n<p>ean section or grand multipara</p>\n<p>\u008d</p>\n<p>Local causes, e.g. cervical cancer</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Ultrasound: To find the site of the placenta and viability of the</p>\n<p>baby, this may not be conclusive for AP (take note of clinical</p>\n<p>signs and symptoms)</p>\n<p>\u0081</p>\n<p>Blood:</p>\n<p>\u0089</p>\n<p>Grouping, cross-matching</p>\n<p>\u0089</p>\n<p>Haemoglobin, fibrinogen levels</p>\n<p>\u0089</p>\n<p>Clotting time and bleeding time</p>"
    },
    {
        "page_number": 795,
        "content": "729\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n\t\n\u0089\nIn case of Abruptio Placentae where the baby is alive\n \n- Deliver by emergency caesarean section (ensure\n \n- you have enough blood)\n\t\n\u0089\nIn case of placenta praevia\n \n- Give steroids (as for PPROM) if <34 weeks\n \n- Emergency cesarean section if bleeding is \nuncontrolled, mother\u2019s or baby\u2019s life in danger or \npregnancy >37 weeks\n \n- If bleeding resolves, keep mother in hospital and\n \n- deliver at >37 weeks\nH\n16.3.7      Pre-Eclampsia\t                     ICD10 CODE: O14\nPre-eclampsia is a hypertensive condition of pregnancy usually diag\u00ad\nnosed after 20 weeks of gestation and can present as late as 4-6 weeks \npostpartum.\nIt is haracterized with hypertension, proteinuria with or without oedema \nand, may result into maternal fits if not managed appropriately.\nIt may also be superimposed on chronic hypertension. It is classified as \nmild to severe pre-eclampsia.\nTYPE OF ECLAMPSIA\nDESCRIPTION\nMild to moderate pre-ec\u00ad\nlampsia\nA diastolic BP of 90-109 mmHg and/ or \nsystolic BP of 140-159 mmHg, with \u00b31+ \nproteinuria; and no organ dysfunction\nSevere pre- eclampsia\nacute severe hypertension (160/110 \nmmHg) and \u00b31+ proteinuria OR any \ndegree of hypertension with evidence of \norgan dysfunction (e.g., renal dysfunction, \nraised liver enzymes, thrombocytopaenia)\nClinical features of severe pre-eclampsia\n \n\u008d\nHeadache, blurring of vision of new onset\n \n\u008d\nEpigastric or right upper quadrant pain, vomiting",
        "formatted_content": "<p>729</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u0089</p>\n<p>In case of Abruptio Placentae where the baby is alive</p>\n<p>- Deliver by emergency caesarean section (ensure</p>\n<p>- you have enough blood)</p>\n<p>\u0089</p>\n<p>In case of placenta praevia</p>\n<p>- Give steroids (as for PPROM) if <34 weeks</p>\n<p>- Emergency cesarean section if bleeding is</p>\n<p>uncontrolled, mother\u2019s or baby\u2019s life in danger or</p>\n<p>pregnancy >37 weeks</p>\n<p>- If bleeding resolves, keep mother in hospital and</p>\n<p>- deliver at >37 weeks</p>\n<p>H</p>\n<p>16.3.7      Pre-Eclampsia\t                     ICD10 CODE: O14</p>\n<p>Pre-eclampsia is a hypertensive condition of pregnancy usually diag\u00ad</p>\n<p>nosed after 20 weeks of gestation and can present as late as 4-6 weeks</p>\n<p>postpartum.</p>\n<p>It is haracterized with hypertension, proteinuria with or without oedema</p>\n<p>and, may result into maternal fits if not managed appropriately.</p>\n<p>It may also be superimposed on chronic hypertension. It is classified as</p>\n<p>mild to severe pre-eclampsia.</p>\n<h3>TYPE OF ECLAMPSIA</h3>\n<h3>DESCRIPTION</h3>\n<p>Mild to moderate pre-ec\u00ad</p>\n<p>lampsia</p>\n<p>A diastolic BP of 90-109 mmHg and/ or</p>\n<p>systolic BP of 140-159 mmHg, with \u00b31+</p>\n<p>proteinuria; and no organ dysfunction</p>\n<p>Severe pre- eclampsia</p>\n<p>acute severe hypertension (160/110</p>\n<p>mmHg) and \u00b31+ proteinuria OR any</p>\n<p>degree of hypertension with evidence of</p>\n<p>organ dysfunction (e.g., renal dysfunction,</p>\n<p>raised liver enzymes, thrombocytopaenia)</p>\n<p>Clinical features of severe pre-eclampsia</p>\n<p>\u008d</p>\n<p>Headache, blurring of vision of new onset</p>\n<p>\u008d</p>\n<p>Epigastric or right upper quadrant pain, vomiting</p>"
    },
    {
        "page_number": 796,
        "content": "730\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nDyspnoea, weakness or general malaise\n \n\u008d\nOedema (swelling of hands, face, legs and other parts of the \nbody), excessive weight gain\n \n\u008d\nSystolic BP >160 mmHg and Diastolic BP >110 mmHg\n \n\u008d\nUrine protein ++, may be oliguria\n \n\u008d\nPre-elampsia related hypertension usually resolves sponta\u00ad\nneously after delivery and almost always within 12 weeks \nfrom delivery.\nDifferential diagnosis\n \n\u008d\nOther causes of oedema and hypertension, e.g., renal diease)\nInvestigations\n \n\u0081\nUrine: for protein\n \n\u0081\nBlood for:\n \n- LFT & RFT\n \n- Serum creatinine\n \n- Clotting time if platelet count is less than 100 X 109\n \n- Fibrinogen levels\n \n\u0081\nUltrasound Scan for foetal Estimated Gestational Age and viability\nManagement\nAny case of pre-eclampsia has to be referred to hospital, lower facilities \ncan give emergency care (Magnesium sulphate, antihypertensive as \navailable).\nGoals of treatment are to:\n \n\u008d\nPrevent convulsions\n \n\u008d\nControl blood pressure\n \n\u008d\nDeliver the baby if indicated",
        "formatted_content": "<p>730</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>Dyspnoea, weakness or general malaise</p>\n<p>\u008d</p>\n<p>Oedema (swelling of hands, face, legs and other parts of the</p>\n<p>body), excessive weight gain</p>\n<p>\u008d</p>\n<p>Systolic BP >160 mmHg and Diastolic BP >110 mmHg</p>\n<p>\u008d</p>\n<p>Urine protein ++, may be oliguria</p>\n<p>\u008d</p>\n<p>Pre-elampsia related hypertension usually resolves sponta\u00ad</p>\n<p>neously after delivery and almost always within 12 weeks</p>\n<p>from delivery.</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Other causes of oedema and hypertension, e.g., renal diease)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine: for protein</p>\n<p>\u0081</p>\n<p>Blood for:</p>\n<h3>- LFT & RFT</h3>\n<p>- Serum creatinine</p>\n<p>- Clotting time if platelet count is less than 100 X 109</p>\n<p>- Fibrinogen levels</p>\n<p>\u0081</p>\n<p>Ultrasound Scan for foetal Estimated Gestational Age and viability</p>\n<p>Management</p>\n<p>Any case of pre-eclampsia has to be referred to hospital, lower facilities</p>\n<p>can give emergency care (Magnesium sulphate, antihypertensive as</p>\n<p>available).</p>\n<p>Goals of treatment are to:</p>\n<p>\u008d</p>\n<p>Prevent convulsions</p>\n<p>\u008d</p>\n<p>Control blood pressure</p>\n<p>\u008d</p>\n<p>Deliver the baby if indicated</p>"
    },
    {
        "page_number": 797,
        "content": "731\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nBed rest, preferably in hospital\n\t\n\u0089\nLifestyle adjustment and diet\n\t\n\u0089\nMonitor BP, urine output, renal and liver function tests, \nplatelet count, foetal condition\n\t\n\u0089\nMother may be hypovolaemic; careful (slow) infusion of \nIV fluids may be necessary\n\t\n\u0089\nConsider delivery if risks to mother outweigh risks of \nprematurity to baby\nHC4\nMild to moderate pre-eclampsia\n\t\n\u0089\nBased on BP response\n\t\n\u0089\nMethyldopa, oral, 250 mg every 8 hours as a starting \ndose, increase to 500 mg 6 hourly according to response, \nMax dose 2 g daily\nAND/OR\n\t\n\u0089\nNifedipine 20-40 mg every 12 hours\nHC3\nSevere pre-eclampsia (hypertensive emergency)\nTo prevent convulsions\n\t\n\u0089\nGive IV fluids (Normal saline) very slowly (1 L in 6-8 \nhours max)\n\t\n\u0089\nGive IV loading dose of magnesium sulphate injection \n(4 g of MgSO4)\n \n-\nDraw 8 mL of a 50% MgSO4 and add 12 mL \nof water for injection or Normal saline: this is \nequal to 4 g of 20% MgSO4\n \n-\nGive the solution as a slow IV bolus over 20\n \n-\nminutes (the 20-20-20 rule)\n\t\n\u0089\nThen give 5 g MgSO4 (10 mL of MgSO4 50%, undiluted) \nin each buttock deep IM (total 10 g) with 1 mL of 2% \nlignocaine in the same syringe\n\t\n\u0089\nIf unable to give IV loading dose, give only the 10 g \ndeep IM\nHC3",
        "formatted_content": "<p>731</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Bed rest, preferably in hospital</p>\n<p>\u0089</p>\n<p>Lifestyle adjustment and diet</p>\n<p>\u0089</p>\n<p>Monitor BP, urine output, renal and liver function tests,</p>\n<p>platelet count, foetal condition</p>\n<p>\u0089</p>\n<p>Mother may be hypovolaemic; careful (slow) infusion of</p>\n<p>IV fluids may be necessary</p>\n<p>\u0089</p>\n<p>Consider delivery if risks to mother outweigh risks of</p>\n<p>prematurity to baby</p>\n<h3>HC4</h3>\n<p>Mild to moderate pre-eclampsia</p>\n<p>\u0089</p>\n<p>Based on BP response</p>\n<p>\u0089</p>\n<p>Methyldopa, oral, 250 mg every 8 hours as a starting</p>\n<p>dose, increase to 500 mg 6 hourly according to response,</p>\n<p>Max dose 2 g daily</p>\n<h3>AND/OR</h3>\n<p>\u0089</p>\n<p>Nifedipine 20-40 mg every 12 hours</p>\n<h3>HC3</h3>\n<p>Severe pre-eclampsia (hypertensive emergency)</p>\n<p>To prevent convulsions</p>\n<p>\u0089</p>\n<p>Give IV fluids (Normal saline) very slowly (1 L in 6-8</p>\n<p>hours max)</p>\n<p>\u0089</p>\n<p>Give IV loading dose of magnesium sulphate injection</p>\n<p>(4 g of MgSO4)</p>\n<p>-</p>\n<p>Draw 8 mL of a 50% MgSO4 and add 12 mL</p>\n<p>of water for injection or Normal saline: this is</p>\n<p>equal to 4 g of 20% MgSO4</p>\n<p>-</p>\n<p>Give the solution as a slow IV bolus over 20</p>\n<p>-</p>\n<p>minutes (the 20-20-20 rule)</p>\n<p>\u0089</p>\n<p>Then give 5 g MgSO4 (10 mL of MgSO4 50%, undiluted)</p>\n<p>in each buttock deep IM (total 10 g) with 1 mL of 2%</p>\n<p>lignocaine in the same syringe</p>\n<p>\u0089</p>\n<p>If unable to give IV loading dose, give only the 10 g</p>\n<p>deep IM</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 798,
        "content": "732\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nAntihypertensives\nIf BP is >95 mmHg diastolic or >160 mmHg systolic\n\t\n\u0089\nGive hydralazine 5 mg IV bolus every 30 minutes until \ndiastolic is BP is down to <100 mmHg\n \n- Alternative if hydralazine not available:\nNifedipine 20-40 mg orally every 12 hours until delivery\nHC4\n HC3\n \n- Or Labetalol 20 mg IV over 2 minutes, double \nthe dose every 30 minutes until diastolic is <100 \nmmHg (total dose not to exceed 160 mg/hour)\n\t\n\u0089\nMaintenance antihypertensive therapy is necessary after \ncontrolling the BP. Maintain the patient on Nifedipine \n20 mg 12 hourly until delivery\n\t\n\u0089\nMonitor BP every 15 minutes until stable (when systolic \nBP <160 and Diastolic <100 mmHg\nRR\nDeliver baby\n\t\n\u0089\nWomen with severe pre-eclampsia should be delivered \nurgently (vaginally or C/S) regardless of gestational age \nin the following situations:\n \n- Non-reassuring foetal heart\n \n- Ruptured membranes\n \n- Uncontrolled BP\n \n- Oligohydramnious\n \n- Features of IUGR\n \n- Oliguria of <500 mL/24 hours\n \n- Pulmonary Oedema\n \n- Headache that is persistent and severe\nAfter delivery\n\t\n\u0089\nMonitor BP every 15 minutes for 2 hours\n\t\n\u0089\nContinue to monitor vital signs (BP, urine protein, etc) \nvery carefully for at least 48 hours\n\t\n\u0089\nContinue antihypertensive to mantain diastolic BP less \nthan 90 mmHg\n\t\n\u0089\nSend home when BP is stable and no urine protein\n\t\n\u0089\nContinue antihypertensive according to clinical monitoring\n \n- Hypertension usually resolves with the birth  \nof the baby but may persist (e.g. in case of \nundiagnosed pre existent hypertension)\nH",
        "formatted_content": "<p>732</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Antihypertensives</p>\n<p>If BP is >95 mmHg diastolic or >160 mmHg systolic</p>\n<p>\u0089</p>\n<p>Give hydralazine 5 mg IV bolus every 30 minutes until</p>\n<p>diastolic is BP is down to <100 mmHg</p>\n<p>- Alternative if hydralazine not available:</p>\n<p>Nifedipine 20-40 mg orally every 12 hours until delivery</p>\n<h3>HC4</h3>\n<h3>HC3</h3>\n<p>- Or Labetalol 20 mg IV over 2 minutes, double</p>\n<p>the dose every 30 minutes until diastolic is <100</p>\n<p>mmHg (total dose not to exceed 160 mg/hour)</p>\n<p>\u0089</p>\n<p>Maintenance antihypertensive therapy is necessary after</p>\n<p>controlling the BP. Maintain the patient on Nifedipine</p>\n<p>20 mg 12 hourly until delivery</p>\n<p>\u0089</p>\n<p>Monitor BP every 15 minutes until stable (when systolic</p>\n<p>BP <160 and Diastolic <100 mmHg</p>\n<p>RR</p>\n<p>Deliver baby</p>\n<p>\u0089</p>\n<p>Women with severe pre-eclampsia should be delivered</p>\n<p>urgently (vaginally or C/S) regardless of gestational age</p>\n<p>in the following situations:</p>\n<p>- Non-reassuring foetal heart</p>\n<p>- Ruptured membranes</p>\n<p>- Uncontrolled BP</p>\n<p>- Oligohydramnious</p>\n<p>- Features of IUGR</p>\n<p>- Oliguria of <500 mL/24 hours</p>\n<p>- Pulmonary Oedema</p>\n<p>- Headache that is persistent and severe</p>\n<p>After delivery</p>\n<p>\u0089</p>\n<p>Monitor BP every 15 minutes for 2 hours</p>\n<p>\u0089</p>\n<p>Continue to monitor vital signs (BP, urine protein, etc)</p>\n<p>very carefully for at least 48 hours</p>\n<p>\u0089</p>\n<p>Continue antihypertensive to mantain diastolic BP less</p>\n<p>than 90 mmHg</p>\n<p>\u0089</p>\n<p>Send home when BP is stable and no urine protein</p>\n<p>\u0089</p>\n<p>Continue antihypertensive according to clinical monitoring</p>\n<p>- Hypertension usually resolves with the birth</p>\n<p>of the baby but may persist (e.g. in case of</p>\n<p>undiagnosed pre existent hypertension)</p>\n<p>H</p>"
    },
    {
        "page_number": 799,
        "content": "733\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nNotes\n \n\u0081\nDo not use ergot-containing medicines\n \n\u0081\nDo not use diuretics or ACE inhibitors\n16.3.8       Eclampsia                                  ICD10 CODE: O15\nOccurrence of generalised tonic-clonic seizures after 20 weeks of preg\u00ad\nnancy, associated with hypertension\nand proteinuria, without any other neurological cause of seizures.\nClinical features\n \n\u008d\nPatient may or may not have had previous clinical features of \nsevere pre-eclampsia\n \n\u008d\nHeadache that is usually frontal, blurring of vision, aura \n(flickering lights)\n \n\u008d\nGeneralized tonic-clonic seizures\n \n\u008d\nRight upper quadrant abdominal pain with nausea\n \n\u008d\nBP raised >140/90 mmHg\n \n\u008d\nOedema of legs and sometimes face and body\n \n\u008d\nUnconsciousness if condition not treated\n \n\u008d\nAmnesia and other mental changes\nDifferential diagnosis\n \n\u008d\nOther causes of fits, e.g. cerebral malaria, meningitis, epilesy, \npoisoning\nInvestigations\n \n\u0081\nUrine for Protein\n \n\u0081\nCBC, LFT, RFT\n \n\u0081\nMalaria parasites\n \n\u0081\nUrea, electrolytes\n \n\u0081\nClotting time if platelet count <100x109\n \n\u0081\nFibrinogen levels",
        "formatted_content": "<p>733</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Notes</p>\n<p>\u0081</p>\n<p>Do not use ergot-containing medicines</p>\n<p>\u0081</p>\n<p>Do not use diuretics or ACE inhibitors</p>\n<p>16.3.8       Eclampsia                                  ICD10 CODE: O15</p>\n<p>Occurrence of generalised tonic-clonic seizures after 20 weeks of preg\u00ad</p>\n<p>nancy, associated with hypertension</p>\n<p>and proteinuria, without any other neurological cause of seizures.</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Patient may or may not have had previous clinical features of</p>\n<p>severe pre-eclampsia</p>\n<p>\u008d</p>\n<p>Headache that is usually frontal, blurring of vision, aura</p>\n<p>(flickering lights)</p>\n<p>\u008d</p>\n<p>Generalized tonic-clonic seizures</p>\n<p>\u008d</p>\n<p>Right upper quadrant abdominal pain with nausea</p>\n<p>\u008d</p>\n<p>BP raised >140/90 mmHg</p>\n<p>\u008d</p>\n<p>Oedema of legs and sometimes face and body</p>\n<p>\u008d</p>\n<p>Unconsciousness if condition not treated</p>\n<p>\u008d</p>\n<p>Amnesia and other mental changes</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Other causes of fits, e.g. cerebral malaria, meningitis, epilesy,</p>\n<p>poisoning</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Urine for Protein</p>\n<p>\u0081</p>\n<h3>CBC, LFT, RFT</h3>\n<p>\u0081</p>\n<p>Malaria parasites</p>\n<p>\u0081</p>\n<p>Urea, electrolytes</p>\n<p>\u0081</p>\n<p>Clotting time if platelet count <100x109</p>\n<p>\u0081</p>\n<p>Fibrinogen levels</p>"
    },
    {
        "page_number": 800,
        "content": "734\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nPrinciples of Management\nEclampsia is a medical emergency and should be referred to hospital \nurgently, after first aid measures as available.\nGoals of treatment are:\n \n\u008d\nControlling/preventing convulsions\n \n\u008d\nControlling blood pressure\n \n\u008d\nDelivering the baby as soon as possible\nTREATMENT\nLOC\nFirst aid\n\t\n\u0089\nProtect the airway by placing the patient on her left side\n \n- Prevent patient from hurting herself\n\t\n\u0089\nPlace padded tongue blade between her teeth to prevent \ntongue bite, and secure it to prevent aspiration \u2013 DO \nNOT attempt this during a convulsion\n\t\n\u0089\nDo not restrict/restrain the patient while fitting\n\t\n\u0089\nRefer to hospital as soon as possible\nHC2\nStop and control convulsions\n\t\n\u0089\nGive IV loading dose of magnesium sulphate\n\t\n\u0089\ninjection (4 g of MgSO4)\n\t\n\u0089\nDraw 8 mL of a 50% MgSO4 and add 12 mL of water \nfor injection or Normal saline: this is equal to 4 g of \n20% MgSO4\n\t\n\u0089\nGive the solution as slow IV bolus over 20 minutes (the \n20-20-20 rule)\n\t\n\u0089\nThen give 5 g of magnesium sulphate (10 mL of MgSO4 \n50% solution, undiluted) in each buttock deep IM (total \n10 g) with 1 mL of 2% lignocaine in the same syringe\nHC3\n\t\n\u0089\nGive IV fluids (Normal saline) very slowly (1 L in 6-8 \nhours max)\n\t\n\u0089\nMonitor BP, pulse, and respiration every 30 minutes; \npass indwelling Foley\u2019s catheter for continuous bladder \ndrainage",
        "formatted_content": "<p>734</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Principles of Management</p>\n<p>Eclampsia is a medical emergency and should be referred to hospital</p>\n<p>urgently, after first aid measures as available.</p>\n<p>Goals of treatment are:</p>\n<p>\u008d</p>\n<p>Controlling/preventing convulsions</p>\n<p>\u008d</p>\n<p>Controlling blood pressure</p>\n<p>\u008d</p>\n<p>Delivering the baby as soon as possible</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First aid</p>\n<p>\u0089</p>\n<p>Protect the airway by placing the patient on her left side</p>\n<p>- Prevent patient from hurting herself</p>\n<p>\u0089</p>\n<p>Place padded tongue blade between her teeth to prevent</p>\n<p>tongue bite, and secure it to prevent aspiration \u2013 DO</p>\n<p>NOT attempt this during a convulsion</p>\n<p>\u0089</p>\n<p>Do not restrict/restrain the patient while fitting</p>\n<p>\u0089</p>\n<p>Refer to hospital as soon as possible</p>\n<h3>HC2</h3>\n<p>Stop and control convulsions</p>\n<p>\u0089</p>\n<p>Give IV loading dose of magnesium sulphate</p>\n<p>\u0089</p>\n<p>injection (4 g of MgSO4)</p>\n<p>\u0089</p>\n<p>Draw 8 mL of a 50% MgSO4 and add 12 mL of water</p>\n<p>for injection or Normal saline: this is equal to 4 g of</p>\n<p>20% MgSO4</p>\n<p>\u0089</p>\n<p>Give the solution as slow IV bolus over 20 minutes (the</p>\n<p>20-20-20 rule)</p>\n<p>\u0089</p>\n<p>Then give 5 g of magnesium sulphate (10 mL of MgSO4</p>\n<p>50% solution, undiluted) in each buttock deep IM (total</p>\n<p>10 g) with 1 mL of 2% lignocaine in the same syringe</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>Give IV fluids (Normal saline) very slowly (1 L in 6-8</p>\n<p>hours max)</p>\n<p>\u0089</p>\n<p>Monitor BP, pulse, and respiration every 30 minutes;</p>\n<p>pass indwelling Foley\u2019s catheter for continuous bladder</p>\n<p>drainage</p>"
    },
    {
        "page_number": 801,
        "content": "735\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n\t\n\u0089\nMonitor fluid balance\nHC3\nIf the facility has capacity, continue with maintenance \ndose after 4 hours from the loading dose, ONLY IF:\n\t\n\u0089\nUrine output >100 mL in 4 hours f Respiratory rate is \n>16 per minute f Patellar reflexes (knee jerk) are present\nSigns of magnesium sulphate toxicity\n\t\n\u0089\nRespiratory depression, rate <16 breaths per minute\n\t\n\u0089\nUrine output <30 mL/hour\n\t\n\u0089\nDepressed patellar reflexes\nAntidote for magnesium sulphate\n\t\n\u0089\nGive calcium gluconate 1 g (10 mL of 10%) slow IV, not \nexceeding 5 mL per minute. Repeat prn until respiratoty \nrate gets back to normal (rate >16 breaths per minute)\nMaintenance dose\n\t\n\u0089\nMagnesium sulphate 5 g IM (10 mL of MgSO4 50% \nsolution) every 4 hours in alternate buttocks for 24 \nhours from the time of loading dose or after the last \nconvulsion; whichever comes first. Add 1 mL of ligno\u00ad\ncaine 2% in the same syringe\nH\nIf there are further convulsions\n\t\n\u0089\nRepeat \u00bd of the loading dose of magnesium sulphate \n(2 g of 20% solution given IV, slowly)\nONLY IF magnesium sulphate is not available use\n\t\n\u0089\nDiazepam 10 mg slow IV over 2 minutes loading dose, \n(repeat once if convulsions recur)\n\t\n\u0089\nDiazepam 40 mg in 500 mL of normal saline IV infusion \nto run slowly, keeping the patient sedated but rousable\nNote\n \n\u0083 Notify the person who will resuscitate the newborn \nthat a benzodiazepine and/or magnesium sulphate \nhas been given to the mother\nControl blood pressure: if BP is >110 mmHg diastolic \nor >170 mmHg systolic\n\t\n\u0089\nGive hydralazine 5 mg IV bolus every 30 minutes until\nH\nRR",
        "formatted_content": "<p>735</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Monitor fluid balance</p>\n<h3>HC3</h3>\n<p>If the facility has capacity, continue with maintenance</p>\n<p>dose after 4 hours from the loading dose, ONLY IF:</p>\n<p>\u0089</p>\n<p>Urine output >100 mL in 4 hours f Respiratory rate is</p>\n<p>>16 per minute f Patellar reflexes (knee jerk) are present</p>\n<p>Signs of magnesium sulphate toxicity</p>\n<p>\u0089</p>\n<p>Respiratory depression, rate <16 breaths per minute</p>\n<p>\u0089</p>\n<p>Urine output <30 mL/hour</p>\n<p>\u0089</p>\n<p>Depressed patellar reflexes</p>\n<p>Antidote for magnesium sulphate</p>\n<p>\u0089</p>\n<p>Give calcium gluconate 1 g (10 mL of 10%) slow IV, not</p>\n<p>exceeding 5 mL per minute. Repeat prn until respiratoty</p>\n<p>rate gets back to normal (rate >16 breaths per minute)</p>\n<p>Maintenance dose</p>\n<p>\u0089</p>\n<p>Magnesium sulphate 5 g IM (10 mL of MgSO4 50%</p>\n<p>solution) every 4 hours in alternate buttocks for 24</p>\n<p>hours from the time of loading dose or after the last</p>\n<p>convulsion; whichever comes first. Add 1 mL of ligno\u00ad</p>\n<p>caine 2% in the same syringe</p>\n<p>H</p>\n<p>If there are further convulsions</p>\n<p>\u0089</p>\n<p>Repeat \u00bd of the loading dose of magnesium sulphate</p>\n<p>(2 g of 20% solution given IV, slowly)</p>\n<p>ONLY IF magnesium sulphate is not available use</p>\n<p>\u0089</p>\n<p>Diazepam 10 mg slow IV over 2 minutes loading dose,</p>\n<p>(repeat once if convulsions recur)</p>\n<p>\u0089</p>\n<p>Diazepam 40 mg in 500 mL of normal saline IV infusion</p>\n<p>to run slowly, keeping the patient sedated but rousable</p>\n<p>Note</p>\n<p>\u0083 Notify the person who will resuscitate the newborn</p>\n<p>that a benzodiazepine and/or magnesium sulphate</p>\n<p>has been given to the mother</p>\n<p>Control blood pressure: if BP is >110 mmHg diastolic</p>\n<p>or >170 mmHg systolic</p>\n<p>\u0089</p>\n<p>Give hydralazine 5 mg IV bolus every 30 minutes until</p>\n<p>H</p>\n<p>RR</p>"
    },
    {
        "page_number": 802,
        "content": "736\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\ndiastolic is BP is down to <100 mmHg\n\t\n\u0089\nAlternative, if hydralazine not available: Nifedipine 20 \nmg orally every 12 hours until delivery\n\t\n\u0089\nOr Labetalol 20 mg IV over 2 minutes, double the dose \nevery 30 minutes until diastolic is <100 mmHg (total \ndose not to exceed 160 mg/hour)\nH\nRR\n\t\n\u0089\nMaintenance antihypertensive therapy is necessary after \ncontrolling the BP. Maintain the patient on Nifedipine \nretard 20 mg 12 hourly until delivery\n\t\n\u0089\nMonitor BP every 15 minutes until stable (when systolic \nBP <170 and Diastolic <100 mmHg)\nH\nRR\nDeliver the baby by the safest and fastest means available \nwithin 6-12 hours\n\t\n\u0089\nAugment labour if mother is approaching second \nstage with nor contraindication to vaginal delivery and \ntheatre is nearby\nH\n\t\n\u0089\nPerform vacuum extraction if mother is in second stage \nand there is no contraindication\n\t\n\u0089\nDeliver by emergency caesarian section if facilities are \navailable\nPost delivery care\n\t\n\u0089\nMonitor BP every 15 minutes for 2 hours\n\t\n\u0089\nContinue to monitor vital signs (BP, urine protein, etc) \nvery carefully for at least 48 hours\n\t\n\u0089\nContinue antihypertensive to mantain BP diastolic \n<90 mmHg\n\t\n\u0089\nSend home when BP is stable and no urine protein\n\t\n\u0089\nContinue antihypertensive according to clinical mon\u00ad\nitoring\nNote\n \n\u0083 Hypertension usually resolves with birth of the \nbaby, but may persist (e.g. in case of undiagnosed \npre existent hypertension)",
        "formatted_content": "<p>736</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>diastolic is BP is down to <100 mmHg</p>\n<p>\u0089</p>\n<p>Alternative, if hydralazine not available: Nifedipine 20</p>\n<p>mg orally every 12 hours until delivery</p>\n<p>\u0089</p>\n<p>Or Labetalol 20 mg IV over 2 minutes, double the dose</p>\n<p>every 30 minutes until diastolic is <100 mmHg (total</p>\n<p>dose not to exceed 160 mg/hour)</p>\n<p>H</p>\n<p>RR</p>\n<p>\u0089</p>\n<p>Maintenance antihypertensive therapy is necessary after</p>\n<p>controlling the BP. Maintain the patient on Nifedipine</p>\n<p>retard 20 mg 12 hourly until delivery</p>\n<p>\u0089</p>\n<p>Monitor BP every 15 minutes until stable (when systolic</p>\n<p>BP <170 and Diastolic <100 mmHg)</p>\n<p>H</p>\n<p>RR</p>\n<p>Deliver the baby by the safest and fastest means available</p>\n<p>within 6-12 hours</p>\n<p>\u0089</p>\n<p>Augment labour if mother is approaching second</p>\n<p>stage with nor contraindication to vaginal delivery and</p>\n<p>theatre is nearby</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Perform vacuum extraction if mother is in second stage</p>\n<p>and there is no contraindication</p>\n<p>\u0089</p>\n<p>Deliver by emergency caesarian section if facilities are</p>\n<p>available</p>\n<p>Post delivery care</p>\n<p>\u0089</p>\n<p>Monitor BP every 15 minutes for 2 hours</p>\n<p>\u0089</p>\n<p>Continue to monitor vital signs (BP, urine protein, etc)</p>\n<p>very carefully for at least 48 hours</p>\n<p>\u0089</p>\n<p>Continue antihypertensive to mantain BP diastolic</p>\n<p><90 mmHg</p>\n<p>\u0089</p>\n<p>Send home when BP is stable and no urine protein</p>\n<p>\u0089</p>\n<p>Continue antihypertensive according to clinical mon\u00ad</p>\n<p>itoring</p>\n<p>Note</p>\n<p>\u0083 Hypertension usually resolves with birth of the</p>\n<p>baby, but may persist (e.g. in case of undiagnosed</p>\n<p>pre existent hypertension)</p>"
    },
    {
        "page_number": 803,
        "content": "737\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.4 LABOUR, DELIVERY AND ACUTE COMPLICATIONS\n16.4.1     Normal Labour and Delivery                       ICD10 CODE: O80\nLabour is a physiological process by which the uterus expels the foetus \nand other products of conception. Labour can last from between 6 to \n18 hours; being longer for first pregnancies.\nNormal labour is characterized by:\n \n\u008d\nOnset of regular uterine contractions at term\n \n\u008d\nProgressive cervical dilatation\n \n\u008d\nExpulsion of the foetus\nFIRST STAGE OF LABOUR\n \n\u008d\nFrom onset of labour to full dilation of the cervix\n \n\u008d\nThe presenting part descends well into the midpelvis\nWhat to do\n\t\n\u0089\nProvide rapid counselling and testing for HIV if it was not done \nduring prenatal period\n\t\n\u0089\nMake correct diagnosis of labour\n\t\n\u0089\nOpen a partogram for the patient and monitor progress of labour\n\t\n\u0089\nVaginal examinations every 2 to 4 hours. Expected rate of cer\u00ad\nvical dilatation is at least 1 cm/hour. Examine every hour once \nan 8 cm dilatation has been reached\n\t\n\u0089\nObserve change of shape of foetal head (moulding), foetal position, \nand caput. Descent is assessed by abdominal palpation noting \nhow much of the head you can feel above the pelvis\n\t\n\u0089\nCheck uterine contractions\n\t\n\u0089\nHourly monitoring of mother\u2019s BP, temperature, pulse and res\u00ad\npiration. Check ketones and proteins in urine, and Hb\nPrevention\n \n\u008d\nRegular attendance of good antenatal care with a skilled \nbirth attendant, and checking of blood pressure and urine \nprotein.",
        "formatted_content": "<p>737</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>16.4 LABOUR, DELIVERY AND ACUTE COMPLICATIONS</h3>\n<p>16.4.1     Normal Labour and Delivery                       ICD10 CODE: O80</p>\n<p>Labour is a physiological process by which the uterus expels the foetus</p>\n<p>and other products of conception. Labour can last from between 6 to</p>\n<p>18 hours; being longer for first pregnancies.</p>\n<p>Normal labour is characterized by:</p>\n<p>\u008d</p>\n<p>Onset of regular uterine contractions at term</p>\n<p>\u008d</p>\n<p>Progressive cervical dilatation</p>\n<p>\u008d</p>\n<p>Expulsion of the foetus</p>\n<h3>FIRST STAGE OF LABOUR</h3>\n<p>\u008d</p>\n<p>From onset of labour to full dilation of the cervix</p>\n<p>\u008d</p>\n<p>The presenting part descends well into the midpelvis</p>\n<p>What to do</p>\n<p>\u0089</p>\n<p>Provide rapid counselling and testing for HIV if it was not done</p>\n<p>during prenatal period</p>\n<p>\u0089</p>\n<p>Make correct diagnosis of labour</p>\n<p>\u0089</p>\n<p>Open a partogram for the patient and monitor progress of labour</p>\n<p>\u0089</p>\n<p>Vaginal examinations every 2 to 4 hours. Expected rate of cer\u00ad</p>\n<p>vical dilatation is at least 1 cm/hour. Examine every hour once</p>\n<p>an 8 cm dilatation has been reached</p>\n<p>\u0089</p>\n<p>Observe change of shape of foetal head (moulding), foetal position,</p>\n<p>and caput. Descent is assessed by abdominal palpation noting</p>\n<p>how much of the head you can feel above the pelvis</p>\n<p>\u0089</p>\n<p>Check uterine contractions</p>\n<p>\u0089</p>\n<p>Hourly monitoring of mother\u2019s BP, temperature, pulse and res\u00ad</p>\n<p>piration. Check ketones and proteins in urine, and Hb</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Regular attendance of good antenatal care with a skilled</p>\n<p>birth attendant, and checking of blood pressure and urine</p>\n<p>protein.</p>"
    },
    {
        "page_number": 804,
        "content": "738\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n\t\n\u0089\nCheck foetal heart rate (FHR) for 1 minute every 30 minutes. \nA normal FHR is 120 to 160 beats per minute; FHR >160 or \n<120 beats per minute indicates foetal distress\n\t\n\u0089\nObserve state of membranes and colour of amniotic fluid if \nmembranes are ruptured\nHydration and nourishment\n\t\n\u0089\nEnsure oral or IV fluid intake especially in prolonged labour, to \navoid dehydration and ketosis\n\t\n\u0089\nGive normal saline and Dextrose solution as required\nAnalgesia\n\t\n\u0089\nProvide appropriate analgesia if desired by the patient e.g. \nmorphine 10 mg IM stat at 4-6 cm dilatation\n2ND STAGE OF LABOUR\n \n\u008d\nFrom full dilatation to expulsion of the foetus\n \n\u008d\nContractions become strong and frequent\n \n\u008d\nPatient bears down\n \n\u008d\nPerineum bulges and overlying skin becomes tense and \nshiny\nWhat to do\n\t\n\u0089\nEnsure full dilatation of the cervix by vaginal examination\n\t\n\u0089\nEncourage the mother to bear down with contractions, and \nrelax in between\n\t\n\u0089\nProtect the perineum from tearing by supporting with fingers \nat crowning\n\t\n\u0089\nDo an epsiotomy under local anaesthesia if required\n\t\n\u0089\nAllow the baby\u2019s head to rest when it is born and loose cord from \naround the neck if present. If cord is too tight, clamp it with two \nartery forceps and cut it.\n\t\n\u0089\nSupport the head during delivery. Anterior shoulder is delivered \nfirst followed by posterior.\n\t\n\u0089\nPlace the baby on mother\u2019s abdomen or arms. Dry the baby, \nwipe eyes\n\t\n\u0089\nIf baby not crying, assess breathing. Rub the back 2-3 times. If \nnot breathing resuscitate (see section 16.5.1)",
        "formatted_content": "<p>738</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u0089</p>\n<p>Check foetal heart rate (FHR) for 1 minute every 30 minutes.</p>\n<p>A normal FHR is 120 to 160 beats per minute; FHR >160 or</p>\n<p><120 beats per minute indicates foetal distress</p>\n<p>\u0089</p>\n<p>Observe state of membranes and colour of amniotic fluid if</p>\n<p>membranes are ruptured</p>\n<p>Hydration and nourishment</p>\n<p>\u0089</p>\n<p>Ensure oral or IV fluid intake especially in prolonged labour, to</p>\n<p>avoid dehydration and ketosis</p>\n<p>\u0089</p>\n<p>Give normal saline and Dextrose solution as required</p>\n<p>Analgesia</p>\n<p>\u0089</p>\n<p>Provide appropriate analgesia if desired by the patient e.g.</p>\n<p>morphine 10 mg IM stat at 4-6 cm dilatation</p>\n<h3>2ND STAGE OF LABOUR</h3>\n<p>\u008d</p>\n<p>From full dilatation to expulsion of the foetus</p>\n<p>\u008d</p>\n<p>Contractions become strong and frequent</p>\n<p>\u008d</p>\n<p>Patient bears down</p>\n<p>\u008d</p>\n<p>Perineum bulges and overlying skin becomes tense and</p>\n<p>shiny</p>\n<p>What to do</p>\n<p>\u0089</p>\n<p>Ensure full dilatation of the cervix by vaginal examination</p>\n<p>\u0089</p>\n<p>Encourage the mother to bear down with contractions, and</p>\n<p>relax in between</p>\n<p>\u0089</p>\n<p>Protect the perineum from tearing by supporting with fingers</p>\n<p>at crowning</p>\n<p>\u0089</p>\n<p>Do an epsiotomy under local anaesthesia if required</p>\n<p>\u0089</p>\n<p>Allow the baby\u2019s head to rest when it is born and loose cord from</p>\n<p>around the neck if present. If cord is too tight, clamp it with two</p>\n<p>artery forceps and cut it.</p>\n<p>\u0089</p>\n<p>Support the head during delivery. Anterior shoulder is delivered</p>\n<p>first followed by posterior.</p>\n<p>\u0089</p>\n<p>Place the baby on mother\u2019s abdomen or arms. Dry the baby,</p>\n<p>wipe eyes</p>\n<p>\u0089</p>\n<p>If baby not crying, assess breathing. Rub the back 2-3 times. If</p>\n<p>not breathing resuscitate (see section 16.5.1)</p>"
    },
    {
        "page_number": 805,
        "content": "739\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n\t\n\u0089\nAfter the baby is born, palpate mother\u2019s abdomen to exclude \nsecond baby\n\t\n\u0089\nThen give Oxytocin 10 IU IM to the mother\n\t\n\u0089\nClamp the cord and cut it (1-3 minutes after birth)\n3RD STAGE OF LABOUR\n \n~\nFrom delivery of the baby to delivery of the placenta\nWhat to do: Child\n\t\n\u0089\nEvaluate baby\u2019s condition using APGAR (Appearance, Pulse, \nGrimace, Activity, Respiration) score, and record in the baby\u2019s \nchart. Resuscitate if necessary\n\t\n\u0089\nGive 1 mg IM stat of phytomenadione (Vitamin K) to baby\n\t\n\u0089\nClean the eyes with sterile warm water and apply tetracycline \neye ointment to baby\u2019s eyes as prophylaxis against ophthalmia \nneonatorum\n\t\n\u0089\nGive identification tag to baby, wrap in warm towels and give to \nthe mother to introduce breast feeding\n\t\n\u0089\nWeigh the baby and compare with chart \n\t\n\u0089\nGive a full physical examination to the baby f Immunize the baby\nWhat to do: Mother\n\t\n\u0089\nExamine fundal height and palpate uterus lightly to determine \nwhether it has contracted well and to exclude undiagnosed twins\n\t\n\u0089\nEnsure oxytocin 10 IU IM was given\n\t\n\u0089\nAwait strong contraction (2-3 minutes) and deliver the placenta \nby controlled cord traction. Deliver the\n\t\n\u0089\nplacenta and examine it for completeness and normalcy. Weigh \nthe placenta. If placenta is not delivered within 30 minutes, see \nRetained Placenta section 16.4.5\n\t\n\u0089\nMassage lower abdomen lightly to stimulate contraction and \nexpel clots\n\t\n\u0089\nExamine the perineum, vagina, and cervix for tears.\n\t\n\u0089\nRepair episiotomy and any tears immediately\n\t\n\u0089\nObserve for 1 to 2 hours. Monitor BP, temperature, and pulse \nrate hourly. Also do uterine palpation, vulva inspection and \nestimation of degree of blood loss\n\t\n\u0089\nRefer to postnatal ward",
        "formatted_content": "<p>739</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u0089</p>\n<p>After the baby is born, palpate mother\u2019s abdomen to exclude</p>\n<p>second baby</p>\n<p>\u0089</p>\n<p>Then give Oxytocin 10 IU IM to the mother</p>\n<p>\u0089</p>\n<p>Clamp the cord and cut it (1-3 minutes after birth)</p>\n<h3>3RD STAGE OF LABOUR</h3>\n<p>~</p>\n<p>From delivery of the baby to delivery of the placenta</p>\n<p>What to do: Child</p>\n<p>\u0089</p>\n<p>Evaluate baby\u2019s condition using APGAR (Appearance, Pulse,</p>\n<p>Grimace, Activity, Respiration) score, and record in the baby\u2019s</p>\n<p>chart. Resuscitate if necessary</p>\n<p>\u0089</p>\n<p>Give 1 mg IM stat of phytomenadione (Vitamin K) to baby</p>\n<p>\u0089</p>\n<p>Clean the eyes with sterile warm water and apply tetracycline</p>\n<p>eye ointment to baby\u2019s eyes as prophylaxis against ophthalmia</p>\n<p>neonatorum</p>\n<p>\u0089</p>\n<p>Give identification tag to baby, wrap in warm towels and give to</p>\n<p>the mother to introduce breast feeding</p>\n<p>\u0089</p>\n<p>Weigh the baby and compare with chart</p>\n<p>\u0089</p>\n<p>Give a full physical examination to the baby f Immunize the baby</p>\n<p>What to do: Mother</p>\n<p>\u0089</p>\n<p>Examine fundal height and palpate uterus lightly to determine</p>\n<p>whether it has contracted well and to exclude undiagnosed twins</p>\n<p>\u0089</p>\n<p>Ensure oxytocin 10 IU IM was given</p>\n<p>\u0089</p>\n<p>Await strong contraction (2-3 minutes) and deliver the placenta</p>\n<p>by controlled cord traction. Deliver the</p>\n<p>\u0089</p>\n<p>placenta and examine it for completeness and normalcy. Weigh</p>\n<p>the placenta. If placenta is not delivered within 30 minutes, see</p>\n<p>Retained Placenta section 16.4.5</p>\n<p>\u0089</p>\n<p>Massage lower abdomen lightly to stimulate contraction and</p>\n<p>expel clots</p>\n<p>\u0089</p>\n<p>Examine the perineum, vagina, and cervix for tears.</p>\n<p>\u0089</p>\n<p>Repair episiotomy and any tears immediately</p>\n<p>\u0089</p>\n<p>Observe for 1 to 2 hours. Monitor BP, temperature, and pulse</p>\n<p>rate hourly. Also do uterine palpation, vulva inspection and</p>\n<p>estimation of degree of blood loss</p>\n<p>\u0089</p>\n<p>Refer to postnatal ward</p>"
    },
    {
        "page_number": 806,
        "content": "740\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.4.2    Induction of Labour\nInduction of labour may be indicated for medical reasons, like, pre-ec\u00ad\nlampsia, diabetes, post-term pregnancy.\nHowever, possible risks of induction are:\n\t\n\u0089\nFailed induction\n\t\n\u0089\nHyperstimulation syndrome, requiring emergency caesarean section.\nInduction is contraindicated in para 5 and above and in patients with a \nprevious scar. In these cases there is indication for caesarean section.\nTREATMENT\nLOC\nCervix favourable in HIV and Hep B negative mothers\n\t\n\u0089\nArtifically rupture the membranes (with amniotic hook \nor Kocher clamp) followed 2 hours later by\n\t\n\u0089\nOxytocin IV 2.5 IU in 500 mL of Normal saline.\n\t\n\u0089\nStart with 10 drops/minute\n\t\n\u0089\nIncrease infusion rate by 10 drops every 30 minutes \n(max 60 minutes) until good contraction pattern is \nestablished (3-5 contractions in 10 minutes each last\u00ad\ning >40 secs), and maintain until delivery is complete\n\t\n\u0089\nIf no good contraction pattern with 60 drops/ minute, \nincrease oxytocin concentration to 5 IU in 500 mL of \nDextrose or Normal saline at 30 drops/minute, increase \nby 10 drops every 30 minutes until maximum of 60 \ndrops/minute\n\t\n\u0089\nONLY IN PRIMIGRAVIDA: if no good contraction \npattern established, increase concentration of oxytocin \nto 10 IU in 500 mL and repeat as above (from 30 to \n60 drops/minute)\n\t\n\u0089\nDO NOT USE 10 IU in 500 mL in MULTIGRAVIDA or \nWOMEN WITH PREVIOUS CAESAREAN SECTION\n\t\n\u0089\nRefer other cases or primigravida not responding to the \nhigher concentration for surgical management\n\t\n\u0089\nNEVER LEAVE THE WOMAN ALONE\nH",
        "formatted_content": "<p>740</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.4.2    Induction of Labour</p>\n<p>Induction of labour may be indicated for medical reasons, like, pre-ec\u00ad</p>\n<p>lampsia, diabetes, post-term pregnancy.</p>\n<p>However, possible risks of induction are:</p>\n<p>\u0089</p>\n<p>Failed induction</p>\n<p>\u0089</p>\n<p>Hyperstimulation syndrome, requiring emergency caesarean section.</p>\n<p>Induction is contraindicated in para 5 and above and in patients with a</p>\n<p>previous scar. In these cases there is indication for caesarean section.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Cervix favourable in HIV and Hep B negative mothers</p>\n<p>\u0089</p>\n<p>Artifically rupture the membranes (with amniotic hook</p>\n<p>or Kocher clamp) followed 2 hours later by</p>\n<p>\u0089</p>\n<p>Oxytocin IV 2.5 IU in 500 mL of Normal saline.</p>\n<p>\u0089</p>\n<p>Start with 10 drops/minute</p>\n<p>\u0089</p>\n<p>Increase infusion rate by 10 drops every 30 minutes</p>\n<p>(max 60 minutes) until good contraction pattern is</p>\n<p>established (3-5 contractions in 10 minutes each last\u00ad</p>\n<p>ing >40 secs), and maintain until delivery is complete</p>\n<p>\u0089</p>\n<p>If no good contraction pattern with 60 drops/ minute,</p>\n<p>increase oxytocin concentration to 5 IU in 500 mL of</p>\n<p>Dextrose or Normal saline at 30 drops/minute, increase</p>\n<p>by 10 drops every 30 minutes until maximum of 60</p>\n<p>drops/minute</p>\n<p>\u0089</p>\n<p>ONLY IN PRIMIGRAVIDA: if no good contraction</p>\n<p>pattern established, increase concentration of oxytocin</p>\n<p>to 10 IU in 500 mL and repeat as above (from 30 to</p>\n<p>60 drops/minute)</p>\n<p>\u0089</p>\n<p>DO NOT USE 10 IU in 500 mL in MULTIGRAVIDA or</p>\n<h3>WOMEN WITH PREVIOUS CAESAREAN SECTION</h3>\n<p>\u0089</p>\n<p>Refer other cases or primigravida not responding to the</p>\n<p>higher concentration for surgical management</p>\n<p>\u0089</p>\n<h3>NEVER LEAVE THE WOMAN ALONE</h3>\n<p>H</p>"
    },
    {
        "page_number": 807,
        "content": "741\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nIf >4 contractions in 10 minutes, or contraction \nlonger than 60 secs or foetal distress:\n\t\n\u0089\nStop rate of infusion\n\t\n\u0089\nGive salbutamol 5 mg in RL or NS 500 mL IV infusion \nat 10 drops/minute\n\t\n\u0089\nMonitor foetal heart rate\nCervix not favourable\n\t\n\u0089\nRipen cervix using either\n\t\n\u0089\nMisoprostol 25 micrograms inserted vaginally every \n6 hours for 2 doses, if no response increase to 50 \nmicrograms every 6 hours, max 200 micrograms in \n24 hours \u2013 stop when in established labour\n\t\n\u0089\nOr misoprostol 20 micrograms orally (dissolve 1 200 \nmicrogram tablet in 200 mL of water and give 20 mL) \nevery 2 hours until labour starts or max 24 hours\nH\n\t\n\u0089\nOr Foley catheter: insert Foley catheter through internal \ncervical os under sterile technique, inflate bulb with 50 \nmL of water, and tape catheter under light traction, leave \nit until contraction begins or up to 12 hours\n\t\n\u0089\nIf cervical ripening, proceed to cesarean section\n\t\n\u0089\nIf cervix ripens but labour does no start, start oxytocin \ninduction\nCaution\n \n\u0083 Do not start oxytocin within 8 hours of using \nmisoprostol\n \n\u0083 Carefully control oxytocin infusion \u2013 do not give \nrapidly\n \n\u0083 Monitor uterine contractions and foetal heart \nrate closely\n \n\u0083 If foetal distress, do emergency cesarean section",
        "formatted_content": "<p>741</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If >4 contractions in 10 minutes, or contraction</p>\n<p>longer than 60 secs or foetal distress:</p>\n<p>\u0089</p>\n<p>Stop rate of infusion</p>\n<p>\u0089</p>\n<p>Give salbutamol 5 mg in RL or NS 500 mL IV infusion</p>\n<p>at 10 drops/minute</p>\n<p>\u0089</p>\n<p>Monitor foetal heart rate</p>\n<p>Cervix not favourable</p>\n<p>\u0089</p>\n<p>Ripen cervix using either</p>\n<p>\u0089</p>\n<p>Misoprostol 25 micrograms inserted vaginally every</p>\n<p>6 hours for 2 doses, if no response increase to 50</p>\n<p>micrograms every 6 hours, max 200 micrograms in</p>\n<p>24 hours \u2013 stop when in established labour</p>\n<p>\u0089</p>\n<p>Or misoprostol 20 micrograms orally (dissolve 1 200</p>\n<p>microgram tablet in 200 mL of water and give 20 mL)</p>\n<p>every 2 hours until labour starts or max 24 hours</p>\n<p>H</p>\n<p>\u0089</p>\n<p>Or Foley catheter: insert Foley catheter through internal</p>\n<p>cervical os under sterile technique, inflate bulb with 50</p>\n<p>mL of water, and tape catheter under light traction, leave</p>\n<p>it until contraction begins or up to 12 hours</p>\n<p>\u0089</p>\n<p>If cervical ripening, proceed to cesarean section</p>\n<p>\u0089</p>\n<p>If cervix ripens but labour does no start, start oxytocin</p>\n<p>induction</p>\n<p>Caution</p>\n<p>\u0083 Do not start oxytocin within 8 hours of using</p>\n<p>misoprostol</p>\n<p>\u0083 Carefully control oxytocin infusion \u2013 do not give</p>\n<p>rapidly</p>\n<p>\u0083 Monitor uterine contractions and foetal heart</p>\n<p>rate closely</p>\n<p>\u0083 If foetal distress, do emergency cesarean section</p>"
    },
    {
        "page_number": 808,
        "content": "742\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCauses\n \n\u008d\nCephalopelvic disproportion (CPD)\n \n\u008d\nLarge baby\n \n\u008d\nFoetal abnormalities: hydrocephalus, conjoined twins\n \n\u008d\nSmall or deformed pelvis\n \n\u008d\nMalpresentation: the presenting part of the foetus is not the \nhead, e.g. breech presentation, shoulder presentation, face, \netc\n \n\u008d\nMalposition: an abnormal position of the foetal head when \nthis is the presenting part, e.g. occipito-posterior\n \n\u008d\nAny barrier that prevents the baby\u2019s descent down the birth \ncanal\nClinical features\n \n\u008d\nContractions are strong but no evidence of descent of the \npresenting part\n \n\u008d\nMalposition or malpresentation may be felt on abdominal \nexamination\n \n\u008d\nIn a first delivery, the pains will just stop spontaneously\n \n\u008d\nFoetal distress with meconium stained liqour\n \n\u008d\nFever and dehydration with maternal exhaustion\n \n\u008d\nIn late stages, the regular colicky strong pains may stop when \nthe uterus is ruptured, and be replaced by a dull continuous \npain\n \n\u008d\nSigns of shock if the uterus has ruptured\n \n\u008d\nPhysical examination reveals signs of shock, tender uterus, \nformation of a Bandl\u2019s ring, vulva may be oedematous, vagi\u00ad\n16.4.3      Obstructed Labour\t\n                   ICD10 CODE: O64-O66\nFailure of labour to progress despite good uterine contractions.",
        "formatted_content": "<p>742</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Cephalopelvic disproportion (CPD)</p>\n<p>\u008d</p>\n<p>Large baby</p>\n<p>\u008d</p>\n<p>Foetal abnormalities: hydrocephalus, conjoined twins</p>\n<p>\u008d</p>\n<p>Small or deformed pelvis</p>\n<p>\u008d</p>\n<p>Malpresentation: the presenting part of the foetus is not the</p>\n<p>head, e.g. breech presentation, shoulder presentation, face,</p>\n<p>etc</p>\n<p>\u008d</p>\n<p>Malposition: an abnormal position of the foetal head when</p>\n<p>this is the presenting part, e.g. occipito-posterior</p>\n<p>\u008d</p>\n<p>Any barrier that prevents the baby\u2019s descent down the birth</p>\n<p>canal</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Contractions are strong but no evidence of descent of the</p>\n<p>presenting part</p>\n<p>\u008d</p>\n<p>Malposition or malpresentation may be felt on abdominal</p>\n<p>examination</p>\n<p>\u008d</p>\n<p>In a first delivery, the pains will just stop spontaneously</p>\n<p>\u008d</p>\n<p>Foetal distress with meconium stained liqour</p>\n<p>\u008d</p>\n<p>Fever and dehydration with maternal exhaustion</p>\n<p>\u008d</p>\n<p>In late stages, the regular colicky strong pains may stop when</p>\n<p>the uterus is ruptured, and be replaced by a dull continuous</p>\n<p>pain</p>\n<p>\u008d</p>\n<p>Signs of shock if the uterus has ruptured</p>\n<p>\u008d</p>\n<p>Physical examination reveals signs of shock, tender uterus,</p>\n<p>formation of a Bandl\u2019s ring, vulva may be oedematous, vagi\u00ad</p>\n<p>16.4.3      Obstructed Labour</p>\n<h3>ICD10 CODE: O64-O66</h3>\n<p>Failure of labour to progress despite good uterine contractions.</p>"
    },
    {
        "page_number": 809,
        "content": "743\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nna is hot and dry, there\u2019s usually a large caput\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nSet up an IV normal saline line and rehydrate the \npatient to maintain plasma volume and treat dehy\u00ad\ndration and ketosis\nHC3\nHC4 \n\t\n\u0089\nStart 5-day course of antibiotics: Amoxicillin 500 mg \nevery 8 hours or erythromycin 500 mg every 6 hours\n\t\n\u0089\nPlus metronidazole 400 mg every 8 hours\n\t\n\u0089\nRefer urgently to HC4/Hospital for further management\nHC3\nHC4 \nH\nNote\n \n\u0081\nEvery woman with prolonged/obstructed labour should receive \nthe management protocol for prevention of obstetric fistula \n(see section 16.6.4)\nPrevention\n \n\u008d\nCareful monitoring of labour using a partogram for early \nrecognition\n \n\u008d\nActive management of labour\n16.4.4   Ruptured Uterus\t                   ICD10 CODE: O71.1\nPartial or complete tearing of the uterus, common in:\n \n\u008d\nMultiparous women (i.e. have had >1 live babies)\n \n\u008d\nWomen with previous caesarean section\nCauses/predisposing factors\n \n\u008d\nAssisted deliveries/obstetric procedures\n \n\u008d\nNeglected obstructed labour\n \n\u008d\nTearing of a poorly-healed uterine scar during labour\n \n\u008d\nShort interpregnancy interval of less than 18 months after \nCaeserean Section\n \n\u008d\nPrevious history of uterine surgery, e.g. myomectomy",
        "formatted_content": "<p>743</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>na is hot and dry, there\u2019s usually a large caput</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Set up an IV normal saline line and rehydrate the</p>\n<p>patient to maintain plasma volume and treat dehy\u00ad</p>\n<p>dration and ketosis</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Start 5-day course of antibiotics: Amoxicillin 500 mg</p>\n<p>every 8 hours or erythromycin 500 mg every 6 hours</p>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg every 8 hours</p>\n<p>\u0089</p>\n<p>Refer urgently to HC4/Hospital for further management</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>H</p>\n<p>Note</p>\n<p>\u0081</p>\n<p>Every woman with prolonged/obstructed labour should receive</p>\n<p>the management protocol for prevention of obstetric fistula</p>\n<p>(see section 16.6.4)</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Careful monitoring of labour using a partogram for early</p>\n<p>recognition</p>\n<p>\u008d</p>\n<p>Active management of labour</p>\n<p>16.4.4   Ruptured Uterus\t                   ICD10 CODE: O71.1</p>\n<p>Partial or complete tearing of the uterus, common in:</p>\n<p>\u008d</p>\n<p>Multiparous women (i.e. have had >1 live babies)</p>\n<p>\u008d</p>\n<p>Women with previous caesarean section</p>\n<p>Causes/predisposing factors</p>\n<p>\u008d</p>\n<p>Assisted deliveries/obstetric procedures</p>\n<p>\u008d</p>\n<p>Neglected obstructed labour</p>\n<p>\u008d</p>\n<p>Tearing of a poorly-healed uterine scar during labour</p>\n<p>\u008d</p>\n<p>Short interpregnancy interval of less than 18 months after</p>\n<p>Caeserean Section</p>\n<p>\u008d</p>\n<p>Previous history of uterine surgery, e.g. myomectomy</p>"
    },
    {
        "page_number": 810,
        "content": "744\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nDamage to uterus due to a blow, e.g. kick or accident\n \n\u008d\nUse of oxytocic herbs\nClinical features\n \n\u008d\nCessation of regular uterine contractions (labour pains)\n \n\u008d\nContinuous abdominal pain\n \n\u008d\nVaginal bleeding\n \n\u008d\nAnxiety, anaemia, and shock\n \n\u008d\nAbdomen is irregular in shape\n \n\u008d\nFoetal parts easily felt under the skin if the foetusis outside \nuterus and foetal heart is not heard\nDifferential diagnosis\n \n\u008d\nAbruptio placentae\n \n\u008d\nPlacenta praevia\n \n\u008d\nOther causes of acute abdomen in late pregnancy\n \n\u008d\nRuptured spleen\n \n\u008d\nBowel obstruction\nInvestigations\n \n\u0081\nBlood: CBC, grouping and cross-matching\nManagement\nMothers with a suspicion of ruptured uterus should be referred im\u00ad\nmediately to hospital for blood transfusion and surgical management.\nTREATMENT\nLOC\n\t\n\u0089\nSet up IV normal saline infusion\n\t\n\u0089\nGive IV ceftriaxone 2 g and IV metronidazole 500 mg \nstat then\n\t\n\u0089\nRefer to hospital immediately for surgical management \n(cesarean section \u00b1 hysterectomy)\nHC3\nH",
        "formatted_content": "<p>744</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>Damage to uterus due to a blow, e.g. kick or accident</p>\n<p>\u008d</p>\n<p>Use of oxytocic herbs</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Cessation of regular uterine contractions (labour pains)</p>\n<p>\u008d</p>\n<p>Continuous abdominal pain</p>\n<p>\u008d</p>\n<p>Vaginal bleeding</p>\n<p>\u008d</p>\n<p>Anxiety, anaemia, and shock</p>\n<p>\u008d</p>\n<p>Abdomen is irregular in shape</p>\n<p>\u008d</p>\n<p>Foetal parts easily felt under the skin if the foetusis outside</p>\n<p>uterus and foetal heart is not heard</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Abruptio placentae</p>\n<p>\u008d</p>\n<p>Placenta praevia</p>\n<p>\u008d</p>\n<p>Other causes of acute abdomen in late pregnancy</p>\n<p>\u008d</p>\n<p>Ruptured spleen</p>\n<p>\u008d</p>\n<p>Bowel obstruction</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: CBC, grouping and cross-matching</p>\n<p>Management</p>\n<p>Mothers with a suspicion of ruptured uterus should be referred im\u00ad</p>\n<p>mediately to hospital for blood transfusion and surgical management.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Set up IV normal saline infusion</p>\n<p>\u0089</p>\n<p>Give IV ceftriaxone 2 g and IV metronidazole 500 mg</p>\n<p>stat then</p>\n<p>\u0089</p>\n<p>Refer to hospital immediately for surgical management</p>\n<p>(cesarean section \u00b1 hysterectomy)</p>\n<h3>HC3</h3>\n<p>H</p>"
    },
    {
        "page_number": 811,
        "content": "745\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nPrevention\n \n\u008d\nGood ANC and education on early arrival to the facility for \nlabour and delivery\n \n\u008d\nSkilled birth attendance at all deliveries\n \n\u008d\nCareful monitoring of labour using a partogram\n \n\u008d\nMinimise the use of oxytocin in multiparous women\n \n\u008d\nDo not attempt fundal pressure during labour\n \n\u008d\nDO NOT use misoprostol for induction of labor\n16.4.5    Retained Placenta\t\n             ICD10 CODE: O73\nFailure of delivery of placenta within 30 minutes of delivery of the baby.\nCauses\n \n\u008d\nPoor management of 3rd stage of labour\n \n\u008d\nFailure of the uterus to contract\n \n\u008d\nFailure of the placenta to separate, e.g. if it is stuck in uterine \nmuscle; placenta accreta\n \n\u008d\nClosing of the cervix before the placenta is expelled\nClinical features\n \n\u008d\nThe umbilical cord protrudes from the vagina\n \n\u008d\nBleeding may be present (in partial separation)\n \n\u008d\nUterus may be poorly contracted and high in the abdomen\n \n\u008d\nMay be signs of infection, e.g. fever, unpleasant bloody dis\u00ad\ncharge if the placenta is retained for long\nDifferential diagnosis\n \n\u008d\nRetained second twin\n \n\u008d\nRuptured uterus",
        "formatted_content": "<p>745</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Good ANC and education on early arrival to the facility for</p>\n<p>labour and delivery</p>\n<p>\u008d</p>\n<p>Skilled birth attendance at all deliveries</p>\n<p>\u008d</p>\n<p>Careful monitoring of labour using a partogram</p>\n<p>\u008d</p>\n<p>Minimise the use of oxytocin in multiparous women</p>\n<p>\u008d</p>\n<p>Do not attempt fundal pressure during labour</p>\n<p>\u008d</p>\n<p>DO NOT use misoprostol for induction of labor</p>\n<p>16.4.5    Retained Placenta</p>\n<h3>ICD10 CODE: O73</h3>\n<p>Failure of delivery of placenta within 30 minutes of delivery of the baby.</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Poor management of 3rd stage of labour</p>\n<p>\u008d</p>\n<p>Failure of the uterus to contract</p>\n<p>\u008d</p>\n<p>Failure of the placenta to separate, e.g. if it is stuck in uterine</p>\n<p>muscle; placenta accreta</p>\n<p>\u008d</p>\n<p>Closing of the cervix before the placenta is expelled</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>The umbilical cord protrudes from the vagina</p>\n<p>\u008d</p>\n<p>Bleeding may be present (in partial separation)</p>\n<p>\u008d</p>\n<p>Uterus may be poorly contracted and high in the abdomen</p>\n<p>\u008d</p>\n<p>May be signs of infection, e.g. fever, unpleasant bloody dis\u00ad</p>\n<p>charge if the placenta is retained for long</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Retained second twin</p>\n<p>\u008d</p>\n<p>Ruptured uterus</p>"
    },
    {
        "page_number": 812,
        "content": "746\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nInvestigations\n \n\u0081\nBlood: Hb, grouping and cross-matching\nManagement\nTREATMENT\nLOC\nIf woman is bleeding, manage as PPH (section 16.4.6)\nIf woman not bleeding\n\t\n\u0089\nSet up IV normal saline infusion\n\t\n\u0089\nEmpty the bladder (voluntarily or catheterise)\n\t\n\u0089\nEncourage breastfeeding\n\t\n\u0089\nRepeat controlled cord contraction\nIf placenta is not delivered in another 30 minutes\n\t\n\u0089\nPerform manual removal of placenta (use\n\t\n\u0089\ndiazepam 10 mg IM/IV)\n\t\n\u0089\nRepeat Oxytocin 10 IU IM or slow IV injection after \nmanual removal\n\t\n\u0089\nIf no signs of infection and no obstructed labour Give \nceftriaxone 2 g IV stat\n\t\n\u0089\nIf signs of infection, give antibiotics as in amnionitis\n\t\n\u0089\nIf obstructed labour, give antibiotic prophylaxis as indi\u00ad\ncated in section 16.4.3\nHC3\nIf unable to remove placenta manually\n\t\n\u0089\nGive ceftriaxone 2 g IV stat\n\t\n\u0089\nGive oxytocin 20 IU in Normal saline 500 cc at 30 \ndrops per minute during transfer\n\t\n\u0089\nRefer to HC4 or Hospital\nHC4 \nH\n16.4.6 Postpartum Haemorrhage (PPH)    ICD10 CODE: O72\nVaginal bleeding of more than 500 mL after vaginal delivery or >1000 \nmL after caesarean section.",
        "formatted_content": "<p>746</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Hb, grouping and cross-matching</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If woman is bleeding, manage as PPH (section 16.4.6)</p>\n<p>If woman not bleeding</p>\n<p>\u0089</p>\n<p>Set up IV normal saline infusion</p>\n<p>\u0089</p>\n<p>Empty the bladder (voluntarily or catheterise)</p>\n<p>\u0089</p>\n<p>Encourage breastfeeding</p>\n<p>\u0089</p>\n<p>Repeat controlled cord contraction</p>\n<p>If placenta is not delivered in another 30 minutes</p>\n<p>\u0089</p>\n<p>Perform manual removal of placenta (use</p>\n<p>\u0089</p>\n<p>diazepam 10 mg IM/IV)</p>\n<p>\u0089</p>\n<p>Repeat Oxytocin 10 IU IM or slow IV injection after</p>\n<p>manual removal</p>\n<p>\u0089</p>\n<p>If no signs of infection and no obstructed labour Give</p>\n<p>ceftriaxone 2 g IV stat</p>\n<p>\u0089</p>\n<p>If signs of infection, give antibiotics as in amnionitis</p>\n<p>\u0089</p>\n<p>If obstructed labour, give antibiotic prophylaxis as indi\u00ad</p>\n<p>cated in section 16.4.3</p>\n<h3>HC3</h3>\n<p>If unable to remove placenta manually</p>\n<p>\u0089</p>\n<p>Give ceftriaxone 2 g IV stat</p>\n<p>\u0089</p>\n<p>Give oxytocin 20 IU in Normal saline 500 cc at 30</p>\n<p>drops per minute during transfer</p>\n<p>\u0089</p>\n<p>Refer to HC4 or Hospital</p>\n<h3>HC4</h3>\n<p>H</p>\n<p>16.4.6 Postpartum Haemorrhage (PPH)    ICD10 CODE: O72</p>\n<p>Vaginal bleeding of more than 500 mL after vaginal delivery or >1000</p>\n<p>mL after caesarean section.</p>"
    },
    {
        "page_number": 813,
        "content": "747\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n- Primary PPH occurs in the first 24 hours after delivery\n \n- Secondary PPH occurs between 24 hours and six weeks \nafter delivery\nPPH is an EMERGENCY. It can occur in any woman and needs prompt \nrecognition and treatment.\nCauses\n \n\u008d\nTone: failure of uterus to contract, precipitated labour\n \n\u008d\nTissues: such as retained placenta (in part or whole) or \nmembranes which may lead to atony as well as infection in \nthe uterus\n \n\u008d\nTears (e.g. damage to/rupture of the perineum, vagina, \ncervix or uterus)\n \n\u008d\nThrombotic disorders which may be due to DIC following \nabruptio placenta or severe APH\nHigh risk patients\n \n\u008d\nHistory of previous PPH, multiple previous C/S, multiple \npregnancy\n \n\u008d\nPlacenta praevia, abruptio placenta\n \n\u008d\nPrecipitated labour, prolonged labour, large baby\n \n\u008d\nPatients with hypertensive disorders\nClinical features\n \n\u008d\nBleeding from the genital tract which may be a gush of blood \nor a small but persistent trickle of blood (>1 pad soaked in \nfive minutes)\n \n\u008d\nThe uterus may still be large, soft, and not contracted escially \nin primary PPH\n\t\n\u0089\nIf uterus is well contracted, look for tears on the perineum, vagina, \ncervix, or uterus",
        "formatted_content": "<p>747</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>- Primary PPH occurs in the first 24 hours after delivery</p>\n<p>- Secondary PPH occurs between 24 hours and six weeks</p>\n<p>after delivery</p>\n<p>PPH is an EMERGENCY. It can occur in any woman and needs prompt</p>\n<p>recognition and treatment.</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Tone: failure of uterus to contract, precipitated labour</p>\n<p>\u008d</p>\n<p>Tissues: such as retained placenta (in part or whole) or</p>\n<p>membranes which may lead to atony as well as infection in</p>\n<p>the uterus</p>\n<p>\u008d</p>\n<p>Tears (e.g. damage to/rupture of the perineum, vagina,</p>\n<p>cervix or uterus)</p>\n<p>\u008d</p>\n<p>Thrombotic disorders which may be due to DIC following</p>\n<p>abruptio placenta or severe APH</p>\n<p>High risk patients</p>\n<p>\u008d</p>\n<p>History of previous PPH, multiple previous C/S, multiple</p>\n<p>pregnancy</p>\n<p>\u008d</p>\n<p>Placenta praevia, abruptio placenta</p>\n<p>\u008d</p>\n<p>Precipitated labour, prolonged labour, large baby</p>\n<p>\u008d</p>\n<p>Patients with hypertensive disorders</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Bleeding from the genital tract which may be a gush of blood</p>\n<p>or a small but persistent trickle of blood (>1 pad soaked in</p>\n<p>five minutes)</p>\n<p>\u008d</p>\n<p>The uterus may still be large, soft, and not contracted escially</p>\n<p>in primary PPH</p>\n<p>\u0089</p>\n<p>If uterus is well contracted, look for tears on the perineum, vagina,</p>\n<p>cervix, or uterus</p>"
    },
    {
        "page_number": 814,
        "content": "748\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nSigns of shock may be present: tachycardia, low BP, cold and \nclammy skin\n \n\u008d\nIn secondary PPH, there may be signs of infection, e.g., \nfever, abdominal tenderness\nInvestigations\n \n\u0081\nHb and blood group should have been already done and recorded \nduring ANC; if not, do them urgently\n \n\u0081\nWomen at high risk of PPH should have blood cross- matched \nand at least 2 units booked\n \n\u0081\nIf time allows (e.g. in secondary PPH), check blood for Hb, \nclotting\nManagement\nThe principles of management include two major components:\n1.\t\nResuscitation and management of obstetric haemorrhage and \npossibly hypovolemic shock\n2.\t\nIdentification and management of underlying causes\nTREATMENT\nLOC\nFirst aid\n\t\n\u0089\nCheck uterus to see if contracted f Massage uterus (to \nexpel clots) f Give oxytocin 10 IU IM or IV slowly Give \ntranexamic acid 1gm IV slowly over 10 mins but within \n3 hours after delivery of the baby \n\t\n\u0089\nEmpty the bladder\n\t\n\u0089\nStart IV fluids (normal saline) using 2 IV lines using \nlarge bore canulae, run 2L as fast as possible then give \n40drops perminute  according to patient BP\nHC3",
        "formatted_content": "<p>748</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>Signs of shock may be present: tachycardia, low BP, cold and</p>\n<p>clammy skin</p>\n<p>\u008d</p>\n<p>In secondary PPH, there may be signs of infection, e.g.,</p>\n<p>fever, abdominal tenderness</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Hb and blood group should have been already done and recorded</p>\n<p>during ANC; if not, do them urgently</p>\n<p>\u0081</p>\n<p>Women at high risk of PPH should have blood cross- matched</p>\n<p>and at least 2 units booked</p>\n<p>\u0081</p>\n<p>If time allows (e.g. in secondary PPH), check blood for Hb,</p>\n<p>clotting</p>\n<p>Management</p>\n<p>The principles of management include two major components:</p>\n<li>.</li>\n<p>Resuscitation and management of obstetric haemorrhage and</p>\n<p>possibly hypovolemic shock</p>\n<p>2.</p>\n<p>Identification and management of underlying causes</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First aid</p>\n<p>\u0089</p>\n<p>Check uterus to see if contracted f Massage uterus (to</p>\n<p>expel clots) f Give oxytocin 10 IU IM or IV slowly Give</p>\n<p>tranexamic acid 1gm IV slowly over 10 mins but within</p>\n<p>3 hours after delivery of the baby</p>\n<p>\u0089</p>\n<p>Empty the bladder</p>\n<p>\u0089</p>\n<p>Start IV fluids (normal saline) using 2 IV lines using</p>\n<p>large bore canulae, run 2L as fast as possible then give</p>\n<p>40drops perminute  according to patient BP</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 815,
        "content": "749\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n\t\n\u0089\nIf oxytocin not available, give misoprostol 800 mi\u00ad\ncrograms sublingually  or ergometrine 0.2mg IM (if a \nnon-hypertensive mother)\nCheck if placenta has been expelled, and is complete\n\t\n\u0089\nIf yes, expel any clots in the birth canal\n\t\n\u0089\nIf not, perform manual removal or refer\n\t\n\u0089\nProphylatic antibiotic: ampicillin 2 g IV stat plus\n\t\n\u0089\nmetronidazole 500 mg IV\n\t\n\u0089\nIf signs of infection, give antibiotics as in puerperal fever\nHC3\nIf uterus contracted and placenta expelled\n\t\n\u0089\nCheck for local causes if bleeding continues\n \n- Inspect carefully the lower genital tract for \nperineal lacerations, haematomas, vaginal and \ncervical tears\nIf bleeding not responding,\n\t\n\u0089\nRepeat oxytocin 10 IUin 0.5L of normal saline run at \n60 drops/min\n\t\n\u0089\nGive misoprostol sublingual 800 micrograms or ergo\u00ad\nmetrine   0.2mg IM (if not given before)\n\t\n\u0089\nRepeat tranexamic acid 1gm after 30 mins of the first dose\n\t\n\u0089\nIf bleeding persists, insert Uterine balloon tamponade \n(UBT) and apply Non-pneumonic anti-shock garment \n(NASG)\n\t\n\u0089\nRestore blood volume with IV fluids\n\t\n\u0089\nRefer to higher level for further management with UBT \n& NASG in situ \n\t\n\u0089\nCheck for coagulation problems\nHC3\nCaution\n \n\u0083 Do not give heat stable carbetocin for treatment of \nPPH. It is used for prevention of PPH.\n \n\u0083  Do not give ergomentrine in hypertensive mothers\nPrevention\n \n\u008d\nEnsure active management of 3rd stage of labour for all \nwomen in labour, and delivery by skilled staff",
        "formatted_content": "<p>749</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If oxytocin not available, give misoprostol 800 mi\u00ad</p>\n<p>crograms sublingually  or ergometrine 0.2mg IM (if a</p>\n<p>non-hypertensive mother)</p>\n<p>Check if placenta has been expelled, and is complete</p>\n<p>\u0089</p>\n<p>If yes, expel any clots in the birth canal</p>\n<p>\u0089</p>\n<p>If not, perform manual removal or refer</p>\n<p>\u0089</p>\n<p>Prophylatic antibiotic: ampicillin 2 g IV stat plus</p>\n<p>\u0089</p>\n<p>metronidazole 500 mg IV</p>\n<p>\u0089</p>\n<p>If signs of infection, give antibiotics as in puerperal fever</p>\n<h3>HC3</h3>\n<p>If uterus contracted and placenta expelled</p>\n<p>\u0089</p>\n<p>Check for local causes if bleeding continues</p>\n<p>- Inspect carefully the lower genital tract for</p>\n<p>perineal lacerations, haematomas, vaginal and</p>\n<p>cervical tears</p>\n<p>If bleeding not responding,</p>\n<p>\u0089</p>\n<p>Repeat oxytocin 10 IUin 0.5L of normal saline run at</p>\n<p>60 drops/min</p>\n<p>\u0089</p>\n<p>Give misoprostol sublingual 800 micrograms or ergo\u00ad</p>\n<p>metrine   0.2mg IM (if not given before)</p>\n<p>\u0089</p>\n<p>Repeat tranexamic acid 1gm after 30 mins of the first dose</p>\n<p>\u0089</p>\n<p>If bleeding persists, insert Uterine balloon tamponade</p>\n<p>(UBT) and apply Non-pneumonic anti-shock garment</p>\n<h3>(NASG)</h3>\n<p>\u0089</p>\n<p>Restore blood volume with IV fluids</p>\n<p>\u0089</p>\n<p>Refer to higher level for further management with UBT</p>\n<p>& NASG in situ</p>\n<p>\u0089</p>\n<p>Check for coagulation problems</p>\n<h3>HC3</h3>\n<p>Caution</p>\n<p>\u0083 Do not give heat stable carbetocin for treatment of</p>\n<p>PPH. It is used for prevention of PPH.</p>\n<p>\u0083  Do not give ergomentrine in hypertensive mothers</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Ensure active management of 3rd stage of labour for all</p>\n<p>women in labour, and delivery by skilled staff</p>"
    },
    {
        "page_number": 816,
        "content": "750\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nGive heat stable Carbetocin 100mcg IV/IM (single dose) or \noxytocin 10 IU IM  or misoprostol 600mcg orally  to the \nmother within 1 minute of delivery, after ruling out presence \nof another baby\n \n\u008d\nClamp the cord and cut it (3-5 minutes after birth) or when \nthe cord stops pulsating.\n \n\u008d\nControlled cord traction during a contraction with count\u00ad\ner-traction to deliver the placenta\n \n\u008d\nMassage the uterus immediately after delivery of the placenta \nto ensure the uterus is contracted\n \n\u008d\nIdentify mothers at risk and manage accordingly\n \n\u008d\nGive 5 days\u2019 prophylactic antibiotics in prolonged or ob\u00ad\nstructed labour, or in presence of other risk factors, e.g. \nrupture of membranes, birth before arrival at health facility, \ninstrument delivery:\n16.4.7      Puerperal Fever/Sepsis \t                              ICD10 CODE: O85\nInfection of the female internal genital tract within 6 weeks of childbirth. \nSigns and symptoms usually occur after 24 hours, although the disease \nmay manifest earlier in settings of prolonged rupture of membranes \nand prolonged labour without prophylactic antibiotics.\nCauses\n \n\u008d\nAscending infection from contamination during delivery or \nabortion\n \n\u008d\nBacteria include: Staphylococcus aureus and Gram- negative \nbacteria from the gut, e.g. Escherichia coli, Bacteroides, \nStreptococcus pyogenes, clostridium spp, chlamydia, gono\u00ad\ncocci\n \n\u008d\nIn peurperal sepsis, multiple organisms are likely\n   NOTE: Carbetocin should be given as a single dose",
        "formatted_content": "<p>750</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>Give heat stable Carbetocin 100mcg IV/IM (single dose) or</p>\n<p>oxytocin 10 IU IM  or misoprostol 600mcg orally  to the</p>\n<p>mother within 1 minute of delivery, after ruling out presence</p>\n<p>of another baby</p>\n<p>\u008d</p>\n<p>Clamp the cord and cut it (3-5 minutes after birth) or when</p>\n<p>the cord stops pulsating.</p>\n<p>\u008d</p>\n<p>Controlled cord traction during a contraction with count\u00ad</p>\n<p>er-traction to deliver the placenta</p>\n<p>\u008d</p>\n<p>Massage the uterus immediately after delivery of the placenta</p>\n<p>to ensure the uterus is contracted</p>\n<p>\u008d</p>\n<p>Identify mothers at risk and manage accordingly</p>\n<p>\u008d</p>\n<p>Give 5 days\u2019 prophylactic antibiotics in prolonged or ob\u00ad</p>\n<p>structed labour, or in presence of other risk factors, e.g.</p>\n<p>rupture of membranes, birth before arrival at health facility,</p>\n<p>instrument delivery:</p>\n<p>16.4.7      Puerperal Fever/Sepsis \t                              ICD10 CODE: O85</p>\n<p>Infection of the female internal genital tract within 6 weeks of childbirth.</p>\n<p>Signs and symptoms usually occur after 24 hours, although the disease</p>\n<p>may manifest earlier in settings of prolonged rupture of membranes</p>\n<p>and prolonged labour without prophylactic antibiotics.</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Ascending infection from contamination during delivery or</p>\n<p>abortion</p>\n<p>\u008d</p>\n<p>Bacteria include: Staphylococcus aureus and Gram- negative</p>\n<p>bacteria from the gut, e.g. Escherichia coli, Bacteroides,</p>\n<p>Streptococcus pyogenes, clostridium spp, chlamydia, gono\u00ad</p>\n<p>cocci</p>\n<p>\u008d</p>\n<p>In peurperal sepsis, multiple organisms are likely</p>\n<p>NOTE: Carbetocin should be given as a single dose</p>"
    },
    {
        "page_number": 817,
        "content": "751\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nClinical features\n \n\u008d\nPersistent fever >38\u00b0C\n \n\u008d\nChills and general malaise\n \n\u008d\nPain in the lower abdomen\n \n\u008d\nPersistent bloody/pus discharge (lochia) from genital tract, \nwhich may have an unpleasant smell\n \n\u008d\nTenderness on palpating the uterus\n \n\u008d\nUterine sub-involution\nRisk factors\n \n\u008d\nAnaemia, malnutrition in pregnancy\n \n\u008d\nProlonged labour, prolonged rupture of membranes\n \n\u008d\nFrequent vaginal exams\n \n\u008d\nTraumatic delivery (instrumental deliveries, tears)\n \n\u008d\nRetained placenta\nDifferential diagnosis\n \n\u008d\nOther causes of fever after childbirth, e.g. malaria, UTI, \nDVT, wound sepsis, mastitis/breast abscess, RTI\nInvestigations\n\t\n\u0089\nBlood: CBC, C&S, BS for malaria parasites / RDT\n\t\n\u0089\nLochia: swab for C&S\n\t\n\u0089\nUrine: For protein, sugar, microscopy, C&S\nManagement\nPuerperal fever carries a high risk of sepsis with a high mortality, and \nneeds immediate attention",
        "formatted_content": "<p>751</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Persistent fever >38\u00b0C</p>\n<p>\u008d</p>\n<p>Chills and general malaise</p>\n<p>\u008d</p>\n<p>Pain in the lower abdomen</p>\n<p>\u008d</p>\n<p>Persistent bloody/pus discharge (lochia) from genital tract,</p>\n<p>which may have an unpleasant smell</p>\n<p>\u008d</p>\n<p>Tenderness on palpating the uterus</p>\n<p>\u008d</p>\n<p>Uterine sub-involution</p>\n<p>Risk factors</p>\n<p>\u008d</p>\n<p>Anaemia, malnutrition in pregnancy</p>\n<p>\u008d</p>\n<p>Prolonged labour, prolonged rupture of membranes</p>\n<p>\u008d</p>\n<p>Frequent vaginal exams</p>\n<p>\u008d</p>\n<p>Traumatic delivery (instrumental deliveries, tears)</p>\n<p>\u008d</p>\n<p>Retained placenta</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Other causes of fever after childbirth, e.g. malaria, UTI,</p>\n<p>DVT, wound sepsis, mastitis/breast abscess, RTI</p>\n<p>Investigations</p>\n<p>\u0089</p>\n<p>Blood: CBC, C&S, BS for malaria parasites / RDT</p>\n<p>\u0089</p>\n<p>Lochia: swab for C&S</p>\n<p>\u0089</p>\n<p>Urine: For protein, sugar, microscopy, C&S</p>\n<p>Management</p>\n<p>Puerperal fever carries a high risk of sepsis with a high mortality, and</p>\n<p>needs immediate attention</p>"
    },
    {
        "page_number": 818,
        "content": "752\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nParenteral antibiotic therapy\n\t\n\u0089\nAmpicillin 500 mg IV or IM every 6 hours\n\t\n\u0089\nPlus gentamicin 5-7 mg/kg IV or IM daily in 2 divided \ndoses (every 12 hours)\n\t\n\u0089\nPlus metronidazole 500 mg IV every 8 hours for at \nleast 3 doses\nAlternative\n\t\n\u0089\nClindamycin 150 mg IV/IM every 6 hours + gentamicin \nas above\nHC3\nHC4\nSupportive/additional therapy\n\t\n\u0089\nGive IV fluids\n\t\n\u0089\nGive analgesics\n\t\n\u0089\nIf anaemic, transfuse with blood\n\t\n\u0089\nLook for retained products and evacuate uterus if \nnecessary\nPrevention\n \n\u008d\nUse of clean delivery kits and ensuring clean deliveries, \nproper hygiene\n \n\u008d\nProphylactic antibiotic when indicated (prolonged labour \nand premature rupture of membranes, manual removal of \nplacenta)\n16.4.8    Care of Mother and Baby Immediately After Delivery\t\nICD10 CODE: Z39\nProvide the following care for the first two hours after complete delivery \nof the placenta.\nGeneral measures\n \n\u008d\nConstant attention; Never leave mother and baby alone\n \n\u008d\nRequest the mother or attendant to report any unusual \nchanges in the mother and baby to the health worker\n \n\u008d\nRecord any findings, treatment, and procedures in the Post\u00ad\npartum Record",
        "formatted_content": "<p>752</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Parenteral antibiotic therapy</p>\n<p>\u0089</p>\n<p>Ampicillin 500 mg IV or IM every 6 hours</p>\n<p>\u0089</p>\n<p>Plus gentamicin 5-7 mg/kg IV or IM daily in 2 divided</p>\n<p>doses (every 12 hours)</p>\n<p>\u0089</p>\n<p>Plus metronidazole 500 mg IV every 8 hours for at</p>\n<p>least 3 doses</p>\n<p>Alternative</p>\n<p>\u0089</p>\n<p>Clindamycin 150 mg IV/IM every 6 hours + gentamicin</p>\n<p>as above</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Supportive/additional therapy</p>\n<p>\u0089</p>\n<p>Give IV fluids</p>\n<p>\u0089</p>\n<p>Give analgesics</p>\n<p>\u0089</p>\n<p>If anaemic, transfuse with blood</p>\n<p>\u0089</p>\n<p>Look for retained products and evacuate uterus if</p>\n<p>necessary</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Use of clean delivery kits and ensuring clean deliveries,</p>\n<p>proper hygiene</p>\n<p>\u008d</p>\n<p>Prophylactic antibiotic when indicated (prolonged labour</p>\n<p>and premature rupture of membranes, manual removal of</p>\n<p>placenta)</p>\n<p>16.4.8    Care of Mother and Baby Immediately After Delivery</p>\n<h3>ICD10 CODE: Z39</h3>\n<p>Provide the following care for the first two hours after complete delivery</p>\n<p>of the placenta.</p>\n<p>General measures</p>\n<p>\u008d</p>\n<p>Constant attention; Never leave mother and baby alone</p>\n<p>\u008d</p>\n<p>Request the mother or attendant to report any unusual</p>\n<p>changes in the mother and baby to the health worker</p>\n<p>\u008d</p>\n<p>Record any findings, treatment, and procedures in the Post\u00ad</p>\n<p>partum Record</p>"
    },
    {
        "page_number": 819,
        "content": "753\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nFor additional information on care of the HIV positive mother, refer to \nsection 16.2.2 above.\n16.4.8.1  Care of Mother Immediately After Delivery\nTREATMENT\nLOC\n \n- Take the blood pressure\n \n- Rapid assessment for danger signs such as \nexcessive PV bleeding, difficulty in breathing, \nsevere headache\n \n- Feel if uterus is hard and round\nHC3\nMonitoring of mother\n \n\u008d\nCheck every 15 minutes for 2 hours, then at 3 \nand 4 hours, then every 4 hours until discharge\nAssess, classify, and treat\n \n\u008d\nRaised diastolic blood pressure\n \n- >110 mmHg with proteinuria 3+ and signs/ \nsympotms of eclampsia: manage as severe \neclampsia (section 16.3.8)\n \n- If 90-110 mmHg with proteinuria: manage as pre\n \n- eclampsia (section 16.3.7)\n \n- If >90 mmHg with no proteinuria and no \nsymptoms of eclampsia: monitor and treat as \nhypertension (section 16.6.1.2)\n \n\u008d\nFever with chills or uterine tenderness or foul \nsmelling discharge, treat as puerperal fever (sec\u00ad\ntion 16.4.7)\n \n- If isolated raised temperature, monitor, hydrate\n \n- and observe for 12 hours. Treat for pueperal fever \nif it persists (section 16.4.7)\n \n\u008d\nIf bleeding perineal tear\n \n- Suture if trained or refer for further management\n \n\u008d\nIf bleeding (If pad soaked in <5 minutes or con\u00ad\nstant trickle of blood) and uterus not hard and \naround:\n \n- Treat as PPH (section 16.4.6)\nHC3",
        "formatted_content": "<p>753</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>For additional information on care of the HIV positive mother, refer to</p>\n<p>section 16.2.2 above.</p>\n<p>16.4.8.1  Care of Mother Immediately After Delivery</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Take the blood pressure</p>\n<p>- Rapid assessment for danger signs such as</p>\n<p>excessive PV bleeding, difficulty in breathing,</p>\n<p>severe headache</p>\n<p>- Feel if uterus is hard and round</p>\n<h3>HC3</h3>\n<p>Monitoring of mother</p>\n<p>\u008d</p>\n<p>Check every 15 minutes for 2 hours, then at 3</p>\n<p>and 4 hours, then every 4 hours until discharge</p>\n<p>Assess, classify, and treat</p>\n<p>\u008d</p>\n<p>Raised diastolic blood pressure</p>\n<p>- >110 mmHg with proteinuria 3+ and signs/</p>\n<p>sympotms of eclampsia: manage as severe</p>\n<p>eclampsia (section 16.3.8)</p>\n<p>- If 90-110 mmHg with proteinuria: manage as pre</p>\n<p>- eclampsia (section 16.3.7)</p>\n<p>- If >90 mmHg with no proteinuria and no</p>\n<p>symptoms of eclampsia: monitor and treat as</p>\n<p>hypertension (section 16.6.1.2)</p>\n<p>\u008d</p>\n<p>Fever with chills or uterine tenderness or foul</p>\n<p>smelling discharge, treat as puerperal fever (sec\u00ad</p>\n<p>tion 16.4.7)</p>\n<p>- If isolated raised temperature, monitor, hydrate</p>\n<p>- and observe for 12 hours. Treat for pueperal fever</p>\n<p>if it persists (section 16.4.7)</p>\n<p>\u008d</p>\n<p>If bleeding perineal tear</p>\n<p>- Suture if trained or refer for further management</p>\n<p>\u008d</p>\n<p>If bleeding (If pad soaked in <5 minutes or con\u00ad</p>\n<p>stant trickle of blood) and uterus not hard and</p>\n<p>around:</p>\n<p>- Treat as PPH (section 16.4.6)</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 820,
        "content": "754\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n \n\u008d\nAnaemia: monitor for bleeding and look for con\u00ad\njunctival or palmar pallor, check Hb if indicated, \nmanage as appropriate\nCare of mother\n \n\u008d\nEncourage mother to pass urine, eat, and drink\n \n\u008d\nAsk the companion to stay with her\n16.4.8.2  Care of Baby Immediately After Delivery\nTREATMENT\nLOC\nMonitoring of baby\n \n\u008d\nCheck every 15 minutes\n \n- Breathing, warmth,pulse, SpO2\n \n- Umbilical cord stump should be well ligatured\nHC3\nCare of baby\n\t\n\u0089\nEnsure the room is warm\n\t\n\u0089\nWipe off blood or meconium with wet cloth\n \n-\nDo not remove vernix or bathe the baby within \nthe first 24 hours\n\t\n\u0089\nApply an eye antimicrobial e.g. tetracycline eye ointment\n \n-\nLeave in place and do not wash it away\n\t\n\u0089\nApply chlorhexidine digluconate gel to the cord stump \ndaily after every bath, until the cord falls off. Provide \nthe gel to the mother and teach her how to use it while \nat home\n\t\n\u0089\nGive vitamin K 1 mg IM\n\t\n\u0089\nKeep baby warm with skin to skin contact\nIf feet are cold or mother and baby are separated\nCover baby with blanket; cover baby\u2019s toes and fingers as \nwell as the head with warm clothing\n\t\n\u0089\nReassess after 1 hour",
        "formatted_content": "<p>754</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u008d</p>\n<p>Anaemia: monitor for bleeding and look for con\u00ad</p>\n<p>junctival or palmar pallor, check Hb if indicated,</p>\n<p>manage as appropriate</p>\n<p>Care of mother</p>\n<p>\u008d</p>\n<p>Encourage mother to pass urine, eat, and drink</p>\n<p>\u008d</p>\n<p>Ask the companion to stay with her</p>\n<p>16.4.8.2  Care of Baby Immediately After Delivery</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Monitoring of baby</p>\n<p>\u008d</p>\n<p>Check every 15 minutes</p>\n<p>- Breathing, warmth,pulse, SpO2</p>\n<p>- Umbilical cord stump should be well ligatured</p>\n<h3>HC3</h3>\n<p>Care of baby</p>\n<p>\u0089</p>\n<p>Ensure the room is warm</p>\n<p>\u0089</p>\n<p>Wipe off blood or meconium with wet cloth</p>\n<p>-</p>\n<p>Do not remove vernix or bathe the baby within</p>\n<p>the first 24 hours</p>\n<p>\u0089</p>\n<p>Apply an eye antimicrobial e.g. tetracycline eye ointment</p>\n<p>-</p>\n<p>Leave in place and do not wash it away</p>\n<p>\u0089</p>\n<p>Apply chlorhexidine digluconate gel to the cord stump</p>\n<p>daily after every bath, until the cord falls off. Provide</p>\n<p>the gel to the mother and teach her how to use it while</p>\n<p>at home</p>\n<p>\u0089</p>\n<p>Give vitamin K 1 mg IM</p>\n<p>\u0089</p>\n<p>Keep baby warm with skin to skin contact</p>\n<p>If feet are cold or mother and baby are separated</p>\n<p>Cover baby with blanket; cover baby\u2019s toes and fingers as</p>\n<p>well as the head with warm clothing</p>\n<p>\u0089</p>\n<p>Reassess after 1 hour</p>"
    },
    {
        "page_number": 821,
        "content": "755\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\nIf breathing difficulty\n\t\n\u0089\nExamine the baby according to first newborn examination \nrequirements, classify the condition, and treat accord\u00ad\ningly (see section 16.5  and section 17.1) Section 17.1)\nBreastfeeding\nEnsure the mother starts breastfeeding as soon as possible (preferably \nwithin the first hour)\n \n\u008d\nOffer mother help to position (attach) the baby correctly onto \nthe breast to avoid cracked nipples\n \n\u008d\nCounsel and reassure mother\nIf unable to start breastfeeding:\n \n\u008d\nPlan for alternative feeding method\n \n- Ensure that alternative method is Affordable, Feasible, \nAcceptable, Sustainable and Safe\n \n- Do not give artificial feeds, sugar water or local feeds\n \n- before baby has attempted to initiate natural breastfeeding\n \n- Consider referral to a higher level\nBaby dead or stillborn\nIn case the baby dies or is stillborn\n \n\u008d\nGive supportive care to the mother\n \n\u008d\nRespect local customs; find out if the mother/family would \nlike to look at or hold the stillborn baby\n \n\u008d\nCheck, identity and give wrapped body to family for dispos\u00ad\nal/burial according to local customs\n \n\u008d\nProvide death certificate and complete required reporting \nformalities",
        "formatted_content": "<p>755</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If breathing difficulty</p>\n<p>\u0089</p>\n<p>Examine the baby according to first newborn examination</p>\n<p>requirements, classify the condition, and treat accord\u00ad</p>\n<p>ingly (see section 16.5  and section 17.1) Section 17.1)</p>\n<p>Breastfeeding</p>\n<p>Ensure the mother starts breastfeeding as soon as possible (preferably</p>\n<p>within the first hour)</p>\n<p>\u008d</p>\n<p>Offer mother help to position (attach) the baby correctly onto</p>\n<p>the breast to avoid cracked nipples</p>\n<p>\u008d</p>\n<p>Counsel and reassure mother</p>\n<p>If unable to start breastfeeding:</p>\n<p>\u008d</p>\n<p>Plan for alternative feeding method</p>\n<p>- Ensure that alternative method is Affordable, Feasible,</p>\n<p>Acceptable, Sustainable and Safe</p>\n<p>- Do not give artificial feeds, sugar water or local feeds</p>\n<p>- before baby has attempted to initiate natural breastfeeding</p>\n<p>- Consider referral to a higher level</p>\n<p>Baby dead or stillborn</p>\n<p>In case the baby dies or is stillborn</p>\n<p>\u008d</p>\n<p>Give supportive care to the mother</p>\n<p>\u008d</p>\n<p>Respect local customs; find out if the mother/family would</p>\n<p>like to look at or hold the stillborn baby</p>\n<p>\u008d</p>\n<p>Check, identity and give wrapped body to family for dispos\u00ad</p>\n<p>al/burial according to local customs</p>\n<p>\u008d</p>\n<p>Provide death certificate and complete required reporting</p>\n<p>formalities</p>"
    },
    {
        "page_number": 822,
        "content": "756\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n\t\n\u0089\nAdvise on postpartum care and hygiene\n\t\n\u0089\nAdvise mother on breast care; wear a firm bra, do not \nexpress the breasts\n\t\n\u0089\nGive paracetamol if breasts are painful\n\t\n\u0089\nYou may give lactation suppression drugs such as\n\t\n\u0089\nbromocriptine 2.5 mg once a day for 2 weeks\n\t\n\u0089\nCounsel on appropriate family planning\nHC3\n16.5  ESSENTIAL CARE OF THE NEWBORN\n16.5.1      Newborn Resuscitation\t           ICD10 CODE: P22\nStart resuscitation within one minute of birth if baby is not breathing \nor is gasping for breath\n \n\u008d\nObserve universal hygiene precautions to prevent infection\n \n\u008d\nPrepare for resuscitation at each delivery even where there \nare no signs of foetal distress, just in case the baby requires it\nMinimum preparation for every birth\nEnsure that the following equipment is available and in good working \norder:\n \n\u008d\nTwo warm cotton cloths and a small one to position the head\n \n\u008d\nHeat source to keep the baby warm\n \n\u008d\nMucus extractor such as a penguin sucker (or bulb syringe)\n \n\u008d\nAmbu bag and new-born masks of varying sizes (0 and 1),   \npulse oximeter\n \n\u008d\nClock or watch\n \n\u008d\nA birth attendant skilled in new-born resuscitation",
        "formatted_content": "<p>756</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Advise on postpartum care and hygiene</p>\n<p>\u0089</p>\n<p>Advise mother on breast care; wear a firm bra, do not</p>\n<p>express the breasts</p>\n<p>\u0089</p>\n<p>Give paracetamol if breasts are painful</p>\n<p>\u0089</p>\n<p>You may give lactation suppression drugs such as</p>\n<p>\u0089</p>\n<p>bromocriptine 2.5 mg once a day for 2 weeks</p>\n<p>\u0089</p>\n<p>Counsel on appropriate family planning</p>\n<h3>HC3</h3>\n<h3>16.5  ESSENTIAL CARE OF THE NEWBORN</h3>\n<p>16.5.1      Newborn Resuscitation\t           ICD10 CODE: P22</p>\n<p>Start resuscitation within one minute of birth if baby is not breathing</p>\n<p>or is gasping for breath</p>\n<p>\u008d</p>\n<p>Observe universal hygiene precautions to prevent infection</p>\n<p>\u008d</p>\n<p>Prepare for resuscitation at each delivery even where there</p>\n<p>are no signs of foetal distress, just in case the baby requires it</p>\n<p>Minimum preparation for every birth</p>\n<p>Ensure that the following equipment is available and in good working</p>\n<p>order:</p>\n<p>\u008d</p>\n<p>Two warm cotton cloths and a small one to position the head</p>\n<p>\u008d</p>\n<p>Heat source to keep the baby warm</p>\n<p>\u008d</p>\n<p>Mucus extractor such as a penguin sucker (or bulb syringe)</p>\n<p>\u008d</p>\n<p>Ambu bag and new-born masks of varying sizes (0 and 1),</p>\n<p>pulse oximeter</p>\n<p>\u008d</p>\n<p>Clock or watch</p>\n<p>\u008d</p>\n<p>A birth attendant skilled in new-born resuscitation</p>"
    },
    {
        "page_number": 823,
        "content": "757\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nMANAGEMENT\nLOC\n\t\n\u0089\nKeep the baby warm by drying the baby using the first cotton \ncloth and change to the second dry cotton cloth. Rub the back \n2-3 times\n \n- Clamp and cut the cord if necessary\n \n- Transfer the baby to a dry clean warm surface\n \n- Tell the mother that the baby is having difficulty \nstarting to breathe and that you will help the baby\n\t\n\u0089\nOpen the airway\n \n- Position the head so that it is slightly extended\n \n- Place a folded towel <2 cm thick under baby\u2019s shoulders\n \n- Suction if secretions in mouth or nose and if baby\n \n- born through meconium stained amniotic fluid: \nHC3\nsuction 5 cm in the mouth, 3 cm in the nose while \nwithdrawing, for max 10 seconds in total.\n \n- Do not suction too deep into the throat as this may \ncause the heart to slow down or breathing to stop\n\t\n\u0089\nIf still not breathing, SELECT APPROPRIATE MASK SIZE \nTO COVER CHIN, MOUTH AND NOSE, AND VENTILATE\n \n- Form a seal with mask covering chin, mouth and nose\n \n- Squeeze bag 5 times\n \n- Observe chest\nIf not rising\n \n- Reposition head, check mask seal, squeeze bag harder\n\t\n\u0089\nOnce good seal and chest rising, ventilate for one minute at 40 \nsqueezes per minute then stop and look for breathing\nCheck for hypertension\nIf breathing >30/minute and no severe chest in- drawing\n\t\n\u0089\nStop ventilating\n\t\n\u0089\nPut baby skin-to-skin on mother\u2019s chest\n\t\n\u0089\nObserve every 15 minutes for breathing and warmth: \ntake temperature, count breaths, observe for chest-in-\ndrawing or grunting respiration.\n\t\n\u0089\nMonitor SpO2",
        "formatted_content": "<p>757</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Keep the baby warm by drying the baby using the first cotton</p>\n<p>cloth and change to the second dry cotton cloth. Rub the back</p>\n<p>2-3 times</p>\n<p>- Clamp and cut the cord if necessary</p>\n<p>- Transfer the baby to a dry clean warm surface</p>\n<p>- Tell the mother that the baby is having difficulty</p>\n<p>starting to breathe and that you will help the baby</p>\n<p>\u0089</p>\n<p>Open the airway</p>\n<p>- Position the head so that it is slightly extended</p>\n<p>- Place a folded towel <2 cm thick under baby\u2019s shoulders</p>\n<p>- Suction if secretions in mouth or nose and if baby</p>\n<p>- born through meconium stained amniotic fluid:</p>\n<h3>HC3</h3>\n<p>suction 5 cm in the mouth, 3 cm in the nose while</p>\n<p>withdrawing, for max 10 seconds in total.</p>\n<p>- Do not suction too deep into the throat as this may</p>\n<p>cause the heart to slow down or breathing to stop</p>\n<p>\u0089</p>\n<p>If still not breathing, SELECT APPROPRIATE MASK SIZE</p>\n<h3>TO COVER CHIN, MOUTH AND NOSE, AND VENTILATE</h3>\n<p>- Form a seal with mask covering chin, mouth and nose</p>\n<p>- Squeeze bag 5 times</p>\n<p>- Observe chest</p>\n<p>If not rising</p>\n<p>- Reposition head, check mask seal, squeeze bag harder</p>\n<p>\u0089</p>\n<p>Once good seal and chest rising, ventilate for one minute at 40</p>\n<p>squeezes per minute then stop and look for breathing</p>\n<p>Check for hypertension</p>\n<p>If breathing >30/minute and no severe chest in- drawing</p>\n<p>\u0089</p>\n<p>Stop ventilating</p>\n<p>\u0089</p>\n<p>Put baby skin-to-skin on mother\u2019s chest</p>\n<p>\u0089</p>\n<p>Observe every 15 minutes for breathing and warmth:</p>\n<p>take temperature, count breaths, observe for chest-in-</p>\n<p>drawing or grunting respiration.</p>\n<p>\u0089</p>\n<p>Monitor SpO2</p>"
    },
    {
        "page_number": 824,
        "content": "758\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nMANAGEMENT\nLOC\nIf breathing >30/minute and no severe chest in- drawing\n\t\n\u0089\nStop ventilating\n\t\n\u0089\nPut baby skin-to-skin on mother\u2019s chest\n\t\n\u0089\nObserve every 15 minutes for breathing and warmth: \ntake temperature, count breaths, observe for chest-in-\ndrawing or grunting respiration.\n\t\n\u0089\nMonitor SpO2\n\t\n\u0089\nEncourage mother to breastfeed within one hour\n\t\n\u0089\nDO NOT LEAVE THE BABY ALONE\nIf breathing <30/minute or severe chest in-drawing\n\t\n\u0089\nContinue ventilating f Arrange for immediate referral \n\t\n\u0089\nGive oxygen if  available f Reassess every 1-2 minutes\n\t\n\u0089\nContinue to ventilate during referral\nIf not gasping or breathing at all after 20 minutes of \nventilation\n\t\n\u0089\nStop ventilation, the baby is dead\nNotes\n \n\u0081\nRoom air is sufficient in the absence of oxygen\n \n\u0081\nCardiac massage is RARELY required; it is dangerous when \ndone incorrectly. A slow heart rate almost always responds \nto good breathing assistance only\n \n\u0081\nUsually, there is no need for drugs if prompt and sufficient \nventilation is provided\nHarmful and ineffective resuscitation practices\n \n\u0083 Routine suction of new-born\u2019s mouth and nose as soon as the   \nhead is born\n \n\u0083 Stimulation of the new-born by slapping or flicking the soles \nof the feet",
        "formatted_content": "<p>758</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>MANAGEMENT</h3>\n<h3>LOC</h3>\n<p>If breathing >30/minute and no severe chest in- drawing</p>\n<p>\u0089</p>\n<p>Stop ventilating</p>\n<p>\u0089</p>\n<p>Put baby skin-to-skin on mother\u2019s chest</p>\n<p>\u0089</p>\n<p>Observe every 15 minutes for breathing and warmth:</p>\n<p>take temperature, count breaths, observe for chest-in-</p>\n<p>drawing or grunting respiration.</p>\n<p>\u0089</p>\n<p>Monitor SpO2</p>\n<p>\u0089</p>\n<p>Encourage mother to breastfeed within one hour</p>\n<p>\u0089</p>\n<h3>DO NOT LEAVE THE BABY ALONE</h3>\n<p>If breathing <30/minute or severe chest in-drawing</p>\n<p>\u0089</p>\n<p>Continue ventilating f Arrange for immediate referral</p>\n<p>\u0089</p>\n<p>Give oxygen if  available f Reassess every 1-2 minutes</p>\n<p>\u0089</p>\n<p>Continue to ventilate during referral</p>\n<p>If not gasping or breathing at all after 20 minutes of</p>\n<p>ventilation</p>\n<p>\u0089</p>\n<p>Stop ventilation, the baby is dead</p>\n<p>Notes</p>\n<p>\u0081</p>\n<p>Room air is sufficient in the absence of oxygen</p>\n<p>\u0081</p>\n<p>Cardiac massage is RARELY required; it is dangerous when</p>\n<p>done incorrectly. A slow heart rate almost always responds</p>\n<p>to good breathing assistance only</p>\n<p>\u0081</p>\n<p>Usually, there is no need for drugs if prompt and sufficient</p>\n<p>ventilation is provided</p>\n<p>Harmful and ineffective resuscitation practices</p>\n<p>\u0083 Routine suction of new-born\u2019s mouth and nose as soon as the</p>\n<p>head is born</p>\n<p>\u0083 Stimulation of the new-born by slapping or flicking the soles</p>\n<p>of the feet</p>"
    },
    {
        "page_number": 825,
        "content": "759\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u0083 Postural drainage (putting the baby upside down) and slapping \nthe back\n \n\u0083 Squeezing the back to remove secretions from airway\n \n\u0083 Routine giving of sodium bicarbonate to new-borns who are \nnot breathing.\n \n\u0083 Intubation by an unskilled person\n16.5.2  General Care of Newborn After Delivery\nProvide the following care up to the time of discharge:\nTYPE OF CARE AND MONITORING\nNOTES\nKeep baby with mother\n \n-\nIn same bed or \nwithin easy reach\n \n-\nUnder mosquito net\nIf baby is in a cot, ensure baby is \ndressed or well-wrapped: covered \nwith blanket, head is covered and \nthe feet and hands have socks\nEnsure room is warm \n(>25\u00b0C) and has no cold \nbreeze (draughts)\nDo NOT put baby in direct sun or \non any cold surface or directly in \nthe line of a cold breeze\nAdvise/teach mother how to:\n \n- Keep the baby warm\n \n- Give cord care\n \n- Ensure hygiene\n \n- If \nmother \nis \nunable \nto take care of baby,  \nprovide required care or \nteach her next of kin\n \n- Wash hands before and \nafter handling baby\n \n- Do not bathe baby for up\n \n- 24 hours\nSupport exclusive breast\u00ad\nfeeding\non demand, day and night, \nwhenever baby wants\nIf breastfeeding difficult:\nHelp mother to position and \nattach the baby\nIf breastfeeding not possible:\nAdvise on safe replacement feed\u00ad\ning (AFASS)",
        "formatted_content": "<p>759</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u0083 Postural drainage (putting the baby upside down) and slapping</p>\n<p>the back</p>\n<p>\u0083 Squeezing the back to remove secretions from airway</p>\n<p>\u0083 Routine giving of sodium bicarbonate to new-borns who are</p>\n<p>not breathing.</p>\n<p>\u0083 Intubation by an unskilled person</p>\n<p>16.5.2  General Care of Newborn After Delivery</p>\n<p>Provide the following care up to the time of discharge:</p>\n<h3>TYPE OF CARE AND MONITORING</h3>\n<h3>NOTES</h3>\n<p>Keep baby with mother</p>\n<p>-</p>\n<p>In same bed or</p>\n<p>within easy reach</p>\n<p>-</p>\n<p>Under mosquito net</p>\n<p>If baby is in a cot, ensure baby is</p>\n<p>dressed or well-wrapped: covered</p>\n<p>with blanket, head is covered and</p>\n<p>the feet and hands have socks</p>\n<p>Ensure room is warm</p>\n<p>(>25\u00b0C) and has no cold</p>\n<p>breeze (draughts)</p>\n<p>Do NOT put baby in direct sun or</p>\n<p>on any cold surface or directly in</p>\n<p>the line of a cold breeze</p>\n<p>Advise/teach mother how to:</p>\n<p>- Keep the baby warm</p>\n<p>- Give cord care</p>\n<p>- Ensure hygiene</p>\n<p>- If</p>\n<p>mother</p>\n<p>is</p>\n<p>unable</p>\n<p>to take care of baby,</p>\n<p>provide required care or</p>\n<p>teach her next of kin</p>\n<p>- Wash hands before and</p>\n<p>after handling baby</p>\n<p>- Do not bathe baby for up</p>\n<p>- 24 hours</p>\n<p>Support exclusive breast\u00ad</p>\n<p>feeding</p>\n<p>on demand, day and night,</p>\n<p>whenever baby wants</p>\n<p>If breastfeeding difficult:</p>\n<p>Help mother to position and</p>\n<p>attach the baby</p>\n<p>If breastfeeding not possible:</p>\n<p>Advise on safe replacement feed\u00ad</p>\n<p>ing (AFASS)</p>"
    },
    {
        "page_number": 826,
        "content": "760\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTYPE OF CARE AND MONITORING\nNOTES\nAsk mother and companion \nto:\nWatch the baby\nReport breastfeeding or \nbreathing problems, cold feet, \nbleeding from cord or other \nbleeding\nCheck every baby at 4 and 8 \nhours then daily for:\nWarm feet\nNormal pink colour\nFeeding\nBreathing problems\nIf feet cold-this is a sign of \nhypothermia:\nTeach mother how to rewarm the \nbaby; apply one to two layers of \nclothes more than adults, and use \nof hats/ caps\nReassess in 1 hour; if no improve\u00ad\nment, take\ntemperature and manage accord\u00ad\ningly\nIf breathing problem\nAssess and manage accordingly\nIf cord tie loose/cord bleeding:\nRetie cord\nIf bleeding persists, refer urgently\nCheck any baby with warning \nsigns at 2, 4, 8,\nand 12 hours:\n \n-\nListen for grunting\n \n-\nLook for chest in \ndrawing\n \n-\nCount breaths/\nminute\n \n-\nMeasure \ntemperature\n \n-\nObserve \nbreastfeeding\nRefer urgently if:\n \n-\nBreathing problem \nworsens or persists for \n>8 hours\n \n-\nTemperature <36.5\u00b0C\n \n-\npersists or decreases\n \n-\nNot able to feed at 8 \nhours\nGive prescribed treatments \naccording to dosage schedule\nIf referring the baby, write treat\u00ad\nments given, when, and why",
        "formatted_content": "<p>760</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TYPE OF CARE AND MONITORING</h3>\n<h3>NOTES</h3>\n<p>Ask mother and companion</p>\n<p>to:</p>\n<p>Watch the baby</p>\n<p>Report breastfeeding or</p>\n<p>breathing problems, cold feet,</p>\n<p>bleeding from cord or other</p>\n<p>bleeding</p>\n<p>Check every baby at 4 and 8</p>\n<p>hours then daily for:</p>\n<p>Warm feet</p>\n<p>Normal pink colour</p>\n<p>Feeding</p>\n<p>Breathing problems</p>\n<p>If feet cold-this is a sign of</p>\n<p>hypothermia:</p>\n<p>Teach mother how to rewarm the</p>\n<p>baby; apply one to two layers of</p>\n<p>clothes more than adults, and use</p>\n<p>of hats/ caps</p>\n<p>Reassess in 1 hour; if no improve\u00ad</p>\n<p>ment, take</p>\n<p>temperature and manage accord\u00ad</p>\n<p>ingly</p>\n<p>If breathing problem</p>\n<p>Assess and manage accordingly</p>\n<p>If cord tie loose/cord bleeding:</p>\n<p>Retie cord</p>\n<p>If bleeding persists, refer urgently</p>\n<p>Check any baby with warning</p>\n<p>signs at 2, 4, 8,</p>\n<p>and 12 hours:</p>\n<p>-</p>\n<p>Listen for grunting</p>\n<p>-</p>\n<p>Look for chest in</p>\n<p>drawing</p>\n<p>-</p>\n<p>Count breaths/</p>\n<p>minute</p>\n<p>-</p>\n<p>Measure</p>\n<p>temperature</p>\n<p>-</p>\n<p>Observe</p>\n<p>breastfeeding</p>\n<p>Refer urgently if:</p>\n<p>-</p>\n<p>Breathing problem</p>\n<p>worsens or persists for</p>\n<p>>8 hours</p>\n<p>-</p>\n<p>Temperature <36.5\u00b0C</p>\n<p>-</p>\n<p>persists or decreases</p>\n<p>-</p>\n<p>Not able to feed at 8</p>\n<p>hours</p>\n<p>Give prescribed treatments</p>\n<p>according to dosage schedule</p>\n<p>If referring the baby, write treat\u00ad</p>\n<p>ments given, when, and why</p>"
    },
    {
        "page_number": 827,
        "content": "761\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nAssess breastfeeding in every \nbaby before planning discharge\nDo not discharge if baby is not \nfeeding well\nDo not discharge baby < 24 hours old\nAdvise mother:\n \n-\nWhen to seek care\n \n-\nWhen to return \nif danger signs \nappear (refusal to \nfeed, excessive \ncrying, bleeding \nfrom the cord \nstump, fever, \nbulging fontanel, \nabdominal \ndistension, grunting \nrespiration)\nDo NOT plan early discharge if:\n \n-\nBaby small (LBW or \npreterm)\n \n-\nNot feeding well\nGive BCG and polio 0 before \ndischarge\nCounsel mother on next routine \ncheck in 3-7 days and next immu\u00ad\nnization in 6 weeks\n16.5.3    Extra Care of Small Babies or Twins in the First Days of \nLife\nProvide the following care for small babies:\n\t\n\u0089\nPreterm up to 1 month early\n\t\n\u0089\nLow Birth Weight <2,500 g\n\t\n\u0089\nRefer very small babies for specialized attention:\n\t\n\u0089\nVery preterm >1 month early\n\t\n\u0089\nVery Low Birth Weight <1,500 g\nTYPE OF CARE AND MONITORING\nNOTES\nEnsure room is warm: Teach \nmother how to keep baby warm\nProvide extra blanket for mother and \nbaby if needed",
        "formatted_content": "<p>761</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Assess breastfeeding in every</p>\n<p>baby before planning discharge</p>\n<p>Do not discharge if baby is not</p>\n<p>feeding well</p>\n<p>Do not discharge baby < 24 hours old</p>\n<p>Advise mother:</p>\n<p>-</p>\n<p>When to seek care</p>\n<p>-</p>\n<p>When to return</p>\n<p>if danger signs</p>\n<p>appear (refusal to</p>\n<p>feed, excessive</p>\n<p>crying, bleeding</p>\n<p>from the cord</p>\n<p>stump, fever,</p>\n<p>bulging fontanel,</p>\n<p>abdominal</p>\n<p>distension, grunting</p>\n<p>respiration)</p>\n<p>Do NOT plan early discharge if:</p>\n<p>-</p>\n<p>Baby small (LBW or</p>\n<p>preterm)</p>\n<p>-</p>\n<p>Not feeding well</p>\n<p>Give BCG and polio 0 before</p>\n<p>discharge</p>\n<p>Counsel mother on next routine</p>\n<p>check in 3-7 days and next immu\u00ad</p>\n<p>nization in 6 weeks</p>\n<p>16.5.3    Extra Care of Small Babies or Twins in the First Days of</p>\n<p>Life</p>\n<p>Provide the following care for small babies:</p>\n<p>\u0089</p>\n<p>Preterm up to 1 month early</p>\n<p>\u0089</p>\n<p>Low Birth Weight <2,500 g</p>\n<p>\u0089</p>\n<p>Refer very small babies for specialized attention:</p>\n<p>\u0089</p>\n<p>Very preterm >1 month early</p>\n<p>\u0089</p>\n<p>Very Low Birth Weight <1,500 g</p>\n<h3>TYPE OF CARE AND MONITORING</h3>\n<h3>NOTES</h3>\n<p>Ensure room is warm: Teach</p>\n<p>mother how to keep baby warm</p>\n<p>Provide extra blanket for mother and</p>\n<p>baby if needed</p>"
    },
    {
        "page_number": 828,
        "content": "762\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTYPE OF CARE AND MONITORING\nNOTES\nTeach mother how to ensure hy\u00ad\ngiene for baby\nDo not bathe the baby\nClean prn with swabs or cloth\nGive special support for breast\u00ad\nfeeding and assess daily\nIf not breastfeeding well, teach mother \nalternative feeding methods\nAssess small baby daily:\n \n-\nMeasure \ntemperature\n \n-\nFeeding progress, \nweight\n \n-\nBreathing\n \n-\nJaundice (see \nsection 17.1.2 and \n17.2.2)\n \n-\nIf breathing or \nbreastfeeding problem \nor hypothermia, \nexamine and manage \naccordingly\n \n-\nIf maternal concern, \nexamine and manage \nthe baby accordingly;\n \n-\nIf breastfeeding \nproblem persists >3 \ndays or weight loss\n \n-\n>10% of birth weight \nand no other problems, \nrefer for breastfeeding \ncounselling and \nmanagement\nKeep mother and baby (or \ntwins) longer before discharge. \nPlan the discharge when:\n \n-\nBreastfeeding well\n \n-\nWeight gain on 3 \nconsecutive days\n \n-\nBody temperature\n \n-\nnormal for 3 \nconsecutive days\n \n-\nMother confident \nin\n \n-\ncaring for baby\n \n-\nIf mother & baby not \nable to stay, ensure \ndaily (home) visits or \nsend to hospital",
        "formatted_content": "<p>762</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TYPE OF CARE AND MONITORING</h3>\n<h3>NOTES</h3>\n<p>Teach mother how to ensure hy\u00ad</p>\n<p>giene for baby</p>\n<p>Do not bathe the baby</p>\n<p>Clean prn with swabs or cloth</p>\n<p>Give special support for breast\u00ad</p>\n<p>feeding and assess daily</p>\n<p>If not breastfeeding well, teach mother</p>\n<p>alternative feeding methods</p>\n<p>Assess small baby daily:</p>\n<p>-</p>\n<p>Measure</p>\n<p>temperature</p>\n<p>-</p>\n<p>Feeding progress,</p>\n<p>weight</p>\n<p>-</p>\n<p>Breathing</p>\n<p>-</p>\n<p>Jaundice (see</p>\n<p>section 17.1.2 and</p>\n<p>17.2.2)</p>\n<p>-</p>\n<p>If breathing or</p>\n<p>breastfeeding problem</p>\n<p>or hypothermia,</p>\n<p>examine and manage</p>\n<p>accordingly</p>\n<p>-</p>\n<p>If maternal concern,</p>\n<p>examine and manage</p>\n<p>the baby accordingly;</p>\n<p>-</p>\n<p>If breastfeeding</p>\n<p>problem persists >3</p>\n<p>days or weight loss</p>\n<p>-</p>\n<p>>10% of birth weight</p>\n<p>and no other problems,</p>\n<p>refer for breastfeeding</p>\n<p>counselling and</p>\n<p>management</p>\n<p>Keep mother and baby (or</p>\n<p>twins) longer before discharge.</p>\n<p>Plan the discharge when:</p>\n<p>-</p>\n<p>Breastfeeding well</p>\n<p>-</p>\n<p>Weight gain on 3</p>\n<p>consecutive days</p>\n<p>-</p>\n<p>Body temperature</p>\n<p>-</p>\n<p>normal for 3</p>\n<p>consecutive days</p>\n<p>-</p>\n<p>Mother confident</p>\n<p>in</p>\n<p>-</p>\n<p>caring for baby</p>\n<p>-</p>\n<p>If mother & baby not</p>\n<p>able to stay, ensure</p>\n<p>daily (home) visits or</p>\n<p>send to hospital</p>"
    },
    {
        "page_number": 829,
        "content": "763\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.5.4  Newborn Hygiene at Home\nCATEGORY\nCARE\nEye care\n\t\n\u0089\nExplain to mother to seek care if eyes drain \npus, and not to apply anything into the eyes\nCord care\n\t\n\u0089\nWash hands before and after cord care\n\t\n\u0089\nPut chlorhexidine gel daily (if not available \nput nothing) for 7 days\n \n-\nKeep stump loosely covered with \nclean clothes\n \n-\nFold nappy below the stump\n \n-\nIf stump soiled, wash with clean \nwater and soap, dry completely with \nclean cloth\n \n-\nDo not bandage the stump or \nabdomen\n \n-\nDo not apply anything else to the \nstump\n \n-\nAvoid touching the stump \nunnecessarily\nIf umbilicus red or draining pus or blood\n\t\n\u0089\nExamine the baby and manage accordingly\nGeneral baby \ncare hygiene\n\t\n\u0089\nWash the face, neck, and under arms daily\n\t\n\u0089\nWash the buttocks when soiled and dry \ncompletely\n \n-\nUse cloth on baby\u2019s bottom to \ncollect\n \n-\nstool\n \n-\nDispose as for sanitary towels/pads \nand wash hands\n \n-\nf Bathe when necessary using warm \nwater\n \n-\nEnsure room is warm with no cold\n \n-\nbreezes\n \n-\nDry completely, then dress and \ncover the baby",
        "formatted_content": "<p>763</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.5.4  Newborn Hygiene at Home</p>\n<h3>CATEGORY</h3>\n<h3>CARE</h3>\n<p>Eye care</p>\n<p>\u0089</p>\n<p>Explain to mother to seek care if eyes drain</p>\n<p>pus, and not to apply anything into the eyes</p>\n<p>Cord care</p>\n<p>\u0089</p>\n<p>Wash hands before and after cord care</p>\n<p>\u0089</p>\n<p>Put chlorhexidine gel daily (if not available</p>\n<p>put nothing) for 7 days</p>\n<p>-</p>\n<p>Keep stump loosely covered with</p>\n<p>clean clothes</p>\n<p>-</p>\n<p>Fold nappy below the stump</p>\n<p>-</p>\n<p>If stump soiled, wash with clean</p>\n<p>water and soap, dry completely with</p>\n<p>clean cloth</p>\n<p>-</p>\n<p>Do not bandage the stump or</p>\n<p>abdomen</p>\n<p>-</p>\n<p>Do not apply anything else to the</p>\n<p>stump</p>\n<p>-</p>\n<p>Avoid touching the stump</p>\n<p>unnecessarily</p>\n<p>If umbilicus red or draining pus or blood</p>\n<p>\u0089</p>\n<p>Examine the baby and manage accordingly</p>\n<p>General baby</p>\n<p>care hygiene</p>\n<p>\u0089</p>\n<p>Wash the face, neck, and under arms daily</p>\n<p>\u0089</p>\n<p>Wash the buttocks when soiled and dry</p>\n<p>completely</p>\n<p>-</p>\n<p>Use cloth on baby\u2019s bottom to</p>\n<p>collect</p>\n<p>-</p>\n<p>stool</p>\n<p>-</p>\n<p>Dispose as for sanitary towels/pads</p>\n<p>and wash hands</p>\n<p>-</p>\n<p>f Bathe when necessary using warm</p>\n<p>water</p>\n<p>-</p>\n<p>Ensure room is warm with no cold</p>\n<p>-</p>\n<p>breezes</p>\n<p>-</p>\n<p>Dry completely, then dress and</p>\n<p>cover the baby</p>"
    },
    {
        "page_number": 830,
        "content": "764\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nNote:\n \n\u0081\nSmall babies need specially careful attention\n \n\u0081\nWash hands before and after baby care\n16.6   POSTPARTUM CONDITIONS\n16.6.1    Postpartum Care     ICD10 CODE: Z39\nThe postpartum period, also known as the puerperium, begins with \nthe delivery of the baby and placenta, up to six weeks after delivery.\nHealthcare providers should be aware of the medical and psychological \nneeds of the postpartum mother, and sensitive to cultural differences \nthat surround childbirth, which\nmay involve eating particular foods and restricting certain activities.\nPostpartum care services\nThe mother and baby should be seen at 6 hours after birth and again \nbefore discharge if in a health facility (and anytime the mother reports \nconcern about herself and her baby) or approximately 6 hours after \ndelivery at home.\nThe routine follow-up visits are at 6 days and 6 weeks, and have the \nfollowing components:\n \n\u008d\nCounselling\n \n\u008d\nAssessment and management of observed or reported prob\u00ad\nlems. Check for hypertension, anaemia, vaginal bleeding and \ndischarge, uterine infection, puerperal fever, malaria, UTI, \nurine dribbling, pus or perineal pain, postpartum depression, \nbreast problems, HIV and any other complaint\n16.6.1.1   Postpartum Counselling\nProvide the following counselling at all postpartum visits.",
        "formatted_content": "<p>764</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Note:</p>\n<p>\u0081</p>\n<p>Small babies need specially careful attention</p>\n<p>\u0081</p>\n<p>Wash hands before and after baby care</p>\n<h3>16.6   POSTPARTUM CONDITIONS</h3>\n<p>16.6.1    Postpartum Care     ICD10 CODE: Z39</p>\n<p>The postpartum period, also known as the puerperium, begins with</p>\n<p>the delivery of the baby and placenta, up to six weeks after delivery.</p>\n<p>Healthcare providers should be aware of the medical and psychological</p>\n<p>needs of the postpartum mother, and sensitive to cultural differences</p>\n<p>that surround childbirth, which</p>\n<p>may involve eating particular foods and restricting certain activities.</p>\n<p>Postpartum care services</p>\n<p>The mother and baby should be seen at 6 hours after birth and again</p>\n<p>before discharge if in a health facility (and anytime the mother reports</p>\n<p>concern about herself and her baby) or approximately 6 hours after</p>\n<p>delivery at home.</p>\n<p>The routine follow-up visits are at 6 days and 6 weeks, and have the</p>\n<p>following components:</p>\n<p>\u008d</p>\n<p>Counselling</p>\n<p>\u008d</p>\n<p>Assessment and management of observed or reported prob\u00ad</p>\n<p>lems. Check for hypertension, anaemia, vaginal bleeding and</p>\n<p>discharge, uterine infection, puerperal fever, malaria, UTI,</p>\n<p>urine dribbling, pus or perineal pain, postpartum depression,</p>\n<p>breast problems, HIV and any other complaint</p>\n<p>16.6.1.1   Postpartum Counselling</p>\n<p>Provide the following counselling at all postpartum visits.</p>"
    },
    {
        "page_number": 831,
        "content": "765\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nGeneral counselling\n \n\u008d\nBreastfeeding/breast care\n \n\u008d\nNutrition, ferrous and folic acid supplements, avoid alcohol \nand tobacco\nComplications and danger signs for the mother\n \n\u008d\nDanger signs (see next table)\n \n\u008d\nReadiness plan in case of an emergency\n \n-\nAdvise her to have someone near for at least 24 hours \nafter delivery to respond to any change in condition\n \n-\nDiscuss emergency issues with her and partner/family:\n \n-\nWhere to go if danger signs appear, how to get there, \ncosts involved, family/community support\n \n-\nAdvise her to seek help from the community if needed\n \n-\nAdvise her to bring any home-based maternal record to \nthe health facility, even for an emergency visit\n \n\u008d\nSelf care and other good health practices, personal hy\u00ad\ngiene, handwashing, genital hygiene (care of the episioto\u00ad\nmy or repaired tears)\n \n\u008d\nPelvic floor exercises\n \n\u008d\nSleeping under mosquito nets\n \n\u008d\nPostpartum checks (6 days and 6 weeks)\n \n\u008d\nProvide information on bonding by encouraging the moth\u00ad\ner to hold, touch, explore her baby as well as rooming-in \n(mother and baby sleeping in the same bedHIV testing\n \n\u008d\nDiscuss with the couple the need for shared care of the \nnewborn\n \n\u008d\nHelp build confidence by providing reassurance that the \nwoman is capable of caring for the newborn",
        "formatted_content": "<p>765</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>General counselling</p>\n<p>\u008d</p>\n<p>Breastfeeding/breast care</p>\n<p>\u008d</p>\n<p>Nutrition, ferrous and folic acid supplements, avoid alcohol</p>\n<p>and tobacco</p>\n<p>Complications and danger signs for the mother</p>\n<p>\u008d</p>\n<p>Danger signs (see next table)</p>\n<p>\u008d</p>\n<p>Readiness plan in case of an emergency</p>\n<p>-</p>\n<p>Advise her to have someone near for at least 24 hours</p>\n<p>after delivery to respond to any change in condition</p>\n<p>-</p>\n<p>Discuss emergency issues with her and partner/family:</p>\n<p>-</p>\n<p>Where to go if danger signs appear, how to get there,</p>\n<p>costs involved, family/community support</p>\n<p>-</p>\n<p>Advise her to seek help from the community if needed</p>\n<p>-</p>\n<p>Advise her to bring any home-based maternal record to</p>\n<p>the health facility, even for an emergency visit</p>\n<p>\u008d</p>\n<p>Self care and other good health practices, personal hy\u00ad</p>\n<p>giene, handwashing, genital hygiene (care of the episioto\u00ad</p>\n<p>my or repaired tears)</p>\n<p>\u008d</p>\n<p>Pelvic floor exercises</p>\n<p>\u008d</p>\n<p>Sleeping under mosquito nets</p>\n<p>\u008d</p>\n<p>Postpartum checks (6 days and 6 weeks)</p>\n<p>\u008d</p>\n<p>Provide information on bonding by encouraging the moth\u00ad</p>\n<p>er to hold, touch, explore her baby as well as rooming-in</p>\n<p>(mother and baby sleeping in the same bedHIV testing</p>\n<p>\u008d</p>\n<p>Discuss with the couple the need for shared care of the</p>\n<p>newborn</p>\n<p>\u008d</p>\n<p>Help build confidence by providing reassurance that the</p>\n<p>woman is capable of caring for the newborn</p>"
    },
    {
        "page_number": 832,
        "content": "766\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCounselling on baby care\n \n\u008d\nHygiene and care of the baby, (see previous sections)\n \n\u008d\nDanger signs for the baby\n \n\u008d\nImmunization schedule\n \n\u008d\nLet baby sleep on the back or side\n \n\u008d\nEnsure the baby is kept warm without overcovering\n \n\u008d\nApply chlorhexidine digluconate gel to the cord stump daily \nafter every bath until the cord falls off. Provide the gel to \nthe mother, and teach her how to use it while at home\n \n\u008d\nKeep baby away from smoke and smokers\n \n\u008d\nKeep baby (especially if small) away from anyone whois ill\n \n\u008d\nDo not share supplies (for example, clothing, feeding uten\u00ad\nsils) with other babies\nAdvise mother on danger signs as follows:\nTYPE OF DANGER SIGN\nACTION TO TAKE\n \n\u008d\nVaginal bleeding (>2 pads soaked \nin 30 minutes after delivery or \nbleeding increases instead of \ndcreases after delivery)\n \n\u008d\nFever or convulsions\n \n\u008d\nFast or difficult breathing\n \n\u008d\nToo weak to get out of bed\nGo to health facility \nimmediately\n \n\u008d\nSevere abdominal pain\n \n\u008d\nSevere headache/blurred vision\n \n\u008d\nPain in the calf (ankle) muscles",
        "formatted_content": "<p>766</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Counselling on baby care</p>\n<p>\u008d</p>\n<p>Hygiene and care of the baby, (see previous sections)</p>\n<p>\u008d</p>\n<p>Danger signs for the baby</p>\n<p>\u008d</p>\n<p>Immunization schedule</p>\n<p>\u008d</p>\n<p>Let baby sleep on the back or side</p>\n<p>\u008d</p>\n<p>Ensure the baby is kept warm without overcovering</p>\n<p>\u008d</p>\n<p>Apply chlorhexidine digluconate gel to the cord stump daily</p>\n<p>after every bath until the cord falls off. Provide the gel to</p>\n<p>the mother, and teach her how to use it while at home</p>\n<p>\u008d</p>\n<p>Keep baby away from smoke and smokers</p>\n<p>\u008d</p>\n<p>Keep baby (especially if small) away from anyone whois ill</p>\n<p>\u008d</p>\n<p>Do not share supplies (for example, clothing, feeding uten\u00ad</p>\n<p>sils) with other babies</p>\n<p>Advise mother on danger signs as follows:</p>\n<h3>TYPE OF DANGER SIGN</h3>\n<h3>ACTION TO TAKE</h3>\n<p>\u008d</p>\n<p>Vaginal bleeding (>2 pads soaked</p>\n<p>in 30 minutes after delivery or</p>\n<p>bleeding increases instead of</p>\n<p>dcreases after delivery)</p>\n<p>\u008d</p>\n<p>Fever or convulsions</p>\n<p>\u008d</p>\n<p>Fast or difficult breathing</p>\n<p>\u008d</p>\n<p>Too weak to get out of bed</p>\n<p>Go to health facility</p>\n<p>immediately</p>\n<p>\u008d</p>\n<p>Severe abdominal pain</p>\n<p>\u008d</p>\n<p>Severe headache/blurred vision</p>\n<p>\u008d</p>\n<p>Pain in the calf (ankle) muscles</p>"
    },
    {
        "page_number": 833,
        "content": "767\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTYPE OF DANGER SIGN\nACTION TO TAKE\n \n~\nFever; abdominal pain; feels ill; \nbreasts red, tender, swollen; sore \nnipple; urine dribbling or pain on \nurination; perineal pain or drain\u00ad\ning pus; foul-smelling lochia\nGo to health facility as \nsoon as possible\n16.5.1.2   Postpartum Examination of the Mother Up to 6 Weeks\nAsk, check record\n \n\u008d\nWhen and where did you deliver?\n \n\u008d\nHow are you feeling?\n \n\u008d\nAny pain or fever or bleeding since delivery?\n \n\u008d\nDo you have any problem with passing urine?\n \n\u008d\nAsk if the woman has started having sex with her partner\n \n\u008d\nHave you decided on any contraception?\n \n\u008d\nHow do your breasts feel?\n \n\u008d\nDo you have any other concerns?\n \n\u008d\nCheck records fo any complications during delivery, any \ntreatments she is receiving, HIV status?\n \n\u008d\nAsk about tobacco use and exposure to second-hand \nsmoke\nLook, listen feel\n \n\u008d\nMeasure blood pressure and temperature\n \n\u008d\nFeel uterus. Is it hard and round?\n \n\u008d\nLook at vulva and perineum for tear, swelling or pus\n \n\u008d\nLook at pad for bleeding and lochia\n \n- Does it smell or is the bleeding profuse?\n \n~\nLook for pallor",
        "formatted_content": "<p>767</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TYPE OF DANGER SIGN</h3>\n<h3>ACTION TO TAKE</h3>\n<p>~</p>\n<p>Fever; abdominal pain; feels ill;</p>\n<p>breasts red, tender, swollen; sore</p>\n<p>nipple; urine dribbling or pain on</p>\n<p>urination; perineal pain or drain\u00ad</p>\n<p>ing pus; foul-smelling lochia</p>\n<p>Go to health facility as</p>\n<p>soon as possible</p>\n<p>16.5.1.2   Postpartum Examination of the Mother Up to 6 Weeks</p>\n<p>Ask, check record</p>\n<p>\u008d</p>\n<p>When and where did you deliver?</p>\n<p>\u008d</p>\n<p>How are you feeling?</p>\n<p>\u008d</p>\n<p>Any pain or fever or bleeding since delivery?</p>\n<p>\u008d</p>\n<p>Do you have any problem with passing urine?</p>\n<p>\u008d</p>\n<p>Ask if the woman has started having sex with her partner</p>\n<p>\u008d</p>\n<p>Have you decided on any contraception?</p>\n<p>\u008d</p>\n<p>How do your breasts feel?</p>\n<p>\u008d</p>\n<p>Do you have any other concerns?</p>\n<p>\u008d</p>\n<p>Check records fo any complications during delivery, any</p>\n<p>treatments she is receiving, HIV status?</p>\n<p>\u008d</p>\n<p>Ask about tobacco use and exposure to second-hand</p>\n<p>smoke</p>\n<p>Look, listen feel</p>\n<p>\u008d</p>\n<p>Measure blood pressure and temperature</p>\n<p>\u008d</p>\n<p>Feel uterus. Is it hard and round?</p>\n<p>\u008d</p>\n<p>Look at vulva and perineum for tear, swelling or pus</p>\n<p>\u008d</p>\n<p>Look at pad for bleeding and lochia</p>\n<p>- Does it smell or is the bleeding profuse?</p>\n<p>~</p>\n<p>Look for pallor</p>"
    },
    {
        "page_number": 834,
        "content": "768\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nLook, listen feel\n \n\u008d\nMeasure blood pressure and temperature\n \n\u008d\nFeel uterus. Is it hard and round?\n \n\u008d\nLook at vulva and perineum for tear, swelling or pus\n \n\u008d\nLook at pad for bleeding and lochia\n \n- Does it smell or is the bleeding profuse?\n \n~\nLook for pallor\nUse the table on the next page to examine mother at any postpartum visit",
        "formatted_content": "<p>768</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Look, listen feel</p>\n<p>\u008d</p>\n<p>Measure blood pressure and temperature</p>\n<p>\u008d</p>\n<p>Feel uterus. Is it hard and round?</p>\n<p>\u008d</p>\n<p>Look at vulva and perineum for tear, swelling or pus</p>\n<p>\u008d</p>\n<p>Look at pad for bleeding and lochia</p>\n<p>- Does it smell or is the bleeding profuse?</p>\n<p>~</p>\n<p>Look for pallor</p>\n<p>Use the table on the next page to examine mother at any postpartum visit</p>"
    },
    {
        "page_number": 835,
        "content": "769\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREAT AND ADVISE\nBlood pressure\n \n\u008d\nHistory of \neclampsia \nor pre-ec\u00ad\nlampsia\n \n\u008d\nDiastolic BP\n \n\u008d\n90 mmHg, \nrepeat after \nan hour\n \n\u008d\nDiastolic \nBP\n \n\u008d\n110 \nmmHg\nSevere Hypertension\n \n\u008d\nAssess and treat for pre-eclamp\u00ad\nsia (section 16.3.7). Refer to \nhospital\n \n\u008d\nIf not pre-eclampsia, give/con\u00ad\ntinue appropriate antihyperten\u00ad\nsive as in non-pregnant women \n(section 4.1.6)\n \n\u008d\nDiastolic \nBP\n \n\u008d\n90 \nmmHg \non 2 \nreadings\nModerate Hyper\u00ad\ntension\n \n\u008d\nAssess for pre-eclampsia\n \n\u008d\nIf no pre-eclampsia, give/contin\u00ad\nue appropriate antihypertensive \nas in non-pregnant women (see) \n(section 4.1.6)\n \n\u008d\nReview in one week\n \n\u008d\nDiastolic \nBP\n \n\u008d\n<90 \nmmHg \non\n \n\u008d\n2 read\u00ad\nings\nBlood Pressure \nNormal\n \n\u008d\nNo additional treatment\nClassify and treat as directed below Check for hypertension",
        "formatted_content": "<p>769</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREAT AND ADVISE</h3>\n<p>Blood pressure</p>\n<p>\u008d</p>\n<p>History of</p>\n<p>eclampsia</p>\n<p>or pre-ec\u00ad</p>\n<p>lampsia</p>\n<p>\u008d</p>\n<p>Diastolic BP</p>\n<p>\u008d</p>\n<p>90 mmHg,</p>\n<p>repeat after</p>\n<p>an hour</p>\n<p>\u008d</p>\n<p>Diastolic</p>\n<p>BP</p>\n<p>\u008d</p>\n<p>110</p>\n<p>mmHg</p>\n<p>Severe Hypertension</p>\n<p>\u008d</p>\n<p>Assess and treat for pre-eclamp\u00ad</p>\n<p>sia (section 16.3.7). Refer to</p>\n<p>hospital</p>\n<p>\u008d</p>\n<p>If not pre-eclampsia, give/con\u00ad</p>\n<p>tinue appropriate antihyperten\u00ad</p>\n<p>sive as in non-pregnant women</p>\n<p>(section 4.1.6)</p>\n<p>\u008d</p>\n<p>Diastolic</p>\n<p>BP</p>\n<p>\u008d</p>\n<p>90</p>\n<p>mmHg</p>\n<p>on 2</p>\n<p>readings</p>\n<p>Moderate Hyper\u00ad</p>\n<p>tension</p>\n<p>\u008d</p>\n<p>Assess for pre-eclampsia</p>\n<p>\u008d</p>\n<p>If no pre-eclampsia, give/contin\u00ad</p>\n<p>ue appropriate antihypertensive</p>\n<p>as in non-pregnant women (see)</p>\n<p>(section 4.1.6)</p>\n<p>\u008d</p>\n<p>Review in one week</p>\n<p>\u008d</p>\n<p>Diastolic</p>\n<p>BP</p>\n<p>\u008d</p>\n<p><90</p>\n<p>mmHg</p>\n<p>on</p>\n<p>\u008d</p>\n<p>2 read\u00ad</p>\n<p>ings</p>\n<p>Blood Pressure</p>\n<p>Normal</p>\n<p>\u008d</p>\n<p>No additional treatment</p>\n<p>Classify and treat as directed below Check for hypertension</p>"
    },
    {
        "page_number": 836,
        "content": "770\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREAT AND ADVISE\nCheck for anaemia\n \n\u008d\nCheck record \nfor bleeding \nin pregnan\u00ad\ncy, delivery \nor after \ndelivery\n \n\u008d\nAsk any \nheavy bleed\u00ad\ning since \ndelivery?\n \n\u008d\nDo you tire \neasily?\n \n\u008d\nAre you \nbreathless \nduring rou\u00ad\ntine house\u00ad\nwork?\n \n\u008d\nMeasure Hb\n \n\u008d\nHb <7 g/dL\n \n\u008d\nAnd/or\n \n\u008d\nSevere palmar \nor conjuctival \npallor\nAny pallor and any of:\n \n\u008d\nRR >30 breaths \nper minute\n \n\u008d\nTires easily\n \n\u008d\nBreathlessness \nat rest\nSevere \nAnaemia\n \n\u008d\nGive double dose of iron \nsulphate 200 mg (or Fe\u00ad\nfol) : 1 tablet 2-3 times \ndaily for 3 months\n \n\u008d\nRefer urgently to hospital\n \n\u008d\nFollow up in 2 weeks to \ncheck clinical progress \nand compliance with \ntreatment\n \n\u008d\nHb 7-11 g/\ndL or\n \n\u008d\nPalmar or con\u00ad\njuctival pallor\nModerate \nAnaemia\n \n\u008d\nGive double dose of \nferrous sulphate 200 mg \n(or Fefol) 1 tablet twice \ndaily for 3 months\n \n\u008d\nReassess in 4 weeks\n \n\u008d\nIf anaemia persists, refer \nto hospital\nCheck for anaemia",
        "formatted_content": "<p>770</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREAT AND ADVISE</h3>\n<p>Check for anaemia</p>\n<p>\u008d</p>\n<p>Check record</p>\n<p>for bleeding</p>\n<p>in pregnan\u00ad</p>\n<p>cy, delivery</p>\n<p>or after</p>\n<p>delivery</p>\n<p>\u008d</p>\n<p>Ask any</p>\n<p>heavy bleed\u00ad</p>\n<p>ing since</p>\n<p>delivery?</p>\n<p>\u008d</p>\n<p>Do you tire</p>\n<p>easily?</p>\n<p>\u008d</p>\n<p>Are you</p>\n<p>breathless</p>\n<p>during rou\u00ad</p>\n<p>tine house\u00ad</p>\n<p>work?</p>\n<p>\u008d</p>\n<p>Measure Hb</p>\n<p>\u008d</p>\n<p>Hb <7 g/dL</p>\n<p>\u008d</p>\n<p>And/or</p>\n<p>\u008d</p>\n<p>Severe palmar</p>\n<p>or conjuctival</p>\n<p>pallor</p>\n<p>Any pallor and any of:</p>\n<p>\u008d</p>\n<p>RR >30 breaths</p>\n<p>per minute</p>\n<p>\u008d</p>\n<p>Tires easily</p>\n<p>\u008d</p>\n<p>Breathlessness</p>\n<p>at rest</p>\n<p>Severe</p>\n<p>Anaemia</p>\n<p>\u008d</p>\n<p>Give double dose of iron</p>\n<p>sulphate 200 mg (or Fe\u00ad</p>\n<p>fol) : 1 tablet 2-3 times</p>\n<p>daily for 3 months</p>\n<p>\u008d</p>\n<p>Refer urgently to hospital</p>\n<p>\u008d</p>\n<p>Follow up in 2 weeks to</p>\n<p>check clinical progress</p>\n<p>and compliance with</p>\n<p>treatment</p>\n<p>\u008d</p>\n<p>Hb 7-11 g/</p>\n<p>dL or</p>\n<p>\u008d</p>\n<p>Palmar or con\u00ad</p>\n<p>juctival pallor</p>\n<p>Moderate</p>\n<p>Anaemia</p>\n<p>\u008d</p>\n<p>Give double dose of</p>\n<p>ferrous sulphate 200 mg</p>\n<p>(or Fefol) 1 tablet twice</p>\n<p>daily for 3 months</p>\n<p>\u008d</p>\n<p>Reassess in 4 weeks</p>\n<p>\u008d</p>\n<p>If anaemia persists, refer</p>\n<p>to hospital</p>\n<p>Check for anaemia</p>"
    },
    {
        "page_number": 837,
        "content": "771\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREAT AND ADVISE\n \n\u008d\nLook for \nconjuc\u00ad\ntival and \npalmar \npallor\n \n\u008d\nCount \nbreaths \nper min\u00ad\nute\n \n\u008d\nHb 7-11 \ng/dL or\n \n\u008d\nPalmar \nor con\u00ad\njuctival\u00ad\npallor\nModerate \nAnaemia\n \n\u008d\nGive double dose of ferrous sulphate \n200 mg (or Fefol) 1 tablet twice daily \nfor 3 months\n \n\u008d\nReassess in 4 weeks\n \n\u008d\nIf anaemia persists, refer to hospital\n \n\u008d\nHb >11 \ng/dL\n \n\u008d\nNo \npallor\nNo Anae\u00ad\nmia\n \n~\nContinue treatment with ferrous \nsulphate 200 mg (or Fefol) once daily \nto complete treatment duration of 3 \nmonths\nCheck for vaginal bleeding and possible uterine/urinary tract or febrile infection\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\n \n\u008d\nHeavy vaginal \nbleeding\n \n\u008d\nMore \nthan \n1 pad \nsoaked \nin 5 \nminutes\nPostpartum \nBleeding\ny\t\nGive oxytocin 10 IU IM\n \n\u008d\nGive appropriate IM/IV antibi\u00ad\notics\n \n\u008d\nRefer urgently to hospital\n \n\u008d\nSee PPH section 16.4.6\n \n\u008d\nHeavy/ light \nvaginal bleed\u00ad\ning after 6 \nweeks\n \n\u008d\nStill \nbleeing \n6 weeks \nafter \ndelivery\nPostpartum \nBleeding\n \n\u008d\nRefer urgently to hospital\n \n\u008d\nSee PPH section 16.4.6",
        "formatted_content": "<p>771</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREAT AND ADVISE</h3>\n<p>\u008d</p>\n<p>Look for</p>\n<p>conjuc\u00ad</p>\n<p>tival and</p>\n<p>palmar</p>\n<p>pallor</p>\n<p>\u008d</p>\n<p>Count</p>\n<p>breaths</p>\n<p>per min\u00ad</p>\n<p>ute</p>\n<p>\u008d</p>\n<p>Hb 7-11</p>\n<p>g/dL or</p>\n<p>\u008d</p>\n<p>Palmar</p>\n<p>or con\u00ad</p>\n<p>juctival\u00ad</p>\n<p>pallor</p>\n<p>Moderate</p>\n<p>Anaemia</p>\n<p>\u008d</p>\n<p>Give double dose of ferrous sulphate</p>\n<p>200 mg (or Fefol) 1 tablet twice daily</p>\n<p>for 3 months</p>\n<p>\u008d</p>\n<p>Reassess in 4 weeks</p>\n<p>\u008d</p>\n<p>If anaemia persists, refer to hospital</p>\n<p>\u008d</p>\n<p>Hb >11</p>\n<p>g/dL</p>\n<p>\u008d</p>\n<p>No</p>\n<p>pallor</p>\n<p>No Anae\u00ad</p>\n<p>mia</p>\n<p>~</p>\n<p>Continue treatment with ferrous</p>\n<p>sulphate 200 mg (or Fefol) once daily</p>\n<p>to complete treatment duration of 3</p>\n<p>months</p>\n<p>Check for vaginal bleeding and possible uterine/urinary tract or febrile infection</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>\u008d</p>\n<p>Heavy vaginal</p>\n<p>bleeding</p>\n<p>\u008d</p>\n<p>More</p>\n<p>than</p>\n<p>1 pad</p>\n<p>soaked</p>\n<p>in 5</p>\n<p>minutes</p>\n<p>Postpartum</p>\n<p>Bleeding</p>\n<p>y</p>\n<p>Give oxytocin 10 IU IM</p>\n<p>\u008d</p>\n<p>Give appropriate IM/IV antibi\u00ad</p>\n<p>otics</p>\n<p>\u008d</p>\n<p>Refer urgently to hospital</p>\n<p>\u008d</p>\n<p>See PPH section 16.4.6</p>\n<p>\u008d</p>\n<p>Heavy/ light</p>\n<p>vaginal bleed\u00ad</p>\n<p>ing after 6</p>\n<p>weeks</p>\n<p>\u008d</p>\n<p>Still</p>\n<p>bleeing</p>\n<p>6 weeks</p>\n<p>after</p>\n<p>delivery</p>\n<p>Postpartum</p>\n<p>Bleeding</p>\n<p>\u008d</p>\n<p>Refer urgently to hospital</p>\n<p>\u008d</p>\n<p>See PPH section 16.4.6</p>"
    },
    {
        "page_number": 838,
        "content": "772\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nSigns\nClassify As\nTreat And Advise\n \n\u008d\nMother \nfeeling well\n \n\u008d\nDid not bleed \n>250 mL\n \n\u008d\nUterus well \ncontracted \nand hard\n \n\u008d\nNo perineal \nswelling\n \n\u008d\nBlood \npressure, \npulse and \ntemperature \nnormal\n \n\u008d\nNo pallor\n \n\u008d\nNo breast \nproblem\n \n\u008d\nNo fever \nor pain or \nconcern\n \n\u008d\nNo problem \nwith \nurination\nNormal\nPostpartum\n \n\u008d\nMake sure woman and \nfamily know what to \nwatch for and when to \nseek care\n \n\u008d\nAdvise on postpartum \ncare, hygiene, and \nnutrition\n \n\u008d\nReinforce counselling \non safer sexual \npractices\n \n\u008d\nCounsel on the \nimportance of birth \nspacing and family \nplanning\n \n\u008d\nDispense 3 months \niron supply and \ncounsel on compliance\n \n\u008d\nGive any treatment or \nprophylaxis due, e.g. \nTT\n \n\u008d\nPromote use of \nimpregnated bednet \nfor the mother and the \nbaby\n \n\u008d\nAdvise on when to \nreturn to the health \nfacility for the next visit\n \n\u008d\nAdvise to avoid use \nof tobacco, alcohol, \ndrugs, and exposure to \nsecond-hand smoke",
        "formatted_content": "<p>772</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Signs</p>\n<p>Classify As</p>\n<p>Treat And Advise</p>\n<p>\u008d</p>\n<p>Mother</p>\n<p>feeling well</p>\n<p>\u008d</p>\n<p>Did not bleed</p>\n<p>>250 mL</p>\n<p>\u008d</p>\n<p>Uterus well</p>\n<p>contracted</p>\n<p>and hard</p>\n<p>\u008d</p>\n<p>No perineal</p>\n<p>swelling</p>\n<p>\u008d</p>\n<p>Blood</p>\n<p>pressure,</p>\n<p>pulse and</p>\n<p>temperature</p>\n<p>normal</p>\n<p>\u008d</p>\n<p>No pallor</p>\n<p>\u008d</p>\n<p>No breast</p>\n<p>problem</p>\n<p>\u008d</p>\n<p>No fever</p>\n<p>or pain or</p>\n<p>concern</p>\n<p>\u008d</p>\n<p>No problem</p>\n<p>with</p>\n<p>urination</p>\n<p>Normal</p>\n<p>Postpartum</p>\n<p>\u008d</p>\n<p>Make sure woman and</p>\n<p>family know what to</p>\n<p>watch for and when to</p>\n<p>seek care</p>\n<p>\u008d</p>\n<p>Advise on postpartum</p>\n<p>care, hygiene, and</p>\n<p>nutrition</p>\n<p>\u008d</p>\n<p>Reinforce counselling</p>\n<p>on safer sexual</p>\n<p>practices</p>\n<p>\u008d</p>\n<p>Counsel on the</p>\n<p>importance of birth</p>\n<p>spacing and family</p>\n<p>planning</p>\n<p>\u008d</p>\n<p>Dispense 3 months</p>\n<p>iron supply and</p>\n<p>counsel on compliance</p>\n<p>\u008d</p>\n<p>Give any treatment or</p>\n<p>prophylaxis due, e.g.</p>\n<p>TT</p>\n<p>\u008d</p>\n<p>Promote use of</p>\n<p>impregnated bednet</p>\n<p>for the mother and the</p>\n<p>baby</p>\n<p>\u008d</p>\n<p>Advise on when to</p>\n<p>return to the health</p>\n<p>facility for the next visit</p>\n<p>\u008d</p>\n<p>Advise to avoid use</p>\n<p>of tobacco, alcohol,</p>\n<p>drugs, and exposure to</p>\n<p>second-hand smoke</p>"
    },
    {
        "page_number": 839,
        "content": "773\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\n \n\u008d\nHave you \nhad fever?\n \n\u008d\nAsk for \npresence of \nfoul-smelling \nlochia, burn\u00ad\ning on urina\u00ad\ntion or heavy \nbleeding\n \n\u008d\nFeel lower \nabdomen and \nflanks and \ntenderness\n \n\u008d\nLook for \nabnormal \nlochia, stiff \nneck and \nlethargy\n \n\u008d\nMeasure\n \n\u008d\ntemperature\nTemperature\n>38\u00b0C and any of:\n \n\u008d\nVery weak\n \n\u008d\nAbdominal \ntenderness\n \n\u008d\nFoul-smell\u00ad\ning lochia\n \n\u008d\nProfuse \nlochia\n \n\u008d\nUterus not \nwell con\u00ad\ntracted\n \n\u008d\nLower \nabdominal \npain\n \n\u008d\nHistory of \nheavy vag\u00ad\ninal bleeding\nUterine Infec\u00ad\ntion/ Puer\u00ad\nperal Fever\n \n\u008d\nInsert IV line and give fluids \nrapidly\n \n\u008d\nGive appropriate IM/IV \nantibiotics\n \n\u008d\nRefer urgently to hospital \n(See puerperal fever 16.4.7)",
        "formatted_content": "<p>773</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>\u008d</p>\n<p>Have you</p>\n<p>had fever?</p>\n<p>\u008d</p>\n<p>Ask for</p>\n<p>presence of</p>\n<p>foul-smelling</p>\n<p>lochia, burn\u00ad</p>\n<p>ing on urina\u00ad</p>\n<p>tion or heavy</p>\n<p>bleeding</p>\n<p>\u008d</p>\n<p>Feel lower</p>\n<p>abdomen and</p>\n<p>flanks and</p>\n<p>tenderness</p>\n<p>\u008d</p>\n<p>Look for</p>\n<p>abnormal</p>\n<p>lochia, stiff</p>\n<p>neck and</p>\n<p>lethargy</p>\n<p>\u008d</p>\n<p>Measure</p>\n<p>\u008d</p>\n<p>temperature</p>\n<p>Temperature</p>\n<p>>38\u00b0C and any of:</p>\n<p>\u008d</p>\n<p>Very weak</p>\n<p>\u008d</p>\n<p>Abdominal</p>\n<p>tenderness</p>\n<p>\u008d</p>\n<p>Foul-smell\u00ad</p>\n<p>ing lochia</p>\n<p>\u008d</p>\n<p>Profuse</p>\n<p>lochia</p>\n<p>\u008d</p>\n<p>Uterus not</p>\n<p>well con\u00ad</p>\n<p>tracted</p>\n<p>\u008d</p>\n<p>Lower</p>\n<p>abdominal</p>\n<p>pain</p>\n<p>\u008d</p>\n<p>History of</p>\n<p>heavy vag\u00ad</p>\n<p>inal bleeding</p>\n<p>Uterine Infec\u00ad</p>\n<p>tion/ Puer\u00ad</p>\n<p>peral Fever</p>\n<p>\u008d</p>\n<p>Insert IV line and give fluids</p>\n<p>rapidly</p>\n<p>\u008d</p>\n<p>Give appropriate IM/IV</p>\n<p>antibiotics</p>\n<p>\u008d</p>\n<p>Refer urgently to hospital</p>\n<p>(See puerperal fever 16.4.7)</p>"
    },
    {
        "page_number": 840,
        "content": "774\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCheck for dribbling of urine\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\nAsk if dribbling \nurine\nContinuous leaking \nof urine (and/or \nfaeces)\nSuspect Obstet\u00ad\nric Fistula\n \n\u008d\nRefer for proper assessment and \nmanagement (section 16.6.4)\nNon continuous \ndribbling or leaking \nurine (urge, stress \netc)\nUrinary Incon\u00ad\ntinence\n \n\u008d\nCheck perineal trauma\n \n\u008d\nAssess for urinary tract infection \nand treat if appropriate\n \n\u008d\nRecommend pelvic floor exercises\n \n\u008d\nRefer if not improving\nCheck for perineal trauma/infection\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\nAsk if there is \npus or perineal \npain\nExcessive swelling of \nvulva or perineum\nPerineal Trau\u00ad\nma\nRefer to hospital\n \n-\nPus in \nperineum\n \n-\nPain in \nperineum\nPerineal Infec\u00ad\ntion or Pain\n \n\u008d\nRemove sutures, if present\n \n\u008d\nClean wound\n \n\u008d\nCounsel on care and hygiene\n \n\u008d\nGive paracetamol for pain\n \n\u008d\nFollow up in 2 days\n \n\u008d\nIf no improvement, refer to \nhospital",
        "formatted_content": "<p>774</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Check for dribbling of urine</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>Ask if dribbling</p>\n<p>urine</p>\n<p>Continuous leaking</p>\n<p>of urine (and/or</p>\n<p>faeces)</p>\n<p>Suspect Obstet\u00ad</p>\n<p>ric Fistula</p>\n<p>\u008d</p>\n<p>Refer for proper assessment and</p>\n<p>management (section 16.6.4)</p>\n<p>Non continuous</p>\n<p>dribbling or leaking</p>\n<p>urine (urge, stress</p>\n<p>etc)</p>\n<p>Urinary Incon\u00ad</p>\n<p>tinence</p>\n<p>\u008d</p>\n<p>Check perineal trauma</p>\n<p>\u008d</p>\n<p>Assess for urinary tract infection</p>\n<p>and treat if appropriate</p>\n<p>\u008d</p>\n<p>Recommend pelvic floor exercises</p>\n<p>\u008d</p>\n<p>Refer if not improving</p>\n<p>Check for perineal trauma/infection</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>Ask if there is</p>\n<p>pus or perineal</p>\n<p>pain</p>\n<p>Excessive swelling of</p>\n<p>vulva or perineum</p>\n<p>Perineal Trau\u00ad</p>\n<p>ma</p>\n<p>Refer to hospital</p>\n<p>-</p>\n<p>Pus in</p>\n<p>perineum</p>\n<p>-</p>\n<p>Pain in</p>\n<p>perineum</p>\n<p>Perineal Infec\u00ad</p>\n<p>tion or Pain</p>\n<p>\u008d</p>\n<p>Remove sutures, if present</p>\n<p>\u008d</p>\n<p>Clean wound</p>\n<p>\u008d</p>\n<p>Counsel on care and hygiene</p>\n<p>\u008d</p>\n<p>Give paracetamol for pain</p>\n<p>\u008d</p>\n<p>Follow up in 2 days</p>\n<p>\u008d</p>\n<p>If no improvement, refer to</p>\n<p>hospital</p>"
    },
    {
        "page_number": 841,
        "content": "775\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCheck for vaginal discharge 4 weeks after delivery\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\nIf vaginal discharge 4 weeks\nafter delivery, ask\n \n\u008d\nAny itching of the \nvulva?\n \n\u008d\nHas your partner had \na urinary problem?\n \n\u008d\nIf partner is present \nin the clinic, ask him \nif he has: urethral \ndischarge or pus, \nburning on passing \nurine\n \n\u008d\nIf partner could not \nbe approached, ex\u00ad\nplain importance of \npartner assessment \nand treatment to \navoid reinfection\n \n\u0081\nAbnormal \nvaginal dis\u00ad\ncharge, and \npartner has \nu r e t h r a l \ndischarge \nor burning \non passing \nurine\nPossible\nGonorrhoea\nand/or\nChlamydia\nInfection\n(see section \n3.2.2)\n \n\u008d\nGive appropriate oral \nantibiotics to woman\n \n\u008d\nTreat partner with \nappropriate oral anti\u00ad\nbiotics\n \n\u008d\nCounsel on safer sex \nincluding use of con\u00ad\ndoms\n \n\u008d\nCurd-like \nvaginal \ndischarge \nand/or\n \n\u008d\nIntense \nvulval \nitching\nPossible Can\u00ad\ndida Infection \n(see section \n2.2.1)\n \n\u008d\nGive clotrimazole pes\u00ad\nsaries 1 each evening \nfor 6 days\n \n\u008d\nCounsel on safer sex \nincluding use of con\u00ad\ndoms\n \n\u008d\nIf no improvement, \nrefer\n \n\u008d\nthe woman to hospital",
        "formatted_content": "<p>775</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Check for vaginal discharge 4 weeks after delivery</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>If vaginal discharge 4 weeks</p>\n<p>after delivery, ask</p>\n<p>\u008d</p>\n<p>Any itching of the</p>\n<p>vulva?</p>\n<p>\u008d</p>\n<p>Has your partner had</p>\n<p>a urinary problem?</p>\n<p>\u008d</p>\n<p>If partner is present</p>\n<p>in the clinic, ask him</p>\n<p>if he has: urethral</p>\n<p>discharge or pus,</p>\n<p>burning on passing</p>\n<p>urine</p>\n<p>\u008d</p>\n<p>If partner could not</p>\n<p>be approached, ex\u00ad</p>\n<p>plain importance of</p>\n<p>partner assessment</p>\n<p>and treatment to</p>\n<p>avoid reinfection</p>\n<p>\u0081</p>\n<p>Abnormal</p>\n<p>vaginal dis\u00ad</p>\n<p>charge, and</p>\n<p>partner has</p>\n<p>u r e t h r a l</p>\n<p>discharge</p>\n<p>or burning</p>\n<p>on passing</p>\n<p>urine</p>\n<p>Possible</p>\n<p>Gonorrhoea</p>\n<p>and/or</p>\n<p>Chlamydia</p>\n<p>Infection</p>\n<p>(see section</p>\n<p>3.2.2)</p>\n<p>\u008d</p>\n<p>Give appropriate oral</p>\n<p>antibiotics to woman</p>\n<p>\u008d</p>\n<p>Treat partner with</p>\n<p>appropriate oral anti\u00ad</p>\n<p>biotics</p>\n<p>\u008d</p>\n<p>Counsel on safer sex</p>\n<p>including use of con\u00ad</p>\n<p>doms</p>\n<p>\u008d</p>\n<p>Curd-like</p>\n<p>vaginal</p>\n<p>discharge</p>\n<p>and/or</p>\n<p>\u008d</p>\n<p>Intense</p>\n<p>vulval</p>\n<p>itching</p>\n<p>Possible Can\u00ad</p>\n<p>dida Infection</p>\n<p>(see section</p>\n<p>2.2.1)</p>\n<p>\u008d</p>\n<p>Give clotrimazole pes\u00ad</p>\n<p>saries 1 each evening</p>\n<p>for 6 days</p>\n<p>\u008d</p>\n<p>Counsel on safer sex</p>\n<p>including use of con\u00ad</p>\n<p>doms</p>\n<p>\u008d</p>\n<p>If no improvement,</p>\n<p>refer</p>\n<p>\u008d</p>\n<p>the woman to hospital</p>"
    },
    {
        "page_number": 842,
        "content": "776\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\n \n\u008d\nDo RDT \nor blood \nslide for \nmalaria \npara\u00ad\nsites\nFever >38 \u00b0C and any of:\n \n\u008d\nBurning on \nurination\n \n\u008d\nFlank pain\nUpper Urinary \nTract Infection\n \n\u008d\nGive appropriate IM/IV antibiotics\n \n\u008d\nRefer urgently to hospital (see UTI in \npregnancy 16.2.6)\n \n\u008d\nBurning on \nurination\nLower Urinary \nTract Infection\n \n\u008d\nGive appropriate oral antibiotic (See \nUTI in pregnancy 16.2.6)\n \n\u008d\nEncourage her to drink more fluids\n \n\u008d\nFollow up in 2 days\n \n\u008d\nFever >38\u00b0C \nand any of:\n \n-\nStiff neck\n \n-\nLethargy\n \n-\nRDT \nnegative\nVery Severe \nFebrile Disease\n \n\u008d\nInsert IV line and give fluids rapidly + \nglucose\n \n\u008d\nGive appropriate IM/IV antibiotics \n(See puerperal fever 16.4.7)Refer \nurgently to hospital\n \n\u008d\nFever >38\u00b0C\n \n\u008d\nRDT or blood \nslide for ma\u00ad\nlaria parasites \npositive\nMalaria\n \n\u008d\nGive oral antimalarial (see section \n16.2.4)\n \n\u008d\nFollow up in 2 days\n \n\u008d\nRefer if not better in 2 days",
        "formatted_content": "<p>776</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>\u008d</p>\n<p>Do RDT</p>\n<p>or blood</p>\n<p>slide for</p>\n<p>malaria</p>\n<p>para\u00ad</p>\n<p>sites</p>\n<p>Fever >38 \u00b0C and any of:</p>\n<p>\u008d</p>\n<p>Burning on</p>\n<p>urination</p>\n<p>\u008d</p>\n<p>Flank pain</p>\n<p>Upper Urinary</p>\n<p>Tract Infection</p>\n<p>\u008d</p>\n<p>Give appropriate IM/IV antibiotics</p>\n<p>\u008d</p>\n<p>Refer urgently to hospital (see UTI in</p>\n<p>pregnancy 16.2.6)</p>\n<p>\u008d</p>\n<p>Burning on</p>\n<p>urination</p>\n<p>Lower Urinary</p>\n<p>Tract Infection</p>\n<p>\u008d</p>\n<p>Give appropriate oral antibiotic (See</p>\n<p>UTI in pregnancy 16.2.6)</p>\n<p>\u008d</p>\n<p>Encourage her to drink more fluids</p>\n<p>\u008d</p>\n<p>Follow up in 2 days</p>\n<p>\u008d</p>\n<p>Fever >38\u00b0C</p>\n<p>and any of:</p>\n<p>-</p>\n<p>Stiff neck</p>\n<p>-</p>\n<p>Lethargy</p>\n<p>-</p>\n<h3>RDT</h3>\n<p>negative</p>\n<p>Very Severe</p>\n<p>Febrile Disease</p>\n<p>\u008d</p>\n<p>Insert IV line and give fluids rapidly +</p>\n<p>glucose</p>\n<p>\u008d</p>\n<p>Give appropriate IM/IV antibiotics</p>\n<p>(See puerperal fever 16.4.7)Refer</p>\n<p>urgently to hospital</p>\n<p>\u008d</p>\n<p>Fever >38\u00b0C</p>\n<p>\u008d</p>\n<p>RDT or blood</p>\n<p>slide for ma\u00ad</p>\n<p>laria parasites</p>\n<p>positive</p>\n<p>Malaria</p>\n<p>\u008d</p>\n<p>Give oral antimalarial (see section</p>\n<p>16.2.4)</p>\n<p>\u008d</p>\n<p>Follow up in 2 days</p>\n<p>\u008d</p>\n<p>Refer if not better in 2 days</p>"
    },
    {
        "page_number": 843,
        "content": "777\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCheck for breast problems\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\nAsk\n \n\u008d\nHow do your \nbreasts feel?\n \n\u008d\nLook at the \nnipple for \nfissure\n \n\u008d\nLook at the \nbreasts for: \nswelling, shini\u00ad\nness, redness\n \n\u008d\nFeel gently for \npainful part of \nthe breast\n \n\u008d\nMeasure tem\u00ad\nperature\n \n\u008d\nObserve a \nbreastfeed if \nnot yet done\n \n\u008d\nNipple sore \nor fissured\n \n\u008d\nBaby \nnot well \nattached\nNipple\nSoreness or\nFissure\nBreast\nEngorgement\n \n\u008d\nEncourage the mother to \ncontinue breastfeeding\n \n\u008d\nTeach correct positioning \nand attachment\n \n\u008d\nReassess after 2 feeds \n(or 1 day). If not better, \nteach the mother how to \nexpress breast milk from \nthe affected breast and \nfeed baby by cup, and \ncontinue breastfeeding \non the healthy side\n \n\u008d\nBoth or \none breasts \nare swol\u00ad\nlen, shiny \nand patchy \nred\n \n\u008d\nTempera\u00ad\nture <38\u00b0C\n \n\u008d\nEncourage the mother to \ncontinue breastfeeding\n \n\u008d\nTeach correct positioning \nand attachment\n \n\u008d\nAdvise to feed more \nfrequently",
        "formatted_content": "<p>777</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Check for breast problems</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>Ask</p>\n<p>\u008d</p>\n<p>How do your</p>\n<p>breasts feel?</p>\n<p>\u008d</p>\n<p>Look at the</p>\n<p>nipple for</p>\n<p>fissure</p>\n<p>\u008d</p>\n<p>Look at the</p>\n<p>breasts for:</p>\n<p>swelling, shini\u00ad</p>\n<p>ness, redness</p>\n<p>\u008d</p>\n<p>Feel gently for</p>\n<p>painful part of</p>\n<p>the breast</p>\n<p>\u008d</p>\n<p>Measure tem\u00ad</p>\n<p>perature</p>\n<p>\u008d</p>\n<p>Observe a</p>\n<p>breastfeed if</p>\n<p>not yet done</p>\n<p>\u008d</p>\n<p>Nipple sore</p>\n<p>or fissured</p>\n<p>\u008d</p>\n<p>Baby</p>\n<p>not well</p>\n<p>attached</p>\n<p>Nipple</p>\n<p>Soreness or</p>\n<p>Fissure</p>\n<p>Breast</p>\n<p>Engorgement</p>\n<p>\u008d</p>\n<p>Encourage the mother to</p>\n<p>continue breastfeeding</p>\n<p>\u008d</p>\n<p>Teach correct positioning</p>\n<p>and attachment</p>\n<p>\u008d</p>\n<p>Reassess after 2 feeds</p>\n<p>(or 1 day). If not better,</p>\n<p>teach the mother how to</p>\n<p>express breast milk from</p>\n<p>the affected breast and</p>\n<p>feed baby by cup, and</p>\n<p>continue breastfeeding</p>\n<p>on the healthy side</p>\n<p>\u008d</p>\n<p>Both or</p>\n<p>one breasts</p>\n<p>are swol\u00ad</p>\n<p>len, shiny</p>\n<p>and patchy</p>\n<p>red</p>\n<p>\u008d</p>\n<p>Tempera\u00ad</p>\n<p>ture <38\u00b0C</p>\n<p>\u008d</p>\n<p>Encourage the mother to</p>\n<p>continue breastfeeding</p>\n<p>\u008d</p>\n<p>Teach correct positioning</p>\n<p>and attachment</p>\n<p>\u008d</p>\n<p>Advise to feed more</p>\n<p>frequently</p>"
    },
    {
        "page_number": 844,
        "content": "778\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\n \n\u008d\nBaby not well \nattached\n \n\u008d\nNot yet breast\u00ad\nfeeding\n \n\u008d\nReassess after 2 \nfeeds\n \n\u008d\n(1 day) If not bet\u00ad\nter, teach mother \nhow to express \nenough breast \nmilk before the \nfeed to relieve \ndiscomfort\n \n\u008d\nPainfulbreast \nswollen and red\n \n\u008d\nTemperature \n>38\u00b0C\n \n\u008d\nFeels ill\nMastitis\nSee section 16.6.3",
        "formatted_content": "<p>778</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>\u008d</p>\n<p>Baby not well</p>\n<p>attached</p>\n<p>\u008d</p>\n<p>Not yet breast\u00ad</p>\n<p>feeding</p>\n<p>\u008d</p>\n<p>Reassess after 2</p>\n<p>feeds</p>\n<p>\u008d</p>\n<p>(1 day) If not bet\u00ad</p>\n<p>ter, teach mother</p>\n<p>how to express</p>\n<p>enough breast</p>\n<p>milk before the</p>\n<p>feed to relieve</p>\n<p>discomfort</p>\n<p>\u008d</p>\n<p>Painfulbreast</p>\n<p>swollen and red</p>\n<p>\u008d</p>\n<p>Temperature</p>\n<h3>>38\u00b0C</h3>\n<p>\u008d</p>\n<p>Feels ill</p>\n<p>Mastitis</p>\n<p>See section 16.6.3</p>"
    },
    {
        "page_number": 845,
        "content": "779\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nCheck for any psychosocial problems\nASSESSMENT\nSIGNS\nCLASSIFY\nTREAT\nAsk if feeling unhappy or \ncrying easily, low energy, \nsleep problems, lack of con\u00ad\ncetration, unable to do usual \nwork or take care of the baby, \nnegatve feeling towards the \nbaby or herself, generalized \nbody pains not otherwise \nexplained\n2 of the \ndescribed \nsigns/ symp\u00ad\ntoms, for \nmore than 2 \nweeks\nPossible Postnatal \nDepression\n\t\n\u0089\nSee section 16.6.2\nAny of the \ndescribed signs \nand symptoms, \nduring the 1st \nweek after \ndelivery\nPossible Baby \nBlues\n \n~\nCounsel, \nreassure and \nreview in 2 \nweeks\n \n~\nIf persisting \nsee section \n16.6.2\nAsk if current or previous \nsmoking, alochol, drug abuse, \nprevious or current history of \nviolence\nPossible Psycho\u00ad\nsocial Problem\n\t\n\u0089\nCounselling and \nrefer for specialist \nmanagement",
        "formatted_content": "<p>779</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Check for any psychosocial problems</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREAT</h3>\n<p>Ask if feeling unhappy or</p>\n<p>crying easily, low energy,</p>\n<p>sleep problems, lack of con\u00ad</p>\n<p>cetration, unable to do usual</p>\n<p>work or take care of the baby,</p>\n<p>negatve feeling towards the</p>\n<p>baby or herself, generalized</p>\n<p>body pains not otherwise</p>\n<p>explained</p>\n<p>2 of the</p>\n<p>described</p>\n<p>signs/ symp\u00ad</p>\n<p>toms, for</p>\n<p>more than 2</p>\n<p>weeks</p>\n<p>Possible Postnatal</p>\n<p>Depression</p>\n<p>\u0089</p>\n<p>See section 16.6.2</p>\n<p>Any of the</p>\n<p>described signs</p>\n<p>and symptoms,</p>\n<p>during the 1st</p>\n<p>week after</p>\n<p>delivery</p>\n<p>Possible Baby</p>\n<p>Blues</p>\n<p>~</p>\n<p>Counsel,</p>\n<p>reassure and</p>\n<p>review in 2</p>\n<p>weeks</p>\n<p>~</p>\n<p>If persisting</p>\n<p>see section</p>\n<p>16.6.2</p>\n<p>Ask if current or previous</p>\n<p>smoking, alochol, drug abuse,</p>\n<p>previous or current history of</p>\n<p>violence</p>\n<p>Possible Psycho\u00ad</p>\n<p>social Problem</p>\n<p>\u0089</p>\n<p>Counselling and</p>\n<p>refer for specialist</p>\n<p>management</p>"
    },
    {
        "page_number": 846,
        "content": "780\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\n \n\u008d\nSeparate the \nlabia and look for \nabnormal vaginal \ndischarge: amount, \ncolour, odour and \nsmell\n \n\u008d\nIf no discharge is \nseen, examine with \na gloved finger \nand look at the \ndischarge on the \nglove\n \n\u008d\nAbnor\u00ad\nmal vag\u00ad\ninal dis\u00ad\ncharge\nPossible \nBacterial or \nTrichomonas \nInfection (see \nsection 3.2.2)\n \n\u008d\nGive metronidazole 2 g \nsingle dose to woman\n \n\u008d\nCounsel on safer sex in\u00ad\ncluding use of condoms\nCheck for HIV infection\nASSESSMENT\nSIGNS\nCLASSIFY\nTREATMENT\nDo counseling and testing if \nnever tested before\nSee chapter 3\nHIV Negative\nCounsel on safe sex and staying \nnegative\nEncourage partner testing\nHIV Positive\nManage mother and baby as per \neMTCT guidelines (see section 16.2.2)",
        "formatted_content": "<p>780</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>\u008d</p>\n<p>Separate the</p>\n<p>labia and look for</p>\n<p>abnormal vaginal</p>\n<p>discharge: amount,</p>\n<p>colour, odour and</p>\n<p>smell</p>\n<p>\u008d</p>\n<p>If no discharge is</p>\n<p>seen, examine with</p>\n<p>a gloved finger</p>\n<p>and look at the</p>\n<p>discharge on the</p>\n<p>glove</p>\n<p>\u008d</p>\n<p>Abnor\u00ad</p>\n<p>mal vag\u00ad</p>\n<p>inal dis\u00ad</p>\n<p>charge</p>\n<p>Possible</p>\n<p>Bacterial or</p>\n<p>Trichomonas</p>\n<p>Infection (see</p>\n<p>section 3.2.2)</p>\n<p>\u008d</p>\n<p>Give metronidazole 2 g</p>\n<p>single dose to woman</p>\n<p>\u008d</p>\n<p>Counsel on safer sex in\u00ad</p>\n<p>cluding use of condoms</p>\n<p>Check for HIV infection</p>\n<h3>ASSESSMENT</h3>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREATMENT</h3>\n<p>Do counseling and testing if</p>\n<p>never tested before</p>\n<p>See chapter 3</p>\n<p>HIV Negative</p>\n<p>Counsel on safe sex and staying</p>\n<p>negative</p>\n<p>Encourage partner testing</p>\n<p>HIV Positive</p>\n<p>Manage mother and baby as per</p>\n<p>eMTCT guidelines (see section 16.2.2)</p>"
    },
    {
        "page_number": 847,
        "content": "781\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.6.2     Postnatal Depression\t\n                        ICD10 CODE: F53\nCondition characterized by persistent low mood developing during the \npuerperium period, usually 1 or 2 weeks following delivery. It needs \nspecialized assessment and treatment.\nMild depressive symptoms (sadness, tearfulness, irritability, anxiety) \ndevelop commonly during the first week after\nthe delivery but resolve within 2 weeks (\u201cbaby blues\u201d): it usually needs \nONLY counseling and support.\nRisk factors\n \n\u008d\nPrevious psychiatric history\n \n\u008d\nRecent stressful events\n \n\u008d\nYoung age, first baby (primigravida) and associated fear of the \nresponsibility for the new baby\n \n\u008d\nPoor marital relationship, poor social support\nClinical features\n \n\u008d\nStarts soon after delivery and may continue for a year or \nmore\n \n\u008d\nFeelings of sadness with episodes of crying, anxiety, marked \nirritability, tension, confusion\n \n\u008d\nGuilty feeling of not loving baby enough\n \n\u008d\nLoss of positive feeling towards loved ones\n \n\u008d\nRefusal to breast feed baby\n \n\u008d\nIdeas to harm the baby\nPostpartum psychosis\n \n\u008d\nDistortions of thinking and perception, as well as inappropri\u00ad\nate or narrowed range of emotions (see section 9.1.1.1)",
        "formatted_content": "<p>781</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>16.6.2     Postnatal Depression</p>\n<h3>ICD10 CODE: F53</h3>\n<p>Condition characterized by persistent low mood developing during the</p>\n<p>puerperium period, usually 1 or 2 weeks following delivery. It needs</p>\n<p>specialized assessment and treatment.</p>\n<p>Mild depressive symptoms (sadness, tearfulness, irritability, anxiety)</p>\n<p>develop commonly during the first week after</p>\n<p>the delivery but resolve within 2 weeks (\u201cbaby blues\u201d): it usually needs</p>\n<p>ONLY counseling and support.</p>\n<p>Risk factors</p>\n<p>\u008d</p>\n<p>Previous psychiatric history</p>\n<p>\u008d</p>\n<p>Recent stressful events</p>\n<p>\u008d</p>\n<p>Young age, first baby (primigravida) and associated fear of the</p>\n<p>responsibility for the new baby</p>\n<p>\u008d</p>\n<p>Poor marital relationship, poor social support</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Starts soon after delivery and may continue for a year or</p>\n<p>more</p>\n<p>\u008d</p>\n<p>Feelings of sadness with episodes of crying, anxiety, marked</p>\n<p>irritability, tension, confusion</p>\n<p>\u008d</p>\n<p>Guilty feeling of not loving baby enough</p>\n<p>\u008d</p>\n<p>Loss of positive feeling towards loved ones</p>\n<p>\u008d</p>\n<p>Refusal to breast feed baby</p>\n<p>\u008d</p>\n<p>Ideas to harm the baby</p>\n<p>Postpartum psychosis</p>\n<p>\u008d</p>\n<p>Distortions of thinking and perception, as well as inappropri\u00ad</p>\n<p>ate or narrowed range of emotions (see section 9.1.1.1)</p>"
    },
    {
        "page_number": 848,
        "content": "782\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRoutine assessment for depressive symptoms during post \nnatal visits or at least once at 6 weeks\n\t\n\u0089\nCounselling and reassurance at first contact and review \nafter 2 weeks\n\t\n\u0089\nIf persisting, refer for specialized treatment\n \n-\nPsychotherapy\n \n-\nAntidepressant (see section 9.2.2)\n\t\n\u0089\nIf suicidal thoghts, or any risk for mother and/or baby, \nrefer urgently to hospital\nHC3\nH\nPrevention\n \n\u008d\nPostpartum counselling, support, and follow up\n \n\u008d\nIdentification of patients at risk\n \n\u008d\nMale involvement and support\n16.6.3    Mastitis/Breast Abscess                \tICD10 CODE: O91\nInfection of the breast usually in a breastfeeding mother. Causes\n \n\u008d\nUsually Staphylococcus aureus enters from the baby\u2019s mouth \nthrough a cracked nipple into an engorged breast. Less \nfrequently Streptococci\nClinical features\n \n\u008d\nPain in the breast, which is swollen, often shiny, and tender \nwith enlarged veins\n \n\u008d\nOften in 2nd postpartum week\n \n\u008d\nFever\n \n\u008d\nMay proceed to become an abscess; a collection of pus with\u00ad\nin the breast tissue\n\t\n\u0089\nThere may be localised erythema (shinny red skin)\n\t\n\u0089\nFirm lump, felt initially but may later become fluctuant\n \n-\nMay drain pus spontaneously",
        "formatted_content": "<p>782</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Routine assessment for depressive symptoms during post</p>\n<p>natal visits or at least once at 6 weeks</p>\n<p>\u0089</p>\n<p>Counselling and reassurance at first contact and review</p>\n<p>after 2 weeks</p>\n<p>\u0089</p>\n<p>If persisting, refer for specialized treatment</p>\n<p>-</p>\n<p>Psychotherapy</p>\n<p>-</p>\n<p>Antidepressant (see section 9.2.2)</p>\n<p>\u0089</p>\n<p>If suicidal thoghts, or any risk for mother and/or baby,</p>\n<p>refer urgently to hospital</p>\n<h3>HC3</h3>\n<p>H</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Postpartum counselling, support, and follow up</p>\n<p>\u008d</p>\n<p>Identification of patients at risk</p>\n<p>\u008d</p>\n<p>Male involvement and support</p>\n<p>16.6.3    Mastitis/Breast Abscess                \tICD10 CODE: O91</p>\n<p>Infection of the breast usually in a breastfeeding mother. Causes</p>\n<p>\u008d</p>\n<p>Usually Staphylococcus aureus enters from the baby\u2019s mouth</p>\n<p>through a cracked nipple into an engorged breast. Less</p>\n<p>frequently Streptococci</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Pain in the breast, which is swollen, often shiny, and tender</p>\n<p>with enlarged veins</p>\n<p>\u008d</p>\n<p>Often in 2nd postpartum week</p>\n<p>\u008d</p>\n<p>Fever</p>\n<p>\u008d</p>\n<p>May proceed to become an abscess; a collection of pus with\u00ad</p>\n<p>in the breast tissue</p>\n<p>\u0089</p>\n<p>There may be localised erythema (shinny red skin)</p>\n<p>\u0089</p>\n<p>Firm lump, felt initially but may later become fluctuant</p>\n<p>-</p>\n<p>May drain pus spontaneously</p>"
    },
    {
        "page_number": 849,
        "content": "783\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nComplications\n \n\u008d\nRecurrent infection, scarring\n \n\u008d\nLoss of breast size, noticeable breast asymmetry\n \n\u008d\nMammary duct fistula formation due to reccurrence\nDifferential diagnosis\n \n\u008d\nBreast engorgement (for mastitis)\n \n\u008d\nBreast lump/cancer (for abscess)\nInvestigations\n \n\u0081\nBreast milk: For C&S\n \n\u0081\nUS scan to rule out breast abscess in patients with recurrent \nmastitis\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nStop breastfeeding on the affected breast but express \nmilk and discard to avoid breast engorgement\n\t\n\u0089\nGive analagesics such as paracetamol 1 g every 8 \nhours for 3 days\n\t\n\u0089\nApply warm compresses to relieve pain in affected breast\n\t\n\u0089\nContinue breastfeeding on the normal breast\n\t\n\u0089\nGive cloxacillin 500 mg 6 hourly for 10 days or\n \n-\n(If not available use amoxicillin 500 mg every \n8 hours for 10 days)\nHC2\nHC3\nH\n\t\n\u0089\nIf penicillin allergies: erythromycin 500 mg every 6 \nhours for 10 days\n \n-\nOr cephalexin 500 mg PO every six hours for \n10 days\nIf not improving\n\t\n\u0089\nRefer to hospital for utrasound scan and further man\u00ad\nagement\n\t\n\u0089\nIf clinical or US scan features of breast abscess: incise \nand drain",
        "formatted_content": "<p>783</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Complications</p>\n<p>\u008d</p>\n<p>Recurrent infection, scarring</p>\n<p>\u008d</p>\n<p>Loss of breast size, noticeable breast asymmetry</p>\n<p>\u008d</p>\n<p>Mammary duct fistula formation due to reccurrence</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Breast engorgement (for mastitis)</p>\n<p>\u008d</p>\n<p>Breast lump/cancer (for abscess)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Breast milk: For C&S</p>\n<p>\u0081</p>\n<p>US scan to rule out breast abscess in patients with recurrent</p>\n<p>mastitis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Stop breastfeeding on the affected breast but express</p>\n<p>milk and discard to avoid breast engorgement</p>\n<p>\u0089</p>\n<p>Give analagesics such as paracetamol 1 g every 8</p>\n<p>hours for 3 days</p>\n<p>\u0089</p>\n<p>Apply warm compresses to relieve pain in affected breast</p>\n<p>\u0089</p>\n<p>Continue breastfeeding on the normal breast</p>\n<p>\u0089</p>\n<p>Give cloxacillin 500 mg 6 hourly for 10 days or</p>\n<p>-</p>\n<p>(If not available use amoxicillin 500 mg every</p>\n<p>8 hours for 10 days)</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>H</p>\n<p>\u0089</p>\n<p>If penicillin allergies: erythromycin 500 mg every 6</p>\n<p>hours for 10 days</p>\n<p>-</p>\n<p>Or cephalexin 500 mg PO every six hours for</p>\n<p>10 days</p>\n<p>If not improving</p>\n<p>\u0089</p>\n<p>Refer to hospital for utrasound scan and further man\u00ad</p>\n<p>agement</p>\n<p>\u0089</p>\n<p>If clinical or US scan features of breast abscess: incise</p>\n<p>and drain</p>"
    },
    {
        "page_number": 850,
        "content": "784\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nPrevention\n \n\u008d\nProper attachment of baby on the breast\n \n\u008d\nFrequent emptying of the breast\n \n\u008d\nEnsure the baby is sucking on the areolar and not the nipple\n \n\u008d\nManage breast engorgement if not breastfeeding, or lost baby \n(Refer to section on care of the mother and baby immediately \nafter delivery)\n16.6.4       Obstetric Fistula                               \tICD10 CODE: 071\nObstetric fistula is an abnormal communication between the birth canal, \nand either the bladder, ureters, or rectum. It is one of the major causes \nof maternal morbidity making the women with the condition suffer from \nconstant urinary incontinence which can lead to skin infections, kidney \ndisorder or death if left untreated.\nCauses\n \n\u008d\nObstructed labour (main cause): most fistula develops in 2 \nweeks after an obstructed labour, causing an often expansive \ncrush injury to the vaginal tissues\n \n\u008d\nSexual abuse and rape (Gender-based violence)\n \n\u008d\nComplication of unsafe abortion\n \n\u008d\nSurgical trauma usually following a caesarean section\n \n\u008d\nGynaecological cancers and radiotheraphy\nPredisposing factors\n \n\u008d\nLack of access to maternity care\n \n\u008d\nLack of/inadequate skilled care at birth\n \n\u008d\nLack of facilities for ANC and childbirth\n \n\u008d\nLack of knowledge to identify danger signs and promptly \nrespond\n \n\u008d\nPoverty and lack of women empowerment\n \n\u008d\nEarly marriage and childbirth",
        "formatted_content": "<p>784</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Proper attachment of baby on the breast</p>\n<p>\u008d</p>\n<p>Frequent emptying of the breast</p>\n<p>\u008d</p>\n<p>Ensure the baby is sucking on the areolar and not the nipple</p>\n<p>\u008d</p>\n<p>Manage breast engorgement if not breastfeeding, or lost baby</p>\n<p>(Refer to section on care of the mother and baby immediately</p>\n<p>after delivery)</p>\n<p>16.6.4       Obstetric Fistula                               \tICD10 CODE: 071</p>\n<p>Obstetric fistula is an abnormal communication between the birth canal,</p>\n<p>and either the bladder, ureters, or rectum. It is one of the major causes</p>\n<p>of maternal morbidity making the women with the condition suffer from</p>\n<p>constant urinary incontinence which can lead to skin infections, kidney</p>\n<p>disorder or death if left untreated.</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Obstructed labour (main cause): most fistula develops in 2</p>\n<p>weeks after an obstructed labour, causing an often expansive</p>\n<p>crush injury to the vaginal tissues</p>\n<p>\u008d</p>\n<p>Sexual abuse and rape (Gender-based violence)</p>\n<p>\u008d</p>\n<p>Complication of unsafe abortion</p>\n<p>\u008d</p>\n<p>Surgical trauma usually following a caesarean section</p>\n<p>\u008d</p>\n<p>Gynaecological cancers and radiotheraphy</p>\n<p>Predisposing factors</p>\n<p>\u008d</p>\n<p>Lack of access to maternity care</p>\n<p>\u008d</p>\n<p>Lack of/inadequate skilled care at birth</p>\n<p>\u008d</p>\n<p>Lack of facilities for ANC and childbirth</p>\n<p>\u008d</p>\n<p>Lack of knowledge to identify danger signs and promptly</p>\n<p>respond</p>\n<p>\u008d</p>\n<p>Poverty and lack of women empowerment</p>\n<p>\u008d</p>\n<p>Early marriage and childbirth</p>"
    },
    {
        "page_number": 851,
        "content": "785\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u008d\nInadequate family planning access\n \n\u008d\nHarmful traditional practices such as Female Genital Mutila\u00ad\ntion\nClinical features\n \n\u008d\nUnncontrolled leakage of urine or faeces from vagina\nDifferential diagnosis\n \n\u008d\nStress, urge or overflow incontinence\n \n\u008d\nUreterovaginal fistula (UVF)\nInvestigations\n \n\u0081\nSpeculum examination to visualise leakage; site, size and amount\n \n\u0081\nConfirm by dye test on pelvic examination/speculum examina\u00ad\ntion, and/or examination under anaesthesia (EUA)\nManagement\nA fundamental part of the management of obstetric fistula is the ap\u00ad\npropriate standard management of ALL women who have survived \nprolonged or obstructed labour, since it can prevent fistula formation \nand cure small ones.\nAims of management are to:\n \n\u008d\nPrevent fistula formation\n \n\u008d\nClose the fistula\n \n\u008d\nMake the woman continent and able to resume a full and \nactive life\nPrinciples of immediate care of women who have survived prolonged/\nobstructed labour, or who present immediately after delivery with \nobstetric fistula",
        "formatted_content": "<p>785</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u008d</p>\n<p>Inadequate family planning access</p>\n<p>\u008d</p>\n<p>Harmful traditional practices such as Female Genital Mutila\u00ad</p>\n<p>tion</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Unncontrolled leakage of urine or faeces from vagina</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Stress, urge or overflow incontinence</p>\n<p>\u008d</p>\n<p>Ureterovaginal fistula (UVF)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Speculum examination to visualise leakage; site, size and amount</p>\n<p>\u0081</p>\n<p>Confirm by dye test on pelvic examination/speculum examina\u00ad</p>\n<p>tion, and/or examination under anaesthesia (EUA)</p>\n<p>Management</p>\n<p>A fundamental part of the management of obstetric fistula is the ap\u00ad</p>\n<p>propriate standard management of ALL women who have survived</p>\n<p>prolonged or obstructed labour, since it can prevent fistula formation</p>\n<p>and cure small ones.</p>\n<p>Aims of management are to:</p>\n<p>\u008d</p>\n<p>Prevent fistula formation</p>\n<p>\u008d</p>\n<p>Close the fistula</p>\n<p>\u008d</p>\n<p>Make the woman continent and able to resume a full and</p>\n<p>active life</p>\n<p>Principles of immediate care of women who have survived prolonged/</p>\n<p>obstructed labour, or who present immediately after delivery with</p>\n<p>obstetric fistula</p>"
    },
    {
        "page_number": 852,
        "content": "786\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTREATMENT\nLOC\n\t\n\u0089\nInsert appropriate sized (Foley size 16-18) catheter and \nleave in situ\n\t\n\u0089\nRefer for follow-up care:\n \n-\nThe vagina should be examined by speculum \nas soon as possible and necrotic tissue gently \nexcised under aseptic conditions\n \n-\nRepeat this until vagina is clean\n\t\n\u0089\nThe mother can be discharged with the catheter and \nadvised on care and to come back for review and/or \nremoval\n\t\n\u0089\nRecommend increase in fluid intake up to 5 litres a day\n\t\n\u0089\nPerineal Sitz or salt baths twice daily to help the peri\u00ad\nneum to heal\n\t\n\u0089\nTreat any intercurrent infection and give prophylaxis \nagainst UTI:\n \n-\nNitrofurantoin 100 mg 1 tablet in the evening\n\t\n\u0089\nRemove the catheter:\n \n-\nAfter 2 weeks, only if no damage is shown to \nhave occurred\n \n-\nAfter 4-6 weeks in case of small fistula\n\t\n\u0089\nAfter removing the catheter, if there is no evidence of \nfistula, discharge with the following advice:\n \n-\nAvoid sexual intercourse for 3 months. Once \nit has resumed, it should be gentle and with \nconsideration for the woman\n \n-\nAvoid pregnancy for about 6 months to one \nyear\nH C 3 \nHC4\n \n-\nAdvise on family planning/contraception and \nspacing of children, and the importance of \ngood ANC during her next pregnancy\n \n-\nAll future babies should be delivered in a unit \nequipped to undertake caesarean section",
        "formatted_content": "<p>786</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Insert appropriate sized (Foley size 16-18) catheter and</p>\n<p>leave in situ</p>\n<p>\u0089</p>\n<p>Refer for follow-up care:</p>\n<p>-</p>\n<p>The vagina should be examined by speculum</p>\n<p>as soon as possible and necrotic tissue gently</p>\n<p>excised under aseptic conditions</p>\n<p>-</p>\n<p>Repeat this until vagina is clean</p>\n<p>\u0089</p>\n<p>The mother can be discharged with the catheter and</p>\n<p>advised on care and to come back for review and/or</p>\n<p>removal</p>\n<p>\u0089</p>\n<p>Recommend increase in fluid intake up to 5 litres a day</p>\n<p>\u0089</p>\n<p>Perineal Sitz or salt baths twice daily to help the peri\u00ad</p>\n<p>neum to heal</p>\n<p>\u0089</p>\n<p>Treat any intercurrent infection and give prophylaxis</p>\n<p>against UTI:</p>\n<p>-</p>\n<p>Nitrofurantoin 100 mg 1 tablet in the evening</p>\n<p>\u0089</p>\n<p>Remove the catheter:</p>\n<p>-</p>\n<p>After 2 weeks, only if no damage is shown to</p>\n<p>have occurred</p>\n<p>-</p>\n<p>After 4-6 weeks in case of small fistula</p>\n<p>\u0089</p>\n<p>After removing the catheter, if there is no evidence of</p>\n<p>fistula, discharge with the following advice:</p>\n<p>-</p>\n<p>Avoid sexual intercourse for 3 months. Once</p>\n<p>it has resumed, it should be gentle and with</p>\n<p>consideration for the woman</p>\n<p>-</p>\n<p>Avoid pregnancy for about 6 months to one</p>\n<p>year</p>\n<h3>H C 3</h3>\n<h3>HC4</h3>\n<p>-</p>\n<p>Advise on family planning/contraception and</p>\n<p>spacing of children, and the importance of</p>\n<p>good ANC during her next pregnancy</p>\n<p>-</p>\n<p>All future babies should be delivered in a unit</p>\n<p>equipped to undertake caesarean section</p>"
    },
    {
        "page_number": 853,
        "content": "787\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement of women who presents with an established obstetric fistula\nThese are women in whom the conservative management described \nabove failed or they presented with an established fistula.\nTREATMENT\nLOC\n\t\n\u0089\nRefer to regional level for assessment and appropriate \nmanagement\n\t\n\u0089\nEach woman who has been successfully repaired should \nreceive a card with details of her history, a diagram of \nthe injury and a summary of the operation done which \nshould be presented to every health worker wherever \nshe may go for care\nRR\nNote\n \n\u0081\nFistula repair has to be performed by a trained doctor\nPrevention\n \n\u008d\nProvide skilled attendance at births and improve on emer\u00ad\ngency obstetric care at all levels\n \n\u008d\nIncrease access to accurate and quality family planning infor\u00ad\nmation and services, especially for adolescents\n \n\u008d\nEstablish appropriate and effective referral system at all levels \n(early referrals)\nENSURE ALL WOMEN WHO HAVE SUFFERED OBSTRUCTED \nLABOUR ARE MANAGED ACCORDING TO THE STANDARD \nMANAGEMENT PROTOCOL FOR FISTULA PREVENTION",
        "formatted_content": "<p>787</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management of women who presents with an established obstetric fistula</p>\n<p>These are women in whom the conservative management described</p>\n<p>above failed or they presented with an established fistula.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer to regional level for assessment and appropriate</p>\n<p>management</p>\n<p>\u0089</p>\n<p>Each woman who has been successfully repaired should</p>\n<p>receive a card with details of her history, a diagram of</p>\n<p>the injury and a summary of the operation done which</p>\n<p>should be presented to every health worker wherever</p>\n<p>she may go for care</p>\n<p>RR</p>\n<p>Note</p>\n<p>\u0081</p>\n<p>Fistula repair has to be performed by a trained doctor</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Provide skilled attendance at births and improve on emer\u00ad</p>\n<p>gency obstetric care at all levels</p>\n<p>\u008d</p>\n<p>Increase access to accurate and quality family planning infor\u00ad</p>\n<p>mation and services, especially for adolescents</p>\n<p>\u008d</p>\n<p>Establish appropriate and effective referral system at all levels</p>\n<p>(early referrals)</p>\n<h3>ENSURE ALL WOMEN WHO HAVE SUFFERED OBSTRUCTED</h3>\n<h3>LABOUR ARE MANAGED ACCORDING TO THE STANDARD</h3>\n<h3>MANAGEMENT PROTOCOL FOR FISTULA PREVENTION</h3>"
    },
    {
        "page_number": 854,
        "content": "788\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n16.7 INTRAUTERINE FETAL DEMISE (IUFD) OR FETAL \nDEATH IN UTERO (FDIU)\nFISTULA PREVENTION\nFetal demise (fetal death) refers to situations in which the fetus is no \nlonger alive, but the uterus has not yet started to expel its contents \nand the cervical os remains closed.  Intrauterine fetal demise or death \nrefers to babies with no signs of life in utero. \u201cearly IUFD\u201d refers to fetal \ndemise before 20 weeks\u2019 gestation and IUFD for demise of a fetus at \n20 weeks gestation through to term.\nCauses\n \n~\nBirth defects (congenital abnormalities of the fetus)\n \n~\nBlood transfer from baby to mother (feto-maternal hem\u00ad\norrhage)\n \n~\nMaternal or fetal infection\n \n~\nGenetic abnormality of the fetus\n \n~\nPlacenta separated from the inner uterine wall (placental \nabruption)\n \n~\nUmbilical cord issues\n \n~\nUterine rupture\nPrevention: \nThis should be done during antenatal and intrapartum to reduce fetal \ndeath\n \n~\nDetection and treatment of syphilis/ Malaria\n \n~\nDetection and management of hypertensive disease of \npregnancy\n \n~\nManagement of sickle cell disease\n \n~\nDetection and management of diabetes\n \n~\nMonitoring during labour",
        "formatted_content": "<p>788</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>16.7 INTRAUTERINE FETAL DEMISE (IUFD) OR FETAL</h3>\n<h3>DEATH IN UTERO (FDIU)</h3>\n<h3>FISTULA PREVENTION</h3>\n<p>Fetal demise (fetal death) refers to situations in which the fetus is no</p>\n<p>longer alive, but the uterus has not yet started to expel its contents</p>\n<p>and the cervical os remains closed.  Intrauterine fetal demise or death</p>\n<p>refers to babies with no signs of life in utero. \u201cearly IUFD\u201d refers to fetal</p>\n<p>demise before 20 weeks\u2019 gestation and IUFD for demise of a fetus at</p>\n<p>20 weeks gestation through to term.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Birth defects (congenital abnormalities of the fetus)</p>\n<p>~</p>\n<p>Blood transfer from baby to mother (feto-maternal hem\u00ad</p>\n<p>orrhage)</p>\n<p>~</p>\n<p>Maternal or fetal infection</p>\n<p>~</p>\n<p>Genetic abnormality of the fetus</p>\n<p>~</p>\n<p>Placenta separated from the inner uterine wall (placental</p>\n<p>abruption)</p>\n<p>~</p>\n<p>Umbilical cord issues</p>\n<p>~</p>\n<p>Uterine rupture</p>\n<p>Prevention:</p>\n<p>This should be done during antenatal and intrapartum to reduce fetal</p>\n<p>death</p>\n<p>~</p>\n<p>Detection and treatment of syphilis/ Malaria</p>\n<p>~</p>\n<p>Detection and management of hypertensive disease of</p>\n<p>pregnancy</p>\n<p>~</p>\n<p>Management of sickle cell disease</p>\n<p>~</p>\n<p>Detection and management of diabetes</p>\n<p>~</p>\n<p>Monitoring during labour</p>"
    },
    {
        "page_number": 855,
        "content": "789\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nDiagnosis: \n \n\u0081\nvaginal bleeding\n \n\u0081\nAbsence or cessation of fetal movements\u2014the usual reason \nfor consultation.\n \n\u0081\nA uterus that is significantly smaller than the expected size i.e., \nfundal height too small for gestational age or decrease in fundal \nheight from a prior visit.\n \n\u0081\nAbsence of fetal heart sounds on electronic auscultation\n \n\u0081\nSometimes, breast engorgement, indicating the end of the \npregnancy.\n \n\u0081\nThe above signs suggest fetal death but are not sufficiently \nsensitive to justify a hasty, rash decision. Errors are common. \nRepeat the exam, do not rush.\n \n\u0081\nUltrasonography paired with indicative clinical findings is es\u00ad\nsential for the accurate diagnosis/ confirmation of Intra-uterine \nFetal Death (IUFD) \nCommon etiologies of IUFD <28weeks gestation: \n\t\n\u0089\nInfection or other medical conditions\n\t\n\u0089\nPlacental abruption or insufficiency/Intrauterine growth restriction\n\t\n\u0089\nCongenital malformations of the fetus\n\t\n\u0089\nUmbilical cord accidents or other complications\nMedical management of IUFD (\u2265 14 to \u2264 28 weeks)\n \n\u0081\nIUFD may be managed expectantly or treated surgically (D&E) \nor medically (with medications).\n \n\u0081\nDiscussions aim to foster shared decision making about the plan \nfor care and support maternal/parental choice. \n \n\u0081\nSupportive social and psychological care should be made avail\u00ad\nable to all bereaved parents \n \n\u0081\na combination of mifepristone and misoprostol should be the \nfirst-line intervention:",
        "formatted_content": "<p>789</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Diagnosis:</p>\n<p>\u0081</p>\n<p>vaginal bleeding</p>\n<p>\u0081</p>\n<p>Absence or cessation of fetal movements\u2014the usual reason</p>\n<p>for consultation.</p>\n<p>\u0081</p>\n<p>A uterus that is significantly smaller than the expected size i.e.,</p>\n<p>fundal height too small for gestational age or decrease in fundal</p>\n<p>height from a prior visit.</p>\n<p>\u0081</p>\n<p>Absence of fetal heart sounds on electronic auscultation</p>\n<p>\u0081</p>\n<p>Sometimes, breast engorgement, indicating the end of the</p>\n<p>pregnancy.</p>\n<p>\u0081</p>\n<p>The above signs suggest fetal death but are not sufficiently</p>\n<p>sensitive to justify a hasty, rash decision. Errors are common.</p>\n<p>Repeat the exam, do not rush.</p>\n<p>\u0081</p>\n<p>Ultrasonography paired with indicative clinical findings is es\u00ad</p>\n<p>sential for the accurate diagnosis/ confirmation of Intra-uterine</p>\n<p>Fetal Death (IUFD)</p>\n<p>Common etiologies of IUFD <28weeks gestation:</p>\n<p>\u0089</p>\n<p>Infection or other medical conditions</p>\n<p>\u0089</p>\n<p>Placental abruption or insufficiency/Intrauterine growth restriction</p>\n<p>\u0089</p>\n<p>Congenital malformations of the fetus</p>\n<p>\u0089</p>\n<p>Umbilical cord accidents or other complications</p>\n<p>Medical management of IUFD (\u2265 14 to \u2264 28 weeks)</p>\n<p>\u0081</p>\n<p>IUFD may be managed expectantly or treated surgically (D&E)</p>\n<p>or medically (with medications).</p>\n<p>\u0081</p>\n<p>Discussions aim to foster shared decision making about the plan</p>\n<p>for care and support maternal/parental choice.</p>\n<p>\u0081</p>\n<p>Supportive social and psychological care should be made avail\u00ad</p>\n<p>able to all bereaved parents</p>\n<p>\u0081</p>\n<p>a combination of mifepristone and misoprostol should be the</p>\n<p>first-line intervention:</p>"
    },
    {
        "page_number": 856,
        "content": "790\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n\u2022\t\nMifepristone (200mg) administered orally followed 1\u20132 days later by re\u00ad\npeat doses of 400 \u03bcg misoprostol administered sublingually or vaginally \nevery 4\u20136 hours. The minimum recommended interval between use of \nmifepristone and misoprostol is 24 hours. Between 24 and 48 hours of \nmifepristone (200mg), the four tablets of misoprostol should be given \nvaginally, sublingually and can be administered by physician, midwife or \nwoman herself.\n\u2022\t\nAlternative regimens: repeat doses of 400\u00a0\u03bcg misoprostol administered \nsublingually or vaginally every 4\u20136 hours. However, research shows that \nthe combination regimen, above is more effective than misoprostol alone.\n \n\u0081\nExpectant Management of IUFD involves awaiting spontaneous \nlabour (may take up to 3 weeks). \n \n\u0081\nRecommendations about labour and birth should take into \naccount the mother\u2019s preferences, her medical condition and \nprevious intra-partum history.\n \n\u0081\nVaginal birth is the recommended mode of delivery for most \nwomen, but caesarean birth may need to be considered in \nindividual cases. \n \n\u0081\nPregnancy tissue should be treated in the same way as other \nbiological material unless the individual expresses a desire for \nit to be managed otherwise.\n \n\u0081\nIf a woman has had a previous caesarean section, a discussion \nas to the safety and benefits of induction of labour needs to be \nundertaken by a consultant obstetrician.\n \n\u0081\nClinical assessment and evaluation are recommended to as\u00ad\nsess maternal wellbeing and to determine the cause of death, \nthe chance of recurrence, and of avoiding future pregnancy \ncomplications.\n \n\u0081\nLaboratory tests are recommended to rule out any maternal \ndisease or risk factor that may have contributed to the IUFD \n \n\u0081\nFetal karyotyping should be considered in all cases.\n \n\u0081\nParents should be offered a full postmortem examination of \nthe baby.",
        "formatted_content": "<p>790</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<li></li>\n<p>Mifepristone (200mg) administered orally followed 1\u20132 days later by re\u00ad</p>\n<p>peat doses of 400 \u03bcg misoprostol administered sublingually or vaginally</p>\n<p>every 4\u20136 hours. The minimum recommended interval between use of</p>\n<p>mifepristone and misoprostol is 24 hours. Between 24 and 48 hours of</p>\n<p>mifepristone (200mg), the four tablets of misoprostol should be given</p>\n<p>vaginally, sublingually and can be administered by physician, midwife or</p>\n<p>woman herself.</p>\n<li></li>\n<p>Alternative regimens: repeat doses of 400\u00a0\u03bcg misoprostol administered</p>\n<p>sublingually or vaginally every 4\u20136 hours. However, research shows that</p>\n<p>the combination regimen, above is more effective than misoprostol alone.</p>\n<p>\u0081</p>\n<p>Expectant Management of IUFD involves awaiting spontaneous</p>\n<p>labour (may take up to 3 weeks).</p>\n<p>\u0081</p>\n<p>Recommendations about labour and birth should take into</p>\n<p>account the mother\u2019s preferences, her medical condition and</p>\n<p>previous intra-partum history.</p>\n<p>\u0081</p>\n<p>Vaginal birth is the recommended mode of delivery for most</p>\n<p>women, but caesarean birth may need to be considered in</p>\n<p>individual cases.</p>\n<p>\u0081</p>\n<p>Pregnancy tissue should be treated in the same way as other</p>\n<p>biological material unless the individual expresses a desire for</p>\n<p>it to be managed otherwise.</p>\n<p>\u0081</p>\n<p>If a woman has had a previous caesarean section, a discussion</p>\n<p>as to the safety and benefits of induction of labour needs to be</p>\n<p>undertaken by a consultant obstetrician.</p>\n<p>\u0081</p>\n<p>Clinical assessment and evaluation are recommended to as\u00ad</p>\n<p>sess maternal wellbeing and to determine the cause of death,</p>\n<p>the chance of recurrence, and of avoiding future pregnancy</p>\n<p>complications.</p>\n<p>\u0081</p>\n<p>Laboratory tests are recommended to rule out any maternal</p>\n<p>disease or risk factor that may have contributed to the IUFD</p>\n<p>\u0081</p>\n<p>Fetal karyotyping should be considered in all cases.</p>\n<p>\u0081</p>\n<p>Parents should be offered a full postmortem examination of</p>\n<p>the baby.</p>"
    },
    {
        "page_number": 857,
        "content": "791\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\n \n\u0081\nPostmortem examination should include external examination \nwith birth weight, histology of relevant tissues and plain radi\u00ad\nography (skeletal survey)\n \n\u0081\nPathological examination of the cord, membranes and placenta \nis recommended in all cases of IUFD \n \n\u0081\n Standardized checklists should be used to ensure that all \nappropriate care options are offered and that each response \nmark is recorded.\n \n\u0081\nA standardized dataset should be collected for all IUFDs.\n \n\u0081\nAll IUFDs should be reviewed in a multi-professional meeting \nusing a standardized approach.\n \n\u0081\nAll term intra-partum deaths with no evidence of a major con\u00ad\ngenital anomaly should be investigated locally.\n \n\u0081\nStaff working with bereaved parents should be provided with \nan opportunity to develop their knowledge and understanding \nof perinatal loss, together with the development of skills in \nworking in this area.\n \n\u0081\nA system should be in place to give clinical and psychological \nsupport to staff involved with an IUFD.\n \n\u0081\nA follow-up appointment with the consultant obstetrician should \nbe arranged and it should be clear who is responsible for making \nthese arrangements.\n \n\u0081\nWomen with a history of IUFD should attend a consultant-led \nhospital-based antenatal clinic in their next pregnancy and \nundergo increased antenatal surveillance.",
        "formatted_content": "<p>791</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>\u0081</p>\n<p>Postmortem examination should include external examination</p>\n<p>with birth weight, histology of relevant tissues and plain radi\u00ad</p>\n<p>ography (skeletal survey)</p>\n<p>\u0081</p>\n<p>Pathological examination of the cord, membranes and placenta</p>\n<p>is recommended in all cases of IUFD</p>\n<p>\u0081</p>\n<p>Standardized checklists should be used to ensure that all</p>\n<p>appropriate care options are offered and that each response</p>\n<p>mark is recorded.</p>\n<p>\u0081</p>\n<p>A standardized dataset should be collected for all IUFDs.</p>\n<p>\u0081</p>\n<p>All IUFDs should be reviewed in a multi-professional meeting</p>\n<p>using a standardized approach.</p>\n<p>\u0081</p>\n<p>All term intra-partum deaths with no evidence of a major con\u00ad</p>\n<p>genital anomaly should be investigated locally.</p>\n<p>\u0081</p>\n<p>Staff working with bereaved parents should be provided with</p>\n<p>an opportunity to develop their knowledge and understanding</p>\n<p>of perinatal loss, together with the development of skills in</p>\n<p>working in this area.</p>\n<p>\u0081</p>\n<p>A system should be in place to give clinical and psychological</p>\n<p>support to staff involved with an IUFD.</p>\n<p>\u0081</p>\n<p>A follow-up appointment with the consultant obstetrician should</p>\n<p>be arranged and it should be clear who is responsible for making</p>\n<p>these arrangements.</p>\n<p>\u0081</p>\n<p>Women with a history of IUFD should attend a consultant-led</p>\n<p>hospital-based antenatal clinic in their next pregnancy and</p>\n<p>undergo increased antenatal surveillance.</p>"
    },
    {
        "page_number": 858,
        "content": "792\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nNOTE\nMedical management of IUFD with mifepristone and misoprostol \ncombined is contraindicated in any person with a known allergy to \neither medication, ectopic pregnancy, chronic adrenal failure, or inher\u00ad\nited porphyria, and used with caution in women with life-threatening \nun-stabilized conditions such as uncontrolled cardiac disease, severe \nanemia, or hemorrhagic disorders, uncontrolled serious asthma or in \nthose with an IUD in place.\nMedical management of induced abortion\nMedical management of induced abortion (for both viable and non-vi\u00ad\nable pregnancies) at early or later gestational ages involves the use of \na single-drug regimen or a combination regimen of medicines used in \nsequence, with specific dosages and routes of administration. \nIn Uganda, the following categories of people who can get services \nfor termination of pregnancy: \n \n\u0081\nsevere maternal illnesses threatening the health of a pregnant \nwoman e.g. severe cardiac disease, renal disease, severe pre-ec\u00ad\nlampsia and eclampsia; \n \n\u0081\nsevere foetal abnormalities which are not compatible with ex\u00ad\ntra-uterine life e.g. molar pregnancy, anencephaly;  cancer cervix. \n \n\u0081\nHIV-positive women requesting for a termination. \n \n\u0081\nRape, incest, and defilement.\nNOTE:\nMedical termination of pregnancy services can be provided at;\n \n\u0081\nHC IV\n \n\u0081\ngeneral hospital, and \n \n\u0081\nreferral hospital levels.\nBy a medical officer, or gynae/surgeon",
        "formatted_content": "<p>792</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>NOTE</h3>\n<p>Medical management of IUFD with mifepristone and misoprostol</p>\n<p>combined is contraindicated in any person with a known allergy to</p>\n<p>either medication, ectopic pregnancy, chronic adrenal failure, or inher\u00ad</p>\n<p>ited porphyria, and used with caution in women with life-threatening</p>\n<p>un-stabilized conditions such as uncontrolled cardiac disease, severe</p>\n<p>anemia, or hemorrhagic disorders, uncontrolled serious asthma or in</p>\n<p>those with an IUD in place.</p>\n<p>Medical management of induced abortion</p>\n<p>Medical management of induced abortion (for both viable and non-vi\u00ad</p>\n<p>able pregnancies) at early or later gestational ages involves the use of</p>\n<p>a single-drug regimen or a combination regimen of medicines used in</p>\n<p>sequence, with specific dosages and routes of administration.</p>\n<p>In Uganda, the following categories of people who can get services</p>\n<p>for termination of pregnancy:</p>\n<p>\u0081</p>\n<p>severe maternal illnesses threatening the health of a pregnant</p>\n<p>woman e.g. severe cardiac disease, renal disease, severe pre-ec\u00ad</p>\n<p>lampsia and eclampsia;</p>\n<p>\u0081</p>\n<p>severe foetal abnormalities which are not compatible with ex\u00ad</p>\n<p>tra-uterine life e.g. molar pregnancy, anencephaly;  cancer cervix.</p>\n<p>\u0081</p>\n<p>HIV-positive women requesting for a termination.</p>\n<p>\u0081</p>\n<p>Rape, incest, and defilement.</p>\n<h3>NOTE:</h3>\n<p>Medical termination of pregnancy services can be provided at;</p>\n<p>\u0081</p>\n<h3>HC IV</h3>\n<p>\u0081</p>\n<p>general hospital, and</p>\n<p>\u0081</p>\n<p>referral hospital levels.</p>\n<p>By a medical officer, or gynae/surgeon</p>"
    },
    {
        "page_number": 859,
        "content": "793\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nManagement\nFor medical management of induced abortion at gestation ages \n<\u00a012 weeks: \n \n\u0081\nTwo-medication regimen: First,\u00a0the use of 200\u00a0mg mifepristone \nis administered orally, followed 1\u20132 days later by 800\u00a0\u03bcg of \nmisoprostol administered vaginally, sublingually, or buccally. The \nminimum recommended interval between use of mifepristone \nand misoprostol is 24 hours. These medications can be taken \nby the person herself, or administered on an outpatient basis \nby trained health workers. \n \n\u0081\nSingle-medication regimen: 800 \u03bcg misoprostol administered \nbuccally, sublingually, or vaginally.\nEvidence from clinical studies demonstrates that the combination \nregimen is more effective than misoprostol alone.\nFor either regimen:\n\t\n\u0089\nRepeat doses of misoprostol can be considered when needed to \nachieve success of the abortion process. In this guideline we do \nnot provide a maximum number of doses of misoprostol.\n\t\n\u0089\nAll routes are included as options for misoprostol administration, \nin consideration of patient and provider preference\nMedical management of induced abortion at gestational \nages \u2265\u00a012 weeks\n \n\u0081\nTwo-medication regimen: 200\u00a0mg mifepristone is administered \norally, followed 1\u20132 days later by repeat doses of 400\u00a0\u03bcg miso\u00ad\nprostol administered buccally, sublingually or vaginally every 3 \nhours.* The minimum recommended interval between use of \nmifepristone and misoprostol is 24 hours. \n \n\u0081\nSingle-medication regimen: When using misoprostol alone: \nrecommend the use of repeat doses of 400\u00a0\u03bcg misoprostol \nadministered vaginally, sublingually or buccally every 3 hours.",
        "formatted_content": "<p>793</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Management</p>\n<p>For medical management of induced abortion at gestation ages</p>\n<p><\u00a012 weeks:</p>\n<p>\u0081</p>\n<p>Two-medication regimen: First,\u00a0the use of 200\u00a0mg mifepristone</p>\n<p>is administered orally, followed 1\u20132 days later by 800\u00a0\u03bcg of</p>\n<p>misoprostol administered vaginally, sublingually, or buccally. The</p>\n<p>minimum recommended interval between use of mifepristone</p>\n<p>and misoprostol is 24 hours. These medications can be taken</p>\n<p>by the person herself, or administered on an outpatient basis</p>\n<p>by trained health workers.</p>\n<p>\u0081</p>\n<p>Single-medication regimen: 800 \u03bcg misoprostol administered</p>\n<p>buccally, sublingually, or vaginally.</p>\n<p>Evidence from clinical studies demonstrates that the combination</p>\n<p>regimen is more effective than misoprostol alone.</p>\n<p>For either regimen:</p>\n<p>\u0089</p>\n<p>Repeat doses of misoprostol can be considered when needed to</p>\n<p>achieve success of the abortion process. In this guideline we do</p>\n<p>not provide a maximum number of doses of misoprostol.</p>\n<p>\u0089</p>\n<p>All routes are included as options for misoprostol administration,</p>\n<p>in consideration of patient and provider preference</p>\n<p>Medical management of induced abortion at gestational</p>\n<p>ages \u2265\u00a012 weeks</p>\n<p>\u0081</p>\n<p>Two-medication regimen: 200\u00a0mg mifepristone is administered</p>\n<p>orally, followed 1\u20132 days later by repeat doses of 400\u00a0\u03bcg miso\u00ad</p>\n<p>prostol administered buccally, sublingually or vaginally every 3</p>\n<p>hours.* The minimum recommended interval between use of</p>\n<p>mifepristone and misoprostol is 24 hours.</p>\n<p>\u0081</p>\n<p>Single-medication regimen: When using misoprostol alone:</p>\n<p>recommend the use of repeat doses of 400\u00a0\u03bcg misoprostol</p>\n<p>administered vaginally, sublingually or buccally every 3 hours.</p>"
    },
    {
        "page_number": 860,
        "content": "794\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nPain Management \nShould be proactive for medical management of induced abortion at \nany gestational age. Pain medication should be offered routinely (e.g. \nnon-steroidal anti-inflammatory drugs [NSAIDs]). It should be provided \nfor the individual to use if and when wanted. Acetominophen can be \nused for pain control when NSAIDS are unavailable. Other methods of \npain control, such as certain anti-emetics and epidural anaesthesia can \nbe considered as necessary, with the goal of proactive, patient-centered \npain management.\n \nPrecaution\n \n\u0081\nEctopic pregnancy should be excluded, and intra-uterine \ngestation confirmed before the medical abortion. The medical \nabortion regimen will not terminate the ectopic pregnancy\n \n\u0081\nFertility can return within two weeks therefore all patients \nshould be given post-abortion contraception where eligible \n \n\u0081\nAccess to appropriate medical care must be assured in case an \nemergency develops; the patient should be given clear verbal \nand written instructions on whom she should contact and \nwhere to go in case of concerns or suspected complications\nThis chapter presents the management of sick infant and child up to \nage 5, following the WHO syndromic approach IMNCI.\nAdditional information about management of childhood illnesses can \nbe found in specific sections:\nTOPIC\nREFERENCE SECTION\nCare of the new born\nSee chapter 16\nImmunisable diseases and \nother infectious diseases\nSee chapter 1 INFECTIONS and \nBODY SYSTEM CHAPTERS\nHIV care in children\nSee chapter 3 HIV/AIDS",
        "formatted_content": "<p>794</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<p>Pain Management</p>\n<p>Should be proactive for medical management of induced abortion at</p>\n<p>any gestational age. Pain medication should be offered routinely (e.g.</p>\n<p>non-steroidal anti-inflammatory drugs [NSAIDs]). It should be provided</p>\n<p>for the individual to use if and when wanted. Acetominophen can be</p>\n<p>used for pain control when NSAIDS are unavailable. Other methods of</p>\n<p>pain control, such as certain anti-emetics and epidural anaesthesia can</p>\n<p>be considered as necessary, with the goal of proactive, patient-centered</p>\n<p>pain management.</p>\n<p>Precaution</p>\n<p>\u0081</p>\n<p>Ectopic pregnancy should be excluded, and intra-uterine</p>\n<p>gestation confirmed before the medical abortion. The medical</p>\n<p>abortion regimen will not terminate the ectopic pregnancy</p>\n<p>\u0081</p>\n<p>Fertility can return within two weeks therefore all patients</p>\n<p>should be given post-abortion contraception where eligible</p>\n<p>\u0081</p>\n<p>Access to appropriate medical care must be assured in case an</p>\n<p>emergency develops; the patient should be given clear verbal</p>\n<p>and written instructions on whom she should contact and</p>\n<p>where to go in case of concerns or suspected complications</p>\n<p>This chapter presents the management of sick infant and child up to</p>\n<p>age 5, following the WHO syndromic approach IMNCI.</p>\n<p>Additional information about management of childhood illnesses can</p>\n<p>be found in specific sections:</p>\n<h3>TOPIC</h3>\n<h3>REFERENCE SECTION</h3>\n<p>Care of the new born</p>\n<p>See chapter 16</p>\n<p>Immunisable diseases and</p>\n<p>other infectious diseases</p>\n<p>See chapter 1 INFECTIONS and</p>\n<h3>BODY SYSTEM CHAPTERS</h3>\n<p>HIV care in children</p>\n<p>See chapter 3 HIV/AIDS</p>"
    },
    {
        "page_number": 861,
        "content": "795\nUganda Clinical Guidelines 2023\nCHAPTER 16: Obstetric Conditions\nTOPIC\nREFERENCE SECTION\nImmunisation\nSee chapter 18 \nIMMUNISATION\nManutrition rehabilitation\nSee chapter 19 \nNUTRITION\nSickle cell disease\nSee chapter 11 BLOOD DISORDERS\nIMNCI (Integrated Management of Newborn and Child\u00ad\nhood Illnesses)\nThe following guidelines use a syndromic approach to the management \nof common childhood conditions at Primary Health Care Level and \nshould be followed page-by-page.\nThe general approach used involves 5 main steps:\n \n- Assess the child\n \n- Classify the illness\n \n- Identify and provide the required treatment\n \n- Counsel the mother\n \n- Provide FOLLOW UP support\nThere are 3 sections, based on age:\n \n- Sick newborn (1st week of life)\n \n- Sick infant (up to 2 months)\n \n- Sick child (2 months to 5 years)",
        "formatted_content": "<p>795</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 16: Obstetric Conditions</p>\n<h3>TOPIC</h3>\n<h3>REFERENCE SECTION</h3>\n<p>Immunisation</p>\n<p>See chapter 18</p>\n<h3>IMMUNISATION</h3>\n<p>Manutrition rehabilitation</p>\n<p>See chapter 19</p>\n<h3>NUTRITION</h3>\n<p>Sickle cell disease</p>\n<p>See chapter 11 BLOOD DISORDERS</p>\n<p>IMNCI (Integrated Management of Newborn and Child\u00ad</p>\n<p>hood Illnesses)</p>\n<p>The following guidelines use a syndromic approach to the management</p>\n<p>of common childhood conditions at Primary Health Care Level and</p>\n<p>should be followed page-by-page.</p>\n<p>The general approach used involves 5 main steps:</p>\n<p>- Assess the child</p>\n<p>- Classify the illness</p>\n<p>- Identify and provide the required treatment</p>\n<p>- Counsel the mother</p>\n<p>- Provide FOLLOW UP support</p>\n<p>There are 3 sections, based on age:</p>\n<p>- Sick newborn (1st week of life)</p>\n<p>- Sick infant (up to 2 months)</p>\n<p>- Sick child (2 months to 5 years)</p>"
    },
    {
        "page_number": 862,
        "content": "796\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.1  SICK NEWBORN\n17.1.1  Newborn Examination/Danger Signs\nUse the following procedures to examine all newborn babies after delivery, \nbefore discharge or if baby is seen as an outpatient for routine, FOLLOW \nUP, or sick newborn visit during first week of life.\nAsk If first visit\n \n~\nHow old is the baby? Where \nwas the baby born?\n \n~\nWho delivered the baby? \nCheck infant record for risk \nfactors\n \n~\nWhat was birth weight? \nLBW? Preterm?Twin?\n \n~\nAny problem at birth? \nBreech? Difficult birth? Was \nresuscitation done?\nAsk the mother\n \n- Has the baby had any \nconvulsions?\n \n- Does the baby have frequent \nheavy vomiting?\n \n- How is the baby feeding? Any \nfeeding problems?\n \n- How many times has baby \nbreastfed in last 24 hours?\n \n- Is baby satisfied with feeds? \nHave you fed baby any other \nfood or drinks?\n \n- Has baby breastfed in previous \nhour?\n \n- How do your breasts feel?\n \n- Do you have any other \nconcerns?\nLook, listen, feel\n \n~\nAssess breathing (baby \nmust be calm)\n \n- Count breaths (normal: 30-60/\nmin)\n \n- Assess for grunting/chest \nin-drawing\n \n- Check SpO2 if available\n \n~\nLook at the movements: \nnormal and symmetrical?\n \n~\nLook at the presenting \npart for swelling or bruises\n \n~\nCheck abdomen for pallor \nand distetion\n \n~\nLook for malformtions\n \n~\nFeel the tone: nomal?\n \n~\nFeel for warmth and check \ntemperature\n \n~\nWeigh the baby\n \n~\nObserve a breastfeed: Is \nthe baby able to attach? \nSuckling effectively? Well- \npositioned?\n \n~\nLook for ulcers and white \npatches in the mouth \n(thrush)\nChildhood Illness\n17",
        "formatted_content": "<p>796</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>17.1  SICK NEWBORN</h3>\n<p>17.1.1  Newborn Examination/Danger Signs</p>\n<p>Use the following procedures to examine all newborn babies after delivery,</p>\n<p>before discharge or if baby is seen as an outpatient for routine, FOLLOW</p>\n<p>UP, or sick newborn visit during first week of life.</p>\n<p>Ask If first visit</p>\n<p>~</p>\n<p>How old is the baby? Where</p>\n<p>was the baby born?</p>\n<p>~</p>\n<p>Who delivered the baby?</p>\n<p>Check infant record for risk</p>\n<p>factors</p>\n<p>~</p>\n<p>What was birth weight?</p>\n<p>LBW? Preterm?Twin?</p>\n<p>~</p>\n<p>Any problem at birth?</p>\n<p>Breech? Difficult birth? Was</p>\n<p>resuscitation done?</p>\n<p>Ask the mother</p>\n<p>- Has the baby had any</p>\n<p>convulsions?</p>\n<p>- Does the baby have frequent</p>\n<p>heavy vomiting?</p>\n<p>- How is the baby feeding? Any</p>\n<p>feeding problems?</p>\n<p>- How many times has baby</p>\n<p>breastfed in last 24 hours?</p>\n<p>- Is baby satisfied with feeds?</p>\n<p>Have you fed baby any other</p>\n<p>food or drinks?</p>\n<p>- Has baby breastfed in previous</p>\n<p>hour?</p>\n<p>- How do your breasts feel?</p>\n<p>- Do you have any other</p>\n<p>concerns?</p>\n<p>Look, listen, feel</p>\n<p>~</p>\n<p>Assess breathing (baby</p>\n<p>must be calm)</p>\n<p>- Count breaths (normal: 30-60/</p>\n<p>min)</p>\n<p>- Assess for grunting/chest</p>\n<p>in-drawing</p>\n<p>- Check SpO2 if available</p>\n<p>~</p>\n<p>Look at the movements:</p>\n<p>normal and symmetrical?</p>\n<p>~</p>\n<p>Look at the presenting</p>\n<p>part for swelling or bruises</p>\n<p>~</p>\n<p>Check abdomen for pallor</p>\n<p>and distetion</p>\n<p>~</p>\n<p>Look for malformtions</p>\n<p>~</p>\n<p>Feel the tone: nomal?</p>\n<p>~</p>\n<p>Feel for warmth and check</p>\n<p>temperature</p>\n<p>~</p>\n<p>Weigh the baby</p>\n<p>~</p>\n<p>Observe a breastfeed: Is</p>\n<p>the baby able to attach?</p>\n<p>Suckling effectively? Well-</p>\n<p>positioned?</p>\n<p>~</p>\n<p>Look for ulcers and white</p>\n<p>patches in the mouth</p>\n<p>(thrush)</p>\n<p>Childhood Illness</p>\n<p>17</p>"
    },
    {
        "page_number": 863,
        "content": "797\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nTREAT\nAny of the following\n \n~\nRespiratory rate > 60 or < 30 or \ngrunting or gasping\n \n~\nSevere chest indrawing or cyanosis\n \n~\nNot feeding well\n \n~\nConvulsions\n \n~\nAbdominal overdistension\n \n~\nHeart rate constantly > 180 beats \nper minutes\n \n~\nFloppy or stiff body or no sponta\u00ad\nneous movements\n \n~\nTemperature > 37.5 or < 35.5\u00b0C \nafter warming\n \n~\nUmbilicus draining pus, redness/ \nswelling extended to skin\n \n~\nSkin pustules >10 or bullae or skin \nswelling and harness\n \n~\nBleeding from stump or cut\n \n~\nPallor\nPossible Se\u00ad\nrious Illness\n(see section \n2.1.7.1, neo\u00ad\nnatal sepsis, \n2.1.5.1 men\u00ad\ningitis, 2.1.8.1 \ntetanus)\n\t\n\u0089\nGive ampicillin 50 mg/kg IM \nevery 12 hours plus gentamicin \n5 mg/kg every 24 hours (4 \nmg/kg if preterm)\n\t\n\u0089\nRefer baby to hospital\n\t\n\u0089\nIf referral not possible continue \ntreatment for 7 days\n\t\n\u0089\nKeep baby warm\n\t\n\u0089\nClean infected umbilicus and \npustules and apply Gentian \nViolet\n\t\n\u0089\nIf risk of staphylococcus infec\u00ad\ntion, give cloxacillin 50 mg/\nKg IV/IM every 6 hours and \ngentamicin 5-7 mg/Kg every \n24 hours\nIf danger signs present, treat as below",
        "formatted_content": "<p>797</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>TREAT</h3>\n<p>Any of the following</p>\n<p>~</p>\n<p>Respiratory rate > 60 or < 30 or</p>\n<p>grunting or gasping</p>\n<p>~</p>\n<p>Severe chest indrawing or cyanosis</p>\n<p>~</p>\n<p>Not feeding well</p>\n<p>~</p>\n<p>Convulsions</p>\n<p>~</p>\n<p>Abdominal overdistension</p>\n<p>~</p>\n<p>Heart rate constantly > 180 beats</p>\n<p>per minutes</p>\n<p>~</p>\n<p>Floppy or stiff body or no sponta\u00ad</p>\n<p>neous movements</p>\n<p>~</p>\n<p>Temperature > 37.5 or < 35.5\u00b0C</p>\n<p>after warming</p>\n<p>~</p>\n<p>Umbilicus draining pus, redness/</p>\n<p>swelling extended to skin</p>\n<p>~</p>\n<p>Skin pustules >10 or bullae or skin</p>\n<p>swelling and harness</p>\n<p>~</p>\n<p>Bleeding from stump or cut</p>\n<p>~</p>\n<p>Pallor</p>\n<p>Possible Se\u00ad</p>\n<p>rious Illness</p>\n<p>(see section</p>\n<p>2.1.7.1, neo\u00ad</p>\n<p>natal sepsis,</p>\n<p>2.1.5.1 men\u00ad</p>\n<p>ingitis, 2.1.8.1</p>\n<p>tetanus)</p>\n<p>\u0089</p>\n<p>Give ampicillin 50 mg/kg IM</p>\n<p>every 12 hours plus gentamicin</p>\n<p>5 mg/kg every 24 hours (4</p>\n<p>mg/kg if preterm)</p>\n<p>\u0089</p>\n<p>Refer baby to hospital</p>\n<p>\u0089</p>\n<p>If referral not possible continue</p>\n<p>treatment for 7 days</p>\n<p>\u0089</p>\n<p>Keep baby warm</p>\n<p>\u0089</p>\n<p>Clean infected umbilicus and</p>\n<p>pustules and apply Gentian</p>\n<p>Violet</p>\n<p>\u0089</p>\n<p>If risk of staphylococcus infec\u00ad</p>\n<p>tion, give cloxacillin 50 mg/</p>\n<p>Kg IV/IM every 6 hours and</p>\n<p>gentamicin 5-7 mg/Kg every</p>\n<p>24 hours</p>\n<p>If danger signs present, treat as below</p>"
    },
    {
        "page_number": 864,
        "content": "798\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\nFeeding well \n(suckling \neffectively >8 \ntimes in 24 \nhours)\n \n~\nWeight \n>2,500 g or \nsmall baby \nbut eating \nand gaining \nweight well\n \n~\nNo danger \nsigns\n \n~\nNo special \ntreatment \nneeds\nWell Baby\n\t\n\u0089\nContinue exclusive breastfeeding on demand\n\t\n\u0089\nEnsure warmth, cord care, hygiene, other baby care f Routine visit at \nage 3-7 days\n\t\n\u0089\nNext immunization at 6 weeks f When to return if danger signs f Record \non home-based record\n\t\n\u0089\nIf first visit (baby not delivered in health facilities) give\n\t\n\u0089\nVitamin K 1 mg IM\n\t\n\u0089\nTetracycline eye ointment\n \n~\nReceiving \nother foods/\ndrinks or giv\u00ad\nen pacifier\nFeeding\nProblem\n\t\n\u0089\nStop other food/drinks\n\t\n\u0089\nFeed more frequently, day and night. Reassure mother she has enough milk\nIf no danger signs present, classify and treat as below",
        "formatted_content": "<p>798</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p>Feeding well</p>\n<p>(suckling</p>\n<p>effectively >8</p>\n<p>times in 24</p>\n<p>hours)</p>\n<p>~</p>\n<p>Weight</p>\n<p>>2,500 g or</p>\n<p>small baby</p>\n<p>but eating</p>\n<p>and gaining</p>\n<p>weight well</p>\n<p>~</p>\n<p>No danger</p>\n<p>signs</p>\n<p>~</p>\n<p>No special</p>\n<p>treatment</p>\n<p>needs</p>\n<p>Well Baby</p>\n<p>\u0089</p>\n<p>Continue exclusive breastfeeding on demand</p>\n<p>\u0089</p>\n<p>Ensure warmth, cord care, hygiene, other baby care f Routine visit at</p>\n<p>age 3-7 days</p>\n<p>\u0089</p>\n<p>Next immunization at 6 weeks f When to return if danger signs f Record</p>\n<p>on home-based record</p>\n<p>\u0089</p>\n<p>If first visit (baby not delivered in health facilities) give</p>\n<p>\u0089</p>\n<p>Vitamin K 1 mg IM</p>\n<p>\u0089</p>\n<p>Tetracycline eye ointment</p>\n<p>~</p>\n<p>Receiving</p>\n<p>other foods/</p>\n<p>drinks or giv\u00ad</p>\n<p>en pacifier</p>\n<p>Feeding</p>\n<p>Problem</p>\n<p>\u0089</p>\n<p>Stop other food/drinks</p>\n<p>\u0089</p>\n<p>Feed more frequently, day and night. Reassure mother she has enough milk</p>\n<p>If no danger signs present, classify and treat as below</p>"
    },
    {
        "page_number": 865,
        "content": "799\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\nBreastfeeding \n<8 times/ 24 \nhours\n \n~\nNot well \nattached/ not \nsuckling well\n\t\n\u0089\nEnsure correct positioning/ attachment\n\t\n\u0089\nIf thrush: teach how to treat at home (apply gentian violet paint 4 times \ndaily for 7 days with clean hands, use a soft cloth)\n \n~\nThrush\n \n~\nPoor weight \ngain\nFeeding \nProblem\n\t\n\u0089\nFOLLOW UP visit in 2 days, re-check weight\n\t\n\u0089\nIf no improvement: Refer for breastfeeding counselling\n \n~\nThrush\n \n~\nPoor weight \ngain\nFeeding \nProblem\n\t\n\u0089\nFOLLOW UP visit in 2 days, re-check weight\n\t\n\u0089\nIf no improvement: Refer for breastfeeding counselling\n \n~\nPreterm\nSmall Baby\n\t\n\u0089\nProvide as close to continuous Kangaroo mother care as possible to \nprevent hypothermia\n\t\n\u0089\nGive special support to breastfeed small baby/twins\n \n~\nPreterm\n \n~\nLow birth \nweight \n(LBW) \n1,500\u2013\n2,500g\n\t\n\u0089\nTeach mother how to care for a small baby\n\t\n\u0089\nTeach alternative feeding method (cup feeding)",
        "formatted_content": "<p>799</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p>Breastfeeding</p>\n<p><8 times/ 24</p>\n<p>hours</p>\n<p>~</p>\n<p>Not well</p>\n<p>attached/ not</p>\n<p>suckling well</p>\n<p>\u0089</p>\n<p>Ensure correct positioning/ attachment</p>\n<p>\u0089</p>\n<p>If thrush: teach how to treat at home (apply gentian violet paint 4 times</p>\n<p>daily for 7 days with clean hands, use a soft cloth)</p>\n<p>~</p>\n<p>Thrush</p>\n<p>~</p>\n<p>Poor weight</p>\n<p>gain</p>\n<p>Feeding</p>\n<p>Problem</p>\n<p>\u0089</p>\n<p>FOLLOW UP visit in 2 days, re-check weight</p>\n<p>\u0089</p>\n<p>If no improvement: Refer for breastfeeding counselling</p>\n<p>~</p>\n<p>Thrush</p>\n<p>~</p>\n<p>Poor weight</p>\n<p>gain</p>\n<p>Feeding</p>\n<p>Problem</p>\n<p>\u0089</p>\n<p>FOLLOW UP visit in 2 days, re-check weight</p>\n<p>\u0089</p>\n<p>If no improvement: Refer for breastfeeding counselling</p>\n<p>~</p>\n<p>Preterm</p>\n<p>Small Baby</p>\n<p>\u0089</p>\n<p>Provide as close to continuous Kangaroo mother care as possible to</p>\n<p>prevent hypothermia</p>\n<p>\u0089</p>\n<p>Give special support to breastfeed small baby/twins</p>\n<p>~</p>\n<p>Preterm</p>\n<p>~</p>\n<p>Low birth</p>\n<p>weight</p>\n<h3>(LBW)</h3>\n<p>1,500\u2013</p>\n<p>2,500g</p>\n<p>\u0089</p>\n<p>Teach mother how to care for a small baby</p>\n<p>\u0089</p>\n<p>Teach alternative feeding method (cup feeding)</p>"
    },
    {
        "page_number": 866,
        "content": "800\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\nTwin\n\t\n\u0089\nAssess daily (if admitted) or every 2 days (if outpatient) until \nfeeding and growing well\n\t\n\u0089\nIf twins, discharge them only when both are fit to go home\n \n~\nVery Low \nBirth \nweight < \n1,500 g\n \n~\nVery  \npreterm (< \n32 weeks)\nVery Small \nBaby\n\t\n\u0089\nRefer urgently to hospital for special care\n\t\n\u0089\nEnsure extra warmth during referral\n \n~\nMother \nvery ill/ \nreceiving \nspecial \ntreatments\n \n~\nMother \ntransferred\nMother \nUnable to \nTake Care \nof Baby\n\t\n\u0089\nHelp mother to express breastmilk (to maintain lactation)\n\t\n\u0089\nConsider other feeding methods until mother can breastfeed\n\t\n\u0089\nEnsure warmth using other methods\n\t\n\u0089\nCord care and hygiene\n\t\n\u0089\nMonitor daily",
        "formatted_content": "<p>800</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p>Twin</p>\n<p>\u0089</p>\n<p>Assess daily (if admitted) or every 2 days (if outpatient) until</p>\n<p>feeding and growing well</p>\n<p>\u0089</p>\n<p>If twins, discharge them only when both are fit to go home</p>\n<p>~</p>\n<p>Very Low</p>\n<p>Birth</p>\n<p>weight <</p>\n<p>1,500 g</p>\n<p>~</p>\n<p>Very</p>\n<p>preterm (<</p>\n<p>32 weeks)</p>\n<p>Very Small</p>\n<p>Baby</p>\n<p>\u0089</p>\n<p>Refer urgently to hospital for special care</p>\n<p>\u0089</p>\n<p>Ensure extra warmth during referral</p>\n<p>~</p>\n<p>Mother</p>\n<p>very ill/</p>\n<p>receiving</p>\n<p>special</p>\n<p>treatments</p>\n<p>~</p>\n<p>Mother</p>\n<p>transferred</p>\n<p>Mother</p>\n<p>Unable to</p>\n<p>Take Care</p>\n<p>of Baby</p>\n<p>\u0089</p>\n<p>Help mother to express breastmilk (to maintain lactation)</p>\n<p>\u0089</p>\n<p>Consider other feeding methods until mother can breastfeed</p>\n<p>\u0089</p>\n<p>Ensure warmth using other methods</p>\n<p>\u0089</p>\n<p>Cord care and hygiene</p>\n<p>\u0089</p>\n<p>Monitor daily</p>"
    },
    {
        "page_number": 867,
        "content": "801\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.1.2   Assess for Special Treatment Needs, Local Infection, and \nJaundice\nAsk (check records)\n \n~\nHas the mother had \n(within 2 days of \ndelivery) fever> 38\u00b0C \nand/or infection \ntreated with antibi\u00ad\notic?\n \n~\nDid the mother have \nmembrane ruptured \n> 18 hours before \ndelivery?\n \n~\nHas the mother test\u00ad\ned RPR positive?\n \n~\nHas the mother \nstarted TB treatment \n< 2 months ago?\n \n~\nIs the mother HIV \npositive? is she on \nARVs?\n \n~\nHas anything been \napplied to the umbi\u00ad\nlicus?\nLook Listen and feel\n \n~\nEyes: Swollen and \ndraining pus?\n \n~\nUmbilicus: Red and \ndraining pus?\n \n~\nSkin: Many or severe \npustules? Swelling, \nhardness or large \nbullae?\n \n~\nJaundice: check face \nif baby < 24 hours, \ncheck palms and \nsoles if > 24 hours\n \n~\nMovements: Less \nthan normal? Limbs \nmoving symmetri\u00ad\ncally?\n \n~\nPresenting part \n(head or buttocks): \nSwelling, bruising?\n \n~\nAny malformation?",
        "formatted_content": "<p>801</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.1.2   Assess for Special Treatment Needs, Local Infection, and</p>\n<p>Jaundice</p>\n<p>Ask (check records)</p>\n<p>~</p>\n<p>Has the mother had</p>\n<p>(within 2 days of</p>\n<p>delivery) fever> 38\u00b0C</p>\n<p>and/or infection</p>\n<p>treated with antibi\u00ad</p>\n<p>otic?</p>\n<p>~</p>\n<p>Did the mother have</p>\n<p>membrane ruptured</p>\n<p>> 18 hours before</p>\n<p>delivery?</p>\n<p>~</p>\n<p>Has the mother test\u00ad</p>\n<p>ed RPR positive?</p>\n<p>~</p>\n<p>Has the mother</p>\n<p>started TB treatment</p>\n<p>< 2 months ago?</p>\n<p>~</p>\n<p>Is the mother HIV</p>\n<p>positive? is she on</p>\n<p>ARVs?</p>\n<p>~</p>\n<p>Has anything been</p>\n<p>applied to the umbi\u00ad</p>\n<p>licus?</p>\n<p>Look Listen and feel</p>\n<p>~</p>\n<p>Eyes: Swollen and</p>\n<p>draining pus?</p>\n<p>~</p>\n<p>Umbilicus: Red and</p>\n<p>draining pus?</p>\n<p>~</p>\n<p>Skin: Many or severe</p>\n<p>pustules? Swelling,</p>\n<p>hardness or large</p>\n<p>bullae?</p>\n<p>~</p>\n<p>Jaundice: check face</p>\n<p>if baby < 24 hours,</p>\n<p>check palms and</p>\n<p>soles if > 24 hours</p>\n<p>~</p>\n<p>Movements: Less</p>\n<p>than normal? Limbs</p>\n<p>moving symmetri\u00ad</p>\n<p>cally?</p>\n<p>~</p>\n<p>Presenting part</p>\n<p>(head or buttocks):</p>\n<p>Swelling, bruising?</p>\n<p>~</p>\n<p>Any malformation?</p>"
    },
    {
        "page_number": 868,
        "content": "802\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\nBaby < \n1 day \nold and \nmembrane \nruptured > \n18 hours\n \n~\nMother \nwith fever \nand/or on \nantibiotics\nRisk of Bacte\u00ad\nrial Infection\n\t\n\u0089\nGive ampicillin 50 mg/kg every 12 hours plus \ngentamicin 5 mg/kg (4 mg if pre-term) once daily \nfor 5 days\n\t\n\u0089\nAssess baby daily\n \n~\nMother \ntested RPR \npositive\nRisk of \nCongenital \nSyphilis\n\t\n\u0089\nGive baby single dose benzathine penicillin 50,000 \nIU/ kg IM\n\t\n\u0089\nEnsure mother and partner are treated (see section \n3.2.7)\n\t\n\u0089\nFOLLOW UP every 2 weeks\n \n~\nMother \nstarted TB \ntreatment \n<2 months \nbefore \ndelivery\nRisk of TB\n\t\n\u0089\nGive baby prophylaxis with isoniazid 5 mg/kg daily \nfor 6 months\n\t\n\u0089\nVaccinate with BCG only after treatment completed\n\t\n\u0089\nReassure breastfeeding is safe\n\t\n\u0089\nFOLLOW UP every 2 weeks\nClassify and treat as below",
        "formatted_content": "<p>802</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p>Baby <</p>\n<p>1 day</p>\n<p>old and</p>\n<p>membrane</p>\n<p>ruptured ></p>\n<p>18 hours</p>\n<p>~</p>\n<p>Mother</p>\n<p>with fever</p>\n<p>and/or on</p>\n<p>antibiotics</p>\n<p>Risk of Bacte\u00ad</p>\n<p>rial Infection</p>\n<p>\u0089</p>\n<p>Give ampicillin 50 mg/kg every 12 hours plus</p>\n<p>gentamicin 5 mg/kg (4 mg if pre-term) once daily</p>\n<p>for 5 days</p>\n<p>\u0089</p>\n<p>Assess baby daily</p>\n<p>~</p>\n<p>Mother</p>\n<p>tested RPR</p>\n<p>positive</p>\n<p>Risk of</p>\n<p>Congenital</p>\n<p>Syphilis</p>\n<p>\u0089</p>\n<p>Give baby single dose benzathine penicillin 50,000</p>\n<p>IU/ kg IM</p>\n<p>\u0089</p>\n<p>Ensure mother and partner are treated (see section</p>\n<p>3.2.7)</p>\n<p>\u0089</p>\n<p>FOLLOW UP every 2 weeks</p>\n<p>~</p>\n<p>Mother</p>\n<p>started TB</p>\n<p>treatment</p>\n<p><2 months</p>\n<p>before</p>\n<p>delivery</p>\n<p>Risk of TB</p>\n<p>\u0089</p>\n<p>Give baby prophylaxis with isoniazid 5 mg/kg daily</p>\n<p>for 6 months</p>\n<p>\u0089</p>\n<p>Vaccinate with BCG only after treatment completed</p>\n<p>\u0089</p>\n<p>Reassure breastfeeding is safe</p>\n<p>\u0089</p>\n<p>FOLLOW UP every 2 weeks</p>\n<p>Classify and treat as below</p>"
    },
    {
        "page_number": 869,
        "content": "803\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\nMother \nknown \nHIV \npositive\nRisk of HIV\n\t\n\u0089\nGive ARV prophylaxis as per national guidelines  (see section \n3.1.9.3)\n\t\n\u0089\nCounsel on infant feeding\n\t\n\u0089\nSpecial counselling if mother breastfeeding\n\t\n\u0089\nFOLLOW UP every 2 weeks\n \n~\nEyes \nswol\u00ad\nlen, \ndrain\u00ad\ning pus\nGonococcal \nEye Infection\n(Possible \nChlamydia \nCoinfection) \n(see section \n3.2.9.1)\n\t\n\u0089\nGive ceftriaxone 125 mg IM stat plus azithromycin syrup 20 \nmg/kg daily for 3 days\n\t\n\u0089\nTeach mother how to treat eye infection at home (clean eyes \nwith clean wet cloth and apply tetracycline ointment 3 times day)\n\t\n\u0089\nAssess and treat mother and partner for possible gonorrhoea \nand chlamydia (see section 3.2.1-3.2.2)\n\t\n\u0089\nFOLLOW UP in 2 days\nIf no improvement: Refer urgently to hospital\n \n~\nRed \numbili\u00ad\ncus\nLocal Umbili\u00ad\ncal Infection\n\t\n\u0089\nTeach mother how to treat at home (wash crust and pus with \nboiled cooled water, dry and apply Gentian Violet 0.5% 3 \ntimes a day)\n\t\n\u0089\nFOLLOW UP in 2 days\n\t\n\u0089\nIf not improved, reclassify and treat or refer",
        "formatted_content": "<p>803</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p>Mother</p>\n<p>known</p>\n<h3>HIV</h3>\n<p>positive</p>\n<p>Risk of HIV</p>\n<p>\u0089</p>\n<p>Give ARV prophylaxis as per national guidelines  (see section</p>\n<p>3.1.9.3)</p>\n<p>\u0089</p>\n<p>Counsel on infant feeding</p>\n<p>\u0089</p>\n<p>Special counselling if mother breastfeeding</p>\n<p>\u0089</p>\n<p>FOLLOW UP every 2 weeks</p>\n<p>~</p>\n<p>Eyes</p>\n<p>swol\u00ad</p>\n<p>len,</p>\n<p>drain\u00ad</p>\n<p>ing pus</p>\n<p>Gonococcal</p>\n<p>Eye Infection</p>\n<p>(Possible</p>\n<p>Chlamydia</p>\n<p>Coinfection)</p>\n<p>(see section</p>\n<p>3.2.9.1)</p>\n<p>\u0089</p>\n<p>Give ceftriaxone 125 mg IM stat plus azithromycin syrup 20</p>\n<p>mg/kg daily for 3 days</p>\n<p>\u0089</p>\n<p>Teach mother how to treat eye infection at home (clean eyes</p>\n<p>with clean wet cloth and apply tetracycline ointment 3 times day)</p>\n<p>\u0089</p>\n<p>Assess and treat mother and partner for possible gonorrhoea</p>\n<p>and chlamydia (see section 3.2.1-3.2.2)</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 2 days</p>\n<p>If no improvement: Refer urgently to hospital</p>\n<p>~</p>\n<p>Red</p>\n<p>umbili\u00ad</p>\n<p>cus</p>\n<p>Local Umbili\u00ad</p>\n<p>cal Infection</p>\n<p>\u0089</p>\n<p>Teach mother how to treat at home (wash crust and pus with</p>\n<p>boiled cooled water, dry and apply Gentian Violet 0.5% 3</p>\n<p>times a day)</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 2 days</p>\n<p>\u0089</p>\n<p>If not improved, reclassify and treat or refer</p>"
    },
    {
        "page_number": 870,
        "content": "804\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\n<10 \npustules\nLocal Skin \nInfection\n\t\n\u0089\nTeach mother to how to treat infection at home (wash crust \nand pus with boiled cooled water, dry and apply Gentian \nViolet 0.5% 3 times a day)\n\t\n\u0089\nReassess after 2 days\n\t\n\u0089\nIf not improved, reclassify and treat or refer\n \n~\nYellow face \n(<24 hours \nold) or\n \n~\nYellow \npalms and \nsoles (>24 \nhours old)\nSevere Jaun\u00ad\ndice\n\t\n\u0089\nRefer urgently to hospital\n \n-\nEncourage breastfeeding\n \n-\nIf breastfeeding problem, give expressed milk by \ncup\n \n~\nBruises or \nswelling on \nbuttocks\n \n~\nSwollen \nhead - \nbump on \none or both \nsides\nBirth Injury\n\t\n\u0089\nExplain to parents that it does not hurt the baby and it will \ndisappear in 1 or 2 weeks by itself\n\t\n\u0089\nDO NOT force the leg into a different position\n\t\n\u0089\nGently handle the limb that is not moving, do not pull",
        "formatted_content": "<p>804</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p><10</p>\n<p>pustules</p>\n<p>Local Skin</p>\n<p>Infection</p>\n<p>\u0089</p>\n<p>Teach mother to how to treat infection at home (wash crust</p>\n<p>and pus with boiled cooled water, dry and apply Gentian</p>\n<p>Violet 0.5% 3 times a day)</p>\n<p>\u0089</p>\n<p>Reassess after 2 days</p>\n<p>\u0089</p>\n<p>If not improved, reclassify and treat or refer</p>\n<p>~</p>\n<p>Yellow face</p>\n<p>(<24 hours</p>\n<p>old) or</p>\n<p>~</p>\n<p>Yellow</p>\n<p>palms and</p>\n<p>soles (>24</p>\n<p>hours old)</p>\n<p>Severe Jaun\u00ad</p>\n<p>dice</p>\n<p>\u0089</p>\n<p>Refer urgently to hospital</p>\n<p>-</p>\n<p>Encourage breastfeeding</p>\n<p>-</p>\n<p>If breastfeeding problem, give expressed milk by</p>\n<p>cup</p>\n<p>~</p>\n<p>Bruises or</p>\n<p>swelling on</p>\n<p>buttocks</p>\n<p>~</p>\n<p>Swollen</p>\n<p>head -</p>\n<p>bump on</p>\n<p>one or both</p>\n<p>sides</p>\n<p>Birth Injury</p>\n<p>\u0089</p>\n<p>Explain to parents that it does not hurt the baby and it will</p>\n<p>disappear in 1 or 2 weeks by itself</p>\n<p>\u0089</p>\n<p>DO NOT force the leg into a different position</p>\n<p>\u0089</p>\n<p>Gently handle the limb that is not moving, do not pull</p>"
    },
    {
        "page_number": 871,
        "content": "805\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY\nMANAGE BY/ADVISE ON\n \n~\nAbnormal \nposition of legs \nafter breech \npresentation\n \n~\nAsymmetrical \narm movement \nor arm does \nnot move\n \n~\nClub foot\n \n~\nCleft palate \nor lip\n \n~\nOdd looking \nunusual \nappearance\n \n~\nOpen tissue \non the head/ \nabdomen/ \nback/ \nperineum or \ngenitalia\nMalformation\n\t\n\u0089\nRefer for special evaluation and treatment\n\t\n\u0089\nHelp mother breastfeed or teach mother alternative \nmethod if not possible\n\t\n\u0089\nCover open tissue with sterile gauze soaked in sterile \nsaline solution before referral",
        "formatted_content": "<p>805</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY</h3>\n<h3>MANAGE BY/ADVISE ON</h3>\n<p>~</p>\n<p>Abnormal</p>\n<p>position of legs</p>\n<p>after breech</p>\n<p>presentation</p>\n<p>~</p>\n<p>Asymmetrical</p>\n<p>arm movement</p>\n<p>or arm does</p>\n<p>not move</p>\n<p>~</p>\n<p>Club foot</p>\n<p>~</p>\n<p>Cleft palate</p>\n<p>or lip</p>\n<p>~</p>\n<p>Odd looking</p>\n<p>unusual</p>\n<p>appearance</p>\n<p>~</p>\n<p>Open tissue</p>\n<p>on the head/</p>\n<p>abdomen/</p>\n<p>back/</p>\n<p>perineum or</p>\n<p>genitalia</p>\n<p>Malformation</p>\n<p>\u0089</p>\n<p>Refer for special evaluation and treatment</p>\n<p>\u0089</p>\n<p>Help mother breastfeed or teach mother alternative</p>\n<p>method if not possible</p>\n<p>\u0089</p>\n<p>Cover open tissue with sterile gauze soaked in sterile</p>\n<p>saline solution before referral</p>"
    },
    {
        "page_number": 872,
        "content": "806\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.2  SICK YOUNG INFANT AGE UP TO 2 MONTHS\n \n~\nAsk the mother what the child\u2019s problems are\n \n~\nCheck if this is an initial or FOLLOW UP visit for this \nproblem\n\t\n\u0089\nIf FOLLOW UP visit: Check up on previous treatments\n\t\n\u0089\nIf initial visit: Continue as below\nAssess, classify and treat for the following:\n\t\n\u0089\nSevere disease and local bacterial infection\n\t\n\u0089\nJaundice\n\t\n\u0089\nDiarrhoea and dehydration\n\t\n\u0089\nHIV\n\t\n\u0089\nFeeding and weight problems\n\t\n\u0089\nAny other problem\n\t\n\u0089\nImmunization status\nCounsel the mother on\n\t\n\u0089\nNutrition and breastfeeding of the child\n\t\n\u0089\nHer own health needs\n\t\n\u0089\nTo return for FOLLOW UP as scheduled\n\t\n\u0089\nTo return immediately at the clinic if the danger signs in the table \nbelow appear:\u2029\nDANGER SIGN\nRETURN\n \n~\nBreastfeeding or drinking poorly\n \n~\nBecomes more ill\n \n~\nDevelops fever\n \n~\nFast or difficult breathing\n \n~\nBlood in stool\nImmediately",
        "formatted_content": "<p>806</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>17.2  SICK YOUNG INFANT AGE UP TO 2 MONTHS</h3>\n<p>~</p>\n<p>Ask the mother what the child\u2019s problems are</p>\n<p>~</p>\n<p>Check if this is an initial or FOLLOW UP visit for this</p>\n<p>problem</p>\n<p>\u0089</p>\n<p>If FOLLOW UP visit: Check up on previous treatments</p>\n<p>\u0089</p>\n<p>If initial visit: Continue as below</p>\n<p>Assess, classify and treat for the following:</p>\n<p>\u0089</p>\n<p>Severe disease and local bacterial infection</p>\n<p>\u0089</p>\n<p>Jaundice</p>\n<p>\u0089</p>\n<p>Diarrhoea and dehydration</p>\n<p>\u0089</p>\n<h3>HIV</h3>\n<p>\u0089</p>\n<p>Feeding and weight problems</p>\n<p>\u0089</p>\n<p>Any other problem</p>\n<p>\u0089</p>\n<p>Immunization status</p>\n<p>Counsel the mother on</p>\n<p>\u0089</p>\n<p>Nutrition and breastfeeding of the child</p>\n<p>\u0089</p>\n<p>Her own health needs</p>\n<p>\u0089</p>\n<p>To return for FOLLOW UP as scheduled</p>\n<p>\u0089</p>\n<p>To return immediately at the clinic if the danger signs in the table</p>\n<p>below appear:</p>\n<h3>DANGER SIGN</h3>\n<h3>RETURN</h3>\n<p>~</p>\n<p>Breastfeeding or drinking poorly</p>\n<p>~</p>\n<p>Becomes more ill</p>\n<p>~</p>\n<p>Develops fever</p>\n<p>~</p>\n<p>Fast or difficult breathing</p>\n<p>~</p>\n<p>Blood in stool</p>\n<p>Immediately</p>"
    },
    {
        "page_number": 873,
        "content": "807\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.2.1\t\nCheck for Very Severe Disease and Local Bacterial \nInfection\nAsk Ask if the infant \nis having difficulty in \nfeeding?\n \n~\nHas the \ninfant \nhad any \nconvulsions?\nLook, listen, feel\n \n~\nCount the number of breaths \nper minute (INFANT MUST \nBE CALM)\n \n-\nRepeat the count if this is > \n60 breaths per minute\n \n\u0081\nLook for severe chest indrawing \nand nasal flaring\n \n\u0081\nLook and listen for grunting\n \n\u0081\nLook and feel for a bulging fontanel\n \n\u0081\nLook for pus draining from the ear\n \n\u0081\nLook at the umbilicus. Is it red or \ndraining pus?\n \n\u0081\nDoes the redness extend to the \nskin?\n \n\u0081\nMeasure the body temperature \n(or feel for fever or low body tem\u00ad\nperature)\n \n\u0081\nLook for skin pustules, if present, \nare they many or severe?\n \n\u0081\nSee if the young infant is lethargic \nor unconscious\n \n\u0081\nObserve the young infant\u2019s move\u00ad\nments\n \n-\nAre they less than normal?\n \n-\nObserve the young infant \nfor any spasms (differentiate \nfrom convulsions)\n \n-\nCheck if young infant has \nstiff neck or lock jaw\n \n-\nFeel the young infants \nabdomen for rigidity",
        "formatted_content": "<p>807</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.2.1</p>\n<p>Check for Very Severe Disease and Local Bacterial</p>\n<p>Infection</p>\n<p>Ask Ask if the infant</p>\n<p>is having difficulty in</p>\n<p>feeding?</p>\n<p>~</p>\n<p>Has the</p>\n<p>infant</p>\n<p>had any</p>\n<p>convulsions?</p>\n<p>Look, listen, feel</p>\n<p>~</p>\n<p>Count the number of breaths</p>\n<p>per minute (INFANT MUST</p>\n<h3>BE CALM)</h3>\n<p>-</p>\n<p>Repeat the count if this is ></p>\n<p>60 breaths per minute</p>\n<p>\u0081</p>\n<p>Look for severe chest indrawing</p>\n<p>and nasal flaring</p>\n<p>\u0081</p>\n<p>Look and listen for grunting</p>\n<p>\u0081</p>\n<p>Look and feel for a bulging fontanel</p>\n<p>\u0081</p>\n<p>Look for pus draining from the ear</p>\n<p>\u0081</p>\n<p>Look at the umbilicus. Is it red or</p>\n<p>draining pus?</p>\n<p>\u0081</p>\n<p>Does the redness extend to the</p>\n<p>skin?</p>\n<p>\u0081</p>\n<p>Measure the body temperature</p>\n<p>(or feel for fever or low body tem\u00ad</p>\n<p>perature)</p>\n<p>\u0081</p>\n<p>Look for skin pustules, if present,</p>\n<p>are they many or severe?</p>\n<p>\u0081</p>\n<p>See if the young infant is lethargic</p>\n<p>or unconscious</p>\n<p>\u0081</p>\n<p>Observe the young infant\u2019s move\u00ad</p>\n<p>ments</p>\n<p>-</p>\n<p>Are they less than normal?</p>\n<p>-</p>\n<p>Observe the young infant</p>\n<p>for any spasms (differentiate</p>\n<p>from convulsions)</p>\n<p>-</p>\n<p>Check if young infant has</p>\n<p>stiff neck or lock jaw</p>\n<p>-</p>\n<p>Feel the young infants</p>\n<p>abdomen for rigidity</p>"
    },
    {
        "page_number": 874,
        "content": "808\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY AS\nTREATMENT\nAny of the following:\n \n~\nNot feeding \nwell or\n \n~\nConvulsions or\n \n~\nFast breathing \n(>60 breaths/\nmin) or\n \n~\nSevere chest in \ndrawing or\n \n~\nFever (>37.5\u00b0C \nor feels hot)\n \n~\nLow body \ntemp (<35.5\u00b0C \nor feels cold)\n \n~\nMovement \nwhen stim\u00ad\nulated or no \nmovements \nat all\n \n~\nBlood in stool\nVery Severe \nDisease\n\t\n\u0089\nGive 1st dose of IM antibiotics: ampicillin 50 \nmg/ kg plus gentamicin 5 mg/kg (if <7 days) or \n7.5 mg/kg (if >7 days)\n\t\n\u0089\nOr if HC2, Benzylpenicillin 50,000 IU/Kg IM \nsingle pre referral dose\n\t\n\u0089\nTreat to prevent low blood sugar (breastfeed or \ngive expressed breast milk or sugar water by \ncup or NGT)\n\t\n\u0089\nAdvise mother how to keep infant warm on the \nway to hospital\n\t\n\u0089\nRefer URGENTLY to Hospital\nIf referral not possible,\n\t\n\u0089\nContinue ampicillin (twice daily if < 7 days, thrice \ndaily if > 7 days)\n\t\n\u0089\nGentamicin once daily for at least 5 days\nClassify and treat possible infection as in the table below:",
        "formatted_content": "<p>808</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY AS</h3>\n<h3>TREATMENT</h3>\n<p>Any of the following:</p>\n<p>~</p>\n<p>Not feeding</p>\n<p>well or</p>\n<p>~</p>\n<p>Convulsions or</p>\n<p>~</p>\n<p>Fast breathing</p>\n<p>(>60 breaths/</p>\n<p>min) or</p>\n<p>~</p>\n<p>Severe chest in</p>\n<p>drawing or</p>\n<p>~</p>\n<p>Fever (>37.5\u00b0C</p>\n<p>or feels hot)</p>\n<p>~</p>\n<p>Low body</p>\n<p>temp (<35.5\u00b0C</p>\n<p>or feels cold)</p>\n<p>~</p>\n<p>Movement</p>\n<p>when stim\u00ad</p>\n<p>ulated or no</p>\n<p>movements</p>\n<p>at all</p>\n<p>~</p>\n<p>Blood in stool</p>\n<p>Very Severe</p>\n<p>Disease</p>\n<p>\u0089</p>\n<p>Give 1st dose of IM antibiotics: ampicillin 50</p>\n<p>mg/ kg plus gentamicin 5 mg/kg (if <7 days) or</p>\n<p>7.5 mg/kg (if >7 days)</p>\n<p>\u0089</p>\n<p>Or if HC2, Benzylpenicillin 50,000 IU/Kg IM</p>\n<p>single pre referral dose</p>\n<p>\u0089</p>\n<p>Treat to prevent low blood sugar (breastfeed or</p>\n<p>give expressed breast milk or sugar water by</p>\n<p>cup or NGT)</p>\n<p>\u0089</p>\n<p>Advise mother how to keep infant warm on the</p>\n<p>way to hospital</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to Hospital</p>\n<p>If referral not possible,</p>\n<p>\u0089</p>\n<p>Continue ampicillin (twice daily if < 7 days, thrice</p>\n<p>daily if > 7 days)</p>\n<p>\u0089</p>\n<p>Gentamicin once daily for at least 5 days</p>\n<p>Classify and treat possible infection as in the table below:</p>"
    },
    {
        "page_number": 875,
        "content": "809\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY AS\nTREATMENT\nAny of the following:\n \n~\nUmbilicus red or \ndischarging pus\n \n~\nSkin pustules\nLocal Bacterial \nInfection\n\t\n\u0089\nGive appropriate oral antibiotic: amoxicillin\n\t\n\u0089\n250 mg DT \u00bc tab (if below 1 month, 4 kg) or \n\u00bd tab (if 1-2 months, 4-6 kg) every 12 hours \nfor 5 days\n\t\n\u0089\nTeach mother to treat local infection at home \n(apply\n\t\n\u0089\nGentian Violet paint twice daily for five days) \n\t\n\u0089\nAdvise mother on home care for the young infant \nf FOLLOW UP in two days:\n \n- If better: praise the mother, advise to \ncomplete\n \n- treatment\n \n- If same or worse: refer to hospital\nNone of the signs of very severe \ndisease or local bacterial infection\nSevere Disease \nor Local Infec\u00ad\ntion Unikely\n\t\n\u0089\nContinue assessment of other problems\n\t\n\u0089\nAdvise mother to give home care\nNotes\n\t\n\u0089\nBody temperatures are based on axillary measurement\n\t\n\u0089\nRectal readings are approximately 0.5\u00b0C higher",
        "formatted_content": "<p>809</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY AS</h3>\n<h3>TREATMENT</h3>\n<p>Any of the following:</p>\n<p>~</p>\n<p>Umbilicus red or</p>\n<p>discharging pus</p>\n<p>~</p>\n<p>Skin pustules</p>\n<p>Local Bacterial</p>\n<p>Infection</p>\n<p>\u0089</p>\n<p>Give appropriate oral antibiotic: amoxicillin</p>\n<p>\u0089</p>\n<p>250 mg DT \u00bc tab (if below 1 month, 4 kg) or</p>\n<p>\u00bd tab (if 1-2 months, 4-6 kg) every 12 hours</p>\n<p>for 5 days</p>\n<p>\u0089</p>\n<p>Teach mother to treat local infection at home</p>\n<p>(apply</p>\n<p>\u0089</p>\n<p>Gentian Violet paint twice daily for five days)</p>\n<p>\u0089</p>\n<p>Advise mother on home care for the young infant</p>\n<p>f FOLLOW UP in two days:</p>\n<p>- If better: praise the mother, advise to</p>\n<p>complete</p>\n<p>- treatment</p>\n<p>- If same or worse: refer to hospital</p>\n<p>None of the signs of very severe</p>\n<p>disease or local bacterial infection</p>\n<p>Severe Disease</p>\n<p>or Local Infec\u00ad</p>\n<p>tion Unikely</p>\n<p>\u0089</p>\n<p>Continue assessment of other problems</p>\n<p>\u0089</p>\n<p>Advise mother to give home care</p>\n<p>Notes</p>\n<p>\u0089</p>\n<p>Body temperatures are based on axillary measurement</p>\n<p>\u0089</p>\n<p>Rectal readings are approximately 0.5\u00b0C higher</p>"
    },
    {
        "page_number": 876,
        "content": "810\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.2.2  Check for Jaundice\nIf jaundice present, Ask\n \n~\nWhen did the \njaundice appear \nfirst?\nLook and feel\n \n~\nLook for jaundice (yellow \neyes or skin)\n \n~\nLook at the young \ninfant\u2019s palms and soles. \nAre they yellow?\nClassify jaundice as in the following table\nSIGNS\nCLASSIFY AS\nTREATMENT\n \n~\nAny \njaundice \nif age less \nthan 24 \nhours or\n \n~\nyellow \npalms \nand soles \nat any \nage\nSevere Jaudice\n\t\n\u0089\nTreat to prevent low \nblood sugar (breast\u00ad\nfeed or give expressed \nbreast milk or sugar \nwater by cup or NGT)\n\t\n\u0089\nRefer urgently to hos\u00ad\npital\n\t\n\u0089\nAdvise mother to keep \ninfant warm .\n\t\n\u0089\nAdvise mother to give \nhome care for the \nyoung infant\n\t\n\u0089\nAdvise mother to re\u00ad\nturn immediately if \npalms and soles ap\u00ad\npear yellow\n\t\n\u0089\nIf the young infant is \nolder than 14 days \nrefer to hospital for \nassessment",
        "formatted_content": "<p>810</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.2.2  Check for Jaundice</p>\n<p>If jaundice present, Ask</p>\n<p>~</p>\n<p>When did the</p>\n<p>jaundice appear</p>\n<p>first?</p>\n<p>Look and feel</p>\n<p>~</p>\n<p>Look for jaundice (yellow</p>\n<p>eyes or skin)</p>\n<p>~</p>\n<p>Look at the young</p>\n<p>infant\u2019s palms and soles.</p>\n<p>Are they yellow?</p>\n<p>Classify jaundice as in the following table</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY AS</h3>\n<h3>TREATMENT</h3>\n<p>~</p>\n<p>Any</p>\n<p>jaundice</p>\n<p>if age less</p>\n<p>than 24</p>\n<p>hours or</p>\n<p>~</p>\n<p>yellow</p>\n<p>palms</p>\n<p>and soles</p>\n<p>at any</p>\n<p>age</p>\n<p>Severe Jaudice</p>\n<p>\u0089</p>\n<p>Treat to prevent low</p>\n<p>blood sugar (breast\u00ad</p>\n<p>feed or give expressed</p>\n<p>breast milk or sugar</p>\n<p>water by cup or NGT)</p>\n<p>\u0089</p>\n<p>Refer urgently to hos\u00ad</p>\n<p>pital</p>\n<p>\u0089</p>\n<p>Advise mother to keep</p>\n<p>infant warm .</p>\n<p>\u0089</p>\n<p>Advise mother to give</p>\n<p>home care for the</p>\n<p>young infant</p>\n<p>\u0089</p>\n<p>Advise mother to re\u00ad</p>\n<p>turn immediately if</p>\n<p>palms and soles ap\u00ad</p>\n<p>pear yellow</p>\n<p>\u0089</p>\n<p>If the young infant is</p>\n<p>older than 14 days</p>\n<p>refer to hospital for</p>\n<p>assessment</p>"
    },
    {
        "page_number": 877,
        "content": "811\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSIGNS\nCLASSIFY AS\nTREATMENT\n \n~\nJaundice \nappear\u00ad\ning after \n24 hours \nof age \nand\n \n~\nPalms \nand \nsoles not \nyellow\nJaundice \n\t\n\u0089\nFOLLOW UP in one day:\n \n-\nIf palms and soles \nare yellow, refer to \nhospital\n \n-\nIf palms and soles \nare not yellow but \njaundice has not \ndecreased, advise \nFOLLOW UP in \none day\n \n-\nIf jaundice is \ndecreasing, \nreassure mother \nand\n \n-\nFOLLOW UP in \ntwo weeks\n \n-\nIf still there in 2 \nweeks, refer to \nhospital\n \n~\nNo \njaundice\nNo \nJaundice\n\t\n\u0089\nAdvise mother to give home \ncare for the young infant\n\t\n\u0089\nContinue assessment for \nother problems\n17.2.3  Check for Diarrhoea/Dehydration\nAsk\n \n~\nIf child has \ndiarrhoea\n \n~\nIf yes, ask for \nhow long it has \nbeen present\nIf yes, Look and feel\n \n~\nInfant\u2019s movements\n \n-\nDoes the infant move on \nhis/her own?\n \n-\nDoes the infant move \nwhen stimulated but then \nstops?\n \n-\nDoes the infant not move \nat all?\n \n-\nIs the infant restless and \nirritable?\n \n-\nCheck the eyes. Are they \nsunken?",
        "formatted_content": "<p>811</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SIGNS</h3>\n<h3>CLASSIFY AS</h3>\n<h3>TREATMENT</h3>\n<p>~</p>\n<p>Jaundice</p>\n<p>appear\u00ad</p>\n<p>ing after</p>\n<p>24 hours</p>\n<p>of age</p>\n<p>and</p>\n<p>~</p>\n<p>Palms</p>\n<p>and</p>\n<p>soles not</p>\n<p>yellow</p>\n<p>Jaundice</p>\n<p>\u0089</p>\n<p>FOLLOW UP in one day:</p>\n<p>-</p>\n<p>If palms and soles</p>\n<p>are yellow, refer to</p>\n<p>hospital</p>\n<p>-</p>\n<p>If palms and soles</p>\n<p>are not yellow but</p>\n<p>jaundice has not</p>\n<p>decreased, advise</p>\n<p>FOLLOW UP in</p>\n<p>one day</p>\n<p>-</p>\n<p>If jaundice is</p>\n<p>decreasing,</p>\n<p>reassure mother</p>\n<p>and</p>\n<p>-</p>\n<p>FOLLOW UP in</p>\n<p>two weeks</p>\n<p>-</p>\n<p>If still there in 2</p>\n<p>weeks, refer to</p>\n<p>hospital</p>\n<p>~</p>\n<p>No</p>\n<p>jaundice</p>\n<p>No</p>\n<p>Jaundice</p>\n<p>\u0089</p>\n<p>Advise mother to give home</p>\n<p>care for the young infant</p>\n<p>\u0089</p>\n<p>Continue assessment for</p>\n<p>other problems</p>\n<p>17.2.3  Check for Diarrhoea/Dehydration</p>\n<p>Ask</p>\n<p>~</p>\n<p>If child has</p>\n<p>diarrhoea</p>\n<p>~</p>\n<p>If yes, ask for</p>\n<p>how long it has</p>\n<p>been present</p>\n<p>If yes, Look and feel</p>\n<p>~</p>\n<p>Infant\u2019s movements</p>\n<p>-</p>\n<p>Does the infant move on</p>\n<p>his/her own?</p>\n<p>-</p>\n<p>Does the infant move</p>\n<p>when stimulated but then</p>\n<p>stops?</p>\n<p>-</p>\n<p>Does the infant not move</p>\n<p>at all?</p>\n<p>-</p>\n<p>Is the infant restless and</p>\n<p>irritable?</p>\n<p>-</p>\n<p>Check the eyes. Are they</p>\n<p>sunken?</p>"
    },
    {
        "page_number": 878,
        "content": "812\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n \n-\nPinch the skin of the \nabdomen. Does it go \nback\n \n-\nVery slowly? (takes >2 \nseconds)\n \n-\nSlowly? (up to 2 seconds)\nClassify and treat the dehydration and diarrhoea as in the table below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\nFor dehydration (see also section 1.1.3.1)\nTwo of these signs:\n \n~\nMove\u00ad\nment \nonly \nwhen\nSevere \nDehydration\nIf infant has no other se\u00ad\nvere classification:\n\t\n\u0089\nGive fluid for severe de\u00ad\nhydration (Plan C) OR\nstimulated or no \nmovement at all\n \n~\nSunken \neyes\n \n~\nSkin \npinch \ngoes \nback very \nslowly.\nIf infant also has another \nsevere classification:\n\t\n\u0089\n Refer URGENTLY to \nhospital with mother \ngiving frequent sips of \nORS on the way\n\t\n\u0089\nAdvise the mother to \ncontinue breastfeeding\nTwo of these signs:\n \n~\nRestless, \nirritable\nSome Dehy\u00ad\ndration\n\t\n\u0089\nGive Plan B (Give fluid \nand breast milk for some \ndehydration)\n\t\n\u0089\nAdvise mother when to \nreturn immediately",
        "formatted_content": "<p>812</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>-</p>\n<p>Pinch the skin of the</p>\n<p>abdomen. Does it go</p>\n<p>back</p>\n<p>-</p>\n<p>Very slowly? (takes >2</p>\n<p>seconds)</p>\n<p>-</p>\n<p>Slowly? (up to 2 seconds)</p>\n<p>Classify and treat the dehydration and diarrhoea as in the table below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>For dehydration (see also section 1.1.3.1)</p>\n<p>Two of these signs:</p>\n<p>~</p>\n<p>Move\u00ad</p>\n<p>ment</p>\n<p>only</p>\n<p>when</p>\n<p>Severe</p>\n<p>Dehydration</p>\n<p>If infant has no other se\u00ad</p>\n<p>vere classification:</p>\n<p>\u0089</p>\n<p>Give fluid for severe de\u00ad</p>\n<p>hydration (Plan C) OR</p>\n<p>stimulated or no</p>\n<p>movement at all</p>\n<p>~</p>\n<p>Sunken</p>\n<p>eyes</p>\n<p>~</p>\n<p>Skin</p>\n<p>pinch</p>\n<p>goes</p>\n<p>back very</p>\n<p>slowly.</p>\n<p>If infant also has another</p>\n<p>severe classification:</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to</p>\n<p>hospital with mother</p>\n<p>giving frequent sips of</p>\n<p>ORS on the way</p>\n<p>\u0089</p>\n<p>Advise the mother to</p>\n<p>continue breastfeeding</p>\n<p>Two of these signs:</p>\n<p>~</p>\n<p>Restless,</p>\n<p>irritable</p>\n<p>Some Dehy\u00ad</p>\n<p>dration</p>\n<p>\u0089</p>\n<p>Give Plan B (Give fluid</p>\n<p>and breast milk for some</p>\n<p>dehydration)</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately</p>"
    },
    {
        "page_number": 879,
        "content": "813\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nSunken \neyes\n \n~\nSkin \npinch \nreturns \nslowly \n(up to 2 \nseconds)\n\t\n\u0089\nFOLLOW UP in 2 days:\n \n-\nIf better, praise \nthe mother \nand advice \nto continue \nbreastfeeding\n \n-\nIf not better, \nreassess and \ntreat accordingly\nIf infant also has another \nsevere classification:\n\t\n\u0089\nRefer URGENTLY to \nhospital with mother \ngiving frequent sips of \nORS on the way\n\t\n\u0089\nAdvise the mother to \ncontinue breastfeeding",
        "formatted_content": "<p>813</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Sunken</p>\n<p>eyes</p>\n<p>~</p>\n<p>Skin</p>\n<p>pinch</p>\n<p>returns</p>\n<p>slowly</p>\n<p>(up to 2</p>\n<p>seconds)</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 2 days:</p>\n<p>-</p>\n<p>If better, praise</p>\n<p>the mother</p>\n<p>and advice</p>\n<p>to continue</p>\n<p>breastfeeding</p>\n<p>-</p>\n<p>If not better,</p>\n<p>reassess and</p>\n<p>treat accordingly</p>\n<p>If infant also has another</p>\n<p>severe classification:</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to</p>\n<p>hospital with mother</p>\n<p>giving frequent sips of</p>\n<p>ORS on the way</p>\n<p>\u0089</p>\n<p>Advise the mother to</p>\n<p>continue breastfeeding</p>"
    },
    {
        "page_number": 880,
        "content": "814\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nNot enough \nsigns to \nclassify\n \n~\nas some or \nsevere\n \n~\ndehydration\nNo Dehydration\n\t\n\u0089\nGive fluids to treat diarrhoea at home and continue \nbreast feeding (Plan A)\n\t\n\u0089\nAdvise mother when to return immediately\n\t\n\u0089\nFOLLOW UP in two days\n \n-\nIf better, praise the mother and advice to \ncontinue breastfeeding\n \n-\nIf not better, reassess and treat \naccordingly\nIf diarrhoea of > 14 days\n \n~\nDiarrhoea \nlasting 14 \ndays or more\nSevere Persistent \nDiarrhoea\n\t\n\u0089\nRefer to hospital\n\t\n\u0089\nTreat dehydration before referral\nNote\n \n\u0083 What is diarrhoea in a young infant?\n \n-\nA young infant has diarrhoea if the stools have changed from usual pattern and are many \nand watery (more water than faecal matter).\n \n-\nThe normally frequent or semi-solid stools of a breastfed baby are not diarrhoea.",
        "formatted_content": "<p>814</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Not enough</p>\n<p>signs to</p>\n<p>classify</p>\n<p>~</p>\n<p>as some or</p>\n<p>severe</p>\n<p>~</p>\n<p>dehydration</p>\n<p>No Dehydration</p>\n<p>\u0089</p>\n<p>Give fluids to treat diarrhoea at home and continue</p>\n<p>breast feeding (Plan A)</p>\n<p>\u0089</p>\n<p>Advise mother when to return immediately</p>\n<p>\u0089</p>\n<p>FOLLOW UP in two days</p>\n<p>-</p>\n<p>If better, praise the mother and advice to</p>\n<p>continue breastfeeding</p>\n<p>-</p>\n<p>If not better, reassess and treat</p>\n<p>accordingly</p>\n<p>If diarrhoea of > 14 days</p>\n<p>~</p>\n<p>Diarrhoea</p>\n<p>lasting 14</p>\n<p>days or more</p>\n<p>Severe Persistent</p>\n<p>Diarrhoea</p>\n<p>\u0089</p>\n<p>Refer to hospital</p>\n<p>\u0089</p>\n<p>Treat dehydration before referral</p>\n<p>Note</p>\n<p>\u0083 What is diarrhoea in a young infant?</p>\n<p>-</p>\n<p>A young infant has diarrhoea if the stools have changed from usual pattern and are many</p>\n<p>and watery (more water than faecal matter).</p>\n<p>-</p>\n<p>The normally frequent or semi-solid stools of a breastfed baby are not diarrhoea.</p>"
    },
    {
        "page_number": 881,
        "content": "815\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.2.4   Check for HIV Infection\nAsk\n \n~\nHas the mother and/or young infant had an HIV test?\nIF YES:\n \n~\nWhat is the mother\u2019s HIV status?\n \n-\nSerological test POSITIVE or NEGATIVE\n \n~\nWhat is the young infant\u2019s HIV status?\n \n-\nVirological test POSITIVE or NEGATIVE\n \n-\nSerological test POSITIVE or NEGATIVE\nIf mother is HIV positive (or serological test of the child is posi\u00ad\ntive) and NO positive virological test in child ASK:\n \n~\nIs the young infant breastfeeding now?\n \n~\nWas the young infant breastfeeding at the time of test or \nbefore it?\n \n~\nIs the mother and young infant on PMTCT ARV prophy\u00ad\nlaxis?\nIF NO test: Mother and young infant status unknown\n \n\u0081\nPerform serological HIV test for the mother (or serological test \nfor the child if the mother is not present); if positive, perform \nvirological test for the young infant",
        "formatted_content": "<p>815</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.2.4   Check for HIV Infection</p>\n<p>Ask</p>\n<p>~</p>\n<p>Has the mother and/or young infant had an HIV test?</p>\n<h3>IF YES:</h3>\n<p>~</p>\n<p>What is the mother\u2019s HIV status?</p>\n<p>-</p>\n<p>Serological test POSITIVE or NEGATIVE</p>\n<p>~</p>\n<p>What is the young infant\u2019s HIV status?</p>\n<p>-</p>\n<p>Virological test POSITIVE or NEGATIVE</p>\n<p>-</p>\n<p>Serological test POSITIVE or NEGATIVE</p>\n<p>If mother is HIV positive (or serological test of the child is posi\u00ad</p>\n<p>tive) and NO positive virological test in child ASK:</p>\n<p>~</p>\n<p>Is the young infant breastfeeding now?</p>\n<p>~</p>\n<p>Was the young infant breastfeeding at the time of test or</p>\n<p>before it?</p>\n<p>~</p>\n<p>Is the mother and young infant on PMTCT ARV prophy\u00ad</p>\n<p>laxis?</p>\n<p>IF NO test: Mother and young infant status unknown</p>\n<p>\u0081</p>\n<p>Perform serological HIV test for the mother (or serological test</p>\n<p>for the child if the mother is not present); if positive, perform</p>\n<p>virological test for the young infant</p>"
    },
    {
        "page_number": 882,
        "content": "816\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat HIV status (see also section 3.1.4)\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nPositive virological \ntesting in young infant\nConfirmed HIV\nInfection\n\t\n\u0089\nGive cotrimoxazole prophylaxis from \nage 6 weeks.\n\t\n\u0089\nGive HIV care and ART\n\t\n\u0089\nAdvise the mother on home care\n\t\n\u0089\nFOLLOW UP regularly as per national \nguidelines\n \n~\nMother HIV positive \nAND negative virological \ntest in young infant \nbreastfeeding or if only \nstopped less than 6 \nweeks ago.OR\n \n~\nMother HIV positive**, \nyoung infant not yet \ntested OR\n \n~\nPositive serological test \nin infant\nHIV Exposed\n\t\n\u0089\nGive cotrimoxazole prophylaxis from \n6 weeks of age\n\t\n\u0089\nStart or continue PMTCT ARV \nprophylaxis as per national \nrecommendations\n\t\n\u0089\nDo virological test at age 6 weeks or \nrepeat 6 weeks after the child stops \nbreastfeeding\n\t\n\u0089\nAdvise the mother on home care\n\t\n\u0089\nFOLLOW UP regularly as per \nnational guidelines\n \n~\nNegative HIV test in \nmother\n \n~\nor young infant\nHIV Infection \nUnlikely\n\t\n\u0089\nTreat, counsel and FOLLOW UP existing \ninfections",
        "formatted_content": "<p>816</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat HIV status (see also section 3.1.4)</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Positive virological</p>\n<p>testing in young infant</p>\n<p>Confirmed HIV</p>\n<p>Infection</p>\n<p>\u0089</p>\n<p>Give cotrimoxazole prophylaxis from</p>\n<p>age 6 weeks.</p>\n<p>\u0089</p>\n<p>Give HIV care and ART</p>\n<p>\u0089</p>\n<p>Advise the mother on home care</p>\n<p>\u0089</p>\n<p>FOLLOW UP regularly as per national</p>\n<p>guidelines</p>\n<p>~</p>\n<p>Mother HIV positive</p>\n<p>AND negative virological</p>\n<p>test in young infant</p>\n<p>breastfeeding or if only</p>\n<p>stopped less than 6</p>\n<p>weeks ago.OR</p>\n<p>~</p>\n<p>Mother HIV positive**,</p>\n<p>young infant not yet</p>\n<p>tested OR</p>\n<p>~</p>\n<p>Positive serological test</p>\n<p>in infant</p>\n<p>HIV Exposed</p>\n<p>\u0089</p>\n<p>Give cotrimoxazole prophylaxis from</p>\n<p>6 weeks of age</p>\n<p>\u0089</p>\n<p>Start or continue PMTCT ARV</p>\n<p>prophylaxis as per national</p>\n<p>recommendations</p>\n<p>\u0089</p>\n<p>Do virological test at age 6 weeks or</p>\n<p>repeat 6 weeks after the child stops</p>\n<p>breastfeeding</p>\n<p>\u0089</p>\n<p>Advise the mother on home care</p>\n<p>\u0089</p>\n<p>FOLLOW UP regularly as per</p>\n<p>national guidelines</p>\n<p>~</p>\n<p>Negative HIV test in</p>\n<p>mother</p>\n<p>~</p>\n<p>or young infant</p>\n<p>HIV Infection</p>\n<p>Unlikely</p>\n<p>\u0089</p>\n<p>Treat, counsel and FOLLOW UP existing</p>\n<p>infections</p>"
    },
    {
        "page_number": 883,
        "content": "817\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.2.5  Check for Feeding Problem or Low Weight-for-Age\n17.2.5.1  All Young Infants Except HIV-exposed Infants Not \nBreastfed\nIf an infant has no indications to \nrefer urgently to hospital:\nAsk\n \n~\nIs there any difficulty feed\u00ad\ning?\n \n~\nIs the infant breastfed?\n \n-\nIf yes, how many times in \na 24-hour period?\n \n~\nDoes the infant usually \nreceive any other foods or \ndrinks, including water?\n \n-\nIf yes, how often?\n \n~\nWhat do you use to feed \nthe infant?\nLook listen and feel\n \n~\nD e t e r m i n e \nweight for age\n \n-\nWeigh the child \nand use the \nchart at the end \nof this chapter \nto determine if \nthe child is low \nweight for its \nage in months\n \n~\nLook for ulcers \nor white patch\u00ad\nes in the mouth \n(thrush)\nAssess breastfeeding\n \n~\nHas the infant breastfed in the previous hour?\n \n-\nIf no, ask the mother to put the infant to the breast.\n \n-\nIf yes, ask the mother if she can wait and tell you when \nthe infant is willing to feed again\n \n~\nObserve breastfeeding for 4 minutes: is the infant able to \nattach properly to the breast? For good attachment, the \nfollowing should be present:\n \n-\nChin touching breast\n \n-\nMouth wide open\n \n-\nLower lip turned outwards\n \n-\nMore areola visible above than below the mouth\n \n~\nIs the infant able to suckle effectively? This means slow, \ndeep sucks with occasional pauses\n \n-\nClear a blocked nose if it interferes with breastfeeding",
        "formatted_content": "<p>817</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.2.5  Check for Feeding Problem or Low Weight-for-Age</p>\n<p>17.2.5.1  All Young Infants Except HIV-exposed Infants Not</p>\n<p>Breastfed</p>\n<p>If an infant has no indications to</p>\n<p>refer urgently to hospital:</p>\n<p>Ask</p>\n<p>~</p>\n<p>Is there any difficulty feed\u00ad</p>\n<p>ing?</p>\n<p>~</p>\n<p>Is the infant breastfed?</p>\n<p>-</p>\n<p>If yes, how many times in</p>\n<p>a 24-hour period?</p>\n<p>~</p>\n<p>Does the infant usually</p>\n<p>receive any other foods or</p>\n<p>drinks, including water?</p>\n<p>-</p>\n<p>If yes, how often?</p>\n<p>~</p>\n<p>What do you use to feed</p>\n<p>the infant?</p>\n<p>Look listen and feel</p>\n<p>~</p>\n<p>D e t e r m i n e</p>\n<p>weight for age</p>\n<p>-</p>\n<p>Weigh the child</p>\n<p>and use the</p>\n<p>chart at the end</p>\n<p>of this chapter</p>\n<p>to determine if</p>\n<p>the child is low</p>\n<p>weight for its</p>\n<p>age in months</p>\n<p>~</p>\n<p>Look for ulcers</p>\n<p>or white patch\u00ad</p>\n<p>es in the mouth</p>\n<p>(thrush)</p>\n<p>Assess breastfeeding</p>\n<p>~</p>\n<p>Has the infant breastfed in the previous hour?</p>\n<p>-</p>\n<p>If no, ask the mother to put the infant to the breast.</p>\n<p>-</p>\n<p>If yes, ask the mother if she can wait and tell you when</p>\n<p>the infant is willing to feed again</p>\n<p>~</p>\n<p>Observe breastfeeding for 4 minutes: is the infant able to</p>\n<p>attach properly to the breast? For good attachment, the</p>\n<p>following should be present:</p>\n<p>-</p>\n<p>Chin touching breast</p>\n<p>-</p>\n<p>Mouth wide open</p>\n<p>-</p>\n<p>Lower lip turned outwards</p>\n<p>-</p>\n<p>More areola visible above than below the mouth</p>\n<p>~</p>\n<p>Is the infant able to suckle effectively? This means slow,</p>\n<p>deep sucks with occasional pauses</p>\n<p>-</p>\n<p>Clear a blocked nose if it interferes with breastfeeding</p>"
    },
    {
        "page_number": 884,
        "content": "818\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat feeding problems\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\nAny of these signs\nFeeding\nNot well attached to breast \nor\nNot suckling effectively or\nLess than 8 breastfeeds in \n24 hours or\nReceives other\nfoods or drinks or\nLow weight for age\nor\nThrush (ulcers or white \npatches in mouth)\nFeeding Problem or \nLow Weight\n\t\n\u0089\nIf not well attached or not suckling effectively, \nteach correct positioning and attachment\n \n-\nIf not able to attach well immediately, \nteach the mother to express breast \nmilk and feed by a cup\n\t\n\u0089\nIf breastfeeding less than 8 times in 24 hours, \nadvise to increase frequency of feeding. Advise \nthe mother to breastfeed as often and as long \nas the infant wants, day and night\n\t\n\u0089\nIf not breastfeeding at all\n\t\n\u0089\nAdvise the mother how to feed and keep the \nlow weight infant warm at home\n\t\n\u0089\nIf thrush, teach the mother to treat thrush at \nhome (apply gentian violet paint 4 times daily \nfor 7 days with clean hands, use a soft cloth)",
        "formatted_content": "<p>818</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat feeding problems</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>Any of these signs</p>\n<p>Feeding</p>\n<p>Not well attached to breast</p>\n<p>or</p>\n<p>Not suckling effectively or</p>\n<p>Less than 8 breastfeeds in</p>\n<p>24 hours or</p>\n<p>Receives other</p>\n<p>foods or drinks or</p>\n<p>Low weight for age</p>\n<p>or</p>\n<p>Thrush (ulcers or white</p>\n<p>patches in mouth)</p>\n<p>Feeding Problem or</p>\n<p>Low Weight</p>\n<p>\u0089</p>\n<p>If not well attached or not suckling effectively,</p>\n<p>teach correct positioning and attachment</p>\n<p>-</p>\n<p>If not able to attach well immediately,</p>\n<p>teach the mother to express breast</p>\n<p>milk and feed by a cup</p>\n<p>\u0089</p>\n<p>If breastfeeding less than 8 times in 24 hours,</p>\n<p>advise to increase frequency of feeding. Advise</p>\n<p>the mother to breastfeed as often and as long</p>\n<p>as the infant wants, day and night</p>\n<p>\u0089</p>\n<p>If not breastfeeding at all</p>\n<p>\u0089</p>\n<p>Advise the mother how to feed and keep the</p>\n<p>low weight infant warm at home</p>\n<p>\u0089</p>\n<p>If thrush, teach the mother to treat thrush at</p>\n<p>home (apply gentian violet paint 4 times daily</p>\n<p>for 7 days with clean hands, use a soft cloth)</p>"
    },
    {
        "page_number": 885,
        "content": "819\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n\t\n\u0089\nAdvise mother to give home care for the \nyoung infant\n\t\n\u0089\nFOLLOW UP any feeding problem or thrush \nin 2 days and reassess.\n \n-\nContinue FOLLOW UP till \nsatisfactory feeding. If loosing weight, \nrefer.\n \n-\nIf thrush is worse, check that \ntreatment is given correctly. If better, \ncomplete 7-day treatment.\n\t\n\u0089\nFOLLOW UP low weight for age in 14 days:\n \n-\nIf no longer low weight for age, \npraise the mother and encourage to \ncontinue.\n \n-\nIf still low weight for age but feeding \nwell, praise the\n \n-\nmother and FOLLOW UP in 14 days\n \n-\nIf low weight for age, still feeding \nproblem or lost weight: refer to \nhospital",
        "formatted_content": "<p>819</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>\u0089</p>\n<p>Advise mother to give home care for the</p>\n<p>young infant</p>\n<p>\u0089</p>\n<p>FOLLOW UP any feeding problem or thrush</p>\n<p>in 2 days and reassess.</p>\n<p>-</p>\n<p>Continue FOLLOW UP till</p>\n<p>satisfactory feeding. If loosing weight,</p>\n<p>refer.</p>\n<p>-</p>\n<p>If thrush is worse, check that</p>\n<p>treatment is given correctly. If better,</p>\n<p>complete 7-day treatment.</p>\n<p>\u0089</p>\n<p>FOLLOW UP low weight for age in 14 days:</p>\n<p>-</p>\n<p>If no longer low weight for age,</p>\n<p>praise the mother and encourage to</p>\n<p>continue.</p>\n<p>-</p>\n<p>If still low weight for age but feeding</p>\n<p>well, praise the</p>\n<p>-</p>\n<p>mother and FOLLOW UP in 14 days</p>\n<p>-</p>\n<p>If low weight for age, still feeding</p>\n<p>problem or lost weight: refer to</p>\n<p>hospital</p>"
    },
    {
        "page_number": 886,
        "content": "820\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nNot \nlow \nweight \nfor age \nand no \nother \nsigns of \ninade\u00ad\nquate \nfeeding\nNo Feeding \nProblem\n\t\n\u0089\nAdvise mother on home \ncare for young infant\n\t\n\u0089\nPraise mother for feeding \nthe infant well\n17.2.5.2  HIV-exposed Non Breastfeeding Infants\nAsk\n \n~\nWhat milk are you giving?\n \n~\nHow many times during \nthe day and night?\n \n~\nHow much is given at each \nfeed?\n \n~\nHow are you preparing the \nmilk?\n \n~\nLet mother demonstrate or \nexplain how a feed is pre\u00ad\npared, and how it is given \nto the infant.\n \n~\nAre you giving any breast \nmilk at all?\n \n~\nWhat foods and fluids in \naddition to replacement \nfeeds is given?\n \n~\nHow is the milk being \ngiven? Cup or bottle?\n \n~\nHow are you cleaning the \nfeeding utensils?\nLook, listen and feel\n \n~\nDetermine \nweight for age\n \n~\nLook for \nulcers or \nwhite patches \nin the mouth \n(thrush)",
        "formatted_content": "<p>820</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Not</p>\n<p>low</p>\n<p>weight</p>\n<p>for age</p>\n<p>and no</p>\n<p>other</p>\n<p>signs of</p>\n<p>inade\u00ad</p>\n<p>quate</p>\n<p>feeding</p>\n<p>No Feeding</p>\n<p>Problem</p>\n<p>\u0089</p>\n<p>Advise mother on home</p>\n<p>care for young infant</p>\n<p>\u0089</p>\n<p>Praise mother for feeding</p>\n<p>the infant well</p>\n<p>17.2.5.2  HIV-exposed Non Breastfeeding Infants</p>\n<p>Ask</p>\n<p>~</p>\n<p>What milk are you giving?</p>\n<p>~</p>\n<p>How many times during</p>\n<p>the day and night?</p>\n<p>~</p>\n<p>How much is given at each</p>\n<p>feed?</p>\n<p>~</p>\n<p>How are you preparing the</p>\n<p>milk?</p>\n<p>~</p>\n<p>Let mother demonstrate or</p>\n<p>explain how a feed is pre\u00ad</p>\n<p>pared, and how it is given</p>\n<p>to the infant.</p>\n<p>~</p>\n<p>Are you giving any breast</p>\n<p>milk at all?</p>\n<p>~</p>\n<p>What foods and fluids in</p>\n<p>addition to replacement</p>\n<p>feeds is given?</p>\n<p>~</p>\n<p>How is the milk being</p>\n<p>given? Cup or bottle?</p>\n<p>~</p>\n<p>How are you cleaning the</p>\n<p>feeding utensils?</p>\n<p>Look, listen and feel</p>\n<p>~</p>\n<p>Determine</p>\n<p>weight for age</p>\n<p>~</p>\n<p>Look for</p>\n<p>ulcers or</p>\n<p>white patches</p>\n<p>in the mouth</p>\n<p>(thrush)</p>"
    },
    {
        "page_number": 887,
        "content": "821\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat feeding problems\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nMilk incor\u00ad\nrectly or un\u00ad\nhygienically \nprepared or\n \n~\nGiving \ninappropriate \nreplacement \nfeeds or\n \n~\nGiving \ninsufficient \nreplacement \nfeeds or\n \n~\nAn HIV posi\u00ad\ntive mother\nFeeding Problem or \nLow Weight\n\t\n\u0089\nCounsel about feeding\n\t\n\u0089\nExplain the guidelines for safe replacement \nfeeding f Identify concerns of mother and \nfamily about feeding f If mother is using a \nbottle, teach cup feeding f Advise the mother \nhow to feed and keep infant warm at home\n\t\n\u0089\nIf thrush, teach the mother to treat thrush at \nhome (apply gentian violet paint 4 times daily \nfor 7 days with clean hands, use a soft cloth)\n\t\n\u0089\nAdvise mother to give home care for the \nyoung infant\n\t\n\u0089\nFOLLOW UP any feeding problem or thrush \nin 2 days\n \n~\nmixing breast \nand other \nfeeds before \n6 months or \nUsing a feed\u00ad\ning bottle or.\n \n-\nContinue FOLLOW UP till \nsatisfactory feeding. If loosing \nweight, refer\n \n-\nIf thrush is worse, check that \ntreatment is given correctly. If better, \ncomplete 7-day treatment",
        "formatted_content": "<p>821</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat feeding problems</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Milk incor\u00ad</p>\n<p>rectly or un\u00ad</p>\n<p>hygienically</p>\n<p>prepared or</p>\n<p>~</p>\n<p>Giving</p>\n<p>inappropriate</p>\n<p>replacement</p>\n<p>feeds or</p>\n<p>~</p>\n<p>Giving</p>\n<p>insufficient</p>\n<p>replacement</p>\n<p>feeds or</p>\n<p>~</p>\n<p>An HIV posi\u00ad</p>\n<p>tive mother</p>\n<p>Feeding Problem or</p>\n<p>Low Weight</p>\n<p>\u0089</p>\n<p>Counsel about feeding</p>\n<p>\u0089</p>\n<p>Explain the guidelines for safe replacement</p>\n<p>feeding f Identify concerns of mother and</p>\n<p>family about feeding f If mother is using a</p>\n<p>bottle, teach cup feeding f Advise the mother</p>\n<p>how to feed and keep infant warm at home</p>\n<p>\u0089</p>\n<p>If thrush, teach the mother to treat thrush at</p>\n<p>home (apply gentian violet paint 4 times daily</p>\n<p>for 7 days with clean hands, use a soft cloth)</p>\n<p>\u0089</p>\n<p>Advise mother to give home care for the</p>\n<p>young infant</p>\n<p>\u0089</p>\n<p>FOLLOW UP any feeding problem or thrush</p>\n<p>in 2 days</p>\n<p>~</p>\n<p>mixing breast</p>\n<p>and other</p>\n<p>feeds before</p>\n<p>6 months or</p>\n<p>Using a feed\u00ad</p>\n<p>ing bottle or.</p>\n<p>-</p>\n<p>Continue FOLLOW UP till</p>\n<p>satisfactory feeding. If loosing</p>\n<p>weight, refer</p>\n<p>-</p>\n<p>If thrush is worse, check that</p>\n<p>treatment is given correctly. If better,</p>\n<p>complete 7-day treatment</p>"
    },
    {
        "page_number": 888,
        "content": "822\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nLow \nweight \nfor age or \nThrush \n(ulcers \nor white \npatches in \nmouth)\n\t\n\u0089\nFOLLOW UP low weight for age in 14 days\n \n-\nIf no longer low weight for age, \npraise the mother and encourage to \ncontinue.\n \n-\nIf still low weight for age but feeding \nwell, praise the mother and FOLLOW \nUP in 14 days\n \n-\nIf low weight for age, still feeding \nproblem or lost weight: refer to \nhospital\n \n~\nNot low \nweight for \nage and \nno other \nsigns of \ninadequate \nfeeding\nNo Feeding\nProblem\n\t\n\u0089\nAdvise mother to give home care for the young \ninfant\n\t\n\u0089\nPraise the mother for feeding the infant well",
        "formatted_content": "<p>822</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Low</p>\n<p>weight</p>\n<p>for age or</p>\n<p>Thrush</p>\n<p>(ulcers</p>\n<p>or white</p>\n<p>patches in</p>\n<p>mouth)</p>\n<p>\u0089</p>\n<p>FOLLOW UP low weight for age in 14 days</p>\n<p>-</p>\n<p>If no longer low weight for age,</p>\n<p>praise the mother and encourage to</p>\n<p>continue.</p>\n<p>-</p>\n<p>If still low weight for age but feeding</p>\n<p>well, praise the mother and FOLLOW</p>\n<p>UP in 14 days</p>\n<p>-</p>\n<p>If low weight for age, still feeding</p>\n<p>problem or lost weight: refer to</p>\n<p>hospital</p>\n<p>~</p>\n<p>Not low</p>\n<p>weight for</p>\n<p>age and</p>\n<p>no other</p>\n<p>signs of</p>\n<p>inadequate</p>\n<p>feeding</p>\n<p>No Feeding</p>\n<p>Problem</p>\n<p>\u0089</p>\n<p>Advise mother to give home care for the young</p>\n<p>infant</p>\n<p>\u0089</p>\n<p>Praise the mother for feeding the infant well</p>"
    },
    {
        "page_number": 889,
        "content": "823\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.2.6   Check Young Infant\u2019s Immunization Status\nCheck immunization card and classify\n \n~\nImuniza\u00ad\ntion not \nup to date \naccording\n \n~\nto national \nschedule \n(see chap\u00ad\nter 18)\nInfant Not \nImmunized \nas per \nSchedule\n \n~\nGive all missed \ndoses on this \nvisit (Include sick \ninfants unless \nbeing referred)\n \n~\nImmuniza\u00ad\ntion upto \ndate as per \nnational \nschedule\nInfant Im\u00ad\nmunized as \nPer Sched\u00ad\nule\n \n~\nAdvise caretaker \nwhen to return \nfor the next \ndose\n17.2.7  Assess Other Problems\nAssess any other presenting problems (e.g. eye problems, rashes) and \nmanage accordingly.\n17.2.8  Assess Mother\u2019s Health Needs\n \n~\nCheck for current health problems\n \n~\nCheck nutritional status and anaemia\n \n~\nCheck whether family planning help is required\n \n~\nCheck on tetanus immunization status\n17.2.9 Summary of IMNCI Medicines Used for Young Infants\nDRUG\nDOSE\nINDICATION\nLOC\nAmpicillin\n50 mg/kg\nPre referral IM dose in \nvery severe disease\nHC3",
        "formatted_content": "<p>823</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.2.6   Check Young Infant\u2019s Immunization Status</p>\n<p>Check immunization card and classify</p>\n<p>~</p>\n<p>Imuniza\u00ad</p>\n<p>tion not</p>\n<p>up to date</p>\n<p>according</p>\n<p>~</p>\n<p>to national</p>\n<p>schedule</p>\n<p>(see chap\u00ad</p>\n<p>ter 18)</p>\n<p>Infant Not</p>\n<p>Immunized</p>\n<p>as per</p>\n<p>Schedule</p>\n<p>~</p>\n<p>Give all missed</p>\n<p>doses on this</p>\n<p>visit (Include sick</p>\n<p>infants unless</p>\n<p>being referred)</p>\n<p>~</p>\n<p>Immuniza\u00ad</p>\n<p>tion upto</p>\n<p>date as per</p>\n<p>national</p>\n<p>schedule</p>\n<p>Infant Im\u00ad</p>\n<p>munized as</p>\n<p>Per Sched\u00ad</p>\n<p>ule</p>\n<p>~</p>\n<p>Advise caretaker</p>\n<p>when to return</p>\n<p>for the next</p>\n<p>dose</p>\n<p>17.2.7  Assess Other Problems</p>\n<p>Assess any other presenting problems (e.g. eye problems, rashes) and</p>\n<p>manage accordingly.</p>\n<p>17.2.8  Assess Mother\u2019s Health Needs</p>\n<p>~</p>\n<p>Check for current health problems</p>\n<p>~</p>\n<p>Check nutritional status and anaemia</p>\n<p>~</p>\n<p>Check whether family planning help is required</p>\n<p>~</p>\n<p>Check on tetanus immunization status</p>\n<p>17.2.9 Summary of IMNCI Medicines Used for Young Infants</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>Ampicillin</p>\n<p>50 mg/kg</p>\n<p>Pre referral IM dose in</p>\n<p>very severe disease</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 890,
        "content": "824\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nDRUG\nDOSE\nINDICATION\nLOC\nGentamicin\nAge < 7 days 5 \nmg/Kg\nPre referral IM dose in \nvery severe disease\nHC3\nAge > 7 days\n7.5 mg/kg\nBenzyl peni\u00ad\ncillin\n50,000 IU/\nKg IM\nPre referral IM dose in \nvery severe disease if \nampicillin/ gentamicin \nnot available\nHC2\nAmoxicillin\n250 mg dis\u00ad\npersible tablets \n(DT)\nBirth-<1 \nmonth (< 4 kg):\n\u00bc tab every 12 \nhours for 5 \ndays\nIn local bacterial infec\u00ad\ntion\nHC1\n1-2 month \n(4-6 kg): \u00bd tab \nevery 12 hours \nfor 5 days\nGentian Violet \n0.5%\nApply in the \nmouth 4 times \na day for 7 days\nIn oral thrush\nHC2\nApply on skin \ntwice daily for \n5 days\nLocal bacterial infection\n(skin pustules or umbilical \ninfection)\nCotrimoxazole\nTab 120 mg \npediatric tablet\n1 tab once daily Prophylaxis in HIV in\u00ad\nfected or HIV exposed \nchildren till\ninfection can be excluded\nHC2\n117.2.10  Counsel the Mother\nTeach correct positioning and attachment for breast feeding\n \n~\nShow mother how to hold the infant:\n\t\n\u0089\nWith the infant\u2019s head and body straight",
        "formatted_content": "<p>824</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>Gentamicin</p>\n<p>Age < 7 days 5</p>\n<p>mg/Kg</p>\n<p>Pre referral IM dose in</p>\n<p>very severe disease</p>\n<h3>HC3</h3>\n<p>Age > 7 days</p>\n<p>7.5 mg/kg</p>\n<p>Benzyl peni\u00ad</p>\n<p>cillin</p>\n<h3>50,000 IU/</h3>\n<p>Kg IM</p>\n<p>Pre referral IM dose in</p>\n<p>very severe disease if</p>\n<p>ampicillin/ gentamicin</p>\n<p>not available</p>\n<h3>HC2</h3>\n<p>Amoxicillin</p>\n<p>250 mg dis\u00ad</p>\n<p>persible tablets</p>\n<h3>(DT)</h3>\n<p>Birth-<1</p>\n<p>month (< 4 kg):</p>\n<p>\u00bc tab every 12</p>\n<p>hours for 5</p>\n<p>days</p>\n<p>In local bacterial infec\u00ad</p>\n<p>tion</p>\n<h3>HC1</h3>\n<p>1-2 month</p>\n<p>(4-6 kg): \u00bd tab</p>\n<p>every 12 hours</p>\n<p>for 5 days</p>\n<p>Gentian Violet</p>\n<p>0.5%</p>\n<p>Apply in the</p>\n<p>mouth 4 times</p>\n<p>a day for 7 days</p>\n<p>In oral thrush</p>\n<h3>HC2</h3>\n<p>Apply on skin</p>\n<p>twice daily for</p>\n<p>5 days</p>\n<p>Local bacterial infection</p>\n<p>(skin pustules or umbilical</p>\n<p>infection)</p>\n<p>Cotrimoxazole</p>\n<p>Tab 120 mg</p>\n<p>pediatric tablet</p>\n<p>1 tab once daily Prophylaxis in HIV in\u00ad</p>\n<p>fected or HIV exposed</p>\n<p>children till</p>\n<p>infection can be excluded</p>\n<h3>HC2</h3>\n<p>117.2.10  Counsel the Mother</p>\n<p>Teach correct positioning and attachment for breast feeding</p>\n<p>~</p>\n<p>Show mother how to hold the infant:</p>\n<p>\u0089</p>\n<p>With the infant\u2019s head and body straight</p>"
    },
    {
        "page_number": 891,
        "content": "825\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n\t\n\u0089\nFacing her breast with infant\u2019s nose opposite the nipple\n\t\n\u0089\nWith infant\u2019s body close to hers\n\t\n\u0089\nSupporting the infant\u2019s whole body, not just the neck and shoulders\n \n~\nShow her how to help the infant attach, she should:\n\t\n\u0089\nTouch her infant\u2019s lips with her nipple\n\t\n\u0089\nWait until her infant\u2019s mouth opens wide\n\t\n\u0089\nMove her infant quickly onto her breast aiming the infant\u2019s lower \nlip well below the nipple\n\t\n\u0089\nLook for signs of good attachment and effective suckling\n\t\n\u0089\nIf either is not good, try again\nAdvise mother on home care for the young infant\n \n~\nFood and fluids: Breastfeed frequently on demand (as of\u00ad\nten and for as long as the infant wants) day and night, \nduring sickness and health\n \n~\nWarmth: Ensure the young infant is always warm\n17.3  SICK CHILD AGE 2 MONTHS TO 5 YEARS\nAssess, classify, and treat\n \n~\nAsk the mother what the child\u2019s problems are\n \n~\nCheck if this is an initial or FOLLOW UP\n \n-\nIf FOLLOW UP visit: Check up on previous problems, \ncheck that the treatment has been given correctly and \nassess any new problems\n \n~\nIf initial visit: Continue as below\nIn assessing a sick child, assess for the following:\n \n-\nGeneral danger signs: URGENT ATTENTION and \nACTION REQUIRED.\nThen check for:\n \n-\nCough or difficult breathing",
        "formatted_content": "<p>825</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>\u0089</p>\n<p>Facing her breast with infant\u2019s nose opposite the nipple</p>\n<p>\u0089</p>\n<p>With infant\u2019s body close to hers</p>\n<p>\u0089</p>\n<p>Supporting the infant\u2019s whole body, not just the neck and shoulders</p>\n<p>~</p>\n<p>Show her how to help the infant attach, she should:</p>\n<p>\u0089</p>\n<p>Touch her infant\u2019s lips with her nipple</p>\n<p>\u0089</p>\n<p>Wait until her infant\u2019s mouth opens wide</p>\n<p>\u0089</p>\n<p>Move her infant quickly onto her breast aiming the infant\u2019s lower</p>\n<p>lip well below the nipple</p>\n<p>\u0089</p>\n<p>Look for signs of good attachment and effective suckling</p>\n<p>\u0089</p>\n<p>If either is not good, try again</p>\n<p>Advise mother on home care for the young infant</p>\n<p>~</p>\n<p>Food and fluids: Breastfeed frequently on demand (as of\u00ad</p>\n<p>ten and for as long as the infant wants) day and night,</p>\n<p>during sickness and health</p>\n<p>~</p>\n<p>Warmth: Ensure the young infant is always warm</p>\n<h3>17.3  SICK CHILD AGE 2 MONTHS TO 5 YEARS</h3>\n<p>Assess, classify, and treat</p>\n<p>~</p>\n<p>Ask the mother what the child\u2019s problems are</p>\n<p>~</p>\n<p>Check if this is an initial or FOLLOW UP</p>\n<p>-</p>\n<p>If FOLLOW UP visit: Check up on previous problems,</p>\n<p>check that the treatment has been given correctly and</p>\n<p>assess any new problems</p>\n<p>~</p>\n<p>If initial visit: Continue as below</p>\n<p>In assessing a sick child, assess for the following:</p>\n<p>-</p>\n<p>General danger signs: URGENT ATTENTION and</p>\n<h3>ACTION REQUIRED.</h3>\n<p>Then check for:</p>\n<p>-</p>\n<p>Cough or difficult breathing</p>"
    },
    {
        "page_number": 892,
        "content": "826\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n \n-\nDiarrhoea and dehydration\n \n-\nFever\n \n-\nEar problems\n \n-\nMalnutrition and feeding problems\n \n-\nAnaemia\n \n-\nHIV\n \n-\nImmunization, deworming and vitamin A\n \n-\nAny other problem\nThen counsel the mother on\n \n-\nExtra fluids for any sick child\n \n-\nNutrition and breastfeeding of the child\n \n-\nHow to give home treatments\n \n-\nHer own health needs\n \n-\nTo return for FOLLOW UP as scheduled\n\t\n\u0089\nTo return immediately if any danger sign appear\nDANGER SIGN\nRETURN\n \n~\nBreastfeeding or drinking poorly\n \n~\nBecomes more ill\n \n~\nDevelops fever\n \n~\nFast or difficult breathing\n \n~\nBlood in stool\nImmediately\n17.3.21   Check for General Danger Signs\nAsk\n \n~\nIs the child unable to \ndrink or breastfeed\n \n~\nIs the child vomiting \neverything\n \n~\nHas the child had \nconvulsions\nLook\n \n~\nSee if the child \nlethargic or uncon\u00ad\nscious\n \n~\nIs the child convuls\u00ad\ning now",
        "formatted_content": "<p>826</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>-</p>\n<p>Diarrhoea and dehydration</p>\n<p>-</p>\n<p>Fever</p>\n<p>-</p>\n<p>Ear problems</p>\n<p>-</p>\n<p>Malnutrition and feeding problems</p>\n<p>-</p>\n<p>Anaemia</p>\n<p>-</p>\n<h3>HIV</h3>\n<p>-</p>\n<p>Immunization, deworming and vitamin A</p>\n<p>-</p>\n<p>Any other problem</p>\n<p>Then counsel the mother on</p>\n<p>-</p>\n<p>Extra fluids for any sick child</p>\n<p>-</p>\n<p>Nutrition and breastfeeding of the child</p>\n<p>-</p>\n<p>How to give home treatments</p>\n<p>-</p>\n<p>Her own health needs</p>\n<p>-</p>\n<p>To return for FOLLOW UP as scheduled</p>\n<p>\u0089</p>\n<p>To return immediately if any danger sign appear</p>\n<h3>DANGER SIGN</h3>\n<h3>RETURN</h3>\n<p>~</p>\n<p>Breastfeeding or drinking poorly</p>\n<p>~</p>\n<p>Becomes more ill</p>\n<p>~</p>\n<p>Develops fever</p>\n<p>~</p>\n<p>Fast or difficult breathing</p>\n<p>~</p>\n<p>Blood in stool</p>\n<p>Immediately</p>\n<p>17.3.21   Check for General Danger Signs</p>\n<p>Ask</p>\n<p>~</p>\n<p>Is the child unable to</p>\n<p>drink or breastfeed</p>\n<p>~</p>\n<p>Is the child vomiting</p>\n<p>everything</p>\n<p>~</p>\n<p>Has the child had</p>\n<p>convulsions</p>\n<p>Look</p>\n<p>~</p>\n<p>See if the child</p>\n<p>lethargic or uncon\u00ad</p>\n<p>scious</p>\n<p>~</p>\n<p>Is the child convuls\u00ad</p>\n<p>ing now</p>"
    },
    {
        "page_number": 893,
        "content": "827\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat as below\nCLINICAL FEATURE\nCLASSIFY \nAS\nMANAGEMENT\n \n~\nAny\n \n~\ngeneral \ndanger \nsign\nVery \nSevere \nDisease\n\t\n\u0089\nGive diazepam if convulsing \n(rectal diazepam 0.5 mg/kg)\n\t\n\u0089\nQuickly complete the assess\u00ad\nment\n\t\n\u0089\nGive any pre referral treatment \nimmediately\n\t\n\u0089\nTreat to prevent low blood sugar \n(breastfeed or give expressed \nbreast milk breastmilk substitute \nor sugar water by cup or NGT)\n\t\n\u0089\nKeep the child warm REFER \nURGENTLY\n17.3.2  Check for Cough or Difficult Breathing\nAsk\n \n~\nIf child \nhas cough \nand/or \ndifficulty in \nbreathing\nIf yes, ask\n \n~\nFor how \nlong child \nhas had \nthis?\nLook Listen and feel\nEnsure the child is calm, then\n \n~\nCount the number of breaths/\nminute\n \n~\nLook for chest indrawing\n \n~\nLook/listen for stridor (stridor \nis an abnormal harsh, high-\npitched sound caused by ob\u00ad\nstructed airflow, usually more \naudible while inhaling)\n \n~\nLook and listen for wheezing\n \n~\nIf pulse oximeter is available, \ndetermine oxygen saturation. \nRefer if < 90%\nIf wheezing with either fast breathing \nor chest indrawing:",
        "formatted_content": "<p>827</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURE</h3>\n<h3>CLASSIFY</h3>\n<p>AS</p>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Any</p>\n<p>~</p>\n<p>general</p>\n<p>danger</p>\n<p>sign</p>\n<p>Very</p>\n<p>Severe</p>\n<p>Disease</p>\n<p>\u0089</p>\n<p>Give diazepam if convulsing</p>\n<p>(rectal diazepam 0.5 mg/kg)</p>\n<p>\u0089</p>\n<p>Quickly complete the assess\u00ad</p>\n<p>ment</p>\n<p>\u0089</p>\n<p>Give any pre referral treatment</p>\n<p>immediately</p>\n<p>\u0089</p>\n<p>Treat to prevent low blood sugar</p>\n<p>(breastfeed or give expressed</p>\n<p>breast milk breastmilk substitute</p>\n<p>or sugar water by cup or NGT)</p>\n<p>\u0089</p>\n<p>Keep the child warm REFER</p>\n<h3>URGENTLY</h3>\n<p>17.3.2  Check for Cough or Difficult Breathing</p>\n<p>Ask</p>\n<p>~</p>\n<p>If child</p>\n<p>has cough</p>\n<p>and/or</p>\n<p>difficulty in</p>\n<p>breathing</p>\n<p>If yes, ask</p>\n<p>~</p>\n<p>For how</p>\n<p>long child</p>\n<p>has had</p>\n<p>this?</p>\n<p>Look Listen and feel</p>\n<p>Ensure the child is calm, then</p>\n<p>~</p>\n<p>Count the number of breaths/</p>\n<p>minute</p>\n<p>~</p>\n<p>Look for chest indrawing</p>\n<p>~</p>\n<p>Look/listen for stridor (stridor</p>\n<p>is an abnormal harsh, high-</p>\n<p>pitched sound caused by ob\u00ad</p>\n<p>structed airflow, usually more</p>\n<p>audible while inhaling)</p>\n<p>~</p>\n<p>Look and listen for wheezing</p>\n<p>~</p>\n<p>If pulse oximeter is available,</p>\n<p>determine oxygen saturation.</p>\n<p>Refer if < 90%</p>\n<p>If wheezing with either fast breathing</p>\n<p>or chest indrawing:</p>"
    },
    {
        "page_number": 894,
        "content": "828\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n\t\n\u0089\nGive a trial of rapid acting inhaled bron\u00ad\ncodilator (with spacer) for up to 3 times \n15-20 min apart. Count the breaths \nand look for chest indrawing again, \nand then classify\nFast breathing:\n \n~\nChild 2\u201312 months: 50 \nbreaths per minute\n \n~\nChild 1\u20135 years: 40 breaths \nper minute\nClassify and treat as below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nAny \ngeneral \ndanger \nsign\n \n~\nOr stridor \nin calm \nchild\n \n~\nSpO2 < \n90%\nSevere Pneu\u00ad\nmonia or Very \nSevere Disease\n\t\n\u0089\nGive 1st dose of appropriate anti\u00ad\nbiotic : ampicillin 50 mg/ Kg IM \nand gentamicin 7.5 mg/Kg IM\n \n-\nOr Benzylpenicillin \n50,000 IU/Kg IM if \nat HC2\n \n-\nOr Amoxicillin DT 40 \nmg/kg if parenteral \nantibiotics not available\n \n-\nRefer URGENTLY to \nHC4/HOSPITAL\nIf referral not possible\n\t\n\u0089\nContinue ampicillin 6 hourly and \ngentamicin once daily for 5 days\n \n-\nIf strong suspicion \nof meningitis, dose \nof ampicillin can be \nincreased 4 times\n \n~\nChest \nindrawing\nPneumonia\n\t\n\u0089\nGive amoxicillin DT 40 mg/kg \nfor 5 days as first line treatment",
        "formatted_content": "<p>828</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>\u0089</p>\n<p>Give a trial of rapid acting inhaled bron\u00ad</p>\n<p>codilator (with spacer) for up to 3 times</p>\n<p>15-20 min apart. Count the breaths</p>\n<p>and look for chest indrawing again,</p>\n<p>and then classify</p>\n<p>Fast breathing:</p>\n<p>~</p>\n<p>Child 2\u201312 months: 50</p>\n<p>breaths per minute</p>\n<p>~</p>\n<p>Child 1\u20135 years: 40 breaths</p>\n<p>per minute</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Any</p>\n<p>general</p>\n<p>danger</p>\n<p>sign</p>\n<p>~</p>\n<p>Or stridor</p>\n<p>in calm</p>\n<p>child</p>\n<p>~</p>\n<p>SpO2 <</p>\n<p>90%</p>\n<p>Severe Pneu\u00ad</p>\n<p>monia or Very</p>\n<p>Severe Disease</p>\n<p>\u0089</p>\n<p>Give 1st dose of appropriate anti\u00ad</p>\n<p>biotic : ampicillin 50 mg/ Kg IM</p>\n<p>and gentamicin 7.5 mg/Kg IM</p>\n<p>-</p>\n<p>Or Benzylpenicillin</p>\n<p>50,000 IU/Kg IM if</p>\n<p>at HC2</p>\n<p>-</p>\n<p>Or Amoxicillin DT 40</p>\n<p>mg/kg if parenteral</p>\n<p>antibiotics not available</p>\n<p>-</p>\n<p>Refer URGENTLY to</p>\n<h3>HC4/HOSPITAL</h3>\n<p>If referral not possible</p>\n<p>\u0089</p>\n<p>Continue ampicillin 6 hourly and</p>\n<p>gentamicin once daily for 5 days</p>\n<p>-</p>\n<p>If strong suspicion</p>\n<p>of meningitis, dose</p>\n<p>of ampicillin can be</p>\n<p>increased 4 times</p>\n<p>~</p>\n<p>Chest</p>\n<p>indrawing</p>\n<p>Pneumonia</p>\n<p>\u0089</p>\n<p>Give amoxicillin DT 40 mg/kg</p>\n<p>for 5 days as first line treatment</p>"
    },
    {
        "page_number": 895,
        "content": "829\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat as below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nFast \nbreathing \n\u2013 Child \n2-12 \nmonths: \n\u00b3 50 \nbreaths/ \nminute\n\t\n\u0089\nIf wheezing give an inhaled bron\u00ad\nchodilator for 5 days (salbutamol \ninhaler every 3-4 hours as nec\u00ad\nessary)t\n\t\n\u0089\nIf coughing for more than 14 days \nor recurrent wheeze, refer for pos\u00ad\nsible TB or asthma assessmen\n\t\n\u0089\nIf chest in drawing in HIV ex\u00ad\nposed/infected child, give first \ndose of amoxicillin DT 40 mg/\nkg and refer\n \n- Children\n \n- 1-5 years: \n \n- 40 breaths/ \nminute\n\t\n\u0089\nSoothe throat/relieve \ncough with safe remedy\n\t\n\u0089\nIf coughing for more than \n14 days or receurrent \nwheeze refer for possible \nTB or asthma assesment .\n\t\n\u0089\nAdvise mother when to \nreturn immediately (danger \nsigns)\n\t\n\u0089\nFOLLOW UP in 3 days \nand reassess\n \n-\nIf better (slower \nbreathing, no \nindrawing, less \nfever, eating \nbetter), praise \nthe mother and \nadvise to complete \ntreatment\n \n-\nIf not better or \nworse, refer \nurgently to \nhospital",
        "formatted_content": "<p>829</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Fast</p>\n<p>breathing</p>\n<p>\u2013 Child</p>\n<p>2-12</p>\n<p>months:</p>\n<p>\u00b3 50</p>\n<p>breaths/</p>\n<p>minute</p>\n<p>\u0089</p>\n<p>If wheezing give an inhaled bron\u00ad</p>\n<p>chodilator for 5 days (salbutamol</p>\n<p>inhaler every 3-4 hours as nec\u00ad</p>\n<p>essary)t</p>\n<p>\u0089</p>\n<p>If coughing for more than 14 days</p>\n<p>or recurrent wheeze, refer for pos\u00ad</p>\n<p>sible TB or asthma assessmen</p>\n<p>\u0089</p>\n<p>If chest in drawing in HIV ex\u00ad</p>\n<p>posed/infected child, give first</p>\n<p>dose of amoxicillin DT 40 mg/</p>\n<p>kg and refer</p>\n<p>- Children</p>\n<p>- 1-5 years:</p>\n<p>- 40 breaths/</p>\n<p>minute</p>\n<p>\u0089</p>\n<p>Soothe throat/relieve</p>\n<p>cough with safe remedy</p>\n<p>\u0089</p>\n<p>If coughing for more than</p>\n<p>14 days or receurrent</p>\n<p>wheeze refer for possible</p>\n<p>TB or asthma assesment .</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately (danger</p>\n<p>signs)</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 3 days</p>\n<p>and reassess</p>\n<p>-</p>\n<p>If better (slower</p>\n<p>breathing, no</p>\n<p>indrawing, less</p>\n<p>fever, eating</p>\n<p>better), praise</p>\n<p>the mother and</p>\n<p>advise to complete</p>\n<p>treatment</p>\n<p>-</p>\n<p>If not better or</p>\n<p>worse, refer</p>\n<p>urgently to</p>\n<p>hospital</p>"
    },
    {
        "page_number": 896,
        "content": "830\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\nNo signs of \nsevere disease \nor pneumonia\nCough or \nCold (No \npneumo\u00ad\nnia)\nMost likely \nviral so no \nantibiotics \nneeded\n\t\n\u0089\nIf wheezing give an inhaled \nbronchodilator (salbutamol \ninhaler every 3-4 hours as \nnecessary) for 5 days\n\t\n\u0089\nSoothe throat/relieve \ncough with safe remedy\n\t\n\u0089\nIf coughing for more \nthan 14 days or recurrent \nwheezing, refer for possible \nTB or asthma assesment\n\t\n\u0089\nAdvise mother when to \nreturn immediately (danger \nsigns)\n\t\n\u0089\nif not improving, FOLLOW \nUP in 5 days\nNote:\n \n\u0081\nUse age-appropriate spacers to administer salbutamol inhaler\n17.3.3  Child Has Diarrhoea\nAsk\n \n~\nDoes the \nchild have \ndiarrhoea?\n \n~\nIf yes, for \nhow long \nchild has had \nthis\n \n~\nUsing appro\u00ad\npriate local \nterms, ask if \nthere is blood \nin the stool\nLook and feel\n\t\n\u0089\nLook at the child\u2019s general condition. \nIs the child:\n\t\n\u0089\nLethargic or unconscious?\n\t\n\u0089\nRestless and irritable?\n\t\n\u0089\nLook for sunken eyes\n\t\n\u0089\nOffer the child fluid. Is the child:\n\t\n\u0089\nUnable to drink or drinks poorly?\n\t\n\u0089\nThirsty, drinks eagerly?\n\t\n\u0089\nPinch the skin of the abdomen. Does \nit go back:\n\t\n\u0089\nVery slowly? (>2 seconds)\n\t\n\u0089\nSlowly?",
        "formatted_content": "<p>830</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>No signs of</p>\n<p>severe disease</p>\n<p>or pneumonia</p>\n<p>Cough or</p>\n<p>Cold (No</p>\n<p>pneumo\u00ad</p>\n<p>nia)</p>\n<p>Most likely</p>\n<p>viral so no</p>\n<p>antibiotics</p>\n<p>needed</p>\n<p>\u0089</p>\n<p>If wheezing give an inhaled</p>\n<p>bronchodilator (salbutamol</p>\n<p>inhaler every 3-4 hours as</p>\n<p>necessary) for 5 days</p>\n<p>\u0089</p>\n<p>Soothe throat/relieve</p>\n<p>cough with safe remedy</p>\n<p>\u0089</p>\n<p>If coughing for more</p>\n<p>than 14 days or recurrent</p>\n<p>wheezing, refer for possible</p>\n<p>TB or asthma assesment</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately (danger</p>\n<p>signs)</p>\n<p>\u0089</p>\n<p>if not improving, FOLLOW</p>\n<p>UP in 5 days</p>\n<p>Note:</p>\n<p>\u0081</p>\n<p>Use age-appropriate spacers to administer salbutamol inhaler</p>\n<p>17.3.3  Child Has Diarrhoea</p>\n<p>Ask</p>\n<p>~</p>\n<p>Does the</p>\n<p>child have</p>\n<p>diarrhoea?</p>\n<p>~</p>\n<p>If yes, for</p>\n<p>how long</p>\n<p>child has had</p>\n<p>this</p>\n<p>~</p>\n<p>Using appro\u00ad</p>\n<p>priate local</p>\n<p>terms, ask if</p>\n<p>there is blood</p>\n<p>in the stool</p>\n<p>Look and feel</p>\n<p>\u0089</p>\n<p>Look at the child\u2019s general condition.</p>\n<p>Is the child:</p>\n<p>\u0089</p>\n<p>Lethargic or unconscious?</p>\n<p>\u0089</p>\n<p>Restless and irritable?</p>\n<p>\u0089</p>\n<p>Look for sunken eyes</p>\n<p>\u0089</p>\n<p>Offer the child fluid. Is the child:</p>\n<p>\u0089</p>\n<p>Unable to drink or drinks poorly?</p>\n<p>\u0089</p>\n<p>Thirsty, drinks eagerly?</p>\n<p>\u0089</p>\n<p>Pinch the skin of the abdomen. Does</p>\n<p>it go back:</p>\n<p>\u0089</p>\n<p>Very slowly? (>2 seconds)</p>\n<p>\u0089</p>\n<p>Slowly?</p>"
    },
    {
        "page_number": 897,
        "content": "831\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat as below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\nAny 2 of these \nsigns:\n \n~\nLethar\u00ad\ngic or \nuncon\u00ad\nscious\n \n~\nSunken \neyes\nSevere Dehy\u00ad\ndration\n\t\n\u0089\nIf child has no other se\u00ad\nvere classification, give \ndehydration Plan C (see \nsection 1.1.3)\n\t\n\u0089\nIf child also has another \nsevere classification:\n \n-\nGive pre-referral \ntreatment and \nrefer urgently \nwith mother \ngiving frequent \nsips of ORS on \nthe way\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nUnable \nto drink \nor drinks \npoorly\n \n~\nSkin \npinch \nreturns \nvery \nslowly \n(>2 sec\u00ad\nonds)\n \n-\nAdvise mother \nto continue \nbreastfeeding\n\t\n\u0089\nIf child is 2 years or older \nand there is cholera in \nyour area:\n\t\n\u0089\nGive 1st dose of erythro\u00ad\nmycin 125 mg (if child < \n2 years) or 250 mg (child \n2-5 years) every 6 hours \nfor 3 days\n\t\n\u0089\nEducate mother on hy\u00ad\ngiene and sanitation\nAny 2 of these \nsigns:\n \n~\nRestless, \nirritable\nSome Dehy\u00ad\ndration\n\t\n\u0089\nGive fluid, zinc supple\u00ad\nments, and food if possible \nSee Dehydration Plan B \n(see section 1.1.3)\n\t\n\u0089\nIf child also has a severe \nclassification:",
        "formatted_content": "<p>831</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>Any 2 of these</p>\n<p>signs:</p>\n<p>~</p>\n<p>Lethar\u00ad</p>\n<p>gic or</p>\n<p>uncon\u00ad</p>\n<p>scious</p>\n<p>~</p>\n<p>Sunken</p>\n<p>eyes</p>\n<p>Severe Dehy\u00ad</p>\n<p>dration</p>\n<p>\u0089</p>\n<p>If child has no other se\u00ad</p>\n<p>vere classification, give</p>\n<p>dehydration Plan C (see</p>\n<p>section 1.1.3)</p>\n<p>\u0089</p>\n<p>If child also has another</p>\n<p>severe classification:</p>\n<p>-</p>\n<p>Give pre-referral</p>\n<p>treatment and</p>\n<p>refer urgently</p>\n<p>with mother</p>\n<p>giving frequent</p>\n<p>sips of ORS on</p>\n<p>the way</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Unable</p>\n<p>to drink</p>\n<p>or drinks</p>\n<p>poorly</p>\n<p>~</p>\n<p>Skin</p>\n<p>pinch</p>\n<p>returns</p>\n<p>very</p>\n<p>slowly</p>\n<p>(>2 sec\u00ad</p>\n<p>onds)</p>\n<p>-</p>\n<p>Advise mother</p>\n<p>to continue</p>\n<p>breastfeeding</p>\n<p>\u0089</p>\n<p>If child is 2 years or older</p>\n<p>and there is cholera in</p>\n<p>your area:</p>\n<p>\u0089</p>\n<p>Give 1st dose of erythro\u00ad</p>\n<p>mycin 125 mg (if child <</p>\n<p>2 years) or 250 mg (child</p>\n<p>2-5 years) every 6 hours</p>\n<p>for 3 days</p>\n<p>\u0089</p>\n<p>Educate mother on hy\u00ad</p>\n<p>giene and sanitation</p>\n<p>Any 2 of these</p>\n<p>signs:</p>\n<p>~</p>\n<p>Restless,</p>\n<p>irritable</p>\n<p>Some Dehy\u00ad</p>\n<p>dration</p>\n<p>\u0089</p>\n<p>Give fluid, zinc supple\u00ad</p>\n<p>ments, and food if possible</p>\n<p>See Dehydration Plan B</p>\n<p>(see section 1.1.3)</p>\n<p>\u0089</p>\n<p>If child also has a severe</p>\n<p>classification:</p>"
    },
    {
        "page_number": 898,
        "content": "832\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nSunken \neyes \nThirsty, \ndrinks \neagerly\n \n~\nSkin \npinch \nreturns \nslowly\n \n-\nRefer \nURGENTLY to \nhospital with \nmother\n \n-\nGiving frequent \nsips of ORS on \nthe way\n \n-\nAdvise the mother \nto continue \nbreastfeeding f \nAdvise mother \nwhen to return \nimmediately \n\t\n\u0089\nFOLLOW UP in 5 days\n \n-\nIf better \n(diarrhoea \nstopped, less than \n3 loose stools\n \n-\nper day, praise \nmother and \nadvise her on \nfeeding)\n \n-\nIf not better (> 3 \nloose stools per \nday), reasses, treat \ndehydration and \nrefer\n\t\n\u0089\nEducate mother on hy\u00ad\ngiene and sanitation\n \n~\nNot \nenough \nsigns to \nclassi\u00ad\nfy as \nsome or \nsevere \ndehydra\u00ad\ntion\nNo Dehydra\u00ad\ntion\n\t\n\u0089\nGive fluid, zinc supple\u00ad\nments, and food to treat \ndiarrhoea at home (Plan \nA) (see section 1.1.3)\n\t\n\u0089\nAdvise mother when to \nreturn immediately",
        "formatted_content": "<p>832</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Sunken</p>\n<p>eyes</p>\n<p>Thirsty,</p>\n<p>drinks</p>\n<p>eagerly</p>\n<p>~</p>\n<p>Skin</p>\n<p>pinch</p>\n<p>returns</p>\n<p>slowly</p>\n<p>-</p>\n<p>Refer</p>\n<p>URGENTLY to</p>\n<p>hospital with</p>\n<p>mother</p>\n<p>-</p>\n<p>Giving frequent</p>\n<p>sips of ORS on</p>\n<p>the way</p>\n<p>-</p>\n<p>Advise the mother</p>\n<p>to continue</p>\n<p>breastfeeding f</p>\n<p>Advise mother</p>\n<p>when to return</p>\n<p>immediately</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 5 days</p>\n<p>-</p>\n<p>If better</p>\n<p>(diarrhoea</p>\n<p>stopped, less than</p>\n<p>3 loose stools</p>\n<p>-</p>\n<p>per day, praise</p>\n<p>mother and</p>\n<p>advise her on</p>\n<p>feeding)</p>\n<p>-</p>\n<p>If not better (> 3</p>\n<p>loose stools per</p>\n<p>day), reasses, treat</p>\n<p>dehydration and</p>\n<p>refer</p>\n<p>\u0089</p>\n<p>Educate mother on hy\u00ad</p>\n<p>giene and sanitation</p>\n<p>~</p>\n<p>Not</p>\n<p>enough</p>\n<p>signs to</p>\n<p>classi\u00ad</p>\n<p>fy as</p>\n<p>some or</p>\n<p>severe</p>\n<p>dehydra\u00ad</p>\n<p>tion</p>\n<p>No Dehydra\u00ad</p>\n<p>tion</p>\n<p>\u0089</p>\n<p>Give fluid, zinc supple\u00ad</p>\n<p>ments, and food to treat</p>\n<p>diarrhoea at home (Plan</p>\n<p>A) (see section 1.1.3)</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately</p>"
    },
    {
        "page_number": 899,
        "content": "833\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n\t\n\u0089\nFOLLOW UP in 5 days\n \n-\nIf better (diarrhoea \nstopped, less than \n3 loose stools per \nday, praise mother \nand advise her on \nfeeding)\n \n-\nIf not better (> 3 \nloose stools per \nday), reasses, treat \ndehydration and \nrefer\n\t\n\u0089\nContinue with breast feeding\n\t\n\u0089\nEducate mother on hygiene \nand sanitation\n \n~\nBlood in \nstool\nDysentery\n\t\n\u0089\nGive ciprofloxacin 15 mg/\nkg for 3 days for Shigella\n\t\n\u0089\nFOLLOW UP in 3 days\n \n-\nIf better (fewer \nstools, less blood \nin stool, less fever, \nless abdominal \npain, better feeding) \npraise the mother, \ncomplete the \nciprofloxacin and \nadvise on feeding\n \n-\nIf not better, refer\nDehydration \npresent\nSevere \nPersistent \nDiarrhoea\n\t\n\u0089\nGive vitamin A\n\t\n\u0089\nTreat dehydration before \nreferral (unless child has \nanother severe classification)\n\t\n\u0089\nRefer to hospital",
        "formatted_content": "<p>833</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>\u0089</p>\n<p>FOLLOW UP in 5 days</p>\n<p>-</p>\n<p>If better (diarrhoea</p>\n<p>stopped, less than</p>\n<p>3 loose stools per</p>\n<p>day, praise mother</p>\n<p>and advise her on</p>\n<p>feeding)</p>\n<p>-</p>\n<p>If not better (> 3</p>\n<p>loose stools per</p>\n<p>day), reasses, treat</p>\n<p>dehydration and</p>\n<p>refer</p>\n<p>\u0089</p>\n<p>Continue with breast feeding</p>\n<p>\u0089</p>\n<p>Educate mother on hygiene</p>\n<p>and sanitation</p>\n<p>~</p>\n<p>Blood in</p>\n<p>stool</p>\n<p>Dysentery</p>\n<p>\u0089</p>\n<p>Give ciprofloxacin 15 mg/</p>\n<p>kg for 3 days for Shigella</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 3 days</p>\n<p>-</p>\n<p>If better (fewer</p>\n<p>stools, less blood</p>\n<p>in stool, less fever,</p>\n<p>less abdominal</p>\n<p>pain, better feeding)</p>\n<p>praise the mother,</p>\n<p>complete the</p>\n<p>ciprofloxacin and</p>\n<p>advise on feeding</p>\n<p>-</p>\n<p>If not better, refer</p>\n<p>Dehydration</p>\n<p>present</p>\n<p>Severe</p>\n<p>Persistent</p>\n<p>Diarrhoea</p>\n<p>\u0089</p>\n<p>Give vitamin A</p>\n<p>\u0089</p>\n<p>Treat dehydration before</p>\n<p>referral (unless child has</p>\n<p>another severe classification)</p>\n<p>\u0089</p>\n<p>Refer to hospital</p>"
    },
    {
        "page_number": 900,
        "content": "834\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEA\u00ad\nTURES\nCLASSIFY \nAS\nMANAGEMENT\nIf diarrhoea for 14 days or more:\nNo dehydra\u00ad\ntion\nPersistent \nDiarrhoea\n\t\n\u0089\nAdvise mother on feeding child \nwith PERSISTENT DIARRHOEA\n\t\n\u0089\nGive vitamin A; multivitamins and \nminerals (including zinc) for 14 days\n\t\n\u0089\nFOLLOW UP in five days\n \n-\nIf better (diarrhoea \nstopped, less than 3 loose \nstools per day, praise \nmother and advise her on \nfeeding)\n \n-\nIf not better (> 3 loose \nstools per day), reasses, \ntreat dehydration and refer\n \n-\nIf symptoms are the same \nor worse, start treating \ndehydration if present and \nrefer to hospital\nNote:\n \n\u0083 The current recommendation for treatment of diarrhoea is \noral rehydration salts (ORS) and zinc salts (Zn sulphate, Zn \ngluconate or Zn acetate).\n \n- Give zinc for 10 days: Child < 6 months: 10 mg per day; \nChild > 6 months: 20 mg per day\n17.3.4  Check for Fever\nAsk\n \n~\nIf the child has fever\n \n- By history, feels hot, \nor temperature 37.5\u00b0C \n(see note 1 in table \nbelow)\n \n~\nIf yes, ask for how \nlong child has had \nthis\nLook and feel\n \n~\nLook/feel for stiff \nneck\n \n~\nLook for runny nose\n \n~\nLook for any \nbacterial cause of \nfever: local",
        "formatted_content": "<p>834</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEA\u00ad</h3>\n<h3>TURES</h3>\n<h3>CLASSIFY</h3>\n<p>AS</p>\n<h3>MANAGEMENT</h3>\n<p>If diarrhoea for 14 days or more:</p>\n<p>No dehydra\u00ad</p>\n<p>tion</p>\n<p>Persistent</p>\n<p>Diarrhoea</p>\n<p>\u0089</p>\n<p>Advise mother on feeding child</p>\n<p>with PERSISTENT DIARRHOEA</p>\n<p>\u0089</p>\n<p>Give vitamin A; multivitamins and</p>\n<p>minerals (including zinc) for 14 days</p>\n<p>\u0089</p>\n<p>FOLLOW UP in five days</p>\n<p>-</p>\n<p>If better (diarrhoea</p>\n<p>stopped, less than 3 loose</p>\n<p>stools per day, praise</p>\n<p>mother and advise her on</p>\n<p>feeding)</p>\n<p>-</p>\n<p>If not better (> 3 loose</p>\n<p>stools per day), reasses,</p>\n<p>treat dehydration and refer</p>\n<p>-</p>\n<p>If symptoms are the same</p>\n<p>or worse, start treating</p>\n<p>dehydration if present and</p>\n<p>refer to hospital</p>\n<p>Note:</p>\n<p>\u0083 The current recommendation for treatment of diarrhoea is</p>\n<p>oral rehydration salts (ORS) and zinc salts (Zn sulphate, Zn</p>\n<p>gluconate or Zn acetate).</p>\n<p>- Give zinc for 10 days: Child < 6 months: 10 mg per day;</p>\n<p>Child > 6 months: 20 mg per day</p>\n<p>17.3.4  Check for Fever</p>\n<p>Ask</p>\n<p>~</p>\n<p>If the child has fever</p>\n<p>- By history, feels hot,</p>\n<p>or temperature 37.5\u00b0C</p>\n<p>(see note 1 in table</p>\n<p>below)</p>\n<p>~</p>\n<p>If yes, ask for how</p>\n<p>long child has had</p>\n<p>this</p>\n<p>Look and feel</p>\n<p>~</p>\n<p>Look/feel for stiff</p>\n<p>neck</p>\n<p>~</p>\n<p>Look for runny nose</p>\n<p>~</p>\n<p>Look for any</p>\n<p>bacterial cause of</p>\n<p>fever: local</p>"
    },
    {
        "page_number": 901,
        "content": "835\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n \n-\nIf >7 days, ask if \nfever has been \npresent every day\n \n-\nAsk if the child has \nhad measles in the \nlast 3 months\n \n~\nDO MALARIA \nTEST in all fever \ncases\n \n~\ntenderness, oral \nsores, refusal to use \na limb, hot tender \nswelling, red tender \nskin or boils, lower \nabdominal pain or \npain on passing \nurine in older \nchildren\n \n~\nLook for signs of \nmeasles:\n \n~\nGeneralised rash\n \n~\nCough, runny nose, \nor red eyes\nIf child has measles now or \nhad measles in last 3 months\n \n~\nLook for mouth \nulcers-are they deep \nor extensive?\n \n~\nLook for pus \ndraining from the \neyes\n \n~\nLook for clouding of \nthe cornea\nClassify and treat as below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nAny \ngeneral \ndanger \nsign\n \n~\nStiff \nneck\nVery Severe Fe\u00ad\nbrile Disease\n\t\n\u0089\nGive 1st dose of rectal ar\u00ad\ntesunate (10 mg/kg) or IM/\nIV artesunate (3 mg/kg if \n< 20 kg, 2.4 mg/kg if > \n20 kg)  (see section 2.5.2)",
        "formatted_content": "<p>835</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>-</p>\n<p>If >7 days, ask if</p>\n<p>fever has been</p>\n<p>present every day</p>\n<p>-</p>\n<p>Ask if the child has</p>\n<p>had measles in the</p>\n<p>last 3 months</p>\n<p>~</p>\n<h3>DO MALARIA</h3>\n<p>TEST in all fever</p>\n<p>cases</p>\n<p>~</p>\n<p>tenderness, oral</p>\n<p>sores, refusal to use</p>\n<p>a limb, hot tender</p>\n<p>swelling, red tender</p>\n<p>skin or boils, lower</p>\n<p>abdominal pain or</p>\n<p>pain on passing</p>\n<p>urine in older</p>\n<p>children</p>\n<p>~</p>\n<p>Look for signs of</p>\n<p>measles:</p>\n<p>~</p>\n<p>Generalised rash</p>\n<p>~</p>\n<p>Cough, runny nose,</p>\n<p>or red eyes</p>\n<p>If child has measles now or</p>\n<p>had measles in last 3 months</p>\n<p>~</p>\n<p>Look for mouth</p>\n<p>ulcers-are they deep</p>\n<p>or extensive?</p>\n<p>~</p>\n<p>Look for pus</p>\n<p>draining from the</p>\n<p>eyes</p>\n<p>~</p>\n<p>Look for clouding of</p>\n<p>the cornea</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Any</p>\n<p>general</p>\n<p>danger</p>\n<p>sign</p>\n<p>~</p>\n<p>Stiff</p>\n<p>neck</p>\n<p>Very Severe Fe\u00ad</p>\n<p>brile Disease</p>\n<p>\u0089</p>\n<p>Give 1st dose of rectal ar\u00ad</p>\n<p>tesunate (10 mg/kg) or IM/</p>\n<p>IV artesunate (3 mg/kg if</p>\n<p>< 20 kg, 2.4 mg/kg if ></p>\n<p>20 kg)  (see section 2.5.2)</p>"
    },
    {
        "page_number": 902,
        "content": "836\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n\t\n\u0089\nGive 1st dose of appro\u00ad\npriate antibiotic for se\u00ad\nrious bacterial infection: \nampicillin 50 mg/Kg IM \nand gentamicin 7.5 mg/\nKg IM or\n \n- Benzylpenicillin \n50,000 IU/Kg IM if \nat HC2\n\t\n\u0089\nTreat child to prevent low \nblood sugar (breastfeed or \ngive expressed breast milk \nor breastmilk substitute or \nsugar water by cup or NGT)\n\t\n\u0089\nGive one dose of paraceta\u00ad\nmol 10 mg/kg for high \nfever (38.5\u00b0C)\n\t\n\u0089\nRefer urgently\n \n~\nMalaria \ntest \npositive\nMalaria\n\t\n\u0089\nGive 1st line malaria treat\u00ad\nment (oral ACT, see section \n2.5.2) \n\t\n\u0089\nGive one dose of paraceta\u00ad\nmol 10 mg/kg for high \nfever (38.5\u00b0C)\n\t\n\u0089\nIf a bacterial infection is \nalso identified, give appro\u00ad\npriate antibiotic treatment\n\t\n\u0089\nAdvise mother when to \nreturn immediately, coun\u00ad\nsel on use of insecticide \ntreated mosquito nets and \neducate on environmental \nsanitation",
        "formatted_content": "<p>836</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>\u0089</p>\n<p>Give 1st dose of appro\u00ad</p>\n<p>priate antibiotic for se\u00ad</p>\n<p>rious bacterial infection:</p>\n<p>ampicillin 50 mg/Kg IM</p>\n<p>and gentamicin 7.5 mg/</p>\n<p>Kg IM or</p>\n<p>- Benzylpenicillin</p>\n<p>50,000 IU/Kg IM if</p>\n<p>at HC2</p>\n<p>\u0089</p>\n<p>Treat child to prevent low</p>\n<p>blood sugar (breastfeed or</p>\n<p>give expressed breast milk</p>\n<p>or breastmilk substitute or</p>\n<p>sugar water by cup or NGT)</p>\n<p>\u0089</p>\n<p>Give one dose of paraceta\u00ad</p>\n<p>mol 10 mg/kg for high</p>\n<p>fever (38.5\u00b0C)</p>\n<p>\u0089</p>\n<p>Refer urgently</p>\n<p>~</p>\n<p>Malaria</p>\n<p>test</p>\n<p>positive</p>\n<p>Malaria</p>\n<p>\u0089</p>\n<p>Give 1st line malaria treat\u00ad</p>\n<p>ment (oral ACT, see section</p>\n<p>2.5.2)</p>\n<p>\u0089</p>\n<p>Give one dose of paraceta\u00ad</p>\n<p>mol 10 mg/kg for high</p>\n<p>fever (38.5\u00b0C)</p>\n<p>\u0089</p>\n<p>If a bacterial infection is</p>\n<p>also identified, give appro\u00ad</p>\n<p>priate antibiotic treatment</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately, coun\u00ad</p>\n<p>sel on use of insecticide</p>\n<p>treated mosquito nets and</p>\n<p>educate on environmental</p>\n<p>sanitation</p>"
    },
    {
        "page_number": 903,
        "content": "837\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n\t\n\u0089\nFOLLOW UP in 3 days if \nfever persists:\n \n- Do a full \nreassessment and \nlook for other causes \nof fever\n \n- Check that the \nchild has completed \nthe full course of \nantimalarials (without \nvomiting any dose)\n \n- Do not repeat RDT if \nit was positive on the \ninitial visit\n \n- If no danger sign, \nno other apparent \ncause of fever and \nantimalarial treatment \nwas given correctly, \nrefer for microscopy \nand/or second line \nantimalarial\n\t\n\u0089\nIf fever every day for >7days, \nrefer for assessment\n \n~\nMalaria \ntest \nNegative\nFever\nNo Malaria\n\t\n\u0089\nGive one dose of paraceta\u00ad\nmol 10 mg/Kg in child with \nhigh fever (38.5oC)\n\t\n\u0089\nIf a bacterial infection is \nidentified, give appropriate \nantibiotic treatment\n\t\n\u0089\nIf no bacterial infection iden\u00ad\ntified, reassure, give par\u00ad\nacetamol, advise to come \nback in 3 days or in case \nof any problem",
        "formatted_content": "<p>837</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>\u0089</p>\n<p>FOLLOW UP in 3 days if</p>\n<p>fever persists:</p>\n<p>- Do a full</p>\n<p>reassessment and</p>\n<p>look for other causes</p>\n<p>of fever</p>\n<p>- Check that the</p>\n<p>child has completed</p>\n<p>the full course of</p>\n<p>antimalarials (without</p>\n<p>vomiting any dose)</p>\n<p>- Do not repeat RDT if</p>\n<p>it was positive on the</p>\n<p>initial visit</p>\n<p>- If no danger sign,</p>\n<p>no other apparent</p>\n<p>cause of fever and</p>\n<p>antimalarial treatment</p>\n<p>was given correctly,</p>\n<p>refer for microscopy</p>\n<p>and/or second line</p>\n<p>antimalarial</p>\n<p>\u0089</p>\n<p>If fever every day for >7days,</p>\n<p>refer for assessment</p>\n<p>~</p>\n<p>Malaria</p>\n<p>test</p>\n<p>Negative</p>\n<p>Fever</p>\n<p>No Malaria</p>\n<p>\u0089</p>\n<p>Give one dose of paraceta\u00ad</p>\n<p>mol 10 mg/Kg in child with</p>\n<p>high fever (38.5oC)</p>\n<p>\u0089</p>\n<p>If a bacterial infection is</p>\n<p>identified, give appropriate</p>\n<p>antibiotic treatment</p>\n<p>\u0089</p>\n<p>If no bacterial infection iden\u00ad</p>\n<p>tified, reassure, give par\u00ad</p>\n<p>acetamol, advise to come</p>\n<p>back in 3 days or in case</p>\n<p>of any problem</p>"
    },
    {
        "page_number": 904,
        "content": "838\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n\t\n\u0089\nAdvise mother when to \nreturn immediately and \ncounsel on use of insec\u00ad\nticide treated mosquito \nnet and educate on en\u00ad\nvironmental sanitation.\n\t\n\u0089\nFOLLOW UP in 3 days \nif fever persists\n\t\n\u0089\nReassess the child for \ndanger signs and other \npossible causes of fever\n \n- Repeat the malaria \ntest and treat if \npositive\n \n- If \nno \napparent \ncause of fever, refer\n \n- If fever every day \nfor >7days, refer \nfor assessment",
        "formatted_content": "<p>838</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately and</p>\n<p>counsel on use of insec\u00ad</p>\n<p>ticide treated mosquito</p>\n<p>net and educate on en\u00ad</p>\n<p>vironmental sanitation.</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 3 days</p>\n<p>if fever persists</p>\n<p>\u0089</p>\n<p>Reassess the child for</p>\n<p>danger signs and other</p>\n<p>possible causes of fever</p>\n<p>- Repeat the malaria</p>\n<p>test and treat if</p>\n<p>positive</p>\n<p>- If</p>\n<p>no</p>\n<p>apparent</p>\n<p>cause of fever, refer</p>\n<p>- If fever every day</p>\n<p>for >7days, refer</p>\n<p>for assessment</p>"
    },
    {
        "page_number": 905,
        "content": "839\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\nIf measles now or in last 3 months, classify as:\n \n~\nAny general \ndanger sign\n \n~\nClouding of \ncornea\n \n~\nDeep or \nextensive \nmouth ulcers\nSevere Compli\u00ad\ncated Measles\n\t\n\u0089\nGive vitamin A\n\t\n\u0089\nGive 1st dose of appropriate antibiotic for severe \nbacterial infection: ampicillin 50 mg/Kg IM and \ngentamicin 7.5 mg/Kg IM or\n \n- Benzylpenicillin 50,000 IU/Kg IM if at HC2\n\t\n\u0089\nIf clouding of cornea or pus draining from eye: apply \ntetracycline eye ointment\n\t\n\u0089\nREFER URGENTLY to hospital\n \n~\nStridor\n \n~\nDifficulty in \nbreathing\n \n~\nDiarrhoea\n \n~\nAcute \nmalnutrition\n \n~\nEar problem\nComplicated \nMeasles\n\t\n\u0089\nRefer to the relevant IMCI sections",
        "formatted_content": "<p>839</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>If measles now or in last 3 months, classify as:</p>\n<p>~</p>\n<p>Any general</p>\n<p>danger sign</p>\n<p>~</p>\n<p>Clouding of</p>\n<p>cornea</p>\n<p>~</p>\n<p>Deep or</p>\n<p>extensive</p>\n<p>mouth ulcers</p>\n<p>Severe Compli\u00ad</p>\n<p>cated Measles</p>\n<p>\u0089</p>\n<p>Give vitamin A</p>\n<p>\u0089</p>\n<p>Give 1st dose of appropriate antibiotic for severe</p>\n<p>bacterial infection: ampicillin 50 mg/Kg IM and</p>\n<p>gentamicin 7.5 mg/Kg IM or</p>\n<p>- Benzylpenicillin 50,000 IU/Kg IM if at HC2</p>\n<p>\u0089</p>\n<p>If clouding of cornea or pus draining from eye: apply</p>\n<p>tetracycline eye ointment</p>\n<p>\u0089</p>\n<p>REFER URGENTLY to hospital</p>\n<p>~</p>\n<p>Stridor</p>\n<p>~</p>\n<p>Difficulty in</p>\n<p>breathing</p>\n<p>~</p>\n<p>Diarrhoea</p>\n<p>~</p>\n<p>Acute</p>\n<p>malnutrition</p>\n<p>~</p>\n<p>Ear problem</p>\n<p>Complicated</p>\n<p>Measles</p>\n<p>\u0089</p>\n<p>Refer to the relevant IMCI sections</p>"
    },
    {
        "page_number": 906,
        "content": "840\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nPus draining \nfrom eye\n \n~\nMouth ulcers\nMeasles + Eye Or \nMouth\nComplications\n\t\n\u0089\nGive vitamin A\n\t\n\u0089\nIf pus draining from eye: Apply tetracycline eye ointment\n\t\n\u0089\nIf mouth ulcers, apply gentian violet paint\n\t\n\u0089\nFOLLOW UP in three days\n\t\n\u0089\nIf eyes still discharging pus and treatment has been \ngiven correctly, refer. If eyes only red or better, com\u00ad\nplete treatment\n\t\n\u0089\nIf mouth ulcers/thrush are the same or better, con\u00ad\ntinue treatment. If worse and/or child has problem \nswallowing, refer\n \n~\nMeasles now \nor \nin \nthe \nlast \nthree \nmonths\nMeasles\n\t\n\u0089\nGive Vitamin A  (see section 2.3.3)\nNote:\n \n\u0081\nBody temperatures are based on axillary measurement. Rectal readings are approximately 0.5\u00b0C \nhigher\n \n\u0081\nFor doses of Vitamin A, Gentian violet and Tetracycline ointment see section 17.3.10.2",
        "formatted_content": "<p>840</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Pus draining</p>\n<p>from eye</p>\n<p>~</p>\n<p>Mouth ulcers</p>\n<p>Measles + Eye Or</p>\n<p>Mouth</p>\n<p>Complications</p>\n<p>\u0089</p>\n<p>Give vitamin A</p>\n<p>\u0089</p>\n<p>If pus draining from eye: Apply tetracycline eye ointment</p>\n<p>\u0089</p>\n<p>If mouth ulcers, apply gentian violet paint</p>\n<p>\u0089</p>\n<p>FOLLOW UP in three days</p>\n<p>\u0089</p>\n<p>If eyes still discharging pus and treatment has been</p>\n<p>given correctly, refer. If eyes only red or better, com\u00ad</p>\n<p>plete treatment</p>\n<p>\u0089</p>\n<p>If mouth ulcers/thrush are the same or better, con\u00ad</p>\n<p>tinue treatment. If worse and/or child has problem</p>\n<p>swallowing, refer</p>\n<p>~</p>\n<p>Measles now</p>\n<p>or</p>\n<p>in</p>\n<p>the</p>\n<p>last</p>\n<p>three</p>\n<p>months</p>\n<p>Measles</p>\n<p>\u0089</p>\n<p>Give Vitamin A  (see section 2.3.3)</p>\n<p>Note:</p>\n<p>\u0081</p>\n<p>Body temperatures are based on axillary measurement. Rectal readings are approximately 0.5\u00b0C</p>\n<p>higher</p>\n<p>\u0081</p>\n<p>For doses of Vitamin A, Gentian violet and Tetracycline ointment see section 17.3.10.2</p>"
    },
    {
        "page_number": 907,
        "content": "841\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.3.5   Check for Ear Problem\nAsk\n \n~\nDoes the child have \nan ear problem?\n \n~\nIf yes,\n \n~\nDoes the child have \near pain?\n \n~\nIs there discharge:\n \n~\nIf yes, ask for how \nlong\nLook and feel\n \n~\nLook for pus drain\u00ad\ning from the ear\n \n~\nFeel for tender swell\u00ad\ning behind the ear\nClassify and treat as below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nTender \nswelling \nbehind \nthe ear\nMastoiditis\n \n~\nGive 1st dose of appro\u00ad\npriate antibiotic ampi\u00ad\ncillin 50 mg/ Kg IM and \ngentamicin 7.5 mg/Kg \nIM or\n \n- Benzylpenicillin 50,000 \nIU/Kg IM\n \n- Amoxicillin DT 40 mg/\nkg if parenteral not \navailable f Give 1st dose of \nparacetamol 10 mg/kg for \npain f REFER URGENTLY\n \n~\nEar pain\n \n~\nPus seen \ndraining\nAcute Ear \nInfection\n \n~\nGive amoxicillin DT 40 \nmg/kg every 12 hours \nfor 5 days\n \n~\nGive paracetamol 10 \nmg/kg for pain\n \n~\nDry ear by wicking",
        "formatted_content": "<p>841</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.3.5   Check for Ear Problem</p>\n<p>Ask</p>\n<p>~</p>\n<p>Does the child have</p>\n<p>an ear problem?</p>\n<p>~</p>\n<p>If yes,</p>\n<p>~</p>\n<p>Does the child have</p>\n<p>ear pain?</p>\n<p>~</p>\n<p>Is there discharge:</p>\n<p>~</p>\n<p>If yes, ask for how</p>\n<p>long</p>\n<p>Look and feel</p>\n<p>~</p>\n<p>Look for pus drain\u00ad</p>\n<p>ing from the ear</p>\n<p>~</p>\n<p>Feel for tender swell\u00ad</p>\n<p>ing behind the ear</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Tender</p>\n<p>swelling</p>\n<p>behind</p>\n<p>the ear</p>\n<p>Mastoiditis</p>\n<p>~</p>\n<p>Give 1st dose of appro\u00ad</p>\n<p>priate antibiotic ampi\u00ad</p>\n<p>cillin 50 mg/ Kg IM and</p>\n<p>gentamicin 7.5 mg/Kg</p>\n<p>IM or</p>\n<p>- Benzylpenicillin 50,000</p>\n<p>IU/Kg IM</p>\n<p>- Amoxicillin DT 40 mg/</p>\n<p>kg if parenteral not</p>\n<p>available f Give 1st dose of</p>\n<p>paracetamol 10 mg/kg for</p>\n<p>pain f REFER URGENTLY</p>\n<p>~</p>\n<p>Ear pain</p>\n<p>~</p>\n<p>Pus seen</p>\n<p>draining</p>\n<p>Acute Ear</p>\n<p>Infection</p>\n<p>~</p>\n<p>Give amoxicillin DT 40</p>\n<p>mg/kg every 12 hours</p>\n<p>for 5 days</p>\n<p>~</p>\n<p>Give paracetamol 10</p>\n<p>mg/kg for pain</p>\n<p>~</p>\n<p>Dry ear by wicking</p>"
    },
    {
        "page_number": 908,
        "content": "842\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.3.6  Check for Malnutrition and Feeding Problems\nAsk\n \n~\nIf child \u00a3 6 m, \nask if the child \nhas breasfeed\u00ad\ning problem \n(how many \ntimes a day, \netc)\n \n~\nIf child \u00b3 6 \nmonths, ask if\n \n~\nchild is able to \nfinish his por\u00ad\ntions (appetite)\n \n~\nAsk about \nusual feeding \nhabits\n \n~\nWhich foods \nare available at \nhome\n \n~\nWhat does the \nchild eat\n \n~\nHow many \ntimes a day\n \n~\nDoes the child \nreceive his/her \nown serving\nLook and feel\n \n~\nLook for signs of acute mal\u00ad\nnutrition like\n \n- Oedema on both feet\n \n- Determine weight for height/\nlength (WFH/L) using WHO \ngrowth charts standards (see \nend of this chapter)\n \n- As an alternative, determine \nweight for age (WFA) using \nWHO growth chart standard\n \n- Measure MUAC (Mid Upper \nArm \nCircumference) \nin \nchildren \u00b3 6 months using \nMUAC tape\nIf WFH/L is less than -3 z-scores or \nMUAC < 115 mm, then\n \n~\nCheck for any medical com\u00ad\nplication present\n \n- Any general danger sign\n \n- Any severe classification\n \n- Pneumonia or chest indrawing\nIf no medical complication presents,\n \n~\nChild \u00b3 6 months: assess \nchild appetite\n \n- offer RUTF (Ready to Use \nTherapeutic Food) and assess \nif child able to finish the \nportion or not\n \n~\nChild \u00a3 6 month: assess \nbreastfeeding",
        "formatted_content": "<p>842</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.3.6  Check for Malnutrition and Feeding Problems</p>\n<p>Ask</p>\n<p>~</p>\n<p>If child \u00a3 6 m,</p>\n<p>ask if the child</p>\n<p>has breasfeed\u00ad</p>\n<p>ing problem</p>\n<p>(how many</p>\n<p>times a day,</p>\n<p>etc)</p>\n<p>~</p>\n<p>If child \u00b3 6</p>\n<p>months, ask if</p>\n<p>~</p>\n<p>child is able to</p>\n<p>finish his por\u00ad</p>\n<p>tions (appetite)</p>\n<p>~</p>\n<p>Ask about</p>\n<p>usual feeding</p>\n<p>habits</p>\n<p>~</p>\n<p>Which foods</p>\n<p>are available at</p>\n<p>home</p>\n<p>~</p>\n<p>What does the</p>\n<p>child eat</p>\n<p>~</p>\n<p>How many</p>\n<p>times a day</p>\n<p>~</p>\n<p>Does the child</p>\n<p>receive his/her</p>\n<p>own serving</p>\n<p>Look and feel</p>\n<p>~</p>\n<p>Look for signs of acute mal\u00ad</p>\n<p>nutrition like</p>\n<p>- Oedema on both feet</p>\n<p>- Determine weight for height/</p>\n<p>length (WFH/L) using WHO</p>\n<p>growth charts standards (see</p>\n<p>end of this chapter)</p>\n<p>- As an alternative, determine</p>\n<p>weight for age (WFA) using</p>\n<p>WHO growth chart standard</p>\n<p>- Measure MUAC (Mid Upper</p>\n<p>Arm</p>\n<p>Circumference)</p>\n<p>in</p>\n<p>children \u00b3 6 months using</p>\n<p>MUAC tape</p>\n<p>If WFH/L is less than -3 z-scores or</p>\n<p>MUAC < 115 mm, then</p>\n<p>~</p>\n<p>Check for any medical com\u00ad</p>\n<p>plication present</p>\n<p>- Any general danger sign</p>\n<p>- Any severe classification</p>\n<p>- Pneumonia or chest indrawing</p>\n<p>If no medical complication presents,</p>\n<p>~</p>\n<p>Child \u00b3 6 months: assess</p>\n<p>child appetite</p>\n<p>- offer RUTF (Ready to Use</p>\n<p>Therapeutic Food) and assess</p>\n<p>if child able to finish the</p>\n<p>portion or not</p>\n<p>~</p>\n<p>Child \u00a3 6 month: assess</p>\n<p>breastfeeding</p>"
    },
    {
        "page_number": 909,
        "content": "843\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClassify and treat as directed below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nOedema of \nboth feet OR\n \n~\nWFH/L less \nthan -3 z \nscores\nor\n \n~\nMUAC less \nthan 115 \nmm or\n \n~\nVisible \nsevere \nwasting \nAND\n \n~\nAny one \nof the \nfollowing:\n \n- Medical \ncomplication \npresent\nOR\n \n- not able to \nfinish RUTF \nOR\n \n- Breastfeeding \nproblem\n \n~\nWFH/L less \nthan \n-3 \nz \nscores \nOR \nMUAC less \nthan \n115 \nmm\nComplicat\u00ad\ned Severe \nAcute Mal\u00ad\nnutrition\nUncompli\u00ad\ncated Severe \nAcute Mal\u00ad\nnutrition\n\t\n\u0089\nGive first dose appro\u00ad\npriate antibiotic (am\u00ad\npicillin 50 mg/Kg IM \nand gentamicin 7.5 \nmg/Kg IM or\n \n- Benzylpenicillin \n50,000 IU/Kg \nIM\n\t\n\u0089\nTreat the child to pre\u00ad\nvent low blood\n\t\n\u0089\nsugar (breastfeed or \ngive expressed breast \nmilk or sugar water by \ncup or NGT)\n\t\n\u0089\nKeep the child warm\n\t\n\u0089\nRefer URGENTLY to \nhospital\n\t\n\u0089\nGive oral antibiotics \namoxicillin DT for 5 \ndays (40 mg/kg twice \na day)\n\t\n\u0089\nGive ready-to-use ther\u00ad\napeutic food (RUTF) \nfor",
        "formatted_content": "<p>843</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Classify and treat as directed below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Oedema of</p>\n<p>both feet OR</p>\n<p>~</p>\n<p>WFH/L less</p>\n<p>than -3 z</p>\n<p>scores</p>\n<p>or</p>\n<p>~</p>\n<p>MUAC less</p>\n<p>than 115</p>\n<p>mm or</p>\n<p>~</p>\n<p>Visible</p>\n<p>severe</p>\n<p>wasting</p>\n<h3>AND</h3>\n<p>~</p>\n<p>Any one</p>\n<p>of the</p>\n<p>following:</p>\n<p>- Medical</p>\n<p>complication</p>\n<p>present</p>\n<p>OR</p>\n<p>- not able to</p>\n<p>finish RUTF</p>\n<p>OR</p>\n<p>- Breastfeeding</p>\n<p>problem</p>\n<p>~</p>\n<p>WFH/L less</p>\n<p>than</p>\n<p>-3</p>\n<p>z</p>\n<p>scores</p>\n<p>OR</p>\n<p>MUAC less</p>\n<p>than</p>\n<p>115</p>\n<p>mm</p>\n<p>Complicat\u00ad</p>\n<p>ed Severe</p>\n<p>Acute Mal\u00ad</p>\n<p>nutrition</p>\n<p>Uncompli\u00ad</p>\n<p>cated Severe</p>\n<p>Acute Mal\u00ad</p>\n<p>nutrition</p>\n<p>\u0089</p>\n<p>Give first dose appro\u00ad</p>\n<p>priate antibiotic (am\u00ad</p>\n<p>picillin 50 mg/Kg IM</p>\n<p>and gentamicin 7.5</p>\n<p>mg/Kg IM or</p>\n<p>- Benzylpenicillin</p>\n<p>50,000 IU/Kg</p>\n<p>IM</p>\n<p>\u0089</p>\n<p>Treat the child to pre\u00ad</p>\n<p>vent low blood</p>\n<p>\u0089</p>\n<p>sugar (breastfeed or</p>\n<p>give expressed breast</p>\n<p>milk or sugar water by</p>\n<p>cup or NGT)</p>\n<p>\u0089</p>\n<p>Keep the child warm</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to</p>\n<p>hospital</p>\n<p>\u0089</p>\n<p>Give oral antibiotics</p>\n<p>amoxicillin DT for 5</p>\n<p>days (40 mg/kg twice</p>\n<p>a day)</p>\n<p>\u0089</p>\n<p>Give ready-to-use ther\u00ad</p>\n<p>apeutic food (RUTF)</p>\n<p>for</p>"
    },
    {
        "page_number": 910,
        "content": "844\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nOr very \nlow \nweight \nfor age\nAND\n \n~\nAble to \nfinish \nRUTF\n \n~\nWFH/L \nbetween \n-3 \nand -2 \nz-scores\nOR \n \n~\nMUAC \n115 up \nto 125 \nmm\n \n~\nOr low \nweight \nfor age\n(SAM)\nSee section 19.2.2.2 \nfor more details\nModerate  Acute \nMalnutrition (MAM)\nSee section 19.2.2.1 \nfor more details\n\t\n\u0089\na child aged 6 months \nor more\n\t\n\u0089\nCounsel the mother on \nhow to feed the child\n\t\n\u0089\nAssess for possible TB \ninfection\n\t\n\u0089\nAdvise mother when to \nreturn immediately\n\t\n\u0089\nFOLLOW UP in 7 days\n \n- Reassess child \nand feeding. If \nno new problem, \nreview again in 7 \ndays.\n\t\n\u0089\nFOLLOW UP in 14 days\n \n- Reassess and \nreclassify and \ncontinue feeding. \nKeep checking \nevery 14 days\n\t\n\u0089\nAssess the child\u2019s \nfeeding and counsel the \nmother on the feeding \nrecommendations\n\t\n\u0089\nIf feeding problem, \ncounsel and FOLLOW \nUP in 7 days\n\t\n\u0089\nAssess for possible TB \ninfection.\n\t\n\u0089\nAdvise mother when to \nreturn immediately\n\t\n\u0089\nFOLLOW UP in 30 \ndays\n \n- Reassess and \nreclassify.",
        "formatted_content": "<p>844</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Or very</p>\n<p>low</p>\n<p>weight</p>\n<p>for age</p>\n<h3>AND</h3>\n<p>~</p>\n<p>Able to</p>\n<p>finish</p>\n<h3>RUTF</h3>\n<p>~</p>\n<h3>WFH/L</h3>\n<p>between</p>\n<p>-3</p>\n<p>and -2</p>\n<p>z-scores</p>\n<p>OR</p>\n<p>~</p>\n<h3>MUAC</h3>\n<p>115 up</p>\n<p>to 125</p>\n<p>mm</p>\n<p>~</p>\n<p>Or low</p>\n<p>weight</p>\n<p>for age</p>\n<h3>(SAM)</h3>\n<p>See section 19.2.2.2</p>\n<p>for more details</p>\n<p>Moderate  Acute</p>\n<p>Malnutrition (MAM)</p>\n<p>See section 19.2.2.1</p>\n<p>for more details</p>\n<p>\u0089</p>\n<p>a child aged 6 months</p>\n<p>or more</p>\n<p>\u0089</p>\n<p>Counsel the mother on</p>\n<p>how to feed the child</p>\n<p>\u0089</p>\n<p>Assess for possible TB</p>\n<p>infection</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 7 days</p>\n<p>- Reassess child</p>\n<p>and feeding. If</p>\n<p>no new problem,</p>\n<p>review again in 7</p>\n<p>days.</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 14 days</p>\n<p>- Reassess and</p>\n<p>reclassify and</p>\n<p>continue feeding.</p>\n<p>Keep checking</p>\n<p>every 14 days</p>\n<p>\u0089</p>\n<p>Assess the child\u2019s</p>\n<p>feeding and counsel the</p>\n<p>mother on the feeding</p>\n<p>recommendations</p>\n<p>\u0089</p>\n<p>If feeding problem,</p>\n<p>counsel and FOLLOW</p>\n<p>UP in 7 days</p>\n<p>\u0089</p>\n<p>Assess for possible TB</p>\n<p>infection.</p>\n<p>\u0089</p>\n<p>Advise mother when to</p>\n<p>return immediately</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 30</p>\n<p>days</p>\n<p>- Reassess and</p>\n<p>reclassify.</p>"
    },
    {
        "page_number": 911,
        "content": "845\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nClinical Features\nClassify As\nManagement\n \n-\nteIrf,bpertaise \nthe mother \nand counsel on \nnutrition.\n \n-\nIf still moderate \nmalnutrition, \ncounsel and\nFOLLOW UP in one \nmonth\n \n-\nIf worse, \nloosing weight, \nfeeding \nproblem: refer\n \n~\nWF\u00ad\nH/L - 2 \nz-scores \nor more\n \n~\nOR \nMUAC \n125 mm \nor more\nno acute Mal\u00ad\nnutrition\n\t\n\u0089\nIf child is < 2 years \nold, assess the child\u2019s \nfeeding and counsel the \nmother on feeding ac\u00ad\ncording to the feeding \nrecommendations\n\t\n\u0089\nIf feeding problem, \nFOLLOW UP in 7 days\n \n- Reassess and \ncounsel\n\t\n\u0089\nIf you advise the moth\u00ad\ner to make significant \nchanges in feeding, ask \nher to bring the child \nback again after 30 days \nto measure the weight\nNote:\n \n\u0083 WFH/L \nis \nWeight-for-Height \nor \nWeight-for-Length \ndetermined by using the WHO growth standards charts\n \n\u0083 MUAC is Mid-Upper Arm Circumference measured using \nMUAC tape in all children \u00b3 6 months",
        "formatted_content": "<p>845</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Clinical Features</p>\n<p>Classify As</p>\n<p>Management</p>\n<p>-</p>\n<p>teIrf,bpertaise</p>\n<p>the mother</p>\n<p>and counsel on</p>\n<p>nutrition.</p>\n<p>-</p>\n<p>If still moderate</p>\n<p>malnutrition,</p>\n<p>counsel and</p>\n<p>FOLLOW UP in one</p>\n<p>month</p>\n<p>-</p>\n<p>If worse,</p>\n<p>loosing weight,</p>\n<p>feeding</p>\n<p>problem: refer</p>\n<p>~</p>\n<h3>WF\u00ad</h3>\n<h3>H/L - 2</h3>\n<p>z-scores</p>\n<p>or more</p>\n<p>~</p>\n<p>OR</p>\n<h3>MUAC</h3>\n<p>125 mm</p>\n<p>or more</p>\n<p>no acute Mal\u00ad</p>\n<p>nutrition</p>\n<p>\u0089</p>\n<p>If child is < 2 years</p>\n<p>old, assess the child\u2019s</p>\n<p>feeding and counsel the</p>\n<p>mother on feeding ac\u00ad</p>\n<p>cording to the feeding</p>\n<p>recommendations</p>\n<p>\u0089</p>\n<p>If feeding problem,</p>\n<p>FOLLOW UP in 7 days</p>\n<p>- Reassess and</p>\n<p>counsel</p>\n<p>\u0089</p>\n<p>If you advise the moth\u00ad</p>\n<p>er to make significant</p>\n<p>changes in feeding, ask</p>\n<p>her to bring the child</p>\n<p>back again after 30 days</p>\n<p>to measure the weight</p>\n<p>Note:</p>\n<h3>\u0083 WFH/L</h3>\n<p>is</p>\n<p>Weight-for-Height</p>\n<p>or</p>\n<p>Weight-for-Length</p>\n<p>determined by using the WHO growth standards charts</p>\n<p>\u0083 MUAC is Mid-Upper Arm Circumference measured using</p>\n<p>MUAC tape in all children \u00b3 6 months</p>"
    },
    {
        "page_number": 912,
        "content": "846\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n \n\u0083 RUTF is Ready-to-Use Therapeutic Food for conducting \nthe appetite test and feeding children with severe acute \nmalnutrition. For doses and more information see chapter \n19.\n \n\u0083 RUTF already contains all the necessary vitamins and \nminerals (folic acid, iron etc) so there is no need of additional \nsupplements\n17.3.7  Check for Anaemia\nAsk\n \n~\nIn appropriate local \nlanguage, ask if \npresence of sickle \ncell anaemia in the \nfamily\nLook\n \n~\nLook for palmar pal\u00ad\nlor. Is it\n \n~\nSevere palmar pallor?\n \n~\nSome palmar pallor?\nClassify and treat as below\nCLINICAL FEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nSevere \npalmar \npallor\nSevere \nAnaemia\n\t\n\u0089\nRefer URGENTLY to \nhospital\n \n~\nSome \npalmar \npallor\nAnaemia\n\t\n\u0089\nGive ferrous sulphate \u00bd tab/\nday if 1-5 years, 1 ml of syrup/\nday if 2-12 months\n \n- If child has severe acute \nmalnutrition and is \nreceiving\nRUTF, DO NOT give \niron because there \nis already adequate \namount of iron in \nRUTF)\n\t\n\u0089\nGive folic acid 2.5 mg/daily in \nchild with sickle cell anaemia",
        "formatted_content": "<p>846</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>\u0083 RUTF is Ready-to-Use Therapeutic Food for conducting</p>\n<p>the appetite test and feeding children with severe acute</p>\n<p>malnutrition. For doses and more information see chapter</p>\n<p>19.</p>\n<p>\u0083 RUTF already contains all the necessary vitamins and</p>\n<p>minerals (folic acid, iron etc) so there is no need of additional</p>\n<p>supplements</p>\n<p>17.3.7  Check for Anaemia</p>\n<p>Ask</p>\n<p>~</p>\n<p>In appropriate local</p>\n<p>language, ask if</p>\n<p>presence of sickle</p>\n<p>cell anaemia in the</p>\n<p>family</p>\n<p>Look</p>\n<p>~</p>\n<p>Look for palmar pal\u00ad</p>\n<p>lor. Is it</p>\n<p>~</p>\n<p>Severe palmar pallor?</p>\n<p>~</p>\n<p>Some palmar pallor?</p>\n<p>Classify and treat as below</p>\n<h3>CLINICAL FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Severe</p>\n<p>palmar</p>\n<p>pallor</p>\n<p>Severe</p>\n<p>Anaemia</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to</p>\n<p>hospital</p>\n<p>~</p>\n<p>Some</p>\n<p>palmar</p>\n<p>pallor</p>\n<p>Anaemia</p>\n<p>\u0089</p>\n<p>Give ferrous sulphate \u00bd tab/</p>\n<p>day if 1-5 years, 1 ml of syrup/</p>\n<p>day if 2-12 months</p>\n<p>- If child has severe acute</p>\n<p>malnutrition and is</p>\n<p>receiving</p>\n<p>RUTF, DO NOT give</p>\n<p>iron because there</p>\n<p>is already adequate</p>\n<p>amount of iron in</p>\n<h3>RUTF)</h3>\n<p>\u0089</p>\n<p>Give folic acid 2.5 mg/daily in</p>\n<p>child with sickle cell anaemia</p>"
    },
    {
        "page_number": 913,
        "content": "847\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nCLINICAL FEA\u00ad\nTURES\nCLASSIFY AS\nMANAGEMENT\n\t\n\u0089\nGive mebendazole if child is \n1 year or older and has not \nhad a dose in the previous \n6 months\n\t\n\u0089\nAdvise mother when to re\u00ad\nturn immediately\n\t\n\u0089\nFOLLOW UP in 14 days:\n\u2013\tReview and give iron tablets \nevery two weeks\n\u2013\tIf child still has palmar pal\u00ad\nlor after two months, refer\n\u2013\tIf better, continue iron \ntreatment for three \nmonths after Hb has \nnormalized\n \n~\nN o \np a l \u00ad\nm a r \np a l \u00ad\nlor\nNo Anaemia\n\t\n\u0089\nIf child is less than two years \nold, assess the child\u2019s feed\u00ad\ning and counsel the mother \naccording to the feeding \nrecommendation\n\t\n\u0089\nIf feeding problem, FOLLOW \nUP in five days\n Check for HIV Infection\nAsk\n \n~\nIs the child already enrolled in HIV care?\nIf not, ask\n \n~\nHas the mother or child had an HIV test?",
        "formatted_content": "<p>847</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>CLINICAL FEA\u00ad</h3>\n<h3>TURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>\u0089</p>\n<p>Give mebendazole if child is</p>\n<p>1 year or older and has not</p>\n<p>had a dose in the previous</p>\n<p>6 months</p>\n<p>\u0089</p>\n<p>Advise mother when to re\u00ad</p>\n<p>turn immediately</p>\n<p>\u0089</p>\n<p>FOLLOW UP in 14 days:</p>\n<p>\u2013\tReview and give iron tablets</p>\n<p>every two weeks</p>\n<p>\u2013\tIf child still has palmar pal\u00ad</p>\n<p>lor after two months, refer</p>\n<p>\u2013\tIf better, continue iron</p>\n<p>treatment for three</p>\n<p>months after Hb has</p>\n<p>normalized</p>\n<p>~</p>\n<p>N o</p>\n<p>p a l \u00ad</p>\n<p>m a r</p>\n<p>p a l \u00ad</p>\n<p>lor</p>\n<p>No Anaemia</p>\n<p>\u0089</p>\n<p>If child is less than two years</p>\n<p>old, assess the child\u2019s feed\u00ad</p>\n<p>ing and counsel the mother</p>\n<p>according to the feeding</p>\n<p>recommendation</p>\n<p>\u0089</p>\n<p>If feeding problem, FOLLOW</p>\n<p>UP in five days</p>\n<p>Check for HIV Infection</p>\n<p>Ask</p>\n<p>~</p>\n<p>Is the child already enrolled in HIV care?</p>\n<p>If not, ask</p>\n<p>~</p>\n<p>Has the mother or child had an HIV test?</p>"
    },
    {
        "page_number": 914,
        "content": "848\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nIf yes: decide HIV status\n \n~\nMother: POSI\u00ad\nTIVE or NEGA\u00ad\nTIVE\n \n~\nChild:\n \n- Virological test \nPOSITIVE or \nNEGATIVE\n \n- Serological test \nPOSITIVE or \nNEGATIVE\nIf no, then test\n \n~\nMother and child status \nunknown: TEST moth\u00ad\ner.\n \n~\nMother HIV positive \nand child status un\u00ad\nknown: TEST child\n \n- If below 18 months: do \nvirological testing\n \n- If above 18 months, do \nserological testing\nIf mother is HIV positive and child is negative or unknown, \nASK:\n \n~\nWas the child breastfeeding at the time or 6 weeks be\u00ad\nfore the test?\n \n~\nIs the child breastfeeding now?\n \n~\nIf breastfeeding ASK: Is the mother and child on ARV \nprophylaxis?\nNote\n \n\u0081\nFor HIV testing algorithm and result interpretation in children, \nsee section 3.1.2\nFEATURES\nCLASSIFY AS\nMANAGEMENT\n \n~\nPosit ive \nvirologi\u00ad\ncal test in \nchild\nConfirmed \nHIV Infection\n(see section \n3.1.3)\n\t\n\u0089\nInitiate ART treatment \nand HIV care\n\t\n\u0089\nGive cotrimoxazole proph\u00ad\nylaxis\n\t\n\u0089\nAssess the child\u2019s feeding \nand provide appropriate \ncounselling to the mother.",
        "formatted_content": "<p>848</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>If yes: decide HIV status</p>\n<p>~</p>\n<p>Mother: POSI\u00ad</p>\n<p>TIVE or NEGA\u00ad</p>\n<h3>TIVE</h3>\n<p>~</p>\n<p>Child:</p>\n<p>- Virological test</p>\n<p>POSITIVE or</p>\n<h3>NEGATIVE</h3>\n<p>- Serological test</p>\n<p>POSITIVE or</p>\n<h3>NEGATIVE</h3>\n<p>If no, then test</p>\n<p>~</p>\n<p>Mother and child status</p>\n<p>unknown: TEST moth\u00ad</p>\n<p>er.</p>\n<p>~</p>\n<p>Mother HIV positive</p>\n<p>and child status un\u00ad</p>\n<p>known: TEST child</p>\n<p>- If below 18 months: do</p>\n<p>virological testing</p>\n<p>- If above 18 months, do</p>\n<p>serological testing</p>\n<p>If mother is HIV positive and child is negative or unknown,</p>\n<h3>ASK:</h3>\n<p>~</p>\n<p>Was the child breastfeeding at the time or 6 weeks be\u00ad</p>\n<p>fore the test?</p>\n<p>~</p>\n<p>Is the child breastfeeding now?</p>\n<p>~</p>\n<p>If breastfeeding ASK: Is the mother and child on ARV</p>\n<p>prophylaxis?</p>\n<p>Note</p>\n<p>\u0081</p>\n<p>For HIV testing algorithm and result interpretation in children,</p>\n<p>see section 3.1.2</p>\n<h3>FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>~</p>\n<p>Posit ive</p>\n<p>virologi\u00ad</p>\n<p>cal test in</p>\n<p>child</p>\n<p>Confirmed</p>\n<p>HIV Infection</p>\n<p>(see section</p>\n<p>3.1.3)</p>\n<p>\u0089</p>\n<p>Initiate ART treatment</p>\n<p>and HIV care</p>\n<p>\u0089</p>\n<p>Give cotrimoxazole proph\u00ad</p>\n<p>ylaxis</p>\n<p>\u0089</p>\n<p>Assess the child\u2019s feeding</p>\n<p>and provide appropriate</p>\n<p>counselling to the mother.</p>"
    },
    {
        "page_number": 915,
        "content": "849\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nFEATURES\nCLASSIFY AS\nMANAGEMENT\nOR\n \n~\nPositive \nsero\u00ad\nlogical \ntest in a \nchild 18 \nmonths \nor older\n\t\n\u0089\nAdvise the mother on \nhome care\n\t\n\u0089\nAssess or refer for TB as\u00ad\nsessment and Isoniazid \n(INH) preventive therapy \n(see section 5.2.9.3)\n\t\n\u0089\nFOLLOW UP regularly \nas per national guidelines\n \n~\nMother \nHIV- \npositive \nAND \nnegative \nvirologi\u00ad\ncal test in \na breast\u00ad\nfeeding \nchild\nor only stopped less \nthan 6 weeks \nago OR\nHIV Exposed\n(see section \n3.1.4)\n\t\n\u0089\nGive cotrimoxazole \nprophylaxis till infection \ncan be excluded by HIV \ntesting after cessation of \nbreastfeeding for at least \n6 weeks\n\t\n\u0089\nStart or continue ARV \nprophylaxis as recom\u00ad\nmended\n\t\n\u0089\nDo virological test to con\u00ad\nfirm HIV status: if nega\u00ad\ntive, repeat 6 weeks after \ncessation of breastfeeding\n \n~\nMother \nHIV- \npositive, \nchild not \nyet tested \nOR\n \n~\nPositive \nsero\u00ad\nlogical \ntest in a \nchild less \nthan 18 \nmonths\n\t\n\u0089\nAssess the child\u2019s feeding \nand provide appropriate \ncounselling to the mother\n\t\n\u0089\nAdvise the mother on \nhome care\n\t\n\u0089\nFOLLOW UP regularly \nas per national guidelines\n \n~\nNegative \nHIV \ntest in \nmother \nor child\nHIV Infection \nUnlikely\n\t\n\u0089\nTreat, counsel and FOL\u00ad\nLOW UP on existing in\u00ad\nfections",
        "formatted_content": "<p>849</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>FEATURES</h3>\n<h3>CLASSIFY AS</h3>\n<h3>MANAGEMENT</h3>\n<p>OR</p>\n<p>~</p>\n<p>Positive</p>\n<p>sero\u00ad</p>\n<p>logical</p>\n<p>test in a</p>\n<p>child 18</p>\n<p>months</p>\n<p>or older</p>\n<p>\u0089</p>\n<p>Advise the mother on</p>\n<p>home care</p>\n<p>\u0089</p>\n<p>Assess or refer for TB as\u00ad</p>\n<p>sessment and Isoniazid</p>\n<p>(INH) preventive therapy</p>\n<p>(see section 5.2.9.3)</p>\n<p>\u0089</p>\n<p>FOLLOW UP regularly</p>\n<p>as per national guidelines</p>\n<p>~</p>\n<p>Mother</p>\n<h3>HIV-</h3>\n<p>positive</p>\n<h3>AND</h3>\n<p>negative</p>\n<p>virologi\u00ad</p>\n<p>cal test in</p>\n<p>a breast\u00ad</p>\n<p>feeding</p>\n<p>child</p>\n<p>or only stopped less</p>\n<p>than 6 weeks</p>\n<p>ago OR</p>\n<p>HIV Exposed</p>\n<p>(see section</p>\n<p>3.1.4)</p>\n<p>\u0089</p>\n<p>Give cotrimoxazole</p>\n<p>prophylaxis till infection</p>\n<p>can be excluded by HIV</p>\n<p>testing after cessation of</p>\n<p>breastfeeding for at least</p>\n<p>6 weeks</p>\n<p>\u0089</p>\n<p>Start or continue ARV</p>\n<p>prophylaxis as recom\u00ad</p>\n<p>mended</p>\n<p>\u0089</p>\n<p>Do virological test to con\u00ad</p>\n<p>firm HIV status: if nega\u00ad</p>\n<p>tive, repeat 6 weeks after</p>\n<p>cessation of breastfeeding</p>\n<p>~</p>\n<p>Mother</p>\n<h3>HIV-</h3>\n<p>positive,</p>\n<p>child not</p>\n<p>yet tested</p>\n<p>OR</p>\n<p>~</p>\n<p>Positive</p>\n<p>sero\u00ad</p>\n<p>logical</p>\n<p>test in a</p>\n<p>child less</p>\n<p>than 18</p>\n<p>months</p>\n<p>\u0089</p>\n<p>Assess the child\u2019s feeding</p>\n<p>and provide appropriate</p>\n<p>counselling to the mother</p>\n<p>\u0089</p>\n<p>Advise the mother on</p>\n<p>home care</p>\n<p>\u0089</p>\n<p>FOLLOW UP regularly</p>\n<p>as per national guidelines</p>\n<p>~</p>\n<p>Negative</p>\n<h3>HIV</h3>\n<p>test in</p>\n<p>mother</p>\n<p>or child</p>\n<p>HIV Infection</p>\n<p>Unlikely</p>\n<p>\u0089</p>\n<p>Treat, counsel and FOL\u00ad</p>\n<p>LOW UP on existing in\u00ad</p>\n<p>fections</p>"
    },
    {
        "page_number": 916,
        "content": "850\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.3.8  Check Immunization, Vitamin A, Deworming\nCheck immunization card and classify\n \n~\nImuni\u00ad\nzation \nnot up \nto date \naccord\u00ad\ning\n \n~\nto \nnational \nsched\u00ad\nule (see \nchapter \n18)\nChild Not \nImmunized as \nPer Schedule\n \n~\nGive all missed \ndoses on this visit\n \n~\n(Include sick child \nunless being \nreferred)\n \n~\nGive vitamin A if \nnot given in the \nlast 6 months\n \n~\nGive mebendazole \nor albendazole (if \nage >1 year) if not \ngiven in the last 6 \nmonths\n \n~\nImmu\u00ad\nnization \nup to \ndate \nas per \nnational \nsched\u00ad\nule\nChild Immu\u00ad\nnized as Per \nSchedule\n \n~\nPraise the mother\n \n~\nAdvise the care\u00ad\ntaker when to re\u00ad\nturn for the next \ndose\n17.3.9  Assess Other Problems\nAssess any other presenting problems (e.g. eye problems, rashes) and \nmanage accordingly\n17.3.10  Summary of Medicines Used\nFor each medicine\n\t\n\u0089\nExplain to the mother why the medicine is needed\n\t\n\u0089\nCalculate the correct dose for the child\u2019s weight or age\n\t\n\u0089\nUse a sterile needle and syringe for injections\n\t\n\u0089\nAccurately measure and administer the dose\n\t\n\u0089\nIf referral is not possible, follow the instructions given",
        "formatted_content": "<p>850</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.3.8  Check Immunization, Vitamin A, Deworming</p>\n<p>Check immunization card and classify</p>\n<p>~</p>\n<p>Imuni\u00ad</p>\n<p>zation</p>\n<p>not up</p>\n<p>to date</p>\n<p>accord\u00ad</p>\n<p>ing</p>\n<p>~</p>\n<p>to</p>\n<p>national</p>\n<p>sched\u00ad</p>\n<p>ule (see</p>\n<p>chapter</p>\n<p>18)</p>\n<p>Child Not</p>\n<p>Immunized as</p>\n<p>Per Schedule</p>\n<p>~</p>\n<p>Give all missed</p>\n<p>doses on this visit</p>\n<p>~</p>\n<p>(Include sick child</p>\n<p>unless being</p>\n<p>referred)</p>\n<p>~</p>\n<p>Give vitamin A if</p>\n<p>not given in the</p>\n<p>last 6 months</p>\n<p>~</p>\n<p>Give mebendazole</p>\n<p>or albendazole (if</p>\n<p>age >1 year) if not</p>\n<p>given in the last 6</p>\n<p>months</p>\n<p>~</p>\n<p>Immu\u00ad</p>\n<p>nization</p>\n<p>up to</p>\n<p>date</p>\n<p>as per</p>\n<p>national</p>\n<p>sched\u00ad</p>\n<p>ule</p>\n<p>Child Immu\u00ad</p>\n<p>nized as Per</p>\n<p>Schedule</p>\n<p>~</p>\n<p>Praise the mother</p>\n<p>~</p>\n<p>Advise the care\u00ad</p>\n<p>taker when to re\u00ad</p>\n<p>turn for the next</p>\n<p>dose</p>\n<p>17.3.9  Assess Other Problems</p>\n<p>Assess any other presenting problems (e.g. eye problems, rashes) and</p>\n<p>manage accordingly</p>\n<p>17.3.10  Summary of Medicines Used</p>\n<p>For each medicine</p>\n<p>\u0089</p>\n<p>Explain to the mother why the medicine is needed</p>\n<p>\u0089</p>\n<p>Calculate the correct dose for the child\u2019s weight or age</p>\n<p>\u0089</p>\n<p>Use a sterile needle and syringe for injections</p>\n<p>\u0089</p>\n<p>Accurately measure and administer the dose</p>\n<p>\u0089</p>\n<p>If referral is not possible, follow the instructions given</p>"
    },
    {
        "page_number": 917,
        "content": "851\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.3.10.1  Medicines Used Only in Health Centers\nDRUG\nDOSE\nINDICATION\nLOC\nAmpicillin\n50 mg/kg\nPre referral IM dose in very \nsevere disease or severe \npneumonia\nHC3\nGentamicin\n7.5 mg/kg\nPre referral IM dose in very \nsevere disease or severe \npneumonia\nHC3\nDiazepam \nrectal (sup\u00ad\npository or \ndiluted IV \nampoule)\n0.5 mg/kg\nPre referral treatment of \nconvulsions\nHC2\nBenzyl peni\u00ad\ncillin\n50,000 IU/kg Pre referral IM dose in very \nsevere disease or severe \npneumonia\nHC2\nRectal ar\u00ad\ntesunate\n1 0  m g / kg \n(see section \n2.5.2.2)\nPre referral dose for very \nsevere febrile disease\nHC1\nArtesunate \nparenteral\n3 mg/kg if\n< 20 kg,\n2.4 mg/kg if\n> 20 kg\nPre referral IM dose for \nvery severe febrile disease\nHC3\nSalbutamol \ninhaler\n2 puff\nFor acute wheezing\nHC3\n17.3.10.2   Medicines for Home Use\nTeach mother/caretaker how to give oral medicines at home\n \n~\nDetermine the correct medicine and dose for the child\u2019s \nweight or age",
        "formatted_content": "<p>851</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.3.10.1  Medicines Used Only in Health Centers</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>Ampicillin</p>\n<p>50 mg/kg</p>\n<p>Pre referral IM dose in very</p>\n<p>severe disease or severe</p>\n<p>pneumonia</p>\n<h3>HC3</h3>\n<p>Gentamicin</p>\n<p>7.5 mg/kg</p>\n<p>Pre referral IM dose in very</p>\n<p>severe disease or severe</p>\n<p>pneumonia</p>\n<h3>HC3</h3>\n<p>Diazepam</p>\n<p>rectal (sup\u00ad</p>\n<p>pository or</p>\n<p>diluted IV</p>\n<p>ampoule)</p>\n<p>0.5 mg/kg</p>\n<p>Pre referral treatment of</p>\n<p>convulsions</p>\n<h3>HC2</h3>\n<p>Benzyl peni\u00ad</p>\n<p>cillin</p>\n<p>50,000 IU/kg Pre referral IM dose in very</p>\n<p>severe disease or severe</p>\n<p>pneumonia</p>\n<h3>HC2</h3>\n<p>Rectal ar\u00ad</p>\n<p>tesunate</p>\n<p>1 0  m g / kg</p>\n<p>(see section</p>\n<p>2.5.2.2)</p>\n<p>Pre referral dose for very</p>\n<p>severe febrile disease</p>\n<h3>HC1</h3>\n<p>Artesunate</p>\n<p>parenteral</p>\n<p>3 mg/kg if</p>\n<p>< 20 kg,</p>\n<p>2.4 mg/kg if</p>\n<p>> 20 kg</p>\n<p>Pre referral IM dose for</p>\n<p>very severe febrile disease</p>\n<h3>HC3</h3>\n<p>Salbutamol</p>\n<p>inhaler</p>\n<p>2 puff</p>\n<p>For acute wheezing</p>\n<h3>HC3</h3>\n<p>17.3.10.2   Medicines for Home Use</p>\n<p>Teach mother/caretaker how to give oral medicines at home</p>\n<p>~</p>\n<p>Determine the correct medicine and dose for the child\u2019s</p>\n<p>weight or age</p>"
    },
    {
        "page_number": 918,
        "content": "852\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nFor each medicine\n \n~\nExplain the reason for giving the medicine\n \n~\nShow how to measure a dose\n \n~\nWatch the mother practice this\n \n- Ask the mother to give the first dose to her child\n \n- Explain carefully how to give the medicine\n \n~\nInclude dose, frequency, and duration\nStress the need to compete the full course of treatment even if the \nchild gets better\nIf child vomits the medicine within one hour from taking it, REPEAT \nthe dose\n \n~\nCollect, measure/count, pack, and label it separately\n \n~\nCheck the mother\u2019s understanding before she leaves\nDRUG\nDOSE\nINDICATION\nLOC\nAmoxicillin \nDT 250 mg\nEvery 12 hours\nfor 5 days\n2-12 months:\n250 mg\n1-3 years:\n500 mg\n3-5 years:\n750 mg\nPneumonia Acute ear \ninfection\nHC1\nArtemether/ \nlumefantrine \n20/120 mg\nEvery 12 hours\nfor 3 days\n2-12 months:\n1 tab\n1-3 years: 1 tab\n3-5 years: 2 tab\nUn-complicated malaria\nHC1",
        "formatted_content": "<p>852</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>For each medicine</p>\n<p>~</p>\n<p>Explain the reason for giving the medicine</p>\n<p>~</p>\n<p>Show how to measure a dose</p>\n<p>~</p>\n<p>Watch the mother practice this</p>\n<p>- Ask the mother to give the first dose to her child</p>\n<p>- Explain carefully how to give the medicine</p>\n<p>~</p>\n<p>Include dose, frequency, and duration</p>\n<p>Stress the need to compete the full course of treatment even if the</p>\n<p>child gets better</p>\n<p>If child vomits the medicine within one hour from taking it, REPEAT</p>\n<p>the dose</p>\n<p>~</p>\n<p>Collect, measure/count, pack, and label it separately</p>\n<p>~</p>\n<p>Check the mother\u2019s understanding before she leaves</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>Amoxicillin</p>\n<p>DT 250 mg</p>\n<p>Every 12 hours</p>\n<p>for 5 days</p>\n<p>2-12 months:</p>\n<p>250 mg</p>\n<p>1-3 years:</p>\n<p>500 mg</p>\n<p>3-5 years:</p>\n<p>750 mg</p>\n<p>Pneumonia Acute ear</p>\n<p>infection</p>\n<h3>HC1</h3>\n<p>Artemether/</p>\n<p>lumefantrine</p>\n<p>20/120 mg</p>\n<p>Every 12 hours</p>\n<p>for 3 days</p>\n<p>2-12 months:</p>\n<p>1 tab</p>\n<p>1-3 years: 1 tab</p>\n<p>3-5 years: 2 tab</p>\n<p>Un-complicated malaria</p>\n<h3>HC1</h3>"
    },
    {
        "page_number": 919,
        "content": "853\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nDRUG\nDOSE\nINDICATION\nLOC\nErythromicin\nEvery 6 hours\nfor 3 days Child \n< 2 years: 125 \nmg\n2-5 years:\n250 mg\nCholera\nHC3\nCiprofloxa\u00ad\ncin\n15 mg/kg every\n12 hours for\n3 days\nIf tab 500 mg: \nChild< 6 months: \n\u00bc tab Child 6 \nmonths-5 years: \n\u00bd tab\nDysentery\nHC2\nFolic acid\n2.5 mg/daily\nAnaemia in child with \nsickle cell anaemia\nHC2\nIron ferrous \nsulphate \n(with or \nwithout folic \nacid)\nOnce daily for 14 \ndays, tab\n200 mg\n1-5 years:\n\u00bd tablet Syrup \n25 mg/ ml\nChild < 1 year:\n1 ml\nAnaemia in non sick\u00ad\nlers\nHC2\nCotri- moxa\u00ad\nzole 120 mg \npaediatric \ntablet\n< 6 months:\n1 tablet\n6 months-\n5 years: 2 tab/ \nday (or half adult \ntablet) Once a \nday\nProphylaxis in HIV \npositive and HIV \nexposed\nHC2",
        "formatted_content": "<p>853</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>Erythromicin</p>\n<p>Every 6 hours</p>\n<p>for 3 days Child</p>\n<p>< 2 years: 125</p>\n<p>mg</p>\n<p>2-5 years:</p>\n<p>250 mg</p>\n<p>Cholera</p>\n<h3>HC3</h3>\n<p>Ciprofloxa\u00ad</p>\n<p>cin</p>\n<p>15 mg/kg every</p>\n<p>12 hours for</p>\n<p>3 days</p>\n<p>If tab 500 mg:</p>\n<p>Child< 6 months:</p>\n<p>\u00bc tab Child 6</p>\n<p>months-5 years:</p>\n<p>\u00bd tab</p>\n<p>Dysentery</p>\n<h3>HC2</h3>\n<p>Folic acid</p>\n<p>2.5 mg/daily</p>\n<p>Anaemia in child with</p>\n<p>sickle cell anaemia</p>\n<h3>HC2</h3>\n<p>Iron ferrous</p>\n<p>sulphate</p>\n<p>(with or</p>\n<p>without folic</p>\n<p>acid)</p>\n<p>Once daily for 14</p>\n<p>days, tab</p>\n<p>200 mg</p>\n<p>1-5 years:</p>\n<p>\u00bd tablet Syrup</p>\n<p>25 mg/ ml</p>\n<p>Child < 1 year:</p>\n<p>1 ml</p>\n<p>Anaemia in non sick\u00ad</p>\n<p>lers</p>\n<h3>HC2</h3>\n<p>Cotri- moxa\u00ad</p>\n<p>zole 120 mg</p>\n<p>paediatric</p>\n<p>tablet</p>\n<p>< 6 months:</p>\n<p>1 tablet</p>\n<p>6 months-</p>\n<p>5 years: 2 tab/</p>\n<p>day (or half adult</p>\n<p>tablet) Once a</p>\n<p>day</p>\n<p>Prophylaxis in HIV</p>\n<p>positive and HIV</p>\n<p>exposed</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 920,
        "content": "854\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nDRUG\nDOSE\nINDICATION\nLOC\nMeben- dazole\nChild 1-2 \nyears:\n250 mg single \ndose\nChild > 2 \nyears: 500 mg \nsingle dose\nRoutine deworming \nevery six months\nHC2\nAlbendazole\nChild 1-2 \nyears:\n200 mg single \ndose\nChild > 2 \nyears: 400 mg \nsingle dose\nRoutine deworming \nevery six months\nHC1\nParacetamol\nEvery 6 hours\n(4 doses/24 \nhours)\nmonth-\nyears: 125 mg\n3-5 years:\n250 mg\nFever > 38.5 oC or \n(ear) pain\nHC1\nVitamin A\nUp to 6 \nmonths:\n50,000 IU\n6\u201312 months:\n100,000 IU\n12 months \u2013\n5 years:\n200,000 IU\nRoutine every 6 \nmonths from\nage six months,\nthree doses for persis\u00ad\ntent diarrhoea, measles \nat day 0, 1 and four \nweeks\nHC2",
        "formatted_content": "<p>854</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>Meben- dazole</p>\n<p>Child 1-2</p>\n<p>years:</p>\n<p>250 mg single</p>\n<p>dose</p>\n<p>Child > 2</p>\n<p>years: 500 mg</p>\n<p>single dose</p>\n<p>Routine deworming</p>\n<p>every six months</p>\n<h3>HC2</h3>\n<p>Albendazole</p>\n<p>Child 1-2</p>\n<p>years:</p>\n<p>200 mg single</p>\n<p>dose</p>\n<p>Child > 2</p>\n<p>years: 400 mg</p>\n<p>single dose</p>\n<p>Routine deworming</p>\n<p>every six months</p>\n<h3>HC1</h3>\n<p>Paracetamol</p>\n<p>Every 6 hours</p>\n<p>(4 doses/24</p>\n<p>hours)</p>\n<p>month-</p>\n<p>years: 125 mg</p>\n<p>3-5 years:</p>\n<p>250 mg</p>\n<p>Fever > 38.5 oC or</p>\n<p>(ear) pain</p>\n<h3>HC1</h3>\n<p>Vitamin A</p>\n<p>Up to 6</p>\n<p>months:</p>\n<h3>50,000 IU</h3>\n<p>6\u201312 months:</p>\n<h3>100,000 IU</h3>\n<p>12 months \u2013</p>\n<p>5 years:</p>\n<h3>200,000 IU</h3>\n<p>Routine every 6</p>\n<p>months from</p>\n<p>age six months,</p>\n<p>three doses for persis\u00ad</p>\n<p>tent diarrhoea, measles</p>\n<p>at day 0, 1 and four</p>\n<p>weeks</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 921,
        "content": "855\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nDRUG\nDOSE\nINDICATION\nLOC\nORS\nAs per plan \nA,B,C\nSee section\n1.1.3\nRehydration\nHC1\nZinc\nDaily for 10 \ndays\nChild 2-6\nmonths: 10 \nmg (1/2 tablet) \nChild> 6\nmonths: 20 \nmg\n(1 tablet)\nTreatment of \ndiarrhoea\nHC1\nNystatin syrup\n1 ml 4 times \ndaily for 7 \ndays\nOral thrush\nHC2\nTetracycline \neye ointment\n5 mm of oint\u00ad\nment inside \nlower lid, 4 \ntimes daily till \npus discharge \nresolves\nEye infection\nHC2\nCiprofloxacin \near drops\n1-2 drops \nthree times \ndaily\nChronic otitis\nReady To Use \nTherapeutic \nFood RUTF)\nSee chapter \n19\nSevere malnutrition\nHC1",
        "formatted_content": "<p>855</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<h3>ORS</h3>\n<p>As per plan</p>\n<h3>A,B,C</h3>\n<p>See section</p>\n<li>.1.3</li>\n<p>Rehydration</p>\n<h3>HC1</h3>\n<p>Zinc</p>\n<p>Daily for 10</p>\n<p>days</p>\n<p>Child 2-6</p>\n<p>months: 10</p>\n<p>mg (1/2 tablet)</p>\n<p>Child> 6</p>\n<p>months: 20</p>\n<p>mg</p>\n<p>(1 tablet)</p>\n<p>Treatment of</p>\n<p>diarrhoea</p>\n<h3>HC1</h3>\n<p>Nystatin syrup</p>\n<p>1 ml 4 times</p>\n<p>daily for 7</p>\n<p>days</p>\n<p>Oral thrush</p>\n<h3>HC2</h3>\n<p>Tetracycline</p>\n<p>eye ointment</p>\n<p>5 mm of oint\u00ad</p>\n<p>ment inside</p>\n<p>lower lid, 4</p>\n<p>times daily till</p>\n<p>pus discharge</p>\n<p>resolves</p>\n<p>Eye infection</p>\n<h3>HC2</h3>\n<p>Ciprofloxacin</p>\n<p>ear drops</p>\n<p>1-2 drops</p>\n<p>three times</p>\n<p>daily</p>\n<p>Chronic otitis</p>\n<p>Ready To Use</p>\n<p>Therapeutic</p>\n<p>Food RUTF)</p>\n<p>See chapter</p>\n<p>19</p>\n<p>Severe malnutrition</p>\n<h3>HC1</h3>"
    },
    {
        "page_number": 922,
        "content": "856\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nDRUG\nDOSE\nINDICATION\nLOC\nARVs\nSee section\n3.1.3\nHIV prophylaxis \nand treatment\nHC3\n17.3.10.3  Treatment of Local Infections at Home\nTeach mother/ caretaker how to treat local infections\n \n~\nExplain what the treatment is and why it is needed\n \n~\nDescribe the treatment steps as detailed below\n \n~\nWatch the mother do the first treatment in the clinic (ex\u00ad\ncept cough/sore throat remedy)\n \n~\nExplain how often to do the treatment and for how long\n \n~\nProvide the required medication for home treatment\n \n~\nCheck that she understands completely before leaving the \nclinic\nINFECTION\nTREATMENT\nEye infection\n\t\n\u0089\nClean both eyes 4 times daily:\n \n- Wash hands\n \n- Ask child to close eyes\n \n- Use clean cloth with clean water to \ngently remove pus\n \n- Use a different part of the cloth for \neach eye\n \n- Clean each eye from nose-side \nto ear-side to avoid passing the \ninfection from one eye to the other\n\t\n\u0089\nApply tetracycline eye ointment 1% to each \neye 4 times daily after cleaning the eyes\n \n- Ask the child to look up\n \n- Squirt a small amount (5 mm length) \non the inside of the lower eyelid\n \n- Wash hands again\n\t\n\u0089\nContinue application until the redness \nhas disappeared\n \n\u0083 Do not put anything else into the eye",
        "formatted_content": "<p>856</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>DRUG</h3>\n<h3>DOSE</h3>\n<h3>INDICATION</h3>\n<h3>LOC</h3>\n<p>ARVs</p>\n<p>See section</p>\n<p>3.1.3</p>\n<p>HIV prophylaxis</p>\n<p>and treatment</p>\n<h3>HC3</h3>\n<p>17.3.10.3  Treatment of Local Infections at Home</p>\n<p>Teach mother/ caretaker how to treat local infections</p>\n<p>~</p>\n<p>Explain what the treatment is and why it is needed</p>\n<p>~</p>\n<p>Describe the treatment steps as detailed below</p>\n<p>~</p>\n<p>Watch the mother do the first treatment in the clinic (ex\u00ad</p>\n<p>cept cough/sore throat remedy)</p>\n<p>~</p>\n<p>Explain how often to do the treatment and for how long</p>\n<p>~</p>\n<p>Provide the required medication for home treatment</p>\n<p>~</p>\n<p>Check that she understands completely before leaving the</p>\n<p>clinic</p>\n<h3>INFECTION</h3>\n<h3>TREATMENT</h3>\n<p>Eye infection</p>\n<p>\u0089</p>\n<p>Clean both eyes 4 times daily:</p>\n<p>- Wash hands</p>\n<p>- Ask child to close eyes</p>\n<p>- Use clean cloth with clean water to</p>\n<p>gently remove pus</p>\n<p>- Use a different part of the cloth for</p>\n<p>each eye</p>\n<p>- Clean each eye from nose-side</p>\n<p>to ear-side to avoid passing the</p>\n<p>infection from one eye to the other</p>\n<p>\u0089</p>\n<p>Apply tetracycline eye ointment 1% to each</p>\n<p>eye 4 times daily after cleaning the eyes</p>\n<p>- Ask the child to look up</p>\n<p>- Squirt a small amount (5 mm length)</p>\n<p>on the inside of the lower eyelid</p>\n<p>- Wash hands again</p>\n<p>\u0089</p>\n<p>Continue application until the redness</p>\n<p>has disappeared</p>\n<p>\u0083 Do not put anything else into the eye</p>"
    },
    {
        "page_number": 923,
        "content": "857\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nINFECTION\nTREATMENT\nEar infection\n\t\n\u0089\nDry the ear at least 3 times daily\n \n- Roll clean absorbent cloth or soft \ngauze into a wick\n \n- Place this in the ear and remove \nwhen wet\n \n- Replace wick with a clean one\n \n- Repeat this process until the ear is \ndry\nIn chronic ear infection:\n \n- Instill ciprofloxacin ear drops 3 \ntimes daily for 3 weeks\n \n\u0083 Do not put anything else into the ear\nMouth ulcers\n\t\n\u0089\nTreat these twice daily\n\t\n\u0089\nWash hands\n\t\n\u0089\nWash child\u2019s mouth with clean soft cloth \nmoistened with salt water and wrapped \naround the finger\n\t\n\u0089\nPaint the mouth with gentian violet aque\u00ad\nous paint 0.5% (if necessary, dilute 1% with \nan equal volume of water and provide this \nfor the mother to use at home)\n\t\n\u0089\nWash hands again\n\t\n\u0089\nContinue giving gentian violet for 48 hours \nafter ulcers are cured\n\t\n\u0089\nGive paracetamol for pain relief\nOral thrush\n\t\n\u0089\nTreat for thrush four times daily for seven \ndays\n\t\n\u0089\nWash hands\n\t\n\u0089\nWash a clean soft cloth with water and \nuse to wash the child\u2019s mouth\n\t\n\u0089\nInstill nystatin 1 ml every six hours\n\t\n\u0089\nAvoid feeding for 20 minutes after med\u00ad\nication",
        "formatted_content": "<p>857</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>INFECTION</h3>\n<h3>TREATMENT</h3>\n<p>Ear infection</p>\n<p>\u0089</p>\n<p>Dry the ear at least 3 times daily</p>\n<p>- Roll clean absorbent cloth or soft</p>\n<p>gauze into a wick</p>\n<p>- Place this in the ear and remove</p>\n<p>when wet</p>\n<p>- Replace wick with a clean one</p>\n<p>- Repeat this process until the ear is</p>\n<p>dry</p>\n<p>In chronic ear infection:</p>\n<p>- Instill ciprofloxacin ear drops 3</p>\n<p>times daily for 3 weeks</p>\n<p>\u0083 Do not put anything else into the ear</p>\n<p>Mouth ulcers</p>\n<p>\u0089</p>\n<p>Treat these twice daily</p>\n<p>\u0089</p>\n<p>Wash hands</p>\n<p>\u0089</p>\n<p>Wash child\u2019s mouth with clean soft cloth</p>\n<p>moistened with salt water and wrapped</p>\n<p>around the finger</p>\n<p>\u0089</p>\n<p>Paint the mouth with gentian violet aque\u00ad</p>\n<p>ous paint 0.5% (if necessary, dilute 1% with</p>\n<p>an equal volume of water and provide this</p>\n<p>for the mother to use at home)</p>\n<p>\u0089</p>\n<p>Wash hands again</p>\n<p>\u0089</p>\n<p>Continue giving gentian violet for 48 hours</p>\n<p>after ulcers are cured</p>\n<p>\u0089</p>\n<p>Give paracetamol for pain relief</p>\n<p>Oral thrush</p>\n<p>\u0089</p>\n<p>Treat for thrush four times daily for seven</p>\n<p>days</p>\n<p>\u0089</p>\n<p>Wash hands</p>\n<p>\u0089</p>\n<p>Wash a clean soft cloth with water and</p>\n<p>use to wash the child\u2019s mouth</p>\n<p>\u0089</p>\n<p>Instill nystatin 1 ml every six hours</p>\n<p>\u0089</p>\n<p>Avoid feeding for 20 minutes after med\u00ad</p>\n<p>ication</p>"
    },
    {
        "page_number": 924,
        "content": "858\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nINFECTION\nTREATMENT\n\t\n\u0089\nIf breastfed, check mother\u2019s breasts for \nthrush and if present treat with nystatin\n\t\n\u0089\nAdvice mother to wash breast after feeds\n\t\n\u0089\nIf baby unable to breastfeed advise mother \nto feed baby with a cup and spoon .\n\t\n\u0089\nGive paracetamol of needed for pain\nSore throat or cough\n\t\n\u0089\nUse a safe remedy to soothe the throat \nand relieve cough:\n \n- Breastmilk (for exclusively breastfed \ninfant)\n \n- Warm (lemon) tea with honey\n \n\u0083 Do not use remedies containing \ncodeine or antihistamines (e.g. \nchlorphenamine, promethazine)\n17.3.11  Counsel the Mother\n17.3.12.1  Feeding Recommendation during Illness\nFor any sick child\n \n~\nBreastfeed more often and for longer at each feed\nIf not exclusively breastfed\n \n~\nIncrease fluid intake, e.g. give soup, rice water, yoghurt \ndrinks or clean water\nFor a child with diarrhoea\n \n~\nGiving extra fluid can be lifesaving\n \n~\nGive fluid according to Plan A or B, depending on the \nstate of dehydration of the child\n17.3.12.2  Assessing Appetite and Feeding\n \n~\nAsk about the child\u2019s usual feeding habits during the cur\u00ad\nrent illness\n \n~\nCompare the answers given with the feeding recommen\u00ad\ndations for the child\u2019s age",
        "formatted_content": "<p>858</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>INFECTION</h3>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>If breastfed, check mother\u2019s breasts for</p>\n<p>thrush and if present treat with nystatin</p>\n<p>\u0089</p>\n<p>Advice mother to wash breast after feeds</p>\n<p>\u0089</p>\n<p>If baby unable to breastfeed advise mother</p>\n<p>to feed baby with a cup and spoon .</p>\n<p>\u0089</p>\n<p>Give paracetamol of needed for pain</p>\n<p>Sore throat or cough</p>\n<p>\u0089</p>\n<p>Use a safe remedy to soothe the throat</p>\n<p>and relieve cough:</p>\n<p>- Breastmilk (for exclusively breastfed</p>\n<p>infant)</p>\n<p>- Warm (lemon) tea with honey</p>\n<p>\u0083 Do not use remedies containing</p>\n<p>codeine or antihistamines (e.g.</p>\n<p>chlorphenamine, promethazine)</p>\n<p>17.3.11  Counsel the Mother</p>\n<p>17.3.12.1  Feeding Recommendation during Illness</p>\n<p>For any sick child</p>\n<p>~</p>\n<p>Breastfeed more often and for longer at each feed</p>\n<p>If not exclusively breastfed</p>\n<p>~</p>\n<p>Increase fluid intake, e.g. give soup, rice water, yoghurt</p>\n<p>drinks or clean water</p>\n<p>For a child with diarrhoea</p>\n<p>~</p>\n<p>Giving extra fluid can be lifesaving</p>\n<p>~</p>\n<p>Give fluid according to Plan A or B, depending on the</p>\n<p>state of dehydration of the child</p>\n<p>17.3.12.2  Assessing Appetite and Feeding</p>\n<p>~</p>\n<p>Ask about the child\u2019s usual feeding habits during the cur\u00ad</p>\n<p>rent illness</p>\n<p>~</p>\n<p>Compare the answers given with the feeding recommen\u00ad</p>\n<p>dations for the child\u2019s age</p>"
    },
    {
        "page_number": 925,
        "content": "859\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSITUATION\nQUESTIONS\nBreastfeeding\n \n- Do you breastfeed the child?\n \n- How many times during the \nday?\n \n- How many times at night?\n \n- Do you give the child any \nother food or fluids?\nOther food or fluids\n \n- What food or fluids?\n \n- How many times daily?\n \n- What do you use to feed the \nchild?\n \n- What foods are available in \nthe home?\nIf severe or moderate \nmalnutrition or any \nspecial concern about \ngrowth (e.g. HIV)\n \n- What foods are available at \nhome?\n \n- What foods does the child \neat?\n \n- How large are the servings?\n \n- Does the child receive his/her \nown serving?\n \n- Who feeds the child and how?\nDuring this illness\n \n- Has the child\u2019s feeding \nchanged?\n \n- If yes, how?\nIf HIV exposed child\n \n- If mother and child on ARVs, \nand child breastfeeding, check \non adherence\n \n- If child not breastfeeding, \ncheck type, quantity and \npreparation of substitute milk, \nincluding cleaning of utensils",
        "formatted_content": "<p>859</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>SITUATION</h3>\n<h3>QUESTIONS</h3>\n<p>Breastfeeding</p>\n<p>- Do you breastfeed the child?</p>\n<p>- How many times during the</p>\n<p>day?</p>\n<p>- How many times at night?</p>\n<p>- Do you give the child any</p>\n<p>other food or fluids?</p>\n<p>Other food or fluids</p>\n<p>- What food or fluids?</p>\n<p>- How many times daily?</p>\n<p>- What do you use to feed the</p>\n<p>child?</p>\n<p>- What foods are available in</p>\n<p>the home?</p>\n<p>If severe or moderate</p>\n<p>malnutrition or any</p>\n<p>special concern about</p>\n<p>growth (e.g. HIV)</p>\n<p>- What foods are available at</p>\n<p>home?</p>\n<p>- What foods does the child</p>\n<p>eat?</p>\n<p>- How large are the servings?</p>\n<p>- Does the child receive his/her</p>\n<p>own serving?</p>\n<p>- Who feeds the child and how?</p>\n<p>During this illness</p>\n<p>- Has the child\u2019s feeding</p>\n<p>changed?</p>\n<p>- If yes, how?</p>\n<p>If HIV exposed child</p>\n<p>- If mother and child on ARVs,</p>\n<p>and child breastfeeding, check</p>\n<p>on adherence</p>\n<p>- If child not breastfeeding,</p>\n<p>check type, quantity and</p>\n<p>preparation of substitute milk,</p>\n<p>including cleaning of utensils</p>"
    },
    {
        "page_number": 926,
        "content": "860\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n17.3.12.3   Feeding Recommendations\nThese recommendations are for both sick and healthy children\nAGE OF CHILD\nFEEDING RECOMMENDATIONS\nBirth up to 6 \nmonths\n \n~\nBreastfeed as often as your child wants\n \n~\nLook for signs of hunger, such as be\u00ad\nginning to fuss, sucking fingers, or \nmoving lips\n \n~\nBreastfeed day and night whenever \nyour baby wants, at least 8 times in 24 \nhours\n \n~\nFrequent feeding produces more milk\n \n~\nDo not give other foods or fluids\n \n~\nBreast milk is all your baby needs\n6-9 months\n \n~\nBreastfeed as often as your child wants\nAlso give thick porridge made with maize, cassava, millet, \nsoya flour, or any mix of these. Add sugar and oil, and \nmix with milk or pounded groundnuts or mixtures of well \nmashed foods, e.g.\nmatooke, potatoes, cassava, posho (maize or millet), rice. \nMix these with fish, beans, or pounded groundnuts. Add \ngreen vegetables\n \n~\nGive a nutritious snack, e.g. egg, ba\u00ad\nnana, bread: 3 times/day if breastfed \nor 5 times/ day if not\n \n~\nIncluding animal source foods and vita\u00ad\nmin A-rich fruits and vegetables\n \n~\nStart by giving 2 to 3 tablespoons of \nfood. Gradually increase to \u00bd cups (1 \ncup = 250 ml)\n \n~\nGive 2 to 3 meals each day\n \n~\nOffer 1 or 2 snacks each day between \nmeals when the child seems hungry",
        "formatted_content": "<p>860</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>17.3.12.3   Feeding Recommendations</p>\n<p>These recommendations are for both sick and healthy children</p>\n<h3>AGE OF CHILD</h3>\n<h3>FEEDING RECOMMENDATIONS</h3>\n<p>Birth up to 6</p>\n<p>months</p>\n<p>~</p>\n<p>Breastfeed as often as your child wants</p>\n<p>~</p>\n<p>Look for signs of hunger, such as be\u00ad</p>\n<p>ginning to fuss, sucking fingers, or</p>\n<p>moving lips</p>\n<p>~</p>\n<p>Breastfeed day and night whenever</p>\n<p>your baby wants, at least 8 times in 24</p>\n<p>hours</p>\n<p>~</p>\n<p>Frequent feeding produces more milk</p>\n<p>~</p>\n<p>Do not give other foods or fluids</p>\n<p>~</p>\n<p>Breast milk is all your baby needs</p>\n<p>6-9 months</p>\n<p>~</p>\n<p>Breastfeed as often as your child wants</p>\n<p>Also give thick porridge made with maize, cassava, millet,</p>\n<p>soya flour, or any mix of these. Add sugar and oil, and</p>\n<p>mix with milk or pounded groundnuts or mixtures of well</p>\n<p>mashed foods, e.g.</p>\n<p>matooke, potatoes, cassava, posho (maize or millet), rice.</p>\n<p>Mix these with fish, beans, or pounded groundnuts. Add</p>\n<p>green vegetables</p>\n<p>~</p>\n<p>Give a nutritious snack, e.g. egg, ba\u00ad</p>\n<p>nana, bread: 3 times/day if breastfed</p>\n<p>or 5 times/ day if not</p>\n<p>~</p>\n<p>Including animal source foods and vita\u00ad</p>\n<p>min A-rich fruits and vegetables</p>\n<p>~</p>\n<p>Start by giving 2 to 3 tablespoons of</p>\n<p>food. Gradually increase to \u00bd cups (1</p>\n<p>cup = 250 ml)</p>\n<p>~</p>\n<p>Give 2 to 3 meals each day</p>\n<p>~</p>\n<p>Offer 1 or 2 snacks each day between</p>\n<p>meals when the child seems hungry</p>"
    },
    {
        "page_number": 927,
        "content": "861\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nAGE OF CHILD\nFEEDING RECOMMENDATIONS\n9 to 12 months\n \n~\nBreastfeed as often as your child \nwants\n \n~\nAlso give a variety of mashed or fine\u00ad\nly chopped family food, including an\u00ad\nimal source foods and vitamin A-rich \nfruits and vegetables\n \n~\nGive 1/2 cup at each meal (1 cup \n==250 ml)\n \n~\nGive 3 to 4 meals each day\n \n~\nOffer 1 or 2 snacks between meals. \nThe child will eat if hungry\n \n~\nFor snacks, give small chewable items \nthat the child can hold. Let your child \ntry to eat the snack, but provide help \nif needed\n12-24\nmonths\n \n~\nBreastfeed as often as your child wants\n \n~\nAlso give a variety of mashed or finely \nchopped family food,including animal \nsource foods and vitamin A-rich fruits \nand vegetables\n \n~\nGive 3/4 cup at each meal (1 cup\n \n~\n= 250 ml)\n \n~\nGive 3 to 4 meals each day\n \n~\nOffer 1 to 2 snacks between meals\n \n~\nContinue to feed your child slowly, pa\u00ad\ntiently. Encourage but do not force your \nchild to eat\n \n~\nBreastfeed on demand, day and night\n \n~\nGive adequate servings of complementa\u00ad\nry foods as above except that you may \nalso add meat to mashed foods",
        "formatted_content": "<p>861</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>AGE OF CHILD</h3>\n<h3>FEEDING RECOMMENDATIONS</h3>\n<p>9 to 12 months</p>\n<p>~</p>\n<p>Breastfeed as often as your child</p>\n<p>wants</p>\n<p>~</p>\n<p>Also give a variety of mashed or fine\u00ad</p>\n<p>ly chopped family food, including an\u00ad</p>\n<p>imal source foods and vitamin A-rich</p>\n<p>fruits and vegetables</p>\n<p>~</p>\n<p>Give 1/2 cup at each meal (1 cup</p>\n<p>==250 ml)</p>\n<p>~</p>\n<p>Give 3 to 4 meals each day</p>\n<p>~</p>\n<p>Offer 1 or 2 snacks between meals.</p>\n<p>The child will eat if hungry</p>\n<p>~</p>\n<p>For snacks, give small chewable items</p>\n<p>that the child can hold. Let your child</p>\n<p>try to eat the snack, but provide help</p>\n<p>if needed</p>\n<p>12-24</p>\n<p>months</p>\n<p>~</p>\n<p>Breastfeed as often as your child wants</p>\n<p>~</p>\n<p>Also give a variety of mashed or finely</p>\n<p>chopped family food,including animal</p>\n<p>source foods and vitamin A-rich fruits</p>\n<p>and vegetables</p>\n<p>~</p>\n<p>Give 3/4 cup at each meal (1 cup</p>\n<p>~</p>\n<p>= 250 ml)</p>\n<p>~</p>\n<p>Give 3 to 4 meals each day</p>\n<p>~</p>\n<p>Offer 1 to 2 snacks between meals</p>\n<p>~</p>\n<p>Continue to feed your child slowly, pa\u00ad</p>\n<p>tiently. Encourage but do not force your</p>\n<p>child to eat</p>\n<p>~</p>\n<p>Breastfeed on demand, day and night</p>\n<p>~</p>\n<p>Give adequate servings of complementa\u00ad</p>\n<p>ry foods as above except that you may</p>\n<p>also add meat to mashed foods</p>"
    },
    {
        "page_number": 928,
        "content": "862\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nAGE OF CHILD\nFEEDING RECOMMENDATIONS\nAge 2 years and \nover\n \n~\nGive a variety of family foods to your \nchild, including animal source foods and \nvitamin A-rich fruits and vegetables\n \n~\nGive at least 1 full cup (250 ml) at each \nmeal\n \n~\nGive 3 to 4 meals each day\n \n~\nOffer 1 or 2 snacks between meals\n \n~\nIf your child refuses a new food, offer \n\u201dtastes\u201d several times. Show that you \nlike the food\n \n~\nBe patient. Talk with your child during a \nmeal, and keep eye contact\nNote:\n \n~\nA good daily diet should be adequate in \nquantity and include an energy-rich food \n(for example, thick cereal with added oil); \nmeat, fish, eggs, or pulses; and fruits and \nvegetables\nStopping breast \nfeeding\nSTOPPING BREASTFEEDING means\nchanging from all breast milk to no breast milk. This \nshould happen gradually over one month. Plan in \nadvance for a safe transition.\nHelp Mother Prepare:\n \n~\nMother should discuss and plan in ad\u00ad\nvance with her family, if possible\n \n~\nExpress milk and give by cup\n \n~\nFind a regular supply of formula or milk \ne.g full cream cow\u2019s milk\n \n~\nLearn how to prepare and store milk \nsafely at home",
        "formatted_content": "<p>862</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>AGE OF CHILD</h3>\n<h3>FEEDING RECOMMENDATIONS</h3>\n<p>Age 2 years and</p>\n<p>over</p>\n<p>~</p>\n<p>Give a variety of family foods to your</p>\n<p>child, including animal source foods and</p>\n<p>vitamin A-rich fruits and vegetables</p>\n<p>~</p>\n<p>Give at least 1 full cup (250 ml) at each</p>\n<p>meal</p>\n<p>~</p>\n<p>Give 3 to 4 meals each day</p>\n<p>~</p>\n<p>Offer 1 or 2 snacks between meals</p>\n<p>~</p>\n<p>If your child refuses a new food, offer</p>\n<p>\u201dtastes\u201d several times. Show that you</p>\n<p>like the food</p>\n<p>~</p>\n<p>Be patient. Talk with your child during a</p>\n<p>meal, and keep eye contact</p>\n<p>Note:</p>\n<p>~</p>\n<p>A good daily diet should be adequate in</p>\n<p>quantity and include an energy-rich food</p>\n<p>(for example, thick cereal with added oil);</p>\n<p>meat, fish, eggs, or pulses; and fruits and</p>\n<p>vegetables</p>\n<p>Stopping breast</p>\n<p>feeding</p>\n<p>STOPPING BREASTFEEDING means</p>\n<p>changing from all breast milk to no breast milk. This</p>\n<p>should happen gradually over one month. Plan in</p>\n<p>advance for a safe transition.</p>\n<p>Help Mother Prepare:</p>\n<p>~</p>\n<p>Mother should discuss and plan in ad\u00ad</p>\n<p>vance with her family, if possible</p>\n<p>~</p>\n<p>Express milk and give by cup</p>\n<p>~</p>\n<p>Find a regular supply of formula or milk</p>\n<p>e.g full cream cow\u2019s milk</p>\n<p>~</p>\n<p>Learn how to prepare and store milk</p>\n<p>safely at home</p>"
    },
    {
        "page_number": 929,
        "content": "863\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nAGE OF CHILD\nFEEDING RECOMMENDATIONS\nHelp Mother Make Transition:\n \n~\nTeach mother to cup feed (See Counsel \nthe mother in next section)\n \n~\nClean all utensils with soap and water\n \n~\nStart giving only formula or cow\u2019s milk \nonce baby feeds by cup\nStop Breastfeeding Completely:\n \n~\nExpress and discard enough breast milk \nto keep comfortable until lactation stops\nChild with persis\u00ad\ntent diarrhoea\nIf still breastfeeding\n \n~\nGive more frequent and longer \nfeeds day and night\nIf taking other milk, replace\n \n~\nWith increased breastfeeding\n \n~\nWith fermented milk products, e.g. \nyoghurt\nOR\n \n~\nHalf the milk with nutritious \nmashed foods\nIf taking other foods\n \n~\nFollow feeding recommendations \nabove for child\u2019s age\n17.3.12.4   Counselling for Feeding Problems\nIf the child is not being fed as above\n \n~\nCounsel the mother accordingly\n \n~\nFOLLOW UP in 5-7 days",
        "formatted_content": "<p>863</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>AGE OF CHILD</h3>\n<h3>FEEDING RECOMMENDATIONS</h3>\n<p>Help Mother Make Transition:</p>\n<p>~</p>\n<p>Teach mother to cup feed (See Counsel</p>\n<p>the mother in next section)</p>\n<p>~</p>\n<p>Clean all utensils with soap and water</p>\n<p>~</p>\n<p>Start giving only formula or cow\u2019s milk</p>\n<p>once baby feeds by cup</p>\n<p>Stop Breastfeeding Completely:</p>\n<p>~</p>\n<p>Express and discard enough breast milk</p>\n<p>to keep comfortable until lactation stops</p>\n<p>Child with persis\u00ad</p>\n<p>tent diarrhoea</p>\n<p>If still breastfeeding</p>\n<p>~</p>\n<p>Give more frequent and longer</p>\n<p>feeds day and night</p>\n<p>If taking other milk, replace</p>\n<p>~</p>\n<p>With increased breastfeeding</p>\n<p>~</p>\n<p>With fermented milk products, e.g.</p>\n<p>yoghurt</p>\n<p>OR</p>\n<p>~</p>\n<p>Half the milk with nutritious</p>\n<p>mashed foods</p>\n<p>If taking other foods</p>\n<p>~</p>\n<p>Follow feeding recommendations</p>\n<p>above for child\u2019s age</p>\n<p>17.3.12.4   Counselling for Feeding Problems</p>\n<p>If the child is not being fed as above</p>\n<p>~</p>\n<p>Counsel the mother accordingly</p>\n<p>~</p>\n<p>FOLLOW UP in 5-7 days</p>"
    },
    {
        "page_number": 930,
        "content": "864\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nPROBLEM\nCOUNSELLING AND FOLLOW UP\nBreastfeeding \nproblems\n \n~\nAssess breastfeeding\n \n~\nAs required, show mother correct posi\u00ad\ntioning and attachment\nIf child <6 months \nold and taking oth\u00ad\ner milk or foods\n \n~\nBuild the mother\u2019s confidence that she \ncan provide all the breast milk needed\n \n~\nSuggest giving more frequent, longer \nfeeds day and night, and gradually reduce \nother milk or foods\nIf mother is away \nfrom the child due \nto work, etc.\n \n~\nSuggest she expresses breast milk to \nleave for the baby\nIf other milk needs \nto be continued\n \n~\nBreastfeed as much as possible, including \nat night\n \n~\nMake sure that any other milk usedis an \nappropriate breastmilk substitute,\n \n~\ne.g. cow\u2019s milk\n \n~\nCorrectly and hygienically prepared given \nin adequate amounts\n \n~\nFinish any prepared milk within 1 hour\nIf the child is being \ngiven diluted milk \nor thin porridge\n \n~\nRemind mother that thick foods rich in \nenergy and nutrients are needed by in\u00ad\nfants and young children\n \n~\nAdvise her not to dilute the milk\n \n~\nAdvise her to make thicker porridge\nIf the mother is \nusing a bottle to \nfeed the child\n \n~\nRecommend using a cup instead of a bot\u00ad\ntle\n \n~\nShow the mother how to feed the child \nwith a cup: press cup on infant\u2019s lower \nlip and allow him to take the milk himself, \ndo not pour the milk into infant\u2019s mouth)",
        "formatted_content": "<p>864</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>PROBLEM</h3>\n<h3>COUNSELLING AND FOLLOW UP</h3>\n<p>Breastfeeding</p>\n<p>problems</p>\n<p>~</p>\n<p>Assess breastfeeding</p>\n<p>~</p>\n<p>As required, show mother correct posi\u00ad</p>\n<p>tioning and attachment</p>\n<p>If child <6 months</p>\n<p>old and taking oth\u00ad</p>\n<p>er milk or foods</p>\n<p>~</p>\n<p>Build the mother\u2019s confidence that she</p>\n<p>can provide all the breast milk needed</p>\n<p>~</p>\n<p>Suggest giving more frequent, longer</p>\n<p>feeds day and night, and gradually reduce</p>\n<p>other milk or foods</p>\n<p>If mother is away</p>\n<p>from the child due</p>\n<p>to work, etc.</p>\n<p>~</p>\n<p>Suggest she expresses breast milk to</p>\n<p>leave for the baby</p>\n<p>If other milk needs</p>\n<p>to be continued</p>\n<p>~</p>\n<p>Breastfeed as much as possible, including</p>\n<p>at night</p>\n<p>~</p>\n<p>Make sure that any other milk usedis an</p>\n<p>appropriate breastmilk substitute,</p>\n<p>~</p>\n<p>e.g. cow\u2019s milk</p>\n<p>~</p>\n<p>Correctly and hygienically prepared given</p>\n<p>in adequate amounts</p>\n<p>~</p>\n<p>Finish any prepared milk within 1 hour</p>\n<p>If the child is being</p>\n<p>given diluted milk</p>\n<p>or thin porridge</p>\n<p>~</p>\n<p>Remind mother that thick foods rich in</p>\n<p>energy and nutrients are needed by in\u00ad</p>\n<p>fants and young children</p>\n<p>~</p>\n<p>Advise her not to dilute the milk</p>\n<p>~</p>\n<p>Advise her to make thicker porridge</p>\n<p>If the mother is</p>\n<p>using a bottle to</p>\n<p>feed the child</p>\n<p>~</p>\n<p>Recommend using a cup instead of a bot\u00ad</p>\n<p>tle</p>\n<p>~</p>\n<p>Show the mother how to feed the child</p>\n<p>with a cup: press cup on infant\u2019s lower</p>\n<p>lip and allow him to take the milk himself,</p>\n<p>do not pour the milk into infant\u2019s mouth)</p>"
    },
    {
        "page_number": 931,
        "content": "865\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nPROBLEM\nCOUNSELLING AND FOLLOW UP\nIf the child is not \nbeing fed actively\n \n~\nCounsel the mother to\n \n- Sit with the child and encourage eating\n \n- Give the child an adequate serving in a \nseparate bowl\nIf the mother is \nnot giving foods \nrich in vitamin A\n \n~\nEncourage her to provide these regularly, \ne.g. eggs, green leafy vegetables, carrots, \nliver, mangoes, yellow sweet potatoes, \nand other dark orange fruit\nIf the child is 6 \nmonths and appro\u00ad\npriate\ncomplementary \nfoods have\nnot been intro\u00ad\nduced\n \n~\nGradually introduce thick porridge mixed \nwith available protein (e.g. milk); add sug\u00ad\nar and fat\n \n~\nGradually introduce mashed foods mixed \nwith relish\n \n~\nAdd green leafy vegetables and fat to this\n \n~\nGive nutritious snacks 3-5 times daily as \nin feeding recommendations above\nIf child eats solid \nfood with insuf\u00ad\nficient nutrient \ndensity or variety\n \n~\nGive a variety of mashed food mixtures \nmade with local staples and mixed with \nanimal or plant protein relish\n \n~\nAdd green leafy vegetables and fat to this\n \n~\nGive nutritious snacks 3 - 5 times daily as \nin feeding recommendations above\n17.3.12.5  Mother\u2019s Health\n \n\u008d\nCounsel mother about her own health\n \n\u008d\nIf she is sick, provide care for her or refer for further manage\u00ad\nment\n \n\u008d\nIf she has a breast problem (e.g. engorgement, sore nipples, \ninfection), provide care for her or refer for further help\n \n\u008d\nAdvise her to eat well to keep up her own strength and health",
        "formatted_content": "<p>865</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>PROBLEM</h3>\n<h3>COUNSELLING AND FOLLOW UP</h3>\n<p>If the child is not</p>\n<p>being fed actively</p>\n<p>~</p>\n<p>Counsel the mother to</p>\n<p>- Sit with the child and encourage eating</p>\n<p>- Give the child an adequate serving in a</p>\n<p>separate bowl</p>\n<p>If the mother is</p>\n<p>not giving foods</p>\n<p>rich in vitamin A</p>\n<p>~</p>\n<p>Encourage her to provide these regularly,</p>\n<p>e.g. eggs, green leafy vegetables, carrots,</p>\n<p>liver, mangoes, yellow sweet potatoes,</p>\n<p>and other dark orange fruit</p>\n<p>If the child is 6</p>\n<p>months and appro\u00ad</p>\n<p>priate</p>\n<p>complementary</p>\n<p>foods have</p>\n<p>not been intro\u00ad</p>\n<p>duced</p>\n<p>~</p>\n<p>Gradually introduce thick porridge mixed</p>\n<p>with available protein (e.g. milk); add sug\u00ad</p>\n<p>ar and fat</p>\n<p>~</p>\n<p>Gradually introduce mashed foods mixed</p>\n<p>with relish</p>\n<p>~</p>\n<p>Add green leafy vegetables and fat to this</p>\n<p>~</p>\n<p>Give nutritious snacks 3-5 times daily as</p>\n<p>in feeding recommendations above</p>\n<p>If child eats solid</p>\n<p>food with insuf\u00ad</p>\n<p>ficient nutrient</p>\n<p>density or variety</p>\n<p>~</p>\n<p>Give a variety of mashed food mixtures</p>\n<p>made with local staples and mixed with</p>\n<p>animal or plant protein relish</p>\n<p>~</p>\n<p>Add green leafy vegetables and fat to this</p>\n<p>~</p>\n<p>Give nutritious snacks 3 - 5 times daily as</p>\n<p>in feeding recommendations above</p>\n<p>17.3.12.5  Mother\u2019s Health</p>\n<p>\u008d</p>\n<p>Counsel mother about her own health</p>\n<p>\u008d</p>\n<p>If she is sick, provide care for her or refer for further manage\u00ad</p>\n<p>ment</p>\n<p>\u008d</p>\n<p>If she has a breast problem (e.g. engorgement, sore nipples,</p>\n<p>infection), provide care for her or refer for further help</p>\n<p>\u008d</p>\n<p>Advise her to eat well to keep up her own strength and health</p>"
    },
    {
        "page_number": 932,
        "content": "866\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\n \n\u008d\nCheck immunization status and give Tetanus Toxoid (TT) if \nneeded\n \n\u008d\nMake sure each mother has access to:\n\t\n\u0089\nFamily planning services\n\t\n\u0089\nCounselling on prevention of STIs, HIV/AIDS\n\t\n\u0089\nAntenatal care (if pregnant)\n \n\u008d\nGive additional counselling if the mother is HIV-positive\n \n\u008d\nReassure her that with regular FOLLOW UP much can be \ndone to prevent serious illness, and maintain her and the \nchild\u2019s health\n \n\u008d\nEmphasize good hygiene, and early treatment of illnesses\n17.4  INTEGRATED COMMUNITY CASE MANAGEMENT\nIntegrated Community Case Management (iCCM) of malaria, pneumo\u00ad\nnia and diarrhoea is a recently adopted strategy for the treatment of \ncommon childhood illness at community level by trained Community \nHealth Workers since 2010. It addresses a gap in delivery of curative \nservices to children below 5 years allowing:\n\t\n\u0089\nprompt and accessible treatment of uncomplicated malaria, pneu\u00ad\nmonia and diarrhoea\n\t\n\u0089\nidentification of danger signs (convulsions, chest in-\n\t\n\u0089\ndrawing, unable to feed, vomiting everything, lethargy/ uncon\u00ad\nsciousness) and pre-referral treatment\n\t\n\u0089\nmonitoring of newborns during the first week of life,\n\t\n\u0089\ncounselling and referral if any problem identified.\nCommunity health workers work in close collaboration with the health \nunit, to which they report and refer cases and from which they receive \nsupplies and supervision.",
        "formatted_content": "<p>866</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>\u008d</p>\n<p>Check immunization status and give Tetanus Toxoid (TT) if</p>\n<p>needed</p>\n<p>\u008d</p>\n<p>Make sure each mother has access to:</p>\n<p>\u0089</p>\n<p>Family planning services</p>\n<p>\u0089</p>\n<p>Counselling on prevention of STIs, HIV/AIDS</p>\n<p>\u0089</p>\n<p>Antenatal care (if pregnant)</p>\n<p>\u008d</p>\n<p>Give additional counselling if the mother is HIV-positive</p>\n<p>\u008d</p>\n<p>Reassure her that with regular FOLLOW UP much can be</p>\n<p>done to prevent serious illness, and maintain her and the</p>\n<p>child\u2019s health</p>\n<p>\u008d</p>\n<p>Emphasize good hygiene, and early treatment of illnesses</p>\n<h3>17.4  INTEGRATED COMMUNITY CASE MANAGEMENT</h3>\n<p>Integrated Community Case Management (iCCM) of malaria, pneumo\u00ad</p>\n<p>nia and diarrhoea is a recently adopted strategy for the treatment of</p>\n<p>common childhood illness at community level by trained Community</p>\n<p>Health Workers since 2010. It addresses a gap in delivery of curative</p>\n<p>services to children below 5 years allowing:</p>\n<p>\u0089</p>\n<p>prompt and accessible treatment of uncomplicated malaria, pneu\u00ad</p>\n<p>monia and diarrhoea</p>\n<p>\u0089</p>\n<p>identification of danger signs (convulsions, chest in-</p>\n<p>\u0089</p>\n<p>drawing, unable to feed, vomiting everything, lethargy/ uncon\u00ad</p>\n<p>sciousness) and pre-referral treatment</p>\n<p>\u0089</p>\n<p>monitoring of newborns during the first week of life,</p>\n<p>\u0089</p>\n<p>counselling and referral if any problem identified.</p>\n<p>Community health workers work in close collaboration with the health</p>\n<p>unit, to which they report and refer cases and from which they receive</p>\n<p>supplies and supervision.</p>"
    },
    {
        "page_number": 933,
        "content": "867\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nSupplies provided to trained community health workers\nICCM commodities\n \n~\nRespiratory timers and Amoxicillin dispersible tablets for \ndiagnosis and treatment of pneumonia\n \n~\nORS sachets and Zinc tablets for treatment of diarrhoea\n \n~\nRDTs and ACTs for diagnosis and treatment of uncompli\u00ad\ncated malaria\n \n~\nRectal artesunate for pre referral treatment of complicated \nmalaria.\n \n~\nExamination gloves\n \n~\nDispensing envelopes\n \n~\nRegisters, referral notes and sick job aids\nOther commodities for community health workers\n \n~\nOther preventive treatments: used in prevention and treat\u00ad\nment of common conditions and neglected topical diseas\u00ad\nes like albendazole, azithromycin syrup and tablets, iver\u00ad\nmectin, tetracycline eye ointment, praziquantel, COC.\nTreatments prescribed by VHTs\nTREATMENT\nINDICATION\nDOSES\nAmoxicillin DT 250 \nmg\nPneumonia (cough \n<\n21 days + in\u00ad\ncreased respirato\u00ad\nry rate)\n2-11 months: 1 tab every\n12 hours for 5 days RED PACK\n1-5 years: 2 tab every\n12 hours for 5 days GREEN \nPACK\nZinc Tablets and \nORS\nDiarrhoea\n< 14 days without \nblood\nZinc\n2-6 months: \u00bd tab once a day \nfor 10 days\n6 months to 5 years: 1 tab \nonce a day for 10 days ORS \nAs much as the chid wants but \nat least \u00bd cup after each loose \nstool",
        "formatted_content": "<p>867</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Supplies provided to trained community health workers</p>\n<p>ICCM commodities</p>\n<p>~</p>\n<p>Respiratory timers and Amoxicillin dispersible tablets for</p>\n<p>diagnosis and treatment of pneumonia</p>\n<p>~</p>\n<p>ORS sachets and Zinc tablets for treatment of diarrhoea</p>\n<p>~</p>\n<p>RDTs and ACTs for diagnosis and treatment of uncompli\u00ad</p>\n<p>cated malaria</p>\n<p>~</p>\n<p>Rectal artesunate for pre referral treatment of complicated</p>\n<p>malaria.</p>\n<p>~</p>\n<p>Examination gloves</p>\n<p>~</p>\n<p>Dispensing envelopes</p>\n<p>~</p>\n<p>Registers, referral notes and sick job aids</p>\n<p>Other commodities for community health workers</p>\n<p>~</p>\n<p>Other preventive treatments: used in prevention and treat\u00ad</p>\n<p>ment of common conditions and neglected topical diseas\u00ad</p>\n<p>es like albendazole, azithromycin syrup and tablets, iver\u00ad</p>\n<p>mectin, tetracycline eye ointment, praziquantel, COC.</p>\n<p>Treatments prescribed by VHTs</p>\n<h3>TREATMENT</h3>\n<h3>INDICATION</h3>\n<h3>DOSES</h3>\n<p>Amoxicillin DT 250</p>\n<p>mg</p>\n<p>Pneumonia (cough</p>\n<p><</p>\n<p>21 days + in\u00ad</p>\n<p>creased respirato\u00ad</p>\n<p>ry rate)</p>\n<p>2-11 months: 1 tab every</p>\n<p>12 hours for 5 days RED PACK</p>\n<p>1-5 years: 2 tab every</p>\n<p>12 hours for 5 days GREEN</p>\n<h3>PACK</h3>\n<p>Zinc Tablets and</p>\n<h3>ORS</h3>\n<p>Diarrhoea</p>\n<p>< 14 days without</p>\n<p>blood</p>\n<p>Zinc</p>\n<p>2-6 months: \u00bd tab once a day</p>\n<p>for 10 days</p>\n<p>6 months to 5 years: 1 tab</p>\n<p>once a day for 10 days ORS</p>\n<p>As much as the chid wants but</p>\n<p>at least \u00bd cup after each loose</p>\n<p>stool</p>"
    },
    {
        "page_number": 934,
        "content": "868\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nTREATMENT\nINDICATION\nDOSES\nACT\nFever\n<7 days\nRDT\npositive\n4 months-2 years: 1 tab\nevery 12 hours for 3 days (YEL\u00ad\nLOW PACK)\n2-5 years: 2 tab every 12 hours \nfor 3 days (BLUE PACK)\nRectal Ar\u00ad\ntesunate\nFever and danger signs, \nprereferral\n4-11 months: 1 capsule\n1-3 years: 2 capsules\n3-5 years: 3 capsules\n17.5  CHILD GROWTH WEIGHT STANDARDS CHARTS\nThe WHO Child Growth Standards charts are used to identify normal \ngrowth for children under 5 years, as well as growth problems or trends \nthat suggest that a child is at risk of a problem.\nWeight-for-Age\n\t\nr\nUsed to show if a child is normal weight or underweight for their \nage. It should not be used to assess obesity and overweight.\nDisadvantages\n\u2022\t\nIf a child\u2019s age is unknown, it is of limited use\n\u2022\t\nIt cannot distinguish between chronic malnutrition (stunting) and acute \nmalnutrition\n\u2022\t\nAlso, if a child has oedema of both feet, fluid retention increases the \nchild\u2019s weight, masking what may actually be very low weight.\nWeight for-Height/Length\n\t\nr\nUsed to diagnose acute malnutrition\n\t\nr\nThe cut-off for severe acute malnutrition is -3 z-scores and be\u00ad\nlow. These children are at a high risk of mortality, but respond \nquickly and safely to re-feeding using therapeutic foods following \nrecommended guidelines.\n\t\nr\nThe cut-off for moderate acute malnutrition is -2 to -3 z-scores \nbelow.",
        "formatted_content": "<p>868</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<h3>TREATMENT</h3>\n<h3>INDICATION</h3>\n<h3>DOSES</h3>\n<h3>ACT</h3>\n<p>Fever</p>\n<p><7 days</p>\n<h3>RDT</h3>\n<p>positive</p>\n<p>4 months-2 years: 1 tab</p>\n<p>every 12 hours for 3 days (YEL\u00ad</p>\n<h3>LOW PACK)</h3>\n<p>2-5 years: 2 tab every 12 hours</p>\n<p>for 3 days (BLUE PACK)</p>\n<p>Rectal Ar\u00ad</p>\n<p>tesunate</p>\n<p>Fever and danger signs,</p>\n<p>prereferral</p>\n<p>4-11 months: 1 capsule</p>\n<p>1-3 years: 2 capsules</p>\n<p>3-5 years: 3 capsules</p>\n<h3>17.5  CHILD GROWTH WEIGHT STANDARDS CHARTS</h3>\n<p>The WHO Child Growth Standards charts are used to identify normal</p>\n<p>growth for children under 5 years, as well as growth problems or trends</p>\n<p>that suggest that a child is at risk of a problem.</p>\n<p>Weight-for-Age</p>\n<p>r</p>\n<p>Used to show if a child is normal weight or underweight for their</p>\n<p>age. It should not be used to assess obesity and overweight.</p>\n<p>Disadvantages</p>\n<li></li>\n<p>If a child\u2019s age is unknown, it is of limited use</p>\n<li></li>\n<p>It cannot distinguish between chronic malnutrition (stunting) and acute</p>\n<p>malnutrition</p>\n<li></li>\n<p>Also, if a child has oedema of both feet, fluid retention increases the</p>\n<p>child\u2019s weight, masking what may actually be very low weight.</p>\n<p>Weight for-Height/Length</p>\n<p>r</p>\n<p>Used to diagnose acute malnutrition</p>\n<p>r</p>\n<p>The cut-off for severe acute malnutrition is -3 z-scores and be\u00ad</p>\n<p>low. These children are at a high risk of mortality, but respond</p>\n<p>quickly and safely to re-feeding using therapeutic foods following</p>\n<p>recommended guidelines.</p>\n<p>r</p>\n<p>The cut-off for moderate acute malnutrition is -2 to -3 z-scores</p>\n<p>below.</p>"
    },
    {
        "page_number": 935,
        "content": "869\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nMean Upper Arm circumference (MUAC)\n\t\nr\nUsed to diagnose acute malnutrition\n\t\nr\nThe cut off for severe acute malnutrition is 115 mm (11.5 cm) \nand below.\nWeight-for-age BOYS\nBirth to 5 years (z-scores)",
        "formatted_content": "<p>869</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Mean Upper Arm circumference (MUAC)</p>\n<p>r</p>\n<p>Used to diagnose acute malnutrition</p>\n<p>r</p>\n<p>The cut off for severe acute malnutrition is 115 mm (11.5 cm)</p>\n<p>and below.</p>\n<p>Weight-for-age BOYS</p>\n<p>Birth to 5 years (z-scores)</p>"
    },
    {
        "page_number": 936,
        "content": "870\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nWeight-for-age GIRLS\nBirth to 5 years (z-scores)",
        "formatted_content": "<p>870</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Weight-for-age GIRLS</p>\n<p>Birth to 5 years (z-scores)</p>"
    },
    {
        "page_number": 937,
        "content": "871\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nWeight-for-Height BOYS\n2 to 5 years (z-scores)",
        "formatted_content": "<p>871</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Weight-for-Height BOYS</p>\n<p>2 to 5 years (z-scores)</p>"
    },
    {
        "page_number": 938,
        "content": "872\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nWeight-for-Height GIRLS\n2 to 5 years (z-scores)",
        "formatted_content": "<p>872</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Weight-for-Height GIRLS</p>\n<p>2 to 5 years (z-scores)</p>"
    },
    {
        "page_number": 939,
        "content": "873\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nArm circumference-for-age BOYS\n3 months to 5 years (z-scores)",
        "formatted_content": "<p>873</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Arm circumference-for-age BOYS</p>\n<p>3 months to 5 years (z-scores)</p>"
    },
    {
        "page_number": 940,
        "content": "874\nUganda Clinical Guidelines 2023\nCHAPTER 17: Childhood Illness\nArm circumference-for-age GIRLS\n3 months to 5 years (z-scores)",
        "formatted_content": "<p>874</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 17: Childhood Illness</p>\n<p>Arm circumference-for-age GIRLS</p>\n<p>3 months to 5 years (z-scores)</p>"
    },
    {
        "page_number": 941,
        "content": "875\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\nImmunization\n18\n18.1  ROUTINE CHILDHOOD VACCINATION\n18.1.1   National Immunization Schedule\nAdapted from the UNEPI/MOH Immunization Schedule, 2022\nVaccine Or \nAntigen\nAge\nDose & Mode Of \nAdministration\nMode Of Ad\u00ad\nministration\nSite Of Ad\u00ad\nministration\nBCG\nAt birth \n(or first \ncontact)\n0-11 months:\n0.05 mL \nAbove 11 \nmonths:\n0.1 mL\nIntradermally Right Up\u00ad\nper Arm\nHepatitis \nB\nAt \nbirth(first \ncontact \nwithin \nthe first \n7 days of \nlife)\n0.5 ml IM\nIntramus\u00ad\ncular\nOuter \naspect of \nleft thigh\nOral Polio\n4 doses:\nat birth, \n6,\n10, and \n14 weeks\n2 drops \nOrally \nMouth\nInactivat\u00ad\ned Polio \nVaccine \n(IPV)\n2 doses: \nAt 6 and \n14\nWeeks of \nage\n0.5 mL \nIntramus\u00ad\ncular\nOuter \naspect of \nright thigh;\n2.5 cm \naway from \nPCV site",
        "formatted_content": "<p>875</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>Immunization</p>\n<p>18</p>\n<h3>18.1  ROUTINE CHILDHOOD VACCINATION</h3>\n<p>18.1.1   National Immunization Schedule</p>\n<p>Adapted from the UNEPI/MOH Immunization Schedule, 2022</p>\n<p>Vaccine Or</p>\n<p>Antigen</p>\n<p>Age</p>\n<p>Dose & Mode Of</p>\n<p>Administration</p>\n<p>Mode Of Ad\u00ad</p>\n<p>ministration</p>\n<p>Site Of Ad\u00ad</p>\n<p>ministration</p>\n<h3>BCG</h3>\n<p>At birth</p>\n<p>(or first</p>\n<p>contact)</p>\n<p>0-11 months:</p>\n<p>0.05 mL</p>\n<p>Above 11</p>\n<p>months:</p>\n<p>0.1 mL</p>\n<p>Intradermally Right Up\u00ad</p>\n<p>per Arm</p>\n<p>Hepatitis</p>\n<p>B</p>\n<p>At</p>\n<p>birth(first</p>\n<p>contact</p>\n<p>within</p>\n<p>the first</p>\n<p>7 days of</p>\n<p>life)</p>\n<p>0.5 ml IM</p>\n<p>Intramus\u00ad</p>\n<p>cular</p>\n<p>Outer</p>\n<p>aspect of</p>\n<p>left thigh</p>\n<p>Oral Polio</p>\n<p>4 doses:</p>\n<p>at birth,</p>\n<p>6,</p>\n<p>10, and</p>\n<p>14 weeks</p>\n<p>2 drops</p>\n<p>Orally</p>\n<p>Mouth</p>\n<p>Inactivat\u00ad</p>\n<p>ed Polio</p>\n<p>Vaccine</p>\n<h3>(IPV)</h3>\n<p>2 doses:</p>\n<p>At 6 and</p>\n<p>14</p>\n<p>Weeks of</p>\n<p>age</p>\n<p>0.5 mL</p>\n<p>Intramus\u00ad</p>\n<p>cular</p>\n<p>Outer</p>\n<p>aspect of</p>\n<p>right thigh;</p>\n<p>2.5 cm</p>\n<p>away from</p>\n<p>PCV site</p>"
    },
    {
        "page_number": 942,
        "content": "876\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\nVaccine Or \nAntigen\nAge\nDose & Mode Of \nAdministration\nMode Of Ad\u00ad\nministration\nSite Of Ad\u00ad\nministration\nDPT-\nHepB\n+ Hib 1\n3 doses:\nat 6, 10 \nand\n14 weeks\n0.5 mL\nIntramus\u00ad\ncular\nOuter \naspect of \nleft thigh\nPCV\n3 doses: \nat\n6, 10 \nand\n14 weeks\n0.5 mL\nIntramus\u00ad\ncular\nOuter \naspect of \nright thigh\nRota\n2 doses: at\n6 and\n10 weeks\n2 drops\norally\nSlow admin \non inner \naspect of \ncheek\nMeasles \nRubella\n2 doses:At \n9 and 18 \nmonths\n0.5 mL \nSubcutaneous\nLeft Upper \nArm\nYellow fever\nAt 9 months\n0.5 ml \nSubcutaneous\nRight Upper \nArm\nAll girls in \nprimary 4 or \n10 year old \ngirls outside \nschool\nHPV\nGive 2 doses IM 6 \nmonths apart\nIntramuscular\nLeft Upper \nArm\nGeneral principles of routine childhood immunization\n \n~\nThe aim is to ensure that all target age groups complete \ntheir immunization schedule as above\n \n~\nAge for vaccinations: Give each vaccine at the recom\u00ad\nmended age or if this is not possible, at any first contact \nwith the child after this age\n \n~\nBCG vaccination\n \n- Give this as early as possible in life, preferably at birth\n \n- Do NOT give BCG vaccine to any child with clinical signs \nand symptoms of immunosuppression, e.g. AIDS",
        "formatted_content": "<p>876</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>Vaccine Or</p>\n<p>Antigen</p>\n<p>Age</p>\n<p>Dose & Mode Of</p>\n<p>Administration</p>\n<p>Mode Of Ad\u00ad</p>\n<p>ministration</p>\n<p>Site Of Ad\u00ad</p>\n<p>ministration</p>\n<h3>DPT-</h3>\n<p>HepB</p>\n<p>+ Hib 1</p>\n<p>3 doses:</p>\n<p>at 6, 10</p>\n<p>and</p>\n<p>14 weeks</p>\n<p>0.5 mL</p>\n<p>Intramus\u00ad</p>\n<p>cular</p>\n<p>Outer</p>\n<p>aspect of</p>\n<p>left thigh</p>\n<h3>PCV</h3>\n<p>3 doses:</p>\n<p>at</p>\n<p>6, 10</p>\n<p>and</p>\n<p>14 weeks</p>\n<p>0.5 mL</p>\n<p>Intramus\u00ad</p>\n<p>cular</p>\n<p>Outer</p>\n<p>aspect of</p>\n<p>right thigh</p>\n<p>Rota</p>\n<p>2 doses: at</p>\n<p>6 and</p>\n<p>10 weeks</p>\n<p>2 drops</p>\n<p>orally</p>\n<p>Slow admin</p>\n<p>on inner</p>\n<p>aspect of</p>\n<p>cheek</p>\n<p>Measles</p>\n<p>Rubella</p>\n<p>2 doses:At</p>\n<p>9 and 18</p>\n<p>months</p>\n<p>0.5 mL</p>\n<p>Subcutaneous</p>\n<p>Left Upper</p>\n<p>Arm</p>\n<p>Yellow fever</p>\n<p>At 9 months</p>\n<p>0.5 ml</p>\n<p>Subcutaneous</p>\n<p>Right Upper</p>\n<p>Arm</p>\n<p>All girls in</p>\n<p>primary 4 or</p>\n<p>10 year old</p>\n<p>girls outside</p>\n<p>school</p>\n<h3>HPV</h3>\n<p>Give 2 doses IM 6</p>\n<p>months apart</p>\n<p>Intramuscular</p>\n<p>Left Upper</p>\n<p>Arm</p>\n<p>General principles of routine childhood immunization</p>\n<p>~</p>\n<p>The aim is to ensure that all target age groups complete</p>\n<p>their immunization schedule as above</p>\n<p>~</p>\n<p>Age for vaccinations: Give each vaccine at the recom\u00ad</p>\n<p>mended age or if this is not possible, at any first contact</p>\n<p>with the child after this age</p>\n<p>~</p>\n<p>BCG vaccination</p>\n<p>- Give this as early as possible in life, preferably at birth</p>\n<p>- Do NOT give BCG vaccine to any child with clinical signs</p>\n<p>and symptoms of immunosuppression, e.g. AIDS</p>"
    },
    {
        "page_number": 943,
        "content": "877\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\n \n~\nUse each vaccine with its corresponding pre-cooled diluent \nfrom the same manufacturer\n \n~\nPolio vaccination (= \u2018birth dose\u2019): This is a primer dose of \noral polio vaccine (OPV), which should be given ideally at \nbirth but otherwise in the first 2 weeks of life\n \n~\nDPT-HepB-Hib vaccine\n \n- Is a combination of DPT vaccine + hepatitis B vaccine (HepB) \n+ haemophilus influenzae type b (Hib) vaccine\n \n- Minimum interval between each of the doses is 4 weeks\n \n~\nMeasles rubella vaccination\n\t\n\u0089\nGiven at 9  and 18 months of age or first contact after this age\n\t\n\u0089\nCan also be given to any unimmunised child of 6-9 months\n\t\n\u0089\nold who has been exposed to measles patients. Children vaccinated \nin this way must have the vaccination repeated at 9 months of age\n \n~\nVaccination of sick children\n\t\n\u0089\nAdmit and treat any child who is severely ill, and vaccinate at the \ntime of discharge\n\t\n\u0089\nMinor illness is not a contraindication to vaccination\n\t\n\u0089\nScreen clients at points of care and administer the due vaccines\n\t\n\u0089\nScreen clients for vaccine preventable diseases for investigation \nand notification\nAdministration and storage of vaccines\nStorage and transport\n \n~\nAt health units, vaccines should be stored between +2\u00b0C to\n \n~\n+8\u00b0C\n \n~\nAt the district and central vaccine stores (static units) where \nfreezers exist, polio and measles rubella vaccines may be \nstored for prolonged periods at -20\u00b0C\n \n~\nDo not freeze DPT-HepB-Hib, PCV, IPV, HPV, hepatitis B, \nyellow fever and TT vaccines\n \n~\nNever freeze the diluents for BCG,yellow fever  and measles \nvaccines",
        "formatted_content": "<p>877</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>~</p>\n<p>Use each vaccine with its corresponding pre-cooled diluent</p>\n<p>from the same manufacturer</p>\n<p>~</p>\n<p>Polio vaccination (= \u2018birth dose\u2019): This is a primer dose of</p>\n<p>oral polio vaccine (OPV), which should be given ideally at</p>\n<p>birth but otherwise in the first 2 weeks of life</p>\n<p>~</p>\n<p>DPT-HepB-Hib vaccine</p>\n<p>- Is a combination of DPT vaccine + hepatitis B vaccine (HepB)</p>\n<p>+ haemophilus influenzae type b (Hib) vaccine</p>\n<p>- Minimum interval between each of the doses is 4 weeks</p>\n<p>~</p>\n<p>Measles rubella vaccination</p>\n<p>\u0089</p>\n<p>Given at 9  and 18 months of age or first contact after this age</p>\n<p>\u0089</p>\n<p>Can also be given to any unimmunised child of 6-9 months</p>\n<p>\u0089</p>\n<p>old who has been exposed to measles patients. Children vaccinated</p>\n<p>in this way must have the vaccination repeated at 9 months of age</p>\n<p>~</p>\n<p>Vaccination of sick children</p>\n<p>\u0089</p>\n<p>Admit and treat any child who is severely ill, and vaccinate at the</p>\n<p>time of discharge</p>\n<p>\u0089</p>\n<p>Minor illness is not a contraindication to vaccination</p>\n<p>\u0089</p>\n<p>Screen clients at points of care and administer the due vaccines</p>\n<p>\u0089</p>\n<p>Screen clients for vaccine preventable diseases for investigation</p>\n<p>and notification</p>\n<p>Administration and storage of vaccines</p>\n<p>Storage and transport</p>\n<p>~</p>\n<p>At health units, vaccines should be stored between +2\u00b0C to</p>\n<p>~</p>\n<h3>+8\u00b0C</h3>\n<p>~</p>\n<p>At the district and central vaccine stores (static units) where</p>\n<p>freezers exist, polio and measles rubella vaccines may be</p>\n<p>stored for prolonged periods at -20\u00b0C</p>\n<p>~</p>\n<p>Do not freeze DPT-HepB-Hib, PCV, IPV, HPV, hepatitis B,</p>\n<p>yellow fever and TT vaccines</p>\n<p>~</p>\n<p>Never freeze the diluents for BCG,yellow fever  and measles</p>\n<p>vaccines</p>"
    },
    {
        "page_number": 944,
        "content": "878\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\n \n~\nUse conditioned ice packs and sponge method for trans\u00ad\nport\nCarefully follow recommended procedures to maintain the cold chain \nfor all vaccines, e.g.:\n\t\n\u0089\nEnsure continuous supply of power/gas\n\t\n\u0089\nRecord fridge temperature twice daily (morning and evening, \nincluding weekends/public holidays)\n\t\n\u0089\nUse sponge method during each immunization session\nReconstitution and administration\n \n~\nNever use the diluents provided for vaccines to mix other \ninjectable medicines\n \n~\nNever use water for injection as a diluent for vaccine re\u00ad\nconstitution\nDo not vaccinate in direct sunlight (always carry out immuniza\u00ad\ntion in a building or under a shade)\n \n~\nRecord every vaccination in the child register and on a \ntally sheet until child has completed all the antigens\n \n~\nUse the child register and child health card for tracking \ndrop outs\n \n~\nA child who received any immunization dose during na\u00ad\ntional immunization campaigns should still get the routine \nvaccination doses\n \n~\nNever use any vaccine:\n \n- After its expiry date\n \n- When the vaccine vial monitor (VVM) has changed to \ndiscard point (stage 3 and 4)\n \n- If there has been contamination, or contamination is\n \n- suspected in open vials\n \n- If the vial labels are lost\n \n- DPT-HepB-Hib, HebB, PCV,rotavirus vaccine, IPV, HPV, \nTT/Td that have been frozen",
        "formatted_content": "<p>878</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>~</p>\n<p>Use conditioned ice packs and sponge method for trans\u00ad</p>\n<p>port</p>\n<p>Carefully follow recommended procedures to maintain the cold chain</p>\n<p>for all vaccines, e.g.:</p>\n<p>\u0089</p>\n<p>Ensure continuous supply of power/gas</p>\n<p>\u0089</p>\n<p>Record fridge temperature twice daily (morning and evening,</p>\n<p>including weekends/public holidays)</p>\n<p>\u0089</p>\n<p>Use sponge method during each immunization session</p>\n<p>Reconstitution and administration</p>\n<p>~</p>\n<p>Never use the diluents provided for vaccines to mix other</p>\n<p>injectable medicines</p>\n<p>~</p>\n<p>Never use water for injection as a diluent for vaccine re\u00ad</p>\n<p>constitution</p>\n<p>Do not vaccinate in direct sunlight (always carry out immuniza\u00ad</p>\n<p>tion in a building or under a shade)</p>\n<p>~</p>\n<p>Record every vaccination in the child register and on a</p>\n<p>tally sheet until child has completed all the antigens</p>\n<p>~</p>\n<p>Use the child register and child health card for tracking</p>\n<p>drop outs</p>\n<p>~</p>\n<p>A child who received any immunization dose during na\u00ad</p>\n<p>tional immunization campaigns should still get the routine</p>\n<p>vaccination doses</p>\n<p>~</p>\n<p>Never use any vaccine:</p>\n<p>- After its expiry date</p>\n<p>- When the vaccine vial monitor (VVM) has changed to</p>\n<p>discard point (stage 3 and 4)</p>\n<p>- If there has been contamination, or contamination is</p>\n<p>- suspected in open vials</p>\n<p>- If the vial labels are lost</p>\n<p>- DPT-HepB-Hib, HebB, PCV,rotavirus vaccine, IPV, HPV,</p>\n<p>TT/Td that have been frozen</p>"
    },
    {
        "page_number": 945,
        "content": "879\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\nAdhere to the WHO recommended Multi-Dose Vial Policy \n(MDVP) as below:\nTYPE OF VACCINE\nMDVP GUIDELINE\nOPV and IPV\nDo not use vaccine if:\nContaminated or has no label\nThe VVM at or beyond discard point (stage 3 & \n4)\nVials have been opened for 4 weeks\nVials opened during outreach\nVaccines have not been stored under cold chain \nconditions\nDPT-HepB-\nHib, Hep B, \nTT,PCV\nDo not use vaccine if:\nContaminated or has no label\nThe VVM is at or beyond discard point\nFrozen\nVials have been opened for 4 weeks or more\nVials opened during out- reach\nVaccines have not been stored under cold chain \nconditions\nBCG,yellow \nfever\nand Measles \nRubella\n \n~\nDiscard remaining doses in the \nopened vials of these vaccines after 6 \nhours\n \n~\nof reconstitution or at the end of the \nimmunization \nsession, \nwhichever \ncomes first\nCommon non-serious side effects of vaccines and patient advice\nVACCINE AND SIDE EFFECTS\nPATIENT ADVICE\nBCG\n \n~\nPain at injec\u00ad\ntion site\n \n~\nThe ulcer that forms at the \ninjection site is a normal and \nexpected reaction that heals \nby itself and leaves a perma\u00ad\nnent scar. It should not be \ncovered with anything",
        "formatted_content": "<p>879</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>Adhere to the WHO recommended Multi-Dose Vial Policy</p>\n<p>(MDVP) as below:</p>\n<h3>TYPE OF VACCINE</h3>\n<h3>MDVP GUIDELINE</h3>\n<p>OPV and IPV</p>\n<p>Do not use vaccine if:</p>\n<p>Contaminated or has no label</p>\n<p>The VVM at or beyond discard point (stage 3 &</p>\n<p>4)</p>\n<p>Vials have been opened for 4 weeks</p>\n<p>Vials opened during outreach</p>\n<p>Vaccines have not been stored under cold chain</p>\n<p>conditions</p>\n<p>DPT-HepB-</p>\n<p>Hib, Hep B,</p>\n<h3>TT,PCV</h3>\n<p>Do not use vaccine if:</p>\n<p>Contaminated or has no label</p>\n<p>The VVM is at or beyond discard point</p>\n<p>Frozen</p>\n<p>Vials have been opened for 4 weeks or more</p>\n<p>Vials opened during out- reach</p>\n<p>Vaccines have not been stored under cold chain</p>\n<p>conditions</p>\n<p>BCG,yellow</p>\n<p>fever</p>\n<p>and Measles</p>\n<p>Rubella</p>\n<p>~</p>\n<p>Discard remaining doses in the</p>\n<p>opened vials of these vaccines after 6</p>\n<p>hours</p>\n<p>~</p>\n<p>of reconstitution or at the end of the</p>\n<p>immunization</p>\n<p>session,</p>\n<p>whichever</p>\n<p>comes first</p>\n<p>Common non-serious side effects of vaccines and patient advice</p>\n<h3>VACCINE AND SIDE EFFECTS</h3>\n<h3>PATIENT ADVICE</h3>\n<h3>BCG</h3>\n<p>~</p>\n<p>Pain at injec\u00ad</p>\n<p>tion site</p>\n<p>~</p>\n<p>The ulcer that forms at the</p>\n<p>injection site is a normal and</p>\n<p>expected reaction that heals</p>\n<p>by itself and leaves a perma\u00ad</p>\n<p>nent scar. It should not be</p>\n<p>covered with anything</p>"
    },
    {
        "page_number": 946,
        "content": "880\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\nVACCINE AND SIDE EFFECTS\nPATIENT ADVICE\nDPT-HepB-Hib, PCV\n \n~\nMild reactions \nat injection site: \nswelling, pain, \nredness\n \n~\nFever within \n24 hours of the \ninjection\n \n~\nAnaphylactic \nreactions\n \n~\nSeizures\n \n~\nDo not apply anything to the \ninjection site\n\t\n\u0089\nTake paracetamol if necessary.\n\u2013 If fever continues after 2 doses of \nparacetamol, report to health facility\n\t\n\u0089\nWiping the child with a cool sponge or cloth \n(with water at room temperature) is also good \nfor reducing fever\n \n~\nIf seizures or severe rash/ diffi\u00ad\nculty in breathing occurs, return \nto health facilty immediately\nOral Polio and Rotavirus \n \n~\nShort-lived \ngas\u00ad\nt r o i n t e s t i n a l \nsymptoms (pain, \ndiarrhoea, irrita\u00ad\ntion)\n \n~\nDispose of the child\u2019s faeces \nproperly as the virus spreads \nthrough the oral-faecal route\n \n~\nWash hands thoroughly after \nchanging the baby\u2019s nappies\nInactivated/Injectable Polio\n \n~\nPain, redness \nand swelling at \ninjection site\n \n~\nFever, headache, \ndrowsiness,\n \n~\nIrritability in \ninfants\n \n~\nDiarrhoea, \nnausea,\n \n~\nvomiting\n \n~\nSide effects usually mild and \nshould not cause worry\n \n~\nTake paracetamol if necessary\n \n~\nIf fever continues after 2 doses \nof paracetamol, report to health \nfacility\n \n~\nReport any severe reaction to \nhealth worker immediately\nMeasles rubella\n \n~\nPain, swelling, \nredness at \ninjection site\n \n~\nFever and \nskin rash 5-12 \ndays after the \nvaccine\n \n~\nChild may get a mild skin \nrash and fever after few \ndays; do not worry\n \n~\nDo not apply anything to \nthe injection site",
        "formatted_content": "<p>880</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<h3>VACCINE AND SIDE EFFECTS</h3>\n<h3>PATIENT ADVICE</h3>\n<p>DPT-HepB-Hib, PCV</p>\n<p>~</p>\n<p>Mild reactions</p>\n<p>at injection site:</p>\n<p>swelling, pain,</p>\n<p>redness</p>\n<p>~</p>\n<p>Fever within</p>\n<p>24 hours of the</p>\n<p>injection</p>\n<p>~</p>\n<p>Anaphylactic</p>\n<p>reactions</p>\n<p>~</p>\n<p>Seizures</p>\n<p>~</p>\n<p>Do not apply anything to the</p>\n<p>injection site</p>\n<p>\u0089</p>\n<p>Take paracetamol if necessary.</p>\n<p>\u2013 If fever continues after 2 doses of</p>\n<p>paracetamol, report to health facility</p>\n<p>\u0089</p>\n<p>Wiping the child with a cool sponge or cloth</p>\n<p>(with water at room temperature) is also good</p>\n<p>for reducing fever</p>\n<p>~</p>\n<p>If seizures or severe rash/ diffi\u00ad</p>\n<p>culty in breathing occurs, return</p>\n<p>to health facilty immediately</p>\n<p>Oral Polio and Rotavirus</p>\n<p>~</p>\n<p>Short-lived</p>\n<p>gas\u00ad</p>\n<p>t r o i n t e s t i n a l</p>\n<p>symptoms (pain,</p>\n<p>diarrhoea, irrita\u00ad</p>\n<p>tion)</p>\n<p>~</p>\n<p>Dispose of the child\u2019s faeces</p>\n<p>properly as the virus spreads</p>\n<p>through the oral-faecal route</p>\n<p>~</p>\n<p>Wash hands thoroughly after</p>\n<p>changing the baby\u2019s nappies</p>\n<p>Inactivated/Injectable Polio</p>\n<p>~</p>\n<p>Pain, redness</p>\n<p>and swelling at</p>\n<p>injection site</p>\n<p>~</p>\n<p>Fever, headache,</p>\n<p>drowsiness,</p>\n<p>~</p>\n<p>Irritability in</p>\n<p>infants</p>\n<p>~</p>\n<p>Diarrhoea,</p>\n<p>nausea,</p>\n<p>~</p>\n<p>vomiting</p>\n<p>~</p>\n<p>Side effects usually mild and</p>\n<p>should not cause worry</p>\n<p>~</p>\n<p>Take paracetamol if necessary</p>\n<p>~</p>\n<p>If fever continues after 2 doses</p>\n<p>of paracetamol, report to health</p>\n<p>facility</p>\n<p>~</p>\n<p>Report any severe reaction to</p>\n<p>health worker immediately</p>\n<p>Measles rubella</p>\n<p>~</p>\n<p>Pain, swelling,</p>\n<p>redness at</p>\n<p>injection site</p>\n<p>~</p>\n<p>Fever and</p>\n<p>skin rash 5-12</p>\n<p>days after the</p>\n<p>vaccine</p>\n<p>~</p>\n<p>Child may get a mild skin</p>\n<p>rash and fever after few</p>\n<p>days; do not worry</p>\n<p>~</p>\n<p>Do not apply anything to</p>\n<p>the injection site</p>"
    },
    {
        "page_number": 947,
        "content": "881\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\nVACCINE AND SIDE EFFECTS\nPATIENT ADVICE\nYellow fever\n \n~\nPain, swelling, \nredness at injec\u00ad\ntion site\n \n~\nFever and skin \nrash 5-12 days \nafter the vaccine\n \n~\nSide effects may occur \nwithin 1\u20132 days of im\u00ad\nmunization; they are usu\u00ad\nally mild and should not \ncause worry\n \n~\nReport to health worker \nimmediately any severe \nreaction\nHPV\n \n~\nInjection site \nreactions: pain, \nredness, itch\u00ad\ning, bruising or \nswelling\n \n~\nHeadaches\n \n~\nGeneral body \naches, nausea\n \n~\nSide effects usually mild \nand should not cause \nworry\n \n~\nReport to health worker \nimmediately any severe \nreaction\nTetanus Toxoid (TT)\n \n~\nIrritation at injec\u00ad\ntion site\n \n~\nFever, malaise\n \n~\nSide effects may occur \nwithin 1\u20132 days of im\u00ad\nmunization; they are usu\u00ad\nally mild and should not \ncause worry\n \n~\nReport to health worker \nimmediately any severe \nreaction\nHep B Vaccine\n \n~\nPain, redness and \nswelling at injec\u00ad\ntion site\n \n~\nFatigue\n \n~\nFever\n \n~\nIf fever develops, give \na single dose of parac\u00ad\netamol\nOTHER VACCINATIONS\n18.1.2  Hepatitis B Vaccination\n \n~\nSince 2005, children are immunised against Hepatitis B in \nthe routine childhood immunization using the DPT-HepB- \nHib vaccine at 6, 10, and 14 weeks of age",
        "formatted_content": "<p>881</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<h3>VACCINE AND SIDE EFFECTS</h3>\n<h3>PATIENT ADVICE</h3>\n<p>Yellow fever</p>\n<p>~</p>\n<p>Pain, swelling,</p>\n<p>redness at injec\u00ad</p>\n<p>tion site</p>\n<p>~</p>\n<p>Fever and skin</p>\n<p>rash 5-12 days</p>\n<p>after the vaccine</p>\n<p>~</p>\n<p>Side effects may occur</p>\n<p>within 1\u20132 days of im\u00ad</p>\n<p>munization; they are usu\u00ad</p>\n<p>ally mild and should not</p>\n<p>cause worry</p>\n<p>~</p>\n<p>Report to health worker</p>\n<p>immediately any severe</p>\n<p>reaction</p>\n<h3>HPV</h3>\n<p>~</p>\n<p>Injection site</p>\n<p>reactions: pain,</p>\n<p>redness, itch\u00ad</p>\n<p>ing, bruising or</p>\n<p>swelling</p>\n<p>~</p>\n<p>Headaches</p>\n<p>~</p>\n<p>General body</p>\n<p>aches, nausea</p>\n<p>~</p>\n<p>Side effects usually mild</p>\n<p>and should not cause</p>\n<p>worry</p>\n<p>~</p>\n<p>Report to health worker</p>\n<p>immediately any severe</p>\n<p>reaction</p>\n<p>Tetanus Toxoid (TT)</p>\n<p>~</p>\n<p>Irritation at injec\u00ad</p>\n<p>tion site</p>\n<p>~</p>\n<p>Fever, malaise</p>\n<p>~</p>\n<p>Side effects may occur</p>\n<p>within 1\u20132 days of im\u00ad</p>\n<p>munization; they are usu\u00ad</p>\n<p>ally mild and should not</p>\n<p>cause worry</p>\n<p>~</p>\n<p>Report to health worker</p>\n<p>immediately any severe</p>\n<p>reaction</p>\n<p>Hep B Vaccine</p>\n<p>~</p>\n<p>Pain, redness and</p>\n<p>swelling at injec\u00ad</p>\n<p>tion site</p>\n<p>~</p>\n<p>Fatigue</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>If fever develops, give</p>\n<p>a single dose of parac\u00ad</p>\n<p>etamol</p>\n<h3>OTHER VACCINATIONS</h3>\n<p>18.1.2  Hepatitis B Vaccination</p>\n<p>~</p>\n<p>Since 2005, children are immunised against Hepatitis B in</p>\n<p>the routine childhood immunization using the DPT-HepB-</p>\n<p>Hib vaccine at 6, 10, and 14 weeks of age</p>"
    },
    {
        "page_number": 948,
        "content": "882\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\n \n~\nFor adolescents and adults, it is recommended that the \nhepatitis B vaccination is given preferably after testing for \nhepatitis B infection (HBsAg and Anti-HBs). Patients with \nHIV and pregnant women should be handled on a case by \ncase basis\n \n~\nVaccination is recommended for high risk groups, e.g:\n \n- Health workers in clinical settings and training\n \n- Intravenous drugs users\n \n- Persons who frequently receive blood transfusions\n \n- Recipients of solid organ transplantation\n \n- High-risk sexual behaviour\n \n- Partners and household contacts of HBsAg positive patients\n \n- Support staff in health facilities\n \n~\nThe schedule has three doses: at 0, 1 month after 1st \ndose, and 6 months after first dose (0, 1, 6 months)\n \n~\nThe storage temperature for the vaccine is 2\u00b0C to 8\u00b0C\n\t\n\u0089\nDose: 0.5 mL given intramuscularly on the deltoid muscle (upper arm)\n\t\n\u0089\nDo NOT give vaccine on the buttocks because of low immune \nresponse (decreased protective antibody response) and risks of \ninjury to the sciatic nerve\n18.1.3  Yellow Fever Vaccination\nThe yellow fever vaccine is live attenuated, and it is reconstituted before \nuse. Ideally, it should be used within 6 hours after reconstitution.\n \n~\nDose: 0.5 mL given intramuscularly on the upper arm as \na single dose\n \n~\nThe storage temperature for the vaccine is 2\u00b0C to 8\u00b0C\n \n~\nImmunity is life-long and international travel certificateis \nissued once and valid for life.\n18.1.4  Tetanus Prevention\n \n~\nAll children should be vaccinated against tetanus during \nroutine childhood immunization using the DPT-HepB-Hib \nvaccine at 6, 10, and 14 weeks of age (see above)\n \n~\nNeonatal tetanus is prevented by routinely immunising all",
        "formatted_content": "<p>882</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>~</p>\n<p>For adolescents and adults, it is recommended that the</p>\n<p>hepatitis B vaccination is given preferably after testing for</p>\n<p>hepatitis B infection (HBsAg and Anti-HBs). Patients with</p>\n<p>HIV and pregnant women should be handled on a case by</p>\n<p>case basis</p>\n<p>~</p>\n<p>Vaccination is recommended for high risk groups, e.g:</p>\n<p>- Health workers in clinical settings and training</p>\n<p>- Intravenous drugs users</p>\n<p>- Persons who frequently receive blood transfusions</p>\n<p>- Recipients of solid organ transplantation</p>\n<p>- High-risk sexual behaviour</p>\n<p>- Partners and household contacts of HBsAg positive patients</p>\n<p>- Support staff in health facilities</p>\n<p>~</p>\n<p>The schedule has three doses: at 0, 1 month after 1st</p>\n<p>dose, and 6 months after first dose (0, 1, 6 months)</p>\n<p>~</p>\n<p>The storage temperature for the vaccine is 2\u00b0C to 8\u00b0C</p>\n<p>\u0089</p>\n<p>Dose: 0.5 mL given intramuscularly on the deltoid muscle (upper arm)</p>\n<p>\u0089</p>\n<p>Do NOT give vaccine on the buttocks because of low immune</p>\n<p>response (decreased protective antibody response) and risks of</p>\n<p>injury to the sciatic nerve</p>\n<p>18.1.3  Yellow Fever Vaccination</p>\n<p>The yellow fever vaccine is live attenuated, and it is reconstituted before</p>\n<p>use. Ideally, it should be used within 6 hours after reconstitution.</p>\n<p>~</p>\n<p>Dose: 0.5 mL given intramuscularly on the upper arm as</p>\n<p>a single dose</p>\n<p>~</p>\n<p>The storage temperature for the vaccine is 2\u00b0C to 8\u00b0C</p>\n<p>~</p>\n<p>Immunity is life-long and international travel certificateis</p>\n<p>issued once and valid for life.</p>\n<p>18.1.4  Tetanus Prevention</p>\n<p>~</p>\n<p>All children should be vaccinated against tetanus during</p>\n<p>routine childhood immunization using the DPT-HepB-Hib</p>\n<p>vaccine at 6, 10, and 14 weeks of age (see above)</p>\n<p>~</p>\n<p>Neonatal tetanus is prevented by routinely immunising all</p>"
    },
    {
        "page_number": 949,
        "content": "883\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\npregnant women/women of child- bearing age (15\u201345 \nyears) against tetanus with Tetanus Toxoid vaccine (see \nbelow)\n18.2.3.1  Prophylaxis Against Neonatal Tetanus\n \n~\nEnsure hygienic deliveries, including proper cutting and \ncare of umbilical cords through the use of skilled birth \nattendants\n \n~\nImmunise all pregnant women/women of child- bearing \nage (15 \u2013 45 years) against tetanus with Tetanus Toxoid \nwith diptheria vaccine (Td)\n \n~\nGive TT vaccine 0.5 mL IM into the upper arm as per the \nrecommended schedule below:\nRoutine TT vaccine schedule and the period of protection\nTT DOSE\nWHEN GIVEN\nDURATION AND \nLEVELS\nOF PROTECTION\nTd1\nAt first contact with woman of childbearing \nage or as early as possible during pregnancy\nNone\nTd2\nAt least 4 weeks after Td1\n3 years;\n80% protection\n\t\nTd3\nAt least 6 months after Td2\n5 years;\n95% protection\nTd4\nAt least 1 year after Td3\n10 years;\n99% protection\nTd5\nAt least 1 year after Td4\n30 years;\n99% protection\nVaccination Against Adult Tetanus\n \n~\nHigh risk groups such as farm workers, military person\u00ad\nnel, miners, safe male circumcision clients, should be vac\u00ad\ncinated as in the table above (if not fully immunized) and \ngiven regular boosters every 10 years",
        "formatted_content": "<p>883</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>pregnant women/women of child- bearing age (15\u201345</p>\n<p>years) against tetanus with Tetanus Toxoid vaccine (see</p>\n<p>below)</p>\n<p>18.2.3.1  Prophylaxis Against Neonatal Tetanus</p>\n<p>~</p>\n<p>Ensure hygienic deliveries, including proper cutting and</p>\n<p>care of umbilical cords through the use of skilled birth</p>\n<p>attendants</p>\n<p>~</p>\n<p>Immunise all pregnant women/women of child- bearing</p>\n<p>age (15 \u2013 45 years) against tetanus with Tetanus Toxoid</p>\n<p>with diptheria vaccine (Td)</p>\n<p>~</p>\n<p>Give TT vaccine 0.5 mL IM into the upper arm as per the</p>\n<p>recommended schedule below:</p>\n<p>Routine TT vaccine schedule and the period of protection</p>\n<h3>TT DOSE</h3>\n<h3>WHEN GIVEN</h3>\n<h3>DURATION AND</h3>\n<h3>LEVELS</h3>\n<h3>OF PROTECTION</h3>\n<p>Td1</p>\n<p>At first contact with woman of childbearing</p>\n<p>age or as early as possible during pregnancy</p>\n<p>None</p>\n<p>Td2</p>\n<p>At least 4 weeks after Td1</p>\n<p>3 years;</p>\n<p>80% protection</p>\n<p>Td3</p>\n<p>At least 6 months after Td2</p>\n<p>5 years;</p>\n<p>95% protection</p>\n<p>Td4</p>\n<p>At least 1 year after Td3</p>\n<p>10 years;</p>\n<p>99% protection</p>\n<p>Td5</p>\n<p>At least 1 year after Td4</p>\n<p>30 years;</p>\n<p>99% protection</p>\n<p>Vaccination Against Adult Tetanus</p>\n<p>~</p>\n<p>High risk groups such as farm workers, military person\u00ad</p>\n<p>nel, miners, safe male circumcision clients, should be vac\u00ad</p>\n<p>cinated as in the table above (if not fully immunized) and</p>\n<p>given regular boosters every 10 years</p>"
    },
    {
        "page_number": 950,
        "content": "884\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\n \n~\nPatients at risk of tetanus as a result of contaminated \nwounds, bites, burns, and victims of road traffic accidents \nbe given Antitetanus Immunoglobulin (TIG) and then be \nvaccinated as indicated in the table below\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nEnsure adequate surgical toilet and proper care of wounds\nPassive immunization: give to any patient at risk, except if \nfully immunized and having had a booster within the last 10 \nyears\n\t\n\u0089\nGive IM tetanus immunoglobulin human (TIG):\nChild <5 years: 75 IU\nChild 5-10 years: 125 IU\nChild >10 years/adult: 250 IU\n\t\n\u0089\nDouble the dose if heavy contamination suspected or if >24 hours \nsince injury was sustained\nAlternative - only if TIG not available:\n\t\n\u0089\nAntitetanus serum (tetanus antitoxin) 1,500 IU deep SC or IM\nHC3\nHC4\nActive immunization\nUnimmunised or partially immunised patients:\n\t\n\u0089\nGive a full course of vaccination for those who are not immunized at \nall (3 doses 0.5 mL IM at intervals of 4 weeks)\nFully immunized patients with booster >10 years before:\n\t\n\u0089\nGive one booster dose of TT 0.5 mL intramuscularly\nFully immunised patients who have had a booster dose within \nthe last 10 years\n\t\n\u0089\nA booster is NOT necessary\nHC3\nNote\n \n\u0083 Giving TIG or TT to a fully immunised person may cause \nan unpleasant reaction, e.g., redness, itching, swelling, and \nfever, but with a severe injury this is justified",
        "formatted_content": "<p>884</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>~</p>\n<p>Patients at risk of tetanus as a result of contaminated</p>\n<p>wounds, bites, burns, and victims of road traffic accidents</p>\n<p>be given Antitetanus Immunoglobulin (TIG) and then be</p>\n<p>vaccinated as indicated in the table below</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Ensure adequate surgical toilet and proper care of wounds</p>\n<p>Passive immunization: give to any patient at risk, except if</p>\n<p>fully immunized and having had a booster within the last 10</p>\n<p>years</p>\n<p>\u0089</p>\n<p>Give IM tetanus immunoglobulin human (TIG):</p>\n<p>Child <5 years: 75 IU</p>\n<p>Child 5-10 years: 125 IU</p>\n<p>Child >10 years/adult: 250 IU</p>\n<p>\u0089</p>\n<p>Double the dose if heavy contamination suspected or if >24 hours</p>\n<p>since injury was sustained</p>\n<p>Alternative - only if TIG not available:</p>\n<p>\u0089</p>\n<p>Antitetanus serum (tetanus antitoxin) 1,500 IU deep SC or IM</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Active immunization</p>\n<p>Unimmunised or partially immunised patients:</p>\n<p>\u0089</p>\n<p>Give a full course of vaccination for those who are not immunized at</p>\n<p>all (3 doses 0.5 mL IM at intervals of 4 weeks)</p>\n<p>Fully immunized patients with booster >10 years before:</p>\n<p>\u0089</p>\n<p>Give one booster dose of TT 0.5 mL intramuscularly</p>\n<p>Fully immunised patients who have had a booster dose within</p>\n<p>the last 10 years</p>\n<p>\u0089</p>\n<p>A booster is NOT necessary</p>\n<h3>HC3</h3>\n<p>Note</p>\n<p>\u0083 Giving TIG or TT to a fully immunised person may cause</p>\n<p>an unpleasant reaction, e.g., redness, itching, swelling, and</p>\n<p>fever, but with a severe injury this is justified</p>"
    },
    {
        "page_number": 951,
        "content": "885\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\n18.2.4  Vaccination against COVID-19.\nWho should be vaccinated?\n\t\n\u0089\n12 years and above   \n\t\n\u0089\nfor children 5years -12 with parental consent\nTable showing vaccines and respective dosing and schedules \nfor primary series\n \n~\nA booster dose that can be administered at least 6 months \nafter completion of the primary series is recommended for \nall those aged 50 years and above, health workers, teach\u00ad\ners both in pre-primary, primary, secondary, and tertiary \ninstitutions, religious leaders, cultural leaders, security per\u00ad\nsonnel, media personnel, drivers and conductors of public \ntransport vehicles, boda boda riders, bar and night club \nworkers, market workers and vendors\nTable: COVID Vaccine Matching and mixing (heterologous \nprimary schedules) /Booster dosing\nFirst Dose\nSecond Dose OR Booster\n1\nAstraZeneca\nPfizer or Moderna\n2\nPfizer\nAstraZeneca\n3\nModerna\nAstraZeneca\n4\nSinopharm\nAstraZeneca or Pfizer or Moderna",
        "formatted_content": "<p>885</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>18.2.4  Vaccination against COVID-19.</p>\n<p>Who should be vaccinated?</p>\n<p>\u0089</p>\n<p>12 years and above</p>\n<p>\u0089</p>\n<p>for children 5years -12 with parental consent</p>\n<p>Table showing vaccines and respective dosing and schedules</p>\n<p>for primary series</p>\n<p>~</p>\n<p>A booster dose that can be administered at least 6 months</p>\n<p>after completion of the primary series is recommended for</p>\n<p>all those aged 50 years and above, health workers, teach\u00ad</p>\n<p>ers both in pre-primary, primary, secondary, and tertiary</p>\n<p>institutions, religious leaders, cultural leaders, security per\u00ad</p>\n<p>sonnel, media personnel, drivers and conductors of public</p>\n<p>transport vehicles, boda boda riders, bar and night club</p>\n<p>workers, market workers and vendors</p>\n<p>Table: COVID Vaccine Matching and mixing (heterologous</p>\n<p>primary schedules) /Booster dosing</p>\n<p>First Dose</p>\n<p>Second Dose OR Booster</p>\n<p>1</p>\n<p>AstraZeneca</p>\n<p>Pfizer or Moderna</p>\n<p>2</p>\n<p>Pfizer</p>\n<p>AstraZeneca</p>\n<p>3</p>\n<p>Moderna</p>\n<p>AstraZeneca</p>\n<p>4</p>\n<p>Sinopharm</p>\n<p>AstraZeneca or Pfizer or Moderna</p>"
    },
    {
        "page_number": 952,
        "content": "886\nUganda Clinical Guidelines 2023\nCHAPTER 18: Immunization\nFirst Dose\nSecond Dose OR Booster\n5\nSinovac\nAstraZeneca or Pfizer or Moderna\n6\nJohnson & Johnson\nPfizer or Moderna\nNutrition is the intake of food, considered in relation to the body\u2019s \ndietary needs. Good nutrition \u2013 an adequate, well balanced diet com\u00ad\nbined with regular physical activity \u2013 is a cornerstone of good health.\nPoor nutrition can lead to reduced immunity, increased susceptibility \nto disease, impaired physical and mental development, and reduced \nproductivity.\nOptimal nutrition means obtaining a balance of macronutrients (carbo\u00ad\nhydrates, proteins and fats) and micronutrients (vitamins and minerals).\nMacronutrients provide energy for organ and tissue functions and growth, \nand micronutrients are needed in small amounts for chemical processes in \nthe body such as metabolism, growth, and protection against infections.\nIn addition, plenty of water is needed to build cells and regulate body \nprocesses.",
        "formatted_content": "<p>886</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 18: Immunization</p>\n<p>First Dose</p>\n<p>Second Dose OR Booster</p>\n<p>5</p>\n<p>Sinovac</p>\n<p>AstraZeneca or Pfizer or Moderna</p>\n<p>6</p>\n<p>Johnson & Johnson</p>\n<p>Pfizer or Moderna</p>\n<p>Nutrition is the intake of food, considered in relation to the body\u2019s</p>\n<p>dietary needs. Good nutrition \u2013 an adequate, well balanced diet com\u00ad</p>\n<p>bined with regular physical activity \u2013 is a cornerstone of good health.</p>\n<p>Poor nutrition can lead to reduced immunity, increased susceptibility</p>\n<p>to disease, impaired physical and mental development, and reduced</p>\n<p>productivity.</p>\n<p>Optimal nutrition means obtaining a balance of macronutrients (carbo\u00ad</p>\n<p>hydrates, proteins and fats) and micronutrients (vitamins and minerals).</p>\n<p>Macronutrients provide energy for organ and tissue functions and growth,</p>\n<p>and micronutrients are needed in small amounts for chemical processes in</p>\n<p>the body such as metabolism, growth, and protection against infections.</p>\n<p>In addition, plenty of water is needed to build cells and regulate body</p>\n<p>processes.</p>"
    },
    {
        "page_number": 953,
        "content": "887\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n19.1  NUTRITION GUIDELINES IN SPECIAL POPULATIONS\n19.1.1  Infant and Young Child Feeding (IYCF)\n1.\t Counsel and support all mothers to initiate breastfeeding within an \nhour of delivery and exclusively breastfeed their infants for the first \nsix months of life, unless medically contraindicated.\n2.\t Teach mother correct positioning and attachment for breastfeeding, \nhow to express and store breast milk hygienically, and how to feed \nthe child by a cup.\n3.\t Counsel and support parents to introduce adequate, safe, and ap\u00ad\npropriate complementary foods at 6 months of age, and to continue \nbreast feeding until the child is 2 years.\n4.\t A good diet should be adequate in quantity and include an energy-rich \nfood (e.g. thick cereal with added oil, meat, fish, eggs, legumes, \nfruits and vegetables)\n5.\t Pregnant women and lactating mothers should consume adequate \nnutritious foods\n6.\t Recommend exclusive breastfeeding for infants of HIV-infected \nwomen for the first 6 months unless the replacement is acceptable, \nfeasible, affordable, sustainable, and safe (AFASS).\n7.\t Malnourished children should be provided with appropriate medical \ncare, nutritional rehabilitation, and follow-up.\n8.\t Encourage mothers of low birth weight infants who can suckle to \nbreastfeed. Assist those who cannot breastfeed to express breast \nmilk and feed the baby.\n9.\t During illness, children should take increased fluids: breastfeed \nmore often, increase amount of milk given, increase fluid intake \n(e.g. soups, yoghurt, and drinking water). Extra fluid in diarrhoea \nis especially life-saving\n10.\t For more information on feeding recommendations in infants and \nyoung children, see IMCI section 17.3.12.3\nNutrition\n19",
        "formatted_content": "<p>887</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>19.1  NUTRITION GUIDELINES IN SPECIAL POPULATIONS</h3>\n<p>19.1.1  Infant and Young Child Feeding (IYCF)</p>\n<li>.\t Counsel and support all mothers to initiate breastfeeding within an</li>\n<p>hour of delivery and exclusively breastfeed their infants for the first</p>\n<p>six months of life, unless medically contraindicated.</p>\n<p>2.\t Teach mother correct positioning and attachment for breastfeeding,</p>\n<p>how to express and store breast milk hygienically, and how to feed</p>\n<p>the child by a cup.</p>\n<p>3.\t Counsel and support parents to introduce adequate, safe, and ap\u00ad</p>\n<p>propriate complementary foods at 6 months of age, and to continue</p>\n<p>breast feeding until the child is 2 years.</p>\n<p>4.\t A good diet should be adequate in quantity and include an energy-rich</p>\n<p>food (e.g. thick cereal with added oil, meat, fish, eggs, legumes,</p>\n<p>fruits and vegetables)</p>\n<p>5.\t Pregnant women and lactating mothers should consume adequate</p>\n<p>nutritious foods</p>\n<p>6.\t Recommend exclusive breastfeeding for infants of HIV-infected</p>\n<p>women for the first 6 months unless the replacement is acceptable,</p>\n<p>feasible, affordable, sustainable, and safe (AFASS).</p>\n<p>7.\t Malnourished children should be provided with appropriate medical</p>\n<p>care, nutritional rehabilitation, and follow-up.</p>\n<p>8.\t Encourage mothers of low birth weight infants who can suckle to</p>\n<p>breastfeed. Assist those who cannot breastfeed to express breast</p>\n<p>milk and feed the baby.</p>\n<p>9.\t During illness, children should take increased fluids: breastfeed</p>\n<p>more often, increase amount of milk given, increase fluid intake</p>\n<p>(e.g. soups, yoghurt, and drinking water). Extra fluid in diarrhoea</p>\n<p>is especially life-saving</p>\n<p>10.\t For more information on feeding recommendations in infants and</p>\n<p>young children, see IMCI section 17.3.12.3</p>\n<p>Nutrition</p>\n<p>19</p>"
    },
    {
        "page_number": 954,
        "content": "888\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n19.1.2  Nutrition in HIV/AIDS\nGood nutrition in HIV/AIDS is important as it helps to:\n \n~\nPrevent malnutrition and wasting\n \n~\nDelay the progress of HIV to AIDS\n \n~\nEnhance the body\u2019s ability to fight opportunistic infections\n \n~\nAchieve and maintain optimal body weight and strength\nRelieve complications, e.g., diarrhoea, nausea, vomiting, thrush\n \n~\nImprove effectiveness and tolerance of medication\n \n~\nImprove quality of life\nSevere malnutrition is diagnosed when:\n \n~\nBMI <16 kg/m2\n \n~\nWeight loss >10% in past 2 months\n \n~\nMUAC <185 mm (<210 mm if pregnant or postpartum)\n \n~\nPersistent diarrhoea or fever\nManagement\nTREATMENT\nLOC\nIf patient has other complications\n\t\n\u0089\nAdmit patient and treat infections and rehydrate\nIf patient has no other medical complications\n\t\n\u0089\nTreat as an outpatient\n\t\n\u0089\nPromote weight gain with high-energy foods, protein, \nvitamins and minerals\n\t\n\u0089\nIf ready-to-use therapeutic food is available, give 3 sa\u00ad\nchets Supplement the patient\u2019s diet with multivitamins \nand minerals, 1-2 tablets per day e.g, a combination of \nselenium and molinga has been proven to be beneficial \nper day in adults, in addition to normal food\n \n- See next section 19.2 for malnutrition in children\n\t\n\u0089\nFollow up in 2 weeks, at 1 month, then every 2 months \nthereafter\nHC4 \nHC3",
        "formatted_content": "<p>888</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>19.1.2  Nutrition in HIV/AIDS</p>\n<p>Good nutrition in HIV/AIDS is important as it helps to:</p>\n<p>~</p>\n<p>Prevent malnutrition and wasting</p>\n<p>~</p>\n<p>Delay the progress of HIV to AIDS</p>\n<p>~</p>\n<p>Enhance the body\u2019s ability to fight opportunistic infections</p>\n<p>~</p>\n<p>Achieve and maintain optimal body weight and strength</p>\n<p>Relieve complications, e.g., diarrhoea, nausea, vomiting, thrush</p>\n<p>~</p>\n<p>Improve effectiveness and tolerance of medication</p>\n<p>~</p>\n<p>Improve quality of life</p>\n<p>Severe malnutrition is diagnosed when:</p>\n<p>~</p>\n<p>BMI <16 kg/m2</p>\n<p>~</p>\n<p>Weight loss >10% in past 2 months</p>\n<p>~</p>\n<p>MUAC <185 mm (<210 mm if pregnant or postpartum)</p>\n<p>~</p>\n<p>Persistent diarrhoea or fever</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If patient has other complications</p>\n<p>\u0089</p>\n<p>Admit patient and treat infections and rehydrate</p>\n<p>If patient has no other medical complications</p>\n<p>\u0089</p>\n<p>Treat as an outpatient</p>\n<p>\u0089</p>\n<p>Promote weight gain with high-energy foods, protein,</p>\n<p>vitamins and minerals</p>\n<p>\u0089</p>\n<p>If ready-to-use therapeutic food is available, give 3 sa\u00ad</p>\n<p>chets Supplement the patient\u2019s diet with multivitamins</p>\n<p>and minerals, 1-2 tablets per day e.g, a combination of</p>\n<p>selenium and molinga has been proven to be beneficial</p>\n<p>per day in adults, in addition to normal food</p>\n<p>- See next section 19.2 for malnutrition in children</p>\n<p>\u0089</p>\n<p>Follow up in 2 weeks, at 1 month, then every 2 months</p>\n<p>thereafter</p>\n<h3>HC4</h3>\n<h3>HC3</h3>"
    },
    {
        "page_number": 955,
        "content": "889\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n19.1.3  Nutrition in Diabetes\nPeople with diabetes should follow normal nutritional guidelines for the \ngeneral population, and can eat the same foods as the whole family since \neveryone benefits from healthy eating.\nHealthy eating and exercise in diabetics help to:\n\t\n\u0089\nMaintain the blood glucose close to normal to prevent complications\n\t\n\u0089\nControl cholesterol levels\n\t\n\u0089\nControl blood pressure, and reduce the risk of complications such \nas heart disease and stroke\nIn addition, diabetics have to take care to balance their food with insulin \nand oral antidiabetic medications to help manage their blood glucose levels.\nHealthy diet involves eating a variety of foods including vegetables, whole \ngrains, fruits, non-fat dairy products, beans, lean meat, poultry, and fish. \nThese are rich in vitamins, minerals and fibre. Avoid processed foods.\nGeneral advice\n \n~\nEat three meals a day. Avoid skipping meals, and space out \nbreakfast, lunch, and evening meal over the day\n \n~\nAt each meal, include moderate amount (around 1/3 of \nthe plate) of starchy carbohydrate foods, e.g., bread, pasta, \nchapatis, potatoes, yams, noodles, rice, and cereals. Eat \nmore slowly absorbed (low glycaemic index) foods, e.g., \npasta, rice, sweet potato and yam, porridge oats, bran, and \nnatural muesli\n \n~\nReduce fat in the diet, especially saturated fats. Use unsat\u00ad\nurated fats or oils e.g. olive oil, sunflower oil\n \n~\nEat more fruit and vegetables. Aim for at least five portions \na day. Eat more beans and lentils.\n \n~\nLimit sugar and sugary foods\n \n~\nReduce salt in the diet to 6 g or less per day\n \n~\nDrink alcohol only in moderation: 1 drink (one beer or one \nsmall glass of wine or one shot of spirit) for women and",
        "formatted_content": "<p>889</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>19.1.3  Nutrition in Diabetes</p>\n<p>People with diabetes should follow normal nutritional guidelines for the</p>\n<p>general population, and can eat the same foods as the whole family since</p>\n<p>everyone benefits from healthy eating.</p>\n<p>Healthy eating and exercise in diabetics help to:</p>\n<p>\u0089</p>\n<p>Maintain the blood glucose close to normal to prevent complications</p>\n<p>\u0089</p>\n<p>Control cholesterol levels</p>\n<p>\u0089</p>\n<p>Control blood pressure, and reduce the risk of complications such</p>\n<p>as heart disease and stroke</p>\n<p>In addition, diabetics have to take care to balance their food with insulin</p>\n<p>and oral antidiabetic medications to help manage their blood glucose levels.</p>\n<p>Healthy diet involves eating a variety of foods including vegetables, whole</p>\n<p>grains, fruits, non-fat dairy products, beans, lean meat, poultry, and fish.</p>\n<p>These are rich in vitamins, minerals and fibre. Avoid processed foods.</p>\n<p>General advice</p>\n<p>~</p>\n<p>Eat three meals a day. Avoid skipping meals, and space out</p>\n<p>breakfast, lunch, and evening meal over the day</p>\n<p>~</p>\n<p>At each meal, include moderate amount (around 1/3 of</p>\n<p>the plate) of starchy carbohydrate foods, e.g., bread, pasta,</p>\n<p>chapatis, potatoes, yams, noodles, rice, and cereals. Eat</p>\n<p>more slowly absorbed (low glycaemic index) foods, e.g.,</p>\n<p>pasta, rice, sweet potato and yam, porridge oats, bran, and</p>\n<p>natural muesli</p>\n<p>~</p>\n<p>Reduce fat in the diet, especially saturated fats. Use unsat\u00ad</p>\n<p>urated fats or oils e.g. olive oil, sunflower oil</p>\n<p>~</p>\n<p>Eat more fruit and vegetables. Aim for at least five portions</p>\n<p>a day. Eat more beans and lentils.</p>\n<p>~</p>\n<p>Limit sugar and sugary foods</p>\n<p>~</p>\n<p>Reduce salt in the diet to 6 g or less per day</p>\n<p>~</p>\n<p>Drink alcohol only in moderation: 1 drink (one beer or one</p>\n<p>small glass of wine or one shot of spirit) for women and</p>"
    },
    {
        "page_number": 956,
        "content": "890\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n2 for men as a maximum amount daily. Alcohol has some cardioprotec\u00ad\ntive effect. It should be consumed with food to prevent hypoglycaemia\n \n~\nDon\u2019t use products marketed as \u201ddiabetic foods, drinks or \nherbs\u201d (they are expensive and of no benefit)\n \n~\nRoutine supplementation with vitamins and minerals with\u00ad\nout underlying actual deficiency is not beneficial, patients \nshould eat lots of fruits and vegetables e.g, a combination \nof selenium and molinga has been proven to be beneficial\n \n~\nObese and overweight patients need to be encouraged to \nreduce weight using exercise and diet modifications\n19.2  MALNUTRITION ICD10 CODE: E40-43\n19.2.1  Introduction on Malnutrition\nMalnutrition is the cellular imbalance between the supply of nutrients \nand energy and the body\u2019s demand for them to ensure growth, mainte\u00ad\nnance, and specific functions. It includes both under- and over nutrition.\nHowever, the term \u201cmalnutrition\u201d commonly refers to\nundernutrition, and is used as such in these guidelines.\nAlthough malnutrition can affect all ages, however, the early stages, \nincluding, foetus, infants and children, are most vulnerable to the effects \nof undernutrition during the period of their most rapid physical growth \nand development during the first two years of life.\nMalnutrition is a significant contributor to morbidity and mortality \namong children under 5 years in Uganda. It also makes the prognosis \nof other diseases poor.\nNote\n \n\u0083 Previously, malnutrition was classified into two types: 1) Protein-\nEnergy Malnutrition (PEM) due to lack of adequate protein and \nenergy in the diet and 2) Micronutrient malnutrition-due to \ndeficiencies in specific micronutrients (vitamins and minerals).\n \n\u0083 These causal names are now avoided because protein and \nenergy deficits are likely to be accompanied by deficiencies of \nother nutrients, and management of malnutrition takes this \ninto consideration.",
        "formatted_content": "<p>890</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>2 for men as a maximum amount daily. Alcohol has some cardioprotec\u00ad</p>\n<p>tive effect. It should be consumed with food to prevent hypoglycaemia</p>\n<p>~</p>\n<p>Don\u2019t use products marketed as \u201ddiabetic foods, drinks or</p>\n<p>herbs\u201d (they are expensive and of no benefit)</p>\n<p>~</p>\n<p>Routine supplementation with vitamins and minerals with\u00ad</p>\n<p>out underlying actual deficiency is not beneficial, patients</p>\n<p>should eat lots of fruits and vegetables e.g, a combination</p>\n<p>of selenium and molinga has been proven to be beneficial</p>\n<p>~</p>\n<p>Obese and overweight patients need to be encouraged to</p>\n<p>reduce weight using exercise and diet modifications</p>\n<h3>19.2  MALNUTRITION ICD10 CODE: E40-43</h3>\n<p>19.2.1  Introduction on Malnutrition</p>\n<p>Malnutrition is the cellular imbalance between the supply of nutrients</p>\n<p>and energy and the body\u2019s demand for them to ensure growth, mainte\u00ad</p>\n<p>nance, and specific functions. It includes both under- and over nutrition.</p>\n<p>However, the term \u201cmalnutrition\u201d commonly refers to</p>\n<p>undernutrition, and is used as such in these guidelines.</p>\n<p>Although malnutrition can affect all ages, however, the early stages,</p>\n<p>including, foetus, infants and children, are most vulnerable to the effects</p>\n<p>of undernutrition during the period of their most rapid physical growth</p>\n<p>and development during the first two years of life.</p>\n<p>Malnutrition is a significant contributor to morbidity and mortality</p>\n<p>among children under 5 years in Uganda. It also makes the prognosis</p>\n<p>of other diseases poor.</p>\n<p>Note</p>\n<p>\u0083 Previously, malnutrition was classified into two types: 1) Protein-</p>\n<p>Energy Malnutrition (PEM) due to lack of adequate protein and</p>\n<p>energy in the diet and 2) Micronutrient malnutrition-due to</p>\n<p>deficiencies in specific micronutrients (vitamins and minerals).</p>\n<p>\u0083 These causal names are now avoided because protein and</p>\n<p>energy deficits are likely to be accompanied by deficiencies of</p>\n<p>other nutrients, and management of malnutrition takes this</p>\n<p>into consideration.</p>"
    },
    {
        "page_number": 957,
        "content": "891\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nCauses/contributing factors to malnutrition\n \n~\nImmediate causes: diet and disease\n\t\n\u0089\nInadequate quantity and quality of food\n\t\n\u0089\nLack of knowledge on appropriate foods provided to children, \npoor food preparation, food taboos\n\t\n\u0089\nInfections: reduce appetite, increase energy and nutrient utilisation, \nand limit the ability to absorb or retain nutrients e.g. in diarrhoea, \nintestinal parasites\n \n~\nRoot causes: food insecurity, poor health services, poor \nenvironmental sanitation, natural disasters, excessive \nworkload for women, poor weaning practices, culture, in\u00ad\nadequate water supply, low literacy levels, low nutrition \nadvocacy/education\n \n~\nUnderlying causes: poverty, corruption, poor governance, \npoor infrastructure.\nConsequences of malnutrition\n \n~\nImpaired growth, physical and mental and development\n \n~\nImpaired body resistance/immune system\n \n~\nIncreased risk of adult chronic diseases\n \n~\nIncreased risk of mortality\n \n~\nIncreased risk for the cycle of inter-generational malnutri\u00ad\ntion\n \n~\nPoor economic well-being for the individual and country\nDifferential diagnosis\n \n~\nNephrotic syndrome (nephritis)\n \n~\nLiver disease\n \n~\nHeart disease\n \n~\nMalabsorption syndrome\n \n~\nMalignancy (e.g., gastrointestinal tract cancer, liver can\u00ad\ncer/hepatocellular carcinoma)",
        "formatted_content": "<p>891</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Causes/contributing factors to malnutrition</p>\n<p>~</p>\n<p>Immediate causes: diet and disease</p>\n<p>\u0089</p>\n<p>Inadequate quantity and quality of food</p>\n<p>\u0089</p>\n<p>Lack of knowledge on appropriate foods provided to children,</p>\n<p>poor food preparation, food taboos</p>\n<p>\u0089</p>\n<p>Infections: reduce appetite, increase energy and nutrient utilisation,</p>\n<p>and limit the ability to absorb or retain nutrients e.g. in diarrhoea,</p>\n<p>intestinal parasites</p>\n<p>~</p>\n<p>Root causes: food insecurity, poor health services, poor</p>\n<p>environmental sanitation, natural disasters, excessive</p>\n<p>workload for women, poor weaning practices, culture, in\u00ad</p>\n<p>adequate water supply, low literacy levels, low nutrition</p>\n<p>advocacy/education</p>\n<p>~</p>\n<p>Underlying causes: poverty, corruption, poor governance,</p>\n<p>poor infrastructure.</p>\n<p>Consequences of malnutrition</p>\n<p>~</p>\n<p>Impaired growth, physical and mental and development</p>\n<p>~</p>\n<p>Impaired body resistance/immune system</p>\n<p>~</p>\n<p>Increased risk of adult chronic diseases</p>\n<p>~</p>\n<p>Increased risk of mortality</p>\n<p>~</p>\n<p>Increased risk for the cycle of inter-generational malnutri\u00ad</p>\n<p>tion</p>\n<p>~</p>\n<p>Poor economic well-being for the individual and country</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Nephrotic syndrome (nephritis)</p>\n<p>~</p>\n<p>Liver disease</p>\n<p>~</p>\n<p>Heart disease</p>\n<p>~</p>\n<p>Malabsorption syndrome</p>\n<p>~</p>\n<p>Malignancy (e.g., gastrointestinal tract cancer, liver can\u00ad</p>\n<p>cer/hepatocellular carcinoma)</p>"
    },
    {
        "page_number": 958,
        "content": "892\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n19.2.1.1  Classification of Malnutrition\nTYPE\nDEFINITION OR FEATURES\nAcute\n \n~\nIs an indicator of current nutritional status, \nreflecting recent weight changes or disrup\u00ad\ntion in nutrient intake\n \n~\nMost appropriate indicator to use in an \nemergency setting (e.g. due to sudden/\nsharp period of food shortage)\n \n~\nAssociated with loss of body fat and severe \nwasting\n \n~\nChildren are thinner than their comparable \nage group of same height\n \n~\nClassified as Moderate or Severe based on \nanthropometry (measurement of the size, \nweight and proportions of the human body), \nbiochemistry and clinical assessment\nChronic\n \n~\nIs an indicator of the nutritional status over\u00ad\ntime; chronically malnourished children are \nshorter (stunted) than their comparable age \ngroup\nClinical features of malnutrition\n \n~\nMarasmus: severe wasting, old man\u2019s face, excess skin\u2019 \nhangs around the buttocks, ribs and zygoma bones are \nprominent, scapular blades and extremities (limbs), eyes \nare sunken\n \n- Apathetic or irritable, appetite is fairly good, skin is almost \nnormal, hair demonstrates some changes but not as dramatic \nas in Kwashiorkor, organomegaly is rare (liver and spleen \nenlargement)\n \n~\nKwashiakor: pitting feet oedema, skin desquamation, hair \nchanges, presence of bilateral pitting oedema (oedema of \nboth feet), moon face",
        "formatted_content": "<p>892</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>19.2.1.1  Classification of Malnutrition</p>\n<h3>TYPE</h3>\n<h3>DEFINITION OR FEATURES</h3>\n<p>Acute</p>\n<p>~</p>\n<p>Is an indicator of current nutritional status,</p>\n<p>reflecting recent weight changes or disrup\u00ad</p>\n<p>tion in nutrient intake</p>\n<p>~</p>\n<p>Most appropriate indicator to use in an</p>\n<p>emergency setting (e.g. due to sudden/</p>\n<p>sharp period of food shortage)</p>\n<p>~</p>\n<p>Associated with loss of body fat and severe</p>\n<p>wasting</p>\n<p>~</p>\n<p>Children are thinner than their comparable</p>\n<p>age group of same height</p>\n<p>~</p>\n<p>Classified as Moderate or Severe based on</p>\n<p>anthropometry (measurement of the size,</p>\n<p>weight and proportions of the human body),</p>\n<p>biochemistry and clinical assessment</p>\n<p>Chronic</p>\n<p>~</p>\n<p>Is an indicator of the nutritional status over\u00ad</p>\n<p>time; chronically malnourished children are</p>\n<p>shorter (stunted) than their comparable age</p>\n<p>group</p>\n<p>Clinical features of malnutrition</p>\n<p>~</p>\n<p>Marasmus: severe wasting, old man\u2019s face, excess skin\u2019</p>\n<p>hangs around the buttocks, ribs and zygoma bones are</p>\n<p>prominent, scapular blades and extremities (limbs), eyes</p>\n<p>are sunken</p>\n<p>- Apathetic or irritable, appetite is fairly good, skin is almost</p>\n<p>normal, hair demonstrates some changes but not as dramatic</p>\n<p>as in Kwashiorkor, organomegaly is rare (liver and spleen</p>\n<p>enlargement)</p>\n<p>~</p>\n<p>Kwashiakor: pitting feet oedema, skin desquamation, hair</p>\n<p>changes, presence of bilateral pitting oedema (oedema of</p>\n<p>both feet), moon face</p>"
    },
    {
        "page_number": 959,
        "content": "893\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n\t\n\u0089\nAppears  adequately nourished due to excess extra cellular fluid, \nbut is very miserable, apathetic\n\t\n\u0089\nSkin changes (dermatosis, flacky paint dermatitis)\n\t\n\u0089\nHair changes: Silky, straight, sparsely distributed; easily, painlessly \npluckable\n\t\n\u0089\nSevere pallor of the conjunctiva, mucous membranes, palms, and \nsoles, loss of skin turgor (dehydration)\n\t\n\u0089\nOrganomegaly (liver, spleen) is common\n \n~\nMarasmus-kwashiakor: most common form, presents with \nfeatures of both Marasmus and Kwashiorkor\n19.2.1.2  Assessing Malnutrition in Children 6 months to 5 years\nThe 4 key features used to diagnose acute malnutrition are:\n\t\n\u0089\nWeight-for-Height/Length (WFH/L) using WHO growth standards \ncharts (see section 15.5). It is the best indicator for diagnosing \nacute malnutrition.\n\t\n\u0089\nMean Upper Arm Circumference (MUAC) in mm using a measuring \ntape (see section 17.5)\n\t\n\u0089\nOedema of both feet (kwashiorkor with or without severe wasting)\n\t\n\u0089\nAppetite test: ability to finish portion of ready-to-use therapeutic \nfood (RUTF).\nWEIGHT FOR AGE (WFA) reflects both long term (stunting) and \nshort term (wasting) nutritional status, so it is not very useful for \ndiagnosis of acute malnutrition.\nIt can also miss out oedematous children, who are very malnourished \nbut may have a near-normal weight because of fluid retention.",
        "formatted_content": "<p>893</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>\u0089</p>\n<p>Appears  adequately nourished due to excess extra cellular fluid,</p>\n<p>but is very miserable, apathetic</p>\n<p>\u0089</p>\n<p>Skin changes (dermatosis, flacky paint dermatitis)</p>\n<p>\u0089</p>\n<p>Hair changes: Silky, straight, sparsely distributed; easily, painlessly</p>\n<p>pluckable</p>\n<p>\u0089</p>\n<p>Severe pallor of the conjunctiva, mucous membranes, palms, and</p>\n<p>soles, loss of skin turgor (dehydration)</p>\n<p>\u0089</p>\n<p>Organomegaly (liver, spleen) is common</p>\n<p>~</p>\n<p>Marasmus-kwashiakor: most common form, presents with</p>\n<p>features of both Marasmus and Kwashiorkor</p>\n<p>19.2.1.2  Assessing Malnutrition in Children 6 months to 5 years</p>\n<p>The 4 key features used to diagnose acute malnutrition are:</p>\n<p>\u0089</p>\n<p>Weight-for-Height/Length (WFH/L) using WHO growth standards</p>\n<p>charts (see section 15.5). It is the best indicator for diagnosing</p>\n<p>acute malnutrition.</p>\n<p>\u0089</p>\n<p>Mean Upper Arm Circumference (MUAC) in mm using a measuring</p>\n<p>tape (see section 17.5)</p>\n<p>\u0089</p>\n<p>Oedema of both feet (kwashiorkor with or without severe wasting)</p>\n<p>\u0089</p>\n<p>Appetite test: ability to finish portion of ready-to-use therapeutic</p>\n<p>food (RUTF).</p>\n<p>WEIGHT FOR AGE (WFA) reflects both long term (stunting) and</p>\n<p>short term (wasting) nutritional status, so it is not very useful for</p>\n<p>diagnosis of acute malnutrition.</p>\n<p>It can also miss out oedematous children, who are very malnourished</p>\n<p>but may have a near-normal weight because of fluid retention.</p>"
    },
    {
        "page_number": 960,
        "content": "894\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nDiagnostic criteria\nTYPE\nCRITERIA\nModerate Acute \nMalnutrition\n \n~\nWFH/L between -3 and -2 z-scores\n \n~\nOr MUAC 115 up to 125 mm\n \n~\nOr low weight for age\nSevere Acute \nMalnutrition\nWithout complications\n \n~\nOedema of both feet (kwashiorkor \nwith or without severe wasting) OR\n \n~\nWFH/L less than -3 z scores OR\n \n~\nMUAC less than 115 mm OR\n \n~\nVisible severe wasting AND\n \n~\nAble to finish RUTF\nWith complications\n \n~\nOedema of both feet OR\n \n~\nWFH/L less than -3 z scores OR\n \n~\nMUAC less than 115 mm OR\n \n~\nVisible severe wasting AND\n \n~\nAny one of the following:\n \n- Medical complication present OR\n \n- Not able to finish RUTF\nSpecific micronu\u00ad\ntrient deficiencies\n \n~\nVitamin A: xerophthalmia\n \n~\nVitamin C: scurvy\n \n~\nVitamin B12 and folic acid: meg\u00ad\naloblastic anaemia (see section \n11.1.1.2)\n \n~\nIron: iron-deficiency anaemia (see \nsection 11.1.1.1)",
        "formatted_content": "<p>894</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Diagnostic criteria</p>\n<h3>TYPE</h3>\n<h3>CRITERIA</h3>\n<p>Moderate Acute</p>\n<p>Malnutrition</p>\n<p>~</p>\n<p>WFH/L between -3 and -2 z-scores</p>\n<p>~</p>\n<p>Or MUAC 115 up to 125 mm</p>\n<p>~</p>\n<p>Or low weight for age</p>\n<p>Severe Acute</p>\n<p>Malnutrition</p>\n<p>Without complications</p>\n<p>~</p>\n<p>Oedema of both feet (kwashiorkor</p>\n<p>with or without severe wasting) OR</p>\n<p>~</p>\n<p>WFH/L less than -3 z scores OR</p>\n<p>~</p>\n<p>MUAC less than 115 mm OR</p>\n<p>~</p>\n<p>Visible severe wasting AND</p>\n<p>~</p>\n<p>Able to finish RUTF</p>\n<p>With complications</p>\n<p>~</p>\n<p>Oedema of both feet OR</p>\n<p>~</p>\n<p>WFH/L less than -3 z scores OR</p>\n<p>~</p>\n<p>MUAC less than 115 mm OR</p>\n<p>~</p>\n<p>Visible severe wasting AND</p>\n<p>~</p>\n<p>Any one of the following:</p>\n<p>- Medical complication present OR</p>\n<p>- Not able to finish RUTF</p>\n<p>Specific micronu\u00ad</p>\n<p>trient deficiencies</p>\n<p>~</p>\n<p>Vitamin A: xerophthalmia</p>\n<p>~</p>\n<p>Vitamin C: scurvy</p>\n<p>~</p>\n<p>Vitamin B12 and folic acid: meg\u00ad</p>\n<p>aloblastic anaemia (see section</p>\n<p>11.1.1.2)</p>\n<p>~</p>\n<p>Iron: iron-deficiency anaemia (see</p>\n<p>section 11.1.1.1)</p>"
    },
    {
        "page_number": 961,
        "content": "895\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nInvestigations\nChildren with SAM should always be first assessed with a full clinical \nexamination to confirm presence of any danger sign, medical com\u00ad\nplications, and tested for appetite.\n \n\u0081\nAssess patient\u2019s history of:\n\t\n\u0089\nRecent intake of food, loss of appetite, breastfeeding\n\t\n\u0089\nUsual diet before current illness (compare the answers to the Feeding \nRecommendations for the Child\u2019s age (section 17.3.12.3)\n\t\n\u0089\nDuration, frequency and type of diarrhoea and vomiting\n\t\n\u0089\nFamily circumstances\n\t\n\u0089\nCough >2 weeks and contact with TB\n\t\n\u0089\nContact with measles\n\t\n\u0089\nKnown or suspected HIV infection/exposure\n \n\u0081\nInitial examination for danger signs and medical complications:\n\t\n\u0089\nShock: lethargy or unconscious, cold hands, slow capillary refill (<3 \nseconds), weak pulse, low blood pressure\n\t\n\u0089\nSigns of dehydration\n\t\n\u0089\nSevere palmar pallor\n\t\n\u0089\nBilateral pitting oedema\n\t\n\u0089\nEye signs of vitamin A deficiency: dry conjunctiva, corneal ulceration, \nkeratomalacia, photophobia\n\t\n\u0089\nLocal signs of infection: ear, throat, skin, pneumonia\n\t\n\u0089\nSigns of HIV (see WHO Clinical Staging section 3.1.1)\n\t\n\u0089\nFever (\u00b337.5\u00b0C) or hypothermia (rectal temp <35.5\u00b0C)\n\t\n\u0089\nMouth ulcers\n\t\n\u0089\nSkin changes of kwashiorkor: hypo- or hyperpigmentation, desqua\u00ad\nmation, ulcerations all over the body, exudative lesions (resembling \nburns) with secondary infection (including candida)",
        "formatted_content": "<p>895</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Investigations</p>\n<p>Children with SAM should always be first assessed with a full clinical</p>\n<p>examination to confirm presence of any danger sign, medical com\u00ad</p>\n<p>plications, and tested for appetite.</p>\n<p>\u0081</p>\n<p>Assess patient\u2019s history of:</p>\n<p>\u0089</p>\n<p>Recent intake of food, loss of appetite, breastfeeding</p>\n<p>\u0089</p>\n<p>Usual diet before current illness (compare the answers to the Feeding</p>\n<p>Recommendations for the Child\u2019s age (section 17.3.12.3)</p>\n<p>\u0089</p>\n<p>Duration, frequency and type of diarrhoea and vomiting</p>\n<p>\u0089</p>\n<p>Family circumstances</p>\n<p>\u0089</p>\n<p>Cough >2 weeks and contact with TB</p>\n<p>\u0089</p>\n<p>Contact with measles</p>\n<p>\u0089</p>\n<p>Known or suspected HIV infection/exposure</p>\n<p>\u0081</p>\n<p>Initial examination for danger signs and medical complications:</p>\n<p>\u0089</p>\n<p>Shock: lethargy or unconscious, cold hands, slow capillary refill (<3</p>\n<p>seconds), weak pulse, low blood pressure</p>\n<p>\u0089</p>\n<p>Signs of dehydration</p>\n<p>\u0089</p>\n<p>Severe palmar pallor</p>\n<p>\u0089</p>\n<p>Bilateral pitting oedema</p>\n<p>\u0089</p>\n<p>Eye signs of vitamin A deficiency: dry conjunctiva, corneal ulceration,</p>\n<p>keratomalacia, photophobia</p>\n<p>\u0089</p>\n<p>Local signs of infection: ear, throat, skin, pneumonia</p>\n<p>\u0089</p>\n<p>Signs of HIV (see WHO Clinical Staging section 3.1.1)</p>\n<p>\u0089</p>\n<p>Fever (\u00b337.5\u00b0C) or hypothermia (rectal temp <35.5\u00b0C)</p>\n<p>\u0089</p>\n<p>Mouth ulcers</p>\n<p>\u0089</p>\n<p>Skin changes of kwashiorkor: hypo- or hyperpigmentation, desqua\u00ad</p>\n<p>mation, ulcerations all over the body, exudative lesions (resembling</p>\n<p>burns) with secondary infection (including candida)</p>"
    },
    {
        "page_number": 962,
        "content": "896\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n \n\u0081\nLaboratory tests\n\t\n\u0089\nBlood glucose\n \n- Complete blood count or Hb, malaria, HIV, electrolytes\n \n- Stool microscopy for ova and cysts, occult blood, and \nparasites\n\t\n\u0089\nChest X-ray: Look for evidence of tuberculosis or other chest \nabnormalities\n\t\n\u0089\nConduct an appetite test\n \n- Assess all children \u00b36 months for appetite at the initial visit \nand at every follow up visit to the health facility\nHOW TO DO APPETITE TEST\n \n~\nArrange a quiet corner where the child and mother can take \ntheir time to eat RUTF. Usually the child eats the RUTF portion \nwithin 30 minutes\nExplain to the mother\n \n~\nThe purpose of assessing the child\u2019s appetite\n \n~\nWhat RUTF is\n \n~\nHow to give RUTF\n \n- Wash hands before giving RUTF\n \n- Sit with child and gently offer RUTF\n \n- Encourage child to eat without feeding by force\n \n- Offer plenty of water to drink from a cup during RUTF feeding\nOffer appropriate amount of RUTF to child to eat:\n \n~\nAfter 30 minutes, check if the child was able to finish or not able \nto finish the amount of RUTF given and decide:\n \n- Child ABLE to finish at least one third of a packet of RUTF portion \n(92 g) or 3 teaspoons from a pot within 30 minutes\n \n- Child NOT ABLE to eat one-third of a packet of RUTF portion (92 g) \nor 3 teaspoons from a pot within 30 minutes\n \n\u0081\nDetermine WFH/L: Measure the child\u2019s height and weight and \nplot the score on the appropriate chart (boy or girl). Match the \nvalue to the z-score on the right y-axis to determine the child\u2019s \nz-score (see section 17.5)\n \n\u0081\nMeasure MUAC: Using a MUAC tape, measure the circumference",
        "formatted_content": "<p>896</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>\u0081</p>\n<p>Laboratory tests</p>\n<p>\u0089</p>\n<p>Blood glucose</p>\n<p>- Complete blood count or Hb, malaria, HIV, electrolytes</p>\n<p>- Stool microscopy for ova and cysts, occult blood, and</p>\n<p>parasites</p>\n<p>\u0089</p>\n<p>Chest X-ray: Look for evidence of tuberculosis or other chest</p>\n<p>abnormalities</p>\n<p>\u0089</p>\n<p>Conduct an appetite test</p>\n<p>- Assess all children \u00b36 months for appetite at the initial visit</p>\n<p>and at every follow up visit to the health facility</p>\n<h3>HOW TO DO APPETITE TEST</h3>\n<p>~</p>\n<p>Arrange a quiet corner where the child and mother can take</p>\n<p>their time to eat RUTF. Usually the child eats the RUTF portion</p>\n<p>within 30 minutes</p>\n<p>Explain to the mother</p>\n<p>~</p>\n<p>The purpose of assessing the child\u2019s appetite</p>\n<p>~</p>\n<p>What RUTF is</p>\n<p>~</p>\n<p>How to give RUTF</p>\n<p>- Wash hands before giving RUTF</p>\n<p>- Sit with child and gently offer RUTF</p>\n<p>- Encourage child to eat without feeding by force</p>\n<p>- Offer plenty of water to drink from a cup during RUTF feeding</p>\n<p>Offer appropriate amount of RUTF to child to eat:</p>\n<p>~</p>\n<p>After 30 minutes, check if the child was able to finish or not able</p>\n<p>to finish the amount of RUTF given and decide:</p>\n<p>- Child ABLE to finish at least one third of a packet of RUTF portion</p>\n<p>(92 g) or 3 teaspoons from a pot within 30 minutes</p>\n<p>- Child NOT ABLE to eat one-third of a packet of RUTF portion (92 g)</p>\n<p>or 3 teaspoons from a pot within 30 minutes</p>\n<p>\u0081</p>\n<p>Determine WFH/L: Measure the child\u2019s height and weight and</p>\n<p>plot the score on the appropriate chart (boy or girl). Match the</p>\n<p>value to the z-score on the right y-axis to determine the child\u2019s</p>\n<p>z-score (see section 17.5)</p>\n<p>\u0081</p>\n<p>Measure MUAC: Using a MUAC tape, measure the circumference</p>"
    },
    {
        "page_number": 963,
        "content": "897\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nof the child\u2019s upper arm and plot the score on the appropriate \nchart (boy or girl, section 17.5). Please note: 1 cm=10 mm, so \n11.5 cm = 115 mm.\n19.2.2   Management of Acute Malnutrition in Children\nGeneral principles of management\n \n~\nAdmit all children with any danger sign, medical complica\u00ad\ntions, pitting oedema or those who fail appetite tests for \ninpatient care and treatment for complicated SAM.\n\t\n\u0089\nKeep them in a warm area separated from infectious children, or \nin a special nutrition area.\n \n~\nChildren with good appetite and no medical complications \ncan be managed as outpatients for uncomplicated SAM.\n \n~\nAdequate facilities and staff to ensure correct preparation \nof therapeutic foods, and to feed child regularly day and \nnight, should be available.\n \n~\nAccurate weighing machines and MUAC tapes should be \navailable\n \n~\nProper records of feeds given and child\u2019s measurements \nshould be kept so that progress can be monitored\n \n~\nExplain to patient/care-giver to handle the child gently\n19.2.2.1   Management of Moderate Acute Malnutrition\nTREATMENT\nLOC\n\t\n\u0089\nAssess the child\u2019s feeding and counsel the mother on \nthe feeding recommendations\n\t\n\u0089\nIf child has any feeding problem, counsel and follow up \nin 7 days (see section 17.3.12.4)\nHC3\n\t\n\u0089\nAssess for possible TB infection\n\t\n\u0089\nAdvise mother when to return immediately (danger signs)",
        "formatted_content": "<p>897</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>of the child\u2019s upper arm and plot the score on the appropriate</p>\n<p>chart (boy or girl, section 17.5). Please note: 1 cm=10 mm, so</p>\n<p>11.5 cm = 115 mm.</p>\n<p>19.2.2   Management of Acute Malnutrition in Children</p>\n<p>General principles of management</p>\n<p>~</p>\n<p>Admit all children with any danger sign, medical complica\u00ad</p>\n<p>tions, pitting oedema or those who fail appetite tests for</p>\n<p>inpatient care and treatment for complicated SAM.</p>\n<p>\u0089</p>\n<p>Keep them in a warm area separated from infectious children, or</p>\n<p>in a special nutrition area.</p>\n<p>~</p>\n<p>Children with good appetite and no medical complications</p>\n<p>can be managed as outpatients for uncomplicated SAM.</p>\n<p>~</p>\n<p>Adequate facilities and staff to ensure correct preparation</p>\n<p>of therapeutic foods, and to feed child regularly day and</p>\n<p>night, should be available.</p>\n<p>~</p>\n<p>Accurate weighing machines and MUAC tapes should be</p>\n<p>available</p>\n<p>~</p>\n<p>Proper records of feeds given and child\u2019s measurements</p>\n<p>should be kept so that progress can be monitored</p>\n<p>~</p>\n<p>Explain to patient/care-giver to handle the child gently</p>\n<p>19.2.2.1   Management of Moderate Acute Malnutrition</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Assess the child\u2019s feeding and counsel the mother on</p>\n<p>the feeding recommendations</p>\n<p>\u0089</p>\n<p>If child has any feeding problem, counsel and follow up</p>\n<p>in 7 days (see section 17.3.12.4)</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>Assess for possible TB infection</p>\n<p>\u0089</p>\n<p>Advise mother when to return immediately (danger signs)</p>"
    },
    {
        "page_number": 964,
        "content": "898\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\nLOC\nFOLLOW-UP CARE\nFollow-up in 30 days\n \n~\nReassess child and re-classify\n \n- If better, praise mother and counsel on nutrition\n \n- If still moderate malnutrition, counsel and follow \nup in 1 month\n \n- If worse, loosing weight, or feeding problem: \nrefer\n19.2.2.2  Management of Uncomplicated Severe Acute \nMalnutrition\nTREATMENT\nLOC\n\t\n\u0089\nGive oral antibiotics: amoxicillin DT 40 mg/kg twice \na day 40 mg/kg for 5 days\n\t\n\u0089\nGive ready-to-use therapeutic food (RUTF) for a child \naged \u00b3 6 months (for doses, see next section)\n\t\n\u0089\nCounsel the mother on how to feed the child (see \nsection 17.3.12.3)\n\t\n\u0089\nAssess for possible TB infection\n\t\n\u0089\nAdvise mother when to return immediately (danger signs)\nHC3\nFOLLOW-UP CARE\nAfter 7 days\n \n\u0083 Reassess child and feeding. If no new problem, \nreview again in 7 days\nAfter 14 days or during regular follow up:\n\t\n\u0089\nDo a full reassessment of the child: check WFH/L, \nMUAC, oedema of both feet and do another appetite test\nIf the child has complicated SAM\n\t\n\u0089\nRefer URGENTLY to hospital\nIf the child has uncomplicated SAM",
        "formatted_content": "<p>898</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<h3>FOLLOW-UP CARE</h3>\n<p>Follow-up in 30 days</p>\n<p>~</p>\n<p>Reassess child and re-classify</p>\n<p>- If better, praise mother and counsel on nutrition</p>\n<p>- If still moderate malnutrition, counsel and follow</p>\n<p>up in 1 month</p>\n<p>- If worse, loosing weight, or feeding problem:</p>\n<p>refer</p>\n<p>19.2.2.2  Management of Uncomplicated Severe Acute</p>\n<p>Malnutrition</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give oral antibiotics: amoxicillin DT 40 mg/kg twice</p>\n<p>a day 40 mg/kg for 5 days</p>\n<p>\u0089</p>\n<p>Give ready-to-use therapeutic food (RUTF) for a child</p>\n<p>aged \u00b3 6 months (for doses, see next section)</p>\n<p>\u0089</p>\n<p>Counsel the mother on how to feed the child (see</p>\n<p>section 17.3.12.3)</p>\n<p>\u0089</p>\n<p>Assess for possible TB infection</p>\n<p>\u0089</p>\n<p>Advise mother when to return immediately (danger signs)</p>\n<h3>HC3</h3>\n<h3>FOLLOW-UP CARE</h3>\n<p>After 7 days</p>\n<p>\u0083 Reassess child and feeding. If no new problem,</p>\n<p>review again in 7 days</p>\n<p>After 14 days or during regular follow up:</p>\n<p>\u0089</p>\n<p>Do a full reassessment of the child: check WFH/L,</p>\n<p>MUAC, oedema of both feet and do another appetite test</p>\n<p>If the child has complicated SAM</p>\n<p>\u0089</p>\n<p>Refer URGENTLY to hospital</p>\n<p>If the child has uncomplicated SAM</p>"
    },
    {
        "page_number": 965,
        "content": "899\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n\t\n\u0089\nCounsel the mother and encourage her to continue \nwith appropriate RUTF feeding. Ask mother to return \nagain in 14 days\nIf the child has moderate acute malnutrition:\n\t\n\u0089\nAdvise the mother to continue RUTF. Counsel her \nto start other foods according to the age appropriate \nfeeding recommendations (see section 17.3.12.3)\n\t\n\u0089\nTell her to return in 14 days. Continue to see the \nchild every 14 days until the child has no more acute \nmalnutrition\nIf the child has no acute malnutrition (WFH/L is -2 \nz-scores or more, or MUAC is 125 mm or more) \n\t\n\u0089\nPraise the mother, STOP RUTF and counsel her about \nage appropriate feeding recommendations\n19.2.2.3  Management of Complicated Severe Acute Malnutri\u00ad\ntion\nIn-patient care\n \n~\nRefer child to hospital: prevent hypoglycaemia by giving \nsmall sips of sugar water, keep the child warm, first dose \nof antibiotics (ampicillin + gentamicin)\n \n~\nTriage the children to fast-track seriously ill patients for \nassessment and care: treat shock, hypoglycaemia, and \ncorneal ulceration, immediately\n \n~\nGeneral treatment involves 10 steps in two phases: initial \nstabilisation for 1 week and rehabilitation (for weeks 2-6) \nas in the table below\nISSUE\nSTABILISATION\nREHABILITATION\nDAYS 1-2\nDAYS 3-7\nWEEKS 2-6\nHypoglycaemia\nHypothermia\nDehydration\nElectrolytes\nInfection",
        "formatted_content": "<p>899</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>\u0089</p>\n<p>Counsel the mother and encourage her to continue</p>\n<p>with appropriate RUTF feeding. Ask mother to return</p>\n<p>again in 14 days</p>\n<p>If the child has moderate acute malnutrition:</p>\n<p>\u0089</p>\n<p>Advise the mother to continue RUTF. Counsel her</p>\n<p>to start other foods according to the age appropriate</p>\n<p>feeding recommendations (see section 17.3.12.3)</p>\n<p>\u0089</p>\n<p>Tell her to return in 14 days. Continue to see the</p>\n<p>child every 14 days until the child has no more acute</p>\n<p>malnutrition</p>\n<p>If the child has no acute malnutrition (WFH/L is -2</p>\n<p>z-scores or more, or MUAC is 125 mm or more)</p>\n<p>\u0089</p>\n<p>Praise the mother, STOP RUTF and counsel her about</p>\n<p>age appropriate feeding recommendations</p>\n<p>19.2.2.3  Management of Complicated Severe Acute Malnutri\u00ad</p>\n<p>tion</p>\n<p>In-patient care</p>\n<p>~</p>\n<p>Refer child to hospital: prevent hypoglycaemia by giving</p>\n<p>small sips of sugar water, keep the child warm, first dose</p>\n<p>of antibiotics (ampicillin + gentamicin)</p>\n<p>~</p>\n<p>Triage the children to fast-track seriously ill patients for</p>\n<p>assessment and care: treat shock, hypoglycaemia, and</p>\n<p>corneal ulceration, immediately</p>\n<p>~</p>\n<p>General treatment involves 10 steps in two phases: initial</p>\n<p>stabilisation for 1 week and rehabilitation (for weeks 2-6)</p>\n<p>as in the table below</p>\n<h3>ISSUE</h3>\n<h3>STABILISATION</h3>\n<h3>REHABILITATION</h3>\n<h3>DAYS 1-2</h3>\n<h3>DAYS 3-7</h3>\n<h3>WEEKS 2-6</h3>\n<p>Hypoglycaemia</p>\n<p>Hypothermia</p>\n<p>Dehydration</p>\n<p>Electrolytes</p>\n<p>Infection</p>"
    },
    {
        "page_number": 966,
        "content": "900\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nISSUE\nSTABILISATION\nREHABILITATION\nDAYS 1-2\nDAYS 3-7\nWEEKS 2-6\nMicronutrients\nNo iron\n*With iron\nInitiate feeding\nCatch-up feeding\nSensory stimulation\nPrepare for fol\u00ad\nlow-up\nNote\n \n\u0083 Iron is given after 2 days on F-100; if patient is taking RUTF, \ndo NOT give iron\nManagement of Complications in SAM\nHypoglycaemia (Blood sugar <3 mmol/L or <54 mg/dL)\n \n~\nAll severly malnourished children are at a risk of hypo\u00ad\nglycaemia, and should be given a feed or 10% glucose or \nsucrose, immediately on admission\n \n~\nFrequent 2 hour feeding is important\nTREATMENT\nImmediately on admission\n\t\n\u0089\nGive 50 ml of glucose or sugar water (one rounded teaspoon of \nsugar in 3 tablespoons of water) orally or by NGT, followed by \nfirst feed as soon as possible\nIf child is able to drink\n \n~\nGive first feed of F-75 therapeutic milk, if available, ev\u00ad\nery 30 minutes for 2 hours, then continue with feeds \nevery 2 hours for 24 hours\n \n- Then give feeds every 2 or 3 hours, day and night\nIf child is unconscious\n\t\n\u0089\nTreat with IV 10% glucose at 5 ml/kg\n\t\n\u0089\nIf IV access cannot be quickly established, give 10% glucose or \nsucrose solution by NGT tube. To make 10% solution, dilute 1 \npart of 50% glucose with 4 parts of water OR 1 part of glucose \n50% with 9 parts of glucose 5%",
        "formatted_content": "<p>900</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>ISSUE</h3>\n<h3>STABILISATION</h3>\n<h3>REHABILITATION</h3>\n<h3>DAYS 1-2</h3>\n<h3>DAYS 3-7</h3>\n<h3>WEEKS 2-6</h3>\n<p>Micronutrients</p>\n<p>No iron</p>\n<p>*With iron</p>\n<p>Initiate feeding</p>\n<p>Catch-up feeding</p>\n<p>Sensory stimulation</p>\n<p>Prepare for fol\u00ad</p>\n<p>low-up</p>\n<p>Note</p>\n<p>\u0083 Iron is given after 2 days on F-100; if patient is taking RUTF,</p>\n<p>do NOT give iron</p>\n<p>Management of Complications in SAM</p>\n<p>Hypoglycaemia (Blood sugar <3 mmol/L or <54 mg/dL)</p>\n<p>~</p>\n<p>All severly malnourished children are at a risk of hypo\u00ad</p>\n<p>glycaemia, and should be given a feed or 10% glucose or</p>\n<p>sucrose, immediately on admission</p>\n<p>~</p>\n<p>Frequent 2 hour feeding is important</p>\n<h3>TREATMENT</h3>\n<p>Immediately on admission</p>\n<p>\u0089</p>\n<p>Give 50 ml of glucose or sugar water (one rounded teaspoon of</p>\n<p>sugar in 3 tablespoons of water) orally or by NGT, followed by</p>\n<p>first feed as soon as possible</p>\n<p>If child is able to drink</p>\n<p>~</p>\n<p>Give first feed of F-75 therapeutic milk, if available, ev\u00ad</p>\n<p>ery 30 minutes for 2 hours, then continue with feeds</p>\n<p>every 2 hours for 24 hours</p>\n<p>- Then give feeds every 2 or 3 hours, day and night</p>\n<p>If child is unconscious</p>\n<p>\u0089</p>\n<p>Treat with IV 10% glucose at 5 ml/kg</p>\n<p>\u0089</p>\n<p>If IV access cannot be quickly established, give 10% glucose or</p>\n<p>sucrose solution by NGT tube. To make 10% solution, dilute 1</p>\n<p>part of 50% glucose with 4 parts of water OR 1 part of glucose</p>\n<p>50% with 9 parts of glucose 5%</p>"
    },
    {
        "page_number": 967,
        "content": "901\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\n \n- If IV glucose not available, give 1 teaspoon of sugar \nmoistened with 1-2 drops of water sublingually, and \nrepeat every 20 minutes to prevent relapse\n \n- Monitor children for early swallowing which delays\n \n- absorption; if it happens, give another dose of sugar\n \n- Start on appropriate IV/IM antibiotics\nMonitoring\nIf initial blood glucose was low, repeat measurement after 30 minutes\n\t\n\u0089\nIf blood glucose falls to <3 mmol/L (<54 mg/dL), repeat the \n10% glucose or oral sugar solution, and ensure antibiotics have \nbeen given\n \n- If it is higher, change to 3 hourly feeds of F-75\n\t\n\u0089\nIf rectal tempearture falls to <35.5\u00b0C, or if level of consciousness \ndeteriorates, repeat the blood glucose measurement and treat \naccordingly\nPrevention\n\t\n\u0089\nFeed every 2 hours, starting immediately (see below), or if child is \ndehydrated, rehydrate first. Continue feeding throught the night\n\t\n\u0089\nEncourage mothers to watch for any deterioration, help feed \nand keep the child warm\n\t\n\u0089\nCheck on abdominal distension\nHypothermia (Axillary temperature <35\u00b0C and rectal tempera\u00ad\nture <35.5\u00b0C)\n \n~\nOften associated with hypoglycaemia or serious infection\nTREATMENT\n\t\n\u0089\nFeed child immediately as in hypoglycaemia above\n\t\n\u0089\nWarm the child: make sure the child is well covered, especially \nthe head, with cloths, hats, and blankets\n \n- If available, use a heater but not pointing directly at the \nchild. DO NOT use hot water bottles or flourescent lamps\n\t\n\u0089\nEncourage caretaker/mother to sleep next to her child and \nkangaroo technique for infants (skin-to-skin contact, direct heat/\nwarmth transfer from mother to child)",
        "formatted_content": "<p>901</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>- If IV glucose not available, give 1 teaspoon of sugar</p>\n<p>moistened with 1-2 drops of water sublingually, and</p>\n<p>repeat every 20 minutes to prevent relapse</p>\n<p>- Monitor children for early swallowing which delays</p>\n<p>- absorption; if it happens, give another dose of sugar</p>\n<p>- Start on appropriate IV/IM antibiotics</p>\n<p>Monitoring</p>\n<p>If initial blood glucose was low, repeat measurement after 30 minutes</p>\n<p>\u0089</p>\n<p>If blood glucose falls to <3 mmol/L (<54 mg/dL), repeat the</p>\n<p>10% glucose or oral sugar solution, and ensure antibiotics have</p>\n<p>been given</p>\n<p>- If it is higher, change to 3 hourly feeds of F-75</p>\n<p>\u0089</p>\n<p>If rectal tempearture falls to <35.5\u00b0C, or if level of consciousness</p>\n<p>deteriorates, repeat the blood glucose measurement and treat</p>\n<p>accordingly</p>\n<p>Prevention</p>\n<p>\u0089</p>\n<p>Feed every 2 hours, starting immediately (see below), or if child is</p>\n<p>dehydrated, rehydrate first. Continue feeding throught the night</p>\n<p>\u0089</p>\n<p>Encourage mothers to watch for any deterioration, help feed</p>\n<p>and keep the child warm</p>\n<p>\u0089</p>\n<p>Check on abdominal distension</p>\n<p>Hypothermia (Axillary temperature <35\u00b0C and rectal tempera\u00ad</p>\n<p>ture <35.5\u00b0C)</p>\n<p>~</p>\n<p>Often associated with hypoglycaemia or serious infection</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Feed child immediately as in hypoglycaemia above</p>\n<p>\u0089</p>\n<p>Warm the child: make sure the child is well covered, especially</p>\n<p>the head, with cloths, hats, and blankets</p>\n<p>- If available, use a heater but not pointing directly at the</p>\n<p>child. DO NOT use hot water bottles or flourescent lamps</p>\n<p>\u0089</p>\n<p>Encourage caretaker/mother to sleep next to her child and</p>\n<p>kangaroo technique for infants (skin-to-skin contact, direct heat/</p>\n<p>warmth transfer from mother to child)</p>"
    },
    {
        "page_number": 968,
        "content": "902\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\n\t\n\u0089\nKeep the ward closed during the night and avoid wind drafts inside\n\t\n\u0089\nGive appropriate IV or IM antibiotics\n\t\n\u0089\nChange wet nappies, clothes and bedding to keep child and \nbed dry\n\t\n\u0089\nQuickly clean the patient with a warm wet towel and dry imme\u00ad\ndiately. Avoid washing the baby directly in the first few weeks \nof admission\nMonitoring\n\t\n\u0089\nTake child\u2019s rectal temperature every 2 hours until it rises to \n<36.5\u00b0C, If using a heater, take it every 30 minutes\n\t\n\u0089\nCover the child at all times, especially at night. Keep head cov\u00ad\nered with hat to prevent heat loss\n\t\n\u0089\nCheck for hypoglycaemia\nDehydration\n \n~\nIn both oedema and non-oedematous SAM, the margin \nof safety between dehydration and over-hydration is very \nnarrow. Exercise care and caution to avoid over-hydration \nand risk of cardiac failure\n\t\n\u0089\nAssume that all children with watery diarrhoea or reduced urine \noutput have some dehydration\nTREATMENT\n\t\n\u0089\nDo NOT use IV route for rehydration, except in cases of shock\n\t\n\u0089\nRehydrate slowly, either orally or by NGT using ReSoMal, a specially prepared \nrehydration solution for malnutrition, The standard ORS has a high sodium \nand low potassium content, which is not suitable for SAM, except if profuse \ndiarrhoea is present\n \n~\nGive ReSoMal more slowly than you would when rehydrating a \nwell-nourished child\n \n- Give 5 ml/kg every 30 minutes for the first 2 hours\n \n- Then give 5-10 ml/kg per hour for the next 4-10 hours, with F-75 \nformula. Exact amount depends on how much the child wants, the \nvolume of stool loss and whether the child is vomiting\nIf ReSoMal not available:\n \n- Give half strength standard ORS, with added potassium and glucose as \nper the ReSoMal recipe below, unless the child has cholera or profuse",
        "formatted_content": "<p>902</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Keep the ward closed during the night and avoid wind drafts inside</p>\n<p>\u0089</p>\n<p>Give appropriate IV or IM antibiotics</p>\n<p>\u0089</p>\n<p>Change wet nappies, clothes and bedding to keep child and</p>\n<p>bed dry</p>\n<p>\u0089</p>\n<p>Quickly clean the patient with a warm wet towel and dry imme\u00ad</p>\n<p>diately. Avoid washing the baby directly in the first few weeks</p>\n<p>of admission</p>\n<p>Monitoring</p>\n<p>\u0089</p>\n<p>Take child\u2019s rectal temperature every 2 hours until it rises to</p>\n<p><36.5\u00b0C, If using a heater, take it every 30 minutes</p>\n<p>\u0089</p>\n<p>Cover the child at all times, especially at night. Keep head cov\u00ad</p>\n<p>ered with hat to prevent heat loss</p>\n<p>\u0089</p>\n<p>Check for hypoglycaemia</p>\n<p>Dehydration</p>\n<p>~</p>\n<p>In both oedema and non-oedematous SAM, the margin</p>\n<p>of safety between dehydration and over-hydration is very</p>\n<p>narrow. Exercise care and caution to avoid over-hydration</p>\n<p>and risk of cardiac failure</p>\n<p>\u0089</p>\n<p>Assume that all children with watery diarrhoea or reduced urine</p>\n<p>output have some dehydration</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Do NOT use IV route for rehydration, except in cases of shock</p>\n<p>\u0089</p>\n<p>Rehydrate slowly, either orally or by NGT using ReSoMal, a specially prepared</p>\n<p>rehydration solution for malnutrition, The standard ORS has a high sodium</p>\n<p>and low potassium content, which is not suitable for SAM, except if profuse</p>\n<p>diarrhoea is present</p>\n<p>~</p>\n<p>Give ReSoMal more slowly than you would when rehydrating a</p>\n<p>well-nourished child</p>\n<p>- Give 5 ml/kg every 30 minutes for the first 2 hours</p>\n<p>- Then give 5-10 ml/kg per hour for the next 4-10 hours, with F-75</p>\n<p>formula. Exact amount depends on how much the child wants, the</p>\n<p>volume of stool loss and whether the child is vomiting</p>\n<p>If ReSoMal not available:</p>\n<p>- Give half strength standard ORS, with added potassium and glucose as</p>\n<p>per the ReSoMal recipe below, unless the child has cholera or profuse</p>"
    },
    {
        "page_number": 969,
        "content": "903\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\n \n- watery diarrhoea\n \n- If rehydration still required at 10 hours, give starter F-75\n \n- Instead of ReSoMal, at the same times. Give the same volume of \nstarter F-75 as of ReSoMal\nIf child is unconscious, in shock or severe dehydration\n\t\n\u0089\nGive IV fluid Darrow\u2019s solution or Ringer\u2019s lactate and 5% glucose (or if not avail\u00ad\nable, \u00bd saline and 5% glucose at 15 mL/kg the first hour and reassess\n \n- If improving, give 15 mL/kg in second hour\n \n- If conscious, give NGT ReSoMal\n \n- If not improving, treat for septic shock\nMonitoring\n \n~\nONLY rehydrate until the weight deficit is corrected and then \nSTOP, DO NOT give extra fluid to \u201dprevent recurrence\u201d (from \nspecialist\u2019s notes)\n \n~\nDuring rehydration, respiration and pulse rate should fall and \nurine passing should start\n \n~\nReturn of tears, moist mouth, improved skin tugor and less sunk\u00ad\nen eyes and fontanelle are a sign of rehydration. SAM children \nwill not show these and so weight gain should be measured\n \n~\nMonitor progress of rehydration every 30 minutes for 2 hours, \nthen every hour for the next 4-10 hours\nBe alert for signs of overhydration, which is dangerous and can lead to \nheart failure. Check for:\n \n- Weight gain (make sure it is not quick or excessive)\n \n- If increase in pulse rate by 25/minute, respiratory rate by 5/minute is \npresent, stop ReSoMal. Reassess after 1 hour\n \n- Urine frequency (if child urinated since last check)\n \n- Enlarging liver size on palpation\n \n- Frequency of stools and vomit\nPrevention\n\t\n\u0089\nSame as in dehydration in well-nourished child, except that ReSoMal is used \ninstead of standard ORS. Give 30-50 ml of ReSoMal (for child <2 years) and 100 \nml (for child \u00b32 years) after each watery stool.\n \n- Small, frequent, unformed stools are common in SAM and should \nnot be confused with profuse watery stools, and they do not require \ntreatment",
        "formatted_content": "<p>903</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>- watery diarrhoea</p>\n<p>- If rehydration still required at 10 hours, give starter F-75</p>\n<p>- Instead of ReSoMal, at the same times. Give the same volume of</p>\n<p>starter F-75 as of ReSoMal</p>\n<p>If child is unconscious, in shock or severe dehydration</p>\n<p>\u0089</p>\n<p>Give IV fluid Darrow\u2019s solution or Ringer\u2019s lactate and 5% glucose (or if not avail\u00ad</p>\n<p>able, \u00bd saline and 5% glucose at 15 mL/kg the first hour and reassess</p>\n<p>- If improving, give 15 mL/kg in second hour</p>\n<p>- If conscious, give NGT ReSoMal</p>\n<p>- If not improving, treat for septic shock</p>\n<p>Monitoring</p>\n<p>~</p>\n<p>ONLY rehydrate until the weight deficit is corrected and then</p>\n<p>STOP, DO NOT give extra fluid to \u201dprevent recurrence\u201d (from</p>\n<p>specialist\u2019s notes)</p>\n<p>~</p>\n<p>During rehydration, respiration and pulse rate should fall and</p>\n<p>urine passing should start</p>\n<p>~</p>\n<p>Return of tears, moist mouth, improved skin tugor and less sunk\u00ad</p>\n<p>en eyes and fontanelle are a sign of rehydration. SAM children</p>\n<p>will not show these and so weight gain should be measured</p>\n<p>~</p>\n<p>Monitor progress of rehydration every 30 minutes for 2 hours,</p>\n<p>then every hour for the next 4-10 hours</p>\n<p>Be alert for signs of overhydration, which is dangerous and can lead to</p>\n<p>heart failure. Check for:</p>\n<p>- Weight gain (make sure it is not quick or excessive)</p>\n<p>- If increase in pulse rate by 25/minute, respiratory rate by 5/minute is</p>\n<p>present, stop ReSoMal. Reassess after 1 hour</p>\n<p>- Urine frequency (if child urinated since last check)</p>\n<p>- Enlarging liver size on palpation</p>\n<p>- Frequency of stools and vomit</p>\n<p>Prevention</p>\n<p>\u0089</p>\n<p>Same as in dehydration in well-nourished child, except that ReSoMal is used</p>\n<p>instead of standard ORS. Give 30-50 ml of ReSoMal (for child <2 years) and 100</p>\n<p>ml (for child \u00b32 years) after each watery stool.</p>\n<p>- Small, frequent, unformed stools are common in SAM and should</p>\n<p>not be confused with profuse watery stools, and they do not require</p>\n<p>treatment</p>"
    },
    {
        "page_number": 970,
        "content": "904\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n\t\n\u0089\nContinue breastfeeding\n\t\n\u0089\nInitiate re-feeding with starter F-75\n\t\n\u0089\nGive ReSoMal between feeds to replace stool lossess.\nGive 50-100 ml after each watery stool\nRecipe for ReSoMal using the standard WHO ORS\nINGREDIENT\nAMOUNT\nWater\n2 litres\nWHO-ORS\nOne 1-litre packet\nSucrose\n50 g\nElectrolyte/mineral solution\n40 ml\nElectrolyte imbalance\n \n~\nAll SAM children have deficiencies of potassium and mag\u00ad\nnesium, which may take up to 2 weeks to correct\n \n~\nOedema is partly due to potassium deficiency and sodium \nretention\n\t\n\u0089\nDo not treat oedema with diuretics\n\t\n\u0089\nGiving high sodium doses could kill the child\nTREATMENT\n\t\n\u0089\nGive extra potassium (3-4 mmol/kg per day) f Give extra mag\u00ad\nnesium (0.4-0.6 mmol/kg per day) f Add extra potassium and \nmagnesium to the feeds. If not already pre-mixed, add 20 ml of \nthe combined electrolyte/mineral solution to 1 litre of feed, or \nuse pre- mixed sachets for SAM\n\t\n\u0089\nUse ReSoMal to rehydrate\n\t\n\u0089\nPrepare food without added salt\nInfections\n \n~\nIn SAM, usual signs of bacterial infection, e.g. fever, are \nusually absent, yet multiple infections are common.\n \n~\nAssume all SAM cases have an infection, and treat with",
        "formatted_content": "<p>904</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>\u0089</p>\n<p>Continue breastfeeding</p>\n<p>\u0089</p>\n<p>Initiate re-feeding with starter F-75</p>\n<p>\u0089</p>\n<p>Give ReSoMal between feeds to replace stool lossess.</p>\n<p>Give 50-100 ml after each watery stool</p>\n<p>Recipe for ReSoMal using the standard WHO ORS</p>\n<h3>INGREDIENT</h3>\n<h3>AMOUNT</h3>\n<p>Water</p>\n<p>2 litres</p>\n<h3>WHO-ORS</h3>\n<p>One 1-litre packet</p>\n<p>Sucrose</p>\n<p>50 g</p>\n<p>Electrolyte/mineral solution</p>\n<p>40 ml</p>\n<p>Electrolyte imbalance</p>\n<p>~</p>\n<p>All SAM children have deficiencies of potassium and mag\u00ad</p>\n<p>nesium, which may take up to 2 weeks to correct</p>\n<p>~</p>\n<p>Oedema is partly due to potassium deficiency and sodium</p>\n<p>retention</p>\n<p>\u0089</p>\n<p>Do not treat oedema with diuretics</p>\n<p>\u0089</p>\n<p>Giving high sodium doses could kill the child</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Give extra potassium (3-4 mmol/kg per day) f Give extra mag\u00ad</p>\n<p>nesium (0.4-0.6 mmol/kg per day) f Add extra potassium and</p>\n<p>magnesium to the feeds. If not already pre-mixed, add 20 ml of</p>\n<p>the combined electrolyte/mineral solution to 1 litre of feed, or</p>\n<p>use pre- mixed sachets for SAM</p>\n<p>\u0089</p>\n<p>Use ReSoMal to rehydrate</p>\n<p>\u0089</p>\n<p>Prepare food without added salt</p>\n<p>Infections</p>\n<p>~</p>\n<p>In SAM, usual signs of bacterial infection, e.g. fever, are</p>\n<p>usually absent, yet multiple infections are common.</p>\n<p>~</p>\n<p>Assume all SAM cases have an infection, and treat with</p>"
    },
    {
        "page_number": 971,
        "content": "905\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nantibiotics immediately. Hypoglycaemia and hypothermia \nare often signs of severe infection\nTREATMENT\nBroad spectrum antibiotics\n\t\n\u0089\nBenzylpenicillin 50,000 IU/kg IM or IV every 6 hours Or ampi\u00ad\ncillin 50 mg/kg every 6 hours for 2 days f Then, oral amoxicillin \n25-40 mg/kg every 8 hours for\n\t\n\u0089\n5 days PLUS\n\t\n\u0089\nGentamicin 7.5 mg/kg once a day for 7 days\n\t\n\u0089\nMeasles vaccination\n\t\n\u0089\nIf child is \u00b3 6 months and not vaccinated, or was vaccinated \nbefore 9 months of age. Delay vaccination if child is in shock\nOther specific infections\n\t\n\u0089\nTreat other specific infections if diagnosed as appropriate, e.g., \nmalaria, pneumonia, dysentery, soft- tissue infections, mengin\u00ad\ngitis, TB, HIV\n\t\n\u0089\nIf parasitic worms are diagnosed, delay treatment until the re\u00ad\nhabilitation phase. Give albendazole 200-400 mg single dose\n \n- In endemic areas, give mebendazole orally twice a day\n \n- for 3 days to all SAM children 7 days after admission\n \n- If HIV diagnosed, start ART as soon as possible after \nstabilisation of metabolic compilcations\nMonitoring\n\t\n\u0089\nIf child is still anorexic after 7 days of antibiotic treatment, continue \nfor a full 10-day course. If anorexia persists, reassess child fully\nMicronutrient deficiencies\n \n~\nAll SAM children have vitamin and mineral deficiencies\n \n~\nAnaemia is common, but DO NOT give iron initially, in\u00ad\nstead wait until the child has a good appetite and has start\u00ad\ned gaining weight, usually in the second week, because iron \ncan make infections worse\n \n~\nRUTF already contains adequate iron so do not add. F-100 does \nnot contain iron, so iron supplements are needed",
        "formatted_content": "<p>905</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>antibiotics immediately. Hypoglycaemia and hypothermia</p>\n<p>are often signs of severe infection</p>\n<h3>TREATMENT</h3>\n<p>Broad spectrum antibiotics</p>\n<p>\u0089</p>\n<p>Benzylpenicillin 50,000 IU/kg IM or IV every 6 hours Or ampi\u00ad</p>\n<p>cillin 50 mg/kg every 6 hours for 2 days f Then, oral amoxicillin</p>\n<p>25-40 mg/kg every 8 hours for</p>\n<p>\u0089</p>\n<p>5 days PLUS</p>\n<p>\u0089</p>\n<p>Gentamicin 7.5 mg/kg once a day for 7 days</p>\n<p>\u0089</p>\n<p>Measles vaccination</p>\n<p>\u0089</p>\n<p>If child is \u00b3 6 months and not vaccinated, or was vaccinated</p>\n<p>before 9 months of age. Delay vaccination if child is in shock</p>\n<p>Other specific infections</p>\n<p>\u0089</p>\n<p>Treat other specific infections if diagnosed as appropriate, e.g.,</p>\n<p>malaria, pneumonia, dysentery, soft- tissue infections, mengin\u00ad</p>\n<p>gitis, TB, HIV</p>\n<p>\u0089</p>\n<p>If parasitic worms are diagnosed, delay treatment until the re\u00ad</p>\n<p>habilitation phase. Give albendazole 200-400 mg single dose</p>\n<p>- In endemic areas, give mebendazole orally twice a day</p>\n<p>- for 3 days to all SAM children 7 days after admission</p>\n<p>- If HIV diagnosed, start ART as soon as possible after</p>\n<p>stabilisation of metabolic compilcations</p>\n<p>Monitoring</p>\n<p>\u0089</p>\n<p>If child is still anorexic after 7 days of antibiotic treatment, continue</p>\n<p>for a full 10-day course. If anorexia persists, reassess child fully</p>\n<p>Micronutrient deficiencies</p>\n<p>~</p>\n<p>All SAM children have vitamin and mineral deficiencies</p>\n<p>~</p>\n<p>Anaemia is common, but DO NOT give iron initially, in\u00ad</p>\n<p>stead wait until the child has a good appetite and has start\u00ad</p>\n<p>ed gaining weight, usually in the second week, because iron</p>\n<p>can make infections worse</p>\n<p>~</p>\n<p>RUTF already contains adequate iron so do not add. F-100 does</p>\n<p>not contain iron, so iron supplements are needed</p>"
    },
    {
        "page_number": 972,
        "content": "906\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n \n~\nF-75, F-100 and RUTF already contain multivitamins (in\u00ad\ncluding vitamin A and folic acid) zinc and copper. Addition\u00ad\nal doses are not needed\n \n~\nIf there are no eye signs or history of measles, then do not \ngive a high dose of vitamin A as therapeutic foods already \ncontain adequate amounts\nManagement\nTREATMENT\nONLY IF child has signs of vitamin A deficiency like corneal ulceration \nor history of measles\n\t\n\u0089\nGive Vitamin A on day 1, and repeat on days 2 and 14\nChild <6 months: 50,000 IU\nChild 6-12 months: 100,000 IU\nChild >12 months: 200,000 IU\nNote: If a first dose was given in the referring centre, treat on days 1 and 14 only\nIron\n\t\n\u0089\nGive iron in the second week of nutritional rehabilitation\n \n- Do not give in the stabilization phase\n \n- Do not give in children receiving RUTF\n\t\n\u0089\nStart iron at 3 mg/kg per day after 2 days on F-100 catch- up formula\nIf child is not on any pre-mixed therapeutic foods, give the following micronutrients \ndaily for at least 2 weeks\n\t\n\u0089\nFolic   acid   at  5  mg  on  day   1;   then  1   mg  daily Multivitamin syrup 5 ml\n\t\n\u0089\nZinc 2 mg/kg per day\n\t\n\u0089\nCopper at 0.3 mg/kg per day\n\t\n\u0089\nOther vitamins and minerals e.g, a combination of selenium and moringa has \nbeen proven to be beneficial\nInitial Re-Feeding during Stabilisation Phase\nIn the initial phase, feeding should be gradual.\nThe essential features of initial feeding are:",
        "formatted_content": "<p>906</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>~</p>\n<p>F-75, F-100 and RUTF already contain multivitamins (in\u00ad</p>\n<p>cluding vitamin A and folic acid) zinc and copper. Addition\u00ad</p>\n<p>al doses are not needed</p>\n<p>~</p>\n<p>If there are no eye signs or history of measles, then do not</p>\n<p>give a high dose of vitamin A as therapeutic foods already</p>\n<p>contain adequate amounts</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<p>ONLY IF child has signs of vitamin A deficiency like corneal ulceration</p>\n<p>or history of measles</p>\n<p>\u0089</p>\n<p>Give Vitamin A on day 1, and repeat on days 2 and 14</p>\n<p>Child <6 months: 50,000 IU</p>\n<p>Child 6-12 months: 100,000 IU</p>\n<p>Child >12 months: 200,000 IU</p>\n<p>Note: If a first dose was given in the referring centre, treat on days 1 and 14 only</p>\n<p>Iron</p>\n<p>\u0089</p>\n<p>Give iron in the second week of nutritional rehabilitation</p>\n<p>- Do not give in the stabilization phase</p>\n<p>- Do not give in children receiving RUTF</p>\n<p>\u0089</p>\n<p>Start iron at 3 mg/kg per day after 2 days on F-100 catch- up formula</p>\n<p>If child is not on any pre-mixed therapeutic foods, give the following micronutrients</p>\n<p>daily for at least 2 weeks</p>\n<p>\u0089</p>\n<p>Folic   acid   at  5  mg  on  day   1;   then  1   mg  daily Multivitamin syrup 5 ml</p>\n<p>\u0089</p>\n<p>Zinc 2 mg/kg per day</p>\n<p>\u0089</p>\n<p>Copper at 0.3 mg/kg per day</p>\n<p>\u0089</p>\n<p>Other vitamins and minerals e.g, a combination of selenium and moringa has</p>\n<p>been proven to be beneficial</p>\n<p>Initial Re-Feeding during Stabilisation Phase</p>\n<p>In the initial phase, feeding should be gradual.</p>\n<p>The essential features of initial feeding are:</p>"
    },
    {
        "page_number": 973,
        "content": "907\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n \n~\nFrequent (every 2-3 hours) oral small feeds of low osmolali\u00ad\nty and low lactose. Never leave the child alone or forcefeed \nthe child, as this can cause aspiration pneumonia\n \n~\nNasogastric tube feeding if the child is eating \u00a3 80% of the \namount offered at two consecutive feeds\n \n~\nCalories at 100 kcal/kg per day (do not exceed)\n \n~\nProtein at 1-1.5 g/kg per day\n \n~\nLiquid at 130 ml/kg per day or 100 ml/kg per day if child \nhas severe oedema\n \n~\nMilk-based formulas, such as F-75 (with 75 kcal and 0.9 g \nprotein/100 ml), will be satisfactory for most children\n \n- Starter F-75 formula can be commercially supplied or\n \n- locally prepared from basic ingredients\n \n- In children who get osmotic diarrhoea with commercial \npreparation, prepare a cereal based F75 as in the table \noverleaf\nTREATMENT\n\t\n\u0089\nIf child is breastfeeding, continue breastfeeding but add the prescribed \namounts of the starter formula as in the table below:\nDays\nFrequency\nVolume/ kg feed\nVolume/ kg per \nday\n1-2\n2 hours\n11 ml\n130 ml\n3-5\n3 hours\n16 ml\n130 ml\n\u00b36\n4 hours\n22 ml\n130 ml\n\t\n\u0089\nFeed from a cup or bowl. Use a spoon, dropper or syringe to feed \nvery weak children\n\t\n\u0089\nTeach the mother or caregiver to help with the feeding\n\t\n\u0089\nNight feeds are essential, since long periods without a feed may \nlead to hypoglycaemia and death",
        "formatted_content": "<p>907</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>~</p>\n<p>Frequent (every 2-3 hours) oral small feeds of low osmolali\u00ad</p>\n<p>ty and low lactose. Never leave the child alone or forcefeed</p>\n<p>the child, as this can cause aspiration pneumonia</p>\n<p>~</p>\n<p>Nasogastric tube feeding if the child is eating \u00a3 80% of the</p>\n<p>amount offered at two consecutive feeds</p>\n<p>~</p>\n<p>Calories at 100 kcal/kg per day (do not exceed)</p>\n<p>~</p>\n<p>Protein at 1-1.5 g/kg per day</p>\n<p>~</p>\n<p>Liquid at 130 ml/kg per day or 100 ml/kg per day if child</p>\n<p>has severe oedema</p>\n<p>~</p>\n<p>Milk-based formulas, such as F-75 (with 75 kcal and 0.9 g</p>\n<p>protein/100 ml), will be satisfactory for most children</p>\n<p>- Starter F-75 formula can be commercially supplied or</p>\n<p>- locally prepared from basic ingredients</p>\n<p>- In children who get osmotic diarrhoea with commercial</p>\n<p>preparation, prepare a cereal based F75 as in the table</p>\n<p>overleaf</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>If child is breastfeeding, continue breastfeeding but add the prescribed</p>\n<p>amounts of the starter formula as in the table below:</p>\n<p>Days</p>\n<p>Frequency</p>\n<p>Volume/ kg feed</p>\n<p>Volume/ kg per</p>\n<p>day</p>\n<p>1-2</p>\n<p>2 hours</p>\n<p>11 ml</p>\n<p>130 ml</p>\n<p>3-5</p>\n<p>3 hours</p>\n<p>16 ml</p>\n<p>130 ml</p>\n<p>\u00b36</p>\n<p>4 hours</p>\n<p>22 ml</p>\n<p>130 ml</p>\n<p>\u0089</p>\n<p>Feed from a cup or bowl. Use a spoon, dropper or syringe to feed</p>\n<p>very weak children</p>\n<p>\u0089</p>\n<p>Teach the mother or caregiver to help with the feeding</p>\n<p>\u0089</p>\n<p>Night feeds are essential, since long periods without a feed may</p>\n<p>lead to hypoglycaemia and death</p>"
    },
    {
        "page_number": 974,
        "content": "908\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n\t\n\u0089\nIf child is vomiting, during or after a feed, estimate amount vomited \nand offer that amount again. If child keeps vomiting, offer half the \namount of feed twice as often (e.g. every 1 hour) until vomiting stops\nMonitoring\nMonitor and record:\n \n- Amounts of feed offered and left over\n \n- Vomiting\n \n- Stool frequency and consistency\n \n- Daily body weight\nRecipe for refeeding formula F-75 and F-100\nIf pre-mixed formulas are not available, prepare as below\nIngredient\nF-75 (Starter) Cereal-Based*\nF-100 (Catch-Up)\nDried skimmed milk\n25 g\n80 g\nSugar\n70 g\n50 g\nCereal flour\n35 g\n\u2014\nVegetable oil\n27 g\n60 g\nElectrolyte/mineral \nsolution mix\n20 g\n20 g\nWater: make up to \n1000 ml\n1000 ml\n1000 ml\nNote\n \n\u0083 Cook cereal-based formula for 4 minutes and add mineral/\nvitamin mix after cooking\nTransition phase\nThis phase is designed to prepare the child for phase 2 or outpatient \nmanagement (catch up growth).\nSigns that a child is ready for transition:\n \n~\nReturn of appetite\n \n~\nNo episodes of hypoglycaemia (metabolically stable)\n \n~\nReduction in or disappearance of all oedema",
        "formatted_content": "<p>908</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>\u0089</p>\n<p>If child is vomiting, during or after a feed, estimate amount vomited</p>\n<p>and offer that amount again. If child keeps vomiting, offer half the</p>\n<p>amount of feed twice as often (e.g. every 1 hour) until vomiting stops</p>\n<p>Monitoring</p>\n<p>Monitor and record:</p>\n<p>- Amounts of feed offered and left over</p>\n<p>- Vomiting</p>\n<p>- Stool frequency and consistency</p>\n<p>- Daily body weight</p>\n<p>Recipe for refeeding formula F-75 and F-100</p>\n<p>If pre-mixed formulas are not available, prepare as below</p>\n<p>Ingredient</p>\n<p>F-75 (Starter) Cereal-Based*</p>\n<p>F-100 (Catch-Up)</p>\n<p>Dried skimmed milk</p>\n<p>25 g</p>\n<p>80 g</p>\n<p>Sugar</p>\n<p>70 g</p>\n<p>50 g</p>\n<p>Cereal flour</p>\n<p>35 g</p>\n<p>\u2014</p>\n<p>Vegetable oil</p>\n<p>27 g</p>\n<p>60 g</p>\n<p>Electrolyte/mineral</p>\n<p>solution mix</p>\n<p>20 g</p>\n<p>20 g</p>\n<p>Water: make up to</p>\n<p>1000 ml</p>\n<p>1000 ml</p>\n<p>1000 ml</p>\n<p>Note</p>\n<p>\u0083 Cook cereal-based formula for 4 minutes and add mineral/</p>\n<p>vitamin mix after cooking</p>\n<p>Transition phase</p>\n<p>This phase is designed to prepare the child for phase 2 or outpatient</p>\n<p>management (catch up growth).</p>\n<p>Signs that a child is ready for transition:</p>\n<p>~</p>\n<p>Return of appetite</p>\n<p>~</p>\n<p>No episodes of hypoglycaemia (metabolically stable)</p>\n<p>~</p>\n<p>Reduction in or disappearance of all oedema</p>"
    },
    {
        "page_number": 975,
        "content": "909\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nMake a transition from starter formula to catch-up formula, gradu\u00ad\nally over 2\u20133 days. DO NOT switch at once.\nManagement\nTREATMENT\n\t\n\u0089\nMake a gradual transition from starter F-75 to catch-up formula \nF-100 or RUTF over 2-3 days, as tolerated\n\t\n\u0089\nGive RUTF or a milk-based formula, e.g, F-100 containing 100 \nkcal/100 mL and 2.9 g of protein per 100 ml. Replace starter \nF-75 with an equal amount of catch- up F-100 for 2 days.\n\t\n\u0089\nIf RUTF is available\n\t\n\u0089\nStart with small but regular meals of RUTF and encourage child \nto eat often (first, 8 meals per day, and later, 5-6 meals per day)\n\t\n\u0089\nIf child cannot eat whole amount of RUTF per meal in the \ntransition phase, top-up with F-75 to complete the feed, until \nchild is able to eat a whole RUTF meal\n\t\n\u0089\nIf child cannot take at least half of the RUTF in 12 hours, stop \nRUTF and give F-75. Try introducing RUTF again in 1-2 days \nuntil the child is able to take adequate amount\n\t\n\u0089\nIf still breastfeeding, offer breast milk first before each RUTF feed\nIf RUTF is not available or child does not accept it, give \nF-100\n \n~\nIn the first 2 days, give F-100 every 3-4 hours (the same \namount of F-75 that they were being given). Do not \nincrease volume for 2 days\n \n~\nOn the 3rd day, increase each successive feed by 10 ml \nuntil child finishes the meal\n \n~\nIf the child does not finish the meal, offer the same \namount for the next meal\n \n~\nKeep adding 10 ml until the child leaves a bit of most \nof his meals (i.e. point at which intake is likely to have \nreached 200 ml/kg per day)",
        "formatted_content": "<p>909</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Make a transition from starter formula to catch-up formula, gradu\u00ad</p>\n<p>ally over 2\u20133 days. DO NOT switch at once.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Make a gradual transition from starter F-75 to catch-up formula</p>\n<p>F-100 or RUTF over 2-3 days, as tolerated</p>\n<p>\u0089</p>\n<p>Give RUTF or a milk-based formula, e.g, F-100 containing 100</p>\n<p>kcal/100 mL and 2.9 g of protein per 100 ml. Replace starter</p>\n<p>F-75 with an equal amount of catch- up F-100 for 2 days.</p>\n<p>\u0089</p>\n<p>If RUTF is available</p>\n<p>\u0089</p>\n<p>Start with small but regular meals of RUTF and encourage child</p>\n<p>to eat often (first, 8 meals per day, and later, 5-6 meals per day)</p>\n<p>\u0089</p>\n<p>If child cannot eat whole amount of RUTF per meal in the</p>\n<p>transition phase, top-up with F-75 to complete the feed, until</p>\n<p>child is able to eat a whole RUTF meal</p>\n<p>\u0089</p>\n<p>If child cannot take at least half of the RUTF in 12 hours, stop</p>\n<p>RUTF and give F-75. Try introducing RUTF again in 1-2 days</p>\n<p>until the child is able to take adequate amount</p>\n<p>\u0089</p>\n<p>If still breastfeeding, offer breast milk first before each RUTF feed</p>\n<p>If RUTF is not available or child does not accept it, give</p>\n<h3>F-100</h3>\n<p>~</p>\n<p>In the first 2 days, give F-100 every 3-4 hours (the same</p>\n<p>amount of F-75 that they were being given). Do not</p>\n<p>increase volume for 2 days</p>\n<p>~</p>\n<p>On the 3rd day, increase each successive feed by 10 ml</p>\n<p>until child finishes the meal</p>\n<p>~</p>\n<p>If the child does not finish the meal, offer the same</p>\n<p>amount for the next meal</p>\n<p>~</p>\n<p>Keep adding 10 ml until the child leaves a bit of most</p>\n<p>of his meals (i.e. point at which intake is likely to have</p>\n<p>reached 200 ml/kg per day)</p>"
    },
    {
        "page_number": 976,
        "content": "910\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\n\t\n\u0089\nIf child is being breasfed, encourage mother to breastfeed in \nbetween F-100 rations\n\t\n\u0089\nAfter a gradual transition, give:\n \n- Frequent feeds, unlimited amounts\n \n- 150-220 kcal/kg per day\n \n- 4-6 g of protein/kg per day\nCaution\n \n\u0083 F-100 should never be given to take home. Transition to \nRUTF\nMonitoring\n\t\n\u0089\nMonitor the child at least every 4 hours during transition\n\t\n\u0089\nReturn child to stabilization phase if:\n \n- Child develops loss of appetite, cannot take 80% of the \nfeeds, develops or increased oedema, medical conditions \nnot improving, any signs of fluid overload, significant re-\nfeeding diarrhoea\nAvoid causing heart failure\nEarly signs of congestive heart failure (e.g. rapid pulse, fast breath\u00ad\ning, basal lung crepitations, enlarging liver, gallop heart rhythm, \nraised jugular venous pressure\nIf pulse is increased by 25 beats/minute and breathing rate by 5 \nbreaths/minute, and the increase is sustained for two successive \n4-hourly readings, then:\n \n- Reduce volume fed to 100 ml/kg per day for 24 hours\n \n~\nThen gradually increase as follows:\n \n- 115 ml/kg per day for next 24 hours\n \n- 130 ml/kg per day for the following 48 hours\n \n~\nThen, increase each feed by 10 ml as described earlier",
        "formatted_content": "<p>910</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>If child is being breasfed, encourage mother to breastfeed in</p>\n<p>between F-100 rations</p>\n<p>\u0089</p>\n<p>After a gradual transition, give:</p>\n<p>- Frequent feeds, unlimited amounts</p>\n<p>- 150-220 kcal/kg per day</p>\n<p>- 4-6 g of protein/kg per day</p>\n<p>Caution</p>\n<p>\u0083 F-100 should never be given to take home. Transition to</p>\n<h3>RUTF</h3>\n<p>Monitoring</p>\n<p>\u0089</p>\n<p>Monitor the child at least every 4 hours during transition</p>\n<p>\u0089</p>\n<p>Return child to stabilization phase if:</p>\n<p>- Child develops loss of appetite, cannot take 80% of the</p>\n<p>feeds, develops or increased oedema, medical conditions</p>\n<p>not improving, any signs of fluid overload, significant re-</p>\n<p>feeding diarrhoea</p>\n<p>Avoid causing heart failure</p>\n<p>Early signs of congestive heart failure (e.g. rapid pulse, fast breath\u00ad</p>\n<p>ing, basal lung crepitations, enlarging liver, gallop heart rhythm,</p>\n<p>raised jugular venous pressure</p>\n<p>If pulse is increased by 25 beats/minute and breathing rate by 5</p>\n<p>breaths/minute, and the increase is sustained for two successive</p>\n<p>4-hourly readings, then:</p>\n<p>- Reduce volume fed to 100 ml/kg per day for 24 hours</p>\n<p>~</p>\n<p>Then gradually increase as follows:</p>\n<p>- 115 ml/kg per day for next 24 hours</p>\n<p>- 130 ml/kg per day for the following 48 hours</p>\n<p>~</p>\n<p>Then, increase each feed by 10 ml as described earlier</p>"
    },
    {
        "page_number": 977,
        "content": "911\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nRecommended amounts for RUTF\nChild\u2019s Weight \n(Kg)\nTransition \nPhase\nRehabilitation Phase\nPackets Per \nDay (92 G,\n500 Kcal)\nPackets Per \nDay (92 G,\n500 Kcal)\nPackets \nPer Week \nSupply\n4-4.9\n1.5\n2\n14\n5-6.9\n2.1\n2.5\n18\n7-8.4\n2.5\n3\n21\n8.5-9.4\n2.8\n3.5\n25\n9.5-10.4\n3.1\n4\n28\n10.5-11.9\n3.6\n4.5\n32\n>12kg\n4.0\n5\n35\nPatient instructions on how to give RUTF\n \n~\nWash hands before giving the RUTF\n \n~\nSit with child on the lap and gently offer RUTF\n \n~\nEncourage child to eat RUTF without force-feeding\n \n~\nGive small, regular meals of RUTF and encourage child to \neat 5-6 meals a day\n \n~\nIf still breastfeeding, continue offering breast milk first be\u00ad\nfore every RUTF feed\n \n~\nGive only the RUTF for 2 weeks, if breastfeeding continue \nto breastfeed and gradually introduce foods recommended \nfor the age (see section 17.3.12.3)\n \n~\nWhen introducing recommended foods, ensure that the \nchild completes his daily ration of RUTF before giving oth\u00ad\ner foods\n \n~\nOffer plenty of clean water, to drink from a cup, when the \nchild is eating the RUTF",
        "formatted_content": "<p>911</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Recommended amounts for RUTF</p>\n<p>Child\u2019s Weight</p>\n<p>(Kg)</p>\n<p>Transition</p>\n<p>Phase</p>\n<p>Rehabilitation Phase</p>\n<p>Packets Per</p>\n<p>Day (92 G,</p>\n<p>500 Kcal)</p>\n<p>Packets Per</p>\n<p>Day (92 G,</p>\n<p>500 Kcal)</p>\n<p>Packets</p>\n<p>Per Week</p>\n<p>Supply</p>\n<p>4-4.9</p>\n<li>.5</li>\n<p>2</p>\n<p>14</p>\n<p>5-6.9</p>\n<p>2.1</p>\n<p>2.5</p>\n<p>18</p>\n<p>7-8.4</p>\n<p>2.5</p>\n<p>3</p>\n<p>21</p>\n<p>8.5-9.4</p>\n<p>2.8</p>\n<p>3.5</p>\n<p>25</p>\n<p>9.5-10.4</p>\n<p>3.1</p>\n<p>4</p>\n<p>28</p>\n<p>10.5-11.9</p>\n<p>3.6</p>\n<p>4.5</p>\n<p>32</p>\n<p>>12kg</p>\n<p>4.0</p>\n<p>5</p>\n<p>35</p>\n<p>Patient instructions on how to give RUTF</p>\n<p>~</p>\n<p>Wash hands before giving the RUTF</p>\n<p>~</p>\n<p>Sit with child on the lap and gently offer RUTF</p>\n<p>~</p>\n<p>Encourage child to eat RUTF without force-feeding</p>\n<p>~</p>\n<p>Give small, regular meals of RUTF and encourage child to</p>\n<p>eat 5-6 meals a day</p>\n<p>~</p>\n<p>If still breastfeeding, continue offering breast milk first be\u00ad</p>\n<p>fore every RUTF feed</p>\n<p>~</p>\n<p>Give only the RUTF for 2 weeks, if breastfeeding continue</p>\n<p>to breastfeed and gradually introduce foods recommended</p>\n<p>for the age (see section 17.3.12.3)</p>\n<p>~</p>\n<p>When introducing recommended foods, ensure that the</p>\n<p>child completes his daily ration of RUTF before giving oth\u00ad</p>\n<p>er foods</p>\n<p>~</p>\n<p>Offer plenty of clean water, to drink from a cup, when the</p>\n<p>child is eating the RUTF</p>"
    },
    {
        "page_number": 978,
        "content": "912\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nCatch-up growth or rehabilitation phase\nCriteria for transfer from transition phase\n \n~\nGood appetite (child takes >80% of daily ration of RUTF)\n \n~\nSignificantly reduced oedema or no oedema\n \n~\nResolved medical complications and completed parenteral \nantibiotics\n \n~\nClinically well and alert\nAfter the transition phase\nChildren with complicated SAM can be transferred to outpatient care \nduring rehabilitation phase. The child will require continuing care as an \noutpatient to complete rehabilitation and prevent relapse.\n \n~\nCarefully assess the child and the available commuinty sup\u00ad\nport\n \n~\nRefer the child for rehabilitation in outpatient care or to a \ncommunity feeding programme if possible, otherwise keep \nthe child admitted\nTREATMENT\nIf the child cannot be managed as outpatient (e.g. no easily \naccessible nutritional rehabilitation services where the child \nlives)\n\t\n\u0089\nKeep the child admitted until full discharge from nutritional \nprogram\n\t\n\u0089\nContinue with RUTF or F-100, but increase amount as the \nchild gains weight\nIf the child can be managed as outpatient\n\t\n\u0089\nDischarge the mother with 2-week supply of RUTF according \nto the table above",
        "formatted_content": "<p>912</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Catch-up growth or rehabilitation phase</p>\n<p>Criteria for transfer from transition phase</p>\n<p>~</p>\n<p>Good appetite (child takes >80% of daily ration of RUTF)</p>\n<p>~</p>\n<p>Significantly reduced oedema or no oedema</p>\n<p>~</p>\n<p>Resolved medical complications and completed parenteral</p>\n<p>antibiotics</p>\n<p>~</p>\n<p>Clinically well and alert</p>\n<p>After the transition phase</p>\n<p>Children with complicated SAM can be transferred to outpatient care</p>\n<p>during rehabilitation phase. The child will require continuing care as an</p>\n<p>outpatient to complete rehabilitation and prevent relapse.</p>\n<p>~</p>\n<p>Carefully assess the child and the available commuinty sup\u00ad</p>\n<p>port</p>\n<p>~</p>\n<p>Refer the child for rehabilitation in outpatient care or to a</p>\n<p>community feeding programme if possible, otherwise keep</p>\n<p>the child admitted</p>\n<h3>TREATMENT</h3>\n<p>If the child cannot be managed as outpatient (e.g. no easily</p>\n<p>accessible nutritional rehabilitation services where the child</p>\n<p>lives)</p>\n<p>\u0089</p>\n<p>Keep the child admitted until full discharge from nutritional</p>\n<p>program</p>\n<p>\u0089</p>\n<p>Continue with RUTF or F-100, but increase amount as the</p>\n<p>child gains weight</p>\n<p>If the child can be managed as outpatient</p>\n<p>\u0089</p>\n<p>Discharge the mother with 2-week supply of RUTF according</p>\n<p>to the table above</p>"
    },
    {
        "page_number": 979,
        "content": "913\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\n\t\n\u0089\nCounsel caregivers on outpatient treatment and link them to \na community nutritional programme if available. Ensure that \nmother/caregiver:\n \n- Brings back the child for weekly supplements\n \n- Is available for child care\nHas received specific counselling on appropriate child feeding practices \n(types, amount, frequency) and basic hygiene\n \n- Has resources to feed child (if not, give advice on available \nsupport)\nMonitoring (by rate of weight gain)\n \n~\nWeigh child every morning before feeding, and plot the \nweight\n \n~\nCalculate and record weight gain every 3 days as g/kg per \nday\nFor example\nCurrent weight of child = 6300 g Weight 3 days ago = 6000 g\nWeight gain in grams: 6300-6000 = 300 g Average daily weight \ngain = 300 g  \u00f7  3 days = 100 g/day\nChild\u2019s average weight: (6000 + 6300)  \u00f7 2 = 6150 g\n(6.15 kg)\nDivide by child\u2019s average weight in kg: 100 g/day \u00f7 6.15 kg = \n16.3 g/kg per day\nIf the weight gain is:\n \n- Poor (<5 g/kg per day), child needs a full reassessment\n \n- Moderate (5-10 g/kg per day), check if intake targets are \nbeing met or if infection has been overlooked\n \n- Good (>10 g/kg/day): continue rehabilitation\nSensory stimulation\nProvide:\n \n~\nTendor loving care\n \n~\nA cheerful, stimulating environment",
        "formatted_content": "<p>913</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Counsel caregivers on outpatient treatment and link them to</p>\n<p>a community nutritional programme if available. Ensure that</p>\n<p>mother/caregiver:</p>\n<p>- Brings back the child for weekly supplements</p>\n<p>- Is available for child care</p>\n<p>Has received specific counselling on appropriate child feeding practices</p>\n<p>(types, amount, frequency) and basic hygiene</p>\n<p>- Has resources to feed child (if not, give advice on available</p>\n<p>support)</p>\n<p>Monitoring (by rate of weight gain)</p>\n<p>~</p>\n<p>Weigh child every morning before feeding, and plot the</p>\n<p>weight</p>\n<p>~</p>\n<p>Calculate and record weight gain every 3 days as g/kg per</p>\n<p>day</p>\n<p>For example</p>\n<p>Current weight of child = 6300 g Weight 3 days ago = 6000 g</p>\n<p>Weight gain in grams: 6300-6000 = 300 g Average daily weight</p>\n<p>gain = 300 g  \u00f7  3 days = 100 g/day</p>\n<p>Child\u2019s average weight: (6000 + 6300)  \u00f7 2 = 6150 g</p>\n<p>(6.15 kg)</p>\n<p>Divide by child\u2019s average weight in kg: 100 g/day \u00f7 6.15 kg =</p>\n<p>16.3 g/kg per day</p>\n<p>If the weight gain is:</p>\n<p>- Poor (<5 g/kg per day), child needs a full reassessment</p>\n<p>- Moderate (5-10 g/kg per day), check if intake targets are</p>\n<p>being met or if infection has been overlooked</p>\n<p>- Good (>10 g/kg/day): continue rehabilitation</p>\n<p>Sensory stimulation</p>\n<p>Provide:</p>\n<p>~</p>\n<p>Tendor loving care</p>\n<p>~</p>\n<p>A cheerful, stimulating environment</p>"
    },
    {
        "page_number": 980,
        "content": "914\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n \n~\nStructured play therapy for 15-30 minutes/day\n \n~\nPhysical activity as soon as the child is well enough\n \n~\nAs much maternal involvement as possible (e.g., comfort\u00ad\ning, feeding, bathing, playing)\n \n~\nProvide suitable toys and play activities for the child\n19.2.2.4  Treatment of Associated Conditions\nEye problems\nTREATMENT\nIf child has signs of vitamin A deficiency like corneal ulcera\u00ad\ntion\n\t\n\u0089\nGive vitamin A on day 1, repeat on days 2 and 14\nChild <6 months: 50,000 IU\nChild 6-12 months: 100,000 IU\nChild >12 months: 200,000 IU\nIf a first dose was given in the referring centre, treat on days 1 and 14 \nonly\nIf eyes show corneal clouding or ulceration, give care below \nto prevent corneal rupture and lens extrusion \n\t\n\u0089\nInstil chloramphenicol or tetracycline eye drops 4 times a day, \nfor 3-5 days\n\t\n\u0089\nInstil atropine eye drops, 1 drop 3 times a day for 3-5 days\n\t\n\u0089\nCover with saline soaked pads\n\t\n\u0089\nBandage the eyes\nSkin lesions in kwashiorkor\nUsually due to zinc deficiency. The child\u2019s skin quickly improves with \nzinc supplementation. In addition:\nTREATMENT\n\t\n\u0089\nBathe or soak affected areas for 10 minutes per day in\n\t\n\u0089\n0.01% potassium permanganate solution",
        "formatted_content": "<p>914</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>~</p>\n<p>Structured play therapy for 15-30 minutes/day</p>\n<p>~</p>\n<p>Physical activity as soon as the child is well enough</p>\n<p>~</p>\n<p>As much maternal involvement as possible (e.g., comfort\u00ad</p>\n<p>ing, feeding, bathing, playing)</p>\n<p>~</p>\n<p>Provide suitable toys and play activities for the child</p>\n<p>19.2.2.4  Treatment of Associated Conditions</p>\n<p>Eye problems</p>\n<h3>TREATMENT</h3>\n<p>If child has signs of vitamin A deficiency like corneal ulcera\u00ad</p>\n<p>tion</p>\n<p>\u0089</p>\n<p>Give vitamin A on day 1, repeat on days 2 and 14</p>\n<p>Child <6 months: 50,000 IU</p>\n<p>Child 6-12 months: 100,000 IU</p>\n<p>Child >12 months: 200,000 IU</p>\n<p>If a first dose was given in the referring centre, treat on days 1 and 14</p>\n<p>only</p>\n<p>If eyes show corneal clouding or ulceration, give care below</p>\n<p>to prevent corneal rupture and lens extrusion</p>\n<p>\u0089</p>\n<p>Instil chloramphenicol or tetracycline eye drops 4 times a day,</p>\n<p>for 3-5 days</p>\n<p>\u0089</p>\n<p>Instil atropine eye drops, 1 drop 3 times a day for 3-5 days</p>\n<p>\u0089</p>\n<p>Cover with saline soaked pads</p>\n<p>\u0089</p>\n<p>Bandage the eyes</p>\n<p>Skin lesions in kwashiorkor</p>\n<p>Usually due to zinc deficiency. The child\u2019s skin quickly improves with</p>\n<p>zinc supplementation. In addition:</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Bathe or soak affected areas for 10 minutes per day in</p>\n<p>\u0089</p>\n<p>0.01% potassium permanganate solution</p>"
    },
    {
        "page_number": 981,
        "content": "915\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\n\t\n\u0089\nApply barrier cream (zinc and castor oil ointment or petroleum \njelly) to the raw areas, and gentian violet or nystatin cream to \nskin sores\n\t\n\u0089\nAvoid using nappies so that the perinuem can stay dry\nSevere anaemia\nTREATMENT\nSevere anaemia\n\t\n\u0089\nGive blood transfusion in the first 24 hours ONLY IF:\n \n- Hb is <4 g/dL\n \n- Hb is 4-6 g/dl, and the child has respiratory distress\n\t\n\u0089\nUse smaller volumes and slower transfusion than for a well-nour\u00ad\nished child. Give:\n \n- Whole blood, 10 ml/kg over 3 hours\n \n- Furosemide, 1 mg/kg at the start of the transfusion\nIf child has signs of heart failure\n\t\n\u0089\nGive 10 mL/kg of packed cells, as whole blood may worsen \nheart failure\nNote\n \n\u0083 Children with SAM and oedema may have redistribution \nof fluid leading to apparent low Hb, which does not require \ntransfusion\nMonitoring\n \n~\nMonitor pulse and breathing rates, listen to lung fields, \nexamine adbomen for liver size, check jugular venous \npressure every 15 minutes during transfusion\n \n- If either breathing rate increases by 5 breaths/minute or \nheart rate increases by 25 beats/minute, transfuse more \nslowly\n \n- If there are basal lung crepitations or an enlarging liver,\nstop transfusion and give IV furosemide IV at 1 mg/kg",
        "formatted_content": "<p>915</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>\u0089</p>\n<p>Apply barrier cream (zinc and castor oil ointment or petroleum</p>\n<p>jelly) to the raw areas, and gentian violet or nystatin cream to</p>\n<p>skin sores</p>\n<p>\u0089</p>\n<p>Avoid using nappies so that the perinuem can stay dry</p>\n<p>Severe anaemia</p>\n<h3>TREATMENT</h3>\n<p>Severe anaemia</p>\n<p>\u0089</p>\n<p>Give blood transfusion in the first 24 hours ONLY IF:</p>\n<p>- Hb is <4 g/dL</p>\n<p>- Hb is 4-6 g/dl, and the child has respiratory distress</p>\n<p>\u0089</p>\n<p>Use smaller volumes and slower transfusion than for a well-nour\u00ad</p>\n<p>ished child. Give:</p>\n<p>- Whole blood, 10 ml/kg over 3 hours</p>\n<p>- Furosemide, 1 mg/kg at the start of the transfusion</p>\n<p>If child has signs of heart failure</p>\n<p>\u0089</p>\n<p>Give 10 mL/kg of packed cells, as whole blood may worsen</p>\n<p>heart failure</p>\n<p>Note</p>\n<p>\u0083 Children with SAM and oedema may have redistribution</p>\n<p>of fluid leading to apparent low Hb, which does not require</p>\n<p>transfusion</p>\n<p>Monitoring</p>\n<p>~</p>\n<p>Monitor pulse and breathing rates, listen to lung fields,</p>\n<p>examine adbomen for liver size, check jugular venous</p>\n<p>pressure every 15 minutes during transfusion</p>\n<p>- If either breathing rate increases by 5 breaths/minute or</p>\n<p>heart rate increases by 25 beats/minute, transfuse more</p>\n<p>slowly</p>\n<p>- If there are basal lung crepitations or an enlarging liver,</p>\n<p>stop transfusion and give IV furosemide IV at 1 mg/kg</p>"
    },
    {
        "page_number": 982,
        "content": "916\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nPersistent diarrhoea\nTREATMENT\nIf Giardiasis suspected or confirmed by stool microscopy\n\t\n\u0089\nGive metronidazole 7.5 mg/kg every 8 hours for 7 days\nIf due to lactose intolerance (very rare)\nDiagnosed if profuse watery diarrhoea only occurs after milk-based \nfeeds are begun and stops when they are withdrawn or reduced\n\t\n\u0089\nReplace feeds with yoghurt or a lactose free infant formula\n\t\n\u0089\nReintroduce milk feeds gradually in the rehabilitation phase\nOsmotic diarrhoea\nSuspect if diarrhoea worsens substantially with hyperosmolar F-75 \nand ceases when sugar and osmolality are reduced\n\t\n\u0089\nUse a cereal-based starter F-75, or if necessary, a commercially \navailable isotonic starter\n\t\n\u0089\nIntroduce catch-up F-100 or RUTF gradually\n19.2.2.5   Discharge from Nutritional Programme\nDischarge children with SAM from nutritional treatment ONLY IF:\n \n~\nWeight-for-height or length is at least \u00b3-2 z score and they \nhave no oedema for at least 2 weeks, or\n \n~\nMid-upper-arm circumference is \u00b3125 mm and they have \nno oedema for at least 2 weeks\n \n~\nThe indicator used at admission should be the same one \nused during follow-up. If only pitting oedema was used at \ndiagnosis, then either WFH/L or MUAC can be used for \nfollow-up\n\t\n\u0089\nPercentage weight gain should not be used as a criterion\nFeeding after discharge from nutritional programme Counsel the mother \non feeding and other issues as in the table below",
        "formatted_content": "<p>916</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Persistent diarrhoea</p>\n<h3>TREATMENT</h3>\n<p>If Giardiasis suspected or confirmed by stool microscopy</p>\n<p>\u0089</p>\n<p>Give metronidazole 7.5 mg/kg every 8 hours for 7 days</p>\n<p>If due to lactose intolerance (very rare)</p>\n<p>Diagnosed if profuse watery diarrhoea only occurs after milk-based</p>\n<p>feeds are begun and stops when they are withdrawn or reduced</p>\n<p>\u0089</p>\n<p>Replace feeds with yoghurt or a lactose free infant formula</p>\n<p>\u0089</p>\n<p>Reintroduce milk feeds gradually in the rehabilitation phase</p>\n<p>Osmotic diarrhoea</p>\n<p>Suspect if diarrhoea worsens substantially with hyperosmolar F-75</p>\n<p>and ceases when sugar and osmolality are reduced</p>\n<p>\u0089</p>\n<p>Use a cereal-based starter F-75, or if necessary, a commercially</p>\n<p>available isotonic starter</p>\n<p>\u0089</p>\n<p>Introduce catch-up F-100 or RUTF gradually</p>\n<p>19.2.2.5   Discharge from Nutritional Programme</p>\n<p>Discharge children with SAM from nutritional treatment ONLY IF:</p>\n<p>~</p>\n<p>Weight-for-height or length is at least \u00b3-2 z score and they</p>\n<p>have no oedema for at least 2 weeks, or</p>\n<p>~</p>\n<p>Mid-upper-arm circumference is \u00b3125 mm and they have</p>\n<p>no oedema for at least 2 weeks</p>\n<p>~</p>\n<p>The indicator used at admission should be the same one</p>\n<p>used during follow-up. If only pitting oedema was used at</p>\n<p>diagnosis, then either WFH/L or MUAC can be used for</p>\n<p>follow-up</p>\n<p>\u0089</p>\n<p>Percentage weight gain should not be used as a criterion</p>\n<p>Feeding after discharge from nutritional programme Counsel the mother</p>\n<p>on feeding and other issues as in the table below</p>"
    },
    {
        "page_number": 983,
        "content": "917\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nFeeding instructions\n \n~\nFeed child at least 5 times a day with meals that contain high \nenergy and high protein content (100 kcal and 2-3 g protein per \n100 g of food)\n \n~\nGive high energy snacks between meals (e.g., milk, banana, \nbread, biscuits)\n \n~\nAssist and encourage child to complete each meal\n \n~\nGive food separately to child so their intake can be checked\n \n~\nBreastfeed as often as the child wants\nAdditional instructions\n \n~\nHow to continue any needed medications at home\n \n~\nDanger signs to bring child back for immediate care\n \n~\nWhen and where to go for planned follow-up: at 1 week, 2 \nweeks, 1 month, 3 months, and 6 months; then twice a year \nuntil when the child is 3 years old\n \n~\nWhere and when to take child for growth monitoring and pro\u00ad\nmotion on monthly basis up to 2 years\n \n~\nWhen to return for next immunisation, vitamin A, and deworing\n \n~\nHow to continue stimulating the child at home with play acti \nities\nFollow-up\nPlanWhen child is discharged, make a follow-up plan until full recovery, \nwith the appropriate clinic (e.g., OPD, nutrition clinic or local health \nworker/clinic).\n \n~\nWeigh the child weekly after discharge\n \n~\nIf child fails to gain weight over 2 weeks, loses weight be\u00ad\ntween 2 measurements, develops loss of appetite or oede\u00ad\nma, refer child back to hospital for a full reassessment\nMonitor child periodically after discharge from the nutritional programme \nto prevent relapse: at 1 week, 2 weeks, 1 month, 3 months, and 6 \nmonths; then twice a year until when the child is 3 years old",
        "formatted_content": "<p>917</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Feeding instructions</p>\n<p>~</p>\n<p>Feed child at least 5 times a day with meals that contain high</p>\n<p>energy and high protein content (100 kcal and 2-3 g protein per</p>\n<p>100 g of food)</p>\n<p>~</p>\n<p>Give high energy snacks between meals (e.g., milk, banana,</p>\n<p>bread, biscuits)</p>\n<p>~</p>\n<p>Assist and encourage child to complete each meal</p>\n<p>~</p>\n<p>Give food separately to child so their intake can be checked</p>\n<p>~</p>\n<p>Breastfeed as often as the child wants</p>\n<p>Additional instructions</p>\n<p>~</p>\n<p>How to continue any needed medications at home</p>\n<p>~</p>\n<p>Danger signs to bring child back for immediate care</p>\n<p>~</p>\n<p>When and where to go for planned follow-up: at 1 week, 2</p>\n<p>weeks, 1 month, 3 months, and 6 months; then twice a year</p>\n<p>until when the child is 3 years old</p>\n<p>~</p>\n<p>Where and when to take child for growth monitoring and pro\u00ad</p>\n<p>motion on monthly basis up to 2 years</p>\n<p>~</p>\n<p>When to return for next immunisation, vitamin A, and deworing</p>\n<p>~</p>\n<p>How to continue stimulating the child at home with play acti</p>\n<p>ities</p>\n<p>Follow-up</p>\n<p>PlanWhen child is discharged, make a follow-up plan until full recovery,</p>\n<p>with the appropriate clinic (e.g., OPD, nutrition clinic or local health</p>\n<p>worker/clinic).</p>\n<p>~</p>\n<p>Weigh the child weekly after discharge</p>\n<p>~</p>\n<p>If child fails to gain weight over 2 weeks, loses weight be\u00ad</p>\n<p>tween 2 measurements, develops loss of appetite or oede\u00ad</p>\n<p>ma, refer child back to hospital for a full reassessment</p>\n<p>Monitor child periodically after discharge from the nutritional programme</p>\n<p>to prevent relapse: at 1 week, 2 weeks, 1 month, 3 months, and 6</p>\n<p>months; then twice a year until when the child is 3 years old</p>"
    },
    {
        "page_number": 984,
        "content": "918\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n19.2.3  SAM in Infants Less than 6 Months\nSAM in infants <6 months is rare. An organic cause or failure to thrive \nshould be considered and treated. Admit the infant with SAM if any of \nthe following are present:\n \n~\nGeneral danger signs or serious condition\n \n~\nRecent weight loss or failure to gain weight\n \n~\nIneffective breastfeeding (attachment, positioning, or suck\u00ad\nling) directly observed for 15-20 minutes\nAny pitting bilateral oedema of feet\n \n~\nAny medical problem needing more assessment\n \n~\nAny social issue needing detailed assesssment or intensive \nsupport e.g depression of caretaker\nManagement\nTREATMENT\nInitial Phase\n\t\n\u0089\nAdmit child\n\t\n\u0089\nGive parenteral antibiotics to treat possible sepsis and appropriate \ntreatment for other medical complications\n\t\n\u0089\nRe-establish effective breastfeeding by mother or give infant \nformula, safely prepared and used\n\t\n\u0089\nIn infants with SAM and oedema, give infant formula (preferably) \nor if not available, F-75 or diluted F-100 (use 1.5 litres instead \nof 1 litre)\n\t\n\u0089\nFor infants with SAM and NO oedema, give expressed breast \nmilk; if not possible, give commercial infant formula, F-75 or \ndiluted F-100 in this order of preference\n\t\n\u0089\nAssess the physical and mental health of mothers or caretakers. \nProvide relevant treatment and support",
        "formatted_content": "<p>918</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>19.2.3  SAM in Infants Less than 6 Months</p>\n<p>SAM in infants <6 months is rare. An organic cause or failure to thrive</p>\n<p>should be considered and treated. Admit the infant with SAM if any of</p>\n<p>the following are present:</p>\n<p>~</p>\n<p>General danger signs or serious condition</p>\n<p>~</p>\n<p>Recent weight loss or failure to gain weight</p>\n<p>~</p>\n<p>Ineffective breastfeeding (attachment, positioning, or suck\u00ad</p>\n<p>ling) directly observed for 15-20 minutes</p>\n<p>Any pitting bilateral oedema of feet</p>\n<p>~</p>\n<p>Any medical problem needing more assessment</p>\n<p>~</p>\n<p>Any social issue needing detailed assesssment or intensive</p>\n<p>support e.g depression of caretaker</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<p>Initial Phase</p>\n<p>\u0089</p>\n<p>Admit child</p>\n<p>\u0089</p>\n<p>Give parenteral antibiotics to treat possible sepsis and appropriate</p>\n<p>treatment for other medical complications</p>\n<p>\u0089</p>\n<p>Re-establish effective breastfeeding by mother or give infant</p>\n<p>formula, safely prepared and used</p>\n<p>\u0089</p>\n<p>In infants with SAM and oedema, give infant formula (preferably)</p>\n<p>or if not available, F-75 or diluted F-100 (use 1.5 litres instead</p>\n<p>of 1 litre)</p>\n<p>\u0089</p>\n<p>For infants with SAM and NO oedema, give expressed breast</p>\n<p>milk; if not possible, give commercial infant formula, F-75 or</p>\n<p>diluted F-100 in this order of preference</p>\n<p>\u0089</p>\n<p>Assess the physical and mental health of mothers or caretakers.</p>\n<p>Provide relevant treatment and support</p>"
    },
    {
        "page_number": 985,
        "content": "919\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nTREATMENT\nDischarge\n \n~\nInfants can be transferred to outpatient care if:\n \n- All clinical conditions, medical complications and oedema \nare resolved, or if child is clinically well and alert\n \n- Child is breastfeeding effectively or feeding well\n \n- Weight gain is satisfactory, e.g., above median WHO \ngrowth velocity standards or >5 g/kg per day for 3 \nsuccessive days\n \n~\nBefore discharge, verify immunisation status, link moth\u00ad\ners and caregivers with community follow-on support \nand ensure that child is breastfeeding well, has an ade\u00ad\nquate weight gain and has WFL \u00b3-2 Z scores\n19.2.4   Obesity and Overweight\t               ICD10 CODE: E66\nOverweight and obesity are an abnormal or excessive fat accumulation \nthat presents a risk to health. It is a risk factor for many diseases and \nis linked to many deaths. Body mass index (BMI) is a simple index of \nweight-for-height used to classify overweight and obesity in adults.\nBMI =       Weight (in kilograms)\n                  Height (in metres) squared (m2)\nInterpretation of BMI values in adults\nCLASSIFICATION\nCRITERIA\nUnderweight\nBMI <18\nHealthy body \nweight\nBMI 18 to 25\nOverweight\nBMI 25 to 30 or\nwaist circumference >88 cm (F) or\n>102 (M)",
        "formatted_content": "<p>919</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>TREATMENT</h3>\n<p>Discharge</p>\n<p>~</p>\n<p>Infants can be transferred to outpatient care if:</p>\n<p>- All clinical conditions, medical complications and oedema</p>\n<p>are resolved, or if child is clinically well and alert</p>\n<p>- Child is breastfeeding effectively or feeding well</p>\n<p>- Weight gain is satisfactory, e.g., above median WHO</p>\n<p>growth velocity standards or >5 g/kg per day for 3</p>\n<p>successive days</p>\n<p>~</p>\n<p>Before discharge, verify immunisation status, link moth\u00ad</p>\n<p>ers and caregivers with community follow-on support</p>\n<p>and ensure that child is breastfeeding well, has an ade\u00ad</p>\n<p>quate weight gain and has WFL \u00b3-2 Z scores</p>\n<p>19.2.4   Obesity and Overweight\t               ICD10 CODE: E66</p>\n<p>Overweight and obesity are an abnormal or excessive fat accumulation</p>\n<p>that presents a risk to health. It is a risk factor for many diseases and</p>\n<p>is linked to many deaths. Body mass index (BMI) is a simple index of</p>\n<p>weight-for-height used to classify overweight and obesity in adults.</p>\n<p>BMI =       Weight (in kilograms)</p>\n<p>Height (in metres) squared (m2)</p>\n<p>Interpretation of BMI values in adults</p>\n<h3>CLASSIFICATION</h3>\n<h3>CRITERIA</h3>\n<p>Underweight</p>\n<h3>BMI <18</h3>\n<p>Healthy body</p>\n<p>weight</p>\n<p>BMI 18 to 25</p>\n<p>Overweight</p>\n<p>BMI 25 to 30 or</p>\n<p>waist circumference >88 cm (F) or</p>\n<h3>>102 (M)</h3>"
    },
    {
        "page_number": 986,
        "content": "920\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nCLASSIFICATION\nCRITERIA\nObesity\nBMI >30 or\nwaist circumference >88 cm (F) or\n>102 (M)\nIn children, age needs to be considered when defining overweight and \nobesity\nCLASSIFICATION\nCRITERIA\nUnderweight\nBMI <18\nHealthy body \nweight\nBMI 18 to 25\nOverweight\nWFH >2 standard deviations above WHO \nChild Growth Standards median\nObesity\nWFH >2 standard deviations above WHO \nChild Growth Standards median\nFor WHO Child Growth Standards Charts, see 17.5\nCauses\n \n~\nHigh energy (i.e. calorie) intake: eating too much, eating \na lot of fatty food\n \n~\nLow expenditure of energy: sedentary lifestyle, no exercise \nor limited activity\n \n~\nDisease: hypothyroidism, diabetes mellitus, pituitary can\u00ad\ncer\nRaised BMI is a major risk factor for:\n \n~\nCardiovascular disease: heart disease and stroke\n \n~\nDiabetes mellitus\n \n~\nMusculoskeletal disorders: osteoarthritis\n \n~\nSome cancers: endometrial, breast, ovarian, prostate, liv\u00ad\ner, kidney, gallbladder, kidney\n \n~\nObstructive sleep apnoea\n \n~\nFatty liver, gallstones",
        "formatted_content": "<p>920</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<h3>CLASSIFICATION</h3>\n<h3>CRITERIA</h3>\n<p>Obesity</p>\n<p>BMI >30 or</p>\n<p>waist circumference >88 cm (F) or</p>\n<h3>>102 (M)</h3>\n<p>In children, age needs to be considered when defining overweight and</p>\n<p>obesity</p>\n<h3>CLASSIFICATION</h3>\n<h3>CRITERIA</h3>\n<p>Underweight</p>\n<h3>BMI <18</h3>\n<p>Healthy body</p>\n<p>weight</p>\n<p>BMI 18 to 25</p>\n<p>Overweight</p>\n<p>WFH >2 standard deviations above WHO</p>\n<p>Child Growth Standards median</p>\n<p>Obesity</p>\n<p>WFH >2 standard deviations above WHO</p>\n<p>Child Growth Standards median</p>\n<p>For WHO Child Growth Standards Charts, see 17.5</p>\n<p>Causes</p>\n<p>~</p>\n<p>High energy (i.e. calorie) intake: eating too much, eating</p>\n<p>a lot of fatty food</p>\n<p>~</p>\n<p>Low expenditure of energy: sedentary lifestyle, no exercise</p>\n<p>or limited activity</p>\n<p>~</p>\n<p>Disease: hypothyroidism, diabetes mellitus, pituitary can\u00ad</p>\n<p>cer</p>\n<p>Raised BMI is a major risk factor for:</p>\n<p>~</p>\n<p>Cardiovascular disease: heart disease and stroke</p>\n<p>~</p>\n<p>Diabetes mellitus</p>\n<p>~</p>\n<p>Musculoskeletal disorders: osteoarthritis</p>\n<p>~</p>\n<p>Some cancers: endometrial, breast, ovarian, prostate, liv\u00ad</p>\n<p>er, kidney, gallbladder, kidney</p>\n<p>~</p>\n<p>Obstructive sleep apnoea</p>\n<p>~</p>\n<p>Fatty liver, gallstones</p>"
    },
    {
        "page_number": 987,
        "content": "921\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\nClinical features\n \n\u0081\nOverweight\n \n\u0081\nDifficulty breathing\n \n\u0081\nPoor sleeping patterns\n \n\u0081\nJoint damage due to weight\n \n\u0081\nLow fertility\n \n\u0081\nPoor self-image, antisocial, depression\n \n\u0081\nIn children, also increased risk of fractures, hypertension, car\u00ad\ndiovascular disease, insulin resistance\nInvestigations\n \n\u0081\nBlood pressure\n \n\u0081\nBlood glucose\n \n\u0081\nCholesterol\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nAdvise patient to reduce carbohydrate and fat intake \nand increase fruit, fibre and vegetable intake\n\t\n\u0089\nRefer patient to a nutritionist for individualised diet \ncounselling, and to compile a diet plan\n\t\n\u0089\nAdvise patient to control appetite, participate in \nhobbies, treat any depression\n\t\n\u0089\nAdvise patient to increase physical activty and exercise \ndaily. Advise to start slowly and build up gradually\n\t\n\u0089\nWarn the patient of their high risk of diabetes, heart \ndisease, hypertension, stroke, and general poor health \nEncourage patient not to give up even when the weight \nloss process is slow\nHC2\nPrevention and health education\n \n~\nSociety and community choices: make healthier food the \nmost accessible, available, and affordable food, and regular \nphysical activity",
        "formatted_content": "<p>921</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>Clinical features</p>\n<p>\u0081</p>\n<p>Overweight</p>\n<p>\u0081</p>\n<p>Difficulty breathing</p>\n<p>\u0081</p>\n<p>Poor sleeping patterns</p>\n<p>\u0081</p>\n<p>Joint damage due to weight</p>\n<p>\u0081</p>\n<p>Low fertility</p>\n<p>\u0081</p>\n<p>Poor self-image, antisocial, depression</p>\n<p>\u0081</p>\n<p>In children, also increased risk of fractures, hypertension, car\u00ad</p>\n<p>diovascular disease, insulin resistance</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood pressure</p>\n<p>\u0081</p>\n<p>Blood glucose</p>\n<p>\u0081</p>\n<p>Cholesterol</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Advise patient to reduce carbohydrate and fat intake</p>\n<p>and increase fruit, fibre and vegetable intake</p>\n<p>\u0089</p>\n<p>Refer patient to a nutritionist for individualised diet</p>\n<p>counselling, and to compile a diet plan</p>\n<p>\u0089</p>\n<p>Advise patient to control appetite, participate in</p>\n<p>hobbies, treat any depression</p>\n<p>\u0089</p>\n<p>Advise patient to increase physical activty and exercise</p>\n<p>daily. Advise to start slowly and build up gradually</p>\n<p>\u0089</p>\n<p>Warn the patient of their high risk of diabetes, heart</p>\n<p>disease, hypertension, stroke, and general poor health</p>\n<p>Encourage patient not to give up even when the weight</p>\n<p>loss process is slow</p>\n<h3>HC2</h3>\n<p>Prevention and health education</p>\n<p>~</p>\n<p>Society and community choices: make healthier food the</p>\n<p>most accessible, available, and affordable food, and regular</p>\n<p>physical activity</p>"
    },
    {
        "page_number": 988,
        "content": "922\nUganda Clinical Guidelines 2023\nCHAPTER 19: Nutrition\n \n~\nIndividuals should:\n \n- Limit energy intake from total fats and sugars: reduce fatty \nmeat, palm cooking oil (replace with sunflower, olive, corn \noil)\n \n- Increase consumption of fruits and vegetables, as well as\n \n- legumes, whole grains and nuts\n \n- Engage in regular physical activity (60 minutes a day for \nchildren and 150 minutes spread through the week for adults)\n \n- Stop other habits that increase risk of non-communicable\n \n- diseases, e.g., tobacco smoking, alcohol abuse",
        "formatted_content": "<p>922</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 19: Nutrition</p>\n<p>~</p>\n<p>Individuals should:</p>\n<p>- Limit energy intake from total fats and sugars: reduce fatty</p>\n<p>meat, palm cooking oil (replace with sunflower, olive, corn</p>\n<p>oil)</p>\n<p>- Increase consumption of fruits and vegetables, as well as</p>\n<p>- legumes, whole grains and nuts</p>\n<p>- Engage in regular physical activity (60 minutes a day for</p>\n<p>children and 150 minutes spread through the week for adults)</p>\n<p>- Stop other habits that increase risk of non-communicable</p>\n<p>- diseases, e.g., tobacco smoking, alcohol abuse</p>"
    },
    {
        "page_number": 989,
        "content": "923\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n20.1  INFECTIONS AND INFLAMMATORY EYE CONDI\u00ad\nTIONS\n20.1.1    Notes on Use of Eye Preparations\n \n~\nEye drops: Apply 1 drop every 2 hours until the condition \nis controlled, then reduce frequency\n \n~\nEye ointment: If used alone, apply 3-4 times daily; if used \nwith drops, apply at night only\n \n~\nContinue treatment for 48 hours after healing\n20.1.2   Conjunctivitis (\u201cRed Eye\u201d)\t\nICD10 CODE: H10\nInflammation of the conjunctiva of the eye.\nCauses\n \n~\nInfection: Bacterial or viral\n \n~\nTrauma: Chemicals, foreign bodies\n \n~\nSmoke, allergy\nClinical features\n \n~\nWatery discharge (viral or chemicals)\n \n~\nPus discharge (bacteria)\n \n~\nCornea is clear and does not stain with fluorescein\n \n~\nVisual acuity is normal\n \n~\nRedness (usually both eyes but may start/be worse in one; \nusually reddest at outer edge of the eye)\n \n~\nSwelling and itching (may be present)\nEye Conditions\n20",
        "formatted_content": "<p>923</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>20.1  INFECTIONS AND INFLAMMATORY EYE CONDI\u00ad</h3>\n<h3>TIONS</h3>\n<p>20.1.1    Notes on Use of Eye Preparations</p>\n<p>~</p>\n<p>Eye drops: Apply 1 drop every 2 hours until the condition</p>\n<p>is controlled, then reduce frequency</p>\n<p>~</p>\n<p>Eye ointment: If used alone, apply 3-4 times daily; if used</p>\n<p>with drops, apply at night only</p>\n<p>~</p>\n<p>Continue treatment for 48 hours after healing</p>\n<p>20.1.2   Conjunctivitis (\u201cRed Eye\u201d)</p>\n<h3>ICD10 CODE: H10</h3>\n<p>Inflammation of the conjunctiva of the eye.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Infection: Bacterial or viral</p>\n<p>~</p>\n<p>Trauma: Chemicals, foreign bodies</p>\n<p>~</p>\n<p>Smoke, allergy</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Watery discharge (viral or chemicals)</p>\n<p>~</p>\n<p>Pus discharge (bacteria)</p>\n<p>~</p>\n<p>Cornea is clear and does not stain with fluorescein</p>\n<p>~</p>\n<p>Visual acuity is normal</p>\n<p>~</p>\n<p>Redness (usually both eyes but may start/be worse in one;</p>\n<p>usually reddest at outer edge of the eye)</p>\n<p>~</p>\n<p>Swelling and itching (may be present)</p>\n<p>Eye Conditions</p>\n<p>20</p>"
    },
    {
        "page_number": 990,
        "content": "924\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nDifferential diagnosis\n \n~\nCorneal ulcer (tends to be in one eye only, rednessis great\u00ad\nest near the cornea, pain is often great)\nInvestigations\n \n\u0081\nClinical features are diagnostic\n \n\u0081\nPus swab for culture and sensitivity\nManagement\nTREATMENT\nLOC\nInfective conjunctivitis\n\t\n\u0089\nApply chloramphenicol or gentamicin eye drops 2 \nor 3 hourly for 2 days then reduce to 1 drop every 6 \nhours for 5 days\n\t\n\u0089\nChange treatment as indicated by results of culture \nand sensitivity where possible\nNote\nNB. Gonococcal conjunctivitis should be treated aggres\u00ad\nsively and in line with management of Sexually Transmit\u00ad\nted Infections (see section 3.2.9)\nAllergic conjunctivitis\n\t\n\u0089\nCold compresses and facial hygiene\n\t\n\u0089\nBetamethasone or hydrocortisone eye drops every \n1-2 hours until inflammation is controlled then apply \n2 times daily\n\t\n\u0089\nLimit use of steroid eye drops to short durations\nHC2\nCaution\n\t\nr\nDo not use steroid preparations unless you are sure of the \ndiagnosis as they may mask infections",
        "formatted_content": "<p>924</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Corneal ulcer (tends to be in one eye only, rednessis great\u00ad</p>\n<p>est near the cornea, pain is often great)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Clinical features are diagnostic</p>\n<p>\u0081</p>\n<p>Pus swab for culture and sensitivity</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Infective conjunctivitis</p>\n<p>\u0089</p>\n<p>Apply chloramphenicol or gentamicin eye drops 2</p>\n<p>or 3 hourly for 2 days then reduce to 1 drop every 6</p>\n<p>hours for 5 days</p>\n<p>\u0089</p>\n<p>Change treatment as indicated by results of culture</p>\n<p>and sensitivity where possible</p>\n<p>Note</p>\n<p>NB. Gonococcal conjunctivitis should be treated aggres\u00ad</p>\n<p>sively and in line with management of Sexually Transmit\u00ad</p>\n<p>ted Infections (see section 3.2.9)</p>\n<p>Allergic conjunctivitis</p>\n<p>\u0089</p>\n<p>Cold compresses and facial hygiene</p>\n<p>\u0089</p>\n<p>Betamethasone or hydrocortisone eye drops every</p>\n<p>1-2 hours until inflammation is controlled then apply</p>\n<p>2 times daily</p>\n<p>\u0089</p>\n<p>Limit use of steroid eye drops to short durations</p>\n<h3>HC2</h3>\n<p>Caution</p>\n<p>r</p>\n<p>Do not use steroid preparations unless you are sure of the</p>\n<p>diagnosis as they may mask infections</p>"
    },
    {
        "page_number": 991,
        "content": "925\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nPrevention\n \n~\nPersonal hygiene; daily face washing\n \n~\nAvoid irritants and allergens\n \n~\n20.1.3     Stye (Hordeolum)\t\n    ICD10 CODE: H00\nA localized infection of the hair follicle of the eyelids\nCause\n \n~\nStaphylococcus aureus\nClinical features\n \n~\nItching in the early stages\n \n~\nSwelling, pain and tenderness\n \n~\nPus formation\n \n~\nMay burst spontaneously\nDifferential diagnosis\n \n~\nOther infections of the eyelids\n \n~\nBlepharitis\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nUsually, the stye will heal spontaneously\n\t\n\u0089\nAvoid rubbing eye as this might spread the infection\n\t\n\u0089\nApply a warm/hot compress to the eye\n\t\n\u0089\nApply tetracycline eye ointment 1% 2-4 times daily \nuntil 2 days after symptoms have disappeared\n\t\n\u0089\nRemove the eye lash when it is loose\nHC2",
        "formatted_content": "<p>925</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Personal hygiene; daily face washing</p>\n<p>~</p>\n<p>Avoid irritants and allergens</p>\n<p>~</p>\n<p>20.1.3     Stye (Hordeolum)</p>\n<h3>ICD10 CODE: H00</h3>\n<p>A localized infection of the hair follicle of the eyelids</p>\n<p>Cause</p>\n<p>~</p>\n<p>Staphylococcus aureus</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Itching in the early stages</p>\n<p>~</p>\n<p>Swelling, pain and tenderness</p>\n<p>~</p>\n<p>Pus formation</p>\n<p>~</p>\n<p>May burst spontaneously</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other infections of the eyelids</p>\n<p>~</p>\n<p>Blepharitis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Usually, the stye will heal spontaneously</p>\n<p>\u0089</p>\n<p>Avoid rubbing eye as this might spread the infection</p>\n<p>\u0089</p>\n<p>Apply a warm/hot compress to the eye</p>\n<p>\u0089</p>\n<p>Apply tetracycline eye ointment 1% 2-4 times daily</p>\n<p>until 2 days after symptoms have disappeared</p>\n<p>\u0089</p>\n<p>Remove the eye lash when it is loose</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 992,
        "content": "926\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nPrevention\n \n~\nRemove any loose eyelashes\n \n~\nGood personal hygiene\n20.1.4    Trachoma\t\n                 ICD10 CODE: A71\nA chronic infection of the outer eye caused by Chlamydia trachomatis, \ntransmitted though direct personal contact, shared towels and cloths, \nand flies that have come into contacat with the eyes or nose of an \ninfected person. It is a common cause of blindness.\nClinical features\n \n~\nEarly stages: reddening of eye, itching, follicles (grain-like \ngrowth) on conjunctiva\n \n~\nIf repeated untreated infections: scar formation on eyelids \ncausing the upper eyelid to turn inwards (entropion) and \nthe eyelashes to scratch the cornea\n \n~\nScarring of the cornea leading to blindness\nDifferential diagnosis\n \n~\nAllergic conjunctivitis (chronic)\n \n~\nOther chronic infections of the eye\nManagement\nTREATMENT\nLOC\nAntibiotics\n\t\n\u0089\nTetracycline eye ointment 1% twice daily for\n\t\n\u0089\n4-6 weeks (until the infection/inflammation has disappeared)\n\t\n\u0089\nOr erythromycin 500 mg every 6 hours for 14 days\n\t\n\u0089\nChild: 10-15 mg/kg per dose\n\t\n\u0089\nOr azithromycin 1 g stat; child 20 mg/kg stat\nIf there are any complications \n\t\n\u0089\nRefer to specialist \n\t\n\u0089\nSurgery for the entropion\nHC3\nHC4",
        "formatted_content": "<p>926</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Remove any loose eyelashes</p>\n<p>~</p>\n<p>Good personal hygiene</p>\n<p>20.1.4    Trachoma</p>\n<h3>ICD10 CODE: A71</h3>\n<p>A chronic infection of the outer eye caused by Chlamydia trachomatis,</p>\n<p>transmitted though direct personal contact, shared towels and cloths,</p>\n<p>and flies that have come into contacat with the eyes or nose of an</p>\n<p>infected person. It is a common cause of blindness.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Early stages: reddening of eye, itching, follicles (grain-like</p>\n<p>growth) on conjunctiva</p>\n<p>~</p>\n<p>If repeated untreated infections: scar formation on eyelids</p>\n<p>causing the upper eyelid to turn inwards (entropion) and</p>\n<p>the eyelashes to scratch the cornea</p>\n<p>~</p>\n<p>Scarring of the cornea leading to blindness</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Allergic conjunctivitis (chronic)</p>\n<p>~</p>\n<p>Other chronic infections of the eye</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Antibiotics</p>\n<p>\u0089</p>\n<p>Tetracycline eye ointment 1% twice daily for</p>\n<p>\u0089</p>\n<p>4-6 weeks (until the infection/inflammation has disappeared)</p>\n<p>\u0089</p>\n<p>Or erythromycin 500 mg every 6 hours for 14 days</p>\n<p>\u0089</p>\n<p>Child: 10-15 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or azithromycin 1 g stat; child 20 mg/kg stat</p>\n<p>If there are any complications</p>\n<p>\u0089</p>\n<p>Refer to specialist</p>\n<p>\u0089</p>\n<p>Surgery for the entropion</p>\n<h3>HC3</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 993,
        "content": "927\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nPrevention\n \n~\nGood personal hygiene, regular face washing\n \n~\nGood hygiene during deliveries\n \n~\nEducation of public on trachoma, and environmental con\u00ad\ntrol\n20.1.5  Keratitis\t                    ICD10 CODE: H16\nInflammation of the cornea.\nCauses\n \n~\nInfection: Bacterial, viral, or fungal; leading to corneal ul\u00ad\nceration\n \n~\nTrauma: Chemical, foreign bodies\nClinical features\n \n~\nRedness and tearing\n \n~\nFear of light\n \n~\nCornea is not clear and will stain with fluorescein in the \ncase of corneal ulcer (pattern of staining depends on the \ncausative agent, for example dendritic in viral keratitis)\n \n~\nVisual acuity is usually reduced\n \n~\nCondition is often unilateral\n \n~\nThe eye is painful\nInvestigations (where facilities are available)\n \n\u0081\nFull ocular examination\n \n\u0081\nFluorescein stain to confirm diagnosis\n \n\u0081\nPus swab for gram stain, culture and sensitivity\n \n\u0081\nCorneal scraping for microscopy, culture and sensitivity",
        "formatted_content": "<p>927</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Good personal hygiene, regular face washing</p>\n<p>~</p>\n<p>Good hygiene during deliveries</p>\n<p>~</p>\n<p>Education of public on trachoma, and environmental con\u00ad</p>\n<p>trol</p>\n<p>20.1.5  Keratitis\t                    ICD10 CODE: H16</p>\n<p>Inflammation of the cornea.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Infection: Bacterial, viral, or fungal; leading to corneal ul\u00ad</p>\n<p>ceration</p>\n<p>~</p>\n<p>Trauma: Chemical, foreign bodies</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Redness and tearing</p>\n<p>~</p>\n<p>Fear of light</p>\n<p>~</p>\n<p>Cornea is not clear and will stain with fluorescein in the</p>\n<p>case of corneal ulcer (pattern of staining depends on the</p>\n<p>causative agent, for example dendritic in viral keratitis)</p>\n<p>~</p>\n<p>Visual acuity is usually reduced</p>\n<p>~</p>\n<p>Condition is often unilateral</p>\n<p>~</p>\n<p>The eye is painful</p>\n<p>Investigations (where facilities are available)</p>\n<p>\u0081</p>\n<p>Full ocular examination</p>\n<p>\u0081</p>\n<p>Fluorescein stain to confirm diagnosis</p>\n<p>\u0081</p>\n<p>Pus swab for gram stain, culture and sensitivity</p>\n<p>\u0081</p>\n<p>Corneal scraping for microscopy, culture and sensitivity</p>"
    },
    {
        "page_number": 994,
        "content": "928\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nAdmission is mandatory for young children, one- eyed \npatients, non-improvement after 72 hours of treatment, \nlarge ulcers (>4 mm diameter), associated occular com\u00ad\nplications such as hypopion or scleritis\nTreat the specific cause\n\t\n\u0089\nIf bacterial, apply gentamicin eye drops alternately with \nchloramphenicol eye drops 1\u20132 hourly until infection \nis controlled\n\t\n\u0089\nIf viral, acyclovir eye ointment 5 times daily for herpes \nsimplex and viral keratitis\n\t\n\u0089\nIf fungal, natamycin ophthalmic suspension 5%\n\t\n\u0089\nOr econazole eye drops\n \n- Supportive treatment\n\t\n\u0089\nAtropine eye drops to relieve pain \n\t\n\u0089\nVitamin A capsules for children\n\t\n\u0089\nSurgery may be necessary in some circumstancesi.e. \nconjunctival flap and tarsorrhaphy\n\t\n\u0089\nDebridement (chemical/mechanical)\nH\nHC2 \nHC4 \nRR\nHC4\nCaution\n\t\nr\nDO NOT use topical corticosteroids in patients with infective \nkeratitis\n20.1.6   Uveitis\t                                         ICD10 CODE: H20\nInflammation of the uvea of the eye. It is classified as either anterior \n(involves iris and ciliary body) or posterior (involves choroid which is \nthe posterior part of the uvea).\nCauses\n \n~\nSystemic diseases (TB, HIV, lymphoma, autoimmune \ndiease, leprosy, toxoplasmosis)\n \n~\nCytomegalovirus (CMV)\n \n~\nPost-trauma\n \n~\nIdiopathic",
        "formatted_content": "<p>928</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Admission is mandatory for young children, one- eyed</p>\n<p>patients, non-improvement after 72 hours of treatment,</p>\n<p>large ulcers (>4 mm diameter), associated occular com\u00ad</p>\n<p>plications such as hypopion or scleritis</p>\n<p>Treat the specific cause</p>\n<p>\u0089</p>\n<p>If bacterial, apply gentamicin eye drops alternately with</p>\n<p>chloramphenicol eye drops 1\u20132 hourly until infection</p>\n<p>is controlled</p>\n<p>\u0089</p>\n<p>If viral, acyclovir eye ointment 5 times daily for herpes</p>\n<p>simplex and viral keratitis</p>\n<p>\u0089</p>\n<p>If fungal, natamycin ophthalmic suspension 5%</p>\n<p>\u0089</p>\n<p>Or econazole eye drops</p>\n<p>- Supportive treatment</p>\n<p>\u0089</p>\n<p>Atropine eye drops to relieve pain</p>\n<p>\u0089</p>\n<p>Vitamin A capsules for children</p>\n<p>\u0089</p>\n<p>Surgery may be necessary in some circumstancesi.e.</p>\n<p>conjunctival flap and tarsorrhaphy</p>\n<p>\u0089</p>\n<p>Debridement (chemical/mechanical)</p>\n<p>H</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>RR</p>\n<h3>HC4</h3>\n<p>Caution</p>\n<p>r</p>\n<p>DO NOT use topical corticosteroids in patients with infective</p>\n<p>keratitis</p>\n<p>20.1.6   Uveitis\t                                         ICD10 CODE: H20</p>\n<p>Inflammation of the uvea of the eye. It is classified as either anterior</p>\n<p>(involves iris and ciliary body) or posterior (involves choroid which is</p>\n<p>the posterior part of the uvea).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Systemic diseases (TB, HIV, lymphoma, autoimmune</p>\n<p>diease, leprosy, toxoplasmosis)</p>\n<p>~</p>\n<p>Cytomegalovirus (CMV)</p>\n<p>~</p>\n<p>Post-trauma</p>\n<p>~</p>\n<p>Idiopathic</p>"
    },
    {
        "page_number": 995,
        "content": "929\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nClinical features\n \n~\nAnterior uveitis: Involves the iris and ciliary body, pain, \nphotophobia, ciliary infection, poor vision, small and ir\u00ad\nregular pupil, cells and flare in the anterior chamber, and \nkeratic precipitates\n \n~\nPosterior uveitis: Involves choroid, poor vision, cells in the \nvitreous\nInvestigations\n \n\u0081\nInvestigation of uveitis is broad and requires a high index of \nsuspicion\n \n\u0081\nDiagnosis of uveitis requires expertise and can only be confirmed \nby slit lamp examinations\nManagement\nTREATMENT\nLOC\nIf at HC2 and HC3\n\t\n\u0089\nDo not give any medicine\n\t\n\u0089\nExplain seriousness of the condition to the patient\n\t\n\u0089\nRefer urgently to a qualified eye health worker\nAnterior uveitis\n\t\n\u0089\nTopical steroids eye drops\n\t\n\u0089\nPeriocular steroids may be used in severe anterior uveitis\n\t\n\u0089\nAtropine eye drops to relieve pain\n\t\n\u0089\nRefer bilateral cases, and where there is poor vision \nand associated ocular complications\nHC2\nHC4\nRR\nPosterior uveitis\n\t\n\u0089\nTreat the primary condition if any\n\t\n\u0089\nTopical, periocular and systemic steroids\n\t\n\u0089\nAtropine/Cyclopegics to relieve pain in anterior uveitis\nPrevention\n \n~\nWear protective goggles when hammering, sawing, chop\u00ad\nping, grinding etc.",
        "formatted_content": "<p>929</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Anterior uveitis: Involves the iris and ciliary body, pain,</p>\n<p>photophobia, ciliary infection, poor vision, small and ir\u00ad</p>\n<p>regular pupil, cells and flare in the anterior chamber, and</p>\n<p>keratic precipitates</p>\n<p>~</p>\n<p>Posterior uveitis: Involves choroid, poor vision, cells in the</p>\n<p>vitreous</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Investigation of uveitis is broad and requires a high index of</p>\n<p>suspicion</p>\n<p>\u0081</p>\n<p>Diagnosis of uveitis requires expertise and can only be confirmed</p>\n<p>by slit lamp examinations</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If at HC2 and HC3</p>\n<p>\u0089</p>\n<p>Do not give any medicine</p>\n<p>\u0089</p>\n<p>Explain seriousness of the condition to the patient</p>\n<p>\u0089</p>\n<p>Refer urgently to a qualified eye health worker</p>\n<p>Anterior uveitis</p>\n<p>\u0089</p>\n<p>Topical steroids eye drops</p>\n<p>\u0089</p>\n<p>Periocular steroids may be used in severe anterior uveitis</p>\n<p>\u0089</p>\n<p>Atropine eye drops to relieve pain</p>\n<p>\u0089</p>\n<p>Refer bilateral cases, and where there is poor vision</p>\n<p>and associated ocular complications</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>RR</p>\n<p>Posterior uveitis</p>\n<p>\u0089</p>\n<p>Treat the primary condition if any</p>\n<p>\u0089</p>\n<p>Topical, periocular and systemic steroids</p>\n<p>\u0089</p>\n<p>Atropine/Cyclopegics to relieve pain in anterior uveitis</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Wear protective goggles when hammering, sawing, chop\u00ad</p>\n<p>ping, grinding etc.</p>"
    },
    {
        "page_number": 996,
        "content": "930\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n \n~\nWarn children playing with sticks about risk of eye injuries\n20.1.7   Orbital Cellulitis\t        ICD10 CODE: H05.01\nOrbital cellulitis is a sudden acute inflammation of the tissues around \nthe eye.\nCauses\n \n~\nChildren- most common cause is post sinus infection by\n \n~\nHaemophilus influenza\n \n~\nAdults- common causes are Staphylococcus aureus, Strep\u00ad\ntococcus pneumonia and beta-haemolytic streptococcus\n \n~\nRisk factors\n \n~\nSinus infection, tooth extraction, orbital trauma\nClinical features\n \n~\nPainful swelling of the eye\n \n~\nPain in the eye especially on eye movements\n \n~\nDecreased vision\n \n~\nFever and headache\nDifferential diagnosis\n \n~\nInfection - Cavernous sinus thrombosis\n \n~\nEndocrine dysfunction - Dysthyroid exophthalmos\n \n~\nIdiopathic inflammation - Orbital myositis, orbital pseudo\u00ad\ntumour, Wegener\u2019s granulomatosis\n \n~\nNeoplasm with inflammation, e.g. Burkitt\u2019s lymphoma\nInvestigations\n \n\u0081\nGood history taking and examination\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nThis is an emergency and needs immediate referral to \nthe ophthalmologist\nH",
        "formatted_content": "<p>930</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>~</p>\n<p>Warn children playing with sticks about risk of eye injuries</p>\n<p>20.1.7   Orbital Cellulitis\t        ICD10 CODE: H05.01</p>\n<p>Orbital cellulitis is a sudden acute inflammation of the tissues around</p>\n<p>the eye.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Children- most common cause is post sinus infection by</p>\n<p>~</p>\n<p>Haemophilus influenza</p>\n<p>~</p>\n<p>Adults- common causes are Staphylococcus aureus, Strep\u00ad</p>\n<p>tococcus pneumonia and beta-haemolytic streptococcus</p>\n<p>~</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Sinus infection, tooth extraction, orbital trauma</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Painful swelling of the eye</p>\n<p>~</p>\n<p>Pain in the eye especially on eye movements</p>\n<p>~</p>\n<p>Decreased vision</p>\n<p>~</p>\n<p>Fever and headache</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Infection - Cavernous sinus thrombosis</p>\n<p>~</p>\n<p>Endocrine dysfunction - Dysthyroid exophthalmos</p>\n<p>~</p>\n<p>Idiopathic inflammation - Orbital myositis, orbital pseudo\u00ad</p>\n<p>tumour, Wegener\u2019s granulomatosis</p>\n<p>~</p>\n<p>Neoplasm with inflammation, e.g. Burkitt\u2019s lymphoma</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Good history taking and examination</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>This is an emergency and needs immediate referral to</p>\n<p>the ophthalmologist</p>\n<p>H</p>"
    },
    {
        "page_number": 997,
        "content": "931\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nPrevention\n \n~\nPrompt treatment of sinus and dental infections\n \n~\nComplete immunization schedule for children, more es\u00ad\npecially Hib vaccine (included in the pentavalent DPT/ \nHepB/Hib vaccine)\n20.1.8    Postoperative Endophthalmitis           ICD10 CODE: H44.0\nPostoperative endophthalmitis is the severe inflammation involving \nboth the anterior and posterior segments of the eye after intraocular \nsurgery.\nCause\n \n~\nPerioperative introduction of microbial organisms into the \neye, followed by inflammation\nClinical features\n \n~\nDecreased vision, and permanent loss of vision\n \n~\nBacterial endophthalmitis: pain, redness, lid swelling, and \ndecreased visual acuity\n \n~\nFungal endophthalmitis: blurred vision, pain, and de\u00ad\ncreased visual acuity\nInvestigations\n \n\u0081\nVitreal tapping for gram stain\n \n\u0081\nCulture and sensitivity\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIt is a medical emergency and treatment should be \ninstituted within an hour of presentation, especially \nin severe cases\n\t\n\u0089\nRefer to an ophthalmologist immediately\n\t\n\u0089\nAdmit patients with severe endophthalmitis and treat \naggressively with topical, periocular and where possible \nintravitreal injections of:\nH \nRR",
        "formatted_content": "<p>931</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Prompt treatment of sinus and dental infections</p>\n<p>~</p>\n<p>Complete immunization schedule for children, more es\u00ad</p>\n<p>pecially Hib vaccine (included in the pentavalent DPT/</p>\n<p>HepB/Hib vaccine)</p>\n<p>20.1.8    Postoperative Endophthalmitis           ICD10 CODE: H44.0</p>\n<p>Postoperative endophthalmitis is the severe inflammation involving</p>\n<p>both the anterior and posterior segments of the eye after intraocular</p>\n<p>surgery.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Perioperative introduction of microbial organisms into the</p>\n<p>eye, followed by inflammation</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Decreased vision, and permanent loss of vision</p>\n<p>~</p>\n<p>Bacterial endophthalmitis: pain, redness, lid swelling, and</p>\n<p>decreased visual acuity</p>\n<p>~</p>\n<p>Fungal endophthalmitis: blurred vision, pain, and de\u00ad</p>\n<p>creased visual acuity</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Vitreal tapping for gram stain</p>\n<p>\u0081</p>\n<p>Culture and sensitivity</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>It is a medical emergency and treatment should be</p>\n<p>instituted within an hour of presentation, especially</p>\n<p>in severe cases</p>\n<p>\u0089</p>\n<p>Refer to an ophthalmologist immediately</p>\n<p>\u0089</p>\n<p>Admit patients with severe endophthalmitis and treat</p>\n<p>aggressively with topical, periocular and where possible</p>\n<p>intravitreal injections of:</p>\n<p>H</p>\n<p>RR</p>"
    },
    {
        "page_number": 998,
        "content": "932\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nTREATMENT\nLOC\n\t\n\u0089\nAntibiotics: vancomycin or ceftriaxone\n \n- Atropine to relieve pain\nH \nRR\nPrevention\n \n~\nApply povidone iodine 5% in the conjunctival sac for a \nminimum of 3 minutes prior to surgery and 10% povidone \niodine painting of the periocular skin\n20.1.9    Xerophthalmia\t         ICD10 CODE: E50\nDryness of the part of the eye ball exposed to air and light Cause\n \n~\nVitamin A deficiency\nClinical features\n \n~\nStarts with night blindness\n \n~\nFollowed by dryness of the conjunctiva and cornea\n \n~\nEventually the cornea melts away, the eye perforates, and \ntotal blindness occurs\nDifferential diagnosis\n \n~\nTrachoma, corneal injury\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nGive vitamin A on day 1, repeat on days 2 and 14\nAdult and child >1 year: 200,000 IU\nChild 6-12 months: 100,000 IU\nChild <6 months: 50,000 IU\nIf eyes show corneal clouding or ulceration, give care below \nto prevent corneal rupture and lens extrusion\n\t\n\u0089\nInstil chloramphenicol or tetracycline eye drops 4 times \na day, for 3-5 days\n\t\n\u0089\nInstil atropine eye drops, one drop 3 times a day for \n3-5 days\nHC2\nHC4",
        "formatted_content": "<p>932</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Antibiotics: vancomycin or ceftriaxone</p>\n<p>- Atropine to relieve pain</p>\n<p>H</p>\n<p>RR</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Apply povidone iodine 5% in the conjunctival sac for a</p>\n<p>minimum of 3 minutes prior to surgery and 10% povidone</p>\n<p>iodine painting of the periocular skin</p>\n<p>20.1.9    Xerophthalmia\t         ICD10 CODE: E50</p>\n<p>Dryness of the part of the eye ball exposed to air and light Cause</p>\n<p>~</p>\n<p>Vitamin A deficiency</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Starts with night blindness</p>\n<p>~</p>\n<p>Followed by dryness of the conjunctiva and cornea</p>\n<p>~</p>\n<p>Eventually the cornea melts away, the eye perforates, and</p>\n<p>total blindness occurs</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Trachoma, corneal injury</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give vitamin A on day 1, repeat on days 2 and 14</p>\n<p>Adult and child >1 year: 200,000 IU</p>\n<p>Child 6-12 months: 100,000 IU</p>\n<p>Child <6 months: 50,000 IU</p>\n<p>If eyes show corneal clouding or ulceration, give care below</p>\n<p>to prevent corneal rupture and lens extrusion</p>\n<p>\u0089</p>\n<p>Instil chloramphenicol or tetracycline eye drops 4 times</p>\n<p>a day, for 3-5 days</p>\n<p>\u0089</p>\n<p>Instil atropine eye drops, one drop 3 times a day for</p>\n<p>3-5 days</p>\n<h3>HC2</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 999,
        "content": "933\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nPrevention\n \n~\nGood balanced diet especially for children, women, and \ninstitutionalised persons, e.g., prisoners, long-term hospi\u00ad\ntal in-patients, boarding school students, etc.\n \n~\nRoutine Vitamin A supplementation\n\t\n\u0089\nChild <5 years with measles or malnutrition: 100,000 IU\n\t\n\u0089\nAll mothers after delivery: 200,000 IU\n\t\n\u0089\nA child above one year: 200,000 IU every 6 months\n20.2  DECREASED OR REDUCED VISION CONDITIONS\n20.2.1     Cataract          ICD10 CODE: H27\nOpacity of the lens inside the eye. It is the most common cause of \nblindness in Uganda.\nRisk factors\n \n~\nOld age\n \n~\nDiabetes (high blood sugar)\n \n~\nCertain drugs e.g. corticosteroids\n \n~\nEye injuries\nClinical features\n \n~\nReduced vision\n \n~\nPupil is not the normal black colour but is grey, white, \nbrown, or reddish in colour\n \n~\nCondition is not painful unless caused by trauma\n \n~\nEye is not red unless condition is caused by trauma\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer for cataract surgery\nHC4",
        "formatted_content": "<p>933</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Good balanced diet especially for children, women, and</p>\n<p>institutionalised persons, e.g., prisoners, long-term hospi\u00ad</p>\n<p>tal in-patients, boarding school students, etc.</p>\n<p>~</p>\n<p>Routine Vitamin A supplementation</p>\n<p>\u0089</p>\n<p>Child <5 years with measles or malnutrition: 100,000 IU</p>\n<p>\u0089</p>\n<p>All mothers after delivery: 200,000 IU</p>\n<p>\u0089</p>\n<p>A child above one year: 200,000 IU every 6 months</p>\n<h3>20.2  DECREASED OR REDUCED VISION CONDITIONS</h3>\n<p>20.2.1     Cataract          ICD10 CODE: H27</p>\n<p>Opacity of the lens inside the eye. It is the most common cause of</p>\n<p>blindness in Uganda.</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Old age</p>\n<p>~</p>\n<p>Diabetes (high blood sugar)</p>\n<p>~</p>\n<p>Certain drugs e.g. corticosteroids</p>\n<p>~</p>\n<p>Eye injuries</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Reduced vision</p>\n<p>~</p>\n<p>Pupil is not the normal black colour but is grey, white,</p>\n<p>brown, or reddish in colour</p>\n<p>~</p>\n<p>Condition is not painful unless caused by trauma</p>\n<p>~</p>\n<p>Eye is not red unless condition is caused by trauma</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer for cataract surgery</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1000,
        "content": "934\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n20.2.1.1    Paediatric Cataract       ICD10 CODE: H26.0\nCataract in children is unique as it may interfere with the normal \ndevelopment of vision resulting in lazy eye (amblyopia).\nCauses\n \n~\nHereditary/genetic disorders\n \n~\nIntrauterine infections (TORCHES)\n \n~\nDrugs, trauma, metabolic diseases, e.g. Diabetes\n \n~\nUnknown\nSymptoms\n \n~\nA white pupil\n \n~\nOlder children may complain of poor vision\n \n~\n\u201cDancing eyes\u201d (nystagmus), squints\nInvestigations\n \n\u0081\nIf at HC2 or HC3, reassure patient and refer to hospital\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nCondition is managed surgically under general an\u00ad\naesthesia\n\t\n\u0089\nSurgery can be done as early as one month of age\n\t\n\u0089\nPatching/occlusion therapy in case of lazy eyes \n(amblyopia)\n\t\n\u0089\nAphakic children /those less than one year who are \nnot implanted should be given aphakic glasses or \ncontact lenses\nRR\nPrevention\n \n~\nWear protective goggles when hammering, sawing, chop\u00ad\nping, grinding, etc.\n \n~\nCaution children playing with sticks about risk of eye in\u00ad\njuries",
        "formatted_content": "<p>934</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>20.2.1.1    Paediatric Cataract       ICD10 CODE: H26.0</p>\n<p>Cataract in children is unique as it may interfere with the normal</p>\n<p>development of vision resulting in lazy eye (amblyopia).</p>\n<p>Causes</p>\n<p>~</p>\n<p>Hereditary/genetic disorders</p>\n<p>~</p>\n<p>Intrauterine infections (TORCHES)</p>\n<p>~</p>\n<p>Drugs, trauma, metabolic diseases, e.g. Diabetes</p>\n<p>~</p>\n<p>Unknown</p>\n<p>Symptoms</p>\n<p>~</p>\n<p>A white pupil</p>\n<p>~</p>\n<p>Older children may complain of poor vision</p>\n<p>~</p>\n<p>\u201cDancing eyes\u201d (nystagmus), squints</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>If at HC2 or HC3, reassure patient and refer to hospital</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Condition is managed surgically under general an\u00ad</p>\n<p>aesthesia</p>\n<p>\u0089</p>\n<p>Surgery can be done as early as one month of age</p>\n<p>\u0089</p>\n<p>Patching/occlusion therapy in case of lazy eyes</p>\n<p>(amblyopia)</p>\n<p>\u0089</p>\n<p>Aphakic children /those less than one year who are</p>\n<p>not implanted should be given aphakic glasses or</p>\n<p>contact lenses</p>\n<p>RR</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Wear protective goggles when hammering, sawing, chop\u00ad</p>\n<p>ping, grinding, etc.</p>\n<p>~</p>\n<p>Caution children playing with sticks about risk of eye in\u00ad</p>\n<p>juries</p>"
    },
    {
        "page_number": 1001,
        "content": "935\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n20.2.2     Glaucoma\t\n         ICD10 CODE: H40\nGlaucoma is a group of disorders characterised by a loss of visual \nfield associated with cupping of the optic disc and optic nerve \ndamage. Although glaucoma is associated with raised intra-ocular \npressure (IOP), it can also occur when this pressure is within the \nnormal range.\nGlaucoma is classified as either open-angle or angle-closure glauco\u00ad\nma. Primary open-angle glaucoma is the most common.\nRisk factors for open-angle glaucoma\n \n~\nOlder age, black people, family history, genetics\n \n~\nVascular dys-regulation (migraine, vasospasm, abnormali\u00ad\nties in ocular blood flow), low ocular perfusion pressure, \ndiabetes \n \n~\nOcular factors: Raised intra-ocular pressure, myopia, cen\u00ad\ntral corneal thickness \u2013 thinner corneas associated with \nincreased risk\nClinical features\nOpen angle glaucoma\n \n~\nMostly asymptomatic\n \n~\nHistory of gradual loss of vision in affected eye or loss of \nvisual field\n \n~\nOften suspected after seeing cupping of optic disc on rou\u00ad\ntine fundoscopy or finding elevated intra-ocular pressure \non screening\nAngle-closure glaucoma\n \n~\nSudden onset of severe eye pain and redness, associated \nwith nausea, vomiting and headache\n \n~\nLoss of vision in the affected eye\n \n~\nColoured halos or bright rings around lights\n \n~\nHazy-looking cornea",
        "formatted_content": "<p>935</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>20.2.2     Glaucoma</p>\n<h3>ICD10 CODE: H40</h3>\n<p>Glaucoma is a group of disorders characterised by a loss of visual</p>\n<p>field associated with cupping of the optic disc and optic nerve</p>\n<p>damage. Although glaucoma is associated with raised intra-ocular</p>\n<p>pressure (IOP), it can also occur when this pressure is within the</p>\n<p>normal range.</p>\n<p>Glaucoma is classified as either open-angle or angle-closure glauco\u00ad</p>\n<p>ma. Primary open-angle glaucoma is the most common.</p>\n<p>Risk factors for open-angle glaucoma</p>\n<p>~</p>\n<p>Older age, black people, family history, genetics</p>\n<p>~</p>\n<p>Vascular dys-regulation (migraine, vasospasm, abnormali\u00ad</p>\n<p>ties in ocular blood flow), low ocular perfusion pressure,</p>\n<p>diabetes</p>\n<p>~</p>\n<p>Ocular factors: Raised intra-ocular pressure, myopia, cen\u00ad</p>\n<p>tral corneal thickness \u2013 thinner corneas associated with</p>\n<p>increased risk</p>\n<p>Clinical features</p>\n<p>Open angle glaucoma</p>\n<p>~</p>\n<p>Mostly asymptomatic</p>\n<p>~</p>\n<p>History of gradual loss of vision in affected eye or loss of</p>\n<p>visual field</p>\n<p>~</p>\n<p>Often suspected after seeing cupping of optic disc on rou\u00ad</p>\n<p>tine fundoscopy or finding elevated intra-ocular pressure</p>\n<p>on screening</p>\n<p>Angle-closure glaucoma</p>\n<p>~</p>\n<p>Sudden onset of severe eye pain and redness, associated</p>\n<p>with nausea, vomiting and headache</p>\n<p>~</p>\n<p>Loss of vision in the affected eye</p>\n<p>~</p>\n<p>Coloured halos or bright rings around lights</p>\n<p>~</p>\n<p>Hazy-looking cornea</p>"
    },
    {
        "page_number": 1002,
        "content": "936\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n \n~\nFixed, semi-dilated pupil\n \n~\nShallow anterior chamber\n \n~\nSeverely elevated IOP. When palpated with a finger, the \naffected eye feels hard, compared to the other eye\n \n~\nIf IOP rises more slowly, the patient may be asymptomatic \nwith gradual loss of vision\nManagement\n \n~\nGoal of treatment is to arrest/delay progress of the dis\u00ad\nease, not for visual improvement. Therapy is usually life \nlong\n \n~\nAngle-closure glaucoma is a medical emergency that re\u00ad\nquires urgent reduction of intra ocular pressure\nRefer all suspects to specialist\nTREATMENT\nLOC\nOpen-angle glaucoma\n\t\n\u0089\nTimolol 0.5% eye drops given 1 drop 12 hourly\n\t\n\u0089\nAngle-closure glaucoma (acute)\n\t\n\u0089\nFor urgent reduction of IOP, give mannitol 20% by \nslow IV infusion until IOP is reduced\n\t\n\u0089\nReduce intracocular pressure with acetazolamide tablets \n500 mg single dose followed by 250 mg every 6 hours\n\t\n\u0089\nPlus timolol 0.5% drops 1 drop 12 hourly\nRR\nCaution\n \n\u0083 Avoid timolol eye drops in patients with asthma, heart \nblock and uncontrolled heart failure\n20.2.3 Diabetic Retinopathy            ICD10 CODE: E10.31, E11.31\nA disease in which small blood vessels are damaged due elevated \nblood sugar over a prolonged period of time.",
        "formatted_content": "<p>936</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>~</p>\n<p>Fixed, semi-dilated pupil</p>\n<p>~</p>\n<p>Shallow anterior chamber</p>\n<p>~</p>\n<p>Severely elevated IOP. When palpated with a finger, the</p>\n<p>affected eye feels hard, compared to the other eye</p>\n<p>~</p>\n<p>If IOP rises more slowly, the patient may be asymptomatic</p>\n<p>with gradual loss of vision</p>\n<p>Management</p>\n<p>~</p>\n<p>Goal of treatment is to arrest/delay progress of the dis\u00ad</p>\n<p>ease, not for visual improvement. Therapy is usually life</p>\n<p>long</p>\n<p>~</p>\n<p>Angle-closure glaucoma is a medical emergency that re\u00ad</p>\n<p>quires urgent reduction of intra ocular pressure</p>\n<p>Refer all suspects to specialist</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Open-angle glaucoma</p>\n<p>\u0089</p>\n<p>Timolol 0.5% eye drops given 1 drop 12 hourly</p>\n<p>\u0089</p>\n<p>Angle-closure glaucoma (acute)</p>\n<p>\u0089</p>\n<p>For urgent reduction of IOP, give mannitol 20% by</p>\n<p>slow IV infusion until IOP is reduced</p>\n<p>\u0089</p>\n<p>Reduce intracocular pressure with acetazolamide tablets</p>\n<p>500 mg single dose followed by 250 mg every 6 hours</p>\n<p>\u0089</p>\n<p>Plus timolol 0.5% drops 1 drop 12 hourly</p>\n<p>RR</p>\n<p>Caution</p>\n<p>\u0083 Avoid timolol eye drops in patients with asthma, heart</p>\n<p>block and uncontrolled heart failure</p>\n<p>20.2.3 Diabetic Retinopathy            ICD10 CODE: E10.31, E11.31</p>\n<p>A disease in which small blood vessels are damaged due elevated</p>\n<p>blood sugar over a prolonged period of time.</p>"
    },
    {
        "page_number": 1003,
        "content": "937\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nRisk factors for Diabetic Retinopathy\n \n~\nLonger duration and poor control of diabetes\n \n~\nHypertension, kidney diseases\n \n~\nPregnancy (associated with rapid disease progression)\n \n~\nHigh Body mass index (BMI), sedentary lifestyle\n \n~\nSmoking and alcohol use\nClinical features\n \n~\nPatients can present either with a sudden painless loss of \nvision or gradual and progressive loss of vision. It may also \nbe discovered on routine examination\nInvestigations\n \n\u0081\nConduct a thorough eye examination\n \n\u0081\nOther investigations: fundus photography, optical coherence \ntomography, fluorescein angiography\nManagement\nTREATMENT\nLOC\nInvolves any or a combination of:\n\t\n\u0089\nPan retinal photocoagulation (PRP)\n\t\n\u0089\nAnti-Vascular Endothelial growth factor (VEGF) eye \ninjections\n\t\n\u0089\nPosterior Vitrectomy\n\t\n\u0089\nLow vision rehabilitation\nRR\nPrevention\n \n\u008d\nControl of diabetes and other risk factors\n20.2.4     Refractive Errors\t\n            ICD10 CODE: H52\nThis is the inability of images to be focused properly on the retina. The \nmost common refractive errors are long sightedness, short sightedness, \npresbyopia and astigmatism.",
        "formatted_content": "<p>937</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Risk factors for Diabetic Retinopathy</p>\n<p>~</p>\n<p>Longer duration and poor control of diabetes</p>\n<p>~</p>\n<p>Hypertension, kidney diseases</p>\n<p>~</p>\n<p>Pregnancy (associated with rapid disease progression)</p>\n<p>~</p>\n<p>High Body mass index (BMI), sedentary lifestyle</p>\n<p>~</p>\n<p>Smoking and alcohol use</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Patients can present either with a sudden painless loss of</p>\n<p>vision or gradual and progressive loss of vision. It may also</p>\n<p>be discovered on routine examination</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Conduct a thorough eye examination</p>\n<p>\u0081</p>\n<p>Other investigations: fundus photography, optical coherence</p>\n<p>tomography, fluorescein angiography</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Involves any or a combination of:</p>\n<p>\u0089</p>\n<p>Pan retinal photocoagulation (PRP)</p>\n<p>\u0089</p>\n<p>Anti-Vascular Endothelial growth factor (VEGF) eye</p>\n<p>injections</p>\n<p>\u0089</p>\n<p>Posterior Vitrectomy</p>\n<p>\u0089</p>\n<p>Low vision rehabilitation</p>\n<p>RR</p>\n<p>Prevention</p>\n<p>\u008d</p>\n<p>Control of diabetes and other risk factors</p>\n<p>20.2.4     Refractive Errors</p>\n<h3>ICD10 CODE: H52</h3>\n<p>This is the inability of images to be focused properly on the retina. The</p>\n<p>most common refractive errors are long sightedness, short sightedness,</p>\n<p>presbyopia and astigmatism.</p>"
    },
    {
        "page_number": 1004,
        "content": "938\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nClinical features\nRefractive Error\nCauses\nClinical Features\nHyperopia, \nlong-sightedness \nor  far-sightedness,  \nalso termed  hy\u00ad\npermetropia   can \nbe physiological \n(axial or refractive) \nor pathological \n(mal-development,  \nanatomical or \ndrug-induced) in \nnature.\n \n\u008d\nAxial etiology \n(length of the \neye, small \neyes)\n \n\u008d\nRefractive \netiology (power \nof the eye)\n \n\u008d\nTrauma\n \n\u008d\nParalysis of ac\u00ad\ncommodation\n \n\u008d\nBlurred \nvision, eye \nstrain\n \n\u008d\nLazy eye\n \n\u008d\nSquint/\n \n\u008d\ncrossed eye\n \n\u008d\nHeadaches\nMyopia, \nshort-sightedness \nor near-sightedness \nIt can be simple \n(length and power), \npathological/de\u00ad\ngenerative (mal-de\u00ad\nvelopment or\nanatomical) in \nnature, induced or \npseudomyopia.\nPresbyopia\nIt is an age-related \nvisual impairment. \nIt results from the \ngradual decrease \nin accommodation \nexpected with \nage and can have \nmultiple effects on \nquality of vision \nand quality of life.\n \n\u008d\nAxial etiolo\u00ad\ngy (length of \nthe eye, big \neyeball)\n \n\u008d\nRefractive \netiology (power \nof the eye)\n \n\u008d\nOcular disease, \ne.g. keratocon\u00ad\nnus\n \n\u008d\nTrauma\n \n\u008d\nAge (35- 40 \nyears)\n \n\u008d\nHyperopia \n(accommoda\u00ad\ntive demand, \nespecially if \nuncorrected)\n \n\u008d\nOcular dis\u00ad\nease/trauma \n(removal or \ninjury to lens, \nciliary body or \nzonules)\n \n\u008d\nBlurred \ndistance \nvision\n \n\u008d\nFlashes \n& floaters \n(high myo\u00ad\npia)\n \n\u008d\nAsthenopia \n(eyestrain, \nheadaches, \netc.)\n \n\u008d\nBlurred \nnear vision\n \n\u008d\nDifficulty \nseeing at \nusual near \nworking \ndistance\n \n\u008d\nAsthenopia \n(fatigue, \neye strain, \nheadaches, \netc.)",
        "formatted_content": "<p>938</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Clinical features</p>\n<p>Refractive Error</p>\n<p>Causes</p>\n<p>Clinical Features</p>\n<p>Hyperopia,</p>\n<p>long-sightedness</p>\n<p>or  far-sightedness,</p>\n<p>also termed  hy\u00ad</p>\n<p>permetropia   can</p>\n<p>be physiological</p>\n<p>(axial or refractive)</p>\n<p>or pathological</p>\n<p>(mal-development,</p>\n<p>anatomical or</p>\n<p>drug-induced) in</p>\n<p>nature.</p>\n<p>\u008d</p>\n<p>Axial etiology</p>\n<p>(length of the</p>\n<p>eye, small</p>\n<p>eyes)</p>\n<p>\u008d</p>\n<p>Refractive</p>\n<p>etiology (power</p>\n<p>of the eye)</p>\n<p>\u008d</p>\n<p>Trauma</p>\n<p>\u008d</p>\n<p>Paralysis of ac\u00ad</p>\n<p>commodation</p>\n<p>\u008d</p>\n<p>Blurred</p>\n<p>vision, eye</p>\n<p>strain</p>\n<p>\u008d</p>\n<p>Lazy eye</p>\n<p>\u008d</p>\n<p>Squint/</p>\n<p>\u008d</p>\n<p>crossed eye</p>\n<p>\u008d</p>\n<p>Headaches</p>\n<p>Myopia,</p>\n<p>short-sightedness</p>\n<p>or near-sightedness</p>\n<p>It can be simple</p>\n<p>(length and power),</p>\n<p>pathological/de\u00ad</p>\n<p>generative (mal-de\u00ad</p>\n<p>velopment or</p>\n<p>anatomical) in</p>\n<p>nature, induced or</p>\n<p>pseudomyopia.</p>\n<p>Presbyopia</p>\n<p>It is an age-related</p>\n<p>visual impairment.</p>\n<p>It results from the</p>\n<p>gradual decrease</p>\n<p>in accommodation</p>\n<p>expected with</p>\n<p>age and can have</p>\n<p>multiple effects on</p>\n<p>quality of vision</p>\n<p>and quality of life.</p>\n<p>\u008d</p>\n<p>Axial etiolo\u00ad</p>\n<p>gy (length of</p>\n<p>the eye, big</p>\n<p>eyeball)</p>\n<p>\u008d</p>\n<p>Refractive</p>\n<p>etiology (power</p>\n<p>of the eye)</p>\n<p>\u008d</p>\n<p>Ocular disease,</p>\n<p>e.g. keratocon\u00ad</p>\n<p>nus</p>\n<p>\u008d</p>\n<p>Trauma</p>\n<p>\u008d</p>\n<p>Age (35- 40</p>\n<p>years)</p>\n<p>\u008d</p>\n<p>Hyperopia</p>\n<p>(accommoda\u00ad</p>\n<p>tive demand,</p>\n<p>especially if</p>\n<p>uncorrected)</p>\n<p>\u008d</p>\n<p>Ocular dis\u00ad</p>\n<p>ease/trauma</p>\n<p>(removal or</p>\n<p>injury to lens,</p>\n<p>ciliary body or</p>\n<p>zonules)</p>\n<p>\u008d</p>\n<p>Blurred</p>\n<p>distance</p>\n<p>vision</p>\n<p>\u008d</p>\n<p>Flashes</p>\n<p>& floaters</p>\n<p>(high myo\u00ad</p>\n<p>pia)</p>\n<p>\u008d</p>\n<p>Asthenopia</p>\n<p>(eyestrain,</p>\n<p>headaches,</p>\n<p>etc.)</p>\n<p>\u008d</p>\n<p>Blurred</p>\n<p>near vision</p>\n<p>\u008d</p>\n<p>Difficulty</p>\n<p>seeing at</p>\n<p>usual near</p>\n<p>working</p>\n<p>distance</p>\n<p>\u008d</p>\n<p>Asthenopia</p>\n<p>(fatigue,</p>\n<p>eye strain,</p>\n<p>headaches,</p>\n<p>etc.)</p>"
    },
    {
        "page_number": 1005,
        "content": "939\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nREFRACTIVE ERROR\nCAUSES\nCLINICAL FEATURES\n \n\u008d\nSystemic dis\u00ad\neases (diabetes, \netc)\n \n\u008d\nDrug side-effect\n \n\u008d\nOccupation \n(near vision \ndemands)\n \n\u008d\nDrowsi\u00ad\nness\n \n\u008d\nDiplopia \n(double \nvision\nInvestigations\n \n\u0081\nHistory (blurred vision, asthenopia, etc.)\n \n\u0081\nVisual Acuity (distance, near and pinhole)\n \n\u0081\nRefraction\n \n\u0081\nOcular motility, Binocular Vision and Accommodation\n \n\u0081\nOcular health assessment (slit lamp, fundus assessment)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nOptical correction with spectacles or contact lenses\n\t\n\u0089\nVision therapy/orthoptics (for pseudomyopia) f For presbyopia: \nmultifocal   lenses f Refractive Surgery\nHC4\n20.2.5    Low Vision   ICD10 CODE: H54\nThis is a loss of eyesight that makes everyday tasks difficult. A person \nwith low vision finds it difficult or impossible to accomplish activities \nsuch as reading, watching television, driving a car or recognizing faces.\nWhen vision cannot be improved with regular eyeglasses, medicine \nor surgery, people with low vision need rehabilitation to learn how to \nmake the most of their remaining sight and keep their independence.\n20.2.25.1    Vision Loss\t\n               ICD10 CODE: H54\nClassification patterns of vision loss include:",
        "formatted_content": "<p>939</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>REFRACTIVE ERROR</h3>\n<h3>CAUSES</h3>\n<h3>CLINICAL FEATURES</h3>\n<p>\u008d</p>\n<p>Systemic dis\u00ad</p>\n<p>eases (diabetes,</p>\n<p>etc)</p>\n<p>\u008d</p>\n<p>Drug side-effect</p>\n<p>\u008d</p>\n<p>Occupation</p>\n<p>(near vision</p>\n<p>demands)</p>\n<p>\u008d</p>\n<p>Drowsi\u00ad</p>\n<p>ness</p>\n<p>\u008d</p>\n<p>Diplopia</p>\n<p>(double</p>\n<p>vision</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>History (blurred vision, asthenopia, etc.)</p>\n<p>\u0081</p>\n<p>Visual Acuity (distance, near and pinhole)</p>\n<p>\u0081</p>\n<p>Refraction</p>\n<p>\u0081</p>\n<p>Ocular motility, Binocular Vision and Accommodation</p>\n<p>\u0081</p>\n<p>Ocular health assessment (slit lamp, fundus assessment)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Optical correction with spectacles or contact lenses</p>\n<p>\u0089</p>\n<p>Vision therapy/orthoptics (for pseudomyopia) f For presbyopia:</p>\n<p>multifocal   lenses f Refractive Surgery</p>\n<h3>HC4</h3>\n<p>20.2.5    Low Vision   ICD10 CODE: H54</p>\n<p>This is a loss of eyesight that makes everyday tasks difficult. A person</p>\n<p>with low vision finds it difficult or impossible to accomplish activities</p>\n<p>such as reading, watching television, driving a car or recognizing faces.</p>\n<p>When vision cannot be improved with regular eyeglasses, medicine</p>\n<p>or surgery, people with low vision need rehabilitation to learn how to</p>\n<p>make the most of their remaining sight and keep their independence.</p>\n<p>20.2.25.1    Vision Loss</p>\n<h3>ICD10 CODE: H54</h3>\n<p>Classification patterns of vision loss include:</p>"
    },
    {
        "page_number": 1006,
        "content": "940\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nCLASSIFICATION\nFEATURES\nCentral vision\nThis is the detailed vision we use when we look directly at \nsomething. Age-related Macular degeneration (AMD) affects \ncentral vision. Diabetic retinopathy can affect central or \nperipheral vision\nPeripheral vision\nThis is the less detailed vision we use to see everything \naround the edges. Glaucoma affects peripheral vision first. \nStrokes can affect one side of the peripheral vision\nContrast sensi\u00ad\ntivity\nThis is the ability to distinguish between objects of similar \ntones like milk in\na white cup or to distinguish facial features. All eye problems \ncan decrease contrast sensitivity\nDepth perception\nThis is the ability to judge the position of objects. New vision \nloss in one eye can affect depth perception, such as the \nheight of a step\nVisual processing\nThe lens in our eye focuses light rays onto our retina. The \nretina converts these light rays into signals that are sent \nthrough the optic nerve to our brain, where they are inter\u00ad\npreted as the images we see. A problem with any of these \nprocesses affects our vision in various ways\nCauses of vision loss\n \n\u008d\nCongenital (e.g., prenatal or postnatal trauma, genetic or \ndevelopmental abnormalities)\n \n\u008d\nHereditary (e.g., retinitis pigmentosa or Stargardt\u2019s macular \ndegeneration)\n \n\u008d\nAcquired conditions (e.g., ocular infection or disease, trauma, \nage-related changes, or systemic disease)\nClinical features\n \n\u008d\nLoss of the ability to read standard-sized print\n \n\u008d\nDifficulty performing work-related tasks or leisure activities\n \n\u008d\nInability to recognise faces or familiar people\nInvestigations\n \n\u0081\nHistory, visual Acuity\n \n\u0081\nRefraction\n \n\u0081\nOcular motility\n \n\u0081\nBinocular Vision Assessment",
        "formatted_content": "<p>940</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>CLASSIFICATION</h3>\n<h3>FEATURES</h3>\n<p>Central vision</p>\n<p>This is the detailed vision we use when we look directly at</p>\n<p>something. Age-related Macular degeneration (AMD) affects</p>\n<p>central vision. Diabetic retinopathy can affect central or</p>\n<p>peripheral vision</p>\n<p>Peripheral vision</p>\n<p>This is the less detailed vision we use to see everything</p>\n<p>around the edges. Glaucoma affects peripheral vision first.</p>\n<p>Strokes can affect one side of the peripheral vision</p>\n<p>Contrast sensi\u00ad</p>\n<p>tivity</p>\n<p>This is the ability to distinguish between objects of similar</p>\n<p>tones like milk in</p>\n<p>a white cup or to distinguish facial features. All eye problems</p>\n<p>can decrease contrast sensitivity</p>\n<p>Depth perception</p>\n<p>This is the ability to judge the position of objects. New vision</p>\n<p>loss in one eye can affect depth perception, such as the</p>\n<p>height of a step</p>\n<p>Visual processing</p>\n<p>The lens in our eye focuses light rays onto our retina. The</p>\n<p>retina converts these light rays into signals that are sent</p>\n<p>through the optic nerve to our brain, where they are inter\u00ad</p>\n<p>preted as the images we see. A problem with any of these</p>\n<p>processes affects our vision in various ways</p>\n<p>Causes of vision loss</p>\n<p>\u008d</p>\n<p>Congenital (e.g., prenatal or postnatal trauma, genetic or</p>\n<p>developmental abnormalities)</p>\n<p>\u008d</p>\n<p>Hereditary (e.g., retinitis pigmentosa or Stargardt\u2019s macular</p>\n<p>degeneration)</p>\n<p>\u008d</p>\n<p>Acquired conditions (e.g., ocular infection or disease, trauma,</p>\n<p>age-related changes, or systemic disease)</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Loss of the ability to read standard-sized print</p>\n<p>\u008d</p>\n<p>Difficulty performing work-related tasks or leisure activities</p>\n<p>\u008d</p>\n<p>Inability to recognise faces or familiar people</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>History, visual Acuity</p>\n<p>\u0081</p>\n<p>Refraction</p>\n<p>\u0081</p>\n<p>Ocular motility</p>\n<p>\u0081</p>\n<p>Binocular Vision Assessment</p>"
    },
    {
        "page_number": 1007,
        "content": "941\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n \n\u0081\nVisual Field Assessment\n \n\u0081\nOcular Health Assessment: external examination, Slit lamp \nexam, tonometry, fundoscopy with dilated pupil\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nLow vision aids\n\t\n\u0089\nMobility instruction and community-based rehabilitation\n\t\n\u0089\nCo-management with optometrist, low vision worker, \ncommunity rehabilitation worker\n\t\n\u0089\nCounselling services (psychiatric, psychological and \nsocial work)\n\t\n\u0089\nOccupational therapy\nHC4\n20.3  TRAUMA AND INJURIES TO THE EYE\nA common cause of blindness in Uganda.\n20.3.1  Foreign Body in the Eye\t      ICD10 CODE: T15 \nPresence of an external object or substance in the eye.   \nCauses\n \n\u008d\nSolids: dust, insects, metal or wood particles\n \n\u008d\nLiquids: Splashes of irritating fluids\nClinical features\n \n\u008d\nSevere pain, tears, or redness\n \n\u008d\nForeign body (FB) may be visible\nDifferential diagnosis\n \n\u008d\nOther injury or trauma\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nMake a thin \u2018finger\u2019 of moistened cotton wool, move \neyelid out of the way, and gently remove FB\nHC2 \nHC4",
        "formatted_content": "<p>941</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>\u0081</p>\n<p>Visual Field Assessment</p>\n<p>\u0081</p>\n<p>Ocular Health Assessment: external examination, Slit lamp</p>\n<p>exam, tonometry, fundoscopy with dilated pupil</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Low vision aids</p>\n<p>\u0089</p>\n<p>Mobility instruction and community-based rehabilitation</p>\n<p>\u0089</p>\n<p>Co-management with optometrist, low vision worker,</p>\n<p>community rehabilitation worker</p>\n<p>\u0089</p>\n<p>Counselling services (psychiatric, psychological and</p>\n<p>social work)</p>\n<p>\u0089</p>\n<p>Occupational therapy</p>\n<h3>HC4</h3>\n<h3>20.3  TRAUMA AND INJURIES TO THE EYE</h3>\n<p>A common cause of blindness in Uganda.</p>\n<p>20.3.1  Foreign Body in the Eye\t      ICD10 CODE: T15</p>\n<p>Presence of an external object or substance in the eye.</p>\n<p>Causes</p>\n<p>\u008d</p>\n<p>Solids: dust, insects, metal or wood particles</p>\n<p>\u008d</p>\n<p>Liquids: Splashes of irritating fluids</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Severe pain, tears, or redness</p>\n<p>\u008d</p>\n<p>Foreign body (FB) may be visible</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Other injury or trauma</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Make a thin \u2018finger\u2019 of moistened cotton wool, move</p>\n<p>eyelid out of the way, and gently remove FB</p>\n<h3>HC2</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1008,
        "content": "942\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nTREATMENT\nLOC\n\t\n\u0089\nIf this fails, refer to an Eye Specialist\nFor irritating fluids in the eye\n\t\n\u0089\nWash the eye with plenty of clean water or normal \nsaline\nIf the cornea is damaged\n\t\n\u0089\nApply tetracycline eye ointment 1%, cover the eye, \nand refer to an Eye Specialist\nHC2 \nHC4\n20.3.2   Ocular and Adnexa Injuries\nAn injury to the eye may result in vision loss. It is important to recog\u00ad\nnize serious eye injuries and give appropriate treatment or refer to a \nspecialist immediately.\nCause\n \n\u008d\nBlunt injury from a blunt object like a ball or a fist\n \n\u008d\nA perforating injury from a sharp object, like, a knife, high \nvelocity projectiles from explosives\n \n\u008d\nExposure to chemicals\n \n\u008d\nThermal injuries\n20.3.2.1    Blunt Injuries\t      ICD10 CODE: S05.1\nA blunt object striking the eye with great force may result in minor or \nsevere injury to the eye.\nDifferent structures of the eye maybe involved.\nClinical features\nANATOMINAL STRUCTURE \nINVOLVED\nCLINICAL FEATURES\nLids, cornea, and the \nconjunctiva\nEyelid swelling and subcutaneous bleed\u00ad\ning. The degree of swelling may be mild \nto severe. There may be corneal abrasions \nand conjunctival swelling and sub conjunc\u00ad\ntival haemorrhages",
        "formatted_content": "<p>942</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>If this fails, refer to an Eye Specialist</p>\n<p>For irritating fluids in the eye</p>\n<p>\u0089</p>\n<p>Wash the eye with plenty of clean water or normal</p>\n<p>saline</p>\n<p>If the cornea is damaged</p>\n<p>\u0089</p>\n<p>Apply tetracycline eye ointment 1%, cover the eye,</p>\n<p>and refer to an Eye Specialist</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>20.3.2   Ocular and Adnexa Injuries</p>\n<p>An injury to the eye may result in vision loss. It is important to recog\u00ad</p>\n<p>nize serious eye injuries and give appropriate treatment or refer to a</p>\n<p>specialist immediately.</p>\n<p>Cause</p>\n<p>\u008d</p>\n<p>Blunt injury from a blunt object like a ball or a fist</p>\n<p>\u008d</p>\n<p>A perforating injury from a sharp object, like, a knife, high</p>\n<p>velocity projectiles from explosives</p>\n<p>\u008d</p>\n<p>Exposure to chemicals</p>\n<p>\u008d</p>\n<p>Thermal injuries</p>\n<p>20.3.2.1    Blunt Injuries\t      ICD10 CODE: S05.1</p>\n<p>A blunt object striking the eye with great force may result in minor or</p>\n<p>severe injury to the eye.</p>\n<p>Different structures of the eye maybe involved.</p>\n<p>Clinical features</p>\n<h3>ANATOMINAL STRUCTURE</h3>\n<h3>INVOLVED</h3>\n<h3>CLINICAL FEATURES</h3>\n<p>Lids, cornea, and the</p>\n<p>conjunctiva</p>\n<p>Eyelid swelling and subcutaneous bleed\u00ad</p>\n<p>ing. The degree of swelling may be mild</p>\n<p>to severe. There may be corneal abrasions</p>\n<p>and conjunctival swelling and sub conjunc\u00ad</p>\n<p>tival haemorrhages</p>"
    },
    {
        "page_number": 1009,
        "content": "943\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nANATOMINAL STRUCTURE \nINVOLVED\nCLINICAL FEATURES\nAnterior chamber, \nlens, vitreous or \nretina\nDecreased visual acuity is an indication \nthat the injury involved either the anterior \nchamber, lens, vitreous, or retina.\nAll the above will result in poor vision and \nare potentially blinding conditions.\nOrbital bones\nA blunt injury may cause orbital bone \nfractures. The commonest is a fracture of \nthe ethmoid bone.\nThe patient may present with swelling of \nthe eye and proptosis if there is haemor\u00ad\nrhage in the orbit or a sunken or retracted \neyeball\ndepending on the site of the fracture.\nThe patient may also complain of double \nvision (Diplopia\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nAssess the visual acuity, and if this is normal and there \nare no signs/symptoms of orbital bone fracture give:\n \n- Gentamicin or chloramphenicol eye drops or\n \n- tetracycline eye ointment\nHC2\n \n- Pain reliever \u2013 Paracetamol\n \n- A cold compress maybe helpful in lid swelling\n\t\n\u0089\nIf the visual acuity is poor, pad the eye, give a pan \nreliever and REFER URGENTLY THE PATIENT \nTO A SPECIALIST as this is an indication of injury \nto deeper structures\nHC4\n20.3.2.2  Penetrating Eye Injuries            ICD10 CODE: S05.2-6\nPenetrating eye injuries are common in children and adults and result \nfrom injury by a sharp object.",
        "formatted_content": "<p>943</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>ANATOMINAL STRUCTURE</h3>\n<h3>INVOLVED</h3>\n<h3>CLINICAL FEATURES</h3>\n<p>Anterior chamber,</p>\n<p>lens, vitreous or</p>\n<p>retina</p>\n<p>Decreased visual acuity is an indication</p>\n<p>that the injury involved either the anterior</p>\n<p>chamber, lens, vitreous, or retina.</p>\n<p>All the above will result in poor vision and</p>\n<p>are potentially blinding conditions.</p>\n<p>Orbital bones</p>\n<p>A blunt injury may cause orbital bone</p>\n<p>fractures. The commonest is a fracture of</p>\n<p>the ethmoid bone.</p>\n<p>The patient may present with swelling of</p>\n<p>the eye and proptosis if there is haemor\u00ad</p>\n<p>rhage in the orbit or a sunken or retracted</p>\n<p>eyeball</p>\n<p>depending on the site of the fracture.</p>\n<p>The patient may also complain of double</p>\n<p>vision (Diplopia</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Assess the visual acuity, and if this is normal and there</p>\n<p>are no signs/symptoms of orbital bone fracture give:</p>\n<p>- Gentamicin or chloramphenicol eye drops or</p>\n<p>- tetracycline eye ointment</p>\n<h3>HC2</h3>\n<p>- Pain reliever \u2013 Paracetamol</p>\n<p>- A cold compress maybe helpful in lid swelling</p>\n<p>\u0089</p>\n<p>If the visual acuity is poor, pad the eye, give a pan</p>\n<p>reliever and REFER URGENTLY THE PATIENT</p>\n<p>TO A SPECIALIST as this is an indication of injury</p>\n<p>to deeper structures</p>\n<h3>HC4</h3>\n<p>20.3.2.2  Penetrating Eye Injuries            ICD10 CODE: S05.2-6</p>\n<p>Penetrating eye injuries are common in children and adults and result</p>\n<p>from injury by a sharp object.</p>"
    },
    {
        "page_number": 1010,
        "content": "944\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nManagement\nTREATMENT\nLOC\nEyelid Injuries\n\t\n\u0089\nA cut involving the lid margin needs to be repaired \nunder magnification so that the margin is well approx\u00ad\nimated, otherwise, if not well repaired, it will heal with \na coloboma effect\n \n- A cut involving the eye lids may injure the lacrimal \nsystem if located in the medial aspect of the lid\nHC4\nCorneal and Scleral Perforations\nAll perforations of the cornea or sclera are serious injuries \nand may lead to blindness.\n\t\n\u0089\nApply an eye shield to protect the eye, give a pain reliever \nand refer the patient immediately to an Ophthalmologist\n\t\n\u0089\nAt the secondary or tertiary level the treatment of \ncorneal/scleral lacerations is immediate repair with \n10/0 sutures under an operating microscope, or if the \nlaceration is extensive, an immediate evisceration of the \neye should be performed\nHC2\nRR\n20.3.2.3      Chemical Injuries to the Eye             ICD10 CODE: S05.8 \nVarious chemicals may injure the eye when they come into contact \nwith the eyes or face. The commonest are acidic or alkaline chemical \nproducts.\nAcids and Alkaline products will cause serious injuries to the lids, \ncornea, and conjunctivae.\nManagement\nTREATMENT\nLOC\nFirst Aid\n\t\n\u0089\nOn exposure to acid or chemical products, the eyes \nshould be immediately irrigated with copious amounts \nof water as a first aid treatment\nHC2",
        "formatted_content": "<p>944</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Eyelid Injuries</p>\n<p>\u0089</p>\n<p>A cut involving the lid margin needs to be repaired</p>\n<p>under magnification so that the margin is well approx\u00ad</p>\n<p>imated, otherwise, if not well repaired, it will heal with</p>\n<p>a coloboma effect</p>\n<p>- A cut involving the eye lids may injure the lacrimal</p>\n<p>system if located in the medial aspect of the lid</p>\n<h3>HC4</h3>\n<p>Corneal and Scleral Perforations</p>\n<p>All perforations of the cornea or sclera are serious injuries</p>\n<p>and may lead to blindness.</p>\n<p>\u0089</p>\n<p>Apply an eye shield to protect the eye, give a pain reliever</p>\n<p>and refer the patient immediately to an Ophthalmologist</p>\n<p>\u0089</p>\n<p>At the secondary or tertiary level the treatment of</p>\n<p>corneal/scleral lacerations is immediate repair with</p>\n<p>10/0 sutures under an operating microscope, or if the</p>\n<p>laceration is extensive, an immediate evisceration of the</p>\n<p>eye should be performed</p>\n<h3>HC2</h3>\n<p>RR</p>\n<p>20.3.2.3      Chemical Injuries to the Eye             ICD10 CODE: S05.8</p>\n<p>Various chemicals may injure the eye when they come into contact</p>\n<p>with the eyes or face. The commonest are acidic or alkaline chemical</p>\n<p>products.</p>\n<p>Acids and Alkaline products will cause serious injuries to the lids,</p>\n<p>cornea, and conjunctivae.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First Aid</p>\n<p>\u0089</p>\n<p>On exposure to acid or chemical products, the eyes</p>\n<p>should be immediately irrigated with copious amounts</p>\n<p>of water as a first aid treatment</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1011,
        "content": "945\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\nTREATMENT\nLOC\nAt health facility\n\t\n\u0089\nOn arrival at a medical centre, continue irrigation with \nnormal saline to wash out the entire chemical\n\t\n\u0089\nAfter irrigation of the eye, apply tetracycline eye oint\u00ad\nment and pad the eye, and refer to an ophthalmologist \nimmediately\n\t\n\u0089\nTear gas, which is used in crowd dispersion can cause \nthe eyes to sting and tear copiously. The individual \nshould irrigate the eyes with plenty of water\n \n- Tear gas injury is usually short lived and does not \nusually require treatment\nHC2\nHC4\n20.4  OCULAR TUMOURS\n20.4.1   Retinoblastoma\t            ICD10 CODE: C69.2\nIt is the most common primary cancer of the retina and affects young \nchildren mostly under 5 years. It is curable if detected and treated early.\nClinical features\n \n\u008d\nWhite pupil (leukocoria)\n \n\u008d\nSquint\n \n\u008d\nRedness and swelling of the eye\n \n\u008d\nGlowing in the dark or cat\u2019s eye reflex\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nOcular examination by midwives immediately after \nbirth for early diagnosis\n\t\n\u0089\nRefer urgently (within 72 hours) all children suspected \nto have retinoblastoma to an ophthalmologist\nHC3 \nRR",
        "formatted_content": "<p>945</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>At health facility</p>\n<p>\u0089</p>\n<p>On arrival at a medical centre, continue irrigation with</p>\n<p>normal saline to wash out the entire chemical</p>\n<p>\u0089</p>\n<p>After irrigation of the eye, apply tetracycline eye oint\u00ad</p>\n<p>ment and pad the eye, and refer to an ophthalmologist</p>\n<p>immediately</p>\n<p>\u0089</p>\n<p>Tear gas, which is used in crowd dispersion can cause</p>\n<p>the eyes to sting and tear copiously. The individual</p>\n<p>should irrigate the eyes with plenty of water</p>\n<p>- Tear gas injury is usually short lived and does not</p>\n<p>usually require treatment</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<h3>20.4  OCULAR TUMOURS</h3>\n<p>20.4.1   Retinoblastoma\t            ICD10 CODE: C69.2</p>\n<p>It is the most common primary cancer of the retina and affects young</p>\n<p>children mostly under 5 years. It is curable if detected and treated early.</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>White pupil (leukocoria)</p>\n<p>\u008d</p>\n<p>Squint</p>\n<p>\u008d</p>\n<p>Redness and swelling of the eye</p>\n<p>\u008d</p>\n<p>Glowing in the dark or cat\u2019s eye reflex</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Ocular examination by midwives immediately after</p>\n<p>birth for early diagnosis</p>\n<p>\u0089</p>\n<p>Refer urgently (within 72 hours) all children suspected</p>\n<p>to have retinoblastoma to an ophthalmologist</p>\n<h3>HC3</h3>\n<p>RR</p>"
    },
    {
        "page_number": 1012,
        "content": "946\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions\n20.4.2   Squamous Cell Carcinoma of Conjunctiva          \n                ICD10 CODE: C69.0\nSquamous cell carcinoma (SCC) of the conjunctiva is a cancer on the \nsurface of the eye that tends to occur in older people (average age of \ndiagnosis is 60 years), and young adults (30-40 years) with HIV/AIDS.\nClinical features\n \n\u008d\nEye irritation, discomfort or foreign body sensation\n \n\u008d\nRed eye\n \n\u008d\nGrowth/tumour on eyeball that may exhibit the following \nfeatures:\n\t\n\u0089\nLeucoplakic (white), flesh-coloured or red patch\n \n- Rounded, elevated growth with a gel-like appearance\n \n- Large dilated blood vessels leading to the tumour\n \n- In early disease, the tumour often appears in the bulbar \nconjunctiva nasally, temporally or at the limbus\nNB: Squamous cell carcinoma should be suspected in cases of \nchronic conjunctivitis that lasts longer than 3 months.\nInvestigations\n \n\u0081\nExcision (total) biopsy for histopathological examination\nDifferential diagnosis\n \n\u008d\nPterygium, solar keratosis, pinguecula\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer patient to ophalmologist and eventually to cancer \ntreatment center\nRR",
        "formatted_content": "<p>946</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>\n<p>20.4.2   Squamous Cell Carcinoma of Conjunctiva</p>\n<h3>ICD10 CODE: C69.0</h3>\n<p>Squamous cell carcinoma (SCC) of the conjunctiva is a cancer on the</p>\n<p>surface of the eye that tends to occur in older people (average age of</p>\n<p>diagnosis is 60 years), and young adults (30-40 years) with HIV/AIDS.</p>\n<p>Clinical features</p>\n<p>\u008d</p>\n<p>Eye irritation, discomfort or foreign body sensation</p>\n<p>\u008d</p>\n<p>Red eye</p>\n<p>\u008d</p>\n<p>Growth/tumour on eyeball that may exhibit the following</p>\n<p>features:</p>\n<p>\u0089</p>\n<p>Leucoplakic (white), flesh-coloured or red patch</p>\n<p>- Rounded, elevated growth with a gel-like appearance</p>\n<p>- Large dilated blood vessels leading to the tumour</p>\n<p>- In early disease, the tumour often appears in the bulbar</p>\n<p>conjunctiva nasally, temporally or at the limbus</p>\n<p>NB: Squamous cell carcinoma should be suspected in cases of</p>\n<p>chronic conjunctivitis that lasts longer than 3 months.</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Excision (total) biopsy for histopathological examination</p>\n<p>Differential diagnosis</p>\n<p>\u008d</p>\n<p>Pterygium, solar keratosis, pinguecula</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer patient to ophalmologist and eventually to cancer</p>\n<p>treatment center</p>\n<p>RR</p>"
    },
    {
        "page_number": 1013,
        "content": "947\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n21.1 EAR CONDITIONS\n21.1.1 Foreign Body in the Ear                                  ICD10 CODE: T16\nFungal infection usually confined to the mucous membranes and external \nlayers of skin. Severe forms are usually associated with immunosuppressive \nconditions, such as HIV/AIDS, diabetes, pregnancy, cancer, prolonged \nantibiotic use, and steroids.\nCauses\nCommon foreign bodies (FB) include:\n \n~\nInsects (flies, cockroaches, ants), seeds, beads, stones\n \n~\nChildren: Usually insert the FB themselves, or their peers may \ndo it\n \n~\nAdults: Usually insects, cotton buds\n \n~\nOccasionally the FB may penetrate adjacent parts and lodge in \nthe middle ear\nClinical features\n \n~\nBlockage, FB may be seen\n \n~\nNoise in the ear if it is a live FB like an insect\n \n~\nHearing loss\nIf attempts have been made to remove the FB:\n \n~\nBleeding/discharge from the ear\nEar,  Nose  & Throat Conditions\n21",
        "formatted_content": "<p>947</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>21.1 EAR CONDITIONS</h3>\n<p>21.1.1 Foreign Body in the Ear                                  ICD10 CODE: T16</p>\n<p>Fungal infection usually confined to the mucous membranes and external</p>\n<p>layers of skin. Severe forms are usually associated with immunosuppressive</p>\n<p>conditions, such as HIV/AIDS, diabetes, pregnancy, cancer, prolonged</p>\n<p>antibiotic use, and steroids.</p>\n<p>Causes</p>\n<p>Common foreign bodies (FB) include:</p>\n<p>~</p>\n<p>Insects (flies, cockroaches, ants), seeds, beads, stones</p>\n<p>~</p>\n<p>Children: Usually insert the FB themselves, or their peers may</p>\n<p>do it</p>\n<p>~</p>\n<p>Adults: Usually insects, cotton buds</p>\n<p>~</p>\n<p>Occasionally the FB may penetrate adjacent parts and lodge in</p>\n<p>the middle ear</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Blockage, FB may be seen</p>\n<p>~</p>\n<p>Noise in the ear if it is a live FB like an insect</p>\n<p>~</p>\n<p>Hearing loss</p>\n<p>If attempts have been made to remove the FB:</p>\n<p>~</p>\n<p>Bleeding/discharge from the ear</p>\n<p>Ear,  Nose  & Throat Conditions</p>\n<p>21</p>"
    },
    {
        "page_number": 1014,
        "content": "948\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nManagement\nTREATMENT\nLOC\nSmooth round FBs\n\t\n\u0089\nSyringe the ear with clean lukewarm water\n\t\n\u0089\nIf  FB cannot be removed by syringing, remove with a \nforeign body hook\n \n- General anaesthesia may be essential in children\n \n- and sensitive adults\n \n- Do NOT use forceps to try to grasp round objects, \nas this will only push them further in the ear\nHC3\nOther FBs\n\t\n\u0089\nIf there is an edge to grab, remove with Hartmann (croc\u00ad\nodile) forceps\nInsects\n\t\n\u0089\nKill these by inserting clean cooking oil or water into the \near, then syringe out with warm water \n\t\n\u0089\nCockroaches are better removed by a crocodile forcep \nsince they have hooks on their legs that make removal \nby syringing impossible\nHC3\nImpacted seeds\n\t\n\u0089\nDo NOT use syringing with water as the seed may swell \nand block the ear\n \n- Refer immediately to ENT specialist if you cannot \nremove with a hook\n\t\n\u0089\nSuction may be useful for certain FBs\n21.1.2 Wax in the Ear                                         \t          ICD10 CODE: H61.2\nAn accumulation of wax in the external ear. Wax in the ear is normal \nand usually comes out naturally from time to time. It may accumulate \nto form a wax plug and cause a problem for the patient.",
        "formatted_content": "<p>948</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Smooth round FBs</p>\n<p>\u0089</p>\n<p>Syringe the ear with clean lukewarm water</p>\n<p>\u0089</p>\n<p>If  FB cannot be removed by syringing, remove with a</p>\n<p>foreign body hook</p>\n<p>- General anaesthesia may be essential in children</p>\n<p>- and sensitive adults</p>\n<p>- Do NOT use forceps to try to grasp round objects,</p>\n<p>as this will only push them further in the ear</p>\n<h3>HC3</h3>\n<p>Other FBs</p>\n<p>\u0089</p>\n<p>If there is an edge to grab, remove with Hartmann (croc\u00ad</p>\n<p>odile) forceps</p>\n<p>Insects</p>\n<p>\u0089</p>\n<p>Kill these by inserting clean cooking oil or water into the</p>\n<p>ear, then syringe out with warm water</p>\n<p>\u0089</p>\n<p>Cockroaches are better removed by a crocodile forcep</p>\n<p>since they have hooks on their legs that make removal</p>\n<p>by syringing impossible</p>\n<h3>HC3</h3>\n<p>Impacted seeds</p>\n<p>\u0089</p>\n<p>Do NOT use syringing with water as the seed may swell</p>\n<p>and block the ear</p>\n<p>- Refer immediately to ENT specialist if you cannot</p>\n<p>remove with a hook</p>\n<p>\u0089</p>\n<p>Suction may be useful for certain FBs</p>\n<p>21.1.2 Wax in the Ear                                         \t          ICD10 CODE: H61.2</p>\n<p>An accumulation of wax in the external ear. Wax in the ear is normal</p>\n<p>and usually comes out naturally from time to time. It may accumulate</p>\n<p>to form a wax plug and cause a problem for the patient.</p>"
    },
    {
        "page_number": 1015,
        "content": "949\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nCauses\n \n~\nExcessive and/or thick wax production\n \n~\nSmall, tortuous and/or hairy ear canal\n \n~\nUse of ear pads\nClinical features\n \n~\nBlocked ears\n \n~\nBuzzing sound\n \n~\nSometimes mild pain\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nSoften the wax by inserting drops of Vegetable oil or \nGlycerine or Sodium bicarbonate into the ear 3 times \na day for a few days. After this the wax may fall out on \nits own\n\t\n\u0089\nSyringe the ear carefully with clean warm water when \nthe wax is soft\nHC2\nCaution\n\uf077\t\nAdvise the patient not to poke anything into the ear in an attempt \nto clean it, as this may damage the eardrums\n\uf077\t\nDo not syringe if (a) there is history of discharge and (b) if there \nis pain\n21.1.3 Otitis External                                                     ICD10 CODE: H60\nInfection of the external ear canal, which may be localised (furunculosis) \nor generalised (diffuse)",
        "formatted_content": "<p>949</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Causes</p>\n<p>~</p>\n<p>Excessive and/or thick wax production</p>\n<p>~</p>\n<p>Small, tortuous and/or hairy ear canal</p>\n<p>~</p>\n<p>Use of ear pads</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Blocked ears</p>\n<p>~</p>\n<p>Buzzing sound</p>\n<p>~</p>\n<p>Sometimes mild pain</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Soften the wax by inserting drops of Vegetable oil or</p>\n<p>Glycerine or Sodium bicarbonate into the ear 3 times</p>\n<p>a day for a few days. After this the wax may fall out on</p>\n<p>its own</p>\n<p>\u0089</p>\n<p>Syringe the ear carefully with clean warm water when</p>\n<p>the wax is soft</p>\n<h3>HC2</h3>\n<p>Caution</p>\n<p>\uf077</p>\n<p>Advise the patient not to poke anything into the ear in an attempt</p>\n<p>to clean it, as this may damage the eardrums</p>\n<p>\uf077</p>\n<p>Do not syringe if (a) there is history of discharge and (b) if there</p>\n<p>is pain</p>\n<p>21.1.3 Otitis External                                                     ICD10 CODE: H60</p>\n<p>Infection of the external ear canal, which may be localised (furunculosis)</p>\n<p>or generalised (diffuse)</p>"
    },
    {
        "page_number": 1016,
        "content": "950\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nCauses\nBacterial, fungal, viral infections\nClinical features\n \n~\nPain, tenderness on pulling the pinna (external ear)\n \n~\nItching (especially for fungal infections)\n \n~\nSwelling\n \n~\nPus discharge\nDifferential diagnosis\n \n~\nForeign body\n \n~\nOtitis media (especially with pus discharge)\n \n~\nTraumatic injury\nInvestigations\n \n\u0081\nGood history and physical examination are important in making \na diagnosis\n \n\u0081\nIf there is a discharge: Pus swab for microscopy, C&S\n \n- If discharge is white or black, it is fungal\n \n- If discharge is yellow, it is bacterial\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nThoroughly clean external ear canal\n\t\n\u0089\nApply antibiotic drops, e.g., Chloramphenicol ear drops \n0.5% 2 drops into the ear every 8 hours for 14 days\n\t\n\u0089\nGive analgesics e.g., Paracetamol\nHC2\nIf severe\n\t\n\u0089\nCloxacillin 250-500 mg every 6 hours for 5-7 days\n\t\n\u0089\nChild: 12.5-25 mg/kg per dose\nHC4",
        "formatted_content": "<p>950</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Causes</p>\n<p>Bacterial, fungal, viral infections</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pain, tenderness on pulling the pinna (external ear)</p>\n<p>~</p>\n<p>Itching (especially for fungal infections)</p>\n<p>~</p>\n<p>Swelling</p>\n<p>~</p>\n<p>Pus discharge</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Foreign body</p>\n<p>~</p>\n<p>Otitis media (especially with pus discharge)</p>\n<p>~</p>\n<p>Traumatic injury</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Good history and physical examination are important in making</p>\n<p>a diagnosis</p>\n<p>\u0081</p>\n<p>If there is a discharge: Pus swab for microscopy, C&S</p>\n<p>- If discharge is white or black, it is fungal</p>\n<p>- If discharge is yellow, it is bacterial</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Thoroughly clean external ear canal</p>\n<p>\u0089</p>\n<p>Apply antibiotic drops, e.g., Chloramphenicol ear drops</p>\n<p>0.5% 2 drops into the ear every 8 hours for 14 days</p>\n<p>\u0089</p>\n<p>Give analgesics e.g., Paracetamol</p>\n<h3>HC2</h3>\n<p>If severe</p>\n<p>\u0089</p>\n<p>Cloxacillin 250-500 mg every 6 hours for 5-7 days</p>\n<p>\u0089</p>\n<p>Child: 12.5-25 mg/kg per dose</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1017,
        "content": "951\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\nIf fungal infection is suspected\n\t\n\u0089\nRemove any crusting by syringing\n\t\n\u0089\nApply Clotrimazole solution once a week for 4-8 weeks\n\t\n\u0089\nOr fluconazole 200 mg once a day for 10 days\nHC3\n21.1.4 Otitis Media (Suppurative)                 \t         ICD10 CODE: H66\nAn acute or chronic infection of the middle ear occurring mostly in \nchildren <2 years\nCauses\n \n~\nBacterial infection, e.g., Streptococcus pneumoniae, Haemoph\u00ad\nilus influenzae\n \n~\nCommonly follows an acute infection of the upper respiratory \ntract\nClinical features\n \n~\nAcute onset of pain in the ear, redness of the ear drum\n \n~\nFever\n \n~\nPus discharge for <14 days\n \n~\nBulging of the eardrum\nIn chronic otitis media\n \n~\nOn and off pus discharge from one or both ears for >14 days\n \n~\nNo systemic symptoms\nDifferential diagnosis\n \n~\nForeign body in the ear\n \n~\nOtitis externa and media with effusion\n \n~\nReferred ear pain, e.g., from toothache",
        "formatted_content": "<p>951</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If fungal infection is suspected</p>\n<p>\u0089</p>\n<p>Remove any crusting by syringing</p>\n<p>\u0089</p>\n<p>Apply Clotrimazole solution once a week for 4-8 weeks</p>\n<p>\u0089</p>\n<p>Or fluconazole 200 mg once a day for 10 days</p>\n<h3>HC3</h3>\n<p>21.1.4 Otitis Media (Suppurative)                 \t         ICD10 CODE: H66</p>\n<p>An acute or chronic infection of the middle ear occurring mostly in</p>\n<p>children <2 years</p>\n<p>Causes</p>\n<p>~</p>\n<p>Bacterial infection, e.g., Streptococcus pneumoniae, Haemoph\u00ad</p>\n<p>ilus influenzae</p>\n<p>~</p>\n<p>Commonly follows an acute infection of the upper respiratory</p>\n<p>tract</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Acute onset of pain in the ear, redness of the ear drum</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Pus discharge for <14 days</p>\n<p>~</p>\n<p>Bulging of the eardrum</p>\n<p>In chronic otitis media</p>\n<p>~</p>\n<p>On and off pus discharge from one or both ears for >14 days</p>\n<p>~</p>\n<p>No systemic symptoms</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Foreign body in the ear</p>\n<p>~</p>\n<p>Otitis externa and media with effusion</p>\n<p>~</p>\n<p>Referred ear pain, e.g., from toothache</p>"
    },
    {
        "page_number": 1018,
        "content": "952\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nInvestigations\n \n\u0081\nGood history and physical examination are important in making \na diagnosis\n \n\u0081\nPus swab for microscopy, C&S\nManagement\nTREATMENT\nLOC\nAcute infection\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours for 5 days\n\t\n\u0089\nChild: 15 mg/kg per dose\n\t\n\u0089\nOr erythromycin 500 mg every 6 hours in penicillin allergy\n\t\n\u0089\nChild: 10-15 mg/kg per dose\n\t\n\u0089\nGive analgesics, e.g., Paracetamol as required\n\t\n\u0089\nReview after 5 days\nHC2\nChronic infection\n\t\n\u0089\nSystemic antibiotics are NOT recommended: they are \nnot useful and can create resistance\n\t\n\u0089\nAural irrigation 2-3 times a day\n \n- 1 spoon of hydrogen peroxide in 1/2 glass of \nclean lukewarm water\n \n- Gently irrigate ear using a syringe without needle\n \n- Avoid directing the flow towards the tympanic \nmembrane\n \n- Gently irrigate ear using a syringe without needle\n \n- Avoid directing the flow towards the tympanic \nmembrane\nHC3\n\t\n\u0089\nDry by wicking 3 times daily for several weeks, until the \near stays dry\n\t\n\u0089\nEach time after drying, apply 2-4 drops of ciprofloxacin \near drops 0.5% into the ear\nHC3",
        "formatted_content": "<p>952</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Good history and physical examination are important in making</p>\n<p>a diagnosis</p>\n<p>\u0081</p>\n<p>Pus swab for microscopy, C&S</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Acute infection</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours for 5 days</p>\n<p>\u0089</p>\n<p>Child: 15 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or erythromycin 500 mg every 6 hours in penicillin allergy</p>\n<p>\u0089</p>\n<p>Child: 10-15 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Give analgesics, e.g., Paracetamol as required</p>\n<p>\u0089</p>\n<p>Review after 5 days</p>\n<h3>HC2</h3>\n<p>Chronic infection</p>\n<p>\u0089</p>\n<p>Systemic antibiotics are NOT recommended: they are</p>\n<p>not useful and can create resistance</p>\n<p>\u0089</p>\n<p>Aural irrigation 2-3 times a day</p>\n<p>- 1 spoon of hydrogen peroxide in 1/2 glass of</p>\n<p>clean lukewarm water</p>\n<p>- Gently irrigate ear using a syringe without needle</p>\n<p>- Avoid directing the flow towards the tympanic</p>\n<p>membrane</p>\n<p>- Gently irrigate ear using a syringe without needle</p>\n<p>- Avoid directing the flow towards the tympanic</p>\n<p>membrane</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>Dry by wicking 3 times daily for several weeks, until the</p>\n<p>ear stays dry</p>\n<p>\u0089</p>\n<p>Each time after drying, apply 2-4 drops of ciprofloxacin</p>\n<p>ear drops 0.5% into the ear</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 1019,
        "content": "953\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\n\t\n\u0089\nDo NOT allow water to enter the ear\nHC3\nNote\n\uf077\t\nRefer if complications occur, e.g., meningitis, mastoid abscess \n(behind the ear), infection in adjacent areas, e.g., tonsils, nose\nPrevention\n \n~\nHealth education, e.g., advising patients on recognizing the dis\u00ad\ncharge of otitis media (believed by some to be \u201cmilk in the ear\u201d)\n \n~\nEarly diagnosis and treatment of acute otitis media and upper \nrespiratory tract infections\n \n~\nTreat infections in adjacent area, e.g., tonsillitis\n21.1.5\t\nGlue Ear (Otitis Media with Effusion)      ICD10 CODE: H65\nA non-suppurative otitis media\nCauses\n \n~\nBlockage of the Eustachian tube by: adenoids, infection in the \ntube, thick mucoid fluid and tumours of the postnasal space\n \n~\nUnresolved acute otitis media\n \n~\nViral infection of the middle ear\n \n~\nAllergy\nClinical features\n \n~\nHearing impairment (the main feature)\n\t\n\u0089\nOften fluctuant, e.g., in children: \u201cthis child hears when s/ he wants \nto and sometimes ignores you\u201d\n \n~\nPresence of non-purulent fluid in middle ear\n \n~\nBuzzing noise in ears/head\n \n~\nRetracted or bulging ear drum\n \n~\nLoss of usual colour of ear drum (dull eardrum)",
        "formatted_content": "<p>953</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Do NOT allow water to enter the ear</p>\n<h3>HC3</h3>\n<p>Note</p>\n<p>\uf077</p>\n<p>Refer if complications occur, e.g., meningitis, mastoid abscess</p>\n<p>(behind the ear), infection in adjacent areas, e.g., tonsils, nose</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Health education, e.g., advising patients on recognizing the dis\u00ad</p>\n<p>charge of otitis media (believed by some to be \u201cmilk in the ear\u201d)</p>\n<p>~</p>\n<p>Early diagnosis and treatment of acute otitis media and upper</p>\n<p>respiratory tract infections</p>\n<p>~</p>\n<p>Treat infections in adjacent area, e.g., tonsillitis</p>\n<p>21.1.5</p>\n<p>Glue Ear (Otitis Media with Effusion)      ICD10 CODE: H65</p>\n<p>A non-suppurative otitis media</p>\n<p>Causes</p>\n<p>~</p>\n<p>Blockage of the Eustachian tube by: adenoids, infection in the</p>\n<p>tube, thick mucoid fluid and tumours of the postnasal space</p>\n<p>~</p>\n<p>Unresolved acute otitis media</p>\n<p>~</p>\n<p>Viral infection of the middle ear</p>\n<p>~</p>\n<p>Allergy</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Hearing impairment (the main feature)</p>\n<p>\u0089</p>\n<p>Often fluctuant, e.g., in children: \u201cthis child hears when s/ he wants</p>\n<p>to and sometimes ignores you\u201d</p>\n<p>~</p>\n<p>Presence of non-purulent fluid in middle ear</p>\n<p>~</p>\n<p>Buzzing noise in ears/head</p>\n<p>~</p>\n<p>Retracted or bulging ear drum</p>\n<p>~</p>\n<p>Loss of usual colour of ear drum (dull eardrum)</p>"
    },
    {
        "page_number": 1020,
        "content": "954\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\n Eliminate known or predisposing causes\n\t\n\u0089\nChlorphenamine 4 mg every 12 hours for 10 days\n \n- Child 1-2 years: 1 mg every 12 hours\n \n- Child 2-5 years: 1 mg every 6 hours (max: 6 mg \ndaily)\n \n- Child 6-12 years: 2 mg every 6 hours (max: 12 \nmg daily)\n\t\n\u0089\nPlus xylometazoline nasal drops 0.1% or ephedrine 2 \ndrops every 8 hours for 2 weeks Child: Use 0.05% drops\n\t\n\u0089\nExercises: Chewing, blowing against closed nose tends \nto open the tube\nIf effusion persists >6 weeks in spite of the above:\n\t\n\u0089\nRefer to ENT specialist\nHC4\n21.1.6 Mastoiditis                          ICD10 CODE: H70.0\nInflammation of the mastoid bone behind the ear\nCauses\n \n~\nUsually a complication of suppurative otitis media\nClinical features\n \n~\nSevere pain felt over the mastoid bone\n \n~\nSwelling in post auricular area (pinna is pushed down and for\u00ad\nward)\n \n~\nCurrent or history of pus discharge from the ear\n \n~\nFever\n \n~\nMental confusion is a grave sign of intracranial spread of infec\u00ad\ntion (Refer to ENT surgeon immediately)",
        "formatted_content": "<p>954</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Eliminate known or predisposing causes</p>\n<p>\u0089</p>\n<p>Chlorphenamine 4 mg every 12 hours for 10 days</p>\n<p>- Child 1-2 years: 1 mg every 12 hours</p>\n<p>- Child 2-5 years: 1 mg every 6 hours (max: 6 mg</p>\n<p>daily)</p>\n<p>- Child 6-12 years: 2 mg every 6 hours (max: 12</p>\n<p>mg daily)</p>\n<p>\u0089</p>\n<p>Plus xylometazoline nasal drops 0.1% or ephedrine 2</p>\n<p>drops every 8 hours for 2 weeks Child: Use 0.05% drops</p>\n<p>\u0089</p>\n<p>Exercises: Chewing, blowing against closed nose tends</p>\n<p>to open the tube</p>\n<p>If effusion persists >6 weeks in spite of the above:</p>\n<p>\u0089</p>\n<p>Refer to ENT specialist</p>\n<h3>HC4</h3>\n<p>21.1.6 Mastoiditis                          ICD10 CODE: H70.0</p>\n<p>Inflammation of the mastoid bone behind the ear</p>\n<p>Causes</p>\n<p>~</p>\n<p>Usually a complication of suppurative otitis media</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Severe pain felt over the mastoid bone</p>\n<p>~</p>\n<p>Swelling in post auricular area (pinna is pushed down and for\u00ad</p>\n<p>ward)</p>\n<p>~</p>\n<p>Current or history of pus discharge from the ear</p>\n<p>~</p>\n<p>Fever</p>\n<p>~</p>\n<p>Mental confusion is a grave sign of intracranial spread of infec\u00ad</p>\n<p>tion (Refer to ENT surgeon immediately)</p>"
    },
    {
        "page_number": 1021,
        "content": "955\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nDifferential diagnosis\n \n~\nInflamed lymph node behind ear\nInvestigations\n \n\u0081\nDiagnosis mainly by clinical features\n \n\u0081\nX-ray: Useful in chronic mastoiditis\n \n\u0081\nBlood: Full blood count, shows leucocytosis\n \n\u0081\nExamine ear with otoscope\nManagement\nTREATMENT\nLOC\n\t\n\u0089\n Admit urgently; give emergency treatment\n\t\n\u0089\nCeftriaxone 2-4 g by IV or deep IM once daily for 10-\n14 days\n \n- Child: 50-80 mg/kg once daily\n \n- Divide IM doses over 1 g between 2 sites\n\t\n\u0089\nPlus metronidazole 400 mg every 8 hours for 10-14 days\n \n- Child: 7.5 mg/kg per dose\n\t\n\u0089\nSurgical drainage may be necessary to remove pus if an \nabscess has formed\n\t\n\u0089\nRefer urgently for specialist care\nHC4\n21.2 NASAL CONDITIONS\n21.2.1 Foreign Body in the Nose      ICD10 CODE: T17.0\nUsually occurs in children <5 years\nCauses\n \n~\nSeeds, e.g., bean, peas, ground nut",
        "formatted_content": "<p>955</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Inflamed lymph node behind ear</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis mainly by clinical features</p>\n<p>\u0081</p>\n<p>X-ray: Useful in chronic mastoiditis</p>\n<p>\u0081</p>\n<p>Blood: Full blood count, shows leucocytosis</p>\n<p>\u0081</p>\n<p>Examine ear with otoscope</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Admit urgently; give emergency treatment</p>\n<p>\u0089</p>\n<p>Ceftriaxone 2-4 g by IV or deep IM once daily for 10-</p>\n<p>14 days</p>\n<p>- Child: 50-80 mg/kg once daily</p>\n<p>- Divide IM doses over 1 g between 2 sites</p>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg every 8 hours for 10-14 days</p>\n<p>- Child: 7.5 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Surgical drainage may be necessary to remove pus if an</p>\n<p>abscess has formed</p>\n<p>\u0089</p>\n<p>Refer urgently for specialist care</p>\n<h3>HC4</h3>\n<h3>21.2 NASAL CONDITIONS</h3>\n<p>21.2.1 Foreign Body in the Nose      ICD10 CODE: T17.0</p>\n<p>Usually occurs in children <5 years</p>\n<p>Causes</p>\n<p>~</p>\n<p>Seeds, e.g., bean, peas, ground nut</p>"
    },
    {
        "page_number": 1022,
        "content": "956\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n \n~\nPaper, foam rubber (e.g., mattress foam)\n \n~\nBeads, stones, metal objects\nClinical features\n \n~\nUsually inserted by the child, and therefore mostly found in the \nright-hand nasal cavity\n \n~\nForeign body noticed by child/parent\n\t\n\u0089\nMay be visible or felt\n\t\n\u0089\nSharp object may cause bleeding\n \n~\nUnilateral foul-smelling discharge from the nose\nDifferential diagnosis\n \n~\nInfection in the nose, sinuses, or adenoids\nInvestigations\n \n\u0081\nUsually not required (Clinical diagnosis is enough)\n \n\u0081\nX-rays may be helpful in case of metallic objects like wires or \nball bearings\nManagement\nTREATMENT\nLOC\n\t\n\u0089\n Sit the child up or wrap in a blanket\nFirst aid\n\t\n\u0089\nBlow through the mouth while blocking the unaffected \nside of the nose\nOther methods of removal\nPaper or foam rubber\n\t\n\u0089\nGrasp firmly and remove with a fine forceps, e.g., Tilley\u2019s \nforceps\nOther objects\nHC2",
        "formatted_content": "<p>956</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>~</p>\n<p>Paper, foam rubber (e.g., mattress foam)</p>\n<p>~</p>\n<p>Beads, stones, metal objects</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Usually inserted by the child, and therefore mostly found in the</p>\n<p>right-hand nasal cavity</p>\n<p>~</p>\n<p>Foreign body noticed by child/parent</p>\n<p>\u0089</p>\n<p>May be visible or felt</p>\n<p>\u0089</p>\n<p>Sharp object may cause bleeding</p>\n<p>~</p>\n<p>Unilateral foul-smelling discharge from the nose</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Infection in the nose, sinuses, or adenoids</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Usually not required (Clinical diagnosis is enough)</p>\n<p>\u0081</p>\n<p>X-rays may be helpful in case of metallic objects like wires or</p>\n<p>ball bearings</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Sit the child up or wrap in a blanket</p>\n<p>First aid</p>\n<p>\u0089</p>\n<p>Blow through the mouth while blocking the unaffected</p>\n<p>side of the nose</p>\n<p>Other methods of removal</p>\n<p>Paper or foam rubber</p>\n<p>\u0089</p>\n<p>Grasp firmly and remove with a fine forceps, e.g., Tilley\u2019s</p>\n<p>forceps</p>\n<p>Other objects</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1023,
        "content": "957\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\n\t\n\u0089\nCarefully pass a blunt hook behind the object, and then \ngently pull it out\nIf the above fails\n\t\n\u0089\nRefer to an ENT specialist\nHC2\nHC2\nPrevention\n \n~\nCaution children about placing objects in mouth, nose, and ears\n21.2.2 Epistaxis (Nose Bleeding)\t \t\nICD10 CODE: R04.0\nBleeding from the nostrils, which may be arterial or venous\nCauses\n \n~\nLocal: nose-picking, trauma, nose infections, tumours\n \n~\nGeneral: hypertension, bleeding disorders, pertussis, Sickle-cell \ntrait/disease, renal failure, often familial\n \n~\nCan also be a symptom of serious disease, e.g., typhoid, malaria, \nviral fevers such as Ebola\nClinical features\n \n~\nOn examination, site of bleeding from nose may be seen\n \n~\nSigns and symptoms of shock if bleeding is severe\n \n~\nSigns and symptoms of predisposing cause\nDifferential diagnosis\n \n~\nClinical assessment to exclude any of above causes\nInvestigations\n \n\u0081\nBlood: Full blood count, platelet count",
        "formatted_content": "<p>957</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Carefully pass a blunt hook behind the object, and then</p>\n<p>gently pull it out</p>\n<p>If the above fails</p>\n<p>\u0089</p>\n<p>Refer to an ENT specialist</p>\n<h3>HC2</h3>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Caution children about placing objects in mouth, nose, and ears</p>\n<p>21.2.2 Epistaxis (Nose Bleeding)</p>\n<h3>ICD10 CODE: R04.0</h3>\n<p>Bleeding from the nostrils, which may be arterial or venous</p>\n<p>Causes</p>\n<p>~</p>\n<p>Local: nose-picking, trauma, nose infections, tumours</p>\n<p>~</p>\n<p>General: hypertension, bleeding disorders, pertussis, Sickle-cell</p>\n<p>trait/disease, renal failure, often familial</p>\n<p>~</p>\n<p>Can also be a symptom of serious disease, e.g., typhoid, malaria,</p>\n<p>viral fevers such as Ebola</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>On examination, site of bleeding from nose may be seen</p>\n<p>~</p>\n<p>Signs and symptoms of shock if bleeding is severe</p>\n<p>~</p>\n<p>Signs and symptoms of predisposing cause</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Clinical assessment to exclude any of above causes</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Blood: Full blood count, platelet count</p>"
    },
    {
        "page_number": 1024,
        "content": "958\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nManagement\nTREATMENT\nLOC\nFirst Aid\n\t\n\u0089\nSit the patient up (if the patient is not in shock) and tilt \nhead forward not backwards to avoid pooling of blood \nin posterior pharynx\n\t\n\u0089\nInstruct patient to pinch the nose between the finger and \nthe thumb for 15 minutes, breathe through the mouth, \nand spit out any blood\nHC2\nIf bleeding continues\n\t\n\u0089\nImpregnate a gauze strip with Soft paraffin or Tetracy\u00ad\ncline eye ointment and pack into the nose using forceps\n\t\n\u0089\nLeave gauze in place for 24-48 hours\nIf bleeding still does not stop after this period\n\t\n\u0089\nRefer to hospital for further management\nPrevention\n \n~\nAvoid picking the nose\n \n~\nTreat/control predisposing conditions\n21.2.3 Nasal Allergy      \t\n\t\n\t\nICD10 CODE: J30\nAn abnormal reaction of the nasal tissues to certain allergens, which \ntends to start in childhood. Vasomotor rhinitis starts in the 20s and 30s.\nCauses\n \n~\nPredisposing\n \n~\nHereditary: Family history of similar or allied complaints\n \n~\nInfections may alter tissue permeability\n \n~\nPsychological and emotional factors in vasomotor rhinitis",
        "formatted_content": "<p>958</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>First Aid</p>\n<p>\u0089</p>\n<p>Sit the patient up (if the patient is not in shock) and tilt</p>\n<p>head forward not backwards to avoid pooling of blood</p>\n<p>in posterior pharynx</p>\n<p>\u0089</p>\n<p>Instruct patient to pinch the nose between the finger and</p>\n<p>the thumb for 15 minutes, breathe through the mouth,</p>\n<p>and spit out any blood</p>\n<h3>HC2</h3>\n<p>If bleeding continues</p>\n<p>\u0089</p>\n<p>Impregnate a gauze strip with Soft paraffin or Tetracy\u00ad</p>\n<p>cline eye ointment and pack into the nose using forceps</p>\n<p>\u0089</p>\n<p>Leave gauze in place for 24-48 hours</p>\n<p>If bleeding still does not stop after this period</p>\n<p>\u0089</p>\n<p>Refer to hospital for further management</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid picking the nose</p>\n<p>~</p>\n<p>Treat/control predisposing conditions</p>\n<p>21.2.3 Nasal Allergy</p>\n<h3>ICD10 CODE: J30</h3>\n<p>An abnormal reaction of the nasal tissues to certain allergens, which</p>\n<p>tends to start in childhood. Vasomotor rhinitis starts in the 20s and 30s.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Predisposing</p>\n<p>~</p>\n<p>Hereditary: Family history of similar or allied complaints</p>\n<p>~</p>\n<p>Infections may alter tissue permeability</p>\n<p>~</p>\n<p>Psychological and emotional factors in vasomotor rhinitis</p>"
    },
    {
        "page_number": 1025,
        "content": "959\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nPrecipitating\n \n~\nChanges in humidity and temperature\n \n~\nDust mite, infections\n \n~\nCertain foods; drugs, e.g. acetylsalicylic acid\n \n~\nAlcohol, aerosols, fumes\nClinical features\n \n~\nOften present in school age children\n \n~\nSometimes preceded or followed by eczema or asthma. Less \ncommon in persons >50 years old\n \n~\nParoxysmal sneezing\n \n~\nProfuse watery nasal discharge\n \n~\nNasal obstruction, variable in intensity and may alternate from \nside to side\n \n~\nPostnasal drip (mucus dripping to the back of the nose)\nInvestigation\n \n\u0081\nCareful history is most important\n \n\u0081\nLarge turbinates on examining the nose\nDifferential diagnosis\n \n~\nNasal infection\n \n~\nForeign body\n \n~\nAdenoids (in children)\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nAvoid precipitating factors (most important)\n\t\n\u0089\nReassure the patient\nHC2",
        "formatted_content": "<p>959</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Precipitating</p>\n<p>~</p>\n<p>Changes in humidity and temperature</p>\n<p>~</p>\n<p>Dust mite, infections</p>\n<p>~</p>\n<p>Certain foods; drugs, e.g. acetylsalicylic acid</p>\n<p>~</p>\n<p>Alcohol, aerosols, fumes</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Often present in school age children</p>\n<p>~</p>\n<p>Sometimes preceded or followed by eczema or asthma. Less</p>\n<p>common in persons >50 years old</p>\n<p>~</p>\n<p>Paroxysmal sneezing</p>\n<p>~</p>\n<p>Profuse watery nasal discharge</p>\n<p>~</p>\n<p>Nasal obstruction, variable in intensity and may alternate from</p>\n<p>side to side</p>\n<p>~</p>\n<p>Postnasal drip (mucus dripping to the back of the nose)</p>\n<p>Investigation</p>\n<p>\u0081</p>\n<p>Careful history is most important</p>\n<p>\u0081</p>\n<p>Large turbinates on examining the nose</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Nasal infection</p>\n<p>~</p>\n<p>Foreign body</p>\n<p>~</p>\n<p>Adenoids (in children)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Avoid precipitating factors (most important)</p>\n<p>\u0089</p>\n<p>Reassure the patient</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1026,
        "content": "960\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\n\t\n\u0089\nAntihistamines, e.g., Chlorphenamine 4 mg every 12 hours \nfor up to 21 days, then as required thereafter if it recurs\n\t\n\u0089\nNasal decongestants, e.g., Pseudoephedrine or\n\t\n\u0089\nxylometazoline\n\t\n\u0089\nSurgery may be required if there is obstruction of the nose\nHC2\nCaution\n\uf077\t\nDo NOT use vasoconstrictor nasal drops, e.g. Pseudoephedrine \nand Xylometazoline for >7 days or repeatedly, since they can \ncause rebound congestion and alter the nasal environment making \nstructures hardened\n21.2.4 Sinusitis (Acute)\t \t\n\t\nICD10 CODE: J01\nInflammation of air sinuses of the skull\nCauses\n \n~\nAllergy\n \n~\nForeign body in the nose\n \n~\nViruses, e.g., rhinovirus, often as a complication of URTI\n \n~\nDental focal infection\n \n~\nBacteria, e.g., Streptococcus pneumoniae, Haemophilus influen\u00ad\nzae, Streptococcus pyogenes\nClinical features\n \n~\nRare in patients <5 years\n \n~\nPain over cheek and radiating to frontal region or teeth, increas\u00ad\ning with straining or bending down\n \n~\nRedness of nose, cheeks, or eyelids\n \n~\nTenderness to pressure over the floor of the frontal sinus imme\u00ad\ndiately above the inner canthus",
        "formatted_content": "<p>960</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Antihistamines, e.g., Chlorphenamine 4 mg every 12 hours</p>\n<p>for up to 21 days, then as required thereafter if it recurs</p>\n<p>\u0089</p>\n<p>Nasal decongestants, e.g., Pseudoephedrine or</p>\n<p>\u0089</p>\n<p>xylometazoline</p>\n<p>\u0089</p>\n<p>Surgery may be required if there is obstruction of the nose</p>\n<h3>HC2</h3>\n<p>Caution</p>\n<p>\uf077</p>\n<p>Do NOT use vasoconstrictor nasal drops, e.g. Pseudoephedrine</p>\n<p>and Xylometazoline for >7 days or repeatedly, since they can</p>\n<p>cause rebound congestion and alter the nasal environment making</p>\n<p>structures hardened</p>\n<p>21.2.4 Sinusitis (Acute)</p>\n<h3>ICD10 CODE: J01</h3>\n<p>Inflammation of air sinuses of the skull</p>\n<p>Causes</p>\n<p>~</p>\n<p>Allergy</p>\n<p>~</p>\n<p>Foreign body in the nose</p>\n<p>~</p>\n<p>Viruses, e.g., rhinovirus, often as a complication of URTI</p>\n<p>~</p>\n<p>Dental focal infection</p>\n<p>~</p>\n<p>Bacteria, e.g., Streptococcus pneumoniae, Haemophilus influen\u00ad</p>\n<p>zae, Streptococcus pyogenes</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Rare in patients <5 years</p>\n<p>~</p>\n<p>Pain over cheek and radiating to frontal region or teeth, increas\u00ad</p>\n<p>ing with straining or bending down</p>\n<p>~</p>\n<p>Redness of nose, cheeks, or eyelids</p>\n<p>~</p>\n<p>Tenderness to pressure over the floor of the frontal sinus imme\u00ad</p>\n<p>diately above the inner canthus</p>"
    },
    {
        "page_number": 1027,
        "content": "961\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n \n~\nReferred pain to the vertex, temple, or occiput\n \n~\nPostnasal discharge\n \n~\nA blocked nose\n \n~\nPersistent coughing or pharyngeal irritation\n \n~\nHyposmia\nDifferential diagnosis\n \n~\nCommon cold, allergic rhinitis\n \n~\nForeign body in the nose\n \n~\nNasal polyps, adenoids rhinitis\nInvnestigations\n \n\u0081\nC&S of the discharge\n \n\u0081\nX-ray of sinuses\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nSteam inhalation may help clear blocked nose\n\t\n\u0089\nAnalgesics e.g. Paracetamol\n\t\n\u0089\nNasal irrigation with normal saline\nIf there are signs of bacterial infection (symptoms persisting > \n1 week, unilateral facial pain, worsening of symptoms after an \ninitial improvement)\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours for 7-10 days\nHC2",
        "formatted_content": "<p>961</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>~</p>\n<p>Referred pain to the vertex, temple, or occiput</p>\n<p>~</p>\n<p>Postnasal discharge</p>\n<p>~</p>\n<p>A blocked nose</p>\n<p>~</p>\n<p>Persistent coughing or pharyngeal irritation</p>\n<p>~</p>\n<p>Hyposmia</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Common cold, allergic rhinitis</p>\n<p>~</p>\n<p>Foreign body in the nose</p>\n<p>~</p>\n<p>Nasal polyps, adenoids rhinitis</p>\n<p>Invnestigations</p>\n<p>\u0081</p>\n<p>C&S of the discharge</p>\n<p>\u0081</p>\n<p>X-ray of sinuses</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Steam inhalation may help clear blocked nose</p>\n<p>\u0089</p>\n<p>Analgesics e.g. Paracetamol</p>\n<p>\u0089</p>\n<p>Nasal irrigation with normal saline</p>\n<p>If there are signs of bacterial infection (symptoms persisting ></p>\n<p>1 week, unilateral facial pain, worsening of symptoms after an</p>\n<p>initial improvement)</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours for 7-10 days</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1028,
        "content": "962\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\n\t\n\u0089\nChild: 15 mg/kg per dose\nIf there is a dental focus of infection\n\t\n\u0089\nExtract the tooth\n\t\n\u0089\nGive antibiotics e.g. Amoxicillin plus\nMetronidazole (see Gingivitis, section 23.2.5)\n\t\n\u0089\nIf there is a foreign body in the nose\n\t\n\u0089\nRefer to hospital for removal\nHC2\nNotes\n\uf077\t\nDo NOT use antibiotics except if there are clear features of bacte\u00ad\nrial sinusitis, e.g., persistent (> 1 week) purulent nasal discharge, \nsinus tenderness, facial or periorbital swelling, persistent fever\n21.2.5 Atrophic Rhinitis\nChronic infection of the nasal mucosa in which various components \nbecome thinner (atrophy) due to fibrosis of the terminal blood vessels.\nCause\n \n~\nUnknown but associated with: HIV/AIDS, poor socio- economic \nstatus, syphilis, rhinoscleroma (early stages)\nClinical features\n \n~\nTends to affect both nasal cavities\n \n~\nAffects females more than males\n \n~\nFoul stench not noticed by patient who cannot smell\n \n~\nCrusts and bleeding points in the nose\n \n~\nEpistaxis when crusts separate\n \n~\nSensation of obstruction in the nose\n \n~\nNasal airway very wide",
        "formatted_content": "<p>962</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Child: 15 mg/kg per dose</p>\n<p>If there is a dental focus of infection</p>\n<p>\u0089</p>\n<p>Extract the tooth</p>\n<p>\u0089</p>\n<p>Give antibiotics e.g. Amoxicillin plus</p>\n<p>Metronidazole (see Gingivitis, section 23.2.5)</p>\n<p>\u0089</p>\n<p>If there is a foreign body in the nose</p>\n<p>\u0089</p>\n<p>Refer to hospital for removal</p>\n<h3>HC2</h3>\n<p>Notes</p>\n<p>\uf077</p>\n<p>Do NOT use antibiotics except if there are clear features of bacte\u00ad</p>\n<p>rial sinusitis, e.g., persistent (> 1 week) purulent nasal discharge,</p>\n<p>sinus tenderness, facial or periorbital swelling, persistent fever</p>\n<p>21.2.5 Atrophic Rhinitis</p>\n<p>Chronic infection of the nasal mucosa in which various components</p>\n<p>become thinner (atrophy) due to fibrosis of the terminal blood vessels.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Unknown but associated with: HIV/AIDS, poor socio- economic</p>\n<p>status, syphilis, rhinoscleroma (early stages)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Tends to affect both nasal cavities</p>\n<p>~</p>\n<p>Affects females more than males</p>\n<p>~</p>\n<p>Foul stench not noticed by patient who cannot smell</p>\n<p>~</p>\n<p>Crusts and bleeding points in the nose</p>\n<p>~</p>\n<p>Epistaxis when crusts separate</p>\n<p>~</p>\n<p>Sensation of obstruction in the nose</p>\n<p>~</p>\n<p>Nasal airway very wide</p>"
    },
    {
        "page_number": 1029,
        "content": "963\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nInvestigations\n \n\u0081\nC&S of smear of nasal material\n \n\u0081\nX-ray: To exclude sinusitis\n \n\u0081\nDifferential diagnosis\n \n\u0081\nAtrophy from other causes\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nClean nasal cavities twice daily to remove crusts (most \nimportant)\n\t\n\u0089\nSyringe nose or douche it with warm normal saline\n\t\n\u0089\nOr sodium bicarbonate solution 5% (dissolve 1 teaspoon \nof powder in 100 ml cup of warm water)\n\t\n\u0089\nThen apply tetracycline eye ointment 1% inside the nose \ntwice daily\n \n- Give amoxicillin 500 mg every 8 hours for 14 \ndaysFor rhinoscleroma: Give 1 g every 8 hours \nfor 6 weeks\nIf atrophic rhinitis not better or is worse after 2 weeks\n\t\n\u0089\nRefer to ENT specialist\nHC3\nHC4\nPrevention\n \n~\nTreat/eliminate known causes, such as syphilis\n21.2.6 Adenoid Disease\t \t\nICD10 CODE: J35.02, J35.2\nEnlargement/inflammation of nasopharyngeal tonsil. Common in small \nchildren.",
        "formatted_content": "<p>963</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>C&S of smear of nasal material</p>\n<p>\u0081</p>\n<p>X-ray: To exclude sinusitis</p>\n<p>\u0081</p>\n<p>Differential diagnosis</p>\n<p>\u0081</p>\n<p>Atrophy from other causes</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Clean nasal cavities twice daily to remove crusts (most</p>\n<p>important)</p>\n<p>\u0089</p>\n<p>Syringe nose or douche it with warm normal saline</p>\n<p>\u0089</p>\n<p>Or sodium bicarbonate solution 5% (dissolve 1 teaspoon</p>\n<p>of powder in 100 ml cup of warm water)</p>\n<p>\u0089</p>\n<p>Then apply tetracycline eye ointment 1% inside the nose</p>\n<p>twice daily</p>\n<p>- Give amoxicillin 500 mg every 8 hours for 14</p>\n<p>daysFor rhinoscleroma: Give 1 g every 8 hours</p>\n<p>for 6 weeks</p>\n<p>If atrophic rhinitis not better or is worse after 2 weeks</p>\n<p>\u0089</p>\n<p>Refer to ENT specialist</p>\n<h3>HC3</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Treat/eliminate known causes, such as syphilis</p>\n<p>21.2.6 Adenoid Disease</p>\n<h3>ICD10 CODE: J35.02, J35.2</h3>\n<p>Enlargement/inflammation of nasopharyngeal tonsil. Common in small</p>\n<p>children.</p>"
    },
    {
        "page_number": 1030,
        "content": "964\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nClinical features\nMay be due to enlargement, inflammation, or both\n \n~\nObstruction of the nose leading to mouth breathing, difficulty \neating, snoring, jaw deformities\n \n~\nObstruction of Eustachian tube leading to hearing loss, which \nfluctuates due to fluid in middle ear (\u201dGlue ear\u201d)\n \n~\nRecurrent otitis\n \n~\nDischarge from the nose\n \n~\nRecurrent cough\n \n~\nPhysical and other developmental retardation, e.g. small size for \nage\nInvestigations\n \n\u0081\nDiagnosis is usually based on history\n \n\u0081\nX-ray for neck soft tissue: lateral view shows narrowing of the \npost-nasal space\nDifferential diagnosis\n \n~\nOther causes of nasal obstruction and discharge, e.g., rhinitis, \nFB, deviated septum, sinusitis\n \n~\nDental and jaw diseases or abnormalities\nManagement\nTREATMENT\nLOC\nMild (If symptoms are not marked)\n\t\n\u0089\nGive conservative treatment with chlorpheniramine 1-2\nmg daily (depending on age) for 7 days\n\t\n\u0089\nTopical nasal steroids if available\nHC2",
        "formatted_content": "<p>964</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Clinical features</p>\n<p>May be due to enlargement, inflammation, or both</p>\n<p>~</p>\n<p>Obstruction of the nose leading to mouth breathing, difficulty</p>\n<p>eating, snoring, jaw deformities</p>\n<p>~</p>\n<p>Obstruction of Eustachian tube leading to hearing loss, which</p>\n<p>fluctuates due to fluid in middle ear (\u201dGlue ear\u201d)</p>\n<p>~</p>\n<p>Recurrent otitis</p>\n<p>~</p>\n<p>Discharge from the nose</p>\n<p>~</p>\n<p>Recurrent cough</p>\n<p>~</p>\n<p>Physical and other developmental retardation, e.g. small size for</p>\n<p>age</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is usually based on history</p>\n<p>\u0081</p>\n<p>X-ray for neck soft tissue: lateral view shows narrowing of the</p>\n<p>post-nasal space</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other causes of nasal obstruction and discharge, e.g., rhinitis,</p>\n<p>FB, deviated septum, sinusitis</p>\n<p>~</p>\n<p>Dental and jaw diseases or abnormalities</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild (If symptoms are not marked)</p>\n<p>\u0089</p>\n<p>Give conservative treatment with chlorpheniramine 1-2</p>\n<p>mg daily (depending on age) for 7 days</p>\n<p>\u0089</p>\n<p>Topical nasal steroids if available</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1031,
        "content": "965\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\nModerate and Severe (If symptoms are marked or do not im\u00ad\nprove on treatment)\n \n~\nRefer to ENT surgeon for surgery\n21.3 THROAT CONDITIONS\n21.3.1\t\nForeign Body (FB) in the Airway\t ICD10 CODE: T17\nMostly occurs in children <5 years\nCause\n \n~\nTypes of FBs include seeds (groundnuts, beans, maize) plastics, \nrubber, metal wires, ball bearings\n \n~\nUsually inhaled from the mouth\n \n~\nChild is chewing, laughing, or crying or there is a sudden distur\u00ad\nbance, which opens the vocal cords so the object is inhaled\nClinical features\n \n~\nSudden onset of choking followed by stridor (noisy breathing) or\n \n~\nCough, difficulty in breathing, wheezing\n \n~\nHoarseness of voice if FB stuck at the vocal cords\n \n~\nSymptoms start suddenly, some symptoms may be transient (may \ndisappear after a short period), but complications may present \nfew days later (sudden death, intractable pneumonia)\n \n~\nUpper airway obstruction as shown by: flaring of the nostrils, \nrecession of the chest inlet and/or below the ribs, rapid chest \nmovements and reduced air entry (usually on the right side)\nInvestigations\n \n\u0081\nOnce the history and examination are suggestive, investigations \ncan be omitted to save time",
        "formatted_content": "<p>965</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Moderate and Severe (If symptoms are marked or do not im\u00ad</p>\n<p>prove on treatment)</p>\n<p>~</p>\n<p>Refer to ENT surgeon for surgery</p>\n<h3>21.3 THROAT CONDITIONS</h3>\n<p>21.3.1</p>\n<p>Foreign Body (FB) in the Airway\t ICD10 CODE: T17</p>\n<p>Mostly occurs in children <5 years</p>\n<p>Cause</p>\n<p>~</p>\n<p>Types of FBs include seeds (groundnuts, beans, maize) plastics,</p>\n<p>rubber, metal wires, ball bearings</p>\n<p>~</p>\n<p>Usually inhaled from the mouth</p>\n<p>~</p>\n<p>Child is chewing, laughing, or crying or there is a sudden distur\u00ad</p>\n<p>bance, which opens the vocal cords so the object is inhaled</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Sudden onset of choking followed by stridor (noisy breathing) or</p>\n<p>~</p>\n<p>Cough, difficulty in breathing, wheezing</p>\n<p>~</p>\n<p>Hoarseness of voice if FB stuck at the vocal cords</p>\n<p>~</p>\n<p>Symptoms start suddenly, some symptoms may be transient (may</p>\n<p>disappear after a short period), but complications may present</p>\n<p>few days later (sudden death, intractable pneumonia)</p>\n<p>~</p>\n<p>Upper airway obstruction as shown by: flaring of the nostrils,</p>\n<p>recession of the chest inlet and/or below the ribs, rapid chest</p>\n<p>movements and reduced air entry (usually on the right side)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Once the history and examination are suggestive, investigations</p>\n<p>can be omitted to save time</p>"
    },
    {
        "page_number": 1032,
        "content": "966\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n \n\u0081\nChest x-ray may show lung collapse, hyperinflation, mediastinal \nshift, shift of heart shadow\nManagement\nTREATMENT\nLOC\nChild\n\t\n\u0089\nIf chocking, attempt to dislodge it by 3 cycles of 5 back \nslaps/5 chest compressions (for infants) or Heimlich \nmanoeuvre (for children)\n\uf077\t\nDo not do blind finger sweeps. If a foreign body is visible \nin the mouth, remove it with a Magill forceps\n\t\n\u0089\nIf severe respiratory distress, refer to higher  level for \nairway visualization. Give oxygen if necessary\nHC2\nAdult\n\t\n\u0089\nDislodge large FB, e.g. chunk of meat, from the phar\u00ad\nynx by cycles of 5 back slaps and Heimlich manoeuvre \n(standing behind the patient with both arms around the \nupper abdomen and giving 5 thrusts)\n \n- If patient pregnant or very obese: Perform 6-10 \nchest thrusts with patient lying on the back\n\t\n\u0089\nIf still suspect of FB, refer for airway visualization\n Prevention\n \n~\nDo not give groundnuts or other small hard food items to chil\u00ad\ndren <2 years\n \n~\nIf a child is found with objects in the mouth, leave the child alone \nto chew and swallow or gently persuade the child to spit out the \nobject\n\t\n\u0089\nDo not struggle with/force the child",
        "formatted_content": "<p>966</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>\u0081</p>\n<p>Chest x-ray may show lung collapse, hyperinflation, mediastinal</p>\n<p>shift, shift of heart shadow</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Child</p>\n<p>\u0089</p>\n<p>If chocking, attempt to dislodge it by 3 cycles of 5 back</p>\n<p>slaps/5 chest compressions (for infants) or Heimlich</p>\n<p>manoeuvre (for children)</p>\n<p>\uf077</p>\n<p>Do not do blind finger sweeps. If a foreign body is visible</p>\n<p>in the mouth, remove it with a Magill forceps</p>\n<p>\u0089</p>\n<p>If severe respiratory distress, refer to higher  level for</p>\n<p>airway visualization. Give oxygen if necessary</p>\n<h3>HC2</h3>\n<p>Adult</p>\n<p>\u0089</p>\n<p>Dislodge large FB, e.g. chunk of meat, from the phar\u00ad</p>\n<p>ynx by cycles of 5 back slaps and Heimlich manoeuvre</p>\n<p>(standing behind the patient with both arms around the</p>\n<p>upper abdomen and giving 5 thrusts)</p>\n<p>- If patient pregnant or very obese: Perform 6-10</p>\n<p>chest thrusts with patient lying on the back</p>\n<p>\u0089</p>\n<p>If still suspect of FB, refer for airway visualization</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Do not give groundnuts or other small hard food items to chil\u00ad</p>\n<p>dren <2 years</p>\n<p>~</p>\n<p>If a child is found with objects in the mouth, leave the child alone</p>\n<p>to chew and swallow or gently persuade the child to spit out the</p>\n<p>object</p>\n<p>\u0089</p>\n<p>Do not struggle with/force the child</p>"
    },
    {
        "page_number": 1033,
        "content": "967\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n21.3.2 Foreign Body in the Food Passage\t       ICD10 CODE: T18\nCauses\n \n~\nTypes of FBs commonly involved include:\n\t\n\u0089\nFish or chicken bones, often lodging in the tonsils, behind the \ntongue, or in the pharynx, occasionally in the oesophagus\n \n~\nCoins, especally in children. Coins are particularly likely to be \ningested. Disc battery is particularly dangerous and requires im\u00ad\nmediate referral\nClinical features\n \n~\nDifficulty and pain in swallowing\n\t\n\u0089\nPatient winces as he attempts to swallow\n \n~\nDrooling of saliva\n \n~\nPatient may point to where foreign body is stuck with a finger \n(pointing sign)\n \n~\nFB may be seen, e.g., in tonsil, pharynx\nDifferential diagnosis\n \n~\nInfection in pharynx\n \n~\nTrauma by foreign body\n \n~\nMedication ulcer (e.g. doxycycline)\nInvestigations\n \n\u0081\nX-ray may reveal radio-opaque FB\n\t\n\u0089\nCoins may appear on X-rays done for other reasons\n \n\u0081\nMany FBs are radiolucent\n\t\n\u0089\nLook for a gas shadow if in the oesophagus",
        "formatted_content": "<p>967</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>21.3.2 Foreign Body in the Food Passage\t       ICD10 CODE: T18</p>\n<p>Causes</p>\n<p>~</p>\n<p>Types of FBs commonly involved include:</p>\n<p>\u0089</p>\n<p>Fish or chicken bones, often lodging in the tonsils, behind the</p>\n<p>tongue, or in the pharynx, occasionally in the oesophagus</p>\n<p>~</p>\n<p>Coins, especally in children. Coins are particularly likely to be</p>\n<p>ingested. Disc battery is particularly dangerous and requires im\u00ad</p>\n<p>mediate referral</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Difficulty and pain in swallowing</p>\n<p>\u0089</p>\n<p>Patient winces as he attempts to swallow</p>\n<p>~</p>\n<p>Drooling of saliva</p>\n<p>~</p>\n<p>Patient may point to where foreign body is stuck with a finger</p>\n<p>(pointing sign)</p>\n<p>~</p>\n<p>FB may be seen, e.g., in tonsil, pharynx</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Infection in pharynx</p>\n<p>~</p>\n<p>Trauma by foreign body</p>\n<p>~</p>\n<p>Medication ulcer (e.g. doxycycline)</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>X-ray may reveal radio-opaque FB</p>\n<p>\u0089</p>\n<p>Coins may appear on X-rays done for other reasons</p>\n<p>\u0081</p>\n<p>Many FBs are radiolucent</p>\n<p>\u0089</p>\n<p>Look for a gas shadow if in the oesophagus</p>"
    },
    {
        "page_number": 1034,
        "content": "968\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nManagement\n \n~\nThe approach depends upon the type of object ingested, the \nlocation of the object, and the patient\u2019s clinical status.\n \n~\nIf negative radiographs, no symptoms and the FB does not be\u00ad\nlong to a dangerous category (magnets, disc batteries, sharp long \nobjects, superabsorbent polymer), expectant management is ad\u00ad\nvised.\n \n~\nIf patient is symptomatic and/or the object is dangerous, imme\u00ad\ndiate referral for further management.\nTREATMENT\nLOC\n\t\n\u0089\nAllow only clear fluids\n\t\n\u0089\nDo NOT try to dislodge/move the FB with solid food\n \n- This may push it into the wall of the oesophagus \ncausing infection and sometimes death\n\t\n\u0089\nGive IV infusion if unable to swallow liquids or if oral \nfluid intake is poor\nHC2\nIf FB is invisible on X-ray or symptoms persist >24 hours from \ntime of ingestion\n\t\n\u0089\nRefer to hospital with ENT facility\nIf FB is visible in the pharynx, tonsil, etc.\n\t\n\u0089\nGrasp and remove it with long forceps\nIf patient tried to push FB with solid food:\n\t\n\u0089\nGive broad-spectrum antibiotic cover with amoxicillin \n500 mg every 8 hours for 5 days\nPrevention\n \n~\nKeep potential FBs out of children\u2019s reach\n \n~\nAdvise on care in eating, i.e., not taking in too large pieces of \nfood, chewing thoroughly before swallowing\n \n~\nAdvise once a FB is stuck to avoid trying to \u201cpush\u201d it down with \nsolid food as this may sometimes be fatal",
        "formatted_content": "<p>968</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>Management</p>\n<p>~</p>\n<p>The approach depends upon the type of object ingested, the</p>\n<p>location of the object, and the patient\u2019s clinical status.</p>\n<p>~</p>\n<p>If negative radiographs, no symptoms and the FB does not be\u00ad</p>\n<p>long to a dangerous category (magnets, disc batteries, sharp long</p>\n<p>objects, superabsorbent polymer), expectant management is ad\u00ad</p>\n<p>vised.</p>\n<p>~</p>\n<p>If patient is symptomatic and/or the object is dangerous, imme\u00ad</p>\n<p>diate referral for further management.</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Allow only clear fluids</p>\n<p>\u0089</p>\n<p>Do NOT try to dislodge/move the FB with solid food</p>\n<p>- This may push it into the wall of the oesophagus</p>\n<p>causing infection and sometimes death</p>\n<p>\u0089</p>\n<p>Give IV infusion if unable to swallow liquids or if oral</p>\n<p>fluid intake is poor</p>\n<h3>HC2</h3>\n<p>If FB is invisible on X-ray or symptoms persist >24 hours from</p>\n<p>time of ingestion</p>\n<p>\u0089</p>\n<p>Refer to hospital with ENT facility</p>\n<p>If FB is visible in the pharynx, tonsil, etc.</p>\n<p>\u0089</p>\n<p>Grasp and remove it with long forceps</p>\n<p>If patient tried to push FB with solid food:</p>\n<p>\u0089</p>\n<p>Give broad-spectrum antibiotic cover with amoxicillin</p>\n<p>500 mg every 8 hours for 5 days</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Keep potential FBs out of children\u2019s reach</p>\n<p>~</p>\n<p>Advise on care in eating, i.e., not taking in too large pieces of</p>\n<p>food, chewing thoroughly before swallowing</p>\n<p>~</p>\n<p>Advise once a FB is stuck to avoid trying to \u201cpush\u201d it down with</p>\n<p>solid food as this may sometimes be fatal</p>"
    },
    {
        "page_number": 1035,
        "content": "969\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n21.3.3 Pharyngitis (Sore Throat) ICD10 CODE: J02\nInflammation of the throat\nCauses\n \n~\nMost cases are viral\n \n~\nBacterial: commonly Group A haemolytic Streptococci, diphthe\u00ad\nria in non-immunized children\n \n~\nGonorrhoea (usually from oral sex)\n \n~\nMay also follow ingestion of undiluted spirits\n \n~\nCandida albicans in the immunosuppressed\nClinical features\n \n~\nAbrupt onset\n \n~\nThroat pain\n \n~\nPain on swallowing\n \n~\nMild fever, loss of appetite, general malaise\n \n~\nIn children: nausea, vomiting, and diarrhoea\n \n~\nThe presence of runny nose, hoarseness, cough, conjunctivitis, \nviral rash, diarrhea suggests viral infection\n \n~\nThe presence of tonsilar exudates, tender neck glands, high fe\u00ad\nver, and absence of cough suggest a bacterial pharyngotonsillitis \n(see section 21.3.4)\nDifferential diagnosis\n \n~\nTonsillitis, epiglottitis, laryngitis\n \n~\nOtitis media if there is referred pain\nInvestigations\n \n\u0081\nThroat examination with torch and tongue depressor\n \n\u0081\nThroat swab for microscopy, C&S",
        "formatted_content": "<p>969</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>21.3.3 Pharyngitis (Sore Throat) ICD10 CODE: J02</p>\n<p>Inflammation of the throat</p>\n<p>Causes</p>\n<p>~</p>\n<p>Most cases are viral</p>\n<p>~</p>\n<p>Bacterial: commonly Group A haemolytic Streptococci, diphthe\u00ad</p>\n<p>ria in non-immunized children</p>\n<p>~</p>\n<p>Gonorrhoea (usually from oral sex)</p>\n<p>~</p>\n<p>May also follow ingestion of undiluted spirits</p>\n<p>~</p>\n<p>Candida albicans in the immunosuppressed</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Abrupt onset</p>\n<p>~</p>\n<p>Throat pain</p>\n<p>~</p>\n<p>Pain on swallowing</p>\n<p>~</p>\n<p>Mild fever, loss of appetite, general malaise</p>\n<p>~</p>\n<p>In children: nausea, vomiting, and diarrhoea</p>\n<p>~</p>\n<p>The presence of runny nose, hoarseness, cough, conjunctivitis,</p>\n<p>viral rash, diarrhea suggests viral infection</p>\n<p>~</p>\n<p>The presence of tonsilar exudates, tender neck glands, high fe\u00ad</p>\n<p>ver, and absence of cough suggest a bacterial pharyngotonsillitis</p>\n<p>(see section 21.3.4)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Tonsillitis, epiglottitis, laryngitis</p>\n<p>~</p>\n<p>Otitis media if there is referred pain</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Throat examination with torch and tongue depressor</p>\n<p>\u0081</p>\n<p>Throat swab for microscopy, C&S</p>"
    },
    {
        "page_number": 1036,
        "content": "970\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n \n\u0081\nBlood: Full blood count\n \n\u0081\nSerological test for haemolytic streptococci (ASOT)\nTREATMENT\nLOC\nSupportive care\nMost cases are viral and do not require antibiotics\n\t\n\u0089\nKeep the patient warm\n\t\n\u0089\nGive plenty of (warm) oral fluids e.g., tea \n\t\n\u0089\nGive analgesics, e.g., Paracetamol for 3 days \n\t\n\u0089\nReview the patient for progress\nFor Streptococcal pharyngitis: see section 21.3.4\nHC2\nNotes\n\uf077\t\nIf not properly treated, streptococcal pharyngitis may \nlead to acute rheumatic fever and retropharyngeal or \nperitonsillar abscess\n \n- Therefore ensure that the full 10-day courses of \nantibiotics are completed where applicable\n21.3.4 Pharyngo-Tonsillitis \t\nICD10 CODE: J03\nInflammation of the tonsils\nCause\n \n~\nStreptococcal infection (most common)\n \n~\nViral infection (less common)\nClinical features\n \n~\nSudden onset, most common in children\n \n~\nSore throat\n \n~\nFever, shivering, headache, vomiting\n \n~\nTonsils enlarged and with exudate and cervical lymph nodes\nComplications\n \n~\nLocal: peritonsillar cellulitis and abscess (quinsy),",
        "formatted_content": "<p>970</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>\u0081</p>\n<p>Blood: Full blood count</p>\n<p>\u0081</p>\n<p>Serological test for haemolytic streptococci (ASOT)</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Supportive care</p>\n<p>Most cases are viral and do not require antibiotics</p>\n<p>\u0089</p>\n<p>Keep the patient warm</p>\n<p>\u0089</p>\n<p>Give plenty of (warm) oral fluids e.g., tea</p>\n<p>\u0089</p>\n<p>Give analgesics, e.g., Paracetamol for 3 days</p>\n<p>\u0089</p>\n<p>Review the patient for progress</p>\n<p>For Streptococcal pharyngitis: see section 21.3.4</p>\n<h3>HC2</h3>\n<p>Notes</p>\n<p>\uf077</p>\n<p>If not properly treated, streptococcal pharyngitis may</p>\n<p>lead to acute rheumatic fever and retropharyngeal or</p>\n<p>peritonsillar abscess</p>\n<p>- Therefore ensure that the full 10-day courses of</p>\n<p>antibiotics are completed where applicable</p>\n<p>21.3.4 Pharyngo-Tonsillitis</p>\n<h3>ICD10 CODE: J03</h3>\n<p>Inflammation of the tonsils</p>\n<p>Cause</p>\n<p>~</p>\n<p>Streptococcal infection (most common)</p>\n<p>~</p>\n<p>Viral infection (less common)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Sudden onset, most common in children</p>\n<p>~</p>\n<p>Sore throat</p>\n<p>~</p>\n<p>Fever, shivering, headache, vomiting</p>\n<p>~</p>\n<p>Tonsils enlarged and with exudate and cervical lymph nodes</p>\n<p>Complications</p>\n<p>~</p>\n<p>Local: peritonsillar cellulitis and abscess (quinsy),</p>"
    },
    {
        "page_number": 1037,
        "content": "971\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n \n~\nSystemic complications: bacterial endocarditis, glomerulonephri\u00ad\ntis, rheumatic fever (see section 4.1.9)\nDifferential diagnosis\n \n~\nPharyngitis\n \n~\nSubmandibular lymphadenitis\n \n~\nInvestigations\n \n~\nThroat swab: For C&S\nManagement\nTREATMENT\nLOC\nBacterial pharyngotonsillitis\n\t\n\u0089\nPhenoxymethylpenicillin 500 mg every 6 hours for 10 days\n\t\n\u0089\nChild: 10-20 mg/kg per dose\n\t\n\u0089\nOr Benzathine penicillin 1.2 MU IM single dose\n\t\n\u0089\nChild: <30 kg: 30,000 IU/kg\nIf allergic to penicillin\n\t\n\u0089\nErythromycin 500 mg every 6 hours for 10 days\n\t\n\u0089\nChild: 12.5 mg/kg per dose\nViral pharyngotonsillitis\n\t\n\u0089\nTreat symptomatically with analgesics and increased \noral fluids\nHC2\n21.3.5 Peritonsillar Abscess (Quinsy) ICD10 CODE: J36\nAn abscess between the tonsil capsule and the lateral wall of the pharynx\nCause\n \n~\nFollows (often mild) tonsillitis attack\nClinical features\n \n~\nSevere throat pain\n \n~\nFever, headache, malaise, rigors may occur\n \n~\nInability to open the mouth; salivation and dribbling",
        "formatted_content": "<p>971</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>~</p>\n<p>Systemic complications: bacterial endocarditis, glomerulonephri\u00ad</p>\n<p>tis, rheumatic fever (see section 4.1.9)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Pharyngitis</p>\n<p>~</p>\n<p>Submandibular lymphadenitis</p>\n<p>~</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Throat swab: For C&S</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Bacterial pharyngotonsillitis</p>\n<p>\u0089</p>\n<p>Phenoxymethylpenicillin 500 mg every 6 hours for 10 days</p>\n<p>\u0089</p>\n<p>Child: 10-20 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or Benzathine penicillin 1.2 MU IM single dose</p>\n<p>\u0089</p>\n<p>Child: <30 kg: 30,000 IU/kg</p>\n<p>If allergic to penicillin</p>\n<p>\u0089</p>\n<p>Erythromycin 500 mg every 6 hours for 10 days</p>\n<p>\u0089</p>\n<p>Child: 12.5 mg/kg per dose</p>\n<p>Viral pharyngotonsillitis</p>\n<p>\u0089</p>\n<p>Treat symptomatically with analgesics and increased</p>\n<p>oral fluids</p>\n<h3>HC2</h3>\n<p>21.3.5 Peritonsillar Abscess (Quinsy) ICD10 CODE: J36</p>\n<p>An abscess between the tonsil capsule and the lateral wall of the pharynx</p>\n<p>Cause</p>\n<p>~</p>\n<p>Follows (often mild) tonsillitis attack</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Severe throat pain</p>\n<p>~</p>\n<p>Fever, headache, malaise, rigors may occur</p>\n<p>~</p>\n<p>Inability to open the mouth; salivation and dribbling</p>"
    },
    {
        "page_number": 1038,
        "content": "972\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\n \n~\nBad mouth odour\n \n~\nThickened muffled (unclear) speech\n \n~\nEar pain\n \n~\nEnlarged cervical lymph nodes\n \n~\nTonsil and soft palate reddish and oedematous\n \n~\nSwelling pushing the uvula to opposite side\n \n~\n\u2013 May be pointing (bulging collection of pus)\nDifferential diagnosis\n \n~\nTumour\n \n~\nTonsillitis\n \n~\nAbscess in the pharynx\nInvestigations\n \n\u0081\nCarry out C&S on pus if present or after drainage\nManagement\nTREATMENT\nLOC\nEarly stages: Disease of adolescents and adults\n\t\n\u0089\nConservative management\n\t\n\u0089\nBed rest\n\t\n\u0089\nAdult: Benzylpenicillin 2 MU IV or IM every 6 hours \nfor 48 hours then switch to amoxicillin 500 mg every 8 \nhours to complete a total of 7 days\nIf not better in 48 hours\n\t\n\u0089\nCeftriaxone 1 g IV once daily for 7 days Child: 50 mg/\nkg IV\n\t\n\u0089\nPlus metronidazole 500 mg IV every 8 hours Child: 10 \nmg/kg IV every 8 hours\nHC2",
        "formatted_content": "<p>972</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<p>~</p>\n<p>Bad mouth odour</p>\n<p>~</p>\n<p>Thickened muffled (unclear) speech</p>\n<p>~</p>\n<p>Ear pain</p>\n<p>~</p>\n<p>Enlarged cervical lymph nodes</p>\n<p>~</p>\n<p>Tonsil and soft palate reddish and oedematous</p>\n<p>~</p>\n<p>Swelling pushing the uvula to opposite side</p>\n<p>~</p>\n<p>\u2013 May be pointing (bulging collection of pus)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Tumour</p>\n<p>~</p>\n<p>Tonsillitis</p>\n<p>~</p>\n<p>Abscess in the pharynx</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Carry out C&S on pus if present or after drainage</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Early stages: Disease of adolescents and adults</p>\n<p>\u0089</p>\n<p>Conservative management</p>\n<p>\u0089</p>\n<p>Bed rest</p>\n<p>\u0089</p>\n<p>Adult: Benzylpenicillin 2 MU IV or IM every 6 hours</p>\n<p>for 48 hours then switch to amoxicillin 500 mg every 8</p>\n<p>hours to complete a total of 7 days</p>\n<p>If not better in 48 hours</p>\n<p>\u0089</p>\n<p>Ceftriaxone 1 g IV once daily for 7 days Child: 50 mg/</p>\n<p>kg IV</p>\n<p>\u0089</p>\n<p>Plus metronidazole 500 mg IV every 8 hours Child: 10</p>\n<p>mg/kg IV every 8 hours</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1039,
        "content": "973\nUganda Clinical Guidelines 2023\nCHAPTER 21 : Ear,  Nose  & Throat Conditions\nTREATMENT\nLOC\nIf unable to take oral fluids\n\t\n\u0089\nSet up an IV drip e.g. Normal saline\nWhen swelling is marked\n\t\n\u0089\nSurgery (which should be done by a trained person)\n \n- Suction facility will be needed\n \n- Carry out incision and drainage at the most \npointing area with the protected tip of no.11 \nsurgical blade\n\t\n\u0089\n6 weeks later: Refer for tonsillectomy as this condition \nmight recur\nPrevention\n \n~\nPrompt and adequate treatment of tonsillitis",
        "formatted_content": "<p>973</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 21 : Ear,  Nose  & Throat Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>If unable to take oral fluids</p>\n<p>\u0089</p>\n<p>Set up an IV drip e.g. Normal saline</p>\n<p>When swelling is marked</p>\n<p>\u0089</p>\n<p>Surgery (which should be done by a trained person)</p>\n<p>- Suction facility will be needed</p>\n<p>- Carry out incision and drainage at the most</p>\n<p>pointing area with the protected tip of no.11</p>\n<p>surgical blade</p>\n<p>\u0089</p>\n<p>6 weeks later: Refer for tonsillectomy as this condition</p>\n<p>might recur</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Prompt and adequate treatment of tonsillitis</p>"
    },
    {
        "page_number": 1040,
        "content": "974\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\n22.1 BACTERIAL SKIN INFECTIONS\n22.1.1 Impetigo\t \t\nICD10 CODE: L01\nA very superficial bacterial infection of the epidermis (upper/outer layer \nof skin), bullous and non bullous impetigo\nCause\n \n~\nStreptococcus or staphylococcus infection, or both\nClinical features\n \n~\nCommon in children, although it can also occur in adults.\n \n~\nLesions usually on face, head, and hands as bullae, or small \nbrown crusts on an erythematous base\n \n~\nIn some cases, large flaccid bullae containing pus and serum are \nformed commonly in the axilla and groin\nDifferential diagnosis\n \n~\nPemphigus foliaceus\nInvestigations\n \n\u0081\nPus swab for Gram stain\n \n\u0081\nCulture and sensitivity (exudate from unroofed lesion)\nSkin Diseases\n22",
        "formatted_content": "<p>974</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>22.1 BACTERIAL SKIN INFECTIONS</h3>\n<p>22.1.1 Impetigo</p>\n<h3>ICD10 CODE: L01</h3>\n<p>A very superficial bacterial infection of the epidermis (upper/outer layer</p>\n<p>of skin), bullous and non bullous impetigo</p>\n<p>Cause</p>\n<p>~</p>\n<p>Streptococcus or staphylococcus infection, or both</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Common in children, although it can also occur in adults.</p>\n<p>~</p>\n<p>Lesions usually on face, head, and hands as bullae, or small</p>\n<p>brown crusts on an erythematous base</p>\n<p>~</p>\n<p>In some cases, large flaccid bullae containing pus and serum are</p>\n<p>formed commonly in the axilla and groin</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Pemphigus foliaceus</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pus swab for Gram stain</p>\n<p>\u0081</p>\n<p>Culture and sensitivity (exudate from unroofed lesion)</p>\n<p>Skin Diseases</p>\n<p>22</p>"
    },
    {
        "page_number": 1041,
        "content": "975\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nManagement\nTREATMENT\nLOC\nCleaning\n\t\n\u0089\nClean affected area with chlorhexidine solution 0.05%\nAntiseptic: if infection mild and localised (<5 lesions)\n\t\n\u0089\nApply gentian violet aqueous paint 0.5% every 12 hours \nfor 3 days\n\t\n\u0089\nOR apply silver sulphadiazine 1% cream 12 hourly for \n5 days OR apply Mupirocin(supirocin) 2% 8 hourly for \n5 to 7 days.\nAntiseptic: if infection mild and localised (<5 lesions)\n\t\n\u0089\nApply gentian violet aqueous paint 0.5% every 12 hours \nfor 3 days\n\t\n\u0089\nOR apply silver sulphadiazine 1% cream 12 hourly for \n5 days\n\t\n\u0089\nKeep skin clean by frequent washing and drying\n\t\n\u0089\nUse soap and water to soften, and gently remove any \nsuperficial crusts\nSystemic antibacterial: if signs of regional or systemic spread, \ne.g., pyrexia, >5 lesions \n\t\n\u0089\nCloxacillin 250\u2013500 mg every 6 hours before food for \n7 days Child: 12.5\u201325 mg/kg per dose\n\t\n\u0089\nOr in penicillin allergy, erythromycin 250-500 mg every \n6 hours for 7 days Child: 7.5 mg/kg per dose\nHC2\nNote\n\uf077\t\nImpetigo is contagious until the lesions have dried up\n\uf077\t\nIsolate/ separate from other patients \u2013 in case of admission",
        "formatted_content": "<p>975</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Cleaning</p>\n<p>\u0089</p>\n<p>Clean affected area with chlorhexidine solution 0.05%</p>\n<p>Antiseptic: if infection mild and localised (<5 lesions)</p>\n<p>\u0089</p>\n<p>Apply gentian violet aqueous paint 0.5% every 12 hours</p>\n<p>for 3 days</p>\n<p>\u0089</p>\n<p>OR apply silver sulphadiazine 1% cream 12 hourly for</p>\n<p>5 days OR apply Mupirocin(supirocin) 2% 8 hourly for</p>\n<p>5 to 7 days.</p>\n<p>Antiseptic: if infection mild and localised (<5 lesions)</p>\n<p>\u0089</p>\n<p>Apply gentian violet aqueous paint 0.5% every 12 hours</p>\n<p>for 3 days</p>\n<p>\u0089</p>\n<p>OR apply silver sulphadiazine 1% cream 12 hourly for</p>\n<p>5 days</p>\n<p>\u0089</p>\n<p>Keep skin clean by frequent washing and drying</p>\n<p>\u0089</p>\n<p>Use soap and water to soften, and gently remove any</p>\n<p>superficial crusts</p>\n<p>Systemic antibacterial: if signs of regional or systemic spread,</p>\n<p>e.g., pyrexia, >5 lesions</p>\n<p>\u0089</p>\n<p>Cloxacillin 250\u2013500 mg every 6 hours before food for</p>\n<p>7 days Child: 12.5\u201325 mg/kg per dose</p>\n<p>\u0089</p>\n<p>Or in penicillin allergy, erythromycin 250-500 mg every</p>\n<p>6 hours for 7 days Child: 7.5 mg/kg per dose</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>\uf077</p>\n<p>Impetigo is contagious until the lesions have dried up</p>\n<p>\uf077</p>\n<p>Isolate/ separate from other patients \u2013 in case of admission</p>"
    },
    {
        "page_number": 1042,
        "content": "976\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nPrevention\n \n~\nProper hygiene with use of antiseptic soap\n22.1.2 Boils (Furuncle)/Carbuncle\t\n ICD CODE: L02\nA boil or furuncle is a deep-seated infection of the hair follicles with a \nwalled-off collection of pus. A carbuncle is a cluster of interconnected \nfuruncles.\nCause\n \n~\nBacterial infection with Staphylococcus aureus, leading to to the \ncollection of pus\nClinical features\n \n~\nCommon in people with poor general health, diabetes, to or the \ndebilitated\n \n~\nPainful mass, warm, and tender\n \n~\nSwelling becomes fluctuant, may point after 3 days\nDifferential diagnosis\n \n~\nAcne\n \n~\nEpidermal cyst\n \n~\nLipoma\n \n~\nLymphadenitis\nInvestigations\n \n\u0081\nPus swab for Gram staining and C&S\n \n\u0081\nIf recurrent, check for diabetes mellitus and HIV infection",
        "formatted_content": "<p>976</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Proper hygiene with use of antiseptic soap</p>\n<p>22.1.2 Boils (Furuncle)/Carbuncle</p>\n<h3>ICD CODE: L02</h3>\n<p>A boil or furuncle is a deep-seated infection of the hair follicles with a</p>\n<p>walled-off collection of pus. A carbuncle is a cluster of interconnected</p>\n<p>furuncles.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Bacterial infection with Staphylococcus aureus, leading to to the</p>\n<p>collection of pus</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Common in people with poor general health, diabetes, to or the</p>\n<p>debilitated</p>\n<p>~</p>\n<p>Painful mass, warm, and tender</p>\n<p>~</p>\n<p>Swelling becomes fluctuant, may point after 3 days</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Acne</p>\n<p>~</p>\n<p>Epidermal cyst</p>\n<p>~</p>\n<p>Lipoma</p>\n<p>~</p>\n<p>Lymphadenitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pus swab for Gram staining and C&S</p>\n<p>\u0081</p>\n<p>If recurrent, check for diabetes mellitus and HIV infection</p>"
    },
    {
        "page_number": 1043,
        "content": "977\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nIntermittent warm compresses to allow lesion to point\n\t\n\u0089\nIncise and drain when ready (most fluctuant point), then \ncover  with dressing (pack cavity)\nAntibiotics\n\t\n\u0089\nMay be useful if instituted early and in carbuncles, lesions \non face and in immunocompromised patients\n\t\n\u0089\nCloxacillin 250-500 mg every 6 hours before food for \n5 days\n \n- Child: 12.5-25 mg/kg per dose\n\t\n\u0089\nOR in penicillin allergy patients, erythromycin\n\t\n\u0089\n500 mg every 6 hours\n \n- Child: 7.5 mg/kg per dose\nHC2\nPrevention\n \n~\nPersonal hygiene with use of antiseptic soap\n22.1.3\t Cellulitis and Erysipelas\t \t\nICD10 CODE: L03\nCellulitis is an acute inflammation of the skin involving the dermis and \nsubcutaneous tissues, caused mainly by streptococci and staphylococci. \nErysipelas has a raised demarcated border, whereas the border is not \ndistinct in cellulitis.\nCauses\n \n~\nStreptococcus and S. Aureus, in adults\n \n~\nHaemophilus influenza type b in children under 3 years",
        "formatted_content": "<p>977</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Intermittent warm compresses to allow lesion to point</p>\n<p>\u0089</p>\n<p>Incise and drain when ready (most fluctuant point), then</p>\n<p>cover  with dressing (pack cavity)</p>\n<p>Antibiotics</p>\n<p>\u0089</p>\n<p>May be useful if instituted early and in carbuncles, lesions</p>\n<p>on face and in immunocompromised patients</p>\n<p>\u0089</p>\n<p>Cloxacillin 250-500 mg every 6 hours before food for</p>\n<p>5 days</p>\n<p>- Child: 12.5-25 mg/kg per dose</p>\n<p>\u0089</p>\n<p>OR in penicillin allergy patients, erythromycin</p>\n<p>\u0089</p>\n<p>500 mg every 6 hours</p>\n<p>- Child: 7.5 mg/kg per dose</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Personal hygiene with use of antiseptic soap</p>\n<p>22.1.3\t Cellulitis and Erysipelas</p>\n<h3>ICD10 CODE: L03</h3>\n<p>Cellulitis is an acute inflammation of the skin involving the dermis and</p>\n<p>subcutaneous tissues, caused mainly by streptococci and staphylococci.</p>\n<p>Erysipelas has a raised demarcated border, whereas the border is not</p>\n<p>distinct in cellulitis.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Streptococcus and S. Aureus, in adults</p>\n<p>~</p>\n<p>Haemophilus influenza type b in children under 3 years</p>"
    },
    {
        "page_number": 1044,
        "content": "978\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\n \n~\nCellulitis is sometimes caused by other organisms e.g, pseudo\u00ad\nmonas picked from bath tubs to a lesser extent\nPredisposing factors\n \n~\nMinor trauma\n \n~\nPre-existing lesion such as ulcer or erosion\n \n~\nIatrogenic, via intra venous therapy (cannulation) and prolonged \nhospitalization\nClinical features\n \n~\nErythema (reddening)\n \n~\nPain, swelling +/- loss of function, tenderness\n \n~\nAcute localised swelling and oedema\n \n~\nIn erysipelas, lesions are more superficial and have a defined \nraised margin\n \n~\nSkin becomes tense and shiny in advanced stages\n \n~\nRegional lymphadentiis may be present\nDifferential diagnosis\n \n~\nLymphoedema\n \n~\nAcute osteomyelitis\n \n~\nDeep vein thrombosis (DVT)\n \n~\nBlunt trauma/fracture\nInvestigations\n \n\u0081\nPus swab for Gram staining and culture and sensitivity\nNB;  Investigations depend on differential  diagnosis   list, e.g. Xray, \nDoppler, CBC.etc.",
        "formatted_content": "<p>978</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>~</p>\n<p>Cellulitis is sometimes caused by other organisms e.g, pseudo\u00ad</p>\n<p>monas picked from bath tubs to a lesser extent</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>Minor trauma</p>\n<p>~</p>\n<p>Pre-existing lesion such as ulcer or erosion</p>\n<p>~</p>\n<p>Iatrogenic, via intra venous therapy (cannulation) and prolonged</p>\n<p>hospitalization</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Erythema (reddening)</p>\n<p>~</p>\n<p>Pain, swelling +/- loss of function, tenderness</p>\n<p>~</p>\n<p>Acute localised swelling and oedema</p>\n<p>~</p>\n<p>In erysipelas, lesions are more superficial and have a defined</p>\n<p>raised margin</p>\n<p>~</p>\n<p>Skin becomes tense and shiny in advanced stages</p>\n<p>~</p>\n<p>Regional lymphadentiis may be present</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Lymphoedema</p>\n<p>~</p>\n<p>Acute osteomyelitis</p>\n<p>~</p>\n<p>Deep vein thrombosis (DVT)</p>\n<p>~</p>\n<p>Blunt trauma/fracture</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Pus swab for Gram staining and culture and sensitivity</p>\n<p>NB;  Investigations depend on differential  diagnosis   list, e.g. Xray,</p>\n<p>Doppler, CBC.etc.</p>"
    },
    {
        "page_number": 1045,
        "content": "979\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nElevate the affected limb\n\t\n\u0089\nGive an analgesic e.g., paracetamol 1 g every 6-8 hours \nas required, Child: 10 mg/kg\n\t\n\u0089\nAntibiotics: cloxacillin 250-500 mg every 6 hours before \nfood for 7 days\n \n- Child: 12.5-25 mg/kg per dose\n\t\n\u0089\nOR in penicillin allergy, erythromycin 500 mg every 6 \nhours\n \n- Child: 7.5 mg/kg per dose\nIf severe\n\t\n\u0089\nIV ceftriaxone\n \n- Adult: 1 g every 12 hours for 3 days\n \n- Child: 50 mg/kg\n\t\n\u0089\nThen oral antibiotics to complete 1 week of antibiotics\nHC3\n22.2 VIRAL SKIN INFECTIONS\n22.2.1 Herpes Simplex \t \t\n\t\nICD10 CODE: B00\nA viral infection transmitted by direct contact, and characterized by a \nlocalized primary lesion, latency, and recurrence. Lesions can be oral \n{lips, oral mucosae \u2013 (HSV 1)} or genital- (HSV 2).\nCause\n \n~\nHerpes simplex virus types 1 and 2 \nClinical features\nTYPE OF HERPES\nFEATURES\nHerpes simplex: Primary \ninfection\n \n~\nMay be asymptomatic",
        "formatted_content": "<p>979</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Elevate the affected limb</p>\n<p>\u0089</p>\n<p>Give an analgesic e.g., paracetamol 1 g every 6-8 hours</p>\n<p>as required, Child: 10 mg/kg</p>\n<p>\u0089</p>\n<p>Antibiotics: cloxacillin 250-500 mg every 6 hours before</p>\n<p>food for 7 days</p>\n<p>- Child: 12.5-25 mg/kg per dose</p>\n<p>\u0089</p>\n<p>OR in penicillin allergy, erythromycin 500 mg every 6</p>\n<p>hours</p>\n<p>- Child: 7.5 mg/kg per dose</p>\n<p>If severe</p>\n<p>\u0089</p>\n<p>IV ceftriaxone</p>\n<p>- Adult: 1 g every 12 hours for 3 days</p>\n<p>- Child: 50 mg/kg</p>\n<p>\u0089</p>\n<p>Then oral antibiotics to complete 1 week of antibiotics</p>\n<h3>HC3</h3>\n<h3>22.2 VIRAL SKIN INFECTIONS</h3>\n<p>22.2.1 Herpes Simplex</p>\n<h3>ICD10 CODE: B00</h3>\n<p>A viral infection transmitted by direct contact, and characterized by a</p>\n<p>localized primary lesion, latency, and recurrence. Lesions can be oral</p>\n<p>{lips, oral mucosae \u2013 (HSV 1)} or genital- (HSV 2).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Herpes simplex virus types 1 and 2</p>\n<p>Clinical features</p>\n<h3>TYPE OF HERPES</h3>\n<h3>FEATURES</h3>\n<p>Herpes simplex: Primary</p>\n<p>infection</p>\n<p>~</p>\n<p>May be asymptomatic</p>"
    },
    {
        "page_number": 1046,
        "content": "980\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTYPE OF HERPES\nFEATURES\nHerpes simplex: Primary \ninfection\n \n~\nIn some cases, there may be fe\u00ad\nver, malaise, gingivostomatitis, \nand vesicular lesions in the oro\u00ad\npharynx, commonly on lips.\n \n~\nIf genital infection, painful vescic\u00ad\nular eruption in the genital area\n \n~\nMeningoencephalitis and ecze\u00ad\nma herpeticum in patients with \natopic eczema, may be the  com\u00ad\nplications\nHerpes simplex Reactivation \nof primary infection\n \n~\nRecurrent Herpes labialis and \ngenitalis\n \n~\nSevere in the immunosuppressed\nDifferential diagnosis\n \n~\nAphthous ulcer\n \n~\nOther causes of genital sores, e.g., syphilis\n \n~\nOther causes of meningoencephalitis\nInvestigations\n \n\u0081\nNo routine investigation necessary. Diagnosis is clinical\nManagement\nTREATMENT\nLOC\nSymptomatic treatment\n\t\n\u0089\nClean lesions with antiseptic, e.g. chlorhexidine solution \n0.05%\n\t\n\u0089\nOr diluted hydrogen peroxide solution 6% f In severe or \nextensive infection, acyclovir 400 mg every 8 hours by \nmouth for 7 days\n \n- Child: 100-200 mg 5 times a day for 5-7 days\nHC2",
        "formatted_content": "<p>980</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TYPE OF HERPES</h3>\n<h3>FEATURES</h3>\n<p>Herpes simplex: Primary</p>\n<p>infection</p>\n<p>~</p>\n<p>In some cases, there may be fe\u00ad</p>\n<p>ver, malaise, gingivostomatitis,</p>\n<p>and vesicular lesions in the oro\u00ad</p>\n<p>pharynx, commonly on lips.</p>\n<p>~</p>\n<p>If genital infection, painful vescic\u00ad</p>\n<p>ular eruption in the genital area</p>\n<p>~</p>\n<p>Meningoencephalitis and ecze\u00ad</p>\n<p>ma herpeticum in patients with</p>\n<p>atopic eczema, may be the  com\u00ad</p>\n<p>plications</p>\n<p>Herpes simplex Reactivation</p>\n<p>of primary infection</p>\n<p>~</p>\n<p>Recurrent Herpes labialis and</p>\n<p>genitalis</p>\n<p>~</p>\n<p>Severe in the immunosuppressed</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Aphthous ulcer</p>\n<p>~</p>\n<p>Other causes of genital sores, e.g., syphilis</p>\n<p>~</p>\n<p>Other causes of meningoencephalitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>No routine investigation necessary. Diagnosis is clinical</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Symptomatic treatment</p>\n<p>\u0089</p>\n<p>Clean lesions with antiseptic, e.g. chlorhexidine solution</p>\n<p>0.05%</p>\n<p>\u0089</p>\n<p>Or diluted hydrogen peroxide solution 6% f In severe or</p>\n<p>extensive infection, acyclovir 400 mg every 8 hours by</p>\n<p>mouth for 7 days</p>\n<p>- Child: 100-200 mg 5 times a day for 5-7 days</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1047,
        "content": "981\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\nNote\n\uf077\t\nAcyclovir only works if it is started within 48 hours of the first \nsymptoms\nPrevention\nProvide health education on\n \n~\nPersonal hygiene\n \n~\nAvoiding direct contact with infected people\n \n~\nUse of gloves and condoms as applicable\n22.2.2 Herpes Zoster (Shingles)\t ICD10 CODE: B02\nAn acute cutaneous infection involving primarily the dorsal root ganglia, \nusually of a single dermatome. It is characterised by a vesicular eruption \nin areas supplied by peripheral sensory nerves in the affected root ganglia.\nCause\n\t\n\u0089\nVaricella zoster virus, usually reactivated from the virus that entered \nthe cutaneous nerves during an earlier episode of chicken pox and \nremained in a latent form. This usually occurs during low immunity.\n \n- For chickenpox, see section 2.3.2\nClinical features\n \n~\nPre-eruptive pain, itching or burning: generally localized to the \ndermatome, precedes the eruption by 4-5 days\n \n~\nThe above are followed by characteristic crops of very painful \nvesicles on the side supplied by affected nerve\n \n~\nMild chills, fever, malaise\nDifferential diagnosis\n \n~\nChicken pox\n \n~\nHerpes simplex",
        "formatted_content": "<p>981</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Note</p>\n<p>\uf077</p>\n<p>Acyclovir only works if it is started within 48 hours of the first</p>\n<p>symptoms</p>\n<p>Prevention</p>\n<p>Provide health education on</p>\n<p>~</p>\n<p>Personal hygiene</p>\n<p>~</p>\n<p>Avoiding direct contact with infected people</p>\n<p>~</p>\n<p>Use of gloves and condoms as applicable</p>\n<p>22.2.2 Herpes Zoster (Shingles)\t ICD10 CODE: B02</p>\n<p>An acute cutaneous infection involving primarily the dorsal root ganglia,</p>\n<p>usually of a single dermatome. It is characterised by a vesicular eruption</p>\n<p>in areas supplied by peripheral sensory nerves in the affected root ganglia.</p>\n<p>Cause</p>\n<p>\u0089</p>\n<p>Varicella zoster virus, usually reactivated from the virus that entered</p>\n<p>the cutaneous nerves during an earlier episode of chicken pox and</p>\n<p>remained in a latent form. This usually occurs during low immunity.</p>\n<p>- For chickenpox, see section 2.3.2</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pre-eruptive pain, itching or burning: generally localized to the</p>\n<p>dermatome, precedes the eruption by 4-5 days</p>\n<p>~</p>\n<p>The above are followed by characteristic crops of very painful</p>\n<p>vesicles on the side supplied by affected nerve</p>\n<p>~</p>\n<p>Mild chills, fever, malaise</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Chicken pox</p>\n<p>~</p>\n<p>Herpes simplex</p>"
    },
    {
        "page_number": 1048,
        "content": "982\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nInvestigations\n \n\u0081\nClinical diagnosis is sufficient\n \n\u0081\nSerology test for HIV, if sero-status not known\nManagement\nTREATMENT\nLOC\nSymptomatic and supportive treatment\n\t\n\u0089\nClean lesions with antiseptic, e.g. chlorhexidine solution \n0.05%\n\t\n\u0089\nOr diluted hydrogen peroxide solution 6% \n\t\n\u0089\nApply calamine lotion 2\u20133 times daily \n\t\n\u0089\nAnalgesics for neuropathic pain e.g. amitriptyline 25 mg \nnocte, or carbamazepine 200 mg nocte as necessary\n\t\n\u0089\nOral aciclovir 800 mg 5 times a day for 7 days can be \ngiven, especially if the disease is diagnosed very early or \nis disseminated\nIf the lesions involve the eye\n\t\n\u0089\nRefer to an ophthalmologist (Eye Specialist)\nHC2\nPrevention\n \n~\nProtect high-risk individuals (e.g., the immuno-suppressed) from \ndirect contact with the disease\n22.3 FUNGAL SKIN INFECTIONS\n22.3.1 Tineas\t\n\t\nICD10 CODE: B35\nSuperficial infection caused by dermatophytes or malassetia fungi, which \ninvade dead tissue of the skin and its appendages (stratum corneum, \nnails and hair). They are not very infectious but are usually recurrent. \nCommon in children, 4 \u2013 14 years of age",
        "formatted_content": "<p>982</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Clinical diagnosis is sufficient</p>\n<p>\u0081</p>\n<p>Serology test for HIV, if sero-status not known</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Symptomatic and supportive treatment</p>\n<p>\u0089</p>\n<p>Clean lesions with antiseptic, e.g. chlorhexidine solution</p>\n<p>0.05%</p>\n<p>\u0089</p>\n<p>Or diluted hydrogen peroxide solution 6%</p>\n<p>\u0089</p>\n<p>Apply calamine lotion 2\u20133 times daily</p>\n<p>\u0089</p>\n<p>Analgesics for neuropathic pain e.g. amitriptyline 25 mg</p>\n<p>nocte, or carbamazepine 200 mg nocte as necessary</p>\n<p>\u0089</p>\n<p>Oral aciclovir 800 mg 5 times a day for 7 days can be</p>\n<p>given, especially if the disease is diagnosed very early or</p>\n<p>is disseminated</p>\n<p>If the lesions involve the eye</p>\n<p>\u0089</p>\n<p>Refer to an ophthalmologist (Eye Specialist)</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Protect high-risk individuals (e.g., the immuno-suppressed) from</p>\n<p>direct contact with the disease</p>\n<h3>22.3 FUNGAL SKIN INFECTIONS</h3>\n<p>22.3.1 Tineas</p>\n<h3>ICD10 CODE: B35</h3>\n<p>Superficial infection caused by dermatophytes or malassetia fungi, which</p>\n<p>invade dead tissue of the skin and its appendages (stratum corneum,</p>\n<p>nails and hair). They are not very infectious but are usually recurrent.</p>\n<p>Common in children, 4 \u2013 14 years of age</p>"
    },
    {
        "page_number": 1049,
        "content": "983\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nCauses\n \n~\nMicrosporum canis- from animal to human (commonest cause \nworldwide) or T. rubrum\nClinical features\n \n~\nFeatures (and name of the infection) depend on the body part \naffected as in table below:\nBody Part \nAffected\nFEATURES\nTinea capitis\n \n~\nAlopecia, scaly patches with hairs broken \noff when very short\n \n~\nThe lesion may sometimes be inflamed \nwith multiple pustules-Kerion, (pockets of \npus)\n \n~\nEspecially in children (4- 14 years and im\u00ad\nmuno-suppressed\nTinea corporis \n(ringworm)\n \n~\nSingle or multiple plaques on hairless skin \nexcept, palm, sole and groin, especially \nthe face,  trunk or limbs.\n \n~\nWell-demarcated, scaly and raised border \nwith a relatively clear centre\n \n~\nPruritus\nTinea (or pityriasis) \nversicolor\n \n~\nA chronic yeast infection caused by malas\u00ad\nsezia fur fur- a normal flora.\n \n~\nWell-defined round/oval patches on the \nchest, upper back, face and arms.\n \n~\nNot scaly, but peels off when scratched\n \n~\nRare in children, onset usually around pu\u00ad\nberty.",
        "formatted_content": "<p>983</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Causes</p>\n<p>~</p>\n<p>Microsporum canis- from animal to human (commonest cause</p>\n<p>worldwide) or T. rubrum</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Features (and name of the infection) depend on the body part</p>\n<p>affected as in table below:</p>\n<p>Body Part</p>\n<p>Affected</p>\n<h3>FEATURES</h3>\n<p>Tinea capitis</p>\n<p>~</p>\n<p>Alopecia, scaly patches with hairs broken</p>\n<p>off when very short</p>\n<p>~</p>\n<p>The lesion may sometimes be inflamed</p>\n<p>with multiple pustules-Kerion, (pockets of</p>\n<p>pus)</p>\n<p>~</p>\n<p>Especially in children (4- 14 years and im\u00ad</p>\n<p>muno-suppressed</p>\n<p>Tinea corporis</p>\n<p>(ringworm)</p>\n<p>~</p>\n<p>Single or multiple plaques on hairless skin</p>\n<p>except, palm, sole and groin, especially</p>\n<p>the face,  trunk or limbs.</p>\n<p>~</p>\n<p>Well-demarcated, scaly and raised border</p>\n<p>with a relatively clear centre</p>\n<p>~</p>\n<p>Pruritus</p>\n<p>Tinea (or pityriasis)</p>\n<p>versicolor</p>\n<p>~</p>\n<p>A chronic yeast infection caused by malas\u00ad</p>\n<p>sezia fur fur- a normal flora.</p>\n<p>~</p>\n<p>Well-defined round/oval patches on the</p>\n<p>chest, upper back, face and arms.</p>\n<p>~</p>\n<p>Not scaly, but peels off when scratched</p>\n<p>~</p>\n<p>Rare in children, onset usually around pu\u00ad</p>\n<p>berty.</p>"
    },
    {
        "page_number": 1050,
        "content": "984\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nBody Part \nAffected\nFEATURES\nTinea (or pityriasis) \nversicolor\n \n~\nTreatment; topical application or sham\u00ad\npoo; \nketoconazole, \nclotrimazole, \nmi\u00ad\nconazole. In severe form, parental applica\u00ad\ntion may be used.\n \n~\nNB: griseofulvin SHOULD not be used \ncause p. versicolor is an yeast infection \u2013 \nnot by dermatophyte hence not effective.\nNails (Onycho- my\u00ad\ncosis)\n \n~\nThickened, discolored nails; can be white, \nyellow, green, or black\n \n~\nBrittle nails that break easily\nTinea capitis\n \n~\nBald, scaly patches with hairs broken off \nwhen very short\n \n~\nThe lesion may sometimes be inflamed \nwith multiple pustules (pockets of pus)\n \n~\nEspecially in children and  mmune- sup\u00ad\npressed\nTinea corporis \n(ringworm)\n \n~\nSingle or multiple plaques on the face, \ntrunk or limbs\n \n~\nWell demarcated, scaly and raised border \nwith relatively clear centre\n \n~\nPruritus\nTinea (or pityriasis) \nversicolor\n \n~\nA chronic fungal infection of large areas \nof skin\n \n~\nWell-defined round/oval patches\n \n~\nPale or discolored spots on the skin, e.g., \nchest, back, face\n \n~\nNot scaly, but peels off when scratched\n \n~\nRare in children, onset usually around pu\u00ad\nberty",
        "formatted_content": "<p>984</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Body Part</p>\n<p>Affected</p>\n<h3>FEATURES</h3>\n<p>Tinea (or pityriasis)</p>\n<p>versicolor</p>\n<p>~</p>\n<p>Treatment; topical application or sham\u00ad</p>\n<p>poo;</p>\n<p>ketoconazole,</p>\n<p>clotrimazole,</p>\n<p>mi\u00ad</p>\n<p>conazole. In severe form, parental applica\u00ad</p>\n<p>tion may be used.</p>\n<p>~</p>\n<p>NB: griseofulvin SHOULD not be used</p>\n<p>cause p. versicolor is an yeast infection \u2013</p>\n<p>not by dermatophyte hence not effective.</p>\n<p>Nails (Onycho- my\u00ad</p>\n<p>cosis)</p>\n<p>~</p>\n<p>Thickened, discolored nails; can be white,</p>\n<p>yellow, green, or black</p>\n<p>~</p>\n<p>Brittle nails that break easily</p>\n<p>Tinea capitis</p>\n<p>~</p>\n<p>Bald, scaly patches with hairs broken off</p>\n<p>when very short</p>\n<p>~</p>\n<p>The lesion may sometimes be inflamed</p>\n<p>with multiple pustules (pockets of pus)</p>\n<p>~</p>\n<p>Especially in children and  mmune- sup\u00ad</p>\n<p>pressed</p>\n<p>Tinea corporis</p>\n<p>(ringworm)</p>\n<p>~</p>\n<p>Single or multiple plaques on the face,</p>\n<p>trunk or limbs</p>\n<p>~</p>\n<p>Well demarcated, scaly and raised border</p>\n<p>with relatively clear centre</p>\n<p>~</p>\n<p>Pruritus</p>\n<p>Tinea (or pityriasis)</p>\n<p>versicolor</p>\n<p>~</p>\n<p>A chronic fungal infection of large areas</p>\n<p>of skin</p>\n<p>~</p>\n<p>Well-defined round/oval patches</p>\n<p>~</p>\n<p>Pale or discolored spots on the skin, e.g.,</p>\n<p>chest, back, face</p>\n<p>~</p>\n<p>Not scaly, but peels off when scratched</p>\n<p>~</p>\n<p>Rare in children, onset usually around pu\u00ad</p>\n<p>berty</p>"
    },
    {
        "page_number": 1051,
        "content": "985\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nBody Part \nAffected\nFEATURES\nNails (Onycho- my\u00ad\ncosis)\n \n~\nThickened, discolored nails, can be white, \nyellow, green, or black\n \n~\nBrittle nails that break easily\nTinea pedis (Ath\u00ad\nletes foot)\n \n~\nWhite scaling usually between the 4th and \n5th toes or between the 3rd and 4th toes \non one foot only\n \n~\nScales, vesicles, cracks, erosion\n \n~\nBurning or itching between toes and  un\u00ad\nder foot especially when shoes and socks \nare removed\n \n~\nMay be secondary bacterial infection\nDifferential diagnosis\n \n~\nSeborrhoeic dermatitis, eczema, contact dermatitis\n \n~\nAlopecia areata\n \n~\nJiggers, hookworm, candida\n \n~\nCellulitis, psoriasis\n \n~\nMaceration from tight footwear\nInvestigations\n \n\u0081\nScales from the active edge of the lesions are scraped off, placed \nin 10-20% potassium hydroxide (KOH) for 30 minutes, and \nexamined microscopically for mycelia\n \n\u0081\nCulture of specimen on Sabouraud\u2019s agar\nManagement\nTREATMENT\nLOC\nTinea capitis",
        "formatted_content": "<p>985</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Body Part</p>\n<p>Affected</p>\n<h3>FEATURES</h3>\n<p>Nails (Onycho- my\u00ad</p>\n<p>cosis)</p>\n<p>~</p>\n<p>Thickened, discolored nails, can be white,</p>\n<p>yellow, green, or black</p>\n<p>~</p>\n<p>Brittle nails that break easily</p>\n<p>Tinea pedis (Ath\u00ad</p>\n<p>letes foot)</p>\n<p>~</p>\n<p>White scaling usually between the 4th and</p>\n<p>5th toes or between the 3rd and 4th toes</p>\n<p>on one foot only</p>\n<p>~</p>\n<p>Scales, vesicles, cracks, erosion</p>\n<p>~</p>\n<p>Burning or itching between toes and  un\u00ad</p>\n<p>der foot especially when shoes and socks</p>\n<p>are removed</p>\n<p>~</p>\n<p>May be secondary bacterial infection</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Seborrhoeic dermatitis, eczema, contact dermatitis</p>\n<p>~</p>\n<p>Alopecia areata</p>\n<p>~</p>\n<p>Jiggers, hookworm, candida</p>\n<p>~</p>\n<p>Cellulitis, psoriasis</p>\n<p>~</p>\n<p>Maceration from tight footwear</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Scales from the active edge of the lesions are scraped off, placed</p>\n<p>in 10-20% potassium hydroxide (KOH) for 30 minutes, and</p>\n<p>examined microscopically for mycelia</p>\n<p>\u0081</p>\n<p>Culture of specimen on Sabouraud\u2019s agar</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Tinea capitis</p>"
    },
    {
        "page_number": 1052,
        "content": "986\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n\t\n\u0089\nOral griseofulvin 10 mg/kg /day as single dose once \ndaily after meals for 6 weeks\n\t\n\u0089\nDo NOT treat with topical antifungal agents; they cannot \nget to the site of infection\nTinea corporis (ringworm)\n\t\n\u0089\nApply Whitfield\u2019s ointment (benzoic acid + salicylic acid) \n12 hourly until 2 weeks after lesions clear\n\t\n\u0089\nClotrimazole 1% cream twice a day\n\t\n\u0089\nOr miconazole 2% cream 12 hourly for 2-3 weeks\nIf topical treatment fails\n\t\n\u0089\nGriseofulvin 10 mg/kg for 3 weeks\nHC2\nHC2\nHC3\nHC3\nPityriasis versicolor\n\t\n\u0089\nApply clotrimazole cream 12 hourly until lesions disappear\n\t\n\u0089\nOr miconazole 2% cream 12 hourly for 2-3 weeks\nIf topical treatment fails\n\t\n\u0089\nFluconazole 300 mg once weekly for 2 weeks\nNB; Griseofulvin should not be used\nHC3\nNails (Onychomycosis)\n\t\n\u0089\nOral griseofulvin 10 mg/kg per day as single dose once \ndaily after meals for 6-12 months\nTinea pedis (Athletes foot)\n\t\n\u0089\nApply clotrimazole cream 12 hourly, continue for 14 \ndays after the lesions have healed\n\t\n\u0089\nOr miconazole cream as above\n\t\n\u0089\nApply powder (not necessarily medicated) to the feet \nrather than to the shoes\nHC3",
        "formatted_content": "<p>986</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Oral griseofulvin 10 mg/kg /day as single dose once</p>\n<p>daily after meals for 6 weeks</p>\n<p>\u0089</p>\n<p>Do NOT treat with topical antifungal agents; they cannot</p>\n<p>get to the site of infection</p>\n<p>Tinea corporis (ringworm)</p>\n<p>\u0089</p>\n<p>Apply Whitfield\u2019s ointment (benzoic acid + salicylic acid)</p>\n<p>12 hourly until 2 weeks after lesions clear</p>\n<p>\u0089</p>\n<p>Clotrimazole 1% cream twice a day</p>\n<p>\u0089</p>\n<p>Or miconazole 2% cream 12 hourly for 2-3 weeks</p>\n<p>If topical treatment fails</p>\n<p>\u0089</p>\n<p>Griseofulvin 10 mg/kg for 3 weeks</p>\n<h3>HC2</h3>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<h3>HC3</h3>\n<p>Pityriasis versicolor</p>\n<p>\u0089</p>\n<p>Apply clotrimazole cream 12 hourly until lesions disappear</p>\n<p>\u0089</p>\n<p>Or miconazole 2% cream 12 hourly for 2-3 weeks</p>\n<p>If topical treatment fails</p>\n<p>\u0089</p>\n<p>Fluconazole 300 mg once weekly for 2 weeks</p>\n<p>NB; Griseofulvin should not be used</p>\n<h3>HC3</h3>\n<p>Nails (Onychomycosis)</p>\n<p>\u0089</p>\n<p>Oral griseofulvin 10 mg/kg per day as single dose once</p>\n<p>daily after meals for 6-12 months</p>\n<p>Tinea pedis (Athletes foot)</p>\n<p>\u0089</p>\n<p>Apply clotrimazole cream 12 hourly, continue for 14</p>\n<p>days after the lesions have healed</p>\n<p>\u0089</p>\n<p>Or miconazole cream as above</p>\n<p>\u0089</p>\n<p>Apply powder (not necessarily medicated) to the feet</p>\n<p>rather than to the shoes</p>\n<h3>HC3</h3>"
    },
    {
        "page_number": 1053,
        "content": "987\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n\t\n\u0089\nFor persistent or non-responsive infection, oral griseoful\u00ad\nvin 10 mg/kg /day as single dose once daily after meals \nfor 4-8 weeks\nHC3\nNote on griseofulvin\n\uf077\t\nDouble the dose in severe infections\n\uf077\t\nTake with fatty food\n\uf077\t\nDo NOT use for tinea versicolor (pityriasis)\n\uf077\t\nAdvise female patient to not get pregnant while on treatment\n\uf077\t\nMen should avoid fathering children while on treatment\nPrevention and health education\n \n~\nClean all contaminated objects, e.g., combs, brushes\n \n~\nAvoid sharing contaminated combs, towels, clothes, etc.\n \n~\nAdvise patient on the need to persist with the long durations of \ntreatment to completely clear infection\n \n~\nPersonal foot hygiene is important. Keep feet clean and dry. \nWash socks  daily\n \n~\nIf patient has repeat fungal infections, refer him/her for   HIV, \ndiabetes counselling and testing.\n22.4 PARASITIC SKIN INFECTIONS\n22.4.1 Scabies\t\n\t\nICD10 CODE: B86\nContagious skin disease associated with severe itch\nCause\n \n~\nA parasitic mite, Sarcopterus scabiei hominis\n \n~\nTransmitted by direct skin contact with infected person",
        "formatted_content": "<p>987</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>For persistent or non-responsive infection, oral griseoful\u00ad</p>\n<p>vin 10 mg/kg /day as single dose once daily after meals</p>\n<p>for 4-8 weeks</p>\n<h3>HC3</h3>\n<p>Note on griseofulvin</p>\n<p>\uf077</p>\n<p>Double the dose in severe infections</p>\n<p>\uf077</p>\n<p>Take with fatty food</p>\n<p>\uf077</p>\n<p>Do NOT use for tinea versicolor (pityriasis)</p>\n<p>\uf077</p>\n<p>Advise female patient to not get pregnant while on treatment</p>\n<p>\uf077</p>\n<p>Men should avoid fathering children while on treatment</p>\n<p>Prevention and health education</p>\n<p>~</p>\n<p>Clean all contaminated objects, e.g., combs, brushes</p>\n<p>~</p>\n<p>Avoid sharing contaminated combs, towels, clothes, etc.</p>\n<p>~</p>\n<p>Advise patient on the need to persist with the long durations of</p>\n<p>treatment to completely clear infection</p>\n<p>~</p>\n<p>Personal foot hygiene is important. Keep feet clean and dry.</p>\n<p>Wash socks  daily</p>\n<p>~</p>\n<p>If patient has repeat fungal infections, refer him/her for   HIV,</p>\n<p>diabetes counselling and testing.</p>\n<h3>22.4 PARASITIC SKIN INFECTIONS</h3>\n<p>22.4.1 Scabies</p>\n<h3>ICD10 CODE: B86</h3>\n<p>Contagious skin disease associated with severe itch</p>\n<p>Cause</p>\n<p>~</p>\n<p>A parasitic mite, Sarcopterus scabiei hominis</p>\n<p>~</p>\n<p>Transmitted by direct skin contact with infected person</p>"
    },
    {
        "page_number": 1054,
        "content": "988\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nClinical features\n \n~\nIntense itching, especially at night\n \n~\nWheals, papules, vesicles, and thread-like burrows\n\t\n\u0089\nCommon in flexural areas, i.e., wrists and inter-digital creases, \naxillae, nipples, buttocks, and genitalia\n \n~\nScratching spreads mites to other areas leading to widespread, \nintensely pruritic eruption\n \n~\nSecondary infection is common\nDifferential diagnosis\n \n~\nPapular urticaria, atopic or seborrhoeic dermatitis\n \n~\nDrug eruptions\n \n~\nOnchocerciasis\n \n~\nContact dermatitis\nInvestigations\n \n\u0081\nMicroscopic identification of mites - diagnosis is largely clinical, \ntheir eggs or faeces obtained from the vesicles or mite burrows.\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nClose contacts and all family members in the house\u00ad\nhold-symptomatic and asymptomatic, should be treated\n\t\n\u0089\nWash with hot water and iron all linen which has touched \nthe infected skin\nHC2\nMedicine treatment\n\t\n\u0089\nWash (scrub) the body well",
        "formatted_content": "<p>988</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Intense itching, especially at night</p>\n<p>~</p>\n<p>Wheals, papules, vesicles, and thread-like burrows</p>\n<p>\u0089</p>\n<p>Common in flexural areas, i.e., wrists and inter-digital creases,</p>\n<p>axillae, nipples, buttocks, and genitalia</p>\n<p>~</p>\n<p>Scratching spreads mites to other areas leading to widespread,</p>\n<p>intensely pruritic eruption</p>\n<p>~</p>\n<p>Secondary infection is common</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Papular urticaria, atopic or seborrhoeic dermatitis</p>\n<p>~</p>\n<p>Drug eruptions</p>\n<p>~</p>\n<p>Onchocerciasis</p>\n<p>~</p>\n<p>Contact dermatitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Microscopic identification of mites - diagnosis is largely clinical,</p>\n<p>their eggs or faeces obtained from the vesicles or mite burrows.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Close contacts and all family members in the house\u00ad</p>\n<p>hold-symptomatic and asymptomatic, should be treated</p>\n<p>\u0089</p>\n<p>Wash with hot water and iron all linen which has touched</p>\n<p>the infected skin</p>\n<h3>HC2</h3>\n<p>Medicine treatment</p>\n<p>\u0089</p>\n<p>Wash (scrub) the body well</p>"
    },
    {
        "page_number": 1055,
        "content": "989\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n\t\n\u0089\nApply benzyl benzoate lotion 25% to the whole body from \nthe scalp to the soles of the feet but taking care to avoid \ncontact with the eyes.  apply at bed time and wash off in \nthe morning. Repeat 2 times except in pregnant women\n\t\n\u0089\nGive an antihistamine to relieve itching: tablet chorphe\u00ad\nniramine 4 mg every 8 hours for 3 days\n \n- Child: 1- 2 mg per dose\n \n- Cetirizine 10mg at bed time for 5 \u2013 7 days-in \nAdults.\nIf treatment ineffective or unsuitable\n\t\n\u0089\nIvermectin 200 micrograms single dose (avoid in preg\u00ad\nnancy, and in children <15 kg or belosw 12 years)\n\t\n\u0089\nFor complete eradication of mites, repeat the dose after \n7 days\nIf secondary infection is present\n\t\n\u0089\nGive an antibiotic as in boils (see section 22.1.2)\nHC2\nHC3\nPrevention\n \n~\nPersonal hygiene (washing clothes and regular bathing)\n \n~\nAvoid close contact with infected people\n22.4.2 Pediculosis/Lice\t \t\n\t\nICD10 CODE: B85\nInfestation by lice, usually in the hairy parts of the body. Usually found \non the scalp, armpits, chest or pubic area.\nCause\n \n~\nPediculosis humanus (capitis, corporis, pubis)\n \n~\nUsually transmitted directly by person-to-person contact but may \nalso be transmitted indirectly via the clothing, towels, and bed\u00ad\nding of infested persons",
        "formatted_content": "<p>989</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Apply benzyl benzoate lotion 25% to the whole body from</p>\n<p>the scalp to the soles of the feet but taking care to avoid</p>\n<p>contact with the eyes.  apply at bed time and wash off in</p>\n<p>the morning. Repeat 2 times except in pregnant women</p>\n<p>\u0089</p>\n<p>Give an antihistamine to relieve itching: tablet chorphe\u00ad</p>\n<p>niramine 4 mg every 8 hours for 3 days</p>\n<p>- Child: 1- 2 mg per dose</p>\n<p>- Cetirizine 10mg at bed time for 5 \u2013 7 days-in</p>\n<p>Adults.</p>\n<p>If treatment ineffective or unsuitable</p>\n<p>\u0089</p>\n<p>Ivermectin 200 micrograms single dose (avoid in preg\u00ad</p>\n<p>nancy, and in children <15 kg or belosw 12 years)</p>\n<p>\u0089</p>\n<p>For complete eradication of mites, repeat the dose after</p>\n<p>7 days</p>\n<p>If secondary infection is present</p>\n<p>\u0089</p>\n<p>Give an antibiotic as in boils (see section 22.1.2)</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Personal hygiene (washing clothes and regular bathing)</p>\n<p>~</p>\n<p>Avoid close contact with infected people</p>\n<p>22.4.2 Pediculosis/Lice</p>\n<h3>ICD10 CODE: B85</h3>\n<p>Infestation by lice, usually in the hairy parts of the body. Usually found</p>\n<p>on the scalp, armpits, chest or pubic area.</p>\n<p>Cause</p>\n<p>~</p>\n<p>Pediculosis humanus (capitis, corporis, pubis)</p>\n<p>~</p>\n<p>Usually transmitted directly by person-to-person contact but may</p>\n<p>also be transmitted indirectly via the clothing, towels, and bed\u00ad</p>\n<p>ding of infested persons</p>"
    },
    {
        "page_number": 1056,
        "content": "990\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nClinical features\n \n~\nSevere itching of affected areas, scratch marks\n \n~\nNits (white eggs) attached to hairs\n \n~\nDirect observation of lice\n \n~\nContinued scratching may lead to secondary bacterial infection \nand eczemas\n \n~\nDifferential diagnosis\n \n~\nSeborrhoeic dermatitis\nInvestigations\n \n\u0081\nDirect observation of lice/nits\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nShave the affected area\n\t\n\u0089\nApply pediculocide to kill lice\n \n- Apply benzyl benzoate lotion 25% and leave on \novernight\n \n- Child 2-12 years: dilute the lotion with an equal \npart of water before application\n \n- Child <2 years: dilute 1 part of lotion with 3 parts \nof water, leave on for 12 hours. Apply ONLY once\n \n- Comb with a fine toothed comb if not shaved\nHC2\nNote\nHead lice\n\uf077\t\nDo not use undiluted Benxyl Benzoate A in children <2 years. It \nis very irritating to the eyes\n\uf077\t\nIf the head is not shaved, ensure that the BBA is massaged well \ninto the scalp\n\uf077\t\nSoak all brushes and combs in BBA for at least 2 hours",
        "formatted_content": "<p>990</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Severe itching of affected areas, scratch marks</p>\n<p>~</p>\n<p>Nits (white eggs) attached to hairs</p>\n<p>~</p>\n<p>Direct observation of lice</p>\n<p>~</p>\n<p>Continued scratching may lead to secondary bacterial infection</p>\n<p>and eczemas</p>\n<p>~</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Seborrhoeic dermatitis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Direct observation of lice/nits</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Shave the affected area</p>\n<p>\u0089</p>\n<p>Apply pediculocide to kill lice</p>\n<p>- Apply benzyl benzoate lotion 25% and leave on</p>\n<p>overnight</p>\n<p>- Child 2-12 years: dilute the lotion with an equal</p>\n<p>part of water before application</p>\n<p>- Child <2 years: dilute 1 part of lotion with 3 parts</p>\n<p>of water, leave on for 12 hours. Apply ONLY once</p>\n<p>- Comb with a fine toothed comb if not shaved</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>Head lice</p>\n<p>\uf077</p>\n<p>Do not use undiluted Benxyl Benzoate A in children <2 years. It</p>\n<p>is very irritating to the eyes</p>\n<p>\uf077</p>\n<p>If the head is not shaved, ensure that the BBA is massaged well</p>\n<p>into the scalp</p>\n<p>\uf077</p>\n<p>Soak all brushes and combs in BBA for at least 2 hours</p>"
    },
    {
        "page_number": 1057,
        "content": "991\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\nPubic lice\n\uf077\t\nTreat all sexual partners at the same time\nPrevention\n \n~\nPersonal hygiene (washing clothes and regular bathing)\n \n~\nAvoid close contact with infected people\n \n~\nTreat the whole family\n \n~\nAvoid sharing combs, towels, etc\n22.4.3 Tungiasis (Jiggers)\t\n\t\nICD10 CODE: B88.1\nAn infestation by the burrowing flea Tunga penetrans. Commonly affects \nthe feet, hands, elbows, and sometimes buttocks.\nCause\n \n~\nA burrowing sand flea, Tunga penetrans\nRisk factors\n \n~\nTravel to areas with T. penetrans\n \n~\nWalking bare feet\n \n~\nLiving in same house with domestic animals such as pigs, dogs \nand rodents like rats\nClinical features\n \n~\nPunctum or ulceration, often described as a white patch with a \nblack dot on affected area\n \n~\nThere may be redness and swelling around affected site\n \n~\nA serosanguineous exudate may ooze from the central opening, \nand eggs may be seen with the naked eye\n \n~\nLesions can be painful and very itchy",
        "formatted_content": "<p>991</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Pubic lice</p>\n<p>\uf077</p>\n<p>Treat all sexual partners at the same time</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Personal hygiene (washing clothes and regular bathing)</p>\n<p>~</p>\n<p>Avoid close contact with infected people</p>\n<p>~</p>\n<p>Treat the whole family</p>\n<p>~</p>\n<p>Avoid sharing combs, towels, etc</p>\n<p>22.4.3 Tungiasis (Jiggers)</p>\n<h3>ICD10 CODE: B88.1</h3>\n<p>An infestation by the burrowing flea Tunga penetrans. Commonly affects</p>\n<p>the feet, hands, elbows, and sometimes buttocks.</p>\n<p>Cause</p>\n<p>~</p>\n<p>A burrowing sand flea, Tunga penetrans</p>\n<p>Risk factors</p>\n<p>~</p>\n<p>Travel to areas with T. penetrans</p>\n<p>~</p>\n<p>Walking bare feet</p>\n<p>~</p>\n<p>Living in same house with domestic animals such as pigs, dogs</p>\n<p>and rodents like rats</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Punctum or ulceration, often described as a white patch with a</p>\n<p>black dot on affected area</p>\n<p>~</p>\n<p>There may be redness and swelling around affected site</p>\n<p>~</p>\n<p>A serosanguineous exudate may ooze from the central opening,</p>\n<p>and eggs may be seen with the naked eye</p>\n<p>~</p>\n<p>Lesions can be painful and very itchy</p>"
    },
    {
        "page_number": 1058,
        "content": "992\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nComplications\n \n~\nTissue necrosis, suppuration, gangrene\n \n~\nDisability, disfigurement\nDifferential diagnosis\n \n~\nCercarial dermatitis, scabies\n \n~\nCreeping eruption (ancylostoma species)\n \n~\nTick or flea bite, myiasis\nInvestigations\n \n~\nClinical features are diagnostic\nManagement\nTREATMENT\nLOC\nSelf-healing\n\t\n\u0089\nIn many cases  tungiasis will heal on its  own  as the \nburrowed flea dies within 2\u20135 weeks, and naturally \nsloughs off as the skin sheds\nSurgical removal\n\t\n\u0089\nPhysical removal of the flea using sterile forceps, or \nneedles, or safety pins\nMedicine treatment and suffocation of flea Apply Dimethicone \noil for treatment of tungiasis\n\t\n\u0089\nWash the feet or the affected part of the body thoroughly \nwith soap\n\t\n\u0089\nLet the feet or body part dry\n\t\n\u0089\nApply a few drops on the black dot of the identified jiggers\n\t\n\u0089\nRepeat after 10 minutes\nHC2",
        "formatted_content": "<p>992</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Complications</p>\n<p>~</p>\n<p>Tissue necrosis, suppuration, gangrene</p>\n<p>~</p>\n<p>Disability, disfigurement</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Cercarial dermatitis, scabies</p>\n<p>~</p>\n<p>Creeping eruption (ancylostoma species)</p>\n<p>~</p>\n<p>Tick or flea bite, myiasis</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Clinical features are diagnostic</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Self-healing</p>\n<p>\u0089</p>\n<p>In many cases  tungiasis will heal on its  own  as the</p>\n<p>burrowed flea dies within 2\u20135 weeks, and naturally</p>\n<p>sloughs off as the skin sheds</p>\n<p>Surgical removal</p>\n<p>\u0089</p>\n<p>Physical removal of the flea using sterile forceps, or</p>\n<p>needles, or safety pins</p>\n<p>Medicine treatment and suffocation of flea Apply Dimethicone</p>\n<p>oil for treatment of tungiasis</p>\n<p>\u0089</p>\n<p>Wash the feet or the affected part of the body thoroughly</p>\n<p>with soap</p>\n<p>\u0089</p>\n<p>Let the feet or body part dry</p>\n<p>\u0089</p>\n<p>Apply a few drops on the black dot of the identified jiggers</p>\n<p>\u0089</p>\n<p>Repeat after 10 minutes</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1059,
        "content": "993\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n\t\n\u0089\nFor severe cases you may require to rubrubbing the oil \ninto the crevises\n\t\n\u0089\nA single treatment as above is enough but can be repeated \nafter two weeks in situations of severe infestation\nPrecautions\n\t\n\u0089\nAvoid contact with eyes. In case of contact, wash the \neye with plenty of clean water\n\t\n\u0089\nThe oil is highly inflammable. Avoid sitting near open \nfires after applying Dimeticone.\n\t\n\u0089\nStore the unused oil away from open fire and children\nContraindications:\n\t\n\u0089\nDo not use dimeticone on people with known hypersen\u00ad\nsitivity reactions to any of the Dimeticone oils\nOR\n\t\n\u0089\nApply benzyl benzoate 25% emulsion twice daily to the \naffected area for 6 days\n\t\n\u0089\nImmerse affected area in potassium permanganate 0.05% \nonce a day for 10 minutes for 10 days\n\t\n\u0089\nThen follow with application of thickpetroleum jelly or \n20% salicylated petrolleum jelly vaseline) daily for 7 days\nIf secondary bacterial infection\n\t\n\u0089\nTreat as per boils (see section 22.1.2)\nHC2\nNote\n\uf077\t\nHealth education to prevent secondary bacterial infections such \nas cellulitis, and  tetanus",
        "formatted_content": "<p>993</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>For severe cases you may require to rubrubbing the oil</p>\n<p>into the crevises</p>\n<p>\u0089</p>\n<p>A single treatment as above is enough but can be repeated</p>\n<p>after two weeks in situations of severe infestation</p>\n<p>Precautions</p>\n<p>\u0089</p>\n<p>Avoid contact with eyes. In case of contact, wash the</p>\n<p>eye with plenty of clean water</p>\n<p>\u0089</p>\n<p>The oil is highly inflammable. Avoid sitting near open</p>\n<p>fires after applying Dimeticone.</p>\n<p>\u0089</p>\n<p>Store the unused oil away from open fire and children</p>\n<p>Contraindications:</p>\n<p>\u0089</p>\n<p>Do not use dimeticone on people with known hypersen\u00ad</p>\n<p>sitivity reactions to any of the Dimeticone oils</p>\n<p>OR</p>\n<p>\u0089</p>\n<p>Apply benzyl benzoate 25% emulsion twice daily to the</p>\n<p>affected area for 6 days</p>\n<p>\u0089</p>\n<p>Immerse affected area in potassium permanganate 0.05%</p>\n<p>once a day for 10 minutes for 10 days</p>\n<p>\u0089</p>\n<p>Then follow with application of thickpetroleum jelly or</p>\n<p>20% salicylated petrolleum jelly vaseline) daily for 7 days</p>\n<p>If secondary bacterial infection</p>\n<p>\u0089</p>\n<p>Treat as per boils (see section 22.1.2)</p>\n<h3>HC2</h3>\n<p>Note</p>\n<p>\uf077</p>\n<p>Health education to prevent secondary bacterial infections such</p>\n<p>as cellulitis, and  tetanus</p>"
    },
    {
        "page_number": 1060,
        "content": "994\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nPrevention\n \n~\nSpray the ground with insecticide such as malathion\n \n~\nProtect feet with socks and shoes\n \n~\nDry laundry on a line instead of the ground\n \n~\nDo not share housing with animals. Animals such as goats, pigs, \ncows can all be infested with jiggers\n \n~\nKeep floors clean and dust free\n \n~\nHealth education\n22.5 INFLAMMATORY AND ALLERGIC SKIN CONDI\u00ad\nTIONS\n22.5.1 Acne\t\nICD10 CODE: L70\nAcne is a common chronic skin disease caused by blockage and/or \ninflammation of hair follicles and sebaceous glands. It commonly occurs \nin puberty and adolescence and is associated with hormonal changes.\nCauses\nAcne develops as a result of the following four factors:\n \n~\nRelease of inflammatory mediators into the skin\n \n~\nFollicular hyperkeratinization with subsequent plugging ofof the \nfollicles\nCauses\n \n~\nAcne develops as a result of the following four factors:\n \n~\nRelease of inflammatory mediators into the skin\n \n~\nFollicular hyperkeratinization with subsequent plugging of the \nfollicles\n \n~\nPropionibacterium acnes follicular colonization\n \n~\nExcess sebum production",
        "formatted_content": "<p>994</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Spray the ground with insecticide such as malathion</p>\n<p>~</p>\n<p>Protect feet with socks and shoes</p>\n<p>~</p>\n<p>Dry laundry on a line instead of the ground</p>\n<p>~</p>\n<p>Do not share housing with animals. Animals such as goats, pigs,</p>\n<p>cows can all be infested with jiggers</p>\n<p>~</p>\n<p>Keep floors clean and dust free</p>\n<p>~</p>\n<p>Health education</p>\n<h3>22.5 INFLAMMATORY AND ALLERGIC SKIN CONDI\u00ad</h3>\n<h3>TIONS</h3>\n<p>22.5.1 Acne</p>\n<h3>ICD10 CODE: L70</h3>\n<p>Acne is a common chronic skin disease caused by blockage and/or</p>\n<p>inflammation of hair follicles and sebaceous glands. It commonly occurs</p>\n<p>in puberty and adolescence and is associated with hormonal changes.</p>\n<p>Causes</p>\n<p>Acne develops as a result of the following four factors:</p>\n<p>~</p>\n<p>Release of inflammatory mediators into the skin</p>\n<p>~</p>\n<p>Follicular hyperkeratinization with subsequent plugging ofof the</p>\n<p>follicles</p>\n<p>Causes</p>\n<p>~</p>\n<p>Acne develops as a result of the following four factors:</p>\n<p>~</p>\n<p>Release of inflammatory mediators into the skin</p>\n<p>~</p>\n<p>Follicular hyperkeratinization with subsequent plugging of the</p>\n<p>follicles</p>\n<p>~</p>\n<p>Propionibacterium acnes follicular colonization</p>\n<p>~</p>\n<p>Excess sebum production</p>"
    },
    {
        "page_number": 1061,
        "content": "995\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nClinical features\n \n~\nTypically affects face, and upper part of chest and back\n \n~\nInflammatory papules, pustules and nodules\n \n~\nInfected parts may be painful\n \n~\nCysts and scars in severe cases\n \n~\nMay worsen during menstruation\nDifferential diagnosis\n \n~\nFuruncles\n \n~\nMolluscum contagiosum\nInvestigations\n \n\u0081\nClinical features are largely diagnostic\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nReassure patient. Inform him or her that diet plays no \nrole in acne\n\t\n\u0089\nDrink water regularly\n\t\n\u0089\nClean face twice daily with mild soap and water\n\t\n\u0089\nDo not use strong soap\n\t\n\u0089\nCommercial facial wash cleansers can decrease skin oiliness\n\t\n\u0089\nDo not use oil, cream or petroleum jelly\n\t\n\u0089\nDo not touch or press the foci\n\t\n\u0089\nSunshine is helpful, but avoid sunburn\n\t\n\u0089\nIf acne is getting worse or pustular, refer to a dermatologist\nHC2",
        "formatted_content": "<p>995</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Typically affects face, and upper part of chest and back</p>\n<p>~</p>\n<p>Inflammatory papules, pustules and nodules</p>\n<p>~</p>\n<p>Infected parts may be painful</p>\n<p>~</p>\n<p>Cysts and scars in severe cases</p>\n<p>~</p>\n<p>May worsen during menstruation</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Furuncles</p>\n<p>~</p>\n<p>Molluscum contagiosum</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Clinical features are largely diagnostic</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Reassure patient. Inform him or her that diet plays no</p>\n<p>role in acne</p>\n<p>\u0089</p>\n<p>Drink water regularly</p>\n<p>\u0089</p>\n<p>Clean face twice daily with mild soap and water</p>\n<p>\u0089</p>\n<p>Do not use strong soap</p>\n<p>\u0089</p>\n<p>Commercial facial wash cleansers can decrease skin oiliness</p>\n<p>\u0089</p>\n<p>Do not use oil, cream or petroleum jelly</p>\n<p>\u0089</p>\n<p>Do not touch or press the foci</p>\n<p>\u0089</p>\n<p>Sunshine is helpful, but avoid sunburn</p>\n<p>\u0089</p>\n<p>If acne is getting worse or pustular, refer to a dermatologist</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1062,
        "content": "996\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\nTopical medicine treatment\n\t\n\u0089\nBenzoyl peroxide 2.5% to 10%, applied at night for not \nmore than 4 months\nHC4\nSystemic antibacterials\n\t\n\u0089\nOnly use if acne is severe and creams are unavailable\n\t\n\u0089\nDuration of treatment depends on response. May last 6 \nmonths to one year\n\t\n\u0089\nDoxycycline 100 mg once daily for 6-12 months.\n\t\n\u0089\nReview treatment monthly to ascertain response\n\t\n\u0089\nOR erythromycin 500 mg every 6 hours for 1 month, \nduring pregnancy or breast feeding\n\t\n\u0089\nRefer to dermatologist if no response occurs\nHC2\nHC3\nOral contraceptives\n\t\n\u0089\nCombined oral contraceptive (see Family Planning, \nsection 15.2.3)\nHC4\n22.5.2 Urticaria/Papular Urticari\t\t\nICD10 CODE: L50\nAn acute, sub-acute or chronic inflammation of the skin, caused by \nendogenous or exogenous agents. Urticaria is an itchy skin rash.\nCauses\n \n~\nEndogenous: familial, also associated with other allergic diseases\n \n~\nExogenous: agents include sunlight, chemicals, certain foods, \ninsect bites\nClinical features\n \n~\nInflammation of skin: transient itching hives and wheals\n \n~\nPapular urticaria: vesicles, redness, oedema, oozing in  case    of \ninsect bites",
        "formatted_content": "<p>996</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Topical medicine treatment</p>\n<p>\u0089</p>\n<p>Benzoyl peroxide 2.5% to 10%, applied at night for not</p>\n<p>more than 4 months</p>\n<h3>HC4</h3>\n<p>Systemic antibacterials</p>\n<p>\u0089</p>\n<p>Only use if acne is severe and creams are unavailable</p>\n<p>\u0089</p>\n<p>Duration of treatment depends on response. May last 6</p>\n<p>months to one year</p>\n<p>\u0089</p>\n<p>Doxycycline 100 mg once daily for 6-12 months.</p>\n<p>\u0089</p>\n<p>Review treatment monthly to ascertain response</p>\n<p>\u0089</p>\n<p>OR erythromycin 500 mg every 6 hours for 1 month,</p>\n<p>during pregnancy or breast feeding</p>\n<p>\u0089</p>\n<p>Refer to dermatologist if no response occurs</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Oral contraceptives</p>\n<p>\u0089</p>\n<p>Combined oral contraceptive (see Family Planning,</p>\n<p>section 15.2.3)</p>\n<h3>HC4</h3>\n<p>22.5.2 Urticaria/Papular Urticari</p>\n<h3>ICD10 CODE: L50</h3>\n<p>An acute, sub-acute or chronic inflammation of the skin, caused by</p>\n<p>endogenous or exogenous agents. Urticaria is an itchy skin rash.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Endogenous: familial, also associated with other allergic diseases</p>\n<p>~</p>\n<p>Exogenous: agents include sunlight, chemicals, certain foods,</p>\n<p>insect bites</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Inflammation of skin: transient itching hives and wheals</p>\n<p>~</p>\n<p>Papular urticaria: vesicles, redness, oedema, oozing in  case    of</p>\n<p>insect bites</p>"
    },
    {
        "page_number": 1063,
        "content": "997\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nDifferential diagnosis\n \n~\nFungal and bacterial infections of the skin\n \n~\nHelminth infestations\nInvestigations\n \n\u0081\nNo satisfactory investigations for skin allergy\n \n\u0081\nBlood: haemogram to demonstrate eosinophilia\n \n\u0081\nStool: microscopy to exclude worms\nTREATMENT\nLOC\nEstablish the cause and treat accordingly. Identify what the \npatient is allergic to.\n\t\n\u0089\nGive an analgesic e.g., paracetamol for any pain or \ndiscomfort as necessary\n\t\n\u0089\nAvoid acetylsalicylic acid\n\t\n\u0089\nGive an antihistamine to relieve itching; chlorphenamine \n4 mg every 8 hours Child: 1-2 mg per dose\n\t\n\u0089\nOr promethazine 25 mg at night. Increase to every 12 \nhours if necessary\n\uf077\t\nChild: 1 mg/kg daily in 1-2 divided doses\nIf severe/unresponsive\n\t\n\u0089\nPrednisolone 1 mg/kg orally once a day for 3-5 days\nHC2\nPrevention\n \n~\nAvoid contact with known allergens\n \n~\nTreat helminth infections\n22.5.3\t Eczema (Dermatitis) \t\n\t\n ICD10 CODE: L20, L23\nAcute or chronic superficial inflammation of the skin",
        "formatted_content": "<p>997</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Fungal and bacterial infections of the skin</p>\n<p>~</p>\n<p>Helminth infestations</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>No satisfactory investigations for skin allergy</p>\n<p>\u0081</p>\n<p>Blood: haemogram to demonstrate eosinophilia</p>\n<p>\u0081</p>\n<p>Stool: microscopy to exclude worms</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Establish the cause and treat accordingly. Identify what the</p>\n<p>patient is allergic to.</p>\n<p>\u0089</p>\n<p>Give an analgesic e.g., paracetamol for any pain or</p>\n<p>discomfort as necessary</p>\n<p>\u0089</p>\n<p>Avoid acetylsalicylic acid</p>\n<p>\u0089</p>\n<p>Give an antihistamine to relieve itching; chlorphenamine</p>\n<p>4 mg every 8 hours Child: 1-2 mg per dose</p>\n<p>\u0089</p>\n<p>Or promethazine 25 mg at night. Increase to every 12</p>\n<p>hours if necessary</p>\n<p>\uf077</p>\n<p>Child: 1 mg/kg daily in 1-2 divided doses</p>\n<p>If severe/unresponsive</p>\n<p>\u0089</p>\n<p>Prednisolone 1 mg/kg orally once a day for 3-5 days</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid contact with known allergens</p>\n<p>~</p>\n<p>Treat helminth infections</p>\n<p>22.5.3\t Eczema (Dermatitis)</p>\n<h3>ICD10 CODE: L20, L23</h3>\n<p>Acute or chronic superficial inflammation of the skin</p>"
    },
    {
        "page_number": 1064,
        "content": "998\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nCause\n \n~\nAllergic dermatitis: reaction to food, chemicals, plants, jewellery \nor other substances\n \n~\nAtopic dermatitis: unknown cause\nClinical features\n \n~\nVesicles (acute stage)\n \n~\nItchy rash with dry rough scaly skin especially in flexural areas-( \nin Atopic Eczema)\n \n~\nOozing due to secondary bacterial infection, causing regional \nlymphadenopathy and fever\nDifferential diagnosis\n \n~\nSeborrhoeic dermatitis\n \n~\nTinea corporis\n \n~\nPsoriasis \nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRemove/avoid cause if known\n\t\n\u0089\nApply betamethasone cream 0.1% every 12 hours for 2 \nweeks on affected parts, EXCEPT the face and genital areas\n\t\n\u0089\nIf face or genitalia affected, apply hydrocortisone cream \n1% every 12 hours for 2 weeks\n\t\n\u0089\nGive an antihistamine to relieve itching; chlorphenamine \n4 mg every 8 hours Child: 1-2 mg per dose\n\t\n\u0089\nOR promethazine 25 mg at night; increase frequency \nto every 12 hours if necessary Child: 1 mg/kg daily in \n1-2 divided doses\nHC2",
        "formatted_content": "<p>998</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Cause</p>\n<p>~</p>\n<p>Allergic dermatitis: reaction to food, chemicals, plants, jewellery</p>\n<p>or other substances</p>\n<p>~</p>\n<p>Atopic dermatitis: unknown cause</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Vesicles (acute stage)</p>\n<p>~</p>\n<p>Itchy rash with dry rough scaly skin especially in flexural areas-(</p>\n<p>in Atopic Eczema)</p>\n<p>~</p>\n<p>Oozing due to secondary bacterial infection, causing regional</p>\n<p>lymphadenopathy and fever</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Seborrhoeic dermatitis</p>\n<p>~</p>\n<p>Tinea corporis</p>\n<p>~</p>\n<p>Psoriasis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Remove/avoid cause if known</p>\n<p>\u0089</p>\n<p>Apply betamethasone cream 0.1% every 12 hours for 2</p>\n<p>weeks on affected parts, EXCEPT the face and genital areas</p>\n<p>\u0089</p>\n<p>If face or genitalia affected, apply hydrocortisone cream</p>\n<p>1% every 12 hours for 2 weeks</p>\n<p>\u0089</p>\n<p>Give an antihistamine to relieve itching; chlorphenamine</p>\n<p>4 mg every 8 hours Child: 1-2 mg per dose</p>\n<p>\u0089</p>\n<p>OR promethazine 25 mg at night; increase frequency</p>\n<p>to every 12 hours if necessary Child: 1 mg/kg daily in</p>\n<p>1-2 divided doses</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1065,
        "content": "999\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n\t\n\u0089\nMoisturizers (eg; Vaseline petroleum jelly) twice daily \nafter bath to keep the body moist.\nIf evidence of secondary infection, treat according to cause.\n\t\n\u0089\nGive a systemic antibiotic as in impetigo  (section 22.1.1) \nIf viral or fungal infection, treat as shown in respective \nsub sections).\nHC2\nHC4\nPrevention\n \n~\nAvoid contact with allergens, Advise on light dressing in hot \nweather to avoid sweating, advise on bathing habits like; reduce \non frequency of bathing \u2013 at most twice daily, use soft sponge.\n22.5.4 Psoriasis\t\t\nICD10 CODE: L40\nA chronic recurrent skin disease characterized by scaling, reddened pap\u00ad\nules or plaques on the scalp, back of the elbows and front of the knees. \nPsoriasis commonly affects skin and joints plus nails.\nThe lesions tend to appear at sites of trauma (Koebner\u2019s reaction).\nCause\n \n~\nUnknown, but usually genetically transmitted\n \n~\nAbout 30% of cases have a family history\nClinical features\n \n~\nUsually in patients 25-40 years old\n \n~\nGradual onset of distinct, red scaling papules which coalesce to \nform plaques\n \n~\nAdherent, silvery white scales, which reveal bleeding points \nwhen removed (Ausiptz sign)\n \n~\nWorsening psoriasis may lead to total erythroderma\n \n~\nExtra articular feature, e.g., pitting or thickening of nail plate \nwith accumulation of debris under the nail plate",
        "formatted_content": "<p>999</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Moisturizers (eg; Vaseline petroleum jelly) twice daily</p>\n<p>after bath to keep the body moist.</p>\n<p>If evidence of secondary infection, treat according to cause.</p>\n<p>\u0089</p>\n<p>Give a systemic antibiotic as in impetigo  (section 22.1.1)</p>\n<p>If viral or fungal infection, treat as shown in respective</p>\n<p>sub sections).</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Avoid contact with allergens, Advise on light dressing in hot</p>\n<p>weather to avoid sweating, advise on bathing habits like; reduce</p>\n<p>on frequency of bathing \u2013 at most twice daily, use soft sponge.</p>\n<p>22.5.4 Psoriasis</p>\n<h3>ICD10 CODE: L40</h3>\n<p>A chronic recurrent skin disease characterized by scaling, reddened pap\u00ad</p>\n<p>ules or plaques on the scalp, back of the elbows and front of the knees.</p>\n<p>Psoriasis commonly affects skin and joints plus nails.</p>\n<p>The lesions tend to appear at sites of trauma (Koebner\u2019s reaction).</p>\n<p>Cause</p>\n<p>~</p>\n<p>Unknown, but usually genetically transmitted</p>\n<p>~</p>\n<p>About 30% of cases have a family history</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Usually in patients 25-40 years old</p>\n<p>~</p>\n<p>Gradual onset of distinct, red scaling papules which coalesce to</p>\n<p>form plaques</p>\n<p>~</p>\n<p>Adherent, silvery white scales, which reveal bleeding points</p>\n<p>when removed (Ausiptz sign)</p>\n<p>~</p>\n<p>Worsening psoriasis may lead to total erythroderma</p>\n<p>~</p>\n<p>Extra articular feature, e.g., pitting or thickening of nail plate</p>\n<p>with accumulation of debris under the nail plate</p>"
    },
    {
        "page_number": 1066,
        "content": "1000\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nDifferential diagnosis\n \n~\nFungal infection, lichen planus\n \n~\nMycosis fungoides\n \n~\nSeborrhoeic dermatitis\n \n~\nMedicine-induced eruptions\nInvestigations\n \n\u0081\nDiagnosis is largely clinical\n \n\u0081\nKOH microscopy to exclude fungal infection\n \n\u0081\nBlood: Serum uric acid, rheumatoid factor, and anti- nuclear \nfactor and histology to rule out other diseases like rheumatoid \narthritis, SLE, skin malignancies etc.\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRemove scales, then apply medicine as below\nMild cases (lesions <10% of the body)\n\t\n\u0089\nGive high potent topical steroids, e.g.  clobetasolo pro\u00ad\nponate 0.05%  cream applied on the lesions twice a \nday  2- 4 weeks\n\t\n\u0089\nApply crude coal tar ointment 1% at night for 2 weeks\nSevere cases (lesions >20% of the body surface area)\n\t\n\u0089\nRefer for specialist management\n\t\n\u0089\nRemove scales, then apply medicine as below\nMild cases (lesions <20% of the body)\n\t\n\u0089\nGive topical steroids, e.g. betamethasone cream applied \non the lesions once in the morning\nHC4\nRR",
        "formatted_content": "<p>1000</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Fungal infection, lichen planus</p>\n<p>~</p>\n<p>Mycosis fungoides</p>\n<p>~</p>\n<p>Seborrhoeic dermatitis</p>\n<p>~</p>\n<p>Medicine-induced eruptions</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is largely clinical</p>\n<p>\u0081</p>\n<p>KOH microscopy to exclude fungal infection</p>\n<p>\u0081</p>\n<p>Blood: Serum uric acid, rheumatoid factor, and anti- nuclear</p>\n<p>factor and histology to rule out other diseases like rheumatoid</p>\n<p>arthritis, SLE, skin malignancies etc.</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Remove scales, then apply medicine as below</p>\n<p>Mild cases (lesions <10% of the body)</p>\n<p>\u0089</p>\n<p>Give high potent topical steroids, e.g.  clobetasolo pro\u00ad</p>\n<p>ponate 0.05%  cream applied on the lesions twice a</p>\n<p>day  2- 4 weeks</p>\n<p>\u0089</p>\n<p>Apply crude coal tar ointment 1% at night for 2 weeks</p>\n<p>Severe cases (lesions >20% of the body surface area)</p>\n<p>\u0089</p>\n<p>Refer for specialist management</p>\n<p>\u0089</p>\n<p>Remove scales, then apply medicine as below</p>\n<p>Mild cases (lesions <20% of the body)</p>\n<p>\u0089</p>\n<p>Give topical steroids, e.g. betamethasone cream applied</p>\n<p>on the lesions once in the morning</p>\n<h3>HC4</h3>\n<p>RR</p>"
    },
    {
        "page_number": 1067,
        "content": "1001\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n\t\n\u0089\nApply crude coal tar ointment 1% at night for 2 weeks\nSevere cases (lesions >20% of the body surface area)\n\t\n\u0089\nRefer for specialist management\nHC4\nRR\nCaution\n\uf077\t\nDrugs that precipitate/exacerbate psoriasis include lithium, be\u00ad\nta-blockers, antimalarials and systemic steroids\n22.6 SKIN ULCERS AND CHRONIC WOUNDS\n22.6.1 Leg Ulcers\t\n\t\nICD10 CODE: L97\nChronic ulcerative skin lesion caused by various aetiologies and often \ntriggered by a minor trauma\nCause/risk factors\n \n~\nVascular, e.g. venous/arterial insufficiency\n \n~\nBacterial: leprosy, Buruli ulcer (by Parasites: guinea worm, leish\u00ad\nmaniasis, jiggers\n \n~\nParasites: guinea worm, leishmaniasis\n \n~\nDiabetes, sickle cell disease, malnutrition\nClinical features\n \n~\nOften in lower third of the leg\n \n~\nUlcerated lesion with necrotic tissue, slough, discharge, oedema \naround the lesion, scarring\n \n~\nFeatures of cellulitis due to secondary infection may be present\n \n~\nFeatures of underlying disease\nInvestigations\n \n\u0081\nSwab for C&S\n \n\u0081\nX-ray\n \n\u0081\nBlood glucose",
        "formatted_content": "<p>1001</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Apply crude coal tar ointment 1% at night for 2 weeks</p>\n<p>Severe cases (lesions >20% of the body surface area)</p>\n<p>\u0089</p>\n<p>Refer for specialist management</p>\n<h3>HC4</h3>\n<p>RR</p>\n<p>Caution</p>\n<p>\uf077</p>\n<p>Drugs that precipitate/exacerbate psoriasis include lithium, be\u00ad</p>\n<p>ta-blockers, antimalarials and systemic steroids</p>\n<h3>22.6 SKIN ULCERS AND CHRONIC WOUNDS</h3>\n<p>22.6.1 Leg Ulcers</p>\n<h3>ICD10 CODE: L97</h3>\n<p>Chronic ulcerative skin lesion caused by various aetiologies and often</p>\n<p>triggered by a minor trauma</p>\n<p>Cause/risk factors</p>\n<p>~</p>\n<p>Vascular, e.g. venous/arterial insufficiency</p>\n<p>~</p>\n<p>Bacterial: leprosy, Buruli ulcer (by Parasites: guinea worm, leish\u00ad</p>\n<p>maniasis, jiggers</p>\n<p>~</p>\n<p>Parasites: guinea worm, leishmaniasis</p>\n<p>~</p>\n<p>Diabetes, sickle cell disease, malnutrition</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Often in lower third of the leg</p>\n<p>~</p>\n<p>Ulcerated lesion with necrotic tissue, slough, discharge, oedema</p>\n<p>around the lesion, scarring</p>\n<p>~</p>\n<p>Features of cellulitis due to secondary infection may be present</p>\n<p>~</p>\n<p>Features of underlying disease</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Swab for C&S</p>\n<p>\u0081</p>\n<p>X-ray</p>\n<p>\u0081</p>\n<p>Blood glucose</p>"
    },
    {
        "page_number": 1068,
        "content": "1002\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nClean the wound\n \n- If exudating/dirty lesions: use chlorhexidine \nsolution 0.05% or hydrogen peroxide solution 6% \nor povidone iodine 2%\n \n- If clean wound: use clean water or normal saline\n\t\n\u0089\nRemove necrotic tissue\n\t\n\u0089\nElevate and rest the leg\n\t\n\u0089\nPerform daily dressing\n \n~\nApply silver sulphadiazine or povidone iodine if the \nwound is dirty and exudative\n \n- Otherwise use gauze moistened with normal saline\n\t\n\u0089\nAnalgesics for pain if needed\nIf sign of cellulitis\n\t\n\u0089\nTreat as per guidelines (see section 22.1.3)\nHC2\nHC3\nPrevention\n \n~\nEnsure personal hygiene\n \n~\nEnsure good nutrition\n \n~\nAvoid trauma\n22.7 DRUG-INDUCED SKIN REACTIONS\n22.7.1 Steven-Johnson Syndrome (SJS) and Toxic Epidermal \nNecrolysis (TEN)\t\t\n\t\nICD10 CODE: L51\nA life threatening hypersensitivity reaction that affects the skin and the \nmucous membranes: SJS affects up to 10% of the body surface area, while \nTEN affects >30%. If it is between 10 and 30%, it is SJS/TEN overlap.",
        "formatted_content": "<p>1002</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Clean the wound</p>\n<p>- If exudating/dirty lesions: use chlorhexidine</p>\n<p>solution 0.05% or hydrogen peroxide solution 6%</p>\n<p>or povidone iodine 2%</p>\n<p>- If clean wound: use clean water or normal saline</p>\n<p>\u0089</p>\n<p>Remove necrotic tissue</p>\n<p>\u0089</p>\n<p>Elevate and rest the leg</p>\n<p>\u0089</p>\n<p>Perform daily dressing</p>\n<p>~</p>\n<p>Apply silver sulphadiazine or povidone iodine if the</p>\n<p>wound is dirty and exudative</p>\n<p>- Otherwise use gauze moistened with normal saline</p>\n<p>\u0089</p>\n<p>Analgesics for pain if needed</p>\n<p>If sign of cellulitis</p>\n<p>\u0089</p>\n<p>Treat as per guidelines (see section 22.1.3)</p>\n<h3>HC2</h3>\n<h3>HC3</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Ensure personal hygiene</p>\n<p>~</p>\n<p>Ensure good nutrition</p>\n<p>~</p>\n<p>Avoid trauma</p>\n<h3>22.7 DRUG-INDUCED SKIN REACTIONS</h3>\n<p>22.7.1 Steven-Johnson Syndrome (SJS) and Toxic Epidermal</p>\n<p>Necrolysis (TEN)</p>\n<h3>ICD10 CODE: L51</h3>\n<p>A life threatening hypersensitivity reaction that affects the skin and the</p>\n<p>mucous membranes: SJS affects up to 10% of the body surface area, while</p>\n<p>TEN affects >30%. If it is between 10 and 30%, it is SJS/TEN overlap.</p>"
    },
    {
        "page_number": 1069,
        "content": "1003\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nCauses\nMost well-known causes are:\n \n~\nCertain medications such as: HIV medication (nevirapine), An\u00ad\nti-TB medications, anticonvulsants, e.g., carbamazepine, lamo\u00ad\ntrigine, sulpha-containg drugs (e.g., co-trimoxazole, allopurinol)\n \n~\nInfections, especially in immunocompromised persons\nClinical features\n \n~\nDark macular skin rash, progressing to confluence with epider\u00ad\nmal necrosis and large flaccid blisters which rupture, leaving \nlarge areas of denuded skin\n \n~\nUsually sparing the scalp but involving mucosa (genitalia, mouth, \nanal area, eyes) with multiple erosions\n \n~\nGeneral  lanning: fever, malaise\n \n~\nComplications: dehydration, electrolyte imbalances, hypoalbu\u00ad\nminemia, secondary infection and sepsis\nInvestigations\n \n\u0081\nDiagnosis is usually clinical\n \n\u0081\nHistory of medicines taken\n \n\u0081\nSerology for HIV, if status unknown\n \n\u0081\nRFTs, pus swab, C&S if indicated\nTREATMENT\nLOC\n\t\n\u0089\nRemove offending medicine or agent, possibly stop all \nmedications\n\t\n\u0089\nRefer all patients to hospital\n\t\n\u0089\nManagement is multi disciplinary and  supportively (as in \nBurns, section 1.2.3)\n \n- Intravenous rehydration\n \n- Care for the skin\nH",
        "formatted_content": "<p>1003</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<p>Causes</p>\n<p>Most well-known causes are:</p>\n<p>~</p>\n<p>Certain medications such as: HIV medication (nevirapine), An\u00ad</p>\n<p>ti-TB medications, anticonvulsants, e.g., carbamazepine, lamo\u00ad</p>\n<p>trigine, sulpha-containg drugs (e.g., co-trimoxazole, allopurinol)</p>\n<p>~</p>\n<p>Infections, especially in immunocompromised persons</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Dark macular skin rash, progressing to confluence with epider\u00ad</p>\n<p>mal necrosis and large flaccid blisters which rupture, leaving</p>\n<p>large areas of denuded skin</p>\n<p>~</p>\n<p>Usually sparing the scalp but involving mucosa (genitalia, mouth,</p>\n<p>anal area, eyes) with multiple erosions</p>\n<p>~</p>\n<p>General  lanning: fever, malaise</p>\n<p>~</p>\n<p>Complications: dehydration, electrolyte imbalances, hypoalbu\u00ad</p>\n<p>minemia, secondary infection and sepsis</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Diagnosis is usually clinical</p>\n<p>\u0081</p>\n<p>History of medicines taken</p>\n<p>\u0081</p>\n<p>Serology for HIV, if status unknown</p>\n<p>\u0081</p>\n<p>RFTs, pus swab, C&S if indicated</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Remove offending medicine or agent, possibly stop all</p>\n<p>medications</p>\n<p>\u0089</p>\n<p>Refer all patients to hospital</p>\n<p>\u0089</p>\n<p>Management is multi disciplinary and  supportively (as in</p>\n<p>Burns, section 1.2.3)</p>\n<p>- Intravenous rehydration</p>\n<p>- Care for the skin</p>\n<p>H</p>"
    },
    {
        "page_number": 1070,
        "content": "1004\nUganda Clinical Guidelines 2023\nCHAPTER 22 : Skin Diseases\nTREATMENT\nLOC\n \n- Maintain good hygiene\n \n- Adequate nutrition\n\t\n\u0089\nIf eyes are involved, consult eye specialist f Treat  if  there \nis secondary bacterial infection \n\t\n\u0089\nThere is no strong evidence to support the use of corticos\u00ad\nteroids, which also increase risk of infection and catabolism\nNB; Avoid unnecessary medication, this may worsen the condition\nH\nPrevention\n \n~\nTake thorough medicine history\n \n~\nAdvise patients to avoid self-medication\n22.8 CONGENITAL DISORDER\nA disorder characterized by complete or partial absence of melanin \npigment in the skin hair and eyes- (albinos) \nCause\n \n~\ndue to absence of defect of tyrosinase enzyme involved in the \nproduction of melanin (skin pigment)\nTreatment\n \n~\nApply sun screen whenever moving under the sun. Stay as much \nas possible in the shed.\n \n~\nDo annual skin assessment to screen skin for cancer or  leisons \nthan can lead to skin cancer",
        "formatted_content": "<p>1004</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 22 : Skin Diseases</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Maintain good hygiene</p>\n<p>- Adequate nutrition</p>\n<p>\u0089</p>\n<p>If eyes are involved, consult eye specialist f Treat  if  there</p>\n<p>is secondary bacterial infection</p>\n<p>\u0089</p>\n<p>There is no strong evidence to support the use of corticos\u00ad</p>\n<p>teroids, which also increase risk of infection and catabolism</p>\n<p>NB; Avoid unnecessary medication, this may worsen the condition</p>\n<p>H</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Take thorough medicine history</p>\n<p>~</p>\n<p>Advise patients to avoid self-medication</p>\n<h3>22.8 CONGENITAL DISORDER</h3>\n<p>A disorder characterized by complete or partial absence of melanin</p>\n<p>pigment in the skin hair and eyes- (albinos)</p>\n<p>Cause</p>\n<p>~</p>\n<p>due to absence of defect of tyrosinase enzyme involved in the</p>\n<p>production of melanin (skin pigment)</p>\n<p>Treatment</p>\n<p>~</p>\n<p>Apply sun screen whenever moving under the sun. Stay as much</p>\n<p>as possible in the shed.</p>\n<p>~</p>\n<p>Do annual skin assessment to screen skin for cancer or  leisons</p>\n<p>than can lead to skin cancer</p>"
    },
    {
        "page_number": 1071,
        "content": "1005\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n23.1 DENTAL DISORDERS\n23.1.1. Halitosis/Bad Breath                                       ICD 10 CODE: R19.6\nUnpleasant odour from the oral cavity\nCauses\n \n~\nPoor brushing techniques\n \n~\nGum disease due to infections in the mouth\n \n~\nTobacco smoking and chewing\n \n~\nSystemic conditions or illnesses, such as liver disease, kidney \ndisease, lung disease etc.\n \n~\nDecayed teeth\n \n~\nDiet\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTreat underlying condition\n\t\n\u0089\nDrink plenty of water every day to encourage saliva \nproduction\n\t\n\u0089\nUse of sugar free gum\n\t\n\u0089\nDietary changes, like use of raw carrots, as recommended \nby your dentist or nutritionist\n\t\n\u0089\nAdvise on brushing teeth thoroughly at least twice daily\n\t\n\u0089\nSee also section 23.2.1 below\nHC2\nOral and Dental Conditions\n23",
        "formatted_content": "<p>1005</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>23.1 DENTAL DISORDERS</h3>\n<p>23.1.1. Halitosis/Bad Breath                                       ICD 10 CODE: R19.6</p>\n<p>Unpleasant odour from the oral cavity</p>\n<p>Causes</p>\n<p>~</p>\n<p>Poor brushing techniques</p>\n<p>~</p>\n<p>Gum disease due to infections in the mouth</p>\n<p>~</p>\n<p>Tobacco smoking and chewing</p>\n<p>~</p>\n<p>Systemic conditions or illnesses, such as liver disease, kidney</p>\n<p>disease, lung disease etc.</p>\n<p>~</p>\n<p>Decayed teeth</p>\n<p>~</p>\n<p>Diet</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Treat underlying condition</p>\n<p>\u0089</p>\n<p>Drink plenty of water every day to encourage saliva</p>\n<p>production</p>\n<p>\u0089</p>\n<p>Use of sugar free gum</p>\n<p>\u0089</p>\n<p>Dietary changes, like use of raw carrots, as recommended</p>\n<p>by your dentist or nutritionist</p>\n<p>\u0089</p>\n<p>Advise on brushing teeth thoroughly at least twice daily</p>\n<p>\u0089</p>\n<p>See also section 23.2.1 below</p>\n<h3>HC2</h3>\n<p>Oral and Dental Conditions</p>\n<p>23</p>"
    },
    {
        "page_number": 1072,
        "content": "1006\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n23.1.2.\t Dentin Hypersensitivity\t\t\nICD10 CODE: K03.9\nThis condition is due to wearing off of the enamel, making it thinner \nleading to exposure of the dentin\nCauses\n \n~\nGum recession due to age or improper tooth brushing\n \n~\nAcidic beverages that cause enamel erosion and dentin exposure\n \n~\nTooth grinding\n \n~\nChipped or fractured tooth may also expose the dentine\n \n~\nEating disorders, e.g. bulimia nervosa and anorexia nervosa (ex\u00ad\nposure to vomitus)\nClinical features\n \n~\nSensitivity to hot, cold, sweet or very acidic foods and drinks, \nand breathing in cold air\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nTopical application of fluoride in form of toothpaste\n\t\n\u0089\nIn severe conditions, refer for root canal therapy\n\t\n\u0089\nProfessional cleaning of teeth\nHC2\nHC4\n23.1.3.\t Malocclusion\t\n\t\n\t\nICD10 CODE: M26.4\nMalocclusion is any deviation from the normal relation of the teeth in \nthe same arch to each other, and to the teeth in the opposite arch\nCauses\n \n~\nAetiology is usually multifactorial\n \n~\nDiscrepancies in the craniofacial skeleton, dentition, or both",
        "formatted_content": "<p>1006</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>23.1.2.\t Dentin Hypersensitivity</p>\n<h3>ICD10 CODE: K03.9</h3>\n<p>This condition is due to wearing off of the enamel, making it thinner</p>\n<p>leading to exposure of the dentin</p>\n<p>Causes</p>\n<p>~</p>\n<p>Gum recession due to age or improper tooth brushing</p>\n<p>~</p>\n<p>Acidic beverages that cause enamel erosion and dentin exposure</p>\n<p>~</p>\n<p>Tooth grinding</p>\n<p>~</p>\n<p>Chipped or fractured tooth may also expose the dentine</p>\n<p>~</p>\n<p>Eating disorders, e.g. bulimia nervosa and anorexia nervosa (ex\u00ad</p>\n<p>posure to vomitus)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Sensitivity to hot, cold, sweet or very acidic foods and drinks,</p>\n<p>and breathing in cold air</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Topical application of fluoride in form of toothpaste</p>\n<p>\u0089</p>\n<p>In severe conditions, refer for root canal therapy</p>\n<p>\u0089</p>\n<p>Professional cleaning of teeth</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>23.1.3.\t Malocclusion</p>\n<h3>ICD10 CODE: M26.4</h3>\n<p>Malocclusion is any deviation from the normal relation of the teeth in</p>\n<p>the same arch to each other, and to the teeth in the opposite arch</p>\n<p>Causes</p>\n<p>~</p>\n<p>Aetiology is usually multifactorial</p>\n<p>~</p>\n<p>Discrepancies in the craniofacial skeleton, dentition, or both</p>"
    },
    {
        "page_number": 1073,
        "content": "1007\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nCases that require treatment\n \n~\nThe main indications for orthodontic treatment are aesthetics \nand function.\n \n~\nCrossbites (as associated occlusal interferences may predispose \nto Temporomandibular Pain Dysfunction Syndrome)\n \n~\nDeep traumatic overbite with palatal impingement of the man\u00ad\ndibular incisors\n \n~\nLarge overjets (increased risk of trauma), severe crowding (as this \nreduces periodontal support for teeth)\n \n~\nWhile severe malocclusion can have a psychologically debilitat\u00ad\ning effect, it is often influenced by social and cultural factors\nManagement\nTREATMENT\nLOC\nMild case\n\t\n\u0089\nRemovable appliance orthodontic therapy in the mixed \ndentition, by a dentist\nModerate to severe case\n\t\n\u0089\nFixed appliance orthodontic therapy in adolescents and \nadults, by an orthodontist\n\t\n\u0089\nCases with discrepancies in the craniofacial skeleton may \nrequire orthognathic surgery by an oral and maxillofacial \nsurgeon\nRR\nRR\n23.1.4.\t Fluorosis (Mottling)\t\n\t\nICD10 CODE: K003\nBrown discolouration of teeth\nCause\n \n~\nOccurs due to long-term excess of fluoride. Endemic in areas of \nhigh fluoride occurring naturally in the water.",
        "formatted_content": "<p>1007</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Cases that require treatment</p>\n<p>~</p>\n<p>The main indications for orthodontic treatment are aesthetics</p>\n<p>and function.</p>\n<p>~</p>\n<p>Crossbites (as associated occlusal interferences may predispose</p>\n<p>to Temporomandibular Pain Dysfunction Syndrome)</p>\n<p>~</p>\n<p>Deep traumatic overbite with palatal impingement of the man\u00ad</p>\n<p>dibular incisors</p>\n<p>~</p>\n<p>Large overjets (increased risk of trauma), severe crowding (as this</p>\n<p>reduces periodontal support for teeth)</p>\n<p>~</p>\n<p>While severe malocclusion can have a psychologically debilitat\u00ad</p>\n<p>ing effect, it is often influenced by social and cultural factors</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Mild case</p>\n<p>\u0089</p>\n<p>Removable appliance orthodontic therapy in the mixed</p>\n<p>dentition, by a dentist</p>\n<p>Moderate to severe case</p>\n<p>\u0089</p>\n<p>Fixed appliance orthodontic therapy in adolescents and</p>\n<p>adults, by an orthodontist</p>\n<p>\u0089</p>\n<p>Cases with discrepancies in the craniofacial skeleton may</p>\n<p>require orthognathic surgery by an oral and maxillofacial</p>\n<p>surgeon</p>\n<p>RR</p>\n<p>RR</p>\n<p>23.1.4.\t Fluorosis (Mottling)</p>\n<h3>ICD10 CODE: K003</h3>\n<p>Brown discolouration of teeth</p>\n<p>Cause</p>\n<p>~</p>\n<p>Occurs due to long-term excess of fluoride. Endemic in areas of</p>\n<p>high fluoride occurring naturally in the water.</p>"
    },
    {
        "page_number": 1074,
        "content": "1008\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nClinical features\n \n~\nVaries from white opacities to severe pitting and discolouration \ndue to incorporation of the excess fluoride in the enamel struc\u00ad\nture\nManagement\nTREATMENT\nLOC\n \n~\nTooth coloured (composite) fillings, veneers\nRR\nPrevention\n \n~\nMonitoring of fluoride levels in drinking water\n \n~\nUse of fluoride-free toothpastes in endemic areas\n23.1.5.\tFalse Teeth (\u201cEbinnyo\u201d)\nTraditional beliefs in many Ugandan communities attribute diarrhoea, \nfever, and vomiting in children to the developing dentition with the belief \nthat if the offending teeth or \u201cebinnyo\u201d are not removed, the child will die. \nFacts on ebinyo\n \n~\nThe practice of extraction of ebinnyo/false teeth is based on \nthe belief that rubbing of herbs on the gum (in the region of \nthe canine), or the removal of the primary and/ or permanent \ncanine tooth buds will lead to the relief of childhood fevers and \ndiarrhoea,\nThe procedure is done as early as 1 month and up to 3 years of age. \nMost studies report a peak age of 4-18 months\n \n~\nWhereas infant illnesses may be attributed to the teething pe\u00ad\nriod, they are in fact a result of the poor health conditions in \nwhich these children are raised\n \n~\nThe term ebinyo encompasses both the child\u2019s ailment, as well \nas the treatment offered by traditional healers\nConsequences of traditional treatment of ebinyo",
        "formatted_content": "<p>1008</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Varies from white opacities to severe pitting and discolouration</p>\n<p>due to incorporation of the excess fluoride in the enamel struc\u00ad</p>\n<p>ture</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>~</p>\n<p>Tooth coloured (composite) fillings, veneers</p>\n<p>RR</p>\n<p>Prevention</p>\n<p>~</p>\n<p>Monitoring of fluoride levels in drinking water</p>\n<p>~</p>\n<p>Use of fluoride-free toothpastes in endemic areas</p>\n<p>23.1.5.\tFalse Teeth (\u201cEbinnyo\u201d)</p>\n<p>Traditional beliefs in many Ugandan communities attribute diarrhoea,</p>\n<p>fever, and vomiting in children to the developing dentition with the belief</p>\n<p>that if the offending teeth or \u201cebinnyo\u201d are not removed, the child will die.</p>\n<p>Facts on ebinyo</p>\n<p>~</p>\n<p>The practice of extraction of ebinnyo/false teeth is based on</p>\n<p>the belief that rubbing of herbs on the gum (in the region of</p>\n<p>the canine), or the removal of the primary and/ or permanent</p>\n<p>canine tooth buds will lead to the relief of childhood fevers and</p>\n<p>diarrhoea,</p>\n<p>The procedure is done as early as 1 month and up to 3 years of age.</p>\n<p>Most studies report a peak age of 4-18 months</p>\n<p>~</p>\n<p>Whereas infant illnesses may be attributed to the teething pe\u00ad</p>\n<p>riod, they are in fact a result of the poor health conditions in</p>\n<p>which these children are raised</p>\n<p>~</p>\n<p>The term ebinyo encompasses both the child\u2019s ailment, as well</p>\n<p>as the treatment offered by traditional healers</p>\n<p>Consequences of traditional treatment of ebinyo</p>"
    },
    {
        "page_number": 1075,
        "content": "1009\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n \n~\nThe procedure is aimed at removal of the primary canine, but \ndamage to the surrounding tissues occurs\n \n~\nThe incisions in the mouth and the herbs can lead to oral sepsis, \nbacteraemia, anaemia, and death\n \n~\nIf initial cause of diarrhoea, fever, and vomiting is not addressed, \ndehydration and death can occur\n \n~\nDepending on the extent of damage, malocclusion can result \nbecause the permanent canine maybe missing, impacted, or mal\u00ad\nformed\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nCounsel the parent/caretaker\n\t\n\u0089\nTreat the condition causing the symptoms\nHC2\nPrevention\n \n~\nOral health education\n \n~\nSensitise community on dangers of  \u201c\u201debinnyo\u201d beliefs\n \n~\nAppropriate treatment of childhood illnesses\n \n~\nProvision of proper nutrition to children \n23.2 ORO-DENTAL INFECTIONS\n23.2.1. Prevention of Dental Caries and Other Conditions Due to \nPoor Oral  lannin\n \n~\nAdvise patient to reduce sugary foods and soft drinks, and to \nhave adequate fresh fruit and vegetables in their diet\n \n~\nAdvise patient to brush their teeth at least twice a day (morn\u00ad\ning and evening) or preferably after every meal (wait at least 30 \nminutes if you have consumed acidic food like lemon, oranges, \ngrapes)",
        "formatted_content": "<p>1009</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>~</p>\n<p>The procedure is aimed at removal of the primary canine, but</p>\n<p>damage to the surrounding tissues occurs</p>\n<p>~</p>\n<p>The incisions in the mouth and the herbs can lead to oral sepsis,</p>\n<p>bacteraemia, anaemia, and death</p>\n<p>~</p>\n<p>If initial cause of diarrhoea, fever, and vomiting is not addressed,</p>\n<p>dehydration and death can occur</p>\n<p>~</p>\n<p>Depending on the extent of damage, malocclusion can result</p>\n<p>because the permanent canine maybe missing, impacted, or mal\u00ad</p>\n<p>formed</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Counsel the parent/caretaker</p>\n<p>\u0089</p>\n<p>Treat the condition causing the symptoms</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Oral health education</p>\n<p>~</p>\n<p>Sensitise community on dangers of  \u201c\u201debinnyo\u201d beliefs</p>\n<p>~</p>\n<p>Appropriate treatment of childhood illnesses</p>\n<p>~</p>\n<p>Provision of proper nutrition to children</p>\n<h3>23.2 ORO-DENTAL INFECTIONS</h3>\n<p>23.2.1. Prevention of Dental Caries and Other Conditions Due to</p>\n<p>Poor Oral  lannin</p>\n<p>~</p>\n<p>Advise patient to reduce sugary foods and soft drinks, and to</p>\n<p>have adequate fresh fruit and vegetables in their diet</p>\n<p>~</p>\n<p>Advise patient to brush their teeth at least twice a day (morn\u00ad</p>\n<p>ing and evening) or preferably after every meal (wait at least 30</p>\n<p>minutes if you have consumed acidic food like lemon, oranges,</p>\n<p>grapes)</p>"
    },
    {
        "page_number": 1076,
        "content": "1010\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n \n~\nDental flossing at least once a day\n \n~\nTooth strengthening and protection by rinsing with fluoride rins\u00ad\nes and applying sealants to susceptible sites on teeth\n \n~\nPrevention and early management of dental caries\n \n~\nAdvise patient to have a dental check-up every six months\n \n~\nGood nutrition\n23.2.2 Dental Caries\t\n\t\n\t\nICD10 CODE: K02\nSugar-dependent disease resulting into cavities or holes in the teeth.\nCauses\n \n~\nPoor oral hygiene results in bacteria accumulation in a plaque on \nthe tooth surface. Acid produced as a by-product of metabolism \nof dietary carbohydrate by the plaque bacteria causes deminer\u00ad\nalization and disintegration of the tooth surface forming a cavity\nClinical features\n \n~\nLocalized toothache\n \n~\nCavitations in the teeth\n \n~\nTooth sensitivity to hot and cold stimuli\n \n~\nSusceptible sites include pits and fissures of the posterior teeth, \ninterproximal surfaces, and teeth in malocclusion\nDifferential diagnosis\n \n~\nDental abscess\n \n~\nReferred pain from ENT infections, commonly sinusitis\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nParacetamol 1 g every 8 hours\n \n- Child: 10-15 mg/kg every 8 hours\nHC2",
        "formatted_content": "<p>1010</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>~</p>\n<p>Dental flossing at least once a day</p>\n<p>~</p>\n<p>Tooth strengthening and protection by rinsing with fluoride rins\u00ad</p>\n<p>es and applying sealants to susceptible sites on teeth</p>\n<p>~</p>\n<p>Prevention and early management of dental caries</p>\n<p>~</p>\n<p>Advise patient to have a dental check-up every six months</p>\n<p>~</p>\n<p>Good nutrition</p>\n<p>23.2.2 Dental Caries</p>\n<h3>ICD10 CODE: K02</h3>\n<p>Sugar-dependent disease resulting into cavities or holes in the teeth.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Poor oral hygiene results in bacteria accumulation in a plaque on</p>\n<p>the tooth surface. Acid produced as a by-product of metabolism</p>\n<p>of dietary carbohydrate by the plaque bacteria causes deminer\u00ad</p>\n<p>alization and disintegration of the tooth surface forming a cavity</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Localized toothache</p>\n<p>~</p>\n<p>Cavitations in the teeth</p>\n<p>~</p>\n<p>Tooth sensitivity to hot and cold stimuli</p>\n<p>~</p>\n<p>Susceptible sites include pits and fissures of the posterior teeth,</p>\n<p>interproximal surfaces, and teeth in malocclusion</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Dental abscess</p>\n<p>~</p>\n<p>Referred pain from ENT infections, commonly sinusitis</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>- Child: 10-15 mg/kg every 8 hours</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1077,
        "content": "1011\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n\t\n\u0089\nOr ibuprofen 400 mg every 8 hours\n \n- Child: 7-13 mg/kg every 8 hours\n\t\n\u0089\nRefer to specialist for filling or extraction\nHC4\n23.2.2.1 Nursing Caries\nThese are anterior caries in the pre-school child, due to prolonged and \nimproper feeding habits.\nCauses\n \n~\nFrequent and prolonged consumption of fluid containing fer\u00ad\nmentable carbohydrates from a bottle, feeder cup, or on- de\u00ad\nmand nightly breast feeding after 15 months of age\nClinical features\n \n~\nRapid progression of decay commencing labially and quickly en\u00ad\ncircling the teeth\n \n~\nTeeth are affected in order of eruption\n \n~\nLower incisors are rarely affected as they are protected by the \ntongue during suckling and directly cleansed by secretions from \nsublingual and submandibular salivary glands\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nDiscontinue night feeding\n\t\n\u0089\nGently brush teeth with a toothpaste approved for children \n(avoid swallowing)\n\t\n\u0089\nBuild-up of the teeth should be done using composites \nto restore shape and function\n\t\n\u0089\nDisc affected teeth interproximally to create self- cleans\u00ad\ning areas\n\t\n\u0089\nRegular fluoride applications\nHC2\nHC4",
        "formatted_content": "<p>1011</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Or ibuprofen 400 mg every 8 hours</p>\n<p>- Child: 7-13 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Refer to specialist for filling or extraction</p>\n<h3>HC4</h3>\n<p>23.2.2.1 Nursing Caries</p>\n<p>These are anterior caries in the pre-school child, due to prolonged and</p>\n<p>improper feeding habits.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Frequent and prolonged consumption of fluid containing fer\u00ad</p>\n<p>mentable carbohydrates from a bottle, feeder cup, or on- de\u00ad</p>\n<p>mand nightly breast feeding after 15 months of age</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Rapid progression of decay commencing labially and quickly en\u00ad</p>\n<p>circling the teeth</p>\n<p>~</p>\n<p>Teeth are affected in order of eruption</p>\n<p>~</p>\n<p>Lower incisors are rarely affected as they are protected by the</p>\n<p>tongue during suckling and directly cleansed by secretions from</p>\n<p>sublingual and submandibular salivary glands</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Discontinue night feeding</p>\n<p>\u0089</p>\n<p>Gently brush teeth with a toothpaste approved for children</p>\n<p>(avoid swallowing)</p>\n<p>\u0089</p>\n<p>Build-up of the teeth should be done using composites</p>\n<p>to restore shape and function</p>\n<p>\u0089</p>\n<p>Disc affected teeth interproximally to create self- cleans\u00ad</p>\n<p>ing areas</p>\n<p>\u0089</p>\n<p>Regular fluoride applications</p>\n<h3>HC2</h3>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1078,
        "content": "1012\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nPrevention\n\t\n\u0089\nEducate care taker to avoid frequent on-demand liquids at night \nincluding breastfeeding, after 15 months\n23.2.2.2 Rampant and Radiation Caries\nRapid carious attack involving several teeth including those surfaces that \nare usually caries-free (e.g. the smooth surface of a tooth)\nCauses\n \n~\nFrequent ingestion of sugary foods and drinks in individuals with \nreduced saliva flow\n \n~\nProlonged and frequent intake of sugar-based syrup medications\n \n~\nUntreated nursing caries\n \n~\nRadiation caries: Radiation for head and neck cancer may result \nin fibrosis of salivary glands and subsequent reduction in saliva \nflow. Patients often resort to sucking sweets to alleviate their dry \nmouth, which further exacerbates the problem\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRemoval of causative factors as mentioned above\n\t\n\u0089\nEducation, fluoride treatment, tooth restoration, endo\u00ad\ndontic therapy, extractions\nHC4\n23.2.3 Pulpitis\t \t\n\t\n\t\nICD10 CODE: K04.0\nInflammation of the pulp of a tooth\nCauses\n \n~\nCommonly presents as a complication of dental caries\n \n~\nThermal, chemical, or traumatic insult to the pulp\nClinical features",
        "formatted_content": "<p>1012</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Prevention</p>\n<p>\u0089</p>\n<p>Educate care taker to avoid frequent on-demand liquids at night</p>\n<p>including breastfeeding, after 15 months</p>\n<p>23.2.2.2 Rampant and Radiation Caries</p>\n<p>Rapid carious attack involving several teeth including those surfaces that</p>\n<p>are usually caries-free (e.g. the smooth surface of a tooth)</p>\n<p>Causes</p>\n<p>~</p>\n<p>Frequent ingestion of sugary foods and drinks in individuals with</p>\n<p>reduced saliva flow</p>\n<p>~</p>\n<p>Prolonged and frequent intake of sugar-based syrup medications</p>\n<p>~</p>\n<p>Untreated nursing caries</p>\n<p>~</p>\n<p>Radiation caries: Radiation for head and neck cancer may result</p>\n<p>in fibrosis of salivary glands and subsequent reduction in saliva</p>\n<p>flow. Patients often resort to sucking sweets to alleviate their dry</p>\n<p>mouth, which further exacerbates the problem</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Removal of causative factors as mentioned above</p>\n<p>\u0089</p>\n<p>Education, fluoride treatment, tooth restoration, endo\u00ad</p>\n<p>dontic therapy, extractions</p>\n<h3>HC4</h3>\n<p>23.2.3 Pulpitis</p>\n<h3>ICD10 CODE: K04.0</h3>\n<p>Inflammation of the pulp of a tooth</p>\n<p>Causes</p>\n<p>~</p>\n<p>Commonly presents as a complication of dental caries</p>\n<p>~</p>\n<p>Thermal, chemical, or traumatic insult to the pulp</p>\n<p>Clinical features</p>"
    },
    {
        "page_number": 1079,
        "content": "1013\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n \n~\nPulsatile pain that lasts for several hours and worsens at night\n \n~\nThermal sensitivity\n \n~\nTooth is very tender to percussion\nDifferential diagnosis\n \n~\nReferred pain of ENT origin, e.g. sinusitis\n \n~\nPain due to temporomandibular joint pain dysfunction syndrome, \nor erupting mandibular wisdom teeth\n \n~\nDentine sensitivity due to thermal, tactile, or osmotic stimulus\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nGive an analgesic for pain relief\n\t\n\u0089\nParacetamol 1 g every 8 hours\n \n- Child: 10-15 mg/kg every 8 hours\n\t\n\u0089\nOr ibuprofen 400 mg every 8 hours\n \n- Child: 7-13 mg/kg every 8 hours\n\t\n\u0089\nRefer to dentist pulpotomy, endodontic (root canal) \ntreatment, or extraction\nHC2\nHC4\n23.2.4 Acute Periapical Abscess or Dental Abscess ICD10 CODE: \nK04.6-7\nInfection with pus formation at the root of a tooth as a sequel to pulpitis \ncaused by dental caries or trauma\nCauses\n \n~\nMixed bacterial flora but mainly Staphylococcus spp\nClinical features\n \n~\nSevere pain that disturbs sleep\n \n~\nFacial swelling may be localized in the gum or extend to adjacent \ntissues",
        "formatted_content": "<p>1013</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>~</p>\n<p>Pulsatile pain that lasts for several hours and worsens at night</p>\n<p>~</p>\n<p>Thermal sensitivity</p>\n<p>~</p>\n<p>Tooth is very tender to percussion</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Referred pain of ENT origin, e.g. sinusitis</p>\n<p>~</p>\n<p>Pain due to temporomandibular joint pain dysfunction syndrome,</p>\n<p>or erupting mandibular wisdom teeth</p>\n<p>~</p>\n<p>Dentine sensitivity due to thermal, tactile, or osmotic stimulus</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give an analgesic for pain relief</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>- Child: 10-15 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Or ibuprofen 400 mg every 8 hours</p>\n<p>- Child: 7-13 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Refer to dentist pulpotomy, endodontic (root canal)</p>\n<p>treatment, or extraction</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>23.2.4 Acute Periapical Abscess or Dental Abscess ICD10 CODE:</p>\n<h3>K04.6-7</h3>\n<p>Infection with pus formation at the root of a tooth as a sequel to pulpitis</p>\n<p>caused by dental caries or trauma</p>\n<p>Causes</p>\n<p>~</p>\n<p>Mixed bacterial flora but mainly Staphylococcus spp</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Severe pain that disturbs sleep</p>\n<p>~</p>\n<p>Facial swelling may be localized in the gum or extend to adjacent</p>\n<p>tissues</p>"
    },
    {
        "page_number": 1080,
        "content": "1014\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n \n~\nAbscesses of the mandibular incisors or molars may discharge \nextra orally\n \n~\nAffected tooth is mobile and tender to percussion\n \n~\nFever and headache may be present if infection has spread\nDifferential diagnosis\n \n~\nGingivitis\n \n~\nSwelling due to trauma\n \n~\nPain due to sinusitis, temporomandibular joint pain dysfunction \nsyndrome, or erupting wisdom teeth\n \n~\nDentine sensitivity due to thermal, tactile, or osmotic stimulus\nManagement\nTREATMENT\nLOC\nInfections localized to a tooth and its surroundings (swelling lim\u00ad\nited to the gum and no signs of infection extending to anatomi\u00ad\ncal structures, or general signs of infection)\n\t\n\u0089\nPain relief (paracetamol and/or ibuprofen)\n\t\n\u0089\nRoot canal therapy if possible or extraction of tooth\n \n- NO NEED of antibiotics since they cannot reach \nthe site of infection\nIf infection is spreading to local adjacent structures (painful \ngingival and buccal swelling) or systemic signs and symptoms \n(fever) are present:\n\t\n\u0089\nSurgical treatment\n\t\n\u0089\nThen amoxicillin 500 mg every 8 hours\n \n- Child: amoxicillin dispersible tablets 25 mg/kg \n(max 250 mg) every 8 hours\nHC4",
        "formatted_content": "<p>1014</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>~</p>\n<p>Abscesses of the mandibular incisors or molars may discharge</p>\n<p>extra orally</p>\n<p>~</p>\n<p>Affected tooth is mobile and tender to percussion</p>\n<p>~</p>\n<p>Fever and headache may be present if infection has spread</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Gingivitis</p>\n<p>~</p>\n<p>Swelling due to trauma</p>\n<p>~</p>\n<p>Pain due to sinusitis, temporomandibular joint pain dysfunction</p>\n<p>syndrome, or erupting wisdom teeth</p>\n<p>~</p>\n<p>Dentine sensitivity due to thermal, tactile, or osmotic stimulus</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Infections localized to a tooth and its surroundings (swelling lim\u00ad</p>\n<p>ited to the gum and no signs of infection extending to anatomi\u00ad</p>\n<p>cal structures, or general signs of infection)</p>\n<p>\u0089</p>\n<p>Pain relief (paracetamol and/or ibuprofen)</p>\n<p>\u0089</p>\n<p>Root canal therapy if possible or extraction of tooth</p>\n<p>- NO NEED of antibiotics since they cannot reach</p>\n<p>the site of infection</p>\n<p>If infection is spreading to local adjacent structures (painful</p>\n<p>gingival and buccal swelling) or systemic signs and symptoms</p>\n<p>(fever) are present:</p>\n<p>\u0089</p>\n<p>Surgical treatment</p>\n<p>\u0089</p>\n<p>Then amoxicillin 500 mg every 8 hours</p>\n<p>- Child: amoxicillin dispersible tablets 25 mg/kg</p>\n<p>(max 250 mg) every 8 hours</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1081,
        "content": "1015\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n\t\n\u0089\nPlus metronidazole 400 mg every 8 hours\n \n- Child: 10-12.5 mg/kg (max 200 mg per dose)\n\t\n\u0089\nParacetamol 1 g every 8 hours\n \n- Child: 10-15 mg/kg every 8 hours\n\t\n\u0089\nOr Ibuprofen 400 mg every 8 hours\n \n- Child: 7-13 mg/kg every 8 hours\n23.2.4.1 Post-Extraction Bleeding\nBleeding socket can be primary (occurring within first 24 hours post \nextraction) or secondary (occurring beyond 24 hours post- extraction)\nCauses\n \n~\nDisturbing the blood clot by the patient through rinsing or inad\u00ad\nequate compression on the gauze\n \n~\nBony/tooth remnants\n \n~\nPhysical exercise following extraction\n \n~\nBleeding disorder of patient\n \n~\nMedication (e.g. aspirin or anticoagulants)\nClinical features\n \n~\nActive bleeding from the socket\n \n~\nThe socket may or may not have a blood clot\n \n~\nIf patient has lost significant amount of blood; decreased pulse \nrate, hypotension, dehydration may be present Traumatic area of \nsurrounding bone of the socket\n \n~\nFeatures of infection or trauma in secondary bleeding",
        "formatted_content": "<p>1015</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg every 8 hours</p>\n<p>- Child: 10-12.5 mg/kg (max 200 mg per dose)</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>- Child: 10-15 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Or Ibuprofen 400 mg every 8 hours</p>\n<p>- Child: 7-13 mg/kg every 8 hours</p>\n<p>23.2.4.1 Post-Extraction Bleeding</p>\n<p>Bleeding socket can be primary (occurring within first 24 hours post</p>\n<p>extraction) or secondary (occurring beyond 24 hours post- extraction)</p>\n<p>Causes</p>\n<p>~</p>\n<p>Disturbing the blood clot by the patient through rinsing or inad\u00ad</p>\n<p>equate compression on the gauze</p>\n<p>~</p>\n<p>Bony/tooth remnants</p>\n<p>~</p>\n<p>Physical exercise following extraction</p>\n<p>~</p>\n<p>Bleeding disorder of patient</p>\n<p>~</p>\n<p>Medication (e.g. aspirin or anticoagulants)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Active bleeding from the socket</p>\n<p>~</p>\n<p>The socket may or may not have a blood clot</p>\n<p>~</p>\n<p>If patient has lost significant amount of blood; decreased pulse</p>\n<p>rate, hypotension, dehydration may be present Traumatic area of</p>\n<p>surrounding bone of the socket</p>\n<p>~</p>\n<p>Features of infection or trauma in secondary bleeding</p>"
    },
    {
        "page_number": 1082,
        "content": "1016\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nRestore airway, breathing and circulation if necessary\n\t\n\u0089\nCheck blood pressure and pulse\n\t\n\u0089\nClear any clot present and examine the socket to identify \nsource of bleeding\n\t\n\u0089\nIf the bleeding is from soft tissue (which is common) \nremove any foreign body like bone spicule if found, \nsmoothen any sharp edges\n\t\n\u0089\nSuture the wound only if necessary\n\t\n\u0089\nCheck and repack the socket with gauze\n \n- Tell patient to bite on gauze pack for 30 minutes, \nnot to rinse or eat hot foods on that day; at least \nfor 12 hours, and avoid touching the wound\nHC4\n\t\n\u0089\nConsider blood transfusion if Hb decreases to <7 g/dL \nin an otherwise healthy patient before extraction\nIf bleeding continues after 24 hours\n\t\n\u0089\nConsult a haematologist or physician for further man\u00ad\nagement\n23.2.5. Gingivitis\t\nICD10 CODE: K05.0\nInflammation of the gum, usually as a result of plaque accumulation.\nClinical features\n \n~\nGingival redness and swelling\n \n~\nIncreased tendency of the gingiva to bleed on gentle probing, \nduring tooth brushing or even on touch",
        "formatted_content": "<p>1016</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Restore airway, breathing and circulation if necessary</p>\n<p>\u0089</p>\n<p>Check blood pressure and pulse</p>\n<p>\u0089</p>\n<p>Clear any clot present and examine the socket to identify</p>\n<p>source of bleeding</p>\n<p>\u0089</p>\n<p>If the bleeding is from soft tissue (which is common)</p>\n<p>remove any foreign body like bone spicule if found,</p>\n<p>smoothen any sharp edges</p>\n<p>\u0089</p>\n<p>Suture the wound only if necessary</p>\n<p>\u0089</p>\n<p>Check and repack the socket with gauze</p>\n<p>- Tell patient to bite on gauze pack for 30 minutes,</p>\n<p>not to rinse or eat hot foods on that day; at least</p>\n<p>for 12 hours, and avoid touching the wound</p>\n<h3>HC4</h3>\n<p>\u0089</p>\n<p>Consider blood transfusion if Hb decreases to <7 g/dL</p>\n<p>in an otherwise healthy patient before extraction</p>\n<p>If bleeding continues after 24 hours</p>\n<p>\u0089</p>\n<p>Consult a haematologist or physician for further man\u00ad</p>\n<p>agement</p>\n<p>23.2.5. Gingivitis</p>\n<h3>ICD10 CODE: K05.0</h3>\n<p>Inflammation of the gum, usually as a result of plaque accumulation.</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Gingival redness and swelling</p>\n<p>~</p>\n<p>Increased tendency of the gingiva to bleed on gentle probing,</p>\n<p>during tooth brushing or even on touch</p>"
    },
    {
        "page_number": 1083,
        "content": "1017\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nDental check up\n\t\n\u0089\nScaling and polishing\n\t\n\u0089\nSee following sections for specific types of gingivitis\nHC4\nPrevention\n \n~\nProper oral hygiene\n23.2.5.1 Chronic Gingivitis\t\n\t\nICD 10 CODE: K05.1\nInflammatory infiltrate in response to the accumulation of undisturbed \ndental plaque next to the gingival margin\nCauses\n \n~\nMixed anaerobic and aerobic oral flora, e.g., Streptococcus vir\u00ad\nidans, facultative streptococci; fusiform bacteria, spirochaetes, \nviruses, fungi\n \n~\nChemicals\n \n~\nPoor oral hygiene with increase in plaque accumulation\nClinical features\nSwelling and erythema of the gingival margins which bleed on brushing\nPlaque and calculus (tartar) deposits adjacent to the gingival margins\nManagement\nTREATMENT\nLOC\nGeneral measures\nRinse mouth with mouthwash 3 times a day\n\t\n\u0089\nWarm salt solution (5 ml spoonful of salt in 200 ml \nwarm water)\nHC4",
        "formatted_content": "<p>1017</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Dental check up</p>\n<p>\u0089</p>\n<p>Scaling and polishing</p>\n<p>\u0089</p>\n<p>See following sections for specific types of gingivitis</p>\n<h3>HC4</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Proper oral hygiene</p>\n<p>23.2.5.1 Chronic Gingivitis</p>\n<h3>ICD 10 CODE: K05.1</h3>\n<p>Inflammatory infiltrate in response to the accumulation of undisturbed</p>\n<p>dental plaque next to the gingival margin</p>\n<p>Causes</p>\n<p>~</p>\n<p>Mixed anaerobic and aerobic oral flora, e.g., Streptococcus vir\u00ad</p>\n<p>idans, facultative streptococci; fusiform bacteria, spirochaetes,</p>\n<p>viruses, fungi</p>\n<p>~</p>\n<p>Chemicals</p>\n<p>~</p>\n<p>Poor oral hygiene with increase in plaque accumulation</p>\n<p>Clinical features</p>\n<p>Swelling and erythema of the gingival margins which bleed on brushing</p>\n<p>Plaque and calculus (tartar) deposits adjacent to the gingival margins</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>Rinse mouth with mouthwash 3 times a day</p>\n<p>\u0089</p>\n<p>Warm salt solution (5 ml spoonful of salt in 200 ml</p>\n<p>warm water)</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1084,
        "content": "1018\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n\t\n\u0089\nOr hydrogen peroxide solution 6%, (add 15 ml to a 200 \nml cup of warm water)\n\t\n\u0089\nOr chlorhexidine solution 0.2%\nMedicine\n\t\n\u0089\nParacetamol 1 g every 8 hours\n \n- Child: 10-15 mg/kg every 8 hours\n\t\n\u0089\nOr Ibuprofen 400 mg every 8 hours\n \n- Child: 7-13 mg/kg every 8 hours\nIf systemic signs and symptoms present, give a 5-day   course    \nof   an   antibiotic: \n\t\n\u0089\nMetronidazole 400 mg every 8 hours\n \n- Child: 10-12.5 mg/kg (max 200 mg per dose) \nevery 8 hours\n\t\n\u0089\nOr Amoxicillin 500 mg every 8 hours\n \n- Child: Amoxicillin Dispersible tablets 25 mg/kg \nevery 8 hours\n\t\n\u0089\nRefer to a dentist for scaling, root planing lanning and \npolishing, to remove plaque and calculus deposits\nHC2\nCaution\n\uf077\t\nAvoid metronidazole in 1st trimester of pregnancy\n23.2.6.\t Acute Necrotizing Ulcerative Gingivitis (ANUG)/Peri\u00ad\nodontitis/Stomatitis   \t \t\nICD10 CODE: A69.0-1\nAlso known as Vincent\u2019s gingivitis or Vincent\u2019s gingivostomatitis. They \nare infections characterized by oral ulcerations and necrosis.\nGingivitis only affects the gums, periodontitis involves the surrounding \ntissue and attaching the teeth.\nIn stomatitis, there is widespread involvement of mucosa and bone loss, \nuntil the most severe form known as noma or cancrum oris, leading to",
        "formatted_content": "<p>1018</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Or hydrogen peroxide solution 6%, (add 15 ml to a 200</p>\n<p>ml cup of warm water)</p>\n<p>\u0089</p>\n<p>Or chlorhexidine solution 0.2%</p>\n<p>Medicine</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>- Child: 10-15 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Or Ibuprofen 400 mg every 8 hours</p>\n<p>- Child: 7-13 mg/kg every 8 hours</p>\n<p>If systemic signs and symptoms present, give a 5-day   course</p>\n<p>of   an   antibiotic:</p>\n<p>\u0089</p>\n<p>Metronidazole 400 mg every 8 hours</p>\n<p>- Child: 10-12.5 mg/kg (max 200 mg per dose)</p>\n<p>every 8 hours</p>\n<p>\u0089</p>\n<p>Or Amoxicillin 500 mg every 8 hours</p>\n<p>- Child: Amoxicillin Dispersible tablets 25 mg/kg</p>\n<p>every 8 hours</p>\n<p>\u0089</p>\n<p>Refer to a dentist for scaling, root planing lanning and</p>\n<p>polishing, to remove plaque and calculus deposits</p>\n<h3>HC2</h3>\n<p>Caution</p>\n<p>\uf077</p>\n<p>Avoid metronidazole in 1st trimester of pregnancy</p>\n<p>23.2.6.\t Acute Necrotizing Ulcerative Gingivitis (ANUG)/Peri\u00ad</p>\n<p>odontitis/Stomatitis</p>\n<h3>ICD10 CODE: A69.0-1</h3>\n<p>Also known as Vincent\u2019s gingivitis or Vincent\u2019s gingivostomatitis. They</p>\n<p>are infections characterized by oral ulcerations and necrosis.</p>\n<p>Gingivitis only affects the gums, periodontitis involves the surrounding</p>\n<p>tissue and attaching the teeth.</p>\n<p>In stomatitis, there is widespread involvement of mucosa and bone loss,</p>\n<p>until the most severe form known as noma or cancrum oris, leading to</p>"
    },
    {
        "page_number": 1085,
        "content": "1019\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nextensive destruction of facial tissues and bones.\nInadequately treated ANUG will lapse into a less symptomatic form \nknown as chronic ulcerative gingivitis.\nCauses\n \n~\nFusospirochaetal complex together with gram negative anaero\u00ad\nbic organisms\nPredisposing factors\n \n~\nAssociated with poor oral hygiene, stress and smoking\n \n~\nUncontrolled diabetes mellitus, and debilitated patients with \npoor hygiene\n \n~\nMalnutrition\n \n~\nHIV infection\nClinical features\n \n~\nSwelling and erythema of the gingival margins, which bleed eas\u00ad\nily when touched, causing difficulty drinking and eating\n \n~\nPainful papillary yellowish-white ulcers\n \n~\nNecrosis and sloughing of gum margins\n \n~\nLoss of gingiva and support bone around teeth\n \n~\nFoul smelling breath\n \n~\nPatient complains of metallic taste and the sensation of their \nteeth being wedged apart\n \n~\nFever, malaise, and regional lymphadenitis may be present\n \n~\nExtensive destruction of the face and jaws in the severe form of \nCancrum Oris or noma (in malnourished patients)\nDifferential diagnosis\n \n~\nDental abscess\n \n~\nSwelling due to trauma\n \n~\nAcute stomatitis",
        "formatted_content": "<p>1019</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>extensive destruction of facial tissues and bones.</p>\n<p>Inadequately treated ANUG will lapse into a less symptomatic form</p>\n<p>known as chronic ulcerative gingivitis.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Fusospirochaetal complex together with gram negative anaero\u00ad</p>\n<p>bic organisms</p>\n<p>Predisposing factors</p>\n<p>~</p>\n<p>Associated with poor oral hygiene, stress and smoking</p>\n<p>~</p>\n<p>Uncontrolled diabetes mellitus, and debilitated patients with</p>\n<p>poor hygiene</p>\n<p>~</p>\n<p>Malnutrition</p>\n<p>~</p>\n<p>HIV infection</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Swelling and erythema of the gingival margins, which bleed eas\u00ad</p>\n<p>ily when touched, causing difficulty drinking and eating</p>\n<p>~</p>\n<p>Painful papillary yellowish-white ulcers</p>\n<p>~</p>\n<p>Necrosis and sloughing of gum margins</p>\n<p>~</p>\n<p>Loss of gingiva and support bone around teeth</p>\n<p>~</p>\n<p>Foul smelling breath</p>\n<p>~</p>\n<p>Patient complains of metallic taste and the sensation of their</p>\n<p>teeth being wedged apart</p>\n<p>~</p>\n<p>Fever, malaise, and regional lymphadenitis may be present</p>\n<p>~</p>\n<p>Extensive destruction of the face and jaws in the severe form of</p>\n<p>Cancrum Oris or noma (in malnourished patients)</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Dental abscess</p>\n<p>~</p>\n<p>Swelling due to trauma</p>\n<p>~</p>\n<p>Acute stomatitis</p>"
    },
    {
        "page_number": 1086,
        "content": "1020\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n \n~\nOral thrush\n \n~\nChemical oral ulcers\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nRinse mouth with mouthwash 3 times a day\n\t\n\u0089\nWarm salt solution (5 ml spoonful of salt in 200 ml \nwarm water)\n\t\n\u0089\nOr hydrogen peroxide solution 6%, (add 15 ml to a 200 \nml cup of warm water)\n\t\n\u0089\nOr chlorhexidine solution 0.2% f  Surgical      debridement \nManage underlying condition\n\t\n\u0089\nMetronidazole 400 mg every 8 hours\n\t\n\u0089\nChild: 10-12.5 mg/kg (max 200 mg per dose) every \n8 hours\n\t\n\u0089\nRefer to dental specialist\nHC4\n23.2.7.\t Periodontitis\t\n\t\n\t\nICD10 CODE: K05.2-3\nPeriodontitis occurs when inflammation or infection of the gums (gingivitis) \noccurs and is not treated. Infection and inflammation spreads from the \ngums (gingiva) to the ligaments and bone that support the teeth. Loss \nof support causes the teeth to become loose and eventually fall out.\nCauses\n \n~\nMixed microbial flora commonly B. gingivalis, B. forsythus, B. \nintermedius, Wolinella sp, and Fusobacter\nClinical features\n \n~\nBleeding of gums on probing and brushing",
        "formatted_content": "<p>1020</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>~</p>\n<p>Oral thrush</p>\n<p>~</p>\n<p>Chemical oral ulcers</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Rinse mouth with mouthwash 3 times a day</p>\n<p>\u0089</p>\n<p>Warm salt solution (5 ml spoonful of salt in 200 ml</p>\n<p>warm water)</p>\n<p>\u0089</p>\n<p>Or hydrogen peroxide solution 6%, (add 15 ml to a 200</p>\n<p>ml cup of warm water)</p>\n<p>\u0089</p>\n<p>Or chlorhexidine solution 0.2% f  Surgical      debridement</p>\n<p>Manage underlying condition</p>\n<p>\u0089</p>\n<p>Metronidazole 400 mg every 8 hours</p>\n<p>\u0089</p>\n<p>Child: 10-12.5 mg/kg (max 200 mg per dose) every</p>\n<p>8 hours</p>\n<p>\u0089</p>\n<p>Refer to dental specialist</p>\n<h3>HC4</h3>\n<p>23.2.7.\t Periodontitis</p>\n<h3>ICD10 CODE: K05.2-3</h3>\n<p>Periodontitis occurs when inflammation or infection of the gums (gingivitis)</p>\n<p>occurs and is not treated. Infection and inflammation spreads from the</p>\n<p>gums (gingiva) to the ligaments and bone that support the teeth. Loss</p>\n<p>of support causes the teeth to become loose and eventually fall out.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Mixed microbial flora commonly B. gingivalis, B. forsythus, B.</p>\n<p>intermedius, Wolinella sp, and Fusobacter</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Bleeding of gums on probing and brushing</p>"
    },
    {
        "page_number": 1087,
        "content": "1021\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n \n~\nFoul smelling breath\n \n~\nPresence of periodontal pockets due to apical migration of the \njunctional epithelium beyond the enamel-cemental junction of \nthe tooth\n \n~\nTooth sensitivity to thermal changes\n \n~\nPresence of sub-gingival calculus with increased tooth mobility\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nGive instructions on oral hygiene\n\t\n\u0089\nOral rinses with mouthwash consisting of\n\t\n\u0089\nchlorhexidine solution 0.2% 3 times a day\n\t\n\u0089\nRefer to a dentist for scaling, root  lanning, and polishing, \nto remove plaque and calculus deposits\nHC2\nHC4\n23.2.8.\t Periodontal Abscess\t\n\t\nICD10 CODE: K05.21\nLocalised collection of pus within a periodontal pocket  \nCauses\n \n~\nEntry of virulent organisms into an existing pocket\n \n~\nImpact of a foreign body, e.g., a fishbone into healthy periodon\u00ad\ntal membrane\nClinical features\n \n~\nLocalised, red and tender swelling of gum\n \n~\nNeed to differentiate it from a dental abscess",
        "formatted_content": "<p>1021</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>~</p>\n<p>Foul smelling breath</p>\n<p>~</p>\n<p>Presence of periodontal pockets due to apical migration of the</p>\n<p>junctional epithelium beyond the enamel-cemental junction of</p>\n<p>the tooth</p>\n<p>~</p>\n<p>Tooth sensitivity to thermal changes</p>\n<p>~</p>\n<p>Presence of sub-gingival calculus with increased tooth mobility</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Give instructions on oral hygiene</p>\n<p>\u0089</p>\n<p>Oral rinses with mouthwash consisting of</p>\n<p>\u0089</p>\n<p>chlorhexidine solution 0.2% 3 times a day</p>\n<p>\u0089</p>\n<p>Refer to a dentist for scaling, root  lanning, and polishing,</p>\n<p>to remove plaque and calculus deposits</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>23.2.8.\t Periodontal Abscess</p>\n<h3>ICD10 CODE: K05.21</h3>\n<p>Localised collection of pus within a periodontal pocket</p>\n<p>Causes</p>\n<p>~</p>\n<p>Entry of virulent organisms into an existing pocket</p>\n<p>~</p>\n<p>Impact of a foreign body, e.g., a fishbone into healthy periodon\u00ad</p>\n<p>tal membrane</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Localised, red and tender swelling of gum</p>\n<p>~</p>\n<p>Need to differentiate it from a dental abscess</p>"
    },
    {
        "page_number": 1088,
        "content": "1022\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nDENTAL ABSCESS-PERI\u00ad\nAPICAL ABSCESS\nPERIODONTAL ABSCESS\nAssociated tooth is non-vital\n \n~\nAssociated tooth is vital\nTooth is tender to vertical \npercussion\n \n~\nTooth is tender to lateral move\u00ad\nments\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIncision and drainage under a local anaesthetic\n\t\n\u0089\nDebridement of the pocket with a scaler\nGive an analgesic for 5-7 days\n\t\n\u0089\nParacetamol 1 g every 8 hours\n \n- Child: 10-15 mg/kg every 8 hours\n\t\n\u0089\nOr ibuprofen 400 mg every 8 hours\n \n- Child: 7-13 mg/kg every 8 hours\n\t\n\u0089\nOr diclofenac 50 mg every 8 hours\nGive antibiotics for 5 days\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours\n\t\n\u0089\nPlus Metronidazole 400 mg every 8 hours\nHC4\n23.2.9.\t Stomatitis\t\n\t\n\t\nICD10 CODE: K12\nInflammation of the epithelial lining of the oral mucosa\nCauses\n \n~\nNutritional deficiency, e.g. vitamin A\n \n~\nHormonal changes\n \n~\nInfections: Spirochaetes, Bacilli, Candida, Measles virus, Herpes \nsimplex virus",
        "formatted_content": "<p>1022</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>DENTAL ABSCESS-PERI\u00ad</h3>\n<h3>APICAL ABSCESS</h3>\n<h3>PERIODONTAL ABSCESS</h3>\n<p>Associated tooth is non-vital</p>\n<p>~</p>\n<p>Associated tooth is vital</p>\n<p>Tooth is tender to vertical</p>\n<p>percussion</p>\n<p>~</p>\n<p>Tooth is tender to lateral move\u00ad</p>\n<p>ments</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Incision and drainage under a local anaesthetic</p>\n<p>\u0089</p>\n<p>Debridement of the pocket with a scaler</p>\n<p>Give an analgesic for 5-7 days</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>- Child: 10-15 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Or ibuprofen 400 mg every 8 hours</p>\n<p>- Child: 7-13 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Or diclofenac 50 mg every 8 hours</p>\n<p>Give antibiotics for 5 days</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours</p>\n<p>\u0089</p>\n<p>Plus Metronidazole 400 mg every 8 hours</p>\n<h3>HC4</h3>\n<p>23.2.9.\t Stomatitis</p>\n<h3>ICD10 CODE: K12</h3>\n<p>Inflammation of the epithelial lining of the oral mucosa</p>\n<p>Causes</p>\n<p>~</p>\n<p>Nutritional deficiency, e.g. vitamin A</p>\n<p>~</p>\n<p>Hormonal changes</p>\n<p>~</p>\n<p>Infections: Spirochaetes, Bacilli, Candida, Measles virus, Herpes</p>\n<p>simplex virus</p>"
    },
    {
        "page_number": 1089,
        "content": "1023\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nClinical features\n \n~\nInflammation of the tongue and lining of mouth - tongueis red, \nraw, and painful\n \n~\nUlcers on the gum, palate, lips\n \n~\nThrush (in babies and HIV/debilitated patients)\n \n~\nSwelling and bleeding of gums\nDifferential diagnosis\n \n~\nAllergic reactions, erythema multiforme, pemphigus\n \n~\nLead poisoning\n \n~\nLichen planus\n \n~\nInvestigations\n \n~\nSwab mouth for microscopy, and culture and sensitivity of bac\u00ad\nteria and fungi (though normal oral flora may give false positives)\n \n~\nBlood: For Rapid Plasma Reagin (RPR) test, HIV serology\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRinse mouth 3 times a day with Salt solution (dissolve 1 \nteaspoon of salt in a cup of warm water)\n\t\n\u0089\nOr Hydrogen peroxide solution 6% (add 15 ml to a \ncup/200 ml of warm water)\n\t\n\u0089\nOr chlorhexidine mouth wash 0.2%\n\t\n\u0089\nParacetamol 1 g every 8 hours\n \n- Child: 10-15 mg/kg every 8 hours\n\t\n\u0089\nOr a topical analgesic\n\t\n\u0089\nContinue treatment until healing takes place\nHC2",
        "formatted_content": "<p>1023</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Inflammation of the tongue and lining of mouth - tongueis red,</p>\n<p>raw, and painful</p>\n<p>~</p>\n<p>Ulcers on the gum, palate, lips</p>\n<p>~</p>\n<p>Thrush (in babies and HIV/debilitated patients)</p>\n<p>~</p>\n<p>Swelling and bleeding of gums</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Allergic reactions, erythema multiforme, pemphigus</p>\n<p>~</p>\n<p>Lead poisoning</p>\n<p>~</p>\n<p>Lichen planus</p>\n<p>~</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Swab mouth for microscopy, and culture and sensitivity of bac\u00ad</p>\n<p>teria and fungi (though normal oral flora may give false positives)</p>\n<p>~</p>\n<p>Blood: For Rapid Plasma Reagin (RPR) test, HIV serology</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Rinse mouth 3 times a day with Salt solution (dissolve 1</p>\n<p>teaspoon of salt in a cup of warm water)</p>\n<p>\u0089</p>\n<p>Or Hydrogen peroxide solution 6% (add 15 ml to a</p>\n<p>cup/200 ml of warm water)</p>\n<p>\u0089</p>\n<p>Or chlorhexidine mouth wash 0.2%</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours</p>\n<p>- Child: 10-15 mg/kg every 8 hours</p>\n<p>\u0089</p>\n<p>Or a topical analgesic</p>\n<p>\u0089</p>\n<p>Continue treatment until healing takes place</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1090,
        "content": "1024\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n23.2.9.1\t\nDenture Stomatitis\nRedness of the palate under a denture with petechial and whitish areas\nCauses\n \n~\n90% of cases due to Candida albicans, 9% other Candida\n \n~\nspecies, and 1% Klebsiella\n \n~\nPoor denture hygiene\n \n~\nNight-time wear of dentures\n \n~\nTrauma\n \n~\nIncreased intake of sugary foods\nClinical features\n \n~\nMild inflammation and redness under denture\n \n~\nPetechial and whitish areas in severe cases\n \n~\nBurning sensation but no pain or tenderness\nDifferential diagnosis\n \n~\nAcrylic allergy\nInvestigations\n \n~\nExclude diabetes, i.e. blood glucose\nManagement",
        "formatted_content": "<p>1024</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>23.2.9.1</p>\n<p>Denture Stomatitis</p>\n<p>Redness of the palate under a denture with petechial and whitish areas</p>\n<p>Causes</p>\n<p>~</p>\n<p>90% of cases due to Candida albicans, 9% other Candida</p>\n<p>~</p>\n<p>species, and 1% Klebsiella</p>\n<p>~</p>\n<p>Poor denture hygiene</p>\n<p>~</p>\n<p>Night-time wear of dentures</p>\n<p>~</p>\n<p>Trauma</p>\n<p>~</p>\n<p>Increased intake of sugary foods</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Mild inflammation and redness under denture</p>\n<p>~</p>\n<p>Petechial and whitish areas in severe cases</p>\n<p>~</p>\n<p>Burning sensation but no pain or tenderness</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Acrylic allergy</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Exclude diabetes, i.e. blood glucose</p>\n<p>Management</p>"
    },
    {
        "page_number": 1091,
        "content": "1025\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n\t\n\u0089\nRemove dentures at night\n\t\n\u0089\nImprove denture hygiene by soaking in hypochlorite \ncleanser (10 drops of household bleach in a denture cup \nor container filled with tap water) and brushing fitting \nsurface with a soft brush\n\t\n\u0089\nReplace ill-fitting dentures\n\t\n\u0089\nReduce sugar intake\n\t\n\u0089\nNystatin suspension 100,000 IU/ml 6 hourly\nHC2\n23.2.10.\tAphthous Ulceration\t\nICD10 CODE: K12.0\nAphthous ulcers or recurrent aphthous stomatitis (RAS) are painful re\u00ad\ncurrent mucous membrane ulcerations. Usually affect the non-keratinized \noral mucous membrane\nClinical features\nThere are 3 types of aphthous ulcers",
        "formatted_content": "<p>1025</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Remove dentures at night</p>\n<p>\u0089</p>\n<p>Improve denture hygiene by soaking in hypochlorite</p>\n<p>cleanser (10 drops of household bleach in a denture cup</p>\n<p>or container filled with tap water) and brushing fitting</p>\n<p>surface with a soft brush</p>\n<p>\u0089</p>\n<p>Replace ill-fitting dentures</p>\n<p>\u0089</p>\n<p>Reduce sugar intake</p>\n<p>\u0089</p>\n<p>Nystatin suspension 100,000 IU/ml 6 hourly</p>\n<h3>HC2</h3>\n<p>23.2.10.\tAphthous Ulceration</p>\n<h3>ICD10 CODE: K12.0</h3>\n<p>Aphthous ulcers or recurrent aphthous stomatitis (RAS) are painful re\u00ad</p>\n<p>current mucous membrane ulcerations. Usually affect the non-keratinized</p>\n<p>oral mucous membrane</p>\n<p>Clinical features</p>\n<p>There are 3 types of aphthous ulcers</p>"
    },
    {
        "page_number": 1092,
        "content": "1026\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTYPE\nFEATURES\nMinor aphthous ulcers\n \n~\nSmall round/oval ulcers (2-4 mm)\n \n~\nSurrounded by erythematous ul\u00ad\ncers\n \n~\nOccur in groups of only a few ul\u00ad\ncers (i.e., 1-6) at a time\n \n~\nMainly on the non-keratinized \nmobile mucosa of the lips, \ncheeks, floor of the mouth, sulci, \nor ventrum of the tongue\n \n~\nHeal spontaneously in 7-10 days\n \n~\nLeave little or no evidence of \nscarring\nMajor aphthous ulcers\n \n~\nPainful ulcers on non-keratinized \noral mucous membrane\n \n~\nLarge (1-3 cm) edged ulcers\n \n~\nSeveral may be present simulta\u00ad\nneously\n \n~\nMarked tissue destruction, some\u00ad\ntimes constantly present\n \n~\nHealing is prolonged often with \nscarring\nHerpetiform ulcers\n \n~\nOccur in a group of small (1-5 \nmm) multiple ulcers and heal \nwithin 7-10 days\nManagement\nGoal of treatment: to offer symptomatic treatment for pain and discomfort, \nespecially when ulcers are causing problems with eating.",
        "formatted_content": "<p>1026</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TYPE</h3>\n<h3>FEATURES</h3>\n<p>Minor aphthous ulcers</p>\n<p>~</p>\n<p>Small round/oval ulcers (2-4 mm)</p>\n<p>~</p>\n<p>Surrounded by erythematous ul\u00ad</p>\n<p>cers</p>\n<p>~</p>\n<p>Occur in groups of only a few ul\u00ad</p>\n<p>cers (i.e., 1-6) at a time</p>\n<p>~</p>\n<p>Mainly on the non-keratinized</p>\n<p>mobile mucosa of the lips,</p>\n<p>cheeks, floor of the mouth, sulci,</p>\n<p>or ventrum of the tongue</p>\n<p>~</p>\n<p>Heal spontaneously in 7-10 days</p>\n<p>~</p>\n<p>Leave little or no evidence of</p>\n<p>scarring</p>\n<p>Major aphthous ulcers</p>\n<p>~</p>\n<p>Painful ulcers on non-keratinized</p>\n<p>oral mucous membrane</p>\n<p>~</p>\n<p>Large (1-3 cm) edged ulcers</p>\n<p>~</p>\n<p>Several may be present simulta\u00ad</p>\n<p>neously</p>\n<p>~</p>\n<p>Marked tissue destruction, some\u00ad</p>\n<p>times constantly present</p>\n<p>~</p>\n<p>Healing is prolonged often with</p>\n<p>scarring</p>\n<p>Herpetiform ulcers</p>\n<p>~</p>\n<p>Occur in a group of small (1-5</p>\n<p>mm) multiple ulcers and heal</p>\n<p>within 7-10 days</p>\n<p>Management</p>\n<p>Goal of treatment: to offer symptomatic treatment for pain and discomfort,</p>\n<p>especially when ulcers are causing problems with eating.</p>"
    },
    {
        "page_number": 1093,
        "content": "1027\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n\t\n\u0089\nSalt mouth wash for cleansing\n\t\n\u0089\nPrednisolone 20 mg every 8 hours for 3 days; then taper \ndose to 10 mg every 8 hours for 2 days; then 5 mg every \n8 hours for 2 days\n\t\n\u0089\nOr topical triamcinolone paste applied twice a day\n\t\n\u0089\nParacetamol 1 g every 8 hours for 3 days\n\t\n\u0089\nRefer to specialist if ulcers persist for more than 3 weeks \napart from the treatment\nHC4\nNote\n\uf077\t\nOral gel containing an anti-inflammatory agent combined with \nanalgesic and antiseptic is ideal treatment\n23.2.11 Pericoronitis\t\n\t\n\t\nICD10 CODE: K05.30\nInflammation of the operculum covering an erupting tooth occurs more \ncommonly in association with the mandibular wisdom teeth.\nCauses\n \n~\nUsually associated with partially erupted and/or impacted third \nmolars\n \n~\nAssociated trauma from a tooth in the opposing archis usually \npresent\nClinical features\n \n~\nPain, trismus, swelling\n \n~\nHalitosis\n \n~\nThe operculum is swollen, red, and often ulcerated\n \n~\nFever and regional lymphadenitis may be present",
        "formatted_content": "<p>1027</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Salt mouth wash for cleansing</p>\n<p>\u0089</p>\n<p>Prednisolone 20 mg every 8 hours for 3 days; then taper</p>\n<p>dose to 10 mg every 8 hours for 2 days; then 5 mg every</p>\n<p>8 hours for 2 days</p>\n<p>\u0089</p>\n<p>Or topical triamcinolone paste applied twice a day</p>\n<p>\u0089</p>\n<p>Paracetamol 1 g every 8 hours for 3 days</p>\n<p>\u0089</p>\n<p>Refer to specialist if ulcers persist for more than 3 weeks</p>\n<p>apart from the treatment</p>\n<h3>HC4</h3>\n<p>Note</p>\n<p>\uf077</p>\n<p>Oral gel containing an anti-inflammatory agent combined with</p>\n<p>analgesic and antiseptic is ideal treatment</p>\n<p>23.2.11 Pericoronitis</p>\n<h3>ICD10 CODE: K05.30</h3>\n<p>Inflammation of the operculum covering an erupting tooth occurs more</p>\n<p>commonly in association with the mandibular wisdom teeth.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Usually associated with partially erupted and/or impacted third</p>\n<p>molars</p>\n<p>~</p>\n<p>Associated trauma from a tooth in the opposing archis usually</p>\n<p>present</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Pain, trismus, swelling</p>\n<p>~</p>\n<p>Halitosis</p>\n<p>~</p>\n<p>The operculum is swollen, red, and often ulcerated</p>\n<p>~</p>\n<p>Fever and regional lymphadenitis may be present</p>"
    },
    {
        "page_number": 1094,
        "content": "1028\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nManagement\nTREATMENT\nLOC\nSurgery\n\t\n\u0089\nOperculectomy done under local anaesthesia\n\t\n\u0089\nExtraction of the third molar associated with the condition\n\t\n\u0089\nGrinding or extraction of the opposing tooth\n\t\n\u0089\nApply caustic agents (trichloracetic acid and glycerine)\nTreat with analgesic and antibiotic for 5-7 days\n\t\n\u0089\nParacetamol 500 mg every 8 hours Child: 10-15 mg/\nkg every 8 hours\n \n- Or ibuprofen 400 mg every 8 hours Child: 7-13 \nmg/kg every 8 hours\n \n- Or diclofenac 50 mg every 8 hours\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours Child: 25 mg/kg \nevery 8 hours\n\t\n\u0089\nAdd metronidazole 400 mg every 8 hours if necessary \nChild:10-12.5 mg/kg per dose\nHC4\n23.2.12.\tOsteomyelitis of the Jaw \t\nICD10 CODE: M27.2\nInflammation of the medullary portion of the jaw bone which extends to \ninvolve the periosteum of the affected area. Infection in the bone ends up \nwith pus formation in the medullary cavity or beneath the periosteum, \nand obstructs the blood supply. The infected bone becomes necrotic \nfollowing ischaemia.\nClinical features\nInitial stage\n \n~\nMalaise and fever; there is no swelling\n \n~\nEnlargement of regional lymphnodes\n \n~\nTeeth in affected area become painful and loose, thus causing \ndifficulty in chewing",
        "formatted_content": "<p>1028</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Surgery</p>\n<p>\u0089</p>\n<p>Operculectomy done under local anaesthesia</p>\n<p>\u0089</p>\n<p>Extraction of the third molar associated with the condition</p>\n<p>\u0089</p>\n<p>Grinding or extraction of the opposing tooth</p>\n<p>\u0089</p>\n<p>Apply caustic agents (trichloracetic acid and glycerine)</p>\n<p>Treat with analgesic and antibiotic for 5-7 days</p>\n<p>\u0089</p>\n<p>Paracetamol 500 mg every 8 hours Child: 10-15 mg/</p>\n<p>kg every 8 hours</p>\n<p>- Or ibuprofen 400 mg every 8 hours Child: 7-13</p>\n<p>mg/kg every 8 hours</p>\n<p>- Or diclofenac 50 mg every 8 hours</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours Child: 25 mg/kg</p>\n<p>every 8 hours</p>\n<p>\u0089</p>\n<p>Add metronidazole 400 mg every 8 hours if necessary</p>\n<p>Child:10-12.5 mg/kg per dose</p>\n<h3>HC4</h3>\n<p>23.2.12.\tOsteomyelitis of the Jaw</p>\n<h3>ICD10 CODE: M27.2</h3>\n<p>Inflammation of the medullary portion of the jaw bone which extends to</p>\n<p>involve the periosteum of the affected area. Infection in the bone ends up</p>\n<p>with pus formation in the medullary cavity or beneath the periosteum,</p>\n<p>and obstructs the blood supply. The infected bone becomes necrotic</p>\n<p>following ischaemia.</p>\n<p>Clinical features</p>\n<p>Initial stage</p>\n<p>~</p>\n<p>Malaise and fever; there is no swelling</p>\n<p>~</p>\n<p>Enlargement of regional lymphnodes</p>\n<p>~</p>\n<p>Teeth in affected area become painful and loose, thus causing</p>\n<p>difficulty in chewing</p>"
    },
    {
        "page_number": 1095,
        "content": "1029\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nLater stage\n \n~\nBone undergoes necrosis and area becomes very painful and \nswollen\n \n~\nPus ruptures through the periosteum into the muscular and sub\u00ad\ncutaneous fascia. Eventually it is discharged on to the skin sur\u00ad\nface through a sinus\nInvestigations\n \n\u0081\nX-ray- Orthopantomograph (OPG) will show characteristic \nfeatures (e.g., widening of periodontal spaces, changes in bone \ntrabeculation, areas of radiolucency and sequestra formation in \nchronic stage)\n \n\u0081\nCulture and sensitivity of pus\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nIncision and adequate drainage of confirmed pus accu\u00ad\nmulation which is accessible\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours for 7-10 days\n\t\n\u0089\nOr cloxacillin 500 mg every 6 hours\n\t\n\u0089\nPlus metronidazole 400 mg every 8 hours\nSurgery\n\t\n\u0089\nRemoval of the sequestrum by surgical intervention\nH\nRR\nNote\n\uf077\t\nChange medication according to the results of culture and sen\u00ad\nsitivity testing\n\uf077\t\nRefer to regional referral hospital in case of long- standing pus \ndischarge and sinuses from the jaws",
        "formatted_content": "<p>1029</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Later stage</p>\n<p>~</p>\n<p>Bone undergoes necrosis and area becomes very painful and</p>\n<p>swollen</p>\n<p>~</p>\n<p>Pus ruptures through the periosteum into the muscular and sub\u00ad</p>\n<p>cutaneous fascia. Eventually it is discharged on to the skin sur\u00ad</p>\n<p>face through a sinus</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>X-ray- Orthopantomograph (OPG) will show characteristic</p>\n<p>features (e.g., widening of periodontal spaces, changes in bone</p>\n<p>trabeculation, areas of radiolucency and sequestra formation in</p>\n<p>chronic stage)</p>\n<p>\u0081</p>\n<p>Culture and sensitivity of pus</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Incision and adequate drainage of confirmed pus accu\u00ad</p>\n<p>mulation which is accessible</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours for 7-10 days</p>\n<p>\u0089</p>\n<p>Or cloxacillin 500 mg every 6 hours</p>\n<p>\u0089</p>\n<p>Plus metronidazole 400 mg every 8 hours</p>\n<p>Surgery</p>\n<p>\u0089</p>\n<p>Removal of the sequestrum by surgical intervention</p>\n<p>H</p>\n<p>RR</p>\n<p>Note</p>\n<p>\uf077</p>\n<p>Change medication according to the results of culture and sen\u00ad</p>\n<p>sitivity testing</p>\n<p>\uf077</p>\n<p>Refer to regional referral hospital in case of long- standing pus</p>\n<p>discharge and sinuses from the jaws</p>"
    },
    {
        "page_number": 1096,
        "content": "1030\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\n23.3 HIV/AIDS ASSOCIATED CONDITIONS\n23.3.1 Oral Candidiasis\t \t\n\t\nICD10 CODE: B37.0\nCause\n \n~\nCaused primarily by Candida albicans\nClinical features\n \n~\nCommon in immunosuppressed, infants, and after prolonged \nantibiotic treatment\n \n~\nIn advanced HIV it can present as intractable oral and oesopha\u00ad\ngeal candidiasis. Angular cheilitis is also common\nManagement\nTREATMENT\nLOC\nOral candidiasis\n\t\n\u0089\nNystatin tablets 500,000-1,000,000 IU every 6 hours for \n10 days (chewed then swallowed) Child <5 years: Nystatin \noral suspension 100,000 IU every 6 hours for 10 days\n \n- Child 5-12years: 200,000 IU per dose every 6 \nhours for 10 days\nHC2\nOropharyngeal candidiasis\n\t\n\u0089\nFluconazole loading dose 400 mg, then 150-200 mg \ndaily for 14-21 days\n \n- Child: loading dose 6 mg/kg, then 3 mg/kg daily\nHC3\n23.3.2 Herpes Infections\t\nICD10 CODE: B00\nInfections caused by virus herpes (simplex and zoster)\nCauses\n \n~\nBoth simplex and zoster infections can affect the face and oral \ncavity",
        "formatted_content": "<p>1030</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>23.3 HIV/AIDS ASSOCIATED CONDITIONS</h3>\n<p>23.3.1 Oral Candidiasis</p>\n<h3>ICD10 CODE: B37.0</h3>\n<p>Cause</p>\n<p>~</p>\n<p>Caused primarily by Candida albicans</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Common in immunosuppressed, infants, and after prolonged</p>\n<p>antibiotic treatment</p>\n<p>~</p>\n<p>In advanced HIV it can present as intractable oral and oesopha\u00ad</p>\n<p>geal candidiasis. Angular cheilitis is also common</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Oral candidiasis</p>\n<p>\u0089</p>\n<p>Nystatin tablets 500,000-1,000,000 IU every 6 hours for</p>\n<p>10 days (chewed then swallowed) Child <5 years: Nystatin</p>\n<p>oral suspension 100,000 IU every 6 hours for 10 days</p>\n<p>- Child 5-12years: 200,000 IU per dose every 6</p>\n<p>hours for 10 days</p>\n<h3>HC2</h3>\n<p>Oropharyngeal candidiasis</p>\n<p>\u0089</p>\n<p>Fluconazole loading dose 400 mg, then 150-200 mg</p>\n<p>daily for 14-21 days</p>\n<p>- Child: loading dose 6 mg/kg, then 3 mg/kg daily</p>\n<h3>HC3</h3>\n<p>23.3.2 Herpes Infections</p>\n<h3>ICD10 CODE: B00</h3>\n<p>Infections caused by virus herpes (simplex and zoster)</p>\n<p>Causes</p>\n<p>~</p>\n<p>Both simplex and zoster infections can affect the face and oral</p>\n<p>cavity</p>"
    },
    {
        "page_number": 1097,
        "content": "1031\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nClinical features\n \n~\nHerpes simplex: cluster of painful vesicles around the mouth \n(cold sores or fever blisters). Can be recurrent\n \n~\nHerpes zoster: multiple small vesicles (2-3 mm) that ulcerate and \ncoalesce to form larger ulcers on the oral mucosa\n \n- Commonly on the vermillion border, gingiva, dorsal tongue, \nand hard palate\n \n- Always present as a unilateral lesion and never cross the\n \n- midline\n \n- Pre-eruption pain followed by the development of painful \nvesicles on the skin or oral mucosa that rupture to give rise to \nulcers or encrusting skin wounds in the distribution outlined \nabove.\n \n- Post herpetic neuralgia may continue for years\nManagement\nTREATMENT\nLOC\nHerpes simplex\n\t\n\u0089\nReassure, it will resolve in most cases\n\t\n\u0089\nFor severe forms consider acyclovir 400 mg every 8 \nhours for 5-7 days\nHerpes Zoster\n\t\n\u0089\nAcyclovir 800 mg 5 times daily for 5 days\n\t\n\u0089\nMay require antibiotic therapy if the area becomes sec\u00ad\nondarily infected\n\t\n\u0089\nAnalgesics, topical anaesthetic (e.g. lidocaine)\nHC2\nHC4\n23.3.3 Kaposi\u2019s Sarcoma\t\t\n\t\nICD10 CODE: C46\nA malignancy of vascular endothelium that, until the advent of AIDS, \nwas seen only occasionally in Jews and immune suppressed patients",
        "formatted_content": "<p>1031</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Herpes simplex: cluster of painful vesicles around the mouth</p>\n<p>(cold sores or fever blisters). Can be recurrent</p>\n<p>~</p>\n<p>Herpes zoster: multiple small vesicles (2-3 mm) that ulcerate and</p>\n<p>coalesce to form larger ulcers on the oral mucosa</p>\n<p>- Commonly on the vermillion border, gingiva, dorsal tongue,</p>\n<p>and hard palate</p>\n<p>- Always present as a unilateral lesion and never cross the</p>\n<p>- midline</p>\n<p>- Pre-eruption pain followed by the development of painful</p>\n<p>vesicles on the skin or oral mucosa that rupture to give rise to</p>\n<p>ulcers or encrusting skin wounds in the distribution outlined</p>\n<p>above.</p>\n<p>- Post herpetic neuralgia may continue for years</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Herpes simplex</p>\n<p>\u0089</p>\n<p>Reassure, it will resolve in most cases</p>\n<p>\u0089</p>\n<p>For severe forms consider acyclovir 400 mg every 8</p>\n<p>hours for 5-7 days</p>\n<p>Herpes Zoster</p>\n<p>\u0089</p>\n<p>Acyclovir 800 mg 5 times daily for 5 days</p>\n<p>\u0089</p>\n<p>May require antibiotic therapy if the area becomes sec\u00ad</p>\n<p>ondarily infected</p>\n<p>\u0089</p>\n<p>Analgesics, topical anaesthetic (e.g. lidocaine)</p>\n<h3>HC2</h3>\n<h3>HC4</h3>\n<p>23.3.3 Kaposi\u2019s Sarcoma</p>\n<h3>ICD10 CODE: C46</h3>\n<p>A malignancy of vascular endothelium that, until the advent of AIDS,</p>\n<p>was seen only occasionally in Jews and immune suppressed patients</p>"
    },
    {
        "page_number": 1098,
        "content": "1032\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nClinical features\n \n~\nPainless purplish swelling on the skin\n \n~\nIn the mouth, the palate is the most frequent site\nInvestigation\n \n\u0081\nBiopsy to confirm histology\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nRefer for chemotherapy\nRR\n23.3.4 Hairy Leukoplakia\nBenign lesion, usually asymptomatic, associated with HIV immunosup\u00ad\npression, and linked to Epstein Barr Virus infection\nClinical features\n \n~\nAdherent white, corrugated plaque, usually found bilaterally on \nthe borders of the tongue\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nPodophyllin resin 25%: Apply to lesion once weekly if \nnecessary\n\t\n\u0089\nManage HIV infection as per national guidelines\nRR\n23.4 ORAL TRAUMA\nInjury to the oral or dental tissues as a result of trauma.\n23.4.1\t Traumatic lesions I\t\n\t\nICD10 CODE: S00.5",
        "formatted_content": "<p>1032</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Painless purplish swelling on the skin</p>\n<p>~</p>\n<p>In the mouth, the palate is the most frequent site</p>\n<p>Investigation</p>\n<p>\u0081</p>\n<p>Biopsy to confirm histology</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Refer for chemotherapy</p>\n<p>RR</p>\n<p>23.3.4 Hairy Leukoplakia</p>\n<p>Benign lesion, usually asymptomatic, associated with HIV immunosup\u00ad</p>\n<p>pression, and linked to Epstein Barr Virus infection</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Adherent white, corrugated plaque, usually found bilaterally on</p>\n<p>the borders of the tongue</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Podophyllin resin 25%: Apply to lesion once weekly if</p>\n<p>necessary</p>\n<p>\u0089</p>\n<p>Manage HIV infection as per national guidelines</p>\n<p>RR</p>\n<h3>23.4 ORAL TRAUMA</h3>\n<p>Injury to the oral or dental tissues as a result of trauma.</p>\n<p>23.4.1\t Traumatic lesions I</p>\n<h3>ICD10 CODE: S00.5</h3>"
    },
    {
        "page_number": 1099,
        "content": "1033\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTYPE OF LESION\nFEATURES\nFibroepithelial polyp\nOver-vigorous response to low grade \nrecurrent trauma resulting in fibrous \nhyperplasia\n \n~\nWell-localized sessile or \npedunculated lump, usu\u00ad\nally located on the palate \nor lateral surface of the \ntongue\nMucocele\nSaliva extravasation into the tissues \nfrom damage to minor salivary gland \nducts. They are commonly seen in \nthe lower labial and ventral lingual \nmucosa\n \n~\nHistory of trauma and \ncharacteristic \nappear\u00ad\nance\nRanula\nA mucocele that occurs from the \nsublingual gland\n \n~\nBlue, transparent sublin\u00ad\ngual swelling\nManagement\nTREATMENT\nLOC\nFibroepithelial polyp\n\t\n\u0089\nExcision biopsy and histological confirmation\nMucocele\n\t\n\u0089\nSurgical removal (recurrence may occur if there is regular \ntrauma)\nRanula\n\t\n\u0089\nExcision of the sublingual gland\nRR\n23.4.2\t Traumatic lesions II\nThese simple lesions are often confused for more severe conditions like \nlichen planus, oral candidiasis, pemphigus, erythema multiforme.",
        "formatted_content": "<p>1033</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TYPE OF LESION</h3>\n<h3>FEATURES</h3>\n<p>Fibroepithelial polyp</p>\n<p>Over-vigorous response to low grade</p>\n<p>recurrent trauma resulting in fibrous</p>\n<p>hyperplasia</p>\n<p>~</p>\n<p>Well-localized sessile or</p>\n<p>pedunculated lump, usu\u00ad</p>\n<p>ally located on the palate</p>\n<p>or lateral surface of the</p>\n<p>tongue</p>\n<p>Mucocele</p>\n<p>Saliva extravasation into the tissues</p>\n<p>from damage to minor salivary gland</p>\n<p>ducts. They are commonly seen in</p>\n<p>the lower labial and ventral lingual</p>\n<p>mucosa</p>\n<p>~</p>\n<p>History of trauma and</p>\n<p>characteristic</p>\n<p>appear\u00ad</p>\n<p>ance</p>\n<p>Ranula</p>\n<p>A mucocele that occurs from the</p>\n<p>sublingual gland</p>\n<p>~</p>\n<p>Blue, transparent sublin\u00ad</p>\n<p>gual swelling</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Fibroepithelial polyp</p>\n<p>\u0089</p>\n<p>Excision biopsy and histological confirmation</p>\n<p>Mucocele</p>\n<p>\u0089</p>\n<p>Surgical removal (recurrence may occur if there is regular</p>\n<p>trauma)</p>\n<p>Ranula</p>\n<p>\u0089</p>\n<p>Excision of the sublingual gland</p>\n<p>RR</p>\n<p>23.4.2\t Traumatic lesions II</p>\n<p>These simple lesions are often confused for more severe conditions like</p>\n<p>lichen planus, oral candidiasis, pemphigus, erythema multiforme.</p>"
    },
    {
        "page_number": 1100,
        "content": "1034\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTYPE OF LESION\nFEATURES\nBurns \nMost Commonest after ingestion \nof hot foods, and particularly seen \non the palate or tongue. Chemical \nburns are usually due to analgesics \npositioned next to a painful tooth or \nchemicals used in restorative dentistry\n \n~\nBurns in the palate lo\u00ad\ncated in characteristic \nsites related to eating, \nrestored or painful tooth\nSharp teeth and restorations \nTrauma from sharp teeth or restora\u00ad\ntions is often worsened in patients \nwith physical or intellectual disability \n[What\u2019s this?] \n \n~\nLesion is site specific and \nis related to a sharp edge\nUlceration due to local anaesthetic \nlceration due to biting the area of \nanaesthetised mucosa\n \n~\nUlcer confined to the \narea of anaesthetised \nmucosa\nTREATMENT\nLOC\nBurns\n\t\n\u0089\nReassurance that healing will occur without scarring\n\t\n\u0089\nTopical anaesthetic lidocaine 2% may help\nSharp teeth and restorations\n\t\n\u0089\nSmooth the edge and/or apply a restorative material \nto the tooth\nSharp teeth and restorations\n\t\n\u0089\nSmooth the edge and/or apply a restorative material \nto the tooth\nRR",
        "formatted_content": "<p>1034</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TYPE OF LESION</h3>\n<h3>FEATURES</h3>\n<p>Burns</p>\n<p>Most Commonest after ingestion</p>\n<p>of hot foods, and particularly seen</p>\n<p>on the palate or tongue. Chemical</p>\n<p>burns are usually due to analgesics</p>\n<p>positioned next to a painful tooth or</p>\n<p>chemicals used in restorative dentistry</p>\n<p>~</p>\n<p>Burns in the palate lo\u00ad</p>\n<p>cated in characteristic</p>\n<p>sites related to eating,</p>\n<p>restored or painful tooth</p>\n<p>Sharp teeth and restorations</p>\n<p>Trauma from sharp teeth or restora\u00ad</p>\n<p>tions is often worsened in patients</p>\n<p>with physical or intellectual disability</p>\n<p>[What\u2019s this?]</p>\n<p>~</p>\n<p>Lesion is site specific and</p>\n<p>is related to a sharp edge</p>\n<p>Ulceration due to local anaesthetic</p>\n<p>lceration due to biting the area of</p>\n<p>anaesthetised mucosa</p>\n<p>~</p>\n<p>Ulcer confined to the</p>\n<p>area of anaesthetised</p>\n<p>mucosa</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Burns</p>\n<p>\u0089</p>\n<p>Reassurance that healing will occur without scarring</p>\n<p>\u0089</p>\n<p>Topical anaesthetic lidocaine 2% may help</p>\n<p>Sharp teeth and restorations</p>\n<p>\u0089</p>\n<p>Smooth the edge and/or apply a restorative material</p>\n<p>to the tooth</p>\n<p>Sharp teeth and restorations</p>\n<p>\u0089</p>\n<p>Smooth the edge and/or apply a restorative material</p>\n<p>to the tooth</p>\n<p>RR</p>"
    },
    {
        "page_number": 1101,
        "content": "1035\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\nUlceration due to local anaesthetic\n\t\n\u0089\nReassurance\n\t\n\u0089\nMay require antibiotic therapy if the area becomes sec\u00ad\nondarily infected\n \n- Amoxicillin 500 mg every 8 hours for 5-7 days if \nnecessary\nRR\n23.4.3 Traumatic lesions III\nTrauma due to physical injury, e.g., a fall, sports, road traffic accident\nManagement\nTREATMENT\nLOC\nGeneral measures\n\t\n\u0089\nGive tetanus booster if needed (see section 18.1.4)\n\t\n\u0089\nCheck for facial fractures and/or lacerations\n\t\n\u0089\nIf evidence of head injury (amnesia, loss of consciousness, \nneurological signs), transfer patient to hospital immediately \n(see Trauma and Head injuries, section 1.2.5)\n\t\n\u0089\nIntra-oral check: for soft-tissue lacerations, dento-alveolar \nfractures, and damage to teeth\n\t\n\u0089\nCheck for the whereabouts of tooth fragments, which \nare commonly embedded in the lip\n\t\n\u0089\nExamine traumatized teeth for mobility\n\t\n\u0089\nCheck occlusion, especially if any teeth have been displaced\nRR\n\t\n\u0089\nRefer for radiographs of affected teeth to check for root \nfracture\n\t\n\u0089\nAvulsed permanent teeth should be re-planted immediately. \nPrognosis is good with immediate treatment, therefore \nrefer the patient to a dentist as soon as possible\nHC4",
        "formatted_content": "<p>1035</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Ulceration due to local anaesthetic</p>\n<p>\u0089</p>\n<p>Reassurance</p>\n<p>\u0089</p>\n<p>May require antibiotic therapy if the area becomes sec\u00ad</p>\n<p>ondarily infected</p>\n<p>- Amoxicillin 500 mg every 8 hours for 5-7 days if</p>\n<p>necessary</p>\n<p>RR</p>\n<p>23.4.3 Traumatic lesions III</p>\n<p>Trauma due to physical injury, e.g., a fall, sports, road traffic accident</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>General measures</p>\n<p>\u0089</p>\n<p>Give tetanus booster if needed (see section 18.1.4)</p>\n<p>\u0089</p>\n<p>Check for facial fractures and/or lacerations</p>\n<p>\u0089</p>\n<p>If evidence of head injury (amnesia, loss of consciousness,</p>\n<p>neurological signs), transfer patient to hospital immediately</p>\n<p>(see Trauma and Head injuries, section 1.2.5)</p>\n<p>\u0089</p>\n<p>Intra-oral check: for soft-tissue lacerations, dento-alveolar</p>\n<p>fractures, and damage to teeth</p>\n<p>\u0089</p>\n<p>Check for the whereabouts of tooth fragments, which</p>\n<p>are commonly embedded in the lip</p>\n<p>\u0089</p>\n<p>Examine traumatized teeth for mobility</p>\n<p>\u0089</p>\n<p>Check occlusion, especially if any teeth have been displaced</p>\n<p>RR</p>\n<p>\u0089</p>\n<p>Refer for radiographs of affected teeth to check for root</p>\n<p>fracture</p>\n<p>\u0089</p>\n<p>Avulsed permanent teeth should be re-planted immediately.</p>\n<p>Prognosis is good with immediate treatment, therefore</p>\n<p>refer the patient to a dentist as soon as possible</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1102,
        "content": "1036\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n\t\n\u0089\nSuture soft tissue lacerations in 3/0 resorbable suture\n\t\n\u0089\nRefer to an oral surgeon for reduction and immobilization \nof mobile teeth and alveolar fragments\nHC4\nMedicines\n\t\n\u0089\nWash mouth with warm salt solution (dissolve a 5 ml \nspoonful of salt in 200 ml of warm water)  f Or hydrogen \nperoxide solution 6% (add 15 ml to\n\t\n\u0089\na cup 200  ml  of  warm  water) f Repeat mouth wash 3 \ntimes daily f Paracetamol 1 g every 8 hours f Or ibuprofen \n400 mg every 8 hours\nGive prophylactic antibiotics if indicated\n\t\n\u0089\nAmoxicillin 500 mg every 8 hours for 5-7 days f Refer \nto a dentist for orthodontics, endodontic\n\t\n\u0089\n(root canal) treatment, or protection of pulp\nHC2\nPrevention\n \n~\nEarly orthodontic treatment in children with large overjets that \nare susceptible to trauma\n \n~\nProvision of a mouth guard (made of vacuum formed thermo\u00ad\nplastic vinyl) for sports\n \n~\nBe alert for evidence of child abuse and notify relevant author\u00ad\nities if any.\n23.5 ORAL TUMOURS\n23.5.1 Burkitt\u2019s Lymphoma\t\nICD10 CODE: C83.7\nBurkitt\u2019s lymphoma (or \u201cBurkitt\u2019s tumour\u201d or \u201cMalignant lymphoma, \nBurkitt\u2019s type\u201d) is a cancer of the lymphatic system (in particular, B \nlymphocytes). It is a non-Hodgkin\u2019s lymphoma and recognised as the \nfastest growing human tumour. Of all cancers involving the same class \nof blood cell, 2% of cases are Burkitt\u2019s lymphoma.",
        "formatted_content": "<p>1036</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Suture soft tissue lacerations in 3/0 resorbable suture</p>\n<p>\u0089</p>\n<p>Refer to an oral surgeon for reduction and immobilization</p>\n<p>of mobile teeth and alveolar fragments</p>\n<h3>HC4</h3>\n<p>Medicines</p>\n<p>\u0089</p>\n<p>Wash mouth with warm salt solution (dissolve a 5 ml</p>\n<p>spoonful of salt in 200 ml of warm water)  f Or hydrogen</p>\n<p>peroxide solution 6% (add 15 ml to</p>\n<p>\u0089</p>\n<p>a cup 200  ml  of  warm  water) f Repeat mouth wash 3</p>\n<p>times daily f Paracetamol 1 g every 8 hours f Or ibuprofen</p>\n<p>400 mg every 8 hours</p>\n<p>Give prophylactic antibiotics if indicated</p>\n<p>\u0089</p>\n<p>Amoxicillin 500 mg every 8 hours for 5-7 days f Refer</p>\n<p>to a dentist for orthodontics, endodontic</p>\n<p>\u0089</p>\n<p>(root canal) treatment, or protection of pulp</p>\n<h3>HC2</h3>\n<p>Prevention</p>\n<p>~</p>\n<p>Early orthodontic treatment in children with large overjets that</p>\n<p>are susceptible to trauma</p>\n<p>~</p>\n<p>Provision of a mouth guard (made of vacuum formed thermo\u00ad</p>\n<p>plastic vinyl) for sports</p>\n<p>~</p>\n<p>Be alert for evidence of child abuse and notify relevant author\u00ad</p>\n<p>ities if any.</p>\n<h3>23.5 ORAL TUMOURS</h3>\n<p>23.5.1 Burkitt\u2019s Lymphoma</p>\n<h3>ICD10 CODE: C83.7</h3>\n<p>Burkitt\u2019s lymphoma (or \u201cBurkitt\u2019s tumour\u201d or \u201cMalignant lymphoma,</p>\n<p>Burkitt\u2019s type\u201d) is a cancer of the lymphatic system (in particular, B</p>\n<p>lymphocytes). It is a non-Hodgkin\u2019s lymphoma and recognised as the</p>\n<p>fastest growing human tumour. Of all cancers involving the same class</p>\n<p>of blood cell, 2% of cases are Burkitt\u2019s lymphoma.</p>"
    },
    {
        "page_number": 1103,
        "content": "1037\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nCauses\n \n~\nAssociated with Epstein-Barr virus (EBV)\nRisk factors\n \n~\nHIV/AIDS\n \n~\nChronic malaria\n \n~\nLow socio-economic status\nClinical features\nOften presents as a tooth ache in the maxilla\nTeeth are mobile\nExtractions do not relieve the swelling\nPeak incidence at 4-7 years of age and more common among boys\nClassification\nBurkitt\u2019s lymphoma is divided into 3 main clinical variants:\n \n~\nEndemic variant: occurs in malaria endemic areas. Chronic ma\u00ad\nlaria is believed to reduce resistance to Epstein-Barr virus (EBV), \nwhich is usually linked with the disease. The disease characteris\u00ad\ntically involves the jaw or other facial bone, distal ileum, caecum, \novaries, kidney, or the breast.\n \n~\nSporadic type: (also known as \u201c\u201dnon-African\u201d) is usually found \noutside of Africa\n \n~\nImmunodeficiency-associated Burkitt\u2019s lymphoma: usually asso\u00ad\nciated with HIV infection or in post- transplant patients taking \nimmunosuppressive drugs. Burkitt\u2019s lymphoma can be the initial \nmanifestation of AIDS.\nDifferential diagnosis\n \n~\nOther cancer diseases\nInvestigations\n \n~\nBiopsy of the mass\nManagement\nTREATMENT\nLOC\n \n~\nRefer to cancer treatment specialist centres for appro\u00ad\npriate management",
        "formatted_content": "<p>1037</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<p>Causes</p>\n<p>~</p>\n<p>Associated with Epstein-Barr virus (EBV)</p>\n<p>Risk factors</p>\n<p>~</p>\n<h3>HIV/AIDS</h3>\n<p>~</p>\n<p>Chronic malaria</p>\n<p>~</p>\n<p>Low socio-economic status</p>\n<p>Clinical features</p>\n<p>Often presents as a tooth ache in the maxilla</p>\n<p>Teeth are mobile</p>\n<p>Extractions do not relieve the swelling</p>\n<p>Peak incidence at 4-7 years of age and more common among boys</p>\n<p>Classification</p>\n<p>Burkitt\u2019s lymphoma is divided into 3 main clinical variants:</p>\n<p>~</p>\n<p>Endemic variant: occurs in malaria endemic areas. Chronic ma\u00ad</p>\n<p>laria is believed to reduce resistance to Epstein-Barr virus (EBV),</p>\n<p>which is usually linked with the disease. The disease characteris\u00ad</p>\n<p>tically involves the jaw or other facial bone, distal ileum, caecum,</p>\n<p>ovaries, kidney, or the breast.</p>\n<p>~</p>\n<p>Sporadic type: (also known as \u201c\u201dnon-African\u201d) is usually found</p>\n<p>outside of Africa</p>\n<p>~</p>\n<p>Immunodeficiency-associated Burkitt\u2019s lymphoma: usually asso\u00ad</p>\n<p>ciated with HIV infection or in post- transplant patients taking</p>\n<p>immunosuppressive drugs. Burkitt\u2019s lymphoma can be the initial</p>\n<p>manifestation of AIDS.</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Other cancer diseases</p>\n<p>Investigations</p>\n<p>~</p>\n<p>Biopsy of the mass</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>~</p>\n<p>Refer to cancer treatment specialist centres for appro\u00ad</p>\n<p>priate management</p>"
    },
    {
        "page_number": 1104,
        "content": "1038\nUganda Clinical Guidelines 2023\nCHAPTER 23 : Oral and Dental Conditions\nTREATMENT\nLOC\n \n~\nTreatment options include: chemotherapy, immuno\u00ad\ntherapy, bone marrow transplants, surgery, radiother\u00ad\napy.\nRR",
        "formatted_content": "<p>1038</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 23 : Oral and Dental Conditions</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>~</p>\n<p>Treatment options include: chemotherapy, immuno\u00ad</p>\n<p>therapy, bone marrow transplants, surgery, radiother\u00ad</p>\n<p>apy.</p>\n<p>RR</p>"
    },
    {
        "page_number": 1105,
        "content": "1039\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\n24.1 SURGERY\n24.1.1 Intestinal Obstruction\t\n\t\nICD10 CODE: K56\nInterruption of the normal flow of intestinal content, due to mechanical \nobstruction (at small or large bowel level), or due to functional paralysis.\nCauses\n \n~\nSmall bowel mechanical obstruction: tumours, adhesions from \nprevious surgeries or infections\n \n~\nLarge bowel obstructions: tumours, volvolus, adhesions, inflam\u00ad\nmatory strictures (e.g. diverticulosis, etc.)\nClinical features\n \n~\nSmall bowel obstruction: cramping abdominal pain, nausea, \nvomiting, abdominal distention. Due to the accumulation of fuids \ninto the dilated intestinal loops, there is usually a varying degree \nof dehydration\n \n~\nLarge bowel obstruction: bloating, abdominal pain, constipation, \nvomiting and nausea less frequent and mainly in proximal colon \nobstruction; signs of dehydration and shock come later.\nInvestigations\n \n\u0081\nAbdominal X-ray (erect or left lateral decubitus, for air- fluid level), \nsee section 24.2.1 for details\nDifferential diagnosis\n \n~\nParalytic ileus (diffuse functional paralysis of small and large bow\u00ad\nel due to drugs, biochemical abnormalities, abdominal infections \netc)\nSurgery, Radiology and \nAnaesthesia\n24",
        "formatted_content": "<p>1039</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>24.1 SURGERY</h3>\n<p>24.1.1 Intestinal Obstruction</p>\n<h3>ICD10 CODE: K56</h3>\n<p>Interruption of the normal flow of intestinal content, due to mechanical</p>\n<p>obstruction (at small or large bowel level), or due to functional paralysis.</p>\n<p>Causes</p>\n<p>~</p>\n<p>Small bowel mechanical obstruction: tumours, adhesions from</p>\n<p>previous surgeries or infections</p>\n<p>~</p>\n<p>Large bowel obstructions: tumours, volvolus, adhesions, inflam\u00ad</p>\n<p>matory strictures (e.g. diverticulosis, etc.)</p>\n<p>Clinical features</p>\n<p>~</p>\n<p>Small bowel obstruction: cramping abdominal pain, nausea,</p>\n<p>vomiting, abdominal distention. Due to the accumulation of fuids</p>\n<p>into the dilated intestinal loops, there is usually a varying degree</p>\n<p>of dehydration</p>\n<p>~</p>\n<p>Large bowel obstruction: bloating, abdominal pain, constipation,</p>\n<p>vomiting and nausea less frequent and mainly in proximal colon</p>\n<p>obstruction; signs of dehydration and shock come later.</p>\n<p>Investigations</p>\n<p>\u0081</p>\n<p>Abdominal X-ray (erect or left lateral decubitus, for air- fluid level),</p>\n<p>see section 24.2.1 for details</p>\n<p>Differential diagnosis</p>\n<p>~</p>\n<p>Paralytic ileus (diffuse functional paralysis of small and large bow\u00ad</p>\n<p>el due to drugs, biochemical abnormalities, abdominal infections</p>\n<p>etc)</p>\n<p>Surgery, Radiology and</p>\n<p>Anaesthesia</p>\n<p>24</p>"
    },
    {
        "page_number": 1106,
        "content": "1040\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nManagement\nTREATMENT\nLOC\nPre-operative management\n \n~\nIV fluids (normal saline, Ringer\u2019s Lactate)\n \n- To correct fluids deficit and replace ongoing losses \nplus maintenance fluids\n \n- Monitor haemodynamic status (pulse, blood\n \n- pressure, skin turgor, level of consciousness, \nhydration of mucosae, urine output at least 0.5\u2013\n1.0 ml/kg/hour)\n \n- It may take up to 6 hours to re-hydrate\n \n- If not responding to IV fluids, suspect septic shock\n \n- Insert urinary catheter to monitor urinary output\n\t\n\u0089\nNasogastric tube decompression\n \n- Pass NGT and connect with a drainage bag to \nempty the stomach in small bowel obstruction or \nwhen clinically indicated\n \n- Nil by mouth\n \n~\nGive appropriate antibiotics\n \n- Ceftriaxone 2 g IV once a day\n \n- Plus metronidazole 500 mg IV every 8 hours\n\t\n\u0089\nIf the patient is in severe colicky pain, administer pethidine \n50-100 mg IV or IM\n\t\n\u0089\nIf surgery is indicated and the patient\u2019s parameters are \nnear normal after resuscitation, take the patient to the \noperating theatre for an appropriate surgical relief of \nthe obstruction\nH\nIntra-operative fluid therapy\n \n- Blood loss, fluid aspirated from the gut and other \nfluid losses must be replaced\n \n- Maintenance fluid should be given: 5 ml/kg/hour",
        "formatted_content": "<p>1040</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Pre-operative management</p>\n<p>~</p>\n<p>IV fluids (normal saline, Ringer\u2019s Lactate)</p>\n<p>- To correct fluids deficit and replace ongoing losses</p>\n<p>plus maintenance fluids</p>\n<p>- Monitor haemodynamic status (pulse, blood</p>\n<p>- pressure, skin turgor, level of consciousness,</p>\n<p>hydration of mucosae, urine output at least 0.5\u2013</p>\n<li>.0 ml/kg/hour)</li>\n<p>- It may take up to 6 hours to re-hydrate</p>\n<p>- If not responding to IV fluids, suspect septic shock</p>\n<p>- Insert urinary catheter to monitor urinary output</p>\n<p>\u0089</p>\n<p>Nasogastric tube decompression</p>\n<p>- Pass NGT and connect with a drainage bag to</p>\n<p>empty the stomach in small bowel obstruction or</p>\n<p>when clinically indicated</p>\n<p>- Nil by mouth</p>\n<p>~</p>\n<p>Give appropriate antibiotics</p>\n<p>- Ceftriaxone 2 g IV once a day</p>\n<p>- Plus metronidazole 500 mg IV every 8 hours</p>\n<p>\u0089</p>\n<p>If the patient is in severe colicky pain, administer pethidine</p>\n<p>50-100 mg IV or IM</p>\n<p>\u0089</p>\n<p>If surgery is indicated and the patient\u2019s parameters are</p>\n<p>near normal after resuscitation, take the patient to the</p>\n<p>operating theatre for an appropriate surgical relief of</p>\n<p>the obstruction</p>\n<p>H</p>\n<p>Intra-operative fluid therapy</p>\n<p>- Blood loss, fluid aspirated from the gut and other</p>\n<p>fluid losses must be replaced</p>\n<p>- Maintenance fluid should be given: 5 ml/kg/hour</p>"
    },
    {
        "page_number": 1107,
        "content": "1041\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nTREATMENT\nLOC\nPost-operative fluid therapy\n \n- Replace all fluid losses\n \n- Maintenance fluid\n \n- Use normal saline or Ringer\u2019s lactate solution and \n5% dextrose in the ratio 1:2 for the first 24-48 \nhours post-operatively\n \n- Monitor for adequate rehydration\nPost-operative antibiotics and analgesics\n\t\n\u0089\nContinue with analgesics in the postoperative period. \n(Tramadol, pethidine, diclofenac, paracetamol; morphine \nmay be used)\n\t\n\u0089\nContinue with antibiotic treatment where\n \n- clinically indicated (metronidazole + ceftriaxone \n+/- gentamycin)\nIn selective cases, non-operative treatment of intestinal obstruc\u00ad\ntion (in particular small bowel obstructions) can be tried\n\t\n\u0089\nIndicated in appendicular mass, acute pyosalpingitis (PID), \nsome patients with adheisions, pseudo obstruction, plastic \nperitonitis of TB, acute pancreatitis\n\t\n\u0089\nInvolves NGT decompression, intravenous fluid therapy \nand antibiotic therapy if indicated\n\t\n\u0089\nMonitor clinical progression of obstruction using param\u00ad\neters of: abdominal pain, abdominal girth, amount and \ncolour of NG aspirate, temperature, pulse\n\t\n\u0089\nIf no improvement after 72 hours or the NG content \nbecomes fecolent, operate the patient\nRR\n24.1.2 Internal Haemorrhage\nInternal bleeding (also called internal haemorrhage) is a loss of blood \nthat occurs from the vascular system into a body cavity or space. It is",
        "formatted_content": "<p>1041</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Post-operative fluid therapy</p>\n<p>- Replace all fluid losses</p>\n<p>- Maintenance fluid</p>\n<p>- Use normal saline or Ringer\u2019s lactate solution and</p>\n<p>5% dextrose in the ratio 1:2 for the first 24-48</p>\n<p>hours post-operatively</p>\n<p>- Monitor for adequate rehydration</p>\n<p>Post-operative antibiotics and analgesics</p>\n<p>\u0089</p>\n<p>Continue with analgesics in the postoperative period.</p>\n<p>(Tramadol, pethidine, diclofenac, paracetamol; morphine</p>\n<p>may be used)</p>\n<p>\u0089</p>\n<p>Continue with antibiotic treatment where</p>\n<p>- clinically indicated (metronidazole + ceftriaxone</p>\n<p>+/- gentamycin)</p>\n<p>In selective cases, non-operative treatment of intestinal obstruc\u00ad</p>\n<p>tion (in particular small bowel obstructions) can be tried</p>\n<p>\u0089</p>\n<p>Indicated in appendicular mass, acute pyosalpingitis (PID),</p>\n<p>some patients with adheisions, pseudo obstruction, plastic</p>\n<p>peritonitis of TB, acute pancreatitis</p>\n<p>\u0089</p>\n<p>Involves NGT decompression, intravenous fluid therapy</p>\n<p>and antibiotic therapy if indicated</p>\n<p>\u0089</p>\n<p>Monitor clinical progression of obstruction using param\u00ad</p>\n<p>eters of: abdominal pain, abdominal girth, amount and</p>\n<p>colour of NG aspirate, temperature, pulse</p>\n<p>\u0089</p>\n<p>If no improvement after 72 hours or the NG content</p>\n<p>becomes fecolent, operate the patient</p>\n<p>RR</p>\n<p>24.1.2 Internal Haemorrhage</p>\n<p>Internal bleeding (also called internal haemorrhage) is a loss of blood</p>\n<p>that occurs from the vascular system into a body cavity or space. It is</p>"
    },
    {
        "page_number": 1108,
        "content": "1042\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\na serious medical emergency and the extent of severity depends on:\n\t\n\u0089\nBleeding rate (hypovolaemic shock)\n\t\n\u0089\nLocation of the bleeding (damage to organs, even with relatively \nlimited amounts: see specific chapters)\nSevere bleeding in a body cavity/space is an emergency condition with \nunstable vital signs (e.g., ruptured spleen, ruptured tubal pregnancy)\nManagement\nTREATMENT\nLOC\nInvasive surgical intervention to control bleeding is life saving\n\t\n\u0089\nDo not delay operation in attempt to stabilise the patient \nas this may not be achieved\n\t\n\u0089\nPrompt resuscitation\n\t\n\u0089\nEstablish IV line and give fluids rapidly\n\t\n\u0089\nDraw blood for grouping and cross matching for volume \nreplacement after surgical haemostasis\n\t\n\u0089\nSurgical intervention\n \n- Rapid sequence induction of general anaesthesia\n \n- Use drugs with minimal or no cardiac depression\n \n- Laparotomy to achieve surgical haemostasis\nRR\n24.1.3 Management of Medical Conditions in Surgical Patient\nPrinciple\nThe medical condition must be stabilised as much as possible before \nsurgery.\nPre-operative management\n \n~\nEstablish whether condition is stable or unstable\n \n~\nIf unstable, control or correct the condition",
        "formatted_content": "<p>1042</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>a serious medical emergency and the extent of severity depends on:</p>\n<p>\u0089</p>\n<p>Bleeding rate (hypovolaemic shock)</p>\n<p>\u0089</p>\n<p>Location of the bleeding (damage to organs, even with relatively</p>\n<p>limited amounts: see specific chapters)</p>\n<p>Severe bleeding in a body cavity/space is an emergency condition with</p>\n<p>unstable vital signs (e.g., ruptured spleen, ruptured tubal pregnancy)</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Invasive surgical intervention to control bleeding is life saving</p>\n<p>\u0089</p>\n<p>Do not delay operation in attempt to stabilise the patient</p>\n<p>as this may not be achieved</p>\n<p>\u0089</p>\n<p>Prompt resuscitation</p>\n<p>\u0089</p>\n<p>Establish IV line and give fluids rapidly</p>\n<p>\u0089</p>\n<p>Draw blood for grouping and cross matching for volume</p>\n<p>replacement after surgical haemostasis</p>\n<p>\u0089</p>\n<p>Surgical intervention</p>\n<p>- Rapid sequence induction of general anaesthesia</p>\n<p>- Use drugs with minimal or no cardiac depression</p>\n<p>- Laparotomy to achieve surgical haemostasis</p>\n<p>RR</p>\n<p>24.1.3 Management of Medical Conditions in Surgical Patient</p>\n<p>Principle</p>\n<p>The medical condition must be stabilised as much as possible before</p>\n<p>surgery.</p>\n<p>Pre-operative management</p>\n<p>~</p>\n<p>Establish whether condition is stable or unstable</p>\n<p>~</p>\n<p>If unstable, control or correct the condition</p>"
    },
    {
        "page_number": 1109,
        "content": "1043\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nOperative and post-operative management\n \n~\nAnaesthesia technique based on condition and nature of surgery\n \n~\nMaintain the stable condition\nTREATMENT\nLOC\nHypertension\n \n- Diastolic of 90 mmHg and systolic of 140 mmHg \nare acceptable\n \n- If \nhypertension \nnot \nadequately \ncontrolled, \nthere is risk of vasoconstriction, hypovolaemia, \nexaggerated \nvasoactive \nresponse \nto \nstress \nleading to hypo or hypertension, hypertensive \ncomplications during anaesthesia\n\t\n\u0089\nControl hypertension pre-operatively\n\t\n\u0089\nPatient should take antihypertensive medicines on schedule \neven on the day of operation\n\t\n\u0089\nGeneral anaesthesia technique is preferred\n\t\n\u0089\nEnsure adequate depth of anaesthesia and analgesia\nAnaemia\nCondition of reduced oxygen carrying capacity; patient prone \nto hypoxia\n \n- Heart failure may occur\n \n- Hypotension or hypoxia can cause cardiac arrest\n\t\n\u0089\nCorrect anaemia to acceptable level depending on urgency \nof surgery (see section of anaemia 11.2.2)\n\t\n\u0089\nRegional anaesthesia is the preferred method\n\t\n\u0089\nIf general anaesthesia is used, avoid myocardial depres\u00ad\nsant, e.g. thiopental\n\t\n\u0089\nUse small doses of anaesthetics\n\t\n\u0089\nUse high oxygen concentration\n \n- Intubate and ventilate except for very short \nprocedures\nHC4",
        "formatted_content": "<p>1043</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>Operative and post-operative management</p>\n<p>~</p>\n<p>Anaesthesia technique based on condition and nature of surgery</p>\n<p>~</p>\n<p>Maintain the stable condition</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Hypertension</p>\n<p>- Diastolic of 90 mmHg and systolic of 140 mmHg</p>\n<p>are acceptable</p>\n<p>- If</p>\n<p>hypertension</p>\n<p>not</p>\n<p>adequately</p>\n<p>controlled,</p>\n<p>there is risk of vasoconstriction, hypovolaemia,</p>\n<p>exaggerated</p>\n<p>vasoactive</p>\n<p>response</p>\n<p>to</p>\n<p>stress</p>\n<p>leading to hypo or hypertension, hypertensive</p>\n<p>complications during anaesthesia</p>\n<p>\u0089</p>\n<p>Control hypertension pre-operatively</p>\n<p>\u0089</p>\n<p>Patient should take antihypertensive medicines on schedule</p>\n<p>even on the day of operation</p>\n<p>\u0089</p>\n<p>General anaesthesia technique is preferred</p>\n<p>\u0089</p>\n<p>Ensure adequate depth of anaesthesia and analgesia</p>\n<p>Anaemia</p>\n<p>Condition of reduced oxygen carrying capacity; patient prone</p>\n<p>to hypoxia</p>\n<p>- Heart failure may occur</p>\n<p>- Hypotension or hypoxia can cause cardiac arrest</p>\n<p>\u0089</p>\n<p>Correct anaemia to acceptable level depending on urgency</p>\n<p>of surgery (see section of anaemia 11.2.2)</p>\n<p>\u0089</p>\n<p>Regional anaesthesia is the preferred method</p>\n<p>\u0089</p>\n<p>If general anaesthesia is used, avoid myocardial depres\u00ad</p>\n<p>sant, e.g. thiopental</p>\n<p>\u0089</p>\n<p>Use small doses of anaesthetics</p>\n<p>\u0089</p>\n<p>Use high oxygen concentration</p>\n<p>- Intubate and ventilate except for very short</p>\n<p>procedures</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1110,
        "content": "1044\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nTREATMENT\nLOC\n \n- Replace blood very carefully\n \n- Extubate patient when fully awake\n \n- Give oxygen in the post-operative period\nFor sickle cell anaemia, the above also applies, as well as avoid\u00ad\ning use of tourniquet\nHC4\nAsthma\n\t\n\u0089\nAvoid drugs and other factors likely to trigger bronchos\u00ad\npasms, e.g., thiopental\n\t\n\u0089\nRegional anaesthesia is the preferred method\nDiabetes\n\t\n\u0089\nAchieve blood glucose control using standard treatment \npre-operatively\n\t\n\u0089\nIf diabetic ketoacidosis:\n \n- Delay surgery even in emergency for 8-12 hours\n \n- Correct and control all associated disturbances\n\t\n\u0089\nHyperglycaemia under general anaesthesia is safer than \nhypoglycaemia\n\t\n\u0089\nPatient should be operated on early in the morning and \nMUST be first on theatre list\n\t\n\u0089\nfRegional anaesthesia is the method of choice where \napplicable\nMinor surgery\n\t\n\u0089\nStop usual antidiabetic dose on the morning of surgery\n\t\n\u0089\nStart infusion of  5% glucose infusion rate of 2 ml/ \nminute in theatre\n\t\n\u0089\nMonitor blood sugar\n\t\n\u0089\nUsual medication is resumed as soon as the patient is \nable to take it orally\nHC4",
        "formatted_content": "<p>1044</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>- Replace blood very carefully</p>\n<p>- Extubate patient when fully awake</p>\n<p>- Give oxygen in the post-operative period</p>\n<p>For sickle cell anaemia, the above also applies, as well as avoid\u00ad</p>\n<p>ing use of tourniquet</p>\n<h3>HC4</h3>\n<p>Asthma</p>\n<p>\u0089</p>\n<p>Avoid drugs and other factors likely to trigger bronchos\u00ad</p>\n<p>pasms, e.g., thiopental</p>\n<p>\u0089</p>\n<p>Regional anaesthesia is the preferred method</p>\n<p>Diabetes</p>\n<p>\u0089</p>\n<p>Achieve blood glucose control using standard treatment</p>\n<p>pre-operatively</p>\n<p>\u0089</p>\n<p>If diabetic ketoacidosis:</p>\n<p>- Delay surgery even in emergency for 8-12 hours</p>\n<p>- Correct and control all associated disturbances</p>\n<p>\u0089</p>\n<p>Hyperglycaemia under general anaesthesia is safer than</p>\n<p>hypoglycaemia</p>\n<p>\u0089</p>\n<p>Patient should be operated on early in the morning and</p>\n<p>MUST be first on theatre list</p>\n<p>\u0089</p>\n<p>fRegional anaesthesia is the method of choice where</p>\n<p>applicable</p>\n<p>Minor surgery</p>\n<p>\u0089</p>\n<p>Stop usual antidiabetic dose on the morning of surgery</p>\n<p>\u0089</p>\n<p>Start infusion of  5% glucose infusion rate of 2 ml/</p>\n<p>minute in theatre</p>\n<p>\u0089</p>\n<p>Monitor blood sugar</p>\n<p>\u0089</p>\n<p>Usual medication is resumed as soon as the patient is</p>\n<p>able to take it orally</p>\n<h3>HC4</h3>"
    },
    {
        "page_number": 1111,
        "content": "1045\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nTREATMENT\nLOC\nMajor surgery\n\t\n\u0089\nControl on sliding scale of insulin\n\t\n\u0089\nInfusion of 5% glucose started on the morning of surgery, \nor glucose insulin potassium infusion\n\t\n\u0089\nMonitor blood sugar 200 mg/dl\nHC4\n24.1.4\t Newborn with Surgical Emergencies\nBabies may be born at lower health facilities with congenital defects that \nrequire emergency surgical intervention at tertiary levels:\n \n- The common surgical emergencies in neonates include: \ngastroschisis (defect of abdominal wall with intestine sticking \noutside the body), tracheoesophageal fistula, imperforate \nanus, and spina bifida\n \n- If diagnosed in lower level health facilities (HCII, HCIII, HCIV, \nDistrict Hospital), apply general principles of supportive \nmanagement of the newborn\n\t\n\u0089\nThe aim should be to avoid hypothermia,  inimize risk of infection, \nensure adequate hydration, and  inimize risk of aspiration and \nhypoglycaemia\nManagement\nTREATMENT\nLOC\n\t\n\u0089\nUse sterile or clean gauze if available to properly cover \nthe defects which are externally visible.\n\t\n\u0089\nFor gastroschisis, moisten the gauze using warm saline \nand use it to properly wrap the exposed intestines\n\t\n\u0089\nProperly cover the newborn using a clean thick linen to \navoid hypothermia\n\t\n\u0089\nInsert IV cannula gauge 24 and administer prophylactic \nantibiotics preferably IV antibiotics (ampicillin + gentamicin)\nHC2",
        "formatted_content": "<p>1045</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>Major surgery</p>\n<p>\u0089</p>\n<p>Control on sliding scale of insulin</p>\n<p>\u0089</p>\n<p>Infusion of 5% glucose started on the morning of surgery,</p>\n<p>or glucose insulin potassium infusion</p>\n<p>\u0089</p>\n<p>Monitor blood sugar 200 mg/dl</p>\n<h3>HC4</h3>\n<p>24.1.4\t Newborn with Surgical Emergencies</p>\n<p>Babies may be born at lower health facilities with congenital defects that</p>\n<p>require emergency surgical intervention at tertiary levels:</p>\n<p>- The common surgical emergencies in neonates include:</p>\n<p>gastroschisis (defect of abdominal wall with intestine sticking</p>\n<p>outside the body), tracheoesophageal fistula, imperforate</p>\n<p>anus, and spina bifida</p>\n<p>- If diagnosed in lower level health facilities (HCII, HCIII, HCIV,</p>\n<p>District Hospital), apply general principles of supportive</p>\n<p>management of the newborn</p>\n<p>\u0089</p>\n<p>The aim should be to avoid hypothermia,  inimize risk of infection,</p>\n<p>ensure adequate hydration, and  inimize risk of aspiration and</p>\n<p>hypoglycaemia</p>\n<p>Management</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Use sterile or clean gauze if available to properly cover</p>\n<p>the defects which are externally visible.</p>\n<p>\u0089</p>\n<p>For gastroschisis, moisten the gauze using warm saline</p>\n<p>and use it to properly wrap the exposed intestines</p>\n<p>\u0089</p>\n<p>Properly cover the newborn using a clean thick linen to</p>\n<p>avoid hypothermia</p>\n<p>\u0089</p>\n<p>Insert IV cannula gauge 24 and administer prophylactic</p>\n<p>antibiotics preferably IV antibiotics (ampicillin + gentamicin)</p>\n<h3>HC2</h3>"
    },
    {
        "page_number": 1112,
        "content": "1046\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nTREATMENT\nLOC\n\t\n\u0089\nKeep the baby well hydrated (see IV fluids in neonates \nsection 1.1.4)\nHC3\n\t\n\u0089\nIf vomiting or signs of intestinal obstruction, pass a ne\u00ad\nonatal feeding tube Fr. G 6 or Fr. G. 8 (if available) and \naspirate all the stomach contents\n\t\n\u0089\nIf tracheoesophageal fistula is suspected, insert the tube \nas above and ensure that the baby is kept in a propped-\nup position\n\t\n\u0089\nUrgently refer the neonate to the nearest regional or \nnational referral hospital for further advanced treatment \nand care\nRR\n24.1.5 Surgical Antibiotic Prophylaxis\nThis is the pre-operative administration of antibiotics to reduce the risk \nof surgical site infection.\nGeneral principles\n \n~\nThe need of prophylaxis depends on the nature of the expected \nwound\n \n- Wounds that are expected to be clean (no inflammation,\n \n- And respiratory, genital, urinary and alimentary tract not \nentered) generally DO NOT require prophylaxis except \nwhere the consequences of surgical site infection could be \nsevere (e.g., joint replacements)\n \n- Prophylaxis is indicated in cases of clean-contaminated \nwounds (entering respiratory, genital, urinary and alimentary \ntracts but no unusual contamination)\n \n- Treatment with a course of antibiotics is indicated in\n \n- procedures with contaminated wounds (fresh open accidental \nwounds, operations with major breaks in sterile techniques), \ndirty or infected wounds (old traumatic wounds with retained \nnecrotic tissue, clinical infection, perforated viscera)\n \n~\nProphylaxis is given <60 minutes before the first incision\n \n~\nRefer to institution-specific protocols for details",
        "formatted_content": "<p>1046</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>TREATMENT</h3>\n<h3>LOC</h3>\n<p>\u0089</p>\n<p>Keep the baby well hydrated (see IV fluids in neonates</p>\n<p>section 1.1.4)</p>\n<h3>HC3</h3>\n<p>\u0089</p>\n<p>If vomiting or signs of intestinal obstruction, pass a ne\u00ad</p>\n<p>onatal feeding tube Fr. G 6 or Fr. G. 8 (if available) and</p>\n<p>aspirate all the stomach contents</p>\n<p>\u0089</p>\n<p>If tracheoesophageal fistula is suspected, insert the tube</p>\n<p>as above and ensure that the baby is kept in a propped-</p>\n<p>up position</p>\n<p>\u0089</p>\n<p>Urgently refer the neonate to the nearest regional or</p>\n<p>national referral hospital for further advanced treatment</p>\n<p>and care</p>\n<p>RR</p>\n<p>24.1.5 Surgical Antibiotic Prophylaxis</p>\n<p>This is the pre-operative administration of antibiotics to reduce the risk</p>\n<p>of surgical site infection.</p>\n<p>General principles</p>\n<p>~</p>\n<p>The need of prophylaxis depends on the nature of the expected</p>\n<p>wound</p>\n<p>- Wounds that are expected to be clean (no inflammation,</p>\n<p>- And respiratory, genital, urinary and alimentary tract not</p>\n<p>entered) generally DO NOT require prophylaxis except</p>\n<p>where the consequences of surgical site infection could be</p>\n<p>severe (e.g., joint replacements)</p>\n<p>- Prophylaxis is indicated in cases of clean-contaminated</p>\n<p>wounds (entering respiratory, genital, urinary and alimentary</p>\n<p>tracts but no unusual contamination)</p>\n<p>- Treatment with a course of antibiotics is indicated in</p>\n<p>- procedures with contaminated wounds (fresh open accidental</p>\n<p>wounds, operations with major breaks in sterile techniques),</p>\n<p>dirty or infected wounds (old traumatic wounds with retained</p>\n<p>necrotic tissue, clinical infection, perforated viscera)</p>\n<p>~</p>\n<p>Prophylaxis is given <60 minutes before the first incision</p>\n<p>~</p>\n<p>Refer to institution-specific protocols for details</p>"
    },
    {
        "page_number": 1113,
        "content": "1047\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nProphylaxis is not recommended for most uncomplicated clean procedures\nOne single dose prior to the procedure is usually sufficient\nRoutine post-operative antimicrobial administration is NOT recom\u00ad\nmended for most surgeries as it causes wastage of limited resources, \ncauses unnecessary side effects to the patient and can lead to anti\u00ad\nmicrobial resistance.\n24.2 DIAGNOSTIC IMAGING\n24.2.1 Diagnostic Imaging: A Clinical Perspective\nMedical imaging is an essential part of the diagnosis of many diseases.\nA diagnostic imaging procedure is indicated when the management of a \npatient depends on the findings of the procedure. Therefore, before any \ndiagnostic imaging procedure is requested, the question of how the results \nwill influence patient management and care should always be asked.\n \n~\nPrior to requesting a procedure, it is useful to determine if the \nrequired information is already available from recent procedures, \nand if the relevant clinical, laboratory, diagnostic imaging, and \ntreatment information is provided.\n \n~\nWhen indicated and available, alternative diagnostic imaging \nprocedures which do not use ionising radiation, e.g. ultrasound, \nshould be chosen first, especially in children.\nQuestions to be answered to prevent unnecessary use of procedure and \nradiation\n \n~\nHas this procedure been done already?\n \n~\nDoes the patient need it?\n \n~\nDoes the patient need it NOW?\n \n~\nIs this the best procedure?\n \n~\nAre all the investigations I am requesting necessary?\n \n~\nHave you provided appropriate clinical information and ques\u00ad\ntions that the procedure should answer?",
        "formatted_content": "<p>1047</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>Prophylaxis is not recommended for most uncomplicated clean procedures</p>\n<p>One single dose prior to the procedure is usually sufficient</p>\n<p>Routine post-operative antimicrobial administration is NOT recom\u00ad</p>\n<p>mended for most surgeries as it causes wastage of limited resources,</p>\n<p>causes unnecessary side effects to the patient and can lead to anti\u00ad</p>\n<p>microbial resistance.</p>\n<h3>24.2 DIAGNOSTIC IMAGING</h3>\n<p>24.2.1 Diagnostic Imaging: A Clinical Perspective</p>\n<p>Medical imaging is an essential part of the diagnosis of many diseases.</p>\n<p>A diagnostic imaging procedure is indicated when the management of a</p>\n<p>patient depends on the findings of the procedure. Therefore, before any</p>\n<p>diagnostic imaging procedure is requested, the question of how the results</p>\n<p>will influence patient management and care should always be asked.</p>\n<p>~</p>\n<p>Prior to requesting a procedure, it is useful to determine if the</p>\n<p>required information is already available from recent procedures,</p>\n<p>and if the relevant clinical, laboratory, diagnostic imaging, and</p>\n<p>treatment information is provided.</p>\n<p>~</p>\n<p>When indicated and available, alternative diagnostic imaging</p>\n<p>procedures which do not use ionising radiation, e.g. ultrasound,</p>\n<p>should be chosen first, especially in children.</p>\n<p>Questions to be answered to prevent unnecessary use of procedure and</p>\n<p>radiation</p>\n<p>~</p>\n<p>Has this procedure been done already?</p>\n<p>~</p>\n<p>Does the patient need it?</p>\n<p>~</p>\n<p>Does the patient need it NOW?</p>\n<p>~</p>\n<p>Is this the best procedure?</p>\n<p>~</p>\n<p>Are all the investigations I am requesting necessary?</p>\n<p>~</p>\n<p>Have you provided appropriate clinical information and ques\u00ad</p>\n<p>tions that the procedure should answer?</p>"
    },
    {
        "page_number": 1114,
        "content": "1048\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nNo procedure should ever be requested in lieu of a thorough clinical \nassessment or as a means of satisfying a difficult patient.\nBasic Diagnostic Imaging Modalities\n\t\n\u0089\nPlain Radiography (Hospital)\n\t\n\u0089\nUltrasound scan (HC4 and Hospital)\n \n- Ultrasound is non-invasive and does not use ionising radiation. \nTherefore, when indicated, it is the most appropriate imaging \nmodality for children and pregnant women.\nOther imaging modalities (at RR and NR)\n \n~\nComputed tomography\n \n~\nFluoroscopy\n \n~\nMagnetic Resonance Imaging\n \n~\nNuclear Medicine\n \n~\nMammography\nIn the following table, a summary of the clinical indication, the suggest\u00ad\ned investigation modality and the possible findings are presented, as a \nguide to request the correct investigation based on the clinical suspicion.\nNote\n\uf077\t\nCT scan is the investigation of choice for intracranial pathological \nprocesses (severe head trauma, stroke, etc.) but it is only available \nat referral facilities.\n\uf077",
        "formatted_content": "<p>1048</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>No procedure should ever be requested in lieu of a thorough clinical</p>\n<p>assessment or as a means of satisfying a difficult patient.</p>\n<p>Basic Diagnostic Imaging Modalities</p>\n<p>\u0089</p>\n<p>Plain Radiography (Hospital)</p>\n<p>\u0089</p>\n<p>Ultrasound scan (HC4 and Hospital)</p>\n<p>- Ultrasound is non-invasive and does not use ionising radiation.</p>\n<p>Therefore, when indicated, it is the most appropriate imaging</p>\n<p>modality for children and pregnant women.</p>\n<p>Other imaging modalities (at RR and NR)</p>\n<p>~</p>\n<p>Computed tomography</p>\n<p>~</p>\n<p>Fluoroscopy</p>\n<p>~</p>\n<p>Magnetic Resonance Imaging</p>\n<p>~</p>\n<p>Nuclear Medicine</p>\n<p>~</p>\n<p>Mammography</p>\n<p>In the following table, a summary of the clinical indication, the suggest\u00ad</p>\n<p>ed investigation modality and the possible findings are presented, as a</p>\n<p>guide to request the correct investigation based on the clinical suspicion.</p>\n<p>Note</p>\n<p>\uf077</p>\n<p>CT scan is the investigation of choice for intracranial pathological</p>\n<p>processes (severe head trauma, stroke, etc.) but it is only available</p>\n<p>at referral facilities.</p>\n<p>\uf077</p>"
    },
    {
        "page_number": 1115,
        "content": "1049\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nSYSTEM/\nBODY AREA\nINDICATIONS\nMODALITY\nINFORMATION PROVIDED\nMusculo- \nskeletal\n \n~\nSuspected \nlesion \nof bony skull, spine \nand extremities\n \n~\nMonitoring progress \nof pathologic condi\u00ad\ntions (osteomyelitis \netc.)\nPlain X-rays\n2 views taken at right \nangles, include the \njoint above and below \nin case of a fracture\n \n~\nFractures\n \n~\nDislocations\n \n~\nForeign bodies (metallic)\n \n~\nBone lesions/destruction\n \n~\nOsteomyelitis\nChest/ \npulmonary\n \n~\nCough for >2 weeks \nnot responding to \ntreatment\n \n~\nHaemoptysis\n \n~\nBlunt chest trauma\n \n~\nAcute \nrespiratory \ninsufficiency/ prob\u00ad\nlems, asthma\n \n~\nForeign bodies\n \n~\n(metallic, coins)\nChest X-ray\n \n~\nChest infections e.g. bronchopneu\u00ad\nmonia, lobar pneumonia, intersti\u00ad\ntial pneumonia\n \n~\nPleurisy (pleural effusion)\n \n~\nTB (Lung infiltrates especially in \nupper lobe, pleural effusion, cav\u00ad\nities, mediastinal /hilar lymph \nnodes)\n \n~\nTrauma complications (pneumo\u00ad\nthorax, fractured ribs, lung contu\u00ad\nsion, haemothorax)\n \n~\nLung masses\n \n~\nOther lung/bronchial disorders \n(COPD)",
        "formatted_content": "<p>1049</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>SYSTEM/</h3>\n<h3>BODY AREA</h3>\n<h3>INDICATIONS</h3>\n<h3>MODALITY</h3>\n<h3>INFORMATION PROVIDED</h3>\n<p>Musculo-</p>\n<p>skeletal</p>\n<p>~</p>\n<p>Suspected</p>\n<p>lesion</p>\n<p>of bony skull, spine</p>\n<p>and extremities</p>\n<p>~</p>\n<p>Monitoring progress</p>\n<p>of pathologic condi\u00ad</p>\n<p>tions (osteomyelitis</p>\n<p>etc.)</p>\n<p>Plain X-rays</p>\n<p>2 views taken at right</p>\n<p>angles, include the</p>\n<p>joint above and below</p>\n<p>in case of a fracture</p>\n<p>~</p>\n<p>Fractures</p>\n<p>~</p>\n<p>Dislocations</p>\n<p>~</p>\n<p>Foreign bodies (metallic)</p>\n<p>~</p>\n<p>Bone lesions/destruction</p>\n<p>~</p>\n<p>Osteomyelitis</p>\n<p>Chest/</p>\n<p>pulmonary</p>\n<p>~</p>\n<p>Cough for >2 weeks</p>\n<p>not responding to</p>\n<p>treatment</p>\n<p>~</p>\n<p>Haemoptysis</p>\n<p>~</p>\n<p>Blunt chest trauma</p>\n<p>~</p>\n<p>Acute</p>\n<p>respiratory</p>\n<p>insufficiency/ prob\u00ad</p>\n<p>lems, asthma</p>\n<p>~</p>\n<p>Foreign bodies</p>\n<p>~</p>\n<p>(metallic, coins)</p>\n<p>Chest X-ray</p>\n<p>~</p>\n<p>Chest infections e.g. bronchopneu\u00ad</p>\n<p>monia, lobar pneumonia, intersti\u00ad</p>\n<p>tial pneumonia</p>\n<p>~</p>\n<p>Pleurisy (pleural effusion)</p>\n<p>~</p>\n<p>TB (Lung infiltrates especially in</p>\n<p>upper lobe, pleural effusion, cav\u00ad</p>\n<p>ities, mediastinal /hilar lymph</p>\n<p>nodes)</p>\n<p>~</p>\n<p>Trauma complications (pneumo\u00ad</p>\n<p>thorax, fractured ribs, lung contu\u00ad</p>\n<p>sion, haemothorax)</p>\n<p>~</p>\n<p>Lung masses</p>\n<p>~</p>\n<p>Other lung/bronchial disorders</p>\n<h3>(COPD)</h3>"
    },
    {
        "page_number": 1116,
        "content": "1050\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nSYSTEM/\nBODY AREA\nINDICATIONS\nMODALITY\nINFORMATION PROVIDED\nCardio- \nvascular\n \n~\nPalpitation\n \n~\nExertion dyspnoea\n \n~\nDifficulty in breath\u00ad\ning\n \n~\nPeripheral oedema\nChest X-ray\n \n~\nHeart enlargement (cardiomegaly \nor pericardial effusion), poorly de\u00ad\nfined cardiac borders\n \n~\nPulmonary oedema (Kerley B lines)\n \n~\nPleural effusion\nParanasal \nsinuses\n \n~\nAcute uncomplicat\u00ad\ned sinusitis\n \n~\nChronic headache\n \n~\nNasal congestion\n \n~\nNasal discharge\nX-rays of the Parana\u00ad\nsal sinuses\n \n~\nAir-fluid levels, opacification, pol\u00ad\nyps, mucosal thickening indicating \nsinusitis\nPostnasal \nspace\n \n~\nSnoring and diffi\u00ad\nculty in breathing in \nsmall children\nX-ray of the postnasal \nspace\n \n~\nHypertrophied adenoids\n \n~\nCompromised airways",
        "formatted_content": "<p>1050</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>SYSTEM/</h3>\n<h3>BODY AREA</h3>\n<h3>INDICATIONS</h3>\n<h3>MODALITY</h3>\n<h3>INFORMATION PROVIDED</h3>\n<p>Cardio-</p>\n<p>vascular</p>\n<p>~</p>\n<p>Palpitation</p>\n<p>~</p>\n<p>Exertion dyspnoea</p>\n<p>~</p>\n<p>Difficulty in breath\u00ad</p>\n<p>ing</p>\n<p>~</p>\n<p>Peripheral oedema</p>\n<p>Chest X-ray</p>\n<p>~</p>\n<p>Heart enlargement (cardiomegaly</p>\n<p>or pericardial effusion), poorly de\u00ad</p>\n<p>fined cardiac borders</p>\n<p>~</p>\n<p>Pulmonary oedema (Kerley B lines)</p>\n<p>~</p>\n<p>Pleural effusion</p>\n<p>Paranasal</p>\n<p>sinuses</p>\n<p>~</p>\n<p>Acute uncomplicat\u00ad</p>\n<p>ed sinusitis</p>\n<p>~</p>\n<p>Chronic headache</p>\n<p>~</p>\n<p>Nasal congestion</p>\n<p>~</p>\n<p>Nasal discharge</p>\n<p>X-rays of the Parana\u00ad</p>\n<p>sal sinuses</p>\n<p>~</p>\n<p>Air-fluid levels, opacification, pol\u00ad</p>\n<p>yps, mucosal thickening indicating</p>\n<p>sinusitis</p>\n<p>Postnasal</p>\n<p>space</p>\n<p>~</p>\n<p>Snoring and diffi\u00ad</p>\n<p>culty in breathing in</p>\n<p>small children</p>\n<p>X-ray of the postnasal</p>\n<p>space</p>\n<p>~</p>\n<p>Hypertrophied adenoids</p>\n<p>~</p>\n<p>Compromised airways</p>"
    },
    {
        "page_number": 1117,
        "content": "1051\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nSYSTEM/\nBODY AREA\nINDICATIONS\nMODALITY\nINFORMATION PROVIDED\nObstetric \n1st trimes\u00ad\nter\n \n~\nFirst-Trimester\n \n~\nPV bleeding\n \n~\nLow abdominal pain\n \n~\nNot sure of date\n \n~\nEmbryo viability\n \n~\nSuspected \nectopic \npregnancy\nObstetric ultrasound \nscan\n \n~\nIntrauterine or extra-uterine preg\u00ad\nnancy, ectopic pregnancy, cardiac \nactivity, number of embryo/foetus, \ngestation age\nObstetric \n2nd and \n3rd tri\u00ad\nmesters\n \n~\n2nd and 3rd trimes\u00ad\nter\n \n~\nFundo-height great\u00ad\ner or less than WOA\n \n~\nPV bleeding\n \n~\nLoss of foetal move\u00ad\nments\n \n~\nFoetal anomalies\nObstetric ultrasound \nscan\n \n~\nFoetal presentation, amniotic fluid \nvolume, cardiac activity, placental \nposition, foetal biometry, and foe\u00ad\ntal number, plus an anatomic sur\u00ad\nvey.\n \n~\nUmbilical cord around the neck",
        "formatted_content": "<p>1051</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>SYSTEM/</h3>\n<h3>BODY AREA</h3>\n<h3>INDICATIONS</h3>\n<h3>MODALITY</h3>\n<h3>INFORMATION PROVIDED</h3>\n<p>Obstetric</p>\n<p>1st trimes\u00ad</p>\n<p>ter</p>\n<p>~</p>\n<p>First-Trimester</p>\n<p>~</p>\n<p>PV bleeding</p>\n<p>~</p>\n<p>Low abdominal pain</p>\n<p>~</p>\n<p>Not sure of date</p>\n<p>~</p>\n<p>Embryo viability</p>\n<p>~</p>\n<p>Suspected</p>\n<p>ectopic</p>\n<p>pregnancy</p>\n<p>Obstetric ultrasound</p>\n<p>scan</p>\n<p>~</p>\n<p>Intrauterine or extra-uterine preg\u00ad</p>\n<p>nancy, ectopic pregnancy, cardiac</p>\n<p>activity, number of embryo/foetus,</p>\n<p>gestation age</p>\n<p>Obstetric</p>\n<p>2nd and</p>\n<p>3rd tri\u00ad</p>\n<p>mesters</p>\n<p>~</p>\n<p>2nd and 3rd trimes\u00ad</p>\n<p>ter</p>\n<p>~</p>\n<p>Fundo-height great\u00ad</p>\n<p>er or less than WOA</p>\n<p>~</p>\n<p>PV bleeding</p>\n<p>~</p>\n<p>Loss of foetal move\u00ad</p>\n<p>ments</p>\n<p>~</p>\n<p>Foetal anomalies</p>\n<p>Obstetric ultrasound</p>\n<p>scan</p>\n<p>~</p>\n<p>Foetal presentation, amniotic fluid</p>\n<p>volume, cardiac activity, placental</p>\n<p>position, foetal biometry, and foe\u00ad</p>\n<p>tal number, plus an anatomic sur\u00ad</p>\n<p>vey.</p>\n<p>~</p>\n<p>Umbilical cord around the neck</p>"
    },
    {
        "page_number": 1118,
        "content": "1052\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nSYSTEM/\nBODY AREA\nINDICATIONS\nMODALITY\nINFORMATION PROVIDED\nGynaecol\u00ad\nogy\n \n~\nLow abdominal pain\n \n~\nAbnormal PV bleed\u00ad\ning or discharges\n \n~\nAmenorrhoea \nand \nirregular periods\n \n~\nPelvic mass(es)\n \n~\nInfertility\nPelvic ultrasound\nTransvaginal ultra\u00ad\nsound\n \n~\nUterine Masses (fibroids, polyps)\n \n~\nOvarian masses/cysts\n \n~\nPelvic inflammatory disease (fluid \nin the pouch of Douglas)\n \n~\nPolycystic ovaries\nAbdomen\n \n~\nSuspected \nsmall \nbowel \nobstruction \n(SBO)\nPlain abdominal\nX-ray (supine and \nnon- dependent (ei\u00ad\nther upright or left \nlateral decubitus)\nUltrasound X-Ray\n \n~\nDilated small bowel, presence of > \ntwo air-fluid levels, air-fluid levels \nwider than 2.5 cm, and\n \n~\nair-fluid levels differing >2 cm in \nheight from one another within the \nsame small bowel loop\n \n~\nLumen of the fluid-filled small bow\u00ad\nel loops dilated to >3 cm, length of \nthe segment is >10 cm, peristalsis \nof the dilated segment is increased, \nas shown by the to-and-fro or whirl\u00ad\ning motion of the bowel contents",
        "formatted_content": "<p>1052</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>SYSTEM/</h3>\n<h3>BODY AREA</h3>\n<h3>INDICATIONS</h3>\n<h3>MODALITY</h3>\n<h3>INFORMATION PROVIDED</h3>\n<p>Gynaecol\u00ad</p>\n<p>ogy</p>\n<p>~</p>\n<p>Low abdominal pain</p>\n<p>~</p>\n<p>Abnormal PV bleed\u00ad</p>\n<p>ing or discharges</p>\n<p>~</p>\n<p>Amenorrhoea</p>\n<p>and</p>\n<p>irregular periods</p>\n<p>~</p>\n<p>Pelvic mass(es)</p>\n<p>~</p>\n<p>Infertility</p>\n<p>Pelvic ultrasound</p>\n<p>Transvaginal ultra\u00ad</p>\n<p>sound</p>\n<p>~</p>\n<p>Uterine Masses (fibroids, polyps)</p>\n<p>~</p>\n<p>Ovarian masses/cysts</p>\n<p>~</p>\n<p>Pelvic inflammatory disease (fluid</p>\n<p>in the pouch of Douglas)</p>\n<p>~</p>\n<p>Polycystic ovaries</p>\n<p>Abdomen</p>\n<p>~</p>\n<p>Suspected</p>\n<p>small</p>\n<p>bowel</p>\n<p>obstruction</p>\n<h3>(SBO)</h3>\n<p>Plain abdominal</p>\n<p>X-ray (supine and</p>\n<p>non- dependent (ei\u00ad</p>\n<p>ther upright or left</p>\n<p>lateral decubitus)</p>\n<p>Ultrasound X-Ray</p>\n<p>~</p>\n<p>Dilated small bowel, presence of ></p>\n<p>two air-fluid levels, air-fluid levels</p>\n<p>wider than 2.5 cm, and</p>\n<p>~</p>\n<p>air-fluid levels differing >2 cm in</p>\n<p>height from one another within the</p>\n<p>same small bowel loop</p>\n<p>~</p>\n<p>Lumen of the fluid-filled small bow\u00ad</p>\n<p>el loops dilated to >3 cm, length of</p>\n<p>the segment is >10 cm, peristalsis</p>\n<p>of the dilated segment is increased,</p>\n<p>as shown by the to-and-fro or whirl\u00ad</p>\n<p>ing motion of the bowel contents</p>"
    },
    {
        "page_number": 1119,
        "content": "1053\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nSYSTEM/\nBODY AREA\nINDICATIONS\nMODALITY\nINFORMATION PROVIDED\n \n~\nExamining the area of transition \nfrom the dilated to normal bowel \nmay identify causes of conditions \ne.g. \nbezoars, \nintussusception, \nCrohn\u2019s disease, hernias and tu\u00ad\nmours\n \n~\nOr suspected large \nbowel obstruction\nUltrasound\n \n~\nColon dilated >6 cm and the cecum \nis not >9 cm in diameter. (Normal \ncolonic caliber 3-8 cm, with the \nlargest diameter in the cecum).\n \n- The colon is dilated proximal \nto the site of obstruction with a \npaucity or absence of gas distal \nto the obstruction.\n \n- Air-fluid levels are often seen in \nthe dilated colon on the upright \nor decubitus radiographs.\n \n- This suggests that the cause \nof obstruction is more acute \nsince the colonic fluid has not \nbeen present long enough to be \nabsorbed",
        "formatted_content": "<p>1053</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>SYSTEM/</h3>\n<h3>BODY AREA</h3>\n<h3>INDICATIONS</h3>\n<h3>MODALITY</h3>\n<h3>INFORMATION PROVIDED</h3>\n<p>~</p>\n<p>Examining the area of transition</p>\n<p>from the dilated to normal bowel</p>\n<p>may identify causes of conditions</p>\n<p>e.g.</p>\n<p>bezoars,</p>\n<p>intussusception,</p>\n<p>Crohn\u2019s disease, hernias and tu\u00ad</p>\n<p>mours</p>\n<p>~</p>\n<p>Or suspected large</p>\n<p>bowel obstruction</p>\n<p>Ultrasound</p>\n<p>~</p>\n<p>Colon dilated >6 cm and the cecum</p>\n<p>is not >9 cm in diameter. (Normal</p>\n<p>colonic caliber 3-8 cm, with the</p>\n<p>largest diameter in the cecum).</p>\n<p>- The colon is dilated proximal</p>\n<p>to the site of obstruction with a</p>\n<p>paucity or absence of gas distal</p>\n<p>to the obstruction.</p>\n<p>- Air-fluid levels are often seen in</p>\n<p>the dilated colon on the upright</p>\n<p>or decubitus radiographs.</p>\n<p>- This suggests that the cause</p>\n<p>of obstruction is more acute</p>\n<p>since the colonic fluid has not</p>\n<p>been present long enough to be</p>\n<p>absorbed</p>"
    },
    {
        "page_number": 1120,
        "content": "1054\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nSYSTEM/\nBODY AREA\nINDICATIONS\nMODALITY\nINFORMATION PROVIDED\nAbdomen\n \n~\nSuspected perfora\u00ad\ntion\nAbdominal\nX-Ray (erect or or left \nlateral decubitus)\n \n~\nGut perforation: Free air below the \nhemidiaphgram on the CXR indi\u00ad\ncate pneumoperitoneum\n \n~\nLiver or gall bladder \ndisease\nUltrasound\n \n~\nGallstones, cholecystitis\n \n~\nHepatomegaly or cirrhosis (fibrotic \nliver)\n \n~\nLiver masses (tumours)\n \n~\nIntra-abdomi nal \nbleeding\n \n~\nAbdominal trauma\nUltrasound\n \n~\nFluids (blood) in peritoneum\n \n~\nLiver/spleen rupture/ haematoma\n \n~\nAortic aneurysm\n \n~\nRenal trauma/haematoma\n \n~\nUrological diseases\nUltrasound\n \n~\nKidney stones\n \n~\nKidney diseases (cancer, chronic \npyelonephritis, hydronephrosis)\n \n~\nProstate enlargement",
        "formatted_content": "<p>1054</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>SYSTEM/</h3>\n<h3>BODY AREA</h3>\n<h3>INDICATIONS</h3>\n<h3>MODALITY</h3>\n<h3>INFORMATION PROVIDED</h3>\n<p>Abdomen</p>\n<p>~</p>\n<p>Suspected perfora\u00ad</p>\n<p>tion</p>\n<p>Abdominal</p>\n<p>X-Ray (erect or or left</p>\n<p>lateral decubitus)</p>\n<p>~</p>\n<p>Gut perforation: Free air below the</p>\n<p>hemidiaphgram on the CXR indi\u00ad</p>\n<p>cate pneumoperitoneum</p>\n<p>~</p>\n<p>Liver or gall bladder</p>\n<p>disease</p>\n<p>Ultrasound</p>\n<p>~</p>\n<p>Gallstones, cholecystitis</p>\n<p>~</p>\n<p>Hepatomegaly or cirrhosis (fibrotic</p>\n<p>liver)</p>\n<p>~</p>\n<p>Liver masses (tumours)</p>\n<p>~</p>\n<p>Intra-abdomi nal</p>\n<p>bleeding</p>\n<p>~</p>\n<p>Abdominal trauma</p>\n<p>Ultrasound</p>\n<p>~</p>\n<p>Fluids (blood) in peritoneum</p>\n<p>~</p>\n<p>Liver/spleen rupture/ haematoma</p>\n<p>~</p>\n<p>Aortic aneurysm</p>\n<p>~</p>\n<p>Renal trauma/haematoma</p>\n<p>~</p>\n<p>Urological diseases</p>\n<p>Ultrasound</p>\n<p>~</p>\n<p>Kidney stones</p>\n<p>~</p>\n<p>Kidney diseases (cancer, chronic</p>\n<p>pyelonephritis, hydronephrosis)</p>\n<p>~</p>\n<p>Prostate enlargement</p>"
    },
    {
        "page_number": 1121,
        "content": "1055\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\n24.3 ANAESTHESIA\nMain objectives of anaesthesia during surgery are to:\n \n~\nRelieve pain\n \n~\nSupport physiological functions\n \n~\nProvide favourable conditions for the operation\n24.3.1 General Considerations\nBody Part \nAffected\nFeatures\nEquipment\n \n~\nAvailable and in a state of readiness at all \ntimes\n \n~\nAppropriate in quality and quantity\n \n~\nCompatible with safety\nStaff\n \n~\nQualified anaesthesia provider\n \n~\nAn assistant for the anaesthesia provider\n \n~\nAdequate assistance in positioning the pa\u00ad\ntient\n \n~\nAdequate technical assistance to ensure \nproper functioning and servicing of all \nequipment\nBefore anaesthesia\n \n~\nRead the notes/medical records of the pa\u00ad\ntient\n \n~\nAssess the patient very carefully\n \n~\nThe drugs, equipment, instruments and \nmaterials to be used must be known\n \n~\nProperly prepare workplace and patient",
        "formatted_content": "<p>1055</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>24.3 ANAESTHESIA</h3>\n<p>Main objectives of anaesthesia during surgery are to:</p>\n<p>~</p>\n<p>Relieve pain</p>\n<p>~</p>\n<p>Support physiological functions</p>\n<p>~</p>\n<p>Provide favourable conditions for the operation</p>\n<p>24.3.1 General Considerations</p>\n<p>Body Part</p>\n<p>Affected</p>\n<p>Features</p>\n<p>Equipment</p>\n<p>~</p>\n<p>Available and in a state of readiness at all</p>\n<p>times</p>\n<p>~</p>\n<p>Appropriate in quality and quantity</p>\n<p>~</p>\n<p>Compatible with safety</p>\n<p>Staff</p>\n<p>~</p>\n<p>Qualified anaesthesia provider</p>\n<p>~</p>\n<p>An assistant for the anaesthesia provider</p>\n<p>~</p>\n<p>Adequate assistance in positioning the pa\u00ad</p>\n<p>tient</p>\n<p>~</p>\n<p>Adequate technical assistance to ensure</p>\n<p>proper functioning and servicing of all</p>\n<p>equipment</p>\n<p>Before anaesthesia</p>\n<p>~</p>\n<p>Read the notes/medical records of the pa\u00ad</p>\n<p>tient</p>\n<p>~</p>\n<p>Assess the patient very carefully</p>\n<p>~</p>\n<p>The drugs, equipment, instruments and</p>\n<p>materials to be used must be known</p>\n<p>~</p>\n<p>Properly prepare workplace and patient</p>"
    },
    {
        "page_number": 1122,
        "content": "1056\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nBody Part \nAffected\nFeatures\nBefore anaesthesia\n \n~\nAnaesthesia is administered (induction and \nmaintenance)\n \n~\nThe patient must be monitored meticu\u00ad\nlously to:\n \n~\nEnsure his/her well-being\n \n~\nDetect dangerous signs as soon as they \narise and appropriately treat them\n \n~\nExpertise in resuscitation is obligatory. If \nin trouble, ask for help\n \n~\nKeep an accurate and legible record of the \nanaesthetic and all measured vital signs on \nthe anaesthetic chart/form\nAfter anaesthesia\n \n~\nThe patient:\n \n- Recovers from effects of anaesthesia\n \n- Has stable vital signs\n \n- Is returned to the ward in the fully \nconscious state\n \n~\nFollow-up patient for next 24 hours\nTypes of Anaesthesia\nAnaesthesia may be produced in a number of ways\nGeneral anaesthesia\n \n~\nBasic elements: Loss of consciousness, analgesia, prevention of \nundesirable reflexes, and muscle relaxation\nRegional or local anaesthesia\n \n~\nSensation of pain is blocked without loss of consciousness. The \nconduction of stimulus from a painful site to the brain can be \ninterrupted at one of the many points:",
        "formatted_content": "<p>1056</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>Body Part</p>\n<p>Affected</p>\n<p>Features</p>\n<p>Before anaesthesia</p>\n<p>~</p>\n<p>Anaesthesia is administered (induction and</p>\n<p>maintenance)</p>\n<p>~</p>\n<p>The patient must be monitored meticu\u00ad</p>\n<p>lously to:</p>\n<p>~</p>\n<p>Ensure his/her well-being</p>\n<p>~</p>\n<p>Detect dangerous signs as soon as they</p>\n<p>arise and appropriately treat them</p>\n<p>~</p>\n<p>Expertise in resuscitation is obligatory. If</p>\n<p>in trouble, ask for help</p>\n<p>~</p>\n<p>Keep an accurate and legible record of the</p>\n<p>anaesthetic and all measured vital signs on</p>\n<p>the anaesthetic chart/form</p>\n<p>After anaesthesia</p>\n<p>~</p>\n<p>The patient:</p>\n<p>- Recovers from effects of anaesthesia</p>\n<p>- Has stable vital signs</p>\n<p>- Is returned to the ward in the fully</p>\n<p>conscious state</p>\n<p>~</p>\n<p>Follow-up patient for next 24 hours</p>\n<p>Types of Anaesthesia</p>\n<p>Anaesthesia may be produced in a number of ways</p>\n<p>General anaesthesia</p>\n<p>~</p>\n<p>Basic elements: Loss of consciousness, analgesia, prevention of</p>\n<p>undesirable reflexes, and muscle relaxation</p>\n<p>Regional or local anaesthesia</p>\n<p>~</p>\n<p>Sensation of pain is blocked without loss of consciousness. The</p>\n<p>conduction of stimulus from a painful site to the brain can be</p>\n<p>interrupted at one of the many points:</p>"
    },
    {
        "page_number": 1123,
        "content": "1057\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\n\t\n\u0089\nSurface anaesthesia\n\t\n\u0089\nInfiltration anaesthesia\n\t\n\u0089\nIntravenous regional anaesthesia\n\t\n\u0089\nNerve block/plexus block\n \n- Epidural anaesthesia\n \n- Spinal anaesthesia\n24.3.1.1 General Anaesthesia\nPREPARATION IN THE OPERATING THEATRE\nShould be in a constant state of preparedness for anaesthesia\nThe following should be available, checked, and ready\n \n~\nOxygen source\n \n~\nOperating table that is adjustable and with its accessories\n \n~\nAnaesthesia machine with accessories\n \n~\nSelf inflating bag for inflating the lungs with oxygen\n \n~\nAppropriate range of face masks\n \n~\nSuction machine with range of suction catheters\n \n~\nAppropriate range of oropharyngeal airways, endotracheal \ntubes, and other airways, e.g., laryngeal mask airway\n \n~\nLaryngoscope with suitable range of blades\n \n~\nMagill\u2019s forceps\n \n~\nIntravenous infusion equipment, appropriate range of cannulae \nand fluids (solutions)\n \n~\nEquipment for regional anaesthesia\n \n~\nAdequate lighting\n \n~\nSafe disposal of items contaminated with body fluids, sharps, \nand waste glass\n \n~\nRefrigeration for storage of fluids, drugs, and blood\n \n~\nAnaesthetic drugs: General and local anaesthetic agents\n \n~\nMuscle relaxants\n \n~\nAppropriate range of sizes of syringes\n \n~\nMonitors: stethoscope, sphygmomanometer, pulse oximeter\n \n~\nAppropriate protection of staff against biological contami\u00ad\nnants. This includes: caps, gowns, gloves, masks, footwear \nand eye shields (personal protective equipment)\n \n~\nDrugs necessary for management of conditions, which may \ncomplicate or co-exist with anaesthesia",
        "formatted_content": "<p>1057</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>\u0089</p>\n<p>Surface anaesthesia</p>\n<p>\u0089</p>\n<p>Infiltration anaesthesia</p>\n<p>\u0089</p>\n<p>Intravenous regional anaesthesia</p>\n<p>\u0089</p>\n<p>Nerve block/plexus block</p>\n<p>- Epidural anaesthesia</p>\n<p>- Spinal anaesthesia</p>\n<p>24.3.1.1 General Anaesthesia</p>\n<h3>PREPARATION IN THE OPERATING THEATRE</h3>\n<p>Should be in a constant state of preparedness for anaesthesia</p>\n<p>The following should be available, checked, and ready</p>\n<p>~</p>\n<p>Oxygen source</p>\n<p>~</p>\n<p>Operating table that is adjustable and with its accessories</p>\n<p>~</p>\n<p>Anaesthesia machine with accessories</p>\n<p>~</p>\n<p>Self inflating bag for inflating the lungs with oxygen</p>\n<p>~</p>\n<p>Appropriate range of face masks</p>\n<p>~</p>\n<p>Suction machine with range of suction catheters</p>\n<p>~</p>\n<p>Appropriate range of oropharyngeal airways, endotracheal</p>\n<p>tubes, and other airways, e.g., laryngeal mask airway</p>\n<p>~</p>\n<p>Laryngoscope with suitable range of blades</p>\n<p>~</p>\n<p>Magill\u2019s forceps</p>\n<p>~</p>\n<p>Intravenous infusion equipment, appropriate range of cannulae</p>\n<p>and fluids (solutions)</p>\n<p>~</p>\n<p>Equipment for regional anaesthesia</p>\n<p>~</p>\n<p>Adequate lighting</p>\n<p>~</p>\n<p>Safe disposal of items contaminated with body fluids, sharps,</p>\n<p>and waste glass</p>\n<p>~</p>\n<p>Refrigeration for storage of fluids, drugs, and blood</p>\n<p>~</p>\n<p>Anaesthetic drugs: General and local anaesthetic agents</p>\n<p>~</p>\n<p>Muscle relaxants</p>\n<p>~</p>\n<p>Appropriate range of sizes of syringes</p>\n<p>~</p>\n<p>Monitors: stethoscope, sphygmomanometer, pulse oximeter</p>\n<p>~</p>\n<p>Appropriate protection of staff against biological contami\u00ad</p>\n<p>nants. This includes: caps, gowns, gloves, masks, footwear</p>\n<p>and eye shields (personal protective equipment)</p>\n<p>~</p>\n<p>Drugs necessary for management of conditions, which may</p>\n<p>complicate or co-exist with anaesthesia</p>"
    },
    {
        "page_number": 1124,
        "content": "1058\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nPREPARATION IN THE OPERATING THEATRE\nPRE-OPERATIVE MANAGEMENT\nThe aim is to make the patient as fit as possible before surgical operation\nAssessment of the patient\n \n- Identify the patient and establish rapport\n \n- A standard history is obtained and an examination done\n \n- Emphasis is on the cardio-respiratory systems\n \n- Investigations appropriately interpreted e.g., Hb\n \n- Health status/condition of the patient\n \n- Classify physical status of the patient according to A.S.A. \n(ASA classification 1-5 with or without E)\n \n- Make a plan for anaesthesia based on the information \nobtained\nPreparation of the patient\n \n- Explain the procedure to the patient and ensure that he/ \nshe has understood\n \n- Ensure informed consent form is signed\n \n- Weight of patient should be taken\n \n- Check site and side of the operation\n \n- Check period of fasting\n \n- Remove: Ornaments/prostheses/dentures that may injure \nthe patient and make-up that may interfere with monitoring\n \n- Any other necessary preparation based on patient\u2019s \ncondition and nature of the operation (condition of deficits/\nimbalances should be corrected, control chronic conditions)\n \n- Ability of the patient to withstand the stresses and adverse \neffects of anaesthesia and the surgical procedure will \ndepend on how well prepared he/she is\n24.3.1.2 General Anaesthetic Agents\nIntravenous agents\nMost anaesthetic agents are included in the specialist essential medicines \nlist meaning that use is restricted to specialised health workers",
        "formatted_content": "<p>1058</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>PREPARATION IN THE OPERATING THEATRE</h3>\n<h3>PRE-OPERATIVE MANAGEMENT</h3>\n<p>The aim is to make the patient as fit as possible before surgical operation</p>\n<p>Assessment of the patient</p>\n<p>- Identify the patient and establish rapport</p>\n<p>- A standard history is obtained and an examination done</p>\n<p>- Emphasis is on the cardio-respiratory systems</p>\n<p>- Investigations appropriately interpreted e.g., Hb</p>\n<p>- Health status/condition of the patient</p>\n<p>- Classify physical status of the patient according to A.S.A.</p>\n<p>(ASA classification 1-5 with or without E)</p>\n<p>- Make a plan for anaesthesia based on the information</p>\n<p>obtained</p>\n<p>Preparation of the patient</p>\n<p>- Explain the procedure to the patient and ensure that he/</p>\n<p>she has understood</p>\n<p>- Ensure informed consent form is signed</p>\n<p>- Weight of patient should be taken</p>\n<p>- Check site and side of the operation</p>\n<p>- Check period of fasting</p>\n<p>- Remove: Ornaments/prostheses/dentures that may injure</p>\n<p>the patient and make-up that may interfere with monitoring</p>\n<p>- Any other necessary preparation based on patient\u2019s</p>\n<p>condition and nature of the operation (condition of deficits/</p>\n<p>imbalances should be corrected, control chronic conditions)</p>\n<p>- Ability of the patient to withstand the stresses and adverse</p>\n<p>effects of anaesthesia and the surgical procedure will</p>\n<p>depend on how well prepared he/she is</p>\n<p>24.3.1.2 General Anaesthetic Agents</p>\n<p>Intravenous agents</p>\n<p>Most anaesthetic agents are included in the specialist essential medicines</p>\n<p>list meaning that use is restricted to specialised health workers</p>"
    },
    {
        "page_number": 1125,
        "content": "1059\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nTYPE OF LESION\nFEATURES\nKetamine \n \n~\nSolution:50mg/ml, \n10 mg/ml\n \n~\nRoute: IV or IM\n \n~\nDose:\n \n- IV 1-2 mg/kg\n \n- IM. 5-7 mg/kg\n \n~\nIndication: Induction of anaes\u00ad\nthesia, maintenance of anaes\u00ad\nthesia (infusion), analgesia\n \n~\nContraindication: Hypertension, \nepilepsy,raised intracranial pres\u00ad\nsure, e.g., head injury\n \n~\nSide effects: Emergency delir\u00ad\nium, hallucinations, increased \nsalivation, increased muscle tone\n \n~\nPrevent salivation by atropine \npremedication, treat emergency \ndelirium by giving diazepam\nPropofol \n \n~\nSolution/emulsion: \n1% or\n \n~\nmg/ml\n \n~\nRoute: IV\n \n~\nDose: 1-2.5 mg/ kg \ntitrated at a rate of 4 \nml per second\n \n~\nIndications: Induction of anaes\u00ad\nthesia, maintenance of anaes\u00ad\nthesia\n \n~\nContraindication:\n \n~\nHypersensitivity, hypotension\n \n~\nSide effects: Pain at site of in\u00ad\njection\nInhalational anaesthetic agents\nHalothane is included in the general essential medicines list but should \nonly be used by health workers confident with the use of this anaesthetic\nMEDICINE\nCHARACTERISTICS AND USE\nHalothane\n \n~\nA volatile liquid at room temperature\n \n~\nIndications\n \n- Induction of anaesthesia (in children, \npatients with airway obstruction)\n \n- Maintenance of anaesthesia",
        "formatted_content": "<p>1059</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>TYPE OF LESION</h3>\n<h3>FEATURES</h3>\n<p>Ketamine</p>\n<p>~</p>\n<p>Solution:50mg/ml,</p>\n<p>10 mg/ml</p>\n<p>~</p>\n<p>Route: IV or IM</p>\n<p>~</p>\n<p>Dose:</p>\n<p>- IV 1-2 mg/kg</p>\n<p>- IM. 5-7 mg/kg</p>\n<p>~</p>\n<p>Indication: Induction of anaes\u00ad</p>\n<p>thesia, maintenance of anaes\u00ad</p>\n<p>thesia (infusion), analgesia</p>\n<p>~</p>\n<p>Contraindication: Hypertension,</p>\n<p>epilepsy,raised intracranial pres\u00ad</p>\n<p>sure, e.g., head injury</p>\n<p>~</p>\n<p>Side effects: Emergency delir\u00ad</p>\n<p>ium, hallucinations, increased</p>\n<p>salivation, increased muscle tone</p>\n<p>~</p>\n<p>Prevent salivation by atropine</p>\n<p>premedication, treat emergency</p>\n<p>delirium by giving diazepam</p>\n<p>Propofol</p>\n<p>~</p>\n<p>Solution/emulsion:</p>\n<p>1% or</p>\n<p>~</p>\n<p>mg/ml</p>\n<p>~</p>\n<p>Route: IV</p>\n<p>~</p>\n<p>Dose: 1-2.5 mg/ kg</p>\n<p>titrated at a rate of 4</p>\n<p>ml per second</p>\n<p>~</p>\n<p>Indications: Induction of anaes\u00ad</p>\n<p>thesia, maintenance of anaes\u00ad</p>\n<p>thesia</p>\n<p>~</p>\n<p>Contraindication:</p>\n<p>~</p>\n<p>Hypersensitivity, hypotension</p>\n<p>~</p>\n<p>Side effects: Pain at site of in\u00ad</p>\n<p>jection</p>\n<p>Inhalational anaesthetic agents</p>\n<p>Halothane is included in the general essential medicines list but should</p>\n<p>only be used by health workers confident with the use of this anaesthetic</p>\n<h3>MEDICINE</h3>\n<h3>CHARACTERISTICS AND USE</h3>\n<p>Halothane</p>\n<p>~</p>\n<p>A volatile liquid at room temperature</p>\n<p>~</p>\n<p>Indications</p>\n<p>- Induction of anaesthesia (in children,</p>\n<p>patients with airway obstruction)</p>\n<p>- Maintenance of anaesthesia</p>"
    },
    {
        "page_number": 1126,
        "content": "1060\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nMEDICINE\nCHARACTERISTICS AND USE\nHalothane\n \n~\nPrecaution: Always use at least 30% oxy\u00ad\ngen with halothane\n \n~\nIt is safe to avoid use of adrenaline to pre\u00ad\nvent high incidence of arrhythmias\n \n~\nAdverse effects which may occur include:\n \n- Atony of the gravid uterus\n \n- Post-operative shivering\n \n- Severe cardiopulmonary depression\n24.3.1.3 Muscle Relaxants\nThey are used to provide muscle relaxation to facilitate a procedure, and \nused in a patient who is unconscious, e.g. general anaesthesia, or sedated.\n \n~\nPrecaution before using a muscle relaxant: always have means of \nsupporting the airway and respiration\n24.3.3 Selection of Type of Anaesthesia for the Patient\nConsider the following factors:\n \n~\nPatient factors: medical state, time of last meal, mental state, \nwish of patient if applicable\n \n~\nSurgical factors: nature of surgery, site of operation, estimated \nduration of surgery, position in which the surgery is to be per\u00ad\nformed\n \n~\nAnaesthetic factors: availability of drugs, experience and compe\u00ad\ntence of the anaesthetic provider\n24.3.3.1\t\nTechniques of General Anaesthesia\nRequirements for all\n \n- Take and record baseline vital signs\n \n- Establish intravenous line and commence infusion",
        "formatted_content": "<p>1060</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>MEDICINE</h3>\n<h3>CHARACTERISTICS AND USE</h3>\n<p>Halothane</p>\n<p>~</p>\n<p>Precaution: Always use at least 30% oxy\u00ad</p>\n<p>gen with halothane</p>\n<p>~</p>\n<p>It is safe to avoid use of adrenaline to pre\u00ad</p>\n<p>vent high incidence of arrhythmias</p>\n<p>~</p>\n<p>Adverse effects which may occur include:</p>\n<p>- Atony of the gravid uterus</p>\n<p>- Post-operative shivering</p>\n<p>- Severe cardiopulmonary depression</p>\n<p>24.3.1.3 Muscle Relaxants</p>\n<p>They are used to provide muscle relaxation to facilitate a procedure, and</p>\n<p>used in a patient who is unconscious, e.g. general anaesthesia, or sedated.</p>\n<p>~</p>\n<p>Precaution before using a muscle relaxant: always have means of</p>\n<p>supporting the airway and respiration</p>\n<p>24.3.3 Selection of Type of Anaesthesia for the Patient</p>\n<p>Consider the following factors:</p>\n<p>~</p>\n<p>Patient factors: medical state, time of last meal, mental state,</p>\n<p>wish of patient if applicable</p>\n<p>~</p>\n<p>Surgical factors: nature of surgery, site of operation, estimated</p>\n<p>duration of surgery, position in which the surgery is to be per\u00ad</p>\n<p>formed</p>\n<p>~</p>\n<p>Anaesthetic factors: availability of drugs, experience and compe\u00ad</p>\n<p>tence of the anaesthetic provider</p>\n<p>24.3.3.1</p>\n<p>Techniques of General Anaesthesia</p>\n<p>Requirements for all</p>\n<p>- Take and record baseline vital signs</p>\n<p>- Establish intravenous line and commence infusion</p>"
    },
    {
        "page_number": 1127,
        "content": "1061\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nRAPID SEQUENCE INDUCTION OF GENERAL ANAESTHESIA\nInduce anaesthesia by:\n \n~\nIntravenous route (adults) or\n \n~\nInhalation route (children, patient with difficult airway)\nMaintenance\n \n~\nSecure a clear airway using an oropharyngeal airway\n \n~\nThe mask is placed on the face\n \n~\nTitrate concentration of inhalation against response of the pa\u00ad\ntient\n \n~\nMonitor, record every 5 minutes or more frequently, BP, pulse, \nrespiration, colour, oximetry\nIndication\n \n~\nThis technique may be used for operations on limbs, perine\u00ad\num, superficial wall of chest, and abdomen\n \n~\nSuitable for operations lasting less than 30 minutes\nInduce anaesthesia:\n \n~\nIntravenous/inhalation (see above)\n \n~\nTracheal intubation\n \n- When spontaneously breathing for anticipated difficult \nairway (for children) or\n \n- Under relaxation by suxamethonium and laryngoscopy\n \n- Confirm correct tube placement by presence of breath \nsounds on both chest sides\n \n- Connect the breathing/delivery system to the endotracheal \ntube\nMaintenance\n \n~\nTitrate concentration of inhalation agent against response of \nthe patient\n \n- A selected, long acting muscle relaxant is given\n \n- Intermittent positive pressure ventilation is done",
        "formatted_content": "<p>1061</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>RAPID SEQUENCE INDUCTION OF GENERAL ANAESTHESIA</h3>\n<p>Induce anaesthesia by:</p>\n<p>~</p>\n<p>Intravenous route (adults) or</p>\n<p>~</p>\n<p>Inhalation route (children, patient with difficult airway)</p>\n<p>Maintenance</p>\n<p>~</p>\n<p>Secure a clear airway using an oropharyngeal airway</p>\n<p>~</p>\n<p>The mask is placed on the face</p>\n<p>~</p>\n<p>Titrate concentration of inhalation against response of the pa\u00ad</p>\n<p>tient</p>\n<p>~</p>\n<p>Monitor, record every 5 minutes or more frequently, BP, pulse,</p>\n<p>respiration, colour, oximetry</p>\n<p>Indication</p>\n<p>~</p>\n<p>This technique may be used for operations on limbs, perine\u00ad</p>\n<p>um, superficial wall of chest, and abdomen</p>\n<p>~</p>\n<p>Suitable for operations lasting less than 30 minutes</p>\n<p>Induce anaesthesia:</p>\n<p>~</p>\n<p>Intravenous/inhalation (see above)</p>\n<p>~</p>\n<p>Tracheal intubation</p>\n<p>- When spontaneously breathing for anticipated difficult</p>\n<p>airway (for children) or</p>\n<p>- Under relaxation by suxamethonium and laryngoscopy</p>\n<p>- Confirm correct tube placement by presence of breath</p>\n<p>sounds on both chest sides</p>\n<p>- Connect the breathing/delivery system to the endotracheal</p>\n<p>tube</p>\n<p>Maintenance</p>\n<p>~</p>\n<p>Titrate concentration of inhalation agent against response of</p>\n<p>the patient</p>\n<p>- A selected, long acting muscle relaxant is given</p>\n<p>- Intermittent positive pressure ventilation is done</p>"
    },
    {
        "page_number": 1128,
        "content": "1062\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\nRAPID SEQUENCE INDUCTION OF GENERAL ANAESTHESIA\n \n- Monitor vital signs (as above)\n \n~\nAt the end of the operation when the patient shows signs of \nrespiratory effort, give\n \n- IV. Neostigmine 0.03 to 0.07 mg/kg to reverse the\n \n- effects of the long acting muscle relaxant\nIndication\n \n~\nAll operations that require a protected airway and controlled \nventilation, e.g, intraabdominal, intrathoracic, and intracranial \noperations\n(Also called crash induction) For patients with \u201cfull stomach\u201d and at \nrisk of regurgitation, e.g., emergency surgery, distended abdomen\nCrash induction steps\n \n~\nEstablish an intravenous line and commence infusions\n \n~\nPreoxygenation for >3 minutes\n \n~\nInduce with selected intravenous anaesthetic agent\n \n~\nAssistant applies cricoid pressure\n \n~\nIV suxamethonium is given\n \n~\nLaryngosopy is done\n \n~\nTrachea is intubated and correct tube placement confirmed\n \n~\nThe cuff of the endotracheal tube is inflated, then cricoid pres\u00ad\nsure released\n \n~\nThe position of the tube is fixed by strapping and an airway \nis inserted\n \n~\nThen connect to breathing circuit/system to maintain anaes\u00ad\nthesia\n24.1.1.1 Techniques for Regional Anaesthesia\n \n~\nDetailed knowledge of anatomy, technique, and possible compli\u00ad\ncations is important for correct injection placement",
        "formatted_content": "<p>1062</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<h3>RAPID SEQUENCE INDUCTION OF GENERAL ANAESTHESIA</h3>\n<p>- Monitor vital signs (as above)</p>\n<p>~</p>\n<p>At the end of the operation when the patient shows signs of</p>\n<p>respiratory effort, give</p>\n<p>- IV. Neostigmine 0.03 to 0.07 mg/kg to reverse the</p>\n<p>- effects of the long acting muscle relaxant</p>\n<p>Indication</p>\n<p>~</p>\n<p>All operations that require a protected airway and controlled</p>\n<p>ventilation, e.g, intraabdominal, intrathoracic, and intracranial</p>\n<p>operations</p>\n<p>(Also called crash induction) For patients with \u201cfull stomach\u201d and at</p>\n<p>risk of regurgitation, e.g., emergency surgery, distended abdomen</p>\n<p>Crash induction steps</p>\n<p>~</p>\n<p>Establish an intravenous line and commence infusions</p>\n<p>~</p>\n<p>Preoxygenation for >3 minutes</p>\n<p>~</p>\n<p>Induce with selected intravenous anaesthetic agent</p>\n<p>~</p>\n<p>Assistant applies cricoid pressure</p>\n<p>~</p>\n<p>IV suxamethonium is given</p>\n<p>~</p>\n<p>Laryngosopy is done</p>\n<p>~</p>\n<p>Trachea is intubated and correct tube placement confirmed</p>\n<p>~</p>\n<p>The cuff of the endotracheal tube is inflated, then cricoid pres\u00ad</p>\n<p>sure released</p>\n<p>~</p>\n<p>The position of the tube is fixed by strapping and an airway</p>\n<p>is inserted</p>\n<p>~</p>\n<p>Then connect to breathing circuit/system to maintain anaes\u00ad</p>\n<p>thesia</p>\n<p>24.1.1.1 Techniques for Regional Anaesthesia</p>\n<p>~</p>\n<p>Detailed knowledge of anatomy, technique, and possible compli\u00ad</p>\n<p>cations is important for correct injection placement</p>"
    },
    {
        "page_number": 1129,
        "content": "1063\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia\n \n~\nPreoperative assessment and preparation of the patient should \nbe done\n \n~\nPatient refusal and local sepsis are the only absolute contraindi\u00ad\ncations\n \n~\nSelect the appropriate technique for operation\nPROCEDURE\n \n~\nDiscuss the procedure with the patient\n \n~\nIdentify the injection site using appropriate landmarks\n \n~\nObserve aseptic conditions\n \n~\nUse small bore needle, which causes less pain during injection\n \n~\nSelect concentration and volume of drug according to the tech\u00ad\nnique\n \n~\nAspirate before injection to avoid accidental intravascular in\u00ad\njection\n \n~\nInject slowly and allow 5-10 minutes for onset of drug action\n \n~\nConfirm desired block effect before surgery commences\n \n~\nThe patient must be monitored throughout the procedure\nNote\n\uf077\t\nSupplemental agents should be available for analgesia or anaes\u00ad\nthesia if technique is inadequate\n\uf077\t\nResuscitative equipment, drugs, and oxygen must be at hand \nbefore administration of any anaesthetic",
        "formatted_content": "<p>1063</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>\n<p>~</p>\n<p>Preoperative assessment and preparation of the patient should</p>\n<p>be done</p>\n<p>~</p>\n<p>Patient refusal and local sepsis are the only absolute contraindi\u00ad</p>\n<p>cations</p>\n<p>~</p>\n<p>Select the appropriate technique for operation</p>\n<h3>PROCEDURE</h3>\n<p>~</p>\n<p>Discuss the procedure with the patient</p>\n<p>~</p>\n<p>Identify the injection site using appropriate landmarks</p>\n<p>~</p>\n<p>Observe aseptic conditions</p>\n<p>~</p>\n<p>Use small bore needle, which causes less pain during injection</p>\n<p>~</p>\n<p>Select concentration and volume of drug according to the tech\u00ad</p>\n<p>nique</p>\n<p>~</p>\n<p>Aspirate before injection to avoid accidental intravascular in\u00ad</p>\n<p>jection</p>\n<p>~</p>\n<p>Inject slowly and allow 5-10 minutes for onset of drug action</p>\n<p>~</p>\n<p>Confirm desired block effect before surgery commences</p>\n<p>~</p>\n<p>The patient must be monitored throughout the procedure</p>\n<p>Note</p>\n<p>\uf077</p>\n<p>Supplemental agents should be available for analgesia or anaes\u00ad</p>\n<p>thesia if technique is inadequate</p>\n<p>\uf077</p>\n<p>Resuscitative equipment, drugs, and oxygen must be at hand</p>\n<p>before administration of any anaesthetic</p>"
    },
    {
        "page_number": 1130,
        "content": "1064\nUganda Clinical Guidelines 2023\nCHAPTER 24 : Surgery, Radiology and Anaesthesia",
        "formatted_content": "<p>1064</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 24 : Surgery, Radiology and Anaesthesia</p>"
    },
    {
        "page_number": 1131,
        "content": "1065\nUganda Clinical Guidelines 2023\nAPPENDIX\nAppendix 1\nStandard Infection Control Precautions\nTransmission of infections in health care facilities can be prevented and \ncontrolled through the application of basic infection control precautions \nwhich can be grouped into:\n \n~\nStandard precautions: basic infection control measures which \nmust be applied to all patients at all times, regardless of diag\u00ad\nnosis or infectious status. They are designed to reduce the risk \nof transmission of micro-organisms from both recognized and \nnon-recognized sources.\n \n~\nAdditional (transmission-based) precautions: measures that are \nused for patients known or suspected to be infected or colonized \nwith highly transmissible or epidemiological important patho\u00ad\ngens for which additional precautions are needed to interrupt \ntransmission in health care facilities.\nFor more details please refer to Uganda National Infection Prevention \nand Control Guidelines December 2013.\nStandard Precautions\nHygiene\nPersonal hygiene\nPersonal Hygiene involves the general cleanliness and care of the whole \nbody: short and clean nails, short or pinned up hair, appropriate clean \nclothing (uniforms), no jewels on the hands, closed shoes.\nHand washing\nHand washing is a major component of standard precautions and \none of the most effective methods to prevent transmission of patho\u00ad\ngens associated with health care.",
        "formatted_content": "<p>1065</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>Appendix 1</p>\n<p>Standard Infection Control Precautions</p>\n<p>Transmission of infections in health care facilities can be prevented and</p>\n<p>controlled through the application of basic infection control precautions</p>\n<p>which can be grouped into:</p>\n<p>~</p>\n<p>Standard precautions: basic infection control measures which</p>\n<p>must be applied to all patients at all times, regardless of diag\u00ad</p>\n<p>nosis or infectious status. They are designed to reduce the risk</p>\n<p>of transmission of micro-organisms from both recognized and</p>\n<p>non-recognized sources.</p>\n<p>~</p>\n<p>Additional (transmission-based) precautions: measures that are</p>\n<p>used for patients known or suspected to be infected or colonized</p>\n<p>with highly transmissible or epidemiological important patho\u00ad</p>\n<p>gens for which additional precautions are needed to interrupt</p>\n<p>transmission in health care facilities.</p>\n<p>For more details please refer to Uganda National Infection Prevention</p>\n<p>and Control Guidelines December 2013.</p>\n<p>Standard Precautions</p>\n<p>Hygiene</p>\n<p>Personal hygiene</p>\n<p>Personal Hygiene involves the general cleanliness and care of the whole</p>\n<p>body: short and clean nails, short or pinned up hair, appropriate clean</p>\n<p>clothing (uniforms), no jewels on the hands, closed shoes.</p>\n<p>Hand washing</p>\n<p>Hand washing is a major component of standard precautions and</p>\n<p>one of the most effective methods to prevent transmission of patho\u00ad</p>\n<p>gens associated with health care.</p>"
    },
    {
        "page_number": 1132,
        "content": "1066\nUganda Clinical Guidelines 2023\nAPPENDIX\n\t\n\u0089\nBefore and after any direct patient contact and between patients\n\t\n\u0089\nWhen any skin area is contaminated with body fluids\n\t\n\u0089\nBefore handling an invasive device or doing any procedures (even \nif gloves will be worn!)\n\t\n\u0089\nAfter removing gloves\n\t\n\u0089\nDuring patient care, when moving from contaminated to a clean \nbody site of the patient\n\t\n\u0089\nAfter contact with inanimate objects in the immediate\n\t\n\u0089\nvicinity of the patient.\n \n~\nHand wash (40-60 sec) with water and soap, rub all surfacs, dry \nwith a single use towel or\n \n~\nHand rub (wtih an alcohol based rub) for 20-30 sec, apply enough \nproduct to cover all areas of the hands and rub hands until dry\nRespiratory hygiene and cough etiquette\n \n~\nPatients with respiratory symptoms should cover their mouth \nand nose with tissue or mask while coughing/ sneezing, dispose \nof used tissues and masks and perform hand hygiene after con\u00ad\ntact with respiratory secretions\n \n~\nPatients with respiratory symptoms should be placed 1 metre \naway from others in waiting areas and hand hygiene, tissues and \nmasks made available in common areas\nInstrument hygiene (decontamination)\nDecontamination is the combination of processes, including cleaning,",
        "formatted_content": "<p>1066</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>\u0089</p>\n<p>Before and after any direct patient contact and between patients</p>\n<p>\u0089</p>\n<p>When any skin area is contaminated with body fluids</p>\n<p>\u0089</p>\n<p>Before handling an invasive device or doing any procedures (even</p>\n<p>if gloves will be worn!)</p>\n<p>\u0089</p>\n<p>After removing gloves</p>\n<p>\u0089</p>\n<p>During patient care, when moving from contaminated to a clean</p>\n<p>body site of the patient</p>\n<p>\u0089</p>\n<p>After contact with inanimate objects in the immediate</p>\n<p>\u0089</p>\n<p>vicinity of the patient.</p>\n<p>~</p>\n<p>Hand wash (40-60 sec) with water and soap, rub all surfacs, dry</p>\n<p>with a single use towel or</p>\n<p>~</p>\n<p>Hand rub (wtih an alcohol based rub) for 20-30 sec, apply enough</p>\n<p>product to cover all areas of the hands and rub hands until dry</p>\n<p>Respiratory hygiene and cough etiquette</p>\n<p>~</p>\n<p>Patients with respiratory symptoms should cover their mouth</p>\n<p>and nose with tissue or mask while coughing/ sneezing, dispose</p>\n<p>of used tissues and masks and perform hand hygiene after con\u00ad</p>\n<p>tact with respiratory secretions</p>\n<p>~</p>\n<p>Patients with respiratory symptoms should be placed 1 metre</p>\n<p>away from others in waiting areas and hand hygiene, tissues and</p>\n<p>masks made available in common areas</p>\n<p>Instrument hygiene (decontamination)</p>\n<p>Decontamination is the combination of processes, including cleaning,</p>"
    },
    {
        "page_number": 1133,
        "content": "1067\nUganda Clinical Guidelines 2023\nAPPENDIX\ndisinfection and/or sterilisation used to render a re- useable medical \ndevice safe for further episodes of use. The level of decontamination \ndepends on the situation involved and the type and use of equipment.\n \n~\nCleaning is the single most important step in making a med\u00ad\nicaldevicereadyforre-use:byremovingorganicmaterial and reduc\u00ad\ning the number of micro-organisms present, it is an essential \nprerequisite of equipment decontamination to ensure effective \ndisinfection or sterilization can be subsequently carried out. It \nutilizes detergents.\n \n~\nDisinfection \u2018is a process used to reduce the number of viable mi\u00ad\ncro-organisms, which may not necessarily inactivate some virus\u00ad\nes and bacterial spores. Disinfection will not achieve the same \nreduction in microbial contamination levels as sterilization. It can \nbe carried out by heat (boiling) or by chemical disinfectants.\n \n~\nSterilization is a process used to render the object free from vi\u00ad\nable micro-organisms, including spores and viruses. Moist Heat \nvia clean steam (autoclaving) is the method of choice. Chemical \ndisinfection may only be used when autoclaving is not possible.\nFacility hygiene\nA clean environment forms the basis of sound infection prevention and \ncontrol practices. This is because there is an important link between \ncleaning of health care facilities and persistence of nosocomial pathogens.\n \n~\nThe purpose of cleaning the environment is toremove visible \ndirt, reduce the level of microorganisms and to minimize the dis\u00ad\nsemination of infectious agents in the facility, thereby providing \nan aesthetically pleasing, sanitary and relatively contamination \n\u2013free environment for patients, staff and visitors\nLinen and laundry\n \n~\nEnsure proper handling of linen/laundry\n\t\n\u0089\nCollect clothing/sheets stained with blood/body-fluids while wearing \ngloves or using a plastic bag and keep separate from other laundry \n\u2013 never touch them directly",
        "formatted_content": "<p>1067</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>disinfection and/or sterilisation used to render a re- useable medical</p>\n<p>device safe for further episodes of use. The level of decontamination</p>\n<p>depends on the situation involved and the type and use of equipment.</p>\n<p>~</p>\n<p>Cleaning is the single most important step in making a med\u00ad</p>\n<p>icaldevicereadyforre-use:byremovingorganicmaterial and reduc\u00ad</p>\n<p>ing the number of micro-organisms present, it is an essential</p>\n<p>prerequisite of equipment decontamination to ensure effective</p>\n<p>disinfection or sterilization can be subsequently carried out. It</p>\n<p>utilizes detergents.</p>\n<p>~</p>\n<p>Disinfection \u2018is a process used to reduce the number of viable mi\u00ad</p>\n<p>cro-organisms, which may not necessarily inactivate some virus\u00ad</p>\n<p>es and bacterial spores. Disinfection will not achieve the same</p>\n<p>reduction in microbial contamination levels as sterilization. It can</p>\n<p>be carried out by heat (boiling) or by chemical disinfectants.</p>\n<p>~</p>\n<p>Sterilization is a process used to render the object free from vi\u00ad</p>\n<p>able micro-organisms, including spores and viruses. Moist Heat</p>\n<p>via clean steam (autoclaving) is the method of choice. Chemical</p>\n<p>disinfection may only be used when autoclaving is not possible.</p>\n<p>Facility hygiene</p>\n<p>A clean environment forms the basis of sound infection prevention and</p>\n<p>control practices. This is because there is an important link between</p>\n<p>cleaning of health care facilities and persistence of nosocomial pathogens.</p>\n<p>~</p>\n<p>The purpose of cleaning the environment is toremove visible</p>\n<p>dirt, reduce the level of microorganisms and to minimize the dis\u00ad</p>\n<p>semination of infectious agents in the facility, thereby providing</p>\n<p>an aesthetically pleasing, sanitary and relatively contamination</p>\n<p>\u2013free environment for patients, staff and visitors</p>\n<p>Linen and laundry</p>\n<p>~</p>\n<p>Ensure proper handling of linen/laundry</p>\n<p>\u0089</p>\n<p>Collect clothing/sheets stained with blood/body-fluids while wearing</p>\n<p>gloves or using a plastic bag and keep separate from other laundry</p>\n<p>\u2013 never touch them directly</p>"
    },
    {
        "page_number": 1134,
        "content": "1068\nUganda Clinical Guidelines 2023\nAPPENDIX\n\t\n\u0089\nDisinfect with hypochlorite if contaminated with body fluids\n\t\n\u0089\nWash with soap and boil for 20 minutes\nPersonal Protective equipment (PPE)\nPersonal Protective Equipment is specialised clothing or equipment \nworn to protect someone against a hazard or infection. PPE is indicated \nwhen health worker-patient interaction indicates that exposure to blood \nor body fluids is anticipated. They provide a physical barrier between \nmicro- organism and the person.\nGloves\n \n~\nWear clean protective gloves when handling body fluids/secre\u00ad\ntions, mucous membranes, nonintact skin contaminated waste,\u00ad\nsoiled bedding or linen instruments, and for when cleaning body \nfluid spills\n \n~\nChange between tasks and procedures on the same patients af\u00ad\nter contact with potentially infectious material\n \n~\nRemove after use, before touching any other surface, and wash \nhands immediately\n \n~\nWear sterile or high-level disinfected gloves when performing \nsterile procedures\nOther PPE\n \n~\nWear a surgical or procedure mask and eye protection (googles \nor glasses) or a face shield when performing activities which are \nlikely to generate splashes or sprays of blood, body fluids, secre\u00ad\ntions or excretions\n \n~\nWear a gown to protect skin and prevent soiling of clothing in \nactivities as above\n \n~\nUse a waterproof bandage to cover wounds\n \n~\nWear protective boots and gloves and where possible, wear a \nwater-proof apron when working in a heavily contaminated area, \ne.g., toilets",
        "formatted_content": "<p>1068</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>\u0089</p>\n<p>Disinfect with hypochlorite if contaminated with body fluids</p>\n<p>\u0089</p>\n<p>Wash with soap and boil for 20 minutes</p>\n<p>Personal Protective equipment (PPE)</p>\n<p>Personal Protective Equipment is specialised clothing or equipment</p>\n<p>worn to protect someone against a hazard or infection. PPE is indicated</p>\n<p>when health worker-patient interaction indicates that exposure to blood</p>\n<p>or body fluids is anticipated. They provide a physical barrier between</p>\n<p>micro- organism and the person.</p>\n<p>Gloves</p>\n<p>~</p>\n<p>Wear clean protective gloves when handling body fluids/secre\u00ad</p>\n<p>tions, mucous membranes, nonintact skin contaminated waste,\u00ad</p>\n<p>soiled bedding or linen instruments, and for when cleaning body</p>\n<p>fluid spills</p>\n<p>~</p>\n<p>Change between tasks and procedures on the same patients af\u00ad</p>\n<p>ter contact with potentially infectious material</p>\n<p>~</p>\n<p>Remove after use, before touching any other surface, and wash</p>\n<p>hands immediately</p>\n<p>~</p>\n<p>Wear sterile or high-level disinfected gloves when performing</p>\n<p>sterile procedures</p>\n<p>Other PPE</p>\n<p>~</p>\n<p>Wear a surgical or procedure mask and eye protection (googles</p>\n<p>or glasses) or a face shield when performing activities which are</p>\n<p>likely to generate splashes or sprays of blood, body fluids, secre\u00ad</p>\n<p>tions or excretions</p>\n<p>~</p>\n<p>Wear a gown to protect skin and prevent soiling of clothing in</p>\n<p>activities as above</p>\n<p>~</p>\n<p>Use a waterproof bandage to cover wounds</p>\n<p>~</p>\n<p>Wear protective boots and gloves and where possible, wear a</p>\n<p>water-proof apron when working in a heavily contaminated area,</p>\n<p>e.g., toilets</p>"
    },
    {
        "page_number": 1135,
        "content": "1069\nUganda Clinical Guidelines 2023\nAPPENDIX\n \n~\nAvoid mouth-to-mouth resuscitation and pipetting by mouth \nwhere possible\n \n~\nIn surgical procedures, use a needle holder and appropriate sized \nneedle, wear double gloves and eye shield\nSafe handling of sharps\n \n~\nEnsure safe sharps handling and disposal\n \n~\nAvoid accidental pricks and cuts with contaminated sharp in\u00ad\nstruments (e.g., needles) by careful handling and proper disposal\n \n~\nUse \u201dhands-free\u201d technique for passing sharp instruments\n \n~\nKeep a puncture-resistant container nearby\n \n~\nUse safe injection practices:\n \n- Use a sterile needle and syringe for every injection\n \n- Do not recap, bend, or break needles after use\n \n~\nDrop all used disposable needles, plastic syringes, and blades \ndirectly into the sharps container without recapping or passing \nto another person\n \n~\nEmpty or send for incineration when container is full\nSafe waste disposal\n \n~\nSeparate hazardous (potentially dangerous) from non- hazardous \n(routine) waste\n \n- Hazardous waste includes: infectious waste (e.g. soiled \nbandages), anatomical waste (placenta), sharps, chemical and \npharmaceutical waste\n \n~\nUse adequate personal protective equipment when handling \nhazardous waste (boots, gown, water proof apron, gloves, face \nprotection)\n \n~\nPractice safe waste disposal as per guidelines (incineration, bury\u00ad\ning)\nAdditional Precautions\nThese are necessary for patients who are known or suspected to be",
        "formatted_content": "<p>1069</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>~</p>\n<p>Avoid mouth-to-mouth resuscitation and pipetting by mouth</p>\n<p>where possible</p>\n<p>~</p>\n<p>In surgical procedures, use a needle holder and appropriate sized</p>\n<p>needle, wear double gloves and eye shield</p>\n<p>Safe handling of sharps</p>\n<p>~</p>\n<p>Ensure safe sharps handling and disposal</p>\n<p>~</p>\n<p>Avoid accidental pricks and cuts with contaminated sharp in\u00ad</p>\n<p>struments (e.g., needles) by careful handling and proper disposal</p>\n<p>~</p>\n<p>Use \u201dhands-free\u201d technique for passing sharp instruments</p>\n<p>~</p>\n<p>Keep a puncture-resistant container nearby</p>\n<p>~</p>\n<p>Use safe injection practices:</p>\n<p>- Use a sterile needle and syringe for every injection</p>\n<p>- Do not recap, bend, or break needles after use</p>\n<p>~</p>\n<p>Drop all used disposable needles, plastic syringes, and blades</p>\n<p>directly into the sharps container without recapping or passing</p>\n<p>to another person</p>\n<p>~</p>\n<p>Empty or send for incineration when container is full</p>\n<p>Safe waste disposal</p>\n<p>~</p>\n<p>Separate hazardous (potentially dangerous) from non- hazardous</p>\n<p>(routine) waste</p>\n<p>- Hazardous waste includes: infectious waste (e.g. soiled</p>\n<p>bandages), anatomical waste (placenta), sharps, chemical and</p>\n<p>pharmaceutical waste</p>\n<p>~</p>\n<p>Use adequate personal protective equipment when handling</p>\n<p>hazardous waste (boots, gown, water proof apron, gloves, face</p>\n<p>protection)</p>\n<p>~</p>\n<p>Practice safe waste disposal as per guidelines (incineration, bury\u00ad</p>\n<p>ing)</p>\n<p>Additional Precautions</p>\n<p>These are necessary for patients who are known or suspected to be</p>"
    },
    {
        "page_number": 1136,
        "content": "1070\nUganda Clinical Guidelines 2023\nAPPENDIX\ninfected or colonized with specific pathogens that are transmitted by \nairborn, droplet or contact route of transmission.\nAirborn precautions\nAirborn precautions are designed to prevent transmission of particles \n< 5 micron in size (e.g. some viruses like measles or chickenpox, M. \ntubeculosis)\n \n~\nPlacement of a patient in a well ventilated room with door closed \nand discharge of air outdoors\n \n~\nUse of appropriate respirators (masks with high filtration power) \nwhen entering the room\n \n~\nLimitation of contacts (visitors)\n \n~\nUse of surgical mask for the patient if leaving the room\n \n~\nAdherence to cough etiquette by the patient\n \n~\nIn particular settings, negative air pressure an be created\nDroplet precautions\nThey are designed to prevent transmission of pathogens transmitted \nby droplets, released by talking, sneezing and coughing: H. Influenza, \nN.meningitis, some viruses, pertussis, influenza etc.\n \n~\nPlace patient in well ventilated room or at least 1 metre distance \nfrom other patients\n \n~\nWear a mask if within 1 metre from the patient\n \n~\nPatient to wear a mask when moving.\n\t\n\u0089\nClosed door and negatve air pressure are not necessary\nContact precautions\nThese precautions are designed to reduce the transmission of organism \nfrom an infected or colonized patient through direct or indirect contact. \nIt applies to microorganisms like HIV, hepatitis B, multi-drug resistant",
        "formatted_content": "<p>1070</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>infected or colonized with specific pathogens that are transmitted by</p>\n<p>airborn, droplet or contact route of transmission.</p>\n<p>Airborn precautions</p>\n<p>Airborn precautions are designed to prevent transmission of particles</p>\n<p>< 5 micron in size (e.g. some viruses like measles or chickenpox, M.</p>\n<p>tubeculosis)</p>\n<p>~</p>\n<p>Placement of a patient in a well ventilated room with door closed</p>\n<p>and discharge of air outdoors</p>\n<p>~</p>\n<p>Use of appropriate respirators (masks with high filtration power)</p>\n<p>when entering the room</p>\n<p>~</p>\n<p>Limitation of contacts (visitors)</p>\n<p>~</p>\n<p>Use of surgical mask for the patient if leaving the room</p>\n<p>~</p>\n<p>Adherence to cough etiquette by the patient</p>\n<p>~</p>\n<p>In particular settings, negative air pressure an be created</p>\n<p>Droplet precautions</p>\n<p>They are designed to prevent transmission of pathogens transmitted</p>\n<p>by droplets, released by talking, sneezing and coughing: H. Influenza,</p>\n<p>N.meningitis, some viruses, pertussis, influenza etc.</p>\n<p>~</p>\n<p>Place patient in well ventilated room or at least 1 metre distance</p>\n<p>from other patients</p>\n<p>~</p>\n<p>Wear a mask if within 1 metre from the patient</p>\n<p>~</p>\n<p>Patient to wear a mask when moving.</p>\n<p>\u0089</p>\n<p>Closed door and negatve air pressure are not necessary</p>\n<p>Contact precautions</p>\n<p>These precautions are designed to reduce the transmission of organism</p>\n<p>from an infected or colonized patient through direct or indirect contact.</p>\n<p>It applies to microorganisms like HIV, hepatitis B, multi-drug resistant</p>"
    },
    {
        "page_number": 1137,
        "content": "1071\nUganda Clinical Guidelines 2023\nAPPENDIX\nbacteria like MRSA, herpes simplex, varicella and haemorrhagic fevers \nviruses, skin staphylococcal infections, scabies, lice, other wound infections.\n \n~\nAppropriate barrier method must be used\n \n~\nIsolate patient, use dedicated equipment if possible\n \n~\nWear gloves before entering the room, change gloves after con\u00ad\ntact with potentially infected material\n \n~\nRemove gloves as soon as leaving the room and wash hands with \nan antimicrobial\n \n~\nWear a gown if necessary\n \n~\nMinimize patient\u2019s movements outside the room\nIn case of blood borne pathogens (HIV, hepatitis B)\n \n~\nUse particular precautions in taking blood samples\n \n~\nDecontaminate any body fluid/blood spillage with 0.5/1% hy\u00ad\npochlorite solutions\nPatients suspected of having hemorrhagic fevers require the strictest \ninfection control procedures (see WHO, 2016. Clinical management of \npatients with viral hemorrhagic fever. http://www.who.int/csr/resources/\npublications/clinical- management-patients/en/)\nPost-Exposure Prophylaxis\nAccidental exposure to blood during medical procedures (needle or \nother sharp injury, splashes of blood on mucosae) carries the risk of \ntransmission of HIV and/or hepatitis B.\nImmunization against hepatitis B is recommended in health workers as \nan effective protection measure.\nSteps for post exposure prophylaxis are described in section 3.1.11.1",
        "formatted_content": "<p>1071</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>bacteria like MRSA, herpes simplex, varicella and haemorrhagic fevers</p>\n<p>viruses, skin staphylococcal infections, scabies, lice, other wound infections.</p>\n<p>~</p>\n<p>Appropriate barrier method must be used</p>\n<p>~</p>\n<p>Isolate patient, use dedicated equipment if possible</p>\n<p>~</p>\n<p>Wear gloves before entering the room, change gloves after con\u00ad</p>\n<p>tact with potentially infected material</p>\n<p>~</p>\n<p>Remove gloves as soon as leaving the room and wash hands with</p>\n<p>an antimicrobial</p>\n<p>~</p>\n<p>Wear a gown if necessary</p>\n<p>~</p>\n<p>Minimize patient\u2019s movements outside the room</p>\n<p>In case of blood borne pathogens (HIV, hepatitis B)</p>\n<p>~</p>\n<p>Use particular precautions in taking blood samples</p>\n<p>~</p>\n<p>Decontaminate any body fluid/blood spillage with 0.5/1% hy\u00ad</p>\n<p>pochlorite solutions</p>\n<p>Patients suspected of having hemorrhagic fevers require the strictest</p>\n<p>infection control procedures (see WHO, 2016. Clinical management of</p>\n<p>patients with viral hemorrhagic fever. http://www.who.int/csr/resources/</p>\n<p>publications/clinical- management-patients/en/)</p>\n<p>Post-Exposure Prophylaxis</p>\n<p>Accidental exposure to blood during medical procedures (needle or</p>\n<p>other sharp injury, splashes of blood on mucosae) carries the risk of</p>\n<p>transmission of HIV and/or hepatitis B.</p>\n<p>Immunization against hepatitis B is recommended in health workers as</p>\n<p>an effective protection measure.</p>\n<p>Steps for post exposure prophylaxis are described in section 3.1.11.1</p>"
    },
    {
        "page_number": 1138,
        "content": "1072\nUganda Clinical Guidelines 2023\nAPPENDIX\nAppendix 2\nPharmacovigilance and Adverse Drug Reaction Re\u00ad\nporting\nPharmacovigilance and Adverse Drug Reaction Reporting\nPharmacovigilance is defined as the science and activities relating to the \ndetection, assessment, understanding and prevention of adverse effects \nor any other drug-related problem.\nThe aims of pharmacovigilance are to enhance patient care and patient \nsafety in relation to the use of medicines; and to support public health \nprogrammes by providing reliable, balanced information for the effective \nassessment of the risk- benefit profile of medicines.\nAny medicine may cause unwanted or unexpected adverse reactions, \nsome of which may be life threatening, for example anaphylactic shock \nor liver failure.\nWhy Should You Report?\nRapid detection and recording of adverse drug reactions (ADR) is of \nvital importance so that unrecognised hazards are identified promptly \nand appropriate regulatory action is taken to ensure medicines are used \nsafely and future events are prevented.\nWhat Should Be Reported\nSuspected adverse events to any  medicine,  vaccines  and herbal products \nshould be reported (including self- medication medicines).\nReport all adverse drug reactions such as:\n \n~\nADRs to to any medicine (whether new or old)\n \n~\nSerious reactions and interactions\n \n~\nADRs which are not clearly stated in the package insert\n \n~\nUnusual or interesting adverse drug reactions",
        "formatted_content": "<p>1072</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>Appendix 2</p>\n<p>Pharmacovigilance and Adverse Drug Reaction Re\u00ad</p>\n<p>porting</p>\n<p>Pharmacovigilance and Adverse Drug Reaction Reporting</p>\n<p>Pharmacovigilance is defined as the science and activities relating to the</p>\n<p>detection, assessment, understanding and prevention of adverse effects</p>\n<p>or any other drug-related problem.</p>\n<p>The aims of pharmacovigilance are to enhance patient care and patient</p>\n<p>safety in relation to the use of medicines; and to support public health</p>\n<p>programmes by providing reliable, balanced information for the effective</p>\n<p>assessment of the risk- benefit profile of medicines.</p>\n<p>Any medicine may cause unwanted or unexpected adverse reactions,</p>\n<p>some of which may be life threatening, for example anaphylactic shock</p>\n<p>or liver failure.</p>\n<p>Why Should You Report?</p>\n<p>Rapid detection and recording of adverse drug reactions (ADR) is of</p>\n<p>vital importance so that unrecognised hazards are identified promptly</p>\n<p>and appropriate regulatory action is taken to ensure medicines are used</p>\n<p>safely and future events are prevented.</p>\n<p>What Should Be Reported</p>\n<p>Suspected adverse events to any  medicine,  vaccines  and herbal products</p>\n<p>should be reported (including self- medication medicines).</p>\n<p>Report all adverse drug reactions such as:</p>\n<p>~</p>\n<p>ADRs to to any medicine (whether new or old)</p>\n<p>~</p>\n<p>Serious reactions and interactions</p>\n<p>~</p>\n<p>ADRs which are not clearly stated in the package insert</p>\n<p>~</p>\n<p>Unusual or interesting adverse drug reactions</p>"
    },
    {
        "page_number": 1139,
        "content": "1073\nUganda Clinical Guidelines 2023\nAPPENDIX\n \n~\nAll adverse reactions or poisonings to traditional or herbal rem\u00ad\nedies\nReport Product Quality Problems such as:\n \n~\nSuspected contamination\n \n~\nQuestionable stability\n \n~\nDefective components\n \n~\nPoor packaging or labelling\n \n~\nTherapeutic failures\n \n~\nNon-adherence (may be due to product characteristic)\nReport medication errors such as:\n \n~\nPrescribing errors\n \n~\nDispensing errors\n \n~\nMedicine preparation error\n \n~\nAdministration errors\n \n~\nMonitoring error\nWho should report?\n \n~\nAll health workers\n \n~\nPatients\n \n~\nAny member of the public\n \n~\nMedical representatives\n \n~\nPharmaceutical Companies, Distributors, Wholesalers and Re\u00ad\ntailers\nWhere and How to Report\nHealth workers are urged  to  immediately  report  suspected ADRs \ndirectly to the National Drug Authority Pharmacovigilance Centre using \nthe ADR forms (see example at the end of this section). The forms can",
        "formatted_content": "<p>1073</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>~</p>\n<p>All adverse reactions or poisonings to traditional or herbal rem\u00ad</p>\n<p>edies</p>\n<p>Report Product Quality Problems such as:</p>\n<p>~</p>\n<p>Suspected contamination</p>\n<p>~</p>\n<p>Questionable stability</p>\n<p>~</p>\n<p>Defective components</p>\n<p>~</p>\n<p>Poor packaging or labelling</p>\n<p>~</p>\n<p>Therapeutic failures</p>\n<p>~</p>\n<p>Non-adherence (may be due to product characteristic)</p>\n<p>Report medication errors such as:</p>\n<p>~</p>\n<p>Prescribing errors</p>\n<p>~</p>\n<p>Dispensing errors</p>\n<p>~</p>\n<p>Medicine preparation error</p>\n<p>~</p>\n<p>Administration errors</p>\n<p>~</p>\n<p>Monitoring error</p>\n<p>Who should report?</p>\n<p>~</p>\n<p>All health workers</p>\n<p>~</p>\n<p>Patients</p>\n<p>~</p>\n<p>Any member of the public</p>\n<p>~</p>\n<p>Medical representatives</p>\n<p>~</p>\n<p>Pharmaceutical Companies, Distributors, Wholesalers and Re\u00ad</p>\n<p>tailers</p>\n<p>Where and How to Report</p>\n<p>Health workers are urged  to  immediately  report  suspected ADRs</p>\n<p>directly to the National Drug Authority Pharmacovigilance Centre using</p>\n<p>the ADR forms (see example at the end of this section). The forms can</p>"
    },
    {
        "page_number": 1140,
        "content": "1074\nUganda Clinical Guidelines 2023\nAPPENDIX\nalso be obtained from the regional pharmacovigilance centres. Encourage \nyour patients to report suspected ADRs to you.\nADRs can also be reported directly online using the following links:\n \n~\nwww.nda.or.ug\n \n~\nhttps://primaryreporting.who-umc.org/Reporting/ \nReport\u00ad\ner?OrganizationID=UG\n \n~\nAll regional referral hospitals have pharmacovigilance coordina\u00ad\ntors\n \n~\nNDA regional offices\nThe following NDA offices can also be contacted for further information:\nNDA Head Office\nPlot 46/48 Lumumba Avenue Kampala\nTel. 0414255665/0414347391/0414344052\nEmail: ndaug@nda.or.ug\nNational Drug Authority\nSouth-Western Regional Office\nHouse No. 29, Mbaguta Estates Kamukuzi Tel. 0485-421088\nMBARARA \u2013 UGANDA\nEastern Regional Office\nSouth Bukedi Cooperative Building Plot No. 6 Busia Road\nTel/Fax 045-45185 TORORO \u2013 UGANDA\nNorthern Region Office\nErute Road\nTel./Fax 0473-420652 LIRA \u2013 UGANDA\nSouth-Eastern Regional Office Stanley Road, Jinja Municipality Tel. \n0465-440688\nJINJA \u2013 UGANDA\nCentral Regional Office Premier Complex Building Tel. 0312-261548 \nNAKAWA - KAMPALA\nWestern Regional Office\nMain Road\nTel. 0465-440688 HOIMA - UGANDA",
        "formatted_content": "<p>1074</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>also be obtained from the regional pharmacovigilance centres. Encourage</p>\n<p>your patients to report suspected ADRs to you.</p>\n<p>ADRs can also be reported directly online using the following links:</p>\n<p>~</p>\n<p>www.nda.or.ug</p>\n<p>~</p>\n<p>https://primaryreporting.who-umc.org/Reporting/</p>\n<p>Report\u00ad</p>\n<p>er?OrganizationID=UG</p>\n<p>~</p>\n<p>All regional referral hospitals have pharmacovigilance coordina\u00ad</p>\n<p>tors</p>\n<p>~</p>\n<p>NDA regional offices</p>\n<p>The following NDA offices can also be contacted for further information:</p>\n<p>NDA Head Office</p>\n<p>Plot 46/48 Lumumba Avenue Kampala</p>\n<p>Tel. 0414255665/0414347391/0414344052</p>\n<p>Email: ndaug@nda.or.ug</p>\n<p>National Drug Authority</p>\n<p>South-Western Regional Office</p>\n<p>House No. 29, Mbaguta Estates Kamukuzi Tel. 0485-421088</p>\n<h3>MBARARA \u2013 UGANDA</h3>\n<p>Eastern Regional Office</p>\n<p>South Bukedi Cooperative Building Plot No. 6 Busia Road</p>\n<p>Tel/Fax 045-45185 TORORO \u2013 UGANDA</p>\n<p>Northern Region Office</p>\n<p>Erute Road</p>\n<p>Tel./Fax 0473-420652 LIRA \u2013 UGANDA</p>\n<p>South-Eastern Regional Office Stanley Road, Jinja Municipality Tel.</p>\n<p>0465-440688</p>\n<h3>JINJA \u2013 UGANDA</h3>\n<p>Central Regional Office Premier Complex Building Tel. 0312-261548</p>\n<h3>NAKAWA - KAMPALA</h3>\n<p>Western Regional Office</p>\n<p>Main Road</p>\n<p>Tel. 0465-440688 HOIMA - UGANDA</p>"
    },
    {
        "page_number": 1141,
        "content": "1075\nUganda Clinical Guidelines 2023\nAPPENDIX\nWhat Will Happen When I Report?\nWhen NDA receives your report, they will assess the likelihood that the \nsuspected adverse reaction is actually due to the medicine, using the \nWHO causality assessment criteria for deciding on the contribution of \nthe medicine towards the adverse event.\nDepending on the outcome of the causality assessment, NDA will give \nfeedback in any of the following ways: medicine alerts, media statements, \npatient information leaflets, newsletters and personal feedback to reporters.\nPrevention of Adverse Drug Reactions (ADRs)\n \n~\nNever use any medicine without a clear indication\n \n~\nIf a patient is pregnant, do not use a medicine unless it is abso\u00ad\nlutely necessary\n \n~\nAsk the patient if they have any allergies, hypersensitivity or \nprevious reactions to the medicine or to similar medicines\n \n~\nReduce doses when necessary, for example, in the young, the \nelderly, and if liver or renal disease is present\n \n~\nAlways prescribe as few medicines as possible\n \n~\nCarefully explain dose regimes to patients, especially those on \nmultiple medicines, the elderly, and anyone likely to misunder\u00ad\nstand. Check for understanding before patient goes away.\n \n~\nAge and liver or kidney disease may affect the way medicines be\u00ad\nhave in the body so that smaller than usual amounts are needed\n \n~\nAsk if patient is taking other medicines including self medication \nmedicines, health supplements, herbal products as interactions \ncan occur\n \n~\nIf possible, always use medicines with which you are familiar\n \n~\nLook out for ADRs when using new or unfamiliar drugs\n \n~\nWarn patients about likely adverse effects and advise them on \nwhat to do if they occur",
        "formatted_content": "<p>1075</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>What Will Happen When I Report?</p>\n<p>When NDA receives your report, they will assess the likelihood that the</p>\n<p>suspected adverse reaction is actually due to the medicine, using the</p>\n<p>WHO causality assessment criteria for deciding on the contribution of</p>\n<p>the medicine towards the adverse event.</p>\n<p>Depending on the outcome of the causality assessment, NDA will give</p>\n<p>feedback in any of the following ways: medicine alerts, media statements,</p>\n<p>patient information leaflets, newsletters and personal feedback to reporters.</p>\n<p>Prevention of Adverse Drug Reactions (ADRs)</p>\n<p>~</p>\n<p>Never use any medicine without a clear indication</p>\n<p>~</p>\n<p>If a patient is pregnant, do not use a medicine unless it is abso\u00ad</p>\n<p>lutely necessary</p>\n<p>~</p>\n<p>Ask the patient if they have any allergies, hypersensitivity or</p>\n<p>previous reactions to the medicine or to similar medicines</p>\n<p>~</p>\n<p>Reduce doses when necessary, for example, in the young, the</p>\n<p>elderly, and if liver or renal disease is present</p>\n<p>~</p>\n<p>Always prescribe as few medicines as possible</p>\n<p>~</p>\n<p>Carefully explain dose regimes to patients, especially those on</p>\n<p>multiple medicines, the elderly, and anyone likely to misunder\u00ad</p>\n<p>stand. Check for understanding before patient goes away.</p>\n<p>~</p>\n<p>Age and liver or kidney disease may affect the way medicines be\u00ad</p>\n<p>have in the body so that smaller than usual amounts are needed</p>\n<p>~</p>\n<p>Ask if patient is taking other medicines including self medication</p>\n<p>medicines, health supplements, herbal products as interactions</p>\n<p>can occur</p>\n<p>~</p>\n<p>If possible, always use medicines with which you are familiar</p>\n<p>~</p>\n<p>Look out for ADRs when using new or unfamiliar drugs</p>\n<p>~</p>\n<p>Warn patients about likely adverse effects and advise them on</p>\n<p>what to do if they occur</p>"
    },
    {
        "page_number": 1142,
        "content": "1076\nUganda Clinical Guidelines 2023\nAPPENDIX\n \n~\nGive patients on certain prolonged treatments, for example anti\u00ad\ncoagulants, corticosteroids, and insulin, a small card which they \ncan carry with them giving information about the treatment\nNote: Please attach additional pages to the ADR reporting form if neces\u00ad\nsary. Even if you do not know some details in the form, do not be put off \nreporting the suspected adverse event",
        "formatted_content": "<p>1076</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>~</p>\n<p>Give patients on certain prolonged treatments, for example anti\u00ad</p>\n<p>coagulants, corticosteroids, and insulin, a small card which they</p>\n<p>can carry with them giving information about the treatment</p>\n<p>Note: Please attach additional pages to the ADR reporting form if neces\u00ad</p>\n<p>sary. Even if you do not know some details in the form, do not be put off</p>\n<p>reporting the suspected adverse event</p>"
    },
    {
        "page_number": 1143,
        "content": "1077\nUganda Clinical Guidelines 2023\nAPPENDIX\nAppendix 3\nNational Laboratory Test Menu\nThe test menu was developed by Ministry of Health/Uganda National \nHealth Laboratory Services (UNHLS). It is a list of tests that are available \nat the specified level of health care. The laboratory system of Uganda is \ndesigned to support the minimum health care package for each level of \ncare, with complexity of tests increasing with the level of care.\nThe laboratory test menu has been included in UCG 2023, in order to \nguide clinicians about the laboratory services available at each level of \nhealth care, and where to refer a patient in need of a particular test.\nThe National Laboratory Test Menu\nHEALTH CENTER II\nSerology\nPregnancy Test\nHepatitis B Test\nSyphilis Test\nHIV testing\nBiochemistry\nMalaria Test\nRapid Blood Sugar\nADDITIONAL TESTS FOR HEALTH CENTER III\nHaematology\nUrobilinogen\nHaemoglobin estimation\nGlucose\nBlood film comments\nKetones (Acetoacetic acid)\nBleeding Time\nSpecific Gravity\nClotting Time\npH\nDifferential count\nBlood\nSickle cell test\nProtein (Albumin)\nSickle cell screening test\nNitrite\nPlasmin Inhibitor\nLeukocytes in urine\nErythrocyte sedimentation rate\nMicrobiology",
        "formatted_content": "<p>1077</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>Appendix 3</p>\n<p>National Laboratory Test Menu</p>\n<p>The test menu was developed by Ministry of Health/Uganda National</p>\n<p>Health Laboratory Services (UNHLS). It is a list of tests that are available</p>\n<p>at the specified level of health care. The laboratory system of Uganda is</p>\n<p>designed to support the minimum health care package for each level of</p>\n<p>care, with complexity of tests increasing with the level of care.</p>\n<p>The laboratory test menu has been included in UCG 2023, in order to</p>\n<p>guide clinicians about the laboratory services available at each level of</p>\n<p>health care, and where to refer a patient in need of a particular test.</p>\n<p>The National Laboratory Test Menu</p>\n<h3>HEALTH CENTER II</h3>\n<p>Serology</p>\n<p>Pregnancy Test</p>\n<p>Hepatitis B Test</p>\n<p>Syphilis Test</p>\n<p>HIV testing</p>\n<p>Biochemistry</p>\n<p>Malaria Test</p>\n<p>Rapid Blood Sugar</p>\n<h3>ADDITIONAL TESTS FOR HEALTH CENTER III</h3>\n<p>Haematology</p>\n<p>Urobilinogen</p>\n<p>Haemoglobin estimation</p>\n<p>Glucose</p>\n<p>Blood film comments</p>\n<p>Ketones (Acetoacetic acid)</p>\n<p>Bleeding Time</p>\n<p>Specific Gravity</p>\n<p>Clotting Time</p>\n<p>pH</p>\n<p>Differential count</p>\n<p>Blood</p>\n<p>Sickle cell test</p>\n<p>Protein (Albumin)</p>\n<p>Sickle cell screening test</p>\n<p>Nitrite</p>\n<p>Plasmin Inhibitor</p>\n<p>Leukocytes in urine</p>\n<p>Erythrocyte sedimentation rate</p>\n<p>Microbiology</p>"
    },
    {
        "page_number": 1144,
        "content": "1078\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR HEALTH CENTER III\nBlood Transfusion\nAFB test\nABO grouping\nStool analysis\nRh grouping\nUrinalysis\nSerology\nParasitology\nCryptoccocal Antigen test\nMalaria test\nBrucella agglutinin test\nFilaria test\nRheumatoid factor\nLeishmania test\nTB LAM Rapid Test\nTrypanosoma test\nTyphoid test\nSkin Snip Test\nHelicobacter pylori IgG\nImmunology /Molecular\nHepatitis B rapid test\nCD4,CD3,CD8 Counts and Ratios\nHepatitis C rapid test\nCD3/CD8 %\nBiochemistry\nReferral Tests\nRapid Blood Sugar\nDNA PCR \u2013EID (Emerging Infec\u00ad\ntious Diseases)\nUrine Chemistry\nRNA PCR -VL\nBilirubin\nADDITIONAL TESTS FOR HC IV\nHaematology\nIndirect bilirubin\nFull blood count\nTotal protein\nCoagulation Tests\nRFTs\nThrombin clotting time (TT)\nUrea\nProthrombin time (PT)\nCreatinine\nBlood Transfusion\nElectrolytes\nCompatibility testing\nSodium\nSerology\nPotassium",
        "formatted_content": "<p>1078</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR HEALTH CENTER III</h3>\n<p>Blood Transfusion</p>\n<p>AFB test</p>\n<p>ABO grouping</p>\n<p>Stool analysis</p>\n<p>Rh grouping</p>\n<p>Urinalysis</p>\n<p>Serology</p>\n<p>Parasitology</p>\n<p>Cryptoccocal Antigen test</p>\n<p>Malaria test</p>\n<p>Brucella agglutinin test</p>\n<p>Filaria test</p>\n<p>Rheumatoid factor</p>\n<p>Leishmania test</p>\n<p>TB LAM Rapid Test</p>\n<p>Trypanosoma test</p>\n<p>Typhoid test</p>\n<p>Skin Snip Test</p>\n<p>Helicobacter pylori IgG</p>\n<p>Immunology /Molecular</p>\n<p>Hepatitis B rapid test</p>\n<p>CD4,CD3,CD8 Counts and Ratios</p>\n<p>Hepatitis C rapid test</p>\n<h3>CD3/CD8 %</h3>\n<p>Biochemistry</p>\n<p>Referral Tests</p>\n<p>Rapid Blood Sugar</p>\n<p>DNA PCR \u2013EID (Emerging Infec\u00ad</p>\n<p>tious Diseases)</p>\n<p>Urine Chemistry</p>\n<h3>RNA PCR -VL</h3>\n<p>Bilirubin</p>\n<h3>ADDITIONAL TESTS FOR HC IV</h3>\n<p>Haematology</p>\n<p>Indirect bilirubin</p>\n<p>Full blood count</p>\n<p>Total protein</p>\n<p>Coagulation Tests</p>\n<p>RFTs</p>\n<p>Thrombin clotting time (TT)</p>\n<p>Urea</p>\n<p>Prothrombin time (PT)</p>\n<p>Creatinine</p>\n<p>Blood Transfusion</p>\n<p>Electrolytes</p>\n<p>Compatibility testing</p>\n<p>Sodium</p>\n<p>Serology</p>\n<p>Potassium</p>"
    },
    {
        "page_number": 1145,
        "content": "1079\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR HC IV\nInfectious Disease\nChloride\nHBcAg IgG\nMicrobiology\nHBeAg IgG\nSwab analysis\nBiochemistry\nHigh Vaginal Swab (HVS) analysis\nLFTS\nPus Swab\nSGOT (AST)\nWound swab analysis\nSGPT (ALT)\nCSF Analysis\nALP\nImmunology /Molecular\nDirect bilirubin\nGene Xpert\nTotal Bilirubin\nADDITIONAL TESTS FOR GENERAL DISTRICT HOSPITALS\nHaematology\nFree T4\nBlood Film comment\nTotal T4\nCoagulation Tests\nTotal T3\nThrombin time in the presence of \nProtamine Sulphate\nTSH (Thyroid Stimulating Hor\u00ad\nmone)\nActivated partial Thromboplastin \nTime (APTT)\nFertility Hormones\nFibrinogen test (Modified Clauss \nAssay)\nFollicle Stimulating Hormone (FSH)\nPlasmin Inhibitor\nLuteinizing Hormone (LH)\nLupus erythromatosous\nCortisol\nPlatelet function tests\nProgesterone\nThin film test\nTestosterone\nBlood Transfusion\nOestrogen\nBlood Transfusion Services\nTumour Markers\nDirect Coombs test\nAlpha fetoprotein",
        "formatted_content": "<p>1079</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR HC IV</h3>\n<p>Infectious Disease</p>\n<p>Chloride</p>\n<p>HBcAg IgG</p>\n<p>Microbiology</p>\n<p>HBeAg IgG</p>\n<p>Swab analysis</p>\n<p>Biochemistry</p>\n<p>High Vaginal Swab (HVS) analysis</p>\n<h3>LFTS</h3>\n<p>Pus Swab</p>\n<h3>SGOT (AST)</h3>\n<p>Wound swab analysis</p>\n<h3>SGPT (ALT)</h3>\n<p>CSF Analysis</p>\n<h3>ALP</h3>\n<p>Immunology /Molecular</p>\n<p>Direct bilirubin</p>\n<p>Gene Xpert</p>\n<p>Total Bilirubin</p>\n<h3>ADDITIONAL TESTS FOR GENERAL DISTRICT HOSPITALS</h3>\n<p>Haematology</p>\n<p>Free T4</p>\n<p>Blood Film comment</p>\n<p>Total T4</p>\n<p>Coagulation Tests</p>\n<p>Total T3</p>\n<p>Thrombin time in the presence of</p>\n<p>Protamine Sulphate</p>\n<p>TSH (Thyroid Stimulating Hor\u00ad</p>\n<p>mone)</p>\n<p>Activated partial Thromboplastin</p>\n<p>Time (APTT)</p>\n<p>Fertility Hormones</p>\n<p>Fibrinogen test (Modified Clauss</p>\n<p>Assay)</p>\n<p>Follicle Stimulating Hormone (FSH)</p>\n<p>Plasmin Inhibitor</p>\n<p>Luteinizing Hormone (LH)</p>\n<p>Lupus erythromatosous</p>\n<p>Cortisol</p>\n<p>Platelet function tests</p>\n<p>Progesterone</p>\n<p>Thin film test</p>\n<p>Testosterone</p>\n<p>Blood Transfusion</p>\n<p>Oestrogen</p>\n<p>Blood Transfusion Services</p>\n<p>Tumour Markers</p>\n<p>Direct Coombs test</p>\n<p>Alpha fetoprotein</p>"
    },
    {
        "page_number": 1146,
        "content": "1080\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR GENERAL DISTRICT HOSPITALS\nIndirect Coombs test\nPancreatic function tests\nImmediate Spin Cross Match (ISCM) Amylase\nSerology\nUric Acid\nAnti Streptolysin O-Test (ASOT)\nLipase\nToxoplasma IgG and IgM\nMetabolic Profile\nTB Lam\nIron\nInfectious Disease\nLactic acid/Lactate\nToxo IgG/IgM\nCSF Chemistry\nCMV IgG/IgM\nProtein\nBiochemistry\nGlucose\nLFTs\nGlobulins\nAlbumin\nMicrobiology\nGGT\nBacteriology\nRFTs\nSemen analysis\nCreatinine Clearance\nOccult blood Test\nLipid profile\nSwab analysis\nTriglycerides\nThroat analysis\nTotal Cholesterol\nEye Swab analysis\nLow Density Lipoproteins (LDL) LDLc Nasal swab analysis\nHigh Density Lipoproteins (HDL) HDLc Ear swab\nCardiac Profile\nHistology/Cytology\nCreatine Kinase (CK-MB) test\nPAP Smear\nCK- NAC (Total)\nHPV Test\nLactate dehydrogenase (LDH\nBiopsy Tissue\nTroponins (C,T,I)\nMycology\nThyroid Function Tests\nKOH\nFree T3\nLactophenol cotton blue",
        "formatted_content": "<p>1080</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR GENERAL DISTRICT HOSPITALS</h3>\n<p>Indirect Coombs test</p>\n<p>Pancreatic function tests</p>\n<p>Immediate Spin Cross Match (ISCM) Amylase</p>\n<p>Serology</p>\n<p>Uric Acid</p>\n<p>Anti Streptolysin O-Test (ASOT)</p>\n<p>Lipase</p>\n<p>Toxoplasma IgG and IgM</p>\n<p>Metabolic Profile</p>\n<p>TB Lam</p>\n<p>Iron</p>\n<p>Infectious Disease</p>\n<p>Lactic acid/Lactate</p>\n<p>Toxo IgG/IgM</p>\n<p>CSF Chemistry</p>\n<p>CMV IgG/IgM</p>\n<p>Protein</p>\n<p>Biochemistry</p>\n<p>Glucose</p>\n<p>LFTs</p>\n<p>Globulins</p>\n<p>Albumin</p>\n<p>Microbiology</p>\n<h3>GGT</h3>\n<p>Bacteriology</p>\n<p>RFTs</p>\n<p>Semen analysis</p>\n<p>Creatinine Clearance</p>\n<p>Occult blood Test</p>\n<p>Lipid profile</p>\n<p>Swab analysis</p>\n<p>Triglycerides</p>\n<p>Throat analysis</p>\n<p>Total Cholesterol</p>\n<p>Eye Swab analysis</p>\n<p>Low Density Lipoproteins (LDL) LDLc Nasal swab analysis</p>\n<p>High Density Lipoproteins (HDL) HDLc Ear swab</p>\n<p>Cardiac Profile</p>\n<p>Histology/Cytology</p>\n<p>Creatine Kinase (CK-MB) test</p>\n<p>PAP Smear</p>\n<p>CK- NAC (Total)</p>\n<p>HPV Test</p>\n<p>Lactate dehydrogenase (LDH</p>\n<p>Biopsy Tissue</p>\n<p>Troponins (C,T,I)</p>\n<p>Mycology</p>\n<p>Thyroid Function Tests</p>\n<h3>KOH</h3>\n<p>Free T3</p>\n<p>Lactophenol cotton blue</p>"
    },
    {
        "page_number": 1147,
        "content": "1081\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR HC IV\nHaematology\nIron\nReticulocyte test\nFerritin\nReticulocyte count\nTransferrin\nReticulocyte count(count (RET#)\nG6PD\nImmature RBC haemoglobin (RBC \n\u2013 HE)\nTumour Markers\nPlasmin Inhibitor\nProstate antigen (PSA)\nErythrocyte sedimentation rate\nCA 19-9 Ag\nD.DIMER\nCA 15-3 Ag\nCRP test\nCA 72-4 Ag\nPeripheral Film Comment\nFertility Hormones\nLupus erythromatous test\n-Hcg\nBlood Transfusion\nMicrobiology\nBlood Transfusion Services\nBacteriology\nDu test\nSemen analysis\nWeak D Typing\nSwab analysis\nSerology\nBlood culture\nMeasles IgM test\nGastric Aspirate\nRubella IgG and IgM Test\nNasopharyngeal/ oropharyngeal \nswab\nBiochemistry\nCervical/Endo-cervical swab\nExtended Electrolytes\nUrethral/Rectal Swab\nLithium\nCatheter Tips\nCalcium\nBacterial identification tests\nMagnesium\nBacterial susceptibility testing\nCardiac Profile\nLymph Node Aspirate\nhs-CRP\nCorneal scraping",
        "formatted_content": "<p>1081</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR HC IV</h3>\n<p>Haematology</p>\n<p>Iron</p>\n<p>Reticulocyte test</p>\n<p>Ferritin</p>\n<p>Reticulocyte count</p>\n<p>Transferrin</p>\n<p>Reticulocyte count(count (RET#)</p>\n<h3>G6PD</h3>\n<p>Immature RBC haemoglobin (RBC</p>\n<h3>\u2013 HE)</h3>\n<p>Tumour Markers</p>\n<p>Plasmin Inhibitor</p>\n<p>Prostate antigen (PSA)</p>\n<p>Erythrocyte sedimentation rate</p>\n<p>CA 19-9 Ag</p>\n<h3>D.DIMER</h3>\n<p>CA 15-3 Ag</p>\n<p>CRP test</p>\n<p>CA 72-4 Ag</p>\n<p>Peripheral Film Comment</p>\n<p>Fertility Hormones</p>\n<p>Lupus erythromatous test</p>\n<p>-Hcg</p>\n<p>Blood Transfusion</p>\n<p>Microbiology</p>\n<p>Blood Transfusion Services</p>\n<p>Bacteriology</p>\n<p>Du test</p>\n<p>Semen analysis</p>\n<p>Weak D Typing</p>\n<p>Swab analysis</p>\n<p>Serology</p>\n<p>Blood culture</p>\n<p>Measles IgM test</p>\n<p>Gastric Aspirate</p>\n<p>Rubella IgG and IgM Test</p>\n<p>Nasopharyngeal/ oropharyngeal</p>\n<p>swab</p>\n<p>Biochemistry</p>\n<p>Cervical/Endo-cervical swab</p>\n<p>Extended Electrolytes</p>\n<p>Urethral/Rectal Swab</p>\n<p>Lithium</p>\n<p>Catheter Tips</p>\n<p>Calcium</p>\n<p>Bacterial identification tests</p>\n<p>Magnesium</p>\n<p>Bacterial susceptibility testing</p>\n<p>Cardiac Profile</p>\n<p>Lymph Node Aspirate</p>\n<p>hs-CRP</p>\n<p>Corneal scraping</p>"
    },
    {
        "page_number": 1148,
        "content": "1082\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR HC IV\nASO (RHD)\nMycology\nNT Pro BNP\nMycology Culture and sensitivity\nMyoglobin\nFungal Identification Tests\nBone profile\nParasitology\nCalcium\nBoleria test\nPhosphates\nSkin Snip test\nBlood gases ABG\nImmunology/Molecular\nHCO3\nMolecular\nPO2\nGene Xpert\nPCO2\nViral load for HIV Virus\nMetabolic Tests\nViral load for HEPATITIS B Virus\nGlycosylated Haemoglobin\nTB DNA PCR\nLactic acid\nLPA\nVitamin B12\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nHaematology\nExtended Electrolytes\nReticulocyte test\nBicarbonate\nLow Fluorescence Ratio (LFR)\nPhosphate\nMedium Fluorescence Ratio (MFR) Cardiac Profile\nHigh Fluorescence Ratio (HFR)\nhs-CRP\nReticulocyte haemoglobin (RET-HE) ASO (RHD)\nImmature RBC haemoglobin (RBC \n\u2013 HE)\nTroponins (C,T,I)\nBody fluid analysis\nNT Pro BNP\nMono Nuclear cell count(MN)\nMyoglobin",
        "formatted_content": "<p>1082</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR HC IV</h3>\n<h3>ASO (RHD)</h3>\n<p>Mycology</p>\n<p>NT Pro BNP</p>\n<p>Mycology Culture and sensitivity</p>\n<p>Myoglobin</p>\n<p>Fungal Identification Tests</p>\n<p>Bone profile</p>\n<p>Parasitology</p>\n<p>Calcium</p>\n<p>Boleria test</p>\n<p>Phosphates</p>\n<p>Skin Snip test</p>\n<p>Blood gases ABG</p>\n<p>Immunology/Molecular</p>\n<h3>HCO3</h3>\n<p>Molecular</p>\n<h3>PO2</h3>\n<p>Gene Xpert</p>\n<h3>PCO2</h3>\n<p>Viral load for HIV Virus</p>\n<p>Metabolic Tests</p>\n<p>Viral load for HEPATITIS B Virus</p>\n<p>Glycosylated Haemoglobin</p>\n<h3>TB DNA PCR</h3>\n<p>Lactic acid</p>\n<h3>LPA</h3>\n<p>Vitamin B12</p>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>Haematology</p>\n<p>Extended Electrolytes</p>\n<p>Reticulocyte test</p>\n<p>Bicarbonate</p>\n<p>Low Fluorescence Ratio (LFR)</p>\n<p>Phosphate</p>\n<p>Medium Fluorescence Ratio (MFR) Cardiac Profile</p>\n<p>High Fluorescence Ratio (HFR)</p>\n<p>hs-CRP</p>\n<p>Reticulocyte haemoglobin (RET-HE) ASO (RHD)</p>\n<p>Immature RBC haemoglobin (RBC</p>\n<h3>\u2013 HE)</h3>\n<p>Troponins (C,T,I)</p>\n<p>Body fluid analysis</p>\n<p>NT Pro BNP</p>\n<p>Mono Nuclear cell count(MN)</p>\n<p>Myoglobin</p>"
    },
    {
        "page_number": 1149,
        "content": "1083\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nPolymorph nuclear cell count (PMN) Arterial Blood gases (ABG)\nMN%\nCa2+ (Free & Bound)\nPMN%\nPH\nTotal Cell count (TC-BF#)\nHb\nPROGENITOR CELL# (HPC)\nHCT\nSickle cell test\nHCO3\nHB electrophoresis test (Sickle cell) Metabolic Tests\nHB \u2013 F\nFolate\nHB \u2013 S\nThyroid Function Tests\nHB-A2\nTSH\nHBA\nAnti -TSH-IgG\nImmunotyping (light and heavy \nchains)\nPTHH\nPlatelet function tests\nFertility Hormones\nThin film report\n-hCG\nClot retraction test\nOestrone (E1)\nThromboerythrogram\nOestradiol (E2)\nCoagulation Tests\nOestriol (E3)\nFibrinogen Antigen Assay by RIA DHEA\nRepitlase Time\nDHEA-S\nBatroxobin\nProlactin\nFactor Assays(II)\nTumour Markers\nFactor Assays(V)\nCEA (Carcino Embryonic Antigen)\nFactor Assays(VII)\n- h CG\nFactor Assays(VIII)\n-FP (alpha fetoprotein)\nFactor Assays(IX)\nNSE (Neuro Specific Enolase)",
        "formatted_content": "<p>1083</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>Polymorph nuclear cell count (PMN) Arterial Blood gases (ABG)</p>\n<h3>MN%</h3>\n<p>Ca2+ (Free & Bound)</p>\n<h3>PMN%</h3>\n<p>PH</p>\n<p>Total Cell count (TC-BF#)</p>\n<p>Hb</p>\n<h3>PROGENITOR CELL# (HPC)</h3>\n<h3>HCT</h3>\n<p>Sickle cell test</p>\n<h3>HCO3</h3>\n<p>HB electrophoresis test (Sickle cell) Metabolic Tests</p>\n<h3>HB \u2013 F</h3>\n<p>Folate</p>\n<h3>HB \u2013 S</h3>\n<p>Thyroid Function Tests</p>\n<h3>HB-A2</h3>\n<h3>TSH</h3>\n<h3>HBA</h3>\n<p>Anti -TSH-IgG</p>\n<p>Immunotyping (light and heavy</p>\n<p>chains)</p>\n<h3>PTHH</h3>\n<p>Platelet function tests</p>\n<p>Fertility Hormones</p>\n<p>Thin film report</p>\n<p>-hCG</p>\n<p>Clot retraction test</p>\n<p>Oestrone (E1)</p>\n<p>Thromboerythrogram</p>\n<p>Oestradiol (E2)</p>\n<p>Coagulation Tests</p>\n<p>Oestriol (E3)</p>\n<p>Fibrinogen Antigen Assay by RIA DHEA</p>\n<p>Repitlase Time</p>\n<h3>DHEA-S</h3>\n<p>Batroxobin</p>\n<p>Prolactin</p>\n<p>Factor Assays(II)</p>\n<p>Tumour Markers</p>\n<p>Factor Assays(V)</p>\n<p>CEA (Carcino Embryonic Antigen)</p>\n<p>Factor Assays(VII)</p>\n<p>- h CG</p>\n<p>Factor Assays(VIII)</p>\n<p>-FP (alpha fetoprotein)</p>\n<p>Factor Assays(IX)</p>\n<p>NSE (Neuro Specific Enolase)</p>"
    },
    {
        "page_number": 1150,
        "content": "1084\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nFactor Assays(X)\nS-100\nOne- stage Intrinsic Assay of prek\u00ad\nallikren(PKK), and High Molecular \nWeight Kininogen (HMWK)\nCyfra 21-1\nPlasmin Inhibitor\nEnolase\nD.DIMER\nMicrobiology\nCRP test\nSwab analysis\nPeripheral Film Comment\nGastric Aspirate\nLupus erythromatous test\nNasopharyngeal/ oropharyngeal \nswab\nANT THROMBIN(AT)\nCervical /Endo-cervical swab\nAnti-Thrombin Liquid (AT)\nUrethral /Rectal Swab\nANTI Xa\nCatheter Tips\nPlasmin Inhibitor (PI)\nLymph Node Aspirate\nBlood Transfusion\nCorneal scraping\nBlood Transfusion services\nSkin/Nail/Hair Scrapping\nDu test\nSpecial staining identification tests\nAnti-body typing\nMycology\nImmediate Spin Cross Match \n(ISCM)\nToluidine Blue-O for pneumocystis \njiroveci\nWeak D Typing\nMycology Culture and sensitivity\nSerology\nFungal Identification Tests\nInfectious Disease\nFungal susceptibility tests\nRubella IgG/IgM\nLactophenol cotton blue\nMeasles IgG/IgM\nMycology Grocotts\u2019 silver stain\nMumps IgG/IgM\nToluidine Blue-O for pneumocystis \njiroveci",
        "formatted_content": "<p>1084</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>Factor Assays(X)</p>\n<h3>S-100</h3>\n<p>One- stage Intrinsic Assay of prek\u00ad</p>\n<p>allikren(PKK), and High Molecular</p>\n<p>Weight Kininogen (HMWK)</p>\n<p>Cyfra 21-1</p>\n<p>Plasmin Inhibitor</p>\n<p>Enolase</p>\n<h3>D.DIMER</h3>\n<p>Microbiology</p>\n<p>CRP test</p>\n<p>Swab analysis</p>\n<p>Peripheral Film Comment</p>\n<p>Gastric Aspirate</p>\n<p>Lupus erythromatous test</p>\n<p>Nasopharyngeal/ oropharyngeal</p>\n<p>swab</p>\n<h3>ANT THROMBIN(AT)</h3>\n<p>Cervical /Endo-cervical swab</p>\n<p>Anti-Thrombin Liquid (AT)</p>\n<p>Urethral /Rectal Swab</p>\n<p>ANTI Xa</p>\n<p>Catheter Tips</p>\n<p>Plasmin Inhibitor (PI)</p>\n<p>Lymph Node Aspirate</p>\n<p>Blood Transfusion</p>\n<p>Corneal scraping</p>\n<p>Blood Transfusion services</p>\n<p>Skin/Nail/Hair Scrapping</p>\n<p>Du test</p>\n<p>Special staining identification tests</p>\n<p>Anti-body typing</p>\n<p>Mycology</p>\n<p>Immediate Spin Cross Match</p>\n<h3>(ISCM)</h3>\n<p>Toluidine Blue-O for pneumocystis</p>\n<p>jiroveci</p>\n<p>Weak D Typing</p>\n<p>Mycology Culture and sensitivity</p>\n<p>Serology</p>\n<p>Fungal Identification Tests</p>\n<p>Infectious Disease</p>\n<p>Fungal susceptibility tests</p>\n<p>Rubella IgG/IgM</p>\n<p>Lactophenol cotton blue</p>\n<p>Measles IgG/IgM</p>\n<p>Mycology Grocotts\u2019 silver stain</p>\n<p>Mumps IgG/IgM</p>\n<p>Toluidine Blue-O for pneumocystis</p>\n<p>jiroveci</p>"
    },
    {
        "page_number": 1151,
        "content": "1085\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nHSV 1 IgG/IgM\nKOH\nHSV 2 IgG/IgM\nHistology / Cytology\nHZV IgG/IgM\nPAS\nBiochemistry\nBiopsy Tissue\nRFTs\nCytological test\nInulin Clearance\nHistological test\nCystatin C\nADDITIONAL TESTS FOR SPECIALISED LABS (NTRL, UBTS, \nUCI and UHI)\nHaematology (UHI)\nBarbiturates\nInhibitor Screening\nBenzodiazepines\nClotting factor inhibitor screening \nbased on APTT\nCannabinoides\nRistocetin cofactor Activity/von \nwillebrand factor Activity (VWF:R\u00ad\nCo or VWF: Act)\nCocaine\nVon willebrand factor Antigen(VW\u00ad\nF:Ag)\nEthanol\nVon willebrand factor Collagen \nbinding assay (VWF:CB)\nMethadone\nFactor VIII binding Assay( VWD \nNormanday)\nMethaqualone\nVWF Multimer Analysis\nOpiates\nBethesda assay\nPhencyclidine\nF VIII inhibitor test\nPropoxyphene\nF IX inhibitor test\nTricyclic antidepressants",
        "formatted_content": "<p>1085</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>HSV 1 IgG/IgM</p>\n<h3>KOH</h3>\n<p>HSV 2 IgG/IgM</p>\n<p>Histology / Cytology</p>\n<p>HZV IgG/IgM</p>\n<h3>PAS</h3>\n<p>Biochemistry</p>\n<p>Biopsy Tissue</p>\n<p>RFTs</p>\n<p>Cytological test</p>\n<p>Inulin Clearance</p>\n<p>Histological test</p>\n<p>Cystatin C</p>\n<h3>ADDITIONAL TESTS FOR SPECIALISED LABS (NTRL, UBTS,</h3>\n<p>UCI and UHI)</p>\n<p>Haematology (UHI)</p>\n<p>Barbiturates</p>\n<p>Inhibitor Screening</p>\n<p>Benzodiazepines</p>\n<p>Clotting factor inhibitor screening</p>\n<p>based on APTT</p>\n<p>Cannabinoides</p>\n<p>Ristocetin cofactor Activity/von</p>\n<p>willebrand factor Activity (VWF:R\u00ad</p>\n<p>Co or VWF: Act)</p>\n<p>Cocaine</p>\n<p>Von willebrand factor Antigen(VW\u00ad</p>\n<p>F:Ag)</p>\n<p>Ethanol</p>\n<p>Von willebrand factor Collagen</p>\n<p>binding assay (VWF:CB)</p>\n<p>Methadone</p>\n<p>Factor VIII binding Assay( VWD</p>\n<p>Normanday)</p>\n<p>Methaqualone</p>\n<p>VWF Multimer Analysis</p>\n<p>Opiates</p>\n<p>Bethesda assay</p>\n<p>Phencyclidine</p>\n<p>F VIII inhibitor test</p>\n<p>Propoxyphene</p>\n<p>F IX inhibitor test</p>\n<p>Tricyclic antidepressants</p>"
    },
    {
        "page_number": 1152,
        "content": "1086\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nF XIII activity assay\nLysergic Acid Diethylamide\nLupus anti-coagulant(LAC) and \nPhospholipid anti- body(APA) tests\nImmunoHistoChemistry\nDilute Russell\u2019s Viper Venom Time \n(DRVVT)\nA Foeto protein\nANTI THROMBIN III (AT3)\nA1 anti chymotrypsin\nPROTEIN S\nA1 anti trypsin\nPROTEIN C\nACE mono\nOther Specialized Tests\nACE mono\nProtein S(PS)\nACTH\nFree Protein S (Free PS)\nActine muscle\nProtein S Activity\nActine muscle lisse\nPlasminogen (PLG)\nActine muscle sp\u00e9\nActivated Protein C Resistance \n\u2013Factor test (APCR-V)\nAdenovirus\nHeparin-UHF (HepXa)\nALK Poumon\nFibrinogen Clauss (Fib-C)\nALK1\n\u03b12-Antiplasmin (APL)\nAndrogen Receptor\nPFDP (P-FDP)\nAnnexin\nHepatocomplex (HPX)\nArginase-1\nChromogenic VIII High (F-VIII Chr \nH)\nB Catenin\nProclot SP (P-ClotSP)\nB HCG\nPro-IL Complex (PCX)\nBCA 225\nSilica Clotting Time (SCT-S, SCT \nScreen)\nBCL2",
        "formatted_content": "<p>1086</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>F XIII activity assay</p>\n<p>Lysergic Acid Diethylamide</p>\n<p>Lupus anti-coagulant(LAC) and</p>\n<p>Phospholipid anti- body(APA) tests</p>\n<p>ImmunoHistoChemistry</p>\n<p>Dilute Russell\u2019s Viper Venom Time</p>\n<h3>(DRVVT)</h3>\n<p>A Foeto protein</p>\n<h3>ANTI THROMBIN III (AT3)</h3>\n<p>A1 anti chymotrypsin</p>\n<h3>PROTEIN S</h3>\n<p>A1 anti trypsin</p>\n<h3>PROTEIN C</h3>\n<p>ACE mono</p>\n<p>Other Specialized Tests</p>\n<p>ACE mono</p>\n<p>Protein S(PS)</p>\n<h3>ACTH</h3>\n<p>Free Protein S (Free PS)</p>\n<p>Actine muscle</p>\n<p>Protein S Activity</p>\n<p>Actine muscle lisse</p>\n<p>Plasminogen (PLG)</p>\n<p>Actine muscle sp\u00e9</p>\n<p>Activated Protein C Resistance</p>\n<p>\u2013Factor test (APCR-V)</p>\n<p>Adenovirus</p>\n<p>Heparin-UHF (HepXa)</p>\n<p>ALK Poumon</p>\n<p>Fibrinogen Clauss (Fib-C)</p>\n<h3>ALK1</h3>\n<p>\u03b12-Antiplasmin (APL)</p>\n<p>Androgen Receptor</p>\n<h3>PFDP (P-FDP)</h3>\n<p>Annexin</p>\n<p>Hepatocomplex (HPX)</p>\n<p>Arginase-1</p>\n<p>Chromogenic VIII High (F-VIII Chr</p>\n<p>H)</p>\n<p>B Catenin</p>\n<p>Proclot SP (P-ClotSP)</p>\n<h3>B HCG</h3>\n<p>Pro-IL Complex (PCX)</p>\n<h3>BCA 225</h3>\n<p>Silica Clotting Time (SCT-S, SCT</p>\n<p>Screen)</p>\n<h3>BCL2</h3>"
    },
    {
        "page_number": 1153,
        "content": "1087\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nHomocysteine (HCY, HCYh)\nbcl-2\nBone marrow report\nBCL6\nBlood Transfusion services (NBTS) BerEP4\nBlood Transfusion services\nBG8\nSerological Testing (Ab, Ag, PCR) BOB.1\nIgG Phenotyping: Fya, Fyb, Jka, \nJKb, S, s, Cellano\nBRAF V600E\nIgM Rh-Kell C, c, E, e, K - Vertical CDX2\nHigh Titer\nCD1a,2,3,4,5,7,8,10,13,14,15, 16,20..68\nDirect Anti globulin Test(DAT)\nCA125\nAntibody screen, commonly known \nas Antibody detection test (ADT)\nCA19.9\nGroup and screen\nCadherin 17\nAnti globulin cross match\nCalcitonin\nPlatelet Compatibility Test\nCalcitonin\nSerological Testing (CMIA, Ab, \nAg, PCR)\nCaldesmon\nSerology\nCalponin\nInfectious Disease\nCalretinin\nHelicobacter pylori IgG/IgM\nCaveolin-1\nHBsAg IgG\nCD1a, 2,3,4,5,7,8,10,13,14,15\n,16,20..68\nHBcAg IgG\nFITC Albumin\nHBeAg IgG\nFITC C1Q\nToxo IgG/IgM\nFITC C3\nCMV IgG/IgM\nFITC C4",
        "formatted_content": "<p>1087</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>Homocysteine (HCY, HCYh)</p>\n<p>bcl-2</p>\n<p>Bone marrow report</p>\n<h3>BCL6</h3>\n<p>Blood Transfusion services (NBTS) BerEP4</p>\n<p>Blood Transfusion services</p>\n<h3>BG8</h3>\n<p>Serological Testing (Ab, Ag, PCR) BOB.1</p>\n<p>IgG Phenotyping: Fya, Fyb, Jka,</p>\n<p>JKb, S, s, Cellano</p>\n<h3>BRAF V600E</h3>\n<p>IgM Rh-Kell C, c, E, e, K - Vertical CDX2</p>\n<p>High Titer</p>\n<p>CD1a,2,3,4,5,7,8,10,13,14,15, 16,20..68</p>\n<p>Direct Anti globulin Test(DAT)</p>\n<h3>CA125</h3>\n<p>Antibody screen, commonly known</p>\n<p>as Antibody detection test (ADT)</p>\n<h3>CA19.9</h3>\n<p>Group and screen</p>\n<p>Cadherin 17</p>\n<p>Anti globulin cross match</p>\n<p>Calcitonin</p>\n<p>Platelet Compatibility Test</p>\n<p>Calcitonin</p>\n<p>Serological Testing (CMIA, Ab,</p>\n<p>Ag, PCR)</p>\n<p>Caldesmon</p>\n<p>Serology</p>\n<p>Calponin</p>\n<p>Infectious Disease</p>\n<p>Calretinin</p>\n<p>Helicobacter pylori IgG/IgM</p>\n<p>Caveolin-1</p>\n<p>HBsAg IgG</p>\n<p>CD1a, 2,3,4,5,7,8,10,13,14,15</p>\n<p>,16,20..68</p>\n<p>HBcAg IgG</p>\n<p>FITC Albumin</p>\n<p>HBeAg IgG</p>\n<h3>FITC C1Q</h3>\n<p>Toxo IgG/IgM</p>\n<h3>FITC C3</h3>\n<p>CMV IgG/IgM</p>\n<h3>FITC C4</h3>"
    },
    {
        "page_number": 1154,
        "content": "1088\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nHCV IgG/IgM\nFITC Fibrinogen\nRubella IgG/IgM\nFITC IgA\nMeasles IgG/IgM\nFITC IgG\nMumps IgG/IgM\nFITC IgM\nHSV 1 IgG/IgM\nFITC Kappa\nHSV 2 IgG/IgM\nFITC Lambda\nHZV IgG/IgM\nCK 34BE12\nHIV combi\nCK AE1\nHIV confirmatory\nSPECIFIC PROTEINS\nAnti HBS\nASLO\nAnti HAV\nAPOA1\nAnti HAV-IgM\nAPO B\nOther Hormones\nC3c\nG.H (Gonadotrophic Hormone)\nC4\nIGF-4\nCRP\nACTH\nhs CRP\nAldosterone\nHbA1c\nCortisol\nCystatin\nGnRH (Gonadotropin Realesing \nHormone)\nFerritin\nVasopressin\nHaptoglobin\nInsulin\nIgA\nBiochemistry (UHI)\nIgG\nLipid profile\nIgM\nvLDLc\nAcid Glycoprotein",
        "formatted_content": "<p>1088</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>HCV IgG/IgM</p>\n<p>FITC Fibrinogen</p>\n<p>Rubella IgG/IgM</p>\n<p>FITC IgA</p>\n<p>Measles IgG/IgM</p>\n<p>FITC IgG</p>\n<p>Mumps IgG/IgM</p>\n<p>FITC IgM</p>\n<p>HSV 1 IgG/IgM</p>\n<p>FITC Kappa</p>\n<p>HSV 2 IgG/IgM</p>\n<p>FITC Lambda</p>\n<p>HZV IgG/IgM</p>\n<h3>CK 34BE12</h3>\n<p>HIV combi</p>\n<h3>CK AE1</h3>\n<p>HIV confirmatory</p>\n<h3>SPECIFIC PROTEINS</h3>\n<p>Anti HBS</p>\n<h3>ASLO</h3>\n<p>Anti HAV</p>\n<h3>APOA1</h3>\n<p>Anti HAV-IgM</p>\n<h3>APO B</h3>\n<p>Other Hormones</p>\n<p>C3c</p>\n<p>G.H (Gonadotrophic Hormone)</p>\n<p>C4</p>\n<h3>IGF-4</h3>\n<h3>CRP</h3>\n<h3>ACTH</h3>\n<p>hs CRP</p>\n<p>Aldosterone</p>\n<p>HbA1c</p>\n<p>Cortisol</p>\n<p>Cystatin</p>\n<p>GnRH (Gonadotropin Realesing</p>\n<p>Hormone)</p>\n<p>Ferritin</p>\n<p>Vasopressin</p>\n<p>Haptoglobin</p>\n<p>Insulin</p>\n<p>IgA</p>\n<p>Biochemistry (UHI)</p>\n<p>IgG</p>\n<p>Lipid profile</p>\n<p>IgM</p>\n<p>vLDLc</p>\n<p>Acid Glycoprotein</p>"
    },
    {
        "page_number": 1155,
        "content": "1089\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nCardiac Profile\nAntitrypsin\nDigitoxin\nMicroglobulin a1\nDigoxin\nMicroglobulin a2\nPro-BNP\nMicroglobulin B2\nPCT\nAlbumin Urine\nIL-6\nMyoglobin\nAnti-CCP\nRF\nIgE\nTransferrin\nBone Profile\nSoluble Transferrin\nPTH (Parathyroid Hormone)\nKappa\nVitamin D3\nFree Kappa\nB-Crosslaps\nLambda\nTotal P1NP\nFree Lambda\nN-MID-Oesteocalcin\nAntithrombin\nThyroid Function Tests\nD-Dimer\nTG\nProtein Electrophoresis\nT-Uptake\nSerum Protein\nAnti-TG\nEnzyme\nAnti-TPO\nHaemoglobin\nFertility Hormones\nHbA1C\ns-Fit-1\nRheumatology Studies\nSHBG (Sex Hormone Binding \nProtein)\nR.F\nPIGF\nC3\nG.H\nC4",
        "formatted_content": "<p>1089</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<p>Cardiac Profile</p>\n<p>Antitrypsin</p>\n<p>Digitoxin</p>\n<p>Microglobulin a1</p>\n<p>Digoxin</p>\n<p>Microglobulin a2</p>\n<p>Pro-BNP</p>\n<p>Microglobulin B2</p>\n<h3>PCT</h3>\n<p>Albumin Urine</p>\n<h3>IL-6</h3>\n<p>Myoglobin</p>\n<p>Anti-CCP</p>\n<p>RF</p>\n<p>IgE</p>\n<p>Transferrin</p>\n<p>Bone Profile</p>\n<p>Soluble Transferrin</p>\n<p>PTH (Parathyroid Hormone)</p>\n<p>Kappa</p>\n<p>Vitamin D3</p>\n<p>Free Kappa</p>\n<p>B-Crosslaps</p>\n<p>Lambda</p>\n<p>Total P1NP</p>\n<p>Free Lambda</p>\n<p>N-MID-Oesteocalcin</p>\n<p>Antithrombin</p>\n<p>Thyroid Function Tests</p>\n<p>D-Dimer</p>\n<p>TG</p>\n<p>Protein Electrophoresis</p>\n<p>T-Uptake</p>\n<p>Serum Protein</p>\n<p>Anti-TG</p>\n<p>Enzyme</p>\n<p>Anti-TPO</p>\n<p>Haemoglobin</p>\n<p>Fertility Hormones</p>\n<p>HbA1C</p>\n<p>s-Fit-1</p>\n<p>Rheumatology Studies</p>\n<p>SHBG (Sex Hormone Binding</p>\n<p>Protein)</p>\n<h3>R.F</h3>\n<h3>PIGF</h3>\n<p>C3</p>\n<h3>G.H</h3>\n<p>C4</p>"
    },
    {
        "page_number": 1156,
        "content": "1090\nUganda Clinical Guidelines 2023\nAPPENDIX\nADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL \nREFERRAL HOSPITAL (NRH)\nIGF-1\nCRP\nACTH\nDsDNA\nC-Peptide\nAnti \u2013 CCP\nCortisol\nANA (antinuclear antibodies)\nGnRH\nANCA (anti neutrophil cytoplasmic \nantibodies)\nInsulin\nCDT(for Alcohol abuse)\nTumour Markers\nNTRL\nFPSA\nTuberculosis Culture\n- h CG-free\nIdentification of Mycobacteria tu\u00ad\nberculosis complex (MTC)\nCyfra-21-1\nDrug susceptibility testing (DST) \nmethods\nDrug Abuse\nXpert MTB/RIF test\nAmphetamines",
        "formatted_content": "<p>1090</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<h3>ADDITIONAL TESTS FOR MULAGO/ BUTABIKA NATIONAL</h3>\n<h3>REFERRAL HOSPITAL (NRH)</h3>\n<h3>IGF-1</h3>\n<h3>CRP</h3>\n<h3>ACTH</h3>\n<p>DsDNA</p>\n<p>C-Peptide</p>\n<p>Anti \u2013 CCP</p>\n<p>Cortisol</p>\n<p>ANA (antinuclear antibodies)</p>\n<p>GnRH</p>\n<p>ANCA (anti neutrophil cytoplasmic</p>\n<p>antibodies)</p>\n<p>Insulin</p>\n<p>CDT(for Alcohol abuse)</p>\n<p>Tumour Markers</p>\n<h3>NTRL</h3>\n<h3>FPSA</h3>\n<p>Tuberculosis Culture</p>\n<p>- h CG-free</p>\n<p>Identification of Mycobacteria tu\u00ad</p>\n<p>berculosis complex (MTC)</p>\n<p>Cyfra-21-1</p>\n<p>Drug susceptibility testing (DST)</p>\n<p>methods</p>\n<p>Drug Abuse</p>\n<p>Xpert MTB/RIF test</p>\n<p>Amphetamines</p>"
    },
    {
        "page_number": 1157,
        "content": "1091\nUganda Clinical Guidelines 2023\nAPPENDIX\nAppendix 4\nReferences\nMinistry of Health Uganda, National Tuberculosis and Leprosy Pro\u00ad\ngramme, 2016. Tuberculosis and Leprosy Manual, 3rd Edition\nMinistry of Health Uganda, Makerere Palliative Care Unit, 2014. \nPalliative Care Guidelines\nWorld Health Organisation, 2010. WHO guide for Rabies Pre and \nPost-Exposure Prophylaxis in Humans. http://www. who.int/rabies/\nPEP_prophylaxis_guidelines_June10.pdf Accessed on 25/11/2016\nMinistry of Health Uganda, 2013. Uganda National Infection Pre\u00ad\nvention and Control Guidelines 2013. http://library. health.go.ug/\npublications/leadership-and-governance- governance/guidelines/\nuganda-national-infection- prevention Accessed on 25/11/2016\nMinistry of Health Uganda, 2010. Guidelines for the Syndromic Man\u00ad\nagement of Sexually Transmitted Infections in Uganda.\nMinistry of Health Uganda, 2022. Essential Maternal and Newborn \nClinical Care Guidelines for Uganda.  \nUganda Guidelines for Prevention, Testing, Care and Treatment of \nHepatitis B and C Virus Infection, May 2019\nMinistry of Health Uganda, 2016. The Uganda Medical Eligibity \nCriteria for Contraceptive Use, MEC Wheel\nMinistry of Health Uganda, 2015. Integrated Community Case Man\u00ad\nagement\nMinistry of Health Uganda, 2015. Integrated Management of Malaria \nTraining, 2nd Edition. Facilitator\u2019s Guide\nMinistry of Health Uganda, 2015. Practical Guideline for Dispensing \nfor Higher Level Health Centres, 2015.\nMinistry of Health Uganda, AIDS Control Programme, 2016. Consol\u00ad\nidated Guidelines for Prevention and Treatment of HIV in Uganda.",
        "formatted_content": "<p>1091</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>Appendix 4</p>\n<p>References</p>\n<p>Ministry of Health Uganda, National Tuberculosis and Leprosy Pro\u00ad</p>\n<p>gramme, 2016. Tuberculosis and Leprosy Manual, 3rd Edition</p>\n<p>Ministry of Health Uganda, Makerere Palliative Care Unit, 2014.</p>\n<p>Palliative Care Guidelines</p>\n<p>World Health Organisation, 2010. WHO guide for Rabies Pre and</p>\n<p>Post-Exposure Prophylaxis in Humans. http://www. who.int/rabies/</p>\n<p>PEP_prophylaxis_guidelines_June10.pdf Accessed on 25/11/2016</p>\n<p>Ministry of Health Uganda, 2013. Uganda National Infection Pre\u00ad</p>\n<p>vention and Control Guidelines 2013. http://library. health.go.ug/</p>\n<p>publications/leadership-and-governance- governance/guidelines/</p>\n<p>uganda-national-infection- prevention Accessed on 25/11/2016</p>\n<p>Ministry of Health Uganda, 2010. Guidelines for the Syndromic Man\u00ad</p>\n<p>agement of Sexually Transmitted Infections in Uganda.</p>\n<p>Ministry of Health Uganda, 2022. Essential Maternal and Newborn</p>\n<p>Clinical Care Guidelines for Uganda.</p>\n<p>Uganda Guidelines for Prevention, Testing, Care and Treatment of</p>\n<p>Hepatitis B and C Virus Infection, May 2019</p>\n<p>Ministry of Health Uganda, 2016. The Uganda Medical Eligibity</p>\n<p>Criteria for Contraceptive Use, MEC Wheel</p>\n<p>Ministry of Health Uganda, 2015. Integrated Community Case Man\u00ad</p>\n<p>agement</p>\n<p>Ministry of Health Uganda, 2015. Integrated Management of Malaria</p>\n<p>Training, 2nd Edition. Facilitator\u2019s Guide</p>\n<p>Ministry of Health Uganda, 2015. Practical Guideline for Dispensing</p>\n<p>for Higher Level Health Centres, 2015.</p>\n<p>Ministry of Health Uganda, AIDS Control Programme, 2016. Consol\u00ad</p>\n<p>idated Guidelines for Prevention and Treatment of HIV in Uganda.</p>"
    },
    {
        "page_number": 1158,
        "content": "1092\nUganda Clinical Guidelines 2023\nAPPENDIX\nMinistry of Health Uganda, 2016. Guidelines for Integrated Manage\u00ad\nment of Nutrition in Uganda.\nUganda Gastroenterology Society, 2016. Pocket Guide: Care and \nTreatment for Hepatitis B Virus Infection for Clinicains in Uganda\nUNAS, CDDEP, GARP-Uganda, Mpairwe, Y., & Wamala\nS. (2015). Antibiotic Resistance in Uganda: Situation Anaysis and \nRecommendations. Kampala, Uganda: Uganda National Academy of \nSciences; Center for Disease Dynamics, Economics & Policy.\nWorld Health Organisation, 2015. Integrated Management of Preg\u00ad\nnancy and Childbirth. 3rd Edition. http://apps.who.\nint/iris/bitstream/10665/249580/1/9789241549356-eng. pdf \nAccessed on 25/11/2016\nWorld Health Organisation, 2002. The Clinical Use of Blood. http://\nwww.who.int/bloodsafety/clinical_use/en/ Handbook_EN.pdf Ac\u00ad\ncessed on 25/11/2016\nWorld Health Organisation, 2013. Pocket Book of Hospital \nCare for Children, 2nd Edition. http://apps.who.int/iris/ bitstr\neam/10665/81170/1/9789241548373_eng.pdf Accessed on \n25/11/2016\nWorld Health Organisation, 2007. Managing Complications in Preg\u00ad\nnancy and Childbirth: A guide for midwives and doctors.\nWorld Health Organisation and UNICEF 2009. WHO child growth \nstandards and the identification of severe acute malnutrition in infants \nand children.\nWorld Health Organisation, 2016. WHO Guidelines for the treatment \nof Treponema Pallidum (syphilis). http://www. who.int\nWorld Health Organisation, 2016. WHO Guidelines for the treatment \nof Neisseria Gonorrhoeae. http://www.who.int\nWorld Health Organisation, 2016. WHO Guidelines for the treatment \nof Chlamydia Trachomatis. http://www.who.int",
        "formatted_content": "<p>1092</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>Ministry of Health Uganda, 2016. Guidelines for Integrated Manage\u00ad</p>\n<p>ment of Nutrition in Uganda.</p>\n<p>Uganda Gastroenterology Society, 2016. Pocket Guide: Care and</p>\n<p>Treatment for Hepatitis B Virus Infection for Clinicains in Uganda</p>\n<p>UNAS, CDDEP, GARP-Uganda, Mpairwe, Y., & Wamala</p>\n<p>S. (2015). Antibiotic Resistance in Uganda: Situation Anaysis and</p>\n<p>Recommendations. Kampala, Uganda: Uganda National Academy of</p>\n<p>Sciences; Center for Disease Dynamics, Economics & Policy.</p>\n<p>World Health Organisation, 2015. Integrated Management of Preg\u00ad</p>\n<p>nancy and Childbirth. 3rd Edition. http://apps.who.</p>\n<p>int/iris/bitstream/10665/249580/1/9789241549356-eng. pdf</p>\n<p>Accessed on 25/11/2016</p>\n<p>World Health Organisation, 2002. The Clinical Use of Blood. http://</p>\n<p>www.who.int/bloodsafety/clinical_use/en/ Handbook_EN.pdf Ac\u00ad</p>\n<p>cessed on 25/11/2016</p>\n<p>World Health Organisation, 2013. Pocket Book of Hospital</p>\n<p>Care for Children, 2nd Edition. http://apps.who.int/iris/ bitstr</p>\n<p>eam/10665/81170/1/9789241548373_eng.pdf Accessed on</p>\n<p>25/11/2016</p>\n<p>World Health Organisation, 2007. Managing Complications in Preg\u00ad</p>\n<p>nancy and Childbirth: A guide for midwives and doctors.</p>\n<p>World Health Organisation and UNICEF 2009. WHO child growth</p>\n<p>standards and the identification of severe acute malnutrition in infants</p>\n<p>and children.</p>\n<p>World Health Organisation, 2016. WHO Guidelines for the treatment</p>\n<p>of Treponema Pallidum (syphilis). http://www. who.int</p>\n<p>World Health Organisation, 2016. WHO Guidelines for the treatment</p>\n<p>of Neisseria Gonorrhoeae. http://www.who.int</p>\n<p>World Health Organisation, 2016. WHO Guidelines for the treatment</p>\n<p>of Chlamydia Trachomatis. http://www.who.int</p>"
    },
    {
        "page_number": 1159,
        "content": "1093\nUganda Clinical Guidelines 2023\nAPPENDIX\nWorld Health Organisation 2015. Medical Eligibility Criteria for \nContraceptive Use. 5th edition (2015). http://www.who. int/repro\u00ad\nductivehealth/en/\nWorld Health Organisation, 2014. Integrated Management of \nChildhood Illness Chart Booklet. http://apps.who.int/ iris/bitstre\nam/10665/104772/16/9789241506823_ Chartbook_eng.pdf \nAccessed on 25/11/2016\nWorld Health Organisation, 2015. Guidelines for the Treatment \nof Malaria, 3rd Edition, 2015. http://apps.who. int/iris/bitstre\nam/10665/162441/1/9789241549127_eng. pdf Accessed on \n25/11/2016\nWorld Health Organisation, 2010. mhGAP Intervention \nGuide. http://apps.who.int/iris/ bitstream/10665/44406/1/ \n9789241548069_eng.pdf Accessed on 25/11/2016\nMedecins Sans Frontieres. Clinical Guidelines - Diagnosis and treat\u00ad\nment manual. 2016 edition. http://refbooks.msf. org/msf_docs/en/\nclinical_guide/cg_en.pdf\nDowell, S. F., Sejvar, J. J., Riek, L., Vandemaele, K. A. H.,\nLamunu, M., Kuesel, A. C., \u2026 Mbonye, A. K. (2013). Nodding Syn\u00ad\ndrome. Emerging Infectious Diseases, 19(9), 1374\u20131373. http://doi.\norg/10.3201/eid1909.130401\nGlobal Inititative for Chronic Obstructive Lung disease, 2015. Pocket \nGuide to COPD diagnosis, management and prevention. http://\ngoldcopd.org/pocket-guide-copd- diagnosis-management-preven\u00ad\ntion-2016/ Accessed on 25/11/2016\nBMJ Group and the Royal Pharmaceutical Society of Great Britain, \n2014. British National Formulary 66, 2013-2014. London, UK\nBMJ Group and the Royal Pharmaceutical Society of Great Britain, \n2014. British National Formulary for Children 2013-2014. London, \nUK",
        "formatted_content": "<p>1093</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>World Health Organisation 2015. Medical Eligibility Criteria for</p>\n<p>Contraceptive Use. 5th edition (2015). http://www.who. int/repro\u00ad</p>\n<p>ductivehealth/en/</p>\n<p>World Health Organisation, 2014. Integrated Management of</p>\n<p>Childhood Illness Chart Booklet. http://apps.who.int/ iris/bitstre</p>\n<p>am/10665/104772/16/9789241506823_ Chartbook_eng.pdf</p>\n<p>Accessed on 25/11/2016</p>\n<p>World Health Organisation, 2015. Guidelines for the Treatment</p>\n<p>of Malaria, 3rd Edition, 2015. http://apps.who. int/iris/bitstre</p>\n<p>am/10665/162441/1/9789241549127_eng. pdf Accessed on</p>\n<p>25/11/2016</p>\n<p>World Health Organisation, 2010. mhGAP Intervention</p>\n<p>Guide. http://apps.who.int/iris/ bitstream/10665/44406/1/</p>\n<p>9789241548069_eng.pdf Accessed on 25/11/2016</p>\n<p>Medecins Sans Frontieres. Clinical Guidelines - Diagnosis and treat\u00ad</p>\n<p>ment manual. 2016 edition. http://refbooks.msf. org/msf_docs/en/</p>\n<p>clinical_guide/cg_en.pdf</p>\n<p>Dowell, S. F., Sejvar, J. J., Riek, L., Vandemaele, K. A. H.,</p>\n<p>Lamunu, M., Kuesel, A. C., \u2026 Mbonye, A. K. (2013). Nodding Syn\u00ad</p>\n<p>drome. Emerging Infectious Diseases, 19(9), 1374\u20131373. http://doi.</p>\n<p>org/10.3201/eid1909.130401</p>\n<p>Global Inititative for Chronic Obstructive Lung disease, 2015. Pocket</p>\n<p>Guide to COPD diagnosis, management and prevention. http://</p>\n<p>goldcopd.org/pocket-guide-copd- diagnosis-management-preven\u00ad</p>\n<p>tion-2016/ Accessed on 25/11/2016</p>\n<p>BMJ Group and the Royal Pharmaceutical Society of Great Britain,</p>\n<p>2014. British National Formulary 66, 2013-2014. London, UK</p>\n<p>BMJ Group and the Royal Pharmaceutical Society of Great Britain,</p>\n<p>2014. British National Formulary for Children 2013-2014. London,</p>\n<p>UK</p>"
    },
    {
        "page_number": 1160,
        "content": "1094\nUganda Clinical Guidelines 2023\nAPPENDIX\nRepublic of Namibia. Ministry of Health and Social Services, 2011. \nNamibia Standard Treatment Guidelines. http://apps.who.int/\nmedicinedocs/documents/s19260en/ s19260en.pdf Accessed on \n25/11/2016\nRepublic of South Africa. Essential Drugs Programme. Hospital \n(Adults) Standard Treatment Guidelines and Essential Medicines List. \n4th ed. Republic of South Africa: National Department of Health; \n2015. http://www. health.gov.za/index.php/component/phocad\u00ad\nownload/ category/197/\nRepublic of South Africa. Essential Drugs Programme. Hospital (Pae\u00ad\ndiatrics) Standard Treatment Guidelines and Essential Medicines List. \n3rd ed. Republic of South Africa: National Department of Health; \n2013. http://www. health.gov.za/index.php/component/phocad\u00ad\nownload/ category/197/\nRepublic of South Africa. Essential Drugs Programme. Primary \nHealth Care Level. Standard Treatment Guidelines and Essential \nMedicines List. 5th ed. Republic of South Africa: National Depart\u00ad\nment of Health; 2014. http://www.health.gov.za/index.php/compo\u00ad\nnent/ phocadownload/category/197/\nMedscape. http://www.medscape.com\nSIAPS. 2015. Developing, Implementing, and Monitoring the Use of \nStandard Treatment Guidelines: A SIAPS How-to Manual. Submitted \nto the US Agency for International Development by the Systems for \nImproved Access\nto Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: \nManagement Sciences for Health. http:// www.siapsprogram.org/\npublication/stg-how-to-manual\nAfrican Snakebite Institute. https://www.africansnakebiteinstitute.\ncom/",
        "formatted_content": "<p>1094</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<h3>APPENDIX</h3>\n<p>Republic of Namibia. Ministry of Health and Social Services, 2011.</p>\n<p>Namibia Standard Treatment Guidelines. http://apps.who.int/</p>\n<p>medicinedocs/documents/s19260en/ s19260en.pdf Accessed on</p>\n<p>25/11/2016</p>\n<p>Republic of South Africa. Essential Drugs Programme. Hospital</p>\n<p>(Adults) Standard Treatment Guidelines and Essential Medicines List.</p>\n<p>4th ed. Republic of South Africa: National Department of Health;</p>\n<p>2015. http://www. health.gov.za/index.php/component/phocad\u00ad</p>\n<p>ownload/ category/197/</p>\n<p>Republic of South Africa. Essential Drugs Programme. Hospital (Pae\u00ad</p>\n<p>diatrics) Standard Treatment Guidelines and Essential Medicines List.</p>\n<p>3rd ed. Republic of South Africa: National Department of Health;</p>\n<p>2013. http://www. health.gov.za/index.php/component/phocad\u00ad</p>\n<p>ownload/ category/197/</p>\n<p>Republic of South Africa. Essential Drugs Programme. Primary</p>\n<p>Health Care Level. Standard Treatment Guidelines and Essential</p>\n<p>Medicines List. 5th ed. Republic of South Africa: National Depart\u00ad</p>\n<p>ment of Health; 2014. http://www.health.gov.za/index.php/compo\u00ad</p>\n<p>nent/ phocadownload/category/197/</p>\n<p>Medscape. http://www.medscape.com</p>\n<p>SIAPS. 2015. Developing, Implementing, and Monitoring the Use of</p>\n<p>Standard Treatment Guidelines: A SIAPS How-to Manual. Submitted</p>\n<p>to the US Agency for International Development by the Systems for</p>\n<p>Improved Access</p>\n<p>to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA:</p>\n<p>Management Sciences for Health. http:// www.siapsprogram.org/</p>\n<p>publication/stg-how-to-manual</p>\n<p>African Snakebite Institute. https://www.africansnakebiteinstitute.</p>\n<p>com/</p>"
    },
    {
        "page_number": 1161,
        "content": "566\nUganda Clinical Guidelines 2023\nCHAPTER 20: Eye Conditions",
        "formatted_content": "<p>566</p>\n<p>Uganda Clinical Guidelines 2023</p>\n<p>CHAPTER 20: Eye Conditions</p>"
    }
]